TY - JOUR AB - The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene plays a critical role in folate metabolism. Studies on the association between MTHFR polymorphisms and length changes in short tandem repeat DNA sequences [microsatellite instability (MSI)] are inconsistent. Using data from colon cancer cases (n = 503) enrolled as part of an existing population-based case-control study, we investigated the association between MTHFR 677 and MTHFR 1298 polymorphisms and MSI. We also examined whether the association was modified by folate intake. Participants were case subjects enrolled as part of the North Carolina Colon Cancer Study. Consenting cases provided information about lifestyle and diet during in-home interviews as well as blood specimens and permission to obtain tumor blocks. DNA from normal and tumor tissue sections was used to determine microsatellite status (MSI). Tumors were classified as MSI if two or more microsatellite markers (BAT25, BAT26, D5S346, D2S123, and D17S250) had changes in the number of DNA sequence repeats compared with matched nontumor tissue. Tumors with one positive marker (MSI-low) or no positive markers (microsatellite stable) were grouped together as non-MSI tumors (microsatellite stable). MTHFR 677 and MTHFR 1298 genotypes were determined by real-time PCR using the 5′ exonuclease (Taqman) assay. Logistic regression was used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). MSI was more common in proximal tumors (OR, 3.8; 95% CI, 1.7-8.4) and in current smokers (OR, 4.0; 95% CI, 1.6-9.7). Compared with MTHFR 677 CC referent, MTHFR 677 CT/TT genotype was inversely associated with MSI among White cases (OR, 0.36; 95% CI, 0.16-0.81) but not significant among African Americans. Although not statistically significant, a similar inverse association was observed between MTHFR 677 CT/TT genotype and MSI among the entire case subjects (OR, 0.54; 95% CI, 0.26-1.10). Among those with adequate folate intake (>400 μg total folate), we found strong inverse associations between combined MTHFR genotypes and MSI (677 CC + 1298 AC/CC, OR, 0.09; 95% CI, 0.01-0.59; 677 CT/TT + 1298 AA, OR, 0.13; 95% CI, 0.02-0.85) compared with the combined wild-type genotypes (677 CC + 1298 AA). This protective effect was not evident among those with low folate (<400 μg total folate) intake. Our results suggest that MTHFR variant genotypes are associated with reduced risk of MSI tumors under conditions of adequate folate intake, although the data are imprecise due to small numbers. These results indicate that the relationship between MTHFR genotypes and MSI is influenced by folate status. Copyright © 2005 American Association for Cancer Research. AD - Department of Epidemiology, Schools of Public Health and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Center for Gastrointestinal Biology and Disease, Schools of Public Health and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Department of Medicine and Cancer Center, University of California at San Diego, San Diego, CA, United States Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7555, United States AU - Eaton, A. M. AU - Sandler, R. AU - Carethers, J. M. AU - Millikan, R. C. AU - Galanko, J. AU - Keku, T. O. DB - Scopus DO - 10.1158/1055-9965.EPI-05-0131 IS - 8 M3 - Article N1 - Cited By :34 Export Date: 22 March 2021 PY - 2005 SP - 2023-2029 ST - 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer T2 - Cancer Epidemiology Biomarkers and Prevention TI - 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-23844446667&doi=10.1158%2f1055-9965.EPI-05-0131&partnerID=40&md5=52f8fe4f8bb80081df2988903ee7ae1e VL - 14 ID - 2591 ER - TY - JOUR AB - OBJECTIVE: To evaluate efficacy, endometrial safety, and overall safety of a single-capsule 17b-estradiol-progesterone (TX-001HR) for treating menopausal moderate-to-severe vasomotor symptoms. METHODS: REPLENISH was a phase 3, 12-month, randomized, double-blind, placebo-controlled, multicenter trial. Women (aged 40-65 years) with vasomotor symptoms and a uterus were randomized to daily estradiol (mg)-progesterone (mg) (1/100, 0.5/100, 0.5/50, or 0.25/50), and women in the vasomotor symptoms substudy (women with moderate-to-severe hot flushes [seven or greater per day or 50 or greater per week]) to those estradiol-progesterone doses or placebo. The primary safety endpoint was endometrial hyperplasia incidence at 12 months in all women (the total population), and the primary efficacy endpoints were frequency and severity changes (from daily diaries) in moderate-to-severe vasomotor symptoms with estradiol-progesterone compared with placebo at weeks 4 and 12 in the vasomotor symptoms substudy. A sample size of 250 women in each active treatment arm with two or less endometrial hyperplasia cases would result in 1% or less annual incidence (upper bound 2.5% or less, one-sided 95% CI). RESULTS: One thousand eight hundred forty-five women were enrolled and randomized from August 2013 to October 2015; 1,835 received medication (safety population); 1,255 were eligible for the endometrial safety population; 726 comprised the vasomotor symptoms substudy; their mean age and body mass index were 55 years and 27, respectively; one third were African American. No endometrial hyperplasia was found. Frequency and severity of vasomotor symptoms significantly decreased from baseline with 1 mg estradiol and 100 mg progesterone and 0.5 mg estradiol and 100 mg progesterone compared with placebo at week 4 (frequency: by 40.6 and 35.1 points [1 mg and 100 mg and 0.5 mg and 100 mg, respectively] vs 26.4 points [placebo]; severity: by 0.48 and 0.51 vs 0.34 points) and week 12 (by 55.1 and 53.7 vs 40.2; severity: by 1.12 and 0.90 vs 0.56); 0.5 mg estradiol and 50 mg progesterone improved (P,.05) frequency and severity at week 12, and 0.25 mg estradiol and 50 mg progesterone frequency but not severity at weeks 4 and 12. CONCLUSION: No endometrial hyperplasia was observed while single-capsule estradiol-progesterone provided clinically meaningfully improvements in moderate-to-severe vasomotor symptoms. This estradiol-progesterone formulation may represent a new option, using naturally occurring hormones, for the estimated millions of women using nonregulatoryapproved, compounded hormone therapy. © 2018 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. AD - Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia; the University of California, San Francisco, San Francisco, and Sutter East Bay Medical Foundation, Berkeley, California; the University of Florida College of Medicine-Jacksonville, Jacksonville, Florida; EndoRheum Consultants, LLC, Malvern, Pennsylvania; and TherapeuticsMD, Boca Raton, Florida Columbia University Medical Center, 622 W 168th Street, New York, NY 10032 AU - Lobo, R. A. AU - Archer, D. F. AU - Kagan, R. AU - Kaunitz, A. M. AU - Constantine, G. D. AU - Pickar, J. H. AU - Graham, S. AU - Bernick, B. AU - Mirkin, S. DB - Scopus DO - 10.1097/AOG.0000000000002645 IS - 1 M3 - Conference Paper N1 - Cited By :24 Export Date: 22 March 2021 PY - 2018 SP - 161-170 ST - A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women a randomized controlled trial T2 - Obstetrics and Gynecology TI - A 17β-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women a randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061219480&doi=10.1097%2fAOG.0000000000002645&partnerID=40&md5=000dc90c7ed415a7d78888734dee0298 VL - 132 ID - 2292 ER - TY - JOUR AB - BACKGROUND: Whether accelerated aging develops over the course of chronic HIV infection or can be observed prior to significant immunosuppression on is unknown. We studied DNA methylation in blood to estimate cellular aging in persons living with HIV (PLWH) prior to the initiation of antiretroviral therapy. METHODS: 378 antiretroviral therapy-naïve PLWH with CD4 T cell counts >500 cells/mm 3 enrolled in the Strategic Timing of Antiretroviral Therapy trial (Pulmonary Substudy) were compared to 34 HIV-negative controls. DNA methylation was performed using the Illumina MethylationEPIC BeadChip. Differentially methylated positions (DMPs) and regions (DMRs) in PLWH compared to controls were identified using a robust linear model. Methylation age was calculated using a previously described epigenetic clock. RESULTS: There were a total of 56,639 DMPs and 6,103 DMRs at a false discovery rate<0.1. The top 5 DMPs corresponded to genes NLRC5, VRK2, B2M, and GPR6 and were highly enriched for cancer-related pathways. PLWH had significantly higher methylation age compared to HIV-negative controls (p=0.001), with black race, low CD4, high CD8 T cell counts, and duration of HIV being risk factors for age acceleration. CONCLUSIONS: PLWH prior to the initiation of antiretroviral therapy and with preserved immune status show evidence of advanced methylation aging. AU - Yang, C. X. AU - Schon, E. AU - Obeidat, M. AU - Kobor, M. S. AU - McEwen, L. AU - MacIsaac, J. AU - Lin, D. AU - Novak, R. M. AU - Hudson, F. AU - Klinker, H. AU - Dharan, N. AU - Horvath, S. AU - Bourbeau, J. AU - Tan, W. AU - Sin, D. D. AU - Man, S. F. P. AU - Kunisaki, K. AU - Leung, J. M. DB - Medline DO - 10.1093/infdis/jiaa599 KW - acceleration adult antiretroviral therapy article Black person CD4 lymphocyte count CD8 lymphocyte count cell aging controlled study DNA methylation epigenetics female human Human immunodeficiency virus infected patient Human immunodeficiency virus infection immune status major clinical study male risk factor tumor-related gene CD4 antigen endogenous compound LA - English M3 - Article in Press N1 - L632950968 2020-09-30 PY - 2020 SN - 1537-6613 ST - Accelerated Epigenetic Aging and Methylation Disruptions Occur in Human Immunodeficiency Virus Infection Prior to Antiretroviral Therapy T2 - The Journal of infectious diseases TI - Accelerated Epigenetic Aging and Methylation Disruptions Occur in Human Immunodeficiency Virus Infection Prior to Antiretroviral Therapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632950968&from=export http://dx.doi.org/10.1093/infdis/jiaa599 ID - 789 ER - TY - JOUR AB - Starting in 2002, the Radiation Therapy Oncology Group in North America began the process of developing multicenter prospective trials in lung cancer using Stereotactic Body Radiation Therapy (SBRT). Much of the work was based on the prospective single institution trials from Indiana University that had been presented and published. In late 2004, RTOG 0236 using SBRT for medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC) was activated for accrual. Prior to activation, representatives from the Lung, Image-Guided Therapy, Physics, and Radiobiology Committees met on regular occasions to design the multicenter study and quality assurance measures. SBRT is not a black box, and the essence of the therapy had to be distilled via guidelines. Issues related to patient selection, method of dosimetry construction, equipment requirements, motion assessments and control, site accreditation, data exchange, and follow-up policies were worked out by compromise and consensus. RTOG 0236 has nearly completed its accrual. The Lung Committee has initiated the development of several other trials, each building on the last, to investigate the therapy in central tumors, in combinations with systemic therapy, in operable patients, and in lung metastases patients. The guidelines developed for RTOG 0236 will be refined to take advantage of more modern innovations including heterogeneity corrections and intensity modulation when appropriate. The development of RTOG 0618 using SBRT in operable patients with early stage NSCLC is a testament to both the enthusiasm from already published works and prospective multicenter clinical testing using SBRT techniques. AD - Department of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9183, USA. robert.timmerman@utsouthwestern.edu AN - 106185419. Language: English. Entry Date: 20071102. Revision Date: 20200708. Publication Type: Journal Article AU - Timmerman, R. AU - Galvin, J. AU - Michalski, J. AU - Straube, W. AU - Ibbott, G. AU - Martin, E. AU - Abdulrahman, R. AU - Swann, S. AU - Fowler, J. AU - Choy, H. DB - CINAHL Complete DO - 10.1080/02841860600902213 DP - EBSCOhost IS - 7 KW - Accreditation -- Administration Carcinoma -- Surgery Clinical Trials -- Methods Lung Neoplasms -- Surgery Multicenter Studies -- Methods Oncology Quality Assurance -- Administration Radiosurgery -- Methods Carcinoma -- Pathology Lung Neoplasms -- Pathology Motion Phantoms, Imaging Radiation Dosage Radiometry Radiotherapy -- Methods N1 - review; tables/charts. Journal Subset: Biomedical; Continental Europe; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8709065. PMID: NLM16982540. PY - 2006 SN - 0284-186X SP - 779-786 ST - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer T2 - Acta Oncologica TI - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106185419&site=ehost-live&scope=site VL - 45 ID - 1840 ER - TY - JOUR AB - Starting in 2002, the Radiation Therapy Oncology Group in North America began the process of developing multicenter prospective trials in lung cancer using Stereotactic Body Radiation Therapy (SBRT). Much of the work was based on the prospective single institution trials from Indiana University that had been presented and published. In late 2004, RTOG 0236 using SBRT for medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC) was activated for accrual. Prior to activation, representatives from the Lung, Image-Guided Therapy, Physics, and Radiobiology Committees met on regular occasions to design the multicenter study and quality assurance measures. SBRT is not a black box, and the essence of the therapy had to be distilled via guidelines. Issues related to patient selection, method of dosimetry construction, equipment requirements, motion assessments and control, site accreditation, data exchange, and follow-up policies were worked out by compromise and consensus. RTOG 0236 has nearly completed its accrual. The Lung Committee has initiated the development of several other trials, each building on the last, to investigate the therapy in central tumors, in combinations with systemic therapy, in operable patients, and in lung metastases patients. The guidelines developed for RTOG 0236 will be refined to take advantage of more modern innovations including heterogeneity corrections and intensity modulation when appropriate. The development of RTOG 0618 using SBRT in operable patients with early stage NSCLC is a testament to both the enthusiasm from already published works and prospective multicenter clinical testing using SBRT techniques. © 2006 Taylor & Francis. AD - Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States Department of Radiation Oncology, Washington University, St. Louis, MO, United States Radiological Physics Center, M.D. Anderson Cancer Center, Houston, TX, United States Quality Assurance and Statistical Sections, Radiation Therapy Oncology Group Headquarters, Philadelphia, PA, United States Department of Radiation Oncology, University of Wisconsin, Madison, WI, United States Department of Radiation Oncology, University of Texas Southwestern Medical Center, 5801 Forest Park Road, Dallas, TX 75390-9183, United States AU - Timmerman, R. AU - Galvin, J. AU - Michalski, J. AU - Straube, W. AU - Ibbott, G. AU - Martin, E. AU - Abdulrahman, R. AU - Swann, S. AU - Fowler, J. AU - Choy, H. DB - Scopus DO - 10.1080/02841860600902213 IS - 7 M3 - Conference Paper N1 - Cited By :94 Export Date: 22 March 2021 PY - 2006 SP - 779-786 ST - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer T2 - Acta Oncologica TI - Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33748854632&doi=10.1080%2f02841860600902213&partnerID=40&md5=9fddd31c1caff2bbb7a4c9030085e13e VL - 45 ID - 2571 ER - TY - JOUR AB - Starting in 2002, the Radiation Therapy Oncology Group in North America began the process of developing multicenter prospective trials in lung cancer using Stereotactic Body Radiation Therapy (SBRT). Much of the work was based on the prospective single institution trials from Indiana University that had been presented and published. In late 2004, RTOG 0236 using SBRT for medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC) was activated for accrual. Prior to activation, representatives from the Lung, Image-Guided Therapy, Physics, and Radiobiology Committees met on regular occasions to design the multicenter study and quality assurance measures. SBRT is not a black box, and the essence of the therapy had to be distilled via guidelines. Issues related to patient selection, method of dosimetry construction, equipment requirements, motion assessments and control, site accreditation, data exchange, and follow-up policies were worked out by compromise and consensus. RTOG 0236 has nearly completed its accrual. The Lung Committee has initiated the development of several other trials, each building on the last, to investigate the therapy in central tumors, in combinations with systemic therapy, in operable patients, and in lung metastases patients. The guidelines developed for RTOG 0236 will be refined to take advantage of more modern innovations including heterogeneity corrections and intensity modulation when appropriate. The development of RTOG 0618 using SBRT in operable patients with early stage NSCLC is a testament to both the enthusiasm from already published works and prospective multicenter clinical testing using SBRT techniques. AN - WOS:000240569600003 AU - Timmerman, R. AU - Galvin, J. AU - Michalski, J. AU - Straube, W. AU - Ibbott, G. AU - Martin, E. AU - Abdulrahman, R. AU - Swann, S. AU - Fowler, J. AU - Choy, H. DA - Sep DO - 10.1080/02841860600902213 IS - 7 N1 - 3rd Acta Oncological Symposium on Stereotactic Body Radiotherapy JUN 15-17, 2006 Copenhagen, DENMARK 16982540 PY - 2006 SN - 0284-186X SP - 779-786 ST - Accreditation and quality assurance for radiation therapy oncology group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer T2 - Acta Oncologica TI - Accreditation and quality assurance for radiation therapy oncology group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer VL - 45 ID - 3210 ER - TY - JOUR AB - The dearth of evidence-based clinical trial education programs may contribute to the underrepresentation of African American and Hispanic American women in cancer research studies. This study used focus group-derived data from 80 women distributed among eight Spanish- and English-language focus groups. These data guided the researchers’ adaptation and refinement of the National Cancer Institute’s various clinical trials education programs into a program that was specifically focused on meeting the information needs of minority women and addressing the barriers to study participation that they perceived. A 'sisterhood' theme was adopted and woven throughout the presentation. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Sadler, Georgia Robins, UCSD School of Medicine, Moores UCSD Cancer Center, 0850, 3855 Health Sciences Drive, La Jolla, CA, US, 92093-0850 AN - 2011-25638-006 AU - Sadler, Georgia Robins AU - Gonzalez, Jenny AU - Mumman, Manpreet AU - Cullen, Lisa AU - LaHousse, Sheila F. AU - Malcarne, Vanessa AU - Conde, Viridiana AU - Riley, Natasha DB - psyh DO - 10.1007/s13187-009-0032-y DP - EBSCOhost IS - 2 KW - African Americans Hispanic Americans women cancer clinical trials education programs Breast Neoplasms Clinical Trials as Topic Consumer Health Information Cultural Competency Female Focus Groups Humans Minority Health Patient Selection Women's Health Educational Programs Human Females Neoplasms Blacks Clinical Trials Latinos/Latinas N1 - Moores UCSD Cancer Center, La Jolla, CA, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20120206. Correction Date: 20141103. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Educational Programs; Human Females; Neoplasms. Minor Descriptor: Blacks; Clinical Trials; Latinos/Latinas. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. References Available: Y. Page Count: 4. Issue Publication Date: Jun, 2010. Publication History: First Posted Date: Feb 10, 2010. Copyright Statement: The Author(s). 2010. Sponsor: California Breast Cancer Research Program (CBCRP), US. Grant: 13AB-3500. Recipients: No recipient indicated Sponsor: National Institutes of Health, US. Grant: 5P30CA023100; 5R25CA65745; U56CA92079; U56CA92081; 1U54CA132379; 1U54CA132384. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Center on Minority Health and Health Disparities, US. Grant: 5P60MD000220. Recipients: No recipient indicated PY - 2010 SN - 0885-8195 1543-0154 SP - 142-145 ST - Adapting a program to inform African American and Hispanic American women about cancer clinical trials T2 - Journal of Cancer Education TI - Adapting a program to inform African American and Hispanic American women about cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-25638-006&site=ehost-live&scope=site gsadler@ucsd.edu VL - 25 ID - 1777 ER - TY - JOUR AB - The dearth of evidence-based clinical trial education programs may contribute to the underrepresentation of African American and Hispanic American women in cancer research studies. This study used focus group-derived data from80women distributed among eight Spanish- and Englishlanguage focus groups. These data guided the researchers' adaptation and refinement of the National Cancer Institute's various clinical trials education programs into a program that was specifically focused on meeting the information needs of minority women and addressing the barriers to study participation that they perceived. A "sisterhood" theme was adopted and woven throughout the presentation. © The Author(s) 2010. AD - Moores UCSD Cancer Center, La Jolla CA, United States UCSD School of Medicine, Moores UCSD Cancer Center 0850, 3855 Health Sciences Drive, La Jolla CA 92093-0850, United States Department of Psychology, San Diego State University, San Diego CA, United States SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego CA, United States Vista Community Clinic, Vista, CA, United States Department of Psychology, Michigan State University, East Lansing MI, United States AU - Sadler, G. R. AU - Gonzalez, J. AU - Mumman, M. AU - Cullen, L. AU - LaHousse, S. F. AU - Malcarne, V. AU - Conde, V. AU - Riley, N. DB - Scopus DO - 10.1007/s13187-009-0032-y IS - 2 KW - African American Breast cancer Clinical trials Disparities Focus groups Hispanic American Latinas MeSH Recruitment M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2010 SP - 142-145 ST - Adapting a program to inform African American and hispanic American women about cancer clinical trials T2 - Journal of Cancer Education TI - Adapting a program to inform African American and hispanic American women about cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956643377&doi=10.1007%2fs13187-009-0032-y&partnerID=40&md5=cd95048020359080c6639bf7d2138379 VL - 25 ID - 2497 ER - TY - JOUR AB - The dearth of evidence-based clinical trial education programs may contribute to the underrepresentation of African American and Hispanic American women in cancer research studies. This study used focus group-derived data from 80 women distributed among eight Spanish- and English-language focus groups. These data guided the researchers' adaptation and refinement of the National Cancer Institute's various clinical trials education programs into a program that was specifically focused on meeting the information needs of minority women and addressing the barriers to study participation that they perceived. A "sisterhood" theme was adopted and woven throughout the presentation. AN - WOS:000278180000006 AU - Sadler, G. R. AU - Gonzalez, J. AU - Mumman, M. AU - Cullen, L. AU - LaHousse, S. F. AU - Malcarne, V. AU - Conde, V. AU - Riley, N. DA - Jun DO - 10.1007/s13187-009-0032-y IS - 2 N1 - 20146043 PY - 2010 SN - 0885-8195 SP - 142-145 ST - Adapting a Program to Inform African American and Hispanic American Women About Cancer Clinical Trials T2 - Journal of Cancer Education TI - Adapting a Program to Inform African American and Hispanic American Women About Cancer Clinical Trials VL - 25 ID - 3112 ER - TY - JOUR AB - Background: Germline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4-5 times less likely to receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 % HER2+, and 17 % had triple-negative disease. Results: A total of seven different predicted deleterious mutations were identified, one newly described and the rest rare. In addition, four variants of unknown effect were found. Conclusions: Application of this strategy on a larger scale could lead to improved cancer care of minority and underserved populations. AD - M. Dean, Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD, United States AU - Dean, M. AU - Boland, J. AU - Yeager, M. AU - Im, K. M. AU - Garland, L. AU - Rodriguez-Herrera, M. AU - Perez, M. AU - Mitchell, J. AU - Roberson, D. AU - Jones, K. AU - Lee, H. J. AU - Eggebeen, R. AU - Sawitzke, J. AU - Bass, S. AU - Zhang, X. AU - Robles, V. AU - Hollis, C. AU - Barajas, C. AU - Rath, E. AU - Arentz, C. AU - Figueroa, J. A. AU - Nguyen, D. D. AU - Nahleh, Z. DB - Embase Medline DO - 10.1186/s13742-015-0088-z IS - 1 KW - BRCA1 protein BRCA2 protein DNA epidermal growth factor receptor 2 estrogen receptor progesterone receptor adult age distribution aged article breast cancer controlled study cost benefit analysis DNA determination DNA splicing genetic variability health disparity Hispanic human informed consent major clinical study population research priority journal questionnaire saliva analysis sequence analysis South and Central America triple negative breast cancer very elderly LA - English M3 - Article N1 - L611418002 2016-08-08 2016-08-17 PY - 2015 SN - 2047-217X ST - Addressing health disparities in Hispanic breast cancer: Accurate and inexpensive sequencing of BRCA1 and BRCA2 T2 - GigaScience TI - Addressing health disparities in Hispanic breast cancer: Accurate and inexpensive sequencing of BRCA1 and BRCA2 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611418002&from=export http://dx.doi.org/10.1186/s13742-015-0088-z VL - 4 ID - 1018 ER - TY - JOUR AB - Background: Germline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4-5 times less likely to receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 % HER2+, and 17 % had triple-negative disease. Results: A total of seven different predicted deleterious mutations were identified, one newly described and the rest rare. In addition, four variants of unknown effect were found. Conclusions: Application of this strategy on a larger scale could lead to improved cancer care of minority and underserved populations. AD - Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702, United States Cancer Genetics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, MD, United States Basic Science Program, Leidos Biomedical Research, Inc., Frederick, MD, United States Nueva Vida Richmond, Richmond, VA, United States Latino Community Development Agency, Oklahoma City, OK, United States Texas Tech University Health Sciences Center, El Paso, TX, United States Texas Tech University Health Sciences Center, Lubbock, TX, United States AU - Dean, M. AU - Boland, J. AU - Yeager, M. AU - Im, K. M. AU - Garland, L. AU - Rodriguez-Herrera, M. AU - Perez, M. AU - Mitchell, J. AU - Roberson, D. AU - Jones, K. AU - Lee, H. J. AU - Eggebeen, R. AU - Sawitzke, J. AU - Bass, S. AU - Zhang, X. AU - Robles, V. AU - Hollis, C. AU - Barajas, C. AU - Rath, E. AU - Arentz, C. AU - Figueroa, J. A. AU - Nguyen, D. D. AU - Nahleh, Z. C7 - 50 DB - Scopus DO - 10.1186/s13742-015-0088-z IS - 1 KW - Breast cancer Genetic testing Health disparity Hispanic populations Underserved populations M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 2015 ST - Addressing health disparities in Hispanic breast cancer: Accurate and inexpensive sequencing of BRCA1 and BRCA2 T2 - GigaScience TI - Addressing health disparities in Hispanic breast cancer: Accurate and inexpensive sequencing of BRCA1 and BRCA2 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979529739&doi=10.1186%2fs13742-015-0088-z&partnerID=40&md5=82bc0d5fadf817f616ed297754b4f252 VL - 4 ID - 2376 ER - TY - JOUR AB - Background: Germline mutations in the BRCA1 and BRCA2 genes account for 20-25 % of inherited breast cancers and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4-5 times less likely to receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2 coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject. Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 % HER2+, and 17 % had triple-negative disease. Results: A total of seven different predicted deleterious mutations were identified, one newly described and the rest rare. In addition, four variants of unknown effect were found. Conclusions: Application of this strategy on a larger scale could lead to improved cancer care of minority and underserved populations. AN - WOS:000365668700001 AU - Dean, M. AU - Boland, J. AU - Yeager, M. AU - Im, K. M. AU - Garland, L. AU - Rodriguez-Herrera, M. AU - Perez, M. AU - Mitchell, J. AU - Roberson, D. AU - Jones, K. AU - Lee, H. J. AU - Eggebeen, R. AU - Sawitzke, J. AU - Bass, S. AU - Zhang, X. J. AU - Robles, V. AU - Hollis, C. AU - Barajas, C. AU - Rath, E. AU - Arentz, C. AU - Figueroa, J. A. AU - Nguyen, D. D. AU - Nahleh, Z. DA - Nov DO - 10.1186/s13742-015-0088-z N1 - 50 26543556 PY - 2015 ST - Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2 T2 - Gigascience TI - Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2 VL - 4 ID - 2963 ER - TY - JOUR AB - Context: Few interventions exist to address patients' existential needs.Objectives: Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression.Methods: A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary-a validated measure of QOL at the end of life and secondary-Functional Assessment of Cancer Therapy-General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies-Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease.Results: Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively.Conclusion: Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. AD - Center for Health Services Research in Primary Care Durham VA Medical Center, Durham, North Carolina, USA Department of Medicine, Division of General Internal Medicine, Duke University, Durham, North Carolina, USA Palliative Care Section, Duke University, Durham, North Carolina, USA Center for the Study of Aging and Human Development, Duke University, Durham, North Carolina, USA Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA Dana Farber Cancer Institute, Boston, Massachusetts, USA Brigham and Women's Hospital, Boston, Massachusetts, USA Department of Cell Biology, New York University Medical Center, New York, New York, U.S.A AN - 126391957. Language: English. Entry Date: 20180706. Revision Date: 20190617. Publication Type: journal article AU - Stechuchak, Karen M. AU - Zervakis, Jennifer AU - Steinhauser, Karen E. AU - Olsen, Maren K. AU - Tulsky, James A. AU - Alexander, Stewart AU - Ammarell, Natalie AU - Byock, Ira DB - CINAHL Complete DO - 10.1016/j.jpainsymman.2017.06.003 DP - EBSCOhost IS - 6 KW - Critical Illness -- Psychosocial Factors Emotions Palliative Care -- Methods Philosophy Interviews Female Aged Prospective Studies Relaxation Techniques Anxiety Spirituality Human Male Quality of Life Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Clinical Assessment Tools Center for Epidemiological Studies Depression Scale Scales Psychological Tests N1 - research; randomized controlled trial. Journal Subset: Biomedical; Core Nursing; Nursing; Peer Reviewed; USA. Instrumentation: Functional Assessment of Cancer Therapy-General (FACT-G); Profile of Mood States (POMS); Center for Epidemiologic Studies Depression Scale (CES-D). NLM UID: 8605836. PMID: NLM28803082. PY - 2017 SN - 0885-3924 SP - 898-908 ST - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial T2 - Journal of Pain & Symptom Management TI - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126391957&site=ehost-live&scope=site VL - 54 ID - 1842 ER - TY - JOUR AB - Context Few interventions exist to address patients' existential needs. Objectives Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. Methods A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary—a validated measure of QOL at the end of life and secondary—Functional Assessment of Cancer Therapy—General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies—Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease. Results Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. Conclusion Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. AD - K.E. Steinhauser, VA and Duke Medical Center, 411 West Chapel Hill Street, Suite 500, Durham, NC, United States AU - Steinhauser, K. E. AU - Alexander, S. AU - Olsen, M. K. AU - Stechuchak, K. M. AU - Zervakis, J. AU - Ammarell, N. AU - Byock, I. AU - Tulsky, J. A. DB - Embase Medline DO - 10.1016/j.jpainsymman.2017.06.003 IS - 6 KW - advanced cancer aged anxiety article chronic obstructive lung disease congestive heart failure controlled study coping behavior depression emotion end stage liver disease end stage renal disease exploratory research female follow up general aspects of disease human interview major clinical study male malignant neoplasm marriage metastasis qualitative analysis quality of life randomized controlled trial social status wellbeing LA - English M3 - Article N1 - L619423163 2017-11-30 2018-07-10 PY - 2017 SN - 1873-6513 0885-3924 SP - 898-908 ST - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial T2 - Journal of Pain and Symptom Management TI - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619423163&from=export http://dx.doi.org/10.1016/j.jpainsymman.2017.06.003 VL - 54 ID - 922 ER - TY - JOUR AB - CONTEXT: Few interventions exist to address patients' existential needs. OBJECTIVES: Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. METHODS: A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary‐a validated measure of QOL at the end of life and secondary‐Functional Assessment of Cancer Therapy‐General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies‐Depression Scale), and spiritual well‐being (Functional Assessment of Chronic Illness Therapy‐Spiritual Well‐Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end‐stage renal disease, or end‐stage liver disease. RESULTS: Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. CONCLUSION: Outlook had an impact on social well‐being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. AN - CN-01431813 AU - Steinhauser, K. E. AU - Alexander, S. AU - Olsen, M. K. AU - Stechuchak, K. M. AU - Zervakis, J. AU - Ammarell, N. AU - Byock, I. AU - Tulsky, J. A. DO - 10.1016/j.jpainsymman.2017.06.003 IS - 6 KW - *quality of life *religion Adult Advanced cancer African American Aged Anxiety Chronic obstructive lung disease Congestive heart failure Controlled study Critical Illness [*psychology] Emotional stress Emotions End stage liver disease End stage renal disease Existentialism [*psychology] Exploratory research Female Follow‐Up Studies Functional assessment Hospice patient Human Humans Interview Interviews as Topic Leisure Major clinical study Male Married person Meditation Palliative Care [*methods] Profile of Mood States Quality of Life Randomized controlled trial Relaxation Therapy Spirituality Veteran Wellbeing M3 - Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2017 SP - 898‐908 ST - Addressing Patient Emotional and Existential Needs During Serious Illness: results of the Outlook Randomized Controlled Trial T2 - Journal of pain and symptom management TI - Addressing Patient Emotional and Existential Needs During Serious Illness: results of the Outlook Randomized Controlled Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01431813/full VL - 54 ID - 1561 ER - TY - JOUR AB - Context: Few interventions exist to address patients' existential needs. Objectives: Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. Methods: A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary—a validated measure of QOL at the end of life and secondary—Functional Assessment of Cancer Therapy—General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies—Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease. Results: Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. Conclusion: Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Steinhauser, Karen E., VA and Duke Medical Center, 411 West Chapel Hill Street, Suite 500, Durham, NC, US, 27701 AN - 2017-54233-018 AU - Steinhauser, Karen E. AU - Alexander, Stewart AU - Olsen, Maren K. AU - Stechuchak, Karen M. AU - Zervakis, Jennifer AU - Ammarell, Natalie AU - Byock, Ira AU - Tulsky, James A. DB - psyh DO - 10.1016/j.jpainsymman.2017.06.003 DP - EBSCOhost IS - 6 KW - Intervention spirituality quality of life Clinical Trials Psychological Needs N1 - Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, US. Release Date: 20180129. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Clinical Trials; Intervention; Psychological Needs; Quality of Life; Spirituality. Classification: Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Modified Brief Profile of Mood States; Functional Assessment of Cancer Therapy-General; Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being; Palliative Performance Scale DOI: 10.1037/t36806-000; Short Portable Mental Status Questionnaire DOI: 10.1037/t04145-000; Center for Epidemiological Studies Depression Scale DOI: 10.1037/t02942-000. Methodology: Clinical Trial; Empirical Study; Interview; Qualitative Study. Page Count: 11. Issue Publication Date: Dec, 2017. Publication History: Accepted Date: Jun 21, 2017. Copyright Statement: Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. 2017. Sponsor: US Department of Veterans Affairs, Office of Research and Development Health Services Research and Development Service, US. Grant: IIR 07-162. Recipients: No recipient indicated Sponsor: Durham VA Medical Center, Center of Innovation for Health Services Research in Primary Care, US. Grant: CIN-13-410. Recipients: No recipient indicated PY - 2017 SN - 0885-3924 1873-6513 SP - 898-908 ST - Addressing patient emotional and existential needs during serious illness: Results of the outlook randomized controlled trial T2 - Journal of Pain and Symptom Management TI - Addressing patient emotional and existential needs during serious illness: Results of the outlook randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-54233-018&site=ehost-live&scope=site karen.steinhauser@duke.edu VL - 54 ID - 1710 ER - TY - JOUR AB - Context Few interventions exist to address patients' existential needs. Objectives Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. Methods A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primary—a validated measure of QOL at the end of life and secondary—Functional Assessment of Cancer Therapy—General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies—Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease. Results Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. Conclusion Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. © 2017 AD - Center for Health Services Research in Primary Care Durham VA Medical Center, Durham, North Carolina, United States Department of Medicine, Division of General Internal Medicine, Duke University, Durham, North Carolina, United States Palliative Care Section, Duke University, Durham, North Carolina, United States School of Nursing, Duke University, Durham, North Carolina, United States Center for the Study of Aging and Human Development, Duke University, Durham, North Carolina, United States Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, United States College of Health and Human Sciences, Purdue University, West Lafayette, Indiana, United States Providence Institute for Human Caring, Torrance, California, United States Geisel School of Medicine, Dartmouth University, Hanover, New Hampshire, United States Dana Farber Cancer Institute, Boston, Massachusetts, United States Brigham and Women's Hospital, Boston, Massachusetts, United States AU - Steinhauser, K. E. AU - Alexander, S. AU - Olsen, M. K. AU - Stechuchak, K. M. AU - Zervakis, J. AU - Ammarell, N. AU - Byock, I. AU - Tulsky, J. A. DB - Scopus DO - 10.1016/j.jpainsymman.2017.06.003 IS - 6 KW - Intervention quality of life spirituality M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2017 SP - 898-908 ST - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial T2 - Journal of Pain and Symptom Management TI - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035004038&doi=10.1016%2fj.jpainsymman.2017.06.003&partnerID=40&md5=52d7055e758b6bd0b81264e8c88f52b9 VL - 54 ID - 2299 ER - TY - JOUR AB - Context. Few interventions exist to address patients' existential needs. Objectives. Determine whether an intervention to address seriously ill patients' existential concerns improves preparation, completion (elements of quality of life [QOL] at end of life), and reduces anxiety and depression. Methods. A randomized controlled trial comparing outlook intervention, relaxation meditation (RM), and usual care (UC). Measures included primaryda validated measure of QOL at the end of life and secondary-Functional Assessment of Cancer Therapy-General, anxiety (Profile of Mood States), depression (Center for Epidemiological Studies-Depression Scale), and spiritual well-being (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being). Qualitative interviews assessed outlook intervention acceptability. Enrolled patients were nonhospice eligible veterans with advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, end-stage renal disease, or end-stage liver disease. Results. Patients (n = 221) were randomly assigned 1:1:1 to outlook, RM, and UC. Patients were 96% males, 46% with cancer, 58.4% married, and 43.9% of African American origin. Compared with UC, outlook participants had higher preparation (a validated measure of QOL at the end of life) (mean difference 1.1; 95% CI 0.2, 2.0; P = 0.02) and mean completion (1.6; 95% CI 0.05, 3.1; P = 0.04) at the first but not second postassessment. Compared with RM, outlook participants did not show significant differences over time. Exploratory analyses indicated that in subgroups with cancer and low sense of peace, outlook participants had improved preparation at first and not second postassessment, as compared with UC (mean difference 1.4; 95% CI 0.03, 2.7; P = 0.04) (mean difference = 1.8; 95% CI 0.3, 3.3; P = 0.02), respectively. Conclusion. Outlook had an impact on social well-being and preparation compared with UC. The lack of impact on anxiety and depression differs from previous results among hospice patients. Results suggest that outlook is not demonstratively effective in populations not experiencing existential or emotional distress. (C) 2017 Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. AN - WOS:000416262400016 AU - Steinhauser, K. E. AU - Alexander, S. AU - Olsen, M. K. AU - Stechuchak, K. M. AU - Zervakis, J. AU - Ammarell, N. AU - Byock, I. AU - Tulsky, J. A. DA - Dec DO - 10.1016/j.jpainsymman.2017.06.003 IS - 6 N1 - 28803082 PY - 2017 SN - 0885-3924 SP - 898-908 ST - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial T2 - Journal of Pain and Symptom Management TI - Addressing Patient Emotional and Existential Needs During Serious Illness: Results of the Outlook Randomized Controlled Trial VL - 54 ID - 2882 ER - TY - JOUR AB - Background: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. Methods: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e.g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40-75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. Results: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p<0.05) and lacking a regular provider (p<0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p<0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). Conclusions: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use. © 2009, Mary Ann Liebert, Inc. AD - C. R. Clark, Brigham and Women's Hospital, Division of General Medicine and Primary Care, Center for Community Health and Health Equity, 1620 Tremont Street, Boston, MA 02120 AU - Clark, C. R. AU - Baril, N. AU - Kunicki, M. AU - Johnson, N. AU - Soukup, J. AU - Ferguson, K. AU - Lipsitz, S. AU - Bigby, J. DB - Embase Medline DO - 10.1089/jwh.2008.0972 IS - 5 KW - adult African American aged article breast cancer cancer center cancer diagnosis cancer screening case manager cervical cancer coalition cohort analysis evaluation study female follow up hazard health care access health care personnel health program high risk patient housing human intervention study language longitudinal study major clinical study mammography methodology outpatient department patient care patient referral primary medical care priority journal proportional hazards model prospective study racial and ethnic approaches to community health social aspect traffic and transport uterine cervix cancer LA - English M3 - Article N1 - L355065591 2009-09-22 PY - 2009 SN - 1540-9996 SP - 677-690 ST - Addressing social determinants of health to improve access to early breast cancer detection: Results of the boston reach 2010 breast and cervical cancer coalition women's health demonstration project T2 - Journal of Women's Health TI - Addressing social determinants of health to improve access to early breast cancer detection: Results of the boston reach 2010 breast and cervical cancer coalition women's health demonstration project UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355065591&from=export http://dx.doi.org/10.1089/jwh.2008.0972 VL - 18 ID - 1193 ER - TY - JOUR AB - Background: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. Methods: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e.g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40–75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. Results: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p < 0.05) and lacking a regular provider (p < 0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p = 0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). Conclusions: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Clark, Cheryl R., Brigham and Women’s Hospital, Division of General Medicine and Primary Care, Center for Community Health and Health Equity, 1620 Tremont Street, Boston, MA, US, 02120 AN - 2009-08105-010 AU - Clark, Cheryl R. AU - Baril, Nashira AU - Kunicki, Marycarmen AU - Johnson, Natacha AU - Soukup, Jane AU - Ferguson, Kathleen AU - Lipsitz, Stuart AU - Bigby, JudyAnn DB - psyh DO - 10.1089/jwh.2008.0972 DP - EBSCOhost IS - 5 KW - case management intervention medical & social obstacles health access to early breast cancer detection Black females Adult African Continental Ancestry Group Aged Boston Breast Neoplasms Breast Self-Examination Cohort Studies Confidence Intervals Female Health Behavior Health Knowledge, Attitudes, Practice Health Promotion Humans Mammography Middle Aged Odds Ratio Prospective Studies Surveys and Questionnaires Women's Health Blacks Cancer Screening Diagnosis Health Care Utilization Case Management Sociocultural Factors N1 - Center for Community Health and Health Equity, Brigham and Women’s Hospital, Boston, MA, US. Institutional Authors: REACH 2010 Breast and Cervical Cancer Coalition. Release Date: 20100118. Correction Date: 20180412. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Biannual meeting of the Minority Women’s Health Summit, Aug, 2007, Washington, DC, US. Grant Information: Clark, Cheryl R. Conference Note: Excerpts of this paper were presented at the aforementioned conference. Major Descriptor: Blacks; Breast Neoplasms; Cancer Screening; Diagnosis; Health Care Utilization. Minor Descriptor: Case Management; Health; Sociocultural Factors. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Study Questionnaire; Women’s Health Questionnaire DOI: 10.1037/t64299-000. Methodology: Empirical Study; Longitudinal Study; Quantitative Study. References Available: Y. Page Count: 14. Issue Publication Date: May, 2009. Copyright Statement: Mary Ann Liebert, Inc. Sponsor: Centers for Disease Control and Prevention. Other Details: REACH 2010 grant. Recipients: No recipient indicated Sponsor: Center for Community Health and Health Equity. Recipients: Clark, Cheryl R. Sponsor: Sponsor name not included. Date: from 2006. Other Details: Miles and Eleanor Shore Minority Faculty Development Award. Recipients: Clark, Cheryl R. PY - 2009 SN - 1540-9996 1931-843X SP - 677-690 ST - Addressing social determinants of health to improve access to early breast cancer detection: Results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project T2 - Journal of Women's Health TI - Addressing social determinants of health to improve access to early breast cancer detection: Results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-08105-010&site=ehost-live&scope=site crclark@partners.org VL - 18 ID - 1758 ER - TY - JOUR AB - BACKGROUND: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. METHODS: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e.g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40-75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. RESULTS: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p < 0.05) and lacking a regular provider (p < 0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p = 0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). CONCLUSIONS: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use. AD - Center for Community Health and Health Equity, Brigham and Women's Hospital, Division of General Medicine and Primary Care, Center for Community Health and Health Equity, 1620 Tremont Street, Boston, MA 02120, USA. crclark@partners.org AN - 105542659. Corporate Author: REACH 2010 Breast and Cervical Cancer Coalition. Language: English. Entry Date: 20090710. Revision Date: 20200708. Publication Type: Journal Article AU - Clark, C. R. AU - Baril, N. AU - Kunicki, M. AU - Johnson, N. AU - Soukup, J. AU - Ferguson, K. AU - Lipsitz, S. AU - Bigby, J. DB - CINAHL Complete DO - 10.1089/jwh.2008.0972 DP - EBSCOhost IS - 5 KW - Cancer Screening Case Management -- Utilization Patient Compliance Socioeconomic Factors Women's Health Services -- Massachusetts Adult Aged Black Persons Breast Neoplasms -- Prevention and Control Chi Square Test Coalition Confidence Intervals Correlational Studies Cox Proportional Hazards Model Descriptive Statistics Fisher's Exact Test Funding Source Health Services Accessibility Housing Linear Regression Logistic Regression Mammography -- Utilization Massachusetts Middle Age Odds Ratio Outcomes Research Primary Health Care Prospective Studies Questionnaires Record Review Rescreening Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Women's Health Questionnaire (WHQ); Study Questionnaire (SQ). Grant Information: REACH 2010 grant from the CDC. NLM UID: 101159262. PMID: NLM19445616. PY - 2009 SN - 1540-9996 SP - 677-690 ST - Addressing social determinants of health to improve access to early breast cancer detection: results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project T2 - Journal of Women's Health (15409996) TI - Addressing social determinants of health to improve access to early breast cancer detection: results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105542659&site=ehost-live&scope=site VL - 18 ID - 1843 ER - TY - JOUR AB - Background: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. Methods: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e.g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40-75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. Results: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p<0.05) and lacking a regular provider (p<0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p<0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). Conclusions: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use. © 2009, Mary Ann Liebert, Inc. AD - Center for Community Health and Health Equity, Brigham and Women's Hospital, Boston, MA, United States Brigham and Women's-Faulkner Hospitalist Program, Brigham and Women's Hospital, Boston, MA, United States Division of General Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, United States Boston REACH 2010 Breast and Cervical Cancer Coalition, Boston, MA, United States Boston Public Health Commission, Boston, MA, United States Executive Office of Health and Human Services, Commonwealth of Massachusetts, Boston, MA, United States Brigham and Women's Hospital, Division of General Medicine and Primary Care, Center for Community Health and Health Equity, 1620 Tremont Street, Boston, MA 02120, United States AU - Clark, C. R. AU - Baril, N. AU - Kunicki, M. AU - Johnson, N. AU - Soukup, J. AU - Ferguson, K. AU - Lipsitz, S. AU - Bigby, J. DB - Scopus DO - 10.1089/jwh.2008.0972 IS - 5 M3 - Article N1 - Cited By :54 Export Date: 22 March 2021 PY - 2009 SP - 677-690 ST - Addressing social determinants of health to improve access to early breast cancer detection: Results of the boston reach 2010 breast and cervical cancer coalition women's health demonstration project T2 - Journal of Women's Health TI - Addressing social determinants of health to improve access to early breast cancer detection: Results of the boston reach 2010 breast and cervical cancer coalition women's health demonstration project UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-68349121468&doi=10.1089%2fjwh.2008.0972&partnerID=40&md5=4446ce27f5cb47a3784c42cb7e2981ee VL - 18 ID - 2525 ER - TY - JOUR AB - Background: The Boston Racial and Ethnic Approaches to Community Health (REACH) 2010 Breast and Cervical Cancer Coalition developed a case management intervention for women of African descent to identify and reduce medical and social obstacles to breast cancer screening and following up abnormal results. Methods: We targeted black women at high risk for inadequate cancer screening and follow-up as evidenced by a prior pattern of missed clinic appointments and frequent urgent care use. Case managers provided referrals to address patient-identified social concerns (e. g., transportation, housing, language barriers), as well as navigation to prompt screening and follow-up of abnormal tests. We recruited 437 black women aged 40-75, who received care at participating primary care sites. The study was conducted as a prospective cohort study rather than as a controlled trial and evaluated intervention effects on mammography uptake and longitudinal screening rates via logistic regression and timely follow-up of abnormal tests via Cox proportional hazards models. Results: A significant increase in screening uptake was found (OR 1.53, 95% CI 1.13-2.08). Housing concerns (p< 0.05) and lacking a regular provider (p< 0.01) predicted poor mammography uptake. Years of participation in the intervention increased odds of obtaining recommended screening by 20% (OR 1.20, 95% CI 1.02-1.40), but this effect was attenuated by covariates (p = 0.53). Timely follow-up for abnormal results was achieved by most women (85%) but could not be attributed to the intervention (HR 0.95, 95% CI 0.50-1.80). Conclusions: Case management was successful at promoting mammography screening uptake, although no change in longitudinal patterns was found. Housing concerns and lacking a regular provider should be addressed to promote mammography uptake. Future research should provide social assessment and address social obstacles in a randomized controlled setting to confirm the efficacy of social determinant approaches to improve mammography use. AN - WOS:000266100900012 AU - Clark, C. R. AU - Baril, N. AU - Kunicki, M. AU - Johnson, N. AU - Soukup, J. AU - Ferguson, K. AU - Lipsitz, S. AU - Bigby, J. DA - May DO - 10.1089/jwh.2008.0972 IS - 5 N1 - Biannual Meeting of the Minority Womens Health Summit AUG, 2007 Washington, DC 19445616 PY - 2009 SN - 1540-9996 SP - 677-690 ST - Addressing Social Determinants of Health to Improve Access to Early Breast Cancer Detection: Results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project T2 - Journal of Womens Health TI - Addressing Social Determinants of Health to Improve Access to Early Breast Cancer Detection: Results of the Boston REACH 2010 Breast and Cervical Cancer Coalition Women's Health Demonstration Project VL - 18 ID - 3151 ER - TY - JOUR AB - Background: Although African ancestry represents a significant risk factor for prostate cancer, few studies have investigated the significance of prostate cancer and relevance of previously defined genetic and epidemiological prostate cancer risk factors within Africa. We recently established the Southern African Prostate Cancer Study (SAPCS), a resource for epidemiological and genetic analysis of prostate cancer risk and outcomes in Black men from South Africa. Biased towards highly aggressive prostate cancer disease, this is the first reported data analysis. Methods: The SAPCS is an ongoing population-based study of Black men with or without prostate cancer. Pilot analysis was performed for the first 837 participants, 522 cases and 315 controls. We investigate 46 pre-defined prostate cancer risk alleles and up to 24 epidemiological measures including demographic, lifestyle and environmental factors, for power to predict disease status and to drive on-going SAPCS recruitment, sampling procedures and research direction. Results: Preliminary results suggest that no previously defined risk alleles significantly predict prostate cancer occurrence within the SAPCS. Furthermore, genetic risk profiles did not enhance the predictive power of prostate specific antigen (PSA) testing. Our study supports several lifestyle/environmental factors contributing to prostate cancer risk including a family history of cancer, diabetes, current sexual activity and erectile dysfunction, balding pattern, frequent aspirin usage and high PSA levels. Conclusions: Despite a clear increased prostate cancer risk associated with an African ancestry, experimental data is lacking within Africa. This pilot study is therefore a significant contribution to the field. While genetic risk factors (largely European-defined) show no evidence for disease prediction in the SAPCS, several epidemiological factors were associated with prostate cancer status. We call for improved study power by building on the SAPCS resource, further validation of associated factors in independent African-based resources, and genome-wide approaches to define African-specific risk alleles. AN - WOS:000329579100001 AU - Tindall, E. A. AU - Bornman, M. S. R. AU - van Zyl, S. AU - Segone, A. M. AU - Monare, L. R. AU - Venter, P. A. AU - Hayes, V. M. DA - Dec DO - 10.1186/1471-2490-13-74 N1 - 74 24373635 PY - 2013 SN - 1471-2490 ST - Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa T2 - Bmc Urology TI - Addressing the contribution of previously described genetic and epidemiological risk factors associated with increased prostate cancer risk and aggressive disease within men from South Africa VL - 13 ID - 3029 ER - TY - JOUR AB - PURPOSE: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study's purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS. METHODS: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student's t test and χ2 tests were used to compare participant characteristics by median adherence scores. RESULTS: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels. IMPLICATIONS FOR CANCER SURVIVORS: The present study extends the literature on AABCS adherence to cancer survivor-specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. AU - Springfield, S. AU - Odoms-Young, A. AU - Tussing-Humphreys, L. AU - Freels, S. AU - Stolley, M. DB - Medline DO - 10.1007/s11764-019-00748-y IS - 2 KW - adult African American article body mass body weight loss breast cancer cancer survival cancer survivor chi square test controlled study dietary compliance dietary intake education female food frequency questionnaire fruit human intervention study legume lifestyle non profit organization obesity processed meat randomized controlled trial statistics student whole grain alcohol carbohydrate LA - English M3 - Article N1 - L627414194 2019-05-14 PY - 2019 SN - 1932-2267 SP - 257-268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of cancer survivorship : research and practice TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627414194&from=export http://dx.doi.org/10.1007/s11764-019-00748-y VL - 13 ID - 853 ER - TY - JOUR AB - PURPOSE: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer‐specific lifestyle recommendations. The study's purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS. METHODS: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community‐based, 6‐month weight loss study, were assessed for socio‐demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student's t test and χ2 tests were used to compare participant characteristics by median adherence scores. RESULTS: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels. IMPLICATIONS FOR CANCER SURVIVORS: The present study extends the literature on AABCS adherence to cancer survivor‐specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. AN - CN-01942324 AU - Springfield, S. AU - Odoms-Young, A. AU - Tussing-Humphreys, L. AU - Freels, S. AU - Stolley, M. DO - 10.1007/s11764-019-00748-y IS - 2 KW - *African American *body weight loss *breast cancer *cancer survival *cancer survivor *dietary compliance *non profit organization *obesity Adult African Americans [*statistics & numerical data] Aged American Cancer Society Article Body mass Breast Neoplasms [complications, diet therapy, ethnology, *rehabilitation] Cancer Survivors [*statistics & numerical data] Chi square test Controlled study Diet Dietary intake Education Exercise Female Food frequency questionnaire Fruit Human Humans Intervention study Legume Life Style Lifestyle Middle Aged Nutrition Policy Overweight [complications, *diet therapy, ethnology] Patient Compliance [*statistics & numerical data] Processed meat Randomized controlled trial Risk Reduction Behavior Societies, Medical [standards] Statistics Student United States Weight Reduction Programs [standards] Whole grain M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2019 SP - 257‐268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of cancer survivorship TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01942324/full VL - 13 ID - 1367 ER - TY - JOUR AB - Purpose: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study’s purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS. Methods: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student’s t test and χ2 tests were used to compare participant characteristics by median adherence scores. Results: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels. Implications for Cancer Survivors: The present study extends the literature on AABCS adherence to cancer survivor–specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Springfield, Sparkle, Stanford Prevention Research Center, School of Medicine, Stanford University, 3300 Hillview Ave, Palo Alto, CA, US, 94304 AN - 2019-23733-010 AU - Springfield, Sparkle AU - Odoms-Young, Angela AU - Tussing-Humphreys, Lisa AU - Freels, Sally AU - Stolley, Melinda DB - psyh DO - 10.1007/s11764-019-00748-y DP - EBSCOhost IS - 2 KW - African American women breast cancer survivors racial-ethnic disparities diet quality dietary adherence African Americans Aged American Cancer Society Breast Neoplasms Cancer Survivors Diet Exercise Female Humans Life Style Middle Aged Nutrition Policy Overweight Patient Compliance Risk Reduction Behavior Societies, Medical United States Weight Reduction Programs Blacks Diets Treatment Compliance Eating Behavior Survivors N1 - Stanford Prevention Research Center, School of Medicine, Stanford University, Palo Alto, CA, US. Release Date: 20200924. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Tussing-Humphreys, Lisa. Major Descriptor: Blacks; Breast Neoplasms; Diets; Overweight; Treatment Compliance. Minor Descriptor: Eating Behavior; Survivors. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Modified Physical Activity Questionnaire; Food Frequency Questionnaire. Methodology: Clinical Trial; Empirical Study; Interview; Quantitative Study. Supplemental Data: Experimental Materials Internet; Tables and Figures Internet. Page Count: 12. Issue Publication Date: Apr 15, 2019. Publication History: First Posted Date: Apr 13, 2019; Accepted Date: Feb 27, 2019; First Submitted Date: Aug 21, 2018. Copyright Statement: Springer Science+Business Media, LLC, part of Springer Nature. 2019. Sponsor: Sponsor name not included. Grant: NCT02482506; R01CA116750. Other Details: Moving Forward, a Community-Based Randomized Weight Loss intervention trial. Recipients: No recipient indicated Sponsor: University of Illinois at Chicago, Cancer Education and Career Development Program, US. Grant: CA057699. Recipients: No recipient indicated Sponsor: National Heart, Lung, and Blood Institute, US. Grant: T32 HL007034. Other Details: Stanford University Prevention Research Center Cardiovascular Disease Prevention Training Program. Recipients: No recipient indicated Sponsor: American Cancer Society, US. Grant: 014-025-01-CNE. Other Details: Mentored Research Science Grant (MRSG). Recipients: Tussing-Humphreys, Lisa PY - 2019 SN - 1932-2259 1932-2267 SP - 257-268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of Cancer Survivorship TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-23733-010&site=ehost-live&scope=site mstolley@mcw.edu sallyf@uic.edu ltussing@uic.edu odmyoung@uic.edu sspring@stanford.edu VL - 13 ID - 1672 ER - TY - JOUR AB - Purpose: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study's purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS.Methods: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student's t test and χ2 tests were used to compare participant characteristics by median adherence scores.Results: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels.Implications For Cancer Survivors: The present study extends the literature on AABCS adherence to cancer survivor-specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. AD - Stanford Prevention Research Center, School of Medicine, Stanford University, 3300 Hillview Ave, 94304, Palo Alto, CA, USA Department of Kinesiology and Nutrition, 646 Applied Health Sciences Building, University of Illinois at Chicago, 1919 West Taylor Street MC 517, 60612, Chicago, IL, USA Division of Academic and Internal Medicine, College of Medicine, University of Illinois, Chicago, IL, USA University of Illinois Cancer Center, Chicago, IL, USA Institute for Health Research and Policy, 416 Westside Research Office Bldg., 1747 West Roosevelt Road, 60608, Chicago, IL, USA School of Public Health, University of Illinois at Chicago, 1603 W Taylor St, 60612, Chicago, IL, USA Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, 53226, Milwaukee, WI, USA AN - 136067657. Language: English. Entry Date: In Process. Revision Date: 20200415. Publication Type: journal article AU - Springfield, Sparkle AU - Odoms-Young, Angela AU - Tussing-Humphreys, Lisa AU - Freels, Sally AU - Stolley, Melinda DB - CINAHL Complete DO - 10.1007/s11764-019-00748-y DP - EBSCOhost IS - 2 KW - Black Persons -- Statistics and Numerical Data Breast Neoplasms -- Rehabilitation Obesity -- Diet Therapy Nutrition Policy Patient Compliance Breast Neoplasms -- Complications Obesity -- Complications Human Breast Neoplasms -- Diet Therapy Life Style Obesity -- Ethnology American Cancer Society Middle Age Aged Breast Neoplasms -- Ethnology Weight Reduction Programs -- Standards Exercise Behavior Diet Medical Organizations -- Standards Female United States Validation Studies Comparative Studies Evaluation Research Multicenter Studies Questionnaires N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Food Frequency Questionnaire (FFQ). Grant Information: T32 CA057699/CA/NCI NIH HHS/United States. NLM UID: 101307557. PMID: NLM30982113. PY - 2019 SN - 1932-2259 SP - 257-268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of Cancer Survivorship TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136067657&site=ehost-live&scope=site VL - 13 ID - 1844 ER - TY - JOUR AB - Purpose: The American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study’s purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS. Methods: Two hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student’s t test and χ2 tests were used to compare participant characteristics by median adherence scores. Results: The mean total ACS/AICR score was 12.7 ± 2.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels. Implications for Cancer Survivors: The present study extends the literature on AABCS adherence to cancer survivor–specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. AD - Stanford Prevention Research Center, School of Medicine, Stanford University, 3300 Hillview Ave, Palo Alto, CA 94304, United States Department of Kinesiology and Nutrition, 646 Applied Health Sciences Building, University of Illinois at Chicago, 1919 West Taylor Street MC 517, Chicago, IL 60612, United States Division of Academic and Internal Medicine, College of Medicine, University of Illinois, Chicago, IL, United States University of Illinois Cancer Center, Chicago, IL, United States Institute for Health Research and Policy, 416 Westside Research Office Bldg., 1747 West Roosevelt Road, Chicago, IL 60608, United States School of Public Health, University of Illinois at Chicago, 1603 W Taylor St, Chicago, IL 60612, United States Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, United States AU - Springfield, S. AU - Odoms-Young, A. AU - Tussing-Humphreys, L. AU - Freels, S. AU - Stolley, M. DB - Scopus DO - 10.1007/s11764-019-00748-y IS - 2 KW - African American women Breast cancer survivors Diet quality Dietary adherence Racial-ethnic disparities M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2019 SP - 257-268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of Cancer Survivorship TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064494797&doi=10.1007%2fs11764-019-00748-y&partnerID=40&md5=828c508774dbcc617021e272b272091d VL - 13 ID - 2233 ER - TY - JOUR AB - PurposeThe American Cancer Society (ACS) and the American Institute for Cancer Research (AICR) each created dietary and physical activity guidelines to improve cancer survivorship. Despite African American breast cancer survivors (AABCS) having the lowest survival rates of any racial or ethnic group, limited information exists on their adherence to cancer-specific lifestyle recommendations. The study's purpose was to measure adherence to ACS/AICR dietary recommendations in AABCS.MethodsTwo hundred ten AABCS enrolled in the Moving Forward intervention trial, a randomized, community-based, 6-month weight loss study, were assessed for socio-demographics, dietary intake (via food frequency questionnaire), and related health factors at baseline. We operationalized the dietary recommendations put forth by ACS/AICR and created component and total adherence index scores. Descriptive statistics were used to calculate the proportion of women who met recommendations. Student's t test and 2 tests were used to compare participant characteristics by median adherence scores.ResultsThe mean total ACS/AICR score was 12.72.5 out of 21 points (median, 13; range, 5 to 21). Over 90% were moderately or completely adherent to limiting alcohol and red & processed meat consumption, but the majority failed to meet the other recommendations to eat whole grains, legumes, fruits, vegetables, and avoid added sugars. Women with total scores below the median were younger, with higher BMI, had fewer years of education, and lower income levels.Implications for Cancer Survivors p id=Par4 The present study extends the literature on AABCS adherence to cancer survivor-specific dietary guidelines. Findings will inform future dietary lifestyle interventions in this population. AN - WOS:000465606400010 AU - Springfield, S. AU - Odoms-Young, A. AU - Tussing-Humphreys, L. AU - Freels, S. AU - Stolley, M. DA - Apr DO - 10.1007/s11764-019-00748-y IS - 2 N1 - 30982113 PY - 2019 SN - 1932-2259 SP - 257-268 ST - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors T2 - Journal of Cancer Survivorship TI - Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors VL - 13 ID - 2826 ER - TY - JOUR AB - Background: Despite evidence that several colorectal cancer (CRC) screening strategies can reduce CRC mortality, screening rates remain low. This study aimed to determine whether the approach by which screening is recommended influences adherence. Methods: We used a cluster randomization design with clinic time block as the unit of randomization. Persons at average risk for development of CRC in a racially/ethnically diverse urban setting were randomized to receive recommendation for screening by fecal occult blood testing (FOBT), colonoscopy, or their choice of FOBT or colonoscopy. The primary outcome was completion of CRC screening within 12 months after enrollment, defined as performance of colonoscopy, or 3 FOBT cards plus colonoscopy for any positive FOBT result. Secondary analyses evaluated sociodemographic factors associated with completion of screening. Results: A total of 997 participants were enrolled; 58% completed the CRC screening strategy they were assigned or chose. However, participants who were recommended colonoscopy completed screening at a significantly lower rate (38%) than participants who were recommended FOBT (67%) (P < .001) or given a choice between FOBT or colonoscopy (69%) (P < .001). Latinos and Asians (primarily Chinese) completed screening more often than African Americans. Moreover, non-white participants adhered more often to FOBT, while white participants adhered more often to colonoscopy. Conclusions: The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities. Significant variation in overall and strategy-specific adherence exists between racial/ethnic groups; however, this may be a proxy for health beliefs and/or language. These results suggest that patient preferences should be considered when making CRC screening recommendations. AN - WOS:000302555300007 AU - Inadomi, J. M. AU - Vijan, S. AU - Janz, N. K. AU - Fagerlin, A. AU - Thomas, J. P. AU - Lin, Y. H. V. AU - Munoz, R. AU - Lau, C. AU - Somsouk, M. AU - El-Nachef, N. AU - Hayward, R. A. DA - Apr IS - 7 N1 - 22493463 PY - 2012 SN - 0003-9926 SP - 575-582 ST - Adherence to Colorectal Cancer Screening A Randomized Clinical Trial of Competing Strategies T2 - Archives of Internal Medicine TI - Adherence to Colorectal Cancer Screening A Randomized Clinical Trial of Competing Strategies VL - 172 ID - 3072 ER - TY - JOUR AB - Background: Despite evidence that several colorectal cancer (CRC) screening strategies can reduce CRC mortality, screening rates remain low. This study aimed to determine whether the approach by which screening is recommended influences adherence. Methods: We used a cluster randomization design with clinic time block as the unit of randomization. Persons at average risk for development of CRC in a racially/ethnically diverse urban setting were randomized to receive recommendation for screening by fecal occult blood testing (FOBT), colonoscopy, or their choice of FOBT or colonoscopy. The primary outcome was completion of CRC screening within 12 months after enrollment, defined as performance of colonoscopy, or 3 FOBT cards plus colonoscopy for any positive FOBT result. Secondary analyses evaluated sociodemographic factors associated with completion of screening. Results: A total of 997 participants were enrolled; 58% completed the CRC screening strategy they were assigned or chose. However, participants who were recommended colonoscopy completed screening at a significantly lower rate (38%) than participants who were recommended FOBT (67%) (P<.001) or given a choice between FOBT or colonoscopy (69%) (P<.001). Latinos and Asians (primarily Chinese) completed screening more often than African Americans. Moreover, nonwhite participants adhered more often to FOBT, while white participants adhered more often to colonoscopy. Conclusions: The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities. Significant variation in overall and strategy-specific adherence exists between racial/ethnic groups; however, this may be a proxy for health beliefs and/or language. These results suggest that patient preferences should be considered when making CRC screening recommendations. Trial Registration: clinicaltrials.gov Identifier: NCT00705731. ©2012 American Medical Association. All rights reserved. AD - J.M. Inadomi, Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Box 356424, Seattle, WA 98195, United States AU - Inadomi, J. M. AU - Vijan, S. AU - Janz, N. K. AU - Fagerlin, A. AU - Thomas, J. P. AU - Lin, Y. V. AU - Munõz, R. AU - Lau, C. AU - Somsouk, M. AU - El-Nachef, N. AU - Hayward, R. A. DB - Embase Medline DO - 10.1001/archinternmed.2012.332 IS - 7 KW - NCT00705731 adult African American article cancer patient cancer risk cancer screening Chinese cluster analysis colonoscopy colorectal cancer controlled study demography ethnic difference female Hispanic human major clinical study male occult blood test outcome assessment priority journal randomization randomized controlled trial (topic) urban area LA - English M3 - Article N1 - L364616932 2012-04-20 2012-04-25 PY - 2012 SN - 0003-9926 1538-3679 SP - 575-582 ST - Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies T2 - Archives of Internal Medicine TI - Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364616932&from=export http://dx.doi.org/10.1001/archinternmed.2012.332 http://archinte.ama-assn.org/cgi/reprint/172/7/575 VL - 172 ID - 1121 ER - TY - JOUR AB - Background: Despite evidence that several colorectal cancer (CRC) screening strategies can reduce CRC mortality, screening rates remain low. This study aimed to determine whether the approach by which screening is recommended influences adherence. Methods: We used a cluster randomization design with clinic time block as the unit of randomization. Persons at average risk for development of CRC in a racially/ethnically diverse urban setting were randomized to receive recommendation for screening by fecal occult blood testing (FOBT), colonoscopy, or their choice of FOBT or colonoscopy. The primary outcome was completion of CRC screening within 12 months after enrollment, defined as performance of colonoscopy, or 3 FOBT cards plus colonoscopy for any positive FOBT result. Secondary analyses evaluated sociodemographic factors associated with completion of screening. Results: A total of 997 participants were enrolled; 58% completed the CRC screening strategy they were assigned or chose. However, participants who were recommended colonoscopy completed screening at a significantly lower rate (38%) than participants who were recommended FOBT (67%) (P<.001) or given a choice between FOBT or colonoscopy (69%) (P<.001). Latinos and Asians (primarily Chinese) completed screening more often than African Americans. Moreover, nonwhite participants adhered more often to FOBT, while white participants adhered more often to colonoscopy. Conclusions: The common practice of universally recommending colonoscopy may reduce adherence to CRC screening, especially among racial/ethnic minorities. Significant variation in overall and strategy-specific adherence exists between racial/ethnic groups; however, this may be a proxy for health beliefs and/or language. These results suggest that patient preferences should be considered when making CRC screening recommendations. Trial Registration: clinicaltrials.gov Identifier: NCT00705731. ©2012 American Medical Association. All rights reserved. AD - Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Box 356424, Seattle, WA 98195, United States GI Health Outcomes, Policy and Economics (HOPE) Research Program, Department of Medicine, University of California, San Francisco, CA, United States Division of Gastroenterology, San Francisco General Hospital, San Francisco, CA, United States Department of Veteran Affairs Ann Arbor, Health Services Research and Development Center of Excellence, Ann Arbor, MI, United States Department of Medicine, University of Michigan, Ann Arbor, MI, United States School of Public Health, University of Michigan, Ann Arbor, MI, United States AU - Inadomi, J. M. AU - Vijan, S. AU - Janz, N. K. AU - Fagerlin, A. AU - Thomas, J. P. AU - Lin, Y. V. AU - Munõz, R. AU - Lau, C. AU - Somsouk, M. AU - El-Nachef, N. AU - Hayward, R. A. DB - Scopus DO - 10.1001/archinternmed.2012.332 IS - 7 M3 - Article N1 - Cited By :331 Export Date: 22 March 2021 PY - 2012 SP - 575-582 ST - Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies T2 - Archives of Internal Medicine TI - Adherence to colorectal cancer screening: A randomized clinical trial of competing strategies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859717249&doi=10.1001%2farchinternmed.2012.332&partnerID=40&md5=88ca0fbc7a090d6b5422a9aafecb4409 VL - 172 ID - 2461 ER - TY - JOUR AB - The effect of adherence to the World Cancer Research Fund (WCRF) lifestyle recommendations on cancer aggressiveness is unknown. We examined associations between adherence to recommendations and risk of highly aggressive prostate cancer in research subjects enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). We examined associations between adherence to WCRF recommendations and risk of highly aggressive prostate cancer among 2212 newly diagnosed African Americans (AA) or Caucasian Americans (CA) aged 40-70 years in PCaP. Prostate cancer aggressiveness was based on Gleason scores, serum prostate-specific antigens, and TNM stage. Adherence to WCRF recommendations was based on point scores and odds ratios estimated. Results showed that adherence to recommendations was significantly and negatively associated with risk of a highly aggressive prostate cancer. Each additional point in the total adherence score corresponded to a 13% risk reduction. Total adherence score <4 predicted increased risk in both AA (OR = 1.36; 95% CI = 1.01-1.85) and CA (OR = 1.41; 95% CI = 1.01-1.98). Consumption of <500 g red meat per week or ≤125 total kcal/100 g solid food per day is a statistically significant protective factor in the overall cohort. Recommendations aimed at preventing all cancers also may reduce risk of highly aggressive prostate cancer. © 2013 Copyright Taylor and Francis Group, LLC. AD - L. Arab, David Geffen School of Medicine, University of California, 12-262 Factor Building, Box 951736, Los Angeles, CA 90095-1736, United States AU - Arab, L. AU - Su, J. AU - Steck, S. E. AU - Ang, A. AU - Fontham, E. T. H. AU - Bensen, J. T. AU - Mohler, J. L. DB - Embase Medline DO - 10.1080/01635581.2013.789540 IS - 5 KW - prostate specific antigen adult African American aged article cancer prevention cancer staging clinical assessment tool cohort analysis cross-sectional study European American food intake Gleason score human lifestyle modification major clinical study male patient compliance prediction prostate cancer red meat research subject risk factor risk reduction World Cancer Research Fund lifestyle recommendation LA - English M3 - Article N1 - L369375880 2013-07-30 2013-08-03 PY - 2013 SN - 0163-5581 1532-7914 SP - 633-643 ST - Adherence to World Cancer Research Fund/American institute for cancer research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans T2 - Nutrition and Cancer TI - Adherence to World Cancer Research Fund/American institute for cancer research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369375880&from=export http://dx.doi.org/10.1080/01635581.2013.789540 VL - 65 ID - 1075 ER - TY - JOUR AB - The effect of adherence to the World Cancer Research Fund (WCRF) lifestyle recommendations on cancer aggressiveness is unknown. We examined associations between adherence to recommendations and risk of highly aggressive prostate cancer in research subjects enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). We examined associations between adherence to WCRF recommendations and risk of highly aggressive prostate cancer among 2212 newly diagnosed African Americans (AA) or Caucasian Americans (CA) aged 40–70 years in PCaP. Prostate cancer aggressiveness was based on Gleason scores, serum prostate-specific antigens, and TNM stage. Adherence to WCRF recommendations was based on point scores and odds ratios estimated. Results showed that adherence to recommendations was significantly and negatively associated with risk of a highly aggressive prostate cancer. Each additional point in the total adherence score corresponded to a 13% risk reduction. Total adherence score <4 predicted increased risk in both AA (OR = 1.36; 95% CI = 1.01–1.85) and CA (OR = 1.41; 95% CI = 1.01–1.98). Consumption of <500 g red meat per week or ≤125 total kcal/100 g solid food per day is a statistically significant protective factor in the overall cohort. Recommendations aimed at preventing all cancers also may reduce risk of highly aggressive prostate cancer. AD - David Geffen School of Medicine , University of California , Los Angeles , California , USA National Cancer Institute, Division of Cancer Control and Population Sciences , Bethesda , Maryland , USA Department of Epidemiology and Biostatistics Statewide Cancer Prevention and Control Program , University of South Carolina , Columbia , South Carolina , USA Louisiana State University Health Sciences Center, School of Public Health , New Orleans , Louisiana , USA Department of Epidemiology, School of Public Health and Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill, School of Medicine , Chapel Hill , North Carolina , USA Lineberger Comprehensive Cancer Center , University of North Carolina at Chapel Hill, School of Medicine , Chapel Hill , North Carolina , USA; Roswell Park Cancer Institute , Buffalo , New York , USA; University of Buffalo School of Medicine and Biotechnology , Buffalo , New York , USA AN - 104194915. Language: English. Entry Date: 20130722. Revision Date: 20200708. Publication Type: Journal Article AU - Arab, Lenore AU - Su, Joseph AU - Steck, Susan E. AU - Ang, Alfonso AU - Fontham, Elizabeth T. H. AU - Bensen, Jeannette T. AU - Mohler, James L. DB - CINAHL Complete DO - 10.1080/01635581.2013.789540 DP - EBSCOhost IS - 5 KW - Practice Guidelines Medical Organizations Prostatic Neoplasms -- Prevention and Control Nutrition Africa Black Persons White Persons Race Factors Academic Medical Centers Life Style Changes Reports Patient Selection Consent Food Intake -- Evaluation Body Mass Index -- Evaluation Demography Male Data Analysis T-Tests Patient Compliance Middle Age Education Descriptive Statistics Smoking -- Evaluation Diet -- Evaluation Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Nutrition; Oncologic Care. NLM UID: 7905040. PMID: NLM23859030. PY - 2013 SN - 0163-5581 SP - 633-643 ST - Adherence to World Cancer Research Fund/American Institute for Cancer Research Lifestyle Recommendations Reduces Prostate Cancer Aggressiveness Among African and Caucasian Americans T2 - Nutrition & Cancer TI - Adherence to World Cancer Research Fund/American Institute for Cancer Research Lifestyle Recommendations Reduces Prostate Cancer Aggressiveness Among African and Caucasian Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104194915&site=ehost-live&scope=site VL - 65 ID - 1846 ER - TY - JOUR AB - The effect of adherence to the World Cancer Research Fund (WCRF) lifestyle recommendations on cancer aggressiveness is unknown. We examined associations between adherence to recommendations and risk of highly aggressive prostate cancer in research subjects enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). We examined associations between adherence to WCRF recommendations and risk of highly aggressive prostate cancer among 2212 newly diagnosed African Americans (AA) or Caucasian Americans (CA) aged 40-70 years in PCaP. Prostate cancer aggressiveness was based on Gleason scores, serum prostate-specific antigens, and TNM stage. Adherence to WCRF recommendations was based on point scores and odds ratios estimated. Results showed that adherence to recommendations was significantly and negatively associated with risk of a highly aggressive prostate cancer. Each additional point in the total adherence score corresponded to a 13% risk reduction. Total adherence score <4 predicted increased risk in both AA (OR = 1.36; 95% CI = 1.01-1.85) and CA (OR = 1.41; 95% CI = 1.01-1.98). Consumption of <500 g red meat per week or ≤125 total kcal/100 g solid food per day is a statistically significant protective factor in the overall cohort. Recommendations aimed at preventing all cancers also may reduce risk of highly aggressive prostate cancer. © 2013 Copyright Taylor and Francis Group, LLC. AD - David Geffen School of Medicine, University of California, 12-262 Factor Building, Box 951736, Los Angeles, CA 90095-1736, United States National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, MD, United States Department of Epidemiology and Biostatistics, Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, United States Louisiana State University Health Sciences Center, School of Public Health, New Orleans, Louisiana, United States Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC, United States Roswell Park Cancer Institute, Buffalo, NY, United States University of Buffalo, School of Medicine and Biotechnology, Buffalo, NY, United States AU - Arab, L. AU - Su, J. AU - Steck, S. E. AU - Ang, A. AU - Fontham, E. T. H. AU - Bensen, J. T. AU - Mohler, J. L. DB - Scopus DO - 10.1080/01635581.2013.789540 IS - 5 M3 - Article N1 - Cited By :27 Export Date: 22 March 2021 PY - 2013 SP - 633-643 ST - Adherence to World Cancer Research Fund/American institute for cancer research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans T2 - Nutrition and Cancer TI - Adherence to World Cancer Research Fund/American institute for cancer research lifestyle recommendations reduces prostate cancer aggressiveness among African and Caucasian Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880410200&doi=10.1080%2f01635581.2013.789540&partnerID=40&md5=31b31f9241e82f16452d0eb13f232f77 VL - 65 ID - 2430 ER - TY - JOUR AB - The effect of adherence to the World Cancer Research Fund (WCRF) lifestyle recommendations on cancer aggressiveness is unknown. We examined associations between adherence to recommendations and risk of highly aggressive prostate cancer in research subjects enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP). We examined associations between adherence to WCRF recommendations and risk of highly aggressive prostate cancer among 2212 newly diagnosed African Americans (AA) or Caucasian Americans (CA) aged 40-70years in PCaP. Prostate cancer aggressiveness was based on Gleason scores, serum prostate-specific antigens, and TNM stage. Adherence to WCRF recommendations was based on point scores and odds ratios estimated. Results showed that adherence to recommendations was significantly and negatively associated with risk of a highly aggressive prostate cancer. Each additional point in the total adherence score corresponded to a 13% risk reduction. Total adherence score <4 predicted increased risk in both AA (OR = 1.36; 95% CI = 1.01-1.85) and CA (OR = 1.41; 95% CI = 1.01-1.98). Consumption of <500g red meat per week or 125 total kcal/100g solid food per day is a statistically significant protective factor in the overall cohort. Recommendations aimed at preventing all cancers also may reduce risk of highly aggressive prostate cancer. AN - WOS:000321887700002 AU - Arab, L. AU - Su, J. AU - Steck, S. E. AU - Ang, A. AU - Fontham, E. T. H. AU - Bensen, J. T. AU - Mohler, J. L. DA - Jul DO - 10.1080/01635581.2013.789540 IS - 5 N1 - 23859030 PY - 2013 SN - 0163-5581 SP - 633-643 ST - Adherence to World Cancer Research Fund/American Institute for Cancer Research Lifestyle Recommendations Reduces Prostate Cancer Aggressiveness Among African and Caucasian Americans T2 - Nutrition and Cancer-an International Journal TI - Adherence to World Cancer Research Fund/American Institute for Cancer Research Lifestyle Recommendations Reduces Prostate Cancer Aggressiveness Among African and Caucasian Americans VL - 65 ID - 3039 ER - TY - JOUR AB - Objective We prospectively evaluated patients with completely resected uterine serous carcinoma (USC) treated with radiation "sandwiched" between carboplatin/paclitaxel (C/T). The primary objective was to determine the safety profile, and the secondary outcome was to evaluate progression-free and overall survival. Methods Surgically staged patients with completely resected USC were enrolled to receive 3 cycles of paclitaxel 175 mg/m2 and carboplatin (area under the curve, 6-7.5) every 21 days, followed by radiotherapy and an additional 3 cycles of T/C at area under the curve of 5-6 (6 cycles + radiotherapy). Toxicity was graded according to National Cancer Institute Common Toxicity Criteria, version 4.03. Kaplan-Meier and log-rank tests were used to compare survival probabilities. Results One hundred forty patients were enrolled, of which 132 were evaluable, completed at least 3 cycles of chemotherapy and radiation. One hundred seven (81%) completed 6 cycles of chemotherapy and radiation. Patients with early-stage (I/II) disease have survival probabilities of 0.96 and 0.81 at 2 and 5 years. Patients with stage I USC and lymphovascular invasion have considerably worse overall survival, with 2.7 times' higher risk of death than those without lymphovascular invasion. Patients with late-stage (III/IV) disease had overall survival probabilities of 0.64 and 0.18 at 2 and 5 years, which is far higher survival than what has been reported in single-modality trials. Interestingly, and different than what is reported in other studies, there is no difference in survival in African Americans versus whites/other races who were evaluable. Of the 779 cycles administered, 22% and 14% of cycles were associated with grades 3 and 4 hematologic toxicities, respectively. Grades 3 and 4 nonhematologic toxicities occurred in 6.9% of cycles. Conclusions The long-term follow-up in this study demonstrates that "sandwich" therapy is an efficacious, well-tolerated treatment approach with acceptable toxicities. Lymphovascular invasion (LVSI) is a significantly poor prognostic factor in stage I USC. Multimodal "sandwich" therapy should be considered in all USC patients who have undergone complete surgical resection and staging. © 2018 by IGCS and ESGO. AD - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Women's Health, Albert Einstein College of Medicine/Montefiore Medical Center, 1554 Northern Blvd, Manhasset, NY 11030, United States Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell, Long Island, NY, United States Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Allegheny Health Network, Pittsburgh, PA, United States Department of Epidemiology and Population Health, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States Division of Gynecologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States Department of Radiation Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, United States Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Women's Health, Rutgers New Jersey Medical School, Newark, NJ, United States AU - Frimer, M. AU - Miller, E. M. AU - Shankar, V. AU - Girda, E. AU - Mehta, K. AU - Smith, H. O. AU - Kuo, D. Y. S. AU - Goldberg, G. L. AU - Einstein, M. H. DB - Scopus DO - 10.1097/IGC.0000000000001359 IS - 9 M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2018 SP - 1781-1788 ST - Adjuvant Pelvic Radiation "sandwiched" between Paclitaxel/Carboplatin Chemotherapy in Women with Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial T2 - International Journal of Gynecological Cancer TI - Adjuvant Pelvic Radiation "sandwiched" between Paclitaxel/Carboplatin Chemotherapy in Women with Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055655774&doi=10.1097%2fIGC.0000000000001359&partnerID=40&md5=3a10bac9d790c4ab89f622a798f79155 VL - 28 ID - 2253 ER - TY - JOUR AB - BACKGROUND: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)-a community-based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. METHODS: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n = 16 CHAs in 8 churches) or web-based ("Technology"; n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church-level data, participant engagement in the workshops, and study staff observations of CHA performance. RESULTS: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL-226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05). CONCLUSIONS: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web-based methods to disseminate and implement evidence-based interventions in faith-based settings and other areas where community health educators work to eliminate health disparities. AU - Santos, S. L. AU - Tagai, E. K. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. AU - Wang, M. Q. AU - Holt, C. L. DB - Medline DO - 10.1186/s13012-017-0566-z IS - 1 KW - adult African American aged attitude to health cluster analysis controlled study female health education health promotion human male middle aged neoplasm procedures randomized controlled trial religion LA - English M3 - Article N1 - L619059131 2017-11-07 PY - 2017 SN - 1748-5908 SP - 36 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation science : IS TI - Adoption, reach, and implementation of a cancer education intervention in African American churches UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619059131&from=export http://dx.doi.org/10.1186/s13012-017-0566-z VL - 12 ID - 941 ER - TY - JOUR AB - BACKGROUND: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE‐AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)‐a community‐based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. METHODS: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n = 16 CHAs in 8 churches) or web‐based ("Technology"; n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church‐level data, participant engagement in the workshops, and study staff observations of CHA performance. RESULTS: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL‐226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05). CONCLUSIONS: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web‐based methods to disseminate and implement evidence‐based interventions in faith‐based settings and other areas where community health educators work to eliminate health disparities. AN - CN-01424461 AU - Santos, S. L. AU - Tagai, E. K. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. AU - Wang, M. Q. AU - Holt, C. L. DO - 10.1186/s13012-017-0566-z IS - 1 KW - Adult African Americans Aged Cluster Analysis Female Health Education [*methods] Health Knowledge, Attitudes, Practice Health Promotion [*methods] Humans Male Middle Aged Neoplasms [diagnosis, *prevention & control, *therapy] Religion and Medicine M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2017 SP - 36 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation science TI - Adoption, reach, and implementation of a cancer education intervention in African American churches UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01424461/full VL - 12 ID - 1356 ER - TY - JOUR AB - BACKGROUND: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE‐AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)‐a community‐based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. METHODS: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n=16 CHAs in 8 churches) or web‐based ("Technology"; n=14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church‐level data, participant engagement in the workshops, and study staff observations of CHA performance. RESULTS: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL‐226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p<.10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M=84 days) to complete the workshop series than churches in the Technology group (M=64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p>.05). CONCLUSIONS: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web‐based methods to disseminate and implement evidence‐based interventions in faith‐based settings and other areas where community health educators work to eliminate health disparities. AN - CN-01431178 AU - Santos, S. L. AU - Tagai, E. K. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. AU - Wang, M. Q. AU - Holt, C. L. DO - 10.1186/s13012-017-0566-z IS - 1 KW - *African American *procedures *religion Adult Aged Attitude to health Cluster analysis Controlled study Female Health education Health promotion Human Male Middle aged Neoplasms/di [Diagnosis] Neoplasms/pc [Prevention] Neoplasms/th [Therapy] Randomized controlled trial M3 - Article PY - 2017 SP - 36 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation science TI - Adoption, reach, and implementation of a cancer education intervention in African American churches UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01431178/full VL - 12 ID - 1478 ER - TY - JOUR AB - Background: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)-a community-based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system.Methods: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n = 16 CHAs in 8 churches) or web-based ("Technology"; n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church-level data, participant engagement in the workshops, and study staff observations of CHA performance.Results: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL-226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05).Conclusions: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web-based methods to disseminate and implement evidence-based interventions in faith-based settings and other areas where community health educators work to eliminate health disparities. AD - Department of Behavioral and Community Health, University of Maryland, School of Public Health, 4200 Valley Dr., 1101 E SPH Building 255, College Park, MD 20742, USA Scheirer Consulting, Princeton, NJ, USA Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Institute for Applied Environmental Health, University of Maryland, School of Public Health, College Park, MD, USA Community Ministry of Prince George's County, Upper Marlboro, MD, USA Department of Behavioral and Community Health, University of Maryland, School of Public Health, 4200 Valley Dr., 1101 E SPH Building 255, College Park, MD, 20742, USA AN - 121933057. Language: English. Entry Date: 20180723. Revision Date: 20180728. Publication Type: journal article AU - Santos, Sherie Lou Zara AU - Tagai, Erin K. AU - Scheirer, Mary Ann AU - Bowie, Janice AU - Haider, Muhiuddin AU - Slade, Jimmie AU - Min Qi, Wang AU - Holt, Cheryl L. AU - Wang, Min Qi DB - CINAHL Complete DO - 10.1186/s13012-017-0566-z DP - EBSCOhost KW - Health Education -- Methods Health Promotion -- Methods Neoplasms -- Therapy Neoplasms -- Prevention and Control Religion and Medicine Black Persons Female Male Neoplasms -- Diagnosis Attitude to Health Cluster Analysis Aged Adult Middle Age Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Funding Source N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; Health Services Administration; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: R01 CA147313/CA/NCI NIH HHS/United States. NLM UID: 101258411. PMID: NLM28292299. PY - 2017 SN - 1748-5908 SP - 1-11 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation Science TI - Adoption, reach, and implementation of a cancer education intervention in African American churches UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121933057&site=ehost-live&scope=site VL - 12 ID - 1847 ER - TY - JOUR AB - Background: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)-a community-based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. Methods: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional" n = 16 CHAs in 8 churches) or web-based ("Technology" n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church-level data, participant engagement in the workshops, and study staff observations of CHA performance. Results: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL-226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05). Conclusions: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web-based methods to disseminate and implement evidence-based interventions in faith-based settings and other areas where community health educators work to eliminate health disparities. © 2017 The Author(s). AD - University of Maryland, School of Public Health, Department of Behavioral and Community Health, 4200 Valley Dr., 1101 E SPH Building 255, College Park, MD 20742, United States Scheirer Consulting, Princeton, NJ, United States Johns Hopkins Bloomberg School of Public Health, Department of Health, Behavior and Society, Baltimore, MD, United States University of Maryland, School of Public Health, Institute for Applied Environmental Health, College Park, MD, United States Community Ministry of Prince George's County, Upper Marlboro, MD, United States AU - Santos, S. L. Z. AU - Tagai, E. K. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. AU - Wang, M. Q. AU - Holt, C. L. C7 - 36 DB - Scopus DO - 10.1186/s13012-017-0566-z IS - 1 M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2017 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation Science TI - Adoption, reach, and implementation of a cancer education intervention in African American churches UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015668802&doi=10.1186%2fs13012-017-0566-z&partnerID=40&md5=431968dadc2cb9489339cc42457b9e19 VL - 12 ID - 2314 ER - TY - JOUR AB - Background: Use of technology is increasing in health promotion and has continued growth potential in intervention research. Guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, this paper reports on the adoption, reach, and implementation of Project HEAL (Health through Early Awareness and Learning)-a community-based implementation trial of a cancer educational intervention in 14 African American churches. We compare adoption, reach, and implementation at the organizational and participant level for churches in which lay peer community health advisors (CHAs) were trained using traditional classroom didactic methods compared with a new online system. Methods: Fifteen churches were randomized to one of two study groups in which two CHAs per church were trained through either classroom ("Traditional"; n = 16 CHAs in 8 churches) or web-based ("Technology"; n = 14 CHAs in 7 churches) training methods. Once trained and certified, all CHAs conducted a series of three group educational workshops in their churches on cancer early detection (breast, prostate, and colorectal). Adoption, reach, and implementation were assessed using multiple data sources including church-level data, participant engagement in the workshops, and study staff observations of CHA performance. Results: The project had a 41% overall adoption rate at the church level. In terms of reach, a total of 375 participants enrolled in Project HEAL-226 participants in the Traditional group (43% reach) and 149 in the Technology group (21% reach; p < .10). Implementation was evaluated in terms of adherence, dosage, and quality. All churches fully completed the three workshops; however, the Traditional churches took somewhat longer (M = 84 days) to complete the workshop series than churches in the Technology group (M = 64 days). Other implementation outcomes were comparable between both the Traditional and Technology groups (p > .05). Conclusions: Overall, the Project HEAL intervention had reasonable adoption, though reach could have been better. Implementation was strong across both study groups, suggesting the promise of using web-based methods to disseminate and implement evidence-based interventions in faith-based settings and other areas where community health educators work to eliminate health disparities. AN - WOS:000396611300002 AU - Santos, S. L. Z. AU - Tagai, E. K. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. AU - Wang, M. Q. AU - Holt, C. L. DA - Mar DO - 10.1186/s13012-017-0566-z N1 - 36 28292299 PY - 2017 SN - 1748-5908 ST - Adoption, reach, and implementation of a cancer education intervention in African American churches T2 - Implementation Science TI - Adoption, reach, and implementation of a cancer education intervention in African American churches VL - 12 ID - 2902 ER - TY - JOUR AD - L. Kendrick, Loma Linda University, School of Nursing, West Hall Room 1149, Loma Linda, CA 92350, United States AU - Kendrick, L. AU - Montgomery, S. AU - Ouattara, D. DB - Medline DO - 10.1080/01612840902754669 IS - 5 KW - adult African American article attitude to health genetic predisposition genetics human male mass screening nursing patient participation practice guideline prostate tumor psychological aspect self concept LA - English M3 - Article N1 - L355052579 2009-09-03 PY - 2009 SN - 0161-2840 1096-4673 SP - 342-343 ST - African American men and self-efficacy in preventing prostate cancer T2 - Issues in Mental Health Nursing TI - African American men and self-efficacy in preventing prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355052579&from=export http://dx.doi.org/10.1080/01612840902754669 VL - 30 ID - 1192 ER - TY - JOUR AB - While African Americans are at a significantly higher risk for developing certain cancers, they also have low rates of participation in cancer research, particularly clinical trials. This study assessed both African American men's and African American women's (1) knowledge of and participation in cancer-related clinical research and (2) barriers to and motivations for participating in clinical research. Data were collected from a total of 81 participants. Phase I of this research consisted of qualitative focus groups (all 81 participants). Phase II included quantitative pre/post survey data from an education program (56 participants). Findings from the study revealed that African American men and women had poor knowledge about clinical trials and the informed consent process, limited experience in participating in clinical trials, and they feared and mistrusted cancer research. Participants identified incentives, assurance of safety, knowledge and awareness, and benefiting others as motivators to participate in clinical trials research. AN - WOS:000326904800031 AU - Owens, O. L. AU - Jackson, D. D. AU - Thomas, T. L. AU - Friedman, D. B. AU - Hebert, J. R. DA - Nov IS - 4 N1 - 24185170 PY - 2013 SN - 1049-2089 SP - 1784-1800 ST - African American Men's and Women's Perceptions of Clinical Trials Research: Focusing on Prostate Cancer among a High-Risk Population in the South T2 - Journal of Health Care for the Poor and Underserved TI - African American Men's and Women's Perceptions of Clinical Trials Research: Focusing on Prostate Cancer among a High-Risk Population in the South VL - 24 ID - 3031 ER - TY - JOUR AB - Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States. African American (AA) men have greater prostate cancer burden than other men. Little is known about AA primary care physicians' (PCPs) practices regarding prostate cancer screening. We analyzed data from the 2007-2008 National Survey of Primary Care Physicians' Practices Regarding Prostate Cancer Screening. The current study included 604 AA PCPs. Outcomes assessed were (a) offering screening using the prostate-specific antigen (PSA) test, (b) use of screening discussions to involve patients in the decision to screen, and (c) having a discussion policy to try to talk the patient into getting the screening tests. Most AA PCPs were male (52%), younger than 50 years (61%), and had 21% to 100% AA patients in their practices (74%). The majority (94%) of AA PCPs offered prostate cancer screening using PSA, discussed the tests with their male patients to involve them in the decision to screen (83%), and had a policy to try to talk the patient into getting the screening tests (77%). Multivariate analysis showed that offering screening, use of discussions, and a usual policy to encourage taking the screening tests varied mainly by practice-related factors, including practice type, practice location, and percentage of AA patients in the practice. Data from this study indicate that most AA PCPs reported high proscreening behaviors for all 3 outcomes. Additionally, practice- and screening-related factors may be important when examining AA PCP screening behaviors. AD - L.E. Ross AU - Ross, L. E. AU - Hall, I. J. DB - Medline DO - 10.1177/2150131913507454 IS - 1 KW - prostate specific antigen adult African American African American primary care physicians article clinical practice decision making doctor patient relationship female general practice human male mass screening methodology middle aged multivariate analysis patient participation patient referral physician practices prostate cancer prostate tumor screening statistics United States LA - English M3 - Article N1 - L373949673 2014-10-02 PY - 2014 SN - 2150-1327 SP - 36-43 ST - African american primary care physicians' prostate cancer screening practices T2 - Journal of primary care & community health TI - African american primary care physicians' prostate cancer screening practices UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373949673&from=export http://dx.doi.org/10.1177/2150131913507454 VL - 5 ID - 1047 ER - TY - JOUR AB - Objective: To examine African-American prostate cancer (PCa) survivors' involvement in treatment decision-making (TDM), and examine the association between TDM and quality of life (QOL), using secondary data. Methods: African-American PCa survivors (181) were recruited from the North Carolina Central Cancer Registry. Participants completed a cross-sectional survey that asked about their chosen cancer treatment, TDM factors, and PCa-specific QOL (using the Expanded Prostate Cancer Index Composite - EPIC). Multivariate analysis of covariance was conducted to determine the association between TDM and QOL, controlling for confounders. Results: Most men reported being active (44.2%) or collaborative (38.1%) in TDM, while 14.4% preferred a passive role. Adjusting for marital status, education and treatment, passive patients reported somewhat better QOL compared to active patients in the following QOL domains: urinary summary (p=0.04), urinary function (p=0.01), and urinary incontinence (p=0.03). Conclusion: Most African-American PCa survivors preferred to be, and were, actively or collaboratively involved in TDM. However, those who preferred a passive role reported better PCa-specific QOL for the urinary domain compared to others. Practice implications: It is important to assess patients' TDM preference. Patients' QOL may differ by their TDM role, such that active patients may be more bothered by treatment side effects than other patients. © 2012 Elsevier Ireland Ltd. AD - N.R.A. Palmer, Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States AU - Palmer, N. R. A. AU - Tooze, J. A. AU - Turner, A. R. AU - Xu, J. AU - Avis, N. E. DB - Embase Medline DO - 10.1016/j.pec.2012.08.007 IS - 1 KW - adult African American aged article cancer survivor Expanded Prostate Cancer Index Composite human major clinical study male medical decision making patient decision making patient participation patient preference priority journal prostate cancer quality of life questionnaire self report United States LA - English M3 - Article N1 - L52188063 2012-09-07 2012-12-25 PY - 2013 SN - 0738-3991 1873-5134 SP - 61-68 ST - African American prostate cancer survivors' treatment decision-making and quality of life T2 - Patient Education and Counseling TI - African American prostate cancer survivors' treatment decision-making and quality of life UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52188063&from=export http://dx.doi.org/10.1016/j.pec.2012.08.007 VL - 90 ID - 1100 ER - TY - JOUR AB - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N = 71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging. AU - Ridley-Merriweather, K. E. AU - Head, K. J. DB - Medline DO - 10.1080/10410236.2016.1250191 IS - 12 KW - African American breast breast tumor donor ethnology female human Internet patient selection psychology qualitative research questionnaire LA - English M3 - Article N1 - L623254034 2018-08-01 PY - 2017 SN - 1532-7027 SP - 1571-1580 ST - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment T2 - Health communication TI - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623254034&from=export http://dx.doi.org/10.1080/10410236.2016.1250191 VL - 32 ID - 926 ER - TY - JOUR AB - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N = 71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging. AD - Susan G. Komen® Tissue Bank at the IU Simon Cancer Center (Indianapolis) Department of Communication Studies, Indiana University–Purdue University Indianapolis AN - 125429005. Language: English. Entry Date: 20171004. Revision Date: 20190527. Publication Type: Article AU - Ridley-Merriweather, Katherine E. AU - Head, Katharine J. DB - CINAHL Complete DO - 10.1080/10410236.2016.1250191 DP - EBSCOhost IS - 12 KW - Black Persons Consumer Attitudes Breast Neoplasms -- Prevention and Control Living Donors Human Female Models, Theoretical Questionnaires World Wide Web Race Factors Research, Medical Data Analysis Software Coding Constant Comparative Method Qualitative Studies Thematic Analysis Accountability N1 - research; tables/charts. Journal Subset: Blind Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Special Interest: Oncologic Care; Women's Health. NLM UID: 8908762. PY - 2017 SN - 1041-0236 SP - 1571-1580 ST - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment T2 - Health Communication TI - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=125429005&site=ehost-live&scope=site VL - 32 ID - 1850 ER - TY - JOUR AB - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N=71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging. AN - WOS:000413794300013 AU - Ridley-Merriweather, K. E. AU - Head, K. J. DO - 10.1080/10410236.2016.1250191 IS - 12 N1 - 27911088 PY - 2017 SN - 1041-0236 SP - 1571-1580 ST - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment T2 - Health Communication TI - African American Women's Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment VL - 32 ID - 2916 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To explore African American women's recollected experiences of breast cancer treatment.
. RESEARCH APPROACH: Qualitative description and narrative analysis.
. SETTING: South Carolina Oncology Associates, an outpatient oncology clinic serving rural and urban populations.
. PARTICIPANTS: 16 African American women with breast cancer previously enrolled in the control arm (n = 93) of a completed randomized, controlled trial. 
. METHODOLOGIC APPROACH: Feminist narrative analysis of in-depth individual interviews.
. FINDINGS: The authors identified three themes within the African American breast cancer survivors' recollected experiences of treatment adherence. INTERPRETATION: Although little evidence was presented of shared decision making with providers, patients were committed to completing the prescribed therapies. The narratives highlighted the value of in-depth examination of patients' perspectives, particularly among minority and underserved groups. With the exception of voicing personal choice of surgical treatment, the women trusted providers' recommendations with a resolve to "just do it." Although trust may enhance treatment adherence, it may also reflect power differentials based on gender, race, education, and culture.
. IMPLICATIONS FOR NURSING: Nurses should listen to patients describe their experience with cancer treatment and compare the themes from this study with their patients' story. This comparison will help nurses support patients through various aspect of diagnosis and treatment. AU - Heiney, S. P. AU - Hilfinger Messias, D. K. AU - Felder, T. M. AU - Phelps, K. W. AU - Quinn, J. C. DB - Medline DO - 10.1188/17.ONF.217-224 IS - 2 KW - adult African American aged attitude to health breast tumor cancer survivor ethnology female human middle aged patient compliance psychology rural population South Carolina urban population very elderly LA - English M3 - Article N1 - L620112335 2018-01-11 PY - 2017 SN - 1538-0688 SP - 217-224 ST - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment T2 - Oncology nursing forum TI - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620112335&from=export http://dx.doi.org/10.1188/17.ONF.217-224 VL - 44 ID - 944 ER - TY - JOUR AN - CN-02111825 AU - Heiney, S. P. AU - Messias, D. K. H. AU - Felder, T. M. AU - Phelps, K. W. AU - Quinn, J. C. DO - 10.1188/17.ONF.217-224 IS - 2 KW - Adult Aged Blacks Breast Neoplasms Cancer Patients Decision Making Descriptive Research Evaluation Female Feminist Critique Field Notes Funding Source Human Interview Guides Middle Age Multidisciplinary Care Team Narratives Patient Attitudes Patient Compliance Professional‐Patient Relations Qualitative Studies Research Subject Recruitment Rural Population Semi‐Structured Interview South Carolina Survivors Thematic Analysis Therapy Trust United States Urban Population M3 - Academic Journal PY - 2017 SP - 217‐224 ST - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment T2 - Oncology nursing forum TI - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02111825/full VL - 44 ID - 1385 ER - TY - JOUR AB - Purpose/Objectives: To explore African American women's recollected experiences of breast cancer treatment. Research Approach: Qualitative description and narrative analysis. Setting: South Carolina Oncology Associates, an outpatient oncology clinic serving rural and urban populations. Participants: 16 African American women with breast cancer previously enrolled in the control arm (n = 93) of a completed randomized, controlled trial. Methodologic Approach: Feminist narrative analysis of in-depth individual interviews. Findings: The authors identified three themes within the African American breast cancer survivors' recollected experiences of treatment adherence: Embarking With Trust, Moving on Down the Road, and Being Actively Involved in Decision Making. Interpretation: Although little evidence was presented of shared decision making with providers, patients were committed to completing the prescribed therapies. The narratives highlighted the value of in-depth examination of patients' perspectives, particularly among minority and underserved groups. With the exception of voicing personal choice of surgical treatment, the women trusted providers' recommendations with a resolve to "just do it." Although trust may enhance treatment adherence, it may also reflect power differentials based on gender, race, education, and culture. Implications for Nursing: Nurses should listen to patients describe their experience with cancer treatment and compare the themes from this study with their patients' story. This comparison will help nurses support patients through various aspect of diagnosis and treatment. AD - Dunn-Shealy professor of nursing in the College of Nursing at the University of South Carolina Professor in the College of Nursing at the University of South Carolina Assistant professor in the College of Nursing at the University of South Carolina Associate clinical professor in the School of Medicine at the University of South Carolina Assistant professor and the program director of graduate nursing in the College of Nursing and Public Health at South University, Columbia, SC AN - 121384451. Language: English. Entry Date: 20170227. Revision Date: 20191121. Publication Type: Article AU - Heiney, Sue P. AU - Messias, DeAnne K. Hilfinger AU - Felder, Tisha M. AU - Phelps, Kenneth W. AU - Quinn, Jada C. DB - CINAHL Complete DO - 10.1188/17.ONF.217-224 DP - EBSCOhost IS - 2 KW - Black Persons -- United States Cancer Patients Patient Compliance Breast Neoplasms -- Therapy Qualitative Studies Narratives -- Evaluation Decision Making Feminist Critique Human Semi-Structured Interview Thematic Analysis Trust Rural Population South Carolina Survivors Professional-Patient Relations Urban Population Interview Guides United States Descriptive Research Patient Attitudes -- Evaluation Multidisciplinary Care Team Research Subject Recruitment Female Adult Middle Age Aged Field Notes Funding Source N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: ONSFoundation. NLM UID: 7809033. PY - 2017 SN - 0190-535X SP - 217-224 ST - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment T2 - Oncology Nursing Forum TI - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121384451&site=ehost-live&scope=site VL - 44 ID - 1851 ER - TY - JOUR AB - Purpose/Objectives: To explore African American women's recollected experiences of breast cancer treatment. Research Approach: Qualitative description and narrative analysis. Setting: South Carolina Oncology Associates, an outpatient oncology clinic serving rural and urban populations. Participants: 16 African American women with breast cancer previously enrolled in the control arm (n = 93) of a completed randomized, controlled trial. Methodologic Approach: Feminist narrative analysis of in-depth individual interviews. Findings: The authors identified three themes within the African American breast cancer survivors' recollected experiences of treatment adherence: Embarking With Trust, Moving on Down the Road, and Being Actively Involved in Decision Making. Interpretation: Although little evidence was presented of shared decision making with providers, patients were committed to completing the prescribed therapies. The narratives highlighted the value of in-depth examination of patients' perspectives, particularly among minority and underserved groups. With the exception of voicing personal choice of surgical treatment, the women trusted providers' recommendations with a resolve to "just do it." Although trust may enhance treatment adherence, it may also reflect power differentials based on gender, race, education, and culture. Implications for Nursing: Nurses should listen to patients describe their experience with cancer treatment and compare the themes from this study with their patients' story. This comparison will help nurses support patients through various aspect of diagnosis and treatment. Copyright 2017 by the Oncology Nursing Society. AD - School of Medicine, University of South Carolina, College of Nursing and Public Health, South University, Columbia, SC, United States AU - Heiney, S. P. AU - Messias, D. K. H. AU - Felder, T. M. AU - Phelps, K. W. AU - Quinn, J. C. DB - Scopus DO - 10.1188/17.ONF.217-224 IS - 2 KW - African American Breast cancer Survivorship Treatment adherence Treatment decision making M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2017 SP - 217-224 ST - African American women's recollected experiences of adherence to breast cancer treatment T2 - Oncology Nursing Forum TI - African American women's recollected experiences of adherence to breast cancer treatment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013884542&doi=10.1188%2f17.ONF.217-224&partnerID=40&md5=0ef0f0f31c3da2463018b49bbbeadb20 VL - 44 ID - 2315 ER - TY - JOUR AB - Purpose/Objectives; To explore African American women's recollected experiences of breast cancer treatment. Research Approach: Qualitative description and narrative analysis. Setting: South Carolina Oncology Associates, an outpatient oncology clinic serving rural and urban populations. Participants: 16 African American women with breast cancer previously enrolled in the control arm (n = 93) of a completed randomized, controlled trial. Methodologic Approach: Feminist narrative analysis of in-depth individual interviews. Findings: The authors identified three themes within the African American breast cancer survivors recollected experiences of treatment adherence: Embarking With Trust, Moving on Down the Road, and Being Actively Involved in Decision Making. Interpretation: Although little evidence was presented of shared decision making with providers, patients were committed to completing the prescribed therapies. The narratives highlighted the value of in-depth examination of patients' perspectives, particularly among minority and underserved groups. With the exception of voicing personal choice of surgical treatment, the women trusted providers' recommendations with a resolve to "just do it." Although trust may enhance treatment adherence, it may also reflect power differentials based on gender, race, education, and culture. Implications for Nursing: Nurses should listen to patients describe their experience with cancer treatment and compare the themes from this study with their patients' story. This comparison will help nurses support patients through various aspect of diagnosis and treatment. AN - WOS:000401160800654 AU - Heiney, S. P. AU - Messias, D. K. H. AU - Felder, T. M. AU - Phelps, K. W. AU - Quinn, J. C. DA - Mar DO - 10.1188/17.ONF.217-224 IS - 2 N1 - 28222084 PY - 2017 SN - 0190-535X SP - 217-224 ST - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment T2 - Oncology Nursing Forum TI - African American Women's Recollected Experiences of Adherence to Breast Cancer Treatment VL - 44 ID - 2903 ER - TY - JOUR AB - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N = 71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Head, Katharine J., Department of Communication Studies, Indiana University–Purdue University Indianapolis, 307C Cavanuagh Hall, Indianapolis, IN, US, 46202 AN - 2017-48547-014 AU - Ridley-Merriweather, Katherine E. AU - Head, Katharine J. DB - psyh DO - 10.1080/10410236.2016.1250191 DP - EBSCOhost IS - 12 KW - tissue donation health promotion health care psychology N1 - Susan G. Komen® Tissue Bank, IU Simon Cancer Center, Indianapolis, IN, US. Other Publishers: Lawrence Erlbaum. Release Date: 20171116. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Health Care Psychology; Health Promotion; Tissue Donation. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. Page Count: 10. Issue Publication Date: Dec, 2017. Copyright Statement: Taylor & Francis Group, LLC. 2017. PY - 2017 SN - 1041-0236 1532-7027 SP - 1571-1580 ST - African American women’s perspectives on donating healthy breast tissue for research: Implications for recruitment T2 - Health Communication TI - African American women’s perspectives on donating healthy breast tissue for research: Implications for recruitment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-48547-014&site=ehost-live&scope=site headkj@iupui.edu VL - 32 ID - 1684 ER - TY - JOUR AB - African American women die of breast cancer at a higher rate than any other racial group. The Komen Tissue Bank (KTB) is an ongoing clinical trial that collects healthy breast tissue from women of all racial groups to use as controls in research and represents a critical tool in efforts to treat and prevent breast cancer; however, African Americans display reticence toward donating breast tissue to the KTB. Through the lens of the Integrated Behavioral Model, this study recruited African American women to share their perspectives on donating breast tissue for research purposes. Seventy-one (N = 71) eligible Black women who were previous tissue donors to the KTB responded to an online questionnaire. Findings revealed that (a) participants had positive instrumental attitudes or reasons for donating; (b) participants felt generally supported in their decision to donate, but revealed that the lack of Black women participating in the KTB meant that they themselves were setting the norm for others; and (c) their race was an important element in their donation decision. While acknowledging the negative history of African Americans in medical research, they offered their perceptions regarding the importance of involving themselves in medical research, and suggested that health communication strategies to recruit African Americans into research should embrace race as part of the message. The findings from this study have important implications for other those who work in applied clinical settings and are interested in addressing racial disparities in medical research through more effective and targeted recruitment messaging. © 2017 Taylor & Francis Group, LLC. AD - Susan G. Komen® Tissue Bank at the IU Simon Cancer Center (Indianapolis), United States Department of Communication Studies, Indiana University–Purdue University Indianapolis, United States AU - Ridley-Merriweather, K. E. AU - Head, K. J. DB - Scopus DO - 10.1080/10410236.2016.1250191 IS - 12 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2017 SP - 1571-1580 ST - African American Women’s Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment T2 - Health Communication TI - African American Women’s Perspectives on Donating Healthy Breast Tissue for Research: Implications for Recruitment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85001104581&doi=10.1080%2f10410236.2016.1250191&partnerID=40&md5=55eb35f25dab5079779a877187a2474f VL - 32 ID - 2294 ER - TY - JOUR AB - Purpose:To assess whether reactions to genetic explanations for disparities in lung cancer incidence among family members of African American patients with lung cancer are associated with willingness to participate in clinical genetics research. Methods: Data are reported for 67 self-identified African Americans aged 18 to 55 years who completed a telephone survey assessing reactions to explanations (i.e., genetics, toxin exposure, menthol cigarettes, and race-related stress) for lung cancer disparities. Majority were female (70%), current smokers (57%), and patients'biological relatives (70%). Results: Family members rated the four explanations similarly, each as believable, fair, and not too worrisome. Participants also indicated a high level of willingness to participate in genetics research (M = 4.1 ± 1.0; scale: 1-5). Endorsements of genetics explanations for disparities as believable and fair, and toxin exposure as believable were associated significantly with willingness to participate in genetics research. Conclusion: These results suggest that strategies to encourage African Americans'participation in genetics research would do well to inform potential participants of how their involvement might be used to better understand important environmental factors that affect health disparities. © 2010 Lippincott Williams & Wilkins. AD - D. B. White, Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, 31 Center Drive, Bldg 31, Bethesda, MD 20892-2073, United States AU - White, D. B. AU - Koehly, L. M. AU - Omogbehin, A. AU - McBride, C. M. DB - Embase Medline DO - 10.1097/GIM.0b013e3181e5e513 IS - 8 KW - adult African American article cancer incidence cigarette smoking clinical research environmental exposure female health care disparity human lung cancer major clinical study male patient attitude patient participation race difference LA - English M3 - Article N1 - L50983938 2010-07-13 2010-09-02 PY - 2010 SN - 1098-3600 SP - 496-502 ST - African Americans' responses to genetic explanations of lung cancer disparities and their willingness to participate in clinical genetics research T2 - Genetics in Medicine TI - African Americans' responses to genetic explanations of lung cancer disparities and their willingness to participate in clinical genetics research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50983938&from=export http://dx.doi.org/10.1097/GIM.0b013e3181e5e513 VL - 12 ID - 1160 ER - TY - JOUR AB - Background: Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors. Methods: AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed. Results: About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors. Conclusion: Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle. Implications for Cancer Survivors: Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Paxton, Raheem J., Department of Behavioral and Community Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, US, 76017 AN - 2014-05971-004 AU - Paxton, Raheem J. AU - Nayak, Pratibha AU - Taylor, Wendell C. AU - Chang, Shine AU - Courneya, Kerry S. AU - Schover, Leslie AU - Hodges, Kelly AU - Jones, Lovell A. DB - psyh DO - 10.1007/s11764-013-0307-5 DP - EBSCOhost IS - 1 KW - African-American women breast cancer survivors preferences physical activity intervention medical factors sociodemographic factors Adult African Americans Aged Breast Neoplasms CD-ROM Comorbidity Data Collection Electronic Mail Female Habits Health Services Needs and Demand Humans Internet Life Style Middle Aged Motor Activity Obesity Pamphlets Patient Education as Topic Patient Preference Practice Guidelines as Topic Quality of Life Resistance Training Sedentary Lifestyle Surveys and Questionnaires Survivors Telephone Texas Blacks Intervention Physical Activity Demographic Characteristics N1 - Department of Behavioral and Community Health, University of North Texas Health Science Center, Fort Worth, TX, US. Release Date: 20140714. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Paxton, Raheem J. Major Descriptor: Blacks; Breast Neoplasms; Intervention; Physical Activity; Preferences. Minor Descriptor: Demographic Characteristics; Survivors. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Mar, 2014. Publication History: First Posted Date: Sep 17, 2013; Accepted Date: Aug 27, 2013; First Submitted Date: Dec 27, 2012. Copyright Statement: Springer Science+Business Media New York. 2013. Sponsor: National Cancer Institute, US. Grant: 5K01CA158000. Recipients: Paxton, Raheem J. Sponsor: MD Anderson's Cancer Center. Grant: CA016672. Recipients: No recipient indicated PY - 2014 SN - 1932-2259 1932-2267 SP - 31-38 ST - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc web-based survey T2 - Journal of Cancer Survivorship TI - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc web-based survey UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-05971-004&site=ehost-live&scope=site ORCID: 0000-0001-9430-7051 Raheem.Paxton@unthsc.edu VL - 8 ID - 1707 ER - TY - JOUR AB - Background: Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors. Methods: AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed. Results: About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors. Conclusion: Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle. Implications for Cancer Survivors: Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using. © 2013 Springer Science+Business Media New York. AD - R. J. Paxton AU - Paxton, R. J. AU - Nayak, P. AU - Taylor, W. C. AU - Chang, S. AU - Courneya, K. S. AU - Schover, L. AU - Hodges, K. AU - Jones, L. A. DB - Medline DO - 10.1007/s11764-013-0307-5 IS - 1 KW - adult African American aged article breast tumor comorbidity compact disk e-mail female habit health service human information processing Internet lifestyle methodology middle aged motor activity obesity patient education patient preference practice guideline psychological aspect publication quality of life questionnaire resistance training sedentary lifestyle survivor telephone United States LA - English M3 - Article N1 - L1052779288 2014-10-09 PY - 2014 SN - 1932-2267 1932-2259 SP - 31-38 ST - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc. web-based survey T2 - Journal of Cancer Survivorship TI - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc. web-based survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L1052779288&from=export http://dx.doi.org/10.1007/s11764-013-0307-5 VL - 8 ID - 1040 ER - TY - JOUR AB - Background: Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors.Methods: AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed.Results: About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors.Conclusion: Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle.Implications For Cancer Survivors: Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using. AD - Department of Behavioral and Community Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76017, USA, Raheem.Paxton@unthsc.edu. AN - 104022436. Language: English. Entry Date: 20141017. Revision Date: 20200708. Publication Type: journal article AU - Paxton, Raheem J. AU - Nayak, Pratibha AU - Taylor, Wendell C. AU - Chang, Shine AU - Courneya, Kerry S. AU - Schover, Leslie AU - Hodges, Kelly AU - Jones, Lovell A. DB - CINAHL Complete DO - 10.1007/s11764-013-0307-5 DP - EBSCOhost IS - 1 KW - Black Persons -- Psychosocial Factors Breast Neoplasms -- Psychosocial Factors Health Services Needs and Demand Motor Activity Patient Education -- Methods Patient Satisfaction Survivors -- Psychosocial Factors Adult Aged Breast Neoplasms -- Therapy CD ROM Comorbidity Data Collection Email Female Habits Human Internet Life Style Middle Age Obesity -- Epidemiology Obesity -- Psychosocial Factors Pamphlets Practice Guidelines Quality of Life Questionnaires Resistance Training Life Style, Sedentary Telephone Texas N1 - research. Journal Subset: Biomedical; USA. Special Interest: Oncologic Care. Grant Information: 5K01CA158000/CA/NCI NIH HHS/United States. NLM UID: 101307557. PMID: NLM24043292. PY - 2014 SN - 1932-2259 SP - 31-38 ST - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey T2 - Journal of Cancer Survivorship TI - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104022436&site=ehost-live&scope=site VL - 8 ID - 1852 ER - TY - JOUR AB - Background: Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors. Methods: AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed. Results: About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors. Conclusion: Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle. Implications for Cancer Survivors: Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using. © 2013 Springer Science+Business Media New York. AD - Department of Behavioral and Community Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76017, United States Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Division of Health Promotion and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United States Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States University of Alberta, Edmonton, AB, Canada Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, United States The Sisters Network Inc., Houston, TX, United States Dorothy I. Height Center for Health Equity and Evaluation Research, Unit #1440, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, United States AU - Paxton, R. J. AU - Nayak, P. AU - Taylor, W. C. AU - Chang, S. AU - Courneya, K. S. AU - Schover, L. AU - Hodges, K. AU - Jones, L. A. DB - Scopus DO - 10.1007/s11764-013-0307-5 IS - 1 KW - African-American women Breast cancer Cancer survivor Cancer survivorship Health disparities Physical activity M3 - Article N1 - Cited By :26 Export Date: 22 March 2021 PY - 2014 SP - 31-38 ST - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc. web-based survey T2 - Journal of Cancer Survivorship TI - African-American breast cancer survivors' preferences for various types of physical activity interventions: A Sisters Network Inc. web-based survey UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897583568&doi=10.1007%2fs11764-013-0307-5&partnerID=40&md5=8927e2edd66b239a4fb7bc01deed7acc VL - 8 ID - 2403 ER - TY - JOUR AB - Background Needs assessments are essential to developing lifestyle interventions for minority populations. To our knowledge, no physical activity (PA) needs assessment studies have been conducted for African-American (AA) breast cancer survivors. The purpose of this study was to determine the PA intervention preferences of AA breast cancer survivors and determine whether these preferences differ according to medical and sociodemographic factors. Methods AA breast cancer survivors (n = 475, mean age = 54 years) were recruited using ads sent via email and social media sites. Preferences for the mode of intervention delivery were assessed via web-based questionnaires. Descriptive statistics were used to characterize their interests in PA interventions, and subgroup differences were assessed. Results About 49 % (142 out of 291) of the participants who completed the survey were obese and 54 % did not meet the recommended guidelines for PA. Most (90 %) participants reported that they could participate in PA, and many (67 %) indicated that they were interested in receiving program materials. Participants expressed the greatest interest in email (50 %)-, web (48 %)-, or mail-based (45 %) over group (39 %), and telephone (10 %). Women also expressed the greatest interest in participating in studies that promoted walking and resistance or strength training. Intervention preferences did not differ significantly (P > 0.05) across sociodemographic or medical factors. Conclusion Most AA breast cancer survivors can participate in PA, and many are interested in interventions that promoted walking and resistance training and were delivered via the email or web. The development of culturally sensitive interventions that provide activities consistent with preferences can assist AA breast cancer survivors to adopt and maintain a healthy lifestyle. Implications for Cancer Survivors Despite evidence that AA breast cancer survivors are at increased risk for poor breast cancer-specific outcomes, they are underrepresented in clinical trials promoting positive health behaviors. In this study, we propose to assess their exercise preferences and receptivity to a culturally appropriate PA intervention developed in collaboration with the Sisters Network Inc. Health promotion programs developed in collaboration with a community-based organization may aid in the development of research tools and resources that AA breast cancer survivors are receptive to using. AN - WOS:000340232000004 AU - Paxton, R. J. AU - Nayak, P. AU - Taylor, W. C. AU - Chang, S. AU - Courneya, K. S. AU - Schover, L. AU - Hodges, K. AU - Jones, L. A. DA - Mar DO - 10.1007/s11764-013-0307-5 IS - 1 N1 - 24043292 PY - 2014 SN - 1932-2259 SP - 31-38 ST - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey T2 - Journal of Cancer Survivorship TI - African-American breast cancer survivors' preferences for various types of physical activity interventions: a Sisters Network Inc. web-based survey VL - 8 ID - 3021 ER - TY - JOUR AB - A genome-wide scan of high-risk prostate cancer families in North America has demonstrated linkage of a particular marker to Chromosome Iq (HPC11. An even greater proportion of African-American families have shown linkage to HPC 1. Therefore, investigators at the National Human Genome Research Institute [NHGRI] in collaboration with Howard University and a predominantly African-American group of urologists established the African-American Hereditary Prostate Cancer (AAHPC) Study Network to confirm the suggested linkage of HPC in African Americans with a gene on Chromosome 1. Blood samples from recruited families were sent to Howard University for extraction of DNA. The DNA was sent to NHGRI at NIH where the genotyping and genetic sequence analysis was conducted. Genotype data are merged with pedigree information so that statistical analysis can be performed to establish potential linkage. From March 1, 1998, to June 1, 1999, a total of 40 African-American families have been recruited who met the study criteria. Preliminary results suggest that racial/ethnicity grouping may affect the incidence and extent of linkage of prostate cancer to specific loci. The importance of these findings lays in the future treatment of genetic-based diseases. AD - Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. AN - 11798061 AU - Powell, I. J. AU - Carpten, J. AU - Dunston, G. AU - Kittles, R. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. A. AU - Boykin, W. AU - Mason, T. AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Bailey-Wilson, J. AU - Berg, K. AU - Trent, J. AU - Collins, F. C2 - PMC2719991 DA - Dec DP - NLM ET - 2002/01/19 IS - 12 Suppl KW - African Continental Ancestry Group/*genetics Human Genome Project Humans Male Middle Aged Patient Selection Prostatic Neoplasms/ethnology/*genetics Research United States LA - eng N1 - Powell, I J Carpten, J Dunston, G Kittles, R Bennett, J Hoke, G Pettaway, C Weinrich, S Vijayakumar, S Ahaghotu, C A Boykin, W Mason, T Royal, C Baffoe-Bonnie, A Bailey-Wilson, J Berg, K Trent, J Collins, F HG 75418/HG/NHGRI NIH HHS/United States Journal Article Research Support, U.S. Gov't, P.H.S. J Natl Med Assoc. 2001 Dec;93(12 Suppl):25S-28S. PY - 2001 SN - 0027-9684 (Print) 0027-9684 SP - 25s-28s ST - African-American heredity prostate cancer study: a model for genetic research T2 - J Natl Med Assoc TI - African-American heredity prostate cancer study: a model for genetic research VL - 93 ID - 674 ER - TY - JOUR AB - A genome-wide scan of high-risk prostate cancer families in North America has demonstrated linkage of a particular marker to Chromosome Iq (HPC11. An even greater proportion of African-American families have shown linkage to HPC 1. Therefore, investigators at the National Human Genome Research Institute [NHGRI] in collaboration with Howard University and a predominantly African-American group of urologists established the African-American Hereditary Prostate Cancer (AAHPC) Study Network to confirm the suggested linkage of HPC in African Americans with a gene on Chromosome 1. Blood samples from recruited families were sent to Howard University for extraction of DNA. The DNA was sent to NHGRI at NIH where the genotyping and genetic sequence analysis was conducted. Genotype data are merged with pedigree information so that statistical analysis can be performed to establish potential linkage. From March 1, 1998, to June 1, 1999, a total of 40 African-American families have been recruited who met the study criteria. Preliminary results suggest that racial/ethnicity grouping may affect the incidence and extent of linkage of prostate cancer to specific loci. The importance of these findings lays in the future treatment of genetic-based diseases. AD - I.J. Powell, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA. AU - Powell, I. J. AU - Carpten, J. AU - Dunston, G. AU - Kittles, R. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. A. AU - Boykin, W. AU - Mason, T. AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Bailey-Wilson, J. AU - Berg, K. AU - Trent, J. AU - Collins, F. DB - Medline IS - 12 Suppl KW - article ethnology genetics human human genome project male middle aged Black person patient selection prostate tumor research United States LA - English M3 - Article N1 - L35572544 2002-01-18 PY - 2001 SN - 0027-9684 SP - 25S-28S ST - African-American heredity prostate cancer study: a model for genetic research T2 - Journal of the National Medical Association TI - African-American heredity prostate cancer study: a model for genetic research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L35572544&from=export VL - 93 ID - 1304 ER - TY - JOUR AB - Background: Geriatric patients and minority patients are often under-represented in cancer clinical trials. The presence of multiple comorbidities makes geriatric patients ineligible for most clinical trials. Racial diversity may vary by geographical location and socio-economically backward areas may have a very different racial mix. The increase in cancer incidence in geriatric patients' raises the question of applicability of the results is such clinical trials. This study also explores the representation of different races in phase 3 clinical trials conducted in the past 10 years. Methods: Data about Phase III trials was extracted from the clinical trials.gov for 3 common solid organs and 3 hematological malignancies [breast, colon, lung, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)]. The time period studied was for the past 10 years and included only adult patients (≥18 years). The age and race distribution of the patient population in these trials were extracted and analyzed. Results: Geriatric patients and minorities are under-represented in all phase III cancer clinical trials. The range of the proportion of geriatric patients varied from 10% to 40%. African American and Asian patients are under-represented in all phase III cancer clinical trials. Conclusions: The results of phase III clinical trials that are currently conducted on non-geriatric and Caucasian patient population may not meaningfully be applicable to geriatric patients and minorities. This study highlights the disparity of age and race for patients enrolled in clinical trials as against the patients seen in the real world. AD - A.K. Guddati, Division of Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, GA, United States AU - Gopishetty, S. AU - Kota, V. AU - Guddati, A. K. DB - Embase IS - 9 KW - acute lymphoblastic leukemia acute myeloid leukemia adult African American article Asian breast cancer incidence case report Caucasian clinical article colon diffuse large B cell lymphoma female geriatric patient human lung male phase 3 clinical trial LA - English M3 - Article N1 - L2008021037 2020-10-19 PY - 2020 SN - 1943-8141 SP - 5977-5983 ST - Age and race distribution in patients in phase III oncology clinical trials T2 - American Journal of Translational Research TI - Age and race distribution in patients in phase III oncology clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2008021037&from=export VL - 12 ID - 824 ER - TY - JOUR AB - Background: Geriatric patients and minority patients are often under-represented in cancer clinical trials. The presence of multiple comorbidities makes geriatric patients ineligible for most clinical trials. Racial diversity may vary by geographical location and socio-economically backward areas may have a very different racial mix. The increase in cancer incidence in geriatric patients' raises the question of applicability of the results is such clinical trials. This study also explores the representation of different races in phase 3 clinical trials conducted in the past 10 years. Methods: Data about Phase III trials was extracted from the clinical trials.gov for 3 common solid organs and 3 hematological malignancies [breast, colon, lung, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)]. The time period studied was for the past 10 years and included only adult patients (≥18 years). The age and race distribution of the patient population in these trials were extracted and analyzed. Results: Geriatric patients and minorities are under-represented in all phase III cancer clinical trials. The range of the proportion of geriatric patients varied from 10% to 40%. African American and Asian patients are under-represented in all phase III cancer clinical trials. Conclusions: The results of phase III clinical trials that are currently conducted on non-geriatric and Caucasian patient population may not meaningfully be applicable to geriatric patients and minorities. This study highlights the disparity of age and race for patients enrolled in clinical trials as against the patients seen in the real world. © 2020 E-Century Publishing Corporation. All rights reserved. AD - Medical Center of Central Georgia, Mercer University, Macon, GA 31201, United States Division of Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, GA 30909, United States AU - Gopishetty, S. AU - Kota, V. AU - Guddati, A. K. DB - Scopus IS - 9 KW - Cancer clinical trial Geriatric population Minorities Racial distribution M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 5977-5983 ST - Age and race distribution in patients in phase III oncology clinical trials T2 - American Journal of Translational Research TI - Age and race distribution in patients in phase III oncology clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092516134&partnerID=40&md5=b5b348f854059b874f3d685fae250cc3 VL - 12 ID - 2208 ER - TY - JOUR AB - Background: Geriatric patients and minority patients are often under-represented in cancer clinical trials. The presence of multiple comorbidities makes geriatric patients ineligible for most clinical trials. Racial diversity may vary by geographical location and socio-economically backward areas may have a very different racial mix. The increase in cancer incidence in geriatric patients' raises the question of applicability of the results is such clinical trials. This study also explores the representation of different races in phase 3 clinical trials conducted in the past 10 years. Methods: Data about Phase III trials was extracted from the clinical trials.gov for 3 common solid organs and 3 hematological malignancies [breast, colon, lung, diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)]. The time period studied was for the past 10 years and included only adult patients (>= 18 years). The age and race distribution of the patient population in these trials were extracted and analyzed. Results: Geriatric patients and minorities are under-represented in all phase III cancer clinical trials. The range of the proportion of geriatric patients varied from 10% to 40%. African American and Asian patients are under-represented in all phase Ill cancer clinical trials. Conclusions: The results of phase III clinical trials that are currently conducted on non-geriatric and Caucasian patient population may not meaningfully be applicable to geriatric patients and minorities. This study highlights the disparity of age and race for patients enrolled in clinical trials as against the patients seen in the real world. AN - WOS:000576793400006 AU - Gopishetty, S. AU - Kota, V. AU - Guddati, A. K. IS - 9 N1 - 33042473 PY - 2020 SN - 1943-8141 SP - 5977-+ ST - Age and race distribution in patients in phase III oncology clinical trials T2 - American Journal of Translational Research TI - Age and race distribution in patients in phase III oncology clinical trials VL - 12 ID - 2797 ER - TY - JOUR AB - Scope: Plant polyphenols are widespread in the American diet, yet estimated intake is uncertain. We examine the application of the Polyphenol Explorer® (PED) database to quantify polyphenol and ellagitannin (ET) intake of men with prostate cancer and tested the implementation of diets restricted in polyphenols or ETs. Methods and results: Twenty-four men enrolled in a 4-week trial were randomized to usual, low-polyphenol or low-ET diet. Estimated polyphenol and ET intakes were calculated from 3-day diet records utilizing the PED. Urine and plasma metabolites were quantified by UPLC-MS. Adherence to the restricted diets was 95% for the low polyphenol and 98% for low-ET diet. In the usual diet, estimated dietary polyphenol intake was 1568 ± 939 mg/day, with coffee/tea beverages (1112 ± 1028 mg/day) being the largest contributors and estimated dietary ET intake was 12 ± 13 mg/day. The low-polyphenol and low-ET groups resulted in a reduction of total polyphenols by 45% and 85%, respectively, and omission of dietary ETs. UPLC analysis of urinary host and microbial metabolites reflect ET intake. Conclusion: PED is a useful database for assessing exposure to polyphenols. Diets restricted in total polyphenol or ET intake are feasible and UPLC assessment of ET metabolites is reflective of dietary intake. © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim AD - The OSU Interdisciplinary Ph.D. Program in Nutrition, Ohio State University, Columbus, OH, United States Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States Division of Biostatistics, Ohio State University, Columbus, OH, United States Department of Food Science and Technology, Ohio State University, Columbus, OH, United States Department of Urology, Ohio State University, Columbus, OH, United States Department of Internal Medicine, Division of Medical Oncology, Ohio State University, Columbus, OH, United States OhioHealth, Columbus, OH, United States AU - Roberts, K. M. AU - Grainger, E. M. AU - Thomas-Ahner, J. M. AU - Hinton, A. AU - Gu, J. AU - Riedl, K. M. AU - Vodovotz, Y. AU - Abaza, R. AU - Schwartz, S. J. AU - Clinton, S. K. C7 - 1600224 DB - Scopus DO - 10.1002/mnfr.201600224 IS - 3 KW - Black raspberries Ellagitannins Polyphenol explorer database Polyphenols Urolithins M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2017 ST - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men T2 - Molecular Nutrition and Food Research TI - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014111547&doi=10.1002%2fmnfr.201600224&partnerID=40&md5=dfea4b282fce41e925145ef106319756 VL - 61 ID - 2319 ER - TY - JOUR AB - Scope: Plant polyphenols arewidespread in the American diet, yet estimated intake is uncertain. We examine the application of the Polyphenol Explorer (R) (PED) database to quantify polyphenol and ellagitannin (ET) intake of men with prostate cancer and tested the implementation of diets restricted in polyphenols or ETs. Methods and results: Twenty-four men enrolled in a 4-week trial were randomized to usual, low-polyphenol or low-ET diet. Estimated polyphenol and ET intakes were calculated from 3-day diet records utilizing the PED. Urine and plasma metabolites were quantified by UPLC-MS. Adherence to the restricted diets was 95% for the low polyphenol and 98% for low-ET diet. In the usual diet, estimated dietary polyphenol intake was 1568 +/- 939 mg/day, with coffee/tea beverages (1112 +/- 1028 mg/day) being the largest contributors and estimated dietary ET intake was 12 +/- 13 mg/day. The low-polyphenol and low-ET groups resulted in a reduction of total polyphenols by 45% and 85%, respectively, and omission of dietary ETs. UPLC analysis of urinary host and microbial metabolites reflect ET intake. Conclusion: PED is a useful database for assessing exposure to polyphenols. Diets restricted in total polyphenol or ET intake are feasible and UPLC assessment of ET metabolites is reflective of dietary intake. AN - WOS:000398095000005 AU - Roberts, K. M. AU - Grainger, E. M. AU - Thomas-Ahner, J. M. AU - Hinton, A. AU - Gu, J. N. AU - Riedl, K. M. AU - Vodovotz, Y. AU - Abaza, R. AU - Schwartz, S. J. AU - Clinton, S. K. DA - Mar DO - 10.1002/mnfr.201600224 IS - 3 N1 - 1600224 27813248 PY - 2017 SN - 1613-4125 ST - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men T2 - Molecular Nutrition & Food Research TI - Application of a low polyphenol or low ellagitannin dietary intervention and its impact on ellagitannin metabolism in men VL - 61 ID - 2905 ER - TY - JOUR AB - Objectives: Although it does not alter the ERCC1 phenotype, the ERCC1 500C>T (rs11615) polymorphism has undergone a myriad of investigations into its role as a marker for nucleotide excision repair (NER) function in different races, diseases and treatment outcomes. The goal of our study was to test the hypothesis that 500C>T is in linkage disequilibrium (LD) with causative alleles, and that these haplotypes are more frequent in Caucasians with melanoma than in healthy Caucasians or African Americans. Design: In this case-control study, we selected racespecific ERCC1 single-nucleotide polymorphism (SNPs), conducted LD analysis with ERCC1 500C>T and compared the frequency of ERCC1 diplotypes in Caucasians with melanoma (n=165), healthy Caucasians (n=150) and healthy African Americans (n=159). The haplotype was further studied using a fusion gene containing multiple ERCC1 SNPs. Setting: Large cancer institute in the USA. Participants: A total of 165 Caucasian melanoma patients, 159 healthy Caucasian controls and 159 African American healthy controls. Men and women were enrolled in the clinical trial; however, since the screening trial included prostate cancer screening in addition to screening for other cancers, only male controls were available. Outcome measures: The outcome measures were melanoma risk in Caucasians, and LD between ERCC1 SNP, N118N and other race-specific allelic variants. Results: When compared to ERCC1 500C>T alone, a race-specific three-SNP variant haplotype in ERCC1 (comprised of rs11615, rs3212950 and rs3212948) was even more frequent in Caucasians with melanoma than in healthy Caucasians (p=0.0034) or African Americans (p<0.0001). A plasmid containing the variant haplotype was not differentially expressed. Conclusions: We demonstrate that ERCC1 500C>T participates in a previously characterised cancer-risk haplotype found more frequently in Caucasians, while LD is weak in African Americans; this haplotype appears to also be related to melanoma. It is therefore likely that ERCC1 500C>T is only a valid NER, disease or treatment outcome marker in Caucasians. AD - W.D. Figg, Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, United States AU - Gao, R. AU - Reece, K. M. AU - Sissung, T. AU - Fu, S. H. AU - Venzon, D. J. AU - Reed, E. AU - Spencer, S. D. AU - Price, D. K. AU - Figg, W. D. DB - Embase DO - 10.1136/bmjopen-2012-002030 IS - 1 KW - excision repair cross complementing protein 1 African American amino acid substitution article cancer prognosis cancer risk cancer screening case control study Caucasian controlled study fusion gene gene expression gene frequency gene linkage disequilibrium genetic analysis genetic risk genetic screening genetic variability haplotype human major clinical study male melanoma outcome assessment plasmid predictive value prostate cancer race difference single nucleotide polymorphism United States LA - English M3 - Article N1 - L368302781 2013-02-20 2013-03-05 PY - 2013 SN - 2044-6055 ST - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? T2 - BMJ Open TI - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368302781&from=export http://dx.doi.org/10.1136/bmjopen-2012-002030 http://bmjopen.bmj.com/content/3/1/e002030.full.pdf+html VL - 3 ID - 1086 ER - TY - JOUR AB - Objectives: Although it does not alter the ERCC1 phenotype, the ERCC1 500C>T (rs11615) polymorphism has undergone a myriad of investigations into its role as a marker for nucleotide excision repair (NER) function in different races, diseases and treatment outcomes. The goal of our study was to test the hypothesis that 500C>T is in linkage disequilibrium (LD) with causative alleles, and that these haplotypes are more frequent in Caucasians with melanoma than in healthy Caucasians or African Americans. Design: In this case-control study, we selected racespecific ERCC1 single-nucleotide polymorphism (SNPs), conducted LD analysis with ERCC1 500C>T and compared the frequency of ERCC1 diplotypes in Caucasians with melanoma (n=165), healthy Caucasians (n=150) and healthy African Americans (n=159). The haplotype was further studied using a fusion gene containing multiple ERCC1 SNPs. Setting: Large cancer institute in the USA. Participants: A total of 165 Caucasian melanoma patients, 159 healthy Caucasian controls and 159 African American healthy controls. Men and women were enrolled in the clinical trial; however, since the screening trial included prostate cancer screening in addition to screening for other cancers, only male controls were available. Outcome measures: The outcome measures were melanoma risk in Caucasians, and LD between ERCC1 SNP, N118N and other race-specific allelic variants. Results: When compared to ERCC1 500C>T alone, a race-specific three-SNP variant haplotype in ERCC1 (comprised of rs11615, rs3212950 and rs3212948) was even more frequent in Caucasians with melanoma than in healthy Caucasians (p=0.0034) or African Americans (p<0.0001). A plasmid containing the variant haplotype was not differentially expressed. Conclusions: We demonstrate that ERCC1 500C>T participates in a previously characterised cancer-risk haplotype found more frequently in Caucasians, while LD is weak in African Americans; this haplotype appears to also be related to melanoma. It is therefore likely that ERCC1 500C>T is only a valid NER, disease or treatment outcome marker in Caucasians. AD - Molecular Pharmacology Section, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, United States Clinical Pharmacology Core, Medical Oncology Branch, Center for Cancer Research, Bethesda, MD, United States Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD, United States Mitchell Cancer Institute, University of South Alabama, Mobile, AL, United States Clinical Pharmacology Program, SAIC-Frederick, NCI-Frederick, Frederick, MD, United States AU - Gao, R. AU - Reece, K. M. AU - Sissung, T. AU - Fu, S. H. AU - Venzon, D. J. AU - Reed, E. AU - Spencer, S. D. AU - Price, D. K. AU - Figg, W. D. C7 - e002030 DB - Scopus DO - 10.1136/bmjopen-2012-002030 IS - 1 M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2013 ST - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? T2 - BMJ Open TI - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873559051&doi=10.1136%2fbmjopen-2012-002030&partnerID=40&md5=fa440733e05dc0e469967c072ea0a150 VL - 3 ID - 2442 ER - TY - JOUR AB - Objectives: Although it does not alter the ERCC1 phenotype, the ERCC1 500C>T (rs11615) polymorphism has undergone a myriad of investigations into its role as a marker for nucleotide excision repair (NER) function in different races, diseases and treatment outcomes. The goal of our study was to test the hypothesis that 500C>T is in linkage disequilibrium (LD) with causative alleles, and that these haplotypes are more frequent in Caucasians with melanoma than in healthy Caucasians or African Americans. Design: In this case-control study, we selected race-specific ERCC1 single-nucleotide polymorphism (SNPs), conducted LD analysis with ERCC1 500C>T and compared the frequency of ERCC1 diplotypes in Caucasians with melanoma (n=165), healthy Caucasians (n=150) and healthy African Americans (n=159). The haplotype was further studied using a fusion gene containing multiple ERCC1 SNPs. Setting: Large cancer institute in the USA. Participants: A total of 165 Caucasian melanoma patients, 159 healthy Caucasian controls and 159 African American healthy controls. Men and women were enrolled in the clinical trial; however, since the screening trial included prostate cancer screening in addition to screening for other cancers, only male controls were available. Outcome measures: The outcome measures were melanoma risk in Caucasians, and LD between ERCC1 SNP, N118N and other race-specific allelic variants. Results: When compared to ERCC1 500C>T alone, a race-specific three-SNP variant haplotype in ERCC1 (comprised of rs11615, rs3212950 and rs3212948) was even more frequent in Caucasians with melanoma than in healthy Caucasians (p=0.0034) or African Americans (p<0.0001). A plasmid containing the variant haplotype was not differentially expressed. Conclusions: We demonstrate that ERCC1 500C>T participates in a previously characterised cancer-risk haplotype found more frequently in Caucasians, while LD is weak in African Americans; this haplotype appears to also be related to melanoma. It is therefore likely that ERCC1 500C>T is only a valid NER, disease or treatment outcome marker in Caucasians. AN - WOS:000315082400040 AU - Gao, R. AU - Reece, K. M. AU - Sissung, T. AU - Fu, S. H. AU - Venzon, D. J. AU - Reed, E. AU - Spencer, S. D. AU - Price, D. K. AU - Figg, W. D. DO - 10.1136/bmjopen-2012-002030 IS - 1 N1 - e002030 23293248 PY - 2013 SN - 2044-6055 ST - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? T2 - Bmj Open TI - Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? VL - 3 ID - 3054 ER - TY - JOUR AB - Background: It is widely claimed that racial and ethnic minorities, especially in the US, are less willing than non-minority individuals to participate in health research. Yet, there is a paucity of empirical data to substantiate this claim. Methods and Findings: We performed a comprehensive literature search to identify all published health research studies that report consent rates by race or ethnicity. We found 20 health research studies that reported consent rates by race or ethnicity. These 20 studies reported the enrollment decisions of over 70,000 individuals for a broad range of research, from interviews to drug treatment to surgical trials. Eighteen of the twenty studies were single-site studies conducted exclusively in the US or multi-site studies where the majority of sites (i.e., at least 2/3) were in the US. Of the remaining two studies, the Concorde study was conducted at 74 sites in the United Kingdom, Ireland, and France, while the Delta study was conducted at 152 sites in Europe and 23 sites in Australia and New Zealand. For the three interview or non-intervention studies, African-Americans had a nonsignificantly lower overall consent rate than non-Hispanic whites (82.2% versus 83.5%; odds ratio [OR] = 0.92; 95% confidence interval [CI] 0.84-1.02). For these same three studies, Hispanics had a nonsignificantly higher overall consent rate than non-Hispanic whites (86.1% versus 83.5%; OR = 1.37; 95% CI 0.94-1.98). For the ten clinical intervention studies, African-Americans' overall consent rate was nonsignificantly higher than that of non-Hispanic whites (45.3% versus 41.8%; OR = 1.06; 95% CI 0.78-1.45). For these same ten studies, Hispanics had a statistically significant higher overall consent rate than non-Hispanic whites (55.9% versus 41.8%; OR = 1.33; 95% CI 1.08-1.65). For the seven surgery trials, which report all minority groups together, minorities as a group had a nonsignificantly higher overall consent rate than non-Hispanic whites (65.8% versus 47.8%; OR = 1.26; 95% CI 0.89-1.77). Given the preponderance of US sites, the vast majority of these individuals from minority groups were African-Americans or Hispanics from the US. Conclusions: We found very small differences in the willingness of minorities, most of whom were African-Americans and Hispanics in the US, to participate in health research compared to non-Hispanic whites. These findings, based on the research enrollment decisions of over 70,000 individuals, the vast majority from the US, suggest that racial and ethnic minorities in the US are as willing as non-Hispanic whites to participate in health research. Hence, efforts to increase minority participation in health research should focus on ensuring access to health research for all groups, rather than changing minority attitudes. Copyright: © 2006 Wendler et al. AD - Department of Clinical Bioethics, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, United States Office of Behavioral and Social Sciences Research, National Institutes of Health, Bethesda, MD, United States National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD, United States Department of Epidemiology, Yale University, School of Medicine, New Haven, CT, United States Statistics Collaborative, Washington, DC, United States Winship Cancer Institute, Emory University, Atlanta, GA, United States Section of General Internal Medicine, Yale University, School of Medicine, New Haven, CT, United States AU - Wendler, D. AU - Kington, R. AU - Madans, J. AU - Van Wye, G. AU - Christ-Schmidt, H. AU - Pratt, L. A. AU - Brawley, O. W. AU - Gross, C. P. AU - Emanuel, E. DB - Scopus DO - 10.1371/journal.pmed.0030019 IS - 2 M3 - Article N1 - Cited By :470 Export Date: 22 March 2021 PY - 2006 SP - 0201-0210 ST - Are racial and ethnic minorities less willing to participate in health research? T2 - PLoS Medicine TI - Are racial and ethnic minorities less willing to participate in health research? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644842676&doi=10.1371%2fjournal.pmed.0030019&partnerID=40&md5=facb4490bfdc3dc5e1e43cd7d8b8a645 VL - 3 ID - 2580 ER - TY - JOUR AB - The purpose of this study was to determine the efficacy of women with breast cancer as teachers of the importance of breast cancer screening to their first-degree female relatives. The sample was restricted to low-income working age women recruited from four hospitals. The study design was a randomized clinical trial. At each hospital, breast cancer patients (probands) were randomized into one of two study groups: (i) intensive, individual educational training on breast cancer screening or (ii) standard clinic education on breast cancer screening. The probands were instructed to teach at least one of their first-degree female relatives (21+ years of age) about breast cancer screening techniques. Three to six months after the enrollment of the probands, their relatives were contacted by telephone to determine breast cancer screening practices. A total of 79 probands and 96 relatives participated in the study. Relatives in the education group when compared with the control group were: 1.25 times more likely to have clinical breast examination (p = 0.005), 2.83 times more likely to have scheduled a clinical breast examination (p = 0.046), and, 1.36 times more likely to have been told about performing breast self-examination (p = 0.05). Additionally, relatives in the education group were more likely to have received a pamphlet on breast cancer screening (RR = 1.58, p = 0.009) and have discussed the importance of breast cancer screening (RR = 1.33, p = 0.020) from the proband. Special education training did not impact mammography utilization of the relatives. From these findings, a tri-ethnic group of low-income women with breast cancer can be effective teachers of breast cancer screening practices, at least for promoting clinical breast examination and transmitting messaging for performance of breast self-examination if given the adequate training. AN - WOS:000243732100004 AU - Oleske, D. M. AU - Galvez, A. AU - Cobleigh, M. A. AU - Ganschow, P. AU - Ayala, L. D. DA - Jan-Feb DO - 10.1111/j.1524-4741.2006.00358.x IS - 1 N1 - 17214789 PY - 2007 SN - 1075-122X SP - 19-27 ST - Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial T2 - Breast Journal TI - Are tri-ethnic low-income women with breast cancer effective teachers of the importance of breast cancer screening to their first-degree relatives? Results from a randomized clinical trial VL - 13 ID - 3202 ER - TY - JOUR AB - Background: NSAIDs appear to moderately reduce prostate cancer risk. However, evidence is limited on whether NSAIDs protect against prostate cancer mortality (death from prostate cancer among men without a cancer history) and case fatality (death from prostate cancer among men with prostate cancer), and whether benefits are consistent in white and black men. This study investigated associations of aspirin and non-aspirin (NA) NSAID use with prostate cancer incidence, mortality, and case fatality in a population-based cohort of white and black men. Methods: We included 6,594 men (5,060 white and 1,534 black) from the Atherosclerosis Risk in Communities study without a cancer history at enrollment from 1987 to 1989. NSAID use was assessed at four study visits (1987–1998). Cancer outcomes were ascertained through 2012. Cox proportional hazards regression was used to estimate adjusted HRs, overall and by race. Results: Aspirin use was not associated with prostate cancer incidence. However, aspirin use was inversely associated with prostate cancer mortality [HR, 0.59; 95% confidence interval (CI), 0.36–0.96]. This association was consistent among white and black men and appeared restricted to men using aspirin daily and/or for cardiovascular disease prevention. Aspirin use was inversely associated with case fatality (HR, 0.45; 95% CI, 0.22–0.94). NA-NSAID use was not associated with these endpoints. Conclusions: Aspirin use was inversely associated with prostate cancer mortality and case fatality among white and black men. Impact: If confirmed by additional studies, benefits of aspirin for preventing prostate cancer mortality may need to be factored into risk–benefit calculations of men considering an aspirin regimen. © 2018 American Association for Cancer Research. AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, United States Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, United States Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States AU - Hurwitz, L. M. AU - Joshu, C. E. AU - Barber, J. R. AU - Prizment, A. E. AU - Vitolins, M. Z. AU - Jones, M. R. AU - Folsom, A. R. AU - Han, M. AU - Platz, E. A. DB - Scopus DO - 10.1158/1055-9965.EPI-18-0965 IS - 3 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2019 SP - 563-569 ST - Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the Atherosclerosis Risk in Communities study T2 - Cancer Epidemiology Biomarkers and Prevention TI - Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the Atherosclerosis Risk in Communities study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062428756&doi=10.1158%2f1055-9965.EPI-18-0965&partnerID=40&md5=0e3d979b0bcb41e9fbeebbaacc5b136f VL - 28 ID - 2239 ER - TY - JOUR AB - Gene‐specific promoter methylation of several genes occurs in aging normal tissues and may predispose to tumorigenesis. In the present study, we investigate the association of blood folate levels and dietary and lifestyle factors with CpG island (CGI) methylation in normal colorectal mucosa. Subjects were enrolled in a multicenter chemoprevention trial of aspirin or folic acid for the prevention of large bowel adenomas. We collected 1,000 biopsy specimens from 389 patients, 501 samples from the right colon and 499 from the rectum at the follow‐up colonoscopy. We measured DNA methylation of estrogen receptor alpha (ERα) and secreted frizzled related protein‐1 (SFRP1), using bisulfite pyrosequencing. We used generalized estimating equations regression analysis to examine the association between methylation and selected variables. For both ERα and SFRP1, percentage methylation was significantly higher in the rectum than in the right colon (P = 0.001). For each 10 years of age, we observed a 1.7% increase in methylation level for ERα and a 2.9% increase for SFRP1 (P < 0.0001). African Americans had a significantly lower level of ERα and SFRP1 methylation than Caucasians and Hispanics. Higher RBC folate levels were associated with higher levels of both ERα (P = 0.03) and SFRP1 methylation (P = 0.01). Our results suggest that CGI methylation in normal colorectal mucosa is related to advancing age, race, rectal location, and RBC folate levels. These data have important implications regarding the safety of supplementary folate administration in healthy adults, given the hypothesis that methylation in normal mucosa may predispose to colorectal neoplasia. AN - CN-00780513 AU - Wallace, K. AU - Grau, M. V. AU - Levine, A. J. AU - Shen, L. AU - Hamdan, R. AU - Chen, X. AU - Gui, J. AU - Haile, R. W. AU - Barry, E. L. AU - Ahnen, D. AU - et al. DO - 10.1158/1940-6207.CAPR-10-0047 IS - 12 KW - Adenoma [blood, *genetics, pathology] Biomarkers, Tumor [blood] Colon [*metabolism, pathology] Colonic Polyps [metabolism, pathology] Colorectal Neoplasms [blood, *genetics, pathology] CpG Islands DNA Methylation Double‐Blind Method Estrogen Receptor alpha [genetics] Female Folic Acid [*blood] Follow‐Up Studies Humans Intercellular Signaling Peptides and Proteins [genetics] Intestinal Mucosa [metabolism] Male Membrane Proteins [genetics] Middle Aged Placebos Prognosis Rectum [*metabolism, pathology] M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2010 SP - 1552‐1564 ST - Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa T2 - Cancer prevention research (Philadelphia, Pa.) TI - Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00780513/full VL - 3 ID - 1604 ER - TY - JOUR AB - Gene-specific promoter methylation of several genes occurs in aging normal tissues and may predispose to tumorigenesis. In the present study, we investigate the association of blood folate levels and dietary and lifestyle factors with CpG island (CGI) methylation in normal colorectal mucosa. Subjects were enrolled in a multicenter chemoprevention trial of aspirin or folic acid for the prevention of large bowel adenomas. We collected 1,000 biopsy specimens from 389 patients, 501 samples from the right colon and 499 from the rectum at the follow-up colonoscopy. We measured DNA methylation of estrogen receptor alpha (ERα) and secreted frizzled related protein-1 (SFRP1), using bisulfite pyrosequencing. We used generalized estimating equations regression analysis to examine the association between methylation and selected variables. For both ERα and SFRP1, percentage methylation was significantly higher in the rectum than in the right colon (P = 0.001). For each 10 years of age, we observed a 1.7% increase in methylation level for ERα and a 2.9% increase for SFRP1 (P < 0.0001). African Americans had a significantly lower level of ERα and SFRP1 methylation than Caucasians and Hispanics. Higher RBC folate levels were associated with higher levels of both ERα (P = 0.03) and SFRP1 methylation (P = 0.01). Our results suggest that CGI methylation in normal colorectal mucosa is related to advancing age, race, rectal location, and RBC folate levels. These data have important implications regarding the safety of supplementary folate administration in healthy adults, given the hypothesis that methylation in normal mucosa may predispose to colorectal neoplasia. ©2010 AACR. AD - J. A. Baron, Department of Medicine, Dartmouth Medical School, Evergreen Center, 46 Centerra Parkway, Lebanon, NH 03756, United States AU - Wallace, K. AU - Grau, M. V. AU - Levine, A. J. AU - Shen, L. AU - Hamdan, R. AU - Chen, X. AU - Gui, J. AU - Haile, R. W. AU - Barry, E. L. AU - Ahnen, D. AU - McKeown-Eyssen, G. AU - Baron, J. A. AU - Issa, J. P. J. C1 - aspirin DB - Embase Medline DO - 10.1158/1940-6207.CAPR-10-0047 IS - 12 KW - acetylsalicylic acid estrogen receptor alpha folic acid placebo secreted frizzled related protein 1 adult article clinical trial colonoscopy colorectal cancer controlled study CpG island demography DNA methylation double blind procedure drug efficacy ethnicity female heredity human large intestine cancer lifestyle major clinical study male multicenter study priority journal pyrosequencing rectum mucosa aspirin LA - English M3 - Article N1 - L360196871 2010-12-29 2011-02-04 PY - 2010 SN - 1940-6207 1940-6215 SP - 1552-1564 ST - Association between folate levels and CpG island hypermethylation in normal colorectal mucosa T2 - Cancer Prevention Research TI - Association between folate levels and CpG island hypermethylation in normal colorectal mucosa UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360196871&from=export http://dx.doi.org/10.1158/1940-6207.CAPR-10-0047 http://cancerpreventionresearch.aacrjournals.org/content/3/12/1552.full.pdf+html VL - 3 ID - 1153 ER - TY - JOUR AB - Gene-specific promoter methylation of several genes occurs in aging normal tissues and may predispose to tumorigenesis. In the present study, we investigate the association of blood folate levels and dietary and lifestyle factors with CpG island (CGI) methylation in normal colorectal mucosa. Subjects were enrolled in a multicenter chemoprevention trial of aspirin or folic acid for the prevention of large bowel adenomas. We collected 1,000 biopsy specimens from 389 patients, 501 samples from the right colon and 499 from the rectum at the follow-up colonoscopy. We measured DNA methylation of estrogen receptor alpha (ERα) and secreted frizzled related protein-1 (SFRP1), using bisulfite pyrosequencing. We used generalized estimating equations regression analysis to examine the association between methylation and selected variables. For both ERα and SFRP1, percentage methylation was significantly higher in the rectum than in the right colon (P = 0.001). For each 10 years of age, we observed a 1.7% increase in methylation level for ERα and a 2.9% increase for SFRP1 (P < 0.0001). African Americans had a significantly lower level of ERα and SFRP1 methylation than Caucasians and Hispanics. Higher RBC folate levels were associated with higher levels of both ERα (P = 0.03) and SFRP1 methylation (P = 0.01). Our results suggest that CGI methylation in normal colorectal mucosa is related to advancing age, race, rectal location, and RBC folate levels. These data have important implications regarding the safety of supplementary folate administration in healthy adults, given the hypothesis that methylation in normal mucosa may predispose to colorectal neoplasia. ©2010 AACR. AD - Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH, United States Department of Medicine, Medical University of South Carolina, Charleston, SC, United States Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States Department of Leukemia, Center for Cancer Epigenetics, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Department of Medicine, University of Colorado Denver School of Medicine, Denver, CO, United States Dala Lana School of Public Health, University of Toronto, Department of Nutritional Sciences, Toronto, ON, Canada AU - Wallace, K. AU - Grau, M. V. AU - Levine, A. J. AU - Shen, L. AU - Hamdan, R. AU - Chen, X. AU - Gui, J. AU - Haile, R. W. AU - Barry, E. L. AU - Ahnen, D. AU - McKeown-Eyssen, G. AU - Baron, J. A. AU - Issa, J. P. J. DB - Scopus DO - 10.1158/1940-6207.CAPR-10-0047 IS - 12 M3 - Article N1 - Cited By :92 Export Date: 22 March 2021 PY - 2010 SP - 1552-1564 ST - Association between folate levels and CpG island hypermethylation in normal colorectal mucosa T2 - Cancer Prevention Research TI - Association between folate levels and CpG island hypermethylation in normal colorectal mucosa UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650352867&doi=10.1158%2f1940-6207.CAPR-10-0047&partnerID=40&md5=55c4f94783f0e621d5d256ee79bac224 VL - 3 ID - 2491 ER - TY - JOUR AB - Gene-specific promoter methylation of several genes occurs in aging normal tissues and may predispose to tumorigenesis. In the present study, we investigate the association of blood folate levels and dietary and lifestyle factors with CpG island (CGI) methylation in normal colorectal mucosa. Subjects were enrolled in a multicenter chemoprevention trial of aspirin or folic acid for the prevention of large bowel adenomas. We collected 1,000 biopsy specimens from 389 patients, 501 samples from the right colon and 499 from the rectum at the follow-up colonoscopy. We measured DNA methylation of estrogen receptor alpha (ER alpha) and secreted frizzled related protein-1(SFRP1), using bisulfite pyrosequencing. We used generalized estimating equations regression analysis to examine the association between methylation and selected variables. For both ER alpha and SFRP1, percentage methylation was significantly higher in the rectum than in the right colon (P = 0.001). For each 10 years of age, we observed a 1.7% increase in methylation level for ER alpha and a 2.9% increase for SFRP1 (P < 0.0001). African Americans had a significantly lower level of ER alpha and SFRP1 methylation than Caucasians and Hispanics. Higher RBC folate levels were associated with higher levels of both ER alpha (P = 0.03) and SFRP1 methylation (P = 0.01). Our results suggest that CGI methylation in normal colorectal mucosa is related to advancing age, race, rectal location, and RBC folate levels. These data have important implications regarding the safety of supplementary folate administration in healthy adults, given the hypothesis that methylation in normal mucosa may predispose to colorectal neoplasia. Cancer Prev Res; 3(12); 1552-64. (C) 2010 AACR. AN - WOS:000285189400008 AU - Wallace, K. AU - Grau, M. V. AU - Levine, A. J. AU - Shen, L. L. AU - Hamdan, R. AU - Chen, X. L. AU - Gui, J. A. AU - Haile, R. W. AU - Barry, E. L. AU - Ahnen, D. AU - McKeown-Eyssen, G. AU - Baron, J. A. AU - Issa, J. P. J. DA - Dec DO - 10.1158/1940-6207.CAPR-10-0047 IS - 12 N1 - 21149331 PY - 2010 SN - 1940-6207 SP - 1552-1564 ST - Association between Folate Levels and CpG Island Hypermethylation in Normal Colorectal Mucosa T2 - Cancer Prevention Research TI - Association between Folate Levels and CpG Island Hypermethylation in Normal Colorectal Mucosa VL - 3 ID - 3107 ER - TY - JOUR AB - background Follow-through of a positive screening test is necessary to reap the potential benefits of cancer screening. Racial variation in follow-through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow-up diagnostic testing after a positive initial screening evaluation. methods Men who had a prostate-specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow-up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow-through according to race using mixed-effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (<65 years and ≥65 years). results Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non-Hispanic black men aged <65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non-Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37-0.82), whereas there was no racial difference in follow-through among older men. conclusions The current results suggest that limitations in access to care among non-Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow-through diagnostic care among non-Hispanic black men in the United States. © 2013 American Cancer Society. AD - D.A. Barocas, Department of Urologic Surgery, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN 37232, United States AU - Barocas, D. A. AU - Grubb Iii, R. AU - Black, A. AU - Penson, D. F. AU - Fowke, J. H. AU - Andriole, G. AU - Crawford, E. D. DB - Embase Medline DO - 10.1002/cncr.28042 IS - 12 KW - prostate specific antigen adult aged article cancer diagnosis cancer incidence cancer mortality cancer screening colorectal cancer controlled study digital rectal examination female health care health care access human human tissue lung cancer major clinical study male ovary cancer priority journal prostate biopsy prostate cancer race race difference screening test United States LA - English M3 - Article N1 - L52527801 2013-04-09 2013-06-26 PY - 2013 SN - 0008-543X 1097-0142 SP - 2223-2229 ST - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial T2 - Cancer TI - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52527801&from=export http://dx.doi.org/10.1002/cncr.28042 VL - 119 ID - 1079 ER - TY - JOUR AB - background Follow-through of a positive screening test is necessary to reap the potential benefits of cancer screening. Racial variation in follow-through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow-up diagnostic testing after a positive initial screening evaluation. methods Men who had a prostate-specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow-up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow-through according to race using mixed-effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (<65 years and ≥65 years). results Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non-Hispanic black men aged <65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non-Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37-0.82), whereas there was no racial difference in follow-through among older men. conclusions The current results suggest that limitations in access to care among non-Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow-through diagnostic care among non-Hispanic black men in the United States. © 2013 American Cancer Society. AD - Department of Urologic Surgery, Vanderbilt University Medical Center, A-1302 Medical Center North, Nashville, TN 37232, United States Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN, United States Division of Urologic Surgery, Washington University, St. Louis, MO, United States Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States Tennessee Valley Veterans Administration Health System, Nashville, TN, United States Division of Epidemiology, Vanderbilt University, Nashville, TN, United States Division of Urology, University of Colorado, Aurora, CO, United States AU - Barocas, D. A. AU - Grubb Iii, R. AU - Black, A. AU - Penson, D. F. AU - Fowke, J. H. AU - Andriole, G. AU - Crawford, E. D. DB - Scopus DO - 10.1002/cncr.28042 IS - 12 KW - biopsy diagnosis health care disparity prostate cancer race screening M3 - Article N1 - Cited By :30 Export Date: 22 March 2021 PY - 2013 SP - 2223-2229 ST - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial T2 - Cancer TI - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878563497&doi=10.1002%2fcncr.28042&partnerID=40&md5=f827147b5d62f1128429c15d7515d04d VL - 119 ID - 2431 ER - TY - JOUR AB - BACKGROUND: Follow‐through of a positive screening test is necessary to reap the potential benefits of cancer screening. Racial variation in follow‐through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow‐up diagnostic testing after a positive initial screening evaluation. METHODS: Men who had a prostate‐specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow‐up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow‐through according to race using mixed‐effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (<65 years and ≥65 years). RESULTS: Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non‐Hispanic black men aged <65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non‐Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37‐0.82), whereas there was no racial difference in follow‐through among older men. CONCLUSIONS: The current results suggest that limitations in access to care among non‐Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow‐through diagnostic care among non‐Hispanic black men in the United States. AN - CN-00964484 AU - Barocas, D. A. AU - Grubb, R. AU - Black, A. AU - Penson, D. F. AU - Fowke, J. H. AU - Andriole, G. AU - Crawford, E. D. DO - 10.1002/cncr.28042 IS - 12 KW - African Americans Aged Biopsy Early Detection of Cancer European Continental Ancestry Group Female Humans Male Middle Aged Multivariate Analysis Prostate‐Specific Antigen [*analysis] Prostatic Neoplasms [*diagnosis] Socioeconomic Factors United States M3 - Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2013 SP - 2223‐2229 ST - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial T2 - Cancer TI - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00964484/full VL - 119 ID - 1372 ER - TY - JOUR AB - BACKGROUND Follow-through of a positive screening test is necessary to reap the potential benefits of cancer screening. Racial variation in follow-through diagnostic care may underlie a proportion of the known disparity in prostate cancer mortality. The authors used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to determine whether race is associated with the use of follow-up diagnostic testing after a positive initial screening evaluation. METHODS Men who had a prostate-specific antigen (PSA) level >4 ng/mL at any time during the study were included. The proportion of men who underwent follow-up evaluation with a repeat PSA, a prostate biopsy, or either test within 9 months was determined, and the authors tested for differences in follow-through according to race using mixed-effects multivariate models with a random effect for accrual site to account for clustering. Models were stratified according to age (<65 years and 65 years). RESULTS Among 6294 men who had a PSA elevation during the study period, 70% underwent a repeat PSA or prostate biopsy within 9 months. Non-Hispanic black men aged <65 years had 45% lower odds of undergoing a repeat PSA test or prostate biopsy compared with non-Hispanic white men (odds ratio, 0.55; 95% confidence interval, 0.37-0.82), whereas there was no racial difference in follow-through among older men. CONCLUSIONS The current results suggest that limitations in access to care among non-Hispanic black men under the age of Medicare eligibility may underlie the paradoxically low use of follow-through diagnostic care among non-Hispanic black men in the United States. Cancer 2013;119:2223-2229. (c) 2013 American Cancer Society. AN - WOS:000319871800007 AU - Barocas, D. A. AU - Grubb, R. AU - Black, A. AU - Penson, D. F. AU - Fowke, J. H. AU - Andriole, G. AU - Crawford, E. D. DA - Jun DO - 10.1002/cncr.28042 IS - 12 N1 - 23559420 PY - 2013 SN - 0008-543X SP - 2223-2229 ST - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial T2 - Cancer TI - Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial VL - 119 ID - 3042 ER - TY - JOUR AB - IMPORTANCE Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. OBJECTIVE To determine if antioxidant supplements (Vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. DESIGN, SETTING, AND PARTICIPANTS The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. INTERVENTIONS Participants were randomized to Vitamin E, selenium, Vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. MAIN OUTCOMES AND MEASURES Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. RESULTS The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95%CI, 0.64-1.20) for Vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. CONCLUSIONS AND RELEVANCE Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men. AD - R.J. Kryscio, Sanders-Brown Center on Aging, University of Kentucky, 800 S Limestone St., Lexington, KY, United States AU - Kryscio, R. J. AU - Abner, E. L. AU - Caban-Holt, A. AU - Lovell, M. AU - Goodman, P. AU - Darke, A. K. AU - Yee, M. AU - Crowley, J. AU - Schmitt, F. A. DB - Embase Medline DO - 10.1001/jamaneurol.2016.5778 IS - 5 KW - alpha tocopherol placebo selenium aged Alzheimer disease article Black person chemoprophylaxis cohort analysis combination drug therapy comorbidity controlled study double blind procedure drug use educational status Hispanic human incidence major clinical study male monotherapy priority journal randomized controlled trial LA - English M3 - Article N1 - L616176258 2017-05-18 2017-06-01 PY - 2017 SN - 2168-6149 SP - 567-573 ST - Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by Vitamin E and selenium trial (PREADViSE) T2 - JAMA Neurology TI - Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by Vitamin E and selenium trial (PREADViSE) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616176258&from=export http://dx.doi.org/10.1001/jamaneurol.2016.5778 VL - 74 ID - 937 ER - TY - JOUR AB - Importance: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. Objective: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. Design, Setting, and Participants: The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double‐blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent‐to‐treat analysis to compare hazard rates among the study arms. Interventions: Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2‐stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2‐stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. Main Outcomes and Measures: Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. Results: The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self‐reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64‐1.20) for vitamin E, 0.83 (0.60‐1.13) for selenium, and 1.00 (0.75‐1.35) for the combination compared with placebo. Conclusions and Relevance: Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long‐term association of antioxidant supplement use and dementia incidence among asymptomatic men. AN - CN-01372521 AU - Kryscio, R. J. AU - Abner, E. L. AU - Caban-Holt, A. AU - Lovell, M. AU - Goodman, P. AU - Darke, A. K. AU - Yee, M. AU - Crowley, J. AU - Schmitt, F. A. DO - 10.1001/jamaneurol.2016.5778 IS - 5 KW - *Alzheimer disease/dt [Drug Therapy] *Alzheimer disease/ep [Epidemiology] *Alzheimer disease/pc [Prevention] *alpha tocopherol/cb [Drug Combination] *alpha tocopherol/cm [Drug Comparison] *alpha tocopherol/ct [Clinical Trial] *alpha tocopherol/dt [Drug Therapy] *selenium/cb [Drug Combination] *selenium/cm [Drug Comparison] *selenium/ct [Clinical Trial] *selenium/dt [Drug Therapy] Aged Alzheimer Disease [prevention & control] Alzheimer disease/dt [Drug Therapy] Antioxidants [administration & dosage, *pharmacology] Article Black person Chemoprophylaxis Cohort analysis Combination drug therapy Comorbidity Controlled study Dementia [*prevention & control] Dietary Supplements Double blind procedure Double‐Blind Method Drug Therapy, Combination Drug use Educational status Hispanic Human Humans Incidence Longitudinal Studies Major clinical study Male Middle Aged Monotherapy Outcome Assessment, Health Care Placebo Priority journal Randomized controlled trial Selenium [administration & dosage, *pharmacology] Vitamin E [administration & dosage, *pharmacology] M3 - Journal Article; Randomized Controlled Trial PY - 2017 SP - 567‐573 ST - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE) T2 - JAMA neurology TI - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01372521/full VL - 74 ID - 1603 ER - TY - JOUR AB - IMPORTANCE Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. OBJECTIVE To determine if antioxidant supplements (Vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. DESIGN, SETTING, AND PARTICIPANTS The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. INTERVENTIONS Participants were randomized to Vitamin E, selenium, Vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. MAIN OUTCOMES AND MEASURES Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. RESULTS The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95%CI, 0.64-1.20) for Vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. CONCLUSIONS AND RELEVANCE Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men. © 2017 American Medical Association. All rights reserved. AD - Sanders-Brown Center on Aging, University of Kentucky, 800 S Limestone St., Lexington, KY 40536, United States Alzheimer's Disease Center, University of Kentucky, Lexington, United States Department of Biostatistics, University of Kentucky, Lexington, United States Department of Statistics, University of Kentucky, Lexington, United States Department of Epidemiology, University of Kentucky, Lexington, United States Department of Chemistry, University of Kentucky, Lexington, United States SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States SWOG Statistical Center, Cancer Research and Biostatistics, Seattle, WA, United States Department of Neurology, College of Medicine, University of Kentucky, Lexington, United States AU - Kryscio, R. J. AU - Abner, E. L. AU - Caban-Holt, A. AU - Lovell, M. AU - Goodman, P. AU - Darke, A. K. AU - Yee, M. AU - Crowley, J. AU - Schmitt, F. A. DB - Scopus DO - 10.1001/jamaneurol.2016.5778 IS - 5 M3 - Article N1 - Cited By :98 Export Date: 22 March 2021 PY - 2017 SP - 567-573 ST - Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by Vitamin E and selenium trial (PREADViSE) T2 - JAMA Neurology TI - Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by Vitamin E and selenium trial (PREADViSE) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016163044&doi=10.1001%2fjamaneurol.2016.5778&partnerID=40&md5=f144c9ce1cfb74500cb5eb1fb3aeadc6 VL - 74 ID - 2309 ER - TY - JOUR AB - IMPORTANCE Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. OBJECTIVE To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. DESIGN, SETTING, AND PARTICIPANTS The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. INTERVENTIONS Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. MAIN OUTCOMES AND MEASURES Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. RESULTS The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. CONCLUSIONS AND RELEVANCE Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men. AN - WOS:000400838900014 AU - Kryscio, R. J. AU - Abner, E. L. AU - Caban-Holt, A. AU - Lovell, M. AU - Goodman, P. AU - Darke, A. K. AU - Yee, M. AU - Crowley, J. AU - Schmitt, F. A. DA - May DO - 10.1001/jamaneurol.2016.5778 IS - 5 N1 - 28319243 PY - 2017 SN - 2168-6149 SP - 567-573 ST - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE) T2 - Jama Neurology TI - Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADViSE) VL - 74 ID - 2898 ER - TY - JOUR AB - Importance: Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia. Objective: To determine if antioxidant supplements (vitamin E or selenium) used alone or in combination can prevent dementia in asymptomatic older men. Design, Setting, and Participants: The Prevention of Alzheimer’s Disease by Vitamin E and Selenium (PREADViSE) trial began as a double-blind randomized clinical trial in May 2002, which transformed into a cohort study from September 2009 to May 2015. The PREADViSE trial was ancillary to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized clinical trial of the same antioxidant supplements for preventing prostate cancer, which closed in 2009 owing to findings from a futility analysis. The PREADViSE trial recruited 7540 men, of whom 3786 continued into the cohort study. Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and Cox proportional hazards models were used in a modified intent-to-treat analysis to compare hazard rates among the study arms. Interventions: Participants were randomized to vitamin E, selenium, vitamin E and selenium, or placebo. While taking study supplements, enrolled men visited their SELECT site and were evaluated for dementia using a 2-stage screen. During the cohort study, men were contacted by telephone and assessed using an enhanced 2-stage cognitive screen. In both phases, men were encouraged to visit their physician if the screen results indicated possible cognitive impairment. Main Outcomes and Measures: Dementia case ascertainment relied on a consensus review of the cognitive screens and medical records for men with suspected dementia who visited their physician for an evaluation or by review of all available information, including a functional assessment screen. Results: The mean (SD) baseline age of the 7540 participants was 67.5 (5.3) years, with 3936 (52.2%) reporting a college education or better, 754 (10.0%) reporting black race, and 505 (6.7%) reporting Hispanic ethnicity. Dementia incidence (325 of 7338 men [4.4%]) was not different among the 4 study arms. A Cox model, which adjusted incidence for participant demographic information and baseline self-reported comorbidities, yielded hazard ratios of 0.88 (95% CI, 0.64-1.20) for vitamin E, 0.83 (0.60-1.13) for selenium, and 1.00 (0.75-1.35) for the combination compared with placebo. Conclusions and Relevance: Neither supplement prevented dementia. To our knowledge, this is the first study to investigate the long-term association of antioxidant supplement use and dementia incidence among asymptomatic men. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Kryscio, Richard J., Sanders Brown Center on Aging, University of Kentucky, 800 S Limestone St, Lexington, KY, US, 40536 AN - 2017-30844-008 AU - Kryscio, Richard J. AU - Abner, Erin L. AU - Caban-Holt, Allison AU - Lovell, Mark AU - Goodman, Phyllis AU - Darke, Amy K. AU - Yee, Monica AU - Crowley, John AU - Schmitt, Frederick A. DB - psyh DO - 10.1001/jamaneurol.2016.5778 DP - EBSCOhost IS - 5 KW - antioxidant supplement use dementia Alzheimer’s Disease Aged Alzheimer Disease Antioxidants Dietary Supplements Double-Blind Method Drug Therapy, Combination Humans Longitudinal Studies Male Middle Aged Outcome Assessment (Health Care) Selenium Vitamin E Alzheimer's Disease N1 - Archives of Neurology. Partial author list: First Author & Affiliation: Kryscio, Richard J.; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, US. Release Date: 20170803. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Alzheimer's Disease; Dementia; Antioxidants. Classification: Neurological Disorders & Brain Damage (3297). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Memory Impairment Screen DOI: 10.1037/t28561-000. Methodology: Empirical Study; Quantitative Study. Supplemental Data: Experimental Materials Internet. Page Count: 7. Issue Publication Date: May, 2017. Publication History: First Posted Date: Mar 20, 2017; Accepted Date: Mar 20, 2017. Copyright Statement: All rights reserved. American Medical Association. 2017. Sponsor: National Institute on Aging, US. Grant: R01 AG038651; P30 AG028383. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: CA37429; UM1 CA182883. Other Details: Selenium and Vitamin E Cancer Prevention Trial. Recipients: No recipient indicated PY - 2017 SN - 2168-6149 2168-6157 SP - 567-573 ST - Association of antioxidant supplement use and dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium trial (PREADViSE) T2 - JAMA Neurology TI - Association of antioxidant supplement use and dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium trial (PREADViSE) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2017-30844-008&site=ehost-live&scope=site kryscio@email.uky.edu VL - 74 ID - 1708 ER - TY - JOUR AB - Background: Obesity‐related cancers disproportionately affect the Black community. We assessed the relationship between diet quality, physical activity, and their combined effect on obesity‐related cancer risk and mortality in Black women enrolled in the Women's Health Initiative (WHI). Methods: Data from postmenopausal (50‐79 years of age) Black women enrolled in WHI clinical trials or observational studies were analyzed. Exposure variables included baseline physical activity [metabolic equivalent of tasks (MET)‐hours/ week of moderate‐to‐vigorous physical activity (MVPA)] and diet quality [Healthy Eating Index (HEI)‐2015]. Outcomes included adjudicated obesity‐related cancer incidence and mortality. Cox proportional hazard models were used to evaluate the association between MVPA and HEI‐2015 and obesity‐related cancer risk and mortality. Results: The analytical sample included 9,886 Black women, with a baseline mean body mass index (BMI) of 31.1 kg/m2 (SD ¼ 6.8); mean HEI‐2015 score of 63.2 (SD ¼ 11.0, possible range 0 to 100); and mean MVPA of 5.0 (SD ¼ 9.4) MET‐hours/week. Over an average of 13 years of follow‐up, 950 (9.6%) obesity‐related cancer cases were observed, with 313 (32.9%) resulting in death. Physical activity [HR, 1.05; 95% confidence interval (CI), 0.86‐1.30], diet quality (HR, 0.99; 95% CI, 0.92‐1.08), and their combination (HR, 1.05; 95% CI, 0.85‐1.29) were not associated with risk for any or site‐specific obesity‐related cancers. Similarly, these health behaviors had no association with mortality. Conclusions: Diet quality, physical activity and their combined effect, as measured, were not associated with obesity‐related cancer risk and mortality in Black women enrolled in WHI. Impact: Other social, behavioral, and biological factors may contribute to racial disparities observed in obesity‐related cancer rates. AN - CN-02097076 AU - Chebet, J. J. AU - Thomson, C. A. AU - Kohler, L. N. AU - Ehiri, J. E. AU - Luo, J. AU - Cheng, T. Yd AU - Pan, K. AU - Chlebowski, R. T. AU - Nassir, R. AU - Sealy-Jefferson, S. AU - et al. DO - 10.1158/1055-9965.EPI-19-1063 IS - 3 KW - *cancer mortality *cancer risk *nutritional parameters *obesity *physical activity Adult Aged Alcohol consumption Article Black person Body mass Breast cancer Cohort analysis Colorectal cancer Controlled study Female Follow up Health behavior Health care disparity Human Intervention study Major clinical study Metabolic equivalent Middle aged Observational study Postmenopause Priority journal Prospective study Questionnaire Randomized controlled trial Sedentary time Smoking Treatment outcome Waist circumference M3 - Journal: Article PY - 2020 SP - 591‐598 ST - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: results from the Women's Health Initiative T2 - Cancer epidemiology biomarkers and prevention TI - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: results from the Women's Health Initiative UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02097076/full VL - 29 ID - 1531 ER - TY - JOUR AB - Background: Obesity-related cancers disproportionately affect the Black community. We assessed the relationship between diet quality, physical activity, and their combined effect on obesity-related cancer risk and mortality in Black women enrolled in the Women's Health Initiative (WHI). Methods: Data from postmenopausal (50-79 years of age) Black women enrolled in WHI clinical trials or observational studies were analyzed. Exposure variables included baseline physical activity [metabolic equivalent of tasks (MET)-hours/ week of moderate-to-vigorous physical activity (MVPA)] and diet quality [Healthy Eating Index (HEI)-2015]. Outcomes included adjudicated obesity-related cancer incidence and mortality. Cox proportional hazard models were used to evaluate the association between MVPA and HEI-2015 and obesity-related cancer risk and mortality. Results: The analytical sample included 9,886 Black women, with a baseline mean body mass index (BMI) of 31.1 kg/m2 (SD ¼ 6.8); mean HEI-2015 score of 63.2 (SD ¼ 11.0, possible range 0 to 100); and mean MVPA of 5.0 (SD ¼ 9.4) MET-hours/week. Over an average of 13 years of follow-up, 950 (9.6%) obesity-related cancer cases were observed, with 313 (32.9%) resulting in death. Physical activity [HR, 1.05; 95% confidence interval (CI), 0.86-1.30], diet quality (HR, 0.99; 95% CI, 0.92-1.08), and their combination (HR, 1.05; 95% CI, 0.85-1.29) were not associated with risk for any or site-specific obesity-related cancers. Similarly, these health behaviors had no association with mortality. Conclusions: Diet quality, physical activity and their combined effect, as measured, were not associated with obesity-related cancer risk and mortality in Black women enrolled in WHI. Impact: Other social, behavioral, and biological factors may contribute to racial disparities observed in obesity-related cancer rates. © 2020 American Association for Cancer Research. AD - Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States University of Arizona Cancer Center, Tucson, AZ, United States Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, United States Department of Epidemiology, University of Florida, Gainesville, FL, United States Los Angeles Biomedical Institute, Torrance, CA, United States Department of Pathology, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, United States Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States College of Medicine, Sulaiman AlRajhi Colleges, Al Bukayriyah, Saudi Arabia AU - Chebet, J. J. AU - Thomson, C. A. AU - Kohler, L. N. AU - Ehiri, J. E. AU - Luo, J. AU - Cheng, T. Y. D. AU - Pan, K. AU - Chlebowski, R. T. AU - Nassir, R. AU - Sealy-Jefferson, S. AU - Manson, J. E. AU - Saquib, N. AU - Bell, M. L. DB - Scopus DO - 10.1158/1055-9965.EPI-19-1063 IS - 3 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 591-598 ST - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: Results from the Women's Health Initiative T2 - Cancer Epidemiology Biomarkers and Prevention TI - Association of diet quality and physical activity on obesity-related cancer risk and mortality in black women: Results from the Women's Health Initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081084214&doi=10.1158%2f1055-9965.EPI-19-1063&partnerID=40&md5=b36f171d8d0c4876695b3087668f15e9 VL - 29 ID - 2211 ER - TY - JOUR AB - Background: Obesity-related cancers disproportionately affect the Black community. We assessed the relationship between diet quality, physical activity, and their combined effect on obesity-related cancer risk and mortality in Black women enrolled in the Women's Health Initiative (WHI). Methods: Data from postmenopausal (50-79 years of age) Black women enrolled in WHI clinical trials or observational studies were analyzed. Exposure variables included baseline physical activity [metabolic equivalent of tasks (MET)-hours/week of moderate-to-vigorous physical activity (MVPA)] and diet quality [Healthy Eating Index (HEI)-2015]. Outcomes included adjudicated obesity- related cancer incidence and mortality. Cox proportional hazard models were used to evaluate the association between MVPA and HEI-2015 and obesity-related cancer risk and mortality. Results: The analytical sample included 9,886 Black women, with a baseline mean body mass index (BMI) of 31.1 kg/m(2) (SD = 6.8); mean HEI-2015 score of 63.2 (SD = 11.0, possible range 0 to 100); and mean MVPA of 5.0 (SD = 9.4) MET-hours/week. Over an average of 13 years of follow-up, 950 (9.6%) obesity-related cancer cases were observed, with 313 (32.9%) resulting in death. Physical activity [HR, 1.05; 95% confidence interval (CI), 0.86-1.30], diet quality (HR, 0.99; 95% CI, 0.92-1.08), and their combination (HR, 1.05; 95% CI, 0.85-1.29) were not associated with risk for any or site-specific obesity-related cancers. Similarly, these health behaviors had no association with mortality. Conclusions: Diet quality, physical activity and their combined effect, as measured, were not associated with obesity-related cancer risk and mortality in Black women enrolled in WHI. Impact: Other social, behavioral, and biological factors may contribute to racial disparities observed in obesity-related cancer rates. AN - WOS:000521288000008 AU - Chebet, J. J. AU - Thomson, C. A. AU - Kohler, L. N. AU - Ehiri, J. E. AU - Luo, J. H. AU - Cheng, T. Y. D. AU - Pan, K. AU - Chlebowski, R. T. AU - Nassir, R. AU - Sealy-Jefferson, S. AU - Manson, J. E. AU - Saquib, N. AU - Bell, M. L. DA - Mar DO - 10.1158/1055-9965.EPI-19-1063 IS - 3 N1 - 31915146 PY - 2020 SN - 1055-9965 SP - 591-598 ST - Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative T2 - Cancer Epidemiology Biomarkers & Prevention TI - Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative VL - 29 ID - 2789 ER - TY - JOUR AB - Higher risk for prostate cancer (PCa) among African Americans is partly associated with exposure to dietary fatty-acids, the carcinogenic effects of which remain controversial. Odds ratio of PCa risk was determined by unconditional logistic regression comparing highest with lowest quartiles of plasma fatty-acids in a case-control design. Mean age for 173 African Americans and 340 Nigerians was 56.9 ± 9.8 and 60.1 ± 14.0, p<.006, median (25th, 75th percentile) plasma fatty-acid was 2598 (2306, 3035) μg/ml and 2420 (2064, 2795) μg/ml, p<.001, with 48 (27.7%) and 66 (19.4%) PCa cases, respectively. African Americans recorded higher total, omega-6, and trans, but lower saturated and omega-3 fatty-acids, with non-significant PCa risk association for total, omega-6 and trans fatty acids. Positive PCa risk trend was observed in both populations with nervonic, erucic, and arachidonic acids, with docosahexaenoic acid (DHA) among African Americans, and with behenic and stearic acids in Nigerians. Non-significant negative PCa risk trend was observed with ecosapentaenoic acid (EPA) in Nigerians only. Tese preliminary findings need to be further explored in a larger study that will include risk analysis of fatty-acid ratios to clarify their combined impact on PCa risk. AD - F. A. Ukoli, Dept. of Surgery, Meharry Medical College, 1005 Dr. D.B. Todd, Jr. Blvd., Nashville, TN 37208, United States AU - Ukoli, F. A. AU - Fowke, J. H. AU - Akumabor, P. AU - Oguike, T. AU - Taher, K. A. AU - Murff, H. J. AU - Amaefuna, E. R. AU - Kittles, R. AU - Ahaghotu, C. AU - Osime, U. AU - Beech, D. J. DB - Medline IS - 1 SUPPL. 1 KW - fatty acid African American aged article blood case control study ethnology fat intake health disparity human male middle aged Black person Nigeria patient selection pilot study prostate tumor risk risk assessment statistical model statistics United States LA - English M3 - Article N1 - L358349434 2011-04-08 PY - 2010 SN - 1049-2089 SP - 127-147 ST - The association of plasma fatty acids with prostate cancer risk in African Americans and Africans T2 - Journal of Health Care for the Poor and Underserved TI - The association of plasma fatty acids with prostate cancer risk in African Americans and Africans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358349434&from=export VL - 21 ID - 1172 ER - TY - JOUR AB - Key Points: Question: What factors are associated with the receipt of nondefinitive therapy and survival among patients aged 70 years and younger who are diagnosed with high-risk prostate cancer? Findings: In this cohort study of 72 036 patients aged 70 years and younger with high-risk prostate cancer entered in the National Cancer Database, we found that 7.3% of patients received nondefinitive therapy; moreover, receipt of nondefinitive therapy was associated with inferior overall survival. Insurance status and race/ethnicity were independently associated with receipt of nondefinitive therapy. Meaning: The findings of this study suggest that significant barriers to life-extending treatment options for younger patients with high-risk prostate cancer remain. This cohort study identifies sociodemographic and health-related factors associated with receipt of nondefinitive therapy among patients aged 70 years and younger with high-risk prostate cancer. Importance: Multiple randomized clinical trials have shown that definitive therapy improves overall survival among patients with high-risk prostate cancer. However, many patients do not receive definitive therapy because of sociodemographic and health-related factors. Objective: To identify factors associated with receipt of nondefinitive therapy (NDT) among patients aged 70 years and younger with high-risk prostate cancer. Design, Setting, and Participants: This cohort study identified 72 036 patients aged 70 years and younger with high-risk prostate cancer and Charlson Comorbidity Index scores of 2 or less who were entered in the National Cancer Database between January 2004 and December 2014. Data analysis was conducted from November 2018 to December 2019. Exposure: Receipt of NDT as an initial treatment approach. Main Outcomes and Measures: Survival rates were compared based on receipt of definitive therapy or NDT, and sociodemographic and health-related factors were associated with the type of therapy received. Residual life expectancy was estimated from the National Center for Health Statistics to calculate person-years of life lost. Results: A total of 72 036 men with a median (range) age of 63 (30-70) years, Charlson Comorbidity Index scores of 2 or less, and high-risk prostate cancer without regional lymph node or distant metastatic disease were analyzed. Among eligible patients, 5252 (7.3%) received NDT as an initial therapeutic strategy. On univariate and multivariate analyses, NDT was associated with worse overall survival (univariate analysis hazard ratio, 2.54; 95% CI, 2.40-2.69; P <.001; multivariate analysis hazard ratio, 2.40; 95% CI, 2.26-2.56; P <.001). Compared with patients with private insurance or managed care, those with no insurance, Medicaid, or Medicare were more likely to receive systemic therapy only (no insurance: odds ratio [OR], 3.34; 95% CI, 2.81-3.98; P <.001; Medicaid: OR, 2.92; 95% CI, 2.48-3.43; P <.001; Medicare: OR, 1.36; 95% CI, 1.20-1.53; P <.001) or no treatment (no insurance: OR, 2.63; 95% CI, 2.24-3.08; P <.001; Medicaid: OR, 1.71; 95% CI, 1.45-2.01; P <.001; Medicare: OR, 1.14; 95% CI, 1.04-1.24; P =.004). Compared with white patients, black patients were more likely to receive systemic therapy only (OR, 1.93; 95% CI, 1.74-2.14; P <.001) or no treatment (OR, 1.46; 95% CI, 1.32-1.61; P <.001), and Hispanic patients were more likely to receive systemic therapy only (OR, 1.36; 95% CI, 1.13-1.64; P =.001) or no treatment (OR, 1.36; 95% CI, 1.14-1.60; P <.001). Between 2004 and 2014, patients without insurance or enrolled in Medicaid had 1.83-fold greater person-years of life lost compared with patients with private insurance (area under the curve, 77 600 vs 42 300 person-years of life lost). Conclusions and Relevance: In this study, receipt of NDT was associated with insurance status and race/ethnicity. While treatment decisions should be individualized for every patient, younger men with high-risk prostate cancer and minimal comorbidities should be encouraged to receive definitive local therapy regardless of other factors. These ata suggest that significant barriers to life-extending treatment options for patients with prostate cancer remain. AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston Department of Urology, The University of Texas MD Anderson Cancer Center, Houston Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston Department of Statistics, The University of Texas MD Anderson Cancer Center, Houston AN - 142358178. Language: English. Entry Date: 20200401. Revision Date: 20200420. Publication Type: Article AU - Bagley, Alexander F. AU - Anscher, Mitchell S. AU - Choi, Seungtaek AU - Frank, Steven J. AU - Hoffman, Karen E. AU - Kuban, Deborah A. AU - McGuire, Sean E. AU - Nguyen, Quynh-Nhu AU - Chapin, Brian AU - Aparicio, Ana AU - Pezzi, Todd A. AU - Smith, Grace L. AU - Smith, Benjamin D. AU - Hess, Kenneth AU - Tang, Chad DB - CINAHL Complete DO - 10.1001/jamanetworkopen.2020.1255 DP - EBSCOhost IS - 3 KW - Men's Health Prostatic Neoplasms -- Therapy Prostatic Neoplasms -- Psychosocial Factors Social Determinants of Health Insurance, Health Human Male Aged Prospective Studies Clinical Assessment Tools Survival Analysis Adult Middle Age Descriptive Statistics Univariate Statistics Multivariate Analysis Confidence Intervals Odds Ratio Logistic Regression Cox Proportional Hazards Model Kaplan-Meier Estimator Data Analysis Software Two-Tailed Test Medicaid Medicare N1 - research; tables/charts. Instrumentation: Charlson Comorbidity Index (CCI). PY - 2020 SP - e201255-e201255 ST - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer T2 - JAMA Network Open TI - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142358178&site=ehost-live&scope=site VL - 3 ID - 1855 ER - TY - JOUR AB - Importance: Multiple randomized clinical trials have shown that definitive therapy improves overall survival among patients with high-risk prostate cancer. However, many patients do not receive definitive therapy because of sociodemographic and health-related factors. Objective: To identify factors associated with receipt of nondefinitive therapy (NDT) among patients aged 70 years and younger with high-risk prostate cancer. Design, Setting, and Participants: This cohort study identified 72036 patients aged 70 years and younger with high-risk prostate cancer and Charlson Comorbidity Index scores of 2 or less who were entered in the National Cancer Database between January 2004 and December 2014. Data analysis was conducted from November 2018 to December 2019. Exposure: Receipt of NDT as an initial treatment approach. Main Outcomes and Measures: Survival rates were compared based on receipt of definitive therapy or NDT, and sociodemographic and health-related factors were associated with the type of therapy received. Residual life expectancy was estimated from the National Center for Health Statistics to calculate person-years of life lost. Results: A total of 72036 men with a median (range) age of 63 (30-70) years, Charlson Comorbidity Index scores of 2 or less, and high-risk prostate cancer without regional lymph node or distant metastatic disease were analyzed. Among eligible patients, 5252 (7.3%) received NDT as an initial therapeutic strategy. On univariate and multivariate analyses, NDT was associated with worse overall survival (univariate analysis hazard ratio, 2.54; 95% CI, 2.40-2.69; P <.001; multivariate analysis hazard ratio, 2.40; 95% CI, 2.26-2.56; P <.001). Compared with patients with private insurance or managed care, those with no insurance, Medicaid, or Medicare were more likely to receive systemic therapy only (no insurance: Odds ratio [OR], 3.34; 95% CI, 2.81-3.98; P <.001; Medicaid: OR, 2.92; 95% CI, 2.48-3.43; P <.001; Medicare: OR, 1.36; 95% CI, 1.20-1.53; P <.001) or no treatment (no insurance: OR, 2.63; 95% CI, 2.24-3.08; P <.001; Medicaid: OR, 1.71; 95% CI, 1.45-2.01; P <.001; Medicare: OR, 1.14; 95% CI, 1.04-1.24; P =.004). Compared with white patients, black patients were more likely to receive systemic therapy only (OR, 1.93; 95% CI, 1.74-2.14; P <.001) or no treatment (OR, 1.46; 95% CI, 1.32-1.61; P <.001), and Hispanic patients were more likely to receive systemic therapy only (OR, 1.36; 95% CI, 1.13-1.64; P =.001) or no treatment (OR, 1.36; 95% CI, 1.14-1.60; P <.001). Between 2004 and 2014, patients without insurance or enrolled in Medicaid had 1.83-fold greater person-years of life lost compared with patients with private insurance (area under the curve, 77600 vs 42300 person-years of life lost). Conclusions and Relevance: In this study, receipt of NDT was associated with insurance status and race/ethnicity. While treatment decisions should be individualized for every patient, younger men with high-risk prostate cancer and minimal comorbidities should be encouraged to receive definitive local therapy regardless of other factors. These data suggest that significant barriers to life-extending treatment options for patients with prostate cancer remain. AD - C. Tang, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, United States AU - Bagley, A. F. AU - Anscher, M. S. AU - Choi, S. AU - Frank, S. J. AU - Hoffman, K. E. AU - Kuban, D. A. AU - McGuire, S. E. AU - Nguyen, Q. N. AU - Chapin, B. AU - Aparicio, A. AU - Pezzi, T. A. AU - Smith, G. L. AU - Smith, B. D. AU - Hess, K. AU - Tang, C. DB - Embase Medline DO - 10.1001/jamanetworkopen.2020.1255 IS - 3 KW - prostate specific antigen adult age aged article cancer survival cancer therapy Charlson Comorbidity Index cohort analysis comorbidity cryoablation demography health insurance Hispanic human life expectancy lymph node metastasis major clinical study male managed care medicaid medicare overall survival priority journal prostate cancer social status systemic therapy LA - English M3 - Article N1 - L631296125 2020-04-07 2020-04-10 PY - 2020 SN - 2574-3805 ST - Association of Sociodemographic and Health-Related Factors with Receipt of Nondefinitive Therapy among Younger Men with High-Risk Prostate Cancer T2 - JAMA Network Open TI - Association of Sociodemographic and Health-Related Factors with Receipt of Nondefinitive Therapy among Younger Men with High-Risk Prostate Cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631296125&from=export http://dx.doi.org/10.1001/jamanetworkopen.2020.1255 VL - 3 ID - 812 ER - TY - JOUR AB - Importance: Multiple randomized clinical trials have shown that definitive therapy improves overall survival among patients with high-risk prostate cancer. However, many patients do not receive definitive therapy because of sociodemographic and health-related factors. Objective: To identify factors associated with receipt of nondefinitive therapy (NDT) among patients aged 70 years and younger with high-risk prostate cancer. Design, Setting, and Participants: This cohort study identified 72 036 patients aged 70 years and younger with high-risk prostate cancer and Charlson Comorbidity Index scores of 2 or less who were entered in the National Cancer Database between January 2004 and December 2014. Data analysis was conducted from November 2018 to December 2019. Exposure: Receipt of NDT as an initial treatment approach. Main Outcomes and Measures: Survival rates were compared based on receipt of definitive therapy or NDT, and sociodemographic and health-related factors were associated with the type of therapy received. Residual life expectancy was estimated from the National Center for Health Statistics to calculate person-years of life lost. Results: A total of 72 036 men with a median (range) age of 63 (30-70) years, Charlson Comorbidity Index scores of 2 or less, and high-risk prostate cancer without regional lymph node or distant metastatic disease were analyzed. Among eligible patients, 5252 (7.3%) received NDT as an initial therapeutic strategy. On univariate and multivariate analyses, NDT was associated with worse overall survival (univariate analysis hazard ratio, 2.54; 95% CI, 2.40-2.69; P < .001; multivariate analysis hazard ratio, 2.40; 95% CI, 2.26-2.56; P < .001). Compared with patients with private insurance or managed care, those with no insurance, Medicaid, or Medicare were more likely to receive systemic therapy only (no insurance: odds ratio [OR], 3.34; 95% CI, 2.81-3.98; P < .001; Medicaid: OR, 2.92; 95% CI, 2.48-3.43; P < .001; Medicare: OR, 1.36; 95% CI, 1.20-1.53; P < .001) or no treatment (no insurance: OR, 2.63; 95% CI, 2.24-3.08; P < .001; Medicaid: OR, 1.71; 95% CI, 1.45-2.01; P < .001; Medicare: OR, 1.14; 95% CI, 1.04-1.24; P = .004). Compared with white patients, black patients were more likely to receive systemic therapy only (OR, 1.93; 95% CI, 1.74-2.14; P < .001) or no treatment (OR, 1.46; 95% CI, 1.32-1.61; P < .001), and Hispanic patients were more likely to receive systemic therapy only (OR, 1.36; 95% CI, 1.13-1.64; P = .001) or no treatment (OR, 1.36; 95% CI, 1.14-1.60; P < .001). Between 2004 and 2014, patients without insurance or enrolled in Medicaid had 1.83-fold greater person-years of life lost compared with patients with private insurance (area under the curve, 77 600 vs 42 300 person-years of life lost). Conclusions and Relevance: In this study, receipt of NDT was associated with insurance status and race/ethnicity. While treatment decisions should be individualized for every patient, younger men with high-risk prostate cancer and minimal comorbidities should be encouraged to receive definitive local therapy regardless of other factors. These data suggest that significant barriers to life-extending treatment options for patients with prostate cancer remain. AD - Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston Department of Urology, University of Texas MD Anderson Cancer Center, Houston Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston Department of Statistics, University of Texas MD Anderson Cancer Center, Houston AU - Bagley, A. F. AU - Anscher, M. S. AU - Choi, S. AU - Frank, S. J. AU - Hoffman, K. E. AU - Kuban, D. A. AU - McGuire, S. E. AU - Nguyen, Q. N. AU - Chapin, B. AU - Aparicio, A. AU - Pezzi, T. A. AU - Smith, G. L. AU - Smith, B. D. AU - Hess, K. AU - Tang, C. DB - Scopus DO - 10.1001/jamanetworkopen.2020.1255 IS - 3 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2020 SP - e201255 ST - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer T2 - JAMA network open TI - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082145231&doi=10.1001%2fjamanetworkopen.2020.1255&partnerID=40&md5=059fe50323ec372f66615142d24e29fa VL - 3 ID - 2201 ER - TY - JOUR AB - Importance Multiple randomized clinical trials have shown that definitive therapy improves overall survival among patients with high-risk prostate cancer. However, many patients do not receive definitive therapy because of sociodemographic and health-related factors. Objective To identify factors associated with receipt of nondefinitive therapy (NDT) among patients aged 70 years and younger with high-risk prostate cancer. Design, Setting, and Participants This cohort study identified 72 036 patients aged 70 years and younger with high-risk prostate cancer and Charlson Comorbidity Index scores of 2 or less who were entered in the National Cancer Database between January 2004 and December 2014. Data analysis was conducted from November 2018 to December 2019. Exposure Receipt of NDT as an initial treatment approach. Main Outcomes and Measures Survival rates were compared based on receipt of definitive therapy or NDT, and sociodemographic and health-related factors were associated with the type of therapy received. Residual life expectancy was estimated from the National Center for Health Statistics to calculate person-years of life lost. Results A total of 72 036 men with a median (range) age of 63 (30-70) years, Charlson Comorbidity Index scores of 2 or less, and high-risk prostate cancer without regional lymph node or distant metastatic disease were analyzed. Among eligible patients, 5252 (7.3%) received NDT as an initial therapeutic strategy. On univariate and multivariate analyses, NDT was associated with worse overall survival (univariate analysis hazard ratio, 2.54; 95% CI, 2.40-2.69; P < .001; multivariate analysis hazard ratio, 2.40; 95% CI, 2.26-2.56; P < .001). Compared with patients with private insurance or managed care, those with no insurance, Medicaid, or Medicare were more likely to receive systemic therapy only (no insurance: odds ratio [OR], 3.34; 95% CI, 2.81-3.98; P < .001; Medicaid: OR, 2.92; 95% CI, 2.48-3.43; P < .001; Medicare: OR, 1.36; 95% CI, 1.20-1.53; P < .001) or no treatment (no insurance: OR, 2.63; 95% CI, 2.24-3.08; P < .001; Medicaid: OR, 1.71; 95% CI, 1.45-2.01; P < .001; Medicare: OR, 1.14; 95% CI, 1.04-1.24; P = .004). Compared with white patients, black patients were more likely to receive systemic therapy only (OR, 1.93; 95% CI, 1.74-2.14; P < .001) or no treatment (OR, 1.46; 95% CI, 1.32-1.61; P < .001), and Hispanic patients were more likely to receive systemic therapy only (OR, 1.36; 95% CI, 1.13-1.64; P = .001) or no treatment (OR, 1.36; 95% CI, 1.14-1.60; P < .001). Between 2004 and 2014, patients without insurance or enrolled in Medicaid had 1.83-fold greater person-years of life lost compared with patients with private insurance (area under the curve, 77 600 vs 42 300 person-years of life lost). Conclusions and Relevance In this study, receipt of NDT was associated with insurance status and race/ethnicity. While treatment decisions should be individualized for every patient, younger men with high-risk prostate cancer and minimal comorbidities should be encouraged to receive definitive local therapy regardless of other factors. These data suggest that significant barriers to life-extending treatment options for patients with prostate cancer remain. AN - WOS:000521963700003 AU - Bagley, A. F. AU - Anscher, M. S. AU - Choi, S. AU - Frank, S. J. AU - Hoffman, K. E. AU - Kuban, D. A. AU - McGuire, S. E. AU - Nguyen, Q. N. AU - Chapin, B. AU - Aparicio, A. AU - Pezzi, T. A. AU - Smith, G. L. AU - Smith, B. D. AU - Hess, K. AU - Tang, C. DA - Mar DO - 10.1001/jamanetworkopen.2020.1255 IS - 3 N1 - e201255 32191331 PY - 2020 SN - 2574-3805 ST - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer T2 - Jama Network Open TI - Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer VL - 3 ID - 2787 ER - TY - JOUR AB - Background: Recent literature suggests that living in a rural setting may be associated with adverse cancer outcomes. This study examines the burden of travel from home to cancer center for clinical trial (CT) enrollees. Materials and Methods: Patients from the University of California San Francisco Clinical Trial Management System database who enrolled in a cancer CT for a breast, genitourinary, or gastrointestinal malignancy between 1993 and 2014 were included. Cancer type, household zip code, race/ethnicity, phase of study, study sponsor, and year of signed consent were exported. Distance traveled from home to center was calculated using a GoogleMaps application programming interface. The relationships of distance with phase of CT, household income, and race/ethnicity were examined. Results: A total of 1,600 patients were enrolled in breast (55.8%), genitourinary (29.4%), or gastrointestinal (14.9%) cancer CTs. The overall median unidirectional distance traveled from home to study site was 25.8 miles (interquartile range [IQR] 11.5–75.3). Of the trial sponsors examined, principal investigator (56.4%), industry (22.2%), cooperative group (11.6%), and National Institutes of Health (NIH; 9.8%), the longest distance traveled was for NIH-sponsored trials, with a median of 39.4 miles (p <.001). Phase I (8.4%) studies had the longest distance traveled, with a median of 41.2 miles (IQR 14.5–101.0 miles; p =.001). White patients (83%) traveled longer compared with black patients (4.4%), with median distances of 29.9 and 13.9 miles, respectively (p <.001). Patients from lower-income areas (n = 799) traveled longer distances compared with patients from higher-income areas (n = 773; 58.3 vs. 17.8 miles, respectively; p <.001). A multivariable linear model where log10 (distance) was the outcome and adjusting for the exported variables and income revealed that cancer type, year of consent, race/ethnicity, and income were significantly associated with distance traveled. Conclusion: This study found that the burden of travel is highest among patients enrolled in NIH-sponsored trials, phase I studies, or living in low-income areas. These data suggest that travel burden for cancer CT participants may be significant. Implications for Practice: This study is one of the first to measure travel distance for patients in cancer clinical trials using a real-world GoogleMaps calculator. Out-of-pocket expenses such as travel are not typically covered by health care payers; therefore, patients may face considerable cost to attend each study visit. Using a single-center clinical trials enrollment database, this study found that the burden of travel is highest for patients enrolled in National Institutes of Health-sponsored trials and phase I studies, as well as for patients living in low-income areas. Results suggest that a significant proportion of patients enrolled in clinical trials face a substantial travel burden. AD - H.T. Borno, Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, United States AU - Borno, H. T. AU - Zhang, L. AU - Siegel, A. AU - Chang, E. AU - Ryan, C. J. DB - Embase Medline DO - 10.1634/theoncologist.2017-0628 IS - 10 KW - article breast cancer cancer patient cancer research clinical trial (topic) cost digestive system cancer ethnicity home human income major clinical study national health organization phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) phase 4 clinical trial (topic) race retrospective study travel urogenital tract cancer LA - English M3 - Article N1 - L621918064 2018-05-03 2020-07-16 PY - 2018 SN - 1549-490X 1083-7159 SP - 1242-1249 ST - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials T2 - Oncologist TI - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621918064&from=export http://dx.doi.org/10.1634/theoncologist.2017-0628 VL - 23 ID - 880 ER - TY - JOUR AB - Background: Recent literature suggests that living in a rural setting may be associated with adverse cancer outcomes. This study examines the burden of travel from home to cancer center for clinical trial (CT) enrollees. Materials and Methods: Patients from the University of California San Francisco Clinical Trial Management System database who enrolled in a cancer CT for a breast, genitourinary, or gastrointestinal malignancy between 1993 and 2014 were included. Cancer type, household zip code, race/ethnicity, phase of study, study sponsor, and year of signed consent were exported. Distance traveled from home to center was calculated using a GoogleMaps application programming interface. The relationships of distance with phase of CT, household income, and race/ethnicity were examined. Results: A total of 1,600 patients were enrolled in breast (55.8%), genitourinary (29.4%), or gastrointestinal (14.9%) cancer CTs. The overall median unidirectional distance traveled from home to study site was 25.8 miles (interquartile range [IQR] 11.5–75.3). Of the trial sponsors examined, principal investigator (56.4%), industry (22.2%), cooperative group (11.6%), and National Institutes of Health (NIH; 9.8%), the longest distance traveled was for NIH‐sponsored trials, with a median of 39.4 miles (p < .001). Phase I (8.4%) studies had the longest distance traveled, with a median of 41.2 miles (IQR 14.5–101.0 miles; p = .001). White patients (83%) traveled longer compared with black patients (4.4%), with median distances of 29.9 and 13.9 miles, respectively (p < .001). Patients from lower‐income areas (n = 799) traveled longer distances compared with patients from higher‐income areas (n = 773; 58.3 vs. 17.8 miles, respectively; p < .001). A multivariable linear model where log10 (distance) was the outcome and adjusting for the exported variables and income revealed that cancer type, year of consent, race/ethnicity, and income were significantly associated with distance traveled. Conclusion: This study found that the burden of travel is highest among patients enrolled in NIH‐sponsored trials, phase I studies, or living in low‐income areas. These data suggest that travel burden for cancer CT participants may be significant. Implications for Practice: This study is one of the first to measure travel distance for patients in cancer clinical trials using a real‐world GoogleMaps calculator. Out‐of‐pocket expenses such as travel are not typically covered by health care payers; therefore, patients may face considerable cost to attend each study visit. Using a single‐center clinical trials enrollment database, this study found that the burden of travel is highest for patients enrolled in National Institutes of Health‐sponsored trials and phase I studies, as well as for patients living in low‐income areas. Results suggest that a significant proportion of patients enrolled in clinical trials face a substantial travel burden. Several barriers to clinical trial participation exist; however, the burden of cost and time associated with travel to visits may contribute to disparities in care. This analysis may inform ways that health care payers and systems can reduce the burden to encourage equitable recruitment and retention in cancer clinical trials. AD - Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco California, USA Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco California, USA AN - 132343569. Language: English. Entry Date: 20181016. Revision Date: 20190710. Publication Type: Article AU - Borno, Hala T. AU - Zhang, Li AU - Siegel, Adam AU - Chang, Emily AU - Ryan, Charles J. DB - CINAHL Complete DO - 10.1634/theoncologist.2017-0628 DP - EBSCOhost IS - 10 KW - Clinical Trials -- Economics Costs and Cost Analysis Travel Cancer Patients Cancer Care Facilities Home Environment Human Retrospective Design Academic Medical Centers -- California California Tomography, X-Ray Computed -- Methods Breast Neoplasms -- Radiography Urogenital Neoplasms -- Radiography Gastrointestinal Neoplasms -- Radiography Income Race Factors Ethnic Groups National Institutes of Health (U.S.) Black Persons Poverty Multiple Linear Regression Consent N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9607837. PY - 2018 SN - 1083-7159 SP - 1242-1249 ST - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials T2 - Oncologist TI - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132343569&site=ehost-live&scope=site VL - 23 ID - 1856 ER - TY - JOUR AB - Background: Recent literature suggests that living in a rural setting may be associated with adverse cancer outcomes. This study examines the burden of travel from home to cancer center for clinical trial (CT) enrollees. Materials and Methods: Patients from the University of California San Francisco Clinical Trial Management System database who enrolled in a cancer CT for a breast, genitourinary, or gastrointestinal malignancy between 1993 and 2014 were included. Cancer type, household zip code, race/ethnicity, phase of study, study sponsor, and year of signed consent were exported. Distance traveled from home to center was calculated using a GoogleMaps application programming interface. The relationships of distance with phase of CT, household income, and race/ethnicity were examined. Results: A total of 1,600 patients were enrolled in breast (55.8%), genitourinary (29.4%), or gastrointestinal (14.9%) cancer CTs. The overall median unidirectional distance traveled from home to study site was 25.8 miles (interquartile range [IQR] 11.5–75.3). Of the trial sponsors examined, principal investigator (56.4%), industry (22.2%), cooperative group (11.6%), and National Institutes of Health (NIH; 9.8%), the longest distance traveled was for NIH-sponsored trials, with a median of 39.4 miles (p <.001). Phase I (8.4%) studies had the longest distance traveled, with a median of 41.2 miles (IQR 14.5–101.0 miles; p =.001). White patients (83%) traveled longer compared with black patients (4.4%), with median distances of 29.9 and 13.9 miles, respectively (p <.001). Patients from lower-income areas (n = 799) traveled longer distances compared with patients from higher-income areas (n = 773; 58.3 vs. 17.8 miles, respectively; p <.001). A multivariable linear model where log10 (distance) was the outcome and adjusting for the exported variables and income revealed that cancer type, year of consent, race/ethnicity, and income were significantly associated with distance traveled. Conclusion: This study found that the burden of travel is highest among patients enrolled in NIH-sponsored trials, phase I studies, or living in low-income areas. These data suggest that travel burden for cancer CT participants may be significant. Implications for Practice: This study is one of the first to measure travel distance for patients in cancer clinical trials using a real-world GoogleMaps calculator. Out-of-pocket expenses such as travel are not typically covered by health care payers; therefore, patients may face considerable cost to attend each study visit. Using a single-center clinical trials enrollment database, this study found that the burden of travel is highest for patients enrolled in National Institutes of Health-sponsored trials and phase I studies, as well as for patients living in low-income areas. Results suggest that a significant proportion of patients enrolled in clinical trials face a substantial travel burden. © AlphaMed Press 2018 AD - Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, United States Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States AU - Borno, H. T. AU - Zhang, L. AU - Siegel, A. AU - Chang, E. AU - Ryan, C. J. DB - Scopus DO - 10.1634/theoncologist.2017-0628 IS - 10 KW - Cancer clinical trial disparities Health care costs Recruitment science Representativeness in clinical trials Travel distance M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2018 SP - 1242-1249 ST - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials T2 - Oncologist TI - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046006150&doi=10.1634%2ftheoncologist.2017-0628&partnerID=40&md5=b23c2f39742768765770e929806939b6 VL - 23 ID - 2256 ER - TY - JOUR AB - Background Recent literature suggests that living in a rural setting may be associated with adverse cancer outcomes. This study examines the burden of travel from home to cancer center for clinical trial (CT) enrollees. Materials and MethodsResultsPatients from the University of California San Francisco Clinical Trial Management System database who enrolled in a cancer CT for a breast, genitourinary, or gastrointestinal malignancy between 1993 and 2014 were included. Cancer type, household zip code, race/ethnicity, phase of study, study sponsor, and year of signed consent were exported. Distance traveled from home to center was calculated using a GoogleMaps application programming interface. The relationships of distance with phase of CT, household income, and race/ethnicity were examined. A total of 1,600 patients were enrolled in breast (55.8%), genitourinary (29.4%), or gastrointestinal (14.9%) cancer CTs. The overall median unidirectional distance traveled from home to study site was 25.8 miles (interquartile range [IQR] 11.5-75.3). Of the trial sponsors examined, principal investigator (56.4%), industry (22.2%), cooperative group (11.6%), and National Institutes of Health (NIH; 9.8%), the longest distance traveled was for NIH-sponsored trials, with a median of 39.4 miles (p<.001). Phase I (8.4%) studies had the longest distance traveled, with a median of 41.2 miles (IQR 14.5-101.0 miles; p=.001). White patients (83%) traveled longer compared with black patients (4.4%), with median distances of 29.9 and 13.9 miles, respectively (p<.001). Patients from lower-income areas (n=799) traveled longer distances compared with patients from higher-income areas (n=773; 58.3 vs. 17.8 miles, respectively; p<.001). A multivariable linear model where log10 (distance) was the outcome and adjusting for the exported variables and income revealed that cancer type, year of consent, race/ethnicity, and income were significantly associated with distance traveled. ConclusionImplications for PracticeThis study found that the burden of travel is highest among patients enrolled in NIH-sponsored trials, phase I studies, or living in low-income areas. These data suggest that travel burden for cancer CT participants may be significant. This study is one of the first to measure travel distance for patients in cancer clinical trials using a real-world GoogleMaps calculator. Out-of-pocket expenses such as travel are not typically covered by health care payers; therefore, patients may face considerable cost to attend each study visit. Using a single-center clinical trials enrollment database, this study found that the burden of travel is highest for patients enrolled in National Institutes of Health-sponsored trials and phase I studies, as well as for patients living in low-income areas. Results suggest that a significant proportion of patients enrolled in clinical trials face a substantial travel burden. Several barriers to clinical trial participation exist; however, the burden of cost and time associated with travel to visits may contribute to disparities in care. This analysis may inform ways that health care payers and systems can reduce the burden to encourage equitable recruitment and retention in cancer clinical trials. AN - WOS:000447162800019 AU - Borno, H. T. AU - Zhang, L. AU - Siegel, A. AU - Chang, E. AU - Ryan, C. J. DA - Oct DO - 10.1634/theoncologist.2017-0628 IS - 10 N1 - 29700209 PY - 2018 SN - 1083-7159 SP - 1242-1249 ST - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials T2 - Oncologist TI - At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials VL - 23 ID - 2845 ER - TY - JOUR AB - Assessed attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. 46 African-American males, 40 yrs of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio-economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower SES. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1997-43650-001 AU - Robinson, Susan B. AU - Ashley, Mary AU - Haynes, M. Alfred DB - psyh DO - 10.1007/BF01682300 DP - EBSCOhost IS - 2 KW - SES attitudes toward prostate cancer clinical trial participation 40 yr old & older African American males Adult African Americans Aged Attitude to Health Clinical Trials as Topic Educational Status Focus Groups Health Education Health Knowledge, Attitudes, Practice Humans Los Angeles Male Middle Aged Motivation Patient Acceptance of Health Care Physician-Patient Relations Prostatic Neoplasms Socioeconomic Factors Urban Population Experimentation Health Attitudes Neoplasms Prostate Socioeconomic Status Blacks Clinical Trials Human Males N1 - Drew U School of Medicine, Drew/Meharry/Morehouse Consortium Cancer Ctr, Los Angeles, CA, US. Release Date: 19980401. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Experimentation; Health Attitudes; Neoplasms; Prostate; Socioeconomic Status. Minor Descriptor: Blacks; Clinical Trials; Human Males. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study. Page Count: 11. Issue Publication Date: Apr, 1996. PY - 1996 SN - 0094-5145 1573-3610 SP - 77-87 ST - Attitudes of African-Americans regarding prostate cancer clinical trials T2 - Journal of Community Health: The Publication for Health Promotion and Disease Prevention TI - Attitudes of African-Americans regarding prostate cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1997-43650-001&site=ehost-live&scope=site VL - 21 ID - 1752 ER - TY - JOUR AB - The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio-economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues. AD - Drew/Meharry/Morehouse Consortium Cancer Center, 12714 South Avalon Boulevard, Suite 301, Los Angeles, CA 90061 AN - 107375464. Language: English. Entry Date: 19960701. Revision Date: 20200701. Publication Type: Journal Article AU - Robinson, S. B. AU - Ashley, M. AU - Haynes, M. A. DB - CINAHL Complete DO - 10.1007/bf01682300 DP - EBSCOhost IS - 2 KW - Prostatic Neoplasms -- Prevention and Control Black Persons Attitude to Illness Clinical Trials -- Utilization Funding Source California Qualitative Studies Focus Groups Socioeconomic Factors Health Beliefs Health Knowledge Male Consumer Attitudes Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: Supported by a grant (CA 54603-02) from the National Cancer Institute. NLM UID: 7600747. PMID: NLM8728357. PY - 1996 SN - 0094-5145 SP - 77-87 ST - Attitudes of African-Americans regarding prostate cancer clinical trials T2 - Journal of Community Health TI - Attitudes of African-Americans regarding prostate cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107375464&site=ehost-live&scope=site VL - 21 ID - 1857 ER - TY - JOUR AB - The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials. Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio- economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues. AD - Department of Family Medicine, Drew/Meharry/Morehouse Consortium Cancer Center, Drew University School of Medicine and Science, United States Drew University, School of Medicine and Science, Drew/Meharry/Morehouse Consortium Cancer Center, United States Drew/Meharry/ Morehouse Consortium Cancer Center, 12714 South Avalon Boulevard, Los Angeles, CA 90061, United States AU - Robinson, S. B. AU - Ashley, M. AU - Haynes, M. A. DB - Scopus DO - 10.1007/BF01682300 IS - 2 M3 - Article N1 - Cited By :94 Export Date: 22 March 2021 PY - 1996 SP - 77-87 ST - Attitudes of African-Americans regarding prostate cancer clinical trials T2 - Journal of Community Health TI - Attitudes of African-Americans regarding prostate cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029666361&doi=10.1007%2fBF01682300&partnerID=40&md5=4d01f7677105fb4ee701f29bffe3b245 VL - 21 ID - 2649 ER - TY - JOUR AB - The purpose of this study was to qualitatively assess attitudes associated with the willingness of African-Americans to participate in prostate cancer clinical trials, Fifty-six African-American males, 40 years of age and older, were recruited from South Central Los Angeles. Respondents were divided into lower or middle socio-economic groups based on education and occupation. Focus group discussions were conducted to assess their knowledge about prostate cancer and willingness to participate in prostate cancer clinical trials. In addition, information was obtained to identify their incentives and barriers toward participating in prostate cancer research. Middle socio-economic respondents expressed a greater willingness to participate in prostate cancer clinical trials than did men of lower socio-economic status. Many indicated that they would be more likely to participate if they were encouraged to do so by a physician or researcher who was viewed as being competent and compassionate. Barriers to participation in prostate cancer clinical trials included concerns about drug toxicity, medical experimentation and distrust of the medical establishment. Endeavors aimed at increasing minority representation in prostate cancer clinical studies should address these issues. AN - WOS:A1996UF41000001 AU - Robinson, S. B. AU - Ashley, M. AU - Haynes, M. A. DA - Apr DO - 10.1007/BF01682300 IS - 2 N1 - 93 8728357 PY - 1996 SN - 0094-5145 SP - 77-87 ST - Attitudes of African-Americans regarding prostate cancer clinical trials T2 - Journal of Community Health TI - Attitudes of African-Americans regarding prostate cancer clinical trials VL - 21 ID - 2737 ER - TY - JOUR AB - Introduction: Black men are diagnosed with prostate cancer at nearly twice the rate of white men and are underrepresented in prostate cancer research, including validation studies of new clinical tools (e.g., genomic testing). Because healthcare system mistrust has contributed to these disparities for centuries, black men may be less inclined to pursue novel testing, and identification of facilitators to their participation in prostate cancer research studies remains warranted. Methods: A community-engaged approach involving a partnership with a community organization was used to conduct seven focus groups in Minnesota, Alabama, and California to explore black men's attitudes toward prostate cancer research participation and genomic testing for prostate cancer. Data were collected and analyzed from April 2015 to April 2017. Results: Identified genomic testing barriers included a lack of terminology understanding, healthcare system mistrust, reluctance to seek medical care, and unfavorable attitudes toward research. Facilitators included family history, value of prevention, and the desire for health education. Lack of prostate cancer knowledge, prostate-specific antigen testing confusion, healthcare system distrust, and misuse of personal health information were barriers to research study participation. Some black men were motivated to participate in research if it was seen as constructive and transparent. Conclusions: Disparities for black men can both motivate and disincentivize participation depending upon a positive or negative view of research. Confusion over prostate cancer clinical care has fueled some mistrust among black men affecting both clinical care and research participation. With increased education, health literacy, and assurances of research integrity and transparency, black men may be more willing to participate in prostate cancer testing and research. Supplement information: This article is part of a supplement entitled African American Men's Health: Research, Practice, and Policy Implications, which is sponsored by the National Institutes of Health. AD - C.R. Rogers, Department of Family and Preventive Medicine, University of Utah School of Medicine, 375 Chipeta Way, Suite A, Salt Lake City, UT, United States AU - Rogers, C. R. AU - Rovito, M. J. AU - Hussein, M. AU - Obidike, O. J. AU - Pratt, R. AU - Alexander, M. AU - Berge, J. M. AU - Dall'Era, M. AU - Nix, J. W. AU - Warlick, C. DB - Embase Medline DO - 10.1016/j.amepre.2018.05.028 IS - 5 KW - prostate specific antigen adult article attitude to health Black person cancer research controlled study doctor patient relationship educational status genetic screening genome analysis health literacy human major clinical study male motivation patient attitude patient education patient participation prostate cancer trust LA - English M3 - Article N1 - L2001164728 2018-11-05 2018-11-13 PY - 2018 SN - 1873-2607 0749-3797 SP - S103-S111 ST - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men T2 - American Journal of Preventive Medicine TI - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001164728&from=export http://dx.doi.org/10.1016/j.amepre.2018.05.028 VL - 55 ID - 876 ER - TY - JOUR AB - Introduction: Black men are diagnosed with prostate cancer at nearly twice the rate of white men and are underrepresented in prostate cancer research, including validation studies of new clinical tools (e.g., genomic testing). Because healthcare system mistrust has contributed to these disparities for centuries, black men may be less inclined to pursue novel testing, and identification of facilitators to their participation in prostate cancer research studies remains warranted. Methods: A community-engaged approach involving a partnership with a community organization was used to conduct seven focus groups in Minnesota, Alabama, and California to explore black men's attitudes toward prostate cancer research participation and genomic testing for prostate cancer. Data were collected and analyzed from April 2015 to April 2017. Results: Identified genomic testing barriers included a lack of terminology understanding, healthcare system mistrust, reluctance to seek medical care, and unfavorable attitudes toward research. Facilitators included family history, value of prevention, and the desire for health education. Lack of prostate cancer knowledge, prostate-specific antigen testing confusion, healthcare system distrust, and misuse of personal health information were barriers to research study participation. Some black men were motivated to participate in research if it was seen as constructive and transparent. Conclusions: Disparities for black men can both motivate and disincentivize participation depending upon a positive or negative view of research. Confusion over prostate cancer clinical care has fueled some mistrust among black men affecting both clinical care and research participation. With increased education, health literacy, and assurances of research integrity and transparency, black men may be more willing to participate in prostate cancer testing and research. (C) 2018 American Journal of Preventive Medicine. Published by Elsevier Inc. AN - WOS:000447618200013 AU - Rogers, C. R. AU - Rovito, M. J. AU - Hussein, M. AU - Obidike, O. J. AU - Pratt, R. AU - Alexander, M. AU - Berge, J. M. AU - Dall'Era, M. AU - Nix, J. W. AU - Warlick, C. DA - Nov DO - 10.1016/j.amepre.2018.05.028 IS - 5 N1 - 1 30670195 PY - 2018 SN - 0749-3797 SP - S103-S111 ST - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men T2 - American Journal of Preventive Medicine TI - Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men VL - 55 ID - 2842 ER - TY - JOUR AB - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for 'natural treatments' or 'religious intervention' over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Linden, Hannah M., Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, University of Washington, Box 358081, 825 Eastlake Ave. E., G3-200, Seattle, WA, US, 98109 AN - 2007-12071-002 AU - Linden, Hannah M. AU - Reisch, Lisa M. AU - Hart, Alton, Jr. AU - Harrington, Margaret A. AU - Nakano, Connie AU - Jackson, J. Carey AU - Elmore, Joann G. DB - psyh DO - 10.1097/01.NCC.0000281732.02738.31 DP - EBSCOhost IS - 4 KW - breast cancer screening African American community client attitudes patient participation Adult African Americans Aged Breast Neoplasms Female Focus Groups Humans Mass Screening Middle Aged Patient Acceptance of Health Care Patient Selection Randomized Controlled Trials as Topic Washington Blacks Cancer Screening Client Participation N1 - Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, US. Release Date: 20080526. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Cancer Screening; Client Attitudes. Minor Descriptor: Client Participation. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Clinical Trial; Empirical Study; Interview; Focus Group; Qualitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Jul-Aug, 2007. Sponsor: Avon Foundation. Recipients: No recipient indicated PY - 2007 SN - 0162-220X 1538-9804 SP - 261-269 ST - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study T2 - Cancer Nursing TI - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2007-12071-002&site=ehost-live&scope=site hmlinden@u.washington.edu VL - 30 ID - 1723 ER - TY - JOUR AB - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for 'natural treatments' or 'religious intervention' over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant. AD - Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA. hmlinden@u.washington.edu AN - 106166176. Language: English. Entry Date: 20071005. Revision Date: 20150820. Publication Type: Journal Article AU - Linden, H. M. AU - Reisch, L. M. AU - Hart, A., Jr. AU - Harrington, M. A. AU - Nakano, C. AU - Jackson, J. C. AU - Elmore, J. G. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Attitude -- Evaluation Black Persons Breast Neoplasms Clinical Trials Research Subjects Adult Antineoplastic Agents Audiorecording Chemotherapy, Adjuvant Convenience Sample Descriptive Statistics Female Focus Groups Funding Source Interview Guides Middle Age Qualitative Studies Research Subject Recruitment Thematic Analysis Trust Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: Avon Foundation. NLM UID: 7805358. PMID: NLM17666974. PY - 2007 SN - 0162-220X SP - 261-269 ST - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study T2 - Cancer Nursing TI - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106166176&site=ehost-live&scope=site VL - 30 ID - 1858 ER - TY - JOUR AB - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for "natural treatments" or "religious intervention" over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant. © 2007 Lippincott Williams & Wilkins, Inc. AD - H.M. Linden, Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave. E., G3-200, Seattle, WA 98109, United States AU - Linden, H. M. AU - Reisch, L. M. AU - Hart Jr, A. AU - Harrington, M. A. AU - Nakano, C. AU - Jackson, J. C. AU - Elmore, J. G. DB - Embase Medline DO - 10.1097/01.NCC.0000281732.02738.31 IS - 4 KW - antiinfective agent adult African American aged article attitude to health breast cancer cancer screening cancer therapy clinical trial controlled clinical trial controlled study cost benefit analysis female human major clinical study medical care personnel priority journal qualitative research randomized controlled trial religion risk LA - English M3 - Article N1 - L47196600 2007-07-01 PY - 2007 SN - 0162-220X SP - 261-269 ST - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study T2 - Cancer Nursing TI - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47196600&from=export http://dx.doi.org/10.1097/01.NCC.0000281732.02738.31 VL - 30 ID - 1229 ER - TY - JOUR AB - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2‐hour audio‐taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for "natural treatments" or "religious intervention" over medical care; (5) cost‐benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open‐mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant. © 2007 Lippincott Williams & Wilkins, Inc. AN - CN-01729033 AU - Linden, H. M. AU - Reisch, L. M. AU - Hart Jr, A. AU - Harrington, M. A. AU - Nakano, C. AU - Jackson, J. C. AU - Elmore, J. G. DO - 10.1097/01.NCC.0000281732.02738.31 IS - 4 KW - *breast cancer /drug therapy Adult African American Aged Article Attitude to health Cancer screening Cancer therapy Clinical trial Controlled clinical trial Controlled study Cost benefit analysis Female Human Major clinical study Medical care Personnel Priority journal Qualitative research Randomized controlled trial Religion Risk M3 - Journal: Article PY - 2007 SP - 261‐269 ST - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study T2 - Cancer nursing TI - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: a focus group study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01729033/full VL - 30 ID - 1408 ER - TY - JOUR AB - Participation of African Americans in research trials is low. Understanding the perspectives of African American patients toward participation in clinical trials is essential to understanding the disparities in participation rates compared with whites. A qualitative study was conducted to discover attitudes of the African American community regarding willingness to participate in breast cancer screening and randomized clinical trials. Six focus groups consisting of 8 to 11 African American women (N = 58), aged 30 to 65, were recruited from local churches. Focus group sessions involved a 2-hour audio-taped discussion facilitated by 2 moderators. A breast cancer randomized clinical trial involving an experimental breast cancer treatment was discussed to identify the issues related to willingness to participate in such research studies. Six themes surrounding willingness to participate in randomized clinical trials were identified: (1) Significance of the research topic to the individual and/or community; (2) level of trust in the system; (3) understanding of the elements of the trial; (4) preference for "natural treatments" or "religious intervention" over medical care; (5) cost-benefit analysis of incentives and barriers; and (6) openness to risk versus a preference for proven treatments. The majority (80%) expressed willingness or open-mindedness to the idea of participating in the hypothetical trial. Lessons learned from this study support the selection of a culturally diverse research staff and can guide the development of research protocols, recruitment efforts, and clinical procedures that are culturally sensitive and relevant. © 2007 Lippincott Williams & Wilkins, Inc. AD - Department of Medicine, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, United States Department of Medicine, Harborview Medical Center, University of Washington, Seattle, WA, United States Department of Internal Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States Human Research Protection Office, Office of the Chief Science Officer, Centers for Disease Control, Atlanta, GA, United States Robert Wood Johnson Clinical Scholars Program, University of Washington School of Medicine, Seattle, WA, United States Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave. E., G3-200, Seattle, WA 98109, United States AU - Linden, H. M. AU - Reisch, L. M. AU - Hart Jr, A. AU - Harrington, M. A. AU - Nakano, C. AU - Jackson, J. C. AU - Elmore, J. G. DB - Scopus DO - 10.1097/01.NCC.0000281732.02738.31 IS - 4 KW - African American Breast cancer Clinical trials Focus group study M3 - Article N1 - Cited By :37 Export Date: 22 March 2021 PY - 2007 SP - 261-269 ST - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study T2 - Cancer Nursing TI - Attitudes toward participation in breast cancer randomized clinical trials in the African American community: A focus group study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547601769&doi=10.1097%2f01.NCC.0000281732.02738.31&partnerID=40&md5=f63c50f44101c1e397eb00a77abb9e9d VL - 30 ID - 2556 ER - TY - JOUR AB - Purpose/Objectives: to Test the Effect of A Supportive, One-time Psychoeducational Intervention on Treatm. Adherence among African Amer. Women Rec. First Adjuvant Ther. for Breast Cancer. Des.: A Pilot, Randomized, Controlled Clin. Trial, Two-Grp. Des., with One-time Intervention and Four Data Collec. Points. Setting: Two Univ. of Pittsburgh Cancer Inst. Clinics. Sample: 24 African Amer. Women. Methods: the Attitudes, Commun., Treatm., and Support Intervention Is A 45-minute One-on-one Session with An African Amer. Woman Recommended to Have Chemother. for Breast Cancer. the Interventionist Is An African Amer. Breast Cancer Survivor. the Intervention Consists of A Discussion about Chemother. and the Importance of Communicating Knowledge Needs and Distress, An Explanation of the Specific Treatm. Plan Acc. to Pathol., and Support Through the Survivor Testimonial and Video Clips from the African Amer. Comm.. Main Res. Variables: Dose of Chemother. Received and Dose of Chemother. Prescribed. Findings: Twenty Patients Completed Chemother., and Four Chose Not to Begin or Discontinued Recommended Chemother.. the Groups Were Equal in Key Sociodemographic Variables. Compared to Usual Care, the ACTS Intervention Participants Demonstrated Trends Toward Initiation of Chemother. , Overall Adherence to Chemother. , and Percentage of Total Dose of Chemother. Received or Prescribed . Compared to Usual Care, the ACTS Intervention Participants Demonstrated More Rapid Initiation of Chemother. and Better Overall Adherence to Chemother.. Conclusions: the Pilot ACTS Intervention Shows Promise As A Psychoeducational Intervention to Assist with Chemother. Decis. Making among African Amer. Women. Implications for Nursing: African Amer. Women Are at High Risk of Not Rec. the Full Dose of Prescribed Chemother. for Breast Cancer for Multiple Reasons. Nurses Must Be Sensitive to the Unique Fears and Concerns of This Pop. Regarding Chemother. Decisions. An Intervention Addressing These Fears and Concerns May Help to Increase Adherence. AD - M. Rosenzweig, University of Pittsburgh, School of Nursing, PA, United States AU - Rosenzweig, M. AU - Brufsky, A. AU - Rastogi, P. AU - Puhalla, S. AU - Simon, J. AU - Underwood, S. DB - Medline DO - 10.1188/11.ONF.85-89 IS - 1 KW - antineoplastic agent adjuvant chemotherapy adult African American article attitude to health breast tumor clinical trial controlled clinical trial controlled study female health care disparity human methodology middle aged nurse patient relationship nursing oncology nursing patient education patient participation pilot study psychological aspect randomized controlled trial social support LA - English M3 - Article N1 - L361504541 2012-01-12 PY - 2011 SN - 0190-535X 1538-0688 SP - 85-89 ST - The Attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity T2 - Oncology Nursing Forum TI - The Attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361504541&from=export http://dx.doi.org/10.1188/11.ONF.85-89 http://ons.metapress.com/content/b0j3n71h15728787/fulltext.pdf VL - 38 ID - 1148 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: to test the effect of a supportive, one‐time psychoeducational intervention on treatment adherence among African American women receiving first adjuvant therapy for breast cancer. DESIGN: a pilot, randomized, controlled clinical trial, two‐group design, with one‐time intervention and four data collection points. SETTING: two University of Pittsburgh Cancer Institute clinics. SAMPLE: 24 African American women. METHODS: the Attitudes, Communication, Treatment, and Support (ACTS) intervention is a 45‐minute one‐on‐one session with an African American woman recommended to have chemotherapy for breast cancer. The interventionist is an African American breast cancer survivor. The intervention consists of a discussion about chemotherapy and the importance of communicating knowledge needs and distress, an explanation of the specific treatment plan according to pathology, and support through the survivor testimonial and video clips from the African American community. MAIN RESEARCH VARIABLES: dose of chemotherapy received and dose of chemotherapy prescribed.Findings: Twenty patients completed chemotherapy, and four chose not to begin or discontinued recommended chemotherapy. The groups were equal in key sociodemographic variables. Compared to usual care, the ACTS intervention participants demonstrated trends toward initiation of chemotherapy (100% versus 82%), overall adherence to chemotherapy (92% versus 73%), and percentage of total dose of chemotherapy received or prescribed (94% versus 74%). Compared to usual care, the ACTS intervention participants demonstrated more rapid initiation of chemotherapy and better overall adherence to chemotherapy. CONCLUSIONS: the pilot ACTS intervention shows promise as a psychoeducational intervention to assist with chemotherapy decision making among African American women.Implications for Nursing: African American women are at high risk of not receiving the full dose of prescribed chemotherapy for breast cancer for multiple reasons. Nurses must be sensitive to the unique fears and concerns of this population regarding chemotherapy decisions. An intervention addressing these fears and concerns may help to increase adherence. AN - CN-00780635 AU - Rosenzweig, M. AU - Brufsky, A. AU - Rastogi, P. AU - Puhalla, S. AU - Simon, J. AU - Underwood, S. DO - 10.1188/11.ONF.85-89 IS - 1 KW - Adult African Americans [*psychology] Antineoplastic Agents [*administration & dosage] Attitude to Health Breast Neoplasms [drug therapy, nursing, psychology] Chemotherapy, Adjuvant Female Healthcare Disparities Humans Middle Aged Nurse‐Patient Relations Oncology Nursing [*methods] Patient Education as Topic [*methods] Patient Participation [psychology] Pilot Projects Social Support M3 - Journal Article; Randomized Controlled Trial PY - 2011 SP - 85‐89 ST - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity T2 - Oncology nursing forum TI - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00780635/full VL - 38 ID - 1379 ER - TY - JOUR AB - Purpose/Objectives: To test the effect of a supportive, one-time psychoeducational intervention on treatment adherence among African American women receiving first adjuvant therapy for breast cancer.Design: A pilot, randomized, controlled clinical trial, two-group design, with one-time intervention and four data collection points.Setting: Two University of Pittsburgh Cancer Institute clinics.Sample: 24 African American women.Methods: The Attitudes, Communication, Treatment, and Support (ACTS) intervention is a 45-minute one-on-one session with an African American woman recommended to have chemotherapy for breast cancer. The interventionist is an African American breast cancer survivor. The intervention consists of a discussion about chemotherapy and the importance of communicating knowledge needs and distress, an explanation of the specific treatment plan according to pathology, and support through the survivor testimonial and video clips from the African American community.Main Research Variables: Dose of chemotherapy received and dose of chemotherapy prescribed.Findings: Twenty patients completed chemotherapy, and four chose not to begin or discontinued recommended chemotherapy. The groups were equal in key sociodemographic variables. Compared to usual care, the ACTS intervention participants demonstrated trends toward initiation of chemotherapy (100% versus 82%), overall adherence to chemotherapy (92% versus 73%), and percentage of total dose of chemotherapy received or prescribed (94% versus 74%). Compared to usual care, the ACTS intervention participants demonstrated more rapid initiation of chemotherapy and better overall adherence to chemotherapy.Conclusions: The pilot ACTS intervention shows promise as a psychoeducational intervention to assist with chemotherapy decision making among African American women.Implications for Nursing: African American women are at high risk of not receiving the full dose of prescribed chemotherapy for breast cancer for multiple reasons. Nurses must be sensitive to the unique fears and concerns of this population regarding chemotherapy decisions. An intervention addressing these fears and concerns may help to increase adherence. AD - University of Pittsburgh School of Nursing, Pennsylvania AN - 104971603. Language: English. Entry Date: 20110218. Revision Date: 20200708. Publication Type: Journal Article AU - Rosenzweig, M. AU - Brufsky, A. AU - Rastogi, P. AU - Puhalla, S. AU - Simon, J. AU - Underwood, S. DB - CINAHL Complete DO - 10.1188/11.ONF.85-89 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Drug Therapy Black Persons -- Pennsylvania Psychoeducation Medication Compliance Human Randomized Controlled Trials Pennsylvania Cancer Care Facilities Descriptive Statistics Chemotherapy, Cancer Pilot Studies Conceptual Framework Models, Theoretical Decision Making, Patient Medication Compliance -- Evaluation Wilcoxon Rank Sum Test Fisher's Exact Test Nonparametric Statistics Female Adult Middle Age Urban Areas Research Subject Recruitment Random Assignment Communication Teaching Methods N1 - research; tables/charts; randomized controlled trial. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033. PMID: NLM21186164. PY - 2011 SN - 0190-535X SP - 85-89 ST - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity T2 - Oncology Nursing Forum TI - The attitudes, communication, treatment, and support intervention to reduce breast cancer treatment disparity UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104971603&site=ehost-live&scope=site VL - 38 ID - 2114 ER - TY - JOUR AB - Context: Common perceptions exist within the medical community that retention of Hispanics in clinical trials is difficult, albeit little data is available to support this conviction. Methods: A total of 541 randomly selected charts from closed clinical trials between 2000 and 2006 were reviewed. Records were from participating institutions in Texas Medical Center, Houston, and targeted diseases of high prevalence, specifically, breast cancer, prostate cancer, and chronic obstructive pulmonary disease (COPD)/asthma. Findings: Overall, 259 participants (48%) completed the trial they were enrolled in (44% whites, 69% Hispanics, 51% blacks; p < .05). Within pediatric trials, whom all were pulmonary patients, retention rates were higher among Hispanics than whites (adjusted odds ratio [OR] = 7.49, 95% confidence interval [CI] = 1.15-58.03, p = .04). Among adults, patient's ethnicity was unrelated to study completion. All associations were adjusted for possible confounders. Reasons for not completing a trial varied by ethnicity: "patient withdrawing consent" was more common among whites (51.4%) than Hispanics (21.7%) or blacks (26.2%) (p < .05). Hispanics were more inclined to be withdrawn from the trial by the investigator (43.5%) than were whites (24%, p = .04), mostly due to non-compliance with the study protocol. Conclusions: Hispanic parents of children with COPD may be more likely to complete a trial than parents of non-Hispanic whites. Among adults, Hispanics had similar completion rates as compared to whites. Culturally sensitive, multi-factorial approaches maybe imperative to increasing patient engagement in clinical trials. © 2009 Elsevier Inc. All rights reserved. AD - H. Sangi-Haghpeykar, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States AU - Sangi-Haghpeykar, H. AU - Meddaugh, H. M. AU - Liu, H. AU - Grino, P. DB - Embase Medline DO - 10.1016/j.cct.2009.06.004 IS - 6 KW - adult aged article asthma breast cancer cancer epidemiology chronic obstructive lung disease confidence interval controlled study disease association ethnic group ethnic difference female human major clinical study male prostate cancer statistical significance LA - English M3 - Article N1 - L50616783 2009-12-01 PY - 2009 SN - 1551-7144 SP - 499-503 ST - Attrition and retention in clinical trials by ethnic origin T2 - Contemporary Clinical Trials TI - Attrition and retention in clinical trials by ethnic origin UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50616783&from=export http://dx.doi.org/10.1016/j.cct.2009.06.004 VL - 30 ID - 1177 ER - TY - JOUR AB - Context: Common perceptions exist within the medical community that retention of Hispanics in clinical trials is difficult, albeit little data is available to support this conviction. Methods: A total of 541 randomly selected charts from closed clinical trials between 2000 and 2006 were reviewed. Records were from participating institutions in Texas Medical Center, Houston, and targeted diseases of high prevalence, specifically, breast cancer, prostate cancer, and chronic obstructive pulmonary disease (COPD)/asthma. Findings: Overall, 259 participants (48%) completed the trial they were enrolled in (44% whites, 69% Hispanics, 51% blacks; p < .05). Within pediatric trials, whom all were pulmonary patients, retention rates were higher among Hispanics than whites (adjusted odds ratio [OR] = 7.49, 95% confidence interval [CI] = 1.15-58.03, p = .04). Among adults, patient's ethnicity was unrelated to study completion. All associations were adjusted for possible confounders. Reasons for not completing a trial varied by ethnicity: "patient withdrawing consent" was more common among whites (51.4%) than Hispanics (21.7%) or blacks (26.2%) (p < .05). Hispanics were more inclined to be withdrawn from the trial by the investigator (43.5%) than were whites (24%, p = .04), mostly due to non-compliance with the study protocol. Conclusions: Hispanic parents of children with COPD may be more likely to complete a trial than parents of non-Hispanic whites. Among adults, Hispanics had similar completion rates as compared to whites. Culturally sensitive, multi-factorial approaches maybe imperative to increasing patient engagement in clinical trials. © 2009 Elsevier Inc. All rights reserved. AD - Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States AU - Sangi-Haghpeykar, H. AU - Meddaugh, H. M. AU - Liu, H. AU - Grino, P. DB - Scopus DO - 10.1016/j.cct.2009.06.004 IS - 6 KW - Clinical trials Culture Minorities Retention M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2009 SP - 499-503 ST - Attrition and retention in clinical trials by ethnic origin T2 - Contemporary Clinical Trials TI - Attrition and retention in clinical trials by ethnic origin UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350573342&doi=10.1016%2fj.cct.2009.06.004&partnerID=40&md5=a3d4f28b704e0866e6b6aeaaf32136f7 VL - 30 ID - 2510 ER - TY - JOUR AB - Context: Common perceptions exist within the medical community that retention of Hispanics in clinical trials is difficult, albeit little data is available to support this conviction. Methods: A total of 541 randomly selected charts from closed clinical trials between 2000 and 2006 were reviewed. Records were from participating institutions in Texas Medical Center, Houston, and targeted diseases of high prevalence, specifically, breast cancer, prostate cancer, and chronic obstructive pulmonary disease (COPD)/asthma. Findings: Overall, 259 participants (48%) completed the trial they were enrolled in (44% whites, 69% Hispanics, 51% blacks; p<.05). Within pediatric trials, whom all were pulmonary patients. retention rates were higher among Hispanics than whites (adjusted odds ratio [OR] = 7.49, 95% confidence interval [CI] = 1.15-58.03, p = .04). Among adults, patient's ethnicity was unrelated to study completion. All associations were adjusted for possible confounders. Reasons for not completing a trial varied by ethnicity: "patient withdrawing consent" was more common among whites (51.4%) than Hispanics (21.7%) or blacks (26.2%) (p<.05). Hispanics were more inclined to be withdrawn from the trial by the investigator (43.5%) than were whites (24%, p=.04), mostly due to non-compliance with the study protocol. Conclusions: Hispanic parents of children with COPD may be more likely to complete a trial than parents of non-Hispanic whites. Among adults, Hispanics had similar completion rates as compared to whites. Culturally sensitive, multi-factorial approaches maybe imperative to increasing patient engagement in clinical trials. (C) 2009 Elsevier Inc. All rights reserved. AN - WOS:000272111000001 AU - Sangi-Haghpeykar, H. AU - Meddaugh, H. M. AU - Liu, H. AU - Grino, P. DA - Nov DO - 10.1016/j.cct.2009.06.004 IS - 6 N1 - 19573625 PY - 2009 SN - 1551-7144 SP - 499-503 ST - Attrition and retention in clinical trials by ethnic origin T2 - Contemporary Clinical Trials TI - Attrition and retention in clinical trials by ethnic origin VL - 30 ID - 3135 ER - TY - JOUR AB - BACKGROUND Minority patients with breast cancer are at risk for undertreatment of cancer-related pain. The authors evaluated the feasibility and efficacy of an automated pain intervention for improving pain and symptom management of underserved African American and Latina women with breast cancer. METHODS Sixty low-income African American and Latina women with breast cancer and cancer-related pain were enrolled in a pilot study of an automated, telephone-based, interactive voice response (IVR) intervention. Women in the intervention group were called twice weekly by the IVR system and asked to rate the intensity of their pain and other symptoms. The patients' oncologists received e-mail alerts if the reported symptoms were moderate to severe. The patients also reported barriers to pain management and received education regarding any reported obstacles. RESULTS The proportion of women in both groups reporting moderate to severe pain decreased during the study, but the decrease was significantly greater for the intervention group. The IVR intervention also was associated with improvements in other cancer-related symptoms, including sleep disturbance and drowsiness. Although patient adherence to the IVR call schedule was good, the oncologists who were treating the patients rated the intervention as only somewhat useful for improving symptom management. CONCLUSIONS The IVR intervention reduced pain and symptom severity for underserved minority women with breast cancer. Additional research on technological approaches to symptom management is needed. © 2015 American Cancer Society. AD - Department of Symptom Research, University of Texas MD Anderson Cancer Center, Unit 1450, 1515 Holcombe Blvd., Houston, TX 77030, United States Office of Cancer Survivorship, University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States London Regional Cancer Program, London Health Sciences Center, London, ON, Canada Department of Psychiatry and Behavioral Sciences, University of Texas Health Sciences Center, Houston, TX, United States Duke Institute on Care at the End of Life, Duke University Divinity School, Durham, NC, United States AU - Anderson, K. O. AU - Palos, G. R. AU - Mendoza, T. R. AU - Cleeland, C. S. AU - Liao, K. P. AU - Fisch, M. J. AU - Garcia-Gonzalez, A. AU - Rieber, A. G. AU - Nazario, L. A. AU - Valero, V. AU - Hahn, K. M. AU - Person, C. L. AU - Payne, R. DB - Scopus DO - 10.1002/cncr.29204 IS - 11 KW - assessment breast cancer minority groups pain symptoms M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2015 SP - 1882-1890 ST - Automated pain intervention for underserved minority women with breast cancer T2 - Cancer TI - Automated pain intervention for underserved minority women with breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929654710&doi=10.1002%2fcncr.29204&partnerID=40&md5=387f11a4ce6afe09ea171f65d670475a VL - 121 ID - 2364 ER - TY - JOUR AB - BACKGROUNDMinority patients with breast cancer are at risk for undertreatment of cancer-related pain. The authors evaluated the feasibility and efficacy of an automated pain intervention for improving pain and symptom management of underserved African American and Latina women with breast cancer. METHODSSixty low-income African American and Latina women with breast cancer and cancer-related pain were enrolled in a pilot study of an automated, telephone-based, interactive voice response (IVR) intervention. Women in the intervention group were called twice weekly by the IVR system and asked to rate the intensity of their pain and other symptoms. The patients' oncologists received e-mail alerts if the reported symptoms were moderate to severe. The patients also reported barriers to pain management and received education regarding any reported obstacles. RESULTSThe proportion of women in both groups reporting moderate to severe pain decreased during the study, but the decrease was significantly greater for the intervention group. The IVR intervention also was associated with improvements in other cancer-related symptoms, including sleep disturbance and drowsiness. Although patient adherence to the IVR call schedule was good, the oncologists who were treating the patients rated the intervention as only somewhat useful for improving symptom management. CONCLUSIONSThe IVR intervention reduced pain and symptom severity for underserved minority women with breast cancer. Additional research on technological approaches to symptom management is needed. Cancer 2015;121:1882-1890. (c) 2015 American Cancer Society. We evaluated the feasibility and efficacy of an automated pain intervention for improving pain and symptom management in underserved African American and Latina women with breast cancer. The intervention reduced pain and symptom severity for the women, indicating that further research on technological approaches to symptom management is warranted. AN - WOS:000354819900025 AU - Anderson, K. O. AU - Palos, G. R. AU - Mendoza, T. R. AU - Cleeland, C. S. AU - Liao, K. P. AU - Fisch, M. J. AU - Garcia-Gonzalez, A. AU - Rieber, A. G. AU - Nazario, L. A. AU - Valero, V. AU - Hahn, K. M. AU - Person, C. L. AU - Payne, R. DA - Jun DO - 10.1002/cncr.29204 IS - 11 N1 - 25711974 PY - 2015 SN - 0008-543X SP - 1882-1890 ST - Automated pain intervention for underserved minority women with breast cancer T2 - Cancer TI - Automated pain intervention for underserved minority women with breast cancer VL - 121 ID - 2975 ER - TY - JOUR AB - Background: Many recently approved medications to manage multiple myeloma (MM) are oral, require supportive medications to prevent adverse effects, and are taken under complex schedules. Medication adherence is a concern; however, little attention has been directed toward understanding adherence in MM or associated barriers and facilitators. Advanced sensored medication devices (SMDs) offer opportunities to intervene; however, acceptability among patients with MM, particularly African American patients, is untested. Objective: This study aimed to explore patients' (1) perceptions of their health before MM including experiences with chronic medications, (2) perceptions of adherence barriers and facilitators, and (3) attitudes toward using SMDs. Methods: An in-person, semistructured, qualitative interview was conducted with a convenience sample of patients being treated for MM. Patients were recruited from within an urban, minority-serving, academic medical center that had an established cancer center. A standardized interview guide included questions targeting medication use, attitudes, adherence, barriers, and facilitators. Demographics included the use of cell phone technology. Patients were shown 2 different pill bottles with sensor technology-Medication Event Monitoring System and the SMRxT bottle. After receiving information on the transmission ability of the bottles, patients were asked to discuss their reactions and concerns with the idea of using such a device. Medical records were reviewed to capture information on medication and diagnoses. The interviews were audio-recorded and transcribed. Interviews were independently coded by 2 members of the team with a third member providing guidance. Results: A total of 20 patients with a mean age of 56 years (median=59 years; range=29-71 years) participated in this study and 80% (16/20) were African American. In addition, 18 (90%, 18/20) owned a smartphone and 85% (17/20) were comfortable using the internet, text messaging, and cell phone apps. The average number of medications reported per patient was 13 medications (median=10; range=3-24). Moreover, 14 (70%, 14/20) patients reported missed doses for a range of reasons such as fatigue, feeling ill, a busy schedule, forgetting, or side effects. Interest in using an SMD ranged from great interest to complete lack of interest. Examples of concerns related to the SMDs included privacy issues, potential added cost, and the size of the bottle (ie, too large). Despite the concerns, 60% (12/20) of the patients expressed interest in trying a bottle in the future. Conclusions: Results identified numerous patient-reported barriers and facilitators to missed doses of oral anticancer therapy. Many appear to be potentially mutable if uncovered and addressed. SMDs may allow for capture of these data. Although patients expressed concerns with SMDs, most remained willing to use one. A feasibility trial with SMDs is planned. AN - WOS:000453447200001 AU - Asfaw, A. A. AU - Yan, C. H. AU - Sweiss, K. AU - Wirth, S. AU - Ramirez, V. H. AU - Pate, P. R. AU - Sharp, L. K. DA - Nov DO - 10.2196/cancer.9918 IS - 2 N1 - e12 30425032 PY - 2018 SN - 2369-1999 ST - Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study T2 - Jmir Cancer TI - Barriers and Facilitators of Using Sensored Medication Adherence Devices in a Diverse Sample of Patients With Multiple Myeloma: Qualitative Study VL - 4 ID - 2840 ER - TY - JOUR AB - Background: Many recently approved medications to manage multiple myeloma (MM) are oral, require supportive medications to prevent adverse effects, and are taken under complex schedules. Medication adherence is a concern; however, little attention has been directed toward understanding adherence in MM or associated barriers and facilitators. Advanced sensored medication devices (SMDs) offer opportunities to intervene; however, acceptability among patients with MM, particularly African American patients, is untested. Objective: This study aimed to explore patients’ (1) perceptions of their health before MM including experiences with chronic medications, (2) perceptions of adherence barriers and facilitators, and (3) attitudes toward using SMDs. Methods: An in-person, semistructured, qualitative interview was conducted with a convenience sample of patients being treated for MM. Patients were recruited from within an urban, minority-serving, academic medical center that had an established cancer center. A standardized interview guide included questions targeting medication use, attitudes, adherence, barriers, and facilitators. Demographics included the use of cell phone technology. Patients were shown 2 different pill bottles with sensor technology—Medication Event Monitoring System and the SMRxT bottle. After receiving information on the transmission ability of the bottles, patients were asked to discuss their reactions and concerns with the idea of using such a device. Medical records were reviewed to capture information on medication and diagnoses. The interviews were audio-recorded and transcribed. Interviews were independently coded by 2 members of the team with a third member providing guidance. Results: A total of 20 patients with a mean age of 56 years (median=59 years; range=29-71 years) participated in this study and 80% (16/20) were African American. In addition, 18 (90%, 18/20) owned a smartphone and 85% (17/20) were comfortable using the internet, text messaging, and cell phone apps. The average number of medications reported per patient was 13 medications (median=10; range=3-24). Moreover, 14 (70%, 14/20) patients reported missed doses for a range of reasons such as fatigue, feeling ill, a busy schedule, forgetting, or side effects. Interest in using an SMD ranged from great interest to complete lack of interest. Examples of concerns related to the SMDs included privacy issues, potential added cost, and the size of the bottle (ie, too large). Despite the concerns, 60% (12/20) of the patients expressed interest in trying a bottle in the future. Conclusions: Results identified numerous patient-reported barriers and facilitators to missed doses of oral anticancer therapy. Many appear to be potentially mutable if uncovered and addressed. SMDs may allow for capture of these data. Although patients expressed concerns with SMDs, most remained willing to use one. A feasibility trial with SMDs is planned. © Alemseged Ayele Asfaw, Connie H Yan, Karen Sweiss, Scott Wirth, Victor H Ramirez, Pritesh R Patel, Lisa K Sharp. AD - Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, South Wood Street, Chicago, IL 60612, United States Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, United States College of Medicine, University of Illinois at Chicago, Chicago, IL, United States Department of Medicine, Section of Hematology/Oncology, College of Medicine, University of Illinois at Chicago, Chicago, IL, United States AU - Asfaw, A. A. AU - Yan, C. H. AU - Sweiss, K. AU - Wirth, S. AU - Ramirez, V. H. AU - Patel, P. R. AU - Sharp, L. K. C7 - e12 DB - Scopus DO - 10.2196/cancer.9918 IS - 11 KW - Antineoplastic therapy Challenges Medication adherence Multiple myeloma Race/ethnicity M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2018 ST - Barriers and facilitators of using sensored medication adherence devices in a diverse sample of patients with multiple myeloma: Qualitative study T2 - Journal of Medical Internet Research TI - Barriers and facilitators of using sensored medication adherence devices in a diverse sample of patients with multiple myeloma: Qualitative study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056512311&doi=10.2196%2fcancer.9918&partnerID=40&md5=f7abaf26b0bf6cee64b1988f29d56d98 VL - 20 ID - 2252 ER - TY - JOUR AB - BACKGROUND: Prostate cancer incidence is about 70% higher among African Americans compared to Whites. Factors associated with this differential remain unclear, although several studies suggest that genetic factors may play a role. Before epidemiologic research can adequately identify factors associated with this differential, we need studies to determine the feasibility of recruiting and retaining African-American men in cohort studies, especially those that collect biological and questionnaire data. METHODS: We conducted 4 focus group discussions among African-American men aged 40 to 64 years in North Carolina, and an additional group comprised of their partners, using a semi-structured interview protocol (total N=55 subjects). Data were analyzed with QRS NU*DIST to identify themes. RESULTS: Participants' willingness to participate in cohort studies seemed to be motivated by a perceived risk of prostate cancer. Barriers to participation included mistrust of the research community, poor knowledge of cancer-site specific heterogeneity, anticipated time commitment, and the invasive nature of disease detection procedures. To foster trust and increase disease knowledge, recommended strategies included: partnering with known civic organizations that provide education on risk factors; discussing early signs and symptoms at the point of recruitment; recruiting participants from community clusters; and providing periodic feedback on biologic samples (if collected) to reassure participants of their proper usage. CONCLUSION: Observational cohort studies focused on African-American men are feasible if certain barriers to participation are addressed. AD - Department of Health Education, North Carolina Central University, Durham 27707, USA. hoyo0001@mc.duke.edu AN - 14632266 AU - Hoyo, C. AU - Reid, M. L. AU - Godley, P. A. AU - Parrish, T. AU - Smith, L. AU - Gammon, M. DA - Fall DP - NLM ET - 2003/11/25 IS - 4 KW - Adult *African Continental Ancestry Group Aged *Attitude to Health Cohort Studies Female Focus Groups Humans Male Middle Aged North Carolina Patient Acceptance of Health Care/ethnology *Patient Selection Prostatic Neoplasms/diagnosis/*ethnology/therapy Risk Factors Surveys and Questionnaires *Treatment Refusal Trust LA - eng N1 - Hoyo, Cathrine Reid, M LaVerne Godley, Paul A Parrish, Theodore Smith, Lenora Gammon, Marilie 1 U56 CA92077-01/CA/NCI NIH HHS/United States Journal Article Research Support, U.S. Gov't, P.H.S. United States Ethn Dis. 2003 Fall;13(4):470-6. PY - 2003 SN - 1049-510X (Print) 1049-510x SP - 470-6 ST - Barriers and strategies for sustained participation of African-American men in cohort studies T2 - Ethn Dis TI - Barriers and strategies for sustained participation of African-American men in cohort studies VL - 13 ID - 640 ER - TY - JOUR AB - Background: Prostate cancer incidence is about 70% higher among African Americans compared to Whites. Factors associated with this differential remain unclear, although several studies suggest that genetic factors may play a role. Before epidemiologic research can adequately identify factors associated with this differential, we need studies to determine the feasibility of recruiting and retaining African-American men in cohort studies, especially those that collect biological and questionnaire data. Methods: We conducted 4 focus group discussions among African-American men aged 40 to 64 years in North Carolina, and an additional group comprised of their partners, using a semi-structured interview protocol (total N=55 subjects). Data were analyzed with QRS NU*DIST to identify themes. Results: Participants' willingness to participate in cohort studies seemed to be motivated by a perceived risk of Prostate cancer. Barriers to participation included mistrust of the research community, poor knowledge of cancer-site specific heterogeneity, anticipated time commitment, and the invasive nature of disease detection procedures. To foster trust and increase disease knowledge, recommended strategies included: partnering with known civic organizations that provide education on risk factors; discussing early signs and symptoms at the point of recruitment; recruiting participants from community clusters; and providing periodic feedback on biologic samples (if collected) to reassure participants of their proper usage. Conclusion: Observational cohort studies focused on African-American men are feasible if certain barriers to participation are addressed. AN - WOS:000220168500007 AU - Hoyo, C. AU - Reid, M. L. AU - Godley, P. A. AU - Parrish, T. AU - Smith, L. AU - Gammon, M. DA - Fal IS - 4 N1 - 23 14632266 PY - 2003 SN - 1049-510X SP - 470-476 ST - Barriers and strategies for sustained participation of African-American men in cohort studies T2 - Ethnicity & Disease TI - Barriers and strategies for sustained participation of African-American men in cohort studies VL - 13 ID - 2694 ER - TY - JOUR AD - D.B. Sellers, Florida A+M University, Dept. of Hlth., Physical Educ./Recr., HPER-206 Gaither's Gym Off. Complex, Tallahassee, FL 32307, United States AU - Hughes, D. G. AU - Sellers, D. B. AU - Fraser Jr, L. B. AU - Knight, B. AU - Areghan, G. A. DB - Embase Medline IS - 4 KW - adult aged article attitude cancer risk cancer screening Caucasian clinical article clinical trial cohort analysis education emotion ethnic group ethnology female human illness behavior male medical decision making medical research methodology Black person patient attitude patient selection perception prostate cancer prostate tumor questionnaire race difference risk factor social status trust United States LA - English M3 - Article N1 - L37428183 2003-12-03 PY - 2003 SN - 1049-510X SP - 534-536 ST - Barriers and strategies for sustained participation of African-American men in cohort studies T2 - Ethnicity and Disease TI - Barriers and strategies for sustained participation of African-American men in cohort studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37428183&from=export VL - 13 ID - 1289 ER - TY - JOUR AB - Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men's barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places. AD - Division of Public Health Sciences, Department of Surgery , Washington University in St. Louis School of Medicine , St. Louis 63110 USA Department of Social Work , Southern Illinois University-Edwardsville , Edwardsville 62026 USA Brown School of Social Work , Washington University in St. Louis , St. Louis 63110 USA Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA Alvin J. Siteman Cancer Center, St. Louis, MO, 63110, USA Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, 63110, USA AN - 121083360. Language: English. Entry Date: 20180830. Revision Date: 20191111. Publication Type: journal article AU - Drake, Bettina AU - Boyd, Danielle AU - Carter, Kimberly AU - Gehlert, Sarah AU - Thompson, Vetta AU - Drake, Bettina F. AU - Thompson, Vetta Sanders DB - CINAHL Complete DO - 10.1007/s13187-015-0905-1 DP - EBSCOhost IS - 1 KW - Patient Selection Black Persons -- Statistics and Numerical Data Prostatic Neoplasms -- Therapy Middle Age Aged, 80 and Over Prostatic Neoplasms -- Prevention and Control Aged Research, Medical Specimen Handling -- Methods Adult Male Focus Groups United States Attitude to Health Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Grant Information: U01 CA114594/CA/NCI NIH HHS/United States. NLM UID: 8610343. PMID: NLM26341221. PY - 2017 SN - 0885-8195 SP - 51-58 ST - Barriers and Strategies to Participation in Tissue Research Among African-American Men T2 - Journal of Cancer Education TI - Barriers and Strategies to Participation in Tissue Research Among African-American Men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121083360&site=ehost-live&scope=site VL - 32 ID - 1859 ER - TY - JOUR AB - Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men's barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places. AU - Drake, B. F. AU - Boyd, D. AU - Carter, K. AU - Gehlert, S. AU - Thompson, V. S. DB - Medline DO - 10.1007/s13187-015-0905-1 IS - 1 KW - adult African American aged attitude to health human information processing male medical research middle aged patient selection procedures prostate tumor specimen handling statistics and numerical data United States very elderly LA - English M3 - Article N1 - L623651521 2018-08-31 PY - 2017 SN - 1543-0154 SP - 51-58 ST - Barriers and Strategies to Participation in Tissue Research Among African-American Men T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Barriers and Strategies to Participation in Tissue Research Among African-American Men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623651521&from=export http://dx.doi.org/10.1007/s13187-015-0905-1 VL - 32 ID - 945 ER - TY - JOUR AB - Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men’s barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places. © 2015, American Association for Cancer Education. AD - Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO 63110, United States Alvin J. Siteman Cancer Center, St. Louis, MO 63110, United States Department of Social Work, Southern Illinois University-Edwardsville, Edwardsville, IL 62026, United States Brown School of Social Work, Washington University in St. Louis, St. Louis, MO 63110, United States AU - Drake, B. F. AU - Boyd, D. AU - Carter, K. AU - Gehlert, S. AU - Thompson, V. S. DB - Scopus DO - 10.1007/s13187-015-0905-1 IS - 1 KW - African-American Biorepository Prostate cancer Recruitment M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2017 SP - 51-58 ST - Barriers and Strategies to Participation in Tissue Research Among African-American Men T2 - Journal of Cancer Education TI - Barriers and Strategies to Participation in Tissue Research Among African-American Men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84940823979&doi=10.1007%2fs13187-015-0905-1&partnerID=40&md5=884ebd8c891a7ae96d2702f5d01f56de VL - 32 ID - 2316 ER - TY - JOUR AB - Before the burgeoning field of biospecimen collection can advance prevention and treatment methods, researchers must access diverse molecular data samples. However, minorities, especially African-American men, remain reticent to join these studies. This study, using theory-based approaches, investigated African-American men's barriers to participating in biorepository research. Fourteen focus groups were conducted among 70 African-American men (ages 40 to 80). The groups were stratified by prostate cancer history and educational attainment background. Participants identified perceived factors that promoted or hindered study participation when questioned about their knowledge and attitudes about biospecimen research. Ninety-four percent of participants indicated never participating in a study that collected biological samples. Barriers to their participation included lack of knowledge and understanding regarding biospecimen research practices and uses. In addition, they extensively cited a prevalent mistrust of the medical community and discomfort with study recruitment practices. African-American males were more willing to participate in biorepository studies with physician endorsement or if they understood that participation could benefit future generations. Men also wanted more recruitment and advertising done in familiar places. AN - WOS:000394145000009 AU - Drake, B. F. AU - Boyd, D. AU - Carter, K. AU - Gehlert, S. AU - Thompson, V. S. DA - Mar DO - 10.1007/s13187-015-0905-1 IS - 1 N1 - 26341221 PY - 2017 SN - 0885-8195 SP - 51-58 ST - Barriers and Strategies to Participation in Tissue Research Among African-American Men T2 - Journal of Cancer Education TI - Barriers and Strategies to Participation in Tissue Research Among African-American Men VL - 32 ID - 2909 ER - TY - JOUR AB - BACKGROUND. Breast carcinoma prevention trials must recruit large cohorts of women who have an above-average risk of developing breast carcinoma. Recruitment for the Study of Tamoxifen and Raloxifene (STAR) trial required volunteers to complete a risk assessment questionnaire form (RAF). Women whose estimated risk of developing breast carcinoma in the next 5 years was ≥ 1.67% based on the Gail model were invited to participate in STAR. Less than 4% of participants in the previously conducted P1 (tamoxifen vs. placebo) trial were minority women. We, therefore, studied barriers to minority participation in STAR among black, white, and Hispanic women who completed an RAF. METHODS. The authors analyzed the association of Gail model risk factors, education, and insurance with race/ethnicity using chi-square tests and two-sided P values. They developed logistic regression models of trial eligibility, controlling for the Gail model risk factors, education, and insurance status. RESULTS. Among 823 women who completed an RAF, white women were 10 times as likely as Hispanic women and 45 times as likely as black women to be eligible for STAR. Age at first birth (P = 0.04), having an affected first-degree relative (P < 0.0001), having had a biopsy (P < 0.0001), education (P < 0.0001), and insurance status (P < 0.0001) varied by race/ethnicity. All variables except insurance status were associated with eligibility when race was excluded from the model. In a model that included race/ethnicity, the same factors remained statistically significant. CONCLUSIONS. These findings suggested that both the race/ethnicity adjustment and socioeconomic factors were barriers to eligibility for and contribute to low minority participation in breast cancer prevention trials. © 2005 American Cancer Society. AD - V.R. Grann, Department of Epidemiology, Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, United States AU - Grann, V. R. AU - Jacobson, J. S. AU - Troxel, A. B. AU - Hershman, D. AU - Karp, J. AU - Myers, C. AU - Neugut, A. I. DB - Embase Medline DO - 10.1002/cncr.21164 IS - 2 KW - raloxifene tamoxifen adult article breast carcinoma cancer prevention cancer risk Caucasian education ethnology female health insurance high risk population Hispanic human major clinical study minority group Black person priority journal risk assessment socioeconomics LA - English M3 - Article N1 - L40993266 2005-08-10 PY - 2005 SN - 0008-543X SP - 374-379 ST - Barriers to minority participation in breast carcinoma prevention trials T2 - Cancer TI - Barriers to minority participation in breast carcinoma prevention trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40993266&from=export http://dx.doi.org/10.1002/cncr.21164 VL - 104 ID - 1264 ER - TY - JOUR AB - BACKGROUND. Breast carcinoma prevention trials must recruit large cohorts of women who have an above-average risk of developing breast carcinoma. Recruitment for the Study of Tamoxifen and Raloxifene (STAR) trial required volunteers to complete a risk assessment questionnaire form (RAF). Women whose estimated risk of developing breast carcinoma in the next 5 years was ≥ 1.67% based on the Gail model were invited to participate in STAR. Less than 4% of participants in the previously conducted P1 (tamoxifen vs. placebo) trial were minority women. We, therefore, studied barriers to minority participation in STAR among black, white, and Hispanic women who completed an RAF. METHODS. The authors analyzed the association of Gail model risk factors, education, and insurance with race/ethnicity using chi-square tests and two-sided P values. They developed logistic regression models of trial eligibility, controlling for the Gail model risk factors, education, and insurance status. RESULTS. Among 823 women who completed an RAF, white women were 10 times as likely as Hispanic women and 45 times as likely as black women to be eligible for STAR. Age at first birth (P = 0.04), having an affected first-degree relative (P < 0.0001), having had a biopsy (P < 0.0001), education (P < 0.0001), and insurance status (P < 0.0001) varied by race/ethnicity. All variables except insurance status were associated with eligibility when race was excluded from the model. In a model that included race/ethnicity, the same factors remained statistically significant. CONCLUSIONS. These findings suggested that both the race/ethnicity adjustment and socioeconomic factors were barriers to eligibility for and contribute to low minority participation in breast cancer prevention trials. © 2005 American Cancer Society. AD - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY, United States Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY, United States Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Department of Epidemiology, Yale School of Public Health, New Haven, CT, United States Department of Sociomedical Sciences, Mailman School of Pulic Health, Columbia University, New York, NY, United States Department of Epidemiology, Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, United States AU - Grann, V. R. AU - Jacobson, J. S. AU - Troxel, A. B. AU - Hershman, D. AU - Karp, J. AU - Myers, C. AU - Neugut, A. I. DB - Scopus DO - 10.1002/cncr.21164 IS - 2 M3 - Article N1 - Cited By :37 Export Date: 22 March 2021 PY - 2005 SP - 374-379 ST - Barriers to minority participation in breast carcinoma prevention trials T2 - Cancer TI - Barriers to minority participation in breast carcinoma prevention trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-22244441782&doi=10.1002%2fcncr.21164&partnerID=40&md5=b47ab2750b8cd3fb958f1701bb6b1676 VL - 104 ID - 2593 ER - TY - JOUR AB - BACKGROUND. Breast carcinoma prevention trials must recruit large cohorts of women who have an above-average risk of developing breast carcinoma. Recruitment for the Study of Tamoxifen and Raloxifene (STAR) trial required volunteers to complete a risk assessment questionnaire form (RAF). Women whose estimated risk of developing breast carcinoma in the next 5 years was >= 1.67% based on the Gail model were invited to participate in STAR. Less than 4% of participants in the previously conducted PI (tamoxifen vs. placebo) trial were minority women. We, therefore, studied barriers to minority participation in STAR among black, white, and Hispanic women who completed an RAF. METHODS. The authors analyzed the association of Gail model risk factors, education, and insurance with race/ethnicity using chi-square tests and two-sided P values. They developed logistic regression models of trial eligibility, controlling for the Gail model risk factors, education, and insurance status. RESULTS. Among 823 women who completed an RAF, white women were 10 times as likely as Hispanic women and 45 times as likely as black women to be eligible for STAR. Age at first birth (P = 0.04), having an affected first-degree relative (P < 0.0001), having had a biopsy (P < 0.0001), education (P < 0.0001), and insurance status (P < 0.0001) varied by race/ethnicity. All variables except insurance status were associated with eligibility when race was excluded from the model. In a model that included race/ethnicity, the same factors remained statistically significant. CONCLUSIONS. These findings suggested that both the race/ethnicity adjustment and socioeconomic factors were barriers to eligibility for and contribute to low minority participation in breast cancer prevention trials. (c) 2005 American Cancer Society. AN - WOS:000230331000021 AU - Grann, V. R. AU - Jacobson, J. S. AU - Troxel, A. B. AU - Hershman, D. AU - Karp, J. AU - Myers, C. AU - Neugut, A. I. DA - Jul DO - 10.1002/cncr.21164 IS - 2 N1 - 15937913 PY - 2005 SN - 0008-543X SP - 374-379 ST - Barriers to minority participation in breast carcinoma prevention trials T2 - Cancer TI - Barriers to minority participation in breast carcinoma prevention trials VL - 104 ID - 3238 ER - TY - JOUR AB - Introduction Cancer clinical trial (CCT) enrollment is low potentially threatening the generalizability of trial results and expedited regulatory approvals. We assessed whether type of initial patient appointment for non-small cell lung cancer (NSCLC) is associated with CCT eligibility. Methods Using a patient-to-accrual framework, we conducted a quasi-retrospective cohort pilot study at Sidney Kimmel Comprehensive Cancer Center (SKCCC), Baltimore, Maryland. 153 NSCLC patients new to SKCCC were categorized based on type of initial appointment: patients diagnosed or treated and patients seen for a consultation. CCT eligibility was determined by comparing eligibility criteria for each open trial to the electronic medical record (EMR) of each patient at every office visit occurring within 6-months of initial visit. Results We found no association between type of initial appointment and CCT eligibility (OR, 1.15; 95% CI, 0.49–2.73). Analyses did suggest current smokers were less likely to be eligible for trials compared to never smokers (OR, 0.15; 95% CI, 0.03–0.64), and stage 4 patients with second line therapy or greater were more likely to be eligible than stage 1 or 2 patients (OR, 5.18; 95% CI, 1.08–24.75). Additional analyses suggested most current smokers and stage 1 or 2 patients had trials available but were still ineligible. Conclusions SKCCC has a diverse portfolio of trials available for NSCLC patients and should consider research strategies to re-examine eligibility criteria for future trials to ensure increased enrollment of current smokers and stage 1 or 2 patients. We could not confirm whether type of initial visit was related to eligibility. © 2017 AD - Johns Hopkins University Bloomberg School of Public Health, United States Johns Hopkins University School of Medicine, Geriatrics Department, United States Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, United States AU - Hardesty, J. J. AU - Kanarek, N. F. DB - Scopus DO - 10.1016/j.conctc.2017.11.010 KW - Barriers Eligibility Lung cancer Trials M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2018 SP - 45-49 ST - Barriers to non-small cell lung cancer trial eligibility T2 - Contemporary Clinical Trials Communications TI - Barriers to non-small cell lung cancer trial eligibility UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037652428&doi=10.1016%2fj.conctc.2017.11.010&partnerID=40&md5=6fd894fdbb77fb3c5a148ceafbd492a1 VL - 9 ID - 2279 ER - TY - JOUR AB - This qualitative study identified barriers to African American women's participation in a community-based behavioral intervention trial to increase mammography screening. Four themes emerged from focus group discussions with community agency providers and research team members. These themes were (1) going to the gatekeepers; (2) knowing the culture; (3) location is everything; and (4) protocols, policies, and possibilities. A checklist of actions that nurse researchers could consider to increase African American women's participation in community trials is provided. © 2008 Elsevier Inc. All rights reserved. AD - K.M. Russell, School of Nursing, Indiana University, Indianapolis, IN 46202, United States AU - Russell, K. M. AU - Maraj, M. S. AU - Wilson, L. R. AU - Shedd-Steele, R. AU - Champion, V. L. DB - Medline DO - 10.1016/j.apnr.2006.05.001 IS - 2 KW - adult African American aged article breast tumor community care ethnology female human information processing mammography middle aged patient attitude patient selection psychological aspect urban population LA - English M3 - Article N1 - L351614983 2008-06-27 PY - 2008 SN - 0897-1897 SP - 90-97 ST - Barriers to recruiting urban African American women into research studies in community settings T2 - Applied Nursing Research TI - Barriers to recruiting urban African American women into research studies in community settings UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351614983&from=export http://dx.doi.org/10.1016/j.apnr.2006.05.001 VL - 21 ID - 1211 ER - TY - JOUR AB - Minority recruitment to cancer trials is low and there are limited data on minority adherence to lifestyle modification interventions. We examined factors related to recruitment and adherence to a pilot weight loss intervention among Hispanic and black breast cancer survivors. Participants completed a detailed screening interview to assess barriers to enrollment. An index was created to assess adherence at 6 months. 112 potentially eligible women were identified; 66 consented and completed a screening interview. After screening, 9 were ineligible; 15 opted to not enroll; and 42 were randomized. Among eligible women, earlier stage at diagnosis, treatment type, and negative beliefs related to exercise and diet after diagnosis were negatively associated with study enrollment ( P < 0.05). Self-reported barriers to adherence included fatigue, family responsibilities, illness, work, transportation, and negative perceptions of exercise and diet. Results from this study emphasize the need to adapt recruitment and adherence strategies to address these factors. AD - Department of Epidemiology, Mailman School of Public Health , Columbia University , New York USA Department of Biostatistics, Mailman School of Public Health , Columbia University , New York USA Department of Medicine, College of Physicians and Surgeons , Columbia University , New York USA Herbert Irving Comprehensive Cancer Center , Columbia University Medical Center , New York USA AN - 121037572. Language: English. Entry Date: 20170208. Revision Date: 20180530. Publication Type: Article AU - Aycinena, A. AU - Valdovinos, Cristina AU - Crew, Katherine AU - Tsai, Wei AU - Mata, Jennie AU - Sandoval, Rossy AU - Hershman, Dawn AU - Greenlee, Heather DB - CINAHL Complete DO - 10.1007/s10903-015-0310-1 DP - EBSCOhost IS - 1 KW - Breast Neoplasms Health Services Diet Weight Loss Exercise Black Persons Fatigue Female Hispanic Americans Human Life Style Quality of Life Minority Groups Survivors Questionnaires Paired T-Tests Chi Square Test Logistic Regression Middle Age Adult N1 - research; tables/charts. Journal Subset: Peer Reviewed; Public Health; USA. NLM UID: 101256527. PY - 2017 SN - 1557-1912 SP - 120-129 ST - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors T2 - Journal of Immigrant & Minority Health TI - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121037572&site=ehost-live&scope=site VL - 19 ID - 1860 ER - TY - JOUR AB - Minority recruitment to cancer trials is low and there are limited data on minority adherence to lifestyle modification interventions. We examined factors related to recruitment and adherence to a pilot weight loss intervention among Hispanic and black breast cancer survivors. Participants completed a detailed screening interview to assess barriers to enrollment. An index was created to assess adherence at 6 months. 112 potentially eligible women were identified; 66 consented and completed a screening interview. After screening, 9 were ineligible; 15 opted to not enroll; and 42 were randomized. Among eligible women, earlier stage at diagnosis, treatment type, and negative beliefs related to exercise and diet after diagnosis were negatively associated with study enrollment (P < 0.05). Self-reported barriers to adherence included fatigue, family responsibilities, illness, work, transportation, and negative perceptions of exercise and diet. Results from this study emphasize the need to adapt recruitment and adherence strategies to address these factors. AU - Aycinena, A. C. AU - Valdovinos, C. AU - Crew, K. D. AU - Tsai, W. Y. AU - Mata, J. M. AU - Sandoval, R. AU - Hershman, D. AU - Greenlee, H. DB - Medline DO - 10.1007/s10903-015-0310-1 IS - 1 KW - adult African American aged attitude to health breast tumor cancer staging cancer survivor diet ethnology exercise female health behavior Hispanic human lifestyle mental health middle aged pathology patient compliance patient selection perception pilot study procedures psychology quality of life randomized controlled trial (topic) self concept social support sociobiology weight loss program young adult LA - English M3 - Article N1 - L619833378 2017-12-26 PY - 2017 SN - 1557-1920 SP - 120-129 ST - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors T2 - Journal of immigrant and minority health TI - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619833378&from=export http://dx.doi.org/10.1007/s10903-015-0310-1 VL - 19 ID - 946 ER - TY - JOUR AB - Minority recruitment to cancer trials is low and there are limited data on minority adherence to lifestyle modification interventions. We examined factors related to recruitment and adherence to a pilot weight loss intervention among Hispanic and black breast cancer survivors. Participants completed a detailed screening interview to assess barriers to enrollment. An index was created to assess adherence at 6 months. 112 potentially eligible women were identified; 66 consented and completed a screening interview. After screening, 9 were ineligible; 15 opted to not enroll; and 42 were randomized. Among eligible women, earlier stage at diagnosis, treatment type, and negative beliefs related to exercise and diet after diagnosis were negatively associated with study enrollment (P < 0.05). Self-reported barriers to adherence included fatigue, family responsibilities, illness, work, transportation, and negative perceptions of exercise and diet. Results from this study emphasize the need to adapt recruitment and adherence strategies to address these factors. © 2016, Springer Science+Business Media New York. AD - Department of Health and Behavioral Studies, Teachers College, Columbia University, 525 W 120th Street, New York, NY 10027, United States Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, United States Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States AU - Aycinena, A. C. AU - Valdovinos, C. AU - Crew, K. D. AU - Tsai, W. Y. AU - Mata, J. M. AU - Sandoval, R. AU - Hershman, D. AU - Greenlee, H. DB - Scopus DO - 10.1007/s10903-015-0310-1 IS - 1 KW - Adherence Behavioral intervention Black Cancer survivor Hispanic Recruitment M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2017 SP - 120-129 ST - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors T2 - Journal of Immigrant and Minority Health TI - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955321728&doi=10.1007%2fs10903-015-0310-1&partnerID=40&md5=c2c9d035c8bc8c1c9e01ee42b9b668af VL - 19 ID - 2321 ER - TY - JOUR AB - Minority recruitment to cancer trials is low and there are limited data on minority adherence to lifestyle modification interventions. We examined factors related to recruitment and adherence to a pilot weight loss intervention among Hispanic and black breast cancer survivors. Participants completed a detailed screening interview to assess barriers to enrollment. An index was created to assess adherence at 6 months. 112 potentially eligible women were identified; 66 consented and completed a screening interview. After screening, 9 were ineligible; 15 opted to not enroll; and 42 were randomized. Among eligible women, earlier stage at diagnosis, treatment type, and negative beliefs related to exercise and diet after diagnosis were negatively associated with study enrollment (P < 0.05). Self-reported barriers to adherence included fatigue, family responsibilities, illness, work, transportation, and negative perceptions of exercise and diet. Results from this study emphasize the need to adapt recruitment and adherence strategies to address these factors. AN - WOS:000394213200015 AU - Aycinena, A. C. AU - Valdovinos, C. AU - Crew, K. D. AU - Tsai, W. Y. AU - Mata, J. M. AU - Sandoval, R. AU - Hershman, D. AU - Greenlee, H. DA - Feb DO - 10.1007/s10903-015-0310-1 IS - 1 N1 - 26801931 PY - 2017 SN - 1557-1912 SP - 120-129 ST - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors T2 - Journal of Immigrant and Minority Health TI - Barriers to Recruitment and Adherence in a Randomized Controlled Diet and Exercise Weight Loss Intervention Among Minority Breast Cancer Survivors VL - 19 ID - 2910 ER - TY - JOUR AB - Background:Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial.Methods:We retrospectively identified 8025 men from REDUCE with at least 2 years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy.Results:In REDUCE, 22% of men did not undergo a 2-year biopsy. On multivariable analysis, the non-North American region was predictive of 42-44% increased likelihood of undergoing a 2-year biopsy (P≤0.001). Being enrolled at a center that enrolled >10 subjects (2nd and 3rd tertile) was associated with a 42-48% increased likelihood of undergoing a 2-year biopsy (P<0.001). In addition, black race predicted 44% lower rate of on-study 2-year biopsy (odds ratio (OR)=0.56; P=0.001). Finally, missing one or more baseline variables was associated with a 32% decreased likelihood of undergoing a 2-year biopsy (OR=0.68; P<0.001).Conclusions:In REDUCE, men outside North America, those at higher volume centers and those with complete baseline data were more likely to undergo study-mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data. AD - S. Fischer, Division of Urology, Duke University, School of Medicine, 614W Main Street, Durham, NC, United States AU - Fischer, S. AU - Sun, S. AU - Howard, L. E. AU - Moreira, D. M. AU - Castro-Santamaria, R. AU - Andriole, G. L. AU - Vidal, A. C. AU - Freedland, S. J. DB - Embase Medline DO - 10.1038/pcan.2016.5 IS - 2 KW - aged alcohol consumption article attitude to illness cancer risk cancer screening controlled study data analysis demography family history female follow up human human tissue lifestyle major clinical study North America patient attitude prediction priority journal prostate biopsy prostate cancer race difference retrospective study risk factor self report smoking LA - English M3 - Article N1 - L608822298 2016-03-11 2016-05-27 PY - 2016 SN - 1476-5608 1365-7852 SP - 202-208 ST - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE T2 - Prostate Cancer and Prostatic Diseases TI - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE UR - https://www.embase.com/search/results?subaction=viewrecord&id=L608822298&from=export http://dx.doi.org/10.1038/pcan.2016.5 VL - 19 ID - 972 ER - TY - JOUR AB - Background:Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial.Methods:We retrospectively identified 8025 men from REDUCE with at least 2 years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy.Results:In REDUCE, 22% of men did not undergo a 2-year biopsy. On multivariable analysis, the non-North American region was predictive of 42-44% increased likelihood of undergoing a 2-year biopsy (P≤0.001). Being enrolled at a center that enrolled >10 subjects (2nd and 3rd tertile) was associated with a 42-48% increased likelihood of undergoing a 2-year biopsy (P<0.001). In addition, black race predicted 44% lower rate of on-study 2-year biopsy (odds ratio (OR)=0.56; P=0.001). Finally, missing one or more baseline variables was associated with a 32% decreased likelihood of undergoing a 2-year biopsy (OR=0.68; P<0.001).Conclusions:In REDUCE, men outside North America, those at higher volume centers and those with complete baseline data were more likely to undergo study-mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data. © 2016 Macmillan Publishers Limited. AD - Division of Urology, Duke University, School of Medicine, 614W Main Street, Durham, NC 27701, United States Surgery Section, Durham VA Medical Center, Durham, NC, United States Department of Biostatistics and Bioinformatics, Duke University, School of Medicine, Durham, NC, United States Department of Urology, Mayo Clinic, Rochester, MN, United States GlaxoSmithKline Inc., R and D Unit, King of Prussia, PA, United States Washington University, School of Medicine in St. Louis, St. Louis, MI, United States Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States AU - Fischer, S. AU - Sun, S. AU - Howard, L. E. AU - Moreira, D. M. AU - Castro-Santamaria, R. AU - Andriole, G. L. AU - Vidal, A. C. AU - Freedland, S. J. DB - Scopus DO - 10.1038/pcan.2016.5 IS - 2 M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2016 SP - 202-208 ST - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE T2 - Prostate Cancer and Prostatic Diseases TI - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959514390&doi=10.1038%2fpcan.2016.5&partnerID=40&md5=b203a508614e9e38406bb6a71bb3b18d VL - 19 ID - 2343 ER - TY - JOUR AB - BACKGROUND: Study compliance is crucial when the study outcome is determined by an invasive procedure, such as prostate biopsy. To investigate predictors of compliance in study-mandated prostate biopsies, we analyzed demographic, clinical and reported lifestyle data from the REDUCE trial. METHODS: We retrospectively identified 8025 men from REDUCE with at least 2 years of follow-up, and used multivariable logistic regression to test the association between baseline demographic and clinical characteristics and undergoing the study-mandated prostate biopsy at 2 years. We then examined whether missing any of these data was associated with undergoing a biopsy. RESULTS: In REDUCE, 22% of men did not undergo a 2-year biopsy. On multivariable analysis, the non-North American region was predictive of 42-44% increased likelihood of undergoing a 2-year biopsy (P <= 0.001). Being enrolled at a center that enrolled >10 subjects (2nd and 3rd tertile) was associated with a 42-48% increased likelihood of undergoing a 2-year biopsy (P < 0.001). In addition, black race predicted 44% lower rate of on-study 2-year biopsy (odds ratio (OR) = 0.56; P = 0.001). Finally, missing one or more baseline variables was associated with a 32% decreased likelihood of undergoing a 2-year biopsy (OR = 0.68; P < 0.001). CONCLUSIONS: In REDUCE, men outside North America, those at higher volume centers and those with complete baseline data were more likely to undergo study-mandated 2-year biopsies. Given prostate biopsy is becoming increasingly utilized as an endpoint in trials that are often multi-national, regional differences in compliance should be considered when designing future trials. Likewise, efforts are needed to ensure compliance in low-volume centers or among subjects missing baseline data. AN - WOS:000375896300014 AU - Fischer, S. AU - Sun, S. AU - Howard, L. E. AU - Moreira, D. M. AU - Castro-Santamaria, R. AU - Andriole, G. L. AU - Vidal, A. C. AU - Freedland, S. J. DA - Jun DO - 10.1038/pcan.2016.5 IS - 2 N1 - 26926927 PY - 2016 SN - 1365-7852 SP - 202-208 ST - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE T2 - Prostate Cancer and Prostatic Diseases TI - Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE VL - 19 ID - 2944 ER - TY - JOUR AB - Importance Few weight loss treatments produce clinically meaningful weight loss outcomes among black women, particularly in the primary care setting. New weight management strategies are necessary for this population. Weight gain prevention might be an effective treatment option, with particular benefits for overweight and class 1 obese black women. OBJECTIVE To compare changes in weight and cardiometabolic risk during a 12-month period among black women randomized to a primary care-based behavioral weight gain prevention intervention, relative to usual care. DESIGN. SETTING. AND PARTICIPANTS Two-arm randomized clinical trial (the Shape Program). We recruited patients from a 6-site community health center system. We randomized 194 overweight and class 1 obese (body mass index [calculated as weight in kilograms divided by height in meters squared], 25-34.9) premenopausal black women aged 25 to 44 years. Enrollment began on December 7,2009; 12- and 18-month assessments were completed in February and October 2,2012. interventions The medium-intensity intervention included tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership. MAIN OUTCOMES AND MEASURES Twelve-month change in weight and body mass index and maintenance of change at 18 months. RESULTS Participants had a mean age of 35.4 years, a mean weight of 81.1 kg. and a mean body mass index of 30.2 at baseline. Most were socioeconomically disadvantaged (79.7% with educational level less than a college degree; 74.3% reporting annual income <$30 000). The 12-month weight change was larger among intervention participants (mean [SD], -1.0 [0.5] kg), relative to usual care (0.5 [0.5] kg; mean difference, -1.4 kg [95% CI. -2.8 to -0.1 kg]; P = .04). At month 12,62% of intervention participants were at or below their baseline weights compared with 45% of usual-care participants (P = .03). By 18 months, intervention participants maintained significantly larger changes in weight (mean difference, -1.7 kg; 95% CI.-3.3 to-0.2 kg). CONCLUSIONS and relevance A medium-intensity primary care-based behavioral intervention demonstrated efficacy for weight gain prevention among socioeconomically disadvantaged black women. A "maintain, don't gain" approach might be a useful alternative treatment for reducing obesity-associated disease risk among some premenopausal black women. AD - Duke Obesity Prevention Program, Duke Global Health Institute, Duke University, Durham, NC, United States Department of Psychology and Neuroscience, Duke University, PO Box 90086, Durham, NC 27708, United States College of Nursing and Health Sciences, University of Massachusetts, Boston, United States Division of Endocrinology, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, United States Department of Exercise and Health Science, Dana-Farber Cancer Institute, Boston, MA, United States Piedmont Health Inc, Carrboro, NC, United States School of Public Health and Health Sciences, University of Massachusetts, Amherst, United States AU - Bennett, G. G. AU - Foley, P. AU - Levine, E. AU - Whiteley, J. AU - Askew, S. AU - Steinberg, D. M. AU - Batch, B. AU - Greaney, M. L. AU - Miranda, H. AU - Wroth, T. H. AU - Holder, M. G. AU - Emmons, K. M. AU - Puleo, E. DB - Scopus DO - 10.1001/jamainternmed.2013.9263 IS - 19 M3 - Article N1 - Cited By :60 Export Date: 22 March 2021 PY - 2013 SP - 1770-1777 ST - Behavioral treatment for weight gain prevention among black women in primary care practice: A randomized clinical trial T2 - JAMA Internal Medicine TI - Behavioral treatment for weight gain prevention among black women in primary care practice: A randomized clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84887037416&doi=10.1001%2fjamainternmed.2013.9263&partnerID=40&md5=227c1ad5b3f2b7a129c4f4c0bcf03170 VL - 173 ID - 2424 ER - TY - JOUR AB - The National Lung Screening Trial (NLST) recently reported that annual computed tomography (CT) screening is associated with decreased lung cancer mortality in high-risk smokers. Beliefs about lung cancer and screening, particularly across race and ethnicity, and their influence on CT screening utilization are largely unexamined. Our study recruited asymptomatic, high-risk smokers, 55-74 years of age from primary care clinics in an academic urban hospital. Guided by the self-regulation theory, we evaluated cognitive and affective beliefs about lung cancer. Intention to screen for lung cancer with a CT scan was assessed by self-report. We used univariate and logistic regression analyses to compare beliefs about screening and intention to screen among minority (Blacks and Hispanics) and non-minority participants. Overall, we enrolled 108 participants, of which 40% were Black and 34% were Hispanic; the mean age was 62.3 years, and median pack-years of smoking was 26. We found that intention to screen was similar among minorities and non-minorities (p= 0.19); however, Hispanics were less likely to report intention to screen if they had to pay for the test (p= 0.02). Fatalistic beliefs, fear of radiation exposure, and anxiety related to CT scans were significantly associated with decreased intention to screen (p< 0.05). Several differences were observed in minority versus non-minority participants' beliefs toward lung cancer and screening. In conclusion, we found that concerns about cost, which were particularly prominent among Hispanics, as well as fatalism and radiation exposure fears may constitute barriers to lung cancer screening. Lung cancer screening programs should address these factors to ensure broad participation, particularly among minorities. © 2012 Elsevier Ireland Ltd. AD - J.P. Wisnivesky, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1087, New York, NY 10029, United States AU - Jonnalagadda, S. AU - Bergamo, C. AU - Lin, J. J. AU - Lurslurchachai, L. AU - Diefenbach, M. AU - Smith, C. AU - Nelson, J. E. AU - Wisnivesky, J. P. DB - Embase Medline DO - 10.1016/j.lungcan.2012.05.095 IS - 3 KW - adult aged anxiety article cancer screening cigarette smoking cognition computer assisted tomography conceptual framework controlled study cross-sectional study educational status ethnic difference female health care cost high risk population Hispanic human lung cancer lung nodule major clinical study male medical history outpatient care patient attitude primary medical care priority journal race difference radiation exposure self report thorax radiography urban area LA - English M3 - Article N1 - L52046791 2012-06-08 2012-08-30 PY - 2012 SN - 0169-5002 1872-8332 SP - 526-531 ST - Beliefs and attitudes about lung cancer screening among smokers T2 - Lung Cancer TI - Beliefs and attitudes about lung cancer screening among smokers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52046791&from=export http://dx.doi.org/10.1016/j.lungcan.2012.05.095 VL - 77 ID - 1110 ER - TY - JOUR AB - The National Lung Screening Trial (NLST) recently reported that annual computed tomography (CT) screening is associated with decreased lung cancer mortality in high-risk smokers. Beliefs about lung cancer and screening, particularly across race and ethnicity, and their influence on CT screening utilization are largely unexamined. Our study recruited asymptomatic, high-risk smokers, 55-74 years of age from primary care clinics in an academic urban hospital. Guided by the self-regulation theory, we evaluated cognitive and affective beliefs about lung cancer. Intention to screen for lung cancer with a CT scan was assessed by self-report. We used univariate and logistic regression analyses to compare beliefs about screening and intention to screen among minority (Blacks and Hispanics) and non-minority participants. Overall, we enrolled 108 participants, of which 40% were Black and 34% were Hispanic; the mean age was 62.3 years, and median pack-years of smoking was 26. We found that intention to screen was similar among minorities and non-minorities (p= 0.19); however, Hispanics were less likely to report intention to screen if they had to pay for the test (p= 0.02). Fatalistic beliefs, fear of radiation exposure, and anxiety related to CT scans were significantly associated with decreased intention to screen (p< 0.05). Several differences were observed in minority versus non-minority participants' beliefs toward lung cancer and screening. In conclusion, we found that concerns about cost, which were particularly prominent among Hispanics, as well as fatalism and radiation exposure fears may constitute barriers to lung cancer screening. Lung cancer screening programs should address these factors to ensure broad participation, particularly among minorities. © 2012 Elsevier Ireland Ltd. AD - Doris Duke Clinical Research Fellows, UMDNJ-Robert Wood Johnson Medical School, One Gustave L. Levy Place, Box 1087, New York, NY 10029, United States Division of General Internal Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1087, New York, NY 10029, United States Division of Urology and Oncological Sciences, Mount Sinai School of Medicine, 5 E 98th Street, 6th Floor, New York, NY 10029, United States Division of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States Division of Pulmonary and Critical Care, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1232, New York, NY 10029, United States AU - Jonnalagadda, S. AU - Bergamo, C. AU - Lin, J. J. AU - Lurslurchachai, L. AU - Diefenbach, M. AU - Smith, C. AU - Nelson, J. E. AU - Wisnivesky, J. P. DB - Scopus DO - 10.1016/j.lungcan.2012.05.095 IS - 3 KW - Cancer Cancer screening Cultural differences Health behavior Health beliefs Race and ethnicity M3 - Article N1 - Cited By :82 Export Date: 22 March 2021 PY - 2012 SP - 526-531 ST - Beliefs and attitudes about lung cancer screening among smokers T2 - Lung Cancer TI - Beliefs and attitudes about lung cancer screening among smokers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865180807&doi=10.1016%2fj.lungcan.2012.05.095&partnerID=40&md5=4b148ddd3dabb2ec63124e2d8802ae77 VL - 77 ID - 2454 ER - TY - JOUR AB - The National Lung Screening Trial (NLST) recently reported that annual computed tomography (CT) screening is associated with decreased lung cancer mortality in high-risk smokers. Beliefs about lung cancer and screening, particularly across race and ethnicity, and their influence on CT screening utilization are largely unexamined. Our study recruited asymptomatic, high-risk smokers, 55-74 years of age from primary care clinics in an academic urban hospital. Guided by the self-regulation theory, we evaluated cognitive and affective beliefs about lung cancer. Intention to screen for lung cancer with a CT scan was assessed by self-report. We used univariate and logistic regression analyses to compare beliefs about screening and intention to screen among minority (Blacks and Hispanics) and non-minority participants. Overall, we enrolled 108 participants, of which 40% were Black and 34% were Hispanic; the mean age was 62.3 years, and median pack-years of smoking was 26. We found that intention to screen was similar among minorities and non-minorities (p = 0.19); however, Hispanics were less likely to report intention to screen if they had to pay for the test (p = 0.02). Fatalistic beliefs, fear of radiation exposure, and anxiety related to CT scans were significantly associated with decreased intention to screen (p < 0.05). Several differences were observed in minority versus non-minority participants' beliefs toward lung cancer and screening. In conclusion, we found that concerns about cost, which were particularly prominent among Hispanics, as well as fatalism and radiation exposure fears may constitute barriers to lung cancer screening. Lung cancer screening programs should address these factors to ensure broad participation, particularly among minorities. (c) 2012 Elsevier Ireland Ltd. All rights reserved. AN - WOS:000308514900009 AU - Jonnalagadda, S. AU - Bergamo, C. AU - Lin, J. J. AU - Lurslurchachai, L. AU - Diefenbach, M. AU - Smith, C. AU - Nelson, J. E. AU - Wisnivesky, J. P. DA - Sep DO - 10.1016/j.lungcan.2012.05.095 IS - 3 N1 - 22681870 PY - 2012 SN - 0169-5002 SP - 526-531 ST - Beliefs and attitudes about lung cancer screening among smokers T2 - Lung Cancer TI - Beliefs and attitudes about lung cancer screening among smokers VL - 77 ID - 3062 ER - TY - JOUR AB - Rationale: The CHRNA5-CHRNA3-CHRNB4 locus is associated with self-reported smoking behavior and also harbors the strongest genetic associations with chronic obstructive pulmonary disease (COPD) and lung cancer. Because the associations with lung disease remain after adjustment for self-reported smoking behaviors, it has been asserted that CHRNA5-CHRNA3-CHRNB4 variants increase COPD and lung cancer susceptibility independently of their effects on smoking. Objectives: To compare the genetic associations of exhaled carbon monoxide (CO), a biomarker of current cigarette exposure, with self-reported smoking behaviors. Methods: A total of 1,521 European American and 247 African American current smokers recruited into smoking cessation studies were assessed for CO at intake before smoking cessation. DNA samples were genotyped using the Illumina Omni2.5 microarray. Genetic associations with CO and smoking behaviors (cigarettes smoked per day, Fagerstrom test for nicotine dependence) were studied. Measurements and Main Results: Variants in the CHRNA5-CHRNA3-CHRNB4 locus, including rs16969968, a nonsynonymous variant in CHRNA5, are genomewide association study-significantly associated with CO (β = 2.66; 95% confidence interval [CI], 1.74 -3.58; P = 1.65 × 10-8), and this association remains strong after adjusting for smoking behavior (β = 2.18; 95% CI, 1.32- 3.04; P = 7.47 × 10-7). The correlation between CO and cigarettes per day is statistically significantly lower ( z = 3.43; P = 6.07 × 10-4 ) in African Americans ( r = 0.14; 95% CI, 0.02- 0.26; P = 0.003) than in European-Americans (r = 0.36; 95% CI, 0.31-0.40; P = 0.0001). Conclusions: Exhaled CO, a biomarker that is simple to measure, captures aspects of cigarette smoke exposure in current smokers beyond the number of cigarettes smoked per day. Behavioral measures of smoking are therefore insufficient indices of cigarette smoke exposure, suggesting that genetic associations with COPD or lung cancer that persist after adjusting for self-reported smoking behavior may still reflect genetic effects on smoking exposure. Copyright © 2014 by the American Thoracic Society AD - Washington University School of Medicine, Department of Psychiatry, Box 8134, 660 South Euclid Avenue, St. Louis, MO 63110, United States Department of Psychology, University of Wisconsin, Madison, WI, United States Department of Psychiatry, University of Minnesota, Minneapolis, MN, United States RTI International, Research Triangle ParkNC, United States Department of Biostatistics, University of Washington, Seattle, WA, United States Department of Genetics, Washington University School of Medicine, St. Louis, MO, United States AU - Bloom, A. J. AU - Hartz, S. M. AU - Baker, T. B. AU - Chen, L. S. AU - Piper, M. E. AU - Fox, L. AU - Martinez, M. AU - Hatsukami, D. AU - Johnson, E. O. AU - Laurie, C. C. AU - Saccone, N. L. AU - Goate, A. AU - Bierut, L. J. DB - Scopus DO - 10.1513/AnnalsATS.201401-010OC IS - 7 KW - Chronic obstructive pulmonary disease Lung cancer Nicotine Nicotinic receptor Smoking M3 - Article N1 - Cited By :28 Export Date: 22 March 2021 PY - 2014 SP - 1003-1010 ST - Beyond cigarettes per day: A genome-wide association study of the biomarker carbon monoxide T2 - Annals of the American Thoracic Society TI - Beyond cigarettes per day: A genome-wide association study of the biomarker carbon monoxide UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911870094&doi=10.1513%2fAnnalsATS.201401-010OC&partnerID=40&md5=328fba191b68f8751f116421581b54e2 VL - 11 ID - 2390 ER - TY - JOUR AB - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-ofstudy biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index ($ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostatespecific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black (v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplementedwith imputed end points). Statin use in SELECT provided anOR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screenedmen enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts. AD - C.M. Tangen, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-C102, Seattle, WA, United States AU - Tangen, C. M. AU - Goodman, P. J. AU - Till, C. AU - Schenk, J. M. AU - Lucia, M. S. AU - Thompson, I. M. DB - Embase Medline DO - 10.1200/JCO.2016.68.1965 IS - 36 KW - acetylsalicylic acid alpha tocopherol hydroxymethylglutaryl coenzyme A reductase inhibitor placebo prostate specific antigen selenium adult age aged article Black person body mass cancer prevention cancer risk cancer screening controlled study diabetes mellitus digital rectal examination education ethnicity family history human human tissue major clinical study male marriage middle aged patient attitude priority journal prospective study prostate biopsy prostate cancer prostate hypertrophy randomized controlled trial risk factor smoking tumor biopsy vasectomy LA - English M3 - Article N1 - L614094064 2017-01-24 2017-01-25 PY - 2016 SN - 1527-7755 0732-183X SP - 4338-4344 ST - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: Results from two large randomized clinical trials T2 - Journal of Clinical Oncology TI - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: Results from two large randomized clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614094064&from=export http://dx.doi.org/10.1200/JCO.2016.68.1965 VL - 34 ID - 951 ER - TY - JOUR AB - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor‐prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end‐ofstudy biopsy, prostate cancer cases were categorized by a preceding prostate‐specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy‐proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index ($ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostatespecific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black (v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic‐like cohort) to 1.83 for PCPT (end‐of‐study biopsy supplementedwith imputed end points). Statin use in SELECT provided anOR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screenedmen enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts. AN - CN-01298726 AU - Tangen, C. M. AU - Goodman, P. J. AU - Till, C. AU - Schenk, J. M. AU - Lucia, M. S. AU - Thompson, I. M. DO - 10.1200/JCO.2016.68.1965 IS - 36 KW - *patient attitude *prostate biopsy *prostate cancer /drug therapy /drug therapy /prevention /surgery *risk factor Adult Age Aged Article Black person Body mass Cancer prevention Cancer risk Cancer screening Controlled study Diabetes mellitus Digital rectal examination Education Ethnicity Family history Human Human tissue Major clinical study Male Marriage Middle aged Priority journal Prospective study Prostate hypertrophy Randomized controlled trial Smoking Tumor biopsy Vasectomy M3 - Journal: Article PY - 2016 SP - 4338‐4344 ST - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials T2 - Journal of clinical oncology TI - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: results from two large randomized clinical trials UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01298726/full VL - 34 ID - 1527 ER - TY - JOUR AB - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-ofstudy biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index ($ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostatespecific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black (v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplementedwith imputed end points). Statin use in SELECT provided anOR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screenedmen enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts. © 2016 by American Society of Clinical Oncology. AD - Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-C102, Seattle, WA 98109-1024, United States Denver School of Medicine, University of Colorado, Denver, CO, United States Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States AU - Tangen, C. M. AU - Goodman, P. J. AU - Till, C. AU - Schenk, J. M. AU - Lucia, M. S. AU - Thompson, I. M., Jr. DB - Scopus DO - 10.1200/JCO.2016.68.1965 IS - 36 M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2016 SP - 4338-4344 ST - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: Results from two large randomized clinical trials T2 - Journal of Clinical Oncology TI - Biases in recommendations for and acceptance of prostate biopsy significantly affect assessment of prostate cancer risk factors: Results from two large randomized clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009799771&doi=10.1200%2fJCO.2016.68.1965&partnerID=40&md5=245dca0f6266719555a58395fbe3cff1 VL - 34 ID - 2328 ER - TY - JOUR AB - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-ofstudy biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/ digital rectal examination prompt (yes/ no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index ($ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostatespecific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black (v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplementedwith imputed end points). Statin use in SELECT provided anOR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screenedmen enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts. (C) 2016 by American Society of Clinical Oncology AN - WOS:000391380500008 AU - Tangen, C. M. AU - Goodman, P. J. AU - Till, C. AU - Schenk, J. M. AU - Lucia, M. S. AU - Thompson, I. M. DA - Dec DO - 10.1200/JCO.2016.68.1965 IS - 36 N1 - 27998216 PY - 2016 SN - 0732-183X SP - 4338-+ ST - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials T2 - Journal of Clinical Oncology TI - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials VL - 34 ID - 2922 ER - TY - JOUR AB - Purpose To identify factors related to who undergoes a prostate biopsy in a screened population and to estimate the impact of biopsy verification on risk factor-prostate cancer associations. Patients and Methods Men who were screened regularly from the placebo arms of two large prostate cancer prevention trials (Prostate Cancer Prevention Trial [PCPT] and Selenium and Vitamin E Cancer Prevention Trial [SELECT]) were examined to define incident prostate cancer cohorts. Because PCPT had an end-of-study biopsy, prostate cancer cases were categorized by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases by biopsy-proven negative status (yes v no). We estimated the association of risk factors (age, ethnicity, family history, body mass index, medication use) with prostate cancer and quantified differences in risk associations across cohorts. Results Men 60 to 69 years of age, those with benign prostatic hyperplasia, and those with a family history of prostate cancer were more likely, and those with a higher body mass index (≥ 25), diabetes, or a smoking history were less likely, to undergo biopsy, adjusting for age and longitudinal prostate-specific antigen and digital rectal examination. Medication use, education, and marital status also influenced who underwent biopsy. Some risk factor estimates for prostate cancer varied substantially across cohorts. Black ( v other ethnicities) had odds ratios (ORs) that varied from 1.20 for SELECT (community screening standards, epidemiologic-like cohort) to 1.83 for PCPT (end-of-study biopsy supplemented with imputed end points). Statin use in SELECT provided an OR of 0.65 and statin use in in PCPT provided an OR of 0.99, a relative difference of 34%. Conclusion Among screened men enrolled in prostate cancer prevention trials, differences in risk factor estimates for prostate cancer likely underestimate the magnitude of bias found in other cohorts with varying screening and biopsy recommendations and acceptance. Risk factors for prostate cancer derived from epidemiologic studies not only may be erroneous but may lead to misdirected research efforts. AD - Fred Hutchinson Cancer Research Center, Seattle, WA University of Colorado Denver School of Medicine, Denver, CO The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX Catherine M. Tangen, Phyllis J. Goodman, Cathee Till, and Jeannette M. Schenk, Fred Hutchinson Cancer Research Center, Seattle, WA; M. Scott Lucia, University of Colorado Denver School of Medicine, Denver, CO; and Ian M. Thompson Jr, The Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX AN - 120356461. Language: English. Entry Date: 20170817. Revision Date: 20190103. Publication Type: journal article. Journal Subset: Biomedical AU - Tangen, Catherine M. AU - Goodman, Phyllis J. AU - Till, Cathee AU - Schenk, Jeannette M. AU - Lucia, M. Scott AU - Thompson Jr, Ian M. AU - Thompson, Ian M., Jr. DB - CINAHL Complete DO - 10.1200/JCO.2016.68.1965 DP - EBSCOhost IS - 36 N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: UM1 CA182883/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM27998216. PY - 2016 SN - 0732-183X SP - 4338-4344 ST - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials T2 - Journal of Clinical Oncology TI - Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120356461&site=ehost-live&scope=site VL - 34 ID - 1861 ER - TY - JOUR AB - Purpose: Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits. Methods: This prospective study recruited women with confirmed hormonal-positive (HR +) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation. Results: Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III +) were more likely to donate biospecimens (p < 0.05).Conclusions: Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination. Implications for cancer survivors: PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Sheppard, Vanessa B., School of Medicine, Virginia Commonwealth University, Richmond, VA, US AN - 2018-04238-008 AU - Sheppard, Vanessa B. AU - Hurtado-de-Mendoza, Alejandra AU - Zheng, Yun-Ling AU - Wang, Ying AU - Graves, Kristi D. AU - Lobo, Tania AU - Xu, Hanfei AU - Jennings, Yvonne AU - Tolsma, Dennis AU - Trout, Martha AU - Robinson, Brandi E. AU - McKinnon, Brittany AU - Tadesse, Mahlet DB - psyh DO - 10.1007/s11764-017-0646-8 DP - EBSCOhost IS - 1 KW - Precision medicine Biospecimen donation Black breast cancer survivors White breast cancer survivors Disparities Adult African Americans Aged Aged, 80 and over Biological Specimen Banks Breast Neoplasms Cancer Survivors European Continental Ancestry Group Female Humans Middle Aged Specimen Handling Racial and Ethnic Differences Survivors Tissue Donation Health Disparities Blacks Whites N1 - School of Medicine, Virginia Commonwealth University, Richmond, VA, US. Release Date: 20181126. Correction Date: 20190613. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Hurtado-de-Mendoza, Alejandra. Major Descriptor: Breast Neoplasms; Racial and Ethnic Differences; Survivors; Tissue Donation; Health Disparities. Minor Descriptor: Blacks; Whites. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Distress Thermometer; Patient Satisfaction Questionnaire Short Form; Medical Outcomes Study Social Support Survey DOI: 10.1037/t04034-000; Functional Assessment of Cancer Therapy DOI: 10.1037/t04236-000; Medical Mistrust Index DOI: 10.1037/t71626-000. Methodology: Empirical Study; Interview; Quantitative Study. Page Count: 8. Issue Publication Date: Feb, 2018. Publication History: First Posted Date: Nov 16, 2017; Accepted Date: Aug 31, 2017; First Submitted Date: Mar 6, 2017. Copyright Statement: Springer Science+Business Media, LLC. 2017. Sponsor: Federal Funds. Other Details: Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS). Recipients: No recipient indicated Sponsor: National Institutes of Health, National Center for Advancing Translational Sciences (NCATS), US. Grant: KL2TR001432. Other Details: Clinical and Translational Science Awards Program (CTSA). Recipients: Hurtado-de-Mendoza, Alejandra Sponsor: National Institutes of Health. Grant: R01CA154848. Recipients: Sheppard, Vanessa B. Sponsor: National Institutes of Health. Grant: R01 CA132996. Recipients: Zheng, Yun-Ling Sponsor: NCI. Grant: NTSR P30 CA51008; P30 CA51008. Other Details: Nontherapeutic Subject Registry Shared Resource at Lombardi Comprehensive Cancer Center; Laboratory of Telomere Health. Recipients: No recipient indicated Sponsor: NIH-NCI. Grant: P30 CA016059. Other Details: Cancer Center Support Grant. Recipients: No recipient indicated PY - 2018 SN - 1932-2259 1932-2267 SP - 74-81 ST - Biospecimen donation among black and white breast cancer survivors: Opportunities to promote precision medicine T2 - Journal of Cancer Survivorship TI - Biospecimen donation among black and white breast cancer survivors: Opportunities to promote precision medicine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-04238-008&site=ehost-live&scope=site vanessa.sheppard@vcuhealth.org VL - 12 ID - 1680 ER - TY - JOUR AB - Purpose: Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits.Methods: This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation.Results: Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05).Conclusions: Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination.Implications For Cancer Survivors: PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation. AD - School of Medicine, Virginia Commonwealth University, Richmond, VA, USA Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA Kaiser Permanente Georgia, Atlanta, GA, USA Southeast Permanente Medical Group, Atlanta, GA, USA Henry Ford Health System, Detroit, MI, USA AN - 127706971. Language: English. Entry Date: In Process. Revision Date: 20190217. Publication Type: journal article AU - Sheppard, Vanessa B. AU - Hurtado-de-Mendoza, Alejandra AU - Zheng, Yun-Ling AU - Wang, Ying AU - Graves, Kristi D. AU - Lobo, Tania AU - Xu, Hanfei AU - Jennings, Yvonne AU - Tolsma, Dennis AU - Trout, Martha AU - Robinson, Brandi E. AU - McKinnon, Brittany AU - Tadesse, Mahlet DB - CINAHL Complete DO - 10.1007/s11764-017-0646-8 DP - EBSCOhost IS - 1 KW - Black Persons -- Statistics and Numerical Data Tissue Banks -- Standards Breast Neoplasms -- Pathology White Persons -- Statistics and Numerical Data Breast Neoplasms -- Ethnology Adult Aged Breast Neoplasms -- Therapy Breast Neoplasms -- Mortality Female Middle Age Specimen Handling -- Methods Aged, 80 and Over Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies Ferrans and Powers Quality of Life Index Scales N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Problem Areas in Diabetes Scale (PAID); Ferrans and Powers Quality of Life Index. Grant Information: P30 CA016059/CA/NCI NIH HHS/United States. NLM UID: 101307557. PMID: NLM29147853. PY - 2018 SN - 1932-2259 SP - 74-81 ST - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine T2 - Journal of Cancer Survivorship TI - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127706971&site=ehost-live&scope=site VL - 12 ID - 1862 ER - TY - JOUR AB - PURPOSE: Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits. METHODS: This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation. RESULTS: Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05). CONCLUSIONS: Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination. IMPLICATIONS FOR CANCER SURVIVORS: PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation. AU - Sheppard, V. B. AU - Hurtado-de-Mendoza, A. AU - Zheng, Y. L. AU - Wang, Y. AU - Graves, K. D. AU - Lobo, T. AU - Xu, H. AU - Jennings, Y. AU - Tolsma, D. AU - Trout, M. AU - Robinson, B. E. AU - McKinnon, B. AU - Tadesse, M. DB - Medline DO - 10.1007/s11764-017-0646-8 IS - 1 KW - adult African American aged biobank breast tumor cancer survivor Caucasian ethnology female human middle aged mortality pathology personalized medicine procedures specimen handling standards statistics and numerical data very elderly LA - English M3 - Article N1 - L625918493 2019-01-18 2019-02-12 PY - 2018 SN - 1932-2267 SP - 74-81 ST - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine T2 - Journal of cancer survivorship : research and practice TI - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625918493&from=export http://dx.doi.org/10.1007/s11764-017-0646-8 VL - 12 ID - 912 ER - TY - JOUR AB - Purpose: Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits. Methods: This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation. Results: Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05). Conclusions: Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination. Implications for cancer survivors: PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation. © 2017, Springer Science+Business Media, LLC. AD - School of Medicine, Virginia Commonwealth University, Richmond, VA, United States Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States Kaiser Permanente Georgia, Atlanta, GA, United States Southeast Permanente Medical Group, Atlanta, GA, United States Henry Ford Health System, Detroit, MI, United States AU - Sheppard, V. B. AU - Hurtado-de-Mendoza, A. AU - Zheng, Y. L. AU - Wang, Y. AU - Graves, K. D. AU - Lobo, T. AU - Xu, H. AU - Jennings, Y. AU - Tolsma, D. AU - Trout, M. AU - Robinson, B. E. AU - McKinnon, B. AU - Tadesse, M. DB - Scopus DO - 10.1007/s11764-017-0646-8 IS - 1 KW - Biospecimen Disparities Precision medicine Survivors M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2018 SP - 74-81 ST - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine T2 - Journal of Cancer Survivorship TI - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85034265180&doi=10.1007%2fs11764-017-0646-8&partnerID=40&md5=b8b4fbbc9a267a72252978776269c086 VL - 12 ID - 2285 ER - TY - JOUR AB - Advances in precision medicine (PM) have potential to reduce and/or eliminate breast cancer disparities in both treatment and survivorship. However, compared to white Americans, black Americans are often underrepresented in genetic research. This report assessed factors that influence receipt of buccal cells via saliva kits. This prospective study recruited women with confirmed hormonal-positive (HR+) breast cancer (BC). A standardized telephone survey collected sociodemographic, socio-cultural (e.g., religiosity), and healthcare process factors. Clinical information was abstracted from medical records. After the baseline survey, return postage-paid envelopes and mouthwash collection kits were mailed. Univariate and adjusted logistic regression models estimated the probability of biospecimen donation. Seventy percent of the sample provided buccal cells which were of good quality. No differences were noted by race or other demographic factors. In the multivariable logistic model, time spent with providers (OR 1.61 per 1-point increase; 95% CI 1.242, 2.088) and religiosity (OR 0.957 per 1-point increase; 95% CI 0.931, 0.984) remained associated with biospecimen provision. Women with lower-stage cancer (vs. higher stage III+) were more likely to donate biospecimens (p < 0.05). Cancer care experiences predicted specimen donation. Understanding the contextual reasons for lower receipt among women with higher religiosity scores and higher stage warrants further examination. PM is relevant to cancer survivors because of its potential to inform targeted therapies, understand disease resistance, and aide in prediction of toxicity and/or recurrence. Future efforts to launch precision medicine trials with BC survivors may benefit from engaging medical oncologists and/or leveraging patient-provider encounters for trial participation. AN - WOS:000423586600008 AU - Sheppard, V. B. AU - Hurtado-de-Mendoza, A. AU - Zheng, Y. L. AU - Wang, Y. AU - Graves, K. D. AU - Lobo, T. AU - Xu, H. F. AU - Jennings, Y. AU - Tolsma, D. AU - Trout, M. AU - Robinson, B. E. AU - McKinnon, B. AU - Tadesse, M. DA - Feb DO - 10.1007/s11764-017-0646-8 IS - 1 N1 - 29147853 PY - 2018 SN - 1932-2259 SP - 74-81 ST - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine T2 - Journal of Cancer Survivorship TI - Biospecimen donation among black and white breast cancer survivors: opportunities to promote precision medicine VL - 12 ID - 2876 ER - TY - JOUR AB - OBJECTIVE: Colonoscopy is considered as a standard method for detecting various kinds of colorectal polyps. However, conventional colonoscopy (CC) still has chances to miss some lesions. Some scholars have already repor ted that transparent hood assisted colonoscopy (THAC) can improve the detection rate of colorectal polyps. However, the efficacy of detection of colorectal polyps with black hood assisted colonoscopy (BHAC) is still unclear. In this study, BHAC was compared with CC for evaluating the efficacy of detection of colorectal polyps. PATIENTS AND METHODS: Between Sep 2014 and Apr 2015, 542 patients underwent CC and meanwhile 534 patients underwent BHAC were enrolled into this prospective randomized controlled study. Comparison of baseline characteristics, cecal intubation time, withdrawal time, total number of detected polyps, detection rate of polyps, location, size, morphology and pathological diagnosis of polyps between these two groups was performed. RESULTS: Cecal intubation time was significantly shorter in BHAC group than in CC group (6.31 ± 3.51 min vs. 7.05 ± 4.15 min, p = 0.002). The total number of detected polyps and detection rate of polyps were significantly higher in BHAC group than in CC group (349/65.36% vs. 264/48.71%, p = 0.004). CONCLUSIONS: Compared with CC, BHAC could significantly improve the detection rate of colorectal polyps, and cecal intubation time was significantly reduced by BHAC. AD - Digestive Endoscopy Center, Huadong Hospital Affiliated, Fudan University, Shanghai, China AU - Huang, R. X. AU - Xiao, Z. L. AU - Li, F. AU - Ji, D. N. AU - Zhou, J. AU - Xiang, P. AU - Bao, Z. J. DB - Scopus IS - 15 KW - Black hood Colonoscopy Colorectal polyps M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2016 SP - 3266-3272 ST - Black hood assisted colonoscopy for detection of colorectal polyps: A prospective randomized controlled study T2 - European Review for Medical and Pharmacological Sciences TI - Black hood assisted colonoscopy for detection of colorectal polyps: A prospective randomized controlled study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017174527&partnerID=40&md5=334aa174e45d978241bd9c5d014f1d14 VL - 20 ID - 2338 ER - TY - JOUR AB - OBJECTIVE: Colonoscopy is considered as a standard method for detecting various kinds of colorectal polyps. However, conventional colonoscopy (CC) still has chances to miss some lesions. Some scholars have already reported that transparent hood assisted colonoscopy (THAC) can improve the detection rate of colorectal polyps. However, the efficacy of detection of colorectal polyps with black hood assisted colonoscopy (BHAC) is still unclear. In this study, BHAC was compared with CC for evaluating the efficacy of detection of colorectal polyps. PATIENTS AND METHODS: Between Sep 2014 and Apr 2015, 542 patients underwent CC and meanwhile 534 patients underwent BHAC were enrolled into this prospective randomized controlled study. Comparison of baseline characteristics, cecal intubation time, withdrawal time, total number of detected polyps, detection rate of polyps, location, size, morphology and pathological diagnosis of polyps between these two groups was performed. RESULTS: Cecal intubation time was significantly shorter in BHAC group than in CC group (6.31 +/- 3.51 min vs. 7.05 +/- 4.15 min, p = 0.002). The total number of detected polyps and detection rate of polyps were significantly higher in BHAC group than in CC group (349/65.36% vs. 264/48.71%, p = 0.004). CONCLUSIONS: Compared with CC, BHAC could significantly improve the detection rate of colorectal polyps, and cecal intubation time was significantly reduced by BHAC. AN - WOS:000382461300020 AU - Huang, R. X. AU - Xiao, Z. L. AU - Li, F. AU - Ji, D. N. AU - Zhou, J. AU - Xiang, P. AU - Bao, Z. J. DA - Aug IS - 15 N1 - 27467003 PY - 2016 SN - 1128-3602 SP - 3266-3272 ST - Black hood assisted colonoscopy for detection of colorectal polyps: a prospective randomized controlled study T2 - European Review for Medical and Pharmacological Sciences TI - Black hood assisted colonoscopy for detection of colorectal polyps: a prospective randomized controlled study VL - 20 ID - 2936 ER - TY - JOUR AB - Objective: The study objective was to identify biobehavioral variables associated with greater intake of nicotine and a tobacco carcinogen among Black light smokers who smoke 1 to 10 cigarettes per day (CPD). Methods: We analyzed baseline data collected from 426 Black light smokers enrolled in Kick It at Swope III (KIS III), a smoking cessation trial for Black smokers. We examined differences in concentrations of tobacco biomarkers, including urinary total nicotine equivalents (TNE) and total 4-(methylnitrosamino)-1-(3)pyridyl-1-butanonol (NNAL; a human carcinogen), across gender, age, plasma nicotine metabolite ratio (NMR), CPD, and measures of tobacco dependence, including time to first cigarette (TFC), using ANOVA. Results: Tobacco biomarker levels were significantly higher among those who smoked more CPD (6–10 vs 1–5 CPD) and those with greater reported physical dependence on tobacco. Concurrently, those who smoked 1–5 CPD smoked each cigarette more intensely than those who smoked 6–10 CPD. While we found no gender differences overall, among those who smoked 1–5 CPD, women had higher NNAL levels compared to men. The rate of nicotine metabolism, measured by the nicotine metabolite ratio, was not significantly related to TNE or NNAL levels. Conclusion: Among Black Light smokers, higher cigarette consumption and greater physical dependence—but not rate of nicotine metabolism, menthol use, or socioeconomic status—were associated with greater toxicant exposure and thus a likely increased risk of tobacco-related diseases. The lack of data on light smokers, and specifically on Blacks, make this observation important given the disproportionate burden of lung cancer in this population. (PsycINFO Database Record (c) 2020 APA, all rights reserved) AD - St. Helen, Gideon, Clinical Pharmacology Research Program, Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, Box 1220, San Francisco, CA, US, 94143-1220 AN - 2020-02625-008 AU - St. Helen, Gideon AU - Benowitz, Neal L. AU - Ahluwalia, Jasjit S. AU - Tyndale, Rachel F. AU - Addo, Newton AU - Gregorich, Steven E. AU - Pérez-Stable, Eliseo J. AU - Cox, Lisa Sanderson DB - psyh DO - 10.1016/j.jnma.2019.04.004 DP - EBSCOhost IS - 5 KW - Black smokers Light smokers Nicotine Carcinogen exposure Correlates of exposure Blacks Tobacco Smoking Biological Markers Metabolism Metabolites N1 - Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, US. Other Publishers: National Medical Assn. Release Date: 20200316. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Cox, Lisa Sanderson. Major Descriptor: Blacks; Nicotine; Tobacco Smoking. Minor Descriptor: Biological Markers; Metabolism; Metabolites. Classification: Drug & Alcohol Usage (Legal) (2990). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Tests & Measures: Fagerström Test of Cigarette Dependence. Methodology: Empirical Study; Quantitative Study. Page Count: 12. Issue Publication Date: Oct, 2019. Copyright Statement: Published by Elsevier Inc. All rights reserved. The National Medical Association. 2019. Sponsor: National Cancer Institute, US. Grant: R01 CA091912. Recipients: Cox, Lisa Sanderson Sponsor: National Institute on Drug Abuse, US. Grant: DA02277. Recipients: Benowitz, Neal L. Sponsor: National Institute on Drug Abuse, US. Grant: DA012393. Other Details: R. Jones. Recipients: No recipient indicated Sponsor: National Institute on Drug Abuse, US. Grant: R25DA035163. Other Details: J. Sorensen. Recipients: No recipient indicated Sponsor: National Institute on Aging, US. Grant: P30AG15272. Recipients: Pérez-Stable, Eliseo J. Sponsor: National Center for Research Resources, US. Grant: S10RR026437. Recipients: No recipient indicated Sponsor: California Tobacco Related Disease Research Program, US. Grant: 22FT-0067. Recipients: St. Helen, Gideon Sponsor: Canada Research Chair in Pharmacogenomics, China. Recipients: Tyndale, Rachel F. Sponsor: Canadian Institutes of Health Research, China. Grant: FDN-154294. Recipients: Tyndale, Rachel F. Sponsor: Centre for Addiction and Mental Health. Recipients: Tyndale, Rachel F. PY - 2019 SN - 0027-9684 1943-4693 SP - 509-520 ST - Black light smokers: How nicotine intake and carcinogen exposure differ across various biobehavioral factors T2 - Journal of the National Medical Association TI - Black light smokers: How nicotine intake and carcinogen exposure differ across various biobehavioral factors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-02625-008&site=ehost-live&scope=site ORCID: 0000-0002-3673-1804 ORCID: 0000-0003-1297-2053 Gideon.Sthelen@ucsf.edu VL - 111 ID - 1681 ER - TY - JOUR AB - Objective: The study objective was to identify biobehavioral variables associated with greater intake of nicotine and a tobacco carcinogen among Black light smokers who smoke 1 to 10 cigarettes per day (CPD). Methods: We analyzed baseline data collected from 426 Black light smokers enrolled in Kick It at Swope III (KIS III), a smoking cessation trial for Black smokers. We examined differences in concentrations of tobacco biomarkers, including urinary total nicotine equivalents (TNE) and total 4-(methylnitrosamino)-1-(3)pyridyl-1-butanonol (NNAL; a human carcinogen), across gender, age, plasma nicotine metabolite ratio (NMR), CPD, and measures of tobacco dependence, including time to first cigarette (TFC), using ANOVA. Results: Tobacco biomarker levels were significantly higher among those who smoked more CPD (6–10 vs 1–5 CPD) and those with greater reported physical dependence on tobacco. Concurrently, those who smoked 1–5 CPD smoked each cigarette more intensely than those who smoked 6–10 CPD. While we found no gender differences overall, among those who smoked 1–5 CPD, women had higher NNAL levels compared to men. The rate of nicotine metabolism, measured by the nicotine metabolite ratio, was not significantly related to TNE or NNAL levels. Conclusion: Among Black Light smokers, higher cigarette consumption and greater physical dependence—but not rate of nicotine metabolism, menthol use, or socioeconomic status—were associated with greater toxicant exposure and thus a likely increased risk of tobacco-related diseases. The lack of data on light smokers, and specifically on Blacks, make this observation important given the disproportionate burden of lung cancer in this population. AD - G. St.Helen, Division of Cardiology Zuckerberg San Francisco General Hospital, University of California, San Francisco, Box 1220, San Francisco, CA, United States AU - St.Helen, G. AU - Benowitz, N. L. AU - Ahluwalia, J. S. AU - Tyndale, R. F. AU - Addo, N. AU - Gregorich, S. E. AU - Pérez-Stable, E. J. AU - Cox, L. S. DB - Embase Medline DO - 10.1016/j.jnma.2019.04.004 IS - 5 KW - cigarette 4 (methylnitrosamino) 1 (3)pyridyl 1 butanonol carcinogen nicotine unclassified drug adult article Black person controlled study female human major clinical study male middle aged priority journal sex difference smoking smoking cessation tobacco dependence LA - English M3 - Article N1 - L2001945422 2019-05-15 2020-01-17 PY - 2019 SN - 1943-4693 0027-9684 SP - 509-520 ST - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors T2 - Journal of the National Medical Association TI - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001945422&from=export http://dx.doi.org/10.1016/j.jnma.2019.04.004 VL - 111 ID - 837 ER - TY - JOUR AB - Objective: The study objective was to identify biobehavioral variables associated with greater intake of nicotine and a tobacco carcinogen among Black light smokers who smoke 1 to 10 cigarettes per day (CPD). Methods: We analyzed baseline data collected from 426 Black light smokers enrolled in Kick It at Swope III (KIS III), a smoking cessation trial for Black smokers. We examined differences in concentrations of tobacco biomarkers, including urinary total nicotine equivalents (TNE) and total 4-(methylnitrosamino)-1-(3)pyridyl-1-butanonol (NNAL; a human carcinogen), across gender, age, plasma nicotine metabolite ratio (NMR), CPD, and measures of tobacco dependence, including time to first cigarette (TFC), using ANOVA. Results: Tobacco biomarker levels were significantly higher among those who smoked more CPD (6–10 vs 1–5 CPD) and those with greater reported physical dependence on tobacco. Concurrently, those who smoked 1–5 CPD smoked each cigarette more intensely than those who smoked 6–10 CPD. While we found no gender differences overall, among those who smoked 1–5 CPD, women had higher NNAL levels compared to men. The rate of nicotine metabolism, measured by the nicotine metabolite ratio, was not significantly related to TNE or NNAL levels. Conclusion: Among Black Light smokers, higher cigarette consumption and greater physical dependence—but not rate of nicotine metabolism, menthol use, or socioeconomic status—were associated with greater toxicant exposure and thus a likely increased risk of tobacco-related diseases. The lack of data on light smokers, and specifically on Blacks, make this observation important given the disproportionate burden of lung cancer in this population. © 2019 National Medical Association AD - Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA, United States Center for Tobacco Control Research and Education (CTCRE), University of California, San Francisco, CA, United States Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, United States Departments of Behavioral and Social Sciences and Medicine, Brown University School of Public Health and Alpert School of Medicine, Providence, RI, United States Campbell Family Mental Health Research Institute and Addictions Division, Centre for Addiction and Mental Health (CAMH), Department of Pharmacology and Toxicology, Department of Psychiatry, University of TorontoON, Canada Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, CA, United States Division of Intramural Research, National Heart, Lung and Blood Institute and Office of the Director, National Institute on Minority Health and Health Disparities, National Institutes of HealthMD, United States Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, United States AU - St.Helen, G. AU - Benowitz, N. L. AU - Ahluwalia, J. S. AU - Tyndale, R. F. AU - Addo, N. AU - Gregorich, S. E. AU - Pérez-Stable, E. J. AU - Cox, L. S. DB - Scopus DO - 10.1016/j.jnma.2019.04.004 IS - 5 KW - Black smokers Carcinogen exposure Correlates of exposure Light smokers Nicotine M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2019 SP - 509-520 ST - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors T2 - Journal of the National Medical Association TI - Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065430027&doi=10.1016%2fj.jnma.2019.04.004&partnerID=40&md5=e253d1d1b199511f976120c4186b2872 VL - 111 ID - 2219 ER - TY - JOUR AB - The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age-adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority-focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer-related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials. AD - F.L. Stallings, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. AU - Stallings, F. L. AU - Ford, M. E. AU - Simpson, N. K. AU - Fouad, M. AU - Jernigan, J. C. AU - Trauth, J. M. AU - Miller, D. S. DB - Medline IS - 6 Suppl KW - adult African American article clinical trial colorectal tumor controlled clinical trial female human lung tumor male mass screening middle aged minority group multicenter study ovary tumor patient selection prostate tumor randomized controlled trial LA - English M3 - Article N1 - L33433721 2001-01-22 PY - 2000 SN - 0197-2456 SP - 379S-389S ST - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Controlled clinical trials TI - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33433721&from=export VL - 21 ID - 1316 ER - TY - JOUR AB - The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age‐adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority‐focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer‐related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials. AN - CN-01779508 AU - Stallings, F. L. AU - Ford, M. E. AU - Simpson, N. K. AU - Fouad, M. AU - Jernigan, J. C. AU - Trauth, J. M. AU - Miller, D. S. IS - 6 Suppl KW - *African American *colorectal tumor /diagnosis /prevention *lung tumor /diagnosis /prevention *mass screening *minority group *ovary tumor /diagnosis /prevention *patient selection *prostate tumor /diagnosis /prevention *randomized controlled trial Adult Article Clinical trial Controlled clinical trial Female Human Male Middle aged Multicenter study M3 - Journal: Article PY - 2000 SP - 379S‐389S ST - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Controlled clinical trials TI - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01779508/full VL - 21 ID - 1370 ER - TY - JOUR AB - The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age-adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority-focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer-related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials. AD - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, United States AU - Stallings, F. L. AU - Ford, M. E. AU - Simpson, N. K. AU - Fouad, M. AU - Jernigan, J. C. AU - Trauth, J. M. AU - Miller, D. S. DB - Scopus DO - 10.1016/s0197-2456(00)00093-3 IS - 6 Suppl M3 - Article N1 - Cited By :48 Export Date: 22 March 2021 PY - 2000 SP - 379S-389S ST - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Controlled clinical trials TI - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034567319&doi=10.1016%2fs0197-2456%2800%2900093-3&partnerID=40&md5=e37cc0694a09aaff1979c060920bd859 VL - 21 ID - 2633 ER - TY - JOUR AB - The primary goal of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is to learn whether widespread use of screening tests to detect these cancers will reduce associated mortality. Blacks have the highest age-adjusted cancer incidence and mortality rates of any population group in the United States, but several barriers to their participation in clinical research such as the PLCO trial exist. These barriers involve sociocultural, economic, and individual factors, as well as factors inherent in trial designs. Population diversity in the PLCO trial is necessary to preserve scientific validity and generalizability of trial results. Therefore, the National Cancer Institute and the Centers for Disease Control and Prevention are collaborating to ensure adequate representation of blacks in the PLCO trial. For example, the agencies have funded several new activities designed to better understand and overcome barriers to participation in the trial. These activities include the African American Men Project, a randomized trial designed to evaluate the efficacy of three-increasingly intensive recruitment interventions in recruiting black men; the establishment of a minority-focused PLCO trial screening center, a study to identify factors that influenced the decisions of black women recruited to participate in the PLCO trial; and a study to examine the psychosocial factors that influence blacks' decision making to engage in cancer screening and participation in research similar to the PLCO trial. The results of these activities will allow for a more thorough examination of cancer-related issues of importance to blacks and will help shed light on factors that influence their decisions to participate in cancer screening and prevention clinical trials. Control Clin Trials 2000;21:379S-389S (C) Elsevier Science Inc. 2000. AN - WOS:000165987600008 AU - Stallings, F. L. AU - Ford, M. E. AU - Simpson, N. K. AU - Fouad, M. AU - Jernigan, J. C. AU - Trauth, J. M. AU - Miller, D. S. DA - Dec DO - 10.1016/S0197-2456(00)00093-3 IS - 6 N1 - S 47 11189689 PY - 2000 SN - 0197-2456 SP - 379S-389S ST - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Controlled Clinical Trials TI - Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial VL - 21 ID - 2713 ER - TY - JOUR AB - Background: In the United States, there are lower rates of breastfeeding among African American mothers, particularly those who are younger women. Recent epidemiological studies have shown a strong association of more aggressive types of breast cancer (estrogen receptor negative) among African American women, with a higher risk in African American women who did not breastfeed their children. Objective: This study aims to describe the process evaluation of recruitment and educational strategies to engage pregnant African American participants for a pilot study designed to determine whether social media messaging about breast cancer risk reduction through breastfeeding may positively influence breastfeeding rates. Methods: This pilot study is conducted in collaboration with a local Women, Infants, and Children (WIC) organization and hospital and prenatal clinics of a local health care network. To engage African American women to enroll in the study, several methods and monitoring processes were explored, including WIC electronic text-based messages sent out to all phones of current WIC recipients (referred to as e-blasts); keyword responses to texts from flyers and posters in local community-based organizations, hospitals, and prenatal clinics; keyword responses using electronic links posted in established Facebook groups; and snowball recruitment of other pregnant women by current participants through Facebook. Once enrolled, participants were randomized to 2 study conditions: (1) an intervention group receiving messages about breast cancer risk reduction and breastfeeding or (2) a control group receiving breastfeeding-only messages. Data were obtained through electronic monitoring, SurveyMonkey, qualitative responses on Facebook, focus groups, and interviews. Results: More than 3000 text messages were sent and received through WIC e-blasts and keyword responses from flyers. A total of 472 women were recruited through WIC e-blast, and 161 responded to flyers and contacts through the local health care network, community-based organizations, Facebook, and friend referrals. A total of 633 women were assessed for eligibility to participate in the study. A total of 288 pregnant African American women were enrolled, consented, and completed presurvey assessments (102.8% of the goal), and 22 participants attended focus groups or interviews reporting on their experiences with Facebook and the educational messages. Conclusions: This process evaluation suggests that using electronic, smartphone apps with social media holds promise for both recruitment and conduct of health education intervention studies for pregnant African American women. Providing messaging and resources through social media to reinforce and educate women about breastfeeding and potentially provide lactation support is intriguing. Convenience (for researchers and participants) is an attribute of social media for this demographic of women and worthy of further research as an educational tool. AD - D. Erwin, Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, United States AU - Dauphin, C. AU - Clark, N. AU - Cadzow, R. AU - Saad-Harfouche, F. AU - Rodriguez, E. AU - Glaser, K. AU - Kiviniemi, M. AU - Keller, M. AU - Erwin, D. DB - Embase Medline DO - 10.2196/16239 IS - 8 KW - NCT03680235 smartphone adolescent adult African American article breast cancer breast feeding controlled study female health education human information processing interview major clinical study patient referral pilot study pregnant woman randomized controlled trial recipient risk reduction social media young adult LA - English M3 - Article N1 - L2007600411 2020-10-12 2020-11-10 PY - 2020 SN - 1438-8871 ST - #BlackBreastsMatter: Process evaluation of recruitment and engagement of pregnant African American women for a social media intervention study to increase breastfeeding T2 - Journal of Medical Internet Research TI - #BlackBreastsMatter: Process evaluation of recruitment and engagement of pregnant African American women for a social media intervention study to increase breastfeeding UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2007600411&from=export http://dx.doi.org/10.2196/16239 VL - 22 ID - 792 ER - TY - JOUR AB - BACKGROUND: In the United States, there are lower rates of breastfeeding among African American mothers, particularly those who are younger women. Recent epidemiological studies have shown a strong association of more aggressive types of breast cancer (estrogen receptor negative) among African American women, with a higher risk in African American women who did not breastfeed their children. OBJECTIVE: This study aims to describe the process evaluation of recruitment and educational strategies to engage pregnant African American participants for a pilot study designed to determine whether social media messaging about breast cancer risk reduction through breastfeeding may positively influence breastfeeding rates. METHODS: This pilot study is conducted in collaboration with a local Women, Infants, and Children (WIC) organization and hospital and prenatal clinics of a local health care network. To engage African American women to enroll in the study, several methods and monitoring processes were explored, including WIC electronic text‐based messages sent out to all phones of current WIC recipients (referred to as e‐blasts); keyword responses to texts from flyers and posters in local community‐based organizations, hospitals, and prenatal clinics; keyword responses using electronic links posted in established Facebook groups; and snowball recruitment of other pregnant women by current participants through Facebook. Once enrolled, participants were randomized to 2 study conditions: (1) an intervention group receiving messages about breast cancer risk reduction and breastfeeding or (2) a control group receiving breastfeeding‐only messages. Data were obtained through electronic monitoring, SurveyMonkey, qualitative responses on Facebook, focus groups, and interviews. RESULTS: More than 3000 text messages were sent and received through WIC e‐blasts and keyword responses from flyers. A total of 472 women were recruited through WIC e‐blast, and 161 responded to flyers and contacts through the local health care network, community‐based organizations, Facebook, and friend referrals. A total of 633 women were assessed for eligibility to participate in the study. A total of 288 pregnant African American women were enrolled, consented, and completed presurvey assessments (102.8% of the goal), and 22 participants attended focus groups or interviews reporting on their experiences with Facebook and the educational messages. CONCLUSIONS: This process evaluation suggests that using electronic, smartphone apps with social media holds promise for both recruitment and conduct of health education intervention studies for pregnant African American women. Providing messaging and resources through social media to reinforce and educate women about breastfeeding and potentially provide lactation support is intriguing. Convenience (for researchers and participants) is an attribute of social media for this demographic of women and worthy of further research as an educational tool. TRIAL REGISTRATION: ClinicalTrials.gov NCT03680235; https://clinicaltrials.gov/ct2/show/NCT03680235. AN - CN-02159444 AU - Dauphin, C. AU - Clark, N. AU - Cadzow, R. AU - Saad-Harfouche, F. AU - Rodriguez, E. AU - Glaser, K. AU - Kiviniemi, M. AU - Keller, M. AU - Erwin, D. DO - 10.2196/16239 IS - 8 KW - *African American *breast cancer *breast feeding *health education *intervention study *mother *pregnancy *smartphone *social media Adult Article Cancer risk Child Controlled study Demography Female Friend Human Human experiment Infant Interview Lactation Major clinical study Organization Pilot study Pregnant woman Randomized controlled trial M3 - Journal: Article PY - 2020 SP - e16239‐ ST - #BlackBreastsMatter: process Evaluation of Recruitment and Engagement of Pregnant African American Women for a Social Media Intervention Study to Increase Breastfeeding T2 - Journal of medical Internet research TI - #BlackBreastsMatter: process Evaluation of Recruitment and Engagement of Pregnant African American Women for a Social Media Intervention Study to Increase Breastfeeding UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02159444/full VL - 22 ID - 1403 ER - TY - JOUR AB - Background: In the United States, there are lower rates of breastfeeding among African American mothers, particularly those who are younger women. Recent epidemiological studies have shown a strong association of more aggressive types of breast cancer (estrogen receptor negative) among African American women, with a higher risk in African American women who did not breastfeed their children. Objective: This study aims to describe the process evaluation of recruitment and educational strategies to engage pregnant African American participants for a pilot study designed to determine whether social media messaging about breast cancer risk reduction through breastfeeding may positively influence breastfeeding rates. Methods: This pilot study is conducted in collaboration with a local Women, Infants, and Children (WIC) organization and hospital and prenatal clinics of a local health care network. To engage African American women to enroll in the study, several methods and monitoring processes were explored, including WIC electronic text-based messages sent out to all phones of current WIC recipients (referred to as e-blasts); keyword responses to texts from flyers and posters in local community-based organizations, hospitals, and prenatal clinics; keyword responses using electronic links posted in established Facebook groups; and snowball recruitment of other pregnant women by current participants through Facebook. Once enrolled, participants were randomized to 2 study conditions: (1) an intervention group receiving messages about breast cancer risk reduction and breastfeeding or (2) a control group receiving breastfeeding-only messages. Data were obtained through electronic monitoring, SurveyMonkey, qualitative responses on Facebook, focus groups, and interviews. Results: More than 3000 text messages were sent and received through WIC e-blasts and keyword responses from flyers. A total of 472 women were recruited through WIC e-blast, and 161 responded to flyers and contacts through the local health care network, community-based organizations, Facebook, and friend referrals. A total of 633 women were assessed for eligibility to participate in the study. A total of 288 pregnant African American women were enrolled, consented, and completed presurvey assessments (102.8% of the goal), and 22 participants attended focus groups or interviews reporting on their experiences with Facebook and the educational messages. Conclusions: This process evaluation suggests that using electronic, smartphone apps with social media holds promise for both recruitment and conduct of health education intervention studies for pregnant African American women. Providing messaging and resources through social media to reinforce and educate women about breastfeeding and potentially provide lactation support is intriguing. Convenience (for researchers and participants) is an attribute of social media for this demographic of women and worthy of further research as an educational tool. © 2020 Journal of Medical Internet Research. All rights reserved. AD - Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, United States Department of Health Services Administration, D'Youville College, Buffalo, NY, United States Department of Health, Behavior and Society, University of Kentucky, Lexington, KY, United States Department of Community Health and Health Behavior, State University of New York at Buffalo, Buffalo, NY, United States AU - Dauphin, C. AU - Clark, N. AU - Cadzow, R. AU - Saad-Harfouche, F. AU - Rodriguez, E. AU - Glaser, K. AU - Kiviniemi, M. AU - Keller, M. AU - Erwin, D. C7 - e16239 DB - Scopus DO - 10.2196/16239 IS - 8 KW - African American mothers Breast cancer education Breastfeeding Facebook Mobile phone Social media M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 ST - #BlackBreastsMatter: Process evaluation of recruitment and engagement of pregnant African American women for a social media intervention study to increase breastfeeding T2 - Journal of Medical Internet Research TI - #BlackBreastsMatter: Process evaluation of recruitment and engagement of pregnant African American women for a social media intervention study to increase breastfeeding UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089319413&doi=10.2196%2f16239&partnerID=40&md5=dd420614bae2325123086d3726572666 VL - 22 ID - 2185 ER - TY - JOUR AB - Objective In a large prospective cohort, we examined the relationship of body mass index (BMI) with mortality among blacks and compared the results to those among whites in this population. Design and Methods The study population consisted of 7,446 non-Hispanic black and 130,598 white participants, ages 49-78 at enrollment, in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BMI at baseline, BMI at age 20, and BMI change were calculated using self-reported and recalled height and weight. Relative risks were stratified by race and sex and adjusted for age, education, marital status, and smoking. Results During follow-up, 1,495 black and 18,236 white participants died (mean = 13 years). Clear J-shaped associations between BMI and mortality were observed among white men and women. Among black men and women, the bottoms of these curves were flatter, and increasing risks of death with greater BMI were observed only at higher BMI levels (≥35.0). Associations for BMI at age 20 and BMI change also appeared to be stronger in magnitude in whites versus blacks, and these racial differences appeared to be more pronounced among women. Conclusion Our results suggest that BMI may be more weakly associated with mortality in blacks, particularly black women, than in whites. Copyright © 2013 The Obesity Society. AD - Q. Xiao, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, United States AU - Xiao, Q. AU - Hsing, A. W. AU - Park, Y. AU - Moore, S. C. AU - Matthews, C. E. AU - De González, A. B. AU - Kitahara, C. M. DB - Embase Medline DO - 10.1002/oby.20412 IS - 1 KW - adult age distribution aged article body height body mass body weight cancer mortality cancer risk cancer screening Caucasian cohort analysis colorectal cancer controlled study education female follow up human lung cancer major clinical study male marriage middle aged Black person ovary cancer population research prospective study prostate cancer race difference self report sex difference smoking LA - English M3 - Article N1 - L52666860 2013-07-08 2014-02-05 PY - 2014 SN - 1930-7381 1930-739X SP - 260-268 ST - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial T2 - Obesity TI - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52666860&from=export http://dx.doi.org/10.1002/oby.20412 VL - 22 ID - 1052 ER - TY - JOUR AB - Objective: In a large prospective cohort, we examined the relationship of body mass index (BMI) with mortality among blacks and compared the results to those among whites in this population.Design and Methods: The study population consisted of 7,446 non-Hispanic black and 130,598 white participants, ages 49-78 at enrollment, in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BMI at baseline, BMI at age 20, and BMI change were calculated using self-reported and recalled height and weight. Relative risks were stratified by race and sex and adjusted for age, education, marital status, and smoking.Results: During follow-up, 1,495 black and 18,236 white participants died (mean = 13 years). Clear J-shaped associations between BMI and mortality were observed among white men and women. Among black men and women, the bottoms of these curves were flatter, and increasing risks of death with greater BMI were observed only at higher BMI levels (≥35.0). Associations for BMI at age 20 and BMI change also appeared to be stronger in magnitude in whites versus blacks, and these racial differences appeared to be more pronounced among women.Conclusion: Our results suggest that BMI may be more weakly associated with mortality in blacks, particularly black women, than in whites. AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA. AN - 104003563. Language: English. Entry Date: 20141010. Revision Date: 20200708. Publication Type: journal article AU - Xiao, Qian AU - Hsing, Ann W. AU - Park, Yikyung AU - Moore, Steven C. AU - Matthews, Charles E. AU - de González, Amy Berrington AU - Kitahara, Cari M. DB - CINAHL Complete DO - 10.1002/oby.20412 DP - EBSCOhost IS - 1 KW - Body Mass Index Mortality Black Persons Aged Colorectal Neoplasms -- Diagnosis White Persons Female Prospective Studies Human Lung Neoplasms -- Diagnosis Male Middle Age Ovarian Neoplasms -- Diagnosis Prostatic Neoplasms -- Diagnosis Questionnaires Clinical Trials Risk Factors Socioeconomic Factors N1 - research. Journal Subset: Biomedical; USA. Grant Information: Z99 CA999999//Intramural NIH HHS/United States. NLM UID: 101264860. PMID: NLM23512729. PY - 2014 SN - 1930-7381 SP - 260-268 ST - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial T2 - Obesity (19307381) TI - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104003563&site=ehost-live&scope=site VL - 22 ID - 1863 ER - TY - JOUR AB - Objective In a large prospective cohort, we examined the relationship of body mass index (BMI) with mortality among blacks and compared the results to those among whites in this population. Design and Methods The study population consisted of 7,446 non-Hispanic black and 130,598 white participants, ages 49-78 at enrollment, in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BMI at baseline, BMI at age 20, and BMI change were calculated using self-reported and recalled height and weight. Relative risks were stratified by race and sex and adjusted for age, education, marital status, and smoking. Results During follow-up, 1,495 black and 18,236 white participants died (mean = 13 years). Clear J-shaped associations between BMI and mortality were observed among white men and women. Among black men and women, the bottoms of these curves were flatter, and increasing risks of death with greater BMI were observed only at higher BMI levels (≥35.0). Associations for BMI at age 20 and BMI change also appeared to be stronger in magnitude in whites versus blacks, and these racial differences appeared to be more pronounced among women. Conclusion Our results suggest that BMI may be more weakly associated with mortality in blacks, particularly black women, than in whites. Copyright © 2013 The Obesity Society. AD - Division of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services, Bethesda, MD, United States Cancer Prevention Institute of California, Stanford Cancer Institute, Fremont, CA, United States AU - Xiao, Q. AU - Hsing, A. W. AU - Park, Y. AU - Moore, S. C. AU - Matthews, C. E. AU - De González, A. B. AU - Kitahara, C. M. DB - Scopus DO - 10.1002/oby.20412 IS - 1 M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2014 SP - 260-268 ST - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial T2 - Obesity TI - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892364263&doi=10.1002%2foby.20412&partnerID=40&md5=f17e409cb06910b758b2c0fc4e92a939 VL - 22 ID - 2407 ER - TY - JOUR AB - Objective In a large prospective cohort, we examined the relationship of body mass index (BMI) with mortality among blacks and compared the results to those among whites in this population. Design and Methods The study population consisted of 7,446 non-Hispanic black and 130,598 white participants, ages 49-78 at enrollment, in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. BMI at baseline, BMI at age 20, and BMI change were calculated using self-reported and recalled height and weight. Relative risks were stratified by race and sex and adjusted for age, education, marital status, and smoking. Results During follow-up, 1,495 black and 18,236 white participants died (mean = 13 years). Clear J-shaped associations between BMI and mortality were observed among white men and women. Among black men and women, the bottoms of these curves were flatter, and increasing risks of death with greater BMI were observed only at higher BMI levels (35.0). Associations for BMI at age 20 and BMI change also appeared to be stronger in magnitude in whites versus blacks, and these racial differences appeared to be more pronounced among women. Conclusion Our results suggest that BMI may be more weakly associated with mortality in blacks, particularly black women, than in whites. AN - WOS:000329613600038 AU - Xiao, Q. AU - Hsing, A. W. AU - Park, Y. AU - Moore, S. C. AU - Matthews, C. E. AU - de Gonzalez, A. B. AU - Kitahara, C. M. DA - Jan DO - 10.1002/oby.20412 IS - 1 N1 - 23512729 PY - 2014 SN - 1930-7381 SP - 260-268 ST - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial T2 - Obesity TI - Body mass index and mortality among blacks and whites adults in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial VL - 22 ID - 3028 ER - TY - JOUR AB - Background: Breast biopsy is essential for definitive breast cancer diagnosis, but may also play a role in determining eligibility for breast cancer preventive measures or clinical trials. In addition, the prevalence of a history of negative breast biopsy can be viewed as an indicator of the adequacy or intensity of health care in a given population. We therefore analyzed the association of a history of breast biopsy with race/ethnicity and other factors in a cohort of women without a cancer diagnosis who completed a risk assessment form for participation in the Study of Tamoxifen and Raloxifene (STAR) and a sociodemographic questionnaire. Methods: Subjects were recruited at our large, urban teaching hospital. We developed a logistic regression model with biopsy (ever/never) as the outcome and age, race/ethnicity, educational attainment, and insurance coverage as the independent variables. Results: Among 805 unaffected predominantly minority subjects, white women were more than three times as likely as black and Hispanic women (OR = 3.3, 95% CI 1.9-5.9), and insured women were twice as likely as uninsured women (OR = 2.0, 95% CI 1.4-2.9) to have had a biopsy. Biopsy results were also associated with race/ethnicity. Discussion: We view these observations as hypothesis-generating rather than definitive. If confirmed, the associations we observed between negative biopsies and insurance status may reflect disparities in the timeliness and effectiveness of follow-up of suspicious lesions found via mammography. Our findings may also be relevant to the well-known association of breast cancer stage at diagnosis with low income and minority race/ethnicity. © 2006 International Society for Preventive Oncology. AD - V.R. Grann, Departments of Epidemiology and Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY 10032, United States AU - Jacobson, J. S. AU - Grann, V. R. AU - Hershman, D. AU - Troxel, A. B. AU - Li, H. AU - Neugut, A. I. DB - Embase Medline DO - 10.1016/j.cdp.2006.02.002 IS - 2 KW - raloxifene tamoxifen adult article breast biopsy breast cancer cancer diagnosis cancer prevention cancer risk controlled study demography education ethnic difference ethnology female health insurance human human tissue mammography priority journal questionnaire risk assessment LA - English M3 - Article N1 - L43766232 2006-06-21 PY - 2006 SN - 0361-090X 1525-1500 SP - 129-133 ST - Breast biopsy and race/ethnicity among women without breast cancer T2 - Cancer Detection and Prevention TI - Breast biopsy and race/ethnicity among women without breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43766232&from=export http://dx.doi.org/10.1016/j.cdp.2006.02.002 VL - 30 ID - 1244 ER - TY - JOUR AB - Background: Breast biopsy is essential for definitive breast cancer diagnosis, but may also play a role in determining eligibility for breast cancer preventive measures or clinical trials. In addition, the prevalence of a history of negative breast biopsy can be viewed as an indicator of the adequacy or intensity of health care in a given population. We therefore analyzed the association of a history of breast biopsy with race/ethnicity and other factors in a cohort of women without a cancer diagnosis who completed a risk assessment form for participation in the Study of Tamoxifen and Raloxifene (STAR) and a sociodemographic questionnaire. Methods: Subjects were recruited at our large, urban teaching hospital. We developed a logistic regression model with biopsy (ever/never) as the outcome and age, race/ethnicity, educational attainment, and insurance coverage as the independent variables. Results: Among 805 unaffected predominantly minority subjects, white women were more than three times as likely as black and Hispanic women (OR = 3.3, 95% CI 1.9-5.9), and insured women were twice as likely as uninsured women (OR = 2.0, 95% CI 1.4-2.9) to have had a biopsy. Biopsy results were also associated with race/ethnicity. Discussion: We view these observations as hypothesis-generating rather than definitive. If confirmed, the associations we observed between negative biopsies and insurance status may reflect disparities in the timeliness and effectiveness of follow-up of suspicious lesions found via mammography. Our findings may also be relevant to the well-known association of breast cancer stage at diagnosis with low income and minority race/ethnicity. © 2006 International Society for Preventive Oncology. AD - Departments of Epidemiology and Health Policy and Management, Mailman School of Public Health, Columbia University, New York, NY 10032, United States Department of Medicine, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, New York, NY 10032, United States Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, United States AU - Jacobson, J. S. AU - Grann, V. R. AU - Hershman, D. AU - Troxel, A. B. AU - Li, H. AU - Neugut, A. I. DB - Scopus DO - 10.1016/j.cdp.2006.02.002 IS - 2 KW - Biopsy Breast cancer Disparities Hyperplasia Insurance Locular carcinoma in situ Mammography National Surgical Adjuvant Breast and Bowel Project NSABP Prevention Race/ethnicity Raloxifene Risk assessment STAR trial Survival Tamoxifen M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2006 SP - 129-133 ST - Breast biopsy and race/ethnicity among women without breast cancer T2 - Cancer Detection and Prevention TI - Breast biopsy and race/ethnicity among women without breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646770668&doi=10.1016%2fj.cdp.2006.02.002&partnerID=40&md5=d38f09b05689f98c1528c49ec4ca9b83 VL - 30 ID - 2576 ER - TY - JOUR AB - Background: Breast biopsy is essential for definitive breast cancer diagnosis. but may also play a role in determining eligibility for breast cancer preventive measures or clinical trials. In addition, the prevalence of a history of negative breast biopsy can be viewed as an indicator of the adequacy or intensity of health care in a given population. We therefore analyzed the association of a history of breast biopsy with race/ethnicity and other factors in a cohort of women without a cancer diagnosis who completed a risk assessment form for participation in the Study of Tamoxifen and Raloxifene (STAR) and a sociodemographic questionnaire. Methods: Subjects were recruited at Our large, urban teaching hospital. We developed a logistic regression model with biopsy (ever/never) as the outcome and age. race/ethnicity. educational attainment, and insurance coverage as the independent variables. Results: Among 805 unaffected predominantly minority subjects. white women were more than three times as likely as black and Hispanic women (OR = 3.3, 95% CI 1.9-5.9), and insured women were twice as likely as uninsured women (OR = 2.0, 95% CI 1.4-2.9) to have had a biopsy. Biopsy results were also associated with race/ethnicity. Discussion: We view these observations as hypothesis-generating rather than definitive. If confirmed, the associations we observed between negative biopsies and insurance status may reflect disparities in the timeliness and effectiveness of follow-up of suspicious lesions found via mammography. Our findings may also be relevant to the well-known association of breast cancer stage at diagnosis with low income and minority race/ethnicity. (c) 2006 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved. AN - WOS:000238467000004 AU - Jacobson, J. S. AU - Grann, V. R. AU - Hershman, D. AU - Troxel, A. B. AU - Li, H. L. AU - Neugut, A. I. DO - 10.1016/j.cdp.2006.02.002 IS - 2 N1 - 16621329 PY - 2006 SN - 0361-090X SP - 129-133 ST - Breast biopsy and race/ethnicity among women without breast cancer T2 - Cancer Detection and Prevention TI - Breast biopsy and race/ethnicity among women without breast cancer VL - 30 ID - 3226 ER - TY - JOUR AB - Chemoprevention with the anti-estrogens, tamoxifen, raloxifene, and aromatase inhibitors, reduce breast cancer incidence in high-risk women; however, uptake has been poor (<5%) in the prevention setting. We assessed use of anti-estrogens for breast cancer prevention, among high-risk women seen at an academic breast center, to observe how uptake rates compare in this setting. We collected data on demographics, breast cancer risk factors, and health behaviors via self-administered questionnaires and medical chart abstraction. Women eligible for chemoprevention with anti-estrogens had a 5-year predicted breast cancer risk according to the Gail model of 1.67%, history of lobular or ductal carcinoma in situ (LCIS/DCIS), and/or BRCA mutation. We dichotomized anti-estrogen use as ever or never. Predictors of use were evaluated using multivariable log-binomial regression. Of 412 high-risk women enrolled, 316 (77%) were eligible for chemoprevention. Among eligible women, 55% were non-Hispanic white, 29% Hispanic, 8% non-Hispanic black, and 7% Asian. Women were grouped based upon their highest category of breast cancer risk (in descending order): BRCA mutation carriers (3%), DCIS (40%), LCIS (22%), and 5-year Gail risk 1.67% (36%). Among those eligible for chemoprevention, 162 (51%) had ever initiated anti-estrogen therapy (71% tamoxifen, 23% raloxifene, 5% aromatase inhibitor). Anti-estrogen use was highest among women with DCIS (73%). In multivariable analysis, women with a 5-year Gail risk 1.67% had approximately a 20% lower likelihood of anti-estrogen use compared to women with DCIS (p=0.01). In the primary prevention setting, excluding women diagnosed with DCIS, anti-estrogen use was 37%. Multivariable analysis showed differences in uptake by education and potentially by race/ethnicity. Among high-risk women seen at a breast center, anti-estrogen use for chemoprevention was relatively high as compared to the published literature. Clinicians can support high-risk women by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention. AN - WOS:000357337700007 AU - Reimers, L. L. AU - Sivasubramanian, P. S. AU - Hershman, D. AU - Terry, M. B. AU - Greenlee, H. AU - Campbell, J. AU - Kalinsky, K. AU - Maurer, M. AU - Jayasena, R. AU - Sandoval, R. AU - Alvarez, M. AU - Crew, K. D. DA - Jul-Aug DO - 10.1111/tbj.12418 IS - 4 N1 - 25879521 PY - 2015 SN - 1075-122X SP - 377-386 ST - Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ T2 - Breast Journal TI - Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ VL - 21 ID - 2973 ER - TY - JOUR AB - Web-based clinical trials matching systems including breast cancer patients are expanding rapidly. However, limited data exist regarding the demographics and attitudes of breast cancer patients using the Internet to search for clinical trials information. Biases in patient populations could be introduced by recruiting patients to trials through the Internet. This study was designed to compare breast cancer patients in the radiation oncology clinic to those using the Internet to search for clinical trials information. A piloted questionnaire assessing demographics and attitudes regarding clinical trials was offered through the radiation oncology clinic at the University of Pennsylvania and on the OncoLink website (www.oncolink.org). The questionnaire consisted of 18 questions and was answered by a total of 157 patients with breast cancer. Breast cancer patients using the Web were more likely to be interested in clinical trials testing new drugs or therapies (71 [53%] versus 4 [17%], p = 0.002). More clinic patients indicated they would need a greater than 50% chance of benefiting from a trial (12 [52%] versus 33 [25%], p = 0.01) and a less than 10% potential for serious toxicity from a trial (15 [65%] versus 51 [38%], p = 0.02) for consideration of enrollment. African Americans were more likely than other races to have never used the Internet to search for cancer-related information (4 [40%] versus 18 [12%], p = 0.01), more likely to indicate that they need a greater than 50% chance of benefit to enroll in clinical trials (8 [80%] versus 37 [25%], p = 0.001), and less likely to be interested in clinical trials testing new drugs or therapies (1 [10%] versus 73 [50%], p = 0.01). Breast cancer patients have different attitudes regarding clinical trials based on race, Internet usage, and previous trial enrollment. Biases may be introduced with recruitment for clinical trials through the Internet. Radiation oncologists must consider these issues when offering clinical trials information through the Internet. © 2006 Blackwell Publishing, Inc. AD - C.M. Dolinsky, Department of Radiation Oncology, Hospital of the University of Pennsylvania, 2 Donner Bldg., 3400 Spruce St., Philadelphia, PA 19104, United States AU - Dolinsky, C. M. AU - Wei, S. J. AU - Hampshire, M. K. AU - Metz, J. M. DB - Embase Medline DO - 10.1111/j.1075-122X.2006.00270.x IS - 4 KW - adult African American article Asian breast cancer cancer patient cancer research Caucasian clinical research female Hispanic human information retrieval Internet major clinical study patient attitude questionnaire race difference United States LA - English M3 - Article N1 - L43989976 2006-07-24 PY - 2006 SN - 1075-122X 1524-4741 SP - 324-330 ST - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the internet T2 - Breast Journal TI - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the internet UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43989976&from=export http://dx.doi.org/10.1111/j.1075-122X.2006.00270.x VL - 12 ID - 1243 ER - TY - JOUR AB - Web-based clinical trials matching systems including breast cancer patients are expanding rapidly. However, limited data exist regarding the demographics and attitudes of breast cancer patients using the Internet to search for clinical trials information. Biases in patient populations could be introduced by recruiting patients to trials through the Internet. This study was designed to compare breast cancer patients in the radiation oncology clinic to those using the Internet to search for clinical trials information. A piloted questionnaire assessing demographics and attitudes regarding clinical trials was offered through the radiation oncology clinic at the University of Pennsylvania and on the OncoLink website (http://www.oncolink.org). The questionnaire consisted of 18 questions and was answered by a total of 157 patients with breast cancer. Breast cancer patients using the Web were more likely to be interested in clinical trials testing new drugs or therapies (71 [53%] versus 4 [17%], p = 0.002). More clinic patients indicated they would need a greater than 50% chance of benefiting from a trial (12 [52%] versus 33 [25%], p = 0.01) and a less than 10% potential for serious toxicity from a trial (15 [65%] versus 51 [38%], p = 0.02) for consideration of enrollment. African Americans were more likely than other races to have never used the Internet to search for cancer-related information (4 [40%] versus 18 [12%], p = 0.01), more likely to indicate that they need a greater than 50% chance of benefit to enroll in clinical trials (8 [80%] versus 37 [25%], p = 0.001), and less likely to be interested in clinical trials testing new drugs or therapies (1 [10%] versus 73 [50%], p = 0.01). Breast cancer patients have different attitudes regarding clinical trials based on race, Internet usage, and previous trial enrollment. Biases may be introduced with recruitment for clinical trials through the Internet. Radiation oncologists must consider these issues when offering clinical trials information through the Internet. AN - 105944484. Language: English. Entry Date: 20140926. Revision Date: 20200623. Publication Type: Journal Article AU - Dolinsky, C. M. AU - Wei, S. J. AU - Hampshire, M. K. AU - Metz, J. M. DB - CINAHL Complete DO - 10.1111/j.1075-122x.2006.00270.x DP - EBSCOhost IS - 4 KW - Breast Neoplasms Clinical Trials Internet Patient Satisfaction -- Ethnology Patient Selection Female Male Middle Age Pennsylvania Pilot Studies Prospective Studies Human N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Peer Reviewed; USA. NLM UID: 9505539. PMID: NLM16848841. PY - 2006 SN - 1075-122X SP - 324-330 ST - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet T2 - Breast Journal TI - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105944484&site=ehost-live&scope=site VL - 12 ID - 1865 ER - TY - JOUR AB - Web-based clinical trials matching systems including breast cancer patients are expanding rapidly. However, limited data exist regarding the demographics and attitudes of breast cancer patients using the Internet to search for clinical trials information. Biases in patient populations could be introduced by recruiting patients to trials through the Internet. This study was designed to compare breast cancer patients in the radiation oncology clinic to those using the Internet to search for clinical trials information. A piloted questionnaire assessing demographics and attitudes regarding clinical trials was offered through the radiation oncology clinic at the University of Pennsylvania and on the OncoLink website (www.oncolink.org). The questionnaire consisted of 18 questions and was answered by a total of 157 patients with breast cancer. Breast cancer patients using the Web were more likely to be interested in clinical trials testing new drugs or therapies (71 [53%] versus 4 [17%], p = 0.002). More clinic patients indicated they would need a greater than 50% chance of benefiting from a trial (12 [52%] versus 33 [25%], p = 0.01) and a less than 10% potential for serious toxicity from a trial (15 [65%] versus 51 [38%], p = 0.02) for consideration of enrollment. African Americans were more likely than other races to have never used the Internet to search for cancer-related information (4 [40%] versus 18 [12%], p = 0.01), more likely to indicate that they need a greater than 50% chance of benefit to enroll in clinical trials (8 [80%] versus 37 [25%], p = 0.001), and less likely to be interested in clinical trials testing new drugs or therapies (1 [10%] versus 73 [50%], p = 0.01). Breast cancer patients have different attitudes regarding clinical trials based on race, Internet usage, and previous trial enrollment. Biases may be introduced with recruitment for clinical trials through the Internet. Radiation oncologists must consider these issues when offering clinical trials information through the Internet. © 2006 Blackwell Publishing, Inc. AD - Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, United States Department of Radiation Oncology, Hospital of the University of Pennsylvania, 2 Donner Bldg., 3400 Spruce St., Philadelphia, PA 19104, United States AU - Dolinsky, C. M. AU - Wei, S. J. AU - Hampshire, M. K. AU - Metz, J. M. DB - Scopus DO - 10.1111/j.1075-122X.2006.00270.x IS - 4 KW - Breast cancer Clinical trials Internet Race Radiation therapy M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2006 SP - 324-330 ST - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the internet T2 - Breast Journal TI - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the internet UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745601368&doi=10.1111%2fj.1075-122X.2006.00270.x&partnerID=40&md5=b3113cf4e470e6d1ab870b59292e4c9a VL - 12 ID - 2573 ER - TY - JOUR AB - Web-based clinical trials matching systems including breast cancer patients are expanding rapidly. However, limited data exist regarding the demographics and attitudes of breast cancer patients using the Internet to search for clinical trials information. Biases in patient populations could be introduced by recruiting patients to trials through the Internet. This study was designed to compare breast cancer patients in the radiation oncology clinic to those using the Internet to search for clinical trials information. A piloted questionnaire assessing demographics and attitudes regarding clinical trials was offered through the radiation oncology clinic at the University of Pennsylvania and on the OncoLink website (www.oncolink.org). The questionnaire consisted of 18 questions and was answered by a total of 157 patients with breast cancer. Breast cancer patients using the Web were more likely to be interested in clinical trials testing new drugs or therapies (71 [53%] versus 4 [17%], p = 0.002). More clinic patients indicated they would need a greater than 50% chance of benefiting from a trial (12 [52%] versus 33 [25%], p = 0.01) and a less than 10% potential for serious toxicity from a trial (15 [65%] versus 51 [38%], p = 0.02) for consideration of enrollment. African Americans were more likely than other races to have never used the Internet to search for cancer-related information (4 [40%] versus 18 [12%], p = 0.01), more likely to indicate that they need a greater than 50% chance of benefit to enroll in clinical trials (8 [80%] versus 37 [25%], p = 0.001), and less likely to be interested in clinical trials testing new drugs or therapies (1 [10%] versus 73 [50%], p = 0.01). Breast cancer patients have different attitudes regarding clinical trials based on race, Internet usage, and previous trial enrollment. Biases may be introduced with recruitment for clinical trials through the Internet. Radiation oncologists must consider these issues when offering clinical trials information through the Internet. AN - WOS:000238656000005 AU - Dolinsky, C. M. AU - Wei, S. J. AU - Hampshire, M. K. AU - Metz, J. M. DA - Jul-Aug DO - 10.1111/j.1075-122X.2006.00270.x IS - 4 N1 - 16848841 PY - 2006 SN - 1075-122X SP - 324-330 ST - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet T2 - Breast Journal TI - Breast cancer patients' attitudes toward clinical trials in the radiation oncology clinic versus those searching for trial information on the Internet VL - 12 ID - 3216 ER - TY - JOUR AB - Early detection decreases breast cancer mortality. The ACR recommends annual mammographic screening beginning at age 40 for women of average risk. Higher-risk women should start mammographic screening earlier and may benefit from supplemental screening modalities. For women with genetics-based increased risk (and their untested first-degree relatives), with a calculated lifetime risk of 20% or more or a history of chest or mantle radiation therapy at a young age, supplemental screening with contrast-enhanced breast MRI is recommended. Breast MRI is also recommended for women with personal histories of breast cancer and dense tissue, or those diagnosed by age 50. Others with histories of breast cancer and those with atypia at biopsy should consider additional surveillance with MRI, especially if other risk factors are present. Ultrasound can be considered for those who qualify for but cannot undergo MRI. All women, especially black women and those of Ashkenazi Jewish descent, should be evaluated for breast cancer risk no later than age 30, so that those at higher risk can be identified and can benefit from supplemental screening. AD - Scott & White Medical Center, Texas A&M University Health Sciences, Temple, Texas Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, New York, New York H. Lee Moffitt Cancer Center, Department of Oncologic Sciences, University of South Florida, Tampa, Florida Division of Diagnostic Radiology, Washington University School of Medicine, St. Louis, Missouri University of California, San Francisco Medical Center, San Francisco, California AN - 128127012. Language: English. Entry Date: 20181230. Revision Date: 20181230. Publication Type: journal article AU - Monticciolo, Debra L. AU - Newell, Mary S. AU - Moy, Linda AU - Niell, Bethany AU - Monsees, Barbara AU - Sickles, Edward A. DB - CINAHL Complete DO - 10.1016/j.jacr.2017.11.034 DP - EBSCOhost IS - 3 KW - Patient Selection Early Detection of Cancer Breast Neoplasms Risk Factors Neoplasm Recurrence, Local Risk Assessment Mammography Breast Neoplasms -- Pathology Age Factors Adult Models, Statistical Magnetic Resonance Imaging Breast Neoplasms -- Ethnology Ultrasonography Female Neoplasms, Radiation-Induced Disease Susceptibility Personal Resource Questionnaire N1 - practice guidelines. Journal Subset: Biomedical; Double Blind Peer Reviewed; Peer Reviewed; USA. Instrumentation: Personal Resource Questionnaire (PRQ). NLM UID: 101190326. PMID: NLM29371086. PY - 2018 SN - 1546-1440 SP - 408-414 ST - Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR T2 - Journal of the American College of Radiology TI - Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128127012&site=ehost-live&scope=site VL - 15 ID - 1866 ER - TY - JOUR AB - Purpose: Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms. Methods: Semistructured interviews were conducted among African-American (n=12) and Caucasian (n=13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed. Results: Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e.g., distance and travel), (3) beliefs about the interventions (e.g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e.g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial. Conclusions: Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors. © 2013 Springer-Verlag. AD - M.M. Schapira, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA, United States AU - Schapira, M. M. AU - Mackenzie, E. R. AU - Lam, R. AU - Casarett, D. AU - Seluzicki, C. M. AU - Barg, F. K. AU - Mao, J. J. DB - Embase Medline DO - 10.1007/s00520-013-2073-3 IS - 5 KW - acupuncture adult African American aged alternative medicine altruism article breast cancer cancer staging cancer survivor cancer therapy Caucasian clinical article clinical trial (topic) female health belief health status hot flush human menopause patient decision making patient participation placebo effect polypharmacy primary tumor priority journal qualitative research quality of life semi structured interview theoretical model trust LA - English M3 - Article N1 - L52928503 2013-12-26 2014-04-18 PY - 2014 SN - 1433-7339 0941-4355 SP - 1207-1215 ST - Breast cancer survivors willingness to participate in an acupuncture clinical trial: A qualitative study T2 - Supportive Care in Cancer TI - Breast cancer survivors willingness to participate in an acupuncture clinical trial: A qualitative study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52928503&from=export http://dx.doi.org/10.1007/s00520-013-2073-3 VL - 22 ID - 1054 ER - TY - JOUR AB - Purpose: Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms.Methods: Semistructured interviews were conducted among African-American (n=12) and Caucasian (n=13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed.Results: Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e.g., distance and travel), (3) beliefs about the interventions (e.g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e.g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial.Conclusions: Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors. AD - The Philadelphia VA Center for Health Equity Research and Promotion, University of Pennsylvania, Philadelphia, PA, USA, mschap@upenn.edu. AN - 104053327. Language: English. Entry Date: 20140704. Revision Date: 20200708. Publication Type: journal article AU - Schapira, Marilyn M. AU - Mackenzie, Elizabeth R. AU - Lam, Regina AU - Casarett, David AU - Seluzicki, Christina M. AU - Barg, Frances K. AU - Mao, Jun J. DB - CINAHL Complete DO - 10.1007/s00520-013-2073-3 DP - EBSCOhost IS - 5 KW - Acupuncture -- Psychosocial Factors Breast Neoplasms -- Psychosocial Factors Breast Neoplasms -- Therapy Patient Attitudes Acupuncture -- Methods Adult Aged Black Persons -- Psychosocial Factors Breast Neoplasms -- Ethnology Breast Neoplasms -- Pathology Decision Making Female Human Middle Age Neoplasm Recurrence, Local -- Ethnology Neoplasm Recurrence, Local -- Psychosocial Factors Neoplasm Recurrence, Local -- Therapy Neoplasm Staging Patient Attitudes -- Ethnology Survivors -- Psychosocial Factors White Persons -- Psychosocial Factors N1 - research. Journal Subset: Biomedical; Continental Europe; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed. Special Interest: Oncologic Care. Grant Information: R21 AT004695/AT/NCCIH NIH HHS/United States. NLM UID: 9302957. PMID: NLM24362843. PY - 2014 SN - 0941-4355 SP - 1207-1215 ST - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study T2 - Supportive Care in Cancer TI - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104053327&site=ehost-live&scope=site VL - 22 ID - 1867 ER - TY - JOUR AB - Purpose: Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms. Methods: Semistructured interviews were conducted among African-American (n=12) and Caucasian (n=13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed. Results: Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e.g., distance and travel), (3) beliefs about the interventions (e.g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e.g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial. Conclusions: Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors. © 2013 Springer-Verlag. AD - Philadelphia VA Center for Health Equity Research and Promotion, University of Pennsylvania, Philadelphia, PA, United States Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA, United States Division of Applied Psychology-Human Development, Graduate School of Education, University of Pennsylvania, Philadelphia, PA, United States Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Department of Anthropology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, United States AU - Schapira, M. M. AU - Mackenzie, E. R. AU - Lam, R. AU - Casarett, D. AU - Seluzicki, C. M. AU - Barg, F. K. AU - Mao, J. J. DB - Scopus DO - 10.1007/s00520-013-2073-3 IS - 5 KW - Acupuncture Breast cancer survivors Clinical trials Decision making M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2014 SP - 1207-1215 ST - Breast cancer survivors willingness to participate in an acupuncture clinical trial: A qualitative study T2 - Supportive Care in Cancer TI - Breast cancer survivors willingness to participate in an acupuncture clinical trial: A qualitative study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897534574&doi=10.1007%2fs00520-013-2073-3&partnerID=40&md5=884cbd409c55f32c142600cce6cfa03c VL - 22 ID - 2402 ER - TY - JOUR AB - Purpose Acupuncture is a complementary and alternative medicine (CAM) modality that shows promise as a component of supportive breast cancer care. Lack of robust recruitment for clinical trial entry has limited the evidence base for acupuncture as a treatment modality among breast cancer survivors. The objective of this study is to identify key decision-making factors among breast cancer survivors considering entry into an acupuncture clinical trial for treatment of symptoms. Methods Semistructured interviews were conducted among African-American (n = 12) and Caucasian (n = 13) breast cancer survivors. Verbatim transcripts were made and analyzed by two or more independent coders using NVivo software. Major recurring themes were identified and a theoretical framework developed. Results Six themes emerged reflecting key attributes of the decision to enter a clinical trial: (1) symptom appraisal, (2) practical barriers (e. g., distance and travel), (3) beliefs about the interventions (e. g., fear of needles and dislike of medications), (4) comfort with elements of clinical trial design (e. g., randomization, the nature of the control intervention, and blinding), (5) trust, and (6) altruism. African-American and Caucasian women weighed similar attributes but differed in the information sources sought regarding clinical trial entry and in concerns regarding the use of a placebo in a clinical trial. Conclusions Our findings contribute to the development of a theoretical model of decision making for breast cancer survivors considering participation in a CAM clinical trial. Insights regarding the decision making process can inform interventions to support informed decision making and robust recruitment to CAM trials among cancer survivors. AN - WOS:000335774600008 AU - Schapira, M. M. AU - Mackenzie, E. R. AU - Lam, R. AU - Casarett, D. AU - Seluzicki, C. M. AU - Barg, F. K. AU - Mao, J. J. DA - May DO - 10.1007/s00520-013-2073-3 IS - 5 N1 - 24362843 PY - 2014 SN - 0941-4355 SP - 1207-1215 ST - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study T2 - Supportive Care in Cancer TI - Breast cancer survivors willingness to participate in an acupuncture clinical trial: a qualitative study VL - 22 ID - 3012 ER - TY - JOUR AB - BACKGROUND. The inclusion of ethnic minorities in cancer-related studies continues to be an important concern for researchers. In this article, the authors present 1) a brief discussion of recruitment and measurement challenges in conducting multiethnic survivorship research, and 2) recruitment outcomes and sample characteristics for a health-related quality-of-life study with a multiethnic sample of breast cancer survivors (BCS). METHODS. A case-control, cross-sectional design with mixed sampling methods was used. The Contextual Model for Recruitment and Enrollment of Diverse Samples was used to guide the protocol. BCS were recruited from the California Cancer Surveillance Program, from hospital registries, and from community agencies. Participation rates, demographic factors, and medical factors were compared. The reliability of standard measures by ethnicity was assessed. RESULTS. Seven hundred three women participated, including 135 African-American women (19%), 206 Asian-American women (29%), 183 Latina-American women (26%), and 179 European-American women (26%). Participation was influenced by ethnicity, age, and site of recruitment. Overall, African Americans were least likely to participate, and European Americans most likely to participate. African Americans and Asian Americans were more likely to refuse, European Americans and Latina Americans were more likely to agree to participate, and European Americans and Asian Americans were most likely to complete the survey after consenting. Measures possessed moderate to excellent reliability (0.64-0.91). CONCLUSIONS. Despite important recruitment and measurement challenges, this study obtained acceptable participation rates and good internal consistency of the measures. The results demonstrate the utility of a culturally responsive approach to health disparities research. © 2004 American Cancer Society. AD - Dept. Psychiat. and Biobehav. Sci., University of California-Los Angeles, Los Angeles, CA, United States California Sch. of Prof. Psychology, Alliant International University, Los Angeles, CA, United States Department of Nursing, Univ. of California-San Francisco, San Francisco, CA, United States Dept. Psychiat. and Biobehav. Sci., University of California-Los Angeles, Box 62, 760 Westwood Plaza, Los Angeles, CA 90095, United States AU - Ashing-Giwa, K. T. AU - Padilla, G. V. AU - Tejero, J. S. AU - Kim, J. DB - Scopus DO - 10.1002/cncr.20370 IS - 3 KW - Breast cancer Ethnic minority Multiethnic Recruitment M3 - Article N1 - Cited By :91 Export Date: 22 March 2021 PY - 2004 SP - 450-465 ST - Breast cancer survivorship in a multiethnic sample: Challenges in recruitment and measurement T2 - Cancer TI - Breast cancer survivorship in a multiethnic sample: Challenges in recruitment and measurement UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-3242758249&doi=10.1002%2fcncr.20370&partnerID=40&md5=ddc1c1db4d0bcd34dd3242471492b6be VL - 101 ID - 2606 ER - TY - JOUR AB - Purpose: A substantial literature describes age-dependent variations in breast cancer treatment, showing that older women are less likely to receive standard treatment than younger women. We sought to identify patient and tumor characteristics associated with the nonreceipt of standard primary tumor and systemic adjuvant therapies.Patients and Methods: We studied 1,859 women age 65 years or older with stage I and II breast cancer diagnosed between 1990 and 1994 who were cared for in six geographically dispersed community-based health care systems. We collected demographic, tumor, treatment, and comorbidity data from electronic data sources, including cancer registry, administrative, and clinical databases, and from subjects' medical records.Results: Women 75 years of age or older and women with higher comorbidity indices were more likely to receive nonstandard primary tumor therapy, to not receive axillary lymph node dissection, and to not receive radiation therapy after breast-conserving surgery (BCS). Asian women were less likely to receive BCS, and African American women were less likely to be prescribed tamoxifen. Although nonreceipt of most therapies was associated with a lower baseline risk of recurrence, an important minority of high-risk women (16% to 30%) did not receive guideline therapies.Conclusion: Age is an independent risk factor for nonreceipt of effective cancer therapies, even when comorbidity and risk of recurrence are taken into account. Information regarding treatment effectiveness in this age group and tools that allow physicians and patients to estimate the benefits versus the risks of therapies, taking into account age and comorbidity burden, are critically needed. AD - Department of Research and Evaluation, Kaiser Permanente Medical Care Program, Pasadena, CA, USA AN - 106022654. Language: English. Entry Date: 20071207. Revision Date: 20161118. Publication Type: journal article AU - Enger, S. M. AU - Thwin, S. S. AU - Buist, D. S. AU - Field, T. AU - Frost, F. AU - Geiger, A. M. AU - Lash, T. L. AU - Prout, M. AU - Yood, M. U. AU - Wei, F. AU - Silliman, R. A. AU - Enger, Shelley M. AU - Thwin, Soe Soe AU - Buist, Diana S. M. AU - Field, Terry AU - Frost, Floyd AU - Geiger, Ann M. AU - Lash, Timothy L. AU - Prout, Marianne AU - Yood, Marianne Ulcickas DB - CINAHL Complete DP - EBSCOhost IS - 27 KW - Breast Neoplasms -- Epidemiology Breast Neoplasms -- Therapy Health Care Delivery, Integrated Patient Selection Black Persons Age Factors Aged Aged, 80 and Over Antineoplastic Agents, Hormonal -- Administration and Dosage Antineoplastic Agents, Combined -- Administration and Dosage Asians Breast Neoplasms -- Drug Therapy Breast Neoplasms -- Pathology Breast Neoplasms -- Radiotherapy Breast Neoplasms -- Surgery Chemotherapy, Adjuvant Comorbidity Female Managed Care Programs Mastectomy -- Methods Mastectomy Medical Records Odds Ratio Radiotherapy, Adjuvant Retrospective Design Risk Assessment Risk Factors Tamoxifen -- Administration and Dosage Treatment Outcomes United States Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: R01 CA093772/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM16983106. PY - 2006 SN - 0732-183X SP - 4377-4383 ST - Breast cancer treatment of older women in integrated health care settings T2 - Journal of Clinical Oncology TI - Breast cancer treatment of older women in integrated health care settings UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106022654&site=ehost-live&scope=site VL - 24 ID - 1868 ER - TY - JOUR AB - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (Σ = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group's risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation. AU - Frierson, G. M. AU - Pinto, B. M. AU - Denman, D. C. AU - Leon, P. A. AU - Jaffe, A. D. DB - Medline DO - 10.1177/1359105317740736 IS - 11 KW - adult African American attitude to health breast tumor ethnology female human medical research middle aged patient participation patient selection LA - English M3 - Article N1 - L629106972 2019-09-03 2020-09-29 PY - 2019 SN - 1461-7277 SP - 1548-1561 ST - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research T2 - Journal of health psychology TI - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629106972&from=export http://dx.doi.org/10.1177/1359105317740736 VL - 24 ID - 841 ER - TY - JOUR AB - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (Σ = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group’s risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Frierson, Georita M., Department of Psychology, College of Science & Mathematics, Rowan University, 201 Mullica Hill, Glassboro, NJ, US, 08028 AN - 2019-49830-009 AU - Frierson, Georita M. AU - Pinto, Bernardine M. AU - Denman, Deanna C. AU - Leon, Pierre A. AU - Jaffe, Alex D. DB - psyh DO - 10.1177/1359105317740736 DP - EBSCOhost IS - 11 KW - breast cancer minority psycho-oncology racial concordance recruitment strategies African American women Blacks Breast Neoplasms Minority Groups Racial and Ethnic Groups Experimental Recruitment Experimental Subjects Health Care Psychology N1 - Rowan University, Glassboro, NJ, US. Release Date: 20190905. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Frierson, Georita M. Major Descriptor: Blacks; Breast Neoplasms; Minority Groups; Racial and Ethnic Groups; Experimental Recruitment. Minor Descriptor: Experimental Subjects; Health Care Psychology. Classification: Research Methods & Experimental Design (2260); Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. Page Count: 14. Issue Publication Date: Sep, 2019. Copyright Statement: The Author(s). 2017. Sponsor: National Cancer Institute, US. Other Details: R25 Transdisciplinary Grant. Recipients: Frierson, Georita M. Sponsor: American Cancer Society, US. Grant: RSG PB-03-243. Other Details: Moving Forward. Recipients: Pinto, Bernardine M.; Pinto, Bernardine M. (Prin Inv) Sponsor: National Cancer Institute, US. Grant: CA 101770. Recipients: No recipient indicated PY - 2019 SN - 1359-1053 1461-7277 SP - 1548-1561 ST - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research T2 - Journal of Health Psychology TI - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-49830-009&site=ehost-live&scope=site georitafrierson@gmail.com VL - 24 ID - 1669 ER - TY - JOUR AB - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (Σ = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group's risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation. AD - Rowan University, USA University of South Carolina, USA Southern Methodist University, USA AN - 138150778. Language: English. Entry Date: 20190823. Revision Date: 20200220. Publication Type: Article AU - Frierson, Georita M. AU - Pinto, Bernardine M. AU - Denman, Deanna C. AU - Leon, Pierre A. AU - Jaffe, Alex D. DB - CINAHL Complete DO - 10.1177/1359105317740736 DP - EBSCOhost IS - 11 KW - Race Factors Black Persons -- Psychosocial Factors Consumer Participation -- Psychosocial Factors Research Subject Recruitment Breast Neoplasms Research, Medical Health Behavior Human Female Adult Middle Age Aged Rhode Island Texas Questionnaires Focus Groups Health Status Disparities Health Knowledge Culture Qualitative Studies Descriptive Statistics N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Europe; Peer Reviewed; UK & Ireland. NLM UID: 9703616. PY - 2019 SN - 1359-1053 SP - 1548-1561 ST - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research T2 - Journal of Health Psychology TI - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138150778&site=ehost-live&scope=site VL - 24 ID - 1869 ER - TY - JOUR AB - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (Σ = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group’s risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation. © The Author(s) 2017. AD - Rowan University, United States University of South Carolina, United States Southern Methodist University, United States AU - Frierson, G. M. AU - Pinto, B. M. AU - Denman, D. C. AU - Leon, P. A. AU - Jaffe, A. D. DB - Scopus DO - 10.1177/1359105317740736 IS - 11 KW - breast cancer minority psycho-oncology racial concordance recruitment strategies M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2019 SP - 1548-1561 ST - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research T2 - Journal of Health Psychology TI - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042176366&doi=10.1177%2f1359105317740736&partnerID=40&md5=eeea416ebfedbbb074857215937fa8b7 VL - 24 ID - 2222 ER - TY - JOUR AB - Lack of African American females in breast cancer research has been receiving substantial attention. This study seeks to identify research perceptions and motivating factors needed to increase racial/ethnic minority participation in breast cancer research. A total of 57 African American women (sigma = 47.8 years), from Rhode Island and Texas, completed a questionnaire and focus group. While many participants were not breast cancer survivors, they reported knowledge of their racial group's risk for breast cancer. One major finding that could be seen as both a facilitator and barrier is racial concordance between participant and researcher. Cultural sensitivity and trust building is recommended to increase minority participation. AN - WOS:000482054500009 AU - Frierson, G. M. AU - Pinto, B. M. AU - Denman, D. C. AU - Leon, P. A. AU - Jaffe, A. D. DA - Sep DO - 10.1177/1359105317740736 IS - 11 N1 - 29172809 PY - 2019 SN - 1359-1053 SP - 1548-1561 ST - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research T2 - Journal of Health Psychology TI - Bridging the Gap: Racial concordance as a strategy to increase African American participation in breast cancer research VL - 24 ID - 2811 ER - TY - JOUR AB - Relative to non‐Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health‐related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease‐specific distress of a tablet‐delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10‐week Cognitive Behavioral Stress Management (CBSM) or attention‐control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10‐week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC‐anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC‐anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC‐anxiety over time compared with all other groups. Tablet‐delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease‐specific distress. AN - CN-01958973 AU - Bouchard, L. C. AU - Yanez, B. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Mohr, D. C. AU - Penedo, F. J. DO - 10.1093/tbm/iby089 KW - *Caucasian *advanced cancer *prostate cancer *tablet Adult Anxiety Article Attention Cancer patient Cognitive behavioral stress management Controlled study Distress syndrome Health promotion Human Major clinical study Male Randomized controlled trial M3 - Journal: Article in Press PY - 2018 ST - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: acceptability and efficacy by race T2 - Translational behavioral medicine TI - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: acceptability and efficacy by race UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01958973/full ID - 1590 ER - TY - JOUR AB - Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress. AD - F.J. Penedo, Departments of Psychology and Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States AU - Bouchard, L. C. AU - Yanez, B. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Mohr, D. C. AU - Penedo, F. J. DB - Embase Medline DO - 10.1093/tbm/iby089 IS - 4 KW - advanced cancer aged anxiety article Black person cancer incidence cancer research Caucasian clinical assessment clinical effectiveness cognitive behavioral stress management controlled study distress syndrome evaluation study health promotion human major clinical study male patient attitude priority journal prostate cancer psychosocial care quality of life race randomized controlled trial LA - English M3 - Article N1 - L631637347 2020-05-13 2020-05-21 PY - 2019 SN - 1613-9860 1869-6716 SP - 629-637 ST - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race T2 - Translational Behavioral Medicine TI - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631637347&from=export http://dx.doi.org/10.1093/tbm/iby089 VL - 9 ID - 844 ER - TY - JOUR AB - Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Penedo, Frank J. AN - 2020-30884-006 AU - Bouchard, Laura C. AU - Yanez, Betina AU - Dahn, Jason R. AU - Flury, Sarah C. AU - Perry, Kent T. AU - Mohr, David C. AU - Penedo, Frank J. DB - psyh DO - 10.1093/tbm/iby089 DP - EBSCOhost IS - 4 KW - tablet-delivered psychosocial intervention advanced prostate cancer Black men older men racial differences health promotion cognitive behavioral stress management African Americans Aged Anxiety Case-Control Studies Cognitive Behavioral Therapy Computers, Handheld Counseling Efficiency, Organizational Health Services Accessibility Humans Incidence Male Middle Aged Patient Acceptance of Health Care Prostatic Neoplasms Psychosocial Support Systems Quality of Life Surveys and Questionnaires Telemedicine Cognitive Behavior Therapy Neoplasms Stress Management Tablet Computers Aging Blacks Intervention Prostate Racial and Ethnic Differences N1 - Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, US. Other Publishers: Springer. Release Date: 20201112. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Penedo, Frank J. Major Descriptor: Cognitive Behavior Therapy; Health Promotion; Neoplasms; Stress Management; Tablet Computers. Minor Descriptor: Aging; Blacks; Intervention; Prostate; Racial and Ethnic Differences. Classification: Behavioral & Psychological Treatment of Physical Illness (3361). Population: Human (10); Male (30); Inpatient (50). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Charlson Comorbidity Index; Memorial Anxiety Scale for Prostate Cancer. Methodology: Empirical Study; Quantitative Study. Page Count: 9. Issue Publication Date: Aug, 2019. Copyright Statement: All rights reserved. Society of Behavioral Medicine. 2018. Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: R01CA157809. Recipients: Penedo, Frank J. (Prin Inv) Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: T32CA193193. Recipients: Bouchard, Laura C. PY - 2019 SN - 1869-6716 1613-9860 SP - 629-637 ST - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race T2 - Translational Behavioral Medicine TI - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-30884-006&site=ehost-live&scope=site frank.penedo@miami.edu VL - 9 ID - 1674 ER - TY - JOUR AB - Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress. © 2018 Society of Behavioral Medicine 2018. All rights reserved. AD - Department of Medical Social Sciences, Northwestern University Feinberg, School of Medicine, Chicago, IL, United States Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami, FL, United States Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg, School of Medicine, Chicago, IL, United States Department of Preventive Medicine, Northwestern University Feinberg, School of Medicine, Chicago, IL, United States Departments of Psychology and Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States AU - Bouchard, L. C. AU - Yanez, B. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Mohr, D. C. AU - Penedo, F. J. DB - Scopus DO - 10.1093/tbm/iby089 IS - 4 KW - Black men Disparities E-health Prostate cancer Psychosocial intervention M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2019 SP - 629-637 ST - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race T2 - Translational Behavioral Medicine TI - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075276911&doi=10.1093%2ftbm%2fiby089&partnerID=40&md5=1b3011fed24ce194bd70639a1faaf5d8 VL - 9 ID - 2225 ER - TY - JOUR AB - Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress. AN - WOS:000492967600006 AU - Bouchard, L. C. AU - Yanez, B. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Mohr, D. C. AU - Penedo, F. J. DA - Aug DO - 10.1093/tbm/iby089 IS - 4 N1 - 30285186 PY - 2019 SN - 1869-6716 SP - 629-637 ST - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race T2 - Translational Behavioral Medicine TI - Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race VL - 9 ID - 2813 ER - TY - JOUR AB - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men's health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men's health educational intervention. Future work should consider optimal ways of providing family support for African-American men's health promotion. AU - Holt, C. L. AU - Le, D. AU - Slade, J. L. AU - Muwwakkil, B. AU - Saunders, D. R. AU - Williams, R. AU - Atkinson, N. L. AU - Naslund, M. DB - Medline DO - 10.1080/10810730.2017.1382616 IS - 12 KW - African American aged controlled study decision making early cancer diagnosis ethnology faith-based organization female follow up health promotion human human relation male middle aged procedures program evaluation prostate tumor psychology randomized controlled trial statistics and numerical data utilization LA - English M3 - Article N1 - L620106312 2018-01-11 PY - 2017 SN - 1087-0415 SP - 964-973 ST - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial T2 - Journal of health communication TI - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620106312&from=export http://dx.doi.org/10.1080/10810730.2017.1382616 VL - 22 ID - 924 ER - TY - JOUR AB - The M‐PACT study compared an all‐male with a mixed‐sex intervention to increase informed decision‐making for prostate cancer screening among African‐American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men's health workshops on informed decision‐making for prostate cancer screening. African‐American male workshop participants completed baseline, post‐workshop, and 12‐month follow‐up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision‐making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision‐making for prostate cancer screening, preference for role in decision‐making, prostate cancer knowledge, and self‐reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision‐making outcomes on several indicators. The current findings suggest mixed results from including women in this men's health educational intervention. Future work should consider optimal ways of providing family support for African‐American men's health promotion. AN - CN-01443035 AU - Holt, C. L. AU - Le, D. AU - Slade, J. L. AU - Muwwakkil, B. AU - Saunders, D. R. AU - Williams, R. AU - Atkinson, N. L. AU - Naslund, M. DO - 10.1080/10810730.2017.1382616 IS - 12 KW - *decision making *ethnology *human relation *procedures *psychology African American African Americans [*psychology, statistics & numerical data] Aged Controlled study Decision Making Early Detection of Cancer [*psychology, statistics & numerical data] Early cancer diagnosis Faith based organization Faith‐Based Organizations Female Follow up Follow‐Up Studies Health Promotion [*methods] Health promotion Human Humans Interpersonal Relations Male Middle Aged Program Evaluation Prostate tumor/di [Diagnosis] Prostatic Neoplasms [diagnosis, *ethnology] Randomized controlled trial Statistics and numerical data Utilization M3 - Journal Article; Randomized Controlled Trial PY - 2017 SP - 964‐973 ST - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial T2 - Journal of health communication TI - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01443035/full VL - 22 ID - 1369 ER - TY - JOUR AB - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men’s health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men’s health educational intervention. Future work should consider optimal ways of providing family support for African-American men’s health promotion. AD - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, Maryland, USA Community Ministry of Prince George's County, Upper Marlboro, Maryland, USA Access to Wholistic & Productive Living, Inc., Lanham, Maryland, USA Westat, Rockville, Maryland, USA Department of Urology, University of Maryland Medical Center, Baltimore, Maryland, USA AN - 126800318. Language: English. Entry Date: 20180108. Revision Date: 20190619. Publication Type: Article. Journal Subset: Biomedical AU - Holt, Cheryl L. AU - Le, Daisy AU - Slade, Jimmie L. AU - Muwwakkil, Bettye AU - Saunders, Darlene R. AU - Williams, Ralph AU - Atkinson, Nancy L. AU - Naslund, Michael DB - CINAHL Complete DO - 10.1080/10810730.2017.1382616 DP - EBSCOhost IS - 12 N1 - Europe; Health Promotion/Education; Peer Reviewed; UK & Ireland. NLM UID: 9604100. PMID: NLM29173037. PY - 2017 SN - 1081-0730 SP - 964-973 ST - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial T2 - Journal of Health Communication TI - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126800318&site=ehost-live&scope=site VL - 22 ID - 1871 ER - TY - JOUR AB - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men's health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men's health educational intervention. Future work should consider optimal ways of providing family support for African-American men's health promotion. AN - WOS:000419116500004 AU - Holt, C. L. AU - Le, D. AU - Slade, J. L. AU - Muwwakkil, B. AU - Saunders, D. R. AU - Williams, R. AU - Atkinson, N. L. AU - Naslund, M. DO - 10.1080/10810730.2017.1382616 IS - 12 N1 - 29173037 PY - 2017 SN - 1081-0730 SP - 964-973 ST - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial T2 - Journal of Health Communication TI - Can Women Facilitate Men's Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial VL - 22 ID - 2913 ER - TY - JOUR AB - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men’s health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men’s health educational intervention. Future work should consider optimal ways of providing family support for African-American men’s health promotion. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Holt, Cheryl L., Department of Behavioral and Community Health, School of Public Health, University of Maryland, 1234W School of Public Health Building (255), College Park, MD, US, 20742 AN - 2018-01878-005 AU - Holt, Cheryl L. AU - Le, Daisy AU - Slade, Jimmie L. AU - Muwwakkil, Bettye AU - Saunders, Darlene R. AU - Williams, Ralph AU - Atkinson, Nancy L. AU - Naslund, Michael DB - psyh DO - 10.1080/10810730.2017.1382616 DP - EBSCOhost IS - 12 KW - prostate cancer screening informed decision-making African-American family support African Americans Aged Decision Making Early Detection of Cancer Faith-Based Organizations Female Follow-Up Studies Health Promotion Humans Interpersonal Relations Male Middle Aged Program Evaluation Prostatic Neoplasms Cancer Screening Blacks Social Support N1 - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, US. Release Date: 20180524. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Decision Making. Minor Descriptor: Blacks; Social Support. Classification: Health Psychology & Medicine (3360). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Survey Measure; Self-Administered Questionnaire Measure. Methodology: Clinical Trial; Empirical Study; Quantitative Study. Page Count: 10. Issue Publication Date: Dec, 2017. Copyright Statement: Taylor & Francis Group, LLC Sponsor: American Cancer Society, US. Grant: RGST-10-113-01-CPPB. Recipients: No recipient indicated PY - 2017 SN - 1081-0730 1087-0415 SP - 964-973 ST - Can women facilitate men’s prostate cancer screening informed decision-making? The M-PACT trial T2 - Journal of Health Communication TI - Can women facilitate men’s prostate cancer screening informed decision-making? The M-PACT trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-01878-005&site=ehost-live&scope=site cholt14@umd.edu VL - 22 ID - 1691 ER - TY - JOUR AB - The M-PACT study compared an all-male with a mixed-sex intervention to increase informed decision-making for prostate cancer screening among African-American men in church settings. We recruited 262 men in 18 churches randomized to the two intervention approaches. Trained and certified lay peer community health advisors in each church led a series of four men’s health workshops on informed decision-making for prostate cancer screening. African-American male workshop participants completed baseline, post-workshop, and 12-month follow-up surveys. Contrary to our expectations, including women in the workshops did not result in increased intervention efficacy for the informed decision-making outcomes as both groups showed significant improvement over time in several study outcomes including stage of decision-making for prostate cancer screening, preference for role in decision-making, prostate cancer knowledge, and self-reports of prostate specific antigen testing. Finally, men who attended multiple workshops had better informed decision-making outcomes on several indicators. The current findings suggest mixed results from including women in this men’s health educational intervention. Future work should consider optimal ways of providing family support for African-American men’s health promotion. Copyright © Taylor & Francis Group, LLC. AD - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, United States Community Ministry of Prince George’s County, Upper Marlboro, MD, United States Access to Wholistic & Productive Living, Inc, Lanham, MD, United States Westat, Rockville, MD, United States Department of Urology, University of Maryland Medical Center, Baltimore, MD, United States AU - Holt, C. L. AU - Le, D. AU - Slade, J. L. AU - Muwwakkil, B. AU - Saunders, D. R. AU - Williams, R. AU - Atkinson, N. L. AU - Naslund, M. DB - Scopus DO - 10.1080/10810730.2017.1382616 IS - 12 M3 - Article N1 - Export Date: 22 March 2021 PY - 2017 SP - 964-973 ST - Can Women Facilitate Men’s Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial T2 - Journal of Health Communication TI - Can Women Facilitate Men’s Prostate Cancer Screening Informed Decision-Making? The M-PACT Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85035085058&doi=10.1080%2f10810730.2017.1382616&partnerID=40&md5=154205f80479498846592b34a32a9d35 VL - 22 ID - 2296 ER - TY - JOUR AB - Background: Lack of African American participation in cancer clinical trials has been identified as a critical problem. Historical interactions related to race, identity, and power may contribute to continued inequity in healthcare and research participation. Objective: The aim of this study was to explore the perceptions of African Americans regarding cancer and research and how these perceptions shape their beliefs about participating as cancer research subjects. Methods: Three African American focus groups were conducted including people who had never participated in cancer research, those who had, and those who were asked but refused (n = 16). Discussion focused on their perceptions of cancer research and actual or potential participation as research subjects. Data were coded using both structured and inductive coding methods. Results: Fear and fatalism emerged in relation to research, race, power, and identity and were related to larger historical and social issues rather than only individual thoughts or feelings. Participants described fears of the unknown, death, mistrust, conspiracy, and discrimination together with positive/negative tensions between self, family, and community responsibilities. Conclusion: Complex identities linked perceptions of cancer and cancer research with broader historical and cultural issues. Fear, fatalism, and current and historical relationships influence how people perceive themselves as research subjects and may influence their decisions to participate in cancer research. Implication for Practice: Acknowledging how complex factors including race and racism contribute to health disparities may give nurses and other healthcare providers a better appreciation of how historical, social, and cultural dynamics at individual, community, and organizational levels influence access to and participation in cancer research. AN - WOS:000349907900014 AU - Somayaji, D. AU - Cloyes, K. G. DA - Mar-Apr DO - 10.1097/NCC.0000000000000144 IS - 2 N1 - 24945262 PY - 2015 SN - 0162-220X SP - 133-144 ST - Cancer Fear and Fatalism How African American Participants Construct the Role of Research Subject in Relation to Clinical Cancer Research T2 - Cancer Nursing TI - Cancer Fear and Fatalism How African American Participants Construct the Role of Research Subject in Relation to Clinical Cancer Research VL - 38 ID - 2983 ER - TY - JOUR AB - Objective. We assessed how Medicaid enrollment and race influence cancer incidence among patients age 65 years and older. Data Sources and Method. Population-based Michigan Tumor Registry was merged with Medicaid eligibility files for 1996 through 2000. All analyses were age-adjusted and gender-specific. We compared cancer incidence in the elderly Medicaid population to the cancer incidence in the Medicare population. We then examined cancer incidence in patients continuously enrolled in Medicaid 12 or more months relative to the incidence in the Medicare population. Principal Findings. When comparing cancer incidence in Medicaid patients without regard to enrollment before diagnosis, the incidence rates of prostate cancer in black men and colorectal cancer in black women were statistically higher relative to the incidence rates in white patients. The overall cancer incidence rate for all cancers combined was statistically significantly higher for black women and men compared with white women and men (incidence rate ratio=1.18 and 1.48, 95 percent confidence interval 1.05-1.32 and 1.28-1.71, respectively). In dually eligible patients enrolled 12 or more months before diagnosis, an excess cancer incident was observed for black patients relative to white patients in every cancer site examined with the exception of lung cancer. Conclusions. Medicaid data in addition to Medicare data revealed patterns of cancer incidence that varied according to Medicaid enrollment and race. These findings suggest that the cancer burden among African Americans and dually eligible patients is substantial. © Health Research and Educational Trust. AD - Department of Health Administration, Massey Cancer Center, Virginia Commonwealth University, 1008 Clay Street, Richmond, VA 23298-0203, United States Behavioral Health Economics Program, RTI International, Research Triangle Park, NC, United States Department of Family Practice, Michigan State University, Clinical Center, East Lansing, MI, United States AU - Bradley, C. J. AU - Luo, Z. AU - Given, C. W. DB - Scopus DO - 10.1111/j.1475-6773.2008.00855.x IS - 5 P1 KW - Cancer Dual eligible Incidence Medicaid Medicare M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2008 SP - 1768-1779 ST - Cancer incidence in elderly medicare and dually eligible beneficiaries T2 - Health Services Research TI - Cancer incidence in elderly medicare and dually eligible beneficiaries UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-52149090105&doi=10.1111%2fj.1475-6773.2008.00855.x&partnerID=40&md5=9d532b081a7f63a22c8125c0a3577c4b VL - 43 ID - 2532 ER - TY - JOUR AB - Background: To explore the willingness of primary care providers (PCPs) to encourage enrollment of patients into cancer prevention trials. Methods: A self-administered survey was mailed to a random sample of PCPs in three geographic regions. Physicians were asked questions about their knowledge and attitudes towards cancer prevention trials. We presented a clinical vignette of a woman at high risk for breast cancer and asked if they would encourage her enrollment into a breast cancer chemoprevention trial (yes/no). Each survey included one of 16 possible clinical vignettes where patient characteristics (age, race socioeconomic status, physical mobility and co-morbidity) varied dichotomously. Bivariate analyses and logistic models were used to examine the independent effects of patient and physician characteristics on physician decisions. Results: Two hundred and sixty-six surveys (50% response) were analyzed. The mean age of respondents was 48; 54% were White, 35% Asian and 5% Black. By design physicians were evenly distributed by gender, specialty and geographic location. Overall, 53% would encourage enrollment into a breast cancer chemoprevention trial. Significant predictors of a recommendation to enroll were: geographic location in California or Georgia, younger vignette patient and anticipating an increase in patient trust after recommending enrollment. Conclusion: PCPs are less likely to encourage elderly patients to enroll into cancer chemoprevention trials. Decisions differ based on geographic location and perceived trust in the patient-provider relationship. To achieve successful enrollment, trial investigators must continue to educate PCPs and ensure a strong PCP-patient relationship is maintained. © 2005 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved. AD - T.A. Battaglia, Section of General Internal Medicine, Evans Department of Medicine, Boston University School of Medicine, 720 Harrison Avenue, Boston, MA 02118-2334, United States AU - Battaglia, T. A. AU - Ash, A. AU - Prout, M. N. AU - Freund, K. M. DB - Embase Medline DO - 10.1016/j.cdp.2005.09.005 IS - 1 KW - article Asian breast cancer cancer prevention cancer risk Caucasian chemoprophylaxis clinical study comorbidity geographic distribution human Black person physical mobility physician primary medical care priority journal race difference social status LA - English M3 - Article N1 - L43374501 2006-03-21 PY - 2006 SN - 0361-090X 1525-1500 SP - 34-37 ST - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment T2 - Cancer Detection and Prevention TI - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43374501&from=export http://dx.doi.org/10.1016/j.cdp.2005.09.005 VL - 30 ID - 1251 ER - TY - JOUR AB - Background: To explore the willingness of primary care providers (PCPs) to encourage enrollment of patients into cancer prevention trials. Methods: A self-administered survey was mailed to a random sample of PCPs in three geographic regions. Physicians were asked questions about their knowledge and attitudes towards cancer prevention trials. We presented a clinical vignette of a woman at high risk for breast cancer and asked if they would encourage her enrollment into a breast cancer chemoprevention trial (yes/no). Each survey included one of 16 possible clinical vignettes where patient characteristics (age, race socioeconomic status, physical mobility and co-morbidity) varied dichotomously. Bivariate analyses and logistic models were used to examine the independent effects of patient and physician characteristics on physician decisions. Results: Two hundred and sixty-six surveys (50% response) were analyzed. The mean age of respondents was 48; 54% were White, 35% Asian and 5% Black. By design physicians were evenly distributed by gender, specialty and geographic location. Overall, 53% would encourage enrollment into a breast cancer chemoprevention trial. Significant predictors of a recommendation to enroll were: geographic location in California or Georgia, younger vignette patient and anticipating an increase in patient trust after recommending enrollment. Conclusion: PCPs are less likely to encourage elderly patients to enroll into cancer chemoprevention trials. Decisions differ based on geographic location and perceived trust in the patient-provider relationship. To achieve successful enrollment, trial investigators must continue to educate PCPs and ensure a strong PCP-patient relationship is maintained. © 2005 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved. AD - Section of General Internal Medicine, Evans Department of Medicine, Boston University School of Medicine, 720 Harrison Avenue, Boston, MA 02118-2334, United States Department of Epidemiology, Boston University, School of Public Health, Boston, MA, United States Women's Health Interdisciplinary Research Center, Boston University, School of Medicine, Boston, MA, United States AU - Battaglia, T. A. AU - Ash, A. AU - Prout, M. N. AU - Freund, K. M. DB - Scopus DO - 10.1016/j.cdp.2005.09.005 IS - 1 KW - Breast neoplasms Chemoprevention Clinical trials Decision making Experimental design High-risk patients Patient-provider relationship Prevention trials Primary care providers Primary prevention Regional variability Response rate Tamoxifen M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2006 SP - 34-37 ST - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment T2 - Cancer Detection and Prevention TI - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644855767&doi=10.1016%2fj.cdp.2005.09.005&partnerID=40&md5=7865a374a12cda5585b1650e12451a9a VL - 30 ID - 2579 ER - TY - JOUR AB - Background: To explore the willingness of primary care providers (PCPs) to encourage enrollment of patients into cancer prevention trials. Methods: A self-administered survey was mailed to a random sample of PCPs in three geographic regions. Physicians were asked questions about their knowledge and attitudes towards cancer prevention trials. We presented a clinical vignette of a woman at high risk for breast cancer and asked if they would encourage her enrollment into a breast cancer chemoprevention trial (yes/no). Each survey included one of 16 possible clinical vignettes where patient characteristics (age, race socioeconomic status, physical mobility and comorbidity) varied dichotomously. Bivariate analyses and logistic models were used to examine the independent effects of patient and physician characteristics on physician decisions. Results: Two hundred and sixty-six surveys (50% response) were analyzed. The mean age of respondents was 48; 54% were White, 35% Asian and 5% Black. By design physicians were evenly distributed by gender, specialty and geographic location. Overall, 53% would encourage enrollment into a breast cancer chernoprevention trial. Significant predictors of a recommendation to enroll were: geographic location in California or Georgia, younger vignette patient and anticipating an increase in patient trust after recommending enrollment. Conclusion: PCPs are less likely to encourage elderly patients to enroll into cancer chemoprevention trials. Decisions differ based on a trust in the patient-provider relationship. To achieve successful enrollment, trial investigators must geographic location and perceived it continue to educate PCPs and ensure a strong PCP-patient relationship is maintained. (c) 2005 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved. AN - WOS:000236494800006 AU - Battaglia, T. A. AU - Ash, A. AU - Prout, M. N. AU - Freund, K. M. DO - 10.1016/j.cdp.2005.09.005 IS - 1 N1 - 16476525 PY - 2006 SN - 0361-090X SP - 34-37 ST - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment T2 - Cancer Detection and Prevention TI - Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment VL - 30 ID - 3225 ER - TY - JOUR AB - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged ≥18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged ≥18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged ≥40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged ≥50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women. © Copyright 2011, Mary Ann Liebert, Inc. AD - L. A. Linnan, University of North Carolina Gillings, School of Global Public Health, Department of Health Behavior and Health Education, 359 Rosenau Hall, CB7440, Chapel Hill, NC 27599-7440, United States AU - Reiter, P. L. AU - Linnan, L. A. DB - Embase DO - 10.1089/jwh.2010.2245 IS - 3 KW - adult African American age aged article breast cancer cancer prevention cancer screening colorectal cancer community based rehabilitation controlled study correlation analysis female human logistic regression analysis major clinical study mammography Papanicolaou test practice guideline priority journal United States uterine cervix cancer LA - English M3 - Article N1 - L361456834 2011-03-25 2011-03-29 PY - 2011 SN - 1540-9996 SP - 429-438 ST - Cancer screening behaviors of african american women enrolled in a community-based cancer prevention trial T2 - Journal of Women's Health TI - Cancer screening behaviors of african american women enrolled in a community-based cancer prevention trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361456834&from=export http://dx.doi.org/10.1089/jwh.2010.2245 VL - 20 ID - 1143 ER - TY - JOUR AB - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged ≥18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged ≥18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged ≥40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged ≥50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Linnan, Laura A., University of North Carolina Gillings School of Global Public Health, Department of Health Behavior and Health Education, 359 Rosenau Hall, CB7440, Chapel Hill, NC, US, 27599-7440 AN - 2011-20959-010 AU - Reiter, Paul L. AU - Linnan, Laura A. DB - psyh DO - 10.1089/jwh.2010.2245 DP - EBSCOhost IS - 3 KW - cancer screening African American women behavior analysis community-based cancer prevention Blacks Human Females Prevention Community Services N1 - Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, US. Release Date: 20111219. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Behavior Analysis; Blacks; Cancer Screening; Human Females; Prevention. Minor Descriptor: Community Services. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Physical Activity Readiness Questionnaire. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Mar, 2011. Copyright Statement: Mary Ann Liebert, Inc. Sponsor: American Cancer Society, US. Grant: TURSG-02-190-01-PBP. Recipients: No recipient indicated Sponsor: Lineberger Comprehensive Cancer Center, Cancer Control Education Program. Grant: R25 CA57726. Recipients: No recipient indicated PY - 2011 SN - 1540-9996 1931-843X SP - 429-438 ST - Cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial T2 - Journal of Women's Health TI - Cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-20959-010&site=ehost-live&scope=site linnan@email.unc.edu VL - 20 ID - 1764 ER - TY - JOUR AB - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged ≥18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged ≥18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged ≥40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged ≥50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women. AN - 104845021. Language: English. Entry Date: 20110420. Revision Date: 20200708. Publication Type: Journal Article AU - Reiter, Paul L. AU - Linnan, Laura A. DB - CINAHL Complete DO - 10.1089/jwh.2010.2245 DP - EBSCOhost IS - 3 KW - Cancer Screening Black Persons Health Behavior Patient Compliance Human Funding Source Female Cross Sectional Studies Adult Grooming -- Organizations -- North Carolina North Carolina Cervical Smears Mammography Age Factors Middle Age Colorectal Neoplasms -- Prevention and Control Health Services Accessibility Secondary Analysis Questionnaires Logistic Regression Bivariate Statistics Correlational Studies Predictive Validity Descriptive Statistics Odds Ratio Confidence Intervals N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: This study was funded by the American Cancer Society (grant No. TURSG-02-190-01-PBP) with additional support from the Cancer Control Education Program at Lineberger Comprehensive Cancer Center (grant No. R25 CA57726).. NLM UID: 101159262. PY - 2011 SN - 1540-9996 SP - 429-438 ST - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial T2 - Journal of Women's Health (15409996) TI - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104845021&site=ehost-live&scope=site VL - 20 ID - 1873 ER - TY - JOUR AB - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged ≥18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged ≥18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged ≥40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged ≥50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women. © Copyright 2011, Mary Ann Liebert, Inc. AD - Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States University of North Carolina Gillings, School of Global Public Health, Department of Health Behavior and Health Education, 359 Rosenau Hall, CB7440, Chapel Hill, NC 27599-7440, United States AU - Reiter, P. L. AU - Linnan, L. A. DB - Scopus DO - 10.1089/jwh.2010.2245 IS - 3 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2011 SP - 429-438 ST - Cancer screening behaviors of african american women enrolled in a community-based cancer prevention trial T2 - Journal of Women's Health TI - Cancer screening behaviors of african american women enrolled in a community-based cancer prevention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952751824&doi=10.1089%2fjwh.2010.2245&partnerID=40&md5=416877f8ac778318dce65d805797b8ad VL - 20 ID - 2481 ER - TY - JOUR AB - Background: African American women have increased mortality rates for cervical, breast, and colorectal cancers, yet not all receive the recommended screening tests for these cancers. We characterized the cancer screening behaviors of African American women enrolled in a community-based cancer prevention trial. Methods: We examined cross-sectional data from 1123 African American customers aged >= 18 years from 37 beauty salons in North Carolina who completed the North Carolina BEAUTY and Health Project baseline survey. Mixed logistic regression models were used to identify correlates of receiving cervical, breast, and colorectal cancer screening tests within recommended screening guidelines. Results: Overall, 94% (1026 of 1089) of women aged >= 18 years reported receiving a Pap smear test within the last 3 years, 70% (298 of 425) of women aged >= 40 years reported receiving a mammography within the last year, and 64% (116 of 180) of women aged >= 50 years were considered to be within recommended screening guidelines for colorectal cancer. Age was correlated with recent Pap smear testing and mammography. Women who reported receiving a recent Pap smear test were more likely to report a mammogram in the last year, and women with a recent mammogram were more likely to be within recommended screening guidelines for colorectal cancer. Many women reported multiple barriers to getting recommended cancer screening tests. Conclusions: Almost all women reported receiving a Pap smear test within the last 3 years. Future interventions should focus on increasing breast and colorectal cancer screening among African American women. AN - WOS:000288435400017 AU - Reiter, P. L. AU - Linnan, L. A. DA - Mar DO - 10.1089/jwh.2010.2245 IS - 3 N1 - 21332413 PY - 2011 SN - 1540-9996 SP - 429-438 ST - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial T2 - Journal of Womens Health TI - Cancer Screening Behaviors of African American Women Enrolled in a Community-Based Cancer Prevention Trial VL - 20 ID - 3097 ER - TY - JOUR AB - This experimental study attempts to determine if an in‐home educational intervention conducted by lay health workers (LHWs) can increase adherence among low‐income, inner‐city black women to schedules for screening for breast cancer and cervical cancer, as well as increase the women's knowledge and change their attitudes regarding these cancers. This paper is a description of the purposes, hypotheses, design, subject recruitment, intervention, and evaluation of the study conducted by Morehouse School of Medicine. Subjects were recruited from a variety of sources, including patients seen in a community health center, women referred by the National Black Women's Health Project (NBWHP), residents of public and senior citizen housing projects, and persons identified in various community settings. Fewer than half of those asked to participate agreed to do so. The 321 women who were recruited were demographically diverse. Overall, about half of these volunteer subjects self‐reported at least one Papanicolaou (Pap) smear and one breast examination within a year before enrollment in the study. There was little variation by source of recruitment in compliance with screening recommendations, except that referrals from NBWHP were more likely (P<0.01) to have had a Pap test and breast self‐examination, while residents of public housing projects were somewhat less likely to have done so. About 35 percent of participants ages 35 and older had a mammogram within an appropriate interval. Participants were randomly assigned to intervention and control groups. Women in the intervention group were visited in their homes by LHWs on three occasions; the LHWs provided education on cancer and reproductive health. The groups were comparable in their baseline sociodemographic status and previous screening history. AN - CN-00182538 AU - Sung, J. F. C. AU - Coates, R. J. AU - Williams, J. E. AU - Liff, J. M. AU - Greenberg, R. S. AU - McGrady, G. A. AU - Avery, B. Y. AU - Blumenthal, D. S. IS - 4 KW - *breast cancer /diagnosis /epidemiology *cancer screening *uterine cervix cancer /diagnosis /epidemiology Adult Aged Article Attitude Black person Breast examination Cancer survival Clinical trial Controlled study Demography Female Health care personnel Health education Health insurance Human Major clinical study Mammography Marriage Papanicolaou test Priority journal Randomized controlled trial Social status United States M3 - Journal: Article PY - 1992 SP - 381‐388 ST - Cancer screening intervention among black women in inner-city Atlanta - Design of a study T2 - Public health reports TI - Cancer screening intervention among black women in inner-city Atlanta - Design of a study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00182538/full VL - 107 ID - 1516 ER - TY - JOUR AB - This experimental study attempts to determine if an in-home educational intervention conducted by lay health workers (LHWs) can increase adherence among low-income, inner-city black women to schedules for screening for breast cancer and cervical cancer, as well as increase the women's knowledge and change their attitudes regarding these cancers. This paper is a description of the purposes, hypotheses, design, subject recruitment, intervention, and evaluation of the study conducted by Morehouse School of Medicine. Subjects were recruited from a variety of sources, including patients seen in a community health center, women referred by the National Black Women's Health Project (NBWHP), residents of public and senior citizen housing projects, and persons identified in various community settings. Fewer than half of those asked to participate agreed to do so. The 321 women who were recruited were demographically diverse. Overall, about half of these volunteer subjects self-reported at least one Papanicolaou (Pap) smear and one breast examination within a year before enrollment in the study. There was little variation by source of recruitment in compliance with screening recommendations, except that referrals from NBWHP were more likely (P<0.01) to have had a Pap test and breast self-examination, while residents of public housing projects were somewhat less likely to have done so. About 35 percent of participants ages 35 and older had a mammogram within an appropriate interval. Participants were randomly assigned to intervention and control groups. Women in the intervention group were visited in their homes by LHWs on three occasions; the LHWs provided education on cancer and reproductive health. The groups were comparable in their baseline sociodemographic status and previous screening history. AD - Morehouse School of Medicine, 720 Westview Dr., SW, Atlanta, GA 30310-1495, United States AU - Sung, J. F. C. AU - Coates, R. J. AU - Williams, J. E. AU - Liff, J. M. AU - Greenberg, R. S. AU - McGrady, G. A. AU - Avery, B. Y. AU - Blumenthal, D. S. DB - Scopus IS - 4 M3 - Article N1 - Cited By :44 Export Date: 22 March 2021 PY - 1992 SP - 381-388 ST - Cancer screening intervention among black women in inner-city Atlanta - Design of a study T2 - Public Health Reports TI - Cancer screening intervention among black women in inner-city Atlanta - Design of a study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026646277&partnerID=40&md5=9684edbfe3a7da0370c69e9f3d6283c8 VL - 107 ID - 2661 ER - TY - JOUR AB - This experimental study attempts to determine if an in-home educational intervention conducted by lay health workers (LHWs) can increase adherence among low-income, inner-city black women to schedules for screening for breast cancer and cervical cancer, as well as increase the women's knowledge and change their attitudes regarding these cancers. This paper is a description of the purposes, hypotheses, design, subject recruitment, intervention, and evaluation of the study conducted by Morehouse School of Medicine. Subjects were recruited from a variety of sources, including patients seen in a community health center, women referred by the National Black Women's Health Project (NBWHP), residents of public and senior citizen housing projects, and persons identified in various community settings. Fewer than half of those asked to participate agreed to do so. The 321 women who were recruited were demographically diverse. Overall, about half of these volunteer subjects self-reported at least one Papanicolaou (Pap) smear and one breast examination within a year before enrollment in the study. There was little variation by source of recruitment in compliance with screening recommendations, except that referrals from NBWHP were more likely (P < 0.01) to have had a Pap test and breast self-examination, while residents of public housing projects were somewhat less likely to have done so. About 35 percent of participants ages 35 and older had a mammogram within an appropriate interval. Participants were randomly assigned to intervention and control groups. Women in the intervention group were visited in their homes by LHWs on three occasions; the LHWs provided education on cancer and reproductive health. The groups were comparable in their baseline sociodemographic status and previous screening history. AN - 107457845. Language: English. Entry Date: 19930201. Revision Date: 20150712. Publication Type: Journal Article AU - Sung, J. F. C. AU - Coates, R. J. AU - Williams, J. E. AU - Liff, J. M. AU - Greenberg, R. S. AU - McGrady, G. A. AU - Avery, B. Y. AU - Blumenthal, D. S. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Breast Neoplasms -- Epidemiology Cancer Screening -- Methods Health Education -- Methods Women's Health Attitude to Health Cervix Neoplasms -- Epidemiology Black Persons Georgia Epidemiological Research Breast Neoplasms -- Diagnosis Cervix Neoplasms -- Diagnosis Urban Areas Cervical Smears Prospective Studies Poverty Convenience Sample Adolescence Adult Middle Age Aged Female Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. NLM UID: 9716844. PMID: NLM1641433. PY - 1992 SN - 0033-3549 SP - 381-388 ST - Cancer screening intervention among Black women in inner-city Atlanta -- design of a study T2 - Public Health Reports TI - Cancer screening intervention among Black women in inner-city Atlanta -- design of a study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107457845&site=ehost-live&scope=site VL - 107 ID - 1874 ER - TY - JOUR AB - This experimental study attempts to determine if an in-home educational intervention conducted by lay health workers (LHWs) can increase adherence among low-income, inner-city black women to schedules for screening for breast cancer and cervical cancer, as well as increase the women's knowledge and change their attitudes regarding these cancers. This paper is a description of the purposes, hypotheses, design, subject recruitment, intervention, and evaluation of the study conducted by Morehouse School of Medicine. Subjects were recruited from a variety of sources, including patients seen in a community health center, women referred by the National Black Women's Health Project (NBWHP), residents of public and senior citizen housing projects, and persons identified in various community settings. Fewer than half of those asked to participate agreed to do so. The 321 women who were recruited were demographically diverse. Overall about half of these volunteer subjects self-reported at least one Papanicolaou (Pap) smear and one breast examination within a year before enrollment in the study. There was little variation by source of recruitment in compliance with screening recommendations, except that referrals from NBWHP were more likely (P < 0.01) to have had a Pap test and breast self-examination, while residents of public housing projects were somewhat less likely to have done so. About 35 percent of participants ages 35 and older had a mammogram within an appropriate interval. Participants were randomly assigned to intervention and control groups. Women in the intervention group were visited in their homes by LHWs on three occasions; the LHWs provided education on cancer and reproductive health. The groups were comparable in their baseline sociodemographic status and previous screening history. AN - WOS:A1992JH96600002 AU - Sung, J. F. C. AU - Coates, R. J. AU - Williams, J. E. AU - Liff, J. M. AU - Greenberg, R. S. AU - McGrady, G. A. AU - Avery, B. Y. AU - Blumenthal, D. S. DA - Jul-Aug IS - 4 N1 - 36 1641433 PY - 1992 SN - 0033-3549 SP - 381-388 ST - Cancer Screening Intervention among Black-Women in Inner-City Atlanta - Design of a Study T2 - Public Health Reports TI - Cancer Screening Intervention among Black-Women in Inner-City Atlanta - Design of a Study VL - 107 ID - 2744 ER - TY - JOUR AB - Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. STUDY DESIGN:: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States. © 2011 by Lippincott Williams & Wilkins. AD - Minnesota Surgical Outcomes Research Center, Department of Surgery, University of Minnesota and Minneapolis VAMC, 420 Delaware Street SE, Minneapolis, MN 55455, United States AU - Al-Refaie, W. B. AU - Vickers, S. M. AU - Zhong, W. AU - Parsons, H. AU - Rothenberger, D. AU - Habermann, E. B. DB - Scopus DO - 10.1097/SLA.0b013e31822a7047 IS - 3 M3 - Conference Paper N1 - Cited By :59 Export Date: 22 March 2021 PY - 2011 SP - 438-443 ST - Cancer trials versus the real world in the United States T2 - Annals of Surgery TI - Cancer trials versus the real world in the United States UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052286823&doi=10.1097%2fSLA.0b013e31822a7047&partnerID=40&md5=90fd7b80fbdf1aaa3cb26028325a4863 VL - 254 ID - 2470 ER - TY - JOUR AB - Background: Federal policies have been implemented to mitigate underenrollment in cancer trials in the United States. We sought to identify patterns and predictors of enrollment patterns to cancer trials in a contemporary era using a real world setting. Study Design: The 2001-2008 California Cancer Registry was used to determine patterns and predictors of enrollment in clinical trials for stage 0 to IV solid organ malignant tumors. Multivariate techniques were used to identify predictors of enrollment in cancer protocols, controlling for covariates. Results: Less than a percent (0.64%) of patients enrolled in clinical trials (1566 of 244,528). Black patients were less likely than whites to enroll in trials (0.48% vs 0.67%, P < 0.05). On multivariate analysis, older persons (>65 years), early stage cancer, and those with lung or gastrointestinal cancers were less likely to be enrolled in cancer trials. Results were consistent when evaluated among only nonbreast cancer protocols. Though approaching significance, black, underinsured, and uninsured patients showed trends toward underenrollment. Conclusion: In addition to profoundly low overall cancer trial accrual, vast underrepresentation by age, cancer stage, and site continue to exist. The generalizability of these trials to a real world perspective remains an open question. Physicians, payers, the National Cancer Institute, and other stakeholders need to develop broader cancer trials to benefit the millions of patients with cancer in the United States. AN - WOS:000294252500005 AU - Al-Refaie, W. B. AU - Vickers, S. M. AU - Zhong, W. AU - Parsons, H. AU - Rothenberger, D. AU - Habermann, E. B. DA - Sep DO - 10.1097/SLA.0b013e31822a7047 IS - 3 N1 - 131st Annual Scientific Meeting of the American-Surgical-Association APR 11-16, 2011 Boca Raton, FL Amer Surg Assoc 21775882 PY - 2011 SN - 0003-4932 SP - 438-443 ST - Cancer Trials Versus the Real World in the United States T2 - Annals of Surgery TI - Cancer Trials Versus the Real World in the United States VL - 254 ID - 3086 ER - TY - JOUR AB - Background: Clinical trial participation among racial and ethnic minorities remains low despite national efforts. We sought to determine how participation in clinical trials by breast surgical oncology patients has changed over time and what characteristics are associated with participation. Methods: Women with breast cancer enrolled in National Cancer Institute-sponsored, cooperative-group trials from 2000 to 2012 and who underwent oncologic surgery (n = 17 125) were compared with trial-eligible women in the National Cancer Database diagnosed in 2000-2012 (n = 792 719). Race-specific trial participation was plotted over time by income and reported as a proportion of the combined cohorts. Factors associated with trial participation were estimated using logistic regression; we report odds ratios (ORs) with 95% confidence intervals (CIs). A P value less than .05 was considered statistically significant for all analyses. All tests were two-sided. Results: Participation declined across all groups over time because of a decrease in the scale and number of trials. In 2000-2003, Asian-Pacific Islander (7.17%), Hispanic (3.48%), and white (7.13%) patients from the highest income group had higher participation than their lower-income counterparts (Asian-Pacific Islander: 3.95%; Hispanic: 2.67%; white: 5.96%), but by 2008-2012, only high-income white patients participated more than lower-income whites (0.32% vs 0.25%, all P<.01). Black (OR = 0.80, 95% CI = 0.75 to 0.85) and Hispanic (OR = 0.84, 95% CI = 0.77 to 0.92) patients were less likely to participate than whites, but there were statistically significant interactions between income and race and ethnicity, with high-income black patients being approximately 50% less likely to participate than lower-income blacks (all P<.001). Conclusions: Multifaceted interventions addressing the intersectionality of race, ethnicity, and other patient characteristics are needed to address persistent disparities in trial participation among breast surgical oncology patients. AN - WOS:000608017100022 AU - Fayanju, O. M. AU - Ren, Y. AU - Thomas, S. M. AU - Greenup, R. A. AU - Hyslop, T. AU - Hwang, E. S. AU - Stewart, J. H. DA - Apr DO - 10.1093/jncics/pkz103 IS - 2 N1 - pkz103 32211583 PY - 2020 ST - A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients T2 - Jnci Cancer Spectrum TI - A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients VL - 4 ID - 2786 ER - TY - JOUR AB - Background: Clinical trial participation among racial and ethnic minorities remains low despite national efforts. We sought to determine how participation in clinical trials by breast surgical oncology patients has changed over time and what characteristics are associated with participation. Methods:Women with breast cancer enrolled in National Cancer Institute-sponsored, cooperative-group trials from 2000 to 2012 and who underwent oncologic surgery (n 17 125) were compared with trial-eligible women in the National Cancer Database diagnosed in 2000-2012 (n 792 719). Race-specific trial participation was plotted over time by income and reported as a proportion of the combined cohorts. Factors associated with trial participation were estimated using logistic regression; we report odds ratios (ORs) with 95% confidence intervals (CIs). A P value less than .05 was considered statistically significant for all analyses. All tests were two-sided. Results: Participation declined across all groups over time because of a decrease in the scale and number of trials. In 2000- 2003, Asian-Pacific Islander (7.17%), Hispanic (3.48%), and white (7.13%) patients from the highest income group had higher participation than their lower-income counterparts (Asian-Pacific Islander: 3.95%; Hispanic: 2.67%; white: 5.96%), but by 2008- 2012, only high-income white patients participated more than lower-income whites (0.32% vs 0.25%, all P<.01). Black (OR 0.80, 95% CI 0.75 to 0.85) and Hispanic (OR 0.84, 95% CI 0.77 to 0.92) patients were less likely to participate than whites, but there were statistically significant interactions between income and race and ethnicity, with high-income black patients being approximately 50% less likely to participate than lower-income blacks (all P<.001). Conclusions: Multifaceted interventions addressing the intersectionality of race, ethnicity, and other patient characteristics are needed to address persistent disparities in trial participation among breast surgical oncology patients. AD - O.M. Fayanju, Department of Surgery, Duke University Medical Center 3513, Durham, NC, United States AU - Fayanju, O. M. AU - Ren, Y. AU - Thomas, S. M. AU - Greenup, R. A. AU - Hyslop, T. AU - Shelley Hwang, E. AU - Stewart, J. H. DB - Embase DO - 10.1093/JNCICS/PKZ103 IS - 2 KW - adult article Black person breast cancer cancer surgery case control study Caucasian controlled clinical trial controlled study ethnicity female highest income group Hispanic human national health organization Pacific Islander surgical oncology LA - English M3 - Article N1 - L2011008681 2021-02-23 PY - 2021 SN - 2515-5091 ST - A case-control study examining disparities in clinical trial participation among breast surgical oncology patients T2 - JNCI Cancer Spectrum TI - A case-control study examining disparities in clinical trial participation among breast surgical oncology patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2011008681&from=export http://dx.doi.org/10.1093/JNCICS/PKZ103 VL - 4 ID - 768 ER - TY - JOUR AB - Background: Clinical trial participation among racial and ethnic minorities remains low despite national efforts. We sought to determine how participation in clinical trials by breast surgical oncology patients has changed over time and what characteristics are associated with participation. Methods:Women with breast cancer enrolled in National Cancer Institute-sponsored, cooperative-group trials from 2000 to 2012 and who underwent oncologic surgery (n 17 125) were compared with trial-eligible women in the National Cancer Database diagnosed in 2000-2012 (n 792 719). Race-specific trial participation was plotted over time by income and reported as a proportion of the combined cohorts. Factors associated with trial participation were estimated using logistic regression; we report odds ratios (ORs) with 95% confidence intervals (CIs). A P value less than .05 was considered statistically significant for all analyses. All tests were two-sided. Results: Participation declined across all groups over time because of a decrease in the scale and number of trials. In 2000- 2003, Asian-Pacific Islander (7.17%), Hispanic (3.48%), and white (7.13%) patients from the highest income group had higher participation than their lower-income counterparts (Asian-Pacific Islander: 3.95%; Hispanic: 2.67%; white: 5.96%), but by 2008- 2012, only high-income white patients participated more than lower-income whites (0.32% vs 0.25%, all P<.01). Black (OR 0.80, 95% CI 0.75 to 0.85) and Hispanic (OR 0.84, 95% CI 0.77 to 0.92) patients were less likely to participate than whites, but there were statistically significant interactions between income and race and ethnicity, with high-income black patients being approximately 50% less likely to participate than lower-income blacks (all P<.001). Conclusions: Multifaceted interventions addressing the intersectionality of race, ethnicity, and other patient characteristics are needed to address persistent disparities in trial participation among breast surgical oncology patients. © The Author(s) 2020. AD - Department of Surgery, Duke University, School of Medicine, Durham, NC, United States Women's Cancer Program, Duke Cancer Institute, Durham, NC, United States Department of Population Health Sciences, Duke University, School of Medicine, Durham, NC, United States Duke Forge, Duke University, Durham, NC, United States Department of Surgery, Durham VA Medical Center, Durham, NC, United States Biostatistics Shared Resource, Duke Cancer Institute, Durham, NC, United States Department of Biostatistics and Bioinformatics, Duke University, School of Medicine, Durham, NC, United States Department of Surgery, University of Illinois at Chicago, Chicago, IL, United States Department of Surgery, University of Illinois Cancer Center, Chicago, IL, United States AU - Fayanju, O. M. AU - Ren, Y. AU - Thomas, S. M. AU - Greenup, R. A. AU - Hyslop, T. AU - Shelley Hwang, E. AU - Stewart, J. H. Iv C7 - pkz103 DB - Scopus DO - 10.1093/JNCICS/PKZ103 IS - 2 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2021 ST - A case-control study examining disparities in clinical trial participation among breast surgical oncology patients T2 - JNCI Cancer Spectrum TI - A case-control study examining disparities in clinical trial participation among breast surgical oncology patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089017883&doi=10.1093%2fJNCICS%2fPKZ103&partnerID=40&md5=33bd5fbccbed991d39cf18f6f7c36ada VL - 4 ID - 2162 ER - TY - JOUR AB - Engaging family members in an intervention to prevent breast and cervical cancer can be a way to reach underserved women; however, little is known about whether family member recruitment reaches at-risk women. This study reports the kin relationship and risk characteristics of family members who chose to participate in the Kin Keeper(SM) cancer prevention intervention, delivered by community health workers (CHWs) via existing community programs. African American, Latina, and Arab family members reported risk factors for inadequate screening, including comorbid health conditions and inadequate breast or cervical cancer literacy. CHW programs can be leveraged to reach underserved families with cancer preventive interventions. AU - Roman, L. A. AU - Zambrana, R. E. AU - Ford, S. AU - Meghea, C. AU - Williams, K. P. DB - Medline DO - 10.5888/pcd13.160114 KW - adult attitude to health breast tumor controlled study early cancer diagnosis education ethnic group family female health auxiliary human mass screening Michigan middle aged neoplasm patient attitude randomized controlled trial statistics and numerical data uterine cervix tumor LA - English M3 - Article N1 - L618592995 2017-10-10 PY - 2016 SN - 1545-1151 SP - E130 ST - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention T2 - Preventing chronic disease TI - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618592995&from=export http://dx.doi.org/10.5888/pcd13.160114 VL - 13 ID - 964 ER - TY - JOUR AD - Michigan State University, East Lansing, Michigan University of Maryland, College Park, Maryland PhD, Nursing Distinguished Professor of Women's Health, College of Nursing, The Ohio State University, 362 Newton Hall, 1585 Neil Ave, Columbus, OH 43210 AN - 118226384. Language: English. Entry Date: 20170929. Revision Date: 20200708. Publication Type: Article. Journal Subset: Blind Peer Reviewed AU - Roman, Lee Anne AU - Zambrana, Ruth Enid AU - Ford, Sabrina AU - Meghea, Cristian AU - Williams, Karen Patricia DB - CINAHL Complete DO - 10.5888/pcd13.160114 DP - EBSCOhost N1 - Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; Public Health; USA. NLM UID: 101205018. PY - 2016 SN - 1545-1151 SP - 1-5 ST - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention T2 - Preventing Chronic Disease TI - Casting a Wider Net: Engaging Community Health Worker Clients and Their Families in Cancer Prevention UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118226384&site=ehost-live&scope=site VL - 13 ID - 1876 ER - TY - JOUR AB - Engaging family members in an intervention to prevent breast and cervical cancer can be a way to reach underserved women; however, little is known about whether family member recruitment reachesat-riskwomen. This study reports the kin relationship and risk characteristics of family members who chose to participate in the Kin KeeperSM cancer prevention intervention, delivered by community health workers (CHWs) via existing community programs. African American, Latina, and Arab family members reported risk factors for inadequate screening, including comorbid health conditions and inadequate breast or cervical cancer literacy. CHW programs can be leveraged to reach underserved families with cancer preventive interventions. AD - Nursing Distinguished Professor of Women's Health, College of Nursing, The Ohio State University, 362 Newton Hall, 1585 Neil Ave, Columbus, OH 43210, United States University of Maryland, College Park, MD, United States AU - Roman, L. A. AU - Zambrana, R. E. AU - Ford, S. AU - Meghea, C. AU - Williams, K. P. C7 - 160114 DB - Scopus DO - 10.5888/pcd13.160114 IS - 9 M3 - Article N1 - Export Date: 22 March 2021 PY - 2016 ST - Casting a wider net: Engaging community health worker clients and their families in cancer prevention T2 - Preventing Chronic Disease TI - Casting a wider net: Engaging community health worker clients and their families in cancer prevention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994140341&doi=10.5888%2fpcd13.160114&partnerID=40&md5=f2e80c73c79a2fdb543cdd3fa92dbb8d VL - 13 ID - 2354 ER - TY - JOUR AB - We describe the use of an online patient portal to recruit and enroll primary care patients in a randomized trial testing the effectiveness of a colorectal cancer (CRC) screening decision support program. We use multiple logistic regression to identify patient characteristics associated with trial recruitment, enrollment, and engagement. We found that compared to Whites, Blacks had lower odds of viewing the portal message (OR = 0.46, 95% CI = 0.37-0.57), opening the attached link containing the study material (OR = 0.75, 95% CI = 0.62-0.92), and consenting to participate in the trial (OR = 0.85, 95% CI = 0.67-0.93). We also found that compared to Whites, Asians had lower odds of viewing the portal message (OR = 0.53, 95% CI = 0.33-0.64), opening the attached link containing the study material (OR = 0.76, 95% CI = 0.54-0.97), consenting to participate in the trial (OR = 0.68, 95% CI = 0.53-0.95), and completing the trial's baseline questionnaire (OR = 0.59, 95% CI = 0.36-0.90). While portals offer an opportunity to mitigate human bias in trial invitations, because of racial disparities - not only in who has a portal account, but in how they interact with trial recruitment and enrollment material within the portal - using portals alone for trial recruitment may generate study samples that are not racially diverse. AD - A.A. Tabriz, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 016 Beard Hall, 301 Pharmacy Lane, Chapel Hill, NC, United States AU - Tabriz, A. A. AU - Fleming, P. J. AU - Shin, Y. AU - Resnicow, K. AU - Jones, R. M. AU - Flocke, S. A. AU - Shires, D. A. AU - Hawley, S. T. AU - Willens, D. AU - Lafata, J. E. DB - Embase Medline DO - 10.1093/jamia/ocz157 IS - 12 KW - adult article Black person cancer screening Caucasian colorectal cancer decision support system female human major clinical study male medical record middle aged online system patient information primary medical care questionnaire LA - English M3 - Article N1 - L630179769 2019-12-19 2019-12-31 PY - 2019 SN - 1527-974X 1067-5027 SP - 1637-1644 ST - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials T2 - Journal of the American Medical Informatics Association TI - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630179769&from=export http://dx.doi.org/10.1093/jamia/ocz157 VL - 26 ID - 833 ER - TY - JOUR AB - We describe the use of an online patient portal to recruit and enroll primary care patients in a randomized trial testing the effectiveness of a colorectal cancer (CRC) screening decision support program. We use multiple logistic regression to identify patient characteristics associated with trial recruitment, enrollment, and engagement. We found that compared to Whites, Blacks had lower odds of viewing the portal message (OR = 0.46, 95% CI = 0.37-0.57), opening the attached link containing the study material (OR = 0.75, 95% CI = 0.62-0.92), and consenting to participate in the trial (OR = 0.85, 95% CI = 0.67-0.93). We also found that compared to Whites, Asians had lower odds of viewing the portal message (OR = 0.53, 95% CI = 0.33-0.64), opening the attached link containing the study material (OR = 0.76, 95% CI = 0.54-0.97), consenting to participate in the trial (OR = 0.68, 95% CI = 0.53-0.95), and completing the trial's baseline questionnaire (OR = 0.59, 95% CI = 0.36-0.90). While portals offer an opportunity to mitigate human bias in trial invitations, because of racial disparities - not only in who has a portal account, but in how they interact with trial recruitment and enrollment material within the portal - using portals alone for trial recruitment may generate study samples that are not racially diverse. © 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 016 Beard Hall, 301 Pharmacy Lane, Chapel Hill, NC 27599-7355, United States Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, United States Department of Epidemiology and Biostatistics, College of Public Health and Fox Chase Cancer Center, Temple University, Philadelphia, PA, United States Department of Family Medicine, Oregon Health Sciences University, Portland, OR, United States School of Social Work, Michigan State University, East Lansing, MI, United States Department of Medicine, Center for Health Communications Research, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, MI, United States Henry Ford Health System, Detroit, MI, United States UNC Lineberger Comprehensive Cancer Center, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States AU - Tabriz, A. A. AU - Fleming, P. J. AU - Shin, Y. AU - Resnicow, K. AU - Jones, R. M. AU - Flocke, S. A. AU - Shires, D. A. AU - Hawley, S. T. AU - Willens, D. AU - Lafata, J. E. DB - Scopus DO - 10.1093/jamia/ocz157 IS - 12 KW - colorectal cancer screening electronic health record health disparities patient portal pragmatic clinical trial M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2019 SP - 1637-1644 ST - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials T2 - Journal of the American Medical Informatics Association TI - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075093981&doi=10.1093%2fjamia%2focz157&partnerID=40&md5=b3db77fb7ac158470cd03714dfe372ff VL - 26 ID - 2217 ER - TY - JOUR AB - We describe the use of an online patient portal to recruit and enroll primary care patients in a randomized trial testing the effectiveness of a colorectal cancer (CRC) screening decision support program. We use multiple logistic regression to identify patient characteristics associated with trial recruitment, enrollment, and engagement. We found that compared to Whites, Blacks had lower odds of viewing the portal message (OR = 0.46, 95% CI = 0.37-0.57), opening the attached link containing the study material (OR = 0.75, 95% CI = 0.62-0.92), and consenting to participate in the trial (OR = 0.85, 95% CI = 0.67-0.93). We also found that compared to Whites, Asians had lower odds of viewing the portal message (OR = 0.53, 95% CI = 0.33-0.64), opening the attached link containing the study material (OR = 0.76, 95% CI = 0.54-0.97), consenting to participate in the trial (OR = 0.68, 95% CI = 0.53-0.95), and completing the trial's baseline questionnaire (OR = 0.59, 95% CI = 0.36-0.90). While portals offer an opportunity to mitigate human bias in trial invitations, because of racial disparities-not only in who has a portal account, but in how they interact with trial recruitment and enrollment material within the portal-using portals alone for trial recruitment may generate study samples that are not racially diverse. AN - WOS:000515125300025 AU - Tabriz, A. A. AU - Fleming, P. J. AU - Shin, Y. AU - Resnicow, K. AU - Jones, R. M. AU - Flocke, S. A. AU - Shires, D. A. AU - Hawley, S. T. AU - Willens, D. AU - Lafata, J. E. DA - Dec DO - 10.1093/jamia/ocz157 IS - 12 N1 - 31532482 PY - 2019 SN - 1067-5027 SP - 1637-1644 ST - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials T2 - Journal of the American Medical Informatics Association TI - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials VL - 26 ID - 2804 ER - TY - JOUR AB - We describe the use of an online patient portal to recruit and enroll primary care patients in a randomized trial testing the effectiveness of a colorectal cancer (CRC) screening decision support program. We use multiple logistic regression to identify patient characteristics associated with trial recruitment, enrollment, and engagement. We found that compared to Whites, Blacks had lower odds of viewing the portal message (OR = 0.46, 95% CI = 0.37-0.57), opening the attached link containing the study material (OR = 0.75, 95% CI = 0.62-0.92), and consenting to participate in the trial (OR = 0.85, 95% CI = 0.67-0.93). We also found that compared to Whites, Asians had lower odds of viewing the portal message (OR = 0.53, 95% CI = 0.33-0.64), opening the attached link containing the study material (OR = 0.76, 95% CI = 0.54-0.97), consenting to participate in the trial (OR = 0.68, 95% CI = 0.53-0.95), and completing the trial's baseline questionnaire (OR = 0.59, 95% CI = 0.36-0.90). While portals offer an opportunity to mitigate human bias in trial invitations, because of racial disparities-not only in who has a portal account, but in how they interact with trial recruitment and enrollment material within the portal-using portals alone for trial recruitment may generate study samples that are not racially diverse. AD - Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia, USA Department of Health Behavior & Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA Department of Epidemiology and Biostatistics, College of Public Health and Fox Chase Cancer Center, Temple University, Philadelphia, Pennsylvania, USA Department of Family Medicine, Oregon Health Sciences University, Portland, Oregon, USA School of Social Work, Michigan State University, East Lansing, Michigan, USA Department of Medicine, Center for Health Communications Research, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, Michigan, USA Henry Ford Health System, Detroit, Michigan, USA UNC Lineberger Comprehensive Cancer Center, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA AN - 139822574. Language: English. Entry Date: 20200517. Revision Date: 20210223. Publication Type: journal article AU - Tabriz, Amir Alishahi AU - Fleming, Patrice Jordan AU - Shin, Yongyun AU - Resnicow, Ken AU - Jones, Resa M. AU - Flocke, Susan A. AU - Shires, Deirdre A. AU - Hawley, Sarah T. AU - Willens, David AU - Lafata, Jennifer Elston AU - Alishahi Tabriz, Amir DB - CINAHL Complete DO - 10.1093/jamia/ocz157 DP - EBSCOhost IS - 12 KW - Colorectal Neoplasms -- Diagnosis Patient Selection Early Detection of Cancer Female Randomized Controlled Trials Health Status Disparities Primary Health Care Human Middle Age Logistic Regression Patient Attitudes -- Ethnology Colorectal Neoplasms -- Ethnology Selection Bias Population Male Aged Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Blind Peer Reviewed; Computer/Information Science; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: R01 CA197205/CA/NCI NIH HHS/United States. NLM UID: 9430800. PMID: NLM31532482. PY - 2019 SN - 1067-5027 SP - 1637-1644 ST - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials T2 - Journal of the American Medical Informatics Association TI - Challenges and opportunities using online portals to recruit diverse patients to behavioral trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139822574&site=ehost-live&scope=site VL - 26 ID - 1878 ER - TY - JOUR AB - Background: African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue by investigating the germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Women were tested for these mutations using a large panel of breast cancer susceptibility genes. In this analysis, we discuss the challenges encountered in recruiting African-American women from an existing biorepository to participate in this study. Methods: We attempted to contact 965 African-American women with a personal and/or family history of breast cancer who participated in Spit for the Cure (SFTC) between 2007 and 2013 and provided consent to be recontacted. The SFTC participants were invited by telephone and email to participate in the genetic study. Enrollment required completion of a phone interview to obtain a family and medical history and return of a signed consent form. Results: Among eligible SFTC participants, 39.6% (382/965) were able to be contacted with the phone numbers and email addresses they provided. Of these, 174 (45.5%) completed a phone interview and returned a signed consent form. Others were not able to be contacted (n=583), declined to participate (n=57), did not keep phone interview appointments (n=82), completed the phone interview but never returned a signed consent (n=54), were deceased (n=13), or were too confused to consent to participate (n=2). Conclusions: Recruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced. AD - K.K. Zorn, Division of Gynecologic Oncology, College of Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St. Slot 793, Little Rock, AR, United States AU - Compadre, A. J. AU - Simonson, M. E. AU - Gray, K. AU - Runnells, G. AU - Kadlubar, S. AU - Zorn, K. K. DB - Embase DO - 10.1186/s13053-018-0091-3 IS - 1 KW - adult African American aged Arkansas article biobank breast cancer cancer genetics family history female genetic analysis germline mutation human human experiment informed consent interview medical history patient participation United States LA - English M3 - Article N1 - L621775762 2018-05-01 2018-05-08 PY - 2018 SN - 1897-4287 1731-2302 ST - Challenges in recruiting African-American women for a breast cancer genetics study T2 - Hereditary Cancer in Clinical Practice TI - Challenges in recruiting African-American women for a breast cancer genetics study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621775762&from=export http://dx.doi.org/10.1186/s13053-018-0091-3 VL - 16 ID - 900 ER - TY - JOUR AB - Background: African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue by investigating the germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Women were tested for these mutations using a large panel of breast cancer susceptibility genes. In this analysis, we discuss the challenges encountered in recruiting African-American women from an existing biorepository to participate in this study. Methods: We attempted to contact 965 African-American women with a personal and/or family history of breast cancer who participated in Spit for the Cure (SFTC) between 2007 and 2013 and provided consent to be recontacted. The SFTC participants were invited by telephone and email to participate in the genetic study. Enrollment required completion of a phone interview to obtain a family and medical history and return of a signed consent form. Results: Among eligible SFTC participants, 39.6% (382/965) were able to be contacted with the phone numbers and email addresses they provided. Of these, 174 (45.5%) completed a phone interview and returned a signed consent form. Others were not able to be contacted (n=583), declined to participate (n=57), did not keep phone interview appointments (n=82), completed the phone interview but never returned a signed consent (n=54), were deceased (n=13), or were too confused to consent to participate (n=2). Conclusions: Recruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced. © 2018 The Author(s). AD - University of Arkansas for Medical Sciences, Division of Gynecologic Oncology, College of Medicine, 4301 W Markham St. Slot 793, Little Rock, AR 72205, United States University of Arkansas for Medical Sciences, Division of Medical Genetics, College of Medicine, 4301 W Markham St., Little Rock, AR 72205, United States AU - Compadre, A. J. AU - Simonson, M. E. AU - Gray, K. AU - Runnells, G. AU - Kadlubar, S. AU - Zorn, K. K. C7 - 8 DB - Scopus DO - 10.1186/s13053-018-0091-3 IS - 1 KW - African American Biorepository Hereditary breast cancer Subject recruitment M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2018 ST - Challenges in recruiting African-American women for a breast cancer genetics study T2 - Hereditary Cancer in Clinical Practice TI - Challenges in recruiting African-American women for a breast cancer genetics study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045877716&doi=10.1186%2fs13053-018-0091-3&partnerID=40&md5=6c502d6fa0029a28645bd143c8adf743 VL - 16 ID - 2274 ER - TY - JOUR AB - Background: African-American women, especially in the southern United States, are underrepresented in cancer genetics research. A study was designed to address this issue by investigating the germline mutation rate in African-American women in Arkansas with a personal and/or family history of breast cancer. Women were tested for these mutations using a large panel of breast cancer susceptibility genes. In this analysis, we discuss the challenges encountered in recruiting African-American women from an existing biorepository to participate in this study. Methods: We attempted to contact 965 African-American women with a personal and/or family history of breast cancer who participated in Spit for the Cure (SFTC) between 2007 and 2013 and provided consent to be recontacted. The SFTC participants were invited by telephone and email to participate in the genetic study. Enrollment required completion of a phone interview to obtain a family and medical history and return of a signed consent form. Results: Among eligible SFTC participants, 39.6% (382/965) were able to be contacted with the phone numbers and email addresses they provided. Of these, 174 (45.5%) completed a phone interview and returned a signed consent form. Others were not able to be contacted (n = 583), declined to participate (n = 57), did not keep phone interview appointments (n = 82), completed the phone interview but never returned a signed consent (n = 54), were deceased (n = 13), or were too confused to consent to participate (n = 2). Conclusions: Recruiting African-American women into our breast cancer genetics study proved challenging primarily due to difficulty establishing contact with potential participants. Given their prior participation in breast cancer research, we anticipated that this would be a highly motivated population. Indeed, when we were able to contact SFTC participants, only 14.9% declined to participate in our study. Innovative communication, retention, and recruitment strategies are needed in future studies to address the recruitment challenges we faced. AN - WOS:000431380900001 AU - Compadre, A. J. AU - Simonson, M. E. AU - Gray, K. AU - Runnells, G. AU - Kadlubar, S. AU - Zorn, K. K. DA - Apr DO - 10.1186/s13053-018-0091-3 N1 - 8 29760829 PY - 2018 SN - 1731-2302 ST - Challenges in recruiting African-American women for a breast cancer genetics study T2 - Hereditary Cancer in Clinical Practice TI - Challenges in recruiting African-American women for a breast cancer genetics study VL - 16 ID - 2864 ER - TY - JOUR AB - Objective: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. Method: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40-80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. Results: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6-12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. Conclusion: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior. © 2011 American Psychological Association. AD - B.A. Glenn, Division of Cancer Prevention and Control Research, School of Public Health and Jonsson Comprehensive Cancer Center, University of California and Los Angeles, 650 Charles Young Dr. South, A2-125 CHS, Los Angeles, CA 90095-6900, United States AU - Glenn, B. A. AU - Herrmann, A. K. AU - Crespi, C. M. AU - Mojica, C. M. AU - Chang, L. C. AU - Maxwell, A. E. AU - Bastani, R. DB - Embase Medline DO - 10.1037/a0024288 IS - 4 KW - adult African American article cancer registry cancer risk cancer screening child clinical evaluation clinical examination colorectal cancer controlled study data analysis data collection method ethnic group female follow up health behavior human hypothesis illness trajectory major clinical study male randomized controlled trial relative sample self report United States LA - English M3 - Article N1 - L362175494 2011-07-27 2011-07-29 PY - 2011 SN - 0278-6133 1930-7810 SP - 481-491 ST - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial T2 - Health Psychology TI - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362175494&from=export http://dx.doi.org/10.1037/a0024288 VL - 30 ID - 1135 ER - TY - JOUR AB - Objective: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. Method: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40–80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. Results: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6–12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. Conclusion: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Glenn, Beth A., Division of Cancer Prevention & Control Research, School of Public Health & Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 650 Charles Young Dr. South, A2-125 CHS, Los Angeles, CA, US, 90095-6900 AN - 2011-13978-005 AU - Glenn, Beth A. AU - Herrmann, Alison K. AU - Crespi, Catherine M. AU - Mojica, Cynthia M. AU - Chang, L. Cindy AU - Maxwell, Annette E. AU - Bastani, Roshan DB - psyh DO - 10.1037/a0024288 DP - EBSCOhost IS - 4 KW - cancer screening colorectal cancer health behavior perceived risk theory Adult Adult Children Aged Aged, 80 and over California Colorectal Neoplasms Early Detection of Cancer Female Health Knowledge, Attitudes, Practice Humans Male Middle Aged Registries Risk Assessment Self-Assessment Siblings Colon Disorders Neoplasms Risk Perception Theories N1 - Division of Cancer Prevention & Control Research, School of Public Health & Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, US. Other Publishers: Lawrence Erlbaum Associates. Release Date: 20110711. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Colon Disorders; Health Behavior; Neoplasms. Minor Descriptor: Risk Perception; Theories. Classification: Cancer (3293); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: National Cancer Institute’s Health Information National Trends Survey. Methodology: Empirical Study; Followup Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Jul, 2011. Copyright Statement: American Psychological Association. 2011. PY - 2011 SN - 0278-6133 1930-7810 SP - 481-491 ST - Changes in risk perceptions in relation to self-reported colorectal cancer screening among first-degree relatives of colorectal cancer cases enrolled in a randomized trial T2 - Health Psychology TI - Changes in risk perceptions in relation to self-reported colorectal cancer screening among first-degree relatives of colorectal cancer cases enrolled in a randomized trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-13978-005&site=ehost-live&scope=site bglenn@ucla.edu VL - 30 ID - 1731 ER - TY - JOUR AB - Objective: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. Method: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40-80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. Results: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6-12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. Conclusion: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior. © 2011 American Psychological Association. AD - Division of Cancer Prevention and Control Research, School of Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, United States Institute for Health Promotion Research, Department of Epidemiology and Biostatistics and School of Medicine, University of Texas Health Science Center at San Antonio, United States AU - Glenn, B. A. AU - Herrmann, A. K. AU - Crespi, C. M. AU - Mojica, C. M. AU - Chang, L. C. AU - Maxwell, A. E. AU - Bastani, R. DB - Scopus DO - 10.1037/a0024288 IS - 4 KW - Cancer screening Colorectal cancer Health behavior Perceived risk Theory M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2011 SP - 481-491 ST - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial T2 - Health Psychology TI - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960490376&doi=10.1037%2fa0024288&partnerID=40&md5=249d413428d50276291ba39745bf271b VL - 30 ID - 2473 ER - TY - JOUR AB - Objective: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. Method: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40-80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. Results: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6-12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. Conclusion: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior. AN - WOS:000292809100013 AU - Glenn, B. A. AU - Herrmann, A. K. AU - Crespi, C. M. AU - Mojica, C. M. AU - Chang, L. C. AU - Maxwell, A. E. AU - Bastani, R. DA - Jul DO - 10.1037/a0024288 IS - 4 N1 - 21744967 PY - 2011 SN - 0278-6133 SP - 481-491 ST - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial T2 - Health Psychology TI - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial VL - 30 ID - 3091 ER - TY - JOUR AB - Objective: This secondary data analysis was conducted to evaluate the applicability of the Risk Reappraisal Hypothesis, which has been proposed to explain the influence of performing a health behavior on perceived risk. Data were collected in the context of a randomized trial, which found that an individually tailored, multicomponent intervention was successful in increasing colorectal cancer (CRC) screening among first-degree relatives of CRC cases. Method: The ethnically diverse study sample (N = 841; 29% Latino, 21% African American, 20% Asian) consisted of adult siblings and children (40-80 years) of CRC cases, identified through the California Cancer Registry. Data were collected at baseline and at 6- and 12-month follow-up. Changes in self-reported risk perception (perceived likelihood of developing CRC) were examined over the study period in relation to study condition and screening status. Results: Greater increases in perceived risk were observed among intervention versus control-group participants over the study period, but increases were limited to intervention participants who had not been screened. We also examined trajectories of perceived risk in relation to timing of screening receipt (e.g., before 6 months, 6-12 months, never). Continued upward shifts in risk were observed during the study period among intervention participants not screened during the study. In contrast, participants screened by 6 months displayed a reduction or leveling off in perceived risk between 6- and 12-month follow-up. Conclusion: Results provide support for the applicability of the Risk Reappraisal Hypothesis within a high-risk sample enrolled in a CRC screening promotion trial. Future research is needed to explore the impact of short-term risk reductions on future CRC screening behavior. AD - Division of Cancer Prevention & Control Research, School of Public Health & Jonsson Comprehensive Cancer Center, University of California, Los Angeles Institute for Health Promotion Research, Department of Epidemiology and Biostatistics, School of Medicine, University of Texas Health Science Center at San Antonio AN - 108243365. Language: English. Entry Date: 20110819. Revision Date: 20200708. Publication Type: Journal Article AU - Glenn, Beth A. AU - Herrmann, Alison K. AU - Crespi, Catherine M. AU - Mojica, Cynthia M. AU - Chang, L. Cindy AU - Maxwell, Annette F. AU - Bastani, Roshan DB - CINAHL Complete DO - 10.1037/a0024288 DP - EBSCOhost IS - 4 KW - Attitude to Risk Colorectal Neoplasms -- Prevention and Control Cancer Screening Family -- Psychosocial Factors Health Behavior Human Self Report Secondary Analysis Family Attitudes Adult Middle Age Aged Aged, 80 and Over Interviews California Male Female Descriptive Statistics Chi Square Test Odds Ratio P-Value Confidence Intervals Prospective Studies Randomized Controlled Trials N1 - equations & formulas; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care; Psychiatry/Psychology. NLM UID: 8211523. PMID: NLM21744967. PY - 2011 SN - 0278-6133 SP - 481-491 ST - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial T2 - Health Psychology TI - Changes in Risk Perceptions in Relation to Self-Reported Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Cases Enrolled in a Randomized Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108243365&site=ehost-live&scope=site VL - 30 ID - 1880 ER - TY - JOUR AB - We describe here the results of the final 8 years of geographical and temporal data of a 33-year study of the cancer experience of 12.8 million man-years of black miners working on the gold fields of South Africa over the period 1964-96. These workers were recruited from 15 territories, the major areas during the most recent period being Lesotho (26.8%), Transkei (21.5%) and Mozambique (15%). The earliest analyses, 1964-71 and 1972-79, showed hepatocellular and oesophageal cancers to be the most frequent cancers. The final analysis, for 1989-96, however, shows marked temporal changes in the relative position of four cancers or grouped malignancies: respiratory cancer up by 236%, hepatocellular carcinoma down to 32%, oesophageal holding steady, and lymphatic system cancers up by 420%, almost certainly because of association with HIV/AIDS infection. Significant geographical variations occurring between the home areas of the miners are important, as mining operations have little to do with the cancers that develop. The causes are essentially socio-environmental rather than occupational, and this means that the rates of the major cancers in the miners are surrogate measures of the same cancers in the home areas. © 2003 Cancer Research UK. AD - Sch. of Geogr./Environ. Studies, University of Tasmania, Hobart, Tasmania, Australia Sch. of Anim., Plant/Environ. Sci., University of the Witwatersrand, Johannesburg, South Africa School of Mathematics and Physics, University of Tasmania, Hobart, Tasmania, Australia Sch. of Geogr./Environ. Studies, University of Tasmania, GPO Box 252C, Hobart, Tasmania 7001, Australia AU - McGlashan, N. D. AU - Harington, J. S. AU - Chelkowska, E. DB - Scopus DO - 10.1038/sj.bjc.6600841 IS - 9 KW - Black gold miners South Africa M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2003 SP - 1361-1369 ST - Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964-1996 T2 - British Journal of Cancer TI - Changes in the geographical and temporal patterns of cancer incidence among black gold miners working in South Africa, 1964-1996 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038485535&doi=10.1038%2fsj.bjc.6600841&partnerID=40&md5=fbb55642ecc24d520074cb84490865ab VL - 88 ID - 2614 ER - TY - JOUR AB - Background Black men (BM) are statistically more likely to experience aggressive cases of prostate cancer (CaP)compared to other racial groups, but are less likely to enroll in clinical trials. Several barriers have been documentedas impacting the participation of BM in clinical trials. To address these barriers, there is need for unique approachesto identify successful strategies that will facilitate the implementation of effective interventions. The overall goal ofthis study is to develop a tailored communication strategy for a CaP intervention trial, the MiCaP Research DigestTrial. Specifically, the primary objective was to identify the best intervention trial recruitment channels and locationsfor US‐born BM (USBM), African‐born BM (ABBM), and Caribbean‐born BM (CBBM). Methods The MiCaPResearch Digest Trial uses a randomized waitlist research design to evaluate the effectiveness of disseminatingCaP scientific discoveries for public health and community applications. It is an ongoing trial, which started in 2017.The current study compared two channels (newspaper and radio) and four locations (churches, barber shops,community outreach events) relative to their effectiveness in recruiting BM for the trial. Study location was OrangeCounty (FL). Recruitment efforts included newspaper stories about the study, study ad in newspaper, study ad onradio, information about study at community events and distribution of study flyers at targeted locations. Assessmentfocused on the following for the recruitment channels and locations: (1) reach, which was operationalized as thenumber of BM reached; and (2) impact, operationalized as the number of BM effectively pre‐screened for the Trial. Results The study period is from May to July, 2019. Results presented are for data collected up to June 30, 2019.The reach for BM were: 30 community locations for newspaper; 27,000 people every week from the radio; 130attendees for church events; an average of 12 customers per day for barber shops; and close to 1,200 attendeescombined for the community events. The highest impact (uptake of the intervention trial) was from communityevents, with 8 BM recruited (6 USBM and 2 CBBM). One USBM was recruited through the newspaper and oneUSBBM through radio. There was no recruitment from church or the barbershop. Also, no ABBM has been recruitedso far. Conclusion The reach for intervention trials does not necessarily translate to impact. Although the reach washighest for the radio, uptake of the intervention trial was highest for the community events. It was not surprising thatthe intervention trials uptake was highest for USBM. While 2 CBBM were recruited, recruiting ABBM continues to bechallenging. Engaging ethnically‐diverse BM through appropriate channels and locations is crucial to effectiveuptake of intervention trials. AN - CN-02213310 AU - Ingraham, M. AU - Odedina, F. AU - Fathi, P. AU - Walsh-Childers, K. AU - Ezeani, A. AU - Elhag, Y. DO - 10.1158/1538-7755.DISP19-A044 IS - 6 SUPPL 2 KW - *intervention study *prostate cancer Adult Caribbean Clinical article Comparative effectiveness Conference abstract Controlled study Hairdresser Human Male Public health Randomized controlled trial Religion M3 - Journal: Conference Abstract PY - 2020 ST - Channels and locations influencing the uptake of prostate cancer intervention trials by ethnically diverse Black men T2 - Cancer epidemiology biomarkers and prevention TI - Channels and locations influencing the uptake of prostate cancer intervention trials by ethnically diverse Black men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213310/full VL - 29 ID - 1512 ER - TY - JOUR AB - PURPOSE: We evaluated demographic and clinical characteristics associated with participation in a clinical trial testing the efficacy of an online tool to support breast cancer risk communication and decision support for risk mitigation to determine the generalizability of trial results. METHODS: Eligible women were members of Kaiser Permanente Washington aged 40-69 years with a recent normal screening mammogram, heterogeneously or extremely dense breasts and a calculated risk of > 1.67% based on the Breast Cancer Surveillance Consortium 5-year breast cancer risk model. Trial outcomes were chemoprevention and breast magnetic resonance imaging by 12-months post-baseline. Women were recruited via mail with phone follow-up using plain language materials notifying them of their density status and higher than average breast cancer risk. Multivariable logistic regression calculated independent odds ratios (ORs) for associations between demographic and clinical characteristics with trial participation. RESULTS: Of 2,569 eligible women contacted, 995 (38.7%) participated. Women with some college (OR = 1.99, 95% confidence interval [CI] 1.34-2.96) or college degree (OR = 3.35, 95% CI 2.29-4.90) were more likely to participate than high school-educated women. Race/ethnicity also was associated with participation (African-American OR = 0.50, 95% CI 0.29-0.87; Asian OR = 0.22, 95% CI 0.12-0.41). Multivariate adjusted ORs for family history of breast/ovarian cancer were not associated with trial participation. DISCUSSION: Use of plain language and potential access to a website providing personal breast cancer risk information and education were insufficient in achieving representative participation in a breast cancer prevention trial. Additional methods of targeting and tailoring, potentially facilitated by clinical and community outreach, are needed to facilitate equitable engagement for all women. AU - Wernli, K. J. AU - Bowles, E. A. AU - Knerr, S. AU - Leppig, K. A. AU - Ehrlich, K. AU - Gao, H. AU - Schwartz, M. D. AU - O'Neill, S. C. DB - Medline DO - 10.7812/TPP/19.205 KW - adult African American article breast cancer cancer prevention cancer risk chemoprophylaxis clinical evaluation clinical feature controlled study decision support system demography ethnicity family history female follow up high school human language major clinical study mammography nuclear magnetic resonance imaging ovary cancer race risk assessment Washington LA - English M3 - Article N1 - L634085997 2021-02-09 PY - 2020 SN - 1552-5775 SP - 1-4 ST - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial T2 - The Permanente journal TI - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634085997&from=export http://dx.doi.org/10.7812/TPP/19.205 VL - 24 ID - 778 ER - TY - JOUR AB - PURPOSE: We evaluated demographic and clinical characteristics associated with participation in a clinical trial testing the efficacy of an online tool to support breast cancer risk communication and decision support for risk mitigation to determine the generalizability of trial results. METHODS: Eligible women were members of Kaiser Permanente Washington aged 40-69 years with a recent normal screening mammogram, heterogeneously or extremely dense breasts and a calculated risk of > 1.67% based on the Breast Cancer Surveillance Consortium 5-year breast cancer risk model. Trial outcomes were chemoprevention and breast magnetic resonance imaging by 12-months post-baseline. Women were recruited via mail with phone follow-up using plain language materials notifying them of their density status and higher than average breast cancer risk. Multivariable logistic regression calculated independent odds ratios (ORs) for associations between demographic and clinical characteristics with trial participation. RESULTS: Of 2,569 eligible women contacted, 995 (38.7%) participated. Women with some college (OR = 1.99, 95% confidence interval [CI] 1.34-2.96) or college degree (OR = 3.35, 95% CI 2.29-4.90) were more likely to participate than high school-educated women. Race/ethnicity also was associated with participation (African-American OR = 0.50, 95% CI 0.29-0.87; Asian OR = 0.22, 95% CI 0.12-0.41). Multivariate adjusted ORs for family history of breast/ovarian cancer were not associated with trial participation. DISCUSSION: Use of plain language and potential access to a website providing personal breast cancer risk information and education were insufficient in achieving representative participation in a breast cancer prevention trial. Additional methods of targeting and tailoring, potentially facilitated by clinical and community outreach, are needed to facilitate equitable engagement for all women. Copyright © 2020 The Permanente Press. All rights reserved. AD - Kaiser Permanente Washington Health Research Institute, Seattle, WA University of Washington, Seattle, WA Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, DCWA AU - Wernli, K. J. AU - Bowles, E. A. AU - Knerr, S. AU - Leppig, K. A. AU - Ehrlich, K. AU - Gao, H. AU - Schwartz, M. D. AU - O'Neill, S. C. DB - Scopus DO - 10.7812/TPP/19.205 M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 1-4 ST - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial T2 - The Permanente journal TI - Characteristics Associated with Participation in ENGAGED 2 - A Web-based Breast Cancer Risk Communication and Decision Support Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100326225&doi=10.7812%2fTPP%2f19.205&partnerID=40&md5=cb6ff150bac789f1162ec3ff5cddc439 VL - 24 ID - 2168 ER - TY - JOUR AB - Our team is designing and fully characterizing black raspberry (BRB) food products suitable for long-term cancer prevention studies. The processing, scale-up, and storage effects on the consistency, quality, bioactive stability, and sensory acceptability of two BRB delivery systems of various matrices are presented. BRB dosage, pH, water activity, and texture were consistent in the scale-up production. Confections retained >90% of anthocyanins and ellagitannin after processing. Nectars had >69% of anthocyanins and >66% of ellagitannin retention, which varied with BRB dosage due to the processing difference. Texture remained unchanged during storage. BRB products consumed in a prostate cancer clinical trial were well accepted in sensory tests. Thus, this study demonstrates that two different BRB foods can be formulated to meet quality standards with a consistent bioactive pattern and successfully scaled up for a large human clinical trial focusing on cancer risk and other health outcomes. AU - Gu, J. AU - Ahn-Jarvis, J. H. AU - Riedl, K. M. AU - Schwartz, S. J. AU - Clinton, S. K. AU - Vodovotz, Y. DB - Medline DO - 10.1021/jf404566p IS - 18 KW - anthocyanin antioxidant analysis chemistry clinical trial diet therapy food handling fruit functional food human male metabolism middle aged neoplasm prostate tumor Rubus LA - English M3 - Article N1 - L609282848 2016-04-01 PY - 2014 SN - 1520-5118 SP - 3997-4006 ST - Characterization of black raspberry functional food products for cancer prevention human clinical trials T2 - Journal of agricultural and food chemistry TI - Characterization of black raspberry functional food products for cancer prevention human clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609282848&from=export http://dx.doi.org/10.1021/jf404566p VL - 62 ID - 1031 ER - TY - JOUR AB - Our team is designing and fully characterizing black raspberry (BRB) food products suitable for long-term cancer prevention studies. The processing, scale-up, and storage effects on the consistency, quality, bioactive stability, and sensory acceptability of two BRB delivery systems of various matrices are presented. BRB dosage, pH, water activity, and texture were consistent in the scale-up production. Confections retained >90% of anthocyanins and ellagitannin after processing. Nectars had >69% of anthocyanins and >66% of ellagitannin retention, which varied with BRB dosage due to the processing difference. Texture remained unchanged during storage. BRB products consumed in a prostate cancer clinical trial were well accepted in sensory tests. Thus, this study demonstrates that two different BRB foods can be formulated to meet quality standards with a consistent bioactive pattern and successfully scaled up for a large human clinical trial focusing on cancer risk and other health outcomes. © 2013 American Chemical Society. AD - Interdisciplinary Ph.D. Program in Nutrition, Ohio State University, Columbus, OH 43210, United States Department of Food Science and Technology, Ohio State University, Columbus, OH 43210, United States Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, United States Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, United States AU - Gu, J. AU - Ahn-Jarvis, J. H. AU - Riedl, K. M. AU - Schwartz, S. J. AU - Clinton, S. K. AU - Vodovotz, Y. DB - Scopus DO - 10.1021/jf404566p IS - 18 KW - black raspberry consistency in characteristics retention of phenolics scale-up production sensory acceptance storage stability M3 - Article N1 - Cited By :26 Export Date: 22 March 2021 PY - 2014 SP - 3997-4006 ST - Characterization of black raspberry functional food products for cancer prevention human clinical trials T2 - Journal of Agricultural and Food Chemistry TI - Characterization of black raspberry functional food products for cancer prevention human clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900335399&doi=10.1021%2fjf404566p&partnerID=40&md5=3e81de4cea7297990d7fd7ddbed19e65 VL - 62 ID - 2395 ER - TY - JOUR AB - Our team is designing and fully characterizing black raspberry (BRB) food products suitable for long-term cancer prevention studies. The processing, scale-up, and storage effects on the consistency, quality, bioactive stability, and sensory acceptability of two BRB delivery systems of various matrices are presented. BRB dosage, pH, water activity, and texture were consistent in the scale-up production. Confections retained >90% of anthocyanins and ellagitannin after processing. Nectars had >69% of anthocyanins and >66% of ellagitannin retention, which varied with BRB dosage due to the processing difference. Texture remained unchanged during storage. BRB products consumed in a prostate cancer clinical trial were well accepted in sensory tests. Thus, this study demonstrates that two different BRB foods can be formulated to meet quality standards with a consistent bioactive pattern and successfully scaled up for a large human clinical trial focusing on cancer risk and other health outcomes. AN - WOS:000335878500018 AU - Gu, J. AU - Ahn-Jarvis, J. H. AU - Riedl, K. M. AU - Schwartz, S. J. AU - Clinton, S. K. AU - Vodovotz, Y. DA - May DO - 10.1021/jf404566p IS - 18 N1 - 24345009 PY - 2014 SN - 0021-8561 SP - 3997-4006 ST - Characterization of Black Raspberry Functional Food Products for Cancer Prevention Human Clinical Trials T2 - Journal of Agricultural and Food Chemistry TI - Characterization of Black Raspberry Functional Food Products for Cancer Prevention Human Clinical Trials VL - 62 ID - 3010 ER - TY - JOUR AB - Although research has been conducted to address specific medical and psychosocial needs of breast cancer survivors, little has been done to address needs along the entire trajectory of care. One such need is chemobrain, a phenomenon recognized as an identifiable psychosocial cognitive change in breast cancer survivors. The purpose of this article is to present the findings of a qualitative study conducted with two focus groups of underserved African American breast cancer survivors. Four themes emerged from the transcribed interviews: the concept of chemobrain, variability among individuals, the stigma of chemobrain, and methods of coping. In addition, findings revealed that health professionals were not used by the participants as a resource to address the issues of chemobrain, which holds significant implications for practice. That fact highlights the implications for oncology nursing with respect to providing education and support for patients experiencing chemobrain. Nursing professionals are in a position to be a frontline resource for breast cancer survivors, providing information, education, and coping methods to help improve their quality of life. AD - South College of Pharmacy, Knoxville, Tennessee College of Social Work, University of Tennessee in Nashville AN - 86417180. Language: English. Entry Date: 20130401. Revision Date: 20190422. Publication Type: Article AU - Rust, Connie AU - Davis, Cindy DB - CINAHL Complete DO - 10.1188/13.CJON.E29-E34 DP - EBSCOhost IS - 2 KW - Cognition Disorders -- Chemically Induced Antineoplastic Agents -- Adverse Effects Breast Neoplasms Cancer Survivors Black Persons -- Tennessee Medically Underserved Human Female Convenience Sample Qualitative Studies Thematic Analysis Focus Groups Stigma Coping Exploratory Research Tennessee Audiorecording Adult Middle Age Aged Support Groups Research Subject Recruitment N1 - research. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9705336. PY - 2013 SN - 1092-1095 SP - E29-E34 ST - Chemobrain in Underserved African American Breast Cancer Survivors: A Qualitative Study T2 - Clinical Journal of Oncology Nursing TI - Chemobrain in Underserved African American Breast Cancer Survivors: A Qualitative Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=86417180&site=ehost-live&scope=site VL - 17 ID - 1882 ER - TY - JOUR AB - Objectives: This feasibility study developed and pilot tested an intervention to: (1) increase knowledge about prostate cancer screening; and (2) promote self-efficacy to participate in the informed decision-making process. Setting.: African American men are a priority audience for prostate cancer screening interventions to promote informed decision making, and faith-based settings have been shown to be an effective venue to reach this population. Therefore we used predominantly African American churches to develop and test our intervention. Participants: Participants (N = 73) were recruited, and the intervention was administered by an African American health educator. Intervention: We developed and pretested a prostate cancer screening informed decision-making intervention based on the Ottawa Decision Support Framework and the health belief model. The intervention included a tool called the "road map," which depicts the potential consequences of a decision to undergo or forgo screening. A quasiexperimental design was used to test the intervention. Main Outcome Measures: The main outcome measures were change in knowledge and self-efficacy post intervention. Results: Prostate cancer knowledge (p<.0001) and self-efficacy (p=.025) significantly increased. Conclusions: A church-based intervention delivered by an African American health educator is a promising strategy for promoting informed decision making among African American men. AN - WOS:000275967000001 AU - Drake, B. F. AU - Shelton, R. C. AU - Gilligan, T. AU - Allen, J. D. DA - Mar DO - 10.1016/S0027-9684(15)30521-6 IS - 3 N1 - 20355345 PY - 2010 SN - 0027-9684 SP - 164-171 ST - A Church-Based Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men T2 - Journal of the National Medical Association TI - A Church-Based Intervention to Promote Informed Decision Making for Prostate Cancer Screening Among African American Men VL - 102 ID - 3122 ER - TY - JOUR AB - Introduction: African American men have a significantly higher incidence of prostate cancer, are diagnosed at younger ages and more advanced stages, and have higher mortality rates from prostate cancer than do White men. Methods: This community-based intervention study employed a quasiexperimental delayed- control (crossover) design with randomization at the church level. Forty-five African American churches were randomly assigned to two study groups: early intervention and delayed intervention. A convenience sample of 430 African American male volunteers (ages 40-70) was enrolled through the churches, and 350 men remained in the study through wave 3. The intervention was a culturally tailored group educational program, which included a video and a question-and-answer session with an African American physician. Results: Within each group, knowledge, perceived threat, and screening prevalence all increased significantly. However, the magnitude of increases was similar, so the groups did not differ significantly at wave 2. Knowledge at wave 2 was associated with greater odds of having a digital rectal exam by wave 3 only for the early-intervention group. The early-intervention group was two times more likely to have talked to a physician about prostate cancer screening by wave 3. Conclusions: The findings suggest that the delayed-intervention group did not function as a pure control and may have unintentionally received a partial intervention. This finding demonstrated that a low-cost prostate cancer awareness campaign within a church may be enough to affect prostate cancer knowledge, attitudes, and behaviors among African American men. Further research should examine the church-specific intervention elements, cultural appropriateness of the messages, and whether group sessions provide additional effect. AD - Center for Health Research, Tennessee State University, Nashville, TN, United States Meharry Medical College, Nashville, TN, United States Center for Health Research, Tennessee State University, 3500 John Merritt Blvd., Nashville, TN 37209-1561, United States AU - Husaini, B. A. AU - Reece, M. C. AU - Emerson, J. S. AU - Scales, S. AU - Hull, P. C. AU - Levine, R. S. DB - Scopus IS - 2 SUPPL. 2 KW - African american men Community-based education Culturally appropriate Faith-based Health disparities Informed decision-making Prostate cancer screening M3 - Article N1 - Cited By :27 Export Date: 22 March 2021 PY - 2008 SP - S2-179-S2-184 ST - A church-based program on prostate cancer screening for African American men: Reducing health disparities T2 - Ethnicity and Disease TI - A church-based program on prostate cancer screening for African American men: Reducing health disparities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-52149104060&partnerID=40&md5=cc36b10fc2705fb1cdf6660ff7e6ec56 VL - 18 ID - 2539 ER - TY - JOUR AB - Question Is enzalutamide combined with androgen deprivation therapy associated with better outcomes than treatment with bicalutamide in Black men with metastatic hormone-sensitive prostate cancer (mHSPC)? Findings In a randomized clinical trial of 71 men with mHSPC, the 7-month prostate-specific antigen response rate was significantly improved with enzalutamide vs bicalutamide among Black patients but not among non-Black patients. Meaning These findings suggest that treatment with enzalutamide is associated with improved outcomes vs bicalutamide in Black men with mHSPC, and incorporation of enzalutamide in the mHSPC treatment plan should be strongly considered. Importance Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). Objective To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. Design, Setting, and Participants In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. Interventions Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. Main Outcomes and Measures The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. Results A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P = .009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. Conclusions and Relevance The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. This randomized clinical trial examines the efficacy of enzalutamide vs bicalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer. AN - WOS:000612823700004 AU - Vaishampayan, U. N. AU - Heilbrun, L. K. AU - Monk, P. AU - Tejwani, S. AU - Sonpavde, G. AU - Hwang, C. AU - Smith, D. AU - Jasti, P. AU - Dobson, K. AU - Dickow, B. AU - Heath, E. I. AU - Semaan, L. AU - Cher, M. L. AU - Fontana, J. A. AU - Chinni, S. DA - Jan DO - 10.1001/jamanetworkopen.2020.34633 IS - 1 N1 - e2034633 33496795 PY - 2021 SN - 2574-3805 ST - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial T2 - Jama Network Open TI - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial VL - 4 ID - 2751 ER - TY - JOUR AB - Key Points: Question: Is enzalutamide combined with androgen deprivation therapy associated with better outcomes than treatment with bicalutamide in Black men with metastatic hormone-sensitive prostate cancer (mHSPC)? Findings: In a randomized clinical trial of 71 men with mHSPC, the 7-month prostate-specific antigen response rate was significantly improved with enzalutamide vs bicalutamide among Black patients but not among non-Black patients. Meaning: These findings suggest that treatment with enzalutamide is associated with improved outcomes vs bicalutamide in Black men with mHSPC, and incorporation of enzalutamide in the mHSPC treatment plan should be strongly considered. This randomized clinical trial examines the efficacy of enzalutamide vs bicalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer. Importance: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). Objective: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. Design, Setting, and Participants: In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. Interventions: Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. Main Outcomes and Measures: The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. Results: A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P =.008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P =.009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. Conclusions and Relevance: The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02058706 AD - Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, Michigan Department of Internal Medicine, University of Michigan, Ann Arbor Department of Internal Medicine, The Ohio State University, Columbus Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan Department of Internal Medicine, Dana Farber Cancer Institute, Boston, Massachusetts John D. Dingell Veterans Affairs Medical Center, Detroit, Michigan Department of Urology, Wayne State University, Detroit, Michigan AN - 148386502. Language: English. Entry Date: 20210204. Revision Date: 20210311. Publication Type: Article AU - Vaishampayan, Ulka N. AU - Heilbrun, Lance K. AU - Monk Iii, Paul AU - Tejwani, Sheela AU - Sonpavde, Guru AU - Hwang, Clara AU - Smith, Daryn AU - Jasti, Pallavi AU - Dobson, Kimberlee AU - Dickow, Brenda AU - Heath, Elisabeth I. AU - Semaan, Louie AU - Cher, Michael L. AU - Fontana, Joseph A. AU - Chinni, Sreenivasa DB - CINAHL Complete DO - 10.1001/jamanetworkopen.2020.34633 DP - EBSCOhost IS - 1 KW - Prostatic Neoplasms -- Drug Therapy Neoplasm Metastasis -- Drug Therapy Androgen Antagonists -- Administration and Dosage Bicalutamide -- Administration and Dosage Drug Efficacy Hormone Therapy Men's Health Outcomes (Health Care) Human Randomized Controlled Trials Random Assignment Black Persons Multicenter Studies Middle Age Aged Aged, 80 and Over Confidence Intervals Survival Immunohistochemistry Gene Expression Kaplan-Meier Estimator Log-Rank Test Cox Proportional Hazards Model Data Analysis Software Chi Square Test Funding Source Fisher's Exact Test N1 - research; tables/charts; randomized controlled trial. Grant Information: This study was supported by Astellas Pharma Global Development, Inc, Cancer Center Support.. PY - 2021 SP - e2034633-e2034633 ST - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial T2 - JAMA Network Open TI - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148386502&site=ehost-live&scope=site VL - 4 ID - 1884 ER - TY - JOUR AB - Importance: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). Objective: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. Design, Setting, and Participants: In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. Interventions: Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. Main Outcomes and Measures: The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. Results: A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P =.008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P =.009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. Conclusions and Relevance: The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02058706. AD - U.N. Vaishampayan, Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI, United States AU - Vaishampayan, U. N. AU - Heilbrun, L. K. AU - Monk, P. AU - Tejwani, S. AU - Sonpavde, G. AU - Hwang, C. AU - Smith, D. AU - Jasti, P. AU - Dobson, K. AU - Dickow, B. AU - Heath, E. I. AU - Semaan, L. AU - Cher, M. L. AU - Fontana, J. A. AU - Chinni, S. DB - Embase Medline DO - 10.1001/jamanetworkopen.2020.34633 KW - adult androgen deprivation therapy article bone marrow bone pain cancer patient cancer survival clinical trial comparative effectiveness controlled study data analysis drug combination drug therapy human kidney liver function major clinical study male multicenter study overall survival phase 2 clinical trial prospective study prostate cancer race randomized controlled trial reaction time seizure bicalutamide endogenous compound enzalutamide hormone prostate specific antigen LA - English M3 - Article in Press N1 - L634019696 2021-02-02 PY - 2021 SN - 2574-3805 ST - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial T2 - JAMA Network Open TI - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634019696&from=export http://dx.doi.org/10.1001/jamanetworkopen.2020.34633 ID - 772 ER - TY - JOUR AB - Importance: Black patients have been underrepresented in prospective clinical trials of advanced prostate cancer. This study evaluated the efficacy of enzalutamide compared with bicalutamide, with planned subset analysis of Black patients with metastatic hormone-sensitive prostate cancer (mHSPC), which is a disease state responsive to androgen deprivation therapy (ADT). Objective: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. Design, Setting, and Participants: In this randomized clinical trial, a phase 2 screening design enabled a nondefinitive comparison of the primary outcome by treatment. Patients were stratified by race (Black or other) and bone pain (present or absent). Accrual of at least 30% Black patients was required. This multicenter trial was conducted at 4 centers in the US. Men with mHSPC with no history of seizures and adequate marrow, renal, and liver function were eligible. Data analysis was performed from February 2019 to March 2020. Interventions: Participants were randomized 1:1 to receive oral enzalutamide (160 mg daily) or bicalutamide (50 mg daily) in addition to ADT. Main Outcomes and Measures: The primary end point was the 7-month prostate-specific antigen (PSA) response (SMPR) rate, a previously accepted surrogate for overall survival (OS) outcome. Secondary end points included adverse reactions, time to PSA progression, and OS. Results: A total of 71 men (median [range] age, 65 [51-86] years) were enrolled; 29 (41%) were Black, 41 (58%) were White, and 1 (1%) was Asian. Thirty-six patients were randomized to receive enzalutamide, and 35 were randomized to receive bicalutamide. Twenty-six patients (37%) had bone pain and 37 patients (52%) had extensive disease. SMPR was achieved in 30 of 32 patients (94%; 95% CI, 80%-98%) taking enzalutamide and 17 of 26 patients (65%; 95% CI, 46%-81%) taking bicalutamide (P = .008) (difference, 29%; 95% CI, 5%-50%). Among Black patients, the SMPR was 93% (95% CI, 69%-99%) among those taking enzalutamide and 42% (95% CI, 19%-68%) among those taking bicalutamide (P = .009); among non-Black patients, the SMPR was 94% (95% CI, 74%-99%) among those taking enzalutamide and 86% (95% CI, 60%-96%) among those taking bicalutamide. The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. Conclusions and Relevance: The findings of this randomized clinical trial comparing enzalutamide with bicalutamide suggest that enzalutamide is associated with improved outcomes compared with bicalutamide, in terms of the rate and duration of PSA response, in Black patients with mHSPC. Trial Registration: ClinicalTrials.gov Identifier: NCT02058706. AD - Department of Oncology, Karmanos Cancer Center, Wayne State University, Detroit, MI, United States Department of Internal Medicine, University of Michigan, Ann Arbor, United States Department of Internal Medicine, Ohio State University, Columbus, United States Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, United States Department of Internal Medicine, Dana Farber Cancer Institute, Boston, MA John D. Dingell Veterans Affairs Medical Center, Detroit, MI, United States Department of Urology, Wayne State University, Detroit, MI, United States AU - Vaishampayan, U. N. AU - Heilbrun, L. K. AU - Monk, P., 3rd AU - Tejwani, S. AU - Sonpavde, G. AU - Hwang, C. AU - Smith, D. AU - Jasti, P. AU - Dobson, K. AU - Dickow, B. AU - Heath, E. I. AU - Semaan, L. AU - Cher, M. L. AU - Fontana, J. A. AU - Chinni, S. DB - Scopus DO - 10.1001/jamanetworkopen.2020.34633 IS - 1 M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 SP - e2034633 ST - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial T2 - JAMA network open TI - Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100516451&doi=10.1001%2fjamanetworkopen.2020.34633&partnerID=40&md5=4f9ed7ce05447f027a3ed78e560592e3 VL - 4 ID - 2157 ER - TY - JOUR AB - Background: We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate cancer (mCRPC) treated with a docetaxel and prednisone (DP)-based regimen. The primary goal of this analysis was to compare progression-free survival (PFS), biochemical PFS, ≥50% decline in prostate-specific antigen (PSA) from baseline and objective response rate (ORR) in white, black and Asian men with mCRPC treated with a DP-based regimen. Patients and methods: Individual patient data from 8820 mCRPC men randomized on nine phase III trials to a DP-containing regimen were combined. Race used in the analysis was based on self-report. End points were PFS, biochemical PSA, ≥50% decline in PSA from baseline and ORR. The proportional hazards and the logistic regression models were employed to assess the prognostic importance of race in predicting outcomes adjusting for established prognostic factors. Results: Of 8820 patients, 7528 (85%) were white, 500 (6%) were black, 424 were Asian (5%) and 368 (4%) had race unspecified. Median PFS were 8.3 [95% confidence interval (CI) 8.2–8.5], 8.2 (95% CI 7.4–8.8) and 8.3 (95% CI 7.6–8.8) months in white, black and Asian men, respectively. Median PSA PFS were 9.9 (95% CI 9.7–10.4), 8.5 (95% CI 8.0–10.3) and 11.1 (95% CI 9.9–12.5) months in white, black and Asian men, respectively. Conclusions: We observed no differences in clinical outcomes by race and ethnic groups in men with mCRPC enrolled on these phase III clinical trials with DP. © 2020 European Society for Medical Oncology AD - Duke University Medical Center and Duke University, Durham, United States Old Dominion University, Norfolk, United States Fred Hutchinson Cancer Research Center, Seattle, United States The Royal Melbourne Hospital, Parkville, Australia Yale School of Medicine, New Haven, United States Christus San Rosa Hospital Medical Center, San Antonio, United States British Columbia Cancer Agency – Vancouver Centre, Vancouver, Canada The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom The University of Texas MD Anderson Cancer Center, Houston, United States The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, United States University of Southern California Norris Comprehensive Cancer Center, Los Angeles, United States Gustave Roussy, Villejuif, France Memorial Sloan Kettering Cancer Center, New York, United States University of Washington and Fred Hutchinson Cancer Research Center, Seattle, United States Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada University of California, San Francisco, San Francisco, United States Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, United States AU - Halabi, S. AU - Dutta, S. AU - Tangen, C. M. AU - Rosenthal, M. AU - Petrylak, D. P. AU - Thompson, I. M., Jr. AU - Chi, K. N. AU - De Bono, J. S. AU - Araujo, J. C. AU - Logothetis, C. AU - Eisenberger, M. A. AU - Quinn, D. I. AU - Fizazi, K. AU - Morris, M. J. AU - Higano, C. S. AU - Tannock, I. F. AU - Small, E. J. AU - Kelly, W. K. DB - Scopus DO - 10.1016/j.annonc.2020.03.309 IS - 7 KW - biochemical progression disparity docetaxel objective response rate progression-free survival PSA decline M3 - Conference Paper N1 - Cited By :2 Export Date: 22 March 2021 PY - 2020 SP - 930-941 ST - Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer T2 - Annals of Oncology TI - Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085284469&doi=10.1016%2fj.annonc.2020.03.309&partnerID=40&md5=3f467f92892b06b30c1aaf75fc7a9aee VL - 31 ID - 2190 ER - TY - JOUR AB - Purpose: Minimal clinical trial participation among adolescents and young adults (AYAs) with cancer limits scientific progress and ultimately their clinical care and outcomes. These analyses examine the current state of AYA clinical research participation at a Midwestern comprehensive cancer center and affiliated pediatric hospital to advise program development and increase availability of trials and AYA participation. Enrollment is examined across all diagnoses, the entire AYA age spectrum (15–39), and both cancer therapeutic and supportive care protocols. Methods: his study was a retrospective review of electronic medical records via existing databases and registries for all AYAs. Data were collected for AYAs seen by an oncologist at the adult outpatient cancer center or at the pediatric hospital between the years 2010 and 2014. Descriptive statistics and logistic regression analyses were conducted to characterize this sample. Results: In the pediatric setting, 42.3% of AYAs were enrolled in a study compared to 11.2% in the adult setting. Regression analyses in the pediatric setting revealed that AYAs with private insurance or Caucasian race were more likely to participate. Within the adult setting, ethnicity, race, insurance, and diagnosis were associated with study participation; 54.8% of study enrollments were for cancer therapeutic and 43.4% for supportive care studies. Conclusions: These results are comparable to previously published data and support the need for new local and national AYA initiatives to increase the availability of and enrollment in therapeutic clinical trials. The same is true for supportive care studies which play a crucial role in improving quality of life. © 2017, Springer-Verlag Berlin Heidelberg. AD - Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 N. St. Clair Street Suite 21-100, Chicago, IL 60611, United States Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611, United States Wake Forest School of Medicine, Winston-Salem, NC 27157, United States AU - Sanford, S. D. AU - Beaumont, J. L. AU - Snyder, M. A. AU - Reichek, J. AU - Salsman, J. M. DB - Scopus DO - 10.1007/s00520-016-3558-7 IS - 5 KW - Adolescents Cancer survivors Clinical trials Young adults M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2017 SP - 1579-1586 ST - Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital T2 - Supportive Care in Cancer TI - Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009223732&doi=10.1007%2fs00520-016-3558-7&partnerID=40&md5=a1f2455ab0ed5177c66c6a007fab4cf4 VL - 25 ID - 2307 ER - TY - JOUR AB - PURPOSE: Internet-based clinical trial information services are being developed to increase recruitment to studies. However, there are limited data that evaluate their ability to reach elderly and underrepresented minority populations. This study was designed to evaluate the ability of an established clinical trials registry to reach these populations based on expected Internet use. PATIENTS AND METHODS: This study compares general Internet users to participants who enrolled in an Internet based colorectal cancer clinical trials registry established by OncoLink (www.oncolink.org) and the National Colorectal Cancer Research Alliance. Observed rates of demographic groupings were compared to those established for general Internet users. RESULTS: Two thousand, four hundred and thirty-seven participants from the continental United States used the Internet to register for the database. New England, the Mid-Atlantic region, and the Southeast had the highest relative frequency of participation in the database, whereas the Upper Midwest, California, and the South had the lowest rates. Compared to general Internet users, there was an overrepresentation of women (73% vs. 50%) and participants over 55 years old (27% vs. 14%). However, there was an underrepresentation of minorities (10.3% vs. 22%), particularly African Americans (3.1% vs. 8%) and Hispanics (2.8% vs. 9%). DISCUSSION: The Internet is a growing medium for registry into clinical trials databases. However, even taking into account the selection bias of Internet accessibility, there are still widely disparate demographics between general Internet users and those registering for clinical trials, particularly the underrepresentation of minorities. Internet-based educational and recruitment services for clinical trials must be designed to reach these underrepresented minorities to avoid selection biases in future clinical trials. Copyright © 2006 Jones and Bartlett Publishers, Inc. AD - J.J. Wilson, Fox Chase Virtua Health Cancer Treatment Center, 106 Carnie Blvd., Voorhies, NJ 08043, United States AU - Wilson, J. J. AU - Mick, R. AU - Wei, S. J. AU - Rustgi, A. K. AU - Markowitz, S. D. AU - Hampshire, M. AU - Metz, J. M. DB - Embase Medline IS - 6 KW - adult African American article cancer prevention cancer registry colorectal cancer data base demography education female Hispanic human human experiment Internet male medical information system minority group priority journal LA - English M3 - Article N1 - L46026196 2007-01-24 PY - 2006 SN - 1528-9117 1540-336X SP - 475-481 ST - Clinical trial resources on the internet must be designed to reach underrepresented minorities T2 - Cancer Journal TI - Clinical trial resources on the internet must be designed to reach underrepresented minorities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46026196&from=export http://docserver.ingentaconnect.com/deliver/connect/jandb/15289117/v12n6/s7.pdf?expires=1167215178&id=34278228&titleid=6269&accname=Elsevier&checksum=71F6FB3B5850F79CC9AB7E9037D7FC0C VL - 12 ID - 1238 ER - TY - JOUR AB - PURPOSE: Internet-based clinical trial information services are being developed to increase recruitment to studies. However, there are limited data that evaluate their ability to reach elderly and underrepresented minority populations. This study was designed to evaluate the ability of an established clinical trials registry to reach these populations based on expected Internet use. PATIENTS AND METHODS: This study compares general Internet users to participants who enrolled in an Internet based colorectal cancer clinical trials registry established by OncoLink (www.oncolink.org) and the National Colorectal Cancer Research Alliance. Observed rates of demographic groupings were compared to those established for general Internet users. RESULTS: Two thousand, four hundred and thirty-seven participants from the continental United States used the Internet to register for the database. New England, the Mid-Atlantic region, and the Southeast had the highest relative frequency of participation in the database, whereas the Upper Midwest, California, and the South had the lowest rates. Compared to general Internet users, there was an overrepresentation of women (73% vs. 50%) and participants over 55 years old (27% vs. 14%). However, there was an underrepresentation of minorities (10.3% vs. 22%), particularly African Americans (3.1% vs. 8%) and Hispanics (2.8% vs. 9%). DISCUSSION: The Internet is a growing medium for registry into clinical trials databases. However, even taking into account the selection bias of Internet accessibility, there are still widely disparate demographics between general Internet users and those registering for clinical trials, particularly the underrepresentation of minorities. Internet-based educational and recruitment services for clinical trials must be designed to reach these underrepresented minorities to avoid selection biases in future clinical trials. Copyright © 2006 Jones and Bartlett Publishers, Inc. AD - Fox Chase Virtua Health Cancer Treatment Center, Voorhies, NJ, United States University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia, PA, United States University of Pennsylvania, Department of Genetics, Abramson Cancer Center, Philadelphia, PA, United States Howard Hughes Medical Institute, Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, United States University of Pennsylvania Cancer Center, Philadelphia, PA, United States Fox Chase Virtua Health Cancer Treatment Center, 106 Carnie Blvd., Voorhies, NJ 08043, United States AU - Wilson, J. J. AU - Mick, R. AU - Wei, S. J. AU - Rustgi, A. K. AU - Markowitz, S. D. AU - Hampshire, M. AU - Metz, J. M. DB - Scopus DO - 10.1097/00130404-200611000-00007 IS - 6 KW - Age Clinical trial Colorectal neoplasms Continental population groups Internet Race Sex M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2006 SP - 475-481 ST - Clinical trial resources on the internet must be designed to reach underrepresented minorities T2 - Cancer Journal TI - Clinical trial resources on the internet must be designed to reach underrepresented minorities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845907942&doi=10.1097%2f00130404-200611000-00007&partnerID=40&md5=ddce8ad4d82b2483d2d23c8b03c7f031 VL - 12 ID - 2569 ER - TY - JOUR AB - PURPOSE Internet-based clinical trial information services are being developed to increase recruitment to studies. However, there are limited data that evaluate their ability to reach elderly and underrepresented minority populations. This study was designed to evaluate the ability of an established clinical trials registry to reach these populations based on expected Internet use. PATIENTS AND METHODS This study compares general Internet users to participants who enrolled in an Internet based colorectal cancer clinical trials registry established by OncoLink (www.oncolink.org) and the National Colorectal Cancer Research Alliance. Observed rates of demographic groupings were compared to those established for general Internet users. RESULTS Two thousand, four hundred and thirty-seven participants from the continental United States used the Internet to register for the database. New England, the Mid-Atlantic region,and the Southeast had the highest relative frequency of participation in the database, whereas the Upper Midwest, California, and the South had the lowest rates. Compared to general Internet users, there was an overrepresentation of women (73% vs. 50%) and participants over 55 years old (27% vs. 14%). However, there was an underrepresentation of minorities (10.3% vs. 22%), particularly African Americans (3.1% vs. 8%) and Hispanics (2.8% vs. 9%). DISCUSSION The Internet is a growing medium for registry into clinical trials databases. However, even taking into account the selection bias of Internet accessibility, there are still widely disparate demographics between general Internet users and those registering for clinical trials, particularly the underrepresentation of minorities. Internet-based educational and recruitment services for clinical trials must be designed to reach these underrepresented minorities to avoid selection biases in future clinical trials. AN - WOS:000243122600007 AU - Wilson, J. J. AU - Mick, R. AU - Wei, S. J. AU - Rustgi, A. K. AU - Markowitz, S. D. AU - Hampshire, M. AU - Metz, J. M. DA - Nov-Dec DO - 10.1097/00130404-200611000-00007 IS - 6 N1 - 17207317 PY - 2006 SN - 1528-9117 SP - 475-481 ST - Clinical trial resources on the Internet must be designed to reach underrepresented minorities T2 - Cancer Journal TI - Clinical trial resources on the Internet must be designed to reach underrepresented minorities VL - 12 ID - 3208 ER - TY - JOUR AB - Purpose: Internet-based clinical trial information services are being developed to increase recruitment to studies. However, there are limited data that evaluate their ability to reach elderly and underrepresented minority populations. This study was designed to evaluate the ability of an established clinical trials registry to reach these populations based on expected Internet use.Patients and Methods: This study compares general Internet users to participants who enrolled in an Internet based colorectal cancer clinical trials registry established by OncoLink (www.oncolink.org) and the National Colorectal Cancer Research Alliance. Observed rates of demographic groupings were compared to those established for general Internet users.Results: Two thousand, four hundred and thirty-seven participants from the continental United States used the Internet to register for the database. New England, the Mid-Atlantic region, and the Southeast had the highest relative frequency of participation in the database, whereas the Upper Midwest, California, and the South had the lowest rates. Compared to general Internet users, there was an overrepresentation of women (73% vs. 50%) and participants over 55 years old (27% vs. 14%). However, there was an underrepresentation of minorities (10.3% vs. 22%), particularly African Americans (3.1% vs. 8%) and Hispanics (2.8% vs. 9%).Discussion: The Internet is a growing medium for registry into clinical trials databases. However, even taking into account the selection bias of Internet accessibility, there are still widely disparate demographics between general Internet users and those registering for clinical trials, particularly the underrepresentation of minorities. Internet-based educational and recruitment services for clinical trials must be designed to reach these underrepresented minorities to avoid selection biases in future clinical trials. AD - Fox Chase Virtua Health Cancer Treatment Center, Voorhies, New Jersey 08043, USA Fox Chase Virtua Health Cancer Treatment Center, Voorhies, New Jersey 08043, USA. johnjameswilson@gmail.com AN - 106199266. Language: English. Entry Date: 20071130. Revision Date: 20200708. Publication Type: journal article AU - Wilson, J. J. AU - Mick, R. AU - Wei, S. J. AU - Rustgi, A. K. AU - Markowitz, S. D. AU - Hampshire, M. AU - Metz, J. M. AU - Wilson, John J. AU - Mick, Rosemarie AU - Wei, S. Jack AU - Rustgi, Anil K. AU - Markowitz, Sanford D. AU - Hampshire, Maggie AU - Metz, James M. DB - CINAHL Complete DO - 10.1097/00130404-200611000-00007 DP - EBSCOhost IS - 6 KW - Clinical Trials Internet Minority Groups Research Subject Recruitment Black Persons Female Funding Source Hispanic Americans Male Middle Age Human N1 - research; tables/charts. Commentary: Freeman HP, Freeman Harold P. Considerations on the use of the internet as a tool for minority recruitment into clinical trials. (CANCER J) Nov/Dec2006; 12 (6): 459-460. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: OncoLink and the NCCRA. NLM UID: 100931981. PMID: NLM17207317. PY - 2006 SN - 1528-9117 SP - 475-481 ST - Clinical trial resources on the internet must be designed to reach underrepresented minorities T2 - Cancer Journal TI - Clinical trial resources on the internet must be designed to reach underrepresented minorities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106199266&site=ehost-live&scope=site VL - 12 ID - 1885 ER - TY - JOUR AB - Objective: Prostate cancer is reported to be more aggressive in Blacks. We studied the clinicopathologic features of prostate cancer in Ghana, in order to determine the factors responsible for them and to find out if there is any relationship between them. Method: Patients referred with a biopsy proven diagnosis of carcinoma of the prostate to the Cancer Center of Korle Bu Teaching Hospital, Accra, Ghana, from 2003 to 2007 were studied. Information with respect to age at diagnosis, presenting symptoms, initial PSA (iPSA), Gleason score, and disease extent were studied. Age was partitioned into 50-65 and >65 years, Gleason score into 2-6, 7, and 8-10, iPSA into 4-20 ng/ml and >20, and disease extent into T1, T2, vs. T3, T4, M1, and the relationship between them was determined. Various presenting symptoms were described. Known risk factors and screening in a context of high grade disease is discussed. Results: A total of 170 patients were studied. Mean age was 65.4 years. Majority of patients (73.7%) presented with an iPSA > 20 ng/ml, whilst 22 (14.1%) had PSA < 10 ng/ml. Gleason score ≥ 7 was found in 95 (56%) of patients. Asymptomatic patients constituted 24.0%, the rest had bone pain (22.6%), urinary (50.4%), and neurologic symptoms (3.0%).There was a statistically significant relationship between age and Gleason score (. P = 0.049), PSA and Gleason score (. P = 0.0001), and between extent of disease and Gleason score (. P = 0.0002). High fat diet and low intake of fruits and vegetables are probable risk factors in Ghana. Conclusion: Majority of patients present with symptomatic disease at a relatively older age. These patients tend to have high Gleason score partly attributable to advanced disease, age, PSA at the time of diagnosis, and race. Screening with PSA should be recommended and individualized in this group of patients in order to allow diagnosis of less aggressive disease until better screening tools are identified. © 2013 Elsevier Inc. AD - National Center for Radiotherapy and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana Department of Surgery/Urology, Korle Bu Teaching Hospital/University of Ghana Medical School, Accra, Ghana AU - Yarney, J. AU - Vanderpuye, V. AU - Mensah, J. DB - Scopus DO - 10.1016/j.urolonc.2011.01.018 IS - 3 KW - Age Black men Cancer Differentiation Gleason score Prostate PSA Risk factors M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2013 SP - 325-330 ST - Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men T2 - Urologic Oncology: Seminars and Original Investigations TI - Clinicopathologic features and determinants of Gleason score of prostate cancer in Ghanaian men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84875377164&doi=10.1016%2fj.urolonc.2011.01.018&partnerID=40&md5=8abe3779a57089020c6990af450d35e1 VL - 31 ID - 2436 ER - TY - JOUR AB - Background: African American women have disproportionately higher rates of breast cancer mortality than all other ethnic groups, thus highlighting the importance of promoting early detection. Methods: African American women (N = 984) from San. Diego, California, participated in a randomized controlled trial testing the efficacy of breast cancer education sessions offered in beauty salons. Cosmetologists received ongoing support, training, and additional culturally aligned educational materials to help them engage their clients in dialogues about the importance of breast cancer early detection. Posters and literature about breast cancer early detection were displayed throughout the salons and cosmetologists used synthetic breast models to show their clients how breast cancer lumps might feel. Participants in the control group received a comparable diabetes education program. Baseline and 6-month follow-up surveys were administered to evaluate changes in women's breast cancer knowledge, attitudes, and screening behaviors. Results: This intervention was well received by the participants and their cosmetologists and did not interfere with or prolong the client's salon visit. Women in the intervention group reported significantly higher rates of mammography compared to women in the control group. Training a single educator proved sufficient to permeate the entire salon with the health message, and salon clients agreed that cosmetologists could become effective health educators. Conclusions: Cosmetologists are in an ideal position to increase African American women's breast cancer knowledge and adherence to breast cancer screening guidelines. AN - WOS:000295911300009 AU - Sadler, G. R. AU - Ko, C. M. AU - Wu, P. AU - Alisangco, J. AU - Castaneda, S. F. AU - Kelly, C. DA - Aug DO - 10.1016/S0027-9684(15)30413-2 IS - 8 N1 - 22046851 PY - 2011 SN - 0027-9684 SP - 735-745 ST - A Cluster Randomized Controlled Trial to Increase Breast Cancer Screening Among African American Women: The Black Cosmetologists Promoting Health Program T2 - Journal of the National Medical Association TI - A Cluster Randomized Controlled Trial to Increase Breast Cancer Screening Among African American Women: The Black Cosmetologists Promoting Health Program VL - 103 ID - 3087 ER - TY - JOUR AB - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate-vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p = .25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p = .15) in PA for intervention (-0.30 MET-hours/week) compared with the comparison (-0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs. AN - WOS:000383212700010 AU - Leone, L. A. AU - Allicock, M. AU - Pignone, M. P. AU - Walsh, J. F. AU - Johnson, L. AU - Armstrong-Brown, J. AU - Carr, C. C. AU - Langford, A. AU - Ni, A. AU - Resnicow, K. AU - Campbell, M. K. DA - Oct DO - 10.1177/1090198115611877 IS - 5 N1 - 26515276 PY - 2016 SN - 1090-1981 SP - 568-576 ST - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans T2 - Health Education & Behavior TI - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans VL - 43 ID - 2933 ER - TY - JOUR AB - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate–vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p = .25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p = .15) in PA for intervention (−0.30 MET-hours/week) compared with the comparison (−0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Leone, Lucia A., Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, State University of New York, 333 Kimball Tower, Buffalo, NY, US, 14214-8028 AN - 2016-44567-010 AU - Leone, Lucia A. AU - Allicock, Marlyn AU - Pignone, Michael P. AU - Walsh, Joan F. AU - Johnson, La-Shell AU - Armstrong-Brown, Janelle AU - Carr, Carol C. AU - Langford, Aisha AU - Ni, Andy AU - Resnicow, Ken AU - Campbell, Marci K. DB - psyh DO - 10.1177/1090198115611877 DP - EBSCOhost IS - 5 KW - African American church-based colorectal cancer screening peer counseling physical activity tailored health messages Blacks Cancer Screening Health Promotion Religion N1 - Health Education Quarterly. Partial author list: First Author & Affiliation: Leone, Lucia A.; University of North Carolina at Chapel Hill, Chapel Hill, NC, US. Release Date: 20161006. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Leone, Lucia A. Major Descriptor: Blacks; Cancer Screening; Health Promotion; Physical Activity; Religion. Minor Descriptor: Peer Counseling. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Followup Study; Quantitative Study. Page Count: 9. Issue Publication Date: Oct, 2016. Copyright Statement: Society for Public Health Education. 2015. Sponsor: Centers for Disease Control and Prevention. Grant: 3-U48-DP000059-02S1. Recipients: No recipient indicated Sponsor: Cancer Health Disparities. Grant: 1T32CA128582-03. Other Details: Training Grant. Recipients: Leone, Lucia A. PY - 2016 SN - 1090-1981 1552-6127 SP - 568-576 ST - Cluster randomized trial of a church-based peer counselor and tailored newsletter intervention to promote colorectal cancer screening and physical activity among older African Americans T2 - Health Education & Behavior TI - Cluster randomized trial of a church-based peer counselor and tailored newsletter intervention to promote colorectal cancer screening and physical activity among older African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-44567-010&site=ehost-live&scope=site lucialeo@buffalo.edu VL - 43 ID - 1700 ER - TY - JOUR AB - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate–vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p = .25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p = .15) in PA for intervention (−0.30 MET-hours/week) compared with the comparison (−0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs. AD - University of North Carolina at Chapel Hill, NC, USA University at Buffalo, Buffalo, NY, USA University of Texas, Dallas, TX, USA RTI International, Research Triangle Park, NC, USA New York University, New York, NY, USA University of Michigan, Ann Arbor, MI, USA AN - 118069506. Language: English. Entry Date: 20161201. Revision Date: 20180530. Publication Type: Article AU - Leone, Lucia A. AU - Allicock, Marlyn AU - Pignone, Michael P. AU - Walsh, Joan F. AU - Johnson, La-Shell AU - Armstrong-Brown, Janelle AU - Carr, Carol C. AU - Langford, Aisha AU - Ni, Andy AU - Resnicow, Ken AU - Campbell, Marci K. DB - CINAHL Complete DO - 10.1177/1090198115611877 DP - EBSCOhost IS - 5 KW - Counseling Newsletters -- Utilization Colorectal Neoplasms -- Prevention and Control -- In Old Age Cancer Screening -- In Old Age Black Persons -- In Old Age Human Randomized Controlled Trials Peer Group Churches Physical Activity North Carolina Urban Areas Multivariate Analysis Outcomes (Health Care) Confidence Intervals Counselors Female Male Aged Random Assignment Michigan Middle Age Surveys Social Learning Theory Data Analysis Software Prospective Studies Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Health Promotion/Education; Peer Reviewed; USA. Special Interest: Gerontologic Care; Oncologic Care. Grant Information: This study was funded by Centers for Disease Control and Prevention (3-U48-DP000059-02S1).. NLM UID: 9704962. PY - 2016 SN - 1090-1981 SP - 568-576 ST - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans T2 - Health Education & Behavior TI - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118069506&site=ehost-live&scope=site VL - 43 ID - 1886 ER - TY - JOUR AB - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate-vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p = .25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p = .15) in PA for intervention (-0.30 MET-hours/week) compared with the comparison (-0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs. AU - Leone, L. A. AU - Allicock, M. AU - Pignone, M. P. AU - Walsh, J. F. AU - Johnson, L. S. AU - Armstrong-Brown, J. AU - Carr, C. C. AU - Langford, A. AU - Ni, A. AU - Resnicow, K. AU - Campbell, M. K. DB - Medline DO - 10.1177/1090198115611877 IS - 5 KW - African American aged attitude to health clinical trial colonoscopy colorectal tumor controlled study counseling early cancer diagnosis ethnology exercise female health promotion human male Michigan middle aged multicenter study multivariate analysis North Carolina procedures program evaluation psychology publication questionnaire randomized controlled trial religion social support LA - English M3 - Article N1 - L621231250 2018-03-19 PY - 2016 SN - 1552-6127 SP - 568-576 ST - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans T2 - Health education & behavior : the official publication of the Society for Public Health Education TI - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621231250&from=export http://dx.doi.org/10.1177/1090198115611877 VL - 43 ID - 963 ER - TY - JOUR AB - Action Through Churches in Time to Save Lives (ACTS) of Wellness was a cluster randomized controlled trial developed to promote colorectal cancer screening and physical activity (PA) within urban African American churches. Churches were recruited from North Carolina (n = 12) and Michigan (n = 7) and were randomized to intervention (n = 10) or comparison (n = 9). Intervention participants received three mailed tailored newsletters addressing colorectal cancer screening and PA behaviors over approximately 6 months. Individuals who were not up-to-date for screening at baseline could also receive motivational calls from a peer counselor. The main outcomes were up-to-date colorectal cancer screening and Metabolic Equivalency Task (MET)-hours/week of moderate–vigorous PA. Multivariate analyses examined changes in the main outcomes controlling for church cluster, gender, marital status, weight, and baseline values. Baseline screening was high in both intervention (75.9%, n = 374) and comparison groups (73.7%, n = 338). Screening increased at follow-up: +6.4 and +4.7 percentage points for intervention and comparison, respectively (p =.25). Baseline MET-hours/week of PA was 7.8 (95% confidence interval [6.8, 8.7]) for intervention and 8.7 (95% confidence interval [7.6, 9.8]) for the comparison group. There were no significant changes (p =.15) in PA for intervention (−0.30 MET-hours/week) compared with the comparison (−0.05 MET-hours/week). Among intervention participants, PA increased more for those who participated in church exercise programs, and screening improved more for those who spoke with a peer counselor or recalled the newsletters. Overall, the intervention did not improve PA or screening in an urban church population. These findings support previous research indicating that structured PA opportunities are necessary to promote change in PA and churches need more support to initiate effective peer counselor programs. © 2015, © 2015 Society for Public Health Education. AD - University of North Carolina at Chapel HillNC, United States University at Buffalo, Buffalo, NY, United States University of Texas, Dallas, TX, United States RTI International, Research Triangle Park, NC, United States New York University, New York, NY, United States University of Michigan, Ann Arbor, MI, United States AU - Leone, L. A. AU - Allicock, M. AU - Pignone, M. P. AU - Walsh, J. F. AU - Johnson, L. S. AU - Armstrong-Brown, J. AU - Carr, C. C. AU - Langford, A. AU - Ni, A. AU - Resnicow, K. AU - Campbell, M. K. DB - Scopus DO - 10.1177/1090198115611877 IS - 5 KW - African American church-based colorectal cancer screening peer counseling physical activity tailored health messages M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2016 SP - 568-576 ST - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans T2 - Health Education and Behavior TI - Cluster Randomized Trial of a Church-Based Peer Counselor and Tailored Newsletter Intervention to Promote Colorectal Cancer Screening and Physical Activity Among Older African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988038805&doi=10.1177%2f1090198115611877&partnerID=40&md5=11343fcc1f7f10ee3b16e21d27befe03 VL - 43 ID - 2335 ER - TY - JOUR AB - PURPOSE: Lack of trust and rapport with health care providers has been identified in the under‐representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. PATIENTS AND METHODS: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6‐month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made biweekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. RESULTS: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6‐month follow‐up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1‐point odds ratio on Functional Assessment of Cancer Treatment‐General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. CONCLUSIONS: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC. AN - CN-00981065 AU - Fracasso, P. M. AU - Goodner, S. A. AU - Creekmore, A. N. AU - Morgan, H. P. AU - Foster, D. M. AU - Hardmon, A. A. AU - Engel, S. J. AU - Springer, B. C. AU - Mathews, K. J. AU - Fisher, E. B. AU - et al. DO - 10.1200/JOP.2013.000982 IS - 6 KW - *advanced cancer *coach intervention *patient education *trust Adult African American African Americans [*psychology] Aged Aged, 80 and over Article Asian American Asian Americans [*psychology] Attitude to Health [*ethnology] Breast cancer Clinical Trials as Topic [methods, *psychology] Colorectal cancer Controlled study Depression Female Follow up Functional assessment Health care personnel Hospital readmission Human Humans Longitudinal Studies Lung cancer Major clinical study Male Middle Aged Minority Groups [*psychology] Neoplasms [*therapy] Patient Patient Education as Topic [*methods] Patient Selection Prostate carcinoma Quality of life Racism Randomized controlled trial Telephone interview United States Usual care Very elderly M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2013 SP - 294‐299 ST - Coaching intervention as a strategy for minority recruitment to cancer clinical trials T2 - Journal of oncology practice TI - Coaching intervention as a strategy for minority recruitment to cancer clinical trials UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00981065/full VL - 9 ID - 1363 ER - TY - JOUR AB - Purpose: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. Patients and Methods: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made bi-weekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. Results: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment-General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. Conclusions: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC. Copyright © 2013 by American Society of Clinical Oncology. AD - P.M. Fracasso, Department of Medicine, University of Virginia, PO Box 800716, Charlottesville, VA 22908, United States AU - Fracasso, P. M. AU - Goodner, S. A. AU - Creekmore, A. N. AU - Morgan, H. P. AU - Foster, D. M. AU - Hardmon, A. A. AU - Engel, S. J. AU - Springer, B. C. AU - Mathews, K. J. AU - Fisher, E. B. AU - Walker, M. S. DB - Embase Medline DO - 10.1200/JOP.2013.000982 IS - 6 KW - adult advanced cancer African American aged article Asian American breast cancer coach intervention colorectal cancer controlled study depression female follow up functional assessment health care personnel hospital readmission human lung cancer major clinical study male patient patient education prostate carcinoma quality of life racism randomized controlled trial telephone interview trust usual care very elderly LA - English M3 - Article N1 - L372612076 2014-03-25 2014-03-27 PY - 2013 SN - 1554-7477 1935-469X SP - 294-299 ST - Coaching intervention as a strategy for minority recruitment to cancer clinical trials T2 - Journal of Oncology Practice TI - Coaching intervention as a strategy for minority recruitment to cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372612076&from=export http://dx.doi.org/10.1200/JOP.2013.000982 http://jop.ascopubs.org/content/9/6/294.full.pdf+html VL - 9 ID - 1067 ER - TY - JOUR AB - Purpose: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. Patients and Methods: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made biweekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. Results: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment- General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. Conclusions: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC. AD - Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St Louis, MO AN - 104157655. Language: English. Entry Date: 20131118. Revision Date: 20200708. Publication Type: Journal Article AU - Fracasso, Paula M. AU - Goodner, Sherry A. AU - Creekmore, Allison N. AU - Morgan, Helen P. AU - Foster, Denise M. AU - Hardmon, Angela A. AU - Engel, Seth J. AU - Springer, Brian C. AU - Mathews, Katherine J. AU - Fisher, Edwin B. AU - Walker, Mark S. DB - CINAHL Complete DO - 10.1200/JOP.2013.000982 DP - EBSCOhost IS - 6 KW - Minority Groups Cancer Patients Research Subject Recruitment Human Male Female Random Assignment Questionnaires Prospective Studies Odds Ratio Fisher's Exact Test Adult Middle Age Aged Aged, 80 and Over Confidence Intervals Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. Special Interest: Oncologic Care. Instrumentation: Functional Assessment of Cancer Therapy-General (FACT-G). Grant Information: This study was supported by National Institutes of Health Grant No. R21 CA101725, Overcoming Barriers to Early Phase Clinical Trials, and the St. Louis Men’s Group Against Cancer.. NLM UID: 101261852. PMID: NLM24130255. PY - 2013 SN - 1554-7477 SP - 294-301 ST - Coaching Intervention As a Strategy for Minority Recruitment to Cancer Clinical Trials T2 - Journal of Oncology Practice TI - Coaching Intervention As a Strategy for Minority Recruitment to Cancer Clinical Trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104157655&site=ehost-live&scope=site VL - 9 ID - 1887 ER - TY - JOUR AB - Purpose: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. Patients and Methods: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made bi-weekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. Results: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment-General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. Conclusions: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC. Copyright © 2013 by American Society of Clinical Oncology. AD - Alvin J. Siteman Cancer Center, Barnes-Jewish Hospital, Washington University School of Medicine, St Louis, MO, United States AU - Fracasso, P. M. AU - Goodner, S. A. AU - Creekmore, A. N. AU - Morgan, H. P. AU - Foster, D. M. AU - Hardmon, A. A. AU - Engel, S. J. AU - Springer, B. C. AU - Mathews, K. J. AU - Fisher, E. B. AU - Walker, M. S. DB - Scopus DO - 10.1200/JOP.2013.000982 IS - 6 M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2013 SP - 294-299 ST - Coaching intervention as a strategy for minority recruitment to cancer clinical trials T2 - Journal of Oncology Practice TI - Coaching intervention as a strategy for minority recruitment to cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896263630&doi=10.1200%2fJOP.2013.000982&partnerID=40&md5=21298de52ba2388a54a22de831312f0f VL - 9 ID - 2447 ER - TY - JOUR AB - Many individuals receive information about genomics from the mass media. When media reports are about conditions that are considered behavioral, such as smoking, they may negatively affect some health-promoting cognitions. We examined how informing adult smokers about the genetic basis for nicotine addiction influenced smoking-related health cognitions and affect and whether responses varied by socio-demographics or genetics beliefs. We recruited 392 smokers (Mage = 44.5, 52.8% African American, 51.3% no college experience, 66.2% women) from public locations in a mid-sized Midwestern city. They were randomly assigned to read a news article describing either a pharmacy's decision to stop selling tobacco (n = 78) or the discovery of a gene associated with increased risk of nicotine addiction and lung cancer (n = 314). Participants also completed a survey assessing socio-demographics, health cognitions (quit intentions, self-efficacy, response efficacy, perceived risk), affect (worry, anticipated regret), genetic determinism, and other genetics beliefs. ANOVAs revealed no statistically significant main effects of genetic information on any health cognitions or affects. Linear regressions revealed that socio-demographics and genetics beliefs moderated very few effects. This suggests that concerns that mass media-based dissemination of genetic discoveries may have detrimental effects on smoking-related cognitions and affects are likely unwarranted. AU - Waters, E. A. AU - Ackerman, N. AU - Wheeler, C. S. DB - Medline DO - 10.1080/10810730.2019.1664676 IS - 9 KW - adolescent adult affect aged cognition controlled study female genetic predisposition genetics human male mass medium medical information middle aged psychology questionnaire randomized controlled trial risk assessment smoking socioeconomics tobacco dependence young adult LA - English M3 - Article N1 - L629342232 2019-09-20 PY - 2019 SN - 1087-0415 SP - 700-710 ST - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers T2 - Journal of health communication TI - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629342232&from=export http://dx.doi.org/10.1080/10810730.2019.1664676 VL - 24 ID - 868 ER - TY - JOUR AB - Many individuals receive information about genomics from the mass media. When media reports are about conditions that are considered behavioral, such as smoking, they may negatively affect some health‐promoting cognitions. We examined how informing adult smokers about the genetic basis for nicotine addiction influenced smoking‐related health cognitions and affect and whether responses varied by socio‐demographics or genetics beliefs. We recruited 392 smokers (Mage = 44.5, 52.8% African American, 51.3% no college experience, 66.2% women) from public locations in a mid‐sized Midwestern city. They were randomly assigned to read a news article describing either a pharmacy's decision to stop selling tobacco (n = 78) or the discovery of a gene associated with increased risk of nicotine addiction and lung cancer (n = 314). Participants also completed a survey assessing socio‐demographics, health cognitions (quit intentions, self‐efficacy, response efficacy, perceived risk), affect (worry, anticipated regret), genetic determinism, and other genetics beliefs. ANOVAs revealed no statistically significant main effects of genetic information on any health cognitions or affects. Linear regressions revealed that socio‐demographics and genetics beliefs moderated very few effects. This suggests that concerns that mass media‐based dissemination of genetic discoveries may have detrimental effects on smoking‐related cognitions and affects are likely unwarranted. AN - CN-01990095 AU - Waters, E. A. AU - Ackerman, N. AU - Wheeler, C. S. DO - 10.1080/10810730.2019.1664676 IS - 9 KW - *genetic risk *mass medium *smoking Adolescent Adult Affect African American Aged Article Cognition Controlled study Drug efficacy Female Genetic Predisposition to Disease Genetic susceptibility Health Communication Human Humans Linear regression analysis Lung cancer Major clinical study Male Mass Media Middle Aged Randomized controlled trial Risk Assessment Self concept Smokers [*psychology, statistics & numerical data] Socioeconomic Factors Surveys and Questionnaires Tobacco Use Disorder [*genetics] Tobacco dependence Young Adult M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2019 SP - 700‐710 ST - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers T2 - Journal of health communication TI - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01990095/full VL - 24 ID - 1530 ER - TY - JOUR AB - Many individuals receive information about genomics from the mass media. When media reports are about conditions that are considered behavioral, such as smoking, they may negatively affect some health-promoting cognitions. We examined how informing adult smokers about the genetic basis for nicotine addiction influenced smoking-related health cognitions and affect and whether responses varied by socio-demographics or genetics beliefs. We recruited 392 smokers (Mage = 44.5, 52.8% African American, 51.3% no college experience, 66.2% women) from public locations in a mid-sized Midwestern city. They were randomly assigned to read a news article describing either a pharmacy’s decision to stop selling tobacco (n = 78) or the discovery of a gene associated with increased risk of nicotine addiction and lung cancer (n = 314). Participants also completed a survey assessing socio-demographics, health cognitions (quit intentions, self-efficacy, response efficacy, perceived risk), affect (worry, anticipated regret), genetic determinism, and other genetics beliefs. ANOVAs revealed no statistically significant main effects of genetic information on any health cognitions or affects. Linear regressions revealed that socio-demographics and genetics beliefs moderated very few effects. This suggests that concerns that mass media-based dissemination of genetic discoveries may have detrimental effects on smoking-related cognitions and affects are likely unwarranted. ©, Copyright © Taylor & Francis Group, LLC. AD - Department of Surgery, Washington University School of Medicine, Saint Louis, MO, United States AU - Waters, E. A. AU - Ackerman, N. AU - Wheeler, C. S. DB - Scopus DO - 10.1080/10810730.2019.1664676 IS - 9 M3 - Article N1 - Export Date: 22 March 2021 PY - 2019 SP - 700-710 ST - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers T2 - Journal of Health Communication TI - Cognitive and Affective Responses to Mass-media Based Genetic Risk Information in a Socio-demographically Diverse Sample of Smokers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073817746&doi=10.1080%2f10810730.2019.1664676&partnerID=40&md5=ac703d893c14c33c29539c19525cb91b VL - 24 ID - 2221 ER - TY - JOUR AB - Background: Patient navigators may increase colorectal cancer (CRC) screening rates among adults in under-served communities, but prior randomized trials have been small or conducted at single sites and have not included substantial numbers of Haitian Creole-speaking or Portuguese-speaking patients. Methods: We identified 465 primary care patients from 4 community health centers and 2 public hospital-based clinics who were not up-to-date with CRC screening and spoke English, Haitian Creole, Portuguese, or Spanish as their primary language. We enrolled participants from September 1, 2008, through March 31, 2009, and followed them up for 1 year after enrollment. We randomly allocated patients to receive a patient navigation-based intervention or usual care. Intervention patients received an introductory letter from their primary care provider with educational material, followed by telephone calls from a language-concordant navigator. The navigators offered patients the option of being screened by fecal occult blood testing or colonoscopy. The primary outcome was completion of any CRC screening within 1 year. Secondary outcomes included the proportions of patients screened by colonoscopy who had adenomas or cancer detected. Results: During a 1-year period, intervention patients were more likely to undergo CRC screening than control patients (33.6% vs 20.0%; P<.001), to be screened by colonoscopy (26.4% vs 13.0%; P<.001), and to have adenomas detected (8.1% vs 3.9%; P=.06). In prespecified subgroup analyses, the navigator intervention was particularly beneficial for patients whose primary language was other than English (39.8% vs 18.6%; P<.001) and black patients (39.7% vs 16.7%; P=.004). Conclusions: Patient navigation increased completion of CRC screening among ethnically diverse patients. Targeting patient navigation to black and non-English-speaking patients may be a useful approach to reducing disparities in CRC screening. AN - WOS:000290874400007 AU - Lasser, K. E. AU - Murillo, J. AU - Lisboa, S. AU - Casimir, A. N. AU - Valley-Shah, L. AU - Emmons, K. M. AU - Fletcher, R. H. AU - Ayanian, J. Z. DA - May DO - 10.1001/archinternmed.2011.201 IS - 10 N1 - 21606094 PY - 2011 SN - 0003-9926 SP - 906-912 ST - Colorectal Cancer Screening Among Ethnically Diverse, Low-Income Patients A Randomized Controlled Trial T2 - Archives of Internal Medicine TI - Colorectal Cancer Screening Among Ethnically Diverse, Low-Income Patients A Randomized Controlled Trial VL - 171 ID - 3096 ER - TY - JOUR AB - Background: Patient navigators may increase colorectal cancer (CRC) screening rates among adults in underserved communities, but prior randomized trials have been small or conducted at single sites and have not included substantial numbers of Haitian Creole-speaking or Portuguese- speaking patients. Methods: We identified 465 primary care patients from 4 community health centers and 2 public hospital- based clinics who were not up-to-date with CRC screening and spoke English, Haitian Creole, Portuguese, or Spanish as their primary language. We enrolled participants from September 1, 2008, through March 31, 2009, and followed them up for 1 year after enrollment. We randomly allocated patients to receive a patient navigation- based intervention or usual care. Intervention patients received an introductory letter from their primary care provider with educational material, followed by telephone calls from a language-concordant navigator. The navigators offered patients the option of being screened by fecal occult blood testing or colonoscopy. The primary outcome was completion of any CRC screening within 1 year. Secondary outcomes included the proportions of patients screened by colonoscopy who had adenomas or cancer detected. Results: During a 1-year period, intervention patients were more likely to undergo CRC screening than control patients (33.6% vs 20.0%; P<.001), to be screened by colonoscopy (26.4% vs 13.0%; P<.001), and to have adenomas detected (8.1% vs 3.9%; P=.06). In prespecified subgroup analyses, the navigator intervention was particularly beneficial for patients whose primary language was other than English (39.8% vs 18.6%; P<.001) and black patients (39.7% vs 16.7%; P=.004). Conclusions: Patient navigation increased completion of CRC screening among ethnically diverse patients. Targeting patient navigation to black and non-Englishspeaking patients may be a useful approach to reducing disparities in CRC screening. © 2011 American Medical Association. AD - K. E. Lasser, Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, Department of Community Health Sciences, Boston University School of Public Health, 801 Massachusetts Ave, Ste 2091, Boston, MA 02118, United States AU - Lasser, K. E. AU - Murillo, J. AU - Lisboa, S. AU - Casimir, A. N. AU - Shah, L. V. AU - Emmons, K. M. AU - Fletcher, R. H. AU - Ayanian, J. Z. DB - Embase Medline DO - 10.1001/archinternmed.2011.201 IS - 10 KW - NCT01141114 adult aged article cancer diagnosis cancer patient cancer screening colonoscopy colorectal adenoma colorectal cancer controlled study ethnic group female health care personnel human intervention study lowest income group major clinical study male multicenter study occult blood test outcome assessment patient care primary medical care priority journal public hospital randomized controlled trial telephone LA - English M3 - Article N1 - L361828607 2011-06-02 2011-06-06 PY - 2011 SN - 0003-9926 1538-3679 SP - 906-912 ST - Colorectal cancer screening among ethnically diverse, low-income patients: A randomized controlled trial T2 - Archives of Internal Medicine TI - Colorectal cancer screening among ethnically diverse, low-income patients: A randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361828607&from=export http://dx.doi.org/10.1001/archinternmed.2011.201 http://archinte.ama-assn.org/cgi/reprint/171/10/906 VL - 171 ID - 1140 ER - TY - JOUR AB - Background: Patient navigators may increase colorectal cancer (CRC) screening rates among adults in underserved communities, but prior randomized trials have been small or conducted at single sites and have not included substantial numbers of Haitian Creole-speaking or Portuguese- speaking patients. Methods: We identified 465 primary care patients from 4 community health centers and 2 public hospital- based clinics who were not up-to-date with CRC screening and spoke English, Haitian Creole, Portuguese, or Spanish as their primary language. We enrolled participants from September 1, 2008, through March 31, 2009, and followed them up for 1 year after enrollment. We randomly allocated patients to receive a patient navigation- based intervention or usual care. Intervention patients received an introductory letter from their primary care provider with educational material, followed by telephone calls from a language-concordant navigator. The navigators offered patients the option of being screened by fecal occult blood testing or colonoscopy. The primary outcome was completion of any CRC screening within 1 year. Secondary outcomes included the proportions of patients screened by colonoscopy who had adenomas or cancer detected. Results: During a 1-year period, intervention patients were more likely to undergo CRC screening than control patients (33.6% vs 20.0%; P<.001), to be screened by colonoscopy (26.4% vs 13.0%; P<.001), and to have adenomas detected (8.1% vs 3.9%; P=.06). In prespecified subgroup analyses, the navigator intervention was particularly beneficial for patients whose primary language was other than English (39.8% vs 18.6%; P<.001) and black patients (39.7% vs 16.7%; P=.004). Conclusions: Patient navigation increased completion of CRC screening among ethnically diverse patients. Targeting patient navigation to black and non-Englishspeaking patients may be a useful approach to reducing disparities in CRC screening. © 2011 American Medical Association. AD - Section of General Internal Medicine, Boston Medical Center and Boston University School of Medicine, Department of Community Health Sciences, Boston University School of Public Health, 801 Massachusetts Ave, Ste 2091, Boston, MA 02118, United States Department of Biomedical Sciences, Boston University School of Medicine, Boston, MA, United States Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, United States Department of Population Medicine/Harvard Medical School, Harvard Pilgrim Health Care, Boston, MA, United States Division of General Medicine, Brigham and Women's Hospital and Department of Health Care Policy, Harvard Medical School, Boston, MA, United States Departments of Medicine, Cambridge Health Alliance and Harvard Medical School, Cambridge, MA, United States Community Affairs, Cambridge Health Alliance and Harvard Medical School, Cambridge, MA, United States Division of Gastroenterology, Cambridge Health Alliance and Harvard Medical School, Cambridge, MA, United States AU - Lasser, K. E. AU - Murillo, J. AU - Lisboa, S. AU - Casimir, A. N. AU - Shah, L. V. AU - Emmons, K. M. AU - Fletcher, R. H. AU - Ayanian, J. Z. DB - Scopus DO - 10.1001/archinternmed.2011.201 IS - 10 M3 - Article N1 - Cited By :144 Export Date: 22 March 2021 PY - 2011 SP - 906-912 ST - Colorectal cancer screening among ethnically diverse, low-income patients: A randomized controlled trial T2 - Archives of Internal Medicine TI - Colorectal cancer screening among ethnically diverse, low-income patients: A randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957567464&doi=10.1001%2farchinternmed.2011.201&partnerID=40&md5=5181041131cb52bc41016fc255d0cc9c VL - 171 ID - 2477 ER - TY - JOUR AB - Introduction: Low-income, low-literacy, limited English-proficient populations have low colorectal cancer (CRC) screening rates and experience poor patient-provider communication and decision-making processes around screening. The purpose of this study was to test the effect of a CRC screening decision aid on screening-related communication and decision making in primary care visits. Study design: RCT with data collected from patients at baseline and immediately after the provider encounter. Setting/participants: Patients aged 50-75 years, due for CRC screening, were recruited from two safety net clinics in North Carolina and New Mexico (data collection, January 2014-September 2015; analysis, 2015). Intervention: Participants viewed a CRC screening decision aid or a food safety (control) video immediately before their provider encounter. Main outcome measures: CRC screening-related knowledge, discussion, intent, test preferences, and test ordering. Results: The study population (N=262) had a mean age of 58.3 years and was 66% female, 61% Latino, 17% non-Latino black, and 16% non-Latino white. Among Latino participants, 71% preferred Spanish. Compared with controls, intervention participants had greater screening-related knowledge (on average 4.6 vs 2.8 of six knowledge items correct, adjusted difference [AD]=1.8, 95% CI=1.5, 2.1) and were more likely to report screening discussion (71.0% vs 45.0%, AD=26.1%, 95% CI=14.3%, 38.0%) and high screening intent (93.1% vs 84.7%, AD=9.0%, 95% CI=2.0%, 16.0%). Intervention participants were more likely to indicate a specific screening test preference (93.1% vs 68.0%, AD=26.5%, 95% CI=17.2%, 35.8%) and to report having a test ordered (56.5% vs 32.1%, AD=25.8%, 95% CI=14.4%, 37.2%). Conclusions: Viewing a CRC screening decision aid before a primary care encounter improves knowledge and shared decision making around screening in a racially, ethnically, and linguistically diverse safety net clinic population. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved. AN - WOS:000386784200010 AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Pignone, M. P. AU - Rhyne, R. L. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - de Hernandez, B. U. AU - Harbi, K. AU - Reuland, D. S. DA - Oct DO - 10.1016/j.amepre.2016.03.025 IS - 4 N1 - 27242081 PY - 2016 SN - 0749-3797 SP - 454-462 ST - Colorectal Cancer Screening in Vulnerable Patients Promoting Informed and Shared Decisions T2 - American Journal of Preventive Medicine TI - Colorectal Cancer Screening in Vulnerable Patients Promoting Informed and Shared Decisions VL - 51 ID - 2932 ER - TY - JOUR AB - Introduction Low-income, low-literacy, limited English-proficient populations have low colorectal cancer (CRC) screening rates and experience poor patient-provider communication and decision-making processes around screening. The purpose of this study was to test the effect of a CRC screening decision aid on screening-related communication and decision making in primary care visits. Study design RCT with data collected from patients at baseline and immediately after the provider encounter. Setting/participants Patients aged 50–75 years, due for CRC screening, were recruited from two safety net clinics in North Carolina and New Mexico (data collection, January 2014–September 2015; analysis, 2015). Intervention Participants viewed a CRC screening decision aid or a food safety (control) video immediately before their provider encounter. Main outcome measures CRC screening-related knowledge, discussion, intent, test preferences, and test ordering. Results The study population (N=262) had a mean age of 58.3 years and was 66% female, 61% Latino, 17% non-Latino black, and 16% non-Latino white. Among Latino participants, 71% preferred Spanish. Compared with controls, intervention participants had greater screening-related knowledge (on average 4.6 vs 2.8 of six knowledge items correct, adjusted difference [AD]=1.8, 95% CI=1.5, 2.1) and were more likely to report screening discussion (71.0% vs 45.0%, AD=26.1%, 95% CI=14.3%, 38.0%) and high screening intent (93.1% vs 84.7%, AD=9.0%, 95% CI=2.0%, 16.0%). Intervention participants were more likely to indicate a specific screening test preference (93.1% vs 68.0%, AD=26.5%, 95% CI=17.2%, 35.8%) and to report having a test ordered (56.5% vs 32.1%, AD=25.8%, 95% CI=14.4%, 37.2%). Conclusions Viewing a CRC screening decision aid before a primary care encounter improves knowledge and shared decision making around screening in a racially, ethnically, and linguistically diverse safety net clinic population. Trial registration This study is registered at www.clinicaltrials.gov NCT02054598. AD - D.S. Reuland, Division of General Internal Medicine and Clinical Epidemiology, University of North Carolina Hospital, 5045 Old Clinic Building, Chapel Hill, United States AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Pignone, M. P. AU - Rhyne, R. L. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - de Hernandez, B. U. AU - Harbi, K. AU - Reuland, D. S. DB - Embase Medline DO - 10.1016/j.amepre.2016.03.025 IS - 4 KW - adult aged article cancer screening colorectal cancer controlled study female food safety Hispanic human information dissemination intervention study knowledge major clinical study male New Mexico North Carolina patient decision making patient information patient preference primary medical care randomized controlled trial screening test vulnerable population LA - English M3 - Article N1 - L610532851 2016-06-03 2016-11-08 PY - 2016 SN - 1873-2607 0749-3797 SP - 454-462 ST - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions T2 - American Journal of Preventive Medicine TI - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610532851&from=export http://dx.doi.org/10.1016/j.amepre.2016.03.025 VL - 51 ID - 960 ER - TY - JOUR AB - Introduction: Low-income, low-literacy, limited English-proficient populations have low colorectal cancer (CRC) screening rates and experience poor patient-provider communication and decision-making processes around screening. The purpose of this study was to test the effect of a CRC screening decision aid on screening-related communication and decision making in primary care visits.Study Design: RCT with data collected from patients at baseline and immediately after the provider encounter.Setting/participants: Patients aged 50-75 years, due for CRC screening, were recruited from two safety net clinics in North Carolina and New Mexico (data collection, January 2014-September 2015; analysis, 2015).Intervention: Participants viewed a CRC screening decision aid or a food safety (control) video immediately before their provider encounter.Main Outcome Measures: CRC screening-related knowledge, discussion, intent, test preferences, and test ordering.Results: The study population (N=262) had a mean age of 58.3 years and was 66% female, 61% Latino, 17% non-Latino black, and 16% non-Latino white. Among Latino participants, 71% preferred Spanish. Compared with controls, intervention participants had greater screening-related knowledge (on average 4.6 vs 2.8 of six knowledge items correct, adjusted difference [AD]=1.8, 95% CI=1.5, 2.1) and were more likely to report screening discussion (71.0% vs 45.0%, AD=26.1%, 95% CI=14.3%, 38.0%) and high screening intent (93.1% vs 84.7%, AD=9.0%, 95% CI=2.0%, 16.0%). Intervention participants were more likely to indicate a specific screening test preference (93.1% vs 68.0%, AD=26.5%, 95% CI=17.2%, 35.8%) and to report having a test ordered (56.5% vs 32.1%, AD=25.8%, 95% CI=14.4%, 37.2%).Conclusions: Viewing a CRC screening decision aid before a primary care encounter improves knowledge and shared decision making around screening in a racially, ethnically, and linguistically diverse safety net clinic population.Trial Registration: This study is registered at www.clinicaltrials.gov NCT02054598. AD - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina Division of General Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa Department of Family Medicine, Carolinas HealthCare System, Charlotte, North Carolina Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico University of New Mexico Cancer Center, Albuquerque, New Mexico; Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina AN - 118027147. Language: English. Entry Date: 20171231. Revision Date: 20200405. Publication Type: journal article AU - Brenner, Alison T. AU - Hoffman, Richard AU - McWilliams, Andrew AU - Pignone, Michael P. AU - Rhyne, Robert L. AU - Tapp, Hazel AU - Weaver, Mark A. AU - Callan, Danelle AU - de Hernandez, Brisa Urquieta AU - Harbi, Khalil AU - Reuland, Daniel S. DB - CINAHL Complete DO - 10.1016/j.amepre.2016.03.025 DP - EBSCOhost IS - 4 KW - Health Screening -- Psychosocial Factors Special Populations -- Psychosocial Factors Colorectal Neoplasms -- Diagnosis Decision Making Decision Support Techniques Middle Age Aged Male Female Special Populations Human Randomized Controlled Trials Random Assignment N1 - research; randomized controlled trial. Journal Subset: Biomedical; Health Promotion/Education; USA. Grant Information: UL1 TR000041/TR/NCATS NIH HHS/United States. NLM UID: 8704773. PMID: NLM27242081. PY - 2016 SN - 0749-3797 SP - 454-462 ST - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions T2 - American Journal of Preventive Medicine TI - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118027147&site=ehost-live&scope=site VL - 51 ID - 1890 ER - TY - JOUR AB - Introduction Low-income, low-literacy, limited English-proficient populations have low colorectal cancer (CRC) screening rates and experience poor patient-provider communication and decision-making processes around screening. The purpose of this study was to test the effect of a CRC screening decision aid on screening-related communication and decision making in primary care visits. Study design RCT with data collected from patients at baseline and immediately after the provider encounter. Setting/participants Patients aged 50–75 years, due for CRC screening, were recruited from two safety net clinics in North Carolina and New Mexico (data collection, January 2014–September 2015; analysis, 2015). Intervention Participants viewed a CRC screening decision aid or a food safety (control) video immediately before their provider encounter. Main outcome measures CRC screening-related knowledge, discussion, intent, test preferences, and test ordering. Results The study population (N=262) had a mean age of 58.3 years and was 66% female, 61% Latino, 17% non-Latino black, and 16% non-Latino white. Among Latino participants, 71% preferred Spanish. Compared with controls, intervention participants had greater screening-related knowledge (on average 4.6 vs 2.8 of six knowledge items correct, adjusted difference [AD]=1.8, 95% CI=1.5, 2.1) and were more likely to report screening discussion (71.0% vs 45.0%, AD=26.1%, 95% CI=14.3%, 38.0%) and high screening intent (93.1% vs 84.7%, AD=9.0%, 95% CI=2.0%, 16.0%). Intervention participants were more likely to indicate a specific screening test preference (93.1% vs 68.0%, AD=26.5%, 95% CI=17.2%, 35.8%) and to report having a test ordered (56.5% vs 32.1%, AD=25.8%, 95% CI=14.4%, 37.2%). Conclusions Viewing a CRC screening decision aid before a primary care encounter improves knowledge and shared decision making around screening in a racially, ethnically, and linguistically diverse safety net clinic population. Trial registration This study is registered at www.clinicaltrials.gov NCT02054598. © 2016 American Journal of Preventive Medicine AD - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina, United States Division of General Internal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States Division of General Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, United States Department of Family Medicine, Carolinas HealthCare System, Charlotte, North Carolina, United States Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States University of New Mexico Cancer Center, Albuquerque, New Mexico, United States Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, United States AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Pignone, M. P. AU - Rhyne, R. L. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - de Hernandez, B. U. AU - Harbi, K. AU - Reuland, D. S. DB - Scopus DO - 10.1016/j.amepre.2016.03.025 IS - 4 M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2016 SP - 454-462 ST - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions T2 - American Journal of Preventive Medicine TI - Colorectal Cancer Screening in Vulnerable Patients: Promoting Informed and Shared Decisions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969916823&doi=10.1016%2fj.amepre.2016.03.025&partnerID=40&md5=00c4b3546566d01539e1f85bc0393347 VL - 51 ID - 2336 ER - TY - JOUR AB - Despite the significant advances in screening methods for early diagnosis, breast cancer remains a global threat and continues to be the leading cancer diagnosed in women, requiring effective therapy. Currently, combination therapy has become the hallmark of breast cancer treatment due to the high incidence of tumor recurrence and disease progression after monotherapeutic treatments, including surgery, radiotherapy, endocrine therapy, and chemotherapy. Over the past decades, there has been considerable interest in studying the anticancer effect of bioactive phytochemicals from medicinal plants combined with these conventional therapies. The rationale for this type of therapy is to use combinations of drugs that work by different mechanisms, thereby decreasing the likelihood that cancer cells will develop resistance, and also reduce the therapeutic dose and toxicity of single treatments. Three agents have received great attention with regard to their anticancer properties: 1) piperine, a dietary phytochemical isolated from black pepper (Piper nigrum L.) and long pepper (Piper longum L.); 2) sulforaphane, an isothiocyanate mainly derived from cruciferous vegetables; and 3) thymoquinone, the active compound from black seed (Nigella sativa L.). This review focused on the combined effect of these 3 compounds on conventional cancer therapy with the objective of observing enhanced efficacy compared with single treatments. This review also highlights the importance of the nanoformulation of such bioactive phytochemicals that could enhance their bioavailability by providing an efficient targeted delivery system with a reduced systemic dose while resulting in a more efficient dosing at the target site. AD - Department of Health Sciences, Faculty of Science, University of Mauritius, Reduit Mauritius AN - 136089728. Language: English. Entry Date: 20200208. Revision Date: 20200514. Publication Type: journal article AU - Aumeeruddy, M. Zakariyyah AU - Mahomoodally, M. Fawzi DB - CINAHL Complete DO - 10.1002/cncr.32022 DP - EBSCOhost IS - 10 KW - Benzoquinones -- Administration and Dosage Heterocyclic Compounds -- Administration and Dosage Medicine, Herbal -- Methods Breast Neoplasms -- Drug Therapy Alkaloids -- Administration and Dosage Piperidines -- Administration and Dosage Amides -- Administration and Dosage Phytochemicals -- Administration and Dosage Combined Modality Therapy Patient Selection In Vitro Studies Sensitivity and Specificity Breast Neoplasms -- Pathology Cell Line, Tumor -- Drug Effects Antineoplastic Agents -- Administration and Dosage Chemotherapy, Adjuvant Female Breast Neoplasms -- Mortality Radiotherapy, Adjuvant Scales N1 - review. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Work Environment Scale (WES) (Moos et al); Global Assessment of Functioning Scale (GAF). NLM UID: 0374236. PMID: NLM30811596. PY - 2019 SN - 0008-543X SP - 1600-1611 ST - Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone T2 - Cancer (0008543X) TI - Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136089728&site=ehost-live&scope=site VL - 125 ID - 1891 ER - TY - JOUR AB - Two regimens of chemotherapy for metastatic breast cancer were compared in a randomized controlled fashion. Regimen 1 consisted of cyclophosphamide, vinblastine, methotrexate and 5‐fluorouracil (CVMF). Regimen 2 consisted of cyclophosphamide, adriamycin, methotrexate and 5‐fluorouracil (CAMF). The patient population consisted of both black and white postmenopausal females who had not received any prior chemotherapy. Objective responses were observed in 25/57 patients treated with CVMF and in 28/51 patients treated with CAMF. Neither race nor choice of chemotherapeutic regimen affected prognosis, although there were differences in the pattern of metastatic involvement between the two racial groups. The median duration of survival of patients who responded to therapy has not yet been reached but will be in excess of 12 months. AN - CN-00021079 AU - Bezwoda, W. R. AU - de Moor, N. G. AU - Derman, D. AU - Lange, M. AU - Saner, R. AU - Dando, R. DO - 10.1002/1097-0142(197908)44:2<392::aid-cncr2820440204>3.0.co IS - 2 KW - Adult Aged Antineoplastic Agents [*administration & dosage, adverse effects] Bone Marrow [drug effects] Breast Neoplasms [*drug therapy, secondary] Clinical Trials as Topic Doxorubicin [*administration & dosage] Drug Therapy, Combination Female Humans Middle Aged Remission, Spontaneous Vinblastine [*administration & dosage] M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial PY - 1979 SP - 392‐397 ST - Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine T2 - Cancer TI - Combination chemotherapy of metastatic breast cancer: a randomized trial comparing the use of adriamycin to that of Vinblastine UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00021079/full VL - 44 ID - 1567 ER - TY - JOUR AB - BACKGROUND: Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. METHODS: A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35‐65. The primary objectives were to determine whether a 20‐week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self‐exam (BSE) proficiency. RESULTS: The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. ‐0.4, P<0.05; 3.3 vs. ‐0.2, P<0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P<0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P<0.05), and a trend for decreased dietary fat (‐2.6% kcal vs. 0.0% kcal, P=0.07) in the intervention compared to the control group. CONCLUSION: Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. AN - CN-00511377 AU - Fitzgibbon, M. L. AU - Stolley, M. R. AU - Schiffer, L. AU - Sanchez-Johnsen, L. A. AU - Wells, A. M. AU - Dyer, A. DO - 10.1016/j.ypmed.2004.06.018 IS - 4 KW - *breast cancer *health *obesity *weight reduction Adult African Continental Ancestry Group [*statistics & numerical data] Aged Article Body Mass Index Body Weight Breast Neoplasms [ethnology, *prevention & control] Breast [metabolism] Cancer prevention Clinical trial Cohort Studies Cohort analysis Controlled clinical trial Controlled study Delivery of Health Care [methods, statistics & numerical data] Diet Dietary intake Educational Status Exercise [*physiology] Fat intake Female Human Humans Life Style Major clinical study Middle Aged Negro Obesity [physiopathology, prevention & control] Physical activity Pilot Projects Pilot study Priority journal Randomized controlled trial Self examination Socioeconomic Factors Weight Loss M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 2005 SP - 373‐383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive medicine TI - A combined breast health/weight loss intervention for Black women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00511377/full VL - 40 ID - 1415 ER - TY - JOUR AB - Background. Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. Methods. A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. Results. The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P < 0.05; 3.3 vs. -0.2, P < 0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P < 0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P < 0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P = 0.07) in the intervention compared to the control group. Conclusion. Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. © 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AD - M.L. Fitzgibbon, Dept. of Psychiat. and Behav. Sci., Feinberg School of Medicine, Northwestern University, 60611-3008, Chicago, IL, United States AU - Fitzgibbon, M. L. AU - Stolley, M. R. AU - Schiffer, L. AU - Sanchez-Johnsen, L. A. P. AU - Wells, A. M. AU - Dyer, A. DB - Embase Medline DO - 10.1016/j.ypmed.2004.06.018 IS - 4 KW - adult article body weight breast cancer cancer prevention clinical trial cohort analysis controlled clinical trial controlled study dietary intake fat intake female health human major clinical study Black person obesity physical activity pilot study priority journal randomized controlled trial self examination body weight loss LA - English M3 - Article N1 - L39458057 2004-11-22 PY - 2005 SN - 0091-7435 SP - 373-383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive Medicine TI - A combined breast health/weight loss intervention for Black women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39458057&from=export http://dx.doi.org/10.1016/j.ypmed.2004.06.018 VL - 40 ID - 1268 ER - TY - JOUR AB - Background: Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. Methods: A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. Results: The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P < 0.05; 3.3 vs. -0.2, P < 0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P < 0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P < 0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P= 0.07) in the intervention compared to the control group. Conclusion. Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Fitzgibbon, Marian L., Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Drive, Suite 1200, Chicago, IL, US, 60611 AN - 2005-00152-002 AU - Fitzgibbon, Marian L. AU - Stolley, Melinda R. AU - Schiffer, Linda AU - Sanchez-Johnsen, Lisa A. P. AU - Wells, Anita M. AU - Dyer, Alan DB - psyh DO - 10.1016/j.ypmed.2004.06.018 DP - EBSCOhost IS - 4 KW - breast health intervention weight loss intervention Black women health behavior lifestyle changes physical activity Adult African Continental Ancestry Group Aged Body Mass Index Body Weight Breast Breast Neoplasms Cohort Studies Delivery of Health Care Diet Educational Status Exercise Female Humans Life Style Middle Aged Obesity Pilot Projects Socioeconomic Factors Weight Loss Intervention Weight Control Blacks Human Females N1 - Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, US. Release Date: 20050627. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Exercise; Health Behavior; Intervention; Lifestyle Changes; Weight Control. Minor Descriptor: Blacks; Breast; Human Females; Weight Loss. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Physical Activity Readiness Questionnaire; Percent Energy From Fat Screener; Breast self-Examination Proficiency Evaluation. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Apr, 2005. PY - 2005 SN - 0091-7435 SP - 373-383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive Medicine: An International Journal Devoted to Practice and Theory TI - A combined breast health/weight loss intervention for Black women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2005-00152-002&site=ehost-live&scope=site mlf056@northwestern.edu VL - 40 ID - 1759 ER - TY - JOUR AB - BACKGROUND: Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. METHODS: A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. RESULTS: The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P<0.05; 3.3 vs. -0.2, P<0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P<0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P<0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P=0.07) in the intervention compared to the control group. CONCLUSION: Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. Copyright © 2005 by Elsevier Science (USA). AD - Dept of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Dr, Suite 1200, Chicago, IL 60611; mfl056@northwestern.edu AN - 106598227. Language: English. Entry Date: 20050325. Revision Date: 20200708. Publication Type: Journal Article AU - Fitzgibbon, M. L. AU - Stolley, M. R. AU - Schiffer, L. AU - Sanchez-Johnsen, L. A. P. AU - Wells, A. M. AU - Dyer, A. DB - CINAHL Complete DO - 10.1016/j.ypmed.2004.06.018 DP - EBSCOhost IS - 4 KW - Black Persons Breast Neoplasms -- Prevention and Control Weight Control Adult Aged Breast Self-Examination Chi Square Test Clinical Trials Conceptual Framework Cultural Competence Descriptive Statistics Dietary Fats Female Illinois Interviews Logistic Regression Middle Age P-Value Physical Activity Pilot Studies Prospective Studies Research Instruments Self Report T-Tests Wilcoxon Rank Sum Test Funding Source Human N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Physical Activity Readiness Questionnaire (PAR-Q) (American College of Sports Medicine). Grant Information: National Cancer Institute (CA88935), a Postdoctoral Research Supplement for Underrepresented Minorities (CA88935-S), 1K07 CA-093946-01A2, 1K01CA098753 and L6MD000577. NLM UID: 0322116. PMID: NLM15530590. PY - 2005 SN - 0091-7435 SP - 373-383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive Medicine TI - A combined breast health/weight loss intervention for Black women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106598227&site=ehost-live&scope=site VL - 40 ID - 1812 ER - TY - JOUR AB - Background. Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. Methods. A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. Results. The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P < 0.05; 3.3 vs. -0.2, P < 0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P < 0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P < 0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P = 0.07) in the intervention compared to the control group. Conclusion. Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. © 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AD - Dept. of Psychiat. and Behav. Sci., Feinberg School of Medicine, Northwestern University, 60611-3008, Chicago, IL, United States Robert H. Lurie Compreh. Cancer Ctr., Chicago, IL, United States Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 60611-3008, Chicago, IL, United States Cancer Research Center of Hawai'i, University of Hawai'i-Manoa, Honolulu, HI, United States Dept. of Psychiat. and Behav. Sci., Feinberg School of Medicine, NW Univ., 710 N. Lake Shore Dr., S., United States AU - Fitzgibbon, M. L. AU - Stolley, M. R. AU - Schiffer, L. AU - Sanchez-Johnsen, L. A. P. AU - Wells, A. M. AU - Dyer, A. DB - Scopus DO - 10.1016/j.ypmed.2004.06.018 IS - 4 KW - African-American Black Breast cancer Breast health Breast self-exam Diet Intervention Minority Physical activity Weight loss M3 - Article N1 - Cited By :44 Export Date: 22 March 2021 PY - 2005 SP - 373-383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive Medicine TI - A combined breast health/weight loss intervention for Black women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-7644220111&doi=10.1016%2fj.ypmed.2004.06.018&partnerID=40&md5=9fb18ff5a70922a99013a4c68287e641 VL - 40 ID - 2595 ER - TY - JOUR AB - Background. Overall incidence of breast cancer is slightly lower, but mortality rates are higher, for Black women compared to White women. Higher body mass index (BMI), sedentary lifestyles, and lower compliance with recommended breast health behaviors may contribute to higher risk and mortality. Methods. A randomized pilot intervention trial was conducted to assess feasibility and efficacy of a combined breast health/weight loss intervention for 64 overweight or obese Black women, ages 35-65. The primary objectives were to determine whether a 20-week (twice weekly) intervention could decrease weight and dietary fat intake and increase physical activity and breast self-exam (BSE) proficiency. Results. The project was implemented in two cohorts and retention was high for both (96% and 89%, respectively). Both cohorts showed increased proficiency in BSE in the intervention versus the control group (2.4 vs. -0.4, P < 0.05; 3.3 vs. -0.2, P < 0.001, respectively), but only cohort 2 showed decreased percent body weight (4.0% decrease vs. 0.9% increase, P < 0.01), increased physical activity frequency (2.4 vs. 0.1 times/week, P < 0.05), and a trend for decreased dietary fat (-2.6% kcal vs. 0.0% kcal, P = 0.07) in the intervention compared to the control group. Conclusion. Few studies have documented weight loss among Black women, and no combined breast health/weight loss intervention has been conducted. This study documents the feasibility of recruiting, randomizing, and retaining women in a combined intervention and demonstrated weight loss and associated lifestyle changes. (C) 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AN - WOS:000226036400002 AU - Fitzgibbon, M. L. AU - Stolley, M. R. AU - Schiffer, L. AU - Sanchez-Johnsen, L. A. P. AU - Wells, A. M. AU - Dyer, A. DA - Apr DO - 10.1016/j.ypmed.2004.06.018 IS - 4 N1 - 15530590 PY - 2005 SN - 0091-7435 SP - 373-383 ST - A combined breast health/weight loss intervention for Black women T2 - Preventive Medicine TI - A combined breast health/weight loss intervention for Black women VL - 40 ID - 3244 ER - TY - JOUR AB - Background: Castration resistance occurs in most patients with metastatic hormone‐sensitive prostate cancer who are receiving androgen‐deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence. Methods: Men with newly diagnosed, metastatic, hormone‐sensitive prostate cancer, a performance status of 0 to 2, and a prostate‐specific antigen (PSA) level of 5. ng per milliliter or higher received a luteinizing hormone‐releasing hormone analogue and an antiandrogen agent for 7 months. We then randomly assigned patients in whom the PSA level fell to 4. ng per milliliter or lower to continuous or intermittent androgen deprivation, with patients stratified according to prior or no prior hormonal therapy, performance status, and extent of disease (minimal or extensive). The coprimary objectives were to assess whether intermittent therapy was noninferior to continuous therapy with respect to survival, with a one‐sided test with an upper boundary of the hazard ratio of 1.20, and whether quality of life differed between the groups 3 months after randomization. Results: A total of 3040 patients were enrolled, of whom 1535 were included in the analysis: 765 randomly assigned to continuous androgen deprivation and 770 assigned to intermittent androgen deprivation. The median follow‐up period was 9.8 years. Median survival was 5.8 years in the continuous‐therapy group and 5.1 years in the intermittent‐therapy group (hazard ratio for death with intermittent therapy, 1.10; 90% confidence interval, 0.99 to 1.23). Intermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003, respectively) at month 3 but not thereafter. There were no significant differences between the groups in the number of treatment‐related high‐grade adverse events. Conclusions: Our findings were statistically inconclusive. In patients with metastatic hormone‐sensitive prostate cancer, the confidence interval for survival exceeded the upper boundary for noninferiority, suggesting that we cannot rule out a 20% greater risk of death with intermittent therapy than with continuous therapy, but too few events occurred to rule out significant inferiority of intermittent therapy. Intermittent therapy resulted in small improvements in quality of life. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00002651.). © 2014 Elsevier Inc. AN - CN-01041441 AU - Eggener, S. DO - 10.1016/j.urolonc.2014.01.009 IS - 6 KW - *cancer risk *low risk patient *prostate cancer /epidemiology /surgery African American Cancer epidemiology Cancer mortality Follow up Health disparity Human Nuclear magnetic resonance imaging Practice guideline Priority journal Prostate biopsy Prostatectomy Race difference Randomized controlled trial Short survey M3 - Journal: Short Survey PY - 2014 SP - 936‐937 ST - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." T2 - Urologic oncology: seminars and original investigations TI - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01041441/full VL - 32 ID - 1519 ER - TY - JOUR AB - Background: Castration resistance occurs in most patients with metastatic hormone-sensitive prostate cancer who are receiving androgen-deprivation therapy. Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence. Methods: Men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, a performance status of 0 to 2, and a prostate-specific antigen (PSA) level of 5. ng per milliliter or higher received a luteinizing hormone-releasing hormone analogue and an antiandrogen agent for 7 months. We then randomly assigned patients in whom the PSA level fell to 4. ng per milliliter or lower to continuous or intermittent androgen deprivation, with patients stratified according to prior or no prior hormonal therapy, performance status, and extent of disease (minimal or extensive). The coprimary objectives were to assess whether intermittent therapy was noninferior to continuous therapy with respect to survival, with a one-sided test with an upper boundary of the hazard ratio of 1.20, and whether quality of life differed between the groups 3 months after randomization. Results: A total of 3040 patients were enrolled, of whom 1535 were included in the analysis: 765 randomly assigned to continuous androgen deprivation and 770 assigned to intermittent androgen deprivation. The median follow-up period was 9.8 years. Median survival was 5.8 years in the continuous-therapy group and 5.1 years in the intermittent-therapy group (hazard ratio for death with intermittent therapy, 1.10; 90% confidence interval, 0.99 to 1.23). Intermittent therapy was associated with better erectile function and mental health (P<0.001 and P=0.003, respectively) at month 3 but not thereafter. There were no significant differences between the groups in the number of treatment-related high-grade adverse events. Conclusions: Our findings were statistically inconclusive. In patients with metastatic hormone-sensitive prostate cancer, the confidence interval for survival exceeded the upper boundary for noninferiority, suggesting that we cannot rule out a 20% greater risk of death with intermittent therapy than with continuous therapy, but too few events occurred to rule out significant inferiority of intermittent therapy. Intermittent therapy resulted in small improvements in quality of life. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00002651.). © 2014 Elsevier Inc. AU - Eggener, S. DB - Scopus DO - 10.1016/j.urolonc.2014.01.009 IS - 6 M3 - Short Survey N1 - Cited By :2 Export Date: 22 March 2021 PY - 2014 SP - 936-937 ST - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." T2 - Urologic Oncology: Seminars and Original Investigations TI - Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905163620&doi=10.1016%2fj.urolonc.2014.01.009&partnerID=40&md5=8088c8a3b7110d1951c0d5f873a63b2f VL - 32 ID - 2415 ER - TY - JOUR AB - Objective: Test the impact of tailoring CRC screening messages for African Americans (AAs) using novel theoretical variables and to examine moderating effect of communication preferences. Methods: Participants were randomized to receive two minimally tailored or two enhanced tailored print newsletters addressing CRC. The enhanced intervention was tailored on Self-Determination Theory and other novel psychological constructs. Minimal tailoring only used information available in the patient's EHR. The primary outcome was CRC screening based on EHR. Participants were AA members aged 50-74 of an integrated health care delivery system not up to date on CRC screening. Results: We enrolled 881 participants. CRC screening participation rates at 1-year follow up were 20.5% and 21.5% in the minimally and enhanced tailored groups, respectively. Communication preferences moderated the impact of the intervention. Specifically, among those with an autonomous communication preference, screening rates in the minimally and enhanced tailored groups were 17.1% and 25.9%, respectively, while no intervention effect was evident among those with a directive preference. Conclusion: Future research is needed to explore the impact of communication preference tailoring for other health behaviors and among other populations. Practice implications: Tailored communications should consider communication style preference to help guide the content and tone of messages. AD - K. Resnicow, University of Michigan School of Public Health, Department of Health Behavior and Health Education, 109 Observatory Street, Room 3867 SPH I, Ann Arbor, MI, United States AU - Resnicow, K. AU - Zhou, Y. AU - Hawley, S. AU - Jimbo, M. AU - Ruffin, M. T. AU - Davis, R. E. AU - Shires, D. AU - Lafata, J. E. DB - Embase DO - 10.1016/j.pec.2014.08.013. IS - 3 KW - adult African American aged article cancer screening colorectal cancer electronic medical record female health behavior health care health care utilization human major clinical study male medical information patient attitude patient participation patient preference publication randomized controlled trial LA - English M3 - Article N1 - L600354434 2014-11-13 2014-11-17 PY - 2014 SN - 1873-5134 0738-3991 SP - 370-375 ST - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans T2 - Patient Education and Counseling TI - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600354434&from=export http://dx.doi.org/10.1016/j.pec.2014.08.013. VL - 97 ID - 1019 ER - TY - JOUR AB - OBJECTIVE: Test the impact of tailoring CRC screening messages for African Americans (AAs) using novel theoretical variables and to examine moderating effect of communication preferences. METHODS: Participants were randomized to receive two minimally tailored or two enhanced tailored print newsletters addressing CRC. The enhanced intervention was tailored on Self-Determination Theory and other novel psychological constructs. Minimal tailoring only used information available in the patient's EHR. The primary outcome was CRC screening based on EHR. Participants were AA members aged 50-74 of an integrated health care delivery system not up to date on CRC screening. RESULTS: We enrolled 881 participants. CRC screening participation rates at 1-year follow up were 20.5% and 21.5% in the minimally and enhanced tailored groups, respectively. Communication preferences moderated the impact of the intervention. Specifically, among those with an autonomous communication preference, screening rates in the minimally and enhanced tailored groups were 17.1% and 25.9%, respectively, while no intervention effect was evident among those with a directive preference. CONCLUSION: Future research is needed to explore the impact of communication preference tailoring for other health behaviors and among other populations. PRACTICE IMPLICATIONS: Tailored communications should consider communication style preference to help guide the content and tone of messages. AU - Resnicow, K. AU - Zhou, Y. AU - Hawley, S. AU - Jimbo, M. AU - Ruffin, M. T. AU - Davis, R. E. AU - Shires, D. AU - Lafata, J. E. DB - Medline DO - 10.1016/j.pec.2014.08.013 IS - 3 KW - African American aged attitude to health colorectal tumor controlled study early cancer diagnosis education ethnology female human male mass screening medical information Michigan middle aged patient attitude patient compliance patient education patient preference procedures psychology randomized controlled trial statistics and numerical data teaching utilization LA - English M3 - Article N1 - L615281344 2017-07-03 PY - 2014 SN - 1873-5134 SP - 370-375 ST - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans T2 - Patient education and counseling TI - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615281344&from=export http://dx.doi.org/10.1016/j.pec.2014.08.013 VL - 97 ID - 1024 ER - TY - JOUR AB - Objective: Test the impact of tailoring CRC screening messages for African Americans (AAs) using novel theoretical variables and to examine moderating effect of communication preferences. Methods: Participants were randomized to receive two minimally tailored or two enhanced tailored print newsletters addressing CRC. The enhanced intervention was tailored on Self-Determination Theory and other novel psychological constructs. Minimal tailoring only used information available in the patient's EHR. The primary outcome was CRC screening based on EHR. Participants were AA members aged 50-74 of an integrated health care delivery system not up to date on CRC screening. Results: We enrolled 881 participants. CRC screening participation rates at 1-year follow up were 20.5% and 21.5% in the minimally and enhanced tailored groups, respectively. Communication preferences moderated the impact of the intervention. Specifically, among those with an autonomous communication preference, screening rates in the minimally and enhanced tailored groups were 17.1% and 25.9%, respectively, while no intervention effect was evident among those with a directive preference. Conclusion: Future research is needed to explore the impact of communication preference tailoring for other health behaviors and among other populations. Practice implications: Tailored communications should consider communication style preference to help guide the content and tone of messages. © 2014 Elsevier Ireland Ltd. AD - University of Michigan School of Public Health, Department of Health Behavior and Health Education, Ann Arbor, United States University of Michigan, Ann Arbor, United States University of South Carolina, Columbia, United States Henry Ford Health System, Detroit, United States Virginia Commonwealth University, Richmond, United States AU - Resnicow, K. AU - Zhou, Y. AU - Hawley, S. AU - Jimbo, M. AU - Ruffin, M. T. AU - Davis, R. E. AU - Shires, D. AU - Lafata, J. E. DB - Scopus DO - 10.1016/j.pec.2014.08.013 IS - 3 KW - African Americans Colorectal cancer screening Tailored intervention M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2014 SP - 370-375 ST - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans T2 - Patient Education and Counseling TI - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047699847&doi=10.1016%2fj.pec.2014.08.013&partnerID=40&md5=9c1aef2c3bc3530906e90b68d63dd1eb VL - 97 ID - 2382 ER - TY - JOUR AB - Objective: Test the impact of tailoring CRC screening messages for African Americans (AAs) using novel theoretical variables and to examine moderating effect of communication preferences. Methods: Participants were randomized to receive two minimally tailored or two enhanced tailored print newsletters addressing CRC. The enhanced intervention was tailored on Self-Determination Theory and other novel psychological constructs. Minimal tailoring only used information available in the patient's EHR. The primary outcome was CRC screening based on EHR. Participants were AA members aged 50-74 of an integrated health care delivery system not up to date on CRC screening. Results: We enrolled 881 participants. CRC screening participation rates at 1-year follow up were 20.5% and 21.5% in the minimally and enhanced tailored groups, respectively. Communication preferences moderated the impact of the intervention. Specifically, among those with an autonomous communication preference, screening rates in the minimally and enhanced tailored groups were 17.1% and 25.9%, respectively, while no intervention effect was evident among those with a directive preference. Conclusion: Future research is needed to explore the impact of communication preference tailoring for other health behaviors and among other populations. Practice implications: Tailored communications should consider communication style preference to help guide the content and tone of messages. (C) 2014 Elsevier Ireland Ltd. All rights reserved. AN - WOS:000345955500010 AU - Resnicow, K. AU - Zhou, Y. AU - Hawley, S. AU - Jimbo, M. AU - Ruffin, M. T. AU - Davis, R. E. AU - Shires, D. AU - Lafata, J. E. DA - Dec DO - 10.1016/j.pec.2014.08.013 IS - 3 N1 - 25224317 PY - 2014 SN - 0738-3991 SP - 370-375 ST - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans T2 - Patient Education and Counseling TI - Communication preference moderates the effect of a tailored intervention to increase colorectal cancer screening among African Americans VL - 97 ID - 2992 ER - TY - JOUR AB - South Dallas experiences significant disparities in breast cancer mortality, with a high proportion of stage III and IV diagnoses. To address these rates, the Dallas Cancer Disparities Community Research Coalition created an educational intervention to promote breast health and early detection efforts. The goals of the intervention were to increase (a) knowledge regarding the chief contributing factors for breast cancer, (b) awareness of the importance of screening for early detection, and (c) the proportion of women who have engaged in appropriate breast cancer screening practices. Eligibility criteria for this nonrandomized, controlled trial included women age 40 and older, English-speaking, and having no personal history of cancer. Control participants received written breast health educational materials. Intervention participants attended 8 weekly sessions that included interactive educational materials, cooking demonstrations, and discussions emphasizing primary and secondary breast cancer prevention. All study participants completed a 1-hour survey at baseline and 4 months later. There were 59 women were enrolled in the intervention and 60 in the control group. At follow-up, after controlling for baseline mammography status, women in the intervention group were 10.4 times more likely (95% confidence interval [CI], 2.9-36.4) to have received a screening mammogram in the last year compared with the control group. Intervention participants demonstrated statistically significantly higher rates of breast self-examination (odds ratio [OR], 3.0; 95% CI, 1.0-8.6) and breast cancer knowledge (p=.003). Lessons learned from this community-based participatory research (CBPR) study can be used to create sustainable cancer disparity reduction models that can be replicated in similar communities. AD - K. Cardarelli, School of Public Health, University of North Texas Health Science Center, and Parkland Health and Hospital System, Dallas, TX, USA. AU - Cardarelli, K. AU - Jackson, R. AU - Martin, M. AU - Linnear, K. AU - Lopez, R. AU - Senteio, C. AU - Weaver, P. AU - Hill, A. AU - Banda, J. AU - Epperson-Brown, M. AU - Morrison, J. AU - Parrish, D. AU - Newton, J. R. AU - Royster, M. AU - Haley, S. AU - Lafayette, C. AU - Harris, P. AU - Vishwanatha, J. K. AU - Johnson, E. S. DB - Medline IS - 4 KW - adult African American article attitude to health breast tumor clinical trial diet early diagnosis ethnology exercise female health behavior health disparity health education human methodology middle aged organization and management participatory research psychological aspect social support socioeconomics United States women's health LA - English M3 - Article N1 - L364999783 2012-06-21 PY - 2011 SN - 1557-0541 SP - 375-385 ST - Community-based participatory approach to reduce breast cancer disparities in south Dallas T2 - Progress in community health partnerships : research, education, and action TI - Community-based participatory approach to reduce breast cancer disparities in south Dallas UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364999783&from=export VL - 5 ID - 1128 ER - TY - JOUR AB - South Dallas experiences significant disparities in breast cancer mortality, with a high proportion of stage III and IV diagnoses. To address these rates, the Dallas Cancer Disparities Community Research Coalition created an educational intervention to promote breast health and early detection efforts. The goals of the intervention were to increase (a) knowledge regarding the chief contributing factors for breast cancer, (b) awareness of the importance of screening for early detection, and (c) the proportion of women who have engaged in appropriate breast cancer screening practices. Eligibility criteria for this nonrandomized, controlled trial included women age 40 and older, English-speaking, and having no personal history of cancer. Control participants received written breast health educational materials. Intervention participants attended 8 weekly sessions that included interactive educational materials, cooking demonstrations, and discussions emphasizing primary and secondary breast cancer prevention. All study participants completed a 1-hour survey at baseline and 4 months later. There were 59 women were enrolled in the intervention and 60 in the control group. At follow-up, after controlling for baseline mammography status, women in the intervention group were 10.4 times more likely (95% confidence interval [CI], 2.9-36.4) to have received a screening mammogram in the last year compared with the control group. Intervention participants demonstrated statistically significantly higher rates of breast self-examination (odds ratio [OR], 3.0; 95% CI, 1.0-8.6) and breast cancer knowledge (p=.003). Lessons learned from this community-based participatory research (CBPR) study can be used to create sustainable cancer disparity reduction models that can be replicated in similar communities. AD - School of Public Health, University of North Texas Health Science Center, and Parkland Health and Hospital System, Dallas, TX, United States AU - Cardarelli, K. AU - Jackson, R. AU - Martin, M. AU - Linnear, K. AU - Lopez, R. AU - Senteio, C. AU - Weaver, P. AU - Hill, A. AU - Banda, J. AU - Epperson-Brown, M. AU - Morrison, J. AU - Parrish, D. AU - Newton, J. R. AU - Royster, M. AU - Haley, S. AU - Lafayette, C. AU - Harris, P. AU - Vishwanatha, J. K. AU - Johnson, E. S. DB - Scopus IS - 4 M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2011 SP - 375-385 ST - Community-based participatory approach to reduce breast cancer disparities in south Dallas T2 - Progress in community health partnerships : research, education, and action TI - Community-based participatory approach to reduce breast cancer disparities in south Dallas UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862268509&partnerID=40&md5=05855d969989f52b12265c8fcedbf54d VL - 5 ID - 2487 ER - TY - JOUR AB - Background: South Dallas experiences significant disparities in breast cancer mortality, with a high proportion of stage III and IV diagnoses. To address these rates, the Dallas Cancer Disparities Community Research Coalition created an educational intervention to promote breast health and early detection efforts. Objectives: The goals of the intervention were to increase (a) knowledge regarding the chief contributing factors for breast cancer, (b) awareness of the importance of screening for early detection, and (c) the proportion of women who have engaged in appropriate breast cancer screening practices. Methods: Eligibility criteria for this nonrandomized, controlled trial included women age 40 and older, English-speaking, and having no personal history of cancer. Control participants received written breast health educational materials. Intervention participants attended 8 weekly sessions that included interactive educational materials, cooking demonstrations, and discussions emphasizing primary and secondary breast cancer prevention. All study participants completed a 1-hour survey at baseline and 4 months later. Results: There were 59 women were enrolled in the intervention and 60 in the control group. At follow-up, after controlling for baseline mammography status, women in the intervention group were 10.4 times more likely (95% confidence interval [CI], 2.9-36.4) to have received a screening mammogram in the last year compared with the control group. Intervention participants demonstrated statistically significantly higher rates of breast self-examination (odds ratio [On 3.0; 95% CI, 1.0-8.6) and breast cancer knowledge (p = .003). Conclusion: Lessons learned from this community-based participatory research (CBPR) study can be used to create sustainable cancer disparity reduction models that can be replicated in similar communities. AN - WOS:000208610200007 AU - Cardarelli, K. AU - Jackson, R. AU - Martin, M. AU - Linnear, K. AU - Lopez, R. AU - Senteio, C. AU - Weaver, P. AU - Hill, A. AU - Banda, J. AU - Epperson-Brown, M. AU - Morrison, J. AU - Parrish, D. AU - Newton, J. R. AU - Royster, M. AU - Haley, S. AU - Lafayette, C. AU - Harris, P. AU - Vishwanatha, J. K. AU - Johnson, E. S. DA - Win IS - 4 N1 - 22616205 PY - 2011 SN - 1557-0541 SP - 375-385 ST - Community-Based Participatory Approach to Reduce Breast Cancer Disparities in South Dallas T2 - Progress in Community Health Partnerships-Research Education and Action TI - Community-Based Participatory Approach to Reduce Breast Cancer Disparities in South Dallas VL - 5 ID - 3081 ER - TY - JOUR AB - BACKGROUND: Intervention studies among individuals in diverse community settings are needed to reduce health disparities in colorectal cancer (CRC) screening and mortality rates. The current study compared the efficacy of 2 intervention conditions promoting CRC screening among black individuals. METHODS: Black individuals ages 50 to 75 years (N = 330) were recruited in community settings in 4 Tampa Bay counties. After obtaining consent and conducting a baseline interview to assess sociodemographic and health-related variables, participants received either a culturally targeted CRC photonovella booklet plus a fecal immunochemical test (FIT) kit or a standard CRC screening brochure plus an FIT kit. The primary outcome was FIT kit screening uptake. RESULTS: FIT screening uptake at 6 months was 86.7% overall (90.3% in the brochure group and 81.9% in the photonovella group). Controlling for baseline between-group differences, there was no influence of intervention on FIT kit uptake (P =.756). Significant predictors of not returning an FIT kit included being unable to work (P =.010), having higher religious belief scores (P =.015), and living farther from the cancer center (P =.015). CONCLUSIONS: Providing FIT kits and educational print materials to black individuals in community settings resulted in high rates of CRC screening. The study also identified subgroups of participants who were less likely to return an FIT kit and provides insight for future interventions. Cancer 2016;122:3288–3296. © 2016 American Cancer Society. AD - C.K. Gwede, Division of Population Science, Moffitt Cancer Center and Research Institute, Tampa, FL, United States AU - Christy, S. M. AU - Davis, S. N. AU - Williams, K. R. AU - Zhao, X. AU - Govindaraju, S. K. AU - Quinn, G. P. AU - Vadaparampil, S. T. AU - Lin, H. Y. AU - Sutton, S. K. AU - Roethzeim, R. R. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DB - Embase Medline DO - 10.1002/cncr.30207 IS - 21 KW - adult aged article Black person cancer screening colorectal cancer occult blood test feces analysis female health behavior health care utilization health education health promotion human immunochemistry immunology test kit intermethod comparison male priority journal religion residential area risk factor work LA - English M3 - Article N1 - L612842692 2016-10-25 2016-11-07 PY - 2016 SN - 1097-0142 0008-543X SP - 3288-3296 ST - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings T2 - Cancer TI - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612842692&from=export http://dx.doi.org/10.1002/cncr.30207 VL - 122 ID - 958 ER - TY - JOUR AB - Background: Intervention studies among individuals in diverse community settings are needed to reduce health disparities in colorectal cancer (CRC) screening and mortality rates. The current study compared the efficacy of 2 intervention conditions promoting CRC screening among black individuals.Methods: Black individuals ages 50 to 75 years (N = 330) were recruited in community settings in 4 Tampa Bay counties. After obtaining consent and conducting a baseline interview to assess sociodemographic and health-related variables, participants received either a culturally targeted CRC photonovella booklet plus a fecal immunochemical test (FIT) kit or a standard CRC screening brochure plus an FIT kit. The primary outcome was FIT kit screening uptake.Results: FIT screening uptake at 6 months was 86.7% overall (90.3% in the brochure group and 81.9% in the photonovella group). Controlling for baseline between-group differences, there was no influence of intervention on FIT kit uptake (P = .756). Significant predictors of not returning an FIT kit included being unable to work (P = .010), having higher religious belief scores (P = .015), and living farther from the cancer center (P = .015).Conclusions: Providing FIT kits and educational print materials to black individuals in community settings resulted in high rates of CRC screening. The study also identified subgroups of participants who were less likely to return an FIT kit and provides insight for future interventions. Cancer 2016;122:3288-3296. © 2016 American Cancer Society. AD - Division of Population Science, Moffitt Cancer Center and Research Institute, Tampa Florida Morsani College of Medicine, University of South Florida, Tampa Florida School of Public Health, Louisiana State University Health Sciences Center, New Orleans Louisiana Department of Surgery, University of Tennessee Health Science Center, Memphis Tennessee AN - 118940665. Language: English. Entry Date: 20171101. Revision Date: 20190711. Publication Type: journal article AU - Christy, Shannon M. AU - Davis, Stacy N. AU - Williams, Kimberly R. AU - Zhao, Xiuhua AU - Govindaraju, Swapomthi K. AU - Quinn, Gwendolyn P. AU - Vadaparampil, Susan T. AU - Lin, Hui‐Yi AU - Sutton, Steven K. AU - Roethzeim, Richard R. AU - Shibata, David AU - Meade, Cathy D. AU - Gwede, Clement K. DB - CINAHL Complete DO - 10.1002/cncr.30207 DP - EBSCOhost IS - 21 KW - Occult Blood Black Persons -- Psychosocial Factors Early Detection of Cancer -- Utilization Community Health Services -- Utilization Reagent Kits, Diagnostic -- Utilization Patient Education Male Middle Age Health Care Delivery Attitude to Health Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Psychosocial Factors Aged Neoplasm Staging Prognosis Immunochemistry Patient Attitudes Colorectal Neoplasms -- Ethnology Early Childhood Intervention Prospective Studies Female Funding Source Human Random Assignment Randomized Controlled Trials N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: P30 CA076292/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM27420119. PY - 2016 SN - 0008-543X SP - 3288-3296 ST - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings T2 - Cancer (0008543X) TI - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118940665&site=ehost-live&scope=site VL - 122 ID - 1813 ER - TY - JOUR AB - BACKGROUND: Intervention studies among individuals in diverse community settings are needed to reduce health disparities in colorectal cancer (CRC) screening and mortality rates. The current study compared the efficacy of 2 intervention conditions promoting CRC screening among black individuals. METHODS: Black individuals ages 50 to 75 years (N = 330) were recruited in community settings in 4 Tampa Bay counties. After obtaining consent and conducting a baseline interview to assess sociodemographic and health-related variables, participants received either a culturally targeted CRC photonovella booklet plus a fecal immunochemical test (FIT) kit or a standard CRC screening brochure plus an FIT kit. The primary outcome was FIT kit screening uptake. RESULTS: FIT screening uptake at 6 months was 86.7% overall (90.3% in the brochure group and 81.9% in the photonovella group). Controlling for baseline between-group differences, there was no influence of intervention on FIT kit uptake (P =.756). Significant predictors of not returning an FIT kit included being unable to work (P =.010), having higher religious belief scores (P =.015), and living farther from the cancer center (P =.015). CONCLUSIONS: Providing FIT kits and educational print materials to black individuals in community settings resulted in high rates of CRC screening. The study also identified subgroups of participants who were less likely to return an FIT kit and provides insight for future interventions. Cancer 2016;122:3288–3296. © 2016 American Cancer Society. © 2016 American Cancer Society AD - Division of Population Science, Moffitt Cancer Center and Research Institute, Tampa, FL, United States Morsani College of Medicine, University of South Florida, Tampa, FL, United States School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, United States Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, United States AU - Christy, S. M. AU - Davis, S. N. AU - Williams, K. R. AU - Zhao, X. AU - Govindaraju, S. K. AU - Quinn, G. P. AU - Vadaparampil, S. T. AU - Lin, H. Y. AU - Sutton, S. K. AU - Roethzeim, R. R. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DB - Scopus DO - 10.1002/cncr.30207 IS - 21 KW - cancer screening colorectal cancer culturally targeted intervention trial minority health M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2016 SP - 3288-3296 ST - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings T2 - Cancer TI - A community-based trial of educational interventions with fecal immunochemical tests for colorectal cancer screening uptake among blacks in community settings UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991628390&doi=10.1002%2fcncr.30207&partnerID=40&md5=463274698c389665bbfe921ecb2dc554 VL - 122 ID - 2332 ER - TY - JOUR AB - BACKGROUND: Intervention studies among individuals in diverse community settings are needed to reduce health disparities in colorectal cancer (CRC) screening and mortality rates. The current study compared the efficacy of 2 intervention conditions promoting CRC screening among black individuals. METHODS: Black individuals ages 50 to 75 years (N = 330) were recruited in community settings in 4 Tampa Bay counties. After obtaining consent and conducting a baseline interview to assess sociodemographic and health-related variables, participants received either a culturally targeted CRC photonovella booklet plus a fecal immunochemical test (FIT) kit or a standard CRC screening brochure plus an FIT kit. The primary outcome was FIT kit screening uptake. RESULTS: FIT screening uptake at 6 months was 86.7% overall (90.3% in the brochure group and 81.9% in the photonovella group). Controlling for baseline between-group differences, there was no influence of intervention on FIT kit uptake (P = .756). Significant predictors of not returning an FIT kit included being unable to work (P = .010), having higher religious belief scores (P = .015), and living farther from the cancer center (P = .015). CONCLUSIONS: Providing FIT kits and educational print materials to black individuals in community settings resulted in high rates of CRC screening. The study also identified subgroups of participants who were less likely to return an FIT kit and provides insight for future interventions. AN - WOS:000388286000008 AU - Christy, S. M. AU - Davis, S. N. AU - Williams, K. R. AU - Zhao, X. H. AU - Govindaraju, S. K. AU - Quinn, G. P. AU - Vadaparampil, S. T. AU - Lin, H. Y. AU - Sutton, S. K. AU - Roethzeim, R. R. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DA - Nov DO - 10.1002/cncr.30207 IS - 21 N1 - 27420119 PY - 2016 SN - 0008-543X SP - 3288-3296 ST - A Community-Based Trial of Educational Interventions With Fecal Immunochemical Tests for Colorectal Cancer Screening Uptake Among Blacks in Community Settings T2 - Cancer TI - A Community-Based Trial of Educational Interventions With Fecal Immunochemical Tests for Colorectal Cancer Screening Uptake Among Blacks in Community Settings VL - 122 ID - 2931 ER - TY - JOUR AB - OBJECTIVE: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. METHODS: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. RESULTS: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. CONCLUSIONS: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DB - Medline DO - 10.1016/j.ypmed.2014.08.016 KW - adult African American Alabama controlled study cultural anthropology ethnology exercise feeding behavior female health behavior health promotion human middle aged participatory research randomized controlled trial rural population LA - English M3 - Article N1 - L612549835 2016-10-12 PY - 2014 SN - 1096-0260 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial T2 - Preventive medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L612549835&from=export http://dx.doi.org/10.1016/j.ypmed.2014.08.016 VL - 69 ID - 1023 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. AD - I.C. Scarinci, Division of Preventive Medicine, University of Alabama, 1717 11th Avenue South, MT 609, Birmingham, AL, United States AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DB - Embase DO - 10.1016/j.ypmed.2014.08.016 KW - adult African American aged article breast cancer cancer screening cultural factor eating feeding behavior female food intake fruit vegetable health promotion human lifestyle major clinical study physical activity randomized controlled trial United States uterine cervix cancer LA - English M3 - Article N1 - L600086320 2014-10-11 2014-10-17 PY - 2014 SN - 1096-0260 0091-7435 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial T2 - Preventive Medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600086320&from=export http://dx.doi.org/10.1016/j.ypmed.2014.08.016 VL - 69 ID - 1026 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. © 2014 Elsevier Inc. AD - I.C. Scarinci, Division of Preventive Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 609, Birmingham, AL 35205, United States AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DB - Embase DO - 10.1016/j.ypmed.2014.08.016 KW - adult African American aged article behavior change breast cancer cancer screening controlled study eating employment status family health feeding behavior female follow up food intake fruit fruit vegetable health care planning health care utilization health disparity health promotion human income lifestyle lifestyle modification major clinical study marriage medicaid medicare middle aged participatory research physical activity priority journal randomized controlled trial rural area rural population United States uterine cervix cancer vegetable LA - English M3 - Article N1 - L373869550 2014-09-10 2014-10-11 PY - 2014 SN - 1096-0260 0091-7435 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial T2 - Preventive Medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373869550&from=export http://dx.doi.org/10.1016/j.ypmed.2014.08.016 VL - 69 ID - 1046 ER - TY - JOUR AB - Objective: We examined the efficacy of a community‐based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45‐65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24‐month follow‐up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12‐month follow‐up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24‐month follow‐up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. AN - CN-01114263 AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DO - 10.1016/j.ypmed.2014.08.016 KW - *African American *eating *health promotion *physical activity Adult African Americans Aged Alabama Article Breast cancer Cancer screening Community‐Based Participatory Research Cultural factor Culture Exercise Feeding Behavior [*ethnology] Feeding behavior Female Food intake Fruit vegetable Health Behavior Health Promotion Human Humans Lifestyle Major clinical study Middle Aged Randomized controlled trial Rural Population United States Uterine cervix cancer M3 - Journal: Article PY - 2014 SP - 13‐20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial T2 - Preventive medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01114263/full VL - 69 ID - 1364 ER - TY - JOUR AB - OBJECTIVE: We examined the efficacy of a community‐based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45‐65 years, residing in rural Alabama. METHODS: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. RESULTS: The overall retention rate at 24‐month follow‐up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12‐month follow‐up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24‐month follow‐up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. CONCLUSIONS: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. AN - CN-01705225 AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DO - 10.1016/j.ypmed.2014.08.016 KW - Adult African Americans Alabama Community‐Based Participatory Research Culture Exercise Feeding Behavior [*ethnology] Female Health Behavior Health Promotion Humans Middle Aged Rural Population M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 13‐20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial T2 - Preventive medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01705225/full VL - 69 ID - 1365 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45–65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the 'healthy lifestyle' arm (63.1%) as compared to the 'screening' arm (45.3%). Participants in the 'healthy lifestyle' arm showed significant positive changes compared to the 'screening' arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Scarinci, Isabel C., Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, US AN - 2014-56469-005 AU - Scarinci, Isabel C. AU - Moore, Artisha AU - Wynn-Wallace, Theresa AU - Cherrington, Andrea AU - Fouad, Mona AU - Li, Yufeng DB - psyh DO - 10.1016/j.ypmed.2014.08.016 DP - EBSCOhost KW - African American Rural Women Healthy lifestyle Behavior change Adult African Americans Alabama Community-Based Participatory Research Culture Exercise Female Food Habits Health Behavior Health Promotion Humans Middle Aged Rural Population Blacks Eating Behavior Human Females Physical Activity Diets Intervention Urban Environments N1 - Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, US. Release Date: 20150914. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Eating Behavior; Health Promotion; Human Females; Physical Activity. Minor Descriptor: Diets; Intervention; Urban Environments. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Behavioral Risk Factor Surveillance Survey. Methodology: Clinical Trial; Empirical Study; Followup Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Dec, 2014. Publication History: First Posted Date: Aug 23, 2014. Copyright Statement: All rights reserved. Elsevier Inc. 2014. Sponsor: National Institute on Minority Health and Health Disparities, US. Grant: MD002747. Recipients: No recipient indicated PY - 2014 SN - 0091-7435 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial T2 - Preventive Medicine: An International Journal Devoted to Practice and Theory TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-56469-005&site=ehost-live&scope=site scarinci@uab.edu VL - 69 ID - 1742 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama.Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011.Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity.Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. AN - 109695070. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Scarinci, Isabel C. AU - Moore, Artisha AU - Wynn-Wallace, Theresa AU - Cherrington, Andrea AU - Fouad, Mona AU - Li, Yufeng DB - CINAHL Complete DO - 10.1016/j.ypmed.2014.08.016 DP - EBSCOhost N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: P20 MD006899/MD/NIMHD NIH HHS/United States. NLM UID: 0322116. PMID: NLM25152504. PY - 2014 SN - 0091-7435 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial T2 - Preventive Medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: findings from a group randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109695070&site=ehost-live&scope=site VL - 69 ID - 1814 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. © 2014 Elsevier Inc. AD - Division of Preventive Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 609, Birmingham, AL 35205, United States AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. DB - Scopus DO - 10.1016/j.ypmed.2014.08.016 KW - African American Behavior change Healthy lifestyle Rural Women M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2014 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial T2 - Preventive Medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906827372&doi=10.1016%2fj.ypmed.2014.08.016&partnerID=40&md5=4b53e0a2ec3fa3e9ce2beac2a85fc00a VL - 69 ID - 2404 ER - TY - JOUR AB - Objective: We examined the efficacy of a community-based, culturally relevant intervention to promote healthy eating and physical activity among African American (AA) women between the ages of 45-65 years, residing in rural Alabama. Methods: We conducted a group randomized controlled trial with counties as the unit of randomization that evaluated two interventions based on health priorities identified by the community: (1) promotion of healthy eating and physical activity; and (2) promotion of breast and cervical cancer screening. A total of 6 counties with 565 participants were enrolled in the study between November 2009 and October 2011. Results: The overall retention rate at 24-month follow-up was 54.7%. Higher retention rate was observed in the "healthy lifestyle" arm (63.1%) as compared to the "screening" arm (45.3%). Participants in the "healthy lifestyle" arm showed significant positive changes compared to the "screening" arm at 12-month follow-up with regard to decrease in fried food consumption and an increase in both fruit/vegetable intake and physical activity. At 24-month follow-up, these positive changes were maintained with healthy eating behaviors, but not engagement in physical activity. Conclusions: A culturally relevant intervention, developed in collaboration with the target audience, can improve (and maintain) healthy eating among AA women living in rural areas. (C) 2014 Elsevier Inc All rights reserved. AN - WOS:000346221600004 AU - Scarinci, I. C. AU - Moore, A. AU - Wynn-Wallace, T. AU - Cherrington, A. AU - Fouad, M. AU - Li, Y. F. DA - Dec DO - 10.1016/j.ypmed.2014.08.016 N1 - 25152504 PY - 2014 SN - 0091-7435 SP - 13-20 ST - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial T2 - Preventive Medicine TI - A community-based, culturally relevant intervention to promote healthy eating and physical activity among middle-aged African American women in rural Alabama: Findings from a group randomized controlled trial VL - 69 ID - 2990 ER - TY - JOUR AB - OBJECTIVES: To test the effectiveness of a preclinical, telephone-based patient navigation intervention to encourage colorectal cancer (CRC) screening among older Black men. METHODS: We conducted a 3-parallel-arm, randomized trial among 731 self-identified Black men recruited at barbershops between 2010 and 2013 in New York City. Participants had to be aged 50 years or older, not be up-to-date on CRC screening, have uncontrolled high blood pressure, and have a working telephone. We randomized participants to 1 of 3 groups: (1) patient navigation by a community health worker for CRC screening (PN), (2) motivational interviewing for blood pressure control by a trained counselor (MINT), or (3) both interventions (PLUS). We assessed CRC screening completion at 6-month follow-up. RESULTS: Intent-to-treat analysis revealed that participants in the navigation interventions were significantly more likely than those in the MINT-only group to be screened for CRC during the 6-month study period (17.5% of participants in PN, 17.8% in PLUS, 8.4% in MINT; P < .01). CONCLUSIONS: Telephone-based preclinical patient navigation has the potential to be effective for older Black men. Our results indicate the importance of community-based health interventions for improving health among minority men. AU - Cole, H. AU - Thompson, H. S. AU - White, M. AU - Browne, R. AU - Trinh-Shevrin, C. AU - Braithwaite, S. AU - Fiscella, K. AU - Boutin-Foster, C. AU - Ravenell, J. DB - Medline DO - 10.2105/AJPH.2017.303885 IS - 9 KW - African American aged attitude to health colorectal tumor community care controlled study early cancer diagnosis ethnology hairdresser health care disparity human male middle aged New York patient care procedures psychology randomized controlled trial LA - English M3 - Article N1 - L617982759 2017-08-29 PY - 2017 SN - 1541-0048 SP - 1433-1440 ST - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial T2 - American journal of public health TI - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617982759&from=export http://dx.doi.org/10.2105/AJPH.2017.303885 VL - 107 ID - 929 ER - TY - JOUR AB - Objectives. To test the effectiveness of a preclinical, telephone-based patient navigation intervention to encourage colorectal cancer (CRC) screening among older Black men. Methods. We conducted a 3-parallel-Arm, randomized trial among 731 self-identified Black men recruited at barbershops between 2010 and 2013 in New York City. Participants had to be aged 50 years or older, not be up-To-date on CRC screening, have uncontrolled high blood pressure, and have a working telephone. We randomized participants to 1 of 3 groups: (1) patient navigation by a community health worker for CRC screening (PN), (2) motivational interviewing for blood pressure control by a trained counselor (MINT), or (3) both interventions (PLUS). We assessed CRC screening completion at 6-month follow-up. Results. Intent-To-Treat analysis revealed that participants in the navigation interventions were significantly more likely than those in the MINT-only group to be screened for CRC during the 6-month study period (17.5% of participants in PN, 17.8% in PLUS, 8.4% in MINT; P < .01). Conclusions. Telephone-based preclinical patient navigation has the potential to be effective for older Black men. Our results indicate the importance of community-based health interventions forimprovinghealth among minoritymen. AD - Department of Population Health, Division of Health Behavior, New York University School of Medicine, New York, NY, United States Population Studies and Disparities Research Program, Communication and Behavioral Oncology, Karmanos Cancer Institute, Detroit, MI, United States Arthur Ashe Institute for Urban Health, Brooklyn, NY, United States Department of Population Health, New York University School of Medicine, United States Departments of Family Medicine and Public Health Sciences, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States Division of Clinical Epidemiology and Evaluative Sciences, Weill Cornell Medical Center, New York, United States Institut Hospital del Mar D'Investigacions Mediques, Carrer del Aiguader, 88, Barcelona, 08003, Spain AU - Cole, H. AU - Thompson, H. S. AU - White, M. AU - Browne, R. AU - Trinh-Shevrin, C. AU - Braithwaite, S. AU - Fiscella, K. AU - Boutin-Foster, C. AU - Ravenell, J. DB - Scopus DO - 10.2105/AJPH.2017.303885 IS - 9 M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2017 SP - 1433-1440 ST - Community-based, preclinical patient navigation for colorectal cancer screening among older black men recruited from barbershops: The MISTER B trial T2 - American Journal of Public Health TI - Community-based, preclinical patient navigation for colorectal cancer screening among older black men recruited from barbershops: The MISTER B trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027880248&doi=10.2105%2fAJPH.2017.303885&partnerID=40&md5=103787eec23b18f3d734462ba95ad0b5 VL - 107 ID - 2300 ER - TY - JOUR AB - Objectives. To test the effectiveness of a preclinical, telephone-based patient navigation intervention to encourage colorectal cancer (CRC) screening among older Black men. Methods. We conducted a 3-parallel-arm, randomized trial among 731 self-identified Black men recruited at barbershops between 2010 and 2013 in New York City. Participants had to be aged 50 years or older, not be up-to-date on CRC screening, have uncontrolled high blood pressure, and have a working telephone. We randomized participants to 1 of 3 groups: (1) patient navigation by a community health worker for CRC screening (PN), (2) motivational interviewing for blood pressure control by a trained counselor (MINT), or (3) both interventions (PLUS). We assessed CRC screening completion at 6-month follow-up. Results. Intent-to-treat analysis revealed that participants in the navigation interventions were significantly more likely than those in the MINT-only group to be screened for CRC during the 6-month study period (17.5% of participants in PN, 17.8% in PLUS, 8.4% in MINT; P <.01). Conclusions. Telephone-based preclinical patient navigation has the potential to be effective for older Black men. Our results indicate the importance of community-based health interventions for improving health among minority men. AN - WOS:000412491700040 AU - Cole, H. AU - Thompson, H. S. AU - White, M. AU - Browne, R. AU - Trinh-Shevrin, C. AU - Braithwaite, S. AU - Fiscella, K. AU - Boutin-Foster, C. AU - Ravenell, J. DA - Sep DO - 10.2105/AJPH.2017.303885 IS - 9 N1 - 28727540 PY - 2017 SN - 0090-0036 SP - 1433-1440 ST - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial T2 - American Journal of Public Health TI - Community-Based, Preclinical Patient Navigation for Colorectal Cancer Screening Among Older Black Men Recruited From Barbershops: The MISTER B Trial VL - 107 ID - 2888 ER - TY - JOUR AB - Objective: Companions play an important role in cancer care. This investigation compared the communication of unaccompanied patients, accompanied patients, and companions during lung cancer consultations. Factors affecting the active participation of companions were analyzed. Methods: Participants included unaccompanied patients (N = 48), accompanied patients (N = 84), and companions (N = 84) of newly diagnosed lung cancer patients seen at a large southern VA medical center. The consultations were audiotaped, then transcribed. Coded utterances included patients' and companions' active participation (asking questions, expressing concerns, and making assertions) and physicians' use of facilitative communication. Mixed linear regression was used for comparisons of accompanied patients' participation to that of their companions and to determine the independent predictors of companion participation and patient satisfaction. Results: The combined companion plus patient participation did not differ from the participation of unaccompanied patients. Patterns of companion participation varied greatly as almost half the interactions had a relatively passive companion (contributed to less than 40% of the patient plus companion active participation) but 33% of the consultations had an active companion and passive patient. Companions with less active participation accompanied black patients and received proportionally less facilitative communication from physicians. Patient satisfaction was lower when companion and patient had similar levels of participation. Conclusion: Companions vary greatly in their participation in lung cancer visits. Physicians facilitate companion participation through the use of partnership-building and supportive communication. The companions of black patients were less active than their white counterparts which parallels other research indicating that black patients are often less active than white patients. Such communicative discrepancies could contribute to racial disparities in cancer care. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Street, Richard L., Department of Communication, Texas A&M University, College Station, TX, US, 77843-4234 AN - 2008-03406-005 AU - Street, Richard L. AU - Gordon, Howard S. DB - psyh DO - 10.1002/pon.1225 DP - EBSCOhost IS - 3 KW - companion participation cancer consultations patients lung cancer Affect Aged Automatic Data Processing Decision Making Female Friends Humans Lung Neoplasms Male Patient Satisfaction Physician-Patient Relations Referral and Consultation Social Facilitation Social Support Verbal Behavior Client Participation Neoplasms Professional Consultation Significant Others Lung Disorders Medical Patients N1 - Department of Communication, Texas A&M University, College Station, TX, US. Release Date: 20080414. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Grant Information: Gordon, Howard S. Major Descriptor: Client Participation; Neoplasms; Professional Consultation; Significant Others; Social Support. Minor Descriptor: Lung Disorders; Medical Patients. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Mar, 2008. Sponsor: Office of Research and Development. Other Details: Career Development Award. Recipients: Gordon, Howard S. Sponsor: US Department of Veterans Affairs, Health Services Research and Development Service, US. Recipients: No recipient indicated Sponsor: Agency for Healthcare Research and Quality. Grant: P01 HS10876. Recipients: No recipient indicated PY - 2008 SN - 1057-9249 1099-1611 SP - 244-251 ST - Companion participation in cancer consultations T2 - Psycho-Oncology TI - Companion participation in cancer consultations UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-03406-005&site=ehost-live&scope=site r-street@tamu.edu VL - 17 ID - 1787 ER - TY - JOUR AB - Background: Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups. Methods: From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators. Results: Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%). Conclusion: Significant improvements were noticed in PBCG's calibrations and net benefits in Whites compared to PCPT. Since PBCG's improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities. AD - A.B. Murphy, Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 16, Chicago, IL, United States AU - Carbunaru, S. AU - Nettey, O. S. AU - Gogana, P. AU - Helenowski, I. B. AU - Jovanovic, B. AU - Ruden, M. AU - Hollowell, C. M. P. AU - Sharifi, R. AU - Kittles, R. A. AU - Schaeffer, E. AU - Gann, P. AU - Murphy, A. B. DB - Embase Medline DO - 10.1186/s12894-019-0553-6 IS - 1 KW - prostate specific antigen adult aged area under the curve article Black person calibration Caucasian cohort analysis comparative effectiveness ethnic group human Illinois major clinical study male prediction prospective study prostate biopsy Prostate Biopsy Collaborative Group Risk Calculator prostate cancer Prostate Cancer Prevention Trial Risk Calculator renal system parameters trend study LA - English M3 - Article N1 - L629994987 2019-12-11 2019-12-18 PY - 2019 SN - 1471-2490 ST - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort T2 - BMC Urology TI - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629994987&from=export http://dx.doi.org/10.1186/s12894-019-0553-6 VL - 19 ID - 832 ER - TY - JOUR AB - Background: Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups.Methods: From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators.Results: Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%).Conclusion: Significant improvements were noticed in PBCG's calibrations and net benefits in Whites compared to PCPT. Since PBCG's improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities. AD - Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 16, 60611, Chicago, IL, USA Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA Division of Urology, Cook County Health and Hospitals System, 303 E Chicago Avenue, Tarry 16, 60611, Chicago, IL, USA Section of Urology, Jesse Brown VA Medical Center, 303 E Chicago Avenue, Tarry 16, 60611, Chicago, IL, USA Department of Urology, University of Illinois at Chicago School of Medicine, Chicago, IL, USA Division of Health Equities, Department of Population Sciences, City of Hope Cancer Center, Duarte, CA, USA Department of Pathology, University of Illinois at Chicago School of Medicine, Chicago, IL, USA AN - 139865500. Language: English. Entry Date: 20200409. Revision Date: 20210304. Publication Type: journal article AU - Carbunaru, Samuel AU - Nettey, Oluwarotimi S. AU - Gogana, Pooja AU - Helenowski, Irene B. AU - Jovanovic, Borko AU - Ruden, Maria AU - Hollowell, Courtney M. P. AU - Sharifi, Roohollah AU - Kittles, Rick A. AU - Schaeffer, Edward AU - Gann, Peter AU - Murphy, Adam B. DB - CINAHL Complete DO - 10.1186/s12894-019-0553-6 DP - EBSCOhost IS - 1 KW - Ethnic Groups Prostatic Neoplasms -- Pathology Risk Assessment -- Methods Prostatic Neoplasms -- Prevention and Control Prospective Studies Male Biopsy Middle Age Human Aged Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: W81XWH-16-PCRP-IDA//Defense Health Agency/. NLM UID: 100968571. PMID: NLM31771578. PY - 2019 SN - 1471-2490 SP - N.PAG-N.PAG ST - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort T2 - BMC Urology TI - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139865500&site=ehost-live&scope=site VL - 19 ID - 1815 ER - TY - JOUR AB - Background: Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups. Methods: From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators. Results: Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%). Conclusion: Significant improvements were noticed in PBCG's calibrations and net benefits in Whites compared to PCPT. Since PBCG's improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities. © 2019 The Author(s). AD - Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Chicago Avenue, Tarry 16, Chicago, IL 60611, United States Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States Division of Urology, Cook County Health and Hospitals System, 303 E Chicago Avenue, Tarry 16, Chicago, IL 60611, United States Section of Urology, Jesse Brown VA Medical Center, 303 E Chicago Avenue, Tarry 16, Chicago, IL 60611, United States Department of Urology, University of Illinois at Chicago School of Medicine, Chicago, IL, United States Division of Health Equities, Department of Population Sciences, City of Hope Cancer Center, Duarte, CA, United States Department of Pathology, University of Illinois at Chicago School of Medicine, Chicago, IL, United States AU - Carbunaru, S. AU - Nettey, O. S. AU - Gogana, P. AU - Helenowski, I. B. AU - Jovanovic, B. AU - Ruden, M. AU - Hollowell, C. M. P. AU - Sharifi, R. AU - Kittles, R. A. AU - Schaeffer, E. AU - Gann, P. AU - Murphy, A. B. C7 - 121 DB - Scopus DO - 10.1186/s12894-019-0553-6 IS - 1 KW - African American validation Prostate biopsy collaborative group risk calculator Prostate Cancer prevention trial risk calculator 2.0 Prostate cancer risk prediction Risk calculator M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2019 ST - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort T2 - BMC Urology TI - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075664347&doi=10.1186%2fs12894-019-0553-6&partnerID=40&md5=0dab66558201af676e1cf171a314bbd0 VL - 19 ID - 2216 ER - TY - JOUR AB - Background Predictive models that take race into account like the Prostate Cancer Prevention Trial Risk Calculator 2.0 (PCPT RC) and the new Prostate Biopsy Collaborative Group (PBCG) RC have been developed to equitably mitigate the overdiagnosis of prostate specific antigen (PSA) screening. Few studies have compared the performance of both calculators across racial groups. Methods From 1485 prospectively recruited participants, 954 men were identified undergoing initial prostate biopsy for abnormal PSA or digital rectal examination in five Chicago hospitals between 2009 and 2014. Discrimination, calibration, and frequency of avoided biopsies were calculated to assess the performance of both risk calculators. Results Of 954 participants, 463 (48.5%) were Black, 355 (37.2%) were White, and 136 (14.2%) identified as Other. Biopsy results were as follows: 310 (32.5%) exhibited no cancer, 323 (33.9%) indolent prostate cancer, and 321 (33.6%) clinically significant prostate cancer (csPCa). Differences in area under the curve (AUC)s for the detection of csPCa between PCPT and PBCG were not statistically different across all racial groups. PBCG did not improve calibration plots in Blacks and Others, as it showed higher levels of overprediction at most risk thresholds. PCPT led to an increased number of avoidable biopsies in minorities compared to PBCG at the 30% threshold (68% vs. 28% of all patients) with roughly similar rates of missed csPCa (23% vs. 20%). Conclusion Significant improvements were noticed in PBCG's calibrations and net benefits in Whites compared to PCPT. Since PBCG's improvements in Blacks are disputable and potentially biases a greater number of low risk Black and Other men towards unnecessary biopsies, PCPT may lead to better biopsy decisions in racial minority groups. Further comparisons of commonly used risk calculators across racial groups is warranted to minimize excessive biopsies and overdiagnosis in ethnic minorities. AN - WOS:000499437600001 AU - Carbunaru, S. AU - Nettey, O. S. AU - Gogana, P. AU - Helenowski, I. B. AU - Jovanovic, B. AU - Ruden, M. AU - Hollowell, C. M. P. AU - Sharifi, R. AU - Kittles, R. A. AU - Schaeffer, E. AU - Gann, P. AU - Murphy, A. B. DA - Nov DO - 10.1186/s12894-019-0553-6 IS - 1 N1 - 121 31771578 PY - 2019 SN - 1471-2490 ST - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort T2 - Bmc Urology TI - A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort VL - 19 ID - 2806 ER - TY - JOUR AB - Micro-Abstract The survival advantage of biologic agents for patients treated for metastatic colorectal cancer was generated from trials from a predominantly white population. We carried out a comparative effectiveness research study in our center that caters to an ethnic minority population. Using a robust multi variable analysis we demonstrate that black and Hispanic patients do not enjoy a similar benefit. Background Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration. Patients and Methods The demographic and clinical characteristics of patients treated for mCRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center. A semiparametric accelerated failure time model was used to assess the survival differences between patients receiving chemotherapy (CT) alone versus CT plus biologic agents (CBT). Results Of the 290 patients (black, 45.9%; Hispanic, 26.2%; and white, 27.9%), 53.8% received biologic agents. The median overall survival was 15.2 months in the CT-alone group and 25.6 months in CBT group (P =.004). On univariate analysis, a lower number of metastatic sites, carcinoembryonic antigen < 41 ng/mL, and more lines of CT were associated with improved overall survival. In a propensity score-based analysis of the entire cohort, CBT offered a survival benefit compared with CT alone (increased median survival, 1.44-fold; 95% confidence interval [CI], 1.11-1.86; P =.038). The results of the subgroup analysis suggested a survival benefit for white patients (2.01; 95% CI, 1.26-3.23; P =.031) but not for Hispanic (1.42; 95% CI, 0.91-2.20; P =.370) or black (1.12; 95% CI, 0.76-1.66; P =.596) patients. Conclusion In the present cohort, CBT was associated with longer survival, with the effect mainly driven by the outcomes for white patients, with black patients not appearing to benefit. These data are provocative and warrant further confirmation. Efforts to increase ethnic minority patients' enrollment in clinical trials is required to prospectively define the benefit from novel therapies. AD - S. Goel, Department of Medical Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, 1695 Eastchester Road, Bronx, NY, United States AU - Goel, S. AU - Negassa, A. AU - Khot, A. AU - Goyal, D. AU - Guo, S. AU - Nandikolla, A. AU - Bakirhan, K. AU - Polineni, R. AU - Shah, U. AU - Chaudhary, I. AU - Ghalib, M. H. AU - Rajdev, L. AU - Kaubisch, A. AU - Chuy, J. AU - Aparo, S. DB - Embase Medline DO - 10.1016/j.clcc.2017.03.004 IS - 4 KW - antineoplastic agent bevacizumab carcinoembryonic antigen cetuximab panitumumab adult African American article cancer chemotherapy cancer registry cancer survival Caucasian clinical outcome comparative effectiveness controlled study ethnic group female health care disparity Hispanic human major clinical study male metastatic colorectal cancer outcome assessment overall survival propensity score secondary analysis LA - English M3 - Article N1 - L615370927 2017-04-19 2018-07-10 PY - 2017 SN - 1938-0674 1533-0028 SP - 286-292 ST - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer T2 - Clinical Colorectal Cancer TI - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615370927&from=export http://dx.doi.org/10.1016/j.clcc.2017.03.004 VL - 16 ID - 921 ER - TY - JOUR AB - The survival advantage of biologic agents for patients treated for metastatic colorectal cancer was generated from trials from a predominantly white population. We carried out a comparative effectiveness research study in our center that caters to an ethnic minority population. Using a robust multi variable analysis we demonstrate that black and Hispanic patients do not enjoy a similar benefit. Background Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration. Patients and Methods The demographic and clinical characteristics of patients treated for mCRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center. A semiparametric accelerated failure time model was used to assess the survival differences between patients receiving chemotherapy (CT) alone versus CT plus biologic agents (CBT). Results Of the 290 patients (black, 45.9%; Hispanic, 26.2%; and white, 27.9%), 53.8% received biologic agents. The median overall survival was 15.2 months in the CT-alone group and 25.6 months in CBT group (P =.004). On univariate analysis, a lower number of metastatic sites, carcinoembryonic antigen < 41 ng/mL, and more lines of CT were associated with improved overall survival. In a propensity score-based analysis of the entire cohort, CBT offered a survival benefit compared with CT alone (increased median survival, 1.44-fold; 95% confidence interval [CI], 1.11-1.86; P =.038). The results of the subgroup analysis suggested a survival benefit for white patients (2.01; 95% CI, 1.26-3.23; P =.031) but not for Hispanic (1.42; 95% CI, 0.91-2.20; P =.370) or black (1.12; 95% CI, 0.76-1.66; P =.596) patients. Conclusion In the present cohort, CBT was associated with longer survival, with the effect mainly driven by the outcomes for white patients, with black patients not appearing to benefit. These data are provocative and warrant further confirmation. Efforts to increase ethnic minority patients' enrollment in clinical trials is required to prospectively define the benefit from novel therapies. © 2017 Elsevier Inc. AD - Department of Medical Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, United States Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States Department of Medical Oncology, Montefiore Medical Center, Bronx, NY, United States Department of Medicine, Montefiore Medical Center, Bronx, NY, United States Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY, United States AU - Goel, S. AU - Negassa, A. AU - Khot, A. AU - Goyal, D. AU - Guo, S. AU - Nandikolla, A. AU - Bakirhan, K. AU - Polineni, R. AU - Shah, U. AU - Chaudhary, I. AU - Ghalib, M. H. AU - Rajdev, L. AU - Kaubisch, A. AU - Chuy, J. AU - Aparo, S. DB - Scopus DO - 10.1016/j.clcc.2017.03.004 IS - 4 KW - Biologic therapy Chemotherapy Colorectal cancer Comparative effectiveness research Race M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2017 SP - 286-292 ST - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer T2 - Clinical Colorectal Cancer TI - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017459748&doi=10.1016%2fj.clcc.2017.03.004&partnerID=40&md5=b1c80ee4d264d3470704da8481864017 VL - 16 ID - 2298 ER - TY - JOUR AB - The survival advantage of biologic agents for patients treated for metastatic colorectal cancer was generated from trials from a predominantly white population. We carried out a comparative effectiveness research study in our center that caters to an ethnic minority population. Using a robust multi variable analysis we demonstrate that black and Hispanic patients do not enjoy a similar benefit. Background: Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration. Patients and Methods: The demographic and clinical characteristics of patients treated form CRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center. A semiparametric accelerated failure time model was used to assess the survival differences between patients receiving chemotherapy (CT) alone versus CT plus biologic agents (CBT). Results: Of the 290 patients (black, 45.9%; Hispanic, 26.2%; and white, 27.9%), 53.8% received biologic agents. The median overall survival was 15.2 months in the CT-alone group and 25.6 months in CBT group (P = .004). On univariate analysis, a lower number of metastatic sites, carcinoembryonic antigen < 41 ng/mL, andmore lines of CT were associated with improved overall survival. In a propensity score-based analysis of the entire cohort, CBT offered a survival benefit compared with CT alone (increased median survival, 1.44-fold; 95% confidence interval [CI], 1.11-1.86; P = .038). The results of the subgroup analysis suggested a survival benefit for white patients (2.01; 95% CI, 1.26-3.23; P = .031) but not for Hispanic (1.42; 95% CI, 0.91-2.20; P = .370) or black (1.12; 95% CI, 0.76-1.66; P = .596) patients. Conclusion: In the present cohort, CBT was associated with longer survival, with the effect mainly driven by the outcomes for white patients, with black patients not appearing to benefit. These data are provocative and warrant further confirmation. Efforts to increase ethnic minority patients' enrollment in clinical trials is required to prospectively define the benefit from novel therapies. (C) 2017 Elsevier Inc. All rights reserved. AN - WOS:000416182900005 AU - Goel, S. AU - Negassa, A. AU - Khot, A. AU - Goyal, D. AU - Guo, S. AU - Nandikolla, A. AU - Bakirhan, K. AU - Polineni, R. AU - Shah, U. AU - Chaudhary, I. AU - Ghalib, M. H. AU - Rajdev, L. AU - Kaubisch, A. AU - Chuy, J. AU - Aparo, S. DA - Dec DO - 10.1016/j.clcc.2017.03.004 IS - 4 N1 - 28412139 PY - 2017 SN - 1533-0028 SP - 286-292 ST - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer T2 - Clinical Colorectal Cancer TI - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer VL - 16 ID - 2881 ER - TY - JOUR AB - Background: Biologic agents have improved the outcomes of patients with metastatic colorectal cancer (mCRC). However, the clinical trials included a predominately white population (85%), with Hispanic and black patients underrepresented. Thus, the real world benefit for the latter remains unknown. Comparative effectiveness research is a tool allowing for this exploration.Patients and Methods: The demographic and clinical characteristics of patients treated for mCRC from 2000 to 2011 were extracted from the medical records of Montefiore Medical Center. A semiparametric accelerated failure time model was used to assess the survival differences between patients receiving chemotherapy (CT) alone versus CT plus biologic agents (CBT).Results: Of the 290 patients (black, 45.9%; Hispanic, 26.2%; and white, 27.9%), 53.8% received biologic agents. The median overall survival was 15.2 months in the CT-alone group and 25.6 months in CBT group (P = .004). On univariate analysis, a lower number of metastatic sites, carcinoembryonic antigen < 41 ng/mL, and more lines of CT were associated with improved overall survival. In a propensity score-based analysis of the entire cohort, CBT offered a survival benefit compared with CT alone (increased median survival, 1.44-fold; 95% confidence interval [CI], 1.11-1.86; P = .038). The results of the subgroup analysis suggested a survival benefit for white patients (2.01; 95% CI, 1.26-3.23; P = .031) but not for Hispanic (1.42; 95% CI, 0.91-2.20; P = .370) or black (1.12; 95% CI, 0.76-1.66; P = .596) patients.Conclusion: In the present cohort, CBT was associated with longer survival, with the effect mainly driven by the outcomes for white patients, with black patients not appearing to benefit. These data are provocative and warrant further confirmation. Efforts to increase ethnic minority patients' enrollment in clinical trials is required to prospectively define the benefit from novel therapies. AD - Department of Medical Oncology, Montefiore Medical Cente r and Albert Einstein College of Medicine, Bronx, NY Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY Department of Medical Oncology Department of Medicine, Montefiore Medical Center, Bronx, NY Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY AN - 127062405. Language: English. Entry Date: 20180708. Revision Date: 20181203. Publication Type: journal article AU - Goel, Sanjay AU - Negassa, Abdissa AU - Khot, Ashish AU - Goyal, Dharmendra AU - Shuang, Guo AU - Nandikolla, Amara AU - Bakirhan, Kamila AU - Polineni, Rahul AU - Shah, Umang AU - Chaudhary, Imran AU - Ghalib, Mohammad H. AU - Rajdev, Lakshmi AU - Kaubisch, Andreas AU - Chuy, Jennifer AU - Aparo, Santiago AU - Guo, Shuang DB - CINAHL Complete DO - 10.1016/j.clcc.2017.03.004 DP - EBSCOhost IS - 4 KW - Models, Theoretical Antineoplastic Agents, Combined -- Therapeutic Use Colorectal Neoplasms -- Drug Therapy Biological Factors -- Administration and Dosage Aged Female Health Services Research Aged, 80 and Over Black Persons -- Statistics and Numerical Data Prospective Studies Hispanic Americans -- Statistics and Numerical Data Adult Treatment Outcomes Survival White Persons -- Statistics and Numerical Data Middle Age Antigens, Tumor -- Blood Male Human Antineoplastic Agents, Combined -- Administration and Dosage Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 101120693. PMID: NLM28412139. PY - 2017 SN - 1533-0028 SP - 286-292 ST - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer T2 - Clinical Colorectal Cancer TI - Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127062405&site=ehost-live&scope=site VL - 16 ID - 1892 ER - TY - JOUR AB - Purpose: To determine whether racial differences in gene and miRNA expression translates to differences in lung tumor biology with clinical relevance in African Americans (AAs) and European Americans (EAs). Experimental Design: The NCI-Maryland Case Control Study includes seven Baltimore City hospitals and is overrepresented with AA patients (∼40%). Patients that underwent curative NSCLC surgery between 1998 and 2014 were enrolled. Comparative molecular profiling used mRNA (n = 22 AAs and 19 EAs) and miRNA (n = 42 AAs and 55 EAs) expression arrays to track differences in paired fresh frozen normal tissues and lung tumor specimens from AAs and EAs. Pathway enrichment, predicted drug response, tumor microenvironment infiltration, cancer immunotherapy antigen profiling, and miRNA target enrichment were assessed. Results: AA-enriched differential gene expression was characterized by stem cell and invasion pathways. Differential gene expression in lung tumors from EAs was primarily characterized by cell proliferation pathways. Population-specific gene expression was partly driven by population-specific miRNA expression profiles. Drug susceptibility predictions revealed a strong inverse correlation between AA resistance and EA sensitivity to the same panel of drugs. Statistically significant differences in M1 and M2 macrophage infiltration were observed in AAs (P < 0.05); however, PD-L1, PD-L2 expression was similar between both. Conclusions: Comparative transcriptomic profiling revealed clear differences in lung tumor biology between AAs and EAs. Increased participation by AAs in lung cancer clinical trials are needed to integrate, and leverage, transcriptomic differences with other clinical information to maximize therapeutic benefit in both AAs and EAs. AD - B.M. Ryan, National Cancer Institute, 37 Convent Drive, Building 37, Room 3060C, Bethesda, MD, United States AU - Mitchell, K. A. AU - Zingone, A. AU - Toulabi, L. AU - Boeckelman, J. AU - Ryan, B. M. DB - Embase Medline DO - 10.1158/1078-0432.CCR-17-0527 IS - 23 KW - biperiden bisoprolol bromocriptine budesonide canadine chelidonine diphenhydramine fenoprofen fluphenazine hexestrol irinotecan microRNA mimosine minaprine monensin mycophenolic acid nalbuphine nilutamide prednisolone primaquine prostaglandin E2 proxyphylline sertaconazole staurosporine succinylsulfathiazole sulfaguanidine sulindac sulfone transcriptome unindexed drug untranslated RNA adult African American article cancer immunotherapy cancer staging case control study cell proliferation cohort analysis comparative study controlled study drug sensitivity European American female gene expression gene expression profiling human lung tumor macrophage major clinical study male non small cell lung cancer priority journal race difference sensitivity analysis tumor microenvironment LA - English M3 - Article N1 - L619582421 2017-12-15 2018-07-20 PY - 2017 SN - 1557-3265 1078-0432 SP - 7412-7425 ST - Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans T2 - Clinical Cancer Research TI - Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619582421&from=export http://dx.doi.org/10.1158/1078-0432.CCR-17-0527 VL - 23 ID - 923 ER - TY - JOUR AB - Purpose: To determine whether racial differences in gene and miRNA expression translates to differences in lung tumor biology with clinical relevance in African Americans (AAs) and European Americans (EAs). Experimental Design: The NCI-Maryland Case Control Study includes seven Baltimore City hospitals and is overrepresented with AA patients (∼40%). Patients that underwent curative NSCLC surgery between 1998 and 2014 were enrolled. Comparative molecular profiling used mRNA (n = 22 AAs and 19 EAs) and miRNA (n = 42 AAs and 55 EAs) expression arrays to track differences in paired fresh frozen normal tissues and lung tumor specimens from AAs and EAs. Pathway enrichment, predicted drug response, tumor microenvironment infiltration, cancer immunotherapy antigen profiling, and miRNA target enrichment were assessed. Results: AA-enriched differential gene expression was characterized by stem cell and invasion pathways. Differential gene expression in lung tumors from EAs was primarily characterized by cell proliferation pathways. Population-specific gene expression was partly driven by population-specific miRNA expression profiles. Drug susceptibility predictions revealed a strong inverse correlation between AA resistance and EA sensitivity to the same panel of drugs. Statistically significant differences in M1 and M2 macrophage infiltration were observed in AAs (P < 0.05); however, PD-L1, PD-L2 expression was similar between both. Conclusions: Comparative transcriptomic profiling revealed clear differences in lung tumor biology between AAs and EAs. Increased participation by AAs in lung cancer clinical trials are needed to integrate, and leverage, transcriptomic differences with other clinical information to maximize therapeutic benefit in both AAs and EAs. ©2017 AACR. AD - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States AU - Mitchell, K. A. AU - Zingone, A. AU - Toulabi, L. AU - Boeckelman, J. AU - Ryan, B. M. DB - Scopus DO - 10.1158/1078-0432.CCR-17-0527 IS - 23 M3 - Article N1 - Cited By :31 Export Date: 22 March 2021 PY - 2017 SP - 7412-7425 ST - Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans T2 - Clinical Cancer Research TI - Comparative transcriptome profiling reveals coding and noncoding RNA differences in NSCLC from African Americans and European Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037619753&doi=10.1158%2f1078-0432.CCR-17-0527&partnerID=40&md5=82206771136dd9bcbf851177975c3387 VL - 23 ID - 2297 ER - TY - JOUR AB - Purpose: To determine whether racial differences in gene and miRNA expression translates to differences in lung tumor biology with clinical relevance in African Americans (AAs) and European Americans (EAs). Experimental Design: The NCI-Maryland Case Control Study includes seven Baltimore City hospitals and is overrepresented with AA patients (similar to 40%). Patients that underwent curative NSCLC surgery between 1998 and 2014 were enrolled. Comparative molecular profiling used mRNA (n = 22 AAs and 19 EAs) and miRNA (n = 42 AAs and 55 EAs) expression arrays to track differences in paired fresh frozen normal tissues and lung tumor specimens from AAs and EAs. Pathway enrichment, predicted drug response, tumor microenvironment infiltration, cancer immunotherapy antigen profiling, and miRNA target enrichment were assessed. Results: AA-enriched differential gene expression was characterized by stem cell and invasion pathways. Differential gene expression in lung tumors from EAs was primarily characterized by cell proliferation pathways. Population-specific gene expression was partly driven by population-specific miRNA expression profiles. Drug susceptibility predictions revealed a strong inverse correlation between AA resistance and EA sensitivity to the same panel of drugs. Statistically significant differences in M1 and M2 macrophage infiltration were observed in AAs (P < 0.05); however, PD-L1, PD-L2 expression was similar between both. Conclusions: Comparative transcriptomic profiling revealed clear differences in lung tumor biology between AAs and EAs. Increased participation by AAs in lung cancer clinical trials are needed to integrate, and leverage, transcriptomic differences with other clinical information to maximize therapeutic benefit in both AAs and EAs. (C) 2017 AACR. AN - WOS:000416908200027 AU - Mitchell, K. A. AU - Zingone, A. AU - Toulabi, L. AU - Boeckelman, J. AU - Ryan, B. M. DA - Dec DO - 10.1158/1078-0432.CCR-17-0527 IS - 23 N1 - 29196495 PY - 2017 SN - 1078-0432 SP - 7412-7425 ST - Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans T2 - Clinical Cancer Research TI - Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans VL - 23 ID - 2880 ER - TY - JOUR AB - RESULTS: Asian/Pacific Islander women had significantly lower total scores for knowledge of heart attack and self-efficacy for heart attack recognition and care seeking behavior compared to the Caucasian women (p = 0.001 and p = 0.002, respectively). However, perceived risk did not differ among the groups. Forty-six percent of the Asian American women, compared to 25% of Caucasian women, falsely believed "breast cancer is the number one cause of death for women (p = 0.002)." In addition, Asian/Pacific Islander women were less likely to report "arm pain, numbness, tingling, or radiating" as one of the heart attack symptoms compared to the Caucasian and the multiracial group (34%, 63% [p < 0.001], and 66% [p = 0.004], respectively). OBJECTIVE: The aim of the study was to compare knowledge and awareness of heart attacks/heart disease and perceived risk for future heart attack in Asian/Pacific Islander women, compared to other racial and ethnic groups. MATERIALS AND METHODS: In this cross-sectional study, 318 women enrolled in a mobile phone-based physical activity education trial were analyzed. Heart attack knowledge, self-efficacy for recognizing and responding to heart attack symptoms, and perceived risk for a future heart attack were measured. Analyses were conducted using logistic, proportional odds, and linear regression models, depending on the outcome and adjusting for age. Pairwise differences between Asian/Pacific Islanders and the other four groups were assessed using a Bonferroni correction (p < 0.0125). CONCLUSIONS: These findings highlight the urgent need to develop effective, tailored campaigns to close the knowledge gap between Asian/Pacific Islander women and Caucasian women. AU - Fukuoka, Y. AU - Lisha, N. E. AU - Vittinghoff, E. DB - Medline DO - 10.1089/jwh.2016.6156 IS - 9 KW - adult African American Asian American attitude to health California Caucasian controlled study cross-sectional study cultural factor epidemiology ethnic group ethnology female health survey heart disease heart infarction Hispanic human middle aged patient attitude psychology randomized controlled trial risk factor self concept statistics and numerical data LA - English M3 - Article N1 - L620877544 2018-03-01 PY - 2017 SN - 1931-843X SP - 1012-1019 ST - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial T2 - Journal of women's health (2002) TI - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620877544&from=export http://dx.doi.org/10.1089/jwh.2016.6156 VL - 26 ID - 930 ER - TY - JOUR AB - OBJECTIVE: The aim of the study was to compare knowledge and awareness of heart attacks/heart disease and perceived risk for future heart attack in Asian/Pacific Islander women, compared to other racial and ethnic groups. MATERIALS AND METHODS: In this cross‐sectional study, 318 women enrolled in a mobile phone‐based physical activity education trial were analyzed. Heart attack knowledge, self‐efficacy for recognizing and responding to heart attack symptoms, and perceived risk for a future heart attack were measured. Analyses were conducted using logistic, proportional odds, and linear regression models, depending on the outcome and adjusting for age. Pairwise differences between Asian/Pacific Islanders and the other four groups were assessed using a Bonferroni correction (p < 0.0125). RESULTS: Asian/Pacific Islander women had significantly lower total scores for knowledge of heart attack and self‐efficacy for heart attack recognition and care seeking behavior compared to the Caucasian women (p = 0.001 and p = 0.002, respectively). However, perceived risk did not differ among the groups. Forty‐six percent of the Asian American women, compared to 25% of Caucasian women, falsely believed "breast cancer is the number one cause of death for women (p = 0.002)." In addition, Asian/Pacific Islander women were less likely to report "arm pain, numbness, tingling, or radiating" as one of the heart attack symptoms compared to the Caucasian and the multiracial group (34%, 63% [p < 0.001], and 66% [p = 0.004], respectively). CONCLUSIONS: These findings highlight the urgent need to develop effective, tailored campaigns to close the knowledge gap between Asian/Pacific Islander women and Caucasian women. AN - CN-01454498 AU - Fukuoka, Y. AU - Lisha, N. E. AU - Vittinghoff, E. DO - 10.1089/jwh.2016.6156 IS - 9 KW - *ethnology *self concept Adult African American African Americans [psychology, statistics & numerical data] Asian American Asian Americans [*psychology, statistics & numerical data] Attitude to Health California California [epidemiology] Caucasian Controlled study Cross‐Cultural Comparison Cross‐Sectional Studies Cross‐sectional study Cultural factor Epidemiology Ethnic Groups [*psychology, statistics & numerical data] Ethnic group European Continental Ancestry Group [psychology, statistics & numerical data] Female Health Knowledge, Attitudes, Practice [*ethnology] Health survey Heart Diseases [diagnosis, *ethnology, *prevention & control] Heart disease/di [Diagnosis] Heart disease/pc [Prevention] Heart infarction/di [Diagnosis] Heart infarction/pc [Prevention] Hispanic Hispanic Americans [psychology, statistics & numerical data] Human Humans Middle Aged Myocardial Infarction [diagnosis, *ethnology, *prevention & control] Patient Acceptance of Health Care Patient attitude Population Surveillance Psychology Randomized controlled trial Risk Factors Risk factor Self Efficacy Statistics and numerical data M3 - Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, N.I.H., Extramural PY - 2017 SP - 1012‐1019 ST - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: the mPED Trial T2 - Journal of women's health (2002) TI - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: the mPED Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01454498/full VL - 26 ID - 1386 ER - TY - JOUR AB - RESULTS: Asian/Pacific Islander women had significantly lower total scores for knowledge of heart attack and self-efficacy for heart attack recognition and care seeking behavior compared to the Caucasian women (p = 0.001 and p = 0.002, respectively). However, perceived risk did not differ among the groups. Forty-six percent of the Asian American women, compared to 25% of Caucasian women, falsely believed "breast cancer is the number one cause of death for women (p = 0.002)." In addition, Asian/Pacific Islander women were less likely to report "arm pain, numbness, tingling, or radiating" as one of the heart attack symptoms compared to the Caucasian and the multiracial group (34%, 63% [p < 0.001], and 66% [p = 0.004], respectively). OBJECTIVE: The aim of the study was to compare knowledge and awareness of heart attacks/heart disease and perceived risk for future heart attack in Asian/Pacific Islander women, compared to other racial and ethnic groups. MATERIALS AND METHODS: In this cross-sectional study, 318 women enrolled in a mobile phone-based physical activity education trial were analyzed. Heart attack knowledge, self-efficacy for recognizing and responding to heart attack symptoms, and perceived risk for a future heart attack were measured. Analyses were conducted using logistic, proportional odds, and linear regression models, depending on the outcome and adjusting for age. Pairwise differences between Asian/Pacific Islanders and the other four groups were assessed using a Bonferroni correction (p < 0.0125). CONCLUSIONS: These findings highlight the urgent need to develop effective, tailored campaigns to close the knowledge gap between Asian/Pacific Islander women and Caucasian women. AD - 3 Department of Epidemiology & Biostatistics, University of California, San Francisco, California, United States AU - Fukuoka, Y. AU - Lisha, N. E. AU - Vittinghoff, E. DB - Scopus DO - 10.1089/jwh.2016.6156 IS - 9 KW - Asian/Pacific Islanders cardiovascular risks heart attack symptoms perceived risk women M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2017 SP - 1012-1019 ST - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial T2 - Journal of women's health (2002) TI - Comparing Asian American Women's Knowledge, Self-Efficacy, and Perceived Risk of Heart Attack to Other Racial and Ethnic Groups: The mPED Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042463693&doi=10.1089%2fjwh.2016.6156&partnerID=40&md5=2fc70048b79e08dc6f976e3a5df7ccb6 VL - 26 ID - 2302 ER - TY - JOUR AB - Objective: Compare effects of narrative and informational videos on use of mammography, cancer‐related beliefs, recall of core content and a range of reactions to the videos.Method: African American women (n=489) ages 40 and older were recruited from low‐income neighborhoods in St. Louis, MO and randomly assigned to watch a narrative video comprised of stories from African American breast cancer survivors (Living Proof) or a content‐equivalent informational video using a more expository and didactic approach (Facts for Life). Effects were measured immediately post‐exposure and at 3‐ and 6‐month follow‐up.Results: The narrative video was better liked, enhanced recall, reduced counterarguing, increased breast cancer discussions with family members and was perceived as more novel. Women who watched the narrative video also reported fewer barriers to mammography, more confidence that mammograms work, and were more likely to perceive cancer as an important problem affecting African Americans. Use of mammography at 6‐month follow‐up did not differ for the narrative vs. informational groups overall (49% vs. 40%, p=.20), but did among women with less than a high school education (65% vs. 32%, p<.01), and trended in the same direction for those who had no close friends or family with breast cancer (49% vs. 31%, p=.06) and those who were less trusting of traditional cancer information sources (48% vs. 30%, p=.06).Conclusions: Narrative forms of communication may increase the effectiveness of interventions to reduce cancer health disparities.Practice implications: Narratives appear to have particular value in certain population sub‐groups; identifying these groups and matching them to specific communication approaches may increase effectiveness. © 2010 Elsevier Ireland Ltd. AN - CN-00803533 AU - Kreuter, M. W. AU - Holmes, K. AU - Alcaraz, K. AU - Kalesan, B. AU - Rath, S. AU - Richert, M. AU - McQueen, A. AU - Caito, N. AU - Robinson, L. AU - Clark, E. M. DO - 10.1016/j.pec.2010.09.008 IS - SUPPL. 1 KW - *mammography *medical informatics Adult African American Article Cancer research Cancer survivor Clinical effectiveness Clinical trial Comparative effectiveness Controlled clinical trial Controlled study Educational status Female Follow up Health belief Health disparity Health education Human Human experiment Lowest income group Narrative Priority journal Randomized controlled trial United States Videorecording Women's health M3 - Journal: Article PY - 2010 SP - S6‐S14 ST - Comparing narrative and informational videos to increase mammography in low-income African American women T2 - Patient education and counseling TI - Comparing narrative and informational videos to increase mammography in low-income African American women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00803533/full VL - 81 ID - 1405 ER - TY - JOUR AB - Objective: Compare effects of narrative and informational videos on use of mammography, cancer-related beliefs, recall of core content and a range of reactions to the videos.Method: African American women (n=489) ages 40 and older were recruited from low-income neighborhoods in St. Louis, MO and randomly assigned to watch a narrative video comprised of stories from African American breast cancer survivors (Living Proof) or a content-equivalent informational video using a more expository and didactic approach (Facts for Life). Effects were measured immediately post-exposure and at 3- and 6-month follow-up.Results: The narrative video was better liked, enhanced recall, reduced counterarguing, increased breast cancer discussions with family members and was perceived as more novel. Women who watched the narrative video also reported fewer barriers to mammography, more confidence that mammograms work, and were more likely to perceive cancer as an important problem affecting African Americans. Use of mammography at 6-month follow-up did not differ for the narrative vs. informational groups overall (49% vs. 40%, p=.20), but did among women with less than a high school education (65% vs. 32%, p<.01), and trended in the same direction for those who had no close friends or family with breast cancer (49% vs. 31%, p=.06) and those who were less trusting of traditional cancer information sources (48% vs. 30%, p=.06).Conclusions: Narrative forms of communication may increase the effectiveness of interventions to reduce cancer health disparities.Practice implications: Narratives appear to have particular value in certain population sub-groups; identifying these groups and matching them to specific communication approaches may increase effectiveness. © 2010 Elsevier Ireland Ltd. AD - Health Communication Research Laboratory, The George Warren Brown School of Social Work, Washington University, St. Louis, MO, United States Siteman Cancer Center, St. Louis, MO, United States Saint Louis University and The Missouri Foundation for Health, St. Louis, MO, United States School of Medicine, Washington University, St. Louis, MO, United States Department of Psychology, Washington University, St. Louis, MO, United States Department of American Studies, Washington University, St. Louis, MO, United States AU - Kreuter, M. W. AU - Holmes, K. AU - Alcaraz, K. AU - Kalesan, B. AU - Rath, S. AU - Richert, M. AU - McQueen, A. AU - Caito, N. AU - Robinson, L. AU - Clark, E. M. DB - Scopus DO - 10.1016/j.pec.2010.09.008 IS - SUPPL. 1 KW - African American Breast cancer Cancer survivors Health disparities Mammography Narrative M3 - Article N1 - Cited By :151 Export Date: 22 March 2021 PY - 2010 SP - S6-S14 ST - Comparing narrative and informational videos to increase mammography in low-income African American women T2 - Patient Education and Counseling TI - Comparing narrative and informational videos to increase mammography in low-income African American women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649635164&doi=10.1016%2fj.pec.2010.09.008&partnerID=40&md5=1c357a27aa6c36aaa76454f3d02041ee VL - 81 ID - 2489 ER - TY - JOUR AB - Induction and maintenance immunosuppression protocols with or without long‐term steroid therapy in kidney transplant recipients are variable and are transplant center‐specific. The aim of this prospective randomized pilot study was to compare 5‐year outcomes in kidney recipients maintained on 4 different calcineurin inhibitor (CNI)‐based immunosuppression protocols without long‐term steroid therapy. Two hundred consenting patients who received kidney transplants between June 2000 and October 2004 were enrolled in 4 immunosuppression protocol groups, with 50 patients in each group: cyclosporine (CSA)/mycophenolate mofetil (MMF), CSA/sirolimus (SRL), tacrolimus (TAC)/MMF, and TAC/SRL. Induction therapy was done with basiliximab and methylprednisolone. Steroids were withdrawn on post‐transplant day 2, and long‐term steroid therapy was not used. Demographic characteristics among the four groups were comparable; approximately 50% of the recipients were African American and > or =80% of the kidneys transplanted were from deceased donors. Clinical acute rejection (CAR) was confirmed by biopsy and treated with intravenous pulse steroid therapy. Steroid‐unresponsive CAR was treated with Thymoglobulin. Surveillance biopsies were performed at 1, 6, 12, 24, 36, 48, and 60 months to evaluate subclinical acute rejection (SCAR), chronic allograft injury (CAI), and other pathological changes per the Banff 2005 schema. The primary end point was CAR, and secondary end points were 5‐year patient and graft survival rates, renal function, SCAR, CAI, and adverse events. In the first year post‐transplant, the incidence of CAR was 18% in the CSA/MMF group, 8% in the CSA/SRL group, 14% in the TAC/MMF group, and 4% in the TAC/SRL group (CSA/MMF vs. TAC/SRL; p=0.05). The incidence of SCAR was 22% in the CSA/MMF group, 8% in the CSA/SRL group, 16% in the TAC/MMF group, and 6% in the TAC/SRL group (CSA/MMF vs. CSA/SRL and TAC/SRL; p=0.05). After the first year, the incidences of CAR and SCAR decreased and were comparable in all 4 groups. At 5 years post‐transplant, cumulative CAI due to interstitial fibrosis/tubular atrophy (IF/TA), hypertension (HTN), and chronic calcineurin inhibitor (CNI) toxicity was observed in 54%, 48%, and 8% of the CSA/MMF group vs. 16%, 36%, and 12% of the CSA/SRL group vs. 38%, 24% and 6% of the TAC/MMF group vs. 14%, 25% and 12% of the TAC/SLR group (IF/TA: CSA/MMF vs. CSA/SRL and TAC/SRL; p=0.04, HTN: CSA/MMF vs. TAC/MMF and TAC/SRL; p=0.05, CNI toxicity: TAC/SRL and CSA/SRL vs. TAC/MMF; p=0.05). Five‐year patient and graft survival rates were 82% and 60% in the CSA/MMF group, 82% and 60% in the CSA/SRL group, 84% and 62% in the TAC/MMF group, and 82% and 64% in the TAC/SRL group (p=0.9). Serum creatinine levels and creatinine clearances at 5 years were comparable among the groups. Our data show that the rates of CAR and SCAR in the first year post‐transplant were significantly lower in the CSA/SRL and TAC/SRL groups and that cumulative CAI rates due to IF/TA and HTN at 5 years were significantly lower in the TAC/MMF, TAC/SRL, and CSA/SRL groups than in the CSA/MMF group. Despite significant differences in the incidences of CAR and SCAR and prevalence of different types of CAI at 5 years, renal function and patient and graft survival rates at 5 years were comparable among kidney recipients maintained on 4 different immunosuppression protocols without long‐term steroid therapy. AN - CN-00684129 AU - Anil Kumar, M. S. AU - Irfan Saeed, M. AU - Ranganna, K. AU - Malat, G. AU - Sustento-Reodica, N. AU - Kumar, A. M. AU - Meyers, W. C. DO - 10.1016/j.trim.2008.08.005 IS - 1‐2 KW - *biopsy *cyclosporin A/ae [Adverse Drug Reaction] *cyclosporin A/cb [Drug Combination] *cyclosporin A/cm [Drug Comparison] *cyclosporin A/ct [Clinical Trial] *cyclosporin A/do [Drug Dose] *cyclosporin A/dt [Drug Therapy] *graft recipient *kidney *kidney graft *methylprednisolone/dt [Drug Therapy] *methylprednisolone/iv [Intravenous Drug Administration] *mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction] *mycophenolic acid 2 morpholinoethyl ester/cb [Drug Combination] *mycophenolic acid 2 morpholinoethyl ester/cm [Drug Comparison] *mycophenolic acid 2 morpholinoethyl ester/ct [Clinical Trial] *mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy] *rapamycin/ae [Adverse Drug Reaction] *rapamycin/cb [Drug Combination] *rapamycin/ct [Clinical Trial] *rapamycin/dt [Drug Therapy] *tacrolimus/ae [Adverse Drug Reaction] *tacrolimus/cb [Drug Combination] *tacrolimus/cm [Drug Comparison] *tacrolimus/ct [Clinical Trial] *tacrolimus/do [Drug Dose] *tacrolimus/dt [Drug Therapy] Acute graft rejection/co [Complication] Acute graft rejection/di [Diagnosis] Acute graft rejection/dt [Drug Therapy] Acute graft rejection/ep [Epidemiology] Acute kidney failure/si [Side Effect] Adult African American Aged Anemia/dt [Drug Therapy] Anemia/si [Side Effect] Antibodies, Monoclonal [administration & dosage] Article Bacterial infection/si [Side Effect] Basiliximab Basiliximab/dt [Drug Therapy] Biopsy technique Bladder cancer/si [Side Effect] Breast cancer/si [Side Effect] Calcineurin Inhibitors Calcineurin inhibitor Clinical trial Colon cancer/co [Complication] Colon cancer/si [Side Effect] Comparative study Controlled clinical trial Controlled study Cotrimoxazole/dt [Drug Therapy] Creatinine [blood] Creatinine blood level Creatinine clearance Creatinine/ec [Endogenous Compound] Cyclosporine [administration & dosage, adverse effects] Cytomegalovirus infection/co [Complication] Cytomegalovirus infection/dt [Drug Therapy] Cytomegalovirus infection/pc [Prevention] Delayed graft function/co [Complication] Delayed graft function/di [Diagnosis] Demography Diabetes mellitus/dt [Drug Therapy] Diabetes mellitus/si [Side Effect] Drug dose increase Drug withdrawal Erythropoietin/dt [Drug Therapy] Female Fibrosing alveolitis Gastrointestinal symptom/si [Side Effect] Graft Rejection [complications, *drug therapy] Graft Survival [drug effects, immunology] Graft survival Human Human tissue Humans Hyperlipidemia/si [Side Effect] Hypertension/ep [Epidemiology] Immunosuppression [*methods] Immunosuppressive Agents [*administration & dosage, adverse effects] Immunosuppressive treatment Infection/si [Side Effect] Insulin/dt [Drug Therapy] Kidney Transplantation [immunology, mortality, pathology] Kidney carcinoma/co [Complication] Kidney carcinoma/si [Side Effect] Kidney donor Kidney function Leukemia/co [Complication] Leukemia/si [Side Effect] Lung cancer/si [Side Effect] Lymphoproliferative disease/co [Complication] Lymphoproliferative disease/si [Side Effect] Major clinical study Male Middle Aged Monitoring Monitoring, Immunologic Morbidity Mouth ulcer/si [Side Effect] Mycophenolic Acid [administration & dosage, adverse effects, analogs & derivatives] Oral antidiabetic agent/dt [Drug Therapy] Oral antidiabetic agent/po [Oral Drug Administration] Outcome assessment Parotid gland cancer/co [Complication] Parotid gland cancer/si [Side Effect] Pilot Projects Pilot study Pneumocystosis/dt [Drug Therapy] Pneumocystosis/pc [Prevention] Prevalence Priority journal Prospective Studies Prospective study Prostate cancer/si [Side Effect] Pyelonephritis/si [Side Effect] Randomized controlled trial Recombinant Fusion Proteins [administration & dosage] Sirolimus [administration & dosage, adverse effects] Steroid therapy Steroids [administration & dosage] Survival rate Tacrolimus [administration & dosage, adverse effects] Thymocyte antibody/dt [Drug Therapy] Thyroid cancer/co [Complication] Thyroid cancer/si [Side Effect] Treatment Outcome Valganciclovir/dt [Drug Therapy] Wound healing impairment/si [Side Effect] Wound healing/si [Side Effect] M3 - Comparative Study; Journal Article; Randomized Controlled Trial PY - 2008 SP - 32‐42 ST - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes T2 - Transplant immunology TI - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00684129/full VL - 20 ID - 1587 ER - TY - JOUR AB - Induction and maintenance immunosuppression protocols with or without long-term steroid therapy in kidney transplant recipients are variable and are transplant center-specific. The aim of this prospective randomized pilot study was to compare 5-year outcomes in kidney recipients maintained on 4 different calcineurin inhibitor (CNI)-based immunosuppression protocols without long-term steroid therapy. Two hundred consenting patients who received kidney transplants between June 2000 and October 2004 were enrolled in 4 immunosuppression protocol groups, with 50 patients in each group: cyclosporine (CSA)/mycophenolate mofetil (MMF), CSA/sirolimus (SRL), tacrolimus (TAC)/MMF, and TAC/SRL. Induction therapy was done with basiliximab and methylprednisolone. Steroids were withdrawn on post-transplant day 2, and long-term steroid therapy was not used. Demographic characteristics among the four groups were comparable; approximately 50% of the recipients were African American and ≥ 80% of the kidneys transplanted were from deceased donors. Clinical acute rejection (CAR) was confirmed by biopsy and treated with intravenous pulse steroid therapy. Steroid-unresponsive CAR was treated with Thymoglobulin. Surveillance biopsies were performed at 1, 6, 12, 24, 36, 48, and 60 months to evaluate subclinical acute rejection (SCAR), chronic allograft injury (CAI), and other pathological changes per the Banff 2005 schema. The primary end point was CAR, and secondary end points were 5-year patient and graft survival rates, renal function, SCAR, CAI, and adverse events. In the first year post-transplant, the incidence of CAR was 18% in the CSA/MMF group, 8% in the CSA/SRL group, 14% in the TAC/MMF group, and 4% in the TAC/SRL group (CSA/MMF vs. TAC/SRL; p = 0.05). The incidence of SCAR was 22% in the CSA/MMF group, 8% in the CSA/SRL group, 16% in the TAC/MMF group, and 6% in the TAC/SRL group (CSA/MMF vs. CSA/SRL and TAC/SRL; p = 0.05). After the first year, the incidences of CAR and SCAR decreased and were comparable in all 4 groups. At 5 years post-transplant, cumulative CAI due to interstitial fibrosis/tubular atrophy (IF/TA), hypertension (HTN), and chronic calcineurin inhibitor (CNI) toxicity was observed in 54%, 48%, and 8% of the CSA/MMF group vs. 16%, 36%, and 12% of the CSA/SRL group vs. 38%, 24% and 6% of the TAC/MMF group vs. 14%, 25% and 12% of the TAC/SLR group (IF/TA: CSA/MMF vs. CSA/SRL and TAC/SRL; p = 0.04, HTN: CSA/MMF vs. TAC/MMF and TAC/SRL; p = 0.05, CNI toxicity: TAC/SRL and CSA/SRL vs. TAC/MMF; p = 0.05). Five-year patient and graft survival rates were 82% and 60% in the CSA/MMF group, 82% and 60% in the CSA/SRL group, 84% and 62% in the TAC/MMF group, and 82% and 64% in the TAC/SRL group (p = 0.9). Serum creatinine levels and creatinine clearances at 5 years were comparable among the groups. Our data show that the rates of CAR and SCAR in the first year post-transplant were significantly lower in the CSA/SRL and TAC/SRL groups and that cumulative CAI rates due to IF/TA and HTN at 5 years were significantly lower in the TAC/MMF, TAC/SRL, and CSA/SRL groups than in the CSA/MMF group. Despite significant differences in the incidences of CAR and SCAR and prevalence of different types of CAI at 5 years, renal function and patient and graft survival rates at 5 years were comparable among kidney recipients maintained on 4 different immunosuppression protocols without long-term steroid therapy. © 2008 Elsevier B.V. All rights reserved. AD - Department of Surgery, Division of Transplantation, Drexel University College of Medicine, PA 19102, United States Department of Medicine, Division of Nephrology, Drexel University College of Medicine, PA 19102, United States Department of Pathology, Drexel University College of Medicine, Hahnemann University Hospital Philadelphia, PA 19102, United States AU - Anil Kumar, M. S. AU - Irfan Saeed, M. AU - Ranganna, K. AU - Malat, G. AU - Sustento-Reodica, N. AU - Kumar, A. M. S. AU - Meyers, W. C. DB - Scopus DO - 10.1016/j.trim.2008.08.005 IS - 1-2 KW - Immunosuppression protocol Kidney transplant Steroid withdrawal M3 - Article N1 - Cited By :56 Export Date: 22 March 2021 PY - 2008 SP - 32-42 ST - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes T2 - Transplant Immunology TI - Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-56049095966&doi=10.1016%2fj.trim.2008.08.005&partnerID=40&md5=53c3ca96c24de069d9eafe609a50c9aa VL - 20 ID - 2531 ER - TY - JOUR AB - PURPOSE: To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. PATIENTS AND METHODS: Chemonaïve patients with a performance status of 0 or 1 and stage IIIB or IV non‐small cell lung cancer were randomized to arm A: gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1; arm B: the same schedule of gemcitabine plus paclitaxel 200 mg/m2 on day 1; or arm C: paclitaxel 225 mg/m2 on day 1 plus carboplatin area under the curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A site selection tool identified institutions with potential to recruit a minority population. Outcome and toxicity data of white and African American patients were compared. RESULTS: Of 1135 total patients, 972 were white (85.6%) and 138 were African American (12.2%). Median survival was 8.3 months for white patients (95% confidence interval [CI]: 7.7‐9.3) and 9.1 months for African American patients (95% CI: 8.2‐11.1). Response rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4 toxicities were comparable. Among African Americans, median survival was 7.2 months (95% CI: 5.1‐10.1) for gemcitabine‐carboplatin (n = 47), 10.5 months (95% CI: 7.1‐15.4) for gemcitabine‐paclitaxel (n = 42), and 10.2 months (95% CI: 8.5‐13.2) for paclitaxel‐carboplatin (n = 49). CONCLUSION: Whites and African Americans had similar outcomes, although there was some variability in survival among African Americans across the three treatment groups. AN - CN-00759518 AU - Obasaju, C. K. AU - Ansari, R. H. AU - Socinski, M. A. AU - Chen, R. AU - Monberg, M. J. AU - Catalano, R. B. AU - Marinucci, D. M. AU - Liles, D. K. AU - Ribeiro, M. J. AU - Comis, R. L. AU - et al. DO - 10.1097/jto.0b013e3181e29cf3 IS - 7 KW - Adult African Americans [*ethnology] Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols [*therapeutic use] Carboplatin [administration & dosage] Carcinoma, Non‐Small‐Cell Lung [*drug therapy, *ethnology] Deoxycytidine [administration & dosage, analogs & derivatives] European Continental Ancestry Group [*ethnology] Female Humans Lung Neoplasms [*drug therapy, *ethnology] Male Middle Aged Paclitaxel [administration & dosage] Survival Rate Treatment Outcome M3 - Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2010 SP - 993‐1000 ST - A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer T2 - Journal of thoracic oncology TI - A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00759518/full VL - 5 ID - 1366 ER - TY - JOUR AB - PURPOSE: To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. PATIENTS AND METHODS: Chemonaïve patients with a performance status of 0 or 1 and stage IIIB or IV non-small cell lung cancer were randomized to arm A: gemcitabine 1000 mg/m on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1; arm B: the same schedule of gemcitabine plus paclitaxel 200 mg/m on day 1; or arm C: paclitaxel 225 mg/m on day 1 plus carboplatin area under the curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A site selection tool identified institutions with potential to recruit a minority population. Outcome and toxicity data of white and African American patients were compared. RESULTS: Of 1135 total patients, 972 were white (85.6%) and 138 were African American (12.2%). Median survival was 8.3 months for white patients (95% confidence interval [CI]: 7.7-9.3) and 9.1 months for African American patients (95% CI: 8.2-11.1). Response rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4 toxicities were comparable. Among African Americans, median survival was 7.2 months (95% CI: 5.1-10.1) for gemcitabine-carboplatin (n = 47), 10.5 months (95% CI: 7.1-15.4) for gemcitabine-paclitaxel (n = 42), and 10.2 months (95% CI: 8.5-13.2) for paclitaxel-carboplatin (n = 49). CONCLUSION: Whites and African Americans had similar outcomes, although there was some variability in survival among African Americans across the three treatment groups. © 2010 by the International Association for the Study of Lung Cancer. AD - C. K. Obasaju, Lilly USA, LLC, Drop Code 6831, Indianapolis, IN 46285, United States AU - Obasaju, C. K. AU - Ansari, R. H. AU - Socinski, M. A. AU - Chen, R. AU - Monberg, M. J. AU - Catalano, R. B. AU - Marinucci, D. M. AU - Liles, D. K. AU - Ribeiro, M. J. AU - Comis, R. L. AU - Treat, J. DB - Embase Medline DO - 10.1097/JTO.0b013e3181e29cf3 IS - 7 KW - carboplatin cimetidine corticosteroid diphenhydramine gemcitabine paclitaxel adult advanced cancer African American aged alopecia anemia area under the curve arthralgia article brain metastasis cancer combination chemotherapy cancer patient cancer radiotherapy cancer survival Caucasian clinical trial constipation controlled clinical trial controlled study diarrhea disease severity drug efficacy drug safety fatigue febrile neutropenia female functional status gastrointestinal disease human infection non small cell lung cancer major clinical study male multicenter study multiple cycle treatment nausea neurologic disease neutropenia outcome assessment phase 3 clinical trial priority journal race difference randomized controlled trial sensory neuropathy thrombocytopenia treatment outcome treatment response LA - English M3 - Article N1 - L50917038 2010-05-25 2010-07-26 PY - 2010 SN - 1556-0864 1556-1380 SP - 993-1000 ST - A comparison of white and african american outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer T2 - Journal of Thoracic Oncology TI - A comparison of white and african american outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50917038&from=export http://dx.doi.org/10.1097/JTO.0b013e3181e29cf3 VL - 5 ID - 1161 ER - TY - JOUR AB - PURPOSE: To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. PATIENTS AND METHODS: Chemonaïve patients with a performance status of 0 or 1 and stage IIIB or IV non-small cell lung cancer were randomized to arm A: gemcitabine 1000 mg/m on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1; arm B: the same schedule of gemcitabine plus paclitaxel 200 mg/m on day 1; or arm C: paclitaxel 225 mg/m on day 1 plus carboplatin area under the curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A site selection tool identified institutions with potential to recruit a minority population. Outcome and toxicity data of white and African American patients were compared. RESULTS: Of 1135 total patients, 972 were white (85.6%) and 138 were African American (12.2%). Median survival was 8.3 months for white patients (95% confidence interval [CI]: 7.7-9.3) and 9.1 months for African American patients (95% CI: 8.2-11.1). Response rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4 toxicities were comparable. Among African Americans, median survival was 7.2 months (95% CI: 5.1-10.1) for gemcitabine-carboplatin (n = 47), 10.5 months (95% CI: 7.1-15.4) for gemcitabine-paclitaxel (n = 42), and 10.2 months (95% CI: 8.5-13.2) for paclitaxel-carboplatin (n = 49). CONCLUSION: Whites and African Americans had similar outcomes, although there was some variability in survival among African Americans across the three treatment groups. © 2010 by the International Association for the Study of Lung Cancer. AD - Lilly USA, LLC, Indianapolis, IN 46285, United States Northern Indiana Cancer Research Consortium, South Bend, IN, United States Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States Drexel University College of Medicine, Philadelphia, PA, United States Leo W. Jenkins Cancer Center, East Carolina University, Greenville, NC, United States Atlanta Veterans Affairs Medical Center, Atlanta, GA, United States AU - Obasaju, C. K. AU - Ansari, R. H. AU - Socinski, M. A. AU - Chen, R. AU - Monberg, M. J. AU - Catalano, R. B. AU - Marinucci, D. M. AU - Liles, D. K. AU - Ribeiro, M. J. AU - Comis, R. L. AU - Treat, J. DB - Scopus DO - 10.1097/JTO.0b013e3181e29cf3 IS - 7 KW - Accrual African American Nonplatinum doublets NSCLC Phase III Race M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2010 SP - 993-1000 ST - A comparison of white and african american outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer T2 - Journal of Thoracic Oncology TI - A comparison of white and african american outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954426249&doi=10.1097%2fJTO.0b013e3181e29cf3&partnerID=40&md5=b2ed2863d680482e7749e3c50b4ffaaf VL - 5 ID - 2505 ER - TY - JOUR AB - Purpose: To investigate the effect of race on the efficacy and safety of standard chemotherapy doublet regimens in African American patients, we conducted a subgroup analysis of a phase III randomized trial. Patients and Methods: Chemonaive patients with a performance status of 0 or 1 and stage IIIB or IV non-small cell lung cancer were randomized to arm A: gemcitabine 1000 mg/m(2) on days 1 and 8 plus carboplatin area under the curve 5.5 on day 1; arm B: the same schedule of gemcitabine plus paclitaxel 200 mg/m(2) on day 1; or arm C: paclitaxel 225 mg/m(2) on day 1 plus carboplatin area under the curve 6.0 on day 1. Cycles were repeated every 21 days up to 6. A site selection tool identified institutions with potential to recruit a minority population. Outcome and toxicity data of white and African American patients were compared. Results: Of 1135 total patients, 972 were white (85.6%) and 138 were African American (12.2%). Median survival was 8.3 months for white patients (95% confidence interval [CI]: 7.7-9.3) and 9.1 months for African American patients (95% CI: 8.2-11.1). Response rates were 29.1 and 29.0%, respectively. Rates of grade 3 or 4 toxicities were comparable. Among African Americans, median survival was 7.2 months (95% CI: 5.1-10.1) for gemcitabine-carboplatin (n = 47), 10.5 months (95% CI: 7.1-15.4) for gemcitabine- paclitaxel (n = 42), and 10.2 months (95% CI: 8.5-13.2) for paclitaxel-carboplatin (n = 49). Conclusion: Whites and African Americans had similar outcomes, although there was some variability in survival among African Americans across the three treatment groups. AN - WOS:000279165200013 AU - Obasaju, C. K. AU - Ansari, R. H. AU - Socinski, M. A. AU - Chen, R. Q. AU - Monberg, M. J. AU - Catalano, R. B. AU - Marinucci, D. M. AU - Liles, D. K. AU - Ribeiro, M. J. AU - Comis, R. L. AU - Treat, J. DA - Jul DO - 10.1097/JTO.0b013e3181e29cf3 IS - 7 N1 - 20593535 PY - 2010 SN - 1556-0864 SP - 993-1000 ST - A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer T2 - Journal of Thoracic Oncology TI - A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer VL - 5 ID - 3111 ER - TY - JOUR AB - The recent decrease in breast cancer mortality has been linked in part to increased breast cancer screening. Although the percentage of women screened once is rising, rate of continued adherence is poor. The purpose of this article is to assess the effects of tailored mammography interventions implemented prospectively in a factorial design contrasting groups receiving either (a) usual care (no intervention), (b) tailored telephone counseling for mammography, (c) tailored mailed materials promoting mammography, or (d) a combination of tailored mail and telephone counseling. This prospective, randomized study with a 2 × 2 factorial design included women 51 years and older (N = 1,367) who were not adherent with mammography at baseline. The intervention is based on integration of the Transtheoretical and Health Belief Models. Participants were enrolled in one of two health maintenance organizations or seen in a university-related primary care clinic. Baseline data were collected on mammography history and beliefs and knowledge related to mammography. Data were collected via telephone interviews using previously developed scales. The follow-up interviewers were conducted with 976 women. The sample was 41% White, 56% African American, and 3% other. Mean age at baseline was 66.5. Logistic regression indicates that postintervention mammography status in all three intervention groups was significantly better than usual care, with odds ratios ranging from 1.66 (telephone only) to 2.16 (telephone plus mail). AD - V.L. Champion, Indiana University School of Nursing, 1111 Middle Drive, Indianapolis, IN 46202-5107, United States AU - Champion, V. L. AU - Skinner, C. S. AU - Menon, U. AU - Seshadri, R. AU - Anzalone, D. C. AU - Rawl, S. M. DB - Embase Medline IS - 3 KW - adult aged article breast carcinoma cancer risk cancer screening cancer susceptibility clinical trial confidence interval controlled clinical trial controlled study family history female genetic predisposition health maintenance organization human major clinical study mammography marriage patient compliance patient counseling primary medical care prospective study randomized controlled trial risk assessment screening test telephone LA - English M3 - Article N1 - L34839941 2002-08-16 PY - 2002 SN - 0883-6612 SP - 211-218 ST - Comparisons of tailored mammography interventions at two months postintervention T2 - Annals of Behavioral Medicine TI - Comparisons of tailored mammography interventions at two months postintervention UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34839941&from=export VL - 24 ID - 1300 ER - TY - JOUR AB - The recent decrease in breast cancer mortality has been linked in part to increased breast cancer screening. Although the percentage of women screened once is rising, rate of continued adherence is poor. The purpose of this article is to assess the effects of tailored mammography interventions implemented prospectively in a factorial design contrasting groups receiving either (a) usual care (no intervention), (b) tailored telephone counseling for mammography, (c) tailored mailed materials promoting mammography, or (d) a combination of tailored mail and telephone counseling. This prospective, randomized study with a 2 x 2 factorial design included women 51 years and older (N = 1,367) who were not adherent with mammography at baseline. The intervention is based on integration of the Transtheoretical and Health Belief Models. Participants were enrolled in one of two health maintenance organizations or seen in a university‐related primary care clinic. Baseline data were collected on mammography history and beliefs and knowledge related to mammography. Data were collected via telephone interviews using previously developed scales. The follow‐up interviewers were conducted with 976 women. The sample was 41% White, 56% African American, and 3% other. Mean age at baseline was 66.5. Logistic regression indicates that postintervention mammography status in all three intervention groups was significantly better than usual care, with odds ratios ranging from 1.66 (telephone only) to 2.16 (telephone plus mail). AN - CN-00443551 AU - Champion, V. L. AU - Skinner, C. S. AU - Menon, U. AU - Seshadri, R. AU - Anzalone, D. C. AU - Rawl, S. M. DO - 10.1207/S15324796ABM2403_06 IS - 3 KW - *breast carcinoma/di [Diagnosis] *cancer screening *mammography Adult Aged Article Attitude to Health Breast Neoplasms [*diagnosis, surgery] Cancer risk Cancer susceptibility Clinical trial Confidence interval Controlled clinical trial Controlled study Family history Female Genetic predisposition Health maintenance organization Human Humans Major clinical study Mammography [*methods] Marriage Middle Aged Patient compliance Patient counseling Postoperative Period Primary medical care Prospective Studies Prospective study Random Allocation Randomized controlled trial Risk assessment Screening test Telephone M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2002 SP - 211‐218 ST - Comparisons of tailored mammography interventions at two months postintervention T2 - Annals of behavioral medicine TI - Comparisons of tailored mammography interventions at two months postintervention UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00443551/full VL - 24 ID - 1467 ER - TY - JOUR AB - The recent decrease in breast cancer mortality has been linked in part to increased breast cancer screening. Although the percentage of women screened once is rising, rate of continued adherence is poor. The purpose of this article is to assess the effects of tailored mammography interventions implemented prospectively in a factorial design contrasting groups receiving either (a) usual care (no intervention), (b) tailored telephone counseling for mammography, (c) tailored mailed materials promoting mammography, or (d) a combination of tailored mail and telephone counseling. This prospective, randomized study with a 2 × 2 factorial design included women 51 years and older (N = 1,367) who were not adherent with mammography at baseline. The intervention is based on integration of the Transtheoretical and Health Belief Models. Participants were enrolled in one of two health maintenance organizations or seen in a university-related primary care clinic. Baseline data were collected on mammography history and beliefs and knowledge related to mammography. Data were collected via telephone interviews using previously developed scales. The follow-up interviewers were conducted with 976 women. The sample was 41% White, 56% African American, and 3% other. Mean age at baseline was 66.5. Logistic regression indicates that postintervention mammography status in all three intervention groups was significantly better than usual care, with odds ratios ranging from 1.66 (telephone only) to 2.16 (telephone plus mail). AD - Indiana University School of Nursing, United States Duke University, Comprehensive Cancer Center, United States University of Utah, United States Chicago, IL, United States Walther Cancer Institute, United States Indiana University, School of Nursing, United States AU - Champion, V. L. AU - Skinner, C. S. AU - Menon, U. AU - Seshadri, R. AU - Anzalone, D. C. AU - Rawl, S. M. DB - Scopus DO - 10.1207/S15324796ABM2403_06 IS - 3 M3 - Article N1 - Cited By :54 Export Date: 22 March 2021 PY - 2002 SP - 211-218 ST - Comparisons of tailored mammography interventions at two months postintervention T2 - Annals of Behavioral Medicine TI - Comparisons of tailored mammography interventions at two months postintervention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036022123&doi=10.1207%2fS15324796ABM2403_06&partnerID=40&md5=7667beacb3ce62d26429d3c6b3840413 VL - 24 ID - 2622 ER - TY - JOUR AB - There is an increasing need for accurate prediction methods of assessing individual risk for breast cancer for both clinical and research purposes. The purpose of this study is to compare the Gail and Claus model risk estimates of breast cancer among women with a family history of breast cancer. This study presents risk estimates from two models of breast cancer risk in 491 women 18 to 74 years of age with a family history of breast cancer who were recruited to risk counseling clinical trials in Seattle, Washington between 1996 and 1997. These trials included women from the general population and additional samples of Ashkenazi Jewish, African-American, and lesbian women. We estimated and compared lifetime (to age 79) and 5-year risk for developing breast cancer using the National Surgical Adjuvant Breast and Bowel Project adaptation of the Gail model and the Claus model. About one-quarter of participants fell into the Gail "high" risk category (≥1.7% risk of developing breast cancer in the next 5 years). The average lifetime risk was estimated at 13.2% by the Gail model and 11.2% by the Claus model. Estimates from the two models were moderately and positively correlated (r = 0.55) with the Gail model yielding a higher estimate than the Claus model for most participants. If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option. AD - A. McTiernan, Fred Hutchinson Can. Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, United States AU - McTiernan, A. AU - Kuniyuki, A. AU - Yasui, Y. AU - Bowen, D. AU - Burke, W. AU - Culver, J. B. AU - Anderson, R. AU - Durfy, S. DB - Embase Medline IS - 4 KW - adult aged article breast cancer calculation cancer risk comparative study controlled study family history female high risk population human major clinical study mathematical analysis model priority journal risk assessment scoring system LA - English M3 - Article N1 - L32703217 2001-08-13 PY - 2001 SN - 1055-9965 SP - 333-338 ST - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer T2 - Cancer Epidemiology Biomarkers and Prevention TI - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32703217&from=export VL - 10 ID - 1309 ER - TY - JOUR AB - There is an increasing need for accurate prediction methods of assessing individual risk for breast cancer for both clinical and research purposes. The purpose of this study is to compare the Gail and Claus model risk estimates of breast cancer among women with a family history of breast cancer. This study presents risk estimates from two models of breast cancer risk in 491 women 18 to 74 years of age with a family history of breast cancer who were recruited to risk counseling clinical trials in Seattle, Washington between 1996 and 1997. These trials included women from the general population and additional samples of Ashkenazi Jewish, African-American, and lesbian women. We estimated and compared lifetime (to age 79) and 5-year risk for developing breast cancer using the National Surgical Adjuvant Breast and Bowel Project adaptation of the Gail model and the Claus model. About one-quarter of participants fell into the Gail "high" risk category (≥1.7% risk of developing breast cancer in the next 5 years). The average lifetime risk was estimated at 13.2% by the Gail model and 11.2% by the Claus model. Estimates from the two models were moderately and positively correlated (r = 0.55) with the Gail model yielding a higher estimate than the Claus model for most participants. If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option. AD - Fred Hutchinson Cancer Research Center, Seattle, WA 98109, United States Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, United States Department of Biostatistics, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, United States Department of Health Services, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, United States Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, United States Department of Medical History and Ethics, School of Medicine, University of Washington, Seattle, WA 98195, United States AU - McTiernan, A. AU - Kuniyuki, A. AU - Yasui, Y. AU - Bowen, D. AU - Burke, W. AU - Culver, J. B. AU - Anderson, R. AU - Durfy, S. DB - Scopus IS - 4 M3 - Article N1 - Cited By :54 Export Date: 22 March 2021 PY - 2001 SP - 333-338 ST - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer T2 - Cancer Epidemiology Biomarkers and Prevention TI - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034894376&partnerID=40&md5=97b4d36631cba58c3dba913f5cb49f76 VL - 10 ID - 2628 ER - TY - JOUR AB - There is an increasing need for accurate prediction methods of assessing individual risk for breast cancer for both clinical and research purposes. The purpose of this study is to compare the Gail and Claus model risk estimates of breast cancer among women with a family history of breast cancer. This study presents risk estimates from two models of breast cancer risk in 491 women 18 to 74 years of age with a family history of breast cancer who were recruited to risk counseling clinical trials in Seattle, Washington between 1996 and 1997. These trials included women from the general population and additional samples of Ashkenazi Jewish, African-American, and lesbian women. We estimated and compared lifetime (to age 79) and 5-year risk for developing breast cancer using the National Surgical Adjuvant Breast and Bowel Project adaptation of the Gail model and the Claus model. About one-quarter of participants fell into the Gail "high" risk category (greater than or equal to1.7% risk of developing breast cancer in the next 5 years). The average lifetime risk was estimated at 13.2% by the Gail model and 11.2% by the Claus model, Estimates from the two models were moderately and positively correlated (r = 0.55) with the Gail model yielding a higher estimate than the Claus model for most participants. If women with a family history of breast cancer are being counseled regarding decisions on genetic testing, tamoxifen use, or other preventive measures, presenting both Claus and Gail estimates may be the best option. AN - WOS:000168384600007 AU - McTiernan, A. AU - Kuniyuki, A. AU - Yasui, Y. AU - Bowen, D. AU - Burke, W. AU - Culver, J. B. AU - Anderson, R. AU - Durfy, S. DA - Apr IS - 4 N1 - 50 11319173 PY - 2001 SN - 1055-9965 SP - 333-338 ST - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer T2 - Cancer Epidemiology Biomarkers & Prevention TI - Comparisons of two breast cancer risk estimates in women with a family history of breast cancer VL - 10 ID - 2708 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas. This focus on urban populations limits the generalizability and dissemination potential of screening interventions. Methods: Using community-based participatory research (CBPR) principles, we designed a cluster-randomized trial, adaptable to a range of settings, including rural and urban health centers. We enrolled 483 participants across 11 health centers representing 2 separate networks. Both networks serve medically-underserved communities; however one is primarily rural and one primarily urban. Results: Our goal in this analysis is to describe baseline characteristics of participants and examine setting-level differences. CBPR was a critical for recruiting networks to the trial. Patient respondents were predominately female (61.3%), African-American (66.5%), and earned <$1200 per month (87.1%). The rural network sample was older; more likely to be female, white, disabled or retired, and have a higher income, but fewer years of education. Conclusions: Variation in the samples partly reflects the CBPR process and partly reflects inherent differences in the communities. This confirmed the importance of using CBPR when planning for eventual dissemination, as it enhanced our ability to work within diverse settings. These baseline findings indicate that using a uniform approach to implementing a trial or intervention across diverse settings might not be effective or efficient. AD - A.S. James, Washington University School of Medicine, 660 South Euclid Ave, Box 8100, Saint Louis, MO, United States AU - Muthukrishnan, M. AU - Sutcliffe, S. AU - Hunleth, J. M. AU - Wang, J. S. AU - Colditz, G. A. AU - James, A. S. DB - Embase DO - 10.1016/j.conctc.2018.02.005 KW - adult African American aged article cancer screening Caucasian colonoscopy colorectal cancer disabled person educational status female human income major clinical study male medically underserved occult blood test participatory research pensioner priority journal randomized controlled trial (topic) rural health care rural population safety net hospital sigmoidoscopy urban health urban population urban rural difference LA - English M3 - Article N1 - L621132357 2018-03-15 2018-03-21 PY - 2018 SN - 2451-8654 SP - 29-35 ST - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research T2 - Contemporary Clinical Trials Communications TI - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621132357&from=export http://dx.doi.org/10.1016/j.conctc.2018.02.005 VL - 10 ID - 896 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas. This focus on urban populations limits the generalizability and dissemination potential of screening interventions. Methods: Using community-based participatory research (CBPR) principles, we designed a cluster-randomized trial, adaptable to a range of settings, including rural and urban health centers. We enrolled 483 participants across 11 health centers representing 2 separate networks. Both networks serve medically-underserved communities; however one is primarily rural and one primarily urban. Results: Our goal in this analysis is to describe baseline characteristics of participants and examine setting-level differences. CBPR was a critical for recruiting networks to the trial. Patient respondents were predominately female (61.3%), African-American (66.5%), and earned <$1200 per month (87.1%). The rural network sample was older; more likely to be female, white, disabled or retired, and have a higher income, but fewer years of education. Conclusions: Variation in the samples partly reflects the CBPR process and partly reflects inherent differences in the communities. This confirmed the importance of using CBPR when planning for eventual dissemination, as it enhanced our ability to work within diverse settings. These baseline findings indicate that using a uniform approach to implementing a trial or intervention across diverse settings might not be effective or efficient. © 2018 The Authors AD - Department of Epidemiology and Biostatistics, Saint Louis University College of Public Health and Social Justice, St. Louis, MO, United States Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, United States Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States AU - Muthukrishnan, M. AU - Sutcliffe, S. AU - Hunleth, J. M. AU - Wang, J. S. AU - Colditz, G. A. AU - James, A. S. DB - Scopus DO - 10.1016/j.conctc.2018.02.005 KW - Colorectal cancer screening Community-based participatory research Dissemination and implementation Health disparities Medically underserved populations Randomized trial M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2018 SP - 29-35 ST - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research T2 - Contemporary Clinical Trials Communications TI - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043390717&doi=10.1016%2fj.conctc.2018.02.005&partnerID=40&md5=6f14f03961d4ef514f2cb77223c48e95 VL - 10 ID - 2271 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas. This focus on urban populations limits the generalizability and dissemination potential of screening interventions. Methods: Using community-based participatory research (CBPR) principles, we designed a cluster-randomized trial, adaptable to a range of settings, including rural and urban health centers. We enrolled 483 participants across 11 health centers representing 2 separate networks. Both networks serve medically-underserved communities; however one is primarily rural and one primarily urban. Results: Our goal in this analysis is to describe baseline characteristics of participants and examine setting-level differences. CBPR was a critical for recruiting networks to the trial. Patient respondents were predominately female (61.3%), African-American (66.5%), and earned<$1200 per month (87.1%). The rural network sample was older; more likely to be female, white, disabled or retired, and have a higher income, but fewer years of education. Conclusions: Variation in the samples partly reflects the CBPR process and partly reflects inherent differences in the communities. This confirmed the importance of using CBPR when planning for eventual dissemination, as it enhanced our ability to work within diverse settings. These baseline findings indicate that using a uniform approach to implementing a trial or intervention across diverse settings might not be effective or efficient. AN - WOS:000433315000005 AU - Muthukrishnan, M. AU - Sutcliffe, S. AU - Hunleth, J. M. AU - Wang, J. S. AU - Colditz, G. A. AU - James, A. S. DA - Jun DO - 10.1016/j.conctc.2018.02.005 N1 - 29696155 PY - 2018 SN - 2451-8654 SP - 29-35 ST - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research T2 - Contemporary Clinical Trials Communications TI - Conducting a randomized trial in rural and urban safety-net health centers: Added value of community-based participatory research VL - 10 ID - 2859 ER - TY - JOUR AB - Background: The purpose of this study was to assess treatment choices among men with prostate cancer who presented at The University of Texas MD Anderson Cancer Center multidisciplinary (MultiD) clinic compared with nationwide trends.Methods: In total, 4451 men with prostate cancer who presented at the MultiD clinic from 2004 to 2016 were analyzed. To assess nationwide trends, the authors analyzed 392,710 men with prostate cancer who were diagnosed between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoint was treatment choice as a function of pretreatment demographics.Results: Univariate analyses revealed similar treatment trends in the MultiD and SEER cohorts. The use of procedural forms of definitive therapy decreased with age, including brachytherapy and prostatectomy (all P < .05). Later year of diagnosis/clinic visit was associated with decreased use of definitive treatments, whereas higher risk grouping was associated with increased use (all P < .001). Patients with low-risk disease treated at the MultiD clinic were more likely to receive nondefinitive therapy than patients in SEER, whereas the opposite trend was observed for patients with high-risk disease, with a substantial portion of high-risk patients in SEER not receiving definitive therapy. In the MultiD clinic, African American men with intermediate-risk and high-risk disease were more likely to receive definitive therapy than white men, but for SEER the opposite was true.Conclusions: Presentation at a MultiD clinic facilitates the appropriate disposition of patients with low-risk disease to nondefinitive strategies of patients with high-risk disease to definitive treatment, and it may obviate the influence of race. AD - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston Texas Department of Radiation Oncology, Summit Medical Group, Summit New Jersey Department of Urology, The University of Texas MD Anderson Cancer Center, Houston Texas Department of genitourinary medical oncology, The University of Texas MD Anderson cancer center, Houston Texas Banner MD Anderson Cancer Center, Mesa Arizona Scripps MD Anderson Cancer Center, San Diego California AN - 141250936. Language: English. Entry Date: 20200901. Revision Date: 20210202. Publication Type: journal article AU - Tang, Chad AU - Hoffman, Karen E. AU - Allen, Pamela K. AU - Gabel, Molly AU - Schreiber, David AU - Choi, Seungtaek AU - Chapin, Brian F. AU - Nguyen, Quynh‐Nhu AU - Davis, John W. AU - Corn, Paul AU - Logothetis, Christopher AU - Ward, John AU - Frank, Steven J. AU - Navai, Neema AU - McGuire, Sean E. AU - Anscher, Mitchell AU - Pisters, Louis AU - Pettaway, Curtis A. AU - Kumar, Rachit AU - Linson, Patrick DB - CINAHL Complete DO - 10.1002/cncr.32570 DP - EBSCOhost IS - 3 KW - Prostatic Neoplasms -- Therapy Prostatic Neoplasms -- Epidemiology Male Middle Age Prostate-Specific Antigen -- Blood Black Persons Brachytherapy -- Trends Registries, Disease White Persons United States Aged Patient Selection Prostatectomy -- Trends Human Prostatic Neoplasms -- Blood Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: P30 CA016672/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM31742674. PY - 2020 SN - 0008-543X SP - 506-514 ST - Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends T2 - Cancer (0008543X) TI - Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141250936&site=ehost-live&scope=site VL - 126 ID - 1896 ER - TY - JOUR AB - Introduction: Information is limited on patient characteristics that influence their preference among screening options and intent to be screened for colorectal cancer (CRC). A mechanistic pathway to intent and preference was examined through a formal mediation analysis.Methods: From 2012 to 2014, a total of 570 adults aged 50-75 years were recruited from 15 primary care practices in Metro Detroit for a trial on decision aids for CRC screening. Confirmatory factor, regression, and mediation analyses were performed in 2015-2016 on baseline cross-sectional data. Main outcomes were patient intent and preference. Perceived risk and self-efficacy were secondary outcomes. Covariates included demographic information, health status, previous CRC screening experience, patient attitudes, and knowledge.Results: Mean age was 57.7 years, 56.1% were women, and 55.1% white and 36.6% black. Women had 32% and 41% lower odds than men of perceiving CRC to be high/moderate risk (OR=0.68, 95% CI=0.47, 0.97, p=0.03) and having high self-efficacy (OR=0.59, 95% CI=0.42, 0.85, p=0.006), respectively. Whites had 63% and 47% lower odds than blacks of having high self-efficacy (OR=0.37, 95% CI=0.25, 0.57, p<0.001) and intent to undergo CRC screening (OR=0.53, 95% CI=0.34, 0.84, p=0.007), respectively. Younger age, higher knowledge, lower level of test worries, and medium/high versus low self-efficacy increased the odds of intent of being screened. Self-efficacy, but not perceived risk, significantly mediated the association between race, attitude, and test worries and patient screening intent.Conclusions: Self-efficacy mediated the association between race, attitude, and test worries and patient intent. AD - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan Department of Biostatistics, University of Michigan, Ann Arbor, Michigan Department of Medicine, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, Michigan Center for Ethics and Humanities in the Life Sciences and Department of Medicine, Michigan State University, East Lansing, Michigan Department of Family and Community Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania AN - 121673067. Language: English. Entry Date: 20180129. Revision Date: 20200222. Publication Type: journal article AU - Jimbo, Masahito AU - Sen, Ananda AU - Plegue, Melissa A. AU - Hawley, Sarah T. AU - Kelly-Blake, Karen AU - Rapai, Mary AU - Zhang, Minling AU - Zhang, Yuhong AU - Ivruffin, Mack T. AU - Ruffin, Mack T. th DB - CINAHL Complete DO - 10.1016/j.amepre.2016.11.026 DP - EBSCOhost IS - 4 KW - Colorectal Neoplasms -- Diagnosis Intention Health Screening -- Psychosocial Factors Decision Support Techniques Patient Satisfaction Human Cross Sectional Studies Male Middle Age Female Colorectal Neoplasms -- Psychosocial Factors Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source N1 - research. Journal Subset: Biomedical; Health Promotion/Education; USA. Grant Information: R01 CA152413/CA/NCI NIH HHS/United States. NLM UID: 8704773. PMID: NLM28169019. PY - 2017 SN - 0749-3797 SP - 443-450 ST - Correlates of Patient Intent and Preference on Colorectal Cancer Screening T2 - American Journal of Preventive Medicine TI - Correlates of Patient Intent and Preference on Colorectal Cancer Screening UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121673067&site=ehost-live&scope=site VL - 52 ID - 1899 ER - TY - JOUR AB - Introduction Information is limited on patient characteristics that influence their preference among screening options and intent to be screened for colorectal cancer (CRC). A mechanistic pathway to intent and preference was examined through a formal mediation analysis. Methods From 2012 to 2014, a total of 570 adults aged 50–75 years were recruited from 15 primary care practices in Metro Detroit for a trial on decision aids for CRC screening. Confirmatory factor, regression, and mediation analyses were performed in 2015–2016 on baseline cross-sectional data. Main outcomes were patient intent and preference. Perceived risk and self-efficacy were secondary outcomes. Covariates included demographic information, health status, previous CRC screening experience, patient attitudes, and knowledge. Results Mean age was 57.7 years, 56.1% were women, and 55.1% white and 36.6% black. Women had 32% and 41% lower odds than men of perceiving CRC to be high/moderate risk (OR=0.68, 95% CI=0.47, 0.97, p=0.03) and having high self-efficacy (OR=0.59, 95% CI=0.42, 0.85, p=0.006), respectively. Whites had 63% and 47% lower odds than blacks of having high self-efficacy (OR=0.37, 95% CI=0.25, 0.57, p<0.001) and intent to undergo CRC screening (OR=0.53, 95% CI=0.34, 0.84, p=0.007), respectively. Younger age, higher knowledge, lower level of test worries, and medium/high versus low self-efficacy increased the odds of intent of being screened. Self-efficacy, but not perceived risk, significantly mediated the association between race, attitude, and test worries and patient screening intent. Conclusions Self-efficacy mediated the association between race, attitude, and test worries and patient intent. AD - A. Sen, University of Michigan, Department of Family Medicine, 1018 Fuller Street, Ann Arbor, MI, United States AU - Jimbo, M. AU - Sen, A. AU - Plegue, M. A. AU - Hawley, S. T. AU - Kelly-Blake, K. AU - Rapai, M. AU - Zhang, M. AU - Zhang, Y. AU - Ruffin, M. T. DB - Embase Medline DO - 10.1016/j.amepre.2016.11.026 IS - 4 KW - NCT01514786 adult aged article cancer screening colonoscopy colorectal cancer demography female health status human knowledge major clinical study male medical decision making occult blood test patient attitude patient preference primary medical care LA - English M3 - Article N1 - L614299849 2017-02-08 2017-03-28 PY - 2017 SN - 1873-2607 0749-3797 SP - 443-450 ST - Correlates of Patient Intent and Preference on Colorectal Cancer Screening T2 - American Journal of Preventive Medicine TI - Correlates of Patient Intent and Preference on Colorectal Cancer Screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614299849&from=export http://dx.doi.org/10.1016/j.amepre.2016.11.026 VL - 52 ID - 939 ER - TY - JOUR AB - Introduction Information is limited on patient characteristics that influence their preference among screening options and intent to be screened for colorectal cancer (CRC). A mechanistic pathway to intent and preference was examined through a formal mediation analysis. Methods From 2012 to 2014, a total of 570 adults aged 50–75 years were recruited from 15 primary care practices in Metro Detroit for a trial on decision aids for CRC screening. Confirmatory factor, regression, and mediation analyses were performed in 2015–2016 on baseline cross-sectional data. Main outcomes were patient intent and preference. Perceived risk and self-efficacy were secondary outcomes. Covariates included demographic information, health status, previous CRC screening experience, patient attitudes, and knowledge. Results Mean age was 57.7 years, 56.1% were women, and 55.1% white and 36.6% black. Women had 32% and 41% lower odds than men of perceiving CRC to be high/moderate risk (OR=0.68, 95% CI=0.47, 0.97, p=0.03) and having high self-efficacy (OR=0.59, 95% CI=0.42, 0.85, p=0.006), respectively. Whites had 63% and 47% lower odds than blacks of having high self-efficacy (OR=0.37, 95% CI=0.25, 0.57, p<0.001) and intent to undergo CRC screening (OR=0.53, 95% CI=0.34, 0.84, p=0.007), respectively. Younger age, higher knowledge, lower level of test worries, and medium/high versus low self-efficacy increased the odds of intent of being screened. Self-efficacy, but not perceived risk, significantly mediated the association between race, attitude, and test worries and patient screening intent. Conclusions Self-efficacy mediated the association between race, attitude, and test worries and patient intent. © 2017 AD - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan, United States Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States Department of Medicine, University of Michigan and Ann Arbor VA Center for Clinical Management Research, Ann Arbor, Michigan, United States Center for Ethics and Humanities in the Life Sciences and Department of Medicine, Michigan State University, East Lansing, Michigan, United States Department of Family and Community Medicine, Penn State Hershey Medical Center, Hershey, Pennsylvania, United States AU - Jimbo, M. AU - Sen, A. AU - Plegue, M. A. AU - Hawley, S. T. AU - Kelly-Blake, K. AU - Rapai, M. AU - Zhang, M. AU - Zhang, Y. AU - Ruffin, M. T. Iv DB - Scopus DO - 10.1016/j.amepre.2016.11.026 IS - 4 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2017 SP - 443-450 ST - Correlates of Patient Intent and Preference on Colorectal Cancer Screening T2 - American Journal of Preventive Medicine TI - Correlates of Patient Intent and Preference on Colorectal Cancer Screening UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85011308889&doi=10.1016%2fj.amepre.2016.11.026&partnerID=40&md5=006ee2a54fcd01130b65ee34138eb05c VL - 52 ID - 2312 ER - TY - JOUR AB - Introduction: Information is limited on patient characteristics that influence their preference among screening options and intent to be screened for colorectal cancer (CRC). A mechanistic pathway to intent and preference was examined through a formal mediation analysis. Methods: From 2012 to 2014, a total of 570 adults aged 50-75 years were recruited from 15 primary care practices in Metro Detroit for a trial on decision aids for CRC screening. Confirmatory factor, regression, and mediation analyses were performed in 2015-2016 on baseline cross-sectional data. Main outcomes were patient intent and preference. Perceived risk and self-efficacy were secondary outcomes. Covariates included demographic information, health status, previous CRC screening experience, patient attitudes, and knowledge. Results: Mean age was 57.7 years, 56.1% were women, and 55.1% white and 36.6% black. Women had 32% and 41% lower odds than men of perceiving CRC to be high/moderate risk (OR = 0.68, 95% CI = 0.47, 0.97, p = 0.03) and having high self-efficacy (OR = 0.59, 95% CI = 0.42, 0.85, p = 0.006), respectively. Whites had 63% and 47% lower odds than blacks of having high self-efficacy (OR = 0.37, 95% CI = 0.25, 0.57, p < 0.001) and intent to undergo CRC screening (OR = 0.53, 95% CI = 0.34, 0.84, p = 0.007), respectively. Younger age, higher knowledge, lower level of test worries, and medium/high versus low self-efficacy increased the odds of intent of being screened. Self-efficacy, but not perceived risk, significantly mediated the association between race, attitude, and test worries and patient screening intent. Conclusions: Self-efficacy mediated the association between race, attitude, and test worries and patient intent. (C) 2016 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine AN - WOS:000401077200007 AU - Jimbo, M. AU - Sen, A. AU - Plegue, M. A. AU - Hawley, S. T. AU - Kelly-Blake, K. AU - Rapai, M. AU - Zhang, M. L. AU - Zhang, Y. H. AU - Ruffin, M. T. DA - Apr DO - 10.1016/j.amepre.2016.11.026 IS - 4 N1 - 28169019 PY - 2017 SN - 0749-3797 SP - 443-450 ST - Correlates of Patient Intent and Preference on Colorectal Cancer Screening T2 - American Journal of Preventive Medicine TI - Correlates of Patient Intent and Preference on Colorectal Cancer Screening VL - 52 ID - 2900 ER - TY - JOUR AB - Background: African Americans continue to suffer disproportionately from cancer morbidity and mortality, with emerging evidence suggesting potential quality of life (QOL) disparities in the survivorship period. Objective: The objective of the study was to assess sociodemographic, clinical, and psychosocial factors associated with physical and mental health QOL (PHQOL and MHQOL) among African American and white cancer survivors. Methods: Patients were recruited from tumor registries. Telephone interviews were conducted with 248 African American and 244 white respondents with a history of breast, prostate, or colorectal cancers. Multivariate regression models were used to assess what factors were associated with PHQOL and MHQOL. Results: Key racial differences in adjusted analyses included poorer MHQOL scores among African Americans compared with white survivors. Furthermore, race moderated the relationship between perceived social support and MHQOL, where higher social support levels were associated with increased MHQOL among African Americans. Other correlates of QOL impacted racial groups similarly. For example, factors associated with PHQOL scores included being unemployed, being uninsured, the presence of medical comorbidities, a longer time since diagnosis, and higher levels of cancer-related stress appraisals. Factors associated with MHQOL scores included being unemployed, higher levels of daily stress, higher levels of stress associated with the diagnosis, higher levels of education, higher levels of perceived social support, and higher levels of spirituality. Conclusion: Interventions aimed at increasing social support may have important implications for improving QOL outcomes among African Americans. Implications for Practice: Measuring and understanding factors associated with QOL have important implications for patient adjustment and clinical decision making. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Matthews, Alicia K., College of Nursing, University of Illinois at Chicago, Chicago, IL, US, 60612 AN - 2013-15301-004 AU - Matthews, Alicia K. AU - Tejeda, Silvia AU - Johnson, Timothy P. AU - Berbaum, Michael L. AU - Manfredi, Clara DB - psyh DO - 10.1097/NCC.0b013e31824131d9 DP - EBSCOhost IS - 5 KW - quality of life cancer survivors sociodemographic variables physical health mental health psychosocial factors African Americans Whites Adult Aged Cross-Sectional Studies European Continental Ancestry Group Female Humans Male Middle Aged Neoplasms Nursing Methodology Research Qualitative Research Registries Social Support Socioeconomic Factors Survivors Blacks Coping Behavior Racial and Ethnic Differences N1 - College of Nursing, University of Illinois at Chicago, Chicago, IL, US. Release Date: 20131021. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Mental Health; Neoplasms; Physical Health; Psychosocial Factors; Quality of Life. Minor Descriptor: Blacks; Coping Behavior; Racial and Ethnic Differences; Whites. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Support Network for Coping Scale; Functional Assessment of Chronic Illness Therapy-Spiritual Factors Scale; SF-36 Health Survey; Social Support Scale; MOS 36-item Short-Form Health Survey DOI: 10.1037/t06708-000. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Sep-Oct, 2012. Publication History: Accepted Date: Nov 19, 2011. Copyright Statement: Wolters Kluwer Health | Lippincott Williams & Wilkins. 2012. Sponsor: National Cancer Institute, US. Grant: R01CA775-01A1; R25CA057699. Recipients: No recipient indicated PY - 2012 SN - 0162-220X 1538-9804 SP - 355-364 ST - Correlates of quality of life among African American and White cancer survivors T2 - Cancer Nursing TI - Correlates of quality of life among African American and White cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-15301-004&site=ehost-live&scope=site aliciak@uic.edu VL - 35 ID - 1725 ER - TY - JOUR AB - BACKGROUND: : African Americans continue to suffer disproportionately from cancer morbidity and mortality, with emerging evidence suggesting potential quality of life (QOL) disparities in the survivorship period. OBJECTIVE: : The objective of the study was to assess sociodemographic, clinical, and psychosocial factors associated with physical and mental health QOL (PHQOL and MHQOL) among African American and white cancer survivors. METHODS: : Patients were recruited from tumor registries. Telephone interviews were conducted with 248 African American and 244 white respondents with a history of breast, prostate, or colorectal cancers. Multivariate regression models were used to assess what factors were associated with PHQOL and MHQOL. RESULTS: : Key racial differences in adjusted analyses included poorer MHQOL scores among African Americans compared with white survivors. Furthermore, race moderated the relationship between perceived social support and MHQOL, where higher social support levels were associated with increased MHQOL among African Americans. Other correlates of QOL impacted racial groups similarly. For example, factors associated with PHQOL scores included being unemployed, being uninsured, the presence of medical comorbidities, a longer time since diagnosis, and higher levels of cancer-related stress appraisals. Factors associated with MHQOL scores included being unemployed, higher levels of daily stress, higher levels of stress associated with the diagnosis, higher levels of education, higher levels of perceived social support, and higher levels of spirituality. CONCLUSION: : Interventions aimed at increasing social support may have important implications for improving QOL outcomes among African Americans. IMPLICATIONS FOR PRACTICE: : Measuring and understanding factors associated with QOL have important implications for patient adjustment and clinical decision making. AD - Author Affiliations: College of Nursing (Dr Matthews), Institute for Health Research and Policy (Drs Tejeda, Johnson, Berbaum, and Manfredi), and Survey Research Laboratory (Dr Johnson), University of Illinois at Chicago. AN - 108097434. Language: English. Entry Date: 20121019. Revision Date: 20150820. Publication Type: Journal Article AU - Matthews, Alicia K. AU - Tejeda, Silvia AU - Johnson, Timothy P. AU - Berbaum, Michael L. AU - Manfredi, Clara DB - CINAHL Complete DP - EBSCOhost IS - 5 KW - Black Persons Cancer Survivors Health Status Mental Health Quality of Life Race Factors White Persons Adult Aged Breast Neoplasms Chi Square Test Colorectal Neoplasms Comorbidity Comparative Studies Descriptive Research Descriptive Statistics Educational Status Employment Status Funding Source Human Illinois Income Interviews Medically Uninsured Middle Age Multiple Regression Prostatic Neoplasms Quality of Life -- Evaluation Registries, Disease Research Subject Recruitment Rural Areas Scales Short Form-36 Health Survey (SF-36) Spirituality -- Evaluation Support, Psychosocial T-Tests Telephone Urban Areas N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care. Instrumentation: Short Form-36 Health Survey (SF-36); Multidimensional Scale of Perceived Social Support (MSPSS); Functional Assessment of Chronic Illness Therapy-Spiritual Factors Scale. Grant Information: National Cancer Institute R01 CA775-01A1 and R25CA57699.. NLM UID: 7805358. PMID: NLM22495496. PY - 2012 SN - 0162-220X SP - 355-364 ST - Correlates of quality of life among african american and white cancer survivors T2 - Cancer Nursing TI - Correlates of quality of life among african american and white cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108097434&site=ehost-live&scope=site VL - 35 ID - 1900 ER - TY - JOUR AB - Objective The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. Methods Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short-form 36 (SF-36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. Results In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African-American, and Asian women had higher positive IOC impact scores compared with White non-Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. Conclusions Quality-of-life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. AD - B. Pakiz, UC San Diego Moores Cancer Center, 3855 Health Sciences Dr., Office 3076, San Diego, CA, United States AU - Pakiz, B. AU - Ganz, P. A. AU - Sedjo, R. L. AU - Flatt, S. W. AU - Demark-Wahnefried, W. AU - Liu, J. AU - Wolin, K. Y. AU - Rock, C. L. DB - Embase Medline DO - 10.1002/pon.3820 IS - 2 KW - antiestrogen antineoplastic agent aromatase inhibitor adult African American age distribution aged altruism article Asian awareness body mass breast cancer cancer chemotherapy cancer hormone therapy cancer survival Caucasian comorbidity controlled clinical trial controlled study ethnic difference female Hispanic human major clinical study mental function multicenter study obesity physical activity quality of life randomized controlled trial rating scale Short Form 36 social status body weight loss LA - English M3 - Article N1 - L604120242 2015-05-07 2016-02-18 PY - 2016 SN - 1099-1611 1057-9249 SP - 142-149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-Oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604120242&from=export http://dx.doi.org/10.1002/pon.3820 VL - 25 ID - 982 ER - TY - JOUR AB - Objective The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. Methods Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short‐form 36 (SF‐36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. Results In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African‐American, and Asian women had higher positive IOC impact scores compared with White non‐Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. Conclusions Quality‐of‐life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. AN - CN-01132707 AU - Pakiz, B. AU - Ganz, P. A. AU - Sedjo, R. L. AU - Flatt, S. W. AU - Demark-Wahnefried, W. AU - Liu, J. AU - Wolin, K. Y. AU - Rock, C. L. DO - 10.1002/pon.3820 IS - 2 KW - *body weight loss *breast cancer /drug therapy /drug therapy /therapy *cancer survival *obesity /disease management /therapy *quality of life Adult African American Age distribution Aged Altruism Article Asian Awareness Body mass Cancer chemotherapy Cancer hormone therapy Caucasian Comorbidity Controlled clinical trial Controlled study Ethnic difference Female Hispanic Human Major clinical study Mental function Multicenter study Physical activity Randomized controlled trial Rating scale Short Form 36 Social status M3 - Journal: Article PY - 2016 SP - 142‐149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01132707/full VL - 25 ID - 1571 ER - TY - JOUR AB - Objective The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. Methods Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short-form 36 (SF-36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. Results In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African-American, and Asian women had higher positive IOC impact scores compared with White non-Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. Conclusions Quality-of-life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. © 2015 John Wiley & Sons, Ltd. AD - Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, CA, United States Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, United States UCLA Fielding School of Public Health, University of California, Los Angeles, CA, United States Department of Community and Behavioral Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, United States Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States Coeus Health LLC, Chicago, IL, United States Scale Down LLC, Atlanta, GA, United States Department of Preventive Medicine, Northwestern University, Chicago, IL, United States UC San Diego Moores Cancer Center, 3855 Health Sciences Dr., Office 3076, San Diego, CA 92093-0901, United States AU - Pakiz, B. AU - Ganz, P. A. AU - Sedjo, R. L. AU - Flatt, S. W. AU - Demark-Wahnefried, W. AU - Liu, J. AU - Wolin, K. Y. AU - Rock, C. L. DB - Scopus DO - 10.1002/pon.3820 IS - 2 M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2016 SP - 142-149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-Oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957435490&doi=10.1002%2fpon.3820&partnerID=40&md5=c04f9613f61b083acd10bf42c903751b VL - 25 ID - 2350 ER - TY - JOUR AB - ObjectiveThe purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. MethodsCorrelates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short-form 36 (SF-36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. ResultsIn multivariate analysis, younger age was associated with higher negative impact scores (p<0.0001). Hispanic, African-American, and Asian women had higher positive IOC impact scores compared with White non-Hispanic women (p<0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p<0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. ConclusionsQuality-of-life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. Copyright (c) 2015 John Wiley & Sons, Ltd. AN - WOS:000369981400003 AU - Pakiz, B. AU - Ganz, P. A. AU - Sedjo, R. L. AU - Flatt, S. W. AU - Demark-Wahnefried, W. AU - Liu, J. X. AU - Wolin, K. Y. AU - Rock, C. L. DA - Feb DO - 10.1002/pon.3820 IS - 2 N1 - 25920528 PY - 2016 SN - 1057-9249 SP - 142-149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-Oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial VL - 25 ID - 2953 ER - TY - JOUR AB - Objective: The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial. Methods: Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short‐form 36 (SF‐36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics. Results: In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African‐American, and Asian women had higher positive IOC impact scores compared with White non‐Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales. Conclusions: Quality‐of‐life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Pakiz, Bilgé, UC San Diego Moores Cancer Center, 3855 Health Sciences Dr., Office 3076, La Jolla, CA, US, 92093-0901 AN - 2015-19360-001 AU - Pakiz, Bilgé AU - Ganz, Patricia A. AU - Sedjo, Rebecca L. AU - Flatt, Shirley W. AU - Demark‐Wahnefried, Wendy AU - Liu, Jingxia AU - Wolin, Kathleen Y. AU - Rock, Cheryl L. DB - psyh DO - 10.1002/pon.3820 DP - EBSCOhost IS - 2 KW - obese breast cancer weight loss quality of life intervention Breast Neoplasms Obesity Psychosocial Factors Survivors N1 - Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla, CA, US. Release Date: 20150504. Correction Date: 20170116. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Obesity; Psychosocial Factors; Quality of Life; Survivors. Minor Descriptor: Intervention; Weight Loss. Classification: Psychological & Physical Disorders (3200). Population: Human (10); Male (30); Female (40). Location: England; US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320). Tests & Measures: Impact of Cancer Scale; Short Form-36; Breast Cancer Prevention Trial Symptom Scale; Godin Leisure Time Exercise Questionnaire--Modified DOI: 10.1037/t54160-000; Center for Epidemiologic Studies Depression Scale. Methodology: Empirical Study; Quantitative Study; Treatment Outcome. Page Count: 8. Issue Publication Date: Feb, 2016. Publication History: First Posted Date: Apr 29, 2015; Accepted Date: Mar 18, 2015; Revised Date: Feb 18, 2015; First Submitted Date: Jul 31, 2014. Copyright Statement: John Wiley & Sons, Ltd. 2015. Sponsor: National Cancer Institute, US. Grant: CA148791. Recipients: No recipient indicated PY - 2016 SN - 1057-9249 1099-1611 SP - 142-149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-Oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-19360-001&site=ehost-live&scope=site bpakiz@ucsd.edu VL - 25 ID - 1695 ER - TY - JOUR AB - Objective: The purpose of this analysis was to examine the correlates of the physical and psychosocial domains of quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss intervention trial.Methods: Correlates of QOL and psychosocial functioning were examined in 692 overweight or obese breast cancer survivors at entry into a weight loss trial. QOL was explored with three measures: Short-form 36 (SF-36), Impact of Cancer scale (IOC), and the Breast Cancer Prevention Trial (BCPT) symptom scales. Available data included information on weight and physical activity, as well as demographic and medical characteristics. Multivariate analyses were used to identify associations adjusted for other characteristics.Results: In multivariate analysis, younger age was associated with higher negative impact scores (p < 0.0001). Hispanic, African-American, and Asian women had higher positive IOC impact scores compared with White non-Hispanic women (p < 0.01). Increased number of comorbidities was associated with lower physical and mental QOL scores (p < 0.01). Body mass index was not independently associated with QOL measures. Physical activity was directly associated with physical and mental QOL and IOC positive impact, and inversely related to IOC negative impact and Breast Cancer Prevention Trial symptom scales.Conclusions: Quality-of-life measures in breast cancer survivors are differentially associated with demographic and other characteristics. When adjusted for these characteristics, degree of adiposity among overweight or obese women does not appear to be independently associated with QOL. Among overweight or obese breast cancer survivors, higher level of physical activity is associated with higher QOL across various scales and dimensions. AD - Department of Family Medicine and Public Health, School of Medicine, University of California, San Diego, La Jolla CA, USA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles CA, USA UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles CA, USA Department of Community and Behavioral Health, University of Colorado Anschutz Medical Campus, Aurora CO, USA Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham AL, USA Division of Biostatistics, Washington University School of Medicine, St. Louis MO, USA Coeus Health LLC, Chicago IL, USA Scale Down LLC, Atlanta GA, USA Department of Preventive Medicine, Northwestern University, Chicago IL, USA AN - 112735061. Language: English. Entry Date: 20161223. Revision Date: 20180620. Publication Type: journal article AU - Pakiz, Bilgé AU - Ganz, Patricia A. AU - Sedjo, Rebecca L. AU - Flatt, Shirley W. AU - Demark‐Wahnefried, Wendy AU - Liu, Jingxia AU - Wolin, Kathleen Y. AU - Rock, Cheryl L. DB - CINAHL Complete DO - 10.1002/pon.3820 DP - EBSCOhost IS - 2 KW - Obesity -- Therapy Breast Neoplasms -- Psychosocial Factors Weight Loss Obesity -- Psychosocial Factors Quality of Life -- Psychosocial Factors Survivors -- Psychosocial Factors Aged Middle Age Female Adult Body Weight Human Body Mass Index Obesity -- Complications Ethnic Groups Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Short Form-36 Health Survey (SF-36) Funding Source Scales N1 - clinical trial; research. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Evidence-Based Practice. Instrumentation: Short Form-36 Health Survey (SF-36); Impact of Cancer (IOC) Scale; Breast Cancer Prevention Trial (BCPT) Symptom Scale. Grant Information: CA148791/CA/NCI NIH HHS/United States. NLM UID: 9214524. PMID: NLM25920528. PY - 2016 SN - 1057-9249 SP - 142-149 ST - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial T2 - Psycho-Oncology TI - Correlates of quality of life in overweight or obese breast cancer survivors at enrollment into a weight loss trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112735061&site=ehost-live&scope=site VL - 25 ID - 1901 ER - TY - JOUR AB - Background: Patient navigation (PN) is being used increasingly to help patients complete screening colonoscopy (SC) to prevent colorectal cancer. At their large, urban academic medical center with an open-access endoscopy system, the authors previously demonstrated that PN programs produced a colonoscopy completion rate of 78.5% in a cohort of 503 patients (predominantly African Americans and Latinos with public health insurance). Very little is known about the direct costs of implementing PN programs. The objective of the current study was to perform a detailed cost analysis of PN programs at the authors' institution from an institutional perspective. Methods: In 2 randomized controlled trials, average-risk patients who were referred for SC by primary care providers were recruited for PN between May 2008 and May 2010. Patients were randomized to 1 of 4 PN groups. The cost of PN and net income to the institution were determined in a cost analysis. Results: Among 395 patients who completed colonoscopy, 53.4% underwent SC alone, 30.1% underwent colonoscopy with biopsy, and 16.5% underwent snare polypectomy. Accounting for the average contribution margins of each procedure type, the total revenue was 95,266.00. The total cost of PN was 14,027.30. Net income was 81,238.70. In a model sample of 1000 patients, net incomes for the institutional completion rate (approximately 80%), the historic PN program (approximately 65%), and the national average (approximately 50%) were compared. The current PN program generated additional net incomes of 35,035.50 and 44,956.00, respectively. Conclusions: PN among minority patients with mostly public health insurance generated additional income to the institution, mainly because of increased colonoscopy completion rates. Cancer 2013. © 2012 American Cancer Society. AD - L. Jandorf, Icahn Medical Institute, 1425 Madison Avenue, New York, NY 10029, United States AU - Jandorf, L. AU - Stossel, L. M. AU - Cooperman, J. L. AU - Graff Zivin, J. AU - Ladabaum, U. AU - Hall, D. AU - Thélémaque, L. D. AU - Redd, W. AU - Itzkowitz, S. H. DB - Embase Medline DO - 10.1002/cncr.27759 IS - 3 KW - adult aged article cancer screening colon biopsy colonoscopy colorectal cancer controlled study cost benefit analysis female health care cost health insurance human income major clinical study male patient attitude patient care polypectomy priority journal randomized controlled trial urban area LA - English M3 - Article N1 - L52133841 2012-07-30 2013-02-07 PY - 2013 SN - 0008-543X 1097-0142 SP - 612-620 ST - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities T2 - Cancer TI - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52133841&from=export http://dx.doi.org/10.1002/cncr.27759 VL - 119 ID - 1094 ER - TY - JOUR AB - Background: Patient navigation (PN) is being used increasingly to help patients complete screening colonoscopy (SC) to prevent colorectal cancer. At their large, urban academic medical center with an open-access endoscopy system, the authors previously demonstrated that PN programs produced a colonoscopy completion rate of 78.5% in a cohort of 503 patients (predominantly African Americans and Latinos with public health insurance). Very little is known about the direct costs of implementing PN programs. The objective of the current study was to perform a detailed cost analysis of PN programs at the authors' institution from an institutional perspective. Methods: In 2 randomized controlled trials, average-risk patients who were referred for SC by primary care providers were recruited for PN between May 2008 and May 2010. Patients were randomized to 1 of 4 PN groups. The cost of PN and net income to the institution were determined in a cost analysis. Results: Among 395 patients who completed colonoscopy, 53.4% underwent SC alone, 30.1% underwent colonoscopy with biopsy, and 16.5% underwent snare polypectomy. Accounting for the average contribution margins of each procedure type, the total revenue was 95,266.00. The total cost of PN was 14,027.30. Net income was 81,238.70. In a model sample of 1000 patients, net incomes for the institutional completion rate (approximately 80%), the historic PN program (approximately 65%), and the national average (approximately 50%) were compared. The current PN program generated additional net incomes of 35,035.50 and 44,956.00, respectively. Conclusions: PN among minority patients with mostly public health insurance generated additional income to the institution, mainly because of increased colonoscopy completion rates. Cancer 2013. © 2012 American Cancer Society. AD - Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, United States Department of Economics, University of California-San Diego, San Diego, CA, United States Department of Medicine, Stanford University, Palo Alto, CA, United States Department of Medicine, Mount Sinai School of Medicine, New York, NY, United States AU - Jandorf, L. AU - Stossel, L. M. AU - Cooperman, J. L. AU - Graff Zivin, J. AU - Ladabaum, U. AU - Hall, D. AU - Thélémaque, L. D. AU - Redd, W. AU - Itzkowitz, S. H. DB - Scopus DO - 10.1002/cncr.27759 IS - 3 KW - colorectal cancer screening cost analysis patient navigation racial disparities screening colonoscopy M3 - Article N1 - Cited By :41 Export Date: 22 March 2021 PY - 2013 SP - 612-620 ST - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities T2 - Cancer TI - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872928577&doi=10.1002%2fcncr.27759&partnerID=40&md5=838af4b33b0400398f373b0a94032b7d VL - 119 ID - 2446 ER - TY - JOUR AB - Background: Patient navigation (PN) is being used increasingly to help patients complete screening colonoscopy (SC) to prevent colorectal cancer. At their large, urban academic medical center with an open-access endoscopy system, the authors previously demonstrated that PN programs produced a colonoscopy completion rate of 78.5% in a cohort of 503 patients (predominantly African Americans and Latinos with public health insurance). Very little is known about the direct costs of implementing PN programs. The objective of the current study was to perform a detailed cost analysis of PN programs at the authors' institution from an institutional perspective.Methods: In 2 randomized controlled trials, average-risk patients who were referred for SC by primary care providers were recruited for PN between May 2008 and May 2010. Patients were randomized to 1 of 4 PN groups. The cost of PN and net income to the institution were determined in a cost analysis.Results: Among 395 patients who completed colonoscopy, 53.4% underwent SC alone, 30.1% underwent colonoscopy with biopsy, and 16.5% underwent snare polypectomy. Accounting for the average contribution margins of each procedure type, the total revenue was $95,266.00. The total cost of PN was $14,027.30. Net income was $81,238.70. In a model sample of 1000 patients, net incomes for the institutional completion rate (approximately 80%), the historic PN program (approximately 65%), and the national average (approximately 50%) were compared. The current PN program generated additional net incomes of $35,035.50 and $44,956.00, respectively.Conclusions: PN among minority patients with mostly public health insurance generated additional income to the institution, mainly because of increased colonoscopy completion rates. AD - Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York. lina.jandorf@mssm.edu. AN - 104300879. Language: English. Entry Date: 20130405. Revision Date: 20200708. Publication Type: journal article AU - Jandorf, L. AU - Stossel, L. M. AU - Cooperman, J. L. AU - Graff Zivin, J. AU - Ladabaum, U. AU - Hall, D. AU - Thélémaque, L. D. AU - Redd, W. AU - Itzkowitz, S. H. AU - Jandorf, Lina AU - Stossel, Lauren M. AU - Cooperman, Julia L. AU - Graff Zivin, Joshua AU - Ladabaum, Uri AU - Hall, Diana AU - Thélémaque, Linda D. AU - Redd, William AU - Itzkowitz, Steven H. DB - CINAHL Complete DO - 10.1002/cncr.27759 DP - EBSCOhost IS - 3 KW - Colonoscopy -- Utilization Health Screening -- Utilization Minority Groups -- Statistics and Numerical Data Patient Compliance Urban Population -- Economics Aged Aged, 80 and Over Black Persons -- Statistics and Numerical Data Carcinoma -- Diagnosis Carcinoma -- Economics Carcinoma -- Epidemiology Carcinoma -- Prevention and Control Colonoscopy -- Economics Colonoscopy -- Psychosocial Factors Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Economics Colorectal Neoplasms -- Epidemiology Colorectal Neoplasms -- Prevention and Control Costs and Cost Analysis Female Health Screening -- Economics Health Screening -- Psychosocial Factors Hispanic Americans -- Statistics and Numerical Data Human Male Middle Age Minority Groups -- Psychosocial Factors Occult Blood Randomized Controlled Trials N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: K05 CA108955/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM22833205. PY - 2013 SN - 0008-543X SP - 612-620 ST - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities T2 - Cancer (0008543X) TI - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104300879&site=ehost-live&scope=site VL - 119 ID - 1902 ER - TY - JOUR AB - BACKGROUND: Patient navigation (PN) is being used increasingly to help patients complete screening colonoscopy (SC) to prevent colorectal cancer. At their large, urban academic medical center with an open-access endoscopy system, the authors previously demonstrated that PN programs produced a colonoscopy completion rate of 78.5% in a cohort of 503 patients (predominantly African Americans and Latinos with public health insurance). Very little is known about the direct costs of implementing PN programs. The objective of the current study was to perform a detailed cost analysis of PN programs at the authors' institution from an institutional perspective. METHODS: In 2 randomized controlled trials, average-risk patients who were referred for SC by primary care providers were recruited for PN between May 2008 and May 2010. Patients were randomized to 1 of 4 PN groups. The cost of PN and net income to the institution were determined in a cost analysis. RESULTS: Among 395 patients who completed colonoscopy, 53.4% underwent SC alone, 30.1% underwent colonoscopy with biopsy, and 16.5% underwent snare polypectomy. Accounting for the average contribution margins of each procedure type, the total revenue was $95,266.00. The total cost of PN was $14,027.30. Net income was $81,238.70. In a model sample of 1000 patients, net incomes for the institutional completion rate (approximately 80%), the historic PN program (approximately 65%), and the national average (approximately 50%) were compared. The current PN program generated additional net incomes of $35,035.50 and $44,956.00, respectively. CONCLUSIONS: PN among minority patients with mostly public health insurance generated additional income to the institution, mainly because of increased colonoscopy completion rates. Cancer 2013. (C) 2012 American Cancer Society. AN - WOS:000313878500022 AU - Jandorf, L. AU - Stossel, L. M. AU - Cooperman, J. L. AU - Zivin, J. G. AU - Ladabaum, U. AU - Hall, D. AU - Thelemaque, L. D. AU - Redd, W. AU - Itzkowitz, S. H. DA - Feb DO - 10.1002/cncr.27759 IS - 3 N1 - 22833205 PY - 2013 SN - 0008-543X SP - 612-620 ST - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities T2 - Cancer TI - Cost analysis of a patient navigation system to increase screening colonoscopy adherence among urban minorities VL - 119 ID - 3052 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To learn from female survivors of Hodgkin disease about their perceptions of their current health status and future health risks, self-care practices to prevent or diminish health risks, and what kind of breast health program could benefit them, including the most effective methods and optimal times for learning about breast health. DESIGN: Participatory research using focus groups. SETTING: Urban pediatric cancer center. SAMPLE: 1 African American and 19 Caucasian female survivors of Hodgkin disease aged 16-26 years, diagnosed at least two years before the start of the study, and treated with mantle radiation therapy. Participants were recruited during visits to an outpatient clinic. METHODS: Six open-ended questions were asked during three separate focus group sessions. Transcribed data were evaluated by content analysis techniques and analyzed to identify common themes. MAIN RESEARCH VARIABLES: Current health status and perceived health risks, current health practices, and effective methods and timing for breast health teaching. FINDINGS: Survivors reported feeling damaged by their cancer and its treatment and perceived that they were at risk for breast cancer. Self-care and risky behaviors also were reported. Internal influences (e.g., fear) and external influences (e.g., family) motivated survivors to participate in health promotion activities. Effective methods identified for learning about breast health included having access to other survivors, being respected as an adult, and having one-on-one staff teaching and peer support. The preferred timing of teaching varied, but survivors generally supported a gradual provision of information. CONCLUSIONS: A positive listening environment is important for developing a breast health program for survivors. An essential first step is to create an opportunity for survivors to tell about their experiences with cancer, including its impact on their lives. Information regarding breast health must be provided in multiple formats during and after treatment if good practices are to be undertaken. IMPLICATIONS FOR NURSING: The provision of adequate information during and after therapy as well as peer counseling in a positive listening environment are important in helping survivors participate in health promotion activities. AD - D.B. Crom, Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. AU - Crom, D. B. AU - Hinds, P. S. AU - Gattuso, J. S. AU - Tyc, V. AU - Hudson, M. M. DB - Medline IS - 6 KW - adolescent adult article attitude to health breast tumor female Hodgkin disease human information processing methodology patient education patient participation program development radiation injury radiotherapy research risk factor second cancer survivor theoretical model LA - English M3 - Article N1 - L41880608 2006-05-29 PY - 2005 SN - 1538-0688 SP - 1131-1141 ST - Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach T2 - Oncology nursing forum TI - Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41880608&from=export VL - 32 ID - 1261 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To develop and test the Cues to Participation in Prostate Cancer Screening Theory, which proposes that exposure to information from certain sources cues or triggers screening. DESIGN: Descriptive correlational. SETTING: 11 counties of a southeastern state. SAMPLE: Convenience sample of 1,867 men at risk for prostate cancer (72% African American; 28% Caucasian). METHODS: Recent exposure to prostate cancer information was measured. Men were offered free screening by prostate specific antigen (PSA) and digital rectal exam (DRE). MAIN RESEARCH VARIABLES: Demographic variables (race, age, education, income, and marital status), exposure (electronic media, print media, healthcare provider recommendation, and interpersonal interactions), and screening as measured by PSA and DRE. FINDINGS: Several major propositions of the Cues to Participation Theory were supported. General exposure to prostate cancer information significantly predicted screening participation. Hearing about prostate cancer from a healthcare provider was the best predictor of screening. CONCLUSIONS: Men's demographic characteristics should be considered when providing information about prostate cancer. Hearing about prostate cancer from family and friends was not significantly related to screening behavior. lMPLICATIONS FOR NURSING PRACTICE: The importance of recommendations for prostate cancer screening is underscored. AD - A.S. Nivens, Department of Nursing at Armstrong Atlantic State University in Savannah, GA, USA. AU - Nivens, A. S. AU - Herman, J. AU - Pweinrich, S. AU - Weinrich, M. C. DB - Medline IS - 9 KW - adult African American aged article attitude to health ethnology health behavior human male mass screening middle aged nursing oncology nursing patient participation prostate tumor psychological aspect United States LA - English M3 - Article N1 - L33539824 2001-10-30 PY - 2001 SN - 0190-535X SP - 1449-1456 ST - Cues to participation in prostate cancer screening: a theory for practice T2 - Oncology nursing forum TI - Cues to participation in prostate cancer screening: a theory for practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33539824&from=export VL - 28 ID - 1306 ER - TY - JOUR AB - Objectives The primary objective of this 2-year pilot study was to evaluate the effectiveness of a culturally adapted family intervention in improving family communication among African American parents coping with cancer and their school-age children. A secondary objective was to determine its impact on other symptoms of psychosocial distress (depression and anxiety). The third objective was to assess for acceptability and feasibility. Methods Using a two-arm pre-intervention and post-intervention prospective design, 12 African American families received five bi-monthly sessions of either a culturally adapted family intervention (n = 7 families) or psycho-education treatment (n = 5 families). Parents and their children completed pre-intervention and post-intervention questionnaires assessing perceptions of family communication, quality of their relationship, and symptoms of depression. School-age children additionally completed a questionnaire assessing their levels of anxiety. Consumer satisfaction was also evaluated at post-intervention. Results Parents and school-age children who completed the culturally adapted family intervention reported significantly better communication with each other and were more satisfied compared with the psycho-education control group. No changes were noted in symptoms of anxiety or depression. The culturally adapted family intervention was acceptable based on our findings, families' feedback, and rates of retention. Feasibility is uncertain because our oncology clinic approach to recruitment was slower than expected. Conclusions Providing culturally adapted family intervention programs to African American families who are coping with parental cancer may result in improved family communication. This pilot study serves as the first step in the development of culturally adapted family intervention programs to help African American families cope with parental cancer. Copyright © 2012 John Wiley & Sons, Ltd. Copyright © 2012 John Wiley & Sons, Ltd. AD - Department of Couple and Family Therapy, Drexel University, Mail Stop 905, 1505 Race Street, Philadelphia, PA 19102, United States Multisystemic Therapy Services, Wilmington, DE, United States School of Nursing, John Hopkins University, Baltimore, MD, United States AU - Davey, M. P. AU - Kissil, K. AU - Lynch, L. AU - Harmon, L. R. AU - Hodgson, N. DB - Scopus DO - 10.1002/pon.3172 IS - 7 KW - African American cancer oncology parental cancer psychosocial support M3 - Article N1 - Cited By :24 Export Date: 22 March 2021 PY - 2013 SP - 1572-1580 ST - A culturally adapted family intervention for African American families coping with parental cancer: Outcomes of a pilot study T2 - Psycho-Oncology TI - A culturally adapted family intervention for African American families coping with parental cancer: Outcomes of a pilot study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879989156&doi=10.1002%2fpon.3172&partnerID=40&md5=1b37955615834ee0a5054809a4848e3d VL - 22 ID - 2429 ER - TY - GEN AB - The article discusses how inadequate screening guidelines for under-served populations has led to racial disparities in lung cancer outcomes. A team of researchers compared patients in a Chicago-based lung cancer screening program with those enrolled in the National Lung Screening Trial (NLST), a large-scale study of current and former smokers sponsored by the NCI. The Chicago screening program reportedly resulted in double the frequency of positive scans. AU - Printz, Carrie CY - Hoboken, New Jersey DB - CINAHL Complete DO - 10.1002/cncr.31898 DP - EBSCOhost J2 - Cancer (0008543X) KW - Lung Neoplasms -- Ethnology Early Detection of Cancer -- Methods Lung Neoplasms -- Diagnosis Human Female Black Persons -- Statistics and Numerical Data Male Illinois -- Ethnology Clinical Trials Early Detection of Cancer -- Statistics and Numerical Data Health Screening Middle Age Hispanic Americans -- Statistics and Numerical Data White Persons -- Statistics and Numerical Data Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - Accession Number: 133686983. Language: English. Entry Date: 20191010. Revision Date: 20201128. Publication Type: research; pictorial. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0374236. PMID: NLM30577092. PB - John Wiley & Sons, Inc. PY - 2019 SN - 0008-543X SP - 10-11 ST - Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities TI - Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133686983&site=ehost-live&scope=site VL - 125 ID - 1903 ER - TY - JOUR AB - There is little documentation about the recruitment process for church-based health education programs. In this study, the authors recruit African American, Latino, and white churches and women members (age 50 to 80) for a randomized church-based trial of mammography promotion in Los Angeles County. Efforts to enhance recruitment began 10 months before churches were invited to participate and included a variety of community-based strategies. Subsequently, 45 churches were recruited over a 5-month period through group pastor breakfast meetings and church-specific follow-up. In close collaboration with the 45 churches, the authors administered church-based surveys over 6 months and identified 1,967 age-eligible women who agreed to be contacted by the program team. It was found that an extended resource intensive period of relationship-building and community-based activities were necessary to conduct church-based programs effectively, particularly among older and ethnically diverse urban populations. AD - K.P. Derose, RAND, Santa Monica, California 90407-2138, USA. AU - Derose, K. P. AU - Hawes-Dawson, J. AU - Fox, S. A. AU - Maldonado, N. AU - Tatum, A. AU - Kington, R. DB - Medline IS - 5 KW - aged article breast tumor clinical trial controlled clinical trial controlled study ethnic group female health care planning health education health promotion health services research human mammography middle aged motivation organization and management patient selection public relations randomized controlled trial religion United States utilization review LA - English M3 - Article N1 - L31372574 2000-12-29 PY - 2000 SN - 1090-1981 SP - 632-648 ST - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion T2 - Health education & behavior : the official publication of the Society for Public Health Education TI - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion UR - https://www.embase.com/search/results?subaction=viewrecord&id=L31372574&from=export VL - 27 ID - 1320 ER - TY - JOUR AB - There is little documentation about the recruitment process for church‐based health education programs. In this study, the authors recruit African American, Latino, and white churches and women members (age 50 to 80) for a randomized church‐based trial of mammography promotion in Los Angeles County. Efforts to enhance recruitment began 10 months before churches were invited to participate and included a variety of community‐based strategies. Subsequently, 45 churches were recruited over a 5‐month period through group pastor breakfast meetings and church‐specific follow‐up. In close collaboration with the 45 churches, the authors administered church‐based surveys over 6 months and identified 1,967 age‐eligible women who agreed to be contacted by the program team. It was found that an extended resource intensive period of relationship‐building and community‐based activities were necessary to conduct church‐based programs effectively, particularly among older and ethnically diverse urban populations. AN - CN-00330551 AU - Derose, K. P. AU - Hawes-Dawson, J. AU - Fox, S. A. AU - Maldonado, N. AU - Tatum, A. AU - Kington, R. DO - 10.1177/109019810002700508 IS - 5 KW - Aged Breast Neoplasms [*prevention & control] Community Health Planning Community‐Institutional Relations Ethnic Groups Female Health Education [*organization & administration] Health Promotion [*organization & administration] Health Services Research Humans Los Angeles Mammography [*statistics & numerical data] Middle Aged Motivation Patient Selection Religion M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2000 SP - 632‐648 ST - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion T2 - Health education & behavior TI - Dealing with diversity: recruiting churches and women for a randomized trial of mammography promotion UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00330551/full VL - 27 ID - 1610 ER - TY - JOUR AB - There is little documentation about the recruitment process for church-based health education programs. In this study, the authors recruit African American, Latino, and white churches and women members (age 50 to 80) for a randomized church-based trial of mammography promotion in Los Angeles County. Efforts to enhance recruitment began 10 months before churches were invited to participate and included a variety of community-based strategies. Subsequently, 45 churches were recruited over a 5-month period through group pastor breakfast meetings and church-specific follow-up. In close collaboration with the 45 churches, the authors administered church-based surveys over 6 months and identified 1,967 age-eligible women who agreed to be contacted by the program team. It was found that an extended resource intensive period of relationship-building and community-based activities were necessary to conduct church-based programs effectively, particularly among older and ethnically diverse urban populations. AD - RAND, Santa Monica, CA, United States RAND, 1700 Main Street, Santa Monica, CA 90407-2138, United States AU - Derose, K. P. AU - Hawes-Dawson, J. AU - Fox, S. A. AU - Maldonado, N. AU - Tatum, A. AU - Kington, R. DB - Scopus DO - 10.1177/109019810002700508 IS - 5 M3 - Article N1 - Cited By :49 Export Date: 22 March 2021 PY - 2000 SP - 632-648 ST - Dealing with diversity: Recruiting churches and women for a randomized trial of mammography promotion T2 - Health Education and Behavior TI - Dealing with diversity: Recruiting churches and women for a randomized trial of mammography promotion UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034296699&doi=10.1177%2f109019810002700508&partnerID=40&md5=38f51a29640f1d30d7247a84e46f66a6 VL - 27 ID - 2637 ER - TY - JOUR AB - There is little documentation about the recruitment process for church-based health education programs. In this study, the authors recruit African American, Latino, and white churches and women members (age 50 to 80) for a randomized church-based trial of mammography promotion in Los Angeles County. Efforts to enhance recruitment began 10 months before churches were invited to participate and included a variety of community-based strategies. Subsequently, 45 churches were recruited over a 5-month period through group pastor breakfast meetings and church-specific follow-up. In close collaboration with the 45 churches, the authors administered church-based surveys over 6 months and identified 1,967 age-eligible women who agreed to be contacted by the program team. It was found that an extended resource intensive period of relationship-building and community-based activities were necessary to conduct church-based programs effectively, particularly among older and ethnically diverse urban populations. AN - WOS:000089417900007 AU - Derose, K. P. AU - Hawes-Dawson, J. AU - Fox, S. A. AU - Maldonado, N. AU - Tatum, A. AU - Kington, R. DA - Oct DO - 10.1177/109019810002700508 IS - 5 N1 - 44 11009131 PY - 2000 SN - 1090-1981 SP - 632-648 ST - Dealing with diversity: Recruiting churches and women for a randomized trial of mammography promotion T2 - Health Education & Behavior TI - Dealing with diversity: Recruiting churches and women for a randomized trial of mammography promotion VL - 27 ID - 2720 ER - TY - JOUR AB - BACKGROUND: Decisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer before any treatment choices were made. METHODS: A total of 70 men were surveyed at a Veterans Administration clinic with newly diagnosed localized prostate cancer enrolled in a randomized trial testing a novel shared decision-making tool. Baseline demographic, clinical, and functional data were collected. Independent variables included age, race, education, comorbidity, relationship status, urinary/sexual dysfunction, and prostate cancer knowledge. Tested outcomes were Decisional Conflict Scale, Uncertainty Subscale, and Perceived Effectiveness Subscale. Multiple linear regression modeling was used to identify factors associated with decisional conflict. RESULTS: Mean age was 63 years, 49% were African American, and 70% reported an income less than $30,000. Poor prostate cancer knowledge was associated with increased decisional conflict and higher uncertainty (P < .001 and P = 0.001, respectively). Poor knowledge was also associated with lower perceived effectiveness (P = 0.003) whereas being in a relationship was associated with higher decisional conflict (P = 0.03). CONCLUSIONS: Decreased patient knowledge about prostate cancer is associated with increased decisional conflict and lower perceived effective decision-making. Interventions to increase comprehension of prostate cancer and its treatments may reduce decisional conflict. Further work is needed to better characterize this relationship and identify effective targeted interventions. (C) 2014 American Cancer Society. AN - WOS:000340559000013 AU - Kaplan, A. L. AU - Crespi, C. M. AU - Saucedo, J. D. AU - Connor, S. E. AU - Litwin, M. S. AU - Saigal, C. S. DA - Sep DO - 10.1002/cncr.28755 IS - 17 N1 - AACR Annual Meeting APR 05-09, 2014 San Diego, CA 24816472 PY - 2014 SN - 0008-543X SP - 2721-2727 ST - Decisional Conflict in Economically Disadvantaged Men With Newly Diagnosed Prostate Cancer T2 - Cancer TI - Decisional Conflict in Economically Disadvantaged Men With Newly Diagnosed Prostate Cancer VL - 120 ID - 2999 ER - TY - JOUR AB - BACKGROUND Decisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer before any treatment choices were made. METHODS A total of 70 men were surveyed at a Veterans Administration clinic with newly diagnosed localized prostate cancer enrolled in a randomized trial testing a novel shared decision-making tool. Baseline demographic, clinical, and functional data were collected. Independent variables included age, race, education, comorbidity, relationship status, urinary/sexual dysfunction, and prostate cancer knowledge. Tested outcomes were Decisional Conflict Scale, Uncertainty Subscale, and Perceived Effectiveness Subscale. Multiple linear regression modeling was used to identify factors associated with decisional conflict. RESULTS Mean age was 63 years, 49% were African American, and 70% reported an income less than $30,000. Poor prostate cancer knowledge was associated with increased decisional conflict and higher uncertainty (P<.001 and P=0.001, respectively). Poor knowledge was also associated with lower perceived effectiveness (P=0.003) whereas being in a relationship was associated with higher decisional conflict (P=0.03). CONCLUSIONS Decreased patient knowledge about prostate cancer is associated with increased decisional conflict and lower perceived effective decision-making. Interventions to increase comprehension of prostate cancer and its treatments may reduce decisional conflict. Further work is needed to better characterize this relationship and identify effective targeted interventions. Cancer 2014;120:2721-2727. © 2014 American Cancer Society. In economically disadvantaged men with newly diagnosed prostate cancer, a poor understanding of the disease is associated with personal conflict surrounding the treatment decision. Targeted educational interventions may mitigate the decisional burden. © 2014 American Cancer Society. AD - A.L. Kaplan, Department of Urology, David Geffen School of Medicine, University of California Los Angeles (UCLA), 10833 Le Conte Avenue, Los Angeles, CA 90095-1738, United States AU - Kaplan, A. L. AU - Crespi, C. M. AU - Saucedo, J. D. AU - Connor, S. E. AU - Litwin, M. S. AU - Saigal, C. S. DB - Embase Medline DO - 10.1002/cncr.28755 IS - 17 KW - adult African American age distribution aged article attitude to illness cohort analysis controlled study cross-sectional study decisional conflict Decisional Conflict Scale Perceived Efficacy subscale Decisional Conflict Scale Uncertainty subscale economically disadvantaged man educational status high risk population human income major clinical study male marriage assessment of humans outcome assessment patient attitude patient decision making population and population related phenomena priority journal prostate cancer risk assessment risk factor LA - English M3 - Article N1 - L373800880 2014-09-02 2014-09-06 PY - 2014 SN - 1097-0142 0008-543X SP - 2721-2727 ST - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: Baseline results from a shared decision-making trial T2 - Cancer TI - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: Baseline results from a shared decision-making trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373800880&from=export http://dx.doi.org/10.1002/cncr.28755 VL - 120 ID - 1028 ER - TY - JOUR AB - Background: Decisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer before any treatment choices were made.Methods: A total of 70 men were surveyed at a Veterans Administration clinic with newly diagnosed localized prostate cancer enrolled in a randomized trial testing a novel shared decision-making tool. Baseline demographic, clinical, and functional data were collected. Independent variables included age, race, education, comorbidity, relationship status, urinary/sexual dysfunction, and prostate cancer knowledge. Tested outcomes were Decisional Conflict Scale, Uncertainty Subscale, and Perceived Effectiveness Subscale. Multiple linear regression modeling was used to identify factors associated with decisional conflict.Results: Mean age was 63 years, 49% were African American, and 70% reported an income less than $30,000. Poor prostate cancer knowledge was associated with increased decisional conflict and higher uncertainty (P < .001 and P = 0.001, respectively). Poor knowledge was also associated with lower perceived effectiveness (P = 0.003) whereas being in a relationship was associated with higher decisional conflict (P = 0.03).Conclusions: Decreased patient knowledge about prostate cancer is associated with increased decisional conflict and lower perceived effective decision-making. Interventions to increase comprehension of prostate cancer and its treatments may reduce decisional conflict. Further work is needed to better characterize this relationship and identify effective targeted interventions. AD - Department of Urology, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, California. AN - 103989127. Language: English. Entry Date: 20141024. Revision Date: 20200708. Publication Type: journal article AU - Kaplan, Alan L. AU - Crespi, Catherine M. AU - Saucedo, Josemanuel D. AU - Connor, Sarah E. AU - Litwin, Mark S. AU - Saigal, Christopher S. DB - CINAHL Complete DO - 10.1002/cncr.28755 DP - EBSCOhost IS - 17 KW - Dissent and Disputes Prostatic Neoplasms -- Therapy Aged Decision Making Cross Sectional Studies Attitude to Health Human Income Male Middle Age Prostatic Neoplasms -- Diagnosis Prostatic Neoplasms -- Economics Special Populations N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: 5R25CA087949-14/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM24816472. PY - 2014 SN - 0008-543X SP - 2721-2727 ST - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial T2 - Cancer (0008543X) TI - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103989127&site=ehost-live&scope=site VL - 120 ID - 1904 ER - TY - JOUR AB - BACKGROUND Decisional conflict is a source of anxiety and stress for men diagnosed with prostate cancer given uncertainty surrounding myriad treatment options. Few data exist to help clinicians identify which patients are at risk for decisional conflict. The purpose of this study was to examine factors associated with decisional conflict in economically disadvantaged men diagnosed with prostate cancer before any treatment choices were made. METHODS A total of 70 men were surveyed at a Veterans Administration clinic with newly diagnosed localized prostate cancer enrolled in a randomized trial testing a novel shared decision-making tool. Baseline demographic, clinical, and functional data were collected. Independent variables included age, race, education, comorbidity, relationship status, urinary/sexual dysfunction, and prostate cancer knowledge. Tested outcomes were Decisional Conflict Scale, Uncertainty Subscale, and Perceived Effectiveness Subscale. Multiple linear regression modeling was used to identify factors associated with decisional conflict. RESULTS Mean age was 63 years, 49% were African American, and 70% reported an income less than $30,000. Poor prostate cancer knowledge was associated with increased decisional conflict and higher uncertainty (P<.001 and P=0.001, respectively). Poor knowledge was also associated with lower perceived effectiveness (P=0.003) whereas being in a relationship was associated with higher decisional conflict (P=0.03). CONCLUSIONS Decreased patient knowledge about prostate cancer is associated with increased decisional conflict and lower perceived effective decision-making. Interventions to increase comprehension of prostate cancer and its treatments may reduce decisional conflict. Further work is needed to better characterize this relationship and identify effective targeted interventions. Cancer 2014;120:2721-2727. © 2014 American Cancer Society. In economically disadvantaged men with newly diagnosed prostate cancer, a poor understanding of the disease is associated with personal conflict surrounding the treatment decision. Targeted educational interventions may mitigate the decisional burden. © 2014 American Cancer Society. AD - Department of Urology, David Geffen School of Medicine, University of California Los Angeles (UCLA), 10833 Le Conte Avenue, Los Angeles, CA 90095-1738, United States Division of Cancer Prevention and Control Research, School of Public Health, UCLA, Los Angeles, CA, United States School of Public Health, UCLA, Los Angeles, CA, United States AU - Kaplan, A. L. AU - Crespi, C. M. AU - Saucedo, J. D. AU - Connor, S. E. AU - Litwin, M. S. AU - Saigal, C. S. DB - Scopus DO - 10.1002/cncr.28755 IS - 17 KW - decisional conflict knowledge low socioeconomic status patient education prostate cancer M3 - Article N1 - Cited By :33 Export Date: 22 March 2021 PY - 2014 SP - 2721-2727 ST - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: Baseline results from a shared decision-making trial T2 - Cancer TI - Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: Baseline results from a shared decision-making trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84906330343&doi=10.1002%2fcncr.28755&partnerID=40&md5=c9ba33676e4e91a22d9fc3d0ccf7ea42 VL - 120 ID - 2391 ER - TY - JOUR AB - African Americans have a substantially increased mortality rate compared to Whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States. AD - E.E. Partridge, University of Alabama at Birmingham, Dept. of Obstetrics and Gynecology, 618 20th Street South, 538 OHB, Birmingham, AL 35233-7333, United States AU - Partridge, E. E. AU - Fouad, M. N. AU - Hinton, A. W. AU - Hardy, C. M. AU - Liscovicz, N. AU - White-Johnson, F. AU - Higginbotham, J. C. DB - Medline DO - 10.1097/00003727-200501000-00004 IS - 1 KW - African American article breast cancer cancer center cancer control cancer mortality European American health program human medical research methodology sustainable development United States uterine cervix cancer LA - English M3 - Article N1 - L40148762 2005-02-04 PY - 2005 SN - 0160-6379 SP - 6-19 ST - The deep south network for cancer control: Eliminating cancer disparities through community - Academic collaboration T2 - Family and Community Health TI - The deep south network for cancer control: Eliminating cancer disparities through community - Academic collaboration UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40148762&from=export http://dx.doi.org/10.1097/00003727-200501000-00004 VL - 28 ID - 1274 ER - TY - JOUR AB - African Americans have a substantially increased mortality rate compared to Whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States. AD - Dept. of Obstetrics and Gynecology, University of Alabama, Birmingham, AL, United States Department of Medicine, Division of Preventive Medicine, University of Alabama, Birmingham, AL, United States Comprehensive Cancer Center, University of Alabama, Birmingham, AL, United States Depts. of Community Health Sciences, Ctr. for Sustainahle Health Outreach, University of Southern Mississippi, Hattiesburg, MS, United States Dept. of Comm. and Rural Medicine, Institute for Rural Health Research, Univ. of Alabama School of Medicine, Tuscaloosa, AL, United States University of Alabama at Birmingham, Dept. of Obstetrics and Gynecology, 618 20th Street South, 538 OHB, Birmingham, AL 35233-7333, United States AU - Partridge, E. E. AU - Fouad, M. N. AU - Hinton, A. W. AU - Hardy, C. M. AU - Liscovicz, N. AU - White-Johnson, F. AU - Higginbotham, J. C. DB - Scopus DO - 10.1097/00003727-200501000-00004 IS - 1 KW - African Americans Cancer control Health disparities Network M3 - Article N1 - Cited By :42 Export Date: 22 March 2021 PY - 2005 SP - 6-19 ST - The deep south network for cancer control: Eliminating cancer disparities through community - Academic collaboration T2 - Family and Community Health TI - The deep south network for cancer control: Eliminating cancer disparities through community - Academic collaboration UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-12444301776&doi=10.1097%2f00003727-200501000-00004&partnerID=40&md5=eeb097cf17d99a93a3ec462e3604eeaa VL - 28 ID - 2600 ER - TY - JOUR AB - African Americans have a substantially increased mortality rate compared to Whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Partridge, Edward E., University of Alabama, Department of Obstetrics & Gynecology, 618 20th Street South, 538 OHB, Birmingham, AL, US, 35233-7333 AN - 2004-22446-003 AU - Partridge, Edward E. AU - Fouad, Mona N. AU - Hinton, Agnes W. AU - Hardy, Claudia M. AU - Liscovicz, Nedra AU - White-Johnson, Freddie AU - Higginbotham, John C. DB - psyh DO - 10.1097/00003727-200501000-00004 DP - EBSCOhost IS - 1 KW - cancer control cancer disparities community-academic collaboration mortality rate African Americans Alabama Breast Neoplasms Clinical Trials as Topic Community Networks Consumer Participation Female Health Promotion Humans Medically Underserved Area Mississippi Schools, Medical Socioeconomic Factors United States Uterine Cervical Neoplasms Death and Dying Health Care Delivery Neoplasms Race and Ethnic Discrimination Blacks Collaboration Community Services Cooperation N1 - Department of Obstetrics, University of Alabama, Birmingham, AL, US. Release Date: 20050124. Correction Date: 20100329. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Death and Dying; Health Care Delivery; Mortality Rate; Neoplasms; Race and Ethnic Discrimination. Minor Descriptor: Blacks; Collaboration; Community Services; Cooperation. Classification: Cancer (3293); Community & Social Services (3373). Population: Human (10). Location: US. References Available: Y. Page Count: 14. Issue Publication Date: Jan-Mar, 2005. PY - 2005 SN - 0160-6379 1550-5057 SP - 6-19 ST - The Deep South Network for Cancer Control: Eliminating Cancer Disparities Through Community-Academic Collaboration T2 - Family & Community Health: The Journal of Health Promotion & Maintenance T3 - Decreasing Health Disparities TI - The Deep South Network for Cancer Control: Eliminating Cancer Disparities Through Community-Academic Collaboration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2004-22446-003&site=ehost-live&scope=site pakers@uabmc.edu VL - 28 ID - 1766 ER - TY - JOUR AB - African Americans have a substantially increased mortality rate compared to Whites in many cancers, including breast and cervix. The Deep South Network for Cancer Control (the Network) was established to develop sustainable community infrastructure to promote cancer awareness, enhance participation of African Americans and other special populations in clinical trials, recruit and train minority investigators, and develop and test innovative community-based cancer control measures to eliminate cancer mortality disparities in special populations. This article describes the steps necessary to form the network and the process and activities required to establish it as an effective infrastructure for eliminating disparities between Whites and African Americans in the United States. AD - Departments of Obstetrics and Gynecology, The University of Alabama at Birmingham, 35233-7333, USA University of Alabama at Birmingham, Department of Obstetrics & Gynecology, 618 20th Street South, 538 OHB, Birmingham, AL 35233-7333; pakers@uabmc.edu AN - 106586361. Language: English. Entry Date: 20070101. Revision Date: 20200624. Publication Type: journal article AU - Partridge, E. E. AU - Fouad, M. N. AU - Hinton, A. W. AU - Hardy, C. M. AU - Liscovicz, N. AU - White-Johnson, F. AU - Higginbotham, J. C. AU - Partridge, Edward E. AU - Fouad, Mona N. AU - Hinton, Agnes W. AU - Hardy, Claudia M. AU - Liscovicz, Nedra AU - White-Johnson, Freddie AU - Higginbotham, John C. DB - CINAHL Complete DO - 10.1097/00003727-200501000-00004 DP - EBSCOhost IS - 1 KW - Black Persons -- United States Neoplasms -- Prevention and Control Program Development United States N1 - statistics. Journal Subset: Biomedical; Core Nursing; Nursing; Peer Reviewed; Public Health; USA. Grant Information: U01 CA86128/CA/NCI NIH HHS/United States. NLM UID: 7809641. PMID: NLM15625502. PY - 2005 SN - 0160-6379 SP - 6-19 ST - The deep South network for cancer control: eliminating cancer disparities through community-academic collaboration T2 - Family & Community Health TI - The deep South network for cancer control: eliminating cancer disparities through community-academic collaboration UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106586361&site=ehost-live&scope=site VL - 28 ID - 2115 ER - TY - JOUR AB - Objectives: The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV-positive individuals with CD4 cell counts above 500cells/μL. We describe the demographics, HIV-specific characteristics and medical history of this cohort. Methods: Data collected at baseline include demographics, HIV-specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age. Results: START enrolled 4685 HIV-positive participants from 215 sites in 35 countries. The median age is 36 years [interquartile range (IQR) 29-44 years], 27% are female, and 45% self-identify as white, 30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is 1.0 year (IQR 0.4-3.0 years) and the median CD4 cell count and HIV RNA values at study entry are 651cells/μL (IQR 584-765cells/μL) and 12754 HIV RNA copies/mL (IQR 3014-43607 copies/mL), respectively. Conclusions: START has enrolled a diverse group of ART-naïve individuals with high CD4 cell counts who are comparable to the HIV-positive population from the regions in which they were enrolled. The information collected with this robust study design will provide a database with which to evaluate the risks and benefits of early ART use for many important outcomes. © 2015 British HIV Association. AD - Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, United States Medical Research Council (MRC) Clinical Trials Unit at University College London, London, United Kingdom The Kirby Institute, University of New South Wales, Sydney, Australia Washington DC Veterans Affairs Medical Center and George Washington University, Washington, DC, United States Department of Infectious Diseases, Copenhagen HIV Programme, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Wojewodzki Szpital Zakazny, Warsaw, Poland Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, United Kingdom University of Chile School of Medicine, Fundacion Arriaran, Santiago, Chile AU - Sharma, S. AU - Babiker, A. AU - Emery, S. AU - Gordin, F. AU - Lundgren, J. AU - Neaton, J. AU - Bakowska, E. AU - Schechter, M. AU - Wiselka, M. AU - Wolff, M. AU - International Network for Strategic Initiatives in Global, H. I. V. Trials Start Study Group DB - Scopus DO - 10.1111/hiv.12231 IS - S1 KW - Clinical trial HIV START trial When to start antiretroviral therapy M3 - Article N1 - (INSIGHT) Cited By :7 Export Date: 22 March 2021 PY - 2015 SP - 30-36 ST - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial T2 - HIV Medicine TI - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923344486&doi=10.1111%2fhiv.12231&partnerID=40&md5=7531763580e9d4c081bbf8be93f67a32 VL - 16 ID - 2367 ER - TY - JOUR AB - OBJECTIVES: The risks and benefits of initiating antiretroviral treatment (ART) at high CD4 cell counts have not been reliably quantified. The Strategic Timing of AntiRetroviral Treatment (START) study is a randomized international clinical trial that compares immediate with deferred initiation of ART for HIV‐positive individuals with CD4 cell counts above 500 cells/μL. We describe the demographics, HIV‐specific characteristics and medical history of this cohort. METHODS: Data collected at baseline include demographics, HIV‐specific laboratory values, prior medical diagnoses and concomitant medications. Baseline characteristics were compared by geographical region, gender and age. RESULTS: START enrolled 4685 HIV‐positive participants from 215 sites in 35 countries. The median age is 36 years [interquartile range (IQR) 29‐44 years], 27% are female, and 45% self‐identify as white, 30% as black, 14% as Latino/Hispanic, 8% as Asian and 3% as other. The route of HIV acquisition is reported as men who have sex with men in 55% of participants, heterosexual sex in 38%, injecting drug use in 1% and other/unknown in 5%. Median time since HIV diagnosis is 1.0 year (IQR 0.4‐3.0 years) and the median CD4 cell count and HIV RNA values at study entry are 651 cells/μL (IQR 584‐765 cells/μL) and 12,754 HIV RNA copies/mL (IQR 3014‐43,607 copies/mL), respectively. CONCLUSIONS: START has enrolled a diverse group of ART‐naïve individuals with high CD4 cell counts who are comparable to the HIV‐positive population from the regions in which they were enrolled. The information collected with this robust study design will provide a database with which to evaluate the risks and benefits of early ART use for many important outcomes. AN - CN-01077428 AU - Sharma, S. AU - Babiker, A. G. AU - Emery, S. AU - Gordin, F. M. AU - Lundgren, J. D. AU - Neaton, J. N. AU - Bakowska, E. AU - Schechter, M. AU - Wiselka, M. J. AU - Wolff, M. J. DO - 10.1111/hiv.12231 KW - *CD4 lymphocyte count *Human immunodeficiency virus infection *demography *medical history Acute heart infarction/di [Diagnosis] Adult Alcoholism/di [Diagnosis] Antidepressant agent Antilipemic agent Antiretroviral Therapy, Highly Active [*methods] Antiretrovirus agent Antiviral therapy Anti‐Retroviral Agents [*therapeutic use] Article Benzodiazepine derivative CD4 Lymphocyte Count Cerebrovascular accident/di [Diagnosis] Chronic kidney disease/di [Diagnosis] Cohort Studies Cohort analysis Congestive heart failure/di [Diagnosis] Coronary artery disease/di [Diagnosis] Deep vein thrombosis/di [Diagnosis] Demography Drug use End stage renal disease/di [Diagnosis] Fatty liver/di [Diagnosis] Female HIV Infections [*drug therapy, immunology, pathology] Heart muscle revascularization Heterosexuality Hormonal therapy Human Human immunodeficiency virus Humans Liver cirrhosis/di [Diagnosis] Lung embolism/di [Diagnosis] Major clinical study Male Men who have sex with men Mental disease/di [Diagnosis] Middle Aged Myocarditis/di [Diagnosis] Nonsteroid antiinflammatory agent Pancreatitis/di [Diagnosis] Pericarditis/di [Diagnosis] Peripheral occlusive artery disease/di [Diagnosis] Priority journal Proton pump inhibitor RNA Self injection Skin cancer/di [Diagnosis] Substance abuse Time Factors Treatment Outcome M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2015 SP - 30‐36 ST - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial T2 - HIV medicine TI - Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01077428/full VL - 16 Suppl 1 ID - 1643 ER - TY - JOUR AB - Objective To describe the methodology of a 2-arm randomized controlled trial that compared the effects of a narrative and didactic version of the Witness CARES (Community Awareness, Reach, & Empowerment for Screening) intervention on colorectal cancer screening behavior among African Americans, as well as the cognitive and affective determinants of screening. Methods Witness CARES targeted cognitive and affective predictors of screening using a culturally competent, community-based, narrative or didactic communication approach. New and existing community partners were recruited in two New York sites. Group randomization allocated programs to the narrative or didactic arm. Five phases of data collection were conducted: baseline, post-intervention, three-month, six-month, and qualitative interviews. The primary outcome was screening behavior; secondary outcomes included cognitive and affective determinants of screening. Results A total of 183 programs were conducted for 2655 attendees. Of these attendees, 19.4% (N = 516) across 158 programs (50% narrative; 50% didactic) were study-eligible and consented to participate. Half (45.6%) of the programs were delivered to new community partners and 34.8% were delivered at faith-based organizations. Mean age of the total sample was 64.7 years and 75.4% were female. Conclusion The planned number of programs was delivered, but the proportion of study-eligible attendees was lower than predicted. This community-based participatory research approach was largely successful in involving the community served in the development and implementation of the intervention and study. AD - E.M. Ellis, Basic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD, United States AU - Ellis, E. M. AU - Erwin, D. O. AU - Jandorf, L. AU - Saad-Harfouche, F. AU - Sriphanlop, P. AU - Clark, N. AU - Dauphin, C. AU - Johnson, D. AU - Klasko-Foster, L. B. AU - Martinez, C. AU - Sly, J. AU - White, D. AU - Winkel, G. AU - Kiviniemi, M. T. DB - Embase Medline DO - 10.1016/j.cct.2017.11.019 KW - adult African American article cancer screening colorectal cancer community controlled study female follow up human interpersonal communication major clinical study male middle aged narrative randomized controlled trial LA - English M3 - Article N1 - L619541171 2017-12-13 2017-12-18 PY - 2018 SN - 1559-2030 1551-7144 SP - 8-18 ST - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans T2 - Contemporary Clinical Trials TI - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619541171&from=export http://dx.doi.org/10.1016/j.cct.2017.11.019 VL - 65 ID - 910 ER - TY - JOUR AB - Objective To describe the methodology of a 2-arm randomized controlled trial that compared the effects of a narrative and didactic version of the Witness CARES (Community Awareness, Reach, & Empowerment for Screening) intervention on colorectal cancer screening behavior among African Americans, as well as the cognitive and affective determinants of screening. Methods Witness CARES targeted cognitive and affective predictors of screening using a culturally competent, community-based, narrative or didactic communication approach. New and existing community partners were recruited in two New York sites. Group randomization allocated programs to the narrative or didactic arm. Five phases of data collection were conducted: baseline, post-intervention, three-month, six-month, and qualitative interviews. The primary outcome was screening behavior; secondary outcomes included cognitive and affective determinants of screening. Results A total of 183 programs were conducted for 2655 attendees. Of these attendees, 19.4% (N = 516) across 158 programs (50% narrative; 50% didactic) were study-eligible and consented to participate. Half (45.6%) of the programs were delivered to new community partners and 34.8% were delivered at faith-based organizations. Mean age of the total sample was 64.7 years and 75.4% were female. Conclusion The planned number of programs was delivered, but the proportion of study-eligible attendees was lower than predicted. This community-based participatory research approach was largely successful in involving the community served in the development and implementation of the intervention and study. © 2017 AD - Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, SUNY, Buffalo, NY 14214, United States Office of Cancer Health Disparities Research, Division of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, United States Department of Population Health Science and Policy, Center for Behavioral Oncology, Division of Cancer Prevention and Control, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, NY 10029, United States AU - Ellis, E. M. AU - Erwin, D. O. AU - Jandorf, L. AU - Saad-Harfouche, F. AU - Sriphanlop, P. AU - Clark, N. AU - Dauphin, C. AU - Johnson, D. AU - Klasko-Foster, L. B. AU - Martinez, C. AU - Sly, J. AU - White, D. AU - Winkel, G. AU - Kiviniemi, M. T. DB - Scopus DO - 10.1016/j.cct.2017.11.019 KW - African American Colonoscopy Colorectal cancer screening Community-based intervention Randomized controlled trial Recruitment M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2018 SP - 8-18 ST - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans T2 - Contemporary Clinical Trials TI - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037345077&doi=10.1016%2fj.cct.2017.11.019&partnerID=40&md5=7ef1827dd0e2c8d9539bacad366598af VL - 65 ID - 2284 ER - TY - JOUR AB - Objective: To describe the methodology of a 2-arm randomized controlled trial that compared the effects of a narrative and didactic version of the Witness CARES (Community Awareness, Reach, & Empowerment for Screening) intervention on colorectal cancer screening behavior among African Americans, as well as the cognitive and affective determinants of screening. Methods: Witness CARES targeted cognitive and affective predictors of screening using a culturally competent, community-based, narrative or didactic communication approach. New and existing community partners were recruited in two New York sites. Group randomization allocated programs to the narrative or didactic arm. Five phases of data collection were conducted: baseline, post-intervention, three-month, six-month, and qualitative interviews. The primary outcome was screening behavior; secondary outcomes included cognitive and affective determinants of screening. Results: A total of 183 programs were conducted for 2655 attendees. Of these attendees, 19.4% (N = 516) across 158 programs (50% narrative; 50% didactic) were study-eligible and consented to participate. Half (45.6%) of the programs were delivered to new community partners and 34.8% were delivered at faith-based organizations. Mean age of the total sample was 64.7 years and 75.4% were female. Conclusion: The planned number of programs was delivered, but the proportion of study-eligible attendees was lower than predicted. This community-based participatory research approach was largely successful in involving the community served in the development and implementation of the intervention and study. AN - WOS:000425201200002 AU - Ellis, E. M. AU - Erwin, D. O. AU - Jandorf, L. AU - Saad-Harfouche, F. AU - Sriphanlop, P. AU - Clark, N. AU - Dauphin, C. AU - Johnson, D. AU - Klasko-Foster, L. B. AU - Martinez, C. AU - Sly, J. AU - White, D. AU - Winkel, G. AU - Kiviniemi, M. T. DA - Feb DO - 10.1016/j.cct.2017.11.019 N1 - 29198730 PY - 2018 SN - 1551-7144 SP - 8-18 ST - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans T2 - Contemporary Clinical Trials TI - Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans VL - 65 ID - 2874 ER - TY - JOUR AB - Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm. © Oxford University Press 2005, all rights reserved. AD - S.M. Lippman, M.D. Anderson Cancer Center, Dept. of Clinical Cancer Prevention, 1515 Holcombe Blvd., Houston, TX 77030-4009, United States AU - Lippman, S. M. AU - Goodman, P. J. AU - Klein, E. A. AU - Parnes, H. L. AU - Thompson Jr, I. M. AU - Kristal, A. R. AU - Santella, R. M. AU - Probstfield, J. L. AU - Moinpour, C. M. AU - Albanes, D. AU - Taylor, P. R. AU - Minasian, L. M. AU - Hoque, A. AU - Thomas, S. M. AU - Crowley, J. J. AU - Gaziano, J. M. AU - Stanford, J. L. AU - Cook, E. D. AU - Fleshner, N. E. AU - Lieber, M. M. AU - Walther, P. J. AU - Khuri, F. R. AU - Karp, D. D. AU - Schwartz, G. G. AU - Ford, L. G. AU - Coltman Jr, C. A. C1 - aspirin DB - Embase Medline DO - 10.1093/jnci/dji009 IS - 2 KW - acetylsalicylic acid alpha tocopherol alpha tocotrienol beta carotene beta tocopherol beta tocotrienol colecalciferol delta tocopherol delta tocotrienol drug metabolite gamma tocopherol gamma tocotrienol inorganic compound methylselenol multivitamin placebo selenite selenium selenomethionine unclassified drug vitamin African American age article brain hemorrhage Canada cancer incidence cancer prevention cancer screening clinical trial community care drug absorption drug activity drug blood level drug dose regimen drug efficacy drug fatality drug formulation drug mechanism drug potentiation drug retention drug safety ethnic difference financial management genotoxicity health hazard heart protection high risk population human long term care lung cancer male medical decision making methodology patient selection planning population research priority journal prostate cancer Puerto Rico retinitis pigmentosa skin cancer standard cerebrovascular accident United States vitamin blood level vitamin supplementation aspirin LA - English M3 - Article N1 - L40277089 2005-03-08 PY - 2005 SN - 0027-8874 SP - 94-102 ST - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Journal of the National Cancer Institute TI - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40277089&from=export http://dx.doi.org/10.1093/jnci/dji009 VL - 97 ID - 1272 ER - TY - JOUR AB - Prostate cancer continues to be a major health threat, especially among African American men. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), which opened on July 25, 2001, was planned to study possible agents for the prevention of prostate cancer in a population of 32 400 men in the United States, including Puerto Rico, and Canada. SELECT is a phase III randomized, placebo-controlled trial of selenium (200 μg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all rac α-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years) in non-African American men at least 55 years of age and African American men at least 50 years of age. SELECT is a large, simple trial that conforms as closely as possible with community standards of care. This commentary discusses the design problems the SELECT investigators had to resolve in developing the trial, including the role of prostate cancer screening, the best forms and doses of the study agents, and estimation of the event (prostate cancer) rate of men on the placebo arm. © Oxford University Press 2005, all rights reserved. AD - The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030-4009, United States Southwest Oncology Group Stat. Ctr., Seattle, WA, United States Cleveland Clinic Foundation, Cleveland, OH, United States National Cancer Institute, Bethesda, MD, United States Univ. of Texas Health Science Ctr., San Antonio, TX, United States Fred Hutchinson Cancer Res. Ctr., Seattle, WA, United States Columbia University, College of Physicians and Surgeons, New York, NY, United States University of Washington, Seattle, WA, United States Louisiana State University, Health Science Center, New Orleans, LA, United States Boston VA Healthcare System, Boston, MA, United States Canadian Urologic Oncology Group, Toronto, Ont., Canada North Central Cancer Treatment Group, Rochester, MN, United States Cancer and Leukemia Group B, Chicago, IL, United States Radiation Therapy Oncology Group, Philadelphia, PA, United States Eastern Cooperative Oncology Group, Brookline, MA, United States Wake Forest Univ. School of Medicine, Winston-Salem, NC, United States Southwest Oncology Group Oper. Off., San Antonio, TX, United States AU - Lippman, S. M. AU - Goodman, P. J. AU - Klein, E. A. AU - Parnes, H. L. AU - Thompson Jr, I. M. AU - Kristal, A. R. AU - Santella, R. M. AU - Probstfield, J. L. AU - Moinpour, C. M. AU - Albanes, D. AU - Taylor, P. R. AU - Minasian, L. M. AU - Hoque, A. AU - Thomas, S. M. AU - Crowley, J. J. AU - Gaziano, J. M. AU - Stanford, J. L. AU - Cook, E. D. AU - Fleshner, N. E. AU - Lieber, M. M. AU - Walther, P. J. AU - Khuri, F. R. AU - Karp, D. D. AU - Schwartz, G. G. AU - Ford, L. G. AU - Coltman Jr, C. A. DB - Scopus DO - 10.1093/jnci/dji009 IS - 2 M3 - Article N1 - Cited By :254 Export Date: 22 March 2021 PY - 2005 SP - 94-102 ST - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Journal of the National Cancer Institute TI - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-13744264090&doi=10.1093%2fjnci%2fdji009&partnerID=40&md5=ce3fc654a15cb493e806511648940bb0 VL - 97 ID - 2598 ER - TY - JOUR AB - Objective: Early and accurate diagnosis of small metastatic brain tumors may affect outcomes and treatment strategies. For this reason, 3-dimensional (3D) thin-section imaging is preferred. However, with conventional contrast-enhanced (CE) 3D imaging, such as magnetization-prepared rapid gradient echo (MP-RAGE), many visually enhanced vessels may mimic small metastatic tumors, hindering tumor detection. CE black-blood single-slab 3D turbo-spin echo imaging (BB-ssTSE) was recently developed, which uses variable refocusing flip angles and flow-sensitizing gradient schemes, to enhance metastatic brain tumors while selectively suppressing blood vessels. The purpose of this work was to investigate the efficiency of the proposed CE BB-ssTSE in detecting small metastatic brain tumors as compared with conventional MP-RAGE. Materials and Methods: Numerical comparisons of MP-RAGE and BB-ssTSE were performed by simulation studies to investigate the signal/contrast behaviors of flowing blood and stationary CE tumors. For in vivo studies, we enrolled 35 patients (18 women; mean age, 58.1 years) with breast or lung cancer who underwent brain magnetic resonance imaging. After administering a double dose of contrast medium, whole-brain 2-dimensional T1-weighted imaging followed by high-resolution isotropic 3D BB-ssTSE and MP-RAGE was performed at 3.0 T. Two reviewers independently evaluated the presence of metastatic brain tumors using: (1) MP-RAGE; (2) BB-ssTSE; and (3) MP-RAGE + BB-ssTSE sequentially in 3 review sessions, 2 weeks apart. The lesions were classified by size into 2 groups: large (<5 mm) and small (<5 mm). Both reviewers marked all tumors detected at each session. Another reviewer combined the results of the 2 reviewers and compared the detection rates of metastatic brain tumors between BB-ssTSE and MP-RAGE by using follow-up imaging. Intraclass correlation coefficients between the 2 reviewers were measured. Results: Numerical simulations showed that the proposed BB-ssTSE effectively attenuated the signal intensity of flowing blood over the entire echo train, resulting in CE tumor-to-white matter contrast comparable with conventional MP-RAGE. The combined evaluation of MP-RAGE + BB-ssTSE showed 242 tumors in 28 patients. Of these, 153 lesions were <5 mm. MP-RAGE found 111 small metastatic brain tumors, BB-ssTSE found 150, and MP-RAGE + BB-ssTSE found 153. Significantly, more small tumors were detected by BB-ssTSE than MP-RAGE (P = 0.001, Wilcoxon signed-rank test). All large tumors were detected similarly by both MP-RAGE and BB-ssTSE. By combined results for MP-RAGE + BB-ssTSE, sensitivities for detection of small metastatic tumors were 72.5% for MP-RAGE and 98.0% for BB-ssTSE (P < 0.0001, McNemar test). Intraclass correlation coefficients between the 2 reviewers were 0.826 for MP-RAGE and 0.954 for BB-ssTSE. Conclusion: Compared with conventional MP-RAGE, the proposed CE BB-ssTSE imaging, which enhances tumors while selectively suppressing blood vessels, leads to significantly better detection of small metastatic brain tumors <5 mm. © 2012 by Lippincott Williams & Wilkins. AD - Biomedical Imaging and Engineering Laboratory, Department of Brain and Cognitive Engineering, Korea University, Seoul, South Korea Department of Radiology, Research Institute of Radiological Science, Yonsei University, 250 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea Department of Radiology, Pochun CHA College of Medicine, Pundang CHA Hospital, Sungnam, South Korea Department of Neurosurgery, Brain Research Institute, Yonsei University College of Medicine, Seoul, South Korea AU - Park, J. AU - Kim, J. AU - Yoo, E. AU - Lee, H. AU - Chang, J. H. AU - Kim, E. Y. DB - Scopus DO - 10.1097/RLI.0b013e3182319704 IS - 2 KW - black-blood brain metastases contrast-enhanced MRI spin echo variable flip angle M3 - Article N1 - Cited By :26 Export Date: 22 March 2021 PY - 2012 SP - 136-141 ST - Detection of small metastatic brain tumors: Comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging T2 - Investigative Radiology TI - Detection of small metastatic brain tumors: Comparison of 3D contrast-enhanced whole-brain black-blood imaging and MP-RAGE imaging UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855827013&doi=10.1097%2fRLI.0b013e3182319704&partnerID=40&md5=b1687221975fe08404126757ae245312 VL - 47 ID - 2466 ER - TY - JOUR AB - Background: African Americans are often diagnosed with advanced stage cancer and experience higher mortality compared with whites in the United States. Contributing factors, like differences in access to medical care and the prevalence of comorbidities, do not entirely explain racial differences in outcomes. Methods: The Detroit Research on Cancer Survivors (ROCS) pilot study was conducted to investigate factors related to short- and long-term outcomes among patients with cancer. Participants completed web-based surveys, and mailed saliva specimens were collected for future genetic studies. Results: We recruited 1,000 participants with an overall response rate of 68%. Thirty-one percent completed the survey without any interviewer support and the remaining participated in an interviewer-administered survey. Seventy-four percent provided a saliva specimen and 64% consented for tumor tissue retrieval. African American survivors required more interviewer support (P < 0.001); however, their response rate (69.6%) was higher than non-Hispanic whites (65.4%). African Americans reported poorer overall cancer-related quality of life compared with non-Hispanic whites, measured by FACT-G score (P < 0.001), however, this relationship was reversed after controlling for socioeconomic factors, marital status, and the presence of comorbidities. Conclusions: In this pilot study, we demonstrated that a web-based survey supplemented with telephone interviews and mailed saliva kits are cost-effective methods to collect patient-reported data and DNA for large studies of cancer survivors with a high proportion of minority patients. The preliminary data collected reinforces differences by race in factors affecting cancer outcomes. Our efforts continue as we expand this unique cohort to include more than 5,000 African American cancer survivors. Impact: Formal investigation of factors influencing adverse outcomes among African American cancer survivors will be critical in closing the racial gap in morbidity and mortality. © 2019 American Association for Cancer Research. AD - Population Studies and Disparities Research Program, Barbara Ann Karmanos Cancer Institute, Detroit, MI, United States Department of Oncology, School of Medicine, Wayne State University, Detroit, MI, United States Department of Family Medicine, School of Medicine, Wayne State University, Detroit, MI, United States Wayne State University School of Medicine, 87 E. Canfield, Detroit, MI 48201, United States AU - Beebe-Dimmer, J. L. AU - Albrecht, T. L. AU - Baird, T. E. AU - Ruterbusch, J. J. AU - Hastert, T. AU - Harper, F. W. K. AU - Simon, M. S. AU - Abrams, J. AU - Schwartz, K. L. AU - Schwartz, A. G. DB - Scopus DO - 10.1158/1055-9965.EPI-18-0123 IS - 4 M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2019 SP - 666-674 ST - The Detroit research on cancer survivors (ROCS) pilot study: A focus on outcomes after cancer in a racially diverse patient population T2 - Cancer Epidemiology Biomarkers and Prevention TI - The Detroit research on cancer survivors (ROCS) pilot study: A focus on outcomes after cancer in a racially diverse patient population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063896183&doi=10.1158%2f1055-9965.EPI-18-0123&partnerID=40&md5=579894014110c5cc5878073ad16e9c50 VL - 28 ID - 2234 ER - TY - JOUR AB - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is ~50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey's framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented. AD - Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC 29208, USA AN - 104446401. Language: English. Entry Date: 20120803. Revision Date: 20200708. Publication Type: journal article AU - Friedman, Daniela AU - Johnson, Kim AU - Owens, Otis AU - Thomas, Tracey AU - Dawkins, DeLisa AU - Gansauer, Lucy AU - Bartelt, Sharon AU - Waddell, Nancy AU - Talley, Pastor AU - Bearden, James AU - Hébert, James AU - Friedman, Daniela B. AU - Johnson, Kim M. AU - Owens, Otis L. AU - Thomas, Tracey L. AU - Dawkins, Delisa S. AU - Waddell, Nancy M. AU - Talley, Pastor J. AU - Bearden, James D., 3rd AU - Hébert, James R. DB - CINAHL Complete DO - 10.1007/s13187-012-0353-0 DP - EBSCOhost IS - 2 KW - Black Persons Health Education Oncologic Care Prostatic Neoplasms -- Education Prostatic Neoplasms -- Ethnology Research Subject Recruitment Action Research Brainstorming Cancer Screening Community-Institutional Relations Female Focus Groups Funding Source Human Male Middle Age Multimedia Oncologic Nursing Pilot Studies Pretest-Posttest Design Prostatic Neoplasms -- Mortality Prostatic Neoplasms -- Nursing Prostatic Neoplasms -- Prevention and Control Questionnaires Scales South Carolina Summated Rating Scaling Surveys N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Special Interest: Men's Health; Oncologic Care. Grant Information: K05 CA136975-03/CA/NCI NIH HHS/United States. NLM UID: 8610343. PMID: NLM22528633. PY - 2012 SN - 0885-8195 SP - 243-249 ST - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team T2 - Journal of Cancer Education TI - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104446401&site=ehost-live&scope=site VL - 27 ID - 1908 ER - TY - JOUR AB - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is ~50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey's framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented. AD - D.B. Friedman, Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC 29208, USA. AU - Friedman, D. B. AU - Johnson, K. M. AU - Owens, O. L. AU - Thomas, T. L. AU - Dawkins, D. S. AU - Gansauer, L. AU - Bartelt, S. AU - Waddell, N. M. AU - Talley, P. J. AU - Bearden 3rd, J. D. AU - Hébert, J. R. DB - Medline DO - 10.1007/s13187-012-0353-0 IS - 2 KW - African American article attitude to health decision making demography female health education human information processing male middle aged organization and management patient selection pilot study prostate tumor psychological aspect United States university hospital LA - English M3 - Article N1 - L365910623 2012-10-31 PY - 2012 SN - 1543-0154 SP - 243-249 ST - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: lessons learned from a community-academic-clinical team UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365910623&from=export http://dx.doi.org/10.1007/s13187-012-0353-0 VL - 27 ID - 1119 ER - TY - JOUR AB - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is ∼50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey's framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented. © 2011 Springer Science+Business Media, LLC. AD - Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, 800 Sumter Street, Columbia, SC 29208, United States Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, United States National Cancer Institute Community Cancer Centers Program, Spartanburg Regional Healthcare System, Gibbs Cancer Center, Spartanburg, SC, United States Arnold School of Public Health, Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, United States AU - Friedman, D. B. AU - Johnson, K. M. AU - Owens, O. L. AU - Thomas, T. L. AU - Dawkins, D. S. AU - Gansauer, L. AU - Bartelt, S. AU - Waddell, N. M. AU - Talley, P. J. AU - Bearden Iii, J. D. AU - Hébert, J. R. DB - Scopus DO - 10.1007/s13187-012-0353-0 IS - 2 KW - African-American men and women Cancer communication Community-based participatory research Multi-media Recruitment Research partnerships M3 - Article N1 - Cited By :28 Export Date: 22 March 2021 PY - 2012 SP - 243-249 ST - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: Lessons learned from a community-academic-clinical team T2 - Journal of Cancer Education TI - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: Lessons learned from a community-academic-clinical team UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864064191&doi=10.1007%2fs13187-012-0353-0&partnerID=40&md5=b2eedd49f6f49bcab6a371a75bce29af VL - 27 ID - 2456 ER - TY - JOUR AB - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is ~50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey’s framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Friedman, Daniela B., Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, 800 Sumter Street, room 220B, Columbia, SC, US, 29208 AN - 2014-36563-008 AU - Friedman, Daniela B. AU - Johnson, Kim M. AU - Owens, Otis L. AU - Thomas, Tracey L. AU - Dawkins, DeLisa S. AU - Gansauer, Lucy AU - Bartelt, Sharon AU - Waddell, Nancy M. AU - Talley, Pastor J. AU - Bearden, James D., III AU - Hébert, James R. DB - psyh DO - 10.1007/s13187-012-0353-0 DP - EBSCOhost IS - 2 KW - African-American men and women Community-based participatory research Research partnerships Recruitment Cancer communication Multi-media Academic Medical Centers African Americans Decision Making Female Focus Groups Health Education Health Knowledge, Attitudes, Practice Humans Male Middle Aged Patient Selection Pilot Projects Prostatic Neoplasms Residence Characteristics South Carolina Cancer Screening Experimentation Neoplasms Prostate Blacks Participation N1 - Arnold School of Public Health, Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Hébert, James R. Major Descriptor: Cancer Screening; Experimentation; Health Education; Neoplasms; Prostate. Minor Descriptor: Blacks; Decision Making; Participation. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). References Available: Y. Page Count: 7. Issue Publication Date: Jun, 2012. Publication History: First Posted Date: Apr 12, 2012. Copyright Statement: Springer Science+Business Media, LLC. 2012. Sponsor: National Cancer Institute, Community Networks Program Centers. Grant: U54 CA153461-01. Other Details: Project Leader: Daniela B. Friedman. Recipients: Hébert, James R. (Prin Inv) Sponsor: National Cancer Institute, Cancer Training Branch. Grant: K05 CA136975. Other Details: Established Investigator Award in Cancer Prevention and Control. Recipients: Hébert, James R. PY - 2012 SN - 0885-8195 1543-0154 SP - 243-249 ST - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: Lessons learned from a Community-Academic-Clinical team T2 - Journal of Cancer Education TI - Developing partnerships and recruiting dyads for a prostate cancer informed decision making program: Lessons learned from a Community-Academic-Clinical team UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-36563-008&site=ehost-live&scope=site dbfriedman@sc.du VL - 27 ID - 1734 ER - TY - JOUR AB - Prostate cancer (PrCA) is the most commonly diagnosed non-skin cancer among men. PrCA mortality in African-American (AA) men in South Carolina is similar to 50% higher than for AAs in the U.S as a whole. AA men also have low rates of participation in cancer research. This paper describes partnership development and recruitment efforts of a Community-Academic-Clinical research team for a PrCA education intervention with AA men and women that was designed to address the discordance between high rates of PrCA mortality and limited participation in cancer research. Guided by Vesey's framework on recruitment and retention of minority groups in research, recruitment strategies were selected and implemented following multiple brainstorming sessions with partners having established community relationships. Based on findings from these sessions culturally appropriate strategies are recommended for recruiting AA men and women for PrCA education research. Community-based research recruitment challenges and lessons learned are presented. AN - WOS:000304144500006 AU - Friedman, D. B. AU - Johnson, K. M. AU - Owens, O. L. AU - Thomas, T. L. AU - Dawkins, D. S. AU - Gansauer, L. AU - Bartelt, S. AU - Waddell, N. M. AU - Talley, P. J. AU - Bearden, J. D. AU - Hebert, J. R. DA - Jun DO - 10.1007/s13187-012-0353-0 IS - 2 N1 - 22528633 PY - 2012 SN - 0885-8195 SP - 243-249 ST - Developing Partnerships and Recruiting Dyads for a Prostate Cancer Informed Decision Making Program: Lessons Learned From a Community-Academic-Clinical Team T2 - Journal of Cancer Education TI - Developing Partnerships and Recruiting Dyads for a Prostate Cancer Informed Decision Making Program: Lessons Learned From a Community-Academic-Clinical Team VL - 27 ID - 3067 ER - TY - JOUR AB - Racial disparities have been found in the use of chemotherapy as cancer treatment. These disparities may be, in part, due to well-documented differences in the quality of communication during clinical interactions with oncologists and Black versus White patients. In this study using a community-based participatory research approach, academic researchers, community members, and oncologists formed a partnership to develop a communication intervention to address racial disparities in cancer care. Partners developed a question prompt list (QPL), a simple tool that can be used to improve communication, and thus treatment, during clinical interactions in which oncologists and Black patients discuss chemotherapy. Partners endorsed the use of a QPL, provided specific suggestions for content and format, conducted and analyzed qualitative interviews with Black patients receiving chemotherapy, and approved the final version. The feasibility and effectiveness of the QPL that resulted from this research process are currently under evaluation in a separate study. AD - S. Eggly, Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, MM03CB, Detroit, 48201, MI, USA. AU - Eggly, S. AU - Tkatch, R. AU - Penner, L. A. AU - Mabunda, L. AU - Hudson, J. AU - Chapman, R. AU - Griggs, J. J. AU - Brown, R. AU - Albrecht, T. DB - Medline IS - 2 KW - adjuvant chemotherapy adjuvant therapy adult African American aged article breast tumor colon tumor doctor patient relationship ethnology female health care disparity human interpersonal communication male middle aged neoplasm participatory research patient education patient participation patient satisfaction psychologic test psychological aspect questionnaire rectum tumor LA - English M3 - Article N1 - L563014597 2014-01-13 PY - 2013 SN - 1543-0154 SP - 282-289 ST - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563014597&from=export VL - 28 ID - 1081 ER - TY - JOUR AB - Racial disparities have been found in the use of chemotherapy as cancer treatment. These disparities may be, in part, due to well-documented differences in the quality of communication during clinical interactions with oncologists and Black versus White patients. In this study using a community-based participatory research approach, academic researchers, community members, and oncologists formed a partnership to develop a communication intervention to address racial disparities in cancer care. Partners developed a question prompt list (QPL), a simple tool that can be used to improve communication, and thus treatment, during clinical interactions in which oncologists and Black patients discuss chemotherapy. Partners endorsed the use of a QPL, provided specific suggestions for content and format, conducted and analyzed qualitative interviews with Black patients receiving chemotherapy, and approved the final version. The feasibility and effectiveness of the QPL that resulted from this research process are currently under evaluation in a separate study. AU - Eggly, S. AU - Tkatch, R. AU - Penner, L. A. AU - Mabunda, L. AU - Hudson, J. AU - Chapman, R. AU - Griggs, J. J. AU - Brown, R. AU - Albrecht, T. DB - Medline DO - 10.1007/s13187-013-0456-2 IS - 2 KW - adjuvant chemotherapy adjuvant therapy adult African American aged breast tumor colon tumor doctor patient relationship ethnology female health care disparity human interpersonal communication male middle aged neoplasm participatory research patient education patient participation patient satisfaction psychologic test psychology questionnaire rectum tumor LA - English M3 - Article N1 - L603060369 2015-03-23 PY - 2013 SN - 1543-0154 SP - 282-289 ST - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603060369&from=export http://dx.doi.org/10.1007/s13187-013-0456-2 VL - 28 ID - 1082 ER - TY - JOUR AB - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating in a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-item WHSR scale had a Cronbach α of. 94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women. Copyright © 2009 Lippincott Williams & Wilkins. AD - A. M. Wagle, Department of Veterans Affairs, Illiana Health Care System, 1900 East Main St, Danville, IL 61832, United States AU - Wagle, A. M. AU - Champion, V. L. AU - Russell, K. M. AU - Rawl, S. M. DB - Embase Medline DO - 10.1097/NCC.0b013e3181aaf0dd IS - 5 KW - African American article breast cancer cancer mortality cancer screening female health belief human mammography priority journal psychometry religion self concept LA - English M3 - Article N1 - L355269832 2009-10-20 PY - 2009 SN - 0162-220X SP - 418-425 ST - Development of wagle health-specific religiousness scale T2 - Cancer Nursing TI - Development of wagle health-specific religiousness scale UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355269832&from=export http://dx.doi.org/10.1097/NCC.0b013e3181aaf0dd VL - 32 ID - 1180 ER - TY - JOUR AB - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating in a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-item WHSR scale had a Cronbach α of .94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Wagle, Ann M., Department of Veterans Affairs, Illiana Health Care System, 1900 East Main St, Danville, IL, US, 61832 AN - 2009-16332-006 AU - Wagle, Ann M. AU - Champion, Victoria L. AU - Russell, Kathleen M. AU - Rawl, Susan M. DB - psyh DO - 10.1097/NCC.0b013e3181aaf0dd DP - EBSCOhost IS - 5 KW - Wagle Health-Specific Religiousness Scale mammography screening breast cancer African American women Adult African Americans Aged Breast Neoplasms Female Health Knowledge, Attitudes, Practice Humans Linear Models Mammography Mass Screening Middle Aged Patient Acceptance of Health Care Poverty Program Development Psychometrics Religion Reproducibility of Results Socioeconomic Factors United States Health Religiosity Blacks Human Females N1 - Department of Veterans Affairs, Illiana Health Care System, Danville, IL, US. Release Date: 20091214. Correction Date: 20160114. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Health; Mammography; Psychometrics; Religiosity. Minor Descriptor: Blacks; Human Females. Classification: Health Psychology Testing (2226); Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Wagle Health-Specific Religiousness Scale DOI: 10.1037/t45258-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Sep-Oct, 2009. Publication History: Accepted Date: Apr 19, 2009. Copyright Statement: Wolters Kluwer Health. 2009. PY - 2009 SN - 0162-220X 1538-9804 SP - 418-425 ST - Development of Wagle Health-Specific Religiousness Scale T2 - Cancer Nursing TI - Development of Wagle Health-Specific Religiousness Scale UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-16332-006&site=ehost-live&scope=site ann.wagle@va.gov VL - 32 ID - 1776 ER - TY - JOUR AB - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating in a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-item WHSR scale had a Cronbach alpha of. 94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women. AD - Department of Veterans Affairs, Illiana Health Care System, 1900 East Main St, Danville, IL 61832, USA. ann.wagle@va.gov AN - 105434061. Language: English. Entry Date: 20091030. Revision Date: 20150820. Publication Type: Journal Article AU - Wagle, A. M. AU - Champion, V. L. AU - Russell, K. M. AU - Rawl, S. M. DB - CINAHL Complete DO - 10.1097/NCC.0b013e3181aaf0dd DP - EBSCOhost IS - 5 KW - Black Persons -- Midwestern United States Breast Neoplasms -- Prevention and Control Health Beliefs Instrument Construction Instrument Validation Mammography Religion and Religions Adult Aged Clinical Trials Coefficient Alpha Conceptual Framework Construct Validity Factor Analysis Female Linear Regression Logistic Regression Middle Age Midwestern United States Poverty Scales Secondary Analysis Self-Efficacy -- Evaluation Summated Rating Scaling Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Wagle Health-Specific Religiousness (WHSR) scale. NLM UID: 7805358. PMID: NLM19661792. PY - 2009 SN - 0162-220X SP - 418-425 ST - Development of Wagle Health-Specific Religiousness scale T2 - Cancer Nursing TI - Development of Wagle Health-Specific Religiousness scale UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105434061&site=ehost-live&scope=site VL - 32 ID - 1910 ER - TY - JOUR AB - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating in a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-item WHSR scale had a Cronbach α of. 94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women. Copyright © 2009 Lippincott Williams & Wilkins. AD - Department of Veterans Affairs, Illiana Health Care System, 1900 East Main St, Danville, IL 61832, United States Center for Nursing Research, Indiana University, School of Nursing, Indianapolis, United States Department of Environments for Health, Indiana University, School of Nursing, Indianapolis, United States Department of Adult Health, Indiana University, School of Nursing, Indianapolis, United States AU - Wagle, A. M. AU - Champion, V. L. AU - Russell, K. M. AU - Rawl, S. M. DB - Scopus DO - 10.1097/NCC.0b013e3181aaf0dd IS - 5 KW - African American women Health beliefs Health-specific religiousness Mammography screening M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2009 SP - 418-425 ST - Development of wagle health-specific religiousness scale T2 - Cancer Nursing TI - Development of wagle health-specific religiousness scale UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349159589&doi=10.1097%2fNCC.0b013e3181aaf0dd&partnerID=40&md5=dc4745e3570f6baf69247694b8bc08cf VL - 32 ID - 2513 ER - TY - JOUR AB - African American women have a lower rate of regular mammography screening, resulting in higher incidence of advanced-stage breast cancer at diagnosis and a lower 5-year survival rate as compared with white women. Researchers have demonstrated that several health beliefs relate to mammography screening in African American women, but little attention has been paid to the importance of religiousness. Although some authors have attempted to determine a link between religiousness and health, we lack a valid and reliable instrument to measure religiousness that can be found in the context of health behaviors. The purpose of this article is to describe the development and psychometric testing of the Wagle Health-Specific Religiousness (WHSR) scale, an instrument used to measure religious beliefs and the influence of those beliefs on mammography screening for African American women. A sample of 344 low-income African American women who were nonadherent to mammography at accrual participating In a randomized trial completed the WHSR. Data from this trial were used to determine the validity and reliability of the WHSR. The 19-Item WHSR scale had a Cronbach alpha of .94. Construct validity was supported via factor analysis and analysis of theoretical relationships. Although further testing is warranted, this analysis indicates that the concept of religiousness is an important component of mammography behavior in African American women. AN - WOS:000270060500012 AU - Wagle, A. M. AU - Champion, V. L. AU - Russell, K. M. AU - Rawl, S. M. DA - Sep-Oct DO - 10.1097/NCC.0b013e3181aaf0dd IS - 5 N1 - 19661792 PY - 2009 SN - 0162-220X SP - 418-425 ST - Development of Wagle Health-Specific Religiousness Scale T2 - Cancer Nursing TI - Development of Wagle Health-Specific Religiousness Scale VL - 32 ID - 3141 ER - TY - JOUR AB - Purpose Cancer of the prostate (CaP) is the leading cancer among men in sub-Saharan Africa (SSA). A substantial proportion of these men with CaP are diagnosed at late (usually incurable) stages, yet little is known about the etiology of CaP in SSA. Methods We established the Men of African Descent and Carcinoma of the Prostate Network, which includes seven SSA centers partnering with five US centers to study the genetics and epidemiology of CaP in SSA. We developed common data elements and instruments, regulatory infrastructure, and biosample collection, processing, and shipping protocols. We tested this infrastructure by collecting epidemiologic, medical record, and genomic data from a total of 311 patients with CaP and 218 matched controls recruited at the seven SSA centers. We extracted genomic DNA from whole blood, buffy coat, or buccal swabs from 265 participants and shipped it to the Center for Inherited Disease Research (Baltimore, MD) and the Centre for Proteomics and Genomics Research (Cape Town, South Africa), where genotypes were generated using the UK Biobank Axiom Array. Results We used common instruments for data collection and entered data into the shared database. Double-entered data from pilot participants showed a 95% to 98% concordance rate, suggesting that data can be collected, entered, and stored with a high degree of accuracy. Genotypes were obtained from 95% of tested DNA samples (100% from blood-derived DNA samples) with high concordance across laboratories. Conclusion We provide approaches that can produce high-quality epidemiologic and genomic data in multicenter studies of cancer in SSA. © 2018 by American Society of Clinical Oncology AD - Dana-Farber Cancer Institute, 1101 Dana, 450 Brookline Ave, Boston, MA 02215, United States Beth Israel Deaconess Medical Center, Iraq Harvard T.H. Chan School of Public Health, Boston, MA, United States Centre for Proteomic and Genomic Research, Iraq Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa National Cancer Registry, National Health Laboratory Service, Iraq University of Witwatersrand, Johannesburg, South Africa Center for Inherited Disease Research, Baltimore, United States National Cancer Institute, National Institutes of Health, Bethesda, MD, United States Bart's Health National Health Services Trust, London, United Kingdom Military Hospital, Iraq Korle-Bu Teaching Hospital, Accra, Ghana, Ghana Albert Einstein College of Medicine, Bronx, United States Columbia University, New York, NY, United States Georgia Institute of Technology, Atlanta, GA, United States Stanford University, Stanford Cancer Institute, Stanford, CA, United States Hôpital Général de Grand Yoff, Institute de Formation et de la Recherche en Urologie et de la Santé de la Famillie, Iraq Ndeye Coumba Toure-Kane, Hôpital Aristide Le Dantec, Dakar, Senegal Institute of Human Virology, H3 African Biorepository Initiative, Iraq University of Abuja, Iraq University of Abuja Teaching Hospital, Abuja, Nigeria Federal Medical Center, Keffi, Nigeria University College Hospital, Ibadan, Nigeria AU - Andrews, C. AU - Fortier, B. AU - Hayward, A. AU - Lederman, R. AU - Petersen, L. AU - McBride, J. AU - Petersen, D. C. AU - Ajayi, O. AU - Kachambwa, P. AU - Seutloali, M. AU - Shoko, A. AU - Mokhosi, M. AU - Hiller, R. AU - Adams, M. AU - Ongaco, C. AU - Pugh, E. AU - Romm, J. AU - Shelford, T. AU - Chinegwundoh, F. AU - Adusei, B. AU - Mante, S. AU - Snyper, N. Y. AU - Agalliu, I. AU - Lounsbury, D. W. AU - Rohan, T. AU - Orfanos, A. AU - Quintana, Y. AU - Jacobson, J. S. AU - Neugut, A. I. AU - Gelmann, E. AU - Lachance, J. AU - Dial, C. AU - Diallo, T. A. AU - Jalloh, M. AU - Gueye, S. M. AU - Kane, P. M. S. AU - Diop, H. AU - Ndiaye, A. J. AU - Sall, A. S. AU - Toure-Kane, N. C. AU - Onyemata, E. AU - Abimiku, A. AU - Adjei, A. A. AU - Biritwum, R. AU - Gyasi, R. AU - Kyei, M. AU - Mensah, J. E. AU - Okine, J. AU - Okyne, V. AU - Rockson, I. AU - Tay, E. AU - Tettey, Y. AU - Yeboah, E. AU - Chen, W. C. AU - Singh, E. AU - Cook, M. B. AU - Duffy, C. N. AU - Hsing, A. AU - Soo, C. C. AU - Fernandez, P. AU - Irusen, H. AU - Aisuodionoe-Shadrach, O. AU - Jamda, A. M. AU - Olabode, P. O. AU - Nwegbu, M. M. AU - Ajibola, O. H. AU - Ajamu, O. J. AU - Ambuwa, Y. G. AU - Adebiyi, A. O. AU - Asuzu, M. AU - Ogunbiyi, O. AU - Popoola, O. AU - Shittu, O. AU - Amodu, O. AU - Odiaka, E. AU - Makinde, I. AU - Joffe, M. AU - Pentz, A. AU - Rebbeck, T. R. DB - Scopus DO - 10.1200/JGO.18.00063 IS - 4 M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2018 ST - Development, evaluation, and implementation of a pan-African cancer research network: Men of African descent and carcinoma of the prostate T2 - Journal of Global Oncology TI - Development, evaluation, and implementation of a pan-African cancer research network: Men of African descent and carcinoma of the prostate UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060561295&doi=10.1200%2fJGO.18.00063&partnerID=40&md5=dc0aeebd82ac372346585c210bdd90fb VL - 2018 ID - 2281 ER - TY - JOUR AB - BACKGROUND: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown. OBJECTIVES: To assess whether comorbidities modify estimated dementia risk based on SMCs. DESIGN: The Prevention of Alzheimer's Disease with Vitamin E and Selenium Study (PREADVISE) was designed as an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized, multi‐center prostate cancer prevention trial with sites in the Unites States, Puerto Rico, and Canada. In 2009, PREADVISE and SELECT were changed into cohort studies. SETTING: Secondary analysis of PREADVISE data. PARTICIPANTS: PREADVISE recruited 7,540 non‐demented male volunteers from participating SELECT sites from 2002 to 2009. SMCs, demographics, and comorbidities including hypertension, diabetes, coronary artery bypass graft (CABG), stroke, sleep apnea, and head injury were ascertained by participant interview. MEASUREMENTS: Cox models were used to investigate whether baseline comorbidities modified hazard ratios (HR) for SMC‐associated dementia risk using two methods: (1) we included one interaction term between SMC and a comorbidity in the model at a time, and (2) we included all two‐way interactions between SMC and covariates of interest and reduced the model by "backward" selection. SMC was operationalized as any complaint vs. no complaint. RESULTS: Baseline SMCs were common (23.6%). In the first analyses, with the exception of stroke, presence of self‐reported comorbidities was associated with lower estimated HR for dementia based on SMC status (complaint vs. no complaint), but this difference was only significant for diabetes. In the second analysis, the two‐way interactions between SMC and race as well as SMC and diabetes were significant. Here, black men without diabetes who reported SMC had the highest estimated dementia risk (HR=5.05, 95% CI 2.55‐10.00), while non‐black men with diabetes who reported SMC had the lowest estimated risk (HR=0.71, 95% CI 0.35‐1.41). CONCLUSIONS: SMCs were more common among men with comorbidities, but these complaints appeared to be less predictive of dementia risk than those originating from men without comorbidities, suggesting that medical conditions such as diabetes may explain SMCs that are unrelated to an underlying neurodegenerative process. AN - CN-01415886 AU - Zhang, X. AU - Schmitt, F. A. AU - Caban-Holt, A. M. AU - Ding, X. AU - Kryscio, R. J. AU - Abner, E. DO - 10.14283/jpad.2017.7 IS - 3 M3 - Journal Article PY - 2017 SP - 143‐148 ST - Diabetes mitigates the role of memory complaint in predicting dementia risk: results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study T2 - The journal of prevention of alzheimer's disease TI - Diabetes mitigates the role of memory complaint in predicting dementia risk: results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01415886/full VL - 4 ID - 1634 ER - TY - JOUR AB - BACKGROUND: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown. OBJECTIVES: To assess whether comorbidities modify estimated dementia risk based on SMCs. DESIGN: The Prevention of Alzheimer's Disease with Vitamin E and Selenium Study (PREADVISE) was designed as an ancillary study to the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a randomized, multi-center prostate cancer prevention trial with sites in the Unites States, Puerto Rico, and Canada. In 2009, PREADVISE and SELECT were changed into cohort studies. SETTING: Secondary analysis of PREADVISE data. PARTICIPANTS: PREADVISE recruited 7,540 non-demented male volunteers from participating SELECT sites from 2002 to 2009. SMCs, demographics, and comorbidities including hypertension, diabetes, coronary artery bypass graft (CABG), stroke, sleep apnea, and head injury were ascertained by participant interview. MEASUREMENTS: Cox models were used to investigate whether baseline comorbidities modified hazard ratios (HR) for SMC-associated dementia risk using two methods: (1) we included one interaction term between SMC and a comorbidity in the model at a time, and (2) we included all two-way interactions between SMC and covariates of interest and reduced the model by "backward" selection. SMC was operationalized as any complaint vs. no complaint. RESULTS: Baseline SMCs were common (23.6%). In the first analyses, with the exception of stroke, presence of self-reported comorbidities was associated with lower estimated HR for dementia based on SMC status (complaint vs. no complaint), but this difference was only significant for diabetes. In the second analysis, the two-way interactions between SMC and race as well as SMC and diabetes were significant. Here, black men without diabetes who reported SMC had the highest estimated dementia risk (HR=5.05, 95% CI 2.55-10.00), while non-black men with diabetes who reported SMC had the lowest estimated risk (HR=0.71, 95% CI 0.35-1.41). CONCLUSIONS: SMCs were more common among men with comorbidities, but these complaints appeared to be less predictive of dementia risk than those originating from men without comorbidities, suggesting that medical conditions such as diabetes may explain SMCs that are unrelated to an underlying neurodegenerative process. AN - WOS:000461783000005 AU - Zhang, X. AU - Schmitt, F. A. AU - Caban-Holt, A. M. AU - Ding, X. AU - Kryscio, R. J. AU - Abner, E. DO - 10.14283/jpad.2017.7 IS - 3 N1 - 28944218 PY - 2017 SN - 2274-5807 SP - 143-148 ST - Diabetes Mitigates the Role of Memory Complaint in Predicting Dementia Risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study T2 - Jpad-Journal of Prevention of Alzheimers Disease TI - Diabetes Mitigates the Role of Memory Complaint in Predicting Dementia Risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study VL - 4 ID - 2921 ER - TY - JOUR AB - The Gail model is used to predict the risk of breast cancer in women of diverse race/ethnic groups for clinical trial protocols. However, this model has only been validated in US white women. Using a nested case-control study design, we evaluated the diagnostic accuracy of the original Gail model (GM) and that of the revised Gail model algorithm for blacks/African-Americans (GM-B) in the Black Women's Health Study (BWHS). Risk profiles were derived via a self reported questionnaire at the time of enrollment into the BWHS in 1995. Biennial questionnaires were obtained from the participants to determine the incident cases of breast cancer. The study of 725 breast cancer cases and 725 controls revealed that the 5-year risk of breast cancer based on the GM ranged from 0.2% to 15.4% among cases and 0.2% to 13.6% among the controls. Based on the GM-B, the 5-year risk of breast cancer ranged from 0.2% to 8.7% among cases and 0.2% to 7.2% among the controls. The sensitivities of the GM and GM-B model with the standard cutoff of 1.7% were 17.9% (95% CI: 15.9-19.9%) and 4.1% (95% CI: 3.0-5.2), respectively. Both the original and the modified version of the Gail model underestimate the risk of developing breast cancer in African-American women. More importantly, the modified Gail Model (GM-B) does a worse job at predicting the development of breast cancer for blacks than the original model (GM). © 2007 Copyright the Authors. AD - L.L. Adams-Campbell, Howard University Cancer Center, 2041 Georgia Avenue, N.W., Washington, DC 20060, United States AU - Adams-Campbell, L. L. AU - Makambi, K. H. AU - Palmer, J. R. AU - Rosenberg, L. DB - Embase Medline DO - 10.1111/j.1524-4741.2007.00439.x IS - 4 KW - adult African American algorithm article breast cancer cancer incidence cancer risk controlled study diagnostic accuracy female human major clinical study mathematical model Black person questionnaire self report sensitivity and specificity women's health LA - English M3 - Article N1 - L46985558 2007-07-01 PY - 2007 SN - 1075-122X 1524-4741 SP - 332-336 ST - Diagnostic accuracy of the gail model in the black women's health study T2 - Breast Journal TI - Diagnostic accuracy of the gail model in the black women's health study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46985558&from=export http://dx.doi.org/10.1111/j.1524-4741.2007.00439.x VL - 13 ID - 1227 ER - TY - JOUR AB - The Gail model is used to predict the risk of breast cancer in women of diverse race/ethnic groups for clinical trial protocols. However, this model has only been validated in US white women. Using a nested case-control study design, we evaluated the diagnostic accuracy of the original Gail model (GM) and that of the revised Gail model algorithm for blacks/African-Americans (GM-B) in the Black Women's Health Study (BWHS). Risk profiles were derived via a self reported questionnaire at the time of enrollment into the BWHS in 1995. Biennial questionnaires were obtained from the participants to determine the incident cases of breast cancer. The study of 725 breast cancer cases and 725 controls revealed that the 5-year risk of breast cancer based on the GM ranged from 0.2% to 15.4% among cases and 0.2% to 13.6% among the controls. Based on the GM-B, the 5-year risk of breast cancer ranged from 0.2% to 8.7% among cases and 0.2% to 7.2% among the controls. The sensitivities of the GM and GM-B model with the standard cutoff of 1.7% were 17.9% (95% CI: 15.9-19.9%) and 4.1% (95% CI: 3.0-5.2), respectively. Both the original and the modified version of the Gail model underestimate the risk of developing breast cancer in African-American women. More importantly, the modified Gail Model (GM-B) does a worse job at predicting the development of breast cancer for blacks than the original model (GM). AN - 106007987. Language: English. Entry Date: 20080229. Revision Date: 20200623. Publication Type: Journal Article AU - Adams-Campbell, L. L. AU - Makambi, K. H. AU - Palmer, J. R. AU - Rosenberg, L. DB - CINAHL Complete DO - 10.1111/j.1524-4741.2007.00439.x DP - EBSCOhost IS - 4 KW - Black Persons Breast Neoplasms -- Etiology Models, Statistical Risk Assessment -- Methods Women's Health Adult Aged Algorithms Breast Neoplasms Case Control Studies Female Maternal Age Middle Age Postmenopause Predictive Value of Tests Premenopause Risk Assessment -- Standards ROC Curve Human N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Peer Reviewed; USA. NLM UID: 9505539. PMID: NLM17593036. PY - 2007 SN - 1075-122X SP - 332-336 ST - Diagnostic accuracy of the Gail model in the Black Women's Health Study T2 - Breast Journal TI - Diagnostic accuracy of the Gail model in the Black Women's Health Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106007987&site=ehost-live&scope=site VL - 13 ID - 1911 ER - TY - JOUR AB - The Gail model is used to predict the risk of breast cancer in women of diverse race/ethnic groups for clinical trial protocols. However, this model has only been validated in US white women. Using a nested case-control study design, we evaluated the diagnostic accuracy of the original Gail model (GM) and that of the revised Gail model algorithm for blacks/African-Americans (GM-B) in the Black Women's Health Study (BWHS). Risk profiles were derived via a self reported questionnaire at the time of enrollment into the BWHS in 1995. Biennial questionnaires were obtained from the participants to determine the incident cases of breast cancer. The study of 725 breast cancer cases and 725 controls revealed that the 5-year risk of breast cancer based on the GM ranged from 0.2% to 15.4% among cases and 0.2% to 13.6% among the controls. Based on the GM-B, the 5-year risk of breast cancer ranged from 0.2% to 8.7% among cases and 0.2% to 7.2% among the controls. The sensitivities of the GM and GM-B model with the standard cutoff of 1.7% were 17.9% (95% CI: 15.9-19.9%) and 4.1% (95% CI: 3.0-5.2), respectively. Both the original and the modified version of the Gail model underestimate the risk of developing breast cancer in African-American women. More importantly, the modified Gail Model (GM-B) does a worse job at predicting the development of breast cancer for blacks than the original model (GM). © 2007 Copyright the Authors. AD - Howard University Cancer Center, Washington, DC, United States Slone Epidemiology Center, Boston University, Boston, MA, United States Howard University Cancer Center, 2041 Georgia Avenue, N.W., Washington, DC 20060, United States AU - Adams-Campbell, L. L. AU - Makambi, K. H. AU - Palmer, J. R. AU - Rosenberg, L. DB - Scopus DO - 10.1111/j.1524-4741.2007.00439.x IS - 4 KW - Blacks Breast cancer Gail model Sensitivity M3 - Article N1 - Cited By :24 Export Date: 22 March 2021 PY - 2007 SP - 332-336 ST - Diagnostic accuracy of the gail model in the black women's health study T2 - Breast Journal TI - Diagnostic accuracy of the gail model in the black women's health study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34250802025&doi=10.1111%2fj.1524-4741.2007.00439.x&partnerID=40&md5=4d4cf1d49a55c0d6f43de2459cf6dc88 VL - 13 ID - 2557 ER - TY - JOUR AB - The Gail model is used to predict the risk of breast cancer in women of diverse race/ethnic groups for clinical trial protocols. However, this model has only been validated in US white women. Using a nested case-control study design, we evaluated the diagnostic accuracy of the original Gail model (GM) and that of the revised Gail model algorithm for blacks/African-Americans (GM-B) in the Black Women's Health Study (BWHS). Risk profiles were derived via a self reported questionnaire at the time of enrollment into the BWHS in 1995. Biennial questionnaires were obtained from the participants to determine the incident cases of breast cancer. The study of 725 breast cancer cases and 725 controls revealed that the 5-year risk of breast cancer based on the GM ranged from 0.2% to 15.4% among cases and 0.2% to 13.6% among the controls. Based on the GM-B, the 5-year risk of breast cancer ranged from 0.2% to 8.7% among cases and 0.2% to 7.2% among the controls. The sensitivities of the GM and GM-B model with the standard cutoff of 1.7% were 17.9% (95% CI: 15.9-19.9%) and 4.1% (95% CI: 3.0-5.2), respectively. Both the original and the modified version of the Gail model underestimate the risk of developing breast cancer in African-American women. More importantly, the modified Gail Model (GM-B) does a worse job at predicting the development of breast cancer for blacks than the original model (GM). AN - WOS:000247478100002 AU - Adams-Campbell, L. L. AU - Makambi, K. H. AU - Palmer, J. R. AU - Rosenberg, L. DA - Jul-Aug DO - 10.1111/j.1524-4741.2007.00439.x IS - 4 N1 - 17593036 PY - 2007 SN - 1075-122X SP - 332-336 ST - Diagnostic accuracy of the Gail model in the Black Women's Health Study T2 - Breast Journal TI - Diagnostic accuracy of the Gail model in the Black Women's Health Study VL - 13 ID - 3191 ER - TY - JOUR AB - Objectives. To examine whether a diet low in fat and high in fiber, fruits, and vegetables and ethnicity had any influence on serum prostate-specific antigen (PSA) levels, because serum PSA is a marker for the presence of prostate cancer. The incidence of prostate cancer increases with age, varies by ethnicity, and is greater among men with a first-degree relative who has had the disease. Large international variations in the rates of prostate cancer incidence and mortality, as well as the incidence changes in migrants and their offspring, also suggest that exogenous factors, including diet, have a strong influence on the development of this disease. Methods. We used data and blood samples from the Polyp Prevention Trial, a multicenter randomized trial designed to evaluate the impact of a diet low in fat and high in fiber, fruits, and vegetables on the recurrence of colorectal adenomas. Recruitment was from 1991 through 1994. Participants were followed up from their baseline recruitment date for 4 years. From this group, we identified 1100 white men and 97 black men who were 35 years of age or older, did not have prostate cancer, and had serum samples available for study. Results. At baseline, no difference was present in the fat intake for the black and white men (mean ± SE, 90 ± 3.6 g/day and 84 ± 1.0 g/day, respectively; P = 0.15). The baseline serum PSA levels did not vary by ethnicity. For black men, the mean serum PSA level was 2.2 ± 0.36 ng/mL compared with 2.0 ± 0.07 ng/mL for white men (P = 0.64). Although all men assigned to the intervention group markedly reduced their fat intake by approximately 15% and increased their fruit and vegetable intake by approximately 2.25 servings per day, no difference was noted in the kinetics of the serum PSA levels by dietary intervention or race. Conclusions. Although ethnic differences in the incidence of prostate cancer are well defined, we found no difference in the baseline fat intake among black and white men that might have contributed to this difference. Serum PSA, a marker often used in early detection programs for prostate cancer, was not associated with manipulation of the amount of fat in the diet, regardless of ethnicity. © 2003 Elsevier Inc. AD - J.A. Eastham, Department of Urology, Mem. Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10021, United States AU - Eastham, J. A. AU - Riedel, E. AU - Latkany, L. AU - Fleisher, M. AU - Schatzkin, A. AU - Lanza, E. AU - Shike, M. DB - Embase Medline DO - 10.1016/S0090-4295(03)00576-4 IS - 4 KW - prostate specific antigen adult article blood level cancer incidence Caucasian clinical trial comparative study diet ethnic difference ethnology evaluation study fat intake fruit high fiber diet human low fat diet male mortality Black person priority journal prostate cancer race difference vegetable vegetarian diet LA - English M3 - Article N1 - L37205004 2003-10-13 PY - 2003 SN - 0090-4295 SP - 677-682 ST - Dietary manipulation, ethnicity, and serum PSA levels T2 - Urology TI - Dietary manipulation, ethnicity, and serum PSA levels UR - https://www.embase.com/search/results?subaction=viewrecord&id=L37205004&from=export http://dx.doi.org/10.1016/S0090-4295(03)00576-4 VL - 62 ID - 1286 ER - TY - JOUR AB - OBJECTIVES: To examine whether a diet low in fat and high in fiber, fruits, and vegetables and ethnicity had any influence on serum prostate‐specific antigen (PSA) levels, because serum PSA is a marker for the presence of prostate cancer. The incidence of prostate cancer increases with age, varies by ethnicity, and is greater among men with a first‐degree relative who has had the disease. Large international variations in the rates of prostate cancer incidence and mortality, as well as the incidence changes in migrants and their offspring, also suggest that exogenous factors, including diet, have a strong influence on the development of this disease. METHODS: We used data and blood samples from the Polyp Prevention Trial, a multicenter randomized trial designed to evaluate the impact of a diet low in fat and high in fiber, fruits, and vegetables on the recurrence of colorectal adenomas. Recruitment was from 1991 through 1994. Participants were followed up from their baseline recruitment date for 4 years. From this group, we identified 1100 white men and 97 black men who were 35 years of age or older, did not have prostate cancer, and had serum samples available for study. RESULTS: At baseline, no difference was present in the fat intake for the black and white men (mean +/‐ SE, 90 +/‐ 3.6 g/day and 84 +/‐ 1.0 g/day, respectively; P = 0.15). The baseline serum PSA levels did not vary by ethnicity. For black men, the mean serum PSA level was 2.2 +/‐ 0.36 ng/mL compared with 2.0 +/‐ 0.07 ng/mL for white men (P = 0.64). Although all men assigned to the intervention group markedly reduced their fat intake by approximately 15% and increased their fruit and vegetable intake by approximately 2.25 servings per day, no difference was noted in the kinetics of the serum PSA levels by dietary intervention or race. CONCLUSIONS: Although ethnic differences in the incidence of prostate cancer are well defined, we found no difference in the baseline fat intake among black and white men that might have contributed to this difference. Serum PSA, a marker often used in early detection programs for prostate cancer, was not associated with manipulation of the amount of fat in the diet, regardless of ethnicity. AN - CN-00450555 AU - Eastham, J. A. AU - Riedel, E. AU - Latkany, L. AU - Fleisher, M. AU - Schatzkin, A. AU - Lanza, E. AU - Shike, M. DO - 10.1016/s0090-4295(03)00576-4 IS - 4 KW - Adult African Continental Ancestry Group Aged Biomarkers, Tumor [blood] Cohort Studies Diet, Fat‐Restricted Dietary Fats [adverse effects] Dietary Fiber [administration & dosage] Ethnic Groups European Continental Ancestry Group Feeding Behavior Follow‐Up Studies Fruit Humans Male Middle Aged Prostate‐Specific Antigen [*blood] Prostatic Neoplasms [blood, *epidemiology, prevention & control] United States [epidemiology] Vegetables M3 - Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial PY - 2003 SP - 677‐682 ST - Dietary manipulation, ethnicity, and serum PSA levels T2 - Urology TI - Dietary manipulation, ethnicity, and serum PSA levels UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00450555/full VL - 62 ID - 1428 ER - TY - JOUR AB - Objectives. To examine whether a diet low in fat and high in fiber, fruits, and vegetables and ethnicity had any influence on serum prostate-specific antigen (PSA) levels, because serum PSA is a marker for the presence of prostate cancer. The incidence of prostate cancer increases with age, varies by ethnicity, and is greater among men with a first-degree relative who has had the disease. Large international variations in the rates of prostate cancer incidence and mortality, as well as the incidence changes in migrants and their offspring, also suggest that exogenous factors, including diet, have a strong influence on the development of this disease. Methods. We used data and blood samples from the Polyp Prevention Trial, a multicenter randomized trial designed to evaluate the impact of a diet low in fat and high in fiber, fruits, and vegetables on the recurrence of colorectal adenomas. Recruitment was from 1991 through 1994. Participants were followed up from their baseline recruitment date for 4 years. From this group, we identified 1100 white men and 97 black men who were 35 years of age or older, did not have prostate cancer, and had serum samples available for study. Results. At baseline, no difference was present in the fat intake for the black and white men (mean ± SE, 90 ± 3.6 g/day and 84 ± 1.0 g/day, respectively; P = 0.15). The baseline serum PSA levels did not vary by ethnicity. For black men, the mean serum PSA level was 2.2 ± 0.36 ng/mL compared with 2.0 ± 0.07 ng/mL for white men (P = 0.64). Although all men assigned to the intervention group markedly reduced their fat intake by approximately 15% and increased their fruit and vegetable intake by approximately 2.25 servings per day, no difference was noted in the kinetics of the serum PSA levels by dietary intervention or race. Conclusions. Although ethnic differences in the incidence of prostate cancer are well defined, we found no difference in the baseline fat intake among black and white men that might have contributed to this difference. Serum PSA, a marker often used in early detection programs for prostate cancer, was not associated with manipulation of the amount of fat in the diet, regardless of ethnicity. © 2003 Elsevier Inc. AD - Department of Urology, Mem. Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10021, United States AU - Eastham, J. A. AU - Riedel, E. AU - Latkany, L. AU - Fleisher, M. AU - Schatzkin, A. AU - Lanza, E. AU - Shike, M. DB - Scopus DO - 10.1016/S0090-4295(03)00576-4 IS - 4 M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2003 SP - 677-682 ST - Dietary manipulation, ethnicity, and serum PSA levels T2 - Urology TI - Dietary manipulation, ethnicity, and serum PSA levels UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141784088&doi=10.1016%2fS0090-4295%2803%2900576-4&partnerID=40&md5=d7858f4147d686ce2c896297f8733c8c VL - 62 ID - 2612 ER - TY - JOUR AB - Objectives. To examine whether a diet low in fat and high in fiber, fruits, and vegetables and ethnicity had any influence on serum prostate-specific antigen (PSA) levels, because serum PSA is a marker for the presence of prostate cancer. The incidence of prostate cancer increases with age, varies by ethnicity, and is greater among men with a first-degree relative who has had the disease. Large international variations in the rates of prostate cancer incidence and mortality, as well as the incidence changes in migrants and their offspring, also suggest that exogenous factors, including diet, have a strong influence on the development of this disease. Methods. We used data and blood samples from the Polyp Prevention Trial, a multicenter randomized trial designed to evaluate the impact of a diet low in fat and high in fiber, fruits, and vegetables on the recurrence of colorectal adenomas. Recruitment was from 1991 through 1994. Participants were followed up from their baseline recruitment date for 4 years. From this group, we identified 1100 white men and 97 black men who were 35 years of age or older, did not have prostate cancer, and had serum samples available for study. Results. At baseline, no difference was present in the fat intake for the black and white men (mean +/- SE, 90 +/- 3.6 g/day and 84 +/- 1.0 g/day, respectively; P = 0.15). The baseline serum PSA levels did not vary by ethnicity. For black men, the mean serum PSA level was 2.2 +/- 0.36 ng/mL compared with 2.0 +/- 0.07 ng/mL for white men (P = 0.64). Although all men assigned to the intervention group markedly reduced their fat intake by approximately 15% and increased their fruit and vegetable intake by approximately 2.25 servings per day, no difference was noted in the kinetics of the serum PSA levels by dietary intervention or race. Conclusions. Although ethnic differences in the incidence of prostate cancer are well defined, we found no difference in the baseline fat intake among black and white men that might have contributed to this difference. Serum PSA, a marker often used in early detection programs for prostate cancer, was not associated with manipulation of the amount of fat in the diet, regardless of ethnicity. (C) 2003 Elsevier Inc. AN - WOS:000188253100019 AU - Eastham, J. A. AU - Riedel, E. AU - Latkany, L. AU - Fleisher, M. AU - Schatzkin, A. AU - Lanza, E. AU - Shike, M. DA - Oct DO - 10.1016/S0090-4295(03)00576-4 IS - 4 N1 - 15 14550442 PY - 2003 SN - 0090-4295 SP - 677-682 ST - Dietary manipulation, ethnicity, and serum PSA levels T2 - Urology TI - Dietary manipulation, ethnicity, and serum PSA levels VL - 62 ID - 2693 ER - TY - JOUR AB - Introduction: Malignant breast tumors are often hormone-dependent, and to this end, both estrogen and progesterone receptors are good prognostic markers for evaluation of the outcomes after therapy. In addition, HER-2/neu, whose expression is increasingly being associated with poor prognosis of breast cancer, has predictive potential after immunotherapy. Cytochrome P450 3A4 is highly involved in the metabolism of steroids. Thus, we investigated the impact of CYP 3A4 gene variants in association with clinical outcomes in African American (AFAM) versus Caucasian (CAU) patients with breast cancer diagnosis. Methods: Patients who had undergone biopsy procedures for diagnosis or for partial or radical mastectomy were recruited. The CYP 3A4 genotypes (A or G) were detected using polymerase chain reaction amplification and primers designed for a single nucleotide polymorphism. The messenger RNA (mRNA) transcriptswere screened by reverse transcription- polymerase chain reaction. Clinical data including tumor staging, pathology grades, and family history were evaluated. Results: Frequency of the CYP 3A4-G (mutated variant) was significantly increased in AFAMpatients as compared with controls (P < 0.001). No statistically significant difference was observed between the genotypes comparing the benign versus ductal carcinomas in situ (DCIS) or infiltrating ductal carcinomas (IDCAs). In AFAM patients, GG alleles were increased in IDCA with stage III tumors, and in CAU patients, the AA alleles were increased with stage III tumors. The mRNA expression was reduced in patients with IDCA versus DCIS or benign tumors (benign vs IDCA, P < 0.0009; DCIS vs IDCA, P G 0.005), as well in HER-2/ neuYpositive tumors versus samples negative for receptors (P < 0.0024). Conclusions: Genotype association was affected by race. Expression levels of total CYP 3A4 mRNA were inversely correlated with clinical diagnosis. This may suggest mRNA testing as an additional tool that accelerates improvement in the diagnosis of the onsets of breast cancer. Copyright © 2011 by The American Federation for Medical Research. AD - School of Medicine, University of MS Medical Center, 2500 N State St, CSB L-126, Jackson, MS 39216-4505, United States Departments of Surgery, Jackson, MS, United States Departments of Pathology, Jackson, MS, United States Departments of Medicine, University of Mississippi Medical Center, Jackson, MS, United States AU - McDaniel, D. O. AU - Thurber, T. AU - Lewis-Traylor, A. AU - Berry, C. AU - Barber, W. H. AU - Zhou, X. AU - Bigler, S. AU - Vance, R. DB - Scopus DO - 10.2310/JIM.0b013e3182277e3b IS - 7 KW - African Americans Breast cancer Caucasians CYP 3A4 genotypes Receptors M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2011 SP - 1096-1103 ST - Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients T2 - Journal of Investigative Medicine TI - Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in african american versus caucasian patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863025210&doi=10.2310%2fJIM.0b013e3182277e3b&partnerID=40&md5=f8327461ed6b2762030d6f3cd6ae826e VL - 59 ID - 2485 ER - TY - JOUR AB - Background: A resect and discard strategy for diminutive (≤5 mm) colon polyps has been proposed to save costs of screening colonoscopy (SC). Prior studies on neoplasia prevalence based on polyp size have involved mostly white patients. Objective: To determine the prevalence of adenomas and advanced histologic features by size among primarily black and Latino patients enrolled in a prospective SC study. Design: Retrospective analysis of data from a prospective clinical trial. Setting: Urban academic medical center. Patients: Average risk, asymptomatic, minority patients aged ≤50 years undergoing SC. Interventions: Screening colonoscopy. Main Outcome Measurements: Rates of neoplasia and advanced histologic features (villous histology, highgrade dysplasia, or cancer) by polyp size and location. Results: A total of 566 polyps from 295 patients were analyzed. Diminutive polyps and small (6-9 mm) polyps had lower prevalence of ≤1 advanced feature compared with large (≤10 mm) polyps (0.9% and 2.7%, respectively, vs 13.6%; P < .001 for both comparisons). Distal polyps were less likely to be neoplastic (31.7% vs 61.4%; P < .001) than proximal polyps in all size categories (P < .001 for all comparisons). After adjusting for sex, ethnicity, age, and location, large polyps were more likely to have ≤1 advanced feature than diminutive polyps (adjusted odds ratio [OR] 19.5; 95% CI, 4.4-85.6) or small polyps (adjusted OR 6.1; 95% CI, 2.2-16.9). Limitations: Use of pathology reports for polyp size. Conclusion: Among a cohort of minority patients, advanced histologic features were very rare in diminutive polyps. Distal polyps were less likely to be neoplastic than proximal polyps in all size categories. This supports a resect and discard strategy for diminutive polyps, especially in the distal colon. AD - S.H. Itzkowitz, Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY, United States AU - Lee, K. K. AU - Jandorf, L. AU - Itzkowitz, S. H. DB - Embase Medline DO - 10.1016/j.gie.2014.11.036 IS - 3 KW - adult article Black person clinical trial (topic) colonoscopy colorectal adenoma colorectal polyp controlled study female Hispanic histology human human tissue major clinical study male middle aged prevalence priority journal tumor localization tumor volume LA - English M3 - Article N1 - L602496957 2015-03-02 2015-03-06 PY - 2015 SN - 1097-6779 0016-5107 SP - 728-732 ST - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: Evidence supporting a resect and discard approach T2 - Gastrointestinal Endoscopy TI - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: Evidence supporting a resect and discard approach UR - https://www.embase.com/search/results?subaction=viewrecord&id=L602496957&from=export http://dx.doi.org/10.1016/j.gie.2014.11.036 VL - 81 ID - 1007 ER - TY - JOUR AB - Background A resect and discard strategy for diminutive (≤5 mm) colon polyps has been proposed to save costs of screening colonoscopy (SC). Prior studies on neoplasia prevalence based on polyp size have involved mostly white patients. Objective To determine the prevalence of adenomas and advanced histologic features by size among primarily black and Latino patients enrolled in a prospective SC study. Design Retrospective analysis of data from a prospective clinical trial. Setting Urban academic medical center. Patients Average risk, asymptomatic, minority patients aged ≥50 years undergoing SC. Interventions Screening colonoscopy. Main Outcome Measurements Rates of neoplasia and advanced histologic features (villous histology, high-grade dysplasia, or cancer) by polyp size and location. Results A total of 566 polyps from 295 patients were analyzed. Diminutive polyps and small (6-9 mm) polyps had lower prevalence of ≥1 advanced feature compared with large (≥10 mm) polyps (0.9% and 2.7%, respectively, vs 13.6%; P < .001 for both comparisons). Distal polyps were less likely to be neoplastic (31.7% vs 61.4%; P < .001) than proximal polyps in all size categories ( P < .001 for all comparisons). After adjusting for sex, ethnicity, age, and location, large polyps were more likely to have ≥1 advanced feature than diminutive polyps (adjusted odds ratio [OR] 19.5; 95% CI, 4.4-85.6) or small polyps (adjusted OR 6.1; 95% CI, 2.2-16.9). Limitations Use of pathology reports for polyp size. Conclusion Among a cohort of minority patients, advanced histologic features were very rare in diminutive polyps. Distal polyps were less likely to be neoplastic than proximal polyps in all size categories. This supports a resect and discard strategy for diminutive polyps, especially in the distal colon. AD - Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA Division of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA AN - 103761942. Language: English. Entry Date: 20150302. Revision Date: 20200708. Publication Type: Journal Article AU - Lee, Kristen K. AU - Jandorf, Lina AU - Itzkowitz, Steven H. DB - CINAHL Complete DO - 10.1016/j.gie.2014.11.036 DP - EBSCOhost IS - 3 KW - Colonoscopy -- Utilization Health Screening -- Methods Colonic Neoplasms -- Prevention and Control Human Academic Medical Centers Black Persons Hispanic Americans Prospective Studies Retrospective Design Record Review Odds Ratio Confidence Intervals N1 - research; tables/charts. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care; Perioperative Care. NLM UID: 0010505. PMID: NLM25708761. PY - 2015 SN - 0016-5107 SP - 728-732 ST - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach T2 - Gastrointestinal Endoscopy TI - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103761942&site=ehost-live&scope=site VL - 81 ID - 1914 ER - TY - JOUR AB - Background: A resect and discard strategy for diminutive (≤5 mm) colon polyps has been proposed to save costs of screening colonoscopy (SC). Prior studies on neoplasia prevalence based on polyp size have involved mostly white patients. Objective: To determine the prevalence of adenomas and advanced histologic features by size among primarily black and Latino patients enrolled in a prospective SC study. Design: Retrospective analysis of data from a prospective clinical trial. Setting: Urban academic medical center. Patients: Average risk, asymptomatic, minority patients aged ≤50 years undergoing SC. Interventions: Screening colonoscopy. Main Outcome Measurements: Rates of neoplasia and advanced histologic features (villous histology, highgrade dysplasia, or cancer) by polyp size and location. Results: A total of 566 polyps from 295 patients were analyzed. Diminutive polyps and small (6-9 mm) polyps had lower prevalence of ≤1 advanced feature compared with large (≤10 mm) polyps (0.9% and 2.7%, respectively, vs 13.6%; P < .001 for both comparisons). Distal polyps were less likely to be neoplastic (31.7% vs 61.4%; P < .001) than proximal polyps in all size categories (P < .001 for all comparisons). After adjusting for sex, ethnicity, age, and location, large polyps were more likely to have ≤1 advanced feature than diminutive polyps (adjusted odds ratio [OR] 19.5; 95% CI, 4.4-85.6) or small polyps (adjusted OR 6.1; 95% CI, 2.2-16.9). Limitations: Use of pathology reports for polyp size. Conclusion: Among a cohort of minority patients, advanced histologic features were very rare in diminutive polyps. Distal polyps were less likely to be neoplastic than proximal polyps in all size categories. This supports a resect and discard strategy for diminutive polyps, especially in the distal colon. Copyright © 2015 by the American Society for Gastrointestinal Endoscopy. AD - Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1069, New York, NY 10029, United States Division of Cancer Prevention and Control, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Lee, K. K. AU - Jandorf, L. AU - Itzkowitz, S. H. DB - Scopus DO - 10.1016/j.gie.2014.11.036 IS - 3 M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2015 SP - 728-732 ST - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: Evidence supporting a resect and discard approach T2 - Gastrointestinal Endoscopy TI - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: Evidence supporting a resect and discard approach UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84923265744&doi=10.1016%2fj.gie.2014.11.036&partnerID=40&md5=6b66d8e868db0235b44c0588971f14f9 VL - 81 ID - 2369 ER - TY - JOUR AB - Background: A resect and discard strategy for diminutive (<= 5 mm) colon polyps has been proposed to save costs of screening colonoscopy (SC). Prior studies on neoplasia prevalence based on polyp size have involved mostly white patients. Objective: To determine the prevalence of adenomas and advanced histologic features by size among primarily black and Latino patients enrolled in a prospective SC study. Design: Retrospective analysis of data from a prospective clinical trial. Setting: Urban academic medical center. Patients: Average risk, asymptomatic, minority patients aged >= 50 years undergoing SC. Interventions: Screening colonoscopy. Main Outcome Measurements: Rates of neoplasia and advanced histologic features (villous histology, high-grade dysplasia, or cancer) by polyp size and location. Results: A total of 566 polyps from 295 patients were analyzed. Diminutive polyps and small (6-9 mm) polyps had lower prevalence of >= 1 advanced feature compared with large (>= 10 mm) polyps (0.9% and 2.7%, respectively, vs 13.6%; P < .001 for both comparisons). Distal polyps were less likely to be neoplastic (31.7% vs 61.4%; P < .001) than proximal polyps in all size categories (P < .001 for all comparisons). After adjusting for sex, ethnicity, age, and location, large polyps were more likely to have >= 1 advanced feature than diminutive polyps (adjusted odds ratio [OR] 19.5; 95% CI, 4.4-85.6) or small polyps (adjusted OR 6.1; 95% CI, 2.2-16.9). Limitations: Use of pathology reports for polyp size. Conclusion: Among a cohort of minority patients, advanced histologic features were very rare in diminutive polyps. Distal polyps were less likely to be neoplastic than proximal polyps in all size categories. This supports a resect and discard strategy for diminutive polyps, especially in the distal colon. AN - WOS:000351666800029 AU - Lee, K. K. AU - Jandorf, L. AU - Itzkowitz, S. H. DA - Mar DO - 10.1016/j.gie.2014.11.036 IS - 3 N1 - 25708761 PY - 2015 SN - 0016-5107 SP - 728-732 ST - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach T2 - Gastrointestinal Endoscopy TI - Diminutive polyps among black and Latino populations undergoing screening colonoscopy: evidence supporting a resect and discard approach VL - 81 ID - 2986 ER - TY - JOUR AB - Objective: To analyze advertising, recruitment methods, and study participant demographics for the National Lung Screening Trial (NLST) site at Wake Forest University School of Medicine to define efficient ways to recruit participants for general clinical trials. Study Design and Setting: Recruitment method data, demographics, geographic location, and date of enrollment were collected from all 1,112 NLST participants. Marketing data and financial records were analyzed to determine the effectiveness of each recruitment method. Results: The total amount spent on advertising was $144,668, with the cost of enrollment per participant averaging $130. For black participants, the recruitment cost per person was $406, whereas for white and other race participants, the cost was $122 (P < 0.0001). To encourage minority enrollment, $13,192 was spent on television advertising geared toward black viewers, resulting in eight black participants at an average cost per person of $1,649. Direct mailing cost $143 per participant recruited, whereas TV ads cost $382 per participant. Conclusion: Direct mailing to a targeted group was the most efficient way to recruit participants. Printed advertising methods, that is, newspaper ads and brochures, were quite effective, whereas television ads were expensive. Appropriate minority recruitment needs sufficient attention and resources to ensure census groups are adequately represented. © 2007 Elsevier Inc. All rights reserved. AD - L.B. Hinshaw, Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States AU - Hinshaw, L. B. AU - Jackson, S. A. AU - Chen, M. Y. DB - Embase Medline DO - 10.1016/j.jclinepi.2006.11.005 IS - 8 KW - adult advertising aged article cancer screening computer assisted tomography controlled study demography female financial management human lung cancer major clinical study male marketing priority journal thorax radiography LA - English M3 - Article N1 - L46990808 2007-08-01 PY - 2007 SN - 0895-4356 SP - 853-857 ST - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial T2 - Journal of Clinical Epidemiology TI - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46990808&from=export http://dx.doi.org/10.1016/j.jclinepi.2006.11.005 VL - 60 ID - 1224 ER - TY - JOUR AB - Objective: To analyze advertising, recruitment methods, and study participant demographics for the National Lung Screening Trial (NLST) site at Wake Forest University School of Medicine to define efficient ways to recruit participants for general clinical trials. Study Design and Setting: Recruitment method data, demographics, geographic location, and date of enrollment were collected from all 1,112 NLST participants. Marketing data and financial records were analyzed to determine the effectiveness of each recruitment method. Results: The total amount spent on advertising was $144,668, with the cost of enrollment per participant averaging $130. For black participants, the recruitment cost per person was $406, whereas for white and other race participants, the cost was $122 (P < 0.0001). To encourage minority enrollment, $13,192 was spent on television advertising geared toward black viewers, resulting in eight black participants at an average cost per person of $1,649. Direct mailing cost $143 per participant recruited, whereas TV ads cost $382 per participant. Conclusion: Direct mailing to a targeted group was the most efficient way to recruit participants. Printed advertising methods, that is, newspaper ads and brochures, were quite effective, whereas television ads were expensive. Appropriate minority recruitment needs sufficient attention and resources to ensure census groups are adequately represented. © 2007 Elsevier Inc. All rights reserved. AD - Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States AU - Hinshaw, L. B. AU - Jackson, S. A. AU - Chen, M. Y. DB - Scopus DO - 10.1016/j.jclinepi.2006.11.005 IS - 8 KW - Advertising Clinical trial Enrollment Lung cancer screening Recruitment method Smokers M3 - Article N1 - Cited By :34 Export Date: 22 March 2021 PY - 2007 SP - 853-857 ST - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial T2 - Journal of Clinical Epidemiology TI - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34250816755&doi=10.1016%2fj.jclinepi.2006.11.005&partnerID=40&md5=d3e57a071a4ac6ce32b1b5a198ccaaed VL - 60 ID - 2554 ER - TY - JOUR AB - Objective: To analyze advertising, recruitment methods, and study participant demographics for the National Lung Screening Trial (NLST) site at Wake Forest University School of Medicine to define efficient ways to recruit participants for general clinical trials. Study Design and Setting: Recruitment method data, demographics, geographic location, and date of enrollment were collected from all 1,112 NLST participants. Marketing data and financial records were analyzed to determine the effectiveness of each recruitment method. Results: The total amount spent on advertising was $144,668, with the cost of enrollment per participant averaging $130. For black participants, the recruitment cost per person was $406, whereas for white and other race participants, the cost was $122 (P < 0.0001). To encourage minority enrollment, $13,192 was spent on television advertising geared toward black viewers, resulting in eight black participants at an average cost per person of $1,649. Direct mailing cost $143 per participant recruited, whereas TV ads cost $382 per participant. Conclusion: Direct mailing to a targeted group was the most efficient way to recruit participants. Printed advertising methods, that is, newspaper ads and brochures. were quite effective, whereas television ads were expensive. Appropriate minority recruitment needs sufficient attention and resources to ensure census groups are adequately represented. (C) 2007 Elsevier Inc. All rights reserved. AN - WOS:000248138700014 AU - Hinshaw, L. B. AU - Jackson, S. A. AU - Chen, M. Y. DA - Aug DO - 10.1016/j.jclinepi.2006.11.005 IS - 8 N1 - 17606183 PY - 2007 SN - 0895-4356 SP - 853-857 ST - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial T2 - Journal of Clinical Epidemiology TI - Direct mailing was a successful recruitment strategy for a lung-cancer screening trial VL - 60 ID - 3188 ER - TY - JOUR AB - Background: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. Methods: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. Results: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P <.05). Conclusions: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics. AD - N.L. Keating, Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA, United States AU - Kehl, K. L. AU - Arora, N. K. AU - Schrag, D. AU - Ayanian, J. Z. AU - Clauser, S. B. AU - Klabunde, C. N. AU - Kahn, K. L. AU - Fletcher, R. H. AU - Keating, N. L. DB - Embase Medline DO - 10.1093/jnci/dju216 IS - 10 KW - adult African American age aged article Asian American cancer chemotherapy cancer staging Caucasian clinical trial (topic) cohort analysis colorectal cancer colorectal tumor comorbidity decision making diagnosis female health survey human income information seeking interpersonal communication lung cancer lung tumor major clinical study male middle aged observational study outcome assessment pathology patient participation patient selection priority journal questionnaire race difference sensitivity analysis socioeconomics statistics therapy United States very elderly LA - English M3 - Article N1 - L604740011 2015-06-10 2015-06-18 PY - 2014 SN - 1460-2105 0027-8874 ST - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer T2 - Journal of the National Cancer Institute TI - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604740011&from=export http://dx.doi.org/10.1093/jnci/dju216 VL - 106 ID - 1027 ER - TY - JOUR AB - Background: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation.Methods: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided.Results: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P < .05).Conclusions: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics. AD - Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA. keating@hcp.med.harvard.edu. AN - 103916678. Language: English. Entry Date: 20141121. Revision Date: 20200708. Publication Type: journal article AU - Kehl, Kenneth L. AU - Arora, Neeraj K. AU - Schrag, Deborah AU - Ayanian, John Z. AU - Clauser, Steven B. AU - Klabunde, Carrie N. AU - Kahn, Katherine L. AU - Fletcher, Robert H. AU - Keating, Nancy L. DB - CINAHL Complete DO - 10.1093/jnci/dju216 DP - EBSCOhost IS - 10 KW - Colorectal Neoplasms -- Diagnosis Communication Decision Making Lung Neoplasms -- Diagnosis Patient Selection Age Factors Aged Aged, 80 and Over Asians -- Statistics and Numerical Data Black Persons -- Statistics and Numerical Data Clinical Trials Colorectal Neoplasms -- Pathology Colorectal Neoplasms -- Therapy Comorbidity Consumer Participation Female Human Income Information Seeking Behavior Lung Neoplasms -- Pathology Lung Neoplasms -- Therapy Male Middle Age Neoplasm Staging Prospective Studies Questionnaires United States White Persons -- Statistics and Numerical Data N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: U01 CA093332/CA/NCI NIH HHS/United States. NLM UID: 7503089. PMID: NLM25217775. PY - 2014 SN - 0027-8874 SP - dju216-dju216 ST - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer T2 - JNCI: Journal of the National Cancer Institute TI - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103916678&site=ehost-live&scope=site VL - 106 ID - 1915 ER - TY - JOUR AB - Background: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. Methods: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. Results: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P <.05). Conclusions: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics. © The Author 2014. Published by Oxford University Press. All rights reserved. AD - Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, United States Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, United States Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, United States Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States University of California, Los Angeles, United States RAND Corporation, Santa Monica, CA, United States Department of Population Medicine, Harvard Medical School, Boston, MA, United States Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, United States AU - Kehl, K. L. AU - Arora, N. K. AU - Schrag, D. AU - Ayanian, J. Z. AU - Clauser, S. B. AU - Klabunde, C. N. AU - Kahn, K. L. AU - Fletcher, R. H. AU - Keating, N. L. C7 - dju216 DB - Scopus DO - 10.1093/jnci/dju216 IS - 10 M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2014 ST - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer T2 - Journal of the National Cancer Institute TI - Discussions about clinical trials among patients with newly diagnosed lung and colorectal cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930406726&doi=10.1093%2fjnci%2fdju216&partnerID=40&md5=c665a8068a401c9c231befcc30be8d24 VL - 106 ID - 2387 ER - TY - JOUR AB - Background Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. Methods We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. Results Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P < .05). Conclusions In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics. AN - WOS:000343038200001 AU - Kehl, K. L. AU - Arora, N. K. AU - Schrag, D. AU - Ayanian, J. Z. AU - Clauser, S. B. AU - Klabunde, C. N. AU - Kahn, K. L. AU - Fletcher, R. H. AU - Keating, N. L. DA - Oct DO - 10.1093/jnci/dju216 IS - 10 N1 - dju216 25217775 PY - 2014 SN - 0027-8874 ST - Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer T2 - Jnci-Journal of the National Cancer Institute TI - Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer VL - 106 ID - 2995 ER - TY - JOUR AB - Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes noted among racial-ethnic subgroups, likely due to disparities in access to effective treatment modalities. Clinical trials can provide access to evidence-based medicine but representation of minorities on therapeutic clinical trials has been dismal. We evaluated the impact of patient race-ethnicity in pooled data from nine large national cooperative group clinical trials in newly diagnosed MM. Among 2896 patients enrolled over more than two decades, only 18% were non-White and enrollment of minorities actually decreased in most recent years (2002-2011). African-Americans were younger and had more frequent poor-risk markers, including anemia and increased lactate dehydrogenase. Hispanics had the smallest proportion of patients on trials utilizing novel therapeutic agents. While adverse demographic (increased age) and clinical (performance status, stage, anemia, kidney dysfunction) factors were associated with inferior survival, patient race-ethnicity did not have an effect on objective response rates, progression-free, or overall survival. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, this disparity seems to be mitigated by access to appropriate therapeutic options, for example, as offered by clinical trials. Improved minority accrual in therapeutic clinical trials needs to be a priority. AD - S. Ailawadhi, Mayo Clinic, Jacksonville, FL, United States AU - Ailawadhi, S. AU - Jacobus, S. AU - Sexton, R. AU - Stewart, A. K. AU - Dispenzieri, A. AU - Hussein, M. A. AU - Zonder, J. A. AU - Crowley, J. AU - Hoering, A. AU - Barlogie, B. AU - Orlowski, R. Z. AU - Rajkumar, S. V. DB - Embase Medline DO - 10.1038/s41408-018-0102-7 IS - 7 KW - bortezomib carmustine cyclophosphamide dexamethasone interferon lactate dehydrogenase lenalidomide melphalan prednisone thalidomide vincristine adult African American age aged anemia article cancer incidence cancer staging cancer survival clinical evaluation clinical outcome clinical trial cohort analysis correlation analysis demography drug megadose ethnic group ethnicity female functional status health disparity Hispanic human kidney dysfunction low drug dose major clinical study male middle aged multiple myeloma overall survival progression free survival race stem cell transplantation whole body radiation LA - English M3 - Article N1 - L622918551 2018-07-16 2018-07-18 PY - 2018 SN - 2044-5385 ST - Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials T2 - Blood Cancer Journal TI - Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622918551&from=export http://dx.doi.org/10.1038/s41408-018-0102-7 VL - 8 ID - 891 ER - TY - JOUR AB - Multiple myeloma (MM) is an incurable hematologic malignancy with disparities in outcomes noted among racial-ethnic subgroups, likely due to disparities in access to effective treatment modalities. Clinical trials can provide access to evidence-based medicine but representation of minorities on therapeutic clinical trials has been dismal. We evaluated the impact of patient race-ethnicity in pooled data from nine large national cooperative group clinical trials in newly diagnosed MM. Among 2896 patients enrolled over more than two decades, only 18% were non-White and enrollment of minorities actually decreased in most recent years (2002-2011). African-Americans were younger and had more frequent poor-risk markers, including anemia and increased lactate dehydrogenase. Hispanics had the smallest proportion of patients on trials utilizing novel therapeutic agents. While adverse demographic (increased age) and clinical (performance status, stage, anemia, kidney dysfunction) factors were associated with inferior survival, patient race-ethnicity did not have an effect on objective response rates, progression-free, or overall survival. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, this disparity seems to be mitigated by access to appropriate therapeutic options, for example, as offered by clinical trials. Improved minority accrual in therapeutic clinical trials needs to be a priority. © 2018 The Author(s). AD - Mayo Clinic, Jacksonville, FL, United States Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, United States South West Oncology Group (SWOG) Statistical Center, Seattle, WA, United States Mayo Clinic, Scottsdale, AZ, United States Mayo Clinic, Rochester, MN, United States Celgene Corporation, Summit, NJ, United States Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Mount Sinai Medical Center, New York, NY, United States MD Anderson Cancer Center, University of Texas, Houston, TX, United States AU - Ailawadhi, S. AU - Jacobus, S. AU - Sexton, R. AU - Stewart, A. K. AU - Dispenzieri, A. AU - Hussein, M. A. AU - Zonder, J. A. AU - Crowley, J. AU - Hoering, A. AU - Barlogie, B. AU - Orlowski, R. Z. AU - Rajkumar, S. V. C7 - 67 DB - Scopus DO - 10.1038/s41408-018-0102-7 IS - 7 M3 - Article N1 - Cited By :23 Export Date: 22 March 2021 PY - 2018 ST - Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials T2 - Blood Cancer Journal TI - Disease and outcome disparities in multiple myeloma: Exploring the role of race/ethnicity in the Cooperative Group clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85049642171&doi=10.1038%2fs41408-018-0102-7&partnerID=40&md5=224e2f5adb67a2b4eff44a455f2082b0 VL - 8 ID - 2266 ER - TY - JOUR AB - IMPORTANCE Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. OBJECTIVE To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. DESIGN, SETTING, AND PARTICIPANTS Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2-positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. INTERVENTIONS Patients randomized to arm 1 received 500 mg/m(2) of fluorouracil, 75 mg/m(2) of epirubicin, and 500 mg/m(2) of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m(2) of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor-positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. MAIN OUTCOMES AND MEASURES The primary outcomes were DFS and OS and pCR in the breast and nodes. RESULTS Two hundred eighty-two women with HER2-positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28-76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease-free survival rates did not differ with respect to treatment arm (stratified log-rank P = .96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56-1.83). Overall survival did not differ with respect to treatment arm (stratified log-rank P = .73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48-2.88). CONCLUSIONS AND RELEVANCE Across a median follow-up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. AN - WOS:000455776100010 AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. W. AU - Royce, M. E. AU - Hunt, K. K. DA - Jan DO - 10.1001/jamaoncol.2018.3691 IS - 1 N1 - 30193295 PY - 2019 SN - 2374-2437 SP - 45-50 ST - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy The ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - Jama Oncology TI - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy The ACOSOG Z1041 (Alliance) Randomized Clinical Trial VL - 5 ID - 2833 ER - TY - JOUR AB - Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease‐free survival (DFS) and overall survival (OS) in women with operable HER2‐positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2‐positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. Interventions: Patients randomized to arm 1 received 500 mg/m2 of fluorouracil, 75 mg/m2 of epirubicin, and 500 mg/m2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor‐positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. Main Outcomes and Measures: The primary outcomes were DFS and OS and pCR in the breast and nodes. Results: Two hundred eighty‐two women with HER2‐positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28‐76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease‐free survival rates did not differ with respect to treatment arm (stratified log‐rank P =.96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56‐1.83). Overall survival did not differ with respect to treatment arm (stratified log‐rank P =.73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48‐2.88). Conclusions and Relevance: Across a median follow‐up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. Trial Registration: ClinicalTrials.gov identifier: NCT00513292. AN - CN-01644657 AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. W. AU - Royce, M. E. AU - Hunt, K. K. DO - 10.1001/jamaoncol.2018.3691 KW - *cancer chemotherapy *cancer patient *cancer survival *disease free survival *human epidermal growth factor receptor 2 positive breast cancer *overall survival Adult Aged Alaska Native American Indian Article Cancer radiotherapy Controlled study Drug combination Drug therapy Ethnicity Female Follow up Hormonal therapy Human Major clinical study Middle aged Multicenter study Phase 3 clinical trial Physician Puerto Rico Race Radiotherapy Randomized controlled trial Registration Remission United States M3 - Journal: Article in Press PY - 2018 SP - E1‐E6 ST - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: the ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - JAMA oncology TI - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: the ACOSOG Z1041 (Alliance) Randomized Clinical Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01644657/full ID - 1650 ER - TY - JOUR AB - Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2-positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. Interventions: Patients randomized to arm 1 received 500 mg/m2 of fluorouracil, 75 mg/m2 of epirubicin, and 500 mg/m2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor-positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. Main Outcomes and Measures: The primary outcomes were DFS and OS and pCR in the breast and nodes. Results: Two hundred eighty-two women with HER2-positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28-76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease-free survival rates did not differ with respect to treatment arm (stratified log-rank P =.96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56-1.83). Overall survival did not differ with respect to treatment arm (stratified log-rank P =.73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48-2.88). Conclusions and Relevance: Across a median follow-up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. Trial Registration: ClinicalTrials.gov identifier: NCT00513292. AD - K.K. Hunt, Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Unit 1434, 1400 Pressler St, Houston, TX, United States AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. W. AU - Royce, M. E. AU - Hunt, K. K. DB - Embase Medline DO - 10.1001/jamaoncol.2018.3691 IS - 1 KW - anthracycline cyclophosphamide epirubicin fluorouracil paclitaxel trastuzumab adult aged Alaska Native American Indian article Asian Black person breast surgery cancer chemotherapy cancer combination chemotherapy cancer hormone therapy cancer patient cancer radiotherapy cancer surgery cancer survival Caucasian clinical outcome controlled study disease free survival female human human epidermal growth factor receptor 2 positive breast cancer human tissue informed consent major clinical study medical decision making multicenter study multiple cycle treatment overall survival phase 3 clinical trial Puerto Rico randomized controlled trial survival rate treatment duration tumor invasion United States LA - English M3 - Article N1 - L623885023 2018-09-19 2019-01-23 PY - 2019 SN - 2374-2445 2374-2437 SP - 45-50 ST - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - JAMA Oncology TI - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623885023&from=export http://dx.doi.org/10.1001/jamaoncol.2018.3691 VL - 5 ID - 864 ER - TY - JOUR AB - Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease‐free survival (DFS) and overall survival (OS) in women with operable HER2‐positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2‐positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. Interventions: Patients randomized to arm 1 received 500 mg/m2 of fluorouracil, 75 mg/m2 of epirubicin, and 500 mg/m2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor‐positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. Main Outcomes and Measures: The primary outcomes were DFS and OS and pCR in the breast and nodes. Results: Two hundred eighty‐two women with HER2‐positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28‐76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease‐free survival rates did not differ with respect to treatment arm (stratified log‐rank P = .96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56‐1.83). Overall survival did not differ with respect to treatment arm (stratified log‐rank P = .73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48‐2.88). Conclusions and Relevance: Across a median follow‐up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. Trial Registration: ClinicalTrials.gov identifier: NCT00513292. AN - CN-02012841 AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. W. AU - Royce, M. E. AU - Hunt, K. K. DO - 10.1001/jamaoncol.2018.3691 IS - 1 KW - Adult Aged Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use] Biomarkers, Tumor [*analysis] Breast Neoplasms [chemistry, *drug therapy, mortality, pathology] Chemotherapy, Adjuvant Cyclophosphamide [administration & dosage] Disease Progression Drug Administration Schedule Epirubicin [administration & dosage] Female Fluorouracil [administration & dosage] Humans Middle Aged Neoadjuvant Therapy [adverse effects, mortality] Paclitaxel [administration & dosage] Progression‐Free Survival Puerto Rico Receptor, ErbB‐2 [*analysis] Risk Factors Time Factors Trastuzumab [administration & dosage] United States M3 - Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2019 SP - 45‐50 ST - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: the ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - JAMA oncology TI - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: the ACOSOG Z1041 (Alliance) Randomized Clinical Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02012841/full VL - 5 ID - 1583 ER - TY - JOUR AB - Key Points: Question: What are the long-term outcomes associated with 2 different approaches to administering trastuzumab with neoadjuvant chemotherapy in patients with HER2-positive breast cancer? Findings: Analysis of the ACOSOG Z1041 (Alliance) study of 280 patients revealed no difference in disease-free or overall survival for patients given a regimen of paclitaxel plus trastuzumab followed by fluorouracil, epirubicin, and cyclophosphamide plus trastuzumab compared with a regimen of fluorouracil, epirubicin, and cyclophosphamide followed by paclitaxel plus trastuzumab. Meaning: Across a median follow-up of 5 years, no differences were found in disease-free or overall survival between the 2 approaches of administering trastuzumab with neoadjuvant chemotherapy in patients with HER2-positive breast cancer. Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2-positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. Interventions: Patients randomized to arm 1 received 500 mg/m2 of fluorouracil, 75 mg/m2 of epirubicin, and 500 mg/m2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor–positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. Main Outcomes and Measures: The primary outcomes were DFS and OS and pCR in the breast and nodes. Results: Two hundred eighty-two women with HER2-positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28-76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease-free survival rates did not differ with respect to treatment arm (stratified log-rank P =.96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56-1.83). Overall survival did not differ with respect to treatment arm (stratified log-rank P =.73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48-2.88). Conclusions and Relevance: Across a median follow-up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. Trial Registration: ClinicalTrials.gov identifier: NCT00513292 This phase 3 randomized clinical trial compares disease-free and overall survival among patients with operable HER2-positive breast cancer who received concurrent vs sequential administration of neoadjuvant chemotherapy. AD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston Department of Health Sciences Research, Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston Department of Surgery, University of Texas Southwestern Medical Center, Dallas Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas Department of Surgery, Mayo Clinic, Rochester, Minnesota Doctor's Hospital of Laredo, Laredo, Texas Department of Medical Oncology, University of New Mexico School of Medicine, Albuquerque Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston AN - 134087580. Language: English. Entry Date: 20190124. Revision Date: 20191120. Publication Type: Article AU - Buzdar, Aman U. AU - Suman, Vera J. AU - Meric-Bernstam, Funda AU - Leitch, Ann Marilyn AU - Ellis, Matthew J. AU - Boughey, Judy C. AU - Unzeitig, Gary W. AU - Royce, Melanie E. AU - Hunt, Kelly K. DB - CINAHL Complete DO - 10.1001/jamaoncol.2018.3691 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Surgery Breast Neoplasms -- Drug Therapy Chemotherapy, Adjuvant HER-2-neu Oncogene Survival Analysis -- Methods Anthracyclines -- Therapeutic Use Trastuzumab -- Therapeutic Use Combined Modality Therapy Human Puerto Rico United States Randomized Controlled Trials Fluorouracil -- Administration and Dosage Epirubicin -- Administration and Dosage Cyclophosphamide -- Administration and Dosage Paclitaxel -- Administration and Dosage Trastuzumab -- Administration and Dosage Antineoplastic Agents, Combined -- Therapeutic Use Female Adult Middle Age Aged Confidence Intervals Receptors, Cell Surface Log-Rank Test Data Analysis Software Treatment Outcomes Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Peer Reviewed; USA. Special Interest: Women's Health. Grant Information: This study was supported by awards U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology and P30CA016672 to The University of Texas MD Anderson Cancer Center, U10CA180790 to the Mayo Clinic, U10CA180858 to The University of Texas MD Anderson Cancer Center, and U10CA180870 to The University of Texas Southwestern Medical Center from the NationalCancer Institute.. PY - 2019 SN - 2374-2437 SP - 45-50 ST - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - JAMA Oncology TI - Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134087580&site=ehost-live&scope=site VL - 5 ID - 1916 ER - TY - JOUR AB - Importance: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment regimens. Objective: To assess DFS and OS for patients treated with sequential vs concurrent anthracycline plus trastuzumab. Design, Setting, and Participants: Phase 3 randomized clinical trial conducted at 36 centers in the continental United States and Puerto Rico. Women 18 years or older with invasive operable HER2-positive breast cancer were enrolled from September 15, 2007, to December 15, 2011, and randomized to 1 of 2 treatment arms. The analysis data set was locked on October 15, 2017, and analysis was completed on December 15, 2017. Interventions: Patients randomized to arm 1 received 500 mg/m 2 of fluorouracil, 75 mg/m 2 of epirubicin, and 500 mg/m 2 of cyclophosphamide (FEC) every 3 weeks for 12 weeks followed by the combination of 80 mg/m 2 of paclitaxel and 2 mg/kg (except initial dose of 4 mg/kg) of trastuzumab weekly for 12 weeks. Patients randomized to arm 2 received the same combination of paclitaxel with trastuzumab weekly for 12 weeks followed by FEC every 3 weeks with weekly trastuzumab for 12 weeks. Women with hormone receptor-positive disease received endocrine therapy, and radiotherapy was delivered at physician discretion. Main Outcomes and Measures: The primary outcomes were DFS and OS and pCR in the breast and nodes. Results: Two hundred eighty-two women with HER2-positive breast cancer were enrolled in the trial, and 2 withdrew consent before treatment. Among the remaining 280 women, the median age was 50 years (range, 28-76 years), 232 (82.9%) were white, 29 (10.3%) were black, 8 (2.9%) were Asian, 4 (1.4%) were American Indian or Alaskan Native, and 7 (2.5%) did not report race/ethnicity. There were 22 disease events in arm 1 and 27 in arm 2. Disease-free survival rates did not differ with respect to treatment arm (stratified log-rank P =.96; stratified hazard ratio [HR] [arm 2 to arm 1], 1.02; 95% CI, 0.56-1.83). Overall survival did not differ with respect to treatment arm (stratified log-rank P =.73; stratified HR [arm 2 to arm 1], 1.17; 95% CI, 0.48-2.88). Conclusions and Relevance: Across a median follow-up of 5.1 years (range, 26 days to 6.2 years), pCR, DFS, and OS did not differ with respect to sequential or concurrent administration of FEC with trastuzumab. Trial Registration: ClinicalTrials.gov identifier: NCT00513292. © 2018 American Medical Association. All rights reserved. AD - Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States Department of Health Sciences Research, Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, United States Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, United States Department of Surgery, University of Texas Southwestern Medical Center, Dallas, United States Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, United States Department of Surgery, Mayo Clinic, Rochester, MN, United States Doctor's Hospital of Laredo, Laredo, TX, United States Department of Medical Oncology, University of New Mexico School of Medicine, Albuquerque, United States Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Unit 1434, 1400 Pressler St, Houston, TX 77030-4008, United States AU - Buzdar, A. U. AU - Suman, V. J. AU - Meric-Bernstam, F. AU - Leitch, A. M. AU - Ellis, M. J. AU - Boughey, J. C. AU - Unzeitig, G. W. AU - Royce, M. E. AU - Hunt, K. K. DB - Scopus DO - 10.1001/jamaoncol.2018.3691 IS - 1 M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2019 SP - 45-50 ST - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial T2 - JAMA Oncology TI - Disease-Free and Overall Survival among Patients with Operable HER2-Positive Breast Cancer Treated with Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053188989&doi=10.1001%2fjamaoncol.2018.3691&partnerID=40&md5=ab813f40244dba43c4766fbb6dadc4ce VL - 5 ID - 2246 ER - TY - JOUR AB - Background: Although there are considerable racial and ethnic disparities in prostate cancer incidence and mortality in the United States and globally, clinical trials often do not reflect disease incidence across racial and ethnic subgroups. This study aims to comprehensively review the reporting of race and ethnicity data and the representation of race and ethnicity across prostate cancer treatment-, prevention-, and screening-based clinical trials. Methods: Seventy-two global phase III and IV prevention, screening, and treatment prostate cancer clinical trials with enrollment start dates between 1987 and 2016 were analyzed in this study, representing a total of 893,378 individual trial participants. Availability and representation of race and ethnicity data by trial funding type, temporal changes in the racial/ethnic diversity of participants, and geographic representation of countries were assessed. Results: Of the 72 trials analyzed, 59 (81.9%) had available race data, and 11 (15.3%) of these trials additionally reported ethnicity. Of the trials reporting data, participants were overwhelmingly white men (with the highest proportion in U.S. nonpublicly funded trials), comprising over 96% of the study population. The proportion of white participants in prostate cancer clinical trials has remained at over 80% since 1990. Geographically, Africa and the Caribbean were particularly underrepresented with only 3% of countries included. Conclusions: Trial participants continue to be majority white despite the known racial disparities in prostate cancer clinical outcomes. Impact: Current and future trials must use novel recruitment strategies to ensure enrollment of underrepresented men. Targeting the inclusion of African and Caribbean medical centers is crucial to achieve equity in representation. © 2020 American Association for Cancer Research. AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, United States Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, United States Department of Oncology, University of California San Diego Moores Cancer Center, San diego, CA, United States Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA, United States Prostate Cancer Clinical Trials Consortium, New York, NY, United States Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States Bayer Oncology, Whippany, NJ, United States Movember Foundation, East Melbourne, Australia Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Oncology, Wayne State University Karmanos Cancer Institute, Detroit, MI, United States Duke Cancer Institute, Durham, NC, United States AU - Rencsok, E. M. AU - Bazzi, L. A. AU - McKay, R. R. AU - Huang, F. W. AU - Friedant, A. AU - Vinson, J. AU - Peisch, S. AU - Zarif, J. C. AU - Simmons, S. AU - Hawthorne, K. AU - Villanti, P. AU - Kantoff, P. W. AU - Heath, E. AU - George, D. J. AU - Mucci, L. A. DB - Scopus DO - 10.1158/1055-9965.EPI-19-1616 IS - 7 M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2020 SP - 1374-1380 ST - Diversity of enrollment in prostate cancer clinical trials: current status and future directions T2 - Cancer Epidemiology Biomarkers and Prevention TI - Diversity of enrollment in prostate cancer clinical trials: current status and future directions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087530437&doi=10.1158%2f1055-9965.EPI-19-1616&partnerID=40&md5=c45a61c74cb667b0d28a8e67fc44b310 VL - 29 ID - 2188 ER - TY - JOUR AB - Most professional organizations, including the American College of Physicians and U.S. Preventive Services Task Force, emphasize that screening for prostate cancer with the prostate-specific antigen (PSA) test should only occur after a detailed discussion between the health-care provider and patient about the known risks and potential benefits of the test. In fact, guidelines strongly advise health-care providers to involve patients, particularly those at elevated risk of prostate cancer, in a "shared decision making" (SDM) process about PSA testing. We analyzed data from the National Cancer Institute's Health Information National Trends Survey 2011-2012-a nationally representative, cross-sectional survey-to examine the extent to which health professionals provided men with information critical to SDM prior to PSA testing, including (1) that patients had a choice about whether or not to undergo PSA testing, (2) that not all doctors recommend PSA testing, and (3) that no one is sure if PSA testing saves lives. Over half (55 %) of men between the ages of 50 and 74 reported ever having had a PSA test. However, only 10 % of men, regardless of screening status, reported receiving all three pieces of information: 55 % reported being informed that they could choose whether or not to undergo testing, 22 % reported being informed that some doctors recommend PSA testing and others do not, and 14 % reported being informed that no one is sure if PSA testing actually saves lives. Black men and men with lower levels of education were less likely to be provided this information. There is a need to improve patient-provider communication about the uncertainties associated with the PSA test. Interventions directed at patients, providers, and practice settings should be considered. AU - Leyva, B. AU - Persoskie, A. AU - Ottenbacher, A. AU - Hamilton, J. G. AU - Allen, J. D. AU - Kobrin, S. C. AU - Taplin, S. H. DB - Medline DO - 10.1007/s13187-015-0870-8 IS - 4 KW - prostate specific antigen tumor marker aged attitude to health blood cross-sectional study decision making early cancer diagnosis epidemiology human interpersonal communication male middle aged patient care patient participation physician procedures prostate tumor psychology questionnaire risk factor United States LA - English M3 - Article N1 - L620716252 2018-02-20 PY - 2016 SN - 1543-0154 SP - 693-701 ST - Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L620716252&from=export http://dx.doi.org/10.1007/s13187-015-0870-8 VL - 31 ID - 955 ER - TY - JOUR AB - Background: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. Objective: To evaluate the impact of an intervention ( Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function ( anxiety and depression), spiritual well-being, and quality of life at the end of life. Design: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. Measurements: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. Results: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer ( 48), heart disease ( 5) lung disease ( 10), and other ( 19) Ages ranged from 28-96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. Conclusions: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. AN - WOS:000261293400019 AU - Steinhauser, K. E. AU - Alexander, S. C. AU - Byock, I. R. AU - George, L. K. AU - Olsen, M. K. AU - Tulsky, J. A. DA - Nov DO - 10.1089/jpm.2008.0078 IS - 9 N1 - 19021487 PY - 2008 SN - 1096-6218 SP - 1234-1240 ST - Do Preparation and Life Completion Discussions Improve Functioning and Quality of Life in Seriously III Patients? Pilot Randomized Control Trial T2 - Journal of Palliative Medicine TI - Do Preparation and Life Completion Discussions Improve Functioning and Quality of Life in Seriously III Patients? Pilot Randomized Control Trial VL - 11 ID - 3162 ER - TY - JOUR AB - Background: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. Objective: To evaluate the impact of an intervention (Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well-being, and quality of life at the end of life. Design: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. Measurements: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. Results: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28-96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. Conclusions: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. © 2008 Mary Ann Liebert, Inc. AD - K. E. Steinhauser, VA and Duke Medical Centers, Center for Palliative CareHock Plaza, 2424 Erwin Road, Box 2720, Durham, NC 27705, United States AU - Steinhauser, K. E. AU - Alexander, S. C. AU - Byock, I. R. AU - George, L. K. AU - Olsen, M. K. AU - Tulsky, J. A. DB - Embase Medline DO - 10.1089/jpm.2008.0078 IS - 9 KW - anxiety article attitude to death clinical article clinical trial controlled clinical trial controlled study degenerative disease depression female heart disease hospice care human kidney failure lung disease male neoplasm outpatient care pain assessment palliative therapy pilot study quality of life randomized controlled trial LA - English M3 - Article N1 - L352741363 2008-12-22 PY - 2008 SN - 1096-6218 SP - 1234-1240 ST - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial T2 - Journal of Palliative Medicine TI - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352741363&from=export http://dx.doi.org/10.1089/jpm.2008.0078 VL - 11 ID - 1200 ER - TY - JOUR AB - BACKGROUND: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. OBJECTIVE: To evaluate the impact of an intervention (Outlook) that promotes discussions of end‐of‐life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well‐being, and quality of life at the end of life. DESIGN: A three‐arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. MEASUREMENTS: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL‐E, Rosow‐Breslau ADL Scale, Profile of Mood States anxiety sub‐scale, the CESD short version, and the Daily Spiritual Experience Scale. RESULTS: Eighty‐two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28‐96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. CONCLUSIONS: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. AN - CN-00668208 AU - Steinhauser, K. E. AU - Alexander, S. C. AU - Byock, I. R. AU - George, L. K. AU - Olsen, M. K. AU - Tulsky, J. A. DO - 10.1089/jpm.2008.0078 IS - 9 KW - *attitude to death *quality of life Activities of Daily Living Adult Aged Aged, 80 and over Anxiety Article Clinical article Clinical trial Controlled clinical trial Controlled study Degenerative disease/th [Therapy] Depression Female Heart disease/th [Therapy] Hospice care Human Humans Interviews as Topic Kidney failure/th [Therapy] Lung disease/th [Therapy] Male Middle Aged Neoplasm/th [Therapy] North Carolina Outpatient care Pain assessment Palliative Care [*methods] Palliative therapy Pilot study Quality of Life [*psychology] Randomized controlled trial Severity of Illness Index Spirituality Terminal Care [psychology] M3 - Journal Article; Randomized Controlled Trial PY - 2008 SP - 1234‐1240 ST - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial T2 - Journal of palliative medicine TI - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00668208/full VL - 11 ID - 1624 ER - TY - JOUR AB - Background: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. Objective: To evaluate the impact of an intervention (Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well-being, and quality of life at the end of life. Design: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. Measurements: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. Results: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28–96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. Conclusions: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Steinhauser, Karen E., Duke Medical Centers, Center for Palliative Care, Hock Plaza, 2424 Erwin Road Suite 1105, Box 2720, Durham, NC, US, 27705 AN - 2008-17032-014 AU - Steinhauser, Karen E. AU - Alexander, Stewart C. AU - Byock, Ira R. AU - George, Linda K. AU - Olsen, Maren K. AU - Tulsky, James A. DB - psyh DO - 10.1089/jpm.2008.0078 DP - EBSCOhost IS - 9 KW - intervention end-of-life preparation intervention effects health outcomes pain symptoms physical function emotional function spiritual well-being quality of life clinical trials Activities of Daily Living Adult Aged Aged, 80 and over Female Humans Interviews as Topic Male Middle Aged North Carolina Palliative Care Severity of Illness Index Spirituality Terminal Care Treatment Effectiveness Evaluation Spiritual Well Being Health Well Being N1 - Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, US. Release Date: 20091005. Correction Date: 20190211. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Intervention; Palliative Care; Treatment Effectiveness Evaluation; Spiritual Well Being. Minor Descriptor: Clinical Trials; Health; Quality of Life; Spirituality; Symptoms; Well Being. Classification: Home Care & Hospice (3375). Population: Human (10); Male (30); Female (40); Inpatient (50); Outpatient (60). Location: US. Tests & Measures: Memorial Symptom Assessment Scale; Rosow-Breslau ADL Scale; Quality of Life at the End of Life Scale; Center for Epidemiologic Studies Depression Scale; Profile of Mood States Questionnaire; Daily Spiritual Experience Scale DOI: 10.1037/t01587-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Nov, 2008. Copyright Statement: Mary Ann Liebert, Inc. Sponsor: US Department of Veterans Affairs, Medical Center, US. Recipients: No recipient indicated PY - 2008 SN - 1096-6218 1557-7740 SP - 1234-1240 ST - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial T2 - Journal of Palliative Medicine TI - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-17032-014&site=ehost-live&scope=site Karen.steinhauser@duke.edu VL - 11 ID - 1805 ER - TY - JOUR AB - BACKGROUND: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. OBJECTIVE: To evaluate the impact of an intervention (Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well-being, and quality of life at the end of life. DESIGN: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. MEASUREMENTS: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. RESULTS: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28-96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. CONCLUSIONS: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. AD - Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, North Carolina 27705, USA. Karen.steinhauser@duke.edu AN - 105587085. Language: English. Entry Date: 20090123. Revision Date: 20200708. Publication Type: Journal Article AU - Steinhauser, K. E. AU - Alexander, S. C. AU - Byock, I. R. AU - George, L. K. AU - Olsen, M. K. AU - Tulsky, J. A. DB - CINAHL Complete DO - 10.1089/jpm.2008.0078 DP - EBSCOhost IS - 9 KW - Death Education Patient Attitudes Quality of Life Spiritual Care Terminally Ill Patients Adult Aged Aged, 80 and Over Center for Epidemiological Studies Depression Scale Clinical Assessment Tools Clinical Trials Female Male Middle Age Random Assignment Scales Human N1 - research; tables/charts; randomized controlled trial. Commentary: von Gunten CF. Be not afraid. (J PALLIAT MED) Nov2008; 11 (9): 1179-1179. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS); Activities of Daily Living (ADL) Scale; Memorial Symptom Assessment Scale (MSAS); Center for Epidemiologic Studies Depression Scale (CES-D). NLM UID: 9808462. PMID: NLM19021487. PY - 2008 SN - 1096-6218 SP - 1234-1240 ST - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial T2 - Journal of Palliative Medicine TI - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105587085&site=ehost-live&scope=site VL - 11 ID - 1920 ER - TY - JOUR AB - Background: Significant palliative care intervention has focused on physical pain and symptom control; yet less empirical evidence supports efforts to address the psychosocial and spiritual dimensions of experience. Objective: To evaluate the impact of an intervention (Outlook) that promotes discussions of end-of-life preparation and completion on health outcomes in dying persons, including pain and symptoms, physical function, emotional function (anxiety and depression), spiritual well-being, and quality of life at the end of life. Design: A three-arm pilot randomized control trial. Subjects were recruited from inpatient and outpatient hospital, palliative care, and hospice settings. Intervention subjects met with a facilitator three times and discussed issues related to life review, forgiveness, and heritage and legacy. Attention control subjects met with a facilitator three times and listened to a nonguided relaxation CD. True control subjects received no intervention. Measurements: Preoutcomes and postoutcomes included the Memorial Symptom Assessment Scale, QUAL-E, Rosow-Breslau ADL Scale, Profile of Mood States anxiety sub-scale, the CESD short version, and the Daily Spiritual Experience Scale. Results: Eighty-two hospice eligible patients enrolled in the study; 38 were women, 35 were African American. Participants' primary diagnoses included cancer (48), heart disease (5) lung disease (10), and other (19) Ages ranged from 28-96. Participants in the active discussion intervention showed improvements in functional status, anxiety, depression, and preparation for end of life. Conclusions: The Outlook intervention was acceptable to patients from a variety of educational and ethnic backgrounds and offers a brief, manualized, intervention for emotional and spiritual concerns. © 2008 Mary Ann Liebert, Inc. AD - Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC, United States Center for Palliative Care, Durham VA Medical Center, Durham, NC, United States Department of Medicine, Duke University, Durham, NC, United States Center for the Study of Aging and Human Development, Duke University, Durham, NC, United States Institute on Care at the End of Life, Duke University, Durham, NC, United States Department of Sociology, Duke University, Durham, NC, United States Dartmouth Medical School, Hanover, NH, United States Department of Biostatisitcs and Bioinformatics, Duke University, Durham, NC, United States VA and Duke Medical Centers, Center for Palliative CareHock Plaza, 2424 Erwin Road, Box 2720, Durham, NC 27705, United States AU - Steinhauser, K. E. AU - Alexander, S. C. AU - Byock, I. R. AU - George, L. K. AU - Olsen, M. K. AU - Tulsky, J. A. DB - Scopus DO - 10.1089/jpm.2008.0078 IS - 9 M3 - Article N1 - Cited By :106 Export Date: 22 March 2021 PY - 2008 SP - 1234-1240 ST - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial T2 - Journal of Palliative Medicine TI - Do preparation and life completion discussions improve functioning and quality of life in seriously ill patients? Pilot randomized control trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-56749160557&doi=10.1089%2fjpm.2008.0078&partnerID=40&md5=800c79294700ed0339305f0525390de4 VL - 11 ID - 2530 ER - TY - GEN AB - Background: In this randomized trial, Project CARE, we examined whether participation in a cognitive-behavioral stress management and breast cancer wellness and education program improved psychological outcomes among a sample of underserved black breast cancer survivors. Methods: Both complementary medicine interventions were 10-sessions, manualized, group-based, and were culturally adapted for black women in the community from evidence-based interventions. Participants were 114 black women (mean age = 51.1, 27-77 years) who had completed breast cancer treatment 0-12 months before enrollment (stages 0-IV, mean time since cancer diagnosis = 14.1 months). Women were enrolled upon completion of curative treatment (ie, surgical, chemotherapy, radiation oncology) and randomized to receive cognitivebehavioral stress management or cancer wellness and education program. Results: There was a remarkable 95% retention rate from baseline to 6-month follow-up. Participants in both conditions showed statistically significant improvement on indices of psychological well-being, including overall quality of life (Functional Assessment of Cancer Therapy-Breast), intrusive thoughts (Impact of Event Scale-Revised), depressive symptoms (Center for Epidemiologic Studies-Depression), and stress levels (Perceived Stress Scale) over the 6-month postintervention follow-up (all repeated measures analysis of variance within-subjects time effects: P < .05, except for overall mood; Profile of Mood States-Short Version). Contrary to hypotheses, however, condition × time effects were not statistically significant. Conclusions: Findings suggest that improvements in multiple measures over time may have been due to intensive training in stress management, extensive provision of breast cancer information, or participation in an ongoing supportive group of individuals from a similar racial background. Implications bear on decisions about appropriate control groups, the timing of intervention delivery during the treatment trajectory, and perceived support from the research team. AD - S.C. Lechner, 1120 NW 14 St, C-202, Miami, FL, United States AU - Lechner, S. C. AU - Whitehead, N. E. AU - Vargas, S. AU - Annane, D. W. AU - Robertson, B. R. AU - Carver, C. S. AU - Kobetz, E. AU - Antoni, M. H. C5 - 25749598 DB - Embase Medline DO - 10.1093/jncimonographs/lgu032 J2 - J. Natl. Cancer Inst. Monogr. KW - adult aged alternative medicine article breast cancer cancer diagnosis cancer staging cancer survivor Center for Epidemiologic Studies Depression cognitive behavioral stress management community care controlled study education program female follow up Functional Assessment of Cancer Therapy Breast human Impact of Events Scale major clinical study Perceived Stress Scale priority journal Profile of Mood States psychological aspect psychological well-being psychophysiologic assessment quality of life randomized controlled trial relaxation training social adaptation LA - English M1 - (Lechner S.C., SLechner@med.miami.edu; Robertson B.R.; Antoni M.H.) Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, United States M3 - Article N1 - L605470724 2015-08-07 2015-08-12 PY - 2014 SN - 1745-6614 1052-6773 SP - 315-322 ST - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? TI - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605470724&from=export http://dx.doi.org/10.1093/jncimonographs/lgu032 VL - 2014 ID - 1063 ER - TY - JOUR AB - BACKGROUND: In this randomized trial, Project CARE, we examined whether participation in a cognitive‐behavioral stress management and breast cancer wellness and education program improved psychological outcomes among a sample of underserved black breast cancer survivors. METHODS: Both complementary medicine interventions were 10‐sessions, manualized, group‐based, and were culturally adapted for black women in the community from evidence‐based interventions. Participants were 114 black women (mean age = 51.1, 27‐77 years) who had completed breast cancer treatment 0‐12 months before enrollment (stages 0‐IV, mean time since cancer diagnosis = 14.1 months). Women were enrolled upon completion of curative treatment (ie, surgical, chemotherapy, radiation oncology) and randomized to receive cognitive‐behavioral stress management or cancer wellness and education program. RESULTS: There was a remarkable 95% retention rate from baseline to 6‐month follow‐up. Participants in both conditions showed statistically significant improvement on indices of psychological well‐being, including overall quality of life (Functional Assessment of Cancer Therapy‐Breast), intrusive thoughts (Impact of Event Scale‐Revised), depressive symptoms (Center for Epidemiologic Studies‐Depression), and stress levels (Perceived Stress Scale) over the 6‐month postintervention follow‐up (all repeated measures analysis of variance within‐subjects time effects: P < .05, except for overall mood; Profile of Mood States‐Short Version). Contrary to hypotheses, however, condition × time effects were not statistically significant. CONCLUSIONS: Findings suggest that improvements in multiple measures over time may have been due to intensive training in stress management, extensive provision of breast cancer information, or participation in an ongoing supportive group of individuals from a similar racial background. Implications bear on decisions about appropriate control groups, the timing of intervention delivery during the treatment trajectory, and perceived support from the research team. AN - CN-01091564 AU - Lechner, S. C. AU - Whitehead, N. E. AU - Vargas, S. AU - Annane, D. W. AU - Robertson, B. R. AU - Carver, C. S. AU - Kobetz, E. AU - Antoni, M. H. DO - 10.1093/jncimonographs/lgu032 IS - 50 KW - *breast cancer/dm [Disease Management] *breast cancer/th [Therapy] *cognitive behavioral stress management *community care *psychological aspect *social adaptation Adaptation, Psychological Adult African Americans [*psychology] Aged Alternative medicine Article Breast Neoplasms [*psychology] Cancer diagnosis Cancer staging Cancer survivor Center for Epidemiologic Studies Depression Cognitive Behavioral Therapy Community Mental Health Services Complementary Therapies Controlled study Depression [psychology] Education program Female Follow up Functional assessment of cancer therapy breast Human Humans Impact of Events Scale Major clinical study Middle Aged Patient Education as Topic Perceived Stress Scale Priority journal Profile of Mood States Psychiatric Status Rating Scales Psychological well being Psychophysiologic assessment Psychotherapy, Group Quality of Life Randomized controlled trial Relaxation training Stress, Psychological [*therapy] Survivors [*psychology] Vulnerable Populations [*psychology] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 315‐322 ST - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? T2 - Journal of the National Cancer Institute. Monographs TI - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01091564/full VL - 2014 ID - 1374 ER - TY - JOUR AB - Background: In this randomized trial, Project CARE, we examined whether participation in a cognitive-behavioral stress management and breast cancer wellness and education program improved psychological outcomes among a sample of underserved black breast cancer survivors.Methods: Both complementary medicine interventions were 10-sessions, manualized, group-based, and were culturally adapted for black women in the community from evidence-based interventions. Participants were 114 black women (mean age = 51.1, 27-77 years) who had completed breast cancer treatment 0-12 months before enrollment (stages 0-IV, mean time since cancer diagnosis = 14.1 months). Women were enrolled upon completion of curative treatment (ie, surgical, chemotherapy, radiation oncology) and randomized to receive cognitive-behavioral stress management or cancer wellness and education program.Results: There was a remarkable 95% retention rate from baseline to 6-month follow-up. Participants in both conditions showed statistically significant improvement on indices of psychological well-being, including overall quality of life (Functional Assessment of Cancer Therapy-Breast), intrusive thoughts (Impact of Event Scale-Revised), depressive symptoms (Center for Epidemiologic Studies-Depression), and stress levels (Perceived Stress Scale) over the 6-month postintervention follow-up (all repeated measures analysis of variance within-subjects time effects: P < .05, except for overall mood; Profile of Mood States-Short Version). Contrary to hypotheses, however, condition × time effects were not statistically significant.Conclusions: Findings suggest that improvements in multiple measures over time may have been due to intensive training in stress management, extensive provision of breast cancer information, or participation in an ongoing supportive group of individuals from a similar racial background. Implications bear on decisions about appropriate control groups, the timing of intervention delivery during the treatment trajectory, and perceived support from the research team. AN - 109707299. Language: English. Entry Date: 20150923. Revision Date: 20161118. Publication Type: journal article AU - Lechner, Suzanne C. AU - Whitehead, Nicole E. AU - Vargas, Sara AU - Annane, Debra W. AU - Robertson, Belinda R. AU - Carver, Charles S. AU - Kobetz, Erin AU - Antoni, Michael H. DB - CINAHL Complete DO - 10.1093/jncimonographs/lgu032 DP - EBSCOhost IS - 50 N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. Special Interest: Oncologic Care. Grant Information: UL1 TR000460/TR/NCATS NIH HHS/United States. NLM UID: 9011255. PMID: NLM25749598. PY - 2014 SN - 1052-6773 SP - 315-322 ST - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? T2 - JNCI Monographs TI - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109707299&site=ehost-live&scope=site VL - 2014 ID - 1921 ER - TY - SER AB - Background: In this randomized trial, Project CARE, we examined whether participation in a cognitive-behavioral stress management and breast cancer wellness and education program improved psychological outcomes among a sample of underserved black breast cancer survivors. Methods: Both complementary medicine interventions were 10-sessions, manualized, group-based, and were culturally adapted for black women in the community from evidence-based interventions. Participants were 114 black women (mean age = 51.1, 27-77 years) who had completed breast cancer treatment 0-12 months before enrollment (stages 0-IV, mean time since cancer diagnosis = 14.1 months). Women were enrolled upon completion of curative treatment (ie, surgical, chemotherapy, radiation oncology) and randomized to receive cognitivebehavioral stress management or cancer wellness and education program. Results: There was a remarkable 95% retention rate from baseline to 6-month follow-up. Participants in both conditions showed statistically significant improvement on indices of psychological well-being, including overall quality of life (Functional Assessment of Cancer Therapy-Breast), intrusive thoughts (Impact of Event Scale-Revised), depressive symptoms (Center for Epidemiologic Studies-Depression), and stress levels (Perceived Stress Scale) over the 6-month postintervention follow-up (all repeated measures analysis of variance within-subjects time effects: P < .05, except for overall mood; Profile of Mood States-Short Version). Contrary to hypotheses, however, condition × time effects were not statistically significant. Conclusions: Findings suggest that improvements in multiple measures over time may have been due to intensive training in stress management, extensive provision of breast cancer information, or participation in an ongoing supportive group of individuals from a similar racial background. Implications bear on decisions about appropriate control groups, the timing of intervention delivery during the treatment trajectory, and perceived support from the research team. © The Author 2014. AD - Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, United States Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States Department of Public Health Sciences (EK), University of Miami Miller School of Medicine, Miami, FL, United States Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, United States The Miriam Hospital, The Warren Alpert Medical School, Brown University, Providence, RI, United States Department of Psycholog, University of Miami, Coral Gables, FL, United States AU - Lechner, S. C. AU - Whitehead, N. E. AU - Vargas, S. AU - Annane, D. W. AU - Robertson, B. R. AU - Carver, C. S. AU - Kobetz, E. AU - Antoni, M. H. DB - Scopus DO - 10.1093/jncimonographs/lgu032 M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2014 SP - 315-322 ST - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? T2 - Journal of the National Cancer Institute - Monographs TI - Does a community-based stress management intervention affect psychological adaptation among underserved black breast cancer survivors? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938295608&doi=10.1093%2fjncimonographs%2flgu032&partnerID=40&md5=44a45ab008e9037d7780befae179b65f VL - 2014 ID - 2385 ER - TY - JOUR AB - Lessons Learned Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. Background The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)-approved for prevention of chemotherapy-induced alopecia. Studies report 50%-80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I-III breast cancer. Methods Black patients who planned to receive at least four cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). Results Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p < .001) and alopecia distress (p = .04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (>50% hair loss). Conclusion SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors. AN - WOS:000618735000001 AU - Dilawari, A. AU - Gallagher, C. AU - Alintah, P. AU - Chitalia, A. AU - Tiwari, S. AU - Paxman, R. AU - Adams-Campbell, L. AU - Dash, C. DO - 10.1002/onco.13690 N1 - 33512741 SN - 1083-7159 ST - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? T2 - Oncologist TI - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? ID - 2746 ER - TY - JOUR AB - LESSONS LEARNED: Despite FDA approval to reduce alopecia, data on efficacy of scalp cooling in Black cancer patients is limited due to lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. BACKGROUND: The Paxman scalp cooling (SC) device is FDA-approved for prevention of chemotherapy-induced alopecia (CIA). Studies report 50%-80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I-III breast cancer. METHODS: Black patients who planned to receive ≥4 cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). CONCLUSION: SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors. RESULTS: 15 patients enrolled in the intervention before the study was closed early due to lack of efficacy. Median MDS and CADS increased after SC suggesting increased hair loss (p < .001) and alopecia distress (p = .04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion due to grade 3 alopecia (>50% hair loss). AU - Dilawari, A. AU - Gallagher, C. AU - Alintah, P. AU - Chitalia, A. AU - Tiwari, S. AU - Paxman, R. AU - Adams-Campbell, L. AU - Dash, C. DB - Medline DO - 10.1002/onco.13690 KW - adult adverse drug reaction alopecia article breast cancer cancer chemotherapy cancer patient cancer staging clinical article clinical trial controlled study cooling system distress syndrome drug efficacy feasibility study female hair loss human patient satisfaction phase 2 clinical trial prevention scalp thickness anthracycline LA - English M3 - Article in Press N1 - L634137785 2021-02-16 PY - 2021 SN - 1549-490X ST - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? T2 - The oncologist TI - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634137785&from=export http://dx.doi.org/10.1002/onco.13690 ID - 757 ER - TY - JOUR AB - Lessons Learned: Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. Background: The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)-approved for prevention of chemotherapy-induced alopecia. Studies report 50%–80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I–III breast cancer. Methods: Black patients who planned to receive at least four cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). Results: Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p <.001) and alopecia distress (p =.04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (>50% hair loss). Conclusion: SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors. AD - A. Dilawari, MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, United States AU - Dilawari, A. AU - Gallagher, C. AU - Alintah, P. AU - Chitalia, A. AU - Tiwari, S. AU - Paxman, R. AU - Adams-Campbell, L. AU - Dash, C. DB - Embase Medline DO - 10.1002/onco.13690 KW - adult adverse drug reaction alopecia article breast cancer cancer chemotherapy cancer patient cancer staging clinical article clinical trial controlled study cooling system distress syndrome drug efficacy feasibility study female Food and Drug Administration hair loss human patient satisfaction phase 2 clinical trial prevention scalp side effect thickness anthracycline LA - English M3 - Article in Press N1 - L2010517989 2021-03-02 PY - 2021 SN - 1549-490X 1083-7159 ST - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? T2 - Oncologist TI - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010517989&from=export http://dx.doi.org/10.1002/onco.13690 ID - 764 ER - TY - JOUR AB - Lessons Learned: Despite U.S. Food and Drug Administration approval to reduce alopecia, data on efficacy of scalp cooling in Black patients with cancer are limited by lack of minority representation in prior clinical trials. Scalp cooling devices may have less efficacy in Black patients; additional studies are required to explore the possible causes for this, including hair texture and cap design. Background: The Paxman scalp cooling (SC) device is U.S. Food and Drug Administration (FDA)-approved for prevention of chemotherapy-induced alopecia. Studies report 50%–80% success rates and high patient satisfaction, yet there have been no studies of SC in Black patients. We conducted a phase II feasibility study of Paxman SC with a planned enrollment of 30 Black patients receiving chemotherapy for stage I–III breast cancer. Methods: Black patients who planned to receive at least four cycles of chemotherapy with non-anthracycline (NAC) or anthracycline (AC) regimens were eligible. Alopecia was assessed by trained oncology providers using the modified Dean scale (MDS) prior to each chemotherapy session. Distress related to alopecia was measured by the Chemotherapy Alopecia Distress Scale (CADS). Results: Fifteen patients enrolled in the intervention before the study was closed early because of lack of efficacy. Median MDS and CADS increased after SC, suggesting increased hair loss (p <.001) and alopecia distress (p =.04). Only one participant was successful in preventing significant hair loss; the majority stopped SC before chemotherapy completion because of grade 3 alopecia (>50% hair loss). Conclusion: SC may not be efficacious in preventing alopecia in Black women. Differences in hair thickness, hair volume, and limitations of cooling cap design are possible contributing factors. © AlphaMed Press; the data published online to support this summary are the property of the authors. AD - MedStar Washington Hospital Center, Washington Cancer Institute, Lombardi Comprehensive Cancer Center, Washington, DC, United States MedStar Health Research Institute, Washington Cancer Institute, Washington, DC, United States Georgetown University, Office of Minority Health and Cancer Prevention and Control, Washington, DC, United States Paxman Scalp Cooling, Huddersfield, United Kingdom AU - Dilawari, A. AU - Gallagher, C. AU - Alintah, P. AU - Chitalia, A. AU - Tiwari, S. AU - Paxman, R. AU - Adams-Campbell, L. AU - Dash, C. DB - Scopus DO - 10.1002/onco.13690 KW - Breast cancer Chemotherapy-induced alopecia Paxman scalp cooling device M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? T2 - Oncologist TI - Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100983081&doi=10.1002%2fonco.13690&partnerID=40&md5=8419b61de45ff40eadb0ee75ef828b28 ID - 2163 ER - TY - JOUR AB - Background: Association studies have suggested that lower circulating 25-hydroxyvitamin D [25(OH)D] in African Americans may partially underlie higher rates of cardiovascular disease and cancer in this population. Nonetheless, the relation between vitamin D supplementation and 25(OH)D concentrations in African Americans remains undefined. Objective: Our primary objective was to determine the doseresponse relation between vitamin D and plasma 25(OH)D. Design: A total of 328 African Americans in Boston, MA, were enrolled over 3 winters from 2007 to 2010 and randomly assigned to receive a placebo or 1000, 2000, or 4000 IU vitamin D3/d for 3 mo. Subjects completed sociodemographic and dietary questionnaires, and plasma samples were drawn at baseline and 3 and 6 mo. Results: Median plasma 25(OH)D concentrations at baseline were 15.1, 16.2, 13.9, and 15.7 ng/mL for subjects randomly assigned to receive the placebo or 1000, 2000, or 4000 IU/d, respectively (P = 0.63). The median plasma 25(OH)D concentration at 3 mo differed significantly between supplementation arms at 13.7, 29.7, 34.8, and 45.9 ng/mL, respectively (P < 0.001). An estimated 1640 IU vitamin D3/d was needed to raise the plasma 25(OH)D concentration to ≥20 ng/mL in ≥97.5% of participants, whereas a dose of 4000 IU/d was needed to achieve concentrations ≥33 ng/mL in ≥80% of subjects. No significant hypercalcemia was seen in a subset of participants. Conclusions: Within African Americans, an estimated 1640 IU vitamin D3/d was required to achieve concentrations of plasma 25(OH)D recommended by the Institute of Medicine, whereas 4000 IU/d was needed to reach concentrations predicted to reduce cancer and cardio-vascular disease risk in prospective observational studies. These results may be helpful for informing future trials of disease prevention. This trial was registered at clinicaltrials.gov as NCT00585637. © 2014 American Society for Nutrition. AD - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States Center for Community-Based Research, Dana-Farber Cancer Institute, Boston, MA, United States Division of Public Health Sciences, Washington University, School of Medicine, St Louis, MO, United States Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, United States Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Division of Pediatrics, Medical University of South Carolina, Charleston, SC, United States Division of General Medicine, Brigham and Women's Hospital, Boston, MA, United States Department of Psychology and Neuroscience, Duke University, Durham, NC, United States Department of Nutrition, Harvard School of Public Health, Boston, MA, United States Department of Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, United States AU - Ng, K. AU - Scott, J. B. AU - Drake, B. F. AU - Chan, A. T. AU - Hollis, B. W. AU - Chandler, P. D. AU - Bennett, G. G. AU - Giovannucci, E. L. AU - Gonzalez-Suarez, E. AU - Meyerhardt, J. A. AU - Emmons, K. M. AU - Fuchs, C. S. DB - Scopus DO - 10.3945/ajcn.113.067777 IS - 3 M3 - Article N1 - Cited By :52 Export Date: 22 March 2021 PY - 2014 SP - 587-598 ST - Dose response to vitamin D supplementation in African Americans: Results of a 4-arm, randomized, placebo-controlled trial T2 - American Journal of Clinical Nutrition TI - Dose response to vitamin D supplementation in African Americans: Results of a 4-arm, randomized, placebo-controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896847461&doi=10.3945%2fajcn.113.067777&partnerID=40&md5=1e0b4c53a6e4f23833364f3d11d00b52 VL - 99 ID - 2398 ER - TY - JOUR AB - Background: Association studies have suggested that lower circulating 25-hydroxyvitamin D [25(OH)D] in African Americans may partially underlie higher rates of cardiovascular disease and cancer in this population. Nonetheless, the relation between vitamin D supplementation and 25(OH)D concentrations in African Americans remains undefined. Objective: Our primary objective was to determine the dose-response relation between vitamin D and plasma 25(OH)D. Design: A total of 328 African Americans in Boston, MA, were enrolled over 3 winters from 2007 to 2010 and randomly assigned to receive a placebo or 1000, 2000, or 4000 IU vitamin D-3/d for 3 mo. Subjects completed sociodemographic and dietary questionnaires, and plasma samples were drawn at baseline and 3 and 6 mo. Results: Median plasma 25(OH)D concentrations at baseline were 15.1, 16.2, 13.9, and 15.7 ng/mL for subjects randomly assigned to receive the placebo or 1000, 2000, or 4000 IU/d, respectively (P = 0.63). The median plasma 25(OH)D concentration at 3 mo differed significantly between supplementation arms at 13.7, 29.7, 34.8, and 45.9 ng/mL, respectively (P < 0.001). An estimated 1640 IU vitamin D-3/d was needed to raise the plasma 25(OH)D concentration to >= 20 ng/mL in >= 97.5% of participants, whereas a dose of 4000 IU/d was needed to achieve concentrations >= 33 ng/mL in >= 80% of subjects. No significant hypercalcemia was seen in a subset of participants. Conclusions: Within African Americans, an estimated 1640 IU vitamin D-3/d was required to achieve concentrations of plasma 25(OH)D recommended by the Institute of Medicine, whereas 4000 IU/d was needed to reach concentrations predicted to reduce cancer and cardiovascular disease risk in prospective observational studies. These results may be helpful for informing future trials of disease prevention. This trial was registered at clinicaltrials.gov as NCT00585637. AN - WOS:000332143900022 AU - Ng, K. AU - Scott, J. B. AU - Drake, B. F. AU - Chan, A. T. AU - Hollis, B. W. AU - Chandler, P. D. AU - Bennett, G. G. AU - Giovannucci, E. L. AU - Gonzalez-Suarez, E. AU - Meyerhardt, J. A. AU - Emmons, K. M. AU - Fuchs, C. S. DA - Mar DO - 10.3945/ajcn.113.067777 IS - 3 N1 - 24368437 PY - 2014 SN - 0002-9165 SP - 587-598 ST - Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial(1-4) T2 - American Journal of Clinical Nutrition TI - Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial(1-4) VL - 99 ID - 3018 ER - TY - JOUR AB - SCOPE: Black raspberry (BRB) phytochemicals demonstrate anti-carcinogenic properties in experimental models, including prostate cancer. Two BRB foods, a confection and nectar, providing a consistent and reproducible product for human clinical studies are designed and characterized. METHODS AND RESULTS: Men with clinically localized prostate cancer are sequentially enrolled to a control group or one of four intervention groups (confection or nectar, 10 or 20 g dose; n = 8 per group) for 4 weeks prior to prostatectomy. Primary outcomes include: safety, adherence, and ellagitannin metabolism. Adherence to the intervention is >96%. No significant (≥grade II) toxicities are detected. Urinary urolithins (A, B, C, and D) and dimethyl ellagic acid (DMEA) quantified by Ultra high performance liquid chromatography tandem mass spectroscopy (UPLC/MS/MS) indicate a dose-dependent excretion yet heterogeneous patterns among men. Men in the BRB confection groups have greater urinary excretion of the microbial urinary metabolites urolithin A and DMEA, suggesting that this food matrix provides greater colonic microflora exposure. CONCLUSION: Fully characterized BRB confections and nectar are ideal for food-based large phase III human clinical studies. BRB products provide a bioavailable source of BRB phytochemicals, however large inter individual variation in polyphenol metabolism suggests that host genetics, microflora, and other factors are critical to understanding bioactivity and metabolism. AU - Roberts, K. M. AU - Grainger, E. M. AU - Thomas-Ahner, J. M. AU - Hinton, A. AU - Gu, J. AU - Riedl, K. AU - Vodovotz, Y. AU - Abaza, R. AU - Schwartz, S. J. AU - Clinton, S. K. DB - Medline DO - 10.1002/mnfr.201900800 IS - 10 KW - adult article biological activity cancer surgery clinical article clinical trial colon flora controlled study drug safety human male nectar nonhuman outcome assessment pharmacokinetics phase 3 clinical trial (topic) prostate cancer prostatectomy raspberry surgery tandem mass spectrometry urinary excretion biological marker ellagitannin phytochemical polyphenol unclassified drug LA - English M3 - Article N1 - L631109032 2020-04-07 PY - 2020 SN - 1613-4133 SP - e1900800 ST - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials T2 - Molecular nutrition & food research TI - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631109032&from=export http://dx.doi.org/10.1002/mnfr.201900800 VL - 64 ID - 808 ER - TY - JOUR AB - Scope: Black raspberry (BRB) phytochemicals demonstrate anti-carcinogenic properties in experimental models, including prostate cancer. Two BRB foods, a confection and nectar, providing a consistent and reproducible product for human clinical studies are designed and characterized. Methods and results: Men with clinically localized prostate cancer are sequentially enrolled to a control group or one of four intervention groups (confection or nectar, 10 or 20 g dose; n = 8 per group) for 4 weeks prior to prostatectomy. Primary outcomes include: safety, adherence, and ellagitannin metabolism. Adherence to the intervention is >96%. No significant (≥grade II) toxicities are detected. Urinary urolithins (A, B, C, and D) and dimethyl ellagic acid (DMEA) quantified by Ultra high performance liquid chromatography tandem mass spectroscopy (UPLC/MS/MS) indicate a dose-dependent excretion yet heterogeneous patterns among men. Men in the BRB confection groups have greater urinary excretion of the microbial urinary metabolites urolithin A and DMEA, suggesting that this food matrix provides greater colonic microflora exposure. Conclusion: Fully characterized BRB confections and nectar are ideal for food-based large phase III human clinical studies. BRB products provide a bioavailable source of BRB phytochemicals, however large inter individual variation in polyphenol metabolism suggests that host genetics, microflora, and other factors are critical to understanding bioactivity and metabolism. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim AD - Department of Human Sciences, The Ohio State University, Columbus, OH, United States Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Division of Biostatistics, The Ohio State University, Columbus, OH, United States Department of Food Science and Technology, The Ohio State University, Columbus, OH, United States Nutrient and Phytochemical Analytic Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Department of Urology, The Ohio State University, Columbus, OH, United States Ohio Health Physician Group Robotic Urologic and Cancer Surgery, Dublin Methodist Hospital, 7450 Hospital Drive, Suite 300, Dublin, OH 8518 43016, United States Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, United States The Ohio State University School of Health and Rehabilitation Sciences, 453 West 10th Avenue, 243C Atwell Hall, Columbus, OH 1280-43210, United States AU - Roberts, K. M. AU - Grainger, E. M. AU - Thomas-Ahner, J. M. AU - Hinton, A. AU - Gu, J. AU - Riedl, K. AU - Vodovotz, Y. AU - Abaza, R. AU - Schwartz, S. J. AU - Clinton, S. K. C7 - 1900800 DB - Scopus DO - 10.1002/mnfr.201900800 IS - 10 KW - black raspberries ellagitannins polyphenol explorer database polyphenols urolithins M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 ST - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials T2 - Molecular Nutrition and Food Research TI - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081747880&doi=10.1002%2fmnfr.201900800&partnerID=40&md5=a17347ca7b991744e5d3315769476452 VL - 64 ID - 2198 ER - TY - JOUR AB - Scope Black raspberry (BRB) phytochemicals demonstrate anti-carcinogenic properties in experimental models, including prostate cancer. Two BRB foods, a confection and nectar, providing a consistent and reproducible product for human clinical studies are designed and characterized. Methods and results Men with clinically localized prostate cancer are sequentially enrolled to a control group or one of four intervention groups (confection or nectar, 10 or 20 g dose; n = 8 per group) for 4 weeks prior to prostatectomy. Primary outcomes include: safety, adherence, and ellagitannin metabolism. Adherence to the intervention is >96%. No significant (>= grade II) toxicities are detected. Urinary urolithins (A, B, C, and D) and dimethyl ellagic acid (DMEA) quantified by Ultra high performance liquid chromatography tandem mass spectroscopy (UPLC/MS/MS) indicate a dose-dependent excretion yet heterogeneous patterns among men. Men in the BRB confection groups have greater urinary excretion of the microbial urinary metabolites urolithin A and DMEA, suggesting that this food matrix provides greater colonic microflora exposure. Conclusion Fully characterized BRB confections and nectar are ideal for food-based large phase III human clinical studies. BRB products provide a bioavailable source of BRB phytochemicals, however large inter individual variation in polyphenol metabolism suggests that host genetics, microflora, and other factors are critical to understanding bioactivity and metabolism. AN - WOS:000536848900009 AU - Roberts, K. M. AU - Grainger, E. M. AU - Thomas-Ahner, J. M. AU - Hinton, A. AU - Gu, J. N. AU - Riedl, K. AU - Vodovotz, Y. AU - Abaza, R. AU - Schwartz, S. J. AU - Clinton, S. K. DA - May DO - 10.1002/mnfr.201900800 IS - 10 N1 - 1900800 32112501 PY - 2020 SN - 1613-4125 ST - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials T2 - Molecular Nutrition & Food Research TI - Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials VL - 64 ID - 2779 ER - TY - JOUR AB - Background: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects. This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy. Patients and methods: Patients with early-stage breast or colon cancer who required postoperative adjuvant chemotherapy were eligible for the study. Enrolled patients were randomly assigned to one of three Chinese herbalists who evaluated and prescribed a combination of single-item packaged herbal extract granules. Patients received either CHM or placebo packages with a corresponding serial number. The placebo package contained nontherapeutic herbs with an artificial smell and taste similar to a typical herbal tea. The primary end points were hematologic and non-hematologic toxicity according to the National Cancer Institute Common Toxicity Criteria Version 2. Results: One hundred and twenty patients were accrued at the time of premature study termination. Patient characteristics of the two groups were similar. The incidence of grade 3/4 anemia, leukopenia, neutropenia, and thrombocytopenia for the CHM and placebo groups were 5.4%, 47.3%, 52.7%, and 1.8% and 1.8%, 32.2%, 44.7%, and 3.6%, respectively (P = 0.27, 0.37, 0.63, and 0.13, respectively). Incidence of grade 2 nausea was the only non-hematologic toxicity that was significantly reduced in the CHM group (14.6% versus 35.7%, P = 0.04). Conclusions: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy. CHM, however, does have a significant impact on control of nausea. © 2007 Oxford University Press. AD - Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Oncology, University of Birmingham, Birmingham, United Kingdom School of Chinese Medicine, Baptist Hospital, Hong Kong Special Administrative Region (HKSAR), Hong Kong Centre for Clinical Trials, School of Public Health, Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong AU - Mok, T. S. K. AU - Yeo, W. AU - Johnson, P. J. AU - Hui, P. AU - Ho, W. M. AU - Lam, K. C. AU - Xu, M. AU - Chak, K. AU - Chan, A. AU - Wong, H. AU - Mo, F. AU - Zee, B. DB - Scopus DO - 10.1093/annonc/mdl465 IS - 4 KW - Alternative and complementary medicine Chemotherapy Chinese herbal medicine Colonic neoplasms Emesis Toxicity M3 - Article N1 - Cited By :66 Export Date: 22 March 2021 PY - 2007 SP - 768-774 ST - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity T2 - Annals of Oncology TI - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34047111338&doi=10.1093%2fannonc%2fmdl465&partnerID=40&md5=061f3e47dfa5d910e73f42ddb4d93cab VL - 18 ID - 2563 ER - TY - JOUR AB - Background: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects. This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy. Patients and methods: Patients with early-stage breast or colon cancer who required postoperative adjuvant chemotherapy were eligible for the study. Enrolled patients were randomly assigned to one of three Chinese herbalists who evaluated and prescribed a combination of single-item packaged herbal extract granules. Patients received either CHM or placebo packages with a corresponding serial number. The placebo package contained nontherapeutic herbs with an artificial smell and taste similar to a typical herbal tea. The primary end points were hematologic and non-hematologic toxicity according to the National Cancer Institute Common Toxicity Criteria Version 2. Results: One hundred and twenty patients were accrued at the time of premature study termination. Patient characteristics of the two groups were similar. The incidence of grade 3/4 anemia, leukopenia, neutropenia, and thrombocytopenia for the CHM and placebo groups were 5.4%, 47.3%, 52.7%, and 1.8% and 1.8%, 32.2%, 44.7%, and 3.6%, respectively (P = 0.27, 0.37, 0.63, and 0.13, respectively). Incidence of grade 2 nausea was the only non-hematologic toxicity that was significantly reduced in the CHM group (14.6% versus 35.7%, P = 0.04). Conclusions: Traditional CHM does not reduce the hematologic toxicity associated with chemotherapy. CHM, however, does have a significant impact on control of nausea. AN - WOS:000245349500023 AU - Mok, T. S. K. AU - Yeo, W. AU - Johnson, P. J. AU - Hui, P. AU - Ho, W. M. AU - Lam, K. C. AU - Xu, M. AU - Chak, K. AU - Chan, A. AU - Wong, H. AU - Mo, F. AU - Zee, B. DA - Apr DO - 10.1093/annonc/mdl465 IS - 4 N1 - 27th Congress of the European-Society-for-Medical-Oncology OCT 18-22, 2002 NICE, FRANCE European Soc Med Oncol 17229769 PY - 2007 SN - 0923-7534 SP - 768-774 ST - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity T2 - Annals of Oncology TI - A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity VL - 18 ID - 3197 ER - TY - JOUR AD - Loyola University Medical Center, Maywood, IL. AN - 103747131. Language: English. Entry Date: 20150417. Revision Date: 20200708. Publication Type: Journal Article AU - Ellimoottil, Chandy AU - Gupta, Gopal N. AU - Quek, Marcus L. DB - CINAHL Complete DO - 10.1016/j.urology.2014.09.066 DP - EBSCOhost IS - 2 KW - Black Persons White Persons Patient Selection Prostatectomy Prostatic Neoplasms -- Surgery Outcomes (Health Care) Male N1 - editorial. Journal Subset: Biomedical; USA. NLM UID: 0366151. PMID: NLM25623716. PY - 2015 SN - 0090-4295 SP - 441-441 ST - Editorial comment T2 - Urology TI - Editorial comment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103747131&site=ehost-live&scope=site VL - 85 ID - 1922 ER - TY - JOUR AB - Background: Quality of bowel preparation and patient knowledge remains a major barrier for completing colorectal cancer screening. Few studies have tested unique ways to impact patient understanding centering on interactive computer programs, pictures, and brochures. Two studies explored instructional videos but focused on patient compliance and anxiety as endpoints. Furthermore, excessive video length and content may limit their impact on a broad patient population. No study so far has studied a video's impact on preparation quality and patient understanding of the colonoscopy procedure. Methods: We conducted a single blinded prospective study of inner city patients presenting for a first time screening colonoscopy. During their initial visit patients were randomized to watch an instructional colonoscopy video or a video discussing gastroesophageal reflux disease (GERD). All patients watched a 6 minutes long video with the same spokesperson, completed a demographic questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) and were enrolled only if screened within 30 days of their visit. On the day of the colonoscopy, patients completed a 14 question quiz of their knowledge. Blinded endoscopist graded patient preparations based on the Ottawa scale. All authors had access to the study data and reviewed and approved the final manuscript. Results: Among the 104 subjects enrolled in the study, 56 were in the colonoscopy video group, 48 were in GERD video group, and 12 were excluded. Overall, 48% were male and 52% female; 90% of patients had less than a high school education, 76% were African American, and 67% used a 4 L split-dose preparation. There were no differences between either video group with regard to any of the above categories. Comparisons between the 2 groups revealed that the colonoscopy video group had significantly better Ottawa bowel preparation score (4.77 vs. 6.85; P=0.01) than the GERD video group. The colonoscopy video group also had less-inadequate repeat bowel preparations versus the GERD video group (9% vs. 23%; P<0.01). The overall score on the knowledge questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) was significantly higher in the colonoscopy video group as compared with the GERD video group (12.77 vs. 11.08; P<0.001. In all patients the overall quiz score positively correlated with preparation quality (odds ratio, 2.31; confidence interval, 1.35-3.94; P<0.001). Conclusions: Our unique population represented an overwhelmingly under-educated (85% had a high school education or less) and minority group (76% African American). They are one of the most at risk of having multiple barriers such as comprehension and reading difficulties resulting in poor preparation examinations and no shows to procedures. Our instructional video proved to be high yield in this population. The patients assigned to watch the colonoscopy video showed a significant increase in "excellent" grade adequate bowel preparation quality by >23% and a significant decrease in "inadequate" bowel preparations by almost 50%. Our study proves that an educational video can improve both comprehension with regard to all aspects of colonoscopy. ClinicalTrials.gov number, NCT02906969. AD - A. Pillai, Division of Gastroenterology and Hepatology, Drexel University College of Medicine, 219 North Broad Street, Philadelphia, PA, United States AU - Pillai, A. AU - Menon, R. AU - Oustecky, D. AU - Ahmad, A. C1 - halflytely DB - Embase Medline DO - 10.1097/MCG.0000000000000893 IS - 6 KW - NCT02906969 bicarbonate plus bisacodyl plus macrogol 3350 plus potassium chloride plus sodium chloride adult African American anxiety article cancer screening colonoscopy comparative study comprehension controlled clinical trial controlled study digestive system disease assessment educational status endoscopist evening dosage female gastroesophageal reflux high school human intestine preparation knowledge major clinical study male morning dosage Ottawa bowel preparation score patient compliance patient education priority journal scoring system single blind procedure urban population videorecording halflytely LA - English M3 - Article N1 - L617517309 2017-08-01 2018-06-29 PY - 2018 SN - 1539-2031 0192-0790 SP - 515-518 ST - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population T2 - Journal of Clinical Gastroenterology TI - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617517309&from=export http://dx.doi.org/10.1097/MCG.0000000000000893 VL - 52 ID - 915 ER - TY - JOUR AB - Background: Quality of bowel preparation and patient knowledge remains a major barrier for completing colorectal cancer screening. Few studies have tested unique ways to impact patient understanding centering on interactive computer programs, pictures, and brochures. Two studies explored instructional videos but focused on patient compliance and anxiety as endpoints. Furthermore, excessive video length and content may limit their impact on a broad patient population. No study so far has studied a video's impact on preparation quality and patient understanding of the colonoscopy procedure.Methods: We conducted a single blinded prospective study of inner city patients presenting for a first time screening colonoscopy. During their initial visit patients were randomized to watch an instructional colonoscopy video or a video discussing gastroesophageal reflux disease (GERD). All patients watched a 6 minutes long video with the same spokesperson, completed a demographic questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) and were enrolled only if screened within 30 days of their visit. On the day of the colonoscopy, patients completed a 14 question quiz of their knowledge. Blinded endoscopist graded patient preparations based on the Ottawa scale. All authors had access to the study data and reviewed and approved the final manuscript.Results: Among the 104 subjects enrolled in the study, 56 were in the colonoscopy video group, 48 were in GERD video group, and 12 were excluded. Overall, 48% were male and 52% female; 90% of patients had less than a high school education, 76% were African American, and 67% used a 4 L split-dose preparation. There were no differences between either video group with regard to any of the above categories. Comparisons between the 2 groups revealed that the colonoscopy video group had significantly better Ottawa bowel preparation score (4.77 vs. 6.85; P=0.01) than the GERD video group. The colonoscopy video group also had less-inadequate repeat bowel preparations versus the GERD video group (9% vs. 23%; P<0.01). The overall score on the knowledge questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) was significantly higher in the colonoscopy video group as compared with the GERD video group (12.77 vs. 11.08; P<0.001. In all patients the overall quiz score positively correlated with preparation quality (odds ratio, 2.31; confidence interval, 1.35-3.94; P<0.001).Conclusions: Our unique population represented an overwhelmingly under-educated (85% had a high school education or less) and minority group (76% African American). They are one of the most at risk of having multiple barriers such as comprehension and reading difficulties resulting in poor preparation examinations and no shows to procedures. Our instructional video proved to be high yield in this population. The patients assigned to watch the colonoscopy video showed a significant increase in "excellent" grade adequate bowel preparation quality by >23% and a significant decrease in "inadequate" bowel preparations by almost 50%. Our study proves that an educational video can improve both comprehension with regard to all aspects of colonoscopy. ClinicalTrials.gov number, NCT02906969. AD - Division of Gastroenterology and Hepatology, Drexel University College of Medicine, Philadelphia, PA AN - 130172272. Language: English. Entry Date: 20190617. Revision Date: 20191002. Publication Type: journal article AU - Pillai, Ajish AU - Menon, Radha AU - Oustecky, David AU - Ahmad, Asyia DB - CINAHL Complete DO - 10.1097/MCG.0000000000000893 DP - EBSCOhost IS - 6 KW - Colonoscopy -- Education Colorectal Neoplasms -- Pathology Early Detection of Cancer -- Methods Cathartics -- Therapeutic Use Urban Health Services Videorecording Attitude to Health Patient Education -- Methods Therapeutic Irrigation -- Methods Colonoscopy -- Methods Pennsylvania Human Cathartics -- Adverse Effects Readability Communication Single-Blind Studies Prospective Studies Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Questionnaires N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. Special Interest: Evidence-Based Practice. Instrumentation: Knowledge Questionnaire. NLM UID: 7910017. PMID: NLM28742732. PY - 2018 SN - 0192-0790 SP - 515-518 ST - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population T2 - Journal of Clinical Gastroenterology TI - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130172272&site=ehost-live&scope=site VL - 52 ID - 1923 ER - TY - JOUR AB - Background: Quality of bowel preparation and patient knowledge remains a major barrier for completing colorectal cancer screening. Few studies have tested unique ways to impact patient understanding centering on interactive computer programs, pictures, and brochures. Two studies explored instructional videos but focused on patient compliance and anxiety as endpoints. Furthermore, excessive video length and content may limit their impact on a broad patient population. No study so far has studied a video's impact on preparation quality and patient understanding of the colonoscopy procedure. Methods: We conducted a single blinded prospective study of inner city patients presenting for a first time screening colonoscopy. During their initial visit patients were randomized to watch an instructional colonoscopy video or a video discussing gastroesophageal reflux disease (GERD). All patients watched a 6 minutes long video with the same spokesperson, completed a demographic questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) and were enrolled only if screened within 30 days of their visit. On the day of the colonoscopy, patients completed a 14 question quiz of their knowledge. Blinded endoscopist graded patient preparations based on the Ottawa scale. All authors had access to the study data and reviewed and approved the final manuscript. Results: Among the 104 subjects enrolled in the study, 56 were in the colonoscopy video group, 48 were in GERD video group, and 12 were excluded. Overall, 48% were male and 52% female; 90% of patients had less than a high school education, 76% were African American, and 67% used a 4 L split-dose preparation. There were no differences between either video group with regard to any of the above categories. Comparisons between the 2 groups revealed that the colonoscopy video group had significantly better Ottawa bowel preparation score (4.77 vs. 6.85; P=0.01) than the GERD video group. The colonoscopy video group also had less-inadequate repeat bowel preparations versus the GERD video group (9% vs. 23%; P<0.01). The overall score on the knowledge questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) was significantly higher in the colonoscopy video group as compared with the GERD video group (12.77 vs. 11.08; P<0.001. In all patients the overall quiz score positively correlated with preparation quality (odds ratio, 2.31; confidence interval, 1.35-3.94; P<0.001). Conclusions: Our unique population represented an overwhelmingly under-educated (85% had a high school education or less) and minority group (76% African American). They are one of the most at risk of having multiple barriers such as comprehension and reading difficulties resulting in poor preparation examinations and no shows to procedures. Our instructional video proved to be high yield in this population. The patients assigned to watch the colonoscopy video showed a significant increase in "excellent" grade adequate bowel preparation quality by >23% and a significant decrease in "inadequate" bowel preparations by almost 50%. Our study proves that an educational video can improve both comprehension with regard to all aspects of colonoscopy. ClinicalTrials.gov number, NCT02906969. © 2017 Wolters Kluwer Health, Inc. All rights reserved. AD - Division of Gastroenterology and Hepatology, Drexel University College of Medicine, 219 North Broad Street, Philadelphia, PA 19107, United States AU - Pillai, A. AU - Menon, R. AU - Oustecky, D. AU - Ahmad, A. DB - Scopus DO - 10.1097/MCG.0000000000000893 IS - 6 KW - colonoscopy colonoscopy preparation comprehension education educational video M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2018 SP - 515-518 ST - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population T2 - Journal of Clinical Gastroenterology TI - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025807632&doi=10.1097%2fMCG.0000000000000893&partnerID=40&md5=845e869fb20791915706ad3e4afa023a VL - 52 ID - 2291 ER - TY - JOUR AB - Background:Quality of bowel preparation and patient knowledge remains a major barrier for completing colorectal cancer screening. Few studies have tested unique ways to impact patient understanding centering on interactive computer programs, pictures, and brochures. Two studies explored instructional videos but focused on patient compliance and anxiety as endpoints. Furthermore, excessive video length and content may limit their impact on a broad patient population. No study so far has studied a video's impact on preparation quality and patient understanding of the colonoscopy procedure.Methods:We conducted a single blinded prospective study of inner city patients presenting for a first time screening colonoscopy. During their initial visit patients were randomized to watch an instructional colonoscopy video or a video discussing gastroesophageal reflux disease (GERD). All patients watched a 6 minutes long video with the same spokesperson, completed a demographic questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) and were enrolled only if screened within 30 days of their visit. On the day of the colonoscopy, patients completed a 14 question quiz of their knowledge. Blinded endoscopist graded patient preparations based on the Ottawa scale. All authors had access to the study data and reviewed and approved the final manuscript.Results:Among the 104 subjects enrolled in the study, 56 were in the colonoscopy video group, 48 were in GERD video group, and 12 were excluded. Overall, 48% were male and 52% female; 90% of patients had less than a high school education, 76% were African American, and 67% used a 4 L split-dose preparation. There were no differences between either video group with regard to any of the above categories. Comparisons between the 2 groups revealed that the colonoscopy video group had significantly better Ottawa bowel preparation score (4.77 vs. 6.85; P=0.01) than the GERD video group. The colonoscopy video group also had less-inadequate repeat bowel preparations versus the GERD video group (9% vs. 23%; P<0.01). The overall score on the knowledge questionnaire (Supplemental Digital Content 1, http://links.lww.com/JCG/A352) was significantly higher in the colonoscopy video group as compared with the GERD video group (12.77 vs. 11.08; P<0.001. In all patients the overall quiz score positively correlated with preparation quality (odds ratio, 2.31; confidence interval, 1.35-3.94; P<0.001).Conclusions:Our unique population represented an overwhelmingly under-educated (85% had a high school education or less) and minority group (76% African American). They are one of the most at risk of having multiple barriers such as comprehension and reading difficulties resulting in poor preparation examinations and no shows to procedures. Our instructional video proved to be high yield in this population. The patients assigned to watch the colonoscopy video showed a significant increase in excellent grade adequate bowel preparation quality by >23% and a significant decrease in inadequate bowel preparations by almost 50%. Our study proves that an educational video can improve both comprehension with regard to all aspects of colonoscopy. ClinicalTrials.gov number, NCT02906969. AN - WOS:000435290800009 AU - Pillai, A. AU - Menon, R. AU - Oustecky, D. AU - Ahmad, A. DA - Jul DO - 10.1097/MCG.0000000000000893 IS - 6 N1 - 28742732 PY - 2018 SN - 0192-0790 SP - 515-518 ST - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population T2 - Journal of Clinical Gastroenterology TI - Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population VL - 52 ID - 2855 ER - TY - JOUR AB - Socioeconomic inequalities cause different tobacco consumption patterns. The purpose of this study was to examine the relationship between educational level and smoking behaviour, including type of tobacco consumption, in lung cancer patients. To this end, epidemiological analyses of 801 lung cancer patients recruited for a case-control study in four public hospitals in Asturias, Spain, between October 2000 and April 2006 were carried out. Smoking behaviour and educational level data were obtained through personal interview. Analyses indicated that the probability of heavy smoking among low educational-level patients was approximately twice as high as for high educational-level patients (RRR>31.2packs/years = 2.04; CI 95%= 1.15-3.62; RRR>52packs/years= 2.14; CI 95%= 0.98-4.64). Low-educated patients were more than three times as likely to be long-time smokers (RRR>40years = 3.30; CI 95%= 1.43-7.62). The probability of smoking exclusively black tobacco was almost four times greater in low educational-level patients (RRRblack only= 3.72; CI 95%= 1.23-11.19). The results show that there are broad educational inequalities with regard to the quantity, duration and type of tobacco consumption among lung cancer patients in Northern Spain. © 2010 Psicothema. AD - Universidad de Oviedo, 33006 Oviedo, Spain CIBER Epidemiología y Salud Pública(CIBERESP), Spain Mount Sinai School of Medicine, New York, United States Hospital de Cabueñes, Gijón, Spain AU - Leader, A. AU - Fernández-Somoano, A. AU - López-Cima, M. F. AU - González-Arriaga, P. AU - Pascual, T. AU - Marrón, M. G. AU - Tardón, A. DB - Scopus IS - 4 M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2010 SP - 634-640 ST - Desigualdades educativas según la cantidad, duración y tipo de tabaco consumido en pacientes con cáncer de pulmón en Asturias: Análisis epidemiológicos. T2 - Psicothema TI - Educational inequalities in quantity, duration and type of tobacco consumption among lung cancer patients in Asturias: Epidemiological analyses UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78549282410&partnerID=40&md5=e787cd7ae2ec4635f6d470454180bb91 VL - 22 ID - 2492 ER - TY - JOUR AB - Only 3% of women with breast cancer participate in cancer clinical trials nationwide. The lack of awareness about clinical trials is a significant barrier towards clinical trials participation. A study was conducted at a large urban Comprehensive Cancer Center to test (1) the effectiveness of an 18-min educational video on improving attitudes toward clinical trials and trials enrollment among new breast cancer patients seen at the Karmanos Cancer Institute, and (2) to assess racial differences in attitudes regarding clinical trials. Participants were randomized to either the educational intervention prior to their first oncology clinic appointment or to standard care. A baseline and 2-week post-intervention survey to assess attitudes toward clinical trials participation was completed by participants. Of 218 subjects recruited, 196 (55% white vs. 45% African American (AA)) eligible patients were included in the analysis. A small increase in therapeutic clinical trial enrollment was observed in the intervention arm but was not statistically significant (10.4% vs. 6.1%; P = 0.277). The intervention also did not result in a clear improvement in patients' attitudes toward clinical trials at posttest. However, a lower enrollment rate for the AA women was noted after adjusting for stage (OR = 0.282, P = 0.049). Significantly more negative scores were noted in 3 out of the 5 baseline attitudinal scales for AA women. The educational video did not significantly increase enrollment in breast cancer clinical trials. The findings that AA women had significantly more negative attitudes toward clinical trials than white women may partially explain the racial disparity in enrollment. An educational video remains a simple and cost-effective way to educate patients. Future studies should focus on designing a new educational video to specifically target cultural and attitudinal barriers in the AA population to more effectively change attitudes and increase trial enrollment. © 2009 Springer Science+Business Media, LLC. AD - W. Du, Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, United States AU - Du, W. AU - Mood, D. AU - Gadgeel, S. AU - Simon, M. S. DB - Embase Medline DO - 10.1007/s10549-009-0311-7 IS - 2 KW - adult African American aged article awareness breast cancer cancer patient clinical trial controlled clinical trial controlled study cost effectiveness analysis cultural factor European American female human major clinical study patient attitude patient care patient education priority journal race difference randomized controlled trial videorecording LA - English M3 - Article N1 - L50394412 2009-10-23 PY - 2009 SN - 0167-6806 1573-7217 SP - 339-347 ST - An educational video to increase clinical trials enrollment among breast cancer patients T2 - Breast Cancer Research and Treatment TI - An educational video to increase clinical trials enrollment among breast cancer patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50394412&from=export http://dx.doi.org/10.1007/s10549-009-0311-7 VL - 117 ID - 1182 ER - TY - JOUR AB - Only 3% of women with breast cancer participate in cancer clinical trials nationwide. The lack of awareness about clinical trials is a significant barrier towards clinical trials participation. A study was conducted at a large urban Comprehensive Cancer Center to test (1) the effectiveness of an 18‐min educational video on improving attitudes toward clinical trials and trials enrollment among new breast cancer patients seen at the Karmanos Cancer Institute, and (2) to assess racial differences in attitudes regarding clinical trials. Participants were randomized to either the educational intervention prior to their first oncology clinic appointment or to standard care. A baseline and 2‐week post‐intervention survey to assess attitudes toward clinical trials participation was completed by participants. Of 218 subjects recruited, 196 (55% white vs. 45% African American (AA)) eligible patients were included in the analysis. A small increase in therapeutic clinical trial enrollment was observed in the intervention arm but was not statistically significant (10.4% vs. 6.1%; P = 0.277). The intervention also did not result in a clear improvement in patients' attitudes toward clinical trials at posttest. However, a lower enrollment rate for the AA women was noted after adjusting for stage (OR = 0.282, P = 0.049). Significantly more negative scores were noted in 3 out of the 5 baseline attitudinal scales for AA women. The educational video did not significantly increase enrollment in breast cancer clinical trials. The findings that AA women had significantly more negative attitudes toward clinical trials than white women may partially explain the racial disparity in enrollment. An educational video remains a simple and cost‐effective way to educate patients. Future studies should focus on designing a new educational video to specifically target cultural and attitudinal barriers in the AA population to more effectively change attitudes and increase trial enrollment. AN - CN-00730607 AU - Du, W. AU - Mood, D. AU - Gadgeel, S. AU - Simon, M. S. DO - 10.1007/s10549-009-0311-7 IS - 2 KW - Attitude to Health [ethnology] Breast Neoplasms [pathology, *therapy] Clinical Trials as Topic Continental Population Groups Female Humans Middle Aged Neoplasm Staging Patient Education as Topic [*methods] Patient Selection Video Recording M3 - Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2009 SP - 339‐347 ST - An educational video to increase clinical trials enrollment among breast cancer patients T2 - Breast cancer research and treatment TI - An educational video to increase clinical trials enrollment among breast cancer patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00730607/full VL - 117 ID - 1435 ER - TY - JOUR AB - Only 3% of women with breast cancer participate in cancer clinical trials nationwide. The lack of awareness about clinical trials is a significant barrier towards clinical trials participation. A study was conducted at a large urban Comprehensive Cancer Center to test (1) the effectiveness of an 18-min educational video on improving attitudes toward clinical trials and trials enrollment among new breast cancer patients seen at the Karmanos Cancer Institute, and (2) to assess racial differences in attitudes regarding clinical trials. Participants were randomized to either the educational intervention prior to their first oncology clinic appointment or to standard care. A baseline and 2-week post-intervention survey to assess attitudes toward clinical trials participation was completed by participants. Of 218 subjects recruited, 196 (55% white vs. 45% African American (AA)) eligible patients were included in the analysis. A small increase in therapeutic clinical trial enrollment was observed in the intervention arm but was not statistically significant (10.4% vs. 6.1%; P = 0.277). The intervention also did not result in a clear improvement in patients' attitudes toward clinical trials at posttest. However, a lower enrollment rate for the AA women was noted after adjusting for stage (OR = 0.282, P = 0.049). Significantly more negative scores were noted in 3 out of the 5 baseline attitudinal scales for AA women. The educational video did not significantly increase enrollment in breast cancer clinical trials. The findings that AA women had significantly more negative attitudes toward clinical trials than white women may partially explain the racial disparity in enrollment. An educational video remains a simple and cost-effective way to educate patients. Future studies should focus on designing a new educational video to specifically target cultural and attitudinal barriers in the AA population to more effectively change attitudes and increase trial enrollment. © 2009 Springer Science+Business Media, LLC. AD - Carman and Ann Adams Department of Pediatrics, Wayne State University, Detroit, MI, United States Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, United States College of Nursing, Wayne State University, Detroit, MI, United States Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States AU - Du, W. AU - Mood, D. AU - Gadgeel, S. AU - Simon, M. S. DB - Scopus DO - 10.1007/s10549-009-0311-7 IS - 2 KW - Attitudes regarding clinical trials Breast cancer Clinical trials enrollment Educational video Racial disparity M3 - Article N1 - Cited By :32 Export Date: 22 March 2021 PY - 2009 SP - 339-347 ST - An educational video to increase clinical trials enrollment among breast cancer patients T2 - Breast Cancer Research and Treatment TI - An educational video to increase clinical trials enrollment among breast cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-68949090547&doi=10.1007%2fs10549-009-0311-7&partnerID=40&md5=c7baf3ad2d812629528fd1eceb46a946 VL - 117 ID - 2514 ER - TY - JOUR AB - Only 3% of women with breast cancer participate in cancer clinical trials nationwide. The lack of awareness about clinical trials is a significant barrier towards clinical trials participation. A study was conducted at a large urban Comprehensive Cancer Center to test (1) the effectiveness of an 18-min educational video on improving attitudes toward clinical trials and trials enrollment among new breast cancer patients seen at the Karmanos Cancer Institute, and (2) to assess racial differences in attitudes regarding clinical trials. Participants were randomized to either the educational intervention prior to their first oncology clinic appointment or to standard care. A baseline and 2-week post-intervention survey to assess attitudes toward clinical trials participation was completed by participants. Of 218 subjects recruited, 196 (55% white vs. 45% African American (AA)) eligible patients were included in the analysis. A small increase in therapeutic clinical trial enrollment was observed in the intervention arm but was not statistically significant (10.4% vs. 6.1%; P = 0.277). The intervention also did not result in a clear improvement in patients' attitudes toward clinical trials at posttest. However, a lower enrollment rate for the AA women was noted after adjusting for stage (OR = 0.282, P = 0.049). Significantly more negative scores were noted in 3 out of the 5 baseline attitudinal scales for AA women. The educational video did not significantly increase enrollment in breast cancer clinical trials. The findings that AA women had significantly more negative attitudes toward clinical trials than white women may partially explain the racial disparity in enrollment. An educational video remains a simple and cost-effective way to educate patients. Future studies should focus on designing a new educational video to specifically target cultural and attitudinal barriers in the AA population to more effectively change attitudes and increase trial enrollment. AN - WOS:000269005500014 AU - Du, W. AU - Mood, D. AU - Gadgeel, S. AU - Simon, M. S. DA - Sep DO - 10.1007/s10549-009-0311-7 IS - 2 N1 - 19152024 PY - 2009 SN - 0167-6806 SP - 339-347 ST - An educational video to increase clinical trials enrollment among breast cancer patients T2 - Breast Cancer Research and Treatment TI - An educational video to increase clinical trials enrollment among breast cancer patients VL - 117 ID - 3140 ER - TY - JOUR AB - INTRODUCTION: Only 3 to 5% of new adult cancer patients participate in clinical trials nationwide. The lack of knowledge and awareness about clinical trials is a significant barrier to clinical trials participation. A randomized trial was conducted to test the effect of an educational video on positively changing patients' knowledge and attitudes regarding clinical trials and thereby increasing enrollment rates. METHODS: Lung cancer patients were randomized to viewing either an 18‐minute video about clinical trials before first clinic appointment or to standard care. Participants completed a baseline and 2‐week postintervention survey to assess their knowledge and attitudes toward trials participation. Fisher's exact test tests, t tests, and regression were used to compare patient characteristics and outcomes between arms. RESULTS: Of 145 subjects randomized, 126 (63/arm) satisfied all inclusion criteria and were included in the analysis. A linear regression showed that the video intervention was significantly associated with patients' self‐assessed likelihood to enroll score measured at 2‐week follow‐up (p = 0.019). Although statistically insignificant, enrollment rates were found to be higher in the intervention arm for therapeutic trials alone (17.5% versus 11.1%) and for therapeutic and nontherapeutic trials combined (25.4% versus 15.9%). CONCLUSIONS: The brief educational video seems to be effective in positively changing lung cancer patients' attitudes about participation in clinical trials. Higher enrollment rates were also observed in the intervention group but the differences did not reach statistical significance. These findings suggest a potential impact of the educational video on clinical trial enrollment; however, larger studies are needed to confirm these findings. AN - CN-00647523 AU - Du, W. AU - Mood, D. AU - Gadgeel, S. AU - Simon, M. S. DO - 10.1097/JTO.0b013e31815e8bb2 IS - 1 KW - African Americans [statistics & numerical data] Carcinoma, Non‐Small‐Cell Lung [pathology, *therapy] Educational Technology European Continental Ancestry Group [statistics & numerical data] Female Health Knowledge, Attitudes, Practice Humans Linear Models Lung Neoplasms [pathology, *therapy] Male Middle Aged Patient Education as Topic [*methods] Surveys and Questionnaires Videotape Recording M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2008 SP - 23‐29 ST - An educational video to increase clinical trials enrollment among lung cancer patients T2 - Journal of thoracic oncology TI - An educational video to increase clinical trials enrollment among lung cancer patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00647523/full VL - 3 ID - 1400 ER - TY - JOUR AB - INTRODUCTION: We conducted a randomized controlled trial to determine if an in‐home educational intervention conducted by lay health workers (LHWs) could increase adherence among low‐income, inner‐city, African‐American women to breast and cervical cancer screening schedules. METHODS: We recruited 321 African‐American women from diverse inner‐city sources. After baseline interviews, they were randomly assigned to either the intervention (n = 163) or the control (n = 158) group. Those in the intervention group were visited in their homes up to three times by LHWs who provided a culturally sensitive educational program that emphasized the need for screening. RESULTS: Ninety‐three (93) women in the intervention group and 102 in the control group completed the postintervention interview. For Pap smears, the increase in screening was similar in both groups. For clinical breast exams (CBEs), however, there was a modest increase in the intervention group. The improvement was greatest for mammography, for which there was a 10% to 12% increase. Among women who were not on recommended schedules at baseline, the improvement was substantial and greater in the intervention group. CONCLUSIONS: LHWs' intervention appeared to improve the rate at which inner‐city women obtained CBEs and mammograms, but had no effect on Pap smears. A high attrition rate weakened our ability to make conclusive statements about the exact impact of the intervention. AN - CN-00136743 AU - Sung, J. F. AU - Blumenthal, D. S. AU - Coates, R. J. AU - Williams, J. E. AU - Alema-Mensah, E. AU - Liff, J. M. IS - 1 KW - Adolescent Adult African Americans Aged Aged, 80 and over Breast Neoplasms [ethnology, *prevention & control] Breast Self‐Examination Community Health Workers Community Participation [statistics & numerical data] Female Follow‐Up Studies Georgia Health Education [*methods] Humans Mass Screening Middle Aged Poverty Urban Population Uterine Cervical Neoplasms [ethnology, *prevention & control] M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 1997 SP - 51‐57 ST - Effect of a cancer screening intervention conducted by lay health workers among inner-city women T2 - American journal of preventive medicine TI - Effect of a cancer screening intervention conducted by lay health workers among inner-city women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00136743/full VL - 13 ID - 1383 ER - TY - JOUR AB - Introduction: We conducted a randomized controlled trial to determine if an in-home educational intervention conducted by lay health workers (LHWs) could increase adherence among low-income, inner-city, African-American women to breast and cervical cancer screening schedules. Methods: We recruited 321 African-American women from diverse inner-city sources. After baseline interviews, they were randomly assigned to either the intervention (n = 163) or the control (n = 158) group. Those in the intervention group were visited in their homes up to three times by LHWs who provided a culturally sensitive educational program that emphasized the need for screening. Results: Ninety- three (93) women in the intervention group and 102 in the control group completed the postintervention interview. For Pap smears, the increase in screening was similar in both groups. For clinical breast exams (CBEs), however, there was a modest increase in the intervention group. The improvement was greatest for mammography, for which there was a 10% to 12% increase. Among women who were not on recommended schedules at baseline, the improvement was substantial and greater in the intervention group. Conclusions: LHWs' intervention appeared to improve the rate at which inner- city women obtained CBEs and mammograms, but had no effect on Pap smears. A high attrition rate weakened our ability to make conclusive statements about the exact impact of the intervention. Medical Subject Headings (MESH): intervention studies, Papanicolaou smear, mammography, urban health, health services, indigenous community health aides, breast. AD - J.F.C. Sung, Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310, United States AU - Sung, J. F. C. AU - Blumenthal, D. S. AU - Coates, R. J. AU - Williams, J. E. AU - Alema-Mensah, E. AU - Lill, J. M. DB - Embase Medline DO - 10.1016/s0749-3797(18)30225-3 IS - 1 KW - adult article breast cancer cancer screening controlled study early diagnosis female health care utilization human major clinical study mammography Black person Papanicolaou test patient compliance patient education urban population uterine cervix cancer LA - English M3 - Article N1 - L27088059 1997-03-05 PY - 1997 SN - 0749-3797 SP - 51-57 ST - Effect of a cancer screening intervention conducted by lay health workers among inner-city women T2 - American Journal of Preventive Medicine TI - Effect of a cancer screening intervention conducted by lay health workers among inner-city women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L27088059&from=export http://dx.doi.org/10.1016/s0749-3797(18)30225-3 VL - 13 ID - 1334 ER - TY - JOUR AB - Introduction: We conducted a randomized controlled trial to determine if an in-home educational intervention conducted by lay health workers (LHWs) could increase adherence among low-income, inner-city, African-American women to breast and cervical cancer screening schedules. Methods: We recruited 321 African-American women from diverse inner-city sources. After baseline interviews, they were randomly assigned to either the intervention (n = 163) or the control (n = 158) group. Those in the intervention group were visited in their homes up to three times by LHWs who provided a culturally sensitive educational program that emphasized the need for screening. Results: Ninety- three (93) women in the intervention group and 102 in the control group completed the postintervention interview. For Pap smears, the increase in screening was similar in both groups. For clinical breast exams (CBEs), however, there was a modest increase in the intervention group. The improvement was greatest for mammography, for which there was a 10% to 12% increase. Among women who were not on recommended schedules at baseline, the improvement was substantial and greater in the intervention group. Conclusions: LHWs' intervention appeared to improve the rate at which inner- city women obtained CBEs and mammograms, but had no effect on Pap smears. A high attrition rate weakened our ability to make conclusive statements about the exact impact of the intervention. Medical Subject Headings (MESH): intervention studies, Papanicolaou smear, mammography, urban health, health services, indigenous community health aides, breast. AD - Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310, United States AU - Sung, J. F. C. AU - Blumenthal, D. S. AU - Coates, R. J. AU - Williams, J. E. AU - Alema-Mensah, E. AU - Lill, J. M. DB - Scopus DO - 10.1016/s0749-3797(18)30225-3 IS - 1 M3 - Article N1 - Cited By :91 Export Date: 22 March 2021 PY - 1997 SP - 51-57 ST - Effect of a cancer screening intervention conducted by lay health workers among inner-city women T2 - American Journal of Preventive Medicine TI - Effect of a cancer screening intervention conducted by lay health workers among inner-city women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031026578&doi=10.1016%2fs0749-3797%2818%2930225-3&partnerID=40&md5=e49e01055e3eb12aebee77b3cace3ac2 VL - 13 ID - 2646 ER - TY - JOUR AB - Introduction: We conducted a randomized controlled trial to determine if an in-home educational intervention conducted by lay health workers (LHWs) could increase adherence among low-income, inner-city, African-American women to breast and cervical cancer screening schedules. Methods: We recruited 321 African-American women from diverse inner-city sources. After baseline interviews, they were randomly assigned to either the intervention (n = 163) or the control (n = 158) group. Those in the intervention group were visited in their homes up to three times by LHWs who provided a culturally sensitive educational program that emphasized the need for screening. Results: Ninety-three (93) women in the intervention group and 102 in the control group completed the postintervention interview. For Pap smears, the increase in screening was similar in both groups. For clinical breast exams (CBEs), however, there was a modest increase in the intervention group. The improvement was greatest for mammography, for which there was a 10% to 12% increase. Among women who were not on recommended schedules at baseline, the improvement was substantial and greater in the intervention group. Conclusions: LHWs' intervention appeared to improve the rate at which inner-city women obtained CBEs and mammograms, but had no effect on Pap smears. A high attrition rate weakened our ability to make conclusive statements about the exact impact of the intervention. AN - WOS:A1997WH26000009 AU - Sung, J. F. C. AU - Blumenthal, D. S. AU - Coates, R. J. AU - Williams, J. F. AU - AlemaMensah, E. AU - Liff, J. M. DA - Jan-Feb IS - 1 N1 - 85 9037342 PY - 1997 SN - 0749-3797 SP - 51-57 ST - Effect of a cancer screening intervention conducted by lay health workers among inner-city women T2 - American Journal of Preventive Medicine TI - Effect of a cancer screening intervention conducted by lay health workers among inner-city women VL - 13 ID - 2733 ER - TY - JOUR AB - Background: Colorectal cancer is the second leading cause of cancer-related death in the United States, in part, because one third of Americans fail to get screened. In a prior randomized controlled trial, we found that an iPad patient decision aid called Mobile Patient Technology for Health-CRC (mPATH-CRC) doubled the proportion of patients who completed colorectal cancer screening. Methods: All data for the current analysis were collected as part of a randomized controlled trial to determine the impact of mPATH-CRC on receipt of colorectal cancer screening within 24 weeks. Participants were enrolled from six community-based primary care practices between June 2014 and May 2016 and randomized to either usual care or mPATH-CRC. Six potential mediators of the intervention effect on screening were considered. The Iacobucci method was used to assess the significance of the mediation. Results: A total of 408 patients had complete data for all potential mediators. Overall, the potential mediators accounted for approximately three fourths (76.3%) of the effect of the program on screening completion. Perceived benefits, self-efficacy, ability to state a screening decision, and patient–provider discussion were statistically significant mediators. Patient–provider discussion accounted for the largest proportion of the effect of mPATH-CRC (70.7%). Conclusions: mPATH-CRC increased completion of colorectal cancer screening by affecting patient-level and system-level mediators. However, the most powerful mediator was the occurrence of a patient–provider discussion about screening. Digital interventions like mPATH-CRC are an important adjunct to the patient–provider encounter. Impact: Understanding the factors that mediated mPATH-CRC's success is paramount to developing other effective interventions. © 2020 American Association for Cancer Research. AD - Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, United States Department of Family and Community Medicine, Wake Forest School of Medicine, Winston Salem, NC, United States AU - Denizard-Thompson, N. M. AU - Miller, D. P. AU - Snavely, A. C. AU - Spangler, J. G. AU - Doug Case, L. AU - Weaver, K. E. DB - Scopus DO - 10.1158/1055-9965.EPI-19-1199 IS - 8 M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 1564-1569 ST - Effect of a digital health intervention on decreasing barriers and increasing facilitators for colorectal cancer screening in vulnerable patients T2 - Cancer Epidemiology Biomarkers and Prevention TI - Effect of a digital health intervention on decreasing barriers and increasing facilitators for colorectal cancer screening in vulnerable patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089128485&doi=10.1158%2f1055-9965.EPI-19-1199&partnerID=40&md5=1d2bce5a76577f128a8ab924b7d9d54a VL - 29 ID - 2187 ER - TY - JOUR AB - This randomized clinical trial compares the effect of a patient decision aid on lung cancer screening vs standard educational information on decision-making outcomes among persons who smoke. Importance Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. Question Does providing a lung cancer screening decision aid through tobacco quitlines improve informed decision-making about lung cancer screening among persons who smoke? Findings In this randomized clinical trial of 516 smokers, use of a patient decision aid compared with standard educational information led to better preparedness to decide about screening, higher reports of feeling informed and clear about screening choices, and greater knowledge of screening benefits and harms. Meaning The findings suggest that decision aids about lung cancer screening can reach large numbers of smokers who are eligible for screening through tobacco quitlines, can inform them about lung cancer screening, and can promote high-quality screening decisions. AN - WOS:000510727500009 AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - Housten, A. J. AU - Luckett, P. G. AU - Esparza, A. AU - Godoy, M. C. AU - Bevers, T. B. DA - Jan DO - 10.1001/jamanetworkopen.2019.20362 IS - 1 N1 - e1920362 32003822 PY - 2020 SN - 2574-3805 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke A Randomized Clinical Trial T2 - Jama Network Open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke A Randomized Clinical Trial VL - 3 ID - 2795 ER - TY - JOUR AB - Importance: Lung cancer screening with low‐dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision‐making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision‐making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision‐making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56‐3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72‐3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60‐3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow‐up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision‐making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. Trial Registration: ClinicalTrials.gov identifier: NCT02286713. AN - CN-02086018 AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - et al. DO - 10.1001/jamanetworkopen.2019.20362 IS - 1 KW - *cancer screening *decision making *lung cancer *tobacco Adult Aged Aged, 80 and over Article Data analysis Decision Support Techniques Early Detection of Cancer [*methods, *psychology] Female Follow up Health insurance High school Human Humans Lung Neoplasms [*diagnosis] Major clinical study Male Mass Screening [*psychology, statistics & numerical data] Middle Aged Outcome assessment Patient Participation [*psychology, statistics & numerical data] Randomized controlled trial Smokers [*psychology, *statistics & numerical data] Smoking Tomography, X‐Ray Computed [*psychology, statistics & numerical data] United States Videorecording M3 - Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2020 SP - e1920362 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: a Randomized Clinical Trial T2 - JAMA network open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: a Randomized Clinical Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02086018/full VL - 3 ID - 1525 ER - TY - JOUR AB - Importance: Lung cancer screening with low‐dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision‐making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision‐making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision‐making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56‐3.44; P <.001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72‐3.79; P <.001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60‐3.51; P <.001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow‐up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision‐making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. AN - CN-02086741 AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - et al. DO - 10.1001/jamanetworkopen.2019.20362 IS - 1 KW - *cancer screening *lung cancer *medical information *patient decision aid *smoking *videorecording Adult Aged Article Controlled study Female Follow up Human Major clinical study Male Outcome assessment Patient decision making Priority journal Randomized controlled trial Risk benefit analysis Smoking cessation Tobacco use M3 - Journal: Article PY - 2020 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: a Randomized Clinical Trial T2 - JAMA network open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: a Randomized Clinical Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02086741/full VL - 3 ID - 1649 ER - TY - JOUR AB - Importance: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P <.001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P <.001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P <.001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. AD - R.J. Volk, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Unit 1444, 1400 Pressler St, Houston, TX, United States AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - Housten, A. J. AU - Luckett, P. G. AU - Esparza, A. AU - Godoy, M. C. AU - Bevers, T. B. DB - Embase DO - 10.1001/jamanetworkopen.2019.20362 IS - 1 KW - NCT02286713 adult aged article cancer screening controlled study female follow up human lung cancer major clinical study male medical information outcome assessment patient decision aid patient decision making priority journal randomized controlled trial risk benefit analysis smoking smoking cessation tobacco use videorecording LA - English M3 - Article N1 - L630771059 2020-02-11 2020-02-17 PY - 2020 SN - 2574-3805 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial T2 - JAMA Network Open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630771059&from=export http://dx.doi.org/10.1001/jamanetworkopen.2019.20362 VL - 3 ID - 818 ER - TY - JOUR AB - Importance: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P <.001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P <.001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P <.001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. AD - R.J. Volk, Department of Health Services Research, University of Texas MD Anderson Cancer Center, 1400 Pressler St, Unit 1444, Houston, TX, United States AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - Housten, A. J. AU - Luckett, P. G. AU - Esparza, A. AU - Godoy, M. C. AU - Bevers, T. B. DB - Embase Medline DO - 10.1001/jamanetworkopen.2019.20362 KW - adult article cancer screening data analysis decision making female follow up health insurance high school human lung cancer major clinical study male outcome assessment randomized controlled trial smoking tobacco videorecording LA - English M3 - Article in Press N1 - L630817997 2020-02-11 PY - 2020 SN - 2574-3805 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial T2 - JAMA Network Open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630817997&from=export http://dx.doi.org/10.1001/jamanetworkopen.2019.20362 ID - 826 ER - TY - JOUR AB - This randomized clinical trial compares the effect of a patient decision aid on lung cancer screening vs standard educational information on decision-making outcomes among persons who smoke. Key Points: Question: Does providing a lung cancer screening decision aid through tobacco quitlines improve informed decision-making about lung cancer screening among persons who smoke? Findings: In this randomized clinical trial of 516 smokers, use of a patient decision aid compared with standard educational information led to better preparedness to decide about screening, higher reports of feeling informed and clear about screening choices, and greater knowledge of screening benefits and harms. Meaning: The findings suggest that decision aids about lung cancer screening can reach large numbers of smokers who are eligible for screening through tobacco quitlines, can inform them about lung cancer screening, and can promote high-quality screening decisions. Importance: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P <.001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P <.001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P <.001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. Trial Registration: ClinicalTrials.gov identifier: NCT02286713 AD - Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston North American Quitline Consortium, Phoenix, Arizona Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston Information & Quality Healthcare Inc, Ridgeland, Mississippi Houston Department for Health and Human Services, Houston, Texas Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston AN - 141494821. Language: English. Entry Date: 20200204. Revision Date: 20210311. Publication Type: Article AU - Volk, Robert J. AU - Lowenstein, Lisa M. AU - Leal, Viola B. AU - Escoto, Kamisha H. AU - Cantor, Scott B. AU - Munden, Reginald F. AU - Rabius, Vance A. AU - Bailey, Linda AU - Cinciripini, Paul M. AU - Lin, Heather AU - Housten, Ashley J. AU - Luckett, Pamela Graef AU - Esparza, Angelina AU - Godoy, Myrna C. AU - Bevers, Therese B. DB - CINAHL Complete DO - 10.1001/jamanetworkopen.2019.20362 DP - EBSCOhost IS - 1 KW - Decision Making, Patient Lung Neoplasms -- Prevention and Control Cancer Screening -- Education Patient Education Smoking Audiovisuals Pamphlets Human Male Female Adolescence Adult Middle Age Aged Randomized Controlled Trials Smoking Cessation Programs Health Knowledge Intention Patient Attitudes Descriptive Statistics Odds Ratio Confidence Intervals Tomography, X-Ray Computed Outcomes of Education Post Hoc Analysis T-Tests Data Analysis Software Logistic Regression Scales Funding Source N1 - research; tables/charts; randomized controlled trial. Instrumentation: Decision Making Scale (DMS); Decisional Conflict Scale (DCS). Grant Information: This study was supported by award CER-1306-03385 from the Patient-Centered Outcomes Research Institute; award P30CA016672 from the National Institutes of Health, National Cancer Institute (DrsVolk, Cantor, and Lin) that used the Biostatistics Resource Group, Clinical Protocol and Data Management, and Shared Decision Making Core, and a grant from The University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment (Drs Volk and Cantor) that supported the Shared Decision Making Collaborative and Center for Community-Engaged Translational Research.. PY - 2020 SP - e1920362-e1920362 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial T2 - JAMA Network Open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141494821&site=ehost-live&scope=site VL - 3 ID - 1924 ER - TY - JOUR AB - Importance: Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective: To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants: This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions: Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures: The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results: Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance: In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. Trial Registration: ClinicalTrials.gov identifier: NCT02286713. AD - Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston Department of Health Disparities Research, University of Texas MD Anderson Cancer Center, Houston Department of Radiology, Wake Forest School of Medicine, Winston-SalemNC Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston North American Quitline Consortium, Phoenix, AZ, United States Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston Information & Quality Healthcare Inc, Ridgeland, MS, United States Houston Department for Health and Human Services, Houston, TX Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Houston Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston AU - Volk, R. J. AU - Lowenstein, L. M. AU - Leal, V. B. AU - Escoto, K. H. AU - Cantor, S. B. AU - Munden, R. F. AU - Rabius, V. A. AU - Bailey, L. AU - Cinciripini, P. M. AU - Lin, H. AU - Housten, A. J. AU - Luckett, P. G. AU - Esparza, A. AU - Godoy, M. C. AU - Bevers, T. B. DB - Scopus DO - 10.1001/jamanetworkopen.2019.20362 IS - 1 M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2020 SP - e1920362 ST - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial T2 - JAMA network open TI - Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078712999&doi=10.1001%2fjamanetworkopen.2019.20362&partnerID=40&md5=2b030554c214304e128607f84825cc63 VL - 3 ID - 2206 ER - TY - JOUR AB - Purpose: African-American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health-related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. Methods: This report examined the effect of a 6-month, 3-arm (supervised exercise, home-based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. Results: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The “exercise group” (supervised group combined with the home-based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6-month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non-significant, data indicated most HRQoL change scores were more favorable in the supervised group. Conclusion: While significant improvement occurred in health change scores in the combined supervised and home-based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non-significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home-based and control groups. Additional research is needed to further explore this topic. AD - L.L. Adams-Campbell, Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, 1000 New Jersey Ave, SE, Washington, DC, United States AU - Taylor, T. R. AU - Dash, C. AU - Sheppard, V. AU - Makambi, K. AU - Ma, X. AU - Adams-Campbell, L. L. DB - Embase Medline DO - 10.1016/j.cct.2018.02.005 KW - adult aerobic exercise African American article breast cancer cancer mortality cancer risk comparative study controlled study exercise intensity female high risk patient human major clinical study metabolic syndrome X middle aged physical activity postmenopause quality of life randomized controlled trial Short Form 36 social interaction Theory of Planned Behavior LA - English M3 - Article N1 - L2000543505 2018-03-21 2018-04-19 PY - 2018 SN - 1559-2030 1551-7144 SP - 121-128 ST - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY T2 - Contemporary Clinical Trials TI - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000543505&from=export http://dx.doi.org/10.1016/j.cct.2018.02.005 VL - 67 ID - 901 ER - TY - JOUR AB - PURPOSE: African‐American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health‐related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. METHODS: This report examined the effect of a 6‐month, 3‐arm (supervised exercise, home‐based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. RESULTS: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The "exercise group" (supervised group combined with the home‐based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6‐month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non‐significant, data indicated most HRQoL change scores were more favorable in the supervised group. CONCLUSION: While significant improvement occurred in health change scores in the combined supervised and home‐based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non‐significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home‐based and control groups. Additional research is needed to further explore this topic. AN - CN-01982696 AU - Taylor, T. R. AU - Dash, C. AU - Sheppard, V. AU - Makambi, K. AU - Ma, X. AU - Adams-Campbell, L. L. DO - 10.1016/j.cct.2018.02.005 KW - African Americans [psychology, statistics & numerical data] Breast Neoplasms [prevention & control] Diet, Reducing [*methods] Exercise Therapy [*methods] Exercise [*psychology] Female Health Status Disparities Humans Metabolic Syndrome [psychology, therapy] Middle Aged Obesity [metabolism, psychology, therapy] Outcome Assessment, Health Care Postmenopause [metabolism, psychology] Quality of Life Weight Reduction Programs [methods] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2018 SP - 121‐128 ST - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY T2 - Contemporary clinical trials TI - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01982696/full VL - 67 ID - 1371 ER - TY - JOUR AB - Purpose: African‐American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health‐related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. Methods: This report examined the effect of a 6‐month, 3‐arm (supervised exercise, home‐based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. Results: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The “exercise group” (supervised group combined with the home‐based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6‐month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non‐significant, data indicated most HRQoL change scores were more favorable in the supervised group. Conclusion: While significant improvement occurred in health change scores in the combined supervised and home‐based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non‐significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home‐based and control groups. Additional research is needed to further explore this topic. AN - CN-01465221 AU - Taylor, T. R. AU - Dash, C. AU - Sheppard, V. AU - Makambi, K. AU - Ma, X. AU - Adams-Campbell, L. L. DO - 10.1016/j.cct.2018.02.005 KW - *breast cancer /disease management *physical activity *quality of life Adult Aerobic exercise African American Article Cancer mortality Cancer risk Comparative study Controlled study Exercise intensity Female High risk patient Human Major clinical study Metabolic syndrome X Middle aged Postmenopause Randomized controlled trial Short Form 36 Social interaction Theory of Planned Behavior M3 - Journal: Article PY - 2018 SP - 121‐128 ST - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY T2 - Contemporary clinical trials TI - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01465221/full VL - 67 ID - 1505 ER - TY - JOUR AB - Purpose: African-American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health-related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. Methods: This report examined the effect of a 6-month, 3-arm (supervised exercise, home-based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. Results: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The “exercise group” (supervised group combined with the home-based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6-month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non-significant, data indicated most HRQoL change scores were more favorable in the supervised group. Conclusion: While significant improvement occurred in health change scores in the combined supervised and home-based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non-significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home-based and control groups. Additional research is needed to further explore this topic. © 2018 Elsevier Inc. AD - Howard University Cancer Center, Howard University, Washington, DC, United States Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, United States AU - Taylor, T. R. AU - Dash, C. AU - Sheppard, V. AU - Makambi, K. AU - Ma, X. AU - Adams-Campbell, L. L. DB - Scopus DO - 10.1016/j.cct.2018.02.005 KW - Blacks Exercise Metabolic syndrome Quality of life Women M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2018 SP - 121-128 ST - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY T2 - Contemporary Clinical Trials TI - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043779207&doi=10.1016%2fj.cct.2018.02.005&partnerID=40&md5=35a5d7bf556878382cd19162d5df10f0 VL - 67 ID - 2276 ER - TY - JOUR AB - Purpose: African-American women (AAW) are more likely to be metabolically unhealthy than White women (WW). Metabolic syndrome (MetS) is associated with increased breast cancer risk and mortality from breast cancer is greater in AAW compared to WW. Data show MetS affects health-related quality of life (HRQoL). Exercise studies report improvements in MetS, however, no study to date has examined HRQoL in metabolically unhealthy AAW enrolled in an exercise trial. Methods: This report examined the effect of a 6-month, 3-arm (supervised exercise, home-based exercise, control) randomized exercise controlled trial on HRQoL among 213 obese, metabolically unhealthy, postmenopausal AAW at high risk for breast cancer. Results: Certain baseline participant characteristics were related to baseline HRQoL dimensions. The "exercise group" (supervised group combined with the home-based group) showed significantly greater improvement in health change scores (M = 13.6, SD = 3.1) compared to the control group (M = 0.7, SD = 4.4) (p = 0.02) over the 6-month study period. There were no significant differences in HRQoL change scores between the 3 study groups, however, although non-significant, data indicated most HRQoL change scores were more favorable in the supervised group. Conclusion: While significant improvement occurred in health change scores in the combined supervised and home-based group compared to the control group, we did not observe any significant differences on HRQoL change scores between all three study groups. However, while non-significant, there was a trend for more favorable HRQoL change scores in the supervised group versus the home-based and control groups. Additional research is needed to further explore this topic. AN - WOS:000430768200017 AU - Taylor, T. R. AU - Dash, C. AU - Sheppard, V. AU - Makambi, K. AU - Ma, X. Y. AU - Adams-Campbell, L. L. DA - Apr DO - 10.1016/j.cct.2018.02.005 N1 - 29428830 PY - 2018 SN - 1551-7144 SP - 121-128 ST - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY T2 - Contemporary Clinical Trials TI - The effect of a randomized controlled physical activity trial on health related quality of life in metabolically unhealthy African-American women: FIERCE STUDY VL - 67 ID - 2866 ER - TY - JOUR AB - IMPORTANCE Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown. OBJECTIVE To determine the combined effect of a CRC screening decision aid and patient navigation compared with usual care on CRC screening completion. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, data were collected from January 2014 to March 2016 at 2 community health center practices, 1 in North Carolina and 1 in New Mexico, serving vulnerable populations. Patients ages 50 to 75 years who had average CRC risk, spoke English or Spanish, were not current with recommended CRC screening, and were attending primary care visits were recruited and randomized 1: 1 to intervention or control arms. INTERVENTIONS Intervention participants viewed a CRC screening decision aid in English or Spanish immediately before their clinician encounter. The decision aid promoted screening and presented colonoscopy and fecal occult blood testing as screening options. After the clinician encounter, intervention patients received support for screening completion from a bilingual patient navigator. Control participants viewed a food safety video before the encounter and otherwise received usual care. MAIN OUTCOMES AND MEASURES The primary outcome was CRC screening completion within 6 months of the index study visit assessed by blinded medical record review. RESULTS Characteristics of the 265 participants were as follows: their mean age was 58 years; 173 (65%) were female, 164 (62%) were Latino; 40 (15%) were white non-Latino; 61 (23%) were black or of mixed race; 191 (78%) had a household income of less than $20 000; 101 (38%) had low literacy; 75 (28%) were on Medicaid; and 91 (34%) were uninsured. Intervention participants were more likely to complete CRC screening within 6 months (68% vs 27%); adjusted-difference, 40 percentage points (95% CI, 29-51 percentage points). The intervention was more effective in women than in men (50 vs 21 percentage point increase, interaction P =.02). No effect modification was observed across other subgroups. CONCLUSIONS AND RELEVANCE A patient decision aid plus patient navigation increased the rate of CRC screening completion in compared with usual care in vulnerable primary care patients. AN - WOS:000404599100017 AU - Reuland, D. S. AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Rhyne, R. L. AU - Getrich, C. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - Cubillos, L. AU - de Hernandez, B. U. AU - Pignone, M. P. DA - Jul DO - 10.1001/jamainternmed.2017.1294 IS - 7 N1 - 28505217 PY - 2017 SN - 2168-6106 SP - 967-974 ST - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population A Randomized Clinical Trial T2 - Jama Internal Medicine TI - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population A Randomized Clinical Trial VL - 177 ID - 2895 ER - TY - JOUR AB - Importance: Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown.Objective: To determine the combined effect of a CRC screening decision aid and patient navigation compared with usual care on CRC screening completion.Design, Setting, and Participants: In this randomized clinical trial, data were collected from January 2014 to March 2016 at 2 community health center practices, 1 in North Carolina and 1 in New Mexico, serving vulnerable populations. Patients ages 50 to 75 years who had average CRC risk, spoke English or Spanish, were not current with recommended CRC screening, and were attending primary care visits were recruited and randomized 1:1 to intervention or control arms.Interventions: Intervention participants viewed a CRC screening decision aid in English or Spanish immediately before their clinician encounter. The decision aid promoted screening and presented colonoscopy and fecal occult blood testing as screening options. After the clinician encounter, intervention patients received support for screening completion from a bilingual patient navigator. Control participants viewed a food safety video before the encounter and otherwise received usual care.Main Outcomes and Measures: The primary outcome was CRC screening completion within 6 months of the index study visit assessed by blinded medical record review.Results: Characteristics of the 265 participants were as follows: their mean age was 58 years; 173 (65%) were female, 164 (62%) were Latino; 40 (15%) were white non-Latino; 61 (23%) were black or of mixed race; 191 (78%) had a household income of less than $20 000; 101 (38%) had low literacy; 75 (28%) were on Medicaid; and 91 (34%) were uninsured. Intervention participants were more likely to complete CRC screening within 6 months (68% vs 27%); adjusted-difference, 40 percentage points (95% CI, 29-51 percentage points). The intervention was more effective in women than in men (50 vs 21 percentage point increase, interaction P = .02). No effect modification was observed across other subgroups.Conclusions and Relevance: A patient decision aid plus patient navigation increased the rate of CRC screening completion in compared with usual care invulnerable primary care patients.Trial Registration: clinicaltrials.gov Identifier: NCT02054598. AD - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill Division of General Medicine & Clinical Epidemiology, University of North Carolina School of Medicine, Chapel Hill Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill Department of Medicine, University of Iowa Carver College of Medicine, Iowa City University of Iowa Holden Comprehensive Cancer Center, University of Iowa, Iowa City Department of Family and Community Medicine, University of New Mexico School of Medicine, Albuquerque Department of Family Medicine, Carolinas HealthCare System, Charlotte, North Carolina University of New Mexico Comprehensive Cancer Center, Albuquerque Department of Anthropology, University of Maryland, College Park Department of Biostatistics, University of North Carolina, Chapel Hill Department of Internal Medicine, University of Texas Dell Medical School, Austin AN - 123983629. Language: English. Entry Date: 20170903. Revision Date: 20200309. Publication Type: journal article AU - Reuland, Daniel S. AU - Brenner, Alison T. AU - Hoffman, Richard AU - McWilliams, Andrew AU - Rhyne, Robert L. AU - Getrich, Christina AU - Tapp, Hazel AU - Weaver, Mark A. AU - Callan, Danelle AU - Cubillos, Laura AU - de Hernandez, Brisa Urquieta AU - Pignone, Michael P. AU - Urquieta de Hernandez, Brisa DB - CINAHL Complete DO - 10.1001/jamainternmed.2017.1294 DP - EBSCOhost IS - 7 KW - Patient Navigation -- Methods Colorectal Neoplasms -- Epidemiology Early Detection of Cancer -- Psychosocial Factors Early Detection of Cancer -- Methods Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Psychosocial Factors Decision Support Techniques Occult Blood Colonoscopy -- Methods North Carolina Primary Health Care -- Methods Decision Making Colonoscopy -- Psychosocial Factors Special Populations Female Middle Age New Mexico Human Aged Black Persons Medical Records -- Statistics and Numerical Data Hispanic Americans Primary Health Care -- Statistics and Numerical Data Male Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. Grant Information: P30 CA086862/CA/NCI NIH HHS/United States. NLM UID: 101589534. PMID: NLM28505217. PY - 2017 SN - 2168-6106 SP - 967-974 ST - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial T2 - JAMA Internal Medicine TI - Effect of Combined Patient Decision Aid and Patient Navigation vs Usual Care for Colorectal Cancer Screening in a Vulnerable Patient Population: A Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123983629&site=ehost-live&scope=site VL - 177 ID - 1925 ER - TY - JOUR AB - IMPORTANCE Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown. OBJECTIVE To determine the combined effect of a CRC screening decision aid and patient navigation compared with usual care on CRC screening completion. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, datawere collected from January 2014 to March 2016 at 2 community health center practices, 1 in North Carolina and 1 in New Mexico, serving vulnerable populations. Patients ages 50 to 75 years who had average CRC risk, spoke English or Spanish, were not current with recommended CRC screening, and were attending primary care visits were recruited and randomized 1:1 to intervention or control arms. INTERVENTIONS Intervention participants viewed a CRC screening decision aid in English or Spanish immediately before their clinician encounter. The decision aid promoted screening and presented colonoscopy and fecal occult blood testing as screening options. After the clinician encounter, intervention patients received support for screening completion from a bilingual patient navigator. Control participants viewed a food safety video before the encounter and otherwise received usual care. MAIN OUTCOMES AND MEASURES The primary outcomewas CRC screening completion within 6 months of the index study visit assessed by blinded medical record review. RESULTS Characteristics of the 265 participants were as follows: their mean age was 58 years; 173 (65%) were female, 164 (62%) were Latino; 40 (15%) were white non-Latino; 61 (23%) were black or of mixed race; 191 (78%) had a household income of less than $20 000; 101 (38%) had low literacy; 75 (28%) were on Medicaid; and 91 (34%) were uninsured. Intervention participants were more likely to complete CRC screening within 6 months (68% vs 27%); adjusted-difference, 40 percentage points (95%CI, 29-51 percentage points). The intervention was more effective in women than in men (50 vs 21 percentage point increase, interaction P = .02). No effect modification was observed across other subgroups. CONCLUSIONS AND RELEVANCE A patient decision aid plus patient navigation increased the rate of CRC screening completion in compared with usual care in vulnerable primary care patients. AD - D.S. Reuland, Division of General Medicine and Clinical Epidemiology, University of North Carolina, School of Medicine, 5045 Old Clinic Building, Chapel Hill, NC, United States AU - Reuland, D. S. AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Rhyne, R. L. AU - Getrich, C. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - Cubillos, L. AU - Urquieta De Hernandez, B. AU - Pignone, M. P. DB - Embase Medline DO - 10.1001/jamainternmed.2017.1294 IS - 7 KW - adult aged article Black person cancer risk cancer screening clinical decision support system colonoscopy colorectal adenoma colorectal cancer colorectal polyp controlled study female Hispanic household income human intestine obstruction literacy major clinical study male medicaid medically uninsured New Mexico North Carolina occult blood test patient care patient decision making primary medical care priority journal randomized controlled trial vulnerable population LA - English M3 - Article N1 - L617402710 2017-07-25 2017-07-27 PY - 2017 SN - 2168-6106 SP - 967-974 ST - Effect of combined patient decision aid and patient navigation vs usual care for colorectal cancer screening in a vulnerable patient population: A randomized clinical trial T2 - JAMA Internal Medicine TI - Effect of combined patient decision aid and patient navigation vs usual care for colorectal cancer screening in a vulnerable patient population: A randomized clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617402710&from=export http://dx.doi.org/10.1001/jamainternmed.2017.1294 VL - 177 ID - 932 ER - TY - JOUR AB - IMPORTANCE Colorectal cancer (CRC) screening is underused, especially among vulnerable populations. Decision aids and patient navigation are potentially complementary interventions for improving CRC screening rates, but their combined effect on screening completion is unknown. OBJECTIVE To determine the combined effect of a CRC screening decision aid and patient navigation compared with usual care on CRC screening completion. DESIGN, SETTING, AND PARTICIPANTS In this randomized clinical trial, datawere collected from January 2014 to March 2016 at 2 community health center practices, 1 in North Carolina and 1 in New Mexico, serving vulnerable populations. Patients ages 50 to 75 years who had average CRC risk, spoke English or Spanish, were not current with recommended CRC screening, and were attending primary care visits were recruited and randomized 1:1 to intervention or control arms. INTERVENTIONS Intervention participants viewed a CRC screening decision aid in English or Spanish immediately before their clinician encounter. The decision aid promoted screening and presented colonoscopy and fecal occult blood testing as screening options. After the clinician encounter, intervention patients received support for screening completion from a bilingual patient navigator. Control participants viewed a food safety video before the encounter and otherwise received usual care. MAIN OUTCOMES AND MEASURES The primary outcomewas CRC screening completion within 6 months of the index study visit assessed by blinded medical record review. RESULTS Characteristics of the 265 participants were as follows: their mean age was 58 years; 173 (65%) were female, 164 (62%) were Latino; 40 (15%) were white non-Latino; 61 (23%) were black or of mixed race; 191 (78%) had a household income of less than $20 000; 101 (38%) had low literacy; 75 (28%) were on Medicaid; and 91 (34%) were uninsured. Intervention participants were more likely to complete CRC screening within 6 months (68% vs 27%); adjusted-difference, 40 percentage points (95%CI, 29-51 percentage points). The intervention was more effective in women than in men (50 vs 21 percentage point increase, interaction P = .02). No effect modification was observed across other subgroups. CONCLUSIONS AND RELEVANCE A patient decision aid plus patient navigation increased the rate of CRC screening completion in compared with usual care in vulnerable primary care patients. © 2017 American Medical Association. All rights reserved. AD - Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, United States Division of General Medicine and Clinical Epidemiology, University of North Carolina, School of Medicine, 5045 Old Clinic Building, Chapel Hill, NC 27599-7110, United States Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, United States Department of Medicine, University of Iowa, Carver College of Medicine, Iowa City, United States University of Iowa Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States Department of Family and Community Medicine, University of New Mexico, School of Medicine, Albuquerque, United States Department of Family Medicine, Carolinas HealthCare System, Charlotte, NC, United States University of New Mexico Comprehensive Cancer Center, Albuquerque, United States Department of Anthropology, University of Maryland, College Park, United States Department of Biostatistics, University of North Carolina, Chapel Hill, United States Department of Internal Medicine, University of Texas dell Medical School, Austin, United States AU - Reuland, D. S. AU - Brenner, A. T. AU - Hoffman, R. AU - McWilliams, A. AU - Rhyne, R. L. AU - Getrich, C. AU - Tapp, H. AU - Weaver, M. A. AU - Callan, D. AU - Cubillos, L. AU - Urquieta De Hernandez, B. AU - Pignone, M. P. DB - Scopus DO - 10.1001/jamainternmed.2017.1294 IS - 7 M3 - Article N1 - Cited By :46 Export Date: 22 March 2021 PY - 2017 SP - 967-974 ST - Effect of combined patient decision aid and patient navigation vs usual care for colorectal cancer screening in a vulnerable patient population: A randomized clinical trial T2 - JAMA Internal Medicine TI - Effect of combined patient decision aid and patient navigation vs usual care for colorectal cancer screening in a vulnerable patient population: A randomized clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024497198&doi=10.1001%2fjamainternmed.2017.1294&partnerID=40&md5=d58e55fc2092f7a86e5591aaa0451151 VL - 177 ID - 2305 ER - TY - JOUR AB - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, "readiness to change," and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates. AD - Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Ave New York 10029 USA AN - 104446405. Language: English. Entry Date: 20120803. Revision Date: 20200708. Publication Type: journal article AU - Lukin, Dana AU - Jandorf, Lina AU - Dhulkifl, Rayhana AU - Thélémaque, Linda AU - Christie, Jennifer AU - Itzkowitz, Steven AU - DuHamel, Katherine AU - Lukin, Dana J. AU - Jandorf, Lina H. AU - Dhulkifl, Rayhana J. AU - Thélémaque, Linda D. AU - Christie, Jennifer A. AU - Itzkowitz, Steven H. AU - Duhamel, Katherine N. DB - CINAHL Complete DO - 10.1007/s13187-011-0303-2 DP - EBSCOhost IS - 2 KW - Black Persons Cancer Screening Colonoscopy -- Utilization Colorectal Neoplasms -- Prevention and Control Comorbidity Patient Compliance Aged Behavioral Changes Data Analysis Software Descriptive Statistics Educational Status Employment Status Female Funding Source Human Income Insurance, Health Interviews Male Marital Status Middle Age New York Occult Blood Odds Ratio Outpatients P-Value Primary Health Care Prospective Studies Randomized Controlled Trials Record Review Referral and Consultation N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: 5R01CA104130-4/CA/NCI NIH HHS/United States. NLM UID: 8610343. PMID: NLM22351374. PY - 2012 SN - 0885-8195 SP - 269-276 ST - Effect of comorbid conditions on adherence to colorectal cancer screening T2 - Journal of Cancer Education TI - Effect of comorbid conditions on adherence to colorectal cancer screening UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104446405&site=ehost-live&scope=site VL - 27 ID - 1926 ER - TY - JOUR AB - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, "readiness to change," and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates. AD - D.J. Lukin, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. AU - Lukin, D. J. AU - Jandorf, L. H. AU - Dhulkifl, R. J. AU - Thélémaque, L. D. AU - Christie, J. A. AU - Itzkowitz, S. H. AU - Duhamel, K. N. DB - Medline DO - 10.1007/s13187-011-0303-2 IS - 2 KW - article clinical trial colorectal tumor comorbidity controlled clinical trial controlled study early diagnosis female human male mass screening methodology middle aged patient compliance prospective study randomized controlled trial risk factor LA - English M3 - Article N1 - L365910619 2012-10-31 PY - 2012 SN - 1543-0154 SP - 269-276 ST - Effect of comorbid conditions on adherence to colorectal cancer screening T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Effect of comorbid conditions on adherence to colorectal cancer screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365910619&from=export http://dx.doi.org/10.1007/s13187-011-0303-2 VL - 27 ID - 1118 ER - TY - JOUR AB - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, 'readiness to change,' and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Jandorf, Lina H., Department of Oncological Sciences, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130, New York, NY, US, 10029 AN - 2014-36563-012 AU - Lukin, Dana J. AU - Jandorf, Lina H. AU - Dhulkifl, Rayhana J. AU - Thélémaque, Linda D. AU - Christie, Jennifer A. AU - Itzkowitz, Steven H. AU - DuHamel, Katherine N. DB - psyh DO - 10.1007/s13187-011-0303-2 DP - EBSCOhost IS - 2 KW - Colorectal cancer Screening colonoscopy Co-morbidities African Americans Screening barriers Colorectal Neoplasms Comorbidity Early Detection of Cancer Female Humans Male Mass Screening Middle Aged Patient Compliance Prospective Studies Risk Factors Cancer Screening Colon Disorders Treatment Compliance Treatment Barriers Blacks Neoplasms N1 - Department of Medicine, Mount Sinai School of Medicine, New York, NY, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Colon Disorders; Comorbidity; Treatment Compliance; Treatment Barriers. Minor Descriptor: Blacks; Neoplasms. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Jun, 2012. Publication History: First Posted Date: Feb 18, 2012. Copyright Statement: Springer Science+Business Media, LLC. 2012. Sponsor: National Institutes of Health. Grant: 5R01CA104130-4. Recipients: No recipient indicated PY - 2012 SN - 0885-8195 1543-0154 SP - 269-276 ST - Effect of comorbid conditions on adherence to colorectal cancer screening T2 - Journal of Cancer Education TI - Effect of comorbid conditions on adherence to colorectal cancer screening UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-36563-012&site=ehost-live&scope=site ORCID: 0000-0002-4519-6057 ORCID: 0000-0003-4581-2267 linda.thelemaque@mssm.edu lina.jandorf@mssm.edu VL - 27 ID - 1721 ER - TY - JOUR AB - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, "readiness to change," and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates. © 2011 Springer Science+Business Media, LLC. AD - Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Ave, New York, NY 10029, United States Department of Oncological Sciences, Mount Sinai School of Medicine, Box 1130, 1425 Madison Avenue, New York, NY 10029, United States Emory University School of Medicine, 1365 Clifton Rd, Atlanta, GA 30322, United States Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, New York, NY 10022, United States AU - Lukin, D. J. AU - Jandorf, L. H. AU - Dhulkifl, R. J. AU - Thélémaque, L. D. AU - Christie, J. A. AU - Itzkowitz, S. H. AU - DuHamel, K. N. DB - Scopus DO - 10.1007/s13187-011-0303-2 IS - 2 KW - African Americans Co-morbidities Colorectal cancer Screening barriers Screening colonoscopy M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2012 SP - 269-276 ST - Effect of comorbid conditions on adherence to colorectal cancer screening T2 - Journal of Cancer Education TI - Effect of comorbid conditions on adherence to colorectal cancer screening UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864039923&doi=10.1007%2fs13187-011-0303-2&partnerID=40&md5=b01c62484888d7cc7b411ece6bb04f87 VL - 27 ID - 2457 ER - TY - JOUR AB - Potential barriers to colorectal cancer (CRC) screening include preexisting medical conditions (comorbidities), physician recommendation, psychosocial factors, and screening preparedness. This study's purpose was to investigate the impact of comorbid conditions on CRC screening among African Americans. A stage-matched randomized clinical trial was performed. Asymptomatic African Americans over age 50, with a primary care physician, and eligible for CRC screening were recruited at The Mount Sinai Hospital from 2005 to 2008. One hundred sixty-one patients were assessed for referral for, and completion of, CRC screening, comorbid conditions, "readiness to change," and number of physician visits within the observation period. Data was compared to a pretrial index to predict the likely effect of comorbid conditions on CRC screening. One hundred fifty-nine patients completed the study; 108 (68.9%) were referred for and 34 (21.2%) completed CRC screening. No demographic characteristics were associated with CRC screening completion. CRC screening referrals were similar for all patients, regardless of comorbidities or clinical visits. Comorbidities rated as having extreme influence on CRC screening showed a trend toward lower screening rates. There was a significant increase in screening rates among participants in advanced stages of readiness at enrollment. These data suggest that while comorbidities did not predict colonoscopy completion, they may play a role in concert with other factors. This is the only study to assess the effect of screening colonoscopy in an African American primary care setting. We must continue to explore interventions to narrow the disparate gap in screening and mortality rates. AN - WOS:000304144500010 AU - Lukin, D. J. AU - Jandorf, L. H. AU - Dhulkifl, R. J. AU - Thelemaque, L. D. AU - Christie, J. A. AU - Itzkowitz, S. H. AU - DuHamel, K. N. DA - Jun DO - 10.1007/s13187-011-0303-2 IS - 2 N1 - 22351374 PY - 2012 SN - 0885-8195 SP - 269-276 ST - Effect of Comorbid Conditions on Adherence to Colorectal Cancer Screening T2 - Journal of Cancer Education TI - Effect of Comorbid Conditions on Adherence to Colorectal Cancer Screening VL - 27 ID - 3068 ER - TY - JOUR AB - OBJECTIVE: Assess impact of a computer‐based patient support system on quality of life in younger women with breast cancer, with particular emphasis on assisting the underserved. DESIGN: Randomized controlled trial conducted between 1995 and 1998. SETTING: Five sites: two teaching hospitals (Madison, Wis, and Chicago, Ill), two nonteaching hospitals (Chicago), and a cancer resource center (Indianapolis, Ill). The latter three sites treat many underserved patients. PARTICIPANTS: Newly diagnosed breast cancer patients (N = 246) under age 60. INTERVENTIONS: Experimental group received Comprehensive Health Enhancement Support System (CHESS), a home‐based computer system providing information, decision‐making, and emotional support. MEASUREMENTS AND MAIN RESULTS: Pretest and two post‐test surveys (at two‐ and five‐month follow‐up) measured aspects of participation in care, social/information support, and quality of life. At two‐month follow‐up, the CHESS group was significantly more competent at seeking information, more comfortable participating in care, and had greater confidence in doctor(s). At five‐month follow‐up, the CHESS group had significantly better social support and also greater information competence. In addition, experimental assignment interacted with several indicators of medical underservice (race, education, and lack of insurance), such that CHESS benefits were greater for the disadvantaged than the advantaged group. CONCLUSIONS: Computer‐based patient support systems such as CHESS may benefit patients by providing information and social support, and increasing their participation in health care. These benefits may be largest for currently underserved populations. AN - CN-00356189 AU - Gustafson, D. H. AU - Hawkins, R. AU - Pingree, S. AU - McTavish, F. AU - Arora, N. K. AU - Mendenhall, J. AU - Cella, D. F. AU - Serlin, R. C. AU - Apantaku, F. M. AU - Stewart, J. AU - et al. DO - 10.1046/j.1525-1497.2001.016007435.x IS - 7 KW - Adult African Americans Breast Neoplasms [ethnology, *psychology] Female Follow‐Up Studies Humans Information Services Linear Models Medically Underserved Area Middle Aged Multivariate Analysis Patient Education as Topic [*methods] Patient Participation Quality of Life Social Support M3 - Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2001 SP - 435‐445 ST - Effect of computer support on younger women with breast cancer T2 - Journal of general internal medicine TI - Effect of computer support on younger women with breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00356189/full VL - 16 ID - 1418 ER - TY - JOUR AB - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre-Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28- and 60-day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12–3.18] P < 0.001 and 2.79, 95% CI: 2.29–3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87–0.96, P < 0.001 and 0.92, 95% CI: 0.88–0.96, P < 0.001, respectively). For preadmission location, the 28- and 60-day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44–0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46–0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61–0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56–0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28- and 60-day mortality: OR = 1.47, 95% CI: 1.09–1.98, P = 0.011; and OR 1.53, 95% CI: 1.15–2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites. AD - Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI, USA Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA AN - 120636719. Language: English. Entry Date: 20170111. Revision Date: 20181206. Publication Type: Article AU - El-Haddad, Haitham AU - Hyejeong, Jang AU - Wei, Chen AU - Haider, Samran AU - Soubani, Ayman O. DB - CINAHL Complete DO - 10.4103/1817-1737.197767 DP - EBSCOhost IS - 1 KW - Respiratory Distress Syndrome, Acute -- Therapy Treatment Outcomes -- Evaluation Respiratory Distress Syndrome, Acute -- Epidemiology Human Geographic Locations Nonconcurrent Prospective Studies Male Female Odds Ratio Confidence Intervals Relative Risk Descriptive Statistics Race Factors Age Factors Respiratory Distress Syndrome, Acute -- Mortality N1 - research; tables/charts. Journal Subset: Biomedical; Middle East; Peer Reviewed. NLM UID: 101280721. PY - 2017 SN - 1817-1737 SP - 17-24 ST - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome T2 - Annals of Thoracic Medicine TI - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120636719&site=ehost-live&scope=site VL - 12 ID - 2116 ER - TY - JOUR AB - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre-Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28- and 60-day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12-3.18] P < 0.001 and 2.79, 95% CI: 2.29-3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87-0.96, P < 0.001 and 0.92, 95% CI: 0.88-0.96, P < 0.001, respectively). For preadmission location, the 28- and 60-day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44-0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46-0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61-0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56-0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28- and 60-day mortality: OR = 1.47, 95% CI: 1.09-1.98, P = 0.011; and OR 1.53, 95% CI: 1.15-2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites. AD - A.O. Soubani, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, 3990 John R- 3 Hudson, Detroit, MI, United States AU - El-Haddad, H. AU - Jang, H. AU - Chen, W. AU - Haider, S. AU - Soubani, A. O. DB - Embase DO - 10.4103/1817-1737.197767 IS - 1 KW - hypertensive factor ketoconazole adolescent adult adult respiratory distress syndrome aged APACHE article artificial ventilation cohort analysis controlled study diabetes mellitus female human intensive care unit lung injury major clinical study male mortality rate pneumonia pulmonary aspiration randomized controlled trial retrospective study sepsis treatment outcome LA - English M3 - Article N1 - L614099615 2017-01-23 2017-01-26 PY - 2017 SN - 1998-3557 1817-1737 SP - 17-24 ST - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome T2 - Annals of Thoracic Medicine TI - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614099615&from=export http://dx.doi.org/10.4103/1817-1737.197767 VL - 12 ID - 947 ER - TY - JOUR AB - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre‐Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28‐ and 60‐day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12‐3.18] P < 0.001 and 2.79, 95% CI: 2.29‐3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87‐0.96, P < 0.001 and 0.92, 95% CI: 0.88‐0.96, P < 0.001, respectively). For preadmission location, the 28‐ and 60‐day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44‐0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46‐0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61‐0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56‐0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28‐ and 60‐day mortality: OR = 1.47, 95% CI: 1.09‐1.98, P = 0.011; and OR 1.53, 95% CI: 1.15‐2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites. AN - CN-01297669 AU - El-Haddad, H. AU - Jang, H. AU - Chen, W. AU - Haider, S. AU - Soubani, A. O. DO - 10.4103/1817-1737.197767 IS - 1 KW - *adult respiratory distress syndrome APACHE Adolescent Adult Aged Article Artificial ventilation Cohort analysis Controlled study Diabetes mellitus Female Human Intensive care unit Lung injury Major clinical study Male Mortality rate Pneumonia Pulmonary aspiration Randomized controlled trial Retrospective study Sepsis Treatment outcome M3 - Journal: Article PY - 2017 SP - 17‐24 ST - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome T2 - Annals of thoracic medicine TI - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01297669/full VL - 12 ID - 1472 ER - TY - JOUR AB - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre-Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28- and 60-day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12-3.18] P < 0.001 and 2.79, 95% CI: 2.29-3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87-0.96, P < 0.001 and 0.92, 95% CI: 0.88-0.96, P < 0.001, respectively). For preadmission location, the 28- and 60-day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44-0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46-0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61-0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56-0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28- and 60-day mortality: OR = 1.47, 95% CI: 1.09-1.98, P = 0.011; and OR 1.53, 95% CI: 1.15-2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites. © 2017 Annals of Thoracic Medicine | Published by Wolters Kluwer - Medknow. AD - Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, 3990 John R- 3 Hudson, Detroit, MI 48201, United States Department of Oncology, Wayne State University School of Medicine, Detroit, MI, United States AU - El-Haddad, H. AU - Jang, H. AU - Chen, W. AU - Haider, S. AU - Soubani, A. O. DB - Scopus DO - 10.4103/1817-1737.197767 IS - 1 KW - Acute respiratory distress syndrome demographics outcome M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2017 SP - 17-24 ST - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome T2 - Annals of Thoracic Medicine TI - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009495970&doi=10.4103%2f1817-1737.197767&partnerID=40&md5=6085473bc02f996db452f3a86aa0f8a2 VL - 12 ID - 2327 ER - TY - JOUR AB - OBJECTIVE: Outcome of acute respiratory distress syndrome (ARDS) in relation to age, gender, race, pre-Intensive Care Unit (ICU) location, and type of ICU. METHODS: Retrospective cohort study of patients enrolled in the ARDS network randomized controlled trials. RESULTS: A total of 2914 patients were included in these trials. Outcomes were adjusted to baseline covariates including APACHE III score, vasopressor use, cause of lung injury, lung injury score, diabetes, cancer status, body mass index, and study ID. Older patients had significantly higher mortality at both 28-and 60-day (odds ratio [OR] 2.59 [95% confidence interval [CI]: 2.12-3.18] P < 0.001 and 2.79, 95% CI: 2.29-3.39, P < 0.001, respectively); less ICU and ventilator free days (relative risk [RR] 0.92, 95% CI: 0.87-0.96, P < 0.001 and 0.92, 95% CI: 0.88-0.96, P < 0.001, respectively). For preadmission location, the 28-and 60-day mortality were lower if the patient was admitted from the operating room (OR)/recovery room (OR 0.65, 95% CI: 0.44-0.95, P = 0.026; and OR = 0.66, 95% CI: 0.46-0.95, P = 0.025, respectively) or emergency department (OR = 0.78, 95% CI: 0.61-0.99, P = 0.039; and OR = 0.71, 95% CI: 0.56-0.89, P = 0.004, respectively), but no statistical differences in ICU and ventilator free days between different preadmission locations. Races other than white and black had a statistically higher mortality (28-and 60-day mortality: OR = 1.47, 95% CI: 1.09-1.98, P = 0.011; and OR 1.53, 95% CI: 1.15-2.04, P = 0.004, respectively). Between whites and blacks, females and males there were no statistically significant differences in all outcomes. CONCLUSION: Older patients and races other than blacks and whites have higher mortality associated with ARDS. Mortality is affected by patients preadmission location. There are no differences in outcome in relation to the type of ICU, gender, or between blacks and whites. AN - WOS:000396397800004 AU - El-Haddad, H. AU - Jang, H. AU - Chen, W. AU - Haider, S. AU - Soubani, A. O. DA - Jan-Mar DO - 10.4103/1817-1737.197767 IS - 1 N1 - 28197217 PY - 2017 SN - 1817-1737 SP - 17-24 ST - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome T2 - Annals of Thoracic Medicine TI - The effect of demographics and patient location on the outcome of patients with acute respiratory distress syndrome VL - 12 ID - 2918 ER - TY - JOUR AB - Importance: Erlotinib is a standard first‐line therapy for patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Median progression‐free survival (PFS) with erlotinib is approximately 10 months. Objective: To determine whether adding bevacizumab to erlotinib treatment results in superior progression‐free survival compared with erlotinib alone. Design, Setting, and Participants: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR‐mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7‐62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Interventions: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and Measures: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). Results: Among 88 patients enrolled, the median (range) age was 63 (31‐84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty‐eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50‐1.31; P =.39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P =.81), and OS (HR, 1.41; 95% CI, 0.71‐2.81; P =.33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and Relevance: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR‐mutant NSCLC. Trial Registration: ClinicalTrials.gov identifier: NCT01532089. AN - CN-01978827 AU - Stinchcombe, T. E. AU - Janne, P. A. AU - Wang, X. AU - Bertino, E. M. AU - Weiss, J. AU - Bazhenova, L. AU - Gu, L. AU - Lau, C. AU - Paweletz, C. AU - Jaslowski, A. AU - et al. DO - 10.1001/jamaoncol.2019.1847 KW - *advanced cancer *cancer patient *cancer survival *gene deletion *non small cell lung cancer *progression free survival Adult Adverse drug reaction African American Article Cancer staging Controlled study Diarrhea Disease exacerbation Drug combination Drug therapy Drug withdrawal Female Human Hypertension Major clinical study Male Oncology Overall survival Phase 2 clinical trial Proteinuria Race Randomized controlled trial Rash Registration Side effect Smoking M3 - Journal: Article in Press PY - 2019 ST - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR -Mutant Non-Small Cell Lung Cancer: a Phase 2 Randomized Clinical Trial T2 - JAMA oncology TI - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR -Mutant Non-Small Cell Lung Cancer: a Phase 2 Randomized Clinical Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01978827/full ID - 1552 ER - TY - JOUR AB - Importance: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective: To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and Participants: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Interventions: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and Measures: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). Results: Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P =.39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P =.81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P =.33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and Relevance: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. AD - T.E. Stinchcombe, Duke Cancer Institute, DUMC 3198, 251788 Morris Building, Durham, NC, United States AU - Stinchcombe, T. E. AU - Jänne, P. A. AU - Wang, X. AU - Bertino, E. M. AU - Weiss, J. AU - Bazhenova, L. AU - Gu, L. AU - Lau, C. AU - Paweletz, C. AU - Jaslowski, A. AU - Gerstner, G. J. AU - Baggstrom, M. Q. AU - Graziano, S. AU - Bearden, J. AU - Vokes, E. E. DB - Embase Medline DO - 10.1001/jamaoncol.2019.1847 IS - 10 KW - NCT01532089 bevacizumab epidermal growth factor receptor erlotinib abdominal pain adult advanced cancer African American aged article Asian cancer growth cancer staging Caucasian controlled study diarrhea drug effect dyspnea EGFR gene exon fatigue female follow up gene gene deletion gene mutation groups by age human hypertension major clinical study male non small cell lung cancer overall survival phase 2 clinical trial progression free survival proteinuria randomized controlled trial rash retrospective study smoking treatment outcome treatment response LA - English M3 - Article N1 - L628902024 2019-08-20 2019-10-31 PY - 2019 SN - 2374-2445 2374-2437 SP - 1448-1455 ST - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial T2 - JAMA Oncology TI - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628902024&from=export http://dx.doi.org/10.1001/jamaoncol.2019.1847 VL - 5 ID - 840 ER - TY - JOUR AB - Importance: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective: To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and Participants: This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. Interventions: Patients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and Measures: The primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). Results: Among 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR, 0.81; 95% CI, 0.50-1.31; P =.39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P =.81), and OS (HR, 1.41; 95% CI, 0.71-2.81; P =.33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and Relevance: Erlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. © 2019 American Medical Association. All rights reserved. AD - Duke Cancer Institute, DUMC 3198, 251788 Morris Building, Durham, NC 27710, United States Dana Farber Cancer Institute, Boston, MA, United States Alliance Data and Statistical Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States Ohio State University, Comprehensive Cancer Center, Columbus, United States University of North Carolina, Lineberger Cancer Center, Chapel Hill, United States Moores Cancer Center, University of California, San Diego, United States Saint Vincent Hospital Cancer Center, Green Bay, WI, United States Illinois Cancer Care-Peoria, Peoria, IL, United States Division of Medical Oncology, Washington University School of Medicine, St Louis, MO, United States Division of Hematology and Oncology, State University of New York, Upstate Medical University, Syracuse, United States Spartanburg Regional Health, Spartanburg, SC, United States Biological Sciences Division, University of Chicago Medicine, Chicago, IL, United States AU - Stinchcombe, T. E. AU - Jänne, P. A. AU - Wang, X. AU - Bertino, E. M. AU - Weiss, J. AU - Bazhenova, L. AU - Gu, L. AU - Lau, C. AU - Paweletz, C. AU - Jaslowski, A. AU - Gerstner, G. J. AU - Baggstrom, M. Q. AU - Graziano, S. AU - Bearden, J. AU - Vokes, E. E. DB - Scopus DO - 10.1001/jamaoncol.2019.1847 IS - 10 M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2019 SP - 1448-1455 ST - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial T2 - JAMA Oncology TI - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070549292&doi=10.1001%2fjamaoncol.2019.1847&partnerID=40&md5=97e27d0a365c3d994bcdda8828bb3d55 VL - 5 ID - 2220 ER - TY - JOUR AB - Key PointsQuestionIs the combination of erlotinib and bevacizumab superior to erlotinib alone to treat epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer? FindingsThis phase 2 randomized clinical trial found that compared with erlotinib alone, the combination of erlotinib and bevacizumab did not result in superior progression-free survival. MeaningThe combination of erlotinib and bevacizumab does not have superior efficacy compared with erlotinib alone. This phase 2 multicenter randomized clinical trial including 88 patients compares progression-free survival, and secondarily overall survival, overall response rate, and adverse events, in patients with stage 4 EGFR-mutant non-small cell lung cancer treated with erlotinib plus bevacizumab vs erlotinib alone. ImportanceErlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. ObjectiveTo determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and ParticipantsThis phase 2 randomized clinical trial compared erlotinib plus bevacizumab with erlotinib alone in EGFR-mutant NSCLC. The trial was conducted in 17 US academic and community medical centers among 88 patients with EGFR exon 19 deletion or exon 21 L858R mutation based on local testing and stage 4 NSCLC who were eligible for bevacizumab. Patients were enrolled between November 2, 2012, and August 22, 2016, and followed up for a median (range) of 33 (0.7-62.5) months. Data were analyzed on August 28, 2018, and included data from November 2, 2012, to August 20, 2018. InterventionsPatients were randomized with equal allocation to 150 mg of oral erlotinib daily alone or with 15 mg/kg of intravenous bevacizumab every 3 weeks. Study therapy continued until disease progression, unacceptable adverse event, or withdrawal of consent. Main Outcomes and MeasuresThe primary outcome was PFS as assessed by the investigator; secondary outcomes were objective response rate (ORR), adverse events, and overall survival (OS). Analysis was designed to detect a hazard ratio (HR) of 0.667 for PFS (an improvement from a median PFS of 10 to 15 months). ResultsAmong 88 patients enrolled, the median (range) age was 63 (31-84) years; 62 patients (70%) were female; 75 (85%) were white, 8 (9%) were African American, 3 (3%) were Asian, and for 2 (2%), data on race were not available. Forty-eight patients (55%) were never smokers, 45 patients (51%) were of Eastern Cooperative Oncology Group performance status 1, and 59 patients (67%) had EGFR exon 19 deletion. Compared with erlotinib, the combination did not result in a significant difference in PFS (HR,0.81; 95% CI, 0.50-1.31; P=.39; median PFS 17.9 [combination] and 13.5 months [erlotinib]), ORR (81% vs 83%; P=.81), and OS (HR,1.41; 95% CI, 0.71-2.81; P=.33; median OS, 32.4 months [combination] and 50.6 months [erlotinib]). Adverse events of grade 3 or higher observed in 5 or more patients in the combination and erlotinib arms were skin eruption in 11 (26%) vs 7 (16%) patients, diarrhea in 4 (9%) vs 6 (13%) patients, hypertension in 17 (40%) vs 9 (20%) patients, and proteinuria in 5 (12%) vs 0 (0%) patients. Conclusions and RelevanceErlotinib plus bevacizumab compared with erlotinib did not result in a significant improvement in PFS in EGFR-mutant NSCLC. Trial RegistrationClinicalTrials.gov identifier: NCT01532089. AN - WOS:000492417200012 AU - Stinchcombe, T. E. AU - Janne, P. A. AU - Wang, X. F. AU - Bertino, E. M. AU - Weiss, J. AU - Bazhenova, L. AU - Gu, L. AU - Lau, C. AU - Paweletz, C. AU - Jaslowski, A. AU - Gerstner, G. J. AU - Baggstrom, M. Q. AU - Graziano, S. AU - Bearden, J. AU - Vokes, E. E. DA - Oct DO - 10.1001/jamaoncol.2019.1847 IS - 10 N1 - 31393548 PY - 2019 SN - 2374-2437 SP - 1448-1455 ST - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial T2 - Jama Oncology TI - Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial VL - 5 ID - 2808 ER - TY - JOUR AB - Background: This study examined the effects of supervised and home-based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. Methods: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home-based walking-based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6-month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high-density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model-based projected breast cancer risk, were examined with intent-to-treat analyses using generalized estimating equation models. Results: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls, + 0.55; home-based arm, –0.97, P <.01; supervised arm, –0.89, P <.01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. Conclusions: Short-term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. © 2018 American Cancer Society. AD - C. Dash, Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States AU - Dash, C. AU - Taylor, T. R. AU - Makambi, K. H. AU - Hicks, J. AU - Hagberg, J. M. AU - Adams-Campbell, L. L. DB - Embase Medline DO - 10.1002/cncr.31569 IS - 16 KW - glucose high density lipoprotein triacylglycerol adult aerobic exercise aged article Black person blood pressure breast cancer cancer risk controlled study exercise intensity family history female glucose blood level high risk population human lipoprotein blood level low risk population major clinical study metabolic syndrome X obesity postmenopause prediction priority journal randomized controlled trial therapy effect triacylglycerol blood level waist circumference walking LA - English M3 - Article N1 - L623270813 2018-08-02 2018-09-06 PY - 2018 SN - 1097-0142 0008-543X SP - 3355-3363 ST - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study T2 - Cancer TI - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623270813&from=export http://dx.doi.org/10.1002/cncr.31569 VL - 124 ID - 890 ER - TY - JOUR AB - BACKGROUND: This study examined the effects of supervised and home‐based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. METHODS: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home‐based walking‐based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6‐month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high‐density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model‐based projected breast cancer risk, were examined with intent‐to‐treat analyses using generalized estimating equation models. RESULTS: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls, + 0.55; home‐based arm, ‐0.97, P < .01; supervised arm, ‐0.89, P < .01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. CONCLUSIONS: Short‐term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. © 2018 American Cancer Society. AN - CN-01982314 AU - Dash, C. AU - Taylor, T. R. AU - Makambi, K. H. AU - Hicks, J. AU - Hagberg, J. M. AU - Adams-Campbell, L. L. DO - 10.1002/cncr.31569 IS - 16 KW - Blood Glucose Breast Neoplasms [blood, complications, pathology, *therapy] Cholesterol, HDL [blood] Exercise Fasting Female Humans Metabolic Syndrome [blood, complications, pathology, *therapy] Middle Aged Triglycerides [blood] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2018 SP - 3355‐3363 ST - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: the FIERCE Study T2 - Cancer TI - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: the FIERCE Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01982314/full VL - 124 ID - 1508 ER - TY - JOUR AB - Background: This study examined the effects of supervised and home‐based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. Methods: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home‐based walking‐based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6‐month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high‐density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model‐based projected breast cancer risk, were examined with intent‐to‐treat analyses using generalized estimating equation models. Results: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls, + 0.55; home‐based arm, –0.97, P <.01; supervised arm, –0.89, P <.01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. Conclusions: Short‐term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. © 2018 American Cancer Society. AN - CN-01646313 AU - Dash, C. AU - Taylor, T. R. AU - Makambi, K. H. AU - Hicks, J. AU - Hagberg, J. M. AU - Adams-Campbell, L. L. DO - 10.1002/cncr.31569 IS - 16 KW - *aerobic exercise *breast cancer *metabolic syndrome X /therapy *walking Adult Aged Article Black person Blood pressure Cancer risk Controlled study Exercise intensity Family history Female Glucose blood level High risk population Human Lipoprotein blood level Low risk population Major clinical study Obesity Postmenopause Prediction Priority journal Randomized controlled trial Therapy effect Triacylglycerol blood level Waist circumference M3 - Journal: Article PY - 2018 SP - 3355‐3363 ST - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: the FIERCE Study T2 - Cancer TI - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: the FIERCE Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01646313/full VL - 124 ID - 1534 ER - TY - JOUR AB - Background: This study examined the effects of supervised and home-based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. Methods: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home-based walking-based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6-month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high-density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model-based projected breast cancer risk, were examined with intent-to-treat analyses using generalized estimating equation models. Results: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls, + 0.55; home-based arm, –0.97, P <.01; supervised arm, –0.89, P <.01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. Conclusions: Short-term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. © 2018 American Cancer Society. © 2018 American Cancer Society AD - Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States Department of Medicine, Howard University Cancer Center, Howard University, Washington, DC, United States Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States Department of Kinesiology, University of Maryland School of Public Health, College Park, MD, United States AU - Dash, C. AU - Taylor, T. R. AU - Makambi, K. H. AU - Hicks, J. AU - Hagberg, J. M. AU - Adams-Campbell, L. L. DB - Scopus DO - 10.1002/cncr.31569 IS - 16 KW - black breast cancer clinical trial exercise metabolic syndrome M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2018 SP - 3355-3363 ST - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study T2 - Cancer TI - Effect of exercise on metabolic syndrome in black women by family history and predicted risk of breast cancer: The FIERCE Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050598542&doi=10.1002%2fcncr.31569&partnerID=40&md5=5cbcb128cc951e68326dd3fe8f9763fa VL - 124 ID - 2262 ER - TY - JOUR AB - Background: This study examined the effects of supervised and home-based exercise interventions on changes in metabolic syndrome (MetS) according to breast cancer risk (high vs low) in black women enrolled in the Focused Intervention on Exercise to Reduce Cancer (FIERCE) trial. Methods: Postmenopausal, obese, metabolically unhealthy black women, 45 to 65 years old, were randomized to supervised aerobic exercise (73 women), home-based walking-based exercise (69 women), or a control arm (71 women). Participants in the exercise arms underwent a 6-month intervention with study assessments conducted at the baseline and 6 months. The primary outcome measure was MetS (fasting glucose, waist circumference, blood pressure, serum triglycerides, and high-density lipoprotein [HDL]). The intervention effects on MetS, stratified by breast cancer risk as measured by the family history of breast cancer and model-based projected breast cancer risk, were examined with intent-to-treat analyses using generalized estimating equation models. Results: Among women with a family history of breast cancer, the exercise arms had lower mean MetS z scores, which suggested an improvement in the metabolic profile, than controls at 6 months (controls,+0.55; home-based arm, -0.97, P<.01; supervised arm, -0.89, P<.01). Stratified analyses by projected breast cancer risk suggested similar but statistically nonsignificant findings, with those at high risk having more favorable changes in the MetS z score in the exercise arms versus the control arm. These changes were primarily attributable to changes in blood pressure, triglycerides, and HDL. Conclusions: Short-term aerobic activity regimens may improve the metabolic profile and thereby reduce breast cancer risk in obese, metabolically unhealthy black women at high risk for cancer. (C) 2018 American Cancer Society. AN - WOS:000442572000012 AU - Dash, C. AU - Taylor, T. R. AU - Makambi, K. H. AU - Hicks, J. AU - Hagberg, J. M. AU - Adams-Campbell, L. L. DA - Aug DO - 10.1002/cncr.31569 IS - 16 N1 - 29975403 PY - 2018 SN - 0008-543X SP - 3355-3363 ST - Effect of Exercise on Metabolic Syndrome in Black Women by Family History and Predicted Risk of Breast Cancer: The FIERCE Study T2 - Cancer TI - Effect of Exercise on Metabolic Syndrome in Black Women by Family History and Predicted Risk of Breast Cancer: The FIERCE Study VL - 124 ID - 2850 ER - TY - JOUR AB - Background: Decision aids can improve decision making processes, but the amount and type of information that they should attempt to communicate is controversial. We sought to compare, in a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the number of screening options presented.Methods: Adults ages 48-75 not currently up to date with screening were recruited from the community and randomized to view one of two versions of our previously tested CRC screening decision aid. The first version included five screening options: fecal occult blood test (FOBT), sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The second discussed only the two most frequently selected screening options, FOBT and colonoscopy. Main outcomes were differences in screening interest and test preferences between groups after decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-$50, and colonoscopy-$200.Results: 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option version. Mean age was 54 (range 48-72), 58% were women, 71% were White, 24% African-American; 58% had completed at least a 4-year college degree. Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were imposed (41% vs. 42%, p = 1.00).Conclusion: The number of screening options available does not appear to have a large effect on interest in colorectal cancer screening. The effect of offering differing numbers of options may affect test choice when out-of-pocket costs are not considered. AD - Center for Decision Making Research, Cecil Sheps Center for Health Services Research, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA Center for Decision Making Research, Cecil Sheps Center for Health Services Research, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA. jgriffith@unc.edu AN - 105685404. Language: English. Entry Date: 20090626. Revision Date: 20200708. Publication Type: journal article AU - Griffith, J. M. AU - Lewis, C. L. AU - Brenner, A. R. AU - Pignone, M. P. AU - Griffith, Jennifer M. AU - Lewis, Carmen L. AU - Brenner, Alison R. T. AU - Pignone, Michael P. DB - CINAHL Complete DO - 10.1186/1472-6947-8-4 DP - EBSCOhost IS - 1 KW - Colorectal Neoplasms -- Diagnosis Consumer Participation -- Statistics and Numerical Data Decision Support Techniques Health Screening -- Methods Patient Satisfaction -- Statistics and Numerical Data Aged Barium -- Diagnostic Use Clinical Trials Colonoscopy -- Economics Colonoscopy -- Utilization Consumer Participation -- Economics Decision Making Economics Enema -- Economics Enema -- Utilization Female Health Screening -- Economics Male Middle Age North Carolina Occult Blood Patient Satisfaction -- Economics Questionnaires Sigmoidoscopy -- Economics Sigmoidoscopy -- Utilization Human N1 - clinical trial; research. Journal Subset: Biomedical; Computer/Information Science; Europe; UK & Ireland. Grant Information: 5K07CA104128/CA/NCI NIH HHS/United States. NLM UID: 101088682. PMID: NLM18218084. PY - 2008 SN - 1472-6947 SP - 4-4 ST - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial T2 - BMC Medical Informatics & Decision Making TI - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105685404&site=ehost-live&scope=site VL - 8 ID - 2117 ER - TY - JOUR AB - Background. Decision aids can improve decision making processes, but the amount and type of information that they should attempt to communicate is controversial. We sought to compare, in a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the number of screening options presented. Methods. Adults ages 48-75 not currently up to date with screening were recruited from the community and randomized to view one of two versions of our previously tested CRC screening decision aid. The first version included five screening options: fecal occult blood test (FOBT), sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The second discussed only the two most frequently selected screening options, FOBT and colonoscopy. Main outcomes were differences in screening interest and test preferences between groups after decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-$50, and colonoscopy-$200. Results. 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option version. Mean age was 54 (range 48-72), 58% were women, 71% were White, 24% African-American; 58% had completed at least a 4-year college degree. Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were imposed (41% vs. 42%, p = 1.00). Conclusion. The number of screening options available does not appear to have a large effect on interest in colorectal cancer screening. The effect of offering differing numbers of options may affect test choice when out-of-pocket costs are not considered. © 2008 Griffith et al; licensee BioMed Central Ltd. AD - J.M. Griffith, Center for Decision Making Research, Cecil Sheps Center for Health Services Research, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States AU - Griffith, J. M. AU - Lewis, C. L. AU - Brenner, A. R. T. AU - Pignone, M. P. DB - Embase Medline DO - 10.1186/1472-6947-8-4 KW - adult aged article barium enema blood examination cancer screening clinical trial colonoscopy colorectal cancer controlled clinical trial controlled study female health care cost human male medical decision making occult blood randomized controlled trial sigmoidoscopy LA - English M3 - Article N1 - L351328661 2008-03-18 PY - 2008 SN - 1472-6947 ST - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: A pilot randomized trial T2 - BMC Medical Informatics and Decision Making TI - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: A pilot randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351328661&from=export http://dx.doi.org/10.1186/1472-6947-8-4 VL - 8 ID - 1220 ER - TY - JOUR AB - Background. Decision aids can improve decision making processes, but the amount and type of information that they should attempt to communicate is controversial. We sought to compare, in a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the number of screening options presented. Methods. Adults ages 48-75 not currently up to date with screening were recruited from the community and randomized to view one of two versions of our previously tested CRC screening decision aid. The first version included five screening options: fecal occult blood test (FOBT), sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The second discussed only the two most frequently selected screening options, FOBT and colonoscopy. Main outcomes were differences in screening interest and test preferences between groups after decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-$50, and colonoscopy-$200. Results. 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option version. Mean age was 54 (range 48-72), 58% were women, 71% were White, 24% African-American; 58% had completed at least a 4-year college degree. Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were imposed (41% vs. 42%, p = 1.00). Conclusion. The number of screening options available does not appear to have a large effect on interest in colorectal cancer screening. The effect of offering differing numbers of options may affect test choice when out-of-pocket costs are not considered. © 2008 Griffith et al; licensee BioMed Central Ltd. AD - Center for Decision Making Research, Cecil Sheps Center for Health Services Research, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States Division of General Internal Medicine, School of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC, United States AU - Griffith, J. M. AU - Lewis, C. L. AU - Brenner, A. R. T. AU - Pignone, M. P. C7 - 4 DB - Scopus DO - 10.1186/1472-6947-8-4 M3 - Article N1 - Cited By :40 Export Date: 22 March 2021 PY - 2008 ST - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: A pilot randomized trial T2 - BMC Medical Informatics and Decision Making TI - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: A pilot randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-40149103499&doi=10.1186%2f1472-6947-8-4&partnerID=40&md5=1b1ac21d41952727a7c988684632dfec VL - 8 ID - 2548 ER - TY - JOUR AB - Background: Decision aids can improve decision making processes, but the amount and type of information that they should attempt to communicate is controversial. We sought to compare, in a pilot randomized trial, two colorectal cancer (CRC) screening decision aids that differed in the number of screening options presented. Methods: Adults ages 48-75 not currently up to date with screening were recruited from the community and randomized to view one of two versions of our previously tested CRC screening decision aid. The first version included five screening options: fecal occult blood test (FOBT), sigmoidoscopy, a combination of FOBT and sigmoidoscopy, colonoscopy, and barium enema. The second discussed only the two most frequently selected screening options, FOBT and colonoscopy. Main outcomes were differences in screening interest and test preferences between groups after decision aid viewing. Patient test preference was elicited first without any associated out-of-pocket costs (OPC), and then with the following costs: FOBT-$10, sigmoidoscopy-$50, barium enema-$ 50, and colonoscopy-$200. Results: 62 adults participated: 25 viewed the 5-option decision aid, and 37 viewed the 2-option version. Mean age was 54 (range 48-72), 58% were women, 71% were White, 24% African-American; 58% had completed at least a 4-year college degree. Comparing participants that viewed the 5-option version with participants who viewed the 2-option version, there were no differences in screening interest after viewing (1.8 vs. 1.9, t-test p = 0.76). Those viewing the 2-option version were somewhat more likely to choose colonoscopy than those viewing the 5-option version when no out of pocket costs were assumed (68% vs. 46%, p = 0.11), but not when such costs were imposed ( 41% vs. 42%, p = 1.00). Conclusion: The number of screening options available does not appear to have a large effect on interest in colorectal cancer screening. The effect of offering differing numbers of options may affect test choice when out-of-pocket costs are not considered. AN - WOS:000253970700001 AU - Griffith, J. M. AU - Lewis, C. L. AU - Brenner, A. R. T. AU - Pignone, M. P. DA - Jan DO - 10.1186/1472-6947-8-4 N1 - 4 18218084 PY - 2008 SN - 1472-6947 ST - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial T2 - Bmc Medical Informatics and Decision Making TI - The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial VL - 8 ID - 3176 ER - TY - JOUR AB - Background: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women.Objective: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD.Design: The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010.Setting: Community-based and clinical setting.Participants: The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were ≥65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls.Interventions: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group).Main Measure: Self-reported receipt of mammography screening within 2 years of the end of the study.Key Results: The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59-3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09-6.38).Conclusion: Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. AD - Division of General Medicine, University of Michigan Health System, Ann Arbor USA Department of Oncology, Johns Hopkins School of Medicine, Baltimore USA Department of Medicine, The Brooklyn Hospital Center, Brooklyn USA Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore USA Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore USA Health Partners Cancer Program and Institute for Education and Research, Minneapolis USA Centers for Medicare and Medicaid Services, Baltimore USA Park West Health Systems, Baltimore USA TVCOFA Corporation, Baltimore USA Formerly of the Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore USA Division of General Medicine, University of Michigan Health System, Ann Arbor, MI, USA Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA Department of Medicine, The Brooklyn Hospital Center, Brooklyn, NY, USA Health Partners Cancer Program and Institute for Education and Research, Minneapolis, MN, USA Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA AN - 112062834. Language: English. Entry Date: 20160826. Revision Date: 20190620. Publication Type: journal article AU - Marshall, Jessie AU - Mbah, Olive AU - Ford, Jean AU - Phelan-Emrick, Darcy AU - Ahmed, Saifuddin AU - Bone, Lee AU - Wenzel, Jennifer AU - Shapiro, Gary AU - Howerton, Mollie AU - Johnson, Lawrence AU - Brown, Qiana AU - Ewing, Altovise AU - Pollack, Craig AU - Marshall, Jessie Kimbrough AU - Mbah, Olive M. AU - Ford, Jean G. AU - Shapiro, Gary R. AU - Pollack, Craig Evan DB - CINAHL Complete DO - 10.1007/s11606-015-3484-2 DP - EBSCOhost IS - 1 KW - Patient Education -- Methods Guideline Adherence Breast Neoplasms -- Ethnology Patient Navigation -- Economics Early Detection of Cancer -- Economics Black Persons Medicare -- Economics Human Breast Neoplasms -- Prevention and Control Attitude to Health Female Mammography -- Economics Aged United States Breast Neoplasms -- Economics Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Funding Source N1 - research; randomized controlled trial. Journal Subset: Biomedical; Continental Europe; Europe. Special Interest: Evidence-Based Practice. Grant Information: K07 CA151910/CA/NCI NIH HHS/United States. NLM UID: 8605834. PMID: NLM26259762. PY - 2016 SN - 0884-8734 SP - 68-76 ST - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial T2 - JGIM: Journal of General Internal Medicine TI - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112062834&site=ehost-live&scope=site VL - 31 ID - 1928 ER - TY - JOUR AB - BACKGROUND: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. OBJECTIVE: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. DESIGN: The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010. SETTING: Community-based and clinical setting. PARTICIPANTS: The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were ≥65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. INTERVENTIONS: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). MAIN MEASURE: Self-reported receipt of mammography screening within 2 years of the end of the study. KEY RESULTS: The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59–3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09–6.38). CONCLUSION: Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. AD - J.G. Ford, Department of Medicine, The Brooklyn Hospital Center, Brooklyn, NY, United States AU - Marshall, J. K. AU - Mbah, O. M. AU - Ford, J. G. AU - Phelan-Emrick, D. AU - Ahmed, S. AU - Bone, L. AU - Wenzel, J. AU - Shapiro, G. R. AU - Howerton, M. AU - Johnson, L. AU - Brown, Q. AU - Ewing, A. AU - Pollack, C. E. DB - Embase Medline DO - 10.1007/s11606-015-3484-2 IS - 1 KW - African American aged article breast cancer cancer screening controlled study female follow up health care utilization health promotion human incidence major clinical study mammography medicare multicenter study patient care randomized controlled trial urban population LA - English M3 - Article N1 - L605585225 2015-08-17 2016-01-15 PY - 2016 SN - 1525-1497 0884-8734 SP - 68-76 ST - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial T2 - Journal of General Internal Medicine TI - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605585225&from=export http://dx.doi.org/10.1007/s11606-015-3484-2 VL - 31 ID - 984 ER - TY - JOUR AB - Background: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. Objective: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. Design: The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010. Setting: Community-based and clinical setting. Participants: The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were ≥65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. Interventions: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). Main Measure: Self-reported receipt of mammography screening within 2 years of the end of the study. Key Results: The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59–3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09–6.38). Conclusion: Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ford, Jean G., Department of Medicine, Brooklyn Hospital Center, Brooklyn, NY, US AN - 2016-00415-047 AU - Marshall, Jessie Kimbrough AU - Mbah, Olive M. AU - Ford, Jean G. AU - Phelan-Emrick, Darcy AU - Ahmed, Saifuddin AU - Bone, Lee AU - Wenzel, Jennifer AU - Shapiro, Gary R. AU - Howerton, Mollie AU - Johnson, Lawrence AU - Brown, Qiana AU - Ewing, Altovise AU - Pollack, Craig Evan DB - psyh DO - 10.1007/s11606-015-3484-2 DP - EBSCOhost IS - 1 KW - patient navigation mammography African American Blacks Breast Neoplasms Cancer Screening Medicare N1 - Division of General Medicine, University of Michigan Health System, Ann Arbor, MI, US. Other Publishers: Blackwell Publishing. Release Date: 20160211. Correction Date: 20160215. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Mbah, Olive M. Major Descriptor: Blacks; Breast Neoplasms; Cancer Screening; Mammography; Medicare. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Followup Study; Interview; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 9. Issue Publication Date: Jan, 2016. Publication History: First Posted Date: Aug 11, 2015; Accepted Date: Feb 4, 2015; Revised Date: Jan 12, 2015; First Submitted Date: Sep 14, 2014. Copyright Statement: Society of General Internal Medicine. 2015. Sponsor: Centers for Medicare and Medicaid Services. Grant: cooperative agreement 1A0CMS300066. Other Details: CPTD for Ethnic and Racial Minorities. Recipients: No recipient indicated Sponsor: National Cancer Institute, Community Networks Program, US. Grant: U54CA153710. Recipients: Mbah, Olive M. Sponsor: Health Resources and Services Administration. Grant: 5 T32 HL007180-34 0. Other Details: National Research Service Award. Recipients: Marshall, Jessie Kimbrough Sponsor: National Cancer Institute, Office of Behavioral and Social Sciences, US. Grant: K07 CA151910. Recipients: Pollack, Craig Evan Sponsor: National Institutes of Health, National Center for Research Resources, National Center for Advancing Translational Sciences (NCATS), US. Grant: 1UL1TR001079. Recipients: No recipient indicated PY - 2016 SN - 0884-8734 1525-1497 SP - 68-76 ST - Effect of patient navigation on breast cancer screening among African American Medicare beneficiaries: A randomized controlled trial T2 - Journal of General Internal Medicine TI - Effect of patient navigation on breast cancer screening among African American Medicare beneficiaries: A randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-00415-047&site=ehost-live&scope=site jgf9001@nyp.org VL - 31 ID - 1690 ER - TY - JOUR AB - BACKGROUND: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. OBJECTIVE: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. DESIGN: The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010. SETTING: Community-based and clinical setting. PARTICIPANTS: The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were ≥65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. INTERVENTIONS: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). MAIN MEASURE: Self-reported receipt of mammography screening within 2 years of the end of the study. KEY RESULTS: The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59–3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09–6.38). CONCLUSION: Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. © 2015, Society of General Internal Medicine. AD - Division of General Medicine, University of Michigan Health System, Ann Arbor, MI, United States Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, United States Department of Medicine, The Brooklyn Hospital Center, Brooklyn, NY, United States Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Acute and Chronic Care, Johns Hopkins School of Nursing, Baltimore, MD, United States Health Partners Cancer Program and Institute for Education and Research, Minneapolis, MN, United States Centers for Medicare and Medicaid Services, Baltimore, MD, United States Park West Health Systems, Baltimore, MD, United States TVCOFA Corporation, Baltimore, MD, United States Formerly of the Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States AU - Marshall, J. K. AU - Mbah, O. M. AU - Ford, J. G. AU - Phelan-Emrick, D. AU - Ahmed, S. AU - Bone, L. AU - Wenzel, J. AU - Shapiro, G. R. AU - Howerton, M. AU - Johnson, L. AU - Brown, Q. AU - Ewing, A. AU - Pollack, C. E. DB - Scopus DO - 10.1007/s11606-015-3484-2 IS - 1 KW - African American mammography patient navigation M3 - Article N1 - Cited By :36 Export Date: 22 March 2021 PY - 2016 SP - 68-76 ST - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial T2 - Journal of General Internal Medicine TI - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953347196&doi=10.1007%2fs11606-015-3484-2&partnerID=40&md5=ca7045542225f541f4805eafecbe42a7 VL - 31 ID - 2352 ER - TY - JOUR AB - There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. The Cancer Prevention and Treatment Demonstration (CPTD), a multi-site study, was a randomized controlled trial conducted from April 2006 through December 2010. Community-based and clinical setting. The CPTD Screening Trial enrolled 1905 community-dwelling African American female Medicare beneficiaries who were a parts per thousand yen65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). Self-reported receipt of mammography screening within 2 years of the end of the study. The median follow-up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow-up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59-3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09-6.38). Patient navigation among urban African American Medicare beneficiaries increased self-reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. AN - WOS:000367540600015 AU - Marshall, J. K. AU - Mbah, O. M. AU - Ford, J. G. AU - Phelan-Emrick, D. AU - Ahmed, S. AU - Bone, L. AU - Wenzel, J. AU - Shapiro, G. R. AU - Howerton, M. AU - Johnson, L. AU - Brown, Q. AU - Ewing, A. AU - Pollack, C. E. DA - Jan DO - 10.1007/s11606-015-3484-2 IS - 1 N1 - 26259762 PY - 2016 SN - 0884-8734 SP - 68-76 ST - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial T2 - Journal of General Internal Medicine TI - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: A Randomized Controlled Trial VL - 31 ID - 2958 ER - TY - JOUR AB - BACKGROUND: There is growing evidence that patient navigation improves breast cancer screening rates; however, there are limited efficacy studies of its effect among African American older adult women. OBJECTIVE: To evaluate the effect of patient navigation on screening mammography among African American female Medicare beneficiaries in Baltimore, MD. DESIGN: The Cancer Prevention and Treatment Demonstration (CPTD), a multi‐site study, was a randomized controlled trial conducted from April 2006 through December 2010. SETTING: Community‐based and clinical setting. PARTICIPANTS: The CPTD Screening Trial enrolled 1905 community‐dwelling African American female Medicare beneficiaries who were >65 years of age and resided in Baltimore, MD. Participants were recruited from health clinics, community centers, health fairs, mailings using Medicare rosters, and phone calls. INTERVENTIONS: Participants were randomized to either: printed educational materials on cancer screening (control group) or printed educational materials + patient navigation services designed to help participants overcome barriers to cancer screening (intervention group). MAIN MEASURE: Self‐reported receipt of mammography screening within 2 years of the end of the study. KEY RESULTS: The median follow‐up period for participants in this analysis was 17.8 months. In weighted multivariable logistic regression analyses, women in the intervention group had significantly higher odds of being up to date on mammography screening at the end of the follow‐up period compared to women in the control group (odds ratio [OR] 2.26, 95 % confidence interval [CI]1.59‐3.22). The effect of the intervention was stronger among women who were not up to date with mammography screening at enrollment (OR 3.63, 95 % CI 2.09‐6.38). CONCLUSION: Patient navigation among urban African American Medicare beneficiaries increased self‐reported mammography utilization. The results suggest that patient navigation for mammography screening should focus on women who are not up to date on their screening. AN - CN-01127833 AU - Marshall, J. K. AU - Mbah, O. M. AU - Ford, J. G. AU - Phelan-Emrick, D. AU - Ahmed, S. AU - Bone, L. AU - Wenzel, J. AU - Shapiro, G. R. AU - Howerton, M. AU - Johnson, L. AU - et al. DO - 10.1007/s11606-015-3484-2 IS - 1 KW - *breast cancer/di [Diagnosis] *cancer screening *mammography *patient care African American African Americans Aged Article Breast Neoplasms [economics, *ethnology, prevention & control] Controlled study Early Detection of Cancer [*economics] Female Follow up Guideline Adherence Health Knowledge, Attitudes, Practice Health care utilization Health promotion Human Humans Incidence Major clinical study Mammography [economics] Medicare Medicare [*economics] Multicenter study Patient Education as Topic [*methods] Patient Navigation [*economics] Randomized controlled trial Surveys and Questionnaires United States [epidemiology] Urban population M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2016 SP - 68‐76 ST - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: a Randomized Controlled Trial T2 - Journal of general internal medicine TI - Effect of Patient Navigation on Breast Cancer Screening Among African American Medicare Beneficiaries: a Randomized Controlled Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01127833/full VL - 31 ID - 1358 ER - TY - JOUR AB - Mammography screening continues to be under-utilized, especially among women from lower socioeconomic groups. In order to determine whether having direct access to health care services has an effect on mammography use among low income women, we conducted a randomized trial of two alternative letter reminders among 1,717 women who were enrolled at two locations of a multi-site inner city health department in Detroit. All participants were 39 1/2 years of age and older and were due for a screening mammogram at randomization. A physician-directed reminder form was placed in each of the participant's medical records at the beginning of the study. In addition participants were randomized to receive either a letter directing them to visit their primary care physician, a letter directing them to contact the clinic directly to schedule a mammogram, or no letter. Study participants were predominantly African - American, two-thirds of whom were over age 50, and who had minimal health insurance coverage. During the intervention year, mammograms were completed by 179 out of 967 study women at site one (18.5%), and 90 out of 750 study women at site two (12%). A multivariate model controlling for the simultaneous effect of age, insurance type, visit history and past mammography use, showed no significant independent effect of either type of letter reminder on mammography completion during the study year. In conclusion, letters targeted at women due for screening mammograms did not have a beneficial effect on mammography utilization above and beyond that of a physician medical record reminder. AD - M.S. Simon, Wayne State Univ. School of Medicine, Harper Hospital - 514 Hudson, 3990 John R, Detroit, MI 48201, United States AU - Simon, M. S. AU - Gimotty, P. A. AU - Moncrease, A. AU - Dews, P. AU - Burack, R. C. DB - Embase Medline DO - 10.1023/A:1006410711370 IS - 1 KW - adult aged article breast cancer breast disease cancer screening clinical trial controlled clinical trial controlled study female human major clinical study mammography medicaid medicare primary medical care priority journal randomized controlled trial screening test urban area LA - English M3 - Article N1 - L32163501 2001-03-06 PY - 2001 SN - 0167-6806 SP - 63-70 ST - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting T2 - Breast Cancer Research and Treatment TI - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32163501&from=export http://dx.doi.org/10.1023/A:1006410711370 VL - 65 ID - 1311 ER - TY - JOUR AB - Mammography screening continues to be under‐utilized, especially among women from lower socioeconomic groups. In order to determine whether having direct access to health care services has an effect on mammography use among low income women, we conducted a randomized trial of two alternative letter reminders among 1,717 women who were enrolled at two locations of a multi‐site inner city health department in Detroit. All participants were 39(1/2) years of age and older and were due for a screening mammogram at randomization. A physician‐directed reminder form was placed in each of the participant's medical records at the beginning of the study. In addition participants were randomized to receive either a letter directing them to visit their primary care physician, a letter directing them to contact the clinic directly to schedule a mammogram, or no letter. Study participants were predominantly African‐American, two‐thirds of whom were over age 50, and who had minimal health insurance coverage. During the intervention year, mammograms were completed by 179 out of 967 study women at site one (18.5%), and 90 out of 750 study women at site two (12%). A multivariate model controlling for the simultaneous effect of age, insurance type, visit history and past mammography use, showed no significant independent effect of either type of letter reminder on mammography completion during the study year. In conclusion, letters targeted at women due for screening mammograms did not have a beneficial effect on mammography utilization above and beyond that of a physician medical record reminder. AN - CN-00327264 AU - Simon, M. S. AU - Gimotty, P. A. AU - Moncrease, A. AU - Dews, P. AU - Burack, R. C. DO - 10.1023/a:1006410711370 IS - 1 KW - Adult Aged Breast Neoplasms [*diagnostic imaging] Female Health Services Accessibility Humans Mammography [*statistics & numerical data] Mass Screening Medical Records Middle Aged Patient Compliance Patient Education as Topic Physician‐Patient Relations Poverty Primary Health Care Reminder Systems Urban Population M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2001 SP - 63‐70 ST - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting T2 - Breast cancer research and treatment TI - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00327264/full VL - 65 ID - 1663 ER - TY - JOUR AB - Mammography screening continues to be under-utilized, especially among women from lower socioeconomic groups. In order to determine whether having direct access to health care services has an effect on mammography use among low income women, we conducted a randomized trial of two alternative letter reminders among 1,717 women who were enrolled at two locations of a multi-site inner city health department in Detroit. All participants were 39 1/2 years of age and older and were due for a screening mammogram at randomization. A physician-directed reminder form was placed in each of the participant's medical records at the beginning of the study. In addition participants were randomized to receive either a letter directing them to visit their primary care physician, a letter directing them to contact the clinic directly to schedule a mammogram, or no letter. Study participants were predominantly African - American, two-thirds of whom were over age 50, and who had minimal health insurance coverage. During the intervention year, mammograms were completed by 179 out of 967 study women at site one (18.5%), and 90 out of 750 study women at site two (12%). A multivariate model controlling for the simultaneous effect of age, insurance type, visit history and past mammography use, showed no significant independent effect of either type of letter reminder on mammography completion during the study year. In conclusion, letters targeted at women due for screening mammograms did not have a beneficial effect on mammography utilization above and beyond that of a physician medical record reminder. AD - Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Department of Internal Medicine, Wayne State University, University Health Center, Detroit, MI, United States AU - Simon, M. S. AU - Gimotty, P. A. AU - Moncrease, A. AU - Dews, P. AU - Burack, R. C. DB - Scopus DO - 10.1023/A:1006410711370 IS - 1 KW - Behavioral intervention Breast neoplasm Mammography Randomized controlled trial M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2001 SP - 63-70 ST - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting T2 - Breast Cancer Research and Treatment TI - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035110049&doi=10.1023%2fA%3a1006410711370&partnerID=40&md5=4e06b9b7f9c7f085a3a95397bc958a58 VL - 65 ID - 2624 ER - TY - JOUR AB - Mammography screening continues to be under-utilized, especially among women from lower socioeconomic groups. In order to determine whether having direct access to health care services has an effect on mammography use among low income women, we conducted a randomized trial of two alternative letter reminders among 1,717 women who were enrolled at two locations of a multi-site inner city health department in Detroit. All participants were 391/2 years of age and older and were due for a screening mammogram at randomization. A physician-directed reminder form was placed in each of the participant's medical records at the beginning of the study. In addition participants were randomized to receive either a letter directing them to visit their primary care physician, a letter directing them to contact the clinic directly to schedule a mammogram, or no letter. Study participants were predominantly African-American, two-thirds of whom were over age 50, and who had minimal health insurance coverage. During the intervention year, mammograms were completed by 179 out of 967 study women at site one (18.5%), and 90 out of 750 study women at site two (12%). A multivariate model controlling for the simultaneous effect of age, insurance type, visit history and past mammography use, showed no significant independent effect of either type of letter reminder on mammography completion during the study year. In conclusion, letters targeted at women due for screening mammograms did not have a beneficial effect on mammography utilization above and beyond that of a physician medical record reminder. AN - WOS:000166616600008 AU - Simon, M. S. AU - Gimotty, P. A. AU - Moncrease, A. AU - Dews, P. AU - Burack, R. C. DA - Jan DO - 10.1023/A:1006410711370 IS - 1 N1 - 21 11245341 PY - 2001 SN - 0167-6806 SP - 63-70 ST - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting T2 - Breast Cancer Research and Treatment TI - The effect of patient reminders on the use of screening mammography in an urban health department primary care setting VL - 65 ID - 2709 ER - TY - JOUR AB - Objectives This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. Methods Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. Results The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women. Conclusions Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education. Copyright © 2011 John Wiley & Sons, Ltd. AD - J.E. Herndon, Department of Biostatistics and Bioinformatics, Hock Plaza, Duke University Medical Center, Durham, NC 27710, United States AU - Herndon, J. E. AU - Kornblith, A. B. AU - Holland, J. C. AU - Paskett, E. D. DB - Embase Medline DO - 10.1002/pon.2094 IS - 2 KW - carmustine cisplatin cyclophosphamide doxorubicin estrogen receptor fluorouracil granulocyte colony stimulating factor megestrol acetate paclitaxel progesterone receptor tamoxifen topotecan trastuzumab adult African American aged article bone marrow transplantation bone metastasis breast cancer cancer hormone therapy cancer mortality cancer patient cancer prognosis cancer radiotherapy cancer staging cancer survival drug megadose educational status female human major clinical study postmenopause risk factor social status tumor volume visceral metastasis LA - English M3 - Article N1 - L51684031 2011-10-27 2013-02-22 PY - 2013 SN - 1057-9249 1099-1611 SP - 315-323 ST - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials T2 - Psycho-Oncology TI - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51684031&from=export http://dx.doi.org/10.1002/pon.2094 VL - 22 ID - 1092 ER - TY - JOUR AB - Objectives: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. Methods: Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. Results: The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non‐African American women who lacked a high school degree had poorer survival than other non‐African American women, and African American women who lacked a high school education had better survival than educated African American women. Conclusions: Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post‐trial survivorship plans need to focus on women with low social status, as measured by education. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Herndon, James E. II, Department of Biostatistics & Bioinformatics, Duke University Medical Center, Hock Plaza, Suite 802, Box 2717, Durham, NC, US, 27710 AN - 2013-03765-010 AU - Herndon, James E., II AU - Kornblith, Alice B. AU - Holland, Jimmie C. AU - Paskett, Electra D. DB - psyh DP - EBSCOhost IS - 2 KW - breast cancer clinical trials socioeconomic status education level drug therapy Adult African Americans Aged Breast Neoplasms Clinical Trials as Topic Educational Status Female Humans Middle Aged Multivariate Analysis Proportional Hazards Models Risk Factors Social Class Survival Rate United States Educational Background N1 - Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC, US. Release Date: 20130325. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Kornblith, Alice B. Major Descriptor: Breast Neoplasms; Clinical Trials; Drug Therapy; Educational Background. Minor Descriptor: Socioeconomic Status. Classification: Cancer (3293); Medical Treatment of Physical Illness (3363). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Followup Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Feb, 2013. Publication History: First Posted Date: Oct 20, 2011; Accepted Date: Oct 5, 2011; Revised Date: Oct 5, 2011; First Submitted Date: Jun 6, 2011. Copyright Statement: John Wiley & Sons, Ltd. 2011. Sponsor: National Cancer Institute, US. Grant: CA31946. Recipients: No recipient indicated Sponsor: Cancer and Leukemia Group B. Other Details: Richard L. Schilsky. Recipients: No recipient indicated Sponsor: CALGB Statistical Center. Grant: CA33601. Other Details: Stephen George. Recipients: No recipient indicated Sponsor: Sponsor name not included. Grant: CA32291. Recipients: Kornblith, Alice B. Sponsor: Sponsor name not included. Grant: CA77651. Recipients: Holland, Jimmie C. Sponsor: Sponsor name not included. Grant: CA77658. Recipients: Paskett, Electra D. PY - 2013 SN - 1057-9249 1099-1611 SP - 315-323 ST - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials T2 - Psycho-Oncology TI - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-03765-010&site=ehost-live&scope=site james.herndon@duke.edu VL - 22 ID - 1718 ER - TY - JOUR AB - Objectives This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. Methods Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. Results The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women. Conclusions Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education. Copyright © 2011 John Wiley & Sons, Ltd. AD - Department of Biostatistics and Bioinformatics, Hock Plaza, Duke University Medical Center, Durham, NC 27710, United States Dana Farber Cancer Institute, Boston, MA, United States Memorial Sloan-Kettering Cancer Center, New York, NY, United States College of Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States AU - Herndon, J. E. AU - Kornblith, A. B. AU - Holland, J. C. AU - Paskett, E. D. DB - Scopus DO - 10.1002/pon.2094 IS - 2 KW - breast cancer education oncology SES survival M3 - Article N1 - Cited By :28 Export Date: 22 March 2021 PY - 2013 SP - 315-323 ST - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials T2 - Psycho-Oncology TI - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873406545&doi=10.1002%2fpon.2094&partnerID=40&md5=674134d87ccf2a496b224902476e5ee3 VL - 22 ID - 2443 ER - TY - JOUR AB - Objectives This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. Methods Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. Results The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women. Conclusions Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education. Copyright (c) 2011 John Wiley & Sons, Ltd. AN - WOS:000314493700010 AU - Herndon, J. E. AU - Kornblith, A. B. AU - Holland, J. C. AU - Paskett, E. D. DA - Feb DO - 10.1002/pon.2094 IS - 2 N1 - 22021121 PY - 2013 SN - 1057-9249 SP - 315-323 ST - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials T2 - Psycho-Oncology TI - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials VL - 22 ID - 3051 ER - TY - JOUR AB - Objectives: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B.Methods: Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors.Results: The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women.Conclusions: Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education. AD - Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA Department of Biostatistics & Bioinformatics, Duke University Medical Center, Durham, NC, USA. AN - 104306061. Language: English. Entry Date: 20130816. Revision Date: 20200708. Publication Type: journal article AU - Herndon, J. E., 2nd AU - Kornblith, A. B. AU - Holland, J. C. AU - Paskett, E. D. AU - Herndon, James E., 2nd AU - Kornblith, Alice B. AU - Holland, Jimmie C. AU - Paskett, Electra D. DB - CINAHL Complete DO - 10.1002/pon.2094 DP - EBSCOhost IS - 2 KW - Breast Neoplasms -- Mortality Social Class Adult Aged Black Persons -- Statistics and Numerical Data Breast Neoplasms -- Ethnology Clinical Trials Cox Proportional Hazards Model Educational Status Female Human Middle Age Multivariate Analysis Risk Factors Survival United States N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Oncologic Care; Psychiatry/Psychology. Grant Information: U10 CA077658/CA/NCI NIH HHS/United States. NLM UID: 9214524. PMID: NLM22021121. PY - 2013 SN - 1057-9249 SP - 315-323 ST - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials T2 - Psycho-Oncology TI - Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104306061&site=ehost-live&scope=site VL - 22 ID - 1930 ER - TY - JOUR AB - Importance: Marine ω-3 fatty acid has been suggested to protect against colorectal cancer. Objective: To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. Design, Setting, and Participants: This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. Interventions: Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. Main Outcomes and Measures: Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. Results: The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P =.03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P =.11 for interaction). Conclusions and Relevance: Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline ω-3 levels or for African American persons requires further confirmation. AD - M. Song, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Kresge 906A, Boston, MA, United States AU - Song, M. AU - Lee, I. M. AU - Manson, J. E. AU - Buring, J. E. AU - Dushkes, R. AU - Gordon, D. AU - Walter, J. AU - Wu, K. AU - Chan, A. T. AU - Ogino, S. AU - Fuchs, C. S. AU - Meyerhardt, J. A. AU - Giovannucci, E. L. DB - Embase Medline DO - 10.1001/jamaoncol.2019.4587 IS - 1 KW - NCT01169259 colecalciferol docosahexaenoic acid icosapentaenoic acid marine omega 3 fatty acid omega 3 fatty acid placebo unclassified drug African American aged article cancer risk colorectal adenoma colorectal cancer colorectal polyp fatty acid blood level female follow up histopathology human major clinical study male race difference risk reduction tumor localization tumor volume United States LA - English M3 - Article N1 - L629982870 2019-12-03 PY - 2020 SN - 2374-2445 2374-2437 SP - 108-115 ST - Effect of Supplementation with Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial T2 - JAMA Oncology TI - Effect of Supplementation with Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629982870&from=export http://dx.doi.org/10.1001/jamaoncol.2019.4587 VL - 6 ID - 825 ER - TY - JOUR AB - Key Points: Question: Does marine ω-3 fatty acid supplementation reduce risk of colorectal cancer precursors in the US general population? Findings: In this randomized clinical trial that included 25 871 adults, daily supplementation of marine ω-3 fatty acid, 1 g, did not reduce risk of conventional adenomas or serrated polyps. A suggestive beneficial association was observed among individuals with low plasma levels of ω-3 fatty acid at baseline and among African American persons. Meaning: Daily supplementation with marine ω-3 fatty acids, 1 g, appears not to reduce the risk of colorectal premalignant lesions in the average-risk US population; however, individuals with low plasma levels of ω-3 or African American persons may benefit. Importance: Marine ω-3 fatty acid has been suggested to protect against colorectal cancer. Objective: To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. Design, Setting, and Participants: This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25 871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. Interventions: Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. Main Outcomes and Measures: Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. Results: The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P =.03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P =.11 for interaction). Conclusions and Relevance: Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline ω-3 levels or for African American persons requires further confirmation. Trial Registration: ClinicalTrials.gov identifier: NCT011692 9 This prespecified ancillary study of a randomized clinical trial compares the effects of daily marine ω-3 fatty acid supplementation vs placebo on risk of colorectal cancer precursors, including conventional adenomas and serrated polyps, in an average-risk US population. AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts Yale Cancer Center, New Haven, Connecticut Department of Medicine, Yale School of Medicine, New Haven, Connecticut Smilow Cancer Hospital, New Haven, Connecticut Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts AN - 141154953. Language: English. Entry Date: 20200122. Revision Date: 20200122. Publication Type: Article AU - Song, Mingyang AU - Lee, I. Min AU - Manson, JoAnn E. AU - Buring, Julie E. AU - Dushkes, Rimma AU - Gordon, David AU - Walter, Joseph AU - Wu, Kana AU - Chan, Andrew T. AU - Ogino, Shuji AU - Fuchs, Charles S. AU - Meyerhardt, Jeffrey A. AU - Giovannucci, Edward L. DB - CINAHL Complete DO - 10.1001/jamaoncol.2019.4587 DP - EBSCOhost IS - 1 KW - Colorectal Neoplasms -- Risk Factors -- United States Adenoma -- Risk Factors -- United States Colonic Polyps -- Risk Factors Fatty Acids, Omega-3 -- Administration and Dosage Dietary Supplementation -- In Adulthood Human United States Female Male Adult Eicosapentaenoic Acid -- Administration and Dosage Docosahexaenoic Acids -- Administration and Dosage Cholecalciferol -- Administration and Dosage Randomized Controlled Trials Random Assignment Control Group Black Persons Placebos Consent (Research) Questionnaires Fatty Acids, Omega-3 -- Adverse Effects Descriptive Statistics Logistic Regression Treatment Outcomes Odds Ratio Confidence Intervals Colonoscopy Sigmoidoscopy Age Factors Sex Factors Ethnic Groups Body Mass Index Data Analysis Software Statistical Significance Middle Age Aged Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Peer Reviewed; USA. Grant Information: Theworkissupportedbygrants U01CA138962,R01CA138962,P01CA87969,R01 CA137178,R35CA197735,K99CA215314,andR00 CA215314fromtheNationalCancerInstitute,the NationalHeart,Lung,andBloodInstitute,the OfficeofDietarySupplements,theNational InstituteofNeurologicalDisordersandStroke,and theNationalCenterforComplementaryand IntegrativeHealth.DrSongwassupportedbya MentoredResearchScholarGrantinAppliedand ClinicalResearch(MRSG-17-220-01–NEC)fromthe AmericanCancerSociety. PY - 2020 SN - 2374-2437 SP - 108-115 ST - Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial T2 - JAMA Oncology TI - Effect of Supplementation With Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141154953&site=ehost-live&scope=site VL - 6 ID - 1931 ER - TY - JOUR AB - Importance: Marine ω-3 fatty acid has been suggested to protect against colorectal cancer. Objective: To assess the effect of daily marine ω-3 fatty acid supplementation on the risk of colorectal cancer precursors, including conventional adenomas and serrated polyps. Design, Setting, and Participants: This study was a prespecified ancillary study of the placebo-controlled randomized clinical trial VITAL (Vitamin D and Omega-3 Trial). An intention-to-treat analysis was used to examine the effect of daily marine ω-3 supplements among 25871 adults in the US general population (including 5106 African American persons) free of cancer and cardiovascular disease at enrollment. Randomization was from November 2011 to March 2014, and intervention ended as planned on December 31, 2017. Interventions: Marine ω-3 fatty acid, 1 g daily (which included eicosapentaenoic acid, 460 mg, and docosahexaenoic acid, 380 mg) and vitamin D3 (2000 IU daily) supplements. Main Outcomes and Measures: Risk of conventional adenomas (including tubular adenoma, tubulovillous adenoma, villous adenoma, and adenoma with high-grade dysplasia) or serrated polyps (including hyperplastic polyp, traditional serrated adenoma, and sessile serrated polyp). In a subset of participants who reported receiving a diagnosis of polyp on follow-up questionnaires, endoscopic and pathologic records were obtained to confirm the diagnosis. Odds ratios (ORs) and 95% CIs were calculated using logistic regression, after adjusting for age, sex, vitamin D treatment assignment, and use of endoscopy. Secondary analyses were performed according to polyp features and participants' characteristics. Results: The demographic characteristics of participants at randomization were well balanced between the treatment and placebo groups; for example, 50.6% vs 50.5% were women, and 19.7% vs 19.8% were African American persons were included in each group. The mean (SD) age was 67.1 (7.1) years in the placebo group and 67.2 (7.1) in the ω-3 treatment group. During a median follow-up of 5.3 years (range, 3.8-6.1 years), 294 cases of conventional adenomas were documented in the ω-3 group and 301 in the control group (multivariable OR, 0.98; 95% CI, 0.83-1.15) (1:1 ratio between number of cases and number of participants). In addition, 174 cases of serrated polyps were documented in the ω-3 group and 167 in the control group (OR, 1.05; 95% CI, 0.84-1.29). Null associations were found for polyp subgroups according to size, location, multiplicity, or histology. In secondary analyses, marine ω-3 treatment appeared to be associated with lower risk of conventional adenomas among individuals with low plasma levels of ω-3 index at baseline (OR, 0.76; 95% CI, 0.57-1.02; P =.03 for interaction by ω-3 index). A beneficial association of supplementation was also noted in the African American population (OR, 0.59; 95% CI, 0.35-1.00) but not in other racial/ethnic groups (P =.11 for interaction). Conclusions and Relevance: Supplementation with marine ω-3 fatty acids, 1 g per day, was not associated with reduced risk of colorectal cancer precursors. A potential benefit of this supplementation for individuals with low baseline ω-3 levels or for African American persons requires further confirmation. © 2019 American Medical Association. All rights reserved. AD - Department of Epidemiology, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Kresge 906A, Boston, MA 02115, United States Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, United States Clinical and Translational Epidemiology Unit, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, United States Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, United States Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, United States Broad Institute of Massachusetts, Institute of Technology and Harvard, Cambridge, United States Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Yale Cancer Center, New Haven, CT, United States Department of Medicine, Yale School of Medicine, New Haven, CT, United States Smilow Cancer Hospital, New Haven, CT, United States Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States AU - Song, M. AU - Lee, I. M. AU - Manson, J. E. AU - Buring, J. E. AU - Dushkes, R. AU - Gordon, D. AU - Walter, J. AU - Wu, K. AU - Chan, A. T. AU - Ogino, S. AU - Fuchs, C. S. AU - Meyerhardt, J. A. AU - Giovannucci, E. L. DB - Scopus DO - 10.1001/jamaoncol.2019.4587 IS - 1 M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2020 SP - 108-115 ST - Effect of Supplementation with Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial T2 - JAMA Oncology TI - Effect of Supplementation with Marine ω-3 Fatty Acid on Risk of Colorectal Adenomas and Serrated Polyps in the US General Population: A Prespecified Ancillary Study of a Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075675986&doi=10.1001%2fjamaoncol.2019.4587&partnerID=40&md5=4244d7a98add0be753e8be1b512e0f3d VL - 6 ID - 2207 ER - TY - JOUR AB - Importance Outpatient colonoscopy is important for colorectal cancer screening. However, nonadherence and poor bowel preparation are common. Objective To determine if an automated text messaging intervention with a focus on informational and reminder functions could improve attendance rates and bowel preparation quality for outpatient colonoscopy. Design, Setting, and Participants This randomized clinical trial was conducted in an endoscopy center at an urban academic medical center. Adult patients scheduled for outpatient colonoscopy between January and September 2019 were enrolled by telephone call (early phase) or by automated text message (late phase). Data were analyzed from October 2019 to January 2020. Interventions After enrollment, patients were randomized in a 1:1 ratio to usual care (ie, written instructions and nurse telephone call) or to the intervention (ie, usual care plus an automated series of 9 educational or reminder text messages in the week prior to scheduled colonoscopy). Main Outcomes and Measures The primary outcome was appointment attendance rate with good or excellent bowel preparation. Secondary outcomes included appointment attendance rate, bowel preparation quality (poor or inadequate, fair or adequate, and good or excellent), and cancellation lead time (in days). Results Among 753 patients included and randomized in the trial (median [interquartile range] age, 56 [49-64] years; 364 [48.3%] men; 429 [57.2%] Black), 367 patients were randomized to the intervention group and 386 patients were randomized to the control group. There was no significant difference in the primary outcome between groups (patients attending appointments with good or excellent bowel preparation: intervention, 195 patients [53.1%]; control, 210 patients [54.4%]; P = .73), including when stratified by early or late phase enrollment groups. Similarly, there were no significant differences in secondary outcomes. Conclusions and Relevance This randomized clinical trial found no significant difference in appointment attendance or bowel preparation quality with an automated text messaging intervention compared with the usual care control. Future work could optimize the content and delivery of text message interventions or identify patient subgroups that may benefit from this approach. This randomized clinical trial examines the effectiveness of information and reminders via automated text message vs usual care for coloscopy attendance and preparation. Question Do automated text messages improve outpatient colonoscopy attendance rate and bowel preparation quality? Findings In this randomized clinical trial including 753 patients, usual care patient instructions were compared with an automated text messaging intervention in the week prior to outpatient colonoscopy. There was no significant difference between groups in appointment attendance rate or bowel preparation quality. Meaning This randomized clinical trial found that automated text message reminders and instructions did not improve outpatient colonoscopy adherence, although future studies may identify patient subgroups that benefit from this approach. AN - WOS:000612826700002 AU - Mahmud, N. AU - Asch, D. A. AU - Sung, J. S. AU - Reitz, C. AU - Coniglio, M. S. AU - McDonald, C. AU - Bernard, D. AU - Mehta, S. J. DA - Jan DO - 10.1001/jamanetworkopen.2020.34553 IS - 1 N1 - e2034553 33492374 PY - 2021 SN - 2574-3805 ST - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy A Randomized Clinical Trial T2 - Jama Network Open TI - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy A Randomized Clinical Trial VL - 4 ID - 2752 ER - TY - JOUR AB - Importance: Outpatient colonoscopy is important for colorectal cancer screening. However, nonadherence and poor bowel preparation are common. Objective: To determine if an automated text messaging intervention with a focus on informational and reminder functions could improve attendance rates and bowel preparation quality for outpatient colonoscopy. Design, Setting, and Participants: This randomized clinical trial was conducted in an endoscopy center at an urban academic medical center. Adult patients scheduled for outpatient colonoscopy between January and September 2019 were enrolled by telephone call (early phase) or by automated text message (late phase). Data were analyzed from October 2019 to January 2020. Interventions: After enrollment, patients were randomized in a 1:1 ratio to usual care (ie, written instructions and nurse telephone call) or to the intervention (ie, usual care plus an automated series of 9 educational or reminder text messages in the week prior to scheduled colonoscopy). Main Outcomes and Measures: The primary outcome was appointment attendance rate with good or excellent bowel preparation. Secondary outcomes included appointment attendance rate, bowel preparation quality (poor or inadequate, fair or adequate, and good or excellent), and cancellation lead time (in days). Results: Among 753 patients included and randomized in the trial (median [interquartile range] age, 56 [49-64] years; 364 [48.3%] men; 429 [57.2%] Black), 367 patients were randomized to the intervention group and 386 patients were randomized to the control group. There was no significant difference in the primary outcome between groups (patients attending appointments with good or excellent bowel preparation: intervention, 195 patients [53.1%]; control, 210 patients [54.4%]; P =.73), including when stratified by early or late phase enrollment groups. Similarly, there were no significant differences in secondary outcomes. Conclusions and Relevance: This randomized clinical trial found no significant difference in appointment attendance or bowel preparation quality with an automated text messaging intervention compared with the usual care control. Future work could optimize the content and delivery of text message interventions or identify patient subgroups that may benefit from this approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03710213. AD - N. Mahmud, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States AU - Mahmud, N. AU - Asch, D. A. AU - Sung, J. AU - Reitz, C. AU - Coniglio, M. S. AU - McDonald, C. AU - Bernard, D. AU - Mehta, S. J. DB - Embase Medline DO - 10.1001/jamanetworkopen.2020.34553 KW - adult article colonoscopy controlled study female human intestine preparation major clinical study male nurse outcome assessment outpatient randomized controlled trial telephone text messaging university hospital LA - English M3 - Article in Press N1 - L634019119 2021-02-02 PY - 2021 SN - 2574-3805 ST - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial T2 - JAMA Network Open TI - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634019119&from=export http://dx.doi.org/10.1001/jamanetworkopen.2020.34553 ID - 770 ER - TY - JOUR AB - Key Points: Question: Do automated text messages improve outpatient colonoscopy attendance rate and bowel preparation quality? Findings: In this randomized clinical trial including 753 patients, usual care patient instructions were compared with an automated text messaging intervention in the week prior to outpatient colonoscopy. There was no significant difference between groups in appointment attendance rate or bowel preparation quality. Meaning: This randomized clinical trial found that automated text message reminders and instructions did not improve outpatient colonoscopy adherence, although future studies may identify patient subgroups that benefit from this approach. This randomized clinical trial examines the effectiveness of information and reminders via automated text message vs usual care for coloscopy attendance and preparation. Importance: Outpatient colonoscopy is important for colorectal cancer screening. However, nonadherence and poor bowel preparation are common. Objective: To determine if an automated text messaging intervention with a focus on informational and reminder functions could improve attendance rates and bowel preparation quality for outpatient colonoscopy. Design, Setting, and Participants: This randomized clinical trial was conducted in an endoscopy center at an urban academic medical center. Adult patients scheduled for outpatient colonoscopy between January and September 2019 were enrolled by telephone call (early phase) or by automated text message (late phase). Data were analyzed from October 2019 to January 2020. Interventions: After enrollment, patients were randomized in a 1:1 ratio to usual care (ie, written instructions and nurse telephone call) or to the intervention (ie, usual care plus an automated series of 9 educational or reminder text messages in the week prior to scheduled colonoscopy). Main Outcomes and Measures: The primary outcome was appointment attendance rate with good or excellent bowel preparation. Secondary outcomes included appointment attendance rate, bowel preparation quality (poor or inadequate, fair or adequate, and good or excellent), and cancellation lead time (in days). Results: Among 753 patients included and randomized in the trial (median [interquartile range] age, 56 [49-64] years; 364 [48.3%] men; 429 [57.2%] Black), 367 patients were randomized to the intervention group and 386 patients were randomized to the control group. There was no significant difference in the primary outcome between groups (patients attending appointments with good or excellent bowel preparation: intervention, 195 patients [53.1%]; control, 210 patients [54.4%]; P =.73), including when stratified by early or late phase enrollment groups. Similarly, there were no significant differences in secondary outcomes. Conclusions and Relevance: This randomized clinical trial found no significant difference in appointment attendance or bowel preparation quality with an automated text messaging intervention compared with the usual care control. Future work could optimize the content and delivery of text message interventions or identify patient subgroups that may benefit from this approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03710213 AD - Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia Leonard David Institute of Health Economics, University of Pennsylvania, Philadelphia Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania Center for Health Care Innovation, University of Pennsylvania, Philadelphia AN - 148386492. Language: English. Entry Date: 20210204. Revision Date: 20210311. Publication Type: Article AU - Mahmud, Nadim AU - Asch, David A. AU - Sung, Jessica AU - Reitz, Catherine AU - Coniglio, Mary S. AU - McDonald, Caitlin AU - Bernard, Donna AU - Mehta, Shivan J. DB - CINAHL Complete DO - 10.1001/jamanetworkopen.2020.34553 DP - EBSCOhost IS - 1 KW - Text Messaging Bowel Preparation Appointments and Schedules Outpatients Colonoscopy Patient Compliance Outcomes (Health Care) Human Randomized Controlled Trials Health Information Urban Areas Academic Medical Centers Middle Age Aged Control Group Quality Improvement Pilot Studies Young Adult Adult Aged, 80 and Over Wilcoxon Rank Sum Test Chi Square Test Data Analysis Software Male N1 - research; tables/charts; randomized controlled trial. PY - 2021 SP - e2034553-e2034553 ST - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial T2 - JAMA Network Open TI - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148386492&site=ehost-live&scope=site VL - 4 ID - 1932 ER - TY - JOUR AB - Importance: Outpatient colonoscopy is important for colorectal cancer screening. However, nonadherence and poor bowel preparation are common. Objective: To determine if an automated text messaging intervention with a focus on informational and reminder functions could improve attendance rates and bowel preparation quality for outpatient colonoscopy. Design, Setting, and Participants: This randomized clinical trial was conducted in an endoscopy center at an urban academic medical center. Adult patients scheduled for outpatient colonoscopy between January and September 2019 were enrolled by telephone call (early phase) or by automated text message (late phase). Data were analyzed from October 2019 to January 2020. Interventions: After enrollment, patients were randomized in a 1:1 ratio to usual care (ie, written instructions and nurse telephone call) or to the intervention (ie, usual care plus an automated series of 9 educational or reminder text messages in the week prior to scheduled colonoscopy). Main Outcomes and Measures: The primary outcome was appointment attendance rate with good or excellent bowel preparation. Secondary outcomes included appointment attendance rate, bowel preparation quality (poor or inadequate, fair or adequate, and good or excellent), and cancellation lead time (in days). Results: Among 753 patients included and randomized in the trial (median [interquartile range] age, 56 [49-64] years; 364 [48.3%] men; 429 [57.2%] Black), 367 patients were randomized to the intervention group and 386 patients were randomized to the control group. There was no significant difference in the primary outcome between groups (patients attending appointments with good or excellent bowel preparation: intervention, 195 patients [53.1%]; control, 210 patients [54.4%]; P = .73), including when stratified by early or late phase enrollment groups. Similarly, there were no significant differences in secondary outcomes. Conclusions and Relevance: This randomized clinical trial found no significant difference in appointment attendance or bowel preparation quality with an automated text messaging intervention compared with the usual care control. Future work could optimize the content and delivery of text message interventions or identify patient subgroups that may benefit from this approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03710213. AD - Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States Leonard David Institute of Health Economics, University of Pennsylvania, Philadelphia, United States Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, United States Center for Health Care Innovation, University of Pennsylvania, Philadelphia, United States AU - Mahmud, N. AU - Asch, D. A. AU - Sung, J. AU - Reitz, C. AU - Coniglio, M. S. AU - McDonald, C. AU - Bernard, D. AU - Mehta, S. J. DB - Scopus DO - 10.1001/jamanetworkopen.2020.34553 IS - 1 M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 SP - e2034553 ST - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial T2 - JAMA network open TI - Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100362394&doi=10.1001%2fjamanetworkopen.2020.34553&partnerID=40&md5=07a123318ca058f7849e53921bd613b9 VL - 4 ID - 2158 ER - TY - JOUR AB - Assessed the role of a timed incentive schedule on response rates in a study of African American and white breast cancer survivors. A mailed quality-of-life battery was sent to 583 breast cancer survivors (50% African American, 50% white). Half of the participants received payment in advance, whereas the other half was promised payment. The overall response rate was 54% (n = 278). The timing of incentives did not affect participation rates in either ethnic group. About 51% of the respondents were from the payment-in-advance condition and 49% were from the paid-on-completion condition. Therefore, the authors conclude that payment on completion may be the more cost-effective approach in studies with higher socioeconomic status patients, such as this sample of breast cancer survivors. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 2001-17245-002 AU - Ashing-Giwa, Kimlin AU - Ganz, Patricia DB - psyh DP - EBSCOhost IS - 11 KW - timed incentives ethnicity participation breast cancer survivors Adult African Americans Aged Aged, 80 and over Breast Neoplasms Data Collection Female Humans Middle Aged Patient Selection Postal Service Quality of Life Reward Time Factors United States Methodology Monetary Incentives Racial and Ethnic Differences Sampling (Experimental) Blacks Whites N1 - U California, Dept of Psychiatry & Biobehavioral Sciences, Los Angeles, CA, US. Other Publishers: Elsevier Science. Release Date: 20010502. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Methodology; Monetary Incentives; Participation; Racial and Ethnic Differences; Sampling (Experimental). Minor Descriptor: Blacks; Breast Neoplasms; Whites. Classification: Research Methods & Experimental Design (2260); Culture & Ethnology (2930). Population: Human (10); Female (40). Location: US. Methodology: Empirical Study. References Available: Y. Page Count: 5. Issue Publication Date: Nov, 2000. PY - 2000 SN - 0027-9684 1943-4693 SP - 528-532 ST - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: Are there ethnic differences? T2 - Journal of the National Medical Association TI - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: Are there ethnic differences? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2001-17245-002&site=ehost-live&scope=site VL - 92 ID - 1800 ER - TY - JOUR AB - The recruitment and retention of African Americans into cancer control studies presents a formidable task to the scientific and policy communities as well as patient and advocacy communities. The purpose of this investigation was to assess the role of a timed incentive schedule on response rates in a study of African American and white breast cancer survivors. A mailed quality-of-life survey battery was sent to 583 breast cancer survivors (50% African American, 50% white). Half of the participants received payment in advance, whereas the other half was promised payment. The overall response rate was 54% (n = 278). The timing of incentives did not affect participation rates in either ethnic group. About 51% of the respondents were from the payment-in-advance condition and 49% were from the paid-on-completion condition. Therefore, we conclude that payment on completion may be the more cost-effective approach in studies with higher socioeconomic status patients, such as this sample of breast cancer survivors. AD - K. Ashing-Giwa, Department of Psychiatry and Biobehavioral Sceinces, University of California, Los Angeles 90024, USA. AU - Ashing-Giwa, K. AU - Ganz, P. A. DB - Medline IS - 11 KW - adult African American aged article breast tumor clinical trial controlled clinical trial controlled study ethnology female human information processing methodology middle aged patient selection postal mail psychological aspect quality of life randomized controlled trial reward time United States LA - English M3 - Article N1 - L33423063 2001-01-09 PY - 2000 SN - 0027-9684 SP - 528-532 ST - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences? T2 - Journal of the National Medical Association TI - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33423063&from=export VL - 92 ID - 1317 ER - TY - JOUR AB - The recruitment and retention of African Americans into cancer control studies presents a formidable task to the scientific and policy communities as well as patient and advocacy communities. The purpose of this investigation was to assess the role of a timed incentive schedule on response rates in a study of African American and white breast cancer survivors. A mailed quality‐of‐life survey battery was sent to 583 breast cancer survivors (50% African American, 50% white). Half of the participants received payment in advance, whereas the other half was promised payment. The overall response rate was 54% (n = 278). The timing of incentives did not affect participation rates in either ethnic group. About 51% of the respondents were from the payment‐in‐advance condition and 49% were from the paid‐on‐completion condition. Therefore, we conclude that payment on completion may be the more cost‐effective approach in studies with higher socioeconomic status patients, such as this sample of breast cancer survivors. AN - CN-00330113 AU - Ashing-Giwa, K. AU - Ganz, P. A. IS - 11 KW - Adult African Americans Aged Aged, 80 and over Breast Neoplasms [*ethnology, psychology] Data Collection [*methods] Female Humans Middle Aged Patient Selection Postal Service Quality of Life Reward Time Factors United States M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2000 SP - 528‐532 ST - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences? T2 - Journal of the National Medical Association TI - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: are there ethnic differences? UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00330113/full VL - 92 ID - 1378 ER - TY - JOUR AB - The recruitment and retention of African Americans into cancer control studies presents a formidable task to the scientific and policy communities as well as patient and advocacy communities. The purpose of this investigation was to assess the role of a timed incentive schedule on response rates in a study of African American and white breast cancer survivors. A mailed quality-of-life survey battery was sent to 583 breast cancer survivors (50% African American, 50% white). Half of the participants received payment in advance, whereas the other half was promised payment. The overall response rate was 54% (n = 278). The timing of incentives did not affect participation rates in either ethnic group. About 51% of the respondents were from the payment-in-advance condition and 49% were from the paid-on-completion condition. Therefore, we conclude that payment on completion may be the more cost-effective approach in studies with higher socioeconomic status patients, such as this sample of breast cancer survivors. AD - Univ. of California, Los Angeles, Dept. Psychiat. Biobehavioral Sci., Box 62, C8-676, 760 Westwood Plaza, Los Angeles, CA 90024, United States AU - Ashing-Giwa, K. AU - Ganz, P. A. DB - Scopus IS - 11 KW - Breast cancer Ethnicity Psychosocial oncology Timed incentives M3 - Article N1 - Cited By :25 Export Date: 22 March 2021 PY - 2000 SP - 528-532 ST - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: Are there ethnic differences? T2 - Journal of the National Medical Association TI - Effect of timed incentives on subject participation in a study of long-term breast cancer survivors: Are there ethnic differences? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034353651&partnerID=40&md5=13d7e6cf611e761a49198580c22ffbe5 VL - 92 ID - 2631 ER - TY - JOUR AB - One in eight women will develop breast cancer over their lifetime with 230,000 women diagnosed in 2015. For this reason, breast cancer prevention efforts are essential. Vitamin D, with anticancer properties, may have a role in prevention of some cancers, including breast cancer. This report discusses the rationale, study protocol, and baseline data for a clinical trial of vitamin D and its effects on breast cancer biomarkers. This study was a randomized controlled trial designed to evaluate the effect of a fixed dose of vitamin D on specific breast cancer biomarkers. Study participants were randomized to take either vitamin D or placebo for a period of one year. All participants had mammograms and blood drawn for serum biomarkers. A subset of participants underwent random periareolar fine needle aspiration to draw tissue for biomarkers. From January 2011 to December 2013, 300 premenopausal women, aged 59 or younger, were recruited from 41 institutions across the United States. A total of 102 women underwent random periareolar fine needle aspiration. The last subject completed the trial in January 2015. Baseline vitamin D levels for all participants ranged from 4 to 72 ng/mL, with 62% of participants being vitamin-D deficient at enrollment (>= 30 ng/mL or >= 75 nmol/L). The mean body mass index (BMI) was 27.0 kg/m(2) (range 15.1-53.6 kg/m(2)). 14% and 11.7% of participants were Hispanic or African American, respectively. Accrual and enrollment of participants is feasible for this type of multicenter prevention trial, and it can readily be carried out in a cooperative group setting. AN - WOS:000406661200002 AU - Apoe, O. AU - Jung, S. H. AU - Liu, H. S. AU - Seisler, D. K. AU - Charlamb, J. AU - Zekan, P. AU - Wang, L. L. X. AU - Unzeitig, G. W. AU - Garber, J. AU - Marshall, J. AU - Wood, M. DA - Jul IS - 7 N1 - 29081880 PY - 2016 SN - 1939-6163 SP - 4-9 ST - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data T2 - American Journal of Hematology-Oncology TI - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data VL - 12 ID - 2942 ER - TY - JOUR AN - CN-02198685 AU - Apoe, O. AU - Sin-Ho, Jung AU - Heshan, Liu AU - Seisler, D. K. AU - Charlamb, J. AU - Zekan, P. AU - Lili, X. Wang AU - Unzeitig, G. W. AU - Garber, J. AU - Marshall, J. AU - et al. IS - 7 KW - Administration and Dosage Biological Markers Biopsy, Needle Blacks Body Mass Index Breast Neoplasms Descriptive Statistics Dietary Supplementation Drug Therapy Evaluation Hispanics Human Mammography Middle Age Placebos Prevention and Control Random Assignment Randomized Controlled Trials Research Subject Recruitment Study Design Therapeutic Use Treatment Outcomes Vitamin D M3 - Academic Journal PY - 2016 SP - 4‐9 ST - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data T2 - American journal of hematology/oncology TI - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02198685/full VL - 12 ID - 1430 ER - TY - JOUR AB - One in eight women will develop breast cancer over their lifetime with 230,000 women diagnosed in 2015. For this reason, breast cancer prevention efforts are essential. Vitamin D, with anticancer properties, may have a role in prevention of some cancers, including breast cancer. This report discusses the rationale, study protocol, and baseline data for a clinical trial of vitamin D and its effects on breast cancer biomarkers. This study was a randomized controlled trial designed to evaluate the effect of a fixed dose of vitamin D on specific breast cancer biomarkers. Study participants were randomized to take either vitamin D or placebo for a period of one year. All participants had mammograms and blood drawn for serum biomarkers. A subset of participants underwent random periareolar fine needle aspiration to draw tissue for biomarkers. From January 2011 to December 2013, 300 premenopausal women, aged 59 or younger, were recruited from 41 institutions across the United States. A total of 102 women underwent random periareolar fine needle aspiration. The last subject completed the trial in January 2015. Baseline vitamin D levels for all participants ranged from 4 to 72 ng/mL, with 62% of participants being vitamin-D deficient at enrollment (≥30 ng/mL or ≥75 nmol/L). The mean body mass index (BMI) was 27.0 kg/m² (range 15.1-53.6 kg/m²). 14% and 11.7% of participants were Hispanic or African American, respectively. Accrual and enrollment of participants is feasible for this type of multicenter prevention trial, and it can readily be carried out in a cooperative group setting. AD - Division of Hematology and Oncology, Department of Medicine, University of Vermont, Burlington VT Alliance Statistics and Data Center, Duke University, Durham, NC Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN State University of New York Upstate Medical University, Syracuse, NY Novant Health Forsyth Medical Center, Winston-Salem, NC Contra Costa Regional Medical Center, Martinez, CA Doctor's Hospital of Laredo, Laredo, TX Dana-Farber/Partners CancerCare, Boston, MA Roswell Park Cancer Institute, Buffalo, NY AN - 143175565. Language: English. Entry Date: 20200516. Revision Date: 20200516. Publication Type: Article AU - Apoe, Ogheneruona AU - Sin-Ho, Jung AU - Heshan, Liu AU - Seisler, Drew K. AU - Charlamb, Jayne AU - Zekan, Patricia AU - Lili, X. Wang AU - Unzeitig, Gary W. AU - Garber, Judy AU - Marshall, James AU - Wood, Marie DB - CINAHL Complete DP - EBSCOhost IS - 7 KW - Treatment Outcomes -- Evaluation Vitamin D -- Therapeutic Use Dietary Supplementation Breast Neoplasms -- Drug Therapy Biological Markers Human Randomized Controlled Trials Random Assignment Study Design Vitamin D -- Administration and Dosage Placebos Mammography Biopsy, Needle Middle Age Research Subject Recruitment Descriptive Statistics Body Mass Index Hispanic Americans Black Persons Breast Neoplasms -- Prevention and Control N1 - pictorial; research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. PY - 2016 SN - 1939-6163 SP - 4-9 ST - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data T2 - American Journal of Hematology/Oncology TI - Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143175565&site=ehost-live&scope=site VL - 12 ID - 1933 ER - TY - JOUR AB - Purpose Health research in low- and middle-income countries can generate novel scientific knowledge and improve clinical care, fostering population health improvements to prevent premature death. Project management is a critical part of the success of this research, applying knowledge, skills, tools, and techniques to accomplish required goals. Here, we describe the development and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing on building strategic and operational capacity. Methods Applying a learning organizational framework, we developed and implemented a project management toolkit (PMT) that includes a management process flowchart, a cyclical center-specific schedule of activities, periodic reporting and communication, and center-specific monitoring and evaluation metrics. Results The PMT was successfully deployed during year one of the project with effective component implementation occurring through periodic cycles of dissemination and feedback to local center project managers. A specific evaluation was conducted 1 year after study initiation to obtain enrollment data, evaluate individual quality control management plans, and undertake risk log assessments and follow-up. Pilot data obtained identified areas in which centers required mentoring, strengthening, and capacity development. Strategies were implemented to improve project goals and operational capacity through local problem solving, conducting quality control checks and following compliancy with study aims. Moving forward, centers will perform quarterly evaluations and initiate strengthening measures as required. Conclusion The PMT has fostered the development of both strategic and operational capacity across project centers. Investment in project management resources is essential to ensuring high-quality, impactful health research in low- and middle-income countries. © 2018 by American Society of Clinical Oncology AD - Dana-Farber Cancer Institute, 1003 Dana, 450 Brookline Ave, Boston, MA 02215, United States University College Hospital, Ibadan, Nigeria University of Abuja, Iraq University of Abuja Teaching Hospital, Abuja, Nigeria Albert Einstein College of Medicine, Bronx, NY, United States Hôpital Général de Grand Yoff, Institut de Formation et de la Recherche en Urologie et de la Santé de la Familliale, Dakar, Senegal Military Hospital, Ghana Korle-Bu Teaching Hospital, University of Ghana, Accra, Ghana Stellenbosch University, Tygerberg Hospital, Iraq Centre for Proteomic and Genomic Research, Cape Town, South Africa University of the Witwatersrand, Johannesburg, South Africa Stanford University, Stanford, CA, United States Beth Israel Deaconess Medical Center, Iraq Harvard TH Chan School of Public Health, Boston, MA, United States AU - Odiaka, E. AU - Lounsbury, D. W. AU - Jalloh, M. AU - Adusei, B. AU - Diallo, T. A. AU - Kane, P. M. S. AU - Rockson, I. AU - Okyne, V. AU - Irusen, H. AU - Pentz, A. AU - Makinde, I. AU - Ajibola, O. H. AU - Petersen, L. AU - McBride, J. AU - Petersen, D. C. AU - Mante, S. AU - Agalliu, I. AU - Adebiyi, A. O. AU - Popoola, O. AU - Yeboah, E. AU - Mensah, J. E. AU - Hsing, A. AU - Fernandez, P. AU - Aisuodionoe-Shadrach, O. AU - Joffe, M. AU - Singh, E. AU - Gueye, S. M. AU - Quintana, Y. AU - Fortier, B. AU - Rebbeck, T. R. AU - Andrews, C. DB - Scopus DO - 10.1200/JGO.18.00062 IS - 4 M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2018 ST - Effective project management of a pan-African cancer research network: Men of African descent and carcinoma of the prostate (MadCap) T2 - Journal of Global Oncology TI - Effective project management of a pan-African cancer research network: Men of African descent and carcinoma of the prostate (MadCap) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060559056&doi=10.1200%2fJGO.18.00062&partnerID=40&md5=f1f771a439b5d7fce379f267bc9f715d VL - 2018 ID - 2280 ER - TY - JOUR AB - BACKGROUND: Community‐based participatory research (CBPR) approaches that involve community and academic partners in activities ranging from protocol design through dissemination of study findings can increase recruitment of medically underserved and underrepresented racial/ethnic minority populations into biomedical research. METHODS: Five cancer screening and prevention trials in three National Cancer Institute (Bethesda, MD)‐funded Community Networks Program Centers (CNPC), in Florida, Kansas, and South Carolina, were conducted across diverse populations. Data were collected on total time period of recruitment, ratios of participants enrolled over potential participants approached, selected CBPR strategies, capacity‐building development, and systematic procedures for community stakeholder involvement. RESULTS: Community‐engaged approaches used included establishing colearning opportunities, participatory procedures for community‐academic involvement, and community and clinical capacity building. A relatively large proportion of individuals identified for recruitment was actually approached (between 50% and 100%). The proportion of subjects who were eligible among all those approached ranged from 25% to more than 70% (in the community setting). Recruitment rates were very high (78%‐100% of eligible individuals approached) and the proportion who refused or who were not interested among those approached was very low (5%‐11%). CONCLUSIONS: Recruitment strategies used by the CNPCs were associated with low refusal and high enrollment ratios of potential subjects. Adherence to CBPR principles in the spectrum of research activities, from strategic planning to project implementation, has significant potential to increase involvement in biomedical research and improve our ability to make appropriate recommendations for cancer prevention and control programming in underrepresented diverse populations. IMPACT: CBPR strategies should be more widely implemented to enhance study recruitment. AN - CN-00985280 AU - Greiner, K. A. AU - Friedman, D. B. AU - Adams, S. A. AU - Gwede, C. K. AU - Cupertino, P. AU - Engelman, K. K. AU - Meade, C. D. AU - Hébert, J. R. DO - 10.1158/1055-9965.EPI-13-0760 IS - 3 KW - *cancer prevention *cancer screening *health program *participatory research *strategic planning African American Article Breast cancer/pc [Prevention] Community Community Networks Community care Community‐Based Participatory Research [*methods, organization & administration] Controlled study Early Detection of Cancer [*methods] Ethnic group Female Florida Follow up Human Humans Kansas Major clinical study Male Middle Aged National health organization Neoplasms [*prevention & control] Patient Selection Pilot Projects Pilot study Priority journal Prostate cancer/pc [Prevention] Randomized controlled trial Social network South Carolina United States M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 416‐423 ST - Effective recruitment strategies and community-based participatory research: community networks program centers' recruitment in cancer prevention studies T2 - Cancer epidemiology, biomarkers & prevention TI - Effective recruitment strategies and community-based participatory research: community networks program centers' recruitment in cancer prevention studies UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00985280/full VL - 23 ID - 1404 ER - TY - JOUR AB - Background: Community-based participatory research (CBPR) approaches that involve community and academic partners in activities ranging from protocol design through dissemination of study findings can increase recruitment of medically underserved and underrepresented racial/ethnic minority populations into biomedical research. Methods: Five cancer screening and prevention trials in three National Cancer Institute (Bethesda, MD)-funded Community Networks Program Centers (CNPC), in Florida, Kansas, and South Carolina, were conducted across diverse populations. Data were collected on total time period of recruitment, ratios of participants enrolled over potential participants approached, selected CBPR strategies, capacity-building development, and systematic procedures for community stakeholder involvement. Results: Community-engaged approaches used included establishing colearning opportunities, participatory procedures for community-Academic involvement, and community and clinical capacity building. A relatively large proportion of individuals identified for recruitment was actually approached (between 50% and 100%). The proportion of subjects who were eligible among all those approached ranged from 25% to more than 70% (in the community setting). Recruitment rates were very high (78%-100% of eligible individuals approached) and the proportion who refused or who were not interested among those approached was very low (5%-11%). Conclusions: Recruitment strategies used by the CNPCs were associated with low refusal and high enrollment ratios of potential subjects. Adherence to CBPR principles in the spectrum of research activities, from strategic planning to project implementation, has significant potential to increase involvement in biomedical research and improve our ability to make appropriate recommendations for cancer prevention and control programming in underrepresented diverse populations. Impact: CBPR strategies should be more widely implemented to enhance study recruitment. © 2014 American Association for Cancer Research. AD - Departments of Family Medicine, United States Departments of Preventive Medicine, University of Kansas Medical Center, United States University of Kansas Medical Center, 4125 Rainbow Boulevard, Kansas KS 66160, United States South Carolina Statewide Cancer Prevention and Control Program, United States Arnold School of Public Health, United States College of Nursing, University of South Carolina, Columbia, SC, United States Moffitt Cancer Center, University of South Florida, Tampa, FL, United States AU - Greiner, K. A. AU - Friedman, D. B. AU - Adams, S. A. AU - Gwede, C. K. AU - Cupertino, P. AU - Engelman, K. K. AU - Meade, C. D. AU - Hebert, J. R. DB - Scopus DO - 10.1158/1055-9965.EPI-13-0760 IS - 3 M3 - Article N1 - Cited By :46 Export Date: 22 March 2021 PY - 2014 SP - 416-423 ST - Effective recruitment strategies and community-based participatory research: Community networks program centers' recruitment in cancer prevention studies T2 - Cancer Epidemiology Biomarkers and Prevention TI - Effective recruitment strategies and community-based participatory research: Community networks program centers' recruitment in cancer prevention studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896517515&doi=10.1158%2f1055-9965.EPI-13-0760&partnerID=40&md5=72e8fc01db4a9cda33b4bbfc28e8f8c1 VL - 23 ID - 2406 ER - TY - JOUR AB - Background: Community-based participatory research (CBPR) approaches that involve community and academic partners in activities ranging from protocol design through dissemination of study findings can increase recruitment of medically underserved and underrepresented racial/ethnic minority populations into biomedical research. Methods: Five cancer screening and prevention trials in three National Cancer Institute (Bethesda, MD)funded Community Networks Program Centers (CNPC), in Florida, Kansas, and South Carolina, were conducted across diverse populations. Data were collected on total time period of recruitment, ratios of participants enrolled over potential participants approached, selected CBPR strategies, capacity-building development, and systematic procedures for community stakeholder involvement. Results: Community-engaged approaches used included establishing colearning opportunities, participatory procedures for community-academic involvement, and community and clinical capacity building. A relatively large proportion of individuals identified for recruitment was actually approached (between 50% and 100%). The proportion of subjects who were eligible among all those approached ranged from 25% to more than 70%(in the community setting). Recruitment rates were very high (78%-100% of eligible individuals approached) and the proportion who refused or who were not interested among those approached was very low (5%-11%). Conclusions: Recruitment strategies used by the CNPCs were associated with low refusal and high enrollment ratios of potential subjects. Adherence to CBPR principles in the spectrum of research activities, from strategic planning to project implementation, has significant potential to increase involvement in biomedical research and improve our ability to make appropriate recommendations for cancer prevention and control programming in underrepresented diverse populations. Impact: CBPR strategies should be more widely implemented to enhance study recruitment. AN - WOS:000335144700007 AU - Greiner, K. A. AU - Friedman, D. B. AU - Adams, S. A. AU - Gwede, C. K. AU - Cupertino, P. AU - Engelman, K. K. AU - Meade, C. D. AU - Hebert, J. R. DA - Mar DO - 10.1158/1055-9965.EPI-13-0760 IS - 3 N1 - 24609851 PY - 2014 SN - 1055-9965 SP - 416-423 ST - Effective Recruitment Strategies and Community-Based Participatory Research: Community Networks Program Centers' Recruitment in Cancer Prevention Studies T2 - Cancer Epidemiology Biomarkers & Prevention TI - Effective Recruitment Strategies and Community-Based Participatory Research: Community Networks Program Centers' Recruitment in Cancer Prevention Studies VL - 23 ID - 3020 ER - TY - JOUR AB - Background: Physician recommendation of colorectal cancer (CRC) screening is a critical facilitator of screening completion. Providing patients a choice of screening options may increase CRC screening completion, particularly among racial and ethnic minorities.Objective: Our purpose was to assess the effectiveness of physician-only and physician-patient interventions on increasing rates of CRC screening discussions as compared to usual care.Design: This study was quasi-experimental. Clinics were allocated to intervention or usual care; patients in intervention clinics were randomized to receipt of patient intervention.Participants: Patients aged 50 to 75 years, due for CRC screening, receiving care at either a federally qualified health care center or an academic health center participated in the study.Intervention: Intervention physicians received continuous quality improvement and communication skills training. Intervention patients watched an educational video immediately before their appointment.Main Measures: Rates of patient-reported 1) CRC screening discussions, and 2) discussions of more than one screening test.Key Results: The physician-patient intervention (n = 167) resulted in higher rates of CRC screening discussions compared to both physician-only intervention (n = 183; 61.1 % vs.50.3 %, p = 0.008) and usual care (n = 153; 61.1 % vs. 34.0 % p = 0.03). More discussions of specific CRC screening tests and discussions of more than one test occurred in the intervention arms than in usual care (44.6 % vs. 22.9 %,p = 0.03) and (5.1 % vs. 2.0 %, p = 0.036), respectively, but discussion of more than one test was uncommon. Across all arms, 143 patients (28.4 %) reported discussion of colonoscopy only; 21 (4.2 %) reported discussion of both colonoscopy and stool tests.Conclusions: Compared to usual care and a physician-only intervention, a physician-patient intervention increased rates of CRC screening discussions, yet discussions overwhelmingly focused solely on colonoscopy. In underserved patient populations where access to colonoscopy may be limited, interventions encouraging discussions of both stool tests and colonoscopy may be needed. AD - Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, 675 N. St. Clair St. Suite 18-200 Chicago 60611 USA Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago USA Division of General Internal Medicine, Department of Medicine, University of Illinois Hospital & Health Sciences System, Chicago USA Department of Family Medicine and Community Health, University of Minnesota, Minneapolis USA Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, 675 N. St. Clair St. Suite 18-200, Chicago, IL, 60611, USA Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA Division of Gastroenterology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA Division of General Internal Medicine, Department of Medicine, University of Illinois Hospital & Health Sciences System, Chicago, IL, USA Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, MN, USA Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA AN - 110811214. Language: English. Entry Date: 20160817. Revision Date: 20190712. Publication Type: journal article AU - Dolan, Nancy AU - Ramirez-Zohfeld, Vanessa AU - Rademaker, Alfred AU - Ferreira, M. AU - Galanter, William AU - Radosta, Jonathan AU - Eder, Milton AU - Cameron, Kenzie AU - Dolan, Nancy C. AU - Rademaker, Alfred W. AU - Ferreira, M. Rosario AU - Galanter, William L. AU - Eder, Milton Mickey AU - Cameron, Kenzie A. DB - CINAHL Complete DO - 10.1007/s11606-015-3381-8 DP - EBSCOhost IS - 12 KW - Black Persons -- Psychosocial Factors Hispanic Americans -- Psychosocial Factors Physician-Patient Relations Early Detection of Cancer -- Psychosocial Factors Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Ethnology Aged Early Detection of Cancer -- Statistics and Numerical Data Colonoscopy -- Statistics and Numerical Data Human Hispanic Americans -- Statistics and Numerical Data Male Black Persons -- Statistics and Numerical Data Middle Age Early Detection of Cancer -- Methods Illinois Patient Education -- Methods Occult Blood Communication Prospective Studies Patient Selection Female Colonoscopy -- Psychosocial Factors Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Funding Source N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Continental Europe; Europe. Special Interest: Evidence-Based Practice. Grant Information: P30 CA060553/CA/NCI NIH HHS/United States. NLM UID: 8605834. PMID: NLM25986137. PY - 2015 SN - 0884-8734 SP - 1780-1787 ST - The Effectiveness of a Physician-Only and Physician-Patient Intervention on Colorectal Cancer Screening Discussions Between Providers and African American and Latino Patients T2 - JGIM: Journal of General Internal Medicine TI - The Effectiveness of a Physician-Only and Physician-Patient Intervention on Colorectal Cancer Screening Discussions Between Providers and African American and Latino Patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=110811214&site=ehost-live&scope=site VL - 30 ID - 2118 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening reduces mortality yet remains underutilized. Low health literacy may contribute to this underutilization by interfering with patients' ability to understand and receive preventive health services. Purpose: To determine if a web-based multimedia CRC screening patient decision aid, developed for a mixed-literacy audience, could increase CRC screening. Design: RCT. Patients aged 50-74 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment. Setting/participants: A large community-based, university-affiliated internal medicine practice serving a socioeconomically disadvantaged population. Main outcome measures: Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening. Charts were abstracted by masked observers to determine if screening tests were ordered and completed. Results: Between November 2007 and September 2008, a total of 264 patients enrolled in the study. Data collection was completed in 2009, and data analysis was completed in 2010. A majority of participants (mean age=57.8 years) were female (67%), African-American (74%), had annual household incomes of <$20,000 (76%), and had limited health literacy (56%). When compared to control participants, more decision-aid participants had a CRC screening preference (84% vs 55%, p<0.0001) and an increase in readiness to receive screening (52% vs 20%, p=0.0001). More decision-aid participants had CRC screening tests ordered (30% vs 21%) and completed (19% vs 14%), but no statistically significant differences were seen (AOR=1.6, 95% C=0.97, 2.8, and AOR=1.7, 95% CI=0.88, 3.2, respectively). Similar results were found across literacy levels. Conclusions: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level. Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening. AN - WOS:000290470400006 AU - Miller, D. P. AU - Spangler, J. G. AU - Case, L. D. AU - Goff, D. C. AU - Singh, S. AU - Pignone, M. P. DA - Jun DO - 10.1016/j.amepre.2011.02.019 IS - 6 N1 - 21565651 PY - 2011 SN - 0749-3797 SP - 608-615 ST - Effectiveness of a Web-Based Colorectal Cancer Screening Patient Decision Aid A Randomized Controlled Trial in a Mixed-Literacy Population T2 - American Journal of Preventive Medicine TI - Effectiveness of a Web-Based Colorectal Cancer Screening Patient Decision Aid A Randomized Controlled Trial in a Mixed-Literacy Population VL - 40 ID - 3094 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening reduces mortality yet remains underutilized. Low health literacy may contribute to this underutilization by interfering with patients' ability to understand and receive preventive health services.Purpose: To determine if a web-based multimedia CRC screening patient decision aid, developed for a mixed-literacy audience, could increase CRC screening.Design: RCT. Patients aged 50-74 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment.Setting/participants: A large community-based, university-affiliated internal medicine practice serving a socioeconomically disadvantaged population.Main Outcome Measures: Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening. Charts were abstracted by masked observers to determine if screening tests were ordered and completed.Results: Between November 2007 and September 2008, a total of 264 patients enrolled in the study. Data collection was completed in 2009, and data analysis was completed in 2010. A majority of participants (mean age=57.8 years) were female (67%), African-American (74%), had annual household incomes of <$20,000 (76%), and had limited health literacy (56%). When compared to control participants, more decision-aid participants had a CRC screening preference (84% vs 55%, p<0.0001) and an increase in readiness to receive screening (52% vs 20%, p=0.0001). More decision-aid participants had CRC screening tests ordered (30% vs 21%) and completed (19% vs 14%), but no statistically significant differences were seen (AOR=1.6, 95% CI=0.97, 2.8, and AOR=1.7, 95% CI=0.88, 3.2, respectively). Similar results were found across literacy levels.Conclusions: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level. Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening. AD - General Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA Wake Forest University School of Medicine, Winston-Salem, North Carolina. AN - 104900617. Language: English. Entry Date: 20110923. Revision Date: 20200708. Publication Type: journal article AU - Miller, D. P., Jr. AU - Spangler, J. G. AU - Case, L. D. AU - Goff, D. C., Jr. AU - Singh, S. AU - Pignone, M. P. AU - Miller, David P., Jr. AU - Spangler, John G. AU - Case, L. Doug AU - Goff, David C., Jr. AU - Singh, Sonal AU - Pignone, Michael P. DB - CINAHL Complete DO - 10.1016/j.amepre.2011.02.019 DP - EBSCOhost IS - 6 KW - Colorectal Neoplasms -- Diagnosis Decision Support Techniques Health Screening -- Methods Internet Aged Female Human Information Literacy Male Middle Age Patient Satisfaction Primary Health Care -- Methods Randomized Controlled Trials Socioeconomic Factors N1 - research; randomized controlled trial. Journal Subset: Biomedical; Health Promotion/Education; USA. Grant Information: K05 CA129166-04/CA/NCI NIH HHS/United States. NLM UID: 8704773. PMID: NLM21565651. PY - 2011 SN - 0749-3797 SP - 608-615 ST - Effectiveness of a web-based colorectal cancer screening patient decision aid: a randomized controlled trial in a mixed-literacy population T2 - American Journal of Preventive Medicine TI - Effectiveness of a web-based colorectal cancer screening patient decision aid: a randomized controlled trial in a mixed-literacy population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104900617&site=ehost-live&scope=site VL - 40 ID - 1934 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening reduces mortality yet remains underutilized. Low health literacy may contribute to this underutilization by interfering with patients' ability to understand and receive preventive health services. Purpose: To determine if a web-based multimedia CRC screening patient decision aid, developed for a mixed-literacy audience, could increase CRC screening. Design: RCT. Patients aged 5074 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment. Setting/participants: A large community-based, university-affiliated internal medicine practice serving a socioeconomically disadvantaged population. Main outcome measures: Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening. Charts were abstracted by masked observers to determine if screening tests were ordered and completed. Results: Between November 2007 and September 2008, a total of 264 patients enrolled in the study. Data collection was completed in 2009, and data analysis was completed in 2010. A majority of participants (mean age=57.8 years) were female (67%), African-American (74%), had annual household incomes of <$20,000 (76%), and had limited health literacy (56%). When compared to control participants, more decision-aid participants had a CRC screening preference (84% vs 55%, p<0.0001) and an increase in readiness to receive screening (52% vs 20%, p=0.0001). More decision-aid participants had CRC screening tests ordered (30% vs 21%) and completed (19% vs 14%), but no statistically significant differences were seen (AOR=1.6, 95% CI=0.97, 2.8, and AOR=1.7, 95% CI=0.88, 3.2, respectively). Similar results were found across literacy levels. Conclusions: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level. Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening. © 2011 American Journal of Preventive Medicine. AD - D. P. Miller Jr., Wake Forest University, School of Medicine, General Internal Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States AU - Miller Jr, D. P. AU - Spangler, J. G. AU - Case, L. D. AU - Goff Jr, D. C. AU - Singh, S. AU - Pignone, M. P. DB - Embase Medline DO - 10.1016/j.amepre.2011.02.019 IS - 6 KW - NCT00558233 adult African American aged article cancer screening colorectal cancer controlled study female health survey human income information literacy Internet major clinical study male medical decision making medical practice outcome assessment population research primary medical care reading LA - English M3 - Article N1 - L361743890 2011-05-18 2011-05-23 PY - 2011 SN - 0749-3797 SP - 608-615 ST - Effectiveness of a web-based colorectal cancer screening patient decision aid: A randomized controlled trial in a mixed-literacy population T2 - American Journal of Preventive Medicine TI - Effectiveness of a web-based colorectal cancer screening patient decision aid: A randomized controlled trial in a mixed-literacy population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361743890&from=export http://dx.doi.org/10.1016/j.amepre.2011.02.019 VL - 40 ID - 1138 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening reduces mortality yet remains underutilized. Low health literacy may contribute to this underutilization by interfering with patients' ability to understand and receive preventive health services. Purpose: To determine if a web-based multimedia CRC screening patient decision aid, developed for a mixed-literacy audience, could increase CRC screening. Design: RCT. Patients aged 5074 years and overdue for CRC screening were randomized to the web-based decision aid or a control program seen immediately before a scheduled primary care appointment. Setting/participants: A large community-based, university-affiliated internal medicine practice serving a socioeconomically disadvantaged population. Main outcome measures: Patients completed surveys to determine their ability to state a screening test preference and their readiness to receive screening. Charts were abstracted by masked observers to determine if screening tests were ordered and completed. Results: Between November 2007 and September 2008, a total of 264 patients enrolled in the study. Data collection was completed in 2009, and data analysis was completed in 2010. A majority of participants (mean age=57.8 years) were female (67%), African-American (74%), had annual household incomes of <$20,000 (76%), and had limited health literacy (56%). When compared to control participants, more decision-aid participants had a CRC screening preference (84% vs 55%, p<0.0001) and an increase in readiness to receive screening (52% vs 20%, p=0.0001). More decision-aid participants had CRC screening tests ordered (30% vs 21%) and completed (19% vs 14%), but no statistically significant differences were seen (AOR=1.6, 95% CI=0.97, 2.8, and AOR=1.7, 95% CI=0.88, 3.2, respectively). Similar results were found across literacy levels. Conclusions: The web-based decision aid increased patients' ability to form a test preference and their intent to receive screening, regardless of literacy level. Further study should examine ways the decision aid can be combined with additional system changes to increase CRC screening. © 2011 American Journal of Preventive Medicine. AD - Wake Forest University, School of Medicine, General Internal Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States Cecil G. Sheps Center for Health Services Research, Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Johns Hopkins University, School of Medicine, Baltimore, MD, United States AU - Miller Jr, D. P. AU - Spangler, J. G. AU - Case, L. D. AU - Goff Jr, D. C. AU - Singh, S. AU - Pignone, M. P. DB - Scopus DO - 10.1016/j.amepre.2011.02.019 IS - 6 M3 - Article N1 - Cited By :78 Export Date: 22 March 2021 PY - 2011 SP - 608-615 ST - Effectiveness of a web-based colorectal cancer screening patient decision aid: A randomized controlled trial in a mixed-literacy population T2 - American Journal of Preventive Medicine TI - Effectiveness of a web-based colorectal cancer screening patient decision aid: A randomized controlled trial in a mixed-literacy population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955792964&doi=10.1016%2fj.amepre.2011.02.019&partnerID=40&md5=08b22d8830672b5bf061ee77848813c6 VL - 40 ID - 2476 ER - TY - JOUR AB - Background: Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high-risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high-risk AA population. Methods: Patients were included in annual one-day outreach events, each held over 3 years (2017–2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. Results: Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). Conclusions: Our education-based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high-risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic. AD - S. Abraksia, Hematology and Medical Oncology Staff, Taussig Cancer Institute, Cleveland Clinic Foundation/South Pointe Hospital, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, United States AU - Carlson, D. S. AU - Grivas, P. AU - Wei, W. AU - Dhillon, P. K. AU - Abraksia, S. DB - Embase Medline DO - 10.1080/07357907.2020.1855441 KW - adult African American article cancer screening cohort analysis comparative effectiveness controlled study digital rectal examination education high risk population human Likert scale major clinical study male prostate cancer randomized controlled trial shared decision making endogenous compound prostate specific antigen LA - English M3 - Article in Press N1 - L2010147804 2021-01-19 PY - 2021 SN - 1532-4192 0735-7907 ST - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial T2 - Cancer Investigation TI - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010147804&from=export http://dx.doi.org/10.1080/07357907.2020.1855441 ID - 761 ER - TY - JOUR AB - Background: Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high‐risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high‐risk AA population. Methods: Patients were included in annual one‐day outreach events, each held over 3 years (2017–2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. Results: Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). Conclusions: Our education‐based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high‐risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic. AN - CN-02231638 AU - Carlson, D. S. AU - Grivas, P. AU - Wei, W. AU - Dhillon, P. K. AU - Abraksia, S. DO - 10.1080/07357907.2020.1855441 KW - *African American *cancer screening *comparative effectiveness *education *high risk population *prostate cancer *shared decision making Adult Article Cohort analysis Controlled study Digital rectal examination Human Likert scale Major clinical study Male Randomized controlled trial M3 - Journal: Article in Press PY - 2021 ST - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: a Randomized Control Trial T2 - Cancer investigation TI - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: a Randomized Control Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02231638/full ID - 1426 ER - TY - JOUR AB - Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high-risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high-risk AA population. Patients were included in annual one-day outreach events, each held over 3 years (2017–2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). Our education-based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high-risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic. AD - Department of Hematology and Medical Oncology, Geisinger Cancer Institute, Geisinger Medical Center, Danville, PA, USA Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Texas Oncology, Oklahoma, TX, USA Department of Hematology and Medical Oncology, South Pointe Hospital, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA AN - 148568372. Language: English. Entry Date: 20210217. Revision Date: 20210217. Publication Type: Article AU - Carlson, Daniel S. AU - Grivas, Petros AU - Wei, Wei AU - Dhillon, Puneet K. AU - Abraksia, Samir DB - CINAHL Complete DO - 10.1080/07357907.2020.1855441 DP - EBSCOhost IS - 2 KW - Prostatic Neoplasms -- Ethnology -- United States Cancer Screening -- Methods Decision Making, Shared -- Evaluation Decision Making -- Evaluation Black Persons Outcome Assessment Human Male United States Random Assignment Randomized Controlled Trials N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Europe; UK & Ireland. NLM UID: 8307154. PY - 2021 SN - 0735-7907 SP - 124-132 ST - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial T2 - Cancer Investigation TI - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148568372&site=ehost-live&scope=site VL - 39 ID - 2119 ER - TY - JOUR AB - Background: Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high-risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high-risk AA population. Methods: Patients were included in annual one-day outreach events, each held over 3 years (2017–2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. Results: Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). Conclusions: Our education-based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high-risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. AD - Department of Hematology and Medical Oncology, Geisinger Cancer Institute, Geisinger Medical Center, Danville, PA, United States Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, United States Texas Oncology, Oklahoma, TX, United States Department of Hematology and Medical Oncology, South Pointe Hospital, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States Seattle Cancer Care Alliance, Seattle, Washington, DC, United States AU - Carlson, D. S. AU - Grivas, P. AU - Wei, W. AU - Dhillon, P. K. AU - Abraksia, S. DB - Scopus DO - 10.1080/07357907.2020.1855441 IS - 2 KW - African American education high-risk population Prostate cancer screening randomized controlled trial shared decision making informed decision making M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 SP - 124-132 ST - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial T2 - Cancer Investigation TI - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099314398&doi=10.1080%2f07357907.2020.1855441&partnerID=40&md5=2660e947696e1fe49b42549a891069dd VL - 39 ID - 2159 ER - TY - JOUR AB - Background: Prostate cancer incidence and mortality in the United States in African Americans (AA) are higher than in Caucasians. Eastern Cuyahoga County in Ohio is majority AA and is considered an underserved population particularly vulnerable to healthcare disparities. There is a paucity of data about shared decision making among high-risk AA men with regard to prostate cancer screening. This study aims to examine shared versus informed decision making (SDM versus IDM) in a randomized, control trial among a large, high-risk AA population. Methods: Patients were included in annual one-day outreach events, each held over 3 years (2017-2019), and were randomized at each event into IDM (control) and SDM (investigational) groups and then were offered screening via prostate specific antigen (PSA) and digital rectal exam (DRE). The primary endpoints were proportion of participants over 40 who did not demonstrate decisional conflict about prostate cancer screening measured by the SURE score, as well as change of knowledge score about prostate cancer screening. Results: Overall, 175 patients were enrolled in the trial; 79 in the SDM arm and 96 in the IDM arm. The investigational (SDM) arm had 3/79 (3.9%) conflict versus 6/96 (6.4%) in the control (IDM) arm (p = 0.74). With regard to knowledge improvement, the SDM cohort demonstrated improvement following educational tools for 66/79 (81%) of participants versus 76/96 (79%) in the IDM cohort (p = 0.85). There was no difference in the proportion (63%) of participants in either group who found the information very helpful (using a Likert scale). Conclusions: Our education-based study showed no significant difference between SDM and IDM with regard to decisional conflict about prostate cancer screening. The study also demonstrated significant improvement in knowledge about prostate cancer screening in a high-risk AA population in both groups. Our results should be interpreted with caution due to several limitations; however, the study can serve as a benchmark for future studies in this very important topic. AN - WOS:000605426000001 AU - Carlson, D. S. AU - Grivas, P. AU - Wei, W. AU - Dhillon, P. K. AU - Abraksia, S. DA - Feb DO - 10.1080/07357907.2020.1855441 IS - 2 N1 - 33410359 PY - 2021 SN - 0735-7907 SP - 124-132 ST - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial T2 - Cancer Investigation TI - The Effectiveness of Shared Compared to Informed Decision Making for Prostate Cancer Screening in a High-Risk African American Population: A Randomized Control Trial VL - 39 ID - 2754 ER - TY - JOUR AB - Objectives Despite the Advisory Committee on Immunization Practices (ACIP) recommendations for young adult females and males to receive the three-dose human papillomavirus (HPV) vaccine, most recent findings show that only 30% of the U.S. females aged 19-26, 2.8% of males aged 19-21, and only 1.7% of males aged 22-26 are initiating vaccination. This study evaluates the effects of a brief (5-10 min) group HPV educational intervention on knowledge and intent to vaccinate among young adults. Methods A sample of 131 18-26 year old females and males was recruited from the 2012 INShape Black and Minority Health Fair in Indiana. We randomized participants into one of two groups: (1) survey completion prior to education (control group) or (2) survey completion following education (intervention group). Written surveys assessed HPV knowledge, vaccination history, and vaccination intent (for unvaccinated participants). Results Respondents were primarily female (70%), single (85%), and the majority self-identified as non-Hispanic Black (77%). Thirty-seven percent had initiated HPV vaccination (≥ 1 dose) and 19% had completed the series. The intervention group had higher HPV knowledge scores (M = 9.1; SD = 1.8) than the control group (M = 7.0; SD = 2.9; F = 22.53). Among unvaccinated individuals (n = 79), the intervention group had higher HPV vaccination intent (86%) compared to the control group (67%) (OR = 3.09; 95%CI = 1.02-9.36). Conclusions Despite ACIP recommendations, young adults continue to have low awareness of vaccine benefits and low vaccination rates. This study suggests that educational interventions to increase HPV awareness and vaccination may help to boost vaccination rates. © 2013 Published by Elsevier Inc. AD - Department of Pediatrics, Indiana University, 410 W. 10th Street, Indianapolis, IN 46202, United States IU Simon Cancer Center, Indianapolis, IN, United States Cervical Cancer-Free America, Chapel Hill, NC, United States AU - Kester, L. M. AU - Shedd-Steele, R. B. AU - Dotson-Roberts, C. A. AU - Smith, J. AU - Zimet, G. D. DB - Scopus DO - 10.1016/j.ygyno.2013.12.033 IS - SUPPL1 KW - Cervical cancer Community education HPV vaccination initiation Human papillomavirus Human papillomavirus vaccination Immunization M3 - Article N1 - Cited By :21 Export Date: 22 March 2021 PY - 2014 SP - S9-S12 ST - The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults T2 - Gynecologic Oncology TI - The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896545779&doi=10.1016%2fj.ygyno.2013.12.033&partnerID=40&md5=e0c8887ecce3f59a257462cd0cae2acc VL - 132 ID - 2421 ER - TY - JOUR AB - Purpose: The purpose of this cohort study was to investigate the association of adjuvant chemotherapy with quality of life (QoL), survival, and recurrence over the 24 months following diagnosis in stage II colon cancer patients. Methods: Overall, 453 patients were recruited from North Carolina from 2009 to 2011 and interviewed with a closed-ended survey detailing quality of life, health behaviors, treatment, and cancer recurrence at three times points: diagnosis, 12-, and 24-months post-diagnosis; mortality was obtained via the National Death Index. Results: In sum, 265 patients received chemotherapy. Receipt of chemotherapy exhibited an inverse association with total Functional Assessment of Cancer Treatment (FACT)-General (P < 0.01), FACT-Colorectal (P < 0.01), physical (P < 0.01), emotional (P = 0.02), and functional (P < 0.01) well-being; the inverse association between receiving chemotherapy and emotional well-being persisted for Caucasians but not African Americans (Pinteraction = 0.049). Those who received chemotherapy demonstrated significantly higher odds of cancer recurrence (odds ratio (OR) 2.74; 95 % confidence interval (CI) 1.18, 6.35) and all-cause mortality (OR: 1.95; 95 % CI: 1.05, 3.62). Conclusions: In this study, stage II colon cancer patients who received chemotherapy treatment were more likely to have poor QoL, recurrence, and all-cause mortality after 24 months compared to those who did not receive chemotherapy. Future research focusing on subtypes of chemotherapy treatment, as well as a longer follow-up period, is needed. © 2015, Springer-Verlag Berlin Heidelberg. AD - Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, 1025 E. Seventh Street, SPH C032, Bloomington, IN 47405, United States AU - Lewis, C. AU - Xun, P. AU - He, K. DB - Scopus DO - 10.1007/s00520-015-2931-2 IS - 4 KW - Chemotherapy Colon cancer Quality of life Recurrence Survival M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2016 SP - 1463-1471 ST - Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up T2 - Supportive Care in Cancer TI - Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959145268&doi=10.1007%2fs00520-015-2931-2&partnerID=40&md5=86a6acaa82b764f1ee8f5f7d0f5fecee VL - 24 ID - 2345 ER - TY - JOUR AB - Background: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages ≥55 years) enrolled in a case management intervention in a cancer screening trial. Methods: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n = 344) or to a case management control group (n = 339). The effects of comorbidities on the screening adherence rates of each group were then assessed. Results: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate-specific antigen test (P = 0.02) and the digital rectal examination for prostate cancer screening (P = 0.01), to the chest X-ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P = 0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X-ray (P = 0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P = 0.05). Conclusions: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening. Copyright © 2008 American Association for Cancer Research. AD - M. E. Ford, Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, United States AU - Ford, M. E. AU - Havstad, S. L. AU - Fields, M. E. AU - Manigo, B. AU - McClary, B. AU - Lamerato, L. DB - Embase Medline DO - 10.1158/1055-9965.EPI-08-0118 IS - 5 KW - prostate specific antigen adult African American aged anamnesis article cancer screening chronic bronchitis colorectal cancer comorbidity controlled study digital rectal examination human lung cancer major clinical study male men's health priority journal sigmoidoscopy smoking statistical analysis thorax radiography L1 - internal-pdf://1726956429/1234.full.pdf LA - English M3 - Article N1 - L352467482 2008-10-24 PY - 2008 SN - 1055-9965 SP - 1234-1239 ST - Effects of baseline comorbidities on cancer screening trial adherence among older African American men T2 - Cancer Epidemiology Biomarkers and Prevention TI - Effects of baseline comorbidities on cancer screening trial adherence among older African American men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352467482&from=export http://dx.doi.org/10.1158/1055-9965.EPI-08-0118 VL - 17 ID - 1212 ER - TY - JOUR AB - BACKGROUND: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages >or=55 years) enrolled in a case management intervention in a cancer screening trial. METHODS: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n = 344) or to a case management control group (n = 339). The effects of comorbidities on the screening adherence rates of each group were then assessed. RESULTS: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate‐specific antigen test (P = 0.02) and the digital rectal examination for prostate cancer screening (P = 0.01), to the chest X‐ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P = 0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X‐ray (P = 0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P = 0.05). CONCLUSIONS: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening. AN - CN-00648403 AU - Ford, M. E. AU - Havstad, S. L. AU - Fields, M. E. AU - Manigo, B. AU - McClary, B. AU - Lamerato, L. DO - 10.1158/1055-9965.EPI-08-0118 IS - 5 KW - African Americans [*statistics & numerical data] Colorectal Neoplasms [*prevention & control] Comorbidity Humans Lung Neoplasms [*prevention & control] Male Mass Screening Middle Aged Patient Compliance Prostatic Neoplasms [*prevention & control] Risk Factors M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2008 SP - 1234‐1239 ST - Effects of baseline comorbidities on cancer screening trial adherence among older African American men T2 - Cancer epidemiology, biomarkers & prevention TI - Effects of baseline comorbidities on cancer screening trial adherence among older African American men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00648403/full VL - 17 ID - 1351 ER - TY - JOUR AB - Background: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages ≥55 years) enrolled in a case management intervention in a cancer screening trial. Methods: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n = 344) or to a case management control group (n = 339). The effects of comorbidities on the screening adherence rates of each group were then assessed. Results: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate-specific antigen test (P = 0.02) and the digital rectal examination for prostate cancer screening (P = 0.01), to the chest X-ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P = 0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X-ray (P = 0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P = 0.05). Conclusions: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening. Copyright © 2008 American Association for Cancer Research. AD - Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC, United States Department of Health Sciences, South Carolina State University, Orangeburg, SC, United States Department of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, Detroit, MI, United States Ford Cancer Center, Henry Ford Health Sciences Center, Detroit, MI, United States Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, United States AU - Ford, M. E. AU - Havstad, S. L. AU - Fields, M. E. AU - Manigo, B. AU - McClary, B. AU - Lamerato, L. DB - Scopus DO - 10.1158/1055-9965.EPI-08-0118 IS - 5 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2008 SP - 1234-1239 ST - Effects of baseline comorbidities on cancer screening trial adherence among older African American men T2 - Cancer Epidemiology Biomarkers and Prevention TI - Effects of baseline comorbidities on cancer screening trial adherence among older African American men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-52649121448&doi=10.1158%2f1055-9965.EPI-08-0118&partnerID=40&md5=c104329e55acd651df80d72f4d110238 VL - 17 ID - 2536 ER - TY - JOUR AB - Background: The purpose of this study was to examine the effects of baseline comorbidities on screening adherence in a sample of older African American men (ages >= 55 years) enrolled in a case management intervention in a cancer screening trial. Methods: Baseline comorbidity data were obtained from 683 African American men who were randomly assigned to a case management intervention group (n=344) or to a case management control group (n=339). The effects of comorbidities on the screening adherence rates of each group were then assessed. Results: No statistically significant interactions were found between each health history characteristic and the intervention. Therefore, analyses were not stratified by intervention status. In general, participants with comorbidities were no less likely to adhere to trial screening than participants without comorbidities. Exceptions were current smokers and participants with chronic bronchitis. Current smokers were less likely than others to adhere to the prostate-specific antigen test (P=0.02) and the digital rectal examination for prostate cancer screening (P=0.01), to the chest X-ray for lung cancer screening (P < 0.01), and to the flexible sigmoidoscopy for colorectal cancer screening (P=0.04). Participants with chronic bronchitis had lower rates of adherence to the chest X-ray (P=0.06). Having a relative with cancer positively influenced adherence to the digital rectal examination (P=0.05). Conclusions: Overall, older African American men with comorbidities appear to be very good candidates for participation in longitudinal cancer screening trials. However, smoking had a statistically significant and deleterious effect on adherence to all types of screening. AN - WOS:000256012800030 AU - Ford, M. E. AU - Havstad, S. L. AU - Fields, M. E. AU - Manigo, B. AU - McClary, B. AU - Lamerato, L. DA - May DO - 10.1158/1055-9965.EPI-08-0118 IS - 5 N1 - 18463399 PY - 2008 SN - 1055-9965 SP - 1234-1239 ST - Effects of baseline comorbidities on cancer screening trial adherence among older African American men T2 - Cancer Epidemiology Biomarkers & Prevention TI - Effects of baseline comorbidities on cancer screening trial adherence among older African American men VL - 17 ID - 3170 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To obtain preliminary data and determine the feasibility of a large-scale experimental study to test the efficacy of the Rogerian Science of Unitary Human Beings-based intervention of dialogue and therapeutic touch (TT) on pre- and postoperative anxiety and mood and postoperative pain from breast cancer surgery. DESIGN: Experimental. SETTING: Mid-Atlantic region; ambulatory. SAMPLE: 29 Caucasian and 2 African American English-speaking women with positive breast cancer biopsy (experimental, n = 14; control, n = 17), ranging in age from 31-84 years old (F = 55.6). METHODS: Treatments administered in subjects' homes within seven days prior to surgery and 24 hours after hospital discharge. Experimental treatment consisted of 10 minutes of TT and 20 minutes of dialogue. Control treatment consisted of 10 minutes of quiet time and 20 minutes of dialogue. Data (Spielberger State-Trait Anxiety Inventory. Affects Balance Scale, and Visual Analog Scale-Pain) were collected at the conclusion of each home visit. MAIN RESEARCH VARIABLES: Anxiety, mood, and pain. FINDINGS: The experimental group had lower preoperative state anxiety than the control groups (p = 0.008). No difference was found for preoperative mood. No differences were found for any postoperative measure. CONCLUSIONS: A large-scale study of dialogue and TT would require changes in design and recruitment strategies. IMPLICATIONS FOR NURSING PRACTICE: Nurses may provide more comprehensive care by incorporating dialogue and TT or quiet time into their pre- and postoperative care. Additional research, however, is recommended to determine the differential effects of dialogue, TT, and quiet time on women's experiences with breast cancer prior to incorporating these noninvasive modalities into clinical practice. AD - N. Samarel, William Paterson University, Wayne, NJ, USA. AU - Samarel, N. AU - Fawcett, J. AU - Davis, M. M. AU - Ryan, F. M. DB - Medline IS - 8 KW - adult affect aged alternative medicine anxiety article breast tumor clinical trial controlled clinical trial controlled study female human interpersonal communication middle aged nurse patient relationship nursing nursing methodology research postoperative care preoperative care psychological aspect LA - English M3 - Article N1 - L128318663 1998-12-03 PY - 1998 SN - 0190-535X SP - 1369-1376 ST - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study T2 - Oncology nursing forum TI - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128318663&from=export VL - 25 ID - 1330 ER - TY - JOUR AB - Purpose/Objectives: To obtain preliminary data and determine the feasibility of a large-scale experimental study to test the efficacy of the Rogerian Science of Unitary Human Beings-based intervention of dialogue and therapeutic touch (TT) on pre- and postoperative anxiety and mood and postoperative pain from breast cancer surgery. Design: Experimental. Setting: Mid-Atlantic region; ambulatory. Sample: 29 Caucasian and 2 African American English-speaking women with positive breast cancer biopsy (experimental, n = 14, control, n = 17), ranging in age from 31-84 years old (F = 55.6). Methods: Treatments administered in subjects' homes within seven days prior to surgery and 24 hours after hospital discharge. Experimental treatment consisted of 10 minutes of TT and 20 minutes of dialogue. Control treatment consisted of 10 minutes of quiet time and 20 minutes of dialogue. Data (Spielberger State-Trait Anxiety Inventory, Affects Balance Scale, and Visual Analog Scale-Pain) were collected at the conclusion of each home visit. Main Research Variables: Anxiety, mood, and pain. Findings: The experimental group had lower preoperative state anxiety than the control groups (p = 0.008). No difference was found for preoperative mood. No differences were found for any postoperative measure. Conclusions: A large-scale study of dialogue and TT would require changes in design and recruitment strategies. Implications for Nursing Practice: Nurses may provide more comprehensive care by incorporating dialogue and TT or quiet time into their pre- and postoperative care, Additional research, however, is recommended to determine the differential effects of dialogue, TT, and quiet time on women's experiences with breast cancer prior to incorporating these noninvasive modalities into clinical practice. AD - William Paterson University, Wayne, NJ AN - 107293025. Language: English. Entry Date: 20000601. Revision Date: 20150819. Publication Type: Journal Article AU - Samarel, N. AU - Fawcett, J. AU - Davis, M. M. AU - Ryan, F. M. DB - CINAHL Complete DP - EBSCOhost IS - 8 KW - Therapeutic Touch Preoperative Care Postoperative Care Breast Neoplasms -- Surgery Oncologic Nursing Nurse-Patient Relations Funding Source Experimental Studies Mid Atlantic Region Rogers Science of Unitary Human Beings Cancer Patients Anxiety Postoperative Pain Research Subject Recruitment Descriptive Statistics Visual Analog Scaling Research Instruments Data Analysis Software Multivariate Analysis of Variance Affect Exploratory Research Correlation Coefficient Adult Middle Age Aged Aged, 80 and Over Outpatients Female Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Spielberger State-Trait Anxiety Inventory (STAI); Affects Balance Scale (ABS) (Derogatis). Grant Information: Funded by the Oncology Nursing Society (Amgen Research Grant). NLM UID: 7809033. PMID: NLM9766290. PY - 1998 SN - 0190-535X SP - 1369-1376 ST - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study T2 - Oncology Nursing Forum TI - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107293025&site=ehost-live&scope=site VL - 25 ID - 1935 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To obtain preliminary data and determine the feasibility of a large-scale experimental study to test the efficacy of the Rogerian Science of Unitary Human Beings-based intervention of dialogue and therapeutic touch (TT) on pre- and postoperative anxiety and mood and postoperative pain from breast cancer surgery. DESIGN: Experimental. SETTING: Mid-Atlantic region; ambulatory. SAMPLE: 29 Caucasian and 2 African American English-speaking women with positive breast cancer biopsy (experimental, n = 14; control, n = 17), ranging in age from 31-84 years old (F = 55.6). METHODS: Treatments administered in subjects' homes within seven days prior to surgery and 24 hours after hospital discharge. Experimental treatment consisted of 10 minutes of TT and 20 minutes of dialogue. Control treatment consisted of 10 minutes of quiet time and 20 minutes of dialogue. Data (Spielberger State-Trait Anxiety Inventory. Affects Balance Scale, and Visual Analog Scale-Pain) were collected at the conclusion of each home visit. MAIN RESEARCH VARIABLES: Anxiety, mood, and pain. FINDINGS: The experimental group had lower preoperative state anxiety than the control groups (p = 0.008). No difference was found for preoperative mood. No differences were found for any postoperative measure. CONCLUSIONS: A large-scale study of dialogue and TT would require changes in design and recruitment strategies. IMPLICATIONS FOR NURSING PRACTICE: Nurses may provide more comprehensive care by incorporating dialogue and TT or quiet time into their pre- and postoperative care. Additional research, however, is recommended to determine the differential effects of dialogue, TT, and quiet time on women's experiences with breast cancer prior to incorporating these noninvasive modalities into clinical practice. AD - William Paterson University, Wayne, NJ, USA. AU - Samarel, N. AU - Fawcett, J. AU - Davis, M. M. AU - Ryan, F. M. DB - Scopus IS - 8 M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 1998 SP - 1369-1376 ST - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study T2 - Oncology nursing forum TI - Effects of dialogue and therapeutic touch on preoperative and postoperative experiences of breast cancer surgery: an exploratory study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032162121&partnerID=40&md5=6554d86139c6536920251ad53fe59ace VL - 25 ID - 2643 ER - TY - JOUR AB - The authors examined the effects that differently framed and targeted health messages have on persuading low-income women to obtain screening mammograms. The authors recruited 752 women over 40 years of age from community health clinics and public housing developments and assigned the women randomly to view videos that were either gain or loss framed and either targeted specifically to their ethnic groups or multicultural. Loss-framed, multicultural messages were most persuasive. The advantage of loss-framed, multicultural messages was especially apparent for Anglo women and Latinas but not for African American women. These effects were stronger after 6 months than after 12 months. AD - P. Salovey, Department of Psychology, Yale University, P.O. Box 208205, New Haven, CT 06520-8205, United States AU - Schneider, T. R. AU - Salovey, P. AU - Apanovitch, A. M. AU - Pizarro, J. AU - McCarthy, D. AU - Zullo, J. AU - Rothman, A. J. DB - Embase Medline DO - 10.1037//0278-6133.20.4.256 IS - 4 KW - adult article behavior modification breast cancer cancer screening clinical trial community care controlled clinical trial controlled study ethnic group female health behavior health center health promotion health service human lowest income group major clinical study mammography randomized controlled trial screening test LA - English M3 - Article N1 - L32738610 2001-08-24 PY - 2001 SN - 0278-6133 SP - 256-266 ST - The effects of message framing and ethnic targeting on mammography use among low-income women T2 - Health Psychology TI - The effects of message framing and ethnic targeting on mammography use among low-income women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32738610&from=export http://dx.doi.org/10.1037//0278-6133.20.4.256 VL - 20 ID - 1308 ER - TY - JOUR AB - The authors examined the effects that differently framed and targeted health messages have on persuading low‐income women to obtain screening mammograms. The authors recruited 752 women over 40 years of age from community health clinics and public housing developments and assigned the women randomly to view videos that were either gain or loss framed and either targeted specifically to their ethnic groups or multicultural. Loss‐framed, multicultural messages were most persuasive. The advantage of loss‐framed, multicultural messages was especially apparent for Anglo women and Latinas but not for African American women. These effects were stronger after 6 months than after 12 months. AN - CN-00442598 AU - Schneider, T. R. AU - Salovey, P. AU - Apanovitch, A. M. AU - Pizarro, J. AU - McCarthy, D. AU - Zullo, J. AU - Rothman, A. J. DO - 10.1037//0278-6133.20.4.256 IS - 4 KW - *mammography Adult Article Behavior modification Breast Neoplasms [diagnosis, epidemiology] Breast cancer/di [Diagnosis] Breast cancer/pc [Prevention] Cancer screening Clinical trial Community care Controlled clinical trial Controlled study Culture Ethnic Groups Ethnic group Female Health Behavior Health Promotion Health center Health service Human Humans Lowest income group Major clinical study Mammography [*psychology, statistics & numerical data] Mass Screening Middle Aged Random Allocation Randomized controlled trial Screening test Socioeconomic Factors Videotape Recording M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 2001 SP - 256‐266 ST - The effects of message framing and ethnic targeting on mammography use among low-income women T2 - Health psychology TI - The effects of message framing and ethnic targeting on mammography use among low-income women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00442598/full VL - 20 ID - 1566 ER - TY - JOUR AB - The authors examined the effects that differently framed and targeted health messages have on persuading low-income women to obtain screening mammograms. The authors recruited 752 women over 40 years of age from community health clinics and public housing developments and assigned the women randomly to view videos that were either gain or loss framed and either targeted specifically to their ethnic groups or multicultural. Loss-framed, multicultural messages were most persuasive. The advantage of loss-framed, multicultural messages was especially apparent for Anglo women and Latinas but not for African American women. These effects were stronger after 6 months than after 12 months. Copyright © 2000 by the American Psychological Association, Inc. AD - Health, Emotion, and Behavior Laboratory, Department of Psychology, Yale University AN - 107072190. Language: English. Entry Date: 20011130. Revision Date: 20150711. Publication Type: Journal Article AU - Schneider, T. R. AU - Salovey, P. AU - Apanovitch, A. M. AU - Pizarro, J. AU - McCarthy, D. AU - Zullo, J. AU - Rothman, A. J. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Breast Neoplasms -- Education Mammography Teaching Methods Female Adult Middle Age Socioeconomic Factors Motivation Hispanic Americans Asians Black Persons White Persons Experimental Studies Questionnaires Pretest-Posttest Design Videorecording -- Utilization Chi Square Test P-Value Descriptive Statistics Logistic Regression Race Factors Odds Ratio Confidence Intervals Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Funded by American Cancer Society Grant RPG-93-028-05-PBP and National Cancer Institute Grant R01-CA68427. NLM UID: 8211523. PMID: NLM11515737. PY - 2001 SN - 0278-6133 SP - 256-266 ST - The effects of message framing and ethnic targeting on mammography use among low-income women T2 - Health Psychology TI - The effects of message framing and ethnic targeting on mammography use among low-income women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107072190&site=ehost-live&scope=site VL - 20 ID - 2120 ER - TY - JOUR AB - Disodium disuccinate astaxanthin ('rac'-dAST; Cardax (TM)) is a water-dispersible C40 carotenoid derivative under development for oral and parenteral administration for cardioprotection of the at-risk ischemic cardiovascular patient. In experimental infarction models in animals (rats, rabbits, and dogs), significant myocardial salvage has been obtained, up to 100% at the appropriate dose in dogs. The documented mechanism of action in vitro includes direct scavenging of biologically produced superoxide anion; in vivo in rabbits, modulation of the complement activity of serum has also been shown. A direct correlation between administration of the test compound in animals and reductions of multiple, independent markers of oxidative stress in serum was recently obtained in a rat experimental infarction model. For the current study, it was hypothesized that oral Cardax (TM) administration would inhibit oxidative damage of multiple relevant biological targets in a representative, well-characterized murine peritoneal inflammation model. A previously developed mass spectrometry-based (LC/ESI/MS/MS) approach was used to interrogate multiple distinct pathways of oxidation in a black mouse (C57/BL6) model system. In vivo markers of oxidant stress from peritoneal lavage samples (supernatants) were evaluated in mice on day eight (8) after treatment with either Cardax (TM) or vehicle (lipophilic emulsion without drug) orally by gavage at 500 mg/kg once per day for seven (7) days at five (5) time points: (1) baseline prior to treatment (t=0); (2) 16 h following intraperitoneal (i.p.) injection with thioglycollate to elicit a neutrophilic infiltrate; (3) 4 h following i.p. injection of yeast cell wall (zymosan; t=16 h/4 h thioglycollate+zymosan); (4) 72 h following i.p. injection with thioglycollate to elicit monocyte/macrophage infiltration; and (5) 72 h/4 It thioglycollate+zymosan. A statistically significant sparing effect on the arachidonic acid (AA) and linoleic acid (LA) substrates was observed at time points two and five. When normalized to the concentration of the oxidative substrates, statistically significant reductions of 8-isoprostane-F-2 alpha (8-iso-F-2 alpha) at time point three (maximal neutrophil recruitment/activation), and 5-HETE, 5-oxo-EET, 11-HETE, 9-HODE, and PGF(2 alpha) at time point five (maximal monocyte/macrophage recruitment/activation) were observed. Subsequently, the direct interaction of the optically inactive stereoisomer of Cardax (TM) (meso-dAST) with human 5-lipoxygenase (5-LOX) was evaluated in vitro with circular dichroism (CD) and electronic absorption (UV/Vis) spectroscopy, and subsequent molecular docking calculations were made using mammalian 15-LOX as a surrogate (for which XRC data has been reported). The results suggested that the meso-compound was capable of interaction with, and binding to, the solvent-exposed surface of the enzyme. These preliminary studies provide the foundation for more detailed evaluation of the therapeutic effects of this compound on the 5-LOX enzyme, important in chronic diseases such as atherosclerosis, asthma, and prostate cancer in humans. (c) 2006 Elsevier Inc. All rights reserved. AN - WOS:000238108100008 AU - Lockwood, S. F. AU - Penn, M. S. AU - Hazen, S. L. AU - Bikadi, Z. AU - Zsila, F. DA - Jun DO - 10.1016/j.lfs.2005.12.052 IS - 2 N1 - 16466747 PY - 2006 SN - 0024-3205 SP - 162-174 ST - The effects of oral Cardax (TM) (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo T2 - Life Sciences TI - The effects of oral Cardax (TM) (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo VL - 79 ID - 3217 ER - TY - JOUR AB - OBJECTIVES: To determine the effects of online narrative and didactic information on breast cancer patients' healthcare participation and the interaction effects of race. METHODS: Sample: 353 breast cancer patients (111 African Americans) using an eHealth program with narratives (audiovisual and text) and didactic information (text only). Measures: healthcare participation scale (0, 4 months), online information use. Analyses: hierarchical regression. RESULTS: Narrative (beta=0.123, p<0.01) and didactic (beta=0.104, p<0.05) information use had independent and positive effects on healthcare participation. Effects of both were significantly greater for African Americans. CONCLUSIONS: Findings are consistent with and advance prior research on online learning processes and outcomes for breast cancer patients: (1) benefits accrue with using a variety of online learning tools; (2) African Americans use and benefit more from online narrative and didactic information than do Caucasians. PRACTICE IMPLICATIONS: eHealth programs should provide both didactic and narrative information‐especially for African Americans and might consider making greater use of interactive and audiovisual formats. As patients increasingly use of the web for cancer information, clinicians should provide lists of web high quality resources that provide both narrative and didactic information. AN - CN-00629401 AU - Wise, M. AU - Han, J. Y. AU - Shaw, B. AU - McTavish, F. AU - Gustafson, D. H. DO - 10.1016/j.pec.2007.11.009 IS - 3 KW - Adaptation, Psychological African Americans [education, ethnology, statistics & numerical data] Breast Neoplasms [*ethnology] European Continental Ancestry Group [education, ethnology, statistics & numerical data] Female Humans Internet [*organization & administration] Middle Aged Narration Patient Education as Topic [*organization & administration] Patient Participation [*psychology, statistics & numerical data] Program Evaluation Regression Analysis Social Support Surveys and Questionnaires M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2008 SP - 348‐356 ST - Effects of using online narrative and didactic information on healthcare participation for breast cancer patients T2 - Patient education and counseling TI - Effects of using online narrative and didactic information on healthcare participation for breast cancer patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00629401/full VL - 70 ID - 1432 ER - TY - JOUR AB - BACKGROUND: Upfront docetaxel (UD) with androgen deprivation therapy (ADT) has been demonstrated to improve survival outcomes in metastatic castration-sensitive prostate cancer (mCSPC). However, existing studies have included predominantly Caucasian patients. STUDY QUESTION: To compare the efficacy of addition of UD to ADT in mCSPC to ADT alone among minority patients. STUDY DESIGN: Retrospective study of mCSPC patients. MEASURES AND OUTCOMES: Patients treated with UD and ADT between January 2014 and December 2017 (UD + ADT, n = 44) were compared with those treated with ADT alone between January 2008 and January 2017 (ADT, n = 38); patients of Caucasian ethnicity were excluded. The outcome of interest was progression-free survival (PFS), which was estimated using Kaplan-Meier analysis and Cox proportional hazard analysis. RESULTS: Overall, 63 (76.8%) patients were African American and 16 (19.5%) were Hispanic. Fifty-five (67%) patients had high-volume mCSPC. The median follow-up was 14 months [95% confidence interval (CI): 10.4-16.5] for UD + ADT and 42 months (95% CI: 17-66.9) for ADT. Median PFS did not differ between groups: UD + ADT: 16 versus ADT: 18 months [hazard ratio (HR) for UD + ADT = 0.88, 95% CI: 0.48-1.62; P = 0.70]. In patients with high-volume disease, median PFS remained similar (UD + ADT: 16 vs. ADT: 14 months (HR for UD + ADT = 0.64, 95% CI: 0.33-1.25; P = 0.19). On multivariable analysis, prolonged time to nadir PSA, HR = 0.83 (95% CI: 0.76-0.90), was independently associated with PFS. The most common toxicities in UD + ADT were anemia and fatigue. Major limitations include small sample size and potential for selection bias due to the retrospective study design. CONCLUSIONS: In this retrospective review of a minority mCSPC cohort, UD + ADT was not associated with improved PFS compared with ADT alone. Although further study with larger sample size is needed, these results underscore the importance of ensuring accrual of minorities in clinical trials, reflective of the real-world setting. AU - Pathak, S. AU - Thekkekara, R. AU - Yadav, U. AU - Ahmed, A. T. AU - Yim, B. AU - Lad, T. E. AU - Mullane, M. AU - Batra, K. K. AU - Aronow, W. S. AU - Psutka, S. P. DB - Medline DO - 10.1097/MJT.0000000000001085 KW - adult African American androgen deprivation therapy anemia article cancer patient cancer size cancer survival castration Caucasian clinical article clinical trial cohort analysis controlled study drug therapy ethnicity fatigue follow up Hispanic human Kaplan Meier method male progression free survival prostate cancer retrospective study sample size selection bias docetaxel endogenous compound prostate specific antigen LA - English M3 - Article in Press N1 - L631701423 2020-05-14 PY - 2020 SN - 1536-3686 ST - Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients T2 - American journal of therapeutics TI - Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631701423&from=export http://dx.doi.org/10.1097/MJT.0000000000001085 ID - 806 ER - TY - JOUR AB - African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy. In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted. Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities. http://www.ClinicalTrials.gov NCT01805622. AD - S.A. Smith, Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, USA. AU - Smith, S. A. AU - Blumenthal, D. S. DB - Medline KW - NCT01805622 African American aged article cluster analysis colorectal tumor controlled clinical trial controlled study early diagnosis ethnology female health disparity health promotion human male methodology middle aged organization and management patient education randomized controlled trial treatment outcome LA - English M3 - Article N1 - L563009306 2014-01-13 PY - 2013 SN - 1748-5908 SP - 86 ST - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial T2 - Implementation science : IS TI - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563009306&from=export VL - 8 ID - 1066 ER - TY - JOUR AB - BACKGROUND: African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy. METHODS/DESIGN: In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted. DISCUSSION: Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities. TRIAL REGISTRATION: http://www.ClinicalTrials.gov NCT01805622. AU - Smith, S. A. AU - Blumenthal, D. S. DB - Medline DO - 10.1186/1748-5908-8-86 KW - ClinicalTrials.gov African American aged cluster analysis colorectal tumor controlled study early diagnosis ethnology female health disparity health promotion human male middle aged organization and management patient education procedures randomized controlled trial treatment outcome LA - English M3 - Article N1 - L603120824 2015-03-24 PY - 2013 SN - 1748-5908 SP - 86 ST - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial T2 - Implementation science : IS TI - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603120824&from=export http://dx.doi.org/10.1186/1748-5908-8-86 VL - 8 ID - 1102 ER - TY - JOUR AB - Background: African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy.Methods/design: In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted.Discussion: Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities.Trial Registration: http://www.ClinicalTrials.gov NCT01805622. AD - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, USA. ssmith@msm.edu. AN - 104087737. Language: English. Entry Date: 20140124. Revision Date: 20190920. Publication Type: journal article AU - Smith, Selina A. AU - Blumenthal, Daniel S. DB - CINAHL Complete DO - 10.1186/1748-5908-8-86 DP - EBSCOhost IS - 1 KW - Colorectal Neoplasms -- Prevention and Control Patient Education -- Methods Black Persons Aged Cluster Analysis Colorectal Neoplasms -- Ethnology Early Detection of Cancer Female Health Promotion -- Administration Health Status Disparities Human Male Middle Age Treatment Outcomes N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; Health Services Administration; UK & Ireland. Grant Information: UL1 TR000454/TR/NCATS NIH HHS/United States. NLM UID: 101258411. PMID: NLM23924263. PY - 2013 SN - 1748-5908 SP - 86-86 ST - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial T2 - Implementation Science TI - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104087737&site=ehost-live&scope=site VL - 8 ID - 1936 ER - TY - JOUR AB - Background: African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy.Methods/design: In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted.Discussion: Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities. © 2013 Smith and Blumenthal; licensee BioMed Central Ltd. AD - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, United States Cancer Research Program, Morehouse School of Medicine, Atlanta, GA, United States AU - Smith, S. A. AU - Blumenthal, D. S. C7 - 86 DB - Scopus DO - 10.1186/1748-5908-8-86 IS - 1 KW - Colorectal cancer screening Community-based participatory research Dissemination Health disparities Implementation M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2013 ST - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): Study protocol of a cluster randomized controlled trial T2 - Implementation Science TI - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): Study protocol of a cluster randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881081850&doi=10.1186%2f1748-5908-8-86&partnerID=40&md5=90a87cbbd6161f1a1746747dc2721733 VL - 8 ID - 2428 ER - TY - JOUR AB - Background: African Americans have the highest incidence and mortality and are less likely than whites to have been screened for colorectal cancer (CRC). Many interventions have been shown to increase CRC screening in research settings, but few have been evaluated specifically for use in African-American communities in real world settings. This study aims to identify the most efficacious approach to disseminate an evidence-based intervention in promoting colorectal screening in African Americans and to identify the factors associated with its efficacy. Methods/design: In this study, investigators will recruit 20 community coalitions and 7,200 African-Americans age 50 to 74 to test passive and active approaches to disseminating the Educational Program to Increase Colorectal Cancer Screening (EPICS); to measure the extent to which EPICS is accepted and the fidelity of implementation in various settings and to estimate the potential translatability and public health impact of EPICS. This four-arm cluster randomized trial compares the following implementation strategies: passive arms, (web access to facilitator training materials and toolkits without technical assistance (TA) and (web access, but with technical assistance (TA); active arms, (in-person access to facilitator training materials and toolkits without TA and (in-person access with TA). Primary outcome measures are the reach (the proportion of representative community coalitions and individuals participating) and efficacy (post-intervention changes in CRC screening rates). Secondary outcomes include adoption (percentage of community coalitions implementing the EPICS sessions) and implementation (quality and consistency of the intervention delivery). The extent to which community coalitions continue to implement EPICS post-implementation (maintenance) will also be measured. Cost-effectiveness analysis will be conducted. Discussion: Implementing EPICS in partnership with community coalitions, we hypothesized, will result in more rapid adoption than traditional top-down approaches, and resulting changes in community CRC screening practices are more likely to be sustainable over time. With its national reach, this study has the potential to enhance our understanding of barriers and enablers to the uptake of educational programs aimed at eliminating cancer disparities. AN - WOS:000322917000001 AU - Smith, S. A. AU - Blumenthal, D. S. DA - Aug DO - 10.1186/1748-5908-8-86 N1 - 86 23924263 PY - 2013 SN - 1748-5908 ST - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial T2 - Implementation Science TI - Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial VL - 8 ID - 3037 ER - TY - JOUR AB - Introduction: Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African-American breast cancer survivors. Methods: Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers. Results: Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. Discusssion/Conclusions: To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples' lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied. Implications for Cancer Survivors: For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible. © 2010 Springer Science+Business Media, LLC. AD - B. B. Germino, School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC 27599, United States AU - Germino, B. B. AU - Mishel, M. H. AU - Alexander, G. R. AU - Jenerette, C. AU - Blyler, D. AU - Baker, C. AU - Vines, A. I. AU - Green, M. AU - Long, D. G. DB - Medline DO - 10.1007/s11764-010-0150-x IS - 1 KW - African American article breast tumor carcinoma communication disorder counseling cultural anthropology demography ethnology evaluation study fear female health care delivery human methodology patient attitude patient selection physiology psychological aspect psychotherapy randomized controlled trial (topic) recurrent disease statistics survivor LA - English M3 - Article N1 - L51093787 2011-06-10 PY - 2011 SN - 1932-2259 1932-2267 SP - 82-91 ST - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community T2 - Journal of Cancer Survivorship TI - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51093787&from=export http://dx.doi.org/10.1007/s11764-010-0150-x VL - 5 ID - 1137 ER - TY - JOUR AB - Introduction: Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African- American breast cancer survivors. Methods: Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers. Results: Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. Discusssion/Conclusions: To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples’ lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied. Implications for Cancer Survivors: For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Germino, Barbara B., School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, US, 27599 AN - 2011-03836-010 AU - Germino, Barbara B. AU - Mishel, Merle H. AU - Alexander, G. Rumay AU - Jenerette, Coretta AU - Blyler, Diane AU - Baker, Carol AU - Vines, Anissa I. AU - Green, Melissa AU - Long, Debra G. DB - psyh DO - 10.1007/s11764-010-0150-x DP - EBSCOhost IS - 1 KW - young survivors breast cancer African Americans intervention trials clinical trials participants recruitment retention minority research participation Breast Neoplasms Carcinoma Communication Barriers Counseling Culture Fear Female Health Services Accessibility Humans Patient Acceptance of Health Care Patient Selection Psychotherapy Randomized Controlled Trials as Topic Recurrence Residence Characteristics Survivors Blacks Experimental Subjects Participation N1 - School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, US. Release Date: 20110801. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Vines, Anissa I. Major Descriptor: Blacks; Breast Neoplasms; Clinical Trials; Experimental Subjects; Participation. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Mar, 2011. Publication History: First Posted Date: Oct 1, 2010; Accepted Date: Sep 14, 2010; First Submitted Date: Feb 24, 2010. Copyright Statement: Springer Science+Business Media, LLC. 2010. Sponsor: National Institutes of Health, National Institute of Nursing Research, US. Grant: 5R01NR010190. Other Details: Younger Breast Cancer Survivors: Managing Uncertainty. Recipients: No recipient indicated Sponsor: University of North Carolina at Chapel Hill, School of Nursing, Faculty Research Opportunity Grants Program, US. Recipients: No recipient indicated Sponsor: National Cancer Institute, Community Networks Program, US. Grant: U01CA114629. Other Details: Reduce Cancer Health Disparities. Recipients: Vines, Anissa I.; Long, Debra G. PY - 2011 SN - 1932-2259 1932-2267 SP - 82-91 ST - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community T2 - Journal of Cancer Survivorship TI - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-03836-010&site=ehost-live&scope=site germino@email.unc.edu VL - 5 ID - 1689 ER - TY - JOUR AB - Introduction: Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African-American breast cancer survivors. Methods: Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers. Results: Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. Discusssion/Conclusions: To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples' lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied. Implications for Cancer Survivors: For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible. © 2010 Springer Science+Business Media, LLC. AD - School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC 27599, United States Office of Multicultural Affairs, School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, United States UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, CB# 7435, Chapel Hill, NC, United States Project CONNECT, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB# 7590, Chapel Hill, NC, United States CrossWorks, Inc., Rocky Mount, NC, United States AU - Germino, B. B. AU - Mishel, M. H. AU - Alexander, G. R. AU - Jenerette, C. AU - Blyler, D. AU - Baker, C. AU - Vines, A. I. AU - Green, M. AU - Long, D. G. DB - Scopus DO - 10.1007/s11764-010-0150-x IS - 1 KW - Culturally informed recruitment and retention strategies Minority research participation Younger breast cancer survivors M3 - Article N1 - Cited By :24 Export Date: 22 March 2021 PY - 2011 SP - 82-91 ST - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community T2 - Journal of Cancer Survivorship TI - Engaging African American breast cancer survivors in an intervention trial: Culture, responsiveness and community UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79951720647&doi=10.1007%2fs11764-010-0150-x&partnerID=40&md5=29a2009d39565f94820bfbfad9fd558f VL - 5 ID - 2480 ER - TY - JOUR AB - Introduction Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African-American breast cancer survivors. Methods Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers. Results Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. Discusssion/Conclusions To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples' lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied. Implications for Cancer Survivors For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible. AN - WOS:000292469400010 AU - Germino, B. B. AU - Mishel, M. H. AU - Alexander, G. R. AU - Jenerette, C. AU - Blyler, D. AU - Baker, C. AU - Vines, A. I. AU - Green, M. AU - Long, D. G. DA - Mar DO - 10.1007/s11764-010-0150-x IS - 1 N1 - 20886374 PY - 2011 SN - 1932-2259 SP - 82-91 ST - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community T2 - Journal of Cancer Survivorship-Research and Practice TI - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community VL - 5 ID - 3099 ER - TY - JOUR AB - Introduction: Younger breast cancer survivors often lead extremely busy lives with multiple demands and responsibilities, making them difficult to recruit into clinical trials. African American women are even more difficult to recruit because of additional historical and cultural barriers. In a randomized clinical trial of an intervention, we successfully used culturally informed, population-specific recruitment and retention strategies to engage younger African-American breast cancer survivors.Methods: Caucasian and African American breast cancer survivors were recruited from multiple communities and sites. A variety of planned recruitment and retention strategies addressed cultural and population-specific barriers and were guided by three key principals: increasing familiarity with the study in the communities of interest; increasing the availability and accessibility of study information and study participation; and using cultural brokers.Results: Accrual of younger African-American breast cancer survivors increased by 373% in 11 months. The steepest rise in the numbers of African-American women recruited came when all strategies were in place and operating simultaneously. Retention rates were 87% for both Caucasian and African American women. DISCUSSSION/CONCLUSIONS: To successfully recruit busy, younger African American cancer survivors, it is important to use a multifaceted approach, addressing cultural and racial/ethnic barriers to research participation; bridging gaps across cultures and communities; including the role of faith and beliefs in considering research participation; recognizing the demands of different life stages and economic situations and the place of research in the larger picture of peoples' lives. Designs for recruitment and retention need to be broadly conceptualized and specifically applied.Implications For Cancer Survivors: For busy cancer survivors, willingness to participate in and complete research participation is enhanced by strategies that address barriers but also acknowledge the many demands on their time by making research familiar, available, accessible and credible. AD - School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC 27599, USA School of Nursing, University of North Carolina at Chapel Hill, CB# 7460, Chapel Hill, NC, 27599, USA, germino@email.unc.edu. AN - 104823782. Language: English. Entry Date: 20110624. Revision Date: 20200708. Publication Type: journal article AU - Germino, B. B. AU - Mishel, M. H. AU - Alexander, G. R. AU - Jenerette, C. AU - Blyler, D. AU - Baker, C. AU - Vines, A. I. AU - Green, M. AU - Long, D. G. AU - Germino, Barbara B. AU - Mishel, Merle H. AU - Alexander, G. Rumay AU - Jenerette, Coretta AU - Blyler, Diane AU - Baker, Carol AU - Vines, Anissa I. AU - Green, Melissa AU - Long, Debra G. DB - CINAHL Complete DO - 10.1007/s11764-010-0150-x DP - EBSCOhost IS - 1 KW - Black Persons -- Psychosocial Factors Breast Neoplasms -- Therapy Carcinoma -- Therapy Culture Patient Selection Clinical Trials Survivors -- Psychosocial Factors Black Persons -- Statistics and Numerical Data Breast Neoplasms -- Ethnology Breast Neoplasms -- Psychosocial Factors Breast Neoplasms -- Rehabilitation Carcinoma -- Ethnology Carcinoma -- Psychosocial Factors Carcinoma -- Rehabilitation Communication Barriers Counseling -- Methods Fear Female Health Services Accessibility Human Patient Attitudes Psychotherapy -- Methods Recurrence Residence Characteristics N1 - research. Journal Subset: Biomedical; USA. Grant Information: R01 NR010190-09/NR/NINR NIH HHS/United States. NLM UID: 101307557. PMID: NLM20886374. PY - 2011 SN - 1932-2259 SP - 82-91 ST - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community T2 - Journal of Cancer Survivorship TI - Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104823782&site=ehost-live&scope=site VL - 5 ID - 1938 ER - TY - JOUR AB - BACKGROUND: African American men (AAM) are under-represented in prostate cancer (PCa) research despite known disparities. Screening with prostate-specific antigen (PSA) has low specificity for high-grade PCa leading to PCa over diagnosis. The Prostate Health Index (PHI) has higher specificity for lethal PCa but needs validation in AAM. Engaging AAM as citizen scientists (CSs) may improve participation of AAM in PCa research.Results and Lessons Learned: Eight CSs completed all training modules and 139 AAM were recruited. Challenges included equity in research leadership among multiple principal investigators (PIs) and coordinating CSs trainings. CONCLUSIONS: Engaging AAM CSs can support engaging/recruiting AAM in PCa biomarker validation research. Equity among multiple stakeholders can be challenging, but proves beneficial in engaging AAM in research. OBJECTIVES: Assess feasibility of mobilizing CSs to recruit AAM as controls for PHI PCa validation biomarker study. METHODS: We highlight social networks/assets of stakeholders, CSs curriculum development/implementation, and recruitment of healthy controls for PHI validation. AU - Watson, K. S. AU - Henderson, V. AU - Murray, M. AU - Murphy, A. B. AU - Levi, J. B. AU - McDowell, T. AU - Holloway-Beth, A. AU - Gogana, P. AU - Dixon, M. A. AU - Moore, L. AU - Hall, I. AU - Kimbrough, A. AU - Molina, Y. AU - Winn, R. A. DB - Medline DO - 10.1353/cpr.2019.0043 IS - 5 KW - prostate specific antigen adult African American age blood community participation early cancer diagnosis human male middle aged motivation organization and management participatory research patient selection procedures prostate tumor social network socioeconomics LA - English M3 - Article N1 - L629022842 2019-08-29 2020-09-04 PY - 2019 SN - 1557-055X SP - 103-112 ST - Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress T2 - Progress in community health partnerships : research, education, and action TI - Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629022842&from=export http://dx.doi.org/10.1353/cpr.2019.0043 VL - 13 ID - 866 ER - TY - JOUR AB - Purpose: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. Design and Methods: We used a randomized trial design. Case managers contacted intervention group participants (n = 352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. Results: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p = .001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p = .011), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p = .012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. Implications: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain. Copyright 2006 by The Gerontological Society of America. AD - M.E. Ford, Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Charleston, SC 29425, United States AU - Ford, M. E. AU - Havstad, S. AU - Vernon, S. W. AU - Davis, S. D. AU - Kroll, D. AU - Lamerato, L. AU - Swanson, G. M. DB - Embase Medline DO - 10.1093/geront/46.4.545 IS - 4 KW - prostate specific antigen adult African American aged article cancer screening case management clinical trial colorectal cancer controlled clinical trial controlled study digital rectal examination elderly care human longitudinal study lowest income group lung cancer major clinical study male men's health patient compliance patient referral prostate cancer randomized controlled trial sigmoidoscopy teleconsultation thorax radiography LA - English M3 - Article N1 - L44384703 2006-09-21 PY - 2006 SN - 0016-9013 SP - 545-550 ST - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial T2 - Gerontologist TI - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44384703&from=export http://dx.doi.org/10.1093/geront/46.4.545 VL - 46 ID - 1242 ER - TY - JOUR AB - PURPOSE: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. DESIGN AND METHODS: We used a randomized trial design. Case managers contacted intervention group participants (n=352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. RESULTS: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate‐specific antigen test for prostate cancer (74.3% vs 53.0%, p=.001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p=.011), and (c) chest x‐ray for lung cancer (70.9% vs 51.3%, p=.012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate‐to‐high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. IMPLICATIONS: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain. AN - CN-00567415 AU - Ford, M. E. AU - Havstad, S. AU - Vernon, S. W. AU - Davis, S. D. AU - Kroll, D. AU - Lamerato, L. AU - Swanson, G. M. DO - 10.1093/geront/46.4.545 IS - 4 KW - African Americans Aged Aged, 80 and over Case Management Clinical Trials as Topic Culture Humans Male Mass Screening Middle Aged Neoplasms [*prevention & control] Patient Compliance [*psychology] Patient Dropouts [*psychology] Patient Selection Poverty Social Support Social Work Telephone M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S.; Research Support, U.S. Gov't, P.H.S. PY - 2006 SP - 545‐550 ST - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial T2 - Gerontologist TI - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00567415/full VL - 46 ID - 1348 ER - TY - JOUR AB - Purpose: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. Design and Methods: We used a randomized trial design. Case managers contacted intervention group participants (n = 352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. Results: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p = .001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p = .01 1), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p = .012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. Implications: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ford, Marvella E., Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Suite 303, P.O. Box 250835, Charleston, SC, US, 29425 AN - 2006-11886-015 AU - Ford, Marvella E. AU - Havstad, Suzanne AU - Vernon, Sally W. AU - Davis, Shawna D. AU - Kroll, David AU - Lamerato, Lois AU - Swanson, G. Marie DB - psyh DO - 10.1093/geront/46.4.545 DP - EBSCOhost IS - 4 KW - older African American men cancer screening trial case management adherence African Americans Aged Aged, 80 and over Clinical Trials as Topic Culture Humans Male Mass Screening Middle Aged Neoplasms Patient Compliance Patient Dropouts Patient Selection Poverty Social Support Social Work Telephone Blacks Cancer Screening Compliance Human Males N1 - Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC, US. Other Publishers: Oxford University Press. Release Date: 20070312. Correction Date: 20131202. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Case Management; Compliance; Human Males. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: Aug, 2006. Sponsor: Centers for Disease Control and Prevention/National Cancer Institute. Grant: NO1-CN-25512. Recipients: No recipient indicated Sponsor: US Department of Defense, US. Grant: DAMD 17-96-1-6246. Recipients: No recipient indicated Sponsor: US Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, US. Grant: RES 02-235. Recipients: No recipient indicated Sponsor: National Institutes of Health, R24 EXPORT Center, METRIC Resource Center. Grant: RFA-MD-04-002. Recipients: No recipient indicated Sponsor: National Institutes of Health. Grant: 1 P30 AG 21677. Recipients: No recipient indicated PY - 2006 SN - 0016-9013 1758-5341 SP - 545-550 ST - Enhancing Adherence Among Older African American Men Enrolled in a Longitudinal Cancer Screening Trial T2 - The Gerontologist TI - Enhancing Adherence Among Older African American Men Enrolled in a Longitudinal Cancer Screening Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-11886-015&site=ehost-live&scope=site fordmar@musc.edu VL - 46 ID - 1709 ER - TY - JOUR AB - Purpose: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. Design and Methods: We used a randomized trial design. Case managers contacted intervention group participants (n = 352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. Results: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p = .001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p = .011), and (c) chest x-ray for lung cancer (70.9% vs 51.3%, p = .012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. Implications: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain. Copyright 2006 by The Gerontological Society of America. AD - Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, 135 Cannon Street, Charleston, SC 29425, United States Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC, United States Department of Biostatistics and Research Epidemiology, Henry Ford Health Sciences Center, Detroit, MI, United States Division of Health Promotion and Behavioral Sciences, School of Public Health, University of Texas Health Sciences Center, Houston, TX, United States Department of Medicine and Section of Health Services Research, Baylor College of Medicine Veterans Affairs Medical Center, Houston, TX, United States Josephine Ford Cancer Center, Henry Ford Health Sciences Center, Detroit, MI, United States Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States AU - Ford, M. E. AU - Havstad, S. AU - Vernon, S. W. AU - Davis, S. D. AU - Kroll, D. AU - Lamerato, L. AU - Swanson, G. M. DB - Scopus DO - 10.1093/geront/46.4.545 IS - 4 KW - African American men Cancer screening Case management M3 - Article N1 - Cited By :21 Export Date: 22 March 2021 PY - 2006 SP - 545-550 ST - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial T2 - Gerontologist TI - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33748649868&doi=10.1093%2fgeront%2f46.4.545&partnerID=40&md5=da452121a11cb5cc2712e5875411515f VL - 46 ID - 2583 ER - TY - JOUR AB - Purpose: The purpose of this study was to enhance adherence among older (aged 55 years and older) African American men enrolled in a cancer screening trial for prostate, lung, and colorectal cancer. For this study, we defined adherence as completing the trial screenings. Design and Methods: We used a randomized trial design. Case managers contacted intervention group participants (n = 352) at least monthly by telephone and provided information and referral services. The control group included 351 participants. Results: Among participants with low income, those in the intervention group had higher screening adherence rates than did participants in the control group for (a) prostate-specific antigen test for prostate cancer (74.3% vs 53.0%, p=.001), (b) digital rectal exam for prostate cancer (66.2% vs 46.1%, p=.011), and (c) chestx-ray for lung cancer (70.9% vs 51.3%, p =.012). We found no statistically significant differences in adherence rates for flexible sigmoidoscopy screening for colorectal cancer. In contrast, among participants with moderate-to-high income, we found no statistically significant differences in adherence rates between intervention and control group participants for any of the screening tests. implications: The case management intervention was effective in enhancing adherence among participants with the lowest income, who in many studies are the most difficult to retain. AN - WOS:000239941000015 AU - Ford, M. E. AU - Havstad, S. AU - Vernon, S. W. AU - Davis, S. D. AU - Kroll, D. AU - Lamerato, L. AU - Swanson, G. M. DA - Aug DO - 10.1093/geront/46.4.545 IS - 4 N1 - 16921009 PY - 2006 SN - 0016-9013 SP - 545-550 ST - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial T2 - Gerontologist TI - Enhancing adherence among older African American men enrolled in a longitudinal cancer screening trial VL - 46 ID - 3214 ER - TY - JOUR AB - Research suggests that community involvement is integral to solving public health problems, including involvement in clinical trials - a gold standard. Significant racial/ethnic disparities exist in the accrual of participants for clinical trials. Location and cultural aspects of clinical trials influence recruitment and accrual to clinical trials. It is increasingly necessary to be aware of defining characteristics, such as location and culture of the populations from which research participants are enrolled. Little research has examined the effect of location and cultural competency in adapting clinical trial research for minority and underserved communities on accrual for clinical trials. Utilizing embedded community academic sites, the authors applied cultural competency frameworks to adapt clinical trial research in order to increase minority participation in nontherapeutic cancer clinical trials. This strategy resulted in successful accrual of participants to new clinical research trials, specifically targeting participation from minority and underserved communities in metropolitan Washington, DC. From 2012 to 2014, a total of 559 participants enrolled across six nontherapeutic clinical trials, representing a 62% increase in the enrollment of blacks in clinical research. Embedding cancer prevention programs and research in the community was shown to be yet another important strategy in the arsenal of approaches that can potentially enhance clinical research enrollment and capacity. The analyses showed that the capacity to acquire cultural knowledge about patients - their physical locales, cultural values, and environments in which they live - is essential to recruiting culturally and ethnically diverse population samples. © 2016 American Journal of Preventive Medicine. AD - GeorgetownLombardi Comprehensive Cancer Center, Research Building, E501, 3970 Reservoir Road, N.W., Washington, DC 20057, United States National Center for Cultural Competence, Department of Pediatrics, Georgetown University Medical Center, Washington, DC, United States Georgetown University Medical Center, Department of Surgery, Washington, DC, United States AU - Wallington, S. F. AU - Dash, C. AU - Sheppard, V. B. AU - Goode, T. D. AU - Oppong, B. A. AU - Dodson, E. E. AU - Hamilton, R. N. AU - Adams-Campbell, L. L. DB - Scopus DO - 10.1016/j.amepre.2015.07.036 IS - 1 M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2016 SP - 111-117 ST - Enrolling Minority and Underserved Populations in Cancer Clinical Research T2 - American Journal of Preventive Medicine TI - Enrolling Minority and Underserved Populations in Cancer Clinical Research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952629796&doi=10.1016%2fj.amepre.2015.07.036&partnerID=40&md5=0aed007d38ceabc3aa418f8ab8614d1c VL - 50 ID - 2351 ER - TY - JOUR AB - PURPOSE: To determine the effect of patient, protocol, geographic, and institutional factors on enrollment of older persons onto cancer trials. METHODS: We conducted a cross-sectional analysis of patients enrolled onto National Cancer Institute-sponsored lung, breast, colorectal, and prostate cancer trials during 1996 to 2002. We used a cross-classified logistic multilevel model to examine the associations between patient, hospital, county, and protocol characteristics, and the likelihood of participants being elderly (>or= 65 years old). RESULTS: The final study sample consisted of 36,167 patients enrolled onto 33 trials. After accounting for cancer type, only 6% of the variation in elderly enrollment onto cancer trials was at the protocol level. In contrast, more than 55% of the variation in elderly enrollment was attributable to patient level variation. In multivariate analysis, nonwhite patients were significantly less likely to be elderly than whites (odds ratio [OR] for blacks, 0.51; 95% CI, 0.44 to 0.58; and OR for Hispanics, 0.49; 95% CI, 0.40 to 0.59 v whites). Participants living less than 7 miles from their recruitment center were significantly more likely to be elderly (OR, 1.31; 95% CI, 1.24 to 1.38). Among the 910 recruitment centers, the median adjusted proportion of patients who were elderly was 24.9% (interquartile range, 24.0% to 26.9%). There were a significantly higher number of outlier centers (or= 29.3% elderly) than would be expected by a normal distribution (68 observed v six expected; P < .0001). CONCLUSION: Race and proximity to trial enrollment centers were significantly related to age of trial participants after adjusting for protocol factors. Additional work should explore why some recruitment centers were outliers regarding enrollment of older persons. AD - Sections of General Internal Medicine and Cardiovascular Medicine, Department of Medicine, Robert Wood Johnson Clinical Scholars Program, Department of Epidermiology and Public Health; cary.gross@yale.edu AN - 106426954. Language: English. Entry Date: 20060414. Revision Date: 20150711. Publication Type: Journal Article AU - Gross, C. P. AU - Herrin, J. AU - Wong, N. AU - Krumholz, H. M. DB - CINAHL Complete DP - EBSCOhost IS - 21 KW - Research Subject Recruitment -- In Old Age Geographic Factors Socioeconomic Factors Neoplasms -- Therapy Cross Sectional Studies Chi Square Test Odds Ratio Confidence Intervals Multivariate Analysis Aged Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Cancer Prevention, Control and Population Sciences Career Development Award (1K07CA-90402), a Beeson Career Development Award (1 K08 AG24842), and the Claude D. Pepper Older Americans Independence Center at Yale (P30AG21342). NLM UID: 8309333. PMID: NLM16034051. PY - 2005 SN - 0732-183X SP - 4755-4763 ST - Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics T2 - Journal of Clinical Oncology TI - Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106426954&site=ehost-live&scope=site VL - 23 ID - 1939 ER - TY - JOUR AB - Purpose: To determine the effect of patient, protocol, geographic, and institutional factors on enrollment of older persons onto cancer trials. Methods: We conducted a cross-sectional analysis of patients enrolled onto National Cancer Institute-sponsored lung, breast, colorectal, and prostate cancer trials during 1996 to 2002. We used a cross-classified logistic multilevel model to examine the associations between patient, hospital, county, and protocol characteristics, and the likelihood of participants being elderly (≥ 65 years old). Results: The final study sample consisted of 36,167 patients enrolled onto 33 trials. After accounting for cancer type, only 6% of the variation in elderly enrollment onto cancer trials was at the protocol level. In contrast, more than 55% of the variation in elderly enrollment was attributable to patient level variation. In multivariate analysis, nonwhite patients were significantly less likely to be elderly than whites (odds ratio [OR] for blacks, 0.51; 95% CI, 0.44 to 0.58; and OR for Hispanics, 0.49; 95% CI, 0.40 to 0.59 y whites). Participants living less than 7 miles from their recruitment center were significantly more likely to be elderly (OR, 1.31; 95% CI, 1.24 to 1.38). Among the 910 recruitment centers, the median adjusted proportion of patients who were elderly was 24.9% (interquartile range, 24.0% to 26.9%). There were a significantly higher number of outlier centers (≤ 20.8% or > 29.3% elderly) than would be expected by a normal distribution (68 observed v six expected; P < .0001). Conclusion: Race and proximity to trial enrollment centers were significantly related to age of trial participants after adjusting for protocol factors. Additional work should explore why some recruitment centers were outliers regarding enrollment of older persons. © 2005 by American Society of Clinical Oncology. AD - Sections of General Internal Medicine and Cardiovascular Medicine; Department of Medicine, Robert Wood Johnson Clinical Scholars Program; Department of Epidemiology and Public Health; Yale University School of Medicine, New Haven, CT; and Flying Buttress Associates, Charlottesville, VA AU - Gross, C. P. AU - Herrin, J. AU - Wong, N. AU - Krumholz, H. M. DB - Scopus DO - 10.1200/JCO.2005.14.365 IS - 21 M3 - Article N1 - Cited By :69 Export Date: 22 March 2021 PY - 2005 SP - 4755-4763 ST - Enrolling older persons in cancer trials: The effect of sociodemographic, protocol, and recruitment center characteristics T2 - Journal of Clinical Oncology TI - Enrolling older persons in cancer trials: The effect of sociodemographic, protocol, and recruitment center characteristics UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-23044505584&doi=10.1200%2fJCO.2005.14.365&partnerID=40&md5=11fd35aa8bb49276d9c6a329f632c93c VL - 23 ID - 2588 ER - TY - JOUR AB - Purpose To determine the effect of patient, protocol, geographic, and institutional factors on enrollment of older persons onto cancer trials. Methods We conducted a cross-sectional analysis of patients enrolled onto National Cancer Institute-sponsored lung, breast, colorectal, and prostate cancer trials during 1996 to 2002. We used a cross-classified logistic multilevel model to examine the associations between patient, hospital, county, and protocol characteristics, and the likelihood of participants being elderly (>= 65 years old). Results The final study sample consisted of 36,167 patients enrolled onto 33 trials. After accounting for cancer type, only 6% of the variation in elderly enrollment onto cancer trials was at the protocol level. In contrast, more than 55% of the variation in elderly enrollment was attributable to patient level variation. In multivariate analysis, nonwhite patients were significantly less likely to be elderly than whites (odds ratio [OR] for blacks, 0.51; 95% Cl, 0.44 to 0.58; and OR for Hispanics, 0.49; 95% Cl, 0.40 to 0.59 v whites). Participants living less than 7 miles from their recruitment center were significantly more likely to be elderly (OR, 1.31; 95% Cl, 1.24 to 1.38). Among the 910 recruitment centers, the median adjusted proportion of patients who were elderly was 24.9% (interquartile range, 24.0% to 26.9%). There were a significantly higher number of outlier centers (<= 20.8% or >= 29.3% elderly) than would be expected by a normal distribution (68 observed v six expected; P <.0001). Conclusion Race and proximity to trial enrollment centers were significantly related to age of trial participants after adjusting for protocol factors. Additional work should explore why some recruitment centers were outliers regarding enrollment of older persons. AN - WOS:000230872000027 AU - Gross, C. P. AU - Herrin, J. AU - Wong, N. AU - Krumholz, H. M. DA - Jul DO - 10.1200/JCO.2005.14.365 IS - 21 N1 - 16034051 PY - 2005 SN - 0732-183X SP - 4755-4763 ST - Enrolling older persons in cancer trials: The effect of sociodemographic, protocol, and recruitment center characteristics T2 - Journal of Clinical Oncology TI - Enrolling older persons in cancer trials: The effect of sociodemographic, protocol, and recruitment center characteristics VL - 23 ID - 3237 ER - TY - JOUR AB - Purpose: Racial/ethnic minorities are often assumed to be less willing to participate in and provide biospecimens for biomedical research. We examined racial/ethnic differences in enrollment of women with breast cancer (probands) and their first-degree relatives in the Northern California site of the Breast Cancer Family Registry from 1996 to 2011. Methods: We evaluated participation in several study components, including biospecimen collection, for probands and relatives by race/ethnicity, cancer history, and other factors. Results: Of 4,780 eligible probands, 76% enrolled in the family registry by completing the family history and risk factor questionnaires and 68% also provided a blood or mouthwash sample. Enrollment was highest (81%) for non-Hispanic whites (NHWs) and intermediate (73–76%) for Hispanics, African Americans, and all Asian American subgroups, except Filipina women (66%). Of 4,279 eligible relatives, 77% enrolled in the family registry, and 65% also provided a biospecimen sample. Enrollment was highest for NHWs (87%) and lowest for Chinese (68%) and Filipinas (67%). Among those enrolled, biospecimen collection rates were similar for NHW, Hispanic, and African American women, both for probands (92–95%) and relatives (82–87%), but lower for some Asian–American subgroups (probands: 72–88%; relatives: 71–88%), foreign-born Asian Americans, and probands those who were more recent immigrants or had low English language proficiency. Conclusions: These results show that racial/ethnic minority populations are willing to provide biospecimen samples for research, although some Asian American subgroups in particular may need more directed recruitment methods. To address long-standing and well-documented cancer health disparities, minority populations need equal opportunities to contribute to biomedical research. AD - E.M. John, Stanford Cancer Institute, 780 Welch Road, Suite CJ250C, Stanford, CA, United States AU - John, E. M. AU - Sangaramoorthy, M. AU - Koo, J. AU - Whittemore, A. S. AU - West, D. W. DB - Embase Medline DO - 10.1007/s10552-019-01154-6 IS - 4 KW - adult African American article Asian American biobank birthplace blood sampling breast cancer California cancer registry cancer risk Caucasian Chinese cohort analysis controlled study English (language) ethnic difference family history family study female Filipino (people) first-degree relative Hispanic human human tissue immigrant language ability major clinical study oncological parameters priority journal questionnaire race difference risk factor risk factor questionnaire LA - English M3 - Article N1 - L626707234 2019-03-14 2019-05-14 PY - 2019 SN - 1573-7225 0957-5243 SP - 395-408 ST - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry T2 - Cancer Causes and Control TI - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626707234&from=export http://dx.doi.org/10.1007/s10552-019-01154-6 VL - 30 ID - 849 ER - TY - JOUR AB - Purpose: Racial/ethnic minorities are often assumed to be less willing to participate in and provide biospecimens for biomedical research. We examined racial/ethnic differences in enrollment of women with breast cancer (probands) and their first-degree relatives in the Northern California site of the Breast Cancer Family Registry from 1996 to 2011.Methods: We evaluated participation in several study components, including biospecimen collection, for probands and relatives by race/ethnicity, cancer history, and other factors.Results: Of 4,780 eligible probands, 76% enrolled in the family registry by completing the family history and risk factor questionnaires and 68% also provided a blood or mouthwash sample. Enrollment was highest (81%) for non-Hispanic whites (NHWs) and intermediate (73-76%) for Hispanics, African Americans, and all Asian American subgroups, except Filipina women (66%). Of 4,279 eligible relatives, 77% enrolled in the family registry, and 65% also provided a biospecimen sample. Enrollment was highest for NHWs (87%) and lowest for Chinese (68%) and Filipinas (67%). Among those enrolled, biospecimen collection rates were similar for NHW, Hispanic, and African American women, both for probands (92-95%) and relatives (82-87%), but lower for some Asian-American subgroups (probands: 72-88%; relatives: 71-88%), foreign-born Asian Americans, and probands those who were more recent immigrants or had low English language proficiency.Conclusions: These results show that racial/ethnic minority populations are willing to provide biospecimen samples for research, although some Asian American subgroups in particular may need more directed recruitment methods. To address long-standing and well-documented cancer health disparities, minority populations need equal opportunities to contribute to biomedical research. AD - Cancer Prevention Institute of California, 94358, Fremont, CA, USA Department of Medicine, Division of Oncology, Stanford University School of Medicine, 94304, Stanford, CA, USA Stanford Cancer Institute, Stanford University School of Medicine, 94304, Stanford, CA, USA Stanford Cancer Institute, 780 Welch Road, Suite CJ250C, 94304-5769, Stanford, CA, USA Department of Health Research and Policy, Stanford University of School of Medicine, 94305, Stanford, CA, USA Department of Biomedical Data Science, Stanford University of School of Medicine, 94305, Stanford, CA, USA AN - 135841769. Language: English. Entry Date: 20190607. Revision Date: 20200403. Publication Type: journal article AU - John, Esther M. AU - Sangaramoorthy, Meera AU - Koo, Jocelyn AU - Whittemore, Alice S. AU - West, Dee W. DB - CINAHL Complete DO - 10.1007/s10552-019-01154-6 DP - EBSCOhost IS - 4 KW - Population Breast Neoplasms -- Epidemiology California Risk Factors Young Adult Breast Neoplasms -- Ethnology Middle Age White Persons -- Statistics and Numerical Data Asians -- Statistics and Numerical Data Adult Data Collection Adolescence Black Persons -- Statistics and Numerical Data Female Hispanic Americans -- Statistics and Numerical Data Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Continental Europe; Europe. Grant Information: U58 DP000807/DP/NCCDPHP CDC HHS/United States. NLM UID: 9100846. PMID: NLM30835011. PY - 2019 SN - 0957-5243 SP - 395-408 ST - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry T2 - Cancer Causes & Control TI - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135841769&site=ehost-live&scope=site VL - 30 ID - 1940 ER - TY - JOUR AB - Purpose: Racial/ethnic minorities are often assumed to be less willing to participate in and provide biospecimens for biomedical research. We examined racial/ethnic differences in enrollment of women with breast cancer (probands) and their first-degree relatives in the Northern California site of the Breast Cancer Family Registry from 1996 to 2011. Methods: We evaluated participation in several study components, including biospecimen collection, for probands and relatives by race/ethnicity, cancer history, and other factors. Results: Of 4,780 eligible probands, 76% enrolled in the family registry by completing the family history and risk factor questionnaires and 68% also provided a blood or mouthwash sample. Enrollment was highest (81%) for non-Hispanic whites (NHWs) and intermediate (73–76%) for Hispanics, African Americans, and all Asian American subgroups, except Filipina women (66%). Of 4,279 eligible relatives, 77% enrolled in the family registry, and 65% also provided a biospecimen sample. Enrollment was highest for NHWs (87%) and lowest for Chinese (68%) and Filipinas (67%). Among those enrolled, biospecimen collection rates were similar for NHW, Hispanic, and African American women, both for probands (92–95%) and relatives (82–87%), but lower for some Asian–American subgroups (probands: 72–88%; relatives: 71–88%), foreign-born Asian Americans, and probands those who were more recent immigrants or had low English language proficiency. Conclusions: These results show that racial/ethnic minority populations are willing to provide biospecimen samples for research, although some Asian American subgroups in particular may need more directed recruitment methods. To address long-standing and well-documented cancer health disparities, minority populations need equal opportunities to contribute to biomedical research. © 2019, Springer Nature Switzerland AG. AD - Cancer Prevention Institute of California, Fremont, CA 94358, United States Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94304, United States Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304, United States Department of Health Research and Policy, Stanford University of School of Medicine, Stanford, CA 94305, United States Department of Biomedical Data Science, Stanford University of School of Medicine, Stanford, CA 94305, United States Stanford Cancer Institute, 780 Welch Road, Suite CJ250C, Stanford, CA 94304-5769, United States AU - John, E. M. AU - Sangaramoorthy, M. AU - Koo, J. AU - Whittemore, A. S. AU - West, D. W. DB - Scopus DO - 10.1007/s10552-019-01154-6 IS - 4 KW - African Americans Asian Americans Biospecimen collection Breast cancer Epidemiology Hispanics Race/ethnicity Study participation M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2019 SP - 395-408 ST - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry T2 - Cancer Causes and Control TI - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062677578&doi=10.1007%2fs10552-019-01154-6&partnerID=40&md5=be92c6a269582018fb711a95185cc895 VL - 30 ID - 2232 ER - TY - JOUR AB - Purpose Racial/ethnic minorities are often assumed to be less willing to participate in and provide biospecimens for biomedical research. We examined racial/ethnic differences in enrollment of women with breast cancer (probands) and their first-degree relatives in the Northern California site of the Breast Cancer Family Registry from 1996 to 2011. Methods We evaluated participation in several study components, including biospecimen collection, for probands and relatives by race/ethnicity, cancer history, and other factors. Results Of 4,780 eligible probands, 76% enrolled in the family registry by completing the family history and risk factor questionnaires and 68% also provided a blood or mouthwash sample. Enrollment was highest (81%) for non-Hispanic whites (NHWs) and intermediate (73-76%) for Hispanics, African Americans, and all Asian American subgroups, except Filipina women (66%). Of 4,279 eligible relatives, 77% enrolled in the family registry, and 65% also provided a biospecimen sample. Enrollment was highest for NHWs (87%) and lowest for Chinese (68%) and Filipinas (67%). Among those enrolled, biospecimen collection rates were similar for NHW, Hispanic, and African American women, both for probands (92-95%) and relatives (82-87%), but lower for some Asian-American subgroups (probands: 72-88%; relatives: 71-88%), foreign-born Asian Americans, and probands those who were more recent immigrants or had low English language proficiency. Conclusions These results show that racial/ethnic minority populations are willing to provide biospecimen samples for research, although some Asian American subgroups in particular may need more directed recruitment methods. To address long-standing and well-documented cancer health disparities, minority populations need equal opportunities to contribute to biomedical research. AN - WOS:000464841100010 AU - John, E. M. AU - Sangaramoorthy, M. AU - Koo, J. AU - Whittemore, A. S. AU - West, D. W. DA - Apr DO - 10.1007/s10552-019-01154-6 IS - 4 N1 - 30835011 PY - 2019 SN - 0957-5243 SP - 395-408 ST - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry T2 - Cancer Causes & Control TI - Enrollment and biospecimen collection in a multiethnic family cohort: the Northern California site of the Breast Cancer Family Registry VL - 30 ID - 2827 ER - TY - JOUR AB - Background: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. Methods: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. Results: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. Conclusion: Significant efforts were made to recruit racial/ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas. AD - P. F. Pinsky, EPN 3064, 6130 Executive Blvd., Bethesda, MD 20892, United States AU - Pinsky, P. F. AU - Ford, M. AU - Gamito, E. AU - Higgins, D. AU - Jenkins, V. AU - Lamerato, L. AU - Tenorio, S. AU - Marcus, P. M. AU - Gohagan, J. K. DB - Embase Medline DO - 10.1016/S0027-9684(15)31241-4 IS - 3 KW - academic achievement adult age distribution aged article Asian cancer center cancer prevention cancer screening clinical trial colorectal cancer controlled clinical trial controlled study demography ethnic group exercise experience female Hispanic human lung cancer major clinical study male multicenter study ovary cancer priority journal prostate cancer randomized controlled trial screening test smoking LA - English M3 - Article N1 - L351441236 2008-04-15 PY - 2008 SN - 0027-9684 SP - 291-298 ST - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial T2 - Journal of the National Medical Association TI - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351441236&from=export http://dx.doi.org/10.1016/S0027-9684(15)31241-4 VL - 100 ID - 1215 ER - TY - JOUR AB - BACKGROUND: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. METHODS: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. RESULTS: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age‐eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age‐eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age‐eligibles. Blacks, Hispanics and (non‐Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. CONCLUSION: Significant efforts were made to recruit racial/ ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age‐eligibles in the overall U.S. population or in the aggregate PLCO catchment areas. AN - CN-00631172 AU - Pinsky, P. F. AU - Ford, M. AU - Gamito, E. AU - Higgins, D. AU - Jenkins, V. AU - Lamerato, L. AU - Tenorio, S. AU - Marcus, P. M. AU - Gohagan, J. K. DO - 10.1016/s0027-9684(15)31241-4 IS - 3 KW - African Americans [statistics & numerical data] Aged Asian Americans [statistics & numerical data] Attitude to Health Colorectal Neoplasms [*diagnosis, epidemiology] Ethnic Groups [*statistics & numerical data] European Continental Ancestry Group [statistics & numerical data] Female Hispanic Americans [statistics & numerical data] Humans Lung Neoplasms [*diagnosis, epidemiology] Male Mass Screening Middle Aged Minority Health Ovarian Neoplasms [*diagnosis, epidemiology] Patient Acceptance of Health Care Patient Satisfaction Patient Selection Prostatic Neoplasms [*diagnosis, epidemiology] United States [epidemiology] M3 - Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial PY - 2008 SP - 291‐298 ST - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial T2 - Journal of the National Medical Association TI - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00631172/full VL - 100 ID - 1347 ER - TY - JOUR AB - Background: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. Methods: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. Results: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. Conclusion: Significant efforts were made to recruit racial/ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas. AD - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States Henry Ford Health System, Detroit, MI, United States University of Colorado Health Sciences Center, Denver, CO, United States University of Alabama at Birmingham, Birmingham, AL, United States Pacific Health Research Institute, Honolulu, HI, United States EPN 3064, 6130 Executive Blvd., Bethesda, MD 20892, United States AU - Pinsky, P. F. AU - Ford, M. AU - Gamito, E. AU - Higgins, D. AU - Jenkins, V. AU - Lamerato, L. AU - Tenorio, S. AU - Marcus, P. M. AU - Gohagan, J. K. DB - Scopus DO - 10.1016/S0027-9684(15)31241-4 IS - 3 KW - African Americans Cancer Clinical investigation Latinos Screening M3 - Article N1 - Cited By :60 Export Date: 22 March 2021 PY - 2008 SP - 291-298 ST - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial T2 - Journal of the National Medical Association TI - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-41149122683&doi=10.1016%2fS0027-9684%2815%2931241-4&partnerID=40&md5=c5fba983c6b277956cdbb8bd2b4227f9 VL - 100 ID - 2541 ER - TY - JOUR AB - Background: minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial. Methods: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics. Results: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population. Conclusion: Significant efforts were made to recruit racial/ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas. AN - WOS:000254549500003 AU - Pinsky, P. F. AU - Ford, M. AU - Gamito, E. AU - Higgins, D. AU - Jenkins, V. AU - Lamerato, L. AU - Tenorio, S. AU - Marcus, P. M. AU - Gohagan, J. K. DA - Mar DO - 10.1016/S0027-9684(15)31241-4 IS - 3 N1 - 18390022 PY - 2008 SN - 0027-9684 SP - 291-298 ST - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial T2 - Journal of the National Medical Association TI - Enrollment of racial and ethnic minorities in the prostate, lung, colorectal and ovarian cancer screening trial VL - 100 ID - 3174 ER - TY - JOUR AB - Background: Minority populations in the United States, especially blacks and Hispanics, are generally underrepresented among participants in clinical trials. Here, we report the experience of enrolling ethnic minorities in a large cancer screening trial.Methods: The Prostate, Colorectal, Lung and Ovarian (PLCO) Cancer Screening Trial is a multicenter randomized trial designed to evaluate the effectiveness of screening for the PLCO cancers. Subjects were recruited at 10 U.S. centers between 1993 and 2001. One screening center had a major special recruitment effort for blacks and another center had a major special recruitment effort for Hispanics.Results: Among almost 155,000 subjects enrolled in PLCO, minority enrollment was as follows: black (5.0%), Hispanic (1.8%) and Asian (3.6%). This compares to an age-eligible population in the combined catchment areas of the PLCO centers that was 14.0% black, 2.9% Hispanic and 5.4% Asian, and an age-eligible population across the U.S. that was 9.5% black, 6.5% Hispanic and 3.0% Asian. About half (45%) of Hispanics were recruited at the center with the special Hispanic recruitment effort. Seventy percent of blacks were recruited at two centers; the one with the major special recruitment effort and a center in Detroit whose catchment area was 20% black among age-eligibles. Blacks, Hispanics and (non-Hispanic) whites were all more highly educated, less likely to currently smoke and more likely to get regular exercise than their counterparts in the general population.Conclusion: Significant efforts were made to recruit racial/ ethnic minorities into PLCO, and these efforts resulted in enrollment levels that were comparable to those seen in many recent cancer screening or prevention trials. Blacks and Hispanics were nonetheless underrepresented in PLCO compared to their levels among age-eligibles in the overall U.S. population or in the aggregate PLCO catchment areas. AD - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA. pp4f@nih.gov AN - 105725765. Language: English. Entry Date: 20080523. Revision Date: 20190612. Publication Type: journal article AU - Pinsky, P. F. AU - Ford, M. AU - Gamito, E. AU - Higgins, D. AU - Jenkins, V. AU - Lamerato, L. AU - Tenorio, S. AU - Marcus, P. M. AU - Gohagan, J. K. AU - Pinsky, Paul F. AU - Ford, Marvella AU - Gamito, Eduard AU - Higgins, Darlene AU - Jenkins, Victoria AU - Lamerato, Lois AU - Tenorio, Sally AU - Marcus, Pamela M. AU - Gohagan, John K. DB - CINAHL Complete DP - EBSCOhost IS - 3 KW - Colorectal Neoplasms -- Diagnosis Ethnic Groups -- Statistics and Numerical Data Health Screening Lung Neoplasms -- Diagnosis Ovarian Neoplasms -- Diagnosis Patient Selection Prostatic Neoplasms -- Diagnosis Aged Asians -- Statistics and Numerical Data Attitude to Health Black Persons -- Statistics and Numerical Data Clinical Trials Colorectal Neoplasms -- Epidemiology Female Hispanic Americans -- Statistics and Numerical Data Lung Neoplasms -- Epidemiology Male Middle Age Ovarian Neoplasms -- Epidemiology Patient Attitudes Patient Satisfaction Prostatic Neoplasms -- Epidemiology United States White Persons -- Statistics and Numerical Data Human N1 - clinical trial; research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 7503090. PMID: NLM18390022. PY - 2008 SN - 0027-9684 SP - 291-298 ST - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial T2 - Journal of the National Medical Association TI - Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105725765&site=ehost-live&scope=site VL - 100 ID - 1942 ER - TY - JOUR AB - Minority U.S. populations are underrepresented in cancer clinical trials. This review appraises the impact of the disparity in clinical trial participation by minority patients in the current era of cancer immunotherapy. Enrollment on pivotal trials leading to U.S. regulatory approval of immune checkpoint inhibitors showed poor representation of minority ethnic groups. Specifically, we found that black patients constitute less than 4% of all patients enrolled across multiple trials that supported the approval of immune checkpoint inhibitors for the treatment of lung cancer. Similar underrepresentation was observed for trials conducted in renal cell carcinoma and other tumor types. Since efficacy of immunotherapy is only observed in a subset of patients, the use of predictive biomarkers to identify responders along with new strategies to expand the benefit to a larger subset of patients are current areas of active investigation. The inadequate representation of minority patients on immunotherapy clinical trials could perpetuate outcome disparity because the unique biology of the host and the tumors from this subpopulation is not accounted for as new treatment algorithms to guide optimal use of immunotherapy are developed for use in the real world. AD - T.K. Owonikoko, Department of Hematology and Medical Oncology, Emory University, School of Medicine, 1365 Clifton Rd., Atlanta, GA, United States AU - Nazha, B. AU - Mishra, M. AU - Pentz, R. AU - Owonikoko, T. K. DB - Embase Medline DO - 10.1200/EDBK_100021 KW - article cancer immunotherapy clinical trial (topic) human malignant neoplasm minority group priority journal race difference LA - English M3 - Article N1 - L2003676048 2019-11-12 2019-11-20 PY - 2019 SN - 1548-8756 1548-8748 SP - 3-10 ST - Enrollment of racial minorities in clinical trials: Old problem assumes new urgency in the age of immunotherapy T2 - American Society of Clinical Oncology Educational Book TI - Enrollment of racial minorities in clinical trials: Old problem assumes new urgency in the age of immunotherapy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003676048&from=export http://dx.doi.org/10.1200/EDBK_100021 VL - 39 ID - 862 ER - TY - JOUR AB - Purpose: Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods: We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results: Enrollment disparity for patients ≥ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P = .020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 (P = .714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P = .020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion: Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer. AD - X. Wang, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, 2424 Erwin Rd, Durham, NC, United States AU - Pang, H. H. AU - Wang, X. AU - Stinchcombe, T. E. AU - Wong, M. L. AU - Cheng, P. AU - Ganti, A. K. AU - Sargent, D. J. AU - Zhang, Y. AU - Hu, C. AU - Mandrekar, S. J. AU - Redman, M. W. AU - Manola, J. B. AU - Schilsky, R. L. AU - Cohen, H. J. AU - Bradley, J. D. AU - Adjei, A. A. AU - Gandara, D. AU - Ramalingam, S. S. AU - Vokes, E. E. DB - Embase Medline DO - 10.1200/JCO.2016.67.7088 IS - 33 KW - age aged article Asian Black person cancer registry clinical trial (topic) comparative study ethnic group ethnicity female health care disparity Hispanic human lung cancer major clinical study male non small cell lung cancer oncological parameters overall survival priority journal race senescence sensitivity analysis sex small cell lung cancer trend study United States LA - English M3 - Article N1 - L613176191 2016-11-18 2016-12-06 PY - 2016 SN - 1527-7755 0732-183X SP - 3992-3999 ST - Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012 T2 - Journal of Clinical Oncology TI - Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613176191&from=export http://dx.doi.org/10.1200/JCO.2016.67.7088 VL - 34 ID - 957 ER - TY - JOUR AB - Purpose: Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods: We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results: Enrollment disparity for patients ≥ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P = .020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 (P = .714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P = .020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion: Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer. © 2016 by American Society of Clinical Oncology. AD - School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong Department of Biostatistics and Bioinformatics, Duke University School of Medicine, 2424 Erwin Rd, Durham, NC 27705, United States Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States University of California, Davis Comprehensive Cancer Center, Sacramento, CA, United States Veterans Affairs Nebraska Western Iowa Health Care System, University of Nebraska Medical Center, Omaha, NE, United States Mayo Clinic, Rochester, MN, United States NRG Oncology Statistics and Data Management Center, Philadelphia, PA, United States Johns Hopkins University School of Medicine, Baltimore, MD, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States Dana-Farber Cancer Institute, Boston, MA, United States ASCO, Alexandria, VA, United States Washington University School of Medicine, St Louis, MO, United States Roswell Park Cancer Institute, Buffalo, NY, United States Winship Cancer Institute of Emory University, Atlanta, GA, United States University of Chicago, Chicago, IL, United States AU - Pang, H. H. AU - Wang, X. AU - Stinchcombe, T. E. AU - Wong, M. L. AU - Cheng, P. AU - Ganti, A. K. AU - Sargent, D. J. AU - Zhang, Y. AU - Hu, C. AU - Mandrekar, S. J. AU - Redman, M. W. AU - Manola, J. B. AU - Schilsky, R. L. AU - Cohen, H. J. AU - Bradley, J. D. AU - Adjei, A. A. AU - Gandara, D. AU - Ramalingam, S. S. AU - Vokes, E. E. DB - Scopus DO - 10.1200/JCO.2016.67.7088 IS - 33 M3 - Article N1 - Cited By :44 Export Date: 22 March 2021 PY - 2016 SP - 3992-3999 ST - Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012 T2 - Journal of Clinical Oncology TI - Enrollment trends and disparity among patients with lung cancer in national clinical trials, 1990 to 2012 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994765427&doi=10.1200%2fJCO.2016.67.7088&partnerID=40&md5=f820e25dfd166c0030824eaf8fde69e7 VL - 34 ID - 2331 ER - TY - JOUR AB - Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results Enrollment disparity for patients $ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P =.020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 (P =.714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P =.020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer. (C) 2016 by American Society of Clinical Oncology AN - WOS:000388927700008 AU - Pang, H. H. AU - Wang, X. F. AU - Stinchcombe, T. E. AU - Wong, M. L. AU - Cheng, P. AU - Ganti, A. K. AU - Sargent, D. J. AU - Zhang, Y. AU - Hu, C. AU - Mandrekar, S. J. AU - Redman, M. W. AU - Manola, J. B. AU - Schilsky, R. L. AU - Cohen, H. J. AU - Bradley, J. D. AU - Adjei, A. A. AU - Gandara, D. AU - Ramalingam, S. S. AU - Vokes, E. E. DA - Nov DO - 10.1200/JCO.2016.67.7088 IS - 33 N1 - 27646951 PY - 2016 SN - 0732-183X SP - 3992-U90 ST - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 T2 - Journal of Clinical Oncology TI - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 VL - 34 ID - 2929 ER - TY - JOUR AB - Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this study was to characterize enrollment trends and disparities by age, sex, and race/ethnicity in lung cancer trials. Methods We analyzed data for 23,006 National Cancer Institute cooperative group lung cancer trial participants and 578,476 patients with lung cancer from the SEER registry from 1990 to 2012. The enrollment disparity difference (EDD) and enrollment disparity ratio (EDR) were calculated on the basis of the proportion of each subgroup in the trial population and the US lung cancer population. Annual percentage changes (APCs) in the subgroup proportions in each population were compared over time. Results Enrollment disparity for patients ≥ 70 years of age with non-small-cell lung cancer improved from 1990 to 2012 (test of parallelism, P = .020), with a remaining EDD of 0.22 (95% CI, 0.19 to 0.25) and EDR of 1.65 (95% CI, 1.51 to 1.82) in 2010 to 2012. No improvement was seen for elderly patients with small-cell lung cancer (SCLC), with an APC of 0.20 ( P = .714) among trial participants, despite a rising proportion of elderly patients with SCLC in the US population (APC, 0.32; P = .020). Enrollment disparity for women with lung cancer improved overall, with the gap closing by 2012 (EDD, 0.03 [95% CI, 0.00 to 0.06]; EDR, 1.07 [95% CI, 1.00 to 1.16]). Enrollment disparities persisted without significant improvement for elderly women, blacks, Asians/Pacific Islanders, and Hispanics. Conclusion Under-representation in lung cancer trials improved significantly from 1990 to 2012 for elderly patients with non-small-cell lung cancer and for women, but ongoing efforts to improve the enrollment of elderly patients with SCLC and minorities are needed. Our study highlights the importance of addressing enrollment disparities by demographic and disease subgroups to better target under-represented groups of patients with lung cancer. AD - School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region, People's Republic of China. Duke University School of Medicine, Durham, NC. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco. Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE. Mayo Clinic, Rochester, MN. ChenHu, NRGOncology Statistics and DataManagement Center, Philadelphia, PA. Johns Hopkins University School of Medicine, Baltimore, MD. Chen Hu, NRG Oncology Statistics and Data Management Center, Philadelphia, PA. Fred Hutchinson Cancer Research Center, Seattle, WA; Judith B. Manola, Dana-Farber Cancer Institute, Boston, MA. Dana-Farber Cancer Institute, Boston, MA. ASCO, Alexandria, VA. Washington University School of Medicine, St Louis, MO. Roswell Park Cancer Institute, Buffalo, NY. University of California, Davis Comprehensive Cancer Center, Sacramento, CA. The Winship Cancer Institute of Emory University, Atlanta, GA. University of Chicago, Chicago, IL. Herbert H. Pang and Perry Cheng, School of Public Health, Li Ka Shing Faculty of Medicine, Hong Kong, Special Administrative Region, People's Republic of China; Herbert H. Pang, Xiaofei Wang, Ying Zhang, Thomas E. Stinchcombe, and Harvey J. Cohen, Duke University School of Medicine, Durham, NC; Melisa L. Wong, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco; David Gandara, University of California, Davis Comprehensive Cancer Center, Sacramento, CA; Apar Kishor Ganti, Veterans Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE; Daniel J. Sargent and Sumithra J. Mandrekar, Mayo Clinic, Rochester, MN; Chen Hu, NRG Oncology Statistics and Data Management Center, Philadelphia, PA; Chen Hu, Johns Hopkins University School of Medicine, Baltimore, MD; Mary W. Redman, Fred Hutchinson Cancer Research Center, Seattle, WA; Judith B. Manola, Dana-Farber Cancer Institute, Boston, MA; Richard L. Schilsky, ASCO, Alexandria, VA; Jeffrey D. Bradley, Washington University School of Medicine, St Louis, MO; Alex A. Adjei, Roswell Park Cancer Institute, Buffalo, NY; Suresh S. Ramalingam, The Winship Cancer Institute of Emory University, Atlanta, GA; and Everett E. Vokes, University of Chicago, Chicago, IL AN - 119373638. Language: English. Entry Date: 20180725. Revision Date: 20200212. Publication Type: journal article AU - Pang, Herbert H. AU - Xiaofei, Wang AU - Stinchcombe, Thomas E. AU - Wong, Melisa L. AU - Perry, Cheng AU - Ganti, Apar Kishor AU - Sargent, Daniel J. AU - Ying, Zhang AU - Chen, Hu AU - Mandrekar, Sumithra J. AU - Redman, Mary W. AU - Manola, Judith B. AU - Schilsky, Richard L. AU - Cohen, Harvey J. AU - Bradley, Jeffrey D. AU - Adjei, Alex A. AU - Gandara, David AU - Ramalingam, Suresh S. AU - Vokes, Everett E. AU - Wang, Xiaofei DB - CINAHL Complete DO - 10.1200/JCO.2016.67.7088 DP - EBSCOhost IS - 33 KW - Healthcare Disparities -- Statistics and Numerical Data Carcinoma, Non-Small-Cell Lung -- Epidemiology Lung Neoplasms -- Therapy Clinical Trials Carcinoma, Non-Small-Cell Lung -- Therapy Lung Neoplasms -- Epidemiology Lung Neoplasms -- Ethnology Male Patient Selection United States Socioeconomic Factors Registries, Disease Age Factors Aged Female Sex Factors Human Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: U10 CA180838/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM27646951. PY - 2016 SN - 0732-183X SP - 3992-3999 ST - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 T2 - Journal of Clinical Oncology TI - Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119373638&site=ehost-live&scope=site VL - 34 ID - 1943 ER - TY - JOUR AB - Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of Contemporary Clinical Trials Communications. The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below. 1. “Intestinal-level anti-inflammatory bioactivities of catechin-rich green tea: Rationale, design, and methods of a double-blind, randomized, placebo-controlled crossover trial in metabolic syndrome and healthy adults” [Contemporary Clinical Trials Communications, 2019; 17: 100495] https://doi.org/10.1016/j.conctc.2019.100495 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.2. “Trauma Management Therapy and Prolonged Exposure Therapy for PTSD in an active duty sample: Design and methodology of a randomized clinical trial” [Contemporary Clinical Trials Communications, 2019; 17: 100491] https://doi.org/10.1016/j.conctc.2019.100491 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.3. “Virtual reality for pain management in patients with heart failure: Study rationale and design” [Contemporary Clinical Trials Communications, 2019; 16: 100470] https://doi.org/10.1016/j.conctc.2019.100470 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.4. “Recruitment and retention of families interested in a parent-based pediatric obesity intervention” [Contemporary Clinical Trials Communications, 2019; 16: 100467] https://doi.org/10.1016/j.conctc.2019.100467 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.5. “2D (2 Dimensional) TEQR design for Determining the optimal Dose for safety and efficacy” [Contemporary Clinical Trials Communications, 2019; 16: 100461] https://doi.org/10.1016/j.conctc.2019.100461 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.6. “Design of a novel digital intervention to promote healthy weight management among postpartum African American women” [Contemporary Clinical Trials Communications, 2019; 16: 100460] https://doi.org/10.1016/j.conctc.2019.100460 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.7. “Integrating smartphone technology, social support and the outdoor built environment to promote community-based aerobic and resistance-based physical activity: Rationale and study protocol for the ‘ecofit’ randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 16: 100457] https://doi.org/10.1016/j.conctc.2019.100457 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.8. “Qualitative analysis of COACH: A community-based behavioral intervention to reduce obesity health disparities within a marginalized community” [Contemporary Clinical Trials Communications, 2019; 16: 100452] https://doi.org/10.1016/j.conctc.2019.100452 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.9. “Statistical considerations for testing an AI algorithm used for rescreening lung CT images” [Contemporary Clinical Trials Communications, 2019; 16: 100434] https://doi.org/10.1016/j.conctc.2019.100434 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.10. “Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention” [Contemporary Clinical Trials Communications, 2019; 16: 100433] https://doi.org/10.1016/j.conctc.2019.100433 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.11. “Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression” [Contemporary Clinical Trials Communications, 2019; 16: 100432] https://doi.org/10.1016/j.conctc.2019.100432 Declaration of competing interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Sanjay Mathew has served as a consultant to Allergan, Alkermes, Bracket, Clexio Biosciences, Janssen, Perception Neurosciences, and Sage Therapeutics. He has served as a co-investigator for clinical trials funded by NeuroRx and Janssen and has received research support from Biohaven Pharmaceuticals and VistaGen Therapeutics. Dr. Marijn Lijffijt has served as principal investigator for trials funded by NeuroRx and Vistagen Therapeutics.12. “A descriptive research: Exclusion from submitted clinical data package in the review process of new drug approval due to GCP violation in Japan” [Contemporary Clinical Trials Communications, 2019; 15: 100416] https://doi.org/10.1016/j.conctc.2019.100416 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.13. “Ultrafiltration-profiled hemodialysis to reduce dialysis-related cardiovascular stress: Study protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100415] https://doi.org/10.1016/j.conctc.2019.100415 Declaration of competing interest: In the last 3 years, JEF has received speaking honoraria from American Renal Associates, the American Society of Nephrology, Dialysis Clinic, Inc., the National Kidney Foundation, and multiple universities. JEF is on the medical advisory board of NxStage Medical, Inc. and has received consulting fees from Fresenius Medical Care, North America and AstraZeneca. In the last 3 years, MMA has received investigator-initiated research funding from the Renal Research Institute, a subsidiary of Fresenius Medical Care, North America and honoraria from the International Society of Nephrology. The remaining authors have no competing interests.14. “Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial” [Contemporary Clinical Trials Communications, 2019; 15: 100412] https://doi.org/10.1016/j.conctc.2019.100412 Declaration of competing interest: “The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PC is fixed-term researcher at University of Catania, Italy and won the 2015 unrestricted grant from Pfizer,GRAND, Global Research Award for Nicotine Dependence, that as declared in the text support this study. MM is fixed-term researcher at Centro per la Prevenzione e Cura del Tabagismo, University of Catania. In relation to his work in the area of tobacco control and respiratory diseases, P has received lecture fees and research funding from Pfizer, Inc., GlaxoSmithKline plc, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Thera eutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Inc., Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), and Health Diplomat (consulting company that delivers solutions to global health problems with special emphasis on harm minimization). Lecture fees from a number of European EC industry and trade associations (including Fédération Interprofessionnelle de la VAPE in France and Federazione Italiana Esercenti Svapo Elettronico in Italy) were directly donated to vaper advocacy no-profit organizations. He is currently Head of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). He is also founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from the Foundation for a Smoke Free World to support 8 independent investigator-initiated research projects on tobacco harm reduction, and scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti- Smoking League). The other authors have no conflict of interests to declare.15. “Recruitment challenges in stroke neurorecovery clinical trials” [Contemporary Clinical Trials Communications, 2019; 15: 100404] https://doi.org/10.1016/j.conctc.2019.100404 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. © 2020 C7 - 100689 DB - Scopus DO - 10.1016/j.conctc.2020.100689 M3 - Erratum N1 - Export Date: 22 March 2021 PY - 2020 ST - Erratum regarding missing Declaration of Competing Interest statements in previously published articles (Contemporary Clinical Trials Communications (2019) 16, (S2451865419302236), (10.1016/j.conctc.2019.100461)) T2 - Contemporary Clinical Trials Communications TI - Erratum regarding missing Declaration of Competing Interest statements in previously published articles (Contemporary Clinical Trials Communications (2019) 16, (S2451865419302236), (10.1016/j.conctc.2019.100461)) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097786347&doi=10.1016%2fj.conctc.2020.100689&partnerID=40&md5=0034aa9c1135ac56ec43e1d4d64949dc VL - 20 ID - 2173 ER - TY - JOUR AB - The Minority-Based Community Clinical Oncology Program (MB-CCOP) at University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center was established to serve an unmet need in a medically, educationally, and socioeconomically underserved community of primarily African American and Latino patients in Newark and Essex County, New Jersey. The MB-CCOP was built on an existing infrastructure of multidisciplinary teams of cancer specialists who collaborated in patient care and an existing clinical research program, which included multilingual staff and a breast cancer navigator. This article highlights some of the unique opportunities and challenges involved in the startup of an MB-CCOP specifically relevant to an academic setting. We present a guide to the necessary infrastructure and institutional support that must be in place before considering such a program and some of the steps an institution can take to overcome barriers preventing successful enrollment of patients onto clinical trials. Copyright © 2012 by American Society of Clinical Oncology. AD - B.J. Weiner, Department of Health Policy and Management, UNC Gillings School of Global Public Health, CB 7411, Chapel Hill, NC 27599-7411, United States AU - Wieder, R. AU - Teal, R. AU - Saunders, T. AU - Weiner, B. J. DB - Embase Medline DO - 10.1200/JOP.2012.000648 IS - 2 KW - African American article breast cancer cancer center clinical research clinical trial (topic) community program cooperation health program Hispanic human medical school minority based community clinical oncology program patient care practice guideline United States university hospital LA - English M3 - Article N1 - L369631418 2013-08-30 2013-09-04 PY - 2013 SN - 1554-7477 1935-469X SP - e48-e54 ST - Establishing a minority-based community clinical oncology program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center experience T2 - Journal of Oncology Practice TI - Establishing a minority-based community clinical oncology program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center experience UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369631418&from=export http://dx.doi.org/10.1200/JOP.2012.000648 http://jop.ascopubs.org/content/9/2/e48.full.pdf+html VL - 9 ID - 1089 ER - TY - JOUR AB - The Minority-Based Community Clinical Oncology Program (MB-CCOP) at University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center was established to serve an unmet need in a medically, educationally, and socioeconomically underserved community of primarily African American and Latino patients in Newark and Essex County, New Jersey. The MB-CCOP was built on an existing infrastructure of multidisciplinary teams of cancer specialists who collaborated in patient care and an existing clinical research program, which included multilingual staff and a breast cancer navigator. This article highlights some of the unique opportunities and challenges involved in the startup of an MBCCOP specifically relevant to an academic setting. We present a guide to the necessary infrastructure and institutional support that must be in place before considering such a program and some of the steps an institution can take to overcome barriers preventing successful enrollment of patients onto clinical trials. AD - University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC AN - 104255625. Language: English. Entry Date: 20130319. Revision Date: 20200708. Publication Type: Journal Article AU - Wieder, Robert AU - Teal, Randall AU - Saunders, Tracie AU - Weiner, Bryan J. DB - CINAHL Complete DO - 10.1200/JOP.2012.000648 DP - EBSCOhost IS - 2 KW - Research Subject Recruitment -- Methods Clinical Trials Oncology Minority Groups Program Development -- Methods -- New Jersey New Jersey Academic Medical Centers Community Health Services N1 - case study; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. Special Interest: Oncologic Care. NLM UID: 101261852. PMID: NLM23814524. PY - 2013 SN - 1554-7477 SP - e48-54 ST - Establishing a Minority-Based Community Clinical Oncology Program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center Experience T2 - Journal of Oncology Practice TI - Establishing a Minority-Based Community Clinical Oncology Program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center Experience UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104255625&site=ehost-live&scope=site VL - 9 ID - 1944 ER - TY - JOUR AB - The Minority-Based Community Clinical Oncology Program (MB-CCOP) at University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center was established to serve an unmet need in a medically, educationally, and socioeconomically underserved community of primarily African American and Latino patients in Newark and Essex County, New Jersey. The MB-CCOP was built on an existing infrastructure of multidisciplinary teams of cancer specialists who collaborated in patient care and an existing clinical research program, which included multilingual staff and a breast cancer navigator. This article highlights some of the unique opportunities and challenges involved in the startup of an MB-CCOP specifically relevant to an academic setting. We present a guide to the necessary infrastructure and institutional support that must be in place before considering such a program and some of the steps an institution can take to overcome barriers preventing successful enrollment of patients onto clinical trials. Copyright © 2012 by American Society of Clinical Oncology. AD - University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center, Newark, NJ; Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill; and Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC AU - Wieder, R. AU - Teal, R. AU - Saunders, T. AU - Weiner, B. J. DB - Scopus DO - 10.1200/JOP.2012.000648 IS - 2 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2013 SP - e48-e54 ST - Establishing a minority-based community clinical oncology program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center experience T2 - Journal of Oncology Practice TI - Establishing a minority-based community clinical oncology program: The University of Medicine and Dentistry of New Jersey, New Jersey Medical School-University Hospital Cancer Center experience UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882768333&doi=10.1200%2fJOP.2012.000648&partnerID=40&md5=02a0a527b1c7ee70238c50b1e8087008 VL - 9 ID - 2437 ER - TY - JOUR AB - BACKGROUND: Historically, groups that are most susceptible to health and healthcare disparities have been underrepresented in medical research. It is imperative to explore approaches that can facilitate the recruitment of underrepresented individuals into research studies. METHODS: Two approaches, hospital and community-based recruitment (CBR), were developed and implemented over 36 months to study the genetics of hereditary breast cancer and associated cancers in Alabama, a medically underserved state with double the national percentage of self-identifying African Americans, establishing the Alabama Hereditary Cancer Cohort. RESULTS: Overall, 242 individuals enrolled. This included 84 cancer probands through hospital recruitment, as well as 76 probands and 82 family members through CBR. Eighty-one percent of the study participants' counties of residence are completely medically underserved. Furthermore, African Americans represent 26% of the hospital probands compared to 49% and 70% of the probands and family members who, respectively, enrolled through CBR. CONCLUSION: Although both recruitment mechanisms were instrumental, the unique trust building, educational, and traveling components of CBR facilitated the enrollment of African Americans resulting in large families for genetic analyses. The ultimate goal is to gain insight from these rudimentary efforts in order to expand recruitment and accrue a unique resource for cancer genetics research. AU - Bishop, M. R. AU - Shah, A. AU - Shively, M. AU - Huskey, A. L. W. AU - Omeler, S. M. AU - Bilgili, E. P. AU - Jackson, E. AU - Daniell, K. AU - Stallworth, E. AU - Spina, S. AU - Shepp, K. AU - Bergstresser, S. AU - Davis, A. AU - Dean, H. AU - Gibson, J. AU - Johnson, B. AU - Merner, N. D. DB - Medline DO - 10.1002/mgg3.443 IS - 5 KW - adult aged Alabama clinical trial cohort analysis family female genetics human male medical genetics middle aged multicenter study neoplasm LA - English M3 - Article N1 - L624125610 2018-10-23 2018-12-20 PY - 2018 SN - 2324-9269 SP - 766-778 ST - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research T2 - Molecular genetics & genomic medicine TI - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624125610&from=export http://dx.doi.org/10.1002/mgg3.443 VL - 6 ID - 886 ER - TY - JOUR AB - Background: Historically, groups that are most susceptible to health and healthcare disparities have been underrepresented in medical research. It is imperative to explore approaches that can facilitate the recruitment of underrepresented individuals into research studies. Methods: Two approaches, hospital and community-based recruitment (CBR), were developed and implemented over 36 months to study the genetics of hereditary breast cancer and associated cancers in Alabama, a medically underserved state with double the national percentage of self-identifying African Americans, establishing the Alabama Hereditary Cancer Cohort. Results: Overall, 242 individuals enrolled. This included 84 cancer probands through hospital recruitment, as well as 76 probands and 82 family members through CBR. Eighty-one percent of the study participants’ counties of residence are completely medically underserved. Furthermore, African Americans represent 26% of the hospital probands compared to 49% and 70% of the probands and family members who, respectively, enrolled through CBR. Conclusion: Although both recruitment mechanisms were instrumental, the unique trust building, educational, and traveling components of CBR facilitated the enrollment of African Americans resulting in large families for genetic analyses. The ultimate goal is to gain insight from these rudimentary efforts in order to expand recruitment and accrue a unique resource for cancer genetics research. © 2018 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. AD - Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, United States Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States East Alabama Medical Center, Cancer Center, Opelika, AL, United States Department of Human Development and Family Studies, College of Human Sciences, Auburn University, Auburn, AL, United States AU - Bishop, M. R. AU - Shah, A. AU - Shively, M. AU - Huskey, A. L. W. AU - Omeler, S. M. AU - Bilgili, E. P. AU - Jackson, E. AU - Daniell, K. AU - Stallworth, E. AU - Spina, S. AU - Shepp, K. AU - Bergstresser, S. AU - Davis, A. AU - Dean, H. AU - Gibson, J. AU - Johnson, B. AU - Merner, N. D. DB - Scopus DO - 10.1002/mgg3.443 IS - 5 KW - African American biobank hereditary breast cancer recruitment underrepresented individuals M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2018 SP - 766-778 ST - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research T2 - Molecular Genetics and Genomic Medicine TI - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050734467&doi=10.1002%2fmgg3.443&partnerID=40&md5=d6767e36d4f07ad2666b9aa10437176c VL - 6 ID - 2258 ER - TY - JOUR AB - BackgroundHistorically, groups that are most susceptible to health and healthcare disparities have been underrepresented in medical research. It is imperative to explore approaches that can facilitate the recruitment of underrepresented individuals into research studies. MethodsTwo approaches, hospital and community-based recruitment (CBR), were developed and implemented over 36months to study the genetics of hereditary breast cancer and associated cancers in Alabama, a medically underserved state with double the national percentage of self-identifying African Americans, establishing the Alabama Hereditary Cancer Cohort. ResultsOverall, 242 individuals enrolled. This included 84 cancer probands through hospital recruitment, as well as 76 probands and 82 family members through CBR. Eighty-one percent of the study participants' counties of residence are completely medically underserved. Furthermore, African Americans represent 26% of the hospital probands compared to 49% and 70% of the probands and family members who, respectively, enrolled through CBR. ConclusionAlthough both recruitment mechanisms were instrumental, the unique trust building, educational, and traveling components of CBR facilitated the enrollment of African Americans resulting in large families for genetic analyses. The ultimate goal is to gain insight from these rudimentary efforts in order to expand recruitment and accrue a unique resource for cancer genetics research. AN - WOS:000445851700008 AU - Bishop, M. R. AU - Shah, A. AU - Shively, M. AU - Huskey, A. L. W. AU - Omeler, S. M. AU - Bilgili, E. P. AU - Jackson, E. AU - Daniell, K. AU - Stallworth, E. AU - Spina, S. AU - Shepp, K. AU - Bergstresser, S. AU - Davis, A. AU - Dean, H. AU - Gibson, J. AU - Johnson, B. AU - Merner, N. D. DA - Sep DO - 10.1002/mgg3.443 IS - 5 N1 - 29962060 PY - 2018 SN - 2324-9269 SP - 766-778 ST - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research T2 - Molecular Genetics & Genomic Medicine TI - Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research VL - 6 ID - 2846 ER - TY - JOUR AB - Purpose: Healthy or unhealthy lifestyle behaviors are often adopted together. We aimed to investigate the combined effect of estrogen-related lifestyle factors on postmenopausal breast cancer risk. Methods: Data from 27,153 women enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were used. We created an estrogen-related lifestyle score (ERLS) by incorporating a previously developed measure of estrogenic diet, alcohol intake, body mass index (BMI), and physical activity. The scores ranged from 0 to 6 with alcohol and BMI accounting for higher weights than the other factors. To evaluate the preventive possibilities of a low estrogen-related lifestyle and to be consistent with other published lifestyle scores, higher scores were set to correspond with potentially lower estrogenic lifestyle. The association between the ERLS and incident breast cancer was examined using Cox proportional hazards models. Results: Participants with an ERLS of 4 or ≥ 5 had a 23% (HR 0.77; 95% CI 0.67–0.89) and 34% (HR 0.66; 95% CI 0.56–0.78) lower risk of breast cancer, respectively, compared to those with an ERLS ≤ 2 after multivariable adjustment. Estimates were similar when restricting to invasive cases or estrogen receptor-positive subtypes. No single lifestyle component appeared to drive the association. Conclusions: Our findings suggest that the combined effect of a lifestyle characterized by a low estrogenic diet, low alcohol consumption, low body weight, and high levels of physical activity are associated with a reduction in postmenopausal breast cancer risk, possibly through an influence on estrogen metabolism. © 2018, Springer Science+Business Media, LLC, part of Springer Nature. AD - Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, United States Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, United States Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208, United States AU - Guinter, M. A. AU - McLain, A. C. AU - Merchant, A. T. AU - Sandler, D. P. AU - Steck, S. E. DB - Scopus DO - 10.1007/s10549-018-4784-0 IS - 3 KW - Behavior Breast cancer Epidemiology Estrogen metabolism Lifestyle score Prospective cohort study M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2018 SP - 613-622 ST - An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort T2 - Breast Cancer Research and Treatment TI - An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045269362&doi=10.1007%2fs10549-018-4784-0&partnerID=40&md5=2ad9f422c7a802dcbdaf2f0a826301a1 VL - 170 ID - 2261 ER - TY - JOUR AB - Behavioral theories developed through research with mainstream, English-speaking populations have been applied to ethnically diverse and underserved communities in the effort to eliminate disparities in early breast cancer detection. This study tests the validity of the transtheoretical model (TTM) decisional balance measure and the application of the TTM stages of change in a multiethnic, multilingual sample. A random sample of 1,463 Filipino, Latino, African American, Chinese, and White women aged 40 to 74 completed a phone survey of mammography beliefs and practices. Consistent with the TTM and independent of ethnicity, decisional balance was associated with mammography stage in all five ethnic groups when controlling for socioeconomic and other factors. In addition, having private insurance and a regular physician and being a long-time resident in the United States were positively associated with mammography maintenance. The application of the TTM for mammography is supported in a multiethnic and multilingual sample. © 2007 by SOPHE. AD - R. Otero-Sabogal, Institute for Health and Aging, University of California-San Francisco, Laurel Heights Campus, San Francisco, CA 94143-0646, United States AU - Otero-Sabogal, R. AU - Stewart, S. AU - Shema, S. J. AU - Pasick, R. J. DB - Medline DO - 10.1177/1090198105277854 IS - 2 KW - adult aged article attitude to health ethnic group female human information processing interview mammography middle aged patient attitude patient participation theoretical model United States utilization review validation study LA - English M3 - Article N1 - L46452147 2007-05-21 PY - 2007 SN - 1090-1981 1552-6127 SP - 278-296 ST - Ethnic differences in decisional balance and stages of mammography adoption T2 - Health Education and Behavior TI - Ethnic differences in decisional balance and stages of mammography adoption UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46452147&from=export http://dx.doi.org/10.1177/1090198105277854 VL - 34 ID - 1233 ER - TY - JOUR AB - Background:Black ethnic groups have a higher breast cancer mortality than Whites. American studies have identified variations in tumour biology and unequal health-care access as causative factors. We compared tumour pathology, treatment and outcomes in three ethnic groups in young breast cancer patients treated in the United Kingdom.Methods:Women aged ≤40 years at breast cancer diagnosis were recruited to the POSH national cohort study (MREC: 00/06/69). Personal characteristics, tumour pathology and treatment data were collected at diagnosis. Follow-up data were collected annually. Overall survival (OS) and distant relapse-free survival (DRFS) were assessed using Kaplan-Meier curves, and multivariate analyses were performed using Cox regression.Results:Ethnicity data were available for 2915 patients including 2690 (91.0%) Whites, 118 (4.0%) Blacks and 87 (2.9%) Asians. Median tumour diameter at presentation was greater in Blacks than Whites (26.0 mm vs 22.0 mm, P=0.0103), and multifocal tumours were more frequent in both Blacks (43.4%) and Asians (37.0%) than Whites (28.9%). ER/PR/HER2-negative tumours were significantly more frequent in Blacks (26.1%) than Whites (18.6%, P=0.043). Use of chemotherapy was similarly high in all ethnic groups (89% B vs 88.6% W vs 89.7% A). A 5-year DRFS was significantly lower in Blacks than Asians (62.8% B vs 77.0% A, P=0.0473) or Whites (62.8 B% vs 77.0% W, P=0.0053) and a 5-year OS for Black patients, 71.1% (95% CI: 61.0-79.1%), was significantly lower than that of Whites (82.4%, 95% CI: 80.8-83.9%, W vs B: P=0.0160). In multivariate analysis, Black ethnicity had an effect on DRFS in oestrogen receptor (ER)-positive patients that is independent of body mass index, tumour size, grade or nodal status, HR: 1.60 (95% CI: 1.03-2.47, P=0.035).Conclusion:Despite equal access to health care, young Black women in the United Kingdom have a significantly poorer outcome than White patients. Black ethnicity is an independent risk factor for reduced DRFS particularly in ER-positive patients. © 2014 Cancer Research UK. AD - Cancer Sciences Academic Unit, University of Southampton Clinical Trials Unit, University Hospital Southampton Foundation Trust, Tremona Road, Southampton SO16 6YA, United Kingdom Centre for Statistics in Medicine, Wolfson College Annexe, Oxford OX2 6UD, United Kingdom Tumour Biology Department, Institute of Cancer, London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ, United Kingdom AU - Copson, E. AU - Maishman, T. AU - Gerty, S. AU - Eccles, B. AU - Stanton, L. AU - Cutress, R. I. AU - Altman, D. G. AU - Durcan, L. AU - Simmonds, P. AU - Jones, L. AU - Tapper, W. AU - Eccles, D. DB - Scopus DO - 10.1038/bjc.2013.650 IS - 1 KW - breast cancer ethnicity prognosis M3 - Article N1 - Cited By :32 Export Date: 22 March 2021 PY - 2014 SP - 230-241 ST - Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study T2 - British Journal of Cancer TI - Ethnicity and outcome of young breast cancer patients in the United Kingdom: The POSH study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891874192&doi=10.1038%2fbjc.2013.650&partnerID=40&md5=a3ea7f9c1b28333645c4a6b439988bc5 VL - 110 ID - 2410 ER - TY - JOUR AB - Background: Black ethnic groups have a higher breast cancer mortality than Whites. American studies have identified variations in tumour biology and unequal health-care access as causative factors. We compared tumour pathology, treatment and outcomes in three ethnic groups in young breast cancer patients treated in the United Kingdom. Methods: Women aged <= 40 years at breast cancer diagnosis were recruited to the POSH national cohort study (MREC: 00/06/69). Personal characteristics, tumour pathology and treatment data were collected at diagnosis. Follow-up data were collected annually. Overall survival (OS) and distant relapse-free survival (DRFS) were assessed using Kaplan-Meier curves, and multivariate analyses were performed using Cox regression. Results: Ethnicity data were available for 2915 patients including 2690 (91.0%) Whites, 118 (4.0%) Blacks and 87 (2.9%) Asians. Median tumour diameter at presentation was greater in Blacks than Whites (26.0 mm vs 22.0 mm, P = 0.0103), and multifocal tumours were more frequent in both Blacks (43.4%) and Asians (37.0%) than Whites (28.9%). ER/PR/HER2-negative tumours were significantly more frequent in Blacks (26.1%) than Whites (18.6%, P = 0.043). Use of chemotherapy was similarly high in all ethnic groups (89% B vs 88.6% W vs 89.7% A). A 5-year DRFS was significantly lower in Blacks than Asians (62.8% B vs 77.0% A, P = 0.0473) or Whites (62.8 B% vs 77.0% W, P = 0.0053) and a 5-year OS for Black patients, 71.1% (95% CI: 61.0-79.1%), was significantly lower than that of Whites (82.4%, 95% CI: 80.8-83.9%, W vs B: P = 0.0160). In multivariate analysis, Black ethnicity had an effect on DRFS in oestrogen receptor (ER)-positive patients that is independent of body mass index, tumour size, grade or nodal status, HR: 1.60 (95% CI: 1.03-2.47, P = 0.035). Conclusion: Despite equal access to health care, young Black women in the United Kingdom have a significantly poorer outcome than White patients. Black ethnicity is an independent risk factor for reduced DRFS particularly in ER-positive patients. AN - WOS:000329493700029 AU - Copson, E. AU - Maishman, T. AU - Gerty, S. AU - Eccles, B. AU - Stanton, L. AU - Cutress, R. I. AU - Altman, D. G. AU - Durcan, L. AU - Simmonds, P. AU - Jones, L. AU - Tapper, W. AU - Eccles, D. DA - Jan DO - 10.1038/bjc.2013.650 IS - 1 N1 - 24149174 PY - 2014 SN - 0007-0920 SP - 230-241 ST - Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study T2 - British Journal of Cancer TI - Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study VL - 110 ID - 3024 ER - TY - JOUR AB - BACKGROUND: Associations between optimal use of a tailored decision‐aid and levels of accuracy of perceived breast cancer risk, confidence in decision‐making, and satisfaction with decisions about HRT were evaluated in a randomized intervention trial with a community sample of women aged 45‐54. METHODS: Data are from 289 women randomized to receive a computer‐tailored three‐step decision‐aid. RESULTS: Forty‐seven percent of participants reported optimal use of the intervention materials. African American women and those with low confidence in decision‐making were less likely to use the intervention optimally than white women and those with higher confidence (P<0.05). Optimal use of the decision‐aid was associated with increased accuracy of perceived risk and confidence to make a decision. DISCUSSION: When used optimally, self‐directed decision‐aids can improve women's ability to make decisions about HRT. Additional refinement of these aids is needed. For some subgroups of women, adjuncts such as telephone counseling also might be considered. AN - CN-00412184 AU - Bastian, L. A. AU - McBride, C. M. AU - Fish, L. AU - Lyna, P. AU - Farrell, D. AU - Lipkus, I. M. AU - Rimer, B. K. AU - Siegler, I. C. DO - 10.1016/s0738-3991(02)00048-4 IS - 3 KW - African Americans [education, psychology] Computer‐Assisted Instruction [standards] Counseling Decision Making, Computer‐Assisted Decision Support Techniques Estrogen Replacement Therapy [adverse effects, *psychology] European Continental Ancestry Group [education, psychology] Female Humans Middle Aged North Carolina Patient Education as Topic [standards] Patient Participation Postmenopause [*psychology] Self Efficacy Women [education, *psychology] M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non‐P.H.S.; Research Support, U.S. Gov't, P.H.S. PY - 2002 SP - 283‐291 ST - Evaluating participants' use of a hormone replacement therapy decision-making intervention T2 - Patient education and counseling TI - Evaluating participants' use of a hormone replacement therapy decision-making intervention UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00412184/full VL - 48 ID - 1394 ER - TY - JOUR AB - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners' perceptions of this community-academic-clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g., both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners' perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs. AD - D.B. Friedman AU - Friedman, D. B. AU - Owens, O. L. AU - Jackson, D. D. AU - Johnson, K. M. AU - Gansauer, L. AU - Dickey, J. AU - Miller, R. AU - Payne, J. AU - Bearden, J. D. AU - Hebert, J. R. DB - Medline DO - 10.1007/s13187-013-0550-5 IS - 1 KW - article community care cooperation ethnology evaluation study health care delivery health care disparity health education human male organization and management pilot study prognosis prostate tumor United States university hospital LA - English M3 - Article N1 - L373975198 2014-10-28 PY - 2014 SN - 1543-0154 SP - 80-85 ST - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373975198&from=export http://dx.doi.org/10.1007/s13187-013-0550-5 VL - 29 ID - 1050 ER - TY - JOUR AB - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners' perceptions of this community-academic-clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g., both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners' perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs. AN - 104052796. Language: English. Entry Date: 20141031. Revision Date: 20200708. Publication Type: journal article AU - Friedman, Daniela B. AU - Owens, Otis L. AU - Jackson, Dawnyea D. AU - Johnson, Kim M. AU - Gansauer, Lucy AU - Dickey, Joe AU - Miller, Ron AU - Payne, Johnny AU - Bearden, James D. AU - Hebert, James R. DB - CINAHL Complete DO - 10.1007/s13187-013-0550-5 DP - EBSCOhost IS - 1 KW - Academic Medical Centers -- Administration Community Networks -- Administration Cooperative Behavior Health Education Health Services Accessibility Healthcare Disparities Prostatic Neoplasms -- Prevention and Control Human Male Pilot Studies Prognosis Prostatic Neoplasms -- Ethnology South Carolina N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: U54 CA153461/CA/NCI NIH HHS/United States. NLM UID: 8610343. PMID: NLM24078315. PY - 2014 SN - 0885-8195 SP - 80-85 ST - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South T2 - Journal of Cancer Education TI - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the South UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104052796&site=ehost-live&scope=site VL - 29 ID - 1854 ER - TY - JOUR AB - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners' perceptions of this community-academic-clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g.; both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners' perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs. © 2013 Springer Science+Business Media New York. AD - Department of Health Promotion, Education, and Behavior, Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208, United States Department of Health Promotion, Education, and Behavior, University of South Carolina, Columbia, SC 29208, United States National Cancer Institute Community Cancer Centers Program, Spartanburg Regional Healthcare System, Gibbs Cancer Center and Research Institute, Spartanburg, SC 29303, United States UsTOO International Prostate Cancer Education and Support Network, Spartanburg, SC 29303, United States UsTOO International Prostate Cancer Education and Support Network, Easley, SC 29640, United States Department of Epidemiology and Biostatistics, Statewide Cancer Prevention and Control Program, University of South Carolina, Columbia, SC 29208, United States Arnold School of Public Health, Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street, Columbia, SC, United States AU - Friedman, D. B. AU - Owens, O. L. AU - Jackson, D. D. AU - Johnson, K. M. AU - Gansauer, L. AU - Dickey, J. AU - Miller, R. AU - Payne, J. AU - Bearden, J. D. AU - Hebert, J. R. DB - Scopus DO - 10.1007/s13187-013-0550-5 IS - 1 KW - Assessment Community and clinical partnerships Prostate cancer Research collaboration M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2014 SP - 80-85 ST - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the south T2 - Journal of Cancer Education TI - An evaluation of a community-academic-clinical partnership to reduce prostate cancer disparities in the south UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898001486&doi=10.1007%2fs13187-013-0550-5&partnerID=40&md5=07a96cdc2488bc8d078a3435546d294b VL - 29 ID - 2399 ER - TY - JOUR AB - Engaging partners in the planning, implementation, and evaluation of cancer education programs is critical for improving the health of our communities. A 2-year pilot education intervention on prostate cancer decision making and participation in medical research was funded by the National Cancer Institute. The partnership involving community members and clinical staff at a cancer center was used to develop recruitment strategies and plan for the implementation of the intervention with African-American middle-age and older men and female family members. We assessed partners' perceptions of this community-academic-clinical research collaboration. In year 2, eight project advisory council members were selected among existing partners and year 1 participants to serve as a formal committee. Council members were required to participate in telephone and in person meetings and actively support recruitment/implementation efforts. At the conclusion of the project, 20 individuals (all clinical and community partners, including the eight advisory council members) were invited to complete a survey to assess their perceived impact of the collaboration on the community and provide suggestions for future collaborations. Most partners agreed that their organization benefitted from the collaboration and that various aspects of the advisory council process (e.g., both formal and informal communication) worked well. The most noted accomplishment of the partnership related to leveraging the collaboration to make men more knowledgeable about prostate cancer decision making. Suggested improvements for future collaborations included distributing more frequent updates regarding project successes. Evaluating partners' perceptions of this collaboration provided important recommendations for future planning, implementation, and evaluation of community-based cancer education programs. AN - WOS:000330972900017 AU - Friedman, D. B. AU - Owens, O. L. AU - Jackson, D. D. AU - Johnson, K. M. AU - Gansauer, L. AU - Dickey, J. AU - Miller, R. AU - Payne, J. AU - Bearden, J. D. AU - Hebert, J. R. DA - Mar DO - 10.1007/s13187-013-0550-5 IS - 1 N1 - 24078315 PY - 2014 SN - 0885-8195 SP - 80-85 ST - An Evaluation of a Community-Academic-Clinical Partnership to Reduce Prostate Cancer Disparities in the South T2 - Journal of Cancer Education TI - An Evaluation of a Community-Academic-Clinical Partnership to Reduce Prostate Cancer Disparities in the South VL - 29 ID - 3019 ER - TY - JOUR AB - PURPOSE: To evaluate the effects of iDecide on prostate cancer knowledge, informed decision-making self-efficacy, technology use self-efficacy, and intention to engage in informed decision-making among African American men. DESIGN: One-group, pretest/posttest. SETTING: Community settings in South Carolina. PARTICIPANTS: African American men, ages 40 years +, without a prior prostate cancer diagnosis (n = 354). INTERVENTION: iDecide, an embodied conversational agent-led, computer-based prostate cancer screening decision aid. MEASURES: Prostate cancer knowledge, informed decision-making self-efficacy, technology use self-efficacy, and intention to engage in informed decision-making. ANALYSIS: Descriptive statistics, paired t tests, general linear modeling, Spearman correlations. RESULTS: On average, participants experienced significant improvements in their prostate cancer knowledge ( P ≤ .001), informed decision-making self-efficacy ( P ≤ .001), and technology use self-efficacy ( P ≤ .001), postintervention. Additionally, 67% of participants reported an intention to engage in informed decision-making. CONCLUSION: Given the significant improvements across all measures, this research demonstrates that embodied conversational agent-led decision aids can be used to enhance the capacity for making informed prostate cancer screening decisions among African American men and increase their technology use self-efficacy. One critical limitation of this study is that most men had received prostate cancer screening prior to engaging in our intervention, so the implications of this intervention may be different for men who do not have a history of screening. Additionally, actual engagement in informed decision-making postintervention was not assessed. AU - Owens, O. L. AU - Felder, T. AU - Tavakoli, A. S. AU - Revels, A. A. AU - Friedman, D. B. AU - Hughes-Halbert, C. AU - Hébert, J. R. DB - Medline DO - 10.1177/0890117118786866 IS - 2 KW - prostate specific antigen adult African American age aged attitude to computers attitude to health decision support system early cancer diagnosis ethnology health promotion human male middle aged patient participation procedures prostate tumor self concept socioeconomics South Carolina LA - English M3 - Article N1 - L626322156 2019-02-14 2019-12-30 PY - 2019 SN - 2168-6602 SP - 267-278 ST - Evaluation of a Computer-Based Decision Aid for Promoting Informed Prostate Cancer Screening Decisions Among African American Men: iDecide T2 - American journal of health promotion : AJHP TI - Evaluation of a Computer-Based Decision Aid for Promoting Informed Prostate Cancer Screening Decisions Among African American Men: iDecide UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626322156&from=export http://dx.doi.org/10.1177/0890117118786866 VL - 33 ID - 859 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To describe the Heiney-Adams Recruitment Framework (H-ARF); to delineate a recruitment plan for a randomized, behavioral trial (RBT) based on H-ARF; and to provide evaluation data on its implementation. DATA SOURCES: All data for this investigation originated from a recruitment database created for an RBT designed to test the effectiveness of a therapeutic group convened via teleconference for African American women with breast cancer. DATA SYNTHESIS: Major H-ARF concepts include social marketing and relationship building. The majority of social marketing strategies yielded 100% participant recruitment. Greater absolute numbers were recruited via Health Insurance Portability and Accountability Act waivers. Using H-ARF yielded a high recruitment rate (66%). CONCLUSIONS: Application of H-ARF led to successful recruitment in an RBT. The findings highlight three areas that researchers should consider when devising recruitment plans: absolute numbers versus recruitment rate, cost, and efficiency with institutional review board-approved access to protected health information. IMPLICATIONS FOR NURSING: H-ARF may be applied to any clinical or population-based research setting because it provides direction for researchers to develop a recruitment plan based on the target audience and cultural attributes that may hinder or help recruitment. AD - S.P. Heiney, Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, USA. AU - Heiney, S. P. AU - Adams, S. A. AU - Wells, L. M. AU - Johnson, H. DB - Medline DO - 10.1188/10.ONF.E160-E167 IS - 3 KW - African American article audiovisual equipment breast tumor cultural competence education ethnology evaluation study female health care quality human human relation model nursing evaluation research patient attitude patient selection program development psychological aspect psychological model randomized controlled trial self help social marketing telecommunication trust LA - English M3 - Article N1 - L359297124 2010-08-12 PY - 2010 SN - 1538-0688 SP - E160-167 ST - Evaluation of conceptual framework for recruitment of African American patients with breast cancer T2 - Oncology nursing forum TI - Evaluation of conceptual framework for recruitment of African American patients with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359297124&from=export http://dx.doi.org/10.1188/10.ONF.E160-E167 VL - 37 ID - 1166 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To describe the Heiney‐Adams Recruitment Framework (H‐ARF); to delineate a recruitment plan for a randomized, behavioral trial (RBT) based on H‐ARF; and to provide evaluation data on its implementation. DATA SOURCES: All data for this investigation originated from a recruitment database created for an RBT designed to test the effectiveness of a therapeutic group convened via teleconference for African American women with breast cancer. DATA SYNTHESIS: Major H‐ARF concepts include social marketing and relationship building. The majority of social marketing strategies yielded 100% participant recruitment. Greater absolute numbers were recruited via Health Insurance Portability and Accountability Act waivers. Using H‐ARF yielded a high recruitment rate (66%). CONCLUSIONS: Application of H‐ARF led to successful recruitment in an RBT. The findings highlight three areas that researchers should consider when devising recruitment plans: absolute numbers versus recruitment rate, cost, and efficiency with institutional review board‐approved access to protected health information. IMPLICATIONS FOR NURSING: H‐ARF may be applied to any clinical or population‐based research setting because it provides direction for researchers to develop a recruitment plan based on the target audience and cultural attributes that may hinder or help recruitment. AN - CN-01760310 AU - Heiney, S. P. AU - Adams, S. A. AU - Wells, L. M. AU - Johnson, H. DO - 10.1188/10.ONF.E160-E167 IS - 3 KW - *African American *breast tumor *female *patient selection *psychological model *social marketing Article Audiovisual equipment Cultural competence Education Ethnology Evaluation study Health care quality Human Human relation Model Nursing evaluation research Patient attitude Program development Psychological aspect Randomized controlled trial Self help Telecommunication Trust M3 - Journal: Article PY - 2010 SP - E160‐167 ST - Evaluation of conceptual framework for recruitment of African American patients with breast cancer T2 - Oncology nursing forum TI - Evaluation of conceptual framework for recruitment of African American patients with breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01760310/full VL - 37 ID - 1474 ER - TY - JOUR AB - Purpose/Objectives: To describe the Heiney-Adams Recruitment Framework (H-ARF); to delineate a recruitment plan for a randomized, behavioral trial (RBT) based on H-ARF; and to provide evaluation data on its implementation.Data Sources: All data for this investigation originated from a recruitment database created for an RBT designed to test the effectiveness of a therapeutic group convened via teleconference for African American women with breast cancer.Data Synthesis: Major H-ARF concepts include social marketing and relationship building. The majority of social marketing strategies yielded 100% participant recruitment. Greater absolute numbers were recruited via Health Insurance Portability and Accountability Act waivers. Using H-ARF yielded a high recruitment rate (66%).Conclusions: Application of H-ARF led to successful recruitment in an RBT. The findings highlight three areas that researchers should consider when devising recruitment plans: absolute numbers versus recruitment rate, cost, and efficiency with institutional review board-approved access to protected health information.Implications for Nursing: H-ARF may be applied to any clinical or population-based research setting because it provides direction for researchers to develop a recruitment plan based on the target audience and cultural attributes that may hinder or help recruitment. AD - Cancer Prevention and Control Program, University of South Carolina, Columbia AN - 105195946. Language: English. Entry Date: 20100702. Revision Date: 20200708. Publication Type: Journal Article AU - Heiney, S. P. AU - Adams, S. A. AU - Wells, L. M. AU - Johnson, H. DB - CINAHL Complete DO - 10.1188/10.ONF.E160-E167 DP - EBSCOhost IS - 3 KW - Black Persons Breast Neoplasms Conceptual Framework -- Evaluation Research Subject Recruitment Databases Marketing Models, Theoretical Professional-Patient Relations Referral and Consultation Research Subject Recruitment -- Methods N1 - statistics; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033. PMID: NLM20439201. PY - 2010 SN - 0190-535X SP - E160-7 ST - Evaluation of conceptual framework for recruitment of African American patients with breast cancer T2 - Oncology Nursing Forum TI - Evaluation of conceptual framework for recruitment of African American patients with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105195946&site=ehost-live&scope=site VL - 37 ID - 1946 ER - TY - JOUR AB - Purpose/Objectives: To describe the Heiney-Adams Recruitment Framework (H-ARF); to delineate a recruitment plan for a randomized, behavioral trial (RBT) based on H-ARF; and to provide evaluation data on its implementation. Data Sources: All data for this investigation originated from a recruitment database created for an RBT designed to test the effectiveness of a therapeutic group convened via teleconference for African American women with breast cancer. Data Synthesis: Major H-ARF concepts include social marketing and relationship building. The majority of social marketing strategies yielded 100% participant recruitment. Greater absolute numbers were recruited via Health Insurance Portability and Accountability Act waivers. Using H-ARF yielded a high recruitment rate (66%). Conclusions: Application of H-ARF led to successful recruitment in an RBT. The findings highlight three areas that researchers should consider when devising recruitment plans: absolute numbers versus recruitment rate, cost, and efficiency with institutional review board-approved access to protected health information. Implications for Nursing: H-ARF may be applied to any clinical or population-based research setting because it provides direction for researchers to develop a recruitment plan based on the target audience and cultural attributes that may hinder or help recruitment. AD - Cancer Prevention and Control Program, College of Nursing, University of South Carolina, Columbia, United States College of Nursing, University of South Carolina, Columbia, United States AU - Heiney, S. P. AU - Adams, S. A. AU - Wells, L. M. AU - Johnson, H. DB - Scopus DO - 10.1188/10.ONF.E160-E167 IS - 3 M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2010 SP - E160-E167 ST - Evaluation of conceptual framework for recruitment of African American patients with Breast Cancer T2 - Oncology Nursing Forum TI - Evaluation of conceptual framework for recruitment of African American patients with Breast Cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955289275&doi=10.1188%2f10.ONF.E160-E167&partnerID=40&md5=9e71817e6da33a8fad4e4d0baf1f8d94 VL - 37 ID - 2500 ER - TY - JOUR AB - Purpose: The objective of this investigation was to assess the impact of race (black v white) on the survival of patients with multiple myeloma treated within the context of a large clinical trial. Patients and Methods: A cohort of patients randomized to receive one of two treatment regimens and monitored for at least 10 years was studied to assess the impact of race as a prognostic factor, after adjusting for other known factors such as stage of disease. Patients were recruited from the referral network of the Southwest Oncology Group (SWOG), a national multiinstitutional consortium that includes both academic and community treatment centers. Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease. They were carefully characterized as to demographic and clinical features, and were randomized to receive one of two treatment regimens, which proved to have virtually identical outcomes. The outcome measure was survival, measured from the date of randomization to the date of last contact. Patients still alive at last contact date were treated as censored observations. Results: Survival for black myeloma patients was similar to that for white patients, both overall and adjusted for prognostic factors such as stage. Conclusion: Observed differences in mortality between blacks and whites cannot be attributed to differences in survival after diagnosis, given comparable treatment. AD - J. Crowley, SOGSC, Fred Hutchinson Cancer Research Ctr., 1124 Columbia St, Seattle, WA 98104, United States AU - Modiano, M. R. AU - Villar-Werstler, P. AU - Crowley, J. AU - Salmon, S. E. DB - Embase Medline DO - 10.1200/JCO.1996.14.3.974 IS - 3 KW - adult aged article cancer staging cancer survival female human major clinical study male multiple myeloma priority journal prognosis race treatment outcome LA - English M3 - Article N1 - L26085545 1996-03-28 PY - 1996 SN - 0732-183X SP - 974-977 ST - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229 T2 - Journal of Clinical Oncology TI - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L26085545&from=export http://dx.doi.org/10.1200/JCO.1996.14.3.974 VL - 14 ID - 1339 ER - TY - JOUR AB - Purpose: The objective of this investigation was to assess the impact of race (black v white) on the survival of patients with multiple myeloma treated within the context of a large clinical trial. Patients and Methods: A cohort of patients randomized to receive one of two treatment regimens and monitored for at least 10 years was studied to assess the impact of race as a prognostic factor, after adjusting for other known factors such as stage of disease. Patients were recruited from the referral network of the Southwest Oncology Group (SWOG), a national multiinstitutional consortium that includes both academic and community treatment centers. Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease. They were carefully characterized as to demographic and clinical features, and were randomized to receive one of two treatment regimens, which proved to have virtually identical outcomes. The outcome measure was survival, measured from the date of randomization to the date of last contact. Patients still alive at last contact date were treated as censored observations. Results: Survival for black myeloma patients was similar to that for white patients, both overall and adjusted for prognostic factors such as stage. Conclusion: Observed differences in mortality between blacks and whites cannot be attributed to differences in survival after diagnosis, given comparable treatment. AD - Arizona Cancer Center, University of Arizona, Tucson, United States AU - Modiano, M. R. AU - Villar-Werstler, P. AU - Crowley, J. AU - Salmon, S. E. DB - Scopus DO - 10.1200/JCO.1996.14.3.974 IS - 3 M3 - Article N1 - Cited By :33 Export Date: 22 March 2021 PY - 1996 SP - 974-977 ST - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229 T2 - Journal of Clinical Oncology TI - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029926247&doi=10.1200%2fJCO.1996.14.3.974&partnerID=40&md5=851149728e38c9c76c1aeb77e70edf4c VL - 14 ID - 2652 ER - TY - JOUR AB - Purpose: The objective of this investigation was to assess the impact of race (black v white) on the survival of patients with multiple myeloma treated within the context of a large clinical trial. Patients and Methods: A cohort of patients randomized to receive one of two treatment regimens and monitored for at least 10 years was studied to assess the impact of race as a prognostic factor, after adjusting for other known factors such as stage of disease, Patients were recruited from the referral network of the Southwest Oncology Group (SWOG), a national multiinstitutional consortium that includes both academic and community treatment centers, Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease. They were carefully characterized as to demographic and clinical features, and were randomized to receive one of two treatment regimens, which proved to have virtually identical outcomes, The outcome measure was survival, measured from the date of randomization to the date of last contact. Patients still alive at last contact date were treated as censored observations. Results: Survival for black myeloma patients was similar to that for white patients, both overall and adjusted for prognostic factors such as stage. Conclusion: Observed differences in mortality between blacks and whites cannot be attributed to differences in survival after diagnosis, given comparable treatment. (C) 1996 by American Society of Clinical Oncology. AN - WOS:A1996TZ73200037 AU - Modiano, M. R. AU - VillarWerstler, P. AU - Crowley, J. AU - Salmon, S. E. DA - Mar DO - 10.1200/JCO.1996.14.3.974 IS - 3 N1 - 27 8622048 PY - 1996 SN - 0732-183X SP - 974-977 ST - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group Study 8229 T2 - Journal of Clinical Oncology TI - Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group Study 8229 VL - 14 ID - 2738 ER - TY - JOUR AB - PURPOSE: The objective of this investigation was to assess the impact of race (black v white) on the survival of patients with multiple myeloma treated within the context of a large clinical trial. PATIENTS AND METHODS: A cohort of patients randomized to receive one of two treatment regimens and monitored for at least 10 years was studied to assess the impact of race as a prognostic factor, after adjusting for other known factors such as stage of disease. Patients were recruited from the referral network of the Southwest Oncology Group (SWOG), a national multiinstitutional consortium that includes both academic and community treatment centers. Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease. They were carefully characterized as to demographic and clinical features, and were randomized to receive one of two treatment regimens, which proved to have virtually identical outcomes. The outcome measure was survival, measured from the date of randomization to the date of last contact. Patients still alive at last contact date were treated as censored observation. RESULTS: Survival for black myeloma patients was similar to that for white patients, both overall and adjusted for prognostic factors such as stage. CONCLUSION: Observed differences in mortality between blacks and whites cannot be attributed to differences in survival after diagnosis, given comparable treatment. AN - CN-00123787 AU - Modiano, M. R. AU - Villar-Werstler, P. AU - Crowley, J. AU - Salmon, S. E. DO - 10.1200/JCO.1996.14.3.974 IS - 3 KW - African Continental Ancestry Group Antineoplastic Combined Chemotherapy Protocols [therapeutic use] Carmustine [administration & dosage] Cohort Studies Cyclophosphamide [administration & dosage] Doxorubicin [administration & dosage] European Continental Ancestry Group Female Humans Male Melphalan [administration & dosage] Middle Aged Multiple Myeloma [drug therapy, *genetics, *mortality] Prednisone [administration & dosage] Retrospective Studies Survival Analysis Vincristine [administration & dosage] M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 1996 SP - 974‐977 ST - Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229 T2 - Journal of clinical oncology TI - Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229 UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00123787/full VL - 14 ID - 1399 ER - TY - JOUR AB - The purpose of this study was to determine in healthy humans whether First Leaf (FL; composed of blackcurrant extract powder, lactoferrin and lutein) and Cassis Anthomix 30 (CAM30; blackcurrant extract powder) can positively modify the colonic microbiota by enhancing the growth of the beneficial bacteria and inactivating the toxic bacterial enzymes which are known to be involved in colonic carcinogenesis. Thirty healthy adult male and female volunteers were recruited for this study. Fluorescent in situ hybridization was carried out to analyse the populations of fecal microbiota. Consumption of FL and CAM30 led to significant increases (P < 0.0001) in the population sizes of lactobacilli and bifidobacteria whereas the population sizes of Clostridium spp. and Bacteroides spp were decreased significantly (P < 0.0001). In addition, feeding of FL and CAM30 decreases the activity of β‐glucuronidase (bacterial enzyme which is considered to be one of the enzymes that increases risk for colorectal cancer) and significantly decreased (P < 0.05) the fecal pH. In conclusion, the results of this study open up the possibility that consumption of FL and CAM30 can offer various benefits to human health through acting as novel prebiotic agents via increasing the numbers of beneficial bacteria (lactobacilli and bifidobacteria) in the gut. AN - CN-00981029 AU - Molan, A. L. AU - Liu, Z. AU - Plimmer, G. DO - 10.1002/ptr.5009 IS - 3 KW - *black currant extract/ct [Clinical Trial] *black currant extract/pd [Pharmacology] *cancer risk *colorectal cancer *intestine flora Adult Antimicrobial activity Article Bacteria [*drug effects] Bacterial enzyme Bacterial growth Beta glucuronidase/ec [Endogenous Compound] Bifidobacteriales Colonic Neoplasms [microbiology, *prevention & control] Controlled study Diet supplementation Drug dosage form comparison Enzyme activity Feces [microbiology] Feces microflora Female Fluorescence in situ hybridization Glucuronidase [metabolism] Healthy Volunteers Human Human experiment Humans Lactobacillus casei Lactoferrin [pharmacology] Lactoferrin/an [Drug Analysis] Lutein [pharmacology] Male Microbiota [*drug effects] Middle Aged Normal human PH Plant Extracts [*pharmacology] Prebiotic agent Prebiotics Randomized controlled trial Ribes [*chemistry] Risk Factors Risk benefit analysis Xanthophyll/an [Drug Analysis] Young Adult beta‐Glucosidase [metabolism] M3 - Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2014 SP - 416‐422 ST - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans T2 - Phytotherapy research : PTR TI - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00981029/full VL - 28 ID - 1465 ER - TY - JOUR AB - The purpose of this study was to determine in healthy humans whether First Leaf (FL; composed of blackcurrant extract powder, lactoferrin and lutein) and Cassis Anthomix 30 (CAM30; blackcurrant extract powder) can positively modify the colonic microbiota by enhancing the growth of the beneficial bacteria and inactivating the toxic bacterial enzymes which are known to be involved in colonic carcinogenesis. Thirty healthy adult male and female volunteers were recruited for this study. Fluorescent in situ hybridization was carried out to analyse the populations of fecal microbiota. Consumption of FL and CAM30 led to significant increases (P < 0.0001) in the population sizes of lactobacilli and bifidobacteria whereas the population sizes of Clostridium spp. and Bacteroides spp were decreased significantly (P < 0.0001). In addition, feeding of FL and CAM30 decreases the activity of β-glucuronidase (bacterial enzyme which is considered to be one of the enzymes that increases risk for colorectal cancer) and significantly decreased (P < 0.05) the fecal pH. In conclusion, the results of this study open up the possibility that consumption of FL and CAM30 can offer various benefits to human health through acting as novel prebiotic agents via increasing the numbers of beneficial bacteria (lactobacilli and bifidobacteria) in the gut. © 2013 John Wiley & Sons, Ltd. AD - Institute of Food, Nutrition and Human Health, College of Health, Massey University, Palmerston North, New Zealand AU - Molan, A. L. AU - Liu, Z. AU - Plimmer, G. DB - Scopus DO - 10.1002/ptr.5009 IS - 3 KW - bacterial enzymes blackcurrant products CAM30 FL prebiotic activity M3 - Article N1 - Cited By :27 Export Date: 22 March 2021 PY - 2014 SP - 416-422 ST - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans T2 - Phytotherapy Research TI - Evaluation of the effect of blackcurrant products on gut microbiota and on markers of risk for colon cancer in humans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84895788485&doi=10.1002%2fptr.5009&partnerID=40&md5=786964d4a83858e076f34d4f8829289b VL - 28 ID - 2418 ER - TY - JOUR AB - Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men. © 2009 BJU International. AD - V. N. Giri, Prostate Cancer Risk Assessment Program, Fox Chase Cancer Center, 510 Township Line Road, Cheltenham, PA 19012, United States AU - Kaplan, D. J. AU - Boorjian, S. A. AU - Ruth, K. AU - Egleston, B. L. AU - Chen, D. Y. T. AU - Viterbo, R. AU - Uzzo, R. G. AU - Buyyounouski, M. K. AU - Raysor, S. AU - Giri, V. N. DB - Embase Medline DO - 10.1111/j.1464-410X.2009.08793.x IS - 3 KW - BRCA1 protein BRCA2 protein prostate specific antigen adult African American aged article cancer diagnosis cancer prevention cancer risk cancer screening cancer staging clinical trial controlled study European American gene mutation Gleason score high risk patient human major clinical study male patient assessment population priority journal prostate cancer prostate secretion risk assessment LA - English M3 - Article N1 - L358179408 2010-02-04 2010-05-04 PY - 2010 SN - 1464-4096 1464-410X SP - 334-337 ST - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population T2 - BJU International TI - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358179408&from=export http://dx.doi.org/10.1111/j.1464-410X.2009.08793.x VL - 105 ID - 1170 ER - TY - JOUR AB - Objective: To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. Patients and Methods: Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. Results: In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score ≥7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason ≥7 prostate cancer vs 15.2% in all other participants (P < 0.001). Conclusion: The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These Results: support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men. © 2009 BJU International. AD - Department of Surgical Oncology Department of Biostatistics Department of Radiation Oncology Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, United States AU - Kaplan, D. J. AU - Boorjian, S. A. AU - Ruth, K. AU - Egleston, B. L. AU - Chen, D. Y. T. AU - Viterbo, R. AU - Uzzo, R. G. AU - Buyyounouski, M. K. AU - Raysor, S. AU - Giri, V. N. DB - Scopus DO - 10.1111/j.1464-410X.2009.08793.x IS - 3 KW - Biopsy Calculator Prediction Prevention Prostate cancer Race M3 - Article N1 - Cited By :17 Export Date: 22 March 2021 PY - 2010 SP - 334-337 ST - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population T2 - BJU International TI - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-75149130978&doi=10.1111%2fj.1464-410X.2009.08793.x&partnerID=40&md5=4e86981f451c1bb8c5fc200835099880 VL - 105 ID - 2503 ER - TY - JOUR AB - OBJECTIVE To evaluate the Prostate Cancer Prevention Trial (PCPT) risk calculator in a screening cohort of young, racially diverse, high-risk men with a low baseline prostate-specific antigen (PSA) level and enrolled in the Prostate Cancer Risk Assessment Program (PRAP). The PCPT calculator provides an assessment of prostate cancer risk based on age, PSA level, race, previous biopsy, and family history. PATIENTS AND METHODS Eligibility for PRAP includes men aged 35-69 years who are African-American, have a family history of prostate cancer, or have a known BRCA1/2 mutation. PCPT risk scores were determined for PRAP participants, and were compared to observed prostate cancer rates. RESULTS In all, 624 participants were evaluated, including 382 (61.2%) African-American men and 242 (38.7%) men with a family history of prostate cancer; the median (range) age was 49.0 (34.0-69.0) years and the median PSA level 0.9 (0.1-27.2) ng/mL. The PCPT risk score correlated with prostate cancer diagnosis, as the median baseline risk score in patients diagnosed with prostate cancer was 31.3%, vs 14.2% in patients not diagnosed with prostate cancer (P < 0.001). The PCPT calculator similarly stratified the risk of diagnosis of Gleason score >= 7 disease, as the median risk score was 36.2% in patients diagnosed with Gleason >= 7 prostate cancer vs 15.2% in all other participants (P < 0.001). CONCLUSION The PCPT risk calculator score was found to stratify prostate cancer risk in a cohort of young, primarily African-American men with a low baseline PSA level. These results support further evaluation of this predictive tool for assessing the risk of prostate cancer in high-risk men. AN - WOS:000273656600009 AU - Kaplan, D. J. AU - Boorjian, S. A. AU - Ruth, K. AU - Egleston, B. L. AU - Chen, D. Y. T. AU - Viterbo, R. AU - Uzzo, R. G. AU - Buyyounouski, M. K. AU - Raysor, S. AU - Giri, V. N. DA - Feb DO - 10.1111/j.1464-410X.2009.08793.x IS - 3 N1 - 19709072 PY - 2010 SN - 1464-4096 SP - 334-337 ST - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population T2 - Bju International TI - Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population VL - 105 ID - 3124 ER - TY - JOUR AB - Purpose: A number of factors have been identified as being associated with the documented low accrual rate of minorities into cancer-related clinical trials in the USA. An important issue is the fundamental interest, or lack thereof, of these specific patient populations in actually considering study participation. Methods: To examine this issue, aggregate data were analyzed from a proprietary Internet-based decision support program (NexProfiler Treatment Option Tools for Cancer, NexCura®, Seattle, WA, USA) embedded into approximately 100 cancer-associated Web sites where responding patients (or their families) were asked, but not required, to identify their race/ethnicity (African-American, Asian-American, Caucasian and Hispanic) and to also respond to the question, "Are you interested in learning about clinical trials?". Results: Of the >60,000 patients who both self-identified their race/ethnicity and responded to the question regarding their desire to learn about clinical trials, approximately 10% were from the minority (non-Caucasian) groups. Of note, in all four malignancies analyzed (breast, colorectal, lung, and prostate) and in both patients ≤60 and >60 years of age, each of the three non-Caucasian populations expressed an interest in learning about such studies that was equal to, if not greater than, that observed in the Caucasian respondents. Conclusion: Assuming these provocative results regarding self-declared desire to learn about clinical trials can be confirmed by others with similar Internet-associated databases, this analysis suggests Web-based recruitment strategies may be an effective method to communicate with minority populations in the US (and, perhaps, elsewhere) with a specific interest in considering participation in cancer clinical trials. © 2007 Springer-Verlag. AD - M. Markman, University of Texas M.D. Anderson Cancer Center, Mail Box #121, 1515 Holcombe Boulevard, Houston, TX 77030, United States AU - Markman, M. AU - Petersen, J. AU - Montgomery, R. DB - Embase Medline DO - 10.1007/s00432-007-0263-4 IS - 1 KW - article breast cancer cancer research clinical research colorectal cancer controlled study ethnicity health education health program health promotion human Internet learning lung cancer major clinical study priority journal prostate cancer race difference LA - English M3 - Article N1 - L350060692 2007-11-21 PY - 2008 SN - 0171-5216 SP - 115-118 ST - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials T2 - Journal of Cancer Research and Clinical Oncology TI - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350060692&from=export http://dx.doi.org/10.1007/s00432-007-0263-4 VL - 134 ID - 1218 ER - TY - JOUR AB - Purpose: A number of factors have been identified as being associated with the documented low accrual rate of minorities into cancer-related clinical trials in the USA. An important issue is the fundamental interest, or lack thereof, of these specific patient populations in actually considering study participation. Methods: To examine this issue, aggregate data were analyzed from a proprietary Internet-based decision support program (NexProfiler Treatment Option Tools for Cancer, NexCura®, Seattle, WA, USA) embedded into approximately 100 cancer-associated Web sites where responding patients (or their families) were asked, but not required, to identify their race/ethnicity (African-American, Asian-American, Caucasian and Hispanic) and to also respond to the question, "Are you interested in learning about clinical trials?". Results: Of the >60,000 patients who both self-identified their race/ethnicity and responded to the question regarding their desire to learn about clinical trials, approximately 10% were from the minority (non-Caucasian) groups. Of note, in all four malignancies analyzed (breast, colorectal, lung, and prostate) and in both patients ≤60 and >60 years of age, each of the three non-Caucasian populations expressed an interest in learning about such studies that was equal to, if not greater than, that observed in the Caucasian respondents. Conclusion: Assuming these provocative results regarding self-declared desire to learn about clinical trials can be confirmed by others with similar Internet-associated databases, this analysis suggests Web-based recruitment strategies may be an effective method to communicate with minority populations in the US (and, perhaps, elsewhere) with a specific interest in considering participation in cancer clinical trials. © 2007 Springer-Verlag. AD - University of Texas M.D. Anderson Cancer Center, Mail Box #121, 1515 Holcombe Boulevard, Houston, TX 77030, United States NexCura, A Thomson Business, Seattle, WA, United States AU - Markman, M. AU - Petersen, J. AU - Montgomery, R. DB - Scopus DO - 10.1007/s00432-007-0263-4 IS - 1 M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2008 SP - 115-118 ST - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials T2 - Journal of Cancer Research and Clinical Oncology TI - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-35848955185&doi=10.1007%2fs00432-007-0263-4&partnerID=40&md5=c72d828a5beaf712aed74a10cf731ac6 VL - 134 ID - 2543 ER - TY - JOUR AB - Purpose A number of factors have been identified as being associated with the documented low accrual rate of minorities into cancer-related clinical trials in the USA. An important issue is the fundamental interest, or lack thereof, of these specific patient populations in actually considering study participation. Methods To examine this issue, aggregate data were analyzed from a proprietary Internet-based decision support program (NexProfiler Treatment Option Tools for Cancer, NexCura((R)), Seattle, WA, USA) embedded into approximately 100 cancer-associated Web sites where responding patients (or their families) were asked, but not required, to identify their race/ethnicity (African-American, Asian-American, Caucasian and Hispanic) and to also respond to the question, "Are you interested in learning about clinical trials?". Results Of the > 60,000 patients who both self-identified their race/ethnicity and responded to the question regarding their desire to learn about clinical trials, approximately 10% were from the minority (non-Caucasian) groups. Of note, in all four malignancies analyzed (breast, colorectal, lung, and prostate) and in both patients <= 60 and > 60 years of age, each of the three non-Caucasian populations expressed an interest in learning about such studies that was equal to, if not greater than, that observed in the Caucasian respondents. Conclusion Assuming these provocative results regarding self-declared desire to learn about clinical trials can be confirmed by others with similar Internet-associated databases, this analysis suggests Web-based recruitment strategies may be an effective method to communicate with minority populations in the US (and, perhaps, elsewhere) with a specific interest in considering participation in cancer clinical trials. AN - WOS:000250722100015 AU - Markman, M. AU - Petersen, J. AU - Montgomery, R. DA - Jan DO - 10.1007/s00432-007-0263-4 IS - 1 N1 - 17598129 PY - 2008 SN - 0171-5216 SP - 115-118 ST - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials T2 - Journal of Cancer Research and Clinical Oncology TI - An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials VL - 134 ID - 3180 ER - TY - JOUR AB - Background: Margin status is an important prognostic factor for local recurrence after breast conserving surgery (BCS) for breast cancer. We designed a prospective randomized trial to evaluate the effect of shave margins on positive margins and locoregional recurrence (LRR). Methods: Patients were randomized to BCS or BCS with resection of 5 additional margins (BCS + M). Tumor margins were classified as negative [>2 mm for ductal carcinoma in situ (DCIS); >1 mm for invasive carcinoma] based on guidelines at the time of accrual. Results: A total of 75 patients with stage 0–III breast cancer (76 samples) were randomized, mean age 59.6 years with median follow-up 39.5 months. Overall, 21 patients (27.6 %) had positive margins: 14 had undergone BCS and 7 BCS + M (p = 0.005). Of the 21 patients with positive margins, 19 had DCIS on final pathology (OR 7.56; 95 % CI 1.52–37.51).All patients with positive margins were offered re-excision; 11 had negative final margins after re-excision surgery. Overall, 6 patients (8.3 %) developed LRR with recurrence being more common in the BCS group when compared with the BCS + M group (17.2 vs 2.3 %; p = 0.025). Conclusions: Taking additional cavity shave margins at the time of initial excision resulted in a reduction in positive margin rate, a decrease in return to operating room for re-excision, and lower LRR. AD - V. Jones, Grady Memorial Hospital, Winship Cancer Institute, Emory University, Atlanta, GA, United States AU - Jones, V. AU - Linebarger, J. AU - Perez, S. AU - Gabram, S. AU - Okoli, J. AU - Bumpers, H. AU - Burns, B. AU - Mosunjac, M. AU - Rizzo, M. DB - Embase Medline DO - 10.1245/s10434-015-4789-4 IS - 2 KW - antineoplastic agent adult African American aged article breast cancer cancer adjuvant therapy cancer recurrence cancer surgery controlled study excision female human intraductal carcinoma invasive carcinoma locoregional recurrence major clinical study partial mastectomy pathology practice guideline prospective study public hospital randomized controlled trial re excision reoperation LA - English M3 - Article N1 - L605558667 2015-08-13 2016-03-07 PY - 2016 SN - 1534-4681 1068-9265 SP - 456-464 ST - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital T2 - Annals of Surgical Oncology TI - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605558667&from=export http://dx.doi.org/10.1245/s10434-015-4789-4 VL - 23 ID - 983 ER - TY - JOUR AB - Background: Margin status is an important prognostic factor for local recurrence after breast conserving surgery (BCS) for breast cancer. We designed a prospective randomized trial to evaluate the effect of shave margins on positive margins and locoregional recurrence (LRR). Methods: Patients were randomized to BCS or BCS with resection of 5 additional margins (BCS + M). Tumor margins were classified as negative [>2 mm for ductal carcinoma in situ (DCIS); >1 mm for invasive carcinoma] based on guidelines at the time of accrual. Results: A total of 75 patients with stage 0‐III breast cancer (76 samples) were randomized, mean age 59.6 years with median follow‐up 39.5 months. Overall, 21 patients (27.6 %) had positive margins: 14 had undergone BCS and 7 BCS + M (p = 0.005). Of the 21 patients with positive margins, 19 had DCIS on final pathology (OR 7.56; 95 % CI 1.52‐37.51).All patients with positive margins were offered re‐excision; 11 had negative final margins after re‐excision surgery. Overall, 6 patients (8.3 %) developed LRR with recurrence being more common in the BCS group when compared with the BCS + M group (17.2 vs 2.3 %; p = 0.025). Conclusions: Taking additional cavity shave margins at the time of initial excision resulted in a reduction in positive margin rate, a decrease in return to operating room for re‐excision, and lower LRR. AN - CN-01138290 AU - Jones, V. AU - Linebarger, J. AU - Perez, S. AU - Gabram, S. AU - Okoli, J. AU - Bumpers, H. AU - Burns, B. AU - Mosunjac, M. AU - Rizzo, M. DO - 10.1245/s10434-015-4789-4 IS - 2 KW - *breast cancer/dt [Drug Therapy] *breast cancer/su [Surgery] *cancer surgery *excision *partial mastectomy *re excision *reoperation Adult African American African Americans [*statistics & numerical data] Aged Aged, 80 and over Antineoplastic agent/dt [Drug Therapy] Article Breast Neoplasms [ethnology, pathology, *surgery] Cancer adjuvant therapy Cancer recurrence Carcinoma, Ductal, Breast [ethnology, pathology, *surgery] Carcinoma, Intraductal, Noninfiltrating [ethnology, pathology, *surgery] Controlled study Female Follow‐Up Studies Hospitals, Public Human Humans Intraductal carcinoma/su [Surgery] Invasive carcinoma/su [Surgery] Locoregional recurrence Major clinical study Mastectomy, Segmental Middle Aged Neoplasm Invasiveness Neoplasm Recurrence, Local [*diagnosis] Neoplasm Staging Neoplasm, Residual [ethnology, pathology, *surgery] Pathology Practice guideline Prognosis Prospective Studies Prospective study Public hospital Randomized controlled trial M3 - Clinical Trial; Journal Article; Randomized Controlled Trial PY - 2016 SP - 456‐464 ST - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: a Report of a Randomized Prospective Study in a Public Hospital T2 - Annals of surgical oncology TI - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: a Report of a Randomized Prospective Study in a Public Hospital UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01138290/full VL - 23 ID - 1360 ER - TY - JOUR AB - Background: Margin status is an important prognostic factor for local recurrence after breast conserving surgery (BCS) for breast cancer. We designed a prospective randomized trial to evaluate the effect of shave margins on positive margins and locoregional recurrence (LRR). Methods: Patients were randomized to BCS or BCS with resection of 5 additional margins (BCS + M). Tumor margins were classified as negative [>2 mm for ductal carcinoma in situ (DCIS); >1 mm for invasive carcinoma] based on guidelines at the time of accrual. Results: A total of 75 patients with stage 0–III breast cancer (76 samples) were randomized, mean age 59.6 years with median follow-up 39.5 months. Overall, 21 patients (27.6 %) had positive margins: 14 had undergone BCS and 7 BCS + M (p = 0.005). Of the 21 patients with positive margins, 19 had DCIS on final pathology (OR 7.56; 95 % CI 1.52–37.51).All patients with positive margins were offered re-excision; 11 had negative final margins after re-excision surgery. Overall, 6 patients (8.3 %) developed LRR with recurrence being more common in the BCS group when compared with the BCS + M group (17.2 vs 2.3 %; p = 0.025). Conclusions: Taking additional cavity shave margins at the time of initial excision resulted in a reduction in positive margin rate, a decrease in return to operating room for re-excision, and lower LRR. © 2015, Society of Surgical Oncology. AD - Grady Memorial Hospital, Winship Cancer Institute, Emory University, Atlanta, GA, United States Winship Cancer Institute, Emory University, Atlanta, GA, United States Department of Surgery, Gundersen Health System, La Crosse, WI, United States Morehouse School of Medicine, Grady Memorial Hospital, Atlanta, GA, United States Department of Surgery, Michigan State University, Lansing, MI, United States Department of Pathology, Grady Memorial Hospital, Emory University, Atlanta, GA, United States AU - Jones, V. AU - Linebarger, J. AU - Perez, S. AU - Gabram, S. AU - Okoli, J. AU - Bumpers, H. AU - Burns, B. AU - Mosunjac, M. AU - Rizzo, M. DB - Scopus DO - 10.1245/s10434-015-4789-4 IS - 2 M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2016 SP - 456-464 ST - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital T2 - Annals of Surgical Oncology TI - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958178875&doi=10.1245%2fs10434-015-4789-4&partnerID=40&md5=a7ad033b0f13b3d951329b915bc483b3 VL - 23 ID - 2349 ER - TY - JOUR AB - Margin status is an important prognostic factor for local recurrence after breast conserving surgery (BCS) for breast cancer. We designed a prospective randomized trial to evaluate the effect of shave margins on positive margins and locoregional recurrence (LRR). Patients were randomized to BCS or BCS with resection of 5 additional margins (BCS + M). Tumor margins were classified as negative [> 2 mm for ductal carcinoma in situ (DCIS); > 1 mm for invasive carcinoma] based on guidelines at the time of accrual. A total of 75 patients with stage 0-III breast cancer (76 samples) were randomized, mean age 59.6 years with median follow-up 39.5 months. Overall, 21 patients (27.6 %) had positive margins: 14 had undergone BCS and 7 BCS + M (p = 0.005). Of the 21 patients with positive margins, 19 had DCIS on final pathology (OR 7.56; 95 % CI 1.52-37.51).All patients with positive margins were offered re-excision; 11 had negative final margins after re-excision surgery. Overall, 6 patients (8.3 %) developed LRR with recurrence being more common in the BCS group when compared with the BCS + M group (17.2 vs 2.3 %; p = 0.025). Taking additional cavity shave margins at the time of initial excision resulted in a reduction in positive margin rate, a decrease in return to operating room for re-excision, and lower LRR. AN - WOS:000368721400016 AU - Jones, V. AU - Linebarger, J. AU - Perez, S. AU - Gabram, S. AU - Okoli, J. AU - Bumpers, H. AU - Burns, B. AU - Mosunjac, M. AU - Rizzo, M. DA - Feb DO - 10.1245/s10434-015-4789-4 IS - 2 N1 - 26254169 PY - 2016 SN - 1068-9265 SP - 456-464 ST - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital T2 - Annals of Surgical Oncology TI - Excising Additional Margins at Initial Breast-Conserving Surgery (BCS) Reduces the Need for Re-excision in a Predominantly African American Population: A Report of a Randomized Prospective Study in a Public Hospital VL - 23 ID - 2954 ER - TY - JOUR AB - Background: Optimizing participant response rates is important for obtaining representative samples and the timely completion of studies. It is a common practice to use participant incentives to boost response rates, but few studies have systematically examined their effectiveness, particularly among minority groups. Methods:We experimentally tested three incentive strategies for their effectiveness in improving response rates among colorectal cancer cases (n = 3,816) and their relatives (n = 2,353). A 2 x 2 x 2 factorial design compared (a) registered versus first class mail, (b) $5 cash with the initial mailing (yes/no), and (c) $20 promise (yes/no) upon completion of the information form (for cases) or $10 promise (yes/no) upon completion of the baseline survey (for relatives). Outcome measures were provision of contact information on first-degree relatives for cases and completion of the baseline survey for relatives. Results: The response rate among cases was low in all ethnic groups (28-37%) and incentive strategies did not have an effect. Among relatives, the overall baseline survey response rate was 71%, ranging from 66% among Asians to 76% among Whites. Modest absolute increases were observed for payment schedules that included a $5 cash enclosure with the initial mailing in the total sample [odds ratio (OR), 1.65 and 1.47] and among Latinos (OR, 1.94 and 1.74) but not among Asians (OR, 1.61 and 1.55) or African Americans (OR, 1.19 and 1.02). Response rates were not influenced by registered versus firstclass mailing. Conclusion: The effects of incentives in this study were modest with some suggestion of differences by ethnic group and type of incentive. Copyright © 2009 American Association for Cancer Research. AD - A. E. Maxwell, CHS, 650 Charles Young Drive South, Los Angeles, CA 90095-6900, United States AU - Maxwell, A. E. AU - Bastani, R. AU - Glenn, B. A. AU - Mojica, C. M. AU - Chang, L. C. DB - Embase Medline DO - 10.1158/1055-9965.EPI-09-0299 IS - 10 KW - adult African American aged article Asian American colorectal cancer controlled study ethnic difference European American experimental test factorial design female Hispanic human major clinical study male medical research money normal human patient participation priority journal relative reward LA - English M3 - Article N1 - L355445502 2009-11-20 PY - 2009 SN - 1055-9965 SP - 2620-2625 ST - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study T2 - Cancer Epidemiology Biomarkers and Prevention TI - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355445502&from=export http://dx.doi.org/10.1158/1055-9965.EPI-09-0299 http://cebp.aacrjournals.org/content/18/10/2620.full.pdf+html VL - 18 ID - 1179 ER - TY - JOUR AB - Background: Optimizing participant response rates is important for obtaining representative samples and the timely completion of studies. It is a common practice to use participant incentives to boost response rates, but few studies have systematically examined their effectiveness, particularly among minority groups. Methods:We experimentally tested three incentive strategies for their effectiveness in improving response rates among colorectal cancer cases (n = 3,816) and their relatives (n = 2,353). A 2 x 2 x 2 factorial design compared (a) registered versus first class mail, (b) $5 cash with the initial mailing (yes/no), and (c) $20 promise (yes/no) upon completion of the information form (for cases) or $10 promise (yes/no) upon completion of the baseline survey (for relatives). Outcome measures were provision of contact information on first-degree relatives for cases and completion of the baseline survey for relatives. Results: The response rate among cases was low in all ethnic groups (28-37%) and incentive strategies did not have an effect. Among relatives, the overall baseline survey response rate was 71%, ranging from 66% among Asians to 76% among Whites. Modest absolute increases were observed for payment schedules that included a $5 cash enclosure with the initial mailing in the total sample [odds ratio (OR), 1.65 and 1.47] and among Latinos (OR, 1.94 and 1.74) but not among Asians (OR, 1.61 and 1.55) or African Americans (OR, 1.19 and 1.02). Response rates were not influenced by registered versus firstclass mailing. Conclusion: The effects of incentives in this study were modest with some suggestion of differences by ethnic group and type of incentive. Copyright © 2009 American Association for Cancer Research. AD - School of Public Health, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, United States AU - Maxwell, A. E. AU - Bastani, R. AU - Glenn, B. A. AU - Mojica, C. M. AU - Chang, L. C. DB - Scopus DO - 10.1158/1055-9965.EPI-09-0299 IS - 10 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2009 SP - 2620-2625 ST - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study T2 - Cancer Epidemiology Biomarkers and Prevention TI - An experimental test of the effect of incentives on recruitment of ethnically diverse colorectal cancer cases and their first-degree relatives into a research study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350123750&doi=10.1158%2f1055-9965.EPI-09-0299&partnerID=40&md5=f16964ef5d643431080e3f23c40fe136 VL - 18 ID - 2511 ER - TY - JOUR AB - Background: Optimizing participant response rates is important for obtaining representative samples and the timely completion of studies. It is a common practice to use participant incentives to boost response rates, but few studies have systematically examined their effectiveness, particularly among minority groups. Methods: We experimentally tested three incentive strategies for their effectiveness in improving response rates among colorectal cancer cases (n = 3,816) and their relatives (n = 2,353). A 2 x 2 x 2 factorial design compared (a) registered versus first class mail, (b) $5 cash with the initial mailing (yes/no), and (c) $20 promise (yes/no) upon completion of the information form (for cases) or $10 promise (yes/no) upon completion of the baseline survey (for relatives). Outcome measures were provision of contact information on first-degree relatives for cases and completion of the baseline survey for relatives. Results: The response rate among cases was low in all ethnic groups (28-37%) and incentive strategies did not have an effect. Among relatives, the overall baseline survey response rate was 71%, ranging from 66% among Asians to 76% among Whites. Modest absolute increases were observed for payment schedules that included a $5 cash enclosure with the initial mailing in the total sample [odds ratio (OR), 1.65 and 1.47] and among Latinos (OR, 1.94 and 1.74) but not among Asians (OR, 1.61 and 1.55) or African Americans (OR, 1.19 and 1.02). Response rates were not influenced by registered versus first-class mailing. Conclusion: The effects of incentives in this study were modest with some suggestion of differences by ethnic group and type of incentive. (Cancer Epidemiol Biomarkers Prev 2009;1.8(10):2620-5) AN - WOS:000270702100006 AU - Maxwell, A. E. AU - Bastani, R. AU - Glenn, B. A. AU - Mojica, C. M. AU - Chang, L. C. DA - Oct DO - 10.1158/1055-9965.EPI-09-0299 IS - 10 N1 - 19755646 PY - 2009 SN - 1055-9965 SP - 2620-2625 ST - An Experimental Test of the Effect of Incentives on Recruitment of Ethnically Diverse Colorectal Cancer Cases and Their First-Degree Relatives into a Research Study T2 - Cancer Epidemiology Biomarkers & Prevention TI - An Experimental Test of the Effect of Incentives on Recruitment of Ethnically Diverse Colorectal Cancer Cases and Their First-Degree Relatives into a Research Study VL - 18 ID - 3138 ER - TY - JOUR AB - INTRODUCTION: African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed‐carboplatin‐bevacizumab and maintenance pemetrexed‐bevacizumab [PemCBev] vs. paclitaxel‐carboplatin‐bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS). MATERIALS AND METHODS: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. RESULTS: Of 939 intent‐to‐treat (ITT) patients, 94 were African American and 805 were white. African‐American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P = .525), progression‐free survival (PFS) (HR, 1.229; P = .251), response (P = .607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P = .209), PFS (HR, 0.902; P = .670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P = .191) or PFS (HR, 0.969; P = .915) in academic versus community practice settings. CONCLUSION: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies. AN - CN-01255011 AU - Reynolds, C. H. AU - Patel, J. D. AU - Garon, E. B. AU - Olsen, M. R. AU - Bonomi, P. AU - Govindan, R. AU - Pennella, E. J. AU - Liu, J. AU - Guba, S. C. AU - Li, S. AU - et al. DO - 10.1016/j.cllc.2014.11.004 IS - 3 KW - Adult African Americans [*ethnology] Aged Antineoplastic Combined Chemotherapy Protocols [*therapeutic use] Bevacizumab [administration & dosage] Carboplatin [administration & dosage] Carcinoma, Non‐Small‐Cell Lung [*drug therapy, ethnology, pathology] Disease‐Free Survival Drug Administration Schedule Female Humans Lung Neoplasms [*drug therapy, ethnology, pathology] Male Middle Aged Neoplasm Staging Paclitaxel [administration & dosage] Pemetrexed [administration & dosage] Retrospective Studies Survival Analysis Treatment Outcome M3 - Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2015 SP - 200‐208 ST - Exploratory Subset Analysis of African Americans From the PointBreak Study: pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer T2 - Clinical lung cancer TI - Exploratory Subset Analysis of African Americans From the PointBreak Study: pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01255011/full VL - 16 ID - 1376 ER - TY - JOUR AB - Introduction: African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS).Materials and Methods: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates.Results: Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P = .525), progression-free survival (PFS) (HR, 1.229; P = .251), response (P = .607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P = .209), PFS (HR, 0.902; P = .670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P = .191) or PFS (HR, 0.969; P = .915) in academic versus community practice settings.Conclusion: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies. AN - 109727363. Language: English. Entry Date: 20150923. Revision Date: 20160502. Publication Type: journal article AU - Reynolds, Craig H. AU - Patel, Jyoti D. AU - Garon, Edward B. AU - Olsen, Mark R. AU - Bonomi, Philip AU - Govindan, Ramaswamy AU - Pennella, Eduardo J. AU - Liu, Jingyi AU - Guba, Susan C. AU - Li, Shi AU - Spigel, David R. AU - Hermann, Robert C. AU - Socinski, Mark A. AU - Obasaju, Coleman K. DB - CINAHL Complete DO - 10.1016/j.cllc.2014.11.004 DP - EBSCOhost IS - 3 N1 - clinical trial; research; randomized controlled trial. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care. NLM UID: 100893225. PMID: NLM25516338. PY - 2015 SN - 1525-7304 SP - 200-208 ST - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer T2 - Clinical Lung Cancer TI - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109727363&site=ehost-live&scope=site VL - 16 ID - 1948 ER - TY - JOUR AB - Introduction African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS). Materials and Methods PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. Results Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P =.525), progression-free survival (PFS) (HR, 1.229; P =.251), response (P =.607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P =.209), PFS (HR, 0.902; P =.670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P =.191) or PFS (HR, 0.969; P =.915) in academic versus community practice settings. Conclusion In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies. © 2015 Elsevier Inc. AD - US Oncology Research, 433 SW 10 Street, Ocala, FL 34471, United States Northwestern University Feinberg School of Medicine, Chicago, IL, United States University of California, Los Angeles, David Geffen School of Medicine, Translational Research in Oncology-United States, Los Angeles, CA, United States Tulsa Cancer Institute, Tulsa, OK, United States Rush University Medical Center, Chicago, IL, United States Washington University School of Medicine, St Louis, MO, United States Eli Lilly and Company, Indianapolis, IN, United States Sarah Cannon Research Institute, Nashville, TN, United States Northwest Georgia Oncology Centers, PC, Marietta, GA, United States Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States Tennessee Oncology, PLLC, Nashville, TN, United States AU - Reynolds, C. H. AU - Patel, J. D. AU - Garon, E. B. AU - Olsen, M. R. AU - Bonomi, P. AU - Govindan, R. AU - Pennella, E. J. AU - Liu, J. AU - Guba, S. C. AU - Li, S. AU - Spigel, D. R. AU - Hermann, R. C. AU - Socinski, M. A. AU - Obasaju, C. K. DB - Scopus DO - 10.1016/j.cllc.2014.11.004 IS - 3 KW - Alimta Avastin Minority groups M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2015 SP - 200-208 ST - Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer T2 - Clinical Lung Cancer TI - Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84928706378&doi=10.1016%2fj.cllc.2014.11.004&partnerID=40&md5=aa582011cbcc6b86f165b6a5761c542d VL - 16 ID - 2372 ER - TY - JOUR AB - The present exploratory analysis of the PointBreak trial showed no significant differences between African Americans and whites for overall survival, progression-free survival, overall response rate, or toxicity when treated with pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab. Consistent with the intent-to-treat population, the median overall survival was not superior for African Americans in either treatment arm. Introduction: African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the patients were African American. PointBreak had negative findings; PemCBev did not demonstrate superior overall survival (OS). Materials and Methods: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and academic versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. Results: Of 939 intent-to-treat (ITT) patients, 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, OS (HR, 1.125; P = .525), progression-free survival (PFS) (HR, 1.229; P = .251), response (P = .607), and toxicity profiles were similar in African Americans versus whites. For African Americans, OS (HR, 1.375; P = .209), PFS (HR, 0.902; P = .670), response (P = 1.000), and toxicity profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in OS (HR, 0.661; P = .191) or PFS (HR, 0.969; P = .915) in academic versus community practice settings. Conclusion: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or toxicity profiles. Consistent with the ITT population negative trial result, for African Americans, the median OS was not superior for either arm. For African Americans, PFS and OS were similar in the academic and community settings. Additional outcomes data for African Americans should be collected in lung cancer studies. AN - WOS:000353350500005 AU - Reynolds, C. H. AU - Patel, J. D. AU - Garon, E. B. AU - Olsen, M. R. AU - Bonomi, P. AU - Govindan, R. AU - Pennella, E. J. AU - Liu, J. Y. AU - Guba, S. C. AU - Li, S. AU - Spigel, D. R. AU - Hermann, R. C. AU - Socinski, M. A. AU - Obasaju, C. K. DA - May DO - 10.1016/j.cllc.2014.11.004 IS - 3 N1 - 25516338 PY - 2015 SN - 1525-7304 SP - 200-208 ST - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer T2 - Clinical Lung Cancer TI - Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer VL - 16 ID - 2977 ER - TY - JOUR AB - Background: Inequalities in cancer research participation are thought to exist with certain groups under-represented in research populations; however, much of the evidence is based on small-scale studies. The aim of this study was to explore data from in-depth interviews with cancer patients and a large national survey to investigate variation in who is asked to participate in research and who takes part. Methods: Factors associated with research discussion and participation were explored in National Cancer Patient Experience Survey data using multivariate logistic regression and during in-depth interviews with 25 breast cancer patients. Results: Survey data were available for 66,953 cancer patients; 30.4 % reported having discussions about, and 18.9 % took part in, research. Barriers to participation at staff, patient and trust level were evident; for example, staff were less likely to discuss research with older patients, Asian and black patients were less likely to take part and patients treated at specialist or teaching trusts had higher levels of discussion and participation. Interviews showed that patients' willingness to participate changed over time and was not synonymous with participation as some were ineligible. Conclusion: Some patient groups were less likely to have discussions about or participate in research. Analysis of this variation vis-à-vis the composition of the patient population may be useful to ensure that there is equity regarding the potential benefits of research participation and that research findings are applicable to target populations in the translational model. AD - L. Mc Grath-Lone, Patient Experience Research Centre, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, St. Mary's Campus, Norfolk Place, Paddington, London, United Kingdom AU - Mc Grath-Lone, L. AU - Day, S. AU - Schoenborn, C. AU - Ward, H. DB - Embase Medline DO - 10.1186/s12885-015-1628-8 IS - 1 KW - adolescent adult age distribution aged article Asian Black person breast cancer cancer patient cancer research Caucasian disease association ethnicity female health survey human major clinical study male middle aged patient participation LA - English M3 - Article N1 - L605870392 2015-09-09 2015-09-11 PY - 2015 SN - 1471-2407 ST - Exploring research participation among cancer patients: Analysis of a national survey and an in-depth interview study T2 - BMC Cancer TI - Exploring research participation among cancer patients: Analysis of a national survey and an in-depth interview study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605870392&from=export http://dx.doi.org/10.1186/s12885-015-1628-8 VL - 15 ID - 994 ER - TY - JOUR AB - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N=36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors. AD - K. Darby, Middle Tennessee State University, TN, USA. AU - Darby, K. AU - Davis, C. AU - Likes, W. AU - Bell, J. DB - Medline DO - 10.1353/hpu.0.0176 IS - 3 KW - adult African American article breast tumor economics ethnology female health care cost health care delivery health care planning human information processing middle aged qualitative research United States LA - English M3 - Article N1 - L355353014 2009-10-07 PY - 2009 SN - 1049-2089 SP - 721-728 ST - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study T2 - Journal of health care for the poor and underserved TI - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355353014&from=export http://dx.doi.org/10.1353/hpu.0.0176 VL - 20 ID - 1183 ER - TY - JOUR AB - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N = 36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Davis, Cindy, University of Tennessee, College of Social Work, 193 Polk Ave., Suite E, Nashville, TN, US, 37210 AN - 2009-11857-008 AU - Darby, Kathleen AU - Davis, Cindy AU - Likes, Wendy AU - Bell, John DB - psyh DO - 10.1353/hpu.0.0176 DP - EBSCOhost IS - 3 KW - financial impacts breast cancer African Americans medically underserved women Adult Breast Neoplasms Female Focus Groups Health Expenditures Health Services Accessibility Humans Medically Underserved Area Middle Aged Qualitative Research Tennessee Blacks Deprivation Financial Strain Human Females N1 - Middle Tennessee State University, Murfreesboro, TN, US. Release Date: 20100104. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Deprivation; Financial Strain; Human Females. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Qualitative Study. Page Count: 8. Issue Publication Date: Aug, 2009. Sponsor: University of Tennessee, Cancer Institute, Department of Energy Funds, US. Recipients: No recipient indicated PY - 2009 SN - 1049-2089 1548-6869 SP - 721-728 ST - Exploring the financial impact of breast cancer for African American medically underserved women: A qualitative study T2 - Journal of Health Care for the Poor and Underserved TI - Exploring the financial impact of breast cancer for African American medically underserved women: A qualitative study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-11857-008&site=ehost-live&scope=site cdavis3@utk.edu VL - 20 ID - 1761 ER - TY - JOUR AB - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N=36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors. AD - Middle Tennessee State University, TN, USA. AN - 105410929. Language: English. Entry Date: 20090925. Revision Date: 20200708. Publication Type: Journal Article AU - Darby, K. AU - Davis, C. AU - Likes, W. AU - Bell, J. DB - CINAHL Complete DO - 10.1353/hpu.0.0176 DP - EBSCOhost IS - 3 KW - Black Persons Breast Neoplasms -- Economics Medically Underserved Area -- Tennessee Women Continuity of Patient Care -- Economics Exploratory Research Female Focus Groups Funding Source Health Services Accessibility Medically Uninsured Qualitative Studies Tennessee Thematic Analysis Treatment Delay Human N1 - research; tables/charts. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. Grant Information: University of Tennessee Cancer Institute, Department of Energy Funds. NLM UID: 9103800. PMID: NLM19648700. PY - 2009 SN - 1049-2089 SP - 721-728 ST - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study T2 - Journal of Health Care for the Poor & Underserved TI - Exploring the financial impact of breast cancer for African American medically underserved women: a qualitative study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105410929&site=ehost-live&scope=site VL - 20 ID - 1949 ER - TY - JOUR AB - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N=36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors. AD - Middle Tennessee State University in Social Work, United States University of Tennessee, College of Social Work, 193 Polk Ave., Nashville, TN 37210, United States Department of Nursing, University of Tennessee, Memphis, United States University of Tennessee, Cancer Institute, Knoxville, United States AU - Darby, K. AU - Davis, C. AU - Likes, W. AU - Bell, J. DB - Scopus DO - 10.1353/hpu.0.0176 IS - 3 KW - African American Breast cancer Financial Minority Underserved M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 2009 SP - 721-728 ST - Exploring the financial impact of breast cancer for african american medically underserved women: A qualitative study T2 - Journal of Health Care for the Poor and Underserved TI - Exploring the financial impact of breast cancer for african american medically underserved women: A qualitative study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349574853&doi=10.1353%2fhpu.0.0176&partnerID=40&md5=729c07f5dfce7617d9d0a5ba5a3a5a20 VL - 20 ID - 2516 ER - TY - JOUR AB - In addition to the physical suffering experienced by cancer survivors, there are considerable financial hardships and access barriers to quality health care. The current study explored the financial burden of breast cancer on African American medically underserved women. Four focus groups were conducted in three major cities across Tennessee. Research participants (N = 36) were recruited by the staff of cancer support and treatment programs in the area. Findings revealed that participants' lack of insurance or inadequate insurance resulted in missed, delayed, or fewer treatment opportunities. The financial burden of cancer was not limited to the acute treatment phase. The women in the current study reported extreme economic hardship resulting from this disease into long-term survivorship. This exploratory study confirms the importance of providing care across the continuum to address the complex needs of low-income cancer survivors. AN - WOS:000268203000011 AU - Darby, K. AU - Davis, C. AU - Likes, W. AU - Bell, J. DA - Aug IS - 3 N1 - 19648700 PY - 2009 SN - 1049-2089 SP - 721-728 ST - Exploring the Financial Impact of Breast Cancer for African American Medically Underserved Women: A Qualitative Study T2 - Journal of Health Care for the Poor and Underserved TI - Exploring the Financial Impact of Breast Cancer for African American Medically Underserved Women: A Qualitative Study VL - 20 ID - 3142 ER - TY - JOUR AB - PURPOSE: To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors. METHODS: A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1-6 years post-diagnosis. RESULTS: Four hundred and sixty-eight participants agreed to participate constituting an 81% participation rate; 65 and 55% completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73%) than Latinas (62%) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation. CONCLUSIONS: Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects' characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals' enrollment and continued participation in studies. AU - Ashing, K. AU - Rosales, M. AU - Fernandez, A. DB - Medline DO - 10.1007/s11136-014-0758-9 IS - 2 KW - adult African American aged breast tumor comorbidity cultural anthropology ethnology female health behavior Hispanic human longitudinal study middle aged patient selection psychology questionnaire statistical model survivor United States LA - English M3 - Article N1 - L604900271 2015-06-23 PY - 2015 SN - 1573-2649 SP - 445-454 ST - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors T2 - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation TI - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604900271&from=export http://dx.doi.org/10.1007/s11136-014-0758-9 VL - 24 ID - 1009 ER - TY - JOUR AB - Purpose: To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors.Methods: A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1–6 years post-diagnosis.Results: Four hundred and sixty-eight participants agreed to participate constituting an 81 % participation rate; 65 and 55 % completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73 %) than Latinas (62 %) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation.Conclusions: Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects’ characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals’ enrollment and continued participation in studies. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ashing, Kimlin, Center of Community Alliance for Research and Education (CCARE), Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA, US, 91010-3000 AN - 2015-16525-017 AU - Ashing, Kimlin AU - Rosales, Monica AU - Fernandez, Alejandro DB - psyh DO - 10.1007/s11136-014-0758-9 DP - EBSCOhost IS - 2 KW - Recruitment Retention Ethnic minority Breast cancer Response bias Adult African Americans Aged Breast Neoplasms Comorbidity Culture Female Health Behavior Hispanic Americans Humans Logistic Models Longitudinal Studies Middle Aged Patient Selection Surveys and Questionnaires Survivors United States Behavior Therapy Intervention Latinos/Latinas Blacks N1 - Center of Community Alliance for Research and Education (CCARE), Department of Population Sciences, City of Hope, Duarte, CA, US. Release Date: 20150518. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Behavior Therapy; Breast Neoplasms; Intervention; Survivors; Latinos/Latinas. Minor Descriptor: Blacks. Classification: Cancer (3293); Behavior Therapy & Behavior Modification (3312). Population: Human (10). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Followup Study; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Feb, 2015. Publication History: First Posted Date: Jul 19, 2014; Accepted Date: Jul 14, 2014. Copyright Statement: Springer International Publishing Switzerland. 2014. Sponsor: US Department of Defense, Breast Cancer Research Program, US. Grant: W81XWH-04-1-0548. Recipients: No recipient indicated PY - 2015 SN - 0962-9343 1573-2649 SP - 445-454 ST - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors T2 - Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation TI - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-16525-017&site=ehost-live&scope=site kashing@coh.org VL - 24 ID - 1688 ER - TY - JOUR AB - Purpose: To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors.Methods: A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1-6 years post-diagnosis.Results: Four hundred and sixty-eight participants agreed to participate constituting an 81% participation rate; 65 and 55% completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73%) than Latinas (62%) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation.Conclusions: Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects' characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals' enrollment and continued participation in studies. AD - Center of Community Alliance for Research and Education (CCARE), Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA, 91010-3000, USA, kashing@coh.org. AN - 109776056. Language: English. Entry Date: 20150703. Revision Date: 20210110. Publication Type: journal article AU - Ashing, Kimlin AU - Rosales, Monica AU - Fernandez, Alejandro DB - CINAHL Complete DO - 10.1007/s11136-014-0758-9 DP - EBSCOhost IS - 2 KW - Black Persons -- Psychosocial Factors Breast Neoplasms -- Ethnology Health Behavior -- Ethnology Hispanic Americans -- Psychosocial Factors Patient Selection Survivors -- Psychosocial Factors Adult Aged Breast Neoplasms -- Psychosocial Factors Breast Neoplasms -- Therapy Comorbidity Culture Female Human Logistic Regression Prospective Studies Middle Age Questionnaires United States N1 - research. Journal Subset: Allied Health; Public Health; USA. Special Interest: Public Health. NLM UID: 9210257. PMID: NLM25037246. PY - 2015 SN - 0962-9343 SP - 445-454 ST - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors T2 - Quality of Life Research TI - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109776056&site=ehost-live&scope=site VL - 24 ID - 1950 ER - TY - JOUR AB - Purpose: To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors. Methods: A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1–6 years post-diagnosis. Results: Four hundred and sixty-eight participants agreed to participate constituting an 81 % participation rate; 65 and 55 % completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73 %) than Latinas (62 %) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation. Conclusions: Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects’ characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals’ enrollment and continued participation in studies. © 2014, Springer International Publishing Switzerland. AD - Center of Community Alliance for Research and Education (CCARE), Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA 91010-3000, United States AU - Ashing, K. AU - Rosales, M. AU - Fernandez, A. DB - Scopus DO - 10.1007/s11136-014-0758-9 IS - 2 KW - Breast cancer Ethnic minority Recruitment Response bias Retention M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2015 SP - 445-454 ST - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors T2 - Quality of Life Research TI - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931093165&doi=10.1007%2fs11136-014-0758-9&partnerID=40&md5=f1b6cbcbedd0d2aeba5a7e3d062fae27 VL - 24 ID - 2370 ER - TY - JOUR AB - To better understand research participation among hard-to-reach populations, this exploratory investigation examined characteristics of enrollees and non-enrollees from a population-based longitudinal study with African-American and Latina-American breast cancer survivors. A mixed-method recruitment approach was utilized to enroll participants from cancer registries and community groups who were 1-6 years post-diagnosis. Four hundred and sixty-eight participants agreed to participate constituting an 81 % participation rate; 65 and 55 % completed Time-1, and both Time-1 and Time-2 assessments, respectively. African-Americans were more likely to agree to participate and complete the T1 assessment (73 %) than Latinas (62 %) (p < 0.05). Participation was influenced by educational attainment and comorbidities (p < 0.05) for African-Americans. Among Latinas, language proficiency, comorbidities and psychological difficulties (p < 0.01) influenced participation. Our findings suggest that enrollment in research studies may be influenced by complex and multi-dimensional factors stemming from subjects' characteristics including ethnicity, culture, language proficiency and literary, and socioeconomic status, as well as medical characteristics including co-occurring chronic illness and psychological status. Thus, comprehensive, multi-method research studies are urgently needed to better understand and address the challenge of minority recruitment in biomedical research. To increase research participation among cancer survivors, it is imperative to implement focused strategies that will support and encourage individuals' enrollment and continued participation in studies. AN - WOS:000349292600018 AU - Ashing, K. AU - Rosales, M. AU - Fernandez, A. DA - Feb DO - 10.1007/s11136-014-0758-9 IS - 2 N1 - 25037246 PY - 2015 SN - 0962-9343 SP - 445-454 ST - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors T2 - Quality of Life Research TI - Exploring the influence of demographic and medical characteristics of African-American and Latinas on enrollment in a behavioral intervention study for breast cancer survivors VL - 24 ID - 2988 ER - TY - JOUR AB - Genetic counseling (GC) for hereditary breast and ovarian cancer is available mainly in academic settings. Despiteequal risk, most low income public hospital patients remain unaware and untested. Remote counseling may be asolution, but research has been limited to phone counseling for insured patients. Our study compares in‐person,phone, and video conference GC among high‐risk patients in 3 public hospitals to determine the comparativeeffectiveness of GC delivered across modes with regard to patients' knowledge, cancer distress, decisional conflict,perceived stress, risk perception, satisfaction, and recall. We also assessed whether patients have a preference forcounseling mode and how that affects outcomes. This report describes the study design and lessons learnedregarding recruitment. We conducted a multicenter partially randomized preference noninferiority trial with English‐,Spanish‐, and Cantonese‐speaking patients assigned by randomization or patients” preference to one of the threeGC modes. High‐risk patients were identified using a family history screener in clinics or by physician referral. Studystaff verified risk by phone, invited participation, conducted informed consent, and administered a baseline survey.Enrollees were asked whether they could be randomized or if they preferred one GC mode. They were then given aGC appointment and called again within 2 weeks of counseling for a follow‐up survey. Power calculations required270 randomized patients. A total of 23,401 screener forms yielded 824 likely to be high‐risk; 656 completed baseline surveys. Race/ethnic composition was 40% Latinx, 25% white, 19% African American, and 8% Asian. Of these, 531were counseled, and 505 completed final surveys (283 from randomized patients). The majority (64%) of non‐randomized patients chose counseling by phone, 33% chose in person, 3% chose video. • At every step,participation exceeded our projections, showing that diverse low‐income patients were interested in participating inresearch that they deemed relevant. • Our greatest recruitment challenges were due more to settings than topatients. Collection of screeners varied greatly by month and/or clinic. Oncologists valued the risk services offered by the study, but intensive engagement was necessary with front‐line staff/supervisors because of their jobdemands. • Partial randomization functioned well. Prior studies showed that many high‐risk women refuserandomization for GC. Adding a preference arm necessitated a larger sample, but greater inclusiveness yields moregeneralizable findings. • Recruitment of Chinese‐speaking patients was low (2.5%) due largely to structural barrierswhich we continue to explore. Practice‐based safety net research presents numerous challenges that require closepartnerships, extensive planning, and highly skilled staff capable of sensitive personnel engagement. The work isrewarded by real‐world findings, the sine qua non in efforts to eliminate cancer disparities. AN - CN-02213309 AU - Guerra, C. AU - Lee, R. AU - Stewart, S. L. AU - Kaplan, C. AU - Joseph, G. AU - Tsoh, J. AU - Dixit, N. AU - Cedermaz, H. AU - Kim, J. AU - Campbell, J. AU - et al. DO - 10.1158/1538-7755.DISP19-A034 IS - 6 SUPPL 2 KW - *genetic counseling Adult African American Calculation Conference abstract Controlled study Distress syndrome Family history Female Follow up High risk patient Human Informed consent Lowest income group Major clinical study Multicenter study Non‐inferiority trial Oncologist Patient referral Perception Race Randomization Randomized controlled trial Recall Risk assessment Satisfaction Speech Stress Videoconferencing M3 - Journal: Conference Abstract PY - 2020 ST - Extending the reach of genetic counseling to the safety net: study design and recruitment challenges of a randomized trial T2 - Cancer epidemiology biomarkers and prevention TI - Extending the reach of genetic counseling to the safety net: study design and recruitment challenges of a randomized trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213309/full VL - 29 ID - 1565 ER - TY - JOUR AB - PURPOSE: The purpose of this study is to describe the factors associated with the decisions of older African American women to join the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial when recruited. METHODS: African American women between ages 55 and 74 years who were never diagnosed with a PLCO cancer were eligible for our study. Two methods of recruitment were used. First, mailings were sent to a random sample of women describing the PLCO followed by a telephone call to determine interest in the PLCO. If women were not interested in PLCO but consented to participate in our study, they were interviewed immediately. Second, we followed up with African American women who responded to mass mailings sent out before the start of our study by the Pittsburgh PLCO office. Women completed an interview about their cancer and clinical trial knowledge, attitudes, beliefs, and behaviors. The responses of women who joined the PLCO Trial are contrasted with the responses of women who did not join. RESULTS: Numerous factors were associated with the decision of older African American women to join the PLCO, including perceptions of cancer prevention and detection, the experience of having a loved one with cancer, knowledge of and experience with clinical trials, and beliefs regarding the benefits and risks of clinical trial participation. CONCLUSION: Minority recruitment to cancer clinical trials could be increased by designing interventions focused on individual, organizational, and community needs. AD - Graduate School of Public Health, 217 Parran Hall, University of Pittsburgh, Pittsburgh, PA 15261, USA. trauth@pitt.edu AN - 106021846. Language: English. Entry Date: 20071207. Revision Date: 20150711. Publication Type: Journal Article AU - Trauth, J. M. AU - Jernigan, J. C. AU - Siminoff, L. A. AU - Musa, D. AU - Neal-Ferguson, D. AU - Weissfeld, J. DB - CINAHL Complete DP - EBSCOhost IS - 34 KW - Black Persons -- Psychosocial Factors Decision Making Health Screening -- Psychosocial Factors Multicenter Studies Neoplasms -- Diagnosis Clinical Trials Aged Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Ethnology Colorectal Neoplasms -- Prevention and Control Female Attitude to Health Lung Neoplasms -- Diagnosis Lung Neoplasms -- Ethnology Lung Neoplasms -- Prevention and Control Male Health Screening -- Methods Middle Age Neoplasms -- Ethnology Neoplasms -- Prevention and Control Ovarian Neoplasms -- Diagnosis Ovarian Neoplasms -- Ethnology Ovarian Neoplasms -- Prevention and Control Pennsylvania Prostatic Neoplasms -- Diagnosis Prostatic Neoplasms -- Ethnology Prostatic Neoplasms -- Prevention and Control Study Design Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM16314633. PY - 2005 SN - 0732-183X SP - 8730-8738 ST - Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial T2 - Journal of Clinical Oncology TI - Factors affecting older african american women's decisions to join the PLCO Cancer Screening Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106021846&site=ehost-live&scope=site VL - 23 ID - 1951 ER - TY - JOUR AB - Purpose: The purpose of this study is to describe the factors associated with the decisions of older African American women to join the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial when recruited. Methods: African American women between ages 55 and 74 years who were never diagnosed with a PLCO cancer were eligible for our study. Two methods of recruitment were used. First, mailings were sent to a random sample of women describing the PLCO followed by a telephone call to determine interest in the PLCO. If women were not interested in PLCO but consented to participate in our study, they were interviewed immediately. Second, we followed up with African American women who responded to mass mailings sent out before the start of our study by the Pittsburgh PLCO office. Women completed an interview about their cancer and clinical trial knowledge, attitudes, beliefs, and behaviors. The responses of women who joined the PLCO Trial are contrasted with the responses of women who did not join. Results: Numerous factors were associated with the decision of older African American women to join the PLCO, including perceptions of cancer prevention and detection, the experience of having a loved one with cancer, knowledge of and experience with clinical trials, and beliefs regarding the benefits and risks of clinical trial participation. Conclusion: Minority recruitment to cancer clinical trials could be increased by designing interventions focused on individual, organizational, and community needs. © 2005 by American Society of Clinical Oncology. AD - Graduate School of Public Health, University of Pittsburgh, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15261, United States AU - Trauth, J. M. AU - Jernigan, J. C. AU - Siminoff, L. A. AU - Musa, D. AU - Neal-Ferguson, D. AU - Weissfeld, J. DB - Scopus DO - 10.1200/JCO.2004.00.9571 IS - 34 M3 - Article N1 - Cited By :23 Export Date: 22 March 2021 PY - 2005 SP - 8730-8738 ST - Factors affecting older African American women's decisions to join the PLCO cancer screening trial T2 - Journal of Clinical Oncology TI - Factors affecting older African American women's decisions to join the PLCO cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644842625&doi=10.1200%2fJCO.2004.00.9571&partnerID=40&md5=1176a9d8ae286b6a8aa0b95114eacac2 VL - 23 ID - 2586 ER - TY - JOUR AB - Purpose The purpose of this study is to describe the factors associated with the decisions of older African American women to join the PLCO (Prostate, Lung, Colorectal and Ovarian) Cancer Screening Trial when recruited. Methods African American women between ages 55 and 74 years who were never diagnosed with a PLCO cancer were eligible for our study. Two methods of recruitment were used. First, mailings were sent to a random sample of women describing the PLCO followed by a telephone call to determine interest in the PLCO. If women were not interested in PLCO but consented to participate in our study, they were interviewed immediately. Second, we followed up with African American women who responded to mass mailings sent out before the start of our study by the Pittsburgh PLCO office. Women completed an interview about their cancer and clinical trial knowledge, attitudes, beliefs, and behaviors. The responses of women who joined the PLCO Trial are contrasted with the responses of women who did not join. Results Numerous factors were associated with the decision of older African American women to join the PLCO, including perceptions of cancer prevention and detection, the experience of having a loved one with cancer, knowledge of and experience with clinical trials, and beliefs regarding the benefits and risks of clinical trial participation. Conclusion Minority recruitment to cancer clinical trials could be increased by designing interventions focused on individual, organizational, and community needs. AN - WOS:000233690200027 AU - Trauth, J. M. AU - Jernigan, J. C. AU - Siminoff, L. A. AU - Musa, D. AU - Neal-Ferguson, D. AU - Weissfeld, J. DA - Dec DO - 10.1200/JCO.2004.00.9571 IS - 34 N1 - 128th Annual Meeting of the American-Public-Health-Association NOV 11-16, 2000 BOSTON, MA Amer Public Hlth Assoc 16314633 PY - 2005 SN - 0732-183X SP - 8730-8738 ST - Factors affecting older African American women's decisions to join the PLCO Cancer Screening Trial T2 - Journal of Clinical Oncology TI - Factors affecting older African American women's decisions to join the PLCO Cancer Screening Trial VL - 23 ID - 3231 ER - TY - JOUR AB - Background. Little is known about the participation of minorities in health behavior research. This manuscript assesses factors associated with participation among women in four racial/ethnic groups. Methods. A total of 2800 Asian/Pacific Islander (API), Black, Latina, and non-Latina White women recruited through the San Francisco Mammography Registry was invited in 2002 and 2003 to participate in a telephone survey about breast cancer prevention. Results. Minorities participated at lower rates (49% for APIs, 60% for Latinas, and 64% for Blacks) than Whites (77%). Increased participation was associated with younger age for Latinas (OR = 1.90, 95% CI 1.05-3.44) and Whites (OR = 1.77, CI 1.08-2.91), and with a family history of breast cancer for APIs (OR = 2.09, CI 1.24-3.52). Decreased participation was associated with having less than a high school education for APIs (OR = 0.47, CI 0.26-0.86), Blacks (OR = 0.29, CI 0.11-0.78), and Latinas (OR = 0.51, CI 0.28-0.94). Conclusions. Results suggest minorities' participation in health behavior research does not match Whites' and should be enhanced. (c) 2005 Elsevier Inc. All rights reserved. AN - WOS:000232638900004 AU - Des Jarlais, G. AU - Kaplan, C. P. AU - Haas, J. S. AU - Gregorich, S. E. AU - Perez-Stable, E. J. AU - Kerlikowske, K. DA - Sep-Oct DO - 10.1016/j.ypmed.2005.04.001 IS - 3-4 N1 - 15936066 PY - 2005 SN - 0091-7435 SP - 720-727 ST - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups T2 - Preventive Medicine TI - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups VL - 41 ID - 3235 ER - TY - JOUR AB - Background: Little is known about the participation of minorities in health behavior research. This manuscript assesses factors associated with participation among women in four racial/ethnic groups. Methods: A total of 2800 Asian/Pacific Islander (API), Black, Latina, and non-Latina White women recruited through the San Francisco Mammography Registry was invited in 2002 and 2003 to participate in a telephone survey about breast cancer prevention. Results: Minorities participated at lower rates (49% for APIs, 60% for Latinas, and 64% for Blacks) than Whites (77%). Increased participation was associated with younger age for Latinas (OR = 1.90, 95% CI 1.05-3.44) and Whites (OR = 1.77, CI 1.08-2.91), and with a family history of breast cancer for APIs (OR = 2.09, CI 1.24-3.52). Decreased participation was associated with having less than a high school education for APIs (OR = 0.47, CI 0.26-0.86), Blacks (OR = 0.29, CI 0.11-0.78), and Latinas (OR = 0.51, CI 0.28-0.94). Conclusions: Results suggest minorities' participation in health behavior research does not match Whites' and should be enhanced. AD - Department of Medicine, Division of General Internal Medicine, Medical Effectiveness Research Center, University of California, 3333 California Street, Suite 335, San Francisco, CA 94143-0856, USA Department of Medicine, Division of General Internal Medicine, Effectiveness Research Center, University of California, 3333 California Street, Suite 335, San Francisco, CA 94143-0856 AN - 106375480. Language: English. Entry Date: 20060106. Revision Date: 20200708. Publication Type: journal article AU - Des Jarlais, G. AU - Kaplan, C. P. AU - Haas, J. S. AU - Gregorich, S. E. AU - Pérez-Stable, E. J. AU - Kerlikowske, K. AU - Des Jarlais, Genevieve AU - Kaplan, Celia Patricia AU - Haas, Jennifer S. AU - Gregorich, Steven E. AU - Pérez-Stable, Eliseo J. AU - Kerlikowske, Karla DB - CINAHL Complete DO - 10.1016/j.ypmed.2005.04.001 DP - EBSCOhost IS - 3/4 KW - Breast Neoplasms -- Risk Factors Race Factors Research Subject Recruitment Adult Age Factors Aged Asians Black Persons California Confidence Intervals Data Analysis Software Data Analysis, Statistical Descriptive Statistics Educational Status Family History Female Hispanic Americans Logistic Regression Middle Age Odds Ratio P-Value Self Report Survey Research White Persons Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: U01CA63740/CA/NCI NIH HHS/United States. NLM UID: 0322116. PMID: NLM15936066. PY - 2005 SN - 0091-7435 SP - 720-727 ST - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups T2 - Preventive Medicine TI - Factors affecting participation in a breast cancer risk reduction telephone survey among women from four racial/ethnic groups UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106375480&site=ehost-live&scope=site VL - 41 ID - 1952 ER - TY - JOUR AB - Purpose. This paper examines factors associated with attendance in a National Cancer Institute-funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). Setting. The study took place at 16 WIC sites in Maryland. Subjects. The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were ≥ 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68 % of eligible women approached agreed to participate). Intervention. Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions. Measures. Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi-square tests of trend and multiple logistic regression, adjusted for within-site correlation, were used in statistical analyses. Results. Fifty-four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast-feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care. Conclusions. The results suggest that numerous barriers hinder participation in nutrition programs aimed at low-income women. These barriers' should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge. AD - D. Damron, Dept. of Epidemiol./Preventive Med., Univ. of Maryland School of Medicine, Baltimore, MD 21201, United States AU - Damron, D. AU - Langenberg, P. AU - Anliker, J. AU - Ballesteros, M. AU - Feldman, R. AU - Havas, S. DB - Embase Medline DO - 10.4278/0890-1171-13.5.268 IS - 5 KW - article female health education human normal human nutritional deficiency nutritional requirement nutritional value statistical analysis United States LA - English M3 - Article N1 - L29289834 1999-07-09 PY - 1999 SN - 0890-1171 SP - 268-275 ST - Factors associated with attendance in a voluntary nutrition education program T2 - American Journal of Health Promotion TI - Factors associated with attendance in a voluntary nutrition education program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L29289834&from=export http://dx.doi.org/10.4278/0890-1171-13.5.268 VL - 13 ID - 1328 ER - TY - JOUR AB - PURPOSE: This paper examines factors associated with attendance in a National Cancer Institute‐funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). SETTING: The study took place at 16 WIC sites in Maryland. SUBJECTS: The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were > or = 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68% of eligible women approached agreed to participate). INTERVENTION: Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions. MEASURES: Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi‐square tests of trend and multiple logistic regression, adjusted for within‐site correlation, were used in statistical analyses. RESULTS: Fifty‐four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast‐feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care. CONCLUSIONS: The results suggest that numerous barriers hinder participation in nutrition programs aimed at low‐income women. These barriers should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge. AN - CN-00380768 AU - Damron, D. AU - Langenberg, P. AU - Anliker, J. AU - Ballesteros, M. AU - Feldman, R. AU - Havas, S. DO - 10.4278/0890-1171-13.5.268 IS - 5 KW - Adolescent Adult Aged Chi‐Square Distribution Community Participation Educational Status Female Fruit Health Promotion [*methods] Humans Logistic Models Maryland Middle Aged Nutritional Sciences [*education] Vegetables Women's Health Services M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 1999 SP - 268‐275 ST - Factors associated with attendance in a voluntary nutrition education program T2 - American journal of health promotion TI - Factors associated with attendance in a voluntary nutrition education program UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00380768/full VL - 13 ID - 1570 ER - TY - JOUR AB - Purpose. This paper examines factors associated with attendance in a National Cancer Institute-funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). Setting. The study took place at 16 WIC sites in Maryland. Subjects. The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were ≥ 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68 % of eligible women approached agreed to participate). Intervention. Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions. Measures. Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi-square tests of trend and multiple logistic regression, adjusted for within-site correlation, were used in statistical analyses. Results. Fifty-four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast-feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education, and lack of transportation or child care. Conclusions. The results suggest that numerous barriers hinder participation in nutrition programs aimed at low-income women. These barriers' should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge. AD - Dept. of Epidemiol. and Prev. Med., Univ. of Maryland School of Medicine, Baltimore, MD, United States Department of Health Education, University of Maryland, College Park, MD, United States Dept. of Epidemiol. and Prev. Med., Univ. of Maryland School of Medicine, Baltimore, MD 21201, United States AU - Damron, D. AU - Langenberg, P. AU - Anliker, J. AU - Ballesteros, M. AU - Feldman, R. AU - Havas, S. DB - Scopus DO - 10.4278/0890-1171-13.5.268 IS - 5 KW - Attendance Fruits Nutrition Education Vegetables WIC M3 - Article N1 - Cited By :26 Export Date: 22 March 2021 PY - 1999 SP - 268-275 ST - Factors associated with attendance in a voluntary nutrition education program T2 - American Journal of Health Promotion TI - Factors associated with attendance in a voluntary nutrition education program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033032498&doi=10.4278%2f0890-1171-13.5.268&partnerID=40&md5=05f9914c506b1c1f9519885ac56f056a VL - 13 ID - 2641 ER - TY - JOUR AB - Purpose. This paper examines factors associated with attendance in a National Cancer Institute-funded randomized trial of nutrition education to increase fruit and vegetable consumption among women served by the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). Setting. The study took place at 16 WIC sites in Maryland. Subjects. The participants were 1528 women who were enrolled in WIC or who had children enrolled in WIC, were greater than or equal to 18 years of age, and planned to continue enrollment at that WIC site for at least 6 months (68% of eligible women approached agreed to participate). Intervention. Women received personal invitations, letters, and telephone reminders from peer educators encouraging their attendance at three bimonthly nutrition sessions. Measures. Demographic data were collected in a baseline survey. Attendance data and telephone and address changes were also collected. The postintervention survey included a question regarding reasons for nonattendance. Focus groups were also held to ascertain reasons for attendance or nonattendance. Chi-square tests of trend and multiple logistic regression, adjusted for within-site correlation, were used in statistical analyses. Results. Fifty-four percent of enrollees attended at least one session. Multiple logistic regression analysis showed increased odds of attending with higher age, breast-feeding, and/or knowledge of the recommendation to eat five or more servings of fruits and vegetables daily. There were decreased odds of attending for pregnant women who already had children. There were nonsignificant trends toward decreased attendance among unmarried women compared with married women and among blacks compared with nonblacks. Reasons given for nonattendance included withdrawal from WIC, moving, conflicting activities, negative feelings about nutrition education,and lack of transportation or child care. Conclusions. The results suggest that numerous barriers hinder participation in nutrition programs aimed at low-income women. These barriers should be considered by health care professionals when planning intervention programs. Overcoming these barriers presents a major challenge. AN - WOS:000081041100004 AU - Damron, D. AU - Langenberg, P. AU - Anliker, J. AU - Ballesteros, M. AU - Feldman, R. AU - Havas, S. DA - May-Jun DO - 10.4278/0890-1171-13.5.268 IS - 5 N1 - 24 10538640 PY - 1999 SN - 0890-1171 SP - 268-275 ST - Factors associated with attendance in a voluntary nutrition education program T2 - American Journal of Health Promotion TI - Factors associated with attendance in a voluntary nutrition education program VL - 13 ID - 2727 ER - TY - JOUR AB - Purpose: The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials. Patients and Methods: From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment. Results: The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered; P = .0005) and black women (21% of blacks offered v 42% of whites; P = .0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment. Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Reasons for failed enrollment included patient refusal (88%) and failed eligibility (12%). Conclusion: It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women. © 2004 by American Society of Clinical Oncology. AD - M.S. Simon, Hudson Webber Cancer Research Building, 4100 John R. St, Detroit, MI 48201, United States AU - Simon, M. S. AU - Du, W. AU - Flaherty, L. AU - Philip, P. A. AU - Lorusso, P. AU - Miree, C. AU - Smith, D. AU - Brown, D. R. DB - Embase Medline DO - 10.1200/JCO.2004.03.005 IS - 11 KW - article breast cancer cancer research clinical trial controlled clinical trial controlled study female health survey human multivariate logistic regression analysis oncology patient participation priority journal university hospital LA - English M3 - Article N1 - L41095136 2005-09-06 PY - 2004 SN - 0732-183X SP - 2046-2052 ST - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center T2 - Journal of Clinical Oncology TI - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41095136&from=export http://dx.doi.org/10.1200/JCO.2004.03.005 VL - 22 ID - 1279 ER - TY - JOUR AB - PURPOSE: The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials.PATIENTS AND METHODS: From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment.RESULTS: The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered; P = .0005) and black women (21% of blacks offered v 42% of whites; P = .0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment. Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Reasons for failed enrollment included patient refusal (88%) and failed eligibility (12%).CONCLUSION: It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women. AD - Karmanos Cancer Institute, Hudson Webber Cancer Research Bldg, 4th floor, 4100 John R St, Detroit, MI 48201; Simonm@karmanos.org AN - 106486395. Language: English. Entry Date: 20050715. Revision Date: 20150711. Publication Type: Journal Article AU - Simon, M. S. AU - Du, W. AU - Flaherty, L. AU - Philip, P. A. AU - Lorusso, P. AU - Miree, C. AU - Smith, D. AU - Brown, D. R. DB - CINAHL Complete DP - EBSCOhost IS - 11 KW - Breast Neoplasms Clinical Trials Health Services Accessibility Minority Groups Research Subject Recruitment Academic Medical Centers Surveys Data Analysis Software T-Tests Fisher's Exact Test Logistic Regression Questionnaires Multiple Logistic Regression Middle Age Female Funding Source Human N1 - research; tables/charts. Commentary: Brawley OW. The study of accrual to clinical trials: can we learn from studying who enters our studies? (J CLIN ONCOL) 6/1/2004; 22 (11): 2039-2040. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Supported in part by the National Action Plan on Breast Cancer Small Grant, Contract Number CA95016, the Barbara Ann Karmanos Cancer Institute Core Grant CA-22453, and the United Foundation of Detroit. NLM UID: 8309333. PMID: NLM15082724. PY - 2004 SN - 0732-183X SP - 2046-2052 ST - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center T2 - Journal of Clinical Oncology TI - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106486395&site=ehost-live&scope=site VL - 22 ID - 1954 ER - TY - JOUR AB - Purpose: The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials. Patients and Methods: From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment. Results: The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered; P = .0005) and black women (21% of blacks offered v 42% of whites; P = .0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment. Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Reasons for failed enrollment included patient refusal (88%) and failed eligibility (12%). Conclusion: It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women. © 2004 by American Society of Clinical Oncology. AD - Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States Hudson Webber Cancer Research Building, 4100 John R. St, Detroit, MI 48201, United States AU - Simon, M. S. AU - Du, W. AU - Flaherty, L. AU - Philip, P. A. AU - Lorusso, P. AU - Miree, C. AU - Smith, D. AU - Brown, D. R. DB - Scopus DO - 10.1200/JCO.2004.03.005 IS - 11 M3 - Article N1 - Cited By :112 Export Date: 22 March 2021 PY - 2004 SP - 2046-2052 ST - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center T2 - Journal of Clinical Oncology TI - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942679469&doi=10.1200%2fJCO.2004.03.005&partnerID=40&md5=146dc0ecfca014635bde5a05685cf32f VL - 22 ID - 2601 ER - TY - JOUR AB - Purpose The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials. Patients and Methods From 1996 to 1997, physicians completed surveys on 319 of 344 newly evaluated female breast cancer patients. The 19-item survey included clinical data, whether patients were offered clinical trial (CT) participation and enrollment, and when applicable, reasons why they were not. Multivariate analyses using logistic regression were performed to evaluate predictors of an offer and enrollment. Results The patients were 57% white, 32% black, and 11% other/unknown race. One hundred six (33%) were offered participation and 36 (34%) were enrolled. In multivariate analysis, CTs were less likely offered to older women (mean age, 52 years for those offered v 57 years for those not offered, P = .0005) and black women (21% of blacks offered v 42% of whites; P = .0009). Women with stage 1 disease, poor performance status, and those who were previously diagnosed were also less likely to be offered trials. None of these factors were significant predictors of enrollment, Women were not offered trials because of ineligibility (57%), lack of available trials (41%), and noncompliance (2%). Re asons for failed enrollment included patient refusal (88%) and failed eligibility (12%). Conclusion It is important for cooperative groups to design studies that will accommodate a broader spectrum of patients. Further work is needed to assess ways to improve communication about breast cancer CT participation to all eligible women. (C) 2004 by American Society of Clinical Oncology. AN - WOS:000221808800004 AU - Simon, M. S. AU - Du, W. AU - Flaherty, L. AU - Philip, P. A. AU - Lorusso, P. AU - Miree, C. AU - Smith, D. AU - Brown, D. R. DA - Jun 1 DO - 10.1200/JCO.2004.03.005 IS - 11 N1 - 107 15082724 PY - 2004 SN - 0732-183X SP - 2046-2052 ST - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center T2 - Journal of Clinical Oncology TI - Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center VL - 22 ID - 2684 ER - TY - JOUR AB - Objectives: To identify patient, hospital, and central venous catheter factors that may influence the use of low-dose heparin infusion for central venous catheter patency in critically ill children. Design: Secondary analysis of an international multicenter observational study. Setting: Fifty-nine PICUs over four study dates in 2012, involving seven countries. Patients: Children less than 18 years old with a central venous catheter who were admitted to a participating unit and enrolled in the completed Prophylaxis against Thrombosis Practice study were included. All overflow patients were excluded. Interventions: None. Measurements and Main Results: Of the 2,484 patients in the Prophylaxis against Thrombosis Practice study, 1,312 patients had a central venous catheter. Five hundred seven of those patients used low-dose heparin infusion. The frequency of low-dose heparin infusion was compared across various patient, hospital, and central venous catheter factors using chi-square, Mann-Whitney U, and Fisher exact tests. In the multivariate analysis, age was not a significant factor for low-dose heparin infusion use. Patients with pulmonary hypertension had decreased low-dose heparin infusion use, whereas those with active surgical or trauma diagnoses had increased low-dose heparin infusion use. All centrally inserted central venous catheters were more likely to use low-dose heparin infusion when compared with peripherally inserted central venous catheters. The Asia-Pacific region showed increased low-dose heparin infusion use, along with community hospitals and smaller ICUs (< 10 beds). Conclusions: Patient, central venous catheter, and hospital factors are associated with the use of low-dose heparin infusion in critically ill children. Further study is needed to evaluate the efficacy and persistence of low-dose heparin infusion use. © 2016 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. AD - Medical College of Wisconsin, Milwaukee, WI, United States Department of Pediatrics, Medical College of WisconsinWI, United States Critical care Division, Children's Hospital of Wisconsin, Milwaukee, WI, United States Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, United States Department of Pediatrics, Yale School of Medicine, New Haven, CT, United States AU - Onyeama, S. J. N. AU - Hanson, S. J. AU - Dasgupta, M. AU - Hoffmann, R. G. AU - Faustino, E. V. S. DB - Scopus DO - 10.1097/PCC.0000000000000854 IS - 8 KW - anticoagulation central venous access device critical care intensive care units, pediatric pediatrics venous thromboembolism M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2016 SP - e352-e361 ST - Factors associated with continuous low-dose heparin infusion for central venous catheter patency in critically ill children worldwide T2 - Pediatric Critical Care Medicine TI - Factors associated with continuous low-dose heparin infusion for central venous catheter patency in critically ill children worldwide UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976603989&doi=10.1097%2fPCC.0000000000000854&partnerID=40&md5=9adcae96d79678a8c7ed20b5cdb5e50e VL - 17 ID - 2339 ER - TY - JOUR AB - Context: Lung cancer is the leading cause of cancer death in the United States. Surgical resection for stage I or II non-small cell cancer remains the only reliable treatment for cure. Patients who do not undergo surgery have a median survival of less than 1 year. Despite the survival disadvantage, many patients with early-stage disease do not receive surgical care and rates are even lower for black patients. Objectives: To identify potentially modifiable factors regarding surgery in patients newly diagnosed with early-stage lung cancer and to explore why blacks undergo surgery less often than whites. Design, Setting, and Patients: Prospective cohort study with patients identified by pulmonary, oncology, thoracic surgery, and generalist practices in 5 communities through study referral or computerized tomography review protocol. A total of 437 patients with biopsy-proven or probable early-stage lung cancer were enrolled between December 2005 and December 2008. Before establishment of treatment plans, patients were administered a survey including questions about trust, patient-physician communication, attitudes toward cancer, and functional status. Information about comorbid illnesses was obtained through chart audits. Main Outcome Measure: Lung cancer surgery within 4 months of diagnosis. Results: A total of 386 patients met full eligibility criteria for lung resection surgery. The median age was 66 years (range, 26-90 years) and 29% of patients were black. The surgical rate was 66% for white patients (n=179/273) compared with 55% for black patients (n=62/113; P=.05). Negative perceptions of patient-physician communication manifested by a 5-point decrement on a 25-point communication scale (odds ratio [OR], 0.42; 95% confidence interval [CI], 0.32-0.74) and negative perception of 1-year prognosis postsurgery (OR, 0.27; 95% CI, 0.14-0.50; absolute risk, 34%) were associated with decisions against surgery. Surgical rates for blacks were particularly low when they had 2 or more comorbid illnesses (13% vs 62% for <2 comorbidities; OR, 0.04 [95% CI, 0.01-0.25]; absolute risk, 49%) and when blacks lacked a regular source of care (42% with no regular care vs 57% with regular care; OR, 0.20 [95% CI, 0.10-0.43]; absolute risk, 15%). Conclusions: A decision not to undergo surgery by patients with newly diagnosed lung cancer was independently associated with perceptions of communication and prognosis, older age, multiple comorbidities, and black race. Interventions to optimize surgery should consider these factors. ©2010 American Medical Association. All rights reserved. AD - Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC, United States Division of General Internal Medicine and Clinical Epidemiology, School of Medicine, University of North Carolina, Chapel Hill, NC, United States Department of Health Policy and Management, UNC Institute on Aging, University of North Carolina, Chapel Hill, NC, United States Department of Biostatistics, University of North Carolina, Chapel Hill, NC, United States Internal Medicine Program, Moses Cone Health System, Greensboro Area Health Education Center, Greensboro, NC, United States Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC, United States Leo Jenkins Cancer Center, Brody School of Medicine, East Carolina University, Greenville, NC, United States Division of Pulmonary and Critical Care Medicine, School of Medicine, University of South Carolina, Columbia, SC, United States AU - Cykert, S. AU - Dilworth-Anderson, P. AU - Monroe, M. H. AU - Walker, P. AU - McGuire, F. R. AU - Corbie-Smith, G. AU - Edwards, L. J. AU - Bunton, A. J. DB - Scopus DO - 10.1001/jama.2010.793 IS - 23 M3 - Article N1 - Cited By :169 Export Date: 22 March 2021 PY - 2010 SP - 2368-2376 ST - Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer T2 - JAMA - Journal of the American Medical Association TI - Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953631515&doi=10.1001%2fjama.2010.793&partnerID=40&md5=a943bf11ed9c5607c5cdd198e935dbdf VL - 303 ID - 2496 ER - TY - JOUR AB - BACKGROUND & AIMS: Endoscopists do not routinely follow guidelines to survey individuals with low‐risk adenomas (LRAs; 1‐2 small tubular adenomas, < 1 cm) every 5‐10 years for colorectal cancer; many recommend shorter surveillance intervals for these individuals. We aimed to identify the reasons that endoscopists recommend shorter surveillance intervals for some individuals with LRAs and determine whether timing affects outcomes at follow‐up examinations. METHODS: We collected data from 1560 individuals (45‐75 years old) who participated in a prospective chemoprevention trial (of vitamin D and calcium) from 2004 through 2008. Participants in the trial had at least 1 adenoma, detected at their index colonoscopy, and were recommended to receive follow‐up colonoscopy examinations at 3 or 5 years after adenoma identification, as recommended by the endoscopist. For this analysis we collected data from only participants with LRAs. These data included characteristics of participants and endoscopists and findings from index and follow‐up colonoscopies. Primary endpoints were frequency of recommending shorter (3‐year) vs longer (5‐year) surveillance intervals, factors associated with these recommendations, and effect on outcome, determined at the follow‐up colonoscopy. RESULTS: A 3‐year surveillance interval was recommended for 594 of the subjects (38.1%). Factors most significantly associated with recommendation of 3‐year vs a 5‐year surveillance interval included African American race (relative risk [RR] to white, 1.41; 95% confidence interval [CI], 1.14‐1.75), Asian/Pacific Islander ethnicity (RR to white, 1.7; 95% CI, 1.22‐2.43), detection of 2 adenomas at the index examination (RR vs 1 adenoma, 1.47; 95% CI, 1.27‐1.71), more than 3 serrated polyps at the index examination (RR=2.16, 95% CI, 1.59‐2.93), or index examination with fair or poor quality bowel preparation (RR vs excellent quality, 2.16; 95% CI, 1.66‐2.83). Other factors that had a significant association with recommendation for a 3‐year surveillance interval included family history of colorectal cancer and detection of 1‐2 serrated polyps at the index examination. In comparisons of outcomes, we found no significant differences between the 3‐year vs 5‐year recommendation groups in proportions of subjects found to have 1 or more adenomas (38.8% vs 41.7% respectively; P = .27), advanced adenomas (7.7% vs 8.2%; P = .73) or clinically significant serrated polyps (10.0% vs 10.3%; P = .82) at the follow‐up colonoscopy. CONCLUSIONS: Possibly influenced by patients' family history, race, quality of bowel preparation, or number or size of polyps, endoscopists frequently recommend 3‐year surveillance intervals instead of guideline‐recommended intervals of 5 years or longer for individuals with LRAs. However, at the follow‐up colonoscopy, similar proportions of participants have 1 or more adenomas, advanced adenomas, or serrated polyps. These findings support the current guideline recommendations of performing follow‐up examinations of individuals with LRAs at least 5 years after the index colonoscopy. AN - CN-01401255 AU - Anderson, J. C. AU - Baron, J. A. AU - Ahnen, D. J. AU - Barry, E. L. AU - Bostick, R. M. AU - Burke, C. A. AU - Bresalier, R. S. AU - Church, T. R. AU - Cole, B. F. AU - Cruz-Correa, M. AU - et al. DO - 10.1053/j.gastro.2017.02.010 IS - 8 KW - Adenoma [*diagnosis, pathology, prevention & control] Aged Anticarcinogenic Agents [therapeutic use] Calcium [therapeutic use] Carcinoma [*diagnosis, pathology, prevention & control] Colon [*pathology] Colonic Neoplasms [*diagnosis, pathology, prevention & control] Colonoscopy [standards, trends] Dietary Supplements Disease Progression Early Detection of Cancer [*methods, standards, trends] Female Gastroenterologists [standards, trends] Guideline Adherence Humans Male Middle Aged Multivariate Analysis North America Odds Ratio Patient Selection Practice Guidelines as Topic Practice Patterns, Physicians' [standards, trends] Predictive Value of Tests Prospective Studies Risk Assessment Risk Factors Time Factors Tumor Burden Vitamin D [therapeutic use] M3 - Journal Article; Multicenter Study; Randomized Controlled Trial PY - 2017 SP - 1933‐1943.e5 ST - Factors Associated With Shorter Colonoscopy Surveillance Intervals for Patients With Low-Risk Colorectal Adenomas and Effects on Outcome T2 - Gastroenterology TI - Factors Associated With Shorter Colonoscopy Surveillance Intervals for Patients With Low-Risk Colorectal Adenomas and Effects on Outcome UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01401255/full VL - 152 ID - 1453 ER - TY - JOUR AB - Objective: To identify the factors associated with weight gain after diagnosis of breast cancer in a heterogeneous population of women. Design: Descriptive cross-sectional study. Subjects: 1,116 patients who had been diagnosed with stage I, stage II, or stage IIIA primary, operable breast cancer within the previous 4 years. Patients were recruited during enrollment into a diet intervention trial to reduce risk for breast cancer recurrence. Analysis Demographic data, weight history, and physical activity information obtained by questionnaire and medical information obtained by chart review; dietary assessment based on four 24-hour dietary recalls collected by telephone. Associations between weight change after the diagnosis of breast cancer and prediction variables were examined using univariate and multiple linear regression analyses. Results: Overall, 60% of the subjects reported weight gain, 26% reported weight loss, and 14% reported no change in weight after the diagnosis of breast cancer. The overall mean weight change was a gain of 2.7 kg (6 lb). Factors positively and independently associated with weight gain were time since diagnosis of breast cancer, adjuvant chemotherapy, African-American ethnicity, current energy intake, and postmenopausal status at time of study entry. Factors inversely and independently associated with weight gain were prediagnosis body mass index, age at diagnosis, education level, and exercise index score. Applications: Higher energy intake and lower level of physical activity are independently associated with increased risk for weight gain after the diagnosis of breast cancer. Strategies to modify these behaviors are likely to influence the long-term pattern of weight change. AD - Dept. of Fam. and Prev. Medicine, University of California, San Diego, San Diego, CA, United States Women's Healthy Eating Living S., Cancer Prev. and Control Program, University of California, San Diego, San Diego, CA, United States Division of Research, Kaiser Foundation Research Institute, Kaiser Permanente No. California, Oakland, CA, United States Dept. of Epidemiol. and Prev. Med., University of California, Davis, CA, United States Department of Medicine, Stanford University, Stanford Ctr. for Res. in Dis. Prev., Palo Alto, CA, United States University of California, San Diego, Cancer Prev. and Control Program, Dept. 0901, 9500 Gilman Dr, San Diego, CA 92093-0901, United States AU - Rock, C. L. AU - Flatt, S. W. AU - Newman, V. AU - Caan, B. J. AU - Haan, M. N. AU - Stefanick, M. L. AU - Faerber, S. AU - Pierce, J. P. DB - Scopus DO - 10.1016/S0002-8223(99)00298-9 IS - 10 M3 - Article N1 - Cited By :169 Export Date: 22 March 2021 PY - 1999 SP - 1212-1218 ST - Factors associated with weight gain in women after diagnosis of breast cancer T2 - Journal of the American Dietetic Association TI - Factors associated with weight gain in women after diagnosis of breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032882357&doi=10.1016%2fS0002-8223%2899%2900298-9&partnerID=40&md5=b1f05df351c8a254fe17378a8ba7a51c VL - 99 ID - 2640 ER - TY - JOUR AB - Objective To identify the factors associated with weight gain after diagnosis of breast cancer in a heterogeneous population of women. Design Descriptive cross-sectional study. Subjects 1,116 patients who had been diagnosed with stage I, stage II, or stage IIIA primary, operable breast cancer within the previous 4 years. Patients were recruited during enrollment into a diet intervention trial to reduce risk for breast cancer recurrence. Analysis Demographic data, weight history, and physical activity information obtained by questionnaire and medical information obtained by chart review; dietary assessment based on four 24-hour dietary recalls collected by telephone. Associations between weight change after the diagnosis of breast cancer and prediction variables were examined using univariate and multiple linear regression analyses. Results Overall, 60% of the subjects reported weight gain, 26% reported weight loss, and 14% reported no change in weight after the diagnosis of breast cancer. The overall mean weight change was a gain of 2.7 kg (6 lb). Factors positively and independently associated with weight gain were time since diagnosis of breast cancer, adjuvant chemotherapy, African-American ethnicity, current energy intake, and postmenopausal status at time of study entry. Factors inversely and independently associated with weight gain were prediagnosis body mass index, age at diagnosis, education level, and exercise index score. Applications Higher energy intake and lower level of physical activity are independently associated with increased risk for weight gain after the diagnosis of breast cancer. Strategies to modify these behaviors are likely to influence the long-term pattern of weight change. AN - WOS:000083014700017 AU - Rock, C. L. AU - Flatt, S. W. AU - Newman, V. AU - Caan, B. J. AU - Haan, M. N. AU - Stefanick, M. L. AU - Faerber, S. AU - Pierce, J. P. DA - Oct DO - 10.1016/S0002-8223(99)00298-9 IS - 10 N1 - 164 10524383 PY - 1999 SN - 0002-8223 SP - 1212-+ ST - Factors associated with weight gain in women after diagnosis of breast cancer T2 - Journal of the American Dietetic Association TI - Factors associated with weight gain in women after diagnosis of breast cancer VL - 99 ID - 2724 ER - TY - JOUR AB - Purpose: We evaluated the survival time of patients with stage D cancer of the prostate (CaP) in Yaounde, Cameroon, so as to lay the groundwork for evaluating patient management and outcomes in such communities in sub-Saharan Africa. Patients and Materials: A cohort of 200 patients was recruited at diagnosis and followed over a 171 month period. They had a standard work-up and staging protocol except for the absence of bone scan. Treatment was offered after they were staged following the Whitemore ABCD-system. Standard statistical analysis was performed for quantitative variables and graphs developed for continuous variables. Pearson correlation and Chi-square tests were used to evaluate associations between variables. The Kaplan-Meier product-limit method was used to estimate survival functions and log-rank test to compare data from complete survival curves. The statistical significance level was fixed at p values less than or equal to 0.05. Results: The mean age of our patients was 67 years and 41.5% of them were in the 60-69 year-bracket. Survival was worse for those 66 years and older (p = 0.013). Patient survival correlated with tumor differentiation such that a Gleason score of 6 or greater meant diminished survival time (p = 0.014). For the entire group, median overall survival was 40.5 months, 44% at 5 years and 17% at 10 years. Patients who received multi-modal therapy (complete androgen ablation by surgical and medical means, and radiation to the pelvis and metastatic sites) seemed to have the best survival (p < 0.001) although patient stratification into treatment groups was not randomized. A comparison of survival of African-American cohorts and this group showed no statistical significance (p = 0.1). Conclusion: Survival of patients with prostate cancer in Yaounde is just as low as in African-Americans. Survival is worse however, for men older than 66 years in Yaounde. A call for comparative and collaborative clinical trials is made. AD - Department of Surgery, Section of Urology, University of Yaounde I, Yaounde, Cameroon Endocrine and Diabetes Unit, Fac. of Med. and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon Howard University Cancer Center, Washington, DC, United States AU - Angwafo Iii, F. F. AU - Atanga, P. N. AU - Minkoulou, E. AU - Fouda, P. J. AU - Kim, K. S. AU - Adams-Campbell, L. AU - Zoung-Kanyi, J. DB - Scopus DO - 10.1080/1561095031000101269 IS - 1 KW - African-Americans Africans Age Prostate cancer Stage D Survival M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2003 SP - 7-11 ST - Factors influencing patient survival in a group of men with prostate cancer in Yaoundé, Cameroon T2 - UroOncology TI - Factors influencing patient survival in a group of men with prostate cancer in Yaoundé, Cameroon UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038677528&doi=10.1080%2f1561095031000101269&partnerID=40&md5=d758699715e122c422ff7335a31eeb71 VL - 3 ID - 2616 ER - TY - JOUR AB - Background: Many African American men have two major risk factors for prostate cancer. By ethnicity alone, they have twice the risk of Euro-American men of developing prostate cancer. Having a family history (brother or father with prostate cancer) also doubles their risk. The major hypotheses tested in this study are that men with a family history perceive their risk to be higher, are more worried about getting prostate cancer, and are more likely to have used cancer screening tests than men without such a history. Methods: A sample of 208 African American men, ages 40 to 74 years, were recruited through relatives or friends whose prostate cancer diagnosis was reported to the California Cancer Registry during the years 1997 to 2001 and from churches and African American social groups. Following a screening interview to determine eligibility, 88 men with self-reported, first-degree family history of prostate cancer and 120 without such history were interviewed by telephone. Logistic regression was used to create models of perceived risk, prostate cancer worries, receipt of a digital rectal exam, and/or prostate-specific antigen (PSA) testing. Results: Men with a self-reported family history of prostate cancer did not perceive their risk as higher than men without a family history, nor did they report more cancer worries. They were more likely to report having a recent PSA test, but not a digital rectal exam. Having a higher than average perceived risk was associated with younger age, a college education, and lower mental well-being, and reporting more prostate cancer worries and being more likely to have had a recent PSA test. Conclusions: Although there continues to be controversy about PSA testing, these data suggest that African American men at above-average risk are inclined to be screened. Copyright © 2006 American Association for Cancer Research. AD - University of California, Berkeley, Berkeley, CA, United States University of California, San Francisco, San Francisco, CA, United States Northern California Cancer Center, Fremont, CA, United States School of Public Health, University of California, 409 Warren Hall, Berkeley, CA 94720-7360, United States AU - Bloom, J. R. AU - Stewart, S. L. AU - Oakley-Girvans, I. AU - Banks, P. J. AU - Chang, S. DB - Scopus DO - 10.1158/1055-9965.EPI-05-0738 IS - 11 M3 - Article N1 - Cited By :64 Export Date: 22 March 2021 PY - 2006 SP - 2167-2173 ST - Family history, perceived risk, and prostate cancer screening among African American men T2 - Cancer Epidemiology Biomarkers and Prevention TI - Family history, perceived risk, and prostate cancer screening among African American men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845300864&doi=10.1158%2f1055-9965.EPI-05-0738&partnerID=40&md5=c47e72656d79d2ae04e7af02b0d8ceca VL - 15 ID - 2568 ER - TY - JOUR AB - Weight management after breast cancer (BC) treatment in African American (AA) women is crucial to reduce comorbid conditions and health disparities. We examined feasibility and potential efficacy of commercial eHealth/mHealth tools for weight management in AA BC survivors in New Jersey. Participants (N = 35) were randomized to an intervention (SparkPeople) plus activity tracker, Fitbit Charge (n = 18), or wait‐list active control group (Fitbit only, n = 17). Anthropometric, behavioral, and quality of life (QOL) outcomes were collected at baseline, 3, 6, and 12 months. Differences in outcomes were assessed using intent‐to‐treat analysis. Retention was 97.1%. Both groups lost weight, with no significant differences between groups. At month 6, mean weight change was: intervention: ‐1.71 kg (SD 2.33; p = .006), 33.3% lost ≥3% of baseline weight; control: ‐2.54 kg (SD 4.00, p = .002), 23.5% lost ≥3% weight. Intervention participants achieved significant improvements in waist circumference (‐3.56 cm, SD 4.70, p = .005), QOL (p = .030), and use of strategies for healthy eating (p = .025) and decreasing calories (p < .001). Number of days logged food per week was associated with decreases in waist circumference at 6 months (β ‐0.79, 95% CI, ‐1.49, ‐0.09, p = .030) and 12 months (β ‐2.16, 95% CI, ‐4.17, ‐0.15, p = .038). Weight loss was maintained at 12 months. This is the first study to demonstrate potential efficacy of commercial eHealth/mHealth tools for weight loss in AA BC survivors, without additional counseling from the research team. If effective, they may be convenient weight loss tools that can be easily and widely disseminated. Clinical Trials registration: ClinicalTrials.gov NCT02699983. AN - CN-01995185 AU - Ferrante, J. M. AU - Devine, K. A. AU - Bator, A. AU - Rodgers, A. AU - Ohman-Strickland, P. A. AU - Bandera, E. V. AU - Hwang, K. O. DO - 10.1093/tbm/iby124 KW - *African American *body weight loss *breast cancer *cancer survival *cancer survivor *feasibility study *telehealth Activity tracker Adult Article Calorie Clinical article Controlled study Counseling Eating Female Human New Jersey Outcome assessment Quality of life Randomized controlled trial Waist circumference M3 - Journal: Article in Press PY - 2018 ST - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial T2 - Translational behavioral medicine TI - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01995185/full ID - 1503 ER - TY - JOUR AB - Weight management after breast cancer (BC) treatment in African American (AA) women is crucial to reduce comorbid conditions and health disparities. We examined feasibility and potential efficacy of commercial eHealth/mHealth tools for weight management in AA BC survivors in New Jersey. Participants (N = 35) were randomized to an intervention (SparkPeople) plus activity tracker, Fitbit Charge (n = 18), or wait-list active control group (Fitbit only, n = 17). Anthropometric, behavioral, and quality of life (QOL) outcomes were collected at baseline, 3, 6, and 12 months. Differences in outcomes were assessed using intent-to-treat analysis. Retention was 97.1%. Both groups lost weight, with no significant differences between groups. At month 6, mean weight change was: intervention: -1.71 kg (SD 2.33; p =. 006), 33.3% lost ≥3% of baseline weight; control: -2.54 kg (SD 4.00, p =. 002), 23.5% lost ≥3% weight. Intervention participants achieved significant improvements in waist circumference (-3.56 cm, SD 4.70, p =. 005), QOL (p =. 030), and use of strategies for healthy eating (p =. 025) and decreasing calories (p <. 001). Number of days logged food per week was associated with decreases in waist circumference at 6 months (β -0.79, 95% CI, -1.49, -0.09, p =. 030) and 12 months (β -2.16, 95% CI, -4.17, -0.15, p =. 038). Weight loss was maintained at 12 months. This is the first study to demonstrate potential efficacy of commercial eHealth/mHealth tools for weight loss in AA BC survivors, without additional counseling from the research team. If effective, they may be convenient weight loss tools that can be easily and widely disseminated. Clinical Trials registration: ClinicalTrials.gov NCT02699983. AD - J.M. Ferrante, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, United States AU - Ferrante, J. M. AU - Devine, K. A. AU - Bator, A. AU - Rodgers, A. AU - Ohman-Strickland, P. A. AU - Bandera, E. V. AU - Hwang, K. O. DB - Embase Medline DO - 10.1093/tbm/iby124 IS - 4 KW - NCT02699983 activity tracker Fitbig Alta Fitbit Charge adult African American article body weight change body weight loss breast cancer calorie cancer survival cancer survivor clinical article clinical effectiveness controlled study feasibility study female health disparity human New Jersey outcome assessment patient compliance patient counseling physical activity pilot study priority journal quality of life randomized controlled trial telehealth treatment outcome waist circumference weight loss program LA - English M3 - Article N1 - L2010621175 2021-01-19 2021-02-04 PY - 2020 SN - 1613-9860 1869-6716 SP - 938-948 ST - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: Pilot randomized controlled trial T2 - Translational Behavioral Medicine TI - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: Pilot randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010621175&from=export http://dx.doi.org/10.1093/tbm/iby124 VL - 10 ID - 793 ER - TY - JOUR AB - Weight management after breast cancer (BC) treatment in African American (AA) women is crucial to reduce comorbid conditions and health disparities. We examined feasibility and potential efficacy of commercial eHealth/mHealth tools for weight management in AA BC survivors in New Jersey. Participants (N = 35) were randomized to an intervention (SparkPeople) plus activity tracker, Fitbit Charge (n = 18), or wait-list active control group (Fitbit only, n = 17). Anthropometric, behavioral, and quality of life (QOL) outcomes were collected at baseline, 3, 6, and 12 months. Differences in outcomes were assessed using intent-to-treat analysis. Retention was 97.1%. Both groups lost weight, with no significant differences between groups. At month 6, mean weight change was: intervention: -1.71 kg (SD 2.33; p =. 006), 33.3% lost ≥3% of baseline weight; control: -2.54 kg (SD 4.00, p =. 002), 23.5% lost ≥3% weight. Intervention participants achieved significant improvements in waist circumference (-3.56 cm, SD 4.70, p =. 005), QOL (p =. 030), and use of strategies for healthy eating (p =. 025) and decreasing calories (p <. 001). Number of days logged food per week was associated with decreases in waist circumference at 6 months (β -0.79, 95% CI, -1.49, -0.09, p =. 030) and 12 months (β -2.16, 95% CI, -4.17, -0.15, p =. 038). Weight loss was maintained at 12 months. This is the first study to demonstrate potential efficacy of commercial eHealth/mHealth tools for weight loss in AA BC survivors, without additional counseling from the research team. If effective, they may be convenient weight loss tools that can be easily and widely disseminated. Clinical Trials registration: ClinicalTrials.gov NCT02699983. © 2018 Society of Behavioral Medicine 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. AD - Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School, New Brunswick, United States Institute for Health, Health Care Policy and Aging Research, New Brunswick, United States Cancer Prevention, Control and Population Research, Rutgers Cancer Institute of New Jersey, New Brunswick, United States Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, United States Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, United States AU - Ferrante, J. M. AU - Devine, K. A. AU - Bator, A. AU - Rodgers, A. AU - Ohman-Strickland, P. A. AU - Bandera, E. V. AU - Hwang, K. O. DB - Scopus DO - 10.1093/tbm/iby124 IS - 4 KW - African Americans Breast cancer survivors Fitness trackers Health status disparities Internet Weight loss programs M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 938-948 ST - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: Pilot randomized controlled trial T2 - Translational Behavioral Medicine TI - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: Pilot randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092749589&doi=10.1093%2ftbm%2fiby124&partnerID=40&md5=7b87bc537ea63aa19b3d4a39bb589981 VL - 10 ID - 2186 ER - TY - JOUR AB - Weight management after breast cancer (BC) treatment in African American (AA) women is crucial to reduce comorbid conditions and health disparities. We examined feasibility and potential efficacy of commercial eHealth/mHealth tools for weight management in AA BC survivors in New Jersey. Participants (N = 35) were randomized to an intervention (SparkPeople) plus activity tracker, Fitbit Charge (n = 18), or wait-list active control group (Fitbit only, n = 17). Anthropometric, behavioral, and quality of life (QOL) outcomes were collected at baseline, 3, 6, and 12 months. Differences in outcomes were assessed using intent-to-treat analysis. Retention was 97.1%. Both groups lost weight, with no significant differences between groups. At month 6, mean weight change was: intervention: -1.71 kg (SD 2.33; p =.006), 33.3% lost >= 3% of baseline weight; control: -2.54 kg (SD 4.00, p =.002), 23.5% lost >= 3% weight. Intervention participants achieved significant improvements in waist circumference (-3.56 cm, SD 4.70, p =.005), QOL (p =.030), and use of strategies for healthy eating (p =.025) and decreasing calories (p <.001). Number of days logged food per week was associated with decreases in waist circumference at 6 months (beta -0.79, 95% CI, -1.49, -0.09, p =.030) and 12 months (beta -2.16, 95% CI, -4.17, -0.15, p =.038). Weight loss was maintained at 12 months. This is the first study to demonstrate potential efficacy of commercial eHealth/mHealth tools for weight loss in AA BC survivors, without additional counseling from the research team. If effective, they may be convenient weight loss tools that can be easily and widely disseminated. AN - WOS:000593255200024 AU - Ferrante, J. M. AU - Devine, K. A. AU - Bator, A. AU - Rodgers, A. AU - Ohman-Strickland, P. A. AU - Bandera, E. V. AU - Hwang, K. O. DA - Aug DO - 10.1093/tbm/iby124 IS - 4 N1 - 30535101 PY - 2020 SN - 1869-6716 SP - 938-948 ST - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial T2 - Translational Behavioral Medicine TI - Feasibility and potential efficacy of commercial mHealth/eHealth tools for weight loss in African American breast cancer survivors: pilot randomized controlled trial VL - 10 ID - 2771 ER - TY - JOUR AB - Objective: The purpose of this pilot study was to test the feasibility of delivering the mobile mindfulness‐based stress reduction for breast cancer (mMBSR(BC)) program using an iPad and to evaluate its impact on symptom improvement. Methods: A single group, pre‐posttest design was implemented among female stages 0‐III breast cancer survivors (BCS) who completed treatment. Data were collected at baseline and week 6 on measures of psychological and physical symptoms and quality of life. The mMBSR(BC) program is a standardized, stress‐reducing intervention that combines sitting and walking meditation, body scan, and yoga and is designed to deliver weekly 2‐hour sessions for 6 weeks using an iPad. Results: The mean age of the 15 enrolled BCS was 57 years; one participant was non‐Hispanic black, and 14 were non‐Hispanic white. Of the 13 who completed the study, there were significant improvements from baseline to 6 weeks post‐mMBSR(BC) in psychological and physical symptoms of depression, state anxiety, stress, fear of recurrence, sleep quality, fatigue, and quality of life (P's <.05). Effect sizes for improvements of multiple symptoms ranged from medium to large. Conclusions: These results provide preliminary support that the mMBSR(BC) program may be feasible and acceptable, showing a clinical impact on decreasing psychological and physical symptoms. This mobile‐based program offers a delivery of a standardized MBSR(BC) intervention to BCS that is convenient for their own schedule while decreasing symptom burden in the survivorship phase after treatment for breast cancer. AN - CN-01461377 AU - Lengacher, C. A. AU - Reich, R. R. AU - Ramesar, S. AU - Alinat, C. B. AU - Moscoso, M. AU - Cousin, L. AU - Marino, V. R. AU - Elias, M. N. AU - Paterson, C. L. AU - Pleasant, M. L. AU - et al. DO - 10.1002/pon.4491 IS - 2 KW - *breast cancer /disease management *mindfulness *mobile application *stress management Adult Anxiety disorder /therapy Article Cancer pain Cancer survivor Clinical article Cognition Controlled study Depression /therapy Fatigue /therapy Fear Feasibility study Female Human Meditation Outcome assessment Patient compliance Quality of life Randomized controlled trial Sleep quality Stress Walking Yoga M3 - Journal: Article PY - 2018 SP - 524‐531 ST - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors T2 - Psycho-oncology TI - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01461377/full VL - 27 ID - 1632 ER - TY - JOUR AB - Objective: The purpose of this pilot study was to test the feasibility of delivering the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program using an iPad and to evaluate its impact on symptom improvement. Methods: A single group, pre-posttest design was implemented among female stages 0-III breast cancer survivors (BCS) who completed treatment. Data were collected at baseline and week 6 on measures of psychological and physical symptoms and quality of life. The mMBSR(BC) program is a standardized, stress-reducing intervention that combines sitting and walking meditation, body scan, and yoga and is designed to deliver weekly 2-hour sessions for 6 weeks using an iPad. Results: The mean age of the 15 enrolled BCS was 57 years; one participant was non-Hispanic black, and 14 were non-Hispanic white. Of the 13 who completed the study, there were significant improvements from baseline to 6 weeks post-mMBSR(BC) in psychological and physical symptoms of depression, state anxiety, stress, fear of recurrence, sleep quality, fatigue, and quality of life (P's <.05). Effect sizes for improvements of multiple symptoms ranged from medium to large. Conclusions: These results provide preliminary support that the mMBSR(BC) program may be feasible and acceptable, showing a clinical impact on decreasing psychological and physical symptoms. This mobile-based program offers a delivery of a standardized MBSR(BC) intervention to BCS that is convenient for their own schedule while decreasing symptom burden in the survivorship phase after treatment for breast cancer. Copyright © 2017 John Wiley & Sons, Ltd. AD - College of Nursing, University of South Florida, Tampa, FL, United States Moffitt Cancer Center and Research Institute, Tampa, FL, United States School of Aging Studies, University of South Florida, Tampa, FL, United States College of Public Health, University of South Florida, Tampa, FL, United States National Cancer Institute, National Institutes of Health, Rockville, MD, United States AU - Lengacher, C. A. AU - Reich, R. R. AU - Ramesar, S. AU - Alinat, C. B. AU - Moscoso, M. AU - Cousin, L. AU - Marino, V. R. AU - Elias, M. N. AU - Paterson, C. L. AU - Pleasant, M. L. AU - Rodriguez, C. S. AU - Wang, H. L. AU - Kip, K. E. AU - Meng, H. AU - Park, J. Y. DB - Scopus DO - 10.1002/pon.4491 IS - 2 KW - breast cancer survivors MBSR mobile-based quality of life symptom managment M3 - Article N1 - Cited By :26 Export Date: 22 March 2021 PY - 2018 SP - 524-531 ST - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors T2 - Psycho-Oncology TI - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041732106&doi=10.1002%2fpon.4491&partnerID=40&md5=faea268661973cb5a053a3b19586f9dd VL - 27 ID - 2287 ER - TY - JOUR AB - ObjectiveThe purpose of this pilot study was to test the feasibility of delivering the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program using an iPad and to evaluate its impact on symptom improvement. MethodsA single group, pre-posttest design was implemented among female stages 0-III breast cancer survivors (BCS) who completed treatment. Data were collected at baseline and week 6 on measures of psychological and physical symptoms and quality of life. The mMBSR(BC) program is a standardized, stress-reducing intervention that combines sitting and walking meditation, body scan, and yoga and is designed to deliver weekly 2-hour sessions for 6weeks using an iPad. ResultsThe mean age of the 15 enrolled BCS was 57years; one participant was non-Hispanic black, and 14 were non-Hispanic white. Of the 13 who completed the study, there were significant improvements from baseline to 6weeks post-mMBSR(BC) in psychological and physical symptoms of depression, state anxiety, stress, fear of recurrence, sleep quality, fatigue, and quality of life (P's<.05). Effect sizes for improvements of multiple symptoms ranged from medium to large. ConclusionsThese results provide preliminary support that the mMBSR(BC) program may be feasible and acceptable, showing a clinical impact on decreasing psychological and physical symptoms. This mobile-based program offers a delivery of a standardized MBSR(BC) intervention to BCS that is convenient for their own schedule while decreasing symptom burden in the survivorship phase after treatment for breast cancer. AN - WOS:000424846500020 AU - Lengacher, C. A. AU - Reich, R. R. AU - Ramesar, S. AU - Alinat, C. B. AU - Moscoso, M. AU - Cousin, L. AU - Marino, V. R. AU - Elias, M. N. AU - Paterson, C. L. AU - Pleasant, M. L. AU - Rodriguez, C. S. AU - Wang, H. L. AU - Kip, K. E. AU - Meng, H. D. AU - Park, J. Y. DA - Feb DO - 10.1002/pon.4491 IS - 2 N1 - 28665541 PY - 2018 SN - 1057-9249 SP - 524-531 ST - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors T2 - Psycho-Oncology TI - Feasibility of the mobile mindfulness-based stress reduction for breast cancer (mMBSR(BC)) program for symptom improvement among breast cancer survivors VL - 27 ID - 2875 ER - TY - JOUR AB - Background: Obesity is associated with tumor aggressiveness and disease‐specific mortality for more than 15 defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restriction and increased physical activity may suppress hormonal, energy‐sensing, and inflammatory factors that drive neoplastic progression; however, exact mechanisms are yet to be determined, and experiments in humans are limited. Methods: We conducted a randomized controlled trial among 40 overweight or obese, newly‐diagnosed prostate cancer patients who elected prostatectomy to explore feasibility of a presurgical weight loss intervention that promoted a weight loss of roughly one kg. week‐1 via caloric restriction and physical activity, as well as to assess effects on tumor biology and circulating biomarkers. Measures of feasibility (accrual, retention, adherence, and safety) were primary endpoints. Exploratory aims were directed at the intervention's effect on tumor proliferation (Ki‐67) and other tumor markers (activated caspase‐3, insulin and androgen receptors, VEGF, TNFbeta, NFkappaB, and 4E‐BP1), circulating biomarkers (PSA, insulin, glucose, VEGF, TNFbeta, leptin, SHBG, and testosterone), lymphocytic gene expression of corresponding factors and cellular bioenergetics in neutrophils, and effects on the gut microbiome. Consenting patients were randomized in a 1:1 ratio to either: 1) weight loss via a healthful, guidelines‐based diet and exercise regimen; or 2) a wait‐list control. While biological testing is currently ongoing, this paper details our methods and feasibility outcomes. Results: The accrual target was met after screening 101 cases (enrollment rate: 39.6 %). Other outcomes included a retention rate of 85 %, excellent adherence (95 %), and no serious reported adverse events. No significant differences by age, race, or weight status were noted between enrollees vs. non‐enrollees. The most common reasons for non‐participation were "too busy" (30 %), medical exclusions (21 %), and "distance" (16 %). Conclusions: Presurgical trials offer a means to study the impact of diet and exercise interventions directly on tumor tissue, and other host factors that are feasible and safe, though modifications are needed to conduct trials within an abbreviated period of time and via distance medicine‐based approaches. Pre‐surgical trials are critical to elucidate the impact of lifestyle interventions on specific mechanisms that mediate carcinogenesis and which can be used subsequently as therapeutic targets. Trial registration: NCT01886677. AN - CN-01139112 AU - Demark-Wahnefried, W. AU - Nix, J. W. AU - Hunter, G. R. AU - Rais-Bahrami, S. AU - Desmond, R. A. AU - Chacko, B. AU - Morrow, C. D. AU - Azrad, M. AU - Fruge, A. D. AU - Tsuruta, Y. AU - et al. DO - 10.1186/s12885-016-2075-x IS - 1) (no pagination KW - *biological marker/ec [Endogenous Compound] *caloric restriction *hospital admission *physical activity *prostate cancer/su [Surgery] *prostatectomy Adult African American Androgen receptor/ec [Endogenous Compound] Article Bioenergy Body composition Body fat Body mass Caloric intake Cancer growth Cancer mortality Cancer patient Cardiorespiratory fitness Caspase 3/ec [Endogenous Compound] Caucasian Clinical article Controlled study Feasibility study Glucose/ec [Endogenous Compound] Human Immunoglobulin enhancer binding protein/ec [Endogenous Compound] Initiation factor 4E binding protein 1/ec [Endogenous Compound] Insulin receptor/ec [Endogenous Compound] Insulin/ec [Endogenous Compound] Ki 67 antigen/ec [Endogenous Compound] Leptin/ec [Endogenous Compound] Lymphotoxin/ec [Endogenous Compound] Male Obesity Phosphatidylinositol 3 kinase/ec [Endogenous Compound] Phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase/ec [Endogenous Compound] Prostate specific antigen/ec [Endogenous Compound] Protein kinase B/ec [Endogenous Compound] Quality of life Randomized controlled trial Risk factor Sex hormone binding globulin/ec [Endogenous Compound] Testosterone/ec [Endogenous Compound] Tumor growth Vasculotropin/ec [Endogenous Compound] Waist circumference Weight gain Weight reduction M3 - Journal: Article PY - 2016 ST - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer T2 - BMC cancer TI - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01139112/full VL - 16 ID - 1494 ER - TY - JOUR AB - Background: Obesity is associated with tumor aggressiveness and disease-specific mortality for more than 15 defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restriction and increased physical activity may suppress hormonal, energy-sensing, and inflammatory factors that drive neoplastic progression; however, exact mechanisms are yet to be determined, and experiments in humans are limited. Methods: We conducted a randomized controlled trial among 40 overweight or obese, newly-diagnosed prostate cancer patients who elected prostatectomy to explore feasibility of a presurgical weight loss intervention that promoted a weight loss of roughly one kg. week-1 via caloric restriction and physical activity, as well as to assess effects on tumor biology and circulating biomarkers. Measures of feasibility (accrual, retention, adherence, and safety) were primary endpoints. Exploratory aims were directed at the intervention's effect on tumor proliferation (Ki-67) and other tumor markers (activated caspase-3, insulin and androgen receptors, VEGF, TNFβ, NFκB, and 4E-BP1), circulating biomarkers (PSA, insulin, glucose, VEGF, TNFβ, leptin, SHBG, and testosterone), lymphocytic gene expression of corresponding factors and cellular bioenergetics in neutrophils, and effects on the gut microbiome. Consenting patients were randomized in a 1:1 ratio to either: 1) weight loss via a healthful, guidelines-based diet and exercise regimen; or 2) a wait-list control. While biological testing is currently ongoing, this paper details our methods and feasibility outcomes. Results: The accrual target was met after screening 101 cases (enrollment rate: 39.6 %). Other outcomes included a retention rate of 85 %, excellent adherence (95 %), and no serious reported adverse events. No significant differences by age, race, or weight status were noted between enrollees vs. non-enrollees. The most common reasons for non-participation were "too busy" (30 %), medical exclusions (21 %), and "distance" (16 %). Conclusions: Presurgical trials offer a means to study the impact of diet and exercise interventions directly on tumor tissue, and other host factors that are feasible and safe, though modifications are needed to conduct trials within an abbreviated period of time and via distance medicine-based approaches. Pre-surgical trials are critical to elucidate the impact of lifestyle interventions on specific mechanisms that mediate carcinogenesis and which can be used subsequently as therapeutic targets. Trial registration: NCT01886677. © 2016 Demark-Wahnefried et al. AD - University of Alabama at Birmingham (UAB), Department of Nutrition Sciences, 346 Webb Nutrition Sciences Bldg., 1675 University Blvd, Birmingham, AL, United States UAB, Department of Urology, Birmingham, AL, United States UAB, Department of Human Studies, Birmingham, AL, United States UAB, Department of Preventive Medicine, Birmingham, AL, United States UAB, Department of Molecular and Cellular Pathology, Birmingham, AL, United States UAB, Department of Cell, Developmental and Integrative Biology, Birmingham, AL, United States UAB, Department of Microbiology, Birmingham, AL, United States Urology Centers of Alabama, Birmingham, AL, United States University of Ottawa, Department of Medicine, Ontario, Canada UAB, Department of Pathology, Birmingham, AL, United States AU - Demark-Wahnefried, W. AU - Nix, J. W. AU - Hunter, G. R. AU - Rais-Bahrami, S. AU - Desmond, R. A. AU - Chacko, B. AU - Morrow, C. D. AU - Azrad, M. AU - Frugé, A. D. AU - Tsuruta, Y. AU - Ptacek, T. AU - Tully, S. A. AU - Segal, R. AU - Grizzle, W. E. C7 - 61 DB - Scopus DO - 10.1186/s12885-016-2075-x IS - 1 KW - Diet Exercise Intervention Obesity Physical activity Presurgical Prostatic neoplasms Weight loss M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2016 ST - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer T2 - BMC Cancer TI - Feasibility outcomes of a presurgical randomized controlled trial exploring the impact of caloric restriction and increased physical activity versus a wait-list control on tumor characteristics and circulating biomarkers in men electing prostatectomy for prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957056947&doi=10.1186%2fs12885-016-2075-x&partnerID=40&md5=9aadd39751e68cf450a82b402369a83f VL - 16 ID - 2348 ER - TY - JOUR AB - Objectives Employment following illness is associated with better physical and psychological functioning. This study aimed to assess the feasibility and acceptability of a theoretically led workbook intervention designed to support patients with cancer returning to work. Design Parallel-group randomised controlled trial with embedded qualitative interviews. Setting Oncology clinics within four English National Health Service Trusts. Participants Patients who had received a diagnosis of breast, gynaecological, prostate or colorectal cancer and who had been receiving treatment for a minimum of two weeks. Intervention A self-guided WorkPlan workbook designed to support patients with cancer to return to work with fortnightly telephone support calls to discuss progress. The control group received treatment as usual and was offered the workbook at the end of their 12-month follow-up. Outcome measures We assessed aspects of feasibility including eligibility, recruitment, data collection, attrition, feasibility of the methodology, acceptability of the intervention and potential to calculate cost-effectiveness. Results The recruitment rate of eligible patients was 44%; 68 participants consented and 58 (85%) completed baseline measures. Randomisation procedures were acceptable, data collection methods (including cost-effectiveness data) were feasible and the intervention was acceptable to participants. Retention rates at 6-month and 12-month follow-up were 72% and 69%, respectively. At 6-month follow-up, 30% of the usual care group had returned to full-time or part-time work (including phased return to work) compared with 43% of the intervention group. At 12 months, the percentages were 47% (usual care) and 68% (intervention). Conclusions The findings confirm the feasibility of a definitive trial, although further consideration needs to be given to increasing the participation rates among men and black and ethnic minority patients diagnosed with cancer. AD - E.A. Grunfeld, Department of Psychological Sciences, Birkbeck University of London, London, United Kingdom AU - Grunfeld, E. A. AU - Schumacher, L. AU - Armaou, M. AU - Woods, P. L. AU - Rolf, P. AU - Sutton, A. J. AU - Zarkar, A. AU - Sadhra, S. S. DB - Embase Medline DO - 10.1136/bmjopen-2018-022746 IS - 1 KW - ISRCTN56342476 adult aged article cancer survivor controlled study feasibility study female follow up full time employment human major clinical study male parttime employment randomized controlled trial return to work social support telemonitoring United Kingdom LA - English M3 - Article N1 - L626017309 2019-02-21 2019-02-28 PY - 2019 SN - 2044-6055 ST - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK T2 - BMJ Open TI - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626017309&from=export http://dx.doi.org/10.1136/bmjopen-2018-022746 VL - 9 ID - 865 ER - TY - JOUR AB - OBJECTIVES: Employment following illness is associated with better physical and psychological functioning. This study aimed to assess the feasibility and acceptability of a theoretically led workbook intervention designed to support patients with cancer returning to work. DESIGN: Parallel‐group randomised controlled trial with embedded qualitative interviews. SETTING: Oncology clinics within four English National Health Service Trusts. PARTICIPANTS: Patients who had received a diagnosis of breast, gynaecological, prostate or colorectal cancer and who had been receiving treatment for a minimum of two weeks. INTERVENTION: A self‐guided WorkPlan workbook designed to support patients with cancer to return to work with fortnightly telephone support calls to discuss progress. The control group received treatment as usual and was offered the workbook at the end of their 12‐month follow‐up. OUTCOME MEASURES: We assessed aspects of feasibility including eligibility, recruitment, data collection, attrition, feasibility of the methodology, acceptability of the intervention and potential to calculate cost‐effectiveness. RESULTS: The recruitment rate of eligible patients was 44%; 68 participants consented and 58 (85%) completed baseline measures. Randomisation procedures were acceptable, data collection methods (including cost‐effectiveness data) were feasible and the intervention was acceptable to participants. Retention rates at 6‐month and 12‐month follow‐up were 72% and 69%, respectively. At 6‐month follow‐up, 30% of the usual care group had returned to full‐time or part‐time work (including phased return to work) compared with 43% of the intervention group. At 12 months, the percentages were 47% (usual care) and 68% (intervention). CONCLUSIONS: The findings confirm the feasibility of a definitive trial, although further consideration needs to be given to increasing the participation rates among men and black and ethnic minority patients diagnosed with cancer. TRIAL REGISTRATION NUMBER: ISRCTN56342476; Pre‐results. AN - CN-01793256 AU - Grunfeld, E. A. AU - Schumacher, L. AU - Armaou, M. AU - Woods, P. L. AU - Rolf, P. AU - Sutton, A. J. AU - Zarkar, A. AU - Sadhra, S. S. DO - 10.1136/bmjopen-2018-022746 IS - 1 KW - *cancer survivor *return to work *social support Adult Aged Article Cancer Survivors [*psychology] Controlled study Cost‐Benefit Analysis Feasibility Studies Feasibility study Female Follow up Full time employment Goals Human Humans Major clinical study Male Middle Aged Neoplasms [economics, therapy] Parttime employment Randomized controlled trial Return to Work [*statistics & numerical data] State Medicine Telemonitoring Time Factors United Kingdom M3 - Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2019 SP - e022746 ST - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK T2 - BMJ open TI - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01793256/full VL - 9 ID - 1608 ER - TY - JOUR AB - Objectives Employment following illness is associated with better physical and psychological functioning. This study aimed to assess the feasibility and acceptability of a theoretically led workbook intervention designed to support patients with cancer returning to work. Design Parallel-group randomised controlled trial with embedded qualitative interviews. Setting Oncology clinics within four English National Health Service Trusts. Participants Patients who had received a diagnosis of breast, gynaecological, prostate or colorectal cancer and who had been receiving treatment for a minimum of two weeks. Intervention A self-guided WorkPlan workbook designed to support patients with cancer to return to work with fortnightly telephone support calls to discuss progress. The control group received treatment as usual and was offered the workbook at the end of their 12-month follow-up. Outcome measures We assessed aspects of feasibility including eligibility, recruitment, data collection, attrition, feasibility of the methodology, acceptability of the intervention and potential to calculate cost-effectiveness. Results The recruitment rate of eligible patients was 44%; 68 participants consented and 58 (85%) completed baseline measures. Randomisation procedures were acceptable, data collection methods (including cost-effectiveness data) were feasible and the intervention was acceptable to participants. Retention rates at 6-month and 12-month follow-up were 72% and 69%, respectively. At 6-month follow-up, 30% of the usual care group had returned to full-time or part-time work (including phased return to work) compared with 43% of the intervention group. At 12 months, the percentages were 47% (usual care) and 68% (intervention). Conclusions The findings confirm the feasibility of a definitive trial, although further consideration needs to be given to increasing the participation rates among men and black and ethnic minority patients diagnosed with cancer. © Author(s) (or their employer(s)) 2018. AD - Department of Psychological Sciences, Birkbeck University of London, London, United Kingdom Faculty of Health and Life Sciences, Coventry University, Coventry, United Kingdom Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom Oncology Department, Queen Elizabeth Hospital, University Hospitals Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom AU - Grunfeld, E. A. AU - Schumacher, L. AU - Armaou, M. AU - Woods, P. L. AU - Rolf, P. AU - Sutton, A. J. AU - Zarkar, A. AU - Sadhra, S. S. C7 - e022746 DB - Scopus DO - 10.1136/bmjopen-2018-022746 IS - 1 KW - cancer employment feasibility intervention randomised controlled trial M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2019 ST - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK T2 - BMJ Open TI - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060372217&doi=10.1136%2fbmjopen-2018-022746&partnerID=40&md5=d0684ac7b64a1f45cf79788b4a5e5695 VL - 9 ID - 2245 ER - TY - JOUR AB - Objectives Employment following illness is associated with better physical and psychological functioning. This study aimed to assess the feasibility and acceptability of a theoretically led workbook intervention designed to support patients with cancer returning to work. Design Parallel-group randomised controlled trial with embedded qualitative interviews. Setting Oncology clinics within four English National Health Service Trusts. Participants Patients who had received a diagnosis of breast, gynaecological, prostate or colorectal cancer and who had been receiving treatment for a minimum of two weeks. Intervention A self-guided WorkPlan workbook designed to support patients with cancer to return to work with fortnightly telephone support calls to discuss progress. The control group received treatment as usual and was offered the workbook at the end of their 12-month follow-up. Outcome measures We assessed aspects of feasibility including eligibility, recruitment, data collection, attrition, feasibility of the methodology, acceptability of the intervention and potential to calculate cost-effectiveness. Results The recruitment rate of eligible patients was 44%; 68 participants consented and 58 (85%) completed baseline measures. Randomisation procedures were acceptable, data collection methods (including costeffectiveness data) were feasible and the intervention was acceptable to participants. Retention rates at 6-month and 12-month follow-up were 72% and 69%, respectively. At 6-month follow-up, 30% of the usual care group had returned to full-time or part-time work (including phased return to work) compared with 43% of the intervention group. At 12 months, the percentages were 47% (usual care) and 68% (intervention). Conclusions The findings confirm the feasibility of a definitive trial, although further consideration needs to be given to increasing the participation rates among men and black and ethnic minority patients diagnosed with cancer. AN - WOS:000471116800057 AU - Grunfeld, E. A. AU - Schumacher, L. AU - Armaou, M. AU - Woods, P. L. AU - Rolf, P. AU - Sutton, A. J. AU - Zarkar, A. AU - Sadhra, S. S. DA - Jun DO - 10.1136/bmjopen-2018-022746 IS - 1 N1 - e022746 30670507 PY - 2019 SN - 2044-6055 ST - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK T2 - Bmj Open TI - Feasibility randomised controlled trial of a guided workbook intervention to support work-related goals among cancer survivors in the UK VL - 9 ID - 2820 ER - TY - JOUR AB - The barbershop is a promising setting where African-American men might receive information and education about prostate cancer. In this study, we assessed the feasibility of engaging rural barbershops as venues for barbers to deliver a prostate cancer education intervention to increase informed decision-making for prostate cancer screening among customers. Twelve barbershops were recruited from two separate micropolitan areas in Georgia as intervention and control sites. Structured interviews were conducted with 11 barbers in both sites about customer characteristics as well as their willingness to participate in the study. The interviews were audio recorded and transcribed for analysis. In the intervention site, six barbers completed a survey and a pre-/posttest prostate cancer knowledge instrument following training classes. Barbers reported a wide average range of customers served per week (50 to 300). African-American men made up an average of 87 % of customers. Barbers thought prostate cancer was an important discussion topic, felt they would be comfortable discussing it, and supported the participation of their barbershop in the study. For intervention group barbers, there was a statistically significant difference between the average pretest knowledge score of 72 % (mean 12.2, SD = 3.2) and the posttest knowledge score of 89 % (mean 15.2, SD = 1.1) (P = 0.03) on the 17-item prostate cancer knowledge instrument. Based on the multiple interactions with the barbers, there was high receptivity to the topic and consensus about the importance of addressing prostate cancer with their customers. Rural barbershops represent feasible venues for delivering a prostate cancer education intervention. AN - WOS:000363048100004 AU - Luque, J. S. AU - Roy, S. AU - Tarasenko, Y. N. AU - Ross, L. AU - Johnson, J. AU - Gwede, C. K. DA - Dec DO - 10.1007/s13187-014-0739-2 IS - 4 N1 - 25288347 PY - 2015 SN - 0885-8195 SP - 623-628 ST - Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities T2 - Journal of Cancer Education TI - Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities VL - 30 ID - 2962 ER - TY - JOUR AB - There are marked racial differences in breast cancer, the second leading cause of death among US women. Understanding the causes of these differences is essential to eliminate breast cancer inequities. More prevalent in African American than in Caucasian women, metabolic syndrome has been associated with breast cancer outcomes. Further research is needed to understand metabolic syndrome’s role in breast cancer disparities, thus novel strategies to increase minority participation in research are important. We embedded two approaches (comprehensive, focused) to increase African American participation in breast cancer research in a state-wide service program and pilot tested both approaches in rural African American women. We conducted three comprehensive and three focused outreach programs (n = 48) and assessed research participation through consent and actual provision of data for four types of data: survey, anthropometric, blood, and mammography records. The majority of participants provided written consent for all data collection procedures (96 % survey; 92 % anthropometric; 94 %, blood; 100 % mammography). There were no between group differences in consent rates. There was variation in the overall proportion of participants who provided data (96 % survey; 92 % anthropometric; 73 % blood; 40 % mammography). Women in the comprehensive approach were less likely to return for a scheduled mammogram than women in the focused approach (19 % vs 64 %, p = 0.0236). Both outreach programs promoted African American engagement in research. Differences in the provision of data by type may have been due to participant burden (i.e., time required to provide data). Study designs that embed research in service programs have promise to increase minority research participation. (PsycINFO Database Record (c) 2018 APA, all rights reserved) AD - Yeary, Karen Hye-cheon Kim AN - 2018-02916-006 AU - Yeary, Karen Hye-cheon Kim AU - Moore, Page AU - Turner, Jerome AU - Dawson, Leah AU - Heo, Seongkum AU - Greene, Paul DB - psyh DO - 10.1007/s13187-016-1032-3 DP - EBSCOhost IS - 1 KW - feasibility test African American participation breast cancer disparities racial differences metabolic syndrome outreach programs research participation Breast Neoplasms Experimental Subjects Racial and Ethnic Differences Health Disparities Blacks Experimentation Participation N1 - University of Arkansas for Medical Sciences, Little Rock, AR, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20181206. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Experimental Subjects; Outreach Programs; Racial and Ethnic Differences; Health Disparities. Minor Descriptor: Blacks; Experimentation; Metabolic Syndrome; Participation. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. Page Count: 8. Issue Publication Date: Feb, 2018. Publication History: First Posted Date: Apr 16, 2016. Copyright Statement: American Association for Cancer Education. 2016. Sponsor: National Institutes of Health, US. Grant: 1 P20 MD002329-01. Recipients: No recipient indicated PY - 2018 SN - 0885-8195 1543-0154 SP - 29-36 ST - Feasibility test of a community-relevant intervention designed to promote African American participation in translational, breast cancer disparities research: Know about health options for women (Know HOW) T2 - Journal of Cancer Education TI - Feasibility test of a community-relevant intervention designed to promote African American participation in translational, breast cancer disparities research: Know about health options for women (Know HOW) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-02916-006&site=ehost-live&scope=site khk@uams.edu VL - 33 ID - 1692 ER - TY - JOUR AB - There are marked racial differences in breast cancer, the second leading cause of death among US women. Understanding the causes of these differences is essential to eliminate breast cancer inequities. More prevalent in African American than in Caucasian women, metabolic syndrome has been associated with breast cancer outcomes. Further research is needed to understand metabolic syndrome's role in breast cancer disparities, thus novel strategies to increase minority participation in research are important. We embedded two approaches (comprehensive, focused) to increase African American participation in breast cancer research in a state-wide service program and pilot tested both approaches in rural African American women. We conducted three comprehensive and three focused outreach programs (n = 48) and assessed research participation through consent and actual provision of data for four types of data: survey, anthropometric, blood, and mammography records. The majority of participants provided written consent for all data collection procedures (96 % survey; 92 % anthropometric; 94 %, blood; 100 % mammography). There were no between group differences in consent rates. There was variation in the overall proportion of participants who provided data (96 % survey; 92 % anthropometric; 73 % blood; 40 % mammography). Women in the comprehensive approach were less likely to return for a scheduled mammogram than women in the focused approach (19 % vs 64 %, p = 0.0236). Both outreach programs promoted African American engagement in research. Differences in the provision of data by type may have been due to participant burden (i.e., time required to provide data). Study designs that embed research in service programs have promise to increase minority research participation. AD - University of Arkansas for Medical Sciences, Little Rock, AR, USA AN - 127247440. Language: English. Entry Date: 20190803. Revision Date: 20210223. Publication Type: journal article. Journal Subset: Biomedical AU - Yeary, Karen Hye-cheon Kim AU - Moore, Page AU - Turner, Jerome AU - Dawson, Leah AU - Heo, Seongkum AU - Greene, Paul DB - CINAHL Complete DO - 10.1007/s13187-016-1032-3 DP - EBSCOhost IS - 1 KW - Attitude to Health -- Ethnology Black Persons Breast Neoplasms -- Ethnology Health Status Disparities Patient Selection Mammography -- Statistics and Numerical Data Female Health Promotion Rural Population Adult Research, Medical Pilot Studies United States Minority Groups Middle Age Aged N1 - Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Wide Range Achievement Test (WRAT). Grant Information: P20 MD002329/MD/NIMHD NIH HHS/United States. NLM UID: 8610343. PMID: NLM27085550. PY - 2018 SN - 0885-8195 SP - 29-36 ST - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW) T2 - Journal of Cancer Education TI - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127247440&site=ehost-live&scope=site VL - 33 ID - 1960 ER - TY - JOUR AB - There are marked racial differences in breast cancer, the second leading cause of death among US women. Understanding the causes of these differences is essential to eliminate breast cancer inequities. More prevalent in African American than in Caucasian women, metabolic syndrome has been associated with breast cancer outcomes. Further research is needed to understand metabolic syndrome's role in breast cancer disparities, thus novel strategies to increase minority participation in research are important. We embedded two approaches (comprehensive, focused) to increase African American participation in breast cancer research in a state-wide service program and pilot tested both approaches in rural African American women. We conducted three comprehensive and three focused outreach programs (n = 48) and assessed research participation through consent and actual provision of data for four types of data: survey, anthropometric, blood, and mammography records. The majority of participants provided written consent for all data collection procedures (96 % survey; 92 % anthropometric; 94 %, blood; 100 % mammography). There were no between group differences in consent rates. There was variation in the overall proportion of participants who provided data (96 % survey; 92 % anthropometric; 73 % blood; 40 % mammography). Women in the comprehensive approach were less likely to return for a scheduled mammogram than women in the focused approach (19 % vs 64 %, p = 0.0236). Both outreach programs promoted African American engagement in research. Differences in the provision of data by type may have been due to participant burden (i.e., time required to provide data). Study designs that embed research in service programs have promise to increase minority research participation. AU - Yeary, K. H. C. K. AU - Moore, P. AU - Turner, J. AU - Dawson, L. AU - Heo, S. AU - Greene, P. DB - Medline DO - 10.1007/s13187-016-1032-3 IS - 1 KW - adult African American aged attitude to health breast tumor ethnology feasibility study female health disparity health promotion human mammography medical research middle aged minority group patient selection questionnaire rural population statistics and numerical data United States LA - English M3 - Article N1 - L625992140 2019-01-23 2019-07-17 PY - 2018 SN - 1543-0154 SP - 29-36 ST - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW) T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Feasibility Test of a Community-Relevant Intervention Designed to Promote African American Participation in Translational, Breast Cancer Disparities Research: Know About Health Options for Women (Know HOW) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625992140&from=export http://dx.doi.org/10.1007/s13187-016-1032-3 VL - 33 ID - 913 ER - TY - JOUR AB - BACKGROUND The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC. METHODS The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability. RESULTS Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P <.05) in depressive symptoms and improvements in relaxation self-efficacy (P <.05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P <.08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. CONCLUSIONS Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. Cancer 2015;121:4407-15. AD - F.J. Penedo, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 North St. Clair, Chicago, IL, United States AU - Yanez, B. AU - McGinty, H. L. AU - Mohr, D. C. AU - Begale, M. J. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Penedo, F. J. DB - Embase Medline DO - 10.1002/cncr.29658 IS - 24 KW - advanced cancer aged article Black person Caucasian clinical effectiveness cognitive behavioral stress management controlled study depression feasibility study health promotion human intermethod comparison Internet leisure major clinical study male patient compliance patient satisfaction priority journal program acceptability prostate cancer quality of life randomized controlled trial self concept self report treatment duration wellbeing wireless communication LA - English M3 - Article N1 - L605950937 2015-09-15 2015-12-21 PY - 2015 SN - 1097-0142 0008-543X SP - 4407-4415 ST - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer T2 - Cancer TI - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605950937&from=export http://dx.doi.org/10.1002/cncr.29658 VL - 121 ID - 989 ER - TY - JOUR AB - BACKGROUND: The utility of psychosocial interventions in reducing symptom burden and improving health‐related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology‐assisted, 10‐week, group‐based psychosocial intervention for diverse men with APC. METHODS: The participants were 74 men (mean age, 68.84 years; non‐Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive‐behavioral stress management (CBSM) treatment or health promotion (HP) attention‐control condition. The participants were assessed at the baseline, weekly throughout the 10‐week program, and 6 months after the baseline. Outcomes were assessed with the Patient‐Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient‐reported acceptability. RESULTS: Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P < .05) in depressive symptoms and improvements in relaxation self‐efficacy (P < .05) at the 6‐month follow‐up. CBSM participants reported trends for improvement in distress and functional well‐being (P < .08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. CONCLUSIONS: Technology‐based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. AN - CN-01125221 AU - Yanez, B. AU - McGinty, H. L. AU - Mohr, D. C. AU - Begale, M. J. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Penedo, F. J. DO - 10.1002/cncr.29658 IS - 24 KW - *Internet *advanced cancer/th [Therapy] *cognitive behavioral stress management *prostate cancer/th [Therapy] African Americans [psychology] Aged Aged, 80 and over Article Black person Caucasian Clinical effectiveness Cognitive Behavioral Therapy [*methods] Controlled study Depression [psychology, *therapy] Depression/th [Therapy] European Continental Ancestry Group [psychology] Feasibility Studies Feasibility study Health promotion Human Humans Intermethod comparison Leisure Major clinical study Male Middle Aged Neoplasm Staging Patient Acceptance of Health Care Patient Satisfaction Patient compliance Priority journal Program acceptability Prostatic Neoplasms [pathology, *psychology] Quality of Life Randomized controlled trial Self Efficacy Self concept Self report Stress, Psychological [psychology, *therapy] Therapy, Computer‐Assisted [*methods] Treatment Outcome Treatment duration Wellbeing Wireless communication M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2015 SP - 4407‐4415 ST - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer T2 - Cancer TI - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01125221/full VL - 121 ID - 1377 ER - TY - JOUR AB - Background: The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC.Methods: The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability.Results: Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P < .05) in depressive symptoms and improvements in relaxation self-efficacy (P < .05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P < .08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful.Conclusions: Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. AD - Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago Illinois Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami Florida Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago Illinois AN - 111405532. Language: English. Entry Date: 20160326. Revision Date: 20190711. Publication Type: journal article AU - Yanez, Betina AU - McGinty, Heather L. AU - Mohr, David C. AU - Begale, Mark J. AU - Dahn, Jason R. AU - Flury, Sarah C. AU - Perry, Kent T. AU - Penedo, Frank J. DB - CINAHL Complete DO - 10.1002/cncr.29658 DP - EBSCOhost IS - 24 KW - Stress, Psychological -- Therapy Therapy, Computer Assisted -- Methods Quality of Life Cognitive Therapy -- Methods Patient Attitudes Depression -- Therapy Prostatic Neoplasms -- Psychosocial Factors Middle Age Prostatic Neoplasms -- Pathology Pilot Studies Stress, Psychological -- Psychosocial Factors Aged White Persons -- Psychosocial Factors Neoplasm Staging Black Persons -- Psychosocial Factors Self-Efficacy Depression -- Psychosocial Factors Male Aged, 80 and Over Patient Satisfaction Treatment Outcomes Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Scales Funding Source Questionnaires N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Health-Related Quality of Life (HRQOL). Grant Information: R01CA157809/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM26348661. PY - 2015 SN - 0008-543X SP - 4407-4415 ST - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer T2 - Cancer (0008543X) TI - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=111405532&site=ehost-live&scope=site VL - 121 ID - 1961 ER - TY - JOUR AB - BACKGROUND The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC. METHODS The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability. RESULTS Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P <.05) in depressive symptoms and improvements in relaxation self-efficacy (P <.05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P <.08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. CONCLUSIONS Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. Cancer 2015;121:4407-15. © 2015 American Cancer Society. AD - Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 North St. Clair, Chicago, IL 60611, United States Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami, FL, United States Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States AU - Yanez, B. AU - McGinty, H. L. AU - Mohr, D. C. AU - Begale, M. J. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Penedo, F. J. DB - Scopus DO - 10.1002/cncr.29658 IS - 24 KW - eHealth prostate cancer psychosocial aspects quality of life randomized trial M3 - Article N1 - Cited By :37 Export Date: 22 March 2021 PY - 2015 SP - 4407-4415 ST - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer T2 - Cancer TI - Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949319975&doi=10.1002%2fcncr.29658&partnerID=40&md5=9f05897c20eeea7cd7f7ef173b84271d VL - 121 ID - 2357 ER - TY - JOUR AB - BACKGROUND: The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC. METHODS: The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability. RESULTS: Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P<.05) in depressive symptoms and improvements in relaxation self-efficacy (P<.05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P<.08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. CONCLUSIONS: Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. (C) 2015 American Cancer Society. AN - WOS:000367984700019 AU - Yanez, B. AU - McGinty, H. L. AU - Mohr, D. C. AU - Begale, M. J. AU - Dahn, J. R. AU - Flury, S. C. AU - Perry, K. T. AU - Penedo, F. J. DA - Dec DO - 10.1002/cncr.29658 IS - 24 N1 - 26348661 PY - 2015 SN - 0008-543X SP - 4407-4415 ST - Feasibility, Acceptability, and Preliminary Efficacy of a Technology-Assisted Psychosocial Intervention for Racially Diverse Men With Advanced Prostate Cancer T2 - Cancer TI - Feasibility, Acceptability, and Preliminary Efficacy of a Technology-Assisted Psychosocial Intervention for Racially Diverse Men With Advanced Prostate Cancer VL - 121 ID - 2960 ER - TY - JOUR AB - Background: The utility of psychosocial interventions in reducing symptom burden and improving health-related quality of life (HRQOL) for men with localized prostate cancer has been demonstrated. However, studies have yet to demonstrate the efficacy of interventions in advanced prostate cancer (APC). This study examined the feasibility, acceptability, and preliminary efficacy of a technology-assisted, 10-week, group-based psychosocial intervention for diverse men with APC. Methods: The participants were 74 men (mean age, 68.84 years; non-Hispanic white, 57%; black, 40.5%) who were randomized to a cognitive-behavioral stress management (CBSM) treatment or health promotion (HP) attention-control condition. The participants were assessed at the baseline, weekly throughout the 10-week program, and 6 months after the baseline. Outcomes were assessed with the Patient-Reported Outcomes Measurement Information System along with established measures of HRQOL, CBSM intervention targets (eg, relaxation skills), and patient-reported acceptability. Results: Feasibility was demonstrated through good retention rates (>85%) and acceptable average attendance rates (>70%), and acceptability was demonstrated through very favorable weekly session evaluations (mean score, 4/5) and exit surveys (mean score, 3.6/4). Men randomized to the CBSM condition reported significant reductions (P < .05) in depressive symptoms and improvements in relaxation self-efficacy (P < .05) at the 6-month follow-up. CBSM participants reported trends for improvement in distress and functional well-being (P < .08) in comparison with those in the HP condition. Effect sizes ranged from medium (0.54) to large (1.87) and, in some instances, were clinically meaningful. Conclusions: Technology-based CBSM interventions among diverse men with APC may be feasible, acceptable, and efficacious. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Penedo, Frank J., Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, 633 North St. Clair, 19th Floor, Chicago, IL, US, 60611 AN - 2015-55351-016 AU - Yanez, Betina AU - McGinty, Heather L. AU - Mohr, David C. AU - Begale, Mark J. AU - Dahn, Jason R. AU - Flury, Sarah C. AU - Perry, Kent T. AU - Penedo, Frank J. DB - psyh DP - EBSCOhost IS - 24 KW - eHealth quality of life prostate cancer psychosocial aspects randomized trial Neoplasms Psychosocial Factors Telemedicine Treatment Effectiveness Evaluation Group Intervention Client Characteristics Cognitive Behavior Therapy Disease Management Diversity Human Males Major Depression Stress Management Symptoms N1 - Department of Medical Social Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL, US. Release Date: 20160303. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Penedo, Frank J. Major Descriptor: Neoplasms; Psychosocial Factors; Telemedicine; Treatment Effectiveness Evaluation; Group Intervention. Minor Descriptor: Client Characteristics; Cognitive Behavior Therapy; Disease Management; Diversity; Human Males; Major Depression; Quality of Life; Stress Management; Symptoms. Classification: Behavioral & Psychological Treatment of Physical Illness (3361). Population: Human (10); Male (30); Inpatient (50). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Patient Reported Outcomes Measurement Information System Measures; Functional Assessment of Cancer Therapy–General; Impact of Event Scale--Revised DOI: 10.1037/t12199-000; Mini Mental State Examination. Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Dec 15, 2015. Publication History: First Posted Date: Sep 8, 2015; Accepted Date: Aug 3, 2015; Revised Date: Jul 20, 2015; First Submitted Date: May 27, 2015. Sponsor: National Cancer Institute, US. Grant: R01CA157809. Recipients: Penedo, Frank J. Sponsor: National Cancer Institute, US. Other Details: Diversity supplement. Recipients: Yanez, Betina PY - 2015 SN - 0008-543X 1097-0142 SP - 4407-4415 ST - Feasibility, acceptability, and preliminary efficacy of a technology‐assisted psychosocial intervention for racially diverse men with advanced prostate cancer T2 - Cancer TI - Feasibility, acceptability, and preliminary efficacy of a technology‐assisted psychosocial intervention for racially diverse men with advanced prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-55351-016&site=ehost-live&scope=site fpenedo@northwestern.edu VL - 121 ID - 1705 ER - TY - JOUR AB - Background: Clinical trials test new ways to prevent, detect, diagnose, or treat diseases. Researchers have found that minority patients are willing to participate in clinical trials, yet these patients have barriers which hinder their access to trials. Methods: To explore African American women's participation in breast cancer clinical trials, eight focus groups were conducted with breast cancer patients, family members/care givers, religious leaders, and healthcare providers to gather information on the perspectives and opinions on the topic. The focus group conversations were transcribed, and transcripts were imported into QSR International's NVivo 10 software. The transcripts were organized into folders based on four categories. The content analysis performed was based on recordings and notes. Results: The following themes were generated as a result of conducting these focus groups and gathering information on the perspectives and opinions about participating in clinical trials, based on the groups who participated: Promoting participation in research; Personal experience with cancer; Support and support services; Awareness, knowledge, and experience with clinical trials; Providers' roles in clinical trials. Conclusion: The data collected in this study present several actionable themes that, if addressed by individual researchers and the medical community at large, could increase participation in clinical trials by African American patients. They also provide a deeper and more nuanced understanding of the factors influencing African American patients' decisions around participating in clinical trials. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license AN - WOS:000399161400025 AU - Robinson, B. N. AU - Newman, A. F. AU - Wallington, S. F. AU - Swain, S. M. DA - Dec DO - 10.1016/j.conctc.2016.09.004 N1 - 28770256 PY - 2016 SN - 2451-8654 SP - 170-178 ST - Focus on You: Cancer clinical trials perspectives T2 - Contemporary Clinical Trials Communications TI - Focus on You: Cancer clinical trials perspectives VL - 4 ID - 2924 ER - TY - JOUR AB - Background: We evaluated the efficacy of a Chicago-based cancer patient navigation program developed to increase the proportion of patients reaching diagnostic resolution and reduce the time from abnormal screening test to definitive diagnostic resolution. Methods: Women with an abnormal breast (n = 352) or cervical (n = 545) cancer screening test were recruited for the quasi-experimental study. Navigation subjects originated from five federally qualified health center sites and one safety net hospital. Records-based concurrent control subjects were selected from 20 sites. Control sites had similar characteristics to the navigated sites in terms of patient volume, racial/ethnic composition, and payor mix. Mixed-effects logistic regression and Cox proportional hazard regression analyses were conducted to compare navigation and control patients reaching diagnostic resolution by 60 days and time to resolution, adjusting for demographic covariates and site. Results: Compared with controls, the breast navigation group had shorter time to diagnostic resolution (aHR = 1.65, CI = 1.20-2.28) and the cervical navigation group had shorter time to diagnostic resolution for those who resolved after 30 days (aHR = 2.31, CI = 1.75-3.06), with no difference before 30 days (aHR = 1.42, CI = 0.83-2.43). Variables significantly associated with longer time to resolution for breast cancer screening abnormalities were being older, never partnered, abnormal mammogram and BI-RADS 3, and being younger and Black for cervical abnormalities. Conclusions: Patient navigation reduces time from abnormal cancer finding to definitive diagnosis in underserved women. Impact: Results support efforts to use patient navigation as a strategy to reduce cancer disparities among socioeconomically disadvantaged women. Cancer Epidemiol Biomarkers Prev; 21(10); 1691-700. (c) 2012 AACR. AN - WOS:000309576100011 AU - Markossian, T. W. AU - Darnell, J. S. AU - Calhoun, E. A. DA - Oct DO - 10.1158/1055-9965.EPI-12-0535 IS - 10 N1 - 23045544 PY - 2012 SN - 1055-9965 SP - 1691-1700 ST - Follow-Up and Timeliness After an Abnormal Cancer Screening Among Underserved, Urban Women in a Patient Navigation Program T2 - Cancer Epidemiology Biomarkers & Prevention TI - Follow-Up and Timeliness After an Abnormal Cancer Screening Among Underserved, Urban Women in a Patient Navigation Program VL - 21 ID - 3059 ER - TY - JOUR AB - Background: Significant disparities exist in colorectal cancer (CRC) screening rates among those of low socioeconomic status, with fewer years of education, lacking health insurance, or living in rural areas. Methods: A randomized controlled trial was conducted to compare the effectiveness of 2 follow-up approaches to a health literacy intervention to improve CRC screening: automated telephone call or personal call. Patients aged 50 to 75 years residing in 4 rural community clinics in Louisiana were given a structured interview that assessed demographic, health literacy and CRC screening barriers, knowledge, and attitudes. All were given health literacy–informed CRC education, a patient-friendly CRC screening pamphlet, simplified fecal immunochemical test (FIT) instructions, and a FIT kit, and a “teach-back” method was used to confirm understanding. Patients were randomized to 1 of 2 telephone follow-up arms. If they did not mail their FIT kit within 4 weeks, they received a reminder call and were called again at 8 weeks if the test still was not received. Results: A total of 620 patients were enrolled. Approximately 55% were female, 66% were African American, and 40% had limited literacy. The overall FIT completion rate was 68%: 69.2% in the automated telephone call arm and 67% in the personal call arm. Greater than one-half of the patients (range, 58%-60%) returned the FIT kit without receiving a telephone call. There was no difference noted with regard to the effectiveness of the follow-up calls; each increased the return rate by 9%. Conclusions: Providing FIT kits and literacy-appropriate education at regularly scheduled clinic visits with a follow-up telephone call when needed was found to increase CRC screening among low-income, rural patients. The lower cost automated call was just as effective as the personal call. AD - C.L. Arnold, Department of Medicine, Louisiana State University Health Sciences Center–Shreveport, Shreveport, LA, United States AU - Arnold, C. L. AU - Rademaker, A. W. AU - Morris, J. D. AU - Ferguson, L. A. AU - Wiltz, G. AU - Davis, T. C. DB - Embase Medline DO - 10.1002/cncr.32398 IS - 20 KW - NCT02360605 adult African American aged article attitude to health cancer screening colorectal cancer comparative effectiveness controlled study cost female follow up health literacy human intervention study lowest income group major clinical study male occult blood test priority journal randomized controlled trial risk factor rural population LA - English M3 - Article N1 - L628824855 2019-08-13 2019-10-31 PY - 2019 SN - 1097-0142 0008-543X SP - 3615-3622 ST - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial T2 - Cancer TI - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628824855&from=export http://dx.doi.org/10.1002/cncr.32398 VL - 125 ID - 836 ER - TY - JOUR AB - Background: Significant disparities exist in colorectal cancer (CRC) screening rates among those of low socioeconomic status, with fewer years of education, lacking health insurance, or living in rural areas.Methods: A randomized controlled trial was conducted to compare the effectiveness of 2 follow-up approaches to a health literacy intervention to improve CRC screening: automated telephone call or personal call. Patients aged 50 to 75 years residing in 4 rural community clinics in Louisiana were given a structured interview that assessed demographic, health literacy and CRC screening barriers, knowledge, and attitudes. All were given health literacy-informed CRC education, a patient-friendly CRC screening pamphlet, simplified fecal immunochemical test (FIT) instructions, and a FIT kit, and a "teach-back" method was used to confirm understanding. Patients were randomized to 1 of 2 telephone follow-up arms. If they did not mail their FIT kit within 4 weeks, they received a reminder call and were called again at 8 weeks if the test still was not received.Results: A total of 620 patients were enrolled. Approximately 55% were female, 66% were African American, and 40% had limited literacy. The overall FIT completion rate was 68%: 69.2% in the automated telephone call arm and 67% in the personal call arm. Greater than one-half of the patients (range, 58%-60%) returned the FIT kit without receiving a telephone call. There was no difference noted with regard to the effectiveness of the follow-up calls; each increased the return rate by 9%.Conclusions: Providing FIT kits and literacy-appropriate education at regularly scheduled clinic visits with a follow-up telephone call when needed was found to increase CRC screening among low-income, rural patients. The lower cost automated call was just as effective as the personal call. AD - Department of Medicine, Louisiana State University Health Sciences Center–Shreveport, Shreveport Louisiana Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago Illinois College of Nursing and Health, Loyola University New Orleans, New Orleans Louisiana Teche Action Clinic, Franklin Louisiana AN - 138831647. Language: English. Entry Date: 20200513. Revision Date: 20210311. Publication Type: journal article AU - Arnold, Connie L. AU - Rademaker, Alfred W. AU - Morris, James D. AU - Ferguson, Laurie Anne AU - Wiltz, Gary AU - Davis, Terry C. DB - CINAHL Complete DO - 10.1002/cncr.32398 DP - EBSCOhost IS - 20 KW - Early Detection of Cancer Colorectal Neoplasms -- Diagnosis Rural Population Health Screening -- Methods Human Male Feces Prospective Studies Louisiana Colorectal Neoplasms -- Blood Information Literacy Health Education -- Statistics and Numerical Data Middle Age Ambulatory Care Facilities Female Colorectal Neoplasms -- Epidemiology Telephone Aged Colorectal Neoplasms -- Pathology Occult Blood Validation Studies Comparative Studies Evaluation Research Multicenter Studies Personal Resource Questionnaire Questionnaires N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Attitudes to Treatment Questionnaire (ATQ); Personal Resource Questionnaire (PRQ). Grant Information: U54 GM104940/GM/NIGMS NIH HHS/United States. NLM UID: 0374236. PMID: NLM31355924. PY - 2019 SN - 0008-543X SP - 3615-3622 ST - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial T2 - Cancer (0008543X) TI - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=138831647&site=ehost-live&scope=site VL - 125 ID - 1962 ER - TY - JOUR AB - Background: Significant disparities exist in colorectal cancer (CRC) screening rates among those of low socioeconomic status, with fewer years of education, lacking health insurance, or living in rural areas. Methods: A randomized controlled trial was conducted to compare the effectiveness of 2 follow-up approaches to a health literacy intervention to improve CRC screening: automated telephone call or personal call. Patients aged 50 to 75 years residing in 4 rural community clinics in Louisiana were given a structured interview that assessed demographic, health literacy and CRC screening barriers, knowledge, and attitudes. All were given health literacy–informed CRC education, a patient-friendly CRC screening pamphlet, simplified fecal immunochemical test (FIT) instructions, and a FIT kit, and a “teach-back” method was used to confirm understanding. Patients were randomized to 1 of 2 telephone follow-up arms. If they did not mail their FIT kit within 4 weeks, they received a reminder call and were called again at 8 weeks if the test still was not received. Results: A total of 620 patients were enrolled. Approximately 55% were female, 66% were African American, and 40% had limited literacy. The overall FIT completion rate was 68%: 69.2% in the automated telephone call arm and 67% in the personal call arm. Greater than one-half of the patients (range, 58%-60%) returned the FIT kit without receiving a telephone call. There was no difference noted with regard to the effectiveness of the follow-up calls; each increased the return rate by 9%. Conclusions: Providing FIT kits and literacy-appropriate education at regularly scheduled clinic visits with a follow-up telephone call when needed was found to increase CRC screening among low-income, rural patients. The lower cost automated call was just as effective as the personal call. © 2019 American Cancer Society AD - Department of Medicine, Louisiana State University Health Sciences Center–Shreveport, Shreveport, LA, United States Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States College of Nursing and Health, Loyola University New Orleans, New Orleans, LA, United States Teche Action Clinic, Franklin, LA, United States AU - Arnold, C. L. AU - Rademaker, A. W. AU - Morris, J. D. AU - Ferguson, L. A. AU - Wiltz, G. AU - Davis, T. C. DB - Scopus DO - 10.1002/cncr.32398 IS - 20 KW - colorectal cancer screening disparities health literacy prevention randomized controlled trial rural community clinics M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2019 SP - 3615-3622 ST - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial T2 - Cancer TI - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070311051&doi=10.1002%2fcncr.32398&partnerID=40&md5=5ab0ab5c55fa93a7fc28ff549f9e5471 VL - 125 ID - 2218 ER - TY - JOUR AB - Background Significant disparities exist in colorectal cancer (CRC) screening rates among those of low socioeconomic status, with fewer years of education, lacking health insurance, or living in rural areas. Methods A randomized controlled trial was conducted to compare the effectiveness of 2 follow-up approaches to a health literacy intervention to improve CRC screening: automated telephone call or personal call. Patients aged 50 to 75 years residing in 4 rural community clinics in Louisiana were given a structured interview that assessed demographic, health literacy and CRC screening barriers, knowledge, and attitudes. All were given health literacy-informed CRC education, a patient-friendly CRC screening pamphlet, simplified fecal immunochemical test (FIT) instructions, and a FIT kit, and a "teach-back" method was used to confirm understanding. Patients were randomized to 1 of 2 telephone follow-up arms. If they did not mail their FIT kit within 4 weeks, they received a reminder call and were called again at 8 weeks if the test still was not received. Results A total of 620 patients were enrolled. Approximately 55% were female, 66% were African American, and 40% had limited literacy. The overall FIT completion rate was 68%: 69.2% in the automated telephone call arm and 67% in the personal call arm. Greater than one-half of the patients (range, 58%-60%) returned the FIT kit without receiving a telephone call. There was no difference noted with regard to the effectiveness of the follow-up calls; each increased the return rate by 9%. Conclusions Providing FIT kits and literacy-appropriate education at regularly scheduled clinic visits with a follow-up telephone call when needed was found to increase CRC screening among low-income, rural patients. The lower cost automated call was just as effective as the personal call. AN - WOS:000479479300001 AU - Arnold, C. L. AU - Rademaker, A. W. AU - Morris, J. D. AU - Ferguson, L. A. AU - Wiltz, G. AU - Davis, T. C. DA - Oct DO - 10.1002/cncr.32398 IS - 20 N1 - 31355924 PY - 2019 SN - 0008-543X SP - 3615-3622 ST - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial T2 - Cancer TI - Follow-up approaches to a health literacy intervention to increase colorectal cancer screening in rural community clinics: A randomized controlled trial VL - 125 ID - 2817 ER - TY - JOUR AD - C. Hoyo AU - Hoyo, C. AU - Reid, M. L. AU - Godley, P. A. AU - Parrish, T. AU - Smith, L. AU - Gammon, M. DB - Medline IS - 4 KW - adult aged article cohort analysis ethnology human male middle aged Black person patient attitude patient education patient selection prostate tumor questionnaire treatment refusal trust United States LA - English M3 - Article N1 - L137588570 2004-03-19 PY - 2003 SN - 1049-510X SP - 547-548 ST - For the patient. Improving participation of African-American men in research studies T2 - Ethnicity & disease TI - For the patient. Improving participation of African-American men in research studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L137588570&from=export VL - 13 ID - 1287 ER - TY - JOUR AB - The author discusses a successful, nurse-coordinated collaborative community-based breast health program that targeted older African American women from the state of South Carolina. Over 16 community organizations and health care partners supported the four-phase program that was funded by the South Carolina Breast and Cervical Risk Reduction Program and the South Carolina Chapter of the American Cancer Society. AD - L.M. Gibson, Clemson University School of Nursing, College of Health, Education, and Human Development, USA. AU - Gibson, L. M. DB - Medline IS - 4 KW - African American aged article attitude to health breast tumor education ethnology female feminism health education health promotion health service human mass screening middle aged nursing organization and management patient selection poverty program development psychological aspect public relations United States LA - English M3 - Article N1 - L33561673 2001-12-11 PY - 2000 SN - 1046-7041 SP - 94-96 ST - A four-phase program to recruit African American women into breast cancer promotion programs T2 - The ABNF journal : official journal of the Association of Black Nursing Faculty in Higher Education, Inc TI - A four-phase program to recruit African American women into breast cancer promotion programs UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33561673&from=export VL - 11 ID - 1322 ER - TY - JOUR AB - The authors prospectively examined the relation of fruit and vegetable intake to breast cancer risk among 51,928 women aged 21-69 years at enrollment in 1995 in the Black Women's Health Study. Dietary intake was assessed by using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate incidence rate ratios and 95% confidence intervals, adjusted for breast cancer risk factors. During 12 years of follow-up, there were 1,268 incident cases of breast cancer. Total fruit, total vegetable, and total fruit and vegetable intakes were not significantly associated with overall risk of breast cancer. However, total vegetable consumption was associated with a decreased risk of estrogen receptor-negative/progesterone receptor-negative breast cancer (incidence rate ratio = 0.57, 95% confidence interval: 0.38, 0.85, for ≥2 servings/day relative to <4/week; Ptrend = 0.02). In addition, there was some evidence of inverse associations with breast cancer risk overall for cruciferous vegetable intake (Ptrend = 0.06) and for carrot intake (Ptrend = 0.02). Study findings suggest that frequent consumption of vegetables is inversely associated with risk of estrogen receptor-negative/progesterone receptor-negative breast cancer, and that specific vegetables may be associated with a decreased risk of breast cancer overall. © 2010 The Author. AD - Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, United States Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States Department of Nutrition, Harvard School of Public Health, Boston, MA, United States Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States AU - Boggs, D. A. AU - Palmer, J. R. AU - Wise, L. A. AU - Spiegelman, D. AU - Stampfer, M. J. AU - Adams-Campbell, L. L. AU - Rosenberg, L. DB - Scopus DO - 10.1093/aje/kwq293 IS - 11 KW - African Americans Brassicaceae breast neoplasms carotenoids fruit risk vegetables women M3 - Article N1 - Cited By :79 Export Date: 22 March 2021 PY - 2010 SP - 1268-1279 ST - Fruit and vegetable intake in relation to risk of breast cancer in the black women's health study T2 - American Journal of Epidemiology TI - Fruit and vegetable intake in relation to risk of breast cancer in the black women's health study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649674127&doi=10.1093%2faje%2fkwq293&partnerID=40&md5=d3c9df6a47878852840bb0bf320345b8 VL - 172 ID - 2490 ER - TY - JOUR AB - Background: Previous research has shown colorectal cancer (CRC) screening disparities by gender. Little research has focused primarily on gender differences among older Black individuals, and reasons for existing gender differences remain poorly understood. Methods: Weused baseline data from the Cancer Prevention and Treatment Demonstration Screening Trial. Participants were recruited from November 2006 to March 2010. In-person interviews were used to assess selfreported CRC screening behavior. Up-to-date CRC screening was defined as self-reported colonoscopy or sigmoidoscopy in the past 10 years or fecal occult blood testing in the past year. We used multivariable logistic regression to examine the association between gender and self-reported screening, adjusting for covariates. The final model was stratified by gender to examine factors differentially associated with screening outcomes for males and females. Results: The final sample consisted of 1,552 female and 586 male Black Medicare beneficiaries in Baltimore, Maryland. Males were significantly less likely than females to report being up-to-date with screening (77.5% vs. 81.6%, P = 0.030), and this difference was significant in the fully adjusted model (OR: 0.72; 95% confidence interval, 0.52-0.99). The association between having a usual source of care and receipt of cancer screening was stronger among males compared with females. Conclusions: Although observed differences in CRC screening were small, several factors suggest that gender-specific approaches may be used to promote screening adherence among Black Medicare beneficiaries. Impact: Given disproportionate CRC mortality between White and Black Medicare beneficiaries, genderspecific interventions aimed at increasing CRC screening may be warranted among older Black patients. © 2013 American Association for Cancer Research. AD - K.A. Martinez, North Campus Research Complex, 2800 Plymouth Road, Ann Arbor, MI 48109, United States AU - Martinez, K. A. AU - Pollack, C. E. AU - Phelan, D. F. AU - Markakis, D. AU - Bone, L. AU - Shapiro, G. AU - Wenzel, J. AU - Howerton, M. AU - Johnson, L. AU - Garza, M. A. AU - Ford, J. G. DB - Embase Medline DO - 10.1158/1055-9965.EPI-12-1215 IS - 6 KW - NCT00379743 aged article cancer screening colorectal cancer female human interview major clinical study male medicare occult blood test outcome assessment priority journal self report sex difference sigmoidoscopy smoking United States LA - English M3 - Article N1 - L369116607 2013-06-24 2013-06-25 PY - 2013 SN - 1055-9965 SP - 1037-1042 ST - Gender differences in correlates of colorectal cancer screening among black medicare beneficiaries in Baltimore T2 - Cancer Epidemiology Biomarkers and Prevention TI - Gender differences in correlates of colorectal cancer screening among black medicare beneficiaries in Baltimore UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369116607&from=export http://dx.doi.org/10.1158/1055-9965.EPI-12-1215 http://cebp.aacrjournals.org/content/22/6/1037.full.pdf+html VL - 22 ID - 1080 ER - TY - JOUR AB - Background: Previous research has shown colorectal cancer (CRC) screening disparities by gender. Little research has focused primarily on gender differences among older Black individuals, and reasons for existing gender differences remain poorly understood. Methods: Weused baseline data from the Cancer Prevention and Treatment Demonstration Screening Trial. Participants were recruited from November 2006 to March 2010. In-person interviews were used to assess selfreported CRC screening behavior. Up-to-date CRC screening was defined as self-reported colonoscopy or sigmoidoscopy in the past 10 years or fecal occult blood testing in the past year. We used multivariable logistic regression to examine the association between gender and self-reported screening, adjusting for covariates. The final model was stratified by gender to examine factors differentially associated with screening outcomes for males and females. Results: The final sample consisted of 1,552 female and 586 male Black Medicare beneficiaries in Baltimore, Maryland. Males were significantly less likely than females to report being up-to-date with screening (77.5% vs. 81.6%, P = 0.030), and this difference was significant in the fully adjusted model (OR: 0.72; 95% confidence interval, 0.52-0.99). The association between having a usual source of care and receipt of cancer screening was stronger among males compared with females. Conclusions: Although observed differences in CRC screening were small, several factors suggest that gender-specific approaches may be used to promote screening adherence among Black Medicare beneficiaries. Impact: Given disproportionate CRC mortality between White and Black Medicare beneficiaries, genderspecific interventions aimed at increasing CRC screening may be warranted among older Black patients. © 2013 American Association for Cancer Research. AD - Department of Health, Policy and Management, United States Department of Epidemiology, United States Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, United States Department of General Internal Medicine, United States Department of Oncology, Johns Hopkins School of Medicine, United States Department of Acute and Chronic Care, Johns Hopkins School of Nursing, United States Park West Health Systems, Baltimore, United States Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, United States Brooklyn Hospital Center, Brooklyn, New York, NY, United States North Campus Research Complex, 2800 Plymouth Road, Ann Arbor, MI 48109, United States AU - Martinez, K. A. AU - Pollack, C. E. AU - Phelan, D. F. AU - Markakis, D. AU - Bone, L. AU - Shapiro, G. AU - Wenzel, J. AU - Howerton, M. AU - Johnson, L. AU - Garza, M. A. AU - Ford, J. G. DB - Scopus DO - 10.1158/1055-9965.EPI-12-1215 IS - 6 M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2013 SP - 1037-1042 ST - Gender differences in correlates of colorectal cancer screening among black medicare beneficiaries in Baltimore T2 - Cancer Epidemiology Biomarkers and Prevention TI - Gender differences in correlates of colorectal cancer screening among black medicare beneficiaries in Baltimore UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879026430&doi=10.1158%2f1055-9965.EPI-12-1215&partnerID=40&md5=8a144513aea7caf159df74d047469006 VL - 22 ID - 2433 ER - TY - JOUR AB - Background: Previous research has shown colorectal cancer (CRC) screening disparities by gender. Little research has focused primarily on gender differences among older Black individuals, and reasons for existing gender differences remain poorly understood. Methods: We used baseline data from the Cancer Prevention and Treatment Demonstration Screening Trial. Participants were recruited from November 2006 to March 2010. In-person interviews were used to assess self reported CRC screening behavior. Up-to-date CRC screening was defined as self-reported colonoscopy or sigmoidoscopy in the past 10 years or fecal occult blood testing in the past year. We used multivariable logistic regression to examine the association between gender and self-reported screening, adjusting for covariates. The final model was stratified by gender to examine factors differentially associated with screening outcomes for males and females. Results: The final sample consisted of 1,552 female and 586 male Black Medicare beneficiaries in Baltimore, Maryland. Males were significantly less likely than females to report being up-to-date with screening (77.5% vs. 81.6%, P = 0.030), and this difference was significant in the fully adjusted model (OR: 0.72; 95% confidence interval, 0.52-0.99). The association between having a usual source of care and receipt of cancer screening was stronger among males compared with females. Conclusions: Although observed differences in CRC screening were small, several factors suggest that gender-specific approaches may be used to promote screening adherence among Black Medicare beneficiaries. Impact: Given disproportionate CRC mortality between White and Black Medicare beneficiaries, gender-specific interventions aimed at increasing CRC screening may be warranted among older Black patients. (C) 2013 AACR. AN - WOS:000320643200005 AU - Martinez, K. A. AU - Pollack, C. E. AU - Phelan, D. F. AU - Markakis, D. AU - Bone, L. AU - Shapiro, G. AU - Wenzel, J. AU - Howerton, M. AU - Johnson, L. AU - Garza, M. A. AU - Ford, J. G. DA - Jun DO - 10.1158/1055-9965.EPI-12-1215 IS - 6 N1 - 23629519 PY - 2013 SN - 1055-9965 SP - 1037-1042 ST - Gender Differences in Correlates of Colorectal Cancer Screening Among Black Medicare Beneficiaries in Baltimore T2 - Cancer Epidemiology Biomarkers & Prevention TI - Gender Differences in Correlates of Colorectal Cancer Screening Among Black Medicare Beneficiaries in Baltimore VL - 22 ID - 3043 ER - TY - JOUR AB - Colorectal cancer rates in Latin American countries are less than half of those observed in the United States. Latin Americans are the resultant of generations of an admixture of Native American, European, and African individuals. The potential role of genetic admixture in colorectal carcinogenesis has not been examined. We evaluate the association of genetic ancestry with colorectal neoplasms in 190 adenocarcinomas, 113 sporadic adenomas and 243 age-and sex-matched controls enrolled in a multicentric case-control study in Colombia. Individual ancestral genetic fractions were estimated using the STRUCTURE software, based on allele frequencies and assuming three distinct population origins. We used the Illumina Cancer Panel to genotype 1,421 sparse single-nucleotide polymorphisms (SNPs), and Northern and Western European ancestry, LWJ and Han Chinese in Beijing, China populations from the HapMap project as references. A total of 678 autosomal SNPs overlapped with the HapMap data set SNPs and were used for ancestry estimations. African mean ancestry fraction was higher in adenomas (0.13, 95% confidence interval (95% CI)=0.11-0.15) and cancer cases (0.14, 95% CI=0.12-0.16) compared with controls (0.11, 95% CI=0.10-0.12). Conditional logistic regression analysis, controlling for known risk factors, showed a positive association of African ancestry per 10% increase with both colorectal adenoma (odds ratio (OR)=1.12, 95% CI=0.97-1.30) and adenocarcinoma (OR=1.19, 95% CI=1.05-1.35). In conclusion, increased African ancestry (or variants linked to it) contributes to the increased susceptibility of colorectal cancer in admixed Latin American population. © 2014 Macmillan Publishers Limited All rights reserved. AD - Grupo de Investigacion Epidemiologica, Instituto Nacional de Cancerologia de Colombia, Avenue 1 No. 9-85, Bogota, Colombia Roslin Institute, University of Edinburgh, Royal (Dick) School of Veterinary Studies, Midlothian, EH259RG, United Kingdom Departamento de Quimica, Universidad Nacional de Colombia, Cundinamarca, Colombia Facultad de Medicina, Universidad Industrial de Santander, Bucaramanga, Colombia Facultad de Medicina, Universidad Libre, Barranquilla, Colombia Fundacion Oftalmologica de Santander, Bucaramanga, Colombia Department of Pediatrics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, United States MRC-Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, United Kingdom AU - Hernandez-Suarez, G. AU - Sanabria, M. C. AU - Serrano, M. AU - Herran, O. F. AU - Perez, J. AU - Plata, J. L. AU - Zabaleta, J. AU - Tenesa, A. DB - Scopus DO - 10.1038/ejhg.2013.310 IS - 10 KW - Colombia colorectal neoplasm genetic Latin America pedigree polymorphism M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2014 SP - 1208-1216 ST - Genetic ancestry is associated with colorectal adenomas and adenocarcinomas in Latino populations T2 - European Journal of Human Genetics TI - Genetic ancestry is associated with colorectal adenomas and adenocarcinomas in Latino populations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926971471&doi=10.1038%2fejhg.2013.310&partnerID=40&md5=c3502bb2fa93e7b5382e87e11b7d6fe0 VL - 22 ID - 2386 ER - TY - JOUR AB - We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two-arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n = 637) or the targeted (n = 595) intervention. Approximately 40% of participants were Black. Based on intention-to-treat analyses, YBCS in the tailored arm reported higher self-efficacy for genetic services (p = 0.0205) at 8-months follow-up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p ≤ 0.001; p < 0.001) and for Black and White/Other YBCS (p < 0.001; p < 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self-efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low-resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC). AD - M.C. Katapodi, Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland M.C. Katapodi, School of Nursing, University of Michigan, Ann Arbor, MI, United States AU - Katapodi, M. C. AU - Ming, C. AU - Northouse, L. L. AU - Duffy, S. A. AU - Duquette, D. AU - Mendelsohn-Victor, K. E. AU - Milliron, K. J. AU - Merajver, S. D. AU - Dinov, I. D. AU - Janz, N. K. DB - Embase DO - 10.3390/cancers12092526 IS - 9 KW - adult age distribution article Black person blood relative breast cancer breast examination cancer epidemiology cancer registry cancer risk cancer survivor Caucasian controlled study female follow up genetic screening human intention to treat analysis major clinical study mammography Michigan patient satisfaction race difference randomized controlled trial sampling self concept LA - English M3 - Article N1 - L2005020753 2020-10-07 2020-11-11 PY - 2020 SN - 2072-6694 SP - 1-20 ST - Genetic testing and surveillance of young breast cancer survivors and blood relatives: A cluster randomized trial T2 - Cancers TI - Genetic testing and surveillance of young breast cancer survivors and blood relatives: A cluster randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005020753&from=export http://dx.doi.org/10.3390/cancers12092526 VL - 12 ID - 790 ER - TY - JOUR AB - We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two‐arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n = 637) or the targeted (n = 595) intervention. Approximately 40% of participants were Black. Based on intention‐to‐treat analyses, YBCS in the tailored arm reported higher self‐efficacy for genetic services (p = 0.0205) at 8‐months follow‐up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p ≤ 0.001; p < 0.001) and for Black and White/Other YBCS (p < 0.001; p < 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self‐efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low‐resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC). AN - CN-02203086 AU - Katapodi, M. C. AU - Ming, C. AU - Northouse, L. L. AU - Duffy, S. A. AU - Duquette, D. AU - Mendelsohn-Victor, K. E. AU - Milliron, K. J. AU - Merajver, S. D. AU - Dinov, I. D. AU - Janz, N. K. DO - 10.3390/cancers12092526 IS - 9 KW - *blood relative *breast cancer /diagnosis *cancer epidemiology *cancer survivor *genetic screening Adult Age distribution Article Black person Breast examination Cancer registry Cancer risk Caucasian Controlled study Female Follow up Human Intention to treat analysis Major clinical study Mammography Michigan Patient satisfaction Race difference Randomized controlled trial Sampling Self concept M3 - Journal: Article PY - 2020 SP - 1‐20 ST - Genetic testing and surveillance of young breast cancer survivors and blood relatives: a cluster randomized trial T2 - Cancers TI - Genetic testing and surveillance of young breast cancer survivors and blood relatives: a cluster randomized trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02203086/full VL - 12 ID - 1448 ER - TY - JOUR AB - Simple Summary: Identifying breast cancer patients with pathogenic mutations that run in their families may improve the follow-up care they receive and breast cancer screening of their close relatives. In this study we identified breast cancer patients with high chances of having a pathogenic mutation and their close female relatives. We developed and tested two different kinds of letters and booklets that presented either personalized or generic information about screening and breast cancer that runs in families, and we encouraged participants to seek genetic evaluation. We found that both types of letters worked equally well for breast cancer patients and for relatives, regardless of their racial background. The personalized letters had slightly better outcomes. Some breast cancer patients and their relatives used genetic services and improved their screening practices. Black patients and their relatives were more satisfied with the booklets than other participants. We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two-arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n = 637) or the targeted (n = 595) intervention. Approximately 40% of participants were Black. Based on intention-to-treat analyses, YBCS in the tailored arm reported higher self-efficacy for genetic services (p = 0.0205) at 8-months follow-up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p ≤ 0.001; p < 0.001) and for Black and White/Other YBCS (p < 0.001; p < 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self-efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low-resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC). AD - Department of Clinical Research, Faculty of Medicine, University of Basel, 4055 Basel, Switzerland School of Nursing, University of Michigan, Ann Arbor, MI 48109-5482, USA College of Nursing, Ohio State University, Columbus, OH 43210, USA Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-5618, USA School of Public Health, University of Michigan, Ann Arbor, MI 48109-5618, USA Statistics Online Computational Resource, School of Nursing, University of Michigan, Ann Arbor, MI 48109-2003, USA AN - 146538626. Language: English. Entry Date: 20201029. Revision Date: 20201029. Publication Type: Article AU - Katapodi, Maria C. AU - Ming, Chang AU - Northouse, Laurel L. AU - Duffy, Sonia A. AU - Duquette, Debra AU - Mendelsohn-Victor, Kari E. AU - Milliron, Kara J. AU - Merajver, Sofia D. AU - Dinov, Ivo D. AU - Janz, Nancy K. DB - CINAHL Complete DO - 10.3390/cancers12092526 DP - EBSCOhost IS - 9 KW - Genetic Screening Disease Surveillance Breast Neoplasms -- Familial and Genetic Cancer Survivors Extended Family Human Mammography Randomized Controlled Trials Random Sample Black Persons Cluster Analysis Sex Factors N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Continental Europe; Europe. NLM UID: 101526829. PY - 2020 SN - 2072-6694 SP - 2526 ST - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial T2 - Cancers TI - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146538626&site=ehost-live&scope=site VL - 12 ID - 1963 ER - TY - JOUR AB - We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two-arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n = 637) or the targeted (n = 595) intervention. Approximately 40% of participants were Black. Based on intention-to-treat analyses, YBCS in the tailored arm reported higher self-efficacy for genetic services (p = 0.0205) at 8-months follow-up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p ≤ 0.001; p < 0.001) and for Black and White/Other YBCS (p < 0.001; p < 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self-efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low-resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC). © 2020 by the authors. Licensee MDPI, Basel, Switzerland. AD - Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, 4055, Switzerland School of Nursing, University of Michigan, Ann Arbor, MI 48109-5482, United States College of Nursing, Ohio State University, Columbus, OH 43210, United States Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-5618, United States School of Public Health, University of Michigan, Ann Arbor, MI 48109-5618, United States Statistics Online Computational Resource, School of Nursing, University of Michigan, Ann Arbor, MI 48109-2003, United States AU - Katapodi, M. C. AU - Ming, C. AU - Northouse, L. L. AU - Duffy, S. A. AU - Duquette, D. AU - Mendelsohn-Victor, K. E. AU - Milliron, K. J. AU - Merajver, S. D. AU - Dinov, I. D. AU - Janz, N. K. C7 - 2526 DB - Scopus DO - 10.3390/cancers12092526 IS - 9 KW - Black participants Cancer survivorship Cascade genetic testing in families Family recruitment HBOC Statewide random sampling Tailored intervention Targeted intervention M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 1-20 ST - Genetic testing and surveillance of young breast cancer survivors and blood relatives: A cluster randomized trial T2 - Cancers TI - Genetic testing and surveillance of young breast cancer survivors and blood relatives: A cluster randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090248687&doi=10.3390%2fcancers12092526&partnerID=40&md5=c43d32c1b1f763eadd8b247c7864eb33 VL - 12 ID - 2183 ER - TY - JOUR AB - Simple Summary Identifying breast cancer patients with pathogenic mutations that run in their families may improve the follow-up care they receive and breast cancer screening of their close relatives. In this study we identified breast cancer patients with high chances of having a pathogenic mutation and their close female relatives. We developed and tested two different kinds of letters and booklets that presented either personalized or generic information about screening and breast cancer that runs in families, and we encouraged participants to seek genetic evaluation. We found that both types of letters worked equally well for breast cancer patients and for relatives, regardless of their racial background. The personalized letters had slightly better outcomes. Some breast cancer patients and their relatives used genetic services and improved their screening practices. Black patients and their relatives were more satisfied with the booklets than other participants. We compared a tailored and a targeted intervention designed to increase genetic testing, clinical breast exam (CBE), and mammography in young breast cancer survivors (YBCS) (diagnosed <45 years old) and their blood relatives. A two-arm cluster randomized trial recruited a random sample of YBCS from the Michigan cancer registry and up to two of their blood relatives. Participants were stratified according to race and randomly assigned as family units to the tailored (n= 637) or the targeted (n= 595) intervention. Approximately 40% of participants were Black. Based on intention-to-treat analyses, YBCS in the tailored arm reported higher self-efficacy for genetic services (p= 0.0205) at 8-months follow-up. Genetic testing increased approximately 5% for YBCS in the tailored and the targeted arm (p <= 0.001;p< 0.001) and for Black and White/Other YBCS (p< 0.001;p< 0.001). CBEs and mammograms increased significantly in both arms, 5% for YBCS and 10% for relatives and were similar for Blacks and White/Others. YBCS and relatives needing less support from providers reported significantly higher self-efficacy and intention for genetic testing and surveillance. Black participants reported significantly higher satisfaction and acceptability. Effects of these two low-resource interventions were comparable to previous studies. Materials are suitable for Black women at risk for hereditary breast/ovarian cancer (HBOC). AN - WOS:000579920400001 AU - Katapodi, M. C. AU - Ming, C. AU - Northouse, L. L. AU - Duffy, S. A. AU - Duquette, D. AU - Mendelsohn-Victor, K. E. AU - Milliron, K. J. AU - Merajver, S. D. AU - Dinov, I. D. AU - Janz, N. K. DA - Sep DO - 10.3390/cancers12092526 IS - 9 N1 - 2526 32899538 PY - 2020 ST - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial T2 - Cancers TI - Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial VL - 12 ID - 2767 ER - TY - JOUR AB - Background: Breast cancer is the most common cancer in women worldwide. Around 50% of breast cancer familial risk has been so far explained by known susceptibility alleles with variable levels of risk and prevalence. The vast majority of these breast cancer associated variations reported to date are from populations of European ancestry. In spite of its heterogeneity and genetic wealth, North-African populations have not been studied by the HapMap and the 1000Genomes projects. Thus, very little is known about the genetic architecture of these populations.Methods: This study aimed to investigate a subset of common breast cancer loci in the general Tunisian population and to compare their genetic composition to those of other ethnic groups. We undertook a genome-wide haplotype study by genotyping 135 Tunisian subjects using the Affymetrix 6.0-Array. We compared Tunisian allele frequencies and linkage disequilibrium patterns to those of HapMap populations and we performed a comprehensive assessment of the functional effects of several selected variants.Results: Haplotype analyses showed that at risk haplotypes on 2p24, 4q21, 6q25, 9q31, 10q26, 11p15, 11q13 and 14q32 loci are considerably frequent in the Tunisian population (> 20%). Allele frequency comparison showed that the frequency of rs13329835 is significantly different between Tunisian and all other HapMap populations. LD-blocks and Principle Component Analysis revealed that the genetic characteristics of breast cancer variants in the Tunisian, and so probably the North-African populations, are more similar to those of Europeans than Africans. Using eQTl analysis, we characterized rs9911630 as the most strongly expression-associated SNP that seems to affect the expression levels of BRCA1 and two long non coding RNAs (NBR2 and LINC008854). Additional in-silico analysis also suggested a potential functional significance of this variant.Conclusions: We illustrated the utility of combining haplotype analysis in diverse ethnic groups with functional analysis to explore breast cancer genetic architecture in Tunisia. Results presented in this study provide the first report on a large number of common breast cancer genetic polymorphisms in the Tunisian population which may establish a baseline database to guide future association studies in North Africa. AD - Laboratory of biomedical genomics and oncogenetics, Institut Pasteur de Tunis, Université Tunis El Manar, 13, Place Pasteur BP 74, 1002, Tunis, Belvédère, Tunisie Department of Genetic Medicine, Weill Cornell Medical College-Qatar, Doha, Qatar Laboratory of Genetics, Immunology and Human Pathology, Department of Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia Department of Human Genetics, Charles Nicolle Hospital, Tunis, Tunisia Medical Oncology Department, Abderrahmen Mami Hospital, Ariana, Tunisia Department of Biology, Faculty of Science of Bizerte, Université Tunis Carthage, Tunis, Tunisia AN - 133780105. Language: English. Entry Date: In Process. Revision Date: 20190424. Publication Type: journal article AU - Hamdi, Yosr AU - Ben Rekaya, Mariem AU - Jingxuan, Shan AU - Nagara, Majdi AU - Messaoud, Olfa AU - Benammar Elgaaied, Amel AU - Mrad, Ridha AU - Chouchane, Lotfi AU - Boubaker, Mohamed Samir AU - Abdelhak, Sonia AU - Boussen, Hamouda AU - Romdhane, Lilia DB - CINAHL Complete DO - 10.1186/s12885-018-5133-8 DP - EBSCOhost IS - 1 KW - Genome Black Persons Breast Neoplasms Sequence Analysis Disease Susceptibility Haplotypes Tunisia Male Research Subjects Adult Human Middle Age Genetics Computer Simulation Female Polymorphism, Genetic Genes Validation Studies Comparative Studies Evaluation Research Multicenter Studies Clinical Assessment Tools Questionnaires N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Instrumentation: Wide Range Achievement Test (WRAT); General Health Questionnaire (GHQ); Functional Living Index: Cancer (FLIC) (Schipper et al). Grant Information: NPRP 08-083-3-031//Qatar National Research Fund/. NLM UID: 100967800. PMID: NLM30594178. PY - 2018 SN - 1471-2407 SP - 1-14 ST - A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci T2 - BMC Cancer TI - A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=133780105&site=ehost-live&scope=site VL - 18 ID - 1818 ER - TY - JOUR AB - Objective Taxane containing chemotherapy extends survival for breast cancer patients. However, taxane-induced peripheral neuropathy (TIPN) cannot be predicted, prevented or effectively treated. Using genome-wide analyses, we sought to identify common risk variants for TIPN. Patients and methods Women with high-risk breast cancer enrolled in SWOG 0221 were genotyped using the Illumina 1M chip. Genome-wide analyses were performed in relation to ≥grade 3 Common Terminology Criteria for Adverse Events (CTCAE) neuropathy in European and African Americans. Data were meta-analyzed with GW associations of CTCAE ≥grade 3 versus = 65 years vs urban, 27.0% aged >= 65 years; difference, 3.7%; 95% CI, 2.5%-4.9%; P < .001), were less likely to be black (rural, 5.4% vs urban, 12.1%; difference, 6.7%; 95% CI, 6.1%-7.3%; P < .001), were similar with respect to sex (rural, 40.4% female vs urban, 39.7% female; difference, 0.6%; 95% CI, -1.4% to 2.6%; P = .53), and were well represented within major US geographic regions (West, Midwest, South, and Northeast). Clinical prognostic factors were similar. In multivariable regression, rural patients with adjuvant-stage estrogen receptor-negative and progesterone receptor-negative breast cancer had worse overall survival (hazard ratio, 1.27; 95% CI, 1.06-151; P = .008) and cancer-specific survival (hazard ratio, 1.26; 95% CI, 1.04-1.52; P = .02). No other statistically significant differences for overall, progression-free, or cancer-specific survival were found. Results were consistent regardless of the definition of rurality. CONCLUSIONS AND RELEVANCE Rural and urban patients with uniform access to cancer care through participation in a SWOG clinical trial had similar outcomes. This finding suggests that improving access to uniform treatment strategies for patients with cancer may help resolve the disparity in cancer outcomes between rural and urban patients. AN - WOS:000452643200039 AU - Unger, J. M. AU - Moseley, A. AU - Symington, B. AU - Chavez-MacGregor, M. AU - Ramsey, S. D. AU - Hershman, D. L. DA - Aug DO - 10.1001/jamanetworkopen.2018.1235 IS - 4 N1 - e181235 30646114 PY - 2018 SN - 2574-3805 ST - Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials T2 - Jama Network Open TI - Geographic Distribution and Survival Outcomes for Rural Patients With Cancer Treated in Clinical Trials VL - 1 ID - 2849 ER - TY - JOUR AB - PURPOSE: There is increased interest in developing and disseminating health behavior interventions for cancer survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. METHODS:: Letters were mailed within specific zip codes near community-based intervention sites in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. RESULTS:: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty-five percent (n = 103) of randomized women self-identified as having a minority racial background and 31.9% (n = 94) self-identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. CONCLUSION:: These results support the use of population-based cancer registries to recruit survivors into community-based interventions and clinical trials. AD - K. H. Schmitz, Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA 19104-6021 AU - Rogerino, A. AU - Grant, L. L. AU - Wilcox, H. AU - Schmitz, K. H. DB - Embase Medline DO - 10.1249/MSS.0b013e31819af871 IS - 7 KW - adult African American age distribution article breast cancer cancer center cancer registry cancer survival cancer survivor clinical trial controlled clinical trial female health behavior human kinesiotherapy lymphedema major clinical study mass medium race race difference randomized controlled trial support group LA - English M3 - Article N1 - L354870143 2009-08-06 PY - 2009 SN - 0195-9131 1530-0315 SP - 1413-1420 ST - Geographic recruitment of breast cancer survivors into community-based exercise interventions T2 - Medicine and Science in Sports and Exercise TI - Geographic recruitment of breast cancer survivors into community-based exercise interventions UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354870143&from=export http://dx.doi.org/10.1249/MSS.0b013e31819af871 VL - 41 ID - 1186 ER - TY - JOUR AB - PURPOSE: There is increased interest in developing and disseminating health behavior interventions for cancer survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. METHODS:: Letters were mailed within specific zip codes near community‐based intervention sites in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. RESULTS:: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty‐five percent (n = 103) of randomized women self‐identified as having a minority racial background and 31.9% (n = 94) self‐identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. CONCLUSION:: These results support the use of population‐based cancer registries to recruit survivors into community‐based interventions and clinical trials. AN - CN-01446552 AU - Rogerino, A. AU - Grant, L. L. AU - Wilcox, H. AU - Schmitz, K. H. DO - 10.1249/MSS.0b013e31819af871 IS - 7 KW - *breast cancer /therapy *kinesiotherapy Adult African American Age distribution Article Cancer center Cancer registry Cancer survival Cancer survivor Clinical trial Controlled clinical trial Female Health behavior Human Lymphedema Major clinical study Mass medium Race Race difference Randomized controlled trial Support group M3 - Journal: Article PY - 2009 SP - 1413‐1420 ST - Geographic recruitment of breast cancer survivors into community-based exercise interventions T2 - Medicine and science in sports and exercise TI - Geographic recruitment of breast cancer survivors into community-based exercise interventions UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01446552/full VL - 41 ID - 1547 ER - TY - JOUR AB - PURPOSE:: There is increased interest in developing and disseminating health behavior interventions for cancer survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. METHODS:: Letters were mailed within specific zip codes near community-based intervention sites in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. RESULTS:: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty-five percent (n = 103) of randomized women self-identified as having a minority racial background and 31.9% (n = 94) self-identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. CONCLUSION:: These results support the use of population-based cancer registries to recruit survivors into community-based interventions and clinical trials. AD - Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, PA AN - 105364237. Language: English. Entry Date: 20090814. Revision Date: 20200708. Publication Type: Journal Article AU - Rogerino, A. AU - Grant, L. L. AU - Wilcox, H., III AU - Schmitz, K. H. DB - CINAHL Complete DO - 10.1249/MSS.0b013e31819af871 DP - EBSCOhost IS - 7 KW - Breast Neoplasms -- Complications Cancer Survivors Community Programs Exercise Neoplasm Recurrence, Local -- Prevention and Control Female Funding Source Health Promotion Mail Pamphlets Patient Selection Registries, Disease Human N1 - research; tables/charts. Journal Subset: Allied Health; Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: National Cancer Institute and by the Public Health Services Research Grant from the NIH. NLM UID: 8005433. PMID: NLM19516160. PY - 2009 SN - 0195-9131 SP - 1413-1420 ST - Geographic recruitment of breast cancer survivors into community-based exercise interventions T2 - Medicine & Science in Sports & Exercise TI - Geographic recruitment of breast cancer survivors into community-based exercise interventions UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105364237&site=ehost-live&scope=site VL - 41 ID - 1964 ER - TY - JOUR AB - PURPOSE: There is increased interest in developing and disseminating health behavior interventions for cancer survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. METHODS:: Letters were mailed within specific zip codes near community-based intervention sites in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. RESULTS:: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty-five percent (n = 103) of randomized women self-identified as having a minority racial background and 31.9% (n = 94) self-identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. CONCLUSION:: These results support the use of population-based cancer registries to recruit survivors into community-based interventions and clinical trials. AD - Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States New Jersey Cancer Registry, State of New Jersey Department of Health and Senior Services, Trenton, NJ, United States Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, 423 Guardian Drive, Philadelphia, PA 19104-6021, United States AU - Rogerino, A. AU - Grant, L. L. AU - Wilcox, H. AU - Schmitz, K. H. DB - Scopus DO - 10.1249/MSS.0b013e31819af871 IS - 7 M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2009 SP - 1413-1420 ST - Geographic recruitment of breast cancer survivors into community-based exercise interventions T2 - Medicine and Science in Sports and Exercise TI - Geographic recruitment of breast cancer survivors into community-based exercise interventions UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650079988&doi=10.1249%2fMSS.0b013e31819af871&partnerID=40&md5=13a9f82b61c4df266df6115d9416a2c0 VL - 41 ID - 2519 ER - TY - JOUR AB - ROGERINO, A., L. L. GRANT, H. WILCOX III, and K. H. SCHMITZ. Geographic Recruitment of Breast Cancer Survivors into Community-Based Exercise Interventions. Med. Sci. Sports Exerc., Vol. 41, No. 7, pp. 1413-1420, 2009. Purpose: There is increased interest in developing and disseminating health behavior interventions for cancer Survivors. Challenges in these efforts include participant burden in traveling to central intervention sites and sustainability. The purpose of this article is to report various methods used to recruit breast cancer survivors into an exercise intervention that attempts to address both of these challenges. Methods: Letters were mailed within specific zip codes near community-based intervention site,., in cooperation with state cancer registries. Additional recruitment methods included flyers at breast care clinics and support groups, mass media, and conferences. Results: Of the 3200 women who responded, 82% (n = 2625) identified having heard about the study through state or hospital registry and 8% (n = 243) through print and broadcast media. Thirty-five percent (n = 103) of randomized women self-identified as having a minority racial background and 31.9% (n = 94) self-identified as African American. Comparisons of participant age and racial distribution to state cancer registries indicate similar age distribution but greater racial diversity among participants. Conclusion: These results support the use of population-based cancer registries to recruit survivors into community-based interventions and clinical trials. AN - WOS:000267256800008 AU - Rogerino, A. AU - Grant, L. L. AU - Wilcox, H. AU - Schmitz, K. H. DA - Jul DO - 10.1249/MSS.0b013e31819af871 IS - 7 N1 - 19516160 PY - 2009 SN - 0195-9131 SP - 1413-1420 ST - Geographic Recruitment of Breast Cancer Survivors into Community-Based Exercise Interventions T2 - Medicine and Science in Sports and Exercise TI - Geographic Recruitment of Breast Cancer Survivors into Community-Based Exercise Interventions VL - 41 ID - 3144 ER - TY - JOUR AB - Despite higher rates of prostate cancer-related mortality and later stage of prostate cancer diagnosis, Black/African American men are significantly less likely than non-Hispanic White men to use early detection screening tools, like prostate-specific antigen (PSA) testing for prostate cancer. Lower screening rates may be due, in part, to controversy over the value of prostate cancer screenings as part of routine preventive care for men, but Black men represent a high-risk group for prostate cancer that may still benefit from PSA testing. Exploring the role of social factors that might be associated with PSA testing can increase knowledge of what might promote screening behaviors for prostate cancer and other health conditions for which Black men are at high risk. Using multilevel logistic regression, this study analyzed self-report lifetime use of PSA test for 829 Black men older than 45 years across 381 Philadelphia census tracts. This study included individual demographic and aggregated social capital data from the Public Health Management Corporation's 2004, 2006, and 2008 waves of the Community Health Database, and sociodemographic characteristics from the 2000 U.S. Census. Each unit increase in community participation was associated with a 3 to 3.5 times greater likelihood of having had a PSA test (odds ratio = 3.35). Findings suggest that structural forms of social capital may play a role in screening behaviors for Black men in Philadelphia. A better understanding of the mechanism underlying the link between social capital and screening behaviors can inform how researchers and interventionists develop tools to promote screening for those who need it. AU - Dean, L. T. AU - Subramanian, S. V. AU - Williams, D. R. AU - Armstrong, K. AU - Zubrinsky Charles, C. AU - Kawachi, I. DB - Medline DO - 10.1177/1557988314546491 IS - 5 KW - prostate specific antigen age Black person blood community participation epidemiology health insurance health survey human income insurance male mass screening middle aged multivariate analysis Pennsylvania prostate tumor social capital statistics and numerical data LA - English M3 - Article N1 - L615277995 2017-06-28 PY - 2015 SN - 1557-9891 SP - 385-396 ST - Getting Black Men to Undergo Prostate Cancer Screening: The Role of Social Capital T2 - American journal of men's health TI - Getting Black Men to Undergo Prostate Cancer Screening: The Role of Social Capital UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615277995&from=export http://dx.doi.org/10.1177/1557988314546491 VL - 9 ID - 997 ER - TY - JOUR AB - Access and recruitment barriers may have contributed to the underrepresentation of Black African/Caribbean men and their partners in current psychosocial research related to prostate cancer survivors. Whilst some studies have explored recruitment barriers and facilitators from participants’ perspectives, little is known from researchers' point of view. This paper aimed to address this gap in the literature. Recruitment strategies included the following: cancer support groups, researchers’ networks, media advertisement, religious organisations, National Health Service hospitals and snowball sampling. Thirty‐six eligible participants (men = 25, partners = 11) were recruited into the study. Recruitment barriers comprised of gate‐keeping and advertisement issues and the stigma associated with prostate cancer disclosure. Facilitators which aided recruitment included collaborating with National Health Service hospitals, snowball sampling, flexible data collection, building rapport with participants to gain their trust and researcher's attributes. Findings highlight that 'hard to reach' Black African/Caribbean populations may be more accessible if researchers adopt flexible but strategic and culturally sensitive recruitment approaches. Such approaches should consider perceptions of stigma associated with prostate cancer within these communities and the influence gatekeepers can have in controlling access to potential participants. Increased engagement with healthcare professionals and gatekeepers could facilitate better access to Black African/Caribbean populations so that their voices can be heard and their specific needs addressed within the healthcare agenda. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Bamidele, Olufikayo O., Institute of Nursing and Health Research, Ulster University, Jordanstown, United Kingdom AN - 2019-14866-026 AU - Bamidele, Olufikayo O. AU - McGarvey, Helen E. AU - Lagan, Briege M. AU - Chinegwundoh, Frank AU - Ali, Nasreen AU - McCaughan, Eilis DB - psyh DP - EBSCOhost IS - 2 KW - African caribbean Black African men partners prostate cancer recruitment Blacks Experimental Subjects Neoplasms Qualitative Methods Health Care Access Survivors N1 - Institute of Nursing and Health Research, Ulster University, Jordanstown, United Kingdom. Other Publishers: Blackwell Publishing. Release Date: 20190513. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Bamidele, Olufikayo O. Major Descriptor: Blacks; Experimental Subjects; Neoplasms; Qualitative Methods; Health Care Access. Minor Descriptor: Survivors. Classification: Cancer (3293); Health & Mental Health Services (3370). Population: Human (10); Male (30). Location: United Kingdom. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Interview; Qualitative Study. Page Count: 11. Issue Publication Date: Mar, 2019. Publication History: Accepted Date: Oct 31, 2018; Revised Date: Oct 26, 2018; First Submitted Date: Jan 11, 2018. Copyright Statement: John Wiley & Sons Ltd. 2018. Sponsor: Ulster University, United Kingdom. Other Details: Vice-Chancellor’s Research Scholarship to OB for her PhD. Recipients: Bamidele, Olufikayo O. PY - 2019 SN - 0961-5423 1365-2354 SP - 1-11 ST - 'Hard to reach, but not out of reach': Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research T2 - European Journal of Cancer Care TI - 'Hard to reach, but not out of reach': Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-14866-026&site=ehost-live&scope=site ORCID: 0000-0001-5536-394X ORCID: 0000-0001-9145-8778 ORCID: 0000-0003-2235-9463 Bamidele-O@ulster.ac.uk VL - 28 ID - 1675 ER - TY - JOUR AB - Access and recruitment barriers may have contributed to the underrepresentation of Black African/Caribbean men and their partners in current psychosocial research related to prostate cancer survivors. Whilst some studies have explored recruitment barriers and facilitators from participants' perspectives, little is known from researchers' point of view. This paper aimed to address this gap in the literature. Recruitment strategies included the following: cancer support groups, researchers' networks, media advertisement, religious organisations, National Health Service hospitals and snowball sampling. Thirty-six eligible participants (men = 25, partners = 11) were recruited into the study. Recruitment barriers comprised of gate-keeping and advertisement issues and the stigma associated with prostate cancer disclosure. Facilitators which aided recruitment included collaborating with National Health Service hospitals, snowball sampling, flexible data collection, building rapport with participants to gain their trust and researcher's attributes. Findings highlight that "hard to reach" Black African/Caribbean populations may be more accessible if researchers adopt flexible but strategic and culturally sensitive recruitment approaches. Such approaches should consider perceptions of stigma associated with prostate cancer within these communities and the influence gatekeepers can have in controlling access to potential participants. Increased engagement with healthcare professionals and gatekeepers could facilitate better access to Black African/Caribbean populations so that their voices can be heard and their specific needs addressed within the healthcare agenda. AU - Bamidele, O. O. AU - E McGarvey, H. AU - Lagan, B. M. AU - Chinegwundoh, F. AU - Ali, N. AU - McCaughan, E. DB - Medline DO - 10.1111/ecc.12977 IS - 2 KW - adolescent adult advertising African American aged Black person Caribbean Islands ethnology female health care delivery human interpersonal communication male middle aged patient attitude patient referral patient selection prostate tumor psychology public relations qualitative research sexuality stereotyping young adult LA - English M3 - Article N1 - L626778135 2019-03-20 2019-08-14 PY - 2019 SN - 1365-2354 SP - e12977 ST - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research T2 - European journal of cancer care TI - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626778135&from=export http://dx.doi.org/10.1111/ecc.12977 VL - 28 ID - 856 ER - TY - JOUR AB - Access and recruitment barriers may have contributed to the underrepresentation of Black African/Caribbean men and their partners in current psychosocial research related to prostate cancer survivors. Whilst some studies have explored recruitment barriers and facilitators from participants' perspectives, little is known from researchers' point of view. This paper aimed to address this gap in the literature. Recruitment strategies included the following: cancer support groups, researchers' networks, media advertisement, religious organisations, National Health Service hospitals and snowball sampling. Thirty‐six eligible participants (men = 25, partners = 11) were recruited into the study. Recruitment barriers comprised of gate‐keeping and advertisement issues and the stigma associated with prostate cancer disclosure. Facilitators which aided recruitment included collaborating with National Health Service hospitals, snowball sampling, flexible data collection, building rapport with participants to gain their trust and researcher's attributes. Findings highlight that "hard to reach" Black African/Caribbean populations may be more accessible if researchers adopt flexible but strategic and culturally sensitive recruitment approaches. Such approaches should consider perceptions of stigma associated with prostate cancer within these communities and the influence gatekeepers can have in controlling access to potential participants. Increased engagement with healthcare professionals and gatekeepers could facilitate better access to Black African/Caribbean populations so that their voices can be heard and their specific needs addressed within the healthcare agenda. AD - Institute of Nursing and Health Research, Ulster University, Jordanstown UK School of Nursing, Ulster University, Londonderry UK Barts Health NHS Trust, London UK School of Health Sciences: City, University of London, London UK Institute for Health Research, University of Bedfordshire, Luton UK Institute of Nursing and Health Research, Ulster University, Coleraine UK AN - 135292662. Language: English. Entry Date: 20190318. Revision Date: 20200302. Publication Type: Article AU - Bamidele, Olufikayo O. AU - E. McGarvey, Helen AU - Lagan, Briege M. AU - Chinegwundoh, Frank AU - Ali, Nasreen AU - McCaughan, Eilis DB - CINAHL Complete DO - 10.1111/ecc.12977 DP - EBSCOhost IS - 2 KW - Health Services Accessibility Prostatic Neoplasms Cancer Survivors Research Subject Recruitment Spouses Black Persons Human Support Groups Qualitative Studies Social Media Advertising Religion and Religions -- Organizations National Health Programs Snowball Sample Male Female Collaboration Grounded Theory Convenience Sample Internet -- Utilization N1 - research; tables/charts. Journal Subset: Core Nursing; Europe; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9301979. PY - 2019 SN - 0961-5423 SP - N.PAG-N.PAG ST - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research T2 - European Journal of Cancer Care TI - "Hard to reach, but not out of reach": Barriers and facilitators to recruiting Black African and Black Caribbean men with prostate cancer and their partners into qualitative research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135292662&site=ehost-live&scope=site VL - 28 ID - 1965 ER - TY - JOUR AB - Purpose: We describe the translation of K. R. Lorig and colleagues' Chronic Disease Self-Management Program (CDSMP) for delivery in a senior center and evaluate pre-post benefits for African American participants. Design and Methods: Modifications to the CDSMP included a name change; an additional introductory session; and course augmentations involving culturally relevant foods, stress reduction techniques, and communicating with racially/ethnically diverse physicians. We recruited participants from senior center members, area churches, and word of mouth. We conducted baseline and 4-month post-interviews. Results: A total of 569 African American elders attended an introductory session, with 519 (91%) enrolling in the 6-session program. Of the 519, 444 (86%) completed ≥4 sessions and 414 (79%) completed pre-post interviews. We found small but statistically significant improvements for exercise (p = .001), use of cognitive management strategies (p = .001), energy/fatigue (p = .001), self-efficacy (p = .001), health distress (p = .001), and illness intrusiveness in different life domains (probabilities from .001-.021). We found no changes for health utilization. Outcomes did not differ by gender, number of sessions attended, number and type of chronic conditions, facilitator, leader, or recruitment site. Implications: The CDSMP can be translated for delivery by trained senior center personnel to African American elders. Participant benefits compare favorably to original trial outcomes. The translated program is replicable and may help to address health disparities. AD - Center for Applied Research on Aging and Health, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA 19107, United States Center for Applied Research on Aging and Health, Thomas Jefferson University, Philadelphia, PA, United States Center in the Park, Philadelphia, PA, United States AU - Gitlin, L. N. AU - Chernett, N. L. AU - Harris, L. F. AU - Palmer, D. AU - Hopkins, P. AU - Dennis, M. P. DB - Scopus DO - 10.1093/geront/48.5.698 IS - 5 KW - Chronic illness Community participation Disease management Evidence-based Program sustainability Translational research M3 - Article N1 - Cited By :34 Export Date: 22 March 2021 PY - 2008 SP - 698-705 ST - Harvest health: Translation of the chronic disease self-management program for older African Americans in a senior setting T2 - Gerontologist TI - Harvest health: Translation of the chronic disease self-management program for older African Americans in a senior setting UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-57149104746&doi=10.1093%2fgeront%2f48.5.698&partnerID=40&md5=14979411f89e5f4466b249ed974f1ab0 VL - 48 ID - 2546 ER - TY - JOUR AB - Background: Primary care physician (PCP) recommendation for cancer screening is a strong predictor of adherence to screening; however, patients with limited health literacy (HL) may have difficulty understanding information about screening. We implemented a continuing medical education program to train PCPs in cancer risk communication with limited HL patients. Our main study objective is to determine whether changes in PCP communication improve patients' adherence to cancer screening. We examined baseline patient characteristics to assess whether patients' cancer screening information needs vary across levels of limited HL and determine which factors may influence adherence to different types of cancer screening tests. Methods: This study is part of a 4‐year randomized controlled trial of a communication skills training program targeting PCPs (11 intervention vs. 8 control) who practice in safety‐net clinics in New Orleans, LA and their patients with limited HL (Rapid Estimate of Adult Literacy in Medicine [REALM] score < 60). For each PCP, we recruited 10 patients (men [age 50‐75]; women [age 40‐75]) who were overdue for at least one cancer screening test (mammography; pap smears; FOBT/ endoscopy/barium enema). We conducted baseline interviews to obtain socio‐demographics, cancer knowledge, cancer screening status and ratings of physician communication style (Perceived Involvement in Care Scale). We conducted baseline chart reviews to confirm cancer screening status. Results: Of 871 clinic patients screened to date, 164 met eligibility criteria (target sample size: 180). The most common reasons for exclusion were HL too high (37%), up‐to‐date on cancer screening (20%), or new patients to the PCP (12%). Most eligible patients are African American (90%), female (77%), insured (61%) and read at the 7th‐8th grade level (67%). Only 35% of the study sample was up‐to‐date by chart review on mammography, 34% on pap smears, and 29% on colorectal cancer screening. Patient ratings of the level of information exchange with their PCPs varied by level of HL with patients with < 3rd grade reading level rating their PCPs significantly lower (mean [SD]: 2.9 [1.4]) than patients with higher reading levels (7th‐8th grade: 3.4 [1.0]; 5th‐6th grade: 3.7 [0.6]). Overall, less than 1/3 of patients knew the age at which to start breast/cervical/CRC screening. Knowledge about the cancer screened for by mammography and the tests available for CRC screening varied significantly by level of HL (7th‐8th grade vs. 5th‐6th grade vs. <3rd grade: Breast, 83% vs. 69% vs. 41%; CRC, 51% vs. 32% vs. 12%). Only 10% of patients knew that pap smears screen for cervical cancer. There was no significant difference in cancer screening status by level of HL, cancer screening knowledge or perceptions of involvement in care. For mammography, the odds of being up‐to‐date increased with having insurance (OR, 95% CI: 3.2 [1.4‐7.5]) and emotional/informational support (1.6 [1.2‐2.2]) whereas receiving care in a community health center reduced the odds (0.42 [0.2‐0.9]). For CRC screening, family history of CRC increased the odds of being up‐to‐date (5.7 [1.3‐23.8]) whereas emotional/informational support reduced the odds (0.63 [0.5‐0.9]). There were no significant factors that influenced cervical cancer screening status. Although patients' perceptions of health information exchange and cancer screening knowledge may depend on their level of health literacy, psychosocial, familial and health system related factors may ultimately influence adherence to cancer screening. Message framing for cancer risk communication should take these factors into consideration. AN - CN-01005664 AU - Price-Haywood, E. G. AU - Harden-Barrios, J. AU - Cooper, L. A. DO - 10.1158/1055-9965.DISP-11-A11 IS - 10 KW - *cancer research *cancer screening *health disparity *health literacy *human *medical information *neoplasm *patient Adult African American Breast Cancer risk Colorectal cancer Communication skill Education program Family history Female General practitioner Health care Health center Hospital Insurance Interpersonal communication Interview Male Mammography Medical education Medical record review Papanicolaou test Physician Randomized controlled trial Reading Safety Sample size Screening Screening test Training United States Uterine cervix cancer M3 - Journal: Conference Abstract PY - 2011 ST - Health information needs and predictors of cancer screening status among patients with limited health literacy T2 - Cancer epidemiology biomarkers and prevention TI - Health information needs and predictors of cancer screening status among patients with limited health literacy UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01005664/full VL - 20 ID - 1569 ER - TY - JOUR AB - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American community, "home health parties" were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive. AD - G.R. Sadler, Community Outreach, Rebecca and John Moores UCSD Cancer Center, 3855 Health Sciences Drive #0850, San Diego, CA 92093-0850, United States AU - Sadler, G. R. AU - York, C. AU - Madlensky, L. AU - Gibson, K. AU - Wasserman, L. AU - Rosenthal, E. AU - Barbier, L. AU - Newman, V. A. AU - Tso, C. DB - Embase Medline DO - 10.1207/s15430154jce2102_6 IS - 2 KW - adult African American article breast cancer breast examination cancer control cancer risk female genetic counseling human leisure medical research minority group normal human nutrition patient participation priority journal risk assessment social aspect social network social support LA - English M3 - Article N1 - L44743652 2006-11-27 PY - 2006 SN - 0885-8195 SP - 71-76 ST - Health parties for African American study recruitment T2 - Journal of Cancer Education TI - Health parties for African American study recruitment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44743652&from=export http://dx.doi.org/10.1207/s15430154jce2102_6 VL - 21 ID - 1245 ER - TY - JOUR AB - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American community, 'home health parties' were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Sadler, Georgia Robins, Community Outreach, Rebecca and John Moores UCSD Cancer Center, 3855 Health Sciences Drive #0850, La Jolla, CA, US, 92093-0850 AN - 2006-20071-004 AU - Sadler, Georgia Robins AU - York, Crystal AU - Madlensky, Lisa AU - Gibson, Kathi AU - Wasserman, Linda AU - Rosenthal, Eric AU - Barbier, Leslie AU - Newman, Vicky A. AU - Tso, Cindy DB - psyh DO - 10.1207/s15430154jce2102_6 DP - EBSCOhost IS - 2 KW - health parties African American social networks breast cancer risk assessment African American women Adult African Americans Attitude to Health Biomedical Research Breast Neoplasms Clinical Trials as Topic Female Health Education Health Promotion Humans Interpersonal Relations Middle Aged Patient Selection Social Support Blacks Health N1 - Rebecca and John Moores UCSD Cancer Center, UCSD School of Medicine, La Jolla, CA, US. Other Publishers: Springer; Taylor & Francis. Release Date: 20061204. Correction Date: 20141103. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Health; Social Networks; Risk Assessment. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 6. Issue Publication Date: 2006. Sponsor: Avon Foundation. Recipients: No recipient indicated Sponsor: National Institutes of Health, Division of National Center on Minority Health and Health Disparities, US. Grant: P60MD00220. Other Details: EXPORT grant. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: R25CA65745. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: 5 P30 CA023100-22. Other Details: Cancer Center Core grant. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: U56 CA92079; U56 CA92081. Other Details: Minority Institution/Cancer Center Partnership Program. Recipients: No recipient indicated PY - 2006 SN - 0885-8195 1543-0154 SP - 71-76 ST - Health Parties for African American Study Recruitment T2 - Journal of Cancer Education TI - Health Parties for African American Study Recruitment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-20071-004&site=ehost-live&scope=site gsadler@ucsd.edu VL - 21 ID - 1726 ER - TY - JOUR AB - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American community, 'home health parties' were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive. AD - Associate Director, Community Outreach, Rebecca and John Moores UCSD Cancer Center, 3855 Health Sciences Drive #0850, La Jolla, CA 92093-0850; gsadler@ucsd.edu AN - 106136284. Language: English. Entry Date: 20070817. Revision Date: 20200624. Publication Type: Journal Article AU - Sadler, G. R. AU - York, C. AU - Madlensky, L. AU - Gibson, K. AU - Wasserman, L. AU - Rosenthal, E. AU - Barbier, L. AU - Newman, V. A. AU - Tso, C. DB - CINAHL Complete DO - 10.1207/s15430154jce2102_6 DP - EBSCOhost IS - 2 KW - Black Persons Research Subject Recruitment -- Methods Research Subjects Social Networks Adult Asians Breast Examination Breast Neoplasms -- Prevention and Control California Cancer Screening Chi Square Test Clinical Assessment Tools Comparative Studies Culture Data Analysis Software Descriptive Statistics Educational Status Female Funding Source Genetic Counseling Health Education Hispanic Americans Middle Age Nutrition Education Pilot Studies Risk Assessment Surveys White Persons Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Gail Model. Grant Information: Avon Foundation; the National Institutes of Health's Division of National Center on Minority Health and Health Disparities EXPORT grant P60MD00220; and the National Cancer Institute's grant R25CA65745, Cancer Center Core grant 5 P30 CA023100-22, and Minority Institution/Cancer Center Partnership Program grants U56 CA92079 and U56 CA92081. NLM UID: 8610343. PMID: NLM17020516. PY - 2006 SN - 0885-8195 SP - 71-76 ST - Health parties for African American study recruitment T2 - Journal of Cancer Education TI - Health parties for African American study recruitment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106136284&site=ehost-live&scope=site VL - 21 ID - 1968 ER - TY - JOUR AB - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American community, "home health parties" were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive. AD - Rebecca and John Moores UCSD Cancer Center, Department of Surgery, UCSD School of Medicine, San Diego, CA, United States Rebecca and John Moores UCSD Cancer Center, United States Rebecca and John Moores UCSD Cancer Center, Department of Family and Preventive Medicine, UCSD School of Medicine, United States Community Outreach, Rebecca and John Moores UCSD Cancer Center, 3855 Health Sciences Drive #0850, San Diego, CA 92093-0850, United States AU - Sadler, G. R. AU - York, C. AU - Madlensky, L. AU - Gibson, K. AU - Wasserman, L. AU - Rosenthal, E. AU - Barbier, L. AU - Newman, V. A. AU - Tso, C. DB - Scopus DO - 10.1207/s15430154jce2102_6 IS - 2 M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2006 SP - 71-76 ST - Health parties for African American study recruitment T2 - Journal of Cancer Education TI - Health parties for African American study recruitment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33344457680&doi=10.1207%2fs15430154jce2102_6&partnerID=40&md5=eecf9302cc58508e191d77bce5edc917 VL - 21 ID - 2575 ER - TY - JOUR AB - Innovative strategies are needed to increase minorities' research participation. Using existing social networks within the African American, community, "home health parties" were tested as a way to recruit African American women to a breast cancer control study. Parties included social, educational, and recruitment components. All women attending health parties consented, completed a survey, and received the study's preliminary breast cancer risk assessment. There were no differences in rates of participation for subsequent study components between women recruited via parties versus other methods. Health parties are viable recruitment strategies, reduce barriers to participation, provide a supportive environment, and are relatively inexpensive. AN - WOS:000241750200005 AU - Sadler, G. R. AU - York, C. AU - Madlensky, L. AU - Gibson, K. AU - Wasserman, L. AU - Rosenthal, E. AU - Barbier, L. AU - Newman, V. A. AU - Tso, C. DA - Sum DO - 10.1207/s15430154jce2102_6 IS - 2 N1 - 17020516 PY - 2006 SN - 0885-8195 SP - 71-76 ST - Health parties for African American study recruitment T2 - Journal of Cancer Education TI - Health parties for African American study recruitment VL - 21 ID - 3219 ER - TY - JOUR AB - Purpose: Understanding the potential consequences of racial differences in prostate cancer outcomes, from survival rates to quality of life considerations, is important for the clinician and patient. We examined demographic, clinical and health related quality of life data comparing black with white patients just after treatment of prostate cancer and 1 year later. Materials and Methods: We analyzed data on 1,178 patients who were newly diagnosed with prostate cancer in the Cancer of the Prostate Strategic Urologic Research Endeavor, a national observational database of men recruited from 35 community and academic urology practices throughout the United States. Patient demographics, clinical characteristics and validated health related quality of life questionnaires were reviewed. A total of 958 white and 161 black patients with prostate cancer who completed at least 2 surveys were compared. Results: The black patients were younger, and had lower income and education levels than white patients. Controlling for age, education and income differences, black patients generally had worse clinical characteristics at presentation and lower baseline health related quality of life data scores in most generic and disease specific categories at treatment. The most notable exception was sexual function, which was the only score that was higher in black patients at treatment. With time, health related quality of life improved in both groups but black patients had slower rates of improvement for general health, bodily pain, physical function, role function, disease worry and bowel function. They continued to have higher sexual function. Conclusions: Significant differences exist in clinical presentation, sociodemographic characteristics, and health related quality of life between black and white men with prostate cancer. These health related quality of life differences remain after treatment. Physicians should not assume that outcomes in black men would be similar to other patients. AD - Department of Urology, UCSF/Mt. Zion Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States Division of Urology, Cook County Hospital, Chicago, IL, United States TAP Pharmaceutical Products, Inc., Lake Forest, IL, United States Department of Urology, University of Washington, School of Medicine, Seattle, WA, United States AU - Lubeck, D. P. AU - Kim, H. AU - Grossfeld, G. AU - Ray, P. AU - Penson, D. F. AU - Flanders, S. C. AU - Carroll, P. R. DB - Scopus DO - 10.1016/S0022-5347(05)65551-6 IS - 6 KW - Minority groups Prostatic neoplasms Quality of life M3 - Article N1 - Cited By :77 Export Date: 22 March 2021 PY - 2001 SP - 2281-2285 ST - Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor T2 - Journal of Urology TI - Health related quality of life differences between black and white men with prostate cancer: Data from the cancer of the prostate strategic urologic research endeavor UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035165172&doi=10.1016%2fS0022-5347%2805%2965551-6&partnerID=40&md5=569336c8fae90430faa1354b7f1642b2 VL - 166 ID - 2629 ER - TY - JOUR AB - Background Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health-related quality of life (HRQOL) in a group-randomized trial at 38 cooperative group sites within the United States. Methods Patients were recruited before breast surgery. Sites were randomly assigned to education-only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a >= 10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy-Breast plus 4 lymphedema items (FACT-B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. Results A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P= .37) or HRQOL (FACT-B+4 total score;P= .8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P= .0825). However, African American patients reported greater lymphedema symptoms (P= .0002) and better emotional functioning (P= .0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P <= .0001), Eastern Cooperative Oncology Group performance status >0 (P= .0002), >= 1 positive lymph nodes (P= .0009), having no education beyond high school (P< .0001), having undergone chemotherapy (P= .0242), and having had only axillary node dissection or sentinel node biopsy versus both (P= .0007). Conclusion The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities. AN - WOS:000579537300001 AU - Naughton, M. J. AU - Liu, H. S. AU - Seisler, D. K. AU - Le-Rademacher, J. AU - Armer, J. M. AU - Oliveri, J. M. AU - Sloan, J. A. AU - Hock, K. AU - Schwartz, M. AU - Unzeitig, G. AU - Melnik, M. AU - Yee, L. D. AU - Fleming, G. F. AU - Taylor, J. R. AU - Loprinzi, C. AU - Paskett, E. D. DA - Jan DO - 10.1002/cncr.33184 IS - 2 N1 - 33079393 PY - 2021 SN - 0008-543X SP - 300-309 ST - Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients T2 - Cancer TI - Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients VL - 127 ID - 2759 ER - TY - JOUR AB - Background: Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health‐related quality of life (HRQOL) in a group‐randomized trial at 38 cooperative group sites within the United States. Methods: Patients were recruited before breast surgery. Sites were randomly assigned to education‐only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy–Breast plus 4 lymphedema items (FACT‐B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. Results: A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P =.37) or HRQOL (FACT‐B+4 total score; P =.8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P =.0825). However, African American patients reported greater lymphedema symptoms (P =.0002) and better emotional functioning (P =.0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P ≤.0001), Eastern Cooperative Oncology Group performance status >0 (P =.0002), ≥1 positive lymph nodes (P =.0009), having no education beyond high school (P <.0001), having undergone chemotherapy (P =.0242), and having had only axillary node dissection or sentinel node biopsy versus both (P =.0007). Conclusion: The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities. AN - CN-02194373 AU - Naughton, M. J. AU - Liu, H. AU - Seisler, D. K. AU - Le-Rademacher, J. AU - Armer, J. M. AU - Oliveri, J. M. AU - Sloan, J. A. AU - Hock, K. AU - Schwartz, M. AU - Unzeitig, G. AU - et al. DO - 10.1002/cncr.33184 KW - *breast cancer *cancer patient *intervention study *lymphedema *quality of life *race Adult African American Age Article Axillary lymph node Breast surgery Cancer chemotherapy Cancer surgery Controlled study Demography Dissection Ethnicity Exercise Female Functional Assessment of Cancer Therapy Breast High school Human Major clinical study Physiotherapy Prevention Randomized controlled trial Sentinel lymph node Surgery United States M3 - Journal: Article in Press PY - 2020 ST - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): a lymphedema prevention intervention trial for newly diagnosed breast cancer patients T2 - Cancer TI - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): a lymphedema prevention intervention trial for newly diagnosed breast cancer patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02194373/full ID - 1554 ER - TY - JOUR AB - Background: Lymphedema is an adverse effect of breast cancer treatment that causes swelling and pain in the arm and hand. We tested 2 lymphedema prevention interventions and their impact on health-related quality of life (HRQOL) in a group-randomized trial at 38 cooperative group sites within the United States. Methods: Patients were recruited before breast surgery. Sites were randomly assigned to education-only (EO) lymphedema prevention or education plus exercise and physical therapy (LEAP). Lymphedema was defined as a ≥10% difference in arm volume at any time from baseline to 18 months postsurgery. HRQOL was assessed using the Functional Assessment of Cancer Therapy–Breast plus 4 lymphedema items (FACT-B+4). Longitudinal mixed model regression analysis, adjusting for key demographic and clinical variables, examined participants' HRQOL by intervention group and lymphedema status. Results: A total of 547 patients (56% LEAP) were enrolled and completed HRQOL assessments. The results revealed no differences between the interventions in preventing lymphedema (P =.37) or HRQOL (FACT-B+4 total score; P =.8777). At 18 months, the presence of lymphedema was associated with HRQOL at borderline significance (P =.0825). However, African American patients reported greater lymphedema symptoms (P =.0002) and better emotional functioning (P =.0335) than patients of other races or ethnicities. Lower HRQOL during the intervention was associated with younger age (P ≤.0001), Eastern Cooperative Oncology Group performance status >0 (P =.0002), ≥1 positive lymph nodes (P =.0009), having no education beyond high school (P <.0001), having undergone chemotherapy (P =.0242), and having had only axillary node dissection or sentinel node biopsy versus both (P =.0007). Conclusion: The tested interventions did not differ in preventing lymphedema or in HRQOL outcomes. African American women reported greater HRQOL impacts due to lymphedema symptoms than women of other races or ethnicities. © 2020 American Cancer Society AD - Department of Internal Medicine, The Ohio State University, Columbus, OH, United States Mayo Clinic, Rochester, MN, United States Department of Health Sciences, Mayo Clinic, Rochester, MN, United States Department of Nursing Research, University of Missouri, Columbia, MO, United States Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Division of Oncology & Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, United States Mount Sinai Medical Center, Miami Beach, FL, United States City of Laredo, Laredo, TX, United States Cancer Research Consortium of West Michigan, Grand Rapids, MI, United States Division of Surgical Oncology, City of Hope, Duarte, CA, United States Department of Hematology/Oncology, University of Chicago, Chicago, IL, United States Alliance for Clinical Trials in Oncology Foundation, Protocol Operations Program Office, Chicago, IL, United States North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN, United States Department of Medicine, The Ohio State University, Columbus, OH, United States AU - Naughton, M. J. AU - Liu, H. AU - Seisler, D. K. AU - Le-Rademacher, J. AU - Armer, J. M. AU - Oliveri, J. M. AU - Sloan, J. A. AU - Hock, K. AU - Schwartz, M. AU - Unzeitig, G. AU - Melnik, M. AU - Yee, L. D. AU - Fleming, G. F. AU - Taylor, J. R. AU - Loprinzi, C. AU - Paskett, E. D. DB - Scopus DO - 10.1002/cncr.33184 IS - 2 KW - breast cancer lymphedema quality of life race symptoms M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 SP - 300-309 ST - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients T2 - Cancer TI - Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092701592&doi=10.1002%2fcncr.33184&partnerID=40&md5=8a68967c33e160d3a61d13d597010749 VL - 127 ID - 2155 ER - TY - JOUR AB - Importance: Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. Objectives: To determine demographic and clinical factors associated with healthcare utilization and costs among clinical trial participants. Design, setting, and patients: We conducted a retrospective analysis among breast cancer patients over the age of 65 treated on SWOG clinical trials from 1999 to 2011 with trial data linked to Medicare claims. Main outcomes and measures: The outcomes were healthcare utilization (emergency room visits (ER), hospitalizations) and costs from Medicare Claims. Demographic, clinical, and prognostic factors were captured from clinical trial records. We identified cardiovascular comorbidities/risk factors (CVD-RFs) of diabetes, hypertension, hypercholesterolemia, and coronary artery disease (CAD) from Medicare claims. Multivariable logistic and linear regression were used to assess the association between CVD-RFs and outcomes. Results: Among the 708 patients included in the analysis, 160 (22.6%) experienced 234 separate hospitalizations, and 193 (27.3%) experienced 311 separate ER visits. Black race was associated with an increase in hospitalizations (OR [95% CI], 2.52 [1.10–5.79], p = 0.03), but not emergency room visits compared to white race. Diabetes, hypertension, hypercholesterolemia, and CAD were all independently associated with increased risk of both hospitalizations and ER visit. Hypertension had the strongest association, with more than a threefold risk of hospitalization for those with hypertension compared to those without (OR [95% CI], 3.16 [1.85–5.40], p < 0.001). For those with ≥ 3 RFs, the risk of hospitalization was nearly 3 times greater compared to 0 or 1 CVD-RFs (OR [95% CI], 2.74 [1.71–4.38], p < 0.001). Similar results were seen for ER visits. In the first 12 months after trial registration, patients with diabetes ($38,324 vs $30,923, 23.9% increase, p = 0.05), hypercholesterolemia ($34,168 vs $30,661, 11.4% increase, p = 0.02), and CAD ($37,781 vs $31,698, 19.2% increase, p = 0.04) had statistically significantly higher total healthcare costs. Additionally, those with ≥ 2 significant CVD-RFs ($35,353 vs. $28,899, 22.3% increase, p = 0.005) had statistically significantly higher total healthcare costs. Conclusions: Among participants treated on clinical trials, black race and presence of multiple cardiovascular comorbidities was associated with a substantial increase in ER visits, hospitalizations and healthcare costs. Efforts to reduce unplanned hospitalizations should focus on this high-risk group. AD - D.L. Hershman, Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, 161 Fort Washington Avenue, 10-1068, New York, NY, United States AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Accordino, M. AU - Vaidya, R. AU - Barlow, W. E. AU - Ramsey, S. AU - Unger, J. M. DB - Embase Medline DO - 10.1007/s10549-020-05634-1 IS - 2 KW - aged article Black person breast cancer cancer patient cancer prognosis cardiovascular risk clinical outcome clinical study comorbidity confidence interval controlled study coronary artery disease demography diabetes mellitus emergency ward female geriatric patient health care cost health care utilization high risk population hospitalization human hypercholesterolemia hypertension linear regression analysis logistic regression analysis medical record medicare odds ratio priority journal race difference retrospective study risk factor very elderly LA - English M3 - Article N1 - L2004740483 2020-05-04 2020-05-13 PY - 2020 SN - 1573-7217 0167-6806 SP - 455-463 ST - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials T2 - Breast Cancer Research and Treatment TI - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004740483&from=export http://dx.doi.org/10.1007/s10549-020-05634-1 VL - 181 ID - 802 ER - TY - JOUR AB - IMPORTANCE: Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. OBJECTIVES: To determine demographic and clinical factors associated with healthcare utilization and costs among clinical trial participants. DESIGN, SETTING, AND PATIENTS: We conducted a retrospective analysis among breast cancer patients over the age of 65 treated on SWOG clinical trials from 1999 to 2011 with trial data linked to Medicare claims. MAIN OUTCOMES AND MEASURES: The outcomes were healthcare utilization (emergency room visits (ER), hospitalizations) and costs from Medicare Claims. Demographic, clinical, and prognostic factors were captured from clinical trial records. We identified cardiovascular comorbidities/risk factors (CVD-RFs) of diabetes, hypertension, hypercholesterolemia, and coronary artery disease (CAD) from Medicare claims. Multivariable logistic and linear regression were used to assess the association between CVD-RFs and outcomes. RESULTS: Among the 708 patients included in the analysis, 160 (22.6%) experienced 234 separate hospitalizations, and 193 (27.3%) experienced 311 separate ER visits. Black race was associated with an increase in hospitalizations (OR [95% CI], 2.52 [1.10-5.79], p = 0.03), but not emergency room visits compared to white race. Diabetes, hypertension, hypercholesterolemia, and CAD were all independently associated with increased risk of both hospitalizations and ER visit. Hypertension had the strongest association, with more than a threefold risk of hospitalization for those with hypertension compared to those without (OR [95% CI], 3.16 [1.85-5.40], p < 0.001). For those with ≥ 3 RFs, the risk of hospitalization was nearly 3 times greater compared to 0 or 1 CVD-RFs (OR [95% CI], 2.74 [1.71-4.38], p < 0.001). Similar results were seen for ER visits. In the first 12 months after trial registration, patients with diabetes ($38,324 vs $30,923, 23.9% increase, p = 0.05), hypercholesterolemia ($34,168 vs $30,661, 11.4% increase, p = 0.02), and CAD ($37,781 vs $31,698, 19.2% increase, p = 0.04) had statistically significantly higher total healthcare costs. Additionally, those with ≥ 2 significant CVD-RFs ($35,353 vs. $28,899, 22.3% increase, p = 0.005) had statistically significantly higher total healthcare costs. CONCLUSIONS: Among participants treated on clinical trials, black race and presence of multiple cardiovascular comorbidities was associated with a substantial increase in ER visits, hospitalizations and healthcare costs. Efforts to reduce unplanned hospitalizations should focus on this high-risk group. AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Accordino, M. AU - Vaidya, R. AU - Barlow, W. E. AU - Ramsey, S. AU - Unger, J. M. DB - Medline DO - 10.1007/s10549-020-05634-1 KW - aged article Black person breast cancer cancer patient cancer prognosis Caucasian comorbidity controlled study coronary artery disease demography diabetic patient emergency ward female health care utilization high risk population hospitalization human hypercholesterolemia hypertension linear regression analysis major clinical study medicare outcome assessment retrospective study risk factor LA - English M3 - Article in Press N1 - L631579187 2020-05-04 PY - 2020 SN - 1573-7217 ST - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials T2 - Breast cancer research and treatment TI - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631579187&from=export http://dx.doi.org/10.1007/s10549-020-05634-1 ID - 810 ER - TY - JOUR AB - Importance: Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. Objectives: To determine demographic and clinical factors associated with healthcare utilization and costs among clinical trial participants. Design, setting, and patients: We conducted a retrospective analysis among breast cancer patients over the age of 65 treated on SWOG clinical trials from 1999 to 2011 with trial data linked to Medicare claims. Main outcomes and measures: The outcomes were healthcare utilization (emergency room visits (ER), hospitalizations) and costs from Medicare Claims. Demographic, clinical, and prognostic factors were captured from clinical trial records. We identified cardiovascular comorbidities/risk factors (CVD-RFs) of diabetes, hypertension, hypercholesterolemia, and coronary artery disease (CAD) from Medicare claims. Multivariable logistic and linear regression were used to assess the association between CVD-RFs and outcomes. Results: Among the 708 patients included in the analysis, 160 (22.6%) experienced 234 separate hospitalizations, and 193 (27.3%) experienced 311 separate ER visits. Black race was associated with an increase in hospitalizations (OR [95% CI], 2.52 [1.10–5.79], p = 0.03), but not emergency room visits compared to white race. Diabetes, hypertension, hypercholesterolemia, and CAD were all independently associated with increased risk of both hospitalizations and ER visit. Hypertension had the strongest association, with more than a threefold risk of hospitalization for those with hypertension compared to those without (OR [95% CI], 3.16 [1.85–5.40], p < 0.001). For those with ≥ 3 RFs, the risk of hospitalization was nearly 3 times greater compared to 0 or 1 CVD-RFs (OR [95% CI], 2.74 [1.71–4.38], p < 0.001). Similar results were seen for ER visits. In the first 12 months after trial registration, patients with diabetes ($38,324 vs $30,923, 23.9% increase, p = 0.05), hypercholesterolemia ($34,168 vs $30,661, 11.4% increase, p = 0.02), and CAD ($37,781 vs $31,698, 19.2% increase, p = 0.04) had statistically significantly higher total healthcare costs. Additionally, those with ≥ 2 significant CVD-RFs ($35,353 vs. $28,899, 22.3% increase, p = 0.005) had statistically significantly higher total healthcare costs. Conclusions: Among participants treated on clinical trials, black race and presence of multiple cardiovascular comorbidities was associated with a substantial increase in ER visits, hospitalizations and healthcare costs. Efforts to reduce unplanned hospitalizations should focus on this high-risk group. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. AD - Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center, 161 Fort Washington Avenue, 10-1068, New York, NY 10032, United States SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Accordino, M. AU - Vaidya, R. AU - Barlow, W. E. AU - Ramsey, S. AU - Unger, J. M. DB - Scopus DO - 10.1007/s10549-020-05634-1 IS - 2 KW - Breast cancer Elderly Hospitalizations Resource utilization M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 455-463 ST - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials T2 - Breast Cancer Research and Treatment TI - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083894751&doi=10.1007%2fs10549-020-05634-1&partnerID=40&md5=26112a4c0043709f356b27dcfaebaaec VL - 181 ID - 2193 ER - TY - JOUR AB - Importance Patients with cancer are at risk for unplanned hospitalizations during treatment which can increase the cost of care. Objectives To determine demographic and clinical factors associated with healthcare utilization and costs among clinical trial participants. Design, setting, and patients We conducted a retrospective analysis among breast cancer patients over the age of 65 treated on SWOG clinical trials from 1999 to 2011 with trial data linked to Medicare claims. Main outcomes and measures The outcomes were healthcare utilization (emergency room visits (ER), hospitalizations) and costs from Medicare Claims. Demographic, clinical, and prognostic factors were captured from clinical trial records. We identified cardiovascular comorbidities/risk factors (CVD-RFs) of diabetes, hypertension, hypercholesterolemia, and coronary artery disease (CAD) from Medicare claims. Multivariable logistic and linear regression were used to assess the association between CVD-RFs and outcomes. Results Among the 708 patients included in the analysis, 160 (22.6%) experienced 234 separate hospitalizations, and 193 (27.3%) experienced 311 separate ER visits. Black race was associated with an increase in hospitalizations (OR [95% CI], 2.52 [1.10-5.79], p = 0.03), but not emergency room visits compared to white race. Diabetes, hypertension, hypercholesterolemia, and CAD were all independently associated with increased risk of both hospitalizations and ER visit. Hypertension had the strongest association, with more than a threefold risk of hospitalization for those with hypertension compared to those without (OR [95% CI], 3.16 [1.85-5.40], p < 0.001). For those with >= 3 RFs, the risk of hospitalization was nearly 3 times greater compared to 0 or 1 CVD-RFs (OR [95% CI], 2.74 [1.71-4.38], p < 0.001). Similar results were seen for ER visits. In the first 12 months after trial registration, patients with diabetes ($38,324 vs $30,923, 23.9% increase, p = 0.05), hypercholesterolemia ($34,168 vs $30,661, 11.4% increase, p = 0.02), and CAD ($37,781 vs $31,698, 19.2% increase, p = 0.04) had statistically significantly higher total healthcare costs. Additionally, those with >= 2 significant CVD-RFs ($35,353 vs. $28,899, 22.3% increase, p = 0.005) had statistically significantly higher total healthcare costs. Conclusions Among participants treated on clinical trials, black race and presence of multiple cardiovascular comorbidities was associated with a substantial increase in ER visits, hospitalizations and healthcare costs. Efforts to reduce unplanned hospitalizations should focus on this high-risk group. AN - WOS:000527440800002 AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Accordino, M. AU - Vaidya, R. AU - Barlow, W. E. AU - Ramsey, S. AU - Unger, J. M. DA - Jun DO - 10.1007/s10549-020-05634-1 IS - 2 N1 - 32306168 PY - 2020 SN - 0167-6806 SP - 455-463 ST - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials T2 - Breast Cancer Research and Treatment TI - Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials VL - 181 ID - 2783 ER - TY - JOUR AB - Background and rationale: East Asian adults are known to have higher levels of visceral adiposity than whites, African Americans, and Hispanic adults in the US. This visceral fat deposition, because of its close proximity to the portal vein, has greater metabolic activity and is associated with a greater risk of cardiometabolic diseases and possibly certain cancers (e.g., breast and colorectal cancers). Newly introduced weight loss interventions, specifically, intermittent energy restriction (IER), have been proposed to be as effective as continuous energy restriction, achieve higher and long‐term compliance, and may predominantly result in a decrease in visceral fat. Thus, implementing this novel weight loss intervention among East Asian Americans with high visceral fat deposition would be particularly beneficial . Goal: This study aims to demonstrate the feasibility to conduct an intermittent energy restriction (IER) nutritional intervention aimed at reducing visceral adiposity in overweight Asian Americans middle‐aged adults. 1. To finalize and implement a protocol for an IER intervention plus exercise with the goal of reducing visceral fat in overweight adult East Asian Americans (EAA). The protocol will include an intensive dietary intervention and an exercise program administered by a dietitian through individual meetings and the use of new technologies to monitor dietary compliance. 2. After eligibility screening, 70 individuals will be randomized to either the intensive intervention diet group or to a non‐intensive intervention (active comparator) diet group for 12 weeks. The intensive intervention group will follow a low carbohydrate‐ low energy IER diet for two consecutive days, and the Mediterranean (MED) diet for the other five days and meet estimated energy requirements (IER + MED group). The active comparator group will follow the Dietary Approaches to Stop Hypertension (DASH) diet for all seven days and meet estimated energy requirements (DASH group). With an expected attrition rate of ~25%, the investigators expect ~50 participants to complete the study. 3. To evaluate study retention, protocol adherence, effect size of the intervention on body weight, total adiposity, DXA measured visceral fat (main outcome), estimated visceral adipose tissue area, and selected clinical measures (e.g., waist circumference, hip circumference). Design: Randomized lifestyle intervention trial to compare the effects of two twelve‐week diets ‐ (i) an IER + MED diet versus (ii) DASH diet‐ on DXA quantified visceral fat deposition distribution in overweight/obese men and women. Both intervention groups will be asked to follow a moderate exercise program (1 hour of walking five days a week). The research will be carried out in the University of Hawaii Cancer Center (UHCC). The investigators will determine and compare the primary and secondary endpoints at least five days after the last 2 energy‐restricted days to a corresponding day of the week in the DASH group at the completion of the 12th week of IER+MED or DASH diets. Assessing dietary intervention adherence: Dietary intake of energy, fat (monounsaturated fatty acids (MUFA), Polyunsaturated fatty acids (PUFA) and saturated fat), carbohydrate, protein, dietary fiber and alcohol will be assessed prior to the first week of intervention, the 5‐6th week, and the 12th week. Participants will capture images of foods eaten and consumed over four days (i.e., before and after images of each eating occasion). A mobile app designed to seamlessly take images of foods/beverages will be loaded to onto each participant's mobile telephones for free and removed at the end of the study. Physical activity level will be assessed at baseline using a physical activity questionnaire. Advice, support and monitoring in both diet groups Foods eaten for the IER+MED and DASH diets will be self‐selected by the participants and not provided by the study team. The IER+MED and DASH groups will receive clear instructions on how to follow the allocated diet in a face‐to‐face die ary consultation with one of the trial dietitians (45‐ 60 minute appointment) at the UHCC. Both groups will receive comprehensive written instructions of how to follow the diets at home, including recommended portion sizes and recipes and suggested meal plans. Both groups will receive appropriate behavioral techniques to promote adherence to diets (i.e., self‐monitoring of diet and goal setting). Participants will be contacted by telephone by an allocated dietitian one week after randomization to check that they have started the diet, to assess understanding of the diet and to provide any trouble shooting advice. Participants will be contacted by an allocated dietitian with weekly phone calls in weeks 1 to 4 to discuss adherence and any problems with the diet; and with every other week phone calls in weeks 5 to 12. Both groups will be asked to record 4‐day dietary records with the mobile food record at Week 6 and Week 11. This will allow assessment to adherence of the allocated diets and better tailor dietary advice. Participants will be asked to report overall compliance to the diet and physical activity plans using a scale of 0‐10 for each, on the weekly and fortnightly phone calls with the dietitian. The IER+MED group will also be asked to record adherence to the 2‐day IER using a scale of 0‐2. All participants will also be advised to become more active, walking at least one hour per day five days per week. The intermittent energy restriction (IER) group will be encouraged to walk on the non‐IER days. Post‐Study At the end of the study all participants will be offered advice on continued weight loss and/or weight loss maintenance if they have reached a target weight and this is appropriate. This will include advice regarding preferred diet, i.e., IER+MED or DASH. If resources permit, the investigators will recontact participants six and twelve months after the end of the intervention to assess dietary intake, physical activity and body weight. Statistical Considerations Statistical analysis will be conducted within Epidemiology Program, UHCC. The primary aim is to determine changes in percentage visceral fat between the IER+MED diet and the DASH diet over a 3 months period. The sample size of 25 participants per group has been chosen to detect a difference of 15 percentage points in the reduction in visceral fat between the two different diets, assuming an estimated 25% drop‐out rate. Calculations assume a two‐sided t‐test with estimated standard deviation of 10% and the conventional 5% significance level. The primary analysis will be performed on an intent‐to‐treat principle, where all participants will be analyzed by randomization group, regardless of compliance. The primary endpoints of visceral fat measurements will be regressed on randomization group and time point, as well as potential confounders, using a mixed model approach accounting for the repeated measures at baseline, and 6 and 12 weeks. The primary hypothesis will be tested by a contrast F test comparing the difference between groups in the change from baseline to 12 weeks. The 6 month assessment will be similarly tested to understand the trend over time. If there is evidence of a linear change in fat over time, time will be entered as a continuous variable and the slope will be compared between groups. Visceral fat will be modelled as an absolute area and as percentage of total area. The secondary analysis will analyze relationship between the IER+MED intervention and total adiposity. Ethical Considerations The study will be performed in accordance with the ethical principles in the Declaration of Helsinki and the University of Hawaii operational and ethical guidelines for research and other applicable regulatory requirements. Participant information and consent Consent to enter the study will be sought from each participant only after a full explanation has been given, information has been provided and time allowed for consideration. The right of the participant to refuse to participate without giving reasons will be respecte . Discontinuation and withdrawal Participants are free to withdraw from the study at any time, without prejudice to further treatment. Participants may also be discontinued from the study at any time, at the discretion of the investigator. Requests by the participant to be withdrawn from the study should be made through the principal investigator. Confidentiality After the participant has consented, any information from the study will be stored on a secure password‐protected computer that will be accessible only to the research team. Trial data on anthropometry and activity meter data will be kept in a secure computer at the UHCC. The food & beverage images from the 4‐day mobile food records will be kept on a secure server. Data Handling and Record Keeping All data will be kept strictly confidential. Any individual volunteering to participate will be assigned a code number, with the link to identifying information only available to the few study staff that require this information. Identifying information will be maintained in separate secure computer files from the remainder of the data. All forms will be stored in locked file cabinets, and those with identifying information will be stored separately from the other forms. No analysis will ever identify participants individually. AN - CN-02041664 AU - Nct PY - 2018 ST - The Healthy Diet and Lifestyle Study T2 - https://clinicaltrials.gov/show/NCT03639350 TI - The Healthy Diet and Lifestyle Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02041664/full ID - 1615 ER - TY - JOUR AB - Background The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV associated anogenital high-grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in human immunodeficiency virus (HIV)-infected men who have sex with men, and women of qHPV to prevent persistent anal HPV infection. Baseline data are presented here. Methods Human immunodeficiency virus-infected men who have sex with men, and women 27 years or older without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high-resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed. Results Five hundred seventy-five (575) participants were enrolled (82% men and 18% women). Median age was 47 years. Race/ethnicity was 46% white, 31% black, and 20% Hispanic. Plasma HIV-1 RNA was less than 50 copies/mL in 83% and median CD4 T count was 602 cells/μL. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16, and 18 were detected in 25%, 13%, 32%, and 18% of the participants, respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with 1 or more qHPV type was detected in 10% of the participants. Study procedures were generally acceptable. Conclusions At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of the participants had anal infection with preventable qHPV types. AD - R.D. Cranston, Department of Medicine, University of Pittsburgh, Pittsburgh, PN, United States AU - Cranston, R. D. AU - Cespedes, M. S. AU - Paczuski, P. AU - Yang, M. AU - Coombs, R. W. AU - Dragavon, J. AU - Saah, A. AU - Godfrey, C. AU - Webster-Cyriaque, J. Y. AU - Chiao, E. Y. AU - Bastow, B. AU - Wilkin, T. DB - Embase Medline DO - 10.1097/OLQ.0000000000000745 IS - 4 KW - NCT01461096 antiretrovirus agent placebo virus RNA Wart virus vaccine adult anus cancer article cancer screening CD4 lymphocyte count controlled study cytology disease marker double blind procedure female genital tract cancer genotype human Human immunodeficiency virus infection Human papillomavirus type 11 Human papillomavirus type 16 Human papillomavirus type 18 Human papillomavirus type 6 human tissue major clinical study male men who have sex with men and women middle aged mouth cancer mouth infection multicenter study oral biopsy persistent infection phase 3 clinical trial prevalence randomized controlled trial serology virus detection Wart virus LA - English M3 - Article N1 - L621356979 2018-03-27 2018-04-03 PY - 2018 SN - 1537-4521 0148-5717 SP - 266-271 ST - High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298 T2 - Sexually Transmitted Diseases TI - High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621356979&from=export http://dx.doi.org/10.1097/OLQ.0000000000000745 VL - 45 ID - 903 ER - TY - JOUR AB - Background The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV associated anogenital high-grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in human immunodeficiency virus (HIV)-infected men who have sex with men, and women of qHPV to prevent persistent anal HPV infection. Baseline data are presented here. Methods Human immunodeficiency virus-infected men who have sex with men, and women 27 years or older without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high-resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed. Results Five hundred seventy-five (575) participants were enrolled (82% men and 18% women). Median age was 47 years. Race/ethnicity was 46% white, 31% black, and 20% Hispanic. Plasma HIV-1 RNA was less than 50 copies/mL in 83% and median CD4 T count was 602 cells/μL. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16, and 18 were detected in 25%, 13%, 32%, and 18% of the participants, respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with 1 or more qHPV type was detected in 10% of the participants. Study procedures were generally acceptable. Conclusions At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of the participants had anal infection with preventable qHPV types. Copyright © 2018 by the American Sexually Transmitted Diseases Association. Unauthorized reproduction of this article is prohibited. AD - Department of Medicine, University of Pittsburgh, Pittsburgh, PN, United States Icahn School of Medicine at Mount Sinai, New York City, NY, United States Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, United States Department of Laboratory Medicine, University of Washington, Seattle, WA, United States Department of Medicine, University of Washington, Seattle, WA, United States Merck and Co Inc., Kenilworth, NJ, United States Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States University of North Carolina, Chapel Hill, NC, United States Baylor College of Medicine, Waco, TX, United States Social and Scientific Systems Inc., Silver Spring, MD, United States Weill Cornell Medicine, New York City, NY, United States AU - Cranston, R. D. AU - Cespedes, M. S. AU - Paczuski, P. AU - Yang, M. AU - Coombs, R. W. AU - Dragavon, J. AU - Saah, A. AU - Godfrey, C. AU - Webster-Cyriaque, J. Y. AU - Chiao, E. Y. AU - Bastow, B. AU - Wilkin, T. DB - Scopus DO - 10.1097/OLQ.0000000000000745 IS - 4 M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2018 SP - 266-271 ST - High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298 T2 - Sexually Transmitted Diseases TI - High baseline anal human papillomavirus and abnormal anal cytology in a phase 3 trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected individuals older than 26 years: ACTG 5298 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044224418&doi=10.1097%2fOLQ.0000000000000745&partnerID=40&md5=b12640137d98e3f4451a51b730937019 VL - 45 ID - 2278 ER - TY - JOUR AB - Background The quadrivalent human papillomavirus (HPV) vaccine (qHPV; types 6, 11, 16, 18) is indicated for men and women aged 9 to 26 years to prevent HPV associated anogenital high-grade squamous intraepithelial lesions (HSIL) and cancer. ACTG 5298 was a randomized placebo controlled Phase 3 study in human immunodeficiency virus (HIV)-infected men who have sex with men, and women of qHPV to prevent persistent anal HPV infection. Baseline data are presented here. Methods Human immunodeficiency virus-infected men who have sex with men, and women 27 years or older without previous anogenital or oral cancer were enrolled. Baseline anal cytology, high-resolution anoscopy and collection of anal, oral, and vaginal specimens for HPV genotyping were performed and acceptability assessed. Results Five hundred seventy-five (575) participants were enrolled (82% men and 18% women). Median age was 47 years. Race/ethnicity was 46% white, 31% black, and 20% Hispanic. Plasma HIV-1 RNA was less than 50 copies/mL in 83% and median CD4 T count was 602 cells/L. Abnormal anal cytology was detected in 62%, with corresponding HSIL on biopsy (bHSIL) in 33%. Anal HPV 6, 11, 16, and 18 were detected in 25%, 13%, 32%, and 18% of the participants, respectively. Prevalence of 0, 1, 2, 3, and 4 qHPV types was 40%, 38%, 17%, 4%, and 1%, respectively. Oral infection with 1 or more qHPV type was detected in 10% of the participants. Study procedures were generally acceptable. Conclusions At study baseline, there was a high prevalence of abnormal anal cytology, bHSIL, and HPV infection. Sixty percent of the participants had anal infection with preventable qHPV types. AN - WOS:000428028200013 AU - Cranston, R. D. AU - Cespedes, M. S. AU - Paczuski, P. AU - Yang, M. AU - Coombs, R. W. AU - Dragavon, J. AU - Saah, A. AU - Godfrey, C. AU - Webster-Cyriaque, J. Y. AU - Chiao, E. Y. AU - Bastow, B. AU - Wilkin, T. DA - Apr DO - 10.1097/OLQ.0000000000000745 IS - 4 N1 - 29528986 PY - 2018 SN - 0148-5717 SP - 266-271 ST - High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298 T2 - Sexually Transmitted Diseases TI - High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298 VL - 45 ID - 2868 ER - TY - JOUR AB - Purpose Diabetes is common, increases with age, and may affect outcomes among people with cancer. Understanding the association between diabetes and cancer outcome is challenging, because patients with diabetes have increased all-cause mortality compared with patients without diabetes. Methods We systematically examined the phase III trial database of SWOG to identify patients enrolled in trials during the period from 1999 to 2011. We linked the SWOG clinical records to Medicare claims data according to Social Security number, sex, and date of birth. Medicare claims were used to identify diabetes with at least 6 months of continuous Medicare coverage immediately before registration. Multivariable Cox regression was used to compare survival outcomes between patients with and without diabetes for each of 10 tumor cohorts. The primary outcome was overall survival. We also examined progression-free survival and cancer-free survival. Results In total, 6,422 patients from 15 trials were ≥ 65.5 years of age, of whom 3,173 patients (49%) met the criteria for linkage to Medicare claims. Thirty percent (n = 952) had claims for diabetes before registration. Patients with diabetes were more likely to be black (P < .001), but no other differences in demographic characteristics were observed. In multivariable Cox regression, no association was found between baseline diabetes and overall or progression-free survival; in one case, patients with diabetes had marginally worse cancer-free survival (advanced non-small-cell lung cancer; P = .05). A global test found that baseline diabetes was associated with worse overall survival (P = .03) across the entire panel of analyses. Conclusion Diabetes is common among elderly patients enrolled in clinical trials. Unlike prior observational studies, among patients treated with uniform treatment regimens, and controlling for known prognostic factors, we did not observe an association between diabetes and progression-free or cancerfree survival. AD - D.L. Hershman, Columbia University Medical Center, 161 Fort Washington Ave, 10-1068, New York, NY, United States AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Ramsey, S. AU - Barlow, W. E. AU - Unger, J. M. DB - Embase Medline DO - 10.1200/CCI.17.00040 IS - 1 KW - advanced cancer aged article body weight loss breast cancer cancer patient cancer prognosis castration resistant prostate cancer cause of death controlled study demography diabetes mellitus female human major clinical study male medicare non small cell lung cancer overall survival priority journal progression free survival questionnaire self report LA - English M3 - Article N1 - L624452784 2018-10-24 2020-01-13 PY - 2017 SN - 2473-4276 SP - 1-12 ST - History of diabetes and survival outcome among participants 65 years or older in SWOG clinical trials T2 - JCO Clinical Cancer Informatics TI - History of diabetes and survival outcome among participants 65 years or older in SWOG clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624452784&from=export http://dx.doi.org/10.1200/CCI.17.00040 VL - 2017 ID - 950 ER - TY - JOUR AB - Purpose Diabetes is common, increases with age, and may affect outcomes among people with cancer. Understanding the association between diabetes and cancer outcome is challenging, because patients with diabetes have increased all-cause mortality compared with patients without diabetes. Methods We systematically examined the phase III trial database of SWOG to identify patients enrolled in trials during the period from 1999 to 2011. We linked the SWOG clinical records to Medicare claims data according to Social Security number, sex, and date of birth. Medicare claims were used to identify diabetes with at least 6 months of continuous Medicare coverage immediately before registration. Multivariable Cox regression was used to compare survival outcomes between patients with and without diabetes for each of 10 tumor cohorts. The primary outcome was overall survival. We also examined progression-free survival and cancer-free survival. Results In total, 6,422 patients from 15 trials were ≥ 65.5 years of age, of whom 3,173 patients (49%) met the criteria for linkage to Medicare claims. Thirty percent (n = 952) had claims for diabetes before registration. Patients with diabetes were more likely to be black (P < .001), but no other differences in demographic characteristics were observed. In multivariable Cox regression, no association was found between baseline diabetes and overall or progression-free survival; in one case, patients with diabetes had marginally worse cancer-free survival (advanced non-small-cell lung cancer; P = .05). A global test found that baseline diabetes was associated with worse overall survival (P = .03) across the entire panel of analyses. Conclusion Diabetes is common among elderly patients enrolled in clinical trials. Unlike prior observational studies, among patients treated with uniform treatment regimens, and controlling for known prognostic factors, we did not observe an association between diabetes and progression-free or cancerfree survival. © 2018 American Society of Clinical Oncology. AD - Columbia University Medical Center, New York, NY, United States SWOGStatistical Center, Fred Hutchinson Cancer Research Center, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Ramsey, S. AU - Barlow, W. E. AU - Unger, J. M. DB - Scopus DO - 10.1200/CCI.17.00040 IS - 1 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2017 SP - 1-12 ST - History of diabetes and survival outcome among participants 65 years or older in SWOG clinical trials T2 - JCO Clinical Cancer Informatics TI - History of diabetes and survival outcome among participants 65 years or older in SWOG clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077486396&doi=10.1200%2fCCI.17.00040&partnerID=40&md5=f8d8434ed638a93aecc177340eff15e1 VL - 2017 ID - 2325 ER - TY - JOUR AB - Purpose Diabetes is common, increases with age, and may affect outcomes among people with cancer. Understanding the association between diabetes and cancer outcome is challenging, because patients with diabetes have increased all-cause mortality compared with patients without diabetes. Methods We systematically examined the phase III trial database of SWOG to identify patients enrolled in trials during the period from 1999 to 2011. We linked the SWOG clinical records to Medicare claims data according to Social Security number, sex, and date of birth. Medicare claims were used to identify diabetes with at least 6 months of continuous Medicare coverage immediately before registration. Multivariable Cox regression was used to compare survival outcomes between patients with and without diabetes for each of 10 tumor cohorts. The primary outcome was overall survival. We also examined progression-free survival and cancer-free survival. Results In total, 6,422 patients from 15 trials were >= 65.5 years of age, of whom 3,173 patients (49%) met the criteria for linkage to Medicare claims. Thirty percent (n = 952) had claims for diabetes before registration. Patients with diabetes were more likely to be black (P< .001), but no other differences in demographic characteristics were observed. In multivariable Cox regression, no association was found between baseline diabetes and overall or progression-free survival; in one case, patients with diabetes had marginally worse cancer-free survival (advanced non-small-cell lung cancer; P= .05). A global test found that baseline diabetes was associated with worse overall survival (P = .03) across the entire panel of analyses. Conclusion Diabetes is common among elderly patients enrolled in clinical trials. Unlike prior observational studies, among patients treated with uniform treatment regimens, and controlling for known prognostic factors, we did not observe an association between diabetes and progression-free or cancer-free survival. (C) 2017 by American Society of Clinical Oncology AN - WOS:000462301600027 AU - Hershman, D. L. AU - Till, C. AU - Wright, J. D. AU - Ramsey, S. AU - Barlow, W. E. AU - Unger, J. M. DO - 10.1200/CCI.17.00040 N1 - 30657402 PY - 2017 SN - 2473-4276 ST - History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials T2 - Jco Clinical Cancer Informatics TI - History of Diabetes and Survival Outcome Among Participants 65 Years or Older in SWOG Clinical Trials VL - 1 ID - 2920 ER - TY - JOUR AB - Background: In the United States, 5-year survival rates of 69% and 84%, respectively, have recently been reported for African-American and Caucasian women diagnosed with breast cancer, Differences in the levels of endogenous sex hormones in these populations could explain some of the variation in survival rates, since estrogen is recognized as a risk factor for this type of cancer. Purpose: Dietary factors are known to affect endogenous hormone levels; therefore, our study was designed to determine the serum hormone levels of African-American women consuming a typical North American diet, to determine the effect of a low-fat and high-fiber diet on their serum hormone levels, and to compare the base-line serum hormone levels in the African-American women with hormone data from our study of Caucasian women (n = 68) consuming the same control diet, Methods: Twenty-one healthy, premenopausal, African-American women who agreed to eat only food prepared in a clinical study unit were recruited into the study, The control diet was similar to their usual diet, being high in fat (40% of calories from fat) and low in fiber (12 g/day), and was consumed on average for 3 weeks, The concentrations of estrone (E(1)), estrone sulfate (E(1)SO(4)), estradiol (E(2)), free E(2), androstenedione, and sex hormone-binding globulin (SHBG) in serum samples obtained from the participants during the last week of the control diet and during the follicular phase of their menstrual cycle were determined, The women were then switched to a diet Low in fat (20% of calories as fat) and high in fiber (40 g/day); they consumed this diet for two menstrual cycles before blood samples were collected for determination of serum hormone levels, Repeated-measures regression modeling was used to investigate the relationship between diet and hormone levels in African-American and Caucasian women, All P values resulted from two-sided statistical tests, Results: Analysis of serum hormone levels in the African-American women indicated that the change in diet caused a significant decrease in E(2) (-8.5%; 95% confidence interval [CI] = -16.1% to -0.3%; P less than or equal to.03) and E(1)SO(4) (-16.2%; 95% CI = -22.1% to -9.8%; P<.0001) and a significant increase in androstenedione levels (+18.3%; 95% CI = +10.3% to +26.8%; P<.0001). SHBG levels of the African-American women were 5.6% (95% CI = -14.0% to +3.7%) lower for those on the experimental diet compared with those on the control diet, but the difference was not statistically significant, Comparison of control serum hormone values in the African-American women in this study with those in Caucasian women previously studied indicated that the Caucasian women had statistically significant lower levels of E(1) (-37%; 95% CI = -61.2% to -16.4%; P less than or equal to.0002), E(2) (-54.5%; 95% CI = -90.9% to -25.1%; P less than or equal to.0001), free E(2) (-30.2%; 95% CI = -65.7% to -2.3%; P<.03), and androstenedione (-48.3%; 95% CI = -83.7% to -19.7%; P less than or equal to.0004), Conclusion: African-American women appear to have higher levels of serum hormones than Caucasian women, and dietary modification can result in a lowering of serum estrogens. AN - WOS:A1996VJ72500012 AU - Woods, M. N. AU - Barnett, J. B. AU - Spiegelman, D. AU - Trail, N. AU - Hertzmark, E. AU - Longcope, C. AU - Gorbach, S. L. DA - Oct 2 DO - 10.1093/jnci/88.19.1369 IS - 19 N1 - 77 8827014 PY - 1996 SN - 0027-8874 SP - 1369-1374 ST - Hormone levels during dietary changes in premenopausal African-American women T2 - Jnci-Journal of the National Cancer Institute TI - Hormone levels during dietary changes in premenopausal African-American women VL - 88 ID - 2735 ER - TY - JOUR AB - Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer. We evaluated the effect of several common, functional interleukin-6 promoter variants in node-positive breast cancer patients enrolled on a multicenter, cooperative group, adjuvant chemotherapy trial to determine whether these variants were associated with clinical outcome overall and by estrogen receptor tumor phenotype. Genomic DNA and clinical data were collected from a clinical trial of adjuvant anthracycline-based chemotherapy followed by randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121). Genotyping for -174G>C (rs1800795), -597G>A (rs1800797), and -572G>C (rs1800796) was done by site-specific PCR and PyroSequencing, whereas the -373AnTn repeat was directly sequenced. Log-rank tests and Cox modeling were used to compare outcomes by genotype/haplotype and other factors. Three hundred forty-six patients (64% of trial) had corresponding genotype/clinical data available and did not differ from overall trial participants. After adjustment, patients with estrogen receptor-positive tumors and genotypes 597 GG or 174 GG had significantly worse disease-free survival [hazard ratio (HR), 1.6; P = 0.02 and HR, 1.71; P = 0.007, respectively], whereas the 373 8A12T repeat appeared to be protective (HR, 0.62; P = 0.02). The presence of at least one copy of the haplotype ([-597G, -572G, -373[10A/11T], -174G]) was associated with worse disease-free survival (HR, 1.46; P = 0.04). Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41). ©2009 American Association for Cancer Research. AD - A. DeMichele, 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, United States AU - DeMichele, A. AU - Gray, R. AU - Horn, M. AU - Chen, J. AU - Aplenc, R. AU - Vaughan, W. P. AU - Tallman, M. S. DB - Embase Medline DO - 10.1158/0008-5472.CAN-08-2989 IS - 10 KW - anthracycline cyclophosphamide doxorubicin estrogen receptor fluorouracil genomic DNA interleukin 6 progesterone receptor tamoxifen thiotepa adjuvant therapy adult amino acid substitution article breast cancer cancer adjuvant therapy cancer combination chemotherapy cancer epidemiology cancer surgery clinical trial controlled study disease free survival drug megadose female genetic variability genotype haplotype hazard ratio human human cell Kaplan Meier method major clinical study multicenter study multiple cycle treatment outcome assessment partial mastectomy phenotype polymerase chain reaction priority journal promoter region pyrosequencing relapse single nucleotide polymorphism statistical significance treatment outcome L1 - internal-pdf://3450939384/4184.full.pdf LA - English M3 - Article N1 - L354662041 2009-06-19 PY - 2009 SN - 0008-5472 1538-7445 SP - 4184-4191 ST - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer T2 - Cancer Research TI - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354662041&from=export http://dx.doi.org/10.1158/0008-5472.CAN-08-2989 VL - 69 ID - 1191 ER - TY - JOUR AB - Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer. We evaluated the effect of several common, functional interleukin-6 promoter variants in node-positive breast cancer patients enrolled on a multicenter, cooperative group, adjuvant chemotherapy trial to determine whether these variants were associated with clinical outcome overall and by estrogen receptor tumor phenotype. Genomic DNA and clinical data were collected from a clinical trial of adjuvant anthracycline-based chemotherapy followed by randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121). Genotyping for -174G>C (rs1800795), -597G>A (rs1800797), and -572G>C (rs1800796) was done by site-specific PCR and PyroSequencing, whereas the -373AnTn repeat was directly sequenced. Log-rank tests and Cox modeling were used to compare outcomes by genotype/haplotype and other factors. Three hundred forty-six patients (64% of trial) had corresponding genotype/clinical data available and did not differ from overall trial participants. After adjustment, patients with estrogen receptor-positive tumors and genotypes 597 GG or 174 GG had significantly worse disease-free survival [hazard ratio (HR), 1.6; P = 0.02 and HR, 1.71; P = 0.007, respectively], whereas the 373 8A12T repeat appeared to be protective (HR, 0.62; P = 0.02). The presence of at least one copy of the haplotype ([-597G, -572G, -373[10A/11T], -174G]) was associated with worse disease-free survival (HR, 1.46; P = 0.04). Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41). ©2009 American Association for Cancer Research. AD - Department of Medicine (Hematology/Oncology), University of Pennsylvania School of Medicine, Philadelphia, PA, United States Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, United States Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Children's Hospital of Philadelphia, Philadelphia, PA, United States Eastern Cooperative Oncology Group, Boston, MA, United States University of Alabama at Birmingham, Birmingham, AL, United States Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, United States Robert Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States 14 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, United States AU - DeMichele, A. AU - Gray, R. AU - Horn, M. AU - Chen, J. AU - Aplenc, R. AU - Vaughan, W. P. AU - Tallman, M. S. DB - Scopus DO - 10.1158/0008-5472.CAN-08-2989 IS - 10 M3 - Article N1 - Cited By :35 Export Date: 22 March 2021 PY - 2009 SP - 4184-4191 ST - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer T2 - Cancer Research TI - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-66249125053&doi=10.1158%2f0008-5472.CAN-08-2989&partnerID=40&md5=91b62f0964ae1a4707cadb74174218fe VL - 69 ID - 2523 ER - TY - JOUR AB - Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer. We evaluated the effect of several common, functional interleukin-6 promoter variants in node-positive breast cancer patients enrolled on a multicenter, cooperative group, adjuvant chemotherapy trial to determine whether these variants were associated with clinical outcome overall and by estrogen receptor tumor phenotype. Genomic DNA and clinical data were collected from a clinical trial of adjuvant anthracycline-based chemotherapy followed by randomization to high-dose cyclophosphamide/thiotepa or observation (Intergroup Trial 0121). Genotyping for -174G > C (rs1800795), -597G > A (rs1800797), and -572G > C (rs1800796) was done by site-specific PCR and PyroSequencing, whereas the -373A(n)T(n) repeat was directly sequenced. Log-rank tests and Cox modeling were used to compare outcomes by genotype/haplotype and other factors. Three hundred forty-six patients (64% of trial) had corresponding genotype/clinical data available and did not differ from overall trial participants. After adjustment, patients with estrogen receptor-positive tumors and genotypes 597 GC or 174 GG had significantly worse disease-free survival [hazard ratio (HR), 1.6; P = 0.02 and HR, 1.71; P = 0.007, respectively], whereas the 373 8A12T repeat appeared to be protective (HR, 0.62; P = 0.02). The presence of at least one copy of the haplotype ([-597G, -572G, -373[10A/11T], -174G]) was associated with worse disease-free survival (HR, 1.46; P = 0.04). Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41). [Cancer Res 2009;69(10);4184-91] AN - WOS:000266214400014 AU - DeMichele, A. AU - Gray, R. AU - Horn, M. AU - Chen, J. B. AU - Aplenc, R. AU - Vaughan, W. P. AU - Tallman, M. S. DA - May DO - 10.1158/0008-5472.CAN-08-2989 IS - 10 N1 - 19435922 PY - 2009 SN - 0008-5472 SP - 4184-4191 ST - Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer T2 - Cancer Research TI - Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer VL - 69 ID - 3149 ER - TY - JOUR AB - Background: Hematopoietic cell transplants (HCTs) are associated with high morbidity and mortality, which complicate the decision-making process for people considering HCT clinical trials. There is a lack of research examining longitudinally how patients make clinical trial participation decisions in US cancer referral centers. Objective: A qualitative study was conducted to examine how patients and their family caregivers decide to participate in HCT research at a US cancer referral center. Methods: Semistructured interviews were conducted with 25 patients enrolled in early-stage phase 2 HCT research studies and with 20 family caregivers. Interviews were conducted before HCT and approximately days 80 and 365 after HCT. Results: Most patients (92%) and their caregivers (75%) decided to participate in research well before consent conferences at the cancer referral center. Patients' reasons for deciding to participate included having "no other option," seeking a cure, and following their home oncologists' recommendations. Conclusion: Currently, US researchers are primarily guided by Federal regulations that view the decision-making process as a cognitive one. Findings confirmed cognition was a part of consent; however, most patients made the decision to participate in high-risk clinical trials long before they had been apprised of the specific information about the study and before the consent conference. Implications for Practice: The high risk of death from the disease and/or the HCT underscored the emotional component of decision making and affirmed that researchers need to acknowledge this emotional component to meet the ethical imperative of providing "informed consent. © 2011 Lippincott Williams & Wilkins. AD - Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 1100 Fairview Ave N, Seattle, WA 98109-1024, United States Nursing Program, University of Washington, Tacoma, United States AU - Shannon-Dorcy, K. AU - Drevdahl, D. J. DB - Scopus DO - 10.1097/NCC.0b013e318207cb03 IS - 6 KW - Clinical trial (or clinicaltrial phase 2) Decision making Ethics Hematologic neoplasms Hematopoietic stem cell Informed consent Qualitative research transplant M3 - Article N1 - Cited By :23 Export Date: 22 March 2021 PY - 2011 SP - 428-433 ST - I had already made up my mind: Patients and caregivers' perspectives on making the decision to participate in research at a us cancer referral center T2 - Cancer Nursing TI - I had already made up my mind: Patients and caregivers' perspectives on making the decision to participate in research at a us cancer referral center UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80255138865&doi=10.1097%2fNCC.0b013e318207cb03&partnerID=40&md5=79291f92b563f6553240b5bfa1cc53a7 VL - 34 ID - 2469 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To describe problems chosen as targets of problem-solving therapy by spouses and partners of patients with prostate cancer. DESIGN: Descriptive, cross-sectional. SETTING: Spouses' and partners' homes. SAMPLE: Spouses and partners (N = 66) aged 32-79 years (mean = 60 years). The sample was predominantly Caucasian (82%) and African American (8%). METHODS: As part of a randomized clinical trial, women received problem-solving therapy to help manage issues related to their husbands' or partners' prostate cancer. The issues they chose to address during therapy and the categorization of the issues fell into four groups: treatment and side-effect issues, patient issues, family issues, and spouse issues. Scores on the Social Problem-Solving Inventory-Revised, which measures everyday problem-solving skills, and the Profile of Mood States, which measures mood disturbance, were contrasted with the problems women chose to address. MAIN RESEARCH VARIABLES: Problems faced by spouses and partners of patients with prostate cancer. FINDINGS: The most frequently reported categories were spouse issues (e.g., women's emotional wellness, balancing their medical concerns with their husbands' condition) and patient issues (e.g., men's lack of communication, fear, or depression). CONCLUSIONS: Findings of this study alert nurses to a variety of key problem areas for spouses and partners of patients with prostate cancer. IMPLICATIONS FOR NURSING: Spouses and partners play a critical role when their loved ones have cancer. Understanding the problems spouses and partners face can help nurses design optimal supportive care interventions. AD - Research Assistant, Rebecca and John Moores University of California, San Diego, Cancer Center AN - 106323409. Language: English. Entry Date: 20060825. Revision Date: 20200708. Publication Type: Journal Article AU - Hawes, S. M. AU - Malcarne, V. L. AU - Ko, C. M. AU - Sadler, G. R. AU - Banthia, R. AU - Sherman, S. A. AU - Varni, J. W. AU - Schmidt, J. DB - CINAHL Complete DO - 10.1188/06.ONF.807-814 DP - EBSCOhost IS - 4 KW - Problem Identification Prostatic Neoplasms Spouses -- Psychosocial Factors Adult Aged California Chi Square Test Coding Communication Cross Sectional Studies Decision Making Descriptive Research Descriptive Statistics Experimental Studies Female Funding Source Interrater Reliability Kappa Statistic Male Middle Age Multivariate Analysis of Variance Nonparametric Statistics Problem Solving -- Education Psychological Tests Psychological Well-Being Questionnaires Record Review Research Subject Recruitment Secondary Analysis Summated Rating Scaling Thematic Analysis Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Instrumentation: Profile of Mood States (POMS); Social Problem-Solving Inventory-Revised (SPSI-R) (D'Zurilla et al). Grant Information: Funded by the California Cancer Research Program (No. 99-00556V-10049), the National Cancer Institute (No. R25 CA 65745), the Rebecca and John Moores UCSD Cancer Center Fund, and by the McNair Scholars program through a grant from the U.S. Department of Education (NO. P217A030016). NLM UID: 7809033. PMID: NLM16858462. PY - 2006 SN - 0190-535X SP - 807-814 ST - Identifying problems faced by spouses and partners of patients with prostate cancer T2 - Oncology Nursing Forum TI - Identifying problems faced by spouses and partners of patients with prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106323409&site=ehost-live&scope=site VL - 33 ID - 1971 ER - TY - THES AB - Rationale: Breast cancer is the most commonly diagnosed cancer, excluding skin cancers, and is the second leading cause of cancer death among women in the United States. Despite advancements in screening, early detection, and cancer treatments, not all women have benefited equally. Racial and ethnic minorities, particularly African American women, and those of low income have higher breast cancer mortality rates compared to the general population. Previous research has identified a number of demographic (e.g., race/ethnicity, age, health insurance, income), medical (e.g., comorbidities with other illnesses, family medical history), environmental (e.g., geographic area), and health system (e.g., type of cancer-related services available) factors associated with breast cancer disparities. However, these factors have largely been examined individually, and no study has comprehensively evaluated how multiple individual and contextual factors impact breast cancer outcomes. Therefore, this dissertation project had two primary aims: 1) to identify distinct subgroups of breast cancer patients based on demographic, medical, environmental, and health system factors that have been shown to influence timeliness of breast cancer care, and 2) to examine differences among emergent classes in timely initiation of breast cancer treatment. Design: The proposed study used archival data from the control arm of the Patient Navigation Research Project (PNRP), a five-year 10-site clinical trial of adult patients from medically underserved populations with an abnormal cancer screening or a new diagnosis of breast, cervical, colorectal, or prostate cancer. For this study, the sample included 198 patients with newly diagnosed Stage I-III breast cancer who received usual standard of care (control arm) from four PNRP sites, and who received a treatment for breast cancer (e.g., surgery, chemotherapy, radiation, hormonal therapy). Control participants were primarily recruited via medical record abstraction for which informed consent was waived. Exploratory Latent Class Analysis (LCA) was used to identify subgroups of breast cancer patients based on demographic (race/ethnicity, age at diagnosis, health insurance status, annual household income), medical (comorbidities [Charlson Comorbidity Index], family history of cancer), environmental (geographic residence [urban vs. rural], and health system (cancer-related services available onsite) factors associated with timeliness of breast cancer care. For the second aim, the study conducted logistic regression analyses to examine if class membership significantly predicted timely breast cancer treatment initiation, defined as initiation of any treatment for breast cancer (e.g., surgery, chemotherapy, radiation, hormonal therapy) within 30 or 60 days of diagnosis, controlling for type of breast cancer treatment. Results: Three classes of breast cancer patients were identified with varying patterns of patient demographic, medical, and health system characteristics. The first class was distinguished by its high endorsement of indicators associated with timely breast cancer care; patients in this class were most likely to be White, have private health insurance, and have a family history of cancer. The second class was characterized by individual and contextual factors associated with treatment delays, including having public health insurance, not having a family history of cancer, and receiving care at a facility with the least amount of breast cancer services available onsite. The third class represented breast cancer patients with the oldest average age at diagnosis and the greatest number of medical comorbidities. Binomial logistic regression analyses demonstrated that the emergent classes did not significantly differ in the likelihood of initiating breast cancer treatment within 30 days or 60 days from breast cancer… (PsycINFO Database Record (c) 2018 APA, all rights reserved) AN - 2018-48575-218 AU - Baik, Sharon Hyun DB - psyh DP - EBSCOhost KW - breast cancer patients treatment initiation topologies Breast Neoplasms Cancer Screening Treatment N1 - Accession Number: 2018-48575-218. Other Journal Title: Dissertation Abstracts International. Partial author list: First Author & Affiliation: Baik, Sharon Hyun; University of California, San Diego, Clin Psychology, US. Release Date: 20181022. Publication Type: Dissertation Abstract (0400). Format Covered: Electronic. Document Type: Dissertation. Dissertation Number: AAI10825538. ISBN: 978-0438204164. Language: English. Major Descriptor: Breast Neoplasms; Cancer Screening; Treatment. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Methodology: Empirical Study; Quantitative Study. PB - ProQuest Information & Learning PY - 2018 SN - 0419-4217 978-0438204164 ST - Identifying typologies of breast cancer patients based on multiple individual and contextual factors for timely treatment initiation TI - Identifying typologies of breast cancer patients based on multiple individual and contextual factors for timely treatment initiation UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-48575-218&site=ehost-live&scope=site VL - 79 ID - 1685 ER - TY - JOUR AB - Purpose: We evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. Materials and Methods: Patients considered at high risk for progression to metastatic disease (prostate specific antigen 10 ng/ml or greater, or prostate specific antigen doubling time 10 months or less) received abiraterone acetate plus prednisone daily in 28-day cycles. The primary study end point was the proportion of patients in whom a 50% or greater prostate specific antigen reduction was achieved during cycles 1 to 6. Secondary end points included time to prostate specific antigen progression, time to radiographic evidence of disease progression and safety. Results: Of the 131 enrolled patients 44 (34%) remained on treatment with a median followup of 40.0 months. Median age was 72 years (range 48 to 90). Of the patients 82.4% were white and 14.5% were black. Median screening prostate specific antigen was 11.9 ng/dl and median prostate specific antigen doubling time was 3.4 months. Prostate specific antigen was significantly reduced (p <0.0001) with a 50% or greater prostate specific antigen reduction in 86.9% of cases and a 90% or greater reduction in 59.8%. Median time to prostate specific antigen progression was 28.7 months (95% CI 21.2–38.2). Median time to radiographic evidence of disease progression was not reached but on sensitivity analysis in 15 patients it was estimated to be 41.4 months (95% CI 27.6–not estimable). Baseline testosterone 12.5 ng/dl or greater and a 90% or greater prostate specific antigen reduction at cycle 3 were associated with longer time to prostate specific antigen progression and radiographic evidence of disease progression. Outcomes in black patients were similar to those in other patients. Adverse events, grade 3 or greater adverse events and serious adverse events were reported in 96.2%, 61.1% and 43.5% of patients, respectively. Conclusions: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone. © 2018 American Urological Association Education and Research, Inc. AD - Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, United States University of Colorado Cancer Center, Aurora, Colorado, United States Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States Roswell Park Cancer Institute, Buffalo, New York, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States AU - Ryan, C. J. AU - Crawford, E. D. AU - Shore, N. D. AU - Underwood, W., III AU - Taplin, M. E. AU - Londhe, A. AU - Francis, P. S. J. AU - Phillips, J. AU - McGowan, T. AU - Kantoff, P. W. DB - Scopus DO - 10.1016/j.juro.2018.03.125 IS - 2 KW - abiraterone acetate adverse events prednisone prostate-specific antigen prostatic neoplasms M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 2018 SP - 344-352 ST - The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer T2 - Journal of Urology TI - The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048726451&doi=10.1016%2fj.juro.2018.03.125&partnerID=40&md5=8bae22cfd64775e5781b1e7c59777dce VL - 200 ID - 2265 ER - TY - JOUR AB - Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia. AN - WOS:000300044800019 AU - Hillman, R. J. AU - Giuliano, A. R. AU - Palefsky, J. M. AU - Goldstone, S. AU - Moreira, E. D. AU - Vardas, E. AU - Aranda, C. AU - Jessen, H. AU - Ferris, D. G. AU - Coutlee, F. AU - Marshall, J. B. AU - Vuocolo, S. AU - Haupt, R. M. AU - Guris, D. AU - Garner, E. I. O. DA - Feb DO - 10.1128/CVI.05208-11 IS - 2 N1 - 22155768 PY - 2012 SN - 1556-6811 SP - 261-267 ST - Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old T2 - Clinical and Vaccine Immunology TI - Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old VL - 19 ID - 3076 ER - TY - JOUR AB - Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia. Copyright © 2012, American Society for Microbiology. All Rights Reserved. AD - R.J. Hillman, STI Research Centre, University of Sydney, Sydney, NSW, Australia AU - Hillman, R. J. AU - Giuliano, A. R. AU - Palefsky, J. M. AU - Goldstone, S. AU - Moreira Jr, E. D. AU - Vardas, E. AU - Aranda, C. AU - Jessen, H. AU - Ferris, D. G. AU - Coutlee, F. AU - Marshall, J. B. AU - Vuocolo, S. AU - Haupt, R. M. AU - Guris, D. AU - Garner, E. I. O. C1 - gardasil(Merck) silgard(Merck) C2 - Merck DB - Embase Medline DO - 10.1128/CVI.05208-11 IS - 2 KW - NCT00090285 aluminum hydroxyphosphate sulfate immunological adjuvant placebo unclassified drug virus antibody Wart virus vaccine adolescent adult African American age antibody response antibody titer article Asian blood sampling Caucasian controlled study double blind procedure drug dose regimen drug efficacy drug safety ethnic difference heterosexual male Hispanic human human experiment Human papillomavirus type 11 Human papillomavirus type 16 Human papillomavirus type 18 Human papillomavirus type 6 immunoassay immunogenicity male multicenter study normal human priority journal randomized controlled trial seroconversion sexuality smoking vaccination gardasil silgard LA - English M3 - Article N1 - L364176939 2012-02-08 2012-02-17 PY - 2012 SN - 1556-6811 1556-679X SP - 261-267 ST - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old T2 - Clinical and Vaccine Immunology TI - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364176939&from=export http://dx.doi.org/10.1128/CVI.05208-11 http://cvi.asm.org/content/19/2/261.full.pdf+html VL - 19 ID - 1125 ER - TY - JOUR AB - Human papillomavirus (HPV) infection can lead to significant disease in males, including anogenital warts, intraepithelial neoplasias, and several types of oral and anogenital cancers. The quadrivalent HPV (type 6/11/16/18) L1 virus-like particle (VLP) vaccine (qHPV vaccine; Gardasil) has recently been demonstrated to prevent persistent infection and associated disease related to vaccine HPV types in males. We report the overall immunogenicity results from a trial of the quadrivalent HPV vaccine in males. Overall, 3,463 heterosexual men and 602 men who had sex with men were enrolled into a randomized, placebo-controlled, double-blind safety, immunogenicity, and efficacy study. Serum samples were collected prior to vaccination at day 1 and at months 7, 24, and 36 postvaccination. Immunogenicity was evaluated with a multiplex, competitive Luminex immunoassay. Almost all subjects (97.4 to 99.2%) seroconverted for vaccine HPV types by month 7. At month 36, 88.9%, 94.0%, 97.9%, and 57.0% of subjects were still seropositive for HPV-6, -11, -16, and -18, respectively. For all vaccine HPV types, black subjects had significantly higher antibody titers at month 7 than did both Caucasian and Asian subjects. An anamnestic antibody response was seen in men seropositive before vaccination. The vaccine was highly immunogenic in males 16 to 23 years of age; responses were comparable to those observed in women. Furthermore, the immune responses were consistent with the established efficacy of the vaccine in the prevention of incident and persistent HPV infection, anogenital warts, and anal intraepithelial neoplasia. Copyright © 2012, American Society for Microbiology. All Rights Reserved. AD - STI Research Centre, University of Sydney, Sydney, NSW, Australia Risk Assessment, Detection, and Intervention Program, H. Lee Moffitt Cancer Center, Research Institute, Tampa, FL, United States Department of Medicine, University of California San Francisco, San Francisco, CA, United States Mount Sinai School of Medicine, New York, NY, United States Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Brazilian Ministry of Health, Bahia, Brazil Division of Medical Virology, University of Stellenbosch, South Africa Lancet Laboratories, Johannesburg, South Africa University Medical Center, National Public Health Institute, Morelos, Mexico J2 Private Clinic for Infectious Diseases, Berlin, Germany Gynecologic Cancer Prevention Center, Georgia Health Sciences University, Augusta, GA, United States Centre de Recherche du CHUM, Université de Montréal, Montréal, QC, Canada Merck and Co., Inc., North Wales, PA, United States AU - Hillman, R. J. AU - Giuliano, A. R. AU - Palefsky, J. M. AU - Goldstone, S. AU - Moreira Jr, E. D. AU - Vardas, E. AU - Aranda, C. AU - Jessen, H. AU - Ferris, D. G. AU - Coutlee, F. AU - Marshall, J. B. AU - Vuocolo, S. AU - Haupt, R. M. AU - Guris, D. AU - Garner, E. I. O. DB - Scopus DO - 10.1128/CVI.05208-11 IS - 2 M3 - Article N1 - Cited By :66 Export Date: 22 March 2021 PY - 2012 SP - 261-267 ST - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old T2 - Clinical and Vaccine Immunology TI - Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856473763&doi=10.1128%2fCVI.05208-11&partnerID=40&md5=2fdde88d53130fcb34cdec9bcf97286f VL - 19 ID - 2465 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] >= 30 kg/m(2)) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change. AN - WOS:000523677900001 AU - Babatunde, O. A. AU - Adams, S. A. AU - Truman, S. AU - Sercy, E. AU - Murphy, A. E. AU - Khan, S. AU - Hurley, T. G. AU - Wirth, M. D. AU - Choi, S. K. AU - Johnson, H. AU - Hebert, J. R. DA - Aug DO - 10.1080/03630242.2020.1746950 IS - 7 N1 - 32248760 PY - 2020 SN - 0363-0242 SP - 792-805 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women T2 - Women & Health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women VL - 60 ID - 2785 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C‐reactive protein (CRP), interleukin‐6 (IL‐6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community‐based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait‐list control group (n = 161). Linear mixed‐effect models were used for analyses of CRP and IL‐6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL‐6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL‐6, a significant decrease was observed in DII score for the intervention group, indicating short‐term positive dietary change. AN - CN-02096503 AU - Babatunde, O. A. AU - Arp Adams, S. AU - Truman, S. AU - Sercy, E. AU - Murphy, A. E. AU - Khan, S. AU - Hurley, T. G. AU - Wirth, M. D. AU - Choi, S. K. AU - Johnson, H. AU - et al. DO - 10.1080/03630242.2020.1746950 KW - *African American *breast cancer *chronic inflammation *diet *obesity *physical activity Adult Article Body fat Body mass Cancer risk Controlled study Female Gene expression Human Human tissue Lifestyle Major clinical study Protein expression Randomized controlled trial South Carolina Waist circumference M3 - Journal: Article in Press PY - 2020 SP - 1‐14 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women T2 - Women & health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02096503/full ID - 1495 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change. AU - Babatunde, O. A. AU - Arp Adams, S. AU - Truman, S. AU - Sercy, E. AU - Murphy, A. E. AU - Khan, S. AU - Hurley, T. G. AU - Wirth, M. D. AU - Choi, S. K. AU - Johnson, H. AU - Hebert, J. R. DB - Medline DO - 10.1080/03630242.2020.1746950 IS - 7 KW - adult African American article body fat body mass breast cancer cancer risk chronic inflammation controlled study diet female gene expression human human tissue lifestyle major clinical study obesity physical activity protein expression randomized controlled trial South Carolina waist circumference C reactive protein endogenous compound interleukin 6 LA - English M3 - Article N1 - L631452361 2020-04-20 PY - 2020 SN - 1541-0331 SP - 792-805 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women T2 - Women & health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631452361&from=export http://dx.doi.org/10.1080/03630242.2020.1746950 VL - 60 ID - 795 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Arp Adams, Swann AN - 2020-25174-001 AU - Babatunde, Oluwole Adeyemi AU - Arp Adams, Swann AU - Truman, Samantha AU - Sercy, Erica AU - Murphy, Angela E. AU - Khan, Samira AU - Hurley, Thomas G. AU - Wirth, Michael D. AU - Choi, Seul Ki AU - Johnson, Hiluv AU - Hebert, James R. DB - psyh DO - 10.1080/03630242.2020.1746950 DP - EBSCOhost KW - African Americans breast cancer c-reactive protein dietary Inflammatory Index inflammation No terms assigned N1 - Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, US. Other Publishers: Haworth Press. Release Date: 20200409. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Language: English. Major Descriptor: No terms assigned. Classification: General Psychology (2100). Publication History: Accepted Date: Mar 15, 2020; Revised Date: Feb 10, 2020; First Submitted Date: Jun 12, 2019. Copyright Statement: Taylor & Francis. 2020. PY - 2020 SN - 0363-0242 1541-0331 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese african-american women T2 - Women & Health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese african-american women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-25174-001&site=ehost-live&scope=site ADAMSS@mailbox.sc.edu ID - 1677 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p =.02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change. AD - Cancer Prevention and Control Program, University of South Carolina, Columbia, South Carolina, USA Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA College of Nursing, University of South Carolina, Columbia, South Carolina, USA Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina, USA Connecting Health Innovations LLC, Columbia, South Carolina, USA Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA AN - 144501444. Language: English. Entry Date: 20200718. Revision Date: 20200718. Publication Type: Article AU - Babatunde, Oluwole Adeyemi AU - Arp Adams, Swann AU - Truman, Samantha AU - Sercy, Erica AU - Murphy, Angela E. AU - Khan, Samira AU - Hurley, Thomas G. AU - Wirth, Michael D. AU - Choi, Seul Ki AU - Johnson, Hiluv AU - Hebert, James R. DB - CINAHL Complete DO - 10.1080/03630242.2020.1746950 DP - EBSCOhost IS - 7 KW - Diet -- Evaluation -- United States Physical Activity -- Evaluation -- United States Inflammation -- Prevention and Control -- United States Obesity -- Prevention and Control -- United States Women's Health -- United States Black Persons -- United States Human Randomized Controlled Trials Adipose Tissue -- Analysis Female C-Reactive Protein -- Blood Interleukins -- Blood Scales Body Mass Index United States Waist Circumference Chronic Disease -- Prevention and Control Breast Neoplasms -- Risk Factors Breast Neoplasms -- Prevention and Control N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Dietary Inflammatory Index (DII). NLM UID: 9421509. PY - 2020 SN - 0363-0242 SP - 792-805 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women T2 - Women & Health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144501444&site=ehost-live&scope=site VL - 60 ID - 2124 ER - TY - JOUR AB - Lifestyle interventions may reduce inflammation and lower breast cancer (BrCa) risk. This randomized trial assessed the impact of the Sistas Inspiring Sistas Through Activity and Support (SISTAS) study on plasma C-reactive protein (CRP), interleukin-6 (IL-6) and Dietary Inflammatory Index (DII). This unblinded, dietary and physical activity trial was implemented in 337 obese (body mass index [BMI] ≥30 kg/m2) African American (AA) women recruited between 2011 and 2015 in South Carolina through a community-based participatory approach with measurements at baseline, 3 months, and 12 months. Participants were randomized into either intervention (n = 176) or wait-list control group (n = 161). Linear mixed-effect models were used for analyses of CRP and IL-6. Baseline CRP was significantly higher in those with greater obesity, body fat percentage, and waist circumference (all p <.01). No difference was observed between groups for CRP or IL-6 at 3 or 12 months; however, improvements in diet were observed in the intervention group compared to the control group (p = .02) at 3 months but were not sustained at 12 months. Although the intervention was not successful at reducing levels of CRP or IL-6, a significant decrease was observed in DII score for the intervention group, indicating short-term positive dietary change. © 2020, © 2020 Taylor & Francis Group, LLC. AD - Cancer Prevention and Control Program, University of South Carolina, Columbia, SC, United States Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States College of Nursing, University of South Carolina, Columbia, SC, United States Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, United States Connecting Health Innovations LLC, Columbia, SC, United States Department of Health Promotion, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States AU - Babatunde, O. A. PhD AU - Arp Adams, S. PhD AU - Truman, S. AU - Sercy, E. Msph AU - Murphy, A. E. PhD AU - Khan, S. Msw AU - Hurley, T. G. Ms AU - Wirth, M. D. PhD AU - Choi, S. K. PhD AU - Johnson, H. Ba AU - Hebert, J. R. ScD DB - Scopus DO - 10.1080/03630242.2020.1746950 IS - 7 KW - African Americans breast cancer c-reactive protein dietary Inflammatory Index inflammation M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2020 SP - 792-805 ST - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women T2 - Women and Health TI - The impact of a randomized dietary and physical activity intervention on chronic inflammation among obese African-American women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082976663&doi=10.1080%2f03630242.2020.1746950&partnerID=40&md5=11668d4683605eed9ed4a18a3320290f VL - 60 ID - 2184 ER - TY - JOUR AB - Objective To evaluate active surveillance (AS) criteria on their ability to predict favorable pathology at prostatectomy within a low-risk African American (AA) cohort. Methods The sensitivity, specificity, positive predictive value, receiver operator curve, and area under the curve (AUC) were compared for 6 published AS criteria (National Comprehensive Cancer Network; Memorial Sloan-Kettering Cancer Center; Prostate Cancer Research International: Active Surveillance Study; Johns Hopkins-Epstein; University of California at San Francisco; and University of Miami) to predict organ-confined Gleason score 6 disease at prostatectomy in AAs and white Americans (WAs) with low-risk cancer. We also compared clinical parameters for AAs with favorable prostatectomy pathology with those for AAs with unfavorable pathology, and then used preoperative variables associated with unfavorable pathology as an additional exclusion criteria for AS. Results Of 468 patients with low-risk disease, 308 of 402 (76.6%) WAs and 55 of 66 (83.3%) AAs were eligible for AS by one or more criteria (P =.23). For WAs, Prostate Cancer Research International: Active Surveillance Study criteria had the highest rate of favorable pathology (81.7%) and the best performance (AUC = 0.70) in determining appropriate candidates for AS. However, all 6 AS criteria performed poorly for AA patients, with all AUCs 0.52. When comparing AAs with favorable pathology with AAs with unfavorable pathology, only family history of prostate cancer was statistically significant (11 of 25 [47.8%] vs 8 of 41 [22.2%]; P =.04). When adjusting AS criteria in AAs to exclude those with a positive family history, the AUC increased most for the University of California at San Francisco (from 0.52 to 0.6) and Memorial Sloan-Kettering Cancer Center criteria (from 0.50 to 0.58). Conclusion Current criteria underperform in appropriately selecting AAs for AS. AAs considering AS should be counseled about their increased risk for occult adverse pathology, particularly if a family history of prostate cancer is present. AD - E.J. Pietzak, Division of Urology, Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA, United States AU - Pietzak, E. J. AU - Van Arsdalen, K. AU - Patel, K. AU - Malkowicz, S. B. AU - Wein, A. J. AU - Guzzo, T. J. DB - Embase Medline DO - 10.1016/j.urology.2014.09.065 IS - 2 KW - active surveillance adult African American article cancer center cancer epidemiology cancer patient cancer surgery cohort analysis controlled study diagnostic test accuracy study hereditary tumor syndrome family history Gleason score human low risk patient major clinical study male middle aged multicenter study parameters pathophysiology patient selection predictive value predictor variable preoperative evaluation priority journal prostate cancer prostatectomy race difference receiver operating characteristic risk factor sensitivity and specificity trend study LA - English M3 - Article N1 - L601696425 2015-01-29 2015-02-06 PY - 2015 SN - 1527-9995 0090-4295 SP - 436-441 ST - Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer T2 - Urology TI - Impact of race on selecting appropriate patients for active surveillance with seemingly low-risk prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L601696425&from=export http://dx.doi.org/10.1016/j.urology.2014.09.065 VL - 85 ID - 1012 ER - TY - JOUR AD - Division of Urology, Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA. Electronic address: Eugene.pietzak@uphs.upenn.edu. Division of Urology, Department of Surgery, Hospital of University of Pennsylvania, Philadelphia, PA. AN - 103747130. Language: English. Entry Date: 20150417. Revision Date: 20200708. Publication Type: Journal Article AU - Pietzak, Eugene J. AU - Van Arsdalen, Keith AU - Patel, Kinnari AU - Malkowicz, S. Bruce AU - Wein, Alan J. AU - Guzzo, Thomas J. DB - CINAHL Complete DO - 10.1016/j.urology.2014.09.065 DP - EBSCOhost IS - 2 KW - Black Persons Outcomes (Health Care) Patient Selection Prostatectomy Prostatic Neoplasms -- Surgery White Persons Clinical Assessment Tools Human Male Middle Age Retrospective Design Risk Assessment N1 - research. Journal Subset: Biomedical; USA. Instrumentation: Gleason Score. NLM UID: 0366151. PMID: NLM25623715. PY - 2015 SN - 0090-4295 SP - 436-441 ST - Impact of Race on Selecting Appropriate Patients for Active Surveillance With Seemingly Low-risk Prostate Cancer T2 - Urology TI - Impact of Race on Selecting Appropriate Patients for Active Surveillance With Seemingly Low-risk Prostate Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103747130&site=ehost-live&scope=site VL - 85 ID - 1973 ER - TY - JOUR AB - Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. Logistic regression generated odds ratios (OR) and 95 % confidence intervals (CI) for the associations of race, ethnicity, and BMI with in-breast pCR adjusting for subtype, study arm, lymph node status, tumor size, and tumor grade. 253 (14.1 %) were black, 199 (11.1 %) Hispanic, 520 (28.9 %) overweight, and 743 (41.4 %) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor subtype. In multivariate analyses, neither race (black vs white: OR 1.18, 95 % CI 0.85–1.62) nor ethnicity (Hispanic vs non-Hispanic; OR 1.30, 95 % CI 0.67–2.53) were significant predictors of pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER+/HER2+, but higher pCR rates in ER−/HER2+ cancers. There was no difference in pCR according to race or ethnicity. Overall, there was no major difference in pCR rates by BMI. These findings suggest that pCR with optimally dosed NST is a function of tumor, rather than patient, biology. AD - E.T. Warner, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, United States AU - Warner, E. T. AU - Ballman, K. V. AU - Strand, C. AU - Boughey, J. C. AU - Buzdar, A. U. AU - Carey, L. A. AU - Sikov, W. M. AU - Partridge, A. H. DB - Embase Medline DO - 10.1007/s10549-016-3918-5 IS - 1 KW - epidermal growth factor receptor 2 estrogen receptor adjuvant chemotherapy adult article Black person body mass breast cancer cancer grading Caucasian ethnic difference ethnicity female Hispanic human major clinical study obesity priority journal prospective study treatment response triple negative breast cancer tumor volume LA - English M3 - Article N1 - L611380923 2016-08-02 2016-09-14 PY - 2016 SN - 1573-7217 0167-6806 SP - 109-118 ST - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) T2 - Breast Cancer Research and Treatment TI - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611380923&from=export http://dx.doi.org/10.1007/s10549-016-3918-5 VL - 159 ID - 967 ER - TY - JOUR AB - Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. Logistic regression generated odds ratios (OR) and 95 % confidence intervals (CI) for the associations of race, ethnicity, and BMI with in-breast pCR adjusting for subtype, study arm, lymph node status, tumor size, and tumor grade. 253 (14.1 %) were black, 199 (11.1 %) Hispanic, 520 (28.9 %) overweight, and 743 (41.4 %) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor subtype. In multivariate analyses, neither race (black vs white: OR 1.18, 95 % CI 0.85–1.62) nor ethnicity (Hispanic vs non-Hispanic; OR 1.30, 95 % CI 0.67–2.53) were significant predictors of pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER+/HER2+, but higher pCR rates in ER−/HER2+ cancers. There was no difference in pCR according to race or ethnicity. Overall, there was no major difference in pCR rates by BMI. These findings suggest that pCR with optimally dosed NST is a function of tumor, rather than patient, biology. © 2016, Springer Science+Business Media New York. AD - Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, United States Alliance Statistics and Data Center, 1216 Second St. SW, Rochester, MN 55902, United States Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, 101 Manning Drive, Chapel Hill, NC 27514, United States Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, 101 Dudley Street, Providence, RI 02905, United States Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, United States Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States AU - Warner, E. T. AU - Ballman, K. V. AU - Strand, C. AU - Boughey, J. C. AU - Buzdar, A. U. AU - Carey, L. A. AU - Sikov, W. M. AU - Partridge, A. H. DB - Scopus DO - 10.1007/s10549-016-3918-5 IS - 1 KW - Body mass index Breast cancer Ethnicity Pathologic complete response Race M3 - Article N1 - Cited By :25 Export Date: 22 March 2021 PY - 2016 SP - 109-118 ST - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) T2 - Breast Cancer Research and Treatment TI - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979300244&doi=10.1007%2fs10549-016-3918-5&partnerID=40&md5=96609bb89615c9e4de38cc08cac97fe3 VL - 159 ID - 2337 ER - TY - JOUR AB - Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status. Logistic regression generated odds ratios (OR) and 95 % confidence intervals (CI) for the associations of race, ethnicity, and BMI with in-breast pCR adjusting for subtype, study arm, lymph node status, tumor size, and tumor grade. 253 (14.1 %) were black, 199 (11.1 %) Hispanic, 520 (28.9 %) overweight, and 743 (41.4 %) obese. Compared to whites, Blacks and Hispanics were more likely to be obese and Blacks were more likely to have triple-negative cancer. pCR rates differed significantly by tumor subtype. In multivariate analyses, neither race (black vs white: OR 1.18, 95 % CI 0.85-1.62) nor ethnicity (Hispanic vs non-Hispanic; OR 1.30, 95 % CI 0.67-2.53) were significant predictors of pCR overall or by subtype. Overweight and obese women had lower pCR rates in ER+/HER2+, but higher pCR rates in ER-/HER2+ cancers. There was no difference in pCR according to race or ethnicity. Overall, there was no major difference in pCR rates by BMI. These findings suggest that pCR with optimally dosed NST is a function of tumor, rather than patient, biology. AN - WOS:000382847800010 AU - Warner, E. T. AU - Ballman, K. V. AU - Strand, C. AU - Boughey, J. C. AU - Buzdar, A. U. AU - Carey, L. A. AU - Sikov, W. M. AU - Partridge, A. H. DA - Aug DO - 10.1007/s10549-016-3918-5 IS - 1 N1 - 27449492 PY - 2016 SN - 0167-6806 SP - 109-118 ST - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) T2 - Breast Cancer Research and Treatment TI - Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) VL - 159 ID - 2935 ER - TY - JOUR AB - BACKGROUND. Older women, and older minorities in particular, are under represented in breast cancer trials. Although socioeconomic status (SES) is associated with both race and age, to the authors' knowledge little is known regarding the impact of SES on trial enrollment among older women with breast cancer. METHODS. The authors performed a case-control study comparing women who were participants in National Cancer Institute cooperative group breast cancer trials (cases) with a population-based sample of breast cancer patients (controls) obtained from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data base. The sample was restricted to women age a 65 years who were living in SEER areas. Proxies for SES included the proportion of the population below poverty level (by zip code) and unemployed (by county) as well those with Medicaid insurance coverage. A multivariable logistic regression model was used to test the association of SES with trial participation after accounting for other patient and county characteristics. RESULTS. In bivariate analysis, trial participants were significantly less likely than community cancer patients to reside in high-poverty zip codes (20.9% vs. 24.9%, respectively; P < 0.001) or to have Medicaid insurance (2.0% vs. 10.0%; P < 0.0001). After adjusting for race, age, and county, trial participation remained inversely related to residing in areas with high poverty (odds ratio [OR] vs. residents of remaining counties, 0.78; 95% confidence interval [95% CI], 0.62-0.98), high unemployment rates (OR vs. residents of residents of counties in the lowest quartile, 0.50; 95% CI, 0.35-0.71), and having Medicaid insurance (OR vs. women without Medicaid, 0.22; 95% CI, 0.13-0.37); black race was not found to be related to trial participation (OR for black vs. white, 1.0; 95% CI, 0.67-1.47). CONCLUSIONS. Low SES was associated inversely with trial enrollment for older women with breast cancer and appeared to account for the enrollment disparities between black patients and white patients. Future efforts to enhance enrollment of elderly women in cancer research should identify specific barriers related to SES that may be amenable to intervention. © 2004 American Cancer Society. AD - C.P. Gross, Primary Care Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, United States AU - Gross, C. P. AU - Filardo, G. AU - Mayne, S. T. AU - Krumholz, H. M. DB - Embase Medline DO - 10.1002/cncr.20792 IS - 3 KW - African American aged article Asian breast cancer cancer epidemiology cancer research case control study Caucasian clinical trial controlled clinical trial controlled study demography female health behavior health insurance Hispanic human major clinical study medicaid Black person patient attitude poverty priority journal race difference social status socioeconomics unemployment LA - English M3 - Article N1 - L40160217 2005-02-11 PY - 2005 SN - 0008-543X SP - 483-491 ST - The impact of socioeconomic status and race on trial participation for older women with breast cancer T2 - Cancer TI - The impact of socioeconomic status and race on trial participation for older women with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40160217&from=export http://dx.doi.org/10.1002/cncr.20792 VL - 103 ID - 1271 ER - TY - JOUR AB - BACKGROUND. Older women, and older minorities in particular, are under represented in breast cancer trials. Although socioeconomic status (SES) is associated with both race and age, to the authors' knowledge little is known regarding the impact of SES on trial enrollment among older women with breast cancer. METHODS. The authors performed a case-control study comparing women who were participants in National Cancer Institute cooperative group breast cancer trials (cases) with a population-based sample of breast cancer patients (controls) obtained from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data base. The sample was restricted to women age a 65 years who were living in SEER areas. Proxies for SES included the proportion of the population below poverty level (by zip code) and unemployed (by county) as well those with Medicaid insurance coverage. A multivariable logistic regression model was used to test the association of SES with trial participation after accounting for other patient and county characteristics. RESULTS. In bivariate analysis, trial participants were significantly less likely than community cancer patients to reside in high-poverty zip codes (20.9% vs. 24.9%, respectively; P < 0.001) or to have Medicaid insurance (2.0% vs. 10.0%; P < 0.0001). After adjusting for race, age, and county, trial participation remained inversely related to residing in areas with high poverty (odds ratio [OR] vs. residents of remaining counties, 0.78; 95% confidence interval [95% CI], 0.62-0.98), high unemployment rates (OR vs. residents of residents of counties in the lowest quartile, 0.50; 95% CI, 0.35-0.71), and having Medicaid insurance (OR vs. women without Medicaid, 0.22; 95% CI, 0.13-0.37); black race was not found to be related to trial participation (OR for black vs. white, 1.0; 95% CI, 0.67-1.47). CONCLUSIONS. Low SES was associated inversely with trial enrollment for older women with breast cancer and appeared to account for the enrollment disparities between black patients and white patients. Future efforts to enhance enrollment of elderly women in cancer research should identify specific barriers related to SES that may be amenable to intervention. © 2004 American Cancer Society. AD - Section of General Internal Medicine, Department of Medicine, R. Wood Johnson Clin. Scholars Prog., New Haven, CT, United States R. Wood Johnson Clin. Scholars Prog., New Haven, CT, United States Dept. of Epidemiol. and Pub. Health, Yale University School of Medicine, New Haven, CT, United States Section of Cardiovascular Medicine, Department of Medicine, R. Wood Johnson Clin. Scholars Prog., New Haven, CT, United States Primary Care Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, United States AU - Gross, C. P. AU - Filardo, G. AU - Mayne, S. T. AU - Krumholz, H. M. DB - Scopus DO - 10.1002/cncr.20792 IS - 3 KW - Age disparities Medicaid eligibility Racial disparities Socioeconomic status clinical trials Trial-enrollment strategies M3 - Article N1 - Cited By :124 Export Date: 22 March 2021 PY - 2005 SP - 483-491 ST - The impact of socioeconomic status and race on trial participation for older women with breast cancer T2 - Cancer TI - The impact of socioeconomic status and race on trial participation for older women with breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-12744279330&doi=10.1002%2fcncr.20792&partnerID=40&md5=96f20e0e004d67700306daf42eff1df5 VL - 103 ID - 2597 ER - TY - JOUR AB - BACKGROUND. Older women, and older minorities in particular, are under represented in breast cancer trials. Although socioeconomic status (SES) is associated with both race and age, to the authors' knowledge little is known regarding the impact of SES on trial enrollment among older women with breast cancer. METHODS. The authors performed a case-control study comparing women who were participants in National Cancer Institute cooperative group breast cancer trials (cases) with a population-based sample of breast cancer patients (controls) obtained from the linked Surveillance, Epidemiology, and End Results (SEER)Medicare data base. The sample was restricted to women age greater than or equal to 65 years who were living in SEER areas. Proxies for SES included the proportion of the population below poverty level (by zip code) and unemployed (by county) as well those with Medicaid insurance coverage. A multivariable logistic regression model was used to test the association of SES with trial participation after accounting for other patient and county characteristics. RESULTS. In bivariate analysis, trial participants were significantly less likely than community cancer patients to reside in high-poverty zip codes (20.9% vs. 24.9%, respectively; P < 0.001) or to have Medicaid insurance (2.0% vs. 10.0%0; P < 0.0001). After adjusting for race, age, and county, trial participation remained inversely related to residing in areas with high poverty (odds ratio [OR] vs. residents of remaining counties, 0.78; 95% confidence interval [95% CI], 0.62-0.98), high unemployment rates (OR vs. residents of residents of counties in the lowest quartile, 0.50; 95% CI, 0.35-0.71), and having Medicaid insurance (OR vs. women without Medicaid, 0.22; 95% CI, 0.13-0.37); black race was not found to be related to trial participation (OR for black vs. white, 1.0; 95% CI, 0.67-1.47). CONCLUSIONS. Low SES was associated inversely with trial enrollment for older women with breast cancer and appeared to account for the enrollment disparities between black patients and white patients. Future efforts to enhance enrollment of elderly women in cancer research should specific barriers related to SES that may be amenable to intervention. (C) 2004 American Cancer Society. AN - WOS:000226480100008 AU - Gross, C. P. AU - Filardo, G. AU - Mayne, S. T. AU - Krumholz, H. M. DA - Feb 1 DO - 10.1002/cncr.20792 IS - 3 N1 - 120 15597407 PY - 2005 SN - 0008-543X SP - 483-491 ST - The impact of socioeconomic status and race on trial participation for older women with breast cancer T2 - Cancer TI - The impact of socioeconomic status and race on trial participation for older women with breast cancer VL - 103 ID - 2666 ER - TY - JOUR AB - Background African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. Purpose To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. Methods Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. Results The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. Limitations Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. Conclusions MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential. AD - E. D. Cook, MD Anderson Cancer Center, University of Texas, Clinical Cancer Prevention, P.O. Box 301439, Houston, TX 77230-1439, United States AU - Cook, E. D. AU - Arnold, K. B. AU - Hermos, J. A. AU - McCaskill-Stevens, W. AU - Moody-Thomas, S. AU - Probstfield, J. L. AU - Hamilton, S. J. AU - Campbell, R. D. AU - Anderson, K. B. AU - Minasian, L. M. DB - Embase Medline DO - 10.1177/1740774509357227 IS - 1 KW - NCT00006392 alpha tocopherol selenium African American article cancer prevention cancer research cancer screening comparative study controlled study funding human major clinical study male patient participation patient selection prevention study priority journal prostate cancer qualitative analysis quantitative study strategic planning LA - English M3 - Article N1 - L358409447 2010-03-16 2010-04-16 PY - 2010 SN - 1740-7745 1740-7753 SP - 90-99 ST - Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial T2 - Clinical Trials TI - Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358409447&from=export http://dx.doi.org/10.1177/1740774509357227 VL - 7 ID - 1173 ER - TY - JOUR AB - Background African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. Purpose To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. Methods Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. Results The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. Limitations Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. Conclusions MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential. AD - MD Anderson Cancer Center, University of Texas, Clinical Cancer Prevention, P.O. Box 301439, Houston, TX 77230-1439, United States Southwest Oncology Group Statistical Center, Seattle, WA, United States VA Cooperative Studies Program, VA Boston Healthcare System, Boston, MA, United States National Cancer Institute, Division of Cancer Prevention, NIH, Bethesda, MD, United States LSU, Health Sciences Center, School of Public Health, New Orleans, LA, United States University of Washington, Seattle, WA, United States Morehouse School of Medicine, Atlanta, GA, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States Cancer Research and Biostatistics, Seattle, WA, United States AU - Cook, E. D. AU - Arnold, K. B. AU - Hermos, J. A. AU - McCaskill-Stevens, W. AU - Moody-Thomas, S. AU - Probstfield, J. L. AU - Hamilton, S. J. AU - Campbell, R. D. AU - Anderson, K. B. AU - Minasian, L. M. DB - Scopus DO - 10.1177/1740774509357227 IS - 1 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2010 SP - 90-99 ST - Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial T2 - Clinical Trials TI - Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77749289999&doi=10.1177%2f1740774509357227&partnerID=40&md5=f37626cb3f5f5f48c73566f3bf48080a VL - 7 ID - 2502 ER - TY - JOUR AB - Background African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. Purpose To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. Methods Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. Results The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. Limitations Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. Conclusions MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential. Clinical Trials 2010; 7: 90-99. http://ctj.sagepub.com. AN - WOS:000275008800009 AU - Cook, E. D. AU - Arnold, K. B. AU - Hermos, J. A. AU - McCaskill-Stevens, W. AU - Moody-Thomas, S. AU - Probstfield, J. L. AU - Hamilton, S. J. AU - Campbell, R. D. AU - Anderson, K. B. AU - Minasian, L. M. DA - Feb DO - 10.1177/1740774509357227 IS - 1 N1 - 20156960 PY - 2010 SN - 1740-7745 SP - 90-99 ST - Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial T2 - Clinical Trials TI - Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial VL - 7 ID - 3125 ER - TY - JOUR AB - Purpose: A prior analysis by the Southwest Oncology Group (SWOG) showed that women and African American patients were adequately represented on cancer clinical treatment trials but that older patients were substantially underrepresented. Twenty-five percent of patients ≥ 65 years old were enrolled onto SWOG trials from 1993 to 1996, whereas 63% of all patients with cancer were ≥ 65 years old. Recognition of this under-representation led to a change in Medicare policy in 2000 to include coverage of routine patient care costs of clinical trials. We conducted an updated analysis of accrual trends. Methods: The proportions of enrollment onto SWOG treatment trials by sex, race/ethnicity, and age (≥ 65 years) were computed for the years 1997 to 2000; corresponding rates in the United States were derived from US Census and National Cancer Institute Surveillance, Epidemiology, and End Results data. Additionally, method of payment data were analyzed over time (1993 to 2003) to assess whether patterns in method of payment changed with the new Year 2000 Medicare policy on clinical trials coverage. Results: The results showed continued adequate representation by sex and race/ethnicity. Older patient accrual on SWOG trials increased significantly since 2000, with 31 % of patients ≥ 65 years old enrolled from 1997 to 2000 and 38% enrolled from 2001 to 2003 (v 25% from 1993 to 1996). The percentage of patients using Medicare plus supplemental insurance also increased beginning in 2000, whereas the percentage of patients using Medicare alone remained the same. Conclusion: Method of payment analyses provided evidence that the Year 2000 Medicare policy change had a positive impact, but only for those patients with supplemental private coverage of coinsurance costs. Improvements in the Medicare payment structure could further increase older patient participation in clinical trials. © 2006 by American Society of Clinical Oncology. AD - Southwest Oncology Group Statistical Center; Puget Sound Oncology Consortium, Seattle, WA; Southwest Oncology Group Operations Office, San Antonio, TX; University of Arkansas for Medical Science, Little Rock, AR; John Wayne Cancer Institute Medical Group, Santa Monica; University of California, Davis, Sacramento, CA; St Vincent's Comprehensive Cancer Center, New York, NY; Oregon Health Sciences University, Portland, OR; University of Colorado Health Science Center, Denver, CO; and Loyola University Chicago, Stritch School of Medicine, Maywood, IL AU - Unger, J. M. AU - Coltman Jr, C. A. AU - Crowley, J. J. AU - Hutchins, L. F. AU - Martino, S. AU - Livingston, R. B. AU - Macdonald, J. S. AU - Blanke, C. D. AU - Gandara, D. R. AU - Crawford, E. D. AU - Albain, K. S. DB - Scopus DO - 10.1200/JCO.2005.02.8928 IS - 1 M3 - Article N1 - Cited By :83 Export Date: 22 March 2021 PY - 2006 SP - 141-144 ST - Impact of the year 2000 medicare policy change on older patient enrollment to cancer clinical trials T2 - Journal of Clinical Oncology TI - Impact of the year 2000 medicare policy change on older patient enrollment to cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33644847203&doi=10.1200%2fJCO.2005.02.8928&partnerID=40&md5=24750a0354a0d96633719c5801ea40c3 VL - 24 ID - 2585 ER - TY - JOUR AB - Arthralgia affects postmenopausal breast cancer survivors (BCSs) receiving aromatase inhibitors (AIs). This study aims to establish the feasibility of studying the impact of yoga on objective functional outcomes, pain, and health-related quality of life (HR-QOL) for AI-associated arthralgia (AIAA). Postmenopausal women with stage I to III breast cancer who reported AIAA were enrolled in a single-arm pilot trial. A yoga program was provided twice a week for 8 weeks. The Functional Reach (FR) and Sit and Reach (SR) were evaluated as primary outcomes. Pain, as measured by the Brief Pain Inventory (BPI), self-reported Patient Specific Functional Scale (PSFS), and Functional Assessment of Cancer Therapy-Breast (FACT-B) were secondary outcomes. Paired t tests were used for analysis, and 90% provided data for assessment at the end of the intervention. Participants experienced significant improvement in balance, as measured by FR, and flexibility, as measured by SR. The PSFS improved from 4.55 to 7.21, and HR-QOL measured by FACT-B also improved; both P < .05. The score for the Pain Severity subscale of the BPI reduced. No adverse events nor development or worsening of lymphedema was observed. In all, 80% of participants adhered to the home program. Preliminary data suggest that yoga may reduce pain and improve balance and flexibility in BCSs with AIAA. A randomized controlled trial is needed to establish the definitive efficacy of yoga for objective functional improvement in BCSs related to AIAA. AN - WOS:000311218800004 AU - Galantino, M. L. AU - Desai, K. AU - Greene, L. AU - DeMichele, A. AU - Stricker, C. T. AU - Mao, J. J. DA - Dec DO - 10.1177/1534735411413270 IS - 4 N1 - 21733988 PY - 2012 SN - 1534-7354 SP - 313-320 ST - Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias T2 - Integrative Cancer Therapies TI - Impact of Yoga on Functional Outcomes in Breast Cancer Survivors With Aromatase Inhibitor-Associated Arthralgias VL - 11 ID - 3058 ER - TY - JOUR AB - Purpose: Arthralgia affects postmenopausal breast cancer survivors (BCS) receiving aromatase inhibitors (AI) which may result in reduced function and long term wellbeing. While there is evidence for yoga to improve subjective report of Quality of Life (QOL) in various cancer populations, no studies reported objective functional improvement associated with yoga. this study aims to establish the feasibility of studying the impact of yoga on objective functional outcomes for AI‐associated arthralgia (AIAA). Methods: Postmenopausal women with stage I‐III breast cancer who reported AIAA were enrolled in a single arm feasibility trial. Yoga was provided twice a week for 8 weeks and participants were instructed to do a home‐based yoga program. An Iyengar yoga program was specifically developed with emphasis on postures, breathing and meditation while attending the safety concerns for individuals with musculoskeletal pain. Certified instructors led the yoga sessions for 1.5 hours with a 15 minute check‐in period to assess progress and function. the Sit and Reach (SR), and Functional Reach (FR) were evaluated by trained physical therapists and served as the primary outcomes. Self‐reported Patient Specific Functional Scale (PSFS) and FACT‐B were secondary outcomes. Paired‐t tests were used for analysis. Results: Among the 10 BCS with AIAA, mean age 58 (SD 6.23), 9 were Caucasian, 1 African American and 90% provided data for assessment at the end of the yoga intervention. From baseline to the end of intervention, participants had significant improvement in flexibility measured by SR (22.90 to 30.10) and in balance measured by FR (25.36 to 39.19), both p<.01. the PSFS also improved from 4.55 to 7.21, as well as QOL measured by FACT‐B (89.33 to 106.05), both p<0.05. No adverse events nor development or worsening of lymphedema was observed. Eighty percent of participants adhered to the home based program of 15 minutes 3 times per week. Conclusion: Preliminary data suggests that yoga may improve flexibility and balance in breast cancer survivors who experience AIAA. A randomized controlled trial is needed to establish the definitive efficacy of yoga for objective functional improvement in BCS with AIAA. AN - CN-01712489 AU - Galantino, M. L. AU - Greene, L. AU - Archetto, B. AU - Baumgartner, M. AU - Hassell, P. IS - 4 KW - *arthralgia *breast cancer *cancer survivor *oncology *society *yoga African American Arm Body position Breathing Caucasian Lymphedema Meditation Musculoskeletal pain Neoplasm Patient Physiotherapist Population Postmenopause Quality of life Randomized controlled trial Safety Student t test Wellbeing M3 - Journal: Conference Abstract PY - 2010 SP - 181‐ ST - Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias T2 - Journal of the Society for Integrative Oncology TI - Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01712489/full VL - 8 ID - 1523 ER - TY - JOUR AB - Context: Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. Background: The study aimed to test a theoretically based "implementation intentions" intervention for improving CRC screening among unscreened adults in urban safety-net clinics. Design: Randomized controlled trial. Setting/participants: Adults (N=470) aged >= 50 years, due for CRC screening, from urban safety-net clinics were recruited. Intervention: The intervention (conducted in 2009-2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or "implementation intentions" questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). Main outcome measures: The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012-2013). Results: The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions based intervention had higher odds (AOR=1.83, 95% CI=1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR=1.57, 95% CI=1.03, 2.39), history of asthma (AOR=2.20, 95% CI=1.26, 3.84), no history of diabetes (AOR=1.86, 95% CI= 1.21, 2.86), and reporting they had never heard that "cutting on cancer" makes it spread (AOR=1.78, 95% CI=1.16, 2.72) were more likely to complete CRC screening. Conclusions: The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors. (C) 2014 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine AN - WOS:000345264200002 AU - Greiner, K. A. AU - Daley, C. M. AU - Epp, A. AU - James, A. AU - Yeh, H. W. AU - Geana, M. AU - Born, W. AU - Engelman, K. K. AU - Shellhorn, J. AU - Hester, C. M. AU - LeMaster, J. AU - Buckles, D. C. AU - Ellerbeck, E. F. DA - Dec DO - 10.1016/j.amepre.2014.08.005 IS - 6 N1 - 25455115 PY - 2014 SN - 0749-3797 SP - 703-714 ST - Implementation Intentions and Colorectal Screening A Randomized Trial in Safety-Net Clinics T2 - American Journal of Preventive Medicine TI - Implementation Intentions and Colorectal Screening A Randomized Trial in Safety-Net Clinics VL - 47 ID - 2993 ER - TY - JOUR AB - [Correction Notice: An Erratum for this article was reported in Vol 49(2) of American Journal of Preventive Medicine (see record [rid]2015-33753-027[/rid]). In the original article, there is an error in results section. The correction is given in the erratum.] Context: Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. Background: The study aimed to test a theoretically based 'implementation intentions' intervention for improving CRC screening among unscreened adults in urban safety-net clinics. Design: Randomized controlled trial. Setting/participants: Adults (N = 470) aged ≥ 50 years, due for CRC screening, from urban safety-net clinics were recruited. Intervention: The intervention (conducted in 2009−2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or 'implementation intentions' questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). Main outcome measures: The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012−2013). Results: The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions−based intervention had higher odds (AOR = 1.83, 95% CI = 1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR = 1.57, 95% CI = 1.03, 2.39), history of asthma (AOR = 2.20, 95% CI = 1.26, 3.84), no history of diabetes (AOR = 1.86, 95% CI = 1.21, 2.86), and reporting they had never heard that 'cutting on cancer' makes it spread (AOR = 1.78, 95% CI = 1.16, 2.72) were more likely to complete CRC screening. Conclusions: The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Greiner, K. Allen, Department of Family Medicine, University of Kansas Medical Center, Mailstop 3064, 4125 Rainbow Boulevard, Kansas City, KS, US, 66160 AN - 2014-49474-005 AU - Greiner, K. Allen AU - Daley, Christine M. AU - Epp, Aaron AU - James, Aimee AU - Yeh, Hung-Wen AU - Geana, Mugur AU - Born, Wendi AU - Engelman, Kimberly K. AU - Shellhorn, Jeremy AU - Hester, Christina M. AU - LeMaster, Joseph AU - Buckles, Daniel C. AU - Ellerbeck, Edward F. DB - psyh DO - 10.1016/j.amepre.2014.08.005 DP - EBSCOhost IS - 6 KW - colorectal screening screening barriers racial ethnic minority populations randomized trial African Americans Colonoscopy Colorectal Neoplasms Computer-Assisted Instruction Diagnosis, Computer-Assisted Early Detection of Cancer European Continental Ancestry Group Female Hispanic Americans Humans Intention Male Mass Screening Middle Aged Occult Blood Outcome Assessment (Health Care) Poverty Safety-net Providers United States Cancer Screening Clinics Colon Disorders Intervention Minority Groups Treatment Barriers Health Disparities N1 - Department of Family Medicine, University of Kansas Medical Center, Kansas City, KS, US. Release Date: 20150622. Correction Date: 20160512. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Clinics; Colon Disorders; Intention; Intervention. Minor Descriptor: Minority Groups; Treatment Barriers; Health Disparities. Classification: Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Tests & Measures: Baseline Survey; Office Exit Interview Survey; Follow-Up Survey. Methodology: Empirical Study; Followup Study; Longitudinal Study; Quantitative Study. References Available: Y. Page Count: 12. Issue Publication Date: Dec, 2014. Copyright Statement: Published by Elsevier Inc. American Journal of Preventive Medicine. 2014. Sponsor: National Cancer Institute, US. Grant: CA123245. Recipients: No recipient indicated PY - 2014 SN - 0749-3797 1873-2607 SP - 703-714 ST - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics T2 - American Journal of Preventive Medicine TI - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-49474-005&site=ehost-live&scope=site ORCID: 0000-0002-1411-9307 agreiner@kumc.edu VL - 47 ID - 1703 ER - TY - JOUR AB - Context Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. Background The study aimed to test a theoretically based "implementation intentions" intervention for improving CRC screening among unscreened adults in urban safety-net clinics. Design Randomized controlled trial. Setting/participants Adults (N=470) aged ≥50 years, due for CRC screening, from urban safety-net clinics were recruited. Intervention The intervention (conducted in 2009-2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or "implementation intentions" questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). Main outcome measures The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012-2013). Results The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions-based intervention had higher odds (AOR=1.83, 95% CI=1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR=1.57, 95% CI=1.03, 2.39), history of asthma (AOR=2.20, 95% CI=1.26, 3.84), no history of diabetes (AOR=1.86, 95% CI=1.21, 2.86), and reporting they had never heard that "cutting on cancer" makes it spread (AOR=1.78, 95% CI=1.16, 2.72) were more likely to complete CRC screening. Conclusions The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors. AD - K.A. Greiner, Department of Family Medicine, United States AU - Greiner, K. A. AU - Daley, C. M. AU - Epp, A. AU - James, A. AU - Yeh, H. W. AU - Geana, M. AU - Born, W. AU - Engelman, K. K. AU - Shellhorn, J. AU - Hester, C. M. AU - Lemaster, J. AU - Buckles, D. C. AU - Ellerbeck, E. F. DB - Embase Medline DO - 10.1016/j.amepre.2014.08.005 IS - 6 KW - adult article asthma cancer screening colonoscopy colorectal cancer software controlled study female follow up health behavior human implementation intention male occult blood test outcome assessment patient decision making randomized controlled trial safety net hospital LA - English M3 - Article N1 - L600593130 2014-12-03 2014-12-12 PY - 2014 SN - 1873-2607 0749-3797 SP - 703-714 ST - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics T2 - American Journal of Preventive Medicine TI - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600593130&from=export http://dx.doi.org/10.1016/j.amepre.2014.08.005 VL - 47 ID - 1020 ER - TY - JOUR AB - Context Low-income and racial/ethnic minority populations experience disproportionate colorectal cancer (CRC) burden and poorer survival. Novel behavioral strategies are needed to improve screening rates in these groups. Background The study aimed to test a theoretically based "implementation intentions" intervention for improving CRC screening among unscreened adults in urban safety-net clinics. Design Randomized controlled trial. Setting/participants Adults (N=470) aged ≥50 years, due for CRC screening, from urban safety-net clinics were recruited. Intervention The intervention (conducted in 2009-2011) was delivered via touchscreen computers that tailored informational messages to decisional stage and screening barriers. The computer then randomized participants to generic health information on diet and exercise (Comparison group) or "implementation intentions" questions and planning (Experimental group) specific to the CRC screening test chosen (fecal immunochemical test or colonoscopy). Main outcome measures The primary study outcome was completion of CRC screening at 26 weeks based on test reports (analysis conducted in 2012-2013). Results The study population had a mean age of 57 years and was 42% non-Hispanic African American, 28% non-Hispanic white, and 27% Hispanic. Those receiving the implementation intentions-based intervention had higher odds (AOR=1.83, 95% CI=1.23, 2.73) of completing CRC screening than the Comparison group. Those with higher self-efficacy for screening (AOR=1.57, 95% CI=1.03, 2.39), history of asthma (AOR=2.20, 95% CI=1.26, 3.84), no history of diabetes (AOR=1.86, 95% CI=1.21, 2.86), and reporting they had never heard that "cutting on cancer" makes it spread (AOR=1.78, 95% CI=1.16, 2.72) were more likely to complete CRC screening. Conclusions The results of this study suggest that programs incorporating an implementation intentions approach can contribute to successful completion of CRC screening even among very low-income and diverse primary care populations. Future initiatives to reduce CRC incidence and mortality disparities may be able to employ implementation intentions in large-scale efforts to encourage screening and prevention behaviors. AD - Department of Family Medicine, United States Center for American Indian Community Health, United States Department of Biostatistics, United States Department of Preventive Medicine, United States Department of Internal Medicine, University of Kansas Medical Center, United States University of Kansas Cancer Center, United States Center of Excellence for Health Communications to Underserved Populations, William Allen White School of Journalism and Mass Communications, United States School of Architecture Design and Planning, University of Kansas, Kansas City, KS, United States Siteman Cancer Center, Washington University, St. Louis, MO, United States AU - Greiner, K. A. AU - Daley, C. M. AU - Epp, A. AU - James, A. AU - Yeh, H. W. AU - Geana, M. AU - Born, W. AU - Engelman, K. K. AU - Shellhorn, J. AU - Hester, C. M. AU - Lemaster, J. AU - Buckles, D. C. AU - Ellerbeck, E. F. DB - Scopus DO - 10.1016/j.amepre.2014.08.005 IS - 6 M3 - Article N1 - Cited By :25 Export Date: 22 March 2021 PY - 2014 SP - 703-714 ST - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics T2 - American Journal of Preventive Medicine TI - Implementation intentions and colorectal screening: A randomized trial in safety-net clinics UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911994473&doi=10.1016%2fj.amepre.2014.08.005&partnerID=40&md5=be6fa2d4ec7e39090db464f5cba1caf0 VL - 47 ID - 2408 ER - TY - JOUR AB - Low-income minorities often face system-based and personal barriers to screening colonoscopy (SC). Culturally targeted patient navigation (CTPN) programs employing professional navigators (Pro-PNs) or community-based peer navigators (Peer-PNs) can help overcome barriers but are not widely implemented. In East Harlem, NY, USA, where approximately half the residents participate in SC, 315 African American patients referred for SC at a primary care clinic with a Direct Endoscopic Referral System were recruited between May 2008 and May 2010. After medical clearance, 240 were randomized to receive CTPN delivered by a Pro-PN (n = 106) or Peer-PN (n = 134). Successful navigation was measured by SC adherence rate, patient satisfaction and navigator trust. Study enrollment was 91.4% with no significant differences in SC adherence rates between Pro-PN (80.0%) and Peer-PN (71.3%) (P = 0.178). Participants in both groups reported high levels of satisfaction and trust. These findings suggest that CTPN Pro-PN and Peer-PN programs are effective in this urban primary care setting. We detail how we recruited and trained navigators, how CTPN was implemented and provide a preliminary answer to our questions of the study aims: can peer navigators be as effective as professionals and what is the potential impact of patient navigation on screening adherence? AD - L. Jandorf AU - Jandorf, L. AU - Cooperman, J. L. AU - Stossel, L. M. AU - Itzkowitz, S. AU - Thompson, H. S. AU - Villagra, C. AU - Thélémaque, L. D. AU - McGinn, T. AU - Winkel, G. AU - Valdimarsdottir, H. AU - Shelton, R. C. AU - Redd, W. DB - Medline IS - 5 KW - African American article colonoscopy colorectal tumor controlled clinical trial controlled study cultural competence human mortality organization and management patient care patient compliance patient referral patient satisfaction peer group poverty program development psychological aspect randomized controlled trial trust United States LA - English M3 - Article N1 - L563071621 2015-02-18 PY - 2013 SN - 1465-3648 SP - 803-815 ST - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system T2 - Health education research TI - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563071621&from=export VL - 28 ID - 1101 ER - TY - JOUR AB - Low-income minorities often face system-based and personal barriers to screening colonoscopy (SC). Culturally targeted patient navigation (CTPN) programs employing professional navigators (Pro-PNs) or community-based peer navigators (Peer-PNs) can help overcome barriers but are not widely implemented. In East Harlem, NY, USA, where approximately half the residents participate in SC, 315 African American patients referred for SC at a primary care clinic with a Direct Endoscopic Referral System were recruited between May 2008 and May 2010. After medical clearance, 240 were randomized to receive CTPN delivered by a Pro-PN (n=106) or Peer-PN (n=134). Successful navigation was measured by SC adherence rate, patient satisfaction and navigator trust. Study enrollment was 91.4% with no significant differences in SC adherence rates between Pro-PN (80.0%) and Peer-PN (71.3%) (P=0.178). Participants in both groups reported high levels of satisfaction and trust. These findings suggest that CTPN Pro-PN and Peer-PN programs are effective in this urban primary care setting. We detail how we recruited and trained navigators, how CTPN was implemented and provide a preliminary answer to our questions of the study aims: can peer navigators be as effective as professionals and what is the potential impact of patient navigation on screening adherence? AD - Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029-6574, United States Population Studies and Disparities Research Program, Department of Oncology, Wayne State University, 4100 John R, MM03CB Detroit, MI 48201, United States Mailman School of Public Health, Columbia University, 722 West, 168th Street, New York, NY 10032, United States AU - Jandorf, L. AU - Cooperman, J. L. AU - Stossel, L. M. AU - Itzkowitz, S. AU - Thompson, H. S. AU - Villagra, C. AU - Thélémaque, L. D. AU - McGinn, T. AU - Winkel, G. AU - Valdimarsdottir, H. AU - Shelton, R. C. AU - Redd, W. DB - Scopus DO - 10.1093/her/cyt003 IS - 5 M3 - Article N1 - Cited By :31 Export Date: 22 March 2021 PY - 2013 SP - 803-815 ST - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system T2 - Health Education Research TI - Implementation of culturally targeted patient navigation system for screening colonoscopy in a direct referral system UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884472829&doi=10.1093%2fher%2fcyt003&partnerID=40&md5=bc4e18a0599902a283d088193eda9ced VL - 28 ID - 2425 ER - TY - JOUR AB - Background: Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions. However, much research is needed to develop standards for genomic screening and to understand the perspectives of people offered this new testing modality. This is particularly true for non-European ancestry populations who are vastly underrepresented in genomic medicine research. Therefore, we implemented a pilot genomic screening program in the BioMe Biobank in New York City, where the majority of participants are of non-European ancestry. Methods: We initiated genomic screening for well-established genes associated with hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). We evaluated and included an additional gene (TTR) associated with hereditary transthyretin amyloidosis (hATTR), which has a common founder variant in African ancestry populations. We evaluated the characteristics of 74 participants who received results associated with these conditions. We also assessed the preferences of 7461 newly enrolled BioMe participants to receive genomic results. Results: In the pilot genomic screening program, 74 consented participants received results related to HBOC (N = 26), LS (N = 6), FH (N = 8), and hATTR (N = 34). Thirty-three of 34 (97.1%) participants who received a result related to hATTR were self-reported African American/African (AA) or Hispanic/Latinx (HL), compared to 14 of 40 (35.0%) participants who received a result related to HBOC, LS, or FH. Among the 7461 participants enrolled after the BioMe protocol modification to allow the return of genomic results, 93.4% indicated that they would want to receive results. Younger participants, women, and HL participants were more likely to opt to receive results. Conclusions: The addition of TTR to a pilot genomic screening program meant that we returned results to a higher proportion of AA and HL participants, in comparison with genes traditionally included in genomic screening programs in the USA. We found that the majority of participants in a multi-ethnic biobank are interested in receiving genomic results for medically actionable conditions. These findings increase knowledge about the perspectives of diverse research participants on receiving genomic results and inform the broader implementation of genomic medicine in underrepresented patient populations. AD - N.S. Abul-Husn, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Abul-Husn, N. S. AU - Soper, E. R. AU - Braganza, G. T. AU - Rodriguez, J. E. AU - Zeid, N. AU - Cullina, S. AU - Bobo, D. AU - Moscati, A. AU - Merkelson, A. AU - Loos, R. J. F. AU - Cho, J. H. AU - Belbin, G. M. AU - Suckiel, S. A. AU - Kenny, E. E. DB - Embase Medline DO - 10.1186/s13073-021-00832-y IS - 1 KW - adult African African American age aged ancestry group article ATTR amyloidosis biobank familial hypercholesterolemia female gene genetic association genetic screening genetic variability hereditary breast and ovarian cancer syndrome hereditary nonpolyposis colorectal cancer Hispanic human major clinical study male patient preference pilot study priority journal self report TTR gene LA - English M3 - Article N1 - L2010385605 2021-02-17 2021-03-03 PY - 2021 SN - 1756-994X ST - Implementing genomic screening in diverse populations T2 - Genome Medicine TI - Implementing genomic screening in diverse populations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010385605&from=export http://dx.doi.org/10.1186/s13073-021-00832-y VL - 13 ID - 753 ER - TY - JOUR AB - Background: Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions. However, much research is needed to develop standards for genomic screening and to understand the perspectives of people offered this new testing modality. This is particularly true for non-European ancestry populations who are vastly underrepresented in genomic medicine research. Therefore, we implemented a pilot genomic screening program in the BioMe Biobank in New York City, where the majority of participants are of non-European ancestry. Methods: We initiated genomic screening for well-established genes associated with hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). We evaluated and included an additional gene (TTR) associated with hereditary transthyretin amyloidosis (hATTR), which has a common founder variant in African ancestry populations. We evaluated the characteristics of 74 participants who received results associated with these conditions. We also assessed the preferences of 7461 newly enrolled BioMe participants to receive genomic results. Results: In the pilot genomic screening program, 74 consented participants received results related to HBOC (N = 26), LS (N = 6), FH (N = 8), and hATTR (N = 34). Thirty-three of 34 (97.1%) participants who received a result related to hATTR were self-reported African American/African (AA) or Hispanic/Latinx (HL), compared to 14 of 40 (35.0%) participants who received a result related to HBOC, LS, or FH. Among the 7461 participants enrolled after the BioMe protocol modification to allow the return of genomic results, 93.4% indicated that they would want to receive results. Younger participants, women, and HL participants were more likely to opt to receive results. Conclusions: The addition of TTR to a pilot genomic screening program meant that we returned results to a higher proportion of AA and HL participants, in comparison with genes traditionally included in genomic screening programs in the USA. We found that the majority of participants in a multi-ethnic biobank are interested in receiving genomic results for medically actionable conditions. These findings increase knowledge about the perspectives of diverse research participants on receiving genomic results and inform the broader implementation of genomic medicine in underrepresented patient populations. © 2021, The Author(s). AD - The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States Cardiogenetics, GeneDx Inc., Gaithersburg, MD, United States The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Abul-Husn, N. S. AU - Soper, E. R. AU - Braganza, G. T. AU - Rodriguez, J. E. AU - Zeid, N. AU - Cullina, S. AU - Bobo, D. AU - Moscati, A. AU - Merkelson, A. AU - Loos, R. J. F. AU - Cho, J. H. AU - Belbin, G. M. AU - Suckiel, S. A. AU - Kenny, E. E. C7 - 17 DB - Scopus DO - 10.1186/s13073-021-00832-y IS - 1 M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Implementing genomic screening in diverse populations T2 - Genome Medicine TI - Implementing genomic screening in diverse populations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100561679&doi=10.1186%2fs13073-021-00832-y&partnerID=40&md5=24bbc0c9357dd4af273324c178a9438f VL - 13 ID - 2150 ER - TY - JOUR AB - Background Population-based genomic screening has the predicted ability to reduce morbidity and mortality associated with medically actionable conditions. However, much research is needed to develop standards for genomic screening and to understand the perspectives of people offered this new testing modality. This is particularly true for non-European ancestry populations who are vastly underrepresented in genomic medicine research. Therefore, we implemented a pilot genomic screening program in the BioMe Biobank in New York City, where the majority of participants are of non-European ancestry. Methods We initiated genomic screening for well-established genes associated with hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome (LS), and familial hypercholesterolemia (FH). We evaluated and included an additional gene (TTR) associated with hereditary transthyretin amyloidosis (hATTR), which has a common founder variant in African ancestry populations. We evaluated the characteristics of 74 participants who received results associated with these conditions. We also assessed the preferences of 7461 newly enrolled BioMe participants to receive genomic results. Results In the pilot genomic screening program, 74 consented participants received results related to HBOC (N = 26), LS (N = 6), FH (N = 8), and hATTR (N = 34). Thirty-three of 34 (97.1%) participants who received a result related to hATTR were self-reported African American/African (AA) or Hispanic/Latinx (HL), compared to 14 of 40 (35.0%) participants who received a result related to HBOC, LS, or FH. Among the 7461 participants enrolled after the BioMe protocol modification to allow the return of genomic results, 93.4% indicated that they would want to receive results. Younger participants, women, and HL participants were more likely to opt to receive results. Conclusions The addition of TTR to a pilot genomic screening program meant that we returned results to a higher proportion of AA and HL participants, in comparison with genes traditionally included in genomic screening programs in the USA. We found that the majority of participants in a multi-ethnic biobank are interested in receiving genomic results for medically actionable conditions. These findings increase knowledge about the perspectives of diverse research participants on receiving genomic results and inform the broader implementation of genomic medicine in underrepresented patient populations. AN - WOS:000617446800001 AU - Abul-Husn, N. S. AU - Soper, E. R. AU - Braganza, G. T. AU - Rodriguez, J. E. AU - Zeid, N. AU - Cullina, S. AU - Bobo, D. AU - Moscati, A. AU - Merkelson, A. AU - Loos, R. J. F. AU - Cho, J. H. AU - Belbin, G. M. AU - Suckiel, S. A. AU - Kenny, E. E. DA - Feb DO - 10.1186/s13073-021-00832-y IS - 1 N1 - 17 33546753 PY - 2021 SN - 1756-994X ST - Implementing genomic screening in diverse populations T2 - Genome Medicine TI - Implementing genomic screening in diverse populations VL - 13 ID - 2749 ER - TY - JOUR AB - This study examined the relationship between demographic factors and other correlates of fatalism, and assessed the impact of fatalistic beliefs on the participation in breast cancer screening in rural women. The subjects were 220 women aged 50 and over recruited from 6 large rural counties in South Carolina. Data were collected using a demographic questionnaire and the revised Powe Fatalism Inventory. Results show significant associations between fatalism and increased age (p = 0.005), race (p = 0.0001), doctor recommendation (p = .0034) and decreased educational level (p = 0.001). Fatalism was associated with noncompliance with mammography screening in univariate analysis among African-American women (OR = .362; 95% CI: 1.11, 11.8). After adjusting for possible confounders (age, education, and doctor recommendation), fatalism was not significantly associated with noncompliance with screening. These results illustrate age, race, and education may be important predictors of fatalism and that fatalism may be one barrier that has previously gone unmeasured and unchallenged in understanding screening behavior in older women. AD - R.M. Mayo, Department of Public Health Sciences, 524 Edwards Hall, Clemson University, Clemson, SC 29634, USA. AU - Mayo, R. M. AU - Ureda, J. R. AU - Parker, V. G. DB - Medline IS - 1 KW - aged article breast tumor elderly care female health human mammography mass screening middle aged patient participation psychological aspect rural population United States women's health LA - English M3 - Article N1 - L33437527 2001-02-19 PY - 2001 SN - 0895-2841 SP - 57-72 ST - Importance of fatalism in understanding mammography screening in rural elderly women T2 - Journal of women & aging TI - Importance of fatalism in understanding mammography screening in rural elderly women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33437527&from=export VL - 13 ID - 1312 ER - TY - JOUR AB - Background: African Americans (AA) and socioeconomic status (SES) disadvantaged older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. However, few studies have evaluated the putative beneficial effects of exercise on these outcomes in older racial minority and SES‐disadvantaged BCS. Methods: This is a mixed‐methods study that includes a randomized‐controlled trial, “IMPROVEâ€�, to evaluate a group‐based exercise intervention compared to a support group program in older BCS, followed by post‐intervention semi‐structured interviews to evaluate the intervention. The trial aims to recruit 220 BCS with 55 in each of four strata defined by race (AA versus Non‐Hispanic Whites) and SES (disadvantaged vs. non‐disadvantaged). Participants are ≥65 years old and within five years of treatment completion for stage I‐III breast cancer. Participants are randomized to a 52‐week, three sessions/week, one‐hour/session, moderate intensity aerobic and resistance group exercise intervention, (n = 110) or a 52‐week, one hour/week, support group intervention [attention‐control arm], (n = 110). The first 20 weeks of both programs are supervised and the last 32 weeks, unsupervised. The primary outcome is the change in Short Physical Performance Battery (SPPB) Scores at 20 weeks from baseline, between the two arms. Secondary outcomes include change in SPPB scores at 52 weeks, change in body composition and biomarkers, at 20 and 52 weeks from baseline, between arms. Discussion: Results of the trial may contribute to a better understanding of factors associated with recruitment, and acceptability, and will inform future exercise programs to optimally improve health outcomes for older BCS. AN - CN-02100361 AU - Owusu, C. AU - Nock, N. L. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - et al. DO - 10.1016/j.cct.2020.106001 KW - *African American *breast cancer *cancer survivor *exercise *functional status *health *social status *support group Aerobic exercise Aged Article Body composition Comparative effectiveness Controlled study Female Human Intervention study Major clinical study Multimethod study Physical performance Prospective study Race Randomized controlled trial Resistance training Scoring system Semi structured interview M3 - Journal: Article PY - 2020 ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: rationale, design and methods T2 - Contemporary clinical trials TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: rationale, design and methods UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02100361/full VL - 92 ID - 1439 ER - TY - JOUR AB - Background: African Americans (AA) and socioeconomic status (SES) disadvantaged older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. However, few studies have evaluated the putative beneficial effects of exercise on these outcomes in older racial minority and SES-disadvantaged BCS. Methods: This is a mixed-methods study that includes a randomized-controlled trial, “IMPROVE”, to evaluate a group-based exercise intervention compared to a support group program in older BCS, followed by post-intervention semi-structured interviews to evaluate the intervention. The trial aims to recruit 220 BCS with 55 in each of four strata defined by race (AA versus Non-Hispanic Whites) and SES (disadvantaged vs. non-disadvantaged). Participants are ≥65 years old and within five years of treatment completion for stage I-III breast cancer. Participants are randomized to a 52-week, three sessions/week, one-hour/session, moderate intensity aerobic and resistance group exercise intervention, (n = 110) or a 52-week, one hour/week, support group intervention [attention-control arm], (n = 110). The first 20 weeks of both programs are supervised and the last 32 weeks, unsupervised. The primary outcome is the change in Short Physical Performance Battery (SPPB) Scores at 20 weeks from baseline, between the two arms. Secondary outcomes include change in SPPB scores at 52 weeks, change in body composition and biomarkers, at 20 and 52 weeks from baseline, between arms. Discussion: Results of the trial may contribute to a better understanding of factors associated with recruitment, and acceptability, and will inform future exercise programs to optimally improve health outcomes for older BCS. AD - C. Owusu, Case Western Reserve University, Seidman Cancer Center-BHC 5055, 11100 Euclid Avenue, Cleveland, OH, United States AU - Owusu, C. AU - Nock, N. L. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Webb-Hooper, M. AU - Atkins, L. AU - Asagba, O. AU - Wimbley, L. AU - Berger, N. A. DB - Embase Medline DO - 10.1016/j.cct.2020.106001 KW - biological marker aerobic exercise African American aged article body composition breast cancer cancer survivor comparative effectiveness controlled study exercise female functional status health human intervention study major clinical study multimethod study physical performance prospective study race randomized controlled trial resistance training scoring system semi structured interview social status support group LA - English M3 - Article N1 - L2005591895 2020-04-22 2020-04-29 PY - 2020 SN - 1559-2030 1551-7144 ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods T2 - Contemporary Clinical Trials TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005591895&from=export http://dx.doi.org/10.1016/j.cct.2020.106001 VL - 92 ID - 807 ER - TY - JOUR AB - Background: African Americans (AA) and socioeconomic status (SES) disadvantaged older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. However, few studies have evaluated the putative beneficial effects of exercise on these outcomes in older racial minority and SES-disadvantaged BCS. Methods: This is a mixed-methods study that includes a randomized-controlled trial, “IMPROVE”, to evaluate a group-based exercise intervention compared to a support group program in older BCS, followed by post-intervention semi-structured interviews to evaluate the intervention. The trial aims to recruit 220 BCS with 55 in each of four strata defined by race (AA versus Non-Hispanic Whites) and SES (disadvantaged vs. non-disadvantaged). Participants are ≥65 years old and within five years of treatment completion for stage I-III breast cancer. Participants are randomized to a 52-week, three sessions/week, one-hour/session, moderate intensity aerobic and resistance group exercise intervention, (n = 110) or a 52-week, one hour/week, support group intervention [attention-control arm], (n = 110). The first 20 weeks of both programs are supervised and the last 32 weeks, unsupervised. The primary outcome is the change in Short Physical Performance Battery (SPPB) Scores at 20 weeks from baseline, between the two arms. Secondary outcomes include change in SPPB scores at 52 weeks, change in body composition and biomarkers, at 20 and 52 weeks from baseline, between arms. Discussion: Results of the trial may contribute to a better understanding of factors associated with recruitment, and acceptability, and will inform future exercise programs to optimally improve health outcomes for older BCS. © 2020 Elsevier Inc. AD - Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH, United States Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States Department of Population and Quantitative Health Sciences, CWRU, Cleveland, OH, United States California Baptist University, Riverside, CA, United States University Hospitals of Cleveland, Cleveland, OH, United States Department of Medicine, Division of Hematology/Oncology, MetroHealth Medical Center, Cleveland, OH, United States Cleveland Clinic, Department of Hematology/Oncology, Cleveland, OH, United States The Gathering Place, Beachwood, OH, United States Penn State University College of Medicine, Hershey, PA, United States West Virginia University School of Medicine, Morgantown, WV, United States AU - Owusu, C. AU - Nock, N. L. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Webb-Hooper, M. AU - Atkins, L. AU - Asagba, O. AU - Wimbley, L. AU - Berger, N. A. C7 - 106001 DB - Scopus DO - 10.1016/j.cct.2020.106001 KW - African American Cancer exercise Older breast socioeconomic status-disadvantaged M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods T2 - Contemporary Clinical Trials TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083328101&doi=10.1016%2fj.cct.2020.106001&partnerID=40&md5=7312ffa06290f33a26e5eea838df3023 VL - 92 ID - 2196 ER - TY - JOUR AB - Background: African Americans (AA) and socioeconomic status (SES) disadvantaged older breast cancer survivors (BCS) are more likely to experience poor functional and health outcomes. However, few studies have evaluated the putative beneficial effects of exercise on these outcomes in older racial minority and SES-disadvantaged BCS. Methods: This is a mixed-methods study that includes a randomized-controlled trial, "IMPROVE", to evaluate a group-based exercise intervention compared to a support group program in older BCS, followed by post-intervention semi-structured interviews to evaluate the intervention. The trial aims to recruit 220 BCS with 55 in each of four strata defined by race (AA versus Non-Hispanic Whites) and SES (disadvantaged vs. non-disadvantaged). Participants are >= 65 years old and within five years of treatment completion for stage I-III breast cancer. Participants are randomized to a 52-week, three sessions/week, one-hour/session, moderate intensity aerobic and resistance group exercise intervention, (n = 110) or a 52-week, one hour/week, support group intervention [attention-control arm], (n = 110). The first 20 weeks of both programs are supervised and the last 32 weeks, unsupervised. The primary outcome is the change in Short Physical Performance Battery (SPPB) Scores at 20 weeks from baseline, between the two arms. Secondary outcomes include change in SPPB scores at 52 weeks, change in body composition and biomarkers, at 20 and 52 weeks from baseline, between arms. Discussion: Results of the trial may contribute to a better understanding of factors associated with recruitment, and acceptability, and will inform future exercise programs to optimally improve health outcomes for older BCS. AN - WOS:000530098300010 AU - Owusu, C. AU - Nock, N. L. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Webb-Hooper, M. AU - Atkins, L. AU - Asagba, O. AU - Wimbley, L. AU - Berger, N. A. DA - May DO - 10.1016/j.cct.2020.106001 N1 - 106001 32304828 PY - 2020 SN - 1551-7144 ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods T2 - Contemporary Clinical Trials TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Rationale, design and methods VL - 92 ID - 2780 ER - TY - JOUR AB - Background Behavioral intervention studies in older breast cancer survivors, particularly older African American (AA) and socioeconomic status-disadvantaged breast cancer survivors, are lacking. To inform future studies, the authors examined recruitment strategies in older breast cancer survivors who participated in an exercise intervention study. Methods IMPROVE is a randomized trial designed to evaluate a group-based exercise intervention versus a support group ( identifier, NCT02763228). Participants were aged >= 65 years who had survived stage I through III breast cancer and were within 5 years of treatment completion. Participants were recruited through multiple approaches, including peripheral, linguistic, and constituent-involving strategies that incorporated the identification of potentially eligible patients from 3 local hospitals and from State of Ohio registries and through direct clinician and community organization referrals. Results Between October 2016 and November 2019, 7487 patients were screened, 4790 were potentially eligible, and 213 were randomized into the study. The eligible:randomization rates were 4.4% overall and 84%, 8%, and 2% for recruitment using direct referrals, hospital registries, and state registries, respectively. The median age of the randomized cohort was 70 years (range, 65-88 years) and included 44% AA and 44% socioeconomic status-disadvantaged breast cancer survivors. Compared with all registry-eligible patients, directly referred-eligible patients were more likely to be AA versus Non-Hispanic White (41% vs 19%; P = .006), to be contacted successfully (100% vs 33%; P < .0001), and to accept study participation (88% vs 16%; P < .0001). Conclusions Direct referrals appeared to be the most efficient strategy for recruiting AA survivors. Behavioral intervention studies seeking to target older AA and socioeconomic status-disadvantaged breast cancer survivors should include strategies that foster direct referrals to study participation. AN - WOS:000614600100001 AU - Owusu, C. AU - Nock, N. L. AU - Feuntes, V. AU - Margevicius, S. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. C. F. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Hooper, M. W. AU - Coccia, S. AU - Nagy, C. AU - Wimbley, L. AU - Berger, N. A. DO - 10.1002/cncr.33430 N1 - 33539554 SN - 0008-543X ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics T2 - Cancer TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics ID - 2750 ER - TY - JOUR AB - Background: Behavioral intervention studies in older breast cancer survivors, particularly older African American (AA) and socioeconomic status–disadvantaged breast cancer survivors, are lacking. To inform future studies, the authors examined recruitment strategies in older breast cancer survivors who participated in an exercise intervention study. Methods: IMPROVE is a randomized trial designed to evaluate a group-based exercise intervention versus a support group (ClinicalTrials.gov identifier, NCT02763228). Participants were aged ≥65 years who had survived stage I through III breast cancer and were within 5 years of treatment completion. Participants were recruited through multiple approaches, including peripheral, linguistic, and constituent-involving strategies that incorporated the identification of potentially eligible patients from 3 local hospitals and from State of Ohio registries and through direct clinician and community organization referrals. Results: Between October 2016 and November 2019, 7487 patients were screened, 4790 were potentially eligible, and 213 were randomized into the study. The eligible:randomization rates were 4.4% overall and 84%, 8%, and 2% for recruitment using direct referrals, hospital registries, and state registries, respectively. The median age of the randomized cohort was 70 years (range, 65-88 years) and included 44% AA and 44% socioeconomic status–disadvantaged breast cancer survivors. Compared with all registry-eligible patients, directly referred-eligible patients were more likely to be AA versus Non-Hispanic White (41% vs 19%; P =.006), to be contacted successfully (100% vs 33%; P <.0001), and to accept study participation (88% vs 16%; P <.0001). Conclusions: Direct referrals appeared to be the most efficient strategy for recruiting AA survivors. Behavioral intervention studies seeking to target older AA and socioeconomic status–disadvantaged breast cancer survivors should include strategies that foster direct referrals to study participation. AD - C. Owusu, Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, United States C. Owusu, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States AU - Owusu, C. AU - Nock, N. L. AU - Feuntes, V. AU - Margevicius, S. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. C. F. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Webb Hooper, M. AU - Coccia, S. AU - Nagy, C. AU - Wimbley, L. AU - Berger, N. A. DB - Embase Medline DO - 10.1002/cncr.33430 KW - African American aged article breast cancer cancer staging cancer survival cancer survivor community controlled study exercise female human intervention study multicenter study (topic) Ohio randomization randomized controlled trial (topic) social status support group systematic review LA - English M3 - Article in Press N1 - L2010367927 2021-02-12 PY - 2021 SN - 1097-0142 0008-543X ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics T2 - Cancer TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010367927&from=export http://dx.doi.org/10.1002/cncr.33430 ID - 762 ER - TY - JOUR AB - Background: Behavioral intervention studies in older breast cancer survivors, particularly older African American (AA) and socioeconomic status–disadvantaged breast cancer survivors, are lacking. To inform future studies, the authors examined recruitment strategies in older breast cancer survivors who participated in an exercise intervention study. Methods: IMPROVE is a randomized trial designed to evaluate a group-based exercise intervention versus a support group (ClinicalTrials.gov identifier, NCT02763228). Participants were aged ≥65 years who had survived stage I through III breast cancer and were within 5 years of treatment completion. Participants were recruited through multiple approaches, including peripheral, linguistic, and constituent-involving strategies that incorporated the identification of potentially eligible patients from 3 local hospitals and from State of Ohio registries and through direct clinician and community organization referrals. Results: Between October 2016 and November 2019, 7487 patients were screened, 4790 were potentially eligible, and 213 were randomized into the study. The eligible:randomization rates were 4.4% overall and 84%, 8%, and 2% for recruitment using direct referrals, hospital registries, and state registries, respectively. The median age of the randomized cohort was 70 years (range, 65-88 years) and included 44% AA and 44% socioeconomic status–disadvantaged breast cancer survivors. Compared with all registry-eligible patients, directly referred-eligible patients were more likely to be AA versus Non-Hispanic White (41% vs 19%; P =.006), to be contacted successfully (100% vs 33%; P <.0001), and to accept study participation (88% vs 16%; P <.0001). Conclusions: Direct referrals appeared to be the most efficient strategy for recruiting AA survivors. Behavioral intervention studies seeking to target older AA and socioeconomic status–disadvantaged breast cancer survivors should include strategies that foster direct referrals to study participation. © 2021 American Cancer Society AD - Division of Hematology/Oncology, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, United States Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, United States Washington University School of Medicine, St Louis, MO, United States Hospice of Western Reserve, Cleveland, OH, United States The Gathering Place, Beachwood, OH, United States Department of Hematology/Oncology, Cleveland Clinic, Cleveland, OH, United States Physical Medicine and Rehabilitation, University Hospitals of Cleveland, Cleveland, OH, United States Penn State University College of Medicine, Hershey, PA, United States AU - Owusu, C. AU - Nock, N. L. AU - Feuntes, V. AU - Margevicius, S. AU - Hergenroeder, P. AU - Austin, K. AU - Bennet, E. AU - Cerne, S. AU - Moore, H. C. F. AU - Petkac, J. AU - Schluchter, M. AU - Schmitz, K. H. AU - Webb Hooper, M. AU - Coccia, S. AU - Nagy, C. AU - Wimbley, L. AU - Berger, N. A. DB - Scopus DO - 10.1002/cncr.33430 KW - African American (AA) exercise older breast cancer socioeconomic status-disadvantaged M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics T2 - Cancer TI - IMPROVE, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and Non-Hispanic White breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100336819&doi=10.1002%2fcncr.33430&partnerID=40&md5=977397196123eaadd55911b84654361a ID - 2160 ER - TY - JOUR AB - Background and Aim. Inadequate bowel preparation is a major impediment in colonoscopy quality outcomes. Aim of this study was to evaluate the role of multimedia education (MME) in improving bowel preparation quality and adenoma detection rate. Methods. This was an IRB‐approved prospective randomized study that enrolled 111 adult patients undergoing outpatient screening or surveillance colonoscopy. After receiving standard colonoscopy instructions, the patients were randomized into MME group (n = 48) and control group (n = 46). The MME group received comprehensive multimedia education including an audio‐visual program, a visual aid, and a brochure. Demographics, quality of bowel preparation, and colonoscopy findings were recorded. Results. MME group had a significantly better bowel preparation in the entire colon (OR 2.65, 95% CI 1.16‐6.09) and on the right side of the colon (OR 2.74, 95% CI 1.12‐6.71) as compared to control group (p < 0.05). Large polyps (>1 cm) were found more frequently in the MME group (11/31, 35.5% versus 0/13; p < 0.05). More polyps and adenomas were detected in MME group (57 versus 39 and 31 versus 13, resp.) but the difference failed to reach statistical significance. Conclusion. MME can lead to significant improvement in the quality of bowel preparation and large adenoma detection in a predominantly African‐American population. AN - CN-01141911 AU - Garg, S. AU - Girotra, M. AU - Chandra, L. AU - Verma, V. AU - Kaur, S. AU - Allawy, A. AU - Secco, A. AU - Anand, R. AU - Dutta, S. K. DO - 10.1155/2016/2072401 KW - *colon adenoma /diagnosis *intestine preparation *multimedia *multimedia education *patient education Adult African American Article Audiovisual aid Colon carcinoma /diagnosis Colon polyp /diagnosis Colonoscopy Controlled study Demography Female Groups by age Human Major clinical study Male Middle aged Outpatient Prospective study Race difference Randomized controlled trial Sex difference Single blind procedure Statistical significance Visual aid M3 - Journal: Article PY - 2016 ST - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: a Randomized Study T2 - Diagnostic and therapeutic endoscopy TI - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: a Randomized Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01141911/full VL - 2016 ID - 1464 ER - TY - JOUR AB - Background and Aim. Inadequate bowel preparation is a major impediment in colonoscopy quality outcomes. Aim of this study was to evaluate the role of multimedia education (MME) in improving bowel preparation quality and adenoma detection rate. Methods. This was an IRB-approved prospective randomized study that enrolled 111 adult patients undergoing outpatient screening or surveillance colonoscopy. After receiving standard colonoscopy instructions, the patients were randomized into MME group (n = 48) and control group (n = 46). The MME group received comprehensive multimedia education including an audio-visual program, a visual aid, and a brochure. Demographics, quality of bowel preparation, and colonoscopy findings were recorded. Results. MME group had a significantly better bowel preparation in the entire colon (OR 2.65, 95% CI 1.16-6.09) and on the right side of the colon (OR 2.74, 95% CI 1.12-6.71) as compared to control group (p < 0.05). Large polyps (>1 cm) were found more frequently in the MME group (11/31, 35.5% versus 0/13; p < 0.05). More polyps and adenomas were detected in MME group (57 versus 39 and 31 versus 13, resp.) but the difference failed to reach statistical significance. Conclusion. MME can lead to significant improvement in the quality of bowel preparation and large adenoma detection in a predominantly African-American population. © 2016 Shashank Garg et al. AD - Division of Gastroenterology, Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, United States Johns Hopkins University-Sinai Program in Internal Medicine, Baltimore, MD 21215, United States Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21215, United States AU - Garg, S. AU - Girotra, M. AU - Chandra, L. AU - Verma, V. AU - Kaur, S. AU - Allawy, A. AU - Secco, A. AU - Anand, R. AU - Dutta, S. K. C7 - 2072401 DB - Scopus DO - 10.1155/2016/2072401 M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2016 ST - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: A Randomized Study T2 - Diagnostic and Therapeutic Endoscopy TI - Improved Bowel Preparation with Multimedia Education in a Predominantly African-American Population: A Randomized Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84960981769&doi=10.1155%2f2016%2f2072401&partnerID=40&md5=2e4f4248b2af3d8b374a3957839ef97c VL - 2016 ID - 2353 ER - TY - JOUR AB - BACKGROUND: Little is known about the effect of health professionals' advice on promoting healthy lifestyle behaviors (diet and exercise) among breast cancer patients. PURPOSE: To identify predictors of receiving lifestyle advice from health professionals and its impact on healthy lifestyle behaviors. METHODS: We used data from a randomized controlled trial of an interactive, cancer‐communication video program using African American breast cancer survivor stories for newly diagnosed African American breast cancer patients (Stages 0‐III). Participants completed five interviews over 2 years. This intervention did not significantly affect changes in quality‐of‐life outcomes. In secondary analysis, we examined differences in baseline variables between women with and without diabetes. Logistic regression models identified independent predictors of receiving advice from "a doctor or other health professional" to improve diet and exercise and of self‐reported change in diet and exercise habits at 2 year follow‐up. RESULTS: Of 193 patients included (85% of 228 enrolled), 53 (28%) had diabetes. At 2 year follow‐up, a greater proportion of women with (vs. without) diabetes reported receiving advice by a doctor/health professional to improve their diet (73% vs. 57%, p = .04,). Predictors of receiving dietary advice were obesity, diabetes, and breast‐conserving surgery (each p < .05). Women receiving dietary advice were 2.75 times more likely to report improving their diet (95% confidence interval: 1.17, 6.46) at follow‐up, but receiving physical activity advice was not significantly associated with patients reporting an increase in exercise. CONCLUSIONS: Although receiving dietary advice predicted dietary improvements, receiving exercise advice did not lead to an increase in physical activity. CLINICAL TRIAL REGISTRATION: Trial Number NCT00929084. AN - CN-02098681 AU - Jarvandi, S. AU - Perez, M. AU - Margenthaler, J. AU - Colditz, G. A. AU - Kreuter, M. W. AU - Jeffe, D. B. DO - 10.1093/abm/kaaa020 KW - *African American *breast cancer *cancer therapy *diabetic obesity *diet *exercise *lifestyle Adult Article Cancer patient Cancer staging Cancer survival Cancer survivor Controlled study Female Follow up Habit Health practitioner Human Interview Major clinical study Partial mastectomy Physical activity Quality of life Randomized controlled trial Secondary analysis Videorecording M3 - Journal: Article in Press PY - 2020 ST - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: role of Health Care Professionals T2 - Annals of behavioral medicine TI - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: role of Health Care Professionals UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02098681/full ID - 1492 ER - TY - JOUR AB - BACKGROUND: Little is known about the effect of health professionals' advice on promoting healthy lifestyle behaviors (diet and exercise) among breast cancer patients. PURPOSE: To identify predictors of receiving lifestyle advice from health professionals and its impact on healthy lifestyle behaviors. METHODS: We used data from a randomized controlled trial of an interactive, cancer-communication video program using African American breast cancer survivor stories for newly diagnosed African American breast cancer patients (Stages 0-III). Participants completed five interviews over 2 years. This intervention did not significantly affect changes in quality-of-life outcomes. In secondary analysis, we examined differences in baseline variables between women with and without diabetes. Logistic regression models identified independent predictors of receiving advice from "a doctor or other health professional" to improve diet and exercise and of self-reported change in diet and exercise habits at 2 year follow-up. RESULTS: Of 193 patients included (85% of 228 enrolled), 53 (28%) had diabetes. At 2 year follow-up, a greater proportion of women with (vs. without) diabetes reported receiving advice by a doctor/health professional to improve their diet (73% vs. 57%, p = .04,). Predictors of receiving dietary advice were obesity, diabetes, and breast-conserving surgery (each p < .05). Women receiving dietary advice were 2.75 times more likely to report improving their diet (95% confidence interval: 1.17, 6.46) at follow-up, but receiving physical activity advice was not significantly associated with patients reporting an increase in exercise. CONCLUSIONS: Although receiving dietary advice predicted dietary improvements, receiving exercise advice did not lead to an increase in physical activity. CLINICAL TRIAL REGISTRATION: Trial Number NCT00929084. AU - Jarvandi, S. AU - Pérez, M. AU - Margenthaler, J. AU - Colditz, G. A. AU - Kreuter, M. W. AU - Jeffe, D. B. DB - Medline DO - 10.1093/abm/kaaa020 IS - 1 KW - NCT00929084 adult African American article breast cancer cancer patient cancer staging cancer survival cancer survivor cancer therapy controlled study diabetic obesity diet exercise female follow up habit health practitioner human interview lifestyle major clinical study partial mastectomy physical activity quality of life randomized controlled trial secondary analysis videorecording LA - English M3 - Article N1 - L631542303 2020-04-28 PY - 2021 SN - 1532-4796 SP - 1-13 ST - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals T2 - Annals of behavioral medicine : a publication of the Society of Behavioral Medicine TI - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631542303&from=export http://dx.doi.org/10.1093/abm/kaaa020 VL - 55 ID - 756 ER - TY - JOUR AB - Background: Little is known about the effect of health professionals' advice on promoting healthy lifestyle behaviors (diet and exercise) among breast cancer patients.Purpose: To identify predictors of receiving lifestyle advice from health professionals and its impact on healthy lifestyle behaviors.Methods: We used data from a randomized controlled trial of an interactive, cancer-communication video program using African American breast cancer survivor stories for newly diagnosed African American breast cancer patients (Stages 0-III). Participants completed five interviews over 2 years. This intervention did not significantly affect changes in quality-of-life outcomes. In secondary analysis, we examined differences in baseline variables between women with and without diabetes. Logistic regression models identified independent predictors of receiving advice from "a doctor or other health professional" to improve diet and exercise and of self-reported change in diet and exercise habits at 2 year follow-up.Results: Of 193 patients included (85% of 228 enrolled), 53 (28%) had diabetes. At 2 year follow-up, a greater proportion of women with (vs. without) diabetes reported receiving advice by a doctor/health professional to improve their diet (73% vs. 57%, p = .04,). Predictors of receiving dietary advice were obesity, diabetes, and breast-conserving surgery (each p < .05). Women receiving dietary advice were 2.75 times more likely to report improving their diet (95% confidence interval: 1.17, 6.46) at follow-up, but receiving physical activity advice was not significantly associated with patients reporting an increase in exercise.Conclusions: Although receiving dietary advice predicted dietary improvements, receiving exercise advice did not lead to an increase in physical activity.Clinical Trial Registration: Trial Number NCT00929084. AD - Department of Family and Consumer Sciences, University of Tennessee , Knoxville, TN, USA Department of Medicine, School of Medicine, Washington University in St. Louis , St. Louis, MO, USA Department of Surgery, School of Medicine, Washington University in St. Louis , St. Louis, MO, USA Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine , St. Louis, MO, USA Brown School of Social Work, Washington University in St. Louis , St. Louis, MO, USA AN - 148717933. Language: English. Entry Date: In Process. Revision Date: 20210223. Publication Type: journal article. Journal Subset: Biomedical AU - Jarvandi, Soghra AU - Pérez, Maria AU - Margenthaler, Julie AU - Colditz, Graham A. AU - Kreuter, Matthew W. AU - Jeffe, Donna B. DB - CINAHL Complete DO - 10.1093/abm/kaaa020 DP - EBSCOhost IS - 1 N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: P50 CA095815/CA/NCI NIH HHS/United States. NLM UID: 8510246. PMID: NLM32298407. PY - 2021 SN - 0883-6612 SP - 1-13 ST - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals T2 - Annals of Behavioral Medicine TI - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148717933&site=ehost-live&scope=site VL - 55 ID - 1975 ER - TY - JOUR AB - BACKGROUND: Little is known about the effect of health professionals' advice on promoting healthy lifestyle behaviors (diet and exercise) among breast cancer patients. PURPOSE: To identify predictors of receiving lifestyle advice from health professionals and its impact on healthy lifestyle behaviors. METHODS: We used data from a randomized controlled trial of an interactive, cancer-communication video program using African American breast cancer survivor stories for newly diagnosed African American breast cancer patients (Stages 0-III). Participants completed five interviews over 2 years. This intervention did not significantly affect changes in quality-of-life outcomes. In secondary analysis, we examined differences in baseline variables between women with and without diabetes. Logistic regression models identified independent predictors of receiving advice from "a doctor or other health professional" to improve diet and exercise and of self-reported change in diet and exercise habits at 2 year follow-up. RESULTS: Of 193 patients included (85% of 228 enrolled), 53 (28%) had diabetes. At 2 year follow-up, a greater proportion of women with (vs. without) diabetes reported receiving advice by a doctor/health professional to improve their diet (73% vs. 57%, p = .04,). Predictors of receiving dietary advice were obesity, diabetes, and breast-conserving surgery (each p < .05). Women receiving dietary advice were 2.75 times more likely to report improving their diet (95% confidence interval: 1.17, 6.46) at follow-up, but receiving physical activity advice was not significantly associated with patients reporting an increase in exercise. CONCLUSIONS: Although receiving dietary advice predicted dietary improvements, receiving exercise advice did not lead to an increase in physical activity. CLINICAL TRIAL REGISTRATION: Trial Number NCT00929084. © Society of Behavioral Medicine 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. AD - Department of Family and Consumer Sciences, University of Tennessee, TN, Knoxville, United States Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA Department of Surgery, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, USA AU - Jarvandi, S. AU - Pérez, M. AU - Margenthaler, J. AU - Colditz, G. A. AU - Kreuter, M. W. AU - Jeffe, D. B. DB - Scopus DO - 10.1093/abm/kaaa020 IS - 1 KW - Advice Breast cancer Diabetes Diet Exercise Healthcare professionals M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2021 SP - 1-13 ST - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals T2 - Annals of behavioral medicine : a publication of the Society of Behavioral Medicine TI - Improving Lifestyle Behaviors After Breast Cancer Treatment Among African American Women With and Without Diabetes: Role of Health Care Professionals UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092588598&doi=10.1093%2fabm%2fkaaa020&partnerID=40&md5=355ef3e482468ead5e117a0f55afd43d VL - 55 ID - 2154 ER - TY - JOUR AD - University of Chicago Medicine, Chicago, IL, United States AU - Ibraheem, A. AU - Polite, B. DB - Scopus DO - 10.1002/cncr.31073 IS - 24 M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2017 SP - 4752-4756 ST - Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes T2 - Cancer TI - Improving the accrual of racial and ethnic minority patients in clinical trials: Time to raise the stakes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032257207&doi=10.1002%2fcncr.31073&partnerID=40&md5=fd45b645bf19ef7f572e735944945cb3 VL - 123 ID - 2293 ER - TY - JOUR AB - ObjectivesTo evaluate the performance of multiparametric magnetic resonance imaging (mpMRI) in predicting prostate cancer on repeat biopsy; and to compare the cancer detection rates (CDRs) of MRI/transrectal ultrasonography (TRUS) fusion-guided biopsy with standard 12-core biopsy in men with at least one previous negative biopsy. Patients and Methods We prospectively enrolled men with elevated or rising PSA levels and/or abnormal digital rectal examination into our MRI/TRUS fusion-guided prostate biopsy trial. Participants underwent a 3 T mpMRI with an endorectal coil. Three radiologists graded all suspicious lesions on a 5-point Likert scale. MRI/TRUS fusion-guided biopsies of suspicious prostate lesions and standard TRUS-guided 12-core biopsies were performed. Analysis of 140 eligible men with at least one previous negative biopsy was performed. We calculated CDRs and estimated area under the receiver operating characteristic curves (AUCs) of mpMRI in predicting any cancer and clinically significant prostate cancer. Results The overall CDR was 65.0% (91/140). Higher level of suspicion on mpMRI was significantly associated with prostate cancer detection (P < 0.001) with an AUC of 0.744 compared with 0.653 and 0.680 for PSA level and PSA density, respectively. The CDRs of MRI/TRUS fusion-guided and standard 12-core biopsy were 52.1% (73/140) and 48.6% (68/140), respectively (P = 0.435). However, fusion biopsy was more likely to detect clinically significant prostate cancer when compared with the 12-core biopsy (47.9% vs 30.7%; P < 0.001). Of the cancers missed by 12-core biopsy, 20.9% (19/91) were clinically significant. Most cancers missed by 12-core biopsy (69.6%) were located in the anterior fibromuscular stroma and transition zone. Using a fusion-biopsy-only approach in men with an MRI suspicion score of ≥4 would have missed only 3.5% of clinically significant prostate cancers. Conclusions Using mpMRI and subsequent MRI/TRUS fusion-guided biopsy platform may improve detection of clinically significant prostate cancer in men with previous negative biopsies. Addition of a 12-core biopsy may be needed to avoid missing some clinically significant prostate cancers. © 2014 The Authors. BJU International © 2014 BJU International. AD - Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, 450 Lakeville Rd, New Hyde Park, NY 11040, United States Department of Diagnostic and Interventional Radiology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, United States Department of Pathology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY, United States Molecular Imaging Program, National Institutes of Health, Bethesda, MD, United States AU - Salami, S. S. AU - Ben-Levi, E. AU - Yaskiv, O. AU - Ryniker, L. AU - Turkbey, B. AU - Kavoussi, L. R. AU - Villani, R. AU - Rastinehad, A. R. DB - Scopus DO - 10.1111/bju.12938 IS - 4 KW - false-negative prostate biopsy negative prostate biopsy prostate cancer screening prostate fusion biopsy prostate imaging M3 - Article N1 - Cited By :109 Export Date: 22 March 2021 PY - 2015 SP - 562-570 ST - In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? T2 - BJU International TI - In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84925652118&doi=10.1111%2fbju.12938&partnerID=40&md5=18d59f1412201db8f3bcc338e29c80b9 VL - 115 ID - 2366 ER - TY - JOUR AB - Metastasis is a major cause of cancer-related death and liver metastasis (LM) is a distinct type for its relatively good prognosis after timely treatment for selected patients. However, a generalizable estimation of incidence and prognosis of LM is lacking. Cancer patients with known LM status in the Surveillance, Epidemiology and End Results database were enrolled in the present study. The incidence and prognosis of LM were calculated by primary cancer type and clinicopathological factors. Among 1,630,725 cases, 105,329 (6.46%) cases present LM at diagnosis, with a median survival of 4 months. LM presents at diagnosis in 39.96% of pancreatic cancer, 16.00% of colorectal cancer (CRC) and 12.68% of lung cancer. Of all LM cases, 25.58% originated from lung cancer, with 24.76% from CRC and 17.55% from pancreatic cancer. LM originated from small intestine cancer shows the best prognosis (median survival: 30 months), followed by testis cancer (25 months) and breast cancer (15 months). Subgroup analyses demonstrated disparities in incidence and prognosis of LM, with higher incidence and poorer prognosis in the older population, African American, male, and patients with inferior socioeconomic status. The current study provides a generalizable data resource for the epidemiology of LM, which may help tailor screening protocol, design clinical trials and estimate disease burden. AD - Y. Ni, Faculty of Me-dicine, Campus Gasthuisberg, Ku Leuven, Leuven, Belgium Y. Li, Shang-hai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China AU - Wang, S. AU - Feng, Y. AU - Swinnen, J. AU - Oyen, R. AU - Li, Y. AU - Ni, Y. DB - Embase IS - 5 KW - adult African American aged article breast cancer cancer incidence cancer patient cancer prognosis cancer staging cancer survival colorectal cancer educational status female health insurance household income human liver metastasis lung cancer major clinical study male marriage median survival time pancreas cancer population research primary tumor sex difference small intestine cancer social status testis cancer unemployment very elderly LA - English M3 - Article N1 - L633283065 2020-11-06 2020-12-18 PY - 2020 SN - 2156-6976 SP - 1477-1517 ST - Incidence and prognosis of liver metastasis at diagnosis: A pan-cancer population-based study T2 - American Journal of Cancer Research TI - Incidence and prognosis of liver metastasis at diagnosis: A pan-cancer population-based study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633283065&from=export VL - 10 ID - 827 ER - TY - JOUR AB - Metastasis is a major cause of cancer-related death and liver metastasis (LM) is a distinct type for its relatively good prognosis after timely treatment for selected patients. However, a generalizable estimation of incidence and prognosis of LM is lacking. Cancer patients with known LM status in the Surveillance, Epidemiology and End Results database were enrolled in the present study. The incidence and prognosis of LM were calculated by primary cancer type and clinicopathological factors. Among 1,630,725 cases, 105,329 (6.46%) cases present LM at diagnosis, with a median survival of 4 months. LM presents at diagnosis in 39.96% of pancreatic cancer, 16.00% of colorectal cancer (CRC) and 12.68% of lung cancer. Of all LM cases, 25.58% originated from lung cancer, with 24.76% from CRC and 17.55% from pancreatic cancer. LM originated from small intestine cancer shows the best prognosis (median survival: 30 months), followed by testis cancer (25 months) and breast cancer (15 months). Subgroup analyses demonstrated disparities in incidence and prognosis of LM, with higher incidence and poorer prognosis in the older population, African American, male, and patients with inferior socioeconomic status. The current study provides a generalizable data resource for the epidemiology of LM, which may help tailor screening protocol, design clinical trials and estimate disease burden. AN - WOS:000537463800015 AU - Wang, S. C. AU - Feng, Y. B. AU - Swinnen, J. AU - Oyen, R. AU - Li, Y. AU - Ni, Y. C. IS - 5 N1 - 32509393 PY - 2020 SN - 2156-6976 SP - 1477-1517 ST - Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study T2 - American Journal of Cancer Research TI - Incidence and prognosis of liver metastasis at diagnosis: a pan-cancer population-based study VL - 10 ID - 2798 ER - TY - JOUR AB - Background: Chest imaging is performed for a variety of reasons in HIV-infected adults. There are limited data on the prevalence of incidental findings, progression of these findings over time and the relationship with inflammation in antiretroviral therapy (ART)-treated HIV-infected adults. Methods: This study utilized data from a randomized clinical trial of rosuvastatin in HIV-infected adults on ART. Incidental findings were reported from chest computed tomography (CT) scans obtained for coronary artery calcium score at entry, week 48 and 96. Markers of immune activation and inflammation were measured concurrently. Poisson regression and generalized estimating equations were used. Results: A total of 147 participants were enrolled. Median age was 46 years, 78% were male, 68% African American and 63% current smokers. At baseline, 57% of participants had at least one incidental lung finding (ILF) and four additional participants had at least one ILF by week 96. At baseline, older age, current smoking, lower nadir CD4+ T-cell count and low-density lipoprotein and higher lipoprotein-associated phospholipase A2 (Lp-PLA2) were independently associated with having a greater number of ILFs. In the longitudinal analyses, older age, lower nadir CD4+ T-cell count and higher baseline soluble tumour necrosis factor α-receptor I (sTNF-RI) were independently associated with having a greater number of ILFs over 96 weeks. Conclusions: Over half of participants had at least one incidental finding on chest CT. Beyond traditional factors of older age and smoking, lower nadir CD4+ T-cell count and higher markers of inflammation were associated with having a greater number of ILFs in HIV-infected adults on ART. AD - G.A. McComsey, Case Western Reserve University School of Medicine, Cleveland, OH, United States AU - Park, M. S. AU - Hileman, C. O. AU - Sattar, A. AU - Gilkeson, R. AU - McComsey, G. A. DB - Embase Medline DO - 10.3851/IMP3090 IS - 2 KW - NCT01218802 1 alkyl 2 acetylglycerophosphocholine esterase low density lipoprotein placebo rosuvastatin tumor necrosis factor receptor 1 adult African American age antiretroviral therapy article atelectasis CD4 lymphocyte count computed tomography scanner computer assisted tomography coronary artery calcium score female human Human immunodeficiency virus infection incidental finding latent tuberculosis lung disease lung nodule major clinical study male parenchymal scar Pneumocystis pneumonia priority journal randomized controlled trial (topic) smoking Somatom Sensation 64 LA - English M3 - Article N1 - L616310458 2017-05-26 2017-05-31 PY - 2017 SN - 2040-2058 1359-6535 SP - 127-133 ST - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults T2 - Antiviral Therapy TI - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616310458&from=export http://dx.doi.org/10.3851/IMP3090 VL - 22 ID - 948 ER - TY - JOUR AB - BACKGROUND: Chest imaging is performed for a variety of reasons in HIV‐infected adults. There are limited data on the prevalence of incidental findings, progression of these findings over time and the relationship with inflammation in antiretroviral therapy (ART)‐treated HIV‐infected adults. METHODS: This study utilized data from a randomized clinical trial of rosuvastatin in HIV‐infected adults on ART. Incidental findings were reported from chest computed tomography (CT) scans obtained for coronary artery calcium score at entry, week 48 and 96. Markers of immune activation and inflammation were measured concurrently. Poisson regression and generalized estimating equations were used. RESULTS: A total of 147 participants were enrolled. Median age was 46 years, 78% were male, 68% African American and 63% current smokers. At baseline, 57% of participants had at least one incidental lung finding (ILF) and four additional participants had at least one ILF by week 96. At baseline, older age, current smoking, lower nadir CD4+ T‐cell count and low‐density lipoprotein and higher lipoprotein‐associated phospholipase A2 (Lp‐PLA2) were independently associated with having a greater number of ILFs. In the longitudinal analyses, older age, lower nadir CD4+ T‐cell count and higher baseline soluble tumour necrosis factor α‐receptor I (sTNF‐RI) were independently associated with having a greater number of ILFs over 96 weeks. CONCLUSIONS: Over half of participants had at least one incidental finding on chest CT. Beyond traditional factors of older age and smoking, lower nadir CD4+ T‐cell count and higher markers of inflammation were associated with having a greater number of ILFs in HIV‐infected adults on ART. AN - CN-01379469 AU - Park, M. S. AU - Hileman, C. O. AU - Sattar, A. AU - Gilkeson, R. AU - McComsey, G. A. DO - 10.3851/IMP3090 IS - 2 KW - 1‐Alkyl‐2‐acetylglycerophosphocholine Esterase [blood] Adult Age Factors Anticholesteremic Agents [therapeutic use] Antiretroviral Therapy, Highly Active CD4 Lymphocyte Count Calcinosis [*diagnostic imaging, pathology] Coronary Vessels [*diagnostic imaging, pathology] Female HIV Infections [*diagnostic imaging, drug therapy, virology] HIV‐1 [drug effects, physiology] Humans Incidental Findings Lipoproteins, LDL [blood] Lung [*diagnostic imaging, pathology] Male Middle Aged Receptors, Tumor Necrosis Factor, Type I [blood] Risk Factors Rosuvastatin Calcium [therapeutic use] Smoking [physiopathology] Tomography, X‐Ray Computed M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2017 SP - 127‐133 ST - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults T2 - Antiviral therapy TI - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01379469/full VL - 22 ID - 1628 ER - TY - JOUR AB - Background: Chest imaging is performed for a variety of reasons in HIV-infected adults. There are limited data on the prevalence of incidental findings, progression of these findings over time and the relationship with inflammation in antiretroviral therapy (ART)-treated HIV-infected adults. Methods: This study utilized data from a randomized clinical trial of rosuvastatin in HIV-infected adults on ART. Incidental findings were reported from chest computed tomography (CT) scans obtained for coronary artery calcium score at entry, week 48 and 96. Markers of immune activation and inflammation were measured concurrently. Poisson regression and generalized estimating equations were used. Results: A total of 147 participants were enrolled. Median age was 46 years, 78% were male, 68% African American and 63% current smokers. At baseline, 57% of participants had at least one incidental lung finding (ILF) and four additional participants had at least one ILF by week 96. At baseline, older age, current smoking, lower nadir CD4+ T-cell count and low-density lipoprotein and higher lipoprotein-associated phospholipase A2 (Lp-PLA2) were independently associated with having a greater number of ILFs. In the longitudinal analyses, older age, lower nadir CD4+ T-cell count and higher baseline soluble tumour necrosis factor α-receptor I (sTNF-RI) were independently associated with having a greater number of ILFs over 96 weeks. Conclusions: Over half of participants had at least one incidental finding on chest CT. Beyond traditional factors of older age and smoking, lower nadir CD4+ T-cell count and higher markers of inflammation were associated with having a greater number of ILFs in HIV-infected adults on ART. ©2017 International Medical Press. AD - Case Western Reserve University School of Medicine, Cleveland, OH, United States MetroHealth Medical Center, Cleveland, OH, United States University Hospitals Case Medical Center, Cleveland, OH, United States AU - Park, M. S. AU - Hileman, C. O. AU - Sattar, A. AU - Gilkeson, R. AU - McComsey, G. A. DB - Scopus DO - 10.3851/IMP3090 IS - 2 M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2017 SP - 127-133 ST - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults T2 - Antiviral Therapy TI - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019886238&doi=10.3851%2fIMP3090&partnerID=40&md5=5f07abce0a309916a624a6e6d649fafe VL - 22 ID - 2326 ER - TY - JOUR AB - Background: Chest imaging is performed for a variety of reasons in HIV-infected adults. There are limited data on the prevalence of incidental findings, progression of these findings over time and the relationship with inflammation in antiretroviral therapy (ART)-treated HIV-infected adults. Methods: This study utilized data from a randomized clinical trial of rosuvastatin in HIV-infected adults on ART. Incidental findings were reported from chest computed tomography (CT) scans obtained for coronary artery calcium score at entry, week 48 and 96. Markers of immune activation and inflammation were measured concurrently. Poisson regression and generalized estimating equations were used. Results: A total of 147 participants were enrolled. Median age was 46 years, 78% were male, 68% African American and 63% current smokers. At baseline, 57% of participants had at least one incidental lung finding (ILF) and four additional participants had at least one ILF by week 96. At baseline, older age, current smoking, lower nadir CD4(+) T-cell count and low-density lipoprotein and higher lipoprotein-associated phospholipase A2 (Lp-PLA2) were independently associated with having a greater number of ILFs. In the longitudinal analyses, older age, lower nadir CD4(+) T-cell count and higher baseline soluble tumour necrosis factor alpha-receptor I (sTNF-RI) were independently associated with having a greater number of ILFs over 96 weeks. Conclusions: Over half of participants had at least one incidental finding on chest CT. Beyond traditional factors of older age and smoking, lower nadir CD4(+) T-cell count and higher markers of inflammation were associated with having a greater number of ILFs in HIV-infected adults on ART. AN - WOS:000423269300004 AU - Park, M. S. AU - Hileman, C. O. AU - Sattar, A. AU - Gilkeson, R. AU - McComsey, G. A. DO - 10.3851/IMP3090 IS - 2 N1 - 27647021 PY - 2017 SN - 1359-6535 SP - 127-133 ST - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults T2 - Antiviral Therapy TI - Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults VL - 22 ID - 2914 ER - TY - JOUR AB - Background: Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. Methods: The Oncology Welcomes New Haven into Trials (OWN IT) initiative at the Yale Cancer Center used a multi-tiered approach to improve breast cancer minority clinical trial accrual through community focus groups, ongoing community outreach, institutional executive council representation, grand rounds presentation, and didactic lectures with healthcare providers. Eligibility criteria of breast cancer trials at Smilow Cancer Center were reviewed using clinicaltrials.gov. Also, an anonymous, 5-min survey was conducted at regular visits with Smilow Breast Center patients to gauge awareness of and access to clinical trials. Survey data were compared to the Yale Cancer Center Clinical Trials Office, Connecticut Tumor Registry, and U.S. Census records. Two-tailed Fisher’s tests were used for all analyses. Results: There was a significant increase in the number of minority patients who participated in clinical trials at Smilow Cancer Center from 2016 (95/750) to 2018 (155/944) (p = 0.0325). Two hundred patients participated in the survey; response rate 92%. There was no significant difference in the rate at which patients were invited to participate in clinical trials or the rate at which they declined to participate based on race or ethnicity. Black and Hispanic patients were significantly less likely to be aware of clinical trials than white patients (p <.001). The review of eligibility criteria showed that over half of the studies reviewed had restrictions regarding increased liver function tests, and many restricted the participation of patients with other chronic conditions. Conclusions: Low participation in clinical trials among black and Hispanic patients is likely multifaceted. This study indicated that there are likely structural factors at work which can be modified with institutional effort. The role of patient education regarding clinical trials and accrual should be studied further as should eligibility criteria as a potential barrier to participation. AD - A.A. Trant, Yale Cancer Center, 300 George Street, Suite 120, New Haven, CT, United States AU - Trant, A. A. AU - Walz, L. AU - Allen, W. AU - DeJesus, J. AU - Hatzis, C. AU - Silber, A. DB - Embase Medline DO - 10.1007/s10549-020-05873-2 IS - 2 KW - adult aged article Black person breast cancer chronic disease clinical trial (topic) health care disparity health survey Hispanic human liver function test minority group patient participation priority journal race LA - English M3 - Article N1 - L2005965767 2020-08-31 PY - 2020 SN - 1573-7217 0167-6806 SP - 499-505 ST - Increasing accrual of minority patients in breast cancer clinical trials T2 - Breast Cancer Research and Treatment TI - Increasing accrual of minority patients in breast cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005965767&from=export http://dx.doi.org/10.1007/s10549-020-05873-2 VL - 184 ID - 781 ER - TY - JOUR AB - Background: Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. Methods: The Oncology Welcomes New Haven into Trials (OWN IT) initiative at the Yale Cancer Center used a multi-tiered approach to improve breast cancer minority clinical trial accrual through community focus groups, ongoing community outreach, institutional executive council representation, grand rounds presentation, and didactic lectures with healthcare providers. Eligibility criteria of breast cancer trials at Smilow Cancer Center were reviewed using clinicaltrials.gov. Also, an anonymous, 5-min survey was conducted at regular visits with Smilow Breast Center patients to gauge awareness of and access to clinical trials. Survey data were compared to the Yale Cancer Center Clinical Trials Office, Connecticut Tumor Registry, and U.S. Census records. Two-tailed Fisher’s tests were used for all analyses. Results: There was a significant increase in the number of minority patients who participated in clinical trials at Smilow Cancer Center from 2016 (95/750) to 2018 (155/944) (p = 0.0325). Two hundred patients participated in the survey; response rate 92%. There was no significant difference in the rate at which patients were invited to participate in clinical trials or the rate at which they declined to participate based on race or ethnicity. Black and Hispanic patients were significantly less likely to be aware of clinical trials than white patients (p <.001). The review of eligibility criteria showed that over half of the studies reviewed had restrictions regarding increased liver function tests, and many restricted the participation of patients with other chronic conditions. Conclusions: Low participation in clinical trials among black and Hispanic patients is likely multifaceted. This study indicated that there are likely structural factors at work which can be modified with institutional effort. The role of patient education regarding clinical trials and accrual should be studied further as should eligibility criteria as a potential barrier to participation. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. AD - Yale Cancer Center, 300 George Street, Suite 120, New Haven, CT 06511, United States AU - Trant, A. A. AU - Walz, L. AU - Allen, W. AU - DeJesus, J. AU - Hatzis, C. AU - Silber, A. DB - Scopus DO - 10.1007/s10549-020-05873-2 IS - 2 KW - Breast cancer Clinical trials Eligibility criteria Health disparities M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 499-505 ST - Increasing accrual of minority patients in breast cancer clinical trials T2 - Breast Cancer Research and Treatment TI - Increasing accrual of minority patients in breast cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089826280&doi=10.1007%2fs10549-020-05873-2&partnerID=40&md5=b19b9189b7133fb4c403c9ede7ac297a VL - 184 ID - 2175 ER - TY - JOUR AB - Background Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. Methods The Oncology Welcomes New Haven into Trials (OWN IT) initiative at the Yale Cancer Center used a multi-tiered approach to improve breast cancer minority clinical trial accrual through community focus groups, ongoing community outreach, institutional executive council representation, grand rounds presentation, and didactic lectures with healthcare providers. Eligibility criteria of breast cancer trials at Smilow Cancer Center were reviewed using clinicaltrials.gov. Also, an anonymous, 5-min survey was conducted at regular visits with Smilow Breast Center patients to gauge awareness of and access to clinical trials. Survey data were compared to the Yale Cancer Center Clinical Trials Office, Connecticut Tumor Registry, and U.S. Census records. Two-tailed Fisher's tests were used for all analyses. Results There was a significant increase in the number of minority patients who participated in clinical trials at Smilow Cancer Center from 2016 (95/750) to 2018 (155/944) (p = 0.0325). Two hundred patients participated in the survey; response rate 92%. There was no significant difference in the rate at which patients were invited to participate in clinical trials or the rate at which they declined to participate based on race or ethnicity. Black and Hispanic patients were significantly less likely to be aware of clinical trials than white patients (p < .001). The review of eligibility criteria showed that over half of the studies reviewed had restrictions regarding increased liver function tests, and many restricted the participation of patients with other chronic conditions. Conclusions Low participation in clinical trials among black and Hispanic patients is likely multifaceted. This study indicated that there are likely structural factors at work which can be modified with institutional effort. The role of patient education regarding clinical trials and accrual should be studied further as should eligibility criteria as a potential barrier to participation. AN - WOS:000563031900001 AU - Trant, A. A. AU - Walz, L. AU - Allen, W. AU - DeJesus, J. AU - Hatzis, C. AU - Silber, A. DA - Nov DO - 10.1007/s10549-020-05873-2 IS - 2 N1 - 32840699 PY - 2020 SN - 0167-6806 SP - 499-505 ST - Increasing accrual of minority patients in breast cancer clinical trials T2 - Breast Cancer Research and Treatment TI - Increasing accrual of minority patients in breast cancer clinical trials VL - 184 ID - 2769 ER - TY - JOUR AB - BACKGROUND: A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. METHODS: A multiethnic sample of Caucasian, African‐American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. RESULTS: At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12‐month follow‐up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95‐2.28). CONCLUSIONS: The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening. AN - CN-00505777 AU - Avis, N. E. AU - Smith, K. W. AU - Link, C. L. AU - Goldman, M. B. DO - 10.1016/j.ypmed.2004.05.024 IS - 3 KW - African Americans [statistics & numerical data] Age Distribution Aged Asian Americans [statistics & numerical data] Attitude to Health [*ethnology] Breast Neoplasms [ethnology, *prevention & control] European Continental Ancestry Group [statistics & numerical data] Female Humans Incidence Logistic Models Mammography [*statistics & numerical data] Mass Screening [statistics & numerical data] Middle Aged Pamphlets Patient Acceptance of Health Care [*ethnology] Patient Compliance Patient Education as Topic [methods] Probability Prospective Studies United States Video Recording M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2004 SP - 498‐506 ST - Increasing mammography screening among women over age 50 with a videotape intervention T2 - Preventive medicine TI - Increasing mammography screening among women over age 50 with a videotape intervention UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00505777/full VL - 39 ID - 1395 ER - TY - JOUR AB - Background: A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. Methods: A multiethnic sample of Caucasian, African-American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. Results: At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12-month follow-up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95-2.28). Conclusions: The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Avis, Nancy E., Section on Social Sciences and Health Policy, Department of Public Health Sciences, Wake Forest University School of Medicine, Piedmont Plaza II, Winston-Salem, NC, US, 27157 AN - 2004-18374-006 AU - Avis, Nancy E. AU - Smith, Kevin W. AU - Link, Carol L. AU - Goldman, Marlene B. DB - psyh DO - 10.1016/j.ypmed.2004.05.024 DP - EBSCOhost IS - 3 KW - mammography screening videotape intervention health attitudes health beliefs African Americans Age Distribution Aged Asian Americans Attitude to Health Breast Neoplasms European Continental Ancestry Group Female Humans Incidence Logistic Models Mammography Mass Screening Middle Aged Pamphlets Patient Acceptance of Health Care Patient Compliance Patient Education as Topic Probability Prospective Studies United States Video Recording Cancer Screening Videotapes Human Females N1 - Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, US. Release Date: 20041012. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Cancer Screening; Health Attitudes; Mammography; Videotapes. Minor Descriptor: Human Females. Classification: Cancer (3293); Medical Treatment of Physical Illness (3363). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Followup Study; Longitudinal Study; Prospective Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Sep, 2004. PY - 2004 SN - 0091-7435 SP - 498-506 ST - Increasing mammography screening among women over age 50 with a videotape intervention T2 - Preventive Medicine: An International Journal Devoted to Practice and Theory TI - Increasing mammography screening among women over age 50 with a videotape intervention UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2004-18374-006&site=ehost-live&scope=site navis@wfubmc.edu VL - 39 ID - 1788 ER - TY - JOUR AB - Background. A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. Methods. A multiethnic sample of Caucasian, African-American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. Results. At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12-month follow-up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95-2.28). Conclusions. The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening. © 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AD - Section on Social Sciences and Health Policy, Department of Public Health Sciences, Wake Forest University School of Medicine, Piedmont Plaza II, Winston-Salem, NC 27157; navis@wfubmc.edu AN - 106561996. Language: English. Entry Date: 20050114. Revision Date: 20200708. Publication Type: Journal Article AU - Avis, N. E. AU - Smith, K. W. AU - Link, C. L. AU - Goldman, M. B. DB - CINAHL Complete DO - 10.1016/j.ypmed.2004.05.024 DP - EBSCOhost IS - 3 KW - Breast Neoplasms -- Prevention and Control Mammography -- Trends Aged Clinical Trials Descriptive Statistics Female Focus Groups Health Beliefs Health Services Accessibility Interviews Logistic Regression Massachusetts Middle Age Odds Ratio P-Value Prospective Studies Questionnaires T-Tests Videorecording Funding Source Human N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: Supported by Grant No. R44 CA76756 from the National Cancer Institute. NLM UID: 0322116. PMID: NLM15313089. PY - 2004 SN - 0091-7435 SP - 498-506 ST - Increasing mammography screening among women over age 50 with a videotape intervention T2 - Preventive Medicine TI - Increasing mammography screening among women over age 50 with a videotape intervention UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106561996&site=ehost-live&scope=site VL - 39 ID - 1976 ER - TY - JOUR AB - Background. A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. Methods. A multiethnic sample of Caucasian, African-American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. Results. At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12-month follow-up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95-2.28). Conclusions. The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening. © 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AD - Department of Public Health Sciences, Wake Forest Univ. School of Medicine, Winston-Salem, NC, United States New England Research Institutes, Watertown, MA, United States Dept. of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA, United States Sect. on Social Sci. and Hlth. Plcy., Department of Public Health Sciences, Wake Forest Univ. Sch. Med., P., United States AU - Avis, N. E. AU - Smith, K. W. AU - Link, C. L. AU - Goldman, M. B. DB - Scopus DO - 10.1016/j.ypmed.2004.05.024 IS - 3 KW - African-American Hispanic Intervention Mammography Videotape M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2004 SP - 498-506 ST - Increasing mammography screening among women over age 50 with a videotape intervention T2 - Preventive Medicine TI - Increasing mammography screening among women over age 50 with a videotape intervention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-4143070192&doi=10.1016%2fj.ypmed.2004.05.024&partnerID=40&md5=3ccd28d9cade3512f9a0c9de51947660 VL - 39 ID - 2605 ER - TY - JOUR AB - Background. A randomized trial was conducted to test the effectiveness of a videotape for increasing mammography screening among a multiethnic sample of older women. Methods. A multiethnic sample of Caucasian, African-American, and Hispanic women between the ages of 50 and 70 was recruited from Resident Lists compiled by the State of Massachusetts. After completing a baseline questionnaire, women were randomized to receive either a videotape or pamphlet about mammography and recontacted at 2 and 12 months after baseline to assess attitudes, beliefs, and mammography screening. A total of 581 women completed questionnaires at all three time points. Results. At baseline, approximately 75% of women reported having a mammogram in the past year and 90% reported having one in the past 2 years. Rates did not differ between groups. At the 12-month follow-up, mammography rates, adjusted for baseline screening, were 80.4% in the video and 74.8% in the pamphlet group. Logistic regression analysis of mammography at 12 months (within past year vs. >1 year ago) controlling for baseline mammogram produced an odds ratio of 1.48 for the video group that was not significantly different from unity (95% CI = 0.95-2.28). Conclusions. The videotape had a small effect on increasing mammography screening. Although the effect was smaller than more intensive interventions, the video is a convenient, low cost, and easily implemented method to increase mammography screening. (C) 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved. AN - WOS:000223760000009 AU - Avis, N. E. AU - Smith, K. W. AU - Link, C. L. AU - Goldman, M. B. DA - Sep DO - 10.1016/j.ypmed.2004.05.024 IS - 3 N1 - 17 15313089 PY - 2004 SN - 0091-7435 SP - 498-506 ST - Increasing mammography screening among women over age 50 with a videotape intervention T2 - Preventive Medicine TI - Increasing mammography screening among women over age 50 with a videotape intervention VL - 39 ID - 2676 ER - TY - JOUR AB - Background: Residential distance from an academic or cancer center is a significant barrier to minority patient participation in cancer research. Most cancer clinical trials (CTs) are only accessible at academic and cancer centers, yet most cancer patients receive treatment in their home communities where access to CTs may be limited. Oncology nurse navigation is an innovative approach for increasing minority CT participation by facilitating access to cancer CTs in communities where minority patients live. The purpose of this study was to evaluate the impact of oncology nurse navigation on community-based recruitment of black patients to breast cancer CTs at a major cancer center. Methods: We merged the roles of a traditional oncology research nurse and a professional patient navigator to create a novel health care provider role, the oncology nurse navigator. The primary duties of the oncology nurse navigator were to engage black cancer patients in the offices of their community physicians and to collaborate with community physicians to increase black patient participation in cancer research. The oncology nurse navigator played a key role in all phases of the CT participation process (e.g., screening for eligibility and completion of informed consent and clinical research forms) and guided each patient around barriers in the health care system. The accrual of eligible patients to breast cancer CTs was used to assess the impact of oncology nurse navigation on community-based recruitment of blacks to cancer CTs. Results: Between January 2007 and December 2008, a total of 132 black breast cancer patients were screened by a single oncology nurse navigator for eligibility to University of Southern Californiasponsored breast cancer CTs. Fifty-nine patients were eligible for CTs, and each was invited to participate in 1 or more CTs for which they were eligible. Fifty-one of 59 eligible black patients (86% of eligible patients) were enrolled to 1 or more research protocols. The estimated cost per enrolled patient was $5,677, nearly half the expected per patient cost of treating patients on CT at an academic or cancer center. Conclusions: Oncology nurse navigation is an effective outreach strategy for increasing black patient participation in cancer research and may be achieved at nearly half the cost of traditional methods of enrolling patients in CTs at cancer centers. © 2012 Elsevier Inc. All rights reserved. AD - D.R. Holmes, University of Southern California, Kenneth Norris Jr. Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, United States AU - Holmes, D. R. AU - Major, J. AU - Lyonga, D. E. AU - Alleyne, R. S. AU - Clayton, S. M. DB - Embase Medline DO - 10.1016/j.amjsurg.2011.02.005 IS - 4 KW - African American article breast cancer cancer center cancer research clinical trial (topic) community health nursing cost benefit analysis cost effectiveness analysis health care personnel health care system human major clinical study oncology nursing patient participation priority journal LA - English M3 - Article N1 - L51662972 2011-10-15 2012-04-12 PY - 2012 SN - 0002-9610 1879-1883 SP - 415-422 ST - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation T2 - American Journal of Surgery TI - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51662972&from=export http://dx.doi.org/10.1016/j.amjsurg.2011.02.005 VL - 203 ID - 1123 ER - TY - JOUR AB - Background: Residential distance from an academic or cancer center is a significant barrier to minority patient participation in cancer research. Most cancer clinical trials (CTs) are only accessible at academic and cancer centers, yet most cancer patients receive treatment in their home communities where access to CTs may be limited. Oncology nurse navigation is an innovative approach for increasing minority CT participation by facilitating access to cancer CTs in communities where minority patients live. The purpose of this study was to evaluate the impact of oncology nurse navigation on community-based recruitment of black patients to breast cancer CTs at a major cancer center. Methods: We merged the roles of a traditional oncology research nurse and a professional patient navigator to create a novel health care provider role, the oncology nurse navigator. The primary duties of the oncology nurse navigator were to engage black cancer patients in the offices of their community physicians and to collaborate with community physicians to increase black patient participation in cancer research. The oncology nurse navigator played a key role in all phases of the CT participation process (e.g., screening for eligibility and completion of informed consent and clinical research forms) and guided each patient around barriers in the health care system. The accrual of eligible patients to breast cancer CTs was used to assess the impact of oncology nurse navigation on community-based recruitment of blacks to cancer CTs. Results: Between January 2007 and December 2008, a total of 132 black breast cancer patients were screened by a single oncology nurse navigator for eligibility to University of Southern Californiasponsored breast cancer CTs. Fifty-nine patients were eligible for CTs, and each was invited to participate in 1 or more CTs for which they were eligible. Fifty-one of 59 eligible black patients (86% of eligible patients) were enrolled to 1 or more research protocols. The estimated cost per enrolled patient was $5,677, nearly half the expected per patient cost of treating patients on CT at an academic or cancer center. Conclusions: Oncology nurse navigation is an effective outreach strategy for increasing black patient participation in cancer research and may be achieved at nearly half the cost of traditional methods of enrolling patients in CTs at cancer centers. © 2012 Elsevier Inc. All rights reserved. AD - University of Southern California, Kenneth Norris Jr. Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, United States Private Practice, Inglewood, CA 90301, United States Private Practice, Los Angeles, CA 90017, United States Private Practice, Martin Luther King Medical Center, Los Angeles, CA 90059, United States AU - Holmes, D. R. AU - Major, J. AU - Lyonga, D. E. AU - Alleyne, R. S. AU - Clayton, S. M. DB - Scopus DO - 10.1016/j.amjsurg.2011.02.005 IS - 4 KW - African American Blacks Community outreach Community partners Community physician Cost-effective Heath disparities Oncology research nurse Underserved communities M3 - Article N1 - Cited By :28 Export Date: 22 March 2021 PY - 2012 SP - 415-422 ST - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation T2 - American Journal of Surgery TI - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859102316&doi=10.1016%2fj.amjsurg.2011.02.005&partnerID=40&md5=d2b650f74a942a46081d627d5b783e81 VL - 203 ID - 2462 ER - TY - JOUR AB - BACKGROUND: Residential distance from an academic or cancer center is a significant barrier to minority patient participation in cancer research. Most cancer clinical trials (CTs) are only accessible at academic and cancer centers, yet most cancer patients receive treatment in their home communities where access to CTs may be limited. Oncology nurse navigation is an innovative approach for increasing minority CT participation by facilitating access to cancer CTs in communities where minority patients live. The purpose of this study was to evaluate the impact of oncology nurse navigation on community-based recruitment of black patients to breast cancer CTs at a major cancer center. METHODS: We merged the roles of a traditional oncology research nurse and a professional patient navigator to create a novel health care provider role, the oncology nurse navigator. The primary duties of the oncology nurse navigator were to engage black cancer patients in the offices of their community physicians and to collaborate with community physicians to increase black patient participation in cancer research. The oncology nurse navigator played a key role in all phases of the CT participation process (e. g., screening for eligibility and completion of informed consent and clinical research forms) and guided each patient around barriers in the health care system. The accrual of eligible patients to breast cancer CTs was used to assess the impact of oncology nurse navigation on community-based recruitment of blacks to cancer CTs. RESULTS: Between January 2007 and December 2008, a total of 132 black breast cancer patients were screened by a single oncology nurse navigator for eligibility to University of Southern California-sponsored breast cancer CTs. Fifty-nine patients were eligible for CTs, and each was invited to participate in 1 or more CTs for which they were eligible. Fifty-one of 59 eligible black patients (86% of eligible patients) were enrolled to 1 or more research protocols. The estimated cost per enrolled patient was $5,677, nearly half the expected per patient cost of treating patients on CT at an academic or cancer center. CONCLUSIONS: Oncology nurse navigation is an effective outreach strategy for increasing black patient participation in cancer research and may be achieved at nearly half the cost of traditional methods of enrolling patients in CTs at cancer centers. (C) 2012 Elsevier Inc. All rights reserved. AN - WOS:000302913700002 AU - Holmes, D. R. AU - Major, J. AU - Lyonga, D. E. AU - Alleyne, R. S. AU - Clayton, S. M. DA - Apr DO - 10.1016/j.amjsurg.2011.02.005 IS - 4 N1 - 21996347 PY - 2012 SN - 0002-9610 SP - 415-422 ST - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation T2 - American Journal of Surgery TI - Increasing minority patient participation in cancer clinical trials using oncology nurse navigation VL - 203 ID - 3073 ER - TY - JOUR AB - Purpose/Objectives: To describe the knowledge base of African American men regarding prostate cancer and evaluate the immediate effects of an educational intervention on short-term knowledge acquisition. Design: Prospective one group pretest/post-test. Setting: Church meetings, Salvation Army senior meetings, health fairs, and senior citizens' meetings in the African American community of a large midwestern city. Sample: Convenience sample of 75 African American men (ages 23-88) who completed a pre- and postintervention questionnaire regarding knowledge and awareness of prostate cancer. Method: The questionnaire was based on patient education material from the American Cancer Society. The instrument consisted of seven statements related to prostate cancer incidence, risk factors, and detection. Following completion of the preintervention questionaire, the investigator provided subjects with information on prostate cancer. Subjects were retested. Main Research Variables: Knowledge and awareness of prostate cancer including incidence, risk factors, and detection in African American men. Findings: Correct responses increased from 23% (preeducation) to 64% (posteducation). The three most frequently missed questions on the pretest related to urinary frequency as an early sign of prostate cancer, incidence of prostate cancer in African American men, and increased risk among African American men for prostate cancer when compared to Caucasian men. These items remained the three most frequently missed questions on the post-test. Conclusions: An educational intervention had a positive effect on short-term knowledge and awareness of prostate cancer in African American men. Additional research is necessary to assess long-term retention of information and what effect, if any, increased knowledge has on health behavior. Implications for Nursing Practice: Continued efforts are warranted to encourage this high-risk group to participate in prostate screenings. To influence health behavior, patient education and information regarding the incidence and mortality of prostate cancer is critical in this high-risk population. AD - Urology/Oncology Department, Indiana University Medical Center, Indianapolis, IN AN - 107312591. Language: English. Entry Date: 19970301. Revision Date: 20150819. Publication Type: Journal Article AU - Collins, M. DB - CINAHL Complete DP - EBSCOhost IS - 1 KW - Black Persons Prostatic Neoplasms Health Knowledge Men's Health -- Education Prospective Studies Pretest-Posttest Design Convenience Sample Prostatic Neoplasms -- Education Health Knowledge -- Evaluation Questionnaires Descriptive Statistics Face Validity Adult Middle Age Aged Aged, 80 and Over Male Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033. PMID: NLM9007911. PY - 1997 SN - 0190-535X SP - 91-95 ST - Increasing prostate cancer awareness in African American men T2 - Oncology Nursing Forum TI - Increasing prostate cancer awareness in African American men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107312591&site=ehost-live&scope=site VL - 24 ID - 1977 ER - TY - JOUR AB - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5 years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities. AU - Odedina, F. T. AU - Reams, R. R. AU - Kaninjing, E. AU - Nguyen, J. AU - Mochona, B. AU - Lyon, D. E. AU - Askins, N. AU - Behar-Horenstein, L. S. DB - Medline DO - 10.1007/s13187-018-1344-6 IS - 3 KW - curriculum decision making education female Florida human male medical research mentoring minority group oncology personnel program evaluation student LA - English M3 - Article N1 - L628515904 2021-01-04 PY - 2019 SN - 1543-0154 SP - 577-583 ST - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628515904&from=export http://dx.doi.org/10.1007/s13187-018-1344-6 VL - 34 ID - 847 ER - TY - JOUR AB - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5 years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Odedina, Folakemi T. AN - 2019-36497-023 AU - Odedina, Folakemi T. AU - Reams, R. R. AU - Kaninjing, E. AU - Nguyen, J. AU - Mochona, B. AU - Lyon, D. E. AU - Askins, N. AU - Behar-Horenstein, L. S. DB - psyh DO - 10.1007/s13187-018-1344-6 DP - EBSCOhost IS - 3 KW - Cancer research training Minority undergraduate research Underrepresented minorities Summer research training program ReTOOL program Biomedical research workforce Diversity in the Workplace Educational Program Planning Medical Education Minority Groups Oncology Blacks Curriculum Development Educational Programs Interdisciplinary Research Leadership Medical Students Neoplasms Undergraduate Education Biomedicine N1 - College of Pharmacy, University of Florida, Orlando, FL, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20190919. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Diversity in the Workplace; Educational Program Planning; Medical Education; Minority Groups; Oncology. Minor Descriptor: Blacks; Curriculum Development; Educational Programs; Interdisciplinary Research; Leadership; Medical Students; Neoplasms; Undergraduate Education; Biomedicine. Classification: Professional Education & Training (3410). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Page Count: 7. Issue Publication Date: Jun 15, 2019. Publication History: First Posted Date: Mar 15, 2018. Copyright Statement: American Association for Cancer Education. 2018. Sponsor: US Department of Defense, Prostate Cancer Research Program, Office of the Congressionally Directed Medical Research Programs, US. Grant: W81XWH-12-1-0083; W81XWH-14-1-0243. Other Details: The ReTOOL program. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: P20CA192992; R25CA21422. Recipients: No recipient indicated PY - 2019 SN - 0885-8195 1543-0154 SP - 577-583 ST - Increasing the representation of minority students in the biomedical workforce: The ReTOOL program T2 - Journal of Cancer Education TI - Increasing the representation of minority students in the biomedical workforce: The ReTOOL program UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-36497-023&site=ehost-live&scope=site ORCID: 0000-0003-3796-1385 fodedina@cop.ufl.edu VL - 34 ID - 1676 ER - TY - JOUR AB - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5 years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities. AD - College of Pharmacy, University of Florida, Orlando, FL, USA College of Medicine, University of Florida, Gainesville, FL, USA Florida A&M University, Tallahassee, FL, USA College of Nursing, University of Florida, Gainesville, FL, USA Colleges of Dentistry, University of Florida, Gainesville, FL, USA College of Education, University of Florida, Gainesville, FL, USA AN - 137162215. Language: English. Entry Date: 20200612. Revision Date: 20200612. Publication Type: journal article AU - Odedina, Folakemi T. AU - Reams, R. R. AU - Kaninjing, E. AU - Nguyen, J. AU - Mochona, B. AU - Lyon, D. E. AU - Askins, N. AU - Behar-Horenstein, L. S. DB - CINAHL Complete DO - 10.1007/s13187-018-1344-6 DP - EBSCOhost IS - 3 KW - Research, Medical -- Education Research Personnel -- Education Minority Groups Female Male Florida Students Career Planning and Development Human Curriculum Program Evaluation Oncology -- Education Validation Studies Comparative Studies Evaluation Research Multicenter Studies Clinical Assessment Tools Impact of Events Scale Scales N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Instrumentation: Basic Knowledge Assessment Tool (BKAT); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Impact of Events Scale (IES). Grant Information: P20 CA192990/CA/NCI NIH HHS/United States. NLM UID: 8610343. PMID: NLM29542061. PY - 2019 SN - 0885-8195 SP - 577-583 ST - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program T2 - Journal of Cancer Education TI - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137162215&site=ehost-live&scope=site VL - 34 ID - 1978 ER - TY - JOUR AB - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5 years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities. © 2018, American Association for Cancer Education. AD - College of Pharmacy, University of Florida, Orlando, FL, United States College of Medicine, University of Florida, Gainesville, FL, United States Florida A&M University, Tallahassee, FL, United States College of Nursing, University of Florida, Gainesville, FL, United States Colleges of Dentistry, University of Florida, Gainesville, FL, United States College of Education, University of Florida, Gainesville, FL, United States AU - Odedina, F. T. AU - Reams, R. R. AU - Kaninjing, E. AU - Nguyen, J. AU - Mochona, B. AU - Lyon, D. E. AU - Askins, N. AU - Behar-Horenstein, L. S. DB - Scopus DO - 10.1007/s13187-018-1344-6 IS - 3 KW - Biomedical research workforce Cancer research training Minority undergraduate research ReTOOL program Summer research training program Underrepresented minorities M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2019 SP - 577-583 ST - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program T2 - Journal of Cancer Education TI - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043703400&doi=10.1007%2fs13187-018-1344-6&partnerID=40&md5=b3f93cbd68b8078ecc4372ba7456a2d8 VL - 34 ID - 2227 ER - TY - JOUR AB - With the growing burden of cancer in minority populations and limited progress in eliminating cancer disparities, it has become important to develop a diverse oncology workforce in basic, clinical, and behavioral research who will address cancer disparities and increase the participation of minority populations in clinical trials. To address the lack of well-trained underrepresented minority cancer scientists in Florida, the University of Florida collaborated with Florida A&M University in 2012 to establish the Florida Prostate Cancer Research Training Opportunities for Outstanding Leaders (ReTOOL) Program. Since 2012, the ReTOOL program has expanded to (1) cover all areas of cancer disparities; (2) offer training opportunities to minority students from all historically Black colleges and universities (HBCUs) in Florida; and (3) successfully secure both intramural and extramural federal funding to continuously provide research training opportunities for minority students in Florida. Focusing primarily on training Black students, the ReTOOL model includes culturally sensitive recruitment, mentorship, didactic curriculum, networking, and hands on experience in cancer research. This paper discusses the lessons learned from administering the ReTOOL program for 5years, which includes having the right inputs (such as majority-minority institutions partnership, funding, faculty advisors, committed mentors, culturally competent staff, and standardized program requirements) and processes (such as pipeline approach, structured applications system, didactic curriculum, research experience, and continuous mentoring) for an effective research training program. The program impact is an increase in the pool of underrepresented minority candidates with scientific and academic career progression paths focused on reducing cancer health disparities. AN - WOS:000472907100023 AU - Odedina, F. T. AU - Reams, R. R. AU - Kaninjing, E. AU - Nguyen, J. AU - Mochona, B. AU - Lyon, D. E. AU - Askins, N. AU - Behar-Horenstein, L. S. DA - Jun DO - 10.1007/s13187-018-1344-6 IS - 3 N1 - 29542061 PY - 2019 SN - 0885-8195 SP - 577-583 ST - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program T2 - Journal of Cancer Education TI - Increasing the Representation of Minority Students in the Biomedical Workforce: the ReTOOL Program VL - 34 ID - 2819 ER - TY - JOUR AB - Background: Underserved ethnic minority populations experience significant disparities in HIV, hepatitis C virus (HCV), colorectal cancer (CRC), and cervical cancer incidence and mortality. Much of the excess burden of these diseases among underserved communities is due to lack of preventive care, including screening. Barriers to disease screening include low awareness, lack of access to care and health insurance, and cultural beliefs regarding disease prevention. Our current trial aims to examine community health worker (CHW)-delivered, home-based multi-modality screening for HIV, HCV, CRC, and cervical cancer simultaneously. Design: We are conducting a randomized pragmatic trial among 900 Haitian, Hispanic, and African-American participants from diverse underserved communities in South Florida. People between the ages of 50 and 65 who have not had appropriate HIV, HCV, CRC, and cervical cancer screening per United States Preventive Services Task Force (USPSTF) recommendations are eligible for the study. Participants are recruited by CHWs and complete a structured interview to assess multilevel determinants of disease risk. Participants are then randomized to receive HIV, HCV, CRC, and cervical cancer screening via navigation to care by a CHW (Group 1) or via CHW-delivered home-based screening (Group 2). The primary outcome is completion of screening for each of these diseases within 6 months post-enrollment. Discussion: Our trial is among the first to examine the effectiveness of a CHW-delivered, multimodality, home-based disease-screening approach. If found to be effective, this approach may represent a cost-effective strategy for disease screening within underserved and underscreened minority groups. Trial registration: Clinical Trials.gov # NCT02970136, registered November 21, 2016. AD - O. Carrasquillo, Sylvester Comprehensive Cancer Center, Clinical Research Building, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL, United States AU - Carrasquillo, O. AU - Seay, J. AU - Jhaveri, V. AU - Long, T. AU - Kenya, S. AU - Thomas, E. AU - Sussman, D. AU - Trevil, D. AU - Koru-Sengul, T. AU - Kobetz, E. DB - Embase Medline DO - 10.1186/s13063-020-4213-7 IS - 1 KW - NCT02970136 adult African American age distribution article clinical protocol colorectal cancer community care controlled study convenience sample evidence based medicine female Florida Haitian health auxiliary health care delivery health program hepatitis C Hispanic home care human Human immunodeficiency virus infection major clinical study male mass screening outcome assessment pragmatic trial program cost effectiveness randomized controlled trial risk assessment uterine cervix cancer LA - English M3 - Article N1 - L631626833 2020-05-14 2020-05-19 PY - 2020 SN - 1745-6215 ST - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: Study protocol for a randomized pragmatic trial T2 - Trials TI - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: Study protocol for a randomized pragmatic trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631626833&from=export http://dx.doi.org/10.1186/s13063-020-4213-7 VL - 21 ID - 809 ER - TY - JOUR AB - Background: Underserved ethnic minority populations experience significant disparities in HIV, hepatitis C virus (HCV), colorectal cancer (CRC), and cervical cancer incidence and mortality. Much of the excess burden of these diseases among underserved communities is due to lack of preventive care, including screening. Barriers to disease screening include low awareness, lack of access to care and health insurance, and cultural beliefs regarding disease prevention. Our current trial aims to examine community health worker (CHW)-delivered, home-based multi-modality screening for HIV, HCV, CRC, and cervical cancer simultaneously.Design: We are conducting a randomized pragmatic trial among 900 Haitian, Hispanic, and African-American participants from diverse underserved communities in South Florida. People between the ages of 50 and 65 who have not had appropriate HIV, HCV, CRC, and cervical cancer screening per United States Preventive Services Task Force (USPSTF) recommendations are eligible for the study. Participants are recruited by CHWs and complete a structured interview to assess multilevel determinants of disease risk. Participants are then randomized to receive HIV, HCV, CRC, and cervical cancer screening via navigation to care by a CHW (Group 1) or via CHW-delivered home-based screening (Group 2). The primary outcome is completion of screening for each of these diseases within 6 months post-enrollment.Discussion: Our trial is among the first to examine the effectiveness of a CHW-delivered, multimodality, home-based disease-screening approach. If found to be effective, this approach may represent a cost-effective strategy for disease screening within underserved and underscreened minority groups.Trial Registration: Clinical Trials.gov # NCT02970136, registered November 21, 2016. AD - Sylvester Comprehensive Cancer Center, Clinical Research Building, University of Miami, Miller School of Medicine, 1120 NW 14th Street, 33136, Miami, FL, USA Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, 33136, Miami, FL, USA Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, 33136, Miami, FL, USA Health Choice Network, 9064 N.W. 13 Terrace, 33172, Miami, FL, USA AN - 142973073. Language: English. Entry Date: In Process. Revision Date: 20200507. Publication Type: journal article. Journal Subset: Biomedical AU - Carrasquillo, Olveen AU - Seay, Julia AU - Jhaveri, Vasanti AU - Long, Timothy AU - Kenya, Sonjia AU - Thomas, Emmanuel AU - Sussman, Daniel AU - Trevil, Dinah AU - Koru-Sengul, Tulay AU - Kobetz, Erin DB - CINAHL Complete DO - 10.1186/s13063-020-4213-7 DP - EBSCOhost IS - 1 N1 - Europe; Peer Reviewed; UK & Ireland. Grant Information: 1U01MD010614-01/MD/NIMHD NIH HHS/United States. NLM UID: 101263253. PMID: NLM32349789. PY - 2020 SN - 1745-6215 SP - 1-9 ST - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial T2 - Trials TI - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142973073&site=ehost-live&scope=site VL - 21 ID - 1979 ER - TY - JOUR AB - Background: Underserved ethnic minority populations experience significant disparities in HIV, hepatitis C virus (HCV), colorectal cancer (CRC), and cervical cancer incidence and mortality. Much of the excess burden of these diseases among underserved communities is due to lack of preventive care, including screening. Barriers to disease screening include low awareness, lack of access to care and health insurance, and cultural beliefs regarding disease prevention. Our current trial aims to examine community health worker (CHW)-delivered, home-based multi-modality screening for HIV, HCV, CRC, and cervical cancer simultaneously. Design: We are conducting a randomized pragmatic trial among 900 Haitian, Hispanic, and African-American participants from diverse underserved communities in South Florida. People between the ages of 50 and 65 who have not had appropriate HIV, HCV, CRC, and cervical cancer screening per United States Preventive Services Task Force (USPSTF) recommendations are eligible for the study. Participants are recruited by CHWs and complete a structured interview to assess multilevel determinants of disease risk. Participants are then randomized to receive HIV, HCV, CRC, and cervical cancer screening via navigation to care by a CHW (Group 1) or via CHW-delivered home-based screening (Group 2). The primary outcome is completion of screening for each of these diseases within 6 months post-enrollment. Discussion: Our trial is among the first to examine the effectiveness of a CHW-delivered, multimodality, home-based disease-screening approach. If found to be effective, this approach may represent a cost-effective strategy for disease screening within underserved and underscreened minority groups. Trial registration: Clinical Trials.gov # NCT02970136, registered November 21, 2016. © 2020 The Author(s). AD - Sylvester Comprehensive Cancer Center, Clinical Research Building, University of Miami, Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, United States Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, United States Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, United States Health Choice Network, 9064 N.W. 13 Terrace, Miami, FL 33172, United States AU - Carrasquillo, O. AU - Seay, J. AU - Jhaveri, V. AU - Long, T. AU - Kenya, S. AU - Thomas, E. AU - Sussman, D. AU - Trevil, D. AU - Koru-Sengul, T. AU - Kobetz, E. C7 - 368 DB - Scopus DO - 10.1186/s13063-020-4213-7 IS - 1 KW - Cervical cancer Colorectal cancer Haitian Hepatitis C Hispanic HIV HPV Immigrant Screening M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 ST - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: Study protocol for a randomized pragmatic trial T2 - Trials TI - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: Study protocol for a randomized pragmatic trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084170604&doi=10.1186%2fs13063-020-4213-7&partnerID=40&md5=8912abf6077322a515bb0860a9994555 VL - 21 ID - 2199 ER - TY - JOUR AB - Background Underserved ethnic minority populations experience significant disparities in HIV, hepatitis C virus (HCV), colorectal cancer (CRC), and cervical cancer incidence and mortality. Much of the excess burden of these diseases among underserved communities is due to lack of preventive care, including screening. Barriers to disease screening include low awareness, lack of access to care and health insurance, and cultural beliefs regarding disease prevention. Our current trial aims to examine community health worker (CHW)-delivered, home-based multi-modality screening for HIV, HCV, CRC, and cervical cancer simultaneously. Design We are conducting a randomized pragmatic trial among 900 Haitian, Hispanic, and African-American participants from diverse underserved communities in South Florida. People between the ages of 50 and 65 who have not had appropriate HIV, HCV, CRC, and cervical cancer screening per United States Preventive Services Task Force (USPSTF) recommendations are eligible for the study. Participants are recruited by CHWs and complete a structured interview to assess multilevel determinants of disease risk. Participants are then randomized to receive HIV, HCV, CRC, and cervical cancer screening via navigation to care by a CHW (Group 1) or via CHW-delivered home-based screening (Group 2). The primary outcome is completion of screening for each of these diseases within 6 months post-enrollment. Discussion Our trial is among the first to examine the effectiveness of a CHW-delivered, multimodality, home-based disease-screening approach. If found to be effective, this approach may represent a cost-effective strategy for disease screening within underserved and underscreened minority groups. AN - WOS:000530481300001 AU - Carrasquillo, O. AU - Seay, J. AU - Jhaveri, V. AU - Long, T. M. AU - Kenya, S. AU - Thomas, E. AU - Sussman, D. AU - Trevil, D. AU - Koru-Sengul, T. AU - Kobetz, E. DA - Apr DO - 10.1186/s13063-020-4213-7 IS - 1 N1 - 368 32349789 PY - 2020 ST - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial T2 - Trials TI - Increasing uptake of evidence-based screening services though a community health worker-delivered multimodality program: study protocol for a randomized pragmatic trial VL - 21 ID - 2782 ER - TY - JOUR AB - Background Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. Objective To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). Design, setting, and participants A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere. Outcome measurements and statistical analysis Adjusted hazard ratios (HRs) were calculated to compare black and white race regarding PFS and OS. Subgroup analyses of mCRPC trials were performed based on the control arm treatments (mitoxantrone or docetaxel). Relevant covariates were used for adjustment in all analyses. Results and limitations A total of 1613 patients were included; 77 were black (4.7%). No significant differences between black and white men's baseline characteristics were noted regarding age, performance status, or pretreatment prostate-specific antigen. The pooled HRs for black race for OS and PFS were 1.01 (95% confidence interval [CI], 0.73–1.35) and 1.29 (95% CI, 0.95–1.76), respectively. The median OS for black compared with white men was 254 versus 238 d (p = 0.92), respectively, with mitoxantrone and 581 versus 546 d (p = 0.53), respectively, with docetaxel. The primary limitation was the relatively small number of black men enrolled in mCRPC clinical trials. Conclusions In the context of RCTs, in which patients receive generally uniform treatment, a significant difference in OS for black men could not be detected in mCRPC. Black men continue to be dramatically underrepresented in RCTs, and efforts are needed to increase minority accrual to these trials. Patient summary We looked at the outcomes of men treated in randomized controlled trials to determine the impact of black race on survival. We found that in the context of modern clinical trials, there does not appear to be a significant difference in survival between black and white races; however, a trend for greater progression in black men was noted. AD - D.E. Spratt, University of Michigan Medical Center, Department of Radiation Oncology, 1500 East Medical Center Drive, Ann Arbor, MI, United States AU - Spratt, D. E. AU - Chen, Y. W. AU - Mahal, B. A. AU - Osborne, J. R. AU - Zhao, S. G. AU - Morgan, T. M. AU - Palapattu, G. AU - Feng, F. Y. AU - Nguyen, P. L. C1 - cnto 328 xrp 6258 DB - Embase DO - 10.1016/j.euf.2016.03.010 IS - 5 KW - aflibercept cabazitaxel docetaxel mitoxantrone prednisone prostate specific antigen siltuximab adult age aged article Black person cancer prognosis castration resistant prostate cancer Caucasian data analysis human major clinical study male metastasis multicenter study (topic) overall survival patient information performance performance status phase 2 clinical trial (topic) phase 3 clinical trial (topic) progression free survival race difference randomized controlled trial (topic) cnto 328 xrp 6258 LA - English M3 - Article N1 - L614513450 2017-02-27 2017-03-20 PY - 2016 SN - 2405-4569 SP - 532-539 ST - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes T2 - European Urology Focus TI - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614513450&from=export http://dx.doi.org/10.1016/j.euf.2016.03.010 VL - 2 ID - 954 ER - TY - JOUR AB - Background Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. Objective To examine the impact of black race on progression‐free survival (PFS) and overall survival (OS) among men with metastatic castration‐resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). Design, setting, and participants A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere. Outcome measurements and statistical analysis Adjusted hazard ratios (HRs) were calculated to compare black and white race regarding PFS and OS. Subgroup analyses of mCRPC trials were performed based on the control arm treatments (mitoxantrone or docetaxel). Relevant covariates were used for adjustment in all analyses. Results and limitations A total of 1613 patients were included; 77 were black (4.7%). No significant differences between black and white men's baseline characteristics were noted regarding age, performance status, or pretreatment prostate‐specific antigen. The pooled HRs for black race for OS and PFS were 1.01 (95% confidence interval [CI], 0.73‐1.35) and 1.29 (95% CI, 0.95‐1.76), respectively. The median OS for black compared with white men was 254 versus 238 d (p = 0.92), respectively, with mitoxantrone and 581 versus 546 d (p = 0.53), respectively, with docetaxel. The primary limitation was the relatively small number of black men enrolled in mCRPC clinical trials. Conclusions In the context of RCTs, in which patients receive generally uniform treatment, a significant difference in OS for black men could not be detected in mCRPC. Black men continue to be dramatically underrepresented in RCTs, and efforts are needed to increase minority accrual to these trials. Patient summary We looked at the outcomes of men treated in randomized controlled trials to determine the impact of black race on survival. We found that in the context of modern clinical trials, there does not appear to be a significant difference in survival between black and white races; however, a trend for greater progression in black men was noted. Copyright © 2016 European Association of Urology AN - CN-01338708 AU - Spratt, D. E. AU - Chen, Y. W. AU - Mahal, B. A. AU - Osborne, J. R. AU - Zhao, S. G. AU - Morgan, T. M. AU - Palapattu, G. AU - Feng, F. Y. AU - Nguyen, P. L. DO - 10.1016/j.euf.2016.03.010 IS - 5 KW - *Black person *cancer prognosis *castration resistant prostate cancer *castration resistant prostate cancer/dt [Drug Therapy] *patient coding *race difference Adult Aflibercept/dt [Drug Therapy] Age Aged Article Cabazitaxel/dt [Drug Therapy] Castration resistant prostate cancer/dt [Drug Therapy] Caucasian Clinical trial Confidence interval Controlled clinical trial Controlled study Data analysis Docetaxel Docetaxel/dt [Drug Therapy] Drug therapy Endogenous compound Hazard ratio Human Major clinical study Male Metastasis/dt [Drug Therapy] Mitoxantrone Mitoxantrone/dt [Drug Therapy] Multicenter study (topic) Overall survival Patient information Performance Performance status Phase 2 clinical trial (topic) Phase 3 clinical trial(topic) Prednisone/dt [Drug Therapy] Progression free survival Prostate specific antigen Prostate specific antigen/ec [Endogenous Compound] Randomized controlled trial Randomized controlled trial (topic) Siltuximab/dt [Drug Therapy] Statistical analysis Treatment outcome M3 - Journal: Article PY - 2016 SP - 532‐539 ST - Individual Patient Data Analysis of Randomized Clinical Trials: impact of Black Race on Castration-resistant Prostate Cancer Outcomes T2 - European urology focus TI - Individual Patient Data Analysis of Randomized Clinical Trials: impact of Black Race on Castration-resistant Prostate Cancer Outcomes UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01338708/full VL - 2 ID - 1484 ER - TY - JOUR AB - Background Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. Objective To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). Design, setting, and participants A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere. Outcome measurements and statistical analysis Adjusted hazard ratios (HRs) were calculated to compare black and white race regarding PFS and OS. Subgroup analyses of mCRPC trials were performed based on the control arm treatments (mitoxantrone or docetaxel). Relevant covariates were used for adjustment in all analyses. Results and limitations A total of 1613 patients were included; 77 were black (4.7%). No significant differences between black and white men's baseline characteristics were noted regarding age, performance status, or pretreatment prostate-specific antigen. The pooled HRs for black race for OS and PFS were 1.01 (95% confidence interval [CI], 0.73–1.35) and 1.29 (95% CI, 0.95–1.76), respectively. The median OS for black compared with white men was 254 versus 238 d (p = 0.92), respectively, with mitoxantrone and 581 versus 546 d (p = 0.53), respectively, with docetaxel. The primary limitation was the relatively small number of black men enrolled in mCRPC clinical trials. Conclusions In the context of RCTs, in which patients receive generally uniform treatment, a significant difference in OS for black men could not be detected in mCRPC. Black men continue to be dramatically underrepresented in RCTs, and efforts are needed to increase minority accrual to these trials. Patient summary We looked at the outcomes of men treated in randomized controlled trials to determine the impact of black race on survival. We found that in the context of modern clinical trials, there does not appear to be a significant difference in survival between black and white races; however, a trend for greater progression in black men was noted. © 2016 European Association of Urology AD - Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI, United States Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, United States AU - Spratt, D. E. AU - Chen, Y. W. AU - Mahal, B. A. AU - Osborne, J. R. AU - Zhao, S. G. AU - Morgan, T. M. AU - Palapattu, G. AU - Feng, F. Y. AU - Nguyen, P. L. DB - Scopus DO - 10.1016/j.euf.2016.03.010 IS - 5 KW - Disparity Prostate cancer Randomized controlled trial M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2016 SP - 532-539 ST - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes T2 - European Urology Focus TI - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013162258&doi=10.1016%2fj.euf.2016.03.010&partnerID=40&md5=e06b7b536f9ecc4247ff983a1f7a78e1 VL - 2 ID - 2329 ER - TY - JOUR AB - Background: Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. Objective: To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). Design, setting, and participants: A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere. Outcome measurements and statistical analysis: Adjusted hazard ratios (HRs) were calculated to compare black and white race regarding PFS and OS. Subgroup analyses of mCRPC trials were performed based on the control arm treatments (mitoxantrone or docetaxel). Relevant covariates were used for adjustment in all analyses. Results and limitations: A total of 1613 patients were included; 77 were black (4.7%). No significant differences between black and white men's baseline characteristics were noted regarding age, performance status, or pretreatment prostate-specific antigen. The pooled HRs for black race for OS and PFS were 1.01 (95% confidence interval [CI], 0.73-1.35) and 1.29 (95% CI, 0.95-1.76), respectively. The median OS for black compared with white men was 254 versus 238 d (p = 0.92), respectively, with mitoxantrone and 581 versus 546 d (p = 0.53), respectively, with docetaxel. The primary limitation was the relatively small number of black men enrolled in mCRPC clinical trials. Conclusions: In the context of RCTs, in which patients receive generally uniform treatment, a significant difference in OS for black men could not be detected in mCRPC. Black men continue to be dramatically underrepresented in RCTs, and efforts are needed to increase minority accrual to these trials. Patient summary: We looked at the outcomes of men treated in randomized controlled trials to determine the impact of black race on survival. We found that in the context of modern clinical trials, there does not appear to be a significant difference in survival between black and white races; however, a trend for greater progression in black men was noted. (C) 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved. AN - WOS:000485927900014 AU - Spratt, D. E. AU - Chen, Y. W. AU - Mahal, B. A. AU - Osborne, J. R. AU - Zhao, S. G. AU - Morgan, T. M. AU - Palapattu, G. AU - Feng, F. Y. AU - Nguyen, P. L. DA - Dec DO - 10.1016/j.euf.2016.03.010 IS - 5 N1 - 28723519 PY - 2016 SP - 532-539 ST - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes T2 - European Urology Focus TI - Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes VL - 2 ID - 2926 ER - TY - JOUR AB - Background: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co-occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co-occurring risk factors in three racial/ethnic groups of underserved women. Methods: Black, Latina, and Arab women (N=514), ages 21 to 70 years, were enrolled into the Kin KeeperSM randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e.g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. Results: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p<0.05. Conclusions: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations. © Copyright 2014, Mary Ann Liebert, Inc. 2014. AD - K.P. Williams, Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, 965 Fee Road, Room A626, East Lansing, MI 48824, United States AU - Roman, L. AU - Meghea, C. AU - Ford, S. AU - Penner, L. AU - Hamade, H. AU - Estes, T. AU - Williams, K. P. DB - Embase Medline DO - 10.1089/jwh.2013.4397 IS - 1 KW - adult aged Arab article breast cancer breast examination cancer screening ethnic group female health literacy Hispanic human mammography Black person Papanicolaou test priority journal race risk factor United States uterine cervix cancer young adult LA - English M3 - Article N1 - L372052096 2014-01-14 2014-01-16 PY - 2014 SN - 1931-843X 1540-9996 SP - 57-64 ST - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women T2 - Journal of Women's Health TI - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372052096&from=export http://dx.doi.org/10.1089/jwh.2013.4397 VL - 23 ID - 1041 ER - TY - JOUR AB - Background: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co‐occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co‐occurring risk factors in three racial/ethnic groups of underserved women. Methods: Black, Latina, and Arab women (N=514), ages 21 to 70 years, were enrolled into the Kin KeeperSM randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e.g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. Results: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p<0.05. Conclusions: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations. Copyright 2014, Mary Ann Liebert, Inc. 2014. AN - CN-00979786 AU - Roman, L. AU - Meghea, C. AU - Ford, S. AU - Penner, L. AU - Hamade, H. AU - Estes, T. AU - Williams, K. P. DO - 10.1089/jwh.2013.4397 IS - 1 KW - *breast cancer *cancer screening *uterine cervix cancer Adult Aged Arab Article Breast examination Ethnic group Female Health literacy Hispanic Human Mammography Negro Papanicolaou test Priority journal Race Risk factor United States Young adult PY - 2014 SP - 57‐64 ST - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women T2 - Journal of women's health TI - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00979786/full VL - 23 ID - 1533 ER - TY - JOUR AB - Background: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co-occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co-occurring risk factors in three racial/ethnic groups of underserved women. Methods: Black, Latina, and Arab women ( N=514), ages 21 to 70 years, were enrolled into the Kin KeeperSM randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e.g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. Results: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p<0.05. Conclusions: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations. AD - Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, East Lansing, Michigan.; Institute for Health Policy, College of Human Medicine, Michigan State University, East Lansing, Michigan. Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, East Lansing, Michigan. Karmanos Cancer Institute, Communication and Behavioral Oncology, Detroit, Michigan. Arab Community Center for Economic and Social Services (ACCESS), Dearborn, Michigan. AN - 104131046. Language: English. Entry Date: 20140106. Revision Date: 20200708. Publication Type: Journal Article AU - Roman, LeeAnne AU - Meghea, Cristian AU - Ford, Sabrina AU - Penner, Louis AU - Hamade, Hiam AU - Estes, Tamika AU - Williams, Karen Patricia DB - CINAHL Complete DO - 10.1089/jwh.2013.4397 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Diagnosis Cervix Neoplasms -- Diagnosis Medically Underserved Professional-Client Relations Ethnic Groups -- Classification Cancer Screening Human Michigan Black Persons Hispanic Americans Arabs Exploratory Research Risk Assessment Female Young Adult Adult Middle Age Aged Multivariate Analysis Logistic Regression Mammography Cervical Smears Health Knowledge Questionnaires Patient Attitudes Confidence Intervals Odds Ratio Data Analysis Software N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care; Women's Health. NLM UID: 101159262. PMID: NLM24283674. PY - 2014 SN - 1540-9996 SP - 57-64 ST - Individual, Provider, and System Risk Factors for Breast and Cervical Cancer Screening Among Underserved Black, Latina, and Arab Women T2 - Journal of Women's Health (15409996) TI - Individual, Provider, and System Risk Factors for Breast and Cervical Cancer Screening Among Underserved Black, Latina, and Arab Women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104131046&site=ehost-live&scope=site VL - 23 ID - 1980 ER - TY - JOUR AB - Background: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co-occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co-occurring risk factors in three racial/ethnic groups of underserved women. Methods: Black, Latina, and Arab women (N=514), ages 21 to 70 years, were enrolled into the Kin KeeperSM randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e.g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. Results: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p<0.05. Conclusions: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations. © Copyright 2014, Mary Ann Liebert, Inc. 2014. AD - Department of Obstetrics, Gynecology, and Reproductive Biology, College of Human Medicine, Michigan State University, 965 Fee Road, Room A626, East Lansing, MI 48824, United States Institute for Health Policy, College of Human Medicine, Michigan State University, East Lansing, MI, United States Karmanos Cancer Institute, Communication and Behavioral Oncology, Detroit, MI, United States Arab Community Center for Economic and Social Services (ACCESS), Dearborn, MI, United States AU - Roman, L. AU - Meghea, C. AU - Ford, S. AU - Penner, L. AU - Hamade, H. AU - Estes, T. AU - Williams, K. P. DB - Scopus DO - 10.1089/jwh.2013.4397 IS - 1 M3 - Article N1 - Cited By :38 Export Date: 22 March 2021 PY - 2014 SP - 57-64 ST - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women T2 - Journal of Women's Health TI - Individual, provider, and system risk factors for breast and cervical cancer screening among underserved black, Latina, and Arab women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891701177&doi=10.1089%2fjwh.2013.4397&partnerID=40&md5=3e3d7c612da5a7801cebb0f18b1e6166 VL - 23 ID - 2405 ER - TY - JOUR AB - Background: Socioeconomic and racial/ethnic disparities in breast and cervical cancer screening persist. An exploratory study was conducted to better understand co-occurring risk factors in underserved groups that could inform interventions to improve screening adherence. The objective of this study was to examine associations between breast and cervical cancer screening adherence and co-occurring risk factors in three racial/ethnic groups of underserved women. Methods: Black, Latina, and Arab women (N=514), ages 21 to 70 years, were enrolled into the Kin Keeper(SM) randomized controlled trial in communities around Detroit, Michigan. We used participant baseline assessments (e. g., demographic characteristics, health literacy) to explore screening risks using an additive approach and multivariate logistic analyses. Results: For black women, having more health literacy risks were associated with reduced odds of a clinical breast exam (CBE), mammogram, and Papanicolaou (Pap) test; more competing priorities were associated with reduced odds of a Pap test; lack of doctor mammogram recommendation was significantly associated with decreased odds of CBE. For Latina women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test. For Arab women, lack of doctor recommendations were significantly associated with decreased odds of CBE, mammogram, and Pap test; more competing priorities were significantly associated with reduced odds of CBE and Pap test. All results were significant at p < 0.05. Conclusions: Characteristics associated with breast and cervical screening adherence differs among Black, Latina, and Arab underserved women. Interventions to improve screening should be tailored for racial/ethnic groups with particular attention to competing survival priorities, health literacy risks factors, and provider recommendations. AN - WOS:000336811900009 AU - Roman, L. AU - Meghea, C. AU - Ford, S. AU - Penner, L. AU - Hamade, H. AU - Estes, T. AU - Williams, K. P. DA - Jan DO - 10.1089/jwh.2013.4397 IS - 1 N1 - 24283674 PY - 2014 SN - 1540-9996 SP - 57-64 ST - Individual, Provider, and System Risk Factors for Breast and Cervical Cancer Screening Among Underserved Black, Latina, and Arab Women T2 - Journal of Womens Health TI - Individual, Provider, and System Risk Factors for Breast and Cervical Cancer Screening Among Underserved Black, Latina, and Arab Women VL - 23 ID - 3026 ER - TY - JOUR AB - Background The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results Almost two-thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions Church attendance and spirituality did not impact mammography use. © 2008 Blanton-Peale Institute. AD - M. L. Katz, College of Public Health, Ohio State University, A-352 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, United States AU - Katz, M. L. AU - Kauffman, R. M. AU - Tatum, C. M. AU - Paskett, E. D. DB - Medline DO - 10.1007/s10943-008-9159-0 IS - 2 KW - adult African American aged American Indian article breast tumor Caucasian clinical trial controlled clinical trial controlled study ethnology female human mammography middle aged poverty randomized controlled trial religion rural population United States utilization review LA - English M3 - Article N1 - L50043618 2009-03-27 PY - 2008 SN - 0022-4197 SP - 227-236 ST - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community T2 - Journal of Religion and Health TI - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50043618&from=export http://dx.doi.org/10.1007/s10943-008-9159-0 VL - 47 ID - 1210 ER - TY - JOUR AB - Background The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results Almost two‐thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions Church attendance and spirituality did not impact mammography use. AN - CN-00685962 AU - Katz, M. L. AU - Kauffman, R. M. AU - Tatum, C. M. AU - Paskett, E. D. DO - 10.1007/s10943-008-9159-0 IS - 2 KW - Adult African Americans Aged Aged, 80 and over Breast Neoplasms [diagnosis, ethnology] European Continental Ancestry Group Female Humans Indians, North American Mammography [*statistics & numerical data] Middle Aged North Carolina Poverty Rural Population Spirituality M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2008 SP - 227‐236 ST - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community T2 - Journal of religion and health TI - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00685962/full VL - 47 ID - 1381 ER - TY - JOUR AB - Background: The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods: A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results: Almost two-thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions: Church attendance and spirituality did not impact mammography use. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Katz, Mira L., College of Public Health, Ohio State University, A-352 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH, US, 43210 AN - 2008-06932-006 AU - Katz, Mira L. AU - Kauffman, Ross M. AU - Tatum, Cathy M. AU - Paskett, Electra D. DB - psyh DO - 10.1007/s10943-008-9159-0 DP - EBSCOhost IS - 2 KW - church attendance spirituality mammography use lower income level tri-racial community rural community Adult African Americans Aged Aged, 80 and over Breast Neoplasms European Continental Ancestry Group Female Humans Indians, North American Mammography Middle Aged North Carolina Poverty Rural Population Racial and Ethnic Differences Religious Practices Cancer Screening Communities Health Care Utilization Religious Buildings Rural Environments N1 - College of Public Health, Ohio State University, Columbus, OH, US. Release Date: 20090525. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Katz, Mira L. Major Descriptor: Mammography; Racial and Ethnic Differences; Religious Practices; Spirituality. Minor Descriptor: Cancer Screening; Communities; Health Care Utilization; Lower Income Level; Religious Buildings; Rural Environments. Classification: Promotion & Maintenance of Health & Wellness (3365); Religion (2920). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Religious Life Scale. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Jun, 2008. Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: CA72022-04; CA57707-08; K07CA107079. Recipients: Katz, Mira L. Sponsor: Walther Cancer Institute, Behavioral Cooperative Oncology Group. Recipients: Kauffman, Ross M. PY - 2008 SN - 0022-4197 1573-6571 SP - 227-236 ST - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community T2 - Journal of Religion and Health TI - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-06932-006&site=ehost-live&scope=site ORCID: 0000-0002-4046-9108 electra.paskett@osumc.edu cathy.tatum@osumc.edu Kauffman.57@osu.edu mira.katz@osumc.edu VL - 47 ID - 1786 ER - TY - JOUR AB - Background The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results Almost two-thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions Church attendance and spirituality did not impact mammography use. © 2008 Blanton-Peale Institute. AD - College of Public Health, Ohio State University, A-352 Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, United States Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, United States AU - Katz, M. L. AU - Kauffman, R. M. AU - Tatum, C. M. AU - Paskett, E. D. DB - Scopus DO - 10.1007/s10943-008-9159-0 IS - 2 KW - Cancer screening Mammography Religion Rural population Spirituality M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2008 SP - 227-236 ST - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community T2 - Journal of Religion and Health TI - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-43449106487&doi=10.1007%2fs10943-008-9159-0&partnerID=40&md5=d5c8ee0123f21e11f48fa1bee546aebf VL - 47 ID - 2535 ER - TY - JOUR AB - Background The influence of church attendance and spirituality on mammography use was studied among Native American, White, and African American women living in a rural county. Methods A randomized trial was conducted to increase mammography use. Women (n = 851) were randomly assigned to receive either an educational program delivered by a lay health advisor or a physician letter and brochure about cervical cancer screening (control group). Church attendance and spirituality were measured at baseline and mammography use was evaluated 12 months after enrollment using medical record review. Results Almost two-thirds of the women reported that they attended church at least once a week, and less than 4% were classified as having low spirituality. Church attendance (P = 0.299) or spirituality (P = 0.401) did not have a significant impact on mammography use. Conclusions Church attendance and spirituality did not impact mammography use. AN - WOS:000255747100007 AU - Katz, M. L. AU - Kauffman, R. M. AU - Tatum, C. M. AU - Paskett, E. D. DA - Jun DO - 10.1007/s10943-008-9159-0 IS - 2 N1 - 19105013 PY - 2008 SN - 0022-4197 SP - 227-236 ST - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community T2 - Journal of Religion & Health TI - Influence of church attendance and spirituality in a randomized controlled trial to increase mammography use among a low-income, tri-racial, rural community VL - 47 ID - 3169 ER - TY - JOUR AB - Purpose: It is unclear why racial differences exist in the frequency of surgery for lung cancer treatment. Comorbidity is an important consideration in selection of patients for lung cancer treatment, including surgery. To assess whether comorbidity contributes to the observed racial differences, we evaluated racial differences in the prevalence of comorbidity and their impact on receipt of surgery.Patients and Methods: A total of 1,314 patients (1,135 white, 179 black) in the Veterans Health Administration diagnosed with early-stage non-small-cell lung cancer in 2007 were included. The effect of comorbidity on surgery was determined by using generalized linear models with a logit link accounting for patient clustering within Veterans Administration Medical Centers.Results: Compared with whites, blacks had greater prevalence of hypertension, liver disease, renal disease, illicit drug abuse, and poor performance status, but lower prevalence of respiratory disease. The impact of most individual comorbidities on receipt of surgery was similar between blacks and whites, and comorbidity did not influence the race-surgery association in a multivariable analysis. The proportion of blacks not receiving surgery as well as refusing surgery was greater than that among whites.Conclusion: Blacks had a greater prevalence of several comorbid conditions and poor performance status; however, the overall comorbidity score did not differ by race. In general, the effect of comorbidity on receipt of surgery was similar in blacks and whites. Racial differences in comorbidity do not fully explain why blacks undergo lung cancer surgery less often than whites. AD - Durham VA Medical Center, Durham, NC 27705, USA Durham VA Medical Center, 508 Fulton St (152), Durham, NC 27705; Christina.Williams4@va.gov. AN - 104301827. Language: English. Entry Date: 20130322. Revision Date: 20200708. Publication Type: journal article AU - Williams, C. D. AU - Stechuchak, K. M. AU - Zullig, L. L. AU - Provenzale, D. AU - Kelley, M. J. AU - Williams, Christina D. AU - Stechuchak, Karen M. AU - Zullig, Leah L. AU - Provenzale, Dawn AU - Kelley, Michael J. DB - CINAHL Complete DO - 10.1200/JCO.2012.44.1170 DP - EBSCOhost IS - 4 KW - Black Persons -- Statistics and Numerical Data Carcinoma, Non-Small-Cell Lung -- Ethnology Carcinoma, Non-Small-Cell Lung -- Surgery Comorbidity White Persons -- Statistics and Numerical Data Health Services Accessibility Lung Neoplasms -- Ethnology Lung Neoplasms -- Surgery Patient Selection Veterans -- Statistics and Numerical Data Aged Aged, 80 and Over Carcinoma, Non-Small-Cell Lung -- Pathology Female Health Services Accessibility -- Statistics and Numerical Data Human Hypertension -- Epidemiology Karnofsky Performance Status Kidney Diseases -- Epidemiology Linear Regression Liver Diseases -- Epidemiology Lung Neoplasms -- Pathology Male Middle Age Multivariate Analysis Neoplasm Staging Pneumonectomy -- Statistics and Numerical Data Prevalence Retrospective Design Substance Use Disorders -- Epidemiology United States N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: T32-HS00079/HS/AHRQ HHS/United States. NLM UID: 8309333. PMID: NLM23269988. PY - 2013 SN - 0732-183X SP - 475-481 ST - Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer T2 - Journal of Clinical Oncology TI - Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104301827&site=ehost-live&scope=site VL - 31 ID - 1982 ER - TY - JOUR AB - Research has suggested that race, gender, and menthol cigarette use influence tobacco-smoke exposure measures and smoking-related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking-related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender × race × menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed. © 2005 Society for Research on Nicotine and Tobacco. AD - T.K. Mustonen, Harvard School of Dental Medicine, Tobacco Dependence Treatment and Research, 188 Longwood Avenue, Boston, MA 02115, United States AU - Mustonen, T. K. AU - Spencer, S. M. AU - Hoskinson Jr, R. A. AU - Sachs, D. P. L. AU - Garvey, A. J. DB - Embase Medline DO - 10.1080/14622200500185199 IS - 4 KW - carbon monoxide cotinine menthol nicotine adult article blood pressure measurement body mass cancer risk clinical trial controlled clinical trial controlled study correlation analysis dose response environmental exposure female human lung cancer male priority journal race difference randomized controlled trial risk assessment risk factor saliva level sex difference smoking cessation statistical significance tobacco dependence transdermal patch United States LA - English M3 - Article N1 - L41600916 2005-11-24 PY - 2005 SN - 1462-2203 1469-994X SP - 581-590 ST - The influence of gender, race, and menthol content on tobacco exposure measures T2 - Nicotine and Tobacco Research TI - The influence of gender, race, and menthol content on tobacco exposure measures UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41600916&from=export http://dx.doi.org/10.1080/14622200500185199 VL - 7 ID - 1263 ER - TY - JOUR AB - Research has suggested that race, gender, and menthol cigarette use influence tobacco‐smoke exposure measures and smoking‐related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking‐related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender × race × menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed. © 2005 Society for Research on Nicotine and Tobacco. AN - CN-01775388 AU - Mustonen, T. K. AU - Spencer, S. M. AU - Hoskinson Jr, R. A. AU - Sachs, D. P. L. AU - Garvey, A. J. DO - 10.1080/14622200500185199 IS - 4 KW - *lung cancer /etiology Adult Article Blood pressure measurement Body mass Cancer risk Clinical trial Controlled clinical trial Controlled study Correlation analysis Dose response Environmental exposure Female Human Male Priority journal Race difference Randomized controlled trial Risk assessment Risk factor Saliva level Sex difference Smoking cessation Statistical significance Tobacco dependence /drug therapy Transdermal patch United States M3 - Journal: Article PY - 2005 SP - 581‐590 ST - The influence of gender, race, and menthol content on tobacco exposure measures T2 - Nicotine & tobacco research TI - The influence of gender, race, and menthol content on tobacco exposure measures UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01775388/full VL - 7 ID - 1621 ER - TY - JOUR AB - Research has suggested that race, gender, and menthol cigarette use influence tobacco-smoke exposure measures and smoking-related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking-related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender × race × menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed. © 2005 Society for Research on Nicotine and Tobacco. AD - Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, United States Massachusetts College of Pharmacy and Health Sciences, Boston, MA, United States Palo Alto Center for Pulmonary Disease Prevention, Palo Alto, CA, United States Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States AU - Mustonen, T. K. AU - Spencer, S. M. AU - Hoskinson Jr, R. A. AU - Sachs, D. P. L. AU - Garvey, A. J. DB - Scopus DO - 10.1080/14622200500185199 IS - 4 M3 - Article N1 - Cited By :65 Export Date: 22 March 2021 PY - 2005 SP - 581-590 ST - The influence of gender, race, and menthol content on tobacco exposure measures T2 - Nicotine and Tobacco Research TI - The influence of gender, race, and menthol content on tobacco exposure measures UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-27744602695&doi=10.1080%2f14622200500185199&partnerID=40&md5=30d75ac54f505c859a90a29dd5e2affe VL - 7 ID - 2592 ER - TY - JOUR AB - Research has suggested that race, gender, and menthol cigarette use influence tobacco-smoke exposure measures and smoking-related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking-related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender × race × menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Mustonen, Taru Kinnunen, Harvard School of Dental Medicine, Tobacco Dependence Treatment and Research, 188 Longwood Avenue, Boston, MA, US, 02115 AN - 2005-09305-011 AU - Mustonen, Taru Kinnunen AU - Spencer, Stacie M. AU - Hoskinson, Randall A., Jr. AU - Sachs, David P. L. AU - Garvey, Arthur J. DB - psyh DO - 10.1080/14622200500185199 DP - EBSCOhost IS - 4 KW - racial differences gender differences menthol content tobacco exposure risk factors smoking cessation Adult African Americans Analysis of Variance Attitude to Health Biomarkers Carbon Monoxide Cotinine European Continental Ancestry Group Female Flavoring Agents Humans Male Menthol Middle Aged Saliva Sex Distribution Smoking United States Human Sex Differences Racial and Ethnic Differences Tobacco Smoking N1 - Harvard School of Dental Medicine, Boston, MA, US. Other Publishers: Oxford University Press. Release Date: 20050906. Correction Date: 20140414. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Human Sex Differences; Racial and Ethnic Differences; Risk Factors; Smoking Cessation; Tobacco Smoking. Classification: Drug & Alcohol Rehabilitation (3383). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Fagerstrom Tolerance Questionnaire DOI: 10.1037/t28829-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 10. Issue Publication Date: Aug, 2005. PY - 2005 SN - 1462-2203 1469-994X SP - 581-590 ST - The influence of gender, race, and menthol content on tobacco exposure measures T2 - Nicotine & Tobacco Research TI - The influence of gender, race, and menthol content on tobacco exposure measures UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2005-09305-011&site=ehost-live&scope=site taru_mustonen@hsdm.harvard.edu VL - 7 ID - 1808 ER - TY - JOUR AB - Research has suggested that race, gender, and menthol cigarette use influence tobacco-smoke exposure measures and smoking-related disease risk. For example, a high proportion of Black smokers prefer menthol cigarettes and, despite smoking fewer cigarettes per day (CPD) than do Whites, tend to have higher cotinine levels. Additionally, Black males are more at risk for smoking-related lung cancer. High cotinine levels and smoking menthol cigarettes may lead to higher toxin intake, which contributes to increased disease risk. We explored the relationship between tobacco exposure variables (i.e., cotinine, CPD, carbon monoxide [CO], nicotine content, and nicotine dependence) with respect to race, gender, and menthol content in a sample of 307 smokers recruited from the greater Boston area to participate in a smoking cessation treatment trial. The pattern of correlations between tobacco exposure measures and cotinine showed a consistently positive correlation between cotinine and CO in all smokers and a correlation between cotinine and CPD in those who smoked nonmenthol cigarettes. Cotinine and CPD correlations varied by gender and race among menthol cigarette smokers. Consistently, we found a significant gender x race x menthol interaction on salivary cotinine level as well as cotinine/CPD ratio. These findings suggest that the relationship between number of cigarettes consumed and salivary cotinine is more complex than previously believed. It is not sufficient to look at race alone; researchers and clinicians need to look at race and gender concurrently, as well as type of cigarette consumed. AN - WOS:000232474700011 AU - Mustonen, T. K. AU - Spencer, S. M. AU - Hoskinson, R. A. AU - Sachs, D. P. L. AU - Garvey, A. J. DA - Aug DO - 10.1080/14622200500185199 IS - 4 N1 - 16085529 PY - 2005 SN - 1462-2203 SP - 581-590 ST - The influence of gender, race, and menthol content on tobacco exposure measures T2 - Nicotine & Tobacco Research TI - The influence of gender, race, and menthol content on tobacco exposure measures VL - 7 ID - 3236 ER - TY - JOUR AB - BACKGROUND: Pain management racial disparities exist, yet it is unclear whether disparities exist in pain management in advanced cancer. OBJECTIVE: To examine the effect of race on physicians' pain assessment and treatment in advanced lung cancer and the moderating effect of patient activation. DESIGN: Randomized field experiment. Physicians consented to see two unannounced standardized patients (SPs) over 18 months. SPs portrayed 4 identical roles‐a 62‐year‐old man with advanced lung cancer and uncontrolled pain‐differing by race (black or white) and role (activated or typical). Activated SPs asked questions, interrupted when necessary, made requests, and expressed opinions. PARTICIPANTS: Ninety‐six primary care physicians (PCPs) and oncologists from small cities, and suburban and rural areas of New York, Indiana, and Michigan. Physicians' mean age was 52 years (SD = 27.17), 59% male, and 64% white. MAIN MEASURES: Opioids prescribed (or not), total daily opioid doses (in oral morphine equivalents), guideline‐concordant pain management, and pain assessment. KEY RESULTS: SPs completed 181 covertly audio‐recorded visits that had complete data for the model covariates. Physicians detected SPs in 15% of visits. Physicians prescribed opioids in 71% of visits; 38% received guideline‐concordant doses. Neither race nor activation was associated with total opioid dose or guideline‐concordant pain management, and there were no interaction effects (p > 0.05). Activation, but not race, was associated with improved pain assessment (ẞ, 0.46, 95% CI 0.18, 0.74). In post hoc analyses, oncologists (but not PCPs) were less likely to prescribe opioids to black SPs (OR 0.24, 95% CI 0.07, 0.81). CONCLUSIONS: Neither race nor activation was associated with opioid prescribing; activation was associated with better pain assessment. In post hoc analyses, oncologists were less likely to prescribe opioids to black male SPs than white male SPs; PCPs had no racial disparities. In general, physicians may be under‐prescribing opioids for cancer pain. TRIAL REGISTRATION: NCT01501006. AN - CN-02145166 AU - Shields, C. G. AU - Griggs, J. J. AU - Fiscella, K. AU - Elias, C. M. AU - Christ, S. L. AU - Colbert, J. AU - Henry, S. G. AU - Hoh, B. G. AU - Hunte, H. E. R. AU - Marshall, M. AU - et al. DO - 10.1007/s11606-018-4785-z IS - 3 KW - Adult Aged Analgesics, Opioid [therapeutic use] Cancer Pain [*drug therapy] Continental Population Groups [*psychology] Drug Prescriptions Female Humans Lung Neoplasms [*drug therapy] Male Middle Aged Pain Management [methods, *psychology] Patient Participation [methods, *psychology] Physicians [*psychology] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2019 SP - 435‐442 ST - The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment T2 - Journal of general internal medicine TI - The Influence of Patient Race and Activation on Pain Management in Advanced Lung Cancer: a Randomized Field Experiment UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02145166/full VL - 34 ID - 1584 ER - TY - JOUR AB - OBJECTIVES: Enrollment of adult cancer patients in clinical trials remains low, particularly in the minority population. Understanding patient attitudes towards clinical trials during the recruitment process may enhance accrual. Unfortunately, data describing patient attitudes towards clinical trials are limited, particularly in the radiation oncology clinic setting. METHODS: A piloted questionnaire assessing basic demographics and attitudes toward clinical trials was offered in 2 radiation oncology clinics between April 2003 and October 2003. The questionnaire was completed by 166 patients. The mean age of the patients completing the questionnaire was 56 years (range, 15-84 years). Of the 166 patients included in the analysis, 108 (65%) were White. The most common cancer diagnoses included prostate (19%), head and neck (16%), and breast (14%). RESULTS: There was no statistical difference between Whites and non-Whites regarding their interest in learning about clinical trials (84.3% versus 84.9%, P = 0.92); nor was there a significant difference in the rate of previous or current trial enrollment (21.3% versus 34.0%, P = 0.08). White patients were more likely to gather information about clinical trials from the Internet (30.6% versus 11.3%, P = 0.007), and they were more likely to use physicians as a source of this information (50.0% versus 34.0%, P = 0.05). Non-White patients were more likely to obtain information about clinical trials from other patients (24.5% versus 12.0%, P = 0.04). In addition, more non-White patients believed they had been treated on clinical trials without their knowledge (21.6% versus 9.3%, P = 0.032). Patients differed somewhat in their expectations of clinical trials. More non-Whites indicated that they would need a >50% chance of benefiting from a trial (64.4% versus 45.0%, P = 0.03) to enroll on that trial, though there were no statistical differences in outlook towards potential toxicities associated with treatment on a clinical trial. CONCLUSIONS: Minority patients historically enroll in clinical trials at a significantly lower rate. Our study of radiation oncology patients documents significant differences in attitudes towards clinical trials between Whites and non-Whites. Understanding the differences in attitudes may allow physicians to overcome barriers that would otherwise hinder the enrollment of non-White patients into clinical trials. © 2006 Lippincott Williams & Wilkins, Inc. AD - Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States Department of Radiation Oncology, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, United States Hospital of the University of Pennsylvania, Department of Radiation Oncology, 2 Donner Building, 3400 Spruce Street, Philadelphia, PA 19104, United States AU - Wood, C. G. AU - Wei, S. J. AU - Hampshire, M. K. AU - Devine, P. A. AU - Metz, J. M. DB - Scopus DO - 10.1097/01.coc.0000236213.61427.84 IS - 6 KW - Attitude Clinical trials Neoplasms Population groups Radiation M3 - Conference Paper N1 - Cited By :23 Export Date: 22 March 2021 PY - 2006 SP - 593-599 ST - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment T2 - American Journal of Clinical Oncology: Cancer Clinical Trials TI - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33845476275&doi=10.1097%2f01.coc.0000236213.61427.84&partnerID=40&md5=e2b892f463cf7442259a17e27dc592d4 VL - 29 ID - 2567 ER - TY - JOUR AB - Objectives: Enrollment of adult cancer patients in clinical trials remains low, particularly in the minority population. Understanding patient attitudes towards clinical trials during the recruitment process may enhance accrual. Unfortunately, data describing patient attitudes towards clinical trials are limited, particularly in the radiation oncology clinic setting. Methods: A piloted questionnaire assessing basic demographics and attitudes toward clinical trials was offered in 2 radiation oncology clinics between April 2003 and October 2003. The questionnaire was completed by 166 patients. The mean age of the patients completing the questionnaire was 56 years (range, 15-84 years). Of the 166 patients included in the analysis, 108 (65%) were White. The most common cancer diagnoses included prostate (19%), head and neck (16%), and breast (14%). Results: There was no statistical difference between Whites and non-Whites regarding their interest in learning about clinical trials (84.3% versus 84.9%, P = 0.92); nor was there a significant difference in the rate of previous or current trial enrollment (21.3% versus 34.0%, P = 0.08). White patients were more likely to gather information about clinical trials from the Internet (30.6% versus 11.3%, P = 0.007), and they were more likely to use physicians as a source of this information (50.0% versus 34.0%, P = 0.05). Non-White patients were more likely to obtain information about clinical trials from other patients (24.5% versus 12.0%, P = 0.04). In addition, more non-White patients believed they had been treated on clinical trials without their knowledge (21.6% versus 9.3%, P = 0.032). Patients differed somewhat in their expectations of clinical trials. More non-Whites indicated that they would need a > 50% chance of benefiting from a trial (64.4% versus 45.0%, P = 0.03) to enroll on that trial, though there were no statistical differences in outlook towards potential toxicities associated with treatment on a clinical trial. Conclusions: Minority patients historically enroll in clinical trials at a significantly lower rate. Our study of radiation oncology patients documents significant differences in attitudes towards clinical trials between Whites and non-Whites. Understanding the differences in attitudes may allow physicians to overcome barriers that would otherwise hinder the enrollment of non-White patients into clinical trials. AN - WOS:000242681700013 AU - Wood, C. G. AU - Wei, S. J. AU - Hampshire, M. K. AU - Devine, P. A. AU - Metz, J. M. DA - Dec DO - 10.1097/01.coc.0000236213.61427.84 IS - 6 N1 - 46th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology OCT 17-20, 2004 Atlanta, GA Amer Soc Therapeut Radiol & Oncol 17148997 PY - 2006 SN - 0277-3732 SP - 593-599 ST - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment T2 - American Journal of Clinical Oncology-Cancer Clinical Trials TI - The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment VL - 29 ID - 3206 ER - TY - JOUR AB - Background: First degree relatives (FDRs) of men diagnosed with prostate cancer (PCa) are at increased risk for developing the disease, due in part to multiple concurrent risk factors. There is a lack of innovative targeted decision aids to help FDRs make an informed decision about whether or not to undergo PCa screening. Purpose: This randomized pilot trial evaluated the efficacy of a targeted PCa screening decision aid in unaffected FDRs of PCa survivors. Methods: Seventy‐eight Black and White FDRs were randomized to one of two decision aid groups; 39 to a FDR‐targeted decision aid and 39 to a general decision aid. The targeted decision aid group received a general PCa decision aid booklet plus a newly developed decision aid DVD targeted specifically for FDRs. PCa screening decision outcomes included knowledge, decisional conflict, distress, and satisfaction with screening decision. Outcomes were assessed at baseline and 4. weeks after baseline. Results: There were no differences by intervention group for knowledge, decisional conflict, distress, or satisfaction with screening decision (p. >. 0.05). However, men in both groups had significant increases in knowledge and decreases in decisional conflict (p. <. 0.001). These changes were most pronounced (p. <. 0.05) for younger men compared to older men. Conclusion: Results suggest that general and targeted information can play an important role in increasing knowledge and decreasing decisional conflict among FDRs. Additional research is needed to identify subgroups of men who benefit the most and better understand the outcomes of a screening decision aid among diverse samples of FDRs. AN - CN-01036660 AU - Davis, S. N. AU - Sutton, S. K. AU - Vadaparampil, S. T. AU - Meade, C. D. AU - Rivers, B. M. AU - Patel, M. V. AU - Torres-Roca, J. F. AU - Heysek, R. V. AU - Spiess, P. AU - Pow-Sang, J. AU - et al. DO - 10.1016/j.cct.2014.10.007 IS - 2 KW - *cancer survivor *clinical decision making *informed decision making *prostate cancer Adult African Americans Aged Article Cancer screening Comparative study Controlled study Decision Making Decision Support Techniques Disease course Early Detection of Cancer European Continental Ancestry Group First degree relative Health Knowledge, Attitudes, Practice Human Humans Major clinical study Male Middle Aged Outcome assessment Pamphlets Patient Participation [*methods] Pilot Projects Pilot study Prostatic Neoplasms [*diagnosis, ethnology, *psychology] Randomized controlled trial Risk factor Screening test Socioeconomic Factors M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2014 SP - 327‐334 ST - Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial T2 - Contemporary clinical trials TI - Informed decision making among first-degree relatives of prostate cancer survivors: a pilot randomized trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01036660/full VL - 39 ID - 1384 ER - TY - JOUR AB - Prostate cancer incidence and mortality are highest among African-American men, and coupled with the controversy around routine prostate cancer screening, reaching African-American men with interventions to help them make an informed decision about whether or not to be screened is critical. This study compares two approaches to delivering a church-based peer community health advisor intervention consisting of a series of four men's health workshops on informed decision-making for prostate cancer screening. In the men-only group, male community health advisors teach group workshops consisting only of men. In the health partner group, male-female pairs of community health advisors teach workshops in a mixed-gender format in which enrolled men are asked to invite a significant woman in their lives (e.g., wife/partner, sister, daughter, friend) with them to the workshops. Eighteen African-American churches were randomized to receive one of the two approaches, and 283 eligible men enrolled in the intervention. Main findings suggested that the workshops had an impact on stage of decision-making, and this increased significantly over time in the health partner group only. The intervention was highly rated by men in both groups, and these ratings increased over time, with some study group differences. Within-workshop study group differences favored the health partner group in some instances; however, men in the men-only groups reported greater increases in their ratings of trust in the workshops over time. The health partner intervention strategy appears to be promising for reaching men of color with health information. AU - Holt, C. L. AU - Le, D. AU - Saunders, D. R. AU - Wang, M. Q. AU - Slade, J. L. AU - Muwwakkil, B. AU - Williams, R. AU - Atkinson, N. L. AU - Whitehead, T. L. AU - Naslund, M. DB - Medline DO - 10.1007/s13187-014-0731-x IS - 3 KW - NCT02131779 African American aged attitude to health controlled study decision making early cancer diagnosis ethnology female health education human information processing male men's health middle aged organization and management patient attitude prostate tumor psychology randomized controlled trial religion satisfaction sex difference United States LA - English M3 - Article N1 - L615285698 2017-07-04 PY - 2015 SN - 1543-0154 SP - 530-534 ST - Informed Decision-Making and Satisfaction with a Church-Based Men's Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Informed Decision-Making and Satisfaction with a Church-Based Men's Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615285698&from=export http://dx.doi.org/10.1007/s13187-014-0731-x VL - 30 ID - 999 ER - TY - JOUR AB - Prostate cancer incidence and mortality are highest among African-American men, and coupled with the controversy around routine prostate cancer screening, reaching African-American men with interventions to help them make an informed decision about whether or not to be screened is critical. This study compares two approaches to delivering a church-based peer community health advisor intervention consisting of a series of four men’s health workshops on informed decision-making for prostate cancer screening. In the men-only group, male community health advisors teach group workshops consisting only of men. In the health partner group, male-female pairs of community health advisors teach workshops in a mixed-gender format in which enrolled men are asked to invite a significant woman in their lives (e.g., wife/partner, sister, daughter, friend) with them to the workshops. Eighteen African-American churches were randomized to receive one of the two approaches, and 283 eligible men enrolled in the intervention. Main findings suggested that the workshops had an impact on stage of decision-making, and this increased significantly over time in the health partner group only. The intervention was highly rated by men in both groups, and these ratings increased over time, with some study group differences. Within-workshop study group differences favored the health partner group in some instances; however, men in the men-only groups reported greater increases in their ratings of trust in the workshops over time. The health partner intervention strategy appears to be promising for reaching men of color with health information. © 2014, Springer Science+Business Media New York (outside the USA (except that a license is reserved to the United States Government for all government purposes and to the University of Maryland College Park for its internal educational and research purposes)). AD - Department of Behavioral and Community Health, School of Public Health, University of Maryland, 2369 School of Public Health Building (255), College Park, MD 20742, United States Community Ministry of Prince George’s County, Upper Marlboro, MD, United States Access to Wholistic and Productive Living Inc., Lanham, MD, United States Westat, Rockville, MD, United States University of Maryland School of Medicine, Baltimore, MD, United States AU - Holt, C. L. AU - Le, D. AU - Saunders, D. R. AU - Wang, M. Q. AU - Slade, J. L. AU - Muwwakkil, B. AU - Williams, R. AU - Atkinson, N. L. AU - Whitehead, T. L. AU - Naslund, M. DB - Scopus DO - 10.1007/s13187-014-0731-x IS - 3 KW - African-American Cancer screening Church-based Community health advisor Health disparities Informed decision-making Men’s health Prostate cancer M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2015 SP - 530-534 ST - Informed Decision-Making and Satisfaction with a Church-Based Men’s Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format T2 - Journal of Cancer Education TI - Informed Decision-Making and Satisfaction with a Church-Based Men’s Health Workshop Series for African-American Men: Men-Only vs. Mixed-Gender Format UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941318208&doi=10.1007%2fs13187-014-0731-x&partnerID=40&md5=3bd16497b5da689300e12f3b16f4ce26 VL - 30 ID - 2360 ER - TY - JOUR AB - IMPORTANCE: Germline mutations in BRCA1 and BRCA2 are relatively common in women with ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime risk of these cancers, but the frequency and relevance of inherited mutations in other genes is less well characterized. OBJECTIVE: To determine the frequency and importance of germline mutations in cancer-associated genes in OC. DESIGN, SETTING, AND PARTICIPANTS: A study population of 1915 woman with OC and available germline DNA were identified from the University of Washington (UW) gynecologic tissue bank (n = 570) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557). Patients were enrolled at diagnosis and were not selected for age or family history. Germline DNA was sequenced from women with OC using a targeted capture and multiplex sequencing assay. MAIN OUTCOMES AND MEASURES: Mutation frequencies in OC were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC). Clinical characteristics and survival were assessed by mutation status. RESULTS: Overall, the median (range) age at diagnosis was 60 (28-91) years in patients recruited from UW and 61 (23-87) years in patients recruited from the GOG trials. A higher number of black women were recruited from the GOG trials (4.3% vs 1.4%; P = .009); but in patients recruited from UW, there was a higher proportion of fallopian tube carcinomas (13.3% vs 5.7%; P < .001); stage I and II disease (14.6% vs 0% [GOG trials were restricted to advanced-stage cancer]); and nonserous carcinomas (29.9% vs 13.1%, P < .001). Of 1915 patients, 280 (15%) had mutations in BRCA1 (n = 182), or BRCA2 (n = 98), and 8 (0.4%) had mutations in DNA mismatch repair genes. Mutations in BRIP1 (n = 26), RAD51C (n = 11), RAD51D (n = 11), PALB2 (n = 12), and BARD1 (n = 4) were significantly more common in patients with OC than in the ESP or ExAC, present in 3.3%. Race, histologic subtype, and disease site were not predictive of mutation frequency. Patients with a BRCA2 mutation from the GOG trials had longer progression-free survival (hazard ratio [HR], 0.60; 95% CI, 0.45-0.79; P < .001) and overall survival (HR, 0.39; 95% CI, 0.25-0.60; P < .001) compared with those without mutations. CONCLUSIONS AND RELEVANCE: Of 1915 patients with OC, 347 (18%) carried pathogenic germline mutations in genes associated with OC risk. PALB2 and BARD1 are suspected OC genes and together with established OC genes (BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH2, MLH1, PMS2, and MSH6) bring the total number of genes suspected to cause hereditary OC to 11. AU - Norquist, B. M. AU - Harrell, M. I. AU - Brady, M. F. AU - Walsh, T. AU - Lee, M. K. AU - Gulsuner, S. AU - Bernards, S. S. AU - Casadei, S. AU - Yi, Q. AU - Burger, R. A. AU - Chan, J. K. AU - Davidson, S. A. AU - Mannel, R. S. AU - DiSilvestro, P. A. AU - Lankes, H. A. AU - Ramirez, N. C. AU - King, M. C. AU - Swisher, E. M. AU - Birrer, M. J. DB - Medline DO - 10.1001/jamaoncol.2015.5495 IS - 4 KW - adult aged disease free survival dna mutational analysis female genetic predisposition genetics germline mutation human middle aged mortality ovary tumor prognosis proportional hazards model very elderly LA - English M3 - Article N1 - L615198628 2017-04-13 PY - 2016 SN - 2374-2445 SP - 482-490 ST - Inherited Mutations in Women With Ovarian Carcinoma T2 - JAMA oncology TI - Inherited Mutations in Women With Ovarian Carcinoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615198628&from=export http://dx.doi.org/10.1001/jamaoncol.2015.5495 VL - 2 ID - 978 ER - TY - JOUR AB - Importance: Germline Mutations in BRCA1 and BRCA2 Are Relatively Com. in Women with Ovarian, Fallopian Tube, and Peritoneal Carcinoma Causing A Greatly Increased Lifetime Risk of These Cancers, but the Frequency and Relevance of Inherited Mutations in Other Genes Is Less Well Characterized. Objective: to Determine the Frequency and Importance of Germline Mutations in Cancer-Assoc. Genes in OC. Des., Setting and Participants: A Stud. Pop. of 1915woman with OC and Available Germline DNA Were Identified from the Univ. OfWashington Gynecologic Tissue Bank and from Gynecologic Oncol. Grp. Phase III Clin. Trials 218 and 262 . Patients Were Enrolled at Diagn. and Were Not Selected for Age or Fam. Hist.. Germline DNA Was Sequenced from Women with OC Using A Targeted Capture and Multiplex Sequencing Assay. Main Outcomes and Measures: Mutation Frequencies in OCwere Compared with the Natl. Heart, Lung and Blood Inst. GO Exome Sequencing Proj. and the Exome Aggregation Consortium . Clin. Characteristics and Survival Were Assessed by Mutation Status. Results: Overall, the Median Age at Diagn. Was 60 Years in Patients Recruited from UW and 61 Years in Patients Recruited from the GOG Trials. A Higher No. of Black Women Were Recruited from the GOG Trials ; but in Patients Recruited from UW, There Was A Higher Proportion of Fallopian Tube Carcinomas ; Stage i and Ii Dis. ; and Nonserous Carcinomas . of 1915 Patients, 280 Had Mutations in BRCA1 , or BRCA2 , and 8 Had Mutations in DNA Mismatch Repair Genes. Mutations in BRIP1 , RAD51C , RAD51D , PALB2 , and BARD1 Were Significantly More Com. in Patients with OC Than in the ESP or ExAC, Present in 3.3%. Race, Histologic Subtype, and Dis. Site Were Not Predictive of Mutation Frequency. Patients with A BRCA2 Mutation from the GOG Trials Had Longer Progression-free Survival and Overall Survival Compared with Those Without Mutations. Conclusions and Relevance: of 1915 Patients with OC, 347 Carried Pathogenic Germline Mutations in Genes Assoc. with OC Risk. PALB2 and BARD1 Are Suspected OC Genes and Together with Estab. OC Genes Bring the Total No. of Genes Suspected to Cause Hered. OC to 11. Copyright © 2016 Amer. Med. Assoc.. All Rights Reserved. AD - Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195-6460, United States NRG Oncology Statistical and Data Center, Roswell Park Cancer Center Institute, Buffalo, NY, United States Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, United States Department of Genome Sciences, University of Washington, Seattle, United States Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, United States Division of Gynecologic Oncology, Sutter Health California Pacific Medical Center, San Francisco, CA, United States Division of Gynecologic Oncology, University of Colorado, Denver, United States Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, United States Division of Gynecologic Oncology, Women and Infants Hospital, Providence, RI, United States Department of Pathology and Laboratory Medicine, Research Institute, Nationwide Children's Hospital, Columbus, OH, United States Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, United States AU - Norquist, B. M. AU - Harrell, M. I. AU - Brady, M. F. AU - Walsh, T. AU - Lee, M. K. AU - Gulsuner, S. AU - Bernards, S. S. AU - Casadei, S. AU - Yi, Q. AU - Burger, R. A. AU - Chan, J. K. AU - Davidson, S. A. AU - Mannel, R. S. AU - DiSilvestro, P. A. AU - Lankes, H. A. AU - Ramirez, N. C. AU - King, M. C. AU - Swisher, E. M. AU - Birrer, M. J. DB - Scopus DO - 10.1001/jamaoncol.2015.5495 IS - 4 M3 - Article N1 - Cited By :313 Export Date: 22 March 2021 PY - 2016 SP - 482-490 ST - Inherited mutations in women with ovarian carcinoma T2 - JAMA Oncology TI - Inherited mutations in women with ovarian carcinoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010702793&doi=10.1001%2fjamaoncol.2015.5495&partnerID=40&md5=666525505a4fb363d3c2ecf6fffa8e20 VL - 2 ID - 2346 ER - TY - JOUR AB - IMPORTANCE Germline mutations in BRCA1 and BRCA2 are relatively common in women with ovarian, fallopian tube, and peritoneal carcinoma (OC) causing a greatly increased lifetime risk of these cancers, but the frequency and relevance of inherited mutations in other genes is less well characterized. OBJECTIVE To determine the frequency and importance of germline mutations in cancer-associated genes in OC. DESIGN, SETTING, AND PARTICIPANTS A study population of 1915 woman with OC and available germline DNA were identified from the University of Washington (UW) gynecologic tissue bank (n = 570) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557). Patients were enrolled at diagnosis and were not selected for age or family history. Germline DNA was sequenced from women with OC using a targeted capture and multiplex sequencing assay. MAIN OUTCOMES AND MEASURES Mutation frequencies in OC were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP) and the Exome Aggregation Consortium (ExAC). Clinical characteristics and survival were assessed by mutation status. RESULTS Overall, the median (range) age at diagnosis was 60 (28-91) years in patients recruited from UW and 61 (23-87) years in patients recruited from the GOG trials. A higher number of black women were recruited from the GOG trials (4.3% vs 1.4%; P = .009); but in patients recruited from UW, there was a higher proportion of fallopian tube carcinomas (13.3% vs 5.7%; P < .001); stage I and II disease (14.6% vs 0%[GOG trials were restricted to advanced-stage cancer]); and nonserous carcinomas (29.9% vs 13.1%, P < .001). Of 1915 patients, 280 (15%) had mutations in BRCA1 (n = 182), or BRCA2 (n = 98), and 8 (0.4%) had mutations in DNA mismatch repair genes. Mutations in BRIP1 (n = 26), RAD51C (n = 11), RAD51D (n = 11), PALB2 (n = 12), and BARD1 (n = 4) were significantly more common in patients with OC than in the ESP or ExAC, present in 3.3%. Race, histologic subtype, and disease site were not predictive of mutation frequency. Patients with a BRCA2 mutation from the GOG trials had longer progression-free survival (hazard ratio [HR], 0.60; 95% CI, 0.45-0.79; P < .001) and overall survival (HR, 0.39; 95% CI, 0.25-0.60; P < .001) compared with those without mutations. CONCLUSIONS AND RELEVANCE Of 1915 patients with OC, 347 (18%) carried pathogenic germline mutations in genes associated with OC risk. PALB2 and BARD1 are suspected OC genes and together with established OC genes (BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, MSH2, MLH1, PMS2, and MSH6) bring the total number of genes suspected to cause hereditary OC to 11. AN - WOS:000383683200017 AU - Norquist, B. M. AU - Harrell, M. I. AU - Brady, M. F. AU - Walsh, T. AU - Lee, M. K. AU - Gulsuner, S. AU - Bernards, S. S. AU - Casadei, S. AU - Yi, Q. AU - Burger, R. A. AU - Chan, J. K. AU - Davidson, S. A. AU - Mannel, R. S. AU - DiSilvestro, P. A. AU - Lankes, H. A. AU - Ramirez, N. C. AU - King, M. C. AU - Swisher, E. M. AU - Birrer, M. J. DA - Apr DO - 10.1001/jamaoncol.2015.5495 IS - 4 N1 - 26720728 PY - 2016 SN - 2374-2437 SP - 482-490 ST - Inherited Mutations in Women With Ovarian Carcinoma T2 - Jama Oncology TI - Inherited Mutations in Women With Ovarian Carcinoma VL - 2 ID - 2948 ER - TY - JOUR AB - Introduction: Racial/ethnic diversity in prostate cancer (CaP) clinical trials (CTs) is essential to address CaP disparities. California Cancer Registry mandated electronic reporting (e-path) of structured data elements from pathologists diagnosing cancer thereby creating an opportunity to identify and approach patients rapidly. This study tested the utility of an online CT matching tool (called Trial Library) used in combination with e-path to improve matching of underrepresented CaP patients into CTs at time of diagnosis. Methods: This was a nonrandomized, single-arm feasibility study among patients with a new pathologic diagnosis of high-risk CaP (Gleason Score ≥8). Eligible patients were sent recruitment materials and enrolled patients were introduced to Trial Library. Results: A total of 419 case listings were assessed. Patients were excluded due to physician contraindication, not meeting baseline eligibility, or unable to be reached. Final participants (N = 52) completed a baseline survey. Among study participants, 77% were White, 10% were Black/Hispanic/Missing, and 14% were Asian. The majority of the study participants were over 65 years of age (81%) and Medicare insured (62%). Additionally, 81% of participants reported using the Internet to learn about CaP. The majority (62%) of participants reported that Trial Library increased their interest in CT participation. Conclusions: The current study demonstrated that leveraging structured e-path data reporting to a population-based cancer registry to recruit men with high risk CaP to clinical research is feasible and acceptable. We observed that e-path may be linked with an online CT matching tool, Trial Library. Future studies will prioritize recruitment from reporting facilities that serve more racially/ethnically diverse patient populations. AD - H.T. Borno, Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, United States AU - Borno, H. T. AU - Duffy, C. AU - Zhang, S. AU - Canchola, A. J. AU - Loya, Z. AU - Golden, T. AU - Oh, D. L. AU - Odisho, A. Y. AU - Gomez, S. DB - Embase Medline DO - 10.1016/j.urolonc.2020.12.010 KW - adult advanced cancer article cancer registry clinical research contraindication controlled study feasibility study Gleason score Hispanic human Internet major clinical study male medicare physician prostate cancer LA - English M3 - Article in Press N1 - L2010573196 2021-01-12 PY - 2021 SN - 1873-2496 1078-1439 ST - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer T2 - Urologic Oncology: Seminars and Original Investigations TI - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010573196&from=export http://dx.doi.org/10.1016/j.urolonc.2020.12.010 ID - 766 ER - TY - JOUR AB - Introduction: Racial/ethnic diversity in prostate cancer (CaP) clinical trials (CTs) is essential to address CaP disparities. California Cancer Registry mandated electronic reporting (e-path) of structured data elements from pathologists diagnosing cancer thereby creating an opportunity to identify and approach patients rapidly. This study tested the utility of an online CT matching tool (called Trial Library) used in combination with e-path to improve matching of underrepresented CaP patients into CTs at time of diagnosis. Methods: This was a nonrandomized, single-arm feasibility study among patients with a new pathologic diagnosis of high-risk CaP (Gleason Score ≥8). Eligible patients were sent recruitment materials and enrolled patients were introduced to Trial Library. Results: A total of 419 case listings were assessed. Patients were excluded due to physician contraindication, not meeting baseline eligibility, or unable to be reached. Final participants (N = 52) completed a baseline survey. Among study participants, 77% were White, 10% were Black/Hispanic/Missing, and 14% were Asian. The majority of the study participants were over 65 years of age (81%) and Medicare insured (62%). Additionally, 81% of participants reported using the Internet to learn about CaP. The majority (62%) of participants reported that Trial Library increased their interest in CT participation. Conclusions: The current study demonstrated that leveraging structured e-path data reporting to a population-based cancer registry to recruit men with high risk CaP to clinical research is feasible and acceptable. We observed that e-path may be linked with an online CT matching tool, Trial Library. Future studies will prioritize recruitment from reporting facilities that serve more racially/ethnically diverse patient populations. © 2020 Elsevier Inc. AD - Department of Medicine, Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, United States Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States Greater Bay Area Cancer Registry, University of California San Francisco, San Francisco, CA, United States Department of Urology, University of California San Francisco, San Francisco, CA, United States Center for Digital Health Innovation, University of California, San Francisco, CA, United States AU - Borno, H. T. AU - Duffy, C. AU - Zhang, S. AU - Canchola, A. J. AU - Loya, Z. AU - Golden, T. AU - Oh, D. L. AU - Odisho, A. Y. AU - Gomez, S. DB - Scopus DO - 10.1016/j.urolonc.2020.12.010 KW - Cancer disparities Clinical trials Early case ascertainment Electronic pathology Prostate cancer M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer T2 - Urologic Oncology: Seminars and Original Investigations TI - Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098976074&doi=10.1016%2fj.urolonc.2020.12.010&partnerID=40&md5=adce4dea771a2205953cf6e449c1ecae ID - 2164 ER - TY - JOUR AB - Although prior studies have shown that African American smokers are likely to carry some of the genetic variants associated with smoking risk, additional research with African American smokers is needed to replicate these findings. Limited information is available on interest in participating in research to identify genetic risk factors for smoking among African American smokers; therefore, the goals of the present study were to describe intentions to participate in smoking and genetics research, and to determine factors that are associated with participation intentions. Subjects were 128 African American male and female adult smokers. Sociodemographic characteristics, clinical factors, attitudes about genetic testing, and intentions to participate in genetics research were evaluated during a structured telephone interview. Overall, 58% of respondents reported that they would be very likely to participate in research to identify genetic risk factors for smoking. Greater beliefs about the benefits of participating in medical research (odds ratio, 3.17; 95% confidence interval, 1.45-6.94; P = 0.004) and fewer perceptions of the limitations and risks of genetic testing (odds ratio, 0.90; 95% confidence interval, 0.82-0.98; P = 0.01) had significant independent associations with reporting a high likelihood of participating in this type of research. Recruitment messages and protocols that address the benefits of research participation, as well as concerns about the limitations and risks of genetic testing, may enhance African American participation in research on genetics and smoking. Copyright © 2006 American Association for Cancer Research. AD - Department of Psychiatry, Abramson Cancer Center, Leonard Davis Institute of Economics, Philadelphia, PA, United States Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA, United States University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, United States AU - Halbert, C. H. AU - Gandy Jr, O. H. AU - Collier, A. AU - Shaker, L. DB - Scopus DO - 10.1158/1055-9965.EPI-05-0437 IS - 1 M3 - Article N1 - Cited By :31 Export Date: 22 March 2021 PY - 2006 SP - 150-153 ST - Intentions to participate in genetics research among African American smokers T2 - Cancer Epidemiology Biomarkers and Prevention TI - Intentions to participate in genetics research among African American smokers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645458032&doi=10.1158%2f1055-9965.EPI-05-0437&partnerID=40&md5=5f209c700a51e1bdd6bbf8992b8306c9 VL - 15 ID - 2584 ER - TY - JOUR AB - Although prior studies have shown that African American smokers are likely to carry some of the genetic variants associated with smoking risk, additional research with African American smokers is needed to replicate these findings. Limited information is available on interest in participating in research to identify genetic risk factors for smoking among African American smokers; therefore, the goals of the present study were to describe intentions to participate in smoking and genetics research, and to determine factors that are associated with participation intentions. Subjects were 128 African American male and female adult smokers. Sociodemographic characteristics, clinical factors, attitudes about genetic testing, and intentions to participate in genetics research were evaluated during a structured telephone interview. Overall, 58% of respondents reported that they would be very likely to participate in research to identify genetic risk factors for smoking. Greater beliefs about the benefits of participating in medical research (odds ratio, 3.17; 95% confidence interval, 1.45-6.94; P = 0.004) and fewer perceptions of the limitations and risks of genetic testing (odds ratio, 0.90; 95% confidence interval, 0.82-0.98; P = 0.01) had significant independent associations with reporting a high likelihood of participating in this type of research. Recruitment messages and protocols that address the benefits of research participation, as well as concerns about the limitations and risks of genetic testing, may enhance African American participation in research on genetics and smoking. AN - WOS:000234866200027 AU - Halbert, C. H. AU - Gandy, O. H. AU - Collier, A. AU - Shaker, L. DA - Jan DO - 10.1158/1055-9965.EPI-05-0437 IS - 1 N1 - 16434602 PY - 2006 SN - 1055-9965 SP - 150-153 ST - Intentions to participate in genetics research among African American smokers T2 - Cancer Epidemiology Biomarkers & Prevention TI - Intentions to participate in genetics research among African American smokers VL - 15 ID - 3228 ER - TY - JOUR AB - Six regions for prostate cancer genes have been identified, and it is anticipated that prostate cancer susceptibility testing will be available in the future. This correlational study identified predictors for interest in prostate cancer susceptibility testing among African American men. Participants were 320 African American men from the African American Hereditary Prostate Cancer Study and the South Carolina Prostate Cancer Education and Screening Study participated. Two questions measured interest in genetic prostate cancer susceptibility testing and family history of prostate cancer. Chi-square analyses by family history as well as demographics (age, education, marital status) were performed. Most of the men (277 [87%]) indicated an interest in genetic prostate cancer susceptibility testing. Interest in undergoing testing did not vary by family history, age, or education. Marital status was the only significant demographic predictor. Men who were married were significantly more likely to respond with a 'yes' to interest in prostate cancer susceptibility testing than were men who were not married. The high 'yes' response rate and the men's confusion between the genetic prostate cancer susceptibility testing and prostate cancer screening highlight the need for public education once prostate cancer genes are identified and available for public testing. AD - School of Nursing, University of Louisville, KY 40292; sally.weinrich@louisville.edu AN - 106911445. Language: English. Entry Date: 20020329. Revision Date: 20150820. Publication Type: Journal Article AU - Weinrich, S. AU - Royal, C. AU - Pettaway, C. A. AU - Dunston, G. AU - Faison-Smith, L. AU - Priest, J. H. AU - Roberson-Smith, P. AU - Frost, J. AU - Jenkins, J. AU - Brooks, K. A. AU - Powell, I. DB - CINAHL Complete DP - EBSCOhost IS - 1 KW - Genetic Screening Disease Susceptibility Prostatic Neoplasms Black Persons -- Texas Black Persons -- South Carolina Correlational Studies Chi Square Test Texas Race Factors South Carolina Descriptive Statistics Consumer Attitudes -- Evaluation Research Subject Recruitment Questionnaires Test-Retest Reliability Family History Adult Middle Age Aged Aged, 80 and Over Male Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7805358. PMID: NLM11838717. PY - 2002 SN - 0162-220X SP - 28-34 ST - Interest in genetic prostate cancer susceptibility testing among African American men T2 - Cancer Nursing TI - Interest in genetic prostate cancer susceptibility testing among African American men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106911445&site=ehost-live&scope=site VL - 25 ID - 1985 ER - TY - JOUR AB - OBJECTIVES: African-American women suffer disproportionately from HIV, breast cancer, and other illnesses. Little is known about the relationship between internalized HIV-related stigma and health beliefs related to other illnesses, including breast cancer. Our study examined (1) the relationship between internalized HIV-related stigma and breast health beliefs over time and (2) the moderating effects of participating in a stigma reduction intervention and/or social support. METHODS: Data from 239 African-American women receiving care for HIV in Chicago, IL, or Birmingham, AL, enrolled in the Unity randomized controlled trial, were used in this secondary analysis. Threat of breast cancer was measured in terms of perceived susceptibility, fear, and adverse consequences as well as an overall perceived threat of breast cancer. We used multivariate models with generalized estimating equations to examine the relationship between internalized HIV-related stigma and breast health beliefs across three time points (baseline, immediately post-workshop, and at 12-month follow-up) and to examine if the study arm (HIV stigma reduction vs. breast cancer education) or social support moderated the relationship. RESULTS: Internalized HIV-related stigma was associated with greater overall perceived threat (p < 0.001), susceptibility (p = 0.03), fear (p < 0.001), and perceived adverse consequences (p < 0.001) of breast cancer. These associations remained consistent across study arms and across all levels of social support. CONCLUSIONS: Future studies that examine co-morbid health conditions among African-American women living with HIV should consider the impact of HIV-related stigma on attitudes and beliefs related to co-morbid conditions. AU - Fabian, K. AU - Molina, Y. AU - Kemp, C. G. AU - Nevin, P. E. AU - McCoy, K. AU - Simoni, J. M. AU - Andrasik, M. AU - Cohn, S. E. AU - Micci, S. AU - Rao, D. DB - Medline DO - 10.1007/s40615-019-00632-6 IS - 1 KW - adult African American article breast cancer controlled study education fear female follow up health belief human Human immunodeficiency virus infected patient Illinois major clinical study randomized controlled trial secondary analysis social support stigma LA - English M3 - Article N1 - L629174527 2021-01-18 PY - 2020 SN - 2196-8837 SP - 45-51 ST - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA T2 - Journal of racial and ethnic health disparities TI - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629174527&from=export http://dx.doi.org/10.1007/s40615-019-00632-6 VL - 7 ID - 817 ER - TY - JOUR AB - OBJECTIVES: African‐American women suffer disproportionately from HIV, breast cancer, and other illnesses. Little is known about the relationship between internalized HIV‐related stigma and health beliefs related to other illnesses, including breast cancer. Our study examined (1) the relationship between internalized HIV‐related stigma and breast health beliefs over time and (2) the moderating effects of participating in a stigma reduction intervention and/or social support. METHODS: Data from 239 African‐American women receiving care for HIV in Chicago, IL, or Birmingham, AL, enrolled in the Unity randomized controlled trial, were used in this secondary analysis. Threat of breast cancer was measured in terms of perceived susceptibility, fear, and adverse consequences as well as an overall perceived threat of breast cancer. We used multivariate models with generalized estimating equations to examine the relationship between internalized HIV‐related stigma and breast health beliefs across three time points (baseline, immediately post‐workshop, and at 12‐month follow‐up) and to examine if the study arm (HIV stigma reduction vs. breast cancer education) or social support moderated the relationship. RESULTS: Internalized HIV‐related stigma was associated with greater overall perceived threat (p < 0.001), susceptibility (p = 0.03), fear (p < 0.001), and perceived adverse consequences (p < 0.001) of breast cancer. These associations remained consistent across study arms and across all levels of social support. CONCLUSIONS: Future studies that examine co‐morbid health conditions among African‐American women living with HIV should consider the impact of HIV‐related stigma on attitudes and beliefs related to co‐morbid conditions. AN - CN-02229564 AU - Fabian, K. AU - Molina, Y. AU - Kemp, C. G. AU - Nevin, P. E. AU - McCoy, K. AU - Simoni, J. M. AU - Andrasik, M. AU - Cohn, S. E. AU - Micci, S. AU - Rao, D. DO - 10.1007/s40615-019-00632-6 IS - 1 KW - *African American *Human immunodeficiency virus infected patient *breast cancer *health belief *stigma Adult Article Controlled study Education Fear Female Follow up Human Illinois Major clinical study Randomized controlled trial Secondary analysis Social support M3 - Journal: Article PY - 2020 SP - 45‐51 ST - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA T2 - Journal of racial and ethnic health disparities TI - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02229564/full VL - 7 ID - 1507 ER - TY - JOUR AB - Objectives African-American women suffer disproportionately from HIV, breast cancer, and other illnesses. Little is known about the relationship between internalized HIV-related stigma and health beliefs related to other illnesses, including breast cancer. Our study examined (1) the relationship between internalized HIV-related stigma and breast health beliefs over time and (2) the moderating effects of participating in a stigma reduction intervention and/or social support. Methods Data from 239 African-American women receiving care for HIV in Chicago, IL, or Birmingham, AL, enrolled in the Unity randomized controlled trial, were used in this secondary analysis. Threat of breast cancer was measured in terms of perceived susceptibility, fear, and adverse consequences as well as an overall perceived threat of breast cancer. We used multivariate models with generalized estimating equations to examine the relationship between internalized HIV-related stigma and breast health beliefs across three time points (baseline, immediately post-workshop, and at 12-month follow-up) and to examine if the study arm (HIV stigma reduction vs. breast cancer education) or social support moderated the relationship. Results Internalized HIV-related stigma was associated with greater overall perceived threat (p < 0.001), susceptibility (p = 0.03), fear (p < 0.001), and perceived adverse consequences (p < 0.001) of breast cancer. These associations remained consistent across study arms and across all levels of social support. Conclusions Future studies that examine co-morbid health conditions among African-American women living with HIV should consider the impact of HIV-related stigma on attitudes and beliefs related to co-morbid conditions. AN - WOS:000514321400011 AU - Fabian, K. AU - Molina, Y. AU - Kemp, C. G. AU - Nevin, P. E. AU - McCoy, K. AU - Simoni, J. M. AU - Andrasik, M. AU - Cohn, S. E. AU - Micci, S. AU - Rao, D. DA - Feb DO - 10.1007/s40615-019-00632-6 IS - 1 N1 - 31452148 PY - 2020 SN - 2197-3792 SP - 45-51 ST - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA T2 - Journal of Racial and Ethnic Health Disparities TI - Internalized HIV-Related Stigma and Breast Health Beliefs Among African-American Women Receiving Care for HIV in the USA VL - 7 ID - 2793 ER - TY - JOUR AB - Objectives: African–American women suffer disproportionately from HIV, breast cancer, and other illnesses. Little is known about the relationship between internalized HIV-related stigma and health beliefs related to other illnesses, including breast cancer. Our study examined (1) the relationship between internalized HIV-related stigma and breast health beliefs over time and (2) the moderating effects of participating in a stigma reduction intervention and/or social support. Methods: Data from 239 African–American women receiving care for HIV in Chicago, IL, or Birmingham, AL, enrolled in the Unity randomized controlled trial, were used in this secondary analysis. Threat of breast cancer was measured in terms of perceived susceptibility, fear, and adverse consequences as well as an overall perceived threat of breast cancer. We used multivariate models with generalized estimating equations to examine the relationship between internalized HIV-related stigma and breast health beliefs across three time points (baseline, immediately post-workshop, and at 12-month follow-up) and to examine if the study arm (HIV stigma reduction vs. breast cancer education) or social support moderated the relationship. Results: Internalized HIV-related stigma was associated with greater overall perceived threat (p < 0.001), susceptibility (p = 0.03), fear (p < 0.001), and perceived adverse consequences (p < 0.001) of breast cancer. These associations remained consistent across study arms and across all levels of social support. Conclusions: Future studies that examine co-morbid health conditions among African–American women living with HIV should consider the impact of HIV-related stigma on attitudes and beliefs related to co-morbid conditions. © 2019, W. Montague Cobb-NMA Health Institute. AD - Department of Global Health, University of Washington, Seattle, WA, United States Community Health Sciences Division, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL 60612, United States Department of Medicine, Northwestern University, Chicago, IL, United States Department of Psychiatry, University of Washington, Seattle, WA, United States Department of Psychology, University of Washington, Seattle, WA, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States CORE Center/Division of Infectious Diseases, Stroger Hospital of Cook County, Chicago, IL, United States School of Nursing & Health Studies, University of Washington Bothell, Bothell, WA, United States AU - Fabian, K. AU - Molina, Y. AU - Kemp, C. G. AU - Nevin, P. E. AU - McCoy, K. AU - Simoni, J. M. AU - Andrasik, M. AU - Cohn, S. E. AU - Micci, S. AU - Rao, D. DB - Scopus DO - 10.1007/s40615-019-00632-6 IS - 1 KW - African–American women Breast cancer HIV Stigma M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 45-51 ST - Internalized HIV-Related Stigma and Breast Health Beliefs Among African–American Women Receiving Care for HIV in the USA T2 - Journal of Racial and Ethnic Health Disparities TI - Internalized HIV-Related Stigma and Breast Health Beliefs Among African–American Women Receiving Care for HIV in the USA UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071425613&doi=10.1007%2fs40615-019-00632-6&partnerID=40&md5=dc3e5dd402207a38e6b788318a7f3e61 VL - 7 ID - 2203 ER - TY - JOUR AB - Background. Older African-American women with single marital status are least likely to use screening procedures. This study aimed to evaluate a breast screening intervention program conducted in this population. Methods. Ten public housing complexes were randomly assigned to either the intervention or the control group. African-American women aged 65 and over were recruited into the study if they were widowed, divorced, separated, or never married and did not have a history of breast cancer (n = 325). The intervention program was delivered by lay health educators at the participant's apartment and was designed to increase knowledge about breast screening, reduce psychological problems, and increase support from significant others. Breast-screening-related cognition and behavior were measured at baseline and at 1 and 2 years postintervention. Results. Comparisons of the preintervention and postintervention measurements showed that while the proportion of women who had a clinical breast examination or mammogram in the preceding year was decreased at 1 year postintervention in the control group, it was increased in the intervention group. However, the differences did not reach a significant level. No consistent patterns could be found in changes of breast self-examination and variables in knowledge, attitudes, and beliefs. When analyses were restricted to women whose significant others had provided information or help on breast screening, results were better, but the differences between the intervention and control groups still did not reach statistical significance. Conclusions. These results did not suggest significant effects of an intervention program that used lay health educators to promote breast cancer screening in older single African-American women. © 2002 American Health Foundation and Elsevier Science (USA). AD - K. Zhu, Dept. of Health Evaluation Sciences, College of Medicine, Pennsylvania State University, Hershey, PA 17033-0855, United States AU - Zhu, K. AU - Hunter, S. AU - Bernard, L. J. AU - Payne-Wilks, K. AU - Roland, C. L. AU - Elam, L. C. AU - Feng, Z. AU - Levine, R. S. DB - Embase Medline DO - 10.1006/pmed.2002.1016 IS - 5 KW - aged article attitude behavior breast cancer breast examination cancer screening clinical trial cognition controlled clinical trial controlled study human major clinical study mammography measurement medical information Black person priority journal randomized controlled trial support group LA - English M3 - Article N1 - L34971677 2002-09-13 PY - 2002 SN - 0091-7435 SP - 536-545 ST - An intervention study on screening for breast cancer among single African-American women aged 65 and older T2 - Preventive Medicine TI - An intervention study on screening for breast cancer among single African-American women aged 65 and older UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34971677&from=export http://dx.doi.org/10.1006/pmed.2002.1016 VL - 34 ID - 1298 ER - TY - JOUR AB - BACKGROUND: Older African‐American women with single marital status are least likely to use screening procedures. This study aimed to evaluate a breast screening intervention program conducted in this population. METHODS: Ten public housing complexes were randomly assigned to either the intervention or the control group. African‐American women aged 65 and over were recruited into the study if they were widowed, divorced, separated, or never married and did not have a history of breast cancer (n = 325). The intervention program was delivered by lay health educators at the participant's apartment and was designed to increase knowledge about breast screening, reduce psychological problems, and increase support from significant others. Breast‐screening‐related cognition and behavior were measured at baseline and at 1 and 2 years postintervention. RESULTS: Comparisons of the preintervention and postintervention measurements showed that while the proportion of women who had a clinical breast examination or mammogram in the preceding year was decreased at 1 year postintervention in the control group, it was increased in the intervention group. However, the differences did not reach a significant level. No consistent patterns could be found in changes of breast self‐examination and variables in knowledge, attitudes, and beliefs. When analyses were restricted to women whose significant others had provided information or help on breast screening, results were better, but the differences between the intervention and control groups still did not reach statistical significance. CONCLUSIONS: These results did not suggest significant effects of an intervention program that used lay health educators to promote breast cancer screening in older single African‐American women. AN - CN-00417439 AU - Zhu, K. AU - Hunter, S. AU - Bernard, L. J. AU - Payne-Wilks, K. AU - Roland, C. L. AU - Elam, L. C. AU - Feng, Z. AU - Levine, R. S. DO - 10.1006/pmed.2002.1016 IS - 5 KW - *breast cancer *cancer screening African Americans [*psychology] Aged Aged, 80 and over Article Attitude Behavior Breast Neoplasms [ethnology, *prevention & control] Breast Self‐Examination Breast examination Clinical trial Cognition Controlled clinical trial Controlled study Data Collection Female Health Knowledge, Attitudes, Practice Human Humans Major clinical study Mammography Mass Screening Measurement Medical information Negro Priority journal Randomized controlled trial Support group Women's Health M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2002 SP - 536‐545 ST - An intervention study on screening for breast cancer among single African-American women aged 65 and older T2 - Preventive medicine TI - An intervention study on screening for breast cancer among single African-American women aged 65 and older UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00417439/full VL - 34 ID - 1355 ER - TY - JOUR AB - Older African-American women with single marital status are least likely to use screening procedures. This study aimed to evaluate a breast screening intervention program conducted in this population. Ten public housing complexes were randomly assigned to either the intervention or the control group. 325 African-American women aged 65 and over were recruited into the study if they were widowed, divorced, separated, or never married and did not have a history of breast cancer. The intervention program was delivered by lay health educators at the S's apartment and was designed to increase knowledge about breast screening, reduce psychological problems, and increase support from significant others. Breast-screening-related cognition and behavior were measured at baseline and at 1 and 2 years postintervention. Comparisons of the pre- and post-interventions showed that while the proportion of women who had a clinical breast exam or mammogram in the preceding year was decreased at 1 year postintervention in the control group, it was increased in the intervention group. However, differences did not reach a significant level. No consistent patterns could be found in changes of breast self-exam and variables in knowledge, attitudes, and beliefs. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Zhu, Kangmin, Pennsylvania State U, Coll of Medicine, Dept of Health Evaluation Sciences, Hershey, PA, US, 17033-0855 AN - 2002-01095-005 AU - Zhu, Kangmin AU - Hunter, Sandra AU - Bernard, Louis J. AU - Payne-Wilks, Kathleen AU - Roland, Chanel L. AU - Elam, Lloyd C. AU - Feng, Ziding AU - Levine, Robert S. DB - psyh DO - 10.1006/pmed.2002.1016 DP - EBSCOhost IS - 5 KW - single African Americans breast cancer screening health attitudes health knowledge African Americans Aged Aged, 80 and over Breast Neoplasms Breast Self-Examination Data Collection Female Health Knowledge, Attitudes, Practice Humans Mammography Mass Screening Women's Health Blacks Cancer Screening Single Persons N1 - Pennsylvania State U, Coll of Medicine, Hershey, PA, US. Release Date: 20020529. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Health Attitudes; Health Knowledge; Single Persons. Minor Descriptor: Breast Neoplasms. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study. References Available: Y. Page Count: 10. Issue Publication Date: May, 2002. PY - 2002 SN - 0091-7435 SP - 536-545 ST - An intervention study on screening for breast cancer among single African-American women aged 65 and older T2 - Preventive Medicine: An International Journal Devoted to Practice and Theory TI - An intervention study on screening for breast cancer among single African-American women aged 65 and older UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2002-01095-005&site=ehost-live&scope=site kzhu@hes.hmc.psu.edu VL - 34 ID - 1781 ER - TY - JOUR AB - Background: Racial disparities in the treatment of non‐small lung cancer (NSCLC) continue to exist leading to poorer outcomes in African‐Americans (AA) compared to Caucasians (C). Our previous multiinstitutional prospective cohort study of 386 patients identified a surgical rate in early stage NSCLC of 66% C but only 55% AA (p = 0.05; OR 0.75; 95% CI 0.57‐0.99). (Cykert et al JAMA 2010) A 3 year retrospective chart review of all patients with early stage NSCLC at the 3 academic institutions involved in this current intervention study identified 714 patients with early stage NSCLC. Baseline surgical rates 69% for C and 66% for AA. Combined stereotactic body radiation therapy (SBRT) with surgery C 80% and AA 76%. Controlling for co‐morbidities, COPD, age and other demographic data, the OR for surgery AA compared to C 0.64 (95% CI 0.43‐0.96) and for combined surgery or SBRT AA compared to C 0.61 (95% CI 0.43‐0.96). Methods: Patients with a stage I or II NSCLC were identified and randomized to each institution's standard of care approach or to an 'intervention' component utilizing a trained navigator to enhance patient communication and treatment understanding. Results: 244 patients were prospectively recruited into this intervention study. Mean age 65.7 years; 54% women; 89 (34%) AA. The intervention group showed an overall surgical rate of 74% (74.8% C, 71.4% AA; p = 0.6). Combined treatment of either surgery or SBRT increased an ablative treatment to 91.9% for C and 94.1% AA patients (p = 0.5). Logistic regression was performed comparing the intervention group to the baseline group. Results showed that overall treatment improved for both C and AA, the surgical and overall treatment disparity between C and AA was no longer present, while age, COPD, and clinical stage remained significant predictors of treatment. Conclusions: A multifaceted intervention designed to enhance patient communication and treatment understanding removed the surgical and overall early lung cancer treatment disparity between AA and C. AN - CN-01781395 AU - Walker, P. R. AU - Cykert, S. AU - Edwards, L. AU - Arya, R. AU - Dilworth-Anderson, P. IS - 15 KW - *intervention study *non small cell lung cancer Ablation therapy African American Aged Cancer staging Cancer therapy Chronic obstructive lung disease Comorbidity Controlled clinical trial Controlled study Demography Disease course Doctor patient relation Drug combination Female Health care quality Human Logistic regression analysis Major clinical study Male Medical record review Prospective study Randomized controlled trial Stereotactic body radiation therapy Surgery M3 - Journal: Conference Abstract PY - 2017 ST - An intervention study to reduce black-white treatment disparities in early stage non-small cell lung cancer T2 - Journal of clinical oncology TI - An intervention study to reduce black-white treatment disparities in early stage non-small cell lung cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781395/full VL - 35 ID - 1390 ER - TY - JOUR AB - This paper reports the results of a practice-based intervention program to increase mammography screening among women 65 and older who receive their health care in the private sector. Forty-three primary-care practices and 2147 women in central and western North Carolina were enrolled in the study, and 1911 women completed all phases of the study. The intervention was a three-stage educational and counseling program designed to become progressively more intensive at each stage. The interventions included provider education in the form of current information on issues in mammography for older women, simply written educational materials on breast cancer and screening mailed to women, and a brief telephone counseling session for the women. While the analysis revealed no overall effect across all three stages of the intervention program, tests for interaction indicated a significant program effect for women who were 80 or older, had less than 9 years of education, were black, or had no private insurance to supplement Medicare. The results suggested that providing primary-care physicians with information on screening older women and providing the women with useful educational materials can increase participation in screening mammography among subgroups of women currently least likely to receive mammography screening. AN - WOS:000227405400004 AU - Michielutte, R. AU - Sharp, P. C. AU - Foley, K. L. AU - Cunningham, L. E. AU - Spangler, J. G. AU - Paskett, E. D. AU - Case, L. D. DA - Apr DO - 10.1093/her/cyg108 IS - 2 N1 - 15254001 PY - 2005 SN - 0268-1153 SP - 149-162 ST - Intervention to increase screening mammography among women 65 and older T2 - Health Education Research TI - Intervention to increase screening mammography among women 65 and older VL - 20 ID - 3243 ER - TY - JOUR AB - Aim The aim of this article was to determine sentinel lymph node (SLN) identification rate (IR) using Patent Blue V in patients with non-small cell lung cancer (NSCLC) and to evaluate the accuracy of SLN for the presence of mediastinal metastasis. Methods. Between 2004 and 2006 the data from 32 patients with clinical stage IA to IIB, who underwent lung resection for NSCLC, were prospectively analyzed. Patent blue V dye was injected in the peritumoral tissue, and the first lymph node to stain was identified as a sentinel node. Results. SLN was identified in fifteen patients (IR=46.9%). SLN with metastatic involvement was observed in four patients. Accuracy, sensitivity and specificity of the sentinel lymph node in predicting the status of other mediastinal lymph node stations were respectively 86.7%, 100%, and 84.6%. In 63.1% patients, the SLNs corresponded to the lymph node stations 10 and 11. In seven patients (36.9%), the SLNs were located in the N2 stations. Conclusion, Although the use of Patent Blue V for SLN identification is feasible, this technique presents relatively low identification rate. The major difficulty on the detection of SLNs was the black coloration of the lymph node, which interfered with the visualization of the dye. AD - C.F. Andrade, Hospital da Criança Santo Antônio, Santa Casa de Porto Alegre, Avenida Independência 155/3 andar, Porto Alegre, 90020-090 Rio Grande do Sul, Brazil AU - Bustos, M. E. F. AU - Camargo, J. J. P. AU - Geyer, G. R. AU - Andrade, C. F. DB - Medline IS - 1 KW - coloring agent diagnostic agent adult aged article cancer staging comparative study evaluation study feasibility study female human lung non small cell lung cancer lung tumor lymph node metastasis male mediastinum metastasis middle aged pathology patient selection peroperative care prospective study sensitivity and specificity sentinel lymph node biopsy LA - English M3 - Article N1 - L351387486 2008-05-21 PY - 2008 SN - 0026-4733 SP - 29-36 ST - Intraoperative detection of sentinel lymph nodes using Patent Blue V in non-small cell lung cancer T2 - Minerva Chirurgica TI - Intraoperative detection of sentinel lymph nodes using Patent Blue V in non-small cell lung cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351387486&from=export VL - 63 ID - 1216 ER - TY - JOUR AB - BACKGROUND. Obesity has a variety of adverse health outcomes, but to the authors' knowledge, the effect of obesity on outcome in patients with advanced prostate cancer is not known. For this reason, the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC) was evaluated. METHODS. A total of 1226 men with CRPC who were enrolled in 9 prospective clinical trials conducted by the Cancer and Leukemia Group B (CALGB) for the treatment of metastatic disease were considered. Eligible patients had progressive prostate cancer during androgen deprivation therapy (with documented castrate levels of testosterone); an Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate hematologic, renal, and hepatic function. Patients were classified based on BMI as normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), and mildly to severely obese (≥30kg/m 2). RESULTS. Approximately 24% of the patients had a normal BMI, 43% were overweight, and 33% were mildly to severely obese. On multivariable analysis, BMI was found to be a statistically significant predictor of overall survival and prostate cancer-specific mortality. Compared with men with normal BMIs, the hazard ratios for death for overweight men and mildly to severely obese men were 0.80 (95% confidence interval [95% CI], 0.68-0.93; P = .001) and 0.80 (95% CI, 0.68-0.94; P = .010), respectively. CONCLUSIONS. In patients with metastatic CRPC, obesity (as defined by an elevated BMI) appears to have a protective effect against overall mortality and prostate cancer-specific mortality. Alternatively, a higher BMI may reflect different cancer biology (ie, the lack of cachexia-producing substances). Further studies to gain a more comprehensive understanding of the mechanisms behind these clinical observations are needed. © 2007 American Cancer Society. AD - Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States CALGB Statistical Center, Durham, NC, United States Nevada Cancer Institute, Las Vegas, NV, United States Department of Medicine, University of California at San Francisco, San Francisco, CA, United States Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, United States AU - Halabi, S. AU - Ou, S. S. AU - Vogelzang, N. J. AU - Small, E. J. DB - Scopus DO - 10.1002/cncr.22932 IS - 7 KW - Castration-recurrent prostate cancer Clinical outcomes Obesity Race M3 - Article N1 - Cited By :43 Export Date: 22 March 2021 PY - 2007 SP - 1478-1484 ST - Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer T2 - Cancer TI - Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34648825008&doi=10.1002%2fcncr.22932&partnerID=40&md5=63a0e17439362bfe691ad5b3006436c8 VL - 110 ID - 2551 ER - TY - JOUR AB - Background: In 1991, Medicare began covering screening mammograms subject to copayment and deductible. This study evaluated the effectiveness of Medicare in removing financial barriers to screening mammography among low-income older women. Methods: In an inner-city public hospital's General Medicine Clinic, 119 consecutive, eligible, and consenting Medicare-enrolled women without known risk factors for breast cancer other than age, and no mammogram in the previous 2 years, were entered into a randomized controlled trial with follow-up after 2 months. The mean age was 71 years; 77% were black, 92% had an annual income below $10 000, and 52% had had a previous mammogram. Ail patients were counseled concerning indications for screening mammograms and Medicare coverage, and all were referred to a low-cost mammography facility. Sixty-one subjects were randomly assigned a voucher for a free screening mammogram at the referral facility. Obtaining a mammogram within 60 days of study entry was the main outcome measure. Results: Of the women given vouchers, 27 (44%) obtained screening mammograms, compared with six (10%) of those without vouchers (P<.001). Adjustment by multiple logistic regression confirmed this association, yielding an adjusted odds ratio of 7.4 (95% confidence interval, 2.5 to 21.4). Knowledge concerning mammography and breast cancer increased significantly overall (and within randomization groups) between initial interview and follow-up; fear did not change. For women without the voucher, the main reason for not obtaining a mammogram was financial; the main reason for women with the voucher was transportation. Conclusion: In a low-income, inner-city population of older women, financial barriers to screening mammography persist despite Medicare coverage. AN - WOS:A1994NQ33000004 AU - Kiefe, C. I. AU - McKay, S. V. AU - Halevy, A. AU - Brody, B. A. DA - Jun 13 DO - 10.1001/archinte.154.11.1217 IS - 11 N1 - 102 8203989 PY - 1994 SN - 0003-9926 SP - 1217-1224 ST - Is Cost a Barrier to Screening Mammography for Low-Income Women Receiving Medicare Benefits - a Randomized Trial T2 - Archives of Internal Medicine TI - Is Cost a Barrier to Screening Mammography for Low-Income Women Receiving Medicare Benefits - a Randomized Trial VL - 154 ID - 2742 ER - TY - JOUR AB - Background: In 1991, Medicare began covering screening mammograms subject to copayment and deductible. This study evaluated the effectiveness of Medicare in removing financial barriers to screening mammography among low- income older women. Methods: In an inner-city public hospital's General Medicine Clinic, 119 consecutive, eligible, and consenting Medicare-enrolled women without known risk factors for breast cancer other than age, and no mammogram in the previous 2 years, were entered into a randomized controlled trial with follow-up after 2 months. The mean age was 71 years; 77% were black, 92% had an annual income below $10 000, and 52% had had a previous mammogram. All patients were counseled concerning indications for screening mammograms and Medicare coverage, and all were referred to a low-cost mammography facility. Sixty-one subjects were randomly assigned a voucher for a free screening mammogram at the referral facility. Obtaining a mammogram within 60 days of study entry was the main outcome measure. Results: Of the women given vouchers, 27 (44%) obtained screening mammograms, compared with six (10%) of those without vouchers (P<.001). Adjustment by multiple logistic regression confirmed this association, yielding an adjusted odds ratio of 7.4 (95% confidence interval, 2.5 to 21.4). Knowledge concerning mammography and breast cancer increased significantly overall (and within randomization groups) between initial interview and follow-up; fear did not change. For women without the voucher, the main reason for not obtaining a mammogram was financial; the main reason for women with the voucher was transportation. Conclusion: In a low-income, inner-city population of older women, financial barriers to screening mammography persist despite Medicare coverage. AD - C.I. Kiefe, Division of Preventive Medicine, MTB 729, University of Alabama, 1717 11th Ave S, Birmingham, AL 35205-4785, United States AU - Kiefe, C. I. AU - McKay, S. V. AU - Halevy, A. AU - Brody, B. A. DB - Embase Medline DO - 10.1001/archinte.154.11.1217 IS - 11 KW - adult aged article breast cancer cancer screening female health behavior health care cost health care policy health insurance human lowest income group major clinical study mammography medicare patient attitude patient compliance patient counseling priority journal reimbursement LA - English M3 - Article N1 - L24180479 1994-06-30 PY - 1994 SN - 0003-9926 SP - 1217-1224 ST - Is cost a barrier to screening mammography for low-income women receiving medicare benefits? A randomized trial T2 - Archives of Internal Medicine TI - Is cost a barrier to screening mammography for low-income women receiving medicare benefits? A randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L24180479&from=export http://dx.doi.org/10.1001/archinte.154.11.1217 VL - 154 ID - 1341 ER - TY - JOUR AB - BACKGROUND: In 1991, Medicare began covering screening mammograms subject to copayment and deductible. This study evaluated the effectiveness of Medicare in removing financial barriers to screening mammography among low‐income older women. METHODS: In an inner‐city public hospital's General Medicine Clinic, 119 consecutive, eligible, and consenting Medicare‐enrolled women without known risk factors for breast cancer other than age, and no mammogram in the previous 2 years, were entered into a randomized controlled trial with follow‐up after 2 months. The mean age was 71 years; 77% were black, 92% had an annual income below $10,000, and 52% had had a previous mammogram. All patients were counseled concerning indications for screening mammograms and Medicare coverage, and all were referred to a low‐cost mammography facility. Sixty‐one subjects were randomly assigned a voucher for a free screening mammogram at the referral facility. Obtaining a mammogram within 60 days of study entry was the main outcome measure. RESULTS: Of the women given vouchers, 27 (44%) obtained screening mammograms, compared with six (10%) of those without vouchers (P < .001). Adjustment by multiple logistic regression confirmed this association, yielding an adjusted odds ratio of 7.4 (95% confidence interval, 2.5 to 21.4). Knowledge concerning mammography and breast cancer increased significantly overall (and within randomization groups) between initial interview and follow‐up; fear did not change. For women without the voucher, the main reason for not obtaining a mammogram was financial; the main reason for women with the voucher was transportation. CONCLUSION: In a low‐income, inner‐city population of older women, financial barriers to screening mammography persist despite Medicare coverage. AN - CN-00101948 AU - Kiefe, C. I. AU - McKay, S. V. AU - Halevy, A. AU - Brody, B. A. IS - 11 KW - Aged Aged, 80 and over Costs and Cost Analysis Federal Government Female Health Behavior Health Knowledge, Attitudes, Practice Health Services Accessibility Humans Mammography [*economics] Medicare Middle Aged Patient Compliance Patient Selection Poverty Socioeconomic Factors United States Urban Health M3 - Clinical Trial; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 1994 SP - 1217‐1224 ST - Is cost a barrier to screening mammography for low-income women receiving Medicare benefits? A randomized trial T2 - Archives of internal medicine TI - Is cost a barrier to screening mammography for low-income women receiving Medicare benefits? A randomized trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00101948/full VL - 154 ID - 1605 ER - TY - JOUR AB - Background: In 1991, Medicare began covering screening mammograms subject to copayment and deductible. This study evaluated the effectiveness of Medicare in removing financial barriers to screening mammography among low- income older women. Methods: In an inner-city public hospital's General Medicine Clinic, 119 consecutive, eligible, and consenting Medicare-enrolled women without known risk factors for breast cancer other than age, and no mammogram in the previous 2 years, were entered into a randomized controlled trial with follow-up after 2 months. The mean age was 71 years; 77% were black, 92% had an annual income below $10 000, and 52% had had a previous mammogram. All patients were counseled concerning indications for screening mammograms and Medicare coverage, and all were referred to a low-cost mammography facility. Sixty-one subjects were randomly assigned a voucher for a free screening mammogram at the referral facility. Obtaining a mammogram within 60 days of study entry was the main outcome measure. Results: Of the women given vouchers, 27 (44%) obtained screening mammograms, compared with six (10%) of those without vouchers (P<.001). Adjustment by multiple logistic regression confirmed this association, yielding an adjusted odds ratio of 7.4 (95% confidence interval, 2.5 to 21.4). Knowledge concerning mammography and breast cancer increased significantly overall (and within randomization groups) between initial interview and follow-up; fear did not change. For women without the voucher, the main reason for not obtaining a mammogram was financial; the main reason for women with the voucher was transportation. Conclusion: In a low-income, inner-city population of older women, financial barriers to screening mammography persist despite Medicare coverage. AD - Department of Medicine, Ctr. Ethics, Med. and Pub. Issues, Ben Taub General Hospital, Houston, TX, United States Division of Preventive Medicine, University of Alabama at Birmingham, MTB 729, 1717 11th Ave S, Birmingham, AL 35205-4785, United States AU - Kiefe, C. I. AU - McKay, S. V. AU - Halevy, A. AU - Brody, B. A. DB - Scopus DO - 10.1001/archinte.154.11.1217 IS - 11 M3 - Article N1 - Cited By :108 Export Date: 22 March 2021 PY - 1994 SP - 1217-1224 ST - Is cost a barrier to screening mammography for low-income women receiving medicare benefits? A randomized trial T2 - Archives of Internal Medicine TI - Is cost a barrier to screening mammography for low-income women receiving medicare benefits? A randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028246051&doi=10.1001%2farchinte.154.11.1217&partnerID=40&md5=a2e1aa3dbf6fbf87dc61c2a62b6e3611 VL - 154 ID - 2658 ER - TY - JOUR AB - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo-controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (<2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (>30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant's depressive symptoms is critical for promoting cessation. © 2008 Springer Science+Business Media B.V. AD - E. Martinez, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States AU - Martinez, E. AU - Tatum, K. L. AU - Weber, D. M. AU - Kuzla, N. AU - Pendley, A. AU - Campbell, K. AU - Ridge, J. A. AU - Langer, C. AU - Miyamoto, C. AU - Schnoll, R. A. C1 - zyban DB - Embase Medline DO - 10.1007/s10552-008-9222-x IS - 1 KW - amfebutamone nicotine patch adult advanced cancer African American alcohol consumption alcoholic beverage article breast cancer cancer patient cancer screening clinical trial controlled study data analysis depression disease severity drug contraindication feasibility study female head and neck cancer human language major clinical study male nicotine replacement therapy priority journal smoking cessation smoking habit tobacco dependence zyban LA - English M3 - Article N1 - L50256767 2009-06-02 PY - 2009 SN - 0957-5243 1573-7225 SP - 97-104 ST - Issues related to implementing a smoking cessation clinical trial for cancer patients T2 - Cancer Causes and Control TI - Issues related to implementing a smoking cessation clinical trial for cancer patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50256767&from=export http://dx.doi.org/10.1007/s10552-008-9222-x VL - 20 ID - 1196 ER - TY - JOUR AB - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo‐controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (<2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (>30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant's depressive symptoms is critical for promoting cessation. AN - CN-00683171 AU - Martinez, E. AU - Tatum, K. L. AU - Weber, D. M. AU - Kuzla, N. AU - Pendley, A. AU - Campbell, K. AU - Ridge, J. A. AU - Langer, C. AU - Miyamoto, C. AU - Schnoll, R. A. DO - 10.1007/s10552-008-9222-x IS - 1 KW - Adult Aged Aged, 80 and over Double‐Blind Method Female Health Promotion Humans Male Middle Aged Neoplasms [complications, epidemiology, *therapy] Smoking Cessation Treatment Outcome M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2009 SP - 97‐104 ST - Issues related to implementing a smoking cessation clinical trial for cancer patients T2 - Cancer causes & control TI - Issues related to implementing a smoking cessation clinical trial for cancer patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00683171/full VL - 20 ID - 1573 ER - TY - JOUR AB - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo-controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (<2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (>30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant’s depressive symptoms is critical for promoting cessation. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Martinez, Elisa, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, US, 19111 AN - 2009-00738-006 AU - Martinez, Elisa AU - Tatum, Kristina L. AU - Weber, Dorothy M. AU - Kuzla, Natalie AU - Pendley, Anna AU - Campbell, Kirsten AU - Ridge, John A. AU - Langer, Corey AU - Miyamoto, Curtis AU - Schnoll, Robert A. DB - psyh DO - 10.1007/s10552-008-9222-x DP - EBSCOhost IS - 1 KW - smoking cessation clinical trials cancer patients depressive symptoms Adult Aged Aged, 80 and over Double-Blind Method Female Health Promotion Humans Male Middle Aged Neoplasms Smoking Cessation Treatment Outcome Clinical Trials Major Depression N1 - Fox Chase Cancer Center, Philadelphia, PA, US. Release Date: 20091130. Correction Date: 20130715. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Clinical Trials; Neoplasms; Smoking Cessation. Minor Descriptor: Major Depression. Classification: Drug & Alcohol Rehabilitation (3383). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Center for Epidemiologic Studies Depression Scale; Mini International Neuropsychiatric Interview DOI: 10.1037/t18597-000; Positive and Negative Affect Scale DOI: 10.1037/t06070-000. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Feb, 2009. Publication History: First Posted Date: Aug 29, 2008; Accepted Date: Aug 13, 2008; First Submitted Date: Feb 14, 2008. Copyright Statement: Springer Science+Business Media B.V. 2008. Sponsor: National Cancer Institute, US. Grant: R01 CA95678. Recipients: No recipient indicated PY - 2009 SN - 0957-5243 1573-7225 SP - 97-104 ST - Issues related to implementing a smoking cessation clinical trial for cancer patients T2 - Cancer Causes & Control TI - Issues related to implementing a smoking cessation clinical trial for cancer patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-00738-006&site=ehost-live&scope=site elisa.martinez@fccc.edu VL - 20 ID - 1665 ER - TY - JOUR AB - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo-controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (<2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (>30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant's depressive symptoms is critical for promoting cessation. © 2008 Springer Science+Business Media B.V. AD - Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States Department of Radiation Oncology, Temple University Hospital, 3401 N. Broad Street, Philadelphia, PA 19140, United States Transdisciplinary Tobacco Use Research Center, Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, United States AU - Martinez, E. AU - Tatum, K. L. AU - Weber, D. M. AU - Kuzla, N. AU - Pendley, A. AU - Campbell, K. AU - Ridge, J. A. AU - Langer, C. AU - Miyamoto, C. AU - Schnoll, R. A. DB - Scopus DO - 10.1007/s10552-008-9222-x IS - 1 KW - Cancer patients Confidence Feasibility data Smoking cessation M3 - Article N1 - Cited By :27 Export Date: 22 March 2021 PY - 2009 SP - 97-104 ST - Issues related to implementing a smoking cessation clinical trial for cancer patients T2 - Cancer Causes and Control TI - Issues related to implementing a smoking cessation clinical trial for cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-58249120765&doi=10.1007%2fs10552-008-9222-x&partnerID=40&md5=95742a675ab825544f70c36d936e860e VL - 20 ID - 2526 ER - TY - JOUR AB - Given high rates of smoking among cancer patients, smoking cessation treatment is crucial; yet limited data exist to guide integration of such trials into the oncologic context. In order to determine the feasibility of conducting smoking cessation clinical trials with cancer patients, screening and baseline data from a large randomized placebo-controlled pharmacotherapy trial were analyzed. Descriptive statistics and regression analyses were used to compare enrollees to decliners, describe program enrollees, and assess correlates of confidence in quitting smoking. Out of 14,514 screened patients, 263 (< 2%) were eligible; 43 (16%) refused enrollment. Among the eligible patients, 220 (84%) enrolled. Enrollment barriers included smoking rate, medical history/contraindicated medication, lack of interest, and language. Compared to enrollees, decliners were more likely to have advanced cancer. The trial enrolled a sample of 67 (> 30%) African Americans; participants had extensive smoking histories; many were highly nicotine dependent; and participants consumed about seven alcoholic beverages/week on average. Head and neck and breast cancer were the most common tumors. About 52 (25%) reported depressive symptoms. A higher level of confidence to quit smoking was related to lower depression and lower tumor stage. Integrating a smoking cessation clinical trial into the oncologic setting is challenging, yet feasible. Recruitment strategies are needed for patients with advanced disease and specific cancers. Once enrolled, addressing participant's depressive symptoms is critical for promoting cessation. AN - WOS:000262504100011 AU - Martinez, E. AU - Tatum, K. L. AU - Weber, D. M. AU - Kuzla, N. AU - Pendley, A. AU - Campbell, K. AU - Ridge, J. A. AU - Langer, C. AU - Miyamoto, C. AU - Schnoll, R. A. DA - Feb DO - 10.1007/s10552-008-9222-x IS - 1 N1 - 18758971 PY - 2009 SN - 0957-5243 SP - 97-104 ST - Issues related to implementing a smoking cessation clinical trial for cancer patients T2 - Cancer Causes & Control TI - Issues related to implementing a smoking cessation clinical trial for cancer patients VL - 20 ID - 3155 ER - TY - JOUR AB - Randomised controlled trials (RCTs) represent the gold standard methodology for determining effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external validity and waste resources. An inherent tension exists between safeguarding informed decision-making by participants and maximising numbers enrolled. This study investigated what occurs during informed consent appointments in an ongoing multi-centre RCT in the UK. Objectives were to investigate: 1] how study staff presented study information to participants; 2] what evidence emerged as to how well-informed participants were when proceeding to randomisation or treatment selection; and 3] what aspects of the communication process may facilitate improvements in providing evidence of informed consent. Qualitative analysis of a purposive sample of 23 recruitment appointments from three study centres and involving several recruitment staff applied techniques of thematic, content and conversation analysis (CA). Thematic analysis and CA revealed variation in appointment content and structure. Appointments were mostly recruiter-led or participant-led, and this structure was associated with what evidence emerged as to how participants understood information provided and whether they were in equipoise. Participant-led appointments provided this evidence more consistently. Detailed CA identified communication techniques which, when employed by recruiters, provided evidence as to how participants understood the choices before them. Strategic use of open questions, pauses and ceding the floor in the interaction facilitated detailed and systematic exploration of each participant's concerns and position regarding equipoise. We conclude that the current focus on content to be provided to achieve informed consent should be broadened to encompass consideration of how information is best conveyed to potential participants. A model of tailored information provision using the communication techniques identified and centred on eliciting and addressing participants' concerns is proposed. Use of these techniques is necessary to make potential participants' understanding of key issues and their position regarding equipoise explicit in order to facilitate truly informed consent. © 2009 Elsevier Ltd. All rights reserved. AD - Department of Social Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol, BS8 2PS, United Kingdom University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Box 279 (S4), Hills Road, Cambridge, CB2 0QQ, United Kingdom Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom AU - Wade, J. AU - Donovan, J. L. AU - Athene Lane, J. AU - Neal, D. E. AU - Hamdy, F. C. DB - Scopus DO - 10.1016/j.socscimed.2009.02.023 IS - 11 KW - Conversation analysis Informed consent Prostate cancer Randomised controlled trial (RCT) Recruitment Shared decision-making UK M3 - Article N1 - Cited By :93 Export Date: 22 March 2021 PY - 2009 SP - 2018-2028 ST - It's not just what you say, it's also how you say it: Opening the 'black box' of informed consent appointments in randomised controlled trials T2 - Social Science and Medicine TI - It's not just what you say, it's also how you say it: Opening the 'black box' of informed consent appointments in randomised controlled trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-65749084314&doi=10.1016%2fj.socscimed.2009.02.023&partnerID=40&md5=38152547ce83f7a8a21970d9139acb42 VL - 68 ID - 2522 ER - TY - JOUR AB - Randomised controlled trials (RCTs) represent the gold standard methodology for determining effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external validity and waste resources. An inherent tension exists between safeguarding informed decision-making by participants and maximising numbers enrolled. This study investigated what occurs during informed consent appointments in an ongoing multi-centre RCT in the UK. Objectives were to investigate: 1] how study staff presented study information to participants; 2] what evidence emerged as to how well-informed participants were when proceeding to randomisation or treatment selection; and 3] what aspects of the communication process may facilitate improvements in providing evidence of informed consent. Qualitative analysis of a purposive sample of 23 recruitment appointments from three study centres and involving several recruitment staff applied techniques of thematic, content and conversation analysis (CA). Thematic analysis and CA revealed variation in appointment content and structure. Appointments were mostly recruiter-led or participant-led, and this structure was associated with what evidence emerged as to how participants understood information provided and whether they were in equipoise. Participant-led appointments provided this evidence more consistently. Detailed CA identified communication techniques which, when employed by recruiters, provided evidence as to how participants understood the choices before them. Strategic use of open questions, pauses and ceding the floor in the interaction facilitated detailed and systematic exploration of each participant's concerns and position regarding equipoise. We conclude that the current focus on content to be provided to achieve informed consent should be broadened to encompass consideration of how information is best conveyed to potential participants. A model of tailored information provision using the communication techniques identified and centred on eliciting and addressing participants' concerns is proposed. Use of these techniques is necessary to make potential participants' understanding of key issues and their position regarding equipoise explicit in order to facilitate truly informed consent. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Wade, Julia, Department of Social Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol, United Kingdom, BS8 2PS AN - 2009-08184-012 AU - Wade, Julia AU - Donovan, Jenny L. AU - Lane, J. Athene AU - Neal, David E. AU - Hamdy, Freddie C. DB - psyh DO - 10.1016/j.socscimed.2009.02.023 DP - EBSCOhost IS - 11 KW - informed consent appointments black box randomised controlled trials treatment selection healthcare interventions communication process Aged Communication Great Britain Humans Informed Consent Male Middle Aged Multicenter Studies as Topic Patient Participation Patient Selection Prostatic Neoplasms Randomized Controlled Trials as Topic Tape Recording Clinical Trials Decision Making Health Care Services N1 - Department of Social Medicine, University of Bristol, Bristol, United Kingdom. Release Date: 20091214. Correction Date: 20110905. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Clinical Trials; Communication; Decision Making; Health Care Services; Informed Consent. Classification: Health & Mental Health Services (3370). Population: Human (10); Male (30). Location: United Kingdom. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Qualitative Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Jun, 2009. Publication History: First Posted Date: Apr 11, 2009. Copyright Statement: All rights reserved. Elsevier Ltd. 2009. Sponsor: National Institute for Health Research, Health Technology Assessment Programme, United Kingdom. Grant: 96/20/06; 96/20/99. Other Details: ProtecT study. Recipients: No recipient indicated Sponsor: Medical Research Council. Other Details: Merran Toerien; Zelda Tomlin; Isabel de Salis; Nicky Mills,Quartet research programme. Recipients: No recipient indicated PY - 2009 SN - 0277-9536 1873-5347 SP - 2018-2028 ST - It's not just what you say, it's also how you say it: Opening the 'Black box' of informed consent appointments in randomised controlled trials T2 - Social Science & Medicine TI - It's not just what you say, it's also how you say it: Opening the 'Black box' of informed consent appointments in randomised controlled trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-08184-012&site=ehost-live&scope=site ORCID: 0000-0002-6033-5086 julia.wade@bristol.ac.uk VL - 68 ID - 1783 ER - TY - JOUR AB - Randomised controlled trials (RCTs) represent the gold standard methodology for determining effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external validity and waste resources. An inherent tension exists between safeguarding informed decision-making by participants and maximising numbers enrolled. This study investigated what occurs during informed consent appointments in an ongoing multi-centre RCT in the UK. Objectives were to investigate: 1] how study staff presented study information to participants; 2] what evidence emerged as to how well-informed participants were when proceeding to randomisation or treatment selection; and 3] what aspects of the communication process may facilitate improvements in providing evidence of informed consent. Qualitative analysis of a purposive sample of 23 recruitment appointments from three study centres and involving several recruitment staff applied techniques of thematic, content and conversation analysis (CA). Thematic analysis and CA revealed variation in appointment content and structure. Appointments were mostly recruiter-led or participant-led, and this structure was associated with what evidence emerged as to how participants understood information provided and whether they were in equipoise. Participant-led appointments provided this evidence more consistently. Detailed CA identified communication techniques which, when employed by recruiters, provided evidence as to how participants understood the choices before them. Strategic use of open questions, pauses and ceding the floor in the interaction facilitated detailed and systematic exploration of each participant's concerns and position regarding equipoise. We conclude that the current focus on content to be provided to achieve informed consent should be broadened to encompass consideration of how information is best conveyed to potential participants. A model of tailored information provision using the communication techniques identified and centred on eliciting and addressing participants' concerns is proposed. Use of these techniques is necessary to make potential participants' understanding of key issues and their position regarding equipoise explicit in order to facilitate truly informed consent. AD - Department of Social Medicine, University of Bristol, 39 Whatley Road, Clifton, Bristol BS8 2PS, United Kingdom. julia.wade@bristol.ac.uk AN - 105308858. Language: English. Entry Date: 20100219. Revision Date: 20150711. Publication Type: Journal Article AU - Wade, J. AU - Donovan, J. L. AU - Lane, J. A. AU - Neal, D. E. AU - Hamdy, F. C. DB - CINAHL Complete DO - 10.1016/j.socscimed.2009.02.023 DP - EBSCOhost IS - 11 KW - Communication Consent Consumer Participation Patient Selection Clinical Trials Aged Great Britain Human Male Middle Age Multicenter Studies Prostatic Neoplasms Audiorecording N1 - research. Journal Subset: Allied Health; Biomedical; Continental Europe; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8303205. PMID: NLM19364625. PY - 2009 SN - 0277-9536 SP - 2018-2028 ST - It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials T2 - Social Science & Medicine TI - It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105308858&site=ehost-live&scope=site VL - 68 ID - 1987 ER - TY - JOUR AB - Randomised controlled trials (RCFs) represent the gold standard methodology for determining effectiveness of healthcare interventions. Poor recruitment to RCTs can threaten external validity and waste resources. An inherent tension exists between safeguarding informed decision-making by participants and maximising numbers enrolled. This study investigated what occurs during informed consent appointments in an ongoing multi-centre RCT in the UK. Objectives were to investigate: 1] how study staff presented study information to participants; 2] what evidence emerged as to how well-informed participants were when proceeding to randomisation or treatment selection; and 3] what aspects of the communication process may facilitate improvements in providing evidence of informed consent. Qualitative analysis of a purposive sample of 23 recruitment appointments from three study centres and involving several recruitment staff applied techniques of thematic, content and conversation analysis (CA). Thematic analysis and CA revealed variation in appointment content and structure. Appointments were mostly recruiter-led or participant-led, and this structure was associated with what evidence emerged as to how participants understood information provided and whether they were in equipoise. Participant-led appointments provided this evidence more consistently. Detailed CA identified communication techniques which, when employed by recruiters, provided evidence as to how participants understood the choices before them. Strategic use of open questions, pauses and ceding the floor in the interaction facilitated detailed and systematic exploration of each participant's concerns and position regarding equipoise. We conclude that the current focus on content to be provided to achieve informed consent should be broadened to encompass consideration of how information is best conveyed to potential participants. A model of tailored information provision using the communication techniques identified and centred on eliciting and addressing participants' concerns is proposed. Use of these techniques is necessary to make potential participants' understanding of key issues and their position regarding equipoise explicit in order to facilitate truly informed consent. (C) 2009 Elsevier Ltd. All rights reserved. AN - WOS:000267200500015 AU - Wade, J. AU - Donovan, J. L. AU - Lane, J. A. AU - Neal, D. E. AU - Hamdy, F. C. DA - Jun DO - 10.1016/j.socscimed.2009.02.023 IS - 11 N1 - 19364625 PY - 2009 SN - 0277-9536 SP - 2018-2028 ST - It's not just what you say, it's also how you say it: Opening the 'black box' of informed consent appointments in randomised controlled trials T2 - Social Science & Medicine TI - It's not just what you say, it's also how you say it: Opening the 'black box' of informed consent appointments in randomised controlled trials VL - 68 ID - 3147 ER - TY - JOUR AB - Background: Although breast and cervical cancer deaths have declined due to early screening, detection, and more effective treatment, racial and ethnic disparities persist. This paper describes the study design and baseline characteristics of a randomized controlled trial (RCT) evaluating the effectiveness of the Kin Keepers(SM) Cancer Prevention Intervention, a family-focused educational intervention for underserved women applied in a community-based setting to promote health literacy and screening adherence to address cancer disparities. Methods: Female public health community health workers (CHWs) were trained to administer the intervention. They recruited female clients from their public health program caseload and asked each to assemble two to four adult female family members for the breast and cervical cancer home-based education sessions the CHWs would deliver in English, Spanish or Arabic. We randomized the clients into the kin keeper group (treatment) or the participant client group (control). Results: Complete data were obtained on 514 Black, Latina, and Arab women. Close to half were unemployed and had yearly family income below $20,000. Thirty-four percent had no medical insurance, and 21% had diabetes. Almost 40% had no mammography in the last year. Treatment and control groups were similar on most sociodemographics but showed differences in breast and cervical screening history. Conclusions: This innovative study demonstrates the implementation of an RCT using community-based participatory research, while delivering cancer prevention education across woman's life span with women not connected to the health care system. (C) 2012 Elsevier Inc. All rights reserved. AN - WOS:000317169100016 AU - Williams, K. P. AU - Roman, L. AU - Meghea, C. I. AU - Penner, L. AU - Hammad, A. AU - Gardiner, J. DA - Mar DO - 10.1016/j.cct.2012.12.005 IS - 2 N1 - 23274402 PY - 2013 SN - 1551-7144 SP - 312-319 ST - Kin Keeper(SM): Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women T2 - Contemporary Clinical Trials TI - Kin Keeper(SM): Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women VL - 34 ID - 3046 ER - TY - JOUR AB - Background: Although breast and cervical cancer deaths have declined due to early screening, detection, and more effective treatment, racial and ethnic disparities persist. This paper describes the study design and baseline characteristics of a randomized controlled trial (RCT) evaluating the effectiveness of the Kin KeeperSM Cancer Prevention Intervention, a family-focused educational intervention for underserved women applied in a community-based setting to promote health literacy and screening adherence to address cancer disparities. Methods: Female public health community health workers (CHWs) were trained to administer the intervention. They recruited female clients from their public health program caseload and asked each to assemble two to four adult female family members for the breast and cervical cancer home-based education sessions the CHWs would deliver in English, Spanish or Arabic. We randomized the clients into the kin keeper group (treatment) or the participant client group (control). Results: Complete data were obtained on 514 Black, Latina, and Arab women. Close to half were unemployed and had yearly family income below $20,000. Thirty-four percent had no medical insurance, and 21% had diabetes. Almost 40% had no mammography in the last year. Treatment and control groups were similar on most sociodemographics but showed differences in breast and cervical screening history. Conclusions: This innovative study demonstrates the implementation of an RCT using community-based participatory research, while delivering cancer prevention education across woman's life span with women not connected to the health care system. © 2012 Elsevier Inc. AD - K.P. Williams, Obstetrics, Gynecology and Reproductive Biology, Michigan State University, 626 E. Fee Hall, East Lansing, MI 48824, United States AU - Williams, K. P. AU - Roman, L. AU - Meghea, C. I. AU - Penner, L. AU - Hammad, A. AU - Gardiner, J. DB - Embase Medline DO - 10.1016/j.cct.2012.12.005 IS - 2 KW - adult aged Arab article cancer screening controlled study educational status employment status ethnicity female health education health promotion human major clinical study medical history Black person Papanicolaou test randomized controlled trial study design uterine cervix cancer LA - English M3 - Article N1 - L368188860 2013-02-01 2013-02-20 PY - 2013 SN - 1551-7144 1559-2030 SP - 312-319 ST - Kin KeeperSM: Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women T2 - Contemporary Clinical Trials TI - Kin KeeperSM: Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368188860&from=export http://dx.doi.org/10.1016/j.cct.2012.12.005 VL - 34 ID - 1087 ER - TY - JOUR AB - BACKGROUND: Although breast and cervical cancer deaths have declined due to early screening, detection, and more effective treatment, racial and ethnic disparities persist. This paper describes the study design and baseline characteristics of a randomized controlled trial (RCT) evaluating the effectiveness of the Kin Keeper(SM) Cancer Prevention Intervention, a family‐focused educational intervention for underserved women applied in a community‐based setting to promote health literacy and screening adherence to address cancer disparities. METHODS: Female public health community health workers (CHWs) were trained to administer the intervention. They recruited female clients from their public health program caseload and asked each to assemble two to four adult female family members for the breast and cervical cancer home‐based education sessions the CHWs would deliver in English, Spanish or Arabic. We randomized the clients into the kin keeper group (treatment) or the participant client group (control). RESULTS: Complete data were obtained on 514 Black, Latina, and Arab women. Close to half were unemployed and had yearly family income below $20,000. Thirty‐four percent had no medical insurance, and 21% had diabetes. Almost 40% had no mammography in the last year. Treatment and control groups were similar on most sociodemographics but showed differences in breast and cervical screening history. CONCLUSIONS: This innovative study demonstrates the implementation of an RCT using community‐based participatory research, while delivering cancer prevention education across woman's life span with women not connected to the health care system. AN - CN-00918893 AU - Williams, K. P. AU - Roman, L. AU - Meghea, C. I. AU - Penner, L. AU - Hammad, A. AU - Gardiner, J. DO - 10.1016/j.cct.2012.12.005 IS - 2 KW - Adult African Americans Aged Arabs Breast Neoplasms [*diagnosis] Community Health Workers Community‐Based Participatory Research [methods] Early Detection of Cancer [*methods] Family Female Health Knowledge, Attitudes, Practice [ethnology] Health Literacy Hispanic Americans House Calls Humans Mammography Middle Aged Patient Education as Topic [*methods] United States Uterine Cervical Neoplasms [*diagnosis] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2013 SP - 312‐319 ST - Kin KeeperSM: design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women T2 - Contemporary clinical trials TI - Kin KeeperSM: design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00918893/full VL - 34 ID - 1380 ER - TY - JOUR AB - Background: Although breast and cervical cancer deaths have declined due to early screening, detection, and more effective treatment, racial and ethnic disparities persist. This paper describes the study design and baseline characteristics of a randomized controlled trial (RCT) evaluating the effectiveness of the Kin KeeperSM Cancer Prevention Intervention, a family-focused educational intervention for underserved women applied in a community-based setting to promote health literacy and screening adherence to address cancer disparities. Methods: Female public health community health workers (CHWs) were trained to administer the intervention. They recruited female clients from their public health program caseload and asked each to assemble two to four adult female family members for the breast and cervical cancer home-based education sessions the CHWs would deliver in English, Spanish or Arabic. We randomized the clients into the kin keeper group (treatment) or the participant client group (control). Results: Complete data were obtained on 514 Black, Latina, and Arab women. Close to half were unemployed and had yearly family income below $20,000. Thirty-four percent had no medical insurance, and 21% had diabetes. Almost 40% had no mammography in the last year. Treatment and control groups were similar on most sociodemographics but showed differences in breast and cervical screening history. Conclusions: This innovative study demonstrates the implementation of an RCT using community-based participatory research, while delivering cancer prevention education across woman's life span with women not connected to the health care system. © 2012 Elsevier Inc. AD - Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine Michigan State University, 965 Fee Road, East Lansing, MI 48824, United States Institute for Health Care Studies, Michigan State University, 965 Fee Road, East Lansing, MI 48824, United States Department of Family Medicine and Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, United States Arab Community Center for Economic and Social Services (ACCESS), 6450 Maple Street, Dearborn, MI 48126, United States Department of Epidemiology and Biostatistics, Michigan State University, 909 Fee Road, Lansing, MI 48824, United States AU - Williams, K. P. AU - Roman, L. AU - Meghea, C. I. AU - Penner, L. AU - Hammad, A. AU - Gardiner, J. DB - Scopus DO - 10.1016/j.cct.2012.12.005 IS - 2 KW - Community-based participatory research Implementation science Randomized controlled trial M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2013 SP - 312-319 ST - Kin KeeperSM: Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women T2 - Contemporary Clinical Trials TI - Kin KeeperSM: Design and baseline characteristics of a community-based randomized controlled trial promoting cancer screening in Black, Latina, and Arab women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872845843&doi=10.1016%2fj.cct.2012.12.005&partnerID=40&md5=65630a0582c8e3ee0c21bb690f7ace7e VL - 34 ID - 2439 ER - TY - JOUR AB - Background: Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials. Methods: From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75. years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering ≥. 1 clinical trial. Participants completed a 30-min telephone interview in English, Spanish, or Chinese. In this cross-sectional population-based study, multivariable logistic regression was used to estimate associations between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate. Results: Of 855 participants, 52% were ≥. 65 years, 42% were white, 24% Latino, 19% African American and 15% Asian American. The majority (81%) had medium-to-high health literacy. Compared to non-Latino white men, African American men were less likely to have above average knowledge of clinical trials (OR. = 0.55; CI. = 0.35-0.86), as were Asian American (OR. = 0.55; CI. = 0.33-0.93) and Latino men (OR. = 0.30; CI. = 0.18-0.48). There were no racial/ethnic differences in willingness to participate. The attitude that "researchers are the main beneficiaries" was negatively associated with willingness (OR. = 0.63; CI. = 0.43-0.93); the attitude that "patients are the main beneficiaries" was positively associated with willingness to participate (OR. = 1.57; CI. = 1.07-2.29). Conclusions: Men with early stage prostate cancer are willing to take part in clinical trials and this willingness does not vary by race/ethnicity. AD - C.P. Kaplan, Division of General Internal Medicine, Department of Medicine University of California San Francisco, 3333 California St. 335, GSan Francisco, CA, United States AU - Kaplan, C. P. AU - Nápoles, A. M. AU - Narine, S. AU - Gregorich, S. AU - Livaudais-Toman, J. AU - Nguyen, T. AU - Leykin, Y. AU - Roach, M. AU - Small, E. J. DB - Embase Medline DO - 10.1016/j.cct.2015.09.023 KW - adult African American aged article Asian American cancer patient clinical trial (topic) cross-sectional study ethnic difference health literacy Hispanic human knowledge major clinical study male patient attitude patient participation prostate cancer race difference telephone interview LA - English M3 - Article N1 - L607072065 2015-12-10 2015-12-14 PY - 2015 SN - 1559-2030 1551-7144 SP - 443-448 ST - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients T2 - Contemporary Clinical Trials TI - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607072065&from=export http://dx.doi.org/10.1016/j.cct.2015.09.023 VL - 45 ID - 992 ER - TY - JOUR AB - Background: Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials. Methods: From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75. years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering ≥. 1 clinical trial. Participants completed a 30-min telephone interview in English, Spanish, or Chinese. In this cross-sectional population-based study, multivariable logistic regression was used to estimate associations between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate. Results: Of 855 participants, 52% were ≥. 65 years, 42% were white, 24% Latino, 19% African American and 15% Asian American. The majority (81%) had medium-to-high health literacy. Compared to non-Latino white men, African American men were less likely to have above average knowledge of clinical trials (OR. = 0.55; CI. = 0.35-0.86), as were Asian American (OR. = 0.55; CI. = 0.33-0.93) and Latino men (OR. = 0.30; CI. = 0.18-0.48). There were no racial/ethnic differences in willingness to participate. The attitude that "researchers are the main beneficiaries" was negatively associated with willingness (OR. = 0.63; CI. = 0.43-0.93); the attitude that "patients are the main beneficiaries" was positively associated with willingness to participate (OR. = 1.57; CI. = 1.07-2.29). Conclusions: Men with early stage prostate cancer are willing to take part in clinical trials and this willingness does not vary by race/ethnicity. © 2015 Elsevier Inc. AD - Department of Medicine, Division of General Internal Medicine, University of CaliforniaSan Francisco, United States Helen Diller Family Comprehensive Cancer Center, University of CaliforniaSan Francisco, United States Department of Psychiatry, University of CaliforniaSan Francisco, United States Radiation Oncology, University of California, San Francisco, United States Department of Medicine, Division of Hematology and Oncology, University of CaliforniaSan Francisco, United States AU - Kaplan, C. P. AU - Nápoles, A. M. AU - Narine, S. AU - Gregorich, S. AU - Livaudais-Toman, J. AU - Nguyen, T. AU - Leykin, Y. AU - Roach, M. AU - Small, E. J. DB - Scopus DO - 10.1016/j.cct.2015.09.023 KW - Clinical trials participation Prostate cancer M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2015 SP - 443-448 ST - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients T2 - Contemporary Clinical Trials TI - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84948739895&doi=10.1016%2fj.cct.2015.09.023&partnerID=40&md5=8ca89999719c0b0cb0f4145f35b9d81c VL - 45 ID - 2359 ER - TY - JOUR AB - Background: Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials. Methods: From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75 years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering >= 1 clinical trial. Participants completed a 30-min telephone interview in English, Spanish, or Chinese. In this cross-sectional population-based study, multivariable logistic regression was used to estimate associations between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate. Results: Of 855 participants, 52% were >= 65 years, 42% were white, 24% Latino, 19% African American and 15% Asian American. The majority (81%) had medium-to-high health literacy. Compared to non-Latino white men, African American men were less likely to have above average knowledge of clinical trials (OR = 0.55; CI = 0.35-0.86), as were Asian American (OR = 0.55; Cl = 033-0.93) and Latino men (OR = 030; Cl = 0.18-0.48). There were no racial/ethnic differences in willingness to participate. The attitude that "researchers are the main beneficiaries" was negatively associated with willingness (OR = 0.63; Cl = 0.43-0.93); the attitude that "patients are the main beneficiaries" was positively associated with willingness to participate (OR = 157; Cl = 1.07-2.29). Conclusions: Men with early stage prostate cancer are willing to take part in clinical trials and this willingness does not vary by race/ethnicity. (C) 2015 Elsevier Inc. All rights reserved. AN - WOS:000367755200042 AU - Kaplan, C. P. AU - Napoles, A. M. AU - Narine, S. AU - Gregorich, S. AU - Livaudais-Toman, J. AU - Nguyen, T. AU - Leykin, Y. AU - Roach, M. AU - Small, E. J. DA - Nov DO - 10.1016/j.cct.2015.09.023 N1 - B 26435199 PY - 2015 SN - 1551-7144 SP - 443-448 ST - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients T2 - Contemporary Clinical Trials TI - Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients VL - 45 ID - 2965 ER - TY - JOUR AB - The vast majority of (BRCA1/2) genetic testing has been conducted in White women, in particular Ashkenazi Jewish women, with limited information available for Black and Hispanic women. Understanding perspectives of those who are underserved is critical to developing interventions to support inclusive approaches to genetic testing. This qualitative study explored knowledge and perceptions of BRCA1/2 genetic testing among diverse women in South Florida. We also explored participants' information needs. Convenience sampling was used to recruit a diverse group of 15 women with a personal or family history of breast cancer. We conducted semi-structured interviews and used grounded theory method to analyze the data. Five themes were identified: (1) lacking awareness and knowledge of BRCA1/2 genetic testing and results among Black women, (2) perceiving BRCA1/2 genetic testing as beneficial to themselves and a way to be proactive about cancer risk, (3) perceiving BRCA1/2 genetic testing as beneficial to family members, (4) interactions with healthcare providers and the healthcare system that shape genetic testing experiences, and (5) information needs for reducing cancer risk and promoting health. Our findings suggest that diverse underserved women perceived genetic testing as beneficial to themselves and family members. Women needed more information about the BRCA genes and genetic testing, prevention strategies, and the latest breast cancer research. Healthcare providers, particularly nurse practitioners, need to engage diverse high-risk women in discussions about their cancer risk, address unmet information needs, and, in particular, educate Black women about the benefits of pursuing genetic testing. AN - WOS:000616020600001 AU - Jones, T. AU - Howard, H. AU - Freeman-Costin, K. AU - Creighton, A. AU - Wisdom-Chambers, K. AU - Underhill-Blazey, M. DO - 10.1007/s12687-021-00507-6 N1 - 33555545 SN - 1868-310X ST - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida T2 - Journal of Community Genetics TI - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida ID - 2748 ER - TY - JOUR AB - The vast majority of (BRCA1/2) genetic testing has been conducted in White women, in particular Ashkenazi Jewish women, with limited information available for Black and Hispanic women. Understanding perspectives of those who are underserved is critical to developing interventions to support inclusive approaches to genetic testing. This qualitative study explored knowledge and perceptions of BRCA1/2 genetic testing among diverse women in South Florida. We also explored participants’ information needs. Convenience sampling was used to recruit a diverse group of 15 women with a personal or family history of breast cancer. We conducted semi-structured interviews and used grounded theory method to analyze the data. Five themes were identified: (1) lacking awareness and knowledge of BRCA1/2 genetic testing and results among Black women, (2) perceiving BRCA1/2 genetic testing as beneficial to themselves and a way to be proactive about cancer risk, (3) perceiving BRCA1/2 genetic testing as beneficial to family members, (4) interactions with healthcare providers and the healthcare system that shape genetic testing experiences, and (5) information needs for reducing cancer risk and promoting health. Our findings suggest that diverse underserved women perceived genetic testing as beneficial to themselves and family members. Women needed more information about the BRCA genes and genetic testing, prevention strategies, and the latest breast cancer research. Healthcare providers, particularly nurse practitioners, need to engage diverse high-risk women in discussions about their cancer risk, address unmet information needs, and, in particular, educate Black women about the benefits of pursuing genetic testing. AD - T. Jones, Christine E. Lynn College of Nursing, Florida Atlantic University, 777 Glades Road, Boca Raton, FL, United States AU - Jones, T. AU - Howard, H. AU - Freeman-Costin, K. AU - Creighton, A. AU - Wisdom-Chambers, K. AU - Underhill-Blazey, M. DB - Embase DO - 10.1007/s12687-021-00507-6 KW - adult article awareness breast cancer cancer research cancer risk clinical article controlled study convenience sample family history female Florida genetic screening grounded theory health care system human human tissue nurse practitioner perception qualitative research semi structured interview BRCA1 protein BRCA2 protein endogenous compound LA - English M3 - Article in Press N1 - L2010434098 2021-02-18 PY - 2021 SN - 1868-6001 1868-310X ST - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida T2 - Journal of Community Genetics TI - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010434098&from=export http://dx.doi.org/10.1007/s12687-021-00507-6 ID - 763 ER - TY - JOUR AB - The vast majority of (BRCA1/2) genetic testing has been conducted in White women, in particular Ashkenazi Jewish women, with limited information available for Black and Hispanic women. Understanding perspectives of those who are underserved is critical to developing interventions to support inclusive approaches to genetic testing. This qualitative study explored knowledge and perceptions of BRCA1/2 genetic testing among diverse women in South Florida. We also explored participants’ information needs. Convenience sampling was used to recruit a diverse group of 15 women with a personal or family history of breast cancer. We conducted semi-structured interviews and used grounded theory method to analyze the data. Five themes were identified: (1) lacking awareness and knowledge of BRCA1/2 genetic testing and results among Black women, (2) perceiving BRCA1/2 genetic testing as beneficial to themselves and a way to be proactive about cancer risk, (3) perceiving BRCA1/2 genetic testing as beneficial to family members, (4) interactions with healthcare providers and the healthcare system that shape genetic testing experiences, and (5) information needs for reducing cancer risk and promoting health. Our findings suggest that diverse underserved women perceived genetic testing as beneficial to themselves and family members. Women needed more information about the BRCA genes and genetic testing, prevention strategies, and the latest breast cancer research. Healthcare providers, particularly nurse practitioners, need to engage diverse high-risk women in discussions about their cancer risk, address unmet information needs, and, in particular, educate Black women about the benefits of pursuing genetic testing. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature. AD - Christine E. Lynn College of Nursing, Florida Atlantic University, 777 Glades Road, Boca Raton, FL 33431, United States College for Design and Social Inquiry, Florida Atlantic University, Boca Raton, FL 33431, United States Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431, United States School of Nursing, University of Rochester, Rochester, NY 14642, United States Dana Farber Cancer Institute, Boston, MA 02215, United States AU - Jones, T. AU - Howard, H. AU - Freeman-Costin, K. AU - Creighton, A. AU - Wisdom-Chambers, K. AU - Underhill-Blazey, M. DB - Scopus DO - 10.1007/s12687-021-00507-6 KW - BRCA1 and BRCA2 Breast cancer Diverse women Genetic testing Personal or family history Qualitative research M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida T2 - Journal of Community Genetics TI - Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100767088&doi=10.1007%2fs12687-021-00507-6&partnerID=40&md5=73d2ea28b4a7165ec39b1f4ff9bfdd3d ID - 2166 ER - TY - JOUR AB - Disparities exist in breast cancer knowledge and education, which tend to influence symptom interpretation and decision to seek screening/care. The present project describes a cohort of women's experiences, knowledge, and health behavior prior to and after a diagnosis of breast cancer. It also studies how knowledge and demographic factors are associated with level of involvement participants had in the treatment of their breast cancer. Women >18 years who have been diagnosed and treated for breast cancer within 10 years were recruited in Pittsburgh, PA, through the Healthy People Cohort Registry, a database of volunteers from the community, and Brooklyn, NY, through the American Cancer Society breast cancer survivor database. Subsequent to institutional ethics approval, a questionnaire was administered by mail and through an electronic interactive format. The study included 124 breast cancer survivors, one-quarter of whom were of African ancestry. Roughly half of the women indicated that their overall knowledge of breast cancer was limited before diagnosis; no significant association between overall knowledge before diagnosis and stage at diagnosis or an active role of the patient in treatment choices was observed. Two-third of the women reported using personal research on internet, books, and other media to increase knowledge on breast cancer after diagnosis; the improvement of knowledge was associated with an active role in therapy choice. White women's self report of breast cancer knowledge prior to diagnosis was higher than that of women of African origin (p = 0.03); the latter experienced more delays in getting results about the diagnosis (p = 0.002), in starting treatment (p = 0.03), and in having treatment available at local facilities (p = 0.007) than white women. White women were more likely to improve their knowledge through their own research (p = 0.08) and through the contribution of their physician (p = 0.06) than women of African origin.There is still a need for addressing breast cancer knowledge among black women, and improvement in physician emotional support and in their contribution to the patient's knowledge is necessary. These efforts may have a positive impact on breast cancer knowledge among black women in the US. AD - E. Taioli AU - Taioli, E. AU - Joseph, G. R. AU - Robertson, L. AU - Eckstein, S. AU - Ragin, C. DB - Medline DO - 10.1007/s13187-013-0540-7 IS - 1 KW - adult aged article attitude to health breast tumor cross-sectional study decision making female follow up health behavior human mammography middle aged patient participation psychological aspect questionnaire survivor LA - English M3 - Article N1 - L373975196 2014-10-28 PY - 2014 SN - 1543-0154 SP - 44-49 ST - Knowledge and prevention practices before breast cancer diagnosis in a cross-sectional study among survivors: impact on patients' involvement in the decision making process T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Knowledge and prevention practices before breast cancer diagnosis in a cross-sectional study among survivors: impact on patients' involvement in the decision making process UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373975196&from=export http://dx.doi.org/10.1007/s13187-013-0540-7 VL - 29 ID - 1049 ER - TY - JOUR AB - The goal of this study was to understand the unique needs and barriers to breast cancer control among African American women in the rural South. This population experiences barriers that surpass that of other minorities. Researchers conducted 6 focus groups to assess barriers of minority women in Mississippi toward breast cancer prevention and clinical trials. These women had little knowledge of treatment options and negative perceptions of screening and clinical trial participation. This research equips others to identify new health education strategies. Conclusions also provide insight into prevention for other minority populations, such as Latina, Asian, and American Indian women. Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins. AD - A. Avis-Williams, Mississippi Department of Education, Jackson, United States AU - Avis-Williams, A. AU - Khoury, A. AU - Lisovicz, N. AU - Graham-Kresge, S. DB - Medline DO - 10.1097/FCH.0b013e3181ab3bbb IS - 3 KW - adult article attitude to health breast tumor clinical trial female health care delivery health care planning human information processing mass screening middle aged patient participation risk factor rural population United States LA - English M3 - Article N1 - L355072192 2009-10-07 PY - 2009 SN - 0160-6379 SP - 238-246 ST - Knowledge, attitudes, and practices of underserved women in the rural south toward breast cancer prevention and detection T2 - Family and Community Health TI - Knowledge, attitudes, and practices of underserved women in the rural south toward breast cancer prevention and detection UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355072192&from=export http://dx.doi.org/10.1097/FCH.0b013e3181ab3bbb VL - 32 ID - 1189 ER - TY - JOUR AB - The KEEPS trial is a randomized, double‐blind, controlled trial designed to test whether menopausal hormone therapy initiated within 3 years of menopause can delay progression of atherosclerosis, as assessed by common carotid artery intirna media thickness (CIMT, primary outcome)and coronary artery calcium (CAC, secondary outcome) over 4 years of treatment. Additional outcomes of interest include cognitive function, menopausal symptoms, quality of life, lipids/CVD biomarker status, and mammographic breast density. Women (n = 727) were randomized to the following regimens: 0.45 mg/d oral conjugated estrogen (CEE), 0.05 mg/d transdermal estradiol, both with cyclic oral micronized progesterone (200 mg/d xl2 days/month), or placebo. Women 42‐58 years old and 6‐36 months from final menses were eligible. Exclusion criteria included: hysterectomy, body mass index (BMI) >35 kg2, LDL cholesterol >160 mg/dL, CAC >50 Agatston Units at baseline, smoking >10 cigarettes/day, and history of diabetes, myocardial infarction, stroke, thromboembolic disease or cancer. Mean age (SD) at enrollment was 52.7 (2.6) years and mean years (SD) from onset of menopause were 1.8 (0.8). About 15% of participants self‐identified as African American or Hispanic, and ~80% were Caucasian. More than two‐thirds had a college education, a similar percentage had moderate‐to‐severe vasomotor symptoms, and mean BMI was 26.2 kg/m2. KEEPS participants were at overall lower risk of CVD than Women's Health Initiative (WHI) participants: lower mean systolic BP, lower mean BMI, more favorable lipid parameters (all P values <0.01). At baseline, CVD risk factors, as well as CIMT and CAC values, were comparable across groups. Mean baseline CIMT for all groups was 0.712 + 0.09 mm. Thus, KEEPS has several design features that are distinctly different from the WHI design, including: enrollment of younger and generally healthier perimenopausal and recently menopausal women; administration of a lower dose of CEE (0.45 mg daily) versus 0.625 mg administered in WHI; one arm that includes estradiol and a transdermal route of delivery; cyclic administration of natural progesterone versus continuous therapy with synthetic medroxyprogesterone acetate in WHI; and inclusion of only those women undergoing natural and non‐surgical menopause. KEEPS findings that will be presented at this plenary session include the effects of the interventions on atherosclerosis progression by CIMT and CAC and effects on cognitive function assessed by a comprehensive and detailed battery of cognitive tests. AN - CN-01029071 AU - Manson, J. E. DO - 10.1097/gme.0b013e3182739e2f IS - 12 KW - *estrogen *menopause *population *prevention study *society African American Arm Atherosclerosis Biological marker Body mass Breast Calcium Caucasian Cerebrovascular accident Cognition College Common carotid artery Conjugated estrogen Controlled study Coronary artery Density Diabetes mellitus Education Estradiol Female Health Heart infarction Hispanic Hormonal therapy Human Hysterectomy Lipid Low density lipoprotein Low density lipoprotein cholesterol Medroxyprogesterone acetate Menstruation Neoplasm Parameters Placebo Progesterone Quality of life Risk Risk factor Smoking Statistical significance Therapy Thickness Thromboembolism Transdermal drug administration M3 - Journal: Conference Abstract PY - 2012 SP - 1365 ST - The kronos early estrogen prevention study (KEEPS): rationale, design & baseline characteristics of the study population T2 - Menopause (new york, N.Y.) TI - The kronos early estrogen prevention study (KEEPS): rationale, design & baseline characteristics of the study population UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01029071/full VL - 19 ID - 1576 ER - TY - JOUR AB - Background and aims: Breast cancer-related death is attributable mainly to metastasis. Inflammatory breast cancer (IBC) is an infrequent subtype of breast cancer that shows a relatively high rate of metastasis. In this study, we aimed to compare the metastatic patterns and prognostic outcomes of IBC and non-inflammatory breast cancer (non-IBC). Methods: We extracted data between 2010 and 2014 from the Surveillance, Epidemiology and End Results (SEER) database. The Chi-square test and Fisher’s exact test were used to compare the categorical parameters among different groups. Logistic regression was applied for multivariate analysis. The Kaplan–Meier method and multivariate Cox regression models were performed to analyze prognosis. Results: We enrolled 233,686 breast cancer patients between 2010 and 2014 in our research, including 2806 IBC and 230,880 non-IBC patients. Compared with the non-IBC group, the IBC group tended to have a higher incidence of the human epidermal growth factor receptor 2 positive (HER2+) and triple-negative breast cancer (TNBC) subtypes, older age, a higher rate of unmarried status, a lower incidence of black race, poorer tumor differentiation, larger tumor sizes, and a higher frequency of regional lymph node invasion. IBC and non-IBC shared similar trends in molecular subtypes among different metastatic organs. The percentage of the hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2–) subtype decreased gradually in patients with lung (IBC 42.5%, non-IBC 55.7%), distant lymph node (IBC 41.5%, non-IBC 54.6%), liver (IBC 31.1%, non-IBC 46.7%), and brain (IBC 30.6%, non-IBC 47.9%) metastases compared with that in patients with bone (IBC 50.8%, non-IBC 69.0%) metastasis in both cohorts. In both the IBC and non-IBC cases, the proportion of visceral metastases increased in the TNBC subtype, especially brain metastasis (IBC 26.4%, non-IBC 21.2%), which had the largest increase. The frequencies of all sites (bone, lung, liver, brain, and distant lymph node) in IBC were much higher than those in non-IBC (bone: IBC 21.1%, non-IBC 3.0%; lung: IBC 11.4%, non-IBC 1.4%; liver: IBC 9.6%, non-IBC 1.2%; brain: IBC 2.6%, non-IBC 0.3%; distant lymph node: IBC 12.9%, non-IBC 1.0%). The most frequent bi-site metastasis was the bone and liver (IBC 2.5%, non-IBC 0.3%), and the most frequent tri-site combination was the bone, lung, and liver (IBC 1.1%, non-IBC 0.2%). Kaplan–Meier curves and multivariate Cox regression models suggested that the IBC cohort had poorer overall survival [hazard ratio (HR) 1.602, 95% confidence interval (CI) 1.496–1.716, p < 0.001] and breast cancer-specific survival (HR 1.511, 95% CI 1.402–1.628, p < 0.001) than the non-IBC cohort. Furthermore, univariate and multivariate analyses indicated that IBC was an independent prognostic factor in patients with different metastatic sites. Conclusion: IBC and non-IBC patients presented with different metastatic frequencies, clinical features and prognostic outcomes. Our findings provide more information for therapeutic decision making and clinical study designs. © The Author(s), 2020. AD - Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai, 200025, China Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Department of Pharmacy, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China AU - Wang, Z. AU - Wang, H. AU - Ding, X. AU - Chen, X. AU - Shen, K. DB - Scopus DO - 10.1177/1758835920932674 KW - advanced breast cancer metastasis molecular subtype prognosis SEER M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2020 ST - A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer T2 - Therapeutic Advances in Medical Oncology TI - A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086031992&doi=10.1177%2f1758835920932674&partnerID=40&md5=c47e04685e717f064ed5d467d7c79290 VL - 12 ID - 2210 ER - TY - JOUR AB - Purpose: Latinas and African-Americans with breast cancer, especially those of lower socioeconomic status and acculturation, have been underrepresented in studies assessing treatment satisfaction, decision-making, and quality of life. A study was designed to recruit a large and representative sample of these subgroups. Materials and Methods: Incident cases were selected by rapid case ascertainment (RCA) in the Los Angeles Surveillance, Epidemiology, and End Results Registry from 2005 to 2006, with oversampling of Latinas and African-Americans. Patients were maileda questionnaire and $10 incentive 5 to 6 months after diagnosis; nonrespondents were contacted by telephone. Multivariate analysis was usedto assess possible response bias. The RCA definition of Hispanic origin was validated by self-reports. The Short Acculturation Scale for Hispanics index for Latina respondents was used. Results: One thousand six hundred and ninety-eight eligible breast cancer cases were selected and 1,223 participated, for a response rate of 72.0%, which varied little by race/ethnicity. Age, race/ethnicity, and clinical factors were not associated with response; however, respondents were slightly more likely to be married and from higher socioeconomic status census tracts than nonrespondents. The RCA definition of Hispanic identity was highly sensitive (94.6%) and specific (90.0%). Lower acculturation was associated with lower education and literacy among Latinas. Discussion: High response rates among all subgroups were achieved due to the use of RCA, an incentive, extensive telephone follow-up, a native Spanish-speaking interviewer, and a focused questionnaire. The low acculturation index category identified a highly vulnerable subgroup. This large sample representing subgroups with greater problems will provide a basis for developing better interventions to assist these women. Copyright © 2009 American Association for Cancer Research. AD - A. S. Hamilton, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089-9175, United States AU - Hamilton, A. S. AU - Hofer, T. P. AU - Hawley, S. T. AU - Morrell, D. AU - Leventhal, M. AU - Deapen, D. AU - Salem, B. AU - Katz, S. J. DB - Embase Medline DO - 10.1158/1055-9965.EPI-09-0238 IS - 7 KW - adult African American aged article breast cancer clinical feature cultural factor diagnostic accuracy ethnic group female follow up Hispanic human major clinical study medical decision making multivariate analysis outcomes research patient satisfaction population research priority journal quality of life questionnaire race difference self report sensitivity and specificity Short Acculturation Scale for Hispanics Index socioeconomics telephone United States L1 - internal-pdf://1967513926/2022.full.pdf LA - English M3 - Article N1 - L354915117 2009-09-09 PY - 2009 SN - 1055-9965 SP - 2022-2029 ST - Latinas and breast cancer outcomes: Population-based sampling, ethnic identity, and acculturation assessment T2 - Cancer Epidemiology Biomarkers and Prevention TI - Latinas and breast cancer outcomes: Population-based sampling, ethnic identity, and acculturation assessment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354915117&from=export http://dx.doi.org/10.1158/1055-9965.EPI-09-0238 VL - 18 ID - 1187 ER - TY - JOUR AB - Purpose: Latinas and African-Americans with breast cancer, especially those of lower socioeconomic status and acculturation, have been underrepresented in studies assessing treatment satisfaction, decision-making, and quality of life. A study was designed to recruit a large and representative sample of these subgroups. Materials and Methods: Incident cases were selected by rapid case ascertainment (RCA) in the Los Angeles Surveillance, Epidemiology, and End Results Registry from 2005 to 2006, with oversampling of Latinas and African-Americans. Patients were maileda questionnaire and $10 incentive 5 to 6 months after diagnosis; nonrespondents were contacted by telephone. Multivariate analysis was usedto assess possible response bias. The RCA definition of Hispanic origin was validated by self-reports. The Short Acculturation Scale for Hispanics index for Latina respondents was used. Results: One thousand six hundred and ninety-eight eligible breast cancer cases were selected and 1,223 participated, for a response rate of 72.0%, which varied little by race/ethnicity. Age, race/ethnicity, and clinical factors were not associated with response; however, respondents were slightly more likely to be married and from higher socioeconomic status census tracts than nonrespondents. The RCA definition of Hispanic identity was highly sensitive (94.6%) and specific (90.0%). Lower acculturation was associated with lower education and literacy among Latinas. Discussion: High response rates among all subgroups were achieved due to the use of RCA, an incentive, extensive telephone follow-up, a native Spanish-speaking interviewer, and a focused questionnaire. The low acculturation index category identified a highly vulnerable subgroup. This large sample representing subgroups with greater problems will provide a basis for developing better interventions to assist these women. Copyright © 2009 American Association for Cancer Research. AD - Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089-9175, United States Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States Ann Arbor Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, United States Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, MI, United States AU - Hamilton, A. S. AU - Hofer, T. P. AU - Hawley, S. T. AU - Morrell, D. AU - Leventhal, M. AU - Deapen, D. AU - Salem, B. AU - Katz, S. J. DB - Scopus DO - 10.1158/1055-9965.EPI-09-0238 IS - 7 M3 - Article N1 - Cited By :67 Export Date: 22 March 2021 PY - 2009 SP - 2022-2029 ST - Latinas and breast cancer outcomes: Population-based sampling, ethnic identity, and acculturation assessment T2 - Cancer Epidemiology Biomarkers and Prevention TI - Latinas and breast cancer outcomes: Population-based sampling, ethnic identity, and acculturation assessment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650439249&doi=10.1158%2f1055-9965.EPI-09-0238&partnerID=40&md5=2e4ef2d6c380c194111a78a9a1378a0f VL - 18 ID - 2520 ER - TY - JOUR AB - African-Americans experience a disproportionate share of thoracic cancer burden compared to Whites. Low socioeconomic status (SES) and race are factors in low clinical trial enrollment, accounting for the disparities between African-Americans and Whites. Less than 3% of newly diagnosed cancer patients enroll in clinical trials, and of that number, only 10% represent ethnic minorities. The value of clinical trials research is not generalizable without sufficient representation by ethnic minorities. Patient navigation, an intervention designed to ensure timely and efficient access to healthcare, may improve clinical trial enrollment among African-Americans in lung and esophageal trials by influencing a patient's perception of clinical trials. The lack of navigation programs and training may negatively influence standardization of navigation techniques. The purpose of this project was to deliver and evaluate an evidence-based navigation-training curriculum for "lay" navigators. The primary outcomes measured were confidence in the role as navigator, understanding a navigator's role, and knowledge and perception of clinical trials. The results revealed overall confidence in the role as lay navigators increased from pre-to-post test. Lessons learned included the need for preparatory classes to build the navigator's confidence, and additional training components in death and dying. A larger study is warranted to confirm the findings. AD - D.C. Bryant, Hollings Cancer Center, Medical University of South Carolina, PO BX 250955, 86 Jonathan Lucas Street, Charleston, SC 29425, USA. AU - Bryant, D. C. AU - Williamson, D. AU - Cartmell, K. AU - Jefferson, M. DB - Medline IS - 2 KW - African American article clinical trial clinical trial (topic) curriculum education educational model ethnology female health auxiliary health care delivery health care disparity human male multicenter study neoplasm patient attitude patient selection pilot study social support United States LA - English M3 - Article N1 - L365956897 2012-11-07 PY - 2011 SN - 0885-6028 SP - 68-75 ST - A lay patient navigation training curriculum targeting disparities in cancer clinical trials T2 - Journal of National Black Nurses' Association : JNBNA TI - A lay patient navigation training curriculum targeting disparities in cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365956897&from=export VL - 22 ID - 1129 ER - TY - JOUR AB - African-Americans experience a disproportionate share of thoracic cancer burden compared to Whites. Low socioeconomic status (SES) and race are factors in low clinical trial enrollment, accounting for the disparities between African-Americans and Whites. Less than 3% of newly diagnosed cancer patients enroll in clinical trials, and of that number, only 10% represent ethnic minorities. The value of clinical trials research is not generalizable without sufficient representation by ethnic minorities. Patient navigation, an intervention designed to ensure timely and efficient access to healthcare, may improve clinical trial enrollment among African-Americans in lung and esophageal trials by influencing a patient's perception of clinical trials. The lack of navigation programs and training may negatively influence standardization of navigation techniques. The purpose of this project was to deliver and evaluate an evidence-based navigation-training curriculum for "lay" navigators. The primary outcomes measured were confidence in the role as navigator, understanding a navigator's role, and knowledge and perception of clinical trials. The results revealed overall confidence in the role as lay navigators increased from pre-to-post test. Lessons learned included the need for preparatory classes to build the navigator's confidence, and additional training components in death and dying. A larger study is warranted to confirm the findings. AD - Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC 29425, United States AU - Bryant, D. C. AU - Williamson, D. AU - Cartmell, K. AU - Jefferson, M. DB - Scopus IS - 2 M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 2011 SP - 68-75 ST - A lay patient navigation training curriculum targeting disparities in cancer clinical trials T2 - Journal of National Black Nurses' Association : JNBNA TI - A lay patient navigation training curriculum targeting disparities in cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868225966&partnerID=40&md5=50404f910c2c97db62c00d036b3982f9 VL - 22 ID - 2484 ER - TY - JOUR AB - Prostate cancer disproportionately affects Black men, who may also encounter barriers to participation in prostate cancer risk assessment. The Prostate Risk, Education and Assessment in the Community with Help (REACH) project was a community-based extension of a comprehensive prostate cancer risk assessment program at a comprehensive cancer center. The goals of the REACH project were the following: (1) establish a community prostate cancer risk assessment clinic, (2) conduct targeted recruitment, and (3) provide navigation services including follow-up for uninsured men. Key implementation steps included the following: (1) choosing a clinic site, (2) establishing patient access procedures, (3) establishing navigator services, (4) developing subsidy fund use guidelines, and (5) designing recruitment and promotion. Through community-based promotion, 64 men inquired about the program and 26 (41 %) participated. Of those screened, 46 % had abnormal results, and 2 men were diagnosed with prostate cancer. Here, we describe a unique demonstration project to implement a comprehensive prostate cancer risk assessment program in an underserved Black community and describe successes and challenges to inform future efforts to promote access to underserved men. AD - Department of Health Outcomes and Behavior, Division of Population Sciences, H. Lee Moffitt Cancer Center, Tampa USA Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Room 1015 Philadelphia 19107 USA Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia USA Office of Health Communications and Health Disparities, Fox Chase Cancer Center, Philadelphia USA Center for Injury Research and Prevention, Children's Hospital of Philadelphia, Philadelphia USA National Comprehensive Cancer Center, Fort Washington USA Department of Health Outcomes and Behavior, Division of Population Sciences, H. Lee Moffitt Cancer Center, Tampa, FL, USA Office of Health Communications and Health Disparities, Fox Chase Cancer Center, Philadelphia, PA, USA Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Room 1015, Philadelphia, PA, 19107, USA AN - 113040737. Language: English. Entry Date: 20161223. Revision Date: 20171115. Publication Type: journal article AU - Fleisher, Linda AU - Davis, Stacy AU - Gross, Laura AU - Bagden, Loretta AU - Zakrzewski, Debra AU - González, Evelyn AU - Kandadai, Venk AU - Rusten, Cheryl AU - Baskett, Jerilyn AU - Obeid, Elias AU - Giri, Veda AU - Davis, Stacy N. AU - González, Evelyn AU - Giri, Veda N. DB - CINAHL Complete DO - 10.1007/s13187-015-0854-8 DP - EBSCOhost IS - 1 KW - Special Populations -- Psychosocial Factors Early Detection of Cancer -- Psychosocial Factors Patient Education Ethnic Groups -- Education Prostatic Neoplasms -- Prevention and Control Male Learning Aged Adult Human Patient Selection Prostatic Neoplasms -- Psychosocial Factors Risk Assessment Prospective Studies Program Evaluation Patient Navigation Prostatic Neoplasms -- Diagnosis Middle Age Prognosis Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. NLM UID: 8610343. PMID: NLM25971432. PY - 2016 SN - 0885-8195 SP - 191-197 ST - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project T2 - Journal of Cancer Education TI - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113040737&site=ehost-live&scope=site VL - 31 ID - 1991 ER - TY - JOUR AB - Prostate cancer disproportionately affects Black men, who may also encounter barriers to participation in prostate cancer risk assessment. The Prostate Risk, Education and Assessment in the Community with Help (REACH) project was a community-based extension of a comprehensive prostate cancer risk assessment program at a comprehensive cancer center. The goals of the REACH project were the following: (1) establish a community prostate cancer risk assessment clinic, (2) conduct targeted recruitment, and (3) provide navigation services including follow-up for uninsured men. Key implementation steps included the following: (1) choosing a clinic site, (2) establishing patient access procedures, (3) establishing navigator services, (4) developing subsidy fund use guidelines, and (5) designing recruitment and promotion. Through community-based promotion, 64 men inquired about the program and 26 (41 %) participated. Of those screened, 46 % had abnormal results, and 2 men were diagnosed with prostate cancer. Here, we describe a unique demonstration project to implement a comprehensive prostate cancer risk assessment program in an underserved Black community and describe successes and challenges to inform future efforts to promote access to underserved men. AU - Fleisher, L. AU - Davis, S. N. AU - Gross, L. AU - Bagden, L. AU - Zakrzewski, D. AU - González, E. AU - Kandadai, V. AU - Rusten, C. AU - Baskett, J. AU - Obeid, E. AU - Giri, V. N. DB - Medline DO - 10.1007/s13187-015-0854-8 IS - 1 KW - adult aged early cancer diagnosis education ethnic group follow up human learning male middle aged patient care patient education patient selection prognosis program evaluation prostate tumor psychology risk assessment vulnerable population LA - English M3 - Article N1 - L615130146 2017-04-07 PY - 2016 SN - 1543-0154 SP - 191-197 ST - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615130146&from=export http://dx.doi.org/10.1007/s13187-015-0854-8 VL - 31 ID - 980 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To describe the process of planning a theory-based support group project for African American women with breast cancer. DATA SOURCES: A needs assessment and recruitment strategies consistent with the Oncology Nursing Society's Multicultural Outcomes: Guidelines for Cultural Competence were used to adapt a support group intervention for newly diagnosed African American women in urban central Texas. DATA SYNTHESIS: The reviewed literature and local cancer survivor leaders indicated the need for education and support of newly diagnosed women. Although researchers worked for several years with lay leaders to gain legitimacy and trust, not enough participants were recruited to test an intervention specifically for African American women.CONCLUSIONS: Recruiting support group research participants from a relatively small minority population is problematic even when collaborating with population leaders. IMPLICATIONS FOR NURSING: Nurses may encounter barriers to conducting research in minority populations. Starting early to build credibility with that population, being flexible with eligibility criteria, beginning with pre-experimental studies, and paying participants may be required. AD - D.D. Coward, School of Nursing, University of Texas, Austin, TX, USA. AU - Coward, D. D. DB - Medline IS - 2 KW - adult African American article breast tumor cultural factor ethnology female human intervention study needs assessment nurse attitude nursing patient advocacy program development psychological aspect public relations self help LA - English M3 - Article N1 - L41877647 2006-04-20 PY - 2005 SN - 1538-0688 SP - 261-266 ST - Lessons learned in developing a support intervention for African American women with breast cancer T2 - Oncology nursing forum TI - Lessons learned in developing a support intervention for African American women with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41877647&from=export VL - 32 ID - 1270 ER - TY - JOUR AB - PURPOSE/OBJECTIVES: To describe the process of planning a theory-based support group project for African American women with breast cancer. DATA SOURCES: A needs assessment and recruitment strategies consistent with the Oncology Nursing Society's Multicultural Outcomes: Guidelines for Cultural Competence were used to adapt a support group intervention for newly diagnosed African American women in urban central Texas. DATA SYNTHESIS: The reviewed literature and local cancer survivor leaders indicated the need for education and support of newly diagnosed women. Although researchers worked for several years with lay leaders to gain legitimacy and trust, not enough participants were recruited to test an intervention specifically for African American women.CONCLUSIONS: Recruiting support group research participants from a relatively small minority population is problematic even when collaborating with population leaders. IMPLICATIONS FOR NURSING: Nurses may encounter barriers to conducting research in minority populations. Starting early to build credibility with that population, being flexible with eligibility criteria, beginning with pre-experimental studies, and paying participants may be required. AD - Associate Professor, School of Nursing, University of Texas at Austin; dcoward@mail.utexas.edu AN - 106606012. Language: English. Entry Date: 20050415. Revision Date: 20150819. Publication Type: Journal Article. Journal Subset: Core Nursing AU - Coward, D. D. DB - CINAHL Complete DO - 10.1188/05.ONF.261-266 DP - EBSCOhost IS - 2 KW - Black Persons Breast Neoplasms Nursing Practice, Theory-Based Oncologic Nursing Support Groups Information Needs -- Evaluation Needs Assessment Patient Education Planning Techniques Research Subject Recruitment Texas Urban Areas N1 - Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 7809033. PMID: NLM15759064. PY - 2005 SN - 0190-535X SP - 261-266 ST - Lessons learned in developing a support intervention for African American women with breast cancer T2 - Oncology Nursing Forum TI - Lessons learned in developing a support intervention for African American women with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106606012&site=ehost-live&scope=site VL - 32 ID - 1992 ER - TY - JOUR AB - Purpose/Objectives: To describe the process of planning a theory-based support group project for African American women with breast cancer. Data Sources: A needs assessment and recruitment strategies consistent with the Oncology Nursing Society's Multicultural Outcomes: Guidelines for Cultural Competence were used to adapt a support group intervention for newly diagnosed African American women in urban central Texas. Data Synthesis: The reviewed literature and local cancer survivor leaders indicated the need for education and support of newly diagnosed women. Although researchers worked for several years with Jay leaders to gain legitimacy and trust, not enough participants were recruited to test an intervention specifically for African American women. Conclusions: Recruiting support group research participants from a relatively small minority population is problematic even when collaborating with population leaders. Implications for Nursing: Nurses may encounter barriers to conducting research in minority populations. Starting early to build credibility with that population, being flexible with eligibility criteria, beginning with pre-experimental studies, and paying participants may be required. AN - WOS:000227752400009 AU - Coward, D. D. DA - Mar DO - 10.1188/05.ONF.261-266 IS - 2 N1 - 11 15759064 PY - 2005 SN - 0190-535X SP - 261-266 ST - Lessons learned in developing a support intervention for African American women with breast cancer T2 - Oncology Nursing Forum TI - Lessons learned in developing a support intervention for African American women with breast cancer VL - 32 ID - 2665 ER - TY - JOUR AB - In a randomized, double‐blind trial for metastatic prostate cancer (Stage D2), 603 men received leuprolide, a gonadotropin‐releasing hormone analog that inhibits the release of gonadotropins, coupled with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. The 303 men receiving androgen blockade with leuprolide and flutamide demonstrated a longer progression‐free survival (16.9 vs. 13.9 months, P = 0.039) and an increased median length of survival (35.0 vs. 27.9 months, P = 0.035). In the subgroup of men with minimal disease and good performance status, the advantages of maximal androgen blockade were more pronounced. It is concluded that combined androgen blockade with leuprolide and flutamide was more effective than leuprolide alone for patients with metastatic cancer of the prostate. The therapeutic benefits, although greatest in patients with minimum disease, need to be evaluated in a prospective, randomized fashion in trials specifically designed for men with minimal disease and good performance status. Exploratory analyses using the black race as an explanatory variable were also performed. Black race is associated with shorter survival times and is also associated with other prognostic factors, including recent weight loss, anemia, elevated phosphatase levels, and pain. These findings suggest the need for future studies of the relationship of black race and response to prostate cancer therapy. AN - CN-00069928 AU - Crawford, E. D. AU - Blumenstein, B. A. AU - Goodman, P. J. AU - Davis, M. A. AU - Eisenberger, M. A. AU - McLeod, D. G. AU - Spaulding, J. T. AU - Benson, R. AU - Dorr, F. A. DO - 10.1002/cncr.1990.66.s5.1039 IS - 5 Suppl KW - Adult African Continental Ancestry Group Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use] Double‐Blind Method Flutamide [administration & dosage] Gonadotropin‐Releasing Hormone [administration & dosage, *analogs & derivatives] Humans Leuprolide Male Middle Aged Neoplasm Staging Prostatic Neoplasms [*drug therapy, ethnology, mortality, pathology] Randomized Controlled Trials as Topic Survival Rate M3 - Clinical Trial; Journal Article; Randomized Controlled Trial PY - 1990 SP - 1039‐1044 ST - Leuprolide with and without flutamide in advanced prostate cancer T2 - Cancer TI - Leuprolide with and without flutamide in advanced prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00069928/full VL - 66 ID - 1414 ER - TY - JOUR AB - Colorectal cancer frustrates with high relapse after the traditional treatment including surgery and chemotherapy. Neoantigen-based therapeutic vaccine has achieved high response rate in the clinical trials rising the immunotherapy as a promising alternative for colorectal cancer. Herein, colon cancer cells derived neoantigen peptide Adpgk were employed to be co-encapsulated with black phosphorus quantum dots into liposome (Adpgk-BPQDs-liposome) as therapeutic vaccine. Adpgk-BPQDs-liposome were dispersed in F127 gel containing GM-CSF. The heat generated by black phosphorus (BP) under 808 nm near-infrared laser irradiation accelerates the F127 gel ablation and the release of GM-CSF, which recruit APC cells and prime the native T cells. The tumor bearing mice received the programmed cell death protein 1 (PD-1) checkpoint blockade antibody combined with photo-thermal gel intensively prevented the tumor progress. Furthermore, the tumor infiltrating CD8(+) T cells were significantly increased which lead to the elimination of the tumor. AN - WOS:000608371300001 AU - Zhang, J. X. AU - Chen, X. L. AU - Xue, T. Y. AU - Cheng, Q. Z. AU - Ye, X. Y. AU - Wang, C. S. AU - Yu, Y. K. AU - Ji, X. Y. AU - Wu, M. Y. AU - Zhang, X. D. AU - Zheng, Y. AU - Wu, B. Q. AU - Liang, X. AU - Mei, L. DA - Sep DO - 10.1166/jbn.2020.2977 IS - 9 N1 - 33419493 PY - 2020 SN - 1550-7033 SP - 1394-1405 ST - Liposomes Encapsulating Neoantigens and Black Phosphorus Quantum Dots for Enhancing Photothermal Immunotherapy T2 - Journal of Biomedical Nanotechnology TI - Liposomes Encapsulating Neoantigens and Black Phosphorus Quantum Dots for Enhancing Photothermal Immunotherapy VL - 16 ID - 2766 ER - TY - JOUR AB - Purpose: Weekly paclitaxel, concurrent radiation, and androgen deprivation (ADT) were evaluated in patients with high‐risk prostate cancer (PC) with or without prior prostatectomy (RP). Methods and Materials: Eligible post‐RP patients included: pathological T3 disease, or rising prostate‐specific antigen (PSA) >0.5 ng/mL post‐RP. Eligible locally advanced PC (LAPC) patients included: 1) cT2b‐4N0N+, M0; 2) Gleason score (GS) 8‐10; 3) GS 7 + PSA 10‐20 ng/mL; or 4) PSA 20‐150 ng/mL. Treatment included ADT (4 or 24 months), weekly paclitaxel (40, 50, or 60 mg/m2/wk), and pelvic radiation therapy (total dose: RP = 64.8 Gy; LAPC = 70.2 Gy). Results: Fifty‐nine patients were enrolled (LAPC, n = 29; RP, n = 30; ADT 4 months, n = 29; 24 months, n = 30; whites n = 29, African Americans [AA], n = 28). Baseline characteristics (median [range]) were: age 67 (45‐86 years), PSA 5.9 (0.1‐92.1 ng/mL), GS 8 (6‐9). At escalating doses of paclitaxel, 99%, 98%, and 95% of doses were given with radiation and ADT, respectively, with dose modifications required primarily in RP patients. No acute Grade 4 toxicities occurred. Grade 3 toxicities were diarrhea 15%, urinary urgency/incontinence 10%, tenesmus 5%, and leukopenia 3%. Median follow‐up was 75.3 months (95% CI: 66.8‐82.3). Biochemical progression occurred in 24 (41%) patients and clinical progression in 11 (19%) patients. The 5‐ and 7‐year OS rates were 83% and 67%. There were no differences in OS between RP and LAPC, 4‐ and 24‐month ADT, white and AA patient categories. Conclusions: In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high‐risk RP patients. With a median follow‐up of 75.3 months, this trial also represents the longest follow‐up of patients treated with taxane‐based chemotherapy with EBRT in high‐risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m2/week in RP patients and 60 mg/m2/week in LAPC patients is feasible and well‐tolerated. Copyright 2012 Elsevier Inc. Printed in the USA. All rights reserved. AN - CN-00901466 AU - Hussain, A. AU - Wu, Y. AU - Mirmiran, A. AU - Dibiase, S. AU - Goloubeva, O. AU - Bridges, B. AU - Mannuel, H. AU - Engstrom, C. AU - Dawson, N. AU - Amin, P. AU - et al. DO - 10.1016/j.ijrobp.2010.09.009 IS - 1 KW - *androgen deprivation therapy *cancer chemotherapy *cancer hormone therapy *cancer radiotherapy *chemoradiotherapy *gonadorelin agonist/ae [Adverse Drug Reaction] *gonadorelin agonist/cb [Drug Combination] *gonadorelin agonist/ct [Clinical Trial] *gonadorelin agonist/dt [Drug Therapy] *multimodality cancer therapy *paclitaxel/ae [Adverse Drug Reaction] *paclitaxel/cb [Drug Combination] *paclitaxel/ct [Clinical Trial] *paclitaxel/dt [Drug Therapy] *prostate cancer/dt [Drug Therapy] *prostate cancer/rt [Radiotherapy] *prostate cancer/su [Surgery] *prostatectomy Adult African American Aged Alopecia/co [Complication] Alopecia/si [Side Effect] Anemia/co [Complication] Anemia/si [Side Effect] Antibiotic therapy Arthralgia/co [Complication] Arthralgia/si [Side Effect] Article Cancer growth Cancer patient Cancer survival Clostridium difficile infection/dt [Drug Therapy] Clostridium difficile infection/si [Side Effect] Computer assisted radiotherapy Constipation/co [Complication] Constipation/si [Side Effect] Controlled clinical trial Controlled study Deep vein thrombosis/co [Complication] Deep vein thrombosis/si [Side Effect] Dehydration/co [Complication] Dehydration/si [Side Effect] Diarrhea/co [Complication] Diarrhea/si [Side Effect] Drug dose escalation Drug dose reduction Drug fever/si [Side Effect] Edema/co [Complication] Edema/si [Side Effect] Erectile dysfunction/co [Complication] Erectile dysfunction/si [Side Effect] External beam radiotherapy Fatigue/co [Complication] Fatigue/si [Side Effect] Fever/co [Complication] Follow up Gastrointestinal reflux/co [Complication] Gastrointestinal reflux/si [Side Effect] Gastrointestinal symptom/si [Side Effect] Gleason score Gynecomastia/co [Complication] Gynecomastia/si [Side Effect] Hematochezia/co [Complication] Hematochezia/si [Side Effect] Hematuria/si [Side Effect] High risk patient Hot flush/co [Complication] Hot flush/si [Side Effect] Human Infection/co [Complication] Infection/si [Side Effect] Leukopenia/co [Complication] Leukopenia/si [Side Effect] Long term care Major clinical study Male Metronidazole/dt [Drug Therapy] Metronidazole/po [Oral Drug Administration] Myalgia/co [Complication] Myalgia/si [Side Effect] Nausea/si [Side Effect] Neuropathy/co [Complication] Neuropathy/si [Side Effect] Neutropenia/co [Complication] Neutropenia/si [Side Effect] Overall survival Partial body radiation Pelvis Phase 1 clinical trial Priority journal Proctitis/si [Side Effect] Prostate specific antigen/ec [Endogenous Compound] Radiation dermatitis/co [Complication] Radiation dose Radiation dose fractionation Radiation sickness/co [Complication] Tenesmus/co [Complication] Tenesmus/si [Side Effect] Thrombocytopenia/co [Complication] Thrombocytopenia/si [Side Effect] Urinary tract obstruction/co [Complication] Urinary tract obstruction/si [Side Effect] Urinary urgency/co [Complication] Urinary urgency/si [Side Effect] Urine incontinence/co [Complication] Urine incontinence/si [Side Effect] Urogenital tract disease/si [Side Effect] M3 - Journal: Article PY - 2012 SP - 167‐174 ST - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy T2 - International journal of radiation oncology biology physics TI - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00901466/full VL - 82 ID - 1515 ER - TY - JOUR AB - Purpose: Weekly paclitaxel, concurrent radiation, and androgen deprivation (ADT) were evaluated in patients with high-risk prostate cancer (PC) with or without prior prostatectomy (RP). Methods and Materials: Eligible post-RP patients included: pathological T3 disease, or rising prostate-specific antigen (PSA) ≥0.5 ng/mL post-RP. Eligible locally advanced PC (LAPC) patients included: 1) cT2b-4N0N+, M0; 2) Gleason score (GS) 8-10; 3) GS 7 + PSA 10-20 ng/mL; or 4) PSA 20-150 ng/mL. Treatment included ADT (4 or 24 months), weekly paclitaxel (40, 50, or 60 mg/m2/wk), and pelvic radiation therapy (total dose: RP = 64.8 Gy; LAPC = 70.2 Gy). Results: Fifty-nine patients were enrolled (LAPC, n = 29; RP, n = 30; ADT 4 months, n = 29; 24 months, n = 30; whites n = 29, African Americans [AA], n = 28). Baseline characteristics (median [range]) were: age 67 (45-86 years), PSA 5.9 (0.1-92.1 ng/mL), GS 8 (6-9). At escalating doses of paclitaxel, 99%, 98%, and 95% of doses were given with radiation and ADT, respectively, with dose modifications required primarily in RP patients. No acute Grade 4 toxicities occurred. Grade 3 toxicities were diarrhea 15%, urinary urgency/incontinence 10%, tenesmus 5%, and leukopenia 3%. Median follow-up was 75.3 months (95% CI: 66.8-82.3). Biochemical progression occurred in 24 (41%) patients and clinical progression in 11 (19%) patients. The 5- and 7-year OS rates were 83% and 67%. There were no differences in OS between RP and LAPC, 4- and 24-month ADT, white and AA patient categories. Conclusions: In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high-risk RP patients. With a median follow-up of 75.3 months, this trial also represents the longest follow-up of patients treated with taxane-based chemotherapy with EBRT in high-risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m2/week in RP patients and 60 mg/m2/week in LAPC patients is feasible and well-tolerated. Copyright © 2012 Elsevier Inc. Printed in the USA. All rights reserved. AD - A. Hussain, Department of Medicine, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD 21201, United States AU - Hussain, A. AU - Wu, Y. AU - Mirmiran, A. AU - Dibiase, S. AU - Goloubeva, O. AU - Bridges, B. AU - Mannuel, H. AU - Engstrom, C. AU - Dawson, N. AU - Amin, P. AU - Kwok, Y. DB - Embase Medline DO - 10.1016/j.ijrobp.2010.09.009 IS - 1 KW - gonadorelin agonist metronidazole paclitaxel prostate specific antigen adult African American aged alopecia androgen deprivation therapy anemia antibiotic therapy arthralgia article cancer chemotherapy cancer growth cancer hormone therapy cancer patient cancer radiotherapy cancer survival chemoradiotherapy Clostridium difficile infection computer assisted radiotherapy constipation controlled clinical trial controlled study deep vein thrombosis dehydration diarrhea drug dose escalation drug dose reduction drug fever edema erectile dysfunction external beam radiotherapy fatigue fever follow up gastrointestinal reflux gastrointestinal symptom Gleason score gynecomastia rectum hemorrhage hematuria high risk patient hot flush human infection leukopenia long term care major clinical study male multimodality cancer therapy myalgia nausea neuropathy neutropenia overall survival partial body radiation pelvis phase 1 clinical trial priority journal proctitis prostate cancer prostatectomy radiation dermatitis radiation dose radiation dose fractionation radiation sickness tenesmus thrombocytopenia urinary tract obstruction urinary urgency urine incontinence urogenital tract disease LA - English M3 - Article N1 - L51132310 2011-12-27 2011-12-30 PY - 2012 SN - 0360-3016 1879-355X SP - 167-174 ST - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy T2 - International Journal of Radiation Oncology Biology Physics TI - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51132310&from=export http://dx.doi.org/10.1016/j.ijrobp.2010.09.009 VL - 82 ID - 1127 ER - TY - JOUR AB - Purpose: Weekly paclitaxel, concurrent radiation, and androgen deprivation (ADT) were evaluated in patients with high-risk prostate cancer (PC) with or without prior prostatectomy (RP). Methods and Materials: Eligible post-RP patients included: pathological T3 disease, or rising prostate-specific antigen (PSA) ≥0.5 ng/mL post-RP. Eligible locally advanced PC (LAPC) patients included: 1) cT2b-4N0N+, M0; 2) Gleason score (GS) 8-10; 3) GS 7 + PSA 10-20 ng/mL; or 4) PSA 20-150 ng/mL. Treatment included ADT (4 or 24 months), weekly paclitaxel (40, 50, or 60 mg/m 2/wk), and pelvic radiation therapy (total dose: RP = 64.8 Gy; LAPC = 70.2 Gy). Results: Fifty-nine patients were enrolled (LAPC, n = 29; RP, n = 30; ADT 4 months, n = 29; 24 months, n = 30; whites n = 29, African Americans [AA], n = 28). Baseline characteristics (median [range]) were: age 67 (45-86 years), PSA 5.9 (0.1-92.1 ng/mL), GS 8 (6-9). At escalating doses of paclitaxel, 99%, 98%, and 95% of doses were given with radiation and ADT, respectively, with dose modifications required primarily in RP patients. No acute Grade 4 toxicities occurred. Grade 3 toxicities were diarrhea 15%, urinary urgency/incontinence 10%, tenesmus 5%, and leukopenia 3%. Median follow-up was 75.3 months (95% CI: 66.8-82.3). Biochemical progression occurred in 24 (41%) patients and clinical progression in 11 (19%) patients. The 5- and 7-year OS rates were 83% and 67%. There were no differences in OS between RP and LAPC, 4- and 24-month ADT, white and AA patient categories. Conclusions: In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high-risk RP patients. With a median follow-up of 75.3 months, this trial also represents the longest follow-up of patients treated with taxane-based chemotherapy with EBRT in high-risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m 2/week in RP patients and 60 mg/m 2/week in LAPC patients is feasible and well-tolerated. Copyright © 2012 Elsevier Inc. Printed in the USA. All rights reserved. AD - University of Maryland Greenebaum Cancer Center, Baltimore, MD, United States Department of Medicine, University of Maryland School of Medicine, 22 S. Greene St., Baltimore, MD 21201, United States Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States Baltimore VA Medical Center, Baltimore, MD, United States Cooper University Hospital, Camden, NJ, United States Lombardi Cancer Center, Georgetown University, Washington, DC, United States AU - Hussain, A. AU - Wu, Y. AU - Mirmiran, A. AU - Dibiase, S. AU - Goloubeva, O. AU - Bridges, B. AU - Mannuel, H. AU - Engstrom, C. AU - Dawson, N. AU - Amin, P. AU - Kwok, Y. DB - Scopus DO - 10.1016/j.ijrobp.2010.09.009 IS - 1 KW - Concurrent chemoradiation High-risk prostate cancer Multimodality therapy Post-prostatectomy radiation M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 2012 SP - 167-174 ST - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy T2 - International Journal of Radiation Oncology Biology Physics TI - Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-83955165998&doi=10.1016%2fj.ijrobp.2010.09.009&partnerID=40&md5=158bfc24f1876f14b09c7709bc35d0af VL - 82 ID - 2467 ER - TY - JOUR AB - Purpose: Weekly paclitaxel, concurrent radiation, and androgen deprivation (ADT) were evaluated in patients with high-risk prostate cancer (PC) with or without prior prostatectomy (RP). Methods and Materials: Eligible post-RP patients included: pathological T3 disease, or rising prostate-specific antigen (PSA) >= 0.5 ng/mL post-RP. Eligible locally advanced PC (LAPC) patients included: 1) cT2b-4NON+, MO; 2) Gleason score (GS) 8-10; 3) GS 7 + PSA 10-20 ng/mL; or 4) PSA 20-150 ng/mL. Treatment included ADT (4 or 24 months), weekly paclitaxel (40, 50, or 60 mg/m(2)/wk), and pelvic radiation therapy (total dose: RP = 64.8 Gy; LAPC = 70.2 Gy). Results: Fifty-nine patients were enrolled (LAPC, n = 29; RP, n = 30; ADT 4 months, n = 29; 24 months, n = 30; whites n = 29, African Americans [AA], n = 28). Baseline characteristics (median [range]) were: age 67 (45-86 years), PSA 5.9 (0.1-92.1 ng/mL), GS 8 (6-9). At escalating doses of paclitaxel, 99%, 98%, and 95% of doses were given with radiation and ADT, respectively, with dose modifications required primarily in RP patients. No acute Grade 4 toxicities occurred. Grade 3 toxicities were diarrhea 15%, urinary urgency/incontinence 10%, tenesmus 5%, and leukopenia 3%. Median follow-up was 75.3 months (95% CI: 66.8-82.3). Biochemical progression occurred in 24 (41%) patients and clinical progression in 11 (19%) patients. The 5- and 7-year OS rates were 83% and 67%. There were no differences in OS between RP and LAPC, 4- and 24-month ADT, white and AA patient categories. Conclusions: In addition to LAPC, to our knowledge, this is the first study to evaluate concurrent chemoradiation with ADT in high-risk RP patients. With a median follow-up of 75.3 months, this trial also represents the longest follow-up of patients treated with taxane-based chemotherapy with EBRT in high-risk prostate cancer. Concurrent ADT, radiation, and weekly paclitaxel at 40 mg/m(2)/week in RP patients and 60 mg/m(2)/week in LAPC patients is feasible and well-tolerated. (C) 2012 Elsevier Inc. AN - WOS:000298526100026 AU - Hussain, A. AU - Wu, Y. AU - Mirmiran, A. AU - DiBiase, S. AU - Goloubeva, O. AU - Bridges, B. AU - Mannuel, H. AU - Engstrom, C. AU - Dawson, N. AU - Amin, P. AU - Kwok, Y. DA - Jan DO - 10.1016/j.ijrobp.2010.09.009 IS - 1 N1 - 21036487 PY - 2012 SN - 0360-3016 SP - 167-174 ST - Long-Term Follow-up of a Prospective Trial of Trimodality Therapy of Weekly Paclitaxel, Radiation, and Androgen Deprivation in High-Risk Prostate Cancer with or without Prior Prostatectomy T2 - International Journal of Radiation Oncology Biology Physics TI - Long-Term Follow-up of a Prospective Trial of Trimodality Therapy of Weekly Paclitaxel, Radiation, and Androgen Deprivation in High-Risk Prostate Cancer with or without Prior Prostatectomy VL - 82 ID - 3078 ER - TY - JOUR AB - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT. AD - J.R. Sly, Memorial Sloan Kettering Cancer Center, New York, NY, United States AU - Sly, J. R. AU - Miller, S. J. AU - Li, Y. AU - Bolutayo, K. AU - Jandorf, L. DB - Embase Medline DO - 10.1080/07347332.2018.1499693 IS - 6 KW - electronic cigarette nicotine gum nicotine patch adult African American article cancer screening clinical article comparative study computer assisted tomography feasibility study female human longitudinal study lung cancer male middle aged radiation dose self concept smoking smoking cessation thorax radiography tobacco dependence LA - English M3 - Article N1 - L627111162 2019-04-11 2019-04-15 PY - 2018 SN - 1540-7586 0734-7332 SP - 784-792 ST - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study T2 - Journal of Psychosocial Oncology TI - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627111162&from=export http://dx.doi.org/10.1080/07347332.2018.1499693 VL - 36 ID - 875 ER - TY - JOUR AB - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Sly, Jamilia R., Memorial Sloan Kettering Cancer Center, New York, NY, US AN - 2018-48254-001 AU - Sly, Jamilia R. AU - Miller, Sarah J. AU - Li, Yaqi AU - Bolutayo, Kemi AU - Jandorf, Lina DB - psyh DO - 10.1080/07347332.2018.1499693 DP - EBSCOhost IS - 6 KW - African Americans cancer prevention lung cancer screening smoking cessation teachable moment Aged Early Detection of Cancer Feasibility Studies Female Humans Intention Lung Neoplasms Male Middle Aged Self Efficacy Smokers Surveys and Questionnaires Tomography, X-Ray Computed Blacks Cancer Screening Tomography Lung N1 - Icahn School of Medicine at Mount Sinai, New York, NY, US. Other Publishers: Haworth Press. Release Date: 20180927. Correction Date: 20200604. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Smoking Cessation; Tomography. Minor Descriptor: Lung. Classification: Drug & Alcohol Rehabilitation (3383). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Smoking Abstinence Self-efficacy Questionnaire DOI: 10.1037/t32110-000. Methodology: Empirical Study; Longitudinal Study; Interview; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Nov-Dec, 2018. Copyright Statement: Taylor & Francis Group, LLC. 2018. PY - 2018 SN - 0734-7332 1540-7586 SP - 784-792 ST - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study T2 - Journal of Psychosocial Oncology TI - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-48254-001&site=ehost-live&scope=site ORCID: 0000-0002-0504-0728 Jamilia.Sly@mssm.edu VL - 36 ID - 1678 ER - TY - JOUR AB - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT. AD - Icahn School of Medicine at Mount Sinai, New York, New York, USA Memorial Sloan Kettering Cancer Center, New York, New York, USA AN - 135800443. Language: English. Entry Date: 20190412. Revision Date: 20190417. Publication Type: Article AU - Sly, Jamilia R. AU - Miller, Sarah J. AU - Li, Yaqi AU - Bolutayo, Kemi AU - Jandorf, Lina DB - CINAHL Complete DO - 10.1080/07347332.2018.1499693 DP - EBSCOhost IS - 6 KW - Tomography, X-Ray Computed -- Methods Lung Neoplasms Cancer Screening Smoking Cessation Black Persons Patient Education Human Prospective Studies Pilot Studies Questionnaires Self-Efficacy N1 - research; tables/charts. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309337. PY - 2018 SN - 0734-7332 SP - 784-792 ST - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study T2 - Journal of Psychosocial Oncology TI - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135800443&site=ehost-live&scope=site VL - 36 ID - 1994 ER - TY - JOUR AB - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT. © 2018, © 2018 Taylor & Francis Group, LLC. AD - Icahn School of Medicine at Mount Sinai, New York, NY, United States Memorial Sloan Kettering Cancer Center, New York, NY, United States AU - Sly, J. R. AU - Miller, S. J. AU - Li, Y. AU - Bolutayo, K. AU - Jandorf, L. DB - Scopus DO - 10.1080/07347332.2018.1499693 IS - 6 KW - African Americans cancer prevention lung cancer screening smoking cessation teachable moment M3 - Article N1 - Export Date: 22 March 2021 PY - 2018 SP - 784-792 ST - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study T2 - Journal of Psychosocial Oncology TI - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063940089&doi=10.1080%2f07347332.2018.1499693&partnerID=40&md5=ded3438548fd94425297d364e40bc18b VL - 36 ID - 2251 ER - TY - JOUR AB - Low-dose computed tomography (LDCT) screening may be a teachable moment for smoking cessation among African Americans. African Americans have been understudied within the context of LDCT and smoking cessation. The study objective was to evaluate the feasibility of recruiting African Americans to a future longitudinal trial and to obtain sample size estimates for that trial. Participants (N = 18) were African Americans eligible for LDCT screening who completed a questionnaire at three time points. Self-efficacy and intention to quit smoking were compared. The results of the current study show that it is feasible to recruit African Americans eligible for LDCT. AN - WOS:000463590500008 AU - Sly, J. R. AU - Miller, S. J. AU - Li, Y. Q. AU - Bolutayo, K. AU - Jandorf, L. DA - Nov DO - 10.1080/07347332.2018.1499693 IS - 6 N1 - 30252615 PY - 2018 SN - 0734-7332 SP - 784-792 ST - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study T2 - Journal of Psychosocial Oncology TI - Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study VL - 36 ID - 2841 ER - TY - JOUR AB - Background Various methods are reported as aids to cecal intubation for cases in which colonoscopy is difficult. This study aimed to investigate prospectively whether a gastroscope with magnification function, narrow-band imaging (NBI), and a soft black hood can aid insertion in cases of difficult colonoscopy and facilitate both accurate diagnosis and safe treatment. Methods This prospective study recruited 177 patients. All were examined with a magnifying gastroscope. A commercially available soft black hood was attached to the gastroscope during insertion and magnification. Difficult colonoscopy was anticipated before colonoscopy in cases of patients with at least one of the following factors: low BMI (<20 kg/m2), adhesion due to previous surgery, or previous colonoscopy that could not reach to the cecum. The success rate and duration of cecal intubation then were assessed. All detected lesions were evaluated by magnifying NBI and then classified as non-neoplastic or neoplastic for endoscopic diagnosis. Subsequently, all the lesions were removed and examined histologically for comparison. Results The overall success rate of cecal intubation was 100% (177/177), and the mean time taken to reach the cecum was 5.9 min. A total of 156 lesions were detected endoscopically, and the overall diagnostic accuracy of NBI with magnification was 98.7%. No associated complications occurred. Conclusion Magnifying gastroscopy using a soft black hood and NBI is useful for cecal intubation in cases wherein colonoscopy is difficult, facilitating accurate diagnosis and safe treatment. © 2011 Springer Science+Business Media, LLC. AD - K. Fu, Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Nerima-takanodai, Nerima, Tokyo 177-0033, Japan AU - Nakamura, H. AU - Fu, K. AU - Yamamura, A. DB - Embase Medline DO - 10.1007/s00464-011-1662-9 IS - 9 KW - adult aged article body mass carcinoid clinical effectiveness clinical evaluation colon adenoma colon cancer colon polyp colonoscopy controlled clinical trial controlled study diagnostic accuracy digestive tract intubation disease association disease classification female gastroscopy histopathology human human tissue major clinical study male medical device narrow band imaging outcome assessment patient safety predictive value priority journal sensitivity and specificity LA - English M3 - Article N1 - L51374133 2011-04-15 2018-10-30 PY - 2011 SN - 1432-2218 0930-2794 SP - 3016-3021 ST - Magnifying gastroscopy using a soft black hood for difficult colonoscopy T2 - Surgical Endoscopy TI - Magnifying gastroscopy using a soft black hood for difficult colonoscopy UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51374133&from=export http://dx.doi.org/10.1007/s00464-011-1662-9 VL - 25 ID - 1150 ER - TY - JOUR AB - Background Various methods are reported as aids to cecal intubation for cases in which colonoscopy is difficult. This study aimed to investigate prospectively whether a gastroscope with magnification function, narrow-band imaging (NBI), and a soft black hood can aid insertion in cases of difficult colonoscopy and facilitate both accurate diagnosis and safe treatment. Methods This prospective study recruited 177 patients. All were examined with a magnifying gastroscope. A commercially available soft black hood was attached to the gastroscope during insertion and magnification. Difficult colonoscopy was anticipated before colonoscopy in cases of patients with at least one of the following factors: low BMI (<20 kg/m2), adhesion due to previous surgery, or previous colonoscopy that could not reach to the cecum. The success rate and duration of cecal intubation then were assessed. All detected lesions were evaluated by magnifying NBI and then classified as non-neoplastic or neoplastic for endoscopic diagnosis. Subsequently, all the lesions were removed and examined histologically for comparison. Results The overall success rate of cecal intubation was 100% (177/177), and the mean time taken to reach the cecum was 5.9 min. A total of 156 lesions were detected endoscopically, and the overall diagnostic accuracy of NBI with magnification was 98.7%. No associated complications occurred. Conclusion Magnifying gastroscopy using a soft black hood and NBI is useful for cecal intubation in cases wherein colonoscopy is difficult, facilitating accurate diagnosis and safe treatment. © 2011 Springer Science+Business Media, LLC. AD - Department of Gastroenterology, Chofu Surgical Clinic, Tokyo, Japan Department of Gastroenterology, Juntendo University Nerima Hospital, 3-1-10 Nerima-takanodai, Nerima, Tokyo 177-0033, Japan Department of Pathology, Tokyo Metropolitan Cancer Detection Center, Tokyo, Japan AU - Nakamura, H. AU - Fu, K. AU - Yamamura, A. DB - Scopus DO - 10.1007/s00464-011-1662-9 IS - 9 KW - Cap-or hood-assisted colonoscopy Cecal intubation Difficult colonoscopy Magnifying gastroscopy Narrow-band imaging M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2011 SP - 3016-3021 ST - Magnifying gastroscopy using a soft black hood for difficult colonoscopy T2 - Surgical Endoscopy TI - Magnifying gastroscopy using a soft black hood for difficult colonoscopy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80055100950&doi=10.1007%2fs00464-011-1662-9&partnerID=40&md5=a8c34720119cb4f17624aa917c950b1a VL - 25 ID - 2488 ER - TY - JOUR AB - Background: Various methods are reported as aids to cecal intubation for cases in which colonoscopy is difficult. This study aimed to investigate prospectively whether a gastroscope with magnification function, narrow-band imaging (NBI), and a soft black hood can aid insertion in cases of difficult colonoscopy and facilitate both accurate diagnosis and safe treatment.Methods: This prospective study recruited 177 patients. All were examined with a magnifying gastroscope. A commercially available soft black hood was attached to the gastroscope during insertion and magnification. Difficult colonoscopy was anticipated before colonoscopy in cases of patients with at least one of the following factors: low BMI (<20 kg/m(2)), adhesion due to previous surgery, or previous colonoscopy that could not reach to the cecum. The success rate and duration of cecal intubation then were assessed. All detected lesions were evaluated by magnifying NBI and then classified as non-neoplastic or neoplastic for endoscopic diagnosis. Subsequently, all the lesions were removed and examined histologically for comparison.Results: The overall success rate of cecal intubation was 100% (177/177), and the mean time taken to reach the cecum was 5.9 min. A total of 156 lesions were detected endoscopically, and the overall diagnostic accuracy of NBI with magnification was 98.7%. No associated complications occurred.Conclusion: Magnifying gastroscopy using a soft black hood and NBI is useful for cecal intubation in cases wherein colonoscopy is difficult, facilitating accurate diagnosis and safe treatment. AD - Department of Gastroenterology, Chofu Surgical Clinic, Tokyo, Japan Department of Gastroenterology, Chofu Surgical Clinic, Tokyo, Japan. AN - 104578292. Language: English. Entry Date: 20120323. Revision Date: 20200708. Publication Type: journal article AU - Nakamura, H. AU - Fu, K. AU - Yamamura, A. AU - Nakamura, Hisashi AU - Fu, Kuangi AU - Yamamura, Akihiko DB - CINAHL Complete DO - 10.1007/s00464-011-1662-9 DP - EBSCOhost IS - 9 KW - Colonoscopy -- Equipment and Supplies Adenocarcinoma -- Diagnosis Adenoma -- Diagnosis Adult Aged Aged, 80 and Over Carcinoid Tumor -- Diagnosis Cecum Colonic Neoplasms -- Diagnosis Colonic Polyps -- Diagnosis Colonoscopy -- Methods Equipment Design Female Human Male Middle Age Prospective Studies Videorecording Young Adult Clinical Trials N1 - clinical trial; research. Journal Subset: Biomedical; Continental Europe; Europe; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8806653. PMID: NLM21487877. PY - 2011 SN - 0930-2794 SP - 3016-3021 ST - Magnifying gastroscopy using a soft black hood for difficult colonoscopy T2 - Surgical Endoscopy TI - Magnifying gastroscopy using a soft black hood for difficult colonoscopy UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104578292&site=ehost-live&scope=site VL - 25 ID - 1995 ER - TY - JOUR AB - Background Various methods are reported as aids to cecal intubation for cases in which colonoscopy is difficult. This study aimed to investigate prospectively whether a gastroscope with magnification function, narrow-band imaging (NBI), and a soft black hood can aid insertion in cases of difficult colonoscopy and facilitate both accurate diagnosis and safe treatment. Methods This prospective study recruited 177 patients. All were examined with a magnifying gastroscope. A commercially available soft black hood was attached to the gastroscope during insertion and magnification. Difficult colonoscopy was anticipated before colonoscopy in cases of patients with at least one of the following factors: low BMI (< 20 kg/m(2)), adhesion due to previous surgery, or previous colonoscopy that could not reach to the cecum. The success rate and duration of cecal intubation then were assessed. All detected lesions were evaluated by magnifying NBI and then classified as non-neoplastic or neoplastic for endoscopic diagnosis. Subsequently, all the lesions were removed and examined histologically for comparison. Results The overall success rate of cecal intubation was 100% (177/177), and the mean time taken to reach the cecum was 5.9 min. A total of 156 lesions were detected endoscopically, and the overall diagnostic accuracy of NBI with magnification was 98.7%. No associated complications occurred. Conclusion Magnifying gastroscopy using a soft black hood and NBI is useful for cecal intubation in cases wherein colonoscopy is difficult, facilitating accurate diagnosis and safe treatment. AN - WOS:000294219800027 AU - Nakamura, H. AU - Fu, K. G. AU - Yamamura, A. DA - Sep DO - 10.1007/s00464-011-1662-9 IS - 9 N1 - 21487877 PY - 2011 SN - 0930-2794 SP - 3016-3021 ST - Magnifying gastroscopy using a soft black hood for difficult colonoscopy T2 - Surgical Endoscopy and Other Interventional Techniques TI - Magnifying gastroscopy using a soft black hood for difficult colonoscopy VL - 25 ID - 3085 ER - TY - JOUR AB - OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high‐vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi‐squared and Kruskal‐Wallis analyses were used to assess between‐group differences at baseline. RESULTS: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty‐six (12%) participants were African‐American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian‐American. There were no significant between‐group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre‐planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. CONCLUSION: The MEAL study shows the feasibility of implementing national, multi‐institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS. AN - CN-01643540 AU - Parsons, J. K. AU - Pierce, J. P. AU - Mohler, J. AU - Paskett, E. AU - Jung, S. H. AU - Morris, M. J. AU - Small, E. AU - Hahn, O. AU - Humphrey, P. AU - Taylor, J. AU - et al. DO - 10.1111/bju.13890 IS - 4 KW - Aged Aged, 80 and over Biopsy Diet [*methods, *statistics & numerical data] Disease Progression Humans Male Middle Aged Prostate‐Specific Antigen [blood] Prostatic Neoplasms [*diet therapy, epidemiology, pathology, *prevention & control] Vegetables M3 - Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2018 SP - 534‐539 ST - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer T2 - BJU international TI - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01643540/full VL - 121 ID - 1468 ER - TY - JOUR AB - Objective: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal–Wallis analyses were used to assess between-group differences at baseline. Results: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. Conclusion: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS. AD - J.K. Parsons, Division of Urologic Oncology, UC San Diego Moores Comprehensive Cancer Center, La Jolla, CA, United States AU - Parsons, J. K. AU - Pierce, J. P. AU - Mohler, J. AU - Paskett, E. AU - Jung, S. H. AU - Morris, M. J. AU - Small, E. AU - Hahn, O. AU - Humphrey, P. AU - Taylor, J. AU - Marshall, J. DB - Embase Medline DO - 10.1111/bju.13890 IS - 4 KW - NCT01238172 adult African American age aged article Asian American cancer control cancer diagnosis cancer epidemiology cancer growth cancer localization cancer screening cancer staging clinical effectiveness controlled study demography diet therapy ethnicity feasibility study geographic distribution Gleason score Hispanic histopathology human human tissue major clinical study male multicenter study patient counseling phase 3 clinical trial priority journal prostate biopsy prostate cancer race randomized controlled trial validity vegetable LA - English M3 - Article N1 - L616363560 2017-05-29 2018-04-16 PY - 2018 SN - 1464-410X 1464-4096 SP - 534-539 ST - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer T2 - BJU International TI - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L616363560&from=export http://dx.doi.org/10.1111/bju.13890 VL - 121 ID - 902 ER - TY - JOUR AB - Objective: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal–Wallis analyses were used to assess between-group differences at baseline. Results: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. Conclusion: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS. © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd AD - Division of Urologic Oncology, UC San Diego Moores Comprehensive Cancer Center, La Jolla, CA, United States Department of Urology, UC San Diego Health System, La Jolla, CA, United States VA San Diego Healthcare System, La Jolla, CA, United States Department of Family Medicine and Public Health and Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States Department of Medicine, College of Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States Alliance Statistics and Data Center, Duke University, Durham, NC, United States Memorial Sloan Kettering Cancer Center, New York, NY, United States UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States Alliance Central Protocol Operations, University of Chicago, Chicago, IL, United States Department of Pathology, Yale University Medical School, New Haven, CT, United States Department of Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, United States AU - Parsons, J. K. AU - Pierce, J. P. AU - Mohler, J. AU - Paskett, E. AU - Jung, S. H. AU - Morris, M. J. AU - Small, E. AU - Hahn, O. AU - Humphrey, P. AU - Taylor, J. AU - Marshall, J. DB - Scopus DO - 10.1111/bju.13890 IS - 4 KW - #PCSM #ProstateCancer active surveillance carotenoids diet outcomes prevention M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2018 SP - 534-539 ST - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer T2 - BJU International TI - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019855963&doi=10.1111%2fbju.13890&partnerID=40&md5=ca3e980a53da64691f9052ca1138e192 VL - 121 ID - 2277 ER - TY - JOUR AB - Objective To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal-Wallis analyses were used to assess between-group differences at baseline. Results Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1)ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. Conclusion The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS. AN - WOS:000428845400009 AU - Parsons, J. K. AU - Pierce, J. P. AU - Mohler, J. AU - Paskett, E. AU - Jung, S. H. AU - Morris, M. J. AU - Small, E. AU - Hahn, O. AU - Humphrey, P. AU - Taylor, J. AU - Marshall, J. DA - Apr DO - 10.1111/bju.13890 IS - 4 N1 - 28437029 PY - 2018 SN - 1464-4096 SP - 534-539 ST - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer T2 - Bju International TI - Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer VL - 121 ID - 2865 ER - TY - JOUR AB - Whether menthol cigarettes confer a higher risk of death than plain cigarettes is not known. The Lung Health Study (LHS) enrolled 5,887 adult smokers in a clinical trial of smoking cessation and ipratropium in the prevention of chronic obstructive pulmonary disease. LHS participants have been subjected to surveillance for mortality from all causes for 14 years. We examined these data for differences between self‐reported smokers of menthol cigarettes versus plain cigarettes. Using proportional hazards regression methods, we found no differences in hazard ratios for coronary heart disease, cardiovascular disease, lung cancer, or death from any cause. Contrary to expectations about nicotine dependence, we found that users of menthol cigarettes had smoked fewer pack‐years at baseline. We found no difference in success at smoking cessation with or without menthol. We conclude that our data contain no evidence that mentholation of cigarettes increases the hazards of smoking. AN - CN-00579280 AU - Murray, R. P. AU - Connett, J. E. AU - Skeans, M. A. AU - Tashkin, D. P. DO - 10.1080/14622200601078418 IS - 1 KW - Adult African Americans [statistics & numerical data] Bronchodilator Agents [therapeutic use] Female Health Behavior Humans Ipratropium [therapeutic use] Lung Diseases [*chemically induced, epidemiology] Male Menthol [*adverse effects] Middle Aged Risk Factors Smoking Cessation [statistics & numerical data] Smoking Prevention Smoking [*epidemiology] Tobacco M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2007 SP - 101‐107 ST - Menthol cigarettes and health risks in Lung Health Study data T2 - Nicotine & tobacco research TI - Menthol cigarettes and health risks in Lung Health Study data UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00579280/full VL - 9 ID - 1427 ER - TY - JOUR AB - Whether menthol cigarettes confer a higher risk of death than plain cigarettes is not known. The Lung Health Study (LHS) enrolled 5,887 adult smokers in a clinical trial of smoking cessation and ipratropium in the prevention of chronic obstructive pulmonary disease. LHS participants have been subjected to surveillance for mortality from all causes for 14 years. We examined these data for differences between self-reported smokers of menthol cigarettes versus plain cigarettes. Using proportional hazards regression methods, we found no differences in hazard ratios for coronary heart disease, cardiovascular disease, lung cancer, or death from any cause. Contrary to expectations about nicotine dependence, we found that users of menthol cigarettes had smoked fewer pack-years at baseline. We found no difference in success at smoking cessation with or without menthol. We conclude that our data contain no evidence that mentholation of cigarettes increases the hazards of smoking. AD - Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada Division of Biostatistics, University of Minnesota, Minneapolis, MN, United States Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States AU - Murray, R. P. AU - Connett, J. E. AU - Skeans, M. A. AU - Tashkin, D. P. DB - Scopus DO - 10.1080/14622200601078418 IS - 1 M3 - Article N1 - Cited By :54 Export Date: 22 March 2021 PY - 2007 SP - 101-107 ST - Menthol cigarettes and health risks in Lung Health Study data T2 - Nicotine and Tobacco Research TI - Menthol cigarettes and health risks in Lung Health Study data UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247882719&doi=10.1080%2f14622200601078418&partnerID=40&md5=3dbc0dff5ab58108701d5793b7047722 VL - 9 ID - 2565 ER - TY - JOUR AB - With the ability to detect Prostate cancer before it has otherwise manifest itself has come a barrage of research, controversy, new data, and now frontiers. One of these frontiers is the nature of the disease in African American men. African Americans hive the greatest incidence of prostate cancer in the United States and also have the highest mortality rates, At the same time, they are underrepresented in large clinical trials, The exploration of these topics is the focus of this article. AN - WOS:000230034900007 AU - French, D. B. AU - Jones, L. A. DA - Jul DO - 10.1016/j.mcna.2005.02.003 IS - 4 N1 - 15925651 PY - 2005 SN - 0025-7125 SP - 805-+ ST - Minority issues in prostate disease T2 - Medical Clinics of North America TI - Minority issues in prostate disease VL - 89 ID - 3240 ER - TY - JOUR AB - PURPOSE: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT). METHODS: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites. RESULTS: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five‐site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site). CONCLUSIONS: We suggest that a long‐term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation. AN - CN-00383725 AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. AU - Ryan, A. M. AU - Hill, M. S. AU - Deantoni, E. AU - et al. DO - 10.1016/s1047-2797(00)00185-x IS - 8 Suppl KW - Aged Continental Population Groups Demography Finasteride [therapeutic use] Humans Life Style [ethnology] Male Middle Aged Minority Groups [*statistics & numerical data] Patient Selection Pilot Projects Placebos Prostatic Neoplasms [*ethnology, *prevention & control] Randomized Controlled Trials as Topic [*statistics & numerical data] M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 2000 SP - S85‐91 ST - Minority recruitment in the prostate cancer prevention trial T2 - Annals of epidemiology TI - Minority recruitment in the prostate cancer prevention trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00383725/full VL - 10 ID - 1393 ER - TY - JOUR AB - PURPOSE: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT). METHODS: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites. RESULTS: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five-site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site). CONCLUSIONS: We suggest that a long term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation. (C) 2000 Elsevier Science Inc. All rights reserved. AN - WOS:000165950000011 AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. AU - Ryan, A. M. AU - Hill, M. S. AU - DeAntoni, E. AU - Gritz, E. R. AU - Thompson, I. M. AU - Coltman, C. A. DA - Nov DO - 10.1016/S1047-2797(00)00185-X IS - 8 N1 - S Workshop on Participation of Minorities and Women in Clinical Cancer Research FEB 26-27, 1999 WASHINGTON, D.C. NCI 55 11189097 PY - 2000 SN - 1047-2797 SP - S85-S91 ST - Minority recruitment in the prostate cancer prevention trial T2 - Annals of Epidemiology TI - Minority recruitment in the prostate cancer prevention trial VL - 10 ID - 2715 ER - TY - JOUR AB - Purpose: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT).Methods: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites.Results: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five-site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site).Conclusions: We suggest that a long-term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation. AD - From the Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA AN - 107005378. Language: English. Entry Date: 20010309. Revision Date: 20191029. Publication Type: journal article AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. AU - Ryan, A. M. AU - Hill, M. S. AU - DeAntoni, E. AU - Gritz, E. R. AU - Thompson, I. M., Jr. AU - Coltman, C. A., Jr. AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. DB - CINAHL Complete DP - EBSCOhost IS - 8 KW - Minority Groups Prostatic Neoplasms -- Prevention and Control Research Subject Recruitment Clinical Trials Funding Source Life Style Male Prostatic Neoplasms -- Epidemiology Human N1 - clinical trial; research; tables/charts. Supplement Title: 2000 Nov Suppl. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: 2 U10 CA37429-09/CA/NCI NIH HHS/United States. NLM UID: 9100013. PMID: NLM11189097. PY - 2000 SN - 1047-2797 SP - S85-91 ST - Minority recruitment in the prostate cancer prevention trial T2 - Annals of Epidemiology TI - Minority recruitment in the prostate cancer prevention trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107005378&site=ehost-live&scope=site VL - 10 ID - 1997 ER - TY - JOUR AB - PURPOSE: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT). METHODS: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites. RESULTS: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five-site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site). CONCLUSIONS: We suggest that a long-term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation. AD - C.M. Moinpour, From the Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. AU - Ryan, A. M. AU - Hill, M. S. AU - Deantoni, E. AU - Gritz, E. R. AU - Thompson Jr, I. M. AU - Coltman Jr, C. A. DB - Medline IS - 8 Suppl KW - finasteride placebo aged article clinical trial controlled clinical trial demography ethnology human lifestyle male middle aged minority group patient selection pilot study prostate tumor race randomized controlled trial statistics LA - English M3 - Article N1 - L33432667 2001-01-19 PY - 2000 SN - 1047-2797 SP - S85-91 ST - Minority recruitment in the prostate cancer prevention trial T2 - Annals of epidemiology TI - Minority recruitment in the prostate cancer prevention trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33432667&from=export VL - 10 ID - 1319 ER - TY - JOUR AB - PURPOSE: African American men have a higher prostate cancer risk profile than that of other men in the United States. The purpose of this manuscript is to summarize the challenges associated with enrolling and randomizing African American and other minority participants in the Prostate Cancer Prevention Trial (PCPT). METHODS: The PCPT is a randomized trial of finasteride versus placebo for preventing prostate cancer in healthy men age 55 years and older; it is coordinated by the Southwest Oncology Group. The manuscript describes demographic and lifestyle characteristics of the PCPT randomized sample (18,882 men) by four racial and ethnic groups (Caucasian, African American, Hispanic, and other). African American men comprised 4% of the total randomized sample compared to our goal of 8%. Minority recruitment was emphasized through the Study Manual and training that occurred at trial activation. Supplemental minority recruitment activities were initiated a year after study activation and continued through the end of the accrual period. Minority recruitment was emphasized as follows: minority recruitment presentations at PCPT training seminars (held during twice yearly Southwest Oncology Group meetings); distribution of additional minority recruitment materials; engagement of four consultants for minority recruitment; production of a Minority Recruitment Manual; and a small pilot study involving minority outreach recruiters at five PCPT sites. RESULTS: The consultants were helpful in implementing the pilot project and in suggesting and reviewing materials for minority recruitment. The five-site pilot project did not increase either enrollment or randomization of minorities (with a possible exception at one site). CONCLUSIONS: We suggest that a long-term perspective is required for successful recruitment of minority participants in clinical trials. Likewise, extensive minority recruitment efforts must be ready to implement at trial activation. AD - From the Southwest Oncology Group Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA. AU - Moinpour, C. M. AU - Atkinson, J. O. AU - Thomas, S. M. AU - Underwood, S. M. AU - Harvey, C. AU - Parzuchowski, J. AU - Lovato, L. C. AU - Ryan, A. M. AU - Hill, M. S. AU - Deantoni, E. AU - Gritz, E. R. AU - Thompson Jr, I. M. AU - Coltman Jr, C. A. DB - Scopus DO - 10.1016/s1047-2797(00)00185-x IS - 8 Suppl M3 - Article N1 - Cited By :60 Export Date: 22 March 2021 PY - 2000 SP - S85-91 ST - Minority recruitment in the prostate cancer prevention trial T2 - Annals of epidemiology TI - Minority recruitment in the prostate cancer prevention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-18044403819&doi=10.1016%2fs1047-2797%2800%2900185-x&partnerID=40&md5=12b603c25d02cd328b500921cbdf7155 VL - 10 ID - 2635 ER - TY - JOUR AB - Background: Previous large chemoprevention studies have not recruited significant numbers of minorities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a large phase III study evaluating the impact of selenium and vitamin E on the clinical incidence of prostate cancer. Over 400 SELECT study sites in the USA, Canada, and Puerto Rico recruited men to this trial. The SELECT recruitment goal was 24% minorities, with 20% black, 3% Hispanic, and 1% Asian participants. The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer. Methods: The minority recruitment strategies in SELECT were to: 1) consider minority recruitment during site selection; 2) expand the eligibility criteria by lowering the age criterion for black men and including men with controlled co-morbid illnesses; 3) develop a national infrastructure; 4) give additional funds to sites with the potential to increase black enrollment; and 5) provide resources to maximize free media opportunities to promote SELECT. Results: SELECT recruitment began in August 2001 and was intended to last five years, but concluded two years ahead of schedule in June 2004. Of the 35 534 participants enrolled, 21% were minorities, with 15% black, 5% Hispanic, and 1% Asian. Conclusions Careful planning, recruitment of large numbers of clinical centers and adequate resources accomplished by the combined efforts of the National Cancer Institute (NCI), Southwest Oncology Group (SWOG), SELECT Recruitment and Adherence Committee (RAC), SELECT Minority and Medically Underserved Subcommittee (MMUS), and the local SELECT sites resulted in attainment of the estimated sample size ahead of schedule and recruitment of the largest percentage of black participants ever randomized to a cancer prevention trial. © Society for Clinical Trials 2005. AD - E.D. Cook, Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Post Office Box 301439, Houston, TX 77230-1439, United States AU - Cook, E. D. AU - Moody-Thomas, S. AU - Anderson, K. B. AU - Campbell, R. AU - Hamilton, S. J. AU - Harrington, J. M. AU - Lippman, S. M. AU - Minasian, L. M. AU - Paskett, E. D. AU - Craine, S. AU - Arnold, K. B. AU - Probstfield, J. L. DB - Embase Medline DO - 10.1191/1740774505cn111oa IS - 5 KW - alpha tocopherol selenium article Asian Canada chemoprophylaxis clinical trial evaluation study Hispanic human medical literature priority journal prostate carcinoma Puerto Rico treatment planning United States LA - English M3 - Article N1 - L41586028 2005-11-30 PY - 2005 SN - 1740-7745 1740-7753 SP - 436-442 ST - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Clinical Trials TI - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41586028&from=export http://dx.doi.org/10.1191/1740774505cn111oa VL - 2 ID - 1260 ER - TY - JOUR AB - Background: Previous large chemoprevention studies have not recruited significant numbers of minorities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a large phase III study evaluating the impact of selenium and vitamin E on the clinical incidence of prostate cancer. Over 400 SELECT study sites in the USA, Canada, and Puerto Rico recruited men to this trial. The SELECT recruitment goal was 24% minorities, with 20% black, 3% Hispanic, and 1% Asian participants. The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer. Methods: The minority recruitment strategies in SELECT were to: 1) consider minority recruitment during site selection; 2) expand the eligibility criteria by lowering the age criterion for black men and including men with controlled co-morbid illnesses; 3) develop a national infrastructure; 4) give additional funds to sites with the potential to increase black enrollment; and 5) provide resources to maximize free media opportunities to promote SELECT. Results: SELECT recruitment began in August 2001 and was intended to last five years, but concluded two years ahead of schedule in June 2004. Of the 35 534 participants enrolled, 21% were minorities, with 15% black, 5% Hispanic, and 1% Asian. Conclusions Careful planning, recruitment of large numbers of clinical centers and adequate resources accomplished by the combined efforts of the National Cancer Institute (NCI), Southwest Oncology Group (SWOG), SELECT Recruitment and Adherence Committee (RAC), SELECT Minority and Medically Underserved Subcommittee (MMUS), and the local SELECT sites resulted in attainment of the estimated sample size ahead of schedule and recruitment of the largest percentage of black participants ever randomized to a cancer prevention trial. © Society for Clinical Trials 2005. AD - University of Texas M. D. Anderson Cancer Center, Houston, TX, United States Louisiana State University Health Science Center, New Orleans, LA, United States Southwest Oncology Group Statistical Center, Seattle, WA, United States Morehouse School of Medicine, Atlanta, GA, United States Rush University Medical Center, Chicago, IL, United States National Cancer Institute, Bethesda, MD, United States Ohio State University, Columbus, OH, United States Cooperative Studies Program, Department of Veterans Affairs, Seattle, WA, United States University of Washington, Seattle, WA, United States Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Post Office Box 301439, Houston, TX 77230-1439, United States Southwest Oncology Group, Operations Office, 14980 Omicron Drive, San Antonio, TX 78245-3217, United States AU - Cook, E. D. AU - Moody-Thomas, S. AU - Anderson, K. B. AU - Campbell, R. AU - Hamilton, S. J. AU - Harrington, J. M. AU - Lippman, S. M. AU - Minasian, L. M. AU - Paskett, E. D. AU - Craine, S. AU - Arnold, K. B. AU - Probstfield, J. L. DB - Scopus DO - 10.1191/1740774505cn111oa IS - 5 M3 - Article N1 - Cited By :36 Export Date: 22 March 2021 PY - 2005 SP - 436-442 ST - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Clinical Trials TI - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-27744502874&doi=10.1191%2f1740774505cn111oa&partnerID=40&md5=c36db9d74a1cdf4e84c40fb783e8898e VL - 2 ID - 2590 ER - TY - JOUR AB - Background Previous large chemoprevention studies have not recruited significant numbers of minorities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a large phase III study evaluating the impact of selenium and vitamin E on the clinical incidence of prostate cancer. Over 400 SELECT study sites in the USA, Canada, and Puerto Rico recruited men to this trial. The SELECT recruitment goal was 24% minorities, with 20% black, 3% Hispanic, and 1% Asian participants. The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer. Methods The minority recruitment strategies in SELECT were to: 1) consider minority recruitment during site selection; 2) expand the eligibility criteria by lowering the age criterion for black men and including men with controlled co-morbid illnesses; 3) develop a national infrastructure; 4) give additional funds to sites with the potential to increase black enrollment; and 5) provide resources to maximize free media opportunities to promote SELECT. Results SELECT recruitment began in August 2001 and was intended to last five years, but concluded two years ahead of schedule in June 2004. Of the 35 534 participants enrolled, 21% were minorities, with 15% black, 5% Hispanic, and 1% Asian. Conclusions Careful planning, recruitment of large numbers of clinical centers and adequate resources accomplished by the combined efforts of the National Cancer Institute (NCl), Southwest Oncology Group (SWOG), SELECT Recruitment and Adherence Committee (RAC), SELECT Minority and Medically Underserved Subcommittee (MMUS), and the local SELECT sites resulted in attainment of the estimated sample size ahead of schedule and recruitment of the largest percentage of black participants ever randomized to a cancer prevention trial. AN - WOS:000233178800007 AU - Cook, E. D. AU - Moody-Thomas, S. AU - Anderson, K. B. AU - Campbell, R. AU - Hamilton, S. J. AU - Harrington, J. M. AU - Lippman, S. M. AU - Minasian, L. M. AU - Paskett, E. D. AU - Craine, S. AU - Arnold, K. B. AU - Probstfield, J. L. DA - 2005 DO - 10.1191/1740774505cn111oa IS - 5 N1 - 38 16315648 PY - 2005 SN - 1740-7745 SP - 436-442 ST - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Clinical Trials TI - Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) VL - 2 ID - 2667 ER - TY - JOUR AB - Purpose:American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data.Materials and Methods:Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population.Results:Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p <0.001). The enrollment difference for African Americans was-9.0% (95% CI-7.6-10.5, p <0.001) in 2003 to 2005 and 1.4% (95% CI 0.2-2.6, p = 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference-5.8%, 95% CI-4.8-6.8, p <0.001). Latino and Asian American men were consistently under enrolled in all trial types.Conclusions:Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials. AD - B.N. Breyer, Department of Urology, Zuckerberg San Francisco General Hospital, University of California-San Francisco, 1001 Potrero Ave., San Francisco, CA, United States AU - Balakrishnan, A. S. AU - Palmer, N. R. AU - Fergus, K. B. AU - Gaither, T. W. AU - Baradaran, N. AU - Ndoye, M. AU - Breyer, B. N. DB - Embase Medline DO - 10.1016/j.juro.2018.09.029 IS - 2 KW - African American article Asian American Caucasian ethnicity Hispanic human major clinical study male metastasis minority group phase 3 clinical trial (topic) priority journal prostate cancer race difference LA - English M3 - Article N1 - L628754931 2019-08-09 2019-08-14 PY - 2019 SN - 1527-3792 0022-5347 SP - 259-266 ST - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement T2 - Journal of Urology TI - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628754931&from=export http://dx.doi.org/10.1016/j.juro.2018.09.029 VL - 201 ID - 860 ER - TY - JOUR AB - Purpose:American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data.Materials and Methods:Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population.Results:Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p <0.001). The enrollment difference for African Americans was-9.0% (95% CI-7.6-10.5, p <0.001) in 2003 to 2005 and 1.4% (95% CI 0.2-2.6, p = 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference-5.8%, 95% CI-4.8-6.8, p <0.001). Latino and Asian American men were consistently under enrolled in all trial types.Conclusions:Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials. © 2019 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. AD - Department of Urology, Zuckerberg San Francisco General Hospital, University of California-San Francisco, 1001 Potrero Ave., San Francisco, CA 94110, United States Division of General Internal Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California-San Francisco, San Francisco, CA, United States AU - Balakrishnan, A. S. AU - Palmer, N. R. AU - Fergus, K. B. AU - Gaither, T. W. AU - Baradaran, N. AU - Ndoye, M. AU - Breyer, B. N. DB - Scopus DO - 10.1016/j.juro.2018.09.029 IS - 2 KW - clinical trials as topic minority health patient selection prostatic neoplasms SEER Program M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2019 SP - 259-266 ST - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement T2 - Journal of Urology TI - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060026219&doi=10.1016%2fj.juro.2018.09.029&partnerID=40&md5=260df73d1cfca2b6b20079f9344ee714 VL - 201 ID - 2241 ER - TY - JOUR AB - Purpose: American minority groups have been historically underrepresented in phase III prostate cancer clinical trials despite often having higher risk disease. We analyzed enrollment trends of major racial/ethnic groups in the United States in phase III prostate cancer trials between 2003 and 2014 compared to SEER (Surveillance, Epidemiology and End Results) incidence data. Materials and Methods: Phase III prostate cancer trials primarily enrolling patients from the United States were identified in the ClinicalTrials.gov database. Enrollment trends were analyzed for major racial/ethnic groups. Prostate cancer incidence data from the SEER registry were used to identify enrollment targets. The enrollment difference was determined by calculating the absolute difference between the percent of a racial/ethnic subgroup in the SEER registry population and the percent of that subgroup in the phase III prostate cancer trial population. Results: Among 39 studies identified African American enrollment in therapeutic trials increased across the study period (p < 0.001). The enrollment difference for African Americans was -9.0% (95% CI -7.6--10.5, p < 0.001) in 2003 to 2005 and 1.4% (95% CI 0.2-2.6, p = 0.020) in 2012 to 2014. However, African American men were under enrolled in metastatic disease trials (enrollment difference -5.8%, 95% CI -4.8--6.8, p < 0.001). Latino and Asian American men were consistently under enrolled in all trial types. Conclusions: Minority groups in the United States were largely under enrolled in phase III prostate cancer trials between 2003 and 2014. While recruitment efforts may have had an impact, as demonstrated by increased enrollment of African American men, there remains a need to expand recruitment efforts to achieve diversity in trials. AN - WOS:000455997500067 AU - Balakrishnan, A. S. AU - Palmer, N. R. AU - Fergus, K. B. AU - Gaither, T. W. AU - Baradaran, N. AU - Ndoye, M. AU - Breyer, B. N. DA - Feb DO - 10.1016/j.juro.2018.09.029 IS - 2 N1 - 30218761 PY - 2019 SN - 0022-5347 SP - 259-266 ST - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement T2 - Journal of Urology TI - Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement VL - 201 ID - 2831 ER - TY - JOUR AN - 105946500. Language: English. Entry Date: 20080201. Revision Date: 20150711. Publication Type: Journal Article AU - Long, K. DB - CINAHL Complete DP - EBSCOhost IS - 5 KW - Cancer Survivors Lymphedema Black Persons Breast Neoplasms Female Research Subject Recruitment N1 - brief item. Journal Subset: Expert Peer Reviewed; Nursing; Peer Reviewed; USA. PY - 2007 SP - 9-9 ST - Mixing beauty and health: lymphedema study looks for participants at beauty shops T2 - NurseWeek TI - Mixing beauty and health: lymphedema study looks for participants at beauty shops UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105946500&site=ehost-live&scope=site VL - 8 ID - 1999 ER - TY - JOUR AN - 105970211. Language: English. Entry Date: 20080215. Revision Date: 20150711. Publication Type: Journal Article AU - Long, K. DB - CINAHL Complete DP - EBSCOhost IS - 19 KW - Beauty Cancer Survivors Lymphedema Black Persons Breast Neoplasms Female Research Subject Recruitment N1 - brief item. Note: Published in multiple journals. Journal Subset: Nursing; USA. NLM UID: 9892047. PY - 2007 SN - 1557-8038 SP - 24-24 ST - Mixing beauty and health: lymphedema study looks for participants at beauty shops T2 - Nursing Spectrum -- New England Edition TI - Mixing beauty and health: lymphedema study looks for participants at beauty shops UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105970211&site=ehost-live&scope=site VL - 11 ID - 2000 ER - TY - JOUR AN - 105958481. Language: English. Entry Date: 20080208. Revision Date: 20150711. Publication Type: Journal Article AU - Long, K. DB - CINAHL Complete DP - EBSCOhost IS - 21 KW - Cancer Survivors Lymphedema Black Persons Breast Neoplasms Female Research Subject Recruitment N1 - brief item. Note: Published in multiple journals. Journal Subset: Nursing; USA. PY - 2007 SN - 2150-9999 SP - 28-28 ST - Mixing beauty and health: lymphedema study looks for participants at beauty shops T2 - Nursing Spectrum -- Greater Chicago TI - Mixing beauty and health: lymphedema study looks for participants at beauty shops UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105958481&site=ehost-live&scope=site VL - 20 ID - 2001 ER - TY - JOUR AB - Objectives: Rural women are underrepresented in cancer research. We hypothesized that providing access to a research study to rural, medically underserved women who were receiving their breast cancer screening using a mobile mammography unit would increase the representation of rural women in a cancer cohort study. Design: This study is a cross-sectional study using a cohort of women who have been recruited to a breast cancer study in Arkansas. Setting: Recruiters accompanied a mobile mammography unit, the MammoVan, to implement a novel method for reaching and recruiting underrepresented rural Arkansas women into the study. Participants include 5850 women recruited from 2010 through 2012 as part of the Arkansas Rural Community Health (ARCH) study. Results: Participants recruited during their mammography screening on the MammoVan tended to be more rural, less educated, and more likely to be non-Hispanic than those recruited in other venues. A significant difference was not noted for race or age. Conclusion: Collaboration with the MammoVan greatly aided the recruitment of rural participants. These strategies can facilitate the representation of this historically underserved and understudied rural population in future research studies. © The Author(s) 2019. AD - Department of Internal Medicine, College of Medicine, University of Arkansas for Medical Sciences Northwest, Fayetteville, AR, United States Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, United States Department of Biostatistics, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, United States Department of Surgery, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States Division of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States AU - McElfish, P. A. AU - Su, L. J. AU - Lee, J. Y. AU - Runnells, G. AU - Henry-Tillman, R. AU - Kadlubar, S. A. DB - Scopus DO - 10.1177/1178223419876296 KW - Breast cancer research mobile mammography rural under-represented population M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2019 ST - Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies T2 - Breast Cancer: Basic and Clinical Research TI - Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073234789&doi=10.1177%2f1178223419876296&partnerID=40&md5=8e339bfe63d12956c4744a40ba66f055 VL - 13 ID - 2242 ER - TY - JOUR AB - BACKGROUND: Clinical trials are critical to advancing cancer treatment. Minority populations are underrepresented among trial participants, and there is limited understanding of their decision-making process and key determinants of decision outcomes regarding trial participation. METHODS: To understand research decision-making among clinical trial-eligible African-American cancer patients at Johns Hopkins, we conducted seven focus groups (n=32) with trial-offered patients ≥ 18 years diagnosed with lung, breast, prostate, or colorectal cancer ≤ 5 years. Three "acceptor" and four "decliner" focus groups were conducted. Questions addressed: attitudes towards clinical trials, reasons for accepting or declining participation, and recommendations to improve minority recruitment and enrollment. Data were transcribed and analyzed using traditional approaches to content and thematic analysis in NVivo 9.0. Data coding resulted in themes that supported model construction. RESULTS: Participant experiences revealed the following themes when describing the decision-making process: Information gathering, Intrapersonal perspectives, and Interpersonal influences. Decision outcomes included the presence or absence of decision regret and satisfaction. From these themes, we generated a Model of Cancer Clinical Trial Decision-making. CONCLUSION: Our model should be tested in hypothesis-driven research to elucidate factors and processes influencing decision balance and outcomes of trial-related decision-making. The model should also be tested in other disparities populations and for diagnoses other than cancer. AU - Wenzel, J. A. AU - Mbah, O. AU - Xu, J. AU - Moscou-Jackson, G. AU - Saleem, H. AU - Sakyi, K. AU - Ford, J. G. DB - Medline DO - 10.1007/s40615-014-0063-x IS - 2 KW - adult African American aged clinical trial (topic) decision making ethnology female health disparity human information processing male middle aged neoplasm psychological model psychology statistics and numerical data LA - English M3 - Article N1 - L615648361 2017-05-01 PY - 2015 SN - 2196-8837 SP - 192-199 ST - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients T2 - Journal of racial and ethnic health disparities TI - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615648361&from=export http://dx.doi.org/10.1007/s40615-014-0063-x VL - 2 ID - 1000 ER - TY - JOUR AB - Background: Clinical trials are critical to advancing cancer treatment. Minority populations are underrepresented among trial participants, and there is limited understanding of their decision-making process and key determinants of decision outcomes regarding trial participation. Methods: To understand research decision-making among clinical trial-eligible African-American cancer patients at Johns Hopkins, we conducted seven focus groups (n = 32) with trial-offered patients ≥ 18 years diagnosed with lung, breast, prostate, or colorectal cancer ≤ 5 years. Three 'acceptor' and four 'decliner' focus groups were conducted. Questions addressed: attitudes towards clinical trials, reasons for accepting or declining participation, and recommendations to improve minority recruitment and enrollment. Data were transcribed and analyzed using traditional approaches to content and thematic analysis in NVivo 9.0. Data coding resulted in themes that supported model construction. Results: Participant experiences revealed the following themes when describing the decision-making process: Information gathering, Intrapersonal perspectives, and Interpersonal influences. Decision outcomes included the presence or absence of decision regret and satisfaction. From these themes, we generated a Model of Cancer Clinical Trial Decision-making. Conclusion: Our model should be tested in hypothesis-driven research to elucidate factors and processes influencing decision balance and outcomes of trial-related decision-making. The model should also be tested in other disparities populations and for diagnoses other than cancer. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Wenzel, Jennifer A., Johns Hopkins School of Nursing, 525 N. Wolfe St, Baltimore, MD, US, 21205-2110 AN - 2016-38688-006 AU - Wenzel, Jennifer A. AU - Mbah, Olive AU - Xu, Jiayun AU - Moscou-Jackson, Gyasi AU - Saleem, Haneefa AU - Sakyi, Kwame AU - Ford, Jean G. DB - psyh DO - 10.1007/s40615-014-0063-x DP - EBSCOhost IS - 2 KW - Clinical trials African-Americans Decision balance Decision regret . Cancer disparities Adult African Americans Aged Clinical Trials as Topic Decision Making Female Focus Groups Health Status Disparities Humans Male Middle Aged Models, Psychological Neoplasms Health Care Psychology Health Disparities Blacks Diagnosis N1 - Johns Hopkins School of Nursing, Baltimore, MD, US. Release Date: 20161006. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Wenzel, Jennifer A. Major Descriptor: Decision Making; Health Care Psychology; Health Disparities. Minor Descriptor: Blacks; Diagnosis. Classification: Health Psychology & Medicine (3360). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Clinical Trial; Empirical Study; Interview; Focus Group; Qualitative Study. Page Count: 8. Issue Publication Date: Jun, 2015. Publication History: First Posted Date: Oct 23, 2014; Accepted Date: Oct 6, 2014; Revised Date: Sep 19, 2014; First Submitted Date: Aug 4, 2014. Copyright Statement: W. Montague Cobb-NMA Health Institute. 2014. Sponsor: National Institutes of Health, National Institute on Minority Health and Health Disparities, US. Grant: U24MD006970. Recipients: No recipient indicated Sponsor: American Cancer Society, US. Grant: MRSGT-09-152-01-CPPB. Recipients: Wenzel, Jennifer A. Sponsor: Community Networks Program Center (CNPC). Grant: U54CA153710. Recipients: Wenzel, Jennifer A.; Mbah, Olive PY - 2015 SN - 2197-3792 2196-8837 SP - 192-199 ST - A model of cancer clinical trial decision-making informed by African-American cancer patients T2 - Journal of Racial and Ethnic Health Disparities TI - A model of cancer clinical trial decision-making informed by African-American cancer patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-38688-006&site=ehost-live&scope=site jwenzel@jhu.edu VL - 2 ID - 1687 ER - TY - JOUR AB - BACKGROUND: Clinical trials are critical to advancing cancer treatment. Minority populations are underrepresented among trial participants, and there is limited understanding of their decision-making process and key determinants of decision outcomes regarding trial participation. METHODS: To understand research decision-making among clinical trial-eligible African-American cancer patients at Johns Hopkins, we conducted seven focus groups (n=32) with trial-offered patients ≥ 18 years diagnosed with lung, breast, prostate, or colorectal cancer ≤ 5 years. Three "acceptor" and four "decliner" focus groups were conducted. Questions addressed: attitudes towards clinical trials, reasons for accepting or declining participation, and recommendations to improve minority recruitment and enrollment. Data were transcribed and analyzed using traditional approaches to content and thematic analysis in NVivo 9.0. Data coding resulted in themes that supported model construction. RESULTS: Participant experiences revealed the following themes when describing the decision-making process: Information gathering, Intrapersonal perspectives, and Interpersonal influences. Decision outcomes included the presence or absence of decision regret and satisfaction. From these themes, we generated a Model of Cancer Clinical Trial Decision-making. CONCLUSION: Our model should be tested in hypothesis-driven research to elucidate factors and processes influencing decision balance and outcomes of trial-related decision-making. The model should also be tested in other disparities populations and for diagnoses other than cancer. AD - Bloomberg School of Public Health, 525 N. Wolfe St, Baltimore, MD 21205-2110, United States AU - Wenzel, J. A. AU - Mbah, O. AU - Xu, J. AU - Moscou-Jackson, G. AU - Saleem, H. AU - Sakyi, K. AU - Ford, J. G. DB - Scopus DO - 10.1007/s40615-014-0063-x IS - 2 KW - African-Americans Cancer disparities Clinical trials Decision balance Decision regret M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2015 SP - 192-199 ST - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients T2 - Journal of racial and ethnic health disparities TI - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018214616&doi=10.1007%2fs40615-014-0063-x&partnerID=40&md5=8109e441e80c6d741ac812324026cf24 VL - 2 ID - 2363 ER - TY - JOUR AB - Background Clinical trials are critical to advancing cancer treatment. Minority populations are underrepresented among trial participants, and there is limited understanding of their decision-making process and key determinants of decision outcomes regarding trial participation. Methods To understand research decision-making among clinical trial-eligible African-American cancer patients at Johns Hopkins, we conducted seven focus groups (n=32) with trial-offered patients >= 18 years diagnosed with lung, breast, prostate, or colorectal cancer <= 5 years. Three "acceptor" and four "decliner" focus groups were conducted. Questions addressed: attitudes towards clinical trials, reasons for accepting or declining participation, and recommendations to improve minority recruitment and enrollment. Data were transcribed and analyzed using traditional approaches to content and thematic analysis in NVivo 9.0. Data coding resulted in themes that supported model construction. Results Participant experiences revealed the following themes when describing the decision-making process: Information gathering, Intrapersonal perspectives, and Interpersonal influences. Decision outcomes included the presence or absence of decision regret and satisfaction. From these themes, we generated a Model of Cancer Clinical Trial Decision-making. Conclusion Our model should be tested in hypothesis-driven research to elucidate factors and processes influencing decision balance and outcomes of trial-related decision-making. The model should also be tested in other disparities populations and for diagnoses other than cancer. AN - WOS:000218510200006 AU - Wenzel, J. A. AU - Mbah, O. AU - Xu, J. Y. AU - Moscou-Jackson, G. AU - Saleem, H. AU - Sakyi, K. AU - Ford, J. G. DA - Jun DO - 10.1007/s40615-014-0063-x IS - 2 N1 - 25960945 PY - 2015 SN - 2197-3792 SP - 192-199 ST - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients T2 - Journal of Racial and Ethnic Health Disparities TI - A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients VL - 2 ID - 2976 ER - TY - JOUR AB - The application of the POCK model of pulmonary clearance and retention to new experimental results of chronic inhalation studies with rats exposed for 2 yr to diesel exhaust or carbon black is reported. For the first time in lifetime studies with these carbonaceous aerosols, experimental data became available for particulate mass burdens in the lung-associated lymph nodes. Furthermore, seven out of eight lifetime runs used exposure rate indices causing lung overload and lung tumors. The simulations of the POCK model were consistent with previous POCK representations of diesel soot and carbon black exposure studies. The new data on lifetime patterns of lymph node loads, however, required an adjustment of the interstitial kinetics in order to account for the apparent lymph-node load stagnation after about 1 yr of chronic exposures leading to lung overload. The consistently observed coincidence of lymph-node load stagnation and tumor induction in the new exposure studies occurred always in a situation where overload caused a pronounced increase of the interstitial particle burden. These observations were thought to support a hypothesis that assumed the rime integral of the interstitial burden as an effective relative dose for a rat-specific overload carcinogenesis. Depending on aerosol material and rat strain, common critical values of this dose relating to both lymph-node load stagnation and tumor induction were postulated and calculated by using the model-inferred simulation data. The low precision of the experimental data indicating lymph-node load stagnation rendered the results semiquantitative. However, a plausible evaluation of the sparse empirical dose-response data of overload carcinogenesis for the two carbonaceous aerosols yielded no-effect thresholds commensurable and compatible with the critical dose values. AN - WOS:A1994PP95500001 AU - Stober, W. AU - Mauderly, J. L. DA - Sep-Oct DO - 10.3109/08958379409040504 IS - 5 N1 - 14 PY - 1994 SN - 0895-8378 SP - 427-457 ST - Model-Inferred Hypothesis of a Critical Dose for Overload Tumor-Induction by Diesel Soot and Carbon-Black T2 - Inhalation Toxicology TI - Model-Inferred Hypothesis of a Critical Dose for Overload Tumor-Induction by Diesel Soot and Carbon-Black VL - 6 ID - 2741 ER - TY - JOUR AB - BACKGROUND: Attrition occurs when a participant fails to respond to one or more study waves. The accumulation of attrition over several waves can lower the sample size and power and create a final sample that could differ in characteristics than those who drop out. The main reason to conduct a longitudinal study is to analyze repeated measures; research subjects who drop out cannot be replaced easily. Our group recently investigated factors affecting nonparticipation (refusal) in the first wave of a population-based study of prostate cancer. In this study we assess factors affecting attrition in the second wave of the same study. We compare factors affecting nonparticipation in the second wave to the ones affecting nonparticipation in the first wave. METHODS: Information available on participants in the first wave was used to model attrition. Different sources of attrition were investigated separately. The overall and race-stratified factors affecting attrition were assessed. Kaplan-Meier survival curve estimates were calculated to assess the impact of follow-up time on participation. RESULTS: High cancer aggressiveness was the main predictor of attrition due to death or frailty. Higher Charlson Comorbidity Index increased the odds of attrition due to death or frailty only in African Americans (AAs). Young age at diagnosis for AAs and low income for European Americans (EAs) were predictors for attrition due to lost to follow-up. High cancer aggressiveness for AAs, low income for EAs, and lower patient provider communication scores for EAs were predictors for attrition due to refusal. These predictors of nonparticipation were not the same as those in wave 1. For short follow-up time, the participation probability of EAs was higher than that of AAs. CONCLUSIONS: Predictors of attrition can vary depending on the attrition source. Examining overall attrition (combining all sources of attrition under one category) instead of distinguishing among its different sources should be avoided. The factors affecting attrition in one wave can be different in a later wave and should be studied separately. AU - Spiers, S. AU - Oral, E. AU - Fontham, E. T. H. AU - Peters, E. S. AU - Mohler, J. L. AU - Bensen, J. T. AU - Brennan, C. S. DB - Medline DO - 10.1186/s12874-018-0518-6 IS - 1 KW - adult African American aged Caucasian ethnology follow up human Kaplan Meier method longitudinal study male middle aged patient participation prostate tumor psychology risk factor statistical model statistics and numerical data United States LA - English M3 - Article N1 - L626306618 2019-02-14 2019-06-19 PY - 2018 SN - 1471-2288 SP - 60 ST - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer T2 - BMC medical research methodology TI - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626306618&from=export http://dx.doi.org/10.1186/s12874-018-0518-6 VL - 18 ID - 892 ER - TY - JOUR AB - Background: Attrition occurs when a participant fails to respond to one or more study waves. The accumulation of attrition over several waves can lower the sample size and power and create a final sample that could differ in characteristics than those who drop out. The main reason to conduct a longitudinal study is to analyze repeated measures; research subjects who drop out cannot be replaced easily. Our group recently investigated factors affecting nonparticipation (refusal) in the first wave of a population-based study of prostate cancer. In this study we assess factors affecting attrition in the second wave of the same study. We compare factors affecting nonparticipation in the second wave to the ones affecting nonparticipation in the first wave. Methods: Information available on participants in the first wave was used to model attrition. Different sources of attrition were investigated separately. The overall and race-stratified factors affecting attrition were assessed. Kaplan-Meier survival curve estimates were calculated to assess the impact of follow-up time on participation. Results: High cancer aggressiveness was the main predictor of attrition due to death or frailty. Higher Charlson Comorbidity Index increased the odds of attrition due to death or frailty only in African Americans (AAs). Young age at diagnosis for AAs and low income for European Americans (EAs) were predictors for attrition due to lost to follow-up. High cancer aggressiveness for AAs, low income for EAs, and lower patient provider communication scores for EAs were predictors for attrition due to refusal. These predictors of nonparticipation were not the same as those in wave 1. For short follow-up time, the participation probability of EAs was higher than that of AAs. Conclusions: Predictors of attrition can vary depending on the attrition source. Examining overall attrition (combining all sources of attrition under one category) instead of distinguishing among its different sources should be avoided. The factors affecting attrition in one wave can be different in a later wave and should be studied separately. © 2018 The Author(s). AD - LSUHSC, School of Public Health, Biostatistics Program, New Orleans, United States LSUHSC, School of Public Health, Epidemiology Program, New Orleans, United States Department of Urology, Roswell Park Cancer Institute, Buffalo, United States Lineberger Comprehensive Cancer Center, UNC-Chapel Hill, Chapel Hill, United States LSUHSC, School of Public Health, Health Policy and Systems Management Program, New Orleans, United States AU - Spiers, S. AU - Oral, E. AU - Fontham, E. T. H. AU - Peters, E. S. AU - Mohler, J. L. AU - Bensen, J. T. AU - Brennan, C. S. C7 - 60 DB - Scopus DO - 10.1186/s12874-018-0518-6 IS - 1 KW - Attrition Longitudinal study Nonresponse bias Prostate cancer Unit nonresponse M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2018 ST - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer T2 - BMC Medical Research Methodology TI - Modelling attrition and nonparticipation in a longitudinal study of prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048879992&doi=10.1186%2fs12874-018-0518-6&partnerID=40&md5=7249a1d7262e28b8c5af81319a5dafe4 VL - 18 ID - 2267 ER - TY - JOUR AB - Objective: To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate interactions between these markers and the study interventions. Methods: The epidemiologic studies within SELECT will be based on 32,400 men aged 55 years or older (age 50 or older for the African-American men) enrolled into an intergroup, randomized, placebo-controlled, double-blind, phase III prevention trial of supplemental selenium and vitamin E developed and funded by the National Cancer Institute, and coordinated by the Southwest Oncology Group. During the 12-year study period approximately 1500-2000 cases of prostate cancer, 800 lung cancers, and 500 colon cancers are estimated to be diagnosed, based on data from the ongoing Prostate Cancer Prevention Trial of finasteride. A modified fasting blood sample will be processed to collect plasma for analysis of micronutrients, hormones, cytokines, and other proteins. Buffy-coat derived white blood cells collected at baseline will be used for isolation of DNA and establishment of immortalized cell lines. Red blood cells will be stored for analysis of hemoglobin adducts and other components. Results: Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5α-reductase type II, CYP17, and β-hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S-transferase M1); DNA and protein adducts; and insulin-like growth factors and leptin. Conclusion: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene-environment interactions and their role in prostate, lung, and colon carcinogenesis. AD - R.M. Santella, Mailman School of Public Health, Columbia University, 701 West 168th St, New York, NY 10032, United States AU - Hoque, A. AU - Albanes, D. AU - Lippman, S. M. AU - Spitz, M. R. AU - Taylor, P. R. AU - Klein, E. A. AU - Thompson, I. M. AU - Goodman, P. AU - Stanford, J. L. AU - Crowley, J. J. AU - Coltman, C. A. AU - Santella, R. M. DB - Embase Medline DO - 10.1023/A:1011277600059 IS - 7 KW - alpha tocopherol leptin selenium sex hormone somatomedin C adult aged article cancer prevention cancer risk carcinogenesis colon cancer controlled study diet supplementation DNA adduct DNA repair environmental factor genetic marker heredity human lung cancer major clinical study male priority journal prostate cancer risk factor LA - English M3 - Article N1 - L32758594 2001-08-30 PY - 2001 SN - 0957-5243 SP - 627-633 ST - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Cancer Causes and Control TI - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32758594&from=export http://dx.doi.org/10.1023/A:1011277600059 VL - 12 ID - 1307 ER - TY - JOUR AB - Objective: To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate interactions between these markers and the study interventions. Methods: The epidemiologic studies within SELECT will be based on 32, 400 men aged 55 years or older (age 50 or older for the African-American men) enrolled into an intergroup, randomized, placebo-controlled, double-blind, phase III prevention trial of supplemental selenium and vitamin E developed and funded by the National Cancer Institute, and coordinated by the Southwest Oncology Group. During the 12-year study period approximately 1500-2000 cases of prostate cancer, 800 lung cancers, and 500 colon cancers are estimated to be diagnosed, based on data from the ongoing Prostate Cancer Prevention Trial of finasteride. A modified fasting blood sample will be processed to collect plasma for analysis of micronutrients, hormones, cytokines, and other proteins. Buffy-coat derived white blood cells collected at baseline will be used for isolation of DNA and establishment of immortalized cell lines. Red blood cells will be stored for analysis of hemoglobin adducts and other components. Results: Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5α-reductase type II, CYP17, and β-hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S-transferase M1); DNA and protein adducts; and insulin-like growth factors and leptin. Conclusion: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene-environment interactions and their role in prostate, lung, and colon carcinogenesis. AD - Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Houston TX 77030, United States Division of Clinical Sciences, National Cancer Institute, Bethesda MD 20892, United States Department of Epidemiology, University of Texas M. D. Anderson Cancer Center, Houston TX 77030, United States Department of Urology, Cleveland Clinic Foundation, Cleveland OH 44195, United States Division of Urology, University of Texas Health Science Center, San Antonio TX 78284, United States Southwest Oncology Group Statistical Center, Seattle WA 98109, United States Fred Hutchinson Cancer Research Center, Seattle WA 98109, United States Southwest Oncology Group, San Antonio TX 78245, United States Department of Environmental Health Sciences, Mailman School of Public Health of Columbia University, New York, NY 10032, United States AU - Hoque, A. AU - Albanes, D. AU - Lippman, S. M. AU - Spitz, M. R. AU - Taylor, P. R. AU - Klein, E. A. AU - Thompson, I. M. AU - Goodman, P. AU - Stanford, J. L. AU - Crowley, J. J. AU - Coltman, C. A. AU - Santella, R. M. C7 - 338675 DB - Scopus DO - 10.1023/A:1011277600059 IS - 7 KW - Molecular epidemiology Primary prevention Prostate cancer Selenium Vitamin E M3 - Article N1 - Cited By :73 Export Date: 22 March 2021 PY - 2001 SP - 627-633 ST - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Cancer Causes and Control TI - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-17944379311&doi=10.1023%2fA%3a1011277600059&partnerID=40&md5=c664bf4be91c750a884b28e73107e79f VL - 12 ID - 2625 ER - TY - JOUR AB - Objective: To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate interactions between these markers and the study interventions. Methods: The epidemiologic studies within SELECT will be based on 32,400 men aged 55 years or older (age 50 or older for the African-American men) enrolled into an intergroup, randomized, placebo-controlled, double-blind, phase III prevention trial of supplemental selenium and vitamin E developed and funded by the National Cancer Institute, and coordinated by the Southwest Oncology Group. During the 12-year study period approximately 1500-2000 cases of prostate cancer, 800 lung cancers, and 500 colon cancers are estimated to be diagnosed, based on data from the ongoing Prostate Cancer Prevention Trial of finasteride. A modified fasting blood sample will be processed to collect plasma for analysis of micronutrients, hormones, cytokines, and other proteins. Buffy-coat derived white blood cells collected at baseline will be used for isolation of DNA and establishment of immortalized cell lines. Red blood cells will be stored for analysis of hemoglobin adducts and other components. Results: Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5 alpha -reductase type II, CYP17, and beta -hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S-transferase M1); DNA and protein adducts; and insulin-like growth factors and leptin. Conclusion: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene-environment interactions and their role in prostate, lung, and colon carcinogenesis. AN - WOS:000170160400006 AU - Hoque, A. AU - Albanes, D. AU - Lippman, S. M. AU - Spitz, M. R. AU - Taylor, P. R. AU - Klein, E. A. AU - Thompson, I. M. AU - Goodman, P. AU - Stanford, J. L. AU - Crowley, J. J. AU - Coltman, C. A. AU - Santella, R. M. DA - Sep DO - 10.1023/A:1011277600059 IS - 7 N1 - 67 11552710 PY - 2001 SN - 0957-5243 SP - 627-633 ST - Molecular epidemiologic studies within the selenium and vitamin e cancer prevention trial (SELECT) T2 - Cancer Causes & Control TI - Molecular epidemiologic studies within the selenium and vitamin e cancer prevention trial (SELECT) VL - 12 ID - 2706 ER - TY - JOUR AB - OBJECTIVE: To conduct timely epidemiologic investigations of molecular/genetic markers that may contribute to the development of prostate, lung, colorectal, or other cancers within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), and to evaluate interactions between these markers and the study interventions. METHODS: The epidemiologic studies within SELECT will be based on 32,400 men aged 55 years or older (age 50 or older for the African‐American men) enrolled into an intergroup, randomized, placebo‐controlled, double‐blind, phase III prevention trial of supplemental selenium and vitamin E developed and funded by the National Cancer Institute, and coordinated by the Southwest Oncology Group. During the 12‐year study period approximately 1500‐2000 cases of prostate cancer, 800 lung cancers, and 500 colon cancers are estimated to be diagnosed, based on data from the ongoing Prostate Cancer Prevention Trial of finasteride. A modified fasting blood sample will be processed to collect plasma for analysis of micronutrients, hormones, cytokines, and other proteins. Buffy‐coat derived white blood cells collected at baseline will be used for isolation of DNA and establishment of immortalized cell lines. Red blood cells will be stored for analysis of hemoglobin adducts and other components. RESULTS: Specific results anticipated from these molecular studies will provide information on factors hypothesized to contribute to prostate cancer risk and that may modify the efficacy of either trial supplement, including: steroid sex hormones and several polymorphic genes that encode proteins affecting androgenic stimulation of the prostate, including the androgen receptor, steroid 5alpha‐reductase type II, CYP17, and beta‐hydroxysteroid dehydrogenase; polymorphisms of DNA repair genes and carcinogen metabolism genes, including those involved in the activation of chemical carcinogens to reactive intermediates (e.g., CYP1A1) or the detoxification of reactive intermediates (e.g., glutathione S‐transferase M1); DNA and protein adducts; and insulin‐like growth factors and leptin. CONCLUSION: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene‐environment interactions and their role in prostate, lung, and colon carcinogenesis. AN - CN-00373823 AU - Hoque, A. AU - Albanes, D. AU - Lippman, S. M. AU - Spitz, M. R. AU - Taylor, P. R. AU - Klein, E. A. AU - Thompson, I. M. AU - Goodman, P. AU - Stanford, J. L. AU - Crowley, J. J. AU - et al. DO - 10.1023/a:1011277600059 IS - 7 KW - Colorectal Neoplasms [epidemiology, genetics, prevention & control] Double‐Blind Method Epidemiologic Studies Genetic Markers Gonadal Steroid Hormones [blood] Humans Leptin [blood] Lung Neoplasms [epidemiology, genetics, prevention & control] Male Middle Aged Prospective Studies Prostatic Neoplasms [epidemiology, genetics, prevention & control] Risk Factors Selenium [therapeutic use] United States [epidemiology] Vitamin E [therapeutic use] M3 - Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2001 SP - 627‐633 ST - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) T2 - Cancer causes & control TI - Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00373823/full VL - 12 ID - 1436 ER - TY - JOUR AB - Objective To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. Subjects and Methods Abstractors from the PLCO trial recorded the types and dates of diagnostic follow-up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120-day period after prostate biopsy was compared with a control rate of deaths in the 120-day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non-infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications. Results Of the 37 345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28 661 had a negative screen and no biopsy. The 120-day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2-1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non-infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non-infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non-infectious complications (OR = 0.3). Conclusion Mortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified. © Published 2013. This article has been contributed to by US Government employees and their work is in the public domain in the USA. BJU International © 2013 BJU International. AD - P.F. Pinsky, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, United States AU - Pinsky, P. F. AU - Parnes, H. L. AU - Andriole, G. DB - Embase Medline DO - 10.1111/bju.12368 IS - 2 KW - adult age distribution aged article cancer mortality cancer screening colorectal cancer comorbidity controlled study disease association ethnic difference follow up human human tissue iatrogenic disease infectious complication lung cancer major clinical study male medical history morbidity multicenter study ovary cancer priority journal prostate biopsy prostate cancer prostate hypertrophy prostatitis randomized controlled trial risk assessment risk factor smoking LA - English M3 - Article N1 - L52887269 2013-11-28 2014-02-06 PY - 2014 SN - 1464-410X 1464-4096 SP - 254-259 ST - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial T2 - BJU International TI - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52887269&from=export http://dx.doi.org/10.1111/bju.12368 VL - 113 ID - 1053 ER - TY - JOUR AB - OBJECTIVE: To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. SUBJECTS AND METHODS: Abstractors from the PLCO trial recorded the types and dates of diagnostic follow‐up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120‐day period after prostate biopsy was compared with a control rate of deaths in the 120‐day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non‐infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications. RESULTS: Of the 37,345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28,661 had a negative screen and no biopsy. The 120‐day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2‐1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non‐infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non‐infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non‐infectious complications (OR = 0.3). CONCLUSION: Mortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified. AN - CN-00979159 AU - Pinsky, P. F. AU - Parnes, H. L. AU - Andriole, G. DO - 10.1111/bju.12368 IS - 2 KW - *cancer mortality *cancer screening *iatrogenic disease/co [Complication] *prostate biopsy Adult Age distribution Aged Article Biomarkers, Tumor [blood] Biopsy [*adverse effects] Colorectal cancer/di [Diagnosis] Comorbidity Controlled study Disease association Early Detection of Cancer Ethnic difference Follow up Human Human tissue Humans Hypertrophy [epidemiology, etiology] Infectious complication/co [Complication] Lung cancer/di [Diagnosis] Major clinical study Male Mass Screening [methods] Medical history Middle Aged Morbidity Multicenter study Ovary cancer/di [Diagnosis] Priority journal Prostate [*pathology] Prostate cancer/di [Diagnosis] Prostate hypertrophy/di [Diagnosis] Prostate‐Specific Antigen [blood] Prostatic Neoplasms [blood, complications, *diagnosis, *mortality] Prostatitis [epidemiology, etiology] Prostatitis/di [Diagnosis] Randomized controlled trial Risk assessment Risk factor Smoking Surveys and Questionnaires United States [epidemiology] M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 254‐259 ST - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial T2 - BJU international TI - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00979159/full VL - 113 ID - 1429 ER - TY - JOUR AB - Objective To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. Subjects and Methods Abstractors from the PLCO trial recorded the types and dates of diagnostic follow-up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120-day period after prostate biopsy was compared with a control rate of deaths in the 120-day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non-infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications. Results Of the 37 345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28 661 had a negative screen and no biopsy. The 120-day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2-1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non-infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non-infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non-infectious complications (OR = 0.3). Conclusion Mortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified. © Published 2013. This article has been contributed to by US Government employees and their work is in the public domain in the USA. BJU International © 2013 BJU International. AD - Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, United States Washington University School of Medicine, St Louis, MO, United States AU - Pinsky, P. F. AU - Parnes, H. L. AU - Andriole, G. DB - Scopus DO - 10.1111/bju.12368 IS - 2 KW - complications mortality prostate biopsy prostate-specific antigen PSA M3 - Article N1 - Cited By :40 Export Date: 22 March 2021 PY - 2014 SP - 254-259 ST - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial T2 - BJU International TI - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892534272&doi=10.1111%2fbju.12368&partnerID=40&md5=f6e35b576bc13f27bdcddd0b27e5eb92 VL - 113 ID - 2411 ER - TY - JOUR AB - Objective To examine mortality and morbidity after prostate biopsy in the intervention arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. Subjects and Methods Abstractors from the PLCO trial recorded the types and dates of diagnostic follow-up procedures after positive screens and documented the types and dates of resultant complications. Cancers and deaths among the participants were tracked. The mortality rate in the 120-day period after prostate biopsy was compared with a control rate of deaths in the 120-day period after a negative screen in men without biopsy. Multivariate analysis was performed to control for potential confounders, including age, comorbidities and smoking. Rates of any complication, infectious and non-infectious complications were computed among men with a negative biopsy. Multivariate analysis was used to examine the risk factors for complications. Results Of the 37345 men enrolled in the PLCO trial (intervention arm), 4861 had at least one biopsy after a positive screen and 28661 had a negative screen and no biopsy. The 120-day mortality rate after biopsy was 0.95 (per 1000), compared with the control group rate of 1.8; the multivariate relative risk was 0.49 (95% CI: 0.2-1.1). Among 3706 negative biopsies, the rates (per 1000) of any complication, infectious and non-infections complications were 20.2, 7.8 and 13.0, respectively. A history of prostate enlargement or inflammation was significantly associated with higher rates of both infectious (odds ratio [OR] = 3.7) and non-infectious (OR = 2.2) complications. Black race was associated with a higher infectious complications rate (OR = 7.1) and repeat biopsy was associated with lower rates of non-infectious complications (OR = 0.3). Conclusion Mortality rates were not found to be higher after prostate biopsy in the PLCO trial and complications were relatively infrequent, with several risk factors identified. AN - WOS:000329544200006 AU - Pinsky, P. F. AU - Parnes, H. L. AU - Andriole, G. DA - Feb DO - 10.1111/bju.12368 IS - 2 N1 - 24053621 PY - 2014 SN - 1464-4096 SP - 254-259 ST - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial T2 - Bju International TI - Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial VL - 113 ID - 3022 ER - TY - JOUR AB - Background: How to identify whether T1-2 colorectal cancers have lymph nodes metastases pre-op or intra-op is a crucial problem in clinic. The purpose of this study was to evaluate the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1-2 colorectal cancers.Methods: A multi-center study was performed between July 2012 and January 2014. Seventy-three patients with T1-2 colorectal cancer identified by pre-op endoscopic ultrasonography (EUS) were recruited. 1 ml carbon nanoparticles suspension was endoscopically injected into the submucosal layer at four points around the site of the primary tumor 1 day before surgery. Laparoscopic radical resection with lymphadenectomy was performed. Sentinel lymph nodes (SLNs) were defined as nodes that were black-dyed by carbon nanoparticles. Pathology confirmed whether lymph nodes have cancer metastases and the SLNs accuracy.Results: SLNs were easily found under laparoscopy. The mean number of SLNs was 3 (range 1-5). All patients had SLNs lying alongside the mesenteric vessel or main arterial vessel. After pathological analysis, 2 patients (9.52%) had lymph node metastasis in 21 patients with EUS T1 cancers, and 10 patients (19.23%) had lymph node metastasis in 52 patients with EUS T2 cancers. In two T1 cases with lymph node metastasis, SLNs were positive with 100% accuracy. In ten T2 cases with lymph node metastasis, SLNs were positive in nine cases. In pathology, carbon nanoparticles were seen in lymphatic vessels, and lymphoid sinus and macrophages in negative SLNs. When SLNs were positive, carbon nanoparticles were seen around cancer cells in lymph nodes. The overall sensitivity, specificity, accuracy of SLNs in T1-2 colorectal cancers were 91.67, 100, 98.63%, respectively.Conclusions: We demonstrated the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1-2 colorectal cancers. Carbon nanoparticles black-dyed lymph nodes play a role as SLNs in T1-2 colorectal cancers. AD - Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China, ynjun@yahoo.com. AN - 109763622. Language: English. Entry Date: 20150717. Revision Date: 20200708. Publication Type: journal article AU - Yan, Jun AU - Xue, Fangqin AU - Chen, Hongyuan AU - Wu, Xiufeng AU - Zhang, Hui AU - Chen, Gang AU - Lu, Jianping AU - Cai, Lisheng AU - Xiang, Gao AU - Deng, Zhenwei AU - Zheng, Yu AU - Zheng, Xiaoling AU - Li, Guoxin DB - CINAHL Complete DO - 10.1007/s00464-014-3608-5 DP - EBSCOhost IS - 12 KW - Carbon -- Diagnostic Use Colorectal Neoplasms -- Pathology Dyes -- Diagnostic Use Lymph Nodes -- Pathology Nanoparticles Adolescence Adult Aged Clinical Trials Colectomy Colorectal Neoplasms -- Surgery Female Human Laparoscopy Lymph Node Excision Lymph Nodes -- Surgery Male Mesentery Middle Age Neoplasm Metastasis Pilot Studies Rectum -- Surgery Sensitivity and Specificity Young Adult N1 - clinical trial; research. Journal Subset: Biomedical; Continental Europe; Europe; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8806653. PMID: NLM24935202. PY - 2014 SN - 0930-2794 SP - 3315-3321 ST - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer T2 - Surgical Endoscopy TI - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1-2 colorectal cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109763622&site=ehost-live&scope=site VL - 28 ID - 1819 ER - TY - JOUR AB - Background: How to identify whether T1–2 colorectal cancers have lymph nodes metastases pre-op or intra-op is a crucial problem in clinic. The purpose of this study was to evaluate the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1–2 colorectal cancers. Methods: A multi-center study was performed between July 2012 and January 2014. Seventy-three patients with T1–2 colorectal cancer identified by pre-op endoscopic ultrasonography (EUS) were recruited. 1 ml carbon nanoparticles suspension was endoscopically injected into the submucosal layer at four points around the site of the primary tumor 1 day before surgery. Laparoscopic radical resection with lymphadenectomy was performed. Sentinel lymph nodes (SLNs) were defined as nodes that were black-dyed by carbon nanoparticles. Pathology confirmed whether lymph nodes have cancer metastases and the SLNs accuracy. Results: SLNs were easily found under laparoscopy. The mean number of SLNs was 3 (range 1–5). All patients had SLNs lying alongside the mesenteric vessel or main arterial vessel. After pathological analysis, 2 patients (9.52 %) had lymph node metastasis in 21 patients with EUS T1 cancers, and 10 patients (19.23 %) had lymph node metastasis in 52 patients with EUS T2 cancers. In two T1 cases with lymph node metastasis, SLNs were positive with 100 % accuracy. In ten T2 cases with lymph node metastasis, SLNs were positive in nine cases. In pathology, carbon nanoparticles were seen in lymphatic vessels, and lymphoid sinus and macrophages in negative SLNs. When SLNs were positive, carbon nanoparticles were seen around cancer cells in lymph nodes. The overall sensitivity, specificity, accuracy of SLNs in T1–2 colorectal cancers were 91.67, 100, 98.63 %, respectively. Conclusions: We demonstrated the feasibility of using carbon nanoparticles to track lymph nodes metastases in T1–2 colorectal cancers. Carbon nanoparticles black-dyed lymph nodes play a role as SLNs in T1–2 colorectal cancers. © 2014, Springer Science+Business Media New York. AD - Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China Department of Surgery, Fujian Provincial Tumor Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, China Department of Surgery, Fujian Provincial Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350001, China Department of Pathology, Fujian Provincial Tumor Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, Fujian 350014, China Department of Surgery, Zhangzhou Hospital, Teaching Hospital of Fujian Medical University, Zhangzhou, Fujian 363000, China Department of Surgery, Nanping Hospital, Teaching Hospital of Fujian Medical University, Nanping, Fujian 353000, China AU - Yan, J. AU - Xue, F. AU - Chen, H. AU - Wu, X. AU - Zhang, H. AU - Chen, G. AU - Lu, J. AU - Cai, L. AU - Xiang, G. AU - Deng, Z. AU - Zheng, Y. AU - Zheng, X. AU - Li, G. DB - Scopus DO - 10.1007/s00464-014-3608-5 IS - 12 KW - Carbon nanoparticles Lymph node metastasis Multi-center study Sentinel lymph nodes T1–2 colorectal cancer Tracer M3 - Article N1 - Cited By :21 Export Date: 22 March 2021 PY - 2014 SP - 3315-3321 ST - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1–2 colorectal cancer T2 - Surgical Endoscopy TI - A multi-center study of using carbon nanoparticles to track lymph node metastasis in T1–2 colorectal cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931374824&doi=10.1007%2fs00464-014-3608-5&partnerID=40&md5=a76aafdc126fb7742c3637dec90e957f VL - 28 ID - 2383 ER - TY - JOUR AB - Background: Reports continue to show that Blacks with curable lung or breast cancer complete treatment less often than similar Whites contributing to worse survival. ACCURE is an intervention trial designed to address this problem. Patients and methods: A pragmatic, quality improvement trial comparing an intervention group to retrospective and concurrent controls. Patients with early stage breast or lung cancer aged 18 to 85 were enrolled (N = 302) at 2 cancer centers between April 2013 and March 2015 for the intervention component. Data from patients seen between January 2007 and December 2012 with these diagnoses were obtained to establish control completion rates. Concurrent data for non-study patients were used to identify secular trends. The intervention included: a real time registry derived from electronic health records of participants to signal missed appointments or unmet care milestones, a navigator, and clinical feedback. The primary outcome was “Treatment Complete”, a composite variable representing completion of surgery, recommended radiation and chemotherapy for each patient. Results: The mean age in the intervention group was 63.1 years; 37.1% of patients were Black. Treatment completion in retrospective and concurrent controls showed significant Black-White differences (Blacks (B) 79.8% vs. Whites (W) 87.3%, p < 0.001; 83.1% B vs. 90.1% W, p < 0.001, respectively). The disparity lessened within the intervention (B 88.4% and W 89.5%, p = 0.77). Multivariate analyses confirmed disparities reduction. OR for Black-White disparity within the intervention was 0.98 (95% CI 0.46–2.1); Black completion in the intervention compared favorably to Whites in retrospective (OR 1.6; 95% CI 0.90–2.9) and concurrent (OR 1.1; 95% CI 0.59–2.0) controls. Conclusion: A real time registry combined with feedback and navigation improved completion of treatment for all breast and lung cancer patients and narrowed disparities. Similar multi-faceted interventions could mitigate disparities in the treatment of other cancers and chronic conditions. AD - S. Cykert, 145 N. Medical Drive, CB# 7165, Chapel Hill, NC, United States AU - Cykert, S. AU - Eng, E. AU - Manning, M. A. AU - Robertson, L. B. AU - Heron, D. E. AU - Jones, N. S. AU - Schaal, J. C. AU - Lightfoot, A. AU - Zhou, H. AU - Yongue, C. AU - Gizlice, Z. DB - Embase Medline DO - 10.1016/j.jnma.2019.03.001 IS - 5 KW - adult aged article Black person breast cancer cancer center cancer patient cancer staging Caucasian chemoradiotherapy chronic disease controlled study drug therapy electronic health record female human intervention study lung cancer major clinical study middle aged multicenter study outcome assessment racism radiation total quality management isotretinoin LA - English M3 - Article N1 - L2001737120 2019-04-01 PY - 2020 SN - 1943-4693 0027-9684 SP - 468-477 ST - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial T2 - Journal of the National Medical Association TI - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001737120&from=export http://dx.doi.org/10.1016/j.jnma.2019.03.001 VL - 112 ID - 784 ER - TY - JOUR AB - Background: Reports continue to show that Blacks with curable lung or breast cancer complete treatment less often than similar Whites contributing to worse survival. ACCURE is an intervention trial designed to address this problem. Patients and methods: A pragmatic, quality improvement trial comparing an intervention group to retrospective and concurrent controls. Patients with early stage breast or lung cancer aged 18 to 85 were enrolled (N = 302) at 2 cancer centers between April 2013 and March 2015 for the intervention component. Data from patients seen between January 2007 and December 2012 with these diagnoses were obtained to establish control completion rates. Concurrent data for non-study patients were used to identify secular trends. The intervention included: a real time registry derived from electronic health records of participants to signal missed appointments or unmet care milestones, a navigator, and clinical feedback. The primary outcome was 'Treatment Complete', a composite variable representing completion of surgery, recommended radiation and chemotherapy for each patient. Results: The mean age in the intervention group was 63.1 years; 37.1% of patients were Black. Treatment completion in retrospective and concurrent controls showed significant Black-White differences (Blacks (B) 79.8% vs. Whites (W) 87.3%, p < 0.001; 83.1% B vs. 90.1% W, p < 0.001, respectively). The disparity lessened within the intervention (B 88.4% and W 89.5%, p = 0.77). Multivariate analyses confirmed disparities reduction. OR for Black-White disparity within the intervention was 0.98 (95% CI 0.46–2.1); Black completion in the intervention compared favorably to Whites in retrospective (OR 1.6; 95% CI 0.90–2.9) and concurrent (OR 1.1; 95% CI 0.59–2.0) controls. Conclusion: A real time registry combined with feedback and navigation improved completion of treatment for all breast and lung cancer patients and narrowed disparities. Similar multi-faceted interventions could mitigate disparities in the treatment of other cancers and chronic conditions. (PsycInfo Database Record (c) 2021 APA, all rights reserved) AD - Cykert, Samuel, 145 N. Medical Drive, CB# 7165, Chapel Hill, NC, US, 27599 AN - 2021-10535-005 AU - Cykert, Samuel AU - Eng, Eugenia AU - Manning, Matthew A. AU - Robertson, Linda B. AU - Heron, Dwight E. AU - Jones, Nora S. AU - Schaal, Jennifer C. AU - Lightfoot, Alexandra AU - Zhou, Haibo AU - Yongue, Christina AU - Gizlice, Ziya DB - psyh DO - 10.1016/j.jnma.2019.03.001 DP - EBSCOhost IS - 5 KW - Cancer disparities Institutional racism Intervention Quality improvement racial differences Neoplasms Blacks Breast Neoplasms Medical Treatment (General) Racial and Ethnic Differences Racism Whites Group Intervention N1 - University of North Carolina School of Medicine, Chapel Hill, NC, US. Other Publishers: National Medical Assn. Release Date: 20210218. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Cykert, Samuel. Major Descriptor: Intervention; Neoplasms. Minor Descriptor: Blacks; Breast Neoplasms; Medical Treatment (General); Racial and Ethnic Differences; Racism; Whites; Group Intervention. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. Page Count: 10. Issue Publication Date: Oct, 2020. Copyright Statement: Published by Elsevier Inc. All rights reserved. National Medical Association. 2019. Sponsor: National Cancer Institute, US. Grant: 1R01CA150980-01A1. Recipients: Cykert, Samuel (Prin Inv); Eng, Eugenia (Prin Inv) PY - 2020 SN - 0027-9684 1943-4693 SP - 468-477 ST - A multi-faceted intervention aimed at Black-White disparities in the treatment of early stage cancers: The ACCURE pragmatic quality improvement trial T2 - Journal of the National Medical Association TI - A multi-faceted intervention aimed at Black-White disparities in the treatment of early stage cancers: The ACCURE pragmatic quality improvement trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2021-10535-005&site=ehost-live&scope=site samuel_cykert@med.unc.edu VL - 112 ID - 1666 ER - TY - JOUR AB - Background: Reports continue to show that Blacks with curable lung or breast cancer complete treatment less often than similar Whites contributing to worse survival. ACCURE is an intervention trial designed to address this problem. Patients and methods: A pragmatic, quality improvement trial comparing an intervention group to retrospective and concurrent controls. Patients with early stage breast or lung cancer aged 18 to 85 were enrolled (N = 302) at 2 cancer centers between April 2013 and March 2015 for the intervention component. Data from patients seen between January 2007 and December 2012 with these diagnoses were obtained to establish control completion rates. Concurrent data for non-study patients were used to identify secular trends. The intervention included: a real time registry derived from electronic health records of participants to signal missed appointments or unmet care milestones, a navigator, and clinical feedback. The primary outcome was “Treatment Complete”, a composite variable representing completion of surgery, recommended radiation and chemotherapy for each patient. Results: The mean age in the intervention group was 63.1 years; 37.1% of patients were Black. Treatment completion in retrospective and concurrent controls showed significant Black-White differences (Blacks (B) 79.8% vs. Whites (W) 87.3%, p < 0.001; 83.1% B vs. 90.1% W, p < 0.001, respectively). The disparity lessened within the intervention (B 88.4% and W 89.5%, p = 0.77). Multivariate analyses confirmed disparities reduction. OR for Black-White disparity within the intervention was 0.98 (95% CI 0.46–2.1); Black completion in the intervention compared favorably to Whites in retrospective (OR 1.6; 95% CI 0.90–2.9) and concurrent (OR 1.1; 95% CI 0.59–2.0) controls. Conclusion: A real time registry combined with feedback and navigation improved completion of treatment for all breast and lung cancer patients and narrowed disparities. Similar multi-faceted interventions could mitigate disparities in the treatment of other cancers and chronic conditions. © 2019 National Medical Association AD - The University of North Carolina School of Medicine, 145 N Medical Drive CB# 7165, Chapel Hill, NC 27599, United States Department of Health Behavior, The Gilling's School of Global Public Health, 360 Rosenau Hall, CB# 7440, Chapel Hill, NC 27599, United States Cone Health Cancer Center, 501 N Elam Ave, Greensboro, NC 27403, United States UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine 5150 Centre Avenue POB2 Cancer Pavilion, Room 438, Pittsburgh, PA 15232, United States Department of Radiation Oncology UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine5230 Centre Ave. PittsburghPA 15232, United States The Partnership Project, 301 S. Elm Street, Suite 414, Greensboro, NC 27401, United States Department of Health Behavior, The Gilling's School of Global Public Health 1700 Martin Luther King, Jr. Boulevard CB #7426, Chapel Hill, NC 27599, United States Department of Biostatistics, The Gilling's School of Global Public Health, The University of North Carolina at Chapel Hill, 3104C McGavran-Greenberg Hall, CB #7420, Chapel Hill, NC 27599, United States Department of Public Health Education, University of North Carolina at Greensboro, P.O. Box 26170, Greensboro, NC 27402-6170, United States Biostatistical Support Unit, The Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin Luther King Jr. Boulevard, CB# 7426, Chapel Hill, NC 27599, United States AU - Cykert, S. AU - Eng, E. AU - Manning, M. A. AU - Robertson, L. B. AU - Heron, D. E. AU - Jones, N. S. AU - Schaal, J. C. AU - Lightfoot, A. AU - Zhou, H. AU - Yongue, C. AU - Gizlice, Z. DB - Scopus DO - 10.1016/j.jnma.2019.03.001 IS - 5 KW - Cancer disparities Institutional racism Intervention Quality improvement M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2020 SP - 468-477 ST - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial T2 - Journal of the National Medical Association TI - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063412493&doi=10.1016%2fj.jnma.2019.03.001&partnerID=40&md5=5f9a2e84013c7bb1757c6ddf9cadc7b3 VL - 112 ID - 2181 ER - TY - JOUR AB - Background: Reports continue to show that Blacks with curable lung or breast cancer complete treatment less often than similar Whites contributing to worse survival. ACCURE is an intervention trial designed to address this problem. Patients and methods: A pragmatic. quality improvement trial comparing an intervention group to retrospective and concurrent controls. Patients with early stage breast or lung cancer aged 18 to 85 were enrolled (N = 302) at 2 cancer centers between April 2013 and March 2015 for the intervention component. Data from patients seen between January 2007 and December 2012 with these diagnoses were obtained to establish control completion rates. Concurrent data for non-study patients were used to identify secular trends. The intervention included: a real time registry derived from electronic health records of participants to signal missed appointments or unmet care milestones, a navigator, and clinical feedback. The primary outcome was "Treatment Complete", a composite variable representing completion of surgery. recommended radiation and chemotherapy for each patient. Results: The mean age in the intervention group was 63.1 years: 37.1% of patients were Black Treatment completion in retrospective and concurrent controls showed significant Black-White differences (Blacks (B) 79.8% vs. Whites (W) 87.3%, p < 0.001; 83.1% B vs. 90.1% W. p < 0.001, respectively). The disparity lessened within the intervention (B 88.4% and W 89.5%, p = 0.77). Multivariate analyses confirmed disparities reduction. OR for Black-White disparity within the intervention was 0.98 (95% CI 0.46-2.1); Black completion in the intervention compared favorably to Whites in retrospective (OR 1.6; 95% CI 0.90-2.9) and concurrent (OR 1.1; 95% CI 0.59-2.0) controls. Conclusion: A real time registry combined with feedback and navigation improved completion of treatment for all breast and lung cancer patients and narrowed disparities. Similar multi-faceted interventions could mitigate disparities in the treatment of other cancers and chronic conditions. AN - WOS:000596260600005 AU - Cykert, S. AU - Eng, E. AU - Manning, M. A. AU - Robertson, L. B. AU - Heron, D. E. AU - Jones, N. S. AU - Schaal, J. C. AU - Lightfoot, A. AU - Zhou, H. B. AU - Yongue, C. AU - Gizlice, Z. DA - Oct DO - 10.1016/j.jnma.2019.03.001 IS - 5 N1 - 30928088 PY - 2020 SN - 0027-9684 SP - 468-477 ST - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial T2 - Journal of the National Medical Association TI - A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trial VL - 112 ID - 2760 ER - TY - JOUR AB - Purpose: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men. AD - S. Punnen, Department of Urology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, 1120 Northwest 14th St., Suite 1560, Miami, Florida, United States AU - Punnen, S. AU - Freedland, S. J. AU - Polascik, T. J. AU - Loeb, S. AU - Risk, M. C. AU - Savage, S. AU - Mathur, S. C. AU - Uchio, E. AU - Dong, Y. AU - Silberstein, J. L. DB - Embase Medline DO - 10.1016/j.juro.2017.11.113 IS - 6 KW - kallikrein prostate specific antigen 4Kscore test African American article blood sampling calibration cancer diagnosis cohort analysis controlled study diagnostic test accuracy study digital rectal examination human human tissue major clinical study male non invasive procedure predictive value priority journal prospective study prostate biopsy prostate cancer scoring system task performance tumor biopsy LA - English M3 - Article N1 - L2000681317 2018-05-01 2018-05-21 PY - 2018 SN - 1527-3792 0022-5347 SP - 1459-1463 ST - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men T2 - Journal of Urology TI - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000681317&from=export http://dx.doi.org/10.1016/j.juro.2017.11.113 VL - 199 ID - 894 ER - TY - JOUR AB - Purpose: The 4Kscore® test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men. © 2018 American Urological Association Education and Research, Inc. AD - Department of Urology, University of Miami and Miami Veterans Affairs Medical Center, Miami, Florida, United States Cedars-Sinai Medical Center, Los Angeles, California, United States Department of Urology, University of California-Irvine, Irvine, California, United States Veterans Affairs Long Beach Health System, Long Beach, California, United States Durham Veterans Affairs Medical Center, Durham, North Carolina, United States Duke Cancer Institute, Durham, North Carolina, United States Department of Urology and Population Health, New York University and Manhattan Veterans Affairs Medical Center, New York, New York, United States Department of Urology, University of Minnesota and Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, United States Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States Pathology and Laboratory Medicine Service, Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States OPKO Diagnostics, Woburn, Massachusetts, United States Tulane University School of Medicine and Southeast Louisiana Veterans Health Care Center, New Orleans, Louisiana, United States AU - Punnen, S. AU - Freedland, S. J. AU - Polascik, T. J. AU - Loeb, S. AU - Risk, M. C. AU - Savage, S. AU - Mathur, S. C. AU - Uchio, E. AU - Dong, Y. AU - Silberstein, J. L. DB - Scopus DO - 10.1016/j.juro.2017.11.113 IS - 6 KW - African Americans biomarkers kallikreins neoplasm grading prostatic neoplasms tumor M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2018 SP - 1459-1463 ST - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men T2 - Journal of Urology TI - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045921236&doi=10.1016%2fj.juro.2017.11.113&partnerID=40&md5=0eca8c021e3ac72803aab130c11a69ae VL - 199 ID - 2269 ER - TY - JOUR AB - Purpose: The 4Kscore (R) test accurately detects aggressive prostate cancer and reduces unnecessary biopsies. However, its performance in African American men has been unknown. We assessed test performance in a cohort of men with a large African American representation. Materials and Methods: Men referred for prostate biopsy at 8 Veterans Affairs medical centers were prospectively enrolled in the study. All men underwent phlebotomy for 4Kscore test assessment prior to prostate biopsy. The primary outcome was the detection of Grade Group 2 or higher cancer on biopsy. We assessed the discrimination, calibration and clinical usefulness of 4Kscore to predict Grade Group 2 or higher prostate cancer and compared it to a base model consisting of age, digital rectal examination and prostate specific antigen. Additionally, we compared test performance in African American and nonAfrican American men. Results: Of the 366 enrolled men 205 (56%) were African American and 131 (36%) had Grade Group 2 or higher prostate cancer. The 4Kscore test showed better discrimination (AUC 0.81 vs 0.74, p <0.01) and higher clinical usefulness on decision curve analysis than the base model. Test prediction closely approximated the observed risk of Grade Group 2 or higher prostate cancer. There was no difference in test performance in African American and nonAfrican American men (0.80 vs 0.84, p = 0.32), The test outperformed the base model in each group. Conclusions: The 4Kscore test accurately predicts aggressive prostate cancer for biopsy decision making in African American and nonAfrican American men. AN - WOS:000431859900073 AU - Punnen, S. AU - Freedland, S. J. AU - Polascik, T. J. AU - Loeb, S. AU - Risk, M. C. AU - Savage, S. AU - Mathur, S. C. AU - Uchio, E. AU - Dong, Y. AU - Silberstein, J. L. DA - Jun DO - 10.1016/j.juro.2017.11.113 IS - 6 PY - 2018 SN - 0022-5347 SP - 1460-1464 ST - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men T2 - Journal of Urology TI - A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men VL - 199 ID - 2861 ER - TY - JOUR AB - Objective: Colon capsule endoscopy (CCE) has shown promise for colorectal neoplasia detection compared with optical colonoscopy (OC), but has not been compared with other screening tests in average risk screening patients. Design: Patients 50 to 75 years of age (African Americans, 45‐75 years) were randomised to CCE or CT colonography (CTC) and subsequent blinded OC. The primary endpoint was diagnostic yield of polyps ≥6 mm with CCE or CTC. Secondary endpoints included accuracy for size and histology, examination completeness, number/proportion of subjects with polyps and adenomas ≥6 mm and ≥10 mm, subject satisfaction and safety. Results: From 320 enrolled subjects, data from 286 (89.4%) were evaluable. The proportion of subjects with any polyp ≥6 mm confirmed by OC was 31.6% for CCE versus 8.6% for CTC (pPr non‐inferiority and superiority=0.999). The diagnostic yield of polyps ≥10 mm was 13.5% with CCE versus 6.3% with CTC (pPr non‐inferiority=0.9954). The sensitivity and specificity of CCE for polyps ≥6 mm was 79.2% and 96.3% while that of CTC was 26.8% and 98.9%. The sensitivity and specificity of CCE for polyps ≥10 mm was 85.7% and 98.2% compared with 50% and 99.1% for CTC. Both tests were well tolerated/safe. Conclusion: CCE was superior to CTC for detection of polyps ≥6 mm and non‐inferior for identification of polyps ≥10 mm. CCE should be considered comparable or superior to CTC as a colorectal neoplasia screening test, although neither test is as effective as OC. AN - CN-02215195 AU - Cash, B. D. AU - Fleisher, M. R. AU - Fern, S. AU - Rajan, E. AU - Haithcock, R. AU - Kastenberg, D. M. AU - Pound, D. AU - Papageorgiou, N. P. AU - Fernandez-Urien, I. AU - Schmelkin, I. J. AU - et al. DO - 10.1136/gutjnl-2020-322578 KW - *cancer screening *capsule endoscopy *colon adenoma *colon polyp *colorectal cancer *computed tomographic colonography *diagnostic value *histology *prospective study Adult African American Aged Article Cancer size Colorectal tumor Controlled study Diagnostic test accuracy study Drug safety Female Histopathology Human Human tissue Major clinical study Male Middle aged Multicenter study Randomized controlled trial Satisfaction Screening test Sensitivity and specificity M3 - Journal: Article in Press PY - 2020 ST - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study) T2 - Gut TI - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02215195/full ID - 1447 ER - TY - JOUR AB - Objective: Colon capsule endoscopy (CCE) has shown promise for colorectal neoplasia detection compared with optical colonoscopy (OC), but has not been compared with other screening tests in average risk screening patients. Design: Patients 50 to 75 years of age (African Americans, 45-75 years) were randomised to CCE or CT colonography (CTC) and subsequent blinded OC. The primary endpoint was diagnostic yield of polyps ≥6 mm with CCE or CTC. Secondary endpoints included accuracy for size and histology, examination completeness, number/proportion of subjects with polyps and adenomas ≥6 mm and ≥10 mm, subject satisfaction and safety. Results: From 320 enrolled subjects, data from 286 (89.4%) were evaluable. The proportion of subjects with any polyp ≥6 mm confirmed by OC was 31.6% for CCE versus 8.6% for CTC (pPr non-inferiority and superiority=0.999). The diagnostic yield of polyps ≥10 mm was 13.5% with CCE versus 6.3% with CTC (pPr non-inferiority=0.9954). The sensitivity and specificity of CCE for polyps ≥6 mm was 79.2% and 96.3% while that of CTC was 26.8% and 98.9%. The sensitivity and specificity of CCE for polyps ≥10 mm was 85.7% and 98.2% compared with 50% and 99.1% for CTC. Both tests were well tolerated/safe. Conclusion: CCE was superior to CTC for detection of polyps ≥6 mm and non-inferior for identification of polyps ≥10 mm. CCE should be considered comparable or superior to CTC as a colorectal neoplasia screening test, although neither test is as effective as OC. AD - B.D. Cash, Department of Gastroenterology, University of Texas Health Science Center at Houston, Houston, TX, United States AU - Cash, B. D. AU - Fleisher, M. R. AU - Fern, S. AU - Rajan, E. AU - Haithcock, R. AU - Kastenberg, D. M. AU - Pound, D. AU - Papageorgiou, N. P. AU - Fernández-Urién, I. AU - Schmelkin, I. J. AU - Rex, D. K. DB - Embase Medline DO - 10.1136/gutjnl-2020-322578 KW - adult African American aged article cancer screening cancer size capsule endoscopy colon adenoma colon polyp colorectal cancer colorectal tumor computed tomographic colonography controlled study diagnostic test accuracy study diagnostic value drug safety female histology histopathology human human tissue major clinical study male middle aged multicenter study prospective study randomized controlled trial satisfaction screening test sensitivity and specificity unclassified drug LA - English M3 - Article in Press N1 - L633756910 2020-12-30 PY - 2020 SN - 1468-3288 0017-5749 ST - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study) T2 - Gut TI - Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633756910&from=export http://dx.doi.org/10.1136/gutjnl-2020-322578 ID - 828 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with "real world" patients.Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for underserved patients.Methods: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857.Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups.Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention. AD - Department of Family Medicine, University of Rochester School of Medicine and Dentistry, New York, USA Department of Family Medicine, University of Rochester School of Medicine and Dentistry, New York, USA. kevin_fiscella@urmc.rochester.edu AN - 108200351. Language: English. Entry Date: 20120323. Revision Date: 20190612. Publication Type: journal article AU - Fiscella, K. AU - Humiston, S. AU - Hendren, S. AU - Winters, P. AU - Idris, A. AU - Li, S. X. AU - Ford, P. AU - Specht, R. AU - Marcus, S. AU - Fiscella, Kevin AU - Humiston, Sharon AU - Hendren, Samantha AU - Winters, Paul AU - Idris, Amna AU - Li, Shirley X. L. AU - Ford, Patricia AU - Specht, Raymond AU - Marcus, Steven DB - CINAHL Complete DP - EBSCOhost IS - 8 KW - Colonoscopy -- Statistics and Numerical Data Health Promotion -- Administration Health Promotion -- Statistics and Numerical Data Mammography -- Statistics and Numerical Data Occult Blood Sigmoidoscopy -- Statistics and Numerical Data Adult Aged Breast Neoplasms -- Prevention and Control Female Human Male Middle Age Multivariate Analysis Urban Population Clinical Trials N1 - clinical trial; research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 7503090. PMID: NLM22046855. PY - 2011 SN - 0027-9684 SP - 762-768 ST - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice T2 - Journal of the National Medical Association TI - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108200351&site=ehost-live&scope=site VL - 103 ID - 1820 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with "real world" patients. Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for under-served patients. Methods: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention. AD - K. Fiscella, 1381 South Ave, Rochester, NY 14620, United States AU - Fiscella, K. AU - Humiston, S. AU - Hendren, S. AU - Winters, P. AU - Idris, A. AU - Li, S. X. L. AU - Ford, P. AU - Specht, R. AU - Marcus, S. DB - Embase Medline DO - 10.1016/S0027-9684(15)30417-X IS - 8 KW - NCT00818857 adult African American aged article breast cancer cancer screening colorectal cancer controlled clinical trial controlled study cost effectiveness analysis ethnicity female general practice health insurance Hispanic human major clinical study male mammography medicaid medicare multivariate analysis point of care testing priority journal race difference safety socioeconomics statistical significance LA - English M3 - Article N1 - L364939049 2012-06-15 2012-06-19 PY - 2011 SN - 0027-9684 SP - 762-768 ST - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice T2 - Journal of the National Medical Association TI - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L364939049&from=export http://dx.doi.org/10.1016/S0027-9684(15)30417-X http://www.nmanet.org/index.php?option=com_content&view=article&id=234&Itemid=363 VL - 103 ID - 1133 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety‐net practices with "real world" patients. Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety‐net practice caring for under‐served patients. Methods: At an inner‐city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12‐month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point‐of‐care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety‐net practice. Further study will identify the most cost‐effective components of the intervention. AN - CN-00900539 AU - Fiscella, K. AU - Humiston, S. AU - Hendren, S. AU - Winters, P. AU - Idris, A. AU - Li, S. X. L. AU - Ford, P. AU - Specht, R. AU - Marcus, S. IS - 8 KW - *breast cancer/di [Diagnosis] *breast cancer/dm [Disease Management] *cancer screening *colorectal cancer/di [Diagnosis] *colorectal cancer/dm [Disease Management] *mammography Adult African American Aged Article Controlled clinical trial Controlled study Cost effectiveness analysis Ethnicity Female General practice Health insurance Hispanic Human Major clinical study Male Medicaid Medicare Multivariate analysis Point of care testing Priority journal Race difference Safety Socioeconomics Statistical significance M3 - Journal: Article PY - 2011 SP - 762‐768 ST - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice T2 - Journal of the national medical association TI - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00900539/full VL - 103 ID - 1457 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with 'real world' patients. Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for under-served patients. Methods: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Fiscella, Kevin, 1381 South Ave, Rochester, NY, US, 14620 AN - 2011-23916-010 AU - Fiscella, Kevin AU - Humiston, Sharon AU - Hendren, Samantha AU - Winters, Paul AU - Idris, Amna AU - Li, Shirley X. L. AU - Ford, Patricia AU - Specht, Raymond AU - Marcus, Steven DB - psyh DO - 10.1016/S0027-9684(15)30417-X DP - EBSCOhost IS - 8 KW - multimodal intervention mammography colorectal cancer screening safety net practice underserved patients Adult Aged Breast Neoplasms Colonoscopy Female Health Promotion Humans Male Middle Aged Multivariate Analysis Occult Blood Sigmoidoscopy Urban Population Cancer Screening Intervention Public Health Colon Disorders N1 - Department of Family Medicine, University of Rochester, School of Medicine and Dentistry, Rochester, NY, US. Other Publishers: Elsevier Science. Release Date: 20120319. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Intervention; Mammography; Public Health. Minor Descriptor: Breast Neoplasms; Colon Disorders. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Aug, 2011. Sponsor: American Cancer Society, US. Grant: RSGT-08-077-01-CPHPS. Recipients: No recipient indicated PY - 2011 SN - 0027-9684 1943-4693 SP - 762-768 ST - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice T2 - Journal of the National Medical Association TI - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-23916-010&site=ehost-live&scope=site kevin_fiscella@urmc.rochester.edu VL - 103 ID - 1729 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with "real world" patients. Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for under-served patients. Methods: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention. AD - Department of Family Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States Emergency Medicine Services Division, Children's Mercy Hospitals and Clinics, Kansas City, MO, United States Department of Surgery, University of Michigan, School of Medicine, Ann Arbor, MI, United States Department of Family Medicine, Highland Hospital, Rochester, NY, United States AU - Fiscella, K. AU - Humiston, S. AU - Hendren, S. AU - Winters, P. AU - Idris, A. AU - Li, S. X. L. AU - Ford, P. AU - Specht, R. AU - Marcus, S. DB - Scopus DO - 10.1016/S0027-9684(15)30417-X IS - 8 KW - Cancer Colorectal Urban population M3 - Article N1 - Cited By :21 Export Date: 22 March 2021 PY - 2011 SP - 762-768 ST - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice T2 - Journal of the National Medical Association TI - A multimodal intervention to promote mammography and colorectal cancer screening in a safety-net practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856408044&doi=10.1016%2fS0027-9684%2815%2930417-X&partnerID=40&md5=327fa0a66dd81dd6386c8266d3742268 VL - 103 ID - 2486 ER - TY - JOUR AB - Background: There are limited data regarding interventions designed to improve cancer screening rates in safety-net practices with "real world" patients. Objective: To examine the impact of a multimodal intervention on mammography and colorectal cancer (CRC) screening rates in a safety-net practice caring for under-served patients. Methods: At an inner-city family medicine practice, all patients past due for mammography or CRC screening were assigned to receive or not receive a screening promotion intervention based on their medical record number. The 12-month intervention included outreach to patients (tailored letters, automated and personal phone calls) and point-of-care patient and clinician prompts. The trial was registered at clinicaltrials.gov, NCT00818857. Results: We enrolled 469 participants aged 40 to 74 years, including 28% African Americans, 5% Latinos, 25% with Medicaid, and 10% without any form of insurance. Participants in the intervention group showed statistically significantly higher rates of cancer screening; rates were 41% vs 16.8% for mammography and 28.8% vs 10% for CRC screening. These findings were confirmed in multivariable analysis. Similar relative improvements in screening were seen across race, ethnicity, socioeconomic status, and insurance groups. Discussion: A multimodal intervention shows promise for improving rates of mammography and colorectal cancer screening within a safety-net practice. Further study will identify the most cost-effective components of the intervention. AN - WOS:000295911300013 AU - Fiscella, K. AU - Humiston, S. AU - Hendren, S. AU - Winters, P. AU - Idris, A. AU - Li, S. X. L. AU - Ford, P. AU - Specht, R. AU - Marcus, S. DA - Aug DO - 10.1016/S0027-9684(15)30417-X IS - 8 N1 - 22046855 PY - 2011 SN - 0027-9684 SP - 762-768 ST - A Multimodal Intervention to Promote Mammography and Colorectal Cancer Screening in a Safety-Net Practice T2 - Journal of the National Medical Association TI - A Multimodal Intervention to Promote Mammography and Colorectal Cancer Screening in a Safety-Net Practice VL - 103 ID - 3088 ER - TY - JOUR AB - Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. This gap in precision oncology research represents a major challenge in the health disparities in the United States. Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431 cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or African-American ancestry. Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and 7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American population. Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to cancer outcome disparities among different racial/ethnic groups. AN - WOS:000406037400001 AU - Kytola, V. AU - Topaloglu, U. AU - Miller, L. D. AU - Bitting, R. L. AU - Goodman, M. M. AU - Agostino, R. B. D. AU - Desnoyers, R. J. AU - Albright, C. AU - Yacoub, G. AU - Qasem, S. A. AU - DeYoung, B. AU - Thorsson, V. AU - Shmulevich, I. AU - Yang, M. AU - Shcherban, A. AU - Pagni, M. AU - Liu, L. AU - Nykter, M. AU - Chen, K. X. AU - Hawkins, G. A. AU - Grant, S. C. AU - Petty, W. J. AU - Alistar, A. T. AU - Levine, E. A. AU - Staren, E. D. AU - Langefeld, C. D. AU - Miller, V. AU - Singal, G. AU - Petro, R. M. AU - Mac, Robinson AU - Blackstock, W. AU - Powell, B. L. AU - Wagner, L. I. AU - Foley, K. L. AU - Abraham, E. AU - Pasche, B. AU - Zhang, W. DO - 10.7150/thno.20355 IS - 11 N1 - 28824725 PY - 2017 SN - 1838-7640 SP - 2914-2923 ST - Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center T2 - Theranostics TI - Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center VL - 7 ID - 2917 ER - TY - JOUR AB - Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. This gap in precision oncology research represents a major challenge in the health disparities in the United States. Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431 cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or African-American ancestry. Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and 7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American population. Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to cancer outcome disparities among different racial/ethnic groups. AD - W. Zhang, Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, 1 Medical School Blvd., Winston-Salem, NC AU - Kytola, V. AU - Topaloglu, U. AU - Miller, L. D. AU - Bitting, R. L. AU - Goodman, M. M. AU - D'Agostino, R. B. AU - Desnoyers, R. J. AU - Albright, C. AU - Yacoub, G. AU - Qasem, S. A. AU - DeYoung, B. AU - Thorsson, V. AU - Shmulevich, I. AU - Yang, M. AU - Shcherban, A. AU - Pagni, M. AU - Liu, L. AU - Nykter, M. AU - Chen, K. AU - Hawkins, G. A. AU - Grant, S. C. AU - Petty, W. J. AU - Alistar, A. T. AU - Levine, E. A. AU - Staren, E. D. AU - Langefeld, C. D. AU - Miller, V. AU - Singal, G. AU - Petro, R. M. AU - Robinson, M. AU - Blackstock, W. AU - Powell, B. L. AU - Wagner, L. I. AU - Foley, K. L. AU - Abraham, E. AU - Pasche, B. AU - Zhang, W. DB - Embase Medline DO - 10.7150/thno.20355 IS - 11 KW - NCT02566421 ATM protein BRCA2 protein protein p53 African American article ATM gene bladder cancer BRCA2 gene Caucasian chromosomal instability colorectal cancer gene gene amplification gene mutation genetic association genomic instability head and neck cancer high frequency mutation human human tissue KMT2C gene KMT2D gene lung cancer major clinical study malignant neoplasm MLL2 gene MLL3 gene mutation rate mutational load smoking smoking related cancer TP53 gene LA - English M3 - Article N1 - L617426089 2017-07-28 2017-07-31 PY - 2017 SN - 1838-7640 SP - 2914-2923 ST - Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist comprehensive Cancer Center T2 - Theranostics TI - Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist comprehensive Cancer Center UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617426089&from=export http://dx.doi.org/10.7150/thno.20355 VL - 7 ID - 949 ER - TY - JOUR AB - Background: Cancers related to tobacco use and African-American ancestry are under-characterized by genomics. This gap in precision oncology research represents a major challenge in the health disparities in the United States. Methods: The Precision Oncology trial at the Wake Forest Baptist Comprehensive Cancer Center enrolled 431 cancer patients from March 2015 to May 2016. The composition of these patients consists of a high representation of tobacco-related cancers (e.g., lung, colorectal, and bladder) and African-American ancestry (13.5%). Tumors were sequenced to identify mutations to gain insight into genetic alterations associated with smoking and/or African-American ancestry. Results: Tobacco-related cancers exhibit a high mutational load. These tumors are characterized by high-frequency mutations in TP53, DNA damage repair genes (BRCA2 and ATM), and chromatin remodeling genes (the lysine methyltransferases KMT2D or MLL2, and KMT2C or MLL3). These tobacco-related cancers also exhibit augmented tumor heterogeneities. Smoking related genetic mutations were validated by The Cancer Genome Atlas dataset that includes 2,821 cases with known smoking status. The Wake Forest and The Cancer Genome Atlas cohorts (431 and 7,991 cases, respectively) revealed a significantly increased mutation rate in the TP53 gene in the African-American subgroup studied. Both cohorts also revealed 5 genes (e.g. CDK8) significantly amplified in the African-American population. Conclusions: These results provide strong evidence that tobacco is a major cause of genomic instability and heterogeneity in cancer. TP53 mutations and key oncogene amplifications emerge as key factors contributing to cancer outcome disparities among different racial/ethnic groups. © Ivyspring International Publisher. AD - Wake Forest Baptist Comprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, United States Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Internal Medicine-Section of Hematology and Oncology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Laboratory Medicine and Pathology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of General Surgery-Section of Surgical Oncology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Radiology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston Salem, NC 27157, United States Institute for Biosciences and Medical Technology, University of Tampere, Tampere, 33520, Finland Institute for Systems Biology, Seattle, WA 98109, United States Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China Foundation Medicine, Cambridge, MA 02141, United States Wake Forest School of Medicine, Winston Salem, NC 27157, United States Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston Salem, NC 27157, United States AU - Kytola, V. AU - Topaloglu, U. AU - Miller, L. D. AU - Bitting, R. L. AU - Goodman, M. M. AU - D'Agostino, R. B., Jr. AU - Desnoyers, R. J. AU - Albright, C. AU - Yacoub, G. AU - Qasem, S. A. AU - DeYoung, B. AU - Thorsson, V. AU - Shmulevich, I. AU - Yang, M. AU - Shcherban, A. AU - Pagni, M. AU - Liu, L. AU - Nykter, M. AU - Chen, K. AU - Hawkins, G. A. AU - Grant, S. C. AU - Petty, W. J. AU - Alistar, A. T. AU - Levine, E. A. AU - Staren, E. D. AU - Langefeld, C. D. AU - Miller, V. AU - Singal, G. AU - Petro, R. M. AU - Robinson, M. AU - Blackstock, W. AU - Powell, B. L. AU - Wagner, L. I. AU - Foley, K. L. AU - Abraham, E. AU - Pasche, B. AU - Zhang, W. DB - Scopus DO - 10.7150/thno.20355 IS - 11 M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2017 SP - 2914-2923 ST - Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist comprehensive Cancer Center T2 - Theranostics TI - Mutational landscapes of smoking-related cancers in Caucasians and African Americans: Precision oncology perspectives at Wake Forest Baptist comprehensive Cancer Center UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85025444732&doi=10.7150%2fthno.20355&partnerID=40&md5=5d85c78d2a0f6be8f3828ca445b4ed86 VL - 7 ID - 2324 ER - TY - JOUR AB - Recent clinical practice guidelines on prostate cancer screening using the prostate-specific antigen (PSA) test (PSA screening) have recommended that clinicians practice shared decision making-a process involving clinician-patient discussion of the pros, cons, and uncertainties of screening. We undertook a study to determine the prevalence of shared decision making in both PSA screening and nonscreening, as well as patient characteristics associated with shared decision making. A nationally representative sample of 3,427 men aged 50 to 74 years participating in the 2010 National Health Interview Survey responded to questions on the extent of shared decision making (past physician-patient discussion of advantages, disadvantages, and scientific uncertainty associated with PSA screening), PSA screening intensity (tests in past 5 years), and sociodemographic and health-related characteristics. Nearly two-thirds (64.3%) of men reported no past physician-patient discussion of advantages, disadvantages, or scientific uncertainty (no shared decision making); 27.8% reported discussion of 1 to 2 elements only (partial shared decision making); 8.0% reported discussion of all 3 elements (full shared decision making). Nearly one-half (44.2%) reported no PSA screening, 27.8% reported low-intensity (less-than-annual) screening, and 25.1% reported high-intensity (nearly annual) screening. Absence of shared decision making was more prevalent in men who were not screened; 88% (95% CI, 86.2%-90.1%) of nonscreened men reported no shared decision making compared with 39% (95% CI, 35.0%-43.3%) of men undergoing high-intensity screening. Extent of shared decision making was associated with black race, Hispanic ethnicity, higher education, health insurance, and physician recommendation. Screening intensity was associated with older age, higher education, usual source of medical care, and physician recommendation, as well as with partial vs no or full shared decision making. Most US men report little shared decision making in PSA screening, and the lack of shared decision making is more prevalent in nonscreened than in screened men. Screening intensity is greatest with partial shared decision making, and different elements of shared decision making are associated with distinct patient characteristics. Shared decision making needs to be improved in decisions for and against PSA screening. AD - P.K. Han, Maine Medical Center Research Institute, Portland, ME 04101, USA. AU - Han, P. K. AU - Kobrin, S. AU - Breen, N. AU - Joseph, D. A. AU - Li, J. AU - Frosch, D. L. AU - Klabunde, C. N. DB - Medline DO - 10.1370/afm.1539 IS - 4 KW - prostate specific antigen tumor marker adult aged article attitude to health blood decision making early diagnosis human male mass screening methodology middle aged patient care patient participation prevalence prostate tumor psychological aspect risk factor United States LA - English M3 - Article N1 - L370054080 2013-10-25 PY - 2013 SN - 1544-1717 SP - 306-314 ST - National evidence on the use of shared decision making in prostate-specific antigen screening T2 - Annals of family medicine TI - National evidence on the use of shared decision making in prostate-specific antigen screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L370054080&from=export http://dx.doi.org/10.1370/afm.1539 VL - 11 ID - 1076 ER - TY - JOUR AB - BACKGROUND: One of the first chemoprevention trials conducted in the western hemisphere, the National Surgical Adjuvant Breast and Bowel Project's (NSABP) Breast Cancer Prevention Trial (BCPT), demonstrated the need to evaluate all aspects of recruitment in real time and to implement strategies to enroll racial and ethnic minority women. PURPOSE: The purpose of this report is to review various patient recruitment efforts the NSABP developed to enhance the participation of racial and ethnic minority women in the Study of Tamoxifen and Raloxifene (STAR) trial and to describe the role that the recruitment process played in the implementation and understanding of breast cancer risk assessment in minority communities. METHODS: The NSABP STAR trial was a randomized, double‐blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5‐year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5‐year predicted breast cancer risk of 1.66% based on the modified Gail Model. For the current report, eligibility and enrollment data were tabulated by race/ethnicity for women who submitted STAR risk assessment forms (RAFs). RESULTS: A total of 184,460 RAFs were received, 145,550 (78.9%) from white women and 38,910 (21.1%) from minority women. Of the latter group, 21,444 (11.6%) were from African Americans/blacks, 7913 (4.5%) from Hispanics/Latinas, and 9553 (5.2%) from other racial or ethnic groups. The percentages of risk‐eligible women among African Americans, Hispanics/Latinas, others, and whites were 14.2%, 23.3%, 13.7%, and 57.4%, respectively. Programs targeting minority enrollment submitted large numbers of RAFs, but the eligibility rates of the women referred from those groups tended to be lower than the rates among women referred outside of those programs. The average number of completed risk assessments increased among minority women over the course of the recruitment period compared to those from whites. LIMITATIONS: We have not addressed all identified barriers to the recruitment of minorities in clinical research. Our risk assessments and recruitment results do not reflect the modified Gail Model for African Americans. CONCLUSIONS: Recruitment strategies used in STAR for racial and ethnic minorities contributed to doubling the minority enrollment compared to that in the BCPT and increased the awareness of breast cancer risk assessment in minority communities. Incorporation of new information into models to improve the risk estimation of diverse populations should prove beneficial. AN - CN-00877648 AU - McCaskill-Stevens, W. AU - Wilson, J. W. AU - Cook, E. D. AU - Edwards, C. L. AU - Gibson, R. V. AU - McElwain, D. L. AU - Figueroa-Moseley, C. D. AU - Paskett, E. D. AU - Roberson, N. L. AU - Wickerham, D. L. AU - et al. DO - 10.1177/1740774512470315 IS - 2 KW - African Americans Antineoplastic Agents [*administration & dosage, therapeutic use] Breast Neoplasms [ethnology, *prevention & control] Chemoprevention Community‐Based Participatory Research [methods] Continental Population Groups [*statistics & numerical data] Double‐Blind Method European Continental Ancestry Group Female Hispanic Americans Humans Patient Education as Topic Patient Selection Raloxifene Hydrochloride [*administration & dosage, therapeutic use] Randomized Controlled Trials as Topic [*methods] Risk Assessment Tamoxifen [*administration & dosage, therapeutic use] M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2013 SP - 280‐291 ST - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities T2 - Clinical trials (London, England) TI - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00877648/full VL - 10 ID - 1375 ER - TY - JOUR AB - Background One of the first chemoprevention trials conducted in the western hemisphere, the National Surgical Adjuvant Breast and Bowel Project's (NSABP) Breast Cancer Prevention Trial (BCPT), demonstrated the need to evaluate all aspects of recruitment in real time and to implement strategies to enroll racial and ethnic minority women. Purpose The purpose of this report is to review various patient recruitment efforts the NSABP developed to enhance the participation of racial and ethnic minority women in the Study of Tamoxifen and Raloxifene (STAR) trial and to describe the role that the recruitment process played in the implementation and understanding of breast cancer risk assessment in minority communities. Methods The NSABP STAR trial was a randomized, double-blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5-year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5-year predicted breast cancer risk of 1.66% based on the modified Gail Model. For the current report, eligibility and enrollment data were tabulated by race/ethnicity for women who submitted STAR risk assessment forms (RAFs). Results A total of 184,460 RAFs were received, 145,550 (78.9%) from white women and 38,910 (21.1%) from minority women. Of the latter group, 21,444 (11.6%) were from African Americans/blacks, 7913 (4.5%) from Hispanics/Latinas, and 9553 (5.2%) from other racial or ethnic groups. The percentages of risk-eligible women among African Americans, Hispanics/Latinas, others, and whites were 14.2%, 23.3%, 13.7%, and 57.4%, respectively. Programs targeting minority enrollment submitted large numbers of RAFs, but the eligibility rates of the women referred from those groups tended to be lower than the rates among women referred outside of those programs. The average number of completed risk assessments increased among minority women over the course of the recruitment period compared to those from whites. Limitations We have not addressed all identified barriers to the recruitment of minorities in clinical research. Our risk assessments and recruitment results do not reflect the modified Gail Model for African Americans. Conclusions Recruitment strategies used in STAR for racial and ethnic minorities contributed to doubling the minority enrollment compared to that in the BCPT and increased the awareness of breast cancer risk assessment in minority communities. Incorporation of new information into models to improve the risk estimation of diverse populations should prove beneficial. © The Author(s) 2013. AD - W. McCaskill-Stevens, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892, United States AU - McCaskill-Stevens, W. AU - Wilson, J. W. AU - Cook, E. D. AU - Edwards, C. L. AU - Gibson, R. V. AU - McElwain, D. L. AU - Figueroa-Moseley, C. D. AU - Paskett, E. D. AU - Roberson, N. L. AU - Wickerham, D. L. AU - Wolmark, N. DB - Embase Medline DO - 10.1177/1740774512470315 IS - 2 KW - NCT00003906 raloxifene tamoxifen African American article breast cancer cancer prevention cancer risk Caucasian drug efficacy ethnic group ethnicity female Hispanic human major clinical study outcome assessment patient selection postmenopause priority journal race randomized controlled trial (topic) risk assessment treatment duration LA - English M3 - Article N1 - L368780527 2013-05-01 2013-05-07 PY - 2013 SN - 1740-7745 1740-7753 SP - 280-291 ST - National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities T2 - Clinical Trials TI - National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368780527&from=export http://dx.doi.org/10.1177/1740774512470315 VL - 10 ID - 1084 ER - TY - JOUR AD - National Cancer Institute (NCI), Bethesda, MD, USA, National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA, USA National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA, USA, Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer Center, Houston, TX, USA Cancer Clinical Trials Office, Karmos Cancer Institute, Detroit, MI Department of Surgery, Breast Surgical Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA York Cancer Center, York, PA, USA California Department of Public Health, California Tobacco Control Program, Sacramento, CA, USA Division of Cancer Prevention and Control, Department of Internal Medicine, Ohio State University – Comprehensive Cancer Center, Columbus, OH, USA Roberson Consulting International, Amherst, NY, USA National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers, Pittsburgh, PA, USA, Department of Hematology/Oncology, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA, USA AN - 104259065. Language: English. Entry Date: 20130408. Revision Date: 20200708. Publication Type: Journal Article AU - McCaskill-Stevens, Worta AU - Wilson, John W. AU - Cook, Elise D. AU - Edwards, Cora L. AU - Gibson, Regina V. AU - McElwain, Diane L. AU - Figueroa-Moseley, Colmar D. AU - Paskett, Electra D. AU - Roberson, Noma L. AU - Wickerham, D. Lawrence AU - Wolmark, Norman DB - CINAHL Complete DO - 10.1177/1740774512470315 DP - EBSCOhost IS - 2 KW - Breast Neoplasms Surgery, Operative Colonic Neoplasms Tamoxifen -- Therapeutic Use Raloxifene -- Therapeutic Use Minority Groups Research Subject Recruitment Human Women Black Persons Hispanic Americans White Persons Adverse Drug Event Risk Assessment Corporations Native Americans Funding Source N1 - forms; research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: This study was supported by Public Health Service grants U10-CA-37377, U10-CA-69974, U10-CA- 12027, and U10-CA-69651 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, AstraZeneca, and Eli Lilly.. NLM UID: 101285473. PMID: NLM23335675. PY - 2013 SN - 1740-7745 SP - 280-291 ST - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities T2 - Clinical Trials TI - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104259065&site=ehost-live&scope=site VL - 10 ID - 2003 ER - TY - JOUR AB - Background One of the first chemoprevention trials conducted in the western hemisphere, the National Surgical Adjuvant Breast and Bowel Project's (NSABP) Breast Cancer Prevention Trial (BCPT), demonstrated the need to evaluate all aspects of recruitment in real time and to implement strategies to enroll racial and ethnic minority women. Purpose The purpose of this report is to review various patient recruitment efforts the NSABP developed to enhance the participation of racial and ethnic minority women in the Study of Tamoxifen and Raloxifene (STAR) trial and to describe the role that the recruitment process played in the implementation and understanding of breast cancer risk assessment in minority communities. Methods The NSABP STAR trial was a randomized, double-blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5-year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5-year predicted breast cancer risk of 1.66% based on the modified Gail Model. For the current report, eligibility and enrollment data were tabulated by race/ethnicity for women who submitted STAR risk assessment forms (RAFs). Results A total of 184,460 RAFs were received, 145,550 (78.9%) from white women and 38,910 (21.1%) from minority women. Of the latter group, 21,444 (11.6%) were from African Americans/blacks, 7913 (4.5%) from Hispanics/Latinas, and 9553 (5.2%) from other racial or ethnic groups. The percentages of risk-eligible women among African Americans, Hispanics/Latinas, others, and whites were 14.2%, 23.3%, 13.7%, and 57.4%, respectively. Programs targeting minority enrollment submitted large numbers of RAFs, but the eligibility rates of the women referred from those groups tended to be lower than the rates among women referred outside of those programs. The average number of completed risk assessments increased among minority women over the course of the recruitment period compared to those from whites. Limitations We have not addressed all identified barriers to the recruitment of minorities in clinical research. Our risk assessments and recruitment results do not reflect the modified Gail Model for African Americans. Conclusions Recruitment strategies used in STAR for racial and ethnic minorities contributed to doubling the minority enrollment compared to that in the BCPT and increased the awareness of breast cancer risk assessment in minority communities. Incorporation of new information into models to improve the risk estimation of diverse populations should prove beneficial. © The Author(s) 2013. AD - Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892, United States National Surgical Adjuvant Breast and Bowel Project (NSABP), Operations and Biostatistical Centers, Pittsburgh, PA, United States Department of Biostatistics, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, United States Department of Clinical Cancer Prevention, University of Texas, MD Anderson Cancer Center, Houston, TX, United States Cancer Clinical Trials Office, Karmos Cancer Institute, Detroit, MI, United States Department of Surgery, Breast Surgical Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, United States York Cancer Center, York, PA, United States California Department of Public Health, California Tobacco Control Program, Sacramento, CA, United States Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States Roberson Consulting International, Amherst, NY, United States Department of Hematology/Oncology, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA, United States AU - McCaskill-Stevens, W. AU - Wilson, J. W. AU - Cook, E. D. AU - Edwards, C. L. AU - Gibson, R. V. AU - McElwain, D. L. AU - Figueroa-Moseley, C. D. AU - Paskett, E. D. AU - Roberson, N. L. AU - Wickerham, D. L. AU - Wolmark, N. DB - Scopus DO - 10.1177/1740774512470315 IS - 2 M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2013 SP - 280-291 ST - National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities T2 - Clinical Trials TI - National surgical adjuvant breast and bowel project study of tamoxifen and raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876590452&doi=10.1177%2f1740774512470315&partnerID=40&md5=3c02573e905d4adc338b335f92348bb3 VL - 10 ID - 2434 ER - TY - JOUR AB - Background One of the first chemoprevention trials conducted in the western hemisphere, the National Surgical Adjuvant Breast and Bowel Project's (NSABP) Breast Cancer Prevention Trial (BCPT), demonstrated the need to evaluate all aspects of recruitment in real time and to implement strategies to enroll racial and ethnic minority women. Purpose The purpose of this report is to review various patient recruitment efforts the NSABP developed to enhance the participation of racial and ethnic minority women in the Study of Tamoxifen and Raloxifene (STAR) trial and to describe the role that the recruitment process played in the implementation and understanding of breast cancer risk assessment in minority communities. Methods The NSABP STAR trial was a randomized, double-blinded study comparing the use of tamoxifen 20 mg/day to raloxifene 60 mg/day, for a 5-year period, to reduce the risk of developing invasive breast cancer. Eligible postmenopausal women were required to have a 5-year predicted breast cancer risk of 1.66% based on the modified Gail Model. For the current report, eligibility and enrollment data were tabulated by race/ethnicity for women who submitted STAR risk assessment forms (RAFs). Results A total of 184,460 RAFs were received, 145,550 (78.9%) from white women and 38,910 (21.1%) from minority women. Of the latter group, 21,444 (11.6%) were from African Americans/blacks, 791 3 (4.5%) from Hispanics/Latinas, and 9553 (5.2%) from other racial or ethnic groups. The percentages of risk-eligible women among African Americans, Hispanics/Latinas, others, and whites were 14.2%, 23.3%, 13.7%, and 57.4%, respectively. Programs targeting minority enrollment submitted large numbers of RAFs, but the eligibility rates of the women referred from those groups tended to be lower than the rates among women referred outside of those programs. The average number of completed risk assessments increased among minority women over the course of the recruitment period compared to those from whites. Limitations We have not addressed all identified barriers to the recruitment of minorities in clinical research. Our risk assessments and recruitment results do not reflect the modified Gail Model for African Americans. Conclusions Recruitment strategies used in STAR for racial and ethnic minorities contributed to doubling the minority enrollment compared to that in the BCPT and increased the awareness of breast cancer risk assessment in minority communities. Incorporation of new information into models to improve the risk estimation of diverse populations should prove beneficial. Clinical Trials 2013; 10: 280-291. http://ctj.sagepub.com AN - WOS:000318263300010 AU - McCaskill-Stevens, W. AU - Wilson, J. W. AU - Cook, E. D. AU - Edwards, C. L. AU - Gibson, R. V. AU - McElwain, D. L. AU - Figueroa-Moseley, C. D. AU - Paskett, E. D. AU - Roberson, N. L. AU - Wickerham, D. L. AU - Wolmark, N. DA - Apr DO - 10.1177/1740774512470315 IS - 2 N1 - 23335675 PY - 2013 SN - 1740-7745 SP - 280-291 ST - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities T2 - Clinical Trials TI - National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: Advancing the science of recruitment and breast cancer risk assessment in minority communities VL - 10 ID - 3045 ER - TY - JOUR AB - Purpose Neoadjuvant chemoradiation for stage II/III rectal cancer results in up to 49% of patients with a clinical complete response. As a result, many have questioned whether surgery can be omitted for this group of patients. Currently, there is insufficient evidence for chemoradiation only, or nonoperative management (NOM), to support its adoption. Despite this, anecdotal evidence suggests there is a trend toward increased use of NOM. Our objective was to examine the use of NOM for rectal cancer over time, as well as the patient- And facility-level factors associated with its use. Methods We included all incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Database from 1998 to 2010. We performed univariate and multivariate analyses to assess for NOM use over time, as well as associated patient- And facility-level factors. Results A total of 146,135 patients met the inclusion criteria: 5,741 had NOM and 140,394 had surgery with or without additional therapy. From 1998 to 2010, NOM doubled, from 2.4% to 5% of all cases annually. Patients who were black (adjusted odds ratio [AOR], 1.71; 95% CI, 1.57 to 1.86), uninsured (AOR, 2.35; 95% CI, 2.08 to 2.65) or enrolled in Medicaid (AOR, 2.10; 95% CI, 1.90 to 2.33), or treated at low-volume facilities (AOR, 1.53; 95% CI, 1.42 to 1.64) were more likely to receive NOM than were patients who were white, privately insured, and treated at a high-volume facility, respectively. Conclusion NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy. AD - C.T. Ellis, MSCR, Department of Surgery, University of North Carolina, 4001 Burnett-Womack Building, CB No. 7050, Chapel Hill, NC, United States AU - Ellis, C. T. AU - Samuel, C. A. AU - Stitzenberg, K. B. DB - Embase Medline DO - 10.1200/JCO.2015.64.2066 IS - 14 KW - antineoplastic agent adult aged article cancer chemotherapy cancer radiotherapy Caucasian Charlson Comorbidity Index chemoradiotherapy education female human income major clinical study male medicaid priority journal race rectum carcinoma social status travel tumor invasion very elderly LA - English M3 - Article N1 - L610185492 2016-06-03 2016-06-14 PY - 2016 SN - 1527-7755 0732-183X SP - 1644-1651 ST - National trends in nonoperative management of rectal adenocarcinoma T2 - Journal of Clinical Oncology TI - National trends in nonoperative management of rectal adenocarcinoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L610185492&from=export http://dx.doi.org/10.1200/JCO.2015.64.2066 VL - 34 ID - 973 ER - TY - JOUR AB - Purpose: Neoadjuvant chemoradiation for stage II/III rectal cancer results in up to 49% of patients with a clinical complete response. As a result, many have questioned whether surgery can be omitted for this group of patients. Currently, there is insufficient evidence for chemoradiation only, or nonoperative management (NOM), to support its adoption. Despite this, anecdotal evidence suggests there is a trend toward increased use of NOM. Our objective was to examine the use of NOM for rectal cancer over time, as well as the patient- and facility-level factors associated with its use.Methods: We included all incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Database from 1998 to 2010. We performed univariate and multivariate analyses to assess for NOM use over time, as well as associated patient- and facility-level factors.Results: A total of 146,135 patients met the inclusion criteria: 5,741 had NOM and 140,394 had surgery with or without additional therapy. From 1998 to 2010, NOM doubled, from 2.4% to 5% of all cases annually. Patients who were black (adjusted odds ratio [AOR], 1.71; 95% CI, 1.57 to 1.86), uninsured (AOR, 2.35; 95% CI, 2.08 to 2.65) or enrolled in Medicaid (AOR, 2.10; 95% CI, 1.90 to 2.33), or treated at low-volume facilities (AOR, 1.53; 95% CI, 1.42 to 1.64) were more likely to receive NOM than were patients who were white, privately insured, and treated at a high-volume facility, respectively.Conclusion: NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy. AD - University of North Carolina, Chapel Hill, NC AN - 115250207. Language: English. Entry Date: 20180619. Revision Date: 20191106. Publication Type: journal article AU - Ellis, Clayton Tyler AU - Samuel, Cleo A. AU - Stitzenberg, Karyn B. DB - CINAHL Complete DO - 10.1200/JCO.2015.64.2066 DP - EBSCOhost IS - 14 KW - Adenocarcinoma -- Therapy Kidney Neoplasms -- Therapy Neoadjuvant Therapy -- Trends United States Neoplasm Staging Adenocarcinoma -- Epidemiology Adenocarcinoma -- Pathology Kidney Neoplasms -- Pathology Aged Male Kidney Neoplasms -- Epidemiology Resource Databases Middle Age Prospective Studies Adult Aged, 80 and Over Female Human N1 - pictorial; research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: T32 HS000032/HS/AHRQ HHS/United States. NLM UID: 8309333. PMID: NLM27022115. PY - 2016 SN - 0732-183X SP - 1644-1651 ST - National Trends in Nonoperative Management of Rectal Adenocarcinoma T2 - Journal of Clinical Oncology TI - National Trends in Nonoperative Management of Rectal Adenocarcinoma UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115250207&site=ehost-live&scope=site VL - 34 ID - 2004 ER - TY - JOUR AB - Purpose Neoadjuvant chemoradiation for stage II/III rectal cancer results in up to 49% of patients with a clinical complete response. As a result, many have questioned whether surgery can be omitted for this group of patients. Currently, there is insufficient evidence for chemoradiation only, or nonoperative management (NOM), to support its adoption. Despite this, anecdotal evidence suggests there is a trend toward increased use of NOM. Our objective was to examine the use of NOM for rectal cancer over time, as well as the patient- And facility-level factors associated with its use. Methods We included all incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Database from 1998 to 2010. We performed univariate and multivariate analyses to assess for NOM use over time, as well as associated patient- And facility-level factors. Results A total of 146,135 patients met the inclusion criteria: 5,741 had NOM and 140,394 had surgery with or without additional therapy. From 1998 to 2010, NOM doubled, from 2.4% to 5% of all cases annually. Patients who were black (adjusted odds ratio [AOR], 1.71; 95% CI, 1.57 to 1.86), uninsured (AOR, 2.35; 95% CI, 2.08 to 2.65) or enrolled in Medicaid (AOR, 2.10; 95% CI, 1.90 to 2.33), or treated at low-volume facilities (AOR, 1.53; 95% CI, 1.42 to 1.64) were more likely to receive NOM than were patients who were white, privately insured, and treated at a high-volume facility, respectively. Conclusion NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy. © 2016 by American Society of Clinical Oncology. AD - MSCR, Department of Surgery, University of North Carolina, 4001 Burnett-Womack Building, CB No. 7050, Chapel Hill, NC 27599-705, United States AU - Ellis, C. T. AU - Samuel, C. A. AU - Stitzenberg, K. B. DB - Scopus DO - 10.1200/JCO.2015.64.2066 IS - 14 M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2016 SP - 1644-1651 ST - National trends in nonoperative management of rectal adenocarcinoma T2 - Journal of Clinical Oncology TI - National trends in nonoperative management of rectal adenocarcinoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970002243&doi=10.1200%2fJCO.2015.64.2066&partnerID=40&md5=909725a3b5ecaa9600a2e72713b78e1d VL - 34 ID - 2344 ER - TY - JOUR AB - Purpose Neoadjuvant chemoradiation for stage II/III rectal cancer results in up to 49% of patients with a clinical complete response. As a result, many have questioned whether surgery can be omitted for this group of patients. Currently, there is insufficient evidence for chemoradiation only, or non-operative management (NOM), to support its adoption. Despite this, anecdotal evidence suggests there is a trend toward increased use of NOM. Our objective was to examine the use of NOM for rectal cancer over time, as well as the patient-and facility-level factors associated with its use. Methods We included all incident cases of invasive, nonmetastatic rectal adenocarcinoma reported to the National Cancer Database from 1998 to 2010. We performed univariate and multivariate analyses to assess for NOM use over time, as well as associated patient-and facility-level factors. Results A total of 146,135 patients met the inclusion criteria: 5,741 had NOM and 140,394 had surgery with or without additional therapy. From 1998 to 2010, NOM doubled, from 2.4% to 5% of all cases annually. Patients who were black (adjusted odds ratio [AOR], 1.71; 95% CI, 1.57 to 1.86), uninsured (AOR, 2.35; 95% CI, 2.08 to 2.65) or enrolled in Medicaid (AOR, 2.10; 95% CI, 1.90 to 2.33), or treated at low-volume facilities (AOR, 1.53; 95% CI, 1.42 to 1.64) were more likely to receive NOM than were patients who were white, privately insured, and treated at a high-volume facility, respectively. Conclusion NOM demonstrates promise for the treatment of rectal cancer; currently, however, the most appropriate strategy is to pursue this approach with well-informed patients in the context of a clinical trial. We observed evidence of increasing NOM use, with this increase occurring more frequently in black and uninsured/Medicaid patients, raising concern that increased NOM use may actually represent increasing disparities in rectal cancer care rather than innovation. Further studies are needed to assess survival differences by treatment strategy. (C) 2016 by American Society of Clinical Oncology AN - WOS:000375309100015 AU - Ellis, C. T. AU - Samuel, C. A. AU - Stitzenberg, K. B. DA - May DO - 10.1200/JCO.2015.64.2066 IS - 14 N1 - 27022115 PY - 2016 SN - 0732-183X SP - 1644-U178 ST - National Trends in Nonoperative Management of Rectal Adenocarcinoma T2 - Journal of Clinical Oncology TI - National Trends in Nonoperative Management of Rectal Adenocarcinoma VL - 34 ID - 2945 ER - TY - JOUR AB - Background:In 2006, the National Health Service Bowel Cancer Screening Programme in England (NHSBCSP) began offering routine population-based biennial faecal occult blood testing (FOBt) at ages 60-69. There is, however, limited information on how characteristics of individuals affect participation and outcomes of screening, and we studied this association by linking NHSBCSP data to a large prospective cohort of women.Methods:Electronic linkage of the NHSBCSP and Million Women Study records identified 899 166 women in the study cohort with at least one invitation for screening. NHSBCSP provided information on screening acceptance, FOBt results, screen-detected colorectal cancer and other outcomes. The Million Women Study provided prospectively collected information on personal and lifestyle factors. Multiple regression was used to estimate relative risks (RRs) of factors associated with acceptance and outcomes of screening.Results:Overall, 70% of women (628 976/899 166) accepted their first invitation for bowel cancer screening, of whom 9133 (1.5%) were FOBt-positive, 743 (0.1%) had screen-detected colorectal cancer and 3056 (0.5%) had screen-detected colorectal adenoma. Acceptance was lower in women from the most than the least deprived tertile, in South Asians and in Blacks than in Whites, in current than in never smokers and in obese than in normal weight women: adjusted RRs (95% confidence interval) for acceptance vs not, 0.90 (0.90-0.90); 0.77 (0.75-79); 0.94 (0.92-0.96); 0.78 (0.77-0.78); and 0.88 (0.88-0.89), respectively: P<0.001 for each. These factors were also associated with an increased risk of being FOBt-positive and of having screen-detected adenoma, but were not strongly associated with the risk of screen-detected colorectal cancer. Relative risks for screen-detected adenoma were 1.22 (1.12-1.34), 2.46 (1.75-3.45), 1.61 (1.05-2.48), 1.53 (1.38-1.68) and 1.77 (1.60-1.95), respectively (P<0.001 for all, except for Blacks vs Whites P=0.03). Use of hormone therapy for menopause was associated with reduced risk of screen-detected adenoma, RR ever vs never use, 0.87 (0.81-0.93), P<0.001 and colorectal cancer, 0.78 (0.68-0.91), P=0.001.Interpretation:Among women in England, socioeconomic and lifestyle factors strongly affect participation in routine bowel cancer screening, risk of being FOBt-positive and risk of having screen-detected colorectal adenoma. However, screen-detected colorectal cancer risk is not strongly related to these factors. AD - R.G. Blanks, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom AU - Blanks, R. G. AU - Benson, V. S. AU - Alison, R. AU - Brown, A. AU - Reeves, G. K. AU - Beral, V. AU - Patnick, J. AU - Green, J. DB - Embase Medline DO - 10.1038/bjc.2015.69 IS - 9 KW - oral contraceptive agent aged alcohol consumption article Black person body mass body weight cancer risk cancer screening Caucasian cohort analysis colonoscopy colorectal adenoma colorectal cancer diagnostic test exercise female hormonal therapy human lifestyle major clinical study menopause outcome assessment patient participation physical activity priority journal prospective study risk factor smoking South Asian LA - English M3 - Article N1 - L602855998 2015-03-16 2015-05-25 PY - 2015 SN - 1532-1827 0007-0920 SP - 1562-1567 ST - Nationwide bowel cancer screening programme in England: Cohort study of lifestyle factors affecting participation and outcomes in women T2 - British Journal of Cancer TI - Nationwide bowel cancer screening programme in England: Cohort study of lifestyle factors affecting participation and outcomes in women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L602855998&from=export http://dx.doi.org/10.1038/bjc.2015.69 VL - 112 ID - 1002 ER - TY - JOUR AB - BACKGROUND: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among veterans with an abnormal prostate cancer screen. METHODS: Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score. RESULTS: Of 490 participants, 68% were African American, 47% were ≥ 65 years old, and 35% had cancer. Among those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus 190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI, 0.82-1.62, p = 0.41). CONCLUSION: Our navigation program did not significantly impact the overall time to resolution or treatment for men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted navigation times, however, and future studies focusing on other outcomes measures are therefore needed. AU - Simon, M. A. AU - Nonzee, N. J. AU - McKoy, J. M. AU - Liu, D. AU - Luu, T. H. AU - Byer, P. AU - Eklund, E. A. AU - Richey, E. A. AU - Wu, Z. AU - Dong, X. AU - Rademaker, A. W. DB - Medline DO - 10.1186/1472-6963-13-314 KW - prostate specific antigen adult aged blood clinical trial early cancer diagnosis human male middle aged organization and management patient care procedures prostate tumor public hospital social work time factor United States very elderly veteran LA - English M3 - Article N1 - L563078095 2017-06-07 PY - 2013 SN - 1472-6963 SP - 314 ST - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study T2 - BMC health services research TI - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563078095&from=export http://dx.doi.org/10.1186/1472-6963-13-314 VL - 13 ID - 1074 ER - TY - JOUR AB - Background: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among veterans with an abnormal prostate cancer screen.Methods: Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score.Results: Of 490 participants, 68% were African American, 47% were ≥ 65 years old, and 35% had cancer. Among those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus 190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI, 0.82-1.62, p = 0.41).Conclusion: Our navigation program did not significantly impact the overall time to resolution or treatment for men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted navigation times, however, and future studies focusing on other outcomes measures are therefore needed. AD - Robert H, Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. m-simon2@northwestern.edu. AN - 104114743. Language: English. Entry Date: 20150508. Revision Date: 20170604. Publication Type: journal article AU - Simon, Melissa A. AU - Nonzee, Narissa J. AU - McKoy, June M. AU - Liu, Dachao AU - Luu, Thanh Ha AU - Byer, Peter AU - Eklund, Elizabeth A. AU - Richey, Elizabeth A. AU - Wu, Zhigang AU - Dong, Xinqi AU - Rademaker, Alfred W. DB - CINAHL Complete DO - 10.1186/1472-6963-13-314 DP - EBSCOhost IS - 1 KW - Early Detection of Cancer Patient Navigation -- Methods Prostatic Neoplasms -- Diagnosis Veterans Adult Aged Aged, 80 and Over Clinical Assessment Tools Hospitals, Veterans -- Administration Human Male Middle Age Prostate-Specific Antigen -- Blood Prostatic Neoplasms -- Therapy Social Work -- Methods Time Factors United States N1 - research. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Instrumentation: Gleason Score. Grant Information: U01 CA116875/CA/NCI NIH HHS/United States. NLM UID: 101088677. PMID: NLM23947435. PY - 2013 SN - 1472-6963 SP - 314-314 ST - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study T2 - BMC Health Services Research TI - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104114743&site=ehost-live&scope=site VL - 13 ID - 2005 ER - TY - JOUR AB - Background: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among veterans with an abnormal prostate cancer screen. Methods. Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score. Results: Of 490 participants, 68% were African American, 47% were ≥ 65 years old, and 35% had cancer. Among those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus 190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI, 0.82-1.62, p = 0.41). Conclusion: Our navigation program did not significantly impact the overall time to resolution or treatment for men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted navigation times, however, and future studies focusing on other outcomes measures are therefore needed. © 2013 Simon et al.; licensee BioMed Central Ltd. AD - Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States Northwestern University Feinberg, School of Medicine, Chicago, IL, United States Jesse Brown VA Medical Center, Chicago, IL, United States Rush University, Chicago, IL, United States Dartmouth College Geisel, School of Medicine, Hanover, NH, United States University of Illinois at Chicago, College of Medicine, Chicago, IL, United States AU - Simon, M. A. AU - Nonzee, N. J. AU - McKoy, J. M. AU - Liu, D. AU - Luu, T. H. AU - Byer, P. AU - Eklund, E. A. AU - Richey, E. A. AU - Wu, Z. AU - Dong, X. AU - Rademaker, A. W. C7 - 314 DB - Scopus DO - 10.1186/1472-6963-13-314 IS - 1 M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2013 ST - Navigating veterans with an abnormal prostate cancer screening test: A quasi-experimental study T2 - BMC Health Services Research TI - Navigating veterans with an abnormal prostate cancer screening test: A quasi-experimental study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881453231&doi=10.1186%2f1472-6963-13-314&partnerID=40&md5=5cc0a2106258d5e27c78dd22c781df46 VL - 13 ID - 2427 ER - TY - JOUR AB - Background: Prostate cancer disproportionately affects low-income and minority men. This study evaluates the impact of a patient navigation intervention on timeliness of diagnostic resolution and treatment initiation among veterans with an abnormal prostate cancer screen. Methods: Participants were enrolled between 2006 and 2010. The intervention involved a social worker and lay health worker navigation team that assisted patients in overcoming barriers to care. For navigated (n = 245) versus control (n = 245) participants, we evaluated rates of diagnostic resolution and treatment and adjusted for race, age, and Gleason score. Results: Of 490 participants, 68% were African American, 47% were >= 65 years old, and 35% had cancer. Among those with an abnormal screen, navigation did not have a significant effect on time to diagnostic resolution compared to controls (median days of 97 versus 111; adj. HR 1.17, 95% CI, 0.96-1.43, p = 0.12). On analysis of the period beyond 80 days, navigated men reached resolution faster than controls (median of 151 days versus 190 days; adj. HR 1.41, 95% CI, 1.07-1.86, p = 0.01). Among those with cancer, navigation did not have a significant effect on time to treatment initiation compared to controls (median of 93 days versus 87 days; adj. HR 1.15, 95% CI, 0.82-1.62, p = 0.41). Conclusion: Our navigation program did not significantly impact the overall time to resolution or treatment for men with prostate cancer compared to controls. The utility of navigation programs may extend beyond targeted navigation times, however, and future studies focusing on other outcomes measures are therefore needed. AN - WOS:000324068300001 AU - Simon, M. A. AU - Nonzee, N. J. AU - McKoy, J. M. AU - Liu, D. C. AU - Luu, T. H. AU - Byer, P. AU - Eklund, E. A. AU - Richey, E. A. AU - Wu, Z. G. AU - Dong, X. Q. AU - Rademaker, A. W. DA - Aug DO - 10.1186/1472-6963-13-314 N1 - 314 23947435 PY - 2013 SN - 1472-6963 ST - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study T2 - Bmc Health Services Research TI - Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study VL - 13 ID - 3036 ER - TY - JOUR AB - Objective. To assess osteoporosis knowledge, beliefs, and preventive behaviors among young adult women and to identify sources that they would mostly likely utilize to learn more about the disease. Methods. Information was gathered through a cross-sectional survey of 321 women (mean age 21.6 years; 63.5% were white, 29.2% were black) enrolled in a required undergraduate health course at a southeastern state university. Results. Two hundred seventy-seven (86%) of the survey participants had heard about osteoporosis, but only 3.8% of respondents reported getting both adequate exercise and the recommended 1,200 mg of calcium per day. Respondents believed that they were unlikely to develop osteoporosis and that osteoporosis is less serious than other common causes of morbidity and mortality in women, such as heart disease and breast cancer (P < 0.0001). Brochures, magazines, and short counseling sessions were preferred information sources for learning about osteoporosis. Conclusions. The majority of young women studied are at risk for developing premature osteoporosis. They prefer brochures, magazines, and short counseling sessions during medical office visits to learn about osteoporosis. © 2001 by the American College of Rheumatology. AD - Department of Kinesiology and Physical Education, College of Education, Valdosta State University, Valdosta, GA, United States Department of Biomechanics and Biomolecular Modeling, Hospital for Special Surgery, New York, NY, United States Division of Sociomedical Sciences, Joseph L. Mailman School of Public Health, Columbia University, New York, NY, United States Research Division, Hospital for Special Surgery, New York, NY, United States Department of Kinesiology and Physical Education, Valdosta State University, Valdosta, GA 31698, United States AU - Kasper, M. J. AU - Peterson, M. G. E. AU - Allegrante, J. P. DB - Scopus DO - 10.1002/1529-0131(200102)45:1<28::aid-anr80>3.0.co;2-g IS - 1 KW - Community intervention Osteoporosis prevention Public health education M3 - Article N1 - Cited By :48 Export Date: 22 March 2021 PY - 2001 SP - 28-34 ST - The need for comprehensive educational osteoporosis prevention programs for young women: Results from a second osteoporosis prevention survey T2 - Arthritis Care and Research TI - The need for comprehensive educational osteoporosis prevention programs for young women: Results from a second osteoporosis prevention survey UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035069794&doi=10.1002%2f1529-0131%28200102%2945%3a1%3c28%3a%3aaid-anr80%3e3.0.co%3b2-g&partnerID=40&md5=8e3bde08a7136ef7e945328a9f1a57f0 VL - 45 ID - 2630 ER - TY - JOUR AB - This article describes a shared model of the breast cancer experience negotiated by the members of a spontaneously organized breast cancer self-help group in eastern North Carolina. In the course of sharing their personal experience narratives with one another, these women worked to negotiate points of agreement among the varying sources of knowledge and oftentimes conflicting belief systems they held about breast cancer. The synthetic model they created rejected many of the assumptions underlying the dominant biomedical view of cancer "survivorship," particularly its emphasis on the autonomous individual as decision maker and its attendant male-gendered sports and military imagery--assumptions that often implicitly structured the agendas and topics discussed in the formal, medically sanctioned support groups these women found unappealing. The implications for theories about the construction of shared cultural models and for continuing efforts to design support groups to meet the needs of a diverse patient population are explored. AD - H.F. Mathews, Department of Anthropology, East Carolina University, USA. AU - Mathews, H. F. DB - Medline IS - 3 KW - African American article attitude to health breast tumor Caucasian cognition cultural anthropology female group process human interpersonal communication patient participation psychological aspect psychological model self help social support sociology United States LA - English M3 - Article N1 - L31378604 2000-12-01 PY - 2000 SN - 0745-5194 SP - 394-413 ST - Negotiating cultural consensus in a breast cancer self-help group T2 - Medical anthropology quarterly TI - Negotiating cultural consensus in a breast cancer self-help group UR - https://www.embase.com/search/results?subaction=viewrecord&id=L31378604&from=export VL - 14 ID - 1321 ER - TY - JOUR AB - Background: The effect of neighborhood and healthcare access factors on cancer outcomes among patients enrolled in navigator programs is not clearly understood. This study assessed associations between: (i) neighborhood factors and diagnostic time to resolution (TTR) and (ii) geographic access and TTR following an abnormal breast or cervical cancer screening test among women participating in the Ohio Patient Navigator Research Program (OPNRP). Methods: Patient (demographic, socioeconomic status, home-to-clinic distance) and neighborhood (deprivation, racial segregation) characteristics of 801 women living in one of 285 census tracts (CT) in greater Columbus, Ohio were examined. Randomization to receive navigation occurred at the clinic level. Multilevel Cox regression and spatial analysis were used to estimate effects of various factors on TTR and assess model assumptions, respectively. Results: TTR increased as neighborhood deprivation increased. After adjustment for age, friend social support, education, and healthcare status, the TTR among women living in a neighborhood with a moderate median household income (between $36,147 and $53,099) was shorter compared with women living in low median household income neighborhoods (<$36,147; P < 0.05). There is little evidence that unmeasured confounders are geographically patterned. Conclusions: Increased neighborhood socioeconomic deprivation was associated with longer TTR following an abnormal breast or cervical cancer screening test. Impact: These results highlight the need for addressing patient- and neighborhood-level factors to reduce cancer disparities among underserved populations. © 2014 American Association for Cancer Research. AD - Department of Health Services, School of Public Health, University of Washington, Box 359455, Seattle, WA 98195-9455, United States RBHS-School of Public Health, Cancer Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick, NJ, United States Division of Biostatistics, College of Public Health, Ohio State University, Columbus, OH, United States Comprehensive Cancer Center, James Cancer Hospital, Solove Research Institute, Columbus, OH, United States Division of Epidemiology, College of Public Health, Ohio State University, Columbus, OH, United States Division of Cancer Control and Prevention, Department of Internal Medicine, College of Medicine, Columbus, OH, United States AU - Plascak, J. J. AU - Llanos, A. A. AU - Pennell, M. L. AU - Weier, R. C. AU - Paskett, E. D. DB - Scopus DO - 10.1158/1055-9965.EPI-14-0348 IS - 12 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2014 SP - 2819-2828 ST - Neighborhood factors associated with time to resolution following an abnormal breast or cervical cancer screening test T2 - Cancer Epidemiology Biomarkers and Prevention TI - Neighborhood factors associated with time to resolution following an abnormal breast or cervical cancer screening test UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919397039&doi=10.1158%2f1055-9965.EPI-14-0348&partnerID=40&md5=89772965685c86074ed20c1024c3c807 VL - 23 ID - 2409 ER - TY - JOUR AB - The Neighborhood Voice is a vehicle customized for conducting health research in community settings. It brings research studies into neighborhoods affected most by health disparities and reaches groups often underrepresented in research samples. This paper reports on the experience and satisfaction of 599 African American women who participated in research on board the Neighborhood Voice. Using bivariate, psychometric, and logistic regression analyses, we examined responses to a brief post-research survey. Most women (71%) reported that they had never previously participated in research, and two-thirds (68%) rated their Neighborhood Voice experience as excellent. Satisfaction scores were highest among first-time research participants (p <.05). Women's ratings of the Neighborhood Voice on Comfort (OR = 4.9; 95% CI = 3.0, 7.9) and Convenience (OR = 1.8; 95% CI = 1.2, 2.9) significantly predicted having an excellent experience. Mobile research facilities may increase participation among disadvantaged and minority populations. Our brief survey instrument is a model for evaluating such outreach. © The Author(s) 2011. AD - K. I. Alcaraz, Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University in St. Louis, 700 Rosedale Avenue, Campus Box 1009, St. Louis, MO 63112, United States AU - Alcaraz, K. I. AU - Weaver, N. L. AU - Andresen, E. M. AU - Christopher, K. AU - Kreuter, M. W. DB - Medline DO - 10.1177/0163278710395933 IS - 3 KW - African American article breast tumor car ethnology evaluation study female health disparity human medical research methodology middle aged patient selection United States LA - English M3 - Article N1 - L362648661 2012-01-26 PY - 2011 SN - 0163-2787 1552-3918 SP - 336-348 ST - The neighborhood voice: Evaluating a mobile research vehicle for recruiting african americans to participate in cancer control studies T2 - Evaluation and the Health Professions TI - The neighborhood voice: Evaluating a mobile research vehicle for recruiting african americans to participate in cancer control studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362648661&from=export http://dx.doi.org/10.1177/0163278710395933 VL - 34 ID - 1132 ER - TY - JOUR AB - The Neighborhood Voice is a vehicle customized for conducting health research in community settings. It brings research studies into neighborhoods affected most by health disparities and reaches groups often underrepresented in research samples. This paper reports on the experience and satisfaction of 599 African American women who participated in research on board the Neighborhood Voice. Using bivariate, psychometric, and logistic regression analyses, we examined responses to a brief post-research survey. Most women (71%) reported that they had never previously participated in research, and two-thirds (68%) rated their Neighborhood Voice experience as excellent. Satisfaction scores were highest among first-time research participants (p < .05). Women’s ratings of the Neighborhood Voice on Comfort (OR = 4.9; 95% CI = 3.0, 7.9) and Convenience (OR = 1.8; 95% CI = 1.2, 2.9) significantly predicted having an excellent experience. Mobile research facilities may increase participation among disadvantaged and minority populations. Our brief survey instrument is a model for evaluating such outreach. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Alcaraz, Kassandra I., Health Communication Research Laboratory, Washington University, 700 Rosedale Avenue, Campus Box 1009, St. Louis, MO, US, 63112 AN - 2011-22573-006 AU - Alcaraz, Kassandra I. AU - Weaver, Nancy L. AU - Andresen, Elena M. AU - Christopher, Kara AU - Kreuter, Matthew W. DB - psyh DO - 10.1177/0163278710395933 DP - EBSCOhost IS - 3 KW - neighborhoods mobile research vehicle African Americans cancer control studies health disparities logistic regression Automobiles Biomedical Research Breast Neoplasms Female Health Status Disparities Humans Middle Aged Missouri Patient Selection Neoplasms Blacks N1 - Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University, St. Louis, MO, US. Release Date: 20111107. Correction Date: 20120618. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Logistic Regression; Neighborhoods; Neoplasms; Health Disparities. Minor Descriptor: Blacks. Classification: Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Interview; Focus Group; Quantitative Study. References Available: Y. Page Count: 13. Issue Publication Date: Sep, 2011. Copyright Statement: The Author(s). 2011. Sponsor: National Cancer Institute, US. Grant: CA-095815. Recipients: No recipient indicated PY - 2011 SN - 0163-2787 1552-3918 SP - 336-348 ST - The neighborhood voice: Evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies T2 - Evaluation & the Health Professions TI - The neighborhood voice: Evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-22573-006&site=ehost-live&scope=site kalcaraz@wustl.edu VL - 34 ID - 1765 ER - TY - JOUR AB - The Neighborhood Voice is a vehicle customized for conducting health research in community settings. It brings research studies into neighborhoods affected most by health disparities and reaches groups often underrepresented in research samples. This paper reports on the experience and satisfaction of 599 African American women who participated in research on board the Neighborhood Voice. Using bivariate, psychometric, and logistic regression analyses, we examined responses to a brief post-research survey. Most women (71%) reported that they had never previously participated in research, and two-thirds (68%) rated their Neighborhood Voice experience as excellent. Satisfaction scores were highest among first-time research participants (p < .05). Women's ratings of the Neighborhood Voice on Comfort (OR = 4.9; 95% CI - 3.0, 7.9) and Convenience (OR - 1.8; 95% CI - 1.2, 2.9) significantly predicted having an excellent experience. Mobile research facilities may increase participation among disadvantaged and minority populations. Our brief survey instrument is a model for evaluating such outreach. AN - WOS:000295326100006 AU - Alcaraz, K. I. AU - Weaver, N. L. AU - Andresen, E. M. AU - Christopher, K. AU - Kreuter, M. W. DA - Sep DO - 10.1177/0163278710395933 IS - 3 N1 - SI 21411475 PY - 2011 SN - 0163-2787 SP - 336-348 ST - The Neighborhood Voice: Evaluating a Mobile Research Vehicle for Recruiting African Americans to Participate in Cancer Control Studies T2 - Evaluation & the Health Professions TI - The Neighborhood Voice: Evaluating a Mobile Research Vehicle for Recruiting African Americans to Participate in Cancer Control Studies VL - 34 ID - 3084 ER - TY - JOUR AB - The Neighborhood Voice is a vehicle customized for conducting health research in community settings. It brings research studies into neighborhoods affected most by health disparities and reaches groups often underrepresented in research samples. This paper reports on the experience and satisfaction of 599 African American women who participated in research on board the Neighborhood Voice. Using bivariate, psychometric, and logistic regression analyses, we examined responses to a brief post-research survey. Most women (71%) reported that they had never previously participated in research, and two-thirds (68%) rated their Neighborhood Voice experience as excellent. Satisfaction scores were highest among first-time research participants (p < .05). Women's ratings of the Neighborhood Voice on Comfort (OR = 4.9; 95% CI = 3.0, 7.9) and Convenience (OR = 1.8; 95% CI = 1.2, 2.9) significantly predicted having an excellent experience. Mobile research facilities may increase participation among disadvantaged and minority populations. Our brief survey instrument is a model for evaluating such outreach. AD - Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, MO 63112, USA 1Health Communication Research Laboratory, George Warren Brown School of Social Work, Washington University in St. Louis, St. Louis, MO, USA. AN - 108195584. Language: English. Entry Date: 20120323. Revision Date: 20200708. Publication Type: journal article AU - Alcaraz, K. I. AU - Weaver, N. L. AU - Andresen, E. M. AU - Christopher, K. AU - Kreuter, M. W. AU - Alcaraz, Kassandra I. AU - Weaver, Nancy L. AU - Andresen, Elena M. AU - Christopher, Kara AU - Kreuter, Matthew W. DB - CINAHL Complete DO - 10.1177/0163278710395933 DP - EBSCOhost IS - 3 KW - Black Persons Automobiles Research, Medical -- Methods Breast Neoplasms -- Ethnology Patient Selection Female Health Status Human Middle Age Missouri N1 - research. Journal Subset: Health Services Administration; Peer Reviewed; USA. Special Interest: Quality Assurance. Grant Information: P50 CA095815/CA/NCI NIH HHS/United States. NLM UID: 7805992. PMID: NLM21411475. PY - 2011 SN - 0163-2787 SP - 336-348 ST - The Neighborhood Voice: evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies T2 - Evaluation & the Health Professions TI - The Neighborhood Voice: evaluating a mobile research vehicle for recruiting African Americans to participate in cancer control studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108195584&site=ehost-live&scope=site VL - 34 ID - 2128 ER - TY - JOUR AB - Background: Breast cancer surgery is usually performed under general anaesthesia (GA) and is frequently associated with postoperative nausea, vomiting and painful restricted movement of the shoulder. GA, with the exception of large doses of opioids, does not eliminate the surgical stress response. Paravertebral nerve blockade (PVB) may be an alternative to GA for this type of surgery especially in those patients with coexisting morbid diseases. However, PVB is associated with an incidence of failed black in 5‐10% of cases. The aim of this study was to detect the success rate and the safety of PVB when guided by nerve stimulator and to compare the efficacy of this technique vs. GA for inhibition of surgical stress response during breast cancer surgery. Methods: Forty women were enrolled in this prospective randomized study, to receive GA (GA group; n = 20) or PVB (PVB group; n = 20) at T1‐T6, using ropivacaine 0.5 % with epinephrine 1:200,000. In the PVB group, success rate and incidence of complications were recorded. In both groups, blood samples for measurement of glucose and cortisol concentrations were obtained before skin incision; 1 hour after skin incision; and at 3 and 24 hours postoperatively. Postoperative visual analogue pain scores (VAS) at rest and on moving the ipsilateral arm at predetermined time intervals postoperatively (1, 2, 6, 12 and 24 h) as well as the incidence of postoperative nausea and vomiting (PONV) throughout the 24 hours postoperatively were recorded in both groups. Results: All PVBs were successful and inadvertent complications other than hypotension (10% incidence) were not reported. There were no significant differences in the plasma glucose or cortisol concentrations between the two groups before skin incision. They were significantly lower in the PVB group 1 h after skin incision and at 3 h postoperatively. However, there were no significant differences in glucose or cortisol concentrations, between the 2 groups, at 24 h postoperatively. Patients in the PVB group had significantly lower VAS scores both at rest and on moving the arm at all the predetermined time intervals postoperatively as well as significantly lower incidence of PONV throughout the 24 h postoperatively. Conclusion: Nerve stimulator‐guided PVB at the level of T1‐T6 with ropivacaine represents a suitable alternative to GA for breast cancer surgery. Important benefits of PVB include reduced surgical stress response, as evidenced by lower plasma cortisol and glucose concentrations, superior postoperative analgesia and lower incidence of PONV. AN - CN-00642338 AU - Omran, A. F. AU - El-Sisi, A. H. IS - 4 KW - *adrenalin/ae [Adverse Drug Reaction] *adrenalin/cb [Drug Combination] *adrenalin/ct [Clinical Trial] *adrenalin/dt [Drug Therapy] *adrenalin/pa [Parenteral Drug Administration] *postoperative pain/dt [Drug Therapy] *ropivacaine/ae [Adverse Drug Reaction] *ropivacaine/cb [Drug Combination] *ropivacaine/cm [Drug Comparison] *ropivacaine/ct [Clinical Trial] *ropivacaine/dt [Drug Therapy] *ropivacaine/pa [Parenteral Drug Administration] Adult Arm movement Article Atracurium/cb [Drug Combination] Atracurium/cm [Drug Comparison] Atracurium/ct [Clinical Trial] Atracurium/do [Drug Dose] Atracurium/dt [Drug Therapy] Blood sampling Breast cancer/su [Surgery] Clinical article Clinical trial Controlled clinical trial Controlled study Drug safety Female Fentanyl/cb [Drug Combination] Fentanyl/cm [Drug Comparison] Fentanyl/ct [Clinical Trial] Fentanyl/do [Drug Dose] Fentanyl/dt [Drug Therapy] Fentanyl/iv [Intravenous Drug Administration] General anesthesia Glucose blood level Human Hydrocortisone blood level Hypotension/si [Side Effect] Lidocaine/ct [Clinical Trial] Lidocaine/dt [Drug Therapy] Lidocaine/sc [Subcutaneous Drug Administration] Nausea and vomiting/si [Side Effect] Nerve block Nerve stimulation Postoperative period Propofol/cb [Drug Combination] Propofol/cm [Drug Comparison] Propofol/ct [Clinical Trial] Propofol/do [Drug Dose] Propofol/dt [Drug Therapy] Propofol/iv [Intravenous Drug Administration] Skin incision Stress Visual analog scale M3 - Journal: Article PY - 2005 SP - 295‐300 ST - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: effect on stress response to breast cancer surgery T2 - Egyptian journal of anaesthesia TI - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: effect on stress response to breast cancer surgery UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00642338/full VL - 21 ID - 1653 ER - TY - JOUR AB - Background: Breast cancer surgery is usually performed under general anaesthesia (GA) and is frequently associated with postoperative nausea, vomiting and painful restricted movement of the shoulder. GA, with the exception of large doses of opioids, does not eliminate the surgical stress response. Paravertebral nerve blockade (PVB) may be an alternative to GA for this type of surgery especially in those patients with coexisting morbid diseases. However, PVB is associated with an incidence of failed black in 5-10% of cases. The aim of this study was to detect the success rate and the safety of PVB when guided by nerve stimulator and to compare the efficacy of this technique vs. GA for inhibition of surgical stress response during breast cancer surgery. Methods: Forty women were enrolled in this prospective randomized study, to receive GA (GA group; n = 20) or PVB (PVB group; n = 20) at T1-T6, using ropivacaine 0.5 % with epinephrine 1:200,000. In the PVB group, success rate and incidence of complications were recorded. In both groups, blood samples for measurement of glucose and cortisol concentrations were obtained before skin incision; 1 hour after skin incision; and at 3 and 24 hours postoperatively. Postoperative visual analogue pain scores (VAS) at rest and on moving the ipsilateral arm at predetermined time intervals postoperatively (1, 2, 6, 12 and 24 h) as well as the incidence of postoperative nausea and vomiting (PONV) throughout the 24 hours postoperatively were recorded in both groups. Results: All PVBs were successful and inadvertent complications other than hypotension (10% incidence) were not reported. There were no significant differences in the plasma glucose or cortisol concentrations between the two groups before skin incision. They were significantly lower in the PVB group 1 h after skin incision and at 3 h postoperatively. However, there were no significant differences in glucose or cortisol concentrations, between the 2 groups, at 24 h postoperatively. Patients in the PVB group had significantly lower VAS scores both at rest and on moving the arm at all the predetermined time intervals postoperatively as well as significantly lower incidence of PONV throughout the 24 h postoperatively. Conclusion: Nerve stimulator-guided PVB at the level of T1-T6 with ropivacaine represents a suitable alternative to GA for breast cancer surgery. Important benefits of PVB include reduced surgical stress response, as evidenced by lower plasma cortisol and glucose concentrations, superior postoperative analgesia and lower incidence of PONV. AD - Department of Anaesthesiology, National Cancer Institute, Cairo, Egypt Department of Clinical Pathology, National Cancer Institute, Cairo, Egypt AU - Omran, A. F. AU - El-Sisi, A. H. DB - Scopus IS - 4 KW - Nausea and vomiting Nerve stimulator Pain Paravertebral nerve block M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2005 SP - 295-300 ST - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: Effect on stress response to breast cancer surgery T2 - Egyptian Journal of Anaesthesia TI - Nerve stimulator-guided thoracic paravertebral ropivacaine versus general anaesthesia: Effect on stress response to breast cancer surgery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33751250791&partnerID=40&md5=75a559cce4d837059348a0a712339b22 VL - 21 ID - 2589 ER - TY - JOUR AD - A. Whitworth AU - Whitworth, A. DB - Medline DO - 10.1093/jnci/djj223 IS - 10 KW - African American article breast tumor clinical trial colorectal tumor female genetics health care delivery human male minority group mortality neoplasm pathology patient selection poverty statistics trust United States LA - English M3 - Article N1 - L43789817 2006-06-01 PY - 2006 SN - 1460-2105 SP - 669 ST - New research suggests access, genetic differences play role in high minority cancer death rate T2 - Journal of the National Cancer Institute TI - New research suggests access, genetic differences play role in high minority cancer death rate UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43789817&from=export http://dx.doi.org/10.1093/jnci/djj223 VL - 98 ID - 1246 ER - TY - JOUR AN - 106022494. Language: English. Entry Date: 20071207. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Whitworth, A. DB - CINAHL Complete DP - EBSCOhost IS - 10 KW - Black Persons Health Services Accessibility Minority Groups Neoplasms Neoplasms -- Mortality Poverty Breast Neoplasms -- Mortality Breast Neoplasms -- Pathology Clinical Trials Colorectal Neoplasms -- Drug Therapy Female Male Neoplasms -- Therapy Patient Selection Trust United States N1 - Peer Reviewed; USA. NLM UID: 7503089. PMID: NLM16705120. PY - 2006 SN - 0027-8874 SP - 669-669 ST - New research suggests access, genetic differences play role in high minority cancer death rate T2 - JNCI: Journal of the National Cancer Institute TI - New research suggests access, genetic differences play role in high minority cancer death rate UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106022494&site=ehost-live&scope=site VL - 98 ID - 2006 ER - TY - JOUR AB - Purpose: To apply our convolutional neural network (CNN) algorithm to predict neoadjuvant chemotherapy (NAC) response using the I‐SPY TRIAL breast MRI dataset. Methods: From the I‐SPY TRIAL breast MRI database, 131 patients from 9 institutions were successfully downloaded for analysis. First post‐contrast MRI images were used for 3D segmentation using 3D slicer. Our CNN was implemented entirely of 3 × 3 convolutional kernels and linear layers. The convolutional kernels consisted of 6 residual layers, totaling 12 convolutional layers. Dropout with a 0.5 keep probability and L2 normalization was utilized. Training was implemented by using the Adam optimizer. A 5‐fold cross validation was used for performance evaluation. Software code was written in Python using the TensorFlow module on a Linux workstation with one NVidia Titan X GPU. Results: Of 131 patients, 40 patients achieved pCR following NAC (group 1) and 91 patients did not achieve pCR following NAC (group 2). Diagnostic accuracy of our CNN two classification model distinguishing patients with pCR vs non‐pCR was 72.5 (SD ± 8.4), with sensitivity 65.5% (SD ± 28.1) and specificity of 78.9% (SD ± 15.2). The area under a ROC Curve (AUC) was 0.72 (SD ± 0.08). Conclusion: It is feasible to use our CNN algorithm to predict NAC response in patients using a multi‐institution dataset. AN - CN-02235821 DO - 10.1016/j.mri.2020.08.021 KW - *breast cancer /diagnosis *convolutional neural network *nuclear magnetic resonance imaging *prediction Adult African American Alaska Native American Indian Area under the curve Article Asian Brain size Caucasian Controlled study Diagnostic accuracy Diagnostic test accuracy study Dynamic contrast‐enhanced magnetic resonance imaging Histogram Human Institutional review Learning algorithm Major clinical study Middle aged Pacific Islander Priority journal Probability M3 - Journal: Article PY - 2020 SP - 148‐151 ST - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database T2 - Magnetic resonance imaging TI - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02235821/full VL - 73 ID - 1541 ER - TY - JOUR AB - Purpose: To apply our convolutional neural network (CNN) algorithm to predict neoadjuvant chemotherapy (NAC) response using the I-SPY TRIAL breast MRI dataset. Methods: From the I-SPY TRIAL breast MRI database, 131 patients from 9 institutions were successfully downloaded for analysis. First post-contrast MRI images were used for 3D segmentation using 3D slicer. Our CNN was implemented entirely of 3 × 3 convolutional kernels and linear layers. The convolutional kernels consisted of 6 residual layers, totaling 12 convolutional layers. Dropout with a 0.5 keep probability and L2 normalization was utilized. Training was implemented by using the Adam optimizer. A 5-fold cross validation was used for performance evaluation. Software code was written in Python using the TensorFlow module on a Linux workstation with one NVidia Titan X GPU. Results: Of 131 patients, 40 patients achieved pCR following NAC (group 1) and 91 patients did not achieve pCR following NAC (group 2). Diagnostic accuracy of our CNN two classification model distinguishing patients with pCR vs non-pCR was 72.5 (SD ± 8.4), with sensitivity 65.5% (SD ± 28.1) and specificity of 78.9% (SD ± 15.2). The area under a ROC Curve (AUC) was 0.72 (SD ± 0.08). Conclusion: It is feasible to use our CNN algorithm to predict NAC response in patients using a multi-institution dataset. © 2020 Elsevier Inc. AD - Department of Medical Physics, Columbia University Medical Center, 177 Ft. Washington Ave., Milstein Bldg Room 3-124B, New York, NY, United States Department of Radiology, Columbia University Medical Center, 622 West 168th Street, PB-1-301, New York, NY, United States Department of Radiological Sciences, Center for Artificial Intelligence in Diagnostic Medicine (CAIDM), University of California, Irvine, Calit2 Building, Suite 4500, 4100 E. Peltason Drive, Irvine, CA, United States Breast Imaging Section, New York Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street, PB-1-301, New York, NY 10032, United States AU - Liu, M. Z. AU - Mutasa, S. AU - Chang, P. AU - Siddique, M. AU - Jambawalikar, S. AU - Ha, R. DB - Scopus DO - 10.1016/j.mri.2020.08.021 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 148-151 ST - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database T2 - Magnetic Resonance Imaging TI - A novel CNN algorithm for pathological complete response prediction using an I-SPY TRIAL breast MRI database UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090243840&doi=10.1016%2fj.mri.2020.08.021&partnerID=40&md5=a88a880ff3d7a6fe5cee187e669cf4c1 VL - 73 ID - 2176 ER - TY - JOUR AB - Background: Black men have the greatest burden of premature death and disability from hypertension (HTN) in the United States, and the highest incidence and mortality from colorectal cancer (CRC). While several clinical trials have reported beneficial effects of lifestyle changes on blood pressure (BP) reduction, and improved CRC screening with patient navigation (PN), the effectiveness of these approaches in community-based settings remains understudied, particularly among Black men.Methods/design: MISTER B is a two-parallel-arm randomized controlled trial that will compare the effect of a motivational interviewing tailored lifestyle intervention (MINT) versus a culturally targeted PN intervention on improvement of BP and CRC screening among black men aged ≥50 with uncontrolled HTN who are eligible for CRC screening. Approximately 480 self-identified black men will be randomly assigned to one of the two study conditions. This innovative research design allows each intervention to serve as the control for the other. Specifically, the MINT arm is the control condition for the PN arm, and vice-versa. This novel, simultaneous testing of two community-based interventions in a randomized fashion is an economical and yet rigorous strategy that also enhances the acceptability of the project. Participants will be recruited during scheduled screening events at barbershops in New York City. Trained research assistants will conduct the lifestyle intervention, while trained community health workers will deliver the PN intervention. The primary outcomes will be 1) within-patient change in systolic and diastolic BP from baseline to six months and 2) CRC screening rates at six months.Discussion: This innovative study will provide a unique opportunity to test two interventions for two health disparities simultaneously in community-based settings. Our study is one of the first to test culturally targeted patient navigation for CRC screening among black men in barbershops. Thus, our study has the potential to improve the reach of hypertension control and cancer prevention efforts within a high-risk population that is under-represented in primary care settings.Trial registration: ClinicalTrials.gov, NCT01092078. © 2013 Ravenell et al.; licensee BioMed Central Ltd. AD - J. Ravenell, Center for Healthful Behavior Change, New York University, School of Medicine, 227 E. 30th St., 6th Floor, New York, NY 10016, United States AU - Ravenell, J. AU - Thompson, H. AU - Cole, H. AU - Plumhoff, J. AU - Cobb, G. AU - Afolabi, L. AU - Boutin-Foster, C. AU - Wells, M. AU - Scott, M. AU - Ogedegbe, G. DB - Embase Medline DO - 10.1186/1745-6215-14-287 IS - 1 KW - NCT01092078 adult article blood pressure regulation cancer screening colorectal cancer community program comparative effectiveness controlled study diastolic blood pressure health auxiliary health care disparity human hypertension intermethod comparison intervention study lifestyle modification major clinical study male motivational interviewing Black person patient care randomized controlled trial study design systolic blood pressure LA - English M3 - Article N1 - L52770070 2013-09-13 2013-09-23 PY - 2013 SN - 1745-6215 ST - A novel community-based study to address disparities in hypertension and colorectal cancer: A study protocol for a randomized control trial T2 - Trials TI - A novel community-based study to address disparities in hypertension and colorectal cancer: A study protocol for a randomized control trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52770070&from=export http://dx.doi.org/10.1186/1745-6215-14-287 http://www.trialsjournal.com/content/14/1/287 VL - 14 ID - 1072 ER - TY - JOUR AB - Background: Black men have the greatest burden of premature death and disability from hypertension (HTN) in the United States, and the highest incidence and mortality from colorectal cancer (CRC). While several clinical trials have reported beneficial effects of lifestyle changes on blood pressure (BP) reduction, and improved CRC screening with patient navigation (PN), the effectiveness of these approaches in community-based settings remains understudied, particularly among Black men.Methods/design: MISTER B is a two-parallel-arm randomized controlled trial that will compare the effect of a motivational interviewing tailored lifestyle intervention (MINT) versus a culturally targeted PN intervention on improvement of BP and CRC screening among black men aged ≥50 with uncontrolled HTN who are eligible for CRC screening. Approximately 480 self-identified black men will be randomly assigned to one of the two study conditions. This innovative research design allows each intervention to serve as the control for the other. Specifically, the MINT arm is the control condition for the PN arm, and vice-versa. This novel, simultaneous testing of two community-based interventions in a randomized fashion is an economical and yet rigorous strategy that also enhances the acceptability of the project. Participants will be recruited during scheduled screening events at barbershops in New York City. Trained research assistants will conduct the lifestyle intervention, while trained community health workers will deliver the PN intervention. The primary outcomes will be 1) within-patient change in systolic and diastolic BP from baseline to six months and 2) CRC screening rates at six months.Discussion: This innovative study will provide a unique opportunity to test two interventions for two health disparities simultaneously in community-based settings. Our study is one of the first to test culturally targeted patient navigation for CRC screening among black men in barbershops. Thus, our study has the potential to improve the reach of hypertension control and cancer prevention efforts within a high-risk population that is under-represented in primary care settings.Trial Registration: ClinicalTrials.gov, NCT01092078. AD - Center for Healthful Behavior Change, New York University School of Medicine, 227 E, 30th St,, 6th Floor, Room 637, New York, NY 10016, USA. Joseph.ravenell@nyumc.org. AN - 104115985. Language: English. Entry Date: 20141024. Revision Date: 20170104. Publication Type: journal article AU - Ravenell, Joseph AU - Thompson, Hayley AU - Cole, Helen AU - Plumhoff, Jordan AU - Cobb, Gia AU - Afolabi, Lola AU - Boutin-Foster, Carla AU - Wells, Martin AU - Scott, Marian AU - Ogedegbe, Gbenga DB - CINAHL Complete DO - 10.1186/1745-6215-14-287 DP - EBSCOhost IS - 1 KW - Black Persons -- Psychosocial Factors Colorectal Neoplasms -- Prevention and Control Early Detection of Cancer Attitude to Health -- Ethnology Hypertension -- Therapy Motivational Interviewing Study Design Behavior Age Factors Occupations and Professions Blood Pressure Protocols Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Ethnology Colorectal Neoplasms -- Psychosocial Factors Community Health Services Culture Health Promotion Health Status Disparities Healthcare Disparities Human Hypertension -- Diagnosis Hypertension -- Ethnology Hypertension -- Physiopathology Hypertension -- Psychosocial Factors Male Middle Age New York Patient Navigation Patient Selection Predictive Value of Tests Risk Factors Sex Factors Time Factors Treatment Outcomes N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland. Grant Information: P60 MD003421/MD/NIMHD NIH HHS/United States. NLM UID: 101263253. PMID: NLM24011142. PY - 2013 SN - 1745-6215 SP - 287-287 ST - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial T2 - Trials TI - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104115985&site=ehost-live&scope=site VL - 14 ID - 1821 ER - TY - JOUR AB - Background: Black men have the greatest burden of premature death and disability from hypertension (HTN) in the United States, and the highest incidence and mortality from colorectal cancer (CRC). While several clinical trials have reported beneficial effects of lifestyle changes on blood pressure (BP) reduction, and improved CRC screening with patient navigation (PN), the effectiveness of these approaches in community-based settings remains understudied, particularly among Black men.Methods/design: MISTER B is a two-parallel-arm randomized controlled trial that will compare the effect of a motivational interviewing tailored lifestyle intervention (MINT) versus a culturally targeted PN intervention on improvement of BP and CRC screening among black men aged ≥50 with uncontrolled HTN who are eligible for CRC screening. Approximately 480 self-identified black men will be randomly assigned to one of the two study conditions. This innovative research design allows each intervention to serve as the control for the other. Specifically, the MINT arm is the control condition for the PN arm, and vice-versa. This novel, simultaneous testing of two community-based interventions in a randomized fashion is an economical and yet rigorous strategy that also enhances the acceptability of the project. Participants will be recruited during scheduled screening events at barbershops in New York City. Trained research assistants will conduct the lifestyle intervention, while trained community health workers will deliver the PN intervention. The primary outcomes will be 1) within-patient change in systolic and diastolic BP from baseline to six months and 2) CRC screening rates at six months.Discussion: This innovative study will provide a unique opportunity to test two interventions for two health disparities simultaneously in community-based settings. Our study is one of the first to test culturally targeted patient navigation for CRC screening among black men in barbershops. Thus, our study has the potential to improve the reach of hypertension control and cancer prevention efforts within a high-risk population that is under-represented in primary care settings.Trial registration: ClinicalTrials.gov, NCT01092078. © 2013 Ravenell et al.; licensee BioMed Central Ltd. AD - Center for Healthful Behavior Change, New York University, School of Medicine, 227 E. 30th St., 6th Floor, New York, NY 10016, United States Population Studies and Disparities Research Program, Karmanos Cancer Institute Department of Oncology, Wayne State University School of Medicine, 4100 John R - MM03CB, Detroit, MI 48201, United States Formerly with the Center for Healthful Behavior Change, 900 Lenox Rd, Apt 2B, Brooklyn, NY 11203, United States 505 East 70th Street, Helmsley Tower, 4th Floor, New York, NY 10021, United States Cornell University, 301 Malott Hall, Ithaca, NY 14853, United States St. Luke's and Roosevelt Hospitals, 555 W. 57th Street, Suite 5-43, New York, NY 10019, United States AU - Ravenell, J. AU - Thompson, H. AU - Cole, H. AU - Plumhoff, J. AU - Cobb, G. AU - Afolabi, L. AU - Boutin-Foster, C. AU - Wells, M. AU - Scott, M. AU - Ogedegbe, G. C7 - 287 DB - Scopus DO - 10.1186/1745-6215-14-287 IS - 1 KW - African Americans Barbershops Hypertension Patient navigation M3 - Article N1 - Cited By :17 Export Date: 22 March 2021 PY - 2013 ST - A novel community-based study to address disparities in hypertension and colorectal cancer: A study protocol for a randomized control trial T2 - Trials TI - A novel community-based study to address disparities in hypertension and colorectal cancer: A study protocol for a randomized control trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883540930&doi=10.1186%2f1745-6215-14-287&partnerID=40&md5=0e473d3c88eafb86c7192c53490292c7 VL - 14 ID - 2426 ER - TY - JOUR AB - Background: Black men have the greatest burden of premature death and disability from hypertension (HTN) in the United States, and the highest incidence and mortality from colorectal cancer (CRC). While several clinical trials have reported beneficial effects of lifestyle changes on blood pressure (BP) reduction, and improved CRC screening with patient navigation (PN), the effectiveness of these approaches in community-based settings remains understudied, particularly among Black men. Methods/design: MISTER B is a two-parallel-arm randomized controlled trial that will compare the effect of a motivational interviewing tailored lifestyle intervention (MINT) versus a culturally targeted PN intervention on improvement of BP and CRC screening among black men aged >= 50 with uncontrolled HTN who are eligible for CRC screening. Approximately 480 self-identified black men will be randomly assigned to one of the two study conditions. This innovative research design allows each intervention to serve as the control for the other. Specifically, the MINT arm is the control condition for the PN arm, and vice-versa. This novel, simultaneous testing of two community-based interventions in a randomized fashion is an economical and yet rigorous strategy that also enhances the acceptability of the project. Participants will be recruited during scheduled screening events at barbershops in New York City. Trained research assistants will conduct the lifestyle intervention, while trained community health workers will deliver the PN intervention. The primary outcomes will be 1) within-patient change in systolic and diastolic BP from baseline to six months and 2) CRC screening rates at six months. Discussion: This innovative study will provide a unique opportunity to test two interventions for two health disparities simultaneously in community-based settings. Our study is one of the first to test culturally targeted patient navigation for CRC screening among black men in barbershops. Thus, our study has the potential to improve the reach of hypertension control and cancer prevention efforts within a high-risk population that is under-represented in primary care settings. Trial registration: ClinicalTrials.gov, NCT01092078 AN - WOS:000324259400001 AU - Ravenell, J. AU - Thompson, H. AU - Cole, H. AU - Plumhoff, J. AU - Cobb, G. AU - Afolabi, L. AU - Boutin-Foster, C. AU - Wells, M. AU - Scott, M. AU - Ogedegbe, G. DA - Sep DO - 10.1186/1745-6215-14-287 N1 - 287 24011142 PY - 2013 SN - 1745-6215 ST - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial T2 - Trials TI - A novel community-based study to address disparities in hypertension and colorectal cancer: a study protocol for a randomized control trial VL - 14 ID - 3035 ER - TY - JOUR AB - Healthy lifestyle behaviors are recommended to reduce cancer risk and overall mortality. Adherence to cancer-preventive health behaviors and subsequent cancer risk has not been evaluated in a diverse sample of postmenopausal women. We examined the association between the American Cancer Society (ACS) Nutrition and Physical Activity Cancer Prevention Guidelines score and risk of incident cancer, cancer-specific mortality, and all-cause mortality in 65,838 postmenopausal women enrolled in the Women's Health Initiative Observational Study. ACS guidelines scores (0-8 points) were determined from a combined measure of diet, physical activity, body mass index (current and at age 18 years), and alcohol consumption. After a mean follow-up of 12.6 years, 8,632 incident cancers and 2,356 cancer deaths were identified. The highest ACS guidelines scores compared with the lowest were associated with a 17% lower risk of any cancer [HR, 0.83; 95% confidence interval (CI), 0.75-0.92], 22% lower risk of breast cancer (HR, 0.78; 95% CI, 0.67-0.92), 52% lower risk of colorectal cancer (HR, 0.48; 95% CI, 0.32-0.73), 27% lower risk of all-cause mortality, and 20% lower risk of cancer-specific mortality (HR, 0.80; 95% CI, 0.71-0.90). Associations with lower cancer incidence and mortality were generally strongest among Asian, black, and Hispanic women and weakest among non-Hispanic whites. Behaviors concordant with Nutrition and Physical Activity Cancer Prevention Guidelines were associated with lower risk of total, breast, and colorectal cancers and lower cancer-specific mortality in postmenopausal women. ©2013 American Association for Cancer Research. AD - Health Promotion Sciences, Canyon Ranch Center for Prevention and Health Promotion, Mel and Enid Zuckerman College of Public Health, 1295 N. Martin Street, Tucson, AZ 85721, United States University of Arizona Cancer Center, Tucson, AZ, United States American Cancer Society, Atlanta, GA, United States Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, United States Moores UCSD Cancer Center, University of California, San Diego, United States Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, CA, United States Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, United States Department of Social and Preventive Medicine, University at Buffalo, SUNY, Buffalo, United States Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, NY, United States Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States Department of Medicine, Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, MA, United States Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, United States Wake Forest School of Medicine, Division of Public Health Sciences, Winston-Salem, NC, United States Department of Gynecology, School of Medicine and Public Healt, Madison, WI, United States Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States AU - Thomson, C. A. AU - McCullough, M. L. AU - Wertheim, B. C. AU - Chlebowski, R. T. AU - Martinez, M. E. AU - Stefanick, M. L. AU - Rohan, T. E. AU - Manson, J. E. AU - Tindle, H. A. AU - Ockene, J. AU - Vitolins, M. Z. AU - Wactawski-Wende, J. AU - Sarto, G. E. AU - Lane, D. S. AU - Neuhouser, M. L. DB - Scopus DO - 10.1158/1940-6207.CAPR-13-0258 IS - 1 M3 - Article N1 - Cited By :113 Export Date: 22 March 2021 PY - 2014 SP - 42-53 ST - Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative T2 - Cancer Prevention Research TI - Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892412107&doi=10.1158%2f1940-6207.CAPR-13-0258&partnerID=40&md5=1b9a2b51b705d0eb5fdb82ea5ed1cc80 VL - 7 ID - 2414 ER - TY - JOUR AB - Background: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. Methods: A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. Results: Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0–2). Fifty percent of patients were Caucasian, 45% African–American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug–drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. Conclusions: Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. Trial registration: ClinicalTrials.gov, NCT02158507. Registered on 12 September 2014 AD - E.S. Yang, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, 1700 6th Avenue South, HSROC Suite 2232 (176F), Birmingham, AL, United States AU - Stringer-Reasor, E. M. AU - May, J. E. AU - Olariu, E. AU - Caterinicchia, V. AU - Li, Y. AU - Chen, D. AU - Della Manna, D. L. AU - Rocque, G. B. AU - Vaklavas, C. AU - Falkson, C. I. AU - Nabell, L. M. AU - Acosta, E. P. AU - Forero-Torres, A. AU - Yang, E. S. DB - Embase Medline DO - 10.1186/s13058-021-01408-9 IS - 1 KW - adult advanced cancer African American antineoplastic activity article cancer patient Caucasian chemotherapy clinical article clinical trial controlled study DNA repair drug combination drug safety drug therapy eligibility exploratory research female gene mutation germ line Hispanic human immunogenicity lethality molecularly targeted therapy pharmacokinetics pilot study signal transduction triple negative breast cancer tumor biopsy anthracycline BRCA1 protein endogenous compound epidermal growth factor receptor lapatinib nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase unclassified drug veliparib LA - English M3 - Article N1 - L2010677346 2021-03-10 PY - 2021 SN - 1465-542X 1465-5411 ST - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer T2 - Breast Cancer Research TI - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010677346&from=export http://dx.doi.org/10.1186/s13058-021-01408-9 VL - 23 ID - 755 ER - TY - JOUR AB - Background: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair, we have previously shown an induced synthetic lethality with combined EGFR inhibition and PARPi. Here, we report the safety and clinical activity of lapatinib and veliparib in patients with metastatic TNBC. Methods: A first-in-human, pilot study of lapatinib and veliparib was conducted in metastatic TNBC (NCT02158507). The primary endpoint was safety and tolerability. Secondary endpoints were objective response rates and pharmacokinetic evaluation. Gene expression analysis of pre-treatment tumor biopsies was performed. Key eligibility included TNBC patients with measurable disease and prior anthracycline-based and taxane chemotherapy. Patients with gBRCA1/2 mutations were excluded. Results: Twenty patients were enrolled, of which 17 were evaluable for response. The median number of prior therapies in the metastatic setting was 1 (range 0–2). Fifty percent of patients were Caucasian, 45% African–American, and 5% Hispanic. Of evaluable patients, 4 demonstrated a partial response and 2 had stable disease. There were no dose-limiting toxicities. Most AEs were limited to grade 1 or 2 and no drug–drug interactions noted. Exploratory gene expression analysis suggested baseline DNA repair pathway score was lower and baseline immunogenicity was higher in the responders compared to non-responders. Conclusions: Lapatinib plus veliparib therapy has a manageable safety profile and promising antitumor activity in advanced TNBC. Further investigation of dual therapy with EGFR inhibition and PARP inhibition is needed. Trial registration: ClinicalTrials.gov, NCT02158507. Registered on 12 September 2014 © 2021, The Author(s). AD - Department of Medicine, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, United States Department of Medicine, Brookwood Baptist Health, Birmingham, AL, United States Department of Pharmacology/Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, United States O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, 1700 6th Avenue South, HSROC Suite 2232 (176F), Birmingham, AL 35249, United States AU - Stringer-Reasor, E. M. AU - May, J. E. AU - Olariu, E. AU - Caterinicchia, V. AU - Li, Y. AU - Chen, D. AU - Della Manna, D. L. AU - Rocque, G. B. AU - Vaklavas, C. AU - Falkson, C. I. AU - Nabell, L. M. AU - Acosta, E. P. AU - Forero-Torres, A. AU - Yang, E. S. C7 - 30 DB - Scopus DO - 10.1186/s13058-021-01408-9 IS - 1 KW - DNA repair PARP inhibitors Synthetic lethality Targeted therapy Triple-negative breast cancer M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer T2 - Breast Cancer Research TI - An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101970607&doi=10.1186%2fs13058-021-01408-9&partnerID=40&md5=27c4187aeae26efc9a75116927dd82ca VL - 23 ID - 2151 ER - TY - JOUR AB - Purpose: Inclusion of women in biomedical cancer research have the potential to close gaps in cancer health disparities and improve adjuvant therapies for women; yet samples needed to advance this area of science are lacking. We developed low-cost educational recruitment strategies to increase our collection of biospecimens from women. Materials and Methods: Women diagnosed with hormone receptor positive (HR+) breast cancer that initiated hormonal therapy were recruited from three integrated health systems. The analytical sample (n = 144) consisted of women who consented but did not return a saliva sample within 1 year of the initial assessment (baseline). Brief informational recruitment materials were developed via published literature and preliminary data. Women received recruitment materials, which included a personalized information letter, a colorful low-literacy instruction sheet, a postage-paid envelope, and collection kits. We evaluated intervention materials and performed descriptive and bivariate statistics to describe factors associated with biospecimen donation. Results: Of the total sample, 61% were white and 34% were black. Overall, 29 surveys (20%) and 25 (17%) saliva kits were returned. Women found the materials helpful and easy to read and understand. Women with higher levels of functional well-being and lower ratings of religiosity were more likely to return biospecimens (p < 0.005) after receiving enhanced materials. Conclusion: This article provides recruitment strategies to enhance biospecimen samples among women. Receipt of brief informational print materials inclusive of personalized messages enhanced our outreach strategies and increased our overall biospecimen provision rate by 17%. The inclusion of messages with a focus on spirituality and other cultural messages may further increase biospecimen provision in racial/ethnic diverse groups of women; however, further study is needed to support this claim. Clinical Trail Registration Number: NCT02992730. AN - WOS:000607276900001 AU - Edmonds, M. C. AU - Sutton, A. L. AU - Cummings, Y. AU - Sheppard, V. B. DO - 10.1089/jwh.2020.8502 N1 - 33428522 SN - 1540-9996 ST - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research T2 - Journal of Womens Health TI - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research ID - 2753 ER - TY - JOUR AB - Purpose: Inclusion of women in biomedical cancer research have the potential to close gaps in cancer health disparities and improve adjuvant therapies for women; yet samples needed to advance this area of science are lacking. We developed low-cost educational recruitment strategies to increase our collection of biospecimens from women. Materials and Methods: Women diagnosed with hormone receptor positive (HR+) breast cancer that initiated hormonal therapy were recruited from three integrated health systems. The analytical sample (n = 144) consisted of women who consented but did not return a saliva sample within 1 year of the initial assessment (baseline). Brief informational recruitment materials were developed via published literature and preliminary data. Women received recruitment materials, which included a personalized information letter, a colorful low-literacy instruction sheet, a postage-paid envelope, and collection kits. We evaluated intervention materials and performed descriptive and bivariate statistics to describe factors associated with biospecimen donation. Results: Of the total sample, 61% were white and 34% were black. Overall, 29 surveys (20%) and 25 (17%) saliva kits were returned. Women found the materials helpful and easy to read and understand. Women with higher levels of functional well-being and lower ratings of religiosity were more likely to return biospecimens (p < 0.005) after receiving enhanced materials. Conclusion: This article provides recruitment strategies to enhance biospecimen samples among women. Receipt of brief informational print materials inclusive of personalized messages enhanced our outreach strategies and increased our overall biospecimen provision rate by 17%. The inclusion of messages with a focus on spirituality and other cultural messages may further increase biospecimen provision in racial/ethnic diverse groups of women; however, further study is needed to support this claim. Clinical Trail Registration Number: NCT02992730. AU - Edmonds, M. C. AU - Sutton, A. L. AU - Cummings, Y. AU - Sheppard, V. B. DB - Medline DO - 10.1089/jwh.2020.8502 KW - NCT02992730 adult article bivariate analysis breast cancer cancer survivor female hormonal therapy human human tissue literacy major clinical study preliminary data religion saliva transcription initiation wellbeing women's health endogenous compound hormone receptor LA - English M3 - Article in Press N1 - L634030292 2021-02-02 PY - 2021 SN - 1931-843X ST - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research T2 - Journal of women's health (2002) TI - Opportunities to Improve Women's Health: Engaging Racial/Ethnic Diverse Women to Provide Biospecimens for Research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634030292&from=export http://dx.doi.org/10.1089/jwh.2020.8502 ID - 759 ER - TY - JOUR AB - Objective: To describe the knowledge of, and attitudes toward, out-of-pocket expenses (OOPE) associated with prostate cancer treatment and the influence of OOPE on the treatment choices of patients with prostate cancer. Materials and Methods: We undertook a qualitative research study for which we recruited patients with clinically localized prostate cancer. Patients answered a series of open-ended questions during a semistructured interview and completed a questionnaire about the physician's role in discussing OOPE, the burden of OOPE, the effect of OOPE on treatment decisions, and previous knowledge of OOPE. Results: A total of 41 (26 white and 15 black) eligible patients were enrolled from the urology and radiation oncology practices of the University of Pennsylvania. Qualitative assessment revealed 5 major themes: (a) "my insurance takes care of it"; (b) "health is more important than cost"; (c) "I did not look into it"; (d) "I cannot afford it but would have chosen the same treatment"; and (e) "It is not my doctor's business." Most patients (38 of 41, 93%) reported that they would not have chosen a different treatment even if they had known the actual OOPE of their treatment. Patients who reported feeling burdened by OOPE were socioeconomically heterogeneous, and their treatment choices remained unaffected. Only 2 patients stated they knew "a lot" about the likely OOPE for different prostate cancer treatments before choosing their treatment. Conclusion: Among insured patients with prostate cancer treated at a large academic medical center, few had knowledge of OOPE before making treatment choices. © 2012 Elsevier Inc. All Rights Reserved. AD - Health Policy Management Doctoral Program, Harvard Business School, Boston, MA, United States Department of Radiation Oncology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, PA 19104, United States Health Care Management Department, University of Pennsylvania, Wharton School of Business, Philadelphia, PA, United States Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States University of Pennsylvania, School of Nursing, Philadelphia, PA, United States Department of Radiation Oncology, Columbia University Medical Center, New York, NY, United States Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States AU - Jung, O. S. AU - Guzzo, T. AU - Lee, D. AU - Mehler, M. AU - Christodouleas, J. AU - Deville, C. AU - Hollis, G. AU - Shah, A. AU - Vapiwala, N. AU - Wein, A. AU - Pauly, M. AU - Bekelman, J. E. DB - Scopus DO - 10.1016/j.urology.2012.08.027 IS - 6 M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2012 SP - 1252-1257 ST - Out-of-pocket expenses and treatment choice for men with prostate cancer T2 - Urology TI - Out-of-pocket expenses and treatment choice for men with prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870695387&doi=10.1016%2fj.urology.2012.08.027&partnerID=40&md5=82df37a6aa9760c8d60c14e49c1bed2f VL - 80 ID - 2451 ER - TY - JOUR AB - Metastatic colorectal cancer outcomes continue to improve, but they vary significantly by race and ethnicity. Hypothesizing that these disparities arise from unequal access to care rather than intrinsic biology, we showed that survival of 103 consecutive patients with metastatic colorectal cancer treated at an academic safety-net hospital that treats the underserved, predominantly minority population of Harris County, Texas, was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial. Our findings suggest that administering high-quality comprehensive cancer care to vulnerable populations can overcome disparities reported in the medical literature. AD - B.L. Musher, Associate Professor of Medicine, Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX, United States AU - Lau-Min, K. AU - Prakash, P. AU - Jo, E. AU - Thrift, A. P. AU - Hilsenbeck, S. AU - Musher, B. L. DB - Embase Medline DO - 10.1016/j.clcc.2019.09.002 IS - 2 KW - bevacizumab capecitabine cetuximab fluoropyrimidine fluorouracil folinic acid irinotecan oxaliplatin panitumumab regorafenib adult article Asian Black person cancer chemotherapy cancer patient cancer radiotherapy cancer surgery cancer survival clinical pathway evidence based practice female financial management health care delivery Hispanic human integration major clinical study male medically uninsured metastatic colorectal cancer middle aged Middle East minority group outcome assessment overall survival retrospective study safety net health care survival rate treatment response vulnerable population LA - English M3 - Article N1 - L2005190164 2020-03-17 Background: Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. Materials and Methods: The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine's Dan L. Duncan Comprehensive Cancer Center, Ben Taub Hospital (BTH) delivers cancer care through multidisciplinary subspecialty that prioritize access to care, adherence to evidence-based clinical pathways, integration of supportive services, and mitigation of financial toxicity. We performed a retrospective analysis of minority patients diagnosed with and treated for metastatic CRC at BTH between January 2010 and December 2012. Kaplan-Meier survival curves were compared with survival curves from randomized control trials reported during that time period. Results: We identified 103 patients; 40% were black, 49% were Hispanic, and 12% were Asian or Middle Eastern. Thirty-five percent reported a language other than English as their preferred language. Seventy-four percent of patients with documented coverage status were uninsured. Eighty-four percent of patients received standard chemotherapy with a clinician-reported response rate of 63%. Overall survival for BTH patients undergoing chemotherapy was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial (median, 24.0 vs. 19.9 months; P = .014). Conclusion: HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care. PY - 2020 SN - 1938-0674 1533-0028 SP - e49-e57 ST - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System T2 - Clinical Colorectal Cancer TI - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005190164&from=export http://dx.doi.org/10.1016/j.clcc.2019.09.002 VL - 19 ID - 803 ER - TY - JOUR AB - Background: Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care.Materials and Methods: The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine's Dan L. Duncan Comprehensive Cancer Center, Ben Taub Hospital (BTH) delivers cancer care through multidisciplinary subspecialty that prioritize access to care, adherence to evidence-based clinical pathways, integration of supportive services, and mitigation of financial toxicity. We performed a retrospective analysis of minority patients diagnosed with and treated for metastatic CRC at BTH between January 2010 and December 2012. Kaplan-Meier survival curves were compared with survival curves from randomized control trials reported during that time period.Results: We identified 103 patients; 40% were black, 49% were Hispanic, and 12% were Asian or Middle Eastern. Thirty-five percent reported a language other than English as their preferred language. Seventy-four percent of patients with documented coverage status were uninsured. Eighty-four percent of patients received standard chemotherapy with a clinician-reported response rate of 63%. Overall survival for BTH patients undergoing chemotherapy was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial (median, 24.0 vs. 19.9 months; P = .014).Conclusion: HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care. AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA Department of Medicine, Baylor College of Medicine, Houston, TX Department of Medicine, Baylor College of Medicine, Houston, TX; Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Houston, TX AN - 146067026. Language: English. Entry Date: In Process. Revision Date: 20200926. Publication Type: journal article. Journal Subset: Biomedical AU - Lau-Min, Kelsey AU - Prakash, Preeti AU - Jo, Eunji AU - Thrift, Aaron P. AU - Hilsenbeck, Susan AU - Musher, Benjamin L. DB - CINAHL Complete DO - 10.1016/j.clcc.2019.09.002 DP - EBSCOhost IS - 2 N1 - Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: P30 CA125123/CA/NCI NIH HHS/United States. NLM UID: 101120693. PMID: NLM32165040. PY - 2020 SN - 1533-0028 SP - e49-e57 ST - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System T2 - Clinical Colorectal Cancer TI - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146067026&site=ehost-live&scope=site VL - 19 ID - 2008 ER - TY - JOUR AB - Metastatic colorectal cancer outcomes continue to improve, but they vary significantly by race and ethnicity. Hypothesizing that these disparities arise from unequal access to care rather than intrinsic biology, we showed that survival of 103 consecutive patients with metastatic colorectal cancer treated at an academic safety-net hospital that treats the underserved, predominantly minority population of Harris County, Texas, was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial. Our findings suggest that administering high-quality comprehensive cancer care to vulnerable populations can overcome disparities reported in the medical literature. © 2020 Elsevier Inc. Background: Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. Materials and Methods: The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine's Dan L. Duncan Comprehensive Cancer Center, Ben Taub Hospital (BTH) delivers cancer care through multidisciplinary subspecialty that prioritize access to care, adherence to evidence-based clinical pathways, integration of supportive services, and mitigation of financial toxicity. We performed a retrospective analysis of minority patients diagnosed with and treated for metastatic CRC at BTH between January 2010 and December 2012. Kaplan-Meier survival curves were compared with survival curves from randomized control trials reported during that time period. Results: We identified 103 patients; 40% were black, 49% were Hispanic, and 12% were Asian or Middle Eastern. Thirty-five percent reported a language other than English as their preferred language. Seventy-four percent of patients with documented coverage status were uninsured. Eighty-four percent of patients received standard chemotherapy with a clinician-reported response rate of 63%. Overall survival for BTH patients undergoing chemotherapy was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial (median, 24.0 vs. 19.9 months; P = .014). Conclusion: HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care. © 2020 Elsevier Inc. AD - Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Department of Medicine, Baylor College of Medicine, Houston, TX, United States Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Houston, TX, United States AU - Lau-Min, K. AU - Prakash, P. AU - Jo, E. AU - Thrift, A. P. AU - Hilsenbeck, S. AU - Musher, B. L. DB - Scopus DO - 10.1016/j.clcc.2019.09.002 IS - 2 KW - Black Disparities Hispanic Stage 4 Survival Underserved M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - e49-e57 ST - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System T2 - Clinical Colorectal Cancer TI - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081197846&doi=10.1016%2fj.clcc.2019.09.002&partnerID=40&md5=ce859329aa91a3d1580b67fe680d634c VL - 19 ID - 2194 ER - TY - JOUR AB - Metastatic colorectal cancer outcomes continue to improve, but they vary significantly by race and ethnicity. Hypothesizing that these disparities arise from unequal access to care rather than intrinsic biology, we showed that survival of 103 consecutive patients with metastatic colorectal cancer treated at an academic safety-net hospital that treats the underserved, predominantly minority population of Harris County, Texas, was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial. Our findings suggest that administering high-quality comprehensive cancer care to vulnerable populations can overcome disparities reported in the medical literature. Background: Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. Materials and Methods: The Harris Health System (HHS) is an integrated health delivery network that provides medical care to the underserved, predominantly minority population of Harris County, Texas. As the largest HHS facility and an affiliate of Baylor College of Medicine's Dan L. Duncan Comprehensive Cancer Center, Ben Taub Hospital (BTH) delivers cancer care through multidisciplinary subspecialty that prioritize access to care, adherence to evidence-based clinical pathways, integration of supportive services, and mitigation of financial toxicity. We performed a retrospective analysis of minority patients diagnosed with and treated for metastatic CRC at BTH between January 2010 and December 2012. Kaplan-Meier survival curves were compared with survival curves from randomized control trials reported during that time period. Results: We identified 103 patients; 40% were black, 49% were Hispanic, and 12% were Asian or Middle Eastern. Thirty-five percent reported a language other than English as their preferred language. Seventy-four percent of patients with documented coverage status were uninsured. Eighty-four percent of patients received standard chemotherapy with a clinician-reported response rate of 63%. Overall survival for BTH patients undergoing chemotherapy was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial (median, 24.0 vs. 19.9 months; P = .014). Conclusion: HHS provides a health delivery infrastructure through which minority patients with socioeconomic challenges experience clinical outcomes comparable with highly selected patients enrolled in randomized control trials. Efforts to resolve CRC disparities should focus on improving access of at-risk populations to high-quality comprehensive cancer care. (C) 2020 Elsevier inc. All rights reserved. AN - WOS:000535736200001 AU - Lau-Min, K. AU - Prakash, P. AU - Jo, E. AU - Thrift, A. P. AU - Hilsenbeck, S. AU - Musher, B. L. DA - Jun DO - 10.1016/j.clcc.2019.09.002 IS - 2 N1 - 32165040 PY - 2020 SN - 1533-0028 SP - E49-E57 ST - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System T2 - Clinical Colorectal Cancer TI - Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System VL - 19 ID - 2776 ER - TY - JOUR AB - BACKGROUND: Previous studies have demonstrated that African‐Americans with colon cancer have worse overall and stage‐specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy‐related toxicities between African‐Americans and Caucasians. In this study, we examined survival and toxic effects among African‐American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer. METHODS: We analyzed data on 3380 patients (344 African‐Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5‐fluorouracil‐based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease‐free survival (DFS) and overall survival (OS) between African‐Americans and Caucasians by the Kaplan‐Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment‐related toxicity rates by Fisher's exact test. All statistical tests were two‐sided. RESULTS: We found no differences in DFS or OS between African‐American and Caucasian patients. Five‐year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African‐Americans and 58% (95% CI = 56% to 60%) for Caucasians (P =.15), and 5‐year OS was 65% (95% CI = 60% to 70%) for African‐Americans and 66% (95% CI = 64% to 68%) for Caucasians (P =.38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African‐Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment‐related toxicity differed between the African‐American and Caucasian patients, with African‐Americans experiencing statistically significantly lower rates of diarrhea (P<.001), nausea (P<.001), vomiting (P =.01), stomatitis (P<.001), and overall toxicity (P =.005). CONCLUSIONS: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5‐year DFS and OS in African‐Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African‐Americans appeared to experience less treatment‐related toxicity. AN - CN-00390717 AU - McCollum, A. D. AU - Catalano, P. J. AU - Haller, D. G. AU - Mayer, R. J. AU - Macdonald, J. S. AU - Benson, A. B. AU - Fuchs, C. S. DO - 10.1093/jnci/94.15.1160 IS - 15 KW - African Continental Ancestry Group Antimetabolites, Antineoplastic [*therapeutic use] Chemotherapy, Adjuvant Colonic Neoplasms [*drug therapy, *ethnology, mortality] European Continental Ancestry Group Fluorouracil [adverse effects, *therapeutic use] Humans Treatment Outcome M3 - Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2002 SP - 1160‐1167 ST - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer T2 - Journal of the National Cancer Institute TI - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00390717/full VL - 94 ID - 1361 ER - TY - JOUR AB - Background: Previous studies have demonstrated that African-Americans with colon cancer have worse overall and stage-specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy-related toxicities between African-Americans and Caucasians. In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer. Methods: We analyzed data on 3380 patients (344 African-Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5-fluorouracil-based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease-free survival (DFS) and overall survival (OS) between African-Americans and Caucasians by the Kaplan-Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment-related toxicity rates by Fisher's exact test. All statistical tests were two-sided. Results: We found no differences in DFS or OS between African-American and Caucasian patients. Five-year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African-Americans and 58% (95% CI = 56% to 60%) for Caucasians (P = .15), and 5-year OS was 65% (95% CI 60% to 70%) for African-Americans and 66% (95% Cl 64% to 68%) for Caucasians (P = .38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African-Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment-related toxicity differed between the African-American and Caucasian patients, with African-Americans experiencing statistically significantly lower rates of diarrhea (P < .001), nausea (P < .001), vomiting (P = .01), stomatitis (P < .001), and overall toxicity (P = .005). Conclusions: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5-year DFS and OS in African-Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African-Americans appeared to experience less treatment-related toxicity. [J Natl Cancer Inst 2002;94:1160-7]. AN - WOS:000177231100013 AU - McCollum, A. D. AU - Catalano, P. J. AU - Haller, D. G. AU - Mayer, R. J. AU - Macdonald, J. S. AU - Benson, A. B. AU - Fuchs, C. S. DA - Aug 7 IS - 15 N1 - 106 12165641 PY - 2002 SN - 0027-8874 SP - 1160-1167 ST - Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer T2 - Jnci-Journal of the National Cancer Institute TI - Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer VL - 94 ID - 2701 ER - TY - JOUR AB - Background: Previous studies have demonstrated that African-Americans with colon cancer have worse overall and stage-specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy-related toxicities between African-Americans and Caucasians. In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer.Methods: We analyzed data on 3380 patients (344 African-Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5-fluorouracil-based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease-free survival (DFS) and overall survival (OS) between African-Americans and Caucasians by the Kaplan-Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment-related toxicity rates by Fisher's exact test. All statistical tests were two-sided.Results: We found no differences in DFS or OS between African-American and Caucasian patients. Five-year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African-Americans and 58% (95% CI = 56% to 60%) for Caucasians (P =.15), and 5-year OS was 65% (95% CI = 60% to 70%) for African-Americans and 66% (95% CI = 64% to 68%) for Caucasians (P =.38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African-Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment-related toxicity differed between the African-American and Caucasian patients, with African-Americans experiencing statistically significantly lower rates of diarrhea (P<.001), nausea (P<.001), vomiting (P =.01), stomatitis (P<.001), and overall toxicity (P =.005).Conclusions: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5-year DFS and OS in African-Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African-Americans appeared to experience less treatment-related toxicity. AN - 7228139. Language: English. Entry Date: 20030110. Revision Date: 20201026. Publication Type: journal article AU - McCollum, A. David AU - Catalano, Paul J. AU - Haller, Daniel G. AU - Mayer, Robert J. AU - Macdonald, John S. AU - Benson Iii, Al B. AU - Fuchs, Charles S. AU - Benson, Al B., 3rd DB - CINAHL Complete DO - 10.1093/jnci/94.15.1160 DP - EBSCOhost IS - 15 KW - Fluorouracil -- Therapeutic Use Colonic Neoplasms -- Ethnology Colonic Neoplasms -- Drug Therapy Antimetabolites, Antineoplastic -- Therapeutic Use Human Fluorouracil -- Adverse Effects Black Persons Colonic Neoplasms -- Mortality White Persons Treatment Outcomes Chemotherapy, Adjuvant Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials N1 - clinical trial; research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: CA21115/CA/NCI NIH HHS/United States. NLM UID: 7503089. PMID: NLM12165641. PY - 2002 SN - 0027-8874 SP - 1160-1167 ST - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer T2 - JNCI: Journal of the National Cancer Institute TI - Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=7228139&site=ehost-live&scope=site VL - 94 ID - 2009 ER - TY - JOUR AB - Background: Previous studies have demonstrated that African-Americans with colon cancer have worse overall and stage-specific survival rates than Caucasians. Such differences could reflect variation in access to health care, in tumor biology, or in treatment efficacy. Little is known about potential differences in chemotherapy-related toxicities between African-Americans and Caucasians. In this study, we examined survival and toxic effects among African-American and Caucasian patients enrolled in a large, randomized phase III trial of adjuvant chemotherapy for resected colon cancer. Methods: We analyzed data on 3380 patients (344 African-Americans and 3036 Caucasians) enrolled in a randomized trial of adjuvant 5-fluorouracil-based chemotherapy in patients with stage II (high risk) and stage III colon cancer to evaluate differences in outcomes and toxicity. We compared disease-free survival (DFS) and overall survival (OS) between African-Americans and Caucasians by the Kaplan-Meier method, computed Cox proportional hazards by multivariable analysis, and compared treatment-related toxicity rates by Fisher's exact test. All statistical tests were two-sided. Results: We found no differences in DFS or OS between African-American and Caucasian patients. Five-year DFS was 57% (95% confidence interval [CI] = 52% to 62%) for African-Americans and 58% (95% CI = 56% to 60%) for Caucasians (P = .15), and 5-year OS was 65% (95% CI = 60% to 70%) for African-Americans and 66% (95% CI= 64% to 68%) for Caucasians (P = .38). On multivariable analysis, no statistically significant difference in disease recurrence or death was detected between the racial/ethnic groups (hazard ratios for African-Americans versus Caucasians: disease recurrence = 1.1, 95% CI = 0.9 to 1.3; death = 1.1, 95% CI = 0.9 to 1.3). Treatment-related toxicity differed between the African-American and Caucasian patients, with African-Americans experiencing statistically significantly lower rates of diarrhea (P<.001), nausea (P<.001), vomiting (P = .01), stomatitis (P<.001), and overall toxicity (P = .005). Conclusions: In this study of patients with similar access to health care resources and treatment with adjuvant chemotherapy, we found similar 5-year DFS and OS in African-Americans and Caucasians with stage II and III colon cancer. The two groups derived similar benefits from adjuvant chemotherapy. Moreover, African-Americans appeared to experience less treatment-related toxicity. AD - Dana-Farber Cancer Institute, Boston, MA, United States Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, Boston, MA, United States University of Pennsylvania Cancer Center, Philadelphia, PA, United States St. Vincent Clinical Cancer Center, New York, NY, United States Division of Hematology-Oncology, Northwestern University, Chicago, IL, United States Dana-Farber Cancer Institute, 44 Binney St., Boston, MA, United States AU - McCollum, A. D. AU - Catalano, P. J. AU - Haller, D. G. AU - Mayer, R. J. AU - Macdonald, J. S. AU - Benson Iii, A. B. AU - Fuchs, C. S. DB - Scopus IS - 15 M3 - Article N1 - Cited By :113 Export Date: 22 March 2021 PY - 2002 SP - 1160-1167 ST - Outcomes and toxicity in African-American and Caucasians patients in a randomized adjuvant chemotherapy trial for colon cancer T2 - Journal of the National Cancer Institute TI - Outcomes and toxicity in African-American and Caucasians patients in a randomized adjuvant chemotherapy trial for colon cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037036689&partnerID=40&md5=a82d1d520a3b314bb33e933f04315c79 VL - 94 ID - 2620 ER - TY - JOUR AB - Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer. To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Among women without cancer, median ovarian volume declined with age from 1.25 cm3 for women between ages 55 and 59 years to 1.0 cm3 for those between ages 65 and 69 years. African American and Caucasian women had larger median ovarian volumes than Asians. Larger ovarian volume was also associated with the highest quartiles of height and weight and ever having smoked. After adjusting for race, age, parity, body mass, smoking, and hormone use, women with median ovarian volumes ≥3.0 cm3 were at increased risk for breast cancer [odds ratio (OR), 1.42; 95% confidence interval (95% CI), 1.11-1.70], endometrial cancer (OR, 1.97; 95% CI, 1.12-3.48), and colon cancer (OR, 2.00; 95% CI, 1.25-3.21). Significant trends of risk with increasing volume were found only for breast and endometrial cancers. We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors. Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women. Copyright © 2006 American Association for Cancer Research. AD - M.E. Sherman, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, United States AU - Sherman, M. E. AU - Lacey, J. V. AU - Buys, S. S. AU - Reding, D. J. AU - Berg, C. D. AU - Williams, C. AU - Hartge, P. DB - Embase Medline DO - 10.1158/1055-9965.EPI-05-0847 IS - 8 KW - adult African American aged article Asian body height body mass body weight breast cancer cancer risk cancer screening Caucasian colon cancer confidence interval demography endometrium cancer female hormonal therapy human major clinical study ovary cancer postmenopause priority journal smoking ultrasound LA - English M3 - Article N1 - L44299331 2006-09-10 PY - 2006 SN - 1055-9965 SP - 1550-1554 ST - Ovarian volume: Determinants and associations with cancer among postmenopausal women T2 - Cancer Epidemiology Biomarkers and Prevention TI - Ovarian volume: Determinants and associations with cancer among postmenopausal women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44299331&from=export http://dx.doi.org/10.1158/1055-9965.EPI-05-0847 VL - 15 ID - 1241 ER - TY - JOUR AB - Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer. To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Among women without cancer, median ovarian volume declined with age from 1.25 cm3 for women between ages 55 and 59 years to 1.0 cm3 for those between ages 65 and 69 years. African American and Caucasian women had larger median ovarian volumes than Asians. Larger ovarian volume was also associated with the highest quartiles of height and weight and ever having smoked. After adjusting for race, age, parity, body mass, smoking, and hormone use, women with median ovarian volumes >or=3.0 cm3 were at increased risk for breast cancer [odds ratio (OR), 1.42; 95% confidence interval (95% CI), 1.11‐1.70], endometrial cancer (OR, 1.97; 95% CI, 1.12‐3.48), and colon cancer (OR, 2.00; 95% CI, 1.25‐3.21). Significant trends of risk with increasing volume were found only for breast and endometrial cancers. We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors. Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women. AN - CN-00571533 AU - Sherman, M. E. AU - Lacey, J. V. AU - Buys, S. S. AU - Reding, D. J. AU - Berg, C. D. AU - Williams, C. AU - Hartge, P. DO - 10.1158/1055-9965.EPI-05-0847 IS - 8 KW - Aged Case‐Control Studies Colonic Neoplasms [etiology, pathology] Endometrial Neoplasms [etiology, pathology] Female Humans Middle Aged Ovarian Neoplasms [*etiology, pathology] Ovary [*pathology] Postmenopause M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural PY - 2006 SP - 1550‐1554 ST - Ovarian volume: determinants and associations with cancer among postmenopausal women T2 - Cancer epidemiology, biomarkers & prevention TI - Ovarian volume: determinants and associations with cancer among postmenopausal women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00571533/full VL - 15 ID - 1466 ER - TY - JOUR AB - Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer. To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Among women without cancer, median ovarian volume declined with age from 1.25 cm3 for women between ages 55 and 59 years to 1.0 cm3 for those between ages 65 and 69 years. African American and Caucasian women had larger median ovarian volumes than Asians. Larger ovarian volume was also associated with the highest quartiles of height and weight and ever having smoked. After adjusting for race, age, parity, body mass, smoking, and hormone use, women with median ovarian volumes ≥3.0 cm3 were at increased risk for breast cancer [odds ratio (OR), 1.42; 95% confidence interval (95% CI), 1.11-1.70], endometrial cancer (OR, 1.97; 95% CI, 1.12-3.48), and colon cancer (OR, 2.00; 95% CI, 1.25-3.21). Significant trends of risk with increasing volume were found only for breast and endometrial cancers. We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors. Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women. Copyright © 2006 American Association for Cancer Research. AD - Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Rockville, MD, United States Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, United States Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States Department of Hematology and Oncology, Marshfield Clinic and Research Foundation, Marshfield, WI, United States Information Management Services, Inc., Rockville, MD, United States Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, United States AU - Sherman, M. E. AU - Lacey, J. V. AU - Buys, S. S. AU - Reding, D. J. AU - Berg, C. D. AU - Williams, C. AU - Hartge, P. DB - Scopus DO - 10.1158/1055-9965.EPI-05-0847 IS - 8 M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2006 SP - 1550-1554 ST - Ovarian volume: Determinants and associations with cancer among postmenopausal women T2 - Cancer Epidemiology Biomarkers and Prevention TI - Ovarian volume: Determinants and associations with cancer among postmenopausal women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33748062946&doi=10.1158%2f1055-9965.EPI-05-0847&partnerID=40&md5=6cf114546aefeab25fdc78a3c648ae5a VL - 15 ID - 2572 ER - TY - JOUR AB - Clinical studies have reported associations between ovarian stromal hyperplasia and the diagnosis of hormonally related tumors such as endometrial cancer. To assess the hypothesis that characteristics of benign ovaries among postmenopausal women are related to risk for breast, endometrial, and colon cancer, we analyzed systematically collected transvaginal ultrasound data for participants enrolled in the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Among women without cancer, median ovarian volume declined with age from 1.25 cm(3) for women between ages 55 and 59 years to 1.0 cm(3) for those between ages 65 and 69 years. African American and Caucasian women had larger median ovarian volumes than Asians. Larger ovarian volume was also associated with the highest quartiles of height and weight and ever having smoked. After adjusting for race, age, parity, body mass, smoking, and hormone use, women with median ovarian volumes : >= 3.0 cm(2) were at increased risk for breast cancer [odds ratio (OR), 1.42; 95% confidence interval (95% CI), 1.11-1.70], endometrial cancer (OR, 1.97; 95% CI, 1.12-3.48), and colon cancer (OR, 2.00; 95% CI, 1.25-3.21). Significant trends of risk with increasing volume were found only for breast and endometrial cancers. We conclude that large ovaries among postmenopausal women may represent a marker of risk for hormonally related tumors. Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women. AN - WOS:000239779500022 AU - Sherman, M. E. AU - Lacey, J. V. AU - Buys, S. S. AU - Reding, D. J. AU - Berg, C. D. AU - Williams, C. AU - Hartge, P. DA - Aug DO - 10.1158/1055-9965.EPI-05-0847 IS - 8 N1 - 16896048 PY - 2006 SN - 1055-9965 SP - 1550-1554 ST - Ovarian volume: Determinants and associations with cancer among postmenopausal women T2 - Cancer Epidemiology Biomarkers & Prevention TI - Ovarian volume: Determinants and associations with cancer among postmenopausal women VL - 15 ID - 3213 ER - TY - JOUR AB - PURPOSE Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration‐resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP‐containing regimen. METHODS Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP‐containing regimen were combined. Race was based on self‐report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate‐specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). RESULTS Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate‐specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men (P, .001). CONCLUSION When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known. AN - CN-01792446 AU - Halabi, S. AU - Dutta, S. AU - Tangen, C. M. AU - Rosenthal, M. AU - Petrylak, D. P. AU - Thompson, I. M. AU - Chi, K. N. AU - Araujo, J. C. AU - Logothetis, C. AU - Quinn, D. I. AU - et al. DO - 10.1200/JCO.18.01279 IS - 5 KW - *cancer survival *castration resistant prostate cancer *overall survival Adult Article Cancer prognosis Controlled study Drug combination Drug therapy Human Major clinical study Male Metastasis Mortality Phase 3 clinical trial Race Randomized controlled trial Risk assessment Risk factor Self report M3 - Journal: Article PY - 2019 SP - 403‐410 ST - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel T2 - Journal of clinical oncology TI - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01792446/full VL - 37 ID - 1524 ER - TY - JOUR AB - PURPOSE Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. METHODS Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). RESULTS Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men (P, .001). CONCLUSION When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known. AD - S. Halabi, Duke University Medical Center, 2424 Erwin Rd, Suite 11088, Durham, NC, United States AU - Halabi, S. AU - Dutta, S. AU - Tangen, C. M. AU - Rosenthal, M. AU - Petrylak, D. P. AU - Thompson, I. M. AU - Chi, K. N. AU - Araujo, J. C. AU - Logothetis, C. AU - Quinn, D. I. AU - Fizazi, K. AU - Morris, M. J. AU - Eisenberger, M. A. AU - George, D. J. AU - De Bono, J. S. AU - Higano, C. S. AU - Tannock, I. F. AU - Small, E. J. AU - Kelly, W. K. DB - Embase Medline DO - 10.1200/JCO.18.01279 IS - 5 KW - NCT00004001 alkaline phosphatase docetaxel hemoglobin prednisone prostate specific antigen testosterone article Asian Black person cancer combination chemotherapy cancer prognosis castration resistant prostate cancer Caucasian clinical outcome controlled study follow up hemoglobin blood level human major clinical study male metastatic castration resistant prostate cancer overall survival phase 3 clinical trial priority journal risk factor LA - English M3 - Article N1 - L2001602583 2019-02-28 2019-04-02 PY - 2019 SN - 1527-7755 0732-183X SP - 403-410 ST - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel T2 - Journal of Clinical Oncology TI - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2001602583&from=export http://dx.doi.org/10.1200/JCO.18.01279 VL - 37 ID - 858 ER - TY - JOUR AB - PURPOSE Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. METHODS Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). RESULTS Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men (P, .001). CONCLUSION When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known. © 2019 American Society of Clinical Oncology. All rights reserved. AD - Duke University Medical Center, Durham, NC, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States Royal Melbourne Hospital, Parkville, VIC, Australia Yale University School of Medicine, New Haven, CT, United States UT Health Science Center, San Antonio, TX, United States BC Cancer Agency Vancouver Centre, Vancouver, BC, Canada University of Texas MD Anderson Cancer Center, Houston, TX, United States University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, United States Gustave Roussy, Villejuif, France Memorial Sloan Kettering Cancer Center, New York, NY, United States Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States Institute of Cancer Research, Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada University of California San Francisco, San Francisco, CA, United States Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States AU - Halabi, S. AU - Dutta, S. AU - Tangen, C. M. AU - Rosenthal, M. AU - Petrylak, D. P. AU - Thompson, I. M., Jr. AU - Chi, K. N. AU - Araujo, J. C. AU - Logothetis, C. AU - Quinn, D. I. AU - Fizazi, K. AU - Morris, M. J. AU - Eisenberger, M. A. AU - George, D. J. AU - De Bono, J. S. AU - Higano, C. S. AU - Tannock, I. F. AU - Small, E. J. AU - Kelly, W. K. DB - Scopus DO - 10.1200/JCO.18.01279 IS - 5 M3 - Article N1 - Cited By :24 Export Date: 22 March 2021 PY - 2019 SP - 403-410 ST - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel T2 - Journal of Clinical Oncology TI - Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85061152154&doi=10.1200%2fJCO.18.01279&partnerID=40&md5=1ba1eb892b205ae97af3f725cac8eca6 VL - 37 ID - 2240 ER - TY - JOUR AB - PurposeSeveral studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen.MethodsIndividual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases).ResultsOf 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men (P < .001).ConclusionWhen adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known. AN - WOS:000458528800006 AU - Halabi, S. AU - Dutta, S. AU - Tangen, C. M. AU - Rosenthal, M. AU - Petrylak, D. P. AU - Thompson, I. M. AU - Chi, K. N. AU - Araujo, J. C. AU - Logothetis, C. AU - Quinn, D. I. AU - Fizazi, K. AU - Morris, M. J. AU - Eisenberger, M. A. AU - George, D. J. AU - De Bono, J. S. AU - Higano, C. S. AU - Tannock, I. F. AU - Small, E. J. AU - Kelly, W. K. DA - Feb DO - 10.1200/JCO.18.01279 IS - 5 N1 - 30576268 PY - 2019 SN - 0732-183X SP - 403-+ ST - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel T2 - Journal of Clinical Oncology TI - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel VL - 37 ID - 2830 ER - TY - JOUR AB - Purpose: Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen.Methods: Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases).Results: Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men ( P < .001).Conclusion: When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known. AD - Duke University Medical Center, Durham, NC Fred Hutchinson Cancer Research Center, Seattle, WA The Royal Melbourne Hospital, Parkville, VIC, Australia Yale University School of Medicine, New Haven, CT UT Health Science Center, San Antonio, TX BC Cancer Agency Vancouver Centre, Vancouver, BC The University of Texas MD Anderson Cancer Center, Houston, TX University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA Gustave Roussy, Villejuif, France Memorial Sloan Kettering Cancer Center, New York, NY The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD The Institute of Cancer Research and The Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada University of California San Francisco, San Francisco, CA Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA 5 UT Health Science Center, San Antonio, TX AN - 134550895. Language: English. Entry Date: 20191219. Revision Date: 20200925. Publication Type: journal article AU - Halabi, Susan AU - Dutta, Sandipan AU - Tangen, Catherine M. AU - Rosenthal, Mark AU - Petrylak, Daniel P. AU - Thompson, Ian M. AU - Chi, Kim N. AU - Araujo, John C. AU - Logothetis, Christopher AU - Quinn, David I. AU - Fizazi, Karim AU - Morris, Michael J. AU - Eisenberger, Mario A. AU - George, Daniel J. AU - De Bono, Johann S. AU - Higano, Celestia S. AU - Tannock, Ian F. AU - Small, Eric J. AU - Kelly, William Kevin AU - Thompson, Ian M., Jr. DB - CINAHL Complete DO - 10.1200/JCO.18.01279 DP - EBSCOhost IS - 5 KW - Prostatic Neoplasms, Castration-Resistant -- Drug Therapy Black Persons -- Statistics and Numerical Data Prostatic Neoplasms, Castration-Resistant -- Ethnology White Persons -- Statistics and Numerical Data Antineoplastic Agents, Combined -- Therapeutic Use Human Prostatic Neoplasms, Castration-Resistant -- Pathology Prednisone -- Administration and Dosage Prostatic Neoplasms, Castration-Resistant -- Mortality Clinical Trials Mitoxantrone -- Administration and Dosage Male Neoplasm Metastasis Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). Grant Information: UG1 CA189974/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM30576268. PY - 2019 SN - 0732-183X SP - 403-410 ST - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel T2 - Journal of Clinical Oncology TI - Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=134550895&site=ehost-live&scope=site VL - 37 ID - 2010 ER - TY - JOUR AB - Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm3 or higher. African American women (AAW) were underrepresented in the PALOMA trials and this may be partially explained by strict requirements for minimal ANC ≥1500/mm3. The ANC of 1500/mm3 for initiation of treatment in those with BEN has been previously challenged. In this study, we propose to lower the ANC cutoff for enrollment to 1000/mm3. PALINA (NCT02692755) is a phase II, single arm, multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients who complete therapy without the development of febrile neutropenia or treatment discontinuation due to neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer. AD - F. Lynce, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC, United States AU - Lynce, F. AU - Saleh, M. AU - Shajahan-Haq, A. AU - Gallagher, C. AU - Dilawari, A. AU - Hahn, O. AU - Abu-Khalaf, M. AU - Cai, L. AU - Pohlmann, P. AU - Mohebtash, M. AU - Kamugisha, L. AU - Isaacs, C. DB - Embase DO - 10.1016/j.conctc.2018.05.012 KW - NCT02692755 fulvestrant letrozole palbociclib anemia article breast cancer clinical article drug dose reduction drug safety female fever human human epidermal growth factor receptor 2 negative breast cancer human epidermal growth factor receptor 2 positive breast cancer infection mass fragmentography mass spectrometry metabolomics multicenter study neutropenia neutrophil count phase 2 clinical trial priority journal thrombocytopenia treatment duration ultra performance liquid chromatography LA - English M3 - Article N1 - L2000754917 2018-05-21 2018-06-04 PY - 2018 SN - 2451-8654 SP - 190-192 ST - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer T2 - Contemporary Clinical Trials Communications TI - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2000754917&from=export http://dx.doi.org/10.1016/j.conctc.2018.05.012 VL - 10 ID - 895 ER - TY - JOUR AB - Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm3 or higher. African American women (AAW) were underrepresented in the PALOMA trials and this may be partially explained by strict requirements for minimal ANC ≥1500/mm3. The ANC of 1500/mm3 for initiation of treatment in those with BEN has been previously challenged. In this study, we propose to lower the ANC cutoff for enrollment to 1000/mm3. PALINA (NCT02692755) is a phase II, single arm, multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients who complete therapy without the development of febrile neutropenia or treatment discontinuation due to neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer. © 2018 AD - MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, United States MedStar Washington Hospital Center, United States Georgetown University, Lombardi Comprehensive Cancer Center, United States University of Chicago, United States Thomas Jefferson University, United States MedStar Union Memorial Hospital, United States MedStar Good Samaritan Hospital, United States AU - Lynce, F. AU - Saleh, M. AU - Shajahan-Haq, A. AU - Gallagher, C. AU - Dilawari, A. AU - Hahn, O. AU - Abu-Khalaf, M. AU - Cai, L. AU - Pohlmann, P. AU - Mohebtash, M. AU - Kamugisha, L. AU - Isaacs, C. DB - Scopus DO - 10.1016/j.conctc.2018.05.012 KW - African-American Fulvestrant Letrozole Palbociclib M3 - Article N1 - Export Date: 22 March 2021 PY - 2018 SP - 190-192 ST - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer T2 - Contemporary Clinical Trials Communications TI - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046845969&doi=10.1016%2fj.conctc.2018.05.012&partnerID=40&md5=38f5e629b8a0951e11cd74f1fbaa9c9a VL - 10 ID - 2270 ER - TY - JOUR AB - Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm(3) or higher. African American women (AAW) were underrepresented in the PALOMA trials and this may be partially explained by strict requirements for minimal ANC >= 1500/mm(3). The ANC of 1500/mm(3) for initiation of treatment in those with BEN has been previously challenged. In this study, we propose to lower the ANC cutoff for enrollment to 1000/mm(3). PALINA (NCT02692755) is a phase II, single arm, multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients who complete therapy without the development of febrile neutropenia or treatment discontinuation due to neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer. AN - WOS:000433315000027 AU - Lynce, F. AU - Saleh, M. AU - Shajahan-Haq, A. AU - Gallagher, C. AU - Dilawari, A. AU - Hahn, O. AU - Abu-Khalaf, M. AU - Cai, L. AU - Pohlmann, P. AU - Mohebtash, M. AU - Kamugisha, L. AU - Isaacs, C. DA - Jun DO - 10.1016/j.conctc.2018.05.012 N1 - 30009277 PY - 2018 SP - 190-192 ST - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer T2 - Contemporary Clinical Trials Communications TI - PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer VL - 10 ID - 2860 ER - TY - JOUR AB - Context: Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective: To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute. Design, Setting, and Patients: Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods. Main Outcome Measure: Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. Results: Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3%; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% CI, 0.68-0.74; P<.001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups, Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. In comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% CI, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1% vs 1.6%, respectively; OR, 1.30; 95% CI, 1.24-1.35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% CI, 1.16-1.31; P<.001). Conclusions: Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years. AD - C.P. Gross, Yale University School of Medicine, Primary Care Center, 333 Cedar St, PO Box 208025, New Haven, CT 06520, United States AU - Murthy, V. H. AU - Krumholz, H. M. AU - Gross, C. P. DB - Embase Medline DO - 10.1001/jama.291.22.2720 IS - 22 KW - adult African American aged aging American Indian article breast cancer malignant neoplasm cancer incidence cancer research Caucasian clinical trial colorectal cancer ethnic group female Hispanic human lung cancer major clinical study male priority journal prostate cancer race difference risk assessment LA - English M3 - Article N1 - L38725421 2004-06-22 PY - 2004 SN - 0098-7484 SP - 2720-2726 ST - Participation in cancer clinical trials: Race-, sex-, and age-based disparities T2 - Journal of the American Medical Association TI - Participation in cancer clinical trials: Race-, sex-, and age-based disparities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38725421&from=export http://dx.doi.org/10.1001/jama.291.22.2720 VL - 291 ID - 1283 ER - TY - JOUR AB - Context: Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials. Objective: To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute. Design, Setting, and Patients: Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods. Main Outcome Measure: Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup. Results: Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3%; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% CI, 0.68-0.74; P<.001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups, Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. In comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% CI, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1% vs 1.6%, respectively; OR, 1.30; 95% CI, 1.24-1.35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% CI, 1.16-1.31; P<.001). Conclusions: Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years. AD - Section of General Internal Medicine, Yale University School of Medicine, New Haven, CT, United States Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States R. Wood Johnson Clin. Scholars Prog., Yale University School of Medicine, New Haven, CT, United States Department of Medicine, Yale-New Haven Hospital Center, Yale University School of Medicine, New Haven, CT, United States Sect. of Hlth. Plcy. and Admin., Yale University School of Medicine, New Haven, CT, United States Dept. of Epidemiol. and Pub. Health, Yale University School of Medicine, New Haven, CT, United States Yale University School of Medicine, Primary Care Center, 333 Cedar St, PO Box 208025, New Haven, CT 06520, United States AU - Murthy, V. H. AU - Krumholz, H. M. AU - Gross, C. P. DB - Scopus DO - 10.1001/jama.291.22.2720 IS - 22 M3 - Article N1 - Cited By :1222 Export Date: 22 March 2021 PY - 2004 SP - 2720-2726 ST - Participation in cancer clinical trials: Race-, sex-, and age-based disparities T2 - Journal of the American Medical Association TI - Participation in cancer clinical trials: Race-, sex-, and age-based disparities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2642573558&doi=10.1001%2fjama.291.22.2720&partnerID=40&md5=aec16e7a314aae7c567180adaea52358 VL - 291 ID - 2607 ER - TY - JOUR AB - Context: Despite the importance of diversity of cancer trial participants with regard to race, ethnicity, age, and sex, there is little recent information about the representation of these groups in clinical trials.Objective: To characterize the representation of racial and ethnic minorities, the elderly, and women in cancer trials sponsored by the National Cancer Institute.Design, Setting, and Patients: Cross-sectional population-based analysis of all participants in therapeutic nonsurgical National Cancer Institute Clinical Trial Cooperative Group breast, colorectal, lung, and prostate cancer clinical trials in 2000 through 2002. In a separate analysis, the ethnic distribution of patients enrolled in 2000 through 2002 was compared with those enrolled in 1996 through 1998, using logistic regression models to estimate the relative risk ratio of enrollment for racial and ethnic minorities to that of white patients during these time periods.Main Outcome Measure: Enrollment fraction, defined as the number of trial enrollees divided by the estimated US cancer cases in each race and age subgroup.Results: Cancer research participation varied significantly across racial/ethnic and age groups. Compared with a 1.8% enrollment fraction among white patients, lower enrollment fractions were noted in Hispanic (1.3%; odds ratio [OR] vs whites, 0.72; 95% confidence interval [CI], 0.68-0.77; P<.001) and black (1.3%; OR, 0.71; 95% CI, 0.68-0.74; P<.001) patients. There was a strong relationship between age and enrollment fraction, with trial participants 30 to 64 years of age representing 3.0% of incident cancer patients in that age group, in comparison to 1.3% of 65- to 74-year-old patients and 0.5% of patients 75 years of age and older. This inverse relationship between age and trial enrollment fraction was consistent across racial and ethnic groups. Although the total number of trial participants increased during our study period, the representation of racial and ethnic minorities decreased. In comparison to whites, after adjusting for age, cancer type, and sex, patients enrolled in 2000 through 2002 were 24% less likely to be black (adjusted relative risk ratio, 0.76; 95% CI, 0.65-0.89; P<.001). Men were more likely than women to enroll in colorectal cancer trials (enrollment fractions: 2.1% vs 1.6%, respectively; OR, 1.30; 95% CI, 1.24-1.35; P<.001) and lung cancer trials (enrollment fractions: 0.9% vs 0.7%, respectively; OR, 1.23; 95% CI, 1.16-1.31; P<.001).Conclusions: Enrollment in cancer trials is low for all patient groups. Racial and ethnic minorities, women, and the elderly were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively. The proportion of trial participants who are black has declined in recent years. AD - Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Conn 06520, USA Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT AN - 106569902. Language: English. Entry Date: 20050128. Revision Date: 20200708. Publication Type: journal article AU - Murthy, V. H. AU - Krumholz, H. M. AU - Gross, C. P. AU - Murthy, Vivek H. AU - Krumholz, Harlan M. AU - Gross, Cary P. DB - CINAHL Complete DO - 10.1001/jama.291.22.2720 DP - EBSCOhost IS - 22 KW - Cancer Patients Clinical Trials Research Subject Recruitment Research Subjects Adult Age Factors Aged Confidence Intervals Cross Sectional Studies Ethnic Groups Health Services Accessibility Logistic Regression Middle Age National Cancer Institute (U.S.) Neoplasms -- Therapy Odds Ratio Pearson's Correlation Coefficient Race Factors Relative Risk Sex Factors Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: 1K07CA-90402/CA/NCI NIH HHS/United States. NLM UID: 7501160. PMID: NLM15187053. PY - 2004 SN - 0098-7484 SP - 2720-2726 ST - Participation in cancer clinical trials: race-, sex-, and age-based disparities T2 - JAMA: Journal of the American Medical Association TI - Participation in cancer clinical trials: race-, sex-, and age-based disparities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106569902&site=ehost-live&scope=site VL - 291 ID - 2012 ER - TY - JOUR AB - Conducted complementary analyses of recent enrollment in National Cancer Institute (NCI)-sponsored Clinical Trial Cooperative Group therapeutic trials. Authors compared patients (Ss) enrolled in breast, colorectal, lung, or prostate trials in 2000 through 2002 with population-based cancer incidence data. They determined whether age, sex, or racial and ethnic disparities in participation exist, and whether the magnitude of disparities varies according to age group and cancer type. They then assessed temporal changes in enrollment among racial and ethnic groups, comparing patients enrolled in 2000-2002 with those enrolled in 1996-1998. Group Ss (aged 30 yrs or older) were either White, Black, Hispanic, Asian/Pacific Islander or American Indian/Alaskan Native. Cancer incidence rates in each 5-yr age , race, and sex category were estimated by dividing the number of cases in the NCI Surveillance, Epidemiology, and End Results (SEER) program by the corresponding population of the SEER counties. These rates were then applied to the corresponding categories in the US population and then summed over all categories for national estimates of annual cancer incidence for each category of interest. Results revealed that magnitude and direction of racial disparities varied with cancer type. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Gross, Gary P., Yale University School of Medicine, Primary Care Center, 333 Cedar St, PO Box 208025, New Haven, CT, US, 06520 AN - 2004-15071-001 AU - Murthy, Vivek H. AU - Krumholz, Harlan M. AU - Gross, Gary P. DB - psyh DO - 10.1001/jama.291.22.2720 DP - EBSCOhost IS - 22 KW - cancer incidence cancer clinical trials racial disparities gender ethnic disparities age breast cancer colon cancer lung cancer prostate cancer therapeutic trials trial particiaption Adult Age Distribution Aged Clinical Trials as Topic Cross-Sectional Studies European Continental Ancestry Group Female Health Services Accessibility Humans Logistic Models Male Middle Aged Minority Groups National Institutes of Health (U.S.) Neoplasms Sex Distribution United States Clinical Trials Epidemiology Participation Treatment Age Differences American Indians Asians Blacks Breast Neoplasms Human Sex Differences Racial and Ethnic Differences Whites Latinos/Latinas N1 - Yale University, School of Medicine, Section of General Internal Medicine, New Haven, CT, US. Release Date: 20040628. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Clinical Trials; Epidemiology; Neoplasms; Participation; Treatment. Minor Descriptor: Age Differences; American Indians; Asians; Blacks; Breast Neoplasms; Human Sex Differences; Racial and Ethnic Differences; Whites; Latinos/Latinas; Racial Disparities. Classification: Research Methods & Experimental Design (2260); Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340). Methodology: Clinical Trial; Empirical Study; Qualitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Jun, 2004. PY - 2004 SN - 0098-7484 1538-3598 SP - 2720-2726 ST - Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities T2 - JAMA: Journal of the American Medical Association TI - Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2004-15071-001&site=ehost-live&scope=site cary.gross@yale.edu VL - 291 ID - 1701 ER - TY - JOUR AB - Participation in cancer clinical trials is low, particularly in racial and ethnic minorities in some cases, which has negative consequences for the generalizability for study findings. The objective of this study was to determine what factors are associated with patients' participation or willingness to participate and whether these factors vary by race/ethnicity. or . White, Hispanic, and black participants were obtained through the Florida cancer registry and who were diagnosed with breast, lung, colorectal, or prostate cancer (N = 1100). Participants were surveyed via telephone to obtain demographic information, past participation, and willingness to participate in clinical trials, as well as barriers and facilitators to participation. Logistic and Poisson regressions were performed. . Respondents were on average 67.4 years old, 42.7% were male, and 50.1% were married. In this population, 7.7% of respondents had participated in a clinical trial, and 36.5% stated that they would be willing to participate. In multivariate models, blacks and Hispanics were equally likely as whites to be willing to participate in cancer trials, but Hispanics were less likely to have participated, and this was especially more likely in non-English-speaking Hispanics compared with English-speaking Hispanics. Notable barriers across race/ethnicity were mistrust and lack of knowledge of clinical trials. Limitations. Cross-sectional design limits cause-and-effect conclusions. . There are racial differences in participation rates but not in willingness to participate. We hypothesize that willingness to participate is not very high because people are uninformed about participating, particularly in non-English-speaking Hispanics. Barriers and facilitators to participation vary by race. Improved understanding of cultural differences that can be addressed by physicians may restore faith, comprehension, and acceptability of clinical trials by all patients. AD - M.M. Byrne AU - Byrne, M. M. AU - Tannenbaum, S. L. AU - Glück, S. AU - Hurley, J. AU - Antoni, M. DB - Medline IS - 1 KW - aged article clinical trial (topic) cohort analysis cross-sectional study female human male middle aged neoplasm patient decision making patient participation population-based studies psychological aspect United States LA - English M3 - Article N1 - L563079693 2015-02-16 PY - 2014 SN - 1552-681X SP - 116-126 ST - Participation in cancer clinical trials: why are patients not participating? T2 - Medical decision making : an international journal of the Society for Medical Decision Making TI - Participation in cancer clinical trials: why are patients not participating? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L563079693&from=export VL - 34 ID - 1060 ER - TY - JOUR AB - Background: Participation in cancer clinical trials is low, particularly in racial and ethnic minorities in some cases, which has negative consequences for the generalizability for study findings. The objective of this study was to determine what factors are associated with patients’ participation or willingness to participate and whether these factors vary by race/ethnicity. Design or Methods: White, Hispanic, and black participants were obtained through the Florida cancer registry and who were diagnosed with breast, lung, colorectal, or prostate cancer (N = 1100). Participants were surveyed via telephone to obtain demographic information, past participation, and willingness to participate in clinical trials, as well as barriers and facilitators to participation. Logistic and Poisson regressions were performed. Results: Respondents were on average 67.4 years old, 42.7% were male, and 50.1% were married. In this population, 7.7% of respondents had participated in a clinical trial, and 36.5% stated that they would be willing to participate. In multivariate models, blacks and Hispanics were equally likely as whites to be willing to participate in cancer trials, but Hispanics were less likely to have participated, and this was especially more likely in non–English-speaking Hispanics compared with English-speaking Hispanics. Notable barriers across race/ethnicity were mistrust and lack of knowledge of clinical trials. Limitations. Cross-sectional design limits cause-and-effect conclusions. Conclusions: There are racial differences in participation rates but not in willingness to participate. We hypothesize that willingness to participate is not very high because people are uninformed about participating, particularly in non–Englishspeaking Hispanics. Barriers and facilitators to participation vary by race. Improved understanding of cultural differences that can be addressed by physicians may restore faith, comprehension, and acceptability of clinical trials by all patients. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Byrne, Margaret M., Department of Epidemiology and Public Health, University of Miami, 1120 NW 14th St, CRB Rm 1035 R669, Miami, FL, US, 33136 AN - 2013-44144-012 AU - Byrne, Margaret M. AU - Tannenbaum, Stacey L. AU - Glück, Stefan AU - Hurley, Judith AU - Antoni, Michael DB - psyh DO - 10.1177/0272989X13497264 DP - EBSCOhost IS - 1 KW - cancer clinical trials patient participation minorities ethnicity faith comprehension Aged Clinical Trials as Topic Cross-Sectional Studies Female Florida Humans Male Middle Aged Neoplasms Client Participation Clinical Trials Ethnic Identity Minority Groups N1 - Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, US. Release Date: 20140224. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Client Participation; Clinical Trials; Neoplasms. Minor Descriptor: Comprehension; Ethnic Identity; Minority Groups; Faith. Classification: Neurological Disorders & Brain Damage (3297); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Tests & Measures: Life Orientation Test–Revised; State Trait Anxiety Inventory. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Jan, 2014. Publication History: Accepted Date: May 22, 2013; First Submitted Date: Oct 25, 2012. Copyright Statement: The Author(s). 2013. Sponsor: Bankhead Coley Florida, Biomedical Research Program, US. Grant: 07BP-01. Recipients: No recipient indicated PY - 2014 SN - 0272-989X 1552-681X SP - 116-126 ST - Participation in cancer clinical trials: Why are patients not participating? T2 - Medical Decision Making TI - Participation in cancer clinical trials: Why are patients not participating? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-44144-012&site=ehost-live&scope=site mbyrne2@med.miami.edu VL - 34 ID - 1713 ER - TY - JOUR AB - Objective: To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI). Methods: The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000-2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis. Results: Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio[OR] vs whites 0.67, P<0.001), Hispanic (0.54%, OR 0.76, P<0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P<0.001). Patients 65-74 years of age (EF 0.45%) were less likely to be enrolled than those 20-44 years of age (EF=2.28%, OR 0.20, P=0.001). Conclusions: The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed. © 2007 The Society of Surgical Oncology, Inc. AD - J.H. Stewart IV, Department of General Surgery, Section on Surgical Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States AU - Stewart, J. H. AU - Bertoni, A. G. AU - Staten, J. L. AU - Levine, E. A. AU - Gross, C. P. DB - Embase Medline DO - 10.1245/s10434-007-9500-y IS - 12 KW - adult African American age distribution aged article Asian breast cancer cancer risk cancer surgery colorectal cancer comparative study data base demography ethnic difference female Hispanic human logistic regression analysis lung cancer major clinical study male outcome assessment Pacific Islander population research prostate cancer race difference sex difference LA - English M3 - Article N1 - L350160101 2007-12-04 PY - 2007 SN - 1534-4681 1068-9265 SP - 3328-3334 ST - Participation in surgical oncology clinical trials: Gender-, race/ethnicity-, and age-based disparities T2 - Annals of Surgical Oncology TI - Participation in surgical oncology clinical trials: Gender-, race/ethnicity-, and age-based disparities UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350160101&from=export http://dx.doi.org/10.1245/s10434-007-9500-y VL - 14 ID - 1235 ER - TY - JOUR AB - Objective: To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI). Methods: The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000-2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis. Results: Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio[OR] vs whites 0.67, P<0.001), Hispanic (0.54%, OR 0.76, P<0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P<0.001). Patients 65-74 years of age (EF 0.45%) were less likely to be enrolled than those 20-44 years of age (EF=2.28%, OR 0.20, P=0.001). Conclusions: The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed. © 2007 The Society of Surgical Oncology, Inc. AD - Department of General Surgery, Section on Surgical Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States Maya Angelou Research Center on Minority Health, Winston-Salem, NC 27157, United States Division of Public Health Sciences, Section on Epidemiology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27157, United States Section of General Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, United States AU - Stewart, J. H. AU - Bertoni, A. G. AU - Staten, J. L. AU - Levine, E. A. AU - Gross, C. P. DB - Scopus DO - 10.1245/s10434-007-9500-y IS - 12 KW - African-Americans Asian/Pacific Islander Breast cancer Clinical trials Colorectal cancer Disparities Enrollment fraction Hispanics Lung cancer Native Americans Prostate cancer M3 - Article N1 - Cited By :159 Export Date: 22 March 2021 PY - 2007 SP - 3328-3334 ST - Participation in surgical oncology clinical trials: Gender-, race/ethnicity-, and age-based disparities T2 - Annals of Surgical Oncology TI - Participation in surgical oncology clinical trials: Gender-, race/ethnicity-, and age-based disparities UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-36349030202&doi=10.1245%2fs10434-007-9500-y&partnerID=40&md5=845cbe0c7fee54653441e8918b276976 VL - 14 ID - 2564 ER - TY - JOUR AB - Objective: To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI). Methodsl: The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000-2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis. Results: Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio[OR] vs whites 0.67, P < 0.001), Hispanic (0.54%, OR 0.76, P < 0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P < 0.001). Patients 65-74 years of age (EF 0.45%) were less likely to be enrolled than those 20-44 years of age (EF=2.28%, OR 0.20, P=0.001). Conclusions: The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed. AN - WOS:000250976500012 AU - Stewart, J. H. AU - Bertoni, A. G. AU - Staten, J. L. AU - Levine, E. A. AU - Gross, C. P. DA - Dec DO - 10.1245/s10434-007-9500-y IS - 12 N1 - 17682824 PY - 2007 SN - 1068-9265 SP - 3328-3334 ST - Participation in surgical oncology clinical trials: Gender-, Race/Ethnicity-, and age-based disparities T2 - Annals of Surgical Oncology TI - Participation in surgical oncology clinical trials: Gender-, Race/Ethnicity-, and age-based disparities VL - 14 ID - 3181 ER - TY - JOUR AB - Purpose: On June 7, 2000 President Clinton issued an executive memorandum directing Medicare payment for routine patient care in qualifying clinical trials. We estimated the proportion of older patients with prostate cancer who were examined as part of a qualifying clinical trial, and the association between participation and patient characteristics. Materials and Methods: We performed an observational study using the Surveillance, Epidemiology and End Results Medicare database to determine participation in qualifying clinical trials in a sample of 37,216 men 66 years old or older who were enrolled in Medicare and diagnosed with prostate cancer between September 2000 and December 2002. Results: Within 3 years of diagnosis 211 men (0.567%) received routine patient care in a qualifying clinical trial. These participants were more likely to be younger than 70 years (OR 1.687, 95% CI 1.27-2.24) and less likely to be less educated and reside in low income, metropolitan neighborhoods. White men were more likely to participate in clinical trials than nonwhite men but this association was not statistically significant (OR 1.426, CI 0.97-2.09). Participation varied significantly by registry site (0% to 1.2%) but not by tumor grade or stage, or prostate specific antigen status. Conclusions: Few older patients with prostate cancer participated in qualifying trials between 2000 and 2002. Those who participated were not representative of the general population of older patients with prostate cancer. Greater efforts are required to expand trial enrollment and decrease disparities in research participation. © 2010 American Urological Association Education and Research, Inc. AD - Health Outcomes and Behavior Program, Moffitt Cancer Center, Tampa, FL, United States Department of Economics, University of South Florida, Tampa, FL, United States Department of Oncologic Sciences, University of South Florida, Tampa College of Medicine, Tampa, FL, United States Department of Urology, University of Florida, Gainesville, FL, United States Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, FL, United States Institute for Child Health Policy, University of Florida, Gainesville, FL, United States Rehabilitation Outcomes Research Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States AU - Craig, B. M. AU - Gilbert, S. M. AU - Herndon, J. B. AU - Vogel, B. AU - Quinn, G. P. DB - Scopus DO - 10.1016/j.juro.2010.04.076 IS - 3 KW - clinical trials as topic health services accessibility Medicare prostate prostatic neoplasms M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2010 SP - 901-906 ST - Participation of older patients with prostate cancer in medicare eligible trials T2 - Journal of Urology TI - Participation of older patients with prostate cancer in medicare eligible trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956642359&doi=10.1016%2fj.juro.2010.04.076&partnerID=40&md5=e5ac97293a6aa0bea7b4ce00717a6ec5 VL - 184 ID - 2494 ER - TY - JOUR AB - Purpose: Despite concerns about declining participation rates in epidemiologic studies in recent years, relatively few papers have discussed obstacles to recruiting study participants or strategies for optimizing response rates. This report describes factors associated with nonparticipation in a population-based, case-control study of breast cancer and discusses ways to overcome barriers to participation.Methods: Contact and cooperation rates were calculated for participants in the Carolina Breast Cancer Study (CBCS), stratified by case status, age, race, and race of interviewer. Demographic and breast cancer risk factor characteristics of partial and full responders also were compared.Results: Contact rates and cooperation rates varied by case/control status and demographic characteristics. Contact rates were lower among controls, younger women, and black women. Cooperation rates were lower among controls, older women, and black cases. Cooperation rates were higher among both black and nonblack women when participants and interviewers were concordant on race.Conclusions: Obstacles to recruitment seem to differ among race and age subgroups, suggesting that recruitment strategies may need to be tailored to potential participants based upon demographic characteristics. Strategies have been implemented to improve response rates in this and other epidemiologic studies; however, additional research and innovation in this area are needed. AD - Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034, USA Dept of Epidemiology and Public Health, Yale University School of Medicine, 60 College St, PO Box 208034, New Haven, CT 06520-8034 AN - 107137973. Language: English. Entry Date: 20001001. Revision Date: 20191029. Publication Type: journal article AU - Moorman, P. G. AU - Newman, B. AU - Millikan, R. C. AU - Tse, C. J. AU - Sandler, D. P. AU - Moorman, P. G. AU - Newman, B. AU - Millikan, R. C. AU - Tse, C. K. AU - Sandler, D. P. DB - CINAHL Complete DP - EBSCOhost IS - 3 KW - Population-Based Case Control Research Subject Recruitment -- Methods Consumer Participation Breast Neoplasms -- Epidemiology Epidemiological Research Registries, Disease Random Sample Interviews Descriptive Statistics Confidence Intervals Patient Compliance Race Factors Age Factors Adult Middle Age Aged Female Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: P50-CA58223/CA/NCI NIH HHS/United States. NLM UID: 9100013. PMID: NLM10192651. PY - 1999 SN - 1047-2797 SP - 188-195 ST - Participation rates in a case-control study: the impact of age, race, and race of interviewer T2 - Annals of Epidemiology TI - Participation rates in a case-control study: the impact of age, race, and race of interviewer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107137973&site=ehost-live&scope=site VL - 9 ID - 2013 ER - TY - JOUR AB - Background: Cancer clinical trials are essential for testing new treatments and represent state‐of‐the‐art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under‐enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient‐physician communication, which is often of poor quality during clinical interactions between African‐American patients and non‐African‐American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African‐American and White men with prostate cancer make an informed decision to participate in a clinical trial. Methods/design: Data collection will occur at two NCI‐designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African‐American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient‐physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African‐American versus White men; and 3) examine the extent to which patient‐physician communication mediates the effect of the interventions on the outcomes. Discussion: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. Trial registration: Clinical Trials.gov registration number: NCT02906241(September 8, 2016). Copyright © 2017 The Author(s). AN - CN-01622882 DO - 10.1186/s12885-017-3804-5 IS - 1 M3 - Article PY - 2017 ST - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - BMC cancer TI - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01622882/full VL - 17 ID - 1387 ER - TY - JOUR AB - BACKGROUND: Cancer clinical trials are essential for testing new treatments and represent state‐of‐the‐art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under‐enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient‐physician communication, which is often of poor quality during clinical interactions between African‐American patients and non‐African‐American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African‐American and White men with prostate cancer make an informed decision to participate in a clinical trial. METHODS/DESIGN: Data collection will occur at two NCI‐designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African‐American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient‐physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African‐American versus White men; and 3) examine the extent to which patient‐physician communication mediates the effect of the interventions on the outcomes. DISCUSSION: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. TRIAL REGISTRATION: Clinical Trials.gov registration number: NCT02906241 (September 8, 2016). AN - CN-01614894 AU - Eggly, S. AU - Hamel, L. M. AU - Heath, E. AU - Manning, M. A. AU - Albrecht, T. L. AU - Barton, E. AU - Wojda, M. AU - Foster, T. AU - Carducci, M. AU - Lansey, D. AU - et al. DO - 10.1186/s12885-017-3804-5 IS - 1 KW - African Americans [psychology] Communication European Continental Ancestry Group [psychology] Humans Male Minority Groups [psychology] Minority Health Models, Theoretical Patient Participation Patient Selection Physician‐Patient Relations Prostatic Neoplasms [*drug therapy, ethnology] M3 - Journal Article; Randomized Controlled Trial PY - 2017 SP - 807 ST - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - BMC cancer TI - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01614894/full VL - 17 ID - 1344 ER - TY - JOUR AB - Background: Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient-physician communication, which is often of poor quality during clinical interactions between African-American patients and non-African-American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African-American and White men with prostate cancer make an informed decision to participate in a clinical trial.Methods/design: Data collection will occur at two NCI-designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African-American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient-physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African-American versus White men; and 3) examine the extent to which patient-physician communication mediates the effect of the interventions on the outcomes.Discussion: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers.Trial Registration: Clinical Trials.gov registration number: NCT02906241 (September 8, 2016). AD - Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA Department of English, Wayne State University, 5057 Woodward Suite 9408, Detroit, MI 48202, USA Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 1M59 Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21287, USA Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 550 North Broadway, 1003-G, Baltimore, MD 21205, USA Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 550 North Broadway, 1003-G, Baltimore, MD, 21205, USA Department of Oncology, Wayne State University/Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA AN - 126902643. Language: English. Entry Date: 20180716. Revision Date: 20190119. Publication Type: journal article AU - Eggly, Susan AU - Hamel, Lauren M. AU - Heath, Elisabeth AU - Manning, Mark A. AU - Albrecht, Terrance L. AU - Barton, Ellen AU - Wojda, Mark AU - Foster, Tanina AU - Carducci, Michael AU - Lansey, Dina AU - Ting, Wang AU - Abdallah, Rehab AU - Abrahamian, Narineh AU - Seongho, Kim AU - Senft, Nicole AU - Penner, Louis A. AU - Wang, Ting AU - Kim, Seongho DB - CINAHL Complete DO - 10.1186/s12885-017-3804-5 DP - EBSCOhost KW - Physician-Patient Relations Prostatic Neoplasms -- Drug Therapy Minority Groups -- Psychosocial Factors Human White Persons -- Psychosocial Factors Patient Selection Prostatic Neoplasms -- Ethnology Models, Theoretical Male Black Persons -- Psychosocial Factors Communication Consumer Participation Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Funding Source N1 - research; randomized controlled trial. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: R01CA200718-01//National Cancer Institute/. NLM UID: 100967800. PMID: NLM29197371. PY - 2017 SN - 1471-2407 SP - 1-12 ST - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - BMC Cancer TI - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126902643&site=ehost-live&scope=site VL - 17 ID - 2014 ER - TY - JOUR AB - Background: Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient-physician communication, which is often of poor quality during clinical interactions between African-American patients and non-African-American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African-American and White men with prostate cancer make an informed decision to participate in a clinical trial. Methods/design: Data collection will occur at two NCI-designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African-American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient-physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African-American versus White men; and 3) examine the extent to which patient-physician communication mediates the effect of the interventions on the outcomes. Discussion: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. Trial registration: Clinical Trials.gov registration number: NCT02906241(September 8, 2016). AD - L.M. Hamel, Wayne State University/Karmanos Cancer Institute, Department of Oncology, 4100 John R, Detroit, MI, United States AU - Eggly, S. AU - Hamel, L. M. AU - Heath, E. AU - Manning, M. A. AU - Albrecht, T. L. AU - Barton, E. AU - Wojda, M. AU - Foster, T. AU - Carducci, M. AU - Lansey, D. AU - Wang, T. AU - Abdallah, R. AU - Abrahamian, N. AU - Kim, S. AU - Senft, N. AU - Penner, L. A. DB - Embase Medline DO - 10.1186/s12885-017-3804-5 IS - 1 KW - NCT02906241 African American article cancer center Caucasian clinical protocol doctor patient relationship health disparity human information processing prostate cancer randomized controlled trial (topic) videorecording LA - English M3 - Article N1 - L619479101 2017-12-08 2018-07-13 PY - 2017 SN - 1471-2407 ST - Partnering around cancer clinical trials (PACCT): Study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - BMC Cancer TI - Partnering around cancer clinical trials (PACCT): Study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619479101&from=export http://dx.doi.org/10.1186/s12885-017-3804-5 VL - 17 ID - 920 ER - TY - JOUR AB - Background: Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient-physician communication, which is often of poor quality during clinical interactions between African-American patients and non-African-American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African-American and White men with prostate cancer make an informed decision to participate in a clinical trial. Methods/design: Data collection will occur at two NCI-designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African-American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient-physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African-American versus White men; and 3) examine the extent to which patient-physician communication mediates the effect of the interventions on the outcomes. Discussion: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. Trial registration: Clinical Trials.gov registration number: NCT02906241(September 8, 2016). © 2017 The Author(s). AD - Wayne State University/Karmanos Cancer Institute, Department of Oncology, 4100 John R, Detroit, MI 48201, United States Wayne State University, Department of English, 5057 Woodward Suite 9408, Detroit, MI 48202, United States Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 1M59 Bunting -Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21287, United States Johns Hopkins School of Medicine/Sidney Kimmel Comprehensive Cancer Center, 550 North Broadway, 1003-G, Baltimore, MD 21205, United States AU - Eggly, S. AU - Hamel, L. M. AU - Heath, E. AU - Manning, M. A. AU - Albrecht, T. L. AU - Barton, E. AU - Wojda, M. AU - Foster, T. AU - Carducci, M. AU - Lansey, D. AU - Wang, T. AU - Abdallah, R. AU - Abrahamian, N. AU - Kim, S. AU - Senft, N. AU - Penner, L. A. C7 - 807 DB - Scopus DO - 10.1186/s12885-017-3804-5 IS - 1 KW - Clinical trials Health disparities Patient-physician communication Prostate cancer M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2017 ST - Partnering around cancer clinical trials (PACCT): Study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - BMC Cancer TI - Partnering around cancer clinical trials (PACCT): Study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85036554190&doi=10.1186%2fs12885-017-3804-5&partnerID=40&md5=4e8a1c5703d2cbb5b9eeecec32f5acf1 VL - 17 ID - 2295 ER - TY - JOUR AB - Background: Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic disparity in cancer care. One understudied cause is patient-physician communication, which is often of poor quality during clinical interactions between African-American patients and non-African-American physicians. Partnering Around Cancer Clinical Trials (PACCT) involves a transdisciplinary theoretical model proposing that patient and physician individual attitudes and beliefs and their interpersonal communication during racially discordant clinical interactions influence outcomes related to patients' decisions to participate in a trial. The overall goal of the study is to test a multilevel intervention designed to increase rates at which African-American and White men with prostate cancer make an informed decision to participate in a clinical trial. Methods/design: Data collection will occur at two NCI-designated comprehensive cancer centers. Participants include physicians who treat men with prostate cancer and their African-American and White patients who are potentially eligible for a clinical trial. The study uses two distinct research designs to evaluate the effects of two behavioral interventions, one focused on patients and the other on physicians. The primary goal is to increase the number of patients who decide to enroll in a trial; secondary goals include increasing rates of physician trial offers, improving the quality of patient-physician communication during video recorded clinical interactions in which trials may be discussed, improving patients' understanding of trials offered, and increasing the number of patients who actually enroll. Aims are to 1) determine the independent and combined effects of the two interventions on outcomes; 2) compare the effects of the interventions on African-American versus White men; and 3) examine the extent to which patient-physician communication mediates the effect of the interventions on the outcomes. Discussion: PACCT has the potential to identify ways to increase clinical trial rates in a diverse patient population. The research can also improve access to high quality clinical care for African American men bearing the disproportionate burden of disparities in prostate and other cancers. AN - WOS:000416968100002 AU - Eggly, S. AU - Hamel, L. M. AU - Heath, E. AU - Manning, M. A. AU - Albrecht, T. L. AU - Barton, E. AU - Wojda, M. AU - Foster, T. AU - Carducci, M. AU - Lansey, D. AU - Wang, T. AU - Abdallah, R. AU - Abrahamian, N. AU - Kim, S. AU - Senft, N. AU - Penner, L. A. DA - Dec DO - 10.1186/s12885-017-3804-5 N1 - 807 29197371 PY - 2017 SN - 1471-2407 ST - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials T2 - Bmc Cancer TI - Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials VL - 17 ID - 2879 ER - TY - JOUR AB - Background/Aims: Reduced minority participation in clinical research challenges researchers to consider novel recruitment modalities. This study describes a formal partnership between the National Educational Foundation of the Zeta Phi Beta Sorority and the Mid-Atlantic Cancer Genetics Network. The goal was to enhance awareness about inherited breast cancer and to increase enrollment in the national Cancer Genetics Network. Methods: In this descriptive, pilot study, two recruitment strategies across four states were undertaken: an onsite educational session at four Annual State Leadership Conferences and a 2-tiered direct mail campaign to the sorority membership. Results: Recruitment methods targeted over 1,200 well-educated African American women. Of the 279 attendees at the state conference educational sessions, only 3 women meeting the high risk eligibility requirement enrolled. Direct mail recruitment elicited 24 eligible women. Lessons learned are described. Conclusion: Despite low accrual, the partnership laid a foundation for broader collaboration with the Zeta Phi Beta Sorority. In the future, collaboration with minority sororities and fraternities as part of standard registry recruitment should be explored. Copyright © 2008 S. Karger AG. AD - S. J. Olsen, Johns Hopkins University, School of Nursing, 525 N Wolfe St, Baltimore, MD 21205, United States AU - Olsen, S. J. AU - Malvern, K. T. AU - May, B. J. AU - Jenkins, I. L. AU - Griffin, C. A. DB - Embase Medline DO - 10.1159/000116880 IS - 4 KW - adult African American aged article breast cancer cancer genetics cancer research descriptive research hereditary tumor syndrome female health education high risk population human organization pilot study postal mail priority journal United States LA - English M3 - Article N1 - L351555888 2008-05-07 PY - 2008 SN - 1422-2795 SP - 201-207 ST - Partnership with an African American sorority to enhance participation in cancer genetics research T2 - Community Genetics TI - Partnership with an African American sorority to enhance participation in cancer genetics research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351555888&from=export http://dx.doi.org/10.1159/000116880 VL - 11 ID - 1213 ER - TY - JOUR AB - Background/Aims: Reduced minority participation in clinical research challenges researchers to consider novel recruitment modalities. This study describes a formal partnership between the National Educational Foundation of the Zeta Phi Beta Sorority and the Mid-Atlantic Cancer Genetics Network. The goal was to enhance awareness about inherited breast cancer and to increase enrollment in the national Cancer Genetics Network. Methods: In this descriptive, pilot study, two recruitment strategies across four states were undertaken: an onsite educational session at four Annual State Leadership Conferences and a 2-tiered direct mail campaign to the sorority membership. Results: Recruitment methods targeted over 1,200 well-educated African American women. Of the 279 attendees at the state conference educational sessions, only 3 women meeting the high risk eligibility requirement enrolled. Direct mail recruitment elicited 24 eligible women. Lessons learned are described. Conclusion: Despite low accrual, the partnership laid a foundation for broader collaboration with the Zeta Phi Beta Sorority. In the future, collaboration with minority sororities and fraternities as part of standard registry recruitment should be explored. Copyright © 2008 S. Karger AG. AD - Mid-Atlantic Cancer Genetics Network, Johns Hopkins University, Baltimore, MD, United States Zeta Phi Beta Sorority, Inc., National Educational Foundation, Washington, DC, United States Johns Hopkins University, School of Nursing, 525 N Wolfe St, Baltimore, MD 21205, United States AU - Olsen, S. J. AU - Malvern, K. T. AU - May, B. J. AU - Jenkins, I. L. AU - Griffin, C. A. DB - Scopus DO - 10.1159/000116880 IS - 4 KW - African American Cancer Cancer Genetics Network Genetics Recruitment Research M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2008 SP - 201-207 ST - Partnership with an African American sorority to enhance participation in cancer genetics research T2 - Community Genetics TI - Partnership with an African American sorority to enhance participation in cancer genetics research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-42349091321&doi=10.1159%2f000116880&partnerID=40&md5=de8b38bb5214376743f9054d886d87c8 VL - 11 ID - 2537 ER - TY - JOUR AB - Background/Aims: Reduced minority participation in clinical research challenges researchers to consider novel recruitment modalities. This study describes a formal partnership between the National Educational Foundation of the Zeta Phi Beta Sorority and the Mid-Atlantic Cancer Genetics Network. The goal was to enhance awareness about inherited breast cancer and to increase enrollment in the national Cancer Genetics Network. Methods: In this descriptive, pilot study, two recruitment strategies across four states were undertaken: an onsite educational session at four Annual State Leadership Conferences and a 2-tiered direct mail campaign to the sorority membership. Results: Recruitment methods targeted over 1,200 well-educated African American women. Of the 279 attendees at the state conference educational sessions, only 3 women meeting the high risk eligibility requirement enrolled. Direct mail recruitment elicited 24 eligible women. Lessons learned are described. Conclusion: Despite low accrual, the partnership laid a foundation for broader collaboration with the Zeta Phi Beta Sorority. In the future, collaboration with minority sororities and fraternities as part of standard registry recruitment should be explored. Copyright (C) 2008 S. Karger AG, Basel. AN - WOS:000255110000004 AU - Olsen, S. J. AU - Malvern, K. T. AU - May, B. J. AU - Jenkins, I. L. AU - Griffin, C. A. DO - 10.1159/000116880 IS - 4 N1 - 18417967 PY - 2008 SN - 1422-2795 SP - 201-207 ST - Partnership with an African American sorority to enhance participation in cancer genetics research T2 - Community Genetics TI - Partnership with an African American sorority to enhance participation in cancer genetics research VL - 11 ID - 3177 ER - TY - JOUR AB - Medical guidelines do not recommend prostate cancer screening, particularly without informed and shared decision making. This study investigates undisclosed opportunistic screening using prostate specific antigen (PSA) testing in black immigrant and African American men. Participants (N = 142) were insured urban men, 45- to 70-years old. Patients' reports of testing were compared with medical claims to assess undisclosed PSA testing. Most (94.4 %) men preferred to share in screening decisions, but few (46.5 %) were aware PSA testing was performed. Four factors predicted being unaware of testing: low formal education, low knowledge about prostate cancer, no intention to screen, and no physician recommendation (all p's < .05). Undisclosed PSA testing was common. Both patient and provider factors increased risk of being uninformed about prostate cancer screening. Interventions combining patient education and physician engagement in shared decision making may better align practice with current prostate cancer screening guidelines. AU - Lepore, S. J. AU - Nair, R. G. AU - Davis, S. N. AU - Wolf, R. L. AU - Basch, C. E. AU - Thomas, N. AU - Shmukler, C. AU - Ullman, R. DB - Medline DO - 10.1007/s10903-016-0468-1 IS - 6 KW - prostate specific antigen African American aged attitude to health decision making early cancer diagnosis ethnology human male middle aged migrant patient participation procedures prostate tumor socioeconomics statistics and numerical data LA - English M3 - Article N1 - L622886585 2018-07-09 PY - 2017 SN - 1557-1920 SP - 1343-1350 ST - Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men T2 - Journal of immigrant and minority health TI - Patient and Physician Factors Associated with Undisclosed Prostate Cancer Screening in a Sample of Predominantly Immigrant Black Men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622886585&from=export http://dx.doi.org/10.1007/s10903-016-0468-1 VL - 19 ID - 925 ER - TY - JOUR AB - PURPOSE: The efficacy of prostate cancer screening is uncertain, and professional organizations recommend educating patients about potential harms and benefits. We evaluated the effect of a videotape decision aid on promoting informed decision making about prostate cancer screening among primary care patients. METHODS: A group of 160 men, 45 to 70 years of age, with no history of prostate cancer, were randomized to view or not to view a 20-minute educational videotape before a routine office visit at a university-based family medicine clinic. The subjects were contacted again 1 year after their visit to assess their receipt of prostate cancer screening (digital rectal examination [DRE] or prostate-specific antigen [PSA] testing), their satisfaction with their screening decision, and knowledge retention since the baseline assessment. RESULTS: Follow-up assessments were completed for 87.5% of the intervention subjects and 83.8% of the control subjects. The rate of DRE did not differ between the 2 groups. Prostate-specific antigen testing was reported by 24 of 70 (34.3%) intervention subjects and 37 of 67 (55.2%) control subjects (P = .01). African American men were more likely to have had PSA testing (9 of 16, 56.3%) than were white men (13 of 46, 28.3%) (P = .044). Satisfaction with the screening decision did not differ between the study groups. Intervention subjects were more knowledgeable of prostate cancer screening than were control subjects, although these differences declined within 1 year (P < .001). CONCLUSIONS: Decision aids for prostate cancer screening can have a long-term effect on screening behavior and appear to promote informed decision making. AD - R.J. Volk, Department of Family and Community Medicine, Baylor College of Medicine, Houston, Tex 77098-3915, USA. AU - Volk, R. J. AU - Spann, S. J. AU - Cass, A. R. AU - Hawley, S. T. DB - Medline DO - 10.1370/afm.7 IS - 1 KW - prostate specific antigen aged article blood clinical trial controlled clinical trial controlled study decision making follow up human male mass screening methodology middle aged patient education physical examination prostate tumor randomized controlled trial rectum videorecording LA - English M3 - Article N1 - L38566222 2004-05-13 PY - 2003 SN - 1544-1709 SP - 22-28 ST - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up T2 - Annals of family medicine TI - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38566222&from=export http://dx.doi.org/10.1370/afm.7 VL - 1 ID - 1293 ER - TY - JOUR AB - PURPOSE: The efficacy of prostate cancer screening is uncertain, and professional organizations recommend educating patients about potential harms and benefits. We evaluated the effect of a videotape decision aid on promoting informed decision making about prostate cancer screening among primary care patients. METHODS: A group of 160 men, 45 to 70 years of age, with no history of prostate cancer, were randomized to view or not to view a 20‐minute educational videotape before a routine office visit at a university‐based family medicine clinic. The subjects were contacted again 1 year after their visit to assess their receipt of prostate cancer screening (digital rectal examination [DRE] or prostate‐specific antigen [PSA] testing), their satisfaction with their screening decision, and knowledge retention since the baseline assessment. RESULTS: Follow‐up assessments were completed for 87.5% of the intervention subjects and 83.8% of the control subjects. The rate of DRE did not differ between the 2 groups. Prostate‐specific antigen testing was reported by 24 of 70 (34.3%) intervention subjects and 37 of 67 (55.2%) control subjects (P = .01). African American men were more likely to have had PSA testing (9 of 16, 56.3%) than were white men (13 of 46, 28.3%) (P = .044). Satisfaction with the screening decision did not differ between the study groups. Intervention subjects were more knowledgeable of prostate cancer screening than were control subjects, although these differences declined within 1 year (P < .001). CONCLUSIONS: Decision aids for prostate cancer screening can have a long‐term effect on screening behavior and appear to promote informed decision making. AN - CN-00470664 AU - Volk, R. J. AU - Spann, S. J. AU - Cass, A. R. AU - Hawley, S. T. DO - 10.1370/afm.7 IS - 1 KW - Aged Decision Making Follow‐Up Studies Humans Male Mass Screening [methods] Middle Aged Patient Education as Topic [*methods] Physical Examination [methods] Prostate‐Specific Antigen [blood] Prostatic Neoplasms [blood, *diagnosis] Rectum Videotape Recording M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 2003 SP - 22‐28 ST - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up T2 - Annals of family medicine TI - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00470664/full VL - 1 ID - 1476 ER - TY - JOUR AB - PURPOSE: The efficacy of prostate cancer screening is uncertain, and professional organizations recommend educating patients about potential harms and benefits. We evaluated the effect of a videotape decision aid on promoting informed decision making about prostate cancer screening among primary care patients. METHODS: A group of 160 men, 45 to 70 years of age, with no history of prostate cancer, were randomized to view or not to view a 20-minute educational videotape before a routine office visit at a university-based family medicine clinic. The subjects were contacted again 1 year after their visit to assess their receipt of prostate cancer screening (digital rectal examination [DRE] or prostate-specific antigen [PSA] testing), their satisfaction with their screening decision, and knowledge retention since the baseline assessment. RESULTS: Follow-up assessments were completed for 87.5% of the intervention subjects and 83.8% of the control subjects. The rate of DRE did not differ between the 2 groups. Prostate-specific antigen testing was reported by 24 of 70 (34.3%) intervention subjects and 37 of 67 (55.2%) control subjects (P = .01). African American men were more likely to have had PSA testing (9 of 16, 56.3%) than were white men (13 of 46, 28.3%) (P = .044). Satisfaction with the screening decision did not differ between the study groups. Intervention subjects were more knowledgeable of prostate cancer screening than were control subjects, although these differences declined within 1 year (P < .001). CONCLUSIONS: Decision aids for prostate cancer screening can have a long-term effect on screening behavior and appear to promote informed decision making. AD - Department of Family and Community Medicine, Baylor College of Medicine, Houston, Tex 77098-3915, United States AU - Volk, R. J. AU - Spann, S. J. AU - Cass, A. R. AU - Hawley, S. T. DB - Scopus DO - 10.1370/afm.7 IS - 1 M3 - Article N1 - Cited By :105 Export Date: 22 March 2021 PY - 2003 SP - 22-28 ST - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up T2 - Annals of family medicine TI - Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2342455751&doi=10.1370%2fafm.7&partnerID=40&md5=b8a71a3a8c5faf13dffdb036b84e6462 VL - 1 ID - 2618 ER - TY - JOUR AB - Introduction Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening. Study design RCT. Setting/participants A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50–75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n=429) or control (n=427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015. Intervention Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone. Main outcome measure Colonoscopy completion within 6 months of study enrollment. Results Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p=0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI=1.12, 2.03, p=0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively). Conclusions Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community. AD - A. DeGroff, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, 4770 Buford Highway, NE, Chamblee Bldg. 107, MS F76, Atlanta, GA, United States AU - DeGroff, A. AU - Schroy, P. C. AU - Morrissey, K. G. AU - Slotman, B. AU - Rohan, E. A. AU - Bethel, J. AU - Murillo, J. AU - Ren, W. AU - Niwa, S. AU - Leadbetter, S. AU - Joseph, D. DB - Embase Medline DO - 10.1016/j.amepre.2017.05.010 IS - 3 KW - adult aged article Black person cancer screening colonoscopy colorectal cancer controlled study female Hispanic human individualization lowest income group major clinical study male patient care patient education patient referral randomized controlled trial support group teleconsultation telephone LA - English M3 - Article N1 - L617046885 2017-07-05 2017-10-18 PY - 2017 SN - 1873-2607 0749-3797 SP - 363-372 ST - Patient Navigation for Colonoscopy Completion: Results of an RCT T2 - American Journal of Preventive Medicine TI - Patient Navigation for Colonoscopy Completion: Results of an RCT UR - https://www.embase.com/search/results?subaction=viewrecord&id=L617046885&from=export http://dx.doi.org/10.1016/j.amepre.2017.05.010 VL - 53 ID - 928 ER - TY - JOUR AB - Introduction: Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening.Study Design: RCT.Setting/participants: A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50-75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n=429) or control (n=427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015.Intervention: Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone.Main Outcome Measure: Colonoscopy completion within 6 months of study enrollment.Results: Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p=0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI=1.12, 2.03, p=0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively).Conclusions: Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community. AD - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia Boston Medical Center, Gastroenterology, Boston, Massachusetts Westat, Rockville, Maryland AN - 123959713. Language: English. Entry Date: 20180724. Revision Date: 20180727. Publication Type: journal article AU - DeGroff, Amy AU - Schroy, Paul C., 3rd AU - Morrissey, Kerry Grace AU - Slotman, Beth AU - Rohan, Elizabeth A. AU - Bethel, James AU - Murillo, Jennifer AU - Ren, Weijia AU - Niwa, Shelley AU - Leadbetter, Steven AU - Joseph, Djenaba DB - CINAHL Complete DO - 10.1016/j.amepre.2017.05.010 DP - EBSCOhost IS - 1 KW - Patient Navigation -- Methods Colorectal Neoplasms Health Screening -- Methods Early Detection of Cancer -- Methods Healthcare Disparities -- Statistics and Numerical Data Academic Medical Centers -- Statistics and Numerical Data Poverty Male Socioeconomic Factors Middle Age Colorectal Neoplasms -- Epidemiology Colonoscopy -- Statistics and Numerical Data Early Detection of Cancer -- Statistics and Numerical Data Massachusetts Health Screening -- Statistics and Numerical Data Referral and Consultation -- Statistics and Numerical Data Aged Program Evaluation Colorectal Neoplasms -- Prevention and Control Incidence Self Report Female Occult Blood Patient Navigation -- Statistics and Numerical Data Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials N1 - research; randomized controlled trial. Journal Subset: Biomedical; Health Promotion/Education; USA. Special Interest: Evidence-Based Practice. NLM UID: 8704773. PMID: NLM28676254. PY - 2017 SN - 0749-3797 SP - N.PAG-N.PAG ST - Patient Navigation for Colonoscopy Completion: Results of an RCT T2 - American Journal of Preventive Medicine TI - Patient Navigation for Colonoscopy Completion: Results of an RCT UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123959713&site=ehost-live&scope=site VL - 53 ID - 2015 ER - TY - JOUR AB - Introduction Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening. Study design RCT. Setting/participants A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50–75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n=429) or control (n=427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015. Intervention Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone. Main outcome measure Colonoscopy completion within 6 months of study enrollment. Results Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p=0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI=1.12, 2.03, p=0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively). Conclusions Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community. © 2017 AD - Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, United States Boston Medical Center, Gastroenterology, Boston, Massachusetts, United States Westat, Rockville, Maryland, United States AU - DeGroff, A. AU - Schroy, P. C., III AU - Morrissey, K. G. AU - Slotman, B. AU - Rohan, E. A. AU - Bethel, J. AU - Murillo, J. AU - Ren, W. AU - Niwa, S. AU - Leadbetter, S. AU - Joseph, D. DB - Scopus DO - 10.1016/j.amepre.2017.05.010 IS - 3 M3 - Article N1 - Cited By :30 Export Date: 22 March 2021 PY - 2017 SP - 363-372 ST - Patient Navigation for Colonoscopy Completion: Results of an RCT T2 - American Journal of Preventive Medicine TI - Patient Navigation for Colonoscopy Completion: Results of an RCT UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021442733&doi=10.1016%2fj.amepre.2017.05.010&partnerID=40&md5=5b28eb4b4937327702cac36b6940e6a3 VL - 53 ID - 2303 ER - TY - JOUR AB - Introduction: Colorectal cancer is a leading cause of cancer-related death in the U.S. Although screening reduces colorectal cancer incidence and mortality, screening rates among U.S. adults remain less than optimal, especially among disadvantaged populations. This study examined the efficacy of patient navigation to increase colonoscopy screening. Study design: RCT. Setting/participants: A total of 843 low-income adults, primarily Hispanic and non-Hispanic blacks, aged 50-75 years referred for colonoscopy at Boston Medical Center were randomized into the intervention (n = 429) or control (n = 427) groups. Participants were enrolled between September 2012 and December 2014, with analysis following through 2015. Intervention: Two bilingual lay navigators provided individualized education and support to reduce patient barriers and facilitate colonoscopy completion. The intervention was delivered largely by telephone. Main outcome measure: Colonoscopy completion within 6 months of study enrollment. Results: Colonoscopy completion was significantly higher for navigated patients (61.1%) than control group patients receiving usual care (53.2%, p = 0.021). Based on regression analysis, the odds of completing a colonoscopy for navigated patients was one and a half times greater than for controls (95% CI = 1.12, 2.03, p = 0.007). There were no differences between navigated and control groups in regard to adequacy of bowel preparation (95.3% vs 97.3%, respectively). Conclusions: Navigation significantly improved colonoscopy screening completion among a racially diverse, low-income population. Results contribute to mounting evidence demonstrating the efficacy of patient navigation in increasing colorectal cancer screening. Screening can be further enhanced when navigation is combined with other evidence-based practices implemented in healthcare systems and the community. (C) 2017 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine AN - WOS:000407924400019 AU - DeGroff, A. AU - Schroy, P. C. AU - Morrissey, K. G. AU - Slotman, B. AU - Rohan, E. A. AU - Bethel, J. AU - Murillo, J. AU - Ren, W. J. AU - Niwa, S. AU - Leadbetter, S. AU - Joseph, D. DA - Sep DO - 10.1016/j.amepre.2017.05.010 IS - 3 N1 - 28676254 PY - 2017 SN - 0749-3797 SP - 363-372 ST - Patient Navigation for Colonoscopy Completion: Results of an RCT T2 - American Journal of Preventive Medicine TI - Patient Navigation for Colonoscopy Completion: Results of an RCT VL - 53 ID - 2890 ER - TY - JOUR AB - BACKGROUND: Profound advances in biomedical science have contributed to increased longevity and improved quality of life for many Americans. Despite this progress, a heavier burden of disease is borne by some population groups in the United States, particularly the poor and underserved. Landmark reports published since 1973 have highlighted these health disparities, explored their causal factors, and outlined strategies to reduce them. More recent research studies underscore the results of these early reports that identify social position, economic status, culture, and environment as critical determinants of who develops and survives cancer and of the quality of life of cancer survivors. METHODS: The Patient Navigation Program was established in Harlem, New York, in 1990 to address the dramatic disparities in breast cancer mortality among minority women in the community. RESULTS AND CONCLUSIONS: The success of the Harlem Patient Navigation Program has provided the impetus for the development of many similar patient navigation programs across the country and for federal support for Patient Navigation research to address the critical need for effective interventions to eliminate cancer health disparities, particularly among minorities and the underserved. AD - H.P. Freeman, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA. AU - Freeman, H. P. DB - Medline IS - 1 Suppl KW - African American article breast tumor cancer staging community hospital ethnology female follow up health care delivery health care quality health center Hispanic human mass screening minority group mortality patient patient selection poverty primary prevention public relations statistics survival rate United States LA - English M3 - Article N1 - L45013874 2006-03-01 PY - 2006 SN - 0885-8195 SP - S11-14 ST - Patient navigation: a community centered approach to reducing cancer mortality T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Patient navigation: a community centered approach to reducing cancer mortality UR - https://www.embase.com/search/results?subaction=viewrecord&id=L45013874&from=export VL - 21 ID - 1252 ER - TY - JOUR AB - Background: The purpose of this article is to describe the background, design, and patient populations of the Patient Safety in Surgery Study, as a preliminary to the articles in this journal that will report the results of the Study. Study Design: The Patient Safety in Surgery Study was a prospective cohort study. Trained nurses collected preoperative risk factors, operative variables, and 30-day postoperative mortality and morbidity outcomes in patients undergoing major general and vascular operations at 128 Veterans Affairs (VA) medical centers and 14 selected university medical centers between October 1, 2001 and September 30, 2004. An Internet-based data collection system was used to input data from the different private medical centers. Semiannual feedback of observed to expected mortality and morbidity ratios was provided to the participating medical centers. Results: During the 3-year study, total accrual in general surgery was 145,618 patients, including 68.5% from the VA and 31.5% from the private sector. Accrual in vascular surgery totaled 39,225 patients, including 77.8% from the VA and 22.2% from the private sector. VA patients were older and included a larger proportion of male patients and African Americans and Hispanics. The VA population included more inguinal, umbilical, and ventral hernia repairs, although the private-sector population included more thyroid and parathyroid, appendectomy, and operations for breast cancer. Preoperative comorbidities were similar in the two populations, but the rates of comorbidities were higher in the VA. American Society of Anesthesiologists classification tended to be higher in the VA. Conclusions: The National Surgical Quality Improvement Program methodology was successfully implemented in the 14 university medical centers. The data from the study provided the basis for the articles in this issue of the Journal of the American College of Surgeons. © 2007 American College of Surgeons. AD - VA Boston Healthcare System, West, Roxbury, MA, United States Department of Surgery, Harvard Medical School, Boston, MA, United States Department of Surgery, Brigham and Women's Hospital, Boston, MA, United States University of Colorado Health Outcomes Program, Aurora, CO, United States Tenet Healthcare Corporation, Dallas, TX, United States Department of Surgery, University of Illinois Hospital, Chicago, IL, United States American College of Surgeons, Chicago, IL, United States Department of Surgery, University of Michigan, Ann Arbor, MI, United States Medical Center, Decatur, GA, United States Department of Surgery, Emory University, Atlanta, GA, United States Wayne State University School of Medicine, Detroit, MI, United States QCMetrix, Inc, Waltham, MA, United States AU - Khuri, S. F. AU - Henderson, W. G. AU - Daley, J. AU - Jonasson, O. AU - Jones, R. S. AU - Campbell Jr, D. A. AU - Fink, A. S. AU - Mentzer Jr, R. M. AU - Steeger, J. E. DB - Scopus DO - 10.1016/j.jamcollsurg.2007.03.028 IS - 6 M3 - Article N1 - Cited By :291 Export Date: 22 March 2021 PY - 2007 SP - 1089-1102 ST - The Patient Safety in Surgery Study: Background, Study Design, and Patient Populations T2 - Journal of the American College of Surgeons TI - The Patient Safety in Surgery Study: Background, Study Design, and Patient Populations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34249312982&doi=10.1016%2fj.jamcollsurg.2007.03.028&partnerID=40&md5=d2547cafd11795cbad4b26f1a84c8847 VL - 204 ID - 2561 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains. Purpose: To characterize the influence of patient trust in care providers on CRC screening behavior. Methods: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50-79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution. Results: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR=1.11, 95% CI=1.03, 1.17), but trust in doctors was not (OR=1.02, 95% CI=0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis. Conclusions: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP. AD - J.M. Inadomi, Division of Gastroenterology, Department of Medicine, University of Washington, 1959 NE Pacific St., Seattle, WA, United States AU - Gupta, S. AU - Brenner, A. T. AU - Ratanawongsa, N. AU - Inadomi, J. M. DB - Embase Medline DO - 10.1016/j.amepre.2014.04.020 IS - 4 KW - adult article Asian Black person cancer screening colonoscopy colorectal cancer controlled study doctor patient relationship ethnicity female follow up Hispanic human intervention study language lowest income group major clinical study male middle aged occult blood test outcome assessment primary medical care public health insurance trust United States LA - English M3 - Article N1 - L53264933 2014-08-01 2015-01-23 PY - 2014 SN - 1873-2607 0749-3797 SP - 417-423 ST - Patient trust in physician influences colorectal cancer screening in low-income patients T2 - American Journal of Preventive Medicine TI - Patient trust in physician influences colorectal cancer screening in low-income patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L53264933&from=export http://dx.doi.org/10.1016/j.amepre.2014.04.020 VL - 47 ID - 1059 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains. Purpose: To characterize the influence of patient trust in care providers on CRC screening behavior. Methods: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50–79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution. Results: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR = 1.11, 95% CI = 1.03, 1.17), but trust in doctors was not (OR = 1.02, 95% CI = 0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis. Conclusions: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Inadomi, John M., Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific St, Box 356424, Seattle, WA, US, 98195 AN - 2014-41295-011 AU - Gupta, Shivani AU - Brenner, Alison T. AU - Ratanawongsa, Neda AU - Inadomi, John M. DB - psyh DO - 10.1016/j.amepre.2014.04.020 DP - EBSCOhost IS - 4 KW - patient trust physician influences colorectal cancer screening low income patients Aged Colonoscopy Colorectal Neoplasms Female Humans Male Mass Screening Middle Aged Occult Blood Patient Acceptance of Health Care Physician-Patient Relations Poverty San Francisco Trust Cancer Screening Client Satisfaction Physicians Trust (Social Behavior) Colon Disorders Health Care Utilization Lower Income Level Neoplasms N1 - Emory University School of Medicine, Atlanta, GA, US. Release Date: 20150615. Correction Date: 20160512. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Georgia Chapter American College of Physicians Annual Meeting, Sep, 2012, Buford, GA, US. Grant Information: Brenner, Alison T. Conference Note: This study was previously presented, in part, at the aforementioned conference and at the American College of Physicians Internal Medicine 2013 Annual Meeting, April 11–13, 2013, San Francisco, California. Major Descriptor: Cancer Screening; Client Satisfaction; Physicians; Trust (Social Behavior). Minor Descriptor: Colon Disorders; Health Care Utilization; Lower Income Level; Neoplasms. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Wake Forest Trust Scale. Methodology: Empirical Study; Quantitative Study; Treatment Outcome. Supplemental Data: Tables and Figures Internet. References Available: Y. Page Count: 7. Issue Publication Date: Oct, 2014. Copyright Statement: Published by Elsevier Inc. American Journal of Preventive Medicine. 2014. Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: R01CA106773. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US. Grant: K24DK080941. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Center for Research Resources, US. Grant: UL1 RR024131. Recipients: No recipient indicated Sponsor: Agency for Healthcare Research and Quality. Other Details: National Research Service Award Training Grant. Recipients: Brenner, Alison T. Sponsor: University of Washington School of Public Health, Department of Health Services, US. Grant: 5T32 HS 13853-9. Recipients: Brenner, Alison T. Sponsor: University of North Carolina at Chapel Hill, Cecil 473 Sheps Center for Health Services Research, US. Grant: 5T32-HS000032. Recipients: Brenner, Alison T. PY - 2014 SN - 0749-3797 1873-2607 SP - 417-423 ST - Patient trust in physician influences colorectal cancer screening in low-income patients T2 - American Journal of Preventive Medicine TI - Patient trust in physician influences colorectal cancer screening in low-income patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-41295-011&site=ehost-live&scope=site jinadomi@medicine.washington.edu VL - 47 ID - 1704 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains.Purpose: To characterize the influence of patient trust in care providers on CRC screening behavior.Methods: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50-79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution.Results: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR=1.11, 95% CI=1.03, 1.17), but trust in doctors was not (OR=1.02, 95% CI=0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis.Conclusions: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP. AD - Emory University School of Medicine, Atlanta, Georgia. Department of Health Services, University of Washington School of Public Health and Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington. Division of General Internal Medicine and Center for Vulnerable Populations, University of California, San Francisco, San Francisco, California. Department of Health Services, University of Washington School of Public Health and Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington. Electronic address: jinadomi@medicine.washington.edu. AN - 109756074. Language: English. Entry Date: 20150918. Revision Date: 20200708. Publication Type: journal article AU - Gupta, Shivani AU - Brenner, Alison T. AU - Ratanawongsa, Neda AU - Inadomi, John M. DB - CINAHL Complete DO - 10.1016/j.amepre.2014.04.020 DP - EBSCOhost IS - 4 KW - Colorectal Neoplasms -- Diagnosis Health Screening -- Methods Physician-Patient Relations Trust Aged Colonoscopy -- Statistics and Numerical Data Colorectal Neoplasms -- Psychosocial Factors Female Human Male Health Screening -- Psychosocial Factors Middle Age Occult Blood Patient Attitudes Poverty California N1 - research; randomized controlled trial. Journal Subset: Biomedical; Health Promotion/Education; USA. Grant Information: R01 CA106773/CA/NCI NIH HHS/United States. NLM UID: 8704773. PMID: NLM25084682. PY - 2014 SN - 0749-3797 SP - 417-423 ST - Patient trust in physician influences colorectal cancer screening in low-income patients T2 - American Journal of Preventive Medicine TI - Patient trust in physician influences colorectal cancer screening in low-income patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109756074&site=ehost-live&scope=site VL - 47 ID - 2017 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains. Purpose: To characterize the influence of patient trust in care providers on CRC screening behavior. Methods: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50-79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution. Results: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR=1.11, 95% CI=1.03, 1.17), but trust in doctors was not (OR=1.02, 95% CI=0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis. Conclusions: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP. © 2014 American Journal of Preventive Medicine. AD - Emory University, School of Medicine, Atlanta, GA, United States Department of Health Services, University of Washington, Division of Gastroenterology, Seattle, WA, United States Division of General Internal Medicine, Center for Vulnerable Populations, University of California, San Francisco, San Francisco, CA, United States AU - Gupta, S. AU - Brenner, A. T. AU - Ratanawongsa, N. AU - Inadomi, J. M. DB - Scopus DO - 10.1016/j.amepre.2014.04.020 IS - 4 M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 2014 SP - 417-423 ST - Patient trust in physician influences colorectal cancer screening in low-income patients T2 - American Journal of Preventive Medicine TI - Patient trust in physician influences colorectal cancer screening in low-income patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920882194&doi=10.1016%2fj.amepre.2014.04.020&partnerID=40&md5=7636eb98e38d342dbacbe8b4f75586c1 VL - 47 ID - 2420 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) screening is effective but underutilized. Although physician recommendation is an important predictor of screening, considerable variation in CRC screening completion remains. Purpose: To characterize the influence of patient trust in care providers on CRC screening behavior. Methods: Data were collected as part of a cluster-randomized CRC screening intervention trial performed in the San Francisco Community Health Network from March 2007 to January 2012 (analysis, Spring 2012). All study participants received a recommendation to complete CRC screening from their primary care provider (PCP). Included participants were aged 50-79 years, not current with screening, and completed the Wake Forest Trust Scale (WFTS) measuring trust in PCPs and doctors in general. Primary outcome was CRC screening completion (colonoscopy or fecal occult blood testing) within 12 months following enrollment. Multivariable association adjusted for race/ethnicity, language, and other sociodemographics was estimated using generalized estimating equations with logit link and binomial distribution. Results: WFTS response was 70.3% (701). Most participants (83%) were Latino, Asian, or black. Most had income <$30,000 (96%) and public health insurance (86%). Higher trust in PCP was associated with screening completion (OR=1.11, 95% CI=1.03, 1.17), but trust in doctors was not (OR=1.02, 95% CI=0.82, 1.28). Race, language, and other sociodemographic factors were not significant in multivariable analysis. Conclusions: After controlling for traditional factors, trust in PCP remained the only significant driver of CRC screening completion in low-income patients. Interventions to promote CRC screening may be improved by including efforts to enhance patient trust in PCP. (C) 2014 American Journal of Preventive Medicine AN - WOS:000342386700008 AU - Gupta, S. AU - Brenner, A. T. AU - Ratanawongsa, N. AU - Inadomi, J. M. DA - Oct DO - 10.1016/j.amepre.2014.04.020 IS - 4 N1 - 25084682 PY - 2014 SN - 0749-3797 SP - 417-423 ST - Patient Trust in Physician Influences Colorectal Cancer Screening in Low-Income Patients T2 - American Journal of Preventive Medicine TI - Patient Trust in Physician Influences Colorectal Cancer Screening in Low-Income Patients VL - 47 ID - 2998 ER - TY - JOUR AB - Objectives: Endocrine therapy is part of standard adjuvant therapy for patients with hormone receptor-positive breast cancer and has been shown to improve recurrence-free and overall survival. However, adherence to endocrine therapy is suboptimal and is difficult to measure. In this study we evaluate the feasibility of using the Morisky Medication Adherence Scale (MMAS) to assess patient adherence to aromatase inhibitor (AI) therapy. Methods: Patients with stage 1 to 3, hormone receptor-positive breast cancer receiving adjuvant AI therapy were prospectively enrolled on an Institutional Review Board approved protocol. The MMAS questionnaire was administered to each patient and adherence was measured. Information on duration of AI therapy, patient and tumor characteristics, and treatment was collected. A multivariable logit model approach was utilized to evaluate potential barriers to adherence. Results: Between 2011 and 2014, 100 patients were enrolled. The distribution of adherence levels was 13% low, 37% medium, and 50% high. High adherence was reported more frequently in white women (58%), patients with stage 2 and 3 disease (54%), and patients who did not receive chemotherapy (62%). Multivariable analysis demonstrated that higher adherence was more likely in white women compared with African American women (estimated odds ratio=2.8). Conclusions: Using the MMAS, only 50% of women with stage 1 to 3 breast cancer reported high adherence to AI therapy, consistent with other reports showing suboptimal adherence to adjuvant endocrine therapy. The MMAS allows for the rapid assessment of adherence to oral adjuvant endocrine therapy and is valuable in a busy clinical setting. © 2016 Wolters Kluwer Health, Inc. All rights reserved. AD - Departments of Surgery, Division of General and Oncologic Surgery, University of Maryland School of Medicine, 29 S. Greene St., Baltimore, MD 21201, United States Departments of Epidemiology and Public Health, University of Maryland, Baltimore, MD, United States Departments of Medicine, Division of Hematology and Oncology, University of Maryland, Baltimore, MD, United States Departments of Radiation Oncology, University of Maryland, Baltimore, MD, United States Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, United States AU - Kesmodel, S. B. AU - Goloubeva, O. G. AU - Rosenblatt, P. Y. AU - Heiss, B. AU - Bellavance, E. C. AU - Chumsri, S. AU - Bao, T. AU - Thompson, J. AU - Nightingale, G. AU - Tait, N. S. AU - Nichols, E. M. AU - Feigenberg, S. J. AU - Tkaczuk, K. H. DB - Scopus DO - 10.1097/COC.0000000000000314 IS - 5 KW - adjuvant endocrine therapy endocrine therapy adherence hormone receptor-positive breast cancer measuring adherence to medication M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2018 SP - 508-512 ST - Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors T2 - American Journal of Clinical Oncology: Cancer Clinical Trials TI - Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84975460513&doi=10.1097%2fCOC.0000000000000314&partnerID=40&md5=f52aeb524a5e813d96a2a2d4fa2c44e8 VL - 41 ID - 2290 ER - TY - JOUR AB - BACKGROUND: Aromatase inhibitors (AIs) have been associated with decrements in patient‐reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. METHODS: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment‐associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual‐center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash‐Related Daily Interference Scale (HFRDI), and the European quality‐of‐life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. RESULTS: The intention‐to‐treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post‐hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non‐African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores. CONCLUSIONS: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. AN - CN-00978457 AU - Bao, T. AU - Cai, L. AU - Snyder, C. AU - Betts, K. AU - Tarpinian, K. AU - Gould, J. AU - Jeter, S. AU - Medeiros, M. AU - Chumsri, S. AU - Bardia, A. AU - et al. DO - 10.1002/cncr.28352 IS - 3 KW - *acupuncture *aromatase inhibitor/ae [Adverse Drug Reaction] *aromatase inhibitor/ct [Clinical Trial] *aromatase inhibitor/dt [Drug Therapy] *breast cancer/dt [Drug Therapy] *outcome assessment *patient reported outcome Acupuncture Therapy Adult Aged Aged, 80 and over Analysis of covariance Analytic method Aromatase Inhibitors [*adverse effects] Article Bone Diseases [chemically induced, *prevention & control] Breast Neoplasms [psychology, *therapy] Clinical article Controlled study Disease severity Double blind procedure Double‐Blind Method Female Hospital Anxiety and Depression Scale Hot flash daily diary Hot flash related daily interference scale Human Humans Middle Aged Multicenter study Muscular Diseases [chemically induced, *prevention & control] Musculoskeletal disease/si [Side Effect] National Surgical Adjuvant Breast and Bowel Project menopausal symptomn questionnaire Pittsburgh Sleep Quality Index Postmenopause Priority journal Psychometry Quality of Life Race difference Randomized controlled trial Very elderly M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2014 SP - 381‐389 ST - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms T2 - Cancer TI - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00978457/full VL - 120 ID - 1578 ER - TY - JOUR AB - Background Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. Methods Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. Results The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P =.022), hot flash severity (P =.006), hot flash frequency (P =.011), the HFRDI (P =.014), and NSABP menopausal symptoms (P =.022); scores in the SA arm improved significantly on the EuroQol (P =.022),the HFRDI (P =.043), and NSABP menopausal symptoms (P =.005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P <.001) and frequency (P <.001) scores. Conclusions Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. © 2013 American Cancer Society. AD - T. Bao, DABMA, 22 South Greene Street, N9E24, Baltimore, MD 21201-1595, United States AU - Bao, T. AU - Cai, L. AU - Snyder, C. AU - Betts, K. AU - Tarpinian, K. AU - Gould, J. AU - Jeter, S. AU - Medeiros, M. AU - Chumsri, S. AU - Bardia, A. AU - Tan, M. AU - Singh, H. AU - Tkaczuk, K. H. R. AU - Stearns, V. DB - Embase Medline DO - 10.1002/cncr.28352 IS - 3 KW - NCT00641303 aromatase inhibitor acupuncture adult aged analysis of covariance analytic method article breast cancer clinical article controlled study disease severity double blind procedure female Hospital Anxiety and Depression Scale hot flash daily diary Hot Flash Related Daily Interference Scale human middle aged multicenter study musculoskeletal disease National Surgical Adjuvant Breast and Bowel Project menopausal symptomn questionnaire outcome assessment patient-reported outcome Pittsburgh Sleep Quality Index postmenopause priority journal psychometry quality of life race difference randomized controlled trial very elderly LA - English M3 - Article N1 - L52936451 2014-01-02 2014-02-14 PY - 2014 SN - 0008-543X 1097-0142 SP - 381-389 ST - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms T2 - Cancer TI - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52936451&from=export http://dx.doi.org/10.1002/cncr.28352 VL - 120 ID - 1038 ER - TY - JOUR AB - Background: Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI.Methods: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks.Results: The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores.Conclusions: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. AD - University of Maryland Greenebaum Cancer Center, Baltimore, Maryland. AN - 104010780. Language: English. Entry Date: 20140404. Revision Date: 20200708. Publication Type: journal article AU - Bao, Ting AU - Cai, Ling AU - Snyder, Claire AU - Betts, Kelly AU - Tarpinian, Karineh AU - Gould, Jeff AU - Jeter, Stacie AU - Medeiros, Michelle AU - Chumsri, Saranya AU - Bardia, Aditya AU - Tan, Ming AU - Singh, Harvinder AU - Tkaczuk, Katherin H. R. AU - Stearns, Vered DB - CINAHL Complete DO - 10.1002/cncr.28352 DP - EBSCOhost IS - 3 KW - Acupuncture Aromatase Inhibitors -- Adverse Effects Bone Diseases -- Prevention and Control Breast Neoplasms -- Therapy Muscular Diseases -- Prevention and Control Adult Aged Aged, 80 and Over Bone Diseases -- Chemically Induced Breast Neoplasms -- Psychosocial Factors Double-Blind Studies Female Human Middle Age Muscular Diseases -- Chemically Induced Psychological Tests Quality of Life Questionnaires Scales N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. Instrumentation: Center for Epidemiologic Studies Depression Scale (CES-D); Pittsburgh Sleep Quality Index (PSQI); EuroQol (EQ-5D); Hospital Anxiety and Depression Scale (HADS); National Surgical Adjuvant Breast and Bowel Project (NSABP) Menopausal Symptoms Questionnaire; Hot Flash Daily Diary; Hot Flash-Related Daily Interference Scale (HFRDI). Grant Information: K12 CA126849/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM24375332. PY - 2014 SN - 0008-543X SP - 381-389 ST - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms T2 - Cancer (0008543X) TI - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104010780&site=ehost-live&scope=site VL - 120 ID - 2018 ER - TY - JOUR AB - Background Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. Methods Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. Results The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P =.022), hot flash severity (P =.006), hot flash frequency (P =.011), the HFRDI (P =.014), and NSABP menopausal symptoms (P =.022); scores in the SA arm improved significantly on the EuroQol (P =.022),the HFRDI (P =.043), and NSABP menopausal symptoms (P =.005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P <.001) and frequency (P <.001) scores. Conclusions Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. © 2013 American Cancer Society. AD - University of Maryland Greenebaum Cancer Center, Baltimore, MD, United States Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, United States Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, United States AU - Bao, T. AU - Cai, L. AU - Snyder, C. AU - Betts, K. AU - Tarpinian, K. AU - Gould, J. AU - Jeter, S. AU - Medeiros, M. AU - Chumsri, S. AU - Bardia, A. AU - Tan, M. AU - Singh, H. AU - Tkaczuk, K. H. R. AU - Stearns, V. DB - Scopus DO - 10.1002/cncr.28352 IS - 3 KW - acupuncture aromatase inhibitor musculoskeletal symptoms patient-reported outcomes M3 - Article N1 - Cited By :32 Export Date: 22 March 2021 PY - 2014 SP - 381-389 ST - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms T2 - Cancer TI - Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892910530&doi=10.1002%2fcncr.28352&partnerID=40&md5=26a64c3578f5fc0f73642f75e670a103 VL - 120 ID - 2400 ER - TY - JOUR AB - BACKGROUNDAromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. METHODSPostmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. RESULTSThe intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P=.022), hot flash severity (P=.006), hot flash frequency (P=.011), the HFRDI (P=.014), and NSABP menopausal symptoms (P=.022); scores in the SA arm improved significantly on the EuroQol (P=.022),the HFRDI (P=.043), and NSABP menopausal symptoms (P=.005). Post-hoc analysis indicated that African American patients (n=9) benefited more from RA than SA compared with non-African American patients (n=38) in reducing hot flash severity (P<.001) and frequency (P<.001) scores. CONCLUSIONSBoth RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. Cancer 2014;120:381-389. (c) 2013 American Cancer Society. AN - WOS:000330267700011 AU - Bao, T. AU - Cai, L. AU - Snyder, C. AU - Betts, K. AU - Tarpinian, K. AU - Gould, J. AU - Jeter, S. AU - Medeiros, M. AU - Chumsri, S. AU - Bardia, A. AU - Tan, M. AU - Singh, H. AU - Tkaczuk, K. H. R. AU - Stearns, V. DA - Feb DO - 10.1002/cncr.28352 IS - 3 N1 - 24375332 PY - 2014 SN - 0008-543X SP - 381-389 ST - Patient-Reported Outcomes in Women With Breast Cancer Enrolled in a Dual-Center, Double-Blind, Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-Induced Musculoskeletal Symptoms T2 - Cancer TI - Patient-Reported Outcomes in Women With Breast Cancer Enrolled in a Dual-Center, Double-Blind, Randomized Controlled Trial Assessing the Effect of Acupuncture in Reducing Aromatase Inhibitor-Induced Musculoskeletal Symptoms VL - 120 ID - 3023 ER - TY - JOUR AB - Background: Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. Methods: Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. Results: The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022), the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores. Conclusions: Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Bao, Ting, 22 South Greene Street, N9E24, Baltimore, MD, US, 21201-1595 AN - 2014-03321-011 AU - Bao, Ting AU - Cai, Ling AU - Snyder, Claire AU - Betts, Kelly AU - Tarpinian, Karineh AU - Gould, Jeff AU - Jeter, Stacie AU - Medeiros, Michelle AU - Chumsri, Saranya AU - Bardia, Aditya AU - Tan, Ming AU - Singh, Harvinder AU - Tkaczuk, Katherin H. R. AU - Stearns, Vered DB - psyh DO - 10.1002/cncr.28352 DP - EBSCOhost IS - 3 KW - acupuncture aromatase inhibitor musculoskeletal symptoms breast cancer Acupuncture Therapy Adult Aged Aged, 80 and over Aromatase Inhibitors Bone Diseases Breast Neoplasms Double-Blind Method Female Humans Middle Aged Muscular Diseases Quality of Life Enzyme Inhibitors Treatment Outcomes Musculoskeletal Disorders Symptoms N1 - University of Maryland, Greenebaum Cancer Center, Baltimore, MD, US. Release Date: 20140728. Correction Date: 20160616. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Bao, Ting. Major Descriptor: Acupuncture; Breast Neoplasms; Enzyme Inhibitors; Treatment Outcomes. Minor Descriptor: Musculoskeletal Disorders; Symptoms. Classification: Cancer (3293); Medical Treatment of Physical Illness (3363). Population: Human (10). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: European Quality of Life Survey Questionnaire; Hospital Anxiety and Depression Scale DOI: 10.1037/t03589-000; Pittsburgh Sleep Quality Index DOI: 10.1037/t05178-000; Center for Epidemiological Studies Depression Scale DOI: 10.1037/t02942-000; Hot Flash Related Daily Interference Scale DOI: 10.1037/t12162-000. Methodology: Empirical Study; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 9. Issue Publication Date: Feb 1, 2014. Publication History: First Posted Date: Dec 23, 2013; Accepted Date: Aug 2, 2013; Revised Date: Jul 29, 2013; First Submitted Date: May 13, 2013. Copyright Statement: American Cancer Society. 2013. Sponsor: American Society of Clinical Oncology Foundation, US. Other Details: Young Investigator’s Award. Recipients: No recipient indicated Sponsor: Susan Komen. Other Details: Postdoctoral Fellowship Award. Recipients: No recipient indicated Sponsor: Breast Cancer Research Foundation. Recipients: No recipient indicated Sponsor: Maryland Affiliate of Susan G. Komen for the Cure. Other Details: Craft grant. Recipients: No recipient indicated Sponsor: Sponsor name not included. Grant: K12 CA126849. Other Details: Paul Calabresi scholar. Recipients: Bao, Ting Sponsor: Sponsor name not included. Grant: R21 CA173263. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: P30 CA006973. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: P30 CA134274. Other Details: University of Maryland Greenebaum Cancer Center. Recipients: No recipient indicated PY - 2014 SN - 0008-543X 1097-0142 SP - 381-389 ST - Patient‐reported outcomes in women with breast cancer enrolled in a dual‐center, double‐blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor‐induced musculoskeletal symptoms T2 - Cancer TI - Patient‐reported outcomes in women with breast cancer enrolled in a dual‐center, double‐blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor‐induced musculoskeletal symptoms UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-03321-011&site=ehost-live&scope=site tbao@umm.edu VL - 120 ID - 1702 ER - TY - JOUR AB - To make informed decisions, patients must have adequate knowledge of key decision-relevant facts. To determine adults' knowledge about information relevant to common types of medication, screening, or surgery decisions they recently made. National sample of US adults identified by random-digit dialing. Cross-sectional survey conducted between November 2006 and May 2007. A total of 2575 English-speaking adults aged 40 y or older who reported having discussed the following medical decisions with a health care provider within the previous 2 y: prescription medications for hypertension, hypercholesterolemia, or depression; screening tests for colorectal, breast, or prostate cancer; or surgeries for knee/hip replacement, cataracts, or lower back pain. Participants answered knowledge questions and rated the importance of their health care provider, family/friends, and the media as sources of information. Accuracy rates varied widely across questions and decision contexts. For example, patients considering cataract surgery were more likely to correctly estimate recovery time than those patients considering lower back pain or knee/hip replacement (78% v. 29% and 39%, P < 0.001). Similarly, participants were more knowledgeable of facts about colorectal cancer screening than those who were asked about breast or prostate cancer. Finally, respondents were consistently more knowledgeable on comparable questions about blood pressure medication than cholesterol medication or antidepressants. The impact of demographic characteristics and sources of information also varied substantially. For example, blacks had lower knowledge than whites about cancer screening decisions (odds ratio [OR] = 0.57; 95% confidence interval [CI] = 0.43, 0.75; P = 0.001) and medication (OR = 0.77; 95% CI = 0.60, 0.97; P = 0.03) even after we controlled for other demographic factors. The same was not true for surgical decisions. The questions did not measure all knowledge relevant to informed decision making, were subject to recall biases, and may have assessed numeracy more than knowledge. Patient knowledge of key facts relevant to recently made medical decisions is often poor and varies systematically by decision type and patient characteristics. Improving patient knowledge about risks, benefits, and characteristics of medical procedures is essential to support informed decision making. AD - A. Fagerlin, VA Health Services Research & Development Center of Excellence, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. AU - Fagerlin, A. AU - Sepucha, K. R. AU - Couper, M. P. AU - Levin, C. A. AU - Singer, E. AU - Zikmund-Fisher, B. J. DB - Medline IS - 5 Suppl KW - prescription drug adult aged article attitude to health confidence interval cross-sectional study decision making early diagnosis education educational status female general surgery human male middle aged multivariate analysis neoplasm patient education patient participation risk statistical model LA - English M3 - Article N1 - L360272758 2011-03-10 PY - 2010 SN - 1552-681X SP - 35S-52S ST - Patients' knowledge about 9 common health conditions: the DECISIONS survey T2 - Medical decision making : an international journal of the Society for Medical Decision Making TI - Patients' knowledge about 9 common health conditions: the DECISIONS survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360272758&from=export VL - 30 ID - 1156 ER - TY - JOUR AB - Objectives. In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivity and to aid in prostate cancer staging. This study evaluated whether the %fPSA cutoff that maintained a 95% sensitivity in a white population yielded the same sensitivity and specificity in a black population and whether %fPSA was useful in predicting postoperative pathologic features in blacks.Methods. We evaluated 647 white and 79 black men, prospectively enrolled at prostate cancer screening and surgical referral centers. Subjects were 50 to 75 years old with digital rectal examination findings that were not suspicious for prostate cancer and total PSA values between 4.0 and 10.0 ng/mL. All had undergone needle biopsy of the prostate. Hybritech's Tandem total and free PSA assays were used.Results. Ninety-five percent sensitivity was attained with a %fPSA cutoff of 25% in both races. Use of this cutoff could have avoided unnecessary biopsies in 20% of white and 17% of black subjects (P = 0.69). In receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) for %fPSA was significantly higher than for total PSA in both blacks (0.76 versus 0.56, P <0.01) and whites (0.70 versus 0.54, P <0.001). In both races, higher %fPSA values indicated a lower risk of cancer and also predicted favorable pathologic features in radical prostatectomy specimens.Conclusions. A 25% fPSA cutoff detected 95% of cancers and reduced unnecessary biopsies in both races. Higher %fPSA values were associated with favorable postoperative histopathologic findings in both races. Copyright (C) 2000 Elsevier Science Inc. AD - W.J. Catalona, Division of Urologic Surgery, Department of Surgery, Washington Univ. School of Medicine, 4960 Children's Place, St. Louis, MO 63110, United States AU - Catalona, W. J. AU - Partin, A. W. AU - Slawin, K. M. AU - Naughton, C. K. AU - Brawer, M. K. AU - Flanigan, R. C. AU - Richie, J. P. AU - Patel, A. AU - Walsh, P. C. AU - Scardino, P. T. AU - Lange, P. H. AU - Dekernion, J. B. AU - Southwick, P. C. AU - Loveland, K. G. AU - Parson, R. E. AU - Gasior, G. H. DB - Embase Medline DO - 10.1016/S0090-4295(99)00547-6 IS - 3 KW - prostate specific antigen adult aged antigen detection article cancer staging Caucasian clinical trial controlled clinical trial controlled study diagnostic accuracy ethnic difference human human tissue major clinical study male multicenter study Black person priority journal prognosis prospective study prostate cancer statistical analysis tumor biopsy LA - English M3 - Article N1 - L30110587 2000-03-08 PY - 2000 SN - 0090-4295 SP - 372-376 ST - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial T2 - Urology TI - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30110587&from=export http://dx.doi.org/10.1016/S0090-4295(99)00547-6 VL - 55 ID - 1323 ER - TY - JOUR AB - Objectives. In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivity and to aid in prostate cancer staging. This study evaluated whether the %fPSA cutoff that maintained a 95% sensitivity in a white population yielded the same sensitivity and specificity in a black population and whether %fPSA was useful in predicting postoperative pathologic features in blacks.Methods. We evaluated 647 white and 79 black men, prospectively enrolled at prostate cancer screening and surgical referral centers. Subjects were 50 to 75 years old with digital rectal examination findings that were not suspicious for prostate cancer and total PSA values between 4.0 and 10.0 ng/mL. All had undergone needle biopsy of the prostate. Hybritech's Tandem total and free PSA assays were used.Results. Ninety-five percent sensitivity was attained with a %fPSA cutoff of 25% in both races. Use of this cutoff could have avoided unnecessary biopsies in 20% of white and 17% of black subjects (P = 0.69). In receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) for %fPSA was significantly higher than for total PSA in both blacks (0.76 versus 0.56, P <0.01) and whites (0.70 versus 0.54, P <0.001). In both races, higher %fPSA values indicated a lower risk of cancer and also predicted favorable pathologic features in radical prostatectomy specimens.Conclusions. A 25% fPSA cutoff detected 95% of cancers and reduced unnecessary biopsies in both races. Higher %fPSA values were associated with favorable postoperative histopathologic findings in both races. Copyright (C) 2000 Elsevier Science Inc. AD - Division of Urologic Surgery, Dept. Surg., Washington Univ. S., St. Louis, MO, United States Department of Urology, Johns Hopkins Hospital, Baltimore, MD, United States Baylor College of Medicine, Houston, TX, United States University of Washington, Seattle, WA, United States Loyola University Medical Center, Maywood, IL, United States Harvard Program in Urology, Brigham and Women's Hospital, Boston, MA, United States University of California, Los Angeles, School of Medicine, Los Angeles, CA, United States Dept. of Research and Development, Hybritech Incorporated, San Diego, CA, United States AU - Catalona, W. J. AU - Partin, A. W. AU - Slawin, K. M. AU - Naughton, C. K. AU - Brawer, M. K. AU - Flanigan, R. C. AU - Richie, J. P. AU - Patel, A. AU - Walsh, P. C. AU - Scardino, P. T. AU - Lange, P. H. AU - Dekernion, J. B. AU - Southwick, P. C. AU - Loveland, K. G. AU - Parson, R. E. AU - Gasior, G. H. DB - Scopus DO - 10.1016/S0090-4295(99)00547-6 IS - 3 M3 - Article N1 - Cited By :39 Export Date: 22 March 2021 PY - 2000 SP - 372-376 ST - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial T2 - Urology TI - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033963023&doi=10.1016%2fS0090-4295%2899%2900547-6&partnerID=40&md5=a66608b2cf0197e676b0e636410d84c6 VL - 55 ID - 2632 ER - TY - JOUR AB - Objectives. In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivity and to aid in prostate cancer staging. This study evaluated whether the %fPSA cutoff that maintained a 95% sensitivity in a white population yielded the same sensitivity and specificity in a black population and whether %fPSA was useful in predicting postoperative pathologic features in blacks. Methods. We evaluated 647 white and 79 black men, prospectively enrolled at prostate cancer screening and surgical referral centers. Subjects were 50 to 75 years old with digital rectal examination findings that were not suspicious for prostate cancer and total PSA values between 4.0 and 10.0 ng/mL. All had undergone needle biopsy of the prostate. Hybritech's Tandem total and free PSA assays were used. Results. Ninety-five percent sensitivity was attained with a %fPSA cutoff of 25% in both races. Use of this cutoff could have avoided unnecessary biopsies in 20% of white and 17% of black subjects (P = 0.69). In receiver operating characteristic (ROC] curve analysis, the area under the curve [AUC) for %fPSA was significantly higher than for total PSA in both blacks (0.76 versus 0.56, P < 0.01) and whites (0.70 versus 0.54, P < 0.001). In both races, higher %fPSA values indicated a lower risk of cancer and also predicted favorable pathologic features in radical prostatectomy specimens. Conclusions. A 25% fPSA cutoff detected 95% of cancers and reduced unnecessary biopsies in both races. Higher %fPSA values were associated with favorable postoperative histopathologic findings in both races. (C) 2000, Elsevier Science Inc. AN - WOS:000085657000017 AU - Catalona, W. J. AU - Partin, A. W. AU - Slawin, K. M. AU - Naughton, C. K. AU - Brawer, M. K. AU - Flanigan, R. C. AU - Richie, J. P. AU - Patel, A. AU - Walsh, P. C. AU - Scardino, P. T. AU - Lange, P. H. AU - deKernion, J. B. AU - Southwick, P. C. AU - Loveland, K. G. AU - Parson, R. E. AU - Gasior, G. H. DA - Mar DO - 10.1016/S0090-4295(99)00547-6 IS - 3 N1 - 40 10699613 PY - 2000 SN - 0090-4295 SP - 372-376 ST - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial T2 - Urology TI - Percentage of free PSA in black versus white men for detection and staging of prostate cancer: A prospective multicenter clinical trial VL - 55 ID - 2722 ER - TY - JOUR AB - BACKGROUND. This article discusses the sometimes unique presentation and course of breast cancer in African-American women and the impact these differences have on the perception of breast disease among African -American women. METHODS. The project described represents the thoughts of many African-American breast cancer survivors, as summarized by three breast cancer survivor-advocates who work through very different national organizations, each of whom has vast experience working directly with African-American breast cancer survivors and their families. RESULTS. In addition to discussions of compelling considerations that have an impact on survivor access, such as agency, culture, and class, other important access questions are raised for research scientists and clinicians that have an impact on the prevention, screening, and detection and treatment of breast cancer in African-American women as well as their accrual to clinical trials. CONCLUSIONS. To eradicate ethnicity-related disparities in breast cancer outcomes for African-American women, it is important for the medical community (clinicians and research scientists) to develop active partnerships with African-American and other breast cancer survivor-advocates in order to establish effective breast health awareness and breast cancer treatment programs and to develop meaningful breast cancer research programs. © 2003 American Cancer Society. AD - Breast Cancer Liaison, Natl. Black Women's Health Project, Washington, DC, United States Mailman School of Public Health, Columbia University, 722 West 168 Street, New York City, NY 10032, United States Women in Touch, South Bend, IN, United States Breast Cancer Resource Committee, Cancer Awareness Prog. Serv., Inc., Washington, DC, United States AU - Lythcott, N. AU - Green, B. L. AU - Brown, Z. K. DB - Scopus DO - 10.1002/cncr.11013 IS - 1 SUPPL. KW - Advocate African American Agency Breast cancer Class Clinical trials Culture Spirituality Survivor M3 - Conference Paper N1 - Cited By :11 Export Date: 22 March 2021 PY - 2003 SP - 324-328 ST - The perspective of African-American breast cancer survivor-advocates T2 - Cancer TI - The perspective of African-American breast cancer survivor-advocates UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037214961&doi=10.1002%2fcncr.11013&partnerID=40&md5=6b00015813ff25446848016bd418d1fa VL - 97 ID - 2617 ER - TY - JOUR AB - BACKGROUND: Community-academic partnerships play a vital role in ensuring the engagement of African American (AA) men in research. Project Brotherhood (PB) is a community organization that has played an integral role in advancing prostate cancer (PCa) research within two pilot projects supported by the Chicago Cancer Health Equity Collaborative (ChicagoCHEC).Community Perspective: It is rare to see community organizations led by AA men acknowledged for their role in advancing health equity research. We provide a community perspective of PB as a model in engaging AA men in research. PB has been recognized nationally by the Centers for Disease Control and Prevention (CDC) and others demonstrating their national footprint in advancing the inclusion of AA men in all aspects of research. We hope to demonstrate that engagement of AA men in research is important and feasible and to highlight PB as a national model in engaging AA men in research. AU - Murray, M. AU - Campbell, C. AU - Kendall, L. AU - Whitt-Glover, M. C. AU - Watson, K. S. DB - Medline DO - 10.1353/cpr.2019.0047 IS - 5 KW - African American community participation ethnology human Illinois male organization and management participatory research patient selection prostate tumor public relations United States LA - English M3 - Article N1 - L629023172 2019-08-29 2020-09-04 PY - 2019 SN - 1557-055X SP - 137-142 ST - Perspectives from Project Brotherhood: Facilitating Engagement of African American Men in Research T2 - Progress in community health partnerships : research, education, and action TI - Perspectives from Project Brotherhood: Facilitating Engagement of African American Men in Research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629023172&from=export http://dx.doi.org/10.1353/cpr.2019.0047 VL - 13 ID - 867 ER - TY - JOUR AB - Objectives: To assess the novel approach of using the community pharmacist as the primary health care team member to facilitate colorectal cancer (CRC) risk counseling and screening in socioeconomically disadvantaged populations. Setting: A collaborative effort between the UConn Health Colon Cancer Prevention Program and UConn School of Pharmacy in conjunction with large independent chain pharmacies (medium to medium-high volume) located in metropolitan areas of Connecticut, including Hartford, Bridgeport, New Haven, and Stamford. Pharmacies located in hospitals, across the street from a large physician practice, or within the community. Practice description: The study involved 2 phases. The first phase involved education and training for community pharmacists regarding counseling approaches for patients on the topic of CRC. The second phase of the study involved patient recruitment and counseling with subsequent fecal immunohistochemical testing (FIT). Practice innovation: A community pharmacist provided face-to-face counseling on CRC risk factor reduction and provided CRC screening to patients who were without insurance or underinsured. No CRC screening or education program existed beforehand. Evaluation: A target sample size of 60 participants was needed with a type 1 error rate of 5% and a power of 80%. Exploration of variables using multivariate logistic regression model included any variable with a univariate P < 0.2. Multivariate P values < 0.05 were considered independent predictors. Results: After approaching 312 consumers, 16 of them consented to the study. The majority of participants (88%) were African American or Latino, and 69% were currently unemployed. Eight participants agreed to complete FIT, and 88% of participants completed FIT correctly. Only 1 positive FIT result was observed, but a subsequent colonoscopy was negative. Of the 12 questions that assessed baseline CRC knowledge in the initial survey, 16 participants answered an average of 2.6 (range, 0–6, SD, 1.6) questions incorrectly. Only 4 participants completed the follow-up survey of CRC knowledge and program satisfaction; thus, exploration of variables was not conducted. Patients indicated high satisfaction with the program of education and FIT dispensing. Conclusion: This study faced difficulty in recruiting pharmacists to participate, with the main reason being lack of compensation and disruption to workflow. Patient participation in the trial was also low because of a lack of time or interest in participation. Of the patients who did participate, the level of satisfaction in having the pharmacist speak to them about CRC screening was high. This service is an excellent example of how the pharmacist can provide a more accessible, convenient, and responsive approach to patients’ needs while improving health equity. Future studies that employ a revenue model to build the infrastructure and capacity necessary to offer this service efficiently and consistently are needed. AD - L.M. Holle, School of Pharmacy, University of Connecticut, 69 North Eagleville Rd, U-3092, Storrs, CT, United States AU - Holle, L. M. AU - Levine, J. AU - Buckley, T. AU - White, C. M. AU - White, C. AU - Hadfield, M. J. DB - Embase Medline DO - 10.1016/j.japh.2020.02.014 IS - 4 KW - adult African American article cancer screening colonoscopy colorectal cancer community pharmacist consumer education program face to face support group female follow up health insurance health survey Hispanic human major clinical study male middle aged occult blood patient counseling patient participation patient satisfaction practice guideline primary health care professional knowledge sample size LA - English M3 - Article N1 - L2005259015 2020-03-24 PY - 2020 SN - 1544-3450 1544-3191 SP - e109-e116 ST - Pharmacist intervention in colorectal cancer screening initiative T2 - Journal of the American Pharmacists Association TI - Pharmacist intervention in colorectal cancer screening initiative UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005259015&from=export http://dx.doi.org/10.1016/j.japh.2020.02.014 VL - 60 ID - 799 ER - TY - JOUR AB - Objectives: To assess the novel approach of using the community pharmacist as the primary health care team member to facilitate colorectal cancer (CRC) risk counseling and screening in socioeconomically disadvantaged populations.Setting: A collaborative effort between the UConn Health Colon Cancer Prevention Program and UConn School of Pharmacy in conjunction with large independent chain pharmacies (medium to medium-high volume) located in metropolitan areas of Connecticut, including Hartford, Bridgeport, New Haven, and Stamford. Pharmacies located in hospitals, across the street from a large physician practice, or within the community.Practice Description: The study involved 2 phases. The first phase involved education and training for community pharmacists regarding counseling approaches for patients on the topic of CRC. The second phase of the study involved patient recruitment and counseling with subsequent fecal immunohistochemical testing (FIT).Practice Innovation: A community pharmacist provided face-to-face counseling on CRC risk factor reduction and provided CRC screening to patients who were without insurance or underinsured. No CRC screening or education program existed beforehand.Evaluation: A target sample size of 60 participants was needed with a type 1 error rate of 5% and a power of 80%. Exploration of variables using multivariate logistic regression model included any variable with a univariate P < 0.2. Multivariate P values < 0.05 were considered independent predictors.Results: After approaching 312 consumers, 16 of them consented to the study. The majority of participants (88%) were African American or Latino, and 69% were currently unemployed. Eight participants agreed to complete FIT, and 88% of participants completed FIT correctly. Only 1 positive FIT result was observed, but a subsequent colonoscopy was negative. Of the 12 questions that assessed baseline CRC knowledge in the initial survey, 16 participants answered an average of 2.6 (range, 0-6, SD, 1.6) questions incorrectly. Only 4 participants completed the follow-up survey of CRC knowledge and program satisfaction; thus, exploration of variables was not conducted. Patients indicated high satisfaction with the program of education and FIT dispensing.Conclusion: This study faced difficulty in recruiting pharmacists to participate, with the main reason being lack of compensation and disruption to workflow. Patient participation in the trial was also low because of a lack of time or interest in participation. Of the patients who did participate, the level of satisfaction in having the pharmacist speak to them about CRC screening was high. This service is an excellent example of how the pharmacist can provide a more accessible, convenient, and responsive approach to patients' needs while improving health equity. Future studies that employ a revenue model to build the infrastructure and capacity necessary to offer this service efficiently and consistently are needed. AN - 144728692. Language: English. Entry Date: In Process. Revision Date: 20210311. Publication Type: journal article AU - Holle, Lisa M. AU - Levine, Joel AU - Buckley, Thomas AU - White, C. Michael AU - White, Cedric AU - Hadfield, Matthew J. DB - CINAHL Complete DO - 10.1016/j.japh.2020.02.014 DP - EBSCOhost IS - 4 N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 101176252. PMID: NLM32197754. PY - 2020 SN - 1544-3191 SP - e109-e116 ST - Pharmacist intervention in colorectal cancer screening initiative T2 - Journal of the American Pharmacists Association: JAPhA TI - Pharmacist intervention in colorectal cancer screening initiative UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=144728692&site=ehost-live&scope=site VL - 60 ID - 2019 ER - TY - JOUR AB - Objectives: To assess the novel approach of using the community pharmacist as the primary health care team member to facilitate colorectal cancer (CRC) risk counseling and screening in socioeconomically disadvantaged populations. Setting: A collaborative effort between the UConn Health Colon Cancer Prevention Program and UConn School of Pharmacy in conjunction with large independent chain pharmacies (medium to medium-high volume) located in metropolitan areas of Connecticut, including Hartford, Bridgeport, New Haven, and Stamford. Pharmacies located in hospitals, across the street from a large physician practice, or within the community. Practice description: The study involved 2 phases. The first phase involved education and training for community pharmacists regarding counseling approaches for patients on the topic of CRC. The second phase of the study involved patient recruitment and counseling with subsequent fecal immunohistochemical testing (FIT). Practice innovation: A community pharmacist provided face-to-face counseling on CRC risk factor reduction and provided CRC screening to patients who were without insurance or underinsured. No CRC screening or education program existed beforehand. Evaluation: A target sample size of 60 participants was needed with a type 1 error rate of 5% and a power of 80%. Exploration of variables using multivariate logistic regression model included any variable with a univariate P < 0.2. Multivariate P values < 0.05 were considered independent predictors. Results: After approaching 312 consumers, 16 of them consented to the study. The majority of participants (88%) were African American or Latino, and 69% were currently unemployed. Eight participants agreed to complete FIT, and 88% of participants completed FIT correctly. Only 1 positive FIT result was observed, but a subsequent colonoscopy was negative. Of the 12 questions that assessed baseline CRC knowledge in the initial survey, 16 participants answered an average of 2.6 (range, 0–6, SD, 1.6) questions incorrectly. Only 4 participants completed the follow-up survey of CRC knowledge and program satisfaction; thus, exploration of variables was not conducted. Patients indicated high satisfaction with the program of education and FIT dispensing. Conclusion: This study faced difficulty in recruiting pharmacists to participate, with the main reason being lack of compensation and disruption to workflow. Patient participation in the trial was also low because of a lack of time or interest in participation. Of the patients who did participate, the level of satisfaction in having the pharmacist speak to them about CRC screening was high. This service is an excellent example of how the pharmacist can provide a more accessible, convenient, and responsive approach to patients’ needs while improving health equity. Future studies that employ a revenue model to build the infrastructure and capacity necessary to offer this service efficiently and consistently are needed. © 2020 American Pharmacists Association® AU - Holle, L. M. AU - Levine, J. AU - Buckley, T. AU - White, C. M. AU - White, C. AU - Hadfield, M. J. DB - Scopus DO - 10.1016/j.japh.2020.02.014 IS - 4 M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2020 SP - e109-e116 ST - Pharmacist intervention in colorectal cancer screening initiative T2 - Journal of the American Pharmacists Association TI - Pharmacist intervention in colorectal cancer screening initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081901122&doi=10.1016%2fj.japh.2020.02.014&partnerID=40&md5=a1ff2a28c5fdc6985b18730e6d6872a5 VL - 60 ID - 2191 ER - TY - JOUR AB - Objectives: To assess the novel approach of using the community pharmacist as the primary health care team member to facilitate colorectal cancer (CRC) risk counseling and screening in socioeconomically disadvantaged populations. Setting: A collaborative effort between the UConn Health Colon Cancer Prevention Program and UConn School of Pharmacy in conjunction with large independent chain pharmacies (medium to medium-high volume) located in metropolitan areas of Connecticut, including Hartford, Bridgeport, New Haven, and Stamford. Pharmacies located in hospitals, across the street from a large physician practice, or within the community. Practice description: The study involved 2 phases. The first phase involved education and training for community pharmacists regarding counseling approaches for patients on the topic of CRC. The second phase of the study involved patient recruitment and counseling with subsequent fecal immunohistochemical testing (FIT). Practice innovation: A community pharmacist provided face-to-face counseling on CRC risk factor reduction and provided CRC screening to patients who were without insurance or underinsured. No CRC screening or education program existed beforehand. Evaluation: A target sample size of 60 participants was needed with a type 1 error rate of 5% and a power of 80%. Exploration of variables using multivariate logistic regression model included any variable with a univariate P < 0.2. Multivariate P values < 0.05 were considered independent predictors. Results: After approaching 312 consumers, 16 of them consented to the study. The majority of participants (88%) were African American or Latino, and 69% were currently unemployed. Eight participants agreed to complete FIT, and 88% of participants completed FIT correctly. Only 1 positive FIT result was observed, but a subsequent colonoscopy was negative. Of the 12 questions that assessed baseline CRC knowledge in the initial survey, 16 participants answered an average of 2.6 (range, 0-6, SD, 1.6) questions incorrectly. Only 4 participants completed the follow-up survey of CRC knowledge and program satisfaction; thus, exploration of variables was not conducted. Patients indicated high satisfaction with the program of education and FIT dispensing. Conclusion: This study faced difficulty in recruiting pharmacists to participate, with the main reason being lack of compensation and disruption to workflow. Patient participation in the trial was also low because of a lack of time or interest in participation. Of the patients who did participate, the level of satisfaction in having the pharmacist speak to them about CRC screening was high. This service is an excellent example of how the pharmacist can provide a more accessible, convenient, and responsive approach to patients' needs while improving health equity. Future studies that employ a revenue model to build the infrastructure and capacity necessary to offer this service efficiently and consistently are needed. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved. AN - WOS:000553906300017 AU - Holle, L. M. AU - Levine, J. AU - Buckley, T. AU - White, C. M. AU - White, C. AU - Hadfield, M. J. DA - Jul-Aug DO - 10.1016/j.japh.2020.02.014 IS - 4 N1 - 32197754 PY - 2020 SN - 1544-3191 SP - E109-E116 ST - Pharmacist intervention in colorectal cancer screening initiative T2 - Journal of the American Pharmacists Association TI - Pharmacist intervention in colorectal cancer screening initiative VL - 60 ID - 2774 ER - TY - JOUR AB - Objectives: Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. Materials and methods: The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75mg/m2 on day 1) and E (100mg/m2 on days 1-3) in a 21-day cycle. The starting dose of V was 60mg (bid days 1-7) with plan to escalate to 100mg (days 1-7) or de-escalate to 40mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naïve, extensive stage SCLC were included. Results: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60. mg (DLT in 0 of 3 patients) and 100. mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100. mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. Conclusions: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLC patients. AD - T.K. Owonikoko, Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, 3rd Floor, 1365C Clifton Road, NE, Atlanta, GA, United States AU - Owonikoko, T. K. AU - Dahlberg, S. E. AU - Khan, S. A. AU - Gerber, D. E. AU - Dowell, J. AU - Moss, R. A. AU - Belani, C. P. AU - Hann, C. L. AU - Aggarwal, C. AU - Ramalingam, S. S. DB - Embase Medline DO - 10.1016/j.lungcan.2015.04.015 IS - 1 KW - NCT01642251 cisplatin etoposide veliparib adult African American aged alopecia anemia article cancer combination chemotherapy cancer patient cancer research cancer staging cancer survival chemotherapy induced emesis chill clinical article constipation dehydration depression diarrhea drug dose escalation drug efficacy drug fever drug induced headache drug safety drug tolerability dysgeusia European American fatigue febrile neutropenia female flushing follow up heart failure human hyperpigmentation hypokalemia hyponatremia infusion related reaction leukopenia lymphocytopenia male medical assessment mucosa inflammation multicenter study multiple cycle treatment nausea neutropenia optimal drug dose oral mucositis outcome assessment overall survival peripheral neuropathy phase 1 clinical trial phase 2 clinical trial priority journal recommended drug dose respiratory failure side effect small cell lung cancer sore throat thrombocytopenia tinnitus treatment response LA - English M3 - Article N1 - L604393042 2015-05-20 2015-06-26 PY - 2015 SN - 1872-8332 0169-5002 SP - 66-70 ST - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) T2 - Lung Cancer TI - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604393042&from=export http://dx.doi.org/10.1016/j.lungcan.2015.04.015 VL - 89 ID - 1014 ER - TY - JOUR AB - Objectives: Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. Materials and methods: The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75mg/m2 on day 1) and E (100mg/m2 on days 1-3) in a 21-day cycle. The starting dose of V was 60mg (bid days 1-7) with plan to escalate to 100mg (days 1-7) or de-escalate to 40mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naïve, extensive stage SCLC were included. Results: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60. mg (DLT in 0 of 3 patients) and 100. mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100. mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. Conclusions: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLC patients. © 2015 Elsevier Ireland Ltd. AD - The Winship Cancer Institute of Emory University, Atlanta, GA, United States Dana-Farber Cancer Institute, Boston, MA, United States University of Texas Southwestern Medical Center, Dallas, TX, United States Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08903-2681, United States Penn State Hershey Cancer Institute, Hershey, PA, United States The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, United States AU - Owonikoko, T. K. AU - Dahlberg, S. E. AU - Khan, S. A. AU - Gerber, D. E. AU - Dowell, J. AU - Moss, R. A. AU - Belani, C. P. AU - Hann, C. L. AU - Aggarwal, C. AU - Ramalingam, S. S. DB - Scopus DO - 10.1016/j.lungcan.2015.04.015 IS - 1 KW - PARP Phase I Small cell Veliparib M3 - Article N1 - Cited By :39 Export Date: 22 March 2021 PY - 2015 SP - 66-70 ST - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) T2 - Lung Cancer TI - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84931578364&doi=10.1016%2fj.lungcan.2015.04.015&partnerID=40&md5=b36161d25575c810c41e4255dea1168f VL - 89 ID - 2375 ER - TY - JOUR AB - Objectives: Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. Materials and methods: The study employed the 3 +3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75 mg/m(2) on day 1) and E (100 mg/m(2) on days 1-3) in a 21-day cycle. The starting dose of V was 60 mg (bid days 1-7) with plan to escalate to 100 mg (days 1-7) or de-escalate to 40 mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naive, extensive stage SCLC were included. Results: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60 mg (DLT in 0 of 3 patients) and 100 mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100 mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. Conclusions: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLC patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved. AN - WOS:000356546300013 AU - Owonikoko, T. K. AU - Dahlberg, S. E. AU - Khan, S. A. AU - Gerber, D. E. AU - Dowell, J. AU - Moss, R. A. AU - Belani, C. P. AU - Hann, C. L. AU - Aggarwal, C. AU - Ramalingam, S. S. DA - Jul DO - 10.1016/j.lungcan.2015.04.015 IS - 1 N1 - 25985977 PY - 2015 SN - 0169-5002 SP - 66-70 ST - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) T2 - Lung Cancer TI - A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511) VL - 89 ID - 2972 ER - TY - JOUR AB - Purpose: Concurrent inhibition of mTOR and PI3K led to improved efficacy in preclinical models and provided the rationale for this phase I study of everolimus and buparlisib (BKM120) in patients with advanced solid tumor. Patients and Methods: We used the Bayesian Escalation with Overdose Control design to test escalating doses of everolimus (5 or 10 mg) and buparlisib (20, 40, 60, 80, and 100 mg) in eligible patients. Pharmacokinetic assessment was conducted using blood samples collected on cycle 1, days 8 and 15. Pharmacodynamic impact on mTOR/PI3K pathway modulation evaluated in paired skin biopsies collected at baseline and end of cycle 1. Results: We enrolled 43 patients, median age of 63 (range, 39–78) years; 25 (58.1%) females, 35 (81.4%) Caucasians, and 8 (18.6%) Blacks. The most frequent toxicities were hyperglycemia, diarrhea, nausea, fatigue, and aspartate aminotransferase elevation. Dose-limiting toxicities observed in 7 patients were fatigue (3), hyperglycemia (2), mucositis (1), acute kidney injury (1), and urinary tract infection (1). The recommended phase II dose (RP2D) for the combination was established as everolimus (5 mg) and buparlisib (60 mg). The best response in 27 evaluable patients was progressive disease and stable disease in 3 (11%) and 24 (89%), respectively. The median progression-free survival and overall survival were 2.7 (1.8–4.2) and 9 (6.4–13.2) months. Steady-state pharmacokinetic analysis showed dose-normalized maximum concentrations and AUC values for everolimus and buparlisib in combination to be comparable with single-agent pharmacokinetic. Conclusions: The combination of everolimus and buparlisib is safe and well-tolerated at the RP2D of 5 and 60 mg on a continuous daily schedule. © 2020 American Association for Cancer Research. AD - Department of Hematology & Medical Oncology, Emory University, Atlanta, GA, United States Winship Cancer Institute of Emory University, Atlanta, GA, United States Department of Statistics, Rollins School of Public Health, Emory University, Atlanta, GA, United States Department of Pathology, Emory University, Atlanta, GA, United States American University of Beirut, Beirut, Lebanon AU - Owonikoko, T. K. AU - Harvey, R. D. AU - Carthon, B. AU - Chen, Z. AU - Lewis, C. AU - Collins, H. AU - Zhang, C. AU - Lawson, D. H. AU - Alese, O. B. AU - Bilen, M. A. AU - Sica, G. L. AU - Steuer, C. E. AU - Shaib, W. L. AU - Wu, C. AU - Harris, W. B. AU - Akce, M. AU - Kudchagkar, R. R. AU - El-Rayes, B. F. AU - Lonial, S. AU - Ramalingam, S. S. AU - Khuri, F. R. DB - Scopus DO - 10.1158/1078-0432.CCR-19-2697 IS - 11 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2020 SP - 2497-2505 ST - A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors T2 - Clinical Cancer Research TI - A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085712760&doi=10.1158%2f1078-0432.CCR-19-2697&partnerID=40&md5=3bc14907c3e7a6902d052c9932244dea VL - 26 ID - 2192 ER - TY - JOUR AB - Taxanes and anthracyclines have been among the best-studied chemotherapy classes in castration-resistant prostate cancer (CRPC). Docetaxel (D) 75 mg/m2 every 3 weeks has been the standard first line chemotherapy for CRPC. Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (PLD) was developed to enhance the safety and efficacy of conventional doxorubicin. We hypothesize that the combination of weekly low dose-D and PLD would result in a high response rate and low toxicity. Eligibility criteria included metastatic progressive CRPC, no prior D or PLD and good organ function. After a short phase I with no dose-limiting toxicity, D 30 mg/m2 was administered on days 1, 8 and 15; and PLD 30 mg/m2 on day 1 only, every 28 days. Thirty-seven patients were enrolled. The PSA response rate was 53%. Twenty-two subjects had measurable disease; one (5%) achieved complete response, five (23%) partial response, and twelve (54%) stable disease. Twenty-seven patients (73%) manifested pain relief. The median time to progression was 3.7 months for all patients and 7.9 months for responders. Median overall survival was 16.3 months. Grade 4 neutropenia without infection and anemia occurred in 1 patient each. Grade 3 treatment-related toxicities included: 15% fatigue; 9% neutropenia, anemia and nausea; 6% dehydration and hand-foot syndrome; and 3% infection, febrile neutropenia, thrombosis, stomatitis, headache, vomiting, weight loss and weakness. In this non-comparative study D-PLD demonstrated a higher activity than previously reported with single agent D with favorable side effect profile. A phase 3 study would be needed to evaluate the true benefit of this combination. ClinicalTrials.gov Identifier: NCT00456989. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. AD - Section of Satellite Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States Division of Hematology/Oncology, Department of Medicine, Morsani School of Medicine, University of South Florida, Tampa, FL, United States Department of Oncologic Sciences, Morsani School of Medicine, University of South Florida, Tampa, FL, United States AU - Laber, D. A. AU - Eatrides, J. AU - Jaglal, M. V. AU - Haider, M. AU - Visweshwar, N. AU - Patel, A. C7 - 95 DB - Scopus DO - 10.1007/s12032-020-01420-7 IS - 10 KW - Castration-resistant prostate cancer Docetaxel Doxorubicin Phase 2 clinical trial Polyethylene glycol-coated liposome M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 ST - A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer T2 - Medical Oncology TI - A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091523216&doi=10.1007%2fs12032-020-01420-7&partnerID=40&md5=b61c1727fe395b9af13468ff56a4d7db VL - 37 ID - 2182 ER - TY - JOUR AB - BACKGROUND: Tasquinimod is an immunomodulating and anti‐antiangiogenic oral agent with anti‐prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m2 every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0.25, 0.5, and 1.0 mg once daily) with prednisone and PEG‐filgastrim support, using a 3 + 3 dose escalation design. Treatment continued until progressive disease or unacceptable toxicity. RESULTS: We enrolled 25 men with chemorefractory mCRPC. The RP2D was 0.5 mg tasquinimod based on excess DLTs (two of three men) observed at dose level 3 (1.0 mg) including grade 3 sensory neuropathy and grade 3 atrial fibrillation. Dose level 2 was expanded to 14 men, where 3 DLTs were observed: grade 3 fatigue, grade 4 febrile neutropenia, and grade 3 liver function abnormalities. The proportion of men with a >30% PSA decline was 63% and the median composite progression‐free survival (PFS) was 8.5 months (95% CI 4.2‐16.4 months) based on 12 PFS events. The median number of cycles of cabazitaxel was 6 (range 1‐13), with six men receiving >10 cycles. Best overall RECIST responses (CR + PR) were observed in three men (12%), with stable disease in 12 (48%). No pharmacokinetic interactions were observed. CONCLUSIONS: We determined the RP2D of tasquinimod combined with cabazitaxel to be 0.5 mg daily following a 3 week lead‐in of tasquinimod 0.25 mg with growth factor support. No unexpected toxicities occurred. Prostate 77: 385‐395, 2017. © 2016 Wiley Periodicals, Inc. Copyright © 2016 Wiley Periodicals, Inc. AN - CN-01328343 AU - Armstrong, A. J. AU - Humeniuk, M. S. AU - Healy, P. AU - Szmulewitz, R. AU - Winters, C. AU - Kephart, J. AU - Harrison, M. R. AU - Martinez, E. AU - Mundy, K. AU - Halabi, S. AU - et al. DO - 10.1002/pros.23277 IS - 4 KW - *angiogenesis *cabazitaxel *cabazitaxel/ae [Adverse Drug Reaction] *cabazitaxel/cb [Drug Combination] *cabazitaxel/ct [Clinical Trial] *cabazitaxel/dt [Drug Therapy] *cabazitaxel/pk [Pharmacokinetics] *castration resistant prostate cancer *castration resistant prostate cancer/dt [Drug Therapy] *controlled study *febrile neutropenia *immunotherapy *metastasis potential *tasquinimod *tasquinimod/ae [Adverse Drug Reaction] *tasquinimod/cb [Drug Combination] *tasquinimod/ct [Clinical Trial] *tasquinimod/do [Drug Dose] *tasquinimod/dt [Drug Therapy] *tasquinimod/pk [Pharmacokinetics] *tasquinimod/po [Oral Drug Administration] Abdominal pain/si [Side Effect] Abiraterone acetate/dt [Drug Therapy] Adult African American Aged Alopecia/si [Side Effect] Anemia/si [Side Effect] Anorexia/si [Side Effect] Antineoplastic activity Area under the curve Article Atrial fibrillation Atrial fibrillation/si [Side Effect] Bleeding/si [Side Effect] Bone metastasis/co [Complication] Cancer immunotherapy Cancer pain/co [Complication] Cancer pain/dt [Drug Therapy] Cancer survival Castration resistant prostate cancer/dt [Drug Therapy] Caucasian Circulating tumor cell Clinical article Clinical trial Colon perforation/si [Side Effect] Congenital malformation Constipation/si [Side Effect] Controlled clinical trial Controlled study Diarrhea/si [Side Effect] Dizziness/si [Side Effect] Docetaxel Docetaxel/dt [Drug Therapy] Drug clearance Drug combination Drug dose escalation Drug response Drug safety Drug therapy Drug tolerability Drug treatment failure Dysgeusia/si [Side Effect] Dyspepsia/si [Side Effect] Electrolyte disturbance/si [Side Effect] Endogenous compound Enzalutamide/dt [Drug Therapy] Fatigue Fatigue/si [Side Effect] Febrile neutropenia/dt [Drug Therapy] Febrile neutropenia/si [Side Effect] Gastritis/si [Side Effect] Growth factor Headache/si [Side Effect] Human Hypertransaminasemia/si [Side Effect] Hypotension/si [Side Effect] Insomnia/si [Side Effect] Karnofsky Performance Status Leg swelling/si [Side Effect] Liver dysfunction/si [Side Effect] Liver function Liver metastasis/co [Complication] Lung metastasis/co [Complication] Lymph node metastasis/co [Complication] Male Maximum tolerated dose Multiple cycle treatment Musculoskeletal pain/si [Side Effect] Nausea/si [Side Effect] Opiate/dt [Drug Therapy] Oral mucositis/si [Side Effect] Overall survival Pain/si [Side Effect] Participant observation Pegfilgrastim/dt [Drug Therapy] Peripheral edema/si [Side Effect] Pharmacokinetics Phase 1 clinical trial Phase 2 clinical trial Prednisone Prednisone/dt [Drug Therapy] Prednisone/po [Oral Drug Administration] Progression free survival Prostate adenocarcinoma Prostate specific antigen/ec [Endogenous Compound] Rash/si [Side Effect] Recommended drug dose Response evaluation criteria in solid tumors Sensory neuropathy Sensory neuropathy/si [Side Effect] Sepsis/si [Side Effect] Stomach ulcer/si [Side Effect] Taste disorder/si [Side Effect] Thrombocytopenia/si [Side Effect] Toxicity Treatment failure Urinary tract infection/si [Side Effect] Visceral metastasis/co [Complication] Volume of distribution Vomiting/si [Side Effect] M3 - Journal: Article PY - 2017 SP - 385‐395 ST - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): the CATCH Trial T2 - Prostate TI - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): the CATCH Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01328343/full VL - 77 ID - 1600 ER - TY - JOUR AB - BACKGROUND: Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC. METHODS: Men with mCRPC who had failed prior docetaxel chemotherapy received cabazitaxel 25 mg/m2 every 3 weeks with oral tasquinimod at 1 of 3 escalating dose levels (0.25, 0.5, and 1.0 mg once daily) with prednisone and PEG-filgastrim support, using a 3 + 3 dose escalation design. Treatment continued until progressive disease or unacceptable toxicity. RESULTS: We enrolled 25 men with chemorefractory mCRPC. The RP2D was 0.5 mg tasquinimod based on excess DLTs (two of three men) observed at dose level 3 (1.0 mg) including grade 3 sensory neuropathy and grade 3 atrial fibrillation. Dose level 2 was expanded to 14 men, where 3 DLTs were observed: grade 3 fatigue, grade 4 febrile neutropenia, and grade 3 liver function abnormalities. The proportion of men with a ≥30% PSA decline was 63% and the median composite progression-free survival (PFS) was 8.5 months (95% CI 4.2–16.4 months) based on 12 PFS events. The median number of cycles of cabazitaxel was 6 (range 1–13), with six men receiving >10 cycles. Best overall RECIST responses (CR + PR) were observed in three men (12%), with stable disease in 12 (48%). No pharmacokinetic interactions were observed. CONCLUSIONS: We determined the RP2D of tasquinimod combined with cabazitaxel to be 0.5 mg daily following a 3 week lead-in of tasquinimod 0.25 mg with growth factor support. No unexpected toxicities occurred. Prostate 77: 385–395, 2017. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc. AD - Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery, Duke Cancer Institute, Durham, NC, United States Department of Biostatistics, Duke University, Durham, NC, United States Department of Medicine, University of Chicago, Chicago, IL, United States AU - Armstrong, A. J. AU - Humeniuk, M. S. AU - Healy, P. AU - Szmulewitz, R. AU - Winters, C. AU - Kephart, J. AU - Harrison, M. R. AU - Martinez, E. AU - Mundy, K. AU - Halabi, S. AU - George, D. DB - Scopus DO - 10.1002/pros.23277 IS - 4 KW - angiogenesis cabazitaxel chemotherapy clinical trial immunotherapy mCRPC phase I prostate cancer tasquinimod M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2017 SP - 385-395 ST - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial T2 - Prostate TI - Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006070822&doi=10.1002%2fpros.23277&partnerID=40&md5=b1aaa69f400b51183a8b1e2eb933691f VL - 77 ID - 2318 ER - TY - JOUR AB - Background: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC. Patients and methods: A Phase II clinical trial included chemonaïve patients with advanced NSCLC and poor performance status (PS). Response rate, progression-free survival, overall survival, QOL using the Functional Assessment of Cancer Therapy – Lung (FACT-L) questionnaire, and Trial Outcome Index (TOI) were evaluated. Results: Twelve out of 19 enrolled patients were evaluable. The median age for the evaluable patients was 68.8 years (59.7–74.6). Out of all the patients, 7 (58.3%) had adenocarcinoma and 5 (41.7%) had squamous cell carcinoma. The median duration of treatment was 62.5 days (26.5–115.0) in the evaluable patients. Grade 3/4 toxicities included fatigue, rash, diarrhea, and nausea. One patient had partial response, eight patients had stable disease (SD), and three patients progressed. The median overall survival for the evaluable population was 4.9 months (2.3–16). The median progression-free survival was 3.7 months (1.9–6.6). TOI was marginally associated with the overall survival, with a hazard ratio of 0.92 (95% confidence interval: 0.84, 1.0) (P = 0.061). FACT-L score and the TOI were highly correlated (r = 0.96, P < 0.0001). TOI scores were higher in African Americans compared to Caucasians and increased with age. Conclusion: Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients. AD - A.R. Jazieh, King Saud bin Abdul-Aziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia AU - Karim, N. A. AU - Musaad, S. AU - Zarzour, A. AU - Patil, S. AU - Jazieh, A. R. DB - Embase DO - 10.4137/CMO.S15172 KW - gefitinib adenocarcinoma advanced cancer African American aged anemia article cancer survival Caucasian clinical article controlled study diarrhea drug efficacy drug response drug safety fatigue female fever human male multiple cycle treatment nausea nephrotoxicity non small cell lung cancer overall survival pain phase 2 clinical trial progression free survival quality of life rash scoring system squamous cell carcinoma survival rate thrush treatment duration LA - English M3 - Article N1 - L600544136 2014-12-05 2014-12-08 PY - 2014 SN - 1179-5549 SP - 121-128 ST - Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status T2 - Clinical Medicine Insights: Oncology TI - Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600544136&from=export http://dx.doi.org/10.4137/CMO.S15172 VL - 8 ID - 1025 ER - TY - JOUR AB - Background: Patients with advanced non-small cell lung cancer (NSCLC) have no curative treatment options; therefore, improving their quality of life (QOL) is an important goal. Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, is a safe oral agent that may be of benefit to a specific population of NSCLC. Patients and methods: A Phase II clinical trial included chemonaïve patients with advanced NSCLC and poor performance status (PS). Response rate, progression-free survival, overall survival, QOL using the Functional Assessment of Cancer Therapy – Lung (FACT-L) questionnaire, and Trial Outcome Index (TOI) were evaluated. Results: Twelve out of 19 enrolled patients were evaluable. The median age for the evaluable patients was 68.8 years (59.7–74.6). Out of all the patients, 7 (58.3%) had adenocarcinoma and 5 (41.7%) had squamous cell carcinoma. The median duration of treatment was 62.5 days (26.5–115.0) in the evaluable patients. Grade 3/4 toxicities included fatigue, rash, diarrhea, and nausea. One patient had partial response, eight patients had stable disease (SD), and three patients progressed. The median overall survival for the evaluable population was 4.9 months (2.3–16). The median progression-free survival was 3.7 months (1.9–6.6). TOI was marginally associated with the overall survival, with a hazard ratio of 0.92 (95% confidence interval: 0.84, 1.0) (P = 0.061). FACT-L score and the TOI were highly correlated (r = 0.96, P < 0.0001). TOI scores were higher in African Americans compared to Caucasians and increased with age. Conclusion: Our results suggest that gefitinib use in patients with NSCLC and poor PS may improve the QOL of older patients and African American patients. © the authors, publisher and licensee Libertas Academica Limited. AD - University of Cincinnati, Cincinnati, OH, United States University of Illinois at Urbana, Champaign, IL, United States Cleveland Clinic Foundation, Cleveland, OH, United States University of Tennessee Cancer Institute, Memphis, TN, United States King Saud bin Abdul-Aziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia AU - Karim, N. A. AU - Musaad, S. AU - Zarzour, A. AU - Patil, S. AU - Jazieh, A. R. DB - Scopus DO - 10.4137/CMO.S15172 KW - Advanced non-small cell lung cancer Gefitinib Poor performance status Quality of life M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2014 SP - 121-128 ST - Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status T2 - Clinical Medicine Insights: Oncology TI - Phase II clinical trial of gefitinib for the treatment of chemonaïve patients with advanced non-small cell lung cancer with poor performance status UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84912068696&doi=10.4137%2fCMO.S15172&partnerID=40&md5=c4d591f181164353ff325cd0b5755f01 VL - 8 ID - 2384 ER - TY - JOUR AB - Purpose: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. Methods: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. Results: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. Conclusions: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC. AD - J.A. Lawrence, Wake Forest University Baptist Medical Center, Winston-Salem, NC, United States AU - Cowherd, S. AU - Miller, L. D. AU - Melin, S. A. AU - Akman, S. AU - Isom, S. AU - Cole, J. AU - Pullikuth, A. AU - Lawrence, J. A. DB - Embase Medline DO - 10.1080/15384047.2015.1026481 IS - 5 KW - carboplatin paclitaxel panitumumab acne adult African American aged area under the curve article metastatic breast cancer cancer combination chemotherapy cancer growth clinical article controlled clinical trial controlled study desquamation diarrhea drug eruption drug safety dry skin female gene expression hand foot syndrome human hypocalcemia hypokalemia hypomagnesemia multiple cycle treatment nail disease neutropenia phase 2 clinical trial pruritus skin toxicity survival time therapy delay thrombocytopenia treatment response triple negative breast cancer visceral metastasis LA - English M3 - Article N1 - L606402368 2015-10-19 2015-10-27 PY - 2015 SN - 1555-8576 1538-4047 SP - 678-683 ST - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer T2 - Cancer Biology and Therapy TI - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L606402368&from=export http://dx.doi.org/10.1080/15384047.2015.1026481 VL - 16 ID - 1017 ER - TY - JOUR AB - Purpose: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. Methods: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. Results: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal‐like subtype. Conclusions: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC. AN - CN-01106255 AU - Cowherd, S. AU - Miller, L. D. AU - Melin, S. A. AU - Akman, S. AU - Isom, S. AU - Cole, J. AU - Pullikuth, A. AU - Lawrence, J. A. DO - 10.1080/15384047.2015.1026481 IS - 5 KW - *breast metastasis/dt [Drug Therapy] *cancer combination chemotherapy *carboplatin/ae [Adverse Drug Reaction] *carboplatin/cb [Drug Combination] *carboplatin/ct [Clinical Trial] *carboplatin/dt [Drug Therapy] *paclitaxel/ae [Adverse Drug Reaction] *paclitaxel/cb [Drug Combination] *paclitaxel/ct [Clinical Trial] *paclitaxel/dt [Drug Therapy] *panitumumab/ae [Adverse Drug Reaction] *panitumumab/cb [Drug Combination] *panitumumab/ct [Clinical Trial] *panitumumab/dt [Drug Therapy] *triple negative breast cancer/dt [Drug Therapy] Acne/si [Side Effect] Adult African American Aged Area under the curve Article Cancer growth Clinical article Controlled clinical trial Controlled study Desquamation/si [Side Effect] Diarrhea/si [Side Effect] Drug eruption/si [Side Effect] Drug safety Dry skin/si [Side Effect] Female Gene expression Hand foot syndrome/si [Side Effect] Human Hypocalcemia/si [Side Effect] Hypokalemia/si [Side Effect] Hypomagnesemia/si [Side Effect] Multiple cycle treatment Nail disease/si [Side Effect] Neutropenia/si [Side Effect] Phase 2 clinical trial Pruritus/si [Side Effect] Skin toxicity/si [Side Effect] Survival time Therapy delay Thrombocytopenia/si [Side Effect] Treatment response Visceral metastasis M3 - Journal: Article PY - 2015 SP - 678‐683 ST - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer T2 - Cancer biology & therapy TI - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01106255/full VL - 16 ID - 1602 ER - TY - JOUR AB - Purpose: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. Methods: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. Results: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. Conclusions: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC. © 2015 Taylor and Francis Group, LLC. AD - Wake Forest University Baptist Medical Center, Winston-Salem, NC, United States Ochsner Medical Center, New Orleans, LA, United States AU - Cowherd, S. AU - Miller, L. D. AU - Melin, S. A. AU - Akman, S. AU - Isom, S. AU - Cole, J. AU - Pullikuth, A. AU - Lawrence, J. A. DB - Scopus DO - 10.1080/15384047.2015.1026481 IS - 5 KW - Epidermal growth factor inhibitor Metastatic breast cancer Pacliataxel carboplatin Triple negative breast cancer M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2015 SP - 678-683 ST - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer T2 - Cancer Biology and Therapy TI - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943762557&doi=10.1080%2f15384047.2015.1026481&partnerID=40&md5=130f8789c755c9d09263a92b08f12cc1 VL - 16 ID - 2374 ER - TY - JOUR AB - Purpose: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. Methods: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6mg/kg on days 1 and 15 for a cycle length of 28days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. Results: Fourteen patients with TNBC were enrolled with a median age of 53years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. Conclusions: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC. AN - WOS:000354981300006 AU - Cowherd, S. AU - Miller, L. D. AU - Melin, S. A. AU - Akman, S. AU - Isom, S. AU - Cole, J. AU - Pullikuth, A. AU - Lawrence, J. A. DA - May DO - 10.1080/15384047.2015.1026481 IS - 5 N1 - 25928118 PY - 2015 SN - 1538-4047 SP - 678-683 ST - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer T2 - Cancer Biology & Therapy TI - A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer VL - 16 ID - 2979 ER - TY - JOUR AB - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy. AD - T.-Y. Chao, Division of Hematology and Oncology, Department of Medicine, Taipei Medical University, Shuang‑Ho Hospital, 291 Zhongzheng Road, Zhonghe, New Taipei, Taiwan AU - Wu, Y. Y. AU - Liu, H. Y. AU - Huang, T. C. AU - Chen, J. H. AU - Chang, P. Y. AU - Ho, C. L. AU - Chao, T. Y. DB - Embase DO - 10.3892/ol.2015.3492 IS - 3 KW - NCT00555516 cyclophosphamide doxorubicin ew02 fluorouracil granulocyte colony stimulating factor receptor interleukin 6 placebo soybean extract unclassified drug adult anorexia article asthenia breast cancer cancer adjuvant therapy cardiovascular disease crossover procedure double blind procedure drug efficacy drug safety drug tolerability febrile neutropenia follow up gastrointestinal symptom human insomnia leukocyte count leukopenia major clinical study middle aged myelopoiesis nausea and vomiting neutropenia neutrophil count phase 2 clinical trial pilot study quality of life randomized controlled trial skin disease LA - English M3 - Article N1 - L605303686 2015-07-28 2015-08-03 PY - 2015 SN - 1792-1082 1792-1074 SP - 1793-1798 ST - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer T2 - Oncology Letters TI - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L605303686&from=export http://dx.doi.org/10.3892/ol.2015.3492 VL - 10 ID - 1016 ER - TY - JOUR AB - EW02, a polysaccharide‐enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‐treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‐blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‐points for determining the blood cell count, and the serum level of granulocyte colony‐stimulating factor (G‐CSF) and interleukin (IL)‐6. All patients tolerated EW02 well without severe side‐effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‐C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‐6 and G‐CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy. AN - CN-01085223 AU - Wu, Y. Y. AU - Liu, H. Y. AU - Huang, T. C. AU - Chen, J. H. AU - Chang, P. Y. AU - Ho, C. L. AU - Chao, T. Y. DO - 10.3892/ol.2015.3492 IS - 3 KW - *breast cancer/dt [Drug Therapy] *drug efficacy *ew02/ae [Adverse Drug Reaction] *ew02/ct [Clinical Trial] *ew02/dt [Drug Therapy] *ew02/po [Oral Drug Administration] *febrile neutropenia *soybean extract/ae [Adverse Drug Reaction] *soybean extract/ct [Clinical Trial] *soybean extract/dt [Drug Therapy] *soybean extract/po [Oral Drug Administration] Adult Anorexia/si [Side Effect] Article Asthenia/si [Side Effect] Cancer adjuvant therapy Cardiovascular disease/si [Side Effect] Crossover procedure Cyclophosphamide/cb [Drug Combination] Cyclophosphamide/dt [Drug Therapy] Double blind procedure Doxorubicin/cb [Drug Combination] Doxorubicin/dt [Drug Therapy] Drug safety Drug tolerability Fluorouracil/cb [Drug Combination] Fluorouracil/dt [Drug Therapy] Follow up Gastrointestinal symptom/si [Side Effect] Granulocyte colony stimulating factor receptor/ec [Endogenous Compound] Human Insomnia/si [Side Effect] Interleukin 6/ec [Endogenous Compound] Leukocyte count Leukopenia/si [Side Effect] Major clinical study Middle aged Myelopoiesis Nausea and vomiting/si [Side Effect] Neutropenia/si [Side Effect] Neutrophil count Phase 2 clinical trial Pilot study Placebo Quality of life Randomized controlled trial Skin disease/si [Side Effect] Unclassified drug M3 - Journal: Article PY - 2015 SP - 1793‐1798 ST - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer T2 - Oncology letters TI - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01085223/full VL - 10 ID - 1635 ER - TY - JOUR AB - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy‑treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double‑blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time‑points for determining the blood cell count, and the serum level of granulocyte colony‑stimulating factor (G‑CSF) and interleukin (IL)‑6. All patients tolerated EW02 well without severe side‑effects. QOL evaluation showed that only the score of one questionnaire section (QLQ‑C30) was significantly increased at C1 day (D)8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL‑6 and G‑CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy. © 2015, Spandidos Publications. All rights reserved. AD - Division of Hematology and Oncology, Department of Medicine, Tri‑Service General Hospital, China Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, China Institute of Clinical Medicine, Taipei Medical University, China Division of Hematology and Oncology, Department of Medicine, Taipei Medical University, Shuang‑Ho Hospital, New Taipei, Taiwan AU - Wu, Y. Y. AU - Liu, H. Y. AU - Huang, T. C. AU - Chen, J. H. AU - Chang, P. Y. AU - Ho, C. L. AU - Chao, T. Y. DB - Scopus DO - 10.3892/ol.2015.3492 IS - 3 KW - Black soybean Breast cancer Chemotherapy Myelopoiesis M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2015 SP - 1793-1798 ST - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer T2 - Oncology Letters TI - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937437156&doi=10.3892%2fol.2015.3492&partnerID=40&md5=7b40a5748867c5bcdb91be2ca6ba222c VL - 10 ID - 2380 ER - TY - JOUR AB - EW02, a polysaccharide-enriched crude extract from black soybean, has been shown to assist hematopoiesis in chemotherapy-treated animals. The present study aimed to clarify the safety, quality of life (QOL) and efficacy for myelopoiesis of EW02 administration in early breast cancer (EBC) patients receiving adjuvant chemotherapy. A total of 60 eligible EBC patients were enrolled in a randomized, double-blinded trial, 40 of whom were prescribed 700 mg oral EW02 three times daily for 15 days in chemotherapy cycle (C)2. The remainder were prescribed a placebo. All subjects took EW02 in C3 for 15 days. Blood samples were collected at different time-points for determining the blood cell count, and the serum level of granulocyte colony-stimulating factor (G-CSF) and interleukin (IL)-6. All patients tolerated EW02 well without severe side-effects. QOL evaluation showed that only the score of one questionnaire section (QLQ-C30) was significantly increased at C1 day (D) 8 to C2D8 when the EW02 and placebo groups were compared (P=0.045). No significant myelopoiesis recovery, and no incremental change in IL-6 and G-CSF levels were found in C2. Subgroup analysis showed a slightly lower decrease in absolute neutrophil count (ANC) in the EW02 patients who underwent Adriamycin + cyclophosphamide treatment compared with the placebo group. Although EW02 failed to show efficacy for myelopoiesis in the present study, EW02 was still well tolerated in EBC patients who underwent adjuvant chemotherapy. AN - WOS:000360923000098 AU - Wu, Y. Y. AU - Liu, H. Y. AU - Huang, T. C. AU - Chen, J. H. AU - Chang, P. Y. AU - Ho, C. L. AU - Chao, T. Y. DA - Sep DO - 10.3892/ol.2015.3492 IS - 3 N1 - 26622752 PY - 2015 SN - 1792-1074 SP - 1793-1798 ST - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer T2 - Oncology Letters TI - A phase II double-blinded study to evaluate the efficacy of EW02 in reducing chemotherapy-induced neutropenia in breast cancer VL - 10 ID - 2969 ER - TY - JOUR AB - Purpose: A multicenter, open-label, phase II trial was conducted to evaluate the efficacy, safety, and tolerability of selumetinib in iodine-refractory papillary thyroid cancer (IRPTC). Experimental Design: Patients with advanced IRPTC with or without follicular elements and documented disease progression within the preceding 12 months were eligible to receive selumetinib at a dose of 100 mg twice daily. The primary endpoint was objective response rate using Response Evaluation Criteria in Solid Tumors. Secondary endpoints were safety, overall survival, and progression-free survival (PFS). Tumor genotype including mutations in BRAF, NRAS, and HRAS was assessed. Results: Best responses in 32 evaluable patients out of 39 enrolled were 1 partial response (3%), 21 stable disease (54%), and 11 progressive disease (28%). Disease stability maintenance occurred for 16 weeks in 49%, 24 weeks in 36%. Median PFS was 32 weeks. BRAF V600E mutants (12 of 26 evaluated, 46%) had a longer median PFS compared with patients with BRAF wild-type (WT) tumors (33 versus 11 weeks, respectively, HR = 0.6, not significant, P = 0.3). The mostcommonadverse events and grades 3 to 4 toxicities included rash, fatigue, diarrhea, and peripheral edema. Two pulmonary deaths occurred in the study and were judged unlikely to be related to the study drug. Conclusions: Selumetinib was well tolerated but the study was negative with regard to the primary outcome. Secondary analyses suggest that future studies of selumetinib and other mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK; MEK) inhibitors in IRPTC should consider BRAF V600E mutation status in the trial design based on differential trends in outcome. ©2012 AACR. AD - University of North Carolina, Lineberger Comprehensive Cancer Center, School of Medicine, Chapel Hill, NC, United States University of North Carolina, Department of Pathology and Laboratory Medicine, Chapel Hill, NC, United States University of Chicago Medical Center, Chicago, IL, United States Fox Chase Cancer Center, Philadelphia, PA, United States Princess Margaret Hospital, Toronto, ON, Canada Vanderbilt University, Nashville, TN, United States H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States Johns Hopkins University School of Medicine, Baltimore, MD, United States AU - Hayes, D. N. AU - Lucas, A. S. AU - Tanvetyanon, T. AU - Krzyzanowska, M. K. AU - Chung, C. H. AU - Murphy, B. A. AU - Gilbert, J. AU - Mehra, R. AU - Moore, D. T. AU - Sheikh, A. AU - Hoskins, J. AU - Hayward, M. C. AU - Zhao, N. AU - O'Connor, W. AU - Weck, K. E. AU - Cohen, R. B. AU - Cohen, E. E. W. DB - Scopus DO - 10.1158/1078-0432.CCR-11-0563 IS - 7 M3 - Article N1 - Cited By :107 Export Date: 22 March 2021 PY - 2012 SP - 2056-2065 ST - Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements T2 - Clinical Cancer Research TI - Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859410770&doi=10.1158%2f1078-0432.CCR-11-0563&partnerID=40&md5=f87fab06f9be25a099163f47279898f1 VL - 18 ID - 2463 ER - TY - JOUR AB - BACKGROUND: We hypothesized that thalidomide would improve the response and toxicity profile of chemotherapy with carboplatin and irinotecan. METHODS: The key eligibility criteria were stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer, measurable disease, no prior chemotherapy, prior radiation only for brain metastasis, performance status 0 or 1, and adequate hematologic, hepatic, and renal function. Treatment consisted of carboplatin at a calculated area under the curve of 5 and infused intravenously for 30 min on day 1 and irinotecan (50 mg/m intravenously for 90 min on days 1 and 8 every 21 days). Thalidomide was given orally every evening starting on day 1 until progressive disease; the starting dose was 200 mg per day, which was escalated by 100 mg per week if tolerated (maximum 1000 mg per day). The objectives were to determine the response rate, time to progression, overall survival, and toxicity profile. RESULTS: In all, 46 patients were enrolled, but three who never received protocol treatment were excluded from the analysis. The characteristics of the 43 eligible and treated patients included median age 63 (47-79), female/male 13/30, black/white 3/40, PS 0/1 in 10/33, and stage 3/4 in 6/37. The objective response rates were complete response 1 (2%), partial response 5 (12%), stable disease 24 (56%), progressive disease 9 (21%), and unevaluable for response 4 (9%). The median time to progression was 3.7 months (95% confidence interval [CI], 2.5-4.9). The median survival time was 8.1 months (95% CI, 5.0-12.9). Frequent toxicities were neutropenia, fatigue/malaise, and nausea/vomiting. Diarrhea was uncommon and mild. CONCLUSIONS: This treatment regimen of carboplatin, irinotecan, and thalidomide was tolerable, with reversible neutropenia as the major toxicity and only minor diarrhea. The overall response rate did not meet our predetermined level of efficacy to merit further investigation. © 2006International Association for the Study of Lung Cancer. AD - A.A. Miller, Comprehensive Cancer Center, Wake Forest University, Medical Center Blvd., Winston-Salem, NC, United States AU - Miller, A. A. AU - Case, D. AU - Atkins, J. N. AU - Giguere, J. K. AU - Bearden, J. D. DB - Embase Medline DO - 10.1097/01243894-200610000-00012 IS - 8 KW - atropine carboplatin dexamethasone granisetron irinotecan ondansetron palonosetron thalidomide adult advanced cancer aged area under the curve article brain metastasis cancer patient cancer radiotherapy cancer staging clinical article clinical protocol clinical trial confidence interval controlled clinical trial controlled study diarrhea disease course disease duration drug cytotoxicity drug dose escalation drug efficacy drug tolerability fatigue febrile neutropenia female hemoptysis human hypertension kidney function liver function non small cell lung cancer malaise male multiple cycle treatment nausea neutropenia overall survival phase 2 clinical trial priority journal survival rate survival time therapy effect thrombocytopenia treatment outcome treatment response vomiting LA - English M3 - Article N1 - L47181389 2006-10-01 PY - 2006 SN - 1556-0864 1556-1380 SP - 832-836 ST - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer T2 - Journal of Thoracic Oncology TI - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47181389&from=export http://dx.doi.org/10.1097/01243894-200610000-00012 VL - 1 ID - 1239 ER - TY - JOUR AB - BACKGROUND: We hypothesized that thalidomide would improve the response and toxicity profile of chemotherapy with carboplatin and irinotecan. METHODS: The key eligibility criteria were stage IIIB (malignant pleural effusion) and IV non-small cell lung cancer, measurable disease, no prior chemotherapy, prior radiation only for brain metastasis, performance status 0 or 1, and adequate hematologic, hepatic, and renal function. Treatment consisted of carboplatin at a calculated area under the curve of 5 and infused intravenously for 30 min on day 1 and irinotecan (50 mg/m intravenously for 90 min on days 1 and 8 every 21 days). Thalidomide was given orally every evening starting on day 1 until progressive disease; the starting dose was 200 mg per day, which was escalated by 100 mg per week if tolerated (maximum 1000 mg per day). The objectives were to determine the response rate, time to progression, overall survival, and toxicity profile. RESULTS: In all, 46 patients were enrolled, but three who never received protocol treatment were excluded from the analysis. The characteristics of the 43 eligible and treated patients included median age 63 (47-79), female/male 13/30, black/white 3/40, PS 0/1 in 10/33, and stage 3/4 in 6/37. The objective response rates were complete response 1 (2%), partial response 5 (12%), stable disease 24 (56%), progressive disease 9 (21%), and unevaluable for response 4 (9%). The median time to progression was 3.7 months (95% confidence interval [CI], 2.5-4.9). The median survival time was 8.1 months (95% CI, 5.0-12.9). Frequent toxicities were neutropenia, fatigue/malaise, and nausea/vomiting. Diarrhea was uncommon and mild. CONCLUSIONS: This treatment regimen of carboplatin, irinotecan, and thalidomide was tolerable, with reversible neutropenia as the major toxicity and only minor diarrhea. The overall response rate did not meet our predetermined level of efficacy to merit further investigation. © 2006International Association for the Study of Lung Cancer. AD - Wake Forest University, Winston-Salem, NC, United States Southeast Cancer Control Consortium, Winston-Salem, NC, United States Cancer Center of the Carolinas, Greenville, SC, United States Gibbs Cancer Center, Spartanburg, SC, United States Comprehensive Cancer Center, Wake Forest University, Medical Center Blvd., Winston-Salem, NC, United States AU - Miller, A. A. AU - Case, D. AU - Atkins, J. N. AU - Giguere, J. K. AU - Bearden, J. D. DB - Scopus DO - 10.1097/01243894-200610000-00012 IS - 8 KW - Carboplatin Irinotecan Non-small cell lung cancer Phase II Thalidomide M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2006 SP - 832-836 ST - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer T2 - Journal of Thoracic Oncology TI - Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34248343502&doi=10.1097%2f01243894-200610000-00012&partnerID=40&md5=861637412f58ecfed267a6197d6943cb VL - 1 ID - 2570 ER - TY - JOUR AB - Introduction: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression ≥90 days after completing first-line therapy) small cell lung cancer. Methods: Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible. Dasatinib was administered orally at 70 mg twice daily continuously (1 cycle = 21 days) until disease progression or unacceptable toxicity. Response was determined after every two cycles. Patients were followed until disease progression or death. The study was prospectively designed to simultaneously discriminate between complete plus partial response rates of 5% versus 20% and progression-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable patients with at least 92% power. The study was to be terminated early and declared negative if 1 or less objective response and 14 or fewer instances of PFS ≥6 weeks were observed among the initial 27 patients; however, patient accrual continued while the initial 27 patients were evaluated. Results: Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31. No objective response was recorded among the 43 eligible and treated patients. Among the initial 27 patients, only 13 instances of PFS ≥6 weeks were observed. With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively. Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%). Toxicity was generally mild to moderate: grade 3 events of >5% frequency included fatigue and pleural and pericardial effusions; and no grade 4 or 5 events were encountered. Conclusions: Dasatinib did not reach our specified efficacy criteria in this clinical setting, and the study was terminated. Copyright © 2010 by the International Association. AD - A. A. Miller, Comprehensive Cancer Center, Wake Forest University, Medical Center Blvd., Winston-Salem, NC 27157, United States AU - Miller, A. A. AU - Pang, H. AU - Hodgson, L. AU - Ramnath, N. AU - Otterson, G. A. AU - Kelley, M. J. AU - Kratzke, R. A. AU - Vokes, E. E. C1 - bms 354825(Bristol) C2 - Bristol DB - Embase Medline DO - 10.1097/JTO.0b013e3181cee36e IS - 3 KW - antiemetic agent dasatinib granisetron loperamide platinum abdominal pain adult aged anorexia article asthenia blood toxicity cancer chemotherapy cancer recurrence cause of death chemosensitivity clinical article clinical trial continuous infusion desquamation diarrhea disease course drug dose reduction drug efficacy lack of drug effect drug withdrawal fatigue female follow up human human tissue kidney function lethargy liver function small cell lung cancer malaise male monotherapy multiple cycle treatment nausea and vomiting observational study overall survival pericardial effusion phase 2 clinical trial pleura effusion priority journal progression free survival prospective study rash survival rate thorax pain treatment response vomiting bms 354825 LA - English M3 - Article N1 - L358400034 2010-03-15 2010-04-20 PY - 2010 SN - 1556-0864 1556-1380 SP - 380-384 ST - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) T2 - Journal of Thoracic Oncology TI - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358400034&from=export http://dx.doi.org/10.1097/JTO.0b013e3181cee36e VL - 5 ID - 1168 ER - TY - JOUR AB - Introduction: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression ≥90 days after completing first-line therapy) small cell lung cancer. Methods: Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible. Dasatinib was administered orally at 70 mg twice daily continuously (1 cycle = 21 days) until disease progression or unacceptable toxicity. Response was determined after every two cycles. Patients were followed until disease progression or death. The study was prospectively designed to simultaneously discriminate between complete plus partial response rates of 5% versus 20% and progression-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable patients with at least 92% power. The study was to be terminated early and declared negative if 1 or less objective response and 14 or fewer instances of PFS ≥6 weeks were observed among the initial 27 patients; however, patient accrual continued while the initial 27 patients were evaluated. Results: Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31. No objective response was recorded among the 43 eligible and treated patients. Among the initial 27 patients, only 13 instances of PFS ≥6 weeks were observed. With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively. Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%). Toxicity was generally mild to moderate: grade 3 events of >5% frequency included fatigue and pleural and pericardial effusions; and no grade 4 or 5 events were encountered. Conclusions: Dasatinib did not reach our specified efficacy criteria in this clinical setting, and the study was terminated. Copyright © 2010 by the International Association. AD - Wake Forest University, Winston-Salem, United States Duke University, Durham, NC, United States Roswell Park Cancer Institute, Buffalo, NY, United States Ohio State University, Columbus, OH, United States University of Minnesota, Minneapolis, MN, United States University of Chicago, Chicago, IL, United States AU - Miller, A. A. AU - Pang, H. AU - Hodgson, L. AU - Ramnath, N. AU - Otterson, G. A. AU - Kelley, M. J. AU - Kratzke, R. A. AU - Vokes, E. E. DB - Scopus DO - 10.1097/JTO.0b013e3181cee36e IS - 3 KW - Dasatinib Phase II Small cell lung cancer M3 - Article N1 - Cited By :40 Export Date: 22 March 2021 PY - 2010 SP - 380-384 ST - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) T2 - Journal of Thoracic Oncology TI - A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77649310705&doi=10.1097%2fJTO.0b013e3181cee36e&partnerID=40&md5=f8c04dab3e8a285d87e8938b5da5f90e VL - 5 ID - 2506 ER - TY - JOUR AB - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent. AD - M. Hussain, 5 Hudson, Harper Hospital, 3990 John R. Road, Detroit, MI 48201, United States AU - Vaishampayan, U. AU - Glode, M. AU - Du, W. AU - Kraft, A. AU - Hudes, G. AU - Wright, J. AU - Hussain, M. C1 - vp 16 DB - Embase Medline IS - 11 KW - antineoplastic agent dolastatin 10 estramustine etoposide paclitaxel prostate specific antigen vinblastine adult aged article bone metastasis cancer chemotherapy clinical article clinical trial drug efficacy drug induced disease drug safety human male neutropenia peripheral neuropathy phase 2 clinical trial priority journal prostate adenocarcinoma prostate cancer vp 16 LA - English M3 - Article N1 - L30840168 2000-12-07 PY - 2000 SN - 1078-0432 SP - 4205-4208 ST - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma T2 - Clinical Cancer Research TI - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30840168&from=export VL - 6 ID - 1315 ER - TY - JOUR AB - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 μg/m2 i.v. every 3 weeks. Dose escalation to 450 μg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 μg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent. AD - Division of Hematology/Oncology, Department of Medicine, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, United States Department of Biostatistics, Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, United States University of Colorado Health and Science Center, Denver, CO, United States Fox Chase Cancer Center, Philadelphia, PA, United States National Cancer Institute, Bethesda, MD, United States AU - Vaishampayan, U. AU - Glode, M. AU - Du, W. AU - Kraft, A. AU - Hudes, G. AU - Wright, J. AU - Hussain, M. DB - Scopus IS - 11 M3 - Article N1 - Cited By :134 Export Date: 22 March 2021 PY - 2000 SP - 4205-4208 ST - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma T2 - Clinical Cancer Research TI - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033739893&partnerID=40&md5=bc79cf5dc7906968fcabe9c44dc62cf0 VL - 6 ID - 2638 ER - TY - JOUR AB - Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 mug/m(2) i.v. every 3 weeks. Dose escalation to 450 mug/m(2) was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 Sears (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 mug/m(2). The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population hut lacks significant clinical activity as a single agent. AN - WOS:000165347600006 AU - Vaishampayan, U. AU - Glode, M. AU - Du, W. AU - Kraft, A. AU - Hudes, G. AU - Wright, J. AU - Hussain, M. DA - Nov IS - 11 N1 - 91st Annual Meeting of the American-Association-for-Cancer-Research APR 01-05, 2000 SAN FRANCISCO, CALIFORNIA Amer Assoc Canc Res 130 11106233 PY - 2000 SN - 1078-0432 SP - 4205-4208 ST - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma T2 - Clinical Cancer Research TI - Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma VL - 6 ID - 2718 ER - TY - JOUR AB - Objective: The tolerability and efficacy of targeted therapy in older adults with cancer has not been adequately studied. Neratinib is a novel HER1, HER2, HER4 tyrosine kinase inhibitor that has recently been granted FDA approval for treatment of breast cancer. The major toxicity of neratinib is diarrhea, which affects up to 90% of patients. This phase II trial evaluates the safety and tolerability of neratinib in adults ≥60. Methods: Patients aged 60 or older with histologically proven metastatic breast cancer and HER2 amplification (defined by ASCO/CAP guideline) or HER2/HER3 activating mutation were enrolled to receive neratinib at 240 mg daily in 28-day cycles. The association between tolerability, defined as dose reduction and number of completed courses, and log2 Cancer and Aging Research Group (CARG) toxicity risk score was assessed using a Student's t-test and linear regression, respectively. Response rate, progression free survival, and overall survival were also evaluated. Results: 25 patients were enrolled with median age of 66 (range 60–79). Seventy-six percent of patients were white, 16% Asian, and 8% African-American. Seventy-six percent were patients with hormone receptor (HR) positive metastatic breast cancer (MBC) and 24% were patients with HR negative MBC. Median number of prior lines of metastatic therapy were 3 (range 0–11). 20/25 (80%) had worst grade toxicities ≥2. A total of 9/25 (36%) had grade 3 toxicities including 5/20 (20%) diarrhea, 2/20 (8%) vomiting, and 2/20 (8%) abdominal pain. There were no grade 4 or 5 toxicities. A total of 9/25 (36%) had dose reduction, and 2/25 (8%) discontinued therapy due to toxicity. The association between dose reductions and CARG toxicity score reached borderline statistical significance suggesting a trend with participants with higher CARG toxicity risk scores being more likely to require a dose modification (p = 0.054). 1/25 (4%) had a partial response, 11/25 (44%) had stable disease, 12/25 (48%) had progression of disease, and 1/25 (4%) was not assessed. Median progression free survival (PFS) was 2.6 months (95% CI [2.56–5.26]), and median overall survival (OS) was 17.4 months (95% CI [10.3, NA]). Conclusions: Neratinib was safe in this population of older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer (BC). Higher CARG toxicity risk score may be associated with greater need for dose adjustments. Future studies are needed to confirm this finding. AD - Y. Yuan, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, United States AU - Yuan, Y. AU - Lee, J. S. AU - Yost, S. E. AU - Stiller, T. AU - Blanchard, M. S. AU - Padam, S. AU - Katheria, V. AU - Kim, H. AU - Sun, C. AU - Tang, A. AU - Martinez, N. AU - Patel, N. D. AU - Sedrak, M. S. AU - Waisman, J. AU - Li, D. AU - Sanani, S. AU - Presant, C. A. AU - Mortimer, J. DB - Embase DO - 10.1016/j.jgo.2021.02.020 KW - abdominal pain adult adverse drug reaction African American aged aging article cancer patient cancer survival clinical article clinical trial controlled study diarrhea drug safety drug therapy enzyme activity female gene amplification gene mutation histopathology human linear regression analysis metastatic breast cancer overall survival pharmacokinetics phase 2 clinical trial practice guideline progression free survival risk assessment statistical significance vomiting endogenous compound epidermal growth factor receptor 2 hormone receptor neratinib LA - English M3 - Article in Press N1 - L2011201796 2021-03-09 PY - 2021 SN - 1879-4068 ST - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer T2 - Journal of Geriatric Oncology TI - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2011201796&from=export http://dx.doi.org/10.1016/j.jgo.2021.02.020 ID - 769 ER - TY - JOUR AB - Objective: The tolerability and efficacy of targeted therapy in older adults with cancer has not been adequately studied. Neratinib is a novel HER1, HER2, HER4 tyrosine kinase inhibitor that has recently been granted FDA approval for treatment of breast cancer. The major toxicity of neratinib is diarrhea, which affects up to 90% of patients. This phase II trial evaluates the safety and tolerability of neratinib in adults ≥60. Methods: Patients aged 60 or older with histologically proven metastatic breast cancer and HER2 amplification (defined by ASCO/CAP guideline) or HER2/HER3 activating mutation were enrolled to receive neratinib at 240 mg daily in 28-day cycles. The association between tolerability, defined as dose reduction and number of completed courses, and log2 Cancer and Aging Research Group (CARG) toxicity risk score was assessed using a Student's t-test and linear regression, respectively. Response rate, progression free survival, and overall survival were also evaluated. Results: 25 patients were enrolled with median age of 66 (range 60–79). Seventy-six percent of patients were white, 16% Asian, and 8% African-American. Seventy-six percent were patients with hormone receptor (HR) positive metastatic breast cancer (MBC) and 24% were patients with HR negative MBC. Median number of prior lines of metastatic therapy were 3 (range 0–11). 20/25 (80%) had worst grade toxicities ≥2. A total of 9/25 (36%) had grade 3 toxicities including 5/20 (20%) diarrhea, 2/20 (8%) vomiting, and 2/20 (8%) abdominal pain. There were no grade 4 or 5 toxicities. A total of 9/25 (36%) had dose reduction, and 2/25 (8%) discontinued therapy due to toxicity. The association between dose reductions and CARG toxicity score reached borderline statistical significance suggesting a trend with participants with higher CARG toxicity risk scores being more likely to require a dose modification (p = 0.054). 1/25 (4%) had a partial response, 11/25 (44%) had stable disease, 12/25 (48%) had progression of disease, and 1/25 (4%) was not assessed. Median progression free survival (PFS) was 2.6 months (95% CI [2.56–5.26]), and median overall survival (OS) was 17.4 months (95% CI [10.3, NA]). Conclusions: Neratinib was safe in this population of older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer (BC). Higher CARG toxicity risk score may be associated with greater need for dose adjustments. Future studies are needed to confirm this finding. © 2021 Elsevier Inc. AD - Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, CA, United States Department of Biostatistics, City of Hope National Medical Center, Duarte, CA, United States City of Hope National Medical Center, Mission Hills, CA, United States City of Hope National Medical Center, West Covina, CA, United States AU - Yuan, Y. AU - Lee, J. S. AU - Yost, S. E. AU - Stiller, T. AU - Blanchard, M. S. AU - Padam, S. AU - Katheria, V. AU - Kim, H. AU - Sun, C. AU - Tang, A. AU - Martinez, N. AU - Patel, N. D. AU - Sedrak, M. S. AU - Waisman, J. AU - Li, D. AU - Sanani, S. AU - Presant, C. A. AU - Mortimer, J. DB - Scopus DO - 10.1016/j.jgo.2021.02.020 KW - CARG toxicity risk score Metastatic breast cancer Neratinib Phase II trial M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer T2 - Journal of Geriatric Oncology TI - Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101879818&doi=10.1016%2fj.jgo.2021.02.020&partnerID=40&md5=c6dbbaea7be4cbf863777593d2a5ebb0 ID - 2165 ER - TY - JOUR AB - BACKGROUND: Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC). METHODS: Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a ≥ 30% decline in prostate-specific antigen [PSA] level) and to correlate germline polymorphisms in androgen metabolism genes with antitumor activity. Secondary objectives included determining safety, post-treatment changes in measurable disease, and time to disease progression. RESULTS: From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P (AA+P); 7 of 10 evaluable patients were docetaxel naive. Post-treatment declines in PSA level of ≥ 30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. CONCLUSION: In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials. AD - M.D. Galsky, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, United States AU - Tsao, C. K. AU - Sfakianos, J. AU - Liaw, B. AU - Gimpel-Tetra, K. AU - Kemeny, M. AU - Bulone, L. AU - Shahin, M. AU - Oh, W. K. AU - Galsky, M. D. C1 - zytiga(Janssen Biotech) C2 - Janssen Biotech DB - Embase Medline DO - 10.1634/theoncologist.2016-0026 IS - 12 KW - NCT01735396 abiraterone acetate alanine aminotransferase alkaline phosphatase aspartate aminotransferase docetaxel prednisone prostate specific antigen adult aged anorexia article backache Black person castration resistant prostate cancer clinical article coughing diarrhea drug safety fatigue hot flush human hyperglycemia hypoalbuminemia hypocalcemia hypokalemia hypophosphatemia limb weakness lymphocyte count male metastasis nausea and vomiting phase 2 clinical trial priority journal prospective study platelet count urine incontinence zytiga LA - English M3 - Article N1 - L613753284 2016-12-27 2017-01-19 PY - 2016 SN - 1549-490X 1083-7159 SP - 1414e1-1414e9 ST - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer T2 - Oncologist TI - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613753284&from=export http://dx.doi.org/10.1634/theoncologist.2016-0026 VL - 21 ID - 987 ER - TY - JOUR AB - BACKGROUND: Self‐identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration‐resistant prostate cancer (mCRPC). METHODS: Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a > 30% decline in prostate‐specific antigen [PSA] level) and to correlate germline polymorphisms in androgen metabolism genes with antitumor activity. Secondary objectives included determining safety, post‐treatment changes in measurable disease, and time to disease progression. RESULTS: From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P (AA+P); 7 of 10 evaluable patients were docetaxel naive. Post‐treatment declines in PSA level of > 30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. CONCLUSION: In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials. Copyright © AlphaMed Press 2016. AN - CN-01299405 AU - Tsao, C. K. AU - Sfakianos, J. AU - Liaw, B. AU - Gimpel-Tetra, K. AU - Kemeny, M. AU - Bulone, L. AU - Shahin, M. AU - Oh, W. K. AU - Galsky, M. D. DO - 10.1634/theoncologist.2016-0026 IS - 12 KW - *abiraterone acetate *abiraterone acetate/ae [Adverse Drug Reaction] *abiraterone acetate/cb [Drug Combination] *abiraterone acetate/ct [Clinical Trial] *abiraterone acetate/dt [Drug Therapy] *abiraterone acetate/po [Oral Drug Administration] *castration resistant prostate cancer *castration resistant prostate cancer/dt [Drug Therapy] *controlled study *metastasis/dt [Drug Therapy] *prednisone *prednisone/cb [Drug Combination] *prednisone/ct [Clinical Trial] *prednisone/dt [Drug Therapy] *prednisone/po [Oral Drug Administration] Acetic acid Adult Aged Alanine aminotransferase/ec [Endogenous Compound] Alkaline phosphatase/ec [Endogenous Compound] Androgen metabolism Anorexia/si [Side Effect] Antineoplastic activity Article Aspartate aminotransferase/ec [Endogenous Compound] Backache/si [Side Effect] Black person Cancer epidemiology Castration resistant prostate cancer/dt [Drug Therapy] Clinical article Clinical trial Controlled clinical trial Coughing/si [Side Effect] Diarrhea/si [Side Effect] Disease free interval Docetaxel Docetaxel/dt [Drug Therapy] Drug safety Endogenous compound Fatigue/si [Side Effect] Gene inactivation Gene mutation Genetic polymorphism Germ line Hot flush/si [Side Effect] Human Hyperglycemia/si [Side Effect] Hypoalbuminemia/si [Side Effect] Hypocalcemia/si [Side Effect] Hypokalemia/si [Side Effect] Hypophosphatemia/si [Side Effect] Limb weakness/si [Side Effect] Lymphocyte count Male Metastasis/dt [Drug Therapy] Nausea and vomiting/si [Side Effect] Pharmacokinetics Phase 2 clinical trial Priority journal Prospective study Prostate specific antigen Prostate specific antigen/ec [Endogenous Compound] Safety Sample size Side effect Thrombocyte count Urine incontinence/si [Side Effect] M3 - Journal: Article PY - 2016 SP - 1414e1‐1414e9 ST - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer T2 - Oncologist TI - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01299405/full VL - 21 ID - 1450 ER - TY - JOUR AB - BACKGROUND: Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC). METHODS: Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a ≥ 30% decline in prostate-specific antigen [PSA] level) and to correlate germline polymorphisms in androgen metabolism genes with antitumor activity. Secondary objectives included determining safety, post-treatment changes in measurable disease, and time to disease progression. RESULTS: From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P (AA+P); 7 of 10 evaluable patients were docetaxel naive. Post-treatment declines in PSA level of ≥ 30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. CONCLUSION: In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials. © AlphaMed Press 2016. AD - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States Queens Hospital Center, Jamaica, NY, United States AU - Tsao, C. K. AU - Sfakianos, J. AU - Liaw, B. AU - Gimpel-Tetra, K. AU - Kemeny, M. AU - Bulone, L. AU - Shahin, M. AU - Oh, W. K. AU - Galsky, M. D. DB - Scopus DO - 10.1634/theoncologist.2016-0026 IS - 12 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2016 SP - 1414e1-1414e9 ST - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer T2 - Oncologist TI - Phase II trial of abiraterone acetate plus prednisone in black men with metastatic prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006751390&doi=10.1634%2ftheoncologist.2016-0026&partnerID=40&md5=affaae4e21c77f9f125795398748d98b VL - 21 ID - 2355 ER - TY - JOUR AB - Background. Self-identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration-resistant prostate cancer (mCRPC). Methods. Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a >= 30% decline in prostate-specific antigen [PSA] level) and to correlate germline polymorphisms in andro-genmetabolism genes with antitumor activity. Secondary objectives included determining safety, post-treatment changes in measurable disease, and time to disease progression. Results. From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P(AA+P); 7 of 10 evaluable patients were docetaxel naive. Post-treatment declines in PSA level of >= 30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. Conclusion. In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials. AN - WOS:000391135800005 AU - Tsao, C. K. AU - Sfakianos, J. AU - Liaw, B. AU - Gimpel-Tetra, K. AU - Kemeny, M. AU - Bulone, L. AU - Shahin, M. AU - Oh, W. K. AU - Galsky, M. D. DA - Dec DO - 10.1634/theoncologist.2016-0026 IS - 12 N1 - 27742908 PY - 2016 SN - 1083-7159 SP - 1414-+ ST - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer T2 - Oncologist TI - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer VL - 21 ID - 2925 ER - TY - JOUR AB - Lessons Learned: The safety and activity findings of abiraterone acetate plus prednisone treatment in black men with mCRPC were similar to results from previously conducted studies with largely white populations.Poor trial accrual continues to be a challenge in black men with mCRPC and further efforts are needed to address such underrepresentation. Background.: Self‐identified black men have higher incidence and mortality from prostate cancer in the United States compared with white men but are dramatically underrepresented in clinical trials exploring novel therapies for metastatic castration‐resistant prostate cancer (mCRPC). Methods.: Black men with mCRPC were treated with abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily. The primary objective was to determine antitumor activity (defined by a ≥30% decline in prostate‐specific antigen [PSA] level) and to correlate germline polymorphisms in androgen metabolism genes with antitumor activity. Secondary objectives included determining safety, post‐treatment changes in measurable disease, and time to disease progression. Results.: From April 2013 to March 2016, a total of 11 black men were enrolled and received AA plus P (AA+P); 7 of 10 evaluable patients were docetaxel naive. Post‐treatment declines in PSA level of ≥30% were achieved in 90% of patients. The side effect profile was consistent with prior clinical trials exploring AA+P in mCRPC. Due to poor accrual, the study was closed prematurely with insufficient sample size for the planned pharmacogenetic analyses. Conclusion.: In this small prospective study terminated for poor accrual, the safety and activity of AA+P in black men with mCRPC was similar to that reported in prior studies exploring AA in largely white populations. Further efforts are needed to address underrepresentation of black men in mCRPC trials. 作者总结 经验 • 醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌 (mCRPC) 黑人男性患者的安全性和有效性与既往主要在白人群体中开展的研究结果相似。 • mCRPC 临床试验中黑人男性患者入组不理想仍然是该人群研究的一大难题, 有必要进一步努力解决这一人群代表性不足的问题。 摘要 背景. 美国黑人男性前列腺癌的发病率和死亡率均高于白人男性, 但在转移性去势抵抗性前列腺癌 (mCRPC) 新治疗研发的临床试验中, 黑人男性的代表性却明显不足。 方法. 患有mCRPC的黑人男性接受醋酸阿比特龙 (AA) 1 000 mg每日1次和泼尼松 (P) 5 mg每日2次治疗。主要目的为确定该治疗方案的抗肿瘤活性[定义为前列腺特异性抗原 (PSA) 水平下降≥30%], 以及雄激素代谢基因生殖系多态性与抗肿瘤活性之间的相关性。次要目的包括确定安全性、可测量病灶在治疗后的改变, 以及至疾病进展时间。 结果. 从2013年4月至2016年3月, 研究共入组11例黑人男性接受AA+P治疗, 7/10例可评价患者未接受过多西他赛治疗。90%的患者治疗后PSA水平下降≥30%。副作用特征与既往研究AA+P治疗mCRPC的临床试验情况一致。研究因招募入组极不理想而提前关闭, 计划的药物遗传学分析样本量不足。 结论. 本项小型前瞻性研究因招募入组过慢而终止, AA+P在mCRPC黑人男性患者中的安全性和有效性与既往主要在白人男性中开展的AA研究相似。有必要进一步努力解决黑人男性在mCRPC临床试验中代表性不足的问题。The Oncologist 2016;21:1414–1415 AD - Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA Queens Hospital Center, Jamaica, New York, USA AN - 120270074. Language: English. Entry Date: 20161223. Revision Date: 20191029. Publication Type: Article AU - Tsao, Che‐Kai AU - Sfakianos, John AU - Liaw, Bobby AU - Gimpel‐Tetra, Kiev AU - Kemeny, Margaret AU - Bulone, Linda AU - Shahin, Mohammad AU - Oh, William Kyu AU - Galsky, Matthew David DB - CINAHL Complete DO - 10.1634/theoncologist.2016-0026 DP - EBSCOhost IS - 12 KW - Abiraterone Acetate -- Therapeutic Use Prednisone -- Therapeutic Use Drug Therapy, Combination Black Persons Prostatic Neoplasms -- Drug Therapy Neoplasm Metastasis -- Drug Therapy Human Clinical Trials Abiraterone Acetate -- Administration and Dosage Prednisone -- Administration and Dosage Prostate-Specific Antigen Androgens -- Metabolism Sample Size Female Polymorphism, Genetic Pilot Studies Prospective Studies Neoplasm Staging Middle Age Aged N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9607837. PY - 2016 SN - 1083-7159 SP - 1414-1414 ST - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer T2 - Oncologist TI - Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120270074&site=ehost-live&scope=site VL - 21 ID - 2020 ER - TY - JOUR AB - Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human cancer cell lines via modulation of protein kinase C (PKC) activity. This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients with advanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1. Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38-76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 μg/m2 of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 μg/m2 starting with the second cycle. The remaining patients were started at 35 μg/m2 and escalated to 40 μg/m2, if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles. Myalgia was the most common toxicity. Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs. AD - P.A. Philip, Div. of Hematology and Oncology, Barbara Ann Karmanos Can. Inst., 509 Hudson Building, 3990 John R. Street, Detroit, MI 48201, United States AU - Zonder, J. A. AU - Shields, A. F. AU - Zalupski, M. AU - Chaplen, R. AU - Heilbrun, L. K. AU - Arlauskas, P. AU - Philip, P. A. C2 - National Cancer Institute DB - Embase Medline IS - 1 KW - bryostatin 1 fluorouracil adult advanced cancer aged article bone marrow suppression cancer growth clinical article clinical trial colorectal cancer dose response drug efficacy drug mechanism female human human cell human tissue male myalgia phase 2 clinical trial priority journal LA - English M3 - Article N1 - L32110203 2001-02-15 PY - 2001 SN - 1078-0432 SP - 38-42 ST - A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer T2 - Clinical Cancer Research TI - A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32110203&from=export VL - 7 ID - 1313 ER - TY - JOUR AB - Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human cancer cell lines via modulation of protein kinase C (PKC) activity. This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients with advanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1. Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38-76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 μg/m2of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 μg/m2starting with the second cycle. The remaining patients were started at 35 μg/m2and escalated to 40 μg/m2if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles. Myalgia was the most common toxicity. Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs. AD - Div. of Hematology and Oncology, Barbara Ann Karmanos Can. Inst., 509 Hudson Building 3990 John R. Street, Detroit, MI 48201, United States AU - Zonder, J. A. AU - Shields, A. F. AU - Zalupski, M. AU - Chaplen, R. AU - Heilbrun, L. K. AU - Arlauskas, P. AU - Philip, P. A. DB - Scopus IS - 1 M3 - Article N1 - Cited By :65 Export Date: 22 March 2021 PY - 2001 SP - 38-42 ST - A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer T2 - Clinical Cancer Research TI - A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035139097&partnerID=40&md5=ac7a7a9b7b0ce8a31c0dedb26255375f VL - 7 ID - 2627 ER - TY - JOUR AB - Current chemotherapy for patients with advanced colorectal cancer is relatively ineffective and may be associated with significant toxicity. Bryostatin 1 (bryo 1) influences cell proliferation, intracellular metabolism and signaling, differentiation, and apoptosis in human canter cell lines via modulation of protein kinase C (PKC) activity, This trial investigates the efficacy and toxicity of bryo 1 as a novel therapeutic agent for patients with advanced colorectal cancer who have had previous 5-fluorouracil therapy. The primary end point was tumor response to bryo 1, Toxicity was also assessed. Twenty-eight patients with advanced colorectal cancer were enrolled. The mean age was 59 years (range, 38-76), with 16 men and 12 women, and good minority representation (11 African-Americans). The first 10 patients initially received 25 (I)mug/m(2) of bryo 1 weekly as a 24-h infusion for 3 weeks of every 4-week cycle, with dose escalation to 35 mug/m(2) starting with the second cycle. The remaining patients were started at 35 mug/m(2) and escalated to 40 mug/m(2), if toxicity was minimal. Twenty-five patients were evaluable for objective tumor response, and complete data on toxicity were collected on 26 patients. No partial or complete tumor responses were observed. All 25 patients had disease progression within four cycles, Myalgia was the most common toxicity, Myelosuppression was not seen. bryo 1 as a weekly 24-h continuous infusion lacks single-agent antitumor activity in advanced colorectal cancer. Toxicity differs from that of traditional chemotherapeutic drugs. AN - WOS:000166595500005 AU - Zonder, J. A. AU - Shields, A. F. AU - Zalupski, M. AU - Chaplen, R. AU - Heilbrun, L. K. AU - Arlauskas, P. AU - Philip, P. A. DA - Jan IS - 1 N1 - 68 11205915 PY - 2001 SN - 1078-0432 SP - 38-42 ST - A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer T2 - Clinical Cancer Research TI - A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer VL - 7 ID - 2710 ER - TY - JOUR AB - Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate‐resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. Methods Patients with progressive mCRPC pretreated with docetaxel‐based regimen were eligible. Performance status of 0‐1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily. Results Twenty‐six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8‐4.3 months), and median overall survival was 12.5 months (90% CI, 7.7‐18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome. Conclusion The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy. AN - CN-01164260 AU - Vaishampayan, U. AU - Shevrin, D. AU - Stein, M. AU - Heilbrun, L. AU - Land, S. AU - Stark, K. AU - Li, J. AU - Dickow, B. AU - Heath, E. AU - Smith, D. AU - et al. DO - 10.1016/j.urology.2015.08.008 IS - 6 KW - *cancer combination chemotherapy *cancer prognosis *carboplatin/ae [Adverse Drug Reaction] *carboplatin/cb [Drug Combination] *carboplatin/ct [Clinical Trial] *carboplatin/dt [Drug Therapy] *carboplatin/iv [Intravenous Drug Administration] *carboplatin/pk [Pharmacokinetics] *castration resistant prostate cancer/dr [Drug Resistance] *castration resistant prostate cancer/dt [Drug Therapy] *docetaxel/dt [Drug Therapy] *everolimus/ae [Adverse Drug Reaction] *everolimus/cb [Drug Combination] *everolimus/ct [Clinical Trial] *everolimus/dt [Drug Therapy] *everolimus/pk [Pharmacokinetics] *everolimus/po [Oral Drug Administration] *prednisone/ae [Adverse Drug Reaction] *prednisone/cb [Drug Combination] *prednisone/ct [Clinical Trial] *prednisone/dt [Drug Therapy] *prednisone/pk [Pharmacokinetics] African American Aged Area under the curve Article Bone marrow Cancer growth Cancer patient Cancer resistance Cancer survival Chronotherapy Clinical article Dose response Drug dose reduction Drug efficacy Drug safety Gene mutation Histopathology Human Human tissue Immunohistochemistry Kidney function Liver function Male Multiple cycle treatment Mutator gene Neutropenia/si [Side Effect] Overall survival Phase 2 clinical trial Priority journal Protein kinase B/ec [Endogenous Compound] Survival rate Survival time Thrombocytopenia/si [Side Effect] Treatment duration Treatment outcome Treatment response Tuberous sclerosis gene 1 M3 - Journal: Article PY - 2015 SP - 1206‐1211 ST - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: a Prostate Cancer Clinical Trial Consortium Study T2 - Urology TI - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: a Prostate Cancer Clinical Trial Consortium Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01164260/full VL - 86 ID - 1596 ER - TY - JOUR AB - Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. Methods Patients with progressive mCRPC pretreated with docetaxel-based regimen were eligible. Performance status of 0-1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily. Results Twenty-six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome. Conclusion The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy. AD - U. Vaishampayan, Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States AU - Vaishampayan, U. AU - Shevrin, D. AU - Stein, M. AU - Heilbrun, L. AU - Land, S. AU - Stark, K. AU - Li, J. AU - Dickow, B. AU - Heath, E. AU - Smith, D. AU - Fontana, J. C1 - rad 001(Novartis) C2 - Novartis DB - Embase Medline DO - 10.1016/j.urology.2015.08.008 IS - 6 KW - NCT01051570 carboplatin docetaxel everolimus prednisone protein kinase B African American aged area under the curve article bone marrow cancer combination chemotherapy cancer growth cancer patient cancer prognosis cancer resistance cancer survival castration resistant prostate cancer chronotherapy clinical article dose response drug dose reduction drug efficacy drug safety gene mutation histopathology human human tissue immunohistochemistry kidney function liver function male multiple cycle treatment mutator gene neutropenia overall survival phase 2 clinical trial priority journal survival rate survival time thrombocytopenia treatment duration treatment outcome treatment response tuberous sclerosis gene 1 rad 001 LA - English M3 - Article N1 - L607391102 2015-12-30 2016-02-09 PY - 2015 SN - 1527-9995 0090-4295 SP - 1206-1211 ST - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study T2 - Urology TI - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607391102&from=export http://dx.doi.org/10.1016/j.urology.2015.08.008 VL - 86 ID - 990 ER - TY - JOUR AB - Objective: To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer.Methods: Patients with progressive mCRPC pretreated with docetaxel-based regimen were eligible. Performance status of 0-1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily.Results: Twenty-six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome.Conclusion: The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy. AD - Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI Department of Oncology, Northshore University Health System, Evanston, IL Department of Oncology, Cancer Institute of New Jersey, New Brunswick, NJ Department of Oncology, Biostatistics Core, Barbara Ann Karmanos Cancer Institute, Detroit, MI Department of Oncology, John D. Dingell Veterans Medical Center, Detroit, MI AN - 111892328. Language: English. Entry Date: 20160507. Revision Date: 20201026. Publication Type: journal article AU - Vaishampayan, Ulka AU - Shevrin, Daniel AU - Stein, Mark AU - Heilbrun, Lance AU - Land, Susan AU - Stark, Karri AU - Li, Jing AU - Dickow, Brenda AU - Heath, Elisabeth AU - Smith, Daryn AU - Fontana, Joseph DB - CINAHL Complete DO - 10.1016/j.urology.2015.08.008 DP - EBSCOhost IS - 6 KW - Antineoplastic Agents, Combined -- Therapeutic Use Prostatic Neoplasms, Castration-Resistant -- Pathology Prostatic Neoplasms, Castration-Resistant -- Drug Therapy Adenocarcinoma -- Drug Therapy Adenocarcinoma Disease Progression Neoplasm Metastasis Hydrocarbons -- Administration and Dosage Male Survival Aged Carboplatin -- Pharmacokinetics Prednisone -- Administration and Dosage Carboplatin -- Administration and Dosage Human Phosphorylation Proteins Prostate-Specific Antigen -- Blood Antineoplastic Agents, Combined -- Adverse Effects Transferases -- Analysis Transferases -- Metabolism Prostatic Neoplasms, Castration-Resistant Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source N1 - clinical trial; research. Journal Subset: Biomedical; USA. Special Interest: Evidence-Based Practice. Grant Information: CA-22453/CA/NCI NIH HHS/United States. NLM UID: 0366151. PMID: NLM26375845. PY - 2015 SN - 0090-4295 SP - 1206-1211 ST - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study T2 - Urology TI - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=111892328&site=ehost-live&scope=site VL - 86 ID - 2022 ER - TY - JOUR AB - Objective To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. Methods Patients with progressive mCRPC pretreated with docetaxel-based regimen were eligible. Performance status of 0-1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily. Results Twenty-six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome. Conclusion The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy. © 2015 Elsevier Inc. AD - Department of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Department of Oncology, Northshore University Health System, Evanston, IL, United States Department of Oncology, Cancer Institute of New Jersey, New Brunswick, NJ, United States Department of Oncology, Biostatistics Core, Barbara Ann Karmanos Cancer Institute, Detroit, MI, United States Department of Oncology, John D. Dingell Veterans Medical Center, Detroit, MI, United States AU - Vaishampayan, U. AU - Shevrin, D. AU - Stein, M. AU - Heilbrun, L. AU - Land, S. AU - Stark, K. AU - Li, J. AU - Dickow, B. AU - Heath, E. AU - Smith, D. AU - Fontana, J. DB - Scopus DO - 10.1016/j.urology.2015.08.008 IS - 6 M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2015 SP - 1206-1211 ST - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study T2 - Urology TI - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated with Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955728958&doi=10.1016%2fj.urology.2015.08.008&partnerID=40&md5=8738450cd564271c69c0d807fe84114a VL - 86 ID - 2358 ER - TY - JOUR AB - OBJECTIVE To conduct a phase II trial of the combination of carboplatin, prednisone, and everolimus in metastatic castrate-resistant prostate cancer (mCRPC) as mTOR inhibition can overcome resistance to chemotherapy in prostate cancer. METHODS Patients with progressive mCRPC pretreated with docetaxel-based regimen were eligible. Performance status of 0-1 and adequate bone marrow, renal, and liver function were required. Primary end point was time to progression. Treatment consisted of carboplatin (starting dose equal to area under the curve (AUC of 5) intravenously every 21 days along with oral everolimus 5 mg once daily and prednisone 5 mg twice daily. RESULTS Twenty-six patients were enrolled with median age of 69 years with 8 patients of African American origin. Grade 3 or 4 thrombocytopenia or neutropenia in 4 of 6 initial patients required dose adjustment of carboplatin to AUC of 4 for subsequent patients. There were no pharmacokinetic interactions between carboplatin and everolimus. The median time to progression was 2.5 months (90% confidence interval [CI], 1.8-4.3 months), and median overall survival was 12.5 months (90% CI, 7.7-18.7 months). Of 10 patients, 8 that demonstrated positive nuclear phosphorylated AKT (pAKT) staining on immunohistochemistry progressed within 9 weeks, whereas 2 patients with negative staining continued without progression for prolonged durations of 30 and 48 weeks. TSC1 gene mutations did not correlate with clinical outcome. CONCLUSION The addition of the mTOR inhibitor everolimus to carboplatin demonstrated minimal clinical efficacy in metastatic prostate cancer. pAKT testing warrants further evaluation as a predictive marker of response to everolimus therapy. (C) 2015 Elsevier Inc. AN - WOS:000368339100037 AU - Vaishampayan, U. AU - Shevrin, D. AU - Stein, M. AU - Heilbrun, L. AU - Land, S. AU - Stark, K. AU - Li, J. AU - Dickow, B. AU - Heath, E. AU - Smith, D. AU - Fontana, J. DA - Dec DO - 10.1016/j.urology.2015.08.008 IS - 6 N1 - 26375845 PY - 2015 SN - 0090-4295 SP - 1206-1211 ST - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study T2 - Urology TI - Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study VL - 86 ID - 2961 ER - TY - JOUR AB - Background: Early chemohormonal therapy in metastatic prostate cancer may offer an advantage by simultaneously targeting androgen-dependent and -independent clones. Hence, a phase II trial was conducted to evaluate the efficacy and toxicity of estramustine and etoposide in hormone-sensitive metastatic prostate cancer. Patient and Methods: Eligibility consisted of untreated metastatic prostate cancer, adequate organ function, and a performance status of 0 to 2 by Zubrod criteria. A 21-day schedule of oral estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) was administered every 28 days. Hormonal therapy was allowed at the end of the protocol therapy. Toxicity was assessed weekly, PSA levels were assessed with each cycle, and objective response was evaluated every 3 cycles. Results: Twenty-one patients were enrolled (10 white, 11 black) with a median age of 59.5 years (range, 42-79 years), a median PSA of 338 ng/mL (range, 0.9-20,000 ng/mL), and a median Gleason score of 8 points. Ten patients had bone-only metastases, 11 had measurable disease, of whom 4 had visceral metastases. A total of 128 cycles were administered (median, 6 cycles). No dose reductions were required. Nineteen patients were able to be evaluated for response. Severe toxicities included thromboembolic events and anemia in 2 patients each and fatigue in 1 patient. There were no episodes of febrile neutropenia. Response was observed in 8 of 11 patients (73%) with measurable disease. Median PSA nadir after therapy was 0.45 ng/mL, and undetectable PSA (<0.1 ng/mL) was achieved in 4 patients. Median time to PSA progression was 16.65 months. At a median follow-up of 34 months, 18 patients were alive. The 1-, 2-, and 3-year overall survival rates were 90%, 82%, and 72% respectively. Median survival has not yet been reached. Conclusion: The combination of estramustine and etoposide is well tolerated, and has promising activity in newly diagnosed metastatic prostate cancer. AD - U. Vaishampayan, Harper Hospital, Division of Hematology/Oncology, Hudson-Webber Cancer Center, Detroit, MI 48201, United States AU - Vaishampayan, U. AU - Fontana, J. AU - Du, W. AU - Hussain, M. DB - Embase Medline DO - 10.1097/01.coc.0000135922.12198.e4 IS - 6 KW - androgen estramustine etoposide prostate specific antigen adult aged alopecia anemia article asthenia bone metastasis cancer survival Caucasian clinical article clinical trial deep vein thrombosis drug dose reduction drug efficacy drug eruption drug tolerability dyspnea edema fatigue febrile neutropenia fluid retention follow up hormonal therapy hot flush human impotence nausea and vomiting Black person nipple phase 2 clinical trial prostate carcinoma scoring system side effect survival rate thrombocytopenia thromboembolism visceral metastasis LA - English M3 - Article N1 - L39603267 2004-12-23 PY - 2004 SN - 0277-3732 SP - 550-554 ST - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma T2 - American Journal of Clinical Oncology: Cancer Clinical Trials TI - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39603267&from=export http://dx.doi.org/10.1097/01.coc.0000135922.12198.e4 VL - 27 ID - 1278 ER - TY - JOUR AB - Background: Early chemohormonal therapy in metastatic prostate cancer may offer an advantage by simultaneously targeting androgen-dependent and -independent clones. Hence, a phase II trial was conducted to evaluate the efficacy and toxicity of estramustine and etoposide in hormone-sensitive metastatic prostate cancer. Patient and Methods: Eligibility consisted of untreated metastatic prostate cancer, adequate organ function, and a performance status of 0 to 2 by Zubrod criteria. A 21-day schedule of oral estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) was administered every 28 days. Hormonal therapy was allowed at the end of the protocol therapy. Toxicity was assessed weekly, PSA levels were assessed with each cycle, and objective response was evaluated every 3 cycles. Results: Twenty-one patients were enrolled (10 white, 11 black) with a median age of 59.5 years (range, 42-79 years), a median PSA of 338 ng/mL (range, 0.9-20,000 ng/mL), and a median Gleason score of 8 points. Ten patients had bone-only metastases, 11 had measurable disease, of whom 4 had visceral metastases. A total of 128 cycles were administered (median, 6 cycles). No dose reductions were required. Nineteen patients were able to be evaluated for response. Severe toxicities included thromboembolic events and anemia in 2 patients each and fatigue in 1 patient. There were no episodes of febrile neutropenia. Response was observed in 8 of 11 patients (73%) with measurable disease. Median PSA nadir after therapy was 0.45 ng/mL, and undetectable PSA (<0.1 ng/mL) was achieved in 4 patients. Median time to PSA progression was 16.65 months. At a median follow-up of 34 months, 18 patients were alive. The 1-, 2-, and 3-year overall survival rates were 90%, 82%, and 72% respectively. Median survival has not yet been reached. Conclusion: The combination of estramustine and etoposide is well tolerated, and has promising activity in newly diagnosed metastatic prostate cancer. AD - Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Inst., Wayne State University, Detroit, MI, United States Division of Hematology/Oncology, Veterans Medical Center, Wayne State University, Detroit, MI, United States Department of Biostatistics, Barbara Ann Karmanos Cancer Inst., Wayne State University, Detroit, MI, United States Division of Hematology/Oncology, Univ. of MI Compreh. Cancer Center, Ann Arbor, MI, United States Harper Hospital, Division of Hematology/Oncology, Hudson-Webber Cancer Center, Detroit, MI 48201, United States AU - Vaishampayan, U. AU - Fontana, J. AU - Du, W. AU - Hussain, M. DB - Scopus DO - 10.1097/01.coc.0000135922.12198.e4 IS - 6 KW - Chemotherapy Clinical trial Hormone sensitive Prostate cancer Untreated M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2004 SP - 550-554 ST - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma T2 - American Journal of Clinical Oncology: Cancer Clinical Trials TI - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-10044264353&doi=10.1097%2f01.coc.0000135922.12198.e4&partnerID=40&md5=f1c303f2e198e92312766f82a664d395 VL - 27 ID - 2602 ER - TY - JOUR AB - Background: Early chemohormonal therapy in metastatic prostate cancer may offer an advantage by simultaneously targeting androgen-dependent and -independent clones. Hence, a phase II trial was conducted to evaluate the efficacy and toxicity of estramustine and etoposide in hormone- sensitive metastatic prostate cancer. Patient and Methods: Eligibility consisted of untreated metastatic prostate cancer, adequate organ function, and a performance status of 0 to 2 by Zubrod criteria. A 21-day schedule of oral estramustine (10 mg/kg/day) and etoposide (50 mg/m(2)/day) was administered every 28 days. Hormonal therapy was allowed at the end of the protocol therapy. Toxicity was assessed weekly, PSA levels were assessed with each cycle, and objective response was evaluated every 3 cycles. Results: Twenty-one patients were enrolled (10 white, 11 black) with a median age of 59.5 years (range, 42-79 years), a median PSA of 338 ng/mL (range, 0.9-20,000 ng/mL), and a median Gleason score of 8 points. Ten patients had bone-only metastases, 11 had measurable disease, of whom 4 had visceral metastases. A total of 128 cycles were administered (median, 6 cycles). No dose reductions were required. Nineteen patients were able to be evaluated for response. Severe toxicities included thromboembolic events and anemia in 2 patients each and fatigue in 1 patient. There were no episodes of febrile neutropenia. Response was observed in 8 of 11 patients (73%) with measurable disease. Median PSA nadir after therapy was 0.45 ng/mL, and undetectable PSA (<0.1 ng/mL) was achieved in 4 patients. Median time to PSA progression was 16.65 months. At a median follow-up of 34 months, 18 patients were alive. The 1-, 2-, and 3-year overall survival rates were 90%, 82%, and 72% respectively. Median survival has not yet been reached. Conclusion: The combination of estramustine and etoposide is well tolerated, and has promising activity in newly diagnosed metastatic prostate cancer. AN - WOS:000225666200002 AU - Vaishampayan, U. AU - Fontana, J. AU - Du, W. AU - Hussain, M. DA - Dec DO - 10.1097/01.coc.0000135922.12198.e4 IS - 6 N1 - 11 15577431 PY - 2004 SN - 0277-3732 SP - 550-554 ST - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma T2 - American Journal of Clinical Oncology-Cancer Clinical Trials TI - Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma VL - 27 ID - 2671 ER - TY - JOUR AB - Purpose: We sought to evaluate the activity and tolerance of the rationally designed sequence of paclitaxel-topotecan-etoposide, a nonplatinum regimen, as induction therapy for limited-stage small-cell lung cancer before combined chemo- and radiotherapy. Patients and Methods: Patients with measurable disease, performance status 0 to 2, no prior therapy, and adequate organ function were eligible. Paclitaxel (110 Mg/m(2), administered intravenously on day 1), topotecan (1.5 Mg/m(2), administered orally on days 2 to 4), and etoposide (160 Mg/m2, administered orally on days 5 to 7 every 21 days), with filgrastim for two cycles, were followed by chest irradiation to 70 Gy (to postinduction tumor volume) concurrent with carboplatin (area under the curve of 5, administered intravenously on day 1) and etoposide (100 Mg/m(2) on days I to 3 every 21 days) without filgrastim for three cycles (five chemotherapy cycles total). We aimed to determine the response rates to induction and overall therapy, overall and failure-free survival, and toxicity. The primary statistical endpoint was to differentiate between complete response rates of 50 and 70% for the overall treatment program. Results: Between June 2001 and January 2003, 65 patients were enrolled, but one never started therapy, and one was ineligible. Patient characteristics included male/female, 27/36; white/black/ other/unknown, 58131111; median age 62 (range, 38-78); performance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six (10%) complete responses and 35 (56%) partial responses. Overall response to chemoradiotherapy included 27 (43%; 95% confidence interval [CI] 30-56%) complete responses and 24 (38%) partial responses. Median progression-free survival is 12 months (95% Cl, 9-15 months). Median overall survival is 20 months (95% Cl, 16-24 months). Frequent (>20%) grade 3/4 toxicities during all therapy included neutropenia, febrile neutropenia, anemia, thrombocytopenia, fatigue, and dysphagia. One patient died of febrile neutropenia, one died of febrile neutropenia and typhlitis, and one patient who declined transfusion for anemia died of cardiac ischemia. Conclusions: This treatment regimen has significant activity in limited-stage small-cell lung cancer but did not meet our prospectively defined criteria for further investigation in this setting. The addition of etoposide and the use of a sequenced administration schedule did not seem to improve overall activity beyond our prior experience with a topotecan-paclitaxel doublet. AN - WOS:000247888600013 AU - Miller, A. A. AU - Wang, X. F. AU - Bogart, J. A. AU - Hodgson, L. D. AU - Lima, Cmsr AU - Radford, J. E. AU - Vokes, E. E. AU - Green, M. R. DA - Jul DO - 10.1097/JTO.0b013e318074bbf5 IS - 7 N1 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology MAY 13-17, 2005 Orlando, FL Amer Soc Clin Oncol 17607121 PY - 2007 SN - 1556-0864 SP - 645-651 ST - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 T2 - Journal of Thoracic Oncology TI - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 VL - 2 ID - 3193 ER - TY - JOUR AB - PURPOSE: We sought to evaluate the activity and tolerance of the rationally designed sequence of paclitaxel-topotecan-etoposide, a nonplatinum regimen, as induction therapy for limited-stage small-cell lung cancer before combined chemo- and radiotherapy. PATIENTS AND METHODS: Patients with measurable disease, performance status 0 to 2, no prior therapy, and adequate organ function were eligible. Paclitaxel (110 mg/m, administered intravenously on day 1), topotecan (1.5 mg/m, administered orally on days 2 to 4), and etoposide (160 mg/m, administered orally on days 5 to 7 every 21 days), with filgrastim for two cycles, were followed by chest irradiation to 70 Gy (to postinduction tumor volume) concurrent with carboplatin (area under the curve of 5, administered intravenously on day 1) and etoposide (100 mg/m on days 1 to 3 every 21 days) without filgrastim for three cycles (five chemotherapy cycles total). We aimed to determine the response rates to induction and overall therapy, overall and failure-free survival, and toxicity. The primary statistical endpoint was to differentiate between complete response rates of 50 and 70% for the overall treatment program. RESULTS: Between June 2001 and January 2003, 65 patients were enrolled, but one never started therapy, and one was ineligible. Patient characteristics included male/female, 27/36; white/black/other/unknown, 58/3/1/1; median age 62 (range, 38-78); performance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six (10%) complete responses and 35 (56%) partial responses. Overall response to chemoradiotherapy included 27 (43%; 95% confidence interval [CI] 30-56%) complete responses and 24 (38%) partial responses. Median progression-free survival is 12 months (95% CI, 9-15 months). Median overall survival is 20 months (95% CI, 16-24 months). Frequent (>20%) grade 3/4 toxicities during all therapy included neutropenia, febrile neutropenia, anemia, thrombocytopenia, fatigue, and dysphagia. One patient died of febrile neutropenia, one died of febrile neutropenia and typhlitis, and one patient who declined transfusion for anemia died of cardiac ischemia. CONCLUSIONS: This treatment regimen has significant activity in limited-stage small-cell lung cancer but did not meet our prospectively defined criteria for further investigation in this setting. The addition of etoposide and the use of a sequenced administration schedule did not seem to improve overall activity beyond our prior experience with a topotecan-paclitaxel doublet. © 2007International Association for the Study of Lung Cancer. AD - A.A. Miller, Comprehensive Cancer Center, Wake Forest University, Medical Center Blvd., Winston-Salem, NC, United States AU - Miller, A. A. AU - Wang, X. F. AU - Bogart, J. A. AU - Hodgson, L. D. AU - Lima, C. M. S. R. AU - Radford, J. E. AU - Vokes, E. E. AU - Green, M. R. C2 - SmithKline Beecham DB - Embase Medline DO - 10.1097/JTO.0b013e318074bbf5 IS - 7 KW - carboplatin cimetidine dexamethasone diphenhydramine etoposide famotidine paclitaxel ranitidine recombinant granulocyte colony stimulating factor topotecan adult aged article cancer chemotherapy cancer radiotherapy cancer survival clinical trial confidence interval disease free survival drug efficacy drug safety drug tolerability female human small cell lung cancer major clinical study male multiple cycle treatment phase 2 clinical trial priority journal survival time treatment response unspecified side effect vomiting LA - English M3 - Article N1 - L47171787 2007-07-01 PY - 2007 SN - 1556-0864 1556-1380 SP - 645-651 ST - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 T2 - Journal of Thoracic Oncology TI - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47171787&from=export http://dx.doi.org/10.1097/JTO.0b013e318074bbf5 VL - 2 ID - 1228 ER - TY - JOUR AB - PURPOSE: We sought to evaluate the activity and tolerance of the rationally designed sequence of paclitaxel-topotecan-etoposide, a nonplatinum regimen, as induction therapy for limited-stage small-cell lung cancer before combined chemo- and radiotherapy. PATIENTS AND METHODS: Patients with measurable disease, performance status 0 to 2, no prior therapy, and adequate organ function were eligible. Paclitaxel (110 mg/m, administered intravenously on day 1), topotecan (1.5 mg/m, administered orally on days 2 to 4), and etoposide (160 mg/m, administered orally on days 5 to 7 every 21 days), with filgrastim for two cycles, were followed by chest irradiation to 70 Gy (to postinduction tumor volume) concurrent with carboplatin (area under the curve of 5, administered intravenously on day 1) and etoposide (100 mg/m on days 1 to 3 every 21 days) without filgrastim for three cycles (five chemotherapy cycles total). We aimed to determine the response rates to induction and overall therapy, overall and failure-free survival, and toxicity. The primary statistical endpoint was to differentiate between complete response rates of 50 and 70% for the overall treatment program. RESULTS: Between June 2001 and January 2003, 65 patients were enrolled, but one never started therapy, and one was ineligible. Patient characteristics included male/female, 27/36; white/black/other/unknown, 58/3/1/1; median age 62 (range, 38-78); performance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six (10%) complete responses and 35 (56%) partial responses. Overall response to chemoradiotherapy included 27 (43%; 95% confidence interval [CI] 30-56%) complete responses and 24 (38%) partial responses. Median progression-free survival is 12 months (95% CI, 9-15 months). Median overall survival is 20 months (95% CI, 16-24 months). Frequent (>20%) grade 3/4 toxicities during all therapy included neutropenia, febrile neutropenia, anemia, thrombocytopenia, fatigue, and dysphagia. One patient died of febrile neutropenia, one died of febrile neutropenia and typhlitis, and one patient who declined transfusion for anemia died of cardiac ischemia. CONCLUSIONS: This treatment regimen has significant activity in limited-stage small-cell lung cancer but did not meet our prospectively defined criteria for further investigation in this setting. The addition of etoposide and the use of a sequenced administration schedule did not seem to improve overall activity beyond our prior experience with a topotecan-paclitaxel doublet. © 2007International Association for the Study of Lung Cancer. AD - Wake Forest University, Winston-Salem, NC, United States CALGB Statistical Center, Duke University Medical Center, Durham, NC, United States State University of New York, Upstate Medical University, Syracuse, NY, United States Medical University of South Carolina, Charleston, SC, United States Southeastern Cancer Control Consortium, Winston-Salem, NC, United States University of Chicago, Chicago, IL, United States Comprehensive Cancer Center, Wake Forest University, Medical Center Blvd., Winston-Salem, NC, United States AU - Miller, A. A. AU - Wang, X. F. AU - Bogart, J. A. AU - Hodgson, L. D. AU - Lima, C. M. S. R. AU - Radford, J. E. AU - Vokes, E. E. AU - Green, M. R. DB - Scopus DO - 10.1097/JTO.0b013e318074bbf5 IS - 7 KW - Etoposide Paclitaxel Phase II Small-cell lung cancer Topotecan M3 - Article N1 - Cited By :27 Export Date: 22 March 2021 PY - 2007 SP - 645-651 ST - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 T2 - Journal of Thoracic Oncology TI - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547440506&doi=10.1097%2fJTO.0b013e318074bbf5&partnerID=40&md5=f1d19c9ee9dd6c574def0e1a686dcc8b VL - 2 ID - 2558 ER - TY - JOUR AB - PURPOSE: We sought to evaluate the activity and tolerance of the rationally designed sequence of paclitaxel‐topotecan‐etoposide, a nonplatinum regimen, as induction therapy for limited‐stage small‐cell lung cancer before combined chemo‐ and radiotherapy. PATIENTS AND METHODS: Patients with measurable disease, performance status 0 to 2, no prior therapy, and adequate organ function were eligible. Paclitaxel (110 mg/m2, administered intravenously on day 1), topotecan (1.5 mg/m2, administered orally on days 2 to 4), and etoposide (160 mg/m2, administered orally on days 5 to 7 every 21 days), with filgrastim for two cycles, were followed by chest irradiation to 70 Gy (to postinduction tumor volume) concurrent with carboplatin (area under the curve of 5, administered intravenously on day 1) and etoposide (100 mg/m2 on days 1 to 3 every 21 days) without filgrastim for three cycles (five chemotherapy cycles total). We aimed to determine the response rates to induction and overall therapy, overall and failure‐free survival, and toxicity. The primary statistical endpoint was to differentiate between complete response rates of 50 and 70% for the overall treatment program. RESULTS: Between June 2001 and January 2003, 65 patients were enrolled, but one never started therapy, and one was ineligible. Patient characteristics included male/female, 27/36; white/black/other/unknown, 58/3/1/1; median age 62 (range, 38‐78); performance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six (10%) complete responses and 35 (56%) partial responses. Overall response to chemoradiotherapy included 27 (43%; 95% confidence interval [CI] 30‐56%) complete responses and 24 (38%) partial responses. Median progression‐free survival is 12 months (95% CI, 9‐15 months). Median overall survival is 20 months (95% CI, 16‐24 months). Frequent (>20%) grade 3/4 toxicities during all therapy included neutropenia, febrile neutropenia, anemia, thrombocytopenia, fatigue, and dysphagia. One patient died of febrile neutropenia, one died of febrile neutropenia and typhlitis, and one patient who declined transfusion for anemia died of cardiac ischemia. CONCLUSIONS: This treatment regimen has significant activity in limited‐stage small‐cell lung cancer but did not meet our prospectively defined criteria for further investigation in this setting. The addition of etoposide and the use of a sequenced administration schedule did not seem to improve overall activity beyond our prior experience with a topotecan‐paclitaxel doublet. AN - CN-00701653 AU - Miller, A. A. AU - Wang, X. F. AU - Bogart, J. A. AU - Hodgson, L. D. AU - Rocha Lima, C. M. AU - Radford, J. E. AU - Vokes, E. E. AU - Green, M. R. DO - 10.1097/JTO.0b013e318074bbf5 IS - 7 KW - Adult Aged Antineoplastic Combined Chemotherapy Protocols [*therapeutic use] Carcinoma, Small Cell [drug therapy, radiotherapy, *therapy] Combined Modality Therapy Dose‐Response Relationship, Drug Etoposide [administration & dosage] Female Follow‐Up Studies Humans Lung Neoplasms [drug therapy, radiotherapy, *therapy] Male Middle Aged Paclitaxel [administration & dosage] Retrospective Studies Severity of Illness Index Survival Rate Topotecan [administration & dosage] Treatment Outcome M3 - Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2007 SP - 645‐651 ST - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 T2 - Journal of thoracic oncology TI - Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002 UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00701653/full VL - 2 ID - 1469 ER - TY - JOUR AB - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC. AD - M.J. Edelman, Division of Hematology, Oncology, VA Nrthn California Hlth Care System, Martinez, CA 94553, United States AU - Edelman, M. J. AU - Meyers, F. J. AU - Grennan, T. AU - Lauder, J. AU - Doroshow, J. DB - Embase Medline DO - 10.1023/A:1006097109088 IS - 2 KW - antineoplastic agent prostate specific antigen pyrazine diazohydroxide adult aged article cancer survival clinical article clinical trial human intravenous drug administration male neutropenia phase 2 clinical trial priority journal prostate cancer survival time thrombocytopenia LA - English M3 - Article N1 - L28495221 1998-11-12 PY - 1998 SN - 0167-6997 SP - 179-182 ST - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer T2 - Investigational New Drugs TI - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28495221&from=export http://dx.doi.org/10.1023/A:1006097109088 VL - 16 ID - 1329 ER - TY - JOUR AB - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC. AD - Division of Hematology/Oncology, UC Davis School of Medicine, Sacramento, CA, United States Division of Hematology/Oncology, VA N. California Health Care System, Martinez, CA, United States Kaiser Permanente Sacramento, Sacramento, CA, United States City of Hope Medical Center, Duarte, CA, United States Division of Hematology/Oncology, VA N. California Health Care System, Martinez, CA 94553, United States AU - Edelman, M. J. AU - Meyers, F. J. AU - Grennan, T. AU - Lauder, J. AU - Doroshow, J. DB - Scopus DO - 10.1023/A:1006097109088 IS - 2 KW - Hormone refractory Phase II trial Prostate cancer Pyrazine diazohydroxide M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 1998 SP - 179-182 ST - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer T2 - Investigational New Drugs TI - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031761823&doi=10.1023%2fA%3a1006097109088&partnerID=40&md5=066b364fddf3e588d06374003d59978c VL - 16 ID - 2645 ER - TY - JOUR AB - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primacy end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m(2) IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a >75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. In summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC. AN - WOS:000076951900011 AU - Edelman, M. J. AU - Meyers, F. J. AU - Grennan, T. AU - Lauder, J. AU - Doroshow, J. DA - 1998 DO - 10.1023/A:1006097109088 IS - 2 N1 - 11 10426670 PY - 1998 SN - 0167-6997 SP - 179-182 ST - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer T2 - Investigational New Drugs TI - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer VL - 16 ID - 2731 ER - TY - JOUR AB - BACKGROUND: Rigosertib (ON 01910.Na), a first‐in‐class Ras mimetic and small‐molecule inhibitor of multiple signaling pathways including polo‐like kinase 1 (PLK1) and phosphoinositide 3‐kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment‐naïve metastatic pancreatic adenocarcinoma. MATERIALS AND METHODS: Patients with metastatic pancreatic adenocarcinoma were randomized in a 2:1 fashion to gemcitabine 1000 mg/m(2) weekly for 3 weeks of a 4‐week cycle plus rigosertib 1800 mg/m(2) via 2‐h continuous IV infusions given twice weekly for 3 weeks of a 4‐week cycle (RIG + GEM) versus gemcitabine 1000 mg/m(2) weekly for 3 weeks in a 4‐week cycle (GEM). RESULTS: A total of 160 patients were enrolled globally and randomly assigned to RIG + GEM (106 patients) or GEM (54). The most common grade 3 or higher adverse events were neutropenia (8% in the RIG + GEM group versus 6% in the GEM group), hyponatremia (17% versus 4%), and anemia (8% versus 4%). The median overall survival was 6.1 months for RIG + GEM versus 6.4 months for GEM [hazard ratio (HR), 1.24; 95% confidence interval (CI) 0.85‐1.81]. The median progression‐free survival was 3.4 months for both groups (HR = 0.96; 95% CI 0.68‐1.36). The partial response rate was 19% versus 13% for RIG + GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene mutations (40 cases). Other mutations detected included TP53 (13 cases) and PIK3CA (1 case). No correlation between mutational status and efficacy was detected. CONCLUSIONS: The combination of RIG + GEM failed to demonstrate an improvement in survival or response compared with GEM in patients with metastatic pancreatic adenocarcinoma. Rigosertib showed a similar safety profile to that seen in previous trials using the IV formulation. AN - CN-01096809 AU - O'Neil, B. H. AU - Scott, A. J. AU - Ma, W. W. AU - Cohen, S. J. AU - Aisner, D. L. AU - Menter, A. R. AU - Tejani, M. A. AU - Cho, J. K. AU - Granfortuna, J. AU - Coveler, L. AU - et al. DO - 10.1093/annonc/mdv264 IS - 9 KW - *drug efficacy *drug safety *gemcitabine/ae [Adverse Drug Reaction] *gemcitabine/cb [Drug Combination] *gemcitabine/cm [Drug Comparison] *gemcitabine/ct [Clinical Trial] *gemcitabine/dt [Drug Therapy] *pancreas adenocarcinoma/dt [Drug Therapy] *rigosertib/ae [Adverse Drug Reaction] *rigosertib/cb [Drug Combination] *rigosertib/cm [Drug Comparison] *rigosertib/ct [Clinical Trial] *rigosertib/dt [Drug Therapy] *rigosertib/iv [Intravenous Drug Administration] Adenocarcinoma [*drug therapy] Adult African American Aged Aged, 80 and over Anemia/si [Side Effect] Antimetabolites, Antineoplastic [therapeutic use] Antineoplastic Combined Chemotherapy Protocols [*therapeutic use] Article Asian Black person Caucasian Cell Cycle Proteins [antagonists & inhibitors] Class I Phosphatidylinositol 3‐Kinases Continuous infusion Controlled study Correlation analysis Decreased appetite/si [Side Effect] Deoxycytidine [adverse effects, *analogs & derivatives, therapeutic use] Diarrhea/si [Side Effect] Disease‐Free Survival Drug Administration Schedule Drug withdrawal Fatigue/si [Side Effect] Female Gene Gene mutation Genetic analysis Glycine [adverse effects, *analogs & derivatives, therapeutic use] Hazard ratio Hispanic Human Human tissue Humans Hypertransaminasemia/si [Side Effect] Hypoalbuminemia/si [Side Effect] Hyponatremia/si [Side Effect] Liver metastasis/co [Complication] Lung metastasis/co [Complication] Major clinical study Male Middle Aged Multicenter study Multiple cycle treatment Nausea/si [Side Effect] Neutropenia/si [Side Effect] Oncogene K ras Overall survival PIK3CA gene Pancreatic Neoplasms [*drug therapy] Peritoneum metastasis/co [Complication] Phase 2 clinical trial Phase 3 clinical trial Phosphatidylinositol 3‐Kinases [genetics] Phosphoinositide‐3 Kinase Inhibitors Priority journal Progression free survival Protein‐Serine‐Threonine Kinases [antagonists & inhibitors] Proto‐Oncogene Proteins [antagonists & inhibitors] Proto‐Oncogene Proteins p21(ras) [genetics] Randomized controlled trial Retroperitoneal cancer/co [Complication] Sulfones [adverse effects, *therapeutic use] Thrombocytopenia/si [Side Effect] Treatment response Tumor Suppressor Protein p53 [genetics] Tumor suppressor gene Very elderly Vomiting/si [Side Effect] M3 - Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2015 SP - 1923‐1929 ST - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer T2 - Annals of oncology : official journal of the european society for medical oncology TI - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01096809/full VL - 26 ID - 1498 ER - TY - JOUR AB - Background: Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. In this study, rigosertib was assessed in combination with gemcitabine in patients with treatment-naïve metastatic pancreatic adenocarcinoma. Materials and methods: Patients with metastatic pancreatic adenocarcinoma were randomized in a 2:1 fashion to gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4-week cycle plus rigosertib 1800 mg/m2 via 2-h continuous IV infusions given twice weekly for 3 weeks of a 4-week cycle (RIG + GEM) versus gemcitabine 1000 mg/m2 weekly for 3 weeks in a 4-week cycle (GEM). Results: A total of 160 patients were enrolled globally and randomly assigned to RIG + GEM (106 patients) or GEM (54). The most common grade 3 or higher adverse events were neutropenia (8% in the RIG + GEM group versus 6% in the GEM group), hyponatremia (17% versus 4%), and anemia (8% versus 4%). The median overall survival was 6.1 months for RIG + GEM versus 6.4 months for GEM [hazard ratio (HR), 1.24; 95% confidence interval (CI) 0.85-1.81]. The median progression-free survival was 3.4 months for both groups (HR = 0.96; 95% CI 0.68-1.36). The partial response rate was 19% versus 13% for RIG + GEM versus GEM, respectively. Of 64 tumor samples sent for molecular analysis, 47 were adequate for multiplex genetic testing and 41 were positive for mutations. The majority of cases had KRAS gene mutations (40 cases). Other mutations detected included TP53 (13 cases) and PIK3CA (1 case). No correlation between mutational status and efficacy was detected. Conclusions: The combination of RIG + GEM failed to demonstrate an improvement in survival or response compared with GEM in patients with metastatic pancreatic adenocarcinoma. Rigosertib showed a similar safety profile to that seen in previous trials using the IV formulation. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. AD - Simon Cancer Center, Indiana University School of Medicine, Indianapolis, United States University of Colorado, Denverm Aurora, United States Roswell Park Cancer Institute, Buffalo, United States Fox Chase Cancer Center, Philadelphia, United States Kaiser Permanente, Lone Tree, United States University of Rochester Medical Center, Rochester, United States Oncare Hawaii, Honolulu, United States Cone Health Cancer Center, Greensboro, United States University of Washington, Seattle, United States University of Cincinnati Cancer Institute, Cincinnati, United States University of Kansas Medical Center, Westwood, United States Mount Sinai Medical Center, Miami Beach, United States Karmanos Cancer Institute, Detroit, United States Rex Cancer Center UNC Healthcare, Raleigh, United States Carolinas Health Care, Charlotte, United States Kaiser Permanante Northwest, Portland, United States NYU Clinical Cancer Center, New York, United States Hendersonville Hematology and Oncology at Pardee, Hendersonville, United States Kaiser Permanante Medical Center, Vallejo, United States McLeod Regional Medical Center, Florence, United States University of Massachusetts Memorial, Worcester, United States UCSD Moores Cancer Center, La Jolla, United States Vanderbilt-Ingram Cancer Center, Nashville, United States UNC Lineberger Comprehensive Cancer Center, Chapel Hill, United States Onconova Therapeutics Inc., Newtown, United States Oncology Consortia of Criterium Inc., Saratoga Springs, United States AU - O'Neil, B. H. AU - Scott, A. J. AU - Ma, W. W. AU - Cohen, S. J. AU - Aisner, D. L. AU - Menter, A. R. AU - Tejani, M. A. AU - Cho, J. K. AU - Granfortuna, J. AU - Coveler, L. AU - Olowokure, O. O. AU - Baranda, J. C. AU - Cusnir, M. AU - Phillip, P. AU - Boles, J. AU - Nazemzadeh, R. AU - Rarick, M. AU - Cohen, D. J. AU - Radford, J. AU - Fehrenbacher, L. AU - Bajaj, R. AU - Bathini, V. AU - Fanta, P. AU - Berlin, J. AU - McRee, A. J. AU - Maguire, R. AU - Wilhelm, F. AU - Maniar, M. AU - Jimeno, A. AU - Gomes, C. L. AU - Messersmith, W. A. C7 - mdv264 DB - Scopus DO - 10.1093/annonc/mdv264 IS - 9 KW - Pancreatic cancer Phase II/III PI3K inhibitor PLK1 inhibitor Ras mimetic Rigosertib M3 - Article N1 - Cited By :36 Export Date: 22 March 2021 PY - 2015 SP - 1923-1929 ST - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer T2 - Annals of Oncology TI - A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941631526&doi=10.1093%2fannonc%2fmdv264&partnerID=40&md5=657d5887f5036fe24628ee3d6e940422 VL - 26 ID - 2362 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p > .05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South. AU - Pekmezi, D. AU - Ainsworth, C. AU - Desmond, R. AU - Pisu, M. AU - Williams, V. AU - Wang, K. AU - Holly, T. AU - Meneses, K. AU - Marcus, B. AU - Demark-Wahnefried, W. DB - Medline DO - 10.1177/1524839918798819 IS - 2 KW - adult African American article behavior change cancer prevention controlled study exercise female health disparity health promotion human human experiment major clinical study minority health physical activity randomized controlled trial women's health LA - English M3 - Article N1 - L630825457 2020-02-11 PY - 2020 SN - 1524-8399 SP - 268-276 ST - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women T2 - Health promotion practice TI - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630825457&from=export http://dx.doi.org/10.1177/1524839918798819 VL - 21 ID - 814 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short‐term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12‐month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home‐based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self‐reported moderate‐to‐vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between‐group p > .05). Results indicate that modest improvements in moderate‐to‐vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0‐6) and were sustained during the tapered maintenance period (months 6‐12). Low‐cost, high‐reach, home‐based strategies have great potential for supporting sustained participation in physical activity and achieving long‐term health benefits among African American women in the Deep South. AN - CN-02087778 AU - Pekmezi, D. AU - Ainsworth, C. AU - Desmond, R. AU - Pisu, M. AU - Williams, V. AU - Wang, K. AU - Holly, T. AU - Meneses, K. AU - Marcus, B. AU - Demark-Wahnefried, W. DO - 10.1177/1524839918798819 IS - 2 KW - *African American *behavior change *cancer prevention *exercise *health disparity *health promotion *minority health *physical activity *women's health Adult Article Controlled study Female Human Human experiment Major clinical study Randomized controlled trial M3 - Journal: Article PY - 2020 SP - 268‐276 ST - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women T2 - Health promotion practice TI - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02087778/full VL - 21 ID - 1480 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p > .05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South. (PsycInfo Database Record (c) 2021 APA, all rights reserved) AD - Pekmezi, Dori, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, US, 35293 AN - 2020-09264-017 AU - Pekmezi, Dori AU - Ainsworth, Cole AU - Desmond, Renee AU - Pisu, Maria AU - Williams, Victoria AU - Wang, Kaiying AU - Holly, Taylor AU - Meneses, Karen AU - Marcus, Bess AU - Demark-Wahnefried, Wendy DB - psyh DO - 10.1177/1524839918798819 DP - EBSCOhost IS - 2 KW - physical activity exercise women’ s health behavior change cancer prevention cancer control health disparities health promotion Blacks African American minority health women Intervention Breast Neoplasms Human Females Obesity Prevention N1 - University of Alabama at Birmingham, Birmingham, AL, US. Release Date: 20210225. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Exercise; Health Promotion; Intervention; Physical Activity. Minor Descriptor: Blacks; Breast Neoplasms; Human Females; Obesity; Prevention; Health Disparities. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Physical Activity Readiness Questionnaire. Methodology: Empirical Study; Quantitative Study. Page Count: 9. Issue Publication Date: Mar, 2020. Copyright Statement: Society for Public Health Education. 2018. Sponsor: American Cancer Society, US. Grant: MRSG-13-156-01-CPPB. Recipients: No recipient indicated Sponsor: National Center for Advancing Translational Sciences. Grant: UL1TR001417. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Heart, Lung, and Blood Institute, US. Grant: T32HL105349. Recipients: No recipient indicated PY - 2020 SN - 1524-8399 1552-6372 SP - 268-276 ST - Physical activity maintenance following home-based, individually tailored print interventions for African American women T2 - Health Promotion Practice TI - Physical activity maintenance following home-based, individually tailored print interventions for African American women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-09264-017&site=ehost-live&scope=site dpekmezi@uab.edu VL - 21 ID - 1670 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p >.05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South. AD - University of Alabama at Birmingham, Birmingham, AL, USA Brown University, Providence, RI, USA AN - 141579205. Language: English. Entry Date: 20200210. Revision Date: 20200210. Publication Type: Article AU - Pekmezi, Dori AU - Ainsworth, Cole AU - Desmond, Renee AU - Pisu, Maria AU - Williams, Victoria AU - Wang, Kaiying AU - Holly, Taylor AU - Meneses, Karen AU - Marcus, Bess AU - Demark-Wahnefried, Wendy DB - CINAHL Complete DO - 10.1177/1524839918798819 DP - EBSCOhost IS - 2 KW - Black Persons Women Health Behavior Behavioral Changes Physical Activity Home Rehabilitation Psychological Well-Being Health Promotion -- Methods Human Health Status Disparities Pilot Studies Randomized Controlled Trials Descriptive Statistics Random Assignment Patient Centered Care Individualized Medicine Obesity -- Prevention and Control Neoplasms -- Prevention and Control Minority Groups N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Nursing; Peer Reviewed; Public Health; USA. Special Interest: Women's Health. NLM UID: 100890609. PY - 2020 SN - 1524-8399 SP - 268-276 ST - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women T2 - Health Promotion Practice TI - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141579205&site=ehost-live&scope=site VL - 21 ID - 2023 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p >.05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South. © 2018 Society for Public Health Education. AD - University of Alabama at Birmingham, Birmingham, AL, United States Brown University, Providence, RI, United States AU - Pekmezi, D. AU - Ainsworth, C. AU - Desmond, R. AU - Pisu, M. AU - Williams, V. AU - Wang, K. AU - Holly, T. AU - Meneses, K. AU - Marcus, B. AU - Demark-Wahnefried, W. DB - Scopus DO - 10.1177/1524839918798819 IS - 2 KW - behavior change Black/African American cancer prevention and control health disparities health promotion minority health physical activity/exercise women’s health M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2020 SP - 268-276 ST - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women T2 - Health Promotion Practice TI - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059354083&doi=10.1177%2f1524839918798819&partnerID=40&md5=e805619e6fc16605a3e8fd80fa880cb8 VL - 21 ID - 2202 ER - TY - JOUR AB - African American women report low participation in physical activity and are disproportionately burdened by related conditions (obesity, breast, and colon cancer). Physical activity interventions have shown promising results among African American women, but most studies in this area have focused on short-term increases. More enduring changes in health behavior will be needed to eliminate existing health disparities. Thus, the current study examined 12-month physical activity and psychosocial outcomes from a pilot randomized controlled trial (N = 84) of a Home-based Individually tailored Physical activity Print (HIPP) intervention for African American women in the Deep South. Retention was 77.4% at 12 months. HIPP participants increased self-reported moderate-to-vigorous physical activity from 35.1 minutes/week (standard deviation [SD] = 47.8) at baseline to 124 minutes/week (SD = 95.5) at 12 months, compared with the wellness contact control participants who reported increases from 48.2 minutes/week (SD = 51.3) to 102.5 minutes/week (SD = 94.5) over 12 months (between-group p > .05). Results indicate that modest improvements in moderate-to-vigorous physical activity and related psychosocial variables occurred during the active intervention phase (months 0-6) and were sustained during the tapered maintenance period (months 6-12). Low-cost, high-reach, home-based strategies have great potential for supporting sustained participation in physical activity and achieving long-term health benefits among African American women in the Deep South. AN - WOS:000511256200017 AU - Pekmezi, D. AU - Ainsworth, C. AU - Desmond, R. AU - Pisu, M. AU - Williams, V. AU - Wang, K. Y. AU - Holly, T. AU - Meneses, K. AU - Marcus, B. AU - Demark-Wahnefried, W. DA - Mar DO - 10.1177/1524839918798819 IS - 2 N1 - 30203677 PY - 2020 SN - 1524-8399 SP - 268-276 ST - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women T2 - Health Promotion Practice TI - Physical Activity Maintenance Following Home-Based, Individually Tailored Print Interventions for African American Women VL - 21 ID - 2791 ER - TY - JOUR AB - OBJECTIVE: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer. METHODS: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors. RESULTS: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors. CONCLUSIONS: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. : Video Summary:http://links.lww.com/MENO/A623. AU - Fogel, J. AU - Rubin, L. H. AU - Kilic, E. AU - Walega, D. R. AU - Maki, P. M. DB - Medline DO - 10.1097/GME.0000000000001608 IS - 11 KW - actimetry adult African American amnesia article breast cancer California verbal learning test cancer survival cancer survivor controlled study female human middle aged mood questionnaire sleep verbal memory videorecording LA - English M3 - Article N1 - L633286751 2020-11-06 PY - 2020 SN - 1530-0374 SP - 1209-1219 ST - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors T2 - Menopause (New York, N.Y.) TI - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L633286751&from=export http://dx.doi.org/10.1097/GME.0000000000001608 VL - 27 ID - 783 ER - TY - JOUR AB - OBJECTIVE: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer. METHODS: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors. RESULTS: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors. CONCLUSIONS: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. : Video Summary:http://links.lww.com/MENO/A623. AU - Fogel, J. AU - Rubin, L. H. AU - Kilic, E. AU - Walega, D. R. AU - Maki, P. M. DB - Medline DO - 10.1097/GME.0000000000001608 KW - actimetry adult African American amnesia article breast cancer California verbal learning test cancer survival cancer survivor controlled study female human middle aged mood questionnaire sleep verbal memory videorecording LA - English M3 - Article in Press N1 - L632509154 2020-08-10 PY - 2020 SN - 1530-0374 ST - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors T2 - Menopause (New York, N.Y.) TI - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632509154&from=export http://dx.doi.org/10.1097/GME.0000000000001608 ID - 796 ER - TY - JOUR AB - Objective: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer.Methods: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors.Results: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors.Conclusions: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. : Video Summary:http://links.lww.com/MENO/A623. AD - Department of Psychology, University of Illinois, Chicago, IL Department of Neurology and Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, IL Department of Psychiatry, University of Illinois at Chicago, Chicago, IL Department of Obstetrics & Gynecology, University of Illinois at Chicago, Chicago, IL AN - 147310565. Language: English. Entry Date: In Process. Revision Date: 20201203. Publication Type: journal article. Journal Subset: Biomedical AU - Fogel, Jessica AU - Rubin, Leah H. AU - Kilic, Ece AU - Walega, David R. AU - Maki, Pauline M. DB - CINAHL Complete DO - 10.1097/GME.0000000000001608 DP - EBSCOhost IS - 11 N1 - Peer Reviewed; USA. NLM UID: 9433353. PMID: NLM32740483. PY - 2020 SN - 1072-3714 SP - 1209-1219 ST - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors T2 - Menopause (10723714) TI - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147310565&site=ehost-live&scope=site VL - 27 ID - 2024 ER - TY - JOUR AB - OBJECTIVE: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer. METHODS: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors. RESULTS: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors. CONCLUSIONS: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. : Video Summary:http://links.lww.com/MENO/A623. AD - Department of Psychology, University of Illinois, Chicago, Mexico Department of Neurology and Psychiatry, Johns Hopkins School of Medicine, MD, Baltimore, United States Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, MD, Baltimore, United States Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Mexico Department of Psychiatry, University of Illinois at Chicago, Chicago, Mexico Department of Obstetrics & Gynecology, University of Illinois at Chicago, Chicago, Mexico AU - Fogel, J. AU - Rubin, L. H. AU - Kilic, E. AU - Walega, D. R. AU - Maki, P. M. DB - Scopus DO - 10.1097/GME.0000000000001608 IS - 11 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 1209-1219 ST - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors T2 - Menopause (New York, N.Y.) TI - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092154241&doi=10.1097%2fGME.0000000000001608&partnerID=40&md5=06fa067efeb4dffef243344b235591c5 VL - 27 ID - 2177 ER - TY - JOUR AB - Objective: Vasomotor symptoms (VMS), sleep disturbance, and cognitive complaints are common among women with a history of breast cancer and contribute to decreased quality of life. Studies in healthy women showed an association between verbal memory performance and physiologic VMS measured with ambulatory skin conductance monitors but not with VMS by self-report. We hypothesized that we would find a similar association in women with breast cancer. Methods: Participants included 30 female breast cancer survivors (mean age 52.7 y; 26.7% African-American) with moderate-to-severe VMS enrolled in a larger clinical trial of a nonhormonal intervention for VMS. At baseline, participants completed assessments of physiologic VMS, actigraphy-based assessments of sleep, questionnaires about mood, and two tests of verbal memory - Logical Memory (LM) and the California Verbal Learning Test (CVLT). Using baseline data, we conducted multivariate regression analyses to examine the association between VMS and memory, controlling for sleep and other factors. Results: On average, women reported 46% of total physiologic VMS. A higher frequency of physiologic VMS - but not reported VMS - was significantly associated with lower scores on the California Verbal Learning Test short-delay free recall (r[28] = -0.41, P = 0.03), long-delay free recall (r[28] = -0.42, P = 0.03), and total clustering, (r[28] = -0.39, P = 0.04). These associations were independent of sleep, mood, and other factors. Conclusions: Independent of their effect on sleep, VMS may be a modifiable contributor to memory difficulties in women with breast cancer. These findings underscore the importance of objective measurement of VMS in cognitive studies. AN - WOS:000588147700005 AU - Fogel, J. AU - Rubin, L. H. AU - Kilic, E. AU - Walega, D. R. AU - Maki, P. M. DA - Nov DO - 10.1097/GME.0000000000001608 IS - 11 N1 - 33110036 PY - 2020 SN - 1072-3714 SP - 1209-1219 ST - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors T2 - Menopause-the Journal of the North American Menopause Society TI - Physiologic vasomotor symptoms are associated with verbal memory dysfunction in breast cancer survivors VL - 27 ID - 2758 ER - TY - JOUR AB - Background. Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes. Methods. Women who reported significant hot flashes (≥ 14 per week) were enrolled. Black cohosh was given in the form of the commercial product Remifemin. The first week was a no-treatment baseline period, and therapy was given for the subsequent 4 weeks. Hot flash data were collected by daily questionnaires during baseline and treatment weeks. Adverse effects were recorded. Results. Twenty-one women completed the study. Their mean age was 56 years (range, 38-80). Thirteen patients had a history of breast cancer. Six patients were taking tamoxifen or raloxifene. Patients reported an average of 8.3 hot flashes per day during the baseline week. The reduction in mean daily hot flash frequency was 50% (95% CI, 34%-65%), while weekly hot flash scores were reduced 56% (95% CI, 40%-71%) at completion of the study. Overall, patients reported less trouble with sleeping, less fatigue, and less abnormal sweating. No patients stopped therapy because of adverse effects. Conclusions. Black cohosh appeared to reduce hot flashes and had a low toxicity. The efficacy found in this trial seems to be more than would be expected by a placebo effect (20%-30% hot flash reduction in previous trials). These results suggest that further evaluation of this black cohosh preparation with a phase III randomized trial is indicated. AD - B.A. Pockaj, Department of Surgery, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ 85259, United States AU - Pockaj, B. A. AU - Loprinzi, C. L. AU - Sloan, J. A. AU - Novotny, P. J. AU - Barton, D. L. AU - Hagenmaier, A. AU - Zhang, H. AU - Lambert, G. H. AU - Reeser, K. A. AU - Wisbey, J. A. C1 - remifemin DB - Embase Medline DO - 10.1081/CNV-200026394 IS - 4 KW - Actaea racemosa extract gabapentin placebo raloxifene tamoxifen venlafaxine adult anorexia anxiety disorder article breast cancer Actaea racemosa clinical article clinical trial constipation controlled clinical trial controlled study drug efficacy fatigue female hot flush human mood disorder morbidity nervousness pilot study postmenopause priority journal questionnaire restlessness scoring system side effect sleep time somnolence sweating treatment outcome xerostomia remifemin LA - English M3 - Article N1 - L39506871 2004-12-01 PY - 2004 SN - 0735-7907 SP - 515-521 ST - Pilot evaluation of black cohosh for the treatment of hot flashes in women T2 - Cancer Investigation TI - Pilot evaluation of black cohosh for the treatment of hot flashes in women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39506871&from=export http://dx.doi.org/10.1081/CNV-200026394 VL - 22 ID - 1277 ER - TY - JOUR AB - Background. Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes. Methods. Women who reported significant hot flashes (≥ 14 per week) were enrolled. Black cohosh was given in the form of the commercial product Remifemin. The first week was a no-treatment baseline period, and therapy was given for the subsequent 4 weeks. Hot flash data were collected by daily questionnaires during baseline and treatment weeks. Adverse effects were recorded. Results. Twenty-one women completed the study. Their mean age was 56 years (range, 38-80). Thirteen patients had a history of breast cancer. Six patients were taking tamoxifen or raloxifene. Patients reported an average of 8.3 hot flashes per day during the baseline week. The reduction in mean daily hot flash frequency was 50% (95% CI, 34%-65%), while weekly hot flash scores were reduced 56% (95% CI, 40%-71%) at completion of the study. Overall, patients reported less trouble with sleeping, less fatigue, and less abnormal sweating. No patients stopped therapy because of adverse effects. Conclusions. Black cohosh appeared to reduce hot flashes and had a low toxicity. The efficacy found in this trial seems to be more than would be expected by a placebo effect (20%-30% hot flash reduction in previous trials). These results suggest that further evaluation of this black cohosh preparation with a phase III randomized trial is indicated. AD - Department of Surgery, Mayo Clinic, Scottsdale, AZ, United States Division of Medical Oncology, Mayo Clinic, Rochester, MN, United States Cancer Center Statistics Unit, Mayo Clinic, Rochester, MN, United States Department of Obstetrics, Mayo Clinic, Rochester, MN, United States Department of Pediatrics, University of Medicine and Dentistry, New Jersey-Robert Wood Johnson M. S., New Brunswick, NJ, United States Department of Surgery, Mayo Clinic, 13400 East Shea Blvd., Scottsdale, AZ 85259, United States AU - Pockaj, B. A. AU - Loprinzi, C. L. AU - Sloan, J. A. AU - Novotny, P. J. AU - Barton, D. L. AU - Hagenmaier, A. AU - Zhang, H. AU - Lambert, G. H. AU - Reeser, K. A. AU - Wisbey, J. A. DB - Scopus DO - 10.1081/CNV-200026394 IS - 4 KW - Alternative medicine Breast cancer Hot flashes Medicine, herbal Menopause M3 - Article N1 - Cited By :81 Export Date: 22 March 2021 PY - 2004 SP - 515-521 ST - Pilot evaluation of black cohosh for the treatment of hot flashes in women T2 - Cancer Investigation TI - Pilot evaluation of black cohosh for the treatment of hot flashes in women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-5444273847&doi=10.1081%2fCNV-200026394&partnerID=40&md5=b56c96e90c1db33adfeab68af117c2e0 VL - 22 ID - 2603 ER - TY - JOUR AB - Background. Hot flashes cause significant morbidity in postmenopausal women, including women with breast cancer. We undertook a pilot study to estimate the effectiveness of black cohosh to reduce hot flashes. Methods. Women who reported significant hot flashes ( greater than or equal to 14 per week) were enrolled. Black cohosh was given in the form of the commercial product Remifemin. The first week was a no-treatment baseline period, and therapy was given for the subsequent 4 weeks. Hot flash data were collected by daily questionnaires during baseline and treatment weeks. Adverse effects were recorded. Results. Twenty-one women completed the study. Their mean age was 56 years (range, 38-80). Thirteen patients had a history of breast cancer. Six patients were taking tamoxifen or raloxifene. Patients reported an average of 8.3 hot flashes per day during the baseline week. The reduction in mean daily hot flash frequency was 50% (95% CI, 34%-65%), while weekly hot flash scores were reduced 56% (95% CI, 40%-71%) at completion of the study. Overall, patients reported less trouble with sleeping, less fatigue, and less abnormal sweating. No patients stopped therapy because of adverse effects. Conclusions. Black cohosh appeared to reduce hot flashes and had a low toxicity. The efficacy found in this trial seems to be more than would be expected by a placebo effect (20%-30% hot flash reduction in previous trials). These results suggest that further evaluation of this black cohosh preparation with a phase III randomized trial is indicated. AN - WOS:000225079900005 AU - Pockaj, B. A. AU - Loprinzi, C. L. AU - Sloan, J. A. AU - Novotny, P. J. AU - Barton, D. L. AU - Hagenmaier, A. AU - Zhang, H. Y. AU - Lambert, G. H. AU - Reeser, K. A. AU - Wisbey, J. A. DA - 2004 DO - 10.1081/CNV-200026394 IS - 4 N1 - 63 15565808 PY - 2004 SN - 0735-7907 SP - 515-521 ST - Pilot evaluation of black cohosh for the treatment of hot flashes in women T2 - Cancer Investigation TI - Pilot evaluation of black cohosh for the treatment of hot flashes in women VL - 22 ID - 2688 ER - TY - JOUR AB - The purpose of this project was to develop and test the feasibility and preliminary efficacy of a video about cancer clinical trials (CCTs) developed for breast cancer patients. We developed 2 brief 7-min videos that focused on breast cancer patients describing their experiences participating in CCTs, supplemented with doctors and research staff explaining key research concepts. One video was culturally tailored to Black patients and the other to White patients. To assess feasibility study, participants and their care providers completed a survey to evaluate their satisfaction with the video. Eligibility criteria for the study included ≥ 21 years of age, English-speaking, no prior experience participating in a CCT, and being potentially eligible for breast CCT enrollment. Preliminary efficacy was evaluated with a pretest-posttest design using a single item asking about intent to enroll in a clinical trial. The mean age of the patient sample (n = 50) was 53.0 years, and 50.0% were Black. Participants reported that the video was in the right length, useful, and easy to understand. Providers' evaluation (n = 5) revealed that viewing the video helped prepare patients for further CCT discussion. Preliminary efficacy showed no statistically significant difference in participant interest in CCT enrollment pre- and post-video. Changes in patients' intent in enrollment were associated with age and education. Culturally adapted video interventions can be helpful in supporting both patients and providers throughout the CCT education process but additional work is needed to improve enrollment into clinical trials. AU - Yeager, K. A. AU - Bai, J. AU - Gogineni, K. AU - Meisel, J. L. AU - Kweon, J. AU - Bruner, D. W. AU - Waldrop-Valverde, D. DB - Medline DO - 10.1007/s13187-020-01826-x KW - adult age article breast cancer cancer patient clinical article controlled study drug efficacy education feasibility study female human pretest posttest design satisfaction speech videorecording LA - English M3 - Article in Press N1 - L632330571 2020-07-22 PY - 2020 SN - 1543-0154 ST - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632330571&from=export http://dx.doi.org/10.1007/s13187-020-01826-x ID - 797 ER - TY - JOUR AB - The purpose of this project was to develop and test the feasibility and preliminary efficacy of a video about cancer clinical trials (CCTs) developed for breast cancer patients. We developed 2 brief 7-min videos that focused on breast cancer patients describing their experiences participating in CCTs, supplemented with doctors and research staff explaining key research concepts. One video was culturally tailored to Black patients and the other to White patients. To assess feasibility study, participants and their care providers completed a survey to evaluate their satisfaction with the video. Eligibility criteria for the study included ≥ 21 years of age, English-speaking, no prior experience participating in a CCT, and being potentially eligible for breast CCT enrollment. Preliminary efficacy was evaluated with a pretest-posttest design using a single item asking about intent to enroll in a clinical trial. The mean age of the patient sample (n = 50) was 53.0 years, and 50.0% were Black. Participants reported that the video was in the right length, useful, and easy to understand. Providers’ evaluation (n = 5) revealed that viewing the video helped prepare patients for further CCT discussion. Preliminary efficacy showed no statistically significant difference in participant interest in CCT enrollment pre- and post-video. Changes in patients’ intent in enrollment were associated with age and education. Culturally adapted video interventions can be helpful in supporting both patients and providers throughout the CCT education process but additional work is needed to improve enrollment into clinical trials. © 2020, American Association for Cancer Education. AD - Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA 30322, United States Winship Cancer Institute, Emory University, 1365-C Clifton Road NE, Atlanta, GA 30322-4207, United States School of Medicine, Emory University, 100 Woodruff Circle, Atlanta, GA 30322, United States AU - Yeager, K. A. AU - Bai, J. AU - Gogineni, K. AU - Meisel, J. L. AU - Kweon, J. AU - Bruner, D. W. AU - Waldrop-Valverde, D. DB - Scopus DO - 10.1007/s13187-020-01826-x KW - Breast cancer Clinical trial Education Video intervention M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 ST - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials T2 - Journal of Cancer Education TI - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087753975&doi=10.1007%2fs13187-020-01826-x&partnerID=40&md5=de483017085d2fb1603e4e787a19097b ID - 2209 ER - TY - JOUR AB - The purpose of this project was to develop and test the feasibility and preliminary efficacy of a video about cancer clinical trials (CCTs) developed for breast cancer patients. We developed 2 brief 7-min videos that focused on breast cancer patients describing their experiences participating in CCTs, supplemented with doctors and research staff explaining key research concepts. One video was culturally tailored to Black patients and the other to White patients. To assess feasibility study, participants and their care providers completed a survey to evaluate their satisfaction with the video. Eligibility criteria for the study included >= 21 years of age, English-speaking, no prior experience participating in a CCT, and being potentially eligible for breast CCT enrollment. Preliminary efficacy was evaluated with a pretest-posttest design using a single item asking about intent to enroll in a clinical trial. The mean age of the patient sample (n = 50) was 53.0 years, and 50.0% were Black. Participants reported that the video was in the right length, useful, and easy to understand. Providers' evaluation (n = 5) revealed that viewing the video helped prepare patients for further CCT discussion. Preliminary efficacy showed no statistically significant difference in participant interest in CCT enrollment pre- and post-video. Changes in patients' intent in enrollment were associated with age and education. Culturally adapted video interventions can be helpful in supporting both patients and providers throughout the CCT education process but additional work is needed to improve enrollment into clinical trials. AN - WOS:000547344600002 AU - Yeager, K. A. AU - Bai, J. B. AU - Gogineni, K. AU - Meisel, J. L. AU - Kweon, J. AU - Bruner, D. W. AU - Waldrop-Valverde, D. DO - 10.1007/s13187-020-01826-x N1 - 32654039 SN - 0885-8195 ST - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials T2 - Journal of Cancer Education TI - Pilot Feasibility Study of a Video Intervention to Educate Patients with Breast Cancer About Clinical Trials ID - 2772 ER - TY - JOUR AB - Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m 2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1-22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1-21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1-68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients. © Springer Science+Business Media, LLC 2010. AD - R. Wieder, Department of Medicine, UMDNJ-New Jersey Medical School, University Hospital Cancer Center, Newark, NJ, United States AU - Bryan, M. AU - Pulte, E. D. AU - Toomey, K. C. AU - Pliner, L. AU - Pavlick, A. C. AU - Saunders, T. AU - Wieder, R. C1 - taxol(Bristol Myers Squibb,United States) tretinoin(Hoffmann La Roche) vesanoid(Hoffmann La Roche) C2 - Bristol Myers Squibb(United States) Hoffmann La Roche DB - Embase Medline DO - 10.1007/s10637-010-9478-3 IS - 6 KW - paclitaxel retinoic acid adult aged alopecia anemia article ataxia bone metastasis breast cancer cancer combination chemotherapy cancer growth cancer staging cancer survival clinical article constipation disease severity dose response drug efficacy drug safety drug tolerability drug withdrawal edema fatigue female gastrointestinal hemorrhage headache human leukopenia lung embolism metastasis multicenter study multiple cycle treatment nausea neuropathy neutropenia outcome assessment pain phase 2 clinical trial priority journal cancer recurrence repeated drug dose seizure supraventricular tachycardia treatment duration visceral metastasis vomiting taxol tretinoin vesanoid LA - English M3 - Article N1 - L50979335 2010-07-07 2012-06-19 PY - 2011 SN - 0167-6997 1573-0646 SP - 1482-1487 ST - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer T2 - Investigational New Drugs TI - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50979335&from=export http://dx.doi.org/10.1007/s10637-010-9478-3 VL - 29 ID - 1130 ER - TY - JOUR AB - Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m 2 PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m 2 IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1-22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1-21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1-68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients. © Springer Science+Business Media, LLC 2010. AD - Department of Medicine, UMDNJ-New Jersey Medical School, University Hospital Cancer Center, Newark, NJ, United States Steeplechase Cancer Center, Somerset Medical Center, Somerville, NJ, United States A. C. Pavlick New York University, Cancer Institute, New York, NY, United States UMDNJ-New Jersey Medical School, Cancer Center H1216, 185 South Orange Avenue, Newark, NJ 07103, United States AU - Bryan, M. AU - Pulte, E. D. AU - Toomey, K. C. AU - Pliner, L. AU - Pavlick, A. C. AU - Saunders, T. AU - Wieder, R. DB - Scopus DO - 10.1007/s10637-010-9478-3 IS - 6 KW - All trans retinoic acid Metastatic breast cancer Potentiation Taxol M3 - Article N1 - Cited By :43 Export Date: 22 March 2021 PY - 2011 SP - 1482-1487 ST - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer T2 - Investigational New Drugs TI - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856050828&doi=10.1007%2fs10637-010-9478-3&partnerID=40&md5=65ce59d02b7f00f3b13c261725d9f2b6 VL - 29 ID - 2468 ER - TY - JOUR AB - Purpose: We investigated a combination therapy with weekly paclitaxel and all trans-retinoic acid (ATRA) for tolerability, response to treatment, time to progression and survival in previously treated patients with metastatic or recurrent breast cancer. Our rationale was based on preclinical studies demonstrating potentiation of the cytotoxic effects of taxanes and induction of differentiation by ATRA. Patients and methods: Seventeen patients with previously treated metastatic or recurrent breast cancer were enrolled to a regimen of all-trans retinoic acid (Vesanoid, tretinoin, Hoffman-La Roche, Inc.) 45 mg/m(2) PO daily for 4 days starting 2 days before a 1 h treatment with paclitaxel (Taxol, Bristol-Myers Squibb, Plainsboro, NJ) 80 mg/m(2) IV administered weekly for 3 weeks, repeated in 28 day cycles until disease progression or until no longer tolerated. Patients were evaluated for toxicity, response, time to progression and survival. Patients were primarily African American and Latino, representative of the population served by our Cancer Center. Results: The regimen was relatively well tolerated. There were nine grade 3 and one grade 4 toxic events. We administered 162 treatment cycles with a mean of 7.5 per patient (range 1-22, median 5). Three patients had a partial response (17.6%) and ten patients had stable disease (58.8%), with an overall clinical benefit of 76.4%. Median time to progression was 6.0 months (range 1-21, mean 7.7 months). Fourteen evaluable patients had a median survival of 16 months (range 1-68 months, mean 25.2 months). Conclusions: The data suggest this is a well tolerated regimen with modest response rates but with time to progression and survival rates similar to those reported for paclitaxel alone and relatively high rates of stable disease in this sample of patients. AN - WOS:000294824200040 AU - Bryan, M. AU - Pulte, E. D. AU - Toomey, K. C. AU - Pliner, L. AU - Pavlick, A. C. AU - Saunders, T. AU - Wieder, R. DA - Dec DO - 10.1007/s10637-010-9478-3 IS - 6 N1 - 20596747 PY - 2011 SN - 0167-6997 SP - 1482-1487 ST - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer T2 - Investigational New Drugs TI - A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer VL - 29 ID - 3082 ER - TY - JOUR AB - Background We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. Methods Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency× severity) at baseline was compared to the end of treatment. Results Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on antidepressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p=0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p=0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. Conclusions Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned. © 2011 Springer-Verlag. AD - T.J. Smith, Palliative Care Research and Medicine, Division of Hematology/Oncology and Palliative Care, Thomas Palliative Care Unit, Richmond, VA 23298-0230, United States AU - Park, H. AU - Parker, G. L. AU - Boardman, C. H. AU - Morris, M. M. AU - Smith, T. J. DB - Embase Medline DO - 10.1007/s00520-011-1099-7 IS - 6 KW - antidepressant agent aromatase inhibitor magnesium oxide tamoxifen adult African American aged article bedtime dosage breast cancer cancer patient Caucasian clinical article constipation controlled study depression diarrhea distress syndrome drug cost drug dose escalation drug response drug withdrawal fatigue female headache hot flush human menopause mood change nausea patient compliance phase 2 clinical trial priority journal scoring system side effect sweating LA - English M3 - Article N1 - L51250177 2011-01-29 2011-08-24 PY - 2011 SN - 0941-4355 1433-7339 SP - 859-863 ST - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients T2 - Supportive Care in Cancer TI - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51250177&from=export http://dx.doi.org/10.1007/s00520-011-1099-7 VL - 19 ID - 1139 ER - TY - JOUR AB - Background We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. Methods Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency× severity) at baseline was compared to the end of treatment. Results Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on antidepressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p=0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p=0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. Conclusions Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned. © 2011 Springer-Verlag. AD - Department of Internal Medicine Residency Program, Virginia Commonwealth University Health System, Richmond, VA, United States Massey Cancer Center Cancer Prevention and Control Program, Virginia Commonwealth University Health System, Richmond, VA, United States Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System, Richmond, VA, United States Department of Radiation Oncology, University of Virginia Radiation Oncology, Charlottesville, VA, United States Palliative Care Research and Medicine, Division of Hematology/Oncology and Palliative Care, Thomas Palliative Care Unit, Richmond, VA 23298-0230, United States AU - Park, H. AU - Parker, G. L. AU - Boardman, C. H. AU - Morris, M. M. AU - Smith, T. J. DB - Scopus DO - 10.1007/s00520-011-1099-7 IS - 6 KW - Breast cancer Drug treatment Hot flashes Menopause Survivorship M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2011 SP - 859-863 ST - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients T2 - Supportive Care in Cancer TI - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051671110&doi=10.1007%2fs00520-011-1099-7&partnerID=40&md5=d3cb06058de56d3d7684bf0f7ca27a46 VL - 19 ID - 2475 ER - TY - JOUR AB - Background We tested if magnesium would diminish bothersome hot flashes in breast cancer patients. Methods Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency x severity) at baseline was compared to the end of treatment. Results Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a > 50% reduction in hot flash score, and 19 (76%) had a > 25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial. Conclusions Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned. AN - WOS:000290029700017 AU - Park, H. AU - Parker, G. L. AU - Boardman, C. H. AU - Morris, M. M. AU - Smith, T. J. DA - Jun DO - 10.1007/s00520-011-1099-7 IS - 6 N1 - 21271347 PY - 2011 SN - 0941-4355 SP - 859-863 ST - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients T2 - Supportive Care in Cancer TI - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients VL - 19 ID - 3095 ER - TY - JOUR AB - Background: We tested if magnesium would diminish bothersome hot flashes in breast cancer patients.Methods: Breast cancer patients with at least 14 hot flashes a week received magnesium oxide 400 mg for 4 weeks, escalating to 800 mg if needed. Hot flash score (frequency × severity) at baseline was compared to the end of treatment.Results: Of 29 who enrolled, 25 women completed treatment. The average age was 53.5 years; six African American, the rest Caucasian; eight were on tamoxifen, nine were on aromatase inhibitors, and 14 were on anti-depressants. Seventeen patients escalated the magnesium dose. Hot flash frequency/week was reduced from 52.2 (standard error (SE), 13.7) to 27.7 (SE, 5.7), a 41.4% reduction, p = 0.02, two-sided paired t test. Hot flash score was reduced from 109.8 (SE, 40.9) to 47.8 (SE, 13.8), a 50.4% reduction, p = 0.04. Of 25 patients, 14 (56%) had a >50% reduction in hot flash score, and 19 (76%) had a >25% reduction. Fatigue, sweating, and distress were all significantly reduced. Side effects were minor: two women stopped the drug including one each with headache and nausea, and two women had grade 1 diarrhea. Compliance was excellent, and many patients continued treatment after the trial.Conclusions: Oral magnesium appears to have helped more than half of the patients and was well tolerated. Side effects and cost ($0.02/tablet) were minimal. A randomized placebo-controlled trial is planned. AD - Department of Internal Medicine Residency Program, Virginia Commonwealth University Health System, Richmond, VA, USA Department of Internal Medicine Residency Program, Virginia Commonwealth University Health System, Richmond, VA, USA. AN - 104890669. Language: English. Entry Date: 20110826. Revision Date: 20170802. Publication Type: journal article AU - Park, H. AU - Parker, G. L. AU - Boardman, C. H. AU - Morris, M. M. AU - Smith, T. J. AU - Park, Haeseong AU - Parker, Gwendolyn L. AU - Boardman, Cecelia H. AU - Morris, Monica M. AU - Smith, Thomas J. DB - CINAHL Complete DO - 10.1007/s00520-011-1099-7 DP - EBSCOhost IS - 6 KW - Breast Neoplasms -- Drug Therapy Hot Flashes -- Drug Therapy Magnesium Compounds -- Therapeutic Use Menopause Adult Aged Breast Neoplasms -- Complications Clinical Trials Female Health Care Costs Hot Flashes -- Etiology Human Medication Compliance Middle Age Pilot Studies Prospective Studies Severity of Illness Indices N1 - clinical trial; research. Journal Subset: Biomedical; Continental Europe; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed. Special Interest: Oncologic Care. Grant Information: P30 CA016059/CA/NCI NIH HHS/United States. NLM UID: 9302957. PMID: NLM21271347. PY - 2011 SN - 0941-4355 SP - 859-863 ST - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients T2 - Supportive Care in Cancer TI - A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104890669&site=ehost-live&scope=site VL - 19 ID - 1822 ER - TY - JOUR AB - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans. AD - Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road South Jacksonville 32224 USA AN - 104446409. Language: English. Entry Date: 20120803. Revision Date: 20200708. Publication Type: journal article AU - Colon-Otero, Gerardo AU - Albertie, Monica AU - Lesperance, Mary AU - Weis, Jennifer AU - Coles, Alton AU - Smith, Nina AU - Mills, Lynette AU - Woodward, Timothy AU - Aspitia, Alvaro AU - Vishnu, Prakash AU - Willis, Floyd AU - Isley, Amber AU - Fonseca, Rafael AU - Vachon, Celine AU - Rajkumar, S. AU - Weis, Jennifer A. AU - Aspitia, Alvaro Moreno AU - Rajkumar, S. Vincent DB - CINAHL Complete DO - 10.1007/s13187-011-0288-x DP - EBSCOhost IS - 2 KW - Black Persons Churches Clinical Research Collaboration Health Education Multiple Myeloma -- Education Research Subject Recruitment Adult Aged Body Mass Index Cancer Care Facilities Clergy Descriptive Statistics Female Florida Funding Source Health Behavior Health Knowledge Health Promotion Human Insurance, Health Interinstitutional Relations Male Middle Age Pilot Studies Questionnaires Surveys N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: UL1 RR024150/RR/NCRR NIH HHS/United States. NLM UID: 8610343. PMID: NLM22072126. PY - 2012 SN - 0885-8195 SP - 294-298 ST - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans T2 - Journal of Cancer Education TI - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104446409&site=ehost-live&scope=site VL - 27 ID - 1823 ER - TY - JOUR AB - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans. AD - G. Colon-Otero, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. AU - Colon-Otero, G. AU - Albertie, M. AU - Lesperance, M. AU - Weis, J. A. AU - Coles, A. AU - Smith, N. AU - Mills, L. AU - Woodward, T. AU - Aspitia, A. M. AU - Vishnu, P. AU - Willis, F. AU - Isley, A. AU - Fonseca, R. AU - Vachon, C. AU - Rajkumar, S. V. DB - Medline DO - 10.1007/s13187-011-0288-x IS - 2 KW - adult African American aged article attitude to health awareness ethnology female health education human male mass screening middle aged multiple myeloma organization and management participatory research patient education pilot study translational research LA - English M3 - Article N1 - L365910599 2012-10-31 PY - 2012 SN - 1543-0154 SP - 294-298 ST - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365910599&from=export http://dx.doi.org/10.1007/s13187-011-0288-x VL - 27 ID - 1117 ER - TY - JOUR AB - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Colon-Otero, Gerardo, Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL, US, 32224 AN - 2014-36563-016 AU - Colon-Otero, Gerardo AU - Albertie, Monica AU - Lesperance, Mary AU - Weis, Jennifer A. AU - Coles, Alton AU - Smith, Nina AU - Mills, Lynette AU - Woodward, Timothy AU - Aspitia, Alvaro Moreno AU - Vishnu, Prakash AU - Willis, Floyd AU - Isley, Amber AU - Fonseca, Rafael AU - Vachon, Celine AU - Rajkumar, S. Vincent DB - psyh DO - 10.1007/s13187-011-0288-x DP - EBSCOhost IS - 2 KW - Healthcare disparities Minority health Cancer Multiple myeloma Monoclonal proteins t(14 18) African Americans Adult Aged Awareness Community-Based Participatory Research Female Health Education Health Knowledge, Attitudes, Practice Humans Male Mass Screening Middle Aged Patient Education as Topic Pilot Projects Translational Medical Research Client Participation Collaboration Experimentation Neoplasms Religious Organizations Blacks Health Disparities N1 - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20150921. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Client Participation; Collaboration; Experimentation; Neoplasms; Religious Organizations. Minor Descriptor: Awareness; Blacks; Health Disparities. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 5. Issue Publication Date: Jun, 2012. Publication History: First Posted Date: Nov 10, 2011. Copyright Statement: Springer Science+Business Media, LLC. 2011. Sponsor: National Cancer Institute, Mayo Clinic Comprehensive Cancer Center. Grant: P50-CA01508. Recipients: No recipient indicated Sponsor: National Center for Research Resources/National Institutes of Health. Grant: 1 UL1 RR024150. Other Details: Mayo Clinic CTSA. Recipients: No recipient indicated Sponsor: Active SPORE. Grant: CA 90297052. Recipients: No recipient indicated PY - 2012 SN - 0885-8195 1543-0154 SP - 294-298 ST - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans T2 - Journal of Cancer Education TI - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-36563-016&site=ehost-live&scope=site ORCID: 0000-0002-5862-1833 ORCID: 0000-0002-5938-3769 gcolonotero@mayo.edu VL - 27 ID - 1706 ER - TY - JOUR AB - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans. © 2011 Springer Science+Business Media, LLC. AD - Division of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, United States Department of Radiation Oncology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, United States Department of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, United States Department of Family Medicine, Mayo Clinic, 4500 San Pablo Road South, Jacksonville, FL 32224, United States Division of Hematology and Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, United States Department of Epidemiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States Division of Hematology and Oncology, Mayo Clinic, 200 First Street, Rochester, MN 55905, United States Community Research Advisory Board (CRAB), Jacksonville, FL, United States Volunteers in Medicine, Jacksonville, FL, United States Leukemia and Lymphoma Society, Northeast Florida Chapter, Jacksonville, FL, United States Center for Translational Science Activities, Research Unit, Mayo Clinic, 200 First St SW, Rochester, MN 55905, United States AU - Colon-Otero, G. AU - Albertie, M. AU - Lesperance, M. AU - Weis, J. A. AU - Coles, A. AU - Smith, N. AU - Mills, L. AU - Woodward, T. AU - Aspitia, A. M. AU - Vishnu, P. AU - Willis, F. AU - Isley, A. AU - Fonseca, R. AU - Vachon, C. AU - Rajkumar, S. V. DB - Scopus DO - 10.1007/s13187-011-0288-x IS - 2 KW - African Americans Cancer Healthcare disparities Minority health Monoclonal proteins Multiple myeloma t (14,18) M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2012 SP - 294-298 ST - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans T2 - Journal of Cancer Education TI - A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864034439&doi=10.1007%2fs13187-011-0288-x&partnerID=40&md5=b6e78adc2d7a33cc8c5833492fd0f689 VL - 27 ID - 2455 ER - TY - JOUR AB - African Americans are underrepresented in cancer research. We evaluate whether collaboration with African American churches can improve cancer awareness and increase participation in translational research protocols among African Americans. From February to April 2010, the Mayo Clinic partnered with African American Jacksonville churches to provide educational programs focused on cancer research and healthy behaviors. Education on multiple myeloma and on-site access to a translational cancer research pilot project evaluating the prevalence of monoclonal gammopathies and t(14,18) in African Americans was offered. Seventy-four percent, 236 out of 318 participants, returned the questionnaires. The majority of participants had never received information on multiple myeloma (67%), had never received clinical research study information (57%), and were enrolled in the translational research studies (55%). Partnerships with African American churches in community education projects that bring research to church venues are effective in improving cancer awareness and in increasing research participation among African Americans. AN - WOS:000304144500014 AU - Colon-Otero, G. AU - Albertie, M. AU - Lesperance, M. AU - Weis, J. A. AU - Coles, A. AU - Smith, N. AU - Mills, L. AU - Woodward, T. AU - Aspitia, A. M. AU - Vishnu, P. AU - Willis, F. AU - Isley, A. AU - Fonseca, R. AU - Vachon, C. AU - Rajkumar, S. V. DA - Jun DO - 10.1007/s13187-011-0288-x IS - 2 N1 - 22072126 PY - 2012 SN - 0885-8195 SP - 294-298 ST - A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans T2 - Journal of Cancer Education TI - A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans VL - 27 ID - 3069 ER - TY - JOUR AB - Objective: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro- Caribbean breast cancer survivors. Design and Methods: Women with stage 0-IIIa breast cancer ≥6 months posttreatment, sedentary, and BMI ≥25 kg/m2 were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a highvegetable/low-fat/calorie-restricted diet. Results: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32-69) and mean BMI 33.2(±5.9) kg/m2; 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (±3.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (62.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). Conclusions: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. AD - H.A. Greenlee, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States AU - Greenlee, H. A. AU - Crew, K. D. AU - Mata, J. M. AU - McKinley, P. S. AU - Rundle, A. G. AU - Zhang, W. AU - Liao, Y. AU - Tsai, W. Y. AU - Hershman, D. L. DB - Embase Medline DO - 10.1038/oby.2012.177 IS - 1 KW - C reactive protein adult African American aged article body mass body weight breast cancer caloric restriction cancer recurrence cancer staging cancer survivor clinical article clinical observation controlled study crossover procedure diet dietary intake exercise female Hispanic human low fat diet male physical activity pilot study randomized controlled trial risk reduction sitting body weight loss LA - English M3 - Article N1 - L52143710 2012-08-06 2013-05-07 PY - 2013 SN - 1930-7381 1930-739X SP - 65-76 ST - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors T2 - Obesity TI - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52143710&from=export http://dx.doi.org/10.1038/oby.2012.177 VL - 21 ID - 1099 ER - TY - JOUR AB - OBJECTIVE: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non‐Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist‐controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro‐Caribbean breast cancer survivors. DESIGN AND METHODS: Women with stage 0‐IIIa breast cancer ≥ 6 months posttreatment, sedentary, and BMI ≥ 25 kg/m(2) were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30‐min exercise circuit and a high‐vegetable/low‐fat/calorie‐restricted diet. RESULTS: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32‐69) and mean BMI 33.2(± 5.9) kg/m(2); 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (± 3.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (± 2.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). CONCLUSIONS: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. AN - CN-00907620 AU - Greenlee, H. A. AU - Crew, K. D. AU - Mata, J. M. AU - McKinley, P. S. AU - Rundle, A. G. AU - Zhang, W. AU - Liao, Y. AU - Tsai, W. Y. AU - Hershman, D. L. DO - 10.1002/oby.20245 IS - 1 KW - Adult African Continental Ancestry Group Aged Body Mass Index Breast Neoplasms [*complications, ethnology] Caloric Restriction Diet, Reducing Dietary Fats [administration & dosage] Exercise Female Hispanic Americans Humans Middle Aged Minority Groups Obesity [complications, diet therapy, ethnology, *therapy] Pilot Projects Survivors Weight Gain Weight Reduction Programs M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2013 SP - 65‐76 ST - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors T2 - Obesity (Silver Spring, Md.) TI - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00907620/full VL - 21 ID - 1425 ER - TY - JOUR AB - Objective: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro- Caribbean breast cancer survivors. Design and Methods: Women with stage 0–IIIa breast cancer ≥ 6 months posttreatment, sedentary, and BMI ≥ 25 kg/m² were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a high-vegetable/ low-fat/calorie-restricted diet. Results: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32–69) and mean BMI 33.2(65.9) kg/m²; 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (63.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (62.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). Conclusions: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 2013-09534-015 AU - Greenlee, Heather A. AU - Crew, Katherine D. AU - Mata, Jennie M. AU - McKinley, Paula S. AU - Rundle, Andrew G. AU - Zhang, Wenfei AU - Liao, Yuyan AU - Tsai, Wei Y. AU - Hershman, Dawn L. DB - psyh DO - 10.1002/oby.20245 DP - EBSCOhost IS - 1 KW - diet exercise weight loss program evaluation breast cancer survivors minority groups Adult African Continental Ancestry Group Aged Body Mass Index Breast Neoplasms Caloric Restriction Diet, Reducing Dietary Fats Female Hispanic Americans Humans Middle Aged Obesity Pilot Projects Survivors Weight Gain Weight Reduction Programs Diets N1 - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, US. Other Publishers: Nature Publishing Group; North American Assn for the Study of Obesity (NAASO). Release Date: 20130708. Correction Date: 20160317. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Greenlee, Heather A. Major Descriptor: Breast Neoplasms; Diets; Exercise; Program Evaluation; Weight Loss. Minor Descriptor: Minority Groups; Survivors. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Block Questionnaire-Spanish Version; Adherence Index; Food Frequency Questionnaire; Kaiser Physical Activity Survey DOI: 10.1037/t23316-000. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 12. Issue Publication Date: Jan, 2013. Publication History: First Posted Date: Aug 2, 2012; Accepted Date: May 21, 2012; First Submitted Date: Jul 7, 2011. Copyright Statement: The Obesity Society. 2013. Sponsor: Gateway for Cancer Research. Recipients: Greenlee, Heather A. Sponsor: Women At Risk. Recipients: Greenlee, Heather A. Sponsor: Susan G. Komen Foundation. Recipients: Hershman, Dawn L. Sponsor: National Institutes of Health, National Center for Research Resources, US. Grant: UL1 RR024156. Recipients: No recipient indicated Sponsor: NIH Roadmap for Medical Research, US. Recipients: No recipient indicated PY - 2013 SN - 1930-7381 1930-739X SP - 65-76 ST - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors T2 - Obesity TI - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-09534-015&site=ehost-live&scope=site ORCID: 0000-0003-0211-7707 VL - 21 ID - 1699 ER - TY - JOUR AB - Objective: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro-Caribbean breast cancer survivors.Design and Methods: Women with stage 0-IIIa breast cancer ≥ 6 months posttreatment, sedentary, and BMI ≥ 25 kg/m(2) were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a high-vegetable/low-fat/calorie-restricted diet.Results: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32-69) and mean BMI 33.2(± 5.9) kg/m(2); 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (± 3.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (± 2.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02).Conclusions: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. AD - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA; Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA. hg2120@columbia.edu. AN - 104252791. Language: English. Entry Date: 20130913. Revision Date: 20200708. Publication Type: journal article AU - Greenlee, Heather A. AU - Crew, Katherine D. AU - Mata, Jennie M. AU - McKinley, Paula S. AU - Rundle, Andrew G. AU - Zhang, Wenfei AU - Liao, Yuyan AU - Tsai, Wei Y. AU - Hershman, Dawn L. DB - CINAHL Complete DO - 10.1002/oby.20245 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Complications Diet, Reducing Exercise Minority Groups Obesity -- Therapy Survivors Weight Reduction Programs Adult Black Persons Aged Body Mass Index Breast Neoplasms -- Ethnology Diet Therapy Dietary Fats -- Administration and Dosage Female Hispanic Americans Human Middle Age Obesity -- Complications Obesity -- Diet Therapy Obesity -- Ethnology Pilot Studies Weight Gain N1 - research; randomized controlled trial. Journal Subset: Biomedical; USA. Grant Information: UL1 RR024156/RR/NCRR NIH HHS/United States. NLM UID: 101264860. PMID: NLM23505170. PY - 2013 SN - 1930-7381 SP - 65-76 ST - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors T2 - Obesity (19307381) TI - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104252791&site=ehost-live&scope=site VL - 21 ID - 1824 ER - TY - JOUR AB - Objective: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro- Caribbean breast cancer survivors. Design and Methods: Women with stage 0-IIIa breast cancer ≥6 months posttreatment, sedentary, and BMI ≥25 kg/m2 were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a highvegetable/low-fat/calorie-restricted diet. Results: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32-69) and mean BMI 33.2(±5.9) kg/m2; 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (±3.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (62.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). Conclusions: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. AD - Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States Department of Medicine, Columbia University, New York, NY, United States Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States Department of Psychiatry and Behavioral Medicine, Columbia University, New York, NY, United States Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, United States AU - Greenlee, H. A. AU - Crew, K. D. AU - Mata, J. M. AU - McKinley, P. S. AU - Rundle, A. G. AU - Zhang, W. AU - Liao, Y. AU - Tsai, W. Y. AU - Hershman, D. L. DB - Scopus DO - 10.1038/oby.2012.177 IS - 1 M3 - Article N1 - Cited By :56 Export Date: 22 March 2021 PY - 2013 SP - 65-76 ST - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors T2 - Obesity TI - A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876292042&doi=10.1038%2foby.2012.177&partnerID=40&md5=48a80cc20a72b5aec1856bb8fa2ca9ab VL - 21 ID - 2448 ER - TY - JOUR AB - Objective: Obesity is associated with poorer breast cancer outcomes and losing weight postdiagnosis may improve survival. As Hispanic and black women have poorer breast cancer prognosis than non-Hispanic whites diagnosed at similar age and stage, and have higher rates of obesity, effective weight loss strategies are needed. We piloted a randomized, waitlist-controlled, crossover study to examine the effects and feasibility of the commercial Curves weight loss program among Hispanic, African American and Afro-Caribbean breast cancer survivors. Design and Methods: Women with stage 0-IIIa breast cancer >= 6 months posttreatment, sedentary, and BMI >= 25 kg/m(2) were randomized to the immediate arm (IA): 6 months of the Curves program followed by 6 months of observation; or the waitlist control arm (WCA): 6 months of observation followed by 6 months of the Curves program. The Curves program uses a 30-min exercise circuit and a high-vegetable/low-fat/calorie-restricted diet. Results: A total of 42 women enrolled (79% Hispanic, 21% black), mean age 51 (range 32-69) and mean BMI 33.2(65.9) kg/m(2); 91% were retained at month 12. At month 6, women in the IA lost an average 3.3% (63.5%) of body weight (range: 1.7% gain to 10.6% loss), as compared with 1.8% (62.9%) weight loss in the WCA (P = 0.04). At month 12, on average women in the IA regained some but not all of the weight lost during the first 6 months (P = 0.02). Conclusions: Minority breast cancer survivors were recruited and retained in a weight loss study. Six months of the Curves program resulted in moderate weight loss, but weight loss was not maintained postintervention. Future interventions should identify methods to increase uptake and maintenance of weight loss behaviors. AN - WOS:000322086900040 AU - Greenlee, H. A. AU - Crew, K. D. AU - Mata, J. M. AU - McKinley, P. S. AU - Rundle, A. G. AU - Zhang, W. F. AU - Liao, Y. Y. AU - Tsai, W. Y. AU - Hershman, D. L. DA - Jan DO - 10.1002/oby.20245 IS - 1 N1 - 23505170 PY - 2013 SN - 1930-7381 SP - 65-76 ST - A Pilot Randomized Controlled Trial of a Commercial Diet and Exercise Weight Loss Program in Minority Breast Cancer Survivors T2 - Obesity TI - A Pilot Randomized Controlled Trial of a Commercial Diet and Exercise Weight Loss Program in Minority Breast Cancer Survivors VL - 21 ID - 3056 ER - TY - JOUR AB - BACKGROUND: Interventions addressing cancer survivors' posttreatment concerns can be time‐intensive and require specialized staff. Research is needed to identify feasible minimal intervention strategies to improve survivors' quality of life after treatment. OBJECTIVES: The objective of this study was to evaluate the feasibility and short‐term impact of a minimal clinic intervention on breast cancer survivors' quality of life, unmet needs, distress, and cancer worry. INTERVENTIONS/METHODS: In this randomized controlled pilot trial, we enrolled breast cancer survivors at the end of treatment and administered baseline surveys. Participants were randomized to study arm (4‐week video plus educational booklet intervention group and usual care group) and completed follow‐up surveys at 10 weeks. Linear regression was used to examine intervention effects on quality of life outcomes controlling for clinical and demographic factors. Open‐ended questions were used to examine program satisfaction and obtain feedback to improve the intervention. RESULTS: We enrolled 92 survivors in the trial. Participants rated the intervention highly and reported feeling less isolated and having more realistic expectations about their recovery after completing the program. Despite positive qualitative findings, no significant intervention effects were observed for quality of life, unmet needs, distress, or cancer worry in unadjusted or adjusted analyses. CONCLUSIONS: Future research is needed to define optimal intervention elements to prepare breast cancer survivors for the posttreatment period. IMPLICATIONS FOR PRACTICE: Effective survivorship interventions may require more intensive components such as clinical input and longer follow‐up periods. AN - CN-01171366 AU - Sterba, K. R. AU - Armeson, K. AU - Franco, R. AU - Harper, J. AU - Patten, R. AU - Kindall, S. AU - Bearden, J. AU - Zapka, J. DO - 10.1097/NCC.0000000000000152 IS - 2 KW - *breast cancer/dm [Disease Management] *breast cancer/dt [Drug Therapy] *cancer survivor *convalescence *health program *minimal clinic intervention Adult African American Aged Antineoplastic agent/dt [Drug Therapy] Anxiety [psychology, therapy] Article Breast Neoplasms [psychology, *rehabilitation] Cancer chemotherapy Cancer hormone therapy Caregiver Caucasian Controlled study Depression Distress syndrome Expectation Feasibility study Female Follow up Health care survey Human Human needs Humans Intervention study Nutrition education Open ended questionnaire Patient attitude Patient education Patient satisfaction Patient worry Pilot Projects Pilot study Priority journal Program feasibility Quality of Life [*psychology] Quality of life Randomized controlled trial Survivors [*psychology] Treatment outcome M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2015 SP - E48‐56 ST - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery T2 - Cancer nursing TI - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01171366/full VL - 38 ID - 1532 ER - TY - JOUR AB - Background: Interventions addressing cancer survivors' posttreatment concerns can be time-intensive and require specialized staff. Research is needed to identify feasible minimal intervention strategies to improve survivors' quality of life after treatment. Objectives: The objective of this study was to evaluate the feasibility and short-term impact of a minimal clinic intervention on breast cancer survivors' quality of life, unmet needs, distress, and cancer worry. Interventions/Methods: In this randomized controlled pilot trial, we enrolled breast cancer survivors at the end of treatment and administered baseline surveys. Participants were randomized to study arm (4-week video plus educational booklet intervention group and usual care group) and completed follow-up surveys at 10 weeks. Linear regression was used to examine intervention effects on quality of life outcomes controlling for clinical and demographic factors. Open-ended questions were used to examine program satisfaction and obtain feedback to improve the intervention. Results: We enrolled 92 survivors in the trial. Participants rated the intervention highly and reported feeling less isolated and having more realistic expectations about their recovery after completing the program. Despite positive qualitative findings, no significant intervention effects were observed for quality of life, unmet needs, distress, or cancer worry in unadjusted or adjusted analyses. Conclusions: Future research is needed to define optimal intervention elements to prepare breast cancer survivors for the posttreatment period. Implications for Practice: Effective survivorship interventions may require more intensive components such as clinical input and longer follow-up periods. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. AD - Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC MSC 955, United States Greenville Health System Cancer Institute, United States Department of Radiation Oncology, Medical University of South Carolina, Charleston, United States Gibbs Cancer Center, Spartanburg Regional Healthcare SystemSC, United States AU - Sterba, K. R. AU - Armeson, K. AU - Franco, R. AU - Harper, J. AU - Patten, R. AU - Kindall, S. AU - Bearden, J. AU - Zapka, J. DB - Scopus DO - 10.1097/NCC.0000000000000152 IS - 2 KW - Breast cancer Intervention Quality of life Survivorship M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2015 SP - E48-E56 ST - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery T2 - Cancer Nursing TI - A pilot randomized controlled trial testing a minimal intervention to prepare breast cancer survivors for recovery UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924288483&doi=10.1097%2fNCC.0000000000000152&partnerID=40&md5=b0a5f45320a18b2a5024dc620e7473d7 VL - 38 ID - 2377 ER - TY - JOUR AB - Most cancer patients do not have an explicit discussion about prognosis and treatment despite documented adverse outcomes. Few decision aids have been developed to assist the difficult discussions of palliative management. We developed decision aids for people with advanced incurable breast, colorectal, lung, and hormone-refractory prostate cancers facing first-, second-, third-, and fourth-line chemotherapy. We recruited patients from our urban oncology clinic after gaining the permission of their treating oncologist. We measured knowledge of curability and treatment benefit before and after the intervention. Twenty-six of 27 (96%) patients completed the aids, with a mean age of 63, 56% female, 56% married, 56% African American, and 67% with a high school education or more. Most patients (14/27, 52%) thought a person with their advanced cancer could be cured, which was reduced (to 8/26, 31%, P = 0.15) after the decision aid. Nearly all overestimated the effect of palliative chemotherapy. No distress was noted, and hope did not change. The majority (20/27, 74%) found the information helpful to them, and almost all (25/27, 93%) wanted to share the information with their family and physicians. It is possible to give incurable patients their prognosis, treatment options, and options for improving end-of-life care without causing distress or lack of hope. Almost all find the information helpful and want to share it with doctors and family. Research is needed to test the findings in a larger sample and measure the outcomes of truthful information on quality of life, quality of care, and costs. © 2011 Elsevier Inc. AD - T.J. Smith, Virginia Commonwealth University, Division of Hematology/Oncology and Palliative Care, MCV Box 980230, Richmond, VA 23298-0230, United States AU - Smith, T. J. AU - Dow, L. A. AU - Virago, E. A. AU - Khatcheressian, J. AU - Matsuyama, R. AU - Lyckholm, L. J. DB - Embase Medline DO - 10.1016/j.suponc.2010.12.005 IS - 2 KW - adult advanced cancer African American aged article breast cancer cancer chemotherapy cancer palliative therapy clinical article clinical trial colorectal cancer decision support system distress syndrome educational status female hope human lung cancer male medical information outcome assessment pilot study prognosis prostate cancer LA - English M3 - Article N1 - L362505253 2011-09-14 2011-09-19 PY - 2011 SN - 1544-6794 1879-596X SP - 79-86 ST - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer T2 - Journal of Supportive Oncology TI - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362505253&from=export http://dx.doi.org/10.1016/j.suponc.2010.12.005 VL - 9 ID - 1144 ER - TY - JOUR AB - Most cancer patients do not have an explicit discussion about prognosis and treatment despite documented adverse outcomes. Few decision aids have been developed to assist the difficult discussions of palliative management. We developed decision aids for people with advanced in curable breast, colorectal, lung, and hormone-refractory prostate cancers facing first-, second-, third-, and fourth-line chemotherapy. We recruited patients from our urban oncology clinic after gaining the permission of their treating oncologist. We measured knowledge of curability and treatment benefit before and after the intervention. Twenty-six of 27 (96%) patients completed the aids, with ameanage of 63, 56% female, 56% married, 56% African American, and 67% with a high school education or more. Most patients (14/27, 52%) thought a person with their advanced cancer could be cured, which was reduced (to 8/26, 31%, P = 0.15) after the decision aid. Nearly all overestimated the effect of palliative chemotherapy. No distress was noted, and hope did not change. The majority (20/27, 74%) found the information helpful to them, and almost all (25/27, 93%) wanted to share the information with their family and physicians. It is possible to give incurable patients their prognosis, treatment options, and options for improving end-of-life care without causing distress or lack of hope. Almost all find the information helpful and want to share it with doctors and family. Research is needed to test the findings in a larger sample and measure the outcomes of truthful information on quality of life, quality of care, and costs. AD - Massey Cancer Center of Virginia Commonwealth University, School of Education, VCU School of Medicine, Department of Social and Behavioral Health, and the Virginia Cancer Institute, Richmond, Virginia 23298-0230, USA. tsmith5@mcvh-vcu.edu AN - 104891051. Language: English. Entry Date: 20110603. Revision Date: 20150711. Publication Type: Journal Article AU - Smith, T. J. AU - Dow, L. A. AU - Virago, E. A. AU - Khatcheressian, J. AU - Matsuyama, R. AU - Lyckholm, L. J. DB - CINAHL Complete DO - 10.1016/j.suponc.2010.12.005 DP - EBSCOhost IS - 2 KW - Decision Support Techniques Neoplasms -- Drug Therapy Aged Female Human Male Middle Age Pilot Studies Prognosis N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 101181305. PMID: NLM21542415. PY - 2011 SN - 1544-6794 SP - 79-86 ST - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer T2 - Journal of Supportive Oncology TI - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104891051&site=ehost-live&scope=site VL - 9 ID - 1825 ER - TY - JOUR AB - Most cancer patients do not have an explicit discussion about prognosis and treatment despite documented adverse outcomes. Few decision aids have been developed to assist the difficult discussions of palliative management. We developed decision aids for people with advanced incurable breast, colorectal, lung, and hormone-refractory prostate cancers facing first-, second-, third-, and fourth-line chemotherapy. We recruited patients from our urban oncology clinic after gaining the permission of their treating oncologist. We measured knowledge of curability and treatment benefit before and after the intervention. Twenty-six of 27 (96%) patients completed the aids, with a mean age of 63, 56% female, 56% married, 56% African American, and 67% with a high school education or more. Most patients (14/27, 52%) thought a person with their advanced cancer could be cured, which was reduced (to 8/26, 31%, P = 0.15) after the decision aid. Nearly all overestimated the effect of palliative chemotherapy. No distress was noted, and hope did not change. The majority (20/27, 74%) found the information helpful to them, and almost all (25/27, 93%) wanted to share the information with their family and physicians. It is possible to give incurable patients their prognosis, treatment options, and options for improving end-of-life care without causing distress or lack of hope. Almost all find the information helpful and want to share it with doctors and family. Research is needed to test the findings in a larger sample and measure the outcomes of truthful information on quality of life, quality of care, and costs. © 2011 Elsevier Inc. AD - Massey Cancer Center of Virginia Commonwealth University, School of Education, VCU School of Medicine, Department of Social and Behavioral Health and the Virginia Cancer Institute, Richmond, VA, United States AU - Smith, T. J. AU - Dow, L. A. AU - Virago, E. A. AU - Khatcheressian, J. AU - Matsuyama, R. AU - Lyckholm, L. J. DB - Scopus DO - 10.1016/j.suponc.2010.12.005 IS - 2 M3 - Article N1 - Cited By :76 Export Date: 22 March 2021 PY - 2011 SP - 79-86 ST - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer T2 - Journal of Supportive Oncology TI - A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80052437434&doi=10.1016%2fj.suponc.2010.12.005&partnerID=40&md5=1d13ee444170dd4b960a6f30eec4f490 VL - 9 ID - 2483 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. AD - Z. Djuric, Department of Family Medicine, University of Michigan, Cancer Center, 1500 E Hospital Dr, Ann Arbor, MI 48109-5930, United States AU - Djuric, Z. AU - Mirasolo, J. AU - Kimbrough, L. AU - Brown, D. R. AU - Heilbrun, L. K. AU - Canar, L. AU - Venkatranamamoorthy, R. AU - Simon, M. S. DB - Embase Medline DO - 10.1016/S0027-9684(15)30940-8 IS - 6 KW - adult African American article breast cancer cancer survivor clinical article controlled study counseling dietitian female health promotion human meditation pilot study priority journal religion telephone body weight loss wellbeing LA - English M3 - Article N1 - L354923193 2009-08-20 PY - 2009 SN - 0027-9684 SP - 552-564 ST - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors T2 - Journal of the National Medical Association TI - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354923193&from=export http://dx.doi.org/10.1016/S0027-9684(15)30940-8 VL - 101 ID - 1190 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian‐led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6‐month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8‐step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian‐only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well‐being (FACIT‐Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. AN - CN-00749808 AU - Djuric, Z. AU - Mirasolo, J. AU - Kimbrough, L. AU - Brown, D. R. AU - Heilbrun, L. K. AU - Canar, L. AU - Venkatranamamoorthy, R. AU - Simon, M. S. DO - 10.1016/s0027-9684(15)30940-8 IS - 6 KW - *breast cancer *cancer survivor *counseling *religion *weight reduction Adult African American African Americans Article Body Mass Index Breast Neoplasms [mortality, *psychology] Clinical article Controlled study Diet Records Dietitian Directive Counseling Female Health promotion Human Humans Meditation Middle Aged Motor Activity Obesity [complications, diet therapy, psychology] Pilot Projects Pilot study Priority journal Quality of Life Religion and Psychology Surveys and Questionnaires Survival Analysis Survivors Telephone United States Weight Loss Wellbeing M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2009 SP - 552‐564 ST - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors T2 - Journal of the National Medical Association TI - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00749808/full VL - 101 ID - 1359 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Djuric, Zora, Department of Family Medicine, University of Michigan, 1500 E Hospital Dr, Rm 2150 Cancer Center, Ann Arbor, MI, US, 48109-5930 AN - 2016-24830-008 AU - Djuric, Zora AU - Mirasolo, Josephine AU - Kimbrough, LaVern AU - Brown, Diane R. AU - Heilbrun, Lance K. AU - Canar, Lisa AU - Venkatranamamoorthy, Raghu AU - Simon, Michael S. DB - psyh DO - 10.1016/S0027-9684(15)30940-8 DP - EBSCOhost IS - 6 KW - weight breast cancer quality of life African Americans Body Mass Index Breast Neoplasms Diet Records Directive Counseling Female Humans Middle Aged Motor Activity Obesity Pilot Projects Religion and Psychology Surveys and Questionnaires Survival Analysis Survivors United States Weight Loss Blacks Counseling Spirituality N1 - Department of Family Medicine, University of Michigan, Ann Arbor, MI, US. Other Publishers: Elsevier Science. Release Date: 20161006. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Counseling; Spirituality; Weight Loss. Minor Descriptor: Survivors. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Brief Multidimensional Measure of Religiousness/Spirituality: 1999; Block ’98 Food Frequency Questionnaire; Functional Analysis of Chronic Illness and Therapy Scale; Stanford 7-Day Physical Activity Recall; Center for Epidemiological Studies Depression Scale DOI: 10.1037/t02942-000. Methodology: Empirical Study; Interview; Focus Group; Qualitative Study; Quantitative Study. Page Count: 13. Issue Publication Date: Jun, 2009. Sponsor: National Institutes of Health, US. Grant: 1R21 CA100720. Recipients: No recipient indicated Sponsor: Weight Watchers Group, US. Recipients: No recipient indicated Sponsor: Sponsor name not included. Grant: CA-22453. Other Details: Cancer Center Support grant. Recipients: No recipient indicated PY - 2009 SN - 0027-9684 1943-4693 SP - 552-564 ST - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors T2 - Journal of the National Medical Association TI - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-24830-008&site=ehost-live&scope=site zoralong@umich.edu VL - 101 ID - 1739 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. AD - Department of Family Medicine, University of Michigan, Cancer Center, 1500 E Hospital Dr, Ann Arbor, MI 48109-5930, United States Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States University of Medicine and Dentistry of New Jersey, Institute for the Elimination of Health Disparities, Newark, NJ, United States AU - Djuric, Z. AU - Mirasolo, J. AU - Kimbrough, L. AU - Brown, D. R. AU - Heilbrun, L. K. AU - Canar, L. AU - Venkatranamamoorthy, R. AU - Simon, M. S. DB - Scopus DO - 10.1016/S0027-9684(15)30940-8 IS - 6 KW - Breast cancer Quality of life Weight M3 - Article N1 - Cited By :55 Export Date: 22 March 2021 PY - 2009 SP - 552-564 ST - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors T2 - Journal of the National Medical Association TI - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650564612&doi=10.1016%2fS0027-9684%2815%2930940-8&partnerID=40&md5=70c5fd4ac7edca72379a6931d9ce9873 VL - 101 ID - 2527 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited, Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. AN - WOS:000267390400006 AU - Djuric, Z. AU - Mirasolo, J. AU - Kimbrough, L. AU - Brown, D. R. AU - Heilbrun, L. K. AU - Canar, L. AU - Venkatranamamoorthy, R. AU - Simon, M. S. DA - Jun DO - 10.1016/S0027-9684(15)30940-8 IS - 6 N1 - 19585923 PY - 2009 SN - 0027-9684 SP - 552-564 ST - A Pilot Trial of Spirituality Counseling for Weight Loss Maintenance in African American Breast Cancer Survivors T2 - Journal of the National Medical Association TI - A Pilot Trial of Spirituality Counseling for Weight Loss Maintenance in African American Breast Cancer Survivors VL - 101 ID - 3146 ER - TY - JOUR AB - A continuing challenge in weight loss treatment is attaining maintenance of weight loss. The goal of this study was to develop a counseling method that would assist African American breast cancer survivors with weight loss maintenance. In this pilot study, 31 obese breast cancer survivors were recruited. Individualized, dietitian-led counseling by telephone and free Weight Watchers coupons were provided to all participants for 18 months. At the 6-month time point, women were randomized to receive spirituality counseling or not in addition to the standard program. The spirituality counseling was delivered via telephone using an 8-step framework. Subjects were asked to utilize daily meditation or prayer, daily readings, and the recording of thoughts in a journal. Mean weight loss from baseline to 6 months was a modest 2.0% of baseline weight. From 6 to 18 months, there was no further weight change in the spirituality arm and a gain of 0.7% in the dietitian-only arm. Despite little effect on weight loss, it did appear that spirituality counseling positively affected spiritual well-being (FACIT-Sp) scores and dietary quality. The spirituality counseling framework therefore may be further refined and useful for other health promotion studies with African American populations. AD - Department of Family Medicine, University of Michigan, Ann Arbor, Michigan 48109-5930, USA Department of Family Medicine, University of Michigan, Ann Arbor, Michigan 48109-5930, USA. zoralong@umich.edu AN - 105221495. Language: English. Entry Date: 20100903. Revision Date: 20190612. Publication Type: journal article AU - Djuric, Z. AU - Mirasolo, J. AU - Kimbrough, L. AU - Brown, D. R. AU - Heilbrun, L. K. AU - Canar, L. AU - Venkatranamamoorthy, R. AU - Simon, M. S. AU - Djuric, Zora AU - Mirasolo, Josephine AU - Kimbrough, LaVern AU - Brown, Diane R. AU - Heilbrun, Lance K. AU - Canar, Lisa AU - Venkatranamamoorthy, Raghu AU - Simon, Michael S. DB - CINAHL Complete DP - EBSCOhost IS - 6 KW - Black Persons Breast Neoplasms -- Psychosocial Factors Counseling Religion and Psychology Weight Loss Body Mass Index Breast Neoplasms -- Mortality Diet Records Female Human Middle Age Motor Activity Obesity -- Complications Obesity -- Diet Therapy Obesity -- Psychosocial Factors Pilot Studies Quality of Life Questionnaires Survival Analysis Survivors United States Clinical Trials N1 - clinical trial; research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: P30 CA022453-229020/CA/NCI NIH HHS/United States. NLM UID: 7503090. PMID: NLM19585923. PY - 2009 SN - 0027-9684 SP - 552-564 ST - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors T2 - Journal of the National Medical Association TI - A pilot trial of spirituality counseling for weight loss maintenance in African American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105221495&site=ehost-live&scope=site VL - 101 ID - 1826 ER - TY - JOUR AB - Tamoxifen (TAM) is widely used for treatment and prevention of breast cancer. TAM is metabolized by cytochrome P450 (CYP450) enzymes, including CYP3A5. Although two genetic polymorphisms in CYP3A5 are known (CYP3A5*3 and CYP3A5*6), the effects of these polymorphisms on TAM metabolism, TAM side effects, and tumor characteristics are unknown. Thus, this work tested the hypothesis that CYP3A5 polymorphisms are associated with differential TAM levels, TAM side effects, and tumor characteristics in breast cancer patients. Postmenopausal women with breast cancer (n=98) were recruited from a single cancer center. Polymorphic status was established using polymerase chain reactions (PCR). The associations between polymorphic status, race, TAM levels, side effects, and tumor characteristics were assessed using t-tests and logistic regression models. The data indicate that 40.7% of the breast cancer patients had the CYP3A5*3 polymorphism, and 9.1% had the CYP3A5*6 polymorphism. In addition, Caucasian women were 26 times more likely to carry the CYP3A5*3 polymorphism than African American (AA) women, whereas AA women were nine times more likely to carry the CYP3A5*6 polymorphism than Caucasian women. No significant differences were seen in TAM or TAM metabolite levels or TAM side effects by polymorphic status. There was a significant difference, however, in mean tumor size in women with the CYP3A5*6 polymorphism (3.6±0.98 cm) compared to those without the polymorphism (2.0±0.18 cm) (P<0.02). Taken together, these data suggest that racial differences in CYP3A5 polymorphisms exist although the polymorphisms do not appear to be associated with levels of TAM metabolites and side effects. © 2004 Elsevier Ireland Ltd. All rights reserved. AD - Dept. of Epidemiol. and Prev. Med., School of Medicine, Univ. Maryland, 600 W. Redwood S., United States Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA, United States MRC Bioanalytical Science Group, Birkbeck, University of London, London, UK, United Kingdom AU - Tucker, A. N. AU - Tkaczuk, K. A. AU - Lewis, L. M. AU - Tomic, D. AU - Lim, C. K. AU - Flaws, J. A. DB - Scopus DO - 10.1016/j.canlet.2004.08.027 IS - 1 KW - Breast cancer Cytochrome P450 3A5 Metabolism Polymorphisms Race/ethnicity Tamoxifen M3 - Article N1 - Cited By :41 Export Date: 22 March 2021 PY - 2005 SP - 61-72 ST - Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients T2 - Cancer Letters TI - Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-10444221019&doi=10.1016%2fj.canlet.2004.08.027&partnerID=40&md5=a892fa01a13992b3e57e060add479675 VL - 217 ID - 2599 ER - TY - JOUR AB - Empiric data on recruitment of minorities into clinical or population studies are limited. The authors evaluated population- and community-based recruitment methods in a 1998-2001 case-control study of lung cancer among African Americans and Latinos. For lung cancer cases in the San Francisco Bay Area of California, rapid case ascertainment by the tumor registry combined with telephone screening identified 470 (9%) African Americans and 262 (5%) Latinos. When random digit dialing (RDD) and Health Care Financing Administration (HCFA) records failed to yield adequate numbers of controls in appropriate age-gender-ethnicity groups, community-based recruitment methods were used. Demographic characteristics and behavioral and occupational risk factors for controls, by recruitment method, were compared with those for lung cancer cases to evaluate potential bias. The average numbers of hours spent per control recruited were 18.6 for RDD, 11.4 for HCFA, and less than 1 for the community-based methods. The prevalence of smoking-related lung cancer risk factors was significantly higher among African-American community-based controls than for those identified through RDD (p < 0.005). Compared with HCFA controls, Latino RDD controls reported significantly higher cumulative smoking exposure (p < 0.05). Further assessment of strategies for successful recruitment of minority participants into epidemiologic studies is warranted. AD - Northern California Cancer Center, 32960 Alvarado-Niles Road, Suite 600, Union City, CA 94587; dcabral@nccc.org AN - 106654197. Language: English. Entry Date: 20041022. Revision Date: 20200624. Publication Type: Journal Article AU - Cabral, D. N. AU - Nápoles-Springer, A. M. AU - Miike, R. AU - McMillan, A. AU - Sison, J. D. AU - Wrensch, M. R. AU - Pérez-Stable, E. J. AU - Wiencke, J. K. DB - CINAHL Complete DO - 10.1093/aje/kwg138 DP - EBSCOhost IS - 3 KW - Black Persons Hispanic Americans Lung Neoplasms -- Epidemiology Research Subject Recruitment Aged Analysis of Variance Bias (Research) California Case Control Studies Descriptive Statistics Epidemiological Research Female Interviews Logistic Regression Male Middle Age P-Value Funding Source Human N1 - research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: Supported by grant ES06717 from the National Institute of Environmental Health Sciences, the Resource Center for Minority Aging Research program of the National Institute on Aging, the National Institute of Nursing Research, and the Office of Research on Minority Health, grant P30 AG15272. NLM UID: 7910653. PMID: NLM12882950. PY - 2003 SN - 0002-9262 SP - 272-279 ST - Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study T2 - American Journal of Epidemiology TI - Population- and community-based recruitment of African Americans and Latinos: the San Francisco Bay Area Lung Cancer Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106654197&site=ehost-live&scope=site VL - 158 ID - 2025 ER - TY - JOUR AB - Purpose: Although many studies clearly demonstrate disparities in cancer clinical trial enrollment, there is a lack of consensus on potential causes. Furthermore, virtually nothing is known about associations between patients’ decision-making style and their participation in clinical trials. Methods: Women with newly diagnosed, stage 0–II breast cancer reported to the Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries in 2013–2014 were surveyed approximately seven months after diagnosis. We investigated two primary outcome variables: (1) invitation to participate in a clinical trial, (2) participation in a clinical trial. We evaluated bivariate associations using Chi-squared tests and used multivariable logistic regression models to investigate associations between patient variables, including decision-making style, and the primary outcomes. Results: 2578 patients responded (71% response rate); 30% were > age 65, 18% were black, 18% were Latina, 29% had ≤ high school education. 10% of patients reported invitation to participate in a clinical trial; 5% reported participation in a clinical trial. After adjustment younger age, receipt of chemotherapy or radiation, disease stage, and a more rational (versus more intuitive) decision-making style were associated with a higher odds of invitation to participate. Being married was associated with a higher odds of participation; having an annual family income ≥ $40,000 was associated with a lower odds of participation. Conclusions: 10% of patients reported invitation to participate in a clinical trial, and half of these reported participation. Invitation to participate varied by age and decision-making style, and participation varied by marital status and income. AD - C.M. Veenstra, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States AU - Patel, M. A. AU - Shah, J. L. AU - Abrahamse, P. H. AU - Jagsi, R. AU - Katz, S. J. AU - Hawley, S. T. AU - Veenstra, C. M. DB - Embase Medline DO - 10.1007/s10549-020-05844-7 IS - 2 KW - adult age aged article breast cancer cancer chemotherapy cancer radiotherapy cancer registry cancer staging clinical decision making clinical outcome clinical trial clinical trial (topic) cohort analysis educational status family income female health disparity health survey human major clinical study marriage mastectomy outcome variable patient participation population research priority journal questionnaire tumor volume LA - English M3 - Article N1 - L2005776298 2020-08-11 PY - 2020 SN - 1573-7217 0167-6806 SP - 507-518 ST - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer T2 - Breast Cancer Research and Treatment TI - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005776298&from=export http://dx.doi.org/10.1007/s10549-020-05844-7 VL - 184 ID - 780 ER - TY - JOUR AB - Purpose: Although many studies clearly demonstrate disparities in cancer clinical trial enrollment, there is a lack of consensus on potential causes. Furthermore, virtually nothing is known about associations between patients’ decision-making style and their participation in clinical trials. Methods: Women with newly diagnosed, stage 0–II breast cancer reported to the Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries in 2013–2014 were surveyed approximately seven months after diagnosis. We investigated two primary outcome variables: (1) invitation to participate in a clinical trial, (2) participation in a clinical trial. We evaluated bivariate associations using Chi-squared tests and used multivariable logistic regression models to investigate associations between patient variables, including decision-making style, and the primary outcomes. Results: 2578 patients responded (71% response rate); 30% were > age 65, 18% were black, 18% were Latina, 29% had ≤ high school education. 10% of patients reported invitation to participate in a clinical trial; 5% reported participation in a clinical trial. After adjustment younger age, receipt of chemotherapy or radiation, disease stage, and a more rational (versus more intuitive) decision-making style were associated with a higher odds of invitation to participate. Being married was associated with a higher odds of participation; having an annual family income ≥ $40,000 was associated with a lower odds of participation. Conclusions: 10% of patients reported invitation to participate in a clinical trial, and half of these reported participation. Invitation to participate varied by age and decision-making style, and participation varied by marital status and income. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. AD - Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, United States Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, MI, United States Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States Department of Health Management and Policy, University of Michigan, Ann Arbor, MI, United States US Department of Veterans Affairs Health Services Research and Development, University of Michigan, Ann Arbor, MI, United States Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States AU - Patel, M. A. AU - Shah, J. L. AU - Abrahamse, P. H. AU - Jagsi, R. AU - Katz, S. J. AU - Hawley, S. T. AU - Veenstra, C. M. DB - Scopus DO - 10.1007/s10549-020-05844-7 IS - 2 KW - Breast cancer Clinical trial Disparities Enrollment Participation M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 507-518 ST - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer T2 - Breast Cancer Research and Treatment TI - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089017111&doi=10.1007%2fs10549-020-05844-7&partnerID=40&md5=d4b14bcf63193360ac57b5b30caa2451 VL - 184 ID - 2178 ER - TY - JOUR AB - Purpose Although many studies clearly demonstrate disparities in cancer clinical trial enrollment, there is a lack of consensus on potential causes. Furthermore, virtually nothing is known about associations between patients' decision-making style and their participation in clinical trials. Methods Women with newly diagnosed, stage 0-II breast cancer reported to the Georgia and Los Angeles County Surveillance, Epidemiology, and End Results (SEER) registries in 2013-2014 were surveyed approximately seven months after diagnosis. We investigated two primary outcome variables: (1) invitation to participate in a clinical trial, (2) participation in a clinical trial. We evaluated bivariate associations using Chi-squared tests and used multivariable logistic regression models to investigate associations between patient variables, including decision-making style, and the primary outcomes. Results 2578 patients responded (71% response rate); 30% were > age 65, 18% were black, 18% were Latina, 29% had <= high school education. 10% of patients reported invitation to participate in a clinical trial; 5% reported participation in a clinical trial. After adjustment younger age, receipt of chemotherapy or radiation, disease stage, and a more rational (versus more intuitive) decision-making style were associated with a higher odds of invitation to participate. Being married was associated with a higher odds of participation; having an annual family income >= $40,000 was associated with a lower odds of participation. Conclusions 10% of patients reported invitation to participate in a clinical trial, and half of these reported participation. Invitation to participate varied by age and decision-making style, and participation varied by marital status and income. AN - WOS:000556156700002 AU - Patel, M. A. AU - Shah, J. L. AU - Abrahamse, P. H. AU - Jagsi, R. AU - Katz, S. J. AU - Hawley, S. T. AU - Veenstra, C. M. DA - Nov DO - 10.1007/s10549-020-05844-7 IS - 2 N1 - 32757135 PY - 2020 SN - 0167-6806 SP - 507-518 ST - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer T2 - Breast Cancer Research and Treatment TI - A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer VL - 184 ID - 2770 ER - TY - JOUR AB - Purpose: To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. Methods: In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women’s Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0–3 points, higher AL: 4–8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. Results: Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). Conclusion: These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors. AD - A.A.M. Llanos, Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States AU - Xing, C. Y. AU - Doose, M. AU - Qin, B. AU - Lin, Y. AU - Carson, T. L. AU - Plascak, J. J. AU - Demissie, K. AU - Hong, C. C. AU - Bandera, E. V. AU - Llanos, A. A. M. DB - Embase Medline DO - 10.1007/s10549-020-05901-1 IS - 3 KW - cholesterol high density lipoprotein cholesterol triacylglycerol adult age distribution article Black person breast cancer cancer diagnosis cancer grading cancer staging cancer survivor cholesterol blood level cohort analysis comorbidity controlled study diastolic blood pressure educational status female Functional Assessment of Cancer Therapy Breast Cancer Instrument high density lipoprotein cholesterol level human longitudinal study low density lipoprotein cholesterol level major clinical study marriage pre diagnostic allostatic load priority journal quality of life quality of life assessment systolic blood pressure triacylglycerol blood level waist circumference LA - English M3 - Article N1 - L2006126070 2020-09-15 PY - 2020 SN - 1573-7217 0167-6806 SP - 901-914 ST - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors T2 - Breast Cancer Research and Treatment TI - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006126070&from=export http://dx.doi.org/10.1007/s10549-020-05901-1 VL - 184 ID - 773 ER - TY - JOUR AB - Purpose: To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. Methods: In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women’s Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0–3 points, higher AL: 4–8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. Results: Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). Conclusion: These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors. © 2020, Springer Science+Business Media, LLC, part of Springer Nature. AD - Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, NJ, United States Division of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States Department of Epidemiology and Biostatistics, SUNY Downstate Health Sciences University School of Public Health, Brooklyn, NY, United States Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States AU - Xing, C. Y. AU - Doose, M. AU - Qin, B. AU - Lin, Y. AU - Carson, T. L. AU - Plascak, J. J. AU - Demissie, K. AU - Hong, C. C. AU - Bandera, E. V. AU - Llanos, A. A. M. DB - Scopus DO - 10.1007/s10549-020-05901-1 IS - 3 KW - Allostatic load Black women Breast cancer survivorship Health-related quality of life Longitudinal study M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 901-914 ST - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors T2 - Breast Cancer Research and Treatment TI - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090503983&doi=10.1007%2fs10549-020-05901-1&partnerID=40&md5=bde67d628cf21cd98b7702b0999ec2ae VL - 184 ID - 2171 ER - TY - JOUR AB - Purpose To determine the association of pre-diagnostic allostatic load (AL) with health-related quality of life (HRQOL) among Black women with breast cancer. Methods In a sample of 409 Black women with non-metastatic breast cancer enrolled in the Women's Circle of Health Follow-Up Study (WCHFS), two pre-diagnostic AL measures were estimated using medical records data from up to 12 months prior to breast cancer diagnosis: AL-lipid/metabolic profile-based measure and AL-inflammatory profile-based measure. HRQOL was assessed approximately 24 months post diagnosis, using the Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) instrument, including 5 subscale scores [presented by physical well-being (PWB), social & family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), and breast cancer-specific scale (BCS)] and 3 derived total scores [presented by trial outcome index (TOI), Functional Assessment of Cancer Therapy-General (FACT-G) and FACT-B]. We used multivariable logistic regression models, using dichotomized AL scores (lower AL: 0-3 points, higher AL: 4-8 points), to assess the associations between the two pre-diagnostic AL measures and HRQOL. Results Higher pre-diagnostic AL was associated with poorer FWB and lower FACT-G, but these associations were statistically significant for the AL-inflammatory profile-based measure (FWB: OR 1.63, 95% CI 1.04, 2.56; FACT-G: OR 1.62, 95% CI 1.04, 2.54), but not the AL-lipid/metabolic profile-based measure (FWB: OR 1.45, 95% CI 0.81, 2.59; FACT-G: OR 1.33, 95% CI 0.75, 2.37). Conclusion These findings suggest that higher AL, particularly when measured using the inflammatory profile-based measure, was associated with poorer HRQOL, namely FWB and FACT-G, among Black breast cancer survivors. AN - WOS:000568716300002 AU - Xing, C. Y. AU - Doose, M. AU - Qin, B. AU - Lin, Y. AU - Carson, T. L. AU - Plascak, J. J. AU - Demissie, K. AU - Hong, C. C. AU - Bandera, E. V. AU - Llanos, A. A. M. DA - Dec DO - 10.1007/s10549-020-05901-1 IS - 3 N1 - 32914357 PY - 2020 SN - 0167-6806 SP - 901-914 ST - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors T2 - Breast Cancer Research and Treatment TI - Pre-diagnostic allostatic load and health-related quality of life in a cohort of Black breast cancer survivors VL - 184 ID - 2765 ER - TY - JOUR AB - Purpose: Although African-Americans experience higher cancer morbidity and mortality rates compared to their White counterparts, their participation in biospecimen research is lower than that of their white peers. This study investigated the prevalence and predictors of biospecimen donation in a large, cohort study of Black women.Methods: The BWHS is a follow-up study of U.S. Black women aged 21-69 years enrolled through postal health questionnaires. Between January 2004 and December 2007, participants were sent a consent form with a postage-paid return envelope, and a mouthwash collection kit. Univariate and age- and educational status-adjusted logistic regression models were used to estimate the association of socio-demographic, lifestyle and medical factors with donation of biospecimens.Results: Buccal cells with consent forms were obtained from 26,790 women, for a response rate of 51 %. The strongest predictors of biospecimen donation were age: response increased from 48.6 % among those aged <40 to 63.1 % among those aged 60 and older [RR 1.30 (95 % CI 1.27, 1.34)]; multivitamin use [RR (95 % CI) 1.32 (1.30, 1.34)]; physician visit in the previous 2 years [RR (95 % CI) 1.61 (1.58, 1.65)], and a history of breast [RR (95 % CI) 1.59 (1.56, 1.63)], colon [RR (95 % CI) 1.18 (1.16, 1.20)], and cervical [RR (95 % CI) 1.63 (1.60, 1.67)] cancer screening.Conclusions: We found that 51 % of women in the geographically-dispersed Black Women's Health Study cohort were willing to provide mouthwash samples to be used for genetic analyses. The response in this study is encouraging given published findings of low overall participation rates of African-Americans in genetic studies. AD - Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, N.W., E501 Washington 20057 USA Slone Epidemiology Center, Boston University, Boston USA Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, N.W., E501, Washington, DC, 20057, USA Slone Epidemiology Center, Boston University, Boston, MA, USA AN - 115398177. Language: English. Entry Date: 20170210. Revision Date: 20190517. Publication Type: journal article AU - Adams-Campbell, Lucile AU - Dash, Chiranjeev AU - Palmer, Julie AU - Wiedemeier, Manuela AU - Russell, Cordelia AU - Rosenberg, Lynn AU - Cozier, Yvette AU - Adams-Campbell, Lucile L. AU - Palmer, Julie R. AU - Wiedemeier, Manuela V. AU - Russell, Cordelia W. AU - Cozier, Yvette C. DB - CINAHL Complete DO - 10.1007/s10552-016-0747-0 DP - EBSCOhost IS - 6 KW - Early Detection of Cancer -- Utilization Black Persons -- Statistics and Numerical Data Health Behavior Patient Selection Young Adult Middle Age Breast Neoplasms -- Diagnosis Prospective Studies Aged Cervix Neoplasms -- Diagnosis Women's Health Female Logistic Regression Sequence Analysis Colonic Neoplasms -- Diagnosis Adult Tissue Banks Specimen Handling Age Factors Vitamins -- Therapeutic Use Human Funding Source N1 - research. Journal Subset: Biomedical; Continental Europe; Europe. Grant Information: UM1 CA164974/CA/NCI NIH HHS/United States. NLM UID: 9100846. PMID: NLM27106577. PY - 2016 SN - 0957-5243 SP - 797-803 ST - Predictors of biospecimen donation in the Black Women's Health Study T2 - Cancer Causes & Control TI - Predictors of biospecimen donation in the Black Women's Health Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115398177&site=ehost-live&scope=site VL - 27 ID - 2027 ER - TY - JOUR AB - BACKGROUND. Clinical trials may offer patients innovative therapeutic options with potentially better outcomes, which are particularly relevant for patients afflicted with lung carcinoma, because current therapies provide only modest survival benefits. Only approximately 5% of patients with newly diagnosed cancer participate in clinical trials nationwide, and African-American (AA) patients are particularly under-represented. METHODS. To determine predictors of clinical trials enrollment, the authors reviewed the medical records of 427 patients with lung carcinoma (175 AA patients and 252 non-AA patients) who were eligible for clinical trials between 1994 and 1998 at the Karmanos Cancer Institute in Detroit, Michigan. Logistic regression analysis was used to assess the association of patient demographic characteristics and clinical trial enrollment. RESULTS. Ninety-one patients (21%) were enrolled onto a lung cancer clinical trial during the period of the current study. Enrollment was associated significantly with race (P < 0.001), gender (P = 0.048), age (P = 0.005), and insurance type (P = 0.024). After multivariable adjustment, only race and gender remained significant predictors of enrollment. AA patients were less likely to enroll than non-AA patients (odds ratio [OR], 0.485; 95% confidence interval [95% CI], 0.243-0.966), and men were more likely than women to enroll (OR, 1.812; 95% CI, 1.033-3.178). CONCLUSIONS. The current results suggest disparities by race and gender in the enrollment of patients onto lung cancer clinical trials and support the need to improve educational and outreach endeavors that would make clinical trials available to a wider range of eligible patients. © 2005 American Cancer Society. AD - W. Du, Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, United States AU - Du, W. AU - Gadgeel, S. M. AU - Simon, M. S. DB - Embase Medline DO - 10.1002/cncr.21638 IS - 2 KW - adult African American age aged article cancer patient cancer survival clinical trial controlled clinical trial controlled study demography female gender health insurance human lung cancer lung carcinoma major clinical study male priority journal race treatment outcome LA - English M3 - Article N1 - L43100453 2006-02-09 PY - 2006 SN - 0008-543X 1097-0142 SP - 420-425 ST - Predictors of enrollment in lung cancer clinical trials T2 - Cancer TI - Predictors of enrollment in lung cancer clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L43100453&from=export http://dx.doi.org/10.1002/cncr.21638 VL - 106 ID - 1254 ER - TY - JOUR AB - BACKGROUND. Clinical trials may offer patients innovative therapeutic options with potentially better outcomes, which are particularly relevant for patients afflicted with lung carcinoma, because current therapies provide only modest survival benefits. Only approximately 5% of patients with newly diagnosed cancer participate in clinical trials nationwide, and African-American (AA) patients are particularly under-represented. METHODS. To determine predictors of clinical trials enrollment, the authors reviewed the medical records of 427 patients with lung carcinoma (175 AA patients and 252 non-AA patients) who were eligible for clinical trials between 1994 and 1998 at the Karmanos Cancer Institute in Detroit, Michigan. Logistic regression analysis was used to assess the association of patient demographic characteristics and clinical trial enrollment. RESULTS. Ninety-one patients (21%) were enrolled onto a lung cancer clinical trial during the period of the current study. Enrollment was associated significantly with race (P < 0.001), gender (P = 0.048), age (P = 0.005), and insurance type (P = 0.024). After multivariable adjustment, only race and gender remained significant predictors of enrollment. AA patients were less likely to enroll than non-AA patients (odds ratio [OR], 0.485; 95% confidence interval [95% CI], 0.243-0.966), and men were more likely than women to enroll (OR, 1.812; 95% CI, 1.033-3.178). CONCLUSIONS. The current results suggest disparities by race and gender in the enrollment of patients onto lung cancer clinical trials and support the need to improve educational and outreach endeavors that would make clinical trials available to a wider range of eligible patients. © 2005 American Cancer Society. AD - Department of Pediatrics, Wayne State University, Detroit, MI, United States Karmanos Cancer Institute, Wayne State University School of Medicine, Division of Hematology and Oncology, Detroit, MI, United States Department of Pediatrics, Wayne State University, Children's Hospital of Michigan, 3901 Beaubien, Detroit, MI 48201, United States AU - Du, W. AU - Gadgeel, S. M. AU - Simon, M. S. DB - Scopus DO - 10.1002/cncr.21638 IS - 2 KW - Clinical trials Disparity Enrollment Lung carcinoma Predictors M3 - Article N1 - Cited By :41 Export Date: 22 March 2021 PY - 2006 SP - 420-425 ST - Predictors of enrollment in lung cancer clinical trials T2 - Cancer TI - Predictors of enrollment in lung cancer clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-30744467162&doi=10.1002%2fcncr.21638&partnerID=40&md5=35805c0bd5f52deb42b685fdb8ce27e0 VL - 106 ID - 2581 ER - TY - JOUR AB - BACKGROUND. Clinical trials may offer patients innovative therapeutic options with potentially better outcomes, which are particularly relevant for patients afflicted with lung carcinoma, because current therapies provide only modest survival benefits. Only approximately 5% of patients with newly diagnosed cancer participate in clinical trials nationwide, and African-American (AA) patients are particularly under-represented. METHODS. To determine predictors of clinical trials enrollment, the authors reviewed the medical records of 427 patients with lung carcinoma (175 AA patients and 252 non-AA patients) who were eligible for clinical trials between 1994 and 1998 at the Karmanos Cancer Institute in Detroit, Michigan. Logistic regression analysis was used to assess the association of patient demographic characteristics and clinical trial enrollment. RESULTS. Ninety-one patients (21%) were enrolled onto a lung cancer clinical trial during the period of the current study. Enrollment was associated significantly with race (P < 0.001), gender (P = 0.048), age (P = 0.005), and insurance type (P = 0.024). After multivariable adjustment, only race and gender remained significant predictors of enrollment. AA patients were less likely to enroll than non-AA patients (odds ratio [OR], 0.485; 95% confidence interval [95% CI], 0.243-0.966), and men were more likely than women to enroll (OR, 1.812; 95% CI, 1.033-3.178). CONCLUSIONS. The current results suggest disparities by race and gender in the enrollment of patients onto lung cancer clinical trials and support the need to improve educational and outreach endeavors that would make clinical trials available to a wider range of eligible patients. AN - WOS:000234588700024 AU - Du, W. AU - Gadgeel, S. M. AU - Simon, M. S. DA - Jan DO - 10.1002/cncr.21638 IS - 2 N1 - 16342295 PY - 2006 SN - 0008-543X SP - 420-425 ST - Predictors of enrollment in lung cancer clinical trials T2 - Cancer TI - Predictors of enrollment in lung cancer clinical trials VL - 106 ID - 3222 ER - TY - JOUR AB - Background: Disparities in breast cancer care are a worsening problem, requiring effective interventions that seek to address the delivery of high quality cancer care. Evidence from interventions designed to improve timeliness of care routinely identify lack of social support as one of the biggest barriers to care. And, social support is associated with adherence to treatment and survival. This study explores predictors of social support in a diverse population of cancer patients. Patients and Methods: This is a secondary analysis of baseline preliminary data from participants enrolled in Project SUPPORT, a randomized controlled comparative effectiveness trial designed to evaluate the impact of patient navigation with or without legal support and services, among women diagnosed with Stages 0‐4 breast cancer between 2014‐2016. Upon enrollment (within one month of a cancer diagnosis) we administered the Medical Outcomes Survey (MOS) of social support to all participants. This validated survey tool addresses functional support, including an overall score (range 0‐95) and 4 distinct domains: Emotional/Informational, Tangible, Affectionate and Positive Social Interaction. Using chi‐squared and t‐tests we compared MOS scores across socio��demographic variables: age, race, language, insurance, health literacy and marital status. Results: Of the 103 participants, mean age is 54.5 (SD = 10.6); 56% Hispanic, 19% Black, and 22% White and 2% identified as other; the majority had public insurance 76%; 66% speak English, 21% Spanish and 13% Haitian Creole. Only 36% have adequate health literacy as measured by the BRIEF. Only 32% are currently partnered. The overall mean total score for social support is 75.8 (+/‐23.6), median of 78.9 (range 60.5‐98.7). Participants scored lowest in tangible support (mean score 67.7 +/‐33.1) and highest in affective support (83.5 +/‐25.8). Non‐White participants scored significantly lower across all domains (mean overall MOS score 73.3 +/‐2.6) when compared with Whites (mean overall MOS score 84.5 +/‐4.8, p value = 0.04). There were no differences in MOS scores by language, insurance, literacy or marital status. Conclusion: This is the first study to describe social support scores (overall and specific domains) from the validated MOS survey tool among a racially diverse, urban cancer patient population. We found significant differences by race. Studies to identify risks for low social support can help inform future targeted interventions. AN - CN-01471522 DO - 10.1158/1538-7445.SABCS16-P3-10-09 IS - 4 Supplement 1 M3 - Conference Abstract PY - 2017 ST - Predictors of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center T2 - Cancer research TI - Predictors of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01471522/full VL - Conference: 39th Annual CTRC‐AACR San Antonio Breast Cancer Symposium. United States. 77 ID - 1652 ER - TY - JOUR AB - Background: Sepsis is characterized by metabolic disturbances, and previous data suggest a relative carnitine deficiency may contribute to metabolic dysfunction. Studies regarding safety and patient-centered efficacy of carnitine during septic shock are lacking. Methods: This was a double-blind randomized control trial of levocarnitine (L-carnitine) infusion vs normal saline for the treatment of vasopressor-dependent septic shock. Patients meeting consensus definition for septic shock with a cumulative vasopressor index ≥3 and sequential organ failure assessment (SOFA) score ≥5 enrolled within 16 hours of the recognition of septic shock were eligible. The primary safety outcome was difference in serious adverse events (SAEs) per patient between groups. Efficacy outcomes included proportion of patients demonstrating a decrease in SOFA score of 2 or more points at 24 hours and short- and long-term survival. Results: Of the 31 patients enrolled, 16 were in the L-carnitine and 15 were in the placebo arm. There was no difference in SAEs between placebo and intervention (2.1 vs 1.8 SAEs per patient, P =.44). There was no difference in the proportion of patients achieving a decrease in SOFA score of 2 or more points at 24 hours between placebo and treatment (53% vs 44%, P =.59). Mortality was significantly lower at 28 days in the L-carnitine group (4/16 vs 9/15, P =.048), with a nonsignificant improved survival at 1 year (P =.06). Conclusion: L-carnitine infusion appears safe in vasopressor-dependent septic shock. Preliminary efficacy data suggest potential benefit of L-carnitine treatment, and further testing is indicated. © 2013 American Society for Parenteral and Enteral Nutrition. AD - Department of Emergency Medicine, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS 39216, United States Department of Emergency Medicine, University of Indiana School of Medicine, Indianapolis, United States Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC, United States AU - Puskarich, M. A. AU - Kline, J. A. AU - Krabill, V. AU - Claremont, H. AU - Jones, A. E. DB - Scopus DO - 10.1177/0148607113495414 IS - 6 KW - carnitine L-carnitine randomized control trial sepsis shock M3 - Article N1 - Cited By :23 Export Date: 22 March 2021 PY - 2014 SP - 736-743 ST - Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: A randomized control trial T2 - Journal of Parenteral and Enteral Nutrition TI - Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: A randomized control trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84904509497&doi=10.1177%2f0148607113495414&partnerID=40&md5=1e6fcf6caa73868888fe92bf290562c4 VL - 38 ID - 2416 ER - TY - JOUR AB - BACKGROUND: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate-specific antigen (PSA) screening test has a high risk of false-positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks. OBJECTIVE: This study aimed to describe the development and pilot testing of an interactive Web-based decision aid (DA; Prostate Cancer Screening Preparation [PCSPrep]) for African American men, designed to promote informed decision making for prostate cancer screening. METHODS: Four focus groups (n=33) were conducted to assess men's reactions to DAs developed in prior studies and gather information to modify the content and format. The pilot test employed a pre-posttest evaluation design. A convenience sample of 41 men aged 45-70 years with no history of prostate cancer was recruited from community settings. Participants completed online surveys before and after using PCSPrep that assessed prostate cancer screening knowledge, decision self-efficacy, decisional conflict, and preparation for decision making. RESULTS: Use of PCSPrep was associated with a significant increase in prostate cancer knowledge (49% vs 62% correct responses; P<.001), and men also experienced less decisional conflict (24 vs 15 on a scale of 0-100; P=.008). No changes in self-efficacy about decision making or screening preferences were observed. Most men (81%) reported that using PCSPrep prepared them to make informed decisions in partnership with their provider. CONCLUSIONS: PCSPrep was an acceptable DA that improved men's knowledge, reduced decisional conflict, and promoted the perception of being prepared for shared decision making. Further research is needed to test the DA in a larger randomized trial. AU - Allen, J. D. AU - Reich, A. AU - Cuevas, A. G. AU - Ladin, K. DB - Medline DO - 10.2196/15502 IS - 5 KW - adult African American aged article cancer screening clinical article controlled study convenience sample decision support system early cancer diagnosis human human tissue male men's health middle aged minority health pretest posttest design prostate cancer randomized controlled trial self concept shared decision making LA - English M3 - Article N1 - L631678156 2020-05-13 PY - 2020 SN - 2291-5222 SP - e15502 ST - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid T2 - JMIR mHealth and uHealth TI - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631678156&from=export http://dx.doi.org/10.2196/15502 VL - 8 ID - 805 ER - TY - JOUR AB - BACKGROUND: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate‐specific antigen (PSA) screening test has a high risk of false‐positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks. OBJECTIVE: This study aimed to describe the development and pilot testing of an interactive Web‐based decision aid (DA; Prostate Cancer Screening Preparation [PCSPrep]) for African American men, designed to promote informed decision making for prostate cancer screening. METHODS: Four focus groups (n=33) were conducted to assess men's reactions to DAs developed in prior studies and gather information to modify the content and format. The pilot test employed a pre‐posttest evaluation design. A convenience sample of 41 men aged 45‐70 years with no history of prostate cancer was recruited from community settings. Participants completed online surveys before and after using PCSPrep that assessed prostate cancer screening knowledge, decision self‐efficacy, decisional conflict, and preparation for decision making. RESULTS: Use of PCSPrep was associated with a significant increase in prostate cancer knowledge (49% vs 62% correct responses; P<.001), and men also experienced less decisional conflict (24 vs 15 on a scale of 0‐100; P=.008). No changes in self‐efficacy about decision making or screening preferences were observed. Most men (81%) reported that using PCSPrep prepared them to make informed decisions in partnership with their provider. CONCLUSIONS: PCSPrep was an acceptable DA that improved men's knowledge, reduced decisional conflict, and promoted the perception of being prepared for shared decision making. Further research is needed to test the DA in a larger randomized trial. AN - CN-02120399 AU - Allen, J. D. AU - Reich, A. AU - Cuevas, A. G. AU - Ladin, K. DO - 10.2196/15502 IS - 5 KW - *African American *cancer screening *decision support system *early cancer diagnosis *men's health *minority health *prostate cancer *shared decision making Adult Aged Article Clinical article Controlled study Convenience sample Human Human tissue Male Middle aged Pretest posttest design Randomized controlled trial Self concept M3 - Journal: Article PY - 2020 SP - e15502‐ ST - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: development and Pilot Testing of an Interactive Online Decision Aid T2 - JMIR mhealth and uhealth TI - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: development and Pilot Testing of an Interactive Online Decision Aid UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02120399/full VL - 8 ID - 1489 ER - TY - JOUR AB - Background: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate-specific antigen (PSA) screening test has a high risk of false-positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks. Objective: This study aimed to describe the development and pilot testing of an interactive Web-based decision aid (DA; Prostate Cancer Screening Preparation [PCSPrep]) for African American men, designed to promote informed decision making for prostate cancer screening. Methods: Four focus groups (n=33) were conducted to assess men’s reactions to DAs developed in prior studies and gather information to modify the content and format. The pilot test employed a pre-posttest evaluation design. A convenience sample of 41 men aged 45-70 years with no history of prostate cancer was recruited from community settings. Participants completed online surveys before and after using PCSPrep that assessed prostate cancer screening knowledge, decision self-efficacy, decisional conflict, and preparation for decision making. Results: Use of PCSPrep was associated with a significant increase in prostate cancer knowledge (49% vs 62% correct responses; P<.001), and men also experienced less decisional conflict (24 vs 15 on a scale of 0-100; P=.008). No changes in self-efficacy about decision making or screening preferences were observed. Most men (81%) reported that using PCSPrep prepared them to make informed decisions in partnership with their provider. Conclusions: PCSPrep was an acceptable DA that improved men’s knowledge, reduced decisional conflict, and promoted the perception of being prepared for shared decision making. Further research is needed to test the DA in a larger randomized trial. ©Jennifer Dacey Allen, Amanda Reich, Adolfo G Cuevas, Keren Ladin. AD - Department of Community Health, Tufts University, Medford, MA, United States AU - Allen, J. D. AU - Reich, A. AU - Cuevas, A. G. AU - Ladin, K. C7 - e15502 DB - Scopus DO - 10.2196/15502 IS - 5 KW - Decision making (shared) Decision support techniques Early detection of cancer Men’s health Minority health Prostate neoplasms M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 ST - Preparing African American men to make informed prostate cancer screening decisions: Development and pilot testing of an interactive online decision aid T2 - JMIR mHealth and uHealth TI - Preparing African American men to make informed prostate cancer screening decisions: Development and pilot testing of an interactive online decision aid UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084272834&doi=10.2196%2f15502&partnerID=40&md5=5bcede4518cc16b877717a74fa50ee0f VL - 8 ID - 2197 ER - TY - JOUR AB - Background: African American men are at a higher risk of developing and dying from prostate cancer compared to white men. The serum prostate-specific antigen (PSA) screening test has a high risk of false-positive results and overdiagnosis; therefore, it is not routinely recommended. Rather, men are encouraged to make individualized decisions with their medical providers, after being fully informed about its potential benefits, limitations, and risks. Objective: This study aimed to describe the development and pilot testing of an interactive Web based decision aid (DA; Prostate Cancer Screening Preparation [PCSPrep]) for African American men, designed to promote informed decision making for prostate cancer screening. Methods: Four focus groups (n=33) were conducted to assess men's reactions to DAs developed in prior studies and gather information to modify the content and format. The pilot test employed a pre-posttest evaluation design. A convenience sample of 41 men aged 45-70 years with no history of prostate cancer was recruited from community settings. Participants completed online surveys before and after using PCSPrep that assessed prostate cancer screening knowledge, decision self-efficacy, decisional conflict, and preparation for decision making. Results: Use of PCSPrep was associated with a significant increase in prostate cancer knowledge (49% vs 62% correct responses; P<.001), and men also experienced less decisional conflict (24 vs 15 on a scale of 0-100; P=.008). No changes in self-efficacy about decision making or screening preferences were observed. Most men (81%) reported that using PCSPrep prepared them to make informed decisions in partnership with their provider. Conclusions: PCSPrep was an acceptable DA that improved men's knowledge, reduced decisional conflict, and promoted the perception of being prepared for shared decision making Further research is needed to test the DA in a larger randomized trial. AN - WOS:000530283500001 AU - Allen, J. D. AU - Reich, A. AU - Cuevas, A. G. AU - Ladin, K. DA - May DO - 10.2196/15502 IS - 5 N1 - e15502 32369032 PY - 2020 SN - 2291-5222 ST - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid T2 - Jmir Mhealth and Uhealth TI - Preparing African American Men to Make Informed Prostate Cancer Screening Decisions: Development and Pilot Testing of an Interactive Online Decision Aid VL - 8 ID - 2778 ER - TY - JOUR AB - OBJECTIVE: To define the prevalence and patterns of self-initiated herbal and vitamin supplementation among men at high risk of developing prostate cancer, as there is increasing public awareness of prostate cancer screening, risk-factor assessment and prevention, leading to increasing interest in the use and systematic study of nutritional therapies for prostate cancer prevention. SUBJECTS AND METHODS: Since 1996 our institution has prospectively maintained a prostate cancer-risk registry through its Prostate Cancer Risk Assessment Program (PRAP). Eligibility includes African-American men, any man with at least one first-degree relative or two or more second-degree relatives with prostate cancer, or men who tested positively for the BRCA1 gene mutation. A 420-item self-administered-questionnaire was completed and included the use of nutritional supplements and complementary therapies. We divided men into groups who used supplements to lessen their cancer risk and those who did not. The prevalence and patterns of use were evaluated and the two groups then compared for differences in demographic, socioeconomic and risk-perception variables. RESULTS: In all, 345 high-risk men were enrolled in the PRAP over a 5-year period. Data on the use of dietary or herbal supplements were available on 333 men (97%), of whom over half (170) reported taking one or more supplements to prevent prostate cancer. Supplement use was divided into eight categories, including vitamins, minerals, extracts from fruits/seeds, organic compounds, flowers/bulbs, leaves/ bark, roots, or animal products. Most commonly used for self-initiated chemoprevention were vitamins (95%), minerals (28%), and fruit/seed extracts (18%). More than a quarter of men (27%) took three or more agents. Men taking proactive preventative measures were statistically more likely to be Caucasian and aged >60 years (P<0.05). African-Americans were less likely to self-initiate preventative steps. Men taking supplements tended to return more often for follow-up and participate in PRAP longer, while those not taking supplements tended to earn less and report less self-perceived risk. CONCLUSIONS: A significant proportion of men at risk of developing prostate cancer initiate measures they perceive to reduce their risk. Although the chemopreventative efficacy of many of these supplements remains unsubstantiated, they are widely perceived by the public to reduce the risk of developing prostate cancer. These data provide an insight into patient perceptions and misconceptions of chemopreventative strategies, and may help to refine recruitment efforts in multiinstitutional prostate cancer prevention trials. AD - Department of Urology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, United States Department of Radiation Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, United States Department of Population Sciences, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, United States Department of Urology, Fox Chase Cancer Center, Temple University School of Medicine, 333 Cottman Avenue, Philadelphia, PA 19111-2497, United States AU - Uzzo, R. G. AU - Brown, J. G. AU - Horwitz, E. M. AU - Hanlon, A. AU - Mazzoni, S. AU - Konski, A. AU - Greenberg, R. E. AU - Pollack, A. AU - Kolenko, V. AU - Watkins-Bruner, D. DB - Scopus DO - 10.1111/j.1464-410X.2004.04759.x IS - 7 KW - Cancer Nutrition Prevention Prostate Supplement M3 - Conference Paper N1 - Cited By :20 Export Date: 22 March 2021 PY - 2004 SP - 955-960 ST - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer T2 - BJU International TI - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-2542639316&doi=10.1111%2fj.1464-410X.2004.04759.x&partnerID=40&md5=5ff464b55bb5476a8d553b2c68296890 VL - 93 ID - 2608 ER - TY - JOUR AB - To define the prevalence and patterns of self-initiated herbal and vitamin supplementation among men at high risk of developing prostate cancer, as there is increasing public awareness of prostate cancer screening, risk-factor assessment and prevention, leading to increasing interest in the use and systematic study of nutritional therapies for prostate cancer prevention. Since 1996 our institution has prospectively maintained a prostate cancer-risk registry through its Prostate Cancer Risk Assessment Program (PRAP). Eligibility includes African-American men, any man with at least one first-degree relative or two or more second-degree relatives with prostate cancer, or men who tested positively for the BRCA1 gene mutation. A 420-item self-administered questionnaire was completed and included the use of nutritional supplements and complementary therapies. We divided men into groups who used supplements to lessen their cancer risk and those who did not. The prevalence and patterns of use were evaluated and the two groups then compared for differences in demographic, socio-economic and risk-perception variables. In all, 345 high-risk men were enrolled in the PRAP over a 5-year period. Data on the use of dietary or herbal supplements were available on 333 men (97%), of whom over half (170) reported taking one or more supplements to prevent prostate cancer. Supplement use was divided into eight categories, including vitamins, minerals, extracts from fruits/seeds, organic compounds, flowers/bulbs, leaves/bark, roots, or animal products. Most commonly used for self-initiated chemoprevention were vitamins (95%), minerals (28%), and fruit/seed extracts (18%). More than a quarter of men (27%) took three or more agents. Men taking proactive preventative measures were statistically more likely to be Caucasian and aged > 60 years (P < 0.05). African-Americans were less likely to self-initiate preventative steps. Men taking supplements tended to return more often for follow-up and participate in PRAP longer, while those not taking supplements tended to earn less and report less self-perceived risk. A significant proportion of men at risk of developing prostate cancer initiate measures they perceive to reduce their risk. Although the chemopreventative efficacy of many of these supplements remains unsubstantiated, they are widely perceived by the public to reduce the risk of developing prostate cancer. These data provide an insight into patient perceptions and misconceptions of chemopreventative strategies, and may help to refine recruitment efforts in multi-institutional prostate cancer prevention trials. AN - WOS:000221254400010 AU - Uzzo, R. G. AU - Brown, J. G. AU - Horwitz, E. M. AU - Hanlon, A. AU - Mazzoni, S. AU - Konski, A. AU - Greenberg, R. E. AU - Pollack, A. AU - Kolenko, V. AU - Watkins-Bruner, D. DA - 2004 DO - 10.1111/j.1464-410X.2004.04759.x IS - 7 N1 - 16 15142142 PY - 2004 SN - 1464-4096 SP - 955-960 ST - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer T2 - Bju International TI - Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer VL - 93 ID - 2687 ER - TY - JOUR AB - BACKGROUND: African-American breast cancer survivors commonly demonstrate low serum 25-hydroxyvitamin D (25(OH)D). Decreased cutaneous conversion, high levels of adiposity, and even breast cancer treatment may influence vitamin D status. Previous investigations have analyzed African-American women in aggregate with other breast cancer survivors and have not comprehensively addressed these influential factors. OBJECTIVES: To determine the prevalence of low serum 25(OH)D in an exclusively African-American cohort of female breast cancer survivors with overweight/obesity and to evaluate the role of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on serum 25(OH)D levels. DESIGN: Cross-sectional. PARTICIPANTS: Pre- and postmenopausal African-American breast cancer survivors (n=244) were recruited from various neighborhoods in the city of Chicago, IL, between September 2011 and September 2014 for a larger weight loss trial. MAIN OUTCOME MEASURES: Demographic, clinical, anthropometric (body mass index [calculated as kg/m2], waist circumference, and hip circumference), blood specimen, dietary intake (food frequency questionnaire), and sun behavior data were collected by trained study personnel before trial participation. Dual-energy x-ray absorptiometry was used to quantify adiposity (total, percentage, regional, visceral) and lean mass. Serum 25(OH)D was used as the biomarker reflective of vitamin D status. STATISTICAL ANALYSES: Mean (±standard deviation), frequencies, and multivariate linear regression modeling. RESULTS: The average participant was 57.4 years old (±10.0), 6.9 years (±5.2) from initial breast cancer diagnosis with a body mass index of 36.2 (±6.2). The majority of participants (60%) reported habitual oral vitamin D supplementation with mean intake of 327 IU (±169). Vitamin D deficiency was prevalent in 81% and 43%, when the cut points of the Endocrine Society (<30 ng/mL or <75 nmol/L) and the Institute of Medicine (<20 ng/mL or <50 nmol/L) were applied, respectively. A multivariate model adjusting for age, seasonality of blood draw, total energy intake, use of supplemental vitamin D, darker skin pigmentation, breast cancer stage, and waist-to-hip ratio was able to explain 28.8% of the observed variance in serum 25(OH)D concentrations. No significant associations were detected for body mass index or any dual-energy x-ray absorptiometry measures of body composition. CONCLUSIONS: Considering the number of women who endorsed use of vitamin D supplementation, the prevalence of vitamin D deficiency among these African-American breast cancer survivors was high. Vitamin D supplementation, sun behavior, and waist-to-hip ratio may serve as future points of intervention to improve the vitamin D status of this minority survivor population. AU - Sheean, P. AU - Arroyo, C. AU - Woo, J. AU - Schiffer, L. AU - Stolley, M. DB - Medline DO - 10.1016/j.jand.2017.10.009 IS - 4 KW - 25 hydroxyvitamin D vitamin D adult African American blood breast tumor cancer survivor complication cross-sectional study dietary supplement female human Illinois middle aged nutritional status prevalence vitamin D deficiency LA - English M3 - Article N1 - L627112892 2019-04-12 2019-10-01 PY - 2018 SN - 2212-2672 SP - 568-577 ST - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors T2 - Journal of the Academy of Nutrition and Dietetics TI - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L627112892&from=export http://dx.doi.org/10.1016/j.jand.2017.10.009 VL - 118 ID - 904 ER - TY - JOUR AB - Background African-American breast cancer survivors commonly demonstrate low serum 25-hydroxyvitamin D (25(OH)D). Decreased cutaneous conversion, high levels of adiposity, and even breast cancer treatment may influence vitamin D status. Previous investigations have analyzed African-American women in aggregate with other breast cancer survivors and have not comprehensively addressed these influential factors. Objectives To determine the prevalence of low serum 25(OH)D in an exclusively African-American cohort of female breast cancer survivors with overweight/obesity and to evaluate the role of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on serum 25(OH)D levels. Design Cross-sectional. Participants Pre- and postmenopausal African-American breast cancer survivors (n=244) were recruited from various neighborhoods in the city of Chicago, IL, between September 2011 and September 2014 for a larger weight loss trial. Main outcome measures Demographic, clinical, anthropometric (body mass index [calculated as kg/m 2 ], waist circumference, and hip circumference), blood specimen, dietary intake (food frequency questionnaire), and sun behavior data were collected by trained study personnel before trial participation. Dual-energy x-ray absorptiometry was used to quantify adiposity (total, percentage, regional, visceral) and lean mass. Serum 25(OH)D was used as the biomarker reflective of vitamin D status. Statistical analyses Mean (±standard deviation), frequencies, and multivariate linear regression modeling. Results The average participant was 57.4 years old (±10.0), 6.9 years (±5.2) from initial breast cancer diagnosis with a body mass index of 36.2 (±6.2). The majority of participants (60%) reported habitual oral vitamin D supplementation with mean intake of 327 IU (±169). Vitamin D deficiency was prevalent in 81% and 43%, when the cut points of the Endocrine Society (<30 ng/mL or <75 nmol/L) and the Institute of Medicine (<20 ng/mL or <50 nmol/L) were applied, respectively. A multivariate model adjusting for age, seasonality of blood draw, total energy intake, use of supplemental vitamin D, darker skin pigmentation, breast cancer stage, and waist-to-hip ratio was able to explain 28.8% of the observed variance in serum 25(OH)D concentrations. No significant associations were detected for body mass index or any dual-energy x-ray absorptiometry measures of body composition. Conclusions Considering the number of women who endorsed use of vitamin D supplementation, the prevalence of vitamin D deficiency among these African-American breast cancer survivors was high. Vitamin D supplementation, sun behavior, and waist-to-hip ratio may serve as future points of intervention to improve the vitamin D status of this minority survivor population. AN - 128517962. Language: English. Entry Date: 20180404. Revision Date: 20180530. Publication Type: Article AU - Sheean, Patricia AU - Arroyo, Claudia AU - Woo, Jennifer AU - Schiffer, Linda AU - Stolley, Melinda DB - CINAHL Complete DO - 10.1016/j.jand.2017.10.009 DP - EBSCOhost IS - 4 KW - Black Persons Vitamin D Deficiency -- Epidemiology Breast Neoplasms Cancer Survivors Obesity Human Female Ultraviolet Rays Body Composition Diet Vitamin D -- Blood Cross Sectional Studies Illinois Prospective Studies Nutritional Assessment Questionnaires Sunlight Environmental Exposure Absorptiometry, Photon Linear Regression Multivariate Analysis Middle Age Aged Descriptive Statistics Dietary Supplementation Epidemiological Research N1 - research. Journal Subset: Allied Health; Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care; Women's Health. Instrumentation: Food Frequency Questionnaire (FFQ). NLM UID: 7503061. PY - 2018 SN - 2212-2672 SP - 568-577 ST - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors T2 - Journal of the Academy of Nutrition & Dietetics TI - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=128517962&site=ehost-live&scope=site VL - 118 ID - 2028 ER - TY - JOUR AB - Background: African-American breast cancer survivors commonly demonstrate low serum 25-hydroxyvitamin D (25(OH)D). Decreased cutaneous conversion, high levels of adiposity, and even breast cancer treatment may influence vitamin D status. Previous investigations have analyzed African-American women in aggregate with other breast cancer survivors and have not comprehensively addressed these influential factors. Objectives: To determine the prevalence of low serum 25(OH)D in an exclusively African-American cohort of female breast cancer survivors with overweight/obesity and to evaluate the role of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on serum 25(OH)D levels. Design: Cross-sectional. Participants: Pre- and postmenopausal African-American breast cancer survivors (n=244) were recruited from various neighborhoods in the city of Chicago, IL, between September 2011 and September 2014 for a larger weight loss trial. Main outcome measures: Demographic, clinical, anthropometric (body mass index [calculated as kg/m2], waist circumference, and hip circumference), blood specimen, dietary intake (food frequency questionnaire), and sun behavior data were collected by trained study personnel before trial participation. Dual-energy x-ray absorptiometry was used to quantify adiposity (total, percentage, regional, visceral) and lean mass. Serum 25(OH)D was used as the biomarker reflective of vitamin D status. Statistical analyses: Mean (±standard deviation), frequencies, and multivariate linear regression modeling. Results: The average participant was 57.4 years old (±10.0), 6.9 years (±5.2) from initial breast cancer diagnosis with a body mass index of 36.2 (±6.2). The majority of participants (60%) reported habitual oral vitamin D supplementation with mean intake of 327 IU (±169). Vitamin D deficiency was prevalent in 81% and 43%, when the cut points of the Endocrine Society (<30 ng/mL or <75 nmol/L) and the Institute of Medicine (<20 ng/mL or <50 nmol/L) were applied, respectively. A multivariate model adjusting for age, seasonality of blood draw, total energy intake, use of supplemental vitamin D, darker skin pigmentation, breast cancer stage, and waist-to-hip ratio was able to explain 28.8% of the observed variance in serum 25(OH)D concentrations. No significant associations were detected for body mass index or any dual-energy x-ray absorptiometry measures of body composition. Conclusions: Considering the number of women who endorsed use of vitamin D supplementation, the prevalence of vitamin D deficiency among these African-American breast cancer survivors was high. Vitamin D supplementation, sun behavior, and waist-to-hip ratio may serve as future points of intervention to improve the vitamin D status of this minority survivor population. © 2018 Academy of Nutrition and Dietetics AU - Sheean, P. AU - Arroyo, C. AU - Woo, J. AU - Schiffer, L. AU - Stolley, M. DB - Scopus DO - 10.1016/j.jand.2017.10.009 IS - 4 KW - African American Breast cancer Obesity Serum 25(OH)D Vitamin D M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2018 SP - 568-577 ST - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors T2 - Journal of the Academy of Nutrition and Dietetics TI - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039808167&doi=10.1016%2fj.jand.2017.10.009&partnerID=40&md5=1f2919f3e6d225150409ea8a0be29285 VL - 118 ID - 2275 ER - TY - JOUR AB - Background African-American breast cancer survivors commonly demonstrate low serum 25-hydroxyvitamin D (25(OH)D). Decreased cutaneous conversion, high levels of adiposity, and even breast cancer treatment may influence vitamin D status. Previous investigations have analyzed African-American women in aggregate with other breast cancer survivors and have not comprehensively addressed these influential factors. Objectives To determine the prevalence of low serum 25(OH)D in an exclusively African-American cohort of female breast cancer survivors with overweight/obesity and to evaluate the role of ultraviolet (UV) light exposure, body composition, and dietary sources of vitamin D on serum 25(OH)D levels. Design Cross-sectional. Participants Pre- and postmenopausal African-American breast cancer survivors (n = 244) were recruited from various neighborhoods in the city of Chicago, IL, between September 2011 and September 2014 for a larger weight loss trial. Main outcome measures Demographic, clinical, anthropometric (body mass index [calculated as kg/m(2)], waist circumference, and hip circumference), blood specimen, dietary intake (food frequency questionnaire), and sun behavior data were collected by trained study personnel before trial participation. Dual-energy x-ray absorptiometry was used to quantify adiposity (total, percentage, regional, visceral) and lean mass. Serum 25(OH)D was used as the biomarker reflective of vitamin D status. Statistical analyses Mean (+/- standard deviation), frequencies, and multivariate linear regression modeling. Results The average participant was 57.4 years old (+/- 10.0), 6.9 years (+/- 5.2) from initial breast cancer diagnosis with a body mass index of 36.2 (+/- 6.2). The majority of participants (60%) reported habitual oral vitamin D supplementation with mean intake of 327 IU (+169). Vitamin D deficiency was prevalent in 81% and 43%, when the cut points of the Endocrine Society (<30 ng/mL or <75 nmol/L) and the Institute of Medicine (<20 ng/mL or <50 nmol/L) were applied, respectively. A multivariate model adjusting for age, seasonality of blood draw, total energy intake, use of supplemental vitamin D, darker skin pigmentation, breast cancer stage, and waist-to-hip ratio was able to explain 28.8% of the observed variance in serum 25(OH)D concentrations. No significant associations were detected for body mass index or any dual-energy x-ray absorptiometry measures of body composition. Conclusions Considering the number of women who endorsed use of vitamin D supplementation, the prevalence of vitamin D deficiency among these African-American breast cancer survivors was high. Vitamin D supplementation, sun behavior, and waist-to-hip ratio may serve as future points of intervention to improve the vitamin D status of this minority survivor population. AN - WOS:000428262900005 AU - Sheean, P. AU - Arroyo, C. AU - Woo, J. AU - Schiffer, L. AU - Stolley, M. DA - Apr DO - 10.1016/j.jand.2017.10.009 IS - 4 N1 - 29305131 PY - 2018 SN - 2212-2672 SP - 568-577 ST - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors T2 - Journal of the Academy of Nutrition and Dietetics TI - Prevalence and Predictors of Low Serum 25-Hydroxyvitamin D among Female African-American Breast Cancer Survivors VL - 118 ID - 2867 ER - TY - JOUR AB - Background Women living with human immunodeficiency virus (WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the general population of women. Anal high-grade squamous intraepithelial lesions (HSILs) precede anal cancer, and accurate studies of HSIL prevalence among WLHIV in the United States are lacking. Methods The AIDS Malignancy Consortium 084 study was a multicenter national trial to evaluate the prevalence of and risk factors for anal HSIL in a US cohort. Eligible participants were WLHIV aged ≥18 years with no history of anal HSIL. Study participants had an examination including collection of cervical/vaginal and anal specimens, followed by high-resolution anoscopy with biopsy. Results We enrolled 256 women with evaluable anal pathology. The mean age was 49.4 years, 64% women were non-Hispanic black, 67% were former or current smokers, and 56% reported ever having anal sex with a man. The median CD4 T-cell count was 664 cells/μL. The prevalence of anal histologic HSIL (hHSIL) was 27% (95% confidence interval [CI], 22%–33%). There was a strong concordance (240/254) between local and consensus pathologists for hHSIL vs less than hHSIL (κ = 0.86 [95% CI,.79–.93]). Current CD4 count of ≤200 cells/μL was the strongest predictor of consensus anal hHSIL diagnosis (adjusted odds ratio [aOR], 10.34 [95% CI, 3.47–30.87]). History of anoreceptive intercourse was also associated with hHSIL (aOR, 2.44 [95% CI, 1.22–4.76]). Conclusions The prevalence of anal hHSIL in WLHIV in the United States was 27% in this study where all participants received high-resolution anoscopy and biopsy. AD - Obstetrics and Gynecology, Boston University School of Medicine, Massachusetts Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock Department of Pathology, Mount Zion Medical Center, University of California, San Francisco (UCSF) Department of Management Policy and Community Health, School of Public Health, University of Texas Health Science Center at Houston Department of Obstetrics/Gynecology and Women's Health, Rutgers–New Jersey Medical School, Newark Department of Medicine, UCSF Anal Neoplasia Clinic, Research, and Education Center, San Francisco, California Division of Hematology Oncology, UCSF Clinical Trials Unit, Department of Medicine, Cornell University, New York, New York School of Nursing, University of California, Los Angeles Department of Internal Medicine, Infectious Diseases, Wake Forest University Health Sciences, Winston-Salem, North Carolina University of Vic, Hospital Germans Trias i Pujol, Badalona, Spain Department of Surgery, Montefiore Medical Center, Bronx, New York Department of Medicine and Department of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan Division of Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois Department of Pathology, Baylor College of Medicine, Houston, Texas Department of Pathology, George Washington University, Washington, District of Columbia Icahn School of Medicine at Mount Sinai, New York, New York Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas AN - 142688534. Language: English. Entry Date: 20200415. Revision Date: 20200415. Publication Type: Article AU - Stier, Elizabeth A. AU - Lensing, Shelly Y. AU - Darragh, Teresa M. AU - Deshmukh, Ashish A. AU - Einstein, Mark H. AU - Palefsky, Joel M. AU - Jay, Naomi AU - Berry-Lawhorn, J. Michael AU - Wilkin, Timothy AU - Wiley, Dorothy J. AU - Barroso, Luis F. AU - Cranston, Ross D. AU - Levine, Rebecca AU - Guiot, Humberto M. AU - French, Audrey L. AU - Citron, Deborah AU - Rezaei, M. Katayoon AU - Goldstone, Stephen E. AU - Chiao, Elizabeth DB - CINAHL Complete DO - 10.1093/cid/ciz408 DP - EBSCOhost IS - 8 KW - Carcinoma, Squamous Cell -- Risk Factors Neoplasia, Anal Intraepithelial -- Risk Factors HIV-Positive Persons Women's Health -- United States Neoplasia, Anal Intraepithelial -- Epidemiology -- United States Human United States Anus Neoplasms -- Diagnosis Minimally Invasive Procedures Middle Age Confidence Intervals Anus -- Anatomy and Histology Biopsy N1 - research; tables/charts. Journal Subset: Biomedical. PY - 2020 SN - 1058-4838 SP - 1701-1707 ST - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus T2 - Clinical Infectious Diseases TI - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142688534&site=ehost-live&scope=site VL - 70 ID - 2029 ER - TY - JOUR AB - Background: Women living with human immunodeficiency virus (WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the general population of women. Anal high-grade squamous intraepithelial lesions (HSILs) precede anal cancer, and accurate studies of HSIL prevalence among WLHIV in the United States are lacking. Methods: The AIDS Malignancy Consortium 084 study was a multicenter national trial to evaluate the prevalence of and risk factors for anal HSIL in a US cohort. Eligible participants were WLHIV aged >= 18 years with no history of anal HSIL. Study participants had an examination including collection of cervical/vaginal and anal specimens, followed by high-resolution anoscopy with biopsy. Results: We enrolled 256 women with evaluable anal pathology. The mean age was 49.4 years, 64% women were non-Hispanic black, 67% were former or current smokers, and 56% reported ever having anal sex with a man. The median CD4 T-cell count was 664 cells/mu L. The prevalence of anal histologic HSIL (hHSIL) was 27% (95% confidence interval [CI], 22%-33%). There was a strong concordance (240/254) between local and consensus pathologists for hHSIL vs less than hHSIL (kappa = 0.86 [95% CI, .79-.93]). Current CD4 count of <= 200 cells/mu L was the strongest predictor of consensus anal hHSIL diagnosis (adjusted odds ratio [aOR], 10.34 [95% CI, 3.47-30.87]). History of anoreceptive intercourse was also associated with hHSIL (aOR, 2.44 [95% CI, 1.22-4.76]). Conclusions: The prevalence of anal hHSIL in WLHIV in the United States was 27% in this study where all participants received high-resolution anoscopy and biopsy. AN - WOS:000536491700027 AU - Stier, E. A. AU - Lensing, S. Y. AU - Darragh, T. M. AU - Deshmukh, A. A. AU - Einstein, M. H. AU - Palefsky, J. M. AU - Jay, N. AU - Berry-Lawhorn, J. M. AU - Wilkin, T. AU - Wiley, D. J. AU - Barroso, L. F. AU - Cranston, R. D. AU - Levine, R. AU - Guiot, H. M. AU - French, A. L. AU - Citron, D. AU - Rezaei, M. K. AU - Goldstone, S. E. AU - Chiao, E. DA - Apr DO - 10.1093/cid/ciz408 IS - 8 N1 - 31292602 PY - 2020 SN - 1058-4838 SP - 1701-1707 ST - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus T2 - Clinical Infectious Diseases TI - Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus VL - 70 ID - 2784 ER - TY - JOUR AB - Background. Women living with human immunodeficiency virus (WLHIV) have disproportionately high rates of squamous cell carcinoma of the anus compared with the general population of women. Anal high-grade squamous intraepithelial lesions (HSILs) precede anal cancer, and accurate studies of HSIL prevalence among WLHIV in the United States are lacking. Methods. The AIDS Malignancy Consortium 084 study was a multicenter national trial to evaluate the prevalence of and risk factors for anal HSIL in a US cohort. Eligible participants were WLHIV aged ≥18 years with no history of anal HSIL. Study participants had an examination including collection of cervical/vaginal and anal specimens, followed by high-resolution anoscopy with biopsy. Results. We enrolled 256 women with evaluable anal pathology. The mean age was 49.4 years, 64% women were non-Hispanic black, 67% were former or current smokers, and 56% reported ever having anal sex with a man. The median CD4 T-cell count was 664 cells/μL. The prevalence of anal histologic HSIL (hHSIL) was 27% (95% confidence interval [CI], 22%-33%). There was a strong concordance (240/254) between local and consensus pathologists for hHSIL vs less than hHSIL (κ = 0.86 [95% CI,.79-.93]). Current CD4 count of ≤200 cells/μL was the strongest predictor of consensus anal hHSIL diagnosis (adjusted odds ratio [aOR], 10.34 [95% CI, 3.47-30.87]). History of anoreceptive intercourse was also associated with hHSIL (aOR, 2.44 [95% CI, 1.22-4.76]). Conclusions. The prevalence of anal hHSIL in WLHIV in the United States was 27% in this study where all participants received high-resolution anoscopy and biopsy. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. AD - Obstetrics and Gynecology, Boston University, School of MedicineMA, United States Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, United States Department of Pathology, Mount Zion Medical Center, University of California, San Francisco (UCSF), Newark, United States Department of Management Policy and Community Health, School of Public Health, University of Texas, Health Science Center at Houston, Newark, United States Department of Obstetrics/Gynecology and Women's Health, Rutgers-New Jersey Medical School, Newark, United States Department of Medicine, UCSF, San Francisco, CA, United States Anal Neoplasia Clinic, Research, and Education Center, San Francisco, CA, United States Division of Hematology Oncology, UCSF, Cornell University, New York, NY, United States Clinical Trials Unit, Department of Medicine, Cornell University, New York, NY, United States School of Nursing, University of California, Los Angeles, United States Department of Internal Medicine, Infectious Diseases, Wake Forest University Health Sciences, Winston-Salem, NC, United States University of Vic, Hospital Germans Trias i Pujol, Badalona, Spain Department of Surgery, Montefiore Medical Center, Bronx, NY, United States Department of Medicine, Department of Microbiology and Medical Zoology, University of Puerto, Rico School of Medicine, San Juan, Puerto Rico Division of Infectious Diseases, CORE Center, Stroger Hospital of Cook County, Chicago, IL, United States Department of Pathology, Baylor College of Medicine, Houston, TX, United States Department of Pathology, George Washington University, Washington, DC, United States Icahn School of Medicine at Mount Sinai, New York, NY, United States Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine, Houston, TX, United States Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, United States AU - Stier, E. A. AU - Lensing, S. Y. AU - Darragh, T. M. AU - Deshmukh, A. A. AU - Einstein, M. H. AU - Palefsky, J. M. AU - Jay, N. AU - Michael Berry-Lawhorn, J. AU - Wilkin, T. AU - Wiley, D. J. AU - Barroso, L. F. AU - Cranston, R. D. AU - Levine, R. AU - Guiot, H. M. AU - French, A. L. AU - Citron, D. AU - Katayoon Rezaei, M. AU - Goldstone, S. E. AU - Chiao, E. DB - Scopus DO - 10.1093/cid/ciz408 IS - 8 KW - Epidemiology HIV HPV HSIL Women's health M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2020 SP - 1701-1707 ST - Prevalence of and risk factors for anal high-grade squamous intraepithelial lesions in women living with human immunodeficiency virus T2 - Clinical Infectious Diseases TI - Prevalence of and risk factors for anal high-grade squamous intraepithelial lesions in women living with human immunodeficiency virus UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083536577&doi=10.1093%2fcid%2fciz408&partnerID=40&md5=e873906ee78e40cb307b4e6160e6bb29 VL - 70 ID - 2200 ER - TY - JOUR AB - Importance: Universal screening of patients with newly diagnosed cancer for hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV is not routine in oncology practice, and experts disagree about whether universal screening should be performed. Objective: To estimate the prevalence of HBV, HCV, and HIV infection among persons with newly diagnosed cancer. Design, Setting, and Participants: Multicenter prospective cohort study of patients with newly diagnosed cancer (ie, identified within 120 days of cancer diagnosis) at 9 academic and 9 community oncology institutions affiliated with SWOG (formerly the Southwest Oncology Group) Cancer Research Network, a member of the National Clinical Trials Network, with enrollment from August 29, 2013, through February 15, 2017. The data analysis was conducted using data available through August 17, 2017. Main Outcomes and Measures: The accrual goal was 3000 patients and the primary end point was the presence of HBV infection (previous or chronic), HCV infection, or HIV infection at enrollment. Patients with previous knowledge of infection as well as patients with unknown viral viral status were evaluated. Results: Of 3092 registered patients, 3051 were eligible and evaluable. Median (range) age was 60.6 (18.2-93.7) years, 1842 (60.4%) were female, 553 (18.1%) were black, and 558 (18.3%) were Hispanic ethnicity. Screened patients had similar clinical and demographic characteristics compared with those registered. The observed infection rate for previous HBV infection was 6.5% (95% CI, 5.6%-7.4%; n = 197 of 3050 patients); chronic HBV, 0.6% (95% CI, 0.4%-1.0%; n = 19 of 3050 patients); HCV, 2.4% (95% CI, 1.9%-3.0%; n = 71 of 2990 patients); and HIV, 1.1% (95% CI, 0.8%-1.6%; n = 34 of 3045). Among those with viral infections, 8 patients with chronic HBV (42.1%; 95% CI, 20.3%-66.5%), 22 patients with HCV (31.0%; 95% CI, 20.5%-43.1%), and 2 patients with HIV (5.9%; 95% CI, 0.7%-19.7%) were newly diagnosed through the study. Among patients with infections, 4 patients with chronic HBV (21.1%; 95% CI, 6.1%-45.6%), 23 patients with HCV (32.4%; 95% CI, 21.8%-44.5%), and 7 patients with HIV (20.6%; 95% CI, 8.7%-37.9%) had no identifiable risk factors. Conclusions and Relevance: Results of this study found that a substantial proportion of patients with newly diagnosed cancer and concurrent HBV or HCV are unaware of their viral infection at the time of cancer diagnosis, and many had no identifiable risk factors for infection. Screening patients with cancer to identify HBV and HCV infection before starting treatment may be warranted to prevent viral reactivation and adverse clinical outcomes. The low rate of undiagnosed HIV infection may not support universal screening of newly diagnosed cancer patients. © 2019 American Medical Association. All rights reserved. AD - Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-B232, Seattle, WA 98109, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States SWOG (Formerly the Southwest Oncology Group), Statistics and Data Management Center, Seattle, WA, United States Rogel Cancer Center, University of Michigan, Ann Arbor, United States Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD, United States Division of Gastroenterology, University California San Diego, Moores Cancer Center, San Diego, United States Department of General Internal Medicine, University of Texas, MD Anderson Cancer Center, Houston, United States Department of Oncology, Kaiser Permanente-Lonetree, Lonetree, CO, United States Department of Oncology, Kaiser Permanente Medical Center, Oakland, CA, United States National Cancer Institute Community Oncology Research, Program of the Carolinas, Greenville Health System National Cancer Institute Community Oncology Research Program, Greenville, SC, United States Gulf South Minority-Underserved National Cancer Institute, Community Oncology Research Program, Louisiana State University Health Sciences Center, Shreveport, United States Department of General Oncology, University of Texas, MD Anderson Cancer Center, Houston, United States Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States AU - Ramsey, S. D. AU - Unger, J. M. AU - Baker, L. H. AU - Little, R. F. AU - Loomba, R. AU - Hwang, J. P. AU - Chugh, R. AU - Konerman, M. A. AU - Arnold, K. AU - Menter, A. R. AU - Thomas, E. AU - Michels, R. M. AU - Jorgensen, C. W. AU - Burton, G. V. AU - Bhadkamkar, N. A. AU - Hershman, D. L. DB - Scopus DO - 10.1001/jamaoncol.2018.6437 IS - 4 M3 - Article N1 - Cited By :25 Export Date: 22 March 2021 PY - 2019 SP - 497-505 ST - Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices T2 - JAMA Oncology TI - Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection among Patients with Newly Diagnosed Cancer from Academic and Community Oncology Practices UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060194521&doi=10.1001%2fjamaoncol.2018.6437&partnerID=40&md5=a038c74db48d659877912e0f6a50260d VL - 5 ID - 2235 ER - TY - JOUR AB - INTRODUCTION: Healthy lifestyle behaviors are an essential component of prostate cancer survivorship; however, it is unknown whether Black participants are adequately represented in randomized controlled trials (RCTs) on lifestyle interventions. The goal of this study was to identify types of lifestyle RCTs that may require improved recruitment resources to enhance generalizability of lifestyle recommendations to Black patients. MATERIALS AND METHODS: ClinicalTrials.gov was used to identify lifestyle RCTs among patients with prostate cancer. Using racial distribution data from the Surveillance, Epidemiology, and End Results (SEER) program as a reference, one-sample proportion tests were performed to assess adequate recruitment of Black participants. RESULTS: Of 31 lifestyle trials, one trial reported race-specific results. Proportion of Black participants was acquired from 26 trials. Compared to the US population, Black participants were overrepresented in the overall study population (17% versus 15%, p = 0.019). Black participants were underrepresented in trials exploring exercise interventions (9% versus 15%, p = 0.041), trials among patients with advanced disease (9% versus 16%, p < 0.001), and in university-funded trials (12% versus 15%, p = 0.026). CONCLUSIONS: The reporting of race data, and race-specific results when feasible, is essential for clinicians to accurately generalize findings from lifestyle trials. Additional resources may be necessary to aid in strategic recruitment of Black participants for trials on exercise interventions, trials among patients with advanced disease, and in university-funded trials. AU - Zuniga, K. B. AU - Borno, H. AU - Chan, J. M. AU - Van Blarigan, E. L. AU - Friedlander, T. W. AU - Wang, S. AU - Zhang, L. AU - Kenfield, S. A. DB - Medline DO - 10.1007/s40615-020-00724-8 IS - 5 KW - adult advanced cancer African American article cancer patient controlled study diet exercise human human tissue lifestyle male prostate cancer race randomized controlled trial (topic) systematic review LA - English M3 - Article N1 - L631022164 2020-02-28 PY - 2020 SN - 2196-8837 SP - 996-1002 ST - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer T2 - Journal of racial and ethnic health disparities TI - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631022164&from=export http://dx.doi.org/10.1007/s40615-020-00724-8 VL - 7 ID - 788 ER - TY - JOUR AB - Introduction: Healthy lifestyle behaviors are an essential component of prostate cancer survivorship; however, it is unknown whether Black participants are adequately represented in randomized controlled trials (RCTs) on lifestyle interventions. The goal of this study was to identify types of lifestyle RCTs that may require improved recruitment resources to enhance generalizability of lifestyle recommendations to Black patients. Materials and Methods: ClinicalTrials.gov was used to identify lifestyle RCTs among patients with prostate cancer. Using racial distribution data from the Surveillance, Epidemiology, and End Results (SEER) program as a reference, one-sample proportion tests were performed to assess adequate recruitment of Black participants. Results: Of 31 lifestyle trials, one trial reported race-specific results. Proportion of Black participants was acquired from 26 trials. Compared to the US population, Black participants were overrepresented in the overall study population (17% versus 15%, p = 0.019). Black participants were underrepresented in trials exploring exercise interventions (9% versus 15%, p = 0.041), trials among patients with advanced disease (9% versus 16%, p ' 0.001), and in university-funded trials (12% versus 15%, p = 0.026). Conclusions: The reporting of race data, and race-specific results when feasible, is essential for clinicians to accurately generalize findings from lifestyle trials. Additional resources may be necessary to aid in strategic recruitment of Black participants for trials on exercise interventions, trials among patients with advanced disease, and in university-funded trials. © 2020, W. Montague Cobb-NMA Health Institute. AD - UCSF Osher Center for Integrative Medicine, University of California, San Francisco, UCSF Box 1726, 1545 Divisadero Street, Suite 301, San Francisco, CA 94143, United States College of Physicians and Surgeons, Columbia University Medical Center, 630 W 168th Street, New York, NY 10032, United States Division of Hematology and Medical Oncology, University of California, San Francisco, San Francisco, CA, United States Department of Urology, University of California, San Francisco, San Francisco, CA, United States Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, United States Division of Hematology-Oncology, San Francisco VA Health Care System, San Francisco, CA, United States AU - Zuniga, K. B. AU - Borno, H. AU - Chan, J. M. AU - Van Blarigan, E. L. AU - Friedlander, T. W. AU - Wang, S. AU - Zhang, L. AU - Kenfield, S. A. DB - Scopus DO - 10.1007/s40615-020-00724-8 IS - 5 KW - African Americans Diet Exercise Prostatic neoplasms Randomized controlled trial M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 996-1002 ST - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer T2 - Journal of Racial and Ethnic Health Disparities TI - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079744605&doi=10.1007%2fs40615-020-00724-8&partnerID=40&md5=4b03922a5f2893c028ad200439ecf9b5 VL - 7 ID - 2179 ER - TY - JOUR AB - Introduction Healthy lifestyle behaviors are an essential component of prostate cancer survivorship; however, it is unknown whether Black participants are adequately represented in randomized controlled trials (RCTs) on lifestyle interventions. The goal of this study was to identify types of lifestyle RCTs that may require improved recruitment resources to enhance generalizability of lifestyle recommendations to Black patients. Materials and Methods was used to identify lifestyle RCTs among patients with prostate cancer. Using racial distribution data from the Surveillance, Epidemiology, and End Results (SEER) program as a reference, one-sample proportion tests were performed to assess adequate recruitment of Black participants. Results Of 31 lifestyle trials, one trial reported race-specific results. Proportion of Black participants was acquired from 26 trials. Compared to the US population, Black participants were overrepresented in the overall study population (17% versus 15%, p = 0.019). Black participants were underrepresented in trials exploring exercise interventions (9% versus 15%, p = 0.041), trials among patients with advanced disease (9% versus 16%, p < 0.001), and in university-funded trials (12% versus 15%, p = 0.026). Conclusions The reporting of race data, and race-specific results when feasible, is essential for clinicians to accurately generalize findings from lifestyle trials. Additional resources may be necessary to aid in strategic recruitment of Black participants for trials on exercise interventions, trials among patients with advanced disease, and in university-funded trials. AN - WOS:000516357600002 AU - Zuniga, K. B. AU - Borno, H. AU - Chan, J. M. AU - Van Blarigan, E. L. AU - Friedlander, T. W. AU - Wang, S. AU - Zhang, L. AU - Kenfield, S. A. DA - Oct DO - 10.1007/s40615-020-00724-8 IS - 5 N1 - 32078741 PY - 2020 SN - 2197-3792 SP - 996-1002 ST - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer T2 - Journal of Racial and Ethnic Health Disparities TI - The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer VL - 7 ID - 2792 ER - TY - JOUR AB - PURPOSE: National health statistics indicate that blacks have lower survival rates from colorectal cancer than do whites. This disparity has been attributed to differences in stage at diagnosis and other disease features, extent and quality of treatment, and socioeconomic factors. We evaluated outcomes for blacks and whites with rectal cancer who participated in randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants. PATIENTS AND METHODS: The study included black (N = 104) or white (N = 1,070) patients from two serially conducted NSABP randomized trials for operable rectal cancer. Recurrence‐free survival and survival were compared using statistical modeling to account for differences in patient and disease characteristics between the groups. RESULTS: Blacks and whites had largely similar disease features at diagnosis. After adjustment for patient and tumor prognostic covariates, the black/white recurrence hazard ratio (HR) was 1.25 (95% confidence interval [CI], 0.94 to 1.66). The mortality HR was somewhat larger at 1.45 (95% CI = 1.09 to 1.93). Outcomes were improved for both groups in the more recent trial, which employed systemic adjuvant chemotherapy in all treatment arms. CONCLUSION: Recurrence‐free survival was modestly less favorable for blacks, whereas overall survival was more disparate. Outcomes between groups were more comparable than those noted in national health statistics surveys and other studies. Adequate treatment access and the identification of new prognostic factors that can identify patients at high risk of recurrence are needed to ensure optimal outcomes for rectal cancer patients of all racial/ethnic backgrounds. AN - CN-00558191 AU - Dignam, J. J. AU - Ye, Y. AU - Colangelo, L. AU - Smith, R. AU - Mamounas, E. P. AU - Wieand, H. S. AU - Wolmark, N. DO - 10.1200/JCO.2003.02.004 IS - 3 KW - African Continental Ancestry Group Aged Disease Progression Disease‐Free Survival European Continental Ancestry Group Female Health Services Accessibility Humans Male Middle Aged Neoplasm Recurrence, Local Odds Ratio Prognosis Randomized Controlled Trials as Topic Rectal Neoplasms [*ethnology, *pathology, therapy] Risk Factors Treatment Outcome M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2003 SP - 413‐420 ST - Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials T2 - Journal of clinical oncology TI - Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00558191/full VL - 21 ID - 1350 ER - TY - JOUR AB - Purpose To our knowledge the optimal treatment of patients following a negative prostate biopsy is unknown. Consequently, resources are increasingly being directed toward risk stratification in this cohort. However, the risk of prostate cancer mortality in this group before the introduction of supplemental biomarkers and imaging techniques is unclear. Materials and Methods The PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) Screening Trial provides survival data prior to the implementation of new diagnostic interventions. We divided men with an initial positive screen and a subsequent prostate biopsy into cohorts based on positive or negative results. Prostate cancer specific mortality was then compared to that in the trial control arm to estimate the prognostic significance of biopsy results relative to the general population. Results A total of 36,525 and 36,560 patients comprised the screening and control arms, respectively. Of 4,064 subjects with a positive first screen 1,233 underwent a linked biopsy, of which 473 were positive and 760 were negative. At a median followup of 12.9 years, 1.1% of men in the negative biopsy cohort had died of prostate cancer. The difference in mortality rates between the negative biopsy and control arms was 0.734 deaths per 1,000 person-years. The proportional subhazard ratios of prostate cancer specific mortality for negative biopsy and positive biopsy relative to the control arm were 2.93 (95% CI 1.44–5.99) and 18.77 (95% CI 12.62–27.93), respectively. Conclusions After a negative prostate biopsy, men face a relatively low risk of death from prostate cancer when followed with traditional markers and biopsy techniques. This suggests limited potential for new diagnostic interventions to improve survival in this group. © 2017 American Urological Association Education and Research, Inc. AD - Department of Urology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, United States Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York, United States AU - Lewicki, P. AU - Shoag, J. AU - Golombos, D. M. AU - Oromendia, C. AU - Ballman, K. V. AU - Halpern, J. A. AU - Stone, B. V. AU - O'Malley, P. AU - Barbieri, C. E. AU - Scherr, D. S. DB - Scopus DO - 10.1016/j.juro.2016.11.002 IS - 4 KW - biopsy diagnosis mortality prostatic neoplasms risk M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2017 SP - 1014-1019 ST - Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial T2 - Journal of Urology TI - Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014080181&doi=10.1016%2fj.juro.2016.11.002&partnerID=40&md5=8c96a1b827a6c9eb62a7097c4db6143e VL - 197 ID - 2311 ER - TY - JOUR AB - INTRODUCTION: Evidence‐based health promotion programs that are disseminated in community settings can improve population health. However, little is known about how effective such programs are when they are implemented in communities. We examined community implementation of an evidence‐based program, Body and Soul, to promote consumption of fruits and vegetables. METHODS: We randomly assigned 19 churches to 1 of 2 arms, a colon cancer screening intervention or Body and Soul. We conducted our study from 2008 through 2010. We used the RE‐AIM (reach, effectiveness, adoption, implementation, and maintenance) framework to evaluate the program and collected data via participant surveys, on‐site observations, and interviews with church coordinators and pastors. RESULTS: Members of 8 churches in Michigan and North Carolina participated in the Body and Soul program. Mean fruit and vegetable consumption increased from baseline (3.9 servings/d) to follow‐up (+0.35, P = .04). The program reached 41.4% of the eligible congregation. Six of the 8 churches partially or fully completed at least 3 of the 4 program components. Six churches expressed intention to maintain the program. Church coordinators reported limited time and help to plan and implement activities, competing church events, and lack of motivation among congregation members as barriers to implementation. CONCLUSIONS: The RE‐AIM framework provided an effective approach to evaluating the dissemination of an evidence‐based program to promote health. Stronger emphasis should be placed on providing technical assistance as a way to improve other community‐based translational efforts. AN - CN-00877070 AU - Allicock, M. AU - Johnson, L. S. AU - Leone, L. AU - Carr, C. AU - Walsh, J. AU - Ni, A. AU - Resnicow, K. AU - Pignone, M. AU - Campbell, M. DO - 10.5888/pcd10.120161 KW - African Americans Colonic Neoplasms [*diagnosis, ethnology] Community Participation Counseling Diet [ethnology] Female Fruit Health Knowledge, Attitudes, Practice Health Promotion Humans Male Michigan Middle Aged Motor Activity North Carolina Program Evaluation Religion and Medicine Vegetables M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2013 SP - E33 ST - Promoting fruit and vegetable consumption among members of black churches, Michigan and North Carolina, 2008-2010 T2 - Preventing chronic disease TI - Promoting fruit and vegetable consumption among members of black churches, Michigan and North Carolina, 2008-2010 UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00877070/full VL - 10 ID - 1373 ER - TY - JOUR AB - The objective of this study was to test the efficacy of a pilot intervention to increase mammography utilization among African-American women recruited from those waiting in the emergency department (ED)for non-urgent complaints. In a 3-armed pilot of a randomized controlled trial we compared the effects of a brief motivational interview delivered by a lay health worker with those of a culturally targeted brochure and a usual care control group. The results showed that one quarter (23%) of the sample reported having never had a mammogram prior to the study. There was no group difference by mammography status at the 3-month interview. More than one quarter of those retained in the study indicated they had received a mammogram during the study (27.4%). The conclusions from the study were that lay health workers are a valuable asset and may be used in innovative settings such as the ED to increase screening among vulnerable populations. AU - Hatcher, J. AU - Schoenberg, N. E. AU - Dignan, M. AU - Rayens, M. K. DB - Medline IS - 1 KW - adult African American aged breast tumor comparative study emergency health service female health care personnel health promotion human human relation mammography middle aged patient education pilot study procedures psychology publication United States very elderly LA - English M3 - Article N1 - L623362324 2018-08-09 PY - 2016 SN - 0885-6028 SP - 38-44 ST - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers T2 - Journal of National Black Nurses' Association : JNBNA TI - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623362324&from=export VL - 27 ID - 971 ER - TY - JOUR AB - The objective of this study was to test the efficacy of a pilot intervention to increase mammography utilization among African-American women recruited from those waiting in the emergency department (ED)for non-urgent complaints. In a 3-armed pilot of a randomized controlled trial we compared the effects of a brief motivational interview delivered by a lay health worker with those of a culturally targeted brochure and a usual care control group. The results showed that one quarter (23%) of the sample reported having never had a mammogram prior to the study. There was no group difference by mammography status at the 3-month interview. More than one quarter of those retained in the study indicated they had received a mammogram during the study (27.4%). The conclusions from the study were that lay health workers are a valuable asset and may be used in innovative settings such as the ED to increase screening among vulnerable populations. AU - Hatcher, J. AU - Schoenberg, N. E. AU - Dignan, M. AU - Rayens, M. K. DB - Scopus IS - 1 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2016 SP - 38-44 ST - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers T2 - Journal of National Black Nurses' Association : JNBNA TI - Promoting Mammography with African-American Women in the Emergency Department Using Lay Health Workers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042342916&partnerID=40&md5=95f973614d72c1684cd81c2516843cfb VL - 27 ID - 2341 ER - TY - JOUR AB - Background: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Objective: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) >= 2 PCa from GG1 PCa and benign disease on initial biopsy. Design, setting, and participants: A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age >= 50 yr and prostate-specific antigen (PSA) 2-10 ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. Outcome measurements and statistical analysis: Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. Results and limitations: In a total of 503 patients, with median age of 64 yr, median PSA 5.4 ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% >= GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n = 519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of >= GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of >= GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. Conclusions: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of >= GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. Patient summary: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2-10 ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict >= GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data. (C) 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. AN - WOS:000450121100018 AU - McKiernan, J. AU - Donovan, M. J. AU - Margolis, E. AU - Partin, A. AU - Carter, B. AU - Brown, G. AU - Torkler, P. AU - Noerholm, M. AU - Skog, J. AU - Shore, N. AU - Andriole, G. AU - Thompson, I. AU - Carroll, P. DA - Dec DO - 10.1016/j.eururo.2018.08.019 IS - 6 N1 - 30237023 PY - 2018 SN - 0302-2838 SP - 731-738 ST - Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy T2 - European Urology TI - Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy VL - 74 ID - 2837 ER - TY - JOUR AB - Background: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption. Objective: Performance and utility assessment of ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay versus standard clinical parameters for discriminating Grade Group (GG) ≥2 PCa from GG1 PCa and benign disease on initial biopsy. Design, setting, and participants: A two-phase adaptive clinical utility study (NCT03031418) comparing EPI results with biopsy outcomes in men, with age ≥50 yr and prostate-specific antigen (PSA) 2–10 ng/ml, scheduled for initial prostate biopsy. After EPI performance assessment during phase I, a clinical implementation document (ie, CarePath) was developed for utilizing the EPI test in phase II, where the biopsy decision is uncertain. Outcome measurements and statistical analysis: Performance evaluation of the EPI test in patients enrolled in phase I and publication of a consensus CarePath for phase II. Results and limitations: In a total of 503 patients, with median age of 64 yr, median PSA 5.4 ng/ml, 14% African American, 70% Caucasian, 53% positive biopsy rate (22% GG1, 17% GG2, and 15% ≥ GG3), EPI was superior to an optimized model of standard clinical parameters with an area under the curve (AUC) 0.70 versus 0.62, respectively, comparable with previously published results (n = 519 patients, EPI AUC 0.71). Validated cut-point 15.6 would avoid 26% of unnecessary prostate biopsies and 20% of total biopsies, with negative predictive value (NPV) 89% and missing 7% of ≥GG2 PCa. Alternative cut-point 20 would avoid 40% of unnecessary biopsies and 31% of total biopsies, with NPV 89% and missing 11% of ≥GG2 PCa. The clinical investigators reached consensus recommending use of the 15.6 cut-point for phase II. Outcome of the decision impact cohort in phase II will be reported separately. Conclusions: EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies. Patient summary: It is challenging to predict which men are likely to have high-grade prostate cancer (PCa) at initial biopsy with prostate-specific antigen 2–10 ng/ml. This study further demonstrates that the ExoDx Prostate (IntelliScore) test can predict ≥GG2 PCa at initial biopsy and defer unnecessary biopsies better than existing risk calculator's and standard clinical data. ExoDx Prostate (IntelliScore) is a urine-based test that relies solely on a three-gene signature to predict high-grade prostate cancer at initial biopsy for men with prostate-specific antigen 2–10 ng/ml. The test has been prospectively validated on over 1000 men from two multisite trials. © 2018 The Author(s) AD - Department of Urology, Columbia University Medical Center, New York City, NY, United States Icahn School of Medicine at Mt. Sinai, New York City, NY, United States Urology Center of Englewood, Englewood, NJ, United States The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States Delaware Valley Urology, Vorhees, NJ, United States Exosome Diagnostics GmbH, Martinsried, Germany Exosome Diagnostics Inc., Waltham, MA, United States Atlantic Urology Clinics, Myrtle Beach, SC, United States Division of Urologic Surgery, Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States UT Health Science Center, San Antonio, TX, United States Department of Urology, University of California at San FranciscoCA, United States AU - McKiernan, J. AU - Donovan, M. J. AU - Margolis, E. AU - Partin, A. AU - Carter, B. AU - Brown, G. AU - Torkler, P. AU - Noerholm, M. AU - Skog, J. AU - Shore, N. AU - Andriole, G. AU - Thompson, I. AU - Carroll, P. DB - Scopus DO - 10.1016/j.eururo.2018.08.019 IS - 6 KW - Exosomes Extended validation study High grade prostate cancer Initial biopsy Prostate cancer Risk assessment tools M3 - Article N1 - Cited By :49 Export Date: 22 March 2021 PY - 2018 SP - 731-738 ST - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy T2 - European Urology TI - A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053354356&doi=10.1016%2fj.eururo.2018.08.019&partnerID=40&md5=8496d86b331da474fad1af6e939d1be3 VL - 74 ID - 2250 ER - TY - JOUR AB - Purpose Breast cancer risk prediction models have underestimated risk for African American women, contributing to lower recruitment rates in prevention trials. A model previously developed for African American women was found to underestimate risk in the Black Women's Health Study (BWHS). Methods We developed a breast cancer risk model for African American women using relative risks derived from 10 years of follow-up of BWHS participants age 30 to 69 years at baseline. Using the subsequent 5 years of follow-up data, we evaluated calibration as the ratio of expected to observed number of breast cancers and assessed discriminatory accuracy using the concordance statistic. Results The BWHS model included family history, previous biopsy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height. There was good agreement between predicted and observed number of breast cancers overall (expected-to-observed ratio, 0.96; 95% CI, 0.88 to 1.05) and in most risk factor categories. Discriminatory accuracy was higher for women younger than age 50 years (area under the curve [AUC], 0.62; 95% CI, 0.58 to 0.65) than for women age ≥ 50 years (AUC, 0.56; 95% CI, 0.53 to 0.59). Using a 5-year predicted risk of 1.66% or greater as a cut point, 2.8% of women younger than 50 years old and 32.2% of women ≥ 50 years old were classified as being at elevated risk of invasive breast cancer. Conclusion The BWHS model was well calibrated overall, and the predictive ability was best for younger women. The proportion of women predicted to meet the 1.66% cut point commonly used to determine eligibility for breast cancer prevention trials was greatly increased relative to previous models. AD - J.R. Palmer, Slone Epidemiology Center, 1010 Commonwealth Ave, Boston, MA, United States AU - Boggs, D. A. AU - Rosenberg, L. AU - Adams-Campbell, L. L. AU - Palmer, J. R. DB - Embase Medline DO - 10.1200/JCO.2014.57.2750 IS - 9 KW - estrogen gestagen adult African American aged area under the curve article biopsy body mass breast biopsy breast cancer cancer diagnosis cancer risk controlled study family history female follow up human major clinical study menarche oral contraceptive use ovariectomy priority journal prospective study women's health LA - English M3 - Article N1 - L603620165 2015-04-17 2015-04-24 PY - 2015 SN - 1527-7755 0732-183X SP - 1038-1044 ST - Prospective approach to breast cancer risk prediction in African American women: The black women's health study model T2 - Journal of Clinical Oncology TI - Prospective approach to breast cancer risk prediction in African American women: The black women's health study model UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603620165&from=export http://dx.doi.org/10.1200/JCO.2014.57.2750 VL - 33 ID - 1005 ER - TY - JOUR AB - Purpose: Breast cancer risk prediction models have underestimated risk for African American women, contributing to lower recruitment rates in prevention trials. A model previously developed for African American women was found to underestimate risk in the Black Women's Health Study (BWHS).Methods: We developed a breast cancer risk model for African American women using relative risks derived from 10 years of follow-up of BWHS participants age 30 to 69 years at baseline. Using the subsequent 5 years of follow-up data, we evaluated calibration as the ratio of expected to observed number of breast cancers and assessed discriminatory accuracy using the concordance statistic.Results: The BWHS model included family history, previous biopsy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height. There was good agreement between predicted and observed number of breast cancers overall (expected-to-observed ratio, 0.96; 95% CI, 0.88 to 1.05) and in most risk factor categories. Discriminatory accuracy was higher for women younger than age 50 years (area under the curve [AUC], 0.62; 95% CI, 0.58 to 0.65) than for women age ≥ 50 years (AUC, 0.56; 95% CI, 0.53 to 0.59). Using a 5-year predicted risk of 1.66% or greater as a cut point, 2.8% of women younger than 50 years old and 32.2% of women ≥ 50 years old were classified as being at elevated risk of invasive breast cancer.Conclusion: The BWHS model was well calibrated overall, and the predictive ability was best for younger women. The proportion of women predicted to meet the 1.66% cut point commonly used to determine eligibility for breast cancer prevention trials was greatly increased relative to previous models. AD - Deborah A. Boggs, Lynn Rosenberg, and Julie R. Palmer, Slone Epidemiology Center at Boston University, Boston, MA; and Lucile L. Adams-Campbell, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Deborah A. Boggs, Lynn Rosenberg, and Julie R. Palmer, Slone Epidemiology Center at Boston University, Boston, MA; and Lucile L. Adams-Campbell, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. jpalmer@bu.edu. AN - 103774654. Language: English. Entry Date: 20150612. Revision Date: 20200708. Publication Type: journal article AU - Boggs, Deborah A. AU - Rosenberg, Lynn AU - Adams-Campbell, Lucile L. AU - Palmer, Julie R. DB - CINAHL Complete DO - 10.1200/JCO.2014.57.2750 DP - EBSCOhost IS - 9 KW - Breast Neoplasms -- Epidemiology Breast Neoplasms -- Ethnology Adult Black Persons Aged Pharmacokinetics Breast Neoplasms -- Diagnosis Calibration Data Analysis, Statistical Female Human Incidence Middle Age Models, Theoretical Prospective Studies Reproducibility of Results Risk Assessment Women's Health N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: U01 CA182898/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM25624428. PY - 2015 SN - 0732-183X SP - 1038-1044 ST - Prospective approach to breast cancer risk prediction in African American women: the black women's health study model T2 - Journal of Clinical Oncology TI - Prospective approach to breast cancer risk prediction in African American women: the black women's health study model UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103774654&site=ehost-live&scope=site VL - 33 ID - 2032 ER - TY - JOUR AB - Purpose Breast cancer risk prediction models have underestimated risk for African American women, contributing to lower recruitment rates in prevention trials. A model previously developed for African American women was found to underestimate risk in the Black Women's Health Study (BWHS). Methods We developed a breast cancer risk model for African American women using relative risks derived from 10 years of follow-up of BWHS participants age 30 to 69 years at baseline. Using the subsequent 5 years of follow-up data, we evaluated calibration as the ratio of expected to observed number of breast cancers and assessed discriminatory accuracy using the concordance statistic. Results The BWHS model included family history, previous biopsy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height. There was good agreement between predicted and observed number of breast cancers overall (expected-to-observed ratio, 0.96; 95% CI, 0.88 to 1.05) and in most risk factor categories. Discriminatory accuracy was higher for women younger than age 50 years (area under the curve [AUC], 0.62; 95% CI, 0.58 to 0.65) than for women age ≥ 50 years (AUC, 0.56; 95% CI, 0.53 to 0.59). Using a 5-year predicted risk of 1.66% or greater as a cut point, 2.8% of women younger than 50 years old and 32.2% of women ≥ 50 years old were classified as being at elevated risk of invasive breast cancer. Conclusion The BWHS model was well calibrated overall, and the predictive ability was best for younger women. The proportion of women predicted to meet the 1.66% cut point commonly used to determine eligibility for breast cancer prevention trials was greatly increased relative to previous models. © 2015 by American Society of Clinical Oncology. AD - Slone Epidemiology Center at, Boston University, Boston, MA, United States Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States Slone Epidemiology Center, 1010 Commonwealth Ave, Boston, MA 02215, United States AU - Boggs, D. A. AU - Rosenberg, L. AU - Adams-Campbell, L. L. AU - Palmer, J. R. DB - Scopus DO - 10.1200/JCO.2014.57.2750 IS - 9 M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2015 SP - 1038-1044 ST - Prospective approach to breast cancer risk prediction in African American women: The black women's health study model T2 - Journal of Clinical Oncology TI - Prospective approach to breast cancer risk prediction in African American women: The black women's health study model UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927127570&doi=10.1200%2fJCO.2014.57.2750&partnerID=40&md5=bcce7f576d3ff5f6214204ae533144e2 VL - 33 ID - 2365 ER - TY - JOUR AB - Purpose Breast cancer risk prediction models have underestimated risk for African American women, contributing to lower recruitment rates in prevention trials. A model previously developed for African American women was found to underestimate risk in the Black Women's Health Study (BWHS). Methods We developed a breast cancer risk model for African American women using relative risks derived from 10 years of follow-up of BWHS participants age 30 to 69 years at baseline. Using the subsequent 5 years of follow-up data, we evaluated calibration as the ratio of expected to observed number of breast cancers and assessed discriminatory accuracy using the concordance statistic. Results The BWHS model included family history, previous biopsy, body mass index at age 18 years, age at menarche, age at first birth, oral contraceptive use, bilateral oophorectomy, estrogen plus progestin use, and height. There was good agreement between predicted and observed number of breast cancers overall (expected-to-observed ratio, 0.96; 95% CI, 0.88 to 1.05) and in most risk factor categories. Discriminatory accuracy was higher for women younger than age 50 years (area under the curve [AUC], 0.62; 95% CI, 0.58 to 0.65) than for women age 50 years (AUC, 0.56; 95% CI, 0.53 to 0.59). Using a 5-year predicted risk of 1.66% or greater as a cut point, 2.8% of women younger than 50 years old and 32.2% of women 50 years old were classified as being at elevated risk of invasive breast cancer. Conclusion The BWHS model was well calibrated overall, and the predictive ability was best for younger women. The proportion of women predicted to meet the 1.66% cut point commonly used to determine eligibility for breast cancer prevention trials was greatly increased relative to previous models. (C) 2015 by American Society of Clinical Oncology AN - WOS:000356056400014 AU - Boggs, D. A. AU - Rosenberg, L. AU - Adams-Campbell, L. L. AU - Palmer, J. R. DA - Mar DO - 10.1200/JCO.2014.57.2750 IS - 9 N1 - 25624428 PY - 2015 SN - 0732-183X SP - 1038-+ ST - Prospective Approach to Breast Cancer Risk Prediction in African American Women: The Black Women's Health Study Model T2 - Journal of Clinical Oncology TI - Prospective Approach to Breast Cancer Risk Prediction in African American Women: The Black Women's Health Study Model VL - 33 ID - 2982 ER - TY - JOUR AB - Background: The purpose of this study was to evaluate baseline demographic characteristics which may be associated with worse health related quality of life (HRQOL) for patients with locally advanced non-small cell lung cancer (NSCLC) receiving definitive chemoradiation (CRT). Materials: Patients with NSCLC were prospectively enrolled on an Institutional Review Board-approved clinical trial between 2009 and 2012. HRQOL assessments were collected pre-radiation therapy (RT), during RT, and within 3 months post-RT using Euroqol (EQ-5D), MD Anderson Symptom Inventory (MDASI), and Functional Assessment of Cancer Therapy General (FACT-G). HRQOL correlation was assessed with categorical variables by Wilcoxon rank sum tests and with continuous variables by Pearson correlation. P<0.05 was defined as statistically significant. Results: Forty-three consecutive patients received definitive concurrent CRT and completed assessments at one or more time-points. Patients most commonly had stage IIIB disease (72%), were married or with a partner (70%) and Caucasian (91%). Median patient age was 65 (range: 39–79) years and Charlson comorbidity index (CCI) was 0 (range: 0–5). Female gender, African-American ethnicity, age, chemotherapy type, baseline hemoglobin, and CCI were associated with worse post-treatment HRQOL measures. Conclusions: We have identified novel characteristics associated with worse quality of life following definitive CRT for lung cancer. Patients at risk for worse post-treatment quality of life may benefit from earlier follow-up and greater supportive measures following treatment. AU - Vogel, J. AU - Wang, X. AU - Troxel, A. B. AU - Simone, C. B. AU - Rengan, R. AU - Lin, L. L. DB - Embase DO - 10.21037/tlcr.2019.08.21 IS - 4 KW - carboplatin cisplatin hemoglobin adult advanced cancer African American aged article cancer localization Caucasian Charlson Comorbidity Index chemoradiotherapy clinical article correlation analysis correlation coefficient demography European Quality of Life 5 Dimensions questionnaire female Functional Assessment of Cancer Therapy General human male non small cell lung cancer prospective study quality of life rank sum test symptom assessment LA - English M3 - Article N1 - L629395134 2019-09-26 2019-09-27 PY - 2019 SN - 2226-4477 2218-6751 SP - 332-339 ST - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer T2 - Translational Lung Cancer Research TI - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L629395134&from=export http://dx.doi.org/10.21037/tlcr.2019.08.21 VL - 8 ID - 869 ER - TY - JOUR AB - Background: The purpose of this study was to evaluate baseline demographic characteristics which may be associated with worse health related quality of life (HRQOL) for patients with locally advanced non-small cell lung cancer (NSCLC) receiving definitive chemoradiation (CRT). Materials: Patients with NSCLC were prospectively enrolled on an Institutional Review Board-approved clinical trial between 2009 and 2012. HRQOL assessments were collected pre-radiation therapy (RT), during RT, and within 3 months post-RT using Euroqol (EQ-5D), MD Anderson Symptom Inventory (MDASI), and Functional Assessment of Cancer Therapy General (FACT-G). HRQOL correlation was assessed with categorical variables by Wilcoxon rank sum tests and with continuous variables by Pearson correlation. P<0.05 was defined as statistically significant. Results: Forty-three consecutive patients received definitive concurrent CRT and completed assessments at one or more time-points. Patients most commonly had stage IIIB disease (72%), were married or with a partner (70%) and Caucasian (91%). Median patient age was 65 (range: 39–79) years and Charlson comorbidity index (CCI) was 0 (range: 0–5). Female gender, African-American ethnicity, age, chemotherapy type, baseline hemoglobin, and CCI were associated with worse post-treatment HRQOL measures. Conclusions: We have identified novel characteristics associated with worse quality of life following definitive CRT for lung cancer. Patients at risk for worse post-treatment quality of life may benefit from earlier follow-up and greater supportive measures following treatment. © Translational lung cancer research. All rights reserved. AD - Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, United States Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd, Houston, TX 77030, United States NYU Langone Medical Center, Division of Biostatistics, 108 Madison Avenue, New York, NY 10016, United States New York Proton Center, 225 East 126th Street, New York, NY 10035, United States University of Washington, Department of Radiation Oncology, 1570 N 115th Street, Seattle, WA 98133, United States AU - Vogel, J. AU - Wang, X. AU - Troxel, A. B. AU - Simone, C. B., II AU - Rengan, R. AU - Lin, L. L. DB - Scopus DO - 10.21037/tlcr.2019.08.21 IS - 4 KW - Chemoradiation (CRT) Non-small cell lung cancer (NSCLC) Quality of life M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2019 SP - 332-339 ST - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer T2 - Translational Lung Cancer Research TI - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072521320&doi=10.21037%2ftlcr.2019.08.21&partnerID=40&md5=2796fef412e555e4d11b99647fcb4c3d VL - 8 ID - 2244 ER - TY - JOUR AB - Background: The purpose of this study was to evaluate baseline demographic characteristics which may be associated with worse health related quality of life (HRQOL) for patients with locally advanced non-small cell lung cancer (NSCLC) receiving definitive chemoradiation (CRT). Materials: Patients with NSCLC were prospectively enrolled on an Institutional Review Board-approved clinical trial between 2009 and 2012. HRQOL assessments were collected pre-radiation therapy (RT), during RT, and within 3 months post-RT using Euroqol (EQ-5D), MD Anderson Symptom Inventory (MDASI), and Functional Assessment of Cancer Therapy General (FACT-G). HRQOL correlation was assessed with categorical variables by Wilcoxon rank sum tests and with continuous variables by Pearson correlation. P<0.05 was defined as statistically significant. Results: Forty-three consecutive patients received definitive concurrent CRT and completed assessments at one or more time-points. Patients most commonly had stage IIIB disease (72%), were married or with a partner (70%) and Caucasian (91%). Median patient age was 65 (range: 39-79) years and Charlson comorbidity index (CCI) was 0 (range: 0-5). Female gender, African-American ethnicity, age, chemotherapy type, baseline hemoglobin, and CCI were associated with worse post-treatment HRQOL measures. Conclusions: We have identified novel characteristics associated with worse quality of life following definitive CRT for lung cancer. Patients at risk for worse post-treatment quality of life may benefit from earlier follow-up and greater supportive measures following treatment. AN - WOS:000484264600004 AU - Vogel, J. AU - Wang, X. M. AU - Troxel, A. B. AU - Simone, C. B. AU - Rengan, R. AU - Lin, L. L. DA - Aug DO - 10.21037/tlcr.2019.08.21 IS - 4 N1 - 31555509 PY - 2019 SN - 2218-6751 SP - 332-339 ST - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer T2 - Translational Lung Cancer Research TI - Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer VL - 8 ID - 2815 ER - TY - JOUR AB - Objective: Symptom burden remains a distressing problem for survivors with non-small-cell lung cancer (stages I-IIIa). This pilot study evaluated feasibility and preliminary effects of a tailored mindfulness-based intervention, Breathe Easier, which encompasses meditation, 2 levels of mindful hatha yoga, breathing exercises, and participant interaction. Methods: Participants were recruited from 2 cancer programs in the US Southeast. A family member was required for participation. Sixty-two participants enrolled (20% recruitment) and 49 completed the intervention (79% retention). Participants chose level 1 yoga (basic) or level 2 (more advanced). Of the completers, survivors were 39% male and 65% Black. A community-based participatory research framework helped identify the specific needs and interests of potential participants and foreseeable barriers to implementation. A 2-month prospective, 1-group, pre-post design evaluated feasibility. Intervention dosage was measured using written protocols. Attendance and completion of daily home assignments measured adherence. Acceptability was assessed using a 10-item questionnaire, completed at three time points. Preliminary outcome data collected pre- and post-intervention tested the hypothesis that participants who received the 8-week intervention Breathe Easier would, post-intervention, demonstrate (a) less dyspnea, (b) less fatigue, (c) less stress, (d) improved sleep, (e) improved anxiety and depression, and (f) improved functional exercise capacity. Exit interviews were conducted, transcribed verbatim, and analyzed for content using descriptive statistics. Results: Quantitative and qualitative measures indicated strong feasibility. Over time, level 1 participants had statistically less dyspnea, fatigue and improved exercise capacity, as well as improved sleep, and stress scores. Level 2 participants experienced slightly increased dyspnea and fatigue but improved sleep, stress, and exercise capacity. All participants experienced anxiety and depression within normal limits pre- and post-intervention. Five major themes emerged out of exit interviews: Learning to Breathe Easier; Interacting with Others as a Personal Benefit; Stretching, Releasing Tension, and Feeling Energized; Enhancing Closeness with Committed Partners; Refocusing on Living; and Sustaining New Skills as a Decision. Conclusions: The study offers insight into the feasibility of an 8-week in-person mindfulness-based intervention with a unique subset of understudied survivors of lung cancer and family members. Outcome data interpretation is limited by the 1-group design and sample size. AD - University of South Carolina, Columbia, SC, USA University of Georgia, Athens, GA, USA Dallas VA Medical Center, Dallas, TX, USA AN - 147842245. Language: English. Entry Date: 20210103. Revision Date: 20210103. Publication Type: Article AU - McDonnell, Karen Kane AU - Gallerani, David G. AU - Newsome, Brandi R. AU - Owens, Otis L. AU - Beer, Jenay AU - Myren-Bennett, Amanda R. AU - Regan, Elizabeth AU - Hardin, James W. AU - Webb, Lisa A. DB - CINAHL Complete DO - 10.1177/1534735420969829 DP - EBSCOhost KW - Mindfulness Lung Neoplasms -- Therapy Family Therapy Cancer Survivors Extended Family Treatment Outcomes Human Pilot Studies Meditation Yoga Breathing Exercises Southeastern United States Male Female Descriptive Statistics Prospective Studies Pretest-Posttest Design Questionnaires Interviews Thematic Analysis Functional Status Dyspnea Sleep Stress, Psychological Cancer Fatigue Anxiety Depression Content Analysis N1 - research; tables/charts. Journal Subset: Alternative/Complementary Therapies; Biomedical; Peer Reviewed; USA. NLM UID: 101128834. PY - 2020 SN - 1534-7354 SP - 1-14 ST - A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier : A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads) T2 - Integrative Cancer Therapies TI - A Prospective Pilot Study Evaluating Feasibility and Preliminary Effects of Breathe Easier : A Mindfulness-based Intervention for Survivors of Lung Cancer and Their Family Members (Dyads) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147842245&site=ehost-live&scope=site ID - 1827 ER - TY - JOUR AB - Purpose: To investigate patients' willingness to participate (WTP) in a randomized controlled trial (RCT) comparing intensity-modulated radiotherapy (IMRT) with proton beam therapy (PBT) for prostate cancer (PCa). Methods and Materials: We undertook a qualitative research study in which we prospectively enrolled patients with clinically localized PCa. We used purposive sampling to ensure a diverse sample based on age, race, travel distance, and physician. Patients participated in a semi-structured interview in which they reviewed a description of a hypothetical RCT, were asked open-ended and focused follow-up questions regarding their motivations for and concerns about enrollment, and completed a questionnaire assessing characteristics such as demographics and prior knowledge of IMRT or PBT. Patients' stated WTP was assessed using a 6-point Likert scale. Results: Forty-six eligible patients (33 white, 13 black) were enrolled from the practices of eight physicians. We identified 21 factors that impacted patients' WTP, which largely centered on five major themes: altruism/desire to compare treatments, randomization, deference to physician opinion, financial incentives, and time demands/scheduling. Most patients (27 of 46, 59%) stated they would either "definitely" or "probably" participate. Seventeen percent (8 of 46) stated they would "definitely not" or "probably not" enroll, most of whom (6 of 8) preferred PBT before their physician visit. Conclusions: A substantial proportion of patients indicated high WTP in a RCT comparing IMRT and PBT for PCa. (C) 2012 Elsevier Inc. AN - WOS:000302993900002 AU - Shah, A. AU - Efstathiou, J. A. AU - Paly, J. J. AU - Halpern, S. D. AU - Bruner, D. W. AU - Christodouleas, J. P. AU - Coen, J. J. AU - Deville, C. AU - Vapiwala, N. AU - Shipley, W. U. AU - Zietman, A. L. AU - Hahn, S. M. AU - Bekelman, J. E. DA - May DO - 10.1016/j.ijrobp.2011.11.072 IS - 1 N1 - 22381899 PY - 2012 SN - 0360-3016 SP - E13-E19 ST - Prospective Preference Assessment of Patients' Willingness to Participate in a Randomized Controlled Trial of Intensity-Modulated Radiotherapy Versus Proton Therapy for Localized Prostate Cancer T2 - International Journal of Radiation Oncology Biology Physics TI - Prospective Preference Assessment of Patients' Willingness to Participate in a Randomized Controlled Trial of Intensity-Modulated Radiotherapy Versus Proton Therapy for Localized Prostate Cancer VL - 83 ID - 3071 ER - TY - JOUR AB - Purpose: To investigate patients' willingness to participate (WTP) in a randomized controlled trial (RCT) comparing intensity-modulated radiotherapy (IMRT) with proton beam therapy (PBT) for prostate cancer (PCa). Methods and Materials: We undertook a qualitative research study in which we prospectively enrolled patients with clinically localized PCa. We used purposive sampling to ensure a diverse sample based on age, race, travel distance, and physician. Patients participated in a semi-structured interview in which they reviewed a description of a hypothetical RCT, were asked open-ended and focused follow-up questions regarding their motivations for and concerns about enrollment, and completed a questionnaire assessing characteristics such as demographics and prior knowledge of IMRT or PBT. Patients' stated WTP was assessed using a 6-point Likert scale. Results: Forty-six eligible patients (33 white, 13 black) were enrolled from the practices of eight physicians. We identified 21 factors that impacted patients' WTP, which largely centered on five major themes: altruism/desire to compare treatments, randomization, deference to physician opinion, financial incentives, and time demands/scheduling. Most patients (27 of 46, 59%) stated they would either "definitely" or "probably" participate. Seventeen percent (8 of 46) stated they would "definitely not" or "probably not" enroll, most of whom (6 of 8) preferred PBT before their physician visit. Conclusions: A substantial proportion of patients indicated high WTP in a RCT comparing IMRT and PBT for PCa. © 2012 Elsevier Inc. All rights reserved. AD - Department of Radiation Oncology, Hospital of the University of Pennsylvania, PCAM, TRC, 3400 Civic Center Boulevard, 4 West, Philadelphia, PA 19104, United States Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States Center for Bioethics, University of Pennsylvania, Philadelphia, PA, United States Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, United States Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, United States Winship Cancer Institute, Emory University, Atlanta, GA, United States AU - Shah, A. AU - Efstathiou, J. A. AU - Paly, J. J. AU - Halpern, S. D. AU - Bruner, D. W. AU - Christodouleas, J. P. AU - Coen, J. J. AU - Deville Jr, C. AU - Vapiwala, N. AU - Shipley, W. U. AU - Zietman, A. L. AU - Hahn, S. M. AU - Bekelman, J. E. DB - Scopus DO - 10.1016/j.ijrobp.2011.11.072 IS - 1 KW - Intensity-modulated radiotherapy Prostate cancer Proton beam therapy Randomized controlled trial M3 - Conference Paper N1 - Cited By :25 Export Date: 22 March 2021 PY - 2012 SP - e13-e19 ST - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer T2 - International Journal of Radiation Oncology Biology Physics TI - Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859823555&doi=10.1016%2fj.ijrobp.2011.11.072&partnerID=40&md5=21f64d5669e22de7334c8a4408c02fcc VL - 83 ID - 2460 ER - TY - JOUR AB - The relation of body mass index (BMI) and weight gain to breast cancer risk is complex, and little information is available on Black women, among whom the prevalence of obesity is high. We assessed BMI and weight gain in relation to breast cancer risk in prospective data from the Black Women's Health Study. In 1995, 59,000 African American women enrolled in the Black Women's Health Study by completing mailed questionnaires. Data on anthropometric factors were obtained at baseline and every 2 years afterwards. In 10 years of follow-up, 1,062 incident cases of breast cancer occurred. Incidence rate ratios (IRR) were computed in multivariable Cox proportional hazards regression. BMI at age 18 years of ≥25 relative to <20 was associated with a reduced risk of breast cancer among both premenopausal women (IRR, 0.68; 95% confidence interval, 0.46-0.98) and postmenopausal women (IRR, 0.53; 95% confidence interval, 0.35-0.81). There was an inverse association of current BMI with premenopausal breast cancer but no association with postmenopausal breast cancer, either overall or among never-users of hormone therapy. Weight gain was not associated with postmenopausal breast cancer risk. In analyses restricted to breast cancers that were estrogen and progesterone receptor positive, IRRs for current BMI and weight gain were elevated but not statistically significant. The findings indicate that being overweight at age 18 years is associated with a reduced risk of both premenopausal and postmenopausal breast cancer in African American women. Understanding the reasons for the association may help elucidate the pathways through which adolescent exposures influence breast cancer risk. The lack of association of obesity with receptor-negative tumors in postmenopausal African American women may partially explain why breast cancer incidence in older Black women is not high relative to other ethnic groups in spite of the high prevalence of obesity in Black women. Copyright © 2007 American Association for Cancer Research. AD - Slone Epidemiology Center, Boston University, Boston, MA, United States Cancer Prevention, Control, and Population Sciences, Howard University Cancer Center, Washington, DC, United States Slone Epidemiology Center, Boston University, 1010 Commonwealth Avenue, Boston, MA 02215, United States AU - Palmer, J. R. AU - Adams-Campbell, L. L. AU - Boggs, D. A. AU - Wise, L. A. AU - Rosenberg, L. DB - Scopus DO - 10.1158/1055-9965.EPI-07-0336 IS - 9 M3 - Article N1 - Cited By :110 Export Date: 22 March 2021 PY - 2007 SP - 1795-1802 ST - A prospective study of body size and breast cancer in black women T2 - Cancer Epidemiology Biomarkers and Prevention TI - A prospective study of body size and breast cancer in black women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548813858&doi=10.1158%2f1055-9965.EPI-07-0336&partnerID=40&md5=386f32b371ba81656454c7b120c64924 VL - 16 ID - 2552 ER - TY - JOUR AB - Introduction Patients with low-risk prostate cancer (PCa) often have excellent oncologic outcomes. However, treatment with curative intent can lead to decrements in health-related quality of life (HRQoL). Patients treated with radical prostatectomy have been shown to suffer declines in urinary and sexual HRQoL as compared to those managed with active surveillance (AS). Similarly, patients treated with external-beam radiation therapy (EBRT) are hypothesized to experience greater declines in bowel HRQoL. As health-related quality-of-life (HRQoL) concerns are paramount when selecting among treatment options for low-risk PCa, this study examined HRQoL outcomes in men undergoing EBRT as compared to AS in a prospective, racially diverse cohort. Methods A prospective study of HRQoL in patients with PCa enrolled in the Center for Prostate Disease Research (CPDR) Multicenter National Database was initiated in 2007. The current study included patients diagnosed through April 2014. HRQoL was assessed with the Expanded Prostate Cancer Index Composite (EPIC) and the Medical Outcomes Study Short Form (SF-36). Temporal changes in HRQoL were compared for patients with low-risk PCa managed on AS vs. EBRT at baseline, 1-, 2-, and 3 years post-PCa diagnosis. Longitudinal patterns were modeled using linear regression models fitted with generalized estimating equations (GEE), adjusting for baseline HRQoL, demographic, and clinical patient characteristics. Results Of the 499 eligible patients with low-risk PCa, 103 (21%) selected AS and 60 (12%) were treated with EBRT. Demographic characteristics of the treatment groups were similar, though a greater proportion of patients in the EBRT group were African American (P = 0.0003). At baseline, both treatment groups reported comparable HRQoL. EBRT patients experienced significantly worse bowel function and bother at 1 year (adjusted mean score: 87 vs. 95, P = 0.001 and 89 vs. 95, P = 0.008, respectively) and 2 years (87 vs. 93, P = 0.007 and 87 vs. 96, P = 0.002, respectively) compared to patients managed on AS. In contrast to those on AS, more than half the number of patients who received EBRT experienced a decline in bowel function (52% vs. 17%, p=0.003) and bother (52% vs. 15%, P = 0.002) from baseline to 1 year. Patients who received EBRT were significantly more likely to experience a decrease in more than one functional domain (urinary, sexual, bowel, or hormonal) at 1 year when compared with those on AS (60% vs. 28%, P = 0.004). Conclusions Patients receiving EBRT for low-risk prostate cancer suffer declines in bowel HRQoL. These declines are not experienced by patients on AS, suggesting that management of low-risk prostate cancer with AS may offer a means for preserving HRQoL following prostate cancer diagnosis. © 2017 Elsevier Inc AD - Section of Urology and Renal Transplantation, Virginia Mason, Seattle, WA, United States Department of Defense, Center for Prostate Disease Research, Rockville, MD, United States Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, United States Department of Surgery, University of Washington, Seattle, WA, United States Walter Reed National Military Medical Center, Urology Service, Bethesda, MD, United States Department of Urology, Madigan Army Medical Center, Tacoma, WA, United States Department of Urology, Naval Medical Center San Diego, San Diego, CA, United States Department of Urology, Tripler Army Medical Center, Honolulu, HI, United States AU - Banerji, J. S. AU - Hurwitz, L. M. AU - Cullen, J. AU - Wolff, E. M. AU - Levie, K. E. AU - Rosner, I. L. AU - Brand, T. C. AU - LʼEsperance, J. O. AU - Sterbis, J. R. AU - Porter, C. R. DB - Scopus DO - 10.1016/j.urolonc.2016.12.015 IS - 5 KW - Active surveillance Prostate cancer Quality of life Radiotherapy Treatment M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2017 SP - 234-242 ST - A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy T2 - Urologic Oncology: Seminars and Original Investigations TI - A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009909061&doi=10.1016%2fj.urolonc.2016.12.015&partnerID=40&md5=dc1791f5fb3c44120423616145d47515 VL - 35 ID - 2308 ER - TY - JOUR AB - Prostate cancer is a significant health problem for African-American men intensified by low participation in screenings, clinical trials, and prospective cohort studies. Ten focus groups were conducted with African-American males and their female partners/spouses. Perceptions and knowledge about prostate cancer, as well as willingness to participate in screening and research studies were measured. Participants had a basic level of knowledge about prostate cancer, and the importance of education was a unified theme. Dialogue with targeted African-American men and their partners/spouses may increase awareness and retention in medical research, while influencing health promotion, education and behavior. AD - G.D. Hughes, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. AU - Hughes, G. D. AU - Sellers, D. B. AU - Fraser Jr, L. AU - Teague, R. AU - Knight, B. DB - Medline IS - 2 KW - African American aged article attitude to health awareness consumer cooperation education ethnology female health education health service human information dissemination information processing male mass screening methodology middle aged nursing methodology research organization and management prostate tumor psychological aspect public relations trust United States LA - English M3 - Article N1 - L354195357 2009-02-26 PY - 2007 SN - 1071-5568 SP - 68-73 ST - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males T2 - Journal of cultural diversity TI - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354195357&from=export VL - 14 ID - 1230 ER - TY - JOUR AB - Prostate cancer is a significant health problem for African-American men intensified by low participation in screenings, clinical trials, and prospective cohort studies. Ten focus groups were conducted with African-American males and their female partners/spouses. Perceptions and knowledge about prostate cancer, as well as willingness to participate in screening and research studies were measured. Participants had a basic level of knowledge about prostate cancer, and the importance of education was a unified theme. Dialogue with targeted African-American men and their partners/spouses may increase awareness and retention in medical research, while influencing health promotion, education and behavior. AD - University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. AU - Hughes, G. D. AU - Sellers, D. B. AU - Fraser Jr, L. AU - Teague, R. AU - Knight, B. DB - Scopus IS - 2 M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2007 SP - 68-73 ST - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males T2 - Journal of cultural diversity TI - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-60549087368&partnerID=40&md5=0aec585e3f80359280fe318c4c106797 VL - 14 ID - 2559 ER - TY - JOUR AB - Prostate cancer is a significant health problem for African-American men intensified by low participation in screenings, clinical trials, and prospective cohort studies. Ten focus groups were conducted with African-American males and their female partners/spouses. Perceptions and knowledge about prostate cancer, as well as willingness to participate in screening and research studies were measured. Participants had a basic level of knowledge about prostate cancer, and the importance of education was a unified theme. Dialogue with targeted African-American men and their partners/spouses may increase awareness and retention in medical research, while influencing health promotion, education and behavior. AD - Assistant Professor, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216. AN - 105917482. Language: English. Entry Date: 20080104. Revision Date: 20150820. Publication Type: Journal Article AU - Hughes, G. D. AU - Sellers, D. B. AU - Fraser, L., Jr. AU - Teague, R. AU - Knight, B. N. DA - Summer2007 DB - CINAHL Complete DP - EBSCOhost IS - 2 KW - Black Persons Health Knowledge Patient Attitudes Prostatic Neoplasms -- Ethnology Audiorecording Cancer Screening Female Focus Groups Interviews Male Mississippi Professional-Patient Relations Prostatic Neoplasms -- Prevention and Control Research Subjects Spouses Trust Human N1 - research; tables/charts. Journal Subset: Blind Peer Reviewed; Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. NLM UID: 9439196. PMID: NLM19175246. PY - 2007 SN - 1071-5568 SP - 68-73 ST - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males T2 - Journal of Cultural Diversity TI - Prostate cancer community collaboration and partnership: education, awareness, recruitment, and outreach to southern African-American males UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105917482&site=ehost-live&scope=site VL - 14 ID - 2033 ER - TY - JOUR AB - Purpose: Men with a family history of prostate cancer and black men are at higher risk for prostate cancer. Recruitment and retention of these men at high risk into early detection programs is challenging. We report a comprehensive analysis of recruitment methods, show rates and participant factors from the Prostate Cancer Risk Assessment Program, a prospective, longitudinal prostate cancer screening study. Materials and Methods: Men 35 to 69 years old were eligible for recruitment if they had a family history of prostate cancer, were black or had a BRCA1/2 mutation. Recruitment methods were analyzed using standard statistical methods with respect to participant demographics and presentation to the first program appointment. Results: Of 707 men recruited 64.9% presented to the initial program appointment. More men were recruited via radio than via referral or other methods (chi-square = 298.13, p <0.0001). Men recruited by radio were more likely to be black (p <0.001), less educated (p = 0.003) and not married or partnered (p = 0.007), and have no prostate cancer family history (p <0.001). Men recruited by referral had a higher income (p = 0.007) and were more likely to attend the initial program visit than those recruited by radio or other methods (chi-square = 27.08, p <0.0001). Conclusions: This comprehensive analysis shows that radio led to higher recruitment of black men with lower socioeconomic status. However, these men at high risk have a lower presentation rate for prostate cancer screening. Targeted motivational measures must be studied to improve the show rate for prostate cancer risk assessment in these men at high risk. © 2009 American Urological Association. AD - V.N. Giri, Cancer Screening Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, United States AU - Giri, V. N. AU - Coups, E. J. AU - Ruth, K. AU - Goplerud, J. AU - Raysor, S. AU - Kim, T. Y. AU - Bagden, L. AU - Mastalski, K. AU - Zakrzewski, D. AU - Leimkuhler, S. AU - Watkins-Bruner, D. DB - Embase Medline DO - 10.1016/j.juro.2009.07.021 IS - 5 KW - BRCA1 protein BRCA2 protein adult African American aged article cancer diagnosis cancer risk cancer screening demography early diagnosis educational status family history follow up gene mutation health education high risk population human income Internet longitudinal study major clinical study male marriage motivation patient referral patient selection priority journal prospective study prostate cancer publication risk assessment social status telecommunication television LA - English M3 - Article N1 - L50638381 2010-02-26 PY - 2009 SN - 0022-5347 SP - 2212-2218 ST - Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk T2 - Journal of Urology TI - Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50638381&from=export http://dx.doi.org/10.1016/j.juro.2009.07.021 VL - 182 ID - 1178 ER - TY - JOUR AB - The use of churches as recruitment sites of African Americans into health promotion activities is a popular theme in the 1990s literature. This research measured the impact of previous exposure to cancer on participation in an educational program and a free prostate cancer screening. Cues to action from the Health Belief Model provided the conceptual framework. Over 500 men attended a prostate cancer educational program at their church. Men who participated in the educational program and completed the questionnaire were given a voucher that they could take to their doctor of choice for a free prostate cancer examination. Having a member of the congregation who was previously diagnosed with cancer was a significant cue to attendance at the educational program (P = 0.03). Recommendations for future cancer screening in churches are given. AD - S. Weinrich, College of Nursing, University of South Carolina, Columbia 29208, USA. AU - Weinrich, S. AU - Holdford, D. AU - Boyd, M. AU - Creanga, D. AU - Cover, K. AU - Johnson, A. AU - Frank-Stromborg, M. AU - Weinrich, M. DB - Medline IS - 3 KW - African American article community health nursing counseling ethnology health care quality health education health promotion human male mass screening middle aged organization and management patient selection prostate tumor questionnaire United States LA - English M3 - Article N1 - L128278153 1998-07-05 PY - 1998 SN - 0737-1209 SP - 188-195 ST - Prostate cancer education in African American churches T2 - Public health nursing (Boston, Mass.) TI - Prostate cancer education in African American churches UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128278153&from=export VL - 15 ID - 1332 ER - TY - JOUR AB - The use of churches as recruitment sites of African Americans into health promotion activities is a popular theme in the 1990s literature. This research measured the impact of previous exposure to cancer on participation in an educational program and a free prostate cancer screening. Cues to action from the Health Belief Model provided the conceptual framework. Over 500 men attended a prostate cancer educational program at their church. Men who participated in the educational program and completed the questionnaire were given a voucher that they could take to their doctor of choice for a free prostate cancer examination. Having a member of the congregation who was previously diagnosed with cancer was a significant cue to attendance at the educational program (P = 0.03). Recommendations for future cancer screening in churches are given. AD - College of Nursing, University of South Carolina, Columbia, SC 29208 AN - 107280475. Language: English. Entry Date: 19980901. Revision Date: 20200701. Publication Type: Journal Article AU - Weinrich, S. AU - Holdford, D. AU - Boyd, M. AU - Creanga, D. AU - Cover, K. AU - Johnson, A. AU - Frank-Stromborg, M. AU - Weinrich, M. DB - CINAHL Complete DO - 10.1111/j.1525-1446.1998.tb00338.x DP - EBSCOhost IS - 3 KW - Prostatic Neoplasms -- Prevention and Control Prostatic Neoplasms -- Education Black Persons Cancer Screening -- Methods Churches -- Utilization Funding Source Descriptive Research Correlational Studies Hypothesis Stratified Random Sample Research Subject Recruitment Questionnaires Interviews Descriptive Statistics Data Analysis Software Health Belief Model Race Factors Adult Middle Age Aged Male Human N1 - research; tables/charts. Journal Subset: Core Nursing; Nursing; Peer Reviewed; Public Health; USA. Grant Information: Grant number R01 CA60561 from the National Cancer Institute. NLM UID: 8501498. PMID: NLM9629032. PY - 1998 SN - 0737-1209 SP - 188-195 ST - Prostate cancer education in African American churches T2 - Public Health Nursing TI - Prostate cancer education in African American churches UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107280475&site=ehost-live&scope=site VL - 15 ID - 2034 ER - TY - JOUR AB - The use of churches as recruitment sites of African Americans into health promotion activities is a popular theme in the 1990s literature. This research measured the impact of previous exposure to cancer on participation in an educational program and a free prostate cancer screening. Cues to action from the Health Belief Model provided the conceptual framework. Over 500 men attended a prostate cancer educational program at their church. Men who participated in the educational program and completed the questionnaire were given a voucher that they could take to their doctor of choice for a free prostate cancer examination. Having a member of the congregation who was previously diagnosed with cancer was a significant cue to attendance at the educational program. Recommendations for future cancer screening in churches are given. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1998-04023-003 AU - Weinrich, Sally P. AU - Holdford, Diane AU - Boyd, Marlyn AU - Creanga, Dana AU - Cover, Kay AU - Johnson, Alonzo AU - Frank-Stromborg, Marilyn AU - Weinrich, Martin DB - psyh DO - 10.1111/j.1525-1446.1998.tb00338.x DP - EBSCOhost IS - 3 KW - previous exposure to cancer participation in church-sponsored cancer education program & free prostate cancer screening 40–70 yr old African American males African Americans Health Education Health Promotion Humans Male Mass Screening Middle Aged Pastoral Care Patient Selection Program Evaluation Prostatic Neoplasms Public Health Nursing South Carolina Surveys and Questionnaires Blacks Cancer Screening Participation Prostate Human Males Religious Buildings N1 - U South Carolina, Coll of Nursing, Columbia, SC, US. Other Publishers: Wiley-Blackwell Publishing Ltd. Release Date: 19980801. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Health Education; Participation; Prostate. Minor Descriptor: Health Promotion; Human Males; Religious Buildings. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study. Page Count: 8. Issue Publication Date: Jun, 1998. PY - 1998 SN - 0737-1209 1525-1446 SP - 188-195 ST - Prostate cancer education in African American churches T2 - Public Health Nursing TI - Prostate cancer education in African American churches UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-04023-003&site=ehost-live&scope=site VL - 15 ID - 1799 ER - TY - JOUR AB - BACKGROUND: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical prostatectomy), external beam radiation therapy and interstitial radiation therapy (brachytherapy) and androgen deprivation. Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials. The VA/NCI/AHRQ Cooperative Studies Program Study #407: Prostate cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. METHODS: We describe the study rationale, design, recruitment methods and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia. RESULTS: We screened 13,022 men with prostate cancer at 52 United States medical centers for potential enrollment. From these, 5023 met initial age, comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one‐third were African‐American. Approximately 85% reported they were fully active. The median prostate specific antigen (PSA) was 7.8 ng/mL (mean 10.2 ng/mL). In three‐fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade and tumor stage, approximately 43% had low risk, 36% had medium risk and 20% had high‐risk prostate cancer. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial. CONCLUSIONS: PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer. AN - CN-00681251 AU - Wilt, T. J. AU - Brawer, M. K. AU - Barry, M. J. AU - Jones, K. M. AU - Kwon, Y. AU - Gingrich, J. R. AU - Aronson, W. J. AU - Nsouli, I. AU - Iyer, P. AU - Cartagena, R. AU - et al. DO - 10.1016/j.cct.2008.08.002 IS - 1 KW - Adult Aged Comorbidity Disease Progression Humans Male Middle Aged Prostatectomy Prostate‐Specific Antigen [blood] Prostatic Neoplasms [mortality, *surgery] Research Design Socioeconomic Factors M3 - Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2009 SP - 81‐87 ST - The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer T2 - Contemporary clinical trials TI - The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00681251/full VL - 30 ID - 1459 ER - TY - JOUR AB - Background: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical prostatectomy). external beam radiation therapy and interstitial radiation therapy (brachytherapy) and androgen deprivation. Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials. The VA/NCI/AHRQ Cooperative Studies Program Study #407: Prostate cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Methods: We describe the study rationale, design, recruitment methods and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia. Results: We screened 13,022 men with prostate cancer at 52 United States medical centers for potential enrollment. From these, 5023 met initial age, comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African-American. Approximately 85% reported they were fully active. The median prostate specific antigen (PSA) was 7.8 ng/mL (mean 102 ng/ml). In three-fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade and tumor stage, approximately 43% had low risk, 36% had medium risk and 20% had high-risk prostate cancer. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial. Conclusions: PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer. Published by Elsevier Inc. AN - WOS:000262603800013 AU - Wilt, T. J. AU - Brawer, M. K. AU - Barry, M. J. AU - Jones, K. M. AU - Kwon, Y. AU - Gingrich, J. R. AU - Aronson, W. J. AU - Nsouli, I. AU - Iyer, P. AU - Cartagena, R. AU - Snider, G. AU - Roehrborn, C. AU - Fox, S. DA - Jan DO - 10.1016/j.cct.2008.08.002 IS - 1 N1 - 18783735 PY - 2009 SN - 1551-7144 SP - 81-87 ST - The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer T2 - Contemporary Clinical Trials TI - The Prostate cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer VL - 30 ID - 3158 ER - TY - GEN AB - Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate-specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external-beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three-fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low-risk, 34% had medium-risk, and 21% had high-risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA-detected clinically localized prostate cancer. Published by Oxford University Press 2012. AD - T.J. Wilt, Minneapolis VA Center for Chronic Disease Outcomes Research, University of Minnesota, Department of Medicine, 1 Veterans Drive (111-0), Minneapolis, MN 55417, United States AU - Wilt, T. J. C5 - 23271771 DB - Embase Medline DO - 10.1093/jncimonographs/lgs041 J2 - J. Natl. Cancer Inst. Monogr. KW - prostate specific antigen adult African American aged article cancer localization cancer mortality cancer patient cancer risk clinical observation comorbidity controlled study diagnostic test accuracy study disease severity ethnic difference Gleason score health program high risk patient histopathology human laboratory test major clinical study male multicenter study patient selection predictive value priority journal prostate biopsy prostate cancer prostatectomy protein blood level randomized controlled trial risk assessment risk factor Scandinavia United States watchful waiting LA - English M1 - (Wilt T.J., tim.wilt@med.va.gov) Minneapolis VA Center for Chronic Disease Outcomes Research, University of Minnesota, Department of Medicine, 1 Veterans Drive (111-0), Minneapolis, MN 55417, United States M3 - Article N1 - L368035646 2013-01-09 2013-01-18 PY - 2012 SN - 1052-6773 1745-6614 SP - 184-190 ST - The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer TI - The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368035646&from=export http://dx.doi.org/10.1093/jncimonographs/lgs041 ID - 1109 ER - TY - JOUR AB - Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate‐specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external‐beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one‐third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three‐fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low‐risk, 34% had medium‐risk, and 21% had high‐risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA‐detected clinically localized prostate cancer. AN - CN-00869782 AU - Wilt, T. J. DO - 10.1093/jncimonographs/lgs041 IS - 45 KW - Adult Aged Biopsy, Needle Disease Progression Humans Male Middle Aged Neoplasm Grading Prostate [pathology, surgery] Prostatectomy Prostate‐Specific Antigen [blood] Prostatic Neoplasms [diagnosis, surgery, therapy] Treatment Outcome Watchful Waiting M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S. PY - 2012 SP - 184‐190 ST - The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer T2 - Journal of the National Cancer Institute. Monographs TI - The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00869782/full VL - 2012 ID - 1452 ER - TY - SER AB - Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. In the United States, 90% of men with prostate cancer are more than age 60 years, diagnosed by early detection with the prostate-specific antigen (PSA) blood test, and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting (WW), surgery to remove the prostate gland (radical prostatectomy), external-beam radiation therapy and interstitial radiation therapy (brachytherapy), and androgen deprivation. Little is known about the relative effectiveness and harms of treatments because of the paucity of randomized controlled trials. The Department of Veterans Affairs/National Cancer Institute/Agency for Healthcare Research and Quality Cooperative Studies Program Study #407:Prostate Cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy with WW in men with clinically localized prostate cancer. We describe the study rationale, design, recruitment methods, and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy vs WW conducted in Scandinavia. We screened 13 022 men with prostate cancer at 52 US medical centers for potential enrollment. From these, 5023 met initial age, comorbidity, and disease eligibility criteria, and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African American. Approximately 85% reported that they were fully active. The median PSA was 7.8ng/mL (mean 10.2ng/mL). In three-fourths of men, the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade, and tumor stage, it was found that approximately 40% had low-risk, 34% had medium-risk, and 21% had high-risk prostate cancer based on local histopathology. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the United States and quite different from men in the Scandinavian trial. PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared with WW for men with predominately PSA-detected clinically localized prostate cancer. Published by Oxford University Press 2012. AD - Minneapolis VA Center for Chronic Disease Outcomes Research, University of Minnesota, Department of Medicine, 1 Veterans Drive (111-0), Minneapolis, MN 55417, United States AU - Wilt, T. J. DB - Scopus DO - 10.1093/jncimonographs/lgs041 M3 - Article N1 - Cited By :37 Export Date: 22 March 2021 PY - 2012 SP - 184-190 ST - The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer T2 - Journal of the National Cancer Institute - Monographs TI - The prostate cancer intervention versus observation trial: VA/NCI/AHRQ cooperative studies program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871779908&doi=10.1093%2fjncimonographs%2flgs041&partnerID=40&md5=fb3c5e216a4c626b299c54a6a3c5246e ID - 2453 ER - TY - JOUR AB - Background: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical prostatectomy), external beam radiation therapy and interstitial radiation therapy (brachytherapy) and androgen deprivation. Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials. The VA/NCI/AHRQ Cooperative Studies Program Study #407: Prostate cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Methods: We describe the study rationale, design, recruitment methods and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia. Results: We screened 13,022 men with prostate cancer at 52 United States medical centers for potential enrollment. From these, 5023 met initial age, comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African-American. Approximately 85% reported they were fully active. The median prostate specific antigen (PSA) was 7.8 ng/mL (mean 10.2 ng/mL). In three-fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade and tumor stage, approximately 43% had low risk, 36% had medium risk and 20% had high-risk prostate cancer. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial. Conclusions: PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer. AD - T.J. Wilt, Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0), Minneapolis, MN 55417, United States AU - Wilt, T. J. AU - Brawer, M. K. AU - Barry, M. J. AU - Jones, K. M. AU - Kwon, Y. AU - Gingrich, J. R. AU - Aronson, W. J. AU - Nsouli, I. AU - Iyer, P. AU - Cartagena, R. AU - Snider, G. AU - Roehrborn, C. AU - Fox, S. DB - Embase Medline DO - 10.1016/j.cct.2008.08.002 IS - 1 KW - prostate specific antigen adult African American aged article cancer diagnosis cancer localization cancer risk cancer staging comorbidity comparative study controlled study Gleason score hospital admission human human tissue major clinical study male methodology prostate biopsy prostate cancer prostatectomy randomized controlled trial Scandinavia United States LA - English M3 - Article N1 - L50279470 2009-01-28 PY - 2009 SN - 1551-7144 SP - 81-87 ST - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer T2 - Contemporary Clinical Trials TI - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50279470&from=export http://dx.doi.org/10.1016/j.cct.2008.08.002 VL - 30 ID - 1198 ER - TY - JOUR AB - Background: Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer death in men. Ninety percent of men with prostate cancer are over aged 60 years, diagnosed by early detection with the prostate specific antigen (PSA) blood test and have disease believed confined to the prostate gland (clinically localized). Common treatments for clinically localized prostate cancer include watchful waiting surgery to remove the prostate gland (radical prostatectomy), external beam radiation therapy and interstitial radiation therapy (brachytherapy) and androgen deprivation. Little is known about the relative effectiveness and harms of treatments due to the paucity of randomized controlled trials. The VA/NCI/AHRQ Cooperative Studies Program Study #407: Prostate cancer Intervention Versus Observation Trial (PIVOT), initiated in 1994, is a multicenter randomized controlled trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Methods: We describe the study rationale, design, recruitment methods and baseline characteristics of PIVOT enrollees. We provide comparisons with eligible men declining enrollment and men participating in another recently reported randomized trial of radical prostatectomy versus watchful waiting conducted in Scandinavia. Results: We screened 13,022 men with prostate cancer at 52 United States medical centers for potential enrollment. From these, 5023 met initial age, comorbidity and disease eligibility criteria and a total of 731 men agreed to participate and were randomized. The mean age of enrollees was 67 years. Nearly one-third were African-American. Approximately 85% reported they were fully active. The median prostate specific antigen (PSA) was 7.8 ng/mL (mean 10.2 ng/mL). In three-fourths of men the primary reason for biopsy leading to a diagnosis of prostate cancer was a PSA elevation or rise. Using previously developed tumor risk categorizations incorporating PSA levels, Gleason histologic grade and tumor stage, approximately 43% had low risk, 36% had medium risk and 20% had high-risk prostate cancer. Comparison to our national sample of eligible men declining PIVOT participation as well as to men enrolled in the Scandinavian trial indicated that PIVOT enrollees are representative of men being diagnosed and treated in the U.S. and quite different from men in the Scandinavian trial. Conclusions: PIVOT enrolled an ethnically diverse population representative of men diagnosed with prostate cancer in the United States. Results will yield important information regarding the relative effectiveness and harms of surgery compared to watchful waiting for men with predominately PSA detected clinically localized prostate cancer. AD - Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive (111-0), Minneapolis, MN 55417, United States URIDEA, Seattle, WA, United States Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, MA, United States Veterans Affairs Cooperative Studies Program Coordinating Center, Perry, Point, MD, United States Hampton VA Medical Center, Hampton, VA, United States University of Pittsburgh, Department of Urology and VA Pittsburgh Health Care System, United States VA Medical Center, Greater Los Angeles Healthcare System, Los Angeles, CA, United States VA Medical Center Syracuse, NY, United States VA Medical Center, Long Beach, CA, United States VA Western New York Health System, Buffalo, NY, United States Louis A. Johnson VA Medical Center, Clarksburg, WV, United States University of Texas, Department of Urology, Southwestern Medical Center, Dallas, TX, United States Agency for Healthcare Research and Quality, Rockville, MD, United States AU - Wilt, T. J. AU - Brawer, M. K. AU - Barry, M. J. AU - Jones, K. M. AU - Kwon, Y. AU - Gingrich, J. R. AU - Aronson, W. J. AU - Nsouli, I. AU - Iyer, P. AU - Cartagena, R. AU - Snider, G. AU - Roehrborn, C. AU - Fox, S. DB - Scopus DO - 10.1016/j.cct.2008.08.002 IS - 1 KW - Prostate cancer Radical prostatectomy Randomized clinical trial Watchful waiting M3 - Article N1 - Cited By :123 Export Date: 22 March 2021 PY - 2009 SP - 81-87 ST - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer T2 - Contemporary Clinical Trials TI - The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-57549083656&doi=10.1016%2fj.cct.2008.08.002&partnerID=40&md5=cabc13276f67439a47025ce38f8083be VL - 30 ID - 2528 ER - TY - JOUR AB - Purpose: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients.Methods: We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration-resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of≥90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups.Results: Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4g/dl, W = 12.3g/dl). The proportion of B patients achieving a≥90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a≥50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and≥30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ.Conclusions: Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA. AD - Duke University Medical Center, Durham, NC Department of Biostatistics and Bioinformatics, Duke University, Durham, NC Duke Cancer Institute, Durham, NC AN - 123341722. Language: English. Entry Date: 20180322. Revision Date: 20180619. Publication Type: journal article AU - Ramalingam, Sundhar AU - Humeniuk, Michael S. AU - Hu, Rachel AU - Rasmussen, Julia AU - Healy, Patrick AU - Wu, Yuan AU - Harrison, Michael R. AU - Armstrong, Andrew J. AU - George, Daniel J. AU - Zhang, Tian DB - CINAHL Complete DO - 10.1016/j.urolonc.2016.12.016 DP - EBSCOhost IS - 6 KW - Blood Coagulation Factors -- Blood Prostate-Specific Antigen -- Blood Prostatic Neoplasms, Castration-Resistant -- Drug Therapy Male Prostatic Neoplasms, Castration-Resistant -- Blood Neoplasm Metastasis Disease Progression Prostatic Neoplasms, Castration-Resistant -- Ethnology Case Control Studies Prospective Studies Black Persons Prostatic Neoplasms, Castration-Resistant -- Pathology White Persons Retrospective Design Human Clinical Assessment Tools Karnofsky Performance Status Scales N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Karnofsky Performance Status Scale (KPS); Gleason Score. NLM UID: 9805460. PMID: NLM28126272. PY - 2017 SN - 1078-1439 SP - 418-424 ST - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer T2 - Urologic Oncology TI - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=123341722&site=ehost-live&scope=site VL - 35 ID - 2035 ER - TY - JOUR AB - Purpose: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. Methods: We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of >= 90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups. Results: Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4 g/dl, W = 12.3 g/dl). The proportion of B patients achieving a >= 90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a >= 50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and >= 30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ. Conclusions: Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA. (C) 2017 Elsevier Inc. All rights reserved. AN - WOS:000405997400015 AU - Ramalingam, S. AU - Humeniuk, M. S. AU - Hu, R. AU - Rasmussen, J. AU - Healy, P. AU - Wu, Y. AU - Harrison, M. R. AU - Armstrong, A. J. AU - George, D. J. AU - Zhang, T. DA - Jun DO - 10.1016/j.urolonc.2016.12.016 IS - 6 N1 - 28126272 PY - 2017 SN - 1078-1439 SP - 418-424 ST - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer T2 - Urologic Oncology-Seminars and Original Investigations TI - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer VL - 35 ID - 2896 ER - TY - JOUR AB - Purpose Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration–resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. Methods We performed a retrospective case-control study of B vs. W patients treated with AA between May 1, 2008 and June 16, 2015 at Duke University Medical Center. Patients were identified (W control patients were matched 2:1 to B patients stratified based on previous docetaxel exposure) through pharmacy records and were eligible if treated with AA for metastatic castration–resistant prostate cancer. Patients with previous enzalutamide use were excluded. The primary objective was to compare the rate of≥90% prostate-specific antigen (PSA) decline from baseline between B vs. W patients. Secondary outcomes included comparing time on therapy, time to PSA progression, and overall survival among groups. Results Baseline characteristics among patients (n = 45 B, n = 90 W) were identified; these included Karnofsky performance status, PSA, Gleason score, alkaline phosphatase, albumin, hemoglobin, lactate dehydrogenase, opiate use for pain, and metastatic sites. Baseline characteristics among groups were similar except for median hemoglobin (B = 11.4 g/dl, W = 12.3 g/dl). The proportion of B patients achieving a≥90% PSA level decline was 37.8% vs. 28.9% for W patients (P = 0.296). Statistically significant differences were found in the proportion of patients achieving a≥50% PSA level decline (B = 68.9%, W = 48.9% [P = 0.028]) and≥30% PSA level decline (B = 77.8%, W = 54.4% [P = 0.008]). Rates of primary abiraterone-refractory disease (PSA increase as best response) trended higher in W (31.1%) than in B (15.6%) patients (P = 0.052). Median treatment duration (B = 9.4 mo, W = 8.3 mo) did not differ (Wilcoxon P = 0.444). Median overall survival (B = 27.3 mo [95% CI: 13.9, not estimable], W = 24.8 mo [95% CI: 19, 31.6] [P = 0.669]) and median time to PSA progression (B = 11.0 mo [95% CI: 4.3, 18.0], W = 9.4 mo [95% CI: 6.2, 13.0] [P = 0.917]) did not differ. Conclusions Black patients may have a higher PSA response to AA than white patients. An ongoing prospective clinical study (NCT01940276) is evaluating outcomes between black and white patients treated with AA. © 2017 Elsevier Inc. AD - Duke University Medical Center, Durham, NC, United States Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, United States Duke Cancer Institute, Durham, NC, United States AU - Ramalingam, S. AU - Humeniuk, M. S. AU - Hu, R. AU - Rasmussen, J. AU - Healy, P. AU - Wu, Y. AU - Harrison, M. R. AU - Armstrong, A. J. AU - George, D. J. AU - Zhang, T. DB - Scopus DO - 10.1016/j.urolonc.2016.12.016 IS - 6 KW - Abirterone acetate Castration-resistant Prostate-specific antigen Prostatic neoplasms Race M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2017 SP - 418-424 ST - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer T2 - Urologic Oncology: Seminars and Original Investigations TI - Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate–resistant prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009959515&doi=10.1016%2fj.urolonc.2016.12.016&partnerID=40&md5=843625adcb4fa8638241b0fa5c16c02c VL - 35 ID - 2306 ER - TY - JOUR AB - Objectives. To estimate the incidence of prostate cancer among African-American men and Caribbean immigrants to the United States, to assess the applicability of large-scale prostate screening trials to a community screening program, and to recruit unscreened men. Methods. African-American and Caribbean-American men were targeted with a community-based prostate cancer screening program in Jamaica, New York. Serum prostate-specific antigen determination and digital rectal examination were used to determine abnormal findings. The incidence of an abnormal screening examination was used to project the incidence of prostate cancer, which was compared with that in other reported trials. Results. The projected incidence of prostate cancer among African-Americans and Caribbean-Americans older than 50 years was 8% and 7%, respectively, similar to that reported in other trials of African-American men. The projected incidence of prostate cancer in Caribbean-American men aged 40 to 49 years was 1%, the same as the high rate reported among Caribbean men. As in other trials, a family history of prostate cancer and age were strong predictors of abnormal findings. Of the recruited men older than 50 years, 58% had never been screened compared with 42% nationally. Conclusions. Large population-based screening trials have identified ethnic groups at high risk of prostate cancer. This trial detected high rates of abnormal screening findings by targeting ethnicity. The incidence of an abnormal examination was high in Caribbean-American men younger than 50 years old. Finally, this trial successfully recruited underscreened men. © 2005 Elsevier Inc. AD - D.S. Scherr, Department of Urologic Oncology, Brady Urology Health Center, Cornell Univ. Weill Medical College, 525 East 68th Street, Starr 900, New York, NY 10021, United States AU - Shelton, J. B. AU - Barocas, D. A. AU - Conway, F. AU - Hart, K. AU - Nelson, K. AU - Richstone, L. AU - Gonzalez, R. R. AU - Raman, J. D. AU - Scherr, D. S. DB - Embase Medline DO - 10.1016/j.urology.2004.11.047 IS - 5 KW - prostate specific antigen adult African American article cancer incidence cancer screening controlled study digital rectal examination ethnic group ethnology family history high risk population human major clinical study male prediction priority journal prostate cancer race difference United States LA - English M3 - Article N1 - L40692985 2005-06-22 PY - 2005 SN - 0090-4295 SP - 931-936 ST - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies T2 - Urology TI - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40692985&from=export http://dx.doi.org/10.1016/j.urology.2004.11.047 VL - 65 ID - 1267 ER - TY - JOUR AB - Objectives. To estimate the incidence of prostate cancer among African-American men and Caribbean immigrants to the United States, to assess the applicability of large-scale prostate screening trials to a community screening program, and to recruit unscreened men. Methods. African-American and Caribbean-American men were targeted with a community-based prostate cancer screening program in Jamaica, New York. Serum prostate-specific antigen determination and digital rectal examination were used to determine abnormal findings. The incidence of an abnormal screening examination was used to project the incidence of prostate cancer, which was compared with that in other reported trials. Results. The projected incidence of prostate cancer among African-Americans and Caribbean-Americans older than 50 years was 8% and 7%, respectively, similar to that reported in other trials of African-American men. The projected incidence of prostate cancer in Caribbean-American men aged 40 to 49 years was 1%, the same as the high rate reported among Caribbean men. As in other trials, a family history of prostate cancer and age were strong predictors of abnormal findings. Of the recruited men older than 50 years, 58% had never been screened compared with 42% nationally. Conclusions. Large population-based screening trials have identified ethnic groups at high risk of prostate cancer. This trial detected high rates of abnormal screening findings by targeting ethnicity. The incidence of an abnormal examination was high in Caribbean-American men younger than 50 years old. Finally, this trial successfully recruited underscreened men. © 2005 Elsevier Inc. AD - Department of Urology, Cornell Univ. Weill Medical College, New York Presbyterian Hospital, New York, NY, United States Department of Urologic Oncology, Brady Urology Health Center, Cornell Univ. Weill Medical College, 525 East 68th Street, Starr 900, New York, NY 10021, United States AU - Shelton, J. B. AU - Barocas, D. A. AU - Conway, F. AU - Hart, K. AU - Nelson, K. AU - Richstone, L. AU - Gonzalez, R. R. AU - Raman, J. D. AU - Scherr, D. S. DB - Scopus DO - 10.1016/j.urology.2004.11.047 IS - 5 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2005 SP - 931-936 ST - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies T2 - Urology TI - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-18844381127&doi=10.1016%2fj.urology.2004.11.047&partnerID=40&md5=26f7c67da558f97b061357adbdc00c9d VL - 65 ID - 2594 ER - TY - JOUR AB - Objectives. To estimate the incidence of prostate cancer among African-American men and Caribbean immigrants to the United States, to assess the applicability of large-scale prostate screening trials to a community screening program, and to recruit unscreened men. Methods. African-American and Caribbean-American men were targeted with a community-based prostate cancer screening program in Jamaica, New York. Serum prostate-specific antigen determination and digital rectal examination were used to determine abnormal -findings. The incidence of an abnormal screening examination was used to project the incidence of prostate cancer, which was compared with that in other reported trials. Results. The projected incidence of prostate cancer among African-Americans and Caribbean-Americans older than 50 years was 8% and 7%, respectively, similar to that reported in other trials of African-American men. The projected incidence of prostate cancer in Caribbean-American men aged 40 to 49 years was 1%, the same as the high rate reported among Caribbean men. As in other trials, a family history of prostate cancer and age were strong predictors of abnormal findings. Of the recruited men older than 50 years, 58% had never been screened compared with 42% nationally. Conclusions. Large population-based screening trials have identified ethnic groups at high risk of prostate cancer. This trial detected high rates of abnormal screening findings by targeting ethnicity. The incidence of an abnormal examination was high in Caribbean-American men younger than 50 years old. Finally, this trial successfully recruited underscreened men. (c) 2005 Elsevier Inc. AN - WOS:000229138800021 AU - Shelton, J. B. AU - Barocas, D. A. AU - Conway, F. AU - Hart, K. AU - Nelson, K. AU - Richstone, L. AU - Gonzalez, R. R. AU - Raman, J. D. AU - Scherr, D. S. DA - May DO - 10.1016/j.urology.2004.11.047 IS - 5 N1 - 15882726 PY - 2005 SN - 0090-4295 SP - 931-936 ST - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies T2 - Urology TI - Prostate-specific antigen screening in a high-risk population: Lessons from the community and how they relate to large-scale population-based studies VL - 65 ID - 3242 ER - TY - JOUR AB - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55-74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate-specific antigen. For lung cancer, men and women receive a posteroanterior view chest X-ray. For colorectal cancer, men and women undergo a 60-cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow-up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on-site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention. AD - J.K. Gohagan AU - Gohagan, J. K. AU - Prorok, P. C. AU - Hayes, R. B. AU - Kramer, B. S. DB - Medline DO - 10.1016/s0197-2456(00)00097-0 IS - 6 Suppl KW - aged article clinical trial colorectal tumor controlled clinical trial female human information processing international cooperation lung tumor male mass screening middle aged multicenter study ovary tumor patient selection prostate tumor randomized controlled trial LA - English M3 - Article N1 - L33433715 2001-01-22 PY - 2000 SN - 0197-2456 SP - 251S-272S ST - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status T2 - Controlled clinical trials TI - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33433715&from=export http://dx.doi.org/10.1016/s0197-2456(00)00097-0 VL - 21 ID - 1324 ER - TY - JOUR AB - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55‐74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate‐specific antigen. For lung cancer, men and women receive a posteroanterior view chest X‐ray. For colorectal cancer, men and women undergo a 60‐cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow‐up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on‐site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention. AN - CN-01779498 AU - Gohagan, J. K. AU - Prorok, P. C. AU - Hayes, R. B. AU - Kramer, B. S. IS - 6 Suppl KW - *colorectal tumor /diagnosis /prevention *lung tumor /diagnosis /prevention *mass screening *ovary tumor /diagnosis /prevention *prostate tumor /diagnosis /prevention *randomized controlled trial Aged Article Clinical trial Controlled clinical trial Female Human Information processing International cooperation Male Middle aged Multicenter study Patient selection M3 - Journal: Article PY - 2000 SP - 251S‐272S ST - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status T2 - Controlled clinical trials TI - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01779498/full VL - 21 ID - 1579 ER - TY - JOUR AB - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55-74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate-specific antigen. For lung cancer, men and women receive a posteroanterior view chest X-ray. For colorectal cancer, men and women undergo a 60-cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow-up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on-site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention. AD - Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 29892-7346, United States AU - Gohagan, J. K. AU - Prorok, P. C. AU - Hayes, R. B. AU - Kramer, B. S. DB - Scopus DO - 10.1016/s0197-2456(00)00097-0 IS - 6 Suppl M3 - Article N1 - Cited By :372 Export Date: 22 March 2021 PY - 2000 SP - 251S-272S ST - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status T2 - Controlled clinical trials TI - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034572611&doi=10.1016%2fs0197-2456%2800%2900097-0&partnerID=40&md5=833f9dc3fb6f0c3bd1a5a1f8882fde35 VL - 21 ID - 2636 ER - TY - JOUR AB - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55-74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate-specific antigen. For lung cancer, men and women receive a posteroanterior view chest X-ray. For colorectal cancer, men and women undergo a 60-cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow-up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on-site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention. Control Clin Trials 2000;21:251S-272S (C) Elsevier Science Inc. 2000. AN - WOS:000165987600002 AU - Gohagan, J. K. AU - Prorok, P. C. AU - Hayes, R. B. AU - Kramer, B. S. DA - Dec DO - 10.1016/S0197-2456(00)00097-0 IS - 6 N1 - S 332 11189683 PY - 2000 SN - 0197-2456 SP - 251S-272S ST - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status T2 - Controlled Clinical Trials TI - The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status VL - 21 ID - 2712 ER - TY - JOUR AB - Purpose: The Community Clinical Oncology Program (CCOP) and Minority-Based Community Clinical Oncology Program (MBCCOP) are provider-based research networks (PBRN) that improve minority enrollment in cancer-focused clinical trials. We hypothesized that affiliation with a PBRN may also mitigate racial differences in hospice enrollment for patients with lung cancer. Methods: We used the SEER-Medicare data, linked to the National Cancer Institute’s CCOP program data, to identify all patients (≥ age 65 years) with lung cancer, diagnosed from 2001 to 2007. We defined clinical treatment settings as CCOP, MBCCOP, academic, or community-affiliated and used multivariable logistic regression analysis to determine factors associated with hospice enrollment. Results: Forty-one thousand eight hundred eighty-five (55.1%) patients with lung cancer enrolled in hospice before death. Approximately 55% of CCOP, 57% of MBCCOP, 57% of academic, and 52% of community patients enrolled. Patients who were more likely to enroll were female (odds ratio [OR], 1.36; 95% CI, 1.31 to 1.40); ≥ age 79 years (OR, 1.11; 95%CI, 1.06 to 1.16); white; lived in more educated areas; had minimal comorbidities; and had distant disease. Asian and black patients in academic (41.1% and 50.4%, respectively) and community practices (35.2% and 43.4%, respectively) were less likely to enroll in hospice compared with white patients (academic, 58.8%; community, 53.1%). However, hospice enrollment was equivalent for black and white patients in MBCCOP (59.5% v 57.2%) and CCOP (52.2% v 56.3%) practices. Conclusion: Minority patients with lung cancer receiving treatment in cancer-focused PBRN- affiliated practices have greater hospice enrollment than those treated in academic and community practices. AD - University of North Carolina School of Medicine, Chapel, Hill, NC University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel, Hill, NC AN - 97019788. Language: English. Entry Date: 20140716. Revision Date: 20190608. Publication Type: Article AU - Penn, Dolly AU - Stitzenberg, Karyn B. AU - Cobran, Ewan K. AU - Godley, Paul A. DB - CINAHL Complete DO - 10.1200/JOP.2013.001268 DP - EBSCOhost IS - 4 KW - Cancer Patients Lung Neoplasms Hospice Care -- Utilization Race Factors Human Aged Aged, 80 and Over Female Male Descriptive Statistics Logistic Regression Odds Ratio Confidence Intervals White Persons Sex Factors Black Persons Asians Pearson's Correlation Coefficient Hispanic Americans Data Analysis Software Databases, Health Funding Source N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. Grant Information: This study was supported by the National Institutes of Health (Grant No. T32 5T32CA12859004; Grant No. T32 5T32CA128582-043; Grant No. HHSN-261200800726P; and Grant No.5R01CA124402); by the Integrated Cancer Information and Surveillance System, University of North Carolina Lineberger Comprehensive Cancer Center with funding provided by the University Cancer Research Fund via the State of North Carolina; by the National Center for Research Resources and the National Center for Advancing Translational Services (Grant No. UL1TR000083).. NLM UID: 101261852. PY - 2014 SN - 1554-7477 SP - e182-e190 ST - Provider-Based Research Networks Demonstrate Greater Hospice Use for Minority Patients With Lung Cancer T2 - Journal of Oncology Practice TI - Provider-Based Research Networks Demonstrate Greater Hospice Use for Minority Patients With Lung Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=97019788&site=ehost-live&scope=site VL - 10 ID - 2036 ER - TY - JOUR AB - Objective. In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer- and treatment-specific mechanisms. Method. The sample consisted of 145 women aged 27-75 years; 75% were Caucasian and 25% African American. A total of 109 participants completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress-related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy. Conclusions. Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes. Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy. © 2013 Jo Lynne W. Robins et al. AD - J.L.W. Robins, Virginia Commonwealth University School of Nursing, Richmond, VA 23298, United States AU - Robins, J. L. W. AU - McCain, N. L. AU - Elswick, R. K. AU - Walter, J. M. AU - Gray, D. P. AU - Tuck, I. DB - Embase DO - 10.1155/2013/372908 KW - endorphin adult African American aged article breast cancer cancer adjuvant therapy Caucasian clinical evaluation controlled study depression early cancer female human immune deficiency major clinical study mental stress priority journal protein blood level psychophysiology quality of life randomized controlled trial religion social psychology stress management Tai Chi LA - English M3 - Article N1 - L369068850 2013-06-14 2013-06-20 PY - 2013 SN - 1741-427X 1741-4288 ST - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer T2 - Evidence-based Complementary and Alternative Medicine TI - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369068850&from=export http://dx.doi.org/10.1155/2013/372908 VL - 2013 ID - 1078 ER - TY - JOUR AB - Objective. In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer‐ and treatment‐specific mechanisms. Method. The sample consisted of 145 women aged 27‐75 years; 75% were Caucasian and 25% African American. A total of 109 participants completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress‐related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy. Conclusions. Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes. Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy. © 2013 Jo Lynne W. Robins et al. AN - CN-00906170 AU - Robins, J. L. W. AU - McCain, N. L. AU - Elswick, R. K. AU - Walter, J. M. AU - Gray, D. P. AU - Tuck, I. DO - 10.1155/2013/372908 KW - *breast cancer *cancer adjuvant therapy *early cancer *psychophysiology *stress management Adult African American Aged Article Caucasian Clinical evaluation Controlled study Depression Female Human Immune deficiency Major clinical study Mental stress Priority journal Protein blood level Quality of life Randomized controlled trial Religion Social psychology Tai Chi M3 - Journal: Article PY - 2013 ST - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer T2 - Evidence-based complementary and alternative medicine TI - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00906170/full VL - 2013 ID - 1553 ER - TY - JOUR AB - Objective. In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer- and treatment-specific mechanisms. Method. The sample consisted of 145 women aged 27-75 years; 75% were Caucasian and 25% African American. A total of 109 participants completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress-related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy. Conclusions. Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes. Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy. © 2013 Jo Lynne W. Robins et al. AD - Virginia Commonwealth University School of Nursing, Richmond, VA 23298, United States Massey Cancer Center, Richmond, VA 23298, United States North Carolina A and T University School of Nursing, Greensboro, NC 27411, United States AU - Robins, J. L. W. AU - McCain, N. L. AU - Elswick, R. K. AU - Walter, J. M. AU - Gray, D. P. AU - Tuck, I. C7 - 372908 DB - Scopus DO - 10.1155/2013/372908 M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2013 ST - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer T2 - Evidence-based Complementary and Alternative Medicine TI - Psychoneuroimmunology-based stress management during adjuvant chemotherapy for early breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84878696725&doi=10.1155%2f2013%2f372908&partnerID=40&md5=fe1b43502d67b621859a2bbb6f612bf5 VL - 2013 ID - 2432 ER - TY - JOUR AB - Objective. In a randomized trial of women with early stage breast cancer undergoing adjuvant chemotherapy, two stress management interventions, tai chi training and spiritual growth groups, were compared to a usual care control group, to evaluate psychosocial functioning, quality of life (QOL), and biological markers thought to reflect cancer-and treatment-specific mechanisms. Method. The sample consisted of 145 women aged 27-75 years; 75% were Caucasian and 25% African American. A total of 109 participants completed the study, yielding a 75% retention rate. Grounded in a psychoneuroimmunology framework, the overarching hypothesis was that both interventions would reduce perceived stress, enhance QOL and psychosocial functioning, normalize levels of stress-related neuroendocrine mediators, and attenuate immunosuppression. Results. While interesting patterns were seen across the sample and over time, the interventions had no appreciable effects when delivered during the period of chemotherapy. Conclusions. Findings highlight the complex nature of biobehavioral interventions in relation to treatment trajectories and potential outcomes. Psychosocial interventions like these may lack sufficient power to overcome the psychosocial or physiological stress experienced during the chemotherapy treatment period. It may be that interventions requiring less activity and/or group attendance would have enhanced therapeutic effects, and more active interventions need to be tested prior to and following recovery from chemotherapy. AN - WOS:000319572500001 AU - Robins, J. L. W. AU - McCain, N. L. AU - Elswick, R. K. AU - Walter, J. M. AU - Gray, D. P. AU - Tuck, I. DO - 10.1155/2013/372908 N1 - 372908 23762127 PY - 2013 SN - 1741-427X ST - Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer T2 - Evidence-Based Complementary and Alternative Medicine TI - Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer VL - 2013 ID - 3053 ER - TY - JOUR AB - Objective: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. Methods: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6 months. Results: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months. In addition, at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. Conclusions: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. Copyright © 2013 John Wiley & Sons, Ltd. AD - D.A. Monti, Thomas Jefferson University, 925 Chestnut Street, Philadelphia, PA 19107, United States AU - Monti, D. A. AU - Kash, K. M. AU - Kunkel, E. J. AU - Moss, A. AU - Mathews, M. AU - Brainard, G. AU - Anne, R. AU - Leiby, B. E. AU - Pequinot, E. AU - Newberg, A. B. DB - Embase Medline DO - 10.1002/pon.3320 IS - 11 KW - adult aged art therapy article breast cancer controlled study female follow up health program health survey human major clinical study mental stress mindfulness based art therapy outcome assessment quality of life randomized controlled trial social care standard educational support support group Symptom Checklist 90 LA - English M3 - Article N1 - L52700051 2013-07-29 2013-11-06 PY - 2013 SN - 1057-9249 1099-1611 SP - 2565-2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-Oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52700051&from=export http://dx.doi.org/10.1002/pon.3320 VL - 22 ID - 1068 ER - TY - JOUR AB - OBJECTIVE: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness‐based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. METHODS: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8‐week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist‐90‐Revised, and quality of life was measured using the Medical Outcomes Study Short‐Form Health Survey at baseline, immediately post‐intervention, and at 6 months. RESULTS: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post‐intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post‐intervention and at 6 months. In addition, at 6 months follow‐up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. CONCLUSIONS: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. AN - CN-00909329 AU - Monti, D. A. AU - Kash, K. M. AU - Kunkel, E. J. AU - Moss, A. AU - Mathews, M. AU - Brainard, G. AU - Anne, R. AU - Leiby, B. E. AU - Pequinot, E. AU - Newberg, A. B. DO - 10.1002/pon.3320 IS - 11 KW - *art therapy *breast cancer/th [Therapy] *mental stress *mindfulness based art therapy *social care *standard educational support *support group Adaptation, Psychological Adult Aged Aged, 80 and over Art Therapy [*methods] Article Breast Neoplasms [psychology, *therapy] Controlled study Female Follow up Follow‐Up Studies Health Status Health program Health survey Human Humans Major clinical study Middle Aged Mindfulness [*methods] Outcome assessment Patient Education as Topic [*methods] Quality of Life [*psychology] Quality of life Randomized controlled trial Socioeconomic Factors Stress, Psychological [diagnosis, psychology, *therapy] Symptom Checklist 90 Treatment Outcome M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2013 SP - 2565‐2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00909329/full VL - 22 ID - 1592 ER - TY - JOUR AB - Objective: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. Methods: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6 months. Results: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months. In addition, at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. Conclusions: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Monti, Daniel A., Thomas Jefferson University, 925 Chestnut Street, Suite 120, Philadelphia, PA, US, 19107 AN - 2013-37637-021 AU - Monti, Daniel A. AU - Kash, Kathryn M. AU - Kunkel, Elisabeth J. AU - Moss, Aleeze AU - Mathews, Michael AU - Brainard, George AU - Anne, Ranni AU - Leiby, Benjamin E. AU - Pequinot, Edward AU - Newberg, Andrew B. DB - psyh DO - 10.1002/pon.3320 DP - EBSCOhost IS - 11 KW - psychosocial benefits mindfulness intervention distressed women breast cancer quality of life Adaptation, Psychological Adult Aged Aged, 80 and over Art Therapy Breast Neoplasms Female Follow-Up Studies Health Status Humans Middle Aged Mindfulness Patient Education as Topic Socioeconomic Factors Stress, Psychological Treatment Outcome Distress Intervention Human Females N1 - Jefferson-Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, PA, US. Release Date: 20140217. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Monti, Daniel A. Major Descriptor: Breast Neoplasms; Distress; Intervention; Mindfulness. Minor Descriptor: Human Females; Quality of Life. Classification: Cancer (3293); Psychotherapy & Psychotherapeutic Counseling (3310). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Tests & Measures: Symptom Checklist-90–Revised DOI: 10.1037/t01210-000; Brief Symptom Inventory-18 DOI: 10.1037/t07502-000. Methodology: Empirical Study; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 11. Issue Publication Date: Nov, 2013. Publication History: First Posted Date: Jul 21, 2013; Accepted Date: May 3, 2013; Revised Date: Apr 30, 2013; First Submitted Date: Dec 24, 2012. Copyright Statement: John Wiley & Sons, Ltd. 2013. Sponsor: National Institutes of Health, US. Grant: RO1 CA111832. Recipients: Monti, Daniel A. (Prin Inv) PY - 2013 SN - 1057-9249 1099-1611 SP - 2565-2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-Oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2013-37637-021&site=ehost-live&scope=site ORCID: 0000-0001-8230-1752 daniel.monti@jefferson.edu VL - 22 ID - 1730 ER - TY - JOUR AB - OBJECTIVE: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. METHODS: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6 months. RESULTS: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months. In addition, at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. CONCLUSIONS: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. Copyright © 2013 John Wiley & Sons, Ltd. AD - Jefferson-Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, PA, USA. AN - 104106782. Language: English. Entry Date: 20140502. Revision Date: 20200708. Publication Type: Journal Article AU - Monti, Daniel A. AU - Kash, Kathryn M. AU - Kunkel, Elisabeth J. AU - Moss, Aleeze AU - Mathews, Michael AU - Brainard, George AU - Anne, Ranni AU - Leiby, Benjamin E. AU - Pequinot, Edward AU - Newberg, Andrew B. DB - CINAHL Complete DO - 10.1002/pon.3320 DP - EBSCOhost IS - 11 KW - Art Therapy -- Methods Breast Neoplasms -- Therapy Mindfulness -- Methods Patient Education -- Methods Quality of Life -- Psychosocial Factors Stress, Psychological -- Therapy Adaptation, Psychological Adult Aged Aged, 80 and Over Breast Neoplasms -- Psychosocial Factors Female Prospective Studies Health Status Human Experimental Studies Middle Age Socioeconomic Factors Stress, Psychological -- Diagnosis Stress, Psychological -- Psychosocial Factors Treatment Outcomes N1 - research; randomized controlled trial. Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland. Special Interest: Oncologic Care; Psychiatry/Psychology. NLM UID: 9214524. PMID: NLM23873790. PY - 2013 SN - 1057-9249 SP - 2565-2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-Oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104106782&site=ehost-live&scope=site VL - 22 ID - 2037 ER - TY - JOUR AB - Objective: It is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. Methods: A total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6 months. Results: Results showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6 months. In addition, at 6 months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. Conclusions: In conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. Copyright © 2013 John Wiley & Sons, Ltd. AD - Jefferson-Myrna Brind Center of Integrative Medicine, Thomas Jefferson University, Philadelphia, PA, United States Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, PA, United States Department of Neurology, Thomas Jefferson University, Philadelphia, PA, United States Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, United States Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, United States AU - Monti, D. A. AU - Kash, K. M. AU - Kunkel, E. J. AU - Moss, A. AU - Mathews, M. AU - Brainard, G. AU - Anne, R. AU - Leiby, B. E. AU - Pequinot, E. AU - Newberg, A. B. DB - Scopus DO - 10.1002/pon.3320 IS - 11 M3 - Article N1 - Cited By :41 Export Date: 22 March 2021 PY - 2013 SP - 2565-2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-Oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886389535&doi=10.1002%2fpon.3320&partnerID=40&md5=1e3dcff84a596db677f392f9dd55d41c VL - 22 ID - 2423 ER - TY - JOUR AB - ObjectiveIt is well documented that stress is associated with negative health outcomes in cancer patients. The purpose of this study was to assess the effects of a novel mindfulness intervention called mindfulness-based art therapy (MBAT) versus standard educational support, on indices of stress and quality of life in breast cancer patients with high stress levels. MethodsA total of 191 women were enrolled, stratified by age and stress level, and randomized to receive either an 8-week MBAT intervention or a breast cancer educational support program of equal time and duration. Psychosocial stress was measured using the Symptoms Checklist-90-Revised, and quality of life was measured using the Medical Outcomes Study Short-Form Health Survey at baseline, immediately post-intervention, and at 6months. ResultsResults showed overall significant improvements in psychosocial stress and quality of life in both the MBAT and educational support groups immediately post-intervention; however, participants with high stress levels at baseline had significantly improved overall outcomes only in the MBAT group, both immediately post-intervention and at 6months. In addition, at 6months follow-up, participants attending five or more sessions trended toward retaining treatment effects better in the MBAT than in the control group. Finally, black women and white women were similar in terms of how they benefited from the MBAT intervention, even though white participants tended to have higher educational level and marital status. ConclusionsIn conclusion, MBAT is associated with significant, sustained benefits across a diverse range of breast cancer patients, particularly those with high stress levels. Copyright (c) 2013 John Wiley & Sons, Ltd. AN - WOS:000326030300020 AU - Monti, D. A. AU - Kash, K. M. AU - Kunkel, E. J. AU - Moss, A. AU - Mathews, M. AU - Brainard, G. AU - Anne, R. AU - Leiby, B. E. AU - Pequinot, E. AU - Newberg, A. B. DA - Nov DO - 10.1002/pon.3320 IS - 11 N1 - 23873790 PY - 2013 SN - 1057-9249 SP - 2565-2575 ST - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer T2 - Psycho-Oncology TI - Psychosocial benefits of a novel mindfulness intervention versus standard support in distressed women with breast cancer VL - 22 ID - 3032 ER - TY - JOUR AB - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammogram in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience. © 2006 Lippincott Williams & Wilkins, Inc. AD - K.M. Russell, Indiana University, School of Nursing, Indianapolis, IN 46202-5107, United States AU - Russell, K. M. AU - Champion, V. L. AU - Skinner, C. S. DB - Embase Medline DO - 10.1097/00002820-200605000-00012 IS - 3 KW - adult African American aged article breast cancer cancer screening cultural factor female health belief health care access human logistic regression analysis major clinical study mammography primary health care priority journal rescreening LA - English M3 - Article N1 - L44309583 2006-09-13 PY - 2006 SN - 0162-220X SP - 236-243 ST - Psychosocial factors related to repeat mammography screening over 5 years in African American women T2 - Cancer Nursing TI - Psychosocial factors related to repeat mammography screening over 5 years in African American women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44309583&from=export http://dx.doi.org/10.1097/00002820-200605000-00012 VL - 29 ID - 1247 ER - TY - JOUR AB - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammogram in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Russell, Kathleen M., Indiana University, School of Nursing, Indianapolis, IN, US, 46202-5107 AN - 2006-11051-004 AU - Russell, Kathleen M. AU - Champion, Victoria L. AU - Skinner, Celette Sugg DB - psyh DO - 10.1097/00002820-200605000-00012 DP - EBSCOhost IS - 3 KW - African American women health beliefs mammography screening psychosocial factors African Americans Aged Aged, 80 and over Educational Status Female Guideline Adherence Health Behavior Health Knowledge, Attitudes, Practice Health Services Accessibility Health Services Needs and Demand Humans Logistic Models Mammography Mass Screening Middle Aged Midwestern United States Nursing Methodology Research Patient Acceptance of Health Care Practice Guidelines as Topic Risk Assessment Self Efficacy Surveys and Questionnaires Time Factors Women Blacks Breast Neoplasms Cancer Screening N1 - Indiana University, School of Nursing, Indianapolis, IN, US. Release Date: 20070319. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Breast Neoplasms; Cancer Screening; Mammography; Psychosocial Factors. Minor Descriptor: Health Behavior. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: May-Jun, 2006. Sponsor: National Institutes of Health, National Institute of Nursing Research. Grant: R01NR04081. Recipients: No recipient indicated PY - 2006 SN - 0162-220X 1538-9804 SP - 236-243 ST - Psychosocial Factors Related to Repeat Mammography Screening Over 5 Years in African American Women T2 - Cancer Nursing TI - Psychosocial Factors Related to Repeat Mammography Screening Over 5 Years in African American Women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-11051-004&site=ehost-live&scope=site katrusse@iupui.edu VL - 29 ID - 1774 ER - TY - JOUR AB - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammogram in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience. AD - Indiana University School of Nursing, Indianapolis, IN 46202-5107; katrusse@iupui.edu AN - 106302402. Language: English. Entry Date: 20060714. Revision Date: 20150820. Publication Type: Journal Article AU - Russell, K. M. AU - Champion, V. L. AU - Skinner, C. S. DB - CINAHL Complete DP - EBSCOhost IS - 3 KW - Black Persons -- Psychosocial Factors -- Midwestern United States Health Beliefs -- Evaluation Mammography -- Utilization Aged Aged, 80 and Over Bivariate Statistics Chi Square Test Clinical Trials Coefficient Alpha Conceptual Framework Correlational Studies Data Analysis Software Descriptive Research Descriptive Statistics Female Funding Source Health Belief Model Health Knowledge -- Evaluation Health Services Accessibility -- Evaluation Logistic Regression Middle Age Midwestern United States Scales Secondary Analysis Self Report Self-Efficacy -- Evaluation Summated Rating Scaling Human N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: National Institute of Nursing Research, National Institutes of Health, #R01NR04081. NLM UID: 7805358. PMID: NLM16783125. PY - 2006 SN - 0162-220X SP - 236-243 ST - Psychosocial factors related to repeat mammography screening over 5 years in African American women T2 - Cancer Nursing TI - Psychosocial factors related to repeat mammography screening over 5 years in African American women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106302402&site=ehost-live&scope=site VL - 29 ID - 2038 ER - TY - JOUR AB - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammogram in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience. © 2006 Lippincott Williams & Wilkins, Inc. AD - Indiana University, School of Nursing, Indianapolis, IN, United States Department of Surgery, Department of Community and Family Medicine, Duke Comprehensive Cancer Center, Durham, NC, United States Indiana University, School of Nursing, Indianapolis, IN 46202-5107, United States AU - Russell, K. M. AU - Champion, V. L. AU - Skinner, C. S. DB - Scopus DO - 10.1097/00002820-200605000-00012 IS - 3 KW - African American Blacks Health beliefs Mammography screening M3 - Article N1 - Cited By :33 Export Date: 22 March 2021 PY - 2006 SP - 236-243 ST - Psychosocial factors related to repeat mammography screening over 5 years in African American women T2 - Cancer Nursing TI - Psychosocial factors related to repeat mammography screening over 5 years in African American women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745895286&doi=10.1097%2f00002820-200605000-00012&partnerID=40&md5=ecac884cb03f286883b65b15805cd1bf VL - 29 ID - 2577 ER - TY - JOUR AB - The purpose of this study was to investigate health beliefs associated with repeat mammography screening in African American women 51 years or older over a 5-year period. Long-term repeat mammography screening is inconsistent in African American women; therefore, this study measured demographic, knowledge, and health belief predictors of repeat screening. The theoretical framework for this study was the health belief model. Baseline data from a larger randomized controlled trial were analyzed using descriptive statistics and logistic regression. The sample consisted of 602 African American women with no breast cancer history and at least 1 reported screening mammograrn in the past 5 years. They were recruited from 3 primary care health settings. Having been screened 4 to 5 times in the past 5 years was associated with more knowledge about screening guidelines and fewer perceived barriers to screening. Results point to the importance of collaborating with African American communities to promote life-long mammography screening by increasing access to culturally appropriate information on screening guidelines and ameliorating barriers to screening within the context of the African American experience. AN - WOS:000241298400008 AU - Russell, K. M. AU - Champion, V. L. AU - Skinner, C. S. DA - May-Jun DO - 10.1097/00002820-200605000-00012 IS - 3 N1 - 16783125 PY - 2006 SN - 0162-220X SP - 236-243 ST - Psychosocial factors related to repeat mammography screening over 5 years in African American women T2 - Cancer Nursing TI - Psychosocial factors related to repeat mammography screening over 5 years in African American women VL - 29 ID - 3220 ER - TY - JOUR AB - A physiology-oriented compartmental kinetics (POCK) model of alveolar retention of respirable, insoluble particles in rats was used to simulate the results of two subchronic inhalation tests with male Fischer rats exposed to submicron anatase TiO2 particles of either 250 or 20 nm average size (Oberdorster et al., 1994). Earlier, the ultrafine variety had been used in a lifetime study with female Wistar rats (Heinrich & Fuhst, 1992) and the results were also subjected to POCK simulations. The database on anatase was not as extensive as in case of previous studies that used submicrometer carbonaceous aerosols. However, besides the usual results for the patterns of total lung burden and lymph node load, the new subchronic tests provided, for the first time, some data on anatase burdens of both the macrophage pool and the interstitium. Due to the scarcity of the data, the POCK simulation was not entirely unique, but good data representation was achieved with plausible model parameters. The substantial increase in interstitial deposits of the ultrafine anatase in comparison to the coarser sample required an increase by an order of magnitude for the rate coefficient of free particle mass transfer through the epithelial wall. The translocation of overloaded macrophages to the interstitium indicated a similar change, but Wistar rats appeared to have a lower base value. In general, the results of the simulations seem to confirm the usefulness and consistency of the model concept. At the end of the lifetime exposure study with ultrafine anatase, conducted under high exposure rate indices up to 1330 mg/m(3) x h/wk to achieve overload, Heinrich and Fuhst found lung tumors in 32% of the rats. This confirmed that overload carcinogenesis in rats is not related to molecular, DNA-reactive carcinogens. A previously proposed hypothesis of a critical dose for overload carcinogenesis in rats, which had been derived from experimental diesel soot and carbon black aerosol inhalation studies, yielded tumor induction characteristics for ultrafine anatase that were commensurable with the parameter values found for carbonaceous aerosols. This suggests that the integral over the residence time of the interstitial retention may be a consistent relative dose surrogate for overload lung tumor induction in rats. Its critical dose would correspond to a no-effect threshold. For the female Wistar rats and ultrafine anatase, this value was about 4000 mg x days. It matched closely, although probably by coincidence, the value for the female Wistar rats derived earlier from experimental diesel soot data. AN - WOS:A1995TC00300002 AU - Stober, W. AU - Morrow, P. E. AU - Oberdorster, G. DA - Oct IS - 7 N1 - 4 PY - 1995 SN - 0895-8378 SP - 1059-1074 ST - Pulmonary Retention of Inhaled Anatase (Tio2) Aerosols and Lung-Tumor Induction in Rats Simulated by a Physiology-Oriented Model T2 - Inhalation Toxicology TI - Pulmonary Retention of Inhaled Anatase (Tio2) Aerosols and Lung-Tumor Induction in Rats Simulated by a Physiology-Oriented Model VL - 7 ID - 2739 ER - TY - JOUR AB - Purpose: Because insurers use performance and quality metrics to inform reimbursement, identifying remediable causes of poor-quality cancer care is imperative. We undertook this descriptive cohort study to assess key predictors of women's perceived quality of their breast cancer care and actual guideline-concordant quality of care received. Patients and Methods: We surveyed inner-city women with newly diagnosed and surgically treated early-stage breast cancer requiring adjuvant treatment who were enrolled onto a randomized controlled trial (RCT) of patient assistance to reduce disparities in care. We assessed women's perceived quality of care and perceived quality of the process of getting care, such as getting referrals, test results, and treatments; we abstracted records to determine the actual quality of care. Results: Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a slight majority of women (55%) perceived their quality of care as excellent; 88% actually received good-quality, guideline-concordant care. Excellent perceived quality (P < .001) was significantly associated with patients' perception of the quality of the process of getting care (adjusted relative risk [RR], 1.78; 95% CI, 1.65 to 1.87). Also associated with perceived quality - and mediated by race - were trust in one's physician (adjusted RR, 1.43; 95% CI, 1.16 to 1.64) and perceived racism, which affected black women more than women of other races/ethnicities (black race-adjusted RR for perceived racism, 0.33 [95% CI, 0.10 to 0.87]; black race-adjusted RR for trust, 1.61 [95% CI, 0.97 to 1.90]; c = 0.82 for the model; P < .001). Actual quality of care provided did not affect perceived quality of care received. Conclusion: Patients' perceived quality of care differs from their receipt of high-quality care. Mutable targets to improve perceived quality of care include the processes of getting care and trusting their physician. © 2012 by American Society of Clinical Oncology. AD - N.A. Bickell, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1077, New York, NY 10029, United States AU - Bickell, N. A. AU - Neuman, J. AU - Fei, K. AU - Franco, R. AU - Joseph, K. A. DB - Embase Medline DO - 10.1200/JCO.2011.38.7605 IS - 15 KW - adult African American aged article breast cancer clinical practice ethnicity female health care disparity health care quality health survey human major clinical study patient care patient referral perception physician priority journal reimbursement LA - English M3 - Article N1 - L365265647 2012-07-25 2012-07-27 PY - 2012 SN - 0732-183X 1527-7755 SP - 1791-1795 ST - Quality of breast cancer care: Perception versus practice T2 - Journal of Clinical Oncology TI - Quality of breast cancer care: Perception versus practice UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365265647&from=export http://dx.doi.org/10.1200/JCO.2011.38.7605 http://jco.ascopubs.org/content/30/15/1791.full.pdf+html VL - 30 ID - 1120 ER - TY - JOUR AB - Purpose: Because insurers use performance and quality metrics to inform reimbursement, identifying remediable causes of poor-quality cancer care is imperative. We undertook this descriptive cohort study to assess key predictors of women's perceived quality of their breast cancer care and actual guideline-concordant quality of care received. Patients and Methods: We surveyed inner-city women with newly diagnosed and surgically treated early-stage breast cancer requiring adjuvant treatment who were enrolled onto a randomized controlled trial (RCT) of patient assistance to reduce disparities in care. We assessed women's perceived quality of care and perceived quality of the process of getting care, such as getting referrals, test results, and treatments; we abstracted records to determine the actual quality of care. Results: Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a slight majority of women (55%) perceived their quality of care as excellent; 88% actually received good-quality, guideline-concordant care. Excellent perceived quality (P < .001) was significantly associated with patients' perception of the quality of the process of getting care (adjusted relative risk [RR], 1.78; 95% CI, 1.65 to 1.87). Also associated with perceived quality - and mediated by race - were trust in one's physician (adjusted RR, 1.43; 95% CI, 1.16 to 1.64) and perceived racism, which affected black women more than women of other races/ethnicities (black race-adjusted RR for perceived racism, 0.33 [95% CI, 0.10 to 0.87]; black race-adjusted RR for trust, 1.61 [95% CI, 0.97 to 1.90]; c = 0.82 for the model; P < .001). Actual quality of care provided did not affect perceived quality of care received. Conclusion: Patients' perceived quality of care differs from their receipt of high-quality care. Mutable targets to improve perceived quality of care include the processes of getting care and trusting their physician. © 2012 by American Society of Clinical Oncology. AD - Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1077, New York, NY 10029, United States Columbia University Medical Center, New York, NY, United States AU - Bickell, N. A. AU - Neuman, J. AU - Fei, K. AU - Franco, R. AU - Joseph, K. A. DB - Scopus DO - 10.1200/JCO.2011.38.7605 IS - 15 M3 - Article N1 - Cited By :29 Export Date: 22 March 2021 PY - 2012 SP - 1791-1795 ST - Quality of breast cancer care: Perception versus practice T2 - Journal of Clinical Oncology TI - Quality of breast cancer care: Perception versus practice UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863936925&doi=10.1200%2fJCO.2011.38.7605&partnerID=40&md5=d3d3cc55a285505cb74a8015f070ba9a VL - 30 ID - 2459 ER - TY - JOUR AB - Purpose: Because insurers use performance and quality metrics to inform reimbursement, identifying remediable causes of poor-quality cancer care is imperative. We undertook this descriptive cohort study to assess key predictors of women's perceived quality of their breast cancer care and actual guideline-concordant quality of care received.Patients and Methods: We surveyed inner-city women with newly diagnosed and surgically treated early-stage breast cancer requiring adjuvant treatment who were enrolled onto a randomized controlled trial (RCT) of patient assistance to reduce disparities in care. We assessed women's perceived quality of care and perceived quality of the process of getting care, such as getting referrals, test results, and treatments; we abstracted records to determine the actual quality of care.Results: Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a slight majority of women (55%) perceived their quality of care as excellent; 88% actually received good-quality, guideline-concordant care. Excellent perceived quality (P < .001) was significantly associated with patients' perception of the quality of the process of getting care (adjusted relative risk [RR], 1.78; 95% CI, 1.65 to 1.87). Also associated with perceived quality-and mediated by race-were trust in one's physician (adjusted RR, 1.43; 95% CI, 1.16 to 1.64) and perceived racism, which affected black women more than women of other races/ethnicities (black race-adjusted RR for perceived racism, 0.33 [95% CI, 0.10 to 0.87]; black race-adjusted RR for trust, 1.61 [95% CI, 0.97 to 1.90]; c = 0.82 for the model; P < .001). Actual quality of care provided did not affect perceived quality of care received.Conclusion: Patients' perceived quality of care differs from their receipt of high-quality care. Mutable targets to improve perceived quality of care include the processes of getting care and trusting their physician. AD - Mount Sinai School of Medicine, New York, NY 10029, USA Mount Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1077, New York, NY 10029; nina.bickell@mssm.edu. AN - 104447602. Language: English. Entry Date: 20120803. Revision Date: 20200708. Publication Type: journal article AU - Bickell, N. A. AU - Neuman, J. AU - Fei, K. AU - Franco, R. AU - Joseph, K. A. AU - Bickell, Nina A. AU - Neuman, Jennifer AU - Fei, Kezhen AU - Franco, Rebeca AU - Joseph, Kathie-Ann DB - CINAHL Complete DO - 10.1200/JCO.2011.38.7605 DP - EBSCOhost IS - 15 KW - Attitude to Health -- Ethnology Breast Neoplasms -- Therapy Mastectomy -- Standards Patients -- Psychosocial Factors Perception Quality of Health Care -- Standards Urban Health Services -- Standards Adult Aged Aged, 80 and Over Breast Neoplasms -- Diagnosis Breast Neoplasms -- Ethnology Breast Neoplasms -- Psychosocial Factors Clinical Trials Ethnic Groups -- Psychosocial Factors Female Guideline Adherence Human Logistic Regression Middle Age Neoplasm Staging New York Odds Ratio Patient Satisfaction Physician-Patient Relations Practice Guidelines Surveys N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: R01 CA107051/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM22493417. PY - 2012 SN - 0732-183X SP - 1791-1795 ST - Quality of breast cancer care: perception versus practice T2 - Journal of Clinical Oncology TI - Quality of breast cancer care: perception versus practice UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104447602&site=ehost-live&scope=site VL - 30 ID - 2040 ER - TY - JOUR AB - Purpose Because insurers use performance and quality metrics to inform reimbursement, identifying remediable causes of poor-quality cancer care is imperative. We undertook this descriptive cohort study to assess key predictors of women's perceived quality of their breast cancer care and actual guideline-concordant quality of care received. Patients and Methods We surveyed inner-city women with newly diagnosed and surgically treated early-stage breast cancer requiring adjuvant treatment who were enrolled onto a randomized controlled trial (RCT) of patient assistance to reduce disparities in care. We assessed women's perceived quality of care and perceived quality of the process of getting care, such as getting referrals, test results, and treatments; we abstracted records to determine the actual quality of care. Results Of the 374 new patients with early-stage breast cancer enrolled onto the RCT, only a slight majority of women (55%) perceived their quality of care as excellent; 88% actually received good-quality, guideline-concordant care. Excellent perceived quality (P < .001) was significantly associated with patients' perception of the quality of the process of getting care (adjusted relative risk [RR], 1.78; 95% CI, 1.65 to 1.87). Also associated with perceived quality-and mediated by race-were trust in one's physician (adjusted RR, 1.43; 95% CI, 1.16 to 1.64) and perceived racism, which affected black women more than women of other races/ethnicities (black race-adjusted RR for perceived racism, 0.33 [95% CI, 0.10 to 0.87]; black race-adjusted RR for trust, 1.61 [95% CI, 0.97 to 1.90]; c = 0.82 for the model; P < .001). Actual quality of care provided did not affect perceived quality of care received. Conclusion Patients' perceived quality of care differs from their receipt of high-quality care. Mutable targets to improve perceived quality of care include the processes of getting care and trusting their physician. J Clin Oncol 30:1791-1795. (c) 2012 by American Society of Clinical Oncology AN - WOS:000304427600013 AU - Bickell, N. A. AU - Neuman, J. AU - Fei, K. Z. AU - Franco, R. AU - Joseph, K. A. DA - May DO - 10.1200/JCO.2011.38.7605 IS - 15 N1 - 22493417 PY - 2012 SN - 0732-183X SP - 1791-1795 ST - Quality of Breast Cancer Care: Perception Versus Practice T2 - Journal of Clinical Oncology TI - Quality of Breast Cancer Care: Perception Versus Practice VL - 30 ID - 3070 ER - TY - JOUR AB - BACKGROUND: Previous research suggests that disparities in non-small-cell lung cancer (NSCLC) survival can be explained in part by disparities in the receipt of cancer treatment. Few studies, however, have considered race and sex disparities in the timing and appropriateness of treatment across stages of diagnosis. OBJECTIVE: To evaluate the relationship of sex and race with the receipt of timely and clinically appropriate NSCLC treatment for each stage of diagnosis. METHOD: Surveillance Epidemiology and End Result data linked to Medicare claims for beneficiaries diagnosed with NSCLC between 1995 and 1999 were used to evaluate the relationship between race and sex with timely and appropriate NSCLC treatment while controlling for other demographic characteristics, comorbidities, socioeconomic status, and provider supply (N = 22,145). RESULTS: Overall adjusted rates of timely and appropriate treatment are 37.2%, 58.1%, and 29.2% for Medicare beneficiaries diagnosed with stage I or II, III, and IV NSCLC, respectively. Among stage I or II patients, women were 25% less likely to receive timely surgical resection relative to men, and blacks were 66% less likely to receive timely and appropriate treatment than whites. Black men were least likely to receive resection (22.2% compared with 43.7% for white men). Blacks were 34% less likely to receive timely surgery, chemotherapy, or radiation for stage III disease and were 51% less likely to receive chemotherapy in a timely fashion for stage IV disease relative to whites. CONCLUSION: Significant variations in appropriate timely treatment were found within and across stages of diagnosis, confirming that sex and race differences in NSCLC treatment exist. AN - 105371088. Language: English. Entry Date: 20090731. Revision Date: 20150711. Publication Type: Journal Article AU - Shugarman, L. R. AU - Mack, K. AU - Sorbero, M. E. AU - Tian, H. AU - Jain, A. K. AU - Ashwood, J. S. AU - Asch, S. M. DB - CINAHL Complete DO - 10.1097/MLR.0b013e3181a393fe DP - EBSCOhost IS - 7 KW - Black Persons -- Statistics and Numerical Data Carcinoma, Non-Small-Cell Lung -- Therapy Health Services Accessibility -- Statistics and Numerical Data Lung Neoplasms -- Therapy White Persons -- Statistics and Numerical Data Aged Aged, 80 and Over Black Persons Carcinoma, Non-Small-Cell Lung -- Diagnosis Carcinoma, Non-Small-Cell Lung -- Ethnology Female Guideline Adherence -- Statistics and Numerical Data Health Services Research Insurance -- Statistics and Numerical Data Logistic Regression Lung Neoplasms -- Diagnosis Lung Neoplasms -- Ethnology Male Medicare -- Statistics and Numerical Data Men Multivariate Analysis Patient Selection Practice Guidelines Practice Patterns -- Statistics and Numerical Data Registries, Disease Sensitivity and Specificity Sex Factors United States White Persons Women Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 0230027. PMID: NLM19536007. PY - 2009 SN - 0025-7079 SP - 774-781 ST - Race and sex differences in the receipt of timely and appropriate lung cancer treatment T2 - Medical Care TI - Race and sex differences in the receipt of timely and appropriate lung cancer treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105371088&site=ehost-live&scope=site VL - 47 ID - 2041 ER - TY - JOUR AB - Background: Previous research suggests that disparities in non-small-cell lung cancer (NSCLC) survival can be explained in part by disparities in the receipt of cancer treatment. Few studies, however, have considered race and sex disparities in the timing and appropriateness of treatment across stages of diagnosis. Objective: To evaluate the relationship of sex and race with the receipt of timely and clinically appropriate NSCLC treatment for each stage of diagnosis. Method: Surveillance Epidemiology and End Result data linked to Medicare claims for beneficiaries diagnosed with NSCLC between 1995 and 1999 were used to evaluate the relationship between race and sex with timely and appropriate NSCLC treatment while controlling for other demographic characteristics, comorbidities, socioeconomic status, and provider supply (N = 22,145). Results: Overall adjusted rates of timely and appropriate treatment are 37.2%, 58.1%, and 29.2% for Medicare beneficiaries diagnosed with stage I or II, III, and IV NSCLC, respectively. Among stage I or II patients, women were 25% less likely to receive timely surgical resection relative to men, and blacks were 66% less likely to receive timely and appropriate treatment than whites. Black men were least likely to receive resection (22.2% compared with 43.7% for white men). Blacks were 34% less likely to receive timely surgery, chemotherapy, or radiation for stage III disease and were 51% less likely to receive chemotherapy in a timely fashion for stage IV disease relative to whites. Conclusion: Significant variations in appropriate timely treatment were found within and across stages of diagnosis, confirming that sex and race differences in NSCLC treatment exist. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Shugarman, Lisa R., RAND Corporation, 1776 Main St, PO Box 2138, Santa Monica, CA, US, 90407-2138 AN - 2009-12444-005 AU - Shugarman, Lisa R. AU - Mack, Katherine AU - Sorbero, Melony E. S. AU - Tian, Haijun AU - Jain, Arvind K. AU - Ashwood, J. Scott AU - Asch, Steven M. DB - psyh DO - 10.1097/MLR.0b013e3181a393fe DP - EBSCOhost IS - 7 KW - racial & sex differences non-small-cell lung cancer treatment treatment timeliness & appropriateness African Americans Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung European Continental Ancestry Group Female Guideline Adherence Health Services Accessibility Health Services Research Healthcare Disparities Humans Insurance Claim Reporting Logistic Models Lung Neoplasms Male Medicare Men Multivariate Analysis Patient Selection Practice Guidelines as Topic Practice Patterns, Physicians' SEER Program Sensitivity and Specificity Sex Factors United States Women Human Sex Differences Lung Neoplasms Racial and Ethnic Differences Treatment Outcomes N1 - RAND Corporation, Santa Monica, CA, US. Release Date: 20100301. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Human Sex Differences; Lung; Neoplasms; Racial and Ethnic Differences; Treatment Outcomes. Classification: Cancer (3293); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380); Very Old (85 yrs & older) (390). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Jul, 2009. Copyright Statement: Lippincott Williams & Wilkins. 2009. Sponsor: Health Resources and Services Administration, Office of Rural Health Policy. Grant: R04-RH03596-01-00. Recipients: No recipient indicated PY - 2009 SN - 0025-7079 1537-1948 SP - 774-781 ST - Race and sex differences in the receipt of timely and appropriate lung cancer treatment T2 - Medical Care TI - Race and sex differences in the receipt of timely and appropriate lung cancer treatment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-12444-005&site=ehost-live&scope=site lisas@rand.org VL - 47 ID - 1755 ER - TY - JOUR AB - Background: The impact of age-, gender-, and race-based differences on safety and efficacy in phase I clinical trials has not been well studied. Methods: We analyzed data from phase I clinical trials evaluating targeted biologic agents in patients with advanced solid malignancies. Race and gender distribution of enrolled patients was compared to the referral population demographics at the city, metro, and state levels. The association between age, gender, and race with type, frequency, and severity of treatment-emergent toxicities and clinical benefit was assessed using univariate and multivariable models. Results: Data from 117 eligible patients - Blacks/Caucasians/Others (27/85/5); male/female (66/51) - were obtained. Blacks were younger than Caucasian patients (median age of 56 vs. 62 years, p = 0.004). Nausea/vomiting was more frequent in female patients (43 vs. 24%, p = 0.03), while hematologic toxicity was more likely in Whites. While median time on treatment was comparable (113 vs. 91; p = 0.840), the median overall survival was significantly shorter for Blacks versus Caucasians (7.4 vs. 11.4 months; p = 0.0227). Black race (HR 2.11; 95% CI 1.24-3.60; p = 0.006) and older age (HR 1.03; 95% CI 1.00-1.06; p = 0.029) were associated with an increased risk of death. Conclusions: Age-, gender-, and race-based disparities were observed with specific toxicity and survival outcomes on phase I clinical trials of anticancer agents. © 2018 S. Karger AG, Basel. Copyright: All rights reserved. AD - Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365-C Clifton Road, NE, Suite C3080, Atlanta, GA 30322, United States Winship Cancer Institute of Emory University, Atlanta, GA, United States Cedars-Sinai Medical Center, Los Angeles, CA, United States Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, United States AU - Owonikoko, T. K. AU - Busari, A. K. AU - Kim, S. AU - Chen, Z. AU - Akintayo, A. AU - Lewis, C. AU - Carthon, B. C. AU - Alese, O. B. AU - El-Rayes, B. F. AU - Ramalingam, S. S. AU - Harvey, R. D. DB - Scopus DO - 10.1159/000488763 IS - 3 KW - Gender Phase I study Race Targeted therapy Tolerability Toxicity M3 - Article N1 - Export Date: 22 March 2021 PY - 2018 SP - 138-146 ST - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase i Trials T2 - Oncology (Switzerland) TI - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase i Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048853544&doi=10.1159%2f000488763&partnerID=40&md5=98a03d309d1b8c094ecacfba9df08bd9 VL - 95 ID - 2263 ER - TY - JOUR AB - Background: The impact of age-, gender-, and race-based differences on safety and efficacy in phase I clinical trials has not been well studied. Methods: We analyzed data from phase I clinical trials evaluating targeted biologic agents in patients with advanced solid malignancies. Race and gender distribution of enrolled patients was compared to the referral population demographics at the city, metro, and state levels. The association between age, gender, and race with type, frequency, and severity of treatment-emergent toxicities and clinical benefit was assessed using univariate and multivariable models. Results: Data from 117 eligible patients - Blacks/Caucasians/Others (27/85/5); male/female (66/51) - were obtained. Blacks were younger than Caucasian patients (median age of 56 vs. 62 years, p = 0.004). Nausea/vomiting was more frequent in female patients (43 vs. 24%, p = 0.03), while hematologic toxicity was more likely in Whites. While median time on treatment was comparable (113 vs. 91; p = 0.840), the median overall survival was significantly shorter for Blacks versus Caucasians (7.4 vs. 11.4 months; p = 0.0227). Black race (HR 2.11; 95% CI 1.24-3.60; p= 0.006) and older age (HR 1.03; 95% CI 1.00-1.06;p= 0.029) were associated with an increased risk of death. Conclusions: Age-, gender-, and race-based disparities were observed with specific toxicity and survival outcomes on phase I clinical trials of anticancer agents. (C) 2018 S. Karger AG, Basel AN - WOS:000443721600002 AU - Owonikoko, T. K. AU - Busari, A. K. AU - Kim, S. AU - Chen, Z. J. AU - Akintayo, A. AU - Lewis, C. AU - Carthon, B. C. AU - Alese, O. B. AU - El-Rayes, B. F. AU - Ramalingam, S. S. AU - Harvey, R. D. DO - 10.1159/000488763 IS - 3 N1 - 29913438 PY - 2018 SN - 0030-2414 SP - 138-146 ST - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials T2 - Oncology TI - Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials VL - 95 ID - 2878 ER - TY - JOUR AB - Purpose: Risk of multiple myeloma is increased in African American (AA) populations compared with European American (EA) cohorts. Current estimates of risk of progression of monoclonal gammopathy of undetermined significance (MGUS) are based largely on studies in EA cohorts. Prospective analyses of this risk in AA cohorts are lacking. Patients and Methods: Between 2003 and 2011, 331 eligible patients with IgG/A monoclonal gammopathy were enrolled in a prospective observational trial (SWOG S0120). Results: Of 331 eligible patients, 57 (17%) were of AA descent. The risk of transformation to clinical malignancy in AA patients was significantly lower than in non-AA cohort (2-year risk 5% vs. 15%; 5-year risk 13% vs. 24%; log-rank P ¼ 0.047). Differences in risk were evident for both MGUS and asymptomatic multiple myeloma. Gene expression profile (GEP) of CD138-purified plasma cells revealed that all molecular multiple myeloma subsets can be identified in both cohorts. However, the proportion of patients with high-risk GEP risk score (GEP-70 gene risk > -0.26) was lower in the AA cohort (0% vs. 33%, P ¼ 0.01). AA cohorts also have higher levels of antibodies against Epstein-Barr nuclear antigen-1 (EBNA-1; P < 0.001). Conclusions: These data provide the first prospective evidence that multiple myeloma precursor states in AA patients may have lower risk of disease compared with non-AA counterparts with lower incidence of high-risk GEP and increased EBV seropositivity. Race-dependent differences in biology and clinical risk of gammopathy may impact optimal management of these patients. © 2020 American Association for Cancer Research. AD - Emory University, Atlanta, GA, United States Cancer Research and Biostatistics, Seattle, WA, United States Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States Mount Sinai Medical Center, New York, NY, United States MD Anderson Cancer Center, Houston, TX, United States AU - Dhodapkar, M. V. AU - Sexton, R. AU - Hoering, A. AU - van Rhee, F. AU - Barlogie, B. AU - Orlowski, R. DB - Scopus DO - 10.1158/1078-0432.CCR-20-2119 IS - 22 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 5814-5819 ST - Race-dependent differences in risk, genomics, and Epstein-barr virus exposure in monoclonal gammopathies: Results of SWOG S0120 T2 - Clinical Cancer Research TI - Race-dependent differences in risk, genomics, and Epstein-barr virus exposure in monoclonal gammopathies: Results of SWOG S0120 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85101113325&doi=10.1158%2f1078-0432.CCR-20-2119&partnerID=40&md5=593cb150a266e81b7a6d0bde46987bc4 VL - 26 ID - 2174 ER - TY - JOUR AB - OBJECTIVE: We examined prostate cancer patients' perceived engagement in treatment decision-making and associated factors by race/ethnicity in a multiethnic sample. METHOD: We identified patients through the California Cancer Registry. Patients completed a cross-sectional telephone interview in English, Spanish, Cantonese, or Mandarin. Multivariable logistic regression models, stratified by race/ethnicity, estimated the associations of patient demographic and health status characteristics on (1) doctor asked patient to help decide treatment plan and (2) patient and doctor worked out a treatment plan together. RESULTS: We included 855 prostate cancer patients: African American (19%), Asian American (15%), Latino (24%), and White (42%). Asian American patients were less likely than White patients to report that their doctors asked them to help decide a treatment plan (OR = 0.31; 95% CI = 0.18-0.53) and that they worked out a treatment plan with their doctors (OR = 0.54; 95% CI = 0.33-0.90). Language of interview was a significant contributing factor in stratified analysis for both outcomes. CONCLUSION: Asian American prostate cancer patients reported less engagement in treatment decision-making, with Chinese language being a significant contributing factor. Future research should identify patient-centered strategies that effectively engage underserved patients and support healthcare providers in shared decision-making with multiethnic and multilingual patients. AU - Palmer, N. R. AU - Gregorich, S. E. AU - Livaudais-Toman, J. AU - Jih, J. AU - Kaplan, C. P. DB - Medline DO - 10.1007/s40615-018-0475-0 IS - 6 KW - adult African American aged Asian American cancer survivor Caucasian cross-sectional study decision making ethnic group ethnology health care disparity Hispanic human male middle aged multivariate analysis patient participation prostate tumor statistical model LA - English M3 - Article N1 - L624880597 2018-11-16 2019-12-13 PY - 2018 SN - 2196-8837 SP - 1273-1283 ST - Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making T2 - Journal of racial and ethnic health disparities TI - Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making UR - https://www.embase.com/search/results?subaction=viewrecord&id=L624880597&from=export http://dx.doi.org/10.1007/s40615-018-0475-0 VL - 5 ID - 873 ER - TY - JOUR AB - Objective: We examined prostate cancer patients’ perceived engagement in treatment decision-making and associated factors by race/ethnicity in a multiethnic sample. Method: We identified patients through the California Cancer Registry. Patients completed a cross-sectional telephone interview in English, Spanish, Cantonese, or Mandarin. Multivariable logistic regression models, stratified by race/ethnicity, estimated the associations of patient demographic and health status characteristics on (1) doctor asked patient to help decide treatment plan and (2) patient and doctor worked out a treatment plan together. Results: We included 855 prostate cancer patients: African American (19%), Asian American (15%), Latino (24%), and White (42%). Asian American patients were less likely than White patients to report that their doctors asked them to help decide a treatment plan (OR = 0.31; 95% CI = 0.18–0.53) and that they worked out a treatment plan with their doctors (OR = 0.54; 95% CI = 0.33–0.90). Language of interview was a significant contributing factor in stratified analysis for both outcomes. Conclusion: Asian American prostate cancer patients reported less engagement in treatment decision-making, with Chinese language being a significant contributing factor. Future research should identify patient-centered strategies that effectively engage underserved patients and support healthcare providers in shared decision-making with multiethnic and multilingual patients. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Palmer, Nynikka R., Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, UCSF Box 1364, 1001 Potrero Avenue, Building 10, 3rd Floor, San Francisco, CA, US, 94143 AN - 2019-40070-013 AU - Palmer, Nynikka R. AU - Gregorich, Steven E. AU - Livaudais-Toman, Jennifer AU - Jih, Jane AU - Kaplan, Celia P. DB - psyh DO - 10.1007/s40615-018-0475-0 DP - EBSCOhost IS - 6 KW - Prostate cancer Treatment decision-making Disparities Men Engagement Asians Clinical Judgment (Not Diagnosis) Neoplasms Physicians Prostate Client Participation Racial and Ethnic Differences N1 - Division of General Internal Medicine, Zuckerberg San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA, US. Release Date: 20191104. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Asians; Clinical Judgment (Not Diagnosis); Neoplasms; Physicians; Prostate. Minor Descriptor: Client Participation; Racial and Ethnic Differences. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Page Count: 11. Issue Publication Date: Dec, 2018. Publication History: First Posted Date: Mar 7, 2018; Accepted Date: Feb 23, 2018; Revised Date: Feb 19, 2018; First Submitted Date: Nov 12, 2017. Copyright Statement: W. Montague Cobb-NMA Health Institute. 2018. PY - 2018 SN - 2197-3792 2196-8837 SP - 1273-1283 ST - Racial and ethnic differences in prostate cancer survivors’ perceived engagement in treatment decision-making T2 - Journal of Racial and Ethnic Health Disparities TI - Racial and ethnic differences in prostate cancer survivors’ perceived engagement in treatment decision-making UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-40070-013&site=ehost-live&scope=site nynikka.palmer@ucsf.edu VL - 5 ID - 1693 ER - TY - JOUR AB - Purpose: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. Patients and Methods: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment‐related toxicities were examined. Results: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. Conclusion: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per‐protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference. © 2008 by American Society of Clinical Oncology. AN - CN-01781995 AU - Polite, B. N. AU - Cirrincione, C. AU - Fleming, G. F. AU - Berry, D. A. AU - Seidman, A. AU - Muss, H. AU - Norton, L. AU - Shapiro, C. AU - Bakri, K. AU - Marcom, K. AU - et al. DO - 10.1200/JCO.2007.13.9782 IS - 16 KW - *breast cancer /drug therapy Adult Aged Anemia /side effect Article Cancer chemotherapy Cancer mortality Cancer survival Clinical trial Cohort analysis Comorbidity Confidence interval Controlled clinical trial Controlled study Female Hazard ratio Human Infection /side effect Leukopenia /side effect Lymphocytopenia /side effect Major clinical study Metastasis /drug therapy Motor neuropathy /side effect Priority journal Prognosis Race difference Randomized controlled trial Sensory neuropathy /side effect Thrombocytopenia /side effect Treatment failure Treatment response M3 - Journal: Article PY - 2008 SP - 2659‐2665 ST - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B T2 - Journal of clinical oncology TI - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01781995/full VL - 26 ID - 1462 ER - TY - JOUR AB - Purpose: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. Patients and Methods: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. Results: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. Conclusion: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference. © 2008 by American Society of Clinical Oncology. AD - University of Chicago, Chicago, IL; Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham; University of North Carolina at Chapel Hill, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York, NY; Vermont Cancer Center, Burlington, VT; The Ohio State University Medical Center, Columbus, OH; and the Dana-Farber Cancer Institute, Boston, MA AU - Polite, B. N. AU - Cirrincione, C. AU - Fleming, G. F. AU - Berry, D. A. AU - Seidman, A. AU - Muss, H. AU - Norton, L. AU - Shapiro, C. AU - Bakri, K. AU - Marcom, K. AU - Lake, D. AU - Schwartz, J. H. AU - Hudis, C. AU - Winer, E. P. DB - Scopus DO - 10.1200/JCO.2007.13.9782 IS - 16 M3 - Article N1 - Cited By :23 Export Date: 22 March 2021 PY - 2008 SP - 2659-2665 ST - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B T2 - Journal of Clinical Oncology TI - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-45749106419&doi=10.1200%2fJCO.2007.13.9782&partnerID=40&md5=97f5f4ab2265db523bb5876881983ca0 VL - 26 ID - 2533 ER - TY - JOUR AB - Purpose African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. Patients and Methods The study cohort consisted of 787 white ( 80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival ( OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. Results With 779 deaths ( 166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites ( hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites ( HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. Conclusion African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference. AN - WOS:000256210100013 AU - Polite, B. N. AU - Cirrincione, C. AU - Fleming, G. F. AU - Berry, D. A. AU - Seidman, A. AU - Muss, H. AU - Norton, L. AU - Shapiro, C. AU - Bakri, K. AU - Marcom, K. AU - Lake, D. AU - Schwartz, J. H. AU - Hudis, C. AU - Winer, E. P. DA - Jun DO - 10.1200/JCO.2007.13.9782 IS - 16 N1 - 18509177 PY - 2008 SN - 0732-183X SP - 2659-2665 ST - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B T2 - Journal of Clinical Oncology TI - Racial differences in clinical outcomes from metastatic breast cancer: A pooled analysis of CALGB 9342 and 9840 - Cancer and leukemia group B VL - 26 ID - 3168 ER - TY - JOUR AB - Purpose: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials.Patients and Methods: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined.Results: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen.Conclusion: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference. AD - The University of Chicago Medical Center, 5841 South Maryland Ave, MC 2115, Chicago, IL 60637-1470, USA AN - 105765559. Language: English. Entry Date: 20080711. Revision Date: 20190612. Publication Type: journal article AU - Polite, B. N. AU - Cirrincione, C. AU - Fleming, G. F. AU - Berry, D. A. AU - Seidman, A. AU - Muss, H. AU - Norton, L. AU - Shapiro, C. AU - Bakri, K. AU - Marcom, K. AU - Lake, D. AU - Schwartz, J. H. AU - Hudis, C. AU - Winer, E. P. AU - Polite, Blase N. AU - Cirrincione, Constance AU - Fleming, Gini F. AU - Berry, Donald A. AU - Seidman, Andrew AU - Muss, Hyman DB - CINAHL Complete DO - 10.1200/JCO.2007.13.9782 DP - EBSCOhost IS - 16 KW - Black Persons Breast Neoplasms -- Mortality Survival Analysis White Persons Adult Aged Antineoplastic Agents -- Therapeutic Use Breast Neoplasms -- Drug Therapy Breast Neoplasms -- Ethnology Female Logistic Regression Middle Age Multicenter Studies Neoplasm Metastasis Paclitaxel -- Therapeutic Use Time Factors Treatment Failure Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: CA77406/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM18509177. PY - 2008 SN - 0732-183X SP - 2659-2665 ST - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B T2 - Journal of Clinical Oncology TI - Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105765559&site=ehost-live&scope=site VL - 26 ID - 2042 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) incidence and mortality rates are higher in African-Americans as compared with other racial/ethnic groups. The women's health initiative (WHI) study sample was used to determine whether differences in CRC risk factors explain racial/ethnic differences in incidence and mortality. Methods: The WHI is a longitudinal study of postmenopausal women recruited from 40 centers. Baseline questionnaires were used to collect sociodemographic and health status information. All CRC diagnoses were centrally adjudicated. Cox regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for invasive CRC by race/ethnicity. Results: The study sample included 131,481 (83.7%) White, 14,323 (9.1%) African-American, 6,362 (4.1%) Hispanic, 694 (0.4%) Native American and 4,148 (2.6%) Asian/Pacific Islanders. After a mean follow-up of 10.8 years (SD 2.9), CRC incidence was the highest in African-Americans (annualized rate = 0.14%), followed by Whites and Native Americans (0.12% each), Asian/Pacific Islanders (0.10%), and Hispanics (0.08%). After adjustment for age and trial assignment, Hispanics had a lower risk compared with Whites, HR 0.73 (95% CI: 0.54-0.97) (P = 0.03), and African-Americans had a marginally greater risk, HR 1.16 (95% CI: 0.99-1.34), P = 0.06. Multivariable adjustment attenuated the difference in incidence between African-Americans and Whites (HR 0.99, 95% CI: 0.82-1.20), while strengthening the lower HR for Hispanics (HR 0.68, 95% CI: 0.48-0.97). Conclusions: African-American/White differences in CRC risk are likely due to sociodemographic/cultural factors other than race. Impact: A number of modifiable exposures could be a focus for reducing CRC risk in African-Americans. ©2011 AACR. AD - M. S. Simon, Barbara Ann Karmanos Cancer Institute, 4221 HWCRC, 4100 John R, Detroit, MI, United States AU - Simon, M. S. AU - Thomson, C. A. AU - Pettijohn, E. AU - Kato, I. AU - Rodabough, R. J. AU - Lane, D. AU - Hubbell, F. A. AU - O'Sullivan, M. J. AU - Adams-Campbell, L. AU - Mouton, C. P. AU - Abrams, J. AU - Chlebowski, R. T. DB - Embase Medline DO - 10.1158/1055-9965.EPI-11-0027 IS - 7 KW - adult African American aged American Indian article cancer incidence cancer mortality cancer risk colorectal cancer confidence interval controlled study demography female follow up hazard ratio health status Hispanic human longitudinal study major clinical study multivariate analysis Pacific Islander postmenopause priority journal proportional hazards model questionnaire race difference risk factor sample women's health LA - English M3 - Article N1 - L362100519 2011-07-15 PY - 2011 SN - 1055-9965 SP - 1368-1378 ST - Racial differences in colorectal cancer incidence and mortality in the women's health initiative T2 - Cancer Epidemiology Biomarkers and Prevention TI - Racial differences in colorectal cancer incidence and mortality in the women's health initiative UR - https://www.embase.com/search/results?subaction=viewrecord&id=L362100519&from=export http://dx.doi.org/10.1158/1055-9965.EPI-11-0027 http://cebp.aacrjournals.org/content/20/7/1368.full.pdf+html VL - 20 ID - 1134 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) incidence and mortality rates are higher in African-Americans as compared with other racial/ethnic groups. The women's health initiative (WHI) study sample was used to determine whether differences in CRC risk factors explain racial/ethnic differences in incidence and mortality. Methods: The WHI is a longitudinal study of postmenopausal women recruited from 40 centers. Baseline questionnaires were used to collect sociodemographic and health status information. All CRC diagnoses were centrally adjudicated. Cox regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for invasive CRC by race/ethnicity. Results: The study sample included 131,481 (83.7%) White, 14,323 (9.1%) African-American, 6,362 (4.1%) Hispanic, 694 (0.4%) Native American and 4,148 (2.6%) Asian/Pacific Islanders. After a mean follow-up of 10.8 years (SD 2.9), CRC incidence was the highest in African-Americans (annualized rate = 0.14%), followed by Whites and Native Americans (0.12% each), Asian/Pacific Islanders (0.10%), and Hispanics (0.08%). After adjustment for age and trial assignment, Hispanics had a lower risk compared with Whites, HR 0.73 (95% CI: 0.54-0.97) (P = 0.03), and African-Americans had a marginally greater risk, HR 1.16 (95% CI: 0.99-1.34), P = 0.06. Multivariable adjustment attenuated the difference in incidence between African-Americans and Whites (HR 0.99, 95% CI: 0.82-1.20), while strengthening the lower HR for Hispanics (HR 0.68, 95% CI: 0.48-0.97). Conclusions: African-American/White differences in CRC risk are likely due to sociodemographic/cultural factors other than race. Impact: A number of modifiable exposures could be a focus for reducing CRC risk in African-Americans. ©2011 AACR. AD - Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, United States Department of Pathology, Wayne State University, Detroit, MI, United States Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Cancer Biology Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Wayne State University School of Medicine, Detroit, MI, United States Arizona Cancer Center, University of Arizona, Tucson, AZ, United States Fred Hutchinson Cancer Research Center, Seattle, WA, United States Department of Preventive Medicine, Stony Brook University School of Medicine, Stony Brook, NY, United States Department of Population Health and Disease Prevention, University of California, Irvine, CA, United States University of Miami, Department of Obstetrics and Gynecology, Division of Research, Miami, FL, United States Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, United States Meharry Medical College, Nashville, TN, United States Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, United States AU - Simon, M. S. AU - Thomson, C. A. AU - Pettijohn, E. AU - Kato, I. AU - Rodabough, R. J. AU - Lane, D. AU - Hubbell, F. A. AU - O'Sullivan, M. J. AU - Adams-Campbell, L. AU - Mouton, C. P. AU - Abrams, J. AU - Chlebowski, R. T. DB - Scopus DO - 10.1158/1055-9965.EPI-11-0027 IS - 7 M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2011 SP - 1368-1378 ST - Racial differences in colorectal cancer incidence and mortality in the women's health initiative T2 - Cancer Epidemiology Biomarkers and Prevention TI - Racial differences in colorectal cancer incidence and mortality in the women's health initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960094988&doi=10.1158%2f1055-9965.EPI-11-0027&partnerID=40&md5=0e0f64564ddea7852a912434a5127bd6 VL - 20 ID - 2472 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) incidence and mortality rates are higher in African-Americans as compared with other racial/ethnic groups. The women's health initiative (WHI) study sample was used to determine whether differences in CRC risk factors explain racial/ethnic differences in incidence and mortality. Methods: The WHI is a longitudinal study of postmenopausal women recruited from 40 centers. Baseline questionnaires were used to collect sociodemographic and health status information. All CRC diagnoses were centrally adjudicated. Cox regression models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for invasive CRC by race/ethnicity. Results: The study sample included 131,481 (83.7%) White, 14,323 (9.1%) African-American, 6,362 (4.1%) Hispanic, 694 (0.4%) Native American and 4,148 (2.6%) Asian/Pacific Islanders. After a mean follow-up of 10.8 years (SD 2.9), CRC incidence was the highest in African-Americans (annualized rate 0.14%), followed by Whites and Native Americans (0.12% each), Asian/Pacific Islanders (0.10%), and Hispanics (0.08%). After adjustment for age and trial assignment, Hispanics had a lower risk compared with Whites, HR 0.73 (95% CI: 0.54-0.97) (P = 0.03), and African-Americans had a marginally greater risk, HR 1.16 (95% CI: 0.99-1.34), P = 0.06. Multivariable adjustment attenuated the difference in incidence between African-Americans and Whites (HR 0.99, 95% CI: 0.82-1.20), while strengthening the lower HR for Hispanics (HR 0.68, 95% CI: 0.48-0.97). Conclusions: African-American/White differences in CRC risk are likely due to sociodemographic/cultural factors other than race. Impact: A number of modifiable exposures could be a focus for reducing CRC risk in African-Americans. Cancer Epidemiol Biomarkers Prev; 20(7); 1368-78. (C)2011 AACR. AN - WOS:000292499700013 AU - Simon, M. S. AU - Thomson, C. A. AU - Pettijohn, E. AU - Kato, I. AU - Rodabough, R. J. AU - Lane, D. AU - Hubbell, F. A. AU - O'Sullivan, M. J. AU - Adams-Campbell, L. AU - Mouton, C. P. AU - Abrams, J. AU - Chlebowski, R. T. DA - Jul DO - 10.1158/1055-9965.EPI-11-0027 IS - 7 N1 - 21602308 PY - 2011 SN - 1055-9965 SP - 1368-1378 ST - Racial Differences in Colorectal Cancer Incidence and Mortality in the Women's Health Initiative T2 - Cancer Epidemiology Biomarkers & Prevention TI - Racial Differences in Colorectal Cancer Incidence and Mortality in the Women's Health Initiative VL - 20 ID - 3092 ER - TY - JOUR AB - BACKGROUND. Whether doctor-patient communication differs by race was investigated in patients with pulmonary nodules or lung cancer. METHODS. Eligible patients (n = 137) had pulmonary nodules or lung cancer and were seen in thoracic surgery or oncology clinics for initial treatment recommendations at a large southern Veterans Affairs Medical Center from 2001-2004. Doctor-patient consultations were audiotaped. Audiotapes were transcribed, unitized into utterances, and utterances were coded as doctors' information-giving or patients' and companions' active participation (asking questions, expressing concerns, and making assertions). Data were compared by patient race and doctor-patient racial concordance using t-tests or chi-square tests as appropriate. Mixed linear regression was used to determine the independent predictors of doctor's information-giving after controlling for clustering of patients by doctor. RESULTS. Patient age, gender, marital status, clinical site, and health status were similar by race (P > .20), but black patients were somewhat less likely to have education beyond high school and to bring a companion to the visit (P = .06) than white patients. Black patients and their companions received significantly less information from doctors (49.3 vs. 87.3 mean utterances; P < .001) and produced significantly fewer active participation utterances (21.4 vs. 37.2; P < .001) than white patients. In mixed regression analyses, after adjusting for patients' and companions' participation, clustering by doctor, and other factors, race no longer predicted information-giving (P =.54). Patients in racially discordant interactions received significantly less information and were significantly less active participants (P < .001) when compared with patients in racially concordant interactions, and after controlling for patients' participation and other factors using mixed regression, racial discordance did not predict information-giving. CONCLUSIONS. The results indicate a pattern of communication that may perpetuate patient passivity and limited information exchange where black patients and patients in discordant interactions do less to prompt doctors for information and doctors in turn provide less information to these patients. © 2006 American Cancer Society. AD - H.S. Gordon, Michael E. DeBakey Veterans Affairs Medical Center (152), 2002 Holcombe Blvd., Houston, TX 77030, United States AU - Gordon, H. S. AU - Street Jr, R. L. AU - Sharf, B. F. AU - Souchek, J. DB - Embase Medline DO - 10.1002/cncr.22122 IS - 6 KW - adult African American aged article chi square distribution doctor patient relationship female gender human information dissemination interpersonal communication linear regression analysis lung cancer major clinical study male marriage patient attitude patient participation priority journal race difference statistical significance Student t test United States LA - English M3 - Article N1 - L44452781 2006-10-10 PY - 2006 SN - 0008-543X 1097-0142 SP - 1313-1320 ST - Racial differences in doctors' information-giving and patients' participation T2 - Cancer TI - Racial differences in doctors' information-giving and patients' participation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L44452781&from=export http://dx.doi.org/10.1002/cncr.22122 VL - 107 ID - 1240 ER - TY - JOUR AB - Background: Lower enrolment of minorities into research studies has been reported frequently. Most studies have little information about nonparticipants, making it difficult to identify characteristics associated with enrolment and how they might vary by race. Methods: Women who had previously participated in a population-based, case-control study of breast cancer in North Carolina were invited to enrol in a cancer genetics registry. Detailed questionnaire data on sociodemographic characteristics and cancer risk factors were available for all women. We compared characteristics of women who agreed to be in the registry with those who were deceased, were unlocatable, or declined enrolment. Unconditional logistic regression analyses were done to identify predictors of enrolment. Results: Enrolment rates were markedly lower among African Americans than Whites (15% and 36%, respectively) due to both lower contact rates (41% versus 63%) and lower enrolment rates among those contacted (37% versus 58%). Logistic regression models suggested that racial differences in enrolment were not due to socioeconomic characteristics or other cancer risk factors; race was the only significant predictor of enrolment in multivariable models (odds ratio 0.41, 95% confidence interval 0.23-0.72). Conclusions: Although all women had previously taken part in a research study, African American women were less likely to enrol in the cancer genetics registry than White women. A possible explanation of these findings is that studies of genetics may present particular concerns for African Americans. Further research is needed to identify attitudes and issues that present barriers to participation among minorities. AN - WOS:000223155500014 AU - Moorman, P. G. AU - Skinner, C. S. AU - Evans, J. P. AU - Newman, B. AU - Sorenson, J. R. AU - Calingaert, B. AU - Susswein, L. AU - Crankshaw, T. S. AU - Hoyo, C. AU - Schildkraut, J. M. DA - Aug IS - 8 N1 - 64 15298957 PY - 2004 SN - 1055-9965 SP - 1349-1354 ST - Racial differences in enrolment in a cancer genetics registry T2 - Cancer Epidemiology Biomarkers & Prevention TI - Racial differences in enrolment in a cancer genetics registry VL - 13 ID - 2678 ER - TY - JOUR AB - Investigated the existence of different rates of surgical treatment and the possible effects of this difference on overall survival rates in Black vs White patients with early-stage lung cancer. Ss included 10,984 Black and White patients (aged 65+ yrs) who were given a diagnosis of resectable non-small-cell lung cancer (stage I or II) between 1985 and 1993 and who resided in 1 of the 10 study areas of the Surveillance, Epidemiology, and End Results (SEER) program. Results indicate that the rate of surgery was 12.7 percentage points lower for Black patients than for White patients, and the 5-year survival rate was also lower for Blacks. However, among the patients undergoing surgery, survival was similar for the 2 racial groups, as it was among those who did not undergo surgery. Furthermore, analyses in which adjustments were made for factors that are predictive of either candidacy for surgery or survival did not alter the influence of race on these outcomes. This analyses suggest that the lower survival rate among Black patients with early-stage, non-small-cell lung cancer, as compared with White patients, is largely explained by the lower rate of surgical treatment among Blacks. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1999-01267-001 AU - Bach, Peter B. AU - Cramer, Laura D. AU - Warren, Joan L. AU - Begg, Colin B. DB - psyh DO - 10.1056/NEJM199910143411606 DP - EBSCOhost IS - 16 KW - different rates of surgical treatment overall survival rate Blacks vs Whites with early-stage lung cancer African Continental Ancestry Group Aged Carcinoma, Non-Small-Cell Lung Comorbidity European Continental Ancestry Group Female Health Services Accessibility Humans Lung Lung Neoplasms Male Medicare Patient Selection Pneumonectomy SEER Program Social Class Survival Rate United States Mortality Rate Neoplasms Race and Ethnic Discrimination Surgery Treatment Outcomes Blacks Racial and Ethnic Differences Whites N1 - Memorial Sloan-Kettering Cancer Ctr, Dept of Epidemology & Biostatistics, Health Outcomes Research Group, New York, NY, US. Release Date: 19991201. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Mortality Rate; Neoplasms; Race and Ethnic Discrimination; Surgery; Treatment Outcomes. Minor Descriptor: Blacks; Lung; Racial and Ethnic Differences; Whites. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study. Page Count: 8. Issue Publication Date: Oct, 1999. PY - 1999 SN - 0028-4793 1533-4406 SP - 1198-1205 ST - Racial differences in the treatment of early-stage lung cancer T2 - The New England Journal of Medicine TI - Racial differences in the treatment of early-stage lung cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1999-01267-001&site=ehost-live&scope=site VL - 341 ID - 1768 ER - TY - JOUR AB - Objective: To determine whether racial differences exist in patient preferences for prostate cancer treatment after being informed about options using a patient‐centered vs. a standard decision aid (DA). Methods: This article reports secondary analyses of a large study of men diagnosed with early stage prostate cancer. Men were recruited from 4 VA Health Systems and randomized to receive a patient‐centered or standard DA about prostate cancer treatment options. Data were collected at 1) baseline, 2) after reading the DA but prior to diagnosis, and 3) after receiving a cancer diagnosis and meeting with a urologist. Results: White patients who received the patient‐centered DA written at a 7th grade reading level were more likely to prefer active surveillance and less likely to prefer radiation compared to those who received the standard DA written at >9th grade reading level. African American patients’ treatment preferences did not differ as a function of DA. Conclusions: When informed about prostate cancer treatment options through a patient‐centered DA, White patients changed their treatment preferences but African American patients did not. Practice Implications: As DAs are increasingly being used in clinical practice, more research is needed regarding the efficacy, relevance, and receptivity of DAs for African Americans. AN - CN-02141517 AU - Langford, A. T. AU - Scherer, L. D. AU - Ubel, P. A. AU - Holmes-Rovner, M. AU - Scherr, K. A. AU - Fagerlin, A. DO - 10.1016/j.pec.2020.06.004 KW - *African American *cancer patient *decision making *patient preference *prostate cancer *race difference *veteran Adult Article Cancer diagnosis Cancer staging Cancer therapy Case report Clinical article Clinical practice Human Male Randomized controlled trial Secondary analysis Urologist M3 - Journal: Article in Press PY - 2020 ST - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: implications for decision making in African American and White men T2 - Patient education and counseling TI - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: implications for decision making in African American and White men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02141517/full ID - 1422 ER - TY - JOUR AB - Objective: To determine whether racial differences exist in patient preferences for prostate cancer treatment after being informed about options using a patient-centered vs. a standard decision aid (DA). Methods: This article reports secondary analyses of a large study of men diagnosed with early stage prostate cancer. Men were recruited from 4 VA Health Systems and randomized to receive a patient-centered or standard DA about prostate cancer treatment options. Data were collected at 1) baseline, 2) after reading the DA but prior to diagnosis, and 3) after receiving a cancer diagnosis and meeting with a urologist. Results: White patients who received the patient-centered DA written at a 7th grade reading level were more likely to prefer active surveillance and less likely to prefer radiation compared to those who received the standard DA written at >9th grade reading level. African American patients’ treatment preferences did not differ as a function of DA. Conclusions: When informed about prostate cancer treatment options through a patient-centered DA, White patients changed their treatment preferences but African American patients did not. Practice Implications: As DAs are increasingly being used in clinical practice, more research is needed regarding the efficacy, relevance, and receptivity of DAs for African Americans. © 2020 Elsevier B.V. AD - Department of Population Health, New York University School of Medicine, New York, NY, United States Clinical and Translational Science Institute, New York University School of Medicine, New York, NY, United States Division of Cardiology, University of Colorado School of Medicine, Denver, CO, United States Colorado Program for Patient Centered Decisions at ACCORDS, University of Colorado School of Medicine, Denver, CO, United States Department of Medicine, Duke University Medical Center, Durham, NC, United States Fuqua School of Business, Duke University, Durham, NC, United States Sanford School of Public Policy, Duke University, Durham, NC, United States Center for Ethics and Department of Medicine, Michigan State University, East Lansing, MI, United States Department of Family Medicine and Community Health, Duke University Medical Center, Durham City, NC, United States Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States Salt Lake City VA Informatics Decision-Enhancement and Analytic Sciences (IDEAS) Center for Innovation, Salt Lake City, UT, United States AU - Langford, A. T. AU - Scherer, L. D. AU - Ubel, P. A. AU - Holmes-Rovner, M. AU - Scherr, K. A. AU - Fagerlin, A. DB - Scopus DO - 10.1016/j.pec.2020.06.004 IS - 12 KW - African Americans Decision making Patient preference Prostatic neoplasms Race factors Therapy M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 2460-2467 ST - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: Implications for decision making in African American and White men T2 - Patient Education and Counseling TI - Racial differences in veterans’ response to a standard vs. patient-centered decision aid for prostate cancer: Implications for decision making in African American and White men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086838152&doi=10.1016%2fj.pec.2020.06.004&partnerID=40&md5=37b147392458e287cd4927d6cbfeadc0 VL - 103 ID - 2167 ER - TY - JOUR AB - BackgroundRacial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG).MethodsWe identified 19457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided.ResultsOf 19457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P =. 007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P <. 001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P =. 002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P =. 001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten-year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early-stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early-stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer.ConclusionsAfrican American patients with sex-specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow-up. AD - K. S. Albain, Loyola University Medical Center, Cardinal Bernardin Cancer Center, 2160 South First Ave, Maywood, IL 60153-5589 AU - Albain, K. S. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A. AU - Hershman, D. L. DB - Embase Medline DO - 10.1093/jnci/djp175 IS - 14 KW - adult advanced cancer African American article breast cancer cancer survival clinical evaluation clinical trial cohort analysis colon cancer colon surgery controlled clinical trial controlled study demography disease classification disease severity education female histology human income leukemia lung cancer lymphoma major clinical study male mortality multiple myeloma neoplasm oncology ovary cancer overall survival postmenopause premenopause priority journal prognosis prospective study prostate cancer race difference randomized controlled trial risk factor social status LA - English M3 - Article N1 - L354954223 2009-07-30 PY - 2009 SN - 0027-8874 1460-2105 SP - 984-992 ST - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group T2 - Journal of the National Cancer Institute TI - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group UR - https://www.embase.com/search/results?subaction=viewrecord&id=L354954223&from=export http://dx.doi.org/10.1093/jnci/djp175 VL - 101 ID - 1188 ER - TY - JOUR AB - BackgroundRacial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG).MethodsWe identified 19457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten‐year overall survival estimates were derived by the Kaplan‐Meier method. All statistical tests were two‐sided.ResultsOf 19457 patients registered, 2308 (11.9%, range = 3.9%‐21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early‐stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P =. 007), early‐stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P <. 001), advanced‐stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P =. 002), and advanced‐stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P =. 001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten‐year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early‐stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early‐stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer.ConclusionsAfrican American patients with sex‐specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow‐up. AN - CN-01726553 AU - Albain, K. S. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A. AU - Hershman, D. L. DO - 10.1093/jnci/djp175 IS - 14 KW - *breast cancer *colon cancer /surgery *leukemia *lung cancer *lymphoma *multiple myeloma *neoplasm *ovary cancer *prostate cancer *race difference Adult Advanced cancer African American Article Cancer survival Clinical evaluation Clinical trial Cohort analysis Colon surgery Controlled clinical trial Controlled study Demography Disease classification Disease severity Education Female Histology Human Income Major clinical study Male Mortality Oncology Overall survival Postmenopause Premenopause Priority journal Prognosis Prospective study Randomized controlled trial Risk factor Social status M3 - Journal: Article PY - 2009 SP - 984‐992 ST - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group T2 - Journal of the national cancer institute TI - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01726553/full VL - 101 ID - 1445 ER - TY - JOUR AB - BackgroundRacial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG).MethodsWe identified 19457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided.ResultsOf 19457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P =. 007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P <. 001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P =. 002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P =. 001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten-year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early-stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early-stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer.ConclusionsAfrican American patients with sex-specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow-up. AD - Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, United States Southwest Oncology Group Statistical Center, Seattle, WA, United States University of Texas Health Science Center at San Antonio, San Antonio, TX, United States Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, United States Loyola University Medical Center, Cardinal Bernardin Cancer Center, 2160 South First Ave, Maywood, IL 60153-5589, United States Southwest Oncology Group, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48106-0483, United States AU - Albain, K. S. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A. AU - Hershman, D. L. DB - Scopus DO - 10.1093/jnci/djp175 IS - 14 M3 - Article N1 - Cited By :310 Export Date: 22 March 2021 PY - 2009 SP - 984-992 ST - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group T2 - Journal of the National Cancer Institute TI - Racial disparities in cancer survival among randomized clinical trials patients of the southwest oncology group UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-67650789395&doi=10.1093%2fjnci%2fdjp175&partnerID=40&md5=b453b27ecea24ed6b38d95c806cc78ef VL - 101 ID - 2518 ER - TY - JOUR AB - Racial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG). We identified 19 457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided. Of 19 457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P = .007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P < .001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P = .002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P = .001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten-year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early-stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early-stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer. African American patients with sex-specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow-up. AN - WOS:000268114300010 AU - Albain, K. S. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A. AU - Hershman, D. L. DA - Jul DO - 10.1093/jnci/djp175 IS - 14 N1 - 19584328 PY - 2009 SN - 0027-8874 SP - 984-992 ST - Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group T2 - Jnci-Journal of the National Cancer Institute TI - Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group VL - 101 ID - 3143 ER - TY - JOUR AB - Background: Racial disparities in cancer outcomes have been observed in several malignancies. However, it is unclear if survival differences persist after adjusting for clinical, demographic, and treatment variables. Our objective was to determine whether racial disparities in survival exist among patients enrolled in consecutive trials conducted by the Southwest Oncology Group (SWOG).Methods: We identified 19 457 adult cancer patients (6676 with breast, 2699 with lung, 1244 with colon, 1429 with ovarian, and 1843 with prostate cancers; 1291 with lymphoma; 2067 with leukemia; and 2208 with multiple myeloma) who were treated on 35 SWOG randomized phase III clinical trials from October 1, 1974, through November 29, 2001. Patients were grouped according to studies of diseases with similar histology and stage. Cox regression was used to evaluate the association between race and overall survival within each disease site grouping, controlling for available prognostic factors plus education and income, which are surrogates for socioeconomic status. Median and ten-year overall survival estimates were derived by the Kaplan-Meier method. All statistical tests were two-sided.Results: Of 19 457 patients registered, 2308 (11.9%, range = 3.9%-21.6%) were African American. After adjustment for prognostic factors, African American race was associated with increased mortality in patients with early-stage premenopausal breast cancer (hazard ratio [HR] for death = 1.41, 95% confidence interval [CI] = 1.10 to 1.82; P = .007), early-stage postmenopausal breast cancer (HR for death = 1.49, 95% CI = 1.28 to 1.73; P < .001), advanced-stage ovarian cancer (HR for death = 1.61, 95% CI = 1.18 to 2.18; P = .002), and advanced-stage prostate cancer (HR for death = 1.21, 95% CI = 1.08 to 1.37; P = .001). No statistically significant association between race and survival for lung cancer, colon cancer, lymphoma, leukemia, or myeloma was observed. Additional adjustments for socioeconomic status did not substantially change these observations. Ten-year (and median) overall survival rates for African American vs all other patients were 68% (not reached) vs 77% (not reached), respectively, for early-stage, premenopausal breast cancer; 52% (10.2 years) vs 62% (13.5 years) for early-stage, postmenopausal breast cancer; 13% (1.3 years) vs 17% (2.3 years) for advanced ovarian cancer; and 6% (2.2 years) vs 9% (2.7 years) for advanced prostate cancer.Conclusions: African American patients with sex-specific cancers had worse survival than white patients, despite enrollment on phase III SWOG trials with uniform stage, treatment, and follow-up. AD - Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA. kalbain@lumc.edu AN - 105384116. Language: English. Entry Date: 20090807. Revision Date: 20200708. Publication Type: journal article AU - Albain, K. S. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A., Jr. AU - Hershman, D. L. AU - Albain, Kathy S. AU - Unger, Joseph M. AU - Crowley, John J. AU - Coltman, Charles A., Jr. AU - Hershman, Dawn L. DB - CINAHL Complete DO - 10.1093/jnci/djp175 DP - EBSCOhost IS - 14 KW - Black Persons -- Statistics and Numerical Data Health Status Neoplasms -- Mortality Adult Aged Breast Neoplasms -- Mortality Clinical Trials Colorectal Neoplasms -- Mortality Confidence Intervals Confounding Variable Cox Proportional Hazards Model Educational Status Female Income Kaplan-Meier Estimator Leukemia -- Mortality Lung Neoplasms -- Mortality Lymphoma -- Mortality Male Middle Age Multiple Myeloma -- Mortality Neoplasm Staging Neoplasms -- Pathology Neoplasms -- Therapy Odds Ratio Ovarian Neoplasms -- Mortality Prognosis Prostatic Neoplasms -- Mortality Risk Assessment Risk Factors Socioeconomic Factors Survival United States White Persons -- Statistics and Numerical Data Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: CA32102/CA/NCI NIH HHS/United States. NLM UID: 7503089. PMID: NLM19584328. PY - 2009 SN - 0027-8874 SP - 984-992 ST - Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group T2 - JNCI: Journal of the National Cancer Institute TI - Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105384116&site=ehost-live&scope=site VL - 101 ID - 2043 ER - TY - JOUR AB - Introduction African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment. Purpose In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non‐African American men. Methods This analysis includes 317 men (African American: n=30, 9%; non‐African American: n=287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow‐up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model. Results Results showed significantly higher levels of traumatic stress for African American men compared to non‐African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score ≥27). These elevations remained across all time points over 24 months. Conclusions This is the first study to showa racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population. © 2011 Springer‐Verlag. AN - CN-00887809 AU - Purnell, J. Q. AU - Palesh, O. G. AU - Heckler, C. E. AU - Adams, M. J. AU - Chin, N. AU - Mohile, S. AU - Peppone, L. J. AU - Atkins, J. N. AU - Moore, D. F. AU - Spiegel, D. AU - et al. DO - 10.1007/s00520-010-0880-3 IS - 7 KW - *posttraumatic stress disorder /therapy *prostate cancer /drug therapy /drug therapy /surgery *race difference Adult African American Aged Article Cancer staging Controlled study Demography Educational status Employment status Follow up Group therapy Human Impact of Events Scale Income Major clinical study Male Marriage Orchiectomy Patient education Prevalence Priority journal Profile of Mood States Psychotherapy Randomized controlled trial Secondary analysis Social psychology Time M3 - Journal: Article PY - 2011 SP - 899‐907 ST - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men T2 - Supportive care in cancer TI - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00887809/full VL - 19 ID - 1451 ER - TY - JOUR AB - Introduction African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment. Purpose In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non-African American men. Methods This analysis includes 317 men (African American: n=30, 9%; non-African American: n=287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow-up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model. Results Results showed significantly higher levels of traumatic stress for African American men compared to non-African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score ≥27). These elevations remained across all time points over 24 months. Conclusions This is the first study to showa racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population. © 2011 Springer-Verlag. AD - J.Q. Purnell, Washington University in St. Louis, Health Communication Research Laboratory, Campus Box 1009, 700 Rosedale Ave., St. Louis, MO 63112, United States AU - Purnell, J. Q. AU - Palesh, O. G. AU - Heckler, C. E. AU - Adams, M. J. AU - Chin, N. AU - Mohile, S. AU - Peppone, L. J. AU - Atkins, J. N. AU - Moore, D. F. AU - Spiegel, D. AU - Messing, E. AU - Morrow, G. R. DB - Embase Medline DO - 10.1007/s00520-010-0880-3 IS - 7 KW - bicalutamide flutamide gonadorelin agonist adult African American aged article cancer staging controlled study demography educational status employment status follow up group therapy human Impact of Events Scale income major clinical study male marriage orchiectomy patient education posttraumatic stress disorder prevalence priority journal Profile of Mood States prostate cancer psychotherapy race difference randomized controlled trial secondary analysis social psychology time LA - English M3 - Article N1 - L50884537 2010-04-27 2011-08-24 PY - 2011 SN - 0941-4355 1433-7339 SP - 899-907 ST - Racial disparities in traumatic stress in prostate cancer patients: Secondary analysis of a National URCC CCOP Study of 317 men T2 - Supportive Care in Cancer TI - Racial disparities in traumatic stress in prostate cancer patients: Secondary analysis of a National URCC CCOP Study of 317 men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50884537&from=export http://dx.doi.org/10.1007/s00520-010-0880-3 VL - 19 ID - 1136 ER - TY - JOUR AB - Introduction African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment. Purpose In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non-African American men. Methods This analysis includes 317 men (African American: n=30, 9%; non-African American: n=287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow-up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model. Results Results showed significantly higher levels of traumatic stress for African American men compared to non-African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score ≥27). These elevations remained across all time points over 24 months. Conclusions This is the first study to showa racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population. © 2011 Springer-Verlag. AD - Washington University in St. Louis, Health Communication Research Laboratory, Campus Box 1009, 700 Rosedale Ave., St. Louis, MO 63112, United States University of Rochester Cancer Center CCOP Research Base, Rochester, NY, United States University of Rochester School of Medicine and Dentistry, Rochester, NY, United States Southeast Cancer Control Consortium, Winston-Salem, NC, United States Wichita CCOP, Wichita, KS, United States Stanford University School of Medicine, Palo Alto, CA, United States AU - Purnell, J. Q. AU - Palesh, O. G. AU - Heckler, C. E. AU - Adams, M. J. AU - Chin, N. AU - Mohile, S. AU - Peppone, L. J. AU - Atkins, J. N. AU - Moore, D. F. AU - Spiegel, D. AU - Messing, E. AU - Morrow, G. R. DB - Scopus DO - 10.1007/s00520-010-0880-3 IS - 7 KW - African American Health disparities Prostate cancer PTSD Traumatic stress M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2011 SP - 899-907 ST - Racial disparities in traumatic stress in prostate cancer patients: Secondary analysis of a National URCC CCOP Study of 317 men T2 - Supportive Care in Cancer TI - Racial disparities in traumatic stress in prostate cancer patients: Secondary analysis of a National URCC CCOP Study of 317 men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-80051593548&doi=10.1007%2fs00520-010-0880-3&partnerID=40&md5=62b1a73f1132972cf6c1006755c33179 VL - 19 ID - 2471 ER - TY - JOUR AB - African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment. In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non-African American men. This analysis includes 317 men (African American: n = 30, 9%; non-African American: n = 287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow-up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model. Results showed significantly higher levels of traumatic stress for African American men compared to non-African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score a parts per thousand yen27). These elevations remained across all time points over 24 months. This is the first study to show a racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population. AN - WOS:000291357100005 AU - Purnell, J. Q. AU - Palesh, O. G. AU - Heckler, C. E. AU - Adams, M. J. AU - Chin, N. AU - Mohile, S. AU - Peppone, L. J. AU - Atkins, J. N. AU - Moore, D. F. AU - Spiegel, D. AU - Messing, E. AU - Morrow, G. R. DA - Jul DO - 10.1007/s00520-010-0880-3 IS - 7 N1 - 20414685 PY - 2011 SN - 0941-4355 SP - 899-907 ST - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men T2 - Supportive Care in Cancer TI - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men VL - 19 ID - 3093 ER - TY - JOUR AB - Introduction: African American men have the highest rates of prostate cancer of any racial group, but very little is known about the psychological functioning of African American men in response to prostate cancer diagnosis and treatment.Purpose: In this secondary analysis of a national trial testing a psychological intervention for prostate cancer patients, we report on the traumatic stress symptoms of African American and non-African American men.Methods: This analysis includes 317 men (African American: n = 30, 9%; non-African American: n = 287, 91%) who were enrolled in the intervention trial, which included 12 weeks of group psychotherapy and 24 months of follow-up. Using mixed model analysis, total score on the Impact of Events Scale (IES) and its Intrusion and Avoidance subscales were examined to determine mean differences in traumatic stress across all time points (0, 3, 6, 12, 18, and 24 months). In an additional analysis, relevant psychosocial, demographic, and clinical variables were added to the model.Results: Results showed significantly higher levels of traumatic stress for African American men compared to non-African American men in all models independently of the intervention arm, demographics, and relevant clinical variables. African Americans also had a consistently higher prevalence of clinically significant traumatic stress symptoms (defined as IES total score ≥ 27). These elevations remained across all time points over 24 months.Conclusions: This is the first study to show a racial disparity in traumatic stress specifically as an aspect of overall psychological adjustment to prostate cancer. Recommendations are made for appropriate assessment, referral, and treatment of psychological distress in this vulnerable population. AD - Washington University in St. Louis, Health Communication Research Laboratory, 700 Rosedale Ave., Campus Box 1009, St. Louis, MO 63112, USA AN - 104806317. Language: English. Entry Date: 20111021. Revision Date: 20170802. Publication Type: journal article AU - Purnell, J. Q. AU - Palesh, O. G. AU - Heckler, C. E. AU - Adams, M. J. AU - Chin, N. AU - Mohile, S. AU - Peppone, L. J. AU - Atkins, J. N. AU - Moore, D. F. AU - Spiegel, D. AU - Messing, E. AU - Morrow, G. R. AU - Purnell, Jason Q. AU - Palesh, Oxana G. AU - Heckler, Charles E. AU - Adams, M. Jacob AU - Chin, Nancy AU - Mohile, Supriya AU - Peppone, Luke J. AU - Atkins, James N. DB - CINAHL Complete DO - 10.1007/s00520-010-0880-3 DP - EBSCOhost IS - 7 KW - Black Persons -- Statistics and Numerical Data Health Status Prostatic Neoplasms -- Psychosocial Factors Stress Disorders, Post-Traumatic -- Psychosocial Factors Stress, Psychological White Persons -- Statistics and Numerical Data Adaptation, Psychological Adult Aged Aged, 80 and Over Health Status Indicators Impact of Events Scale Male Middle Age Prostatic Neoplasms -- Epidemiology Psychological Tests Psychometrics Quality of Life -- Psychosocial Factors Scales Stress Disorders, Post-Traumatic -- Epidemiology United States N1 - research. Journal Subset: Biomedical; Continental Europe; Double Blind Peer Reviewed; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed. Special Interest: Oncologic Care. Instrumentation: Impact of Events Scale (IES). Grant Information: CA037420/CA/NCI NIH HHS/United States. NLM UID: 9302957. PMID: NLM20414685. PY - 2011 SN - 0941-4355 SP - 899-907 ST - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men T2 - Supportive Care in Cancer TI - Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104806317&site=ehost-live&scope=site VL - 19 ID - 2044 ER - TY - JOUR AB - PURPOSE: Black women with breast cancer have poorer survival than do white women, but little is known about racial disparities in male breast cancer. We analyzed race and other predictors of treatment and survival among men with stage I-III breast cancer. PATIENTS AND METHODS: We used the Surveillance, Epidemiology, and End Results (SEER) Medicare database to identify men 65 years of age or older diagnosed with stage I-III breast cancer from 1991 to 2002. Multivariate regression was used to compare those treated with those not treated with either chemotherapy or radiation therapy, adjusting for known clinical and demographic factors. Cox proportional hazards regression models were used to analyze survival. RESULTS: Of 510 male breast cancer cases (456 white, 34 black), 94% underwent mastectomy, 28% received adjuvant chemotherapy, and 29% received radiation therapy. Among those with known hormone receptors, 95% had hormone-sensitive tumors. In a multivariate analysis, chemotherapy was associated with younger age, advanced stage, and hormone receptor-negative tumors. Radiation therapy was associated with younger age and advanced stage. Black men were approximately 50% less likely to undergo consultation with an oncologist and subsequently receive chemotherapy; however, the results did not reach statistical significance. The breast cancer-specific mortality hazard ratio was more than tripled for black versus white men (hazard ratio = 3.29; 95% CI, 1.10 to 9.86). CONCLUSION: After adjustment for known clinical, demographic, and treatment factors, there was an association of black race with increased male breast cancer-specific mortality. Although male breast cancer is rare, the reasons for these disparities need to be better understood. AN - 105950544. Language: English. Entry Date: 20080201. Revision Date: 20150711. Publication Type: Journal Article AU - Crew, K. D. AU - Neugut, A. I. AU - Wang, X. AU - Jacobson, J. S. AU - Grann, V. R. AU - Raptis, G. AU - Hershman, D. L. DB - CINAHL Complete DP - EBSCOhost IS - 9 KW - Black Persons Breast Neoplasms, Male -- Mortality Breast Neoplasms, Male -- Therapy White Persons Age Factors Aged Aged, 80 and Over Breast Neoplasms, Male -- Ethnology Breast Neoplasms, Male -- Pathology Chemotherapy, Adjuvant Cox Proportional Hazards Model Kaplan-Meier Estimator Male Mastectomy Medicare Neoplasm Staging Odds Ratio Patient Selection Predictive Value of Tests Prognosis Prospective Studies Radiotherapy, Adjuvant Referral and Consultation Time Factors Treatment Outcomes United States Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM17369572. PY - 2007 SN - 0732-183X SP - 1089-1098 ST - Racial disparities in treatment and survival of male breast cancer T2 - Journal of Clinical Oncology TI - Racial disparities in treatment and survival of male breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105950544&site=ehost-live&scope=site VL - 25 ID - 2045 ER - TY - JOUR AB - Background African Americans (AAs) in the United States are known to have a higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological disparity are multifactorial, including socioeconomic factors leading to lifestyle and dietary issues, healthcare access problems, and potentially tumor biology. Recent findings Although recent evidence suggests once access is equal, AA men have equal outcomes to Caucasian American (CA) men, differences in PCa incidence remain, and there is much to do to reverse disparities in mortality across the USA. A deeper understanding of these issues, both at the clinical and molecular level, can facilitate improved outcomes in the AA population. This review first discusses PCa oncogenesis in the context of its diverse hallmarks before benchmarking key molecular and genomic differences for PCa in AA men that have emerged in the recent literature. Studies have emphasized the importance of tumor microenvironment that contributes to both the unequal cancer burden and differences in clinical outcome between the races. Management of comorbidities like obesity, hypertension, and diabetes will provide an essential means of reducing prostate cancer incidence in AA men. Although requiring further AA specific research, several new treatment strategies such as immune checkpoint inhibitors used in combination PARP inhibitors and other emerging vaccines, including Sipuleucel-T, have demonstrated some proven efficacy. Conclusion Genomic profiling to integrate clinical and genomic data for diagnosis, prognosis, and treatment will allow physicians to plan a "Precision Medicine" approach to AA men. There is a pressing need for further research for risk stratification, which may allow early identification of AA men with higher risk disease based on their unique clinical, genomic, and immunological profiles, which can then be mapped to appropriate clinical trials. Treatment options are outlined, with a concise description of recent work in AA specific populations, detailing several targeted therapies, including immunotherapy. Also, a summary of current clinical trials involving AA men is presented, and it is important that policies are adopted to ensure that AA men are actively recruited. Although it is encouraging that many of these explore the lifestyle and educational initiatives and therapeutic interventions, there is much still work to be done to reduce incidence and mortality in AA men and equalize current racial disparities. AN - WOS:000620125300001 AU - Dovey, Z. S. AU - Nair, S. S. AU - Chakravarty, D. AU - Tewari, A. K. DO - 10.1002/cnr2.1340 N1 - e1341 33599076 ST - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies T2 - Cancer Reports TI - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies ID - 2745 ER - TY - JOUR AB - Background: African Americans (AAs) in the United States are known to have a higher incidence and mortality for Prostate Cancer (PCa). The drivers of this epidemiological disparity are multifactorial, including socioeconomic factors leading to lifestyle and dietary issues, healthcare access problems, and potentially tumor biology. Recent findings: Although recent evidence suggests once access is equal, AA men have equal outcomes to Caucasian American (CA) men, differences in PCa incidence remain, and there is much to do to reverse disparities in mortality across the USA. A deeper understanding of these issues, both at the clinical and molecular level, can facilitate improved outcomes in the AA population. This review first discusses PCa oncogenesis in the context of its diverse hallmarks before benchmarking key molecular and genomic differences for PCa in AA men that have emerged in the recent literature. Studies have emphasized the importance of tumor microenvironment that contributes to both the unequal cancer burden and differences in clinical outcome between the races. Management of comorbidities like obesity, hypertension, and diabetes will provide an essential means of reducing prostate cancer incidence in AA men. Although requiring further AA specific research, several new treatment strategies such as immune checkpoint inhibitors used in combination PARP inhibitors and other emerging vaccines, including Sipuleucel-T, have demonstrated some proven efficacy. Conclusion: Genomic profiling to integrate clinical and genomic data for diagnosis, prognosis, and treatment will allow physicians to plan a “Precision Medicine” approach to AA men. There is a pressing need for further research for risk stratification, which may allow early identification of AA men with higher risk disease based on their unique clinical, genomic, and immunological profiles, which can then be mapped to appropriate clinical trials. Treatment options are outlined, with a concise description of recent work in AA specific populations, detailing several targeted therapies, including immunotherapy. Also, a summary of current clinical trials involving AA men is presented, and it is important that policies are adopted to ensure that AA men are actively recruited. Although it is encouraging that many of these explore the lifestyle and educational initiatives and therapeutic interventions, there is much still work to be done to reduce incidence and mortality in AA men and equalize current racial disparities. AD - Z.S. Dovey, The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States S.S. Nair, The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States A.K. Tewari, The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, United States AU - Dovey, Z. S. AU - Nair, S. S. AU - Chakravarty, D. AU - Tewari, A. K. DB - Embase Medline DO - 10.1002/cnr2.1340 KW - adult African American benchmarking cancer incidence cancer prognosis carcinogenesis clinical outcome comorbidity diabetes mellitus diet drug combination European American genetic susceptibility health care access human hypertension immunotherapy lifestyle male molecularly targeted therapy mortality obesity personalized medicine physician prognosis prostate cancer protein fingerprinting race review socioeconomics tumor microenvironment biological marker immune checkpoint inhibitor nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor sipuleucel T LA - English M3 - Article in Press N1 - L2010525134 2021-02-24 PY - 2021 SN - 2573-8348 ST - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies T2 - Cancer Reports TI - Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010525134&from=export http://dx.doi.org/10.1002/cnr2.1340 ID - 765 ER - TY - JOUR AB - Comments on the article by P. B. Bach et al (see record [rid]1999-01267-001[/rid]), which showed that after accounting for the confounding effects of sex, coexisting illness, socioeconomic status, insurance coverage, and availability of care, Black patients were less likely than White patients with early-stage lung cancer to undergo surgical resection. The authors of the present article address the fact that in Bach et al 35.4% of the Black patients were excluded from the study due to inadequate tumor documentation, a crucial step in treatment. The authors believe that in the future more effective screening will make surgical resection for early-stage lung caner more important, and that any racial disparity in resection rates, if not corrected, will be even more glaring. Therefore any barrier preventing Blacks from using the health care system for the prevention, diagnosis, and treatment of cancer must be removed. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AN - 1999-01267-002 AU - King, Talmadge E., Jr. AU - Brunetta, Paul DB - psyh DO - 10.1056/NEJM199910143411612 DP - EBSCOhost IS - 16 KW - different rates of surgical treatment overall survival rate Blacks vs Whites with early-stage lung cancer comment African Continental Ancestry Group Aged Biomedical Research Carcinoma, Non-Small-Cell Lung European Continental Ancestry Group Health Services Accessibility Humans Lung Neoplasms Patient Selection Physician-Patient Relations Prejudice Survival Rate United States Mortality Rate Neoplasms Race and Ethnic Discrimination Surgery Treatment Outcomes Blacks Lung Racial and Ethnic Differences Whites Racial Disparities N1 - U California, San Francisco, CA, US. Release Date: 19991201. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Comment/Reply. Language: English. Major Descriptor: Mortality Rate; Neoplasms; Race and Ethnic Discrimination; Surgery; Treatment Outcomes. Minor Descriptor: Blacks; Lung; Racial and Ethnic Differences; Whites; Racial Disparities. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Page Count: 3. Issue Publication Date: Oct, 1999. PY - 1999 SN - 0028-4793 1533-4406 SP - 1231-1233 ST - Racial disparity in rates of surgery for lung cancer T2 - The New England Journal of Medicine TI - Racial disparity in rates of surgery for lung cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1999-01267-002&site=ehost-live&scope=site VL - 341 ID - 1769 ER - TY - JOUR AB - Background Relatively little is known about the relationship between race/ethnicity and patient‐reported outcomes after contemporary treatments for localized prostate cancer. Objective To test the hypothesis that treatment‐related changes in urinary, bowel, sexual, and hormonal function vary by race/ethnicity. Design, setting, and participants The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population‐based, observational study that enrolled 3708 men diagnosed with localized prostate cancer in 2011‐2012. Outcome measurements and statistical analysis Patient‐reported disease‐specific function was measured using the 26‐item Expanded Prostate Index Composite (EPIC) at baseline and 6 and 12 mo after enrollment. Mean treatment differences in function were compared by race using risk‐adjusted generalized estimating equations. Results and limitations While all race/ethnic groups reported considerable declines in scores for urinary incontinence after radical prostatectomy (RP) when compared to active surveillance, African‐American men reported a greater difference than white men did (adjusted difference‐in‐differences 8.4 points, 95% confidence interval 2.0‐14.8; p = 0.01). No difference in bother scores was noted and the overall proportion of explained variation attributable to race/ethnicity was relatively small in comparison to primary treatment and baseline function. No clinically significant racial variation was noted for the sexual, bowel, irritative voiding, or hormone domains. Limitations include the lack of well‐established thresholds for clinical significance using the EPIC instrument. Conclusion While these data demonstrate that incontinence at 1 yr after RP may be worse for African‐American compared to white men, the difference appears to be modest overall. Treatment selection and baseline function explain a much greater proportion of the variation in function after treatment. Patient summary We observed that the effect of treatment for prostate cancer on patient‐reported function did not vary dramatically by race/ethnicity. Compared to white men, African‐American men experienced a somewhat more pronounced decline in urinary continence after radical prostatectomy, but the corresponding changes in bother scores were not significantly different between the two groups. Copyright © 2016 European Association of Urology AN - CN-01393747 AU - Tyson, M. D. AU - Alvarez, J. AU - Koyama, T. AU - Hoffman, K. E. AU - Resnick, M. J. AU - Wu, X. C. AU - Cooperberg, M. R. AU - Goodman, M. AU - Greenfield, S. AU - Hamilton, A. S. AU - et al. DO - 10.1016/j.eururo.2016.10.036 IS - 2 KW - *ethnic difference *patient reported outcome *prostate cancer/rt [Radiotherapy] *prostate cancer/su [Surgery] *race difference Adult African American Aged Article Cancer patient Cancer radiotherapy Cancer surgery Caucasian Comparative effectiveness Controlled clinical trial Controlled study Expanded Prostate Index Composite Genital system disease assessment Hispanic Human Intensity modulated radiation therapy Intestine function Kidney function Longitudinal study Major clinical study Male Observational study Priority journal Prospective study Prostate specific antigen/ec [Endogenous Compound] Prostatectomy Sensitivity analysis Sexual function Urine incontinence/co [Complication] M3 - Article PY - 2017 SP - 307‐314 ST - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: results from the CEASAR Study T2 - European urology TI - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: results from the CEASAR Study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01393747/full VL - 72 ID - 1563 ER - TY - JOUR AB - Background Relatively little is known about the relationship between race/ethnicity and patient-reported outcomes after contemporary treatments for localized prostate cancer. Objective To test the hypothesis that treatment-related changes in urinary, bowel, sexual, and hormonal function vary by race/ethnicity. Design, setting, and participants The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based, observational study that enrolled 3708 men diagnosed with localized prostate cancer in 2011–2012. Outcome measurements and statistical analysis Patient-reported disease-specific function was measured using the 26-item Expanded Prostate Index Composite (EPIC) at baseline and 6 and 12 mo after enrollment. Mean treatment differences in function were compared by race using risk-adjusted generalized estimating equations. Results and limitations While all race/ethnic groups reported considerable declines in scores for urinary incontinence after radical prostatectomy (RP) when compared to active surveillance, African-American men reported a greater difference than white men did (adjusted difference-in-differences 8.4 points, 95% confidence interval 2.0–14.8; p = 0.01). No difference in bother scores was noted and the overall proportion of explained variation attributable to race/ethnicity was relatively small in comparison to primary treatment and baseline function. No clinically significant racial variation was noted for the sexual, bowel, irritative voiding, or hormone domains. Limitations include the lack of well-established thresholds for clinical significance using the EPIC instrument. Conclusion While these data demonstrate that incontinence at 1 yr after RP may be worse for African-American compared to white men, the difference appears to be modest overall. Treatment selection and baseline function explain a much greater proportion of the variation in function after treatment. Patient summary We observed that the effect of treatment for prostate cancer on patient-reported function did not vary dramatically by race/ethnicity. Compared to white men, African-American men experienced a somewhat more pronounced decline in urinary continence after radical prostatectomy, but the corresponding changes in bother scores were not significantly different between the two groups. AD - M.D. Tyson, Department of Urologic Surgery, Vanderbilt University Medical Center, A1302 Medical Center North, Nashville, TN, United States AU - Tyson, M. D. AU - Alvarez, J. AU - Koyama, T. AU - Hoffman, K. E. AU - Resnick, M. J. AU - Wu, X. C. AU - Cooperberg, M. R. AU - Goodman, M. AU - Greenfield, S. AU - Hamilton, A. S. AU - Hashibe, M. AU - Paddock, L. E. AU - Stroup, A. AU - Chen, V. W. AU - Penson, D. F. AU - Barocas, D. A. DB - Embase Medline DO - 10.1016/j.eururo.2016.10.036 IS - 2 KW - NCT0136286 prostate specific antigen adult African American aged article cancer patient cancer radiotherapy cancer surgery Caucasian comparative effectiveness controlled clinical trial controlled study ethnic difference Expanded Prostate Index Composite genital system disease assessment Hispanic human intensity modulated radiation therapy intestine function kidney function longitudinal study major clinical study male observational study patient-reported outcome priority journal prospective study prostate cancer prostatectomy race difference sensitivity analysis sexual function urine incontinence LA - English M3 - Article N1 - L613729363 2016-12-20 2017-07-26 PY - 2017 SN - 1873-7560 0302-2838 SP - 307-314 ST - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study T2 - European Urology TI - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613729363&from=export http://dx.doi.org/10.1016/j.eururo.2016.10.036 VL - 72 ID - 931 ER - TY - JOUR AB - Background Relatively little is known about the relationship between race/ethnicity and patient-reported outcomes after contemporary treatments for localized prostate cancer. Objective To test the hypothesis that treatment-related changes in urinary, bowel, sexual, and hormonal function vary by race/ethnicity. Design, setting, and participants The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based, observational study that enrolled 3708 men diagnosed with localized prostate cancer in 2011–2012. Outcome measurements and statistical analysis Patient-reported disease-specific function was measured using the 26-item Expanded Prostate Index Composite (EPIC) at baseline and 6 and 12 mo after enrollment. Mean treatment differences in function were compared by race using risk-adjusted generalized estimating equations. Results and limitations While all race/ethnic groups reported considerable declines in scores for urinary incontinence after radical prostatectomy (RP) when compared to active surveillance, African-American men reported a greater difference than white men did (adjusted difference-in-differences 8.4 points, 95% confidence interval 2.0–14.8; p = 0.01). No difference in bother scores was noted and the overall proportion of explained variation attributable to race/ethnicity was relatively small in comparison to primary treatment and baseline function. No clinically significant racial variation was noted for the sexual, bowel, irritative voiding, or hormone domains. Limitations include the lack of well-established thresholds for clinical significance using the EPIC instrument. Conclusion While these data demonstrate that incontinence at 1 yr after RP may be worse for African-American compared to white men, the difference appears to be modest overall. Treatment selection and baseline function explain a much greater proportion of the variation in function after treatment. Patient summary We observed that the effect of treatment for prostate cancer on patient-reported function did not vary dramatically by race/ethnicity. Compared to white men, African-American men experienced a somewhat more pronounced decline in urinary continence after radical prostatectomy, but the corresponding changes in bother scores were not significantly different between the two groups. © 2016 European Association of Urology AD - Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, United States Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, United States Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, United States The Geriatric Research, Education and Clinical Center, Tennessee Valley Veterans Affairs Health Care System, Nashville, TN, United States School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, United States Department of Urology, University of California, San Francisco Medical Center, San Francisco, CA, United States Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States Center for Health Policy Research and Department of Medicine, University of California, Irvine, CA, United States Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States Department of Family and Preventive Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States AU - Tyson, M. D. AU - Alvarez, J. AU - Koyama, T. AU - Hoffman, K. E. AU - Resnick, M. J. AU - Wu, X. C. AU - Cooperberg, M. R. AU - Goodman, M. AU - Greenfield, S. AU - Hamilton, A. S. AU - Hashibe, M. AU - Paddock, L. E. AU - Stroup, A. AU - Chen, V. W. AU - Penson, D. F. AU - Barocas, D. A. DB - Scopus DO - 10.1016/j.eururo.2016.10.036 IS - 2 KW - Active surveillance Comparative effectiveness Patient-reported function Prostate cancer Radiation Surgery M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2017 SP - 307-314 ST - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study T2 - European Urology TI - Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85005769272&doi=10.1016%2fj.eururo.2016.10.036&partnerID=40&md5=51a0a61d8a6f1d12c5b78ac0bffcfd54 VL - 72 ID - 2304 ER - TY - JOUR AB - BACKGROUND This study examined racial/ethnic differences among patients in clinical trial (CT) enrollment, refusal rates, ineligibility, and desire to participate in research within the National Cancer Institute's Community Cancer Centers Program (NCCCP) Clinical Trial Screening and Accrual Log. METHODS Data from 4509 log entries were evaluated in this study. Four logistic regression models were run using physical/medical conditions, enrollment into a CT, patient eligible but declined a CT, and no desire to participate in research as dependent variables. RESULTS Age ≥ 65 years (OR = 1.51, 95% CI = 1.28-1.79), males (OR = 2.28, 95% CI = 1.92-2.71), and non-Hispanic black race (OR = 1.53, 95% CI = 1.2-1.96) were significantly associated with more physical/medical conditions. Age ≥ 65 years was significantly associated with lower CT enrollment (OR = 0.83, 95% CI = 0.7-0.98). Males (OR = 0.78, 95% CI = 0.65-0.94) and a higher grade level score for consent form readability (OR = 0.9, 95% CI = 0.83-0.97) were significantly associated with lower refusal rates. Consent page length ≥ 20 was significantly associated with lower odds of "no desire to participate in research" among CT decliners (OR = 0.75, 95% CI = 0.58-0.98). CONCLUSIONS There were no racial/ethnic differences in CT enrollment, refusal rates, or "no desire to participate in research" as the reason given for CT refusal. Higher odds of physical/medical conditions were associated with older age, males, and non-Hispanic blacks. Better management of physical/medical conditions before and during treatment may increase the pool of eligible patients for CTs. Future work should examine the role of comorbidities, sex, age, and consent form characteristics on CT participation. Cancer 2014;120:877-884. © 2013 American Cancer Society. There were no racial/ethnic differences in clinical trial (CT) enrollment, refusal rates, or "no desire to participate in research" as the reason given for CT refusal; however, higher odds of physical/medical conditions were associated with older age, males, and non-Hispanic blacks. Better management of physical/medical conditions before and during treatment may increase the pool of eligible patients for CTs. © 2013 American Cancer Society. AD - University of Michigan, School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, United States Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States EMMES Corporation, Rockville, MD, United States Clinical Research Directorate/CMRP, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States Billings Clinic Cancer Center, Billings, MN, United States Gundersen Health System, La Crosse, WI, United States AU - Langford, A. T. AU - Resnicow, K. AU - Dimond, E. P. AU - Denicoff, A. M. AU - Germain, D. S. AU - McCaskill-Stevens, W. AU - Enos, R. A. AU - Carrigan, A. AU - Wilkinson, K. AU - Go, R. S. DB - Scopus DO - 10.1002/cncr.28483 IS - 6 KW - African Americans cancer clinical trials Hispanic medical research minorities racial/ethnic M3 - Article N1 - Cited By :45 Export Date: 22 March 2021 PY - 2014 SP - 877-884 ST - Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program T2 - Cancer TI - Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896731433&doi=10.1002%2fcncr.28483&partnerID=40&md5=4f024027474bed057501603750273f80 VL - 120 ID - 2397 ER - TY - JOUR AB - Background: Five-year breast cancer survival rates are lower among Hispanic and African-American women than among Non-Hispanic White women. Differences in breast cancer treatment likely play a role. Adjuvant hormonal therapies increase overall survival among women with hormone receptor-positive breast cancer. Methods: We examined racial/ethnic differences in use and duration of adjuvant hormonal therapy among 3,588 postmenopausal women enrolled in the Women's Health Initiative (WHI) Extension Study. Women diagnosed with hormone receptor-positive localized or regional stage breast cancer after study enrollment were surveyed between September 2009 and August 2010 and asked to recall prior use and duration of adjuvant hormonal breast cancer therapy. ORs comparing self-reported use and duration with race/ethnicity (Hispanic, African-American, Asian/Pacific Islander vs. Non-Hispanic White) were estimated using multivariableadjusted logistic regression. Results: Of the 3,588 women diagnosed from 1994 to 2009; 3,039 (85%) reported any use of adjuvant hormonal therapy, and 67% of women reporting ever-use who were diagnosed before 2005 reported using adjuvant hormonal therapy for the optimal duration of 5 years or more. In adjusted analysis, no statistically significant differences in use or duration by race/ethnicity were observed. Conclusions: This study did not find significant differences in use or duration of use of adjuvant hormonal therapy by race/ethnicity. Impact: Findings should be confirmed in other population-based samples, and potential reasons for discontinuation of therapy across all racial/ethnic groups should be explored. © 2013 American Association for Cancer Research. AD - Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, United States University of Washington School of Public Health, Seattle, WA, United States David Geffen School of Medicine, University of California, Los Angeles, United States Kaiser Division of Research, Oakland, CA, United States Karmanos Cancer Center, Detroit, MI, United States School of Public Health and Health Professions, State University of New York at Buffalo, Buffalo, NY, United States School of Medicine, University of California, Irvine, CA, United States Center for Health Research, Kaiser Permanente Northwest, Portland, OR, United States AU - Livaudais, J. C. AU - LaCroix, A. AU - Chlebowski, R. T. AU - Li, C. I. AU - Habel, L. A. AU - Simon, M. S. AU - Thompson, B. AU - Erwin, D. O. AU - Hubbell, F. A. AU - Coronado, G. D. DB - Scopus DO - 10.1158/1055-9965.EPI-12-1225 IS - 3 M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2013 SP - 365-373 ST - Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative T2 - Cancer Epidemiology Biomarkers and Prevention TI - Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876528190&doi=10.1158%2f1055-9965.EPI-12-1225&partnerID=40&md5=3be189a53f53185b913ebe93be448217 VL - 22 ID - 2438 ER - TY - JOUR AB - Objectives: To summarize the ongoing Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. Design: PREADViSE was designed as a double blind randomized controlled trial (RCT). Setting: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. Participants: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 μg of selenium or placebo using a 2x2 factorial structure. Measurements: In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a Modified Telephone Interview of Cognitive Status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes. Results: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. Conclusion: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. © 2012 Serdi and Springer Verlag France. AD - R.J. Kryscio, University of Kentucky Sanders-Brown Center on Aging, Lexington, KY, United States AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DB - Embase DO - 10.1007/s12603-012-0083-3 KW - placebo alpha tocopherol selenium antioxidant telephone screening prophylaxis prevention study exposure Alzheimer disease prevention human male dementia tic memory disorder African American procedures memory examination randomized controlled trial physician prostate cancer diagnosis cancer prevention teleconsultation medical examination register consensus turnover rate family history education volunteer cognitive defect long term exposure oncology neoplasm clinical trial France LA - English M3 - Article in Press N1 - L52121689 2012-07-23 PY - 2012 SN - 1279-7707 1760-4788 SP - 1-4 ST - A randomized controlled Alzheimer's disease Prevention trial's evolution into an exposure trial: The Preadvise trial T2 - Journal of Nutrition, Health and Aging TI - A randomized controlled Alzheimer's disease Prevention trial's evolution into an exposure trial: The Preadvise trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52121689&from=export http://dx.doi.org/10.1007/s12603-012-0083-3 ID - 1111 ER - TY - JOUR AB - Objectives: To summarize the ongoing Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. Design: PREADViSE was designed as a double blind randomized controlled trial (RCT). Setting: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. Participants: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 μg of selenium or placebo using a 2x2 factorial structure. Measurements: In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS‐T) screen. If they fail the MIS‐T, a Modified Telephone Interview of Cognitive Status (TICS‐M) exam is given. A failed TICS‐M exam also leads to a visit to their clinician for an in‐depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS‐T also take the TICS‐M exam for validation purposes. Results: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS‐T increased fourfold to 7.2%. Of the 257 men who took the TICS‐M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. Conclusion: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. © 2012 Serdi and Springer Verlag France. AN - CN-01736688 AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DO - 10.1007/s12603-012-0083-3 KW - *Alzheimer disease *exposure *prevention *prevention study *prophylaxis *screening *telephone African American Cancer prevention Clinical trial Cognitive defect Consensus Dementia Diagnosis Education Examination Family history France Human Long term exposure Male Medical examination Memory Memory disorder Neoplasm Oncology Physician Procedures Prostate cancer Randomized controlled trial Register Teleconsultation Tic Turnover rate Volunteer M3 - Journal: Article in Press PY - 2012 SP - 1‐4 ST - A randomized controlled Alzheimer's disease Prevention trial's evolution into an exposure trial: the Preadvise trial T2 - Journal of nutrition, health & aging TI - A randomized controlled Alzheimer's disease Prevention trial's evolution into an exposure trial: the Preadvise trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01736688/full ID - 1454 ER - TY - JOUR AB - Objectives: To summarize the ongoing Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. Design: PREADViSE was designed as a double blind randomized controlled trial (RCT). Setting: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. Participants: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 μg of selenium or placebo using a 2×2 factorial structure. Measurements: In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a Modified Telephone Interview of Cognitive Status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes. Results: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. Conclusion: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. © 2013 Serdi and Springer-Verlag France. AD - R.J. Kryscio, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DB - Embase Medline DO - 10.1007/s12603-013-0004-0 IS - 1 KW - alpha tocopherol placebo selenium adult African American aged Alzheimer disease article cognition cognitive defect controlled study drug exposure family history human major clinical study male memory memory disorder priority journal randomized controlled trial teleconsultation treatment outcome LA - English M3 - Article N1 - L368131594 2013-01-25 2013-02-01 PY - 2013 SN - 1279-7707 1760-4788 SP - 72-75 ST - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: The preadvise trial T2 - Journal of Nutrition, Health and Aging TI - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: The preadvise trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L368131594&from=export http://dx.doi.org/10.1007/s12603-013-0004-0 VL - 17 ID - 1097 ER - TY - JOUR AB - OBJECTIVES: To summarize the ongoing prevention of Alzheimer's disease (AD) by vitamin E and selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. DESIGN: PREADViSE was designed as a double blind randomized controlled trial (RCT). SETTING: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. PARTICIPANTS: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 µg of selenium or placebo using a 2x2 factorial structure. MEASUREMENTS: In the RCT, participants completed the memory impairment screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS‐T) screen. If they fail the MIS‐T, a modified telephone interview of cognitive status (TICS‐M) exam is given. A failed TICS‐M exam also leads to a visit to their clinician for an in‐depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS‐T also take the TICS‐M exam for validation purposes. RESULTS: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS‐T increased fourfold to 7.2%. Of the 257 men who took the TICS‐M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. CONCLUSION: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. AN - CN-00865336 AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DO - 10.1007/s12603-012-0083-3 IS - 1 KW - Aged Alzheimer Disease [*prevention & control] Antioxidants [administration & dosage] Dietary Supplements Double‐Blind Method Follow‐Up Studies Humans Male Middle Aged Selenium [*administration & dosage] Vitamin E [*administration & dosage] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2013 SP - 72‐75 ST - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial T2 - Journal of nutrition, health & aging TI - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00865336/full VL - 17 ID - 1545 ER - TY - JOUR AB - Objectives: To summarize the ongoing Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. Design: PREADViSE was designed as a double blind randomized controlled trial (RCT). Setting: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. Participants: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 ± 5.2 years, 15.3 ± 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 μg of selenium or placebo using a 2×2 factorial structure. Measurements: In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a Modified Telephone Interview of Cognitive Status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes. Results: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. Conclusion: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. © 2013 Serdi and Springer-Verlag France. AD - University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Department of Biostatistics, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Department of Statistics, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Department of Neurology, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Department of Psychiatry and Psychology, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Department of Behavioral Sciences, University of Kentucky Sanders, Brown Center on Aging, Lexington, KY, United States Cancer Research and Biostatistics, SWOG Statistical Center, Seattle, WA, United States Cleveland Clinic, Cleveland, OH, United States AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DB - Scopus DO - 10.1007/s12603-013-0004-0 IS - 1 KW - Alzheimer's disease case ascertainment cognitive assessments prevention telephone screening M3 - Article N1 - Cited By :38 Export Date: 22 March 2021 PY - 2013 SP - 72-75 ST - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: The preadvise trial T2 - Journal of Nutrition, Health and Aging TI - A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: The preadvise trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027924487&doi=10.1007%2fs12603-013-0004-0&partnerID=40&md5=04c17f25f7424db4d11f6b6d339d49a7 VL - 17 ID - 2450 ER - TY - JOUR AB - Objectives: To summarize the ongoing Prevention of Alzheimer's Disease (AD) by Vitamin E and Selenium (PREADViSE) trial as an ancillary study to SELECT (a large prostate cancer prevention trial) and to present the blinded results of the first year as an exposure study. Design: PREADViSE was designed as a double blind randomized controlled trial (RCT). Setting: SELECT terminated after median of 5.5 years of exposure to supplements due to a futility analysis. Both trials then converted into an exposure study. Participants: In the randomized component PREADViSE enrolled 7,547 men age 62 or older (60 if African American). Once the trial terminated 4,246 of these men volunteered for the exposure study. Demographics were similar for both groups with exposure volunteers having baseline mean age 67.3 +/- 5.2 years, 15.3 +/- 2.4 years of education, 9.8% African Americans, and 22.0% reporting a family history of dementia. Intervention: In the RCT men were randomly assigned to either daily doses of 400 IU of vitamin E or placebo and 200 mu g of selenium or placebo using a 2x2 factorial structure. Measurements: In the RCT, participants completed the Memory Impairment Screen (MIS), and if they failed, underwent a longer screening (based on an expanded Consortium to Establish a Registry in AD [CERAD] battery). CERAD failure resulted in visits to their clinician for medical examination with records of these examinations forwarded to the PREADViSE center for further review. In the exposure study, men are contacted by telephone and complete the telephone version of the memory impairment screen (MIS-T) screen. If they fail the MIS-T, a Modified Telephone Interview of Cognitive Status (TICS-M) exam is given. A failed TICS-M exam also leads to a visit to their clinician for an in-depth examination and forwarding of records for a centralized consensus diagnosis by expert clinicians. A subgroup of the men who pass the MIS-T also take the TICS-M exam for validation purposes. Results: While this ancillary trial was open to all 427 SELECT clinical sites, only 130 (30.0%) of the sites chose to participate in PREADViSE. Staff turnover at the sites presented challenges when training persons unfamiliar with cognitive testing procedures to conduct the memory screens. In the RCT few participants (1.6%) failed the MIS screen and among those who passed this screen a significant practice effect was encountered. In the exposure study 3,581 men were reached by phone in year 1, 15.7% could not be reached after 5 calls, and of those contacted 6.0% refused the screen even after consenting to the procedures at their clinical site. Most notable is that the failure rate for the MIS-T increased fourfold to 7.2%. Of the 257 men who took the TICS-M, 84.0% failed and were asked to contact their physicians for a more detailed memory assessment, and approximately half of these had some form of dementia or cognitive impairment. Several of these dementia cases are not AD. Conclusion: Partnering with SELECT led to an AD prevention trial conducted at a very reasonable cost by taking advantage of the experience and efficient clinical trial management found in a cancer cooperative group (Southwest Oncology Group or SWOG). Once unblinded, the RCT and exposure study data have the potential to yield new information on long term exposure to antioxidant supplements under controlled conditions. AN - WOS:000315537200014 AU - Kryscio, R. J. AU - Abner, E. L. AU - Schmitt, F. A. AU - Goodman, P. J. AU - Mendiondo, M. AU - Caban-Holt, A. AU - Dennis, B. C. AU - Mathews, M. AU - Klein, E. A. AU - Crowley, J. J. DA - Jan DO - 10.1007/s12603-013-0004-0 IS - 1 N1 - 23299383 PY - 2013 SN - 1279-7707 SP - 72-75 ST - A Randomized Controlled Alzheimer's Disease Prevention Trial's Evolution into an Exposure Trial: The Preadvise Trial T2 - Journal of Nutrition Health & Aging TI - A Randomized Controlled Alzheimer's Disease Prevention Trial's Evolution into an Exposure Trial: The Preadvise Trial VL - 17 ID - 3055 ER - TY - JOUR AB - Background: The objective of the current study was to improve colorectal cancer (CRC) screening uptake with the fecal immunochemical test (FIT). The current study investigated the differential impact of a multicomponent, targeted, low-literacy educational intervention compared with a standard, nontargeted educational intervention.Methods: Patients aged 50 to 75 years who were of average CRC risk and not up-to-date with CRC screening were recruited from either a federally qualified health center or a primary care community health clinic. Patients were randomized to the intervention condition (targeted photonovella booklet/DVD plus FIT kit) or comparison condition (standard Centers for Disease Control and Prevention brochure plus FIT kit). The main outcome was screening with FIT within 180 days of delivery of the intervention.Results: Of the 416 participants, 54% were female; the participants were racially and ethnically diverse (66% white, 10% Hispanic, and 28% African American), predominantly of low income, and insured (the majority had county health insurance). Overall, the FIT completion rate was 81%, with 78.1% of participants in the intervention versus 83.5% of those in the comparison condition completing FIT (P =  .17). In multivariate analysis, having health insurance was found to be the primary factor predicting a lack of FIT screening (adjusted odds ratio, 2.10; 95% confidence interval, 1.04-4.26 [P =  .04]).Conclusions: The multicomponent, targeted, low-literacy materials were not found to be significantly different or more effective in increasing FIT uptake compared with the nontargeted materials. Provision of a FIT test plus education may provide a key impetus to improve the completion of CRC screening. The type of educational material (targeted vs nontargeted) may matter less. The findings of the current study provide a unique opportunity for clinics to adopt FIT and to choose the type of patient education materials based on clinic, provider, and patient preferences. Cancer 2017;123:1390-1400. © 2016 American Cancer Society. AD - Health Education and Behavioral Science, Rutgers School of Public Health, Piscataway, New Jersey Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida Florida Department of Health, St. Petersburg, Florida Premier Community HealthCare Group Inc, Dade City, Florida Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee AN - 119885172. Language: English. Entry Date: 20170601. Revision Date: 20180417. Publication Type: journal article AU - Davis, Stacy N. AU - Christy, Shannon M. AU - Chavarria, Enmanuel A. AU - Abdulla, Rania AU - Sutton, Steven K. AU - Schmidt, Alyssa R. AU - Vadaparampil, Susan T. AU - Quinn, Gwendolyn P. AU - Simmons, Vani N. AU - Ufondu, Chukwudi B. AU - Ravindra, Chitra AU - Schultz, Ida AU - Roetzheim, Richard G. AU - Shibata, David AU - Meade, Cathy D. AU - Gwede, Clement K. DB - CINAHL Complete DO - 10.1002/cncr.30481 DP - EBSCOhost IS - 23 KW - Patient Education Feces Colorectal Neoplasms -- Epidemiology Colorectal Neoplasms -- Diagnosis Early Detection of Cancer Health Screening Risk Factors Odds Ratio Aged Male Middle Age Human Female Validation Studies Comparative Studies Evaluation Research Multicenter Studies Randomized Controlled Trials Impact of Events Scale N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Evidence-Based Practice. Instrumentation: Impact of Events Scale (IES). Grant Information: R25 CA090314/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM27906448. PY - 2016 SN - 0008-543X SP - N.PAG-N.PAG ST - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics T2 - Cancer (0008543X) TI - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119885172&site=ehost-live&scope=site VL - 122 ID - 1828 ER - TY - JOUR AB - BACKGROUND: The objective of the current study was to improve colorectal cancer (CRC) screening uptake with the fecal immunochemical test (FIT). The current study investigated the differential impact of a multicomponent, targeted, low-literacy educational intervention compared with a standard, nontargeted educational intervention. METHODS: Patients aged 50 to 75 years who were of average CRC risk and not up-to-date with CRC screening were recruited from either a federally qualified health center or a primary care community health clinic. Patients were randomized to the intervention condition (targeted photonovella booklet/DVD plus FIT kit) or comparison condition (standard Centers for Disease Control and Prevention brochure plus FIT kit). The main outcome was screening with FIT within 180 days of delivery of the intervention. RESULTS: Of the 416 participants, 54% were female; the participants were racially and ethnically diverse (66% white, 10% Hispanic, and 28% African American), predominantly of low income, and insured (the majority had county health insurance). Overall, the FIT completion rate was 81%, with 78.1% of participants in the intervention versus 83.5% of those in the comparison condition completing FIT (P =.17). In multivariate analysis, having health insurance was found to be the primary factor predicting a lack of FIT screening (adjusted odds ratio, 2.10; 95% confidence interval, 1.04-4.26 [P =.04]). CONCLUSIONS: The multicomponent, targeted, low-literacy materials were not found to be significantly different or more effective in increasing FIT uptake compared with the nontargeted materials. Provision of a FIT test plus education may provide a key impetus to improve the completion of CRC screening. The type of educational material (targeted vs nontargeted) may matter less. The findings of the current study provide a unique opportunity for clinics to adopt FIT and to choose the type of patient education materials based on clinic, provider, and patient preferences. Cancer 2017;123:1390–1400. © 2016 American Cancer Society. AD - C.K. Gwede, Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States AU - Davis, S. N. AU - Christy, S. M. AU - Chavarria, E. A. AU - Abdulla, R. AU - Sutton, S. K. AU - Schmidt, A. R. AU - Vadaparampil, S. T. AU - Quinn, G. P. AU - Simmons, V. N. AU - Ufondu, C. B. AU - Ravindra, C. AU - Schultz, I. AU - Roetzheim, R. G. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DB - Embase Medline DO - 10.1002/cncr.30481 IS - 8 KW - adult African American aged article awareness cancer awareness score cancer control cancer prevention cancer risk cancer screening clinical effectiveness clinical study colonoscopy colorectal cancer community care controlled study demography educational status ethnicity family history fecal immunochemical testing female health belief health care system health insurance health literacy Hispanic human immunochemistry lowest income group major clinical study male multicomponent study patient preference physical examination polyp prediction randomized controlled trial rectum cancer religion self concept social support socioeconomics trust LA - English M3 - Article N1 - L613768420 2016-12-22 2017-05-08 PY - 2017 SN - 1097-0142 0008-543X SP - 1390-1400 ST - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics T2 - Cancer TI - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613768420&from=export http://dx.doi.org/10.1002/cncr.30481 VL - 123 ID - 938 ER - TY - JOUR AB - BACKGROUND: The objective of the current study was to improve colorectal cancer (CRC) screening uptake with the fecal immunochemical test (FIT). The current study investigated the differential impact of a multicomponent, targeted, low-literacy educational intervention compared with a standard, nontargeted educational intervention. METHODS: Patients aged 50 to 75 years who were of average CRC risk and not up-to-date with CRC screening were recruited from either a federally qualified health center or a primary care community health clinic. Patients were randomized to the intervention condition (targeted photonovella booklet/DVD plus FIT kit) or comparison condition (standard Centers for Disease Control and Prevention brochure plus FIT kit). The main outcome was screening with FIT within 180 days of delivery of the intervention. RESULTS: Of the 416 participants, 54% were female; the participants were racially and ethnically diverse (66% white, 10% Hispanic, and 28% African American), predominantly of low income, and insured (the majority had county health insurance). Overall, the FIT completion rate was 81%, with 78.1% of participants in the intervention versus 83.5% of those in the comparison condition completing FIT (P =.17). In multivariate analysis, having health insurance was found to be the primary factor predicting a lack of FIT screening (adjusted odds ratio, 2.10; 95% confidence interval, 1.04-4.26 [P =.04]). CONCLUSIONS: The multicomponent, targeted, low-literacy materials were not found to be significantly different or more effective in increasing FIT uptake compared with the nontargeted materials. Provision of a FIT test plus education may provide a key impetus to improve the completion of CRC screening. The type of educational material (targeted vs nontargeted) may matter less. The findings of the current study provide a unique opportunity for clinics to adopt FIT and to choose the type of patient education materials based on clinic, provider, and patient preferences. Cancer 2017;123:1390–1400. © 2016 American Cancer Society. © 2016 American Cancer Society AD - Health Education and Behavioral Science, Rutgers School of Public Health, Piscataway, NJ, United States Division of Population Science, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, United States Florida Department of Health, St. Petersburg, FL, United States Premier Community HealthCare Group Inc, Dade City, FL, United States Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, United States AU - Davis, S. N. AU - Christy, S. M. AU - Chavarria, E. A. AU - Abdulla, R. AU - Sutton, S. K. AU - Schmidt, A. R. AU - Vadaparampil, S. T. AU - Quinn, G. P. AU - Simmons, V. N. AU - Ufondu, C. B. AU - Ravindra, C. AU - Schultz, I. AU - Roetzheim, R. G. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DB - Scopus DO - 10.1002/cncr.30481 IS - 8 KW - colorectal cancer early detection of cancer fecal immunochemical test health promotion intervention studies medically underserved M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2017 SP - 1390-1400 ST - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics T2 - Cancer TI - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006246878&doi=10.1002%2fcncr.30481&partnerID=40&md5=6407be9a2072fb404b5e32c83eba2b52 VL - 123 ID - 2310 ER - TY - JOUR AB - BACKGROUNDThe objective of the current study was to improve colorectal cancer (CRC) screening uptake with the fecal immunochemical test (FIT). The current study investigated the differential impact of a multicomponent, targeted, low-literacy educational intervention compared with a standard, nontargeted educational intervention. METHODSPatients aged 50 to 75 years who were of average CRC risk and not up-to-date with CRC screening were recruited from either a federally qualified health center or a primary care community health clinic. Patients were randomized to the intervention condition (targeted photonovella booklet/DVD plus FIT kit) or comparison condition (standard Centers for Disease Control and Prevention brochure plus FIT kit). The main outcome was screening with FIT within 180 days of delivery of the intervention. RESULTSOf the 416 participants, 54% were female; the participants were racially and ethnically diverse (66% white, 10% Hispanic, and 28% African American), predominantly of low income, and insured (the majority had county health insurance). Overall, the FIT completion rate was 81%, with 78.1% of participants in the intervention versus 83.5% of those in the comparison condition completing FIT (P= .17). In multivariate analysis, having health insurance was found to be the primary factor predicting a lack of FIT screening (adjusted odds ratio, 2.10; 95% confidence interval, 1.04-4.26 [P= .04]). CONCLUSIONSThe multicomponent, targeted, low-literacy materials were not found to be significantly different or more effective in increasing FIT uptake compared with the nontargeted materials. Provision of a FIT test plus education may provide a key impetus to improve the completion of CRC screening. The type of educational material (targeted vs nontargeted) may matter less. The findings of the current study provide a unique opportunity for clinics to adopt FIT and to choose the type of patient education materials based on clinic, provider, and patient preferences. Cancer 2017;123:1390-1400. (c) 2016 American Cancer Society. Disparities in colorectal cancer screening among medically underserved communities are addressed in an intervention to increase the uptake of the fecal immunochemical test (FIT). Although there do not appear to be any significant differences in FIT uptake between the targeted and nontargeted intervention conditions, high FIT uptake rates suggest that the provision of a FIT kit removes a crucial barrier to care. AN - WOS:000398809700017 AU - Davis, S. N. AU - Christy, S. M. AU - Chavarria, E. A. AU - Abdulla, R. AU - Sutton, S. K. AU - Schmidt, A. R. AU - Vadaparampil, S. T. AU - Quinn, G. P. AU - Simmons, V. N. AU - Ufondu, C. B. AU - Ravindra, C. AU - Schultz, I. AU - Roetzheim, R. G. AU - Shibata, D. AU - Meade, C. D. AU - Gwede, C. K. DA - Apr DO - 10.1002/cncr.30481 IS - 8 N1 - 27906448 PY - 2017 SN - 0008-543X SP - 1390-1400 ST - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics T2 - Cancer TI - A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics VL - 123 ID - 2899 ER - TY - JOUR AB - Purpose: This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients. Patients and Methods: One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2:1 ratio) to a 12-week yoga intervention (n = 84) or a 12-week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3-month follow-up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. Results: Regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (P < .0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well-being (P < .015), social well-being (P < .004), spiritual well-being (P < .009), and distressed mood (P < .031). Sixty-nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 ± 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). Conclusion: Despite limited adherence, this intent-to-treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well-being and mood and may serve to buffer deterioration in both overall and specific domains of QOL. © 2007 by American Society of Clinical Oncology. AD - A.B. Moadel, Albert Einstein College of Medicine, Department of Epidemiology and Population Health, 1300 Morris Park Ave, Bronx, NY 10461, United States AU - Moadel, A. B. AU - Shah, C. AU - Wylie-Rosett, J. AU - Harris, M. S. AU - Patel, S. R. AU - Hall, C. B. AU - Sparano, J. A. DB - Embase Medline DO - 10.1200/JCO.2006.06.6027 IS - 28 KW - adult African American analytic method article breast cancer breathing cancer patient clinical trial comparative study controlled study distress syndrome ethnic difference fatigue female Hispanic human major clinical study male meditation outcome assessment priority journal quality of life regression analysis spiritual care wellbeing yoga LA - English M3 - Article N1 - L350013844 2007-10-01 PY - 2007 SN - 0732-183X SP - 4387-4395 ST - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life T2 - Journal of Clinical Oncology TI - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life UR - https://www.embase.com/search/results?subaction=viewrecord&id=L350013844&from=export http://dx.doi.org/10.1200/JCO.2006.06.6027 http://jco.ascopubs.org/cgi/reprint/25/28/4387 VL - 25 ID - 1221 ER - TY - JOUR AB - PURPOSE: This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well‐being among a multiethnic sample of breast cancer patients. PATIENTS AND METHODS: One hundred twenty‐eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2:1 ratio) to a 12‐week yoga intervention (n = 84) or a 12‐week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3‐month follow‐up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. RESULTS: Regression analyses indicated that the control group had a greater decrease in social well‐being compared with the intervention group after controlling for baseline social well‐being and covariates (P < .0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well‐being (P < .015), social well‐being (P < .004), spiritual well‐being (P < .009), and distressed mood (P < .031). Sixty‐nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 +/‐ 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). CONCLUSION: Despite limited adherence, this intent‐to‐treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well‐being and mood and may serve to buffer deterioration in both overall and specific domains of QOL. AN - CN-00611865 AU - Moadel, A. B. AU - Shah, C. AU - Wylie-Rosett, J. AU - Harris, M. S. AU - Patel, S. R. AU - Hall, C. B. AU - Sparano, J. A. DO - 10.1200/JCO.2006.06.6027 IS - 28 KW - Adaptation, Psychological Adult Aged Breast Neoplasms [ethnology, psychology, *therapy] Female Humans Middle Aged Quality of Life Regression Analysis Social Adjustment Yoga M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2007 SP - 4387‐4395 ST - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life T2 - Journal of clinical oncology TI - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00611865/full VL - 25 ID - 1589 ER - TY - JOUR AB - PURPOSE: This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients. PATIENTS AND METHODS: One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2:1 ratio) to a 12-week yoga intervention (n = 84) or a 12-week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3-month follow-up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. RESULTS: Regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (P < .0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well-being (P < .015), social well-being (P < .004), spiritual well-being (P < .009), and distressed mood (P < .031). Sixty-nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 +/- 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). CONCLUSION: Despite limited adherence, this intent-to-treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well-being and mood and may serve to buffer deterioration in both overall and specific domains of QOL. AN - 105962254. Language: English. Entry Date: 20080208. Revision Date: 20150711. Publication Type: Journal Article AU - Moadel, A. B. AU - Shah, C. AU - Wylie-Rosett, J. AU - Harris, M. S. AU - Patel, S. R. AU - Hall, C. B. AU - Sparano, J. A. DB - CINAHL Complete DP - EBSCOhost IS - 28 KW - Breast Neoplasms -- Therapy Quality of Life Yoga Adaptation, Psychological Adult Aged Breast Neoplasms -- Ethnology Breast Neoplasms -- Psychosocial Factors Randomized Controlled Trials Female Middle Age Regression Social Adjustment Human N1 - research; randomized controlled trial. Commentary: Carlson RH. Chemotherapy completion rates, quality-of-life indicators improve with exercise. (ONCOL TIMES) 2007 Nov 25; 29 (22): 44-45. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM17785709. PY - 2007 SN - 0732-183X SP - 4387-4395 ST - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life T2 - Journal of Clinical Oncology TI - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105962254&site=ehost-live&scope=site VL - 25 ID - 2048 ER - TY - JOUR AB - Purpose: This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients. Patients and Methods: One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2:1 ratio) to a 12-week yoga intervention (n = 84) or a 12-week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3-month follow-up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. Results: Regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (P < .0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well-being (P < .015), social well-being (P < .004), spiritual well-being (P < .009), and distressed mood (P < .031). Sixty-nine percent of intervention participants attended classes (mean number of classes attended by active class participants = 7.00 ± 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). Conclusion: Despite limited adherence, this intent-to-treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well-being and mood and may serve to buffer deterioration in both overall and specific domains of QOL. © 2007 by American Society of Clinical Oncology. AD - Albert Einstein College of Medicine; Montefiore Medical Center, Bronx; Columbia University, New York State Psychiatric Institute, New York, NY; and Private Oncology Practice, Ahmedabad, India AU - Moadel, A. B. AU - Shah, C. AU - Wylie-Rosett, J. AU - Harris, M. S. AU - Patel, S. R. AU - Hall, C. B. AU - Sparano, J. A. DB - Scopus DO - 10.1200/JCO.2006.06.6027 IS - 28 M3 - Article N1 - Cited By :234 Export Date: 22 March 2021 PY - 2007 SP - 4387-4395 ST - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life T2 - Journal of Clinical Oncology TI - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-35348819350&doi=10.1200%2fJCO.2006.06.6027&partnerID=40&md5=52072c65d5367ea537453781c2d70b51 VL - 25 ID - 2550 ER - TY - JOUR AB - Purpose This study examines the impact of yoga, including physical poses, breathing, and meditation exercises, on quality of life (QOL), fatigue, distressed mood, and spiritual well-being among a multiethnic sample of breast cancer patients. Patients and Methods One hundred twenty-eight patients (42% African American, 31% Hispanic) recruited from an urban cancer center were randomly assigned (2: 1 ratio) to a 12-week yoga intervention (n = 84) or a 12-week waitlist control group (n = 44). Changes in QOL (eg, Functional Assessment of Cancer Therapy) from before random assignment (T1) to the 3-month follow-up (T3) were examined; predictors of adherence were also assessed. Nearly half of all patients were receiving medical treatment. Results Regression analyses indicated that the control group had a greater decrease in social well-being compared with the intervention group after controlling for baseline social well-being and covariates (P <. 0001). Secondary analyses of 71 patients not receiving chemotherapy during the intervention period indicated favorable outcomes for the intervention group compared with the control group in overall QOL (P < .008), emotional well-being (P < .015), social well-being (P < .004), spiritual well-being (P < .009), and distressed mood (P <.031). Sixty-nine percent of intervention participants attended classes ( mean number of classes attended by active class participants = 7.00 +/- 3.80), with lower adherence associated with increased fatigue (P < .001), radiotherapy (P < .0001), younger age (P < .008), and no antiestrogen therapy (P < .02). Conclusion Despite limited adherence, this intent-to-treat analysis suggests that yoga is associated with beneficial effects on social functioning among a medically diverse sample of breast cancer survivors. Among patients not receiving chemotherapy, yoga appears to enhance emotional well-being and mood and may serve to buffer deterioration in both overall and specific domains of QOL. AN - WOS:000251073300012 AU - Moadel, A. B. AU - Shah, C. AU - Wylie-Rosett, J. AU - Harris, M. S. AU - Patel, S. R. AU - Hall, C. B. AU - Sparano, J. A. DA - Oct DO - 10.1200/JCO.2006.06.6027 IS - 28 N1 - 7th World Congress of Psycho-Oncology AUG 25-28, 2004 Copenhagen, DENMARK 17785709 PY - 2007 SN - 0732-183X SP - 4387-4395 ST - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life T2 - Journal of Clinical Oncology TI - Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: Effects on quality of life VL - 25 ID - 3184 ER - TY - JOUR AB - Organizational barriers play a key role in colorectal cancer (CRC) screening disparities in low‐income minorities. This is a prospective, randomized trial to determine whether a patient navigator (PN) can help overcome the organizational barriers low‐income minorities face in trying to obtain screening colonoscopy. Patients of average risk for CRC were referred by their primary care physician for screening colonoscopy. After the PN received the referral, patients were randomly assigned to either receive navigation (PN+) to screening colonoscopy or not receive navigation (PN‐). We hypothesized that a PN would increase patient compliance with screening colonoscopy. A total of 21 patients were enrolled in the pilot study (PN+ = 13, PN‐ = 8); 54% of navigated patients completed screening colonoscopy versus 13% of nonnavigated patients (p = 0.058). Eighty‐six percent of navigated patients had an excellent or very good colon prep; however, there was no difference in prep quality between groups ( p = 0.10). One‐hundred percent of navigated patients were very satisfied with navigation services. A PN improves compliance with screening colonoscopy in low‐income minorities. Larger studies are needed to evaluate what features of navigation are most effective in facilitating completion of screening colonoscopy. AN - CN-00631171 AU - Christie, J. AU - Itzkowitz, S. AU - Lihau-Nkanza, I. AU - Castillo, A. AU - Redd, W. AU - Jandorf, L. DO - 10.1016/s0027-9684(15)31240-2 IS - 3 KW - African Americans Appointments and Schedules Attitude to Health Colonoscopy [*statistics & numerical data] Colorectal Neoplasms [*diagnosis, ethnology, prevention & control] Female Health Behavior Health Services Accessibility Hispanic Americans Humans Male Mass Screening [*statistics & numerical data] Middle Aged Minority Health Patient Acceptance of Health Care Patient Education as Topic Patient Satisfaction Poverty Prospective Studies Reminder Systems Socioeconomic Factors United States M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2008 SP - 278‐284 ST - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities T2 - Journal of the National Medical Association TI - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00631171/full VL - 100 ID - 1440 ER - TY - JOUR AB - Organizational barriers play a key role in colorectal cancer (CRC) screening disparities in low-income minorities. This is a prospective, randomized trial to determine whether a patient navigator (PN) can help overcome the organizational barriers low-income minorities face in trying to obtain screening colonoscopy. Patients of average risk for CRC were referred by their primary care physician for screening colonoscopy. After the PN received the referral, patients were randomly assigned to either receive navigation (PN+) to screening colonoscopy or not receive navigation (PN-). We hypothesized that a PN would increase patient compliance with screening colonoscopy. A total of 21 patients were enrolled in the pilot study (PN+ = 13, PN- = 8); 54% of navigated patients completed screening colonoscopy versus 13% of nonnavigated patients (p = 0.058). Eighty-six percent of navigated patients had an excellent or very good colon prep; however, there was no difference in prep quality between groups ( p = 0.10). One-hundred percent of navigated patients were very satisfied with navigation services. A PN improves compliance with screening colonoscopy in low-income minorities. Larger studies are needed to evaluate what features of navigation are most effective in facilitating completion of screening colonoscopy. AD - Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA. jennifer.christie@emoryhealthcare.org AN - 105725763. Language: English. Entry Date: 20080523. Revision Date: 20190612. Publication Type: journal article AU - Christie, J. AU - Itzkowitz, S. AU - Lihau-Nkanza, I. AU - Castillo, A. AU - Redd, W. AU - Jandorf, L. AU - Christie, Jennifer AU - Itzkowitz, Steven AU - Lihau-Nkanza, Irene AU - Castillo, Anabella AU - Redd, William AU - Jandorf, Lina DB - CINAHL Complete DP - EBSCOhost IS - 3 KW - Colonoscopy -- Utilization Colorectal Neoplasms -- Diagnosis Health Screening -- Utilization Health Services Accessibility Patient Attitudes Poverty Appointments and Schedules Attitude to Health Black Persons Randomized Controlled Trials Colonoscopy -- Statistics and Numerical Data Colorectal Neoplasms -- Ethnology Colorectal Neoplasms -- Prevention and Control Female Health Behavior Health Screening -- Statistics and Numerical Data Hispanic Americans Male Middle Age Patient Education Patient Satisfaction Prospective Studies Reminder Systems Socioeconomic Factors United States Human N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: U01-CA86107/CA/NCI NIH HHS/United States. NLM UID: 7503090. PMID: NLM18390020. PY - 2008 SN - 0027-9684 SP - 278-284 ST - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities T2 - Journal of the National Medical Association TI - A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105725763&site=ehost-live&scope=site VL - 100 ID - 1829 ER - TY - JOUR AB - Objective: The objective of the study is to test theoretical intervention fidelity and feasibility of MOVING ON, a self-directed, home-based, randomized controlled trial to increase exercise outcome expectations (OEs) (what one expects to obtain or avoid as a result of a behavior or lack thereof), among breast cancer survivors. Method: Stage Ia to IIb survivors (n = 60) were given the MOVING ON intervention or control booklet. Data were collected through online surveys and an accelerometer at baseline, 4, 8, and 12 weeks postintervention. Fidelity was measured by questions assessing participant perceptions of MOVING ON (score ≥2) and direction of intervention effects. Feasibility was measured by recruitment rate (target of 60 participants in 6 months), retention (total attrition <17%), and acquisition of accelerometer data (% ≥subjective exercise data obtained). Analyses consisted of descriptive statistics, mixed models, and content analysis. Results: Fidelity met a priori criteria (mean = 3.31, SD = 0.87). Outcome expectations increased 0.01 points, and weekly steps increased by 970 every 4 weeks in the intervention arm compared to the control arm. All effect sizes were small, ranging from 0.01 to 0.09. Target enrollment, achieved in 17 weeks, met a priori feasibility criteria. Retention (66%) and accelerometer data acquisition (60%) (compared to 73% of subjective exercise data) did not. Conclusion: MOVING ON influenced OEs as intended and was well received by participants. A fully powered study, of this low-cost, easy-to-implement intervention, is warranted. Intervention and measurement strategies used in MOVING ON can be incorporated in any study targeting OEs as a mediator of exercise or collecting exercise data with an accelerometer. © 2018 John Wiley & Sons, Ltd. AD - University of North Carolina, Chapel Hill, NC, United States Duke University Medical Center, Duke Cancer Institute, Durham, NC, United States Duke University School of Nursing, Durham, NC, United States Duke Women's Cancer Care, Raleigh, NC, United States AU - Hirschey, R. AU - Kimmick, G. AU - Hockenberry, M. AU - Shaw, R. AU - Pan, W. AU - Page, C. AU - Lipkus, I. DB - Scopus DO - 10.1002/pon.4849 IS - 10 KW - behavior change breast cancer cancer cancer survivor exercise outcome expectations physical activity survivorship M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2018 SP - 2450-2457 ST - A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors T2 - Psycho-Oncology TI - A randomized phase II trial of MOVING ON: An intervention to increase exercise outcome expectations among breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053427761&doi=10.1002%2fpon.4849&partnerID=40&md5=5be17cef1b185df7b3d9a3cc3c039766 VL - 27 ID - 2255 ER - TY - JOUR AB - To investigate the effect of electro‐acupuncture (EA) as a non‐pharmacological intervention to prevent or reduce chemotherapy‐induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I‐III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory‐Short Form (BPI‐SF), Functional Assessment of Cancer Therapy‐Taxane neurotoxicity subscale (FACT‐NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI‐SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI‐SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham‐controlled trial of EA for prevention of taxane‐induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN. AN - CN-01154151 AU - Greenlee, H. AU - Crew, K. D. AU - Capodice, J. AU - Awad, D. AU - Buono, D. AU - Shi, Z. AU - Jeffres, A. AU - Wyse, S. AU - Whitman, W. AU - Trivedi, M. S. AU - et al. DO - 10.1007/s10549-016-3759-2 IS - 3 KW - *breast cancer/dt [Drug Therapy] *chemotherapy induced peripheral neuropathy/pc [Prevention] *chemotherapy induced peripheral neuropathy/si [Side Effect] *chemotherapy induced peripheral neuropathy/th [Therapy] *docetaxel/ae [Adverse Drug Reaction] *docetaxel/cb [Drug Combination] *docetaxel/ct [Clinical Trial] *docetaxel/dt [Drug Therapy] *electroacupuncture *paclitaxel/ae [Adverse Drug Reaction] *paclitaxel/cb [Drug Combination] *paclitaxel/ct [Clinical Trial] *paclitaxel/dt [Drug Therapy] *peripheral neuropathy/pc [Prevention] *peripheral neuropathy/si [Side Effect] *peripheral neuropathy/th [Therapy] Adult Aged Article Breast Neoplasms [*drug therapy, ethnology, *pathology] Bridged‐Ring Compounds [*adverse effects, therapeutic use] Cancer adjuvant therapy Cancer staging Clinical effectiveness Controlled clinical trial Controlled study Double‐Blind Method Drug efficacy Drug safety Drug tolerability Electroacupuncture [*methods] Female Follow up Human Humans Injection site contusion/co [Complication] Injection site reaction/co [Complication] Injection site swelling/co [Complication] Middle Aged Multiple cycle treatment Pain assessment Peripheral Nervous System Diseases [chemically induced, *prevention & control] Pilot Projects Priority journal Randomized controlled trial Scoring system Taxoids [*adverse effects, therapeutic use] Treatment Outcome M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2016 SP - 453‐464 ST - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer T2 - Breast cancer research and treatment TI - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01154151/full VL - 156 ID - 1595 ER - TY - JOUR AB - To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN. AD - H. Greenlee, Columbia University, 722 W. 168th Street, Room 733, New York, NY, United States AU - Greenlee, H. AU - Crew, K. D. AU - Capodice, J. AU - Awad, D. AU - Buono, D. AU - Shi, Z. AU - Jeffres, A. AU - Wyse, S. AU - Whitman, W. AU - Trivedi, M. S. AU - Kalinsky, K. AU - Hershman, D. L. DB - Embase Medline DO - 10.1007/s10549-016-3759-2 IS - 3 KW - NCT01163682 docetaxel paclitaxel adult article breast cancer cancer adjuvant therapy cancer staging chemotherapy-induced peripheral neuropathy clinical effectiveness controlled clinical trial controlled study drug efficacy drug safety drug tolerability electroacupuncture female follow up human injection site contusion injection site reaction injection site swelling middle aged multiple cycle treatment pain assessment peripheral neuropathy priority journal randomized controlled trial scoring system LA - English M3 - Article N1 - L609267954 2016-04-01 2016-05-03 PY - 2016 SN - 1573-7217 0167-6806 SP - 453-464 ST - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer T2 - Breast Cancer Research and Treatment TI - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L609267954&from=export http://dx.doi.org/10.1007/s10549-016-3759-2 VL - 156 ID - 976 ER - TY - JOUR AB - To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN. © 2016, Springer Science+Business Media New York. AD - Mailman School of Public Health, Columbia University, New York, NY, United States Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States College of Physicians and Surgeons, Columbia University, New York, NY, United States Mount Sinai School of Medicine, New York, NY, United States Columbia University, 722 W. 168th Street, Room 733, New York, NY 10032, United States AU - Greenlee, H. AU - Crew, K. D. AU - Capodice, J. AU - Awad, D. AU - Buono, D. AU - Shi, Z. AU - Jeffres, A. AU - Wyse, S. AU - Whitman, W. AU - Trivedi, M. S. AU - Kalinsky, K. AU - Hershman, D. L. DB - Scopus DO - 10.1007/s10549-016-3759-2 IS - 3 KW - Acupuncture Breast cancer Chemotherapy-induced peripheral neuropathy Electro-acupuncture Taxane M3 - Article N1 - Cited By :32 Export Date: 22 March 2021 PY - 2016 SP - 453-464 ST - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer T2 - Breast Cancer Research and Treatment TI - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961673937&doi=10.1007%2fs10549-016-3759-2&partnerID=40&md5=eda3272ae6766dcfc09e6a7e9dc5d53c VL - 156 ID - 2347 ER - TY - JOUR AB - To investigate the effect of electro-acupuncture (EA) as a non-pharmacological intervention to prevent or reduce chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients undergoing chemotherapy of taxane. Women with stage I-III breast cancer scheduled to receive taxane therapy were randomized to receive a standardized protocol of 12 true or sham EA (SEA) weekly treatments concurrent with taxane treatment. Subjects completed the Brief Pain Inventory-Short Form (BPI-SF), Functional Assessment of Cancer Therapy-Taxane neurotoxicity subscale (FACT-NTX), and other assessments at baseline and weeks 6, 12, and 16. A total of 180 subjects were screened, 63 enrolled and 48 completed week 16 assessments. Mean age was 50 with 25 % white, 25 % black, and 43 % Hispanic; 52 % had no prior chemotherapy. At week 12, both groups reported an increase in mean BPI-SF worst pain score, but no mean differences were found between groups (SEA 2.8 vs. EA 2.6, P = .86). By week 16, the SEA group returned to baseline, while the EA group continued to worsen (SEA 1.7 vs. EA 3.4, P = .03). The increase in BPI-SF worst pain score was 1.62 points higher in the EA group than in the SEA group at week 16 (P = .04). In a randomized, sham-controlled trial of EA for prevention of taxane-induced CIPN, there were no differences in pain or neuropathy between groups at week 12. Of concern, subjects on EA had a slower recovery than SEA subjects. Future studies should focus on EA for treatment as opposed to prevention of CIPN. AN - WOS:000374666500006 AU - Greenlee, H. AU - Crew, K. D. AU - Capodice, J. AU - Awad, D. AU - Buono, D. AU - Shi, Z. X. AU - Jeffres, A. AU - Wyse, S. AU - Whitman, W. AU - Trivedi, M. S. AU - Kalinsky, K. AU - Hershman, D. L. DA - Apr DO - 10.1007/s10549-016-3759-2 IS - 3 N1 - 27013473 PY - 2016 SN - 0167-6806 SP - 453-464 ST - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer T2 - Breast Cancer Research and Treatment TI - Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer VL - 156 ID - 2947 ER - TY - JOUR AB - Context: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men. Methods: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of 1 of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1,170 masons. The primary outcome was knowledge of prostate cancer screening. Results: There were 87 participants in the sample with a mean age of 52 years (standard deviation=6.9). forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (ñ=0.01). Concision: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Webbased sites may be effective in facilitating discussions about screening between patients and health care providers. AD - G.L. Ellison, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd., Executive Plaza North, Bethesda, MD 20892, United States AU - Ellison, G. L. AU - Weinrich, S. P. AU - Lou, M. AU - Xu, H. AU - Powell, I. J. AU - Baquet, C. R. DB - Embase Medline DO - 10.1016/S0027-9684(15)31481-4 IS - 10 KW - adult African American anamnesis article bivariate analysis cancer screening decision support system demography human Internet knowledge base male multivariate analysis priority journal prostate cancer LA - English M3 - Article N1 - L352611185 2008-12-03 PY - 2008 SN - 0027-9684 SP - 1139-1145 ST - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men T2 - Journal of the National Medical Association TI - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352611185&from=export http://dx.doi.org/10.1016/S0027-9684(15)31481-4 VL - 100 ID - 1204 ER - TY - JOUR AB - OBJECTIVES: Few decision aids are tailored for African‐American men. We sought to determine if web‐based decision aids increased knowledge of prostate cancer screening among African men. METHODS: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African‐American men following receipt of 1 of 2 web‐based decision aids: enhanced or usual care. Men ages 40‐65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1170 masons. The primary outcome was knowledge of prostate cancer screening. RESULTS: There were 87 participants in the sample with a mean age of 52 years (standard deviation = 6.9). Forty‐six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (p = 0.01). CONCLUSION: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Web‐based sites may be effective in facilitating discussions about screening between patients and health care providers. AN - CN-00651470 AU - Ellison, G. L. AU - Weinrich, S. P. AU - Lou, M. AU - Xu, H. AU - Powell, I. J. AU - Baquet, C. R. DO - 10.1016/s0027-9684(15)31481-4 IS - 10 KW - Adult African Americans Aged Decision Making, Computer‐Assisted Health Knowledge, Attitudes, Practice Humans Internet Male Middle Aged Prostatic Neoplasms United States M3 - Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2008 SP - 1139‐1145 ST - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men T2 - Journal of the National Medical Association TI - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00651470/full VL - 100 ID - 1349 ER - TY - JOUR AB - Objectives: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men. Methods: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of 1 of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1170 masons. The primary outcome was knowledge of prostate cancer screening. Results: There were 87 participants in the sample with a mean age of 52 years (standard deviation = 6.9). Forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (p = 0.01). Conclusion: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Web-based sites may be effective in facilitating discussions about screening between patients and health care providers. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ellison, Gary L., Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd., Executive Plaza North, Bethesda, MD, US, 20892 AN - 2008-15042-002 AU - Ellison, Gary L. AU - Weinrich, Sally P. AU - Lou, Mimi AU - Xu, Hongyan AU - Powell, Isaac J. AU - Baquet, Claudia R. DB - psyh DO - 10.1016/S0027-9684(15)31481-4 DP - EBSCOhost IS - 10 KW - web-based decision aids prostate cancer African American men cancer screening knowledge Adult African Americans Aged Decision Making, Computer-Assisted Health Knowledge, Attitudes, Practice Humans Internet Male Middle Aged Prostatic Neoplasms United States Decision Making Neoplasms Prostate Blacks Human Males Knowledge Level Websites N1 - Department of Family and Community Medicine, School of Medicine, University of Maryland, Baltimore, MD, US. Other Publishers: Elsevier Science. Release Date: 20091109. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Grant Information: Weinrich, Sally P. Major Descriptor: Cancer Screening; Decision Making; Neoplasms; Prostate. Minor Descriptor: Blacks; Human Males; Knowledge Level; Websites. Classification: Cancer (3293). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Supplemental Data: Web Sites Internet. References Available: Y. Page Count: 7. Issue Publication Date: Oct, 2008. Copyright Statement: 2008. Sponsor: Georgia Cancer Coalition Distinguished Cancer Scholar. Recipients: Weinrich, Sally P. Sponsor: National Cancer Institute, US. Recipients: No recipient indicated Sponsor: Research Supplement to Promote Diversity in Health. Grant: NCI U01 CA114650. Recipients: Ellison, Gary L. PY - 2008 SN - 0027-9684 1943-4693 SP - 1139-1145 ST - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men T2 - Journal of the National Medical Association TI - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-15042-002&site=ehost-live&scope=site gellison@som.umaryland.edu VL - 100 ID - 1737 ER - TY - JOUR AB - Context: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men. Methods: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of 1 of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1,170 masons. The primary outcome was knowledge of prostate cancer screening. Results: There were 87 participants in the sample with a mean age of 52 years (standard deviation=6.9). forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (ñ=0.01). Concision: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Webbased sites may be effective in facilitating discussions about screening between patients and health care providers. AD - Department of Family and Community Medicine, School of Medicine, University of Maryland, Baltimore, MD, United States Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, United States School of Nursing, Medical College of Georgia, Augusta, GA, United States Department of Biostatistics, Medical College of Georgia, Augusta, GA, United States Department of Urology, Wayne State University and Karmanos Cancer Institute, Detroit, MI, United States Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd., Executive Plaza North, Bethesda, MD 20892, United States AU - Ellison, G. L. AU - Weinrich, S. P. AU - Lou, M. AU - Xu, H. AU - Powell, I. J. AU - Baquet, C. R. DB - Scopus DO - 10.1016/S0027-9684(15)31481-4 IS - 10 KW - African Americans Prostate cancer screening M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2008 SP - 1139-1145 ST - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men T2 - Journal of the National Medical Association TI - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-55349083372&doi=10.1016%2fS0027-9684%2815%2931481-4&partnerID=40&md5=75a2002987090c7911e46f648b181ca1 VL - 100 ID - 2544 ER - TY - JOUR AB - Objectives: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men. Methods: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of I of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1, 1 70,masons. The primary outcome was knowledge of prostate cancer screening. Results: There were 87 participants in the sample with a mean age of 52 years (standard deviation=6.9). Forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid, Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (p=0.01). Conclusion: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Web-based sites may be effective in facilitating discussions about screening between patients and health care providers. AN - WOS:000260135200003 AU - Ellison, G. L. AU - Weinrich, S. P. AU - Lou, M. AU - Xu, H. AU - Powell, I. J. AU - Baquet, C. R. DA - Oct DO - 10.1016/S0027-9684(15)31481-4 IS - 10 N1 - 18942274 PY - 2008 SN - 0027-9684 SP - 1139-1145 ST - A Randomized Trial Comparing Web-Based Decision Aids on Prostate Cancer Knowledge for African-American Men T2 - Journal of the National Medical Association TI - A Randomized Trial Comparing Web-Based Decision Aids on Prostate Cancer Knowledge for African-American Men VL - 100 ID - 3164 ER - TY - JOUR AB - Objectives: Few decision aids are tailored for African-American men. We sought to determine if web-based decision aids increased knowledge of prostate cancer screening among African men.Methods: This postintervention, quasiexperimental research measured knowledge of prostate cancer screening among African-American men following receipt of 1 of 2 web-based decision aids: enhanced or usual care. Men ages 40-65 were recruited at the annual convention of the Prince Hall Masons in the summer of 2007, which was attended by 1170 masons. The primary outcome was knowledge of prostate cancer screening.Results: There were 87 participants in the sample with a mean age of 52 years (standard deviation = 6.9). Forty-six masons were randomized to the enhanced decision aid, and 41 masons were randomized to the usual care decision aid. Knowledge scores were statistically significantly higher among the men receiving the enhanced decision aid compared to the usual care decision aid after simultaneously adjusting for age, educational level, marital status, family history, previous prostate specific antigen test and digital rectal exam (p = 0.01).Conclusion: We found evidence that the enhanced web decision aid was significantly more effective than the usual care decision aid in promoting knowledge of the benefits, limitations and risks of prostate cancer screening. Web-based sites may be effective in facilitating discussions about screening between patients and health care providers. AD - Department of Family and Community Medicine, School of Medicine, University of Maryland, Baltimore, MD, USA Department of Family and Community Medicine, School of Medicine, University of Maryland, Baltimore, MD AN - 105709320. Language: English. Entry Date: 20081205. Revision Date: 20190612. Publication Type: journal article AU - Ellison, G. L. AU - Weinrich, S. P. AU - Lou, M. AU - Xu, H. AU - Powell, I. J. AU - Baquet, C. R. AU - Ellison, Gary L. AU - Weinrich, Sally P. AU - Lou, Mimi AU - Xu, Hongyan AU - Powell, Isaac J. AU - Baquet, Claudia R. DB - CINAHL Complete DP - EBSCOhost IS - 10 KW - Attitude to Health Black Persons Internet Prostatic Neoplasms Adult Aged Clinical Trials Decision Making, Computer Assisted Funding Source Male Middle Age United States Human N1 - clinical trial; research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: U01 CA114650/CA/NCI NIH HHS/United States. NLM UID: 7503090. PMID: NLM18942274. PY - 2008 SN - 0027-9684 SP - 1139-1145 ST - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men T2 - Journal of the National Medical Association TI - A randomized trial comparing web-based decision aids on prostate cancer knowledge for African-American men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105709320&site=ehost-live&scope=site VL - 100 ID - 1830 ER - TY - JOUR AB - PURPOSE: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. PATIENTS AND METHODS: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4‐day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle‐stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. RESULTS: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. CONCLUSION: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents. AN - CN-00347917 AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. AU - Moore, A. AU - Rosenman, P. J. AU - Kaufman, E. L. AU - et al. DO - 10.1200/JCO.2001.19.10.2739 IS - 10 KW - Antineoplastic Agents, Hormonal [adverse effects, *therapeutic use] Breast Neoplasms [*drug therapy, radiotherapy] Combined Modality Therapy Double‐Blind Method Female Follicle Stimulating Hormone [blood] Hot Flashes [*drug therapy] Humans Luteinizing Hormone [blood] Middle Aged Plant Extracts [*therapeutic use] Tamoxifen [adverse effects, *therapeutic use] M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't PY - 2001 SP - 2739‐2745 ST - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer T2 - Journal of clinical oncology TI - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00347917/full VL - 19 ID - 1506 ER - TY - JOUR AB - Purpose: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. Patients and Methods: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. Results: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. Conclusion: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents. © 2001 by American Society of Clinical Oncology. AD - J.S. Jacobson, Division of Epidemiology, Mailman School of Public Health, Columbia University, 600 West 168th St., New York, NY 10032, United States AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. S. AU - Moore, A. AU - Rosenman, P. J. AU - Kaufman, E. L. AU - Neugut, A. I. AU - Grann, V. R. DB - Embase Medline DO - 10.1200/JCO.2001.19.10.2739 IS - 10 KW - cimifuga racemosa extract follitropin herbaceous agent luteinizing hormone placebo plant extract tamoxifen unclassified drug adult article breast cancer cancer survival Actaea racemosa clinical trial constipation controlled clinical trial controlled study double blind procedure drug efficacy drug safety endometrium hyperplasia female follitropin blood level heart arrhythmia herbal medicine hot flush human indigestion luteinizing hormone blood level major clinical study menopause muscle cramp plant root priority journal questionnaire randomized controlled trial rash vagina bleeding body weight gain LA - English M3 - Article N1 - L32441380 2001-05-29 PY - 2001 SN - 0732-183X SP - 2739-2745 ST - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer T2 - Journal of Clinical Oncology TI - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L32441380&from=export http://dx.doi.org/10.1200/JCO.2001.19.10.2739 VL - 19 ID - 1310 ER - TY - JOUR AB - Purpose: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. Patients and Methods: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. Results: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. Conclusion: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents. © 2001 by American Society of Clinical Oncology. AD - Division of Epidemiology, Mailman School of Public Health, Columbia University, 600 West 168th St. PH18-105, New York, NY 10032, United States AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. S. AU - Moore, A. AU - Rosenman, P. J. AU - Kaufman, E. L. AU - Neugut, A. I. AU - Grann, V. R. DB - Scopus DO - 10.1200/JCO.2001.19.10.2739 IS - 10 M3 - Article N1 - Cited By :322 Export Date: 22 March 2021 PY - 2001 SP - 2739-2745 ST - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer T2 - Journal of Clinical Oncology TI - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035873937&doi=10.1200%2fJCO.2001.19.10.2739&partnerID=40&md5=20849b393c83508b2f3eabd6299ecdb4 VL - 19 ID - 2623 ER - TY - JOUR AB - Purpose: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. Patients and Methods: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. Results: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. Conclusion: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents. (C) 2001 by American Society of Clinical Oncology. AN - WOS:000168757200018 AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. S. AU - Moore, A. AU - Rosenman, P. J. AU - Kaufman, E. L. AU - Neugut, A. I. AU - Grann, V. R. DA - May 15 DO - 10.1200/JCO.2001.19.10.2739 IS - 10 N1 - 245 11352967 PY - 2001 SN - 0732-183X SP - 2739-2745 ST - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer T2 - Journal of Clinical Oncology TI - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer VL - 19 ID - 2707 ER - TY - JOUR AB - Purpose: Most breast cancer survivors experience hot flashes; many use complementary or alternative remedies for these symptoms. We undertook a randomized clinical trial of black cohosh, a widely used herbal remedy for menopausal symptoms, among breast cancer patients. Patients and Methods: Patients diagnosed with breast cancer who had completed their primary treatment were randomly assigned to black cohosh or placebo, stratified on tamoxifen use. At enrollment, patients completed a questionnaire about demographic factors and menopausal symptoms. Before starting to take the pills and at 30 and 60 days, they completed a 4-day hot flash diary. At the final visit, they completed another menopausal symptom questionnaire. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured in a subset of patients at the first and final visits. Results: Of 85 patients (59 on tamoxifen, 26 not on tamoxifen) enrolled in the study, 42 were assigned to treatment and 43 were assigned to placebo; 69 completed all three hot flash diaries. Both treatment and placebo groups reported declines in number and intensity of hot flashes; the differences between the groups were not statistically significant. Both groups also reported improvements in menopausal symptoms that were, for the most part, not significantly different. Changes in blood levels of FSH and LH also did not differ in the two groups. Conclusion: Black cohosh was not significantly more efficacious than placebo against most menopausal symptoms, including number and intensity of hot flashes. Our study illustrates the feasibility and value of standard clinical trial methodology in assessing the efficacy and safety of herbal agents. AD - Herbert Irving Comprehensive Cancer Center and Joseph L. Mailman School of Public Health, Columbia University, and Weill-Cornell Medical College, New York, NY 10032, USA AN - 107042647. Language: English. Entry Date: 20010803. Revision Date: 20170424. Publication Type: journal article AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. S. AU - Moore, A. AU - Rosenman, P. J. AU - Kaufman, E. L. AU - Neugut, A. I. AU - Grann, V. R. AU - Jacobson, J. S. AU - Troxel, A. B. AU - Evans, J. AU - Klaus, L. AU - Vahdat, L. AU - Kinne, D. AU - Lo, K. M. AU - Moore, A. DB - CINAHL Complete DP - EBSCOhost IS - 10 KW - Breast Neoplasms -- Complications Perimenopausal Symptoms -- Drug Therapy Plant Extracts -- Therapeutic Use Diaries Tamoxifen -- Therapeutic Use Combined Modality Therapy Follicle-Stimulating Hormone -- Blood Luteinizing Hormone -- Blood Clinical Trials Placebos Double-Blind Studies Analysis of Covariance Wilcoxon Rank Sum Test Middle Age Male Funding Source Human N1 - clinical trial; research; tables/charts. Commentary: Brown DJ. Clinical update. Black cohosh extract found ineffective in treating hot flashes in women with a history of breast cancer. (HERBALGRAM) 2002; (55): 18-23; Verrill M. [Commentary on] Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. (WOMENS ONCOL REV) 2001 Sep; 1 (3): 288-288. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: Supported by grants from Schaper & Brümmer, the American Cancer Society (CRTG-98-260-01), the Sindab African American Breast Cancer Project, the Avon Breast Cancer Research and Care Program, and the Breast Cancer Alliance. NLM UID: 8309333. PMID: NLM11352967. PY - 2001 SN - 0732-183X SP - 2739-2745 ST - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer T2 - Journal of Clinical Oncology TI - Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107042647&site=ehost-live&scope=site VL - 19 ID - 2049 ER - TY - JOUR AB - Background: Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the USA. The United States Preventive Services Task Force (USPSTF) encourages prostate-specific antigen (PSA) testing decisions to be based on shared decision-making (SDM) clinician professional judgment, and patient preferences. However, evidence suggests that SDM is underutilized in clinical practice, especially among the most vulnerable patients. The purpose of this study is to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate SDM for prostate cancer screening among Black men in the primary care setting, with the ultimate aim of improving/optimizing decision quality. Methods: We proposed a CHW-led decision-coaching program to facilitate SDM for prostate cancer screening discussions in Black men at a primary care FQHC. This study enrolled Black men who were patients at the participating clinical site and up to 15 providers who cared for them. We estimated to recruit 228 participants, ages 40–69 to be randomized to either (1) a decision aid along with decision coaching on PSA screening from a CHW or (2) receiving a decision aid along with CHW-led interaction on modifying dietary and lifestyle to serve as an attention control. The independent randomization process was implemented within each provider and we controlled for age by dividing patients into two strata: 40–54 years and 55–69 years. This sample size sufficiently powered the detection differences in the primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates. Primary outcome measures for patients will be decision quality and decision regarding whether to undergo PSA screening. Primary outcome measures for providers will be acceptability and feasibility of the intervention. We will examine how decision coaching about prostate cancer screening impact patient-provider communication. These outcomes will be analyzed quantitatively through objective, validated scales and qualitatively through semi-structured, in-depth interviews, and thematic analysis of clinical encounters. Through a conceptual model combining elements of the Preventative Health Care Model (PHM) and Informed Decision-Making Model, we hypothesize that the prostate cancer screening decision coaching intervention will result in a preference-congruent decision and decisional satisfaction. We also hypothesize that this intervention will improve physician satisfaction with counseling patients about prostate cancer screening. Discussion: Decision coaching is an evidence-based approach to improve decision quality in many clinical contexts, but its efficacy is incompletely explored for PSA screening among Black men in primary care. Our proposal to evaluate a CHW-led decision-coaching program for PSA screening has high potential for scalability and public health impact. Our results will determine the efficacy, cost-effectiveness, and sustainability of a CHW intervention in a community clinic setting in order to inform subsequent widespread dissemination, a critical research area highlighted by USPSTF. Trial registration: The trial was registered prospectively with the National Institute of Health registry (www.clinicaltrials.gov), registration number NCT03726320, on October 31, 2018. AD - D.V. Makarov, VA New York Harbor Healthcare System, 423 E 23rd St, New York, NY, United States AU - Makarov, D. V. AU - Feuer, Z. AU - Ciprut, S. AU - Lopez, N. M. AU - Fagerlin, A. AU - Shedlin, M. AU - Gold, H. T. AU - Li, H. AU - Lynch, G. AU - Warren, R. AU - Ubel, P. AU - Ravenell, J. E. DB - Embase Medline DO - 10.1186/s13063-021-05064-4 IS - 1 KW - adult aged article attention cancer screening comparative effectiveness conceptual model controlled study cost effectiveness analysis counseling diet feasibility study health auxiliary human interview lifestyle major clinical study male national health organization preventive health service primary medical care prostate cancer quantitative analysis randomization randomized controlled trial sample size satisfaction shared decision making thematic analysis prostate specific antigen LA - English M3 - Article N1 - L2010454432 2021-03-01 PY - 2021 SN - 1745-6215 ST - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers T2 - Trials TI - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2010454432&from=export http://dx.doi.org/10.1186/s13063-021-05064-4 VL - 22 ID - 754 ER - TY - JOUR AB - Background: Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the USA. The United States Preventive Services Task Force (USPSTF) encourages prostate-specific antigen (PSA) testing decisions to be based on shared decision-making (SDM) clinician professional judgment, and patient preferences. However, evidence suggests that SDM is underutilized in clinical practice, especially among the most vulnerable patients. The purpose of this study is to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate SDM for prostate cancer screening among Black men in the primary care setting, with the ultimate aim of improving/optimizing decision quality.Methods: We proposed a CHW-led decision-coaching program to facilitate SDM for prostate cancer screening discussions in Black men at a primary care FQHC. This study enrolled Black men who were patients at the participating clinical site and up to 15 providers who cared for them. We estimated to recruit 228 participants, ages 40-69 to be randomized to either (1) a decision aid along with decision coaching on PSA screening from a CHW or (2) receiving a decision aid along with CHW-led interaction on modifying dietary and lifestyle to serve as an attention control. The independent randomization process was implemented within each provider and we controlled for age by dividing patients into two strata: 40-54 years and 55-69 years. This sample size sufficiently powered the detection differences in the primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates. Primary outcome measures for patients will be decision quality and decision regarding whether to undergo PSA screening. Primary outcome measures for providers will be acceptability and feasibility of the intervention. We will examine how decision coaching about prostate cancer screening impact patient-provider communication. These outcomes will be analyzed quantitatively through objective, validated scales and qualitatively through semi-structured, in-depth interviews, and thematic analysis of clinical encounters. Through a conceptual model combining elements of the Preventative Health Care Model (PHM) and Informed Decision-Making Model, we hypothesize that the prostate cancer screening decision coaching intervention will result in a preference-congruent decision and decisional satisfaction. We also hypothesize that this intervention will improve physician satisfaction with counseling patients about prostate cancer screening.Discussion: Decision coaching is an evidence-based approach to improve decision quality in many clinical contexts, but its efficacy is incompletely explored for PSA screening among Black men in primary care. Our proposal to evaluate a CHW-led decision-coaching program for PSA screening has high potential for scalability and public health impact. Our results will determine the efficacy, cost-effectiveness, and sustainability of a CHW intervention in a community clinic setting in order to inform subsequent widespread dissemination, a critical research area highlighted by USPSTF.Trial Registration: The trial was registered prospectively with the National Institute of Health registry ( www.clinicaltrials.gov ), registration number NCT03726320 , on October 31, 2018. AD - VA New York Harbor Healthcare System, 423 E 23rd St, New York, NY, USA Departments of Urology, NYU Langone Health, 227 E 30th St, New York, NY, USA Population Health, NYU Langone Health, 227 E 30th St, New York, NY, USA Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA NYU College of Nursing, 433 First Avenue, New York, NY, USA Sunset Park Health Council, Brooklyn, NY, USA National Center for Bioethics in Research and Health Care, Tuskegee University, Tuskegee, USA The Fuqua School of Business, Duke University, Durham, NC, USA AN - 148628790. Language: English. Entry Date: In Process. Revision Date: 20210215. Publication Type: Journal Article. Journal Subset: Biomedical AU - Makarov, Danil V. AU - Feuer, Zachary AU - Ciprut, Shannon AU - Lopez, Natalia Martinez AU - Fagerlin, Angela AU - Shedlin, Michele AU - Gold, Heather T. AU - Li, Huilin AU - Lynch, Gina AU - Warren, Rueben AU - Ubel, Peter AU - Ravenell, Joseph E. DB - CINAHL Complete DO - 10.1186/s13063-021-05064-4 DP - EBSCOhost IS - 1 N1 - Europe; Peer Reviewed; UK & Ireland. Grant Information: R01MD012243/MD/NIMHD NIH HHS/United States. NLM UID: 101263253. PMID: NLM33568208. PY - 2021 SN - 1745-6215 SP - 1-11 ST - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers T2 - Trials TI - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148628790&site=ehost-live&scope=site VL - 22 ID - 2050 ER - TY - JOUR AB - Background: Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the USA. The United States Preventive Services Task Force (USPSTF) encourages prostate-specific antigen (PSA) testing decisions to be based on shared decision-making (SDM) clinician professional judgment, and patient preferences. However, evidence suggests that SDM is underutilized in clinical practice, especially among the most vulnerable patients. The purpose of this study is to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate SDM for prostate cancer screening among Black men in the primary care setting, with the ultimate aim of improving/optimizing decision quality. Methods: We proposed a CHW-led decision-coaching program to facilitate SDM for prostate cancer screening discussions in Black men at a primary care FQHC. This study enrolled Black men who were patients at the participating clinical site and up to 15 providers who cared for them. We estimated to recruit 228 participants, ages 40–69 to be randomized to either (1) a decision aid along with decision coaching on PSA screening from a CHW or (2) receiving a decision aid along with CHW-led interaction on modifying dietary and lifestyle to serve as an attention control. The independent randomization process was implemented within each provider and we controlled for age by dividing patients into two strata: 40–54 years and 55–69 years. This sample size sufficiently powered the detection differences in the primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates. Primary outcome measures for patients will be decision quality and decision regarding whether to undergo PSA screening. Primary outcome measures for providers will be acceptability and feasibility of the intervention. We will examine how decision coaching about prostate cancer screening impact patient-provider communication. These outcomes will be analyzed quantitatively through objective, validated scales and qualitatively through semi-structured, in-depth interviews, and thematic analysis of clinical encounters. Through a conceptual model combining elements of the Preventative Health Care Model (PHM) and Informed Decision-Making Model, we hypothesize that the prostate cancer screening decision coaching intervention will result in a preference-congruent decision and decisional satisfaction. We also hypothesize that this intervention will improve physician satisfaction with counseling patients about prostate cancer screening. Discussion: Decision coaching is an evidence-based approach to improve decision quality in many clinical contexts, but its efficacy is incompletely explored for PSA screening among Black men in primary care. Our proposal to evaluate a CHW-led decision-coaching program for PSA screening has high potential for scalability and public health impact. Our results will determine the efficacy, cost-effectiveness, and sustainability of a CHW intervention in a community clinic setting in order to inform subsequent widespread dissemination, a critical research area highlighted by USPSTF. Trial registration: The trial was registered prospectively with the National Institute of Health registry (www.clinicaltrials.gov), registration number NCT03726320, on October 31, 2018. © 2021, The Author(s). AD - VA New York Harbor Healthcare System, 423 E 23rd St, New York, NY, United States Departments of Urology, NYU Langone Health, 227 E 30th St, New York, NY, United States Population Health, NYU Langone Health, 227 E 30th St, New York, NY, United States Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, United States NYU College of Nursing, 433 First Avenue, New York, NY, United States Sunset Park Health Council, Brooklyn, NY, United States National Center for Bioethics in Research and Health Care, Tuskegee University, Tuskegee, United States The Fuqua School of Business, Duke University, Durham, NC, United States AU - Makarov, D. V. AU - Feuer, Z. AU - Ciprut, S. AU - Lopez, N. M. AU - Fagerlin, A. AU - Shedlin, M. AU - Gold, H. T. AU - Li, H. AU - Lynch, G. AU - Warren, R. AU - Ubel, P. AU - Ravenell, J. E. C7 - 128 DB - Scopus DO - 10.1186/s13063-021-05064-4 IS - 1 KW - Community health worker Prostate cancer PSA Racial disparity Randomized controlled trial Screening Shared decision-making M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 ST - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers T2 - Trials TI - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100966868&doi=10.1186%2fs13063-021-05064-4&partnerID=40&md5=a32a83c02bd69280dc0ff8fda1580b6f VL - 22 ID - 2152 ER - TY - JOUR AB - Background: Black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the USA. The United States Preventive Services Task Force (USPSTF) encourages prostate-specific antigen (PSA) testing decisions to be based on shared decision-making (SDM) clinician professional judgment, and patient preferences. However, evidence suggests that SDM is underutilized in clinical practice, especially among the most vulnerable patients. The purpose of this study is to evaluate the efficacy of a community health worker (CHW)-led decision-coaching program to facilitate SDM for prostate cancer screening among Black men in the primary care setting, with the ultimate aim of improving/optimizing decision quality. Methods: We proposed a CHW-led decision-coaching program to facilitate SDM for prostate cancer screening discussions in Black men at a primary care FQHC. This study enrolled Black men who were patients at the participating clinical site and up to 15 providers who cared for them. We estimated to recruit 228 participants, ages 40-69 to be randomized to either (1) a decision aid along with decision coaching on PSA screening from a CHW or (2) receiving a decision aid along with CHW-led interaction on modifying dietary and lifestyle to serve as an attention control. The independent randomization process was implemented within each provider and we controlled for age by dividing patients into two strata: 40-54 years and 55-69 years. This sample size sufficiently powered the detection differences in the primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates. Primary outcome measures for patients will be decision quality and decision regarding whether to undergo PSA screening. Primary outcome measures for providers will be acceptability and feasibility of the intervention. We will examine how decision coaching about prostate cancer screening impact patient-provider communication. These outcomes will be analyzed quantitatively through objective, validated scales and qualitatively through semi-structured, in-depth interviews, and thematic analysis of clinical encounters. Through a conceptual model combining elements of the Preventative Health Care Model (PHM) and Informed Decision-Making Model, we hypothesize that the prostate cancer screening decision coaching intervention will result in a preference-congruent decision and decisional satisfaction. We also hypothesize that this intervention will improve physician satisfaction with counseling patients about prostate cancer screening. Discussion: Decision coaching is an evidence-based approach to improve decision quality in many clinical contexts, but its efficacy is incompletely explored for PSA screening among Black men in primary care. Our proposal to evaluate a CHW-led decision-coaching program for PSA screening has high potential for scalability and public health impact. Our results will determine the efficacy, cost-effectiveness, and sustainability of a CHW intervention in a community clinic setting in order to inform subsequent widespread dissemination, a critical research area highlighted by USPSTF. Trial registration: The trial was registered prospectively with the National Institute of Health registry (www.clinicaltrials.gov), registration number NCT03726320, on October 31, 2018. AN - WOS:000619638000002 AU - Makarov, D. V. AU - Feuer, Z. AU - Ciprut, S. AU - Lopez, N. M. AU - Fagerlin, A. AU - Shedlin, M. AU - Gold, H. T. AU - Li, H. L. AU - Lynch, G. AU - Warren, R. AU - Ubel, P. AU - Ravenell, J. E. DA - Feb DO - 10.1186/s13063-021-05064-4 IS - 1 N1 - 128 33568208 PY - 2021 ST - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers T2 - Trials TI - Randomized trial of community health worker-led decision coaching to promote shared decision-making for prostate cancer screening among Black male patients and their providers VL - 22 ID - 2747 ER - TY - JOUR AB - Purpose: We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility-related distress for African American breast cancer survivors. Patients and Methods: Women were randomly assigned to immediate counseling or a 3-month waitlist. Three peer counselors conducted a 3-session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3-month follow-up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. Results: Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SD], 8 years) and a mean follow-up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty-one percent rated the program as "very useful to me." Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3-month follow-up (P < .0001), as did emotional distress (P = .0047) and menopause symptoms (P = .0128). Sexually dysfunctional women became less distressed (P = .0167). Conclusion: Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms. © 2006 by American Society of Clinical Oncology. AD - L.R. Schover, Department of Behavioral Science - Unit 1330, UT M.D. Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439, United States AU - Schover, L. R. AU - Jenkins, R. AU - Sui, D. AU - Adams, J. H. AU - Marion, M. S. AU - Jackson, K. E. DB - Embase Medline DO - 10.1200/JCO.2005.04.7159 IS - 10 KW - tamoxifen adult African American article breast cancer cancer survivor clinical trial controlled clinical trial controlled study emotional stress female female infertility follow up human major clinical study menopausal syndrome peer counseling priority journal questionnaire randomized controlled trial reproductive health sexual function LA - English M3 - Article N1 - L46638786 2006-04-01 PY - 2006 SN - 0732-183X SP - 1620-1626 ST - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors T2 - Journal of Clinical Oncology TI - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46638786&from=export http://dx.doi.org/10.1200/JCO.2005.04.7159 VL - 24 ID - 1250 ER - TY - JOUR AB - PURPOSE: We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility‐related distress for African American breast cancer survivors. PATIENTS AND METHODS: Women were randomly assigned to immediate counseling or a 3‐month waitlist. Three peer counselors conducted a 3‐session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3‐month follow‐up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. RESULTS: Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SD], 8 years) and a mean follow‐up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty‐one percent rated the program as "very useful to me." Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3‐month follow‐up (P < .0001), as did emotional distress (P = .0047) and menopause symptoms (P = .0128). Sexually dysfunctional women became less distressed (P = .0167). CONCLUSION: Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms. AN - CN-00555961 AU - Schover, L. R. AU - Jenkins, R. AU - Sui, D. AU - Adams, J. H. AU - Marion, M. S. AU - Jackson, K. E. DO - 10.1200/JCO.2005.04.7159 IS - 10 KW - Adaptation, Psychological Adult African Americans Aged Breast Neoplasms [ethnology, *psychology] Counseling Female Hot Flashes [prevention & control] Humans Knowledge Middle Aged Reproductive Medicine M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2006 SP - 1620‐1626 ST - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors T2 - Journal of clinical oncology TI - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00555961/full VL - 24 ID - 1353 ER - TY - JOUR AB - PURPOSE: We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility-related distress for African American breast cancer survivors. PATIENTS AND METHODS: Women were randomly assigned to immediate counseling or a 3-month waitlist. Three peer counselors conducted a 3-session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3-month follow-up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. RESULTS: Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SD], 8 years) and a mean follow-up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty-one percent rated the program as 'very useful to me.' Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3-month follow-up (P < .0001), as did emotional distress (P = .0047) and menopause symptoms (P = .0128). Sexually dysfunctional women became less distressed (P = .0167). CONCLUSION: Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms. AD - University of Texas M.D. Anderson Cancer Center and Sisters Network Inc, National Headquarters, Houston, TX 77230-1439, USA. Lschover@mdanderson.org AN - 106020352. Language: English. Entry Date: 20071207. Revision Date: 20150711. Publication Type: Journal Article AU - Schover, L. R. AU - Jenkins, R. AU - Sui, D. AU - Adams, J. H. AU - Marion, M. S. AU - Jackson, K. E. DB - CINAHL Complete DP - EBSCOhost IS - 10 KW - Breast Neoplasms -- Psychosocial Factors Counseling Reproductive Health Adaptation, Psychological Adult Black Persons Aged Breast Neoplasms -- Ethnology Female Hot Flashes -- Prevention and Control Knowledge Middle Age Human N1 - clinical trial; research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM16575013. PY - 2006 SN - 0732-183X SP - 1620-1626 ST - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors T2 - Journal of Clinical Oncology TI - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106020352&site=ehost-live&scope=site VL - 24 ID - 2051 ER - TY - JOUR AB - Purpose: We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility-related distress for African American breast cancer survivors. Patients and Methods: Women were randomly assigned to immediate counseling or a 3-month waitlist. Three peer counselors conducted a 3-session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3-month follow-up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. Results: Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SD], 8 years) and a mean follow-up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty-one percent rated the program as "very useful to me." Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3-month follow-up (P < .0001), as did emotional distress (P = .0047) and menopause symptoms (P = .0128). Sexually dysfunctional women became less distressed (P = .0167). Conclusion: Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms. © 2006 by American Society of Clinical Oncology. AD - University of Texas M.D. Anderson Cancer Center, Sisters Network Inc., National Headquarters, P.O. Box 301439, Houston, TX 77230-1439, United States AU - Schover, L. R. AU - Jenkins, R. AU - Sui, D. AU - Adams, J. H. AU - Marion, M. S. AU - Jackson, K. E. DB - Scopus DO - 10.1200/JCO.2005.04.7159 IS - 10 M3 - Article N1 - Cited By :75 Export Date: 22 March 2021 PY - 2006 SP - 1620-1626 ST - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors T2 - Journal of Clinical Oncology TI - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-33645729861&doi=10.1200%2fJCO.2005.04.7159&partnerID=40&md5=6a8d06a8d16bc689d314af50eccfb0f5 VL - 24 ID - 2578 ER - TY - JOUR AB - Purpose We designed a peer counseling program to improve sexual function, increase knowledge about reproductive health, and decrease menopausal symptoms and infertility-related distress for African American breast cancer survivors. Patients and Methods Women were randomly assigned to immediate counseling or a 3-month waitlist. Three peer counselors conducted a 3-session intervention using a detailed workbook. Questionnaires at baseline, after the waitlist period, at posttreatment, and at 3-month follow-up assessed spirituality, sexual function, menopause symptoms, emotional distress, relationship satisfaction, fertility concerns, and knowledge about reproductive health and breast cancer. At the postcounseling assessment, women rated the workbook, their counselor, and the program. Results Of 93 women screened, 60 women (65%) enrolled in the study. Women who completed counseling (80%; N = 48) had a mean age of 49 years (standard deviation [SDI, 8 years) and a mean follow-up of 4.5 years (SD, 3.8 years) since cancer diagnosis. Almost all rated the workbook as very easy to understand (94%) and their counselor as very knowledgeable (96%) and very skillful (98%). Eighty-one percent rated the program as "very useful to me." Immediate counseling and waitlist groups did not differ at baseline in psychologic adjustment, nor did scores change during the waitlist period. Therefore, the groups were combined in analyzing outcomes. Knowledge of reproductive issues improved significantly from baseline to 3-month follow-up (P <.0001), as did emotional distress (P =.0047) and menopause symptoms (P =.0128). Sexually dysfunctional women became less distressed (P =.0167). Conclusion Women valued the Sisters Peer Intervention in Reproductive Issues After Treatment program highly and found it relevant. The program had positive effects on knowledge and target symptoms. AN - WOS:000236660200021 AU - Schover, L. R. AU - Jenkins, R. AU - Sui, D. W. AU - Adams, J. H. AU - Marion, M. S. AU - Jackson, K. E. DA - Apr DO - 10.1200/JCO.2005.04.7159 IS - 10 N1 - 9th Biennial Symposium on Minorities, the Medically Underserved, and Cancer MAR 24-28, 2004 Washington, DC Intercultural Canc Council 16575013 PY - 2006 SN - 0732-183X SP - 1620-1626 ST - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors T2 - Journal of Clinical Oncology TI - Randomized trial of peer counseling on reproductive health in African American breast cancer survivors VL - 24 ID - 3221 ER - TY - JOUR AB - OBJECTIVE: Although African American (AA) men are at elevated risk for prostate cancer, medical guidelines do not present consistent screening recommendations for this group. However, all guidelines stress the need for screening decision making with a provider. This study evaluated the effectiveness of a brochure for the female partners of AA men, designed to help promote such discussion on the part of their mates. We also explored the effect of the partner's monitoring style (i.e., the extent to which the partner typically attends to health threats) on promoting discussion. METHODS: Female partners of AA men (N = 231) were randomized to receive either a prostate cancer screening Centers for Disease Control brochure for AA men, combined with a 'partner' brochure containing strategies to promote men's initiation of a provider visit to discuss screening, or the Centers for Disease Control brochure only and completed preintervention and post‐intervention surveys online. RESULTS: The message groups did not differ on taking active steps to engage in provider discussion: relative risk ratio (RRR) = 0.99, p = .98; thinking about it: RRR = 1.13, p = .74. However, among partners who received the partner brochure, monitoring style was associated with 'thinking about initiating a provider visit' on the part of the mate (RRR = 1.74, p < .01). Across conditions, monitoring style was also associated with 'taking active steps to initiate a provider visit' on the part of the mate (RRR = 1.38, p < .05). CONCLUSIONS: High monitoring partners may be effective in influencing their AA mates to initiate provider discussion, particularly when tailored messaging is provided. AN - CN-00984300 AU - Miller, S. M. AU - Roussi, P. AU - Scarpato, J. AU - Wen, K. Y. AU - Zhu, F. AU - Roy, G. DO - 10.1002/pon.3437 IS - 4 KW - *cancer control *cancer screening *health promotion *partner cancer monitoring *prostate cancer/di [Diagnosis] Adult African American African Americans Age Factors Aged Article Cancer epidemiology Cancer risk Clinical effectiveness Controlled study Decision Making Early Detection of Cancer Female Health belief Human Humans Major clinical study Male Middle Aged Odds Ratio Pamphlets Patient Education as Topic [*methods] Patient Participation Prospective study Prostatic Neoplasms [*diagnosis, ethnology] Randomized controlled trial Risk factor Spouse Spouses [*education] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 404‐411 ST - Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men T2 - Psycho-oncology TI - Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00984300/full VL - 23 ID - 1357 ER - TY - JOUR AB - BACKGROUND: Incidence rates for many types of cancer are higher among African American men than in the general population, yet African American men are less likely to participate in cancer screening trials. This paper describes the outcomes of a randomized trial (the AAMEN Project) designed to recruit African American men aged 55-74 years to a prostate, lung and colorectal cancer screening trial. METHODS: The recruitment interventions address four types of barriers to clinical trial participation: sociocultural barriers, economic barriers, individual barriers and barriers inherent in study design. Subjects were randomized to a control group or one of three increasingly intensive intervention arms, which used different combinations of mail, phone and in person church-based recruitment. RESULTS: Of the 39,432 African American men residing in the geographically defined study population (southeastern Michigan and northern Ohio), 17,770 men (45%) could be contacted, and 12,400 (31% of 39,432) were found to be eligible to participate. No statistically significant differences in age, education or income level were found among participants in the four study arms. A significantly greater enrollment yield (3.9%) was seen in the most intensive, church-based intervention arm, compared to the enrollment yields in the other two intervention arms (2.5 and 2.8%) or the control group (2.9%) (P < 0.01). CONCLUSIONS: The intervention that involved the highest rate of face-to-face contact with the study participants produced the highest enrollment yield, but several strategies that were thought could improve yield had no effect. These findings, which are consistent with current literature on population-based recruitment, should facilitate the development of future recruitment efforts involving older African American men. AD - M.E. Ford, Department of Medicine, Section of Health Services Research, Baylor College of Medicine Veterans Affairs Medical Center, Houston, TX 77030, USA. AU - Ford, M. E. AU - Havstad, S. L. AU - Davis, S. D. DB - Medline IS - 4 KW - African American aged article clinical trial colorectal tumor controlled clinical trial controlled study female human lung tumor male middle aged ovary tumor patient selection prostate tumor randomized controlled trial socioeconomics United States LA - English M3 - Article N1 - L41838495 2006-02-24 PY - 2004 SN - 1740-7745 SP - 343-351 ST - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Clinical trials (London, England) TI - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41838495&from=export VL - 1 ID - 1280 ER - TY - JOUR AB - BACKGROUND: Incidence rates for many types of cancer are higher among African American men than in the general population, yet African American men are less likely to participate in cancer screening trials. This paper describes the outcomes of a randomized trial (the AAMEN Project) designed to recruit African American men aged 55‐74 years to a prostate, lung and colorectal cancer screening trial. METHODS: The recruitment interventions address four types of barriers to clinical trial participation: sociocultural barriers, economic barriers, individual barriers and barriers inherent in study design. Subjects were randomized to a control group or one of three increasingly intensive intervention arms, which used different combinations of mail, phone and in person church‐based recruitment. RESULTS: Of the 39,432 African American men residing in the geographically defined study population (southeastern Michigan and northern Ohio), 17,770 men (45%) could be contacted, and 12,400 (31% of 39,432) were found to be eligible to participate. No statistically significant differences in age, education or income level were found among participants in the four study arms. A significantly greater enrollment yield (3.9%) was seen in the most intensive, church‐based intervention arm, compared to the enrollment yields in the other two intervention arms (2.5 and 2.8%) or the control group (2.9%) (P < 0.01). CONCLUSIONS: The intervention that involved the highest rate of face‐to‐face contact with the study participants produced the highest enrollment yield, but several strategies that were thought could improve yield had no effect. These findings, which are consistent with current literature on population‐based recruitment, should facilitate the development of future recruitment efforts involving older African American men. AN - CN-00531825 AU - Ford, M. E. AU - Havstad, S. L. AU - Davis, S. D. DO - 10.1191/1740774504cn029oa IS - 4 KW - African Americans Aged Colorectal Neoplasms [*diagnosis] Female Humans Lung Neoplasms [*diagnosis] Male Middle Aged Ovarian Neoplasms [*diagnosis] Patient Selection Prostatic Neoplasms [*diagnosis] Socioeconomic Factors United States M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non‐P.H.S.; Research Support, U.S. Gov't, P.H.S. PY - 2004 SP - 343‐351 ST - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial T2 - Clinical trials (London, England) TI - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00531825/full VL - 1 ID - 1352 ER - TY - JOUR AB - Background Incidence rates for many types of cancer are higher among African American men than in the general population, yet African American men are less likely to participate in cancer screening trials. This paper describes the outcomes of a randomized trial (the AAMEN Project) designed to recruit African American men aged 55–74 years to a prostate, lung and colorectal cancer screening trial. Methods The recruitment interventions address four types of barriers to clinical trial participation: sociocultural barriers, economic barriers, individual barriers and barriers inherent in study design. Subjects were randomized to a control group or one of three increasingly intensive intervention arms, which used different combinations of mail, phone and in person church-based recruitment. Results Of the 39 432 African American men residing in the geographically defined study population (southeastern Michigan and northern Ohio), 17 770 men (45%) could be contacted, and 12 400 (31% of 39 432) were found to be eligible to participate. No statistically significant differences in age, education or income level were found among participants in the four study arms. A significantly greater enrollment yield (3.9%) was seen in the most intensive, church-based intervention arm, compared to the enrollment yields in the other two intervention arms (2.5 and 2.8%) or the control group (2.9%) (P, 0.01). Conclusions The intervention that involved the highest rate of face-to-face contact with the study participants produced the highest enrollment yield, but several strategies that were thought could improve yield had no effect. These findings, which are consistent with current literature on population-based recruitment, should facilitate the development of future recruitment efforts involving older African American men. © 2004, Sage Publications. All rights reserved. AD - Department of Medicine, Section of Health Services Research, Baylor College of Medicine, Veterans Affairs Medical Center (152), 2002 Holcombe Boulevard, Houston, TX 77030, United States Henry Ford Health Sciences Center, Department of Biostatistics and Research Epidemiology, Detroit, MI, United States Department of Medicine, Section of Health Services Research, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, United States AU - Ford, M. E. AU - Havstad, S. L. AU - Davis, S. D. DB - Scopus DO - 10.1191/1740774504cn029oa IS - 4 M3 - Article N1 - Cited By :61 Export Date: 22 March 2021 PY - 2004 SP - 343-351 ST - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial T2 - Clinical Trials TI - A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-32944456391&doi=10.1191%2f1740774504cn029oa&partnerID=40&md5=7ac6cb96765bc3f4b843cec87fdb9c05 VL - 1 ID - 2610 ER - TY - JOUR AB - BACKGROUND: Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. METHODS: A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. RESULTS: The study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans. CONCLUSIONS: Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses. Cancer 2015;121:2951-2959. AD - R. Bastani, Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California at Los Angeles, 650 Charles Young Dr, A2-125 CHS, Los Angeles, CA, United States AU - Bastani, R. AU - Glenn, B. A. AU - Maxwell, A. E. AU - Ganz, P. A. AU - Mojica, C. M. AU - Alber, S. AU - Crespi, C. M. AU - Chang, L. C. DB - Embase Medline DO - 10.1002/cncr.29403 IS - 17 KW - adult African American aged article Asian cancer risk cancer screening Caucasian colorectal cancer controlled study counseling ethnicity family history female first-degree relative Hispanic human intervention study major clinical study male priority journal risk assessment LA - English M3 - Article N1 - L604295351 2015-05-14 2015-08-27 PY - 2015 SN - 1097-0142 0008-543X SP - 2951-2959 ST - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives T2 - Cancer TI - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604295351&from=export http://dx.doi.org/10.1002/cncr.29403 VL - 121 ID - 995 ER - TY - JOUR AB - Background: Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases.Methods: A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months.Results: The study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans.Conclusions: Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses. AN - 109625057. Language: English. Entry Date: 20150923. Revision Date: 20200708. Publication Type: journal article AU - Bastani, Roshan AU - Glenn, Beth A. AU - Maxwell, Annette E. AU - Ganz, Patricia A. AU - Mojica, Cynthia M. AU - Alber, Susan AU - Crespi, Catherine M. AU - Chang, L. Cindy DB - CINAHL Complete DO - 10.1002/cncr.29403 DP - EBSCOhost IS - 17 N1 - research; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: KL2 TR001118/TR/NCATS NIH HHS/United States. NLM UID: 0374236. PMID: NLM25946376. PY - 2015 SN - 0008-543X SP - 2951-2959 ST - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives T2 - Cancer (0008543X) TI - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109625057&site=ehost-live&scope=site VL - 121 ID - 2052 ER - TY - JOUR AB - BACKGROUND: Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. METHODS: A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. RESULTS: The study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans. CONCLUSIONS: Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses. Cancer 2015;121:2951-2959. © 2015 American Cancer Society. AD - Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California at Los Angeles, 650 Charles Young Dr, A2-125 CHS, Los Angeles, CA 90095-6900, United States Department of Epidemiology and Biostatistics, Institute for Health Promotion Research, University of Texas, Health Science Center at San Antonio, San Antonio, TX, United States Department of Statistics, Volgenau School of Engineering, George Mason University, Fairfax, VA, United States AU - Bastani, R. AU - Glenn, B. A. AU - Maxwell, A. E. AU - Ganz, P. A. AU - Mojica, C. M. AU - Alber, S. AU - Crespi, C. M. AU - Chang, L. C. DB - Scopus DO - 10.1002/cncr.29403 IS - 17 KW - colorectal cancer disparities first-degree relatives intervention research screening M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2015 SP - 2951-2959 ST - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives T2 - Cancer TI - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939568990&doi=10.1002%2fcncr.29403&partnerID=40&md5=9d4b7ff80f0b1e265463c16a4fa006b6 VL - 121 ID - 2361 ER - TY - JOUR AB - BACKGROUNDEthnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first-degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. METHODSA statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual-care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. RESULTSThe study sample of 1280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African-Americans. CONCLUSIONSOverall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses. Cancer 2015;121:2951-2959. (c) 2015 American Cancer Society. AN - WOS:000360244100017 AU - Bastani, R. AU - Glenn, B. A. AU - Maxwell, A. E. AU - Ganz, P. A. AU - Mojica, C. M. AU - Alber, S. AU - Crespi, C. M. AU - Chang, L. C. DA - Sep DO - 10.1002/cncr.29403 IS - 17 N1 - 25946376 PY - 2015 SN - 0008-543X SP - 2951-2959 ST - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives T2 - Cancer TI - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first-degree relatives VL - 121 ID - 2970 ER - TY - JOUR AB - Background: Ethnic minorities, especially African Americans and Latinos, bear a disproportionate burden of colorectal cancer (CRC), as reflected in incidence, cancer stage, and mortality statistics. In all ethnic groups, first‐degree relatives (FDRs) of CRC cases are at an elevated disease risk. However, underuse of CRC screening persists and is particularly evident among minority groups. The current study tested a stepped intervention to increase CRC screening among an ethnically diverse sample of FDRs of CRC cases. Methods: A statewide cancer registry was used to recruit CRC cases and through them their FDRs. Relatives who were not current on CRC screening were randomized to intervention or usual‐care control arms. The stepped intervention consisted of ethnically targeted and individually tailored print materials followed by telephone counseling for those unscreened at 6 months. Results: The study sample of 1,280 individuals consisted of 403 Latino, 284 African American, 242 Asian, and 351 white FDRs. Statistically significant effects were observed for the cumulative print plus telephone intervention at 12 months (26% in the intervention vs 18% in the control group) and the print intervention alone at 6 months (15% in the intervention vs 10% in the control group). The effect of the print intervention alone versus the cumulative interventions was not statistically significantly different. Stratified analyses indicated that the intervention was effective among white, Latino, and Asian individuals, but not among African‐Americans. Conclusions: Overall, the intervention was effective in increasing screening rates. Oversampling racial/ethnic minorities allowed for the examination of effects within subgroups, revealing no effect among African American individuals. This finding illustrates the importance of including sufficient numbers of participants from diverse ethnic subgroups in intervention research to enable such stratified analyses. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Bastani, Roshan, Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California at Los Angeles, 650 Charles Young Dr, A2-125 CHS, Los Angeles, CA, US, 90095-6900 AN - 2015-38876-014 AU - Bastani, Roshan AU - Glenn, Beth A. AU - Maxwell, Annette E. AU - Ganz, Patricia A. AU - Mojica, Cynthia M. AU - Alber, Susan AU - Crespi, Catherine M. AU - Chang, L. Cindy DB - psyh DO - 10.1002/cncr.29403 DP - EBSCOhost IS - 17 KW - screening disparities intervention research first‐degree relatives colorectal cancer Adult African Americans Aged Asian Americans Colorectal Neoplasms Early Detection of Cancer Female Hispanic Americans Humans Male Middle Aged Cancer Screening Clinical Trials Colon Disorders Cross Cultural Differences Health Disparities Asians Blacks Family Relations Health Promotion Latinos/Latinas N1 - Fielding School of Public Health, Jonsson Comprehensive Cancer Center, UCLA Kaiser Permanente Center for Health Equity, University of California at Los Angeles, Los Angeles, CA, US. Release Date: 20151214. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Crespi, Catherine M. Major Descriptor: Cancer Screening; Clinical Trials; Colon Disorders; Cross Cultural Differences; Health Disparities. Minor Descriptor: Asians; Blacks; Family Relations; Health Promotion; Latinos/Latinas. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Health Behavior Framework. Methodology: Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Sep 1, 2015. Publication History: First Posted Date: May 6, 2015; Accepted Date: Mar 12, 2015; Revised Date: Mar 6, 2015; First Submitted Date: Nov 20, 2014. Copyright Statement: American Cancer Society. 2015. Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: 1R01 CA75367. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: CA16024. Recipients: Crespi, Catherine M. PY - 2015 SN - 0008-543X 1097-0142 SP - 2951-2959 ST - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first‐degree relatives T2 - Cancer TI - Randomized trial to increase colorectal cancer screening in an ethnically diverse sample of first‐degree relatives UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2015-38876-014&site=ehost-live&scope=site bastani@ucla.edu VL - 121 ID - 1694 ER - TY - JOUR AB - Background: Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits. Objectives We performed a randomized, double-blind, placebo-controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self-reported fatigue, depression, and quality of life (QOL). Methods: Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed-effects models were used to assess treatment differences in outcomes over time. Results: Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28-85 years), pathologic stage (stage 0, 91%; stage I, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 μg/mL, respectively; the 24-week CoQ10 levels were 1.83 and 0.79 μg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States-Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy-Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy-Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies-Depression scale (11.6 vs 12.3, P = .632). Conclusions: Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self-reported fatigue or QOL after 24 weeks of treatment. AD - G.J. Lesser, Comprehensive Cancer Center of Wake Forest University, Medical Center Boulevard, Winston-Salem, NC, United States AU - Lesser, G. J. AU - Case, D. AU - Stark, N. AU - Williford, S. AU - Giguere, J. AU - Astrid Garino, L. AU - Naughton, M. J. AU - Vitolins, M. Z. AU - Lively, M. O. AU - Shaw, E. G. C2 - Soft Gel Technologies(United States) DB - Embase Medline IS - 1 KW - NCT00096356 alpha tocopherol anthracycline placebo ubidecarenone adult aged article Black person breast cancer cancer chemotherapy cancer fatigue cancer radiotherapy Caucasian Center for Epidemiologic Studies Depression scale controlled study double blind procedure drug blood level female Functional Assessment of Cancer Therapy Breast Cancer instrument Functional Assessment of Chronic Illness Therapy Fatigue tool Hispanic human limit of quantitation major clinical study Mood States Fatigue questionnaire patient compliance questionnaire randomized controlled trial self report treatment duration treatment outcome LA - English M3 - Article N1 - L611048805 2016-07-06 2019-10-31 PY - 2013 SN - 1879-596X 1544-6794 SP - 31-42 ST - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer T2 - Journal of Supportive Oncology TI - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611048805&from=export VL - 11 ID - 1091 ER - TY - JOUR AB - Background: Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits. Objectives We performed a randomized, double-blind, placebo-controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self-reported fatigue, depression, and quality of life (QOL). Methods: Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed-effects models were used to assess treatment differences in outcomes over time. Results: Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28-85 years), pathologic stage (stage 0, 91%; stage I, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 μg/mL, respectively; the 24-week CoQ10 levels were 1.83 and 0.79 μg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States-Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy-Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy-Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies-Depression scale (11.6 vs 12.3, P = .632). Conclusions: Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self-reported fatigue or QOL after 24 weeks of treatment. © 2013 Frontline Medical Communications. AD - Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC, United States Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, United States Southeast Cancer Control Consortium, Emerywood Hematology and Oncology, High Point, NC, United States Greenville Community Clinical Oncology Program, Cancer Center of the Carolinas, Greenville, SC, United States Metro-Minnesota CCOP, Minnesota Oncology, Coon Rapids, MN, United States Departments of Biochemistry, Wake Forest School of Medicine, United States Departments of Radiation Oncology, Wake Forest School of Medicine, United States AU - Lesser, G. J. AU - Case, D. AU - Stark, N. AU - Williford, S. AU - Giguere, J. AU - Astrid Garino, L. AU - Naughton, M. J. AU - Vitolins, M. Z. AU - Lively, M. O. AU - Shaw, E. G. AU - for the Wake Forest University Community Clinical Oncology Program Research, Base DB - Scopus IS - 1 M3 - Article N1 - Cited By :45 Export Date: 22 March 2021 PY - 2013 SP - 31-42 ST - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer T2 - Journal of Supportive Oncology TI - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879326542&partnerID=40&md5=0b922cce0cabccaee48f3b5a2e20c438 VL - 11 ID - 2441 ER - TY - JOUR AB - BACKGROUND: Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits. OBJECTIVES: We performed a randomized, double‐blind, placebo‐controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self‐reported fatigue, depression, and quality of life (QOL). Methods Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed‐effects models were used to assess treatment differences in outcomes over time. RESULTS: Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28‐85 years), pathologic stage (stage 0, 91%; stage 1, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 microg/mL, respectively; the 24‐week CoQ10 levels were 1.83 and 0.79 microg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States‐Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy‐Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy‐Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies‐Depression scale (11.6 vs 12.3, P = .632). CONCLUSIONS: Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self‐reported fatigue or QOL after 24 weeks of treatment. AN - CN-00869862 AU - Lesser, G. J. AU - Case, D. AU - Stark, N. AU - Williford, S. AU - Giguere, J. AU - Garino, L. A. AU - Naughton, M. J. AU - Vitolins, M. Z. AU - Lively, M. O. AU - Shaw, E. G. DO - 10.1016/j.suponc.2012.03.003 IS - 1 KW - Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Agents [*adverse effects] Breast Neoplasms [*complications, diagnosis, drug therapy] Dietary Supplements Double‐Blind Method Fatigue [chemically induced, *drug therapy] Female Follow‐Up Studies Humans Middle Aged Outcome Assessment, Health Care Patient Participation Prognosis Quality of Life Self Report [*statistics & numerical data] Ubiquinone [administration & dosage, *analogs & derivatives] Vitamins [*administration & dosage] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2013 SP - 31‐42 ST - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer T2 - Journal of supportive oncology TI - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00869862/full VL - 11 ID - 1616 ER - TY - JOUR AB - BACKGROUND: Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits. OBJECTIVES: We performed a randomized, double-blind, placebo-controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self-reported fatigue, depression, and quality of life (QOL). Methods Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed-effects models were used to assess treatment differences in outcomes over time. RESULTS: Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28-85 years), pathologic stage (stage 0, 91%; stage 1, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 microg/mL, respectively; the 24-week CoQ10 levels were 1.83 and 0.79 microg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States-Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy-Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy-Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies-Depression scale (11.6 vs 12.3, P = .632). CONCLUSIONS: Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self-reported fatigue or QOL after 24 weeks of treatment. AD - Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. glesser@wakehealth.edu AN - 107945175. Corporate Author: Wake Forest University Community Clinical Oncology Program Research Base. Language: English. Entry Date: 20130719. Revision Date: 20150712. Publication Type: Journal Article AU - Lesser, Glenn J. AU - Case, Doug AU - Stark, Nancy AU - Williford, Susan AU - Giguere, Jeff AU - Garino, L. Astrid AU - Naughton, Michelle J. AU - Vitolins, Mara Z. AU - Lively, Mark O. AU - Shaw, Edward G. DB - CINAHL Complete DP - EBSCOhost IS - 1 KW - Antineoplastic Agents -- Adverse Effects Breast Neoplasms -- Complications Coenzyme Q Fatigue -- Drug Therapy Outcome Assessment Self Report -- Utilization Vitamins -- Administration and Dosage Administration, Oral Adult Aged Aged, 80 and Over Breast Neoplasms -- Diagnosis Breast Neoplasms -- Drug Therapy Center for Epidemiological Studies Depression Scale Coenzyme Q -- Administration and Dosage Consumer Participation Dietary Supplements Double-Blind Studies Fatigue -- Chemically Induced Female Human Middle Age Prognosis Prospective Studies Psychological Tests Quality of Life Questionnaires Scales N1 - research; randomized controlled trial. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care; Palliative Care/Hospice. Instrumentation: Center for Epidemiologic Studies Depression Scale (CES-D); Functional Assessment of Chronic Illness Therapy-Fatigue; Functional Assessment of Cancer Therapy-Breast Cancer; Profile of Mood States-Fatigue. NLM UID: 101181305. PMID: NLM22682875. PY - 2013 SN - 1544-6794 SP - 31-42 ST - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer T2 - Journal of Supportive Oncology TI - A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107945175&site=ehost-live&scope=site VL - 11 ID - 1831 ER - TY - JOUR AB - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy. © 2012 Informa Healthcare USA, Inc. AD - L. Lyckholm, Virginia Commonwealth University Health System, Division of Hematology/Oncology and Palliative Care, P.O. Box 980230, Richmond, VA 23298-0230, United States AU - Lyckholm, L. AU - Heddinger, S. P. AU - Parker, G. AU - Coyne, P. J. AU - Ramakrishnan, V. AU - Smith, T. J. AU - Henkin, R. I. DB - Embase Medline DO - 10.3109/15360288.2012.676618 IS - 2 KW - antineoplastic agent bevacizumab capecitabine carboplatin cisplatin cyclophosphamide cytarabine dactinomycin docetaxel doxorubicin etoposide fluorouracil gemcitabine idarubicin ifosfamide irinotecan mitoxantrone vinorelbine tartrate oxaliplatin paclitaxel placebo rituximab trastuzumab vincristine zinc absence of side effects adult article cancer chemotherapy cancer radiotherapy clinical article controlled study diet supplementation double blind procedure female head and neck cancer head injury human liver disease male neoplasm quality of life randomized controlled trial smelling disorder taste disorder wellbeing LA - English M3 - Article N1 - L365191594 2012-07-16 2012-07-20 PY - 2012 SN - 1536-0288 1536-0539 SP - 111-114 ST - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders T2 - Journal of Pain and Palliative Care Pharmacotherapy TI - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365191594&from=export http://dx.doi.org/10.3109/15360288.2012.676618 VL - 26 ID - 1116 ER - TY - JOUR AB - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well‐being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double‐blinded, placebo‐controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0‐100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty‐nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty‐one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy. AN - CN-00968729 AU - Lyckholm, L. AU - Heddinger, S. P. AU - Parker, G. AU - Coyne, P. J. AU - Ramakrishnan, V. AU - Smith, T. J. AU - Henkin, R. I. DO - 10.3109/15360288.2012.676618 IS - 2 KW - Antineoplastic Agents [*adverse effects, therapeutic use] Double‐Blind Method Female Humans Male Middle Aged Neoplasms [drug therapy] Olfaction Disorders [chemically induced, *drug therapy] Taste Disorders [chemically induced, *drug therapy] Time Factors Treatment Outcome Zinc Sulfate [administration & dosage, *therapeutic use] M3 - Journal Article; Randomized Controlled Trial PY - 2012 SP - 111‐114 ST - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders T2 - Journal of pain & palliative care pharmacotherapy TI - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00968729/full VL - 26 ID - 1622 ER - TY - JOUR AB - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0–100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Lyckholm, Laurel, Virginia Commonwealth University Health System, Division of Hematology, P.O. Box 980230, Richmond, VA, US, 23298-0230 AN - 2012-18144-005 AU - Lyckholm, Laurel AU - Heddinger, Steven P. AU - Parker, Gwendolyn AU - Coyne, Patrick J. AU - Ramakrishnan, Viswanathan AU - Smith, Thomas J. AU - Henkin, Robert I. DB - psyh DO - 10.3109/15360288.2012.676618 DP - EBSCOhost IS - 2 KW - oral zinc chemotherapy taste disorders smell disorders placebo well being quality of life Antineoplastic Agents Double-Blind Method Female Humans Male Middle Aged Neoplasms Olfaction Disorders Time Factors Treatment Outcome Zinc Sulfate Olfactory Perception Zinc N1 - Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, US. Other Publishers: Haworth Press; Informa Healthcare. Release Date: 20121119. Correction Date: 20150928. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Chemotherapy; Olfactory Perception; Taste Disorders. Minor Descriptor: Placebo; Quality of Life; Well Being; Zinc. Classification: Vision & Hearing & Sensory Disorders (3299); Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 4. Issue Publication Date: Jun, 2012. Publication History: Accepted Date: Mar 8, 2012; First Submitted Date: Mar 8, 2012. Copyright Statement: Informa Healthcare USA, Inc. 2012. PY - 2012 SN - 1536-0288 1536-0539 SP - 111-114 ST - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders T2 - Journal of Pain & Palliative Care Pharmacotherapy TI - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-18144-005&site=ehost-live&scope=site lyckholm@vcu.edu VL - 26 ID - 1762 ER - TY - JOUR AB - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0-100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy. AD - Laurel Lyckholm, MD, is Professor of Hematology/Oncology and Palliative Care, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA; Steven P. Heddinger, MD, is a member of Medical Oncology and Hematology Associates, Cancer Center of Iowa, Des Moines, Iowa, USA; Gwendolyn Parker, MS, FNP-C, is a clinician and research nurse at Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA; Patrick J. Coyne, MSN, APRN, FAAN, is Clinical Director, Pain and Palliative Care, Thomas Palliative Care Services, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA; Viswanathan Ramakrishnan, PhD, is Professor, Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA; Thomas J. Smith, MD, is Professor and Director of Palliative Medicine, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, Maryland, USA; and Robert I. Henkin, MD, PhD, is Director of the Center for AN - 104471424. Language: English. Entry Date: 20120801. Revision Date: 20200708. Publication Type: Journal Article AU - Lyckholm, Laurel AU - Heddinger, Steven P. AU - Parker, Gwendolyn AU - Coyne, Patrick J. AU - Ramakrishnan, Viswanathan AU - Smith, Thomas J. AU - Henkin, Robert I. DB - CINAHL Complete DO - 10.3109/15360288.2012.676618 DP - EBSCOhost IS - 2 KW - Zinc -- Administration and Dosage Administration, Oral Chemotherapy, Cancer -- Adverse Effects Taste Disorders -- Drug Therapy Olfaction Disorders -- Drug Therapy Neoplasms -- Drug Therapy Treatment Outcomes Human Male Female Middle Age Repeated Measures Questionnaires Analysis of Variance Data Analysis Software Pilot Studies N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care; Pain and Pain Management; Palliative Care/Hospice. NLM UID: 101125608. PMID: NLM22764846. PY - 2012 SN - 1536-0288 SP - 111-114 ST - A Randomized, Placebo Controlled Trial of Oral Zinc for Chemotherapy-Related Taste and Smell Disorders T2 - Journal of Pain & Palliative Care Pharmacotherapy TI - A Randomized, Placebo Controlled Trial of Oral Zinc for Chemotherapy-Related Taste and Smell Disorders UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104471424&site=ehost-live&scope=site VL - 26 ID - 1832 ER - TY - JOUR AB - Abnormalities in taste and smell are commonly reported in patients receiving chemotherapy and may hinder appetite, dietary intake, nutritional well-being, and quality of life. Oral zinc has been used to treat taste and smell abnormalities in several altered physiologic states, including renal failure, liver disease, head trauma, and pregnancy, with varying results. The authors conducted a double-blinded, placebo-controlled randomized clinic trial over 3 months. Eligible patients were those taking chemotherapy that had alterations in taste and/or smell. The measurement of the primary end point, improvement in altered taste and smell, was made using a 0100 scale (100 describing no loss or distortion in taste and smell, and 0 describing the worst distortion or loss of taste and smell). Twenty-nine subjects were enrolled in each treatment group, of whom 31 were white, 26 African American, and 1 Native American. Forty-one patients were female. A wide range of cancer types was represented, with breast the most common (21 patients). The zinc dose was 220 mg orally twice daily (equivalent of 50 mg elemental zinc twice daily). There was no statistically significant improvement in loss or distortion of taste or smell with the addition of zinc. There was a trend toward improvement over time in all groups, except in the zinc group where there was a nonsignificant worsening in loss of smell over time. Zinc at standard doses did not provide significant benefit to taste or smell in patients receiving chemotherapy. © 2012 Informa Healthcare USA, Inc. AD - Department of Hematology/Oncology and Palliative Care, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States Medical Oncology and Hematology Associates, Cancer Center of Iowa, Des Moines, IA, United States Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States Pain and Palliative Care, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States Division of Biostatistics and Epidemiology, Medical University of South Carolina, Charleston, SC, United States Palliative Medicine, Johns Hopkins Medical Institutions, Johns Hopkins University, Baltimore, MD, United States Center for Molecular Nutrition and Sensory Disorders, Taste and Smell Clinic, Washington, DC, United States AU - Lyckholm, L. AU - Heddinger, S. P. AU - Parker, G. AU - Coyne, P. J. AU - Ramakrishnan, V. AU - Smith, T. J. AU - Henkin, R. I. DB - Scopus DO - 10.3109/15360288.2012.676618 IS - 2 KW - Cancer Chemotherapy Smell Taste Zinc M3 - Article N1 - Cited By :40 Export Date: 22 March 2021 PY - 2012 SP - 111-114 ST - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders T2 - Journal of Pain and Palliative Care Pharmacotherapy TI - A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84863596829&doi=10.3109%2f15360288.2012.676618&partnerID=40&md5=13238dd170ce15a764fb994d1dadf5d9 VL - 26 ID - 2458 ER - TY - JOUR AB - The American Cancer Society (ACS) defines cancer survivorship as beginning at diagnosis with cancer and continuing for the balance of life and views quality of life (QOL) as a key outcome. In this article, the authors describe the rationale, methodology, and sample characteristics of the 2 ACS Studies of Cancer Survivors (SCS): 1) a longitudinal study identifying and surveying survivors approximately 1 year postdiagnosis that includes plans to resurvey the panel at 2 years, 7 years, and 12 years postdiagnosis to identify predictors of QOL; and 2) a cross-sectional study of QOL among 3 separate cohorts of survivors who were approximately 3 years, 6 years, and 11 years postdiagnosis at the time of data collection. Survivors of prostate, breast, lung, colorectal, bladder, skin, kidney, ovarian, and uterine cancers and of non-Hodgkin lymphoma were sampled from 25 different central cancer registries, with African-American and Hispanic survivors over sampled. Survivors completed either mail or telephone surveys that described their physical, psychological, social, and spiritual functioning. The overall recruitment rate was 34.0%; 15411 participants completed surveys, of whom 40.1% had a high school education or less and 19.4% were racial/ethnic minorities. The SCS surveys provide a large diagnostically, geographically, and demographically diverse database on cancer survivorship that was designed to overcome some of the limitations of past research. Future reports will compare QOL of survivors at different well-defined times postdiagnosis, investigate the issues of understudied populations and diagnostic groups, and describe survivor QOL at state levels. Insights valuable to those considering registry-based studies are offered on issues of ascertainment, sampling, and recruitment. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Smith, Tenbroeck, Behavioral Research Center, American Cancer Society, 1599 Clifton Road NE, Atlanta, GA, US, 30329 AN - 2008-13392-002 AU - Smith, Tenbroeck AU - Stein, Kevin D. AU - Mehta, C. Christina AU - Kaw, Chiewkwei AU - Kepner, James L. AU - Buskirk, Trent AU - Stafford, Jeremy AU - Baker, Frank DB - psyh DO - 10.1002/cncr.22387 DP - EBSCOhost IS - 1 KW - cancer survivorship American Cancer Society diagnosis balance of life quality of life methodology Adolescent Adult Continental Population Groups Cross-Sectional Studies Female Humans Longitudinal Studies Male Middle Aged Minority Groups Neoplasms Patient Selection Registries Surveys and Questionnaires Survivors United States N1 - Behavioral Research Center, American Cancer Society, Atlanta, GA, US. Release Date: 20090921. Correction Date: 20190912. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Diagnosis; Methodology; Neoplasms; Quality of Life; Survivors. Classification: Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360). Tests & Measures: Satisfaction with Life Domains Scale-Cancer; Cancer Problems in Living Scale; Modified Rotterdam Symptom Checklist; Functional Assessment of Chronic Illness Therapy-Spiritual Well-being; Medical Outcomes Study Short Form-36; POMS-37; Lifestyle Behavior Scale; Multidimensional Scale of Perceived Social Support—Military Peers Items Addition DOI: 10.1037/t03506-000. Methodology: Empirical Study; Longitudinal Study; Quantitative Study. References Available: Y. Page Count: 12. Issue Publication Date: Jan, 2007. Sponsor: American Cancer Society, US. Recipients: No recipient indicated PY - 2007 SN - 0008-543X 1097-0142 SP - 1-12 ST - The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors T2 - Cancer TI - The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-13392-002&site=ehost-live&scope=site tenbroeck.smith@cancer.org VL - 109 ID - 1773 ER - TY - GEN AB - Presents correspondence on prognosis and treatment of patient with breast tumors. Emphasis on the need for definitive clinical trials for acceptance of adjuvant chemotherapy; Risks and benefits to adjuvant hormonal treatment; Impact of breast cancer recurrence in older patients. AU - Mirchandani, Deepu AU - Muggia, Franco AU - Mirchandani, D. AU - Muggia, F. DB - CINAHL Complete DO - 10.1093/jnci/93.18.1420-a DP - EBSCOhost J2 - JNCI: Journal of the National Cancer Institute KW - Breast Neoplasms -- Drug Therapy Selective Estrogen Receptor Modulators -- Therapeutic Use Chemotherapy, Adjuvant Antineoplastic Agents, Hormonal -- Therapeutic Use Proteins -- Drug Effects Female Middle Age Breast Neoplasms -- Mortality Tamoxifen -- Therapeutic Use Breast Neoplasms Adult Prognosis Neoplasm Recurrence, Local Aged Relative Risk Selective Estrogen Receptor Modulators -- Adverse Effects Proteins -- Analysis Tamoxifen -- Adverse Effects Patient Selection Hematologic Diseases -- Mortality Risk Assessment Human Hematologic Diseases -- Chemically Induced Lymph Nodes -- Pathology Black Persons Age Factors Antineoplastic Agents, Hormonal -- Adverse Effects Clinical Trials -- Methods Ethnic Groups Neoplasm Staging Treatment Outcomes Breast Neoplasms -- Pathology Validation Studies Comparative Studies Evaluation Research Multicenter Studies Impact of Events Scale Scales N1 - Accession Number: 6777494. Language: English. Entry Date: 20020215. Revision Date: 20190523. Publication Type: commentary; letter; research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Impact of Events Scale (IES). NLM UID: 7503089. PMID: NLM11562395. PB - Oxford University Press / USA PY - 2001 SN - 0027-8874 SP - 1420-1421 ST - Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes TI - Re: Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=6777494&site=ehost-live&scope=site VL - 93 ID - 2053 ER - TY - JOUR AN - 20075366 AU - Montoya, M. J. AU - Kent, E. E. DA - Feb 24 DO - 10.1093/jnci/djp507 DP - NLM ET - 2010/01/16 IS - 4 KW - African Americans/*statistics & numerical data Breast Neoplasms/etiology/mortality Environmental Exposure/adverse effects European Continental Ancestry Group/*statistics & numerical data Female *Health Status Disparities Humans Male Neoplasms/ethnology/*etiology/*mortality Neoplasms, Hormone-Dependent/etiology/mortality Prognosis Prostatic Neoplasms/etiology/mortality *Randomized Controlled Trials as Topic Risk Factors Socioeconomic Factors Survival Rate United States/epidemiology LA - eng N1 - 1460-2105 Montoya, Michael J Kent, Erin E Comment Letter United States J Natl Cancer Inst. 2010 Feb 24;102(4):277-8; author reply 280-2. doi: 10.1093/jnci/djp507. Epub 2010 Jan 14. PY - 2010 SN - 0027-8874 SP - 277-8; author reply 280-2 ST - Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group T2 - J Natl Cancer Inst TI - Re: Racial disparities in cancer survival among randomized clinical trials of the Southwest Oncology Group VL - 102 ID - 436 ER - TY - JOUR AB - A Breast Health Research Champion training program was a developed targeting self-identified community breast health advocates from a predominant African-American community with a significant breast cancer mortality disparity. Twelve individuals completed the program that provided training in breast cancer risk and screening, breast cancer research, biospecimen in cancer research, and human research subject protection. The training emphasized four key messages to be disseminated to the community. Trainees hosted a minimum of two social chats with individuals from their social networks and functioned as community researchers, acquiring consent and gathering follow-up data from attendees. Trainees reached 199 individuals from their social networks, and chats were diverse in the venue selected, mode of message transmission, and the audience reached. Post/pre questionnaire data from attendees at the chats showed significant improvement in knowledge, attitudes, and intended behaviors as it relates to breast cancer screening, clinical research, and biospecimen in research. Forty percent of attendees provided 4-week follow-up information. Of respondents eligible for mammography, 38 % had taken action to be screened, and 86 % of respondents had spoken about the information to someone else in their social network. Trainees expressed feelings of empowerment after completing the project, "feeling like the expert," and all trainees were surprised at the enthusiastic response from attendees of their chats. Trainees continued to disseminate the information learned from the training program during the 6 months following the training, reaching an additional 786 individuals in the community. AU - Rafie, C. AU - Ayers, A. AU - Cadet, D. AU - Quillin, J. AU - Hackney, M. H. DB - Medline DO - 10.1007/s13187-014-0720-0 IS - 3 KW - adult African American aged attitude to health breast tumor early cancer diagnosis education ethnology female health auxiliary health disparity health education human information dissemination mammography medical research middle aged organization and management procedures research subject risk assessment risk factor LA - English M3 - Article N1 - L615278935 2017-06-28 PY - 2015 SN - 1543-0154 SP - 599-606 ST - Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615278935&from=export http://dx.doi.org/10.1007/s13187-014-0720-0 VL - 30 ID - 998 ER - TY - JOUR AB - Background: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).Methods: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal.Results: In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively.Conclusions: PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings. AD - Division of Medical Oncology, Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle Washington Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham North Carolina Division of Urology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham North Carolina Section of Hematology and Medical Oncology, Department of Medicine, Tulane Cancer Center and Tulane University School of Medicine, New Orleans Louisiana Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas Nevada Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York New York Department of Surgery, Center for Prostate Disease Research at the Uniformed Services of Health Sciences, Bethesda Maryland Associated Medical Professionals, Syracuse New York Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville Tennessee Department of Health Policy, Vanderbilt University Medical Center, Nashville Tennessee Department of Urology, Carolina Urologic Research Center, Myrtle Beach South Carolina New York Cancer and Blood Specialists, New York New York Urology Associates PC, Nashville Tennessee Chesapeake Urology, Towson Maryland Department of Medical Oncology, GU Research Network, Omaha Nebraska Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles California Advanced Urology, Atlanta Georgia Prostate Cancer Research Institute, Marina del Rey California Department of Biometrics, Dendreon Pharmaceuticals LLC, Seattle Washington Department of Medical Affairs, Dendreon Pharmaceuticals LLC, Seattle Washington AN - 139686451. Language: English. Entry Date: 20200514. Revision Date: 20201130. Publication Type: journal article AU - Higano, Celestia S. AU - Armstrong, Andrew J. AU - Sartor, A. Oliver AU - Vogelzang, Nicholas J. AU - Kantoff, Philip W. AU - McLeod, David G. AU - Pieczonka, Christopher M. AU - Penson, David F. AU - Shore, Neal D. AU - Vacirca, Jeffrey AU - Concepcion, Raoul S. AU - Tutrone, Ronald F. AU - Nordquist, Luke T. AU - Quinn, David I. AU - Kassabian, Vahan AU - Scholz, Mark C. AU - Harmon, Matt AU - Tyler, Robert C. AU - Chang, Nancy N. AU - Tang, Hong DB - CINAHL Complete DO - 10.1002/cncr.32445 DP - EBSCOhost IS - 23 KW - Tissue Extracts -- Therapeutic Use Prostatic Neoplasms, Castration-Resistant -- Drug Therapy Data Collection Neoplasm Metastasis Human Prostatic Neoplasms, Castration-Resistant -- Pathology Aged Prospective Studies Tissue Extracts -- Pharmacodynamics Male Validation Studies Comparative Studies Evaluation Research Multicenter Studies N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Longitudinal Interval Follow-Up Evaluation (LIFE). Grant Information: R01 CA233585/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM31483485. PY - 2019 SN - 0008-543X SP - 4172-4180 ST - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer T2 - Cancer (0008543X) TI - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139686451&site=ehost-live&scope=site VL - 125 ID - 2054 ER - TY - JOUR AB - Background: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Methods: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal. Results: In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T–related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results–Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively. Conclusions: PROCEED provides contemporary survival data for sipuleucel-T–treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings. AD - C.S. Higano, Division of Medical Oncology, Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, United States AU - Higano, C. S. AU - Armstrong, A. J. AU - Sartor, A. O. AU - Vogelzang, N. J. AU - Kantoff, P. W. AU - McLeod, D. G. AU - Pieczonka, C. M. AU - Penson, D. F. AU - Shore, N. D. AU - Vacirca, J. AU - Concepcion, R. S. AU - Tutrone, R. F. AU - Nordquist, L. T. AU - Quinn, D. I. AU - Kassabian, V. AU - Scholz, M. C. AU - Harmon, M. AU - Tyler, R. C. AU - Chang, N. N. AU - Tang, H. AU - Cooperberg, M. R. DB - Embase Medline DO - 10.1002/cncr.32445 IS - 23 KW - adverse drug reaction African American aged article cancer growth cancer patient cancer prognosis cancer survival castration resistant prostate cancer cerebrovascular disease controlled study drug safety drug therapy drug withdrawal follow up gene expression human immunotherapy incidence major clinical study male medicare overall survival pharmacokinetics prospective study protein expression side effect abiraterone cabazitaxel docetaxel endogenous compound enzalutamide prostate specific antigen radium sipuleucel T LA - English M3 - Article N1 - L2002721234 2019-09-10 PY - 2019 SN - 1097-0142 0008-543X SP - 4172-4180 ST - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer T2 - Cancer TI - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2002721234&from=export http://dx.doi.org/10.1002/cncr.32445 VL - 125 ID - 830 ER - TY - JOUR AB - Background: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Methods: PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for ≥3 years or until death or study withdrawal. Results: In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T–related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results–Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively. Conclusions: PROCEED provides contemporary survival data for sipuleucel-T–treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings. © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. AD - Division of Medical Oncology, Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, United States Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, NC, United States Division of Urology, Duke University Medical Center, Duke Cancer Institute, Duke University, Durham, NC, United States Section of Hematology and Medical Oncology, Department of Medicine, Tulane Cancer Center and Tulane University School of Medicine, New Orleans, LA, United States Division of Hematology/Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States Department of Surgery, Center for Prostate Disease Research at the Uniformed Services of Health Sciences, Bethesda, MD, United States Associated Medical Professionals, Syracuse, NY, United States Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, United States Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN, United States Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, United States New York Cancer and Blood Specialists, New York, NY, United States Urology Associates PC, Nashville, TN, United States Chesapeake Urology, Towson, MD, United States Department of Medical Oncology, GU Research Network, Omaha, NE, United States Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States Advanced Urology, Atlanta, GA, Georgia Prostate Cancer Research Institute, Marina del Rey, CA, United States Department of Biometrics, Dendreon Pharmaceuticals LLC, Seattle, WA, United States Department of Medical Affairs, Dendreon Pharmaceuticals LLC, Seattle, WA, United States Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States Department of Epidemiology and Biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States AU - Higano, C. S. AU - Armstrong, A. J. AU - Sartor, A. O. AU - Vogelzang, N. J. AU - Kantoff, P. W. AU - McLeod, D. G. AU - Pieczonka, C. M. AU - Penson, D. F. AU - Shore, N. D. AU - Vacirca, J. AU - Concepcion, R. S. AU - Tutrone, R. F. AU - Nordquist, L. T. AU - Quinn, D. I. AU - Kassabian, V. AU - Scholz, M. C. AU - Harmon, M. AU - Tyler, R. C. AU - Chang, N. N. AU - Tang, H. AU - Cooperberg, M. R. DB - Scopus DO - 10.1002/cncr.32445 IS - 23 KW - immunotherapy overall survival prostate cancer safety M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2019 SP - 4172-4180 ST - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer T2 - Cancer TI - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071758135&doi=10.1002%2fcncr.32445&partnerID=40&md5=09a266dd32313176f4aca6a4d1011660 VL - 125 ID - 2215 ER - TY - JOUR AB - Background The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Methods PROCEED enrolled patients with mCRPC receiving 3 biweekly sipuleucel-T infusions. Assessments included overall survival (OS), serious adverse events (SAEs), cerebrovascular events (CVEs), and anticancer interventions (ACIs). Follow-up was for >= 3 years or until death or study withdrawal. Results In 2011-2017, 1976 patients were followed for 46.6 months (median). The median age was 72 years, and the baseline median prostate-specific antigen level was 15.0 ng/mL; 86.7% were white, and 11.6% were African American. Among the patients, 1902 had 1 or more sipuleucel-T infusions. The median OS was 30.7 months (95% confidence interval [CI], 28.6-32.2 months). Known prognostic factors were independently associated with OS in a multivariable analysis. Among the 1255 patients who died, 964 (76.8%) died of prostate cancer (PC) progression. The median time from the first infusion to PC death was 42.7 months (95% CI, 39.4-46.2 months). The incidence of sipuleucel-T-related SAEs was 3.9%. The incidence of CVEs was 2.8%, and the rate per 100 person-years was 1.2 (95% CI, 0.9-1.6). The CVE incidence among 11,972 patients with mCRPC from the Surveillance, Epidemiology, and End Results-Medicare database was 2.8%; the rate per 100 person-years was 1.5 (95% CI, 1.4-1.7). One or more ACIs (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium 223) were received by 77.1% of the patients after sipuleucel-T; 32.5% and 17.4% of the patients experienced 1- and 2-year treatment-free intervals, respectively. Conclusions PROCEED provides contemporary survival data for sipuleucel-T-treated men in a real-world setting of new life-prolonging agents, which will be useful in discussing treatment options with patients and in powering future trials with sipuleucel-T. The safety and tolerability of sipuleucel-T in PROCEED were consistent with previous findings. AN - WOS:000496338300010 AU - Higano, C. S. AU - Armstrong, A. J. AU - Sartor, A. O. AU - Vogelzang, N. J. AU - Kantoff, P. W. AU - McLeod, D. G. AU - Pieczonka, C. M. AU - Penson, D. F. AU - Shore, N. D. AU - Vacirca, J. AU - Concepcion, R. S. AU - Tutrone, R. F. AU - Nordquist, L. T. AU - Quinn, D. I. AU - Kassabian, V. AU - Scholz, M. C. AU - Harmon, M. AU - Tyler, R. C. AU - Chang, N. N. AU - Tang, H. AU - Cooperberg, M. R. DA - Dec DO - 10.1002/cncr.32445 IS - 23 N1 - 31483485 PY - 2019 SN - 0008-543X SP - 4172-4180 ST - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer T2 - Cancer TI - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer VL - 125 ID - 2805 ER - TY - JOUR AB - In a study of psychosocial factors related to prostate cancer screening (PCS) of African American men, researchers achieved significant success in recruitment. Key strategies included addressing specific barriers to PCS for African American men and placing recruitment efforts in a conceptual framework that addressed cultural issues (PEN-3 model). To conduct cancer prevention research in the African American community, to engage in health promotion in collaboration with churches, and to recruit African American men, a culturally competent approach that incorporates the values of the community is essential. Implications for addressing specific barriers to recruitment and building partnerships in health promotion research are discussed. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Abernethy, Alexis D., Graduate School of Psychology, Fuller Theological Seminary, 180 North Oakland Ave., Pasadena, CA, US, 91101 AN - 2005-07626-002 AU - Abernethy, Alexis D. AU - Magat, Maricar M. AU - Houston, Tina R. AU - Arnold, Harold L., Jr. AU - Bjorck, Jeffrey P. AU - Gorsuch, Richard L. DB - psyh DO - 10.1177/1090198104272253 DP - EBSCOhost IS - 4 KW - psychosocial factors prostate cancer screening African American men recruitment efforts cultural issues African Americans Culture Diagnostic Tests, Routine Gender Identity Health Behavior Health Promotion Health Services Accessibility Health Services Research Humans Male Patient Acceptance of Health Care Patient Selection Prostatic Neoplasms Religion Social Environment Socioeconomic Factors Sociology, Medical Blacks Cancer Screening Cultural Sensitivity Prostate N1 - Health Education Quarterly. Partial author list: First Author & Affiliation: Abernethy, Alexis D.; Graduate School of Psychology, Fuller Theological Seminary, Pasadena, CA, US. Release Date: 20050718. Correction Date: 20110725. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Society of Behavioral Medicine, 2002, Washington, DC, US. Conference Note: This article received a Citation at the aforementioned annual meeting. Major Descriptor: Blacks; Cancer Screening; Cultural Sensitivity; Health Promotion; Psychosocial Factors. Minor Descriptor: Prostate. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300). References Available: Y. Page Count: 11. Issue Publication Date: Aug, 2005. PY - 2005 SN - 1090-1981 1552-6127 SP - 441-451 ST - Recruiting African American Men for Cancer Screening Studies: Applying a Culturally Based Model T2 - Health Education & Behavior TI - Recruiting African American Men for Cancer Screening Studies: Applying a Culturally Based Model UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2005-07626-002&site=ehost-live&scope=site aabernet@fuller.edu VL - 32 ID - 1793 ER - TY - JOUR AB - In a study of psychosocial factors related to prostate cancer screening (PCS) of African American men, researchers achieved significant success in recruitment. Key strategies included addressing specific barriers to PCS for African American men and placing recruitment efforts in a conceptual framework that addressed cultural issues (PEN-3 model). To conduct cancer prevention research in the African American community, to engage in health promotion in collaboration with churches, and to recruit African American men, a culturally competent approach that incorporates the values of the community is essential. Implications for addressing specific barriers to recruitment and building partnerships in health promotion research are discussed. AD - Graduate School of Psychology, Fuller Theological Seminary, 180 North Oakland Ave., Pasadena, CA 91101; aabernet@fuller.edu AN - 106534103. Language: English. Entry Date: 20051104. Revision Date: 20150711. Publication Type: Journal Article AU - Abernethy, A. D. AU - Magat, M. M. AU - Houston, T. R. AU - Arnold, H. L., Jr. AU - Bjorck, J. P. AU - Gorsuch, R. L. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Black Persons Cancer Screening Research Subject Recruitment Churches Conceptual Framework Cross Sectional Studies Culture Funding Source Health Behavior Health Education Health Promotion Male Models, Theoretical Prostatic Neoplasms -- Prevention and Control Human N1 - research; tables/charts. Commentary: Lewis RK. Using a culturally relevant theory to recruit African American men for prostate cancer screening. (HEALTH EDUC BEHAV) Aug2005; 32 (4): 452-454. Journal Subset: Health Promotion/Education; Peer Reviewed; USA. Grant Information: Supported by the Cancer Research Fund, under Interagency Agreement 97-12013 (University of California, Davis, contract 98 -- 00924V), with the Department of Health Services, Cancer Research Program. NLM UID: 9704962. PMID: NLM16009743. PY - 2005 SN - 1090-1981 SP - 441-451 ST - Recruiting African American men for cancer screening studies: applying a culturally based model T2 - Health Education & Behavior TI - Recruiting African American men for cancer screening studies: applying a culturally based model UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106534103&site=ehost-live&scope=site VL - 32 ID - 2055 ER - TY - JOUR AB - Purpose: This study evaluated the process of recruiting African American women to participate in genetic counseling research for BRCA1 and BRCA2 (BHCA1/2) mutations with respect to referral, study enrollment, and participation in genetic counseling. Patients and Methods: African American women (n = 783) were referred for study enrollment. Results: Of 783 referrals, 164 (21%) women were eligible for enrollment. Eligible women were most likely to be referred from oncology clinics (44%) and were least likely to be referred from general medical practices (11%; χ2 = 96.80; P = .0001). Overall, 62% of eligible women enrolled onto the study and 50% of enrollees completed genetic counseling. Women with a stronger family history of cancer (odds ratio [OR] = 3.18; 95% CI, 1.36 to 7.44; P = .01) and those referred from oncology clinics and community oncology resources (OR = 2.97; 95% CI, 1.34 to 6.58; P = .01) were most likely to enroll onto the study. Referral from oncology clinics was associated significantly with participation in genetic counseling (OR = 5.46; 95% CI, 1.44 to 20.60; P = .01). Conclusion: Despite receiving a large number of referrals, only a small subset of women were eligible for enrollment. Oncology settings were the most effective at identifying eligible African American women and general medical practices were the least effective. Factors associated with enrollment included having a stronger family history of cancer and being referred from oncology clinics and community oncology resources. Referral from oncology clinics was the only factor associated significantly with participation in genetic counseling. Education about hereditary breast cancer may be needed among primary care providers to enhance appropriate referral of African American women to genetic counseling for BRCA1/2 mutations. © 2005 by American Society of Clinical Oncology. AD - C.H. Halbert, University of Pennsylvania, 3535 Market St, Philadelphia, PA 19104, United States AU - Halbert, C. H. AU - Brewster, K. AU - Collier, A. AU - Smith, C. AU - Kessler, L. AU - Weathers, B. AU - Stopfer, J. E. AU - Domchek, S. AU - Wileyto, E. P. DB - Embase Medline DO - 10.1200/JCO.2004.00.4952 IS - 31 KW - BRCA1 protein BRCA2 protein adult African American article breast cancer cancer center cancer research community care controlled study hereditary tumor syndrome female gene mutation genetic counseling human major clinical study medical practice patient referral priority journal LA - English M3 - Article N1 - L46657397 2005-12-01 PY - 2005 SN - 0732-183X SP - 7967-7973 ST - Recruiting African American women to participate in hereditary breast cancer research T2 - Journal of Clinical Oncology TI - Recruiting African American women to participate in hereditary breast cancer research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46657397&from=export http://dx.doi.org/10.1200/JCO.2004.00.4952 VL - 23 ID - 1259 ER - TY - JOUR AB - PURPOSE: This study evaluated the process of recruiting African American women to participate in genetic counseling research for BRCA1 and BRCA2 (BRCA1/2) mutations with respect to referral, study enrollment, and participation in genetic counseling. PATIENTS AND METHODS: African American women (n = 783) were referred for study enrollment. RESULTS: Of 783 referrals, 164 (21%) women were eligible for enrollment. Eligible women were most likely to be referred from oncology clinics (44%) and were least likely to be referred from general medical practices (11%; chi(2) = 96.80; P = .0001). Overall, 62% of eligible women enrolled onto the study and 50% of enrollees completed genetic counseling. Women with a stronger family history of cancer (odds ratio [OR] = 3.18; 95% CI, 1.36 to 7.44; P = .01) and those referred from oncology clinics and community oncology resources (OR = 2.97; 95% CI, 1.34 to 6.58; P = .01) were most likely to enroll onto the study. Referral from oncology clinics was associated significantly with participation in genetic counseling (OR = 5.46; 95% CI, 1.44 to 20.60; P = .01). CONCLUSION: Despite receiving a large number of referrals, only a small subset of women were eligible for enrollment. Oncology settings were the most effective at identifying eligible African American women and general medical practices were the least effective. Factors associated with enrollment included having a stronger family history of cancer and being referred from oncology clinics and community oncology resources. Referral from oncology clinics was the only factor associated significantly with participation in genetic counseling. Education about hereditary breast cancer may be needed among primary care providers to enhance appropriate referral of African American women to genetic counseling for BRCA1/2 mutations. AD - Abramson Cancer Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, 19104, USA. Chanita@mail.med.upenn.edu AN - 106021684. Language: English. Entry Date: 20071207. Revision Date: 20150711. Publication Type: Journal Article. Journal Subset: Biomedical AU - Halbert, C. H. AU - Brewster, K. AU - Collier, A. AU - Smith, C. AU - Kessler, L. AU - Weathers, B. AU - Stopfer, J. E. AU - Domchek, S. AU - Wileyto, E. P. DB - CINAHL Complete DP - EBSCOhost IS - 31 KW - Black Persons Breast Neoplasms -- Ethnology Breast Neoplasms Genes, BRCA Genetic Counseling -- Utilization Referral and Consultation Attitude to Health -- Ethnology Breast Neoplasms -- Psychosocial Factors Female Genetic Counseling -- Psychosocial Factors Middle Age Mutation Patient Selection Risk Factors Socioeconomic Factors N1 - Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM16258097. PY - 2005 SN - 0732-183X SP - 7967-7973 ST - Recruiting African American women to participate in hereditary breast cancer research T2 - Journal of Clinical Oncology TI - Recruiting African American women to participate in hereditary breast cancer research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106021684&site=ehost-live&scope=site VL - 23 ID - 2056 ER - TY - JOUR AB - Purpose: This study evaluated the process of recruiting African American women to participate in genetic counseling research for BRCA1 and BRCA2 (BHCA1/2) mutations with respect to referral, study enrollment, and participation in genetic counseling. Patients and Methods: African American women (n = 783) were referred for study enrollment. Results: Of 783 referrals, 164 (21%) women were eligible for enrollment. Eligible women were most likely to be referred from oncology clinics (44%) and were least likely to be referred from general medical practices (11%; χ2 = 96.80; P = .0001). Overall, 62% of eligible women enrolled onto the study and 50% of enrollees completed genetic counseling. Women with a stronger family history of cancer (odds ratio [OR] = 3.18; 95% CI, 1.36 to 7.44; P = .01) and those referred from oncology clinics and community oncology resources (OR = 2.97; 95% CI, 1.34 to 6.58; P = .01) were most likely to enroll onto the study. Referral from oncology clinics was associated significantly with participation in genetic counseling (OR = 5.46; 95% CI, 1.44 to 20.60; P = .01). Conclusion: Despite receiving a large number of referrals, only a small subset of women were eligible for enrollment. Oncology settings were the most effective at identifying eligible African American women and general medical practices were the least effective. Factors associated with enrollment included having a stronger family history of cancer and being referred from oncology clinics and community oncology resources. Referral from oncology clinics was the only factor associated significantly with participation in genetic counseling. Education about hereditary breast cancer may be needed among primary care providers to enhance appropriate referral of African American women to genetic counseling for BRCA1/2 mutations. © 2005 by American Society of Clinical Oncology. AD - Abramson Cancer Center, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States University of Pennsylvania, 3535 Market St, Philadelphia, PA 19104, United States AU - Halbert, C. H. AU - Brewster, K. AU - Collier, A. AU - Smith, C. AU - Kessler, L. AU - Weathers, B. AU - Stopfer, J. E. AU - Domchek, S. AU - Wileyto, E. P. DB - Scopus DO - 10.1200/JCO.2004.00.4952 IS - 31 M3 - Article N1 - Cited By :40 Export Date: 22 March 2021 PY - 2005 SP - 7967-7973 ST - Recruiting African American women to participate in hereditary breast cancer research T2 - Journal of Clinical Oncology TI - Recruiting African American women to participate in hereditary breast cancer research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-32944474116&doi=10.1200%2fJCO.2004.00.4952&partnerID=40&md5=7698ef5560ae30bc09f97c42f1294c8f VL - 23 ID - 2587 ER - TY - JOUR AB - Purpose This study evaluated the process of recruiting African American women to participate in genetic counseling research for BRCA1 and BRCA2 (BRCA1/2) mutations with respect to referral, study enrollment, and participation in genetic counseling. Patients and Methods African American women (n = 783) were referred for study enrollment. Results Of 783 referrals, 164 (21%) women were eligible for enrollment. Eligible women were most likely to be referred from oncology clinics (44%) and were least likely to be referred from general medical practices (11%; chi(2) = 96.80; P = .0001). Overall, 62% of eligible women enrolled onto the study and 50% of enrollees completed genetic counseling. Women with a stronger family history of cancer (odds ratio [OR] = 3.18; 95% CI, 1.36 to 7.44; P = .01) and those referred from oncology clinics and community oncology resources (OR = 2.97; 95% CI, 1.34 to 6.58; P = .01) were most likely to enroll onto the study. Referral from oncology clinics was associated significantly with participation in genetic counseling (OR = 5.46; 95% CI, 1.44 to 20.60; P = .01). Conclusion Despite receiving a large number of referrals, only a small subset of women were eligible for enrollment. Oncology settings were the most effective at identifying eligible African American women and general medical practices were the least effective. Factors associated with enrollment included having a stronger family history of cancer and being referred from oncology clinics and community oncology resources. Referral from oncology clinics was the only factor associated significantly with participation in genetic counseling. Education about hereditary breast cancer may be needed among primary care providers to enhance appropriate referral of African American women to genetic counseling for BRCA1/2 mutations. AN - WOS:000233066700031 AU - Halbert, C. H. AU - Brewster, K. AU - Collier, A. AU - Smith, C. AU - Kessler, L. AU - Weathers, B. AU - Stopfer, J. E. AU - Domchek, S. AU - Wileyto, E. P. DA - Nov DO - 10.1200/JCO.2004.00.4952 IS - 31 N1 - 16258097 PY - 2005 SN - 0732-183X SP - 7967-7973 ST - Recruiting African American women to participate in hereditary breast cancer research T2 - Journal of Clinical Oncology TI - Recruiting African American women to participate in hereditary breast cancer research VL - 23 ID - 3233 ER - TY - JOUR AB - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, it is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Hart, Alton Jr., Division of Quality Health Care, Department of Internal Medicine, Virginia Commonwealth University, PO Box 980306, Richmond, VA, US, 23298-0306 AN - 2008-13810-004 AU - Hart, Alton, Jr. AU - Underwood, Sandra M. AU - Smith, Wally R. AU - Bowen, Deborah J. AU - Rivers, Brian M. AU - Jones, Randy A. AU - Parker, Dennis AU - Allen, Johnnie DB - psyh DO - 10.1016/S0027-9684(15)31437-1 DP - EBSCOhost IS - 9 KW - African American men barbershops prostate cancer health education Adult African Americans Barbering Humans Male Prostatic Neoplasms United States Blacks Neoplasms Prostate Small Businesses Human Males N1 - (Chip) Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, US. Other Publishers: Elsevier Science. Release Date: 20091102. Correction Date: 20160502. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Health Education; Neoplasms; Prostate; Small Businesses. Minor Descriptor: Human Males. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Sep, 2008. Sponsor: American Cancer Society. Grant: MRS-GT-04-209-01-CPPB. Recipients: No recipient indicated PY - 2008 SN - 0027-9684 1943-4693 SP - 1012-1020 ST - Recruiting African-American barbershops for prostate cancer education T2 - Journal of the National Medical Association TI - Recruiting African-American barbershops for prostate cancer education UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2008-13810-004&site=ehost-live&scope=site ahart@vcu.edu VL - 100 ID - 1754 ER - TY - JOUR AB - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, if is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research. AN - WOS:000259690700005 AU - Hart, A. AU - Underwood, S. M. AU - Smith, W. R. AU - Bowen, D. J. AU - Rivers, B. M. AU - Jones, R. A. AU - Parker, D. AU - Allen, J. DA - Sep DO - 10.1016/S0027-9684(15)31437-1 IS - 9 N1 - 18807428 PY - 2008 SN - 0027-9684 SP - 1012-1020 ST - Recruiting African-American barbershops for prostate cancer education T2 - Journal of the National Medical Association TI - Recruiting African-American barbershops for prostate cancer education VL - 100 ID - 3166 ER - TY - JOUR AB - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, it is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research. AD - Massey Cancer Center, Richmond, VA, USA Massey Cancer Center, Richmond, VA, USA. ahart@vcu.edu AN - 105686253. Language: English. Entry Date: 20081107. Revision Date: 20190612. Publication Type: journal article AU - Hart, A., Jr. AU - Underwood, S. M. AU - Smith, W. R. AU - Bowen, D. J. AU - Rivers, B. M. AU - Jones, R. A. AU - Parker, D. AU - Allen, J. C. AU - Hart, Alton, Jr. AU - Underwood, Sandra M. AU - Smith, Wally R. AU - Bowen, Deborah J. AU - Rivers, Brian M. AU - Jones, Randy A. AU - Parker, Dennis AU - Allen, Johnnie Chip DB - CINAHL Complete DP - EBSCOhost IS - 9 KW - Black Persons Health Education -- Methods Occupations and Professions Prostatic Neoplasms -- Prevention and Control Adult Male United States N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. NLM UID: 7503090. PMID: NLM18807428. PY - 2008 SN - 0027-9684 SP - 1012-1020 ST - Recruiting African-American barbershops for prostate cancer education T2 - Journal of the National Medical Association TI - Recruiting African-American barbershops for prostate cancer education UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105686253&site=ehost-live&scope=site VL - 100 ID - 2057 ER - TY - JOUR AB - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, it is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research. AD - A. Hart Jr., Division of Quality Health Care, Department of Internal Medicine, Virginia Commonwealth University, PO Box 980306, Richmond, VA 23298-0306, United States AU - Hart Jr, A. AU - Underwood, S. M. AU - Smith, W. R. AU - Bowen, D. J. AU - Rivers, B. M. AU - Jones, R. A. AU - Parker, D. AU - Allen, J. DB - Embase Medline DO - 10.1016/S0027-9684(15)31437-1 IS - 9 KW - adult African American aged article computer human major clinical study male patient education priority journal prostate cancer public health LA - English M3 - Article N1 - L352413129 2008-10-17 PY - 2008 SN - 0027-9684 SP - 1012-1020 ST - Recruiting African-American barbershops for prostate cancer education T2 - Journal of the National Medical Association TI - Recruiting African-American barbershops for prostate cancer education UR - https://www.embase.com/search/results?subaction=viewrecord&id=L352413129&from=export http://dx.doi.org/10.1016/S0027-9684(15)31437-1 VL - 100 ID - 1206 ER - TY - JOUR AB - Prostate cancer is the most common cause of cancer in men and the second leading cause of cancer deaths. African-American men bear a disproportionate burden of prostate cancer diagnosis and mortality. Current guidelines for prostate cancer screening differ among various medical organizations. Therefore, it is important that African-American men have the appropriate information needed to make informed decisions about prostate cancer screening. Unfortunately, a large percentage of African-American men could potentially be excluded from receiving culturally appropriate prostate cancer education. Therefore, a study was designed to recruit and intervene with African-American men and barbershops for increasing prostate cancer screening decision-making. The purpose of this study was to learn effective strategies for recruiting African-American barbershops for prostate cancer education and to determine barbershop proprietors' willingness to allow their barbershops to be used for research. In this paper, we present the outcomes of our recruitment methods for African-American barbershops, including a comparative description of participating and nonparticipating barbershops using the iMark Data System. One-hundred percent of the surveyed proprietors reported that they would allow their clients to learn about prostate cancer. Ninety-six percent reported they would consider allowing their clients to have access to handheld computers to learn about prostate cancer. We conclude from this study that African-American barbershops in general are welcoming environments in which to implement community-based prostate cancer education and public health research. AD - Massey Cancer Center, Richmond, VA, United States Internal Medicine, Richmond, VA, United States Virginia Commonwealth University, Richmond, VA, United States University of Wisconsin, Milwaukee, WI, United States Boston University, Boston, MA, United States Moffitt Cancer Center, Tampa, FL, United States University of Virginia, Charlottesville, VA, United States Ohio Department of Health, Columbus, OH, United States Division of Quality Health Care, Department of Internal Medicine, Virginia Commonwealth University, PO Box 980306, Richmond, VA 23298-0306, United States AU - Hart Jr, A. AU - Underwood, S. M. AU - Smith, W. R. AU - Bowen, D. J. AU - Rivers, B. M. AU - Jones, R. A. AU - Parker, D. AU - Allen, J. DB - Scopus DO - 10.1016/S0027-9684(15)31437-1 IS - 9 KW - African Americans Prostate cancer M3 - Article N1 - Cited By :35 Export Date: 22 March 2021 PY - 2008 SP - 1012-1020 ST - Recruiting African-American barbershops for prostate cancer education T2 - Journal of the National Medical Association TI - Recruiting African-American barbershops for prostate cancer education UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-52449115118&doi=10.1016%2fS0027-9684%2815%2931437-1&partnerID=40&md5=94f287e50756a6e819b7b3882ec84011 VL - 100 ID - 2542 ER - TY - JOUR AB - BACKGROUND: Improving the health of black and minority ethnic (BME) men in the US continues to be a public health priority. Compared with men of other races and ethnicities, African-American men have higher rates of mortality and morbidity from chronic illness and diseases including cancer, heart disease, prostate cancer, diabetes and HIV/AIDS. One way to address these disparities is to include African-American men in health research, to elicit their perspectives on health risks and protective factors. These can then inform interventions aimed at reducing health disparities. However, challenges remain in recruiting and engaging African-American men in health research. AIM: To provide strategies for recruiting African-American men in health research, using as an exemplar a qualitative study of fathers' perspectives of sexual health promotion with young African-American males. DISCUSSION: Efforts are needed to increase the representation of African-American men in health research. Ensuring that researchers are aware of the cultural, social and environmental factors related to decisions to participate in research can lead to effective methods to recruit and engage them. CONCLUSION: There are several essential strategies for increasing African-American men's participation in health research: ensuring the research team is culturally and gender-sensitive; recruiting in trusted environments; using respected gatekeepers; developing trust with participants; and being transparent. IMPLICATIONS FOR PRACTICE: Implementing strategies to include African-American men in health research has the potential to improve health disparities in the US. AU - Randolph, S. AU - Coakley, T. AU - Shears, J. DB - Medline DO - 10.7748/nr.2018.e1569 IS - 1 KW - adult African American aged ethnic group female human male medical research middle aged minority group patient selection procedures qualitative research socioeconomics statistics and numerical data United States very elderly LA - English M3 - Article N1 - L623252721 2018-08-01 PY - 2018 SN - 1351-5578 SP - 8-12 ST - Recruiting and engaging African-American men in health research T2 - Nurse researcher TI - Recruiting and engaging African-American men in health research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L623252721&from=export http://dx.doi.org/10.7748/nr.2018.e1569 VL - 26 ID - 893 ER - TY - JOUR AB - Background Improving the health of black and minority ethnic (BME) men in the US continues to be a public health priority. Compared with men of other races and ethnicities, African-American men have higher rates of mortality and morbidity from chronic illness and diseases including cancer, heart disease, prostate cancer, diabetes and HIV/AIDS. One way to address these disparities is to include African-American men in health research, to elicit their perspectives on health risks and protective factors. These can then inform interventions aimed at reducing health disparities. However, challenges remain in recruiting and engaging African-American men in health research. Aim To provide strategies for recruiting African-American men in health research, using as an exemplar a qualitative study of fathers' perspectives of sexual health promotion with young African-American males. Discussion Efforts are needed to increase the representation of African-American men in health research. Ensuring that researchers are aware of the cultural, social and environmental factors related to decisions to participate in research can lead to effective methods to recruit and engage them. Conclusion There are several essential strategies for increasing African-American men's participation in health research: ensuring the research team is culturally and gender-sensitive; recruiting in trusted environments; using respected gatekeepers; developing trust with participants; and being transparent. Implications for practice Implementing strategies to include African-American men in health research has the potential to improve health disparities in the US. AD - Assistant professor, Duke University School of Nursing, Durham, North Carolina, United States Professor in University of North Carolina at Greensboro, Greensboro NC, United States Professor, North Carolina A&T State University/University of North Carolina at Greensboro, Greensboro NC, United States AN - 129505150. Language: English. Entry Date: 20180510. Revision Date: 20180530. Publication Type: Article. Journal Subset: Core Nursing AU - Randolph, Schenita AU - Coakley, Tanya AU - Shears, Jeffrey DB - CINAHL Complete DO - 10.7748/nr.2018.e1569 DP - EBSCOhost KW - Sexual Health Black Persons Research Subject Recruitment Health Promotion Healthcare Disparities -- United States United States N1 - Double Blind Peer Reviewed; Europe; Nursing; Peer Reviewed; UK & Ireland. NLM UID: 9435953. PY - 2018 SN - 1351-5578 SP - 1-1 ST - Recruiting and engaging African-American men in health research T2 - Nurse Researcher TI - Recruiting and engaging African-American men in health research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129505150&site=ehost-live&scope=site ID - 2058 ER - TY - JOUR AB - Background Improving the health of black and minority ethnic (BME) men in the US continues to be a public health priority. Compared with men of other races and ethnicities, African-American men have higher rates of mortality and morbidity from chronic illness and diseases including cancer, heart disease, prostate cancer, diabetes and HIV/AIDS. One way to address these disparities is to include African-American men in health research, to elicit their perspectives on health risks and protective factors. These can then inform interventions aimed at reducing health disparities. However, challenges remain in recruiting and engaging African-American men in health research. Aim To provide strategies for recruiting African-American men in health research, using as an exemplar a qualitative study of fathers' perspectives of sexual health promotion with young African-American males. Discussion Efforts are needed to increase the representation of African-American men in health research. Ensuring that researchers are aware of the cultural, social and environmental factors related to decisions to participate in research can lead to effective methods to recruit and engage them. Conclusion There are several essential strategies for increasing African-American men's participation in health research: ensuring the research team is culturally and gender-sensitive; recruiting in trusted environments; using respected gatekeepers; developing trust with participants; and being transparent. Implications for practice Implementing strategies to include African-American men in health research has the potential to improve health disparities in the US. AD - Duke University School of Nursing, Durham, North Carolina, United States University of North Carolina at Greensboro, North Carolina, United States North Carolina A&T State University/University of North Carolina at Greensboro, North Carolina, United States AN - 130020096. Language: English. Entry Date: 20180611. Revision Date: 20180612. Publication Type: Article. Journal Subset: Core Nursing AU - Randolph, Schenita AU - Coakley, Tanya AU - Shears, Jeffrey DB - CINAHL Complete DO - 10.7748/nr.2018.e1569 DP - EBSCOhost IS - 1 KW - Black Persons Minority Groups Men Research Subject Recruitment Male Health Services Research Qualitative Studies Sexual Health Health Promotion Men's Health N1 - Double Blind Peer Reviewed; Europe; Nursing; Peer Reviewed; UK & Ireland. Special Interest: Men's Health. NLM UID: 9435953. PY - 2018 SN - 1351-5578 SP - 8-12 ST - Recruiting and engaging African-American men in health research T2 - Nurse Researcher TI - Recruiting and engaging African-American men in health research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130020096&site=ehost-live&scope=site VL - 26 ID - 2059 ER - TY - JOUR AB - Background Improving the health of black and minority ethnic (BME) men in the US continues to be a public health priority. Compared with men of other races and ethnicities, African-American men have higher rates of mortality and morbidity from chronic illness and diseases including cancer, heart disease, prostate cancer, diabetes and HIV/AIDS. One way to address these disparities is to include African-American men in health research, to elicit their perspectives on health risks and protective factors. These can then inform interventions aimed at reducing health disparities. However, challenges remain in recruiting and engaging African-American men in health research. Aim To provide strategies for recruiting African-American men in health research, using as an exemplar a qualitative study of fathers' perspectives of sexual health promotion with young African-American males. Discussion Efforts are needed to increase the representation of African-American men in health research. Ensuring that researchers are aware of the cultural, social and environmental factors related to decisions to participate in research can lead to effective methods to recruit and engage them. Conclusion There are several essential strategies for increasing African-American men's participation in health research: ensuring the research team is culturally and gender-sensitive; recruiting in trusted environments; using respected gatekeepers; developing trust with participants; and being transparent. Implications for practice Implementing strategies to include African-American men in health research has the potential to improve health disparities in the US. AN - WOS:000455831600003 AU - Randolph, S. AU - Coakley, T. AU - Shears, J. DA - Jun DO - 10.7748/nr.2018.e1569 IS - 1 N1 - 29738190 PY - 2018 SN - 1351-5578 SP - 8-12 ST - Recruiting and engaging African-American men in health research T2 - Nurse Researcher TI - Recruiting and engaging African-American men in health research VL - 26 ID - 2856 ER - TY - JOUR AB - The effectiveness of multiple innovative recruitment strategies for enrolling Black/African American participants to the Adventist Health Study-2 (AHS-2) is described. The study's focus is diet and breast, prostate and colon cancer. Promotions centered on trust, relationship building and incentives for increasing enrollment and questionnaire return rate. Of the sub-studies described, one had a randomized control group, and the others, informal controls. The subjects are from all states of the U.S. and some provinces of Canada. The offer of a Black art piece, follow-up calls, a competitive tournament as well as other strategies accounted for nearly 3,000 additional returns even though they were often used in small subsets. Flexibility and multiple strategies proved advantageous in gaining the cooperation of Blacks, who are usually reluctant to participate in research studies. Lessons learned during initial enrollment should help us retain our final Black cohort of 26,000, and obtain new information when required. AD - P. Herring AU - Herring, P. AU - Butler, T. AU - Hall, S. AU - Bennett, H. AU - Montgomery, S. B. AU - Fraser, G. DB - Medline DO - 10.1186/1471-2288-14-46 KW - African American article breast tumor Canada cohort analysis colon tumor cost benefit analysis diet doctor patient relationship female human male motivation patient selection prostate tumor psychological aspect questionnaire reward United States LA - English M3 - Article N1 - L373967344 2014-10-08 PY - 2014 SN - 1471-2288 SP - 46 ST - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies T2 - BMC medical research methodology TI - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373967344&from=export http://dx.doi.org/10.1186/1471-2288-14-46 VL - 14 ID - 1048 ER - TY - JOUR AB - Background: The effectiveness of multiple innovative recruitment strategies for enrolling Black/African American participants to the Adventist Health Study-2 (AHS-2) is described. The study's focus is diet and breast, prostate and colon cancer.Methods: Promotions centered on trust, relationship building and incentives for increasing enrollment and questionnaire return rate. Of the sub-studies described, one had a randomized control group, and the others, informal controls. The subjects are from all states of the U.S. and some provinces of Canada. The offer of a Black art piece, follow-up calls, a competitive tournament as well as other strategies accounted for nearly 3,000 additional returns even though they were often used in small subsets.Results: Flexibility and multiple strategies proved advantageous in gaining the cooperation of Blacks, who are usually reluctant to participate in research studies.Conclusions: Lessons learned during initial enrollment should help us retain our final Black cohort of 26,000, and obtain new information when required. AD - School of Public Health, Health Promotion & Education, Loma Linda University, 24951 North Circle Dr, NH 1511, Loma Linda, CA 92350, USA. pherring@llu.edu. AN - 103928263. Language: English. Entry Date: 20150508. Revision Date: 20161117. Publication Type: journal article AU - Herring, Patti AU - Butler, Terry AU - Hall, Sonja AU - Bennett, Hannelore AU - Montgomery, Susanne B. AU - Fraser, Gary DB - CINAHL Complete DO - 10.1186/1471-2288-14-46 DP - EBSCOhost IS - 1 KW - Black Persons -- Psychosocial Factors Motivation Patient Selection Questionnaires Breast Neoplasms -- Epidemiology Canada Prospective Studies Colonic Neoplasms -- Epidemiology Cost Benefit Analysis Diet Female Human Male Physician-Patient Relations Prostatic Neoplasms -- Epidemiology Reward United States N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: 5R01 CA 094594/CA/NCI NIH HHS/United States. NLM UID: 100968545. PMID: NLM24708740. PY - 2014 SN - 1471-2288 SP - 46-46 ST - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies T2 - BMC Medical Research Methodology TI - Recruiting and motivating black subjects to complete a lengthy survey in a large cohort study: an exploration of different strategies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103928263&site=ehost-live&scope=site VL - 14 ID - 2060 ER - TY - JOUR AB - Objective: The goal of the prospective Adventist Health Study-2 (AHS-2) was to examine the relationship between diet and risk of breast, prostate and colon cancers in Black and White participants. This paper describes the study design, recruitment methods, response rates, and characteristics of Blacks in the AHS-2, thus providing insights about effective strategies to recruit Blacks to participate in research studies.Design: We designed a church-based recruitment model and trained local recruiters who used various strategies to recruit participants in their churches. Participants completed a 50-page self-administered dietary and lifestyle questionnaire.Participants: Participants are Black Seventh-day Adventists, aged 30-109 years, and members of 1,209 Black churches throughout the United States and Canada.Results: Approximately 48,328 Blacks from an estimated target group of over 90,000 signed up for the study and 25,087 completed the questionnaire, comprising about 26% of the larger 97,000 AHS-2-member cohort. Participants were diverse in age, geographic location, education, and income. Seventy percent were female with a median age of 59 years.Conclusion: In spite of many recruitment challenges and barriers, we successfully recruited a large cohort whose data should provide some answers as to why Blacks have poorer health outcomes than several other ethnic groups, and help explain existing health disparities. AD - Department of Health Promotion and Education, Loma Linda University, School of Public Health, 24951 North Circle Drive, Nichol Hall 1410, Loma Linda, CA 92350, USA. pherring@llu.edu AN - 104828719. Language: English. Entry Date: 20110401. Revision Date: 20161117. Publication Type: journal article AU - Herring, R. Patti AU - Butler, Terry AU - Hall, Sonja AU - Montgomery, Susanne B. AU - Fraser, Gary E. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Black Persons Breast Neoplasms -- Ethnology Colonic Neoplasms -- Ethnology Diet Patient Selection Prostatic Neoplasms -- Ethnology Adult Aged Aged, 80 and Over Canada Prospective Studies Female Human Male Middle Age Program Development Christianity Study Design United States N1 - research. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. Grant Information: R25 GM060507-02/GM/NIGMS NIH HHS/United States. NLM UID: 9109034. PMID: NLM21305834. PY - 2010 SN - 1049-510X SP - 437-443 ST - Recruiting black Americans in a large cohort study: the Adventist Health Study-2 (AHS-2) design, methods and participant characteristics T2 - Ethnicity & Disease TI - Recruiting black Americans in a large cohort study: the Adventist Health Study-2 (AHS-2) design, methods and participant characteristics UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104828719&site=ehost-live&scope=site VL - 20 ID - 2061 ER - TY - JOUR AN - 107303699. Language: English. Entry Date: 19981201. Revision Date: 20151019. Publication Type: Journal Article DB - CINAHL Complete DP - EBSCOhost IS - 33 KW - Research Subject Recruitment Clinical Trials Black Persons Prostatic Neoplasms -- Ethnology Prostatic Neoplasms -- Prevention and Control Patient Selection Male Middle Age Aged Michigan N1 - tables/charts. Journal Subset: Biomedical; Public Health; USA. NLM UID: 7802429. PMID: NLM9733417. PY - 1998 SN - 0149-2195 SP - 694-696 ST - Recruiting black men to a clinical trial to evaluate prostate cancer screening -- Detroit, Michigan, 1998 T2 - MMWR: Morbidity & Mortality Weekly Report TI - Recruiting black men to a clinical trial to evaluate prostate cancer screening -- Detroit, Michigan, 1998 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107303699&site=ehost-live&scope=site VL - 47 ID - 2062 ER - TY - JOUR AB - In 1998, an estimated 184,500 cases of prostate cancer will be diagnosed and approximately 39,200 men will die from this disease (1). Black men have higher prostate cancer incidence and mortality rates than white men (2). Representation of blacks in clinical trials that investigate the treatment of cancer is proportional to the burden of this disease in the black population (3). However, blacks have generally been underrepresented in clinical trials of preventive interventions (4). To determine the effect of socioeconomic status (SES) on the enrollment of black men in a trial that includes screening for prostate cancer, the African American Men (AAMEN) project in Detroit, Michigan, analyzed data from local recruitment efforts. This report summarizes preliminary results of this analysis, which indicate that SES was not an important factor in refusal to participate in the screening trial. DB - Medline IS - 33 KW - African American aged article clinical protocol clinical trial ethnology human male middle aged Black person patient selection prostate tumor United States LA - English M3 - Article N1 - L128305862 1998-09-10 PY - 1998 SN - 0149-2195 SP - 694-696 ST - Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998 T2 - MMWR. Morbidity and mortality weekly report TI - Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L128305862&from=export VL - 47 ID - 1331 ER - TY - JOUR AB - BACKGROUND. Black/African American men die of prostate cancer at a greater rate relative to other males. During the period from 1992 to 1998, prostate cancer incidence rates in the United States were 234.2 per 100,000 persons among non-Hispanic black males and 144.6 per 100,000 persons among white males. The reasons for these increased rates of prostate cancer among black males are largely unknown, but increased mortality is associated with late detection. The authors conducted a longitudinal study of black men that investigated prostate cancer prevention behaviors within this population. The purpose of the current article is to identify successful recruitment strategies that were reported by participants in this study of prevention behaviors. METHODS. Qualitative research methods were used to elucidate men's thoughts, attitudes, beliefs, and practices regarding prostate cancer prevention behaviors and to identify strategies for attracting black men to research programs and retaining them in these programs. RESULTS. Ethnocentric recruitment strategies that were identified included the development of tailored printed materials; the use of targeted locations; and a personalized, participatory approach for engaging potential participants. We contacted 498 black men and enrolled a cohort of 277 non-Hispanic black males (75% of whom were recruited within a 9-week period) in the current study. CONCLUSIONS. Unlike other studies that reported difficulty in recruiting African American men, the current study did not encounter such difficulties. The authors attribute their success to culturally attractive Afrocentric materials; cultural sensitivity; a caring, professional, personalized ethnic approach; respect; and participatory involvement of the target population. Nonetheless, the authors did encounter barriers, such as lack of physician interest and lack of trust in quality medical care. These barriers must be overcome before black males can be engaged and retained in research studies on prostate cancer prevention. © 2004 American Cancer Society. AD - V.D. Woods, Dept. of Hlth. Prom. and Education, School of Public Health, Loma Linda University, 10970 Parkland Street, Loma Linda, CA 92350, United States AU - Woods, V. D. AU - Montgomery, S. B. AU - Herring, R. P. DB - Embase Medline DO - 10.1002/cncr.20029 IS - 5 KW - adult African American aged article cancer incidence cancer mortality cancer prevention cancer research cultural factor ethnology human longitudinal study priority journal prostate cancer United States LA - English M3 - Article N1 - L38222863 2004-03-05 PY - 2004 SN - 0008-543X SP - 1017-1025 ST - Recruiting Black/African American Men for Research on Prostate Cancer Prevention T2 - Cancer TI - Recruiting Black/African American Men for Research on Prostate Cancer Prevention UR - https://www.embase.com/search/results?subaction=viewrecord&id=L38222863&from=export http://dx.doi.org/10.1002/cncr.20029 VL - 100 ID - 1285 ER - TY - JOUR AB - BACKGROUND. Black/African American men die of prostate cancer at a greater rate relative to other males. During the period from 1992 to 1998, prostate cancer incidence rates in the United States were 234.2 per 100,000 persons among non-Hispanic black males and 144.6 per 100,000 persons among white males. The reasons for these increased rates of prostate cancer among black males are largely unknown, but increased mortality is associated with late detection. The authors conducted a longitudinal study of black men that investigated prostate cancer prevention behaviors within this population. The purpose of the current article is to identify successful recruitment strategies that were reported by participants in this study of prevention behaviors. METHODS. Qualitative research methods were used to elucidate men's thoughts, attitudes, beliefs, and practices regarding prostate cancer prevention behaviors and to identify strategies for attracting black men to research programs and retaining them in these programs. RESULTS. Ethnocentric recruitment strategies that were identified included the development of tailored printed materials; the use of targeted locations; and a personalized, participatory approach for engaging potential participants. We contacted 498 black men and enrolled a cohort of 277 non-Hispanic black males (75% of whom were recruited within a 9-week period) in the current study. CONCLUSIONS. Unlike other studies that reported difficulty in recruiting African American men, the current study did not encounter such difficulties. The authors attribute their success to culturally attractive Afrocentric materials; cultural sensitivity; a caring, professional, personalized ethnic approach; respect; and participatory involvement of the target population. Nonetheless, the authors did encounter barriers, such as lack of physician interest and lack of trust in quality medical care. These barriers must be overcome before black males can be engaged and retained in research studies on prostate cancer prevention. © 2004 American Cancer Society. AD - Dept. of Hlth. Prom. and Education, School of Public Health, Loma Linda University, Loma Linda, CA, United States Dept. of Hlth. Prom. and Education, School of Public Health, Loma Linda University, 10970 Parkland Street, Loma Linda, CA 92350, United States AU - Woods, V. D. AU - Montgomery, S. B. AU - Herring, R. P. DB - Scopus DO - 10.1002/cncr.20029 IS - 5 KW - African American men Afrocentric prevention research Black men Prostate cancer prevention Recruitment M3 - Article N1 - Cited By :60 Export Date: 22 March 2021 PY - 2004 SP - 1017-1025 ST - Recruiting Black/African American Men for Research on Prostate Cancer Prevention T2 - Cancer TI - Recruiting Black/African American Men for Research on Prostate Cancer Prevention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-1242336802&doi=10.1002%2fcncr.20029&partnerID=40&md5=918698a60ab3a04b8aa86f8ddfc33f4c VL - 100 ID - 2609 ER - TY - JOUR AB - BACKGROUND. Black/African American men die of prostate cancer at a greater rate relative to other males. During the period from 1992 to 1998, prostate cancer incidence rates in the United States were 234.2 per 100,000 persons among non-Hispanic black males and 144.6 per 100,000 persons among white males. The reasons for these increased rates of prostate cancer among black males are largely unknown, but increased mortality is associated with late detection. The authors conducted a longitudinal study of black men that investigated prostate cancer prevention behaviors within this population. The purpose of the current article is to identify successful recruitment strategies that were reported by participants in this study of prevention behaviors. METHODS. Qualitative research methods were used to elucidate men's thoughts, attitudes, beliefs, and practices regarding prostate cancer prevention behaviors and to identify strategies for attracting black men to research programs and retaining them in these programs. RESULTS. Ethnocentric recruitment strategies that were identified included the development of tailored printed materials; the use of targeted locations; and a personalized, participatory approach for engaging potential participants. We contacted 498 black men and enrolled a cohort of 277 non-Hispanic black males (75% of whom were recruited within a 9-week period) in the current study. CONCLUSIONS. Unlike other studies that reported difficulty in recruiting African American men, the current study did not encounter such difficulties. The authors attribute their success to culturally attractive Afrocentric materials; cultural sensitivity; a caring, professional, personalized ethnic approach; respect; and participatory involvement of the target population. Nonetheless, the authors did encounter barriers, such as lack of physician interest and lack of trust in quality medical care. These barriers must be overcome before black males can be engaged and retained in research studies on prostate cancer prevention. (C) 2004 American Cancer Society. AN - WOS:000189085000019 AU - Woods, V. D. AU - Montgomery, S. B. AU - Herring, R. P. DA - Mar 1 DO - 10.1002/cncr.20029 IS - 5 N1 - 55 14983498 PY - 2004 SN - 0008-543X SP - 1017-1025 ST - Recruiting Black/African American men for research on prostate cancer prevention T2 - Cancer TI - Recruiting Black/African American men for research on prostate cancer prevention VL - 100 ID - 2685 ER - TY - JOUR AB - Low participation among underserved populations in health research constrains progress in public health practices. From 2003 to 2005, Women's Health Clinic patients at the VCU Health System were-recruited to a trial investigating breast cancer risk communication. In secondary analyses, we examined dimensions of the recruitment of these diverse women. The sample characteristics (age, insurance, race and previous mammograms) were compared to the overall clinic. Of recruitment attempts for eligible women, 45% consented; of those who declined, the top cited reasons were lack of time (40%) and lack of interest (18%). Of 899 participants, 35% qualified for the indigent care program, compared to 31% of the overall clinic (P<.001). Forty-five percent of participants were African American, compared to 54% of overall clinic patients (P<.001). Participants were younger (50 vs. 53 years, P<.001) than the overall clinic population. Nonrepresentative enrollment of patients in clinical trials is common and could lead to suboptimal applicability of findings. Although there were statistically significant race and age differences between the study sample and the overall population, we demonstrate that waiting room recruitment can engage diverse women in a clinical trial and cancer risk communication. AD - Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, United States Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, VA, United States Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, United States Department of Epidemiology and Community Health, Virginia Commonwealth University, Richmond, VA, United States Fred Hutchison Cancer Center, University of Washington, Seattle, WA, United States Department of Human Genetics, Virginia Commonwealth University, 1101 E. Marshall St., Richmond, VA 23298, United States AU - Bodurtha, J. N. AU - Quillin, J. M. AU - Tracy, K. A. AU - Borzelleca, J. AU - McClish, D. AU - Wilson, D. B. AU - Jones, R. M. AU - Quillin, J. AU - Bowen, D. DB - Scopus IS - 8 KW - Clinical investigation Women's health M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2007 SP - 917-922 ST - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access T2 - Journal of the National Medical Association TI - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547912533&partnerID=40&md5=f0cfa96e8aa6dd5efd80687b9f1badbf VL - 99 ID - 2553 ER - TY - JOUR AB - Low participation among underserved populations in health research constrains progress in public health practices. From 2003 to 2005, Women's Health Clinic patients at the VCU Health System were recruited to a trial investigating breast cancer risk communication. In secondary analyses, we examined dimensions of the recruitment of these diverse women. The sample characteristics (age, insurance, race and previous mammograms) were compared to the overall clinic. Of recruitment attempts for eligible women, 45% consented; of those who declined, the top cited reasons were lack of time (40%) and lack of interest (187.). Of 899 participants, 35% qualified for the indigent care program, compared to 31% of the overall clinic (P<0.001). Forty-five percent of participants' were African American, compared to 54% of overall clinic patients (P<0.001). Participants were younger (50 vs. 53 years, P<0.001) than the overall clinic population. Nonrepresentative enrollment of patients in clinical trials is common and could lead to suboptimal applicability of findings. Although there were statistically significant race and age differences between the study sample and the overall population, we demonstrate that waiting room recruitment can engage diverse women in a clinical trial and cancer risk communication. AN - WOS:000248645800009 AU - Bodurtha, J. N. AU - Quillin, J. M. AU - Tracy, K. A. AU - Borzelleca, J. AU - McClish, D. AU - Wilson, D. B. AU - Jones, R. M. AU - Quillin, J. AU - Bowen, D. DA - Aug IS - 8 N1 - 17722671 PY - 2007 SN - 0027-9684 SP - 917-922 ST - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access T2 - Journal of the National Medical Association TI - Recruiting diverse patients to a breast cancer risk communication trial - Waiting rooms can improve access VL - 99 ID - 3189 ER - TY - JOUR AB - Low participation among underserved populations in health research constrains progress in public health practices. From 2003 to 2005, Women's Health Clinic patients at the VCU Health System were recruited to a trial investigating breast cancer risk communication. In secondary analyses, we examined dimensions of the recruitment of these diverse women. The sample characteristics (age, insurance, race and previous mammograms) were compared to the overall clinic. Of recruitment attempts for eligible women, 45% consented; of those who declined, the top cited reasons were lack of time (40%) and lack of interest (18%). Of 899 participants, 35% qualified for the indigent care program, compared to 31% of the overall clinic (P<0.001). Forty-five percent of participants were African American, compared to 54% of overall clinic patients (P<0.001). Participants were younger (50 vs. 53 years, P<0.001) than the overall clinic population. Nonrepresentative enrollment of patients in clinical trials is common and could lead to suboptimal applicability of findings. Although there were statistically significant race and age differences between the study sample and the overall population, we demonstrate that waiting room recruitment can engage diverse women in a clinical trial and cancer risk communication. AD - Department of Human Genetics, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA Professor, Department of Human Genetics, Virginia Commonwealth University, 1101 E. marshall Street, Richmond, VA 23298; bodurtha@vcu.edu AN - 105993516. Language: English. Entry Date: 20080222. Revision Date: 20161114. Publication Type: journal article AU - Bodurtha, J. N. AU - Quillin, J. M. AU - Tracy, K. A. AU - Borzelleca, J. AU - McClish, D. AU - Wilson, D. B. AU - Jones, R. M. AU - Quillin, J. AU - Bowen, D. AU - Bodurtha, Joann N. AU - Quillin, John M. AU - Tracy, Kelly A. AU - Borzelleca, Joseph AU - McClish, Donna AU - Wilson, Diane Baer AU - Jones, Resa M. AU - Quillin, Julie AU - Bowen, Deborah DB - CINAHL Complete DP - EBSCOhost IS - 8 KW - Breast Neoplasms -- Therapy Clinical Trials Communication Patient Attitudes Patient Selection Adult Aged Female Middle Age Relative Risk Human N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R01 CA94213/CA/NCI NIH HHS/United States. NLM UID: 7503090. PMID: NLM17722671. PY - 2007 SN - 0027-9684 SP - 917-922 ST - Recruiting diverse patients to a breast cancer risk communication trial--waiting rooms can improve access T2 - Journal of the National Medical Association TI - Recruiting diverse patients to a breast cancer risk communication trial--waiting rooms can improve access UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105993516&site=ehost-live&scope=site VL - 99 ID - 2063 ER - TY - JOUR AB - Purpose: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors-YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives.Methods: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS' willingness to contact at-risk relatives.Results: The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS.Conclusion: It is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine. AD - Michigan Department of Health and Human Services , 333 S. Grand Ave. Lansing 48909 USA University of Michigan School of Nursing , 400 North Ingalls Building Ann Arbor 48109 USA Nursing Science, Faculty of Medicine , Bernoullistrasse 28 4056 Basel Switzerland Ohio State University College of Nursing , 1585 Neil Ave Columbus 43210 USA University of Michigan Comprehensive Cancer Center , 1500 East Medical Center Drive, CCGC 6-303 Ann Arbor 48109-0944 USA Swiss Tropical and Public Health Institute, University of Basel , Socinstrasse 57 4051 Basel Switzerland University of Michigan, School of Medicine , 1500 E Medical Center Dr Ann Arbor 48109 USA University of Michigan, School of Public Health , 1415 Washington Heights Ann Arbor 48109 USA Michigan Cancer Surveillance Program , 333 S. Grand Ave Lansing 48909 USA Nursing Science, Faculty of Medicine, Bernoullistrasse 28, 4056, Basel, Switzerland University of Michigan School of Nursing, 400 North Ingalls Building, Ann Arbor, MI, 48109, USA University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, CCGC 6-303, Ann Arbor, MI, 48109-0944, USA AN - 121442437. Language: English. Entry Date: 20170606. Revision Date: 20190308. Publication Type: journal article AU - Katapodi, Maria AU - Duquette, Deb AU - Yang, James AU - Mendelsohn-Victor, Kari AU - Anderson, Beth AU - Nikolaidis, Christos AU - Mancewicz, Emily AU - Northouse, Laurel AU - Duffy, Sonia AU - Ronis, David AU - Milliron, Kara AU - Probst-Herbst, Nicole AU - Merajver, Sofia AU - Janz, Nancy AU - Copeland, Glenn AU - Roberts, Scott AU - Katapodi, Maria C. AU - Yang, James J. AU - Northouse, Laurel L. AU - Milliron, Kara J. DB - CINAHL Complete DO - 10.1007/s10552-017-0858-2 DP - EBSCOhost IS - 3 KW - Ovarian Neoplasms Data Collection Patient Selection Breast Neoplasms Family -- Psychosocial Factors Adult Risk Factors Middle Age Depression Survivors Female Ovarian Neoplasms -- Psychosocial Factors Counseling Breast Neoplasms -- Psychosocial Factors Human Randomized Controlled Trials Random Assignment N1 - research; tables/charts; randomized controlled trial. Journal Subset: Biomedical; Continental Europe; Europe. NLM UID: 9100846. PMID: NLM28197806. PY - 2017 SN - 0957-5243 SP - 191-201 ST - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study T2 - Cancer Causes & Control TI - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121442437&site=ehost-live&scope=site VL - 28 ID - 2064 ER - TY - JOUR AB - Purpose: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors‐YBCS) and at‐risk relatives. We present recruitment of YBCS, identification and recruitment of at‐risk relatives, and YBCS willingness to contact their cancer‐free, female relatives. Methods: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population‐based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS' willingness to contact at‐risk relatives. Results: The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at‐risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at‐risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS. Conclusion: It is feasible to recruit diverse families at risk for hereditary cancer from a population‐based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large‐scale public health genomic initiatives in the era of precision medicine. Copyright © 2017, Springer International Publishing Switzerland. AN - CN-01336858 AU - Katapodi, M. C. AU - Duquette, D. AU - Yang, J. J. AU - Mendelsohn-Victor, K. AU - Anderson, B. AU - Nikolaidis, C. AU - Mancewicz, E. AU - Northouse, L. L. AU - Duffy, S. AU - Ronis, D. AU - et al. DO - 10.1007/s10552-017-0858-2 IS - 3 KW - *breast cancer *cancer registry *cancer survivor *family history *family size *family study *female *genetic predisposition *hereditary breast and ovarian cancer syndrome *hereditary tumor *high risk population *ovary cancer *public health *relative Adult Age distribution Article Black person Cancer epidemiology Cancer survivor Caucasian Controlled clinical trial Controlled study Depression Diagnosis Educational status External validity Female Gene mutation Genetic counseling Genetic service Health care access Human Major clinical study Motivation Patient preference Personalized medicine Race Random sample Randomized controlled trial Theory of Planned Behavior Tumor suppressor gene M3 - Journal: Article PY - 2017 SP - 191‐201 ST - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study T2 - Cancer causes & control TI - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01336858/full VL - 28 ID - 1591 ER - TY - JOUR AB - Purpose: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors—YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives. Methods: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS’ willingness to contact at-risk relatives. Results: The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS. Conclusion: It is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine. AD - M.C. Katapodi, Nursing Science, Faculty of Medicine, Bernoullistrasse 28, Basel, Switzerland AU - Katapodi, M. C. AU - Duquette, D. AU - Yang, J. J. AU - Mendelsohn-Victor, K. AU - Anderson, B. AU - Nikolaidis, C. AU - Mancewicz, E. AU - Northouse, L. L. AU - Duffy, S. AU - Ronis, D. AU - Milliron, K. J. AU - Probst-Herbst, N. AU - Merajver, S. D. AU - Janz, N. K. AU - Copeland, G. AU - Roberts, S. DB - Embase Medline DO - 10.1007/s10552-017-0858-2 IS - 3 KW - adult age distribution article Black person cancer survivor Caucasian controlled study depression educational status family history female gene mutation genetic counseling health care access hereditary breast and ovarian cancer syndrome high risk population human major clinical study motivation patient preference tumor suppressor gene LA - English M3 - Article N1 - L614436837 2017-02-21 2017-03-27 PY - 2017 SN - 1573-7225 0957-5243 SP - 191-201 ST - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study T2 - Cancer Causes and Control TI - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L614436837&from=export http://dx.doi.org/10.1007/s10552-017-0858-2 VL - 28 ID - 943 ER - TY - JOUR AB - Purpose: Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors—YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives. Methods: A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS’ willingness to contact at-risk relatives. Results: The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS. Conclusion: It is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine. © 2017, Springer International Publishing Switzerland. AD - Nursing Science, Faculty of Medicine, Bernoullistrasse 28, Basel, 4056, Switzerland University of Michigan School of Nursing, 400 North Ingalls Building, Ann Arbor, MI 48109, United States Michigan Department of Health and Human Services, 333 S. Grand Ave., P.O. Box 30195, Lansing, MI 48909, United States Ohio State University College of Nursing, 1585 Neil Ave, Columbus, OH 43210, United States University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, CCGC 6-303, Ann Arbor, MI 48109-0944, United States Swiss Tropical and Public Health Institute, University of Basel, Socinstrasse 57, Basel, 4051, Switzerland University of Michigan, School of Medicine, 1500 E Medical Center Dr, Ann Arbor, MI 48109, United States University of Michigan, School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, United States Michigan Cancer Surveillance Program, 333 S. Grand Ave, P.O. Box 30195, Lansing, MI 48909, United States AU - Katapodi, M. C. AU - Duquette, D. AU - Yang, J. J. AU - Mendelsohn-Victor, K. AU - Anderson, B. AU - Nikolaidis, C. AU - Mancewicz, E. AU - Northouse, L. L. AU - Duffy, S. AU - Ronis, D. AU - Milliron, K. J. AU - Probst-Herbst, N. AU - Merajver, S. D. AU - Janz, N. K. AU - Copeland, G. AU - Roberts, S. DB - Scopus DO - 10.1007/s10552-017-0858-2 IS - 3 KW - At-risk relatives Cancer registry Public health genomic trials Recruitment Young breast cancer survivors M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2017 SP - 191-201 ST - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study T2 - Cancer Causes and Control TI - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85012902725&doi=10.1007%2fs10552-017-0858-2&partnerID=40&md5=91fb93d376814fb439199e6859674313 VL - 28 ID - 2317 ER - TY - JOUR AB - Cancer genetic services (counseling/testing) are recommended for women diagnosed with breast cancer younger than 45 years old (young breast cancer survivors-YBCS) and at-risk relatives. We present recruitment of YBCS, identification and recruitment of at-risk relatives, and YBCS willingness to contact their cancer-free, female relatives. A random sample of 3,000 YBCS, stratified by race (Black vs. White/Other), was identified through a population-based cancer registry and recruited in a randomized trial designed to increase use of cancer genetic services. Baseline demographic, clinical, and family characteristics, and variables associated with the Theory of Planned Behavior (TPB) were assessed as predictors of YBCS' willingness to contact at-risk relatives. The 883 YBCS (33.2% response rate; 40% Black) who returned a survey had 1,875 at-risk relatives and were willing to contact 1,360 (72.5%). From 853 invited at-risk relatives (up to two relatives per YBCS), 442 responded (51.6% response rate). YBCS with larger families, with a previous diagnosis of depression, and motivated to comply with recommendations from family members were likely to contact a greater number of relatives. Black YBCS were more likely to contact younger relatives and those living further than 50 miles compared to White/Other YBCS. It is feasible to recruit diverse families at risk for hereditary cancer from a population-based cancer registry. This recruitment approach can be used as a paradigm for harmonizing processes and increasing internal and external validity of large-scale public health genomic initiatives in the era of precision medicine. AN - WOS:000394986000002 AU - Katapodi, M. C. AU - Duquette, D. AU - Yang, J. J. AU - Mendelsohn-Victor, K. AU - Anderson, B. AU - Nikolaidis, C. AU - Mancewicz, E. AU - Northouse, L. L. AU - Duffy, S. AU - Ronis, D. AU - Milliron, K. J. AU - Probst-Herbst, N. AU - Merajver, S. D. AU - Janz, N. K. AU - Copeland, G. AU - Roberts, S. DA - Mar DO - 10.1007/s10552-017-0858-2 IS - 3 N1 - 28197806 PY - 2017 SN - 0957-5243 SP - 191-201 ST - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study T2 - Cancer Causes & Control TI - Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study VL - 28 ID - 2908 ER - TY - JOUR AB - PURPOSE: This article describes the demographic characteristics of participants in a randomized trial (the AAMEN Project) designed to recruit older (aged 55+ years) African American men to a cancer screening trial. DESIGN AND METHODS: The AAMEN Project is a recruitment trial developed for African American men aged 55+ years living in southeastern Michigan. RESULTS: Of the 34,376 African American men in the study, 37.6% had low incomes and 62.4% had moderate‐to‐high incomes. The average age of the men was 63.3 years (SD = 5.9 years). Among men who were eligible and interested in participating, the proportion of men with low incomes was significantly greater than the proportion of men with moderate‐to‐high incomes (p <.001). IMPLICATIONS: The AAMEN Project demonstrated success in recruiting a substantial proportion of men with low incomes as well as men with moderate‐to‐high incomes. These findings may facilitate the development of future recruitment efforts involving older African American men. AN - CN-00422817 AU - Ford, M. E. AU - Havstad, S. L. AU - Tilley, B. C. DO - 10.1093/geront/43.1.27 IS - 1 KW - African Americans Aged Analysis of Variance Chi‐Square Distribution Humans Male Mass Screening [*methods] Michigan [ethnology] Middle Aged Patient Selection Pilot Projects Prostatic Neoplasms [*diagnosis, ethnology] Socioeconomic Factors M3 - Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non‐P.H.S.; Research Support, U.S. Gov't, P.H.S. PY - 2003 SP - 27‐35 ST - Recruiting older African American men to a cancer screening trial (the AAMEN Project) T2 - Gerontologist TI - Recruiting older African American men to a cancer screening trial (the AAMEN Project) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00422817/full VL - 43 ID - 1354 ER - TY - JOUR AB - Purpose: This article describes the demographic characteristics of participants in a randomized trial (the AAMEN Project) designed to recruit older (aged 55+ years) African American men to a cancer screening trial. Design and Methods: The AAMEN Project is a recruitment trial developed for African American men aged 55+ years living in southeastern Michigan. Results: Of the 34,376 African American men in the study, 37.6% had low incomes and 62.4% had moderate-to-high incomes. The average age of the men was 63.3 years (SD = 5.9 years). Among men who were eligible and interested in participating, the proportion of men with low incomes was significantly greater than the proportion of men with moderate-to-high incomes ( p < .001). Implications: The AAMEN Project demonstrated success in recruiting a substantial proportion of men with low incomes as well as men with moderate-to-high incomes. These findings may facilitate the development of future recruitment efforts involving older African American men. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ford, Marvella E., Department of Medicine and Section of Health Services Research, Baylor College of Medicine, Veterans Affairs Medical Center (152), 2002 Holcombe Boulevard, Houston, TX, US, 77030 AN - 2003-04891-004 AU - Ford, Marvella E. AU - Havstad, Suzanne L. AU - Tilley, Barbara C. DB - psyh DO - 10.1093/geront/43.1.27 DP - EBSCOhost IS - 1 KW - African American men income levels demographic characteristics experimental subject recruitment efforts cancer screening trial African Americans Aged Analysis of Variance Chi-Square Distribution Humans Male Mass Screening Michigan Middle Aged Patient Selection Pilot Projects Prostatic Neoplasms Socioeconomic Factors Blacks Cancer Screening Experimental Subjects Human Males Income Level N1 - Henry Ford Health Sciences Center, Center for Research in Diverse Populations, Detroit, MI, US. Other Publishers: Oxford University Press. Release Date: 20040202. Correction Date: 20131202. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Demographic Characteristics; Experimental Subjects. Minor Descriptor: Human Males; Income Level. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Feb, 2003. PY - 2003 SN - 0016-9013 1758-5341 SP - 27-35 ST - Recruiting Older African American Men to a Cancer Screening Trial (The AAMEN Project) T2 - The Gerontologist TI - Recruiting Older African American Men to a Cancer Screening Trial (The AAMEN Project) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2003-04891-004&site=ehost-live&scope=site mford@bcm.tmc.edu VL - 43 ID - 1757 ER - TY - JOUR AB - Purpose: This article describes the demographic characteristics of participants in a randomized trial (the AAMEN Project) designed to recruit older (aged 55+ years) African American men to a cancer screening trial. Design and Methods: The AAMEN Project is a recruitment trial developed for African American men aged 55+ years living in southeastern Michigan. Results: Of the 34,376 African American men in the study, 37.6% had low incomes and 62.4% had moderate-to-high incomes. The average age of the men was 63.3 years (SD = 5.9 years). Among men who were eligible and interested in participating, the proportion of men with low incomes was significantly greater than, the proportion of men with moderate-to-high incomes (p < .001). Implications: The AAMEN Project demonstrated success in recruiting a substantial proportion of men with low incomes as well as men with mode rate-to-high incomes. These findings may facilitate the development of future recruitment efforts involving older African American men. AN - WOS:000180943600004 AU - Ford, M. E. AU - Havstad, S. L. AU - Tilley, B. C. DA - Feb DO - 10.1093/geront/43.1.27 IS - 1 N1 - 34 12604743 PY - 2003 SN - 0016-9013 SP - 27-35 ST - Recruiting older African American men to a cancer screening trial (the AAMEN Project) T2 - Gerontologist TI - Recruiting older African American men to a cancer screening trial (the AAMEN Project) VL - 43 ID - 2699 ER - TY - JOUR AB - More than 80% of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher's exact tests. The reasons of being "too sick" or "overwhelmed" were given by less than 12% of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P = .01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health. AN - WOS:000293534100001 AU - Sikorskii, A. AU - Wyatt, G. K. AU - Siddiqi, A. E. A. AU - Tamkus, D. DO - 10.1093/ecam/nep051 N1 - 19620179 PY - 2011 SN - 1741-427X SP - 1-7 ST - Recruitment and Early Retention of Women with Advanced Breast Cancer in a Complementary and Alternative Medicine Trial T2 - Evidence-Based Complementary and Alternative Medicine TI - Recruitment and Early Retention of Women with Advanced Breast Cancer in a Complementary and Alternative Medicine Trial VL - 2011 ID - 3100 ER - TY - JOUR AB - More than 80 of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher's exact tests. The reasons of being too sick or overwhelmed were given by less than 12 of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P =.01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health. Copyright © 2011 Alla Sikorskii et al. AD - G. K. Wyatt, College of Nursing, Michigan State University, East Lansing, MI 48824, United States AU - Wyatt, G. K. AU - Sikorskii, A. AU - Siddiqi, A. E. A. AU - Tamkus, D. DB - Embase DO - 10.1093/ecam/nep051 KW - adult alternative medicine article breast cancer cancer center cancer chemotherapy cancer recurrence chi square distribution controlled study deterioration female Fisher exact test hormonal therapy human interview major clinical study priority journal prognosis randomized controlled trial reflexology screening Wilcoxon signed ranks test LA - English M3 - Article N1 - L361536444 2011-04-08 2011-04-14 PY - 2011 SN - 1741-427X 1741-4288 ST - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial T2 - Evidence-based Complementary and Alternative Medicine TI - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L361536444&from=export http://dx.doi.org/10.1093/ecam/nep051 VL - 2011 ID - 1141 ER - TY - JOUR AB - More than 80 of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t‐, chi‐squared and Fisher's exact tests. The reasons of being too sick or overwhelmed were given by less than 12 of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P =.01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health. Copyright © 2011 Alla Sikorskii et al. AN - CN-00887953 AU - Wyatt, G. K. AU - Sikorskii, A. AU - Siddiqi, A. E. A. AU - Tamkus, D. DO - 10.1093/ecam/nep051 KW - *alternative medicine *breast cancer Adult Article Cancer center Cancer chemotherapy Cancer recurrence Chi square distribution Controlled study Deterioration Female Fisher exact test Hormonal therapy Human Interview Major clinical study Priority journal Prognosis Randomized controlled trial Reflexology Screening Wilcoxon signed ranks test M3 - Journal: Article PY - 2011 ST - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial T2 - Evidence-based complementary and alternative medicine TI - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00887953/full VL - 2011 ID - 1496 ER - TY - JOUR AB - More than 80 of women with breast cancer are now reported to be using complementary and alternative medicine (CAM) therapies during conventional treatment. A randomized clinical trial (RCT) of reflexology with late stage breast cancer patients serves as the data source for this article. The purposes were to investigate: (i) reasons for refusal to participate in a RCT of reflexology; (ii) the differences between those who completed the baseline interview and those who dropped out before baseline; and (iii) the utility of the Palliative Prognostic Score (PPS) as a prognostic screening tool in minimizing early attrition (before baseline) from the trial. Eligible women (N = 400) approached at 12 cancer centers in the Midwest had advanced breast cancer, were on chemotherapy or hormonal therapy, and had a PPS of 11 or less. Comparisons of those who dropped out early (N = 33) to those who stayed in the trial (N = 240) were carried out using Wilcoxon rank, t-, chi-squared and Fisher's exact tests. The reasons of being too sick or overwhelmed were given by less than 12 of the women who refused to participate. There was a higher early dropout rate among black women compared to other (primarily white) women (P =.01). Cancer recurrence and metastasis, age, and the PPS were not predictive of early retention of women. Specialized techniques may be needed to ensure black women remain in the trial once consented. Women with advanced disease were likely to enter and remain in the trial despite deterioration in health. Copyright © 2011 Alla Sikorskii et al. AD - Department of Statistics and Probability, College of Natural Science, Michigan State University, East Lansing, MI 48824, United States College of Nursing, Michigan State University, East Lansing, MI 48824, United States College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States AU - Wyatt, G. K. AU - Sikorskii, A. AU - Siddiqi, A. E. A. AU - Tamkus, D. C7 - 734517 DB - Scopus DO - 10.1093/ecam/nep051 M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2011 ST - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial T2 - Evidence-based Complementary and Alternative Medicine TI - Recruitment and early retention of women with advanced breast cancer in a complementary and alternative medicine trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953288979&doi=10.1093%2fecam%2fnep051&partnerID=40&md5=9474172d46c9afee48856ace1b56c1e2 VL - 2011 ID - 2478 ER - TY - JOUR AD - K. Ashing-Giwa, Beckman Research Institute, United States AU - Ashing-Giwa, K. AU - Rosales, M. DB - Medline DO - 10.1188/12.ONF.E434-E442 IS - 5 KW - adult African American aged article breast tumor female follow up health survey Hispanic human income middle aged patient patient education patient participation patient selection prospective study psychological aspect publication quality of life socioeconomics survivor telephone United States LA - English M3 - Article N1 - L365597187 2013-02-14 PY - 2012 SN - 0190-535X 1538-0688 SP - E434-E442 ST - Recruitment and retention strategies of African American and Latina American breast cancer survivors in a longitudinal psycho-oncology study T2 - Oncology Nursing Forum TI - Recruitment and retention strategies of African American and Latina American breast cancer survivors in a longitudinal psycho-oncology study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L365597187&from=export http://dx.doi.org/10.1188/12.ONF.E434-E442 http://ons.metapress.com/content/q5591546u3146314/fulltext.pdf VL - 39 ID - 1108 ER - TY - JOUR AB - Purpose/Objectives: To describe recruitment and retention strategies of a psychosocial intervention with African American and Latina American breast cancer survivors (BCSs).Design: Prospective design with pre- and post-testing.Setting: A mailed survey and assignment to telephone counseling or education booklet only.Sample: 587 African American and Latina American BCSs were recruited.Methods: The sample was drawn from the population-based California cancer and hospital registries, as well as community agencies. Mailed self-report health-related quality-of-life assessments were at baseline and 4-6 months follow-up.Main Research Variables: Accrual outcomes; recruitment and retention strategies.Findings: A total of 375 (64%) completed the baseline survey and 320 (55%) completed both baseline and follow-up assessments. The recruitment outcomes suggest that very special attention must be paid to the initial recruitment of Latina Americans to engage their interest and participation. For African Americans, particular attention must be devoted to their retention to address potential attrition.Conclusions: Findings suggest that the inclusion of lower-income and ethnic minority cancer survivors in a longitudinal intervention study is doable. The results indicate that recruitment outcomes are influenced by participant and study characteristics. Successful enrollment requires investigations that attend to culturally and socioecologically informed recruitment and retention strategies, from staff selection, training, and supervision to overall study approach protocol, to address barriers to participation.Implications for Nursing: Nursing research and practice have championed survivorship care, including psychosocial care. This article outlines practical strategies to recruit and retain population-based samples, ethnic minorities, and underserved survivors. AD - Department of Population Sciences, Center of Community Alliance for Research and Education City of Hope National Medical Center, Duarte, CA AN - 79629451. Language: English. Entry Date: 20120907. Revision Date: 20190102. Publication Type: Article AU - Ashing-Giwa, Kimlin AU - Rosales, Monica DB - CINAHL Complete DO - 10.1188/12.ONF.E434-E442 DP - EBSCOhost IS - 5 KW - Cancer Survivors Research Subject Recruitment Research Subject Retention Black Persons Hispanic Americans Human Prospective Studies Pretest-Posttest Design Surveys Self Report Quality of Life Female Questionnaires Short Form-36 Health Survey (SF-36) Scales Telephone Funding Source N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care. Instrumentation: Short Form-36 Health Survey (SF-36); Medical Outcomes Study (MOS) Social Support Survey; Functional Assessment of Cancer Therapy-Breast (FACT-B); Life Stress Scale. Grant Information: This studywas supported by a grant from the Department of Defense–Breast Cancer Research Program (W81XWH-04-1-0548).. NLM UID: 7809033. PY - 2012 SN - 0190-535X SP - E434-E442 ST - Recruitment and Retention Strategies of African American and Latina American Breast Cancer Survivors in a Longitudinal Psycho-Oncology Study T2 - Oncology Nursing Forum TI - Recruitment and Retention Strategies of African American and Latina American Breast Cancer Survivors in a Longitudinal Psycho-Oncology Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=79629451&site=ehost-live&scope=site VL - 39 ID - 2065 ER - TY - JOUR AB - Purpose/Objectives: To describe recruitment and retention strategies of a psychosocial intervention with African American and Latina American breast cancer survivors (BCSs).Design: Prospective design with pre- and post-testing.Setting: A mailed survey and assignment to telephone counseling or education booklet only.Sample: 587 African American and Latina American BCSs were recruited.Methods: The sample was drawn from the population-based California cancer and hospital registries, as well as community agencies. Mailed self-report health-related quality-of-life assessments were at baseline and 4-6 months follow-up.Main Research Variables: Accrual outcomes; recruitment and retention strategies.Findings: A total of 375 (64%) completed the baseline survey and 320 (55%) completed both baseline and follow-up assessments. The recruitment outcomes suggest that very special attention must be paid to the initial recruitment of Latina Americans to engage their interest and participation. For African Americans, particular attention must be devoted to their retention to address potential attrition.Conclusions: Findings suggest that the inclusion of lower-income and ethnic minority cancer survivors in a longitudinal intervention study is doable. The results indicate that recruitment outcomes are influenced by participant and study characteristics. Successful enrollment requires investigations that attend to culturally and socioecologically informed recruitment and retention strategies, from staff selection, training, and supervision to overall study approach protocol, to address barriers to participation.Implications for Nursing: Nursing research and practice have championed survivorship care, including psychosocial care. This article outlines practical strategies to recruit and retain population-based samples, ethnic minorities, and underserved survivors. AD - Department of Population Sciences, Center of Community Alliance for Research and Education City of Hope National Medical Center, Duarte, CA AN - 104503108. Language: English. Entry Date: 20120907. Revision Date: 20150819. Publication Type: Journal Article AU - Ashing-Giwa, Kimlin AU - Rosales, Monica DB - CINAHL Complete DP - EBSCOhost IS - 5 KW - Cancer Survivors Research Subject Recruitment Research Subject Retention Black Persons Hispanic Americans Human Prospective Studies Pretest-Posttest Design Surveys Self Report Quality of Life Female Questionnaires Short Form-36 Health Survey (SF-36) Scales Telephone Funding Source N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Special Interest: Oncologic Care. Instrumentation: Short Form-36 Health Survey (SF-36); Medical Outcomes Study (MOS) Social Support Survey; Functional Assessment of Cancer Therapy-Breast (FACT-B); Life Stress Scale. Grant Information: This study was supported by a grant from the Department of Defense– Breast Cancer Research Program (W81XWH-04-1-0548).. NLM UID: 7809033. PMID: NLM22940523. PY - 2012 SN - 0190-535X SP - E434-42 ST - Recruitment and Retention Strategies of African American and Latina American Breast Cancer Survivors in a Longitudinal Psycho-Oncology Study T2 - Oncology Nursing Forum TI - Recruitment and Retention Strategies of African American and Latina American Breast Cancer Survivors in a Longitudinal Psycho-Oncology Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104503108&site=ehost-live&scope=site VL - 39 ID - 2066 ER - TY - JOUR AB - The African American Hereditary Prostate Cancer (AAHPC) Study is an ongoing multicenter genetic linkage study organized by Howard University and the National Human Genome Research Institute (NHGRI), with support from the Office for Research on Minority Health and the National Cancer Institute. The goals of the study are to: (i) look for evidence of involvement of chromosome 1q24-25 (HPC1) in African American men with hereditary prostate cancer (HPC) and (ii) conduct a genome-wide search for other loci associated with HPC in African American men. To accomplish these goals, a network has been established including Howard University, the NHGRI, and six Collaborative Recruitment Centers (CRCs). The CRCs are responsible for the identification and enrollment of 100 African American families. To date, 43 families have been enrolled. Recruitment strategies have included mass media campaigns, physician referrals, community health-fairs/prostate cancer screenings, support groups, tumor registries, as well as visits to churches, barber shops, and universities. By far, the most productive recruitment mechanisms have been physician referrals and tumor registries, yielding a total of 35 (81%) families. Approximately 41% (n = 3400) of probands initially contacted by phone or mail expressed interest in participating; the families of 2% of these met the eligibility criteria, and 75% of those families have been enrolled in the study, indicating a 0.5% recruitment yield (ratio of participants to contacts). As the first large-scale genetic linkage study of African Americans, on a common disease, the challenges and successes of the recruitment process for the AAHPC Study should serve to inform future efforts to involve this population in similar studies. AN - 107005372. Language: English. Entry Date: 20010309. Revision Date: 20191029. Publication Type: journal article AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Kittles, R. AU - Powell, I. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. AU - Mason, T. AU - Johnson, E. AU - Obeikwe, M. AU - Simpson, C. AU - Mejia, R. AU - Boykin, W. AU - Roberson, P. AU - Frost, J. AU - Faison-Smith, L. AU - Meegan, C. DB - CINAHL Complete DP - EBSCOhost IS - 8 KW - Research Subject Recruitment Black Persons Prostatic Neoplasms -- Familial and Genetic Prostatic Neoplasms -- Epidemiology Communication Barriers N1 - tables/charts. Supplement Title: 2000 Nov Suppl. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. Grant Information: N01-HG-75418/HG/NHGRI NIH HHS/United States. NLM UID: 9100013. PMID: NLM11189095. PY - 2000 SN - 1047-2797 SP - S68-77 ST - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study T2 - Annals of Epidemiology TI - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107005372&site=ehost-live&scope=site VL - 10 ID - 2067 ER - TY - JOUR AB - The African American Hereditary Prostate Cancer (AAHPC) Study is an ongoing multicenter genetic linkage study organized by Howard University and the National Human Genome Research Institute (NHGRI), with support from the Office for Research on Minority Health and the National Cancer Institute. The goals of the study are to: (i) look for evidence of involvement of chromosome 1q24-25 (HPC1) in African American men with hereditary prostate cancer (HPC) and (ii) conduct a genome-wide search for other loci associated with HPC in African American men. To accomplish these goals, a network has been established including Howard University, the NHGRI, and six Collaborative Recruitment Centers (CRCs). The CRCs are responsible for the identification and enrollment of 100 African American families. To date, 43 families have been enrolled. Recruitment strategies have included mass media campaigns, physician referrals, community health-fairs/prostate cancer screenings, support groups, tumor registries, as well as visits to churches, barber shops, and universities. By far, the most productive recruitment mechanisms have been physician referrals and tumor registries, yielding a total of 35 (81%) families. Approximately 41% (n = 3400) of probands initially contacted by phone or mail expressed interest in participating; the families of 2% of these met the eligibility criteria, and 75% of those families have been enrolled in the study, indicating a 0.5% recruitment yield (ratio of participants to contacts). As the first large-scale genetic linkage study of African Americans, on a common disease, the challenges and successes of the recruitment process for the AAHPC Study should serve to inform future efforts to involve this population in similar studies. AD - C. Royal, National Human Genome Center, Howard University, Washington, DC 20059, USA. AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Kittles, R. AU - Powell, I. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. AU - Mason, T. AU - Johnson, E. AU - Obeikwe, M. AU - Simpson, C. AU - Mejia, R. AU - Boykin, W. AU - Roberson, P. AU - Frost, J. AU - Faison-Smith, L. AU - Meegan, C. AU - Foster, N. AU - Furbert-Harris, P. AU - Carpten, J. AU - Bailey-Wilson, J. AU - Trent, J. AU - Berg, K. AU - Dunston, G. AU - Collins, F. DB - Medline IS - 8 Suppl KW - African American article clinical trial ethnology family genetics human male patient selection prostate tumor procedures United States LA - English M3 - Article N1 - L33432665 2001-01-19 PY - 2000 SN - 1047-2797 SP - S68-77 ST - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study T2 - Annals of epidemiology TI - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L33432665&from=export VL - 10 ID - 1318 ER - TY - JOUR AB - The African American Hereditary Prostate Cancer (AAHPC) Study is an ongoing multicenter genetic linkage study organized by Howard University and the National Human Genome Research Institute (NHGRI), with support from the Office for Research on Minority Health and the National Cancer Institute. The goals of the study are to: (i) look for evidence of involvement of chromosome 1q24-25 (HPC1) in African American men with hereditary prostate cancer (HPC) and (ii) conduct a genome-wide search for other loci associated with HPC in African American men. To accomplish these goals, a network has been established including Howard University, the NHGRI, and six Collaborative Recruitment Centers (CRCs). The CRCs are responsible for the identification and enrollment of 100 African American families. To date, 43 families have been enrolled. Recruitment strategies have included mass media campaigns, physician referrals, community health-fairs/prostate cancer screenings, support groups, tumor registries, as well as visits to churches, barber shops, and universities. By far, the most productive recruitment mechanisms have been physician referrals and tumor registries, yielding a total of 35 (81%) families. Approximately 41% (n = 3400) of probands initially contacted by phone or mail expressed interest in participating; the families of 2% of these met the eligibility criteria, and 75% of those families have been enrolled in the study, indicating a 0.5% recruitment yield (ratio of participants to contacts). As the first large-scale genetic linkage study of African Americans, on a common disease, the challenges and successes of the recruitment process for the AAHPC Study should serve to inform future efforts to involve this population in similar studies. AD - National Human Genome Center, Howard University, Washington, DC 20059, USA. AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Kittles, R. AU - Powell, I. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. AU - Mason, T. AU - Johnson, E. AU - Obeikwe, M. AU - Simpson, C. AU - Mejia, R. AU - Boykin, W. AU - Roberson, P. AU - Frost, J. AU - Faison-Smith, L. AU - Meegan, C. AU - Foster, N. AU - Furbert-Harris, P. AU - Carpten, J. AU - Bailey-Wilson, J. AU - Trent, J. AU - Berg, K. AU - Dunston, G. AU - Collins, F. DB - Scopus DO - 10.1016/s1047-2797(00)00194-0 IS - 8 Suppl M3 - Article N1 - Cited By :85 Export Date: 22 March 2021 PY - 2000 SP - S68-77 ST - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study T2 - Annals of epidemiology TI - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0008045593&doi=10.1016%2fs1047-2797%2800%2900194-0&partnerID=40&md5=73f0f6ef53bbad2815e44aec77a8a45d VL - 10 ID - 2634 ER - TY - JOUR AB - The African American Hereditary Prostate Cancer (AAHPC) Study is an ongoing multicenter genetic linkage study organized by Howard University and the National Human Genome Research Institute (NHGRI), with support from the Office for Research on Minority Health and the National Cancer institute. The goals of the study are to: (i) look for evidence of involvement of chromosome 1q24-25 (HPC1) in African American men with hereditary prostate cancer (HPC) and (ii) conduct a genome wide search for other loci associated with HPC in African American men. To accomplish these goals, a network has been established including Howard University, the NHGRI, and sh Collaborative Recruitment Centers (CRCs). The CRCs are responsible for the identification and enrollment of 100 African American families. To date, 43 families have been enrolled. Recruitment strategies have included mass media campaigns, physician referrals, community health-fairs/prostate cancer screenings, support groups, tumor registries, as well as visits to churches, barber shops, and universities. By far, the most productive recruitment mechanisms have been physician referrals and tumor registries, yielding a total of 35 (81%) families. Approximately 41% (n = 3400) of probands initially contacted by phone or mail expressed interest in participating; the families of 2% of these mel the eligibility criteria, and 75% of those families have been enrolled in the study, indicating a 0.5% recruitment yield (ratio of participants to contacts). As the first large-scale genetic linkage study of African Americans, on a common disease, the challenges and successes of the recruitment process for the AAHPC Study should serve to inform future efforts to involve this population in similar studies. (C) 2000 Elsevier Science Inc. All rights reserved. AN - WOS:000165950000009 AU - Royal, C. AU - Baffoe-Bonnie, A. AU - Kittles, R. AU - Powell, I. AU - Bennett, J. AU - Hoke, G. AU - Pettaway, C. AU - Weinrich, S. AU - Vijayakumar, S. AU - Ahaghotu, C. AU - Mason, T. AU - Johnson, E. AU - Obeikwe, M. AU - Simpson, C. AU - Mejia, R. AU - Boykin, W. AU - Roberson, P. AU - Frost, J. AU - Faison-Smith, L. AU - Meegan, C. AU - Foster, N. AU - Furbert-Harris, P. AU - Carpten, J. AU - Bailey-Wilson, J. AU - Trent, J. AU - Berg, K. AU - Dunston, G. AU - Collins, F. DA - Nov DO - 10.1016/S1047-2797(00)00194-0 IS - 8 N1 - S Workshop on Participation of Minorities and Women in Clinical Cancer Research FEB 26-27, 1999 WASHINGTON, D.C. NCI 77 11189095 PY - 2000 SN - 1047-2797 SP - S68-S77 ST - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) Study T2 - Annals of Epidemiology TI - Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) Study VL - 10 ID - 2716 ER - TY - JOUR AN - 106083792. Language: English. Entry Date: 20070101. Revision Date: 20200624. Publication Type: Journal Article AU - Patterson, A. AU - Davis, H. AU - Euhus, D. AU - Neuhausen, S. AU - Strong, L. AU - Tomlinson, G. DB - CINAHL Complete DO - 10.1111/j.1075-122x.2005.21542.x DP - EBSCOhost IS - 1 KW - Black Persons Breast Neoplasms -- Ethnology Breast Neoplasms Disease Susceptibility Medically Underserved Area Patient Selection Breast Neoplasms -- Prevention and Control Female United States Women's Health N1 - letter. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Peer Reviewed; USA. NLM UID: 9505539. PMID: NLM15647088. PY - 2005 SN - 1075-122X SP - 79-82 ST - Recruitment for breast cancer predisposition studies in an underserved African American population T2 - Breast Journal TI - Recruitment for breast cancer predisposition studies in an underserved African American population UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106083792&site=ehost-live&scope=site VL - 11 ID - 2068 ER - TY - JOUR AB - Given that Black women remain underrepresented in clinical research studies, we sought to recruit a population-based sample of young Black women with breast cancer through a state cancer registry. Demographic and clinical information on all Black women diagnosed with invasive breast cancer at or below age 50 between 2009 and 2012 in Florida was obtained through the state cancer registry. Survivors were invited to participate in the study through state-mandated recruitment methods. Participant demographic and clinical characteristics were compared using Chi-squared tests for categorical variables and the two sample t-test for continuous variables to identify differences between: (i) consented participants versus all other eligible; and (ii) living versus deceased. Of the 1,647 young Black women with breast cancer, mean age at diagnosis was 42.5, with the majority having localized or regional disease, unmarried, privately insured, and employed. There were no significant differences in demographic and clinical variables between the 456 consented study participants versus the remaining 1,191 presumed eligible individuals. Compared to potential participants, women determined to be deceased prior to recruitment ( n = 182) were significantly more likely to have distant disease and a triple-negative phenotype. They were also significantly more likely to be unemployed, and uninsured or have public insurance (i.e., Medicaid or Medicare). Our results demonstrate that recruitment of a population-based sample of breast cancer survivors through a state cancer registry is a feasible strategy in this underserved and underrepresented population. However, survival bias, which was observed due to the lag time between diagnosis and recruitment, is important to adjust for when generalizing findings to all young Black breast cancer patients. AD - H. Lee Moffitt Cancer Center, Tampa Florida Department of Oncologic Science, College of Medicine, University of South Florida, Tampa Florida AN - 113417293. Language: English. Entry Date: 20160302. Revision Date: 20180530. Publication Type: Article AU - Bonner, Devon AU - Cragun, Deborah AU - Reynolds, Monique AU - Vadaparampil, Susan T. AU - Pal, Tuya DB - CINAHL Complete DO - 10.1111/tbj.12545 DP - EBSCOhost IS - 2 KW - Research Subject Recruitment -- Methods Black Persons Women Breast Neoplasms -- Ethnology Cancer Survivors Registries, Disease -- Utilization -- Florida Florida Chi Square Test T-Tests Descriptive Statistics Data Analysis Software P-Value Human Female Adult Middle Age Socioeconomic Factors Funding Source Pilot Studies N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Peer Reviewed; USA. Grant Information: This study was supported by grants through the Bankhead Coley Granting Agency (IBG10-34199), the American Cancer Society (RSG-11-268-01-CPPB) and the National Cancer Institute (R25). The work contained within this publication was supported in part by the Survey Methods Core Facility at the H. Lee Moffitt Cancer Center & Research Institute. Support also provided by a NCI R25T training grant awarded to Moffitt Cancer Center (5R25CA147832-04).. NLM UID: 9505539. PY - 2016 SN - 1075-122X SP - 166-172 ST - Recruitment of a Population-Based Sample of Young Black Women with Breast Cancer through a State Cancer Registry T2 - Breast Journal TI - Recruitment of a Population-Based Sample of Young Black Women with Breast Cancer through a State Cancer Registry UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113417293&site=ehost-live&scope=site VL - 22 ID - 2069 ER - TY - JOUR AB - Given that Black women remain underrepresented in clinical research studies, we sought to recruit a population-based sample of young Black women with breast cancer through a state cancer registry. Demographic and clinical information on all Black women diagnosed with invasive breast cancer at or below age 50 between 2009 and 2012 in Florida was obtained through the state cancer registry. Survivors were invited to participate in the study through state-mandated recruitment methods. Participant demographic and clinical characteristics were compared using Chi-squared tests for categorical variables and the two sample t-test for continuous variables to identify differences between: (i) consented participants versus all other eligible; and (ii) living versus deceased. Of the 1,647 young Black women with breast cancer, mean age at diagnosis was 42.5, with the majority having localized or regional disease, unmarried, privately insured, and employed. There were no significant differences in demographic and clinical variables between the 456 consented study participants versus the remaining 1,191 presumed eligible individuals. Compared to potential participants, women determined to be deceased prior to recruitment (n = 182) were significantly more likely to have distant disease and a triple-negative phenotype. They were also significantly more likely to be unemployed, and uninsured or have public insurance (i.e., Medicaid or Medicare). Our results demonstrate that recruitment of a population-based sample of breast cancer survivors through a state cancer registry is a feasible strategy in this underserved and underrepresented population. However, survival bias, which was observed due to the lag time between diagnosis and recruitment, is important to adjust for when generalizing findings to all young Black breast cancer patients. AN - WOS:000372140300005 AU - Bonner, D. AU - Cragun, D. AU - Reynolds, M. AU - Vadaparampil, S. T. AU - Pal, T. DA - Mar-Apr DO - 10.1111/tbj.12545 IS - 2 N1 - 26661631 PY - 2016 SN - 1075-122X SP - 166-172 ST - Recruitment of a Population-Based Sample of Young Black Women with Breast Cancer through a State Cancer Registry T2 - Breast Journal TI - Recruitment of a Population-Based Sample of Young Black Women with Breast Cancer through a State Cancer Registry VL - 22 ID - 2952 ER - TY - JOUR AB - Background. African-Americans have the highest overall age-adjusted cancer incidence and mortality rates of any population group in the United States. Despite this fact, this group remains underrepresented in cancer prevention and control research studies, primarily because most recruitment strategies result in limited access to African-American populations. Methods. As part of three large-scale cancer prevention and control studies, effective strategies for recruiting African-American participants were developed and implemented. Results. Eight strategies have been identified as successful recruitment strategies for involving African-Americans in cancer prevention and control studies. Utilizing these strategies resulted in recruiting a representative number of African-American participants, in relation to the local population, into the three studies. Conclusions. African-Americans can be recruited to participate in cancer control and prevention studies if plans include special strategies targeted to addressing unique barriers, beliefs, and concerns. AD - E.D. Paskett, Department of Public Health Sciences, Bowman Gray School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157-1063, United States AU - Paskett, E. D. AU - DeGraffinreid, C. AU - Tatum, C. M. AU - Margitić, S. E. DB - Embase Medline DO - 10.1006/pmed.1996.0088 IS - 5 KW - article breast cancer cancer control cancer incidence cancer mortality cancer prevention cancer screening clinical trial colon polyp double blind procedure ethnic group female human major clinical study male multicenter study Black person phase 3 clinical trial priority journal prostate cancer LA - English M3 - Article N1 - L26315226 1996-10-02 PY - 1996 SN - 0091-7435 SP - 547-553 ST - The recruitment of African-Americans to cancer prevention and control studies T2 - Preventive Medicine TI - The recruitment of African-Americans to cancer prevention and control studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L26315226&from=export http://dx.doi.org/10.1006/pmed.1996.0088 VL - 25 ID - 1336 ER - TY - JOUR AB - Describes effective strategies which were developed and implemented for recruiting African Americans (AFAs) in 3 cancer prevention and control studies (CPCSs). The Polyp Prevention Trial involved 379 Ss randomized at 4 clinical sites. The Prostrate Cancer Prevention Trial involved recruitment of healthy men aged 55 yrs and older. The Forsyth County Cancer Prevention Trial targets low income AFA women in public housing communities. Eight recruitment strategies were found effective for involving AFAs in CPCSs. Utilizing these strategies resulted in recruiting a representative number of AFA participants, in relation to the local population, into the 3 studies. Identified barriers to AFA participation included historical, economic, social, cultural, knowledge and accessibility issues. Results show that AFAs can be recruited to participate in CPCSs if plans include special strategies addressing unique barriers, beliefs, and concerns. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AN - 1996-06638-006 AU - Paskett, Electra D. AU - DeGraffinreid, Cecilia AU - Tatum, Cathy M. AU - Margitić, Susan E. DB - psyh DO - 10.1006/pmed.1996.0088 DP - EBSCOhost IS - 5 KW - effective strategies for recruiting African-Americans as part of cancer prevention & control studies adults conference presentation Adult African Americans Breast Neoplasms Clinical Trials, Phase III as Topic Colonic Polyps Female Health Education Humans Male Mass Screening Neoplasms North Carolina Patient Selection Prostatic Neoplasms Randomized Controlled Trials as Topic Uterine Cervical Neoplasms Cancer Screening Health Promotion Prevention Strategies Blacks N1 - Bowman Gray School of Medicine, Dept of Public Health Sciences, Winston-Salem, NC, US. Release Date: 19960101. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Health Promotion; Prevention; Strategies. Minor Descriptor: Blacks. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10). Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study. Page Count: 7. Issue Publication Date: Sep-Oct, 1996. PY - 1996 SN - 0091-7435 SP - 547-553 ST - The recruitment of African-Americans to cancer prevention and control studies T2 - Preventive Medicine: An International Journal Devoted to Practice and Theory TI - The recruitment of African-Americans to cancer prevention and control studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1996-06638-006&site=ehost-live&scope=site VL - 25 ID - 1748 ER - TY - JOUR AB - Background. African-Americans have the highest overall age-adjusted cancer incidence and mortality rates of any population group in the United States. Despite this fact, this group remains underrepresented in cancer prevention and control research studies, primarily because most recruitment strategies result in limited access to African-American populations. Methods. As part of three large-scale cancer prevention and control studies, effective strategies for recruiting African-American participants were developed and implemented. Results. Eight strategies have been identified as successful recruitment strategies for involving African-Americans in cancer prevention and control studies. Utilizing these strategies resulted in recruiting a representative number of African-American participants, in relation to the local population, into the three studies. Conclusions. African-Americans can be recruited to participate in cancer control and prevention studies if plans include special strategies targeted to addressing unique barriers, beliefs, and concerns. AD - Department of Public Health Sciences, Bowman Gray School of Medicine, Compreh. Cancer Ctr. of Wake F., Winston-Salem, NC 27157, United States Bowman Gray School of Medicine, Department of Public Health Sciences, Medical Center Blvd., Winston-Salem, NC 27157-1063, United States AU - Paskett, E. D. AU - DeGraffinreid, C. AU - Tatum, C. M. AU - Margitić, S. E. DB - Scopus DO - 10.1006/pmed.1996.0088 IS - 5 KW - African-Americans cancer prevention cancer screening recruitment M3 - Article N1 - Cited By :73 Export Date: 22 March 2021 PY - 1996 SP - 547-553 ST - The recruitment of African-Americans to cancer prevention and control studies T2 - Preventive Medicine TI - The recruitment of African-Americans to cancer prevention and control studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030249147&doi=10.1006%2fpmed.1996.0088&partnerID=40&md5=85d2fae0ad947af6a093b56772fc5bb1 VL - 25 ID - 2651 ER - TY - JOUR AB - The recruitment of African Americans into cancer prevention and control studies has presented a major challenge to scientific investigators. Scientific findings, whether biomedical or behavioral, may not be appropriate and applicable to ethnic minority populations unless they are adequately represented as study participants. Moreover, the need to involve greater numbers of ethnic minorities is quite urgent due to the poor morbidity and mortality outcomes associated with ethnic minority group membership. Such is the case with breast cancer survivorship. The purpose of the study was to test a personalized recruitment strategy on response rate in African-American women. The response rate of 45% (n = 117) African Americans and 64% (n = 161) white subjects indicated only limited success in the recruitment of the African-American breast cancer survivors. The recruitment result suggests that culturally relevant recruitment strategies (e.g., inclusion of African-American investigators, culturally consistent letter of recruitment) may be insufficient in adequately increasing research participation. Therefore, further studies on investigating factors that influence research participation (eg, type of incentives, and schedule of payment as well as type of stationery and stamps used) are needed. AD - K. Ashing-Giwa, California School of Professional Psychology, Alhambra 91803-1360, USA. AU - Ashing-Giwa, K. DB - Medline IS - 5 KW - African American article breast tumor Caucasian ethnology female human middle aged mortality Black person patient selection statistics LA - English M3 - Article N1 - L129432804 1999-07-05 PY - 1999 SN - 0027-9684 SP - 255-260 ST - The recruitment of breast cancer survivors into cancer control studies: a focus on African-American women T2 - Journal of the National Medical Association TI - The recruitment of breast cancer survivors into cancer control studies: a focus on African-American women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L129432804&from=export VL - 91 ID - 1327 ER - TY - JOUR AB - Abstract:This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20-month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD=10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty-three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies. AN - 108252747. Language: English. Entry Date: 20110923. Revision Date: 20200706. Publication Type: Journal Article AU - Dignan, Mark AU - Evans, Mary AU - Kratt, Polly AU - Pollack, Lori A. AU - Pisu, Maria AU - Smith, Judith Lee AU - Prayor-Patterson, Heather AU - Houston, Peter AU - Watson, Christopher AU - Hullett, Sandral AU - Martin, Michelle Y. DB - CINAHL Complete DO - 10.1353/hpu.2011.0069 DP - EBSCOhost IS - 3 KW - Black Persons Cancer Survivors Minority Groups Randomized Controlled Trials Research Subject Recruitment Adult Aged Alabama Consent (Research) Demography Descriptive Statistics Female Funding Source Health Education Hospitals, Public Human Male Medically Underserved Middle Age Research Subject Retention Socioeconomic Factors Surveys Telephone N1 - research; tables/charts. Journal Subset: Health Services Administration; Peer Reviewed; Public Health; USA. Special Interest: Oncologic Care; Public Health. Grant Information: Cooperative Agreement Number U48/DP000567-1 from the Centers for Disease Control and Prevention. NLM UID: 9103800. PMID: NLM21841287. PY - 2011 SN - 1049-2089 SP - 912-924 ST - Recruitment of Low Income, Predominantly Minority Cancer Survivors to a Randomized Trial of the 'I Can Cope' Cancer Education Program T2 - Journal of Health Care for the Poor & Underserved TI - Recruitment of Low Income, Predominantly Minority Cancer Survivors to a Randomized Trial of the 'I Can Cope' Cancer Education Program UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=108252747&site=ehost-live&scope=site VL - 22 ID - 2071 ER - TY - JOUR AB - This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20‐month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD=10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty‐three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies. AN - CN-00806552 AU - Dignan, M. AU - Evans, M. AU - Kratt, P. AU - Pollack, L. A. AU - Pisu, M. AU - Smith, J. L. AU - Prayor-Patterson, H. AU - Houston, P. AU - Watson, C. AU - Hullett, S. AU - et al. DO - 10.1353/hpu.2011.0069 IS - 3 KW - Adaptation, Psychological Adult African Americans [education] Aged Alabama American Cancer Society Female Health Education [*methods] Humans Male Middle Aged Minority Groups [*education] Neoplasms [*ethnology] Patient Selection Poverty Program Evaluation Survivors [*psychology] United States M3 - Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. PY - 2011 SP - 912‐924 ST - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program T2 - Journal of health care for the poor and underserved TI - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00806552/full VL - 22 ID - 1382 ER - TY - JOUR AB - This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20-month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD = 10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty-three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Martin, Michelle Y., Division of Preventive Medicine, University of Alabama at Birmingham, 617 Medical Towers, 1530 3rd Ave. South, Birmingham, AL, US, 35294-4410 AN - 2011-19274-012 AU - Dignan, Mark AU - Evans, Mary AU - Kratt, Polly AU - Pollack, Lori A. AU - Pisu, Maria AU - Smith, Judith Lee AU - Prayor-Patterson, Heather AU - Houston, Peter AU - Watson, Christopher AU - Hullett, Sandral AU - Martin, Michelle Y. DB - psyh DO - 10.1353/hpu.2011.0069 DP - EBSCOhost IS - 3 KW - lower income minority groups cancer cancer survivors randomized trial I Can Cope cancer education program Adaptation, Psychological Adult African Americans Aged Alabama American Cancer Society Female Health Education Humans Male Middle Aged Neoplasms Patient Selection Poverty Program Evaluation Survivors United States Coping Behavior Educational Programs Health Promotion Lower Income Level N1 - Prevention Research Center, University of Kentucky (UK), Lexington, KY, US. Release Date: 20120319. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Coping Behavior; Educational Programs; Health Education; Health Promotion; Neoplasms. Minor Descriptor: Lower Income Level; Minority Groups; Survivors. Classification: Cancer (3293); Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Clinical Trial; Empirical Study; Interview; Quantitative Study. References Available: Y. Page Count: 13. Issue Publication Date: Aug, 2011. Copyright Statement: Meharry Medical College Sponsor: Centers for Disease Control and Prevention, US. Grant: Cooperative Agreement Number U48/DP000567-1. Recipients: No recipient indicated PY - 2011 SN - 1049-2089 1548-6869 SP - 912-924 ST - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program T2 - Journal of Health Care for the Poor and Underserved TI - Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-19274-012&site=ehost-live&scope=site mymartin@uab.edu VL - 22 ID - 1698 ER - TY - JOUR AB - This report describes recruitment of minority cancer survivors for a randomized trial of I Can Cope, a support program of the American Cancer Society. Survivor Education and Evaluation (SURE), was designed to recruit patients, age 19 and older, with a primary cancer diagnosis. Recruitment was primarily carried out in a public hospital in Birmingham, Alabama. Of 373 patients approached, 226 were eligible for the study, 175 consented, and 140 were randomized during the 20-month recruitment period. Only 43 declined participation. This resulted in a 61.9% recruitment yield. The mean age of participants was 54.2 years (SD=10.9), 92 (65.7%) were female, and 111 (79.3%) were African American. Twenty-three different cancers were represented including breast (37.1%), colorectal (12.1%), hematologic (12.9%), and lung (7.1%). Over half (63%) had been diagnosed within 12 months. The experience of the SURE project provides evidence for optimism in recruiting racial minorities to cancer research studies. AN - WOS:000294088000016 AU - Dignan, M. AU - Evans, M. AU - Kratt, P. AU - Pollack, L. A. AU - Pisu, M. AU - Smith, J. L. AU - Prayor-Patterson, H. AU - Houston, P. AU - Watson, C. AU - Hullett, S. AU - Martin, M. Y. DA - Aug IS - 3 N1 - 21841287 PY - 2011 SN - 1049-2089 SP - 912-924 ST - Recruitment of Low Income, Predominantly Minority Cancer Survivors to a Randomized Trial of the I Can Cope Cancer Education Program T2 - Journal of Health Care for the Poor and Underserved TI - Recruitment of Low Income, Predominantly Minority Cancer Survivors to a Randomized Trial of the I Can Cope Cancer Education Program VL - 22 ID - 3089 ER - TY - JOUR AB - Background: The importance of recruiting and retaining women from diverse populations is well recognized; however, the recruitment process often presents greater challenges at higher costs than initially anticipated. Objectives: To describe recruitment strategies and costs from a study evaluating women's preferences regarding tamoxifen use for primary prevention of breast cancer. Design: Description and analysis of recruitment strategies, outcomes, and costs for a cross-sectional interview study. Setting: University hospital and community sites. Participants: 932 racially and ethnically diverse women respondents, of whom 771 completed the screening process (aged 27-87). Intervention: Women were recruited and screened by using the Breast Cancer Risk Assessment Program (BCRA version 1, National Cancer Institute). Eligibility required an estimated five-year breast cancer risk of at least 1.7%. Recruitment goals targeted a high percentage of ethnic minorities. Methods: Recruitment strategies included direct mail, flyers, newspapers, media advertising, and community outreach. Results: Of the 771 screened women, 341 (44%) met eligibility criteria and 255 (33%) completed interviews (76.9% White, 10.6% Latina, 7.0% Asian, 3.9% African American, 1.6% Native American). Recruitment costs averaged US $113/screened participant. Direct mail and community contact yielded the largest number of participants (312 screened, 205 eligible). Radio advertising provided few participants (one screened, one eligible) at high cost. Conclusions: Recruiting an ethnically diverse sample presented multiple challenges. We recommend that future studies budget adequately for recruitment time and costs, develop ongoing relationships with key community leaders, evaluate recruitment strategies closely, and report detailed recruitment findings to the research community. AN - WOS:000231199700006 AU - Keyzer, J. F. AU - Melnikow, J. AU - Kuppermann, M. AU - Birch, S. AU - Kuenneth, C. AU - Nuovo, J. AU - Azari, R. AU - Oto-Kent, D. AU - Rooney, M. DA - Sum IS - 3 N1 - 16108298 PY - 2005 SN - 1049-510X SP - 395-406 ST - Recruitment strategies for minority participation: Challenges and cost lessons from the power interview T2 - Ethnicity & Disease TI - Recruitment strategies for minority participation: Challenges and cost lessons from the power interview VL - 15 ID - 3241 ER - TY - JOUR AB - BACKGROUND: Recruiting ethnically diverse Black participants to an innovative, community-based research study to reduce colorectal cancer screening disparities requires multipronged recruitment techniques. OBJECTIVES: This article describes active, passive, and snowball recruitment techniques, and challenges and lessons learned in recruiting a diverse sample of Black participants. METHODS: For each of the three recruitment techniques, data were collected on strategies, enrollment efficiency (participants enrolled/participants evaluated), and reasons for ineligibility. RESULTS: Five hundred sixty individuals were evaluated, and 330 individuals were enrolled. Active recruitment yielded the highest number of enrolled participants, followed by passive and snowball. Snowball recruitment was the most efficient technique, with enrollment efficiency of 72.4%, followed by passive (58.1%) and active (55.7%) techniques. There were significant differences in gender, education, country of origin, health insurance, and having a regular physician by recruitment technique (p < .05). DISCUSSION: Multipronged recruitment techniques should be employed to increase reach, diversity, and study participation rates among Blacks. Although each recruitment technique had a variable enrollment efficiency, the use of multipronged recruitment techniques can lead to successful enrollment of diverse Blacks into cancer prevention and control interventions. AU - Davis, S. N. AU - Govindaraju, S. AU - Jackson, B. AU - Williams, K. R. AU - Christy, S. M. AU - Vadaparampil, S. T. AU - Quinn, G. P. AU - Shibata, D. AU - Roetzheim, R. AU - Meade, C. D. AU - Gwede, C. K. DB - Medline DO - 10.1097/NNR.0000000000000274 IS - 3 KW - African American colorectal tumor early cancer diagnosis educational status female health insurance human male middle aged migrant participatory research patient selection sex factor United States LA - English M3 - Article N1 - L626223563 2019-02-08 2019-02-21 PY - 2018 SN - 1538-9847 SP - 212-221 ST - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry T2 - Nursing research TI - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry UR - https://www.embase.com/search/results?subaction=viewrecord&id=L626223563&from=export http://dx.doi.org/10.1097/NNR.0000000000000274 VL - 67 ID - 899 ER - TY - JOUR AB - Background: Recruiting ethnically diverse Black participants to an innovative, community-based research study to reduce colorectal cancer screening disparities requires multipronged recruitment techniques. Objectives: This article describes active, passive, and snowball recruitment techniques, and challenges and lessons learned in recruiting a diverse sample of Black participants. Methods: For each of the three recruitment techniques, data were collected on strategies, enrollment efficiency (participants enrolled/participants evaluated), and reasons for ineligibility. Results: Five hundred sixty individuals were evaluated, and 330 individuals were enrolled. Active recruitment yielded the highest number of enrolled participants, followed by passive and snowball. Snowball recruitment was the most efficient technique, with enrollment efficiency of 72.4%, followed by passive (58.1%) and active (55.7%) techniques. There were significant differences in gender, education, country of origin, health insurance, and having a regular physician by recruitment technique (p < .05). Discussion: Multipronged recruitment techniques should be employed to increase reach, diversity, and study participation rates among Blacks. Although each recruitment technique had a variable enrollment efficiency, the use of multipronged recruitment techniques can lead to successful enrollment of diverse Blacks into cancer prevention and control interventions. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Davis, Stacy N., Rutgers School of Public Health, 683 Hoes Lane West, Room 321, Piscataway, NJ, US, 08854 AN - 2018-22896-005 AU - Davis, Stacy N. AU - Govindaraju, Swapamthi AU - Jackson, Brittany AU - Williams, Kimberly R. AU - Christy, Shannon M. AU - Vadaparampil, Susan T. AU - Quinn, Gwendolyn P. AU - Shibata, David AU - Roetzheim, Richard AU - Meade, Cathy D. AU - Gwede, Clement K. DB - psyh DO - 10.1097/NNR.0000000000000274 DP - EBSCOhost IS - 3 KW - African American/Black ancestry colorectal cancer screening community-based participatory research recruitment techniques and strategies African Americans Colorectal Neoplasms Early Detection of Cancer Educational Status Emigrants and Immigrants Female Humans Insurance, Health Male Middle Aged Patient Selection Sex Factors United States Blacks Cancer Screening Action Research Community Health Experimental Recruitment Colon Disorders Health Disparities N1 - School of Public Health, Rutgers, State University of New Jersey, New Brunswick, NJ, US. Release Date: 20190613. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Grant Information: Gwede, Clement K. Major Descriptor: Blacks; Cancer Screening; Action Research; Community Health; Experimental Recruitment. Minor Descriptor: Colon Disorders; Health Disparities. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Page Count: 10. Issue Publication Date: May-Jun, 2018. Publication History: Accepted Date: Nov 20, 2017. Copyright Statement: All rights reserved. Wolters Kluwer Health, Inc. 2018. Sponsor: American Cancer Society, US. Grant: RSGT-11-012-01-CPPB. Other Details: Research Scholar Grant Award. Recipients: Gwede, Clement K. (Prin Inv) Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: R25CA090314-12. Recipients: Davis, Stacy N.; Christy, Shannon M.; Jacobsen, P. B. (Prin Inv) Sponsor: H. Lee Moffitt Cancer Center & Research Institute. Other Details: Biostatistics Core and the Survey Methods Core. Recipients: No recipient indicated Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: P30-CA076292. Other Details: NCI-designated Comprehensive Cancer Center. Recipients: No recipient indicated PY - 2018 SN - 0029-6562 1538-9847 SP - 212-221 ST - Recruitment techniques and strategies in a community-based colorectal cancer screening study of men and women of African ancestry T2 - Nursing Research TI - Recruitment techniques and strategies in a community-based colorectal cancer screening study of men and women of African ancestry UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2018-22896-005&site=ehost-live&scope=site ORCID: 0000-0002-4208-9889 Stacy.davis@rutgers.edu VL - 67 ID - 1683 ER - TY - JOUR AB - Background: Recruiting ethnically diverse Black participants to an innovative, community-based research study to reduce colorectal cancer screening disparities requires multipronged recruitment techniques. Objectives: This article describes active, passive, and snowball recruitment techniques, and challenges and lessons learned in recruiting a diverse sample of Black participants. Methods: For each of the three recruitment techniques, data were collected on strategies, enrollment efficiency (participants enrolled/participants evaluated), and reasons for ineligibility. Results: Five hundred sixty individuals were evaluated, and 330 individuals were enrolled. Active recruitment yielded the highest number of enrolled participants, followed by passive and snowball. Snowball recruitment was the most efficient technique, with enrollment efficiency of 72.4%, followed by passive (58.1%) and active (55.7%) techniques. There were significant differences in gender, education, country of origin, health insurance, and having a regular physician by recruitment technique (p < .05). Discussion:Multipronged recruitment techniques should be employed to increase reach, diversity, and study participation rates among Blacks. Although each recruitment technique had a variable enrollment efficiency, the use of multipronged recruitment techniques can lead to successful enrollment of diverse Blacks into cancer prevention and control interventions. AD - Instructor, School of Public Health, the Rutgers, the State University of New Jersey, New Brunswick Research Assistant, Moffitt Cancer Center and Research Institute, Tampa, Florida Assistant Professor, University of Tennessee Health Science Center, Memphis Senior Member, Moffitt Cancer Center and Research Institute, Tampa, Florida Professor, University of South Florida College of Medicine, Tampa, Florida Livia Wan Endowed Chair, New York University Medical Center, New York Professor, University of Tennessee Health Science Center, Memphis AN - 129524574. Language: English. Entry Date: 20180517. Revision Date: 20180530. Publication Type: Article AU - Davis, Stacy N. AU - Govindaraju, Swapamthi AU - Jackson, Brittany AU - Williams, Kimberly R. AU - Christy, Shannon M. AU - Vadaparampil, Susan T. AU - Quinn, Gwendolyn P. AU - Shibata, David AU - Roetzheim, Richard AU - Meade, Cathy D. AU - Gwede, Clement K. DB - CINAHL Complete DO - 10.1097/NNR.0000000000000274 DP - EBSCOhost IS - 3 KW - Research Subject Recruitment Colorectal Neoplasms Cancer Screening Black Persons Healthcare Disparities Human Male Female Snowball Sample Florida Health Information Middle Age Funding Source N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: the study was funded by Research ScholarGrant Award RSGT-11-012-01-CPPB (PI: C. K. Gwede) from the AmericanCancer Society. The work of the first and fifth authors were funded byR25CA090314-12 (PI: P. B. Jacobsen) from the National Cancer Instituteat the NIH. The work conducted was also supported by the BiostatisticsCore and the Survey Methods Core at the H. Lee Moffitt Cancer Center& Research Institute, an NCI-designated Comprehensive Cancer Center(NIH/NCI Grant P30-CA076292). NLM UID: 0376404. PY - 2018 SN - 0029-6562 SP - 212-221 ST - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry T2 - Nursing Research TI - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=129524574&site=ehost-live&scope=site VL - 67 ID - 2073 ER - TY - JOUR AB - Background Recruiting ethnically diverse Black participants to an innovative, community-based research study to reduce colorectal cancer screening disparities requires multipronged recruitment techniques. Objectives This article describes active, passive, and snowball recruitment techniques, and challenges and lessons learned in recruiting a diverse sample of Black participants. Methods For each of the three recruitment techniques, data were collected on strategies, enrollment efficiency (participants enrolled/participants evaluated), and reasons for ineligibility. Results Five hundred sixty individuals were evaluated, and 330 individuals were enrolled. Active recruitment yielded the highest number of enrolled participants, followed by passive and snowball. Snowball recruitment was the most efficient technique, with enrollment efficiency of 72.4%, followed by passive (58.1%) and active (55.7%) techniques. There were significant differences in gender, education, country of origin, health insurance, and having a regular physician by recruitment technique (p < .05). Discussion Multipronged recruitment techniques should be employed to increase reach, diversity, and study participation rates among Blacks. Although each recruitment technique had a variable enrollment efficiency, the use of multipronged recruitment techniques can lead to successful enrollment of diverse Blacks into cancer prevention and control interventions. AN - WOS:000432189200006 AU - Davis, S. N. AU - Govindaraju, S. AU - Jackson, B. AU - Williams, K. R. AU - Christy, S. M. AU - Vadaparampil, S. T. AU - Quinn, G. P. AU - Shibata, D. AU - Roetzheim, R. AU - Meade, C. D. AU - Gwede, C. K. DA - May-Jun DO - 10.1097/NNR.0000000000000274 IS - 3 N1 - 29698327 PY - 2018 SN - 0029-6562 SP - 212-221 ST - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry T2 - Nursing Research TI - Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry VL - 67 ID - 2862 ER - TY - JOUR AB - Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials. AD - B.M. Ryan, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States AU - Mitchell, K. A. AU - Nichols, N. AU - Tang, W. AU - Walling, J. AU - Stevenson, H. AU - Pineda, M. AU - Stefanescu, R. AU - Edelman, D. C. AU - Girvin, A. T. AU - Zingone, A. AU - Sinha, S. AU - Bowman, E. AU - Rossi, E. L. AU - Arauz, R. F. AU - Jack Zhu, Y. AU - Lack, J. AU - Weingartner, E. AU - Waterfall, J. AU - Pine, S. R. AU - Simmons, J. AU - Meltzer, P. AU - Ryan, B. M. DB - Embase Medline DO - 10.1038/s41467-019-13732-y IS - 1 KW - NCT00339859 spectrophotometer interleukin 6 Janus kinase 2 microRNA 21 receptor like protein tyrosine phosphatase STAT3 protein adolescent adult African American aged article cancer incidence carcinogenesis case control study child clinical article clinical trial controlled study DNA extraction epigenetics female gene expression gene frequency gene mutation gene sequence human human tissue infant lung adenocarcinoma lung cancer male molecularly targeted therapy mutation rate mutational analysis newborn polymerase chain reaction prevalence signal transduction single nucleotide polymorphism smoking spectrophotometry squamous cell lung carcinoma whole exome sequencing NanoDrop LA - English M3 - Article N1 - L2003868709 2019-12-24 2019-12-30 PY - 2019 SN - 2041-1723 ST - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans T2 - Nature Communications TI - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2003868709&from=export http://dx.doi.org/10.1038/s41467-019-13732-y VL - 10 ID - 831 ER - TY - JOUR AB - Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials. © 2019, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. AD - Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States Palantir Technologies, 1025 Thomas Jefferson St, Washington, DC 20007, United States Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States NIAID Collaborative Bioinformatics Resource, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, United States Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick, MD 21702, United States Personal Genome Diagnostics, Baltimore, MD 21124, United States Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, United States AU - Mitchell, K. A. AU - Nichols, N. AU - Tang, W. AU - Walling, J. AU - Stevenson, H. AU - Pineda, M. AU - Stefanescu, R. AU - Edelman, D. C. AU - Girvin, A. T. AU - Zingone, A. AU - Sinha, S. AU - Bowman, E. AU - Rossi, E. L. AU - Arauz, R. F. AU - Jack Zhu, Y. AU - Lack, J. AU - Weingartner, E. AU - Waterfall, J. AU - Pine, S. R. AU - Simmons, J. AU - Meltzer, P. AU - Ryan, B. M. C7 - 5735 DB - Scopus DO - 10.1038/s41467-019-13732-y IS - 1 M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2019 ST - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans T2 - Nature Communications TI - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076589365&doi=10.1038%2fs41467-019-13732-y&partnerID=40&md5=05724ef5cb13148efb27e8cafea019ca VL - 10 ID - 2214 ER - TY - JOUR AB - Reducing or eliminating persistent disparities in lung cancer incidence and survival has been challenging because our current understanding of lung cancer biology is derived primarily from populations of European descent. Here we show results from a targeted sequencing panel using NCI-MD Case Control Study patient samples and reveal a significantly higher prevalence of PTPRT and JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans. This increase in mutation frequency was validated with independent WES data from the NCI-MD Case Control Study and TCGA. We find that patients carrying these mutations have a concomitant increase in IL-6/STAT3 signaling and miR-21 expression. Together, these findings suggest the identification of these potentially actionable mutations could have clinical significance for targeted therapy and the enrollment of minority populations in clinical trials. AN - WOS:000502776400001 AU - Mitchell, K. A. AU - Nichols, N. AU - Tang, W. AU - Walling, J. AU - Stevenson, H. AU - Pineda, M. AU - Stefanescu, R. AU - Edelman, D. C. AU - Girvin, A. T. AU - Zingone, A. AU - Sinha, S. AU - Bowman, E. AU - Rossi, E. L. AU - Arauz, R. F. AU - Zhu, Y. J. AU - Lack, J. AU - Weingartner, E. AU - Waterfall, J. AU - Pine, S. R. AU - Simmons, J. AU - Meltzer, P. AU - Ryan, B. M. DA - Dec DO - 10.1038/s41467-019-13732-y N1 - 5735 31844068 PY - 2019 SN - 2041-1723 ST - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans T2 - Nature Communications TI - Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans VL - 10 ID - 2803 ER - TY - JOUR AB - We investigated the relationship of body size and prostate cancer risk in the Multiethnic Cohort, a longitudinal study of individuals ages 45 to 75 in Hawaii and in California. Self-reported measures of height and weight were obtained at baseline. Of 83,879 men enrolled from 1993 to 1996, a total of 5,554 were diagnosed with prostate cancer during an average of 9.6 years of follow-up. The influence of baseline weight and weight change since age 21 varied by ethnic group. Whites gaining more than 10 lbs had a nonlinear, increased risk of advanced and high-grade prostate cancer [relative risks (RR), 2.12; 95% confidence intervals (CI), 1.19-3.78 for 25-39.9 lbs; P trend 0.43; and RR, 1.49; 95% CI, 1.04-2.14, for ≥40 lbs; P trend 0.20, respectively]. African American men gaining 40 lbs or more (relative to <10 lbs) had a nonmonotonic, increased risk of localized prostate cancers (RR, 1.26; 95% CI, 1.02-1.54; P trend 0.09) and those who gained 25 lbs or more were at increased risk of low-grade disease (RR, 1.28; 95% CI, 1.03-1.58, for ≥40 versus 10 lbs, respectively; P trend 0.07). Japanese men had a statistically significant, inverse association of weight gain and localized disease (RR, 0.80; 95% CI, 0.65-0.99 for ≥40 versus 10 lbs; P trend 0.05). Our findings provide evidence that adiposity and changes in adiposity between younger and older adulthood influence the development of prostate cancer. Ethnic differences in risk may be explained by variation in the distribution of accumulated body fat that could differentially affect prostate carcinogenesis. Copyright © 2009 American Association for Cancer Research. AD - Epidemiology Department, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, United States Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States 1236 Lauhala Street, Honolulu, HI 96813, United States AU - Hernandez, B. Y. AU - Park, S. Y. AU - Wilkens, L. R. AU - Henderson, B. E. AU - Kolonel, L. N. DB - Scopus DO - 10.1158/1055-9965.EPI-09-0293 IS - 9 M3 - Article N1 - Cited By :30 Export Date: 22 March 2021 PY - 2009 SP - 2413-2421 ST - Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort T2 - Cancer Epidemiology Biomarkers and Prevention TI - Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349307394&doi=10.1158%2f1055-9965.EPI-09-0293&partnerID=40&md5=c2d1ea4e9ff80a0a14895abe99d1f690 VL - 18 ID - 2515 ER - TY - JOUR AB - Background: Early-onset baldness has been linked to prostate cancer; however, little is known about this relationship in AfricanAmericans who are at elevated prostate cancer risk. Methods: We recruited 219 African-American controls and 318 African-American prostate cancer cases. We determined age-stratified associations of baldness with prostate cancer occurrence and severity defined by high stage (T3/T4) or high grade (Gleason 7+.) Associations of androgen metabolism genotypes (CYP3A4, CYP3A5, CYP3A43, AR-CAG, SRD5A2 A49T, and SRD5A2 V89L), family history, alcohol intake, and smoking were examined by baldness status and age group by using multivariable logistic regression models. Results: Baldness was associated with odds of prostate cancer [OR 1.69; 95% confidence interval (CI), 1.05- 2.74]. Frontal baldness was associated with high-stage (OR 2.61; 95% CI, 1.10-6.18) and high-grade (OR 2.20; 95% CI, 1.05-4.61) tumors. Formendiagnosed less than the age of 60 years, frontal baldness was associated with high stage (OR 6.51; 95% CI, 2.11-20.06) and high grade (OR 4.23; 95% CI, 1.47-12.14). We also observed a suggestion of an interaction among smoking, median age, and any baldness (P 0.02). Conclusions: We observed significant associations between early-onset baldness and prostate cancer in African-American men. Interactions with age and smoking were suggested in these associations. Studies are needed to investigate the mechanisms influencing the relationship between baldness and prostate cancer in African-American men. Impact: African-American men present with unique risk factors including baldness patterns that may contribute to prostate cancer disparities. © 2013 American Association for Cancer Research. AD - Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, 220 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104, United States AU - Zeigler-Johnson, C. AU - Morales, K. H. AU - Spangler, E. AU - Chang, B. L. AU - Rebbeck, T. R. DB - Scopus DO - 10.1158/1055-9965.EPI-12-0944 IS - 4 M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2013 SP - 589-596 ST - Relationship of early-onset baldness to prostate cancer in african-american men T2 - Cancer Epidemiology Biomarkers and Prevention TI - Relationship of early-onset baldness to prostate cancer in african-american men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876515014&doi=10.1158%2f1055-9965.EPI-12-0944&partnerID=40&md5=ef745221aaa52948e8f3c7e9cf06ceaf VL - 22 ID - 2435 ER - TY - JOUR AB - Purpose: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test–retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). Methods: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7–10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. Results: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach’s α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). Conclusions: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7–10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Atkinson, Thomas M. AN - 2019-22220-001 AU - Atkinson, Thomas M. AU - Palefsky, Joel AU - Li, Yuelin AU - Webb, Andrew AU - Berry, J. Michael AU - Goldstone, Stephen AU - Levine, Rebecca AU - Wilkin, Timothy J. AU - Bucher, Gary AU - Cella, David AU - Burkhalter, Jack E. DB - psyh DO - 10.1007/s11136-018-2089-8 DP - EBSCOhost IS - 5 KW - patient-reported outcomes health-related quality of life clinical outcome assessments neoplasms ANCHOR trial Acquired Immunodeficiency Syndrome Adult Anus Neoplasms Female Humans Male Middle Aged Quality of Life Reproducibility of Results Self Report Squamous Intraepithelial Lesions of the Cervix Surveys and Questionnaires Treatment Outcome Watchful Waiting AIDS Lesions Measurement Health Related Quality of Life HIV Symptoms Test Reliability Test Validity N1 - University of California-San Francisco, San Francisco, CA, US. Institutional Authors: The ANCHOR HRQoL Implementation Group. Release Date: 20200702. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: AIDS; Lesions; Measurement; Neoplasms; Health Related Quality of Life. Minor Descriptor: HIV; Symptoms; Test Reliability; Test Validity. Classification: Health Psychology Testing (2226); Cancer (3293). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: ANCHOR Health-Related Symptom Index. Methodology: Empirical Study; Quantitative Study. Page Count: 5. Issue Publication Date: May 15, 2019. Publication History: First Posted Date: Jan 7, 2019; Accepted Date: Dec 13, 2018. Copyright Statement: Springer Nature Switzerland AG. 2019. PY - 2019 SN - 0962-9343 1573-2649 SP - 1265-1269 ST - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: An AIDS Malignancy Consortium Study (AMC-A03) T2 - Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation TI - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: An AIDS Malignancy Consortium Study (AMC-A03) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2019-22220-001&site=ehost-live&scope=site atkinsot@mskcc.org VL - 28 ID - 1682 ER - TY - JOUR AB - Purpose: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI).Methods: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item.Results: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16).Conclusions: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. AD - Memorial Sloan Kettering Cancer Center, New York, NY, USA University of California-San Francisco, San Francisco, CA, USA Laser Surgery Care, New York, NY, USA Montefiore Medical Center, New York, NY, USA Weill Cornell Medicine, New York, NY, USA Anal Dysplasia Clinic Midwest, Chicago, IL, USA Northwestern University Feinberg School of Medicine, Chicago, IL, USA AN - 135927723. Corporate Author: ANCHOR HRQoL Implementation Group. Language: English. Entry Date: In Process. Revision Date: 20200701. Publication Type: journal article. Journal Subset: Allied Health AU - Atkinson, Thomas M. AU - Palefsky, Joel AU - Li, Yuelin AU - Webb, Andrew AU - Berry, J. Michael AU - Goldstone, Stephen AU - Levine, Rebecca AU - Wilkin, Timothy J. AU - Bucher, Gary AU - Cella, David AU - Burkhalter, Jack E. DB - CINAHL Complete DO - 10.1007/s11136-018-2089-8 DP - EBSCOhost IS - 5 KW - Cervix Dysplasia -- Therapy Quality of Life -- Psychosocial Factors Outcomes (Health Care) -- Methods Anus Neoplasms -- Prevention and Control Cervix Dysplasia -- Psychosocial Factors Self Report Acquired Immunodeficiency Syndrome -- Complications Female Middle Age Male Treatment Outcomes Cervix Dysplasia -- Pathology Reproducibility of Results Adult Scales N1 - Public Health; USA. Instrumentation: Health-Related Hardiness Scale (HRHS). Grant Information: 3U54CA137788-08S1/NH/NIH HHS/United States. NLM UID: 9210257. PMID: NLM30617704. PY - 2019 SN - 0962-9343 SP - 1265-1269 ST - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) T2 - Quality of Life Research TI - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135927723&site=ehost-live&scope=site VL - 28 ID - 2075 ER - TY - JOUR AB - Purpose: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test–retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). Methods: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7–10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. Results: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach’s α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). Conclusions: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7–10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. AD - T.M. Atkinson, Memorial Sloan Kettering Cancer Center, New York, NY, United States AU - Atkinson, T. M. AU - Palefsky, J. AU - Li, Y. AU - Webb, A. AU - Berry, J. M. AU - Goldstone, S. AU - Levine, R. AU - Wilkin, T. J. AU - Bucher, G. AU - Cella, D. AU - Burkhalter, J. E. AU - Holland, S. M. AU - Lee, J. AU - Lubetkin, E. I. AU - Lynch, K. A. AU - Taylor, J. AU - Watsula-Morley, A. DB - Embase Medline DO - 10.1007/s11136-018-2089-8 IS - 5 KW - adult African American aged anal high grade squamous intraepithelial lesion anus carcinoma article burning sensation cancer diagnosis constipation correlation coefficient depression disease surveillance female human Human immunodeficiency virus infected patient incidence intestinal bleeding major clinical study male outcomes research patient-reported outcome priority journal quality of life sexual behavior test retest reliability LA - English M3 - Article N1 - L625852485 2019-01-15 2019-05-14 PY - 2019 SN - 1573-2649 0962-9343 SP - 1265-1269 ST - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) T2 - Quality of Life Research TI - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625852485&from=export http://dx.doi.org/10.1007/s11136-018-2089-8 VL - 28 ID - 848 ER - TY - JOUR AB - Purpose: The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test–retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). Methods: ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7–10 days later to complete the A-HRSI and a participant global impression of change (PGIC) item. Results: Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach’s α was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). Conclusions: The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7–10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. © 2019, Springer Nature Switzerland AG. AD - Memorial Sloan Kettering Cancer Center, New York, NY, United States University of California-San Francisco, San Francisco, CA, United States Laser Surgery Care, New York, NY, United States Montefiore Medical Center, New York, NY, United States Weill Cornell Medicine, New York, NY, United States Anal Dysplasia Clinic Midwest, Chicago, IL, United States Northwestern University Feinberg School of Medicine, Chicago, IL, United States AU - Atkinson, T. M. AU - Palefsky, J. AU - Li, Y. AU - Webb, A. AU - Berry, J. M. AU - Goldstone, S. AU - Levine, R. AU - Wilkin, T. J. AU - Bucher, G. AU - Cella, D. AU - Burkhalter, J. E. AU - Holland, S. M. AU - Lee, J. AU - Lubetkin, E. I. AU - Lynch, K. A. AU - Taylor, J. AU - Watsula-Morley, A. AU - the, Anchor HRQoL Implementation Group DB - Scopus DO - 10.1007/s11136-018-2089-8 IS - 5 KW - ANCHOR trial Clinical outcome assessments Health-related quality of life Neoplasms Patient-reported outcomes M3 - Article N1 - Export Date: 22 March 2021 PY - 2019 SP - 1265-1269 ST - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) T2 - Quality of Life Research TI - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059681847&doi=10.1007%2fs11136-018-2089-8&partnerID=40&md5=56a970d25c7410c7f7d6880b4019074d VL - 28 ID - 2229 ER - TY - JOUR AB - Purpose The Anal Cancer HSIL Outcomes Research (ANCHOR) trial aims to determine whether treating precancerous anal high-grade squamous intraepithelial lesions (HSIL), versus active surveillance, is effective in reducing anal cancer incidence in HIV-infected individuals. We evaluated the reliability (i.e., internal consistency, test-retest) and between-group stability of a 25-item ANCHOR Health-Related Symptom Index (A-HRSI). Methods ANCHOR participants at least 1-month post-randomization to treatment or active surveillance completed the A-HRSI via telephone. Participants were contacted 7-10days later to complete the A-HRSI and a participant global impression of change (PGIC) item. Results Participants (n = 100) were enrolled (mean age = 51.4, 79% cisgender-male, 73% African American, 9% Hispanic) from five ANCHOR sites. Cronbach's alpha was good for the physical symptoms (0.82) domain and fair for the physical impacts (0.79) and psychological symptoms (0.73) domains. Intraclass correlation coefficients were good for each of respective domains (i.e., 0.80, 0.85, and 0.82). There were no significant differences in PGIC between the treatment (n = 56) and active surveillance (n = 44) groups (F(1,98) = 2.03, p = 0.16). Conclusions The A-HRSI is able to reliably assess participant-reported symptoms and impacts of anal HSIL across a 7-10 days of timeframe. Future work will involve the establishment of construct and discriminant validity prior to inclusion in the full ANCHOR trial. AN - WOS:000466734100014 AU - Atkinson, T. M. AU - Palefsky, J. AU - Li, Y. L. AU - Webb, A. AU - Berry, J. M. AU - Goldstone, S. AU - Levine, R. AU - Wilkin, T. J. AU - Bucher, G. AU - Cella, D. AU - Burkhalter, J. E. AU - Holland, S. M. AU - Lee, J. AU - Lubetkin, E. I. AU - Lynch, K. A. AU - Taylor, J. AU - Watsula-Morley, A. DA - May DO - 10.1007/s11136-018-2089-8 IS - 5 N1 - 30617704 PY - 2019 SN - 0962-9343 SP - 1265-1269 ST - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) T2 - Quality of Life Research TI - Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: an AIDS Malignancy Consortium Study (AMC-A03) VL - 28 ID - 2822 ER - TY - JOUR AB - Incidence and mortality rates for cancers vary by ethnic background and patient age. Accrual of diverse patient populations to cancer clinical trials is essential in order to ensure that findings related to new management strategies can be generalized. The goal of this study was to evaluate accrual patterns for patients participating in the American College of Surgeons Oncology Group (ACOSOG) cancer protocols. Ethnic diversity among clinical trial investigators may also influence accrual patterns, so the ethnic background of the ACOSOG membership was also evaluated. Demographics for the patients registered on ACOSOG breast, thoracic, and colorectal clinical trials were evaluated and compared with data on the general population and the cancer population in the United States. Accrual patterns for patients from other reported cancer clinical trials were also presented, and the self-reported ethnic distribution of the ACOSOG membership was analyzed. Distribution of African Americans, Hispanic Americans, and Asian Americans to the ACOSOG breast and colorectal clinical trials was relatively proportionate to the cancer population. African Americans were underrepresented in the thoracic clinical trials, and this disparity was partially offset by data on the proportion of African Americans with stage-eligible lung cancer. Accrual rates for patients age 65 years and older were better than those reported by most other clinical trialists. Elderly patients are successfully recruited into surgical clinical trials, and this will provide important data for future analyses regarding cancer outcomes in this growing population of cancer patients. Aggressive outreach to minority-ethnicity cancer patients for accrual into clinical trials should continue. © 2004 American College of Surgeons. AD - Department of Surgery, University of Michigan, Ann Arbor, MI, United States AU - Newman, L. A. AU - Hurd, T. AU - Leitch, M. AU - Kuerer, H. M. AU - Diehl, K. AU - Lucci, A. AU - Giuliano, A. AU - Hunt, K. K. AU - Putnam, W. AU - Wells, S. A. DB - Embase Medline DO - 10.1016/j.jamcollsurg.2004.05.282 IS - 4 KW - African American article Asian American breast cancer cancer patient colorectal cancer data analysis demography ethnology evaluation study human lung cancer minority group population priority journal register LA - English M3 - Article N1 - L39420219 2004-11-09 PY - 2004 SN - 1072-7515 SP - 644-651 ST - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the american college of surgeons oncology group T2 - Journal of the American College of Surgeons TI - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the american college of surgeons oncology group UR - https://www.embase.com/search/results?subaction=viewrecord&id=L39420219&from=export http://dx.doi.org/10.1016/j.jamcollsurg.2004.05.282 VL - 199 ID - 1281 ER - TY - JOUR AB - Incidence and mortality rates for cancers vary by ethnic background and patient age. Accrual of diverse patient populations to cancer clinical trials is essential in order to ensure that findings related to new management strategies can be generalized. The goal of this study was to evaluate accrual patterns for patients participating in the American College of Surgeons Oncology Group (ACOSOG) cancer protocols. Ethnic diversity among clinical trial investigators may also influence accrual patterns, so the ethnic background of the ACOSOG membership was also evaluated. Demographics for the patients registered on ACOSOG breast, thoracic, and colorectal clinical trials were evaluated and compared with data on the general population and the cancer population in the United States. Accrual patterns for patients from other reported cancer clinical trials were also presented, and the self-reported ethnic distribution of the ACOSOG membership was analyzed. Distribution of African Americans, Hispanic Americans, and Asian Americans to the ACOSOG breast and colorectal clinical trials was relatively proportionate to the cancer population. African Americans were underrepresented in the thoracic clinical trials, and this disparity was partially offset by data on the proportion of African Americans with stage-eligible lung cancer. Accrual rates for patients age 65 years and older were better than those reported by most other clinical trialists. Elderly patients are successfully recruited into surgical clinical trials, and this will provide important data for future analyses regarding cancer outcomes in this growing population of cancer patients. Aggressive outreach to minority-ethnicity cancer patients for accrual into clinical trials should continue. © 2004 American College of Surgeons. AD - Department of Surgery, University of Michigan, Ann Arbor, MI, United States Roswell Park Cancer Institute, Buffalo, NY, United States University of Texas Southwestern, Dallas, TX; University of Texas, United States MD Anderson Cancer Center, Houston, TX, United States Baylor University, Houston, TX, United States John Wayne Cancer Center, Santa Monica, CA, United States Vanderbilt University, Nashville, TN, United States Duke University, Durham, NC, United States University of Michigan, Comprehensive Cancer Center, 1500 Med. Ctr. Dr, Ann Arbor, M., United States AU - Newman, L. A. AU - Hurd, T. AU - Leitch, M. AU - Kuerer, H. M. AU - Diehl, K. AU - Lucci, A. AU - Giuliano, A. AU - Hunt, K. K. AU - Putnam, W. AU - Wells, S. A. DB - Scopus DO - 10.1016/j.jamcollsurg.2004.05.282 IS - 4 M3 - Article N1 - Cited By :30 Export Date: 22 March 2021 PY - 2004 SP - 644-651 ST - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the american college of surgeons oncology group T2 - Journal of the American College of Surgeons TI - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the american college of surgeons oncology group UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-6944244104&doi=10.1016%2fj.jamcollsurg.2004.05.282&partnerID=40&md5=1c3c9163228d0cc31e41f2bf00dbbc22 VL - 199 ID - 2604 ER - TY - JOUR AB - BACKGROUND: Incidence and mortality rates for cancers vary by ethnic background and patient age. Accrual of diverse patient populations to cancer clinical trials is essential in order to ensure that findings related to new management strategies can be generalized. The goal of this study was to evaluate accrual patterns for patients participating in the American College of Surgeons Oncology Group (ACOSOG) cancer protocols. Ethnic diversity among clinical trial investigators may also influence accrual patterns, so the ethnic background of the ACOSOG membership was also evaluated. STUDY DESIGN: Demographics for the patients registered on ACOSOG breast, thoracic, and colorectal clinical trials were evaluated and compared with data on the general population and the cancer population in the United States. Accrual patterns for patients from other reported cancer clinical trials were also presented, and the self-reported ethnic distribution of the ACOSOG membership was analyzed. RESULTS: Distribution of African Americans, Hispanic Americans, and Asian Americans to the ACOSOG breast and colorectal clinical trials was relatively proportionate to the cancer population. African Americans were underrepresented in the thoracic clinical trials, and this disparity was partially offset by data on the proportion of African Americans with stage-eligible lung cancer. Accrual rates for patients age 65 years and older were better than those reported by most other clinical trialists. CONCLUSIONS: Elderly patients are successfully recruited into surgical clinical trials, and this will provide important data for future analyses regarding cancer outcomes in this growing population of cancer patients. Aggressive outreach to minority-ethnicity cancer patients for accrual into clinical trials should continue. (C) 2004 by the American College of Surgeons. AN - WOS:000224368400020 AU - Newman, L. A. AU - Hurd, T. AU - Leitch, M. AU - Kuerer, H. M. AU - Diehl, K. AU - Lucci, A. AU - Giuliano, A. AU - Hunt, K. K. AU - Putnam, W. AU - Wells, S. A. DA - Oct DO - 10.1016/j.jamcollsurg.2004.05.282 IS - 4 N1 - 26 15454152 PY - 2004 SN - 1072-7515 SP - 644-651 ST - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group T2 - Journal of the American College of Surgeons TI - A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group VL - 199 ID - 2675 ER - TY - JOUR AB - Racial and ethnic minorities are significantly underrepresented in clinical research trials. Several sociocultural and systemic barriers, ranging from discrimination by the health care system, medical mistrust, to low physician referral rates and lack of knowledge of research studies have been identified as impacting participation. One hundred and fifteen participants were culturally matched and were interviewed followed by up to an additional four interviews over a 12 month period. Responses were analyzed to understand the perceived benefits to participating in a prospective, randomized, longitudinal clinical research trial about screening colonoscopy. Over two-thirds (64.4%) of participants reported "knowledge, awareness, and/or information about colonoscopy and general health" as being the greatest benefit they received. Desire to undergo the screening and the pride of completing the study was ranked second and third, respectively. Understanding the reasons that participants choose to participate in research studies will ultimately assist researchers close the gap in minority representation, allowing for greater generalizability of research findings. AN - WOS:000300367700009 AU - Castillo, A. G. AU - Jandorf, L. AU - Thelemaque, L. D. AU - King, S. AU - Duhamel, K. DA - Feb DO - 10.1007/s10900-011-9416-0 IS - 1 N1 - 21644025 PY - 2012 SN - 0094-5145 SP - 59-64 ST - Reported Benefits of Participation in a Research Study T2 - Journal of Community Health TI - Reported Benefits of Participation in a Research Study VL - 37 ID - 3075 ER - TY - JOUR AB - The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported: expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios. AD - P.F. Pinsky, Division of Cancer Prevention, National Cancer Institute, EPN 3064, 6130 Executive Blvd., Bethesda, MD 20892, United States AU - Pinsky, P. F. AU - Kramer, B. S. AU - Reding, D. AU - Buys, S. DB - Embase Medline DO - 10.1093/aje/kwg043 IS - 9 KW - adult aged article Asian bladder cancer bone cancer brain cancer breast cancer cancer incidence cancer risk cancer screening Caucasian clinical trial colorectal cancer controlled clinical trial controlled study ethnic group family history female genetic predisposition human liver cancer lung cancer lymphoma major clinical study male melanoma Black person ovary cancer prevalence prostate cancer questionnaire randomized controlled trial sex difference stomach cancer testis cancer LA - English M3 - Article N1 - L36529419 2003-05-12 PY - 2003 SN - 0002-9262 SP - 792-799 ST - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial T2 - American Journal of Epidemiology TI - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36529419&from=export http://dx.doi.org/10.1093/aje/kwg043 VL - 157 ID - 1292 ER - TY - JOUR AB - The authors analyzed data from almost 150,000 subjects aged 55‐74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self‐administered baseline questionnaire (1993‐2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater‐than‐average reported: expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower‐than‐average ratios. AN - CN-01725530 AU - Pinsky, P. F. AU - Kramer, B. S. AU - Reding, D. AU - Buys, S. DO - 10.1093/aje/kwg043 IS - 9 KW - *cancer screening *colorectal cancer /diagnosis /epidemiology *lung cancer /diagnosis /epidemiology *ovary cancer /diagnosis /epidemiology *prostate cancer /diagnosis /epidemiology Adult Aged Article Asian Black person Bladder cancer /diagnosis /epidemiology Bone cancer /diagnosis /epidemiology Brain cancer /diagnosis /epidemiology Breast cancer /diagnosis /epidemiology Cancer incidence Cancer risk Caucasian Clinical trial Controlled clinical trial Controlled study Ethnic group Family history Female Genetic predisposition Human Liver cancer /diagnosis /epidemiology Lymphoma /diagnosis /epidemiology Major clinical study Male Melanoma /diagnosis /epidemiology Prevalence Questionnaire Randomized controlled trial Sex difference Stomach cancer /diagnosis /epidemiology Testis cancer /diagnosis /epidemiology M3 - Journal: Article PY - 2003 SP - 792‐799 ST - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial T2 - American journal of epidemiology TI - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01725530/full VL - 157 ID - 1557 ER - TY - JOUR AB - The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios. AD - Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd., EPN 3064, Bethesda, MD 20892; pinskyp@mail.nih.gov AN - 106759038. Corporate Author: PLCO Project Team. Language: English. Entry Date: 20040723. Revision Date: 20200708. Publication Type: Journal Article AU - Pinsky, P. F. AU - Kramer, B. S. AU - Reding, D. AU - Buys, S. DB - CINAHL Complete DO - 10.1093/aje/kwg043 DP - EBSCOhost IS - 9 KW - Cancer Screening Family History Neoplasms -- Familial and Genetic Aged Clinical Trials Colorectal Neoplasms -- Epidemiology Colorectal Neoplasms -- Familial and Genetic Confidence Intervals Female Logistic Regression Lung Neoplasms -- Epidemiology Lung Neoplasms -- Familial and Genetic Male Middle Age Ovarian Neoplasms -- Epidemiology Ovarian Neoplasms -- Familial and Genetic P-Value Poisson Distribution Prostatic Neoplasms -- Epidemiology Prostatic Neoplasms -- Familial and Genetic Questionnaires Sex Factors Human N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; Public Health; USA. NLM UID: 7910653. PMID: NLM12727673. PY - 2003 SN - 0002-9262 SP - 792-799 ST - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial T2 - American Journal of Epidemiology TI - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106759038&site=ehost-live&scope=site VL - 157 ID - 2077 ER - TY - JOUR AB - The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported: expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios. AD - Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, United States Office of Disease Prevention, Office of the Director, National Institutes of Health, Bethesda, MD, United States Marshfield Med. Res./Educ. Found., Marshfield, WI, United States Division of Hematology-Oncology, Department of Internal Medicine, Univ. of Utah School of Medicine, Salt Lake City, UT, United States Division of Cancer Prevention, National Cancer Institute, EPN 3064, 6130 Executive Blvd., Bethesda, MD 20892, United States AU - Pinsky, P. F. AU - Kramer, B. S. AU - Reding, D. AU - Buys, S. DB - Scopus DO - 10.1093/aje/kwg043 IS - 9 KW - Ethnic groups Family characteristics Genetic predisposition to disease Neoplasms Questionnaires Sex factors M3 - Article N1 - Cited By :58 Export Date: 22 March 2021 PY - 2003 SP - 792-799 ST - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial T2 - American Journal of Epidemiology TI - Reported family history of cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038754764&doi=10.1093%2faje%2fkwg043&partnerID=40&md5=f9e7d1874d3cb078a537a35a34a98fb8 VL - 157 ID - 2615 ER - TY - JOUR AB - The authors analyzed data from almost 150,000 subjects aged 55-74 years enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who completed a self-administered baseline questionnaire (1993-2001) that included items about family history of cancer. Male respondents reported significantly less family history of cancer than females. The relative underreporting by male respondents relative to females was greater for female family members (28% lower for sisters and 21% lower for mothers) than for male family members (13% lower for brothers and 9% lower for fathers). Black, Hispanic, and Asian respondents reported significantly less family history of cancer than Whites. Reported family history prevalences for parents decreased with respondents' age, while those for siblings increased with respondents' age. The four most commonly reported cancers in families were breast (11.8%), lung (10.1%), colorectal (9.4%), and prostate (7.3%) cancer. Expected prevalences in family members of history of cancer overall and history of specific types of cancer were calculated using incidence rates and life table data obtained from the Surveillance, Epidemiology, and End Results Program. Overall, the ratio of reported cancer rates to expected cancer rates in family members was approximately 0.7. Liver, bone, stomach, and brain cancer had greater-than-average reported:expected ratios, while lymphoma, bladder cancer, melanoma, and testicular cancer had lower-than-average ratios. AN - WOS:000182635300005 AU - Pinsky, P. F. AU - Kramer, B. S. AU - Reding, D. AU - Buys, S. DA - May 1 DO - 10.1093/aje/kwg043 IS - 9 N1 - 59 12727673 PY - 2003 SN - 0002-9262 SP - 792-799 ST - Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial T2 - American Journal of Epidemiology TI - Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial VL - 157 ID - 2695 ER - TY - JOUR AB - Health disparities in breast cancer outcomes according to race/ethnicity are well documented. Randomized clinical trials (RCT) offer an opportunity to evaluate differences in disease biology and response to therapy that may contribute to disparities. We conducted a PubMed search to identify all English language original reports of breast cancer RCT from October 2001 to October 2006. The primary outcomes of interest were reporting of accrual and results by race or ethnicity of trial subjects. We evaluated the correlation between study characteristics and reporting of race/ethnicity. A total of 197 eligible trials were identified among 29 journals. Accrual was reported by race in 17% of studies and results analyzed by race in only 2%. Reporting of race was associated with National Cancer Institute funding (38 vs. 13%, P = 0.001), US cooperative group trials (52 vs. 13%, P < 0.0001), trials with US sites (43 vs. 5%, P < 0.0001), and trials enrolling > 500 subjects (24 vs. 12%, P = 0.055). Pharmaceutical industry funding, # of centers, stage of disease, nature of experimental intervention and study outcomes were not associated with reporting of race. Among US studies reporting trial accrual by race/ethnicity, the mean accrual distribution was 81% white, 7.6% black, 9.6% Asian, and 7.2% Hispanic subjects. The majority of breast cancer RCT fail to report the race/ethnicity of participants. Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer. © 2009 Springer Science+Business Media, LLC. AD - J. Peppercorn, Division of Medical Oncology, Duke University, Medical Center, CB# 3446, Durham, NC, United States AU - Mitchell, K. W. AU - Carey, L. A. AU - Peppercorn, J. DB - Embase Medline DO - 10.1007/s10549-009-0411-4 IS - 3 KW - article breast cancer cancer research drug industry ethnicity health disparity medical literature Medline priority journal race LA - English M3 - Article N1 - L50510388 2009-12-09 PY - 2009 SN - 0167-6806 1573-7217 SP - 511-517 ST - Reporting of race and ethnicity in breast cancer research: Room for improvement T2 - Breast Cancer Research and Treatment TI - Reporting of race and ethnicity in breast cancer research: Room for improvement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50510388&from=export http://dx.doi.org/10.1007/s10549-009-0411-4 VL - 118 ID - 1175 ER - TY - JOUR AB - Health disparities in breast cancer outcomes according to race/ethnicity are well documented. Randomized clinical trials (RCT) offer an opportunity to evaluate differences in disease biology and response to therapy that may contribute to disparities. We conducted a PubMed search to identify all English language original reports of breast cancer RCT from October 2001 to October 2006. The primary outcomes of interest were reporting of accrual and results by race or ethnicity of trial subjects. We evaluated the correlation between study characteristics and reporting of race/ethnicity. A total of 197 eligible trials were identified among 29 journals. Accrual was reported by race in 17% of studies and results analyzed by race in only 2%. Reporting of race was associated with National Cancer Institute funding (38 vs. 13%, P = 0.001), US cooperative group trials (52 vs. 13%, P < 0.0001), trials with US sites (43 vs. 5%, P < 0.0001), and trials enrolling > 500 subjects (24 vs. 12%, P = 0.055). Pharmaceutical industry funding, # of centers, stage of disease, nature of experimental intervention and study outcomes were not associated with reporting of race. Among US studies reporting trial accrual by race/ethnicity, the mean accrual distribution was 81% white, 7.6% black, 9.6% Asian, and 7.2% Hispanic subjects. The majority of breast cancer RCT fail to report the race/ethnicity of participants. Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer. © 2009 Springer Science+Business Media, LLC. AD - Department of Medicine, University of North Carolina, School of Medicine, Chapel Hill, NC, United States Division of Hematology/Oncology, University of North Carolina, School of Medicine, Chapel Hill, NC, United States Division of Medical Oncology, Duke University, Medical Center, CB# 3446, Durham, NC, United States AU - Mitchell, K. W. AU - Carey, L. A. AU - Peppercorn, J. DB - Scopus DO - 10.1007/s10549-009-0411-4 IS - 3 KW - Breast cancer Clinical trials Health disparities Race M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2009 SP - 511-517 ST - Reporting of race and ethnicity in breast cancer research: Room for improvement T2 - Breast Cancer Research and Treatment TI - Reporting of race and ethnicity in breast cancer research: Room for improvement UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449567435&doi=10.1007%2fs10549-009-0411-4&partnerID=40&md5=03808aa9b44896c3178bf77418ae7c2d VL - 118 ID - 2508 ER - TY - JOUR AB - Health disparities in breast cancer outcomes according to race/ethnicity are well documented. Randomized clinical trials (RCT) offer an opportunity to evaluate differences in disease biology and response to therapy that may contribute to disparities. We conducted a PubMed search to identify all English language original reports of breast cancer RCT from October 2001 to October 2006. The primary outcomes of interest were reporting of accrual and results by race or ethnicity of trial subjects. We evaluated the correlation between study characteristics and reporting of race/ethnicity. A total of 197 eligible trials were identified among 29 journals. Accrual was reported by race in 17% of studies and results analyzed by race in only 2%. Reporting of race was associated with National Cancer Institute funding (38 vs. 13%, P = 0.001), US cooperative group trials (52 vs. 13%, P < 0.0001), trials with US sites (43 vs. 5%, P < 0.0001), and trials enrolling > 500 subjects (24 vs. 12%, P = 0.055). Pharmaceutical industry funding, # of centers, stage of disease, nature of experimental intervention and study outcomes were not associated with reporting of race. Among US studies reporting trial accrual by race/ethnicity, the mean accrual distribution was 81% white, 7.6% black, 9.6% Asian, and 7.2% Hispanic subjects. The majority of breast cancer RCT fail to report the race/ethnicity of participants. Low accrual of black subjects and failure to report accrual and outcomes by race in RCT may contribute to difficulty in understanding and overcoming health disparities in breast cancer. AN - WOS:000271640900007 AU - Mitchell, K. W. AU - Carey, L. A. AU - Peppercorn, J. DA - Dec DO - 10.1007/s10549-009-0411-4 IS - 3 N1 - 19444602 PY - 2009 SN - 0167-6806 SP - 511-517 ST - Reporting of race and ethnicity in breast cancer research: room for improvement T2 - Breast Cancer Research and Treatment TI - Reporting of race and ethnicity in breast cancer research: room for improvement VL - 118 ID - 3131 ER - TY - JOUR AB - Background: The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. Purpose: Our objectives were to evaluate the inclusion of African-Americans, Hispanics, and non-Hispanic whites in NCI- sponsored treatment trials and to determine if there is proportional racial/ethnic representation. Methods: During the period of January 1, 1991, through June 30, 1994, 99 495 cancer patients were enrolled in clinical trials and declared themselves as non-Hispanic black, non-Hispanic white, or Hispanic (of any race). In the analysis, participants in NCI treatment trials were subdivided into three age groups: birth to 19 years, 20-49 years, and 50 or more years. The racial/ethnic composition of each of these age groups was compared with the racial/ethnic makeup of the American population with cancer. Estimates of the number of incident cancer cases per year were made for each racial/ethnic group within each age group using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the 1990 Census. The percentage of all cancer patients who were in each racial/ethnic group were compared with the population that entered clinical trials. Comparisons are also made separately for patients with leukemia and breast, colorectal, lung, and prostate cancers. Results: Among patients 0-19 years old, 20-49 years old, and 50 years old or older there is relatively proportional representation of non-Hispanic blacks, Hispanics, and non- Hispanic whites in trials. It is noted that more than 70% of cancer patients aged 0-19 years are estimated to enter cooperative group clinical trials compared with 4.0% of cancer patients aged 20-49 years and 1.5% of patients aged 50 years or older. Conclusions: Accrual of American cancer patients to NCI-sponsored treatment trials generally parallels the incident burden of disease among non-Hispanic African-Americans, Hispanics, and non-Hispanic whites. Implications: This study shows that the NCI clinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials. AD - H.A. Tejeda, Department of Medicine, St. Peter's Medical Center (UMDNJ), 254 Easton Ave., New Brunswick, NJ 08903-0591, United States AU - Tejeda, H. A. AU - Green, S. B. AU - Trimble, E. L. AU - Ford, L. AU - High, J. L. AU - Ungerleider, R. S. AU - Friedman, M. A. AU - Brawley, O. W. DB - Embase Medline DO - 10.1093/jnci/88.12.812 IS - 12 KW - article malignant neoplasm cancer epidemiology cancer patient cancer risk Caucasian ethnic group ethnology human major clinical study Black person race LA - English M3 - Article N1 - L26187390 1996-07-02 PY - 1996 SN - 0027-8874 SP - 812-816 ST - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials T2 - Journal of the National Cancer Institute TI - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L26187390&from=export http://dx.doi.org/10.1093/jnci/88.12.812 VL - 88 ID - 1337 ER - TY - JOUR AB - Background: The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. Purpose: Our objectives were to evaluate the inclusion of African-Americans, Hispanics, and non-Hispanic whites in NCI- sponsored treatment trials and to determine if there is proportional racial/ethnic representation. Methods: During the period of January 1, 1991, through June 30, 1994, 99 495 cancer patients were enrolled in clinical trials and declared themselves as non-Hispanic black, non-Hispanic white, or Hispanic (of any race). In the analysis, participants in NCI treatment trials were subdivided into three age groups: birth to 19 years, 20-49 years, and 50 or more years. The racial/ethnic composition of each of these age groups was compared with the racial/ethnic makeup of the American population with cancer. Estimates of the number of incident cancer cases per year were made for each racial/ethnic group within each age group using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the 1990 Census. The percentage of all cancer patients who were in each racial/ethnic group were compared with the population that entered clinical trials. Comparisons are also made separately for patients with leukemia and breast, colorectal, lung, and prostate cancers. Results: Among patients 0-19 years old, 20-49 years old, and 50 years old or older there is relatively proportional representation of non-Hispanic blacks, Hispanics, and non- Hispanic whites in trials. It is noted that more than 70% of cancer patients aged 0-19 years are estimated to enter cooperative group clinical trials compared with 4.0% of cancer patients aged 20-49 years and 1.5% of patients aged 50 years or older. Conclusions: Accrual of American cancer patients to NCI-sponsored treatment trials generally parallels the incident burden of disease among non-Hispanic African-Americans, Hispanics, and non-Hispanic whites. Implications: This study shows that the NCI clinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials. AD - Early Detection Comm. Oncol. Prog., Div. of Cancer Prev. and Control, National Cancer Institute, Bethesda, MD, United States Biometry Branch, Div. of Cancer Prev. and Control, National Cancer Institute, Bethesda, MD, United States Cancer Treatment Evaluation Program, Div. Cancer Treatm. Diagn., Centers, National Cancer Institute, Bethesda, MD, United States Food and Drug Administration, Rockville, MD, United States St. Peter's Medical Center (UMDNJ), Department of Medicine (962), 254 Easten Ave., New Brunswick, NJ 08903-0591, United States AU - Tejeda, H. A. AU - Green, S. B. AU - Trimble, E. L. AU - Ford, L. AU - High, J. L. AU - Ungerleider, R. S. AU - Friedman, M. A. AU - Brawley, O. W. DB - Scopus DO - 10.1093/jnci/88.12.812 IS - 12 M3 - Article N1 - Cited By :197 Export Date: 22 March 2021 PY - 1996 SP - 812-816 ST - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials T2 - Journal of the National Cancer Institute TI - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029950085&doi=10.1093%2fjnci%2f88.12.812&partnerID=40&md5=3ed0b458498655da34f748b2095a03ff VL - 88 ID - 2648 ER - TY - JOUR AB - Background: The National Cancer Institute (NCI)-sponsored clinical trials cooperative groups place more than 25 000 American patients in treatment trials every year. Equal access and proportional representation of all races/ethnicities is desired. Purpose: Our objectives were to evaluate the inclusion of African-Americans, Hispanics, and non-Hispanic whites in NCI-sponsored treatment trials and to determine if there is proportional racial/ethnic representation. Methods: During the period of January 1, 1991, through June 30, 1994, 99 495 cancer patients were enrolled in clinical trials and declared themselves as non-Hispanic black, non-Hispanic white, or Hispanic (of any race). In the analysis, participants in NCI treatment trials were subdivided into three age groups: birth to 19 years, 20-49 years, and 50 or more years. The racial/ethnic composition of each of these age groups was compared with the racial/ethnic makeup of the American population with cancer. Estimates of the number of incident cancer cases per year were made for each racial/ethnic group within each age group using data from the Surveillance, Epidemiology, and End Results (SEER) Program and the 1990 Census. The percentage of all cancer patients who were in each racial/ethnic group were compared with the population that entered clinical trials. Comparisons are also made separately for patients with leukemia and breast, colorectal, lung, and prostate cancers. Results: Among patients 0-19 years old, 20-49 years old, and 50 years old or older there is relatively proportional representation of non-Hispanic blacks, Hispanics, and non-Hispanic whites in trials. It is noted that more than 70% of cancer patients aged 0-19 years are estimated to enter cooperative group clinical trials compared with 4.0% of cancer patients aged 20-49 years and 1.5% of patients aged 50 years or older. Conclusions: Accrual of American cancer patients to NCI-sponsored treatment trials generally parallels the incident burden of disease among non-Hispanic African-Americans, Hispanics, and non-Hispanic whites. Implications: This study shows that the NCI clinical trials are, as a whole, racially/ethnically representative of the American population and suggests that there is equal access to NCI clinical trials. AN - WOS:A1996UR09400011 AU - Tejeda, H. A. AU - Green, S. B. AU - Trimble, E. L. AU - Ford, L. AU - High, J. L. AU - Ungerleider, R. S. AU - Friedman, M. A. AU - Brawley, O. W. DA - Jun 19 DO - 10.1093/jnci/88.12.812 IS - 12 N1 - 187 8637047 PY - 1996 SN - 0027-8874 SP - 812-816 ST - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials T2 - Journal of the National Cancer Institute TI - Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials VL - 88 ID - 2736 ER - TY - JOUR AB - Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p <.0001) and Hispanic patients (EF 0.04%, p <.0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients. AD - N. Duma, Division of Hematology, Mayo Clinic, Rochester, MN, United States AU - Duma, N. AU - Azam, T. AU - Riaz, I. B. AU - Gonzalez-Velez, M. AU - Ailawadhi, S. AU - Go, R. DB - Embase Medline DO - 10.1634/theoncologist.2017-0592 IS - 9 KW - adult age distribution aged article cancer patient female Hispanic human major clinical study male multiple myeloma phase 1 clinical trial phase 2 clinical trial phase 3 clinical trial prevalence priority journal LA - English M3 - Article N1 - L621918062 2018-05-03 2018-09-20 PY - 2018 SN - 1549-490X 1083-7159 SP - 1076-1078 ST - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials T2 - Oncologist TI - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L621918062&from=export http://dx.doi.org/10.1634/theoncologist.2017-0592 VL - 23 ID - 885 ER - TY - JOUR AB - Multiple myeloma (MM) occurs in all races, but the incidence in non-Hispanic black patients (NHBs) is two to three times higher than in non-Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p <.0001) and Hispanic patients (EF 0.04%, p <.0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients. © AlphaMed Press 2018 AD - Division of Hematology, Mayo Clinic, Rochester, MN, United States Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States Internal Medicine, Rutgers University-New Jersey Medical School, Newark, NJ, United States Hematology, Mayo Clinic, Jacksonville, FL, United States AU - Duma, N. AU - Azam, T. AU - Riaz, I. B. AU - Gonzalez-Velez, M. AU - Ailawadhi, S. AU - Go, R. DB - Scopus DO - 10.1634/theoncologist.2017-0592 IS - 9 KW - Clinical trials Elderly Hematologic malignancies Minorities Multiple myeloma M3 - Article N1 - Cited By :5 Export Date: 22 March 2021 PY - 2018 SP - 1076-1078 ST - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials T2 - Oncologist TI - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046013985&doi=10.1634%2ftheoncologist.2017-0592&partnerID=40&md5=5331fb3dca604e12d5be77bf363515f7 VL - 23 ID - 2257 ER - TY - JOUR AB - Abstract: Multiple myeloma (MM) occurs in all races, but the incidence in non‐Hispanic black patients (NHBs) is two to three times higher than in non‐Hispanic white patients (NHWs). We determined the representation of minorities and elderly patients in MM clinical trials. Enrollment data from all therapeutic trials reported in ClinicalTrials.gov from 2000 to 2016 were analyzed. Enrollment fraction (EF) was defined as the number of trial enrollees divided by the 2014 MM prevalence. Participation in MM clinical trials varied significantly across racial and ethnic groups; NHWs were more likely to be enrolled in clinical trials (EF 0.18%) than NHBs (EF 0.06%, p < .0001) and Hispanic patients (EF 0.04%, p < .0001). The median age of trial participants was 62 years, with 7,956 participants (66%) being less than 65 years of age. Collaborations between investigators, sponsors, and the community are necessary to increase access to clinical trials to our minority and elderly patients. AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Internal Medicine, Rutgers University‐New Jersey Medical School, Newark, New Jersey, USA Hematology, Mayo Clinic, Jacksonville, Florida, USA AN - 131719661. Language: English. Entry Date: 20180914. Revision Date: 20180917. Publication Type: Article AU - Duma, Narjust AU - Azam, Tariq AU - Riaz, Irbaz Bin AU - Gonzalez‐Velez, Miguel AU - Ailawadhi, Sikander AU - Go, Ronald DB - CINAHL Complete DO - 10.1634/theoncologist.2017-0592 DP - EBSCOhost IS - 9 KW - Multiple Myeloma -- Epidemiology -- In Old Age Clinical Trials Minority Groups Black Persons White Persons Human Aged Race Factors Ethnic Groups Hispanic Americans Middle Age N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 9607837. PY - 2018 SN - 1083-7159 SP - 1076-1078 ST - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials T2 - Oncologist TI - Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131719661&site=ehost-live&scope=site VL - 23 ID - 2078 ER - TY - JOUR AB - Purpose Many cancer clinical trials lack appropriate representation of specific patient populations, limiting their generalizability. Therefore, we determined the representation of ethnic minorities and women in cancer clinical trials. Methods Enrollment data from all therapeutic trials reported as completed in ClinicalTrials.gov from 2003 to 2016 were analyzed. We calculated enrollment fractions (EFs) for each group, defined as the number of enrollees divided by the 2013 Surveillance, Epidemiology, and End Results (SEER) database cancer prevalence. Results Of 1,012 clinical trials, 310 (31%) reported ethnicity with a total of 55,689 enrollees. Participation varied significantly across ethnic groups. Non-Hispanic whites were more likely to be enrolled in clinical trials (EF, 1.2%) than African Americans (EF, 0.7%; P,.001) and Hispanics (EF, 0.4%; P , .001). A decrease in African American (6% v 9.2%) and Hispanic (2.6% v 3.1%) enrollment was observed when compared with historical data from 1996 to 2002. Younger patients (age younger than 65 years) were more likely to be enrolled in clinical trials than the elderly (64% v 36%; P,.001). Low recruitment of female patients was observed in clinical trials for melanoma (35%), lung cancer (39%), and pancreatic cancer (40%). Conclusion Weobserved a decrease in recruitment of minorities over the past14 years compared with historical data. African Americans, Hispanics, and women were less likely to be enrolled in cancer clinical trials. Future trials should take extra measures to recruit participants that adequately represent the US cancer population. AD - Mayo Clinic, Rochester, MN Rutgers University-New Jersey Medical School, Newark, NJ AN - 127278418. Language: English. Entry Date: 20180122. Revision Date: 20180703. Publication Type: Article AU - Duma, Narjust AU - Aguilera, Jesus Vera AU - Paludo, Jonas AU - Haddox, Candace L. AU - Velez, Miguel Gonzalez AU - Yucai, Wang AU - Leventakos, Konstantinos AU - Hubbard, Joleen M. AU - Mansfield, Aaron S. AU - Go, Ronald S. AU - Adjei, Alex A. DB - CINAHL Complete DO - 10.1200/JOP.2017.025288 DP - EBSCOhost IS - 1 KW - Oncology Clinical Trials Human Female Minority Groups Databases Time Factors Systematic Review Bias (Research) N1 - research; systematic review. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; USA. Special Interest: Evidence-Based Practice. NLM UID: 101261852. PY - 2018 SN - 1554-7477 SP - e1-e10 ST - Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years T2 - Journal of Oncology Practice TI - Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=127278418&site=ehost-live&scope=site VL - 14 ID - 2079 ER - TY - JOUR AB - Background: Many clinical trials supporting new drug applications underrepresent minority patients. Trials conducted by the National Cancer Institute's National Clinical Trial's Network (NCTN) have greater outreach to community sites, potentially allowing better representation. We compared the representation of Black patients in pharmaceutical company-sponsored cancer clinical trials with NCTN trials and with the US cancer population. Methods: We established a large cohort of study publications representing the results of trials that supported new US Food and Drug Administration drug approvals from 2008 to 2018. NCTN trial data were from the SWOG Cancer Research Network. US cancer population rates were estimated using Surveillance, Epidemiology, and End Results survey data. We compared the proportion of Black patients by enrollment year for each cancer type and overall. Tests of proportions were used. All statistical tests were 2-sided. Results: A total 358 trials (pharmaceutical company-sponsored trials, 85; SWOG trials, 273) comprised of 93 825 patients (pharmaceutical company-sponsored trials, 46 313; SWOG trials, 47 512) for 15 cancer types were analyzed. Overall, the proportion of Black patients was 2.9% for pharmaceutical company-sponsored trials, 9.0% for SWOG trials, and 12.1% for the US cancer population (P<.001 for each pairwise comparison). These findings were generally consistent across individual cancer types. Conclusions: The poor representation of Black patients in pharmaceutical company-sponsored trials supporting new drug applications could result in the use of new drugs with little data about efficacy or side effects in this key population. Moreover, because pharmaceutical company-sponsored trials test the newest available therapies, limited access to these trials represents a disparity in access to potential breakthrough therapies. © 2020 Oxford University Press. All rights reserved. AD - SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Columbia University, New York, NY, United States Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, United States Baylor University, Houston, TX, United States Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, United States BC Cancer, Vancouver, BC, Canada AU - Unger, J. M. AU - Hershman, D. L. AU - Osarogiagbon, R. U. AU - Gothwal, A. AU - Anand, S. AU - Dasari, A. AU - Overman, M. AU - Loree, J. M. AU - Raghav, K. C7 - pkaa034 DB - Scopus DO - 10.1093/JNCICS/PKAA034 IS - 4 M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2021 ST - Representativeness of black patients in cancer clinical trials sponsored by the national cancer institute compared with pharmaceutical companies T2 - JNCI Cancer Spectrum TI - Representativeness of black patients in cancer clinical trials sponsored by the national cancer institute compared with pharmaceutical companies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100813698&doi=10.1093%2fJNCICS%2fPKAA034&partnerID=40&md5=595e00d80c438da3ec9d6d85bff5618b VL - 4 ID - 2161 ER - TY - JOUR AB - Background: The research goals of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium are to determine how characteristics and beliefs of patients, providers, and health care organizations influence the treatments and outcomes of individuals with newly diagnosed lung and colorectal cancers. As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers. Research Design: This study assessed the representativeness of the CanCORS cohort of 10,547 patients with lung cancer (LC) or colorectal cancer (CRC) enrolled between 2003 and 2005. We compared characteristics (sex, race, age, and disease stage) with the Surveillance, Epidemiology, and End Results (SEER) population of 234,464 patients with new onset of these cancers during the CanCORS recruitment period. Results: The CanCORS sample is well matched to the SEER Program for both cancers. In CanCORS, 41% LC/47% CRC were female versus 47% LC/49% CRC in SEER. African American, Hispanic, and Asian cases differed by no more than 5 percentage points between CanCORS and SEER. The SEER population is slightly older, with the percentage of patients older than 75 years 33.1% LC/37.3% CRC in SEER versus 26.9% LC/29.4% in CanCORS, and also has a slightly higher proportion of early stage patients. We also found that the CanCORS cohort was representative within specific SEER regions that map closely to CanCORS sites. Conclusions: This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions. © 2012 by Lippincott Williams & Wilkins. AD - P.J. Catalano, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, United States AU - Catalano, P. J. AU - Ayanian, J. Z. AU - Weeks, J. C. AU - Kahn, K. L. AU - Landrum, M. B. AU - Zaslavsky, A. M. AU - Lee, J. AU - Pendergast, J. AU - Harrington, D. P. DB - Embase Medline DO - 10.1097/MLR.0b013e318222a711 IS - 2 KW - adult African American aged article Asian Cancer Care Outcomes Research and Surveillance Consortium cancer diagnosis cancer patient cancer registry cancer research cohort analysis colorectal cancer controlled study demography disease severity female groups by age health program health survey Hispanic human lung cancer major clinical study male medical record review multicenter study priority journal race difference risk factor sex difference United States LA - English M3 - Article N1 - L51902620 2012-03-14 2013-02-06 PY - 2013 SN - 0025-7079 1537-1948 SP - e9-e15 ST - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program T2 - Medical Care TI - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51902620&from=export http://dx.doi.org/10.1097/MLR.0b013e318222a711 VL - 51 ID - 1093 ER - TY - JOUR AB - Background: The research goals of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium are to determine how characteristics and beliefs of patients, providers, and health care organizations influence the treatments and outcomes of individuals with newly diagnosed lung and colorectal cancers. As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers. Research Design: This study assessed the representativeness of the CanCORS cohort of 10,547 patients with lung cancer (LC) or colorectal cancer (CRC) enrolled between 2003 and 2005. We compared characteristics (sex, race, age, and disease stage) with the Surveillance, Epidemiology, and End Results (SEER) population of 234,464 patients with new onset of these cancers during the CanCORS recruitment period. Results: The CanCORS sample is well matched to the SEER Program for both cancers. In CanCORS, 41% LC/47% CRC were female versus 47% LC/49% CRC in SEER. African American, Hispanic, and Asian cases differed by no more than 5 percentage points between CanCORS and SEER. The SEER population is slightly older, with the percentage of patients older than 75 years 33.1% LC/37.3% CRC in SEER versus 26.9% LC/29.4% in CanCORS, and also has a slightly higher proportion of early stage patients. We also found that the CanCORS cohort was representative within specific SEER regions that map closely to CanCORS sites. Conclusions: This study demonstrates that the CanCORS Consortium was successful in enrolling a demographically representative sample within the CanCORS regions. © 2012 by Lippincott Williams & Wilkins. AD - Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215-5450, United States Department of Biostatistics, United States Department of Health Care Policy and Brigham, Harvard School of Public Health, United States Division of General Medicine, Women's Hospital, United States Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States RAND Corporation, Santa Monica, United States Division of General Internal Medicine, Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States Department of Biostatistics, University of Iowa College of Public Health, Iowa City, IA, United States AU - Catalano, P. J. AU - Ayanian, J. Z. AU - Weeks, J. C. AU - Kahn, K. L. AU - Landrum, M. B. AU - Zaslavsky, A. M. AU - Lee, J. AU - Pendergast, J. AU - Harrington, D. P. DB - Scopus DO - 10.1097/MLR.0b013e318222a711 IS - 2 M3 - Article N1 - Cited By :64 Export Date: 22 March 2021 PY - 2013 SP - e9-e15 ST - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program T2 - Medical Care TI - Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872858774&doi=10.1097%2fMLR.0b013e318222a711&partnerID=40&md5=bcb5584fb44752e9acd4be4dc7e935b0 VL - 51 ID - 2445 ER - TY - JOUR AB - Background Triple-negative (ie, estrogen receptor [ER], progesterone receptor, and HER2 negative) breast cancer occurs disproportionately among African American women compared with white women and is associated with a worse prognosis than ER-positive (ER+) breast cancer. Hormonally mediated risk factors may be differentially related to risk of triple-negative and ER+ breast cancers. Methods Using data from 155723 women enrolled in the Women's Health Initiative, we assessed associations between reproductive and menstrual history, breastfeeding, oral contraceptive use, and subtype-specific breast cancer risk. We used Cox regression to evaluate associations with triple-negative (N = 307) and ER+ (N = 2610) breast cancers and used partial likelihood methods to test for differences in subtype-specific hazard ratios (HRs). Results Reproductive history was differentially associated with risk of triple-negative and ER+ breast cancers. Nulliparity was associated with decreased risk of triple-negative breast cancer (HR = 0.61, 95% confidence interval [CI] = 0.37 to 0.97) but increased risk of ER+ breast cancer (HR = 1.35, 95% CI = 1.20 to 1.52). Age-adjusted absolute rates of triple-negative breast cancer were 2.71 and 1.54 per 10000 person-years in parous and nulliparous women, respectively; by comparison, rates of ER+ breast cancer were 21.10 and 28.16 per 10000 person-years in the same two groups. Among parous women, the number of births was positively associated with risk of triple-negative disease (HR for three births or more vs one birth = 1.46, 95% CI = 0.82 to 2.63) and inversely associated with risk of ER+ disease (HR = 0.88, 95% CI = 0.74 to 1.04). Ages at menarche and menopause were modestly associated with risk of ER+ but not triple-negative breast cancer; breastfeeding and oral contraceptive use were not associated with either subtype. Conclusion The association between parity and breast cancer risk differs appreciably for ER+ and triple-negative breast cancers. These findings require further confirmation because the biological mechanisms underlying these differences are uncertain. © 2011 The Author. Published by Oxford University Press. All rights reserved. AD - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109-1024, United States Department of Medicine, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Los Angeles, CA, United States Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, United States Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States Department of Preventive Medicine, State University of New York at Stony Brook, Stony Brook, NY, United States Department of Medicine, School of Medicine, Stanford University, Palo Alto, CA, United States Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, United States Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States AU - Phipps, A. I. AU - Chlebowski, R. T. AU - Prentice, R. AU - McTiernan, A. AU - Wactawski-Wende, J. AU - Kuller, L. H. AU - Adams-Campbell, L. L. AU - Lane, D. AU - Stefanick, M. L. AU - Vitolins, M. AU - Kabat, G. C. AU - Rohan, T. E. AU - Li, C. I. DB - Scopus DO - 10.1093/jnci/djr030 IS - 6 M3 - Article N1 - Cited By :150 Export Date: 22 March 2021 PY - 2011 SP - 470-477 ST - Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer T2 - Journal of the National Cancer Institute TI - Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952857018&doi=10.1093%2fjnci%2fdjr030&partnerID=40&md5=7478e889695aa3fc84ba5f3971cc3e1e VL - 103 ID - 2479 ER - TY - JOUR AB - Background: Black men are three times more likely to develop prostate cancer (PCa) and often present with more aggressive disease. Nevertheless, black men are consistently underrepresented in research studies. We aimed to get more insight into the reasons for this reduced recruitment, as it is important for future research to include results that are also applicable to black men with PCa. Methods: Two focus groups (n = 10 and n = 6) of black males currently under treatment for PCa at Guys Hospital, London, UK were held to gather information regarding the understanding of and exposure to research, as well as the barriers and facilitators for recruitment into research studies. Results: Barriers to recruitment included; mistrust of researchers, lack of understanding of the research process and the mechanisms of PCa and a reliance on herbal medicine. Suggested facilitators for recruitment improvement included thorough explanations of the research process, media advertisement and word of mouth. Financial incentives were also discussed but received mixed reception. Conclusion: We uncovered a number of barriers to recruitment of black men with PCa into research and accompanying strategies for improving involvement. Many are consistent with the literature, emphasising that current efforts have not been successful in ameliorating the concerns of the black community. Beliefs in herbal medicine and aversion to financial incentives appear to be novel themes, and so further insight into these issues could prove beneficial. © the authors; licensee ecancermedicalscience. AD - King's College London, Division of Cancer Studies, Cancer Epidemiology Group, London, SE1 9RT, United Kingdom AU - Toms, C. AU - Cahill, F. AU - George, G. AU - Van Hemelrijck, M. C7 - 695 DB - Scopus DO - 10.3332/ecancer.2016.695 KW - Black ethnicity Consent Prostate cancer M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2016 ST - Research engagement among black men with prostate cancer T2 - ecancermedicalscience TI - Research engagement among black men with prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85002377932&doi=10.3332%2fecancer.2016.695&partnerID=40&md5=2a361ce8233bd3c01a3daa32e1ea85d4 VL - 10 ID - 2330 ER - TY - JOUR AB - Background: Black men are three times more likely to develop prostate cancer (PCa) and often present with more aggressive disease. Nevertheless, black men are consistently underrepresented in research studies. We aimed to get more insight into the reasons for this reduced recruitment, as it is important for future research to include results that are also applicable to black men with PCa. Methods: Two focus groups (n = 10 and n = 6) of black males currently under treatment for PCa at Guys Hospital, London, UK were held to gather information regarding the understanding of and exposure to research, as well as the barriers and facilitators for recruitment into research studies. Results: Barriers to recruitment included; mistrust of researchers, lack of understanding of the research process and the mechanisms of PCa and a reliance on herbal medicine. Suggested facilitators for recruitment improvement included thorough explanations of the research process, media advertisement and word of mouth. Financial incentives were also discussed but received mixed reception. Conclusion: We uncovered a number of barriers to recruitment of black men with PCa into research and accompanying strategies for improving involvement. Many are consistent with the literature, emphasising that current efforts have not been successful in ameliorating the concerns of the black community. Beliefs in herbal medicine and aversion to financial incentives appear to be novel themes, and so further insight into these issues could prove beneficial. AN - WOS:000390651400001 AU - Toms, C. AU - Cahill, F. AU - George, G. AU - Van Hemelrijck, M. DA - Nov DO - 10.3332/ecancer.2016.695 N1 - 695 28101138 PY - 2016 SN - 1754-6605 ST - Research engagement among black men with prostate cancer T2 - Ecancermedicalscience TI - Research engagement among black men with prostate cancer VL - 10 ID - 2928 ER - TY - JOUR AB - Although retention is a critical component of longitudinal cancer genetics research, limited empirical data are available on predictors of study retention among populations that are difficult to enroll. We evaluated predictors of retention in cancer genetics research among African American women at increased risk for having a BRCA1 and BRCA2 (BRCA1/2) mutation. Participants were African American women (n = 192) at increased risk for hereditary breast-ovarian cancer who were enrolled in a longitudinal genetic counseling research study. Retention was evaluated separately for the 1-and 6-month follow-ups and in terms of overall retention (e.g., completion of both telephone interviews). Seventy-three percent of women and 65% of women were retained at the 1- and 6-month follow-ups respectively; in terms of overall retention, 60% of women were retained in both follow-up telephone interviews. Predictors of retention at 1-month included being employed (OR = 2.47, 95% CI = 1.24, 4.93, P = 0.01) whereas predictors of overall retention included having a personal history of breast and/or ovarian cancer (OR = 2.06, 95% CI = 1.07, 3.95, P = 0.03) and having completed genetic counseling (OR = 2.63, 95% CI = 1.39, 4.98, P = 0.003). These data suggest that once enrolled in genetic counseling research, the majority of African American women will continue to participate, especially if concrete clinical services are provided. © 2007 Wiley-Liss, Inc. AD - Department of Psychiatry, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Lincoln University of Pennsylvania, Pennsylvania Consortium, University of Pennsylvania, Philadelphia, PA, United States Cheyney University of Pennsylvania, Cheyney, PA, United States Center of Excellence for Diversity in Health Education and Research, University of Pennsylvania, Philadelphia, PA, United States Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, United States Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Department of Health Services, School of Public Health, University of Washington, Seattle, WA, United States Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104, United States AU - Halbert, C. H. AU - Love, D. AU - Mayes, T. AU - Collier, A. AU - Weathers, B. AU - Kessler, L. AU - Stopfer, J. AU - Bowen, D. AU - Domchek, S. DB - Scopus DO - 10.1002/ajmg.a.32067 IS - 2 KW - African American Cancer genetics Research Retention M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 2008 SP - 166-173 ST - Retention of African American women in cancer genetics research T2 - American Journal of Medical Genetics, Part A TI - Retention of African American women in cancer genetics research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-37849043106&doi=10.1002%2fajmg.a.32067&partnerID=40&md5=701b8de179acbd35c645d307af5ec0ce VL - 146 ID - 2540 ER - TY - JOUR AB - Background: Disproportionally low retention of minority populations can adversely affect the generaliz‐ability of clinical research trials. We determine the overall retention rates for White and Black participants from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and explore participant and site characteristics associated with retention failure (study disengagement) for these groups. Methods: A secondary analysis of 28,118 White (age >55), and 4,322 Black (age > 50) SELECT participants used multivariate Cox regression to estimate overall retention rates and to calculate HRs and 95% confidence intervals (CI). Results: Blacks had higher age‐adjusted risk of disengagement than Whites (HR, 1.92; 95% CI, 1.77‐2.08). Among Black participants, those ages 50 to 54 were at three times the risk of disengagement than those >65 years of age (HR, 3.61; 95% CI, 2.41‐5.41). Blacks age >65 had 1.6 times the risk of disengagement than Whites age >65 (HR, 1.60; 95% CI, 1.38‐1.87). By 6 years after randomization, 84% of Whites and 69% of Blacks remained engaged in the study. Current smoking status was an independent risk factor for study disengagement for both White and Black participants. For both groups, sites whose staffs missed SELECT training sessions or who received SELECT Retention and Adherence grants were associated with increased and decreased disengagement risks, respectively. Conclusions: SELECT retention was disproportionately lower for Blacks than for Whites. Impact: The observed difference in retention rates for Blacks and Whites and factors identified by race for study disengagement in SELECT may inform retention efforts for future long‐term, cancer prevention trials. AN - CN-01084618 AU - Arnold, K. B. AU - Hermos, J. A. AU - Anderson, K. B. AU - Minasian, L. AU - Tangen, C. M. AU - Probstfield, J. F. AU - Cook, E. D. DO - 10.1158/1055-9965.EPI-14-0724 IS - 12 KW - *alpha tocopherol/ct [Clinical Trial] *alpha tocopherol/dt [Drug Therapy] *cancer prevention *prostate cancer/dt [Drug Therapy] *prostate cancer/pc [Prevention] *race difference *selenium/ct [Clinical Trial] *selenium/dt [Drug Therapy] Adult African Americans Aged Aged, 80 and over Article Black person Caucasian Comorbidity Controlled clinical trial Controlled study Double blind procedure European Continental Ancestry Group Female Human Humans Major clinical study Male Middle Aged Minority Groups Neoplasms [*prevention & control] Phase 3 clinical trial Risk factor Selenium [*metabolism] Smoking Vitamin E [*metabolism] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2014 SP - 2895‐2905 ST - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000) T2 - Cancer epidemiology, biomarkers & prevention TI - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01084618/full VL - 23 ID - 1343 ER - TY - JOUR AB - Background: Disproportionally low retention of minority populations can adversely affect the generaliz-ability of clinical research trials. We determine the overall retention rates for White and Black participants from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and explore participant and site characteristics associated with retention failure (study disengagement) for these groups. Methods: A secondary analysis of 28,118 White (age ≥55), and 4,322 Black (age ≥ 50) SELECT participants used multivariate Cox regression to estimate overall retention rates and to calculate HRs and 95% confidence intervals (CI). Results: Blacks had higher age-adjusted risk of disengagement than Whites (HR, 1.92; 95% CI, 1.77-2.08). Among Black participants, those ages 50 to 54 were at three times the risk of disengagement than those ≥65 years of age (HR, 3.61; 95% CI, 2.41-5.41). Blacks age ≥65 had 1.6 times the risk of disengagement than Whites age >65 (HR, 1.60; 95% CI, 1.38-1.87). By 6 years after randomization, 84% of Whites and 69% of Blacks remained engaged in the study. Current smoking status was an independent risk factor for study disengagement for both White and Black participants. For both groups, sites whose staffs missed SELECT training sessions or who received SELECT Retention and Adherence grants were associated with increased and decreased disengagement risks, respectively. Conclusions: SELECT retention was disproportionately lower for Blacks than for Whites. Impact: The observed difference in retention rates for Blacks and Whites and factors identified by race for study disengagement in SELECT may inform retention efforts for future long-term, cancer prevention trials. © 2014 American Association for Cancer Research. AD - SWOG Statistical Center, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109-1024, United States VA Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, MA, United States SWOG Data Management, Cancer Research and Biostatistics, Seattle, WA, United States Division of Cancer Prevention, National Cancer Institute, Rockville, MD, United States Clinical Trials Service Unit, Department of Medicine, University of Washington, Seattle, WA, United States University of Texas MD Anderson Cancer Center, Houston, TX, United States AU - Arnold, K. B. AU - Hermos, J. A. AU - Anderson, K. B. AU - Minasian, L. AU - Tangen, C. M. AU - Probstfield, J. F. AU - Cook, E. D. DB - Scopus DO - 10.1158/1055-9965.EPI-14-0724 IS - 12 M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2014 SP - 2895-2905 ST - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000) T2 - Cancer Epidemiology Biomarkers and Prevention TI - Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919394808&doi=10.1158%2f1055-9965.EPI-14-0724&partnerID=40&md5=3d7a845ce7ac3f87b9802e21d3343375 VL - 23 ID - 2381 ER - TY - JOUR AB - Background: Disproportionally low retention of minority populations can adversely affect the generalizability of clinical research trials. We determine the overall retention rates for White and Black participants from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) and explore participant and site characteristics associated with retention failure (study disengagement) for these groups. Methods: A secondary analysis of 28,118 White (age >= 55), and 4,322 Black (age >= 50) SELECT participants used multivariate Cox regression to estimate overall retention rates and to calculate HRs and 95% confidence intervals (CI). Results: Blacks had higher age-adjusted risk of disengagement than Whites (HR, 1.92; 95% CI, 1.77-2.08). Among Black participants, those ages 50 to 54 were at three times the risk of disengagement than those >= 65 years of age (HR, 3.61; 95% CI, 2.41-5.41). Blacks age >= 65 had 1.6 times the risk of disengagement than Whites age >= 65 (HR, 1.60; 95% CI, 1.38-1.87). By 6 years after randomization, 84% of Whites and 69% of Blacks remained engaged in the study. Current smoking status was an independent risk factor for study disengagement for both White and Black participants. For both groups, sites whose staffs missed SELECT training sessions or who received SELECT Retention and Adherence grants were associated with increased and decreased disengagement risks, respectively. Conclusions: SELECT retention was disproportionately lower for Blacks than for Whites. Impact: The observed difference in retention rates for Blacks and Whites and factors identified by race for study disengagement in SELECT may inform retention efforts for future long-term, cancer prevention trials. (C) 2014 AACR. AN - WOS:000345967300031 AU - Arnold, K. B. AU - Hermos, J. A. AU - Anderson, K. B. AU - Minasian, L. AU - Tangen, C. M. AU - Probstfield, J. F. AU - Cook, E. D. DA - Dec DO - 10.1158/1055-9965.EPI-14-0724 IS - 12 N1 - 25242051 PY - 2014 SN - 1055-9965 SP - 2895-2905 ST - Retention of Black and White Participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000) T2 - Cancer Epidemiology Biomarkers & Prevention TI - Retention of Black and White Participants in the Selenium and Vitamin E Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S0000) VL - 23 ID - 2991 ER - TY - JOUR AB - Recruitment of controls remains a challenge in case-control studies and particularly in studies involving minority populations. We compared characteristics of controls recruited through random digit dialing (RDD) to those of community controls enrolled through churches, health events and other outreach sources among women of African ancestry (AA) participating in the Women's Circle of Health Study, a case-control study of breast cancer. Odds ratios and 95% confidence intervals were also computed using unconditional logistic regression to evaluate the impact of including the community controls for selected variables relevant to breast cancer and for which there were significant differences in distribution between the two control groups. Compared to community controls (n=347), RDD controls (n=207) had more years of education and higher income, lower body mass index, were more likely to have private insurance, and less likely to be single. While the percentage of nulliparous women in the two groups was similar, community controls tended to have more children, have their first child at a younger age, and were less likely to breastfeed their children. Dietary intake was similar in the two groups. Compared to census data, the combination of RDD and community controls seems to be more representative of the general population than RDD controls alone. Furthermore, the inclusion of the community group had little impact on the magnitude of risk estimates for most variables, while enhancing statistical power. Community-based recruitment was found to be an efficient and feasible method to recruit AA controls. AD - E.V. Bandera, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901, USA. AU - Bandera, E. V. AU - Chandran, U. AU - Zirpoli, G. AU - McCann, S. E. AU - Ciupak, G. AU - Ambrosone, C. B. DB - Medline DO - 10.1186/1471-2288-13-71 KW - adult aged article breast tumor case control study Caucasian control group female human intraductal carcinoma male methodology middle aged minority group Black person patient selection risk factor LA - English M3 - Article N1 - L369801042 2013-09-19 PY - 2013 SN - 1471-2288 SP - 71 ST - Rethinking sources of representative controls for the conduct of case-control studies in minority populations T2 - BMC medical research methodology TI - Rethinking sources of representative controls for the conduct of case-control studies in minority populations UR - https://www.embase.com/search/results?subaction=viewrecord&id=L369801042&from=export http://dx.doi.org/10.1186/1471-2288-13-71 VL - 13 ID - 1071 ER - TY - JOUR AB - Background: Recruitment of controls remains a challenge in case-control studies and particularly in studies involving minority populations.Methods: We compared characteristics of controls recruited through random digit dialing (RDD) to those of community controls enrolled through churches, health events and other outreach sources among women of African ancestry (AA) participating in the Women's Circle of Health Study, a case-control study of breast cancer. Odds ratios and 95% confidence intervals were also computed using unconditional logistic regression to evaluate the impact of including the community controls for selected variables relevant to breast cancer and for which there were significant differences in distribution between the two control groups.Results: Compared to community controls (n=347), RDD controls (n=207) had more years of education and higher income, lower body mass index, were more likely to have private insurance, and less likely to be single. While the percentage of nulliparous women in the two groups was similar, community controls tended to have more children, have their first child at a younger age, and were less likely to breastfeed their children. Dietary intake was similar in the two groups. Compared to census data, the combination of RDD and community controls seems to be more representative of the general population than RDD controls alone. Furthermore, the inclusion of the community group had little impact on the magnitude of risk estimates for most variables, while enhancing statistical power.Conclusions: Community-based recruitment was found to be an efficient and feasible method to recruit AA controls. AD - The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ, 08901, USA. elisa.bandera@umdnj.edu. AN - 104228485. Language: English. Entry Date: 20140919. Revision Date: 20161210. Publication Type: journal article AU - Bandera, Elisa V. AU - Chandran, Urmila AU - Zirpoli, Gary AU - McCann, Susan E. AU - Ciupak, Gregory AU - Ambrosone, Christine B. DB - CINAHL Complete DO - 10.1186/1471-2288-13-71 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Epidemiology Adenocarcinoma -- Epidemiology Case Control Studies Control Group Minority Groups Adult Black Persons Aged White Persons Female Human Male Middle Age Patient Selection Study Design Risk Factors Young Adult N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: P30CA072720/CA/NCI NIH HHS/United States. NLM UID: 100968545. PMID: NLM23721229. PY - 2013 SN - 1471-2288 SP - 71-71 ST - Rethinking sources of representative controls for the conduct of case-control studies in minority populations T2 - BMC Medical Research Methodology TI - Rethinking sources of representative controls for the conduct of case-control studies in minority populations UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104228485&site=ehost-live&scope=site VL - 13 ID - 2081 ER - TY - JOUR AB - Objective African American men have higher prostate cancer incidence rates than White men, for reasons not completely understood. This review summarizes the existing literature of race-specific associations between risk factors and prostate cancer in order to examine whether associations differ. Methods We reviewed epidemiologic studies published between January 1970 and December 2008 that reported race-specific effect estimates. We focused mainly on modifiable risk factors related to lifestyle and health. A total of 37 articles from 21 study populations met our inclusion criteria. Results We found no evidence of racial differences in associations between prostate cancer and alcohol intake, tobacco use, and family history of prostate cancer. Research suggests that a modest positive association may exist between height and prostate cancer risk (all prostate cancer and advanced prostate cancer) among Whites only. No clear patterns were observed for associations with physical activity, weight/body mass index, dietary factors, occupational history, sexual behavior, sexually transmissible infections, and other health conditions. Discussion Our results suggest few differences in prostate cancer risk factors exist between racial groups and underscore areas where additional research is needed. Future studies should enroll higher numbers of African American participants and report results for advanced prostate cancer. © Springer Science+Business Media B.V. 2010. AD - A. F. Olshan, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, McGavran- Greenberg Hall, Chapel Hill, NC, United States AU - Mordukhovich, I. AU - Reiter, P. L. AU - Backes, D. M. AU - Family, L. AU - McCullough, L. E. AU - O'Brien, K. M. AU - Razzaghi, H. AU - Olshan, A. F. DB - Embase Medline DO - 10.1007/s10552-010-9712-5 IS - 3 KW - advanced cancer African American alcohol consumption article body mass body weight cancer risk Caucasian cigarette smoking family history health hazard human lifestyle occupational hazard physical activity population research priority journal prostate cancer race difference risk assessment sexual behavior sexually transmitted disease LA - English M3 - Article N1 - L51205310 2011-05-17 2011-06-01 PY - 2011 SN - 0957-5243 1573-7225 SP - 341-357 ST - A review of African American-white differences in risk factors for cancer: Prostate cancer T2 - Cancer Causes and Control TI - A review of African American-white differences in risk factors for cancer: Prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L51205310&from=export http://dx.doi.org/10.1007/s10552-010-9712-5 VL - 22 ID - 1145 ER - TY - JOUR AB - Objective: African American men have higher prostate cancer incidence rates than White men, for reasons not completely understood. This review summarizes the existing literature of race-specific associations between risk factors and prostate cancer in order to examine whether associations differ. Methods: We reviewed epidemiologic studies published between January 1970 and December 2008 that reported race-specific effect estimates. We focused mainly on modifiable risk factors related to lifestyle and health. A total of 37 articles from 21 study populations met our inclusion criteria. Results: We found no evidence of racial differences in associations between prostate cancer and alcohol intake, tobacco use, and family history of prostate cancer. Research suggests that a modest positive association may exist between height and prostate cancer risk (all prostate cancer and advanced prostate cancer) among Whites only. No clear patterns were observed for associations with physical activity, weight/body mass index, dietary factors, occupational history, sexual behavior, sexually transmissible infections, and other health conditions. Discussion: Our results suggest few differences in prostate cancer risk factors exist between racial groups and underscore areas where additional research is needed. Future studies should enroll higher numbers of African American participants and report results for advanced prostate cancer. (PsycINFO Database Record (c) 2017 APA, all rights reserved) AD - Olshan, Andrew F., Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, CB #7435, McGavran- Greenberg Hall, Chapel Hill, NC, US AN - 2011-03861-002 AU - Mordukhovich, Irina AU - Reiter, Paul L. AU - Backes, Danielle M. AU - Family, Leila AU - McCullough, Lauren E. AU - O'Brien, Katie M. AU - Razzaghi, Hilda AU - Olshan, Andrew F. DB - psyh DO - 10.1007/s10552-010-9712-5 DP - EBSCOhost IS - 3 KW - African Americans men Whites risk factors prostate cancer racial differences African Continental Ancestry Group European Continental Ancestry Group Humans Life Style Male Prostatic Neoplasms Retrospective Studies Blacks Neoplasms Prostate Racial and Ethnic Differences Human Males N1 - Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, US. Release Date: 20111128. Correction Date: 20170213. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Neoplasms; Prostate; Racial and Ethnic Differences; Risk Factors. Minor Descriptor: Human Males; Whites. Classification: Cancer (3293); Culture & Ethnology (2930). Population: Human (10). Location: US. Methodology: Literature Review. References Available: Y. Page Count: 17. Issue Publication Date: Mar, 2011. Publication History: First Posted Date: Dec 24, 2010; Accepted Date: Dec 4, 2010; First Submitted Date: May 29, 2010. Copyright Statement: Springer Science+Business Media B.V. 2010. Sponsor: National Cancer Institute. Grant: 2-T32-CA09330. Recipients: No recipient indicated Sponsor: Lineberger Comprehensive Cancer Center, Cancer Control Education Program. Grant: R25 CA57726. Recipients: No recipient indicated Sponsor: National Institute of Environmental Health Sciences, US. Grant: P30ES10126; T32ES007018. Recipients: No recipient indicated PY - 2011 SN - 0957-5243 1573-7225 SP - 341-357 ST - A review of African American-White differences in risk factors for cancer: Prostate cancer T2 - Cancer Causes & Control TI - A review of African American-White differences in risk factors for cancer: Prostate cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2011-03861-002&site=ehost-live&scope=site ORCID: 0000-0002-1931-1349 andy_olshan@unc.edu VL - 22 ID - 1738 ER - TY - JOUR AB - Objective African American men have higher prostate cancer incidence rates than White men, for reasons not completely understood. This review summarizes the existing literature of race-specific associations between risk factors and prostate cancer in order to examine whether associations differ. Methods We reviewed epidemiologic studies published between January 1970 and December 2008 that reported race-specific effect estimates. We focused mainly on modifiable risk factors related to lifestyle and health. A total of 37 articles from 21 study populations met our inclusion criteria. Results We found no evidence of racial differences in associations between prostate cancer and alcohol intake, tobacco use, and family history of prostate cancer. Research suggests that a modest positive association may exist between height and prostate cancer risk (all prostate cancer and advanced prostate cancer) among Whites only. No clear patterns were observed for associations with physical activity, weight/body mass index, dietary factors, occupational history, sexual behavior, sexually transmissible infections, and other health conditions. Discussion Our results suggest few differences in prostate cancer risk factors exist between racial groups and underscore areas where additional research is needed. Future studies should enroll higher numbers of African American participants and report results for advanced prostate cancer. © Springer Science+Business Media B.V. 2010. AD - Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, McGavran- Greenberg Hall, Chapel Hill, NC, United States Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States Department of Health Behavior and Health Education, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States AU - Mordukhovich, I. AU - Reiter, P. L. AU - Backes, D. M. AU - Family, L. AU - McCullough, L. E. AU - O'Brien, K. M. AU - Razzaghi, H. AU - Olshan, A. F. DB - Scopus DO - 10.1007/s10552-010-9712-5 IS - 3 KW - African American Epidemiology Prostate cancer Race Review M3 - Article N1 - Cited By :35 Export Date: 22 March 2021 PY - 2011 SP - 341-357 ST - A review of African American-white differences in risk factors for cancer: Prostate cancer T2 - Cancer Causes and Control TI - A review of African American-white differences in risk factors for cancer: Prostate cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-79955780237&doi=10.1007%2fs10552-010-9712-5&partnerID=40&md5=7ad48053fb522aa5e2d791981e21cd91 VL - 22 ID - 2482 ER - TY - JOUR AB - Objective: The purpose of this paper is to critically review intervention studies that aimed to increase African-Americans' participation in colorectal cancer (CRC) screening.Data Source: Potential studies were identified using a combination of key words in five computerized databases.Study Inclusion and Exclusion Criteria: Articles were selected if they met all of the inclusion criteria: (1) The study's purpose was to test an intervention to increase CRC screening. (2) At least 50% of the sample was African-American. (3) The study focused on individuals 50 years and older. (4) The study was published between 2000 and 2008.Data Extraction: Abstracts and reference lists were scanned to determine relevance and a copy of the article was obtained.Data Synthesis: Data from each study were extracted and placed in a matrix for synthesis.Results: Interventions focused on recruitment from health care centers, churches, housing projects, and senior centers. Both direct and indirect strategies were used to identify the barriers to CRC screening.Conclusions: Findings suggest that interventions are most successful when they target individuals or communities, address known barriers to screening, deliver tailored messages, use multiple methods of message delivery, and are delivered over multiple time points. AD - Underserved Populations Research, Behavioral Research Center, American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA AN - 104937180. Language: English. Entry Date: 20110325. Revision Date: 20200708. Publication Type: journal article AU - Powe, B. D. AU - Faulkenberry, R. AU - Harmond, L. AU - Powe, Barbara D. AU - Faulkenberry, Rachel AU - Harmond, Lokie DB - CINAHL Complete DO - 10.4278/ajhp.080826-LIT-162 DP - EBSCOhost IS - 2 KW - Black Persons -- Psychosocial Factors Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Ethnology Health Promotion -- Methods Colorectal Neoplasms -- Prevention and Control Community-Institutional Relations Consumer Participation Early Detection of Cancer -- Methods Early Detection of Cancer -- Psychosocial Factors Human Experimental Studies Middle Age United States N1 - research. Journal Subset: Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. NLM UID: 8701680. PMID: NLM21039289. PY - 2010 SN - 0890-1171 SP - 92-99 ST - A review of intervention studies that seek to increase colorectal cancer screening among African-Americans T2 - American Journal of Health Promotion TI - A review of intervention studies that seek to increase colorectal cancer screening among African-Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104937180&site=ehost-live&scope=site VL - 25 ID - 1833 ER - TY - JOUR AB - Introduction: Lymphedema is a potentially debilitating condition that occurs among breast cancer survivors. This study examines the incidence of self-reported lymphedema, timing of lymphedema onset, and associations between sociodemographic, clinical and lifestyle factors and lymphedema risk across racial-ethnic groups using data from a multicenter, multiethnic prospective cohort study of breast cancer survivors, the Health, Eating, Activity and Lifestyle Study. Methods: A total of 666 women diagnosed with breast cancer staged as in situ, localized or regional disease at ages 35 to 64years were recruited through the Surveillance, Epidemiology, and End Results registries in New Mexico (non-Hispanic white and Hispanic white), Los Angeles County (black), and Western Washington (non-Hispanic white) and followed for a median of 10.2years. We evaluated sociodemographic factors, breast cancer- and treatment-related factors, comorbidities, body mass index (BMI), hormonal factors, and lifestyle factors in relation to self-reported lymphedema by fitting Cox proportional hazards models, estimating hazard ratios (HR) and 95% confidence intervals (CI). Results: Over the follow-up period, 190 women (29%) reported lymphedema. The median time from breast cancer diagnosis to onset of lymphedema was 10.5months (range: 0.5 to 134.9months). Factors independently associated with lymphedema were total/modified radical mastectomy (versus partial/less than total mastectomy; HR = 1.37, 95% CI: 1.01 to 1.85), chemotherapy (versus no chemotherapy; HR = 1.48, 95% CI: 1.09 to 2.02), no lymph nodes removed (versus ≥10 lymph nodes removed; HR = 0.17, 95% CI: 0.08 to 0.33), pre-diagnostic BMI ≥30kg/m2 (versus BMI <25kg/m2; HR = 1.59, 95% CI: 1.09 to 2.31), and hypertension (versus no hypertension; HR = 1.49, 95% CI: 1.06 to 2.10). After adjusting for demographics and breast cancer- and treatment-related factors, no significant difference in lymphedema risk was observed across racial/ethnic groups. Analyses stratified by race/ethnicity showed that hypertension and chemotherapy were lymphedema risk factors only for black women. Conclusions: Breast cancer patients who have undergone extensive surgery or extensive lymph node dissection, or who have a higher BMI should be closely monitored for detection and treatment of lymphedema. Further studies are needed to understand the roles of chemotherapy and hypertension in the development of lymphedema. © 2014 Togawa et al.; licensee BioMed Central. AD - University of Southern California, Department of Preventive Medicine, Keck School of Medicine, 1975 Zonal Avenue, Los Angeles, CA 90032, United States Beckman Research Institute, Division of Cancer Etiology, Department of Population Sciences, City of Hope, 1500 E Duarte Road, Duarte, CA 91010, United States Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, 1100 Fairview Avenue North, Seattle, WA 98109, United States University of Louisville, Department of Epidemiology and Population Health, 485 East Gray Street, Louisville, KY 40202, United States National Cancer Institute, Division of Cancer Control and Population Sciences, 9609 Medical Center Drive, Bethesda, MD 20892, United States AU - Togawa, K. AU - Ma, H. AU - Sullivan-Halley, J. AU - Neuhouser, M. L. AU - Imayama, I. AU - Baumgartner, K. B. AU - Smith, A. W. AU - Alfano, C. M. AU - McTiernan, A. AU - Ballard-Barbash, R. AU - Bernstein, L. C7 - 414 DB - Scopus DO - 10.1186/s13058-014-0414-x IS - 4 M3 - Article N1 - Cited By :53 Export Date: 22 March 2021 PY - 2014 ST - Risk factors for self-reported arm lymphedema among female breast cancer survivors: A prospective cohort study T2 - Breast Cancer Research TI - Risk factors for self-reported arm lymphedema among female breast cancer survivors: A prospective cohort study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929023486&doi=10.1186%2fs13058-014-0414-x&partnerID=40&md5=b7389a20e332334382c88c41a1bfdb59 VL - 16 ID - 2392 ER - TY - JOUR AB - Introduction: Lymphedema is a potentially debilitating condition that occurs among breast cancer survivors. This study examines the incidence of self‐reported lymphedema, timing of lymphedema onset, and associations between sociodemographic, clinical and lifestyle factors and lymphedema risk across racial‐ethnic groups using data from a multicenter, multiethnic prospective cohort study of breast cancer survivors, the Health, Eating, Activity and Lifestyle Study. Methods: A total of 666 women diagnosed with breast cancer staged as in situ, localized or regional disease at ages 35 to 64years were recruited through the Surveillance, Epidemiology, and End Results registries in New Mexico (non‐Hispanic white and Hispanic white), Los Angeles County (black), and Western Washington (non‐Hispanic white) and followed for a median of 10.2years. We evaluated sociodemographic factors, breast cancer‐ and treatment‐related factors, comorbidities, body mass index (BMI), hormonal factors, and lifestyle factors in relation to self‐reported lymphedema by fitting Cox proportional hazards models, estimating hazard ratios (HR) and 95% confidence intervals (CI). Results: Over the follow‐up period, 190 women (29%) reported lymphedema. The median time from breast cancer diagnosis to onset of lymphedema was 10.5months (range: 0.5 to 134.9months). Factors independently associated with lymphedema were total/modified radical mastectomy (versus partial/less than total mastectomy; HR = 1.37, 95% CI: 1.01 to 1.85), chemotherapy (versus no chemotherapy; HR = 1.48, 95% CI: 1.09 to 2.02), no lymph nodes removed (versus >10 lymph nodes removed; HR = 0.17, 95% CI: 0.08 to 0.33), pre‐diagnostic BMI >30kg/m2 (versus BMI <25kg/m2; HR = 1.59, 95% CI: 1.09 to 2.31), and hypertension (versus no hypertension; HR = 1.49, 95% CI: 1.06 to 2.10). After adjusting for demographics and breast cancer‐ and treatment‐related factors, no significant difference in lymphedema risk was observed across racial/ethnic groups. Analyses stratified by race/ethnicity showed that hypertension and chemotherapy were lymphedema risk factors only for black women. Conclusions: Breast cancer patients who have undergone extensive surgery or extensive lymph node dissection, or who have a higher BMI should be closely monitored for detection and treatment of lymphedema. Further studies are needed to understand the roles of chemotherapy and hypertension in the development of lymphedema. AN - CN-01104956 AU - Togawa, K. AU - Ma, H. AU - Sullivan-Halley, J. AU - Neuhouser, M. L. AU - Imayama, I. AU - Baumgartner, K. B. AU - Smith, A. W. AU - Alfano, C. M. AU - McTiernan, A. AU - Ballard-Barbash, R. AU - et al. DO - 10.1186/s13058-014-0414-x IS - 4 KW - *breast cancer/dt [Drug Therapy] *breast cancer/su [Surgery] *lymphedema *risk assessment *risk factor *self report Adult Article Black person Body mass Cancer chemotherapy Cancer staging Cancer survivor Caucasian Cohort analysis Comorbidity Contraceptive agent Controlled clinical trial Controlled study Demography Estrogen Female Follow up Gestagen Hispanic Human Hypertension Lifestyle Major clinical study Mastectomy Multicenter study Prospective study Social status Tamoxifen/ct [Clinical Trial] Tamoxifen/dt [Drug Therapy] M3 - Journal: Article PY - 2014 ST - Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study T2 - Breast cancer research TI - Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01104956/full VL - 16 ID - 1593 ER - TY - JOUR AB - Background: Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first-degree family history of breast cancer. Methods: This research was conducted within The Sister Study, a cohort of 50 884 US and Puerto Rican women age 35 to 74 years enrolled from 2003 to 2009. Eligible women were breast cancer-free at enrollment and had a sister who had been diagnosed with breast cancer. Participants reported tamoxifen use, ages started and stopped taking tamoxifen, and total duration of use at enrollment. We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment who had no history of contraindicating factors (stroke, transient ischemic attack, cataract, endometrial or uterine cancer). Characteristics associated with tamoxifen initiation were evaluated with multivariable conditional logistic regression. All statistical tests were two-sided. Results: Based on published risk-benefit indices, 20% of women who used tamoxifen had insufficient evidence that the benefits of tamoxifen outweigh the risk of serious side effects. After 4.5 years, 46% of women had discontinued tamoxifen. Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention. AD - Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, 2102A McGavran-Greenberg Hall, 135 Dauer Drive, Chapel Hill, NC 27599-7435, United States Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway Westat, Durham, NC, United States Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States AU - Nichols, H. B. AU - DeRoo, L. A. AU - Scharf, D. R. AU - Sandler, D. P. C7 - dju354 DB - Scopus DO - 10.1093/jnci/dju354 IS - 1 M3 - Article N1 - Cited By :38 Export Date: 22 March 2021 PY - 2015 ST - Risk-benefit profiles of women using tamoxifen for chemoprevention T2 - Journal of the National Cancer Institute TI - Risk-benefit profiles of women using tamoxifen for chemoprevention UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84930387437&doi=10.1093%2fjnci%2fdju354&partnerID=40&md5=5d6bcda9131860ba7abede54da914093 VL - 107 ID - 2378 ER - TY - JOUR AB - BACKGROUND:: Public willingness to donate tissue samples is critical to genetic research. Prior work has linked minority status and mistrust with less willingness to provide specimens. Some have suggested recruitment of prior research participants to address these barriers. We present data from a genetic epidemiology study with a request for blood and/or saliva specimens to (1) measure willingness to donate tissue/blood samples, (2) identify demographic, trust, and other factors associated with willingness to donate samples, and (3) measure willingness to participate in future genetic research. METHODS:: We surveyed participants in the North Carolina Colorectal Cancer Study, which included biologic sample collection from consenting participants. Participants were later asked about sample provision; trust in researchers, and future research participation. RESULTS:: African Americans were less likely to give a blood sample, when compared with whites (21% vs. 13%, P < 0.05). After controlling for "trust," this difference was no longer statistically significant (17% vs. 13%, P = 0.27). Those who had given samples were more likely to express willingness to participate in future research. CONCLUSION:: Despite prior participation in a genetic epidemiology study, factors associated with provision of tissue samples reflected many previously identified demographic factors (race and trust). Interventions to improve and demonstrate the trustworthiness of the research team and recruitment of subjects with a record of sample donation might enhance future study participation. © 2010 Lippincott Williams & Wilkins. AD - J. Bussey-Jones, School of Medicine, Emory University, 49 Jessie Hill Jr. Drive, Atlanta, GA 30331, United States AU - Bussey-Jones, J. AU - Garrett, J. AU - Henderson, G. AU - Moloney, M. AU - Blumenthal, C. AU - Corbie-Smith, G. DB - Embase Medline DO - 10.1097/GIM.0b013e3181cd6689 IS - 2 KW - adult aged article blood donor blood sampling colorectal cancer controlled study demography female genetic counseling genetic epidemiology genetics human human tissue major clinical study male patient participation race racism saliva trust United States LA - English M3 - Article N1 - L358333716 2010-03-02 2010-03-09 PY - 2010 SN - 1098-3600 SP - 116-121 ST - The role of race and trust in tissue/blood donation for genetic research T2 - Genetics in Medicine TI - The role of race and trust in tissue/blood donation for genetic research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358333716&from=export http://dx.doi.org/10.1097/GIM.0b013e3181cd6689 VL - 12 ID - 1171 ER - TY - JOUR AB - BACKGROUND:: Public willingness to donate tissue samples is critical to genetic research. Prior work has linked minority status and mistrust with less willingness to provide specimens. Some have suggested recruitment of prior research participants to address these barriers. We present data from a genetic epidemiology study with a request for blood and/or saliva specimens to (1) measure willingness to donate tissue/blood samples, (2) identify demographic, trust, and other factors associated with willingness to donate samples, and (3) measure willingness to participate in future genetic research. METHODS:: We surveyed participants in the North Carolina Colorectal Cancer Study, which included biologic sample collection from consenting participants. Participants were later asked about sample provision; trust in researchers, and future research participation. RESULTS:: African Americans were less likely to give a blood sample, when compared with whites (21% vs. 13%, P < 0.05). After controlling for "trust," this difference was no longer statistically significant (17% vs. 13%, P = 0.27). Those who had given samples were more likely to express willingness to participate in future research. CONCLUSION:: Despite prior participation in a genetic epidemiology study, factors associated with provision of tissue samples reflected many previously identified demographic factors (race and trust). Interventions to improve and demonstrate the trustworthiness of the research team and recruitment of subjects with a record of sample donation might enhance future study participation. © 2010 Lippincott Williams & Wilkins. AD - School of Medicine, Emory University, 49 Jessie Hill Jr. Drive, Atlanta, GA 30331, United States University of North Carolina, Chapel Hill, NC, United States AU - Bussey-Jones, J. AU - Garrett, J. AU - Henderson, G. AU - Moloney, M. AU - Blumenthal, C. AU - Corbie-Smith, G. DB - Scopus DO - 10.1097/GIM.0b013e3181cd6689 IS - 2 KW - Biologic samples Genetics Research participation Trust M3 - Article N1 - Cited By :70 Export Date: 22 March 2021 PY - 2010 SP - 116-121 ST - The role of race and trust in tissue/blood donation for genetic research T2 - Genetics in Medicine TI - The role of race and trust in tissue/blood donation for genetic research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77149180429&doi=10.1097%2fGIM.0b013e3181cd6689&partnerID=40&md5=c638fe27d5b686f2e027074b99081bdc VL - 12 ID - 2504 ER - TY - JOUR AB - Background: Public willingness to donate tissue samples is critical to genetic research. Prior work has linked minority status and mistrust with less willingness to provide specimens. Some have suggested recruitment of prior research participants to address these barriers. We present data from a genetic epidemiology study with a request for blood and/or saliva specimens to (1) measure willingness to donate tissue/blood samples, (2) identify demographic, trust, and other factors associated with willingness to donate samples, and (3) measure willingness to participate in future genetic research. Methods: We surveyed participants in the North Carolina Colorectal Cancer Study, which included biologic sample collection from consenting participants. Participants were later asked about sample provision; trust in researchers, and future research participation. Results: African Americans were less likely to give a blood sample, when compared with whites (21% vs. 13%, P < 0.05). After controlling for "trust," this difference was no longer statistically significant (17% vs. 13%, P = 0.27). Those who had given samples were more likely to express willingness to participate in future research. Conclusion: Despite prior participation in a genetic epidemiology study, factors associated with provision of tissue samples reflected many previously identified demographic factors (race and trust). Interventions to improve and demonstrate the trustworthiness of the research team and recruitment of subjects with a record of sample donation might enhance future study participation. Genet Med 2010:12(2):116-121. AN - WOS:000275265100007 AU - Bussey-Jones, J. AU - Garrett, J. AU - Henderson, G. AU - Moloney, M. AU - Blumenthal, C. AU - Corbie-Smith, G. DA - Feb DO - 10.1097/GIM.0b013e3181cd6689 IS - 2 N1 - 20098329 PY - 2010 SN - 1098-3600 SP - 116-121 ST - The role of race and trust in tissue/blood donation for genetic research T2 - Genetics in Medicine TI - The role of race and trust in tissue/blood donation for genetic research VL - 12 ID - 3126 ER - TY - JOUR AB - STUDY QUESTION Can asoprisnil, a selective progesterone receptor modulator, provide clinically meaningful improvements in heavy menstrual bleeding (HMB) associated with uterine fibroids with an acceptable safety profile? SUMMARY ANSWER Uninterrupted treatment with asoprisnil for 12 months effectively controlled HMB and reduced fibroid and uterine volume with few adverse events. WHAT IS KNOWN ALREADY In a 3-month study, asoprisnil (5, 10 and 25 mg) suppressed uterine bleeding, reduced fibroid and uterine volume, and improved hematological parameters in a dose-dependent manner. STUDY DESIGN, SIZE, DURATION In two Phase 3, double-blind, randomized, placebo-controlled, multicentre studies, women received oral asoprisnil 10 mg, asoprisnil 25 mg or placebo (2:2:1) once daily for up to 12 months. PARTICIPANTS/MATERIALS, SETTING, METHODS Premenopausal women ≥18 years of age in North America with HMB associated with uterine fibroids were included (N = 907). The primary efficacy endpoint was the percentage of women who met all three predefined criteria at 12 months or the final month for patients who prematurely discontinued: (1) ≥50% reduction in monthly blood loss (MBL) by menstrual pictogram, (2) hemoglobin concentration ≥11 g/dL or an increase of ≥1 g/dL, and (3) no interventional therapy for uterine fibroids. Secondary efficacy endpoints included changes in other menstrual bleeding parameters, volume of the largest fibroids, uterine volume and health-related quality of life (HRQL). MAIN RESULTS AND THE ROLE OF CHANCE In all, 90% and 93% of women in the asoprisnil 10-mg and 25-mg groups, respectively, and 35% of women in the placebo group met the primary endpoint (P < 0.001). Similar results were observed at month 6 (P < 0.001). The percentage of women who achieved amenorrhea in any specified month ranged from 66-78% in the asoprisnil 10-mg group and 83-93% in the asoprisnil 25-mg group, significantly higher than with placebo (3-12%, P < 0.001). Hemoglobin increased rapidly (by month 2) with asoprisnil treatment and was significantly higher versus placebo throughout treatment. The primary fibroid and uterine volumes were significantly reduced from baseline through month 12 with asoprisnil 10 mg (median changes up to-48% and-28%, respectively) and 25 mg (median changes up to-63% and-39%, respectively) versus placebo (median changes up to +16% and +13%, respectively; all P < 0.001). Dose-dependent, significant improvements in HRQL (Uterine Fibroid Symptom and Quality of Life instrument) were observed with asoprisnil treatment. Asoprisnil was generally well tolerated. Endometrial biopsies indicated dose-and time-dependent decreases in proliferative patterns and increases in quiescent or minimally stimulated endometrium at month 12 of treatment. Although not statistically significantly different at month 6, mean endometrial thickness at month 12 increased by ∼2 mm in both asoprisnil groups compared with placebo (P < 0.01). This effect was associated with cystic changes in the endometrium on MRI and ultrasonography, which led to invasive diagnostic and therapeutic procedures in some asoprisnil-treated women. LIMITATIONS, REASONS FOR CAUTION Most study participants were black; few Asian and Hispanic women participated. The study duration may have been insufficient to fully characterize the endometrial effects. WIDER IMPLICATIONS OF THE FINDINGS Daily uninterrupted treatment with asoprisnil was highly effective in controlling menstrual bleeding, improving anemia, reducing fibroid and uterine volume, and increasing HRQL in women with HMB associated with uterine fibroids. However, this treatment led to an increase in endometrial thickness and invasive diagnostic and therapeutic procedures, with potential unknown consequences. STUDY FUNDING/COMPETING INTEREST(S) This trial was funded by AbbVie Inc. (prior sponsors: TAP Pharmaceutical Products Inc., Abbott Laboratories). E.A. Stewart was a site investigator in the Phase 2 study of asoprisnil and consulted for TAP during the design and conduct of these studies while at Har ard Medical School and Brigham and Women's Hospital. She received support from National Institutes of Health grants HD063312, HS023418 and HD074711 and research funding, paid to Mayo Clinic for patient care costs related to an NIH-funded trial from InSightec Ltd. She consulted for AbbVie, Allergan, Bayer HealthCare AG, Gynesonics, and Welltwigs. She received royalties from UpToDate and the Med Learning Group. M.P. Diamond received research funding for the conduct of the studies paid to the institution and consulted for AbbVie. He is a stockholder and board and director member of Advanced Reproductive Care. He has also received funding for study conduct paid to the institution from Bayer and ObsEva. A.R.W. Williams consulted for TAP and Repros Therapeutics Inc. He has current consultancies with PregLem SA, Gedeon Richter, HRA Pharma and Bayer. B.R. Carr consulted for and received research funding from AbbVie. E.R. Myers consulted for AbbVie, Allergan and Bayer. R.A. Feldman received compensation for serving as a principal investigator and participating in the conduct of the trial. W. Elger was co-inventor of several patents related to asoprisnil. C. Mattia-Goldberg is a former employee of AbbVie and may own AbbVie stock or stock options. B.M. Schwefel and K. Chwalisz are employees of AbbVie and may own AbbVie stock or stock options. TRIAL REGISTRATION NUMBER NCT00152269, NCT00160381 (clinicaltrials.gov). TRIAL REGISTRATION DATE 7 September 2005; 8 September 2005. DATE OF FIRST PATIENT'S ENROLMENT 12 September 2002; 6 September 2002. © 2019 The Author(s). AD - Departments of Obstetrics and Gynecology and Surgery, Mayo Clinic, Mayo Medical School, Rochester, MN, United States Department of Obstetrics and Gynecology, Augusta University, Augusta, GA, United States Department of Pathology, University of Edinburgh, Edinburgh, United Kingdom Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, United States Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States Miami Research Assoc., Miami, FL, United States Evestra GmbH, Berlin-Dahlem, Germany AbbVie Inc., North Chicago, IL, United States AU - Stewart, E. A. AU - Diamond, M. P. AU - Williams, A. R. W. AU - Carr, B. R. AU - Myers, E. R. AU - Feldman, R. A. AU - Elger, W. AU - Mattia-Goldberg, C. AU - Schwefel, B. M. AU - Chwalisz, K. DB - Scopus DO - 10.1093/humrep/dez007 IS - 4 KW - asoprisnil fibroids heavy menstrual bleeding J867 selective progesterone receptor modulator uterine fibroid uterine leiomyoma uterine leiomyomata M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2019 SP - 623-634 ST - Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: Pooled analysis of two 12-month, placebo-controlled, randomized trials T2 - Human Reproduction TI - Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: Pooled analysis of two 12-month, placebo-controlled, randomized trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064123541&doi=10.1093%2fhumrep%2fdez007&partnerID=40&md5=b3d3ef09a0a08e5b6254085d35946df1 VL - 34 ID - 2236 ER - TY - JOUR AB - Background: Awareness that cancer impacts not only the person with the disease but also the family has increased, yet existing data provide limited information, primarily because of reliance on small geographically restricted samples. The current study used population-based sampling to develop a formula to compute the probability of survivors completing a survivor survey and nominating their family caregivers. Methods: Eleven SEER/NPCR state cancer registries participated in the American Cancer Society Study of Cancer Survivors survey, providing information about the survivors, including their age, race/ethnicity, gender, type of cancer, and stage of cancer. A total of 19,294 cancer survivors met the inclusion criteria (≥18 years old and diagnosed with one of the 10 common cancers). Results: Approximately 30% of survivors identified from state cancer registries completed the survivor survey, of whom 42% nominated a caregiver. Logistic regression analysis revealed that middle-aged, female, or non-black survivors and survivors diagnosed with breast or ovarian cancer were more likely to complete the survey and nominate a caregiver, whereas survivors with bladder or lung cancer and survivors with advanced-stage cancer were less likely to complete the survey and nominate a caregiver. Conclusions: Using the formula based on the logistic regression analysis results, a number of certain groups of survivors to be recruited from state registry can be calculated in order to have a present number of caregivers to contact for participation into a caregiver study. This is practical and valuable information, which fosters research that uses state cancer registries and increases the generalizability of findings to multiple types of cancer and different stages of cancer. © 2009 Springer Science+Business Media B.V. AD - Y. Kim, Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL 33124-0751, United States AU - Kim, Y. AU - Kashy, D. A. AU - Kaw, C. K. AU - Smith, T. AU - Spillers, R. L. DB - Embase Medline DO - 10.1007/s11136-009-9518-7 IS - 8 KW - adult aged article bladder cancer breast cancer cancer registry cancer research cancer staging cancer survivor caregiver controlled study female groups by age health survey human lung cancer major clinical study male neoplasm non profit organization ovary cancer priority journal race difference sex difference LA - English M3 - Article N1 - L50602519 2009-10-13 PY - 2009 SN - 0962-9343 SP - 981-989 ST - Sampling in population-based cancer caregivers research T2 - Quality of Life Research TI - Sampling in population-based cancer caregivers research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50602519&from=export http://dx.doi.org/10.1007/s11136-009-9518-7 VL - 18 ID - 1199 ER - TY - JOUR AB - Background: Awareness that cancer impacts not only the person with the disease but also the family has increased, yet existing data provide limited information, primarily because of reliance on small geographically restricted samples. The current study used population-based sampling to develop a formula to compute the probability of survivors completing a survivor survey and nominating their family caregivers. Methods: Eleven SEER/NPCR state cancer registries participated in the American Cancer Society Study of Cancer Survivors survey, providing information about the survivors, including their age, race/ethnicity, gender, type of cancer, and stage of cancer. A total of 19,294 cancer survivors met the inclusion criteria (≥18 years old and diagnosed with one of the 10 common cancers). Results: Approximately 30% of survivors identified from state cancer registries completed the survivor survey, of whom 42% nominated a caregiver. Logistic regression analysis revealed that middle-aged, female, or non-black survivors and survivors diagnosed with breast or ovarian cancer were more likely to complete the survey and nominate a caregiver, whereas survivors with bladder or lung cancer and survivors with advanced-stage cancer were less likely to complete the survey and nominate a caregiver. Conclusions: Using the formula based on the logistic regression analysis results, a number of certain groups of survivors to be recruited from state registry can be calculated in order to have a present number of caregivers to contact for participation into a caregiver study. This is practical and valuable information, which fosters research that uses state cancer registries and increases the generalizability of findings to multiple types of cancer and different stages of cancer. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Kim, Youngmee, Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL, US, 33124-0751 AN - 2009-16750-004 AU - Kim, Youngmee AU - Kashy, Deborah A. AU - Kaw, Chiew Kwei AU - Smith, Tenbroeck AU - Spillers, Rachel L. DB - psyh DO - 10.1007/s11136-009-9518-7 DP - EBSCOhost IS - 8 KW - cancer caregivers survivor survey family caregivers Adult Aged Aged, 80 and over Awareness Biomedical Research Caregivers Female Health Surveys Humans Logistic Models Male Middle Aged Neoplasms Prospective Studies Quality of Life Regression Analysis SEER Program Survival Analysis United States Home Care Personnel Survivors N1 - American Cancer Society, Atlanta, GA, US. Release Date: 20100111. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Caregivers; Home Care Personnel; Neoplasms; Survivors. Classification: Cancer (3293); Home Care & Hospice (3375). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 9. Issue Publication Date: Oct, 2009. Publication History: First Posted Date: Aug 5, 2009; Accepted Date: Jul 13, 2009. Copyright Statement: Springer Science+Business Media B.V. 2009. Sponsor: American Cancer Society, National Home Office, US. Other Details: Intramural research. Recipients: No recipient indicated PY - 2009 SN - 0962-9343 1573-2649 SP - 981-989 ST - Sampling in population-based cancer caregivers research T2 - Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation TI - Sampling in population-based cancer caregivers research UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-16750-004&site=ehost-live&scope=site ORCID: 0000-0002-3109-6362 ykim@psy.miami.edu VL - 18 ID - 1760 ER - TY - JOUR AB - Background: Awareness that cancer impacts not only the person with the disease but also the family has increased, yet existing data provide limited information, primarily because of reliance on small geographically restricted samples. The current study used population-based sampling to develop a formula to compute the probability of survivors completing a survivor survey and nominating their family caregivers. Methods: Eleven SEER/NPCR state cancer registries participated in the American Cancer Society Study of Cancer Survivors survey, providing information about the survivors, including their age, race/ethnicity, gender, type of cancer, and stage of cancer. A total of 19,294 cancer survivors met the inclusion criteria (≥18 years old and diagnosed with one of the 10 common cancers). Results: Approximately 30% of survivors identified from state cancer registries completed the survivor survey, of whom 42% nominated a caregiver. Logistic regression analysis revealed that middle-aged, female, or non-black survivors and survivors diagnosed with breast or ovarian cancer were more likely to complete the survey and nominate a caregiver, whereas survivors with bladder or lung cancer and survivors with advanced-stage cancer were less likely to complete the survey and nominate a caregiver. Conclusions: Using the formula based on the logistic regression analysis results, a number of certain groups of survivors to be recruited from state registry can be calculated in order to have a present number of caregivers to contact for participation into a caregiver study. This is practical and valuable information, which fosters research that uses state cancer registries and increases the generalizability of findings to multiple types of cancer and different stages of cancer. © 2009 Springer Science+Business Media B.V. AD - American Cancer Society, Atlanta, GA, United States Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL 33124-0751, United States Michigan State University, East Lansing, MI, United States AU - Kim, Y. AU - Kashy, D. A. AU - Kaw, C. K. AU - Smith, T. AU - Spillers, R. L. DB - Scopus DO - 10.1007/s11136-009-9518-7 IS - 8 KW - Caregivers Methodology Population-based research Sampling Survivorship M3 - Article N1 - Cited By :13 Export Date: 22 March 2021 PY - 2009 SP - 981-989 ST - Sampling in population-based cancer caregivers research T2 - Quality of Life Research TI - Sampling in population-based cancer caregivers research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349235345&doi=10.1007%2fs11136-009-9518-7&partnerID=40&md5=b1c76baf8f15f52c4e8feeed53ba4d6e VL - 18 ID - 2512 ER - TY - JOUR AD - T. Reynolds AU - Reynolds, T. DB - Medline DO - 10.1093/jnci/88.18.1265 IS - 18 KW - African American article breast tumor clinical trial female Hispanic human male mass screening minority group neoplasm prostate tumor statistics United States LA - English M3 - Article N1 - L126271519 1996-10-09 PY - 1996 SN - 0027-8874 SP - 1265-1267 ST - Screening and prevention trials step up minority recruitment T2 - Journal of the National Cancer Institute TI - Screening and prevention trials step up minority recruitment UR - https://www.embase.com/search/results?subaction=viewrecord&id=L126271519&from=export http://dx.doi.org/10.1093/jnci/88.18.1265 VL - 88 ID - 1335 ER - TY - JOUR AU - Reynolds, T. DB - Scopus DO - 10.1093/jnci/88.18.1265 IS - 18 M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 1996 SP - 1265-1267 ST - Screening and prevention trials step up minority recruitment T2 - Journal of the National Cancer Institute TI - Screening and prevention trials step up minority recruitment UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030592307&doi=10.1093%2fjnci%2f88.18.1265&partnerID=40&md5=e860a9964f436f8069f20b3294216775 VL - 88 ID - 2650 ER - TY - JOUR AN - 105854988. Language: English. Entry Date: 20080314. Revision Date: 20190522. Publication Type: journal article. Journal Subset: Biomedical AU - Reynolds, T. AU - Reynolds, T. DB - CINAHL Complete DP - EBSCOhost IS - 18 KW - Clinical Trials Health Screening -- Statistics and Numerical Data Minority Groups -- Statistics and Numerical Data Neoplasms -- Prevention and Control Black Persons -- Statistics and Numerical Data Breast Neoplasms -- Prevention and Control Female Hispanic Americans -- Statistics and Numerical Data Male Prostatic Neoplasms -- Prevention and Control United States N1 - Peer Reviewed; USA. NLM UID: 7503089. PMID: NLM8797765. PY - 1996 SN - 0027-8874 SP - 1265-1267 ST - Screening and prevention trials step up minority recruitment T2 - JNCI: Journal of the National Cancer Institute TI - Screening and prevention trials step up minority recruitment UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105854988&site=ehost-live&scope=site VL - 88 ID - 2083 ER - TY - JOUR AB - OBJECTIVE: HIV-infected women (WLHIV) have more than 10-fold higher risk for squamous cell cancer of the anus. Experts suggest cytology-based strategies developed for cervical cancer screening may prevent anal cancer by detecting anal cytologic or histological high-grade squamous intraepithelial lesion (hHSIL) for treatment. Currently, there is no consensus on anal-hHSIL screening strategies for WLHIV. DESIGN: Between 2014 and 2016, 276 WLHIV were recruited at 12 US AIDS Malignancy Consortium clinical trials sites to evaluate hHSIL prevalence and (test) screening strategies. METHODS: Participants completed detailed questionnaire, underwent anal assessments including high-risk human papillomavirus (hrHPV) testing using hrHPV-Hybrid Capture 2 (HC2) and hrHPV-APTIMA, anal cytology, and concurrent high-resolution anoscopy. Screening test characteristics for predicting hHSIL validated by central review of histologic diagnosis were estimated sensitivity, specificity, positive predictive value, and false-omission rate. Paired analyses compared sensitivity and specificity for hrHPV single tests to anal cytology alone. RESULTS: 83% (229/276) of enrolled WLHIV had complete anal assessment data and were included in this analysis. Mean age was 50, 62% black and 60 (26%) had hHSIL. Anal cyotology (>atypical squamous cells of undetermined significance), hrHPV-HC2, and hrHPV-APTIMA sensitivity estimates were similarly high (83, 77, and 75%, respectively, P values > 0.2). Specificity was higher for both hrHPV-APTIMA and hrHPV-HC2 compared with anal cytology (67 vs. 50%, P < 0.001) and (61 vs. 50%, P = 0.020), respectively. CONCLUSION: Anal hrHPV testing demonstrated similar sensitivity for anal cytology (>atypical squamous cells of undetermined significance) to predict anal hHSIL. Among tests with similar sensitivity, the specificity was significantly higher for hrHPV-APTIMA and hrHPV-HC2. Thus, anal hrHPV testing may be an important alternative strategy to anal cytology for anal hHSIL screening among WLHIV. AU - Chiao, E. Y. AU - Lensing, S. Y. AU - Wiley, D. J. AU - Deshmukh, A. A. AU - Lee, J. AU - Darragh, T. M. AU - Einstein, M. H. AU - Jay, N. AU - Berry-Lawhorn, J. M. AU - Palefsky, J. M. AU - Wilkin, T. AU - Barroso, L. F. AU - Cranston, R. D. AU - Levine, R. AU - Guiot, H. M. AU - French, A. L. AU - Citron, D. AU - Rezaei, M. K. AU - Goldstone, S. E. AU - Stier, E. A. DB - Medline DO - 10.1097/QAD.0000000000002694 IS - 15 KW - anus tumor early cancer diagnosis female human Human immunodeficiency virus infection middle aged papillomavirus infection pathology virology LA - English M3 - Article N1 - L632909094 2020-09-25 2021-03-03 PY - 2020 SN - 1473-5571 SP - 2249-2258 ST - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV T2 - AIDS (London, England) TI - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632909094&from=export http://dx.doi.org/10.1097/QAD.0000000000002694 VL - 34 ID - 777 ER - TY - JOUR AB - Objective: HIV-infected women (WLHIV) have more than 10-fold higher risk for squamous cell cancer of the anus. Experts suggest cytology-based strategies developed for cervical cancer screening may prevent anal cancer by detecting anal cytologic or histological high-grade squamous intraepithelial lesion (hHSIL) for treatment. Currently, there is no consensus on anal-hHSIL screening strategies for WLHIV.Design: Between 2014 and 2016, 276 WLHIV were recruited at 12 US AIDS Malignancy Consortium clinical trials sites to evaluate hHSIL prevalence and (test) screening strategies.Methods: Participants completed detailed questionnaire, underwent anal assessments including high-risk human papillomavirus (hrHPV) testing using hrHPV-Hybrid Capture 2 (HC2) and hrHPV-APTIMA, anal cytology, and concurrent high-resolution anoscopy. Screening test characteristics for predicting hHSIL validated by central review of histologic diagnosis were estimated sensitivity, specificity, positive predictive value, and false-omission rate. Paired analyses compared sensitivity and specificity for hrHPV single tests to anal cytology alone.Results: 83% (229/276) of enrolled WLHIV had complete anal assessment data and were included in this analysis. Mean age was 50, 62% black and 60 (26%) had hHSIL. Anal cyotology (>atypical squamous cells of undetermined significance), hrHPV-HC2, and hrHPV-APTIMA sensitivity estimates were similarly high (83, 77, and 75%, respectively, P values > 0.2). Specificity was higher for both hrHPV-APTIMA and hrHPV-HC2 compared with anal cytology (67 vs. 50%, P < 0.001) and (61 vs. 50%, P = 0.020), respectively.Conclusion: Anal hrHPV testing demonstrated similar sensitivity for anal cytology (>atypical squamous cells of undetermined significance) to predict anal hHSIL. Among tests with similar sensitivity, the specificity was significantly higher for hrHPV-APTIMA and hrHPV-HC2. Thus, anal hrHPV testing may be an important alternative strategy to anal cytology for anal hHSIL screening among WLHIV. AD - Department of Epidemiology and General Oncology, University of Texas- MD Anderson Cancer Center, Houston, Texas. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, Arkansas. School of Nursing, University of California, Los Angeles, Los Angeles, California. Department of Management Policy and Community Health, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. Department of Pathology, UCSF Mt. Zion Medical Center, San Francisco, California. Department of OB/GYN & Women’s Health, Rutgers-NJMS, Newark, New Jersey. Department of Medicine, Anal Neoplasia Clinic, Research, and Education Center. Clinical Trials Unit, Department of Medicine, Cornell University, New York, New York. Department of Internal Medicine (Infectious Diseases), Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA. University of Vic, Hospital Germans Trias i Pujol, Barcelona, Spain. Department of Surgery, Montefiore, Bronx, New York. Division of Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois. Department of Pathology, Baylor College of Medicine, Houston, Texas. Department of Pathology, George Washington University, Washington, District of Columbia. Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, Massachusetts, USA. AN - 147742324. Language: English. Entry Date: 20201225. Revision Date: 20210223. Publication Type: journal article AU - Chiao, Elizabeth Y. AU - Lensing, Shelly Y. AU - Wiley, Dorothy J. AU - Deshmukh, Ashish A. AU - Lee, Jeannette AU - Darragh, Teresa M. AU - Einstein, Mark H. AU - Jay, Naomi AU - Berry-Lawhorn, John Michael AU - Palefsky, Joel M. AU - Wilkin, Timothy AU - Barroso, Luis F. AU - Cranston, Ross D. AU - Levine, Rebecca AU - Guiot, Humberto M. AU - French, Audrey L. AU - Citron, Deborah AU - Rezaei, Masoumeh Katayoon AU - Goldstone, Stephen E. AU - Stier, Elizabeth A. DB - CINAHL Complete DO - 10.1097/QAD.0000000000002694 DP - EBSCOhost IS - 15 KW - Papillomavirus Infections -- Pathology Anus Neoplasms HIV Infections -- Pathology Anus Neoplasms -- Pathology Anus Neoplasms -- Diagnosis Female Middle Age Early Detection of Cancer Human Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins). Grant Information: R01 CA163103/CA/NCI NIH HHS/United States. NLM UID: 8710219. PMID: NLM32947592. PY - 2020 SN - 0269-9370 SP - 2249-2258 ST - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV T2 - AIDS (02699370) TI - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147742324&site=ehost-live&scope=site VL - 34 ID - 2084 ER - TY - JOUR AB - OBJECTIVE: HIV-infected women (WLHIV) have more than 10-fold higher risk for squamous cell cancer of the anus. Experts suggest cytology-based strategies developed for cervical cancer screening may prevent anal cancer by detecting anal cytologic or histological high-grade squamous intraepithelial lesion (hHSIL) for treatment. Currently, there is no consensus on anal-hHSIL screening strategies for WLHIV. DESIGN: Between 2014 and 2016, 276 WLHIV were recruited at 12 US AIDS Malignancy Consortium clinical trials sites to evaluate hHSIL prevalence and (test) screening strategies. METHODS: Participants completed detailed questionnaire, underwent anal assessments including high-risk human papillomavirus (hrHPV) testing using hrHPV-Hybrid Capture 2 (HC2) and hrHPV-APTIMA, anal cytology, and concurrent high-resolution anoscopy. Screening test characteristics for predicting hHSIL validated by central review of histologic diagnosis were estimated sensitivity, specificity, positive predictive value, and false-omission rate. Paired analyses compared sensitivity and specificity for hrHPV single tests to anal cytology alone. RESULTS: 83% (229/276) of enrolled WLHIV had complete anal assessment data and were included in this analysis. Mean age was 50, 62% black and 60 (26%) had hHSIL. Anal cyotology (>atypical squamous cells of undetermined significance), hrHPV-HC2, and hrHPV-APTIMA sensitivity estimates were similarly high (83, 77, and 75%, respectively, P values > 0.2). Specificity was higher for both hrHPV-APTIMA and hrHPV-HC2 compared with anal cytology (67 vs. 50%, P < 0.001) and (61 vs. 50%, P = 0.020), respectively. CONCLUSION: Anal hrHPV testing demonstrated similar sensitivity for anal cytology (>atypical squamous cells of undetermined significance) to predict anal hHSIL. Among tests with similar sensitivity, the specificity was significantly higher for hrHPV-APTIMA and hrHPV-HC2. Thus, anal hrHPV testing may be an important alternative strategy to anal cytology for anal hHSIL screening among WLHIV. AD - Department of Epidemiology and General Oncology, University of Texas- MD Anderson Cancer Center, Houston, TX Department of Biostatistics, University of Arkansas for Medical Sciences, Little RockAR School of Nursing, University of California, Los Angeles, CA, Mexico Department of Management Policy and Community Health, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX Department of Pathology, UCSF Mt. Zion Medical Center, San Francisco, CA, Mexico Department of OB/GYN & Women's Health, Rutgers-NJMS, Newark, NJ, United States Department of Medicine, Anal Neoplasia Clinic, Research, Education Center Division of Hematology Oncology Department of Medicine, University of California, San Francisco, CA, Mexico Clinical Trials Unit, Department of Medicine, Cornell UniversityNY Department of Internal Medicine (Infectious Diseases), Wake Forest University Health Sciences, Winston-SalemNC, United States University of Vic, Hospital Germans Trias i Pujol, Barcelona, Spain Department of Surgery, Montefiore, Bronx, New York Department of Medicine Department of Microbiology & Medical Zoology, University of Puerto Rico School of MedicineSan Juan, Puerto Rico Division of Infectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, IL, Mexico Department of Pathology, Baylor College of Medicine, Houston, TX Department of Pathology, George Washington University, Washington, District of Columbia Department of Surgery, Icahn School of Medicine at Mount SinaiNY Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA, United States AU - Chiao, E. Y. AU - Lensing, S. Y. AU - Wiley, D. J. AU - Deshmukh, A. A. AU - Lee, J. AU - Darragh, T. M. AU - Einstein, M. H. AU - Jay, N. AU - Berry-Lawhorn, J. M. AU - Palefsky, J. M. AU - Wilkin, T. AU - Barroso, L. F. AU - Cranston, R. D. AU - Levine, R. AU - Guiot, H. M. AU - French, A. L. AU - Citron, D. AU - Rezaei, M. K. AU - Goldstone, S. E. AU - Stier, E. A. DB - Scopus DO - 10.1097/QAD.0000000000002694 IS - 15 M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 2249-2258 ST - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV T2 - AIDS (London, England) TI - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096347530&doi=10.1097%2fQAD.0000000000002694&partnerID=40&md5=4a579d3466409e3a7cc5683b5bce0c26 VL - 34 ID - 2169 ER - TY - JOUR AB - Objective: HIV-infected women (WLHIV) have more than 10-fold higher risk for squamous cell cancer of the anus. Experts suggest cytology-based strategies developed for cervical cancer screening may prevent anal cancer by detecting anal cytologic or histological high-grade squamous intraepithelial lesion (hHSIL) for treatment. Currently, there is no consensus on anal-hHSIL screening strategies for WLHIV. Design: Between 2014 and 2016, 276 WLHIV were recruited at 12 US AIDS Malignancy Consortium clinical trials sites to evaluate hHSIL prevalence and (test) screening strategies. Methods: Participants completed detailed questionnaire, underwent anal assessments including high-risk human papillomavirus (hrHPV) testing using hrHPV-Hybrid Capture 2 (HC2) and hrHPV-APTIMA, anal cytology, and concurrent high-resolution anoscopy. Screening test characteristics for predicting hHSIL validated by central review of histologic diagnosis were estimated sensitivity, specificity, positive predictive value, and false-omission rate. Paired analyses compared sensitivity and specificity for hrHPV single tests to anal cytology alone. Results: 83% (229/276) of enrolled WLHIV had complete anal assessment data and were included in this analysis. Mean age was 50, 62% black and 60 (26%) had hHSIL. Anal cyotology (>atypical squamous cells of undetermined significance), hrHPV-HC2, and hrHPV-APTIMA sensitivity estimates were similarly high (83, 77, and 75%, respectively, P values > 0.2). Specificity was higher for both hrHPV-APTIMA and hrHPV-HC2 compared with anal cytology (67 vs. 50%, P < 0.001) and (61 vs. 50%, P = 0.020), respectively. Conclusion: Anal hrHPV testing demonstrated similar sensitivity for anal cytology (>atypical squamous cells of undetermined significance) to predict anal hHSIL. Among tests with similar sensitivity, the specificity was significantly higher for hrHPV-APTIMA and hrHPV-HC2. Thus, anal hrHPV testing may be an important alternative strategy to anal cytology for anal hHSIL screening among WLHIV. AN - WOS:000596037900009 AU - Chiao, E. Y. AU - Lensing, S. Y. AU - Wiley, D. J. AU - Deshmukh, A. A. AU - Lee, J. AU - Darragh, T. M. AU - Einstein, M. H. AU - Jay, N. AU - Berry-Lawhorn, J. M. AU - Palefsky, J. M. AU - Wilkin, T. AU - Barroso, L. F. AU - Cranston, R. D. AU - Levine, R. AU - Guiot, H. M. AU - French, A. L. AU - Citron, D. AU - Rezaei, M. K. AU - Goldstone, S. E. AU - Stier, E. A. DA - Dec DO - 10.1097/QAD.0000000000002694 IS - 15 N1 - 32947592 PY - 2020 SN - 0269-9370 SP - 2249-2258 ST - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV T2 - Aids TI - Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV VL - 34 ID - 2756 ER - TY - JOUR AB - Preclinical, epidemiological, and phase III data from randomized, placebo‐controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. In vitro evidence suggests that selenium and vitamin E work synergistically to cause cell‐cycle arrest, induce caspase‐mediated apoptosis, and act as antiandrogens in arresting clonal expansion of nascent tumors. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), sponsored by the National Cancer Institute, is an intergroup Phase III, randomized, double‐blind, placebo‐controlled, population‐based clinical trial designed to test the efficacy of selenium and vitamin E alone and in combination in the prevention of prostate cancer. The study has a 2 × 2 factorial design with a target accrual of 32,400. Eligibility criteria include an age of at least 50 years for African Americans and of at least 55 years for Caucasians; a DRE not suspicious for cancer; a serum PSA no greater than 4 ng/mL; and a normal blood pressure. Randomization will be equally distributed among the four study arms, with intervention consisting of a daily oral dose of study supplement (200 μg I‐selenomethionine or 400 mg of racemic α‐tocopheryl) or matched placebo. Study duration is planned for 12 years, with a 5‐year uniform accrual period and a minimum of 7 and maximum of 12 years of intervention. The primary endpoint for SELECT is the clinical incidence of prostate cancer as determined by a recommended routine clinical diagnostic work‐up, including yearly DRE and serum PSA level. SELECT is the second large‐scale study of chemoprevention for prostate cancer. Enrollment began in 2001, with final results anticipated in 2013. © 2004 New York Academy of Sciences. AN - CN-01412457 AU - Klein, E. A. DO - 10.1196/annals.1331.023 KW - *cancer prevention *diet supplementation *prostate cancer /diagnosis /epidemiology /prevention Adult Cancer risk Clinical trial Conference paper Controlled clinical trial Controlled study Double blind procedure Drug efficacy Human Major clinical study Male Phase 3 clinical trial Prostate biopsy Randomized controlled trial Treatment outcome Vitamin intake M3 - Book Series: Conference Paper PY - 2004 SP - 234‐241 ST - Selenium and vitamin E cancer prevention trial T2 - Annals of the new york academy of sciences TI - Selenium and vitamin E cancer prevention trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01412457/full VL - 1031 ID - 1490 ER - TY - SER AB - Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. In vitro evidence suggests that selenium and vitamin E work synergistically to cause cell-cycle arrest, induce caspase-mediated apoptosis, and act as antiandrogens in arresting clonal expansion of nascent tumors. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), sponsored by the National Cancer Institute, is an intergroup Phase III, randomized, double-blind, placebo-controlled, population-based clinical trial designed to test the efficacy of selenium and vitamin E alone and in combination in the prevention of prostate cancer. The study has a 2 × 2 factorial design with a target accrual of 32,400. Eligibility criteria include an age of at least 50 years for African Americans and of at least 55 years for Caucasians; a DRE not suspicious for cancer; a serum PSA no greater than 4 ng/mL; and a normal blood pressure. Randomization will be equally distributed among the four study arms, with intervention consisting of a daily oral dose of study supplement (200 μg I-selenomethionine or 400 mg of racemic α-tocopheryl) or matched placebo. Study duration is planned for 12 years, with a 5-year uniform accrual period and a minimum of 7 and maximum of 12 years of intervention. The primary endpoint for SELECT is the clinical incidence of prostate cancer as determined by a recommended routine clinical diagnostic work-up, including yearly DRE and serum PSA level. SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001, with final results anticipated in 2013. © 2004 New York Academy of Sciences. AD - Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clin. Lerner Coll. of Med., Cleveland, OH 44195, United States Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, United States AU - Klein, E. A. DB - Scopus DO - 10.1196/annals.1331.023 KW - Chemoprevention Prostate cancer Selenium Vitamin E M3 - Conference Paper N1 - Cited By :54 Export Date: 22 March 2021 PY - 2004 SP - 234-241 ST - Selenium and vitamin E cancer prevention trial T2 - Annals of the New York Academy of Sciences TI - Selenium and vitamin E cancer prevention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-14944338731&doi=10.1196%2fannals.1331.023&partnerID=40&md5=5790deda29b320c9ee44c25992933fdb VL - 1031 ID - 2611 ER - TY - CHAP AB - Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. In vitro evidence suggests that selenium and vitamin E work synergistically to cause cell-cycle arrest, induce caspase-mediated apoptosis, and act as antiandrogens in arresting clonal expansion of nascent tumors. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), sponsored by the National Cancer Institute, is an intergroup Phase III, randomized, double-blind, placebo-controlled, population-based clinical trial designed to test the efficacy of selenium and vitamin E alone and in combination in the prevention of prostate cancer. The study has a 2 X 2 factorial design with a target accrual of 32,400. Eligibility criteria include an age of at least 50 years for African Americans and of at least 55 years for Caucasians; a DRE not suspicious for cancer; a serum PSA no greater than 4 ng/mL; and a normal blood pressure. Randomization will be equally distributed among the four study arms, with intervention consisting of a daily oral dose of study supplement (200 mu g I-selenomethionine or 400 mg of racemic alpha-tocopheryl) or matched placebo. Study duration is planned for 12 years, with a 5year uniform accrual period and a minimum of 7 and maximum of 12 years of intervention. The primary endpoint for SELECT is the clinical incidence of prostate cancer as determined by a recommended routine clinical diagnostic work-up, including yearly DRE and serum PSA level. SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001, with final results anticipated in 2013. AN - WOS:000228129200021 AU - Klein, E. A. N1 - Conference on Vitamin E and Health MAY 22-24, 2004 Boston, MA Cognis Nutr & Hlth; BASF AG; NIH; NIDDK, Off Dietary Supplements; USDA, Natl Res Initiat, CSREES PY - 2004 SN - 0077-8923 1-57331-528-1; 1-57331-527-3 SP - 234-241 ST - Selenium and vitamin E cancer prevention trial T2 - Vitamin E and Health T3 - Annals of the New York Academy of Sciences TI - Selenium and vitamin E cancer prevention trial VL - 1031 ID - 2690 ER - TY - CHAP AB - Prostate cancer continues to be both a major health threat, especially among African-American men, and a public health burden. However, growing evidence suggests that selenium and vitamin E may decrease the risk of this disease. The Selenium and Vitamin E Cancer Prevention Trial (SELECT), a phase III randomized, placebo-controlled study, is designed to determine whether selenium and vitamin E, alone or in combination, decrease the risk of prostate cancer in healthy men. SELECT opened to accrual on 25 July 2001 in more than 400 clinical sites across the United States, Puerto Rico, and Canada; the goal was to randomize 32,400 men. Accrual was completed in June 2004, 2 years ahead of schedule, with a total of 35,534 men randomized. Eligibility requirements include age of at least 55 years (African-American then at least 50 years), and no evidence of prostate cancer as determined by a serum PSA level of no more than 4 ng/ml and a digital rectal exam (DRE) not suspicious for prostate cancer. Participants were randomized to receive selenium (200 mu g/day of l-selenomethionine) and/or vitamin E (400 IU/day of all-rue-alpha-tocopheryl acetate) supplementation for a minimum of 7 years (maximum of 12 years). The rationale for choosing these agents was based on preclinical data as well as analyses of secondary endpoints in cancer prevention clinical trials. The primary endpoint of SELECT is occurrence of prostate cancer based on community standards of diagnosis. Several other non-cancer endpoints are also being explored. AN - WOS:000262395600017 AU - Dunn, B. K. AU - Ryan, A. AU - Ford, L. G. N1 - 5th International Cancer Prevention Conference 2008 St Gallen, SWITZERLAND Int Soc Canc Prevent, European Sch Oncol, European Soc Med Oncol, Canc Res UK, Union Int Contre Canc, European Assoc Canc Res, Amer Canc Soc, Swiss Canc League PY - 2009 SN - 0080-0015 978-3-540-69296-6 SP - 183-193 ST - Selenium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention T2 - Cancer Prevention Ii T3 - Recent Results in Cancer Research TI - Selenium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention VL - 181 ID - 3156 ER - TY - JOUR AB - PURPOSE: To determine the reasons why men fail to participate in a free prostate cancer screening. DESIGN: Survey and secondary analyses using correlational design. SETTING: Community sites in the Southeastern United States. SAMPLE: The sample (N = 241) ranged in age from 40-68 years. Mean age was 50 years (SD = 7.4). Most of the men were African American (79%) and married (70%). Almost half of the subjects (44%) earned between $9,601 and $25,020 per year. METHOD: Telephone survey of men who did not participate in initial prostate cancer screening after educational program. MAIN RESEARCH VARIABLES: Demographics, self-reported reasons men decided not to participate in a free screening following a prostate cancer educational program, and predictors for subsequent participation in screening. FINDINGS: The main self-reported reason for not participating in a free prostate cancer screening opportunity was time problems. A significant relationship between income and physician problems existed among the men who did not participate. Twenty-one percent of the 241 men participated in a second opportunity for free prostate cancer screening. Men who cited "lost packet" as their reason for not participating in the first free screening were more than twice as likely to go for the second opportunity for free screening when offered another packet or voucher for a free screening with their physician of choice. CONCLUSIONS: "Time problems" was the most frequent self-reported reason men gave for failure to participate. Providing a follow-up phone call and vouchers a second time for reimbursement of the cost associated with a screening increased participation. Men often need assistance with locating physicians and nurse practitioners who will file for financial reimbursement. Appointment reminders are critical. IMPLICATIONS FOR NURSING: The findings of this study of the significant relationship between income and "physician problems" for not participating has implications for healthcare providers. Future programs could provide telephone follow-up with men and remail vouchers, as needed. In addition, men could be encouraged to designate one place in their households for health-related papers (for safekeeping). AD - S.P. Weinrich, School of Nursing, University of Louisville, KY, USA. AU - Weinrich, S. P. AU - Weinrich, M. C. AU - Priest, J. AU - Fodi, C. DB - Medline IS - 1 KW - adult African American aged article attitude to health Caucasian health care delivery health survey human male mass screening middle aged nursing patient attitude patient participation prostate tumor socioeconomics statistics United States LA - English M3 - Article N1 - L36474175 2003-01-07 PY - 2003 SN - 1538-0688 SP - E12-16 ST - Self-reported reasons men decide not to participate in free prostate cancer screening T2 - Oncology nursing forum TI - Self-reported reasons men decide not to participate in free prostate cancer screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L36474175&from=export VL - 30 ID - 1297 ER - TY - JOUR AB - Background: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. Objective: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. Design: Secondary analysis of the Polyp Prevention Trial (PPT) data. Setting: United States. Patients: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. Main Outcome Measurements: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. Results: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] =.98; 95% CI,.80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI,.68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI,.84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI,.60-1.79). Limitation: There were few blacks in the long-term follow-up study. Conclusions: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity. © 2013 American Society for Gastrointestinal Endoscopy. AD - A.O. Laiyemo, Division of Gastroenterology, Department of Medicine, Howard University College of Medicine, 2041 Georgia Avenue, NW, Washington, DC 20060, United States AU - Laiyemo, A. O. AU - Doubeni, C. AU - Brim, H. AU - Ashktorab, H. AU - Schoen, R. E. AU - Gupta, S. AU - Charabaty, A. AU - Lanza, E. AU - Smoot, D. T. AU - Platz, E. AU - Cross, A. J. DB - Embase Medline DO - 10.1016/j.gie.2012.11.027 IS - 3 KW - adult article Caucasian colonoscopy colorectal adenoma controlled study ethnicity female follow up health disparity human major clinical study male medical history Black person priority journal race difference recurrence risk risk assessment tumor localization United States LA - English M3 - Article N1 - L52402336 2013-01-22 2013-03-13 PY - 2013 SN - 0016-5107 1097-6779 SP - 447-454 ST - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks T2 - Gastrointestinal Endoscopy TI - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52402336&from=export http://dx.doi.org/10.1016/j.gie.2012.11.027 VL - 77 ID - 1090 ER - TY - JOUR AB - Background: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. Objective: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. Design: Secondary analysis of the Polyp Prevention Trial (PPT) data. Setting: United States. Patients: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. Main Outcome Measurements: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. Results: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI, .80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60-1.79). Limitation: There were few blacks in the long-term follow-up study. Conclusions: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity. AN - 104317967. Language: English. Entry Date: 20130318. Revision Date: 20200708. Publication Type: Journal Article AU - Laiyemo, Adeyinka O. AU - Doubeni, Chyke AU - Brim, Hassan AU - Ashktorab, Hassan AU - Schoen, Robert E. AU - Gupta, Samir AU - Charabaty, Aline AU - Lanza, Elaine AU - Smoot, Duane T. AU - Platz, Elizabeth AU - Cross, Amanda J. DB - CINAHL Complete DO - 10.1016/j.gie.2012.11.027 DP - EBSCOhost IS - 3 KW - Colorectal Neoplasms -- Prognosis Adenoma -- Risk Factors Recurrence Human White Persons Black Persons Education, Continuing (Credit) United States Academic Medical Centers Quality of Health Care Wilcoxon Rank Sum Test Mann-Whitney U Test Poisson Distribution Regression Confidence Intervals Relative Risk Data Analysis Software Sensitivity and Specificity Male Female Middle Age Aged Descriptive Statistics Funding Source N1 - CEU; research; tables/charts. Journal Subset: Biomedical; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: Funded by the Division of Cancer Prevention and the Intramural Research Program of the Divn. of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.. NLM UID: 0010505. PMID: NLM23337636. PY - 2013 SN - 0016-5107 SP - 447-454 ST - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks T2 - Gastrointestinal Endoscopy TI - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104317967&site=ehost-live&scope=site VL - 77 ID - 2086 ER - TY - JOUR AB - Background: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. Objective: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. Design: Secondary analysis of the Polyp Prevention Trial (PPT) data. Setting: United States. Patients: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. Main Outcome Measurements: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. Results: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] =.98; 95% CI,.80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI,.68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI,.84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI,.60-1.79). Limitation: There were few blacks in the long-term follow-up study. Conclusions: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity. © 2013 American Society for Gastrointestinal Endoscopy. AD - Division of Gastroenterology, Department of Medicine, Howard University College of Medicine, 2041 Georgia Avenue, NW, Washington, DC 20060, United States Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States Department of Pathology, Howard University Hospital, Washington, DC, United States Department of Medicine and Epidemiology, University of Pittsburgh, Pittsburgh, PA, United States Division of Gastroenterology, University of Texas Southwestern Medical Center, Dallas, TX, United States Division of Gastroenterology, Department of Medicine, Georgetown University, Washington, DC, United States Laboratory of Cancer Prevention, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States Department of Medicine, Meharry Medical Center, Nashville, TN, United States Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States AU - Laiyemo, A. O. AU - Doubeni, C. AU - Brim, H. AU - Ashktorab, H. AU - Schoen, R. E. AU - Gupta, S. AU - Charabaty, A. AU - Lanza, E. AU - Smoot, D. T. AU - Platz, E. AU - Cross, A. J. DB - Scopus DO - 10.1016/j.gie.2012.11.027 IS - 3 M3 - Article N1 - Cited By :18 Export Date: 22 March 2021 PY - 2013 SP - 447-454 ST - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks T2 - Gastrointestinal Endoscopy TI - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873730785&doi=10.1016%2fj.gie.2012.11.027&partnerID=40&md5=19f56e9cfafc968bee32729d64a37cd4 VL - 77 ID - 2440 ER - TY - JOUR AB - Background: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. Objective: To determine whether non-Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non-Hispanic whites (whites) after removal of colorectal adenoma. Design: Secondary analysis of the Polyp Prevention Trial (PPT) data. Setting: United States. Patients: Patients were 1668 self-identified whites and 153 blacks who completed the 4-year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow-up Study (PPT-CFS) and underwent another colonoscopy. Main Outcome Measurements: Recurrence and location of the adenoma and advanced adenoma by race-ethnicity during PPT and cumulative recurrence over a mean follow-up of 8.3 years (range, 4.9-12.4 years) among PPT-CFS enrollees. Results: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI,.80-1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68-2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT-CFS enrollees, the cumulative recurrence rate over a maximal follow-up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84-1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60-1.79). Limitation: There were few blacks in the long-term follow-up study. Conclusions: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity. (Gastrointest Endosc 2013;77:447-54.) AN - WOS:000314831000016 AU - Laiyemo, A. O. AU - Doubeni, C. AU - Brim, H. AU - Ashktorab, H. AU - Schoen, R. E. AU - Gupta, S. AU - Charabaty, A. AU - Lanza, E. AU - Smoot, D. T. AU - Platz, E. AU - Cross, A. J. DA - Mar DO - 10.1016/j.gie.2012.11.027 IS - 3 N1 - 53rd Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW) / Meeting of the Pancreas-Club MAY 17-22, 2012 San Diego, CA Amer Assoc Study Liver Dis (AASLD), Amer Gastroenterol Assoc (AGA), Amer Soc Gastrointestinal Endoscopy (ASGE), Soc Surg Alimentary Tract (SSAT), Pancreas Club 23337636 PY - 2013 SN - 0016-5107 SP - 447-454 ST - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks T2 - Gastrointestinal Endoscopy TI - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks VL - 77 ID - 3047 ER - TY - JOUR AB - BACKGROUND: It is unclear whether the higher burden from colorectal cancer among blacks is due to an increased biological susceptibility. OBJECTIVE: To determine whether non‐Hispanic blacks (blacks) have a higher risk of adenoma recurrence than non‐Hispanic whites (whites) after removal of colorectal adenoma. DESIGN: Secondary analysis of the Polyp Prevention Trial (PPT) data. SETTING: United States. PATIENTS: Patients were 1668 self‐identified whites and 153 blacks who completed the 4‐year trial. Of these, 688 whites and 55 blacks enrolled in a posttrial, passive Polyp Prevention Trial Continued Follow‐up Study (PPT‐CFS) and underwent another colonoscopy. MAIN OUTCOME MEASUREMENTS: Recurrence and location of the adenoma and advanced adenoma by race‐ethnicity during PPT and cumulative recurrence over a mean follow‐up of 8.3 years (range, 4.9‐12.4 years) among PPT‐CFS enrollees. RESULTS: Blacks had similar risk of recurrence of adenoma (39.2% vs 39.4%; incidence risk ratio [RR] = .98; 95% CI, .80‐1.20) and advanced adenoma (8.5% vs 6.4%; RR = 1.18; 95% CI, .68‐2.05) as whites at the end of PPT. Recurrence risk did not differ by colon subsite. Among PPT‐CFS enrollees, the cumulative recurrence rate over a maximal follow‐up period of 12 years was similar for blacks and whites for adenoma (67.3% vs 67.0%; RR = 1.01; 95% CI, .84‐1.21) and advanced adenoma (14.5% vs 16.9%; RR = 1.03; 95% CI, .60‐1.79). LIMITATION: There were few blacks in the long‐term follow‐up study. CONCLUSIONS: Adenoma and advanced adenoma recurrence did not differ by race. Our study does not support more frequent surveillance colonoscopies for blacks with a personal history of adenoma as an intervention to reduce colorectal cancer disparity. AN - CN-00965841 AU - Laiyemo, A. O. AU - Doubeni, C. AU - Brim, H. AU - Ashktorab, H. AU - Schoen, R. E. AU - Gupta, S. AU - Charabaty, A. AU - Lanza, E. AU - Smoot, D. T. AU - Platz, E. AU - et al. DO - 10.1016/j.gie.2012.11.027 IS - 3 KW - Adenoma [*ethnology, surgery] Adult African Americans [*statistics & numerical data] Aged Chi‐Square Distribution Colonoscopy Colorectal Neoplasms [*ethnology, surgery] Confidence Intervals European Continental Ancestry Group [*statistics & numerical data] Female Humans Incidence Male Middle Aged Neoplasm Recurrence, Local [*ethnology] Statistics, Nonparametric United States [epidemiology] M3 - Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural PY - 2013 SP - 447‐454 ST - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks T2 - Gastrointestinal endoscopy TI - Short- and long-term risk of colorectal adenoma recurrence among whites and blacks UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00965841/full VL - 77 ID - 1346 ER - TY - JOUR AB - Background: Video-assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early-stage non-small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation-based training could help trainees overcome the first part of the learning curve, but no virtual-reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy. Methods: Twenty-eight surgical residents were randomized to either virtual-reality training on a nephrectomy module or traditional black-box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool. Results: The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black-box group was significantly faster during the test scenario than the virtual-reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non-anatomical errors. Conclusion: Simulation-based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black-box training was more effective than virtual-reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual-reality training programs for trainees in thoracic surgery. © 2014 Springer Science+Business Media. AD - K. Jensen, Department of Cardiothoracic Surgery, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark AU - Jensen, K. AU - Ringsted, C. AU - Hansen, H. J. AU - Petersen, R. H. AU - Konge, L. DB - Embase Medline DO - 10.1007/s00464-013-3392-7 IS - 6 KW - adult article controlled study female human intermethod comparison lung lobectomy male outcome assessment priority journal randomized controlled trial resident simulation simulator thoracoscopic lobectomy video assisted thoracoscopic surgery virtual reality LA - English M3 - Article N1 - L52964726 2014-01-24 2018-10-30 PY - 2014 SN - 1432-2218 0930-2794 SP - 1821-1829 ST - Simulation-based training for thoracoscopic lobectomy: A randomized controlled trial: Virtual-reality versus black-box simulation T2 - Surgical Endoscopy TI - Simulation-based training for thoracoscopic lobectomy: A randomized controlled trial: Virtual-reality versus black-box simulation UR - https://www.embase.com/search/results?subaction=viewrecord&id=L52964726&from=export http://dx.doi.org/10.1007/s00464-013-3392-7 VL - 28 ID - 1056 ER - TY - JOUR AB - BACKGROUND: Video‐assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early‐stage non‐small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation‐based training could help trainees overcome the first part of the learning curve, but no virtual‐reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy. METHODS: Twenty‐eight surgical residents were randomized to either virtual‐reality training on a nephrectomy module or traditional black‐box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool. RESULTS: The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black‐box group was significantly faster during the test scenario than the virtual‐reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non‐anatomical errors. CONCLUSION: Simulation‐based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black‐box training was more effective than virtual‐reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual‐reality training programs for trainees in thoracic surgery. AN - CN-00995177 AU - Jensen, K. AU - Ringsted, C. AU - Hansen, H. J. AU - Petersen, R. H. AU - Konge, L. DO - 10.1007/s00464-013-3392-7 IS - 6 KW - *lung lobectomy *thoracoscopic lobectomy *virtual reality Adult Animals Article Carcinoma, Non‐Small‐Cell Lung [surgery] Computer Simulation Computer‐Assisted Instruction [*methods] Controlled study Female Human Humans Intermethod comparison Internship and Residency [*methods] Learning Curve Male Outcome assessment Pneumonectomy [*methods] Priority journal Randomized controlled trial Resident Simulation Simulator Swine Thoracic Surgery, Video‐Assisted [*education] Thoracoscopy [*education] User‐Computer Interface Video assisted thoracoscopic surgery M3 - Comparative Study; Journal Article; Randomized Controlled Trial PY - 2014 SP - 1821‐1829 ST - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation T2 - Surgical endoscopy TI - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00995177/full VL - 28 ID - 1437 ER - TY - JOUR AB - Background: Video-assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early-stage non-small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation-based training could help trainees overcome the first part of the learning curve, but no virtual-reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy.Methods: Twenty-eight surgical residents were randomized to either virtual-reality training on a nephrectomy module or traditional black-box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool.Results: The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black-box group was significantly faster during the test scenario than the virtual-reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non-anatomical errors.Conclusion: Simulation-based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black-box training was more effective than virtual-reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual-reality training programs for trainees in thoracic surgery. AD - Department of Cardiothoracic Surgery, University Hospital of Copenhagen, Rigshospitalet, Thoraxkirurgisk afd. 2152, Blegdamsvej 9, 2100, Copenhagen, Denmark, katrine.jensen@regionh.dk. AN - 103824971. Language: English. Entry Date: 20150116. Revision Date: 20171020. Publication Type: journal article AU - Jensen, Katrine AU - Ringsted, Charlotte AU - Hansen, Henrik Jessen AU - Petersen, René Horsleben AU - Konge, Lars DB - CINAHL Complete DO - 10.1007/s00464-013-3392-7 DP - EBSCOhost IS - 6 KW - Computer Simulation Computer Assisted Instruction Internship and Residency Pneumonectomy -- Methods Thoracic Surgery -- Education Thoracoscopy -- Education User-Computer Interface Adult Animals Carcinoma, Non-Small-Cell Lung -- Surgery Female Human Learning Male Swine N1 - research; randomized controlled trial. Journal Subset: Biomedical; Continental Europe; Europe; Expert Peer Reviewed; Peer Reviewed. NLM UID: 8806653. PMID: NLM24442678. PY - 2014 SN - 0930-2794 SP - 1821-1829 ST - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation T2 - Surgical Endoscopy TI - Simulation-based training for thoracoscopic lobectomy: a randomized controlled trial: virtual-reality versus black-box simulation UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103824971&site=ehost-live&scope=site VL - 28 ID - 2087 ER - TY - JOUR AB - Background: Video-assisted thoracic surgery is gradually replacing conventional open thoracotomy as the method of choice for the treatment of early-stage non-small cell lung cancers, and thoracic surgical trainees must learn and master this technique. Simulation-based training could help trainees overcome the first part of the learning curve, but no virtual-reality simulators for thoracoscopy are commercially available. This study aimed to investigate whether training on a laparoscopic simulator enables trainees to perform a thoracoscopic lobectomy. Methods: Twenty-eight surgical residents were randomized to either virtual-reality training on a nephrectomy module or traditional black-box simulator training. After a retention period they performed a thoracoscopic lobectomy on a porcine model and their performance was scored using a previously validated assessment tool. Results: The groups did not differ in age or gender. All participants were able to complete the lobectomy. The performance of the black-box group was significantly faster during the test scenario than the virtual-reality group: 26.6 min (SD 6.7 min) versus 32.7 min (SD 7.5 min). No difference existed between the two groups when comparing bleeding and anatomical and non-anatomical errors. Conclusion: Simulation-based training and targeted instructions enabled the trainees to perform a simulated thoracoscopic lobectomy. Traditional black-box training was more effective than virtual-reality laparoscopy training. Thus, a dedicated simulator for thoracoscopy should be available before establishing systematic virtual-reality training programs for trainees in thoracic surgery. © 2014 Springer Science+Business Media. AD - Department of Cardiothoracic Surgery, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark Wilson Centre, University of Toronto, University Health Network, Toronto, ON, Canada Centre for Clinical Education, University of Copenhagen, Copenhagen, Denmark AU - Jensen, K. AU - Ringsted, C. AU - Hansen, H. J. AU - Petersen, R. H. AU - Konge, L. DB - Scopus DO - 10.1007/s00464-013-3392-7 IS - 6 KW - Simulation Simulator training Thoracoscopy VATS lobectomy Virtual-reality M3 - Article N1 - Cited By :46 Export Date: 22 March 2021 PY - 2014 SP - 1821-1829 ST - Simulation-based training for thoracoscopic lobectomy: A randomized controlled trial: Virtual-reality versus black-box simulation T2 - Surgical Endoscopy TI - Simulation-based training for thoracoscopic lobectomy: A randomized controlled trial: Virtual-reality versus black-box simulation UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903634836&doi=10.1007%2fs00464-013-3392-7&partnerID=40&md5=cbe4874424ebcd155b3ef29bef328c9d VL - 28 ID - 2417 ER - TY - JOUR AB - Few eligible postmenopausal women participate in clinical trial research to prevent breast cancer or coronary heart disease, making it impossible to adequately assess the efficacy of tested interventions for this vulnerable group. To elucidate the causal factors and decision model underlying participation behavior, 180 white, African American, and Hispanic postmenopausal women judged their likelihood of participation in a breast cancer or coronary heart disease prevention clinical trial in scenarios with varied cost/remuneration, perceived risk, doctor's recommendation, and expected toxicity. In addition, 293 white, African American, and Hispanic male and female physicians judged the strength of their participation recommendation in scenarios with varied cost/remuneration, expected toxicity, patient's age, and the source of the information about the clinical trial. An additive and constant-weight-averaging model were rejected. The same configural-weight-range model accounted for judgments in both breast cancer and coronary heart disease scenarios, with different parameter values for each group. According to this model, white and Hispanic women under 70 years of age are most likely to participate, even under somewhat adverse conditions; costs and high toxicity levels act as severe barriers to physicians' positive recommendations and women's participation. Perceived risk was the most important factor for women, yet only 8% and 15% reported ever having received risk information from their doctor for breast cancer and coronary heart disease, respectively. For these two diseases, respectively, 75% and 48% of women rated their risk of the disease as low and 76% and 88% reported they had never heard of a randomized clinical trial or of a prevention clinical trial being conducted. These results have implications for education, information dissemination, and prevention clinical-trial planners. AD - Publications Department, RAND, 1700 Main Street, Santa Monica, CA 90407-2138 AN - 106627260. Language: English. Entry Date: 20050506. Revision Date: 20200624. Publication Type: Journal Article AU - Veit, C. T. DB - CINAHL Complete DO - 10.1177/0272989x04267007 DP - EBSCOhost IS - 4 KW - Breast Neoplasms -- Prevention and Control Cardiovascular Diseases -- Prevention and Control Decision Making, Patient Models, Statistical Physician-Patient Relations Research Subject Recruitment Adult Aged Aged, 80 and Over Analysis of Variance Black Persons California Clinical Trials -- Economics Experimental Studies Female Hispanic Americans Middle Age Research Instruments White Persons Funding Source Human N1 - equations & formulas; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Background and Opinion Survey Questionnaire; Clinical Trial Scenario Questionnaire. Grant Information: Supported by a combined grant from the National Institute on Aging and from the Office of Research on Women's Health. NLM UID: 8109073. PMID: NLM15271272. PY - 2004 SN - 0272-989X SP - 330-350 ST - A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease T2 - Medical Decision Making TI - A single mathematical model predicts physicians' recommendations and postmenopausal women's decisions to participate in a clinical trial to prevent breast cancer or coronary heart disease UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106627260&site=ehost-live&scope=site VL - 24 ID - 1834 ER - TY - JOUR AB - Introduction: Recruiting racial, ethnic, and other underserved minorities into conventional clinic-based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one-year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants. Methods: SISTAS was developed using community-based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C-reactive protein (CRP) and interleukin-6 (IL-6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post-intervention measurements were assessed at 12-week and 12-month follow-ups. Results: We recruited a total of 337 women who tended to: be middle-aged (mean age 48.2 years); have some college education; be employed full-time; have Medicare as their primary insurance; be non-smokers; and perceive their personal health as good. On average, the women were pre-hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI >40.0 kg/m2); the mean fat mass and fat-free mass among participants were 106.4 lb and 121.0 lb, respectively. Conclusion: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR-based studies to decrease BrCa risk. AD - S.A. Adams, College of Nursing, University of South Carolina, 1601 Greene St, Columbia, SC, United States AU - Bevel, M. AU - Babatunde, O. A. AU - Heiney, S. P. AU - Brandt, H. M. AU - Wirth, M. D. AU - Hurley, T. G. AU - Khan, S. AU - Johnson, H. AU - Wineglass, C. M. AU - Warren, T. Y. AU - Angela Murphy, E. AU - Sercy, E. AU - Thomas, A. S. AU - Hébert, J. R. AU - Adams, S. A. DB - Embase Medline DO - 10.18865/ed.28.2.75 IS - 2 KW - C reactive protein interleukin 6 adult African American article controlled study diastolic blood pressure educational status fat free mass female follow up full time employment health program human major clinical study medicare middle aged participatory research physical activity Sistas Inspiring Sistas Through Activity and Support Program smoking South Carolina systolic blood pressure urban area LA - English M3 - Article N1 - L622069139 2018-05-16 2018-05-28 PY - 2018 SN - 1945-0826 1049-510X SP - 75-84 ST - Sistas inspiring sistas through activity and support (SISTAS): Study design and demographics of participants T2 - Ethnicity and Disease TI - Sistas inspiring sistas through activity and support (SISTAS): Study design and demographics of participants UR - https://www.embase.com/search/results?subaction=viewrecord&id=L622069139&from=export http://dx.doi.org/10.18865/ed.28.2.75 VL - 28 ID - 908 ER - TY - JOUR AB - Introduction: Recruiting racial, ethnic, and other underserved minorities into conventional clinic-based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one-year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants. Methods: SISTAS was developed using community-based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C-reactive protein (CRP) and interleukin-6 (IL-6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post-intervention measurements were assessed at 12-week and 12-month follow-ups. Results: We recruited a total of 337 women who tended to: be middle-aged (mean age 48.2 years); have some college education; be employed full-time; have Medicare as their primary insurance; be non-smokers; and perceive their personal health as good. On average, the women were pre-hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI >40.0 kg/m2); the mean fat mass and fat-free mass among participants were 106.4 lb and 121.0 lb, respectively. Conclusion: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR-based studies to decrease BrCa risk. © 2018 ISHIB. All rights reserved. AD - Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina, United States College of Nursing, University of South Carolina, United States Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, United States Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, United States Community Works, Bon Secours Baltimore Health Systems, Baltimore, MD, United States Department of Pathology, Microbiology, and Immunology, School of Medicine, University of South Carolina, United States AU - Bevel, M. AU - Babatunde, O. A. AU - Heiney, S. P. AU - Brandt, H. M. AU - Wirth, M. D. AU - Hurley, T. G. AU - Khan, S. AU - Johnson, H. AU - Wineglass, C. M. AU - Warren, T. Y. AU - Angela Murphy, E. AU - Sercy, E. AU - Thomas, A. S. AU - Hébert, J. R. AU - Adams, S. A. DB - Scopus DO - 10.18865/ed.28.2.75 IS - 2 KW - African American Breast cancer Community-based participatory research Diet Physical activity M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2018 SP - 75-84 ST - Sistas inspiring sistas through activity and support (SISTAS): Study design and demographics of participants T2 - Ethnicity and Disease TI - Sistas inspiring sistas through activity and support (SISTAS): Study design and demographics of participants UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046653295&doi=10.18865%2fed.28.2.75&partnerID=40&md5=30a34b5bcabbd664ac099cdb9e5fcc3d VL - 28 ID - 2282 ER - TY - JOUR AB - Introduction: Recruiting racial, ethnic, and other underserved minorities into conventional clinic‐based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one‐year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants. Methods: SISTAS was developed using community‐based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C‐reactive protein (CRP) and interleukin‐6 (IL‐6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post‐intervention measurements were assessed at 12‐week and 12‐month follow‐ups. Results: We recruited a total of 337 women who tended to: be middle‐aged (mean age 48.2 years); have some college education; be employed full‐time; have Medicare as their primary insurance; be non‐smokers; and perceive their personal health as good. On average, the women were pre‐hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI >40.0 kg/m(2)); the mean fat mass and fat‐free mass among participants were 106.4 lb and 121.0 lb, respectively. Conclusion: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR‐based studies to decrease BrCa risk. AN - CN-01994700 AU - Bevel, M. AU - Babatunde, O. A. AU - Heiney, S. P. AU - Brandt, H. M. AU - Wirth, M. D. AU - Hurley, T. G. AU - Khan, S. AU - Johnson, H. AU - Wineglass, C. M. AU - Warren, T. Y. AU - et al. DO - 10.18865/ed.28.2.75 IS - 2 KW - African Americans [psychology, statistics & numerical data] Community‐Based Participatory Research Diet, Healthy [ethnology, psychology] Exercise [physiology, psychology] Female Health Knowledge, Attitudes, Practice Health Promotion [methods] Humans Middle Aged Obesity, Morbid [diagnosis, ethnology, psychology] Outcome Assessment, Health Care Patient Selection United States [epidemiology] M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non‐U.S. Gov't PY - 2018 SP - 75‐84 ST - Sistas Inspiring Sistas Through Activity and Support (SISTAS): study Design and Demographics of Participants T2 - Ethnicity & disease TI - Sistas Inspiring Sistas Through Activity and Support (SISTAS): study Design and Demographics of Participants UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01994700/full VL - 28 ID - 1417 ER - TY - JOUR AB - Introduction: Recruiting racial, ethnic, and other underserved minorities into conventional clinic-based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one-year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants.Methods: SISTAS was developed using community-based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C-reactive protein (CRP) and interleukin-6 (IL-6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post-intervention measurements were assessed at 12-week and 12-month follow-ups.Results: We recruited a total of 337 women who tended to: be middle-aged (mean age 48.2 years); have some college education; be employed full-time; have Medicare as their primary insurance; be non-smokers; and perceive their personal health as good. On average, the women were pre-hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI >40.0 kg/m2); the mean fat mass and fat-free mass among participants were 106.4 lb and 121.0 lb, respectively.Conclusion: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR-based studies to decrease BrCa risk. AD - Cancer Prevention and Control Program, Arnold School of Public Health, University of South Carolina College of Nursing, University of South Carolina Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina Community Works, Bon Secours Baltimore Health Systems Department of Pathology, Microbiology, and Immunology, School of Medicine, University of South Carolina AN - 131456730. Language: English. Entry Date: In Process. Revision Date: 20200123. Publication Type: journal article AU - Bevel, Malcolm AU - Babatunde, Oluwole A. AU - Heiney, Sue P. AU - Brandt, Heather M. AU - Wirth, Michael D. AU - Hurley, Thomas G. AU - Khan, Samira AU - Johnson, Hiluv AU - Wineglass, Cassandra M. AU - Warren, Tatiana Y. AU - Murphy, E. Angela AU - Sercy, Erica AU - Thomas, Amanda S. AU - Hébert, James R. AU - Adams, Swann Arp DA - Spring2018 DB - CINAHL Complete DO - 10.18865/ed.28.2.75 DP - EBSCOhost IS - 2 KW - Obesity, Morbid -- Psychosocial Factors Exercise Obesity, Morbid -- Ethnology Obesity, Morbid -- Diagnosis Exercise -- Psychosocial Factors United States Outcome Assessment Black Persons -- Statistics and Numerical Data Patient Selection Human Health Services Research Female Middle Age Black Persons -- Psychosocial Factors Health Promotion -- Methods Attitude to Health Validation Studies Comparative Studies Evaluation Research Multicenter Studies Personal Resource Questionnaire Scales N1 - research. Journal Subset: Biomedical; Peer Reviewed; Public Health; USA. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Personal Resource Questionnaire (PRQ). Grant Information: R44 DK103377/DK/NIDDK NIH HHS/United States. NLM UID: 9109034. PMID: NLM29725191. PY - 2018 SN - 1049-510X SP - 75-84 ST - Sistas Inspiring Sistas Through Activity and Support (SISTAS): Study Design and Demographics of Participants T2 - Ethnicity & Disease TI - Sistas Inspiring Sistas Through Activity and Support (SISTAS): Study Design and Demographics of Participants UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131456730&site=ehost-live&scope=site VL - 28 ID - 2088 ER - TY - JOUR AB - Introduction: Recruiting racial, ethnic, and other underserved minorities into conventional clinic-based and other trials is known to be challenging. The Sistas Inspiring Sistas Through Activity and Support (SISTAS) Program was a one-year randomized controlled trial (RCT) to promote physical activity and healthy eating among AA women in SC to reduce inflammatory biomarkers, which are linked to increased breast cancer (BrCa) risk and mortality. This study describes the development, recruitment, and implementation of the SISTAS clinical trial and provides baseline characteristics of the study participants. Methods: SISTAS was developed using community-based participatory research (CBPR) approaches. At baseline, study participants completed assessments and underwent clinical measurements and blood draws to measure C-reactive protein (CRP) and interleukin-6 (IL-6). Participants randomized to the intervention received 12 weekly classes followed by nine monthly booster sessions. Post-intervention measurements were assessed at 12-week and 12-month follow-ups. Results: We recruited a total of 337 women who tended to: be middle-aged (mean age 48.2 years); have some college education; be employed full-time; have Medicare as their primary insurance; be non-smokers; and perceive their personal health as good. On average, the women were pre-hypertensive at baseline (mean systolic blood pressure = 133.9 mm Hg; mean diastolic blood pressure = 84.0 mm Hg) and morbidly obese (mean BMI > 40.0 kg/m(2)); the mean fat mass and fat-free mass among participants were 106.4 lb and 121.0 lb, respectively. Conclusion: The SISTAS RCT addresses some of the gaps in the literature with respect to CBPR interventions targeting AA women, such as implementing diet and physical activity in CBPR-based studies to decrease BrCa risk. AN - WOS:000447640400002 AU - Bevel, M. AU - Babatunde, O. A. AU - Heiney, S. P. AU - Brandt, H. M. AU - Wirth, M. D. AU - Hurley, T. G. AU - Khan, S. AU - Johnson, H. AU - Wineglass, C. M. AU - Warren, T. Y. AU - Murphy, E. A. AU - Sercy, E. AU - Thomas, A. S. AU - Hebert, J. R. AU - Adams, S. A. DA - Spr DO - 10.18865/ed.28.2.75 IS - 2 N1 - 29725191 PY - 2018 SN - 1049-510X SP - 75-84 ST - Sistas Inspiring Sistas through Activity and Support (Sistas): Study Design and Demographics of Participants T2 - Ethnicity & Disease TI - Sistas Inspiring Sistas through Activity and Support (Sistas): Study Design and Demographics of Participants VL - 28 ID - 2869 ER - TY - JOUR AB - African American women are substantially underrepresented in breast cancer genetic research studies and clinical trials, yet they are more likely to die from breast cancer. Lack of trust in the medical community is a major barrier preventing the successful recruitment of African Americans into research studies. When considering the city of Memphis, TN, where the percentage of African Americans is significantly higher than the national average and it has a high rate of breast cancer mortality inequities among African American women, we evaluated the feasibility of utilizing a community-based participatory (CBPR) approach for recruiting African American women into a breast cancer genetic study, called the Sistas Taking A Stand for Breast Cancer Research (STAR) study. From June 2016 and December 2017, African American women age 18 and above were recruited to provide a 2 mL saliva specimen and complete a health questionnaire. A total of 364 African American women provided a saliva sample and completed the health questionnaire. Greater than 85% agreed to be contacted for future studies. Educational workshops on the importance of participating in cancer genetic research studies, followed by question and answer sessions, were most successful in recruitment. Overall, the participants expressed a strong interest and a willingness to participate in the STAR study. Our findings highlight the importance of implementing a CBPR approach that provides an educational component detailing the importance of participating in cancer genetic research studies and that includes prominent community advocates to build trust within the community. AD - A. Starlard-Davenport, Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States AU - Smith, A. AU - Vidal, G. A. AU - Pritchard, E. AU - Blue, R. AU - Martin, M. Y. AU - Rice, L. J. AU - Brown, G. AU - Starlard-Davenport, A. DB - Embase Medline DO - 10.3390/ijerph15122899 IS - 12 KW - adult African American article breast cancer cancer research female genetic analysis health education health equity health status human interpersonal communication major clinical study middle aged participatory research patient advocacy patient attitude patient participation questionnaire saliva analysis Tennessee workshop LA - English M3 - Article N1 - L625532840 2019-01-11 2019-03-07 PY - 2018 SN - 1660-4601 1661-7827 ST - Sistas taking a stand for breast cancer research (STAR) study: A community-based participatory genetic research study to enhance participation and breast cancer equity among African American women in Memphis, TN T2 - International Journal of Environmental Research and Public Health TI - Sistas taking a stand for breast cancer research (STAR) study: A community-based participatory genetic research study to enhance participation and breast cancer equity among African American women in Memphis, TN UR - https://www.embase.com/search/results?subaction=viewrecord&id=L625532840&from=export http://dx.doi.org/10.3390/ijerph15122899 VL - 15 ID - 871 ER - TY - JOUR AB - African American women are substantially underrepresented in breast cancer genetic research studies and clinical trials, yet they are more likely to die from breast cancer. Lack of trust in the medical community is a major barrier preventing the successful recruitment of African Americans into research studies. When considering the city of Memphis, TN, where the percentage of African Americans is significantly higher than the national average and it has a high rate of breast cancer mortality inequities among African American women, we evaluated the feasibility of utilizing a community-based participatory (CBPR) approach for recruiting African American women into a breast cancer genetic study, called the Sistas Taking A Stand for Breast Cancer Research (STAR) study. From June 2016 and December 2017, African American women age 18 and above were recruited to provide a 2 mL saliva specimen and complete a health questionnaire. A total of 364 African American women provided a saliva sample and completed the health questionnaire. Greater than 85% agreed to be contacted for future studies. Educational workshops on the importance of participating in cancer genetic research studies, followed by question and answer sessions, were most successful in recruitment. Overall, the participants expressed a strong interest and a willingness to participate in the STAR study. Our findings highlight the importance of implementing a CBPR approach that provides an educational component detailing the importance of participating in cancer genetic research studies and that includes prominent community advocates to build trust within the community. © 2018 by the authors. Licensee MDPI, Basel, Switzerland. AD - Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38163, United States Department of Medicine, The University of Tennessee West Cancer Center, Memphis, TN 38163, United States Division of Hematology and Oncology, Department of Medicine, University of Tennessee Health Science Center, 7945 Wolf River Boulevard, Memphis, TN 38138, United States College of Nursing, University of Tennessee Health Science Center, Memphis, TN 38163, United States Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, United States School of Health Sciences, Online Learning, Stratford University, 3201 Jermantown Road, Ste 500, Fairfax, VA 22030, United States Carin and Sharin Breast Cancer Support Group, Memphis, TN 38613, United States AU - Smith, A. AU - Vidal, G. A. AU - Pritchard, E. AU - Blue, R. AU - Martin, M. Y. AU - Rice, L. J. AU - Brown, G. AU - Starlard-Davenport, A. C7 - 2899 DB - Scopus DO - 10.3390/ijerph15122899 IS - 12 KW - African American women Breast cancer Community-based participatory research Genetics Health equity Memphis TN M3 - Article N1 - Cited By :3 Export Date: 22 March 2021 PY - 2018 ST - Sistas taking a stand for breast cancer research (STAR) study: A community-based participatory genetic research study to enhance participation and breast cancer equity among African American women in Memphis, TN T2 - International Journal of Environmental Research and Public Health TI - Sistas taking a stand for breast cancer research (STAR) study: A community-based participatory genetic research study to enhance participation and breast cancer equity among African American women in Memphis, TN UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058888207&doi=10.3390%2fijerph15122899&partnerID=40&md5=e95c2b25b7fed9a9603c01889b9ccd41 VL - 15 ID - 2249 ER - TY - JOUR AB - African American women are substantially underrepresented in breast cancer genetic research studies and clinical trials, yet they are more likely to die from breast cancer. Lack of trust in the medical community is a major barrier preventing the successful recruitment of African Americans into research studies. When considering the city of Memphis, TN, where the percentage of African Americans is significantly higher than the national average and it has a high rate of breast cancer mortality inequities among African American women, we evaluated the feasibility of utilizing a community-based participatory (CBPR) approach for recruiting African American women into a breast cancer genetic study, called the Sistas Taking A Stand for Breast Cancer Research (STAR) study. From June 2016 and December 2017, African American women age 18 and above were recruited to provide a 2 mL saliva specimen and complete a health questionnaire. A total of 364 African American women provided a saliva sample and completed the health questionnaire. Greater than 85% agreed to be contacted for future studies. Educational workshops on the importance of participating in cancer genetic research studies, followed by question and answer sessions, were most successful in recruitment. Overall, the participants expressed a strong interest and a willingness to participate in the STAR study. Our findings highlight the importance of implementing a CBPR approach that provides an educational component detailing the importance of participating in cancer genetic research studies and that includes prominent community advocates to build trust within the community. AN - WOS:000456527000290 AU - Smith, A. AU - Vidal, G. A. AU - Pritchard, E. AU - Blue, R. AU - Martin, M. Y. AU - Rice, L. J. AU - Brown, G. AU - Starlard-Davenport, A. DA - Dec DO - 10.3390/ijerph15122899 IS - 12 N1 - 2899 30567326 PY - 2018 SN - 1660-4601 ST - Sistas Taking a Stand for Breast Cancer Research (STAR) Study: A Community-Based Participatory Genetic Research Study to Enhance Participation and Breast Cancer Equity among African American Women in Memphis, TN T2 - International Journal of Environmental Research and Public Health TI - Sistas Taking a Stand for Breast Cancer Research (STAR) Study: A Community-Based Participatory Genetic Research Study to Enhance Participation and Breast Cancer Equity among African American Women in Memphis, TN VL - 15 ID - 2834 ER - TY - JOUR AB - PURPOSE: Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens. METHODS: Detailed information on patient, disease, and treatment factors was collected prospectively on 957 patients who were receiving breast cancer adjuvant chemotherapy in 101 oncology practices throughout the United States. Adjuvant chemotherapy regimens included in any of several published guidelines were considered standard. Receipt of nonstandard regimens was examined according to clinical and nonclinical factors. Differences between groups were assessed using chi2 tests. Multivariate logistic regression was used to identify factors associated with use of nonstandard regimens. RESULTS: Black race (P = .008), lower educational attainment (P = .003), age 70 years (P = .001), higher stage (P < .0001), insurance type (P = .048), employment status (P = .045), employment type (P = .025), and geographic location (P = .021) were associated with the use of nonstandard regimens in univariate analyses. In multivariate analysis, black race (P = .020), lower educational attainment (P = .024), age > or = 70 years (P = .032), and higher stage (P < .0001) were associated with receipt of nonstandard regimens. CONCLUSION: The more frequent use of non-guideline-concordant adjuvant chemotherapy regimens in black women and women with lower educational attainment may contribute to less favorable outcomes in these populations. Addressing such differences in care may improve cancer outcomes in vulnerable populations. AN - 105953864. Language: English. Entry Date: 20080201. Revision Date: 20150711. Publication Type: Journal Article AU - Griggs, J. J. AU - Culakova, E. AU - Sorbero, M. E. AU - Poniewierski, M. S. AU - Wolff, D. A. AU - Crawford, J. AU - Dale, D. C. AU - Lyman, G. H. DB - CINAHL Complete DP - EBSCOhost IS - 18 KW - Antineoplastic Agents, Combined -- Therapeutic Use Breast Neoplasms -- Drug Therapy Breast Neoplasms -- Ethnology Adult Age Factors Aged Aged, 80 and Over Chemotherapy, Adjuvant Chi Square Test Educational Status Employment Female Insurance, Health Logistic Regression Middle Age Neoplasm Staging Patient Selection Prospective Studies Risk Factors Treatment Outcomes United States Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. NLM UID: 8309333. PMID: NLM17577029. PY - 2007 SN - 0732-183X SP - 2522-2527 ST - Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens T2 - Journal of Clinical Oncology TI - Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105953864&site=ehost-live&scope=site VL - 25 ID - 2091 ER - TY - JOUR AB - PURPOSE: A sample survey was conducted to assess the feasibility of recruiting participants, specifically African Americans, and to determine social factors influencing participation in a prostate cancer chemoprevention trial. METHODS: A convenience sample of adults visiting a hospital was identified and asked to participate in the survey. The survey included brief background information about prostate cancer and questions concerning four independent (age, marital status, race, insurance status) and three dependent (willingness to join a trial, involvement in long-term drug intake, interest in receiving more information) variables. RESULTS: The study analyzed 165 responses. Of the 165 respondents, 67% were African American. Marital status was a significant predictor of general willingness to participate (p = 0.047) for male respondents. No significant predictor was found for female respondents. Furthermore, for men, ethnicity/race showed a significant difference (30% white men vs 70% of minority men) for willingness to take the pills. CONCLUSION: The results suggest that African Americans are receptive to participating in chemopreventive trials. Thus, future studies exploring chemoprevention trials as an effective tool for reaching African Americans are warranted. AD - Department of Radiation and Cellular Oncology, Michael Reese/University of Chicago Center for Radiation Therapy, Chicago, IL AN - 107096009. Language: English. Entry Date: 20000301. Revision Date: 20150711. Publication Type: Journal Article AU - Lee, M. M. AU - Chamberlain, R. M. AU - Catchatourian, R. AU - Hiang, J. AU - Kopnick, M. AU - Ray, P. AU - Vijayakumar, S. DA - 1999 Summer DB - CINAHL Complete DP - EBSCOhost IS - 2 KW - Research Subjects -- Psychosocial Factors Consumer Participation Preventive Trials Prostatic Neoplasms -- Prevention and Control Exploratory Research Research Subject Recruitment Chemoprevention Surveys Convenience Sample Questionnaires Univariate Statistics Bivariate Statistics Data Analysis Software Pearson's Correlation Coefficient P-Value Logistic Regression Age Factors Sex Factors Race Factors Marital Status Middle Age Male Female Black Persons Poverty Areas Hospitals, Urban Illinois Human N1 - clinical trial; questionnaire/scale; research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Health Promotion/Education; Peer Reviewed; USA. NLM UID: 8610343. PMID: NLM10397483. PY - 1999 SN - 0885-8195 SP - 88-92 ST - Social factors affecting interest in participating in a prostate cancer chemoprevention trial T2 - Journal of Cancer Education TI - Social factors affecting interest in participating in a prostate cancer chemoprevention trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107096009&site=ehost-live&scope=site VL - 14 ID - 2092 ER - TY - JOUR AB - Greater attention to social factors, such as race/ethnicity, socioeconomic position, and others, are needed across the cancer continuum, including breast cancer, given differences in tumor biology and genetic variants have not completely explained the persistent Black/White breast cancer mortality disparity. In this commentary, we use examples in breast cancer risk assessment and survivorship to demonstrate how the failure to appropriately incorporate social factors into the design, recruitment, and analysis of research studies has resulted in missed opportunities to reduce persistent cancer disparities. The conclusion offers recommendations for how to better document and use information on social factors in cancer research and care by (1) increasing education and awareness about the importance of inclusion of social factors in clinical research; (2) improving testing and documentation of social factors by incorporating them into journal guidelines and reporting stratified results; and (3) including social factors to refine extant tools that assess cancer risk and assign cancer care. Implementing the recommended changes would enable more effective design and implementation of interventions and work toward eliminating cancer disparities by accounting for the social and environmental contexts in which cancer patients live and are treated. AD - Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health and Department of Oncology, Johns Hopkins School of Medicine, 615 N Wolfe St, E6650, 21205, Baltimore, MD, USA College of Social Work, University of South Carolina, Columbia, SC, USA Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Behavioral Research Program Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, United States Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA Department of Biostatistics, College of Global Public Health, New York University, New York, NY, USA Department of Public Health Sciences, College of Medicine, Pennsylvania State University, Hershey, PA, USA AN - 130148309. Language: English. Entry Date: 20190820. Revision Date: 20190820. Publication Type: journal article. Journal Subset: Biomedical AU - Dean, Lorraine T. AU - Gehlert, Sarah AU - Neuhouser, Marian L. AU - Oh, April AU - Zanetti, Krista AU - Goodman, Melody AU - Thompson, Beti AU - Visvanathan, Kala AU - Schmitz, Kathryn H. DB - CINAHL Complete DO - 10.1007/s10552-018-1043-y DP - EBSCOhost IS - 7 KW - Neoplasms -- Psychosocial Factors Ethnic Groups Socioeconomic Factors Neoplasms -- Ethnology Population Risk Factors Scales Social Readjustment Rating Scale N1 - Continental Europe; Europe. Instrumentation: Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Work Environment Scale (WES) (Moos et al); Social Readjustment Rating Scale (SRRS) (Holmes and Rahe). Grant Information: U54 CA155496/CA/NCI NIH HHS/United States. NLM UID: 9100846. PMID: NLM29846844. PY - 2018 SN - 0957-5243 SP - 611-618 ST - Social factors matter in cancer risk and survivorship T2 - Cancer Causes & Control TI - Social factors matter in cancer risk and survivorship UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130148309&site=ehost-live&scope=site VL - 29 ID - 2093 ER - TY - JOUR AB - Objectives: This study assessed the importance of socioeconomic status, race, and likelihood of receiving surgery in explaining mortality among patients with stage-I non-small cell lung cancer. Methods: Analyses focused on Black and White individuals 75 years of age and younger (n = 5189) diagnosed between 1980 and 1982 with stage-I non-small cell lung cancer in Detroit, San Francisco, and Seattle. The main outcome measure was months of survival after diagnosis. Results: Patients in the highest income decile were 45% more likely to receive surgical treatment and 102% more likely to attain 5-year survival than those in the lowest decile. Whites were 20% more likely to undergo surgery than Blacks and 31% more likely to survive 5 years. Multivariate procedures controlling for age and sex confirmed these observations. Conclusions: Socioeconomic status and race appear to independently influence likelihood of survival. Failure to receive surgery explains much excess mortality. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Greenwald, Howard P., School of Policy, Planning, and Development, University of Southern California, Sacramento Center, 1201 J St, Sacramento, CA, US, 95814-2919 AN - 2012-10351-008 AU - Greenwald, Howard P. AU - Polissar, Nayak L. AU - Borgatta, Edgar F. AU - McCorkle, Ruth AU - Goodman, Gary DB - psyh DO - 10.2105/AJPH.88.11.1681 DP - EBSCOhost IS - 11 KW - social factors disease treatment survivors lung cancer surgery African Americans Aged Carcinoma, Non-Small-Cell Lung European Continental Ancestry Group Female Humans Income Lung Neoplasms Male Michigan Middle Aged Multivariate Analysis Patient Selection SEER Program San Francisco Socioeconomic Factors Survival Analysis Washington Lung Disorders Neoplasms Social Processes Treatment N1 - School of Public Administration, University of Southern California, Sacramento, CA, US. Release Date: 20130325. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Surgery. Minor Descriptor: Lung Disorders; Neoplasms; Social Processes; Survivors; Treatment. Classification: Medical Treatment of Physical Illness (3363). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 4. Issue Publication Date: Nov, 1998. Publication History: Accepted Date: Apr 9, 1998. Sponsor: American Cancer Society, US. Grant: PDT-393. Recipients: No recipient indicated PY - 1998 SN - 0090-0036 1541-0048 SP - 1681-1684 ST - Social factors, treatment, and survival in early-stage non-small cell lung cancer T2 - American Journal of Public Health TI - Social factors, treatment, and survival in early-stage non-small cell lung cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-10351-008&site=ehost-live&scope=site greenwa@usc.edu VL - 88 ID - 1775 ER - TY - JOUR AB - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: (1) the PN needs to address access to quality care issues; (2) the PN needs to address the emotional and practical concerns of the cancer survivor; (3) the PN needs to address family concerns; (4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met. AD - C. Davis, College of Social Work, University of Tennessee, 193E Polk Ave., Nashville, TN 37210, United States AU - Davis, C. AU - Darby, K. AU - Likes, W. AU - Bell, J. DB - Medline DO - 10.1080/00981380902765212 IS - 6 KW - adult African American aged article attitude to health breast tumor case management family female health care delivery health care planning human information processing middle aged needs assessment quality of life social work survivor United States urban population LA - English M3 - Article N1 - L355647690 2011-06-14 PY - 2009 SN - 0098-1389 1541-034X SP - 561-578 ST - Social workers as patient navigators for breast cancer survivors: What do african-american medically underserved women think of this idea? T2 - Social Work in Health Care TI - Social workers as patient navigators for breast cancer survivors: What do african-american medically underserved women think of this idea? UR - https://www.embase.com/search/results?subaction=viewrecord&id=L355647690&from=export http://dx.doi.org/10.1080/00981380902765212 VL - 48 ID - 1184 ER - TY - JOUR AB - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: (1) the PN needs to address access to quality care issues; (2) the PN needs to address the emotional and practical concerns of the cancer survivor; (3) the PN needs to address family concerns; (4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Davis, Cindy, College of Social Work, University of Tennessee, 193E Polk Ave, Nashville, TN, US, 37210 AN - 2010-11593-001 AU - Davis, Cindy AU - Darby, Kathleen AU - Likes, Wendy AU - Bell, John DB - psyh DO - 10.1080/00981380902765212 DP - EBSCOhost IS - 6 KW - social workers patient navigators breast cancer survivors African-American medically underserved women health care system health disparities Adult African Americans Aged Aged, 80 and over Breast Neoplasms Case Management Family Female Focus Groups Health Knowledge, Attitudes, Practice Health Services Accessibility Humans Medically Underserved Area Middle Aged Needs Assessment Quality of Life Social Work Survivors Tennessee Urban Population Health Care Services Blacks Human Females N1 - College of Social Work, University of Tennessee, Nashville, TN, US. Other Publishers: Haworth Press. Release Date: 20100830. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Breast Neoplasms; Health Care Services; Social Workers; Survivors; Health Disparities. Minor Descriptor: Blacks; Human Females. Classification: Cancer (3293); Health & Mental Health Services (3370). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Young Adulthood (18-29 yrs) (320); Thirties (30-39 yrs) (340); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Interview; Focus Group; Qualitative Study. References Available: Y. Page Count: 18. Issue Publication Date: Aug, 2009. Publication History: Accepted Date: Nov 17, 2008; First Submitted Date: Sep 25, 2008. Copyright Statement: Taylor & Francis Group, LLC Sponsor: University of Tennessee Cancer Institute, US. Recipients: No recipient indicated PY - 2009 SN - 0098-1389 1541-034X SP - 561-578 ST - Social workers as patient navigators for breast cancer survivors: What do African-American medically underserved women think of this idea? T2 - Social Work in Health Care TI - Social workers as patient navigators for breast cancer survivors: What do African-American medically underserved women think of this idea? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-11593-001&site=ehost-live&scope=site cdavis3@utk.edu VL - 48 ID - 1741 ER - TY - JOUR AB - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: (1) the PN needs to address access to quality care issues; (2) the PN needs to address the emotional and practical concerns of the cancer survivor; (3) the PN needs to address family concerns; (4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met. AD - College of Social Work, University of Tennessee, 193E Polk Avenue, Nashville, TN 37210; cdavis3@utk.edu AN - 105443535. Language: English. Entry Date: 20091009. Revision Date: 20200708. Publication Type: Journal Article AU - Davis, C. AU - Darby, K. AU - Likes, W. AU - Bell, J. DB - CINAHL Complete DO - 10.1080/00981380902765212 DP - EBSCOhost IS - 6 KW - Black Persons Cancer Patients Health Services Accessibility Patient Advocacy Social Workers Breast Neoplasms Cancer Survivors Continuity of Patient Care Exploratory Research Family Relations Female Focus Groups -- Tennessee Funding Source Health Care Delivery -- Methods Health Services Needs and Demand Holistic Care Medically Uninsured Poverty Professional Role Program Development Qualitative Studies Quality Assurance Support Groups Tennessee Thematic Analysis Treatment Delay -- Prevention and Control Human N1 - research. Journal Subset: Allied Health; Blind Peer Reviewed; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: University of Tennessee Cancer Institute. NLM UID: 7603729. PMID: NLM19860292. PY - 2009 SN - 0098-1389 SP - 561-578 ST - Social workers as patient navigators for breast cancer survivors: what do African-American medically underserved women think of this idea? T2 - Social Work in Health Care TI - Social workers as patient navigators for breast cancer survivors: what do African-American medically underserved women think of this idea? UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105443535&site=ehost-live&scope=site VL - 48 ID - 2095 ER - TY - JOUR AB - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: (1) the PN needs to address access to quality care issues; (2) the PN needs to address the emotional and practical concerns of the cancer survivor; (3) the PN needs to address family concerns; (4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met. AD - College of Social Work, University of Tennessee, 193E Polk Ave., Nashville, TN 37210, United States Department of Social Work, Middle Tennessee State University, Murfreesboro, TN, United States School of Nursing, University of Tennessee, Memphis, TN, United States University of Tennessee Cancer Institute, Knoxville, TN, United States AU - Davis, C. AU - Darby, K. AU - Likes, W. AU - Bell, J. DB - Scopus DO - 10.1080/00981380902765212 IS - 6 KW - Breast cancer Health disparities Medically underserved Patient navigation Psychosocial Social work M3 - Article N1 - Cited By :35 Export Date: 22 March 2021 PY - 2009 SP - 561-578 ST - Social workers as patient navigators for breast cancer survivors: What do african-american medically underserved women think of this idea? T2 - Social Work in Health Care TI - Social workers as patient navigators for breast cancer survivors: What do african-american medically underserved women think of this idea? UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70449645432&doi=10.1080%2f00981380902765212&partnerID=40&md5=e80602570090b93444cfcf91b2979737 VL - 48 ID - 2517 ER - TY - JOUR AB - Patient navigation (PN) is a new initiative in health care aimed at reducing disparities by assisting patients in overcoming barriers within the health care system. As PN programs grow around the country, it is important to consult the key stakeholders in the development of these programs. The purpose of this qualitative study was to discuss the needs of medically underserved cancer patients and allow them the opportunity to provide input on models of care to meet their needs. Four focus groups were conducted in three major cities across Tennessee. Research participants (n = 36) were recruited by the staff in area cancer support programs and treatment programs across the state and through recruitment flyers at various treatment centers and community organizations. Findings revealed four key themes in the development of PN programs: ( 1) the PN needs to address access to quality care issues; ( 2) the PN needs to address the emotional and practical concerns of the cancer survivor; ( 3) the PN needs to address family concerns; ( 4) the PN needs to be involved across the continuum of care from time of diagnosis into long-term survivorship. Oncology social workers have a unique opportunity to meet the needs of medically underserved cancer patients through the PN movement. Our profession is a key stakeholder in this movement. We need to advocate for trained oncology social workers to actively pursue the role of patient navigators to ensure that the needs of medically underserved cancer survivors and their families are met. AN - WOS:000268787600001 AU - Davis, C. AU - Darby, K. AU - Likes, W. AU - Bell, J. DO - 10.1080/00981380902765212 IS - 6 N1 - 19860292 PY - 2009 SN - 0098-1389 SP - 561-578 ST - Social Workers as Patient Navigators for Breast Cancer Survivors: What Do African-American Medically Underserved Women Think of This Idea? T2 - Social Work in Health Care TI - Social Workers as Patient Navigators for Breast Cancer Survivors: What Do African-American Medically Underserved Women Think of This Idea? VL - 48 ID - 3159 ER - TY - JOUR AB - Purpose: To assess the degree to which the sociodemographic characteristics of patients enrolled in Radiation Therapy Oncology Group (RTOG) clinical trails are representative of the general population. Methods and Materials: Sociodemographic data were collected on 4016 patients entered in 33 open RTOG studies between July 1991 and June 1994. The data analyzed included educational attainment, age, gender, and race. For comparison, we obtained similar data from the U.S. Department of Census. We also compared our RTOG data with Surveillance Epidemiology and End Results (SEER) data for patients who received radiation therapy, to determine how RTOG patients compared with cancer patients in general, and with patients with cancers at sites typically treated with radiotherapy. Results: Overall, the sociodemographic characteristics of patients entered in RTOG trials were similar to those of the Census data. We found that, in every age group of African-American men and at nearly every level of educational attainment the proportion of RTOG trial participants mirrored the proportion in the census data. Significant differences were noted only in the youngest category of African-American men, where the RTOG accrues more in the lower educational categories and fewer with college experience. For African-American women, we found a similar pattern in every age group and at each level of educational attainment. As with men, RTOG trials accrued a considerably larger proportion of younger, less educated African-American women than the census reported. Using SEER for comparison, the RTOG enrolled proportionately more African- American men to trials all cancer sites combined, and for prostate and head and neck cancer. In head and neck trials, the RTOG enrolled nearly twice as many African-American men than would be predicted by SEER data. In lung cancer trials, RTOG underrepresented African-American men significantly; however, there was no difference for brain cancer trials. There were no racial differences in RTOG accrual and SEER incidence data for women on trials in brain, lung, and head and neck cancer. However, the RTOG trials accrued nearly twice the proportion of African-American women in cervical cancer trials and in all sites combined, compared to the SEER data. Conclusions. Comparisons with the U.S. Census and SEER show that African- Americans are proportionally well represented in cancer clinical trials conducted by the Radiation Therapy Oncology Group. The comparative analysis indicates that all educational levels in each age group of African-Americans generally mirror the U.S. Census, with one exception. The exception is a significant overrepresentation of less-educated African-Americans in the youngest age category. This exception is counter to the expectation that better-educated patients are more likely to enroll in trials. When compared with SEER data the RTOG trials either parallel or overrepresent African- American men and women, with the only exception being in lung cancer, where men are underrepresented. These results show that, in comparison to the Census and SEER data, the RTOG has fulfilled its commitment to enroll African-American patients in its clinical trials. AD - M.L. Bondy, Department of Epidemiology, Box 189, Texas Univ. M.D. Anderson Can. Ctr., 1515 Holcombe Blvd., Houston, TX 77030, United States AU - Chamberlain, R. M. AU - Winter, K. A. AU - Vijayakumar, S. AU - Porter, A. T. AU - Roach Iii, M. AU - Streeter, O. AU - Cox, J. D. AU - Bondy, M. L. DB - Embase Medline DO - 10.1016/S0360-3016(97)00833-X IS - 1 KW - article cancer epidemiology cancer radiotherapy cancer survival Caucasian data analysis demography head and neck cancer human lung cancer major clinical study Black person patient education priority journal race difference sociology treatment indication treatment planning uterine cervix cancer LA - English M3 - Article N1 - L28027561 1998-02-03 PY - 1998 SN - 0360-3016 SP - 9-15 ST - Sociodemographic analysis of patients in Radiation Therapy Oncology Group clinical trials T2 - International Journal of Radiation Oncology Biology Physics TI - Sociodemographic analysis of patients in Radiation Therapy Oncology Group clinical trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L28027561&from=export http://dx.doi.org/10.1016/S0360-3016(97)00833-X VL - 40 ID - 1333 ER - TY - JOUR AB - Purpose: To assess the degree to which the sociodemographic characteristics of patients enrolled in Radiation Therapy Oncology Group (RTOG) clinical trails are representative of the general population. Methods and Materials: Sociodemographic data were collected on 4016 patients entered in 33 open RTOG studies between July 1991 and June 1994. The data analyzed included educational attainment, age, gender, and race. For comparison, we obtained similar data from the U.S. Department of Census. We also compared our RTOG data with Surveillance Epidemiology and End Results (SEER) data for patients who received radiation therapy, to determine how RTOG patients compared with cancer patients in general, and with patients with cancers at sites typically treated with radiotherapy. Results: Overall, the sociodemographic characteristics of patients entered in RTOG trials were similar to those of the Census data. We found that, in every age group of African-American men and at nearly every level of educational attainment the proportion of RTOG trial participants mirrored the proportion in the census data. Significant differences were noted only in the youngest category of African-American men, where the RTOG accrues more in the lower educational categories and fewer with college experience. For African-American women, we found a similar pattern in every age group and at each level of educational attainment. As with men, RTOG trials accrued a considerably larger proportion of younger, less educated African-American women than the census reported. Using SEER for comparison, the RTOG enrolled proportionately more African- American men to trials all cancer sites combined, and for prostate and head and neck cancer. In head and neck trials, the RTOG enrolled nearly twice as many African-American men than would be predicted by SEER data. In lung cancer trials, RTOG underrepresented African-American men significantly; however, there was no difference for brain cancer trials. There were no racial differences in RTOG accrual and SEER incidence data for women on trials in brain, lung, and head and neck cancer. However, the RTOG trials accrued nearly twice the proportion of African-American women in cervical cancer trials and in all sites combined, compared to the SEER data. Conclusions. Comparisons with the U.S. Census and SEER show that African- Americans are proportionally well represented in cancer clinical trials conducted by the Radiation Therapy Oncology Group. The comparative analysis indicates that all educational levels in each age group of African-Americans generally mirror the U.S. Census, with one exception. The exception is a significant overrepresentation of less-educated African-Americans in the youngest age category. This exception is counter to the expectation that better-educated patients are more likely to enroll in trials. When compared with SEER data the RTOG trials either parallel or overrepresent African- American men and women, with the only exception being in lung cancer, where men are underrepresented. These results show that, in comparison to the Census and SEER data, the RTOG has fulfilled its commitment to enroll African-American patients in its clinical trials. AD - Department of Epidemiology, Univ. of Texas M. D. Anderson C., Houston, TX, United States Department of Radiation Oncology, Univ. of Texas M. D. Anderson C., Houston, TX, United States Radiation Therapy Oncology Group, Philadelphia, PA, United States Department of Radiation Oncology, University of Chicago, Chicago, IL, United States Department of Radiation Oncology, Wayne State University, Detroit, MI, United States Department of Radiation Oncology, University of California, San Francisco, CA, United States Department of Radiation Oncology, University of Southern California, Los Angeles, CA, United States Department of Epidemiology, Box 189, Univ. of Texas M. D. Anderson C., 1515 Holcombe Blvd., Houston, TX 77030, United States AU - Chamberlain, R. M. AU - Winter, K. A. AU - Vijayakumar, S. AU - Porter, A. T. AU - Roach Iii, M. AU - Streeter, O. AU - Cox, J. D. AU - Bondy, M. L. DB - Scopus DO - 10.1016/S0360-3016(97)00833-X IS - 1 KW - Accrual African- Americans Cancer clinical trials Cooperative groups Enrollment Minority representation Recruitment M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 1998 SP - 9-15 ST - Sociodemographic analysis of patients in Radiation Therapy Oncology Group clinical trials T2 - International Journal of Radiation Oncology Biology Physics TI - Sociodemographic analysis of patients in Radiation Therapy Oncology Group clinical trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031974281&doi=10.1016%2fS0360-3016%2897%2900833-X&partnerID=40&md5=e68ecad92f4c2144315314a39f803268 VL - 40 ID - 2644 ER - TY - JOUR AB - Purpose: To assess the degree to which the sociodemographic characteristics of patients enrolled in Radiation Therapy Oncology Group (RTOG) clinical trails are representative of the general population. Methods and Materials: Sociodemographic data were collected on 4016 patients entered in 33 open RTOG studies between July 1991 and June 1994. The data analyzed included educational attainment, age, gender, and race. For comparison, we obtained similar data from the U.S. Department of Census. We also compared our RTOG data with Surveillance Epidemiology and End Results (SEER) data for patients who received radiation therapy, to determine how RTOG patients compared with cancer patients in general, and with patients with cancers at sites typically treated with radiotherapy. Results: Overall, the sociodemographic characteristics of patients entered in RTOG trials were similar to those of the Census data. We found that, in every age group of African-American men and at nearly every level of educational attainment, the proportion of RTOG trial participants mirrored the proportion in the census data. Significant differences were noted only in the youngest category of African-American men, where the RTOG accrues more in the lower educational categories and fewer with college experience. For African-American women, we found a similar pattern in every age group and at each level of educational attainment. As with men, RTOG trials accrued a considerably larger proportion of younger, less educated African-American women than the census reported. Using SEER for comparison, the RTOG enrolled proportionately more African-American men to trials all cancer sites combined, and for prostate and head and neck cancer. In head and neck trials, the RTOG enrolled nearly twice as many African-American men than would be predicted by SEER data. In lung cancer trials, RTOG underrepresented African-American men significantly; however, there was no difference for brain cancer trials. There were no racial differences in RTOG accrual and SEER incidence data for women on trials in brain, lung, and head and neck cancer. However, the RTOG trials accrued nearly twice the proportion of African-American women in cervical cancer trials and in all sites combined, compared to the SEER data. Conclusions: Comparisons with the U.S. Census and SEER show that African-Americans are proportionally well represented in cancer clinical trials conducted by the Radiation Therapy Oncology Group. The comparative analysis indicates that all educational levels in each age group of African-Americans generally mirror the U.S. Census, with one exception. The exception is a significant overrepresentation of less-educated African-Americans in the youngest age category. This exception is counter to the expectation that better-educated patients are more likely to enroll in trials. When compared with SEER data, the RTOG trials either parallel or overrepresent African-American men and women, with the only exception being in lung cancer, where men are underrepresented. These results show that, in comparison to the Census and SEER data, the RTOG has fulfilled its commitment to enroll African-American patients in its clinical trials. (C) 1998 Elsevier Science Inc. AN - WOS:000071164200004 AU - Chamberlain, R. M. AU - Winter, K. A. AU - Vijayakumar, S. AU - Porter, A. T. AU - Roach, M. AU - Streeter, O. AU - Cox, J. D. AU - Bondy, M. L. DA - Jan 1 DO - 10.1016/S0360-3016(97)00833-X IS - 1 N1 - 16 9422552 PY - 1998 SN - 0360-3016 SP - 9-15 ST - Sociodemographic analysis of patients in radiation therapy oncology group clinical trials T2 - International Journal of Radiation Oncology Biology Physics TI - Sociodemographic analysis of patients in radiation therapy oncology group clinical trials VL - 40 ID - 2730 ER - TY - JOUR AB - Objectives: African Americans have the highest incidence and mortality rates from colorectal cancer in the United States. Endoscopic screening, while effective in reducing both, is greatly underutilized. This research sought to understand sociodemographic factors related to stage of readiness for endoscopic screening. Design: One hundred fifty nine African American women (76.1%) and men (mean age=57.0 years) who were non-adherent to endoscopic screening guidelines were recruited and asked to complete semi-structured interviews. Setting: Participants were all being seen for a non-acute primary care medical visit at one of two urban hospitals. The theoretical framework that informed this study was the Transtheoretical Model (TTM) and the emphasis on Stage of Change or intention for undergoing endoscopic screening. Main Outcome and Measures: Based on their stage of readiness to undergo screening, 67 (42%) were categorized as precontemplative (Has no plans to have a colonoscopy) while 92 were categoriezed as being in a contemplative or preparation stage. Using chi-square and Student t-tests, differences were examined between the two groups. Results: No sociodemographic variables distinguished the two groups. However, people in the contemplative/preparation group were more likely to: have a regularly seen healthcare professional (63.7% vs 36.3%; P=.005), have had a previous recommendation for screening (65.7% vs 34.3%; P=.003); had heard of a colonoscopy (63.6% vs 36.4%; P=.000) and have been told by a healthcare professional that they needed a colonoscopy (73.1% vs 26.9%; P=.000). Conclusions: This study helps us to better understand the relevance of sociodemographic characteristics that may be associated with completing endoscopic colorectal cancer screening. In addition, we confirm that physician recommendation and individual awareness of the procedure are significant factors in readiness to get screened. AD - Emory University School of Medicine, 1365 Clifton Rd, Atlanta, GA 30322, United States Mount Sinai School of Medicine, United States Department of Medicine, United States Department of Oncological Sciences, United States AU - Christie, J. AU - Jandorf, L. AU - Itzkowitz, S. AU - Halm, E. AU - Freeman, K. AU - King, S. AU - Dhulkifl, R. AU - McNair, M. AU - Thelemaque, L. AU - Lawsin, C. AU - Duhamel, K. DB - Scopus IS - 3 KW - African Americans Cancer prevention Colorectal cancer screening M3 - Article N1 - Cited By :16 Export Date: 22 March 2021 PY - 2009 SP - 323-329 ST - Sociodemographic correlates of stage of adoption for colorectal cancer screening in African Americans T2 - Ethnicity and Disease TI - Sociodemographic correlates of stage of adoption for colorectal cancer screening in African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349761670&partnerID=40&md5=805a1a8940e13f39b070dd7f5b0a2ca7 VL - 19 ID - 2521 ER - TY - JOUR AB - Purpose: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle-aged and older breast cancer survivors. Methods: Sixty breast cancer survivors with self-reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home-based SOP training (n = 30) or no-contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test®), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. Results: SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6-month follow-up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. Conclusion: Home-based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function. AD - J. Frank, Office of Research and Scholarship, School of Nursing, University of Alabama at Birmingham, Medical Towers 501H1, 1720 Second Avenue South, Birmingham, AL, United States AU - Meneses, K. AU - Benz, R. AU - Bail, J. R. AU - Vo, J. B. AU - Triebel, K. AU - Fazeli, P. AU - Frank, J. AU - Vance, D. E. DB - Embase Medline DO - 10.1007/s10549-017-4564-2 IS - 1 KW - adult African American article breast cancer cancer survivor clinical effectiveness cognition cognitive defect cognitive therapy controlled study executive function female follow up general condition improvement geography home care human major clinical study middle aged neuropsychological test outcome assessment pilot study pretest posttest design priority journal randomized controlled trial self report speed of processing training LA - English M3 - Article N1 - L619199131 2017-11-16 2018-03-02 PY - 2018 SN - 1573-7217 0167-6806 SP - 259-267 ST - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot T2 - Breast Cancer Research and Treatment TI - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot UR - https://www.embase.com/search/results?subaction=viewrecord&id=L619199131&from=export http://dx.doi.org/10.1007/s10549-017-4564-2 VL - 168 ID - 909 ER - TY - JOUR AB - Purpose: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle‐aged and older breast cancer survivors. Methods: Sixty breast cancer survivors with self‐reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home‐based SOP training (n = 30) or no‐contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test®), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. Results: SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6‐month follow‐up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. Conclusion: Home‐based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function. AN - CN-01429909 AU - Meneses, K. AU - Benz, R. AU - Bail, J. R. AU - Vo, J. B. AU - Triebel, K. AU - Fazeli, P. AU - Frank, J. AU - Vance, D. E. DO - 10.1007/s10549-017-4564-2 IS - 1 KW - *breast cancer *cancer survivor *cognition *cognitive therapy *speed of processing training Adult African American Age Factors Article Breast Neoplasms [*complications, mortality, therapy] Cancer Survivors Clinical effectiveness Cognition Disorders [diagnosis, etiology, *therapy] Cognition [physiology] Cognitive defect /therapy Controlled study Executive Function [physiology] Executive function Female Follow up General condition improvement Geography Home care Human Humans Major clinical study Middle Aged Neuropsychological Tests Neuropsychological test Outcome assessment Pilot Projects Pilot study Practice, Psychological Pretest posttest design Priority journal Quality of Life Randomized controlled trial Reaction Time [*physiology] Self Report Treatment Outcome M3 - Journal Article; Randomized Controlled Trial PY - 2018 SP - 259‐267 ST - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot T2 - Breast cancer research and treatment TI - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01429909/full VL - 168 ID - 1510 ER - TY - JOUR AB - Purpose: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle‐aged and older breast cancer survivors. Methods: Sixty breast cancer survivors with self‐reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home‐based SOP training (n = 30) or no‐contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test®), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. Results: SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6‐month follow‐up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. Conclusion: Home‐based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function. AN - CN-01456809 AU - Meneses, K. AU - Benz, R. AU - Bail, J. R. AU - Vo, J. B. AU - Triebel, K. AU - Fazeli, P. AU - Frank, J. AU - Vance, D. E. DO - 10.1007/s10549-017-4564-2 IS - 1 KW - *breast cancer *cancer survivor *cognition *cognitive therapy *speed of processing training Adult African American Article Clinical effectiveness Cognitive defect /therapy Controlled study Executive function Female Follow up General condition improvement Geography Home care Human Major clinical study Middle aged Neuropsychological test Outcome assessment Pilot study Pretest posttest design Priority journal Randomized controlled trial Self report M3 - Journal: Article PY - 2018 SP - 259‐267 ST - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot T2 - Breast cancer research and treatment TI - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01456809/full VL - 168 ID - 1550 ER - TY - JOUR AB - Purpose: Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle-aged and older breast cancer survivors. Methods: Sixty breast cancer survivors with self-reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home-based SOP training (n = 30) or no-contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test ® ), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. Results: SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6-month follow-up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. Conclusion: Home-based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function. © 2017, The Author(s). AD - School of Nursing, University of Alabama at Birmingham, Birmingham, AL, United States School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, United States School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States Center for Translational Research on Aging and Mobility, University of Alabama at Birmingham, Birmingham, AL, United States Office of Research and Scholarship, School of Nursing, University of Alabama at Birmingham, Medical Towers 501H1, 1720 Second Avenue South, Birmingham, AL 35294-4410, United States AU - Meneses, K. AU - Benz, R. AU - Bail, J. R. AU - Vo, J. B. AU - Triebel, K. AU - Fazeli, P. AU - Frank, J. AU - Vance, D. E. DB - Scopus DO - 10.1007/s10549-017-4564-2 IS - 1 KW - Aging Breast cancer survivors Cognitive changes Cognitive impairment Speed of processing interventions M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2018 SP - 259-267 ST - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot T2 - Breast Cancer Research and Treatment TI - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033485781&doi=10.1007%2fs10549-017-4564-2&partnerID=40&md5=33b7b9f7a9ff042c91532aa7aecb96ad VL - 168 ID - 2286 ER - TY - JOUR AB - Cognitive changes are common among breast cancer survivors. There is limited evidence to guide management of cognitive changes. This randomized controlled pilot evaluated the preliminary efficacy of a speed of processing (SOP) training among middle-aged and older breast cancer survivors. Sixty breast cancer survivors with self-reported cognitive changes were recruited to the SOAR study. Participants were randomized to either a home-based SOP training (n = 30) or no-contact control group (n = 30). Primary outcomes were SOP (Useful Field of View Test(A (R))), and executive function (NIH Toolbox Cognition Battery). Neuropsychological assessments were completed at baseline, 6 weeks, and 6 months post study entry. Data were analyzed using repeated measures t tests, analysis of covariance, and sensitivity analyses. SOP training resulted in improvement in objective measures of SOP and executive function. Immediate (6 week) posttest and 6-month follow-up demonstrated large SOP training effects over time. Large representation of African American women (51.2%) and 96% retention in the SOAR study add to study strengths. Home-based SOP training shows promise for remediating cognitive changes following breast cancer treatment, particularly improved SOP, and executive function. AN - WOS:000425747200026 AU - Meneses, K. AU - Benz, R. AU - Bail, J. R. AU - Vo, J. B. AU - Triebel, K. AU - Fazeli, P. AU - Frank, J. AU - Vance, D. E. DA - Feb DO - 10.1007/s10549-017-4564-2 IS - 1 N1 - 29128897 PY - 2018 SN - 0167-6806 SP - 259-267 ST - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot T2 - Breast Cancer Research and Treatment TI - Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot VL - 168 ID - 2872 ER - TY - JOUR AB - Colorectal cancer screening, while effective for reducing mortality, remains underutilized particularly among underserved populations such as African Americans. The present study evaluated a spiritually based approach to increasing Health Belief Model-based pre-screening outcomes in a Community Health Advisor-led intervention conducted in African American churches. Sixteen urban churches were randomized to receive either the spiritually based intervention or a nonspiritual comparison of the same structure and core colorectal cancer content. Trained Community Health Advisors led a series of two educational sessions on colorectal cancer early detection. The educational sessions were delivered over a 1-month period. Participants (N = 316) completed a baseline survey at enrollment and a follow-up survey one month after the first session. Both interventions resulted in significant pre/post increases in knowledge, perceived benefits of screening, and decreases in perceived barriers to screening. Among women, the spiritually based intervention resulted in significantly greater increases in perceived benefits of screening relative to the nonspiritual comparison. This finding was marginal in the sample as a whole. In addition, perceived benefits to screening were associated with behavioral intention for screening. It is concluded that in this population, the spiritually based was generally as effective as the nonspiritual (secular) communication. AD - C.L. Holt, Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, Maryland 20742, USA. AU - Holt, C. L. AU - Scarinci, I. C. AU - Debnam, K. AU - McDavid, C. AU - Litaker, M. AU - McNeal, S. F. AU - Southward, V. AU - Lee, C. AU - Eloubeidi, M. AU - Crowther, M. AU - Bolland, J. AU - Martin, M. Y. DB - Medline IS - 9 KW - African American aged article attitude to health clinical trial colorectal tumor controlled clinical trial controlled study education ethnology female follow up health care quality health education human male methodology middle aged psychological aspect randomized controlled trial religion urban population LA - English M3 - Article N1 - L366361412 2013-01-14 PY - 2012 SN - 1087-0415 SP - 1028-1049 ST - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial T2 - Journal of health communication TI - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L366361412&from=export VL - 17 ID - 1103 ER - TY - JOUR AB - Colorectal cancer screening, while effective for reducing mortality, remains underutilized particularly among underserved populations such as African Americans. The present study evaluated a spiritually based approach to increasing Health Belief Model–based pre-screening outcomes in a Community Health Advisor–led intervention conducted in African American churches. Sixteen urban churches were randomized to receive either the spiritually based intervention or a nonspiritual comparison of the same structure and core colorectal cancer content. Trained Community Health Advisors led a series of two educational sessions on colorectal cancer early detection. The educational sessions were delivered over a 1-month period. Participants (N = 316) completed a baseline survey at enrollment and a follow-up survey one month after the first session. Both interventions resulted in significant pre/post increases in knowledge, perceived benefits of screening, and decreases in perceived barriers to screening. Among women, the spiritually based intervention resulted in significantly greater increases in perceived benefits of screening relative to the nonspiritual comparison. This finding was marginal in the sample as a whole. In addition, perceived benefits to screening were associated with behavioral intention for screening. It is concluded that in this population, the spiritually based was generally as effective as the nonspiritual (secular) communication. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Holt, Cheryl L., University of Maryland at College Park, School of Public Health, Department of Behavioral and Community Health, 2369 SPH Building, College Park, MD, US, 20742 AN - 2012-28227-004 AU - Holt, Cheryl L. AU - Scarinci, Isabel C. AU - Debnam, Katrina AU - McDavid, Chastity AU - Litaker, Mark AU - McNeal, Sandre F. AU - Southward, Vivian AU - Lee, Crystal AU - Eloubeidi, Mohamad AU - Crowther, Martha AU - Bolland, John AU - Martin, Michelle Y. DB - psyh DO - 10.1080/10810730.2012.665418 DP - EBSCOhost IS - 9 KW - randomized trial spirituality based intervention cancer awareness African Americans Aged Colorectal Neoplasms Female Follow-Up Studies Health Education Health Knowledge, Attitudes, Practice Humans Male Middle Aged Program Evaluation Spirituality Urban Population Cancer Screening Health Promotion Religious Practices Blacks Clinical Trials N1 - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, US. Release Date: 20130114. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Health Promotion; Religious Practices; Spirituality. Minor Descriptor: Blacks; Clinical Trials. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 22. Issue Publication Date: Oct, 2012. Copyright Statement: Taylor & Francis Group, LLC Sponsor: Centers for Disease Control and Prevention, US. Grant: 5U48DP00046-03. Recipients: No recipient indicated Sponsor: Sponsor name not included. Grant: X051004002. Recipients: No recipient indicated PY - 2012 SN - 1081-0730 1087-0415 SP - 1028-1049 ST - Spiritually based intervention to increase colorectal cancer awareness among African Americans: Intermediate outcomes from a randomized trial T2 - Journal of Health Communication TI - Spiritually based intervention to increase colorectal cancer awareness among African Americans: Intermediate outcomes from a randomized trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2012-28227-004&site=ehost-live&scope=site cholt14@umd.edu VL - 17 ID - 1728 ER - TY - JOUR AB - Colorectal cancer screening, while effective for reducing mortality, remains under-utilized particularly among underserved populations such as African Americans. The present study evaluated a spiritually based approach to increasing Health Belief Model-based pre-screening outcomes in a Community Health Advisor-led intervention conducted in African American churches. Sixteen urban churches were randomized to receive either the spiritually based intervention or a nonspiritual comparison of the same structure and core colorectal cancer content. Trained Community Health Advisors led a series of two educational sessions on colorectal cancer early detection. The educational sessions were delivered over a 1-month period. Participants (N = 316) completed a baseline survey at enrollment and a follow-up survey one month after the first session. Both interventions resulted in significant pre/post increases in knowledge, perceived benefits of screening, and decreases in perceived barriers to screening. Among women, the spiritually based intervention resulted in significantly greater increases in perceived benefits of screening relative to the nonspiritual comparison. This finding was marginal in the sample as a whole. In addition, perceived benefits to screening were associated with behavioral intention for screening. It is concluded that in this population, the spiritually based was generally as effective as the nonspiritual (secular) communication. AN - WOS:000310591000004 AU - Holt, C. L. AU - Scarinci, I. C. AU - Debnam, K. AU - McDavid, C. AU - Litaker, M. AU - McNeal, S. F. AU - Southward, V. AU - Lee, C. AU - Eloubeidi, M. AU - Crowther, M. AU - Bolland, J. AU - Martin, M. Y. DO - 10.1080/10810730.2012.665418 IS - 9 N1 - 22724562 PY - 2012 SN - 1081-0730 SP - 1028-1049 ST - Spiritually Based Intervention to Increase Colorectal Cancer Awareness Among African Americans: Intermediate Outcomes From a Randomized Trial T2 - Journal of Health Communication TI - Spiritually Based Intervention to Increase Colorectal Cancer Awareness Among African Americans: Intermediate Outcomes From a Randomized Trial VL - 17 ID - 3079 ER - TY - JOUR AB - Colorectal cancer screening, while effective for reducing mortality, remains underutilized particularly among underserved populations such as African Americans. The present study evaluated a spiritually based approach to increasing Health Belief Model-based pre-screening outcomes in a Community Health Advisor-led intervention conducted in African American churches. Sixteen urban churches were randomized to receive either the spiritually based intervention or a nonspiritual comparison of the same structure and core colorectal cancer content. Trained Community Health Advisors led a series of two educational sessions on colorectal cancer early detection. The educational sessions were delivered over a 1-month period. Participants (N = 316) completed a baseline survey at enrollment and a follow-up survey one month after the first session. Both interventions resulted in significant pre/post increases in knowledge, perceived benefits of screening, and decreases in perceived barriers to screening. Among women, the spiritually based intervention resulted in significantly greater increases in perceived benefits of screening relative to the nonspiritual comparison. This finding was marginal in the sample as a whole. In addition, perceived benefits to screening were associated with behavioral intention for screening. It is concluded that in this population, the spiritually based was generally as effective as the nonspiritual (secular) communication. AD - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, Maryland 20742, USA AN - 104375056. Language: English. Entry Date: 20130201. Revision Date: 20200708. Publication Type: journal article AU - Holt, C. L. AU - Scarinci, I. C. AU - Debnam, K. AU - McDavid, C. AU - Litaker, M. AU - McNeal, S. F. AU - Southward, V. AU - Lee, C. AU - Eloubeidi, M. AU - Crowther, M. AU - Bolland, J. AU - Martin, M. Y. AU - Holt, Cheryl L. AU - Scarinci, Isabel C. AU - Debnam, Katrina AU - McDavid, Chastity AU - Litaker, Mark AU - McNeal, Sandre F. AU - Southward, Vivian AU - Lee, Crystal DB - CINAHL Complete DO - 10.1080/10810730.2012.665418 DP - EBSCOhost IS - 9 KW - Black Persons -- Education Colorectal Neoplasms -- Ethnology Health Education -- Methods Attitude to Health -- Ethnology Spirituality Black Persons -- Psychosocial Factors Aged Female Prospective Studies Human Male Middle Age Program Evaluation Urban Population Clinical Trials N1 - clinical trial; research. Journal Subset: Biomedical; Europe; Health Promotion/Education; Peer Reviewed; UK & Ireland. Grant Information: 5U48DP00046-03/DP/NCCDPHP CDC HHS/United States. NLM UID: 9604100. PMID: NLM22724562. PY - 2012 SN - 1081-0730 SP - 1028-1049 ST - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial T2 - Journal of Health Communication TI - Spiritually based intervention to increase colorectal cancer awareness among african americans: intermediate outcomes from a randomized trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104375056&site=ehost-live&scope=site VL - 17 ID - 2098 ER - TY - JOUR AB - Introduction: Few lung cancer studies have focused on lung cancer survival in underserved populations. We conducted a prospective cohort study among 81,697 racially diverse and medically underserved adults enrolled in the Southern Community Cohort Study throughout an 11-state area of the Southeast from March 2002 to September 2009. Methods: Using linkages with state cancer registries, we identified 501 incident non-small-cell lung cancer cases. We applied Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for subsequent mortality among black and white participants. Results: The mean observed follow-up time (the time from diagnosis to death or end of follow-up) was 1.25 years (range, 0-8.3 years) and 75% (n = 376) of cases died during follow-up. More blacks were diagnosed at distant stage than whites (57 versus 45%; p = 0.03). In multivariable analyses adjusted for pack-years of smoking, age, body mass index, health insurance, socioeconomic status and disease stage, the lung cancer mortality HR was higher for men versus women (HR = 1.41; 95% CI, 1.09-1.81) but similar for blacks versus whites (HR = 0.99; 95% CI, 0.74-1.32). Conclusion: These findings suggest that although proportionally more blacks present with distant-stage disease there is no difference in stage-adjusted lung cancer mortality between blacks and whites of similar low socioeconomic status. Copyright © 2013 by the International Association for the Study of Lung Cancer. AD - Department of Thoracic Surgery and Medicine, Vanderbilt University Medical Center, 609 Oxford House, 1313 21st Avenue South, Nashville, TN 37232, United States Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States Institute for Medicine and Public Health, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, United States International Epidemiology Institute, Rockville, MD, United States Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States AU - Aldrich, M. C. AU - Grogan, E. L. AU - Munro, H. M. AU - Signorello, L. B. AU - Blot, W. J. DB - Scopus DO - 10.1097/JTO.0b013e3182a406f6 IS - 10 KW - Disparities Lung cancer Race Socioeconomic status Survival M3 - Article N1 - Cited By :11 Export Date: 22 March 2021 PY - 2013 SP - 1248-1254 ST - Stage-adjusted lung cancer survival does not differ between low-income blacks and whites T2 - Journal of Thoracic Oncology TI - Stage-adjusted lung cancer survival does not differ between low-income blacks and whites UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892424116&doi=10.1097%2fJTO.0b013e3182a406f6&partnerID=40&md5=236cc537b2ab757077b1351a56272e82 VL - 8 ID - 2449 ER - TY - JOUR AB - BACKGROUND: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial. METHODS: Subjects for this community-based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study-related certified lymphedema therapist to confirm the presence of lymphedema. RESULTS: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema. CONCLUSIONS: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95-104. © 2017 American Cancer Society. AD - K.H. Schmitz, Department of Public Health Sciences, Pennsylvania State University, Hershey, PA, United States AU - Sturgeon, K. M. AU - Hackley, R. AU - Fornash, A. AU - Dean, L. T. AU - Laudermilk, M. AU - Brown, J. C. AU - Sarwer, D. B. AU - DeMichele, A. M. AU - Troxel, A. B. AU - Schmitz, K. H. DB - Embase Medline DO - 10.1002/cncr.30935 IS - 1 KW - telephone adult aged article breast cancer cancer patient cancer survivor cohort analysis community controlled study ethnicity exercise female hospital human Internet lifestyle modification lymphedema major clinical study middle aged obesity patient education Pennsylvania physiotherapist priority journal questionnaire randomization randomized controlled trial register research subject screening test body weight loss LA - English M3 - Article N1 - L618271655 2017-09-19 2017-12-28 PY - 2018 SN - 1097-0142 0008-543X SP - 95-104 ST - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema T2 - Cancer TI - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema UR - https://www.embase.com/search/results?subaction=viewrecord&id=L618271655&from=export http://dx.doi.org/10.1002/cncr.30935 VL - 124 ID - 916 ER - TY - JOUR AB - BACKGROUND: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial. METHODS: Subjects for this community‐based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study‐related certified lymphedema therapist to confirm the presence of lymphedema. RESULTS: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema. CONCLUSIONS: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95‐104. © 2017 American Cancer Society. AN - CN-01417493 AU - Sturgeon, K. M. AU - Hackley, R. AU - Fornash, A. AU - Dean, L. T. AU - Laudermilk, M. AU - Brown, J. C. AU - Sarwer, D. B. AU - DeMichele, A. M. AU - Troxel, A. B. AU - Schmitz, K. H. DO - 10.1002/cncr.30935 IS - 1 KW - *breast cancer *cancer survivor *lymphedema /complication /diagnosis /therapy *obesity /therapy Adult Aged Article Body weight loss Cancer patient Cohort analysis Community Controlled study Ethnicity Exercise Female Hospital Human Internet Lifestyle modification Major clinical study Middle aged Patient education Pennsylvania Physiotherapist Priority journal Questionnaire Randomization Randomized controlled trial Register Research subject Screening test M3 - Journal: Article PY - 2018 SP - 95‐104 ST - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema T2 - Cancer TI - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01417493/full VL - 124 ID - 1513 ER - TY - JOUR AB - Background: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial.Methods: Subjects for this community-based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study-related certified lymphedema therapist to confirm the presence of lymphedema.Results: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema.Conclusions: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95-104. © 2017 American Cancer Society. AD - Department of Public Health Sciences, Pennsylvania State University, Hershey, Pennsylvania Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland EXOS, Phoenix, Arizona Division of Population Sciences, Dana‐Farber Cancer Institute, Boston, Massachusetts College of Public Health, Temple University, Philadelphia, Pennsylvania Department of Population Health, New York University, New York City, New York AN - 126850044. Language: English. Entry Date: 20171231. Revision Date: 20190110. Publication Type: journal article. Journal Subset: Biomedical AU - Sturgeon, Kathleen M. AU - Hackley, Renata AU - Fornash, Anna AU - Dean, Lorraine T. AU - Laudermilk, Monica AU - Brown, Justin C. AU - Sarwer, David B. AU - DeMichele, Angela M. AU - Troxel, Andrea B. AU - Schmitz, Kathryn H. DB - CINAHL Complete DO - 10.1002/cncr.30935 DP - EBSCOhost IS - 1 KW - White Persons Patient Selection Breast Neoplasms Therapeutic Exercise Black Persons Obesity -- Therapy Weight Reduction Programs Weight Loss Minority Groups Female Ethnic Groups Obesity -- Complications Clinical Trials Aged Middle Age Exercise of Self-Care Agency Scale Scales N1 - Peer Reviewed; USA. Instrumentation: Exercise of Self-Care Agency Scale (ESCA) (Kearney and Fleischer); Clinical Decision Making in Nursing Scale (CDMNS) (Jenkins); Philadelphia Geriatric Center Morale Scale (PGCMS). Grant Information: K01 CA184288/CA/NCI NIH HHS/United States. NLM UID: 0374236. PMID: NLM28881471. PY - 2018 SN - 0008-543X SP - 95-104 ST - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema T2 - Cancer (0008543X) TI - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126850044&site=ehost-live&scope=site VL - 124 ID - 2099 ER - TY - JOUR AB - BACKGROUND: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial. METHODS: Subjects for this community-based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study-related certified lymphedema therapist to confirm the presence of lymphedema. RESULTS: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema. CONCLUSIONS: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95-104. © 2017 American Cancer Society. © 2017 American Cancer Society AD - Department of Public Health Sciences, Pennsylvania State University, Hershey, PA, United States Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, United States Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States EXOS, Phoenix, AZ, United States Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, United States College of Public Health, Temple University, Philadelphia, PA, United States Department of Population Health, New York University, New York City, NY, United States AU - Sturgeon, K. M. AU - Hackley, R. AU - Fornash, A. AU - Dean, L. T. AU - Laudermilk, M. AU - Brown, J. C. AU - Sarwer, D. B. AU - DeMichele, A. M. AU - Troxel, A. B. AU - Schmitz, K. H. DB - Scopus DO - 10.1002/cncr.30935 IS - 1 KW - African American body weight breast cancer lymphedema exercise patient recruitment patient selection M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2018 SP - 95-104 ST - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema T2 - Cancer TI - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029234325&doi=10.1002%2fcncr.30935&partnerID=40&md5=b730efbf6b8bd83badc7da27e821f4d3 VL - 124 ID - 2288 ER - TY - JOUR AB - BACKGROUND: Black women are more likely to experience adverse effects from cancer treatment such as lymphedema. Thus, black women may particularly benefit from research regarding interventions to improve lymphedema. Herein, the authors report the challenges and strategies related to the recruitment of minority survivors of breast cancer and to the recruitment of survivors of breast cancer with lymphedema into the Women In Steady Exercise Research (WISER) Survivor Clinical Trial. METHODS: Subjects for this community-based trial were recruited from the Philadelphia area through active (mailings) and passive (printed materials and Web site) recruitment strategies. In addition, education sessions coordinated through partner hospitals in communities with a predominantly minority population were conducted to increase awareness of lymphedema in survivors of breast cancer. Women who were interested in the study were screened for lymphedema via telephone questionnaire and invited to see a study-related certified lymphedema therapist to confirm the presence of lymphedema. RESULTS: Screening was conducted among 2295 women: 628 were eligible, 450 consented, and 351 were randomized. Minority women comprised 38% of the study population. Letters to women on state and hospital registries resulted in a 0.4% randomization rate; education sessions yielded a 10% randomization rate. The authors observed that approximately 23.6% of the study sample had no previous diagnosis of lymphedema. CONCLUSIONS: The WISER Survivor Clinical Trial faced multiple recruitment challenges and used unique strategies to successfully enroll minority survivors of breast cancer into a lifestyle intervention. Cancer 2018;124:95-104. (c) 2017 American Cancer Society. AN - WOS:000418251600012 AU - Sturgeon, K. M. AU - Hackley, R. AU - Fornash, A. AU - Dean, L. T. AU - Laudermilk, M. AU - Brown, J. C. AU - Sarwer, D. B. AU - DeMichele, A. M. AU - Troxel, A. B. AU - Schmitz, K. H. DA - Jan DO - 10.1002/cncr.30935 IS - 1 N1 - 28881471 PY - 2018 SN - 0008-543X SP - 95-104 ST - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema T2 - Cancer TI - Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema VL - 124 ID - 2877 ER - TY - JOUR AB - The enrollment of ethnically diverse populations in genetic and genomic research is vital to the parity of benefits resulting from research with biological specimens. Herein, we discuss strategies that may effectively improve the recruitment of African Americans into genetics studies. Specifically, we show that engaging physicians, genetic counselors, and community members is essential to enrolling participants into genetic studies. We demonstrate the impact of utilizing African American genetic counselors on study enrollment rates and implementing a two-page consent form that improved on a lengthy and inefficient consenting process. Lastly, we provided participants with the option of donating saliva instead of blood for study purposes. Descriptive statistics were used. Using the aforementioned strategies, recruitment goals for the Genetic Basis of Breast Cancer Subtype Study at Howard University (HU) were met. Our overall results yielded 182 participants in 18 months. Recruitment strategies that involve the engagement of physicians, genetic counselors, and community members may help researchers increase the enrollment of ethnically diverse and hard-to-reach participants into genetic studies. AU - Ewing, A. AU - Thompson, N. AU - Ricks-Santi, L. DB - Medline DO - 10.1007/s13187-014-0669-z IS - 1 KW - African American attitude to health breast tumor female genetics human medical research organization and management patient compliance patient participation patient selection LA - English M3 - Article N1 - L615281195 2017-07-03 PY - 2015 SN - 1543-0154 SP - 108-115 ST - Strategies for enrollment of African Americans into cancer genetic studies T2 - Journal of cancer education : the official journal of the American Association for Cancer Education TI - Strategies for enrollment of African Americans into cancer genetic studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615281195&from=export http://dx.doi.org/10.1007/s13187-014-0669-z VL - 30 ID - 1008 ER - TY - JOUR AB - The enrollment of ethnically diverse populations in genetic and genomic research is vital to the parity of benefits resulting from research with biological specimens. Herein, we discuss strategies that may effectively improve the recruitment of African Americans into genetics studies. Specifically, we show that engaging physicians, genetic counselors, and community members is essential to enrolling participants into genetic studies. We demonstrate the impact of utilizing African American genetic counselors on study enrollment rates and implementing a two-page consent form that improved on a lengthy and inefficient consenting process. Lastly, we provided participants with the option of donating saliva instead of blood for study purposes. Descriptive statistics were used. Using the aforementioned strategies, recruitment goals for the Genetic Basis of Breast Cancer Subtype Study at Howard University (HU) were met. Our overall results yielded 182 participants in 18 months. Recruitment strategies that involve the engagement of physicians, genetic counselors, and community members may help researchers increase the enrollment of ethnically diverse and hard-to-reach participants into genetic studies. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Ewing, Altovise, Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, 624 N. Broadway St., Room 904, Baltimore, MD, US, 21205 AN - 2016-24275-017 AU - Ewing, Altovise AU - Thompson, Nicole AU - Ricks-Santi, Luisel DB - psyh DO - 10.1007/s13187-014-0669-z DP - EBSCOhost IS - 1 KW - African Americans Genetic counseling Cancer genetic research Research strategies Biomedical Research Breast Neoplasms Female Genetic Research Health Knowledge, Attitudes, Practice Humans Patient Compliance Patient Participation Patient Selection Blacks Counseling Genetics Neoplasms Experimentation N1 - Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, US. Other Publishers: Lawrence Erlbaum; Taylor & Francis. Release Date: 20160822. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Counseling; Genetics; Neoplasms. Minor Descriptor: Experimentation. Classification: Cancer (3293). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 8. Issue Publication Date: Mar, 2015. Publication History: First Posted Date: Jun 3, 2014. Copyright Statement: Springer Science+Business Media New York. 2014. PY - 2015 SN - 0885-8195 1543-0154 SP - 108-115 ST - Strategies for enrollment of African Americans into cancer genetic studies T2 - Journal of Cancer Education TI - Strategies for enrollment of African Americans into cancer genetic studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2016-24275-017&site=ehost-live&scope=site Luisel.RicksSanti@Hamptonu.edu NThompson@huhosp.org altovisee@gmail.com VL - 30 ID - 1696 ER - TY - JOUR AB - The enrollment of ethnically diverse populations in genetic and genomic research is vital to the parity of benefits resulting from research with biological specimens. Herein, we discuss strategies that may effectively improve the recruitment of African Americans into genetics studies. Specifically, we show that engaging physicians, genetic counselors, and community members is essential to enrolling participants into genetic studies. We demonstrate the impact of utilizing African American genetic counselors on study enrollment rates and implementing a two-page consent form that improved on a lengthy and inefficient consenting process. Lastly, we provided participants with the option of donating saliva instead of blood for study purposes. Descriptive statistics were used. Using the aforementioned strategies, recruitment goals for the Genetic Basis of Breast Cancer Subtype Study at Howard University (HU) were met. Our overall results yielded 182 participants in 18 months. Recruitment strategies that involve the engagement of physicians, genetic counselors, and community members may help researchers increase the enrollment of ethnically diverse and hard-to-reach participants into genetic studies. © 2014, Springer Science+Business Media New York. AD - Department of Health, Behavior and Society, The Johns Hopkins University Bloomberg School of Public Health, 624 N. Broadway St., Room 904, Baltimore, MD 21205, United States Cancer Genetics Program, Howard University Cancer Center, Howard University Hospital, 2041 Georgia Avenue, NW #219, Washington, DC 20060, United States Cancer Research Center, Hampton University, 39 Tyler Street, Hampton, VA 23668, United States AU - Ewing, A. AU - Thompson, N. AU - Ricks-Santi, L. DB - Scopus DO - 10.1007/s13187-014-0669-z IS - 1 KW - African Americans Cancer genetic research Genetic counseling Research strategies M3 - Article N1 - Cited By :8 Export Date: 22 March 2021 PY - 2015 SP - 108-115 ST - Strategies for Enrollment of African Americans into Cancer Genetic Studies T2 - Journal of Cancer Education TI - Strategies for Enrollment of African Americans into Cancer Genetic Studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939872689&doi=10.1007%2fs13187-014-0669-z&partnerID=40&md5=04ff2bb994cedcdbb83861364caeab18 VL - 30 ID - 2368 ER - TY - JOUR AB - The enrollment of ethnically diverse populations in genetic and genomic research is vital to the parity of benefits resulting from research with biological specimens. Herein, we discuss strategies that may effectively improve the recruitment of African Americans into genetics studies. Specifically, we show that engaging physicians, genetic counselors, and community members is essential to enrolling participants into genetic studies. We demonstrate the impact of utilizing African American genetic counselors on study enrollment rates and implementing a two-page consent form that improved on a lengthy and inefficient consenting process. Lastly, we provided participants with the option of donating saliva instead of blood for study purposes. Descriptive statistics were used. Using the aforementioned strategies, recruitment goals for the Genetic Basis of Breast Cancer Subtype Study at Howard University (HU) were met. Our overall results yielded 182 participants in 18 months. Recruitment strategies that involve the engagement of physicians, genetic counselors, and community members may help researchers increase the enrollment of ethnically diverse and hard-to-reach participants into genetic studies. AN - WOS:000349759300017 AU - Ewing, A. AU - Thompson, N. AU - Ricks-Santi, L. DA - Mar DO - 10.1007/s13187-014-0669-z IS - 1 N1 - 24882437 PY - 2015 SN - 0885-8195 SP - 108-115 ST - Strategies for Enrollment of African Americans into Cancer Genetic Studies T2 - Journal of Cancer Education TI - Strategies for Enrollment of African Americans into Cancer Genetic Studies VL - 30 ID - 2984 ER - TY - JOUR AB - Background: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. Objectives: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. Methods: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. Results: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. Discussion: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Jones, Randy A., School of Nursing, University of Virginia, PO Box 800782, Charlottesville, VA, US, 22908-0782 AN - 2009-22896-007 AU - Jones, Randy A. AU - Sleeves, Richard AU - Williams, Ishan DB - psyh DO - 10.1097/NNR.0b013e3181b4bade DP - EBSCOhost IS - 6 KW - African American men recruiting strategies prostate cancer screening Adult African Americans Aged Decision Making Humans Male Middle Aged Patient Selection Prostatic Neoplasms Virginia Blacks Cancer Screening Human Males Strategies N1 - School of Nursing, University of Virginia, Charlottesville, VA, US. Release Date: 20100503. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Human Males. Minor Descriptor: Strategies. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360). Methodology: Empirical Study; Qualitative Study. References Available: Y. Page Count: 5. Issue Publication Date: Nov-Dec, 2009. Publication History: Accepted Date: Jun 23, 2009. Sponsor: National Institutes of Health, National Institute of Nursing Research, US. Grant: P-20. Recipients: No recipient indicated Sponsor: University of Virginia, School of Nursing, Rural Health Care Research Center, US. Recipients: No recipient indicated PY - 2009 SN - 0029-6562 1538-9847 SP - 452-456 ST - Strategies for recruiting African American men into prostate cancer screening studies T2 - Nursing Research TI - Strategies for recruiting African American men into prostate cancer screening studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2009-22896-007&site=ehost-live&scope=site raj9c@virginia.edu VL - 58 ID - 1756 ER - TY - JOUR AB - Background: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. Objectives: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. Methods: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. Results: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. Discussion: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail.Copyright © 2009 Lippincott Williams & Wilkins. AD - R. A. Jones, School of Nursing, University of Virginia, PO Box 800782, Charlottesville, VA 22908-0782, United States AU - Jones, R. A. AU - Steeves, R. AU - Williams, I. DB - Medline DO - 10.1097/NNR.0b013e3181b4bade IS - 6 KW - adult African American aged article decision making human male middle aged patient selection prostate tumor psychological aspect United States LA - English M3 - Article N1 - L358061385 2009-11-01 PY - 2009 SN - 0029-6562 SP - 452-456 ST - Strategies for recruiting African American men into prostate cancer screening studies T2 - Nursing Research TI - Strategies for recruiting African American men into prostate cancer screening studies UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358061385&from=export http://dx.doi.org/10.1097/NNR.0b013e3181b4bade VL - 58 ID - 1176 ER - TY - JOUR AB - BACKGROUND: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. OBJECTIVES: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. METHODS: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. RESULTS: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. DISCUSSION: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail. AD - School of Nursing, University of Virginia, PO Box 800782, Charlottesville, VA 22908-0782; raj9c@virginia.edu AN - 105253854. Language: English. Entry Date: 20100115. Revision Date: 20150818. Publication Type: Journal Article AU - Jones, R. A. AU - Steeves, R. AU - Williams, I. DB - CINAHL Complete DO - 10.1097/NNR.0b013e3181b4bade DP - EBSCOhost IS - 6 KW - Black Persons -- Virginia Cancer Screening Decision Making Prostatic Neoplasms -- Prevention and Control Research Subject Recruitment -- Methods Adult Aged Convenience Sample Descriptive Statistics Funding Source Interpersonal Relations Interviews Male Middle Age Phenomenological Research Public Spaces Rural Areas -- Virginia Trust Virginia N1 - research; tables/charts. Journal Subset: Core Nursing; Double Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Nursing; Peer Reviewed; USA. Grant Information: P-20 grant awarded by NIH/National Institute of Nursing Research and by additional funds from the Rural Health Care Research Center at the University of Virginia School of Nursing.. NLM UID: 0376404. PMID: NLM19918156. PY - 2009 SN - 0029-6562 SP - 452-456 ST - Strategies for recruiting African American men into prostate cancer screening studies T2 - Nursing Research TI - Strategies for recruiting African American men into prostate cancer screening studies UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105253854&site=ehost-live&scope=site VL - 58 ID - 2100 ER - TY - JOUR AB - Background: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. Objectives: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. Methods: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. Results: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. Discussion: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail.Copyright © 2009 Lippincott Williams & Wilkins. AD - School of Nursing, University of Virginia, Charlottesville, United States AU - Jones, R. A. AU - Steeves, R. AU - Williams, I. DB - Scopus DO - 10.1097/NNR.0b013e3181b4bade IS - 6 KW - African American Health disparities Minority recruitment Prostate cancer M3 - Article N1 - Cited By :38 Export Date: 22 March 2021 PY - 2009 SP - 452-456 ST - Strategies for recruiting African American men into prostate cancer screening studies T2 - Nursing Research TI - Strategies for recruiting African American men into prostate cancer screening studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-73549106799&doi=10.1097%2fNNR.0b013e3181b4bade&partnerID=40&md5=9fab4195feec9602a50e507b631b170a VL - 58 ID - 2509 ER - TY - JOUR AB - Background: Recruitment for research and clinical trials continues to be challenging. Prostate cancer is the most commonly diagnosed cancer in men and disproportionately affects African American men; thus, effective recruitment strategies are essential for this population. Objectives: The aim of this study was to focus on innovative and effective recruitment strategies for research on prostate cancer with minorities. Methods: A systematic description is provided of the recruitment efforts for a hermeneutic phenomenological qualitative study of African American men's experiences in decision making on whether to have a prostate cancer screening. Results: Seventeen African American men were enrolled from rural Central Virginia. Recruiting strategies were targeted on places where African American men usually are found but that are rarely used for recruitment: barbershops, community health centers, and churches. Word of mouth was also used, and most of the participants (n = 11) were reached through this method. Discussion: Recruitment efforts have been noted to be particularly challenging among minorities, for numerous reasons. Making minority recruitment a priority in any research or clinical trial is essential in gaining a representative sample. Word of mouth is a powerful tool that is often forgotten but should be looked at in further detail. AN - WOS:000272516900010 AU - Jones, R. A. AU - Steeves, R. AU - Williams, I. DA - Nov-Dec DO - 10.1097/NNR.0b013e3181b4bade IS - 6 N1 - 19918156 PY - 2009 SN - 0029-6562 SP - 452-456 ST - Strategies for Recruiting African American Men Into Prostate Cancer Screening Studies T2 - Nursing Research TI - Strategies for Recruiting African American Men Into Prostate Cancer Screening Studies VL - 58 ID - 3136 ER - TY - JOUR AB - Background: Although African American women have an overall lower incidence of breast cancer, African American women <40 years of age are more likely than Caucasian women of all ages and postmenopausal African American women to be diagnosed with breast cancer and exhibit tumor characteristics associated with poorer survival. To begin to address this disparity, studies must be conducted to examine breast cancer preventive factors in this subpopulation of women. However, the strategies needed to recruit younger African American women have not been well defined. Methods: In this study, we assessed methods used for recruiting and retaining healthy premenopausal African American women into the African American Nutrition for Life (A NULIFE) Study. The number of women contacted, enrolled, and retained by each recruitment strategy and the efficiency of individual strategies were calculated. Results: Overall, recruitment through social networking was most effective in contacting large numbers of healthy premenopausal African American women. The worksite recruitment method was the most efficient recruitment strategy employed, with a ratio of 40%. The study participants (n=164) were more likely to be ≥35 years of age and have completed some college. Additionally, the interpersonal relationships recruitment approach proved most efficient (33%) in retaining participants who completed the yearlong study. Conclusions: The findings from this study add to the evolving research literature on minority recruitment strategies for research studies but specifically address effective recruitment of healthy young premenopausal African American women. The results demonstrate the need to use multiple recruitment strategies when recruiting this subgroup of African American women. © 2010, Mary Ann Liebert, Inc. AD - D. W. King, M.D. Anderson Cancer Center, Center for Research on Minority Health, Unit 639, PO Box 301402, Houston, TX 77230, United States AU - King, D. W. AU - Duello, T. M. AU - Miranda, P. Y. AU - Hodges, K. P. AU - Shelton, A. J. AU - Chukelu, P. AU - Jones, L. A. DB - Embase Medline DO - 10.1089/jwh.2009.1682 IS - 5 KW - adult African American age distribution article cancer research controlled study educational status female high risk population human minority group patient participation premenopause priority journal research subject social network women's health LA - English M3 - Article N1 - L358831459 2010-05-26 2010-06-04 PY - 2010 SN - 1540-9996 SP - 855-862 ST - Strategies for recruitment of healthy premenopausal women into the African American nutrition for life (A NULIFE) study T2 - Journal of Women's Health TI - Strategies for recruitment of healthy premenopausal women into the African American nutrition for life (A NULIFE) study UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358831459&from=export http://dx.doi.org/10.1089/jwh.2009.1682 VL - 19 ID - 1165 ER - TY - JOUR AB - Background: Although African American women have an overall lower incidence of breast cancer, African American women <40 years of age are more likely than Caucasian women of all ages and postmenopausal African American women to be diagnosed with breast cancer and exhibit tumor characteristics associated with poorer survival. To begin to address this disparity, studies must be conducted to examine breast cancer preventive factors in this subpopulation of women. However, the strategies needed to recruit younger African American women have not been well defined. Methods: In this study, we assessed methods used for recruiting and retaining healthy premenopausal African American women into the African American Nutrition for Life (A NULIFE) Study. The number of women contacted, enrolled, and retained by each recruitment strategy and the efficiency of individual strategies were calculated. Results: Overall, recruitment through social networking was most effective in contacting large numbers of healthy premenopausal African American women. The worksite recruitment method was the most efficient recruitment strategy employed, with a ratio of 40%. The study participants ( n = 164) were more likely to be >=35 years of age and have completed some college. Additionally, the interpersonal relationships recruitment approach proved most efficient (33%) in retaining participants who completed the yearlong study. Conclusions: The findings from this study add to the evolving research literature on minority recruitment strategies for research studies but specifically address effective recruitment of healthy young premenopausal African American women. The results demonstrate the need to use multiple recruitment strategies when recruiting this subgroup of African American women. AD - University of Texas, M.D. Anderson Cancer Center, Center for Research on Minority Health, Houston, Texas. AN - 105203075. Language: English. Entry Date: 20100702. Revision Date: 20200708. Publication Type: Journal Article AU - King, D. W. AU - Duello, T. M. AU - Miranda, P. Y. AU - Hodges, K. P. AU - Shelton, A. J. AU - Chukelu, P. AU - Jones, L. A. DB - CINAHL Complete DO - 10.1089/jwh.2009.1682 DP - EBSCOhost IS - 5 KW - Black Persons Nutrition Premenopause Research Subject Recruitment -- Methods Adult Breast Neoplasms -- Prevention and Control Descriptive Statistics Diabetes Mellitus -- Prevention and Control Funding Source Human Interpersonal Relations Organizational Efficiency Paired T-Tests Research Subject Retention -- Methods Social Networks Work Environment N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: American Cancer Society (TURSG-01-247-01-PBP); National Center on Minority Health and Health Disparities (5P60MD00503); and Kellogg Health Scholars Program (P0117943). NLM UID: 101159262. PMID: NLM20392156. PY - 2010 SN - 1540-9996 SP - 855-862 ST - Strategies for recruitment of healthy premenopausal women into the African American Nutrition for Life (A NULIFE) Study T2 - Journal of Women's Health (15409996) TI - Strategies for recruitment of healthy premenopausal women into the African American Nutrition for Life (A NULIFE) Study UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105203075&site=ehost-live&scope=site VL - 19 ID - 2101 ER - TY - JOUR AB - Background: Although African American women have an overall lower incidence of breast cancer, African American women <40 years of age are more likely than Caucasian women of all ages and postmenopausal African American women to be diagnosed with breast cancer and exhibit tumor characteristics associated with poorer survival. To begin to address this disparity, studies must be conducted to examine breast cancer preventive factors in this subpopulation of women. However, the strategies needed to recruit younger African American women have not been well defined. Methods: In this study, we assessed methods used for recruiting and retaining healthy premenopausal African American women into the African American Nutrition for Life (A NULIFE) Study. The number of women contacted, enrolled, and retained by each recruitment strategy and the efficiency of individual strategies were calculated. Results: Overall, recruitment through social networking was most effective in contacting large numbers of healthy premenopausal African American women. The worksite recruitment method was the most efficient recruitment strategy employed, with a ratio of 40%. The study participants (n=164) were more likely to be ≥35 years of age and have completed some college. Additionally, the interpersonal relationships recruitment approach proved most efficient (33%) in retaining participants who completed the yearlong study. Conclusions: The findings from this study add to the evolving research literature on minority recruitment strategies for research studies but specifically address effective recruitment of healthy young premenopausal African American women. The results demonstrate the need to use multiple recruitment strategies when recruiting this subgroup of African American women. © 2010, Mary Ann Liebert, Inc. AD - University of Texas, M.D. Anderson Cancer Center, Center for Research on Minority Health, Houston, TX, United States Department of Obstetrics and Gynecology, University of Wisconsin-Madison, WI, United States Department of Health Sciences, Texas Southern University, Houston, TX, United States AU - King, D. W. AU - Duello, T. M. AU - Miranda, P. Y. AU - Hodges, K. P. AU - Shelton, A. J. AU - Chukelu, P. AU - Jones, L. A. DB - Scopus DO - 10.1089/jwh.2009.1682 IS - 5 M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2010 SP - 855-862 ST - Strategies for recruitment of healthy premenopausal women into the African American nutrition for life (A NULIFE) study T2 - Journal of Women's Health TI - Strategies for recruitment of healthy premenopausal women into the African American nutrition for life (A NULIFE) study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952346347&doi=10.1089%2fjwh.2009.1682&partnerID=40&md5=8adda4d11ee27a86a9d9417058c927f0 VL - 19 ID - 2499 ER - TY - JOUR AB - Background: Although African American women have an overall lower incidence of breast cancer, African American women <40 years of age are more likely than Caucasian women of all ages and postmenopausal African American women to be diagnosed with breast cancer and exhibit tumor characteristics associated with poorer survival. To begin to address this disparity, studies must be conducted to examine breast cancer preventive factors in this subpopulation of women. However, the strategies needed to recruit younger African American women have not been well defined. Methods: In this study, we assessed methods used for recruiting and retaining healthy premenopausal African American women into the African American Nutrition for Life (A NULIFE) Study. The number of women contacted, enrolled, and retained by each recruitment strategy and the efficiency of individual strategies were calculated. Results: Overall, recruitment through social networking was most effective in contacting large numbers of healthy premenopausal African American women. The worksite recruitment method was the most efficient recruitment strategy employed, with a ratio of 40%. The study participants (n = 164) were more likely to be >= 35 years of age and have completed some college. Additionally, the interpersonal relationships recruitment approach proved most efficient (33%) in retaining participants who completed the yearlong study. Conclusions: The findings from this study add to the evolving research literature on minority recruitment strategies for research studies but specifically address effective recruitment of healthy young premenopausal African American women. The results demonstrate the need to use multiple recruitment strategies when recruiting this subgroup of African American women. AN - WOS:000277602300005 AU - King, D. W. AU - Duello, T. M. AU - Miranda, P. Y. AU - Hodges, K. P. AU - Shelton, A. J. AU - Chukelu, P. AU - Jones, L. A. DA - May DO - 10.1089/jwh.2009.1682 IS - 5 N1 - 20392156 PY - 2010 SN - 1540-9996 SP - 855-862 ST - Strategies for Recruitment of Healthy Premenopausal Women into the African American Nutrition for Life (A NULIFE) Study T2 - Journal of Womens Health TI - Strategies for Recruitment of Healthy Premenopausal Women into the African American Nutrition for Life (A NULIFE) Study VL - 19 ID - 3114 ER - TY - JOUR AB - Background: Breast cancer survival rates are significantly lower among African-American women compared to white women. In addition, African-American women with breast cancer are more likely than white women to die from co-morbid conditions. Obesity is common among African-American women, and it contributes to breast cancer progression and the development and exacerbation of many weight-related conditions. Intervening upon obesity may decrease breast cancer and all-cause mortality among African-American breast cancer survivors. Methods/Design: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist:hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6-month guided weight loss intervention that involves twice weekly classes and text messaging or a self-guided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African-American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community-based efforts. Data collection occurs at baseline, post-intervention (6 months) and at a 12-month follow-up. Discussion: This study evaluates a community-based, guided lifestyle intervention designed to improve the health of African-American breast cancer survivors. Few studies have addressed behavioral interventions in this high-risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co-morbid conditions, as well as improve quality of life. Trial registration: U.S. Clinicaltrials.gov number: NCT02482506 , April 2015 AD - M.R. Stolley, University of Illinois at Chicago (UIC), Institute for Health Research and Policy, Chicago, IL, United States AU - Stolley, M. R. AU - Sharp, L. K. AU - Fantuzzi, G. AU - Arroyo, C. AU - Sheean, P. AU - Schiffer, L. AU - Campbell, R. AU - Gerber, B. DB - Embase Medline DO - 10.1186/s12885-015-2004-4 IS - 1 KW - NCT02482506 adult African American article body composition body mass breast cancer cancer recurrence cancer registry cancer survivor clinical protocol community sample comorbidity conceptual framework controlled study diet therapy feeding behavior female health behavior health status high risk population human major clinical study metastasis obesity outcome assessment patient guidance physical activity quality of life randomized controlled trial recurrence risk risk reduction self report social psychology social support study design text messaging treatment duration United States waist hip ratio weight loss program LA - English M3 - Article N1 - L607412720 2016-01-14 2016-01-19 PY - 2015 SN - 1471-2407 ST - Study design and protocol for moving forward: A weight loss intervention trial for African-American breast cancer survivors T2 - BMC Cancer TI - Study design and protocol for moving forward: A weight loss intervention trial for African-American breast cancer survivors UR - https://www.embase.com/search/results?subaction=viewrecord&id=L607412720&from=export http://dx.doi.org/10.1186/s12885-015-2004-4 VL - 15 ID - 988 ER - TY - JOUR AB - Background: Breast cancer survival rates are significantly lower among African‐American women compared to white women. In addition, African‐American women with breast cancer are more likely than white women to die from co‐morbid conditions. Obesity is common among African‐American women, and it contributes to breast cancer progression and the development and exacerbation of many weight‐related conditions. Intervening upon obesity may decrease breast cancer and all‐cause mortality among African‐American breast cancer survivors. Methods/Design: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist:hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6‐month guided weight loss intervention that involves twice weekly classes and text messaging or a self‐guided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African‐American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community‐based efforts. Data collection occurs at baseline, post‐intervention (6 months) and at a 12‐month follow‐up. Discussion: This study evaluates a community‐based, guided lifestyle intervention designed to improve the health of African‐American breast cancer survivors. Few studies have addressed behavioral interventions in this high‐risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co‐morbid conditions, as well as improve quality of life. Trial registration: U.S. Clinicaltrials.gov number: NCT02482506 , April 2015 AN - CN-01127705 AU - Stolley, M. R. AU - Sharp, L. K. AU - Fantuzzi, G. AU - Arroyo, C. AU - Sheean, P. AU - Schiffer, L. AU - Campbell, R. AU - Gerber, B. DO - 10.1186/s12885-015-2004-4 IS - 1) (no pagination KW - *breast cancer *cancer survivor *clinical protocol *obesity/th [Therapy] *study design *weight loss program Adult African American Article Body composition Body mass Cancer recurrence Cancer registry Community sample Comorbidity Conceptual framework Controlled study Diet therapy Feeding behavior Female Health behavior Health status High risk population Human Major clinical study Metastasis Outcome assessment Patient guidance Physical activity Quality of life Randomized controlled trial Recurrence risk Risk reduction Self report Social psychology Social support Text messaging Treatment duration United States Waist hip ratio M3 - Journal: Article PY - 2015 ST - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors T2 - BMC cancer TI - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01127705/full VL - 15 ID - 1485 ER - TY - JOUR AB - Background: Breast cancer survival rates are significantly lower among African-American women compared to white women. In addition, African-American women with breast cancer are more likely than white women to die from co-morbid conditions. Obesity is common among African-American women, and it contributes to breast cancer progression and the development and exacerbation of many weight-related conditions. Intervening upon obesity may decrease breast cancer and all-cause mortality among African-American breast cancer survivors.Methods/design: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist:hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6-month guided weight loss intervention that involves twice weekly classes and text messaging or a self-guided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African-American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community-based efforts. Data collection occurs at baseline, post-intervention (6 months) and at a 12-month follow-up.Discussion: This study evaluates a community-based, guided lifestyle intervention designed to improve the health of African-American breast cancer survivors. Few studies have addressed behavioral interventions in this high-risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co-morbid conditions, as well as improve quality of life.Trial Registration: U.S. Clinicaltrials.gov number: NCT02482506, April 2015. AD - Cancer Center and Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226-3548, USA Institute for Health Research and Policy, University of Illinois at Chicago (UIC), Chicago, IL, USA Department of Pharmacy Systems, Outcome & Policy, UIC, College of Pharmacy, Chicago, IL, USA Department of Kinesiology and Nutrition, UIC, College of Applied Health Sciences, Chicago, IL, USA School of Nursing, Loyola University, Maywood, IL, 60153, USA AN - 113857801. Language: English. Entry Date: 20150923. Revision Date: 20180802. Publication Type: journal article AU - Stolley, Melinda R. AU - Sharp, Lisa K. AU - Fantuzzi, Giamila AU - Arroyo, Claudia AU - Sheean, Patricia AU - Schiffer, Linda AU - Campbell, Richard AU - Gerber, Ben DB - CINAHL Complete DO - 10.1186/s12885-015-2004-4 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Mortality Survivors -- Psychosocial Factors Black Persons -- Psychosocial Factors Weight Loss Female Human Breast Neoplasms -- Psychosocial Factors Illinois -- Ethnology Quality of Life Random Assignment Treatment Outcomes Clinical Trials Validation Studies Comparative Studies Evaluation Research Multicenter Studies Funding Source N1 - clinical trial; research. Journal Subset: Biomedical; Europe; UK & Ireland. Special Interest: Evidence-Based Practice. Grant Information: R01CA15440/CA/NCI NIH HHS/United States. NLM UID: 100967800. PMID: NLM26715447. PY - 2015 SN - 1471-2407 SP - 1018-1018 ST - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors T2 - BMC Cancer TI - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=113857801&site=ehost-live&scope=site VL - 15 ID - 2102 ER - TY - JOUR AB - Background: Breast cancer survival rates are significantly lower among African-American women compared to white women. In addition, African-American women with breast cancer are more likely than white women to die from co-morbid conditions. Obesity is common among African-American women, and it contributes to breast cancer progression and the development and exacerbation of many weight-related conditions. Intervening upon obesity may decrease breast cancer and all-cause mortality among African-American breast cancer survivors. Methods/Design: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist:hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6-month guided weight loss intervention that involves twice weekly classes and text messaging or a self-guided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African-American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community-based efforts. Data collection occurs at baseline, post-intervention (6 months) and at a 12-month follow-up. Discussion: This study evaluates a community-based, guided lifestyle intervention designed to improve the health of African-American breast cancer survivors. Few studies have addressed behavioral interventions in this high-risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co-morbid conditions, as well as improve quality of life. Trial registration: U.S. Clinicaltrials.gov number: NCT02482506 , April 2015 © 2015 Stolley et al. AD - Medical College of Wisconsin, Cancer Center and Department of Medicine, 8701 Watertown Plank Road, Milwaukee, WI 53226-3548, United States University of Illinois at Chicago (UIC), Institute for Health Research and Policy, Chicago, IL, United States UIC, College of Pharmacy, Department of Pharmacy Systems, Outcome and Policy, Chicago, IL, United States UIC, College of Applied Health Sciences, Department of Kinesiology and Nutrition, Chicago, IL, United States School of Nursing, Loyola University, Maywood, IL 60153, United States AU - Stolley, M. R. AU - Sharp, L. K. AU - Fantuzzi, G. AU - Arroyo, C. AU - Sheean, P. AU - Schiffer, L. AU - Campbell, R. AU - Gerber, B. C7 - 1018 DB - Scopus DO - 10.1186/s12885-015-2004-4 IS - 1 KW - African-American Breast cancer Survivorship Weight loss M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2015 ST - Study design and protocol for moving forward: A weight loss intervention trial for African-American breast cancer survivors T2 - BMC Cancer TI - Study design and protocol for moving forward: A weight loss intervention trial for African-American breast cancer survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953409025&doi=10.1186%2fs12885-015-2004-4&partnerID=40&md5=5b0fc2aacd0035ab154c5873a8b1500a VL - 15 ID - 2356 ER - TY - JOUR AB - Background: Breast cancer survival rates are significantly lower among African-American women compared to white women. In addition, African-American women with breast cancer are more likely than white women to die from co-morbid conditions. Obesity is common among African-American women, and it contributes to breast cancer progression and the development and exacerbation of many weight-related conditions. Intervening upon obesity may decrease breast cancer and all-cause mortality among African-American breast cancer survivors. Methods/Design: Moving Forward is a weight loss intervention being evaluated in a randomized trial with a projected sample of 240 African American breast cancer survivors. Outcomes include body mass index, body composition, waist: hip ratio, and behavioral, psychosocial and physiological measures. Survivors are randomized to either a 6-month guided weight loss intervention that involves twice weekly classes and text messaging or a selfguided weight loss intervention based on the same materials offered in the guided program. The guided intervention is being conducted in partnership with the Chicago Park District at park facilities in predominantly African-American neighborhoods in Chicago. Recruitment strategies include direct contact to women identified in hospital cancer registries, as well as community-based efforts. Data collection occurs at baseline, post-intervention (6 months) and at a 12-month follow-up. Discussion: This study evaluates a community-based, guided lifestyle intervention designed to improve the health of African-American breast cancer survivors. Few studies have addressed behavioral interventions in this high-risk population. If successful, the intervention may help reduce the risk for breast cancer recurrence, secondary cancers, and co-morbid conditions, as well as improve quality of life. AN - WOS:000367315600001 AU - Stolley, M. R. AU - Sharp, L. K. AU - Fantuzzi, G. AU - Arroyo, C. AU - Sheean, P. AU - Schiffer, L. AU - Campbell, R. AU - Gerber, B. DA - Dec DO - 10.1186/s12885-015-2004-4 N1 - 1018 26715447 PY - 2015 SN - 1471-2407 ST - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors T2 - Bmc Cancer TI - Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors VL - 15 ID - 2959 ER - TY - JOUR AB - In the Breast Cancer Prevention Trial (BCPT, P1) tamoxifen reduced the risk of invasive breast cancer by 49% in women at increased risk. In subset analyses of older postmenopausal women taking raloxifene for the treatment of osteoporosis (MORE trial) breast cancer incidence was reduced by more than 70%. These findings led the National Surgical Adjuvant Breast and Bowel Project (NSABP) to design and launch the Study of Tamoxifen and Raloxifene (STAR trial). Eligible women are at least 35 years of age and postmenopausal, and they must have either lobular carcinoma in situ (LCIS) or a 5-year risk of invasive breast cancer of at least 1.67% as determined by the Gail model. Subjects are randomly assigned to receive either tamoxifen 20 mg or raloxifene 60 mg daily in a double-blind, double dummy design. The trial opened for subject accrual on July 1, 1999. After 22 months of active recruitment at 193 clinical centers in North America through April 30, 2001, risk assessments have been performed in 83,057 women (85.2% white, 8.6% black, 3.4% Hispanic. 2.8% other), and 47,325 (57.0%) were eligible for the trial. Of the eligible subjects. 9,710 have been randomized (20.5% of those eligible). The median age of randomized women is 58 yrs (mean 58), 94.6% are white, and their median 5-yr risk of breast cancer is 3.3% (mean 4.0%). Hysterectomy was reported by 52.1 % of the randomized women; LCIS was reported by 8.5% of subjects prior to randomization. The proportion of randomized subjects with Gail model risk 3.0% by race was white, 27.9%; black, 44.1%; Hispanic, 59.3%. The trial is designed to recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer. Additional endpoints include the incidence of cardiovascular events and bone fractures. Thromboembolic events and endometrial cancer are the predicted toxicities. Serum and lymphocytes are being collected for future studies after appropriate informed consent. Ancillary studies of cognitive function will also be performed. The successful recruitment of nearly 10,000 subjects in less than 2 years demonstrates the willingness of high-risk postmenopausal women to participate in breast cancer chemoprevention clinical trials. AD - The National Surgical Adjuvant Breast and Bowel Project, NSABP Foundation Inc., Pittsburgh, PA, United States AU - Vogel, V. G. AU - Costantino, J. P. AU - Wickerham, D. L. AU - Cronin, W. M. AU - Wolmark, N. DB - Scopus DO - 10.3816/CBC.2002.n.020 IS - 3 M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2001 SP - 225 ST - The study of Tamoxifen and Raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial T2 - Breast Cancer Research and Treatment TI - The study of Tamoxifen and Raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0005468211&doi=10.3816%2fCBC.2002.n.020&partnerID=40&md5=b93cbb3a7c81c107295f2c6b9062cfe0 VL - 69 ID - 2626 ER - TY - JOUR AB - Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Surgical Adjuvant Breast and Bowel Project to design and launch the Study of Tamoxifen and Raloxifene. Risk-eligible women are ≥ 35 years of age and postmenopausal; they have either lobular carcinoma in situ (LCIS) or a 5-year risk of invasive breast cancer of at least 1.67% as determined by the Gail model. Participants are randomly assigned to receive either tamoxifen 20 mg or raloxifene 60 mg daily. The trial opened for accrual on July 1, 1999. After 32 months of recruitment at 194 clinical centers in North America, risk assessments have been performed in 107,855 women (83.8% white, 9.4% black, 3.8% Hispanic, 3.1% other race/ethnic groups). Of the eligible patients, 12,637 have been randomized (20.9% of risk-eligible women); the median age is 58 years (mean, 58 years), and the median 5-year risk of breast cancer is 3.3% (mean, 4.0%). LCIS was reported in 8.4% of women prior to randomization. Gail model risk was ≥ 3.0% in 5 years for 59.3% of white women, 45.0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer. AD - V.G. Vogel, Department of Medicine/Epidemiology, Univ. of Pittsburgh School Medicine, NSABP Foundation Inc., 300 Halket St., Pittsburgh, PA 15213-3180, United States AU - Vogel, V. G. AU - Costantino, J. P. AU - Wickerham, D. L. AU - Cronin, W. M. AU - Wolmark, N. C2 - Astra Zeneca DB - Embase Medline DO - 10.3816/CBC.2002.n.020 IS - 2 KW - placebo raloxifene tamoxifen adult article breast cancer cancer incidence cancer risk Caucasian clinical trial controlled clinical trial controlled study deep vein thrombosis drug efficacy drug safety endometrium cancer ethnic difference ethnic group female histopathology human human tissue invasive carcinoma lung carcinoma lung embolism Black person postmenopause randomized controlled trial risk assessment risk benefit analysis cerebrovascular accident LA - English M3 - Article N1 - L34885059 2002-08-26 PY - 2002 SN - 1526-8209 SP - 153-159 ST - The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial T2 - Clinical Breast Cancer TI - The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L34885059&from=export http://dx.doi.org/10.3816/CBC.2002.n.020 VL - 3 ID - 1303 ER - TY - JOUR AB - Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P‐1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Surgical Adjuvant Breast and Bowel Project to design and launch the Study of Tamoxifen and Raloxifene. Risk‐eligible women are = 35 years of age and postmenopausal; they have either lobular carcinoma in situ (LCIS) or a 5‐year risk of invasive breast cancer of at least 1.67% as determined by the Gail model. Participants are randomly assigned to receive either tamoxifen 20 mg or raloxifene 60 mg daily. The trial opened for accrual on July 1, 1999. After 32 months of recruitment at 194 clinical centers in North America, risk assessments have been performed in 107,855 women (83.8% white, 9.4% black, 3.8% Hispanic, 3.1% other race/ethnic groups). Of the eligible patients, 12,637 have been randomized (20.9% of risk‐eligible women); the median age is 58 years (mean, 58 years), and the median 5‐year risk of breast cancer is 3.3% (mean, 4.0%). LCIS was reported in 8.4% of women prior to randomization. Gail model risk was = 3.0% in 5 years for 59.3% of white women, 45.0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast AN - CN-00390319 AU - Vogel, V. G. AU - Costantino, J. P. AU - Wickerham, D. L. AU - Cronin, W. M. AU - Wolmark, N. DO - 10.3816/CBC.2002.n.020 IS - 2 KW - Adult Aged Anticarcinogenic Agents [adverse effects, *therapeutic use] Breast Neoplasms [*etiology, pathology, *prevention & control] Female Humans Middle Aged Neoplasm Invasiveness [prevention & control] Patient Participation [*statistics & numerical data] Raloxifene Hydrochloride [adverse effects, *therapeutic use] Risk Assessment Risk Factors Selective Estrogen Receptor Modulators [adverse effects, *therapeutic use] Tamoxifen [adverse effects, *therapeutic use] M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non‐U.S. Gov't; Research Support, U.S. Gov't, P.H.S. PY - 2002 SP - 153‐159 ST - The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial T2 - Clinical breast cancer TI - The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00390319/full VL - 3 ID - 1419 ER - TY - JOUR AB - Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Surgical Adjuvant Breast and Bowel Project to design and launch the Study of Tamoxifen and Raloxifene. Risk-eligible women are ≥ 35 years of age and postmenopausal; they have either lobular carcinoma in situ (LCIS) or a 5-year risk of invasive breast cancer of at least 1.67% as determined by the Gail model. Participants are randomly assigned to receive either tamoxifen 20 mg or raloxifene 60 mg daily. The trial opened for accrual on July 1, 1999. After 32 months of recruitment at 194 clinical centers in North America, risk assessments have been performed in 107,855 women (83.8% white, 9.4% black, 3.8% Hispanic, 3.1% other race/ethnic groups). Of the eligible patients, 12,637 have been randomized (20.9% of risk-eligible women); the median age is 58 years (mean, 58 years), and the median 5-year risk of breast cancer is 3.3% (mean, 4.0%). LCIS was reported in 8.4% of women prior to randomization. Gail model risk was ≥ 3.0% in 5 years for 59.3% of white women, 45.0% of black women, and 44.5% of Hispanic women. The trial will recruit a total of 22,000 postmenopausal women and is powered to demonstrate superior efficacy of either agent or their equivalence in reducing the incidence of primary breast cancer. AD - Department of Medicine/Epidemiology, Univ. of Pittsburgh School Medicine, NSABP Foundation Inc., 300 Halket St., Pittsburgh, PA 15213-3180, United States AU - Vogel, V. G. AU - Costantino, J. P. AU - Wickerham, D. L. AU - Cronin, W. M. AU - Wolmark, N. DB - Scopus DO - 10.3816/CBC.2002.n.020 IS - 2 KW - Gail risk scores Lobular carcinoma in situ Raloxifene Risk reduction Tamoxifen M3 - Article N1 - Cited By :71 Export Date: 22 March 2021 PY - 2002 SP - 153-159 ST - The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial T2 - Clinical Breast Cancer TI - The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036347450&doi=10.3816%2fCBC.2002.n.020&partnerID=40&md5=883563e4fa905d87cb82a1a2e341d9bd VL - 3 ID - 2621 ER - TY - JOUR AB - Introduction Colorectal cancer (CRC) is preventable, as screening leads to the identification and removal of precancerous polyps. African-American men consistently have the highest CRC mortality rates, and their CRC-screening uptake remains low for complex reasons. Culture-specific masculinity barriers to care may contribute to the low uptake among African-American men. Examining these barriers to care is vital as CRC screening may challenge cultural role expectations of African-American men, whose tendency is to delay help-seeking medical care. Barbershops provide a pathway for reaching African-American men with masculinity barriers to care who are not regularly receiving healthcare services and CRC screening. This study aims to develop and pilot test a theory-driven, culture-specific, barbershop-based intervention targeting masculinity barriers to care and CRC-screening uptake among African-American men ages 45-75. Methods and analysis Guided by the theory of planned behaviour and the behaviour change wheel, we will use a multistage mixed-methods study design, beginning with an exploratory sequential approach to validate items for subsequent use in a pilot mixed-methods intervention. First, we will collect and analyse qualitative data from focus groups, cognitive interviews and expert item review to validate and test a culture-specific Masculinity Barriers to Care Scale (MBCS) among African-American men. Next, we will administer the MBCS to our target population as an online quantitative survey and evaluate the association between scores and CRC-screening uptake. Then, we will consider existing evidence-based approaches, our integrated results (qualitative +quantitative), and community input to design a culture-specific, behavioural intervention aimed at increasing CRC-screening uptake among African-American men and feasible for barbershop delivery. We will test the peer intervention in a pilot study with a two-Arm cluster randomised design (six barbershops, randomised by site) to reduce contamination and account for barbershop culture differences. Our primary outcomes for the pilot are recruitment, sample size estimation, preliminary efficacy and acceptability. Ethics and dissemination Ethics approval was obtained from the University of Utah Institutional Review Board (00113679), who will also be responsible for receiving communication updates regarding important protocol modifications. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information. Study results will be disseminated through publications in peer-reviewed journals, community dialogue sessions, and presentations at conferences. Trial registration number ClinicalTrials.gov identifier: NCT03733197 (Pre-results);https://clinicaltrials.gov/ct2/show/NCT03733197 AD - C.R. Rogers, Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States AU - Rogers, C. R. AU - Okuyemi, K. AU - Paskett, E. D. AU - Thorpe, R. J. AU - Rogers, T. N. AU - Hung, M. AU - Zickmund, S. AU - Riley, C. AU - Fetters, M. D. DB - Embase Medline DO - 10.1136/bmjopen-2019-030000 IS - 7 KW - NCT03733197 adult African American aged article behavior change behavioral risk factor surveillance system cancer screening cancer survival colorectal cancer human male masculinity masculinity barriers to care scale patient care pilot study qualitative analysis quantitative analysis scoring system Theory of Planned Behavior LA - English M3 - Article N1 - L628694877 2019-08-05 2019-08-07 PY - 2019 SN - 2044-6055 ST - Study protocol for developing #CuttingCRC: A barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design T2 - BMJ Open TI - Study protocol for developing #CuttingCRC: A barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628694877&from=export http://dx.doi.org/10.1136/bmjopen-2019-030000 VL - 9 ID - 845 ER - TY - JOUR AB - Introduction Colorectal cancer (CRC) is preventable, as screening leads to the identification and removal of precancerous polyps. African-American men consistently have the highest CRC mortality rates, and their CRC-screening uptake remains low for complex reasons. Culture-specific masculinity barriers to care may contribute to the low uptake among African-American men. Examining these barriers to care is vital as CRC screening may challenge cultural role expectations of African-American men, whose tendency is to delay help-seeking medical care. Barbershops provide a pathway for reaching African-American men with masculinity barriers to care who are not regularly receiving healthcare services and CRC screening. This study aims to develop and pilot test a theory-driven, culture-specific, barbershop-based intervention targeting masculinity barriers to care and CRC-screening uptake among African-American men ages 45-75. Methods and analysis Guided by the theory of planned behaviour and the behaviour change wheel, we will use a multistage mixed-methods study design, beginning with an exploratory sequential approach to validate items for subsequent use in a pilot mixed-methods intervention. First, we will collect and analyse qualitative data from focus groups, cognitive interviews and expert item review to validate and test a culture-specific Masculinity Barriers to Care Scale (MBCS) among African-American men. Next, we will administer the MBCS to our target population as an online quantitative survey and evaluate the association between scores and CRC-screening uptake. Then, we will consider existing evidence-based approaches, our integrated results (qualitative +quantitative), and community input to design a culture-specific, behavioural intervention aimed at increasing CRC-screening uptake among African-American men and feasible for barbershop delivery. We will test the peer intervention in a pilot study with a two-Arm cluster randomised design (six barbershops, randomised by site) to reduce contamination and account for barbershop culture differences. Our primary outcomes for the pilot are recruitment, sample size estimation, preliminary efficacy and acceptability. Ethics and dissemination Ethics approval was obtained from the University of Utah Institutional Review Board (00113679), who will also be responsible for receiving communication updates regarding important protocol modifications. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information. Study results will be disseminated through publications in peer-reviewed journals, community dialogue sessions, and presentations at conferences. Trial registration number ClinicalTrials.gov identifier: NCT03733197 (Pre-results);https://clinicaltrials.gov/ct2/show/NCT03733197 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. AD - Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States Internal Medicine, College of Medicine, Ohio State University, Columbus, OH, United States Program for Research on Men's Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States Sorenson Impact Center, University of Utah Eccles School of Business, Salt Lake City, Utah, United States College of Dental Medicine, Roseman University of Health Sciences, South Jordan, UT, United States Internal Medicine, University of Utah, Salt Lake City, UT, United States Department of Family Medicine, University of Michigan Medical School, Ann Arbor, MI, United States AU - Rogers, C. R. AU - Okuyemi, K. AU - Paskett, E. D. AU - Thorpe, R. J. AU - Rogers, T. N. AU - Hung, M. AU - Zickmund, S. AU - Riley, C. AU - Fetters, M. D. C7 - e030000 DB - Scopus DO - 10.1136/bmjopen-2019-030000 IS - 7 KW - african-Americans colonic neoplasms community-based participatory research men's health minority health M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2019 ST - Study protocol for developing #CuttingCRC: A barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design T2 - BMJ Open TI - Study protocol for developing #CuttingCRC: A barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069928820&doi=10.1136%2fbmjopen-2019-030000&partnerID=40&md5=4c18b6c5f03e66ac66ce5d58d61d8fd2 VL - 9 ID - 2226 ER - TY - JOUR AB - Introduction Colorectal cancer (CRC) is preventable, as screening leads to the identification and removal of precancerous polyps. African-American men consistently have the highest CRC mortality rates, and their CRC-screening uptake remains low for complex reasons. Culture-specific masculinity barriers to care may contribute to the low uptake among African-American men. Examining these barriers to care is vital as CRC screening may challenge cultural role expectations of African-American men, whose tendency is to delay help-seeking medical care. Barbershops provide a pathway for reaching African-American men with masculinity barriers to care who are not regularly receiving healthcare services and CRC screening. This study aims to develop and pilot test a theory-driven, culture-specific, barbershop-based intervention targeting masculinity barriers to care and CRC-screening uptake among African-American men ages 45-75. Methods and analysis Guided by the theory of planned behaviour and the behaviour change wheel, we will use a multistage mixed-methods study design, beginning with an exploratory sequential approach to validate items for subsequent use in a pilot mixed-methods intervention. First, we will collect and analyse qualitative data from focus groups, cognitive interviews and expert item review to validate and test a culture-specific Masculinity Barriers to Care Scale (MBCS) among African-American men. Next, we will administer the MBCS to our target population as an online quantitative survey and evaluate the association between scores and CRC-screening uptake. Then, we will consider existing evidence-based approaches, our integrated results (qualitative + quantitative), and community input to design a culture-specific, behavioural intervention aimed at increasing CRC-screening uptake among African-American men and feasible for barbershop delivery. We will test the peer intervention in a pilot study with a two-arm cluster randomised design (six barbershops, randomised by site) to reduce contamination and account for barbershop culture differences. Our primary outcomes for the pilot are recruitment, sample size estimation, preliminary efficacy and acceptability. Ethics and dissemination Ethics approval was obtained from the University of Utah Institutional Review Board (00113679), who will also be responsible for receiving communication updates regarding important protocol modifications. To ensure confidentiality, data dispersed to project team members will be blinded of any identifying participant information. Study results will be disseminated through publications in peer-reviewed journals, community dialogue sessions, and presentations at conferences. AN - WOS:000485269700134 AU - Rogers, C. R. AU - Okuyemi, K. AU - Paskett, E. D. AU - Thorpe, R. J. AU - Rogers, T. N. AU - Hung, M. AU - Zickmund, S. AU - Riley, C. AU - Fetters, M. D. DA - Aug DO - 10.1136/bmjopen-2019-030000 IS - 7 N1 - e030000 31345981 PY - 2019 SN - 2044-6055 ST - Study protocol for developing #CuttingCRC: a barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design T2 - Bmj Open TI - Study protocol for developing #CuttingCRC: a barbershop-based trial on masculinity barriers to care and colorectal cancer screening uptake among African-American men using an exploratory sequential mixed-methods design VL - 9 ID - 2814 ER - TY - JOUR AB - Focuses on the African American Hereditary Prostate Cancer study which will examine the genetic basis of prostate cancer in African Americans. Study background; Recruitment process; Prostate cancer incidence and mortality. AN - 11013776. Language: English. Entry Date: 20040312. Revision Date: 20190525. Publication Type: journal article. Journal Subset: Biomedical AU - Reynolds, Tom DB - CINAHL Complete DO - 10.1093/jnci/95.18.1356 DP - EBSCOhost IS - 18 KW - Prostatic Neoplasms Black Persons -- Statistics and Numerical Data Patient Selection Trust Black Persons Black Persons -- Psychosocial Factors United States Prostatic Neoplasms -- Ethnology Male N1 - Peer Reviewed; USA. NLM UID: 7503089. PMID: NLM13130105. PY - 2003 SN - 0027-8874 SP - 1356-1357 ST - Study seeks to clarify genetic basis of prostate cancer in African Americans T2 - JNCI: Journal of the National Cancer Institute TI - Study seeks to clarify genetic basis of prostate cancer in African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=11013776&site=ehost-live&scope=site VL - 95 ID - 2103 ER - TY - JOUR AB - Background: The CORRECT trial (NCT01103323 ) showed that REG improves overall survival (OS) vs placebo (PBO) in patients with mCRC who failed approved therapies (OS HR 0.77; 1sided p = 0.0052; Grothey 2013). A total of 760 patients were randomized to REG (n = 505) or PBO (n = 255) in more than 100 centers across North America, Europe, Asia, and Australia. We conducted a posthoc exploratory subgroup analysis of the 83 (11%) patients from 18 US centers. Methods: Eligible patients had an ECOG PS 1 and had received approved therapies, including a fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab, and if KRAS wild‐type cetuximab and/or panitumumab. Data from the overall cohort, including US patients, are provided for perspective. Descriptive statistics are shown. Results: Of the 83 US patients, 36 (43%) were randomized to PBO and 47 (57%) to REG. Baseline characteristics of the US group were consistent with the overall cohort: median age in the US was 58 yr (range, 34 ‐ 85) vs 61 (22 ‐ 85) overall, 49% of US patients were ECOG PS1 (vs 46%), and 46% received 3 treatments for mCRC (vs 52%). KRAS status mutant/wild‐type was 57%/34% in the US vs 57%/39% overall. All patients in the trial had prior bevacizumab and 57% of US patients also had prior cetuximab and/or panitumumab (vs 51% overall). However, higher proportion of patients in the US were Black (11% vs 2%), KRAS status unknown (10% vs 4%), and had colon as the primary disease site (82% vs 65%). Mean percentages of planned REG dose were similar (76% US vs 79% overall) and mean REG treatment duration was 3.1 mos in US vs 2.8 mos overall. Rates of dose modifications REG/PBO were 87%/47% in the US vs 76%/38% overall and grade 3 adverse events REG/PBO were 74%/64% vs 78%/49%, respectively. Based on 44 total death events, the HR for OS in the US subgroup was 0.46 (95%CI 0.25 ‐ 0.84) favoring REG; median OS was 4.7 mos for PBO, but could not be estimated for REG due to censored data. However, this analysis was based on a relatively small sample size and event count. Conclusions: Patients treated in the CORRECT study in the US appear similar to the overall cohort and results are generally consistent with the overall findings of the trial. AN - CN-01130155 AU - Kim, G. P. AU - Van Cutsem, E. AU - Lenz, H. J. AU - Verma, U. N. AU - Saltzman, M. AU - Fuloria, J. AU - Khojasteh, A. AU - Wiesenfeld, M. AU - Cihon, F. AU - Wagner, A. AU - et al. IS - 15 SUPPL. 1 KW - *American *United States *human *metastatic colorectal cancer *oncology *patient *phase 3 clinical trial *regorafenib *society Asia Australia Bevacizumab Cetuximab Death Electrocorticography Europe Fluoropyrimidine Irinotecan North America Overall survival Oxaliplatin Panitumumab Placebo Sample size Statistics Therapy Treatment duration Wild type M3 - Journal: Conference Abstract PY - 2015 ST - Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC) T2 - Journal of clinical oncology TI - Subgroup analysis of patients enrolled in the United States in the CORRECT phase 3 trial of the multikinase inhibitor regorafenib (REG) in metastatic colorectal cancer (mCRC) UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01130155/full VL - 33 ID - 1646 ER - TY - JOUR AB - Objective: The aim of this analysis is to evaluate the relative weight of different epidemiological risk factors on the development of different breast cancer subtypes (i.e. luminal, Her2+ overexpressed or triple negative). Methods: De-identified datasets of female participants recruited within the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial were accessed. Multivariate Cox regression analysis was utilized to assess factors affecting the development of breast cancer (regardless of subtype). Additional multivariate analyses were conducted to assess factors affecting the development of the three principal subtypes of breast cancer (ER+/Her2− breast cancer; Her2 overexpressed breast cancer and ER−/Her2− breast cancer). Results: A total of 73,570 eligible participants were evaluated in the current analysis of which 2370 participants subsequently developed breast cancer. The following factors were associated with a higher risk of ER+/Her2− breast cancer: white race (P < 0.001), nulliparity (P < 0.001), higher body mass index (P = 0.003), prior exposure to hormone treatment (P = 0.004) and breast cancer in first-degree female relatives (P < 0.001). The following factors were associated with a higher risk of Her2 overexpressed breast cancer: prior exposure to hormone treatment (P = 0.002) and breast cancer in first-degree female relatives (P = 0.001). The following factors were associated with a higher risk of ER−/Her2− breast cancer: black race (P = 0.013), younger age (P = 0.017) and breast cancer in first-degree female relatives (P 0.023). Conclusions: There is considerable heterogeneity in risk factors among patients with different subtypes of breast cancer. In particular, factors associated with high estrogen levels seem to be associated with luminal breast cancer rather than other breast cancer subtypes. AD - O. Abdel-Rahman, Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt AU - Abdel-Rahman, O. AU - Tang, P. A. AU - Cheung, W. Y. DB - Embase Medline DO - 10.1007/s12094-020-02329-3 IS - 10 KW - epidermal growth factor receptor 2 estrogen estrogen receptor progesterone receptor adult article body mass breast cancer cancer growth cancer mortality cancer prognosis cancer risk cancer screening cancer staging cohort analysis colorectal cancer female histology hormonal therapy human lung cancer major clinical study nullipara obesity ovary cancer overall survival postmenopause prostate cancer risk factor LA - English M3 - Article N1 - L2004389138 2020-03-16 PY - 2020 SN - 1699-3055 1699-048X SP - 1885-1891 ST - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial T2 - Clinical and Translational Oncology TI - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2004389138&from=export http://dx.doi.org/10.1007/s12094-020-02329-3 VL - 22 ID - 785 ER - TY - JOUR AB - Objective: The aim of this analysis is to evaluate the relative weight of different epidemiological risk factors on the development of different breast cancer subtypes (i.e. luminal, Her2+ overexpressed or triple negative). Methods: De-identified datasets of female participants recruited within the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial were accessed. Multivariate Cox regression analysis was utilized to assess factors affecting the development of breast cancer (regardless of subtype). Additional multivariate analyses were conducted to assess factors affecting the development of the three principal subtypes of breast cancer (ER+/Her2− breast cancer; Her2 overexpressed breast cancer and ER−/Her2− breast cancer). Results: A total of 73,570 eligible participants were evaluated in the current analysis of which 2370 participants subsequently developed breast cancer. The following factors were associated with a higher risk of ER+/Her2− breast cancer: white race (P < 0.001), nulliparity (P < 0.001), higher body mass index (P = 0.003), prior exposure to hormone treatment (P = 0.004) and breast cancer in first-degree female relatives (P < 0.001). The following factors were associated with a higher risk of Her2 overexpressed breast cancer: prior exposure to hormone treatment (P = 0.002) and breast cancer in first-degree female relatives (P = 0.001). The following factors were associated with a higher risk of ER−/Her2− breast cancer: black race (P = 0.013), younger age (P = 0.017) and breast cancer in first-degree female relatives (P 0.023). Conclusions: There is considerable heterogeneity in risk factors among patients with different subtypes of breast cancer. In particular, factors associated with high estrogen levels seem to be associated with luminal breast cancer rather than other breast cancer subtypes. © 2020, Federación de Sociedades Españolas de Oncología (FESEO). AD - Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N4N1, Canada AU - Abdel-Rahman, O. AU - Tang, P. A. AU - Cheung, W. Y. DB - Scopus DO - 10.1007/s12094-020-02329-3 IS - 10 KW - Breast cancer Epidemiology Risk factors Subtypes M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 1885-1891 ST - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial T2 - Clinical and Translational Oncology TI - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081354399&doi=10.1007%2fs12094-020-02329-3&partnerID=40&md5=bf06ef89fa1dcfcd9e7881e449ed01cf VL - 22 ID - 2180 ER - TY - JOUR AB - Objective The aim of this analysis is to evaluate the relative weight of different epidemiological risk factors on the development of different breast cancer subtypes (i.e. luminal, Her2+ overexpressed or triple negative). Methods De-identified datasets of female participants recruited within the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial were accessed. Multivariate Cox regression analysis was utilized to assess factors affecting the development of breast cancer (regardless of subtype). Additional multivariate analyses were conducted to assess factors affecting the development of the three principal subtypes of breast cancer (ER+/Her2- breast cancer; Her2 overexpressed breast cancer and ER-/Her2- breast cancer). Results A total of 73,570 eligible participants were evaluated in the current analysis of which 2370 participants subsequently developed breast cancer. The following factors were associated with a higher risk of ER+/Her2- breast cancer: white race (P < 0.001), nulliparity (P < 0.001), higher body mass index (P = 0.003), prior exposure to hormone treatment (P = 0.004) and breast cancer in first-degree female relatives (P < 0.001). The following factors were associated with a higher risk of Her2 overexpressed breast cancer: prior exposure to hormone treatment (P = 0.002) and breast cancer in first-degree female relatives (P = 0.001). The following factors were associated with a higher risk of ER-/Her2- breast cancer: black race (P = 0.013), younger age (P = 0.017) and breast cancer in first-degree female relatives (P 0.023). Conclusions There is considerable heterogeneity in risk factors among patients with different subtypes of breast cancer. In particular, factors associated with high estrogen levels seem to be associated with luminal breast cancer rather than other breast cancer subtypes. AN - WOS:000519502200001 AU - Abdel-Rahman, O. AU - Tang, P. A. AU - Cheung, W. Y. DA - Oct DO - 10.1007/s12094-020-02329-3 IS - 10 N1 - 32157561 PY - 2020 SN - 1699-048X SP - 1885-1891 ST - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial T2 - Clinical & Translational Oncology TI - Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial VL - 22 ID - 2788 ER - TY - JOUR AD - N. Agarwal, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, United States AU - Hahn, A. W. AU - Bilen, M. A. AU - Agarwal, N. DB - Embase Medline DO - 10.1001/jamanetworkopen.2020.34652 KW - achievement adult controlled study human male note prostate cancer LA - English M3 - Article in Press N1 - L634019434 2021-02-02 PY - 2021 SN - 2574-3805 ST - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials - A Lesson in Achievement T2 - JAMA Network Open TI - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials - A Lesson in Achievement UR - https://www.embase.com/search/results?subaction=viewrecord&id=L634019434&from=export http://dx.doi.org/10.1001/jamanetworkopen.2020.34652 ID - 771 ER - TY - JOUR AD - Divison of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, United States AU - Hahn, A. W. AU - Bilen, M. A. AU - Agarwal, N. DB - Scopus DO - 10.1001/jamanetworkopen.2020.34652 IS - 1 M3 - Article N1 - Export Date: 22 March 2021 PY - 2021 SP - e2034652 ST - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement T2 - JAMA network open TI - Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100487451&doi=10.1001%2fjamanetworkopen.2020.34652&partnerID=40&md5=e56f4be5133a5d7c656b7d4b7fe0281d VL - 4 ID - 2156 ER - TY - JOUR AB - BACKGROUND: Study of genomic data obtained from patient biospecimens is frequent in research of subjects with prostate and other epithelial malignancies. Understanding of the characteristics of healthy men who participate in genomic research is limited. METHODS: Patients were identified through the Prostate Cancer Genetic Risk Evaluation of SNPs Study and the Indiana University Cancer Biomarker Study, 2 population-based biomarker and cohort studies. Between 2006 and 2010, healthy Caucasian (n = 774) and healthy African American (n 381) men were recruited and enrolled at high-volume free community health fairs. Each participant completed a demographic questionnaire and provided a blood sample for genomic research investigations. Frequency differences between demographic features of healthy African American and Caucasian men were compared and analyzed by 2-sample t test and multivariate logistic regression after adjusting potential confounding variables with significance at the P <. 05 level. Features examined included: age, body mass index (BMI), income, education, marital status, tobacco, alcohol, family history, prostate-specific antigen (PSA) level, and prior prostate cancer screening history. RESULTS: Significant differences between healthy Caucasian and African American men participating in genomic research included: marital status (married, 69% Caucasian vs 46% African American, P <<. 001), mean age (years, 58 Caucasian vs 54 African American, P <. 001), mean BMI (kg/m(2), 30.9 Caucasian vs 32.3 African American, P = .004), annual income (P = .038), education (P = .002), and mean PSA (ng/mL, 1.2 Caucasian vs 2.0 African American, P = .005). CONCLUSIONS: Significant demographic differences exist between healthy Caucasian and African American men choosing to participate in genomic research. These differences may be important in designing genomic research study recruitment strategies. Cancer 2012;118:1075-82. (C) 2011 American Cancer Society. AN - WOS:000299834300026 AU - Patel, Y. R. AU - Carr, K. A. AU - Magjuka, D. AU - Mohammadi, Y. AU - Dropcho, E. F. AU - Reed, A. D. AU - Moore, M. L. AU - Waddell, M. J. AU - Shedd-Steele, R. AU - Sweeney, C. J. AU - Hahn, N. M. DA - Feb DO - 10.1002/cncr.26328 IS - 4 N1 - 21766294 PY - 2012 SN - 0008-543X SP - 1075-1082 ST - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs T2 - Cancer TI - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs VL - 118 ID - 3074 ER - TY - JOUR AD - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. AN - 104512488. Language: English. Entry Date: 20120427. Revision Date: 20150711. Publication Type: Journal Article AU - Patel, Y. R. AU - Carr, K. A. AU - Magjuka, D. AU - Mohammadi, Y. AU - Dropcho, E. F. AU - Reed, A. D. AU - Moore, M. L. AU - Waddell, M. J. AU - Shedd-Steele, R. AU - Sweeney, C. J. AU - Hahn, N. M. DB - CINAHL Complete DO - 10.1002/cncr.26328 DP - EBSCOhost IS - 4 KW - Black Persons Research, Medical -- Trends Community Health Services -- Trends Genome Minority Groups Patient Selection Prostatic Neoplasms Age Factors Educational Status White Persons Disease Susceptibility -- Ethnology Disease Susceptibility Human Indiana Male Marital Status Middle Age Polymorphism, Genetic Prostatic Neoplasms -- Epidemiology Prostatic Neoplasms -- Ethnology Retrospective Design Risk Factors Socioeconomic Factors N1 - research. Journal Subset: Biomedical; Peer Reviewed; USA. Special Interest: Oncologic Care. NLM UID: 0374236. PMID: NLM21766294. PY - 2012 SN - 0008-543X SP - 1075-1082 ST - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations T2 - Cancer (0008543X) TI - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104512488&site=ehost-live&scope=site VL - 118 ID - 2106 ER - TY - JOUR AB - Background: Study of genomic data obtained from patient biospecimens is frequent in research of subjects with prostate and other epithelial malignancies. Understanding of the characteristics of healthy men who participate in genomic research is limited. Methods: Patients were identified through the Prostate Cancer Genetic Risk Evaluation of SNPs Study and the Indiana University Cancer Biomarker Study, 2 population-based biomarker and cohort studies. Between 2006 and 2010, healthy Caucasian (n = 774) and healthy African American (n = 381) men were recruited and enrolled at high-volume free community health fairs. Each participant completed a demographic questionnaire and provided a blood sample for genomic research investigations. Frequency differences between demographic features of healthy African American and Caucasian men were compared and analyzed by 2-sample t test and multivariate logistic regression after adjusting potential confounding variables with significance at the P <.05 level. Features examined included: age, body mass index (BMI), income, education, marital status, tobacco, alcohol, family history, prostate-specific antigen (PSA) level, and prior prostate cancer screening history. Results: Significant differences between healthy Caucasian and African American men participating in genomic research included: marital status (married, 69% Caucasian vs 46% African American, P< <.001), mean age (years, 58 Caucasian vs 54 African American, P <.001), mean BMI (kg/m 2, 30.9 Caucasian vs 32.3 African American, P =.004), annual income (P =.038), education (P =.002), and mean PSA (ng/mL, 1.2 Caucasian vs 2.0 African American, P =.005). Conclusions: Significant demographic differences exist between healthy Caucasian and African American men choosing to participate in genomic research. These differences may be important in designing genomic research study recruitment strategies. © 2011 American Cancer Society. AD - Indiana University Melvin, Bren Simon Cancer Center, Indiana Cancer Pavilion, 535 Barnhill Drive, Indianapolis, IN 46202, United States Dana Farber Cancer Institute, Boston, MA, United States AU - Patel, Y. R. AU - Carr, K. A. AU - Magjuka, D. AU - Mohammadi, Y. AU - Dropcho, E. F. AU - Reed, A. D. AU - Moore, M. L. AU - Waddell, M. J. AU - Shedd-Steele, R. AU - Sweeney, C. J. AU - Hahn, N. M. DB - Scopus DO - 10.1002/cncr.26328 IS - 4 KW - African American community health fairs demographics genomic research healthy population M3 - Article N1 - Cited By :4 Export Date: 22 March 2021 PY - 2012 SP - 1075-1082 ST - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations T2 - Cancer TI - Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856793738&doi=10.1002%2fcncr.26328&partnerID=40&md5=91fe22f6aead7ba1ce7ef839b71eb107 VL - 118 ID - 2464 ER - TY - JOUR AB - Objective: To determine whether prior success in recruiting African Americans to an in-house cancer genetics registry could be duplicated when recruiting to a national registry requiring a significantly increased level of commitment. Additionally, to determine which recruitment sources and practices yielded the highest number of African American participants. Methods: A retrospective analysis of recruitment sources, practices, and results for recruitment to the Cancer Genetics Network (CGN; a national research registry), from 2000 to 2005 was conducted. These results were compared to previous experience in recruiting African Americans to the Family Cancer Registry (FCR; an in-house registry) during the period 1992-2005. Results: In the 1st year of recruitment to the CGN, African Americans accounted for 24% of those consenting to participate in the CGN registry from our center. This compares to an average annual rate of 27% for the FCR during the years 1998-2005, and a rate of less than 1% from 1992 to 1998. By 2005, African Americans accounted for 27% of CGN participants recruited through the University of Texas Southwestern Medical Center, one of eighteen participating institutions in the CGN. Hospital-based resources such as cancer treatment clinics and tumor registries yielded the highest percentage of African American participants (66.5%), and self-referral yielded the lowest (0%). Seventy-seven percent of African Americans were actively sought out and recruited from treatment clinics, whereas the vast majority of Caucasian participants were recruited passively during the course of genetic counseling sessions that were scheduled for reasons unrelated to participation in cancer research. There were no known instances of African Americans contacting CGN staff after reading printed recruitment materials or internet advertisements. Conclusions: The increased level of commitment required of CGN participants did not deter African Americans from participating in cancer genetics research. Recruitment strategies responsible for dramatically increasing recruitment rates to the FCR from 1998 to 2000 were equally effective when used for recruitment to the CGN. The most effective recruitment sources were high-yield venues such as cancer treatment clinics and tumor registries, and active recruitment methods yielded the highest number of African American participants. Advertising through internet announcements and printed recruitment materials did not appear to be effective. Copyright (C) 2008 S. Karger AG, Basel. AN - WOS:000255110000005 AU - Patterson, A. R. AU - Davis, H. AU - Shelby, K. AU - McCoy, J. AU - Robinson, L. D. AU - Rao, S. AU - Banerji, P. AU - Tomlinson, G. E. DO - 10.1159/000116881 IS - 4 N1 - 18417968 PY - 2008 SN - 1422-2795 SP - 208-214 ST - Successful strategies for increasing African American participation in cancer genetic studies: Hopeful signs for equalizing the benefits of genetic medicine T2 - Community Genetics TI - Successful strategies for increasing African American participation in cancer genetic studies: Hopeful signs for equalizing the benefits of genetic medicine VL - 11 ID - 3178 ER - TY - JOUR AB - Background Inadequate participant recruitment, which may lead to unrepresentative study samples that threaten a study's validity, is often a major challenge in the conduct of research studies. Purpose The purpose of this article is to describe the development and implementation of a recruitment plan and evaluate the different recruitment strategies for a prostate cancer behavioral intervention trial. Methods Our recruitment plan was based on a framework (The Heiney-Adams Recruitment Model) that we developed, which combines relationship building and social marketing. We evaluated the success of our model using several different recruitment sources including: mailed letters, physician referral, and self-referral. Results Recruitment rates ranged from 67% for a support services department mailing to 100% for physician referral. While our original list of contacted patients was comprised of only 13% African American (AA) men, 22% of our recruited participants were AA. Limitations One of the strongest barriers to recruitment was strict patient eligibility. Another significant barrier was the lack of electronic records systems to allow for the identification of large numbers of potential participants. Conclusions In conclusion, our model incorporating social marketing and relationship building was quite successful in recruiting for a prostate cancer behavioral study, particularly AA participants. In developing strategies, future researchers should attend to issues of staffing, financial resources, physician support, and eligibility criteria in the light of study accrual. Clinical Trials 2010; 7: 411-417. http://ctj.sagepub.com. AN - WOS:000280741400011 AU - Heiney, S. P. AU - Adams, S. A. AU - Drake, B. F. AU - Bryant, L. H. AU - Bridges, L. AU - Hebert, J. R. DA - Aug DO - 10.1177/1740774510373491 IS - 4 N1 - 20571136 PY - 2010 SN - 1740-7745 SP - 411-417 ST - Successful subject recruitment for a prostate cancer behavioral intervention trial T2 - Clinical Trials TI - Successful subject recruitment for a prostate cancer behavioral intervention trial VL - 7 ID - 3110 ER - TY - JOUR AD - College of Nursing and the Department of Epidemiology and Biostatistics, The Cancer Prevention and Control Program, University of South Carolina, 915 Green Street, Room 244, Columbia, SC, USA. E-mail: swann.adams@sc.edu AN - 104927893. Language: English. Entry Date: 20110114. Revision Date: 20200708. Publication Type: Journal Article AU - Heiney, S. P. AU - Adams, S. A. AU - Drake, B. F. AU - Bryant, L. H. AU - Bridges, L. AU - Herbert, J. R. DB - CINAHL Complete DO - 10.1177/1740774510373491 DP - EBSCOhost IS - 4 KW - Black Persons -- Psychosocial Factors Prostatic Neoplasms Research Subject Recruitment -- Methods Social Marketing Adult Aged Aged, 80 and Over Behavior Funding Source Human Information Systems Male Middle Age Program Development Program Implementation Socioeconomic Factors Study Design N1 - research; tables/charts. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: The study (PC020466 A Diet, Physical Activity and Meditation Intervention in Men with Rising Prostate-Specific Antigen (PSA) is partially funded by the Department of Defense US Army Medical Research and Materiel Command (USAMRMC) Congressionally Directed Medical Research Programs (CDMRP), and 2002 Prostate Cancer Research Program (PCRP), grant DAMD17-03-1-0139. NLM UID: 101285473. PMID: NLM20571136. PY - 2010 SN - 1740-7745 SP - 411-417 ST - Successful subject recruitment for a prostate cancer behavioral intervention trial T2 - Clinical Trials TI - Successful subject recruitment for a prostate cancer behavioral intervention trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104927893&site=ehost-live&scope=site VL - 7 ID - 2107 ER - TY - JOUR AB - Background Inadequate participant recruitment, which may lead to unrepresentative study samples that threaten a studys validity, is often a major challenge in the conduct of research studies. Purpose The purpose of this article is to describe the development and implementation of a recruitment plan and evaluate the different recruitment strategies for a prostate cancer behavioral intervention trial. Methods Our recruitment plan was based on a framework (The Heiney-Adams Recruitment Model) that we developed, which combines relationship building and social marketing. We evaluated the success of our model using several different recruitment sources including: mailed letters, physician referral, and self-referral. Results Recruitment rates ranged from 67% for a support services department mailing to 100% for physician referral. While our original list of contacted patients was comprised of only 13% African American (AA) men, 22% of our recruited participants were AA. Limitations One of the strongest barriers to recruitment was strict patient eligibility. Another significant barrier was the lack of electronic records systems to allow for the identification of large numbers of potential participants. Conclusions In conclusion, our model incorporating social marketing and relationship building was quite successful in recruiting for a prostate cancer behavioral study, particularly AA participants. In developing strategies, future researchers should attend to issues of staffing, financial resources, physician support, and eligibility criteria in the light of study accrual. © The Author(s), 2010. AD - S. Arp Adams, Department of Epidemiology and Biostatistics, Cancer Prevention and Control Program, University of South Carolina, 915 Green Street, Columbia, SC, United States AU - Heiney, S. P. AU - Arp Adams, S. AU - Drake, B. F. AU - Bryant, L. H. AU - Bridges, L. AU - Hebert, J. R. DB - Embase Medline DO - 10.1177/1740774510373491 IS - 4 KW - adult aged article conceptual framework controlled study doctor patient relationship health behavior health care planning human intervention study major clinical study male patient referral patient selection physician self-referral postal mail priority journal prostate cancer social marketing LA - English M3 - Article N1 - L359343513 2010-08-23 2010-09-01 PY - 2010 SN - 1740-7745 1740-7753 SP - 411-417 ST - Successful subject recruitment for a prostate cancer behavioral intervention trial T2 - Clinical Trials TI - Successful subject recruitment for a prostate cancer behavioral intervention trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L359343513&from=export http://dx.doi.org/10.1177/1740774510373491 VL - 7 ID - 1159 ER - TY - JOUR AB - Background Inadequate participant recruitment, which may lead to unrepresentative study samples that threaten a studys validity, is often a major challenge in the conduct of research studies. Purpose The purpose of this article is to describe the development and implementation of a recruitment plan and evaluate the different recruitment strategies for a prostate cancer behavioral intervention trial. Methods Our recruitment plan was based on a framework (The Heiney-Adams Recruitment Model) that we developed, which combines relationship building and social marketing. We evaluated the success of our model using several different recruitment sources including: mailed letters, physician referral, and self-referral. Results Recruitment rates ranged from 67% for a support services department mailing to 100% for physician referral. While our original list of contacted patients was comprised of only 13% African American (AA) men, 22% of our recruited participants were AA. Limitations One of the strongest barriers to recruitment was strict patient eligibility. Another significant barrier was the lack of electronic records systems to allow for the identification of large numbers of potential participants. Conclusions In conclusion, our model incorporating social marketing and relationship building was quite successful in recruiting for a prostate cancer behavioral study, particularly AA participants. In developing strategies, future researchers should attend to issues of staffing, financial resources, physician support, and eligibility criteria in the light of study accrual. © The Author(s), 2010. AD - College of Nursing, University of South Carolina, Columbia, SC, United States Department of Epidemiology and Biostatistics, Cancer Prevention and Control Program, University of South Carolina, 915 Green Street, Columbia, SC, United States Department of Surgery, Washington University, School of Medicine, St. Louis, MO, United States Neuropsychiatry and Pediatrics, University of South Carolina, School of Medicine, Columbia, SC, United States Caring House, South Carolina Cancer Center, Columbia, SC, United States South Carolina Cancer Prevention and Control Program, Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, United States AU - Heiney, S. P. AU - Arp Adams, S. AU - Drake, B. F. AU - Bryant, L. H. AU - Bridges, L. AU - Hebert, J. R. DB - Scopus DO - 10.1177/1740774510373491 IS - 4 M3 - Article N1 - Cited By :15 Export Date: 22 March 2021 PY - 2010 SP - 411-417 ST - Successful subject recruitment for a prostate cancer behavioral intervention trial T2 - Clinical Trials TI - Successful subject recruitment for a prostate cancer behavioral intervention trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955580250&doi=10.1177%2f1740774510373491&partnerID=40&md5=1b465f9658e6d1358c4ea111b3c68cde VL - 7 ID - 2495 ER - TY - JOUR AB - Background: Attention to psycho-socio-spiritual needs is considered critical by patients with life-threatening illnesses and their caregivers. Palliative care interventions that address these needs - particularly spirituality - are lacking. Objective: To evaluate the effects of an innovative program to address psycho-socio-spiritual needs in patients with life-threatening illnesses. Design: A group intervention entitled Life-Threatening Illness Supportive-Affective Group Experience (LTI-SAGE) was developed for reducing patient spiritual, emotional, and death-related distress. Setting/subjects: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life-threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI-SAGE groups over a 12-month period. Control patients received standard care. Measurements: Outcome measures were depression symptoms, anxiety, spiritual well-being, and death-related emotional distress. Results: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death-related feelings of meaninglessness and significantly better spiritual well-being than did control patients. Conclusions: The use of the LTI-SAGE model for enhancing the end-of-life illness experience is promising. © Mary Ann Liebert, Inc. AD - D.K. Miller, Indiana University Center for Aging Research, Indiana University School of Medicine, 1050 Wishard Boulevard, RG-6, Indianapolis, IN 46202, United States AU - Miller, D. K. AU - Chibnall, J. T. AU - Videen, S. D. AU - Duckro, P. N. DB - Embase Medline DO - 10.1089/jpm.2005.8.333 IS - 2 KW - adult African American anxiety article malignant neoplasm cardiovascular disease Caucasian clinical trial controlled clinical trial controlled study depression distress syndrome dying emotional stress geriatric disorder human Human immunodeficiency virus infection kidney disease liver disease lung disease major clinical study outcomes research randomized controlled trial religion school child support group terminal disease wellbeing LA - English M3 - Article N1 - L40703882 2005-06-09 PY - 2005 SN - 1096-6218 SP - 333-343 ST - Supportive-affective group experience for persons with life-threatening illness: Reducing spiritual, psychological, and death-related distress in dying patients T2 - Journal of Palliative Medicine TI - Supportive-affective group experience for persons with life-threatening illness: Reducing spiritual, psychological, and death-related distress in dying patients UR - https://www.embase.com/search/results?subaction=viewrecord&id=L40703882&from=export http://dx.doi.org/10.1089/jpm.2005.8.333 VL - 8 ID - 1269 ER - TY - JOUR AB - BACKGROUND: Attention to psycho‐socio‐spiritual needs is considered critical by patients with life‐threatening illnesses and their caregivers. Palliative care interventions that address these needs‐‐particularly spirituality‐‐are lacking. OBJECTIVE: To evaluate the effects of an innovative program to address psycho‐socio‐spiritual needs in patients with life‐threatening illnesses. DESIGN: A group intervention entitled Life‐Threatening Illness Supportive‐Affective Group Experience (LTI‐SAGE) was developed for reducing patient spiritual, emotional, and death‐related distress. SETTING/SUBJECTS: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life‐threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI‐SAGE groups over a 12‐month period. Control patients received standard care. MEASUREMENTS: Outcome measures were depression symptoms, anxiety, spiritual well‐being, and death‐related emotional distress. RESULTS: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death‐related feelings of meaninglessness and significantly better spiritual well‐being than did control patients. CONCLUSIONS: The use of the LTI‐SAGE model for enhancing the end‐of‐life illness experience is promising. AN - CN-00511874 AU - Miller, D. K. AU - Chibnall, J. T. AU - Videen, S. D. AU - Duckro, P. N. DO - 10.1089/jpm.2005.8.333 IS - 2 KW - *support group *terminal disease Adult African American Analysis of Variance Anxiety Anxiety [therapy] Article Cancer/th [Therapy] Cardiovascular disease Caucasian Chi‐Square Distribution Clinical trial Controlled clinical trial Controlled study Depression Depression [therapy] Distress syndrome Dying Emotional stress Female Geriatric disorder/th [Therapy] Human Human immunodeficiency virus infection/th [Therapy] Humans Kidney disease/th [Therapy] Liver disease/th [Therapy] Longitudinal Studies Lung disease Major clinical study Male Middle Aged Outcomes research Palliative Care [*psychology] Principal Component Analysis Program Evaluation Psychotherapy, Group [*methods] Randomized controlled trial Religion School child Spirituality Terminally Ill [*psychology] Wellbeing M3 - Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial PY - 2005 SP - 333‐343 ST - Supportive-affective group experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients T2 - Journal of palliative medicine TI - Supportive-affective group experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-00511874/full VL - 8 ID - 1574 ER - TY - JOUR AB - Background: Attention to psycho-socio-spiritual needs is considered critical by patients with life-threatening illnesses and their caregivers. Palliative care interventions that address these needs--particularly spirituality--are lacking. Objective: To evaluate the effects of an innovative program to address psycho-socio-spiritual needs in patients with life-threatening illnesses. Design: A group intervention entitled Life-Threatening Illness Supportive-Affective Group Experience (LTI-SAGE) was developed for reducing patient spiritual, emotional, and death-related distress. Setting/subjects: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life-threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI-SAGE groups over a 12-month period. Control patients received standard care. Measurements: Outcome measures were depression symptoms, anxiety, spiritual well-being, and death-related emotional distress. Results: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death-related feelings of meaninglessness and significantly better spiritual well-being than did control patients. Conclusions: The use of the LTI-SAGE model for enhancing the end-of-life illness experience is promising. (PsycINFO Database Record (c) 2019 APA, all rights reserved) AD - Miller, Douglas K., Indiana University Center for Aging Research, Indiana University School of Medicine, 1050 Wishard Boulevard, RG-6, Indianapolis, IN, US, 46202 AN - 2006-05290-010 AU - Miller, Douglas K. AU - Chibnall, John T. AU - Videen, Susan D. AU - Duckro, Paul N. DB - psyh DO - 10.1089/jpm.2005.8.333 DP - EBSCOhost IS - 2 KW - innovative program dying patients death distress life threatening illness psycho socio spiritual needs caregivers palliative care interventions Analysis of Variance Anxiety Chi-Square Distribution Depression Female Humans Longitudinal Studies Male Middle Aged Palliative Care Principal Component Analysis Program Evaluation Psychotherapy, Group Spirituality Terminally Ill Illness Behavior Needs Outreach Programs Terminally Ill Patients Death and Dying Intervention Psychosocial Factors N1 - Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, IN, US. Release Date: 20061030. Correction Date: 20190613. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Distress; Illness Behavior; Needs; Outreach Programs; Terminally Ill Patients. Minor Descriptor: Caregivers; Death and Dying; Intervention; Palliative Care; Psychosocial Factors; Spirituality. Classification: Home Care & Hospice (3375). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Tests & Measures: Death Distress Scale; Illness Disability Index; Perceived Social Support Inventory; Spiritual Well-Being Scale DOI: 10.1037/t00534-000; Beck Depression Inventory DOI: 10.1037/t00741-000; Spielberger State Trait Anxiety Inventory. Methodology: Empirical Study; Quantitative Study. References Available: Y. Page Count: 11. Issue Publication Date: Apr, 2005. Sponsor: Supportive Care of the Dying, Coalition for Compassionate Care, US. Recipients: No recipient indicated Sponsor: Project on Death in America, US. Recipients: No recipient indicated PY - 2005 SN - 1096-6218 1557-7740 SP - 333-343 ST - Supportive-Affective Group Experience for Persons with Life-Threatening Illness: Reducing Spiritual, Psychological, and Death-Related Distress in Dying Patients T2 - Journal of Palliative Medicine TI - Supportive-Affective Group Experience for Persons with Life-Threatening Illness: Reducing Spiritual, Psychological, and Death-Related Distress in Dying Patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-05290-010&site=ehost-live&scope=site dokmille@iupui.edu VL - 8 ID - 1811 ER - TY - JOUR AB - BACKGROUND: Attention to psycho-socio-spiritual needs is considered critical by patients with life-threatening illnesses and their caregivers. Palliative care interventions that address these needs--particularly spirituality--are lacking. OBJECTIVE: To evaluate the effects of an innovative program to address psycho-socio-spiritual needs in patients with life-threatening illnesses. DESIGN: A group intervention entitled Life-Threatening Illness Supportive-Affective Group Experience (LTI-SAGE) was developed for reducing patient spiritual, emotional, and death-related distress. SETTING/SUBJECTS: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life-threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI-SAGE groups over a 12-month period. Control patients received standard care. MEASUREMENTS: Outcome measures were depression symptoms, anxiety, spiritual well-being, and death-related emotional distress. RESULTS: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death-related feelings of meaninglessness and significantly better spiritual well-being than did control patients. CONCLUSIONS: The use of the LTI-SAGE model for enhancing the end-of-life illness experience is promising. AD - Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, Indiana; dokmille@iupui.edu AN - 106425166. Language: English. Entry Date: 20060414. Revision Date: 20200708. Publication Type: Journal Article AU - Miller, D. K. AU - Chibnall, J. T. AU - Videen, S. D. AU - Duckro, P. N. DB - CINAHL Complete DO - 10.1089/jpm.2005.8.333 DP - EBSCOhost IS - 2 KW - Attitude to Death Stress, Psychological -- Prevention and Control Support Groups Terminal Care -- Psychosocial Factors Caregivers Clinical Assessment Tools Clinical Trials Data Analysis, Statistical Descriptive Statistics Female Health Status Indicators Male Middle Age Missouri Program Development Psychological Tests Scales State-Trait Anxiety Inventory Funding Source Human N1 - clinical trial; research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Beck Depression Inventory (BDI); Death Distress Scale (DDS); Spielberger State Anxiety Inventory (SSAI); Spiritual Well-Being Scale (SWS) (Paloutzian and Ellison); Illness Disability Index (IDI); Perceived Social Support Inventory (PSSI). Grant Information: Supportive Care of the Dying: A Coalition for Compassionate Care, Portland, Oregon; Project on Death in America, New York, New York. NLM UID: 9808462. PMID: NLM15890044. PY - 2005 SN - 1096-6218 SP - 333-343 ST - Supportive-Affective Group Experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients T2 - Journal of Palliative Medicine TI - Supportive-Affective Group Experience for persons with life-threatening illness: reducing spiritual, psychological, and death-related distress in dying patients UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106425166&site=ehost-live&scope=site VL - 8 ID - 2108 ER - TY - JOUR AB - Background: Attention to psycho-socio-spiritual needs is considered critical by patients with life-threatening illnesses and their caregivers. Palliative care interventions that address these needs - particularly spirituality - are lacking. Objective: To evaluate the effects of an innovative program to address psycho-socio-spiritual needs in patients with life-threatening illnesses. Design: A group intervention entitled Life-Threatening Illness Supportive-Affective Group Experience (LTI-SAGE) was developed for reducing patient spiritual, emotional, and death-related distress. Setting/subjects: African American and Caucasian patients (n = 69) from two hospitals in St. Louis, Missouri, with life-threatening medical conditions (cancer; human immunodeficiency virus/acquired immune deficiency syndrome [HIV/AIDS]; geriatric frailty; liver, kidney, pulmonary, or cardiovascular disease) were randomly assigned to intervention or control groups. Intervention patients participated in a maximum of 12 LTI-SAGE groups over a 12-month period. Control patients received standard care. Measurements: Outcome measures were depression symptoms, anxiety, spiritual well-being, and death-related emotional distress. Results: After attrition, 51 (73.9%) patients completed the trial. At the end of the trial, after factoring in compliance, intervention patients had significantly fewer depression symptoms and death-related feelings of meaninglessness and significantly better spiritual well-being than did control patients. Conclusions: The use of the LTI-SAGE model for enhancing the end-of-life illness experience is promising. © Mary Ann Liebert, Inc. AD - Indiana University Center for Aging Research, Regenstrief Institute, Inc., Indianapolis, IN, United States Department of Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, United States Pastoral Care, Saint Louis University Health Sciences Center, St. Louis, MO, United States Department of Community and Family Medicine, Saint Louis University School of Medicine, St. Louis, MO, United States Indiana University Center for Aging Research, Indiana University School of Medicine, 1050 Wishard Boulevard, RG-6, Indianapolis, IN 46202, United States AU - Miller, D. K. AU - Chibnall, J. T. AU - Videen, S. D. AU - Duckro, P. N. DB - Scopus DO - 10.1089/jpm.2005.8.333 IS - 2 M3 - Article N1 - Cited By :55 Export Date: 22 March 2021 PY - 2005 SP - 333-343 ST - Supportive-affective group experience for persons with life-threatening illness: Reducing spiritual, psychological, and death-related distress in dying patients T2 - Journal of Palliative Medicine TI - Supportive-affective group experience for persons with life-threatening illness: Reducing spiritual, psychological, and death-related distress in dying patients UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-18944398572&doi=10.1089%2fjpm.2005.8.333&partnerID=40&md5=21fcad551df2c5da63fcca78b02e4c05 VL - 8 ID - 2596 ER - TY - JOUR AB - Aim: African‐Americans (AA) have increased prostate cancer risk and a greater mortality rate than European‐Americans (EA). AA exhibit a high prevalence of vitamin D deficiency. We examined the global prostate transcriptome in AA and EA, and the effect of vitamin D3 supplementation. Patients & methods: Twenty‐seven male subjects (ten AA and 17 EA), slated to undergo prostatectomy were enrolled in the study. Fourteen subjects received vitamin D3 (4000 IU daily) and 13 subjects received placebo for 2 months prior to surgery. Results: AA show higher expression of genes associated with immune response and inflammation. Conclusion: Systems level analyses support the concept that Inflammatory processes may contribute to disease progression in AA. These transcripts can be modulated by a short course of vitamin D3 supplementation. AN - CN-01177243 AU - Hardiman, G. AU - Savage, S. J. AU - Hazard, E. S. AU - Wilson, R. C. AU - Courtney, S. M. AU - Smith, M. T. AU - Hollis, B. W. AU - Halbert, C. H. AU - Gattoni-Celli, S. DO - 10.2217/pgs-2016-0025 IS - 10 KW - *African American *European American *prostate cancer /etiology /surgery *race difference Adult Aged Article Cancer mortality Cancer risk Clinical article Controlled study Disease course Gene expression Gene expression profiling Gleason score High throughput sequencing Human Human tissue Immune response Inflammation Male Middle aged Open study Prevalence Prostate biopsy Prostatectomy Randomized controlled trial System analysis Vitamin D deficiency /drug therapy Vitamin supplementation M3 - Journal: Article PY - 2016 SP - 1129‐1143 ST - Systems analysis of the prostate transcriptome in African-American men compared with European-American men T2 - Pharmacogenomics TI - Systems analysis of the prostate transcriptome in African-American men compared with European-American men UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01177243/full VL - 17 ID - 1407 ER - TY - JOUR AB - Aim: African-Americans (AA) have increased prostate cancer risk and a greater mortality rate than European-Americans (EA). AA exhibit a high prevalence of vitamin D deficiency. We examined the global prostate transcriptome in AA and EA, and the effect of vitamin D3 supplementation. Patients & methods: Twenty-seven male subjects (ten AA and 17 EA), slated to undergo prostatectomy were enrolled in the study. Fourteen subjects received vitamin D3 (4000 IU daily) and 13 subjects received placebo for 2 months prior to surgery. Results: AA show higher expression of genes associated with immune response and inflammation. Conclusion: Systems level analyses support the concept that Inflammatory processes may contribute to disease progression in AA. These transcripts can be modulated by a short course of vitamin D3 supplementation. © 2016 Future Medicine Ltd. AD - Department of Medicine and Public Health, Medical University of South Carolina, Charleston, SC, United States Center for Genomics Medicine, Medical University of South Carolina, Charleston, SC, United States Library Science and Informatics, Medical University of South Carolina, Charleston, SC, United States Department of Urology, Charleston, SC, United States Ralph H Johnson VA Medical Center, Charleston, SC, United States Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, United States Department of Pediatrics, Medical University of South Carolina, Charleston, SC, United States Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, United States AU - Hardiman, G. AU - Savage, S. J. AU - Hazard, E. S. AU - Wilson, R. C. AU - Courtney, S. M. AU - Smith, M. T. AU - Hollis, B. W. AU - Halbert, C. H. AU - Gattoni-Celli, S. DB - Scopus DO - 10.2217/pgs-2016-0025 IS - 10 KW - African-American health disparities prostate RNA-seq transcription Vitamin D M3 - Article N1 - Cited By :32 Export Date: 22 March 2021 PY - 2016 SP - 1129-1143 ST - Systems analysis of the prostate transcriptome in African-American men compared with European-American men T2 - Pharmacogenomics TI - Systems analysis of the prostate transcriptome in African-American men compared with European-American men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979582168&doi=10.2217%2fpgs-2016-0025&partnerID=40&md5=a5bec5c02afb94fa166a69fff4bdcb59 VL - 17 ID - 2340 ER - TY - JOUR AB - African American men bear disproportionate burden of prostate cancer (PCa) that can be reduced by early detection. A 15-minute culturally appropriate PCa education intervention developed to communicate effective, relevant, and balanced PCa screening information to low-income African American men was evaluated in men 42 years and older who had not been screened in one year. Of 539 men enrolled, 392 (72.7%) completed the six-month follow-up. Mean age was 54.4±8.9, 34.7% had no high school diploma, and 65.3% earned less than $25,000 annually. Barriers to screening included health insurance (41.4%), discomfort of digital rectal exam (32.1%), and fear of cancer diagnosis (29.9%). Mean knowledge score of 21 points increased from 13.27±3.51 to 14.95±4.14 (p<.001), and prostate-specific antigen screening from 22.1% to 62.8%. Men without high school diploma recorded the lowest post-intervention PCa knowledge and screening rate (47.7%), suggestive of the need for more than a single education session. Annual physicals with free prostate examination can maintain the positive trend observed. AU - Ukoli, F. A. AU - Patel, K. AU - Hargreaves, M. AU - Beard, K. AU - Moton, P. J. AU - Bragg, R. AU - Beech, D. AU - Davis, R. DB - Medline DO - 10.1353/hpu.2013.0033 IS - 1 KW - adult African American aged attitude to health clinical trial early diagnosis education health care delivery human male middle aged patient education poverty procedures prostate tumor psychology statistics and numerical data very elderly LA - English M3 - Article N1 - L603736097 2015-04-20 PY - 2013 SN - 1548-6869 SP - 311-331 ST - A tailored prostate cancer education intervention for low-income African Americans: impact on knowledge and screening T2 - Journal of health care for the poor and underserved TI - A tailored prostate cancer education intervention for low-income African Americans: impact on knowledge and screening UR - https://www.embase.com/search/results?subaction=viewrecord&id=L603736097&from=export http://dx.doi.org/10.1353/hpu.2013.0033 VL - 24 ID - 1096 ER - TY - JOUR AB - African American men bear disproportionate burden of prostate cancer (PCa) that can be reduced by early detection. A 15-minute culturally appropriate PCa education intervention developed to communicate effective, relevant, and balanced PCa screening information to low-income African American men was evaluated in men 42 years and older who had not been screened in one year. Of 539 men enrolled, 392 (72.7%) completed the six-month follow-up. Mean age was 54.4±8.9, 34.7% had no high school diploma, and 65.3% earned less than $25,000 annually. Barriers to screening included health insurance (41.4%), discomfort of digital rectal exam (32.1%), and fear of cancer diagnosis (29.9%). Mean knowledge score of 21 points increased from 13.27±3.51 to 14.95±4.14 (p<.001), and prostate-specific antigen screening from 22.1% to 62.8%. Men without high school diploma recorded the lowest post-intervention PCa knowledge and screening rate (47.7%), suggestive of the need for more than a single education session. Annual physicals with free prostate examination can maintain the positive trend observed. © Meharry Medical College. AD - Meharry Medical College, United States Matthew Walker Comprehensive Health Center, Nashville, United States Fisk University, United States Centers for Medicare and Medicaid Services, United States Vanderbilt University, United States AU - Ukoli, F. A. AU - Patel, K. AU - Hargreaves, M. AU - Beard, K. AU - Moton, P. J. AU - Bragg, R. AU - Beech, D. AU - Davis, R. DB - Scopus DO - 10.1353/hpu.2013.0033 IS - 1 KW - African americans Education intervention Informed decision Prostate cancer Screening M3 - Article N1 - Cited By :19 Export Date: 22 March 2021 PY - 2013 SP - 311-331 ST - A tailored prostate cancer education intervention for low-income African Americans: Impact on knowledge and screening T2 - Journal of Health Care for the Poor and Underserved TI - A tailored prostate cancer education intervention for low-income African Americans: Impact on knowledge and screening UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873460234&doi=10.1353%2fhpu.2013.0033&partnerID=40&md5=456739b0e39e8b3ad61409c00db3db33 VL - 24 ID - 2444 ER - TY - JOUR AB - Objective: Despite efforts to reduce cancer disparities, Black women remain underrepresented in cancer research. Virtual health assistants (VHAs) are one promising digital technology for communicating health messages and promoting health behaviors to diverse populations. This study describes participant responses to a VHA-delivered intervention promoting colorectal cancer (CRC) screening with a home-stool test. Methods: We recruited 53 non-Hispanic Black women 50 to 73 years old to participate in focus groups and think-aloud interviews and test a web-based intervention delivered by a race- and gender-concordant VHA. A user-centered design approach prioritized modifications to three successive versions of the intervention based on participants' comments. Results: Participants identified 26 cues relating to components of the VHA's credibility, including trustworthiness, expertise, and authority. Comments on early versions revealed preferences for communicating with a human doctor and negative critiques of the VHA's appearance and movements. Modifications to specific cues improved the user experience, and participants expressed increased willingness to engage with later versions of the VHA and the screening messages it delivered. Informed by the Modality, Agency, Interactivity, Navigability Model, we present a framework for developing credible VHA-delivered cancer screening messages. Conclusions: VHAs provide a systematic way to deliver health information. A culturally sensitive intervention designed for credibility promoted user interest in engaging with guideline-concordant CRC screening messages. We present strategies for effectively using cues to engage audiences with health messages, which can be applied to future research in varying contexts. AD - M.J. Vilaro, STEM Translational Communication Center, College of Journalism & Communications, University of Florida, Gainesville, FL, United States AU - Vilaro, M. J. AU - Wilson-Howard, D. S. AU - Griffin, L. N. AU - Tavassoli, F. AU - Zalake, M. S. AU - Lok, B. C. AU - Modave, F. P. AU - George, T. J. AU - Carek, P. J. AU - Krieger, J. L. DB - Embase Medline DO - 10.1002/pon.5538 IS - 12 KW - adult aged article cancer screening colorectal cancer colorectal tumor controlled study early cancer diagnosis feces analysis female gender human human experiment interview major clinical study male medical information practice guideline psycho-oncology qualitative research race transcription initiation web-based intervention LA - English M3 - Article N1 - L2006724717 2020-09-22 PY - 2020 SN - 1099-1611 1057-9249 SP - 2048-2056 ST - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women T2 - Psycho-Oncology TI - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2006724717&from=export http://dx.doi.org/10.1002/pon.5538 VL - 29 ID - 774 ER - TY - JOUR AB - Objective: Despite efforts to reduce cancer disparities, Black women remain underrepresented in cancer research. Virtual health assistants (VHAs) are one promising digital technology for communicating health messages and promoting health behaviors to diverse populations. This study describes participant responses to a VHA-delivered intervention promoting colorectal cancer (CRC) screening with a home-stool test. Methods: We recruited 53 non-Hispanic Black women 50 to 73 years old to participate in focus groups and think-aloud interviews and test a web-based intervention delivered by a race- and gender-concordant VHA. A user-centered design approach prioritized modifications to three successive versions of the intervention based on participants' comments. Results: Participants identified 26 cues relating to components of the VHA's credibility, including trustworthiness, expertise, and authority. Comments on early versions revealed preferences for communicating with a human doctor and negative critiques of the VHA's appearance and movements. Modifications to specific cues improved the user experience, and participants expressed increased willingness to engage with later versions of the VHA and the screening messages it delivered. Informed by the Modality, Agency, Interactivity, Navigability Model, we present a framework for developing credible VHA-delivered cancer screening messages. Conclusions: VHAs provide a systematic way to deliver health information. A culturally sensitive intervention designed for credibility promoted user interest in engaging with guideline-concordant CRC screening messages. We present strategies for effectively using cues to engage audiences with health messages, which can be applied to future research in varying contexts. © 2020 The Authors. Psycho-Oncology published by John Wiley & Sons Ltd. AD - STEM Translational Communication Center, College of Journalism & Communications, University of Florida, Gainesville, FL, United States Department of Chemistry, Bethune-Cookman University, Daytona Beach, FL, United States Department of Computer & Information Science & Engineering, College of Engineering, University of Florida, Gainesville, FL, United States Department of Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States Division of Hematology & Oncology, College of Medicine, University of Florida, Gainesville, FL, United States Department of Community Health & Family Medicine, College of Medicine, University of Florida, Gainesville, FL, United States AU - Vilaro, M. J. AU - Wilson-Howard, D. S. AU - Griffin, L. N. AU - Tavassoli, F. AU - Zalake, M. S. AU - Lok, B. C. AU - Modave, F. P. AU - George, T. J. AU - Carek, P. J. AU - Krieger, J. L. DB - Scopus DO - 10.1002/pon.5538 IS - 12 KW - colorectal neoplasms cues early detection of cancer health communication internet-based intervention oncology psycho-oncology qualitative research M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - 2048-2056 ST - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women T2 - Psycho-Oncology TI - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091018677&doi=10.1002%2fpon.5538&partnerID=40&md5=915b8e2bdab601d569a76edae265039f VL - 29 ID - 2170 ER - TY - JOUR AB - Objective: Despite efforts to reduce cancer disparities, Black women remain underrepresented in cancer research. Virtual health assistants (VHAs) are one promising digital technology for communicating health messages and promoting health behaviors to diverse populations. This study describes participant responses to a VHA-delivered intervention promoting colorectal cancer (CRC) screening with a home-stool test. Methods: We recruited 53 non-Hispanic Black women 50 to 73 years old to participate in focus groups and think-aloud interviews and test a web-based intervention delivered by a race-and gender-concordant VHA. A user-centered design approach prioritized modifications to three successive versions of the intervention based on participants' comments. Results: Participants identified 26 cues relating to components of the VHA's credibility, including trustworthiness, expertise, and authority. Comments on early versions revealed preferences for communicating with a human doctor and negative critiques of the VHA's appearance and movements. Modifications to specific cues improved the user experience, and participants expressed increased willingness to engage with later versions of the VHA and the screening messages it delivered. Informed by the Modality, Agency, Interactivity, Navigability Model, we present a framework for developing credible VHA-delivered cancer screening messages. Conclusions: VHAs provide a systematic way to deliver health information. A culturally sensitive intervention designed for credibility promoted user interest in engaging with guideline-concordant CRC screening messages. We present strategies for effectively using cues to engage audiences with health messages, which can be applied to future research in varying contexts. AN - WOS:000569080900001 AU - Vilaro, M. J. AU - Wilson-Howard, D. S. AU - Griffin, L. N. AU - Tavassoli, F. AU - Zalake, M. S. AU - Lok, B. C. AU - Modave, F. P. AU - George, T. J. AU - Carek, P. J. AU - Krieger, J. L. DA - Dec DO - 10.1002/pon.5538 IS - 12 N1 - 32893399 PY - 2020 SN - 1057-9249 SP - 2048-2056 ST - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women T2 - Psycho-Oncology TI - Tailoring virtual human-delivered interventions: A digital intervention promoting colorectal cancer screening for Black women VL - 29 ID - 2764 ER - TY - JOUR AB - Objective: Despite efforts to reduce cancer disparities, Black women remain underrepresented in cancer research. Virtual health assistants (VHAs) are one promising digital technology for communicating health messages and promoting health behaviors to diverse populations. This study describes participant responses to a VHA‐delivered intervention promoting colorectal cancer (CRC) screening with a home‐stool test. Methods: We recruited 53 non‐Hispanic Black women 50 to 73 years old to participate in focus groups and think‐aloud interviews and test a web‐based intervention delivered by a race‐ and gender‐concordant VHA. A user‐centered design approach prioritized modifications to three successive versions of the intervention based on participants' comments. Results: Participants identified 26 cues relating to components of the VHA's credibility, including trustworthiness, expertise, and authority. Comments on early versions revealed preferences for communicating with a human doctor and negative critiques of the VHA's appearance and movements. Modifications to specific cues improved the user experience, and participants expressed increased willingness to engage with later versions of the VHA and the screening messages it delivered. Informed by the Modality, Agency, Interactivity, Navigability Model, we present a framework for developing credible VHA‐delivered cancer screening messages. Conclusions: VHAs provide a systematic way to deliver health information. A culturally sensitive intervention designed for credibility promoted user interest in engaging with guideline‐concordant CRC screening messages. We present strategies for effectively using cues to engage audiences with health messages, which can be applied to future research in varying contexts. (PsycInfo Database Record (c) 2021 APA, all rights reserved) AD - Vilaro, Melissa J., STEM Translational Communication Center, College of Journalism & Communications, University of Florida, Gainesville, FL, US, 32611 AN - 2021-06082-004 AU - Vilaro, Melissa J. AU - Wilson-Howard, Danyell S. AU - Griffin, Lauren N. AU - Tavassoli, Fatemeh AU - Zalake, Mohan S. AU - Lok, Benjamin C. AU - Modave, Francois P. AU - George, Thomas J. AU - Carek, Peter J. AU - Krieger, Janice L. DB - psyh DO - 10.1002/pon.5538 DP - EBSCOhost IS - 12 KW - colorectal neoplasms cues early detection of cancer health communication internet‐based intervention oncology psycho‐ oncology qualitative research Cancer Screening Health Promotion Intervention Neoplasms Telemedicine Blacks Colon Disorders N1 - STEM Translational Communication Center, College of Journalism & Communications, University of Florida, Gainesville, FL, US. Release Date: 20210304. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Health Promotion; Intervention; Neoplasms; Telemedicine. Minor Descriptor: Blacks; Colon Disorders; Oncology. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Black Women Focus Group Interview; Think-Aloud Interview. Methodology: Clinical Trial; Empirical Study; Interview; Focus Group; Qualitative Study. Supplemental Data: Tables and Figures Internet. Page Count: 9. Issue Publication Date: Dec, 2020. Publication History: Accepted Date: Aug 23, 2020; Revised Date: Jul 18, 2020; First Submitted Date: Apr 14, 2020. Copyright Statement: Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. The Authors—Psycho‐Oncology. 2020. Sponsor: National Institutes of Health, National Cancer Institute, US. Grant: R01CA207689. Recipients: No recipient indicated PY - 2020 SN - 1057-9249 1099-1611 SP - 2048-2056 ST - Tailoring virtual human‐delivered interventions: A digital intervention promoting colorectal cancer screening for black women T2 - Psycho-Oncology TI - Tailoring virtual human‐delivered interventions: A digital intervention promoting colorectal cancer screening for black women UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2021-06082-004&site=ehost-live&scope=site ORCID: 0000-0001-9950-9170 ORCID: 0000-0002-6249-9180 ORCID: 0000-0003-4366-0757 ORCID: 0000-0002-1190-3729 ORCID: 0000-0003-3975-0274 mgraveley@ufl.edu VL - 29 ID - 1667 ER - TY - JOUR AB - Background. Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of CYP2D6 genotype-guided dose escalation and investigate concentration differences between races. Methods. PM and IM breast cancer patients currently receiving tamoxifen at 20 mg/day were enrolled for genotype-guided escalation to 40 mg/day. Endoxifen was measured at baseline and after 4 months. Quality-of-life data were collected using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Breast Cancer Prevention Trial Menopausal Symptom Scale at baseline and after 4 months. Results. In 353 newly enrolled patients, genotype-guided dose escalation eliminated baseline concentration differences in IM (p = .08), but not PM (p = .009), patients. Endoxifen concentrations were similar in black and white patients overall (p = .63) and within CYP2D6 phenotype groups (p > .05). In the quality-of-life analysis of 480 patients, dose escalation did not meaningfully diminish quality of life; in fact, improvements were seen in several measures including the FACT Breast Cancer subscale (p = .004) and limitations in range of motion (p < .0001) in IM patients. Conclusion. Differences in endoxifen concentration during treatment can be eliminated by doubling the tamoxifen dose in IM patients, without an appreciable effect on quality of life. Validation of the association between endoxifen concentration and efficacy or prospective demonstration of improved efficacy is necessary to warrant clinical uptake of this personalized treatment strategy. AD - University of Michigan, Ann Arbor, Michigan, USA University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Moffitt Cancer Center, Tampa, Florida, USA Laboratory Corporation of America, Burlington, North Carolina, USA Moses Cone Health Cancer Center, Greensboro, North Carolina, USA REX Hematology Oncology Associates, Raleigh, North Carolina, USA Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA Levine Cancer Institute, Charlotte, North Carolina, USA Palmetto Hematology Oncology, Spartanburg, South Carolina, USA Levine Cancer Institute Concord, Concord, North Carolina, USA Waverly Hematology/Oncology, Cary, North Carolina, USA Duke University, Durham, North Carolina, USA Indiana University, Indianapolis, Indiana, USA AN - 116805042. Language: English. Entry Date: 20160720. Revision Date: 20160720. Publication Type: Article AU - Hertz, Daniel L. AU - Deal, Allison AU - Ibrahim, Joseph G. AU - Walko, Christine M. AU - Weck, Karen E. AU - Anderson, Steven AU - Magrinat, Gustav AU - Olajide, Oludamilola AU - Moore, Susan AU - Raab, Rachel AU - Carrizosa, Daniel R. AU - Corso, Steven AU - Schwartz, Garry AU - Graham, Mark AU - Peppercorn, Jeffrey M. AU - Jones, David R. AU - Desta, Zeruesenay AU - Flockhart, David A. AU - Evans, James P. AU - McLeod, Howard L. DB - CINAHL Complete DO - 10.1634/theoncologist.2015-0480 DP - EBSCOhost IS - 7 KW - Tamoxifen -- Administration and Dosage Tamoxifen -- Analogs and Derivatives Tamoxifen -- Pharmacokinetics Cytochrome P-450 Enzyme System -- Metabolism Genotype Polymorphism, Genetic Pharmacogenetics Dose-Response Relationship, Drug Tamoxifen -- Adverse Effects Cancer Patients Quality of Life Functional Assessment Perimenopausal Symptoms Clinical Assessment Tools Scales Prospective Studies Secondary Analysis Cancer Care Facilities North Carolina Chromatography, High Pressure Liquid Mass Spectrometry Summated Rating Scaling Activities of Daily Living Analysis of Variance Paired T-Tests Linear Regression Data Analysis Software Clinical Trials Socioeconomic Factors Treatment Duration Chemotherapy, Cancer P-Value Female Adult Middle Age Aged Aged, 80 and Over Breast Neoplasms -- Classification Neoplasm Invasiveness Carcinoma, Ductal, Breast Carcinoma in Situ Treatment Outcomes Confidence Intervals Neoplasm Recurrence, Local Human N1 - research; tables/charts. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Special Interest: Women's Health. Instrumentation: Functional Assessment of Cancer Therapy-Breast (FACT-B); Breast Cancer Prevention Trial Menopausal Symptom Scale (BCPT-MSS); Endocrine Subscale of the Functional Assessment of Cancer Therapy-Breast (FACT-B [ES]) (Version 3). NLM UID: 9607837. PY - 2016 SN - 1083-7159 SP - 795-803 ST - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity T2 - Oncologist TI - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116805042&site=ehost-live&scope=site VL - 21 ID - 2112 ER - TY - JOUR AB - Background. Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen doseto 40mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of CYP2D6 genotypeguided dose escalation and investigate concentration differences between races. Methods. PM and IM breast cancer patients currently receiving tamoxifen at 20 mg/day were enrolled for genotype-guided escalation to 40 mg/day. Endoxifen was measured at baseline and after 4 months. Quality-of-life datawere collected using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Breast Cancer Prevention Trial Menopausal Symptom Scale at baseline and after 4 months. Results. In 353 newly enrolled patients, genotype-guided dose escalation eliminated baseline concentration differences in IM (p = .08), but not PM (p = .009), patients. Endoxifen concentrations were similar in black and white patients overall (p = .63) and within CYP2D6 phenotype groups (p>.05). In the quality-oflife analysis of 480 patients, dose escalation did not meaningfully diminish quality of life; infact,improvements were seen in several measures including the FACT Breast Cancer subscale (p 5 .004) and limitations in range of motion (p>.0001) in IM patients. Conclusion. Differences in endoxifen concentration during treatment can be eliminated by doubling the tamoxifen dose in IM patients, without an appreciable effecton quality of life. Validation of the association between endoxifen concentration and efficacy or prospective demonstration of improvedefficacy is necessary to warrant clinical uptake of this personalized treatment strategy. AD - W.J. Irvin, Bon Secours Virginia Health System, Bon Secours Cancer Institute, 14051 St. Francis Boulevard, Suite 2210, Midlothian, VA, United States AU - Hertz, D. L. AU - Deal, A. AU - Ibrahim, J. G. AU - Walko, C. M. AU - Weck, K. E. AU - Anderson, S. AU - Magrinat, G. AU - Olajide, O. AU - Moore, S. AU - Raab, R. AU - Carrizosa, D. R. AU - Corso, S. AU - Schwartz, G. AU - Graham, M. AU - Peppercorn, J. M. AU - Jones, D. R. AU - Desta, Z. AU - Flockhart, D. A. AU - Evans, J. P. AU - McLeod, H. L. AU - Carey, L. A. AU - Irvin, W. J. DB - Embase Medline DO - 10.1634/theoncologist.2015-0480 IS - 7 KW - cytochrome P450 2D6 endoxifen tamoxifen adult article blood sampling breast cancer breast tenderness cancer patient drug dose escalation drug dose increase enzyme activity female genotype high performance liquid chromatography hormonal therapy human major clinical study menopause phenotype priority journal quality of life race tandem mass spectrometry vagina bleeding vaginal dryness vomiting LA - English M3 - Article N1 - L611220414 2016-07-25 2016-07-28 PY - 2016 SN - 1549-490X 1083-7159 SP - 795-803 ST - Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity T2 - Oncologist TI - Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity UR - https://www.embase.com/search/results?subaction=viewrecord&id=L611220414&from=export http://dx.doi.org/10.1634/theoncologist.2015-0480 VL - 21 ID - 969 ER - TY - JOUR AB - Background. Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen doseto 40mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of CYP2D6 genotypeguided dose escalation and investigate concentration differences between races. Methods. PM and IM breast cancer patients currently receiving tamoxifen at 20 mg/day were enrolled for genotype-guided escalation to 40 mg/day. Endoxifen was measured at baseline and after 4 months. Quality-of-life datawere collected using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Breast Cancer Prevention Trial Menopausal Symptom Scale at baseline and after 4 months. Results. In 353 newly enrolled patients, genotype-guided dose escalation eliminated baseline concentration differences in IM (p = .08), but not PM (p = .009), patients. Endoxifen concentrations were similar in black and white patients overall (p = .63) and within CYP2D6 phenotype groups (p>.05). In the quality-oflife analysis of 480 patients, dose escalation did not meaningfully diminish quality of life; infact,improvements were seen in several measures including the FACT Breast Cancer subscale (p 5 .004) and limitations in range of motion (p>.0001) in IM patients. Conclusion. Differences in endoxifen concentration during treatment can be eliminated by doubling the tamoxifen dose in IM patients, without an appreciable effecton quality of life. Validation of the association between endoxifen concentration and efficacy or prospective demonstration of improvedefficacy is necessary to warrant clinical uptake of this personalized treatment strategy. © AlphaMed Press 2016. AD - University of Michigan, Ann Arbor, MI, United States University of North Carolina at Chapel Hill, Chapel Hill, NC, United States Moffitt Cancer Center, Tampa, FL, United States Laboratory Corporation of America, Burlington, NC, United States Moses Cone Health Cancer Center, Greensboro, NC, United States REX Hematology Oncology Associates, Raleigh, NC, United States Brody School of Medicine, East Carolina University, Greenville, NC, United States Levine Cancer Institute, Charlotte, NC, United States PalmettoHematology Oncology, Spartanburg, SC, United States Levine Cancer Institute Concord, Concord, NC, United States Waverly Hematology/Oncology, Cary, NC, United States Duke University, Durham, NC, United States Indiana University, Indianapolis, IN, United States Bon Secours Cancer Institute, Richmond, VA, United States AU - Hertz, D. L. AU - Deal, A. AU - Ibrahim, J. G. AU - Walko, C. M. AU - Weck, K. E. AU - Anderson, S. AU - Magrinat, G. AU - Olajide, O. AU - Moore, S. AU - Raab, R. AU - Carrizosa, D. R. AU - Corso, S. AU - Schwartz, G. AU - Graham, M. AU - Peppercorn, J. M. AU - Jones, D. R. AU - Desta, Z. AU - Flockhart, D. A. AU - Evans, J. P. AU - McLeod, H. L. AU - Carey, L. A. AU - Irvin, W. J., Jr. DB - Scopus DO - 10.1634/theoncologist.2015-0480 IS - 7 KW - CYP2D6 Endoxifen Genotype Pharmacogenetics Quality of life Race Tamoxifen Toxicity M3 - Article N1 - Cited By :21 Export Date: 22 March 2021 PY - 2016 SP - 795-803 ST - Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity T2 - Oncologist TI - Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84978538810&doi=10.1634%2ftheoncologist.2015-0480&partnerID=40&md5=f7a4e6ddbbe2017dfbe3bd9611fd1edb VL - 21 ID - 2342 ER - TY - JOUR AB - Background. Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metabolizer (PM), patients achieve endoxifen concentrations similar to those of extensive metabolizer patients on 20 mg/day. We expanded enrollment to assess the safety of CYP2D6 genotype-guided dose escalation and investigate concentration differences between races. Methods. PM and IM breast cancer patients currently receiving tamoxifen at 20 mg/day were enrolled for genotype-guided escalation to 40 mg/day. Endoxifen was measured at baseline and after 4 months. Quality-of-life data were collected using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and Breast Cancer Prevention Trial Menopausal Symptom Scale at baseline and after 4 months. Results. In 353 newly enrolled patients, genotype-guided dose escalation eliminated baseline concentration differences in IM (p = .08), but not PM (p = .009), patients. Endoxifen concentrations were similar in black and white patients overall (p = .63) and within CYP2D6 phenotype groups (p > .05). In the quality-of life analysis of 480 patients, dose escalation did not meaningfully diminish quality of life; in fact, improvements were seen in several measures including the FACT Breast Cancer subscale (p = .004) and limitations in range of motion (p < .0001) in IM patients. Conclusion. Differences in endoxifen concentration during treatment can be eliminated by doubling the tamoxifen dose in IM patients, without an appreciable effect on quality of life. Validation of the association between endoxifen concentration and efficacy or prospective demonstration of improved efficacy is necessary to warrant clinical uptake of this personalized treatment strategy. AN - WOS:000380957400006 AU - Hertz, D. L. AU - Deal, A. AU - Ibrahim, J. G. AU - Walko, C. M. AU - Weck, K. E. AU - Anderson, S. AU - Magrinat, G. AU - Olajide, O. AU - Moore, S. AU - Raab, R. AU - Carrizosa, D. R. AU - Corso, S. AU - Schwartz, G. AU - Graham, M. AU - Peppercorn, J. M. AU - Jones, D. R. AU - Desta, Z. AU - Flockhart, D. A. AU - Evans, J. P. AU - McLeod, H. L. AU - Carey, L. A. AU - Irvin, W. J. DA - Jul DO - 10.1634/theoncologist.2015-0480 IS - 7 N1 - 27226358 PY - 2016 SN - 1083-7159 SP - 795-803 ST - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity T2 - Oncologist TI - Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity VL - 21 ID - 2941 ER - TY - JOUR AB - Competing causes of mortality in the elderly decrease the potential net benefit from colorectal cancer screening and increase the likelihood of potential harms. Individualized decision making has been recommended, so that the elderly can decide whether or not to undergo colorectal cancer (CRC) screening. The objective is to develop and test a decision aid designed to promote individualized colorectal cancer screening decision making for adults age 75 and over. We used formative research and cognitive testing to develop and refine the decision aid. We then tested the decision aid in an uncontrolled trial. The primary outcome was the proportion of patients who were prepared to make an individualized decision, defined a priori as having adequate knowledge (10/15 questions correct) and clear values (25 or less on values clarity subscale of decisional conflict scale). Secondary outcomes included overall score on the decisional conflict scale, and preferences for undergoing screening. We enrolled 46 adults in the trial. The decision aid increased the proportion of participants with adequate knowledge from 4% to 52% (p < 0.01) and the proportion prepared to make an individualized decision from 4% to 41% (p < 0.01). The proportion that preferred to undergo CRC screening decreased from 67% to 61% (p = 0. 76); 7 participants (15%) changed screening preference (5 against screening, 2 in favor of screening) In an uncontrolled trial, the elderly participants appeared better prepared to make an individualized decision about whether or not to undergo CRC screening after using the decision aid. AD - C.L. Lewis, Department of Medicine, University of North Carolina, Chapel Hill , NC, USA. AU - Lewis, C. L. AU - Golin, C. E. AU - DeLeon, C. AU - Griffith, J. M. AU - Ivey, J. AU - Trevena, L. AU - Pignone, M. DB - Medline KW - aged article Caucasian clinical trial colonoscopy colorectal tumor decision support system educational status ethnology female health literacy human informed consent male mass screening Black person patient patient education patient selection psychological aspect statistics LA - English M3 - Article N1 - L360307294 2010-12-01 PY - 2010 SN - 1472-6947 SP - 54 ST - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial T2 - BMC medical informatics and decision making TI - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L360307294&from=export VL - 10 ID - 1154 ER - TY - JOUR AB - Background: Competing causes of mortality in the elderly decrease the potential net benefit from colorectal cancer screening and increase the likelihood of potential harms. Individualized decision making has been recommended, so that the elderly can decide whether or not to undergo colorectal cancer (CRC) screening. The objective is to develop and test a decision aid designed to promote individualized colorectal cancer screening decision making for adults age 75 and over.Methods: We used formative research and cognitive testing to develop and refine the decision aid. We then tested the decision aid in an uncontrolled trial. The primary outcome was the proportion of patients who were prepared to make an individualized decision, defined a priori as having adequate knowledge (10/15 questions correct) and clear values (25 or less on values clarity subscale of decisional conflict scale). Secondary outcomes included overall score on the decisional conflict scale, and preferences for undergoing screening.Results: We enrolled 46 adults in the trial. The decision aid increased the proportion of participants with adequate knowledge from 4% to 52% (p < 0.01) and the proportion prepared to make an individualized decision from 4% to 41% (p < 0.01). The proportion that preferred to undergo CRC screening decreased from 67% to 61% (p = 0. 76); 7 participants (15%) changed screening preference (5 against screening, 2 in favor of screening)Conclusion: In an uncontrolled trial, the elderly participants appeared better prepared to make an individualized decision about whether or not to undergo CRC screening after using the decision aid. AD - Department of Medicine, University of North Carolina, Chapel Hill. NC, USA Department of Medicine, University of North Carolina, Chapel Hill , NC, USA. carmen_lewis@med.unc.edu AN - 104349348. Language: English. Entry Date: 20130222. Revision Date: 20200708. Publication Type: journal article AU - Lewis, C. L. AU - Golin, C. E. AU - DeLeon, C. AU - Griffith, J. M. AU - Ivey, J. AU - Trevena, L. AU - Pignone, M. AU - Lewis, Carmen L. AU - Golin, Carol E. AU - DeLeon, Chris AU - Griffith, Jennifer M. AU - Ivey, Jena AU - Trevena, Lyndal AU - Pignone, Michael DB - CINAHL Complete DO - 10.1186/1472-6947-10-54 DP - EBSCOhost IS - 1 KW - Colonoscopy -- Psychosocial Factors Colorectal Neoplasms -- Diagnosis Decision Support Techniques Health Screening -- Psychosocial Factors Aged Aged, 80 and Over Black Persons -- Psychosocial Factors Black Persons -- Statistics and Numerical Data Clinical Trials Colorectal Neoplasms -- Ethnology Consent Disabled -- Psychosocial Factors Disabled -- Statistics and Numerical Data Educational Status Female Human Information Literacy Male Patient Education Patient Selection White Persons -- Psychosocial Factors White Persons -- Statistics and Numerical Data N1 - clinical trial; research. Journal Subset: Biomedical; Computer/Information Science; Europe; UK & Ireland. Grant Information: 5K07CA104128/CA/NCI NIH HHS/United States. NLM UID: 101088682. PMID: NLM20849625. PY - 2010 SN - 1472-6947 SP - 54-54 ST - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial T2 - BMC Medical Informatics & Decision Making TI - A targeted decision aid for the elderly to decide whether to undergo colorectal cancer screening: development and results of an uncontrolled trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104349348&site=ehost-live&scope=site VL - 10 ID - 1836 ER - TY - JOUR AB - BACKGROUND: Long‐term use of adjuvant endocrine therapy (AET) among women with early‐stage, hormone receptor‐positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web‐enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web‐enabled app that collects and transmits patient‐reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence. METHODS: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12‐months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self‐efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self‐report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence. DISCUSSION: A successful web‐enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" ‐ reduce costs while improving health outcomes and the patient care experience. TRIAL REGISTRATION: NCT03592771. Prospectively registered on July 19, 2018. AN - CN-02075779 AU - Paladino, A. J. AU - Anderson, J. N. AU - Krukowski, R. A. AU - Waters, T. AU - Kocak, M. AU - Graff, C. AU - Blue, R. AU - Jones, T. N. AU - Buzaglo, J. AU - Vidal, G. AU - et al. DO - 10.1186/s12913-019-4588-x IS - 1 KW - *breast cancer *cancer adjuvant therapy *hormonal therapy *medication compliance *patient‐reported outcome *quality of life *transcription initiation Adult Article Controlled study Drug monitoring Electronic health record Female Health care utilization Human Major clinical study Patient care Race Randomized controlled trial Self report M3 - Journal: Article PY - 2019 SP - 977‐ ST - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer T2 - BMC health services research TI - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02075779/full VL - 19 ID - 1651 ER - TY - JOUR AB - BACKGROUND: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor-positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence. METHODS: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence. DISCUSSION: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience. TRIAL REGISTRATION: NCT03592771. Prospectively registered on July 19, 2018. AU - Paladino, A. J. AU - Anderson, J. N. AU - Krukowski, R. A. AU - Waters, T. AU - Kocak, M. AU - Graff, C. AU - Blue, R. AU - Jones, T. N. AU - Buzaglo, J. AU - Vidal, G. AU - Schwartzberg, L. AU - Graetz, I. DB - Medline DO - 10.1186/s12913-019-4588-x IS - 1 KW - NCT03592771 African American breast tumor Caucasian female human Internet medication compliance mobile application multimodality cancer therapy patient compliance psychology quality of life questionnaire randomized controlled trial (topic) reminder system self report tumor recurrence LA - English M3 - Article N1 - L630374602 2020-01-02 2020-04-07 PY - 2019 SN - 1472-6963 SP - 977 ST - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer T2 - BMC health services research TI - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L630374602&from=export http://dx.doi.org/10.1186/s12913-019-4588-x VL - 19 ID - 829 ER - TY - JOUR AB - Background: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor-positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence.Methods: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence.Discussion: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience.Trial Registration: NCT03592771. Prospectively registered on July 19, 2018. AD - Department of Health Policy and Management, Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA, USA The West Cancer Center & Research Institute, Memphis, TN, USA College of Nursing, The University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN, USA Department of Preventive Medicine, The University of Tennessee Health Science Center, College of Medicine, 66 N Pauline St, Memphis, TN, USA Department of Health Management and Policy, The University of Kentucky, College of Public Health, Lexington, KY, USA Department of Patient Reported Outcomes, Vector Oncology, Memphis, TN, USA AN - 140452896. Language: English. Entry Date: In Process. Revision Date: 20200506. Publication Type: journal article. Journal Subset: Biomedical AU - Paladino, Andrew J. AU - Anderson, Janeane N. AU - Krukowski, Rebecca A. AU - Waters, Teresa AU - Kocak, Mehmet AU - Graff, Carolyn AU - Blue, Ryan AU - Jones, Tameka N. AU - Buzaglo, Joanne AU - Vidal, Gregory AU - Schwartzberg, Lee AU - Graetz, Ilana DB - CINAHL Complete DO - 10.1186/s12913-019-4588-x DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Drug Therapy Mobile Applications Clinical Trials Quality of Life Combined Modality Therapy Reminder Systems Medication Compliance Black Persons -- Statistics and Numerical Data Self Report Breast Neoplasms -- Psychosocial Factors White Persons -- Statistics and Numerical Data Female Internet Patient Compliance Neoplasm Recurrence, Local -- Drug Therapy Ferrans and Powers Quality of Life Index Impact of Events Scale N1 - Europe; Peer Reviewed; UK & Ireland. Instrumentation: Longitudinal Interval Follow-Up Evaluation (LIFE); Impact of Events Scale (IES); Ferrans and Powers Quality of Life Index. Grant Information: 1R01CA218155/CA/NCI NIH HHS/United States. NLM UID: 101088677. PMID: NLM31856812. PY - 2019 SN - 1472-6963 SP - 1-12 ST - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer T2 - BMC Health Services Research TI - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=140452896&site=ehost-live&scope=site VL - 19 ID - 2130 ER - TY - JOUR AB - Background: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor-positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence. Methods: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence. Discussion: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience. Trial registration: NCT03592771. Prospectively registered on July 19, 2018. © 2019 The Author(s). AD - Department of Health Policy and Management, Emory University, Rollins School of Public Health, 1518 Clifton Road, Atlanta, GA, United States West Cancer Center and Research Institute, Memphis, TN, United States College of Nursing, University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN, United States Department of Preventive Medicine, University of Tennessee Health Science Center, College of Medicine, 66 N Pauline St, Memphis, TN, United States Department of Health Management and Policy, University of Kentucky, College of Public Health, Lexington, KY, United States Department of Patient Reported Outcomes, Vector Oncology, Memphis, TN, United States AU - Paladino, A. J. AU - Anderson, J. N. AU - Krukowski, R. A. AU - Waters, T. AU - Kocak, M. AU - Graff, C. AU - Blue, R. AU - Jones, T. N. AU - Buzaglo, J. AU - Vidal, G. AU - Schwartzberg, L. AU - Graetz, I. C7 - 977 DB - Scopus DO - 10.1186/s12913-019-4588-x IS - 1 KW - Adjuvant endocrine therapy Breast cancer Medication adherence Mhealth Patient-reported outcomes Quality of life Randomized controlled trial M3 - Article N1 - Cited By :2 Export Date: 22 March 2021 PY - 2019 ST - THRIVE study protocol: A randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer T2 - BMC Health Services Research TI - THRIVE study protocol: A randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076983761&doi=10.1186%2fs12913-019-4588-x&partnerID=40&md5=8534135a0458a1aa25eb8e4cb2a3090a VL - 19 ID - 2213 ER - TY - JOUR AB - Background: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence. Methods: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence. Discussion: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience. AN - WOS:000506201200002 AU - Paladino, A. J. AU - Anderson, J. N. AU - Krukowski, R. A. AU - Waters, T. AU - Kocak, M. AU - Graff, C. AU - Blue, R. AU - Jones, T. N. AU - Buzaglo, J. AU - Vidal, G. AU - Schwartzberg, L. AU - Graetz, I. DA - Dec DO - 10.1186/s12913-019-4588-x IS - 1 N1 - 977 31856812 PY - 2019 ST - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer T2 - Bmc Health Services Research TI - THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer VL - 19 ID - 2802 ER - TY - JOUR AB - Objectives: Recruiting underserved women in breast cancer research studies remains a significant challenge. We present our experience attempting to locate and recruit minority and medically underserved women identified in a Nashville, Tennessee public hospital for a mammography follow-up study. Study design: The study design was a retrospective hospital-based case-control study. Methods: We identified 227 women (88 African-American, 65 Caucasian, 36 other minority, 38 race undocumented in the medical record) who had undergone screening mammography and received an abnormal result during 2003-2004. Of the 227 women identified, 159 women were successfully located with implementation of a tracking protocol and more rigorous attempts to locate the women using online directory assistance and public record search engines. Women eligible for the study were invited to participate in a telephone research survey. Study completion was defined as fully finishing the telephone survey. Results: An average of 4.6 telephone calls (range 1-19) and 2.7 months (range 1-490 days) were required to reach the 159 women contacted. Within three contact attempts, more cases were located than controls (61% cases vs. 49% controls, p = 0.03). African-American women cases were four times likely to be recruited than African-American controls, (OR, 4.07; 95% CI, 1.59-10.30) (p = 0.003). After 3 months of effort, we located 67% of African-American women, 63% of Caucasian women, and 56% of other minorities. Ultimately, after a maximum of 12 attempts to contact women, 77% of African-American women and 71% of Caucasian women were eventually found. Of these, 59% of African-American women, 69% Caucasian women, and 50% other minorities were located and completed the study survey for an overall response rate of 59%, 71%, and 47% respectively. Conclusions: Data collection and study recruitment efforts were more challenging in racial and ethnic minorities. Continuing attempts to contact women may increase minority group study participation but does not guarantee retention or study completion. © 2008 Elsevier Inc. All rights reserved. AD - A.M. Fair, Department of Surgery, Meharry Medical College, 1005 Dr. D.B. Todd Boulevard, Nashville, TN 37208, United States AU - Fair, A. M. AU - Wujcik, D. AU - Lin, J. M. S. AU - Egan, K. M. AU - Grau, A. M. AU - Zheng, W. DB - Embase Medline DO - 10.1016/j.cct.2008.01.003 IS - 4 KW - adult African American aged article breast cancer cancer screening case control study clinical protocol European American female follow up human lowest income group major clinical study mammography minority group patient compliance patient participation LA - English M3 - Article N1 - L50070300 2008-06-18 PY - 2008 SN - 1551-7144 SP - 537-546 ST - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research T2 - Contemporary Clinical Trials TI - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50070300&from=export http://dx.doi.org/10.1016/j.cct.2008.01.003 VL - 29 ID - 1208 ER - TY - JOUR AB - Objectives: Recruiting underserved women in breast cancer research studies remains a significant challenge. We present our experience attempting to locate and recruit minority and medically underserved women identified in a Nashville, Tennessee public hospital for a mammography follow-up study. Study design: The study design was a retrospective hospital-based case-control study. Methods: We identified 227 women (88 African-American, 65 Caucasian, 36 other minority, 38 race undocumented in the medical record) who had undergone screening mammography and received an abnormal result during 2003-2004. Of the 227 women identified, 159 women were successfully located with implementation of a tracking protocol and more rigorous attempts to locate the women using online directory assistance and public record search engines. Women eligible for the study were invited to participate in a telephone research survey. Study completion was defined as fully finishing the telephone survey. Results: An average of 4.6 telephone calls (range 1-19) and 2.7 months (range 1-490 days) were required to reach the 159 women contacted. Within three contact attempts, more cases were located than controls (61% cases vs. 49% controls, p = 0.03). African-American women cases were four times likely to be recruited than African-American controls, (OR, 4.07; 95% CI, 1.59-10.30) (p = 0.003). After 3 months of effort, we located 67% of African-American women, 63% of Caucasian women, and 56% of other minorities. Ultimately, after a maximum of 12 attempts to contact women, 77% of African-American women and 71% of Caucasian women were eventually found. Of these, 59% of African-American women, 69% Caucasian women, and 50% other minorities were located and completed the study survey for an overall response rate of 59%, 71%, and 47% respectively. Conclusions: Data collection and study recruitment efforts were more challenging in racial and ethnic minorities. Continuing attempts to contact women may increase minority group study participation but does not guarantee retention or study completion. © 2008 Elsevier Inc. All rights reserved. AD - Department of Surgery, Meharry Medical College, 1005 Dr. D.B. Todd Boulevard, Nashville, TN 37208, United States Clinical Trials Office, Meharry/Vanderbilt Cancer Partnership, Nashville General Hospital, 1818 Albion Street, Nashville, TN 37208, United States Chronic Viral Diseases Branch, National Center for Zoonotic, Vector borne and Enteric Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., Atlanta, GA 30333, United States H. Lee Moffitt Cancer Center, Research Institute, the University of South Florida, Tampa, FL 33612, United States Division of Surgical Oncology, Vanderbilt University, Nashville, TN 37232, United States Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Center for Epidemiologic Research, Nashville, TN 37232, United States AU - Fair, A. M. AU - Wujcik, D. AU - Lin, J. M. S. AU - Egan, K. M. AU - Grau, A. M. AU - Zheng, W. DB - Scopus DO - 10.1016/j.cct.2008.01.003 IS - 4 KW - Abnormal mammography follow-up Case-control studies Medically underserved females Study recruitment M3 - Article N1 - Cited By :14 Export Date: 22 March 2021 PY - 2008 SP - 537-546 ST - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research T2 - Contemporary Clinical Trials TI - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-44249122605&doi=10.1016%2fj.cct.2008.01.003&partnerID=40&md5=a8d8f4eb1c1426372da4546290b2e646 VL - 29 ID - 2534 ER - TY - JOUR AB - Objectives: Recruiting underserved women in breast cancer research studies remains a significant challenge. We present our experience attempting to locate and recruit minority and medically underserved women identified in a Nashville, Tennessee public hospital for a mammography follow-up study. Study design: The study design was a retrospective hospital-based case-control study. Methods: We identified 227 women (88 African-American, 65 Caucasian, 36 other minority, 38 race undocumented in the medical record) who had undergone screening mammography and received an abnormal result during 2003-2004. Of the 227 women identified, 159 women were successfully located with implementation of a tracking protocol and more rigorous attempts to locate the women using online directory assistance and public record search engines. Women eligible for the study were invited to participate in a telephone research survey. Study completion was defined as fully finishing the telephone survey. Results: An average of 4.6 telephone calls (range 1-19) and 2.7 months (range 1-490 days) were required to reach the 159 women contacted. Within three contact attempts, more cases were located than controls (61% cases vs. 49% controls, p=0.03). African-American women cases were four times likely to be recruited than African-American controls, (OR, 4.07; 95% CI, 1.59-10.30) (p=0.003). After 3 months of effort, we located 67% of African-American women, 63% of Caucasian women, and 56% of other minorities. Ultimately, after a maximum of 12 attempts to contact women, 77% of African-American women and 71% of Caucasian women were eventually found. Of these, 59% of African-American women, 69% Caucasian women, and 50% other minorities were located and completed the study survey for an overall response rate of 59%, 71%, and 47% respectively. Conclusions: Data collection and study recruitment efforts were more challenging in racial and ethnic minorities. Continuing attempts to contact women may increase minority group study participation but does not guarantee retention or study completion. (c) 2008 Elsevier Inc. All rights reserved. AN - WOS:000257014600011 AU - Fair, A. M. AU - Wujcik, D. AU - Lin, J. M. S. AU - Egan, K. M. AU - Grau, A. M. AU - Zheng, W. DA - Jul DO - 10.1016/j.cct.2008.01.003 IS - 4 N1 - 18289943 PY - 2008 SN - 1551-7144 SP - 537-546 ST - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research T2 - Contemporary Clinical Trials TI - Timing is everything: Methodologic issues locating and recruiting medically underserved women for abnormal mammography follow-up research VL - 29 ID - 3167 ER - TY - JOUR AB - Ages at menarche and first birth are established risk factors for breast cancer. The interval between these ages may also affect risk, since the breast is more susceptible to carcinogenic insults during this period than during the parous period. However, few investigators have studied this relation. Using logistic regression, the authors evaluated associations between the timing of reproductive events and breast cancer risk among 4,013 cases and 4,069 controls enrolled in a multicenter, population-based US case-control study of White and African-American women (1994-1998). For White, parous premenopausal and postmenopausal women, those who had an interval of ≥16 years between the ages of menarche and first birth had 1.5-fold (95% confidence interval (CI): 1.0, 2.2) and 1.4-fold (95% CI: 1.1, 1.8) increased risks of breast cancer, respectively, in comparison with those who had ≤5 years between these ages. Adjusting for age at first birth altered these risk estimates somewhat, to odds ratios of 1.5 (95% CI: 0.8, 2.9) and 1.0 (95% CI: 0.6, 1.5), respectively. These associations were stronger for lobular and hormone-receptor-positive tumors but were absent among premenopausal African-American women. The authors conclude that the interval between age at menarche and age at first birth is associated with the risk of hormonally sensitive types of breast cancer, particularly among White women. © The Author 2007. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. AD - Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States Department of Biostatistics and Epidemiology, School of Medicine, University of Pennsylvania, Philadelphia, PA, United States Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States Department of Nutrition, Faculty of Medicine, University of Oslo, Oslo, Norway Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, MA, United States Contraception and Reproductive Branch, Center for Population Research, National Institute of Child Health and Human Development, Bethesda, MD, United States Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-C308, Seattle, WA 98109-1024, United States AU - Li, C. I. AU - Malone, K. E. AU - Daling, J. R. AU - Potter, J. D. AU - Bernstein, L. AU - Marchbanks, P. A. AU - Strom, B. L. AU - Simon, M. S. AU - Press, M. F. AU - Ursin, G. AU - Burkman, R. T. AU - Folger, S. G. AU - Norman, S. AU - McDonald, J. A. AU - Spirtas, R. DB - Scopus DO - 10.1093/aje/kwm271 IS - 2 KW - Breast neoplasms Histology Menarche Menopause Pregnancy Premenopause Receptors, estrogen Receptors, progesterone M3 - Article N1 - Cited By :72 Export Date: 22 March 2021 PY - 2008 SP - 230-239 ST - Timing of menarche and first full-term birth in relation to breast cancer risk T2 - American Journal of Epidemiology TI - Timing of menarche and first full-term birth in relation to breast cancer risk UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-38349186350&doi=10.1093%2faje%2fkwm271&partnerID=40&md5=e1fb312da84ce20ba6b34129826eb8fe VL - 167 ID - 2545 ER - TY - JOUR AB - Public health actions to improve African American men's ability to make informed decisions about participation in prostate cancer control activities have a greater likelihood of success when they are theory driven and informed by members of the target population. This article reports on formative research to evaluate the usefulness of the theory of reasoned action as a model to explain and predict prostate cancer information-seeking behavior by African American men. Fifty-two men participated in eight focus group interviews. Positive behavioral beliefs for obtaining prostate cancer information from physicians included increasing awareness of and obtaining accurate information about the disease, early detection and screening, and treatment. Negative beliefs included fear, distrust, and inconvenience. Significant others, peers, siblings, and religious leaders were identified as individuals who could influence this behavior. These findings provide additional insight into ways to reach and intervene with African American men to influence this important cancer control activity. © 2007 by SOPHE. AD - L. Ross, 203-B FSH Science Research Center, College of Pharmacy and Pharmaceutical Sciences, Florida A and M University, Tallahassee, FL 32307 AU - Ross, L. AU - Kohler, C. L. AU - Grimley, D. M. AU - Green, B. L. AU - Anderson-Lewis, C. DB - Medline DO - 10.1177/1090198106290751 IS - 3 KW - adult African American aged article human information processing information service male middle aged patient attitude patient education patient participation prostate tumor theoretical model United States utilization review LA - English M3 - Article N1 - L46836335 2007-08-16 PY - 2007 SN - 1090-1981 1552-6127 SP - 422-440 ST - Toward a model of prostate cancer information seeking: Identifying salient behavioral and normative beliefs among African American men T2 - Health Education and Behavior TI - Toward a model of prostate cancer information seeking: Identifying salient behavioral and normative beliefs among African American men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L46836335&from=export http://dx.doi.org/10.1177/1090198106290751 VL - 34 ID - 1232 ER - TY - JOUR AB - Introduction: For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. Patients and Methods: From February 2017 through February 2019, we enrolled subjects in a trial examining telephone-based navigation during low-dose computed tomography (LDCT) for lung cancer screening. We identified patients for whom LDCT was ordered and who were approached, but not enrolled, in the trial. We categorized nonenrollment as the patient had declined or could not be reached. We compared the characteristics and LDCT completion rates among these groups and the enrolled population using the 2-sample t test and χ2 test. Results: Of 900 individuals approached for participation (mean age, 62 years; 45% women, 53% black), 447 were enrolled in the screening clinical trial. No significant demographic differences were found between the enrolled and nonenrolled cohorts. Of the 453 individuals not enrolled, 251 (55%) had declined participation and 202 (45%) could not be reached, despite up to 6 attempts. LDCT completion was significantly associated with enrollment status: 81% of enrolled individuals, 73% of individuals who declined participation, and 49% of those who could not be reached (P < .001). Conclusions: In the present single-center study, demographic factors did not predict for participation in a lung cancer screening trial. Lung cancer screening adherence rates were substantially lower for those not enrolled in a screening trial, especially for those who could not be contacted. These findings may inform the broader implementation of screening programs. AD - D.E. Gerber, Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Mail Code 8852, Dallas, TX, United States AU - Gerber, D. E. AU - Hamann, H. A. AU - Chavez, C. AU - Dorsey, O. AU - Santini, N. O. AU - Browning, T. AU - Ochoa, C. D. AU - Adesina, J. AU - Natchimuthu, V. S. AU - Steen, E. AU - Zhu, H. AU - Lee, S. J. C. DB - Embase Medline DO - 10.1016/j.cllc.2020.02.010 IS - 4 KW - NCT02758054 adult article cancer screening chi square test cohort analysis comparative study computer assisted tomography controlled study demography female health behavior human lung cancer major clinical study male middle aged patient compliance patient participation prospective study randomized controlled trial Student t test Texas LA - English M3 - Article N1 - L2005225652 2020-03-19 Data on lung cancer screening come from prospective clinical trials. We determined the characteristics and screening adherence among individuals eligible for, but not enrolled in, a trial. Although the demographic data did not differ, adherence was significantly lower among nonenrolled individuals, especially those who could not be reached. These findings may inform the broader implementation of screening programs. PY - 2020 SN - 1938-0690 1525-7304 SP - 326-332 ST - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial T2 - Clinical Lung Cancer TI - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L2005225652&from=export http://dx.doi.org/10.1016/j.cllc.2020.02.010 VL - 21 ID - 798 ER - TY - JOUR AB - Introduction: For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial.Patients and Methods: From February 2017 through February 2019, we enrolled subjects in a trial examining telephone-based navigation during low-dose computed tomography (LDCT) for lung cancer screening. We identified patients for whom LDCT was ordered and who were approached, but not enrolled, in the trial. We categorized nonenrollment as the patient had declined or could not be reached. We compared the characteristics and LDCT completion rates among these groups and the enrolled population using the 2-sample t test and χ2 test.Results: Of 900 individuals approached for participation (mean age, 62 years; 45% women, 53% black), 447 were enrolled in the screening clinical trial. No significant demographic differences were found between the enrolled and nonenrolled cohorts. Of the 453 individuals not enrolled, 251 (55%) had declined participation and 202 (45%) could not be reached, despite up to 6 attempts. LDCT completion was significantly associated with enrollment status: 81% of enrolled individuals, 73% of individuals who declined participation, and 49% of those who could not be reached (P < .001).Conclusions: In the present single-center study, demographic factors did not predict for participation in a lung cancer screening trial. Lung cancer screening adherence rates were substantially lower for those not enrolled in a screening trial, especially for those who could not be contacted. These findings may inform the broader implementation of screening programs. AD - Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX Department of Psychology, University of Arizona, Tucson, AZ Department of Family and Community Medicine, University of Arizona, Tucson, AZ Parkland Health and Hospital System, Dallas, TX Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX Division of General Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX AN - 143768503. Language: English. Entry Date: In Process. Revision Date: 20201107. Publication Type: journal article AU - Gerber, David E. AU - Hamann, Heidi A. AU - Chavez, Claudia AU - Dorsey, Olivia AU - Santini, Noel O. AU - Browning, Travis AU - Ochoa, Cristhiaan D. AU - Adesina, Joyce AU - Natchimuthu, Vijaya Subbu AU - Steen, Eric AU - Zhu, Hong AU - Lee, Simon J. Craddock DB - CINAHL Complete DO - 10.1016/j.cllc.2020.02.010 DP - EBSCOhost IS - 4 N1 - research. Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: K24 CA201543/CA/NCI NIH HHS/United States. NLM UID: 100893225. PMID: NLM32184050. PY - 2020 SN - 1525-7304 SP - 326-332 ST - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial T2 - Clinical Lung Cancer TI - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143768503&site=ehost-live&scope=site VL - 21 ID - 2131 ER - TY - JOUR AB - Introduction: For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. Patients and Methods: From February 2017 through February 2019, we enrolled subjects in a trial examining telephone-based navigation during low-dose computed tomography (LDCT) for lung cancer screening. We identified patients for whom LDCT was ordered and who were approached, but not enrolled, in the trial. We categorized nonenrollment as the patient had declined or could not be reached. We compared the characteristics and LDCT completion rates among these groups and the enrolled population using the 2-sample t test and χ2 test. Results: Of 900 individuals approached for participation (mean age, 62 years; 45% women, 53% black), 447 were enrolled in the screening clinical trial. No significant demographic differences were found between the enrolled and nonenrolled cohorts. Of the 453 individuals not enrolled, 251 (55%) had declined participation and 202 (45%) could not be reached, despite up to 6 attempts. LDCT completion was significantly associated with enrollment status: 81% of enrolled individuals, 73% of individuals who declined participation, and 49% of those who could not be reached (P < .001). Conclusions: In the present single-center study, demographic factors did not predict for participation in a lung cancer screening trial. Lung cancer screening adherence rates were substantially lower for those not enrolled in a screening trial, especially for those who could not be contacted. These findings may inform the broader implementation of screening programs. © 2020 Elsevier Inc. Data on lung cancer screening come from prospective clinical trials. We determined the characteristics and screening adherence among individuals eligible for, but not enrolled in, a trial. Although the demographic data did not differ, adherence was significantly lower among nonenrolled individuals, especially those who could not be reached. These findings may inform the broader implementation of screening programs. © 2020 Elsevier Inc. AD - Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States Department of Psychology, University of Arizona, Tucson, AZ, United States Department of Family and Community Medicine, University of Arizona, Tucson, AZ, United States Parkland Health and Hospital System, Dallas, TX, United States Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, United States Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States Division of General Internal Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States AU - Gerber, D. E. AU - Hamann, H. A. AU - Chavez, C. AU - Dorsey, O. AU - Santini, N. O. AU - Browning, T. AU - Ochoa, C. D. AU - Adesina, J. AU - Natchimuthu, V. S. AU - Steen, E. AU - Zhu, H. AU - Lee, S. J. C. DB - Scopus DO - 10.1016/j.cllc.2020.02.010 IS - 4 KW - Adherence Communication Computed tomography Demographics Underserved M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2020 SP - 326-332 ST - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial T2 - Clinical Lung Cancer TI - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081660175&doi=10.1016%2fj.cllc.2020.02.010&partnerID=40&md5=81900858a8479320e5437fb309f95da5 VL - 21 ID - 2189 ER - TY - JOUR AB - Data on lung cancer screening come from prospective clinical trials. We determined the characteristics and screening adherence among individuals eligible for, but not enrolled in, a trial. Although the demographic data did not differ, adherence was significantly lower among nonenrolled individuals, especially those who could not be reached. These findings may inform the broader implementation of screening programs. Introduction: For lung cancer screening, the available data are often derived from patients enrolled prospectively in clinical trials. We, therefore, investigated lung cancer screening patterns among individuals eligible for, but not enrolled in, a screening trial. Patients and Methods: From February 2017 through February 2019, we enrolled subjects in a trial examining telephone-based navigation during low-dose computed tomography (LDCT) for lung cancer screening. We identified patients for whom LDCT was ordered and who were approached, but not enrolled, in the trial. We categorized nonenrollment as the patient had declined or could not be reached. We compared the characteristics and LDCT completion rates among these groups and the enrolled population using the 2-sample t test and chi(2) test. Results: Of 900 individuals approached for participation (mean age, 62 years; 45% women, 53% black), 447 were enrolled in the screening clinical trial. No significant demographic differences were found between the enrolled and nonenrolled cohorts. Of the 453 individuals not enrolled, 251 (55%) had declined participation and 202 (45%) could not be reached, despite up to 6 attempts. LDCT completion was significantly associated with enrollment status: 81% of enrolled individuals, 73% of individuals who declined participation, and 49% of those who could not be reached (P < .001). Conclusions: In the present single-center study, demographic factors did not predict for participation in a lung cancer screening trial. Lung cancer screening adherence rates were substantially lower for those not enrolled in a screening trial, especially for those who could not be contacted. These findings may inform the broader implementation of screening programs. (C) 2020 Elsevier Inc. All rights reserved. AN - WOS:000541467800023 AU - Gerber, D. E. AU - Hamann, H. A. AU - Chavez, C. AU - Dorsey, O. AU - Santini, N. O. AU - Browning, T. AU - Ochoa, C. D. AU - Adesina, J. AU - Natchimuthu, V. S. AU - Steen, E. AU - Zhu, H. AU - Lee, S. J. C. DA - Jul DO - 10.1016/j.cllc.2020.02.010 IS - 4 N1 - 32184050 PY - 2020 SN - 1525-7304 SP - 326-332 ST - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial T2 - Clinical Lung Cancer TI - Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial VL - 21 ID - 2775 ER - TY - JOUR AB - OBJECTIVE: Few decision aids emphasize active surveillance (AS) for localized prostate cancer. Concept mapping was used to produce a conceptual framework incorporating AS and treatment. METHODS: Fifty-four statements about what men need to make a decision for localized prostate cancer were derived from focus groups with African American, Latino and white men previously screened for prostate cancer and partners (n = 80). In the second phase, 89 participants sorted and rated the importance of statements. RESULTS: An eight cluster map was produced for the overall sample. Clusters were labelled Doctor-patient exchange, Big picture comparisons, Weighing the options, Seeking and using information, Spirituality and inner strength, Related to active treatment, Side-effects and Family concerns. A major division was between medical and home-based clusters. Ethnic groups and genders had similar sorting, but some variation in importance. Latinos rated Big picture comparisons as less important. African Americans saw Spirituality and inner strength most important, followed by Latinos, then whites. Ethnic- and gender-specific concept maps were not analysed because of high similarity in their sorting patterns. CONCLUSIONS: We identified a conceptual framework for management of early-stage prostate cancer that included coverage of AS. Eliciting the conceptual framework is an important step in constructing decision aids which will address gaps related to AS. AU - McFall, S. L. AU - Mullen, P. D. AU - Byrd, T. L. AU - Cantor, S. B. AU - Le, Y. C. AU - Torres-Vigil, I. AU - Pettaway, C. AU - Volk, R. J. DB - Medline DO - 10.1111/hex.12175 IS - 6 KW - aged decision making decision support system disease management doctor patient relationship ethnology human information processing male middle aged patient participation procedures prostate tumor watchful waiting LA - English M3 - Article N1 - L615282950 2017-07-03 PY - 2015 SN - 1369-7625 SP - 2079-2090 ST - Treatment decisions for localized prostate cancer: a concept mapping approach T2 - Health expectations : an international journal of public participation in health care and health policy TI - Treatment decisions for localized prostate cancer: a concept mapping approach UR - https://www.embase.com/search/results?subaction=viewrecord&id=L615282950&from=export http://dx.doi.org/10.1111/hex.12175 VL - 18 ID - 991 ER - TY - JOUR AB - PURPOSE The treatment of childhood nasopharyngeal carcinoma has been adapted from adult regimens; pediatric-specific studies are limited. The ARAR0331 study sought to evaluate the impact of induction chemotherapy (IC) and concurrent chemoradiotherapy (CCR). PATIENTS AND METHODS Patients with American Joint Committee on Cancer stages IIb to IV were scheduled to receive three cycles of IC with cisplatin and fluorouracil, followed by CCR with three cycles of cisplatin. Patients with complete or partial response to IC received 61.2 Gy to the nasopharynx and neck, and patients with stable disease received 71.2 Gy. RESULTS Between February 2006 and January 2012, 111 patients (75 male) were enrolled. Median age was 15 years, and 46.8% of the patients were African American. After a feasibility analysis, the study was amended to reduce cisplatin to two cycles during CCR. The 5-year event-free survival (EFS) and overall survival estimates were 84.3% and 89.2%, respectively. The 5-year EFS for stages IIb, III, and IV were 100%, 82.8%, and 82.7%, respectively. The 5-year cumulative incidence estimates of local, distant, and combined relapse were 3.7%, 8.7%, and 1.8%, respectively. Patients treated with three versus two CCR cycles of cisplatin had improved 5-year postinduction EFS (90.7% v 81.2%, P = .14). CONCLUSION Patients in ARAR0331 were characterized by advanced disease and by a high proportion of black children and adolescents. Treatment with IC and CRT resulted in excellent outcomes. A radiation dose reduction is possible for patients responding to IC. Although the outcomes are comparable, we observed a trend toward decreased EFS for patients assigned to receive fewer doses of cisplatin during CCR. © 2019 American Society of Clinical Oncology. All rights reserved. AD - St Jude Children's Research Hospital, Memphis, TN, United States Children's Oncology Group, Monrovia, CA, United States University of Southern California, Los Angeles, CA, United States Texas Children's Hospital, Houston, TX, United States Yale University School of Medicine, New Haven, CT, United States AU - Rodriguez-Galindo, C. AU - Krailo, M. D. AU - Krasin, M. J. AU - Huang, L. AU - Beth McCarville, M. AU - Hicks, J. AU - Pashankar, F. AU - Pappo, A. S. DB - Scopus DO - 10.1200/JCO.19.01276 IS - 35 M3 - Article N1 - Cited By :6 Export Date: 22 March 2021 PY - 2019 SP - 3369-3376 ST - Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 study T2 - Journal of Clinical Oncology TI - Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 study UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076194545&doi=10.1200%2fJCO.19.01276&partnerID=40&md5=ae215b89ffa8fb17bd7fbd0c9d19cf7a VL - 37 ID - 2243 ER - TY - JOUR AB - Purpose: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. Methods: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. Results: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. Discussion: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation. AN - WOS:000337688200001 AU - Parsons, H. M. AU - Harlan, L. C. AU - Stevens, J. L. AU - Ullmann, C. D. DA - Mar-Apr DO - 10.1097/PPO.0000000000000039 IS - 2 N1 - 24667952 PY - 2014 SN - 1528-9117 SP - 97-104 ST - Treatment of Small Cell Lung Cancer in Academic and Community Settings Factors Associated With Receiving Standard Therapy and Survival T2 - Cancer Journal TI - Treatment of Small Cell Lung Cancer in Academic and Community Settings Factors Associated With Receiving Standard Therapy and Survival VL - 20 ID - 3017 ER - TY - JOUR AB - PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation. Copyright © 2014 Lippincott Williams & Wilkins. AD - H.M. Parsons, Department of Epidemiology and Biostatistics, School of Medicine, Versity of Texas Health Science Center at San Antonio, 03 Floyd Curl Dr, San Antonio, TX 78229-3900, United States AU - Parsons, H. M. AU - Harlan, L. C. AU - Stevens, J. L. AU - Ullmann, C. D. DB - Embase Medline DO - 10.1097/PPO.0000000000000039 IS - 2 KW - antineoplastic agent carboplatin cisplatin etoposide irinotecan adult aged article atelectasis cancer chemotherapy cancer mortality cancer radiotherapy cancer staging cancer survival cancer therapy chemoradiotherapy clinical trial (topic) community hospital controlled study female health hazard human small cell lung cancer major clinical study male national health organization phase 3 clinical trial (topic) pneumonia positron emission tomography priority journal residential care treatment planning treatment refusal United States university hospital LA - English M3 - Article N1 - L372762541 2014-04-15 2014-04-23 PY - 2014 SN - 1540-336X 1528-9117 SP - 97-104 ST - Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival T2 - Cancer Journal (United States) TI - Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival UR - https://www.embase.com/search/results?subaction=viewrecord&id=L372762541&from=export http://dx.doi.org/10.1097/PPO.0000000000000039 VL - 20 ID - 1044 ER - TY - JOUR AB - Purpose: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known.Methods: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death.Results: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality.Discussion: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation. AD - From the *Applied Research Program, National Cancer Institute, Bethesda, MD; tInformation Management Services, Inc, Calverton, MD; and tCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD. AN - 107791077. Language: English. Entry Date: 20150116. Revision Date: 20161204. Publication Type: journal article. Journal Subset: Biomedical AU - Parsons, Helen M. AU - Harlan, Linda C. AU - Stevens, Jennifer L. AU - Ullmann, Claudio Dansky DB - CINAHL Complete DO - 10.1097/PPO.0000000000000039 DP - EBSCOhost IS - 2 KW - Carcinoma, Non-Small-Cell Lung -- Drug Therapy Carcinoma, Non-Small-Cell Lung -- Epidemiology Quality of Health Care Adult Aged Aged, 80 and Over Antineoplastic Agents, Combined -- Administration and Dosage Cisplatin -- Administration and Dosage Clinical Trials Combined Modality Therapy Etoposide -- Administration and Dosage Female Male Middle Age Neoplasm Staging Carcinoma, Non-Small-Cell Lung -- Pathology N1 - Peer Reviewed; USA. Special Interest: Oncologic Care. Grant Information: HHSN261201000028C//PHS HHS/United States. NLM UID: 100931981. PMID: NLM24667952. PY - 2014 SN - 1528-9117 SP - 97-104 ST - Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival T2 - Cancer Journal TI - Treatment of small cell lung cancer in academic and community settings: factors associated with receiving standard therapy and survival UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107791077&site=ehost-live&scope=site VL - 20 ID - 2132 ER - TY - JOUR AB - PURPOSE: Small cell lung cancer (SCLC) historically has had poor prognosis. Clinical trials have demonstrated improved survival among patients receiving standard platinum-/etoposide-based chemotherapy. Whereas treatment patterns and outcomes have been evaluated for patients with SCLC in clinical trials, population-based practice patterns are not well known. METHODS: The National Cancer Institute's Patterns of Care study was used to evaluate patient and provider factors associated with standard treatment, clinical trial enrollment, and 12-month relative hazard of death. RESULTS: Among 931 patients with SCLC diagnosed in 2007 in academic and community settings, 72.2% of patients with limited-stage (LS) disease received chemoradiation and 42.2% of patients with extensive-stage (ES) disease received chemotherapy only; the expected treatment scenarios by stage. Less than 1% of the patients enrolled in clinical trials and 2.1% of the patients with LS disease and 3.4% of the patients with ES disease refused any type of treatment. Patients 80 years or older at diagnosis and those with pneumonia/lung collapse were less likely to receive chemoradiation for LS disease. Patients treated in hospitals with residency programs were more likely to receive chemotherapy for ES disease, and patients 80 years or older were less likely to receive chemotherapy for ES disease. Finally, female patients with LS disease, black patients with ES disease, and all patients who received chemotherapy compared to receiving radiation alone or no therapy experienced significantly lower mortality. DISCUSSION: Despite the demonstrated lower mortality, a relatively large proportion of patients with SCLC are not treated with a standard treatment regimen. Future studies should evaluate efforts to promote use of appropriate treatment regimens and encourage clinical trial participation. Copyright © 2014 Lippincott Williams & Wilkins. AD - Applied Research Program, National Cancer Institute, Bethesda, MD, United States Information Management Services Inc., Calverton, MD, United States Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States AU - Parsons, H. M. AU - Harlan, L. C. AU - Stevens, J. L. AU - Ullmann, C. D. DB - Scopus DO - 10.1097/PPO.0000000000000039 IS - 2 KW - lung cancer small cell survival treatment patterns M3 - Article N1 - Cited By :12 Export Date: 22 March 2021 PY - 2014 SP - 97-104 ST - Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival T2 - Cancer Journal (United States) TI - Treatment of small cell lung cancer in academic and community settings: Factors associated with receiving standard therapy and survival UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84897555023&doi=10.1097%2fPPO.0000000000000039&partnerID=40&md5=0e8f4c67a8405ab198ea8f585589b550 VL - 20 ID - 2413 ER - TY - JOUR AB - Purpose: Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays and discontinue adjuvant breast cancer therapy early compared with white women. We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials. Patients and Methods: AA and white women from Southwest Oncology Group adjuvant breast cancer trials (S8814/ S8897) were matched by age and protocol. Only the treatment arms in which patients were scheduled to receive six cycles of chemotherapy were analyzed. Results: A total of 317 pairs of patients (n = 634) were analyzed. At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009). AA women were more likely to have tumors that were ≥ 2 cm (P = .01) and hormone receptor negative (P < .0001). AA women, versus white women, were marginally more likely to discontinue treatment early (11% v 7%, respectively; P = .07) or have one or more treatment delays (85% v 79%, respectively; P = .07) and were significantly more likely to experience the combined end point (discontinuation/delay; 87% v 81%, respectively; P = .04). The mean relative dose-intensity (RDI) was similar for both groups (87% in AA women v 86% in white women); however, overall, 43% had an RDI of less than 85%. After adjusting for baseline WBC and prognostic factors in a multivariate model, AA women had worse disease-free survival (hazard ratio [HR] = 1.56; 95% CI, 1.15 to 2.11; P = .005) and overall survival (HR = 1.95; 95% CI, 1.36 to 2.78; P = .0002). The inclusion of RDI and treatment delivery/quality in the regression had little impact on the results. Conclusion: On cooperative group breast cancer trials, AA and white women had similar RDIs, but AA women were more likely to experience early discontinuation or treatment delay. Despite correcting for these factors and known predictors of outcome, AA women still had worse survival. © 2009 by American Society of Clinical Oncology. AD - D.L. Hershman, Southwest Oncology Group, 24 Frank Lloyd Wright Dr, Ann Arbor, MI 4810483, United States AU - Hershman, D. L. AU - Unger, J. M. AU - Barlow, W. E. AU - Hutchins, L. F. AU - Martino, S. AU - Osborne, C. K. AU - Livingston, R. B. AU - Albain, K. S. DB - Embase Medline DO - 10.1200/JCO.2008.19.1163 IS - 13 KW - cyclophosphamide doxorubicin fluorouracil granulocyte colony stimulating factor hormone receptor methotrexate tamoxifen adult African American age distribution aged article body surface breast cancer cancer chemotherapy cancer patient cancer survival clinical protocol controlled study disease association disease free survival European American febrile neutropenia female health care delivery health care quality human leukocyte count major clinical study multiple cycle treatment overall survival priority journal prognosis race difference retrospective study therapy delay treatment outcome treatment withdrawal LA - English M3 - Article N1 - L358015693 2010-01-18 PY - 2009 SN - 0732-183X SP - 2157-2162 ST - Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of southwest oncology studies S8814/S8897 T2 - Journal of Clinical Oncology TI - Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of southwest oncology studies S8814/S8897 UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358015693&from=export http://dx.doi.org/10.1200/JCO.2008.19.1163 http://jco.ascopubs.org/cgi/reprint/27/13/2157 VL - 27 ID - 1194 ER - TY - JOUR AB - Purpose: Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays and discontinue adjuvant breast cancer therapy early compared with white women. We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials. Patients and Methods: AA and white women from Southwest Oncology Group adjuvant breast cancer trials (S8814/ S8897) were matched by age and protocol. Only the treatment arms in which patients were scheduled to receive six cycles of chemotherapy were analyzed. Results: A total of 317 pairs of patients (n = 634) were analyzed. At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009). AA women were more likely to have tumors that were ≥ 2 cm (P = .01) and hormone receptor negative (P < .0001). AA women, versus white women, were marginally more likely to discontinue treatment early (11% v 7%, respectively; P = .07) or have one or more treatment delays (85% v 79%, respectively; P = .07) and were significantly more likely to experience the combined end point (discontinuation/delay; 87% v 81%, respectively; P = .04). The mean relative dose-intensity (RDI) was similar for both groups (87% in AA women v 86% in white women); however, overall, 43% had an RDI of less than 85%. After adjusting for baseline WBC and prognostic factors in a multivariate model, AA women had worse disease-free survival (hazard ratio [HR] = 1.56; 95% CI, 1.15 to 2.11; P = .005) and overall survival (HR = 1.95; 95% CI, 1.36 to 2.78; P = .0002). The inclusion of RDI and treatment delivery/quality in the regression had little impact on the results. Conclusion: On cooperative group breast cancer trials, AA and white women had similar RDIs, but AA women were more likely to experience early discontinuation or treatment delay. Despite correcting for these factors and known predictors of outcome, AA women still had worse survival. © 2009 by American Society of Clinical Oncology. AU - Hershman, D. L. AU - Unger, J. M. AU - Barlow, W. E. AU - Hutchins, L. F. AU - Martino, S. AU - Osborne, C. K. AU - Livingston, R. B. AU - Albain, K. S. DB - Scopus DO - 10.1200/JCO.2008.19.1163 IS - 13 M3 - Article N1 - Cited By :92 Export Date: 22 March 2021 PY - 2009 SP - 2157-2162 ST - Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of southwest oncology studies S8814/S8897 T2 - Journal of Clinical Oncology TI - Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of southwest oncology studies S8814/S8897 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-65549105066&doi=10.1200%2fJCO.2008.19.1163&partnerID=40&md5=7cd287998a466f2c7a9e11a81c57398f VL - 27 ID - 2524 ER - TY - JOUR AB - Purpose Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays and discontinue adjuvant breast cancer therapy early compared with white women. We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials. Patients and Methods AA and white women from Southwest Oncology Group adjuvant breast cancer trials (S8814/S8897) were matched by age and protocol. Only the treatment arms in which patients were scheduled to receive six cycles of chemotherapy were analyzed. Results A total of 317 pairs of patients (n = 634) were analyzed. At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009). AA women were more likely to have tumors that were >= 2 cm (P = .01) and hormone receptor negative (P < .0001). AA women, versus white women, were marginally more likely to discontinue treatment early (11% v 7%, respectively; P = .07) or have one or more treatment delays (85% v 79%, respectively; P = .07) and were significantly more likely to experience the combined end point (discontinuation/delay; 87% v 81%, respectively; P = .04). The mean relative dose-intensity (RDI) was similar for both groups (87% in AA women v 86% in white women); however, overall, 43% had an RDI of less than 85%. After adjusting for baseline WBC and prognostic factors in a multivariate model, AA women had worse disease-free survival (hazard ratio [HR] = 1.56; 95% CI, 1.15 to 2.11; P = .005) and overall survival (HR = 1.95; 95% CI, 1.36 to 2.78; P = .0002). The inclusion of RDI and treatment delivery/quality in the regression had little impact on the results. Conclusion On cooperative group breast cancer trials, AA and white women had similar RDIs, but AA women were more likely to experience early discontinuation or treatment delay. Despite correcting for these factors and known predictors of outcome, AA women still had worse survival. AN - WOS:000266195000010 AU - Hershman, D. L. AU - Unger, J. M. AU - Barlow, W. E. AU - Hutchins, L. F. AU - Martino, S. AU - Osborne, C. K. AU - Livingston, R. B. AU - Albain, K. S. DA - May DO - 10.1200/JCO.2008.19.1163 IS - 13 N1 - 19307504 PY - 2009 SN - 0732-183X SP - 2157-2162 ST - Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897 T2 - Journal of Clinical Oncology TI - Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897 VL - 27 ID - 3150 ER - TY - JOUR AB - Purpose: Women of African ancestry (AA) have lower WBC counts and are more likely to have treatment delays and discontinue adjuvant breast cancer therapy early compared with white women. We assessed the association between race and treatment discontinuation/delay, WBC counts, and survival in women enrolled onto breast cancer clinical trials.Patients and Methods: AA and white women from Southwest Oncology Group adjuvant breast cancer trials (S8814/S8897) were matched by age and protocol. Only the treatment arms in which patients were scheduled to receive six cycles of chemotherapy were analyzed.Results: A total of 317 pairs of patients (n = 634) were analyzed. At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009). AA women were more likely to have tumors that were > or = 2 cm (P = .01) and hormone receptor negative (P < .0001). AA women, versus white women, were marginally more likely to discontinue treatment early (11% v 7%, respectively; P = .07) or have one or more treatment delays (85% v 79%, respectively; P = .07) and were significantly more likely to experience the combined end point (discontinuation/delay; 87% v 81%, respectively; P = .04). The mean relative dose-intensity (RDI) was similar for both groups (87% in AA women v 86% in white women); however, overall, 43% had an RDI of less than 85%. After adjusting for baseline WBC and prognostic factors in a multivariate model, AA women had worse disease-free survival (hazard ratio [HR] = 1.56; 95% CI, 1.15 to 2.11; P = .005) and overall survival (HR = 1.95; 95% CI, 1.36 to 2.78; P = .0002). The inclusion of RDI and treatment delivery/quality in the regression had little impact on the results.Conclusion: On cooperative group breast cancer trials, AA and white women had similar RDIs, but AA women were more likely to experience early discontinuation or treatment delay. Despite correcting for these factors and known predictors of outcome, AA women still had worse survival. AD - Columbia University, New York, NY, USA Columbia University, New York, NY, USA. AN - 105518028. Language: English. Entry Date: 20090522. Revision Date: 20180811. Publication Type: journal article AU - Hershman, D. L. AU - Unger, J. M. AU - Barlow, W. E. AU - Hutchins, L. F. AU - Martino, S. AU - Osborne, C. K. AU - Livingston, R. B. AU - Albain, K. S. AU - Hershman, Dawn L. AU - Unger, Joseph M. AU - Barlow, William E. AU - Hutchins, Laura F. AU - Martino, Silvana AU - Osborne, C. Kent AU - Livingston, Robert B. AU - Albain, Kathy S. DB - CINAHL Complete DO - 10.1200/JCO.2008.19.1163 DP - EBSCOhost IS - 13 KW - Black Persons Breast Neoplasms -- Drug Therapy Breast Neoplasms -- Ethnology White Persons Adult Aged Breast Neoplasms -- Blood Breast Neoplasms -- Mortality Chemotherapy, Adjuvant Clinical Trials Female Health Status Leukocyte Count Middle Age Treatment Outcomes Human N1 - research. Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA. Grant Information: CA46282/CA/NCI NIH HHS/United States. NLM UID: 8309333. PMID: NLM19307504. PY - 2009 SN - 0732-183X SP - 2157-2162 ST - Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897 T2 - Journal of Clinical Oncology TI - Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897 UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105518028&site=ehost-live&scope=site VL - 27 ID - 2133 ER - TY - JOUR AB - BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans. METHODS: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged ≥50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months. RESULTS: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant. CONCLUSIONS: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome. © 2010 American Cancer Society. AD - D. S. Blumenthal, Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, United States AU - Blumenthal, D. S. AU - Smith, S. A. AU - Majett, C. D. AU - Alema-Mensah, E. DB - Embase Medline DO - 10.1002/cncr.24842 IS - 4 KW - adult African American aged article cancer screening clinical trial cohort analysis colorectal cancer controlled clinical trial controlled study education program female follow up human major clinical study male outcome assessment priority journal randomized controlled trial screening test LA - English M3 - Article N1 - L358265856 2010-02-17 2010-02-26 PY - 2010 SN - 0008-543X 1097-0142 SP - 922-929 ST - A trial of 3 interventions to promote colorectal cancer screening in African Americans T2 - Cancer TI - A trial of 3 interventions to promote colorectal cancer screening in African Americans UR - https://www.embase.com/search/results?subaction=viewrecord&id=L358265856&from=export http://dx.doi.org/10.1002/cncr.24842 http://www3.interscience.wiley.com/cgi-bin/fulltext/123233189/PDFSTART VL - 116 ID - 1169 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans. Method: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged ≥50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months. Results: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant. Conclusions: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Blumenthal, Daniel S., Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, US, 30310 AN - 2010-03692-004 AU - Blumenthal, Daniel S. AU - Smith, Selina A. AU - Majett, Charlye D. AU - Alema-Mensah, Ernest DB - psyh DO - 10.1002/cncr.24842 DP - EBSCOhost IS - 4 KW - colorectal cancer screening African Americans intervention trial Aged Colorectal Neoplasms Continuity of Patient Care Early Detection of Cancer Female Financing, Organized Humans Male Middle Aged Outcome Assessment (Health Care) Patient Education as Topic Blacks Cancer Screening Clinical Trials Intervention Neoplasms N1 - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, GA, US. Release Date: 20100809. Correction Date: 20130128. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Cancer Screening; Clinical Trials; Intervention; Neoplasms. Classification: Cancer (3293); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study; Treatment Outcome. References Available: Y. Page Count: 8. Issue Publication Date: Feb 15, 2010. Publication History: First Posted Date: Jan 5, 2010; Accepted Date: Jun 18, 2009; Revised Date: Jun 16, 2009; First Submitted Date: Feb 8, 2009. Copyright Statement: American Cancer Society. 2010. Sponsor: Centers for Disease Control and Prevention. Grant: U57CCU42068. Other Details: Community Cancer Control. Recipients: No recipient indicated Sponsor: Centers for Disease Control and Prevention. Grant: 5U48DP000049. Other Details: Prevention Research Center. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: 1U01CA1146520. Other Details: Community Networks Program. Recipients: No recipient indicated Sponsor: National Cancer Institute, US. Grant: 2U54CA118638. Other Details: Minority Institution/Cancer Center Partnership. Recipients: No recipient indicated Sponsor: National Center for Research Resources, US. Grant: 1UL1RR025008. Other Details: Clinical Research Center. Recipients: No recipient indicated Sponsor: National Center for Research Resources, US. Grant: UL1RR025008. Other Details: CTSA. Recipients: No recipient indicated PY - 2010 SN - 0008-543X 1097-0142 SP - 922-929 ST - A trial of 3 interventions to promote colorectal cancer screening in African Americans T2 - Cancer TI - A trial of 3 interventions to promote colorectal cancer screening in African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-03692-004&site=ehost-live&scope=site ORCID: 0000-0002-2186-0232 dblumenthal@msm.edu VL - 116 ID - 1720 ER - TY - JOUR AB - BACKGROUND: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans. METHODS: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged ≥50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months. RESULTS: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant. CONCLUSIONS: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome. © 2010 American Cancer Society. AD - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, United States Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA, United States Clinical Research Center, Morehouse School of Medicine, Atlanta, GA, United States AU - Blumenthal, D. S. AU - Smith, S. A. AU - Majett, C. D. AU - Alema-Mensah, E. DB - Scopus DO - 10.1002/cncr.24842 IS - 4 KW - Colorectal cancer Community-based participatory research Health education Health status disparities Minority health Screening M3 - Article N1 - Cited By :38 Export Date: 22 March 2021 PY - 2010 SP - 922-929 ST - A trial of 3 interventions to promote colorectal cancer screening in African Americans T2 - Cancer TI - A trial of 3 interventions to promote colorectal cancer screening in African Americans UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-76249111565&doi=10.1002%2fcncr.24842&partnerID=40&md5=b452e5b407307327a815f3e0eaac35ac VL - 116 ID - 2501 ER - TY - JOUR AB - Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans. METHODS: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged >= 50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months. RESULTS: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant. CONCLUSIONS: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome. Cancer 2010;116:922-9. (C) 2070 American Cancer Society. AN - WOS:000274315800021 AU - Blumenthal, D. S. AU - Smith, S. A. AU - Majett, C. D. AU - Alema-Mensah, E. DA - Feb DO - 10.1002/cncr.24842 IS - 4 N1 - 20052732 PY - 2010 SN - 0008-543X SP - 922-929 ST - A Trial of 3 Interventions to Promote Colorectal Cancer Screening in African Americans T2 - Cancer TI - A Trial of 3 Interventions to Promote Colorectal Cancer Screening in African Americans VL - 116 ID - 3123 ER - TY - JOUR AB - Background: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. CRC incidence and mortality rates are higher among blacks than among whites, and screening rates are lower in blacks than in whites. For the current study, the authors tested 3 interventions that were intended to increase the rate of CRC screening among African Americans.Methods: The following interventions were chosen to address evidence gaps in the Centers for Disease Control and Prevention's Guide to Community Preventive Services: one-on-one education, group education, and reducing out-of-pocket costs. Three hundred sixty-nine African-American men and women aged > or =50 years were enrolled in this randomized, controlled community intervention trial. The main outcome measures were postintervention increase in CRC knowledge and obtaining a screening test within 6 months.Results: There was substantial attrition: Two hundred fifty-seven participants completed the intervention and were available for follow-up 3 months to 6 months later. Among completers, there were significant increases in knowledge in both educational cohorts but in neither of the other 2 cohorts. By the 6-month follow-up, 17.7% (11 of 62 participants) of the Control cohort reported having undergone screening compared with 33.9% (22 of 65 participants) of the Group Education cohort (P = .039). Screening rate increases in the other 2 cohorts were not statistically significant.Conclusions: The current results indicated that group education could increase CRC cancer screening rates among African Americans. The screening rate of <35% in a group of individuals who participated in an educational program through multiple sessions over a period of several weeks indicated that there still are barriers to overcome. AD - Department of Community Health and Preventive Medicine, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310, USA Department of Community Health and Preventive Medicine, Morehouse School of Medicine, Atlanta, Georgia. AN - 105316727. Language: English. Entry Date: 20100326. Revision Date: 20200708. Publication Type: journal article AU - Blumenthal, D. S. AU - Smith, S. A. AU - Majett, C. D. AU - Alema-Mensah, E. AU - Blumenthal, Daniel S. AU - Smith, Selina A. AU - Majett, Charlye D. AU - Alema-Mensah, Ernest DB - CINAHL Complete DO - 10.1002/cncr.24842 DP - EBSCOhost IS - 4 KW - Black Persons Colorectal Neoplasms -- Diagnosis Colorectal Neoplasms -- Ethnology Early Detection of Cancer Patient Education Aged Colorectal Neoplasms -- Economics Continuity of Patient Care Female Financing, Organized Human Male Middle Age Outcome Assessment Clinical Trials N1 - clinical trial; research. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: UL1 TR000454/TR/NCATS NIH HHS/United States. NLM UID: 0374236. PMID: NLM20052732. PY - 2010 SN - 0008-543X SP - 922-929 ST - A trial of 3 interventions to promote colorectal cancer screening in African Americans T2 - Cancer (0008543X) TI - A trial of 3 interventions to promote colorectal cancer screening in African Americans UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105316727&site=ehost-live&scope=site VL - 116 ID - 1838 ER - TY - JOUR AB - BACKGROUND US Food and Drug Administration (FDA) approval of new drugs depends on results from clinical trials that must be generalized to the US population. However, racial minorities are frequently under-represented in clinical studies. The enrollment of racial minorities was compared in key clinical studies submitted to the FDA in the last 10 years in support of potential marketing approval for prostate cancer (PCa) prevention or treatment. METHODS Patient demographic data were obtained from archival data sets of large registration trials submitted to the FDA to support proposed PCa indications. Six countries/regions were analyzed: the United States, Canada, Australia, Europe, the United Kingdom, and Eastern Europe. Background racial demographics were collected from national census data. RESULTS Seventeen key PCa clinical trials were analyzed. These trials were conducted in the past 20 years, comprising 39,574 patients with known racial information. Most patients were enrolled in the United States, but there appeared to be a trend toward increased non-US enrollment over time. In all countries, racial minorities were generally under-represented. There was no significant improvement in racial minority enrollment over time. The United States enrolled the largest nonwhite population (7.1%). CONCLUSIONS Over the past 20 years, racial minorities were consistently under-represented in key PCa trials. There is a need for effective measures that will improve enrollment of racial minorities. With increased global enrollment, drug developers should aim to recruit a patient population that resembles the racial demographics of the patient population to which drug use will be generalized upon approval. © 2014 American Cancer Society. AD - Office of Hematology and Oncology Products, Office of New Drugs, Center for Drug Evaluation Research, US Food and Drug Administration, Building 22, 10903 New Hampshire Avenue, Silver Spring, MD 20993, United States Office of Minority Health, US Food and Drug Administration, Silver Spring, MD, United States AU - Wissing, M. D. AU - Kluetz, P. G. AU - Ning, Y. M. AU - Bull, J. AU - Merenda, C. AU - Murgo, A. J. AU - Pazdur, R. DB - Scopus DO - 10.1002/cncr.28809 IS - 19 KW - clinical trial phase 3 prostate cancer race relations US Food and Drug Administration M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2014 SP - 3025-3032 ST - Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013 T2 - Cancer TI - Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013 UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908512546&doi=10.1002%2fcncr.28809&partnerID=40&md5=5c68f06976549c12cc63c7d9d97d9dd9 VL - 120 ID - 2388 ER - TY - JOUR AB - BACKGROUND: US Food and Drug Administration (FDA) approval of newdrugs depends on results from clinical trials that must be generalized to the US population. However, racial minorities are frequently under-represented in clinical studies. The enrollment of racial minorities was compared in key clinical studies submitted to the FDA in the last 10 years in support of potential marketing approval for prostate cancer (PCa) prevention or treatment. METHODS: Patient demographic data were obtained from archival data sets of large registration trials submitted to the FDA to support proposed PCa indications. Six countries/regions were analyzed: the United States, Canada, Australia, Europe, the United Kingdom, and Eastern Europe. Background racial demographics were collected from national census data. RESULTS: Seventeen key PCa clinical trials were analyzed. These trials were conducted in the past 20 years, comprising 39,574 patients with known racial information. Most patients were enrolled in the United States, but there appeared to be a trend toward increased non-US enrollment over time. In all countries, racial minorities were generally under-represented. There was no significant improvement in racial minority enrollment over time. The United States enrolled the largest nonwhite population (7.1%). CONCLUSIONS: Over the past 20 years, racial minorities were consistently under-represented in key PCa trials. There is a need for effective measures that will improve enrollment of racial minorities. With increased global enrollment, drug developers should aim to recruit a patient population that resembles the racial demographics of the patient population to which drug use will be generalized upon approval. (C) 2014 American Cancer Society. AN - WOS:000342630000015 AU - Wissing, M. D. AU - Kluetz, P. G. AU - Ning, Y. M. AU - Bull, J. AU - Merenda, C. AU - Murgo, A. J. AU - Pazdur, R. DA - Oct DO - 10.1002/cncr.28809 IS - 19 N1 - 24965506 PY - 2014 SN - 0008-543X SP - 3025-3032 ST - Under-Representation of Racial Minorities in Prostate Cancer Studies Submitted to the US Food and Drug Administration to Support Potential Marketing Approval, 1993-2013 T2 - Cancer TI - Under-Representation of Racial Minorities in Prostate Cancer Studies Submitted to the US Food and Drug Administration to Support Potential Marketing Approval, 1993-2013 VL - 120 ID - 2996 ER - TY - JOUR AB - Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P<0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P<0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. AD - L.F. Hutchins, Southwest Oncology Group, Operations Office, 4980 Omicron Dr., San Antonio, TX 78245-3217, United States AU - Hutchins, L. F. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman Jr, C. A. AU - Albain, K. S. DB - Embase Medline DO - 10.1056/NEJM199912303412706 IS - 27 KW - adult age aged article cancer patient cancer research controlled study female human major clinical study male methodology Black person population research priority journal sex difference LA - English M3 - Article N1 - L30035956 2000-01-20 PY - 1999 SN - 0028-4793 SP - 2061-2067 ST - Underrepresentation of patients 65 years of age or older in cancer- treatment trials T2 - New England Journal of Medicine TI - Underrepresentation of patients 65 years of age or older in cancer- treatment trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L30035956&from=export http://dx.doi.org/10.1056/NEJM199912303412706 VL - 341 ID - 1325 ER - TY - JOUR AB - Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P<0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P<0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. AD - Department of Medicine, Division of Hematology and Oncology, Univ. of Arkansas for Med. Sciences, Little Rock, AR, United States SW Oncology Group Statistical Center, Fred Hutchinson Cancer Res. Center, Seattle, WA, United States Department of Medical Oncology, Univ. Texas Hlth. Sci. Ctr. S. A., San Antonio, TX, United States Department of Medicine, Division of Hematology and Oncology, Loyola University Medical Center, Maywood, IL, United States AU - Hutchins, L. F. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman Jr, C. A. AU - Albain, K. S. DB - Scopus DO - 10.1056/NEJM199912303412706 IS - 27 M3 - Article N1 - Cited By :1701 Export Date: 22 March 2021 PY - 1999 SP - 2061-2067 ST - Underrepresentation of patients 65 years of age or older in cancer- treatment trials T2 - New England Journal of Medicine TI - Underrepresentation of patients 65 years of age or older in cancer- treatment trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033619959&doi=10.1056%2fNEJM199912303412706&partnerID=40&md5=483137959ff2607ffe95b03e1112073a VL - 341 ID - 2639 ER - TY - JOUR AB - Background: Studies have documented the underrepresentation of women and blacks in clinical trials, and their recruitment is now federally mandated. However, little is known about the level of participation of elderly patients. We determined the rates of enrollment of patients 65 years of age or older in trials of treatment for cancer. Methods: We analyzed data on 16,396 patients consecutively enrolled in 164 Southwest Oncology Group treatment trials between 1993 and 1996 according to sex, race (black or white), and age under 65 years or 65 or older. These rates were compared with the corresponding rates in the general population of patients with cancer, derived from the 1990 U.S. Census and from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program for the period from 1992 through 1994. Fifteen types of cancer were included in the analysis. Results: The overall proportions of women and blacks enrolled in Southwest Oncology Group trials were similar to or the same as the estimated proportions in the U.S. population of patients with cancer (women, 41 percent and 43 percent; blacks, 10 percent and 10 percent, respectively). In contrast, patients 65 years of age or older were underrepresented overall (25 percent vs. 63 percent, P < 0.001) and in trials involving all 15 types of cancer except lymphoma. The underrepresentation was particularly notable in trials of treatment for breast cancer (9 percent vs. 49 percent, P < 0.001). The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials that excluded older patients were eliminated from the analysis, and when community-based enrollment was analyzed separately from enrollment at academic centers. Conclusions: There is substantial underrepresentation of patients 65 years of age or older in studies of treatment for cancer. The reasons should be clarified, and policies adopted to correct this underrepresentation. (N Engl J Med 1999;341:2061-7.) (C)1999, Massachusetts Medical Society. AN - WOS:000084573300006 AU - Hutchins, L. F. AU - Unger, J. M. AU - Crowley, J. J. AU - Coltman, C. A. AU - Albain, K. S. DA - Dec 30 DO - 10.1056/NEJM199912303412706 IS - 27 N1 - 1565 10615079 PY - 1999 SN - 0028-4793 SP - 2061-2067 ST - Underrepresentation of patients 65 years of age or older in cancer-treatment trials T2 - New England Journal of Medicine TI - Underrepresentation of patients 65 years of age or older in cancer-treatment trials VL - 341 ID - 2723 ER - TY - JOUR AU - Printz, C. DB - Scopus DO - 10.1002/cncr.29247 IS - 3 M3 - Short Survey N1 - Cited By :1 Export Date: 22 March 2021 PY - 2015 SP - 325-327 ST - Understanding disparity: Researchers strive to recruit more African Americans and other minorities to studies T2 - Cancer TI - Understanding disparity: Researchers strive to recruit more African Americans and other minorities to studies UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84921529579&doi=10.1002%2fcncr.29247&partnerID=40&md5=3b217afc8ffb29edbb571536d9d17480 VL - 121 ID - 2371 ER - TY - JOUR AB - Low unit response rates can increase bias and compromise study validity. Response rates have continued to fall over the past decade despite all efforts to increase participation. Many factors have been linked to reduced response, yet relatively few studies have employed multivariate approaches to identify characteristics that differentiate respondents from nonrespondents since it is hard to collect information on the latter. We aimed to assess factors contributing to enrollment of prostate cancer (PCa) patients. We combined data from the North Carolina-Louisiana (LA) PCa Project's LA cohort, with additional sources such as US census tract and LA tumor registry data. We included specific analyses focusing on blacks, a group often identified as hard to enroll in health-related research. The ability to study the effect of Hurricane Katrina, which occurred amidst enrollment, as a potential determinant of nonresponse makes our study unique. Older age (≥ 70) for blacks (OR 0.65) and study phase with respect to Hurricane Katrina for both races (OR 0.59 for blacks, OR 0.48 for whites) were significant predictors of participation with lower odds. Neighborhood poverty for whites (OR 1.53) also was a significant predictor of participation, but with higher odds. Among blacks, residence in Orleans parish was associated with lower odds of participation (OR 0.33) before Katrina. The opposite occurred in whites, with lower odds (OR 0.43) after Katrina. Our results overall underscore the importance of tailoring enrollment approaches to specific target population characteristics to confront the challenges posed by nonresponse. Our results also show that recruitment-related factors may change when outside forces bring major alterations to a population's environment and demographics. AU - Oral, E. AU - Simonsen, N. AU - Brennan, C. AU - Berken, J. AU - Su, L. J. AU - Mohler, J. L. AU - Bensen, J. T. AU - Fontham, E. T. H. DB - Embase Medline DO - 10.1371/journal.pone.0168364 IS - 12 KW - adult age aged article Black person cancer patient Caucasian controlled study demography environment human hurricane major clinical study male patient participation prostate cancer sampling unit nonresponse LA - English M3 - Article N1 - L613725862 2016-12-27 2017-01-23 PY - 2016 SN - 1932-6203 ST - Unit nonresponse in a population-based study of prostate cancer T2 - PLoS ONE TI - Unit nonresponse in a population-based study of prostate cancer UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613725862&from=export http://dx.doi.org/10.1371/journal.pone.0168364 VL - 11 ID - 953 ER - TY - JOUR AB - Low unit response rates can increase bias and compromise study validity. Response rates have continued to fall over the past decade despite all efforts to increase participation. Many factors have been linked to reduced response, yet relatively few studies have employed multivariate approaches to identify characteristics that differentiate respondents from nonrespondents since it is hard to collect information on the latter. We aimed to assess factors contributing to enrollment of prostate cancer (PCa) patients. We combined data from the North Carolina-Louisiana (LA) PCa Project's LA cohort, with additional sources such as US census tract and LA tumor registry data. We included specific analyses focusing on blacks, a group often identified as hard to enroll in health-related research. The ability to study the effect of Hurricane Katrina, which occurred amidst enrollment, as a potential determinant of nonresponse makes our study unique. Older age (>= 70) for blacks (OR 0.65) and study phase with respect to Hurricane Katrina for both races (OR 0.59 for blacks, OR 0.48 for whites) were significant predictors of participation with lower odds. Neighborhood poverty for whites (OR 1.53) also was a significant predictor of participation, but with higher odds. Among blacks, residence in Orleans parish was associated with lower odds of participation (OR 0.33) before Katrina. The opposite occurred in whites, with lower odds (OR 0.43) after Katrina. Our results overall underscore the importance of tailoring enrollment approaches to specific target population characteristics to confront the challenges posed by nonresponse. Our results also show that recruitment-related factors may change when outside forces bring major alterations to a population's environment and demographics. AN - WOS:000392758000040 AU - Oral, E. AU - Simonsen, N. AU - Brennan, C. AU - Berken, J. AU - Su, L. J. AU - Mohler, J. L. AU - Bensen, J. T. AU - Fontham, E. T. H. DA - Dec DO - 10.1371/journal.pone.0168364 IS - 12 N1 - e0168364 27992587 PY - 2016 SN - 1932-6203 ST - Unit Nonresponse in a Population-Based Study of Prostate Cancer T2 - Plos One TI - Unit Nonresponse in a Population-Based Study of Prostate Cancer VL - 11 ID - 2923 ER - TY - JOUR AB - Research increasingly points to inadequate treatment as a factor in the excess breast cancer mortality experienced by African Americans. Likely causes include lack of guideline‐concordant care, under use of medical advances, and limited opportunities to participate in clinical trials and genetic counseling. African Americans are disproportionately affected because they are more likely to receive care in low‐resource settings. Importantly, emerging research shows that NCI‐designated Comprehensive Cancer Centers (CCCs) have the best cancer outcomes compared with other clinical settings ‐ yet African Americans and Latinx are under‐represented as patients in CCCs. It is as if the leading cancer clinicians and the resources at their disposal are locked in a vault inaccessible to those with the greatest need. We used ethnographic methods to explore the feasibility of and extent to which the simple mechanism of a CCC 2nd opinion can improve the quality of treatment offered to African American breast cancer patients receiving care in a range of other institutions. Through community outreach, 14 patients were recruited and17 CCC consultations were conducted at no charge. Each visit was observed and audio‐taped to capture the consulting oncologist's recommendations. Patients were interviewed 3 weeks after the consultation and again up to1 year later to document the impact of the consultation on their treatment. Consulting oncologists were also inter viewed. Our findings reveal a variety of ways in which the CCC 2nd opinion substantially improved the quality of treatment for African American breast cancer patients. In all cases CCC clinicians offered important recommendations, from complete revision of a treatment plan to adding/changing medications, modifying the plan for monitoring, and/or improving management of side effects. Patients reported that all major recommendations were implemented by their treating clinicians. In one dramatic case, chemotherapy was failing to slow the growth a young public hospital patient's stage 3 tumor associated with a P53 mutation. The CCC clinician recommended and advocated for an entirely different treatment. In remission two years later, the patient has had another child. To our knowledge, this is the first study to explore the CCC consultation as an intervention to reduce mortality disparities. It appears highly feasible to target CCC 2nd opinions to vulnerable patients at relatively low cost to the CCC. Many CCC clinicians are eager to see high‐risk under‐represented patients, and go beyond the consultation by communicating with treating clinicians and seeing patients more than once. Patients readily recognized the expertise of CCC clinicians and were deeply grateful for the opportunity. Based on this pilot study, the 2nd opinion concept warrants further testing via a randomized trial. Comprehensive Cancer Centers can and must take greater responsibility for disparities in their region through innovations that extend their expertise beyond their walls. AN - CN-02213311 AU - Pasick, R. J. AU - Campbell, B. AU - Rugo, H. S. AU - Dillard, C. AU - Harris, M. AU - Joseph, G. DO - 10.1158/1538-7755.DISP19-D078 IS - 6 SUPPL 2 KW - *African American *breast cancer *cancer center Cancer chemotherapy Cancer patient Cancer staging Child Clinical article Conference abstract Consultation Controlled study Feasibility study Female Gene mutation Human Mortality Oncologist Pilot study Public hospital Randomized controlled trial Remission Responsibility Risk assessment Side effect Treatment failure M3 - Journal: Conference Abstract PY - 2020 ST - Unlocking the vault: can 2nd opinions by Comprehensive Cancer Center breast oncologistsimprove treatment quality for African Americans? T2 - Cancer epidemiology biomarkers and prevention TI - Unlocking the vault: can 2nd opinions by Comprehensive Cancer Center breast oncologistsimprove treatment quality for African Americans? UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02213311/full VL - 29 ID - 1398 ER - TY - JOUR AB - PURPOSE Cancer clinical trial accrual rates are low, and information about contributing factors is needed. We examined video-recorded clinical interactions to identify circumstances under which patients potentially eligible for a trial at a major cancer center were offered a trial. METHODS We conducted a qualitative directed content analysis of 62 recorded interactions with physicians (n = 13) and patients with intermediate- or high-risk prostate cancer (n = 43). Patients were screened and potentially eligible for a trial. We observed and coded the interactions in 3 steps: (1) classification of all interactions as explicit offer, offer pending, trial discussed/not offered, or trial not discussed; (2) in interactions with no explicit offer, classification of whether the cancer had progressed; (3) in interactions classified as progression but no trial offered, identification of factors discussed that may explain the lack of an offer. RESULTS Of the 62 interactions, 29% were classified as explicit offer, 12% as offer pending, 18% as trial discussed/not offered, and 39% as trial not discussed. Of those with no offer, 57% included information that the cancer had not progressed. In 68% of the remaining interactions with patients whose cancer had progressed but did not receive an offer, reasons for the lack of offer were identified, but in 32%, no explanation was provided. CONCLUSION Even in optimal circumstances, few patients were offered a trial, often because their cancer had not progressed. Findings support professional recommendations to broaden trial inclusion criteria. Findings suggest accrual rates should reflect the proportion of eligible patients who enroll. © 2019 by American Society of Clinical Oncology. AD - Wayne State University/Karmanos Cancer Institute, Detroit, MI, United States Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States Johns Hopkins/Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States Vanderbilt University, Nashville, TN, United States AU - Hamel, L. M. AU - Dougherty, D. W. AU - Albrecht, T. L. AU - Wojda, M. AU - Jordan, A. AU - Moore, T. F. AU - Senft, N. AU - Carducci, M. AU - Heath, E. I. AU - Manning, M. A. AU - Penner, L. A. AU - Kim, S. AU - Eggly, S. DB - Scopus DO - 10.1200/JOP.19.00444 IS - 2 M3 - Article N1 - Export Date: 22 March 2021 PY - 2020 SP - E124-E131 ST - Unpacking trial offers and low accrual rates: A qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial T2 - JCO Oncology Practice TI - Unpacking trial offers and low accrual rates: A qualitative analysis of clinic visits with physicians and patients potentially eligible for a prostate cancer clinical trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084542985&doi=10.1200%2fJOP.19.00444&partnerID=40&md5=eefc17f06f83d9bb9113f809b5b9bd38 VL - 16 ID - 2205 ER - TY - JOUR AB - Background: Recent advances in mobile technologies have created new opportunities to reach broadly into populations that are vulnerable to health disparities. However, mobile health (mHealth) strategies could paradoxically increase health disparities, if low socioeconomic status individuals lack the technical or literacy skills needed to navigate mHealth programs. Objective: The aim of this study was to determine whether patients from vulnerable populations could successfully navigate and complete an mHealth patient decision aid. Methods: We analyzed usability data from a randomized controlled trial of an iPad program designed to promote colorectal cancer (CRC) screening. The trial was conducted in six primary care practices and enrolled 450 patients, aged 50-74 years, who were due for CRC screening. The iPad program included a self-survey and randomly displayed either a screening decision aid or a video about diet and exercise. We measured participant ability to complete the program without assistance and participant-rated program usability. Results: Two-thirds of the participants (305/450) were members of a vulnerable population (limited health literacy, annual income < US $20,000, or black race). Over 92% (417/450) of the participants rated the program highly on all three usability items (90.8% for vulnerable participants vs 96.6% for nonvulnerable participants, P=.006). Only 6.9% (31/450) of the participants needed some assistance to complete the program. In multivariable logistic regression, being a member of a vulnerable population was not associated with needing assistance. Only older age, less use of text messaging (short message service, SMS), and lack of Internet use predicted needing assistance. Conclusions: Individuals who are vulnerable to health disparities can successfully use well-designed mHealth programs. Future research should investigate whether mHealth interventions can reduce health disparities. ©David P Miller Jr, Kathryn E Weaver, L Doug Case, Donald Babcock, Donna Lawler, Nancy Denizard-Thompson, Michael P Pignone, John G Spangler. AD - Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, NC, United States Wake Forest School of Medicine, Department of Social Sciences & Health Policy, Winston-Salem, NC, United States Wake Forest School of Medicine, Department of Biostatistical Sciences, Winston-Salem, NC, United States Wake Forest Health Sciences, Enterprise Information Management, Winston-Salem, NC, United States University of Texas Dell Medical School, Department of Internal Medicine, Austin, TX, United States Wake Forest School of Medicine, Department of Family & Community Medicine, Winston-Salem, NC, United States AU - Miller, D. P., Jr. AU - Weaver, K. E. AU - Case, L. D. AU - Babcock, D. AU - Lawler, D. AU - Denizard-Thompson, N. AU - Pignone, M. P. AU - Spangler, J. G. C7 - e43 DB - Scopus DO - 10.2196/mhealth.7268 IS - 4 KW - Decision support techniques Health literacy Primary care Technology assessment Vulnerable populations M3 - Article N1 - Cited By :22 Export Date: 22 March 2021 PY - 2017 ST - Usability of a novel mobile health iPad app by vulnerable populations T2 - JMIR mHealth and uHealth TI - Usability of a novel mobile health iPad app by vulnerable populations UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85045928521&doi=10.2196%2fmhealth.7268&partnerID=40&md5=011c63e5a17c8dc193a5a985f9ec626b VL - 5 ID - 2313 ER - TY - JOUR AB - Background: Recent advances in mobile technologies have created new opportunities to reach broadly into populations that are vulnerable to health disparities. However, mobile health (mHealth) strategies could paradoxically increase health disparities, if low socioeconomic status individuals lack the technical or literacy skills needed to navigate mHealth programs. Objective: The aim of this study was to determine whether patients from vulnerable populations could successfully navigate and complete an mHealth patient decision aid. Methods: We analyzed usability data from a randomized controlled trial of an iPad program designed to promote colorectal cancer (CRC) screening. The trial was conducted in six primary care practices and enrolled 450 patients, aged 50-74 years, who were due for CRC screening. The iPad program included a self-survey and randomly displayed either a screening decision aid or a video about diet and exercise. We measured participant ability to complete the program without assistance and participant-rated program usability. Results: Two-thirds of the participants (305/450) were members of a vulnerable population (limited health literacy, annual income < US $20,000, or black race). Over 92% (417/450) of the participants rated the program highly on all three usability items (90.8% for vulnerable participants vs 96.6% for nonvulnerable participants, P=.006). Only 6.9% (31/450) of the participants needed some assistance to complete the program. In multivariable logistic regression, being a member of a vulnerable population was not associated with needing assistance. Only older age, less use of text messaging (short message service, SMS), and lack of Internet use predicted needing assistance. Conclusions: Individuals who are vulnerable to health disparities can successfully use well-designed mHealth programs. Future research should investigate whether mHealth interventions can reduce health disparities. AN - WOS:000399383500001 AU - Miller, D. P. AU - Weaver, K. E. AU - Case, L. D. AU - Babcock, D. AU - Lawler, D. AU - Denizard-Thompson, N. AU - Pignone, M. P. AU - Spangler, J. G. DA - Apr DO - 10.2196/mhealth.7268 IS - 4 N1 - e43 28400354 PY - 2017 SN - 2291-5222 ST - Usability of a Novel Mobile Health iPad App by Vulnerable Populations T2 - Jmir Mhealth and Uhealth TI - Usability of a Novel Mobile Health iPad App by Vulnerable Populations VL - 5 ID - 2901 ER - TY - JOUR AB - Background: For postmenopausal women with hormone receptor‐positive breast cancer, long‐term use of aromatase inhibitors (AI) significantly reduces the risk of cancer recurrence and improves disease free and overall survival. Despite the known benefits of AIs, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial of a web‐enabled application (app) to provide real‐time monitoring and better management of treatment‐related adverse symptoms among patients with hormonereceptor positive breast cancer and a new AI prescription. Methods: Eligible patients who agreed to participate were randomized into either: App: had access to the app and received weekly reminders to use it; or Usual Care: had access to the app but did not receive reminders. Concerning responses and trends triggered email alerts to the patient's providers, who then could review responses to manage ongoing treatment and make therapeutic adjustments. The main analyses compared overall AI adherence using the Morisky Medication Adherence Scale and quality of life using the Functional Assessment of Cancer Therapy Endocrine Symptoms (FACT‐ES). Results: We enrolled 44 patients, 21 in the App and 23 in the Usual Care groups; 83% of patients approached agreed to participate, 23% were African‐American, and 32% were over the age of 65. Overall, 74% of participants in the App group used the app at least once per week compared with 38% in the Usual Care group (p<0.01). Reported AI adherence at 8 weeks after initiation was significantly higher among App compared with the Usual care group at 8 weeks (100% vs. 72%, p=0.01). Using a differences‐in‐differences analysis, we found a substantially larger decrease in quality of life in the Usual Care group compared with the App (‐11.5 vs. ‐3.9, p=0.191), although this difference did not reach statistical significance. Conclusions: App use with weekly reminders significantly improved short‐term AI adherence. If short‐term gains in adherence persist, this low‐cost intervention could improve survival outcomes for women with hormonereceptor positive breast cancer. AN - CN-01423647 AU - Graetz, I. AU - McKillop, C. N. AU - Stepanski, E. J. AU - Vidal, G. A. AU - Schwartzberg, L. S. IS - 5 KW - *breast cancer *symptom African American Aged Cancer therapy Clinical article Controlled clinical trial Controlled study Endocrine disease E‐mail Female Functional assessment Human Medication compliance Monitoring Prescription Quality of life Randomized controlled trial Statistical significance M3 - Journal: Conference Abstract PY - 2017 ST - Use of a web-based app to improve breast cancer symptom management and aromatase inhibitor adherence T2 - Journal of clinical oncology TI - Use of a web-based app to improve breast cancer symptom management and aromatase inhibitor adherence UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01423647/full VL - 35 ID - 1528 ER - TY - JOUR AB - Introduction African-American women have higher rates of early-onset breast cancer compared with their Caucasian counterparts; yet, when diagnosed with breast cancer at a young age, they underuse genetic counseling and testing to manage their risk of developing future cancers. Methods Self-reported baseline data were collected between September 2012 and January 2013 and analyzed in 2014 from a subpopulation of 340 African-American young breast cancer survivors (YBCSs) enrolled in an RCT. YBCSs were diagnosed with invasive breast cancer or ductal carcinoma in situ between ages 20 and 45 years and were randomly selected from a statewide cancer registry. Logistic regression examined predictors of using cancer genetics services. Results Overall, 28% of the sample reported having genetic counseling and 21% reported having genetic testing, which were significantly lower (p≤0.005) compared with white/other YBCSs participating in the parent study. In a multivariate analysis, income was positively associated with counseling (B=0.254, p≤0.01) and testing (B=0.297, p≤0.01), whereas higher education levels (B=−0.328, p≤0.05) and lack of access to healthcare services owing to cost (B=−1.10, p≤0.03) were negatively associated with genetic counseling. Lower income and lack of care because of high out-of-pocket costs were commonly reported barriers. Conclusions Despite national recommendations for genetic evaluation among women with early-onset breast cancer, few African-American YBCSs reported undergoing genetic counseling and testing. Most reported that their healthcare provider did not recommend these services. Interventions addressing patient, provider, and structural healthcare system barriers to using genetic counseling and testing in this population are needed. © 2016 American Journal of Preventive Medicine AD - The Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, Boston, Massachusetts, United States Duquesne University School of Nursing, Pittsburgh, Pennsylvania, United States University of Michigan School of Nursing, Ann Arbor, Michigan, United States Michigan Department of Health and Human Services, Cancer Genomics Program, Lansing, Michigan, United States Ohio State University College of Nursing, Columbus, Ohio, United States University of Michigan School of Medicine, Ann Arbor, Michigan, United States University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States University of Michigan School of Public Health, Ann Arbor, Michigan, United States University of Basel, Institute of Nursing Science, Basel, Switzerland AU - Jones, T. AU - Lockhart, J. S. AU - Mendelsohn-Victor, K. E. AU - Duquette, D. AU - Northouse, L. L. AU - Duffy, S. A. AU - Donley, R. AU - Merajver, S. D. AU - Milliron, K. J. AU - Roberts, J. S. AU - Katapodi, M. C. DB - Scopus DO - 10.1016/j.amepre.2016.03.016 IS - 4 M3 - Article N1 - Cited By :24 Export Date: 22 March 2021 PY - 2016 SP - 427-436 ST - Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors T2 - American Journal of Preventive Medicine TI - Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973121828&doi=10.1016%2fj.amepre.2016.03.016&partnerID=40&md5=df14599d78d7969ca5a1fc290cb82bff VL - 51 ID - 2334 ER - TY - JOUR AB - BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design. AN - WOS:000234358200024 AU - Newman, L. A. AU - Lee, C. T. AU - Parekh, L. P. AU - Stewart, A. K. AU - Thomas, C. R. AU - Beltran, R. A. AU - Lucci, A. AU - Green, B. AU - Ota, D. AU - Nelson, H. DA - Jan DO - 10.1002/cncr.21592 IS - 1 N1 - 16333856 PY - 2006 SN - 0008-543X SP - 188-195 ST - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients - A report from the American College of Surgeons Oncology Group (ACOSOG) Special Populations Committee T2 - Cancer TI - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients - A report from the American College of Surgeons Oncology Group (ACOSOG) Special Populations Committee VL - 106 ID - 3224 ER - TY - JOUR AB - BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design. © 2005 American Cancer Society. AD - Department of Surgery, University of Michigan, Ann Arbor, MI, United States Department of Urology, University of Michigan, Ann Arbor, MI, United States American College of Surgeons Commission on Cancer, Chicago, IL, United States Department of Radiation Oncology, Oregon Health and Science University School of Medicine, Portland, OR, United States Latino Med Policy Group, Chicago, IL, United States Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States Department of Surgery, Duke University, Durham, NC, United States Department of Surgery, Mayo Clinic, Rochester, MN, United States Breast Care Center, University of Michigan Comprehensive Cancer Center, 3308 Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0932, United States AU - Newman, L. A. AU - Lee, C. T. AU - Parekh, L. P. AU - Stewart, A. K. AU - Thomas Jr, C. R. AU - Beltran, R. A. AU - Lucci, A. AU - Green, B. AU - Ota, D. AU - Nelson, H. DB - Scopus DO - 10.1002/cncr.21592 IS - 1 KW - Breast cancer Colorectal cancer Disease stage Ethnicity Minority National Cancer Data Base Nonsmall cell lung cancer Prostate cancer M3 - Article N1 - Cited By :28 Export Date: 22 March 2021 PY - 2006 SP - 188-195 ST - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee T2 - Cancer TI - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-29744432215&doi=10.1002%2fcncr.21592&partnerID=40&md5=ed6191cb081b3e4a224a2b0d012b4145 VL - 106 ID - 2582 ER - TY - JOUR AD - Department of Psychology, Wichita State University, 1845 N. Fairmount, Box 34, Wichita, KS 67620-0034; rhonda.lewis@wichita.edu AN - 106534104. Language: English. Entry Date: 20051104. Revision Date: 20150711. Publication Type: Journal Article AU - Lewis, R. K. DB - CINAHL Complete DP - EBSCOhost IS - 4 KW - Black Persons Models, Theoretical Research Subject Recruitment Cancer Screening Culture Health Behavior Male Prostatic Neoplasms -- Prevention and Control N1 - commentary. Original Study: Abernethy AD, Magat MM, Houston TR, Arnold HL Jr., Bjorck JP, Gorsuch RL. Recruiting African American men for cancer screening studies: applying a culturally based model. (HEALTH EDUC BEHAV) Aug2005; 32 (4): 441-451. Journal Subset: Health Promotion/Education; Peer Reviewed; USA. NLM UID: 9704962. PMID: NLM16708456. PY - 2005 SN - 1090-1981 SP - 452-454 ST - Using a culturally relevant theory to recruit African American men for prostate cancer screening T2 - Health Education & Behavior TI - Using a culturally relevant theory to recruit African American men for prostate cancer screening UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106534104&site=ehost-live&scope=site VL - 32 ID - 2137 ER - TY - JOUR AB - Purpose: To adapt ethnically appropriate radio and newspaper messages in order to increase information-seeking and recruitment to the high-risk Prostate Cancer Risk Assessment Program (PRAP) using input from focus groups. Methods: We conducted four gender- and ethnic specificfocus groups composed of up to eight participants each. Group participants ranged in age from 35-69 and were either at risk for prostate cancer or were married to someone at risk. Participants evaluated both print and radio advertisements for a PRAP media recruitment campaign, and their recommendations were used to adapt the advertisements. Results: Trigger words, e.g., "research program," were found to be a particular, issue for African-American men who cited concerns about "experimentation," while the other groups cited concerns about time commitments and cost. In the print messages, familial themes garnered an overall favorable response, but Caucasian-American participants responded negatively to the use of photos of age-appropriate models. Conclusion: Focus groups are useful in checking health professional assumptions about health messages prior to developing awareness or recruitment advertisements or materials. There was an implied preference for "younger" models among Caucasian Americans. Radio and print messages were adapted using the focus group recommendations, i.e., focusing on familial themes, adding race-specific risk estimates and using younger-than-target group models. AD - D. W. Bruner, University of Pennsylvania, Claire M. Fagin Hall, Schoo of Nursing, 418 Curie Blvd., Philadelphia, PA 19104-6096, United States AU - Bryan, C. J. AU - Wetmore-Arkader, L. AU - Calvano, T. AU - Deatrick, J. A. AU - Giri, V. N. AU - Bruner, D. W. DB - Embase Medline DO - 10.1016/S0027-9684(15)31340-7 IS - 6 KW - adult advertising African American aged article cancer risk cancer screening clinical article ethnic difference European American experimentation human information center information processing male medical research patient participation priority journal prostate cancer LA - English M3 - Article N1 - L351874444 2008-08-13 PY - 2008 SN - 0027-9684 SP - 674-682 ST - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk T2 - Journal of the National Medical Association TI - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk UR - https://www.embase.com/search/results?subaction=viewrecord&id=L351874444&from=export http://dx.doi.org/10.1016/S0027-9684(15)31340-7 VL - 100 ID - 1209 ER - TY - JOUR AB - Purpose: To adapt ethnically appropriate radio and newspaper messages in order to increase information-seeking and recruitment to the high-risk Prostate Cancer Risk Assessment Program (PRAP) using input from focus groups. Methods: We conducted four gender- and ethnic specificfocus groups composed of up to eight participants each. Group participants ranged in age from 35-69 and were either at risk for prostate cancer or were married to someone at risk. Participants evaluated both print and radio advertisements for a PRAP media recruitment campaign, and their recommendations were used to adapt the advertisements. Results: Trigger words, e.g., "research program," were found to be a particular, issue for African-American men who cited concerns about "experimentation," while the other groups cited concerns about time commitments and cost. In the print messages, familial themes garnered an overall favorable response, but Caucasian-American participants responded negatively to the use of photos of age-appropriate models. Conclusion: Focus groups are useful in checking health professional assumptions about health messages prior to developing awareness or recruitment advertisements or materials. There was an implied preference for "younger" models among Caucasian Americans. Radio and print messages were adapted using the focus group recommendations, i.e., focusing on familial themes, adding race-specific risk estimates and using younger-than-target group models. AD - School of Nursing, University of Pennsylvania, Philadelphia, PA, United States Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States Fox Chase Cancer Center, Philadelphia, PA, United States University of Pennsylvania, Claire M. Fagin Hall, Schoo of Nursing, 418 Curie Blvd., Philadelphia, PA 19104-6096, United States AU - Bryan, C. J. AU - Wetmore-Arkader, L. AU - Calvano, T. AU - Deatrick, J. A. AU - Giri, V. N. AU - Bruner, D. W. DB - Scopus DO - 10.1016/S0027-9684(15)31340-7 IS - 6 KW - Minority health Prostate cancer Screening M3 - Article N1 - Cited By :10 Export Date: 22 March 2021 PY - 2008 SP - 674-682 ST - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk T2 - Journal of the National Medical Association TI - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-45749137116&doi=10.1016%2fS0027-9684%2815%2931340-7&partnerID=40&md5=569944edfbd3f52b305a5fdfd77e0e88 VL - 100 ID - 2547 ER - TY - JOUR AB - Purpose: To adapt ethnically appropriate radio and newspaper messages in order to increase information-seeking and recruitment to the high-risk Prostate Cancer Risk Assessment Program (PRAP) using input from focus groups.Methods: We conducted four gender- and ethnic specific-focus groups composed of up to eight participants each. Group participants ranged in age from 35-69 and were either at risk for prostate cancer or were married to someone at risk. Participants evaluated both print and radio advertisements for a PRAP media recruitment campaign, and their recommendations were used to adapt the advertisements.Results: Trigger words, e.g,, "research program," were found to be a particular issue for African-American men who cited concerns about "experimentation," while the other groups cited concerns about time commitments and cost. In the print messages, familial themes garnered an overall favorable response, but Caucasian-American participants responded negatively to the use of photos of age-appropriate models.Conclusion: Focus groups are useful in checking health professional assumptions about health messages prior to developing awareness or recruitment advertisements or materials. There was an implied preference for "younger" models among Caucasian Americans. Radio and print messages were adapted using the focus group recommendations, i.e., focusing on familial themes, adding race-specific risk estimates and using younger-than-target group models. AD - School of Nursing, University of Pennsylvania, PA, USA School of Nursing, University of Pennsylvania, Philadelphia, PA AN - 105789909. Language: English. Entry Date: 20080815. Revision Date: 20190612. Publication Type: journal article AU - Bryan, C. J. AU - Wetmore-Arkader, L. AU - Calvano, T. AU - Deatrick, J. A. AU - Giri, V. N. AU - Bruner, D. W. AU - Bryan, Charlene J. AU - Wetmore-Arkader, Lindsay AU - Calvano, Tammy AU - Deatrick, Janet A. AU - Giri, Veda N. AU - Bruner, Deborah Watkins DB - CINAHL Complete DP - EBSCOhost IS - 6 KW - Cancer Screening Culture Program Development Prostatic Neoplasms -- Prevention and Control Adult Aged Cultural Diversity Descriptive Research Digital Rectal Examination Early Intervention Female Focus Groups Male Middle Age Minority Groups Patient Selection Prostate-Specific Antigen -- Blood Prostatic Neoplasms -- Epidemiology Qualitative Studies Thematic Analysis Human N1 - research; tables/charts. Journal Subset: Biomedical; Peer Reviewed; USA. Grant Information: R01 CA114321-01A1/CA/NCI NIH HHS/United States. NLM UID: 7503090. PMID: NLM18595569. PY - 2008 SN - 0027-9684 SP - 674-682 ST - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk T2 - Journal of the National Medical Association TI - Using focus groups to adapt ethnically appropriate, information-seeking and recruitment messages for a prostate cancer screening program for men at high risk UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105789909&site=ehost-live&scope=site VL - 100 ID - 2139 ER - TY - JOUR AB - BACKGROUND: While information websites have been developed by major cancer organizations, their appropriateness for patients in multiethnic, multilingual public hospital settings has received limited attention. OBJECTIVE: The objective of the study was to determine the utility of cancer information websites for a public hospital patient population. METHODS: A 70-item questionnaire was developed to evaluate cancer information seeking behavior, Internet access and use, and content appropriateness of two cancer information websites: People Living with Cancer from the American Society of Clinical Oncology (ASCO) and Breast Cancer Info from the Susan Komen Breast Cancer Foundation (SKF). Interviews were conducted with consecutive consenting oncology patients seen in a public hospital oncology clinic. RESULTS: Fifty-nine persons participated in the survey. The response rate was 80%. Participants were Caucasian (25%), African American (19%), Hispanic (42%), and Asian/Pacific Islander (11%). English was the primary language in 53% of participants, 56% had a high school education or less, and 74% had an annual income less than US 35000 dollars. With respect to computer and Internet use, 71% had computer access, and 44% searched for cancer information online, with more being interested in obtaining online information in the future (63%). Participants who had computer access were likely to be English speaking (P = .04). Those less likely to have previously used a computer tended to have a lower annual income (P = .02) or to be males aged 55 years or older (P < .05). When shown sample content from the two websites, almost all participants stated that it was "easy to understand" (ASCO 96%, SKF 96%) and had "easy to understand terms" (ASCO 94%, SKF 92%). Somewhat fewer respondents agreed that the websites provided "information they could use" (ASCO 88%, SKF 80%) or that they would return to these websites (ASCO 73%, SKF 68%). The majority planned to "discuss website information with their oncologists" (ASCO 82%, SKF 70%). CONCLUSIONS: Multiethnic, multilingual cancer patients at a public county hospital commonly had Internet access and found the content of two websites representative of major cancer organizations to be both understandable and useful. AD - K.D. Nguyen, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA. AU - Nguyen, K. D. AU - Hara, B. AU - Chlebowski, R. T. DB - Medline IS - 3 KW - article attitude to computers cross-sectional study educational status ethnic group female health survey human income Internet male neoplasm non profit organization organization and management patient selection psychological aspect public hospital questionnaire reproducibility United States LA - English M3 - Article N1 - L41884912 2006-08-16 PY - 2005 SN - 1438-8871 SP - e28 ST - Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey T2 - Journal of medical Internet research TI - Utility of two cancer organization websites for a multiethnic, public hospital oncology population: comparative cross-sectional survey UR - https://www.embase.com/search/results?subaction=viewrecord&id=L41884912&from=export VL - 7 ID - 1265 ER - TY - JOUR AB - Background: While information websites have been developed by major cancer organizations, their appropriateness for patients in multiethnic, multilingual public hospital settings has received limited attention. Objective: The objective of the study was to determine the utility of cancer information websites for a public hospital patient population. Methods: A 70-item questionnaire was developed to evaluate cancer information seeking behavior, Internet access and use, and content appropriateness of two cancer information websites: People Living with Cancer from the American Society of Clinical Oncology (ASCO) and Breast Cancer Info from the Susan Komen Breast Cancer Foundation (SKF). Interviews were conducted with consecutive consenting oncology patients seen in a public hospital oncology clinic. Results: Fifty-nine persons participated in the survey. The response rate was 80%. Participants were Caucasian (25%), African American (19%), Hispanic (42%), and Asian/Pacific Islander (11%). English was the primary language in 53% of participants, 56% had a high school education or less, and 74% had an annual income less than US $35000. With respect to computer and Internet use, 71% had computer access, and 44% searched for cancer information online, with more being interested in obtaining online information in the future (63%). Participants who had computer access were likely to be English speaking (P = .04). Those less likely to have previously used a computer tended to have a lower annual income (P = .02) or to be males aged 55 years or older (P < .05). When shown sample content from the two websites, almost all participants stated that it was 'easy to understand' (ASCO 96%, SKF 96%) and had 'easy to understand terms' (ASCO 94%, SKF 92%). Somewhat fewer respondents agreed that the websites provided 'information they could use' (ASCO 88%, SKF 80%) or that they would return to these websites (ASCO 73%, SKF 68%). The majority planned to 'discuss website information with their oncologists' (ASCO 82%, SKF 70%). Conclusions: Multiethnic, multilingual cancer patients at a public county hospital commonly had Internet access and found the content of two websites representative of major cancer organizations to be both understandable and useful. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Chlebowski, Rowan T., Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, 1124 W Carson Street, Building J-3, Torrance, CA, US, 90502 AN - 2006-02998-004 AU - Nguyen, Katherine D. AU - Hara, Belinda AU - Chlebowski, Rowan T. DB - psyh DO - 10.2196/jmir.7.3.e28 DP - EBSCOhost IS - 3 KW - cancer organization websites multiethnic public hospital oncology population multilingual public hospital hospital patient population American Cancer Society Attitude to Computers Cross-Sectional Studies Educational Status Ethnic Groups Female Health Surveys Hospitals, Public Humans Income Internet Male Neoplasms Patient Selection Reproducibility of Results Surveys and Questionnaires United States Hospitalized Patients Hospitals Organizations At Risk Populations Multilingualism Population Racial and Ethnic Groups Websites Oncology N1 - Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA, US. Other Publishers: JMIR Publications. Release Date: 20060327. Correction Date: 20201012. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Hospitalized Patients; Hospitals; Internet; Neoplasms; Organizations. Minor Descriptor: At Risk Populations; Multilingualism; Population; Racial and Ethnic Groups; Websites; Oncology. Classification: Cancer (3293); Health & Mental Health Services (3370). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study; Quantitative Study. References Available: Y. Issue Publication Date: 2005. PY - 2005 SN - 1439-4456 1438-8871 ST - Utility of Two Cancer Organization Websites for a Multiethnic, Public Hospital Oncology Population: Comparative Cross-Sectional Survey T2 - Journal of Medical Internet Research TI - Utility of Two Cancer Organization Websites for a Multiethnic, Public Hospital Oncology Population: Comparative Cross-Sectional Survey UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2006-02998-004&site=ehost-live&scope=site rchlebow@whi.org VL - 7 ID - 1778 ER - TY - JOUR AB - Aims: We evaluated the immunogenicity, efficacy, and safety of succinylnorcocaine conjugated to cholera toxin B protein as a vaccine for cocaine dependence. Methods: This 6-site, 24 week Phase III randomized double-blind placebo-controlled trial assessed efficacy during weeks 8 to 16. We measured urine cocaine metabolites thrice weekly as the main outcome. Results: The 300 subjects (76% male, 72% African-American, mean age 46 years) had smoked cocaine on average for 13 days monthly at baseline. We hypothesized that retention might be better and positive urines lower for subjects with anti-cocaine IgG levels of ≥42. μg/mL (high IgG), which was attained by 67% of the 130 vaccine subjects receiving five vaccinations. Almost 3-times fewer high than low IgG subjects dropped out (7% vs 20%). Although for the full 16 weeks cocaine positive urine rates showed no significant difference between the three groups (placebo, high, low IgG), after week 8, more vaccinated than placebo subjects attained abstinence for at least two weeks of the trial (24% vs 18%), and the high IgG group had the most cocaine-free urines for the last 2 weeks of treatment (OR. = 3.02), but neither were significant. Injection site reactions of induration and tenderness differed between placebo and active vaccine, and the 29 serious adverse events did not lead to treatment related withdrawals, or deaths. Conclusions: The vaccine was safe, but it only partially replicated the efficacy found in the previous study based on retention and attaining abstinence. © 2014 Elsevier Ireland Ltd. AD - Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe, Bldg. 121, Rm 141, Houston, TX 77030, United States University of Texas, Houston, TX 77030, United States University of Cincinnati, Cincinnati, OH, United States Columbia University, New York, NY, United States Johns Hopkins University, Baltimore, MD, United States NYU/VA NYHHS, New York, NY, United States University of Pennsylvania, PhiladelphiaPA, United States AU - Kosten, T. R. AU - Domingo, C. B. AU - Shorter, D. AU - Orson, F. AU - Green, C. AU - Somoza, E. AU - Sekerka, R. AU - Levin, F. R. AU - Mariani, J. J. AU - Stitzer, M. AU - Tompkins, D. A. AU - Rotrosen, J. AU - Thakkar, V. AU - Smoak, B. AU - Kampman, K. DB - Scopus DO - 10.1016/j.drugalcdep.2014.04.003 KW - Clinical trial Cocaine Immunotherapy Vaccine M3 - Article N1 - Cited By :54 Export Date: 22 March 2021 PY - 2014 SP - 42-47 ST - Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial T2 - Drug and Alcohol Dependence TI - Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924840368&doi=10.1016%2fj.drugalcdep.2014.04.003&partnerID=40&md5=fb595f2325d80709f8c92617b0066110 VL - 140 ID - 2419 ER - TY - JOUR AB - Background: Socioculturally relevant measures of medical mistrust are needed to better address health disparities, especially among Black men, a group with lower life expectancy and higher death rates compared to other race/gender groups. OBJECTIVES: The study aim was to investigate the psychometric properties of the Group-Based Medical Mistrust Scale (GBMMS) in a Black male sample. Design: Data were collected as part of a randomized controlled trial testing educational strategies to support Black men's decisions about prostate cancer screening. Participants: Participants included 201 Black men ages 40-75 years recruited in New York City during 2006-2007. MAIN MEASURES: The primary measures included: race-based medical mistrust, health care participation, avoidance of health care, perceived access to health care, health care satisfaction, racial identity, residential racial segregation, attitudes towards prostate cancer screening, and past prostate cancer screening behavior. KEY Results: An exploratory factor analysis suggested a three-factor structure. Confirmatory factor analysis supported the three-factor model. Internal consistency was high for the total GBMMS and the three sub-scales: Suspicion, Discrimination, and Lack of Support. Construct validity was supported by: significant positive correlations between GBMMS and avoidance of health care and racial identity as well as significant negative correlations with health care access, health care satisfaction, and attitudes about prostate cancer screening. ANOVA showed that the GBMMS was associated with greater residential racial segregation. Higher total GBMMS scores were associated with not visiting a physician in the last year and not having a regular physician. Conclusions: The present findings provide strong additional evidence that the GBMMS is a valid and reliable measure that may be used among urban Black men. © 2010 Society of General Internal Medicine. AD - R. C. Shelton, Department of Oncological Science/Cancer Prevention and Control, Mount Sinai School of Medicine, Box 1130, 1425 Madison Avenue, New York, NY 10029, United States AU - Shelton, R. C. AU - Winkel, G. AU - Davis, S. N. AU - Roberts, N. AU - Valdimarsdottir, H. AU - Hall, S. J. AU - Thompson, H. S. DB - Embase Medline DO - 10.1007/s11606-010-1288-y IS - 6 KW - adult aged analysis of variance article attitude to health cancer screening construct validity demography exploratory research group based medical mistrust scale health care access human internal consistency major clinical study male medical decision making Black person patient participation patient satisfaction physician prostate cancer psychometry race race difference rating scale reliability United States urban population validation study LA - English M3 - Article N1 - L50819518 2010-08-06 2010-08-16 PY - 2010 SN - 1525-1497 0884-8734 SP - 549-555 ST - Validation of the group-based medical mistrust scale among urban black men T2 - Journal of General Internal Medicine TI - Validation of the group-based medical mistrust scale among urban black men UR - https://www.embase.com/search/results?subaction=viewrecord&id=L50819518&from=export http://dx.doi.org/10.1007/s11606-010-1288-y VL - 25 ID - 1163 ER - TY - JOUR AB - Background: Socioculturally relevant measures of medical mistrust are needed to better address health disparities, especially among Black men, a group with lower life expectancy and higher death rates compared to other race/gender groups. Objectives: The study aim was to investigate the psychometric properties of the Group-Based Medical Mistrust Scale (GBMMS) in a Black male sample. Design: Data were collected as part of a randomized controlled trial testing educational strategies to support Black men’s decisions about prostate cancer screening. Participants: Participants included 201 Black men ages 40–75 years recruited in New York City during 2006–2007. Main measures: The primary measures included: race-based medical mistrust, health care participation, avoidance of health care, perceived access to health care, health care satisfaction, racial identity, residential racial segregation, attitudes towards prostate cancer screening, and past prostate cancer screening behavior. Key results: An exploratory factor analysis suggested a three-factor structure. Confirmatory factor analysis supported the three-factor model. Internal consistency was high for the total GBMMS and the three sub-scales: Suspicion, Discrimination, and Lack of Support. Construct validity was supported by: significant positive correlations between GBMMS and avoidance of health care and racial identity as well as significant negative correlations with health care access, health care satisfaction, and attitudes about prostate cancer screening. ANOVA showed that the GBMMS was associated with greater residential racial segregation. Higher total GBMMS scores were associated with not visiting a physician in the last year and not having a regular physician. Conclusions: The present findings provide strong additional evidence that the GBMMS is a valid and reliable measure that may be used among urban Black men. (PsycINFO Database Record (c) 2016 APA, all rights reserved) AD - Shelton, Rachel C., Department of Oncological Science/Cancer Prevention and Control, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1130, New York, NY, US, 10029 AN - 2010-09876-014 AU - Shelton, Rachel C. AU - Winkel, Gary AU - Davis, Stacy N. AU - Roberts, Nicole AU - Valdimarsdottir, Heiddis AU - Hall, Simon J. AU - Thompson, Hayley S. DB - psyh DO - 10.1007/s11606-010-1288-y DP - EBSCOhost IS - 6 KW - Group Based Medical Mistrust Scale Blacks males psychometrics test validity clinical trials Adult African Continental Ancestry Group Aged Factor Analysis, Statistical Healthcare Disparities Humans Male Middle Aged New York City Randomized Controlled Trials as Topic Trust Urban Population Test Construction Human Males N1 - Department of Oncological Science/Cancer Prevention and Control, Mount Sinai School of Medicine, New York, NY, US. Other Publishers: Blackwell Publishing. Release Date: 20100830. Correction Date: 20121126. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Conference Information: Society of Behavioral Medicine Conference, Apr, 2009. Grant Information: Shelton, Rachel C. Conference Note: A portion of these results were presented during a poster presentation at the aforementioned conference. Major Descriptor: Clinical Trials; Psychometrics; Test Construction; Test Validity. Minor Descriptor: Blacks; Human Males. Classification: Health Psychology Testing (2226); Health & Mental Health Treatment & Prevention (3300). Population: Human (10); Male (30). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Tests & Measures: Avoids Contact with Health Care Scale; Perceived Access to Health Services Scale; Group-Based Medical Mistrust Scale DOI: 10.1037/t16933-000; Multidimensional Inventory of Black Identity DOI: 10.1037/t03182-000. Methodology: Clinical Trial; Empirical Study; Quantitative Study. References Available: Y. Page Count: 7. Issue Publication Date: Jun, 2010. Publication History: First Posted Date: Mar 2, 2010; Accepted Date: Feb 1, 2010; Revised Date: Jan 27, 2010; First Submitted Date: Sep 10, 2009. Copyright Statement: Society of General Internal Medicine. 2010. Sponsor: US Department of Defense, Prostate Cancer Research Program, US. Grant: W81XWH- 04-1-0026. Recipients: No recipient indicated Sponsor: Mount Sinai Program in Cancer Prevention and Control : Multidisciplinary Training. Grant: 5R25-CA081137. Recipients: Shelton, Rachel C. PY - 2010 SN - 0884-8734 1525-1497 SP - 549-555 ST - Validation of the Group-Based Medical Mistrust Scale among urban Black men T2 - Journal of General Internal Medicine TI - Validation of the Group-Based Medical Mistrust Scale among urban Black men UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2010-09876-014&site=ehost-live&scope=site rshelton@post.harvard.edu VL - 25 ID - 1784 ER - TY - JOUR AB - Background: Socioculturally relevant measures of medical mistrust are needed to better address health disparities, especially among Black men, a group with lower life expectancy and higher death rates compared to other race/gender groups. OBJECTIVES: The study aim was to investigate the psychometric properties of the Group-Based Medical Mistrust Scale (GBMMS) in a Black male sample. Design: Data were collected as part of a randomized controlled trial testing educational strategies to support Black men's decisions about prostate cancer screening. Participants: Participants included 201 Black men ages 40-75 years recruited in New York City during 2006-2007. MAIN MEASURES: The primary measures included: race-based medical mistrust, health care participation, avoidance of health care, perceived access to health care, health care satisfaction, racial identity, residential racial segregation, attitudes towards prostate cancer screening, and past prostate cancer screening behavior. KEY Results: An exploratory factor analysis suggested a three-factor structure. Confirmatory factor analysis supported the three-factor model. Internal consistency was high for the total GBMMS and the three sub-scales: Suspicion, Discrimination, and Lack of Support. Construct validity was supported by: significant positive correlations between GBMMS and avoidance of health care and racial identity as well as significant negative correlations with health care access, health care satisfaction, and attitudes about prostate cancer screening. ANOVA showed that the GBMMS was associated with greater residential racial segregation. Higher total GBMMS scores were associated with not visiting a physician in the last year and not having a regular physician. Conclusions: The present findings provide strong additional evidence that the GBMMS is a valid and reliable measure that may be used among urban Black men. © 2010 Society of General Internal Medicine. AD - Department of Oncological Science/Cancer Prevention and Control, Mount Sinai School of Medicine, Box 1130, 1425 Madison Avenue, New York, NY 10029, United States Graduate Center, City University of New York, New York, NY, United States Department of Public Health, Ritter Annex, Temple University, Philadelphia, PA, United States Jack and Pearl Resnick Campus, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States School of Health and Education, Reykjavik University, Reykjavik, Iceland Mount Sinai School of Medicine, Deane Prostate Health and Research Center, New York, NY, United States AU - Shelton, R. C. AU - Winkel, G. AU - Davis, S. N. AU - Roberts, N. AU - Valdimarsdottir, H. AU - Hall, S. J. AU - Thompson, H. S. DB - Scopus DO - 10.1007/s11606-010-1288-y IS - 6 KW - Black men Medical mistrust Psychometrics M3 - Article N1 - Cited By :53 Export Date: 22 March 2021 PY - 2010 SP - 549-555 ST - Validation of the group-based medical mistrust scale among urban black men T2 - Journal of General Internal Medicine TI - Validation of the group-based medical mistrust scale among urban black men UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84947648642&doi=10.1007%2fs11606-010-1288-y&partnerID=40&md5=54b1e7ca1d07d9b1c458b794e164fe52 VL - 25 ID - 2498 ER - TY - JOUR AB - Socioculturally relevant measures of medical mistrust are needed to better address health disparities, especially among Black men, a group with lower life expectancy and higher death rates compared to other race/gender groups. The study aim was to investigate the psychometric properties of the Group-Based Medical Mistrust Scale (GBMMS) in a Black male sample. Data were collected as part of a randomized controlled trial testing educational strategies to support Black men's decisions about prostate cancer screening. Participants included 201 Black men ages 40-75 years recruited in New York City during 2006-2007. The primary measures included: race-based medical mistrust, health care participation, avoidance of health care, perceived access to health care, health care satisfaction, racial identity, residential racial segregation, attitudes towards prostate cancer screening, and past prostate cancer screening behavior. An exploratory factor analysis suggested a three-factor structure. Confirmatory factor analysis supported the three-factor model. Internal consistency was high for the total GBMMS and the three sub-scales: Suspicion, Discrimination, and Lack of Support. Construct validity was supported by: significant positive correlations between GBMMS and avoidance of health care and racial identity as well as significant negative correlations with health care access, health care satisfaction, pt?> and attitudes about prostate cancer screening. ANOVA showed that the GBMMS was associated with greater residential racial segregation. Higher total GBMMS scores were associated with not visiting a physician in the last year and not having a regular physician. The present findings provide strong additional evidence that the GBMMS is a valid and reliable measure that may be used among urban Black men. AN - WOS:000277712200014 AU - Shelton, R. C. AU - Winkel, G. AU - Davis, S. N. AU - Roberts, N. AU - Valdimarsdottir, H. AU - Hall, S. J. AU - Thompson, H. S. DA - Jun DO - 10.1007/s11606-010-1288-y IS - 6 N1 - 20195782 PY - 2010 SN - 0884-8734 SP - 549-555 ST - Validation of the Group-Based Medical Mistrust Scale Among Urban Black Men T2 - Journal of General Internal Medicine TI - Validation of the Group-Based Medical Mistrust Scale Among Urban Black Men VL - 25 ID - 3113 ER - TY - JOUR AB - We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited. AD - B.R. Konety, Department of Urology, University of Minnesota MMC 394, 420 Delaware St. Southeast, Minneapolis, MI, United States AU - Paul, K. AU - Sathianathen, N. AU - Dahm, P. AU - Le, C. AU - Konety, B. R. DB - Embase Medline DO - 10.1097/JU.0000000000000294 IS - 2 KW - African African American article bladder cancer breast cancer clinical trial protocol colorectal cancer ethnicity government human kidney cancer lung cancer priority journal prostate cancer race secondary analysis testis cancer urinary tract cancer urinary tract disease LA - English M3 - Article N1 - L628788149 2019-08-14 2019-08-30 PY - 2019 SN - 1527-3792 0022-5347 SP - 385-390 ST - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials T2 - Journal of Urology TI - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L628788149&from=export http://dx.doi.org/10.1097/JU.0000000000000294 VL - 202 ID - 842 ER - TY - JOUR AB - Purpose:We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. AD - B.R. Konety, Department of Urology, University of Minnesota, 420 Delaware St. Southeast, Minneapolis, MN, United States AU - Paul, K. AU - Sathianathen, N. AU - Dahm, P. AU - Le, C. AU - Konety, B. R. DB - Embase DO - 10.1097/JU.0000000000000294 IS - 2 KW - adult African African American aged article bladder cancer breast cancer colorectal cancer ethnic or racial aspects female human kidney cancer lung cancer male priority journal prostate cancer secondary analysis testis cancer urinary tract cancer LA - English M3 - Article N1 - L632726525 2020-09-07 2020-09-11 PY - 2019 SN - 1527-3792 0022-5347 SP - 385-390 ST - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials T2 - Journal of Urology TI - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials UR - https://www.embase.com/search/results?subaction=viewrecord&id=L632726525&from=export http://dx.doi.org/10.1097/JU.0000000000000294 VL - 202 ID - 870 ER - TY - JOUR AB - We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited. © 2019 American Urological Association Education and Research, Inc. Unauthorized. AD - Department of Urology, University of Minnesota MMC 394, 420 Delaware St. Southeast, Minneapolis, MI 55455, United States School of Public Health, University of Minnesota, Minneapolis, MI, United States AU - Paul, K. AU - Sathianathen, N. AU - Dahm, P. AU - Le, C. AU - Konety, B. R. DB - Scopus DO - 10.1097/JU.0000000000000294 IS - 2 KW - African Americans clinical trial protocols as topic registries research design urogenital neoplasms M3 - Article N1 - Cited By :1 Export Date: 22 March 2021 PY - 2019 SP - 385-390 ST - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials T2 - Journal of Urology TI - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069296282&doi=10.1097%2fJU.0000000000000294&partnerID=40&md5=d1fccc16efe2f3a006fd9533f70cfe69 VL - 202 ID - 2223 ER - TY - JOUR AB - Purpose: We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors. Materials and Methods: We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting. Results: A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p < 0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity. Conclusions: Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. AN - WOS:000475859600047 AU - Paul, K. AU - Sathianathen, N. AU - Dahm, P. AU - Le, C. AU - Konety, B. R. DA - Aug DO - 10.1097/JU.0000000000000294 IS - 2 N1 - 31074679 PY - 2019 SN - 0022-5347 SP - 385-391 ST - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials T2 - Journal of Urology TI - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials VL - 202 ID - 2816 ER - TY - JOUR AB - IMPORTANCE Colorectal cancers are a leading cause of cancer mortality, and their primary prevention by diet is highly desirable. The relationship of vegetarian dietary patterns to colorectal cancer risk is not well established. OBJECTIVE To evaluate the association between vegetarian dietary patterns and incident colorectal cancers. DESIGN, SETTING, AND PARTICIPANTS The Adventist Health Study 2 (AHS-2) is a large, prospective, North American cohort trial including 96 354 Seventh-Day Adventist men and women recruited between January 1, 2002, and December 31, 2007. Follow-up varied by state and was indicated by the cancer registry linkage dates. Of these participants, an analytic sample of 77 659 remained after exclusions. Analysis was conducted using Cox proportional hazards regression, controlling for important demographic and lifestyle confounders. The analysis was conducted between June 1, 2014, and October 20, 2014. EXPOSURES Diet was assessed at baseline by a validated quantitative food frequency questionnaire and categorized into 4 vegetarian dietary patterns (vegan, lacto-ovo vegetarian, pescovegetarian, and semivegetarian) and a nonvegetarian dietary pattern. MAIN OUTCOMES AND MEASURES The relationship between dietary patterns and incident cancers of the colon and rectum; colorectal cancer cases were identified primarily by state cancer registry linkages. RESULTS During a mean follow-up of 7.3 years, 380 cases of colon cancer and 110 cases of rectal cancer were documented. The adjusted hazard ratios (HRs) in all vegetarians combined vs nonvegetarians were 0.78 (95%CI, 0.64-0.95) for all colorectal cancers, 0.81 (95%CI, 0.65-1.00) for colon cancer, and 0.71 (95%CI, 0.47-1.06) for rectal cancer. The adjusted HR for colorectal cancer in vegans was 0.84 (95%CI, 0.59-1.19); in lacto-ovo vegetarians, 0.82 (95%CI, 0.65-1.02); in pescovegetarians, 0.57 (95%CI, 0.40-0.82); and in semivegetarians, 0.92 (95%CI, 0.62-1.37) compared with nonvegetarians. Effect estimates were similar for men and women and for black and nonblack individuals. CONCLUSIONS AND RELEVANCE Vegetarian diets are associated with an overall lower incidence of colorectal cancers. Pescovegetarians in particular have a much lower risk compared with nonvegetarians. If such associations are causal, theymay be important for primary prevention of colorectal cancers. AD - M.J. Orlich, School of Public Health, Loma Linda University, 24951 N Circle Dr, NH 2031, Loma Linda, CA, United States AU - Orlich, M. J. AU - Singh, P. N. AU - Sabaté, J. AU - Fan, J. AU - Sveen, L. AU - Bennett, H. AU - Knutsen, S. F. AU - Beeson, W. L. AU - Jaceldo-Siegl, K. AU - Butler, T. L. AU - Herring, R. P. AU - Fraser, G. E. DB - Embase Medline DO - 10.1001/jamainternmed.2015.59 IS - 5 KW - acetylsalicylic acid hydroxymethylglutaryl coenzyme A reductase inhibitor saturated fatty acid adult alcohol consumption article calcium intake caloric intake cancer incidence cancer risk cohort analysis colon cancer colonoscopy colorectal cancer comparative study controlled study diabetes mellitus dietary fiber disease association fat intake female follow up food frequency questionnaire human lactoovovegetarian diet lifestyle major clinical study male peptic ulcer pescovegetarian diet priority journal processed meat prospective study rectum cancer red meat Seventh-day Adventist sigmoidoscopy smoking vegan vegetarian diet LA - English M3 - Article N1 - L604333575 2015-05-18 2015-05-28 PY - 2015 SN - 2168-6106 SP - 767-776 ST - Vegetarian dietary patterns and the risk of colorectal cancers T2 - JAMA Internal Medicine TI - Vegetarian dietary patterns and the risk of colorectal cancers UR - https://www.embase.com/search/results?subaction=viewrecord&id=L604333575&from=export http://dx.doi.org/10.1001/jamainternmed.2015.59 VL - 175 ID - 1001 ER - TY - JOUR AB - Importance: Colorectal cancers are a leading cause of cancer mortality, and their primary prevention by diet is highly desirable. The relationship of vegetarian dietary patterns to colorectal cancer risk is not well established.Objective: To evaluate the association between vegetarian dietary patterns and incident colorectal cancers.Design, Setting, and Participants: The Adventist Health Study 2 (AHS-2) is a large, prospective, North American cohort trial including 96,354 Seventh-Day Adventist men and women recruited between January 1, 2002, and December 31, 2007. Follow-up varied by state and was indicated by the cancer registry linkage dates. Of these participants, an analytic sample of 77,659 remained after exclusions. Analysis was conducted using Cox proportional hazards regression, controlling for important demographic and lifestyle confounders. The analysis was conducted between June 1, 2014, and October 20, 2014.Exposures: Diet was assessed at baseline by a validated quantitative food frequency questionnaire and categorized into 4 vegetarian dietary patterns (vegan, lacto-ovo vegetarian, pescovegetarian, and semivegetarian) and a nonvegetarian dietary pattern.Main Outcomes and Measures: The relationship between dietary patterns and incident cancers of the colon and rectum; colorectal cancer cases were identified primarily by state cancer registry linkages.Results: During a mean follow-up of 7.3 years, 380 cases of colon cancer and 110 cases of rectal cancer were documented. The adjusted hazard ratios (HRs) in all vegetarians combined vs nonvegetarians were 0.78 (95% CI, 0.64-0.95) for all colorectal cancers, 0.81 (95% CI, 0.65-1.00) for colon cancer, and 0.71 (95% CI, 0.47-1.06) for rectal cancer. The adjusted HR for colorectal cancer in vegans was 0.84 (95% CI, 0.59-1.19); in lacto-ovo vegetarians, 0.82 (95% CI, 0.65-1.02); in pescovegetarians, 0.57 (95% CI, 0.40-0.82); and in semivegetarians, 0.92 (95% CI, 0.62-1.37) compared with nonvegetarians. Effect estimates were similar for men and women and for black and nonblack individuals.Conclusions and Relevance: Vegetarian diets are associated with an overall lower incidence of colorectal cancers. Pescovegetarians in particular have a much lower risk compared with nonvegetarians. If such associations are causal, they may be important for primary prevention of colorectal cancers. AN - 109784635. Language: English. Entry Date: 20150821. Revision Date: 20200708. Publication Type: journal article AU - Orlich, Michael J. AU - Singh, Pramil N. AU - Sabaté, Joan AU - Fan, Jing AU - Sveen, Lars AU - Bennett, Hannelore AU - Knutsen, Synnove F. AU - Beeson, W. Lawrence AU - Jaceldo-Siegl, Karen AU - Butler, Terry L. AU - Herring, R. Patti AU - Fraser, Gary E. DB - CINAHL Complete DO - 10.1001/jamainternmed.2015.59 DP - EBSCOhost IS - 5 KW - Colorectal Neoplasms -- Mortality Colorectal Neoplasms -- Prevention and Control Colorectal Neoplasms -- Psychosocial Factors Food Habits Life Style Vegetarianism -- Psychosocial Factors Adult Aged Data Collection Female Human Incidence Male Middle Age Mortality Prospective Studies Questionnaires Relative Risk United States Funding Source N1 - research. Commentary: Wise Jacqui. Vegetarians have lower risk of colorectal cancers, study finds. (BMJ BR MED J (CLIN RES ED)) 2015; 350: h1313-h1313. Journal Subset: Biomedical; Peer Reviewed; USA. Instrumentation: Food Frequency Questionnaire (FFQ). Grant Information: U01 CA152939/CA/NCI NIH HHS/United States. NLM UID: 101589534. PMID: NLM25751512. PY - 2015 SN - 2168-6106 SP - 767-776 ST - Vegetarian dietary patterns and the risk of colorectal cancers T2 - JAMA Internal Medicine TI - Vegetarian dietary patterns and the risk of colorectal cancers UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109784635&site=ehost-live&scope=site VL - 175 ID - 2141 ER - TY - JOUR AB - IMPORTANCE Colorectal cancers are a leading cause of cancer mortality, and their primary prevention by diet is highly desirable. The relationship of vegetarian dietary patterns to colorectal cancer risk is not well established. OBJECTIVE To evaluate the association between vegetarian dietary patterns and incident colorectal cancers. DESIGN, SETTING, AND PARTICIPANTS The Adventist Health Study 2 (AHS-2) is a large, prospective, North American cohort trial including 96 354 Seventh-Day Adventist men and women recruited between January 1, 2002, and December 31, 2007. Follow-up varied by state and was indicated by the cancer registry linkage dates. Of these participants, an analytic sample of 77 659 remained after exclusions. Analysis was conducted using Cox proportional hazards regression, controlling for important demographic and lifestyle confounders. The analysis was conducted between June 1, 2014, and October 20, 2014. EXPOSURES Diet was assessed at baseline by a validated quantitative food frequency questionnaire and categorized into 4 vegetarian dietary patterns (vegan, lacto-ovo vegetarian, pescovegetarian, and semivegetarian) and a nonvegetarian dietary pattern. MAIN OUTCOMES AND MEASURES The relationship between dietary patterns and incident cancers of the colon and rectum; colorectal cancer cases were identified primarily by state cancer registry linkages. RESULTS During a mean follow-up of 7.3 years, 380 cases of colon cancer and 110 cases of rectal cancer were documented. The adjusted hazard ratios (HRs) in all vegetarians combined vs nonvegetarians were 0.78 (95%CI, 0.64-0.95) for all colorectal cancers, 0.81 (95%CI, 0.65-1.00) for colon cancer, and 0.71 (95%CI, 0.47-1.06) for rectal cancer. The adjusted HR for colorectal cancer in vegans was 0.84 (95%CI, 0.59-1.19); in lacto-ovo vegetarians, 0.82 (95%CI, 0.65-1.02); in pescovegetarians, 0.57 (95%CI, 0.40-0.82); and in semivegetarians, 0.92 (95%CI, 0.62-1.37) compared with nonvegetarians. Effect estimates were similar for men and women and for black and nonblack individuals. CONCLUSIONS AND RELEVANCE Vegetarian diets are associated with an overall lower incidence of colorectal cancers. Pescovegetarians in particular have a much lower risk compared with nonvegetarians. If such associations are causal, theymay be important for primary prevention of colorectal cancers. © Copyright 2015 American Medical Association. All rights reserved. AD - School of Public Health, Loma Linda University, 24951 N Circle Dr, NH 2031, Loma Linda, CA 92350, United States School of Medicine, Loma Linda University, Loma Linda, CA, United States AU - Orlich, M. J. AU - Singh, P. N. AU - Sabaté, J. AU - Fan, J. AU - Sveen, L. AU - Bennett, H. AU - Knutsen, S. F. AU - Beeson, W. L. AU - Jaceldo-Siegl, K. AU - Butler, T. L. AU - Herring, R. P. AU - Fraser, G. E. DB - Scopus DO - 10.1001/jamainternmed.2015.59 IS - 5 M3 - Article N1 - Cited By :121 Export Date: 22 March 2021 PY - 2015 SP - 767-776 ST - Vegetarian dietary patterns and the risk of colorectal cancers T2 - JAMA Internal Medicine TI - Vegetarian dietary patterns and the risk of colorectal cancers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926322761&doi=10.1001%2fjamainternmed.2015.59&partnerID=40&md5=5c776986346dec0cd5a82dae576b0516 VL - 175 ID - 2379 ER - TY - JOUR AB - IMPORTANCE Colorectal cancers are a leading cause of cancer mortality, and their primary prevention by diet is highly desirable. The relationship of vegetarian dietary patterns to colorectal cancer risk is not well established. OBJECTIVE To evaluate the association between vegetarian dietary patterns and incident colorectal cancers. DESIGN, SETTING, AND PARTICIPANTS The Adventist Health Study 2 (AHS-2) is a large, prospective, North American cohort trial including 96 354 Seventh-Day Adventist men and women recruited between January 1, 2002, and December 31, 2007. Follow-up varied by state and was indicated by the cancer registry linkage dates. Of these participants, an analytic sample of 77 659 remained after exclusions. Analysis was conducted using Cox proportional hazards regression, controlling for important demographic and lifestyle confounders. The analysis was conducted between June 1, 2014, and October 20, 2014. EXPOSURES Diet was assessed at baseline by a validated quantitative food frequency questionnaire and categorized into 4 vegetarian dietary patterns (vegan, lacto-ovo vegetarian, pescovegetarian, and semivegetarian) and a nonvegetarian dietary pattern. MAIN OUTCOMES AND MEASURES The relationship between dietary patterns and incident cancers of the colon and rectum; colorectal cancer cases were identified primarily by state cancer registry linkages. RESULTS During a mean follow-up of 7.3 years, 380 cases of colon cancer and 110 cases of rectal cancer were documented. The adjusted hazard ratios (HRs) in all vegetarians combined vs nonvegetarians were 0.78 (95% CI, 0.64-0.95) for all colorectal cancers, 0.81 (95% CI, 0.65-1.00) for colon cancer, and 0.71 (95% CI, 0.47-1.06) for rectal cancer. The adjusted HR for colorectal cancer in vegans was 0.84 (95% CI, 0.59-1.19); in lacto-ovo vegetarians, 0.82 (95% CI, 0.65-1.02); in pescovegetarians, 0.57 (95% CI, 0.40-0.82); and in semivegetarians, 0.92 (95% CI, 0.62-1.37) compared with nonvegetarians. Effect estimates were similar for men and women and for black and nonblack individuals. CONCLUSIONS AND RELEVANCE Vegetarian diets are associated with an overall lower incidence of colorectal cancers. Pescovegetarians in particular have a much lower risk compared with nonvegetarians. If such associations are causal, they may be important for primary prevention of colorectal cancers. AN - WOS:000356178400016 AU - Orlich, M. J. AU - Singh, P. N. AU - Sabate, J. AU - Fan, J. AU - Sveen, L. AU - Bennett, H. AU - Knutsen, S. F. AU - Beeson, W. L. AU - Jaceldo-Siegl, K. AU - Butler, T. L. AU - Herring, R. P. AU - Fraser, G. E. DA - May DO - 10.1001/jamainternmed.2015.59 IS - 5 N1 - 25751512 PY - 2015 SN - 2168-6106 SP - 767-776 ST - Vegetarian Dietary Patterns and the Risk of Colorectal Cancers T2 - Jama Internal Medicine TI - Vegetarian Dietary Patterns and the Risk of Colorectal Cancers VL - 175 ID - 2980 ER - TY - JOUR AB - There is a striking racial and ethnic disparity in incidence and mortality of cancer yet minorities remain markedly underrepresented in clinical trials. This pilot study set out to determine the impact of a 15-min culturally tailored educational video on three outcomes relating to clinical trials: likely participation, attitudes (assessed based on six barriers), and actual enrollment. Breast cancer patients with Stage I-III, if diagnosed within previous 6 months, or metastatic disease who self-identified as black or African American were invited to participate. The primary outcome measure was the decision to participate in a therapeutic clinical trial after the intervention. Patients' intention to enroll on a therapeutic clinical trial and the change in attitudes toward clinical trials were measured by the previously developed Attitudes and Intention to Enroll in Therapeutic Clinical Trials (AIET) questionnaire. Of the 200 patients that participated, 39 (19.5%) patients signed consent to participate in a therapeutic clinical trial; 27 (13.5%) patients enrolled, resulting in a 7.5% increase from our baseline comparison of 6% clinical trial enrollment rate in black cancer patients (p < .001). Pre-test versus post-test assessment demonstrated the proportion of patients expressing likelihood to enroll in a therapeutic trial following the intervention increased by 14% (p < .001). Among 31 AIET items, 25 (81%) showed statistically significant and positive change post-intervention. The findings suggest the promising utility of a culturally tailored video intervention for improving black patients' attitudes regarding clinical trial participation and resultant enrollment. Future efforts should continue to target facilitators of population-specific recruitment, enrollment, and retention in therapeutic and non-therapeutic clinical trials. AN - WOS:000411101600001 AU - Robinson, B. N. AU - Newman, A. F. AU - Tefera, E. AU - Herbolsheimer, P. AU - Nunes, R. AU - Gallagher, C. AU - Randolph-Jackson, P. AU - Omogbehin, A. AU - Dilawari, A. AU - Pohlmann, P. R. AU - Mohebtash, M. AU - Lee, Y. AU - Ottaviano, Y. AU - Mohapatra, A. AU - Lynce, F. AU - Brown, R. AU - Mete, M. AU - Swain, S. M. DA - Sep DO - 10.1038/s41523-017-0039-1 N1 - 36 28944289 PY - 2017 ST - Video intervention increases participation of black breast cancer patients in therapeutic trials T2 - Npj Breast Cancer TI - Video intervention increases participation of black breast cancer patients in therapeutic trials VL - 3 ID - 2886 ER - TY - JOUR AB - Purpose: The association between vitamin D and prostate biopsy outcomes has not been evaluated. We examine serum vitamin D levels with prostate biopsy results in men with an abnormal prostate‐specific antigen and/or digital rectal examination. Experimental Design: Serum 25‐hydroxyvitamin D (25‐OH D) was obtained from 667 men, ages 40 to 79 years, prospectively enrolled from Chicago urology clinics undergoing first prostate biopsy. Logistic regression was used to evaluate the associations between 25‐OH D status and incident prostate cancer, Gleason score, and tumor stage. Results: Among European American (EA) men, there was an association of 25‐OH D <12 ng/mL with higher Gleason score>4+4 [OR, 3.66;95%confidence interval (CI), 1.41‐9.50; P=0.008] and tumor stage [stage>cT2b vs. 4+4 [OR, 4.89 (1.59‐15.07); P=0.006]. There was an association with tumor stage>cT2b vs.= 4+4 [OR, 3.66; 95% confidence interval (CI), 1.41-9.50; P=0.008] and tumor stage [stage >= cT2b vs. <= cT2a, OR, 2.42 (1.14-5.10); P=0.008]. In African American (AA) men, we find increased odds of prostate cancer diagnosis on biopsy with 25- OHD < 20 ng/ mL [ OR, 2.43 (1.20-4.94); P=0.01]. AA men demonstrated an association between 25-OH D < 12 ng/mL and Gleason >= 4+4 [OR, 4.89 (1.59-15.07); P=0.006]. There was an association with tumor stage >= cT2b vs. <= cT2a [OR, 4.22 (1.52-11.74); P=0.003]. Conclusions: In AA men, vitamin D deficiency was associated with increased odds of prostate cancer diagnosis on biopsy. In both EA and AA men, severe deficiency was positively associated with higher Gleason grade and tumor stage. (C) 2014 AACR. AN - WOS:000335915200007 AU - Murphy, A. B. AU - Nyame, Y. AU - Martin, I. K. AU - Catalona, W. J. AU - Hollowell, C. M. P. AU - Nadler, R. B. AU - Kozlowski, J. M. AU - Perry, K. T. AU - Kajdacsy-Balla, A. AU - Kittles, R. DA - May DO - 10.1158/1078-0432.CCR-13-3085 IS - 9 N1 - 24789033 PY - 2014 SN - 1078-0432 SP - 2289-2299 ST - Vitamin D Deficiency Predicts Prostate Biopsy Outcomes T2 - Clinical Cancer Research TI - Vitamin D Deficiency Predicts Prostate Biopsy Outcomes VL - 20 ID - 3011 ER - TY - JOUR AB - Black Americans have lower levels of serum 25(OH)D but superior bone health compared to white Americans. There is controversy over whether they should be screened for vitamin D deficiency and have higher vitamin D requirements than recommended by the Institute of Medicine (IOM). The purpose of this trial was to determine whether Vitamin D supplementation in elderly black women prevents bone loss. A total of 260 healthy black American women, 60 years of age and older were recruited to take part in a two‐arm, double‐dummy 3‐year randomized controlled trial (RCT) of vitamin D3 versus placebo. The study was conducted in an ambulatory clinical research center. Vitamin D3 dose was adjusted to maintain serum 25(OH)D above 75 nmol/L. Bone mineral density (BMD) and serum were measured for parathyroid hormone (PTH), C‐terminal crosslink telopeptide (CTX), and bone‐specific alkaline phosphatase (BSAP) every 6 months. Baseline serum 25(OH)D3 was 54.8 ± 16.8 nmol/L. There was no group × time interaction effect for any BMD measurement. For all BMD measurements, except for total body and spine, there was a statistically significant negative effect of time (p < 0.001). An equivalency analysis showed that the treatment group was equivalent to the control group. Serum PTH and BSAP declined, with a greater decline of PTH in the treatment group. The rate of bone loss with serum 25(OH)D above 75 nmol/L is comparable to the rate of loss with serum 25(OH)D at the Recommended Dietary Allowance (RDA) of 50 nmol/L. Black Americans should have the same exposure to vitamin D as white Americans. © 2018 American Society for Bone and Mineral Research. AN - CN-01630422 AU - Aloia, J. AU - Fazzari, M. AU - Islam, S. AU - Mikhail, M. AU - Shieh, A. AU - Katumuluwa, S. AU - Dhaliwal, R. AU - Stolberg, A. AU - Usera, G. AU - Ragolia, L. DO - 10.1002/jbmr.3521 IS - 11 KW - *osteolysis *osteoporosis /drug therapy /prevention *vitamin supplementation African American African Americans Aged Aging Alkaline phosphatase blood level Application site reaction /side effect Article Benign neoplasm /side effect Bone Density [drug effects] Bone Resorption [*drug therapy, *prevention & control] Bone density Breast disease /side effect Clinical research Congenital disorder /side effect Connective tissue disease /side effect Controlled study Dietary Supplements Dietary reference intake Double blind procedure Drug dose increase Ear disease /side effect Endocrine disease /side effect Eye disease /side effect Familial disease /side effect Female Femur Gastrointestinal disease /side effect Genetic disorder /side effect Heart disease /side effect Hematologic disease /side effect Hepatobiliary disease /side effect Human Humans Hypercalciuria /side effect Immunopathology /side effect Infection /side effect Infestation /side effect Injury /side effect Inner ear disease /side effect Intoxication /side effect Kidney disease /side effect Lymphatic system disease /side effect Major clinical study Malignant neoplasm /side effect Mediastinum disease /side effect Medication compliance Mental disease /side effect Metabolic disorder /side effect Musculoskeletal disease /side effect Neurologic disease /side effect Nutritional disorder /side effect Parathyroid hormone blood level Patient compliance Prospective study Protein cross linking Randomized controlled trial Respiratory tract disease /side effect Risk reduction Serum Side effect /side effect Skin disease /side effect Spine Thorax disease /side effect Urinary tract disease /side effect Vascular disease /side effect Vitamin D [adverse effects, pharmacology, *therapeutic use] Vitamin blood level M3 - Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural PY - 2018 SP - 1916‐1922 ST - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: a Randomized Controlled Trial T2 - Journal of bone and mineral research TI - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: a Randomized Controlled Trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01630422/full VL - 33 ID - 1345 ER - TY - JOUR AB - Black Americans have lower levels of serum 25(OH)D but superior bone health compared to white Americans. There is controversy over whether they should be screened for vitamin D deficiency and have higher vitamin D requirements than recommended by the Institute of Medicine (IOM). The purpose of this trial was to determine whether Vitamin D supplementation in elderly black women prevents bone loss. A total of 260 healthy black American women, 60 years of age and older were recruited to take part in a two-arm, double-dummy 3-year randomized controlled trial (RCT) of vitamin D3 versus placebo. The study was conducted in an ambulatory clinical research center. Vitamin D3 dose was adjusted to maintain serum 25(OH)D above 75 nmol/L. Bone mineral density (BMD) and serum were measured for parathyroid hormone (PTH), C-terminal crosslink telopeptide (CTX), and bone-specific alkaline phosphatase (BSAP) every 6 months. Baseline serum 25(OH)D3 was 54.8 ± 16.8 nmol/L. There was no group × time interaction effect for any BMD measurement. For all BMD measurements, except for total body and spine, there was a statistically significant negative effect of time (p < 0.001). An equivalency analysis showed that the treatment group was equivalent to the control group. Serum PTH and BSAP declined, with a greater decline of PTH in the treatment group. The rate of bone loss with serum 25(OH)D above 75 nmol/L is comparable to the rate of loss with serum 25(OH)D at the Recommended Dietary Allowance (RDA) of 50 nmol/L. Black Americans should have the same exposure to vitamin D as white Americans. © 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research AD - Bone Mineral Research Center, New York University (NYU) Winthrop Hospital, Mineola, NY, United States AU - Aloia, J. AU - Fazzari, M. AU - Islam, S. AU - Mikhail, M. AU - Shieh, A. AU - Katumuluwa, S. AU - Dhaliwal, R. AU - Stolberg, A. AU - Usera, G. AU - Ragolia, L. DB - Scopus DO - 10.1002/jbmr.3521 IS - 11 KW - ANALYSIS/QUANTITATION OF BONE BIOCHEMICAL MARKERS OF BONE TURNOVER BONE MODELING AND REMODELING CELL/TISSUE SIGNALING CLINICAL TRIALS DISEASES AND DISORDERS OF/RELATED TO BONE DXA ENDOCRINE PATHWAYS OSTEOPOROSIS PTH/VIT D/FGF23 M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 2018 SP - 1916-1922 ST - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial T2 - Journal of Bone and Mineral Research TI - Vitamin D Supplementation in Elderly Black Women Does Not Prevent Bone Loss: A Randomized Controlled Trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85050600277&doi=10.1002%2fjbmr.3521&partnerID=40&md5=bc580c3050c933182a4637562db95ad5 VL - 33 ID - 2254 ER - TY - JOUR AB - Studies on informed consent to medical research conducted in low or middle-income settings have increased, including empirical investigations of consent to genetic research. We investigated voluntary participation and comprehension of informed consent among women involved in a genetic epidemiological study on breast cancer in an urban setting of Nigeria comparing women in the case and control groups. Surveys were administered in face-to-face interviews with 215 participants following their enrollment in the genetic study (106 patients, 109 controls). Audio-taped in-depth interviews were conducted with a sub-sample of 17 (8%) women who completed the survey. The majority of all participants reported being told that participation in the genetic study was voluntary (97%), that they did not feel pressured to participate in the study (99%), and that they could withdraw from the study (81%). The majority of the breast cancer patients (83%) compared to 58% of women in the control group reported that the study purpose was to learn about the genetic inheritance of breast cancer (OR 3.44; 95% CI =1.66, 7.14, p value = 0.001). Most participants reported being told about study procedures (95%) and study benefits (98%). Sixty-eight percent of the patients, compared to 47% of the control group reported being told about study risks (p-value <0.001). Of the 165 married women, 19% reported asking permission from their husbands to enroll in the breast cancer study; no one sought permission from local elders. In-depth interviews highlight the use of persuasion and negotiation between a wife and her husband regarding study participation. The global expansion of genetic and genomic research highlights our need to understand informed consent practices for studies in ethnically diverse cultural environments such as Africa. Quantitative and qualitative empirical investigations of the informed consent process for genetic and genomic research will further our knowledge of complex issues associated with communication of information, comprehension, decisional authority and voluntary participation. In the future, the development and testing of innovative strategies to promote voluntary participation and comprehension of the goals of genomic research will contribute to our understanding of strategies that enhance the consent process. AD - P.A. Marshall AU - Marshall, P. A. AU - Adebamowo, C. A. AU - Adeyemo, A. A. AU - Ogundiran, T. O. AU - Strenski, T. AU - Zhou, J. AU - Rotimi, C. N. DB - Medline DO - 10.1186/1472-6939-15-38 KW - adult article attitude to health Black person breast tumor comprehension ethics ethnology female genetic predisposition genetics human informed consent male molecular epidemiology Nigeria patient selection psychological aspect questionnaire refusal to participate statistics LA - English M3 - Article N1 - L373983107 2014-11-10 PY - 2014 SN - 1472-6939 SP - 38 ST - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria T2 - BMC medical ethics TI - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria UR - https://www.embase.com/search/results?subaction=viewrecord&id=L373983107&from=export http://dx.doi.org/10.1186/1472-6939-15-38 VL - 15 ID - 1051 ER - TY - JOUR AB - Background: Studies on informed consent to medical research conducted in low or middle-income settings have increased, including empirical investigations of consent to genetic research. We investigated voluntary participation and comprehension of informed consent among women involved in a genetic epidemiological study on breast cancer in an urban setting of Nigeria comparing women in the case and control groups.Methods: Surveys were administered in face-to-face interviews with 215 participants following their enrollment in the genetic study (106 patients, 109 controls). Audio-taped in-depth interviews were conducted with a sub-sample of 17 (8%) women who completed the survey.Results: The majority of all participants reported being told that participation in the genetic study was voluntary (97%), that they did not feel pressured to participate in the study (99%), and that they could withdraw from the study (81%). The majority of the breast cancer patients (83%) compared to 58% of women in the control group reported that the study purpose was to learn about the genetic inheritance of breast cancer (OR 3.44; 95% CI =1.66, 7.14, p value = 0.001). Most participants reported being told about study procedures (95%) and study benefits (98%). Sixty-eight percent of the patients, compared to 47% of the control group reported being told about study risks (p-value <0.001). Of the 165 married women, 19% reported asking permission from their husbands to enroll in the breast cancer study; no one sought permission from local elders. In-depth interviews highlight the use of persuasion and negotiation between a wife and her husband regarding study participation.Conclusions: The global expansion of genetic and genomic research highlights our need to understand informed consent practices for studies in ethnically diverse cultural environments such as Africa. Quantitative and qualitative empirical investigations of the informed consent process for genetic and genomic research will further our knowledge of complex issues associated with communication of information, comprehension, decisional authority and voluntary participation. In the future, the development and testing of innovative strategies to promote voluntary participation and comprehension of the goals of genomic research will contribute to our understanding of strategies that enhance the consent process. AD - Department of Bioethics, School of Medicine, Room TA 227Case Western Reserve University10900 Euclid Avenue Cleveland, Ohio 44106-4976 Cleveland, USA. pam20@case.edu. AN - 103954537. Language: English. Entry Date: 20141114. Revision Date: 20161117. Publication Type: journal article AU - Marshall, Patricia A. AU - Adebamowo, Clement A. AU - Adeyemo, Adebowale A. AU - Ogundiran, Temidayo O. AU - Strenski, Teri AU - Zhou, Jie AU - Rotimi, Charles N. DB - CINAHL Complete DO - 10.1186/1472-6939-15-38 DP - EBSCOhost IS - 1 KW - Breast Neoplasms -- Epidemiology Breast Neoplasms Readability Genetic Research -- Ethical Issues Consent -- Ethical Issues Consent -- Statistics and Numerical Data Adult Black Persons Breast Neoplasms -- Psychosocial Factors Female Disease Susceptibility Attitude to Health Human Male Epidemiology, Molecular Nigeria Nigeria -- Ethnology Patient Selection Questionnaires Refusal to Participate N1 - research. Journal Subset: Biomedical; Europe; UK & Ireland. Grant Information: P20 MD006899/MD/NIMHD NIH HHS/United States. NLM UID: 101088680. PMID: NLM24885380. PY - 2014 SN - 1472-6939 SP - 38-38 ST - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria T2 - BMC Medical Ethics TI - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=103954537&site=ehost-live&scope=site VL - 15 ID - 2142 ER - TY - JOUR AB - Background: Studies on informed consent to medical research conducted in low or middle-income settings have increased, including empirical investigations of consent to genetic research. We investigated voluntary participation and comprehension of informed consent among women involved in a genetic epidemiological study on breast cancer in an urban setting of Nigeria comparing women in the case and control groups. Methods. Surveys were administered in face-to-face interviews with 215 participants following their enrollment in the genetic study (106 patients, 109 controls). Audio-taped in-depth interviews were conducted with a sub-sample of 17 (8%) women who completed the survey. Results: The majority of all participants reported being told that participation in the genetic study was voluntary (97%), that they did not feel pressured to participate in the study (99%), and that they could withdraw from the study (81%). The majority of the breast cancer patients (83%) compared to 58% of women in the control group reported that the study purpose was to learn about the genetic inheritance of breast cancer (OR 3.44; 95% CI =1.66, 7.14, p value = 0.001). Most participants reported being told about study procedures (95%) and study benefits (98%). Sixty-eight percent of the patients, compared to 47% of the control group reported being told about study risks (p-value <0.001). Of the 165 married women, 19% reported asking permission from their husbands to enroll in the breast cancer study; no one sought permission from local elders. In-depth interviews highlight the use of persuasion and negotiation between a wife and her husband regarding study participation. Conclusions: The global expansion of genetic and genomic research highlights our need to understand informed consent practices for studies in ethnically diverse cultural environments such as Africa. Quantitative and qualitative empirical investigations of the informed consent process for genetic and genomic research will further our knowledge of complex issues associated with communication of information, comprehension, decisional authority and voluntary participation. In the future, the development and testing of innovative strategies to promote voluntary participation and comprehension of the goals of genomic research will contribute to our understanding of strategies that enhance the consent process. © 2014 Marshall et al.; licensee BioMed Central Ltd. AD - Department of Bioethics, School of Medicine, Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-4976, United States Department of Epidemiology and Public Health, Institute of Human Virology, University of Maryland School of Medicine, 660 W. Redwood Street, Baltimore, MD 21201, United States Center for Research on Genomics and Global Health, National Institutes of Health, Building 12A, 12 South Dr, Bethesda, MD 20892-5635, United States Division of Oncology, Department of Surgery, University College Hospital, Ibadan, Nigeria Feinberg School of Medicine, Northwestern University, 750 N Lake Shore Dr, Chicago, IL 60611, United States AU - Marshall, P. A. AU - Adebamowo, C. A. AU - Adeyemo, A. A. AU - Ogundiran, T. O. AU - Strenski, T. AU - Zhou, J. AU - Rotimi, C. N. C7 - 38 DB - Scopus DO - 10.1186/1472-6939-15-38 IS - 1 KW - Breast cancer Genetic epidemiological research Informed consent Nigeria M3 - Article N1 - Cited By :20 Export Date: 22 March 2021 PY - 2014 ST - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria T2 - BMC Medical Ethics TI - Voluntary participation and comprehension of informed consent in a genetic epidemiological study of breast cancer in Nigeria UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901625794&doi=10.1186%2f1472-6939-15-38&partnerID=40&md5=4743087333d7ca10ee9b604b458cb2b7 VL - 15 ID - 2394 ER - TY - JOUR AB - PURPOSE: Most breast cancer (BC) survivorship research focuses on the general population of survivors. Scant research investigates the potentially unique experiences of minorities, especially during and after the difficult transition from primary treatment to post-treatment. This qualitative study explored African American BC survivors' and caregivers' quality-of-life in the post-treatment period with a focus on social and spiritual well-being. METHODS: Participants included a convenience sample of African American women with stage I-III BC (N = 23) who completed treatment 6-24 months before enrollment. Primary caregivers (N = 22) included friends, spouses and other family members (21 complete dyads). Participants completed separate semi-structured telephone interviews. Template analysis was used to evaluate themes related to religiousness and spirituality, both across and within dyads. RESULTS: After treatment, religiousness and spirituality played a major role in both survivors' and caregivers' lives by: (1) providing global guidance, (2) guiding illness management efforts and (3) facilitating recovery. Participants described a spiritual connectedness with God and others in their social networks. Dyad members shared the goal of keeping a positive attitude and described positive growth from cancer. Few future concerns were expressed due to the belief that survivors were healed and "done" with cancer. Beyond practical and emotional support, provision of spiritual assistance was common. CONCLUSIONS: Results highlight the principal, positive role of religiousness and spirituality for African American BC survivors and caregivers after treatment. Findings emphasize the need to assess the importance of religious and spiritual beliefs and practices, and if appropriate, to provide resources that promote spiritual well-being. AD - Department of Public Health Sciences, Hollings Cancer Center, Medical University of South Carolina, 68 President Street MSC 955, Charleston, SC 29425, United States AU - Sterba, K. R. AU - Burris, J. L. AU - Heiney, S. P. AU - Ruppel, M. B. AU - Ford, M. E. AU - Zapka, J. DB - Scopus DO - 10.1007/s11136-014-0654-3 IS - 7 M3 - Article N1 - Cited By :31 Export Date: 22 March 2021 PY - 2014 SP - 1909-1920 ST - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers T2 - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation TI - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85027950871&doi=10.1007%2fs11136-014-0654-3&partnerID=40&md5=4c76b84053004b9bb816cc47ede65a09 VL - 23 ID - 2389 ER - TY - JOUR AB - Most breast cancer (BC) survivorship research focuses on the general population of survivors. Scant research investigates the potentially unique experiences of minorities, especially during and after the difficult transition from primary treatment to post-treatment. This qualitative study explored African American BC survivors' and caregivers' quality-of-life in the post-treatment period with a focus on social and spiritual well-being. Participants included a convenience sample of African American women with stage I-III BC (N = 23) who completed treatment 6-24 months before enrollment. Primary caregivers (N = 22) included friends, spouses and other family members (21 complete dyads). Participants completed separate semi-structured telephone interviews. Template analysis was used to evaluate themes related to religiousness and spirituality, both across and within dyads. After treatment, religiousness and spirituality played a major role in both survivors' and caregivers' lives by: (1) providing global guidance, (2) guiding illness management efforts and (3) facilitating recovery. Participants described a spiritual connectedness with God and others in their social networks. Dyad members shared the goal of keeping a positive attitude and described positive growth from cancer. Few future concerns were expressed due to the belief that survivors were healed and "done" with cancer. Beyond practical and emotional support, provision of spiritual assistance was common. Results highlight the principal, positive role of religiousness and spirituality for African American BC survivors and caregivers after treatment. Findings emphasize the need to assess the importance of religious and spiritual beliefs and practices, and if appropriate, to provide resources that promote spiritual well-being. AN - WOS:000340597900001 AU - Sterba, K. R. AU - Burris, J. L. AU - Heiney, S. P. AU - Ruppel, M. B. AU - Ford, M. E. AU - Zapka, J. DA - Sep DO - 10.1007/s11136-014-0654-3 IS - 7 N1 - 24578149 PY - 2014 SN - 0962-9343 SP - 1909-1920 ST - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers T2 - Quality of Life Research TI - "We both just trusted and leaned on the Lord": a qualitative study of religiousness and spirituality among African American breast cancer survivors and their caregivers VL - 23 ID - 3000 ER - TY - JOUR AB - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs) - in-person ("Traditional") versus web-based ("Technology") - to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40-75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p <. 001). There were significant increases in digital rectal exam (p <. 05), fecal occult blood test (p <. 001), and colonoscopy (p <. 01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p <. 05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings. AD - C.L. Holt, Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, United States AU - Holt, C. L. AU - Tagai, E. K. AU - Santos, S. L. Z. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. DB - Embase Medline DO - 10.1093/tbm/iby065 IS - 4 KW - adult African American aged article behavior change breast cancer cancer screening colonoscopy colorectal cancer digital rectal examination e-learning evidence based practice female follow up health disparity health education health promotion human knowledge lay health worker major clinical study male mammography occult blood test priority journal prostate cancer public health sigmoidoscopy telehealth workshop LA - English M3 - Article N1 - L631636852 2020-05-14 2020-06-02 PY - 2019 SN - 1613-9860 1869-6716 SP - 573-582 ST - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial T2 - Translational Behavioral Medicine TI - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial UR - https://www.embase.com/search/results?subaction=viewrecord&id=L631636852&from=export http://dx.doi.org/10.1093/tbm/iby065 VL - 9 ID - 843 ER - TY - JOUR AB - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs)‐in‐person ("Traditional") versus web‐based ("Technology")‐to conduct a series of three evidence‐based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40‐75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p < .001). There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p < .05) than those who attended only one. These findings suggest that lay individuals can receive web‐based training to successfully implement an evidence‐based health promotion intervention that results in participant‐level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence‐based health promotion interventions through training lay persons in community settings. AN - CN-02075052 AU - Holt, C. L. AU - Tagai, E. K. AU - Santos, S. L. Z. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. DO - 10.1093/tbm/iby065 IS - 4 KW - *African American *breast cancer *health promotion *learning *public health Adult African Americans [education] Aged Article Awareness Breast Neoplasms [diagnosis, epidemiology] Cluster Analysis Colonoscopy Colonoscopy [methods] Colorectal Neoplasms [diagnosis, epidemiology] Colorectal cancer Community Health Workers [*education, trends] Controlled study Digital rectal examination Early Detection of Cancer [methods] Education [statistics & numerical data] Female Health Knowledge, Attitudes, Practice [ethnology] Health Promotion [*methods] Human Humans Internet‐Based Intervention [*statistics & numerical data] Layperson Male Mammography Mammography [methods] Maryland [ethnology] Mass Screening [psychology] Middle Aged Occult Blood Prostate cancer Prostatic Neoplasms [diagnosis, epidemiology] Randomized controlled trial Religion M3 - Comparative Study; Journal Article; Randomized Controlled Trial PY - 2019 SP - 573‐582 ST - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial T2 - Translational behavioral medicine TI - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02075052/full VL - 9 ID - 1368 ER - TY - JOUR AB - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs)—in-person ('Traditional') versus web-based ('Technology')—to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George’s County, MD, and enrolled 375 church members age 40–75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p < .001). There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p < .05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AD - Holt, Cheryl L. AN - 2020-30884-001 AU - Holt, Cheryl L. AU - Tagai, Erin K. AU - Santos, Sherie Lou Zara AU - Scheirer, Mary Ann AU - Bowie, Janice AU - Haider, Muhiuddin AU - Slade, Jimmie DB - psyh DO - 10.1093/tbm/iby065 DP - EBSCOhost IS - 4 KW - community health advisors health promotion workshops cancer educational workshops African American churches knowledge screening breast cancer prostate cancer colorectal cancer Adult African Americans Aged Awareness Breast Neoplasms Cluster Analysis Colonoscopy Colorectal Neoplasms Community Health Workers Early Detection of Cancer Education Female Health Knowledge, Attitudes, Practice Health Promotion Humans Internet-Based Intervention Male Mammography Maryland Mass Screening Middle Aged Occult Blood Prostatic Neoplasms Cancer Screening Health Knowledge Religious Buildings Community Health Blacks Prostate Training N1 - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, US. Other Publishers: Springer. Release Date: 20201112. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Electronic. Document Type: Journal Article. Language: English. Major Descriptor: Cancer Screening; Health Knowledge; Health Promotion; Religious Buildings; Community Health. Minor Descriptor: Blacks; Breast Neoplasms; Prostate; Training. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Male (30); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300); Middle Age (40-64 yrs) (360); Aged (65 yrs & older) (380). Methodology: Empirical Study; Quantitative Study. Supplemental Data: Tables and Figures Internet. Page Count: 10. Issue Publication Date: Aug, 2019. Copyright Statement: All rights reserved. Society of Behavioral Medicine. 2018. Sponsor: National Cancer Institute, US. Grant: R01CA147313. Recipients: No recipient indicated PY - 2019 SN - 1869-6716 1613-9860 SP - 573-582 ST - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial T2 - Translational Behavioral Medicine TI - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2020-30884-001&site=ehost-live&scope=site cholt14@umd.edu VL - 9 ID - 1668 ER - TY - JOUR AB - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs) - in-person ("Traditional") versus web-based ("Technology") - to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40-75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p <. 001). There were significant increases in digital rectal exam (p <. 05), fecal occult blood test (p <. 001), and colonoscopy (p <. 01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p <. 05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings. © 2018 Society of Behavioral Medicine 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. AD - Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, United States Scheirer Consulting, Princeton, NJ, United States Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States School of Public Health, Institute for Applied Environmental Health, University of Maryland, College Park, MD, United States Community Ministry of Prince George's County, Upper Marlboro, MD, United States AU - Holt, C. L. AU - Tagai, E. K. AU - Santos, S. L. Z. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. DB - Scopus DO - 10.1093/tbm/iby065 IS - 4 KW - African Americans Cancer early detection Community health advisors Implementation Web-based learning M3 - Article N1 - Cited By :7 Export Date: 22 March 2021 PY - 2019 SP - 573-582 ST - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial T2 - Translational Behavioral Medicine TI - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: Participant outcomes from a cluster-randomized trial UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078340799&doi=10.1093%2ftbm%2fiby065&partnerID=40&md5=cd2e26e0df747fd7ad525e0b76fe7f65 VL - 9 ID - 2224 ER - TY - JOUR AB - Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs)-in-person ("Traditional") versus web-based ("Technology")-to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40-75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p < .001). There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p < .05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings. AN - WOS:000492967600001 AU - Holt, C. L. AU - Tagai, E. K. AU - Santos, S. L. Z. AU - Scheirer, M. A. AU - Bowie, J. AU - Haider, M. AU - Slade, J. DA - Aug DO - 10.1093/tbm/iby065 IS - 4 N1 - 29955889 PY - 2019 SN - 1869-6716 SP - 573-582 ST - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial T2 - Translational Behavioral Medicine TI - Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial VL - 9 ID - 2812 ER - TY - JOUR AB - Background: The patient voice remains underrepresented in clinical and public health interventions. To inform interventions that strive to improve access to breast and cervical cancer screening and follow-up among low-income populations, we explored recommendations from low-income women pursuing health care in the safety net. Methods: Semi-structured interviews were conducted among women receiving follow-up care for an abnormal breast or cervical cancer screening result or a positive cancer diagnosis in federally qualified health centers, free clinics, or an academic cancer center in the Chicago metropolitan area. Findings: Of the 138 women interviewed in the parent study, 52 women provided recommendations for improving access to screening and follow-up care. Most were between 41 and 65years old (62%) and African American (60%) or White (25%). Recommendations included strengthening community-based health education with more urgent messaging, strategic partnerships, and active learning experiences to increase patient engagement, which women regarded as a key driver of access. Women also suggested increasing access by way of changes to health care delivery systems and policy, including more direct patient-provider and patient-clinic communications, addressing delays caused by high patient volume, combining preventive services, expanding insurance coverage, and adjusting screening guidelines. Conclusions: This exploratory study demonstrates important insights from the patient lens that may help to increase the acceptability and efficacy of community and clinical interventions aimed at improving access to breast and cervical cancer screening and follow-up. Further research is needed to identify appropriate integration of patient input into interventions, practice, and policy change. AD - M.A. Simon, Department of Obstetrics and Gynecology, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Northwestern University Institute for Public Health and Medicine, 633 N St. Clair, Suite 1800, Chicago, IL, United States AU - Ragas, D. M. AU - Nonzee, N. J. AU - Tom, L. S. AU - Phisuthikul, A. M. AU - Luu, T. H. AU - Dong, X. AU - Simon, M. A. DB - Embase Medline DO - 10.1016/j.whi.2014.06.011 IS - 5 KW - adult aged article breast cancer cancer screening exploratory research female follow up health care access health care delivery health care policy health education human information dissemination insurance interpersonal communication lowest income group major clinical study medical information multicenter study patient care patient participation practice guideline preventive health service psychosocial care public-private partnership qualitative research therapy delay uterine cervix cancer young adult LA - English M3 - Article N1 - L600224185 2014-10-29 2014-11-04 PY - 2014 SN - 1878-4321 1049-3867 SP - 511-518 ST - What Women Want: Patient Recommendations for Improving Access to Breast and Cervical Cancer Screening and Follow-up T2 - Women's Health Issues TI - What Women Want: Patient Recommendations for Improving Access to Breast and Cervical Cancer Screening and Follow-up UR - https://www.embase.com/search/results?subaction=viewrecord&id=L600224185&from=export http://dx.doi.org/10.1016/j.whi.2014.06.011 VL - 24 ID - 1061 ER - TY - JOUR AB - Purpose: To identify factors significantly influencing accrual to clinical protocols by analyzing radiation Patterns of Care Study (PCS) surveys of 3,047 randomly selected radiotherapy (RT) patients. Methods and Materials: Patterns of Care Study surveys from disease sites studied for the periods 1992-1994 and 1996-1999 (breast cancer, n = 1,080; prostate cancer, n = 1,149; esophageal cancer, n = 818) were analyzed. The PCS is a National Cancer Institute-funded national survey of randomly selected RT institutions in the United States. Patients with nonmetastatic disease who received RT as definitive or adjuvant therapy were randomly selected from eligible patients at each institution. To determine national estimates, individual patient records were weighted by the relative contribution of each institution and patients within each institution. Data regarding participation in clinical trials were recorded. The factors age, gender, race, type of insurance, and practice type of treating institution (academic or not) were studied by univariate and multivariate analyses. Results: Overall, only 2.7% of all patients were accrued to clinical protocols. Of these, 57% were enrolled on institutional review board-approved institutional trials, and 43% on National Cancer Institute collaborative group studies. On multivariate analysis, patients treated at academic facilities (p = 0.0001) and white patients (vs. African Americans, p = 0.0002) were significantly more likely to participate in clinical oncology trials. Age, gender, type of cancer, and type of insurance were not predictive. Conclusions: Practice type and race significantly influence enrollment onto clinical oncology trials. This suggests that increased communication and education regarding protocols, particularly focusing on physicians in nonacademic settings and minority patients, will be essential to enhance accrual. © 2007 Elsevier Inc. All rights reserved. AD - B. Movsas, Department of Radiation Oncology, Henry Ford Health System, Detroit, MI, United States AU - Movsas, B. AU - Moughan, J. AU - Owen, J. AU - Coia, L. R. AU - Zelefsky, M. J. AU - Hanks, G. AU - Wilson, J. F. DB - Embase Medline DO - 10.1016/j.ijrobp.2007.01.051 IS - 4 KW - adult African American aged article breast cancer cancer patient clinical protocol education esophagus cancer female gender health insurance human institutional care interpersonal communication male medical practice medical record multivariate analysis oncology physician priority journal prostate cancer race radiation statistical significance United States univariate analysis university hospital LA - English M3 - Article N1 - L47048577 2007-07-15 PY - 2007 SN - 0360-3016 SP - 1145-1150 ST - Who Enrolls Onto Clinical Oncology Trials? A Radiation Patterns of Care Study Analysis T2 - International Journal of Radiation Oncology Biology Physics TI - Who Enrolls Onto Clinical Oncology Trials? A Radiation Patterns of Care Study Analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L47048577&from=export http://dx.doi.org/10.1016/j.ijrobp.2007.01.051 VL - 68 ID - 1226 ER - TY - JOUR AB - Purpose: To identify factors significantly influencing accrual to clinical protocols by analyzing radiation Patterns of Care Study (PCS) surveys of 3,047 randomly selected radiotherapy (RT) patients. Methods and Materials: Patterns of Care Study surveys from disease sites studied for the periods 1992-1994 and 1996-1999 (breast cancer, n = 1,080; prostate cancer, n = 1,149; esophageal cancer, n = 818) were analyzed. The PCS is a National Cancer Institute-funded national survey of randomly selected RT institutions in the United States. Patients with nonmetastatic disease who received RT as definitive or adjuvant therapy were randomly selected from eligible patients at each institution. To determine national estimates, individual patient records were weighted by the relative contribution of each institution and patients within each institution. Data regarding participation in clinical trials were recorded. The factors age, gender, race, type of insurance, and practice type of treating institution (academic or not) were studied by univariate and multivariate analyses. Results: Overall, only 2.7% of all patients were accrued to clinical protocols. Of these, 57% were enrolled on institutional review board-approved institutional trials, and 43% on National Cancer Institute collaborative group studies. On multivariate analysis, patients treated at academic facilities (p = 0.0001) and white patients (vs. African Americans, p = 0.0002) were significantly more likely to participate in clinical oncology trials. Age, gender, type of cancer, and type of insurance were not predictive. Conclusions: Practice type and race significantly influence enrollment onto clinical oncology trials. This suggests that increased communication and education regarding protocols, particularly focusing on physicians in nonacademic settings and minority patients, will be essential to enhance accrual. © 2007 Elsevier Inc. All rights reserved. AD - Department of Radiation Oncology, Henry Ford Health System, Detroit, MI, United States American College of Radiology, Philadelphia, PA, United States Department of Radiation Oncology, Community Medical Center, Toms River, NJ, United States Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States AU - Movsas, B. AU - Moughan, J. AU - Owen, J. AU - Coia, L. R. AU - Zelefsky, M. J. AU - Hanks, G. AU - Wilson, J. F. DB - Scopus DO - 10.1016/j.ijrobp.2007.01.051 IS - 4 KW - Barriers to participation Clinical trials M3 - Article N1 - Cited By :31 Export Date: 22 March 2021 PY - 2007 SP - 1145-1150 ST - Who Enrolls Onto Clinical Oncology Trials? A Radiation Patterns of Care Study Analysis T2 - International Journal of Radiation Oncology Biology Physics TI - Who Enrolls Onto Clinical Oncology Trials? A Radiation Patterns of Care Study Analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447268693&doi=10.1016%2fj.ijrobp.2007.01.051&partnerID=40&md5=6110db221b548b13083579c75b92f636 VL - 68 ID - 2555 ER - TY - JOUR AB - Purpose: To identify factors significantly influencing accrual to clinical protocols by analyzing radiation Patterns of Care Study (PCS) surveys of 3,047 randomly selected radiotherapy (RT) patients. Methods and Materials: Patterns of Care Study surveys from disease sites studied for the periods 1992-1994 and 1996-1999 (breast cancer, n = 1,080; prostate cancer, n = 1,149; esophageal cancer, n = 818) were analyzed. The PCS is a National Cancer Institute-funded national survey of randomly selected RT institutions in the United States. Patients with nonmetastatic disease who received RT as definitive or adjuvant therapy were randomly selected from eligible patients at each institution. To determine national estimates, individual patient records were weighted by the relative contribution of each institution and patients within each institution. Data regarding participation in clinical trials were recorded. The factors age, gender, race, type of insurance, and practice type of treating institution (academic or not) were studied by univariate and multivariate analyses. Results: Overall, only 2.7% of all patients were accrued to clinical protocols. Of these, 57% were enrolled on institutional review board-approved institutional trials, and 43% on National Cancer Institute collaborative group studies. On multivariate analysis, patients treated at academic facilities (p = 0.0001) and white patients (vs. African Americans, p = 0.0002) were significantly more likely to participate in clinical oncology trials. Age, gender, type of cancer, and type of insurance were not predictive. Conclusions: Practice type and race significantly influence enrollment onto clinical oncology trials. This suggests that increased communication and education regarding protocols, particularly focusing on physicians in nonacademic settings and minority patients, will be essential to enhance accrual. (C) 2007 Elsevier Inc. AN - WOS:000247749700027 AU - Movsas, B. AU - Moughan, J. AU - Owen, J. AU - Coia, L. R. AU - Zelefsky, M. J. AU - Hanks, G. AU - Wilson, J. F. DA - Jul DO - 10.1016/j.ijrobp.2007.01.051 IS - 4 N1 - 17418963 PY - 2007 SN - 0360-3016 SP - 1145-1150 ST - Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis T2 - International Journal of Radiation Oncology Biology Physics TI - Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis VL - 68 ID - 3190 ER - TY - JOUR AB - This study was premised on the assumption that learning more about Black American women's beliefs and values regarding health and illness could inform public policy initiatives in the area of cancer prevention and control so that a more equitable basis for participation could be achieved in future medical and scientific research. Qualitative methods of research were used. A semi-structured interview guide was used in 36 hrs of in-depth and face-to-face interviews with 13 Black American women recruited to the study using a snowball technique. The Ss were middle-class, professional, and semi-professional. Results indicate that there is a poor understanding by the dominant White medical community concerning the beliefs and values of Black patients and that this compromises their health and illness care. Coexisting with well- founded, deep-seated fears and wariness that are expressed by these Ss, are their optimistic and even hopeful feelings that there is benefit in scientific research and that they have a desire to contribute to medical inquiry. Results indicate the importance of using specific research methodologies. A number of recommendations are presented. (PsycInfo Database Record (c) 2020 APA, all rights reserved) AN - 1998-10387-005 AU - Freedman, Tovia G. DB - psyh DO - 10.1016/S0277-9536(98)00167-1 DP - EBSCOhost IS - 7 KW - beliefs & values about health & illness African American females implications for public policy initiatives on cancer prevention & control & clinical trials participation Adult African Americans Aged Attitude to Health Breast Neoplasms Clinical Trials as Topic Female Health Services Needs and Demand Humans Interviews as Topic Middle Aged Physician-Patient Relations Religion Social Values United States Women Blacks Health Attitudes Values Experimental Subjects Neoplasms Preventive Health Services N1 - U Pennsylvania, School of Nursing, Philadelphia, PA, US. Release Date: 19981101. Correction Date: 20200713. Publication Type: Journal (0100), Peer Reviewed Journal (0110). Format Covered: Print. Document Type: Journal Article. Language: English. Major Descriptor: Blacks; Health Attitudes; Values. Minor Descriptor: Experimental Subjects; Neoplasms; Preventive Health Services. Classification: Promotion & Maintenance of Health & Wellness (3365). Population: Human (10); Female (40). Location: US. Age Group: Adulthood (18 yrs & older) (300). Methodology: Empirical Study. Page Count: 7. Issue Publication Date: Oct, 1998. PY - 1998 SN - 0277-9536 1873-5347 SP - 941-947 ST - 'Why don't they come to Pike street and ask us'?: Black American women's health concerns T2 - Social Science & Medicine TI - 'Why don't they come to Pike street and ask us'?: Black American women's health concerns UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1998-10387-005&site=ehost-live&scope=site VL - 47 ID - 1763 ER - TY - JOUR AB - It is well known that black American women are poorly represented in medically oriented research and that this has far reaching implications for their personal health, the health of their families and the overall health of the larger society. The research reported was premised on the assumption that learning more about black American women's beliefs and values regarding health and illness could inform public policy initiatives in the area of cancer prevention and control so that a more equitable basis for participation could be achieved in future medical and scientific research. Qualitative methods of research were used in this investigation. A semi-structured interview guide was used in 36 h. of in-depth and face-to-face interviews with 13 black American women recruited to the study using a snowball technique. The women interviewed were middle-class, professional and semi-professional women. The results of the study indicate that there is a poor understanding by the dominant white medical community concerning the beliefs and values of black patients and that this compromises their health and illness care. The Tuskegee Syphilis Experiment is often used as the rationale for the low recruitment of black women into clinical trials - both therapeutic and non-therapeutic. The women interviewed do not agree with this claim. These women suggest that if they were asked to participate in trials and the trial was relevant to their primary medical concerns they would consider joining. The research results indicate the importance of using specific research methodologies and a number of recommendations are presented. AD - University of Pennsylvania, School of Nursing, NEB-2012, 420 Guardian Drive, Philadelphia, PA 19104-6096, United States AU - Freedman, T. G. DB - Scopus DO - 10.1016/S0277-9536(98)00167-1 IS - 7 KW - Black women Cancer prevention Clinical trials Health beliefs Woman M3 - Article N1 - Cited By :74 Export Date: 22 March 2021 PY - 1998 SP - 941-947 ST - 'Why don't they come to Pike Street and ask us'?: Black american women's health concerns T2 - Social Science and Medicine TI - 'Why don't they come to Pike Street and ask us'?: Black american women's health concerns UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031850763&doi=10.1016%2fS0277-9536%2898%2900167-1&partnerID=40&md5=0803d0a58f6653e0125b897ff530dd6e VL - 47 ID - 2642 ER - TY - JOUR AB - Importance: Black individuals are underrepresented in cancer clinical trials. Objective: To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient‐level barriers statistically mediate racial differences. Design, Setting, and Participants: This cross‐sectional survey study used baseline data from Partnering Around Cancer Clinical Trials, a randomized clinical trial to increase Black individuals' enrollment in prostate cancer clinical trials. Data were collected from 2016 through 2019 at 2 National Cancer Institute‐designated comprehensive cancer centers; participants were Black and White men with intermediate‐risk to high‐risk prostate cancer. In mediation analysis, path models regressed willingness onto race and each potential mediator, simultaneously including direct paths from race to each mediator. Significant indirect effect sizes served as evidence for mediation. Exposures: Race was the primary exposure. Potential mediators included age, education, household income, perceived economic burden, pain/physical limitation, health literacy, general trust in physicians, and group‐based medical suspicion. Main Outcomes and Measures: The primary outcome was the answer to a single question: "If you were offered a cancer clinical trial, would you be willing to hear more information about it?"Results: A total of 205 participants were included (92 Black men and 113 White men), with a mean (range) age of 65.7 (45‐89) years; 32% had a high school education or lower, and 27.5% had a household income of less than $40000. Most (88.3%) reported being definitely or probably willing to discuss trials, but White participants were more likely to endorse this highest category of willingness than Black participants (82% vs 64%; χ22 = 8.81; P =.01). Compared with White participants, Black participants were younger (F1,182 = 8.67; P <.001), less educated (F1,182 = 22.79; P <.001), with lower income (F1,182 = 79.59; P <.001), greater perceived economic burden (F1,182 = 42.46; P <.001), lower health literacy (F1,184 = 9.84; P =.002), and greater group‐based medical suspicion (F1,184 = 21.48; P <.001). Only group‐based medical suspicion significantly mediated the association between race and willingness to discuss trials (indirect effect,‐0.22; P =.002). Conclusions and Relevance: In this study of men with prostate cancer, most participants were willing to discuss trials, but Black men were significantly less willing than White men. Black men were more likely to believe that members of their racial group should be suspicious of the health care system, and this belief was associated with lower willingness to discuss trials. Addressing medical mistrust may improve equity in clinical research. AN - CN-02194985 AU - Senft, N. AU - Hamel, L. M. AU - Manning, M. A. AU - Kim, S. AU - Penner, L. A. AU - Moore, T. F. AU - Carducci, M. A. AU - Heath, E. I. AU - Lansey, D. G. AU - Albrecht, T. L. AU - et al. DO - 10.1001/jamaoncol.2020.3697 KW - *prostate cancer Aged Article Clinical research Controlled study Effect size Female Health care system Health literacy High school Household income Human Major clinical study Male National health organization Pain Physician Race difference Randomized controlled trial Trust M3 - Journal: Article in Press PY - 2020 ST - Willingness to Discuss Clinical Trials among Black vs White Men with Prostate Cancer T2 - JAMA oncology TI - Willingness to Discuss Clinical Trials among Black vs White Men with Prostate Cancer UR - https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02194985/full ID - 1514 ER - TY - JOUR AB - This cross-sectional survey study examines whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians, and if so, whether patient-level barriers are associated with racial differences. Key Points: Question: Are Black men with prostate cancer less willing than White men to discuss clinical trials with their physicians, and are patient-level barriers associated with racial differences? Findings: In this cross-sectional survey study of 205 patients with prostate cancer, most participants reported being willing to discuss trials, but Black men were significantly less willing than White men. Racial differences were associated with greater medical suspicion among Black men. Meaning: Addressing Black patients' medical suspicion may promote equity in clinical trial participation. Importance: Black individuals are underrepresented in cancer clinical trials. Objective: To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. Design, Setting, and Participants: This cross-sectional survey study used baseline data from Partnering Around Cancer Clinical Trials, a randomized clinical trial to increase Black individuals' enrollment in prostate cancer clinical trials. Data were collected from 2016 through 2019 at 2 National Cancer Institute–designated comprehensive cancer centers; participants were Black and White men with intermediate-risk to high-risk prostate cancer. In mediation analysis, path models regressed willingness onto race and each potential mediator, simultaneously including direct paths from race to each mediator. Significant indirect effect sizes served as evidence for mediation. Exposures: Race was the primary exposure. Potential mediators included age, education, household income, perceived economic burden, pain/physical limitation, health literacy, general trust in physicians, and group-based medical suspicion. Main Outcomes and Measures: The primary outcome was the answer to a single question: "If you were offered a cancer clinical trial, would you be willing to hear more information about it?" Results: A total of 205 participants were included (92 Black men and 113 White men), with a mean (range) age of 65.7 (45-89) years; 32% had a high school education or lower, and 27.5% had a household income of less than $40 000. Most (88.3%) reported being definitely or probably willing to discuss trials, but White participants were more likely to endorse this highest category of willingness than Black participants (82% vs 64%; χ22 = 8.81; P =.01). Compared with White participants, Black participants were younger (F1,182 = 8.67; P <.001), less educated (F1,182 = 22.79; P <.001), with lower income (F1,182 = 79.59; P <.001), greater perceived economic burden (F1,182 = 42.46; P <.001), lower health literacy (F1,184 = 9.84; P =.002), and greater group-based medical suspicion (F1,184 = 21.48; P <.001). Only group-based medical suspicion significantly mediated the association between race and willingness to discuss trials (indirect effect, −0.22; P =.002). Conclusions and Relevance: In this study of men with prostate cancer, most participants were willing to discuss trials, but Black men were significantly less willing than White men. Black men were more likely to believe that members of their racial group should be suspicious of the health care system, and this belief was associated with lower willingness to discuss trials. Addressing medical mistrust may improve equity in clinical research. AD - Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee Karmanos Cancer Institute, Wayne State University, Detroit, Michigan The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland AN - 148448102. Language: English. Entry Date: 20210215. Revision Date: 20210311. Publication Type: Article AU - Senft, Nicole AU - Hamel, Lauren M. AU - Manning, Mark A. AU - Kim, Seongho AU - Penner, Louis A. AU - Moore, Tanina Foster AU - Carducci, Michael A. AU - Heath, Elisabeth I. AU - Lansey, Dina G. AU - Albrecht, Terrance L. AU - Wojda, Mark AU - Jordan, Alice AU - Eggly, Susan DB - CINAHL Complete DO - 10.1001/jamaoncol.2020.3697 DP - EBSCOhost IS - 11 KW - Men's Health Black Persons White Persons Prostatic Neoplasms Cancer Patients Patient Attitudes Clinical Trials Physician-Patient Relations Race Factors Human Male Cross Sectional Studies Mediation Analysis Path Analysis Socioeconomic Factors Middle Age Aged Aged, 80 and Over Chi Square Test Multivariate Analysis of Variance Data Analysis Software Analysis of Variance Funding Source N1 - research; tables/charts. Journal Subset: Peer Reviewed; USA. Special Interest: Men's Health. Grant Information: This research was funded by the National Cancer Institute under R01CA200718 (PI: Dr Eggly) and P30CA022453 (PI: Dr Bepler).. PY - 2020 SN - 2374-2437 SP - 1773-1777 ST - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer T2 - JAMA Oncology TI - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer UR - http://proxy.lib.umich.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148448102&site=ehost-live&scope=site VL - 6 ID - 2144 ER - TY - JOUR AB - IMPORTANCE Black individuals are underrepresented in cancer clinical trials. OBJECTIVE To examine whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians and, if so, whether patient-level barriers statistically mediate racial differences. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional survey study used baseline data from Partnering Around Cancer Clinical Trials, a randomized clinical trial to increase Black individuals' enrollment in prostate cancer clinical trials. Data were collected from 2016 through 2019 at 2 National Cancer Institute-designated comprehensive cancer centers; participants were Black and White men with intermediate-risk to high-risk prostate cancer. In mediation analysis, path models regressed willingness onto race and each potential mediator, simultaneously including direct paths from race to each mediator. Significant indirect effect sizes served as evidence for mediation. EXPOSURES Race was the primary exposure. Potential mediators included age, education, household income, perceived economic burden, pain/physical limitation, health literacy, general trust in physicians, and group-based medical suspicion. MAIN OUTCOMES AND MEASURES The primary outcomewas the answer to a single question: "If you were offered a cancer clinical trial, would you be willing to hear more information about it?" RESULTS A total of 205 participants were included (92 Black men and 113 White men), with a mean (range) age of 65.7 (45-89) years; 32% had a high school education or lower, and 27.5% had a household income of less than $40 000. Most (88.3%) reported being definitely or probably willing to discuss trials, but White participants were more likely to endorse this highest category of willingness than Black participants (82% vs 64%;.2 2=8.81; P=.01). Compared with White participants, Black participants were younger (F-1,F-182=8.67; P <.001), less educated (F-1,F-182=22.79; P <.001), with lower income (F-1,F-182=79.59; P <.001), greater perceived economic burden (F-1,F-182=42.46; P <.001), lower health literacy (F-1,F-184=9.84; P=.002), and greater group-based medical suspicion (F-1,F-184=21.48; P <.001). Only group-based medical suspicion significantly mediated the association between race and willingness to discuss trials (indirect effect, -0.22; P=.002). CONCLUSIONS AND RELEVANCE In this study of men with prostate cancer, most participants were willing to discuss trials, but Black men were significantly less willing than White men. Black men were more likely to believe that members of their racial group should be suspicious of the health care system, and this belief was associated with lower willingness to discuss trials. Addressing medical mistrust may improve equity in clinical research. AN - WOS:000574294400007 AU - Senft, N. AU - Hamel, L. M. AU - Manning, M. A. AU - Kim, S. AU - Penner, L. A. AU - Moore, T. F. AU - Carducci, M. A. AU - Heath, E. I. AU - Lansey, D. G. AU - Albrecht, T. L. AU - Wojda, M. AU - Jordan, A. AU - Eggly, S. DA - Nov DO - 10.1001/jamaoncol.2020.3697 IS - 11 N1 - 32940630 PY - 2020 SN - 2374-2437 SP - 1773-1777 ST - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer T2 - Jama Oncology TI - Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate Cancer VL - 6 ID - 2762 ER - TY - JOUR AB - Zinc is an essential dietary element that has been implicated in the pathogenesis of prostate cancer, a cancer that disproportionately affects men of African descent. Studies assessing the association of zinc intake and prostate cancer have yielded inconsistent results. Furthermore, very little is known about the relationship between zinc intake and prostate cancer among African Americans. We examined the association between self-reported zinc intake and prostate cancer in a hospital-based case-control study of African Americans. We then compared our results with previous studies by performing a meta-analysis to summarize the evidence regarding the association between zinc and prostate cancer. Newly diagnosed African American men with histologically confirmed prostate cancer (n = 127) and controls (n = 81) were recruited from an urban academic urology clinic in Washington, DC. Controls had higher zinc intake, with a mean of 14 mg/day versus 11 mg/day for cases. We observed a non-significant, non-linear increase in prostate cancer when comparing tertiles of zinc intake (OR <6.5sv6.5-12.5mg/day 1.8, 95% CI: 0.6,5.6; OR <6.5 vs>12.5mg/day 1.3, 95% CI: 0.2,6.5). The pooled estimate from 17 studies (including 3 cohorts, 2 nested case-control, 11 case-control studies, and 1 randomized clinical trial, with a total of 111,199 participants and 11,689 cases of prostate cancer) was 1.07hi vs lo 95% CI: 0.98-1.16. Using a dose-response meta-analysis, we observed a non-linear trend in the relationship between zinc intake and prostate cancer (p for nonlinearity = 0.0022). This is the first study to examine the relationship between zinc intake in black men and risk of prostate cancer and systematically evaluate available epidemiologic evidence about the magnitude of the relationship between zinc intake and prostate cancer. Despite of the lower intake of zinc by prostate cancer patients, our meta-analysis indicated that there is no evidence for an association between zinc intake and prostate cancer. AU - Mahmoud, A. M. AU - Al-Alem, U. AU - Dabbous, F. AU - Ali, M. M. AU - Batai, K. AU - Shah, E. AU - Kittles, R. A. DB - Embase Medline DO - 10.1371/journal.pone.0165956 IS - 11 KW - zinc adult African American aged article cancer risk cohort analysis controlled study dietary intake disease association District of Columbia evidence based practice histopathology hospital based case control study human major clinical study male prostate cancer randomized controlled trial (topic) risk assessment self report systematic review trend study LA - English M3 - Article N1 - L613121339 2016-11-17 2016-12-05 PY - 2016 SN - 1932-6203 ST - Zinc intake and risk of prostate cancer: Case-control study and meta-analysis T2 - PLoS ONE TI - Zinc intake and risk of prostate cancer: Case-control study and meta-analysis UR - https://www.embase.com/search/results?subaction=viewrecord&id=L613121339&from=export http://dx.doi.org/10.1371/journal.pone.0165956 VL - 11 ID - 959 ER - TY - JOUR AB - Zinc is an essential dietary element that has been implicated in the pathogenesis of prostate cancer, a cancer that disproportionately affects men of African descent. Studies assessing the association of zinc intake and prostate cancer have yielded inconsistent results. Furthermore, very little is known about the relationship between zinc intake and prostate cancer among African Americans. We examined the association between self-reported zinc intake and prostate cancer in a hospital-based case-control study of African Americans. We then compared our results with previous studies by performing a meta-analysis to summarize the evidence regarding the association between zinc and prostate cancer. Newly diagnosed African American men with histologically confirmed prostate cancer (n = 127) and controls (n = 81) were recruited from an urban academic urology clinic in Washington, DC. Controls had higher zinc intake, with a mean of 14 mg/day versus 11 mg/day for cases. We observed a non-significant, non-linear increase in prostate cancer when comparing tertiles of zinc intake (OR <6.5sv6.5-12.5mg/day 1.8, 95% CI: 0.6,5.6; OR <6.5 vs>12.5mg/day 1.3, 95% CI: 0.2,6.5). The pooled estimate from 17 studies (including 3 cohorts, 2 nested case-control, 11 case-control studies, and 1 randomized clinical trial, with a total of 111,199 participants and 11,689 cases of prostate cancer) was 1.07hi vs lo 95% CI: 0.98-1.16. Using a dose-response meta-analysis, we observed a non-linear trend in the relationship between zinc intake and prostate cancer (p for nonlinearity = 0.0022). This is the first study to examine the relationship between zinc intake in black men and risk of prostate cancer and systematically evaluate available epidemiologic evidence about the magnitude of the relationship between zinc intake and prostate cancer. Despite of the lower intake of zinc by prostate cancer patients, our meta-analysis indicated that there is no evidence for an association between zinc intake and prostate cancer. © 2016 Mahmoud et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. AD - Department of Kinesiology and Nutrition, Department of Physical Therapy, School of Applied Health Sciences, University of Illinois at Chicago, Chicago, IL, United States Department of Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL, United States James R. and Helen D. Russell Institute for Research and Innovation, Advocate Lutheran General Hospital, Park Ridge, IL, United States Department of Surgery, College of Medicine, University of Arizona, Tucson, AZ, United States AU - Mahmoud, A. M. AU - Al-Alem, U. AU - Dabbous, F. AU - Ali, M. M. AU - Batai, K. AU - Shah, E. AU - Kittles, R. A. C7 - e0165956 DB - Scopus DO - 10.1371/journal.pone.0165956 IS - 11 M3 - Article N1 - Cited By :9 Export Date: 22 March 2021 PY - 2016 ST - Zinc intake and risk of prostate cancer: Case-control study and meta-analysis T2 - PLoS ONE TI - Zinc intake and risk of prostate cancer: Case-control study and meta-analysis UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994460203&doi=10.1371%2fjournal.pone.0165956&partnerID=40&md5=0ac127793874375aab4d48a8cb2812a6 VL - 11 ID - 2333 ER - TY - JOUR AB - Zinc is an essential dietary element that has been implicated in the pathogenesis of prostate cancer, a cancer that disproportionately affects men of African descent. Studies assessing the association of zinc intake and prostate cancer have yielded inconsistent results. Furthermore, very little is known about the relationship between zinc intake and prostate cancer among African Americans. We examined the association between self-reported zinc intake and prostate cancer in a hospital-based case-control study of African Americans. We then compared our results with previous studies by performing a meta-analysis to summarize the evidence regarding the association between zinc and prostate cancer. Newly diagnosed African American men with histologically confirmed prostate cancer (n = 127) and controls (n = 81) were recruited from an urban academic urology clinic in Washington, DC. Controls had higher zinc intake, with a mean of 14 mg/day versus 11 mg/day for cases. We observed a non-significant, non-linear increase in prostate cancer when comparing tertiles of zinc intake (OR (<6.5 vs 6.5-12.5mg/day) 1.8, 95% CI: 0.6,5.6; OR (<6.5 vs >12.5mg/day) 1.3, 95% CI: 0.2,6.5). The pooled estimate from 17 studies (including 3 cohorts, 2 nested case-control, 11 case-control studies, and 1 randomized clinical trial, with a total of 111,199 participants and 11,689 cases of prostate cancer) was 1.07 (hi vs lo) 95% CI: 0.98-1.16. Using a dose-response meta-analysis, we observed a non-linear trend in the relationship between zinc intake and prostate cancer (p for nonlinearity = 0.0022). This is the first study to examine the relationship between zinc intake in black men and risk of prostate cancer and systematically evaluate available epidemiologic evidence about the magnitude of the relationship between zinc intake and prostate cancer. Despite of the lower intake of zinc by prostate cancer patients, our meta-analysis indicated that there is no evidence for an association between zinc intake and prostate cancer. AN - WOS:000387615200049 AU - Mahmoud, A. M. AU - Al-Alem, U. AU - Dabbous, F. AU - Ali, M. M. AU - Batai, K. AU - Shah, E. AU - Kittles, R. A. DA - Nov DO - 10.1371/journal.pone.0165956 IS - 11 N1 - e0165956 27824905 PY - 2016 SN - 1932-6203 ST - Zinc Intake and Risk of Prostate Cancer: Case-Control Study and Meta-Analysis T2 - Plos One TI - Zinc Intake and Risk of Prostate Cancer: Case-Control Study and Meta-Analysis VL - 11 ID - 2930 ER -